<SEC-DOCUMENT>0000950170-25-034903.txt : 20250306
<SEC-HEADER>0000950170-25-034903.hdr.sgml : 20250306
<ACCEPTANCE-DATETIME>20250306171358
ACCESSION NUMBER:		0000950170-25-034903
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250306
DATE AS OF CHANGE:		20250306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvation Bio Inc.
		CENTRAL INDEX KEY:			0001811063
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				850862255
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39351
		FILM NUMBER:		25716314

	BUSINESS ADDRESS:	
		STREET 1:		357 TEHAMA STREET, FLOOR 3
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		(415) 754-3517

	MAIL ADDRESS:	
		STREET 1:		357 TEHAMA STREET, FLOOR 3
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Panacea Acquisition Corp
		DATE OF NAME CHANGE:	20200430
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nuvb-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-06T17:09:36.5087+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:nuvb="http://nuvationbio.com/20241231" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c256e67e-65b1-456e-8082-26044c0f9ea9" name="dei:AmendmentFlag" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81">false</ix:nonNumeric><ix:nonNumeric id="F_1b365542-d97d-4178-852e-c4076abbdd7e" name="dei:DocumentFiscalPeriodFocus" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81">FY</ix:nonNumeric><ix:nonNumeric id="F_be77b654-62d0-41a4-837f-fb3f4c1fd6cc" name="dei:EntityCentralIndexKey" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81">0001811063</ix:nonNumeric><ix:nonFraction id="F_f102744e-e5de-4779-9087-28320d26aca8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_bc4c8e53-d632-4d98-8fdd-d3c798496e59" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nuvb-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80f9920f-001e-4ee0-bc41-726bea9c2be2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8480017c-198b-4473-b4ab-8b7816a14484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85891461-e727-4c8a-a45e-24ce144694c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86eee26d-a7c8-4971-a02e-0c536e6bb91b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:NkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b229bac-622e-41dd-87db-5a7e8d379dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:SanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c1b26be-f804-4b3f-992e-e5e76af52068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d9345df-39ad-447f-a1af-a822c985ade5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e6407a5-bcf1-4464-971c-f6b91e19a697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8cdc8e-8210-4b4d-9cd5-f1a28755b54e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fd6169f-7ab5-46a7-a6cc-3a2bc4eb6868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_926d281c-c192-41fa-9469-55fc53c364ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_933286c8-e34a-49bc-beba-8abcc047b16c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93ac93d0-60a9-4a06-90a6-fd3ede540eb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:ConsiderationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_942a2b2b-70da-4457-a462-954c54372c8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_943111d4-1cca-4ec9-9b87-c18a3c9909ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:ForwardPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_952278b9-3008-410e-b399-83d1341da7e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9748bbba-55ba-4df0-8e3a-bd402ef3408d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:FoodAndDrugAdministrationApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a955a31-b3a1-4541-96dc-cc575ee9a1d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bfa5b92-b29a-404b-9eb6-c8b1699ee7f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c555376-54aa-4690-a07a-8995c5f1de8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1fa561b-037b-48f9-b6e6-35db1b21440b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2bdff39-def8-4415-a8b5-6832e22064e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4328f73-2497-4e2b-ab79-aaa0f3d84e59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5a3ec93-d622-45c2-8770-84e991a7b996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7fd337a-9497-4d90-be00-2699c0401c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8df6974-75d8-4cdd-aa79-237e8cd65e90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9328880-f63c-496f-99d3-ea644af60276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithChinaMerchantsBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aac49177-7f36-4ea5-b068-584c31c660b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abb8df07-b97c-4a48-aefb-b20f734b97a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abba69cb-6d7c-456b-a9e7-8c60b7df5832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aca3d405-cc0e-4215-b0e3-ff17e649ad8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acea1f01-0d21-43fb-b399-83953ae01873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acf04de5-17e7-45a9-89d8-b6eb52400fba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nuvb:InternalRevenueCode174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b05136ff-fb6b-4102-a36c-cf37b5c03746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b09ceff4-bb66-4ef2-9cdf-6517cbd7196b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1434390-9c27-4f94-8077-b738947d29fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b15e2718-f40d-4bdc-b3db-1dc125497868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2ddc1f0-c371-4813-af10-cf895f6e3373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-09</xbrli:startDate><xbrli:endDate>2024-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3414614-96e7-4ae2-b1f7-055df470e8ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:NkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3a3ed53-7933-4dff-be9b-82cf2713934b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4189f91-e001-4361-b114-dc6380eac776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b432f621-66c8-4177-856f-0710048eeb24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5db802e-98fe-4d8f-8ce3-efda58046123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5f38a77-58df-4c07-a7ce-d20e2e695546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5fad4a0-b4e2-4fff-9d5d-16ef79716219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b647e270-1e2a-41ed-99c4-b1fdac51fdee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b68630d3-6944-4401-9af4-dc2436cb5eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6964028-a1f5-4562-8dd6-ab7b2f917574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7745198-d60e-4f1b-a9f3-33740d640e7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b84b1da0-aedf-4620-881d-35579afeb08f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:AssumedShareBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b84cd312-fd39-4b1d-8699-fda7c967c8b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8ceb7cf-3e46-43f2-a0e3-ded43479a354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b98b6295-0101-48a0-af40-21586c6ade2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3e4516b-f8d6-469d-9172-f8b2294ea29b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c53952fa-847c-4ce2-a41b-24de9e826c90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5581c71-90c7-436b-aaba-8f1f78e6dc28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c671dc80-de5d-4aa6-a09f-d6f224165348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:RedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c982e94f-abaf-48a7-a575-7a406ffb1b30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca424ba3-3e9c-4fc8-943e-50b54d3eb6a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce6f0d2b-c086-4763-b947-870bbe14d4f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfda41d6-83a3-4e48-ba69-343cbe55f56b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4d1928d-1758-446a-9b41-e8b4d12651af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:ClassAAndClassBCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d630f863-0d98-4a3a-a20e-783e2c04a4e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7bd32b5-b034-49be-9ebf-85bf65031ef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d83e520c-196f-42be-bff1-f66d4956ab03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da21c4c3-938d-42bc-bc80-ba4f2ce5c849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da7ecdf1-4156-4924-8c2b-91c1bbf48649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2513bc6-e23a-4295-b2e3-1e55986d0108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e48fcc9a-b0c1-44cf-86db-3afdf6eb9d8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e555de18-2b2c-49fe-b7c4-7fc47b8d8119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e59de91c-61ea-4944-9861-5e3a0c84322c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6904180-de0a-402e-a43d-2eb3649975e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceMarketAndPerformanceConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6f673b3-21bf-40a8-945b-58d5fc5eb19a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e720fa47-bca7-4ca0-8f9f-5310a1a2429a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e781b479-dd2a-4691-8eb1-89cc93788c93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e97bbbfd-29be-4b48-8399-0c877e55e63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab07c10-f6ec-4739-8ac1-c72a472fe56e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb8419be-c990-483e-98aa-581ed2dfd11f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed2589a9-11fc-46c5-a588-1f840166c29f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed404de3-f206-47f2-9ddc-6680cc0e8957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efe682e8-6905-4a59-a9b1-a74dcdb4a136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f04153c5-2436-41de-9120-dcd4ef68be2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f196edb9-bd73-43fb-8ae1-2133c0857f5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:SagardHealthcarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1bab928-2d56-4296-a932-20dbf7274283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3542591-19a8-4b91-a21e-e2ed9f8b23a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4520a62-400d-4bbb-bc6f-dfcca29c01bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4d88de7-a689-43dc-94ed-786f211f10b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nuvb:InternalRevenueCode59Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f54ce4b1-75d3-4c3a-841f-2d8ce4cc5489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f600fe9a-155a-446b-92c8-a7fc4ddd37e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f64c1371-e223-4a9e-939d-999f45e6fda0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f65e2027-f5ac-4490-8e99-bc62d9e131dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6d0b85e-30b4-4e3d-90ba-0b428c795f3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f73a9537-952a-476b-a1b9-94ceb77e4027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f77ce2c2-1105-4078-a520-6f9949541a3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9007fb3-c6d1-4f58-99a8-9b1c076139b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9dc1391-a88d-47a7-b7e3-f1a434ed0445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceMarketAndPerformanceConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd25faa1-dc18-456c-8ff2-cfd565b81886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdd8837c-b00d-4e16-b06b-aaf29e21f38f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe9e98bb-bd80-487d-b08c-3e44af1635e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feb7f3f7-75e8-4c18-a40f-52dbffc94964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02eea57f-659f-4ea9-a9be-e8bf4cf97e78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_044c0715-8d17-4f49-8eef-b09c4726ce1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07229a6d-6da2-40c2-88a0-037159cfa57e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0727c878-248f-4686-86bc-a4597d7f4e1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07f313fd-524b-46d2-99aa-b951b4324490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b0d4681-373d-40ee-a05b-cf4167b76104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c652882-855e-465e-8c03-230c6f70279d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dded1bb-24a8-4a81-9bbe-145757df1e2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ec4baa0-50bf-4ee8-bab3-3ce9c13fadb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f03a15b-3abb-4776-a53a-0c003dafb17a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_101e91ce-9660-46bb-af18-7822809f659f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10ac330b-db11-468f-b855-d1877a78ce3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11048d21-d2dd-4d6a-8603-844e4ce4caa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_123f4631-c9de-4408-9fbf-82e1d9db0a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:NkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12761058-5ed6-4b90-92ad-003f0933b78a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12b28d30-7841-4345-96a7-0f6603d08fb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1632c343-8902-43c4-8df1-34be8034ddec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16f76ae8-82d8-4ad7-884d-2c31f5e8ddc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17baa364-63a5-4662-be7d-3a569f3f9131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b58aa7a-19df-4858-9619-311b52c1a5ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fe9b1fa-5c06-41bc-904a-8d55067e5f76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23995f85-8e92-4f98-835d-389f59c1c8ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceMarketAndPerformanceConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c3ae60-037a-4b82-a8ea-fb789a61b20b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24401d38-47d2-484c-ba0b-f6174eb508ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26a84641-0351-4435-853e-2d9c28676213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27aec131-424f-4703-abb2-81c1cfb32c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28c85cf7-f7fc-4376-b2ea-94cb2e1e8f60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_292c1c1e-5581-4c9b-8157-24e0d07be12b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2da576e1-d49e-45c4-bfa3-24d20530d615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fa726a6-4678-4715-b671-32d7fc4b3458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fcaddbe-59b4-4dd8-acff-d235bcf3608a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_308b572c-bcec-40d0-86b6-45262da0d663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30c42ef8-e350-413e-8d4a-0cb11d19dd8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30e55683-04d9-41a0-bd33-67d960b1716c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">nuvb:FounderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_331fb293-9d15-4ccd-b119-469a710b3daa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3321395a-631d-476b-8f7d-c59b5665b1b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvb:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34e78618-c534-4284-bb6e-1a7b083eb1da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36730653-ff82-4c63-a01f-ca2dd3b496b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3757f3f2-4eb9-4da5-87da-348aee145967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38dfcba2-bd95-458c-a352-b4df776e9ce0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39922b23-3d3c-4025-8814-7b066e6e395d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39d9ef20-3367-48ef-9bd5-5cb516f43747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a62758c-8331-43c7-b65a-8ceaebefba74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b40daf5-2951-4982-9dc4-35739b254bf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c8db28e-2317-426a-ae9d-38906384d4dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cb6dc20-b571-4ae0-9e67-6ab4aff1d9d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cba4440-12d3-4ee9-9032-9e8572c8aa7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d24e6c8-77cc-422b-ba78-255de1017179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:OtherThanUnitedStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e12a88b-ec80-4a4c-95d8-aee1b5d352ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_412486e3-9ba5-40f0-bf1b-da7b97f1b931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_418e0a4f-214f-4bbb-a57c-9eed0f7d967b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_418fbc05-c30f-4227-9cfe-1386e01c9955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42013ae0-ddac-4812-88ab-b99d2d7149ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44998c3a-718b-48fb-8220-6e156a09eee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44d82460-2e05-4f7c-9c55-b545075fb034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4681f739-9c28-49fc-bde8-0490bae0f771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_474282e8-2bd8-473d-b449-c1749a573ed7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:SanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_484ef476-4e04-4c47-b500-750696fee41c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nuvb:ConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b3274d8-aece-4320-b574-aac0c61b61d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b9f43a9-9d6b-48e7-8cc3-ca1f86613de6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:ClassAAndClassBCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d5e27ff-5781-4fd0-ad66-8f80196d9597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e84c14b-26d4-4b95-88a1-d3d37077db29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f00ab19-70eb-452a-a67c-0c577ad86cfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-09</xbrli:startDate><xbrli:endDate>2024-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_529b7cca-f4b7-4116-a505-7babb7b8fa92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_532ddbb7-20a6-413d-b66d-5c3445bb8db6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54b6680f-d764-4c4f-bd20-7ff2e11edc6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54d22bf6-7851-4a61-9f26-acc23b794faa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvb:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55955901-09db-418b-89e5-7cba4fc0a390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5634f3f1-5114-4a3c-9c5e-9f28b9b642a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_573fc90e-3384-4e88-bebb-411d7823adc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57ac3f3b-9cda-4711-b678-dd10a4a451ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5915e704-6a60-4fe4-b048-5cb37f86d627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59e21847-16f9-4084-92e3-35afa293d947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bade152-78d3-45ae-93eb-5920249b2833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c1f1a22-82b1-4d98-9857-c486ab81f376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ed535ca-023f-4c23-9afe-8ae365dc24de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ef65c87-2f51-4661-a7fb-5e58e7086ef2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60d2085a-baaf-4b22-8edb-e7cc340aab3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60d86b53-364b-4bb8-a244-c7731ef29c6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_612babb2-a261-40cd-b2ca-5ceb1ce31e71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61525415-3259-4e81-b1a8-a96d13e75e0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62336d85-1efb-4a6d-a379-5fc3378a8347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63c9b400-5728-40d4-a6f1-9117ecc729d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64371941-b776-4c3c-ab99-a54d91207dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_643df37d-2f04-4154-b398-b0bb4de05827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66e37e69-8ac7-4c73-be34-2b5741857629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_673b8d54-13ef-4cf8-98c1-1882bd894e37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68c26585-4b66-4439-9588-4c1bd035ebe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_694fe0ae-e3fc-4dfc-a41f-7d05ec59e408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69989213-f1c9-4257-8e6c-cc9e8660ba6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a5444ea-1b3c-444f-8c39-856c8ccbdd74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d9872a7-adc1-43ff-8f43-9e26797a3c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ed882e8-da6b-4efe-bc8b-354008a8cc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f054bef-1755-4a9e-b507-73b2cd109b47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f4cfee1-80ef-4add-9e23-106b99b62a74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:ConsiderationWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70942f4b-acda-4d74-b1c9-cadcea492b15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70f4ad29-01fb-4717-94fc-a3ad777c8950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71aaefa0-51ea-4664-bacf-7f5628476895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7950894a-1811-4b80-ae40-787e405417b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:ConsiderationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79e5ffa3-86c1-447a-bb2e-bece04e75439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001811063</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_sqm"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_4f3bb437-a8b3-4cff-8b4c-0918d5764aee" fromRefs="F_801b7957-e7ce-45ce-af71-3084ea02dc16"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_563dd183-07f4-4e61-8c2d-ef4770f63d0a" fromRefs="F_73151569-7198-451b-a2ba-1634232ea74a"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_227f6045-fd63-4e82-9ac3-e6f2c0dda3b3" fromRefs="F_27913815-f03d-44ad-ae06-0585e506afd5"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_37026355-c90c-4fba-bff4-dc06521eb3a1" fromRefs="F_c9f3c6cf-2103-4802-bf64-c4e3996706c0"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_8344d213-e047-4112-8b2d-a4031ed59257" fromRefs="F_4bd79f76-27a9-417e-b329-b47366d2c6dd F_7bd7a3ca-4745-4447-8ef4-f1bb5370e779"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.133%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40.13%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a189c457-4057-42a0-8d13-77a284c68f72" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.133%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40.13%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_312f2c6a-fc96-4cef-80c4-ebd9da92827d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efe4dceb-03d1-413b-b754-9a8d2dcb7b6f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9cf69fa-fc41-41af-9514-6c63c6792881" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb1bf9cf-9a91-45ed-ae4d-ba21240da868" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a3878f3-9fec-4f6b-a6a0-e35fc398230f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:46.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.87%;box-sizing:content-box;"/>
    <td style="width:15.217%;box-sizing:content-box;"/>
    <td style="width:6.522%;box-sizing:content-box;"/>
    <td style="width:17.391%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">FOR THE TRANSITION PERIOD FROM</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dac8b3a-b7b9-4523-9048-b8aba6feb8d8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39351</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.133%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40.13%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d6d78b5-e616-4bde-9f00-e2d0fbb988e7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.133%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40.13%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9d03e33b-f3c9-47e3-b807-cbd09d9e5d7b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b126628c-38e2-41c4-962b-318d1b62c6c9" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">85-0862255</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_58b94f6a-602a-4f92-b4cd-3be7ca134411" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1500 Broadway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">,</span><span style="font-size:8pt;"><ix:nonNumeric id="F_1b6d7c00-e6c2-46d9-a407-571151db0d81" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> Suite 1401</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_afebbdcd-784f-4123-b4cc-def161680bce" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_9ab5b006-cb6a-456c-b3ee-3e4bb17cae6c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_5d5435db-a414-4187-ab96-c7b541b5627c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10036</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cf2a0a1-ac1f-46a0-b85d-4f4c9b831e4f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">332</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32e620bc-edf7-4179-a8d1-e1faaf566fd0" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">208-6102</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.133%;padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40.13%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.228%;box-sizing:content-box;"/>
    <td style="width:18.884%;box-sizing:content-box;"/>
    <td style="width:38.888%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:6pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">on which registered</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_1715e657-fc10-462a-823b-b91f4275ba84" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A Common Stock, Par Value $0.0001 Per Share</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9b8a8bd8-b653-4ecb-9dca-3152674f8ae7" contextRef="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants to Purchase Class A Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c5f0a450-f0e1-4f86-a1d9-cf471225e895" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NUVB</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2e605851-1881-4a2c-9083-2e7b286e2200" contextRef="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NUVB.WS</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_56a8db6d-0a27-4648-8090-3fbf2f75938c" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York Stock Exchange</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2dd03639-78df-43c2-ba0c-4bd19399d0b1" contextRef="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York Stock Exchange</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    YES  &#9744;    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a22469f-1a27-499f-951d-1d2a4c3e953c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.    YES  &#9744;    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_895fc282-4886-41dd-af22-0285ba11189e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07bef960-3c02-48e4-9cc0-68acaae5813d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    NO  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_369af07d-2631-4ffa-8318-391882853891" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    NO  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.08%;box-sizing:content-box;"/>
    <td style="width:55%;box-sizing:content-box;"/>
    <td style="width:25%;box-sizing:content-box;"/>
    <td style="width:1.92%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ecf1d241-af16-447a-8fa1-61049dd58e45" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_a2765452-d793-453a-bd1a-55614719afc4" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_68c53109-34ad-49fe-9994-93d74413e138" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb494c83-0257-45b1-a8a9-6ee65fe6d508" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6ec9839-cc52-48e1-b7eb-837debf014ee" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  &#9744;    </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d95b60dc-3e57-4efb-a0fb-0c24a0e69a13" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting common stock, par value $0.0001 per share, held by non-affiliates of the registrant computed by reference to the closing sales price for the registrant&#8217;s common stock on June 30, 2024, as reported on the New York Stock Exchange was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7970eb9e-8248-4aa4-a3fb-84ae4f1fce25" contextRef="C_a4328f73-2497-4e2b-ab79-aaa0f3d84e59" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">522,742,050</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the market value of the voting stock held by any non-affiliates, shares of common stock of the registrant beneficially owned by directors and officers have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 28, 2025, the registrant had</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61c7ca43-37d0-49ad-b956-f875652dcd7e" contextRef="C_36730653-ff82-4c63-a01f-ca2dd3b496b8" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">337,678,855</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ares of Class A common stock and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c215fe31-abc2-4c3f-8300-bc3c6383b13f" contextRef="C_11048d21-d2dd-4d6a-8603-844e4ce4caa3" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_9756ec20-3544-40c8-8f90-0e8f435f8fb8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain portions of the registrant's definitive proxy statement relating to the Company's Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.58%;box-sizing:content-box;"/>
    <td style="width:78.04%;box-sizing:content-box;"/>
    <td style="width:8.38%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i_"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#business_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factors_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#properties_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#legal_proceedings_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mine_safety_disclosures_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii_"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#registrant_common_equity_related_stock_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#selected_financial_data_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Selected Financial Data</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#discussion_analysis_financial_condition_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#quantitative_and_qualitative_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_stmt_supplementary_data_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#changes_in_disagreement_with_account_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#controls_and_procedure_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#other_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#disclosure_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#directors_executive_officers_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#executive_compensation_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#security_owner_certain_beneficial_owner_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#certain_relationship_related_trans_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#principal_acct_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv_"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits_financial_statement_schedules_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#form_10_summary_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K for the year ended December 31, 2024, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described herein under &#8220;Item 1A&#8212;Risk Factors.&#8221; You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the filing date of this Annual Report on Form 10-K. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the Securities and Exchange Commission, or the SEC, after the date of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY RISK FACTORS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found in the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; in Item 1A of this Annual Report on Form 10-K. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described in the section titled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; as part of your evaluation of an investment in our securities:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical-stage product candidates as well as our other pipeline assets will require significant further investment and regulatory approvals prior to commercialization. The FDA recently accepted for priority review the NDA for taletrectinib and we will need to obtain regulatory approval, manufacture sufficient commercial supply, build a U.S. commercial organization, and make other substantial investments before we generate any revenues from product sales. Even so, we may never achieve or maintain profitability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need substantial funding to pursue our business objectives. If we are unable to raise capital when needed or on favorable terms, or receive significant revenues from the sales of our product, we could be forced to delay, reduce or terminate our product development, other operations or commercialization efforts. Additionally, raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not obtain regulatory approval for and successfully commercialize our product candidates in one or more indications or we experience significant delays in doing so, we may never generate any revenue or become profitable.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our level of indebtedness and debt service obligations could adversely affect our financial condition and make it more difficult for us to fund our operations, and impose numerous other obligations and restrictions that will limit our operational flexibility.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our approach to the discovery and development of product candidates based on our Drug-Drug Conjugate platform is unproven and is based on novel technology, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our platform obsolete.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are very expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our preclinical studies or clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any of our products that receive regulatory approval on our own or together with collaborators.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, health information privacy and security laws and other healthcare laws and regulations including equivalent foreign laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following our recent Acquisition of AnHeart, we may have difficulty integrating AnHeart&#8217;s business, operations and employees, including those based in China.  This may cause disruption to ongoing business, divert the attention of management, and the process of combining the companies may cost more and take longer than originally anticipated.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to perform the chemistry work associated with our drug discovery and preclinical activities and to conduct our preclinical studies and future clinical trials, and our business could be substantially harmed if these third parties cease performing services or perform in an unsatisfactory manner.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of taletrectinib, safusidenib, NUV-1511, NUV-868 and our other current and future product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to maintain existing collaborations or establish new collaborations, we may have to alter some of our future development and commercialization plans.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, protect and enforce sufficient patent and other intellectual property rights for our product candidates and technology, or if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business, operations and clinical development plans and timelines and supply chain could be adversely affected by the effects of health epidemics, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our contract manufacturing organizations ("CMOs"), contract research organizations ("CROs"), shippers and others.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain Dr. Hung and our other key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dual-class structure of our common stock has the effect of concentrating voting power with our Chief Executive Officer, which limits other stockholders&#8217; ability to influence the outcome of important transactions, including a change in control.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="business_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, (the &#8220;Closing Date&#8221;), Nuvation Bio Inc., a Delaware corporation (&#8220;Legacy Nuvation Bio&#8221;), Panacea Acquisition Corp. (&#8220;Panacea&#8221;), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (&#8220;Merger Sub&#8221;) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (&#8220;Merger Agreement&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the &#8220;Merger&#8221;). On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the &#8220;Company&#8221; or &#8220;Nuvation Bio&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the closing of the Merger, our Class A common stock and warrants to purchase shares of our Class A common stock began trading on The New York Stock Exchange under the symbols &#8220;NUVB&#8221; and &#8220;NUVB.WS,&#8221; respectively, on February 11, 2021. The disclosure in Items 1 and 1A of this report gives effect to the Merger and includes the operations of Legacy Nuvation Bio prior to the Merger.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024 (the "Acquisition Date"), the Company completed its acquisition of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands (&#8220;AnHeart&#8221;), pursuant to that certain Agreement and Plan of Merger (the "AnHeart Merger Agreement"), by and among the Company, AnHeart, Artemis Merger Sub I, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company, and Artemis Merger Sub II, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Nuvation Bio&#8221; is a registered trademark of Nuvation Bio Inc. in the U.S. and other countries.  Other trademarks or service marks appearing in this report may be trademarks or service marks of other owners.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. We were founded in 2018 by our chief executive officer, David Hung, M.D., who founded Medivation, Inc. and led its successful development of oncology drugs Xtandi&#174; and talazoparib (now marketed as Talzenna&#174;), leading to its $14.3 billion sale to Pfizer Inc. (&#8220;Pfizer&#8221;) in 2016.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We leverage our team&#8217;s extensive expertise in medicinal chemistry, preclinical development, drug development, business development, manufacturing, and commercialization to pursue oncology targets validated by strong clinical or preclinical data and develop novel small molecules that improve the activity and overcome the liabilities of currently marketed drugs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foundations of our approach include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The pursuit of validated targets: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identify and pursue oncology targets validated by strong clinical or preclinical data that provide a high degree of confidence in generating clinically meaningful benefit. We focus on targets where there has been some progress by others in generating clinical candidates or approved drugs, and we then attempt to design or acquire novel or potential best-in-class product candidates to overcome the encountered safety liabilities or limitations in efficacy.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Innovative medicinal chemistry expertise:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We use our medicinal chemistry proficiency to generate differentiated product candidates, focused on improving their safety, anti-tumor activity and pharmacologic profiles over other standard of care (&#8220;SOC&#8221;) therapies. We also use innovative medicinal chemistry approaches to generate novel classes of molecules such as our drug-drug-conjugates (&#8220;DDCs&#8221;).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Human capital management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: We believe our employees are our greatest assets. Attracting, motivating and retaining talent at all levels is vital to our continued success. We are building a culture that fosters a productive, professional and inclusive work environment, where people can thrive, have fun, and be inspired to perform their best work.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our product candidate pipeline:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img58233625_0.jpg" alt="img58233625_0.jpg" style="width:624px;height:232px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (&#8220;ROS1&#8221;) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer ("NSCLC"). In October 2024, we announced submission of a U.S. New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the full approval of taletrectinib for the treatment of patients with advanced ROS1+ NSCLC (line agnostic).  On December 22, 2024, the FDA accepted the NDA and assigned a Prescription Drug User Fee Action (&#8220;PDUFA&#8221;) target action date of June 23, 2025. In China, taletrectinib has been approved for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 tyrosine kinase inhibitors ("TKIs"), and is being commercialized in China by our partner Innovent Biologics (Suzhou) Co. Ltd. (&#8220;Innovent&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to taletrectinib, our clinical-stage pipeline includes differentiated, novel oncology product candidates that have been generated from our proprietary drug discovery and development programs or acquired through business development activities:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (&#8220;mIDH1&#8221;). Safusidenib is being evaluated in a global Phase 2 study for the treatment of patients with diffuse mIDH1 glioma. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-1511, our first clinical-stage DDC fuses a targeting agent to a widely used chemotherapy agent that suppresses the growth of various advanced solid tumors. NUV-1511 is being evaluated in a Phase 1/2 study for the treatment of patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu&#174; and/or Trodelvy&#174; per approved U.S. FDA labeling, human epidermal </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">growth factor receptor 2-negative (&#8220;HER2-&#8221;) metastatic breast cancer, mCRPC, advanced pancreatic cancer, and platinum-resistant ovarian cancer (&#8220;PROC&#8221;).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-868, a binding domain 2 (&#8220;BD2&#8221;)-selective, oral, small molecule bromodomain and extra-terminal (&#8220;BET&#8221;) inhibitor that inhibits bromodomain-containing protein 4 (&#8220;BRD4&#8221;). We are evaluating next steps for the NUV-868 program, including external partnership opportunities or further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to deliver meaningful benefit to patients with serious unmet medical needs in oncology by developing and commercializing novel and differentiated therapies. The core elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Building a fully integrated biotechnology company that includes research, development, manufacturing, and commercial capabilities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rapidly developing taletrectinib for the treatment of advanced ROS1+ NSCLC and seeking global regulatory approvals. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advancing the ongoing clinical development of our other clinical-stage product candidates: safusidenib, NUV-1511 and NUV-868.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leveraging our deep insights in medicinal chemistry to pursue innovative clinical candidates and our business development expertise to identify and in-license or acquire additional promising drug candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying strategic opportunities to accelerate development timelines and maximize the value of our pipeline.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taletrectinib: ROS1 Inhibitor Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. In October 2024, we announced submission of a U.S. NDA to the FDA for the full approval of taletrectinib for the treatment of patients with advanced ROS1+ NSCLC (line agnostic). On December 22, 2024, the FDA accepted the NDA and assigned a PDUFA target action date of June 23, 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each year, more than one million people globally are diagnosed with NSCLC, the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease (Lin et al 2017; Zhang et al 2019). Up to 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that spread to their brain, increasing up to 55% for those whose cancer has progressed following initial treatment (Ou et al 2019). There are currently three FDA approved TKIs for the treatment of patients with ROS1+ NSCLC: Xalkori (crizotinib), Rozlytrek (entrectinib) and, most recently, Augtyro (repotrectinib). However, there remains a need for more effective and tolerable treatment options. We believe taletrectinib has a potentially best-in-class efficacy and safety profile, including overall response rate, durable responses, prolonged progression-free survival, brain penetrance to improve outcomes for patients with brain metastases, activity against tumors that have developed resistance mutations to approved ROS1 TKIs such as G2032R, and a low rate of treatment discontinuation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taletrectinib Phase 2 Clinical Studies Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taletrectinib is currently being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study. TRUST-I is a pivotal Phase 2, multicenter, single-arm, open-label study evaluating taletrectinib as a monotherapy in 173 patients with advanced ROS1+ NSCLC in China who had either not previously been treated with a ROS1 TKI (&#8220;TKI-na&#239;ve&#8221;) or had previously been treated with a crizotinib (&#8220;TKI-pretreated&#8221;). Almost all patients received 600 mg of taletrectinib orally once-a-day in 21-day treatment cycles. 21% of TKI-na&#239;ve patients and 34% of TKI-pretreated patients had received prior chemotherapy. TRUST-II is a pivotal Phase 2, global, multicenter, single-arm, open-label study evaluating taletrectinib as a monotherapy in 153 patients (Cohort 1 - 4) with advanced ROS1+ NSCLC.  Pivotal cohorts of TRUST-II consisted of Cohort 1 who are TKI-na&#239;ve patients and Cohort 2 who had one prior line of TKI (crizotinib or entrectinib). Cohorts 3 and 4 are exploratory cohorts.  All patients received 600 mg of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taletrectinib orally once-a-day in 21-day treatment cycles. 20% of TKI-na&#239;ve patients (Cohort 1) and 38% of TKI-pretreated patients (Cohort 2) had received prior chemotherapy. For both TRUST-I and TRUST-II, the primary endpoint is confirmed objective response rate (&#8220;cORR&#8221;) as assessed by independent review committee (&#8220;IRC&#8221;), and key secondary endpoints include duration of response (&#8220;DOR&#8221;), progression-free survival (&#8220;PFS&#8221;), and safety.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img58233625_1.jpg" alt="img58233625_1.jpg" style="width:624px;height:291px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pooled Phase 2 TRUST-1 and TRUST-II Study Results (Interim)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced interim pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in patients with advanced ROS1+ NSCLC, which was presented at the European Society of Medical Oncology Congress 2024. These pooled results utilized a June 7, 2024 data cut off and were used to support our U.S. NDA submission that was submitted in October 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">       </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pooled pivotal data included 337 patients with advanced ROS1+ NSCLC who received 600mg of taletrectinib orally once a day in 21-day treatment cycles. The pooled efficacy analyses included 273 response evaluable patients, including 160 patients who had not previously been treated with a ROS1 TKI (&#8220;TKI-na&#239;ve&#8221;) and 113 patients who had previously been treated with crizotinib or entrectinib (&#8220;TKI-pretreated&#8221;). Among these two populations, 94% of patients had stage IV NSCLC. In addition, 20% of TKI-na&#239;ve and 37% of TKI-pretreated patients received prior chemotherapy, while 23% of TKI-na&#239;ve and 49% of TKI-pretreated patients had brain metastases at baseline. The pooled safety population (n=337) included patients enrolled from 5 Phase 1 or 2 trials involving cancer patients, including TRUST-I, TRUST-II.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OVERVIEW OF POOLED PHASE 2 TRUST-I AND TRUST-II RESPONSE EVALUABLE POPULATION</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img58233625_2.jpg" alt="img58233625_2.jpg" style="width:624px;height:300px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efficacy results of the pooled analysis, as independently assessed by an IRC, showed:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In TKI-na&#239;ve patients (n=160):</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tumors shrank in 89% of taletrectinib-treated patients (cORR).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Measurable brain metastases shrank in 77% (13/17) of taletrectinib-treated patients (intracranial cORR).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After median follow-up of 21 months, the median DOR and the median PFS were 44 months and 46 months, respectively.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In TKI-pretreated patients (n=113):</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tumors shrank in 56% of taletrectinib-treated patients (cORR).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Measurable brain metastases shrank in 66% (21/32) of taletrectinib-treated patients (intracranial cORR).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tumors shrank in 62% (8/13) of taletrectinib-treated patients with G2032R mutations (cORR).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After median follow-up of 21 months, the median DOR and the median PFS were 17 months and 10 months, respectively.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pooled safety analysis included 337 patients with advanced ROS1+ NSCLC. The results demonstrated a favorable safety and tolerability profile, with a low incidence and a limited spectrum of neurologic TEAEs and a low rate of treatment discontinuation. The most frequent TEAEs were increased aspartate aminotransferase (72%; 8% &#8805; Grade 3), alanine aminotransferase (68%; 10% &#8805; Grade 3), diarrhea (63%; 2% &#8805; Grade 3), and nausea (47%; 2% &#8805; Grade 3). The incidence of neurologic TEAEs was low; the most common were dizziness (21%) and dysgeusia (15%), most of which were Grade 1. The rate of treatment discontinuation due to TEAEs was 7% and the rate of dose reduction due to TEAEs was 29%.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Clinical Studies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are evaluating other potential clinical studies of taletrectinib for the treatment of various ROS1+ cancer indications.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taletrectinib Regulatory Status</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2024, we announced submission of a U.S. NDA to the FDA for the full approval of taletrectinib for the treatment of patients with advanced ROS1+ NSCLC (line agnostic).  In December 2024, the FDA accepted the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NDA with Priority Review designation and assigned a PDUFA target action date of June 23, 2025. Taletrectinib has been granted Orphan Drug Designation by the FDA for the treatment of patients with ROS1+ NSCLC and other NSCLC indications, and Breakthrough Therapy Designation for the treatment of adult patients with advanced or metastatic ROS1+ NSCLC who are ROS1 TKI treatment na&#239;ve or previously treated with crizotinib.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In China, taletrectinib has been approved for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Taletrectinib In-License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, AnHeart Therapeutics Inc. (&#8220;AHT&#8221;), a wholly owned subsidiary of AnHeart, entered into a license agreement with Daiichi Sankyo, pursuant to which Daiichi Sankyo granted to AHT exclusive worldwide rights to develop and commercialize taletrectinib (the &#8220;Taletrectinib In-License Agreement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, under the Taletrectinib In-License Agreement, we have paid Daiichi Sankyo $9.0 million in connection with an upfront payment and the achievement of development and regulatory milestones. In addition, we are obligated to pay up to $14.0 million upon achievement of additional regulatory milestones, up to $20.0 million upon achievement of commercial sales milestones, and a high single-digit percentage royalty based on worldwide net sales subject to certain adjustments. Our obligation to pay royalties under the Taletrectinib In-License Agreement will expire on a country-by-country basis upon the later of the expiration of the last valid claim of a patent licensed under the Taletrectinib In-License Agreement covering taletrectinib, and ten years after the first commercial sale of taletrectinib in such country.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Taletrectinib In-License Agreement will continue in effect until we cease all commercial activity related to taletrectinib. We may terminate the Taletrectinib In-License Agreement on a country-by-country basis or in its entirety upon 6 months prior written notice if we have bona fide material concerns regarding the lack of efficacy of taletrectinib, if patent claim(s) covering taletrectinib are invalidated in the relevant jurisdiction, or if taletrectinib is determined to infringe one or more claims of a third-party patent. Daiichi Sankyo may terminate the Taletrectinib In-License Agreement due to our insolvency or bankruptcy, or if we challenge any patents licensed under the Taletrectinib In-License Agreement. Either party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days (or, if such material breach cannot be cured within 90 days, if the other party does not commence and diligently continue actions to cure such breach during such 90 days).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We need Daiichi Sankyo&#8217;s prior written consent to grant sublicenses under the rights licensed to us under the Taletrectinib In-License Agreement, provided that any denial of approval by Daiichi Sankyo must be made in good faith based on reasonable concerns. Furthermore, under certain circumstances, we need Daiichi Sankyo&#8217;s prior consent to assign our rights under the Taletrectinib In-License Agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taletrectinib Out-License Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, AnHeart Therapeutics (Hangzhou) Co. Ltd. (&#8220;AHT Hangzhou&#8221;), a wholly owned subsidiary of AnHeart, entered into a collaboration and license agreement with Innovent (the &#8220;Innovent Agreement&#8221;), pursuant to which AHT Hangzhou granted to Innovent exclusive rights to commercialize taletrectinib in mainland China, Hong Kong, Macau and Taiwan (collectively, the &#8220;Innovent Territory&#8221;), as well as certain development rights within the Innovent Territory. To date, pursuant to the Innovent Agreement, AHT Hangzhou has received $67.0 million in connection with an upfront payment, reimbursement of research and development expenses, and achievement of regulatory milestones. In addition, we may receive up to $17.0 million upon achievement of additional regulatory milestones, up to $105.0 million upon achievement of commercial milestones, and tiered percentage royalties ranging from mid-teen to low-twenties on annual net sales of taletrectinib in the Innovent Territory subject to certain adjustments. Innovent&#8217;s obligation to pay royalties under the Innovent Agreement will expire on a country-by-country basis upon the later of the expiration of the last valid claim of a patent licensed under the Taletrectinib In-License Agreement covering taletrectinib, and ten years after the first commercial sale of taletrectinib in such country. The Innovent Agreement will continue in effect until Innovent ceases all commercial activity related to taletrectinib in the Innovent Territory or termination of the Taletrectinib In-License Agreement. We may terminate the Innovent Agreement if Innovent challenges any patents licensed to it under the Innovent Agreement. Innovent may terminate the Innovent Agreement upon one-month&#8217;s prior written notice if it has bona fide material concerns regarding the lack of safety or efficacy of taletrectinib. Either party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days (or, if such material breach cannot be cured within 90 days, if the other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">party does not commence and diligently continue actions to cure such breach during such 90 days), or due to insolvency or bankruptcy of the other party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, AHT entered into a collaboration and license agreement with Nippon Kayaku Co., Ltd. (&#8220;NK&#8221;, and such agreement, the &#8220;NK Agreement&#8221;), pursuant to which AHT granted to NK exclusive rights to commercialize taletrectinib for all human indications in Japan (the &#8220;NK Territory&#8221;), and exclusive rights to research and develop taletrectinib for any indication other than ROS1+ NSCLC in Japan subject to AnHeart&#8217;s prior approval. Pursuant to the NK Agreement, AHT received a $40.0 million upfront payment. In addition, we may receive $25.0 million upon achievement of a regulatory milestone, up to $35.0 million upon achievement of commercial milestones, and a lower-mid double digit percentage royalty on net sales of taletrectinib in the NK Territory. The NK Agreement will continue in effect until the later of first sale of a first generic for taletrectinib for which a drug reimbursement price has been established in the NK Territory, and our obligation to pay royalties under the Taletrectinib In-License Agreement for net sales of taletrectinib in the NK Territory. We may terminate the NK Agreement if NK challenges any patents licensed to it under the NK Agreement. NK may terminate the NK Agreement upon 90 days prior written notice if it has bona fide material concerns regarding the lack of safety or efficacy of taletrectinib, or at any time after first commercial sale of taletrectinib upon 6 month&#8217;s prior written notice. Either party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days (or, if such material breach cannot be cured within 90 days, if the other party does not commence and diligently continue actions to cure such breach during such 90 days), and AHT may terminate the agreement due to insolvency or bankruptcy of NK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safusidenib: mIDH1 Inhibitor Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mIDH1, which is detected in various tumors, including gliomas. IDH proteins play a critical role in the citric acid cycle, also known as the tricarboxylic acid cycle or Krebs cycle, by catalyzing the conversion of isocitrate to &#945;-ketoglutarate. Mutant IDH catalyzes abnormal conversion of &#945;-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG). Accumulation of 2-HG leads to tumorigenesis by inducing changes in various cellular processes, including epigenetic dysregulation. Most patients with IDH mutant glioma harbor the mIDH1 subtype known as IDH1R132H (Machida et al 2020). The Central Brain Tumor Registry of the United States estimated that the incidence of IDH-mutant glioma in the United States in 2018-2021 to be approximately 9,600 total cases (approximately 2,400 new cases per year).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safusidenib has high blood&#8211;brain barrier (&#8220;BBB&#8221;) permeability and inhibits mIDH1, including the subtype IDH1R132H. Continuous administration of safusidenib impaired tumor growth and decreased 2-HG levels in subcutaneous and intracranial xenograft models derived from a patient with mIDH1-positive glioblastoma. Moreover, the expression of glial fibrillary acidic protein was strongly induced by safusidenib, suggesting that inhibition of mIDH1 promotes glial differentiation (Machida et al 2020).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Study Results</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Phase 1 (NCT03030066) multicenter, open-label, dose-escalation study evaluating safusidenib as a monotherapy in 47 patients was conducted in Japan and sponsored by Daiichi Sankyo Co., Ltd. Patients were divided into enhancing and non-enhancing groups based on the presence or absence of tumor contrast enhancement judged by each investigator at the time of enrollment. Tumor response was assessed by Response Assessment in Neuro-Oncology (&#8220;RANO&#8221;) for enhancing tumors and RANO-low grade glioma (&#8220;RANO-LGG&#8221;) for non-enhancing tumors. Tumors that show enhancement on MRI scans tend to have more vascularization and disruption to the blood-brain barrier and are generally associated with a higher degree of malignancy compared with non-enhancing tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The objective response rates were 17.1% for enhancing tumors and 33.3% for non-enhancing tumors. Two complete responses were observed: one complete response in a grade 4 astrocytoma and one complete response in the target lesions of a grade 3 oligodendroglioma (with stable disease in non-target lesions).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum tolerated dose was not reached.  Most adverse events (AEs) were grade 1-2. Twenty patients (42.6%) experienced at least one grade 3 AE. No grade 4 or 5 AEs or serious drug-related AEs were reported. Common AEs (&gt;20%) were skin hyperpigmentation, diarrhea, pruritus, alopecia, arthralgia, nausea, headache, rash, back pain, and dry skin. Seven on-treatment brain tumor samples showed a significantly lower amount of D-2-HG compared with pre-study archived samples.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAFUSIDENIB EARLY-STAGE DATA SHOWED HIGHER RESPONSE RATES THAN VORASIDENIB IN LOW-GRADE (NON-ENHANCING) AND HIGH-GRADE (ENHANCING) DIFFUSE mIDH1 GLIOMA</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img58233625_3.jpg" alt="img58233625_3.jpg" style="width:624px;height:271px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan for Safusidenib in mIDH1 Glioma</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting a Phase 2 global study to evaluate safusidenib&#8217;s safety, efficacy, and pharmacokinetics in patients with diffuse mIDH1 glioma. In the first stage of the study, we are exploring five dosing regimens and will evaluate safety parameters including adverse events and efficacy including objective response rate. We are evaluating potential designs for the second, dose-expansion stage of the study, and for potential pivotal studies.</span><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safusidenib Phase 1 and Phase 2 Clinical Study Overview</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img58233625_4.jpg" alt="img58233625_4.jpg" style="width:624px;height:254px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safusidenib In-License Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2020, AHT entered into a license agreement with Daiichi Sankyo, pursuant to which Daiichi Sankyo granted to AHT exclusive worldwide (other than Japan) rights to develop and commercialize safusidenib for all human prophylactic or therapeutic uses (the &#8220;Safusidenib In-License Agreement&#8221;). Daiichi Sankyo retains the right to develop and commercialize safusidenib in Japan.</span><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, under the Safusidenib In-License Agreement, AHT has paid Daiichi Sankyo $9.0 million in connection with an upfront payment and the achievement of a development milestone. In addition, we are obligated to pay up to $6.0 million upon achievement of additional development milestones, up to $50.0 million upon achievement of regulatory milestones, up to $45.0 million upon achievement of commercial sales milestones, and a high single-digit percentage royalty based on worldwide net sales subject to certain adjustments. Our obligation to pay royalties under</span><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Safusidenib In-License Agreement will expire on a country-by-country basis upon the later of the expiration of the last valid claim of a patent licensed under the Safusidenib In-License Agreement covering safusidenib, and ten years after the first commercial sale of safusidenib in such country.</span><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Safusidenib In-License Agreement will continue in effect until we cease all development and commercial activity related to safusidenib. We may terminate the Safusidenib In-License Agreement on a country-by-country basis or in its entirety upon 6 months prior written notice if we have bona fide material concerns regarding the lack of efficacy of safusidenib, if all patent claims covering safusidenib are invalidated in the relevant jurisdiction, or if safusidenib is determined to infringe one or more claims of a third-party patent. Daiichi Sankyo may terminate the Safusidenib In-License Agreement if due to our insolvency or bankruptcy, or if we challenge any patents licensed under the Safusidenib In-License Agreement. Either party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days (or, if such material breach cannot be cured within 90 days, if the other party does not commence and diligently continue actions to cure such breach during such 90 days).</span><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We need Daiichi Sankyo&#8217;s prior written consent to grant sublicenses under the rights exclusively licensed to us under the Safusidenib In-License Agreement, which Daiichi Sankyo shall not unreasonably withhold. Furthermore, we need Daiichi Sankyo&#8217;s prior consent to assign our rights under the Safusidenib In-License Agreement, such consent not to be unreasonably withheld.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Our DDC Platform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foundations of our DDCs are built by employing tissue-targeting small molecules fused to anti-cancer warheads of existing drugs with well- understood mechanisms of action. Our platform leverages our drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Our DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues. The figure below depicts our DDC approach.</span><span style="color:#1d242a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DRUG-DRUG CONJUGATES ARE DESIGNED TO BIND TWO DIFFERENT TARGETS SIMULTANEOUSLY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img58233625_5.jpg" alt="img58233625_5.jpg" style="width:624px;height:276px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key potential benefits of our DDCs include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tissue-selective targeting improves therapeutic index vs. untargeted warhead; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Oral or IV delivery;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Binds intracellular and cell membrane targets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Highly cell permeable; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simpler and less expensive to manufacture than antibody-drug conjugates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NUV-1511: A Targeted DDC Derived from a Widely Used Chemotherapy Agent for Advanced Solid Tumors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-1511, our first clinical-stage DDC, fuses a targeting agent to a widely used chemotherapy agent that suppresses the growth of various advanced solid tumors. We believe NUV-1511 may be able to limit the adverse side effects of the chemotherapy agent while effectively targeting various advanced solid tumors, including prostate and breast cancer.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical data for NUV-1511</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The potential anti-tumor efficacy of NUV-1511 was evaluated in a prostate cancer cell line derived xenograft model (LNCaP). As shown in the figure below, NUV-1511 demonstrated significant tumor growth inhibition with IV dosing. Of note, the DDC targeting ligand or chemotherapy agent alone did not inhibit tumor growth to the extent of NUV-1511.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-1511 was also examined in an ER+/PR+ breast cancer cell line derived xenograft model (T47D). As shown below, NUV-1511 caused significant tumor regressions. The DDC targeting ligand or the chemotherapeutic agent were less effective in inhibiting tumor growth.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-1511, A DDC DERIVATIVE OF A WIDELY USED CHEMO AGENT, SUPPRESSES PROSTATE AND BREAST CANCER GROWTH IN XENOGRAFTS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img58233625_6.jpg" alt="img58233625_6.jpg" style="width:624px;height:276px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, as shown in the figure below, in a prostate cancer xenograft model, intermittent dosing regimens with NUV-1511 were sufficient to cause significant tumor regression up to 28-days, while continuous or intermittent dosing with the chemotherapeutic agent were markedly less effective in inhibiting tumor growth.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">INTERMITTENT DOSING OF NUV-1511 LEADS TO SUSTAINED TUMOR INHIBITION FOR WEEKS</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img58233625_7.jpg" alt="img58233625_7.jpg" style="width:623px;height:293px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan for NUV-1511</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we treated the first patient in a Phase 1/2 study of NUV-1511. The study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for signs of clinical activity in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu&#174; and/or Trodelvy&#174; per approved U.S. FDA labeling, human epidermal growth factor receptor 2-negative (&#8220;HER2-&#8221;) metastatic breast cancer, mCRPC, advanced pancreatic cancer, and platinum-resistant ovarian cancer (&#8220;PROC&#8221;). The dose escalation portion of the study employs a flexible design that allows for the potential to explore two dosing schedules for NUV-1511, with the goal of establishing the recommended Phase 2 dose.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NUV-1511 Clinical Study Overview</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img58233625_8.gif" alt="img58233625_8.gif" style="width:624px;height:255px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NUV-868: BET Inhibitor Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-868, a BD2-selective oral small molecule BET inhibitor, inhibits BRD4, a key member of the BET family that epigenetically regulates proteins that control tumor growth and differentiation. BETs consist of two sub-domains: BD1, the inhibition of which is known to contribute to toxicity, and BD2, the inhibition of which is expected to be important for efficacy. BET inhibitors have historically targeted both BD1 and BD2 less selectively, causing gastrointestinal toxicity and bone marrow suppressive effects like thrombocytopenia.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging evidence suggests distinct roles for the BD1 and BD2 domains of BET proteins (Gilan et al 2020). Inhibition of BD1 may play a predominant role in regulating steady state gene expression through the displacement of BET proteins already associated with histones. Inhibition of BD1 has also been associated with toxicity (including bone marrow suppression and gastrointestinal effects), which together may limit the therapeutic window for agents which potently inhibit BD1. In contrast, inhibition of the BD2 domain may play a predominant role in regulating rapid gene induction by preventing BET proteins from associating with histones. BD2 selective agents have demonstrated efficacy in both cancer and inflammatory models, while having more limited effects on bone marrow and gastrointestinal cells and may therefore have a wider therapeutic window than non-BD2 selective BET inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Potential Solution&#8212;NUV-868</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-868 is a small molecule BD2-selective BETi for the treatment of solid tumors that is almost 1,500 times more selective for BD2 than BD1, which may potentially enable this molecule to reduce the toxicities associated with other non-BD2 selective inhibitors. Given BET&#8217;s potential as an oncology target, there are several BET inhibitors in development for several cancers. Other BET inhibitors that are not as selective for BD2, have been associated with toxicities including bone marrow, gastrointestinal and thrombocytopenia. The selectivity of several BET inhibitors that are currently in development is shown in the table below.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-868 IS A MORE SELECTIVE BD2 INHIBITOR</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IC50 values of NUV-868 and other BET inhibitors in development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
<br/></span><img src="img58233625_9.jpg" alt="img58233625_9.jpg" style="width:624px;height:249px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Study Results in Advanced Solid Tumors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we initiated a Phase 1 monotherapy dose escalation study of NUV-868 in patients with advanced solid tumors to determine a maximum tolerated dose. In December 2022, we initiated a Phase 1b dose escalation study of NUV-868 in combination with olaparib in patients with ovarian cancer, pancreatic cancer, mCRPC, TNBC, and other solid tumors, and in combination with enzalutamide in patients with mCRPC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we announced completion of an internal analysis of efficacy and safety data collected from the Phase 1 monotherapy and Phase 1b combination studies of NUV-868. Following this analysis, Nuvation Bio decided not to initiate a Phase 2 study of NUV-868 as a monotherapy or in combination with olaparib or enzalutamide in the advanced solid tumor indications that were part of the Phase 1 and Phase 1b study designs. We are evaluating next steps for the NUV-868 program, including external partnership opportunities or further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries for our investigational products, to operate without infringing valid and enforceable patents and proprietary rights of others, and to prevent others from infringing on our proprietary or intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We generally seek to protect our proprietary position by pursuing patents that cover the compositions of matter, formulations, methods of use or methods of synthesis relating to our investigational products, as well as other discoveries, technologies, inventions and improvements that may be commercially important to our business. For our product candidates, we generally seek patent protection in the U.S. and in certain foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, taletrectinib is covered by patent families that we either own or have exclusively licensed from Daiichi Sankyo worldwide. These patent families cover the composition of matter of taletrectinib, methods of use thereof, or methods of manufacturing thereof. These patents families include issued patents as well as pending patent applications in the U.S. and certain foreign jurisdictions, and patents that have issued or may issue from these patent families are expected to expire from 2033 to 2042 (not including patent term adjustment or extension that may be available to extend the term of such patents).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For safusidenib, as of December 31, 2024, we have an exclusive worldwide (other than Japan) license from Daiichi Sankyo to patent families that cover the composition of matter of safusidenib, methods of use thereof, or methods of manufacturing thereof. These patents families include issued patents as well as pending patent applications in the U.S. and certain foreign jurisdictions, and patents that have issued or may issue from these patent families are expected to expire from 2035 to 2041 (not including patent term adjustment or extension that may be available to extend the term of such patents).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For the DDC platform, as of December 31, 2024, we own patent families that cover the composition of matter of our DDC compounds, including NUV-1511, or methods of use thereof. These patent families include issued patents as well as pending patent applications in the U.S. and certain foreign jurisdictions, and patents that have issued or may issue from these patent families are expected to expire from 2039 to 2043 (not including patent term adjustment or extension that may be available to extend the term of such patents).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For NUV-868, as of December 31, 2024, we own patent families that cover the composition of matter of NUV-868 or methods of use thereof. These patents families include issued patents as well as pending patent applications in the U.S. and certain foreign jurisdictions, and patents that have issued or may issue from these patent families are expected to expire from 2040 to 2044 (not including patent term adjustment or extension that may be available to extend the term of such patents).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the extensive time required for development, testing and regulatory review of an investigational product, it is possible that, before a product can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. In the U.S., the term of a patent covering an FDA-approved product may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended and the amount of available extension to any patent term extension-eligible patent depends on a variety of factors, including the date on which the patent issues and certain dates related to the regulatory review period. Possible extensions may be available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved product. While we intend to seek patent term extensions in any jurisdictions where they are available to us, there is no guarantee that the applicable authorities, including the FDA or the USPTO, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our trademarks are protected under the common law and/or by registration in the United States and other countries. We also rely on trade secrets to protect our technology and product candidates, especially where we do not believe patent protection is appropriate or obtainable.  We seek to protect our proprietary information, in part, using confidentiality agreements with our partners, collaborators, employees and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success may depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strategies, obtain licenses or cease certain activities. Our failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drug products may have a material adverse impact on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The intellectual property positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific, and factual issues. For information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our investigational products for preclinical and clinical testing, as well as for commercial manufacture. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational products, as well as for our commercial products if regulatory approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently developing a second source for taletrectinib API and drug product, respectively.  For our other investigational products, we have obtained APIs and drug product from various single-source third-party CMOs. We are in the process of developing our supply chain for each of our investigational products and intend to put in place framework agreements under which CMOs will generally provide us with necessary quantities of API and drug product on a project-by-project basis based on our development needs, and which agreements will provide us with intellectual property rights necessary to conduct the business. We seek to use a different CMO for each investigational product and will consider further diversification of drug product and supply organizations as circumstances warrant. Overall, as we advance our investigational products through development, we will start by seeking multiple sources for raw materials and address other potential points of concern over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our investigational products on our own, or potentially with a partner, in the U.S. and other regions. For example, we have out-licensed the commercialization of taletrectinib in certain countries in Asia as described above under the caption &#8220;Taletrectinib: ROS1 Inhibitor Program&#8212; Taletrectinib Out-License Agreements&#8221;, except that we assist Innovent with certain commercialization activities in China.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the U.S. and potentially other regions, we intend to build the necessary infrastructure and sales, marketing and commercial product distribution capabilities. Clinical data, the size of the addressable patient population and the size of the commercial infrastructure and manufacturing needs and economics related to the foregoing may all influence or alter our commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of cancer therapies. Any investigational products that we successfully develop and commercialize will compete with new therapies that may become available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients. There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation (&#8220;Novartis&#8221;), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Roche.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved for the treatment of advanced ROS1+ NSCLC, we expect that taletrectinib would compete against approved drugs including Pfizer&#8217;s Xalkori&#174;, Roche&#8217;s Rozlytrek&#174;, and BMS&#8217;s Augtyro&#174;. Other ROS1 inhibitors currently in clinical-stage development include Nuvalent&#8217;s zidesamtinib.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved for the treatment of mIDH1 low grade glioma, we expect that safusidenib would compete against Servier&#8217;s Voranigo&#174; (vorasidenib).  Another mIDH1 currently in clinical development for mIDH1 glioma is Rigel&#8217;s olutasidenib.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DDC programs targeting hormone receptors in cancer cells apply to types of cancer that may depend on hormone receptors for their growth, such as ER+ mBC, prostate cancer and ovarian cancer. All of these tumors have commercially available therapies including therapies from AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Janssen Pharmaceutical Companies, Novartis, Pfizer, Roche and Sanofi. In addition, many new product candidates are being developed as monotherapy or in combination with other drugs for these tumors type, and the most advanced of these development programs are in Phase 3 and may lead to near-term regulatory approval and subsequent commercialization. These development programs include those of the companies named above as well as numerous others. Some of these drugs and drug candidates target hormone receptor pathways directly, while many others may affect cancer cell growth through different mechanisms of action.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For NUV-868, we are aware of several clinical-stage BET inhibitors being developed for patients with hematological malignancies and solid tumors, including, but not limited to, product candidates from MorphoSys, Opna Bio, Plexxikon, Zenith Epigenetics, Incyte, Boehringer Ingelheim, Abbvie, BMS, Jacobio, Foghorn Therapeutics, GSK, Betta Pharmaceuticals, Ranok Therapeutics and Epigenetix. In addition, there are a number of BET inhibitors at the preclinical stage. To our knowledge, there is currently no commercially available BET inhibitor and the most advanced BET inhibitor is in a Phase 3 clinical trial (pelabresib for myelofibrosis).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and enrolling subjects for our clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer or more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or comparable foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our investigational products, if approved, are likely to be their degree of efficacy, tolerability profile, convenience and price, the effectiveness of companion diagnostics (if required), the level of biosimilar or generic competition and the availability of reimbursement from government and other third-party payors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the U.S. at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. The requirements and processes governing these activities vary from country to country. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Drug Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the FDA regulates drugs under the Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;). Drugs also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are considered small molecule drugs and must be approved by the FDA through the new drug application (&#8220;NDA&#8221;) process before they may be legally marketed in the U.S. The process generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well controlled human clinical trials in accordance with applicable IND regulations, current Good Clinical Practice ("GCP") requirements and other clinical trial-related protocols and regulations to establish substantial evidence of the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA after completion of all pivotal trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA filing to assess compliance with GCP; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) and the potential requirement to conduct post-approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any current and future product candidates will be granted on a timely basis, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies and IND</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and eligibility criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB must also approve the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will generally accept a well-designed and well conducted foreign clinical trial not conducted under an IND if the clinical trial is conducted in compliance with GCP and the FDA is able to validate the data through an onsite inspection, if deemed necessary. An NDA based solely or predominantly on foreign clinical data meeting U.S. criteria for marketing approval may be approved if (1) the foreign data are applicable to the U.S. population and U.S. medical practice, (2) the studies have been performed by clinical investigators of recognized competence and (3) the FDA is able to validate the data through an onsite inspection or other appropriate means, if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials in the U.S. generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:5.463%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.799179157366956%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.463%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.799179157366956%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose and dosing schedule required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.463%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.799179157366956%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, are conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Sponsor is also responsible for submitting written IND safety reports, including reports of serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">testing that suggest a significant risk for human subjects, and any clinically significant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides recommendations for whether a trial may move forward at designated check-points based on access to certain data from the trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal safety studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process, as performed by the manufacturing facility, must be capable of consistently producing quality batches of our product candidates. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their labeled shelf life.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Regulation of Companion Diagnostics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate may rely upon an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostic for use in selecting the patients that will be more likely to respond to that therapy. If an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostic is essential to the safe and effective use of the therapeutic product, then the FDA generally will require approval or clearance of the diagnostic at the same time that the FDA approves the therapeutic product. According to FDA guidance, a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;IDE&#8221;) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational trial, if the trial meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the trial plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuing FDA approval of an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostic would require either a pre-market notification, also called 510(k) clearance, or a pre-market approval (&#8220;PMA&#8221;) for that diagnostic. The review of companion diagnostics involves coordination of review with the FDA&#8217;s Center for Devices and Radiological Health. The original PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years or longer. The applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, including information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reliable results in the context of its intended use. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NDA Review Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submitted to the FDA as part of an NDA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for approval to market the drug in the U.S. for one or more specified indications and must contain proof of safety and efficacy for a drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The application must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be legally marketed in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), as amended, each NDA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for each marketed human drug. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies and/or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making the product available in the U.S. for this type of disease or condition will be recovered from sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our product candidates for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication. If one of our product candidates designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting with the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. FDA may further require that any required confirmatory trial(s) are substantially underway at the time of accelerated approval.  FDA may withdraw drug approval or require changes to the labeled indication of the drug if confirmatory post-market trials fail to verify clinical benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse events and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &#8220;off-label promotion,&#8221; and limitations on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters, or holds on post-approval clinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or revocation of product approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and such promotion must be consistent with FDA-approved labelling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other U.S. Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical manufacturers are subject to various healthcare laws, regulations, and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Our conduct, including those of our employees, as well as our business operations and relationships with third parties, including current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market, and distribute any products for which we obtain marketing approval. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, (collectively, the &#8220;Affordable Care Act&#8221;) provides that the government may assert that a claim including items or services </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal false claims laws, including the civil False Claims Act that can be enforced by private citizens through civil whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> actions, and civil monetary penalties law prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their implementing regulations also impose obligations on covered entities such as health insurance plans, healthcare clearinghouses, and certain healthcare providers and their respective business associates and their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information regarding certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and require the registration of their sales representatives, state laws that require biotechnology companies to report information on the pricing of certain drug products, and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. In addition, the distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act as well as other applicable consumer safety requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to comply can result in significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Patent-Term Restoration and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents, or U.S. patent applications, if issued, may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever is later, and the submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;), or a 505(b)(2) NDA submitted by another company for a generic version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness or generate such data themselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union Drug Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, medicinal products are subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory authorities has been obtained.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20, or CTD, and related national implementing legislation of EU Member States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increasing their transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. The CTR foresaw a three-year transition period that ended on January 31, 2025. Since this date, all new or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ongoing trials are subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union Drug Review and Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Economic Area (&#8220;EEA&#8221;), which comprises the 27 Member States of the European Union and three European Free Trade Association States (Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain an MA for a product in the EEA, an applicant must submit a Marketing Authorization Application (&#8220;MAA&#8221;) either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in the EEA countries (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The centralized procedure provides for the grant of a single MA by the European Commission that is valid for all EEA countries. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure in the EEA, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EEA country in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EEA countries who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EEA countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EEA country to apply for this authorization to be recognized by the competent authorities in other EEA countries. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EEA countries of the MA of a medicinal product by the competent authorities of other EEA countries. The holder of a national MA may submit an application to the competent authority of an EEA country requesting that this authority recognize the MA delivered by the competent authority of another EEA country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EEA country in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the eCTD (Common Technical Document) providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the EEA countries may decide on justified grounds relating to pharmacovigilance, to proceed with one further five- year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EEA country within three years after authorization ceases to be valid (the so-called sunset clause).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our products, if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., for example, principal decisions about reimbursement for new products are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of our products. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Additionally, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;), established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment limitations in setting their own payment rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in case a drug product needs companion diagnostics, then companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, in the EEA, some countries provide that products may be marketed only after a reimbursement price has been agreed, and other countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called Health Technology Assessments (&#8220;HTAs&#8221;) in order to obtain reimbursement or pricing approval. HTAs of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. In December 2021, Regulation No 2021/2282 on HTA, was adopted in the EU. This Regulation, which entered into application on January 12, 2025 and has a phased implementation, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation permits EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. In addition, some EEA countries may approve a specific price for a product, or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EEA countries allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the Affordable Care Act substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been executive, judicial and Congressional challenges and amendments to certain aspects of the Affordable Care Act. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and other litigation, and the healthcare reform measures of the second Trump administration will impact the Affordable Care Act.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted in the U.S. since the Affordable Care Act was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect until 2032, unless additional congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overpayments to providers from three to five years. Additionally, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. For example, at the federal level, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs  covered under Medicare that have been on the market for at least 7 years and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon prices for the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional drugs covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. On February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. We are unable to predict the future course of federal or state healthcare legislation in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located in New York, New York, where we lease approximately 7,900 square feet of office space under a lease that terminates in 2027, with an option for us to extend the lease for an additional five years which is not reasonably assured of exercise, and in San Francisco, where we lease approximately 19,418 square feet of office space that terminates in 2029. We also occupy office space located in Burlington, Massachusetts, where we lease approximately 2,235 square feet of office space under a lease that terminates in 2027, as well as a total of approximately 1,735 square meters of office space in the People&#8217;s Republic of China, in the cities of Beijing, Guangzhou, Hangzhou and Shanghai, under leases that terminate in 2026 through 2027.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employees</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 220 full-time employees, 49 of whom hold Ph.D.s, M.D.s or both. Of our total workforce, 135 employees are engaged in research and development, and 85 employees in general and administrative. Our workforce also includes 43 independent contractors. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages nor are we aware of any employment circumstances that are likely to disrupt work at any of our facilities. We consider our relationship with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Human Capital Management</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our employees are a significant asset, and we aim to create an environment that is equitable, inclusive and representative in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our current pipeline and future business goals. By focusing on employee retention and engagement, we also improve our ability to support our clinical-stage platform, business and operations, and also protect the long-term interests of our securityholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation and benefits packages and ensuring we listen to our employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We value agility, passion and teamwork, and are building a diverse environment where our employees can thrive and one that inspires exceptional contributions and professional and personal development in order to achieve our mission to significantly change the practice of oncology. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We are committed to providing a competitive and comprehensive benefits package to our employees. Our benefits package provides a balance of protection along with the flexibility to meet the individual health and wellness needs of our employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Diversity and Inclusion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diversity and inclusion are priorities for us. We believe that a rich culture of inclusion and diversity enables us to create, develop and fully leverage the strengths of our workforce. Our workforce comprises approximately 52% female employees and approximately 33% racial/ethnic minority employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in Delaware in April 2020 as a blank check company under the name Panacea Acquisition Corp. On February 10, 2021, Nuvation Bio and Panacea consummated the transactions contemplated under the Merger Agreement, following the approval at a special meeting of our stockholders. In connection with the closing of the Merger, we changed our name to Nuvation Bio Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file electronically with the U.S. Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. We make available on our website at www.nuvationbio.com, free of charge, copies of these reports as soon as reasonably practicable after filing these reports with, or furnishing them to, the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="risk_factors_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and investing in our securities involve significant risks, some of which are described below. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed in the section titled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Cautionary Information Regarding Forward-Looking Statements,&#8221; you should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described in the following risk factors and the risks described elsewhere in this report could harm our business, financial condition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">results of operations, cash flows, the trading price of our common stock and our growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described in the following risk factors and the risks described elsewhere in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Except in China where taletrectinib is being commercialized by our partner Innovent, our product candidates are all in development. As a result, we are unable to predict if or when we will successfully develop or commercialize our product candidates, and to generate revenue or profits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical-stage product candidates as well as our other pipeline assets will require significant further investment and regulatory approvals prior to commercialization. Our product candidates will require additional clinical development, management of clinical, preclinical and manufacturing activities, obtaining regulatory approval, obtaining manufacturing supply, build out of a commercial organization, substantial investment and significant marketing efforts, before we generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The FDA accepted for priority review our NDA for taletrectinib for the treatment of advanced ROS1+ NSCLC with a target PDUFA date of June 23, 2025. However, we have not previously submitted an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval.  Our other clinical-stage product candidates include safusidenib, which is in a Phase 2 study, and NUV-1511, which is in a Phase 1 study. Our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we successfully obtain regulatory approvals to market one or more of our product candidates, we anticipate incurring significant costs associated with launching and commercializing our current and future product candidates, including as a result of payment obligations under the Taletrectinib In-License Agreement, the Safusidenib In-License Agreement, our revenue interest financing agreement with Sagard Healthcare Partners (Delaware) II LP (the &#8220;RIF Agreement&#8221;), and our credit agreement and guaranty with Sagard Holdings Manager LP (the &#8220;Loan Agreement&#8221;). Furthermore, if the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products. Our revenues will also depend, in part, upon our current collaborators&#8217; and future collaborators&#8217; ability to obtain regulatory approval and successfully commercialize our product candidates in their respective territories. We would continue to bear the risk that the FDA or similar foreign regulatory authorities such as the European Medicines Agency (&#8220;EMA&#8221;), the U.K. Medicines &amp; Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) or the National Medical Product Administration of China (&#8220;NMPA&#8221;), could revoke approval, or that safety, efficacy, manufacturing or supply issues could arise that negatively impact product sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we generate sufficient revenue to achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in value also could cause you to lose all or part of your investment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need substantial funding to pursue our business objectives. If we are unable to raise capital when needed or on favorable terms, or receive significant revenues from the sales of our product, we could be forced to delay, reduce or terminate our product development, other operations or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying and developing potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and begin selling any approved products. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical studies and clinical trials, initiate additional clinical trials for our product candidates and seek regulatory approval for our current product candidates and any future product candidates we may develop. Our expenses could increase beyond our current expectations if the FDA, or comparable foreign regulatory authorities, require us to perform clinical trials and other studies in addition to those that we currently anticipate. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we will be forced to delay, reduce or terminate our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $502.7 million in cash and investments, and an accumulated deficit of $910.7 million. Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next 12 months. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities and changes in regulation. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and development requirements of product candidates that we may pursue, and other indications for our current product candidates that we may pursue; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and costs of manufacturing development and commercial manufacturing activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost associated with commercializing any approved product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of developing our ability to establish sales and marketing capabilities, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining, enforcing and protecting our intellectual property rights, defending intellectual property-related claims and obtaining licenses to third-party intellectual property; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all; and  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies and associated intellectual property, and payments required under such acquisitions or in-licenses.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional capital to complete our planned clinical development programs for our clinical stage product candidates as well as our preclinical product candidates to obtain regulatory approval. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we cannot guarantee that future financing will be available on a timely basis, in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and our issuance of additional securities, whether equity or debt, or the market perception that such issuances are likely to occur, could cause the market price of our common stock to decline. If we are unable to obtain funding on a timely basis on acceptable terms, we may be required to delay, reduce or terminate one or more of our research and development programs or the commercialization of any product candidates that may be approved. This could harm our business and could potentially cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our earnings. Any new taxes could adversely affect our business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us, which could require us to pay additional taxes on a prospective or retroactive basis, as well as penalties, interest and other costs, including compliance costs. The Tax Cuts and Jobs Act enacted in 2017 (the &#8220;Tax Act&#8221;), the Coronavirus Aid, Relief, and Economic Security Act enacted in 2020 and the Inflation Reduction Act enacted in 2022 made many significant changes to the U.S. tax laws. For example, effective January 1, 2022, the Tax Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and instead requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Although there have been legislative proposals to repeal or defer the capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. Future guidance from the Internal Revenue Service and other tax authorities with respect to any such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our tax obligations and effective tax rate could increase, including as a result of the base erosion and profit shifting (&#8220;BEPS&#8221;) project that is being led by the Organization for Economic Co-operation and Development (&#8220;OECD&#8221;), and other initiatives led by the OECD. For example, the OECD is leading work on proposals, commonly referred to as &#8220;BEPS 2.0&#8221;, which to the extent implemented, would make important changes to the international tax system. These proposals are based on two &#8220;pillars&#8221;, involving the reallocation of taxing rights in respect of certain multinational enterprises above a fixed profit margin to the jurisdictions in which they carry on business (referred to as &#8220;Pillar One&#8221;) and imposing a minimum effective corporate tax rate on certain multinational enterprises (referred to as &#8220;Pillar Two&#8221;). A number of countries have enacted, or are in the process of enacting, core elements of the Pillar Two rules. Based on our current understanding of the minimum revenue thresholds, we currently expect to be outside the scope of both the Pillar One and Pillar Two proposals but could fall within their scope in the future. We are monitoring developments and evaluating the potential impacts these new rules may have on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $194.3 million and $270.3 million, respectively. Under current law, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but such federal NOL carryforwards are permitted to be used in any taxable year to offset only up to 80% of taxable income in such year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally is defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income or taxes may be limited. The completion of the 2021 merger of Nuvation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bio Inc. and Panacea Acquisition Corp., together with private placements and other transactions that have occurred since our inception, may have triggered such an ownership change pursuant to Section 382. We have not completed a Section 382 analysis, and therefore, there can be no assurances that our NOL carryforwards are not already limited. We also may experience ownership changes as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which potentially could result in increased future tax liability to us. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, this could harm our future operating results by effectively increasing our future tax obligations.  In addition, due to changes in laws and regulations, including changes proposed or implemented by the current or a future U.S. presidential administration, such as alternative minimum taxes, or other unforeseen reasons, our existing net operating losses could become unavailable to reduce future income tax liabilities.  Further, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2023 and before 2027.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Indebtedness</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, the Company announced the closing of a non-dilutive financing of up to $250.0 million from entities affiliated with Sagard Healthcare Partners (collectively, &#8220;Sagard&#8221;). The financing is comprised of a $150.0 million (the &#8220;Investment Amount&#8221;) synthetic royalty financing under the RIF Agreement and a $100.0 million senior secured term loan under the Loan Agreement. The Investment Amount and the first $50.0 million tranche of the term loan will be funded conditioned upon FDA&#8217;s approval of taletrectinib on or prior to September 30, 2025. The second $50 million tranche of the term loan will be available at our option until June 30, 2026, as long as we have achieved first U.S. commercial sale of taletrectinib.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the RIF Agreement, in exchange for the Investment Amount, we have agreed to make tiered royalty payments to Sagard on U.S. net sales of taletrectinib equal to 5.5% of annual U.S. net sales up to $600 million and 3.0% of annual U.S. net sales between $600 million and $1 billion.  We will retain all annual U.S. net sales above $1 billion. Our obligation to make the royalty payments will cease upon the earliest occurrence of total royalty payments reaching 1.6 times of the Investment Amount by the calendar quarter ending on June 30, 2031, 1.75 times of the Investment Amount by the calendar quarter ending on June 30, 2034, or 2.0 times of the Investment Amount thereafter. To the extent we have not made royalty payments totaling at least 1.0 time of the Investment Amount by February 1, 2043, we will be required to make a true up payment in an amount equal to such shortfall (the &#8220;True Up Payment&#8221;). In addition, if certain events occur, including certain bankruptcy events, non-payment of Payments, a change of control, expiration or termination of certain intellectual property rights or marketing authorization, an out-license or sale of all of the rights in and to taletrectinib in the United States and (subject to applicable cure periods) non-compliance with the covenants in the RIF Agreement, we may be required to repurchase the synthetical royalty financing at a repurchase price ranging from 1.4 to 2.0 times of the Investment Amount, depending on the time of such event, less all royalty payments we made by then (the &#8220;Put/Call Payment&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Loan Agreement, the term loan will bear interest at the secured overnight financing rate ("SOFR") plus a margin of 6.00%, subject to a 4.00% SOFR floor. There are no scheduled amortization payments associated with the term loan, with all outstanding principal due at maturity. Before we would consider drawing down any tranche under the Loan Agreement, if available, we must first satisfy ourselves that we will have access to future alternate sources of capital, such as from commercial revenues or the equity capital markets or debt capital markets, in order to repay any additional principal borrowed, which we may be unable to do, in which case, our liquidity and ability to fund our operations may be substantially impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All obligations under the Loan Agreement are secured by substantially all of our assets, including our intellectual property, and all obligations under the RIF Agreement are secured by accounts receivable arising from U.S. net sales of taletrectinib and intellectual property, product registrations and regulatory approvals related to commercialization and development of taletrectinib in the United States. Further, the terms of the Loan Agreement and the RIF Agreement place restrictions on our operating and financial flexibility, and limit or prohibit our ability to dispose of certain assets and engage in other significant transactions. This indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outstanding debt obligations at maturity. If we draw down any of the tranches under the Loan Agreement, our indebtedness will increase, which would further increase our risk of being unable to pay off or refinance our outstanding debt obligations at maturity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our indebtedness could also have important negative consequences, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will need to make tiered royalty payments under the RIF Agreement, and under certain circumstances, the True Up Payment or the Put/Call Payment, and to repay the Loan Agreement by making payments of interest and principal, all of which will reduce the amount of cash available to finance our operations, our research and development efforts and other general corporate activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to comply with the obligations of our affirmative and restrictive covenants in the Loan Agreement and the RIF Agreement could result in an event of default that, if not cured or waived, would permit Sagard to accelerate our obligation to repay this indebtedness, and Sagard could seek to enforce their security interest against certain of our assets that are collateral; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the RIF Agreement, upon occurrence of certain events, we may be required to repurchase the synthetical royalty financing at a repurchase price ranging from 1.4 to 2.0 times of the Investment Amount, depending on the time of such event, less all royalty payments we made by then. In addition, we may borrow additional capital in the future to fund clinical development and our future growth, including pursuant to the Loan Agreement or potentially pursuant to new arrangements with different lenders. To the extent additional debt is added to our current debt levels, the risks described above could increase.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The terms of the Loan Agreement and the RIF Agreement place restrictions on our operating and financial flexibility.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Loan Agreement and the RIF Agreement collectively impose operating and other restrictions on us. Such restrictions will affect, and in many respects limit or prohibit, our ability and the ability of our subsidiaries to, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dispose of certain assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in mergers, acquisitions or consolidations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional indebtedness;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create liens on assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enter into certain licensing transactions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make certain payments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pay dividends and make contributions or repurchase our capital stock; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in certain transactions with affiliates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not have cash available in an amount sufficient to enable us to make interest, principal or other payments on our indebtedness when due.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to make scheduled interest payments on or to refinance our indebtedness depends on our future performance and ability to raise additional sources of cash, which is subject to economic, financial, competitive and other factors beyond our control. If we are unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets, restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. If we desire to refinance our indebtedness, our ability to do so will depend on the state of the capital and lending markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to satisfy our current and future debt obligations under the Loan Agreement, the RIF Agreement, or to comply with certain covenants in such agreements could result in an event of default, the occurrence and continuance of which provides Sagard with the right to demand immediate repayment of all outstanding obligations under such agreements (and in the case of certain insolvency, liquidation, bankruptcy or similar events, automatically requires</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immediate repayment of all outstanding obligations under such agreements), and to exercise remedies against us and the collateral securing such agreements. These events of default include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to make payments required by the agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insolvency, liquidation, bankruptcy or similar events;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to observe covenants under the Loan Agreement, the RIF Agreement, and ancillary collateral documents, which failure, in certain limited cases, is not cured within applicable time periods;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of FDA&#8217;s authorization of taletrectinib, if approved in the U.S., and certain other regulatory actions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of a material adverse change;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material misrepresentations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain cross-default of third-party indebtedness or certain default or termination events of hedging assessments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain money judgments being entered against us which are not timely paid, discharged or stayed; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our assets are attached or seized.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of default, the lenders could accelerate all of the amounts due under the Loan Agreement or the RIF Agreement, as applicable. Sagard could also exercise its rights to take possession and dispose of certain of our assets that are collateral.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the RIF Agreement, if certain events occur, including certain bankruptcy events, non-payment of Payments, a change of control, expiration or termination of certain intellectual property rights or marketing authorization, an out-license or sale of all of the rights in and to taletrectinib in the United States and (subject to applicable cure periods) non-compliance with the covenants in the RIF Agreement, we may be required to repurchase the synthetical royalty financing at a repurchase price ranging from 1.4 to 2.0 times of the Investment Amount, depending on the time of such event, less all royalty payments we made by then.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under such circumstances, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time of such acceleration. In that case, we may be required to delay, limit, reduce or terminate our taletrectinib commercialization efforts, our research and development efforts, or grant to others rights to develop and market taletrectinib. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The RIF Agreement place certain restrictions on our operational flexibility</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RIF Agreement contains covenants that impose on us certain obligations with respect to commercial effort, reporting, indemnification and other matters and certain restrictions with respect to intellectual property transfers, licensing, acquisitions, divestitures, and other actions. The RIF Agreement also limits our ability to create or incur liens or dispose of certain assets related to taletrectinib. If we want to early terminate the RIF Agreement, we will need to pay Sagard an amount ranging from 1.4 to 2.0 times of the Investment Amount (depending on the timing of the early termination and less all royalty payments we made by then), thereby limiting our ability to eliminate future applicability of the covenants contained in the RIF Agreement. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might otherwise be advantageous to us and our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Development of our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain regulatory approval for and successfully commercialize one or more of our product candidates or we experience significant delays in doing so, we may never generate any revenue or become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any products that have received regulatory approval and may never be able to develop marketable product candidates. We have invested substantially all of our efforts in developing and identifying potential product candidates and conducting preclinical and clinical studies. As a result, our business currently depends heavily on the successful development, regulatory approval and, if approved, commercialization of one or more of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taletrectinib, safusidenib, NUV-1511 and NUV-868. We cannot be certain that any of these or any other product candidates will receive regulatory approval or will be successfully commercialized even if we receive regulatory approval. The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of product candidates is, and will remain, subject to comprehensive regulation by the FDA and similar foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through preclinical studies and clinical trials that the product candidate is safe and effective for use in each target indication. The FDA and similar foreign regulatory authorities may not agree that the clinical data demonstrates safety and efficacy of our product candidates. For example, while we recently submitted an NDA for taletrectinib for the treatment of patients with advanced ROS1+ NSCLC, FDA may not agree that the pooled data from the TRUST-I and TRUST-II trials have sufficient North American patients to support safety and efficacy for a U.S. population, and may not believe that we have identified optimal dosing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our preclinical studies or clinical trials. For example, based on our preclinical or clinical experience since February 2022, we have discontinued or deprioritized three of the five programs, including the lead program, that we were pursuing at that time.  Failure to obtain regulatory approval for our product candidates will prevent us from commercializing and marketing our product candidates. The success of our product candidates will depend on several additional factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful initiation of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in, and completion, of clinical trials that demonstrate their safety and efficacy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receiving marketing approvals from applicable regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining, maintaining, protecting and enforcing patent, trade secret and other intellectual property rights and regulatory exclusivity for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing any post-marketing studies required by applicable regulatory authorities;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making and maintaining arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution capabilities and successfully launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of adverse events experienced with our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our product candidates by patients, the medical community and third-party payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of the products following approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining healthcare coverage and adequate reimbursement for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing effectively with other cancer therapies, including with respect to the sales and marketing of our product candidates, if approved; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining licenses to any third-party intellectual property we deem necessary or desirable. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these factors are beyond our control, including the time needed to adequately complete preclinical studies, clinical testing and the regulatory submission process, our ability to obtain and protect intellectual property rights and changes in the competitive landscape. It is possible that none of our product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete clinical trials, obtain regulatory approval or, if approved, commercialize our product candidates, which would materially harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the clinical trial requirements of the FDA, the European Commission, competent authorities of EU Member States, the MHRA, the NMPA and other comparable regulatory authorities and the criteria regulators may use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are currently conducting, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting clinical trials outside the United States, including in China, and we expect to continue to conduct clinical trials internationally in the future. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. healthcare system practices and (ii) the clinical trials were performed by clinical investigators of recognized competence and pursuant to GCP; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCPs and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign clinical trials are subject to the applicable local laws of the foreign jurisdictions where the clinical trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from clinical trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional clinical trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach to the discovery and development of product candidates based on our DDC platform is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our platform obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business depends in part upon our ability to identify, develop and commercialize products based on our proprietary Drug-Drug Conjugate (&#8220;DDC&#8221;) platform, which leverages a novel and unproven therapeutic approach within the drug-conjugate class of anti-cancer therapies. While our first DDC clinical product candidate, NUV-1511, is in a Phase 1 dose escalation trial that began in the first quarter of 2024, we have not yet demonstrated safety or efficacy for NUV-1511 or any other DDC product candidate. Our research methodology and novel approach to oncology using our DDC platform may be unsuccessful in identifying additional product candidates, and any product candidates based on our technology may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. In addition, adverse developments with respect to one of our DDC platform-based programs may have a significant adverse impact on the actual or perceived likelihood of success and value of similar programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will depend in part on our ability to maintain a competitive position with our DDC platform. If we fail to stay at the forefront of technological change in utilizing our DDC platform to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our DDC platform obsolete, or limit the commercial value of our product candidates, by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. By contrast, adverse developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value of our DDC platform and potential of our DDC platform-based product candidates. If any of these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">events occur, we may be forced to abandon our development efforts for a program or programs, which would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our DDC platform-based product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our product research and development efforts on our novel DDC platform, and our future success depends in part on the successful development of product candidates arising from our DDC platform. There can be no assurance that any development problems we may experience in the future related to our DDC platform will not cause significant delays or unanticipated costs, or that such development problems can be efficiently solved. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may in the future develop product candidates in combination with other therapies and that may expose us to additional risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may develop future product candidates for use in combination with one or more currently approved cancer therapies. Even if any product candidate we develop was to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also evaluate our product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar foreign regulatory authorities. We will not be able to market and sell our product candidates we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or similar foreign regulatory authorities do not approve or revoke the approval of these other drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trials are very expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of failure for our product candidates is high. It is impossible to predict when or if any of our product candidates will prove safe or effective in humans or will receive regulatory approval. To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans for use in each target indication. Preclinical investigation and clinical testing is expensive and can take many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the preclinical investigation or clinical trial process.  For example, in August 2022, we announced the discontinuation of development of our former lead program, NUV-422, following the emergence of a safety signal, uveitis, which is a form of inflammation of the eye.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the results of preclinical studies and earlier clinical trials may not be predictive of the results of later-stage preclinical studies or clinical trials. The results generated to date in preclinical studies for our product candidates do not ensure that later preclinical studies or clinical trials will demonstrate similar results.  Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and earlier stage clinical trials. In later-stage clinical trials, we will likely be subject to more rigorous statistical analyses than in completed earlier stage clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other clinical trial protocols, and the rate of dropout among clinical trial participants. If we fail to produce positive results in our planned preclinical studies or clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product or product candidate, and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our preclinical studies or clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate for its intended indications. Preclinical studies and clinical trials are expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more preclinical studies or clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of preclinical or clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in conducting experiments or preclinical studies or unsatisfactory results from such experiments or studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on trial design, dose optimization or dose selection; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement or failing to agree on acceptable terms with prospective CROs and clinical trial sites; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in opening sites and recruiting suitable patients to participate in our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in enrollment due to travel or quarantine policies, or other factors, related to health epidemics, other pandemics or other events outside our control; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations or trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For instance, health epidemics and the measures taken in response by the governmental authorities could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for our product candidates for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities, impede the ability of patients to enroll or continue in clinical trials, or impede testing, monitoring, data collection and analysis or other related activities, any of which could delay our clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to timely and successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to achieve regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable drugs to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed or unsuccessful in obtaining marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have regulatory authorities withdraw, vary or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS, or comparable foreign restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be sued; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we, the FDA or comparable foreign regulatory authorities, an Institutional Review Board, or an Ethics Committee may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with applicable regulatory requirements, including the FDA&#8217;s current Good Clinical Practice, (&#8220;GCP&#8221;) and foreign equivalents, regulators find that we are exposing participants to unacceptable health risks or if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities find deficiencies in our Investigational New Drugs, clinical trial applications or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed or eliminated entirely.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter continued or new difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have experienced and may in the future experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including challenges resulting from health epidemics, labor shortages, and global supply chain interruptions. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and health of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to study sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial site. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies rather than enroll patients in any future clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our current or planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or third parties are unable to successfully develop companion diagnostics for taletrectinib, safusidenib, or any of our other product candidates that are targeted therapies, or if we experience significant delays in doing so, we may not achieve marketing approval or realize the full commercial potential of such product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key part of our development strategy for taletrectinib, safusidenib, and any of our other product candidates that are targeted therapies, is to identify subsets of patients with specific types of tumors that express specific genetic markers. Identification of these patients may require the development and use of companion diagnostics. The FDA generally will require either approval or clearance of the diagnostic at the same time the FDA approves the therapeutic product, or as a post-marketing commitment at the time of the therapeutic product's approval. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. A companion diagnostic for ROS-1 positive NSCLC will require the conduct of a clinical bridging study with high sample ascertainment, as the TRUST-I and TRUST-II trials were conducted using multiple investigational devices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and may require separate regulatory approval prior to commercialization of the associated product candidate. If we or third parties are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development of these product candidates may be delayed because it may be difficult to identify patients for enrollment in our clinical trials in a timely manner;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not realize the full commercial potential of these product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients or types of tumors with the specific genetic alterations targeted by these product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Even if our product candidates and any associated companion diagnostics are approved for marketing, the need for companion diagnostics may slow or limit adoption of our product candidates. Although we believe genetic testing is becoming more prevalent in the diagnosis and treatment of cancer, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, due to either the additional cost of the companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these events were to occur, our business and growth prospects would be harmed, possibly materially.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications, even those that we have begun investigating and that may have shown promise, that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial therapies or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives regulatory approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal, variation, suspension or limitation by regulatory authorities of approvals of such product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidate is approved under 21 CFR 314 (Subpart H, accelerated approval) or we receive a conditional marketing authorization but required confirmatory trials may fail to verify clinical benefit or we may fail to fulfill requirements of the conditional marketing authorization;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seizure of the product by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing of the product or the manufacturing process for any component thereof; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirement by regulatory authorities of additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements that we implement a REMS, or comparable foreign strategies, or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commitment to expensive additional safety studies prior to approval or post-marketing studies required by regulatory authorities of such product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse impact on the product&#8217;s competitiveness; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of regulatory investigations and government enforcement actions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of legal action against us to hold us liable for harm caused to patients; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">harm to our reputation and resulting harm to physician or patient acceptance of our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. We currently have no products that have been approved for commercial sale. However, the current and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend or settle, and could compromise the market acceptance of our product candidates or any prospects for commercialization of our product candidates, if approved. For more information regarding the risks associated with intellectual property-related litigation, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen or rare side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive Fast Track designation or granting of other FDA expedited programs, or other comparable foreign expedited programs, for any of our product candidates, there is no guarantee that such product candidates will experience a faster regulatory review or obtain regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we receive Fast Track designation for any of our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA approval timelines, and the FDA may still decline to approve such product candidates. The FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program or for any other reason. Similarly, the FDA&#8217;s other expedited drug development programs (e.g., Breakthrough Therapy, Accelerated Approval, Priority Review) do not guarantee a product candidate&#8217;s faster regulatory review or regulatory approval. Although taletrectinib</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been granted Breakthrough Therapy Designations by both the FDA and China&#8217;s NMPA for the treatment of advanced or metastatic ROS1+ NSCLC, such designations may be rescinded and may not lead to faster regulatory review or regulatory approval. The EMA has a similar program called PRIME.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive Orphan Drug designation for any of our product candidates, we may be unable to maintain the benefits associated with such designation, including the potential for market exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as Orphan Drugs. Under the Orphan Drug Act, the FDA may designate a drug as an Orphan Drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax credits for certain clinical trial costs and user-fee waivers. Generally, if a drug with an Orphan Drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive Orphan Drug designation for any of our product candidates, there is no guarantee that we will obtain approval or Orphan Drug exclusivity for such product candidates. Even if we obtain Orphan Drug exclusivity for any of our product candidates, that exclusivity may not effectively protect the product candidates from competition because different therapies can be approved for the same condition and the same therapy could be approved for different conditions. Even after an Orphan Drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.  Moreover, Orphan Drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan Drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate on our own and we may lack the necessary expertise, personnel and resources to successfully commercialize any of our products that receive regulatory approval on our own.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate on our own. To achieve commercial success of our product candidates, if any are approved, we will have to develop our own sales, marketing and manufacturing capabilities, or outsource some or all of these activities to third parties as we have done in China and Japan for taletrectinib.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of qualified scientific, clinical, manufacturing, and sales and marketing personnel, persuading adequate numbers of physicians to prescribe our approved product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization in the U.S., the European Union or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may have difficulties generating revenue from them.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies among others. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. There are other companies working to develop immunotherapies for the treatment of cancer including divisions of large pharmaceutical and biotechnology companies of various sizes. Some of these competitive products and therapies are based on scientific approaches that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing our initial product candidates for the treatment of cancer, and currently none of these therapies are approved. There are already a variety of available drug therapies marketed for cancer and some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic products. This may make it difficult for us to achieve our business strategy of replacing existing therapies with our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop. In addition, most of these companies have substantially greater sales, marketing and other experience and reserves than we do. Competition may further increase as a result of advances in the commercial applicability of technologies for drug discovery and development and greater availability of capital for investment in cancer therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge for any product candidate we commercialize, if any. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If taletrectinib, safusidenib, NUV-1511, NUV-868 and our other current and future product candidates receive marketing approval, whether as a single agent or in combination with other therapies, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current approved immunotherapies, and other cancer treatments like chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these therapies. If any of our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may never become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our product candidates to treat cancer, as compared with other available drugs, treatments or therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the labeling approved for our product candidates by the FDA or comparable foreign regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the target patient population, and the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support and timing of market introduction of competitive products; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity for our product candidates and competing products and treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing and cost effectiveness; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales and marketing strategies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain sufficient third-party coverage and adequate reimbursement. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, comparable foreign healthcare programs, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates and, if desired, attract collaboration partners to invest in the development of our product candidates. Coverage under certain government programs, such as Medicare, Medicaid, the 340B drug pricing program and TRICARE, or comparable foreign healthcare programs, may not be available for certain of our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., the European Union, China or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on products that we may develop.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In China, the Ministry of Human Resources and Social Security of China or provincial or local human resources and social security authorities, together with other government authorities, review the inclusion or removal of drugs from China&#8217;s National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List (&#8220;NRDL&#8221;), or provincial or local medical insurance catalogues for the National Medical Insurance Program regularly, and the tier under which a drug will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those drugs. There can be no assurance that taletrecinib or any of our product candidates, if approved, will be included in the NRDL. Products included in the NRDL have been typically generic and essential drugs. Innovative drugs similar to taletrectinb have historically been more limited on their inclusion in the NRDL due to the affordability of the government&#8217;s Basic Medical Insurance, although this has been changing in recent years. Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any products for which we may obtain regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to set a price that we believe is fair for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenues and achieve or maintain profitability; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, in case a drug product needs companion diagnostics, then companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for the pharmaceutical or biological product. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taletrectinib has been approved in China for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs. Approved products are subject to extensive and ongoing regulatory requirements for manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, sampling and record-keeping. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;), regulations and GCPs, for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval for any future product candidates we may develop, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. However, if we are found to have promoted such off-label uses, we may become subject to significant liability.  The FDA or comparable foreign regulatory authorities may also require a REMS, or comparable foreign regulatory strategies as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, the U.S. Supreme Court&#8217;s June 2024 decision in Loper Bright Enterprises v. Raimondo overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper decision could result in additional legal challenges to regulations and decisions issued by federal agencies, including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the Loper decision may result in increased regulatory uncertainty,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. Moreover, if there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuing warning or untitled letters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking an injunction or imposing civil or criminal penalties or monetary fines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or imposition of restrictions on operations, including product manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seizure or detention of products, refusal to permit the import or export of products or request that we initiate a product recall; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension, variation or withdrawal of our marketing authorizations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to applications submitted by us; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. If approved in the U.S., we plan to commercialize taletrectinib by ourselves. We have out-licensed commercial rights to taletrectinib to Innovent in mainland China, Hong Kong, Macau and Taiwan, and to NK in Japan. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, taletretinib in territories outside of the U.S. and territories subject to existing partnerships, or for our other product candidates if and when they are approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to perform the chemistry work associated with our drug discovery and preclinical activities and to conduct our preclinical studies and future clinical trials, and our business could be substantially harmed if these third parties cease performing services or perform in an unsatisfactory manner.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any laboratory facilities and have relied on CROs to perform most of the medicinal chemistry work associated with our drug discovery activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also do not currently have the ability to independently conduct preclinical studies or clinical trials without outside assistance. We have relied on CROs to conduct all of our preclinical studies to date and intends to conduct our future clinical trials by leveraging expertise and assistance from CROs as appropriate. We plan to rely upon medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or assist us in conducting GCP-compliant clinical trials on our product candidates properly and on time, and may not currently have all of the necessary contractual relationships in place to do so. Once we have established contractual relationships with such third-party CROs, we will have only limited control over their actual performance of these activities.
</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our CROs and other vendors are required to comply with cGMP, GCP, and good laboratory practice (&#8220;GLP&#8221;), which are regulations and guidelines enforced by the FDA, the competent authorities of EU Member States and any comparable foreign regulatory authorities for all of our product candidates in preclinical and clinical development. Regulatory authorities enforce these regulations through periodic inspections of trial sponsors, principal investigators, clinical trial sites and other contractors. Although we will rely on CROs to conduct any current or planned GLP-compliant preclinical studies and GCP-compliant clinical trials and has limited influence over their actual performance, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, European Commission, MHRA, NMPA or any other comparable foreign regulatory authority may require us to perform additional preclinical studies and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that all of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, the competent authorities of EU Member States, the MHRA, the NMPA or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMP. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, the competent authorities of EU Member States, the MHRA, the NMPA or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. This may result in shutdown of the third-party vendor or invalidation of drug product lots or processes. In some cases, a product recall may be warranted or required, which would materially affect our ability to supply and market our drug products. Our failure to comply with these requirements may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we or our CROs have or will have agreements governing their activities, we will not be able to control whether or not they devote sufficient time and resources to our future chemistry work and preclinical and clinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other chemistry or drug discovery or development activities. We face the risk of potential unauthorized disclosure, infringement, misappropriation or other violation of our intellectual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">property by CROs, which may reduce our trade secret protection and allow our potential competitors, and other third parties, to access and exploit our proprietary technology. CROs also may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property-related proceedings that could jeopardize or invalidate our proprietary information and intellectual property. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials or other drug discovery or development activities may be extended, delayed or terminated, the clinical data generated in our clinical trials may be deemed unreliable, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.
</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our relationships with our CROs were to terminate, we might not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus, and could delay the discovery, development and commercialization of our product candidates. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business and financial condition.
</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of taletrectinib, safusidenib, NUV-1511, NUV-868 and our other current and future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in drug formulation and manufacturing and do not own or operate, and we do not expect to own or operate, facilities for drug manufacturing, storage, distribution or testing. We currently have a single source for taletrectinib API and drug product, which we obtain pursuant to long-term supply agreements. We are currently developing a second source for paleotectonic drug product.  To date, we have obtained active pharmaceutical ingredients (&#8220;APIs&#8221;) and drug product for our investigational products mostly from single-source third-party CMOs. We are in the process of developing our supply chain for each of our investigational products and intend to put in place framework agreements under which CMOs will generally provide us with necessary quantities of API and drug product on a project-by-project basis based on our development needs. We seek to use a different CMO for each investigational product and will consider further diversification of drug product and supply organizations as circumstances warrant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party CMOs may be unable or unwilling to supply us with sufficient clinical and commercial grade quantities of our clinical materials due to production shortages or other supply interruptions resulting from health epidemics, because they are purchased by one of our competitors or another company that decides not to continue supplying us with these materials, or for other reasons. If one or more of these events occur and we are unable to timely establish an alternate supply from one or more third-party CMOs, we could experience delays in our development efforts as we locate and qualify new manufacturers. Under such circumstances, we may be required to receive drug substance for use on a purchase order basis, and as such, there can be no assurance that we actually receive sufficient quantities. See also the risk factor titled &#8220;&#8212;Our business, operations and clinical development plans and timelines and supply chain could be adversely affected by the effects of health epidemics, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our CMOs, CROs, shippers and others.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our reliance on third-party manufacturers exposes us to risks beyond our control, including the risk of:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to meet our product specifications and quality requirements consistently; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or inability to procure or expand sufficient manufacturing capacity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing and quality issues, including related to scale-up of manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs and validation of new equipment and facilities required for additional scale-up; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of the manufacturer to comply with cGMP and similar foreign standards; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to negotiate manufacturing agreements with third parties on commercially reasonable terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on a limited number of sources, and in some cases, single sources for components, such that if we are unable to secure a sufficient supply of these drug components, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or the issuance of a FDA Form 483 notice, warning letter, or cease and desist order; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to deliver our products under specified storage conditions and in a timely manner. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of these events could be the basis for FDA or comparable foreign regulatory authority action, including injunction, recall, seizure or total or partial suspension of production. In addition, our third-party manufacturers and suppliers are subject to FDA inspection and may be subject to inspections from comparable foreign regulatory authorities from time to time. Failure by our third-party manufacturers and suppliers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen, or comparable foreign regulatory authorities' approval regimen, with respect to our product candidate may result in non-approval for our product candidates or regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses. In addition, our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Based on the severity of the regulatory action, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our CMOs are or may be engaged with other companies to supply and manufacture materials or products for such companies, which also exposes our suppliers and manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier&#8217;s or manufacturer&#8217;s facility. If the FDA or a comparable foreign regulatory authority finds these facilities unsatisfactory in compliance with applicable regulations, does not approve these facilities for the supply or manufacture of our product candidates, or if it withdraws its approval in the future, we may need to find alternative supply or manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval of or market our product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we prepare for later-stage clinical trials and potential commercialization, we will need to take steps to increase the scale of production of our product candidates, which may include transferring production to new third-party suppliers or manufacturers. In order to conduct larger or late-stage clinical trials for our product candidates and supply sufficient commercial quantities of the resulting drug product and our components, if that product candidate is approved for sale, our CMOs and suppliers will need to produce our product candidates in larger quantities, more cost effectively and, in certain cases, at higher yields than they currently achieve. These third-party contractors may not be able to successfully increase the manufacturing capacity for any such product candidates in a timely or cost-effective manner or at all. Significant scale up of manufacturing may require additional processes, technologies and validation studies, which are costly, may not be successful and which the FDA and comparable foreign regulatory authorities must review and approve. In addition, quality issues may arise during those scale-up activities because of the inherent properties of a product candidate itself or of a product candidate in combination with other components added during the manufacturing and packaging process, or during shipping and storage of the APIs or the finished product. If our third-party CMOs are unable to successfully scale up the manufacture of any of our product candidates in sufficient quality and quantity and at commercially reasonable prices, and we are unable to find one or more replacement suppliers or manufacturers capable of production at a substantially equivalent cost in substantially equivalent volumes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and quality, and we are unable to successfully transfer the processes on a timely basis, the development of that product candidate and regulatory approval or commercial launch for any resulting products may be delayed, or there may be a shortage in supply, either of which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to maintain the License Agreement between Daiichi Sankyo Company, Limited and AnHeart Therapeutics Inc., dated December 7, 2018, as amended (the &#8220;Taletrectinib In-License Agreement&#8221;) and the License Agreement between Daiichi Sankyo Company, Limited and AnHeart Therapeutics Inc., dated September 7, 2020 (the &#8220;Safusidenib In-License Agreement&#8221;) could negatively impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Taletrectinib In-License Agreement and the Safusidenib In-License Agreement, we received certain exclusive licenses to develop, manufacture and commercialize taletrectinib and safusidenib, respectively. Consequently, our ability to develop and commercialize taletrectinib and safusidenib depends on our ability to maintain these agreements with Daiichi Sankyo. We are subject to a number of other risks associated with our dependence on the Taletrectinib In-License Agreement and the Safusidenib In-License Agreement, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations to make certain milestone and royalty payments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligation to use commercially reasonable efforts to perform certain development and commercialization activities and to achieve certain milestones;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain obligations not to develop or commercialize products that compete with taletrectinib or safusidenib; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential disputes between us and Daiichi Sankyo, including disagreements regarding the Taletrectinib In-License Agreement and the Safusidenib In-License Agreement.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If either the Taletrectinib In-License Agreement or the Safusidenib In-License Agreement is terminated early, we may be unable to pursue continued development, manufacture and commercialization of taletrectinib or safusidenib.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to establish and maintain collaborations, we may have to alter some of our future development and commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital to fund expenses. The commercial rights to taletrectinib have been out-licensed in China and Japan, and we may enter into other collaboration agreements with pharmaceutical and biotechnology companies for the future development and potential commercialization of our product candidates. We will likely have limited control over the amount and timing of resources that our current and future collaborators dedicate to the development or commercialization of any product candidates we may seek to develop and commercialize with them. We cannot predict the success of any current or future collaboration that we may enter into.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization experience and capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, European Commission, MHRA, NMPA or other similar foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to negotiate collaboration agreements on a timely basis, on acceptable terms, or at all. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. Our collaboration partners, if any, may not prioritize our product candidates or otherwise not effectively pursue the development of our product candidates which may delay, reduce or terminate the development of such product candidate, reduce or delay its development program or delay its potential commercialization. Further if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain and protect the existing intellectual property rights we have, we may have to delay, reduce or terminate the development of our product candidates, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. Doing so will likely harm our ability to execute our business plans. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Compliance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;Affordable Care Act&#8221;), includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers. There have been judicial, executive and congressional challenges and amendments to certain aspects of the Affordable Care Act.. For example, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program.  It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future.  It is unclear how any such challenges and the healthcare reform measures of the second Trump administration will impact the Affordable Care Act and our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction, which triggered the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year until 2032 unless Congress takes additional action. Additionally, the American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently, there has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. presidential executive orders, congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. For example, at the federal level, the IRA, among other things, (1) directs the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to negotiate the price of certain single-source drugs covered under Medicare that have been on the market for at least 7 years and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions took effect progressively starting in fiscal year 2023.  On August 15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional drugs covered under Part</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program.  On February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. Also in 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, in January 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (&#8220;SIP&#8221;) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are unable to predict the future course of federal or state healthcare legislation in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, particularly in light of the recent U.S. Presidential and Congressional elections. These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, health information privacy and security laws and other healthcare laws and regulations, including comparable foreign healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not currently have any products on the market, our current and future operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. The laws that may affect our ability to operate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal false claims, including the False Claims Act, which can be enforced through whistleblower actions, and Civil Monetary Penalties Laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, (&#8220;HITECH&#8221;), and its implementing regulations, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by &#8220;covered entities&#8221;, i.e. health plans, healthcare clearinghouses and certain healthcare providers, as well as their &#8220;business associates&#8221; and covered subcontractors that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services ("CMS") information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European, Chinese and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance regulations promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and non-U.S. laws also govern the privacy and security</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.  Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of revenue or profits; and other adverse business consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business information, trade secrets, intellectual property, information we collect about trial participants in connection with clinical trials, and sensitive third-party information (collectively, sensitive data).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. Additionally, in the past few years, numerous U.S. states &#8211; including California, Virginia, Colorado, Connecticut, and Utah &#8211; have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, or CCPA, applies to personal data of California residents and requires businesses subject to the CCPA to provide specific disclosures in privacy notices and respond to requests of such individuals to exercise certain privacy rights. Although there are minimum revenue thresholds for entities to be subject to these laws and there are limited exemptions for clinical trial data under the CCPA and similar US state comprehensive privacy laws, such laws may impact (possibly significantly) our business activities depending on how they are interpreted, should we become subject to the CCPA or other such state comprehensive privacy laws in the future. Similar laws are being considered in other states, as well as at the federal and local levels, and we expect more laws related to personal data to become effective in the future. These developments may further complicate compliance efforts and increase our legal risk and compliance costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom&#8217;s GDPR, or UK GDPR, Australia&#8217;s Privacy Act, and China&#8217;s Personal Information Protection Law, or PIPL, impose strict requirements for processing personal data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, under GDPR, companies may face private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests, temporary or definitive prohibitions on data processing and other corrective actions, or fines of up to the greater of 20 million Euros under the EU GDPR / 17.5 million pounds under the UK GDPR, or 4% of their worldwide annual revenue, whichever is higher.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.  In particular, the European Economic Area, or EEA, and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate.  Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.  If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.  Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security.  If these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to data privacy and security (and individuals&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.  Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work (such as contract research organizations and clinical trial sites) may fail (or be perceived to have failed) to comply with such obligations, which could negatively impact our business operations. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans or restrictions on processing personal data (including clinical trial data); orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands.  Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations (including, as relevant, clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trials); inability to process sensitive data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, protect and enforce sufficient patent and other intellectual property rights for our product candidates and technology, or if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in significant part on our ability and the ability of any licensors and collaborators to obtain, maintain, protect and enforce patents and other intellectual property rights with respect to our product candidates and technology and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is uncertain, expensive and time-consuming. We and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our future licensors will fail to identify patentable aspects of our research and development output in time to obtain patent protection or fail to file patent applications covering inventions made in the course of development and commercialization activities before a competitor or another third party files a patent application covering, or publishes information disclosing, a same or similar, independently-developed invention. Such competitor&#8217;s or other third party&#8217;s patent application or published information may pose obstacles to or prohibit our ability to obtain patent protection or limit the scope of the patent protection we may obtain. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection in certain jurisdictions. In addition, publications of discoveries in the scientific literature often lag behind actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until approximately 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our future licensors were the first to conceive the inventions claimed in our owned or licensed patents or pending patent applications, or were the first to file for patent protection of such inventions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is uncertain, involves complex legal and factual questions and is the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217; patent rights are uncertain. Our and our licensors&#8217; pending and future patent applications may not mature into patents or result in issued patents that protect our technology or product candidates, in whole or in part, or effectively exclude others from commercializing competitive technologies and product candidates. The patent examination process may require us or our licensors to narrow the scope of the claims of our pending and future patent applications, and therefore, even if such patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our and our licensors&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover such technology. Any patents that we hold or in-license may be challenged or,  circumvented by third parties or narrowed, invalidated or held unenforceable in litigation or post-grant proceedings. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The patent protection we obtain for our product candidates and technology may be challenged or not sufficient to provide us with any competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our owned or licensed patent applications issue as patents, the issuance of any such patents is not conclusive as to their inventorship, scope, validity or enforceability, and such patents may be challenged, invalidated, narrowed or held to be unenforceable, including in the courts or patent offices in the U.S. and abroad, or circumvented. We may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;USPTO&#8221;), a federal court or equivalent foreign bodies, or become involved in opposition, derivation, revocation, re-examination, post-grant and inter partes review or interference proceedings, or other similar proceedings, challenging our patent rights or the patent rights of others. An adverse determination as a result of any such submission, proceeding or litigation could reduce the scope of, invalidate, or render unenforceable, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference or derivation proceedings declared by the USPTO to determine priority or ownership of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such proceedings and any other patent challenges may result in loss of patent rights, loss of exclusivity, loss of priority or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other developments related to any of the foregoing proceedings. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, some of our owned or in-licensed patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, who could market competing products and technology. In addition, we may need the cooperation of any such co-owners in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we rely on third parties to discover, develop and manufacture our product candidates, we must, at times, share certain of our trade secrets with them. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality provisions, including if applicable, confidentiality agreements, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these agreements with third parties, sharing trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could impair our competitive position and may harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate our issued patents or other intellectual property or the patents or other intellectual property of our licensors. In addition, our patents or the patents of our licensors may become involved in inventorship or priority disputes. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents or that our patents are invalid and/or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours is invalid and/or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated and/or held unenforceable, interpreted narrowly or interpreted in a manner that would not prevent competitors from entering the market. Further, we may find it impractical or undesirable to enforce our intellectual property against some third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including, e.g., lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the applicable product candidates or technology covered by the patent rendered invalid and/or unenforceable. Such a loss of patent protection could materially harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the ownership or priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or in-licensed patents. The loss of exclusivity or the narrowing of scope of our owned and/or licensed patents could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects. Even if we are successful in any of the foregoing disputes, it could result in substantial costs and be a distraction to management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceeding.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, more likely to be able to sustain the costs of complex patent litigation or proceedings than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Any of the foregoing events could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property rights on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S.. As such, we may choose not to seek to protect our intellectual property in certain jurisdictions, which could leave us without recourse to prevent competitive products from being manufactured or commercialized in such jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S.. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries or from selling or importing products made using our inventions in all jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or other intellectual property rights to develop their own products and may export otherwise infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement rights are not as strong as those in the U.S.. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not identify relevant third-party patents or pending patent applications or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing certain product candidates in highly competitive areas and cannot guarantee that any patent searches or analyses that we may conduct, including the identification of relevant patents or pending patent applications, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the U.S. and abroad that is or may be relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patents or pending patent applications covering our product candidates could have been or may be filed in the future by third parties without our knowledge. Additionally, patents and pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the manufacturing or use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending patent application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or pending patent application or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents or pending patent applications may negatively impact our ability to develop and market our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to identify or correctly interpret relevant patents or pending patent applications or if we are unable to obtain licenses to relevant patents or pending patent applications, we may be subject to infringement claims.  We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, potentially including in the form of future royalties, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be necessary for us to use the patented or other proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license or ownership from these third parties. The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources or greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to license or acquire such intellectual property or technology, or if we are forced to in-license such intellectual property or technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, or the cost of development, manufacture or commercialization may be materially increased, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under any future license agreements, such counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or commercialize, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates, if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, and a given patent may be subject to other term adjustments, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive products, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and one or more of our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign patents may be eligible for patent term extension under similar legislation, for example, in the European Union. In the U.S., the Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process provided other requirements are met. However, there are no assurances that the FDA, USPTO or any comparable foreign regulatory authority or national patent office will grant such extensions, in whole or in part and the length of any available extension may vary based on a number of factors. For example, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and enforcing patents in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the patent laws. Depending on decisions by Congress, the federal courts, and the USPTO and equivalent institutions in other jurisdictions, the laws and regulations governing patents, and interpretation thereof, could change in unpredictable ways that could weaken our and our licensors&#8217; or collaborators&#8217; ability to obtain new patents or to enforce existing or future patents. For example, in recent years the U.S. Supreme Court has ruled on several patent cases that have been interpreted to have either narrowed the scope of patent protection or weakened the rights of patent owners in certain situations. Therefore, there is increased uncertainty with regard to our and our licensors&#8217; or collaborators&#8217; ability to obtain patents in the future, as well as uncertainty with respect to the value of patents once obtained.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; or collaborators&#8217; issued patents. Assuming that other requirements for patentability are met, prior to March 16, 2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. On March 16, 2013, under the Leahy-Smith America Invents Act enacted in September 2011 (the &#8220;Leahy-Smith Act&#8221;), the U.S. transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first inventor-to-file provisions. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents, all of which could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patents and certain pending patent applications are required to be paid to the USPTO or foreign patent agencies in several</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stages over the lifetime of a patent. In certain circumstances, we may rely on our licensors to pay these fees. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar requirements during the patent application and prosecution process. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official communications within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in irrevocable abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market with similar or identical products or technology, which would harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or be threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including re-examination, interference, post-grant review, inter partes review or derivation proceedings, or other similar proceedings, before the USPTO, a federal court or an equivalent foreign body. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. In the event that any of these patents were asserted against us, we believe that we would have defenses against any such action, including that such patents are invalid and/or unenforceable, that our product candidates do not infringe such patents, or that we would be able to replace such technology with alternative, non-infringing technology. However, if any such patents were to be asserted against us and our defenses to such assertion were unsuccessful and such alternative technology was not available or technologically or commercially practical, unless we obtain a license to such patents, we could be liable for damages, which could be significant and include treble damages and attorneys&#8217; fees if we are found to willfully infringe such patents, and we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents. Any potential future legal proceedings relating to these patents could cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. If we are unsuccessful in our challenges to these patents and become subject to litigation or are unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that third-party patents asserted against us are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that such rights are invalid or unenforceable, we could be required to obtain a license from such a third party in order to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease commercializing the infringing technology or product candidates. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties and other fees, redesign</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing events would harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of others, such as any such individual&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives, develops or reduces to practice intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in litigating such claims, litigation could result in substantial costs, delay development of our product candidates and be a distraction to management. Any of the foregoing events would harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development collaborations that would help us commercialize our product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on trade secrets and agreements containing confidentiality obligations to protect our unpatented know-how, technology and other proprietary information and to maintain our competitive position. With respect to our research and development programs, we consider trade secrets and know-how to be one of our important sources of intellectual property, including our extensive knowledge of certain drug delivery techniques and drug conjugation. Trade secrets and know-how can be difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to rely on both registered and common law rights for our trademarks. We have applied to register certain of our trademarks with the USPTO and trademark authorities in certain other countries and may in the future seek to register additional trademarks in the U.S. or other countries. Our current and future trademark applications may not mature to registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced.  In the U.S. and some foreign jurisdictions, our ability to obtain and maintain trademark registrations and acquire enforceable trademark rights depends on making use of our marks in commerce, meaning we must make a certain amount of progress, depending on the jurisdiction, in our clinical studies or in the commercialization of our products.  If we fail to satisfy these requirements or any other requirements of applicable regulatory authorities, we may not have enforceable trademark rights or registrations in such jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may be unable to develop any enforceable trademark rights in relevant countries, or to protect the rights that we do develop. We may be forced to stop using our trademarks or trade names, which we need for name recognition by potential partners and customers in our markets of interest, and spend time and money rebranding. In addition, third parties have filed, and may in the future file, for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in enforcing our rights, we may not be able to use these trademarks to develop brand recognition of our company, technologies, products or services. In addition, there could be potential trade name or trademark infringement litigation brought against us by owners of other trademarks that incorporate variations of our registered or unregistered trademarks or trade names.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the trademark registration process, we may receive office actions from the USPTO or from comparable agencies in foreign jurisdictions refusing to register our trademarks. Although we would be given an opportunity to respond to those refusals, we may be unable to overcome them. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may in the future be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. In addition, third parties may file first for our trademarks or similar variations thereof in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may be unable to compete effectively, which could have an adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we own or license now or in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors, might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license now or in the future; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending owned or licensed patent applications or those that we may own or license in the future will not lead to issued patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by other persons; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in the U.S. under FDA-related safe harbor patent infringement exemptions and/or in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents or pending patent applications of others may harm our business; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file for patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently file for and obtain a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AnHeart could be difficult to integrate, divert the attention of management, and disrupt our business, and the anticipated synergies and other benefits of the AnHeart acquisition may not be realized in the amounts anticipated, or may not be realized within the anticipated timeframe, or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that there could be a loss of our existing or AnHeart&#8217;s key employees and customers, disruption of either company&#8217;s or both companies&#8217; ongoing businesses or unexpected issues, higher than expected costs and an overall post-completion process that takes longer than originally anticipated. Specifically, the following issues, among others, must be addressed in combining AnHeart&#8217;s operations with ours in order to realize the anticipated benefits of the AnHeart acquisition so the combined company performs as the parties hope:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">combining the companies&#8217; corporate functions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">combining their business with our business in a manner that permits us to achieve the synergies anticipated to result from the Acquisition, the failure of which would result in the anticipated benefits of the Acquisition not being realized in the time frame currently anticipated or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining existing and new agreements with customers, service providers, and vendors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determining whether and how to address possible differences in corporate cultures, management philosophies and strategies relating to channels, resellers, and partners;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrating the companies&#8217; administrative and information technology infrastructure;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing products and technology that allow value to be unlocked in the future; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating and forecasting the financial impact of the Acquisition transaction, including accounting impacts.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to address any of the above-listed issues could have a material adverse effect on our business, results of operations and financial position. In addition, at times the attention of certain members of our management and resources may be focused on integration planning of the businesses of the two companies and diverted from day-to-day business operations, which may disrupt our ongoing business and the business of the combined company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to meet the challenges involved in combining the two companies could, among other things, cause an interruption of, or a loss of momentum in, our activities and could adversely affect our results of operations. The overall combination of the two companies may also result in, among other things, material unanticipated problems, expenses, liabilities, competitive responses and loss of customer and other business relationships. The difficulties of combining our operations include, among others:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management and employee attention to integration matters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in integrating operations and systems, including, but not limited to, communications systems, administrative and information technology infrastructure, financial reporting and internal control systems;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges in conforming standards, controls, procedures and accounting and other policies, business cultures and compensation structures between the two companies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in integrating employees and teams of the respective businesses and attracting and retaining key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges in retaining and obtaining customers, suppliers and other commercial relationships;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in managing the expanded operations of a larger and more complex company; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential unknown liabilities, adverse consequences and unforeseen increased expenses associated with the integration.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these factors are outside of our control and any of them could result in lower revenues, higher costs and diversion of management time and energy, which could materially impact our business, financial condition and results of operations. In addition, even if the operations of the companies are integrated successfully, the full benefits of the AnHeart acquisition may not be realized, including, among others, the synergies, cost savings or sales or growth opportunities that are expected. These benefits may not be achieved within the anticipated time frame or at all. As a result, it cannot be assured that the integration will result in the realization of the full benefits expected from the AnHeart acquisition within the anticipated time frames, or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business, operations and clinical development plans and timelines and supply chain could be adversely affected by the effects of health epidemics, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our CMOs, CROs, shippers and others.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business could be adversely affected by health epidemics wherever we have clinical trial sites or other business operations. In addition, health epidemics could cause significant disruption in the operations of CMOs, CROs and other third parties upon whom we rely. For example, the COVID-19 pandemic presented a substantial public health and economic challenge around the world and affected employees, patients, communities and business operations, as well as the U.S. economy and financial markets. Geographic regions imposed &#8220;shelter-in-place&#8221; orders, quarantines or similar orders or restrictions to control the spread of epidemic disease. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on a worldwide supply chain for products to be used in our clinical trials and, if approved by the regulatory authorities, for commercialization. Quarantines, shelter-in-place and similar government orders, or the expectation that such orders, shutdowns or other restrictions could occur may impact personnel at third-party manufacturing facilities in the U.S. and other countries, or the availability or cost of materials or supplies, which could disrupt our supply chain or our ability to enroll patients in or perform testing for our clinical trials. In addition, closures of transportation carriers and modal hubs could materially impact our clinical development and any future commercialization timelines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our relationships with our suppliers or other vendors are terminated or scaled back as a result of health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Switching or adding additional suppliers or vendors involves</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays generally occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. See &#8220;Risk Factors&#8212;Risks Related to Our Dependence on Third Parties.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials may be affected by health epidemics. In the future, clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward such health epidemics or concerns among patients about participating in clinical trials during a health epidemic and public health measures imposed by the respective national governments of countries in which the clinical sites are located. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our inability to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to epidemic disease or experience additional restrictions by their institutions, city or state governments could adversely impact our clinical trial operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health epidemics may lead to disruption and volatility in the global capital markets, which increases the cost of, and adversely impacts access to, capital and increases economic uncertainty. Health epidemics may also result in volatile trading prices for the common stock of biopharmaceutical companies. To the extent health epidemics adversely affect our business, financial results and value of our common stock, it may also affect our ability to access capital, which could in the future negatively affect our liquidity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain Dr. Hung and our other key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on the management, research and development, clinical, financial and business development expertise of Dr. Hung and our executive officers, as well as the other members of our scientific, clinical and commercial teams. Although we have employment offer letters with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining qualified scientific and clinical personnel and, if we are successful in obtaining marketing approval for our product candidates, commercial personnel, is critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, in light of Dr. Hung&#8217;s central role in the discovery of all of our current product candidates, our ongoing discovery activities and development programs, the recruitment of our other executives and key employees and all other aspects of our strategy and operations, we believe our loss of Dr. Hung&#8217;s services for any reason would severely impair our business and prospects. Replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Furthermore, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited, and could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our development, regulatory, sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 220 employees. As our preclinical and clinical development progresses, we expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of research, clinical operations, regulatory affairs, general and administrative and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violates (1) the laws, regulations and guidance of the FDA, the European Commission, the EMA, the MHRA, NMPA and other similar regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, (3) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad and (4) laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product candidates, which could result in regulatory sanctions and serious harm to our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm and the delay, reduction, termination or restructuring of our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we and the third parties with whom we work, process sensitive data, and, as a result, we and the third parties with whom we work face a variety of evolving threats that could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon with whom we work.  Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by artificial intelligence (&#8220;AI&#8221;), telecommunications failures, earthquakes, fires, floods, and other similar threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds.  Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our personnel utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit or in public locations.  Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our reliance on third parties could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations.  We rely on various third parties and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, personnel email, and other functions.  We also rely on third parties to provide other products, services, parts, or otherwise to operate our business.  Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place.  If the third parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if such third parties fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.  In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective.  We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis.  Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities.  Vulnerabilities could be exploited and result in a security incident.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work.  A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, regulators, and investors, of security incidents, or to implement other requirements, such as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">providing credit monitoring.  Such disclosures and compliance with such requirements are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.  We cannot be sure that our insurance coverage, if any, will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with our personnel&#8217;s or vendors&#8217; use of generative AI technologies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Doing Business in China and Our International Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the political and economic policies or in relations between China and the United States may affect our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to our operations in China, our business, results of operations, financial condition and prospects may be influenced to a certain degree by economic, political, legal and social conditions in China or changes in government relations between China and the United States or other governments. The Chinese government may intervene in or influence our operations, which could result in a change in our operations. Any economic downturn, whether actual or perceived, further decrease in economic growth rates or an otherwise uncertain economic outlook could affect our business, financial condition and results of operations. In addition, the global macroeconomic environment is facing challenges. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic conditions, and our business operations in the long term. There is significant uncertainty about the future relationship between the United States and China with respect to trade policies, treaties, government regulations and tariffs. The Chinese government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures may benefit the overall Chinese economy, but may have a negative effect on us. Due to our operations in China, any future Chinese, U.S. or other rules and regulations that place restrictions on capital raising or other activities by companies with operations in China could affect our business and results of operations. If the business environment in China deteriorates from the perspective of domestic or international investment, or if relations between China and the United States or other governments deteriorate and geopolitical tensions between China and the United States increase, our business in China and United States may also be affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. and Chinese regulations may impact our business, our operating results, and our ability to raise capital.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. government, including the SEC, has made statements and taken certain actions that led to changes to United States and international relations, and will impact companies with connections to the United States or China, including imposing several rounds of tariffs affecting certain products manufactured in China, imposing certain sanctions and restrictions in relation to China and issuing statements indicating enhanced review of companies with certain operations based in China. It is unknown whether and to what extent new legislation, executive orders, tariffs, laws or regulations will be adopted, or the effect that any such actions would have on companies with significant connections to the United States or to China, our industry or on us. We conduct research activities and have business operations both in the United States and China. Any unfavorable government policies on cross-border relations and/or international trade, including increased scrutiny on companies with certain operations based in China, capital controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or tariffs, may affect the competitive position of our drug products, the hiring of scientists and other research and development personnel, the demand for our drug products, the import or export of raw materials in relation to drug development, our ability to raise capital, or prevent us from selling our drug products in certain countries. Furthermore, the SEC has issued statements primarily focused on companies with certain operations based in China, such as us. For example, in 2021, the Chairman of the SEC, issued a Statement on Investor Protection Related to Recent Developments in China, pursuant to which he stated that he has asked the SEC staff to engage in targeted additional reviews of filings for companies with certain operations based in China. The statement also addressed risks inherent in companies with variable interest entity (&#8220;VIE&#8221;) structures. We do not have a VIE structure and are not in an industry that is subject to foreign ownership limitations by China. However, it is possible that our periodic reports and other filings with the SEC may be subject to enhanced review by the SEC and this additional scrutiny could affect our ability to effectively raise capital in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In response to the SEC&#8217;s 2021 statement, the China Securities Regulatory Commission (&#8220;CSRC&#8221;) announced in August 2021, that &#8220;it is our belief that Chinese and U.S. regulators shall continue to enhance communication with the principle of mutual respect and cooperation, and properly address the issues related to the supervision of China-based companies listed in the U.S. so as to form stable policy expectations and create benign rules framework for the market.&#8221; While the CSRC will continue to collaborate &#8220;closely with different stakeholders including investors, companies, and relevant authorities to further promote transparency and certainty of policies and implementing measures,&#8221; it emphasized that it &#8220;has always been open to companies&#8217; choices to list their securities on international or domestic markets in compliance with relevant laws and regulations.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any new legislation, executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated or if the U.S. or Chinese governments take retaliatory actions due to the recent U.S.-China tension, such changes could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with China&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">China has implemented or will implement rules and is considering a number of additional proposals relating to data protection. China&#8217;s new Data Security Law took effect in September 2021. The Data Security Law provides that the data processing activities must be conducted based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities in China from transferring data stored in China to foreign law enforcement agencies or judicial authorities without prior approval by the Chinese government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, China&#8217;s Cyber Security Law, promulgated by the Standing Committee of the National People&#8217;s Congress in 2016 and came into effect in 2017, and the Administrative Measures for the Hierarchical Protection of Information Security promulgated by the Ministry of Public Security, National Administration of State Secrets Protection, State Cryptography Administration and other government authority in 2007, requires companies to take certain organizational, technical and administrative measures and other necessary measures to ensure the security of their networks and data stored on their networks. Specifically, the Cyber Security Law provides that China adopt a multi-level protection scheme (&#8220;MLPS&#8221;), under which network operators are required to perform obligations of security protection to ensure that the network is free from interference, disruption or unauthorized access, and prevent network data from being disclosed, stolen or tampered. Under the MLPS, entities operating information systems must have a thorough assessment of the risks and the conditions of their information and network systems to determine the level of the entity&#8217;s information and network systems. These levels range from the lowest Level 1 to the highest Level 5 pursuant to a series of national standards on the grading and implementation of the classified protection of cyber security. The grading result will determine the set of security protection obligations that entities must comply with. Entities classified as Level 2 or above should report the grade to the relevant government authority for examination and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2021, the Cyberspace Administration of China (&#8220;CAC&#8221;) published a draft revision to the existing Cybersecurity Review Measures for public comment (the &#8220;Revised Draft CAC Measures&#8221;). In 2022, together with 12 other Chinese regulatory authorities, the CAC released the final version of the Revised Draft CAC Measures (the &#8220;Revised CAC Measures&#8221;), which came into effect in 2022. Pursuant to the Revised CAC Measures, critical information infrastructure operators procuring network products and services, and online platform operators (as opposed to &#8220;data processors&#8221; in the Revised Draft CAC Measures) carrying out data processing activities which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions therein. In addition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">online platform operators possessing personal information of more than one million users seeking to be listed on foreign stock markets must apply for a cybersecurity review. In 2021, the CAC further published the Regulations on Network Data Security Management (Draft for Comment) (the &#8220;Draft Management Regulations&#8221;), under which data processors refer to individuals and organizations who determine the data processing activities in terms of the purpose and methods at their discretion. The Draft Management Regulations reiterate that data processors shall be subject to cybersecurity review if (i) they process personal information of more than one million persons and they are aiming to list on foreign stock markets, or (ii) their data processing activities affect or may affect Chinese national security. The Draft Management Regulations also request data processors seeking to list on foreign stock markets to annually assess their data security by themselves or through data security service organizations, and submit the assessment reports to relevant competent authorities. As the Draft Management Regulations are released only for public comment, the final version and the effective date thereof is subject to change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this Report, we have not received any notice from any Chinese regulatory authority identifying us as a &#8220;critical information infrastructure operator,&#8221; &#8220;online platform operator&#8221; or &#8220;data processor,&#8221; or requiring us to go through the cybersecurity review procedures pursuant to the Revised CAC Measures and the Draft Management Regulations. Based on our understanding of the Revised CAC Measures, and the Draft Management Regulations if enacted as currently proposed, we do not expect to become subject to cybersecurity review by the CAC for issuing securities to foreign investors because: (i) the clinical and preclinical data we handle in our business operations, either by its nature or in scale, do not normally trigger significant concerns over PRC national security; and (ii) we have not processed, and do not anticipate to process in the foreseeable future, personal information for more than one million users or persons. However, there remains uncertainty as to how the Revised CAC Measures, and the Draft Management Regulations if enacted as currently proposed, will be interpreted or implemented; for example, neither the Revised CAC Measures nor the Draft Management Regulations provides further clarification or interpretation on the criteria for determining those activities that &#8220;affect or may affect national security&#8221; and relevant Chinese regulatory authorities may interpret it broadly. Furthermore, there remains uncertainty as to whether the Chinese regulatory authorities may adopt new laws, regulations, rules, or detailed implementation and interpretation in relation, or in addition, to the Revised CAC Measures and the Draft Management Regulations. While we intend to closely monitor the evolving laws and regulations in this area and take all reasonable measures to mitigate compliance risks, we cannot guarantee that our business and operations will not be adversely affected by the potential impact of the Revised CAC Measures, the Draft Management Regulations or other laws and regulations related to privacy, data protection and information security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, the National People&#8217;s Congress released the Personal Information Protection Law, which became effective in 2021. The Personal Information Protection Law provides a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in China, and the processing of personal information of persons in China outside of China if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in China. The Personal Information Protection Law also provides that critical information infrastructure operators and personal information processing entities who process personal information meeting a volume threshold set by Chinese cyberspace regulators are also required to store in China personal information generated or collected in China, and to pass a security assessment administered by Chinese cyberspace regulators for any export of such personal information. Lastly, the Personal Information Protection Law contains proposals for significant fines for serious violations of up to RMB 50 million or 5% of annual revenues from the prior year and may also be ordered to suspend any related activity by competent authorities. We do not maintain, nor do we intend to maintain in the future, personally identifiable health information of patients in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain industry-specific laws and regulations affect the collection and transfer of data in the PRC. The Regulations on the Administration of Human Genetic Resources of the PRC (the &#8220;HGR Regulation&#8221;), promulgated by the State Council, came into effect in 2019. It stipulates that foreign organizations, individuals, and the entities established or actually controlled by foreign organizations or individuals are forbidden to collect, preserve and export China&#8217;s human genetic resources. Foreign organizations and the entities established or actually controlled by foreign organizations or individuals may only utilize and be provided with China&#8217;s human genetic resources after satisfaction of all requirements under the HGR Regulation and other applicable laws, such as (i) China&#8217;s human genetic resources being utilized only in international cooperation with Chinese scientific research institutions, universities, medical institutions, and enterprises for scientific research and clinical trials after completion of requisite approval or filing formalities with competent governmental authorities, and (ii) China&#8217;s human genetic resources</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information being provided after required filing and information backup procedures have been gone through. In 2020, the SCNPC promulgated the Biosecurity Law of the PRC, which reaffirms the regulatory requirements stipulated by the HGR Regulation while potentially increasing the administrative sanctions where China&#8217;s human genetic resources are collected, preserved, exported or used in international cooperation in violation of applicable laws. The Ministry of Science and Technology published the Implementing Rules for the Regulations on the Administration of Human Genetic Resources (the &#8220;HGR Implementing Rules&#8221;), which came into effect in 2023. The HGR Implementing Rules have, among other things, further clarified the scope of China&#8217;s human genetic resources information, improved the procedure rules for applicable approval, filing and security review, and refined the provisions with respect to the forbiddance on the collection, preservation and export of China&#8217;s human genetic resources by foreign organizations, individuals, and the entities established or actually controlled by foreign organizations or individuals. There remain significant uncertainties as to how various provisions of the HGR Regulation and the related laws and regulations may be interpreted and implemented. Given such uncertainty, although we have made great efforts to comply with mandatory requirements of laws and government authorities in this regard, we cannot assure you that we will be deemed at all times in full compliance with the HGR Regulation, the Biosecurity Law of the PRC, the HGR Implementing Rules and other applicable laws in our utilizing of and dealing with China&#8217;s human genetic resources. As a result, we may be exposed to compliance risks under the HGR Regulation, the Biosecurity Law of the PRC and the HGR Implementing Rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation, application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with China&#8217;s new Cyber Security Law and Data Security Law could significantly increase the cost to us of providing our service offerings, require significant changes to our operations or even prevent us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in the future. Despite our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security, it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed on us by the Cyber Security Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with such law or regulations or any other obligations relating to privacy, data protection or information security, or any compromise of security that results in unauthorized access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties from contracting with us or result in investigations, fines, suspension or other penalties by Chinese government authorities and private claims or litigation, any of which could adversely affect our business, financial condition and results of operations. Even if our practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and brand and adversely affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law, the Revised CAC Measures and the recent Chinese government actions could adversely affect our ability, on favorable terms, to raise capital, including engaging in follow-on offerings of our securities in the U.S. market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pharmaceutical companies operating in China are required to comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our current and planned operations in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical industry in China is subject to extensive government regulation and supervision. The regulatory framework addresses all aspects of operating in the pharmaceutical industry, including product development activities, clinical trials, registration, production, distribution, packaging, labeling, storage and shipment, advertising, licensing and post-approval pharmacovigilance certification requirements and procedures, periodic renewal and reassessment processes, data security and data privacy protection requirements and compliance and environmental protection. In particular, we are subject to many of these laws and regulations because our wholly-owned subsidiary, AnHeart Therapeutics (Hangzhou) Co., Ltd., is the Marketing Authorization Holder (&#8220;MAH&#8221;) for taletrectinib in China, and conducts research, development, and assists Innovent with certain commercialization activities in China. Violation of applicable laws and regulations may materially and adversely affect our business. The regulatory framework governing the pharmaceutical industry in China is subject to change and amendment from time to time. Any such change or amendment could materially and adversely impact our business, financial condition and prospects. The Chinese government has introduced various reforms to the Chinese healthcare system in recent years and may continue to do so, with an overall objective to expand basic medical insurance coverage and improve the quality and reliability of healthcare services. The specific regulatory changes under the various reform initiatives</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">remain uncertain. The implementing measures to be issued may not be sufficiently effective to achieve the stated goals, and as a result, we may not be able to benefit from such reform to the extent we expect, if at all. Moreover, the various reform initiatives could give rise to regulatory developments, such as more burdensome administrative procedures, which may have an adverse effect on our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As a company with operations and business relationships outside of the United States, our business is subject to economic, political, regulatory and other risks associated with international operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company with operations in China, our business is subject to risks associated with conducting business outside the United States. In addition to our activities conducted by AnHeart Therapeutics (Hangzhou) Co., Ltd. in China, some of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing and changing regulatory requirements for product approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially reduced protection for intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in non-U.S. regulations and customs, tariffs and trade barriers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in non-U.S. currency exchange rates of the RMB; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increasing geopolitical tensions between the U.S. and China and changes in a specific country&#8217;s or region&#8217;s political or economic environment especially with respect to a particular country&#8217;s treatment of or stance towards other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing reimbursement regimes and price controls in certain non-U.S. markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative consequences from changes in tax laws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variable tax treatment in different jurisdictions of options granted under our equity incentive plans;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, health epidemics, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with Chinese environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, fire safety and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Despite our efforts to comply fully with environmental and safety regulations, any violation of these regulations may result in substantial fines, criminal sanctions, revocations of operating permits, the shutdown of our facilities and the incurrence of obligations to take corrective measures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover costs and expenses incurred due to on-the-job injuries to our employees and public liability insurance to cover costs and expenses that may be incurred if third parties are injured on our property, such insurance may not provide adequate coverage against potential liabilities. Furthermore, the Chinese government may take steps towards the adoption of more stringent environmental</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations, and, due to the possibility of unanticipated regulatory or other developments, the amount and timing of future environmental expenditures may vary substantially from those currently anticipated. If there is any unanticipated change in the environmental regulations, our third-party manufacturers and other service providers may incur substantial capital expenditures to install, replace, upgrade or supplement their manufacturing facilities and equipment or make operational changes to limit any adverse impact or potential adverse impact on the environment in order to comply with new environmental protection laws and regulations. If such costs become prohibitively expensive, we may be forced to cease certain aspects of our business operations and our business may be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development in the Chinese legal system could materially and adversely affect us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chinese laws and regulations govern our operations in China and the PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. As the laws and regulations are relatively new and the PRC legal system continues to evolve, there may be room for discretion in the implementation of these laws and regulations. And as these laws and regulations are evolving in response to changing economic and other conditions, factors related to the application and implementation of these laws and regulations may affect our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), and similar anti-corruption and anti-bribery laws of China and other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of China and other countries in which we operate. The FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from, directly or indirectly, offering, authorizing or making improper payments to non-U.S. government officials for the purpose of obtaining or retaining business or other advantage. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. If our procedures and controls to monitor anti-bribery compliance fail to protect us from reckless or criminal acts committed by our employees or agents or if we, or our employees, agents, contractors or other collaborators, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory requirements on currency exchange may limit our ability to receive and use effectively financing in foreign currencies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chinese subsidiaries&#8217; ability to obtain currency exchange is subject to certain foreign exchange regulations and, in the case of transactions under the capital account, requires the approval of and/or registration with Chinese</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government authorities, including the State Administration of Foreign Exchange (&#8220;SAFE&#8221;). In particular, if we finance our Chinese subsidiaries by means of foreign debt from us or other foreign lenders, the amount is not allowed to, among other things, exceed the statutory limits and such loans must be registered with the local branch of SAFE. If we finance our Chinese subsidiaries by means of additional capital contributions, these capital contributions are subject to registration with the State Administration for Market Regulation or its local branch, reporting of foreign investment information with the Ministry of Commerce of the People&#8217;s Republic of China (&#8220;MOFCOM&#8221;), or its local branch or registration with other governmental authorities in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In light of the various requirements imposed by Chinese regulations on loans to, and direct investment in, China-based entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government requirements or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans or capital contributions by us to our Chinese subsidiaries. If we fail to adhere to such requirements or obtain such approval, our ability to fund our Chinese operations, including research and development activities through AnHeart Therapeutics (Hangzhou) Co., Ltd., may be negatively affected, which could materially and adversely affect our ability to fund and expand our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chinese regulations relating to the establishment of offshore special purpose companies by residents in China may subject our China resident beneficial owners or our wholly foreign-owned subsidiaries in China to liability or penalties, limit our ability to inject capital into these subsidiaries, limit these subsidiaries&#8217; ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2014, SAFE promulgated the SAFE Circular 37, which requires residents of China to register with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such residents&#8217; legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a &#8220;special purpose vehicle.&#8221; The term &#8220;control&#8221; under SAFE Circular 37 is broadly defined as the operation rights, beneficiary rights or decision-making rights acquired by residents of China in the offshore special purpose vehicles or Chinese companies by such means as acquisition, trust, proxy, voting rights, repurchase, convertible bonds or other arrangements. SAFE Circular 37 further requires amendment to the registration in the event of any changes with respect to the basic information of or any significant changes with respect to the special purpose vehicle, such as an increase or decrease of capital contributed by China residents, share transfer or exchange, merger, division or other material events. If the shareholders of the offshore holding company who are residents of China do not complete their registration with the local SAFE branches, the Chinese subsidiaries may be prohibited from making distributions of profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore parent company and from carrying out subsequent cross-border foreign exchange activities, and the offshore parent company may be restricted in its ability to contribute additional capital into its Chinese subsidiaries. Moreover, failure to comply with the SAFE registration and amendment requirements described above could result in liability under Chinese law for evasion of applicable foreign exchange restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain residents of China may hold direct or indirect interests in our company, and we will request residents of China who we know hold direct or indirect interests in our company, if any, to make the necessary applications, filings and amendments as required under SAFE Circular 37 and other related rules. However, we may not at all times be fully aware or informed of the identities of our shareholders or beneficial owners that are required to make such registrations, and we cannot provide any assurance that these residents will comply with our requests to make or obtain any applicable registrations or comply with other requirements under SAFE Circular 37 or other related rules. The failure or inability of our China resident shareholders to comply with the registration procedures set forth in these regulations may subject us to fines or legal sanctions, restrictions on our cross-border investment activities or those of our China subsidiaries and limitations on the ability of our wholly foreign-owned subsidiaries in China to distribute dividends or the proceeds from any reduction in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into these subsidiaries. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under Chinese law for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to make distributions to you could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and our shareholders face uncertainties in China with respect to indirect transfers of equity interests in China resident enterprises.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indirect transfer of equity interests in China resident enterprises by a non-China resident enterprise (&#8220;Indirect Transfer&#8221;), is potentially subject to income tax in China at a rate of 10% on the gain if such transfer is considered as not having a commercial purpose and is carried out for tax avoidance. The State Administration of Taxation (&#8220;SAT&#8221;) has issued several rules and notices to tighten the scrutiny over acquisition transactions in recent years. The Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises (&#8220;SAT Circular 7&#8221;), sets out the scope of Indirect Transfers, which includes any changes in the shareholder&#8217;s ownership of a foreign enterprise (excluding any China resident enterprise) holding Chinese Taxable Assets directly or indirectly in the course of a group&#8217;s overseas restructuring, and the factors to be considered in determining whether an Indirect Transfer has a commercial purpose. The term &#8220;Chinese Taxable Assets&#8221; refers to the assets of a branch or establishment in China, real estate located within China, and equity interests of a China resident enterprise, among others, which are directly held by a non-China resident enterprise and for which the proceeds from its/their transfer are subject to income tax in China according to the relevant provisions of China&#8217;s tax laws. An Indirect Transfer satisfying all the following criteria will be deemed to lack a bona fide commercial purpose and be taxable under Chinese laws: (i) 75% or more of the equity value of the foreign enterprise being transferred is derived directly or indirectly from the Chinese Taxable Assets; (ii) at any time during the one-year period before the indirect transfer, 90% or more of the total asset value of the foreign enterprise (excluding cash) is comprised directly or indirectly of investments in China, or during the one-year period before such Indirect Transfer, 90% or more of the foreign enterprise&#8217;s income is derived directly or indirectly from China; (iii) the functions performed and risks assumed by the foreign enterprise and any of its subsidiaries that directly or indirectly hold the Chinese Taxable Assets are limited and are insufficient to prove their economic substance; and (iv) the non-Chinese tax payable on the gain derived from the indirect transfer of the Chinese Taxable Assets is lower than the potential Chinese income tax on the direct transfer of such Chinese Taxable Assets. A transaction that does not satisfy all four tests in the immediately preceding sentence may nevertheless be deemed to lack a bona fide commercial purpose if the taxpayer cannot justify such purpose from a totality approach, taking into account the transferred group&#8217;s value, income, asset composition, the history and substance in the structure, the non-Chinese tax implications, any tax treaty benefit and the availability of alternative transactions. Nevertheless, a non-China resident enterprise&#8217;s buying and selling shares of the same listed foreign enterprise on the public market will fall under the safe harbor available under SAT Circular 7 if the shares sold were purchased on the public market as well and will not be subject to Chinese tax pursuant to SAT Circular 7.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face uncertainties regarding the reporting requirements for and impact on (i) future private equity financing transactions, share exchanges or other transactions involving the transfer of shares in our company by investors that are non-China resident enterprises, or (ii) the sale or purchase of shares of other non-China resident companies directly or indirectly holding Chinese Taxable Assets by us. For example, the Chinese tax authorities may consider that a future securities offering involves an indirect change of shareholding in our Chinese subsidiaries and therefore it may be regarded as an Indirect Transfer under SAT Circular 7. Even if we believe no SAT Circular 7 reporting is required on the basis that such an offering has commercial purposes and is not conducted for tax avoidance, Chinese tax authorities may urge us to report under SAT Circular 7 and request that we and our Chinese subsidiaries assist with the filing. As a result, we and our Chinese subsidiaries may be required to spend significant resources to provide assistance and comply with SAT Circular 7, or to establish that we or our investors that are non-China resident enterprises should not be subject to tax under SAT Circular 7, for such an offering or other transactions, which may have an adverse effect on our and our Chinese subsidiaries&#8217; financial condition and day-to-day operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any failure to comply with Chinese regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies (the &#8220;Stock Option Rules&#8221;). In accordance with the Stock Option Rules and other relevant rules and regulations, Chinese citizens or non-Chinese citizens residing in China for a continuous period of not less than one year who participate in any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a Chinese subsidiary of such overseas listed company, and complete certain procedures. Our employees who are Chinese citizens or who reside in China for a continuous period of not less than one year and who participate in our stock incentive plans are subject to such regulation. We plan to assist our employees to register their equity awards. However, any failure of our Chinese individual beneficial owners and holders of equity awards to comply with the SAFE registration requirements may subject them to fines and legal sanctions and may limit the ability of our Chinese subsidiaries to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our employees under Chinese law.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our securities may be volatile and fluctuate substantially, which could result in substantial losses for our investors and may subject us to securities litigation suits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our securities may be volatile. The stock market in general and the market for pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their securities or above the price they paid. The market price for our securities may be influenced by many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of health epidemics; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of any future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results from, delays in or termination of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lower than expected market acceptance of our product candidates following approval for commercialization;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates by us or by any securities analysts who might cover our securities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions or trends in our industry; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the pharmaceutical industry; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investors&#8217; general perception of our company and our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment or departure of key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our securities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to intellectual property rights, including patents, litigation matters and our ability to obtain, maintain, defend, protect and enforce patent and other intellectual property rights for our technologies; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proposed changes to healthcare laws in the U.S., China or other foreign jurisdictions, or speculation regarding such changes including changes in the structure of healthcare payment systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general political and economic conditions; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The dual-class structure of our common stock has the effect of concentrating voting power with our Chief Executive Officer, which limits other stockholders&#8217; ability to influence the outcome of important transactions, including a change in control.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Hung holds all of the outstanding shares of our Class B common stock and approximately 18% of our Class A and Class B common stock outstanding. In addition to voting together with the Class A common stock (with one vote per share) on all matters, the holders of Class B common stock have (i) the right to elect and remove without cause three of our directors plus at least 50% of all directors in excess of seven and (ii) an approval right over any acquisition (whether by merger, sale of shares or sale of assets) or our liquidation. Accordingly, Dr. Hung has the ability to control or exert substantial influence over all matters submitted to our stockholders for approval, including the election of directors and amendments of our organizational documents, and an approval right over any acquisition or liquidation of our company. Dr. Hung may have interests that differ from those of the other stockholders and may vote in a way with which the other stockholders disagree and which may be adverse to their interests. This concentrated control may have the effect of delaying, preventing or deterring a change in control, could deprive our stockholders of an opportunity to receive a premium for their capital stock as part of a sale of our company, and might ultimately affect the market price of shares of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot predict the impact our dual-class structure may have on the market price of our Class A common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict whether our dual-class structure, combined with the concentrated voting power of Dr. Hung by virtue of his ownership of 100% of the outstanding shares of our Class B common stock, will result in a lower or more volatile market price of our Class A common stock in the future, or in adverse publicity or other adverse consequences. Certain index providers have announced restrictions on including companies with multi-class share structures in certain of their indices. For example, in 2017, FTSE Russell and Standard &amp; Poor&#8217;s announced that they would cease to allow most newly public companies utilizing dual or multi-class capital structures to be included in their indices. Under the announced policies, our dual-class capital structure makes us ineligible for inclusion in any of these indices. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, exclusion from stock indices would likely preclude investment by many of these funds and could make our securities less attractive to other investors. As a result, the market price of our Class A common stock could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There can be no assurance that we will be able to comply with the continued listing standards of the NYSE.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Class A common stock and warrants are listed on the NYSE under the symbols &#8220;NUVB&#8221; and &#8220;NUVBW,&#8221; respectively. Our continued eligibility for listing will depend on our compliance with the continued listing standards of the NYSE and may depend on the number of our shares that are redeemed. If the NYSE delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limited availability of market quotations for our securities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a limited amount of analyst coverage; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decreased ability to issue additional securities or obtain additional financing in the future. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales, or the perception of future sales, by us or our stockholders in the public market could cause the market price for our securities to decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sale of our securities in the public market, or the perception that such sales could occur, could harm the prevailing market price of our securities. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to our acquisition of AnHeart, we had a total of approximately 219,083,219 shares of Common Stock outstanding, consisting of approximately 218,083,219 shares of Class A Common Stock and 1,000,000 shares of Class B Common Stock. All of these shares are freely tradable without registration under the Securities Act, and without restriction by persons other than our &#8220;affiliates&#8221; (as defined under Rule 144 of the Securities Act, &#8220;Rule 144&#8221;), including our directors, executive officers and other affiliates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 3, 2024, the Company held its Annual Meeting at which the Company&#8217;s stockholders approved for the purpose of complying with the listing rules of the New York Stock Exchange, the issuance of up to 85,120,200 shares of Class A Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock issued in April 2024. The conversion of the Convertible Preferred Stock into 85,120,200 shares of Class A Common Stock was completed and those shares were issued and outstanding as of September 30, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the shares of Class A Common Stock reserved for future issuance under our equity incentive plans will become eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements, lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144, as applicable. Our compensation committee of our board of directors may determine the exact number of shares to be reserved for future issuance under our equity incentive plans at its discretion. We have filed and expect to file registration statements on Form S-8 under the Securities Act to register shares of Class A Common Stock or securities convertible into or exchangeable for shares of Class A Common Stock issued pursuant to our equity incentive plans. Any such Form S-8 registration statements will automatically become effective upon filing. Accordingly, shares registered under such registration statements will be available for sale in the open market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may also issue our securities in connection with investments or acquisitions. The amount of shares of Class A Common Stock issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding shares of Class A Common Stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our Class A common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our securities unless you sell your securities for a price greater than that which you paid for it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is no guarantee that our warrants will be in the money at the time they become exercisable, and they may expire worthless.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise price for our outstanding warrants is $11.50 per share of Class A common stock. There is no guarantee that any of our warrants will be in the money following the time they become exercisable and prior to their expiration, and as such, the warrants may expire worthless.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may issue additional securities without your approval, which would dilute your ownership interests and may depress the market price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have options outstanding to purchase approximately 57,729,709 shares of Class A Common Stock. Pursuant to the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) and the Employee Stock Purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan (the &#8220;2021 ESPP&#8221;), we may issue under the 2021 Plan an aggregate of up to 46,146,268 shares of Class A Common Stock and Class B Common Stock, which amount will be subject to increase from time to time. In addition, in the AnHeart acquisition, we assumed the AnHeart equity incentive plans and reserved an aggregate of approximately 15,943,933 shares of Class A Common Stock for issuance upon exercise of outstanding options or settlement of outstanding restricted stock units issued under those plans. We may also issue additional shares of Class A Common Stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of additional shares or other equity securities of equal or senior rank would have the following effects:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">existing stockholders&#8217; proportionate ownership interest in our company will decrease; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount of cash available per share, including for payment of dividends in the future, may decrease;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relative voting strength of each previously outstanding common stock may be diminished; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market price of our securities may decline. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our amended and restated certificate of incorporation and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult, and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation contains provisions that may delay or prevent an acquisition of the company or change in our management in addition to the significant rights of Dr. Hung as the holder of 100% of the outstanding shares of our Class B common stock. These provisions may make it more difficult for stockholders to replace or remove members of our board of directors. Because the board of directors is responsible for appointing the members of the management team, these provisions could in turn frustrate or prevent any attempt by our stockholders to replace or remove our current management. In addition, these provisions could limit the price that investors might be willing to pay in the future for shares of our Class A common stock. Among other things, these provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the limitation of the liability of, and the indemnification of, our directors and officers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on actions by our stockholders except at an annual or special meeting of stockholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on actions by our stockholders by written consent; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of the board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the board of directors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent a third party from acquiring or merging with us, whether or not it is desired by, or beneficial to, our stockholders. This could also have the effect of discouraging others from making tender offers for our Class A common stock, including transactions that may be in our stockholders&#8217; best interests. Finally, these provisions establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. These provisions would apply even if the offer may be considered beneficial by some stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a breach of fiduciary duty; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine or otherwise related to our internal affairs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are eligible to report as a &#8220;smaller reporting company,&#8221; and as a result of the reduced reporting requirements applicable to &#8220;smaller reporting companies,&#8221; our securities may be less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are eligible to report as a smaller reporting company.  For as long as we continue to be eligible to report as a &#8220;smaller reporting company,&#8221; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies,&#8221; including exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive because we rely on any of these exemptions, there may be a less active trading market for our securities and the price of our securities may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the NYSE. Section 302 of the Sarbanes-Oxley Act requires, among other things, that public companies report on the effectiveness of our disclosure controls and procedures in our quarterly and annual reports and, beginning with this report, Section 404 of the Sarbanes-Oxley Act requires that we perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Annual Report</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on Form 10-K for that year. This has required us to incur substantial additional professional fees and internal costs to expand our accounting and finance functions and to expend significant management efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the NYSE, the SEC or other regulatory authorities. In addition, our securities may not be able to remain listed on the NYSE or any other securities exchange.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will incur costs and demands upon our management as a result of complying with the laws and regulations affecting public companies in the U.S., which may harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company listed in the U.S., we incur on an ongoing basis significant legal, accounting and other expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and the NYSE may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from regular business activities to compliance activities. If, notwithstanding our efforts, we fail to comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with these rules might also make it more difficult for us to obtain certain types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our securities adversely, the price and trading volume of our securities could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity research analysts may cease providing research coverage of our securities at any time, and such lack of research coverage may adversely affect the market price of our securities. In any event, we do not have any control over the analysts or the content and opinions included in their reports and the price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our securities&#8217; prices or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unresolved_staff_comments_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolved </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_ce117189-0836-44cb-8e9c-4bac9608af83" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_ce117189-0836-44cb-8e9c-4bac9608af83_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bersecurity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property and confidential information that is proprietary, strategic or competitive in nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee, together with our information security function and third-party service providers  help identify, assess, and manage the Company&#8217;s cybersecurity threats and risks. Additionally they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods including, for example using automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#8217;s risk profile, evaluating threats reported to us, conducting internal and/or external audits,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ce117189-0836-44cb-8e9c-4bac9608af83_1" continuedAt="F_ce117189-0836-44cb-8e9c-4bac9608af83_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting threat assessments for internal and external threats, third party threat assessments, conducting vulnerability assessments to identify vulnerabilities, and using external intelligence feeds.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: cybersecurity-related policies and procedures (including incident response plans and policies, a vulnerability management policy, disaster recovery/business continuity plans), incident detection and response, periodic risk assessments, implementation of security standards/certifications, encryption of data, network security and system monitoring controls (including technology solutions such as antivirus, firewalls and monitoring tools), awareness training for all employees, security measures, asset management, tracking and disposal, penetration testing, cybersecurity insurance coverage, and a dedicated cybersecurity staff.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f46447b-1b56-4282-8b26-0e0ed3abcb41" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba83c675-0623-4d90-976b-65fda94f46c1" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into the Company&#8217;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#8217;s enterprise risk management program; (2) security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk, and (4) we have a cybersecurity incident response plan to identify, assess, respond to, and inform escalating levels of management based on the nature and severity of such incidents.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5148af86-a983-4a51-ac01-4640f7751850" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party service providers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example Professional services firms, including legal counsel, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers (including SIEM tools and 24/7 managed detection and response), penetration testing firms, and dark web monitoring services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business,  such as application providers, hosting companies, and contract research organizations. We have a vendor management program to manage cybersecurity risks associated with our use of these providers.  The program includes a risk assessment for each vendor, a security questionnaire, review of the vendor's written security program, review of security assessments and other reports. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60798e41-7935-409a-a7c0-73ebacc773e8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendor management process</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03618b92-aa4b-48a5-9916-d831e898beb7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affect</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company and how they may do so, see the section titled &#8220;Risk Factors&#8221; in Item 1A of this Annual Report on Form 10-K, including the risk factor titled &#8220;&#8212;Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or experience security breaches or other unauthorized or improper access.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><ix:nonNumeric id="F_00d3a543-f5ed-4640-b9b6-7fa5d92f0285" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_00d3a543-f5ed-4640-b9b6-7fa5d92f0285_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37f2f9dd-31df-4a5f-94b8-353ad397c52f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for oversight of the Company&#8217;s cybersecurity risk.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_dd5561ee-14e4-4c88-b829-969b00dc7027" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a64b5aab-2c69-41aa-8fa3-f44639d038a6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true" continuedAt="F_a64b5aab-2c69-41aa-8fa3-f44639d038a6_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure, Operations and Cyber Security</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a64b5aab-2c69-41aa-8fa3-f44639d038a6_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> who has  fifteen years of experience in the industry and oversees the Company&#8217;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.</span></ix:continuation></span></p><div><ix:nonNumeric id="F_61ddaf5a-9acf-4f21-92e0-67c543ca564e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true" continuedAt="F_61ddaf5a-9acf-4f21-92e0-67c543ca564e_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c9980b3-4910-4071-a021-5dfa75131cba" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7b9d1b8-dc19-4e8a-a765-b0135919220e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#8217;s overall risk management strategy,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#8217;s cybersecurity program.</span></p><div><ix:nonNumeric id="F_1e63d364-05e1-42cb-9974-c60c572c2154" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true" continuedAt="F_1e63d364-05e1-42cb-9974-c60c572c2154_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ce117189-0836-44cb-8e9c-4bac9608af83_2"><div><ix:continuation id="F_00d3a543-f5ed-4640-b9b6-7fa5d92f0285_1"><div><ix:continuation id="F_61ddaf5a-9acf-4f21-92e0-67c543ca564e_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1e63d364-05e1-42cb-9974-c60c572c2154_1" continuedAt="F_1e63d364-05e1-42cb-9974-c60c572c2154_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and policies include </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b7c172f-96a7-43db-bb1b-09b7a509cf1d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting to the audit committee</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the board of directors for certain cybersecurity incidents.</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_1e63d364-05e1-42cb-9974-c60c572c2154_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors and audit committee receive periodic reports concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="properties_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Prop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">erties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located in New York, New York, where we lease approximately 7,900 square feet of office space under a lease that terminates in 2027, with an option for us to extend the lease for an additional five years which is not reasonably assured of exercise, and in San Francisco, where we lease approximately 19,418 square feet of office space that terminates in 2029. We also occupy office space located in Burlington, Massachusetts, where we lease approximately 2,235 square feet of office space under a lease that terminates in 2027, as well as a total of approximately 1,735 square meters of office space in the People&#8217;s Republic of China, in the cities of Beijing, Guangzhou, Hangzhou and Shanghai, under leases that terminate in 2026 through 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="legal_proceedings_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="mine_safety_disclosures_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Sa</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fety Disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="registrant_common_equity_related_stock_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Com</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mon Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, Panacea and Legacy Nuvation Bio completed the Merger. Following the Merger, we changed the name of the combined company to Nuvation Bio Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Class A common stock and warrants to purchase Class A common stock originally began trading as units on The New York Stock Exchange on July 1, 2020. Prior to July 1, 2020, there was no public market for our securities. Following the Merger, beginning February 11, 2021, our Class A common stock and warrants to purchase Class A common stock continued trading on The New York Stock Exchange under the symbols &#8220;NUVB&#8221; and &#8220;NUVB.WS,&#8221; respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Record</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 14, 2025, there were approximately 55 holders of record of our Class A common stock and 20 holders of record of our warrants to purchase shares of our Class A common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="selected_financial_data_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:1.067%;text-indent:-11.579%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="discussion_analysis_financial_condition_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inancial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are identified by words such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part I, Item 1A &#8212; &#8220;Risk Factors,&#8221; and elsewhere in this report. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. We were founded in 2018 by our chief executive officer, David Hung, M.D., who founded Medivation, Inc. and led its successful development of oncology drugs Xtandi&#174; and talazoparib (now marketed as Talzenna&#174;), leading to its $14.3 billion sale to Pfizer Inc. (&#8220;Pfizer&#8221;) in 2016. We leverage our team&#8217;s extensive expertise in medicinal chemistry, preclinical development, drug development, business development, manufacturing, and commercialization to pursue oncology targets validated by strong clinical or preclinical data and develop novel small molecules that improve the activity and overcome the liabilities of currently marketed drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of our April 2024 acquisition of AnHeart Therapeutics Ltd. ("AnHeart"), our most advanced clinical-stage product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer ("NSCLC"). Taletrectinib is being evaluated in patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I in China, and TRUST-II, a global study. Taletrectinib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of patients with ROS1+ NSCLC and other NSCLC indications, and Breakthrough Therapy Designations by both the U.S. FDA and China&#8217;s National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC. Based on pooled results of the TRUST-I and TRUST-II studies, the Company submitted a New Drug Application (&#8220;NDA&#8221;) for taletrectinib to the U.S. FDA in October 2024 for the treatment of patients with advanced ROS1+ NSCLC who either have or have not previously been treated with a ROS1 tyrosine kinase inhibitor (&#8220;TKI&#8221;). Based on results of the TRUST-I clinical study, China&#8217;s NMPA has accepted and granted Priority Review Designations to New Drug Applications for taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs. Worldwide development and commercial rights to taletrectinib have been in-licensed from Daiichi Sankyo. Commercial rights to taletrectinib have been out-licensed in China and Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to taletrectinib, our clinical-stage pipeline includes differentiated, novel oncology product candidates that have been generated from our proprietary drug discovery and development programs or acquired through business development activities:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 ("mIDH1"). Safusidenib is being evaluated in a Phase 2 study in patients with diffuse IDH1-mutant </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">glioma. The Company is advancing its clinical development strategy for safusidenib with registrational intent based on clinical data generated to date, including two complete responses in high-grade glioma.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-1511 is our first clinical-stage drug-drug conjugate ("DDC"), which fuses a targeting agent to a widely used chemotherapy agent. NUV-1511 is being evaluated in a Phase 1/2 study in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu&#174; and/or Trodelvy&#174; per approved U.S. FDA labeling, human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer, metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;), advanced pancreatic cancer, and platinum-resistant ovarian cancer ("PROC").</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal ("BET") inhibitor that inhibits BRD4. As previously announced, we are evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Developments
</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in patients with advanced ROS1+ NSCLC, which was presented at the European Society of Medical Oncology Congress 2024.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, was appointed as Chairman of the Board of Directors. Additionally, Robert Bazemore was appointed as the lead independent director.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we announced the appointment of Philippe Sauvage as the Company&#8217;s Chief Financial Officer.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we announced submission of a NDA to the FDA for the full approval of taletrectinib for the treatment of patients with advanced ROS1+ NSCLC (line agnostic). In December 2024, the FDA accepted the NDA with Priority Review designation and assigned a Prescription Drug User Fee Action (&#8220;PDUFA&#8221;) target action date of June 23, 2025. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, China&#8217;s NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not been previously treated with ROS1 TKIs. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we announced that we had entered into a non-dilutive financing of up to $250.0 million from Sagard. The financing is comprised of a $150.0 million synthetic royalty financing and a $100.0 million senior secured term loan.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception in 2018, we have focused substantially all of our resources on conducting research and development activities, including drug discovery, preclinical studies, clinical trials, establishing and maintaining our intellectual property portfolio, developing our manufacturing network and managing the manufacture of clinical and research material, hiring personnel, raising capital and providing general and administrative support for these operations. Our revenue related to its out-licensing collaborative agreements consists of upfront license fees and research and development services revenue from its collaboration agreements. We have funded our operations to date primarily from the issuance and sale of our common and preferred stock, including through the Merger and a Private Investment in Public Equity ("PIPE") financing in connection with the Merger.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses in each year since inception. As of December 31, 2024, we had an accumulated deficit of $910.7 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations as well as a charge related to the acquisition of an in-process research and development asset. We expect to continue to incur</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant expenses and increasing operating losses over at least the next several years. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance product candidates through clinical trials;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursue regulatory approval of product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operate as a public company;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our preclinical programs and clinical development efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue research activities for the discovery of new product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture supplies for our preclinical studies and clinical trials.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, audit, accounting, regulatory, tax-related, director and officer insurance, investor relations and other expenses that we did not incur as a private company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the public or private sale of equity, government or private party grants, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or any commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our Common Stock. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, we announced the closing of a non-dilutive financing of up to $250.0 million from Sagard. The financing is comprised of a $150.0 million synthetic royalty financing and a $100.0 million senior secured term loan. The $150 million from the synthetic royalty financing and the first $50.0 million tranche of the term loan will be funded conditioned upon FDA&#8217;s approval of taletrectinib on or prior to September 30, 2025. The transaction will support the U.S. launch of taletrectinib and general corporate purposes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into collaborative arrangements for the research and development, and commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license in-licensed compound to other parties. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost reimbursement arrangements and royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We receive payments from our customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until we perform our obligations under the arrangement.   In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with third-party contract organizations, and consultants;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to production of drug substance, including fees paid to contract manufacturers;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical trials; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, which include salaries, benefits and stock-based compensation.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks and estimates of services performed using information and data provided to us by our vendors and third-party service providers. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and as services are performed. We expense in-process research and development projects acquired as part of asset acquisitions that have no alternative future use.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our research and development expenses to increase for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, and as we begin to conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel-related costs, facilities costs, depreciation and amortization expenses and professional services expenses, including legal, human resources, audit and accounting services. Personnel-related costs consist of salaries, benefits and stock-based compensation. Facilities costs consist of rent and maintenance of facilities. We anticipate increased expenses related to compliance with the rules and regulations of the SEC, NYSE, insurance premiums, investor relations activities and other administrative and professional services.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense) consists of change in fair value of warrant liabilities, interest earned on our cash equivalents and investments, interest expense, advisory expense related to our investments and realized gains and losses on marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations for the Years Ended December 31, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenue related to its out-licensing collaborative agreements consist of upfront license fees and research and development services revenue from its collaboration agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total revenue recognized for the year ended December 31, 2024:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:74.14%;box-sizing:content-box;"/>
    <td style="width:1.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:21.919999999999998%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,086</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,873</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a breakdown of our operating expenses by functional category:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.88%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase /</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,119</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,289</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,830</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425,070</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425,070</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,233</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,533</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,700</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,422</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,822</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">493,600</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $27.8 million for the year ended December 31, 2024 compared to 2023. The increase was primarily due to a $25.0 million increase in personnel-related costs driven by the acquisition of AnHeart as well as stock-based compensation and other benefits and $0.4 million increase in amortization of assembled workforce and $2.4 million increase in third-party costs related to clinical trial expense for taletrectinib offset by decrease in research services and drug manufacturing as a result of completing the Phase 1 monotherapy study of NUV-868.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired In-process Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024, as a result of the acquisition of AnHeart, we recorded a $425.1 million charge representing an acquired in-process research and development asset with no alternative future use in acquired in-process research and development expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $40.7 million for the year ended December 31, 2024, compared to 2023. The increase was due to a $18.3 million increase in personnel-related costs as a result of the acquisition of AnHeart, $13.2 million increase in sales and marketing expenses, $3.6 million increase in professional fees, $0.5 million increase in occupancy expenses, $1.5 million increase in legal fees, $0.1 million increase in amortization of assembled workforce, $0.1 million increase in taxes, $0.4 million increase in foreign currency impact and $3.9 million increase in other expenses as a result of the integration of AnHeart offset by $0.9 million decrease in insurance expense.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a breakdown of our other income (expense):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.751%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.802000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.802000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.802000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,062</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,611</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,451</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(341</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(341</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment advisory fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(976</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(949</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(27</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(936</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">497</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,433</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized loss on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(139</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(109</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(109</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,688</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,020</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">668</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net increased by $0.7 million for the year ended December 31, 2024 compared to 2023 primarily related to an increase in interest income from investments of $2.5 million primarily due to higher treasury yield offset by a $1.4 million increase in the change in fair value of warrant liability, a $0.3 million increase in interest expense, and a $0.1 million increase in other expense.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity, Capital Resources and Plan of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From inception through December 31, 2024, our operations have been financed primarily by the sale and issuance of Series A preferred stock and common stock, including through the Merger and the PIPE Investment. As of December 31, 2024, we had $502.7 million in cash, cash equivalents and marketable securities and an accumulated deficit of $910.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary use of cash is to fund operating expenses, which consist of research and development expenses related to our clinical-stage product candidates and preclinical programs, and to a lesser extent, general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, we announced the closing of a non-dilutive financing of up to $250.0 million from Sagard. The financing is comprised of a $150.0 million (the "Investment Amount") synthetic royalty financing under the RIF Agreement and a $100.0 million of senior secured term loan under the Loan Agreement. The Investment Amount and a $50.0 million tranche of the term loan will be funded conditioned upon FDA&#8217;s approval of taletrectinib on or prior to September 30, 2025. The second tranche of $50 million of the term loan will be available at our option until June 30, 2026, as long as we have achieved first U.S. commercial sale of taletrectinib.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the RIF Agreement, in exchange for the Investment Amount, we have agreed to make tiered royalty payments to Sagard on U.S. net sales of taletrectinib equal to 5.5% of annual U.S. net sales up to $600 million and 3.0% of annual U.S. net sales between $600 million and $1 billion.  We will retain all annual U.S. net sales above $1 billion. Our obligation to make the royalty payments will cease upon the earliest occurrence of total royalty payments reaching 1.6 times of the Investment Amount by the calendar quarter ending on June 30, 2031, 1.75 times of the Investment Amount by the calendar quarter ending on June 30, 2034, or 2.0 times of the Investment Amount thereafter. To the extent we have not made royalty payments totaling at least 100% of the Investment Amount by February 1, 2043, we will be required to make a true up payment in an amount equal to such shortfall (the &#8220;True Up Payment&#8221;). In addition, if certain events occur, including certain bankruptcy events, non-payment of Payments, a change of control, expiration or termination of certain intellectual property rights or marketing authorization, an out-license or sale of all of the rights in and to taletrectinib in the United States and (subject to applicable cure periods) non-compliance with the covenants in the RIF Agreement, we may be required to repurchase the synthetical royalty financing at a repurchase price ranging from 1.4 to 2.0 times of the Investment Amount, depending on the time of such event, less all royalty payments we made by then under the Loan Agreement, the term loan will bear interest at the secured overnight financing rate ("SOFR") plus a margin of 6.00%, subject to a 4.00% SOFR floor. There are no scheduled amortization payments associated with the term loan, with all outstanding principal due at maturity. The transaction will support the U.S. commercial launch of taletrectinib and general corporate purposes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of December 31, 2024, will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur substantial expenses in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our current and future preclinical studies and clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(130,413</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,999</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,703</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,921</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">331</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of foreign exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,926</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(58,450</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, cash used in operating activities of $130.4 million was attributable to a net loss of $567.9 million, a net change of $12.5 million in our net operating assets and liabilities offset by non-cash charges of $450.0 million. The change in operating assets and liabilities was primarily due to a $12.7 million increase in accounts receivable, $6.0 million increase in other non-current assets, $3.0 million increase in prepaid expenses and other current assets and $1.6 million decrease in accounts payable offset by a $6.8 million increase in accrued expenses, $3.9 million increase in contract liabilities and $0.1 million decrease in interest receivable on marketable securities.  The non-cash charges consisted primarily of $425.1 million of acquired in-process research and development, stock-based compensation of $32.3 million, changes in fair value of warrant liability of $0.9 million, $0.7 million of depreciation and amortization and $0.2 million of net loss on disposal of property and equipment offset by amortization of premium on marketable securities of $9.0 million and $0.2 million of non cash lease expense.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, cash used in operating activities of $68.0 million was attributable to a net loss of $75.8 million offset by a net change of $0.6 million in our net operating assets and liabilities and non-cash charges of $7.2 million. The change in operating assets and liabilities was primarily due to a $2.3 million decrease in prepaid expenses and $0.1 million increase in accounts payable offset by $1.2 million increase in interest receivable on marketable securities and $0.6 million increase in other non-current assets. The non-cash charges consisted primarily of stock-based compensation of $19.5 million, realized loss on marketable securities of $0.1 million, depreciation and amortization of $0.2 million offset by changes in fair value of warrant liability of $0.5 million and amortization of premium on marketable securities of $12.1 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, cash provided by investing activities of $122.7 million was related to the  $450.1 million of proceeds from the sale of marketable securities, $19.9 million cash acquired from the acquisition of AnHeart offset by purchase of marketable securities of $339.7 million, $7.4 million of transaction costs related to the acquisition of AnHeart and purchase of property and equipment of $0.2 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, cash provided by investing activities of $8.9 million was related to the purchase of marketable securities of $703.4 million and purchases of property and equipment of $0.1 million offset by $712.4 million of proceeds from the sale of marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, cash provided by financing activities of $0.3 million was related to the $4.5 million proceeds from exercise of options and $0.4 million of proceeds from issuance of Common Stock under the Employee Stock Purchase Plan and $12.6 million of proceeds from borrowings offset by $17.2 million of debt repayments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, cash provided by financing activities of $0.6 million was related to the $0.4 million of proceeds from exercise of options and $0.2 million of proceeds from issuance of common stock under the Employee Stock Purchase Plan.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Financing Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we did not have any off-balance sheet arrangements, as defined in Regulation S-K, Item 303(a)(4)(ii).</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. While our significant accounting policies are described in the notes to our consolidated financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in the notes to our consolidated financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply ASC Topic 606, "Revenue from Contracts with Customers" ("ASC 606") to account for our revenue transactions.  Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the five-step model. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.  Once a contract is determined to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.  Accounts receivable represent amounts invoiced and revenues recognized prior to invoicing when we have satisfied our performance obligation and have the unconditional right to payment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the FASB issued Topic 808, "Collaborative Arrangements" ("ASC 808"): Clarifying the Interaction between ASC 808 and ASC 606. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We adopted this standard for all periods presented. We enter into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. We assessed and determined that none of the collaboration agreements entered into during the periods presented were within the scope of ASC 808, as all of the agreements did not involve active participation by both parties in a joint research activity, and therefore did not qualify as collaborative arrangements under ASC 808.  We have determined that all the elements of the above collaborations are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, we perform the five-step model under ASC 606 noted above. We recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.  Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, we consider competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, we recognize revenue from the portion of the transaction price allocated to the license at a point in time, when the license is transferred to the customer and the customer is able to benefit from the license.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs based on the use of an input method.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A customer's right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If we are not presently obligated to provide and does not have a right to consideration for delivering additional goods or services, the item is considered an option. We evaluate the customer options for material rights, such as the ability to acquire additional goods or services for free or a discount. Optional future services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. The optional future services do not include a material right to be accounted for as performance obligations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration agreements include development and regulatory milestones. We evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For sales-based royalties, including milestone payments based on the level of sales, we determine whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, we recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any sales-based royalty revenue resulting from our collaboration agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We receive payments from our customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until we perform our obligations under the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled. For a complete discussion of accounting for revenue, see the section titled "Collaboration and License Agreements" in Note 5 to our consolidated financial statements appearing elsewhere in this report.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition of assets and businesses</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), no goodwill is recognized and acquired in-process research and development is expensed in acquired in-process research and development expenses. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks and estimates of services performed using information and data provided to us by our vendors and third-party service providers. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and as services are performed. We expense in-process research and development projects acquired as part of asset acquisitions that have no alternative future use.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of Public and Forward Purchase Warrants was determined using the closing price of the warrants on the NYSE market. The fair value of the Private Warrants was estimated using the Black-Scholes option pricing formula (see Note 4).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the fair value of our stock-based awards to employees and non-employees that are based on a service condition only using the Black-Scholes option-pricing model, which is impacted by our common stock price as well as other variables including, but not limited to, expected term that options will remain outstanding, expected common stock price volatility over the term of the option awards, risk-free interest rates and expected dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determine the fair value of stock-based awards that are based on both a service condition and achievement of the first to occur of a market or performance condition using a Monte Carlo simulation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of a stock-based award is recognized over the period during which a recipient is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period) on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">straight-line basis. Stock-based compensation expense is recognized based on the fair value determined on the date of grant and is reduced for forfeitures as they occur.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimating the fair value of stock-based awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected Term&#8212;We have opted to use the &#8220;simplified method&#8221; for estimating the expected term of options whose vesting is based on service condition only, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected Volatility&#8212;Due to our limited operating history and a lack of company specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of our stock options at the time of the grant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected Dividend&#8212;We have not issued any dividends in our history and do not expect to issue dividends over the life of the options and therefore have estimated the dividend yield to be zero.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to use judgment in evaluating the expected volatility, and interest rates utilized for our stock-based compensation expense calculations on a prospective basis.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For information about recent accounting pronouncements, see the sections titled &#8220;Significant Accounting Policies&#8212;Recent Accounting Pronouncements&#8221; in Note 2 to our consolidated financial statements for the year ended December 31, 2024 appearing elsewhere in this report.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="quantitative_and_qualitative_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitativ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Disclosures about Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had cash and investments of $502.7 million as of December 31, 2024, consisting of cash, money market funds, municipal bonds, certificate of deposits, exchange traded fund, government securities, commercial paper, and corporate bonds. To date, fluctuations in interest income have not been significant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. We have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses are generally denominated in U.S. dollars. A 10% increase or decrease in current exchange rates would not have a material effect on our financial results.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="financial_stmt_supplementary_data_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Supplementary Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This information appears following Item 15 of this report and is included herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="changes_in_disagreement_with_account_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ccountants on Accounting and Financial Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="controls_and_procedure_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Control</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a&#8211;15(e) and 15d&#8211;15(e) of the Exchange Act, as of December 31, 2024. Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Controls Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_f16a4597-5ab1-492b-88d0-fa9f801392c3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:AuditorOpinionTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2024, as required by Rule 13a-15(c) under the Exchange Act. In making this assessment, we used the criteria set forth in the framework in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted by SEC guidance, management may omit an assessment of a newly acquired operation&#8217;s internal control over financial reporting for up to one year from the date of acquisition. Accordingly, we excluded the portion of AnHeart&#8217;s operations that represented approximately 17% of total operating expenses for the year ended December 31, 2024 and 4% of total assets as of December 31, 2024 from management&#8217;s assessment of internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our evaluation, and subject to the exclusion above, management has concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="other_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insider Trading Arrangements and Policies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2024, no director or Section 16 officer </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0264d1c-acbb-4e5a-916f-281a909c40f7" contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_13fd8bad-3cc8-429f-8bce-1624c9e57321" contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd0f1e48-df28-4d27-8239-0528f4f55e94" contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d0b9b147-ff31-4b12-a7d3-da4e5f558b58" contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="disclosure_foreign"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Rega</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rding Foreign Jurisdictions That Prevent Inspections</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated herein by reference to our definitive Proxy Statement for our next Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), which we intend to file pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, within 120 days after December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="directors_executive_officers_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item concerning our directors and corporate governance is incorporated by reference to the information set forth in the section titled &#8220;Directors and Corporate Governance&#8221; in our Proxy Statement. Information required by this Item concerning our executive officers is incorporated by reference to the information set forth in the section entitled &#8220;Executive Officers of the Company&#8221; in our Proxy Statement. Information required by this Item regarding our Section 16 reporting compliance and code of business conduct and ethics is incorporated by reference to the information set forth in the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; in our Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our written code of business conduct and ethics (the &#8220;Code of Conduct&#8221;) applies to all of our employees, officers and directors, including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Conduct is available on our corporate website at investors.nuvationbio.com in the Investors section under &#8220;Governance Documents.&#8221; If we make any substantive amendments to our Code of Conduct or grant any of our directors or executive officers any waiver, including any implicit waiver, from a provision of our Code of Conduct, we will disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6c6d5b2-4c9a-44af-964c-9e60a30a78d4" contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conformance with updated SEC regulations, we have adopted amended insider trading policies and procedures governing the purchase, sale and/or other dispositions of our securities by directors, officers and employees, or the Company itself, that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and New York Stock Exchange standards. A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="executive_compensation_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Execu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tive Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item regarding executive compensation is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; and &#8220;Compensation for Directors&#8221; in our Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="security_owner_certain_beneficial_owner_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Owners and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; in our Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="certain_relationship_related_trans_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Trans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item regarding executive compensation is incorporated by reference to the information set forth in the sections titled &#8220;Certain Relationships and Related-Person Transactions,&#8221; &#8220;Directors and Corporate Governance,&#8221; and &#8220;Board of Directors and Committees&#8221; in our Proxy Statement.</span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="principal_acct_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cipal Accountant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item regarding principal accountant fees and services is incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:1.133%;text-indent:-11.504%;padding-left:10.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibits_financial_statement_schedules_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financia</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">l Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Consolidated Financial Statements:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.26%;box-sizing:content-box;"/>
    <td style="width:6.74%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_ind_registered_public_acc_firm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(</span><span><ix:nonNumeric id="F_64fc9965-089e-4f67-b7e0-be0deb59b3b0" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d3c726f2-b27b-4d01-bad9-b5e0e1af2b66" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, NY</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, Auditor Firm ID: </span><span><ix:nonNumeric id="F_f0e088e6-9517-422d-87b3-467dd361d0be" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_of_operation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#conso_stmt_of_change_in_stock_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity as of December 31, 2024 and 2023</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_state"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Consolidated Financial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hereby file or incorporate by reference as part of this Annual Report on Form 10-K the exhibits listed in the attached Exhibit Index.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:7.94%;box-sizing:content-box;"/>
    <td style="width:18.06%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule/</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1+</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521005360/d13601ds4a.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated October 20, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 8, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001811063/000119312521005360/d13601dex44.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Class A Common Stock Certificate</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 8, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000121390020015592/fs12020a1ex4-4_panacea.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Warrant Certificate</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239138</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 23, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000121390020015592/fs12020a1ex4-4_panacea.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant Agreement, dated June 30, 2020, between Continental Stock Transfer  &amp; Trust Company and the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-239138</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 23, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521077880/d124332dex44.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000121390020032470/ea128648ex10-1_panaceaacq.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of PIPE Subscription Agreements</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000121390020016747/ea123822ex10-7_panacea.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forward Purchase Agreement, dated June 30, 2020, between Registrant, EcoR1 Panacea Holdings, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-39315</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 6, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Option Grant Notice and Option Agreement under the 2021 Equity Incentive Plan</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of RSU Award Grant Notice and Agreement under the 2021 Equity Incentive Plan</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312520291761/d13601dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2019 Equity Incentive Plan, as amended, of Legacy Nuvation Bio</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312520291761/d13601dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan, as amended, of Legacy Nuvation Bio</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521010705/d13601dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 19, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10#</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001811063/000119312521005360/d13601dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Severance and Change in Control Plan</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 8, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Registration Rights Agreement, dated February 10, 2021, by and among the Registrant, the EcoR1 Panacea Holdings, LLC, Cowen Investments and certain other stockholders of the Registrant party thereto</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000121390020016747/ea123822ex10-1_panacea.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, dated June 30, 2020, by and among the Registrant, EcoR1 Panacea Holdings, LLC, Cowen Investments, and the Registrant&#8217;s officers and directors</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 6, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312520321577/d13601dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement of Lease by and between Zapco 1500 Investment, L.P. and Legacy Nuvation Bio, dated June 30, 2019</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:7.94%;box-sizing:content-box;"/>
    <td style="width:18.06%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14&#134;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312520321577/d13601dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Asset Acquisition Agreement by and between RePharmation Inc., GIRAFPHARMA LLC and David Hung, dated January 21, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312520291761/d13601dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Stock Restriction Agreement by and between the Legacy Nuvation Bio and David Hung, dated June 17, 2019</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250036</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000121390020032470/ea128648ex10-6_panaceaacq.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Lock-Up Agreement</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2020</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/d837366dex103.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Commercialization Agreement between Nippon Kayaku Co., Ltd. and AnHeart Therapeutics Inc, dated October 27, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 20, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/d837366dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement between Innovent Biologics (Suzhou) Co. Ltd. and AnHeart Therapeutics Inc, dated May 31, 2021.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 20, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/d837366dex102.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Collaboration and License Agreement between Innovent Biologics (Suzhou) Co. Ltd. and AnHeart Therapeutics Inc, dated November 30, 2022.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K/A</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 20, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000095017024059622/nuvb-ex10_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement between Daiichi Sankyo Company, Limited and AnHeart Therapeutics Inc., dated December 7, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000095017024059622/nuvb-ex10_4.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to License Agreement between Daiichi Sankyo Company, Limited and AnHeart Therapeutics Inc., dated August 17, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000095017024059622/nuvb-ex10_5.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement between Daiichi Sankyo Company, Limited and AnHeart Therapeutics Inc., dated September 7, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23*&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Credit Agreement and Guaranty, dated March 3, 2025, among Registrant, Sagard Holdings Manager LP and other parties thereto</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24*&#135;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex10_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revenue Interest Financing Agreement, dated March 3, 2025, between Registrant and Sagard Healthcare Partners (Delaware) II LP</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex141.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Feb</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861dex161.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter from Withum</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 12, 2021</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000095017024023247/nuvb-ex19_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of KPMG LLP, independent registered public accounting firm</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section  302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a),</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:7.94%;box-sizing:content-box;"/>
    <td style="width:18.06%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">as adopted pursuant to Section  302 of the Sarbanes-Oxley Act of 2002.</span><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></span><span style=""></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1811063/000095017024023247/nuvb-ex97_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Incentive Compensation Recoupment Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39351</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:6.55pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.2#*</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvb-ex97_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employee Incentive Plan, dated January 21, 2025</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;text-indent:6.55pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ 	Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K 	Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its 	request.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># 	Indicates a management contract or compensatory plan, contract or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; 	Portions of this exhibit, as marked by asterisks, have been omitted in accordance with Regulation S-K Item 601.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* 	Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**	Filed herewith and not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#135; 	</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and the Company agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.</span></p>
  <p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="form_10_summary_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0K Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:1.333%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:41.94%;box-sizing:content-box;"/>
    <td style="width:9.66%;box-sizing:content-box;"/>
    <td style="width:4.54%;box-sizing:content-box;"/>
    <td style="width:43.86%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">UVATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">IO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">NC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David Hung, M.D.</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">David Hung, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints David Hung, M.D. and Philippe Sauvage, and each of them, with full power of substitution and resubstitution and full power to act without</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.66%;box-sizing:content-box;"/>
    <td style="width:40.86%;box-sizing:content-box;"/>
    <td style="width:16.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ DAVID HUNG, M.D.</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairmain of the Board, President and Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">David Hung, M.D.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ PHILIPPE SAUVAGE</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Financial Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Philippe Sauvage</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ MOSES MAKUNJE</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VP, Finance</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Moses Makunje</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ MIN CUI</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Min Cui</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ ROBERT B. BAZEMORE, JR.</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lead Independent Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Robert B. Bazemore, Jr.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ KIM BLICKENSTAFF</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Kim Blickenstaff</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ KATHRYN E. FALBERG</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Kathryn E. Falberg</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ ROBERT MASHAL, M.D.</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Robert Mashal, M.D.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/S/ W. ANTHONY VERNON</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">W. Anthony Vernon</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:85%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_ind_registered_public_acc_firm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated Financial Statements:</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_of_operation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#conso_stmt_of_change_in_stock_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_state"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_ind_registered_public_acc_firm"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation Bio Inc.:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Nuvation Bio Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB.Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sufficiency of audit evidence over accounting for the acquisition of AnHeart Therapeutics Ltd.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart Therapeutics Ltd. (the Acquisition). On the acquisition date, the Company issued to AnHeart securityholders (i) Class A Common Stock, (ii) Series A non-voting convertible preferred stock, and (iii) warrants. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired. At the acquisition date, the company recorded a $425.1 million charge representing an acquired in-process research and development asset with no alternative future use. The Company also recorded $25.8 million of assets acquired primarily consisting of cash and liabilities assumed of $53.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified the sufficiency of audit evidence over the accounting for the Acquisition as a critical audit matter. Subjective auditor judgment and an increased extent of effort was required to evaluate the sufficiency of audit evidence over accounting for the Acquisition due to the complexity involved in interpreting and applying the guidance for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accounting treatment as an asset acquisition, including impact of the fair value of certain acquired assets on the accounting conclusion, and the accounting for stock transactions associated with the Acquisition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are the primary procedures we performed to address this critical audit matter. We applied auditor judgment to determine the nature and extent of procedures to be performed over the accounting for the Acquisition. We evaluated the design of certain controls related to the Company's accounting for the Acquisition. We performed sensitivity analyses over the fair value conclusions for certain assets acquired to assess the impact on the Company&#8217;s asset acquisition conclusion and the resulting purchase price allocation. We involved professionals with specialized skills and knowledge, who assisted in:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.745293988246756%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspecting the AnHeart Merger Agreement to understand the terms and conditions that were relevant to 		the accounting for the Acquisition and related stock transactions</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.745293988246756%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspecting the Company's accounting analysis for the Acquisition and evaluating whether the Company&#8217;s 		analysis considered all relevant terms and conditions</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.745293988246756%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating whether the Company&#8217;s conclusion of the Acquisition&#8217;s treatment as an asset acquisition is in 		accordance with the relevant accounting guidance</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.745293988246756%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating whether the Company&#8217;s accounting analysis for the stock transactions related to the Acquisition 		is in accordance with the relevant accounting guidance</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the sufficiency of audit evidence obtained related to the accounting for the Acquisition by evaluating the cumulative results of procedures performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2019.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 6, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC. and Subsidiaries</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CON</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OLIDATED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a75e01e-e5e7-4b8b-815c-28e5dbd65ef0" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,723</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c060ed18-c7f5-4edc-8a5d-0ad9a6dc395f" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,649</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net of allowance for credit loss of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_203b54c4-bb50-4cfa-9a6a-6bb3487089ad" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_214bca7c-7308-47a2-b90a-a1404991a9ca" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29ddd845-9187-41b2-b482-dd3c9d3ca03c" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,722</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c5ddb8c-088f-48d3-b728-aca6d350a8d3" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36832755-9324-41de-85da-9ffe082fe221" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fef66559-de6d-4e29-a260-05e8ef7ced4f" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,519</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ac7e1d3-23bc-4c89-9919-c02a80f23f93" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,969</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a698cffa-dff8-4b4b-a747-8e939b6d1137" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,564</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable on marketable securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8d91337-f52a-40f8-93bb-3721baa6fb61" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:InterestReceivableOnMarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,570</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02bfe2ac-dd94-4277-ad4f-dfe0548ad496" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:InterestReceivableOnMarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,702</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b328679c-9864-4ccc-917f-528a837e734b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">526,255</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afccf4e1-d19e-4f83-a858-e53d0334d8e7" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">616,434</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net of accumulated depreciation of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceb89de5-d717-4a24-a784-ede3e17daa02" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9afd19e6-46e3-4b71-b268-503c79f2ee94" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a57df3d8-9cf4-4f77-8170-b40c72c29ef0" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">586</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86fb8170-dfe3-47f3-b6f4-6e047385ff9a" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net of accumulated amortization of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_793b7257-6433-4354-b411-3c682e6d2aa1" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:IntangibleAssetsNetOfAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bd96a65f-48c9-4f03-9b23-787f224dccee" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:IntangibleAssetsNetOfAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48112ab6-2d2f-4051-85e9-7d146ba405c8" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,622</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c93798f9-1ca4-4500-80ec-089405f44c47" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease security deposit</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c10e6b1-91ce-40a2-9fb2-c7755215b5b9" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:LeaseSecurityDepositNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee961c56-bbbe-4224-ae44-049b71b3c595" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:LeaseSecurityDepositNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9afabb97-7dec-45df-8b8d-7a9a1e0e4774" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,402</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10b6670f-ce8d-40a0-beef-b7532f89a23e" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,605</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_095115e3-60e6-45da-b019-b60dfaf68263" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,616</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ba5bcf2-2919-49b6-9d12-03ea6b479962" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_899828c3-edf9-4af5-88d1-07cd69e7741b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540,626</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb111c47-ad3c-4dfb-b512-eeb3fa8e4a19" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,484</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75d761a2-a6f3-4630-a133-6628e838810f" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6727c53-a187-480c-a18e-97fe3681ca6d" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,209</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current operating lease liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df6013b4-9869-44b3-8a48-f036ad98b94c" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,663</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85e5a31f-90f8-4d3d-809b-21d8b622f20f" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,972</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities, current portion</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_271dec5d-71d9-45da-b770-d582f18fef17" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,117</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1f72370-5a4e-45d9-822f-3a9da5bded49" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term borrowings</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85dc515a-3b6e-4f53-90cf-bc60a09c4536" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:ShortTermBorrowings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,283</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a611ad6-63bd-450f-850c-5e0a09031d49" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:ShortTermBorrowings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f977a52-f632-410f-84f4-dcf9abf18006" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,833</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57cf257f-0da6-4dee-baab-b2dcc4fb2ba8" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,793</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d82400b-9e26-457c-bd73-714a3161303f" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,244</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60b64d5e-5c2f-430a-a11b-4ea47bf1e22b" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,974</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a753672-e0e0-4d64-a9fa-4f7543a06d42" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:WarrantLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,053</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88a3ff0-02b7-4f28-99d9-6e02571daa14" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:WarrantLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities, net of current portion</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2454e258-3e5a-46e6-9f06-ada98f9c1f77" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00ee1b51-b7d8-463f-9604-bc2d49b22634" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60097fd9-dcf3-45cb-9301-acc1b8dc5cc1" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">969</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09dd33e5-eb05-4fe4-8c38-2339968832f6" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,035</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2ced7da-eeb3-494d-b4b8-d24373a00689" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,838</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39f79dfd-6fef-45ba-87af-a0156e4129ec" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,362</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f102744e-e5de-4779-9087-28320d26aca8;"><span style="-sec-ix-hidden:F_bc4c8e53-d632-4d98-8fdd-d3c798496e59;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 17)</span></span></span></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A and Class B common stock and additional paid in capital, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de690f6c-ce18-44b5-8078-0fb211c49912" contextRef="C_292c1c1e-5581-4c9b-8157-24e0d07be12b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5ded1d5a-72d5-482e-8d39-f8b7093aee27" contextRef="C_3e12a88b-ec80-4a4c-95d8-aee1b5d352ca" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_427cabee-839f-434a-888c-7d5a133d5a5d" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_18475f50-30c4-49d1-9d34-9ed07ff586e9" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6e893e-7f91-4153-818d-d779d55f1092" contextRef="C_292c1c1e-5581-4c9b-8157-24e0d07be12b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b6c07015-d11f-4010-9e26-ad925a1339ec" contextRef="C_3e12a88b-ec80-4a4c-95d8-aee1b5d352ca" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,060,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Class A </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f69a0e01-811a-418b-bff8-ae75a866daeb" contextRef="C_4d5e27ff-5781-4fd0-ad66-8f80196d9597" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b0576026-90ba-4d0b-a11e-9f43af540baf" contextRef="C_6f4cfee1-80ef-4add-9e23-106b99b62a74" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, Class B </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10a02a33-4e5e-4df9-8562-4c3f52deeebb" contextRef="C_23c3ae60-037a-4b82-a8ea-fb789a61b20b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a875cf9b-4c23-4385-b4f9-b06766c91dbd" contextRef="C_e59de91c-61ea-4944-9861-5e3a0c84322c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">60,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) shares authorized as of December 31, 2024 and December 31, 2023 respectively, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63023b1e-5a0a-4f42-9c6e-0d2cbfd2b72a" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6b2b60c8-b3a0-4685-95d0-ca5edc331397" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">337,837,872</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Class A </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3a641bc-50e7-4ae1-96ae-174e682a8da4" contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e977b119-1442-42b2-bbc6-ea86bce1bd7e" contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">336,837,872</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, Class B </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc0f4499-62dd-4e6c-88fc-ef0736ca01a6" contextRef="C_10ac330b-db11-468f-b855-d1877a78ce3f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_92b46357-f8fa-4e7e-8fe5-86352ccf4ddc" contextRef="C_10ac330b-db11-468f-b855-d1877a78ce3f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b4df941-37b6-4d37-b536-1bdf9595bf8b" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9e60de2e-95fd-44aa-b269-d96d80f26da4" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">219,046,219</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Class A </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e131096-d3f1-45ea-b87e-1c75d44dfa91" contextRef="C_e781b479-dd2a-4691-8eb1-89cc93788c93" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f62d2b12-161d-4916-9ee1-f016996db1cc" contextRef="C_e781b479-dd2a-4691-8eb1-89cc93788c93" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">218,046,219</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, Class B </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e3bc3f4-d165-4915-9322-ad1630e2bd24" contextRef="C_42013ae0-ddac-4812-88ab-b99d2d7149ae" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b3c91d59-f452-4b92-a112-8a97affa2b25" contextRef="C_42013ae0-ddac-4812-88ab-b99d2d7149ae" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">) shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45607dfa-64ba-431e-96be-5c6349672a23" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373,958</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_198d38d7-2062-4c6f-9520-f2dcc74495ea" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947,745</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c040b0ce-39bb-4768-adb5-b7bf6212465c" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">910,743</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8009dd-c6e6-4f38-ac91-c32e91cf9b97" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">342,804</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e02311b-f0a5-4a0e-a298-e47dada460c8" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a3e57f-bebd-4cdd-ac20-6a51bff4b03f" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff89139-5514-47cc-915b-cbbcd154e003" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463,788</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1dd74e5-edce-434e-999b-5526a3b551a5" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605,122</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_202bd83c-9ad3-4f92-a1e7-9f5f924b3636" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540,626</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ba53ac0-29ba-4e1f-961b-edbab74b2297" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,484</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC. and Subsidiaries</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_of_operation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AND COMPREHENSIVE LOSS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3380096a-5030-471b-ba6b-8586b8b09ba5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,873</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eeb20e0-1c7a-403e-938e-3c6c430fa8b0" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21fae73b-974f-41d6-8e8a-636bb84141f6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,078</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb286dd9-6201-4c9f-bcc2-0b4ad9dd974a" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff2eb0d5-f4c5-49e5-ab0b-ddd22acadfc3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">795</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5189a3bb-48ea-445f-bd49-0f97e898709a" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9655db7d-6594-434f-aabc-0bc46769c67a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,119</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2aa4cf1-fb93-4ed9-8b02-3d77e816e79e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,289</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ac2e149-4bfd-4370-a0cd-6475a14374d3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b5868e4-4fc9-4c5f-b368-09203388d607" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec8a879-c288-4cee-b077-3cb4938899a6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,233</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e87e2112-bbb9-499a-9e60-c8d5fd77b1d2" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,533</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72907b3b-6af2-4461-a190-5f786f309fd2" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,422</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4606dcaa-0352-49cf-8f05-0ffd5ea2aa0a" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,822</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb47511-4722-447b-9e33-3761f2f6f791" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">592,627</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_195168e2-6f4a-4d03-a207-7cca3371d9bd" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,822</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b92a0af4-795a-47d7-b971-e90f9e52d4e1" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:InterestIncomeOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a62af4a-5df5-4e5a-b670-160729c1a2e3" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:InterestIncomeOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d968458-667d-4c2e-ad4e-8128549bac75" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51e22113-bdb2-459c-a4cc-d628396029f4" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment advisory fees</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_536d3c5e-34ae-4a80-bced-aaaf94e5ca4f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">976</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21392e47-974f-4af3-b1db-49e093ffaf96" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb4cf92e-113d-4d04-8862-42292e802456" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">936</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abefb52b-8e54-4acc-bd58-4224cf779336" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized loss on marketable securities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68359078-5979-40b9-86c5-9038e7f3bcf7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebe6ad12-dac5-485e-a6d2-05df693ebd1d" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cccb2330-97a1-4336-95c4-dd5bffe0842d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3561a946-74bb-4c6a-8319-629d3b1c841f" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d063fb7-00c8-41a1-b42e-3bc2b3e3f636" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,688</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6b78800-cfe4-4b97-804e-0e79a7180f49" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,020</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_048f83b2-2b13-4aae-9cbc-d2ec87b1e139" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6a95e8c-9e5e-4221-8376-0a69ecbb83d5" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,802</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86a26cbc-1f4d-49c8-93db-a18e6fe9ad71" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c63328c7-ceb8-483e-8fc7-de8192aa06f0" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e1e3924-f296-4c5c-b49e-86241d07eea2" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe429d0-eea5-4b38-ac88-0a5a491f0326" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,802</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4cfa408-36cd-490a-9dcf-dcbf73126dc8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fa4a351f-e22b-41aa-b1ca-5113bc170380" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.11</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b189d66d-e658-4f84-b6c8-1d298cd472a7" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a543c521-716d-4fc5-b6a5-de18f78d15d5" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a31ed06-4ce1-4be9-9c8b-8a540bacb95f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5b78cecd-eaaa-4951-ad55-97e09abc65ec" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">268,772</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256a23a6-cd22-47f3-993f-2b8d5826bdd5" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cf3e6df8-e011-46c0-b559-496cfbaaab01" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">218,880</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4da3d2b8-6d20-41bc-ab90-2ef8280911f3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a455ac-7b91-44ef-a195-c4f5464f2ee1" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,802</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss, net of taxes:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency translation adjustment</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b116014-d788-415f-bbd5-397e93436cae" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cff63d2-c90c-48be-8ef3-e81b8bcb7eea" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in unrealized (loss) gain on available-for-sale securities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4cced9f-03be-4bbe-b2c0-1ca22baabf18" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DebtSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f7b8f19-2364-4cef-8193-86c325fa1eb5" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:DebtSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,707</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49230a78-a2a9-4d10-ac8f-df9a4979f518" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,547</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88ecd2d9-cb82-4e98-b060-d5b3277a7a61" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,095</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC. and Subsidiaries</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="conso_stmt_of_change_in_stock_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.4%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock and<br/>Additional Paid-in Capital</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders'</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A Shares</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A Shares</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class B Shares</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_745f9a34-fdda-4acf-b1d9-06ecb34a495d" contextRef="C_1b58aa7a-19df-4858-9619-311b52c1a5ca" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">217,632,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d978bc6d-41cf-4b90-a87c-df78276d487c" contextRef="C_f64c1371-e223-4a9e-939d-999f45e6fda0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ceac582-8f1f-429b-8340-0b4ad495181d" contextRef="C_5bade152-78d3-45ae-93eb-5920249b2833" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bb349a5-c181-4ef7-aa92-0a1d9cdc155c" contextRef="C_6d9872a7-adc1-43ff-8f43-9e26797a3c00" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">267,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8a2282e-0eec-4402-85b6-6b2f2dde351a" contextRef="C_3a62758c-8331-43c7-b65a-8ceaebefba74" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,526</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad881f02-8125-49dc-be17-4a1541b9a38d" contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">655,076</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec01bb9-c5f5-4496-95fd-8f1a5429aac3" contextRef="C_8e6407a5-bcf1-4464-971c-f6b91e19a697" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">215,614</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a236fc0-589a-4b8b-98e1-8f9e267bd837" contextRef="C_34e78618-c534-4284-bb6e-1a7b083eb1da" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1da789de-9e8b-460c-b2f0-dcdb29e1b73e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for purchase under ESPP</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae3cdfe7-9c34-4e19-86d4-0eb23fce8c1d" contextRef="C_8e6407a5-bcf1-4464-971c-f6b91e19a697" name="nuvb:IssuanceOfCommonStockForPurchaseUnderEsppShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,906</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d245fe06-65ad-4dcb-9c45-a82dabb8fe90" contextRef="C_34e78618-c534-4284-bb6e-1a7b083eb1da" name="nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2c9a8d5-995c-4c34-aca0-460d9de4ff73" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44d55ed6-b137-4f89-ae64-225122d7ce20" contextRef="C_34e78618-c534-4284-bb6e-1a7b083eb1da" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6773343e-e7f1-46ac-81c9-07ebfbd04efe" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08732515-b8f3-460c-9d0b-89ce6c17d1a2" contextRef="C_aac49177-7f36-4ea5-b068-584c31c660b2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,802</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f246a3e4-ff6a-401f-be60-c24f1c364499" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,802</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39f46942-6dbe-4d43-aba7-22688c037154" contextRef="C_418e0a4f-214f-4bbb-a57c-9eed0f7d967b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,707</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5675f645-0407-4c90-aa82-7e169c6cb9b2" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,707</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_900918d7-f25d-419d-8a74-b4c19a4f47c5" contextRef="C_044c0715-8d17-4f49-8eef-b09c4726ce1d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">218,046,219</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75de169d-306d-455e-ba70-88c4e09983e8" contextRef="C_c53952fa-847c-4ce2-a41b-24de9e826c90" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ae4fa3a-636e-408a-94a2-c29db4a45906" contextRef="C_b8ceb7cf-3e46-43f2-a0e3-ded43479a354" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947,745</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e31425-02a5-465a-8c35-ba1ba28ad56f" contextRef="C_e6f673b3-21bf-40a8-945b-58d5fc5eb19a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">342,804</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_831d7eac-9ee1-424f-84c8-25a4dd86436d" contextRef="C_e97bbbfd-29be-4b48-8399-0c877e55e63f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c074f6d3-fdd6-47a1-bbe3-7eab310df87c" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605,122</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for AnHeart acquisition</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ba8d5bc-0f8d-406f-86e5-c2c2d07ad393" contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03" name="nuvb:IssuanceOfCommonStockForAnheartAcquisitionShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,646,255</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_891b916a-145b-4bb1-ac87-f21ff9273650" contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d" name="nuvb:IssuanceOfCommonStockForAnheartAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,297</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f2c384f-5b21-4283-ab74-b5ba83903d23" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfCommonStockForAnheartAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,297</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of convertible preferred stock related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9dcc7d3-28e1-4092-8783-1e7efdf9917f" contextRef="C_484ef476-4e04-4c47-b500-750696fee41c" name="nuvb:IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">851,202</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6876c8aa-ca00-4292-8bd0-90629fa1afbf" contextRef="C_eab07c10-f6ec-4739-8ac1-c72a472fe56e" name="nuvb:IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of preferred stock to common stock related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68173b07-849d-44ee-821b-e27eaab839ca" contextRef="C_484ef476-4e04-4c47-b500-750696fee41c" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">851,202</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4224408b-42e9-454f-affb-4c9727c39e63" contextRef="C_eab07c10-f6ec-4739-8ac1-c72a472fe56e" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7309687-c144-4bb6-b4f8-241f4d4fd649" contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,120,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_751c9d01-9773-4bf5-978f-2be6b8c4297e" contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f2c451-3a54-4d7e-abb7-2c4a44d208e3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of replacement awards related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16c8d5cc-04c1-4171-8645-6e8c12ba58d8" contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d" name="nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cb89fd8-51e9-4c17-875b-d3804b175630" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for purchase under ESPP</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ad9e691-a9b4-422f-ab67-7676983baac2" contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03" name="nuvb:IssuanceOfCommonStockForPurchaseUnderEsppShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">238,982</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb387bf4-6437-405d-ab39-cbfde724d1db" contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d" name="nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d29d46-40f1-45b4-a826-2aaafb80dbdb" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for RSUs vested</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56fb691d-4484-4bc6-a76c-1f186c266463" contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03" name="nuvb:IssuanceOfCommonStockForRsusVestedShare" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">618,340</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51633e4f-a2da-4456-ac88-40f3e496e42f" contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,167,876</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfbf4a48-856a-40d2-82be-c50dcdf7088b" contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f651544-b0ba-4931-b66c-c245920ccf16" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0351f57-b5e6-41ea-b449-b232b537593d" contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,275</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f443ef-16fc-4015-b7c6-48683b354065" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,275</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d144fd30-801c-4754-a39c-6d63ff211e91" contextRef="C_4e84c14b-26d4-4b95-88a1-d3d37077db29" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7febf5e-9677-420f-b1fe-7aa35a429173" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency translation adjustment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf4e42d6-95d8-42e9-b9f2-3c17734c2595" contextRef="C_e720fa47-bca7-4ca0-8f9f-5310a1a2429a" name="nuvb:CurrencyTranslationAdjustmentValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb989c7a-b11e-4497-8de1-efbfed68b5f7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:CurrencyTranslationAdjustmentValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68722e6a-ace9-4a09-83f9-5e14a9144e93" contextRef="C_e720fa47-bca7-4ca0-8f9f-5310a1a2429a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f21e8d0-684f-4b43-9e7a-5b2ea8d79166" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f6a31f2-9294-4cac-8670-787dd4591ba6" contextRef="C_643df37d-2f04-4154-b398-b0bb4de05827" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">336,837,872</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfd9bc7b-808b-4599-a1ca-cdc059cef2d4" contextRef="C_9bfa5b92-b29a-404b-9eb6-c8b1699ee7f0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21b2755b-63ce-426f-9a6a-4637e70ff6d7" contextRef="C_e2513bc6-e23a-4295-b2e3-1e55986d0108" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373,958</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cc5b567-8357-49b0-aa42-b1d86b073031" contextRef="C_55955901-09db-418b-89e5-7cba4fc0a390" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">910,743</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e5d39a-5302-4f06-8918-886cb6c34230" contextRef="C_ed404de3-f206-47f2-9ddc-6680cc0e8957" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7d28e09-378a-4d99-a320-134aa908c3b0" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463,788</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC. and Subsidiaries</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.046%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.238%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.238%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ad2d8a-dbaa-4c5c-ac27-eed85417ac07" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1149169-a4ef-441c-803b-888823b133ab" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75,802</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73a36ab4-df61-4f85-b091-1410b8a0fdab" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,275</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcc3d59c-65f1-4c16-b4c9-3cd7f437985c" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c092b8ad-79a6-4935-974c-41191db23e38" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">683</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed21e01b-e8f7-4ed9-8a13-66a788e8c21c" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60886d93-a302-468c-a694-544dd5546cef" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4ea2a20-feed-4a9a-a469-96beab23c45d" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e12a12f6-8fd6-4bc9-846c-73eec8bae6e0" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">936</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cafa1b5d-ae53-413d-921b-181ee1d65fa4" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of premium and discounts on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2ae5e8e-9514-46c0-b43d-d99096024139" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:AmortizationOfPremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_283c6391-8487-4a29-a6be-da76eb0fca48" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:AmortizationOfPremiumOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,057</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized loss on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81c7ce58-deb5-429d-839c-0286a4fe5a92" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b0c27ba-470e-4b80-8980-ef2549906a0d" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss on disposal of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4777b1-0b48-463d-b2d4-cc88617dacd4" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">229</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ad00928-a406-4437-990f-9a20f7ca2d1e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f7a8cb2-e952-4ed5-8e98-6ac281077be0" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24ff2bef-29f9-4bad-82e4-75b88d4d5cdb" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in operating assets and liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b814552b-d12c-4c45-9ead-c6a05539ed3f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,722</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e58f6b8a-f2c2-4708-b514-3043f9f8bc60" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ada797-a0ec-4c1d-9a97-fdbb9b31575e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,010</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a4bd80d-2739-405f-9363-afff9172957f" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc3d7d64-b6a0-40b2-a303-f794496fb9f1" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a6e4a6-033c-42bc-954b-1e3bf9740126" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,217</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease security deposit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1756d72-354c-4459-b9ab-83bb1ac681b8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d899c36-dc67-4a61-b31c-f6e9687f9e46" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d92391c-7b50-456c-b1c7-16fccb0301e4" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,029</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28ed75b0-154c-420c-991f-498cdbacec94" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acbb6e39-c033-4ce8-90b7-feb97767ef57" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,654</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd3f10d-1c91-49bf-8b81-a03bb9c68be6" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a57edb9-2c3f-4cb5-8dde-ff90badf2565" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,942</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c422fac-b380-4a2c-95ac-0d50d9dab826" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:16pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:16pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13c2b5cb-7d8e-42fc-88b4-5a9bd7b30bcb" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,838</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f28459cc-1741-4d5e-baaf-085f8f5ffcc3" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5b47a7b-2279-4142-b188-e37efb705d18" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18fae18a-87cd-4b01-9a81-b745347fde8b" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,999</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flow from investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash acquired from AnHeart acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b9d61b-e009-4115-9c16-25b1d446c2db" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,862</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_662dfbf4-5608-4192-b58c-41e7128effbe" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs related to AnHeart acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38a0e12f-ae43-4941-a901-84cebab85760" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:TransactionCostsRelatedToAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,434</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e09f0112-e2bc-411c-8ca4-dbce9193e456" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:TransactionCostsRelatedToAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_446468b4-a2d2-45c6-bec9-1d9c767b4cc4" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">339,645</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01ea83c6-cbe7-4cc6-ba60-caf001c5aea1" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">703,373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4ffc699-5f8a-437a-b29c-482fd35f838b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450,082</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f75c4a48-9b9d-4efe-87a3-bf6ad986ad20" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629efb39-eaee-41ed-9999-fbb9050d2422" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfbdce12-59fc-4f45-afec-3b0442215950" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dada74b9-420f-4870-821e-518f9107a7cf" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0b1e189-ab12-4126-ab56-e15b87b9f850" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3103b1a-1308-417a-b276-0c77f32319ed" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,703</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edc8ac25-4fa7-4426-a5b0-3617ad11d52e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,921</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flow from financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7958876-6d45-4d2a-a128-b953f1771b04" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ProceedsFromShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10969d6e-47e6-4cab-8f52-f7453994b42f" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ProceedsFromShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on borrowings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5a062e4-9ab0-4259-9dea-6672674c5270" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,163</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e347e77-4034-47e5-8310-50d2141c0c72" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under ESPP</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f171f8d-5c32-450c-b8d9-3d2b8eeeabb9" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:ProceedsFromIssuanceOfCommonStockUnderEspp" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5abafe5a-45d6-4c70-8366-439fddce1329" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:ProceedsFromIssuanceOfCommonStockUnderEspp" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercises of options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac2c305c-cbd4-476d-bbc9-10c53d4345ee" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52ef267c-2ac8-4fb2-a215-47e5f8cab4c9" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fa84458-0330-427a-9b96-1ca4a14a6815" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0caf983f-b8ef-4ae3-8b9b-49db821b245e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Effect of foreign exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04ea3e4d-ba77-46b7-8a74-639e73fce073" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09b099ef-1633-4aa0-a1b6-0e738310851f" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c6b950-8376-4f60-ada5-a52f3375228b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,926</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d09fc5e1-4b94-4bbe-8ab4-2f568ccea5e2" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,450</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, beginning of the period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c5f3f76-4b58-4ca8-b5ec-7f02c7fd10ef" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,649</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77bd5038-df20-42ca-bf08-e09602a19eec" contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,099</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, end of the period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d4eb03-42af-461c-9025-41e83c6564df" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,723</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c4c9b25-1dad-43d7-84b1-73575f3f4c95" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,649</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f002fd39-2230-46d7-ae45-8a5331dbfebe" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ae0766b-cc20-4b8e-8bbe-e96b4cbcabf4" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for tax</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e9bb180-7d90-43b9-a513-0abf3830e27f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">373</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aafc20b-57a7-45da-acb5-acc0e838e786" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset recognized</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d700a3-553b-4188-a323-d498599d7fcd" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70cd8c47-ab33-4fba-a3c8-4b81f0272df1" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability recognized</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58f52a1b-c70b-4729-b115-ba3b16371880" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:OperatingLeaseLiabilityRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">608</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa977e16-7831-4777-8b3a-dd37dc095e67" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:OperatingLeaseLiabilityRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b60f400d-90bf-411c-a976-3e12d30aa2a3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfCommonStockRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,297</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99a7976c-6a72-47f6-bf8f-6477cc97ca21" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:IssuanceOfCommonStockRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of convertible preferred stock related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f44f02-b5d8-43a8-a723-d685e8039451" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64af6838-e5e5-48b4-a9bb-6753f2b86d01" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of warrants related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40493f91-7c92-40d7-a2b1-49449f8f07b2" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfWarrantsRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52627db7-18bb-42e5-92b1-dda4c361346e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:IssuanceOfWarrantsRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of replacement awards related to the AnHeart acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3924d147-3ebf-4d49-9f0d-33b71c4124ac" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f86ca094-9283-4153-9181-a66a3a7c1363" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC. and Subsidiaries</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_state"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57e95ae1-65e8-4be9-bfbb-7cfe683a5f7e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation Bio Inc. and subsidiaries (&#8220;Nuvation Bio&#8221;), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, (the &#8220;Closing Date&#8221;), Nuvation Bio Inc., a Delaware corporation (&#8220;Legacy Nuvation Bio&#8221;), Panacea Acquisition Corp. (&#8220;Panacea&#8221;), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (&#8220;Merger Sub&#8221;) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (&#8220;Merger Agreement&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the &#8220;Merger&#8221;) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the &#8220;Company&#8221; or &#8220;Nuvation Bio&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024 (the "Acquisition Date"), the Company completed its acquisition of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands (&#8220;AnHeart&#8221;), pursuant to that certain Agreement and Plan of Merger (the "AnHeart Merger Agreement"), by and among the Company, AnHeart, Artemis Merger Sub I, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company, and Artemis Merger Sub II, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 2. SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_390356ad-a767-4e9e-a225-7e796900f36e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">a.	Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_913a551e-982e-435a-a334-e1e2e2e36dac" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">b.	Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the balances of the Company and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c65a11b9-c97d-4da7-b04f-57ae21c77ab4" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">c.	Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company has an accumulated deficit of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f90a8e-061e-498e-aa12-da4508433718" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">910.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and net cash used in operating activities was approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12704dee-aaa6-46f2-b95c-3bce15c26733" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">130.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2024. Management expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17f55eeb-405f-4a2a-ac93-2073c56142e8" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:CashAndCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">502.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. The Company believes that its existing cash, cash equivalents, and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that these consolidated financial statements are issued. The Company&#8217;s research and development activities can be costly, and the timing and outcomes are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the progress of the Company&#8217;s research and development activities and the level of financial resources available.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_264fcbbf-7357-4246-b257-a1d833b5848d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" escape="true" continuedAt="F_264fcbbf-7357-4246-b257-a1d833b5848d_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">d.	Significant Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_1" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_264fcbbf-7357-4246-b257-a1d833b5848d_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company&#8217;s products, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except in China where taletrectinib is being commercialized by our partner Innovent, there can be no assurance that the Company&#8217;s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and vendors and obtaining and protecting intellectual property.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a332efa-08c8-40e6-8226-bee55abe234e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.	Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd7107f3-85b7-44f4-b006-648a5953069f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">f.	Functional Currency and Foreign Currency Translations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's reporting currency is the U.S. dollar ("USD"). The functional currency of the Company's subsidiaries incorporated in People Republic of China ("PRC") is Renminbi ("RMB"). The functional currency of the Company and its subsidiaries incorporated outside the PRC is USD. Transactions denominated in currencies other than the functional currencies are re-measured into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are re-measured at the balance sheet date exchange rate. The resulting exchange differences are included in the net loss of the statements of operations and comprehensive loss. Assets and liabilities of the Company with functional currency other than USD are translated into USD at fiscal year-end exchange rates. Equity amounts are translated at historical exchange rates. Income and expense items are translated at average exchange rates during the fiscal year. Translation adjustments arising from these are reported as foreign currency translation adjustments and are shown as a component of other comprehensive income (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d38951e1-c150-495a-aca9-0073beae85e3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">g.	Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts, a money market mutual fund and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_12e4a0fd-20c7-42dc-a98f-28ec5808fa0e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:InvestmentPolicyTextBlock" escape="true" continuedAt="F_12e4a0fd-20c7-42dc-a98f-28ec5808fa0e_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">h.	Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt securities have been classified as available-for-sale which may be sold before maturity as they are not classified as trading securities or as held-to-maturity securities. Marketable debt securities classified as available-for-sale are carried at fair value with unrealized gains or losses reported in other comprehensive income (loss). Exchange traded funds are equity securities, which are reported as marketable securities with readily determinable fair values, are also carried at fair value with unrealized gains and losses included in other (expense) income, net. Realized gains and losses on both debt and equity securities are included in other (expense) income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For securities in an unrealized loss position, management considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. Management also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If management determines there is any other than temporary impairment, the entire difference between amortized cost and fair value is recognized as impairment through earnings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_2" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_12e4a0fd-20c7-42dc-a98f-28ec5808fa0e_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to credit losses primarily through its available-for-sale investments. The Company assesses whether its available-for sale investments are impaired at each reporting period. Unrealized losses or impairments resulting from the amortized cost basis of any available-for-sale debt security exceeding its fair value are evaluated for identification of credit losses and non-credit related losses. Any credit losses are charged to earnings against the allowance for credit losses of the debt security, limited to the difference between the fair value and the amortized cost basis of the debt security. Any difference between the fair value of the debt security and the amortized cost basis, less the allowance for expected credit losses, are reported in other comprehensive income (loss). Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for expected credit losses subject to the total allowance previously recognized. The Company&#8217;s expected loss allowance methodology for the debt securities includes reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. As of December 31, 2024, the Company has not recognized an allowance for expected credit losses related to available-for-sale investments as the Company has not identified any unrealized losses for these investments attributable to credit factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income includes amortization and accretion of purchase premium and discount. Premiums and discounts on debt securities are amortized on the effective-interest method. Gains and losses on sales are recorded on the settlement date and determined using the specific identification method.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0963bbb-c386-47b6-9516-6910d72b41b3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:AssetAcquisitionTextBlock" escape="true" continuedAt="F_b0963bbb-c386-47b6-9516-6910d72b41b3_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.	Acquisition of assets and businesses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in GAAP, no goodwill is recognized and acquired in-process research and development is expensed in acquired in-process research and development expenses. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_b0963bbb-c386-47b6-9516-6910d72b41b3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div><ix:nonNumeric id="F_1346a31d-4de2-4d8a-9cfa-33302055000a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_1346a31d-4de2-4d8a-9cfa-33302055000a_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">j.	Concentration of Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of credit risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of customers</span></p><div><ix:nonNumeric id="F_fc9be060-84df-4ca4-a092-cd372c06a151" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true" continuedAt="F_fc9be060-84df-4ca4-a092-cd372c06a151_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customers represent more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d44afd55-b777-4ea5-b442-cdfba63b014d" contextRef="C_418fbc05-c30f-4227-9cfe-1386e01c9955" name="nuvb:ConcentrationRiskThresholdPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e6001ef7-0335-415c-949f-84ea3d1851d7" contextRef="C_b3a3ed53-7933-4dff-be9b-82cf2713934b" name="nuvb:ConcentrationRiskThresholdPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9251d0a-4bce-40e6-b252-be3d7f8e70b2" contextRef="C_4b3274d8-aece-4320-b574-aac0c61b61d0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_3" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_4"><div><ix:continuation id="F_1346a31d-4de2-4d8a-9cfa-33302055000a_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_fc9be060-84df-4ca4-a092-cd372c06a151_1" continuedAt="F_fc9be060-84df-4ca4-a092-cd372c06a151_2">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.528%;box-sizing:content-box;"/>
          <td style="width:1.1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.437%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.837%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd67f466-f7b4-4780-9e8b-14974b203914" contextRef="C_da21c4c3-938d-42bc-bc80-ba4f2ce5c849" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,148</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_682a7db5-99c5-4c1d-b417-c508cf7ee786" contextRef="C_fe9e98bb-bd80-487d-b08c-3e44af1635e2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1de9d75-29f7-46d5-b1be-b2611ae3c48a" contextRef="C_07f313fd-524b-46d2-99aa-b951b4324490" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,725</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64d95218-119c-450c-89df-0010330ddf6f" contextRef="C_8fd6169f-7ab5-46a7-a6cc-3a2bc4eb6868" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customer represents more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56ec0254-c4aa-4457-9c0f-f0a633ff471d" contextRef="C_6a5444ea-1b3c-444f-8c39-856c8ccbdd74" name="nuvb:ConcentrationRiskThresholdPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's balances of accounts receivable as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.38%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_909de292-f65b-4ff0-9097-b67368ce7844" contextRef="C_f6d0b85e-30b4-4e3d-90ba-0b428c795f3b" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,610</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:continuation></div><div><ix:continuation id="F_fc9be060-84df-4ca4-a092-cd372c06a151_2" continuedAt="F_fc9be060-84df-4ca4-a092-cd372c06a151_3"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b38457e7-2352-415f-94a5-0b245c071ad5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_fc9be060-84df-4ca4-a092-cd372c06a151_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">k.	</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets of generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aaaf0e5b-0349-4a41-905e-6439d3dedd5b" contextRef="C_abb8df07-b97c-4a48-aefb-b20f734b97a2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for computers and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b93fe89-713f-47c5-a83c-033b764d0dfa" contextRef="C_8d9345df-39ad-447f-a1af-a822c985ade5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for furniture and equipment. The cost of leasehold improvements is amortized on the straight-line method over the lesser of the estimated asset life or remaining term of the lease. Maintenance costs are expensed as incurred, while major betterments are capitalized.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5017bff3-d058-414b-a5b1-fc9aa8f48902" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">l.	Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and an impairment assessment may be performed on the recoverability or the carrying amounts. If an impairment occurs, the loss is measured by comparing the fair value of the asset to its carrying amount.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_dc93a43f-60c8-425d-bb51-0e740c3fe9f5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:WarrantsPolicyTextBlock" escape="true" continuedAt="F_dc93a43f-60c8-425d-bb51-0e740c3fe9f5_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">m.	Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a25666f9-d6eb-414d-a29a-f283c7c2e9dd" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,787,472</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase common stock outstanding, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd83e10-89a2-40b8-9cf5-fa1eae4359a9" contextRef="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,791,639</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Public Warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03e706aa-68bc-44a7-a666-299039f36ca0" contextRef="C_38dfcba2-bd95-458c-a352-b4df776e9ce0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">162,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Private Placement Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2dfb6dd-ae5e-4093-891b-b5b60dc17250" contextRef="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">833,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Forward Purchase Warrants (as defined below). Each whole warrant entitles the registered holder to purchase one share of our Class A common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481c9285-2d3c-486d-b08d-f63dc8589fd4" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the consideration for AnHeart, the Company issued warrants collectively exercisable for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe4a714-e401-4890-b42d-79e67d363f24" contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,893,720</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A Common Stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0d5a97c-1d91-4b24-a450-f5fb79512db7" contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Consideration Warrants&#8221;). The fair value of the Consideration Warrants was determined to approximate the public warrant trading price as of closing of the Acquisition, yielding a fair value of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_918d200a-bfe4-4410-b6f1-981e6caeb826" contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1" name="nuvb:FairValueOfWarrantsTradingPrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_4" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_dc93a43f-60c8-425d-bb51-0e740c3fe9f5_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stockholder </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants. Accordingly, the Company classified the Consideration Warrants as liabilities, consistent with the classification of the Company&#8217;s Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer based on the stockholder approval from the 2024 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) on September 3, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated Public Warrants, Private Placement Warrants, Consideration Warrants, and Forward Purchase Warrants (the &#8220;Warrants&#8221;) under ASC 815-40, Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders&#8217; equity. Specifically, the settlement value of the Warrants is dependent, in part, on the holder of the Warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on our Common Stock, the Warrants fail the indexation guidance in ASC 815-40, which would preclude classification in stockholders&#8217; equity. Additionally, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3e650d5-f0e2-430f-9a21-aaaef677ecd0" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SaleOfStockDescriptionOfTransaction"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#8217;s Common Stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Because not all of the Company&#8217;s stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Warrants do not meet the conditions to be classified in equity. Since the Warrants meet the definition of a derivative under ASC 815, the Company recorded these Warrants as liabilities on the balance sheet at fair value upon the closing of the Merger, with subsequent changes in their respective fair values recognized in the consolidated statement of operations and comprehensive loss at each reporting date. The fair value of Consideration, Public, and Forward Purchase Warrants was determined using the closing price of the publicly traded warrants on the NYSE market.  The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (see Note 4).</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0325db27-7ff5-4d46-8abe-07036bd3045a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:RevenueRecognitionPolicyPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">n.	Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies ASC Topic 606, "Revenue from Contracts with Customers" ("ASC 606") to account for its revenue transactions.  Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the five-step model. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.  Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.  Accounts receivable represent amounts invoiced and revenues recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_cff6cf32-59b2-4cf2-880c-648d3ee76160" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:CollaborativeArrangementAccountingPolicy" escape="true" continuedAt="F_cff6cf32-59b2-4cf2-880c-648d3ee76160_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">o.	Collaborative Arrangement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the FASB issued Topic 808, "Collaborative Arrangements" ("ASC 808"): Clarifying the Interaction between ASC 808 and ASC 606. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard for all periods presented. The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. The Company assessed and determined that none of the collaboration agreements entered into during the periods presented were within the scope of ASC 808, as all of the agreements did not involve active participation by both parties in a joint research activity, and therefore did not qualify as collaborative arrangements under ASC 808.  The Company has determined that all the elements of the above collaborations are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. The Company recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.  The Company's collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_5" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_6"><div><ix:continuation id="F_cff6cf32-59b2-4cf2-880c-648d3ee76160_1" continuedAt="F_cff6cf32-59b2-4cf2-880c-648d3ee76160_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from the portion of the transaction price allocated to the license at a point in time, when the license is transferred to the customer and the customer is able to benefit from the license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs based on the use of an input method.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A customer's right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or a discount. Optional future services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. The optional future services do not include a material right to be accounted for as performance obligations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's collaboration agreements include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company's collaboration agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company receives payments from its customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until the Company performs its obligations under the arrangement.</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_6" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_cff6cf32-59b2-4cf2-880c-648d3ee76160_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a complete discussion of accounting for revenue, see Note 5, "Collaboration and License Agreements."</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47231fea-f02b-4a2e-b4cf-2395c446dbb7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p.	Costs to Fulfill a Contract with a Customer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not capitalized any costs for the years ended December 31, 2024 and 2023.  The Company is required to capitalize costs incurred to fulfill customer contracts. These costs are required to be amortized to expense on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates, compared to previously being expensed as incurred. Elements of the costs primarily include (i) payroll and other related costs of personnel related directly to the contract activities; (ii) costs related to pre-clinical testing and clinical trials such as payments to contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"), investigators, and clinical trial sites that conduct the contract activities; (iv) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses; and (v) other research and development costs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5d6ed07-b1ee-4c16-b4b9-379e90702273" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:LeasesPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">q.	Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in operating lease right-of-use, or ROU assets; current operating lease liabilities; and non-current operating lease liabilities on its balance sheets. The Company currently does not have any finance leases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#8217;s leases generally do not provide an implicit rate. The incremental borrowing rate is reevaluated upon a lease modification. The operating lease ROU asset also includes any initial direct costs and prepaid lease payments made less any lease incentives. The Company considered information available at the adoption date of  Topic 842, "Leases" ("ASC 842") to determine the incremental borrowing rate for leases in existence as of this date. The incremental borrowing rate used was the weighted average rate between secured and unsecured lending arrangement.  Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the option will be exercised. Variable payments included in the lease agreement are expensed as incurred. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company elected to apply each of the practical expedients described in ASC 842-10-65-1(f) which allow companies not to reassess: (i) whether any expired or existing agreements contain leases, (ii) the classification of any expired or existing leases, and (iii) the capitalization of initial direct costs for any existing leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term operating leases. A short-term operating lease is a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.  The Company also elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_3505eb3c-d432-4747-8bcf-36eea5ad1d79" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_3505eb3c-d432-4747-8bcf-36eea5ad1d79_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">r.	Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s operations are focused on oncology development activities. Substantially all revenues were derived from customers located in China and Japan. For the year ended December 31, 2024, the revenues derived from customers located in China and Japan were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf81bfd2-eadf-45e4-ba96-8e1be9971e62" contextRef="C_30c42ef8-e350-413e-8d4a-0cb11d19dd8f" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74805c62-3606-402e-9195-7314358daa61" contextRef="C_f54ce4b1-75d3-4c3a-841f-2d8ce4cc5489" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_318749d1-1c75-4404-84cf-20b01324cf43" contextRef="C_4b3274d8-aece-4320-b574-aac0c61b61d0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation's Chief Executive Officer is the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM utilizes the Company&#8217;s strategic product development roadmaps and financial models, as a key input to resource allocation. The CODM is regularly provided with actual, budgeted and forecasted expense information to make decisions on resource</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_7" continuedAt="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_8"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3505eb3c-d432-4747-8bcf-36eea5ad1d79_1" continuedAt="F_3505eb3c-d432-4747-8bcf-36eea5ad1d79_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocation and assess performance of the business and monitor budget versus actual results using income from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant expenses within income from operations, as well as within net income, include cost of revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss. Other segment items within net income include interest income, interest expense, investment advisory fees, change in fair value of warrant liability, realized loss on marketable securities and other expense, net, and income tax expense.</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_3505eb3c-d432-4747-8bcf-36eea5ad1d79_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-lived assets consist primarily of property, plant and equipment, net. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d3ff474-19e2-4deb-a9b5-e2c54d1edf6a" contextRef="C_a2bdff39-def8-4415-a8b5-6832e22064e8" name="nuvb:PercentageOfLongLivedAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of long-lived assets were in the U.S. As of December 31, 2024, no individual country other than the U.S. accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b69ee61a-c54a-4b74-9eef-4e39d25b3cd9" contextRef="C_3d24e6c8-77cc-422b-ba78-255de1017179" name="nuvb:PercentageOfLongLivedAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more of these assets.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a3ad3dd-9189-4589-ad00-fb635f036967" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">s.	Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred in connection with research and development activities are expensed as incurred. These costs include fees paid to consultants, vendors and various entities that perform certain research and testing on behalf of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new product compound, as well as pre-commercial milestone payments, are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new product compound did not also include processes or activities that would constitute a "business" as defined under U.S. GAAP, and the product candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval which meet the capitalization criteria would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. If the conditions enabling capitalization of development costs as an asset have not yet been met, all development expenditures are recognized in profit or loss when incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04b1c791-466d-4d0b-9e08-49eaa4d2de1b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">t.	Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes compensation cost for grants of employee stock options using a fair-value measurement method, that is recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the fair value of stock-based awards that are based only on a service condition using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, volatility, dividend yield, and expected life of the options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the fair value of stock-based awards that are based on both a service condition and achievement of the first to occur of a market or performance condition using a Monte Carlo simulation.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_07c2339a-d33c-4ae3-9e08-31b3f98bf663" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_07c2339a-d33c-4ae3-9e08-31b3f98bf663_1"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">u.	Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. The difference between the financial statement and tax basis of assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the years in which they are expected to affect taxable income. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of the tax provision. Returns for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba_8"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_07c2339a-d33c-4ae3-9e08-31b3f98bf663_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years beginning with those filed for the period ended December 31, 2018 are open to federal and state tax examination.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_984d7f58-e9ef-49cd-b0cf-27d8e94b3072" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">v.	Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07&#8212;Segment Reporting (Topic 280):  Topic 280 "Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted ASU 2023-07 effective December 31, 2024. The adoption of the guidance did not have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements. See Note 2(r) for further information on Nuvation's segment reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09 &#8211; Income Taxes (Topic 740): "Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. This guidance is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_213f0f05-cd53-489d-9c3b-00059790ff49" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" continuedAt="F_213f0f05-cd53-489d-9c3b-00059790ff49_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 3. ACQUISITION</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024, the Company completed the acquisition of AnHeart. Pursuant to the terms of the AnHeart Merger Agreement, at the effective time of the First Merger (as defined in the Merger Agreement) (the &#8220;First Effective Time&#8221;), the Company issued to AnHeart securityholders (i) approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_625821e9-a895-41bd-9406-b05388f003c4" contextRef="C_4f00ab19-70eb-452a-a67c-0c577ad86cfe" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,646,255</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2ebdd81-4cb0-447a-9186-76bc04c74b1a" contextRef="C_b2ddc1f0-c371-4813-af10-cf895f6e3373" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">851,202</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A Non-Voting Convertible Preferred Stock of the Company, and (iii) the Consideration Warrants. The shares of our Series A Non-Voting Convertible Preferred Stock were automatically convertible into an aggregate of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_273f18a9-7af6-4d1c-98c2-4a70bce1a5e3" contextRef="C_cfda41d6-83a3-4e48-ba69-343cbe55f56b" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,120,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock upon the approval of such conversion by the Company&#8217;s stockholders in accordance with the rules of the New York Stock Exchange. Since the preferred stock was not mandatorily redeemable and the exception for a deemed liquidation event was not met, all of the outstanding convertible preferred stock was classified as mezzanine equity in the balance sheet at the Acquisition Date. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 3, 2024, the Company held its Annual Meeting at which the Company&#8217;s stockholders approved for the purpose of complying with the listing rules of the New York Stock Exchange, the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_570c4cee-9de2-4bd1-84ca-1714792dfef2" contextRef="C_70942f4b-acda-4d74-b1c9-cadcea492b15" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,120,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock issued in April 2024. Additionally, the Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting. The conversion of the Convertible Preferred Stock into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f08df6e-17d6-47f1-ab6b-4c2965952f29" contextRef="C_c982e94f-abaf-48a7-a575-7a406ffb1b30" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,120,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock was completed and those shares were issued and outstanding as of September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the First Effective Time, (i) each option to purchase shares of Ordinary Shares (as defined in the Merger Agreement) of AnHeart (an &#8220;AnHeart Option&#8221;) held by a Continuing Company Service Provider (as defined in the Merger Agreement), whether or not vested, was assumed and converted into an option to purchase Class A Common Stock (each such option, an &#8220;Assumed Option&#8221;), and (ii) each restricted stock unit reflecting the right to receive Ordinary Shares of AnHeart (an &#8220;AnHeart RSU&#8221;) held by a Continuing Company Service Provider (as defined in the Merger Agreement) was assumed and became a restricted stock unit with respect to a number of shares of Class A Common Stock (each such restricted stock unit, an &#8220;Assumed RSU&#8221;). Each Assumed Option and Assumed RSU is subject to the same terms and conditions (including vesting and exercise schedule) as were applicable to the corresponding AnHeart Option or AnHeart RSU immediately prior to the First Effective Time, subject to limited exceptions set forth in the Merger Agreement. Any other AnHeart Option and AnHeart RSU that remained unexercised and outstanding as of immediately prior to the First Effective Time was canceled without payment. From and after the Effective Time:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of shares of Class A Common Stock subject to each Assumed Option was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart Option immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio (as defined in the Merger Agreement) and rounding down to the nearest whole number of shares;</span></div></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_213f0f05-cd53-489d-9c3b-00059790ff49_1"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the per-share exercise price for Class A Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per-share exercise price of each AnHeart Option, as in effect immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio and rounding up to the nearest whole cent; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of shares of Class A Common Stock subject to each Assumed RSU was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart RSU immediately prior to the First Effective Time, by (B) 1.7551 and rounding down to the nearest whole number of shares.</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_7e44956a-35eb-4622-a9ca-72eed49667d5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The final allocable purchase price consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"/>
        <td style="width:10.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A Common Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_801b7957-e7ce-45ce-af71-3084ea02dc16" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="nuvb:AllocablePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,297</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Non-Voting Convertible Preferred Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73151569-7198-451b-a2ba-1634232ea74a" contextRef="C_1632c343-8902-43c4-8df1-34be8034ddec" name="nuvb:AllocablePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,938</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27913815-f03d-44ad-ae06-0585e506afd5" contextRef="C_7950894a-1811-4b80-ae40-787e405417b7" name="nuvb:AllocablePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assumed share-based awards </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f3c6cf-2103-4802-bf64-c4e3996706c0" contextRef="C_b84b1da0-aedf-4620-881d-35579afeb08f" name="nuvb:AllocablePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,818</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5315ce0f-4d5b-47f8-9b89-1be9a5be8d2a" contextRef="C_28c85cf7-f7fc-4376-b2ea-94cb2e1e8f60" name="nuvb:AllocablePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocable purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f9fbe51-75bc-4605-b4f8-44b3e9fb04a1" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:AllocablePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,251</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">____________________________</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)     </span><ix:footnote id="FNT_4f3bb437-a8b3-4cff-8b4c-0918d5764aee" xml:lang="en-US"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d02963a2-fc87-44d3-9f4b-063d0af6b3c3" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,646,255</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_230504a1-4f52-444e-90b2-2d9ba1c2e6fb" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of the Acquisition Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:footnote></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)     </span><ix:footnote id="FNT_563dd183-07f4-4e61-8c2d-ef4770f63d0a" xml:lang="en-US"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d70d6f58-69f8-4212-ab12-0806d7afe9f5" contextRef="C_1632c343-8902-43c4-8df1-34be8034ddec" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">851,202</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at as-converted value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eddbdf85-cc64-492b-b980-d9f629c382aa" contextRef="C_d630f863-0d98-4a3a-a20e-783e2c04a4e9" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" decimals="0" format="ixt:num-dot-decimal">323</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></ix:footnote></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)     </span><ix:footnote id="FNT_227f6045-fd63-4e82-9ac3-e6f2c0dda3b3" xml:lang="en-US"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e804059d-202e-4f35-a9e9-f7ec157b9b3c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,893,720</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued at the estimated fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ed9906f-5207-49ab-98e9-6dba7aee0d72" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:EstimatedFairValueWarrantPerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.2641</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant.</span></ix:footnote></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><ix:footnote id="FNT_37026355-c90c-4fba-bff4-dc06521eb3a1" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp; Assumed RSUs) attributable to precombination services.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the transaction as an asset acquisition since the lead asset, taletrectinib, represented substantially all of the fair value of the gross assets acquired, which excludes cash acquired. At the Acquisition Date, we recorded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a459de90-e8fc-480d-be5a-d7692589c314" contextRef="C_0f03a15b-3abb-4776-a53a-0c003dafb17a" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">425.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million charge representing an acquired in-process research and development asset with no alternative future use in acquired in-process research and development expenses, of which the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6ae818a-4e0c-4d2d-a281-bebd90933b12" contextRef="C_0f03a15b-3abb-4776-a53a-0c003dafb17a" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">425.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_100180d7-578b-4a9f-9bf0-67d5905bf29f" contextRef="C_a7fd337a-9497-4d90-be00-2699c0401c1b" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of assets acquired primarily consisting of cash and liabilities assumed were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de14e972-f420-4182-9c22-0884930789b6" contextRef="C_a7fd337a-9497-4d90-be00-2699c0401c1b" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">53.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_4d42af2f-ab66-442c-808a-1514a40fef55" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_4d42af2f-ab66-442c-808a-1514a40fef55_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 4. FAIR VALUE MEASUREMENTS AND MARKETABLE SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8212; Unobservable inputs that reflect the Company&#8217;s estimates of the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following table presents information about the Company&#8217;s marketable securities and the Warrant liability as of December 31, 2024 and 2023, measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company&#8217;s Warrant liabilities are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_4d42af2f-ab66-442c-808a-1514a40fef55_1" continuedAt="F_4d42af2f-ab66-442c-808a-1514a40fef55_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">included </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">within the Level 1 and Level 3 fair value hierarchy.  The fair value of the Consideration, Public and Forward Purchase Warrants is determined using the closing price of the warrants on the NYSE market. The fair value of the Private Placement Warrants is determined using the Black-Scholes option pricing formula. The primary unobservable input utilized in determining the fair value of the Private Warrants is the expected volatility. The expected volatility was estimated considering observable Public Warrant pricing, the Company's own historical volatility and the volatility of guideline public companies.  </span><span><ix:nonNumeric id="F_56bf933e-1864-485f-a5bf-36e9b930e41a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_56bf933e-1864-485f-a5bf-36e9b930e41a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have not been any transfers between the levels during the periods.</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_56bf933e-1864-485f-a5bf-36e9b930e41a_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b909a0-6c9d-4f38-8130-6710d27a36e9" contextRef="C_3c8db28e-2317-426a-ae9d-38906384d4dc" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ba7bc15-f756-4c78-8392-b856813c823a" contextRef="C_feb7f3f7-75e8-4c18-a40f-52dbffc94964" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e20580-1fc3-4ee9-8344-eddf98f873ec" contextRef="C_71aaefa0-51ea-4664-bacf-7f5628476895" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_644c104b-8f30-4a41-84f0-73601ec927dd" contextRef="C_c5581c71-90c7-436b-aaba-8f1f78e6dc28" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5273dea5-2a4d-4235-8fc2-f4549dcf4b3b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e92e8bba-1362-417a-a01c-03c11332d623" contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8ac75a9-73f1-44d2-8bbb-485c96cc7cc9" contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2878228d-4cb0-489a-9f01-98a7452d0da8" contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f1f463-5f55-47a1-9453-fbf0d567770e" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbf07409-16ab-4ebf-8e3e-4ec34ffbab05" contextRef="C_1fe9b1fa-5c06-41bc-904a-8d55067e5f76" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cce1312-4e88-4bed-a1ef-8b3fe3ea1243" contextRef="C_2da576e1-d49e-45c4-bfa3-24d20530d615" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5f34afd-e680-483a-aac9-897ea57b2505" contextRef="C_64371941-b776-4c3c-ab99-a54d91207dee" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f27e4d-f34f-459c-9f8b-213c43cc225b" contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bbe9b14-cef6-46cc-af48-d025c609cbe1" contextRef="C_02eea57f-659f-4ea9-a9be-e8bf4cf97e78" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39941429-ca8f-41f7-ba1a-b7088ce0191b" contextRef="C_79e5ffa3-86c1-447a-bb2e-bece04e75439" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c05d48f-b74a-4bfa-9b51-0a30f2f5a414" contextRef="C_9c555376-54aa-4690-a07a-8995c5f1de8e" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a5c4c8c-3a89-4f7f-8655-01ed753b171d" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51083e92-894c-41da-9d33-9ab056474302" contextRef="C_529b7cca-f4b7-4116-a505-7babb7b8fa92" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a61d069-890c-44b6-ab7c-5ac79aea3955" contextRef="C_532ddbb7-20a6-413d-b66d-5c3445bb8db6" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba013076-0088-4084-9d80-c7e734d0f220" contextRef="C_f65e2027-f5ac-4490-8e99-bc62d9e131dd" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dd9a8a6-53f9-43ab-b803-c117bd10aab0" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee82d514-314f-40ac-8716-a6779f00196d" contextRef="C_5c1f1a22-82b1-4d98-9857-c486ab81f376" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d84abf6-da52-4c40-b3c0-ac8a1928b9f4" contextRef="C_f04153c5-2436-41de-9120-dcd4ef68be2a" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a025dc42-829f-4241-ae4e-ca37e1244c85" contextRef="C_0ec4baa0-50bf-4ee8-bab3-3ce9c13fadb7" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8d8af87-5fa4-4855-91e6-47e98e4edc90" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14f8e422-83c1-42eb-ad65-bf452532321c" contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f6c9fdc-b247-49a4-95d6-db0479b7f7cd" contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2267d2fc-3c29-49d0-a640-2504dc0d7d90" contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets:</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db134bf-2208-489b-b90a-61c4d565c130" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bd77373-05c6-4215-b850-b7b9715b0317" contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ca6465b-8d73-4f6b-978d-48c3f492bb12" contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1b9fb2-bddb-4842-908e-156e067581f3" contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d474c18-e1a3-4b11-afd4-38240fee7fed" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,053</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1aaad65-86c5-4920-a3ba-14adb1fbdfbc" contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,959</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24aa59d7-60f1-4156-a42a-c809f95304b7" contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67a25d57-0df3-4fc8-8d6c-0f57408099cb" contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.121%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.189%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74e69c5c-70a7-4c09-9aa8-5a5edd309cbf" contextRef="C_66e37e69-8ac7-4c73-be34-2b5741857629" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62faf4dc-a074-467a-94c6-b38e769fa6fd" contextRef="C_57ac3f3b-9cda-4711-b678-dd10a4a451ad" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6a76582-0088-4aed-865f-ed3eb8eb44d9" contextRef="C_8e8cdc8e-8210-4b4d-9cd5-f1a28755b54e" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0635ded-dbfe-429f-874a-215c30109ebd" contextRef="C_54b6680f-d764-4c4f-bd20-7ff2e11edc6d" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb07401-5e55-46ff-9f2a-19f68edc5ea6" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_897bcef7-6746-435d-b09f-d19e29931bc5" contextRef="C_0dded1bb-24a8-4a81-9bbe-145757df1e2c" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbbfe3c1-e593-4b5d-a8ec-deecae1289e1" contextRef="C_f600fe9a-155a-446b-92c8-a7fc4ddd37e1" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6444b151-4dee-4205-9c95-ffb7292fc715" contextRef="C_17baa364-63a5-4662-be7d-3a569f3f9131" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_431b0390-e3d0-4532-a399-e05d326d8770" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1f89724-49fc-4936-8bea-9a8e52c270f5" contextRef="C_ce6f0d2b-c086-4763-b947-870bbe14d4f9" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46a5902d-a983-48ee-9cf5-f54e2c02654f" contextRef="C_b5fad4a0-b4e2-4fff-9d5d-16ef79716219" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6c7fbfa-4c06-4978-b137-8a56c186e1fa" contextRef="C_952278b9-3008-410e-b399-83d1341da7e8" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ec7d6dc-861e-4e26-9f6d-cef18a65202b" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,509</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ad6e56c-3efc-49e0-82d6-cb7f256f829c" contextRef="C_b432f621-66c8-4177-856f-0710048eeb24" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97bfe77d-f8b1-42ec-9dde-3711ef14f021" contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,935</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d12ebce7-59ae-4df0-b130-521435c46df4" contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72ee47f0-6c8b-4d8e-aa3c-839589843176" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,176</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e6f75d5-f894-4577-874e-394f7a427478" contextRef="C_16f76ae8-82d8-4ad7-884d-2c31f5e8ddc5" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84bc6ba3-f385-43fd-a1e7-eac17147daeb" contextRef="C_07229a6d-6da2-40c2-88a0-037159cfa57e" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,176</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_738ca240-9679-4d03-bdf0-4510c22a70ab" contextRef="C_b68630d3-6944-4401-9af4-dc2436cb5eb7" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_123340e2-5dbf-486a-b045-170384ec3d42" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,628</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b329acb-7b21-41dc-94b1-2669e313b477" contextRef="C_673b8d54-13ef-4cf8-98c1-1882bd894e37" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d6d573f-2eb6-48c3-bc8a-aab05e36200f" contextRef="C_8c1b26be-f804-4b3f-992e-e5e76af52068" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,628</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea4180dd-299a-4534-a400-6b3341f86f4a" contextRef="C_3cba4440-12d3-4ee9-9032-9e8572c8aa7e" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0767f530-2d7f-40a9-8c83-c1b28915046e" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453,175</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91d4903b-aab0-4e16-a98d-0c5f999136a8" contextRef="C_0dded1bb-24a8-4a81-9bbe-145757df1e2c" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b06026dc-cfd0-472e-bee2-6ff50619246a" contextRef="C_f600fe9a-155a-446b-92c8-a7fc4ddd37e1" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453,175</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95b759f9-17bb-4e43-a94a-be2b42cd2678" contextRef="C_17baa364-63a5-4662-be7d-3a569f3f9131" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33cdcdf4-b79c-4096-a365-5b34d28e67f5" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,585</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0126c36c-bb7d-41e0-a35b-cc26b5fb58f5" contextRef="C_ce6f0d2b-c086-4763-b947-870bbe14d4f9" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2de7a66-9c9c-46c8-a982-f5af8b38a944" contextRef="C_b5fad4a0-b4e2-4fff-9d5d-16ef79716219" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,585</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed96ff1f-f2c5-4296-8e31-5bb30dc98a3d" contextRef="C_952278b9-3008-410e-b399-83d1341da7e8" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e76e9347-f496-48ec-8f38-874d493c3e2e" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,564</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5848a80f-4a7d-46a0-b2ef-482dbee4f984" contextRef="C_b432f621-66c8-4177-856f-0710048eeb24" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91014a36-5505-48e0-b3e7-2ea8390e2d54" contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,564</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd49ad0-5320-4122-be38-5e91865f2b7b" contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets:</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdfaae88-136e-47dd-83fb-e720c0faff92" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fdcf5b7-06b1-4de9-a2de-493a7e270839" contextRef="C_b432f621-66c8-4177-856f-0710048eeb24" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06918515-9408-45bb-bbca-392b242a2a5a" contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">574,499</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_537972ad-5577-4829-aeaa-402ce8cc7aef" contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5" name="nuvb:TotalFinancialAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ae0010d-d5e4-4dee-8a25-f6cdbd55a4da" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b487c56f-0280-4b5d-9867-1617e7ee32ef" contextRef="C_b432f621-66c8-4177-856f-0710048eeb24" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bb7df95-9cc9-47a1-be0f-f4d63897dadd" contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4310be93-1ebd-4f81-a5bf-16d88c0d9548" contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consist primarily of U.S. government and government agency, certificate of deposits, commercial paper, corporate bond and municipal securities ("Debt Securities"). Based on the Company&#8217;s intentions regarding its marketable securities, all Debt Securities are classified as available-for-sale and are carried at fair value based on the price that would be received upon sale of the security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_0796cf9c-c456-4c6e-a406-417952d13c3e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true" continuedAt="F_0796cf9c-c456-4c6e-a406-417952d13c3e_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides the amortized cost, aggregate fair value, and unrealized gains (losses) of marketable securities as of December 31, 2024 and December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_4d42af2f-ab66-442c-808a-1514a40fef55_2" continuedAt="F_4d42af2f-ab66-442c-808a-1514a40fef55_3"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_0796cf9c-c456-4c6e-a406-417952d13c3e_1">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.438%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.684000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.684000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.904%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.684000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb8974ba-4bf8-4584-af71-ba06eb8abc9a" contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_272b1e46-9b08-4659-a5e8-394e9461532a" contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f1b485b-cd22-4776-b791-3e693dad5663" contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b57d290d-98ae-4326-9704-75e66d92994f" contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7da80998-38ec-4249-8ad4-d94a7ea9a575" contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f08df3ba-515b-42e8-a2ce-eb86576702bf" contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70199e28-629b-486b-b634-563039f6f882" contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d946391c-cdf9-41f6-be11-dcceaa5352e8" contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_821bce0b-29c6-4d2c-8e98-8f51905cdfbe" contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,628</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d5e866-2c3e-4ff2-986b-b6f3a46c53d3" contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89a31881-9e72-4545-b8b6-f92ea15d3da2" contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_178b8d0f-5bda-4381-9207-ad2a06dee3bb" contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6434383c-91b3-4640-aa40-9cdc44f85748" contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_736e48f7-a954-456c-bf08-04412149c767" contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ad82065-d6ec-4fdc-8cc4-b4be66ea8164" contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1972502f-83a8-4f72-8850-ec444c291863" contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f2d4a89-a360-4dc9-beb4-2ac2215ce5b1" contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57377c37-a32a-465d-aa75-7fbd8e330b79" contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42b45c4f-3fa9-4124-b367-2885453f4c46" contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8ee1150-1a2e-47b7-a21f-abecaf9e3d5f" contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31e97a18-0162-46da-9149-9593d13b4408" contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,891</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4744eff-f77f-44a5-8846-82f9c24552c1" contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c85a0a28-f9f0-493f-86dc-64399863aa0c" contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d137fea7-a7f4-4ce3-a27e-75070dbc120f" contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978c5834-ea2e-4cbe-9507-7062ae014010" contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91c4fd77-0671-4acf-9925-46d0ae470da6" contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256d5e81-427d-48d8-8654-a40e6a1acd6c" contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">560</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb1d34b3-6006-4ffc-9359-761b1389e53f" contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b7a7cfb-86af-4532-a9ce-500216842f60" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,482</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ae15019-f861-4e52-a362-310e78e59535" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_957ff2bb-7be3-41ef-bdc3-6036aab5079b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">560</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c9fcac8-88f5-4e7e-bf43-c814db0cd38f" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.447%;box-sizing:content-box;"/>
        <td style="width:1.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.687999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.687999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.687999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.687999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_865fbe4b-5bf3-4ed0-b956-c7da1f7b8fb1" contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e2fe15-a9ad-4a43-9e10-48d34a15c579" contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a401640c-6615-4229-8080-ff67652d7d88" contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c1aa8a2-d180-481b-9559-62471187101c" contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8bbe3b2-a439-4f60-bae3-16a851aab99e" contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,987</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0d22dd5-0348-41a6-8960-3ccd90b77a1e" contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19120425-2cb4-47b0-accc-6ba1e6e0f40d" contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c36d4b9-6076-4728-976a-0f2a9bae745d" contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5dbd01d-96cb-49c8-ba12-f95d4a6b80a9" contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5378f222-1110-4dde-8cb4-c923b42689a3" contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f404c542-b28f-4322-abd1-9cc5d1ac146c" contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a93ed7-ec41-478f-a3ae-54b69e4bb924" contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">947</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea3c4cfb-1cdb-43e5-b08e-84282627ec11" contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074dad0e-8efd-44b7-93e8-ab2c960b5718" contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_170ceb0d-f306-4552-86ea-b10605a47cb1" contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a230eca-1c4c-448a-a650-65918458a064" contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,509</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d19d179-6f02-4904-83ba-3603b003635d" contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,171</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddb4af51-0eae-46fb-b2f6-5c74a69d6429" contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8647bfc-cbd4-49fe-ba0e-c70b39888788" contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa3fc681-7f28-4d98-b8e3-f42000ce01ed" contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,176</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8451ba9e-a14b-414f-9391-c4c954beaf85" contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,609</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88f9d01b-7860-49b7-aae4-9c2409bcf864" contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f19c9c77-af2c-4631-9b3b-29e12c64388f" contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c37fa64-29b4-4efa-8c4d-da0e671a905f" contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,628</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4def715e-f23d-4d44-9a94-2e4012127d77" contextRef="C_26a84641-0351-4435-853e-2d9c28676213" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452,813</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0149b638-311b-41cd-bd64-50218395b1e9" contextRef="C_26a84641-0351-4435-853e-2d9c28676213" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f5e9e4-8930-4eec-adcc-df9a0f8421ff" contextRef="C_26a84641-0351-4435-853e-2d9c28676213" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa92f94e-f1b0-4020-bd31-739f7e5d2f7c" contextRef="C_26a84641-0351-4435-853e-2d9c28676213" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453,175</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00813b2f-04ec-45af-8237-e16a9244d031" contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,791</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff953a08-5509-4a7e-9818-faf2c4d03845" contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2b32e6c-2e39-4711-9016-d56aad670499" contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ee00702-50df-4029-be5a-6c9de3e8253a" contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,585</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_016035d6-a6e5-41b9-8b46-e8baa3a044ba" contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,384</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab9a660c-d6ab-4cf5-945d-ddfcc90154cd" contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1878efb6-5eca-4c3a-b1fb-21d574cf33c2" contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_336afa57-c81d-4b8e-ae18-7fb913f5e311" contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568,564</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f640365-a6bc-4171-bcae-e6c0d6a45e5f" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594,892</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd462bf-112e-47fa-8a9f-aaebe9925f35" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,193</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_979cffd4-ffa8-4ffa-a077-0ba863c8e5f9" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,012</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b2bbfc-9710-4d5a-b69a-9390b1615bd8" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595,073</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_627d4ed9-9235-4f11-97df-0e799071fefb" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfRealizedGainLossTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the activity related to the net gains (losses) on marketable securities included in other income (expense) on the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized gains (losses) on available-for-sale securities were as follows:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized gains from sales of available-for-sale securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db0b125b-99bb-497f-bc8f-68551200e26a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_952d7aa5-4961-4af7-890e-ab2fb2132a01" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized losses from sales of available-for-sale securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_874ad33b-0a47-49e7-b709-9ed8d443837d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c900e4d-666c-4aaa-b93e-fa72500824ce" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized losses on marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e604827-0977-491e-905c-ee5607907112" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a758002-a5c1-4770-b083-96cf3709249d" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div><ix:nonNumeric id="F_206bce17-301d-4630-a84e-069f0010a6a2" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true" continuedAt="F_206bce17-301d-4630-a84e-069f0010a6a2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables provide marketable securities with continuous unrealized losses for less than 12 months and 12 months or greater and the related fair values as of December 31, 2024 and 2023 were as follows:</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_4d42af2f-ab66-442c-808a-1514a40fef55_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_206bce17-301d-4630-a84e-069f0010a6a2_1">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:34.412%;box-sizing:content-box;"/>
        <td style="width:1.219%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.712%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.219%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.712%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.219%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.712%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.219%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.712%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.219%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.712%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.219%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.712%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_856eb7b8-10f0-440f-8ceb-bc13779daa90" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6afe8c3-a786-4636-8030-aa77091983f7" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98aaff29-373b-403e-b896-05849cde8c49" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_153895c6-94cc-4c55-84f3-636e7bac628c" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f855074-6f92-4bd4-b1b8-00cca94f737f" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_895dde7c-b1b2-410d-8111-3e16385e4341" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe5368e-fcfb-4b36-8593-4ef82e186a5e" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,021</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33263703-820e-4a8f-9507-bb719da2e8d5" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beb66c42-d683-44ed-8b9e-4c344a1f2d99" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,099</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18f566c4-2fde-42ff-8e3f-c716df5fd334" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d21d9f7d-682c-455d-b7fc-fe81b6741ae4" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,120</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b1261e-2530-44a9-8aab-766480dac51b" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e986897-a71b-49c8-a3bc-a4d89be2e59b" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,659</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3104536b-c566-4c2e-95b0-977d5df38ab6" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83f991f2-d892-4f53-854f-08fdd1920043" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,911</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b100c444-cd99-42ef-9e71-a7116902a1b2" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2068d7ed-7ee0-41ae-abe3-60009496137c" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d91016c-657e-4242-a6a0-5a43e365113d" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbface63-2046-4fe6-a170-9d4a913ea4db" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,923</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0f5d72c-e66b-4a67-bec0-6fb3cf0c37dc" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84c87568-bf3e-4bb2-851c-2ebfca8ec5d7" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,010</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cdb52b7-0708-4d6b-afe2-50539399133b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca849331-8409-43c8-9017-f7cb53cfc48c" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f16b7b-142f-4368-8720-e4800ca501f0" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">560</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:31.295%;box-sizing:content-box;"/>
        <td style="width:1.279%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.172%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.279%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.172%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.279%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.172%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.279%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.172%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.279%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.172%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.279%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.172%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 Months</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcd72ffb-d883-470e-8f14-e0f9e1d9e7fb" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,693</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f44bde-2416-4036-96b2-4cd8b6a10ebd" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db4c2be2-c721-405a-8876-58639379dbd8" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfefb7c9-cd9d-4ade-9ad2-5ada53d05c21" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b1aeef8-edce-413d-91bd-0c5f334b50a7" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,693</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f34537c0-0228-4b69-9efb-46070cfc7c03" contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0ac895a-3be9-4569-af22-02b67b8152b8" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,101</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af45f56d-d964-47a0-ba07-3bd80b082782" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8996358b-fd49-4004-b2d8-236703228589" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d590c0f-9551-4568-b10f-195644b884c0" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab0abfa9-43bd-4f02-9598-c26aca4598c3" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,101</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b448b848-6bd6-4822-acfc-21ba565746c0" contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9726097e-99b7-4b6a-a654-11071fd8a4ed" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,552</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2670f60c-1cbe-4fda-a810-1e0750a1760d" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">694</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_583d45fc-39ec-4e44-865f-577bac8c2746" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f634e3d4-cba7-4915-915c-351afd5dc71f" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6381b9c9-5f79-4bcd-8b2d-bb59812324a6" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,313</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a21142-1f5f-4ae5-bb29-26f27b2d6e41" contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a45524-b22d-4d79-93a4-09b0d23a04a2" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,844</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d11ca76-e556-4f7b-b1eb-e4e49e9d324f" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ccf6180-d2e6-49cb-a978-8a0997654076" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,484</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_714236f0-19c4-467e-b719-35834f6ba6ba" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f3714c4-2262-4fbb-b562-b8f25bf7025c" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,328</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b406dd7-0368-4bc4-80ee-ffc42a82847a" contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_476d9a55-4232-42bc-86bc-a36ef63e2a3c" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,190</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3999450-39d6-4119-9271-59cc737190a6" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d3a179e-7d39-4f7a-8d77-7d6db86b3572" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be52b51a-d04f-4004-ab5d-a15e73241476" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_338c0553-5c74-4d73-9816-f3ec9779b40e" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,435</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e195504-4c11-49bf-82ac-86ac5355bee1" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,011</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80845963-bf01-47e6-9a05-fb5fc988f158" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity information based on fair value of the available-for-sale securities is as follows as of December 31, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.58%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.74%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Within one year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After one year<br/>through five years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ffeee7d-f21b-4a17-acce-ae6be3aac6df" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b0f0b39-be94-4aea-b244-6b526269fc15" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd16c63-8036-46cb-bc34-40bb405b0992" contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_196800ff-6632-4ae3-8518-57625659ce64" contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77c76aef-0ddd-409c-9a2a-60c87c165e72" contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54f0a3d8-b295-46ee-84fa-3f24c1dd97db" contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,227</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_257477d6-11db-4458-a00c-7b8ed85d6426" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,295</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_252ea92a-9c2c-4764-86a6-9cc30717ef37" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,875</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d128d04b-ef9e-4621-a032-99f691eabd21" contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12caa9ee-afbd-4fe2-8b72-04439778ff60" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,865</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_244d02a1-36a9-4691-920e-0fb09e8aed56" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,065</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86ca1121-9158-43e4-9d5e-ffe3e858af9f" contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b05d3f9b-f7fe-4acb-90a2-b7621c952848" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384,029</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41945ea7-a76d-4529-bf3e-ca057c9e5589" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,940</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea2548cb-94c0-409f-8fef-cc1aeb973e05" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_fccdb240-df7b-471f-b578-136b01b9d4ad" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:CollaborationAndLicenseAgreementsTextblock" escape="true" continuedAt="F_fccdb240-df7b-471f-b578-136b01b9d4ad_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 5. COLLABORATION AND LICENSE AGREEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into collaborative arrangements for the research and development, and commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license and in-license compound to other parties. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost reimbursement arrangements and royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-Licensing Arrangements with Daiichi Sankyo Company Ltd. ("DS")</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments and royalty payments. All upfront and development milestones were expensed in research and development expense as incurred. We have reached </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e89ede9-1d0b-4eb6-8563-69f8930c95c6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:NumberOfMilestones"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestones in 2024, which require payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6cd8657-ebc4-4db9-88ad-ee32e3f4f1b2" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:MilestonesRequirePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to DS under the arrangement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Out-Licensing Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's revenue related to its out-licensing collaborative agreements consist of upfront license fees and research and development services revenue from its collaboration agreements with Innovent Biologics Co. Ltd. ("Innovent") and Nippon Kayaku Co., Ltd. ("NK") for </span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taletrectinib </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("AB-106").</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_fccdb240-df7b-471f-b578-136b01b9d4ad_1" continuedAt="F_fccdb240-df7b-471f-b578-136b01b9d4ad_2"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_1323a416-ab5e-4896-9d28-28856ed3eea3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total revenue recognized for the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.14%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.919999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ea14c46-4ca2-42e6-bf19-7746c61763a5" contextRef="C_59e21847-16f9-4084-92e3-35afa293d947" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,086</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d400767f-8f10-43ee-9ead-380756ffb10e" contextRef="C_573fc90e-3384-4e88-bebb-411d7823adc7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,787</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76c3c656-e3ce-4e21-91d8-0e0d971c289a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,873</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no revenue for 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with NewG Lab</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2020, AnHeart entered into an agreement with NewG Lab. under which they will grant a sub-licensable, royalty-bearing, exclusive right and license to NewG Lab to develop and commercialize AB-106 in Korea (the " NewG Lab Territory"), with NewG Lab responsible for funding ongoing clinical trials of AB-106, regulatory submissions after development and for commercialization upon regulatory approvals. They also granted NewG Lab the option to obtain the same aforementioned rights to AB-106 in Malaysia (the "NewG Lab Option").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During July 2024, the Company terminated the agreement with NewG Lab.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement with Innovent</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, AnHeart entered into an agreement with Innovent, granting Innovent a sub-licensable, royalty-bearing, exclusive right and license to commercialize AB-106 in the People's Republic of China and Taiwan (the "Innovent Territory"). AnHeart is responsible for funding ongoing clinical trials of AB-106, regulatory submissions after development with Innovent responsible for commercialization upon regulatory approvals. They also granted Innovent the option to obtain a license to commercialize AB-329 once they provide proof of concept behind the compound in a region in the Innovent Territory (the "Innovent Option"). Under the agreement, AnHeart received a non-refundable upfront cash payment, is owed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_548ca069-6fc5-4d0d-a532-bdeb166ca057" contextRef="C_24401d38-47d2-484c-ba0b-f6174eb508ff" name="nuvb:RepaymentsOfNonRefundableUpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for achievement of certain regulatory approval milestones,  and is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_738998c7-6044-4f25-9641-4ad57394bb10" contextRef="C_24401d38-47d2-484c-ba0b-f6174eb508ff" name="nuvb:ReceivedNonRefundableUpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of additional regulatory milestones, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22ee5020-6832-4975-8700-fcdc8f36d19d" contextRef="C_24401d38-47d2-484c-ba0b-f6174eb508ff" name="us-gaap:LongTermPurchaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of commercial milestones, and tiered percentage royalties ranging from mid-teen to low-twenties on annual net sales of taletrectinib in the Innovent Territory subject to certain adjustments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AnHeart determined that the license represents a single performance obligation. The research and development services represent a material promise and were determined to be a separate performance obligation at the outset of the agreement as the promise is distinct and has standalone value to Innovent. They concluded that, at the inception of the agreement, the Innovent Option did not constitute a material right as it does not represent a discount to the fair value of the exclusive license that Innovent would not have received without entering into the agreement and is therefore not considered a distinct performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfied the license performance obligation at a point in time when the license was delivered and the transfer of know-how completed. The portion of the transaction price allocated to the research and development services was deferred and is being recognized as research and development service revenue using an input method. Estimated costs to complete are reassessed on a periodic basis and any updates to the revenue earned are recognized on a prospective basis. The China NMPA approvals for first and second line indications of ROS1+ NSCLC represent achievement of two regulatory milestones. As such, the Company is owed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b09927ea-c4bb-462a-8c01-cf4724cc6303" contextRef="C_60d2085a-baaf-4b22-8edb-e7cc340aab3b" name="nuvb:OwedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments under the agreement, of which the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6058948f-9dbc-4e35-b9bf-8a851be54162" contextRef="C_63c9b400-5728-40d4-a6f1-9117ecc729d2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of license revenue at a point in time and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c55e7ce-7a9b-4a2b-bb9f-2998f5d2b184" contextRef="C_573fc90e-3384-4e88-bebb-411d7823adc7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the milestone payments is deferred and recognized as research and development service revenue using an input method. For the year ended December 31, 2024, the Company recognized license revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96b37548-fb34-4123-b606-5a3d1f9820bd" contextRef="C_a8df6974-75d8-4cdd-aa79-237e8cd65e90" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and research and development service revenue of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e549c770-7275-46f7-8b17-5a05d7e122dc" contextRef="C_60d2085a-baaf-4b22-8edb-e7cc340aab3b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million under the Innovent agreement.  As of December 31, 2024, the accounts receivable of Innovent was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b00bc862-d26a-4c09-b89f-aa9854532a10" contextRef="C_39922b23-3d3c-4025-8814-7b066e6e395d" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement with NK</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fccdb240-df7b-471f-b578-136b01b9d4ad_2"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, AnHeart entered into an agreement with NK, granting NK a sub-licensable, royalty-bearing, exclusive right and license to commercialize AB-106 in Japan (the "NK Territory"). AnHeart is responsible for funding ongoing clinical trials of AB-106 in the NK Territory, with NK responsible for funding regulatory submissions in the NK Territory. The Company also granted NK a sub-licensable, royalty-bearing, exclusive right and license to research, develop and commercialize any new indications of AB-106 in the NK Territory ("NK New Indication Right"). Under the agreement, AnHeart received a non-refundable upfront cash payment and is eligible to receive $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d838383-31c9-4a9f-9d97-45a75df0bbc1" contextRef="C_86eee26d-a7c8-4971-a02e-0c536e6bb91b" name="nuvb:ReceivedNonRefundableUpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of a regulatory milestone, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0c4660e-5e17-4212-83b0-2cc330d90ef7" contextRef="C_86eee26d-a7c8-4971-a02e-0c536e6bb91b" name="us-gaap:LongTermPurchaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of commercial milestones, and a lower-mid double digit percentage royalty on net sales of taletrectinib in the NK Territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AnHeart determined that the license represents a single performance obligation. The research and development services represent a material promise and were determined to be a separate performance obligation at the outset of the agreement as the promise is distinct and has standalone value to NK. They concluded that, at the inception of the agreement, the NK New Indication Right did not constitute a material right.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion of the transaction price allocated to the research and development services was deferred and is being recognized as research and development service revenue using an input method. Estimated costs to complete are reassessed on a periodic basis and any updates to the revenue earned are recognized on a prospective basis. The Company recognized research and development service revenue of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44ad2fe0-3d1f-40a6-bb1f-5b6cb0ded8e4" contextRef="C_123f4631-c9de-4408-9fbf-82e1d9db0a2e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2024. As of December 31, 2024, the accounts receivable of NK was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98b86e45-6314-4f38-80cf-58d51fadcfea" contextRef="C_b3414614-96e7-4ae2-b1f7-055df470e8ab" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract assets and contract liabilities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the Company satisfies its performance obligations by providing services to a customer before the customer pays consideration and before payment is due, the Company recognizes its rights to consideration as a contract asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1357fa5-fb88-41bf-80dd-004a53cb7bb5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:ContractWithCustomerAssets" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any contract assets as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When a customer pays consideration before the Company provide services, the Company records its obligation as a contract liability. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_108f9e9b-7eb8-44d7-a409-e4d2157b4d00" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to recognize all of this balance as revenue as research and development services are provided over the next 4 years.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_9d93533e-ee84-4ba6-a270-a9b619e865a8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract liabilities of the Company as of December 31, 2024 is listed in the table below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ce9360-5597-4f32-aa7b-50596e4c1f16" contextRef="C_101e91ce-9660-46bb-af18-7822809f659f" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,689</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_837f6d3e-27f1-43c5-9f65-08c500f5b92f" contextRef="C_0f03a15b-3abb-4776-a53a-0c003dafb17a" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue in 2024 that was included in the contract liability balance recorded upon the acquisition of AnHeart.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The balance of contract liabilities as of December 31, 2024 represents the transaction price allocated to the remaining performance obligations. The contract liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c56b5a-4abd-4c21-aeb8-e49a21b81cf6" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is expected to be recognized within one year and the rest in the following three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs incurred to fulfill customer contracts were capitalized and amortized to cost of revenue on a systematic basis that is consistent with the transfer of research and development services to the customer to which the asset relates. For the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd53e9c0-7d3f-42bf-9bd2-c6d26f6147b4" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion of costs incurred to fulfill customer contracts were capitalized and expensed in the same period. There were no balances related to the costs incurred to fulfill customer contracts as of December 31, 2024.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_d7955b66-5563-43af-b5eb-8a8764bffb31" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SubordinatedBorrowingsDisclosureTextBlock" escape="true" continuedAt="F_d7955b66-5563-43af-b5eb-8a8764bffb31_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 6. BORROWING</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2020, AnHeart entered into loan agreements with Bank of Hangzhou to obtain short-term borrowings to supplement its working capital. As of December 31, 2024, the outstanding balance net of repayments was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06951e2b-26a8-4448-82cf-eab524e67f1c" contextRef="C_c3e4516b-f8d6-469d-9172-f8b2294ea29b" name="us-gaap:ShorttermDebtAverageOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For the year ended December 31, 2024, the Company had drawn down $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8416d7d8-b68a-48fc-b63c-f2dc53707575" contextRef="C_d7bd32b5-b034-49be-9ebf-85bf65031ef7" name="nuvb:ShortTermBorrowingsDrawnDown" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and repaid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55f74d89-432d-4374-8ad4-25abfaffd6d4" contextRef="C_c3e4516b-f8d6-469d-9172-f8b2294ea29b" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fixed interest rate of these borrowings is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b37f2952-2147-420c-be1f-f2f96bcf6a46" contextRef="C_5915e704-6a60-4fe4-b048-5cb37f86d627" name="us-gaap:SubordinatedBorrowingInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb38f8cb-c42e-4929-9fb4-7b196a0f3142" contextRef="C_85891461-e727-4c8a-a45e-24ce144694c7" name="us-gaap:SubordinatedBorrowingInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d7955b66-5563-43af-b5eb-8a8764bffb31_1"><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, AnHeart entered into loan agreements with China Merchants Bank to obtain short-term borrowings to supplement its working capital. As of December 31, 2024, the outstanding balance was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51297f38-eaaf-4e0c-9504-ecaade25c6dc" contextRef="C_aca3d405-cc0e-4215-b0e3-ff17e649ad8a" name="us-gaap:ShorttermDebtAverageOutstandingAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company repaid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9a70f7a-9aee-4601-b017-536981f35586" contextRef="C_a9328880-f63c-496f-99d3-ea644af60276" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. The fixed interest rate of these borrowings was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07dd1a8c-8a59-42de-bf74-13ba509e6a57" contextRef="C_a9328880-f63c-496f-99d3-ea644af60276" name="us-gaap:SubordinatedBorrowingInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 4, 2023, AnHeart entered into a Loan and Security Agreement ("2023 SSVB Agreement") with Shanghai Pudong Development Bank in Silicon Valley for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8b8034f-87f0-44c5-b7c4-48aebe6556c1" contextRef="C_3b40daf5-2951-4982-9dc4-35739b254bf0" name="srt:BankLoans" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million RMB or equivalent in optional currency USD term loans ("SSVB Loan"). The SSVB Loan consists of a short-term working capital loan of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fefcf9fc-c8aa-427b-b3f8-dfea7bad7f91" contextRef="C_3b40daf5-2951-4982-9dc4-35739b254bf0" name="nuvb:ShortTermWorkingCapital" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million RMB and a long-term loan of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bfa9ef3-5426-4b69-91bd-877fdb78d150" contextRef="C_3b40daf5-2951-4982-9dc4-35739b254bf0" name="nuvb:LongTermBorroing" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million RMB, which matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49e5813b-7b75-4072-9959-169a595e2097" contextRef="C_f3542591-19a8-4b91-a21e-e2ed9f8b23a8" name="us-gaap:LongTermDebtMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 4, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbb1b9c7-c389-4e25-ac06-fea1a6a6cdb0" contextRef="C_3757f3f2-4eb9-4da5-87da-348aee145967" name="us-gaap:LongTermDebtMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 4, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, at which time all outstanding balances are due. Draws on the line of credit for the short-term loans are payable on the maturity date of the SSVB Loan. Draws on the line of credit for the long-term loans are payable in equal instalments monthly over the shorter of 24 months or from the date the draw took place till the SSVB loan matures. Outstanding balances will bear interest at a fixed rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30053e94-a407-42c4-b4e4-df69de226208" contextRef="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8" name="us-gaap:SubordinatedBorrowingInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. As of December 31, 2024, the outstanding line of credit balance net of repayments was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3adc2d16-c59e-45bf-bef2-5b66fa2973d9" contextRef="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. For the year ended December 31, 2024, the Company repaid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1562619a-909c-45bc-a9a3-58bc55e8062a" contextRef="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe3a13d6-62df-4ade-a073-d03ebba4199f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 7. PROPERTY AND EQUIPMENT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4778f30c-8c1c-4b2f-a70a-18c710135d9d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_269ba596-335e-401c-867e-0c0d2ab5b3b7" contextRef="C_abb8df07-b97c-4a48-aefb-b20f734b97a2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">629</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_056ac03b-3955-4618-919d-dd5292a61d64" contextRef="C_b84cd312-fd39-4b1d-8699-fda7c967c8b2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">488</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_375627d3-20b6-413c-84e5-1ede1def72a8" contextRef="C_8d9345df-39ad-447f-a1af-a822c985ade5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87499da2-dff0-41af-a5db-a743a9696f4c" contextRef="C_da7ecdf1-4156-4924-8c2b-91c1bbf48649" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">553</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0891070-97ca-47cd-8702-3aba16660907" contextRef="C_e48fcc9a-b0c1-44cf-86db-3afdf6eb9d8c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3cfd827-7094-4638-bbb3-fbcc4282dbf5" contextRef="C_9a955a31-b3a1-4541-96dc-cc575ee9a1d3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">342</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4e89764-84ce-441d-bd35-89bcd481c078" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,460</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e36fab1-d7e8-499d-8202-45beb615d177" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,383</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e007f596-eeff-4b10-b284-e8f896fe1fa4" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fe7649f-129a-40f6-85bb-158bb9746692" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a887ea05-63ae-4419-9c61-afc41f6819d5" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">586</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ca2c202-fb82-4800-986a-1424a33c5a4b" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense related to property and equipment was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56fdaa9c-d895-4a90-95a9-878ce8a8c2a3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c4642c0-1e83-4ce9-99b7-7b0bae3bcf82" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 20223, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_b5942fe6-192f-400a-9688-54f8922a04ac" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 8. ACCRUED EXPENSES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_9b749ede-8490-4217-9b3c-c332b7bfa596" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_9b749ede-8490-4217-9b3c-c332b7bfa596_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued consultant fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a8f7d09-2fa8-40bd-aabe-afb2ea53a550" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,243</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57106c20-7e84-4d9c-8659-380ae5464f9a" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,917</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3350539-6920-481e-a756-e55fb923edf5" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,818</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e2c4a04-2b84-491e-a9e0-e88cb7fa3d96" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_356fd3c1-4eea-45e0-a233-976ea63daed8" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">827</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b1d00d0-d5cb-4351-8add-d2d1771998ed" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deb0be03-47c6-4a03-91fe-77db85802cf0" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedIncomeTaxesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">679</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e50332f-ae07-4062-8928-a216ee2ac8bd" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedIncomeTaxesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d46aff4-e3d6-4518-b0c4-67159b94b001" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0406f9f7-b81f-49fc-8830-4b29426e1d05" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bca909a2-ea29-4b09-8fb6-17918be9baa9" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,833</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98ed353e-d45b-40a0-acc6-0f1f93405513" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_9b749ede-8490-4217-9b3c-c332b7bfa596_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_8fccbd99-b8a9-417c-8ad6-139a275641e7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_8fccbd99-b8a9-417c-8ad6-139a275641e7_1"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 9. LEASES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located in New York, New York, where we lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05a58829-29cd-480b-b4ec-6befb946c58f" contextRef="C_5634f3f1-5114-4a3c-9c5e-9f28b9b642a2" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">7,900</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space under a lease that terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7171dfb9-9edc-4cce-b19b-ede04e8b6ce6" contextRef="C_2fa726a6-4678-4715-b671-32d7fc4b3458" name="nuvb:LesseeOperatingLeaseExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an option for us to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25ab8ff5-f14d-4644-afe7-ac91d39b4329" contextRef="C_2fa726a6-4678-4715-b671-32d7fc4b3458" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41c5f5ee-f8ea-4ece-8861-602022d563a4" contextRef="C_2fa726a6-4678-4715-b671-32d7fc4b3458" name="nuvb:LeaseAdditionalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which is not reasonably assured of exercise, and in San Francisco, where we lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec8d301-ccec-4733-8170-98e274c1cfcd" contextRef="C_8b229bac-622e-41dd-87db-5a7e8d379dd4" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">19,418</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space that terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_436cf2d6-94b8-4f19-9ded-3f0dce5e9c83" contextRef="C_474282e8-2bd8-473d-b449-c1749a573ed7" name="nuvb:LesseeOperatingLeaseExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also occupy office space located in Burlington, Massachusetts, where we lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98e93af4-5ba9-49a9-a546-6daa8c671fe5" contextRef="C_d83e520c-196f-42be-bff1-f66d4956ab03" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">2,235</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space under a lease that terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efc8984d-511e-4460-b979-db7be1ab9f55" contextRef="C_2fcaddbe-59b4-4dd8-acff-d235bcf3608a" name="nuvb:LesseeOperatingLeaseExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as a total of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d64d3f7-271e-44a6-889b-256a586e630e" contextRef="C_694fe0ae-e3fc-4dfc-a41f-7d05ec59e408" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqm" decimals="0" format="ixt:num-dot-decimal">1,735</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square meters of office space in the People&#8217;s Republic of China, in the cities of Beijing, Guangzhou, Hangzhou and Shanghai, under leases that terminate in 2026 through 2027.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8fccbd99-b8a9-417c-8ad6-139a275641e7_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55d46922-f213-414a-ac4e-0d01078273af" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a750fe48-e4ed-463b-9d6e-f5fa7e8dbf0c" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. Expense related to variable leases was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1d98c94-a6c7-4a02-a4b2-6607663aa39c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2ef0236a-985a-4b16-b397-03fa826c874c" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t significant for the years ended December 31, 2024 and 2023.  Operating cash flows for the year ended December 31, 2024 and 2023 included</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cab8435-81fa-4998-a2c5-6dc024d6c644" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dd3138a-ef8b-4af6-88f4-0e4b513d9c57" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8db823f5-a28f-493b-8224-940ce73a7ed8" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the future minimum lease analysis of the Company's operating lease liabilities showing the aggregate lease payments as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.757%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1437834d-711b-4930-a6f7-1062021b1630" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,767</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d02b626-f96c-42c2-bbc3-3e10a03fbb63" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49d8e8eb-190d-45d1-b2fe-14df433da7f5" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f08386-b7c5-44bd-8ef0-b9278dff6788" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,775</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9aab4a4-e099-4bad-9e10-eceaa0966b14" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_777d4034-ef16-4f2a-829a-760933493b4b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,632</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average incremental borrowing rate used to determine the operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf370c14-0627-41f6-83eb-9f96f3265379" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The Company's weighted average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_807e3fda-896c-4da5-8e5a-d95b7004c24b" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.63</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> y</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ears as of December 31, 2024.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_772a0889-8ce7-42bf-8a0b-846c62c3703d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 10. STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Founder owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d88da15c-8238-4731-8274-a7296824630f" contextRef="C_30e55683-04d9-41a0-bd33-67d960b1716c" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding Class B common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Restriction Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Merger, the shares subject to the &#8220;Stock Restriction Agreement&#8221; between the Company and the Founder was adjusted based on the Exchange Ratio. The number of shares, as adjusted, subject to repurchase per the terms of the Stock Restriction Agreement is reduced each month by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edfca42f-0e9c-4485-9eb0-934f7cd7df68" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="nuvb:NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,101,240</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class A common shares and no common shares will be subject to repurchase by June 2022. As of December 31, 2024, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48317266-f652-4dc3-b2c0-f7fcd0437b12" contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock subject to the repurchase option.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dfdb655-45f9-473d-8584-4d509ad6920c" contextRef="C_4b9f43a9-9d6b-48e7-8cc3-ca1f86613de6" name="us-gaap:BusinessCombinationControlObtainedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Class A and Class B common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb1d0132-50f9-4bff-bdb3-fbcdfe2599c4" contextRef="C_4b9f43a9-9d6b-48e7-8cc3-ca1f86613de6" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one vote per share on all matters</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, except that the holders of Class A common stock do not participate in the election of the directors who are elected exclusively by the holders of Class B common stock. Holders of Class A and Class B common stock vote together as a single class on all matters, except that (i) the holders of Class B common stock have the right, voting as a separate class, to elect and remove without cause three directors plus at least 50% of any directors in excess of seven, and (ii) the approval of the holders of a majority of Class B common stock, voting as a separate class, is required for approval by the stockholders of any acquisition (whether by merger, sale of shares or sale of assets) or liquidation. There are no cumulative voting rights.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conversion</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of Class B common stock will automatically convert into one share of Class A common stock upon transfer to a non-authorized holder. In addition, the Class B common stock is subject to a &#8220;sunset&#8221; provision under which all outstanding shares of Class B common stock will automatically convert into an equal number of shares of Class A common stock if ownership of shares of Class A and Class B common stock held by our President and Chief executive Officer, David Hung, M.D., falls below an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19687831-739e-41c4-82c6-09d1bf2289d6" contextRef="C_d4d1928d-1758-446a-9b41-e8b4d12651af" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,188,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares or if Dr. Hung dies, becomes disabled or ceases to be our Chief Executive Officer, unless he is terminated from such position by us without cause.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_a7dd5898-d4c2-429c-b92b-6eeaeec29906" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_a7dd5898-d4c2-429c-b92b-6eeaeec29906_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 11. NET LOSS PER SHARE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic loss per share is computed by dividing net loss by the weighted-average number of shares of Class A and Class B common stock outstanding, but excluding shares of common stock subject to repurchase for the period. The number of common stock shares subject to repurchase was determined prospectively from the date of the Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a7dd5898-d4c2-429c-b92b-6eeaeec29906_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restriction Agreement described in Note 10. Diluted loss per share reflects the potential dilution that could occur if the stock options to issue common stock were exercised. The Company had a net loss in all periods presented thus the dilutive net loss per common share is the same as the basic net loss per common share as the effect of any options or conversions is anti-dilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The earnings per share amounts are the same for the different classes of common stock because the holders of each class are legally entitled to equal per share distributions whether through dividends or liquidation.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6461d9e5-dc10-41ad-921b-22dc33d53ad5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities outstanding at December 31, 2024 and 2023 have been excluded from the calculation of weighted average shares outstanding:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd5d184-87ca-43c5-bd69-ff82c049bace" contextRef="C_e555de18-2b2c-49fe-b7c4-7fc47b8d8119" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,681,182</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1555809d-fbc5-4b91-84db-5d2164ba7a9e" contextRef="C_a1fa561b-037b-48f9-b6e6-35db1b21440b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,787,462</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock options</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f318ce7-ac01-403f-bf29-0db40a8740a0" contextRef="C_612babb2-a261-40cd-b2ca-5ceb1ce31e71" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,729,709</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24c991c1-9150-43aa-acb8-a6d832c65c0c" contextRef="C_f4520a62-400d-4bbb-bc6f-dfcca29c01bc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,649,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25a0ac79-ccea-41a8-86bb-9f42f9960d83" contextRef="C_4681f739-9c28-49fc-bde8-0490bae0f771" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,420,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fb3591f-b543-465a-ab1a-4487bcf21c1a" contextRef="C_69989213-f1c9-4257-8e6c-cc9e8660ba6c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_7cb440da-7b7e-42ec-8202-331778e1a206" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 12. ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e81dfba-91b1-432a-95d0-a24d8283d9fb" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" escape="true" continuedAt="F_2e81dfba-91b1-432a-95d0-a24d8283d9fb_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a rollforward of the changes in accumulated other comprehensive (loss) income for the years ended December 31, 2024 and 2023, which is all attributable to unrealized gains (losses) on available-for-sale securities. All amounts are net of tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at beginning of period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1755576a-e16e-4794-a5ce-3ff4debde5a5" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854c2379-a06e-4d2f-b10a-89203619cf80" contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,526</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6adb066-5d14-4cb0-9a38-530d32f6319e" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377e9a07-f1cb-492d-95d9-7996c054ef66" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amount reclassified for realized loss on marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d39894b-b21f-44f7-94fa-f02e1f90c3fd" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:RealizedLossOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9687d5f-6572-4a90-ba7a-6bd8ed924d79" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:RealizedLossOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency translation adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93790d04-f7fe-4d93-b5d0-901bf5fcf2fa" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:CurrencyTranslationAdjustmentValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c894eb75-469e-45c1-a88e-77891c3b026c" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:CurrencyTranslationAdjustmentValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd23b51c-be68-4829-883a-cd2a95e84262" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_990def73-bd57-48f6-b10a-500b456dd846" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_2e81dfba-91b1-432a-95d0-a24d8283d9fb_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c882cfab-2dd4-4abd-b013-9f0be6605da3" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_c882cfab-2dd4-4abd-b013-9f0be6605da3_1"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 13. STOCK-BASED COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The 2021 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2019, the Company adopted the 2019 Equity Incentive Plan or (&#8220;2019 Plan&#8221;), which provided for the grant of options, stock appreciation rights, restricted stock, and other stock awards.  In January 2021, our board of directors adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan was approved by our stockholders in February 2021 and became effective immediately upon the Closing Date of the Merger.  Shares available for future issuance under the 2019 Plan were canceled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The 2021 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), within the meaning of Section 422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorized Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The maximum number of shares of Class A common stock that may be issued under the 2021 Plan was initially set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b80df18c-3546-4f5d-85aa-e672ec72a37f" contextRef="C_eb8419be-c990-483e-98aa-581ed2dfd11f" name="nuvb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,684,047</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1005448c-c3eb-46b3-90aa-11c97c120c9f" contextRef="C_efe682e8-6905-4a59-a9b1-a74dcdb4a136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f50d38e8-953f-46fc-a97d-92769453ad3f" contextRef="C_efe682e8-6905-4a59-a9b1-a74dcdb4a136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31 of the preceding year, or (2) a lesser number of shares of Class A common stock determined by our board of directors prior to the date of the increase</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares of Class A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c882cfab-2dd4-4abd-b013-9f0be6605da3_1" continuedAt="F_c882cfab-2dd4-4abd-b013-9f0be6605da3_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock that may be issued on the exercise of ISOs under the 2021 Plan is three times the number of shares available for issuance upon the 2021 Plan becoming effective or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e24e88-faa5-4f26-8202-724ed23c3712" contextRef="C_3cb6dc20-b571-4ae0-9e67-6ab4aff1d9d2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">152,052,141</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, our board of directors adopted the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by our stockholders in February 2021 and became effective immediately upon the Closing Date of the Merger.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Reserve.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The maximum number of shares of Class A common stock that may be issued under the 2021 ESPP was initially set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a96641f-d58b-4332-a3b2-8ae6cded627c" contextRef="C_b5db802e-98fe-4d8f-8ce3-efda58046123" name="nuvb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,750,354</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95125c33-4335-4426-94e2-5a8d8df9aa7a" contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Class A common stock reserved for issuance under the 2021 ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_465b4e0b-66b9-4be9-bf88-c50e58579f32" contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31st of the preceding calendar year or such lesser number of shares of Class A common stock as determined by our board of directors.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Shares subject to purchase rights granted under the 2021 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the 2021 ESPP.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f87be34f-dc75-4ee4-b6ea-bfa60f6afc05" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock-based compensation expense included in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0a9681f-8008-44f1-9f3f-8523285a60fa" contextRef="C_926d281c-c192-41fa-9469-55fc53c364ef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,450</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_636a040b-343a-4aef-9f70-48ef70c171fe" contextRef="C_80f9920f-001e-4ee0-bc41-726bea9c2be2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,797</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54556b59-ef12-4b86-80ba-bf2adf71a744" contextRef="C_b09ceff4-bb66-4ef2-9cdf-6517cbd7196b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,825</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a6b4016-63ef-4194-8952-e5b133e9aa81" contextRef="C_b1434390-9c27-4f94-8077-b738947d29fb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,716</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b006c31-2394-46e5-8dc2-29e6b6f453ff" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,275</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1e48a0f-bec9-4ca9-81ae-52a2058b5bcc" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,513</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Options with Service Conditions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted with only service conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bca5d2c4-d45e-4a24-9a00-462d8313ad6f" contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb4fd996-6cc9-4fbf-95b0-f93d08278f05" contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span><ix:nonNumeric id="F_e7e4547b-1599-4106-bb6a-1f1b0cf00489" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_e7e4547b-1599-4106-bb6a-1f1b0cf00489_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity with service condition only for employees and members of the Company&#8217;s Board of Directors for the year ended December 31, 2024 is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e7e4547b-1599-4106-bb6a-1f1b0cf00489_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Issuable<br/>Pursuant to<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic<br/>Value (in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a7c2b4d-001e-4668-a7e3-1acfe4391ca2" contextRef="C_0c652882-855e-465e-8c03-230c6f70279d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,834,045</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b5d2ed-922d-44d8-a6e9-3344fa47aa35" contextRef="C_0c652882-855e-465e-8c03-230c6f70279d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.51</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options assumed for acquisition of AnHeart</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cbda862-eb78-4123-8d96-9169b5924a29" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,742,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aef2d74-ae6b-4849-af5b-bad9309f85ef" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.90</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ff86f6-da0b-43f8-bb18-0e51ddbf1cf1" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,175,083</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_627f3119-2f12-40de-ae84-f75b27d9e9d5" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba580367-909d-47e1-a14e-ed718ca32202" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,750,547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4da625c-dbe1-439f-a1be-699a4ad999d2" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.12</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9672cfff-41a9-453a-b3a7-7e74ca054e02" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,192,263</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65d33d7-554f-43d8-9b1b-5231cf4350c2" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.86</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14a7cd52-fe6d-4b59-9475-51672b345d26" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,808,557</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_301d4311-774e-48fe-9816-e1a0cf2004c5" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a1cc583f-89dd-40a9-9322-025ddc444651" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.72</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_603732db-bf29-4ae6-bc4f-1e6b558a69ce" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,475</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09a79026-2c0f-41a3-a972-ebc90173a2a5" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,245,561</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8129f6f2-a52d-4d7d-8209-ea2e7d2b9345" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.90</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bf2939bb-102c-4710-9da4-bb985580dae5" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.43</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6deec8f-5696-4280-867e-5b11c004813b" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All unvested options as of December 31, 2024 are expected to vest.  The weighted average grant-date fair value of stock options outstanding on December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5174f55d-f7b9-458f-9005-af049ad43d50" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa86898d-862f-45a0-8275-c3541e869738" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share, respectively. Total</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c882cfab-2dd4-4abd-b013-9f0be6605da3_2" continuedAt="F_c882cfab-2dd4-4abd-b013-9f0be6605da3_3"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unrecognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensation costs related to non-vested stock options at December 31, 2024 was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cd967e1-ec09-42c7-931f-0f37d8087a0e" contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and is expected to be recognized within future operating results over a weighted-average period of</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f251158-1916-4c87-b11d-7da0a542c678" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ears.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9017c98f-2fbe-4b45-b9a3-56c0cd01414c" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock options granted with only service conditions during the years ended December 31, 2024 and 2023, the inputs in the Black-Scholes option-pricing model to determine the fair value is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.287%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:14.857%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:14.857%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_243379a1-4669-44ef-94f6-5af23a4dfcc0" contextRef="C_b7745198-d60e-4f1b-a9f3-33740d640e7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">0.08</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_157c33b5-5aac-4029-b577-a203610a37ff" contextRef="C_943111d4-1cca-4ec9-9b87-c18a3c9909ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">3.83</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_754966d2-3049-4fc6-a055-4fa679665c61" contextRef="C_fdd8837c-b00d-4e16-b06b-aaf29e21f38f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">1.61</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdde98c6-e686-4d43-8420-e445a5a6e30d" contextRef="C_6ed882e8-da6b-4efe-bc8b-354008a8cc06" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">1.94</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e84134a1-7b60-4056-8def-b5dc3d21ddf6" contextRef="C_12761058-5ed6-4b90-92ad-003f0933b78a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.63</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf6e61db-a15a-4645-b155-27a83e54cf27" contextRef="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccff0117-391c-483f-acaa-4a4f6fca5709" contextRef="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1853f3b5-599d-4097-ae7d-a94dcbe48ae0" contextRef="C_f73a9537-952a-476b-a1b9-94ceb77e4027" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e45033e5-57a3-40ea-8f77-3b6bb05254b6" contextRef="C_12761058-5ed6-4b90-92ad-003f0933b78a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c281080b-1ff5-44e2-b030-db65c899b96f" contextRef="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fe12a39-df1b-45fc-8bf8-f4f204054cb6" contextRef="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63d8dda0-2a7b-40b2-9146-dcadc3766fca" contextRef="C_f73a9537-952a-476b-a1b9-94ceb77e4027" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_752c72c4-cb1e-4841-9d05-1042e0fe16d0" contextRef="C_12761058-5ed6-4b90-92ad-003f0933b78a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_01252936-ea49-4675-8bf8-357fab4111c1" contextRef="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7ba1c22e-cb6d-4654-9333-ca8281fdf528" contextRef="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_41688a5b-0691-40d1-a35d-3bf95bc73c4c" contextRef="C_f73a9537-952a-476b-a1b9-94ceb77e4027" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d793e86-1bde-49e6-af16-0fa7abf71569" contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51251392-d8b3-4b2c-9828-266d890cf4ee" contextRef="C_abba69cb-6d7c-456b-a9e7-8c60b7df5832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company estimated its expected stock volatility based on the blended average of its historical volatility and of publicly traded set of peer companies.  The expected term of the Company&#8217;s options has been determined utilizing the &#8220;simplified&#8221; method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Dividend yield is based on the expectation that the Company will not pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Options with Service, Market, and Performance Conditions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted with combined service, market, and performance conditions will vest based on achievement of various service conditions and either a market-based or performance-based goals in three tranches with multiple categories such as the Company&#8217;s market capitalization, and clinical and regulatory milestones. The market-based and performance-based goals period ends in October 2030. The explicit service periods are </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_465fe6e3-ce6c-4cfe-a26b-22aebc0cb4b1" contextRef="C_0727c878-248f-4686-86bc-a4597d7f4e1c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for tranche 1, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d342385b-0641-4334-b538-bff79cd52848" contextRef="C_44d82460-2e05-4f7c-9c55-b545075fb034" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for tranche 2, and</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56d0c4f3-59aa-4920-9425-c965953ba8c7" contextRef="C_412486e3-9ba5-40f0-bf1b-da7b97f1b931" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for tranche 3. Upon the vesting requirement, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10609f40-13e2-4d93-84bc-d093fb7aa7f1" contextRef="C_0727c878-248f-4686-86bc-a4597d7f4e1c" name="nuvb:SharesBasedStockOptionGrantedVestingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2d3d2059-886c-4d6b-8753-6a5cf7d760d5" contextRef="C_ca424ba3-3e9c-4fc8-943e-50b54d3eb6a4" name="nuvb:SharesBasedStockOptionGrantedVestingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options will vest for each of tranche 1 and 2, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f07b4edf-c9c7-4f1b-a609-962dd0e84f8b" contextRef="C_412486e3-9ba5-40f0-bf1b-da7b97f1b931" name="nuvb:SharesBasedStockOptionGrantedVestingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted for tranche 3 will vest. The Company recognizes the fair value of the options within each tranche over the longer of their explicit service period or derived service period. The achievement of the performance condition was not deemed probable on the date of grant. As of December 31, 2024, the performance condition was not deemed probable.  The expense recognized is based on the fair value of the market condition for the years ended December 31, 2024 and 2023. </span><span><ix:nonNumeric id="F_4b3cf77f-316c-45ce-b157-6c7e4c1fdbb8" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_4b3cf77f-316c-45ce-b157-6c7e4c1fdbb8_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity with combined service, market, and performance conditions for employees for the year ended December 31, 2024 is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4b3cf77f-316c-45ce-b157-6c7e4c1fdbb8_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Issuable<br/>Pursuant to<br/>Stock Options</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic<br/>Value (in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf86e1e9-e218-4495-933d-3315c3f77ae0" contextRef="C_f9007fb3-c6d1-4f58-99a8-9b1c076139b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,815,194</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a371c157-e8e8-4be6-946d-9c253a223050" contextRef="C_f9007fb3-c6d1-4f58-99a8-9b1c076139b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.31</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e815a871-0e5c-4ed0-9d90-5afa77d34a53" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a1a4bf1-23f1-41f9-8dc8-08cedda8e417" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6658ff3-1b0c-4427-9b03-83b11d481bcf" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">144,042</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3831f96-12a0-4dd7-b368-c17e53a34137" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.60</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c522bb84-9cb4-4cd7-95a1-1a38216ef710" contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,921,152</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5c0237b-ec73-4da4-b89d-a7ae40b75f80" contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.18</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_67bed1ad-2b18-4dcb-9046-b0f313a34898" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.74</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2322fc2-bf1e-4a77-88a0-abb4ecc7923e" contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adc52435-4972-4a96-b449-10b9553a9948" contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">748,375</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eaa6aeb-6bf3-4d4b-8f0f-d40b4528f828" contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.87</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bc348039-9338-4a5f-974b-c4ef8da8d2c6" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.91</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b1c2726-2523-46c1-91c5-0fee88bb535f" contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value of stock options outstanding on December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa891fb-5a72-4738-804a-f20b0b0b9c3d" contextRef="C_e6904180-de0a-402e-a43d-2eb3649975e4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_987b6e25-09c0-4302-87ba-e655571fb986" contextRef="C_23995f85-8e92-4f98-835d-389f59c1c8ec" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. Total unrecognized compensation costs related to non-vested stock options at December 31, 2024 was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92962dac-15df-4ec5-b721-cd96c382b5ad" contextRef="C_f9dc1391-a88d-47a7-b7e3-f1a434ed0445" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion and is expected to be recognized within future operating results over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3af63da1-ed4f-423c-96dc-ad5f4c077be0" contextRef="C_e6904180-de0a-402e-a43d-2eb3649975e4" name="nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c882cfab-2dd4-4abd-b013-9f0be6605da3_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b17c851-4470-495c-b553-a7576fc67d19" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the stock options granted with combined service, market, and performance conditions was based on a Monte Carlo simulation with an embedded Black-Sholes pricing model. For the years ended December 31, 2024 and 2023, the fair value was computed using the following assumptions:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.3%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:14.86%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d448588c-d8bb-40c0-beb1-31461bc77e3d" contextRef="C_b647e270-1e2a-41ed-99c4-b1fdac51fdee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca098fb3-7a37-4128-a153-431a30af0727" contextRef="C_60d86b53-364b-4bb8-a244-c7731ef29c6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.61</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f4a84f-5539-4ed2-9027-fb9315fc4c5b" contextRef="C_62336d85-1efb-4a6d-a379-5fc3378a8347" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.94</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e17ca42-ea74-4a05-b611-44ebeed9ba67" contextRef="C_c671dc80-de5d-4aa6-a09f-d6f224165348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.27</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35fc21e4-4a6e-4452-8693-1c5c0ff182a3" contextRef="C_70f4ad29-01fb-4717-94fc-a3ad777c8950" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7959da51-2cac-456b-a9ff-0a79f1b4b39e" contextRef="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db993f3-9f5b-4535-bc42-78bc6b408b05" contextRef="C_c671dc80-de5d-4aa6-a09f-d6f224165348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee078d72-848c-4a72-ab67-cbd018ceea65" contextRef="C_70f4ad29-01fb-4717-94fc-a3ad777c8950" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_190942e0-156b-4f93-9f0f-bf84da1b15b7" contextRef="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_745608a1-199f-4f67-817f-75500fcb9dda" contextRef="C_c671dc80-de5d-4aa6-a09f-d6f224165348" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fb6e597f-2257-4890-a9e5-bcb6e9f1e514" contextRef="C_70f4ad29-01fb-4717-94fc-a3ad777c8950" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.17</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_e6b5f6ed-a1f6-48ef-ada8-1d7aa27c39c2" contextRef="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.30</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aab8c32-be86-4ec8-a45e-52432ca309d8" contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e63baebc-7358-445d-83c4-6a8c06df0a60" contextRef="C_b05136ff-fb6b-4102-a36c-cf37b5c03746" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The determination of expected volatility, risk- free rate, and dividend yield was the same approach as used for the above stock options granted with service only conditions. The expected term period represents the time used as an input in the embedded Black-Sholes pricing model which is based on the midpoint between the vest and expiration dates for each tranche.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_0db439e0-65c7-400f-a3d4-351bec5c6deb" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity for the restricted stock units assumed in the AnHeart acquisition for the year ended December 31, 2024.</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"/>
        <td style="width:9.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a616760-1425-4e5e-a1e1-a9372d03db44" contextRef="C_b98b6295-0101-48a0-af40-21586c6ade2e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs assumed for the acquisition of AnHeart</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c18f78d-7547-4656-b4ff-f5970974fa14" contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,201,694</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc72ec01-ee96-4265-8095-79beb671fcab" contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3a0bb76-32f6-44a6-98b4-97d02a710f12" contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">618,340</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or canceled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a13a0c2a-c8d5-4bc6-86a7-53222c4ce01a" contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">163,223</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9e5ec95-acb1-4ea3-bd4a-7875af493b63" contextRef="C_5ef65c87-2f51-4661-a7fb-5e58e7086ef2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,420,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value of stock options outstanding on December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ded0037b-805a-4ec9-b200-314ede144642" contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Total unrecognized compensation costs related to non-vested stock options at December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ecd6151-2456-44bb-80b8-f6569b37a522" contextRef="C_5ef65c87-2f51-4661-a7fb-5e58e7086ef2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and is expected to be recognized within future operating results over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cea5343a-2b85-4727-93ce-4dbe853cfb0e" contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c" name="nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54961673-9bb2-41f6-868a-59c57f406720" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DefinedContributionPlanTextBlock" escape="true" continuedAt="F_54961673-9bb2-41f6-868a-59c57f406720_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 14. 401(K) PLAN</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_54961673-9bb2-41f6-868a-59c57f406720_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sponsors a 401(k) plan (the &#8220;Plan&#8221;) covering substantially all employees of the Company. The Plan allows employees to contribute tax deferred salary deductions into the Plan under the provisions of Section 401(k) of the Internal Revenue Code. Matching contributions are made by the Company up to a maximum amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04df22f4-f018-40eb-bfe1-c63d80ec2d2d" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employee contributions, subject to certain limitations as defined in the Plan. The Company made matching contributions o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15dbea47-6a99-4c57-bf13-0f3214d6c65c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_614ab884-3f38-4765-beb0-b6efedf7cb5a" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <div><ix:nonNumeric id="F_21f543af-03c5-4f51-b2f6-cfbff3bac196" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:WarrantDisclosureTextBlock" escape="true" continuedAt="F_21f543af-03c5-4f51-b2f6-cfbff3bac196_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 15. WARRANTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efd636aa-2af1-4eef-837a-2ad237346c3b" contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,787,472</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase Common Stock outstanding, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e37e4c4a-2e25-4023-8401-91e850c9f40e" contextRef="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,791,639</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Public Warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ba0c26c-0381-4959-865c-2718c3e701d4" contextRef="C_38dfcba2-bd95-458c-a352-b4df776e9ce0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">162,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Private Placement Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38e67249-0ee1-49cb-b24c-c3dd54434c82" contextRef="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">833,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Forward Purchase Warrants. Each whole warrant entitles the registered holder to purchase one share of our Class A Common Stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_863bfc38-a3c9-40b6-bc79-cb0f767cdc5a" contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A Common Stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Acquisition, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60135ffe-f0d4-41d8-b6e9-c0dd3004a09b" contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,893,720</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consideration Warrants. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_21f543af-03c5-4f51-b2f6-cfbff3bac196_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, there were an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf2f0e2a-40ad-4ee6-aa7c-73ab91875820" contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,681,182</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the Consideration Warrants, Public Warrants, Private Warrants and Forward Purchase Warrants do not meet the conditions to be classified in equity.  The warrants were recorded at fair value with subsequent changes in fair value reflected in earnings (see Note 4). The change in fair value resulted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9672419-25e7-408e-9522-b8a5887e760c" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:MarketRiskBenefitChangeInFairValueGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million during the year ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of Consideration, Public and Forward Purchase Warrants is determined using the closing price of the warrants on the NYSE market and the related Warrant liability is included in Level 1 fair value measurements. The Company utilizes the Black-Scholes option pricing formula to determine the fair value of the Private Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liability for the Private Warrants is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The annualized volatility of the Warrant was based on a calibration to the publicly traded warrant price as of the valuation date. The risk-free interest rate was estimated using linear interpolation assuming a term consistent with the time until the warrants expire, and yield information was based on U.S. Treasury Constant Maturities.  The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned warrant liabilities are not subject to qualified hedge accounting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_873db7ab-a4e6-4c59-87d1-baa45d20f7b2" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Levels 1, 2 or 3 during the period ended December 31, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_454a31b9-07a6-45a4-a960-72e00d47f73f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides quantitative assumptions regarding Level 3 fair value measurements:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:62.04%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b5759d7-9557-498b-9aae-4ef1872468ea" contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de655fd-8428-45dc-b41d-8c2095ac3bf1" contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.51</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Strike price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82faf3cc-638d-4c62-8abb-5e386d07f66e" contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e73f7a7-b403-4aa7-84b8-5a834c48de1b" contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0fa1b84a-fceb-42a2-9043-68089583c3a8" contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_eb5c9530-2274-42af-b38f-227e9cab7d1a" contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6f277aa-b48c-4663-be4d-ad59a97ccc12" contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">137.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_863324b1-aa1a-4268-93d4-7d0f44aa8d53" contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">82.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c31e1a0-1a77-46ec-a025-78989e4dc548" contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11844513-6dd6-48d9-a163-470d5d7b47b2" contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9213ec0b-3d5d-42b2-80dc-86e7dfb64a10" contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54a225bd-5918-4735-9c7c-e020d404ba6f" contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7974b1f6-187d-4e2b-a591-697db5a6ad7b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined the following fair values for the outstanding Warrants (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.757%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Public Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a0c3e91-3117-4ddf-a74c-d025e040cdc3" contextRef="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,102</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a62c0f7f-7ef2-41ff-84be-1892812c5c59" contextRef="C_38dfcba2-bd95-458c-a352-b4df776e9ce0" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forward Purchase Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4abe300e-260c-4be0-97a2-adb770efd35f" contextRef="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f95e69e1-210c-4297-a4fa-b4121c4b4e00" contextRef="C_93ac93d0-60a9-4a06-90a6-fd3ede540eb6" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">665</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e90815c2-445c-4f1b-b33a-ef4a5ce0b2a2" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,053</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d88819ff-1327-4b2a-93e0-89a5bcb7614b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following presents changes in liabilities classified in Level 3 of the fair value hierarchy for the year ended December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79f6d160-8817-4a92-aa5c-a0aa3030e8bc" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Private Warrants liability recognized in earnings</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24f2e584-c8a5-43f6-ba85-3ae5e9bab38a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82b4ecde-47e8-41a9-aa87-9489a1c23eb2" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_6ee6846c-3268-40cc-8bed-530e3dfd4eae" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_6ee6846c-3268-40cc-8bed-530e3dfd4eae_1"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 16. INCOME TAXES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not record a provision or benefit for income taxes for the years ended December 31, 2024 and 2023. </span><span><ix:nonNumeric id="F_d4ea26c7-3ea4-418c-afc3-52566c89d6a1" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true" continuedAt="F_d4ea26c7-3ea4-418c-afc3-52566c89d6a1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the net deferred tax asset as of December 31, 2024 and 2023 are as follows:</span></ix:nonNumeric></span></p><div><ix:continuation id="F_d4ea26c7-3ea4-418c-afc3-52566c89d6a1_1" continuedAt="F_d4ea26c7-3ea4-418c-afc3-52566c89d6a1_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_6ee6846c-3268-40cc-8bed-530e3dfd4eae_1" continuedAt="F_6ee6846c-3268-40cc-8bed-530e3dfd4eae_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d4ea26c7-3ea4-418c-afc3-52566c89d6a1_2">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2431b45c-1631-408c-8aa0-a3f800a3294f" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,698</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20ca2ec7-0986-491e-9b5c-790346bda01d" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,290</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a874d8b1-e447-47a5-9a77-af710ddcf436" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,379</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_612f6787-d84d-4b27-b05a-9868cb40cab5" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,133</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs*</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd7a3ca-4745-4447-8ef4-f1bb5370e779" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,294</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd79f76-27a9-417e-b329-b47366d2c6dd" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c6fd469-9860-4291-9d26-b205a45fe78e" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,172</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde3b27c-fa5c-4628-ac1c-9848ed663b7a" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecc9c07f-a198-4bb0-a5b9-0b7a1a8117bc" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,116</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3cd4c63-ac8c-4d24-932f-fb716e2b4306" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,124</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f703a0a-a545-48e4-85fb-ff17b81b2a6f" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="nuvb:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">930</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d086f977-57dd-4785-a17b-ef0a38d4f133" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="nuvb:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b102d183-03ef-4b87-a43a-1c3ffe6d272e" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01ee3cf1-c756-4fdc-a3b8-8b22af7f9e25" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cb60681-5fdb-400d-8e33-38b51064ea46" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242,589</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b8cf332-9cc4-4577-a39e-527cf12da51d" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,412</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daf86816-2de9-4cd8-aa52-6a6052d51717" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">853</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ee07bd2-bc00-467f-b58c-87ee161900e9" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">931</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc25a3f1-9a49-489c-a49e-0977c07ca6ee" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,591</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f77a3e9f-f0bc-421d-982f-04d563c5e6a6" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_384007ce-354c-4784-9c91-0c4885bed19d" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,444</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67d79891-a677-4c60-bcf9-a3adc0c5cc08" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">931</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6220e282-c01c-4bd9-9fbc-4b5e65a9545e" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,145</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_824e6628-6d5e-4c59-bbba-1412171fab96" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,481</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dadbb427-a20d-4854-b585-1b53627242a7" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca5ea240-0aa3-472c-8945-b5d1fffca337" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><ix:footnote id="FNT_8344d213-e047-4112-8b2d-a4031ed59257" xml:lang="en-US"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aebcf3e-5c9c-444b-a55d-08e0a49d8fa8" contextRef="C_f4d88de7-a689-43dc-94ed-786f211f10b1" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 59(e) and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_714a7e53-6025-4659-b71f-04cd1fa84550" contextRef="C_acf04de5-17e7-45a9-89d8-b6eb52400fba" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 174.</span></p></ix:footnote></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf6c5c47-0ce4-4e43-b549-7b2fd6bce9c7" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate for the years ended December 31, 2024 and 2023 are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:14.883%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:14.883%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba5b32d5-3fb0-4f22-aebd-43814da4a0ab" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_529cc618-f939-4852-9018-26aa435ae365" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal tax benefit</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2233aa83-16cd-42af-bd37-233a382c0884" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce09176-84e9-479e-a025-5b3c18a0dacf" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff61bb04-c404-43f5-9fed-f6145d141bff" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">19.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_563b652b-1e43-4b5a-9bf3-7e9ddd164baf" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2c400d5-2260-4589-ad9e-b008f455af64" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10bed00b-d6be-4d77-a771-76733a876088" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb912349-60a7-4537-9fa0-a5800b7c481a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0d93997-7529-46a6-a939-b1a92808193e" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">True-up</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a077faf-21f9-4ad4-8454-797f79e3ffe6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:EffectiveIncomeTaxRateReconciliationTrueUp" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7f91287-38c0-4413-8910-a211a7215dbd" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:EffectiveIncomeTaxRateReconciliationTrueUp" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">3.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4354225-c2a4-4473-a298-16db52d5724a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf4b6ef8-5768-4db3-bf71-aa734033ed8d" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="nuvb:EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33ee00ee-9404-4d8f-a42c-23787b9d8b5f" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5046d76a-c7ef-4f14-b193-4178aa00223a" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">4.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83579698-458f-4184-b84c-8b2cac1a03b6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36c72841-ef1a-4e9f-a44c-6bae297158b6" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54c2a5e3-d154-43e3-8af2-a80889ab5eb6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">24.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ed6dfe1-7d20-4a10-b3d7-d76fe1f4025c" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">19.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa398ed8-bcb6-4b34-b55a-0f764fcfb88b" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd3b410-ea46-4825-b61e-b6b6ae21abe9" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal net operating loss carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe839b9-666b-4760-9e57-f6d0dbc3a361" contextRef="C_27aec131-424f-4703-abb2-81c1cfb32c8e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">194.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c814c435-a478-4857-97a7-12f602a691ef" contextRef="C_b4189f91-e001-4361-b114-dc6380eac776" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">270.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The federal net operating losses have an unlimited carryover period and state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4b1baa4-121f-4072-ba43-dae7f59599ab" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:OperatingLossCarryforwardsExpiration"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal research and development tax credit carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a90725ad-1b4f-4d70-aa4d-24314cad16ad" contextRef="C_27aec131-424f-4703-abb2-81c1cfb32c8e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and state research and development tax credit carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dc533f9-23f9-4cba-bfd7-483031c140fc" contextRef="C_b4189f91-e001-4361-b114-dc6380eac776" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The federal resea</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rch and development tax credits begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba6036fb-22c4-4daa-8adc-f4eb93273c61" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="nuvb:TaxCreditCarryforwardsExpiration"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and state research and development tax credits have an unlimited carryover period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal orphan drug tax credit carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2726d7d-767a-4a7b-9fc3-bfe85ec96f37" contextRef="C_3321395a-631d-476b-8f7d-c59b5665b1b3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The federal orphan drug tax credits begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59b1508c-9e09-4299-9563-72a419095cdc" contextRef="C_54d22bf6-7851-4a61-9f26-acc23b794faa" name="nuvb:TaxCreditCarryforwardsExpiration"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the federal and state net operating losses may be subject to change of ownership limitations provided by the Internal Revenue Code and similar state provisions. An annual loss limitation may result in the expiration or reduced utilization of the net operating losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage-point cumulative change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6ee6846c-3268-40cc-8bed-530e3dfd4eae_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of AnHeart Therapeutics, Inc.'s previous mergers with AnHeart Hangzhou in March 2019 and AnHeart Ltd (Cayman) in September 2021, we are subject to the Section 382 limitation. Our utilization of these pre-merger NOL and tax credit carryforwards is limited to the amount of income that the related entity contributes to our consolidated taxable income.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company maintained a full valuation allowance on its net deferred tax assets. The valuation allowance was determined in accordance with the provisions of ASC 740, Accounting for Income Taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. The Company&#8217;s history of cumulative losses, along with expected future U.S. losses required that a full valuation allowance be recorded against all net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.	</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company&#8217;s total amount of unrecognized tax benefits was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_952d1999-b369-4ae2-9140-cf810851ab5d" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llion, none of which would impact the Company&#8217;s effective tax rate, if recognized. The Company does not anticipate that the amount of unrecognized tax benefit will significantly increase within the next 12 months.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_af93af72-7ff3-423c-8cd1-851d0e9e1fea" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the activity related to the unrecognized tax benefits were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58cdc74b-9007-4976-830a-42a9f6e0ceb4" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e12062b-3fe8-4380-9123-a41ab9f3b1ab" contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,068</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross increases - current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7227e58-8d12-46a0-865f-08396855eca5" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c90d1c4-dd1d-467d-a0e9-a85d13e49508" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,019</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross decreases - prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5d670c-e9db-4ecd-9aa0-3c6cf699ed1a" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f64c9dee-e45e-4b52-a6c8-607cc764d81a" contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">458</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_093e69f3-247d-4ce4-b762-ead5f29ecf06" contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,391</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a04442c-37a7-48f3-aa68-cfd9f442d95a" contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to taxation in the United States and various state jurisdictions. All tax years remain subject to examination for U.S. federal and state purposes. All net operating losses generated to date are subject to adjustment for U.S. federal and state purposes. The Company is not currently under examination in federal or state jurisdictions.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6302108-d78b-4e1d-ba93-cb1cb1e3a3d6" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 17. COMMITMENTS AND CONTINGE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NCIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases its office space under non-cancellable operating lease agreements. The leases also require the Company to pay real estate taxes and other operational expenses associated with the leased location and is included in rent expense. The effect of graduating rents, net of the rent credits, is being amortized over the life of the lease so as to result in equal monthly rent expense over the lease term. Deferred rent liability reported in the accompanying consolidated balance sheets represents the cumulative excess of straight-line rental costs over the actual rental payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has standby letters of credit with banks in the aggregate amount of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87c46aa7-c9e3-4cd3-90fc-7b2ddc600f99" contextRef="C_39d9ef20-3367-48ef-9bd5-5cb516f43747" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million which serve as security for the New York and San Francisco spaces operating leases. The standby letters of credit automatically renew </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1e44252-3249-4656-a178-d8c5153cd2f0" contextRef="C_68c26585-4b66-4439-9588-4c1bd035ebe4" name="us-gaap:LineOfCreditFacilityFrequencyOfCommitmentFeePayment"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annually</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party, for which management believes the ultimate outcome would have a material adverse effect on the Company&#8217;s financial position.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_9c472d51-d825-46c6-8d7f-49bb7dd7c370" contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_9c472d51-d825-46c6-8d7f-49bb7dd7c370_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 18. SUBSEQUENT EVENT</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, the Company announced the closing of a non-dilutive financing of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03267d08-05ba-42eb-b89d-b34eb8f63a85" contextRef="C_f196edb9-bd73-43fb-8ae1-2133c0857f5e" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Sagard. The financing is comprised of a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53f6a62a-7786-4bfd-9ffc-0b1039e5c5f5" contextRef="C_0b0d4681-373d-40ee-a05b-cf4167b76104" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million synthetic royalty and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e69809e5-573a-4940-928f-06137cdb996e" contextRef="C_5ed535ca-023f-4c23-9afe-8ae365dc24de" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of senior secured debt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9c472d51-d825-46c6-8d7f-49bb7dd7c370_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">synthetic royalty and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_475f6cd0-a98d-407f-a063-c76130da88ff" contextRef="C_9748bbba-55ba-4df0-8e3a-bd402ef3408d" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of debt will be funded conditioned upon FDA&#8217;s approval of taletrectinib on or prior to September 30, 2025. The transaction will support the U.S. launch of taletrectinib,  and general corporate purposes.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>nuvb-ex10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html>
 <head>
  <title>EX-10.23</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x1f;CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#x201c;[***]&#x201d;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.23</font></p>
  <p style="border-top:0.5pt solid;padding-top:1pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CREDIT AGREEMENT AND GUARANTY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dated as of March 3, 2025<br>by and among</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.,<br>as the Borrower,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO,<br>as the Subsidiary Guarantors,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE LENDERS FROM TIME TO TIME PARTY HERETO<br>as the Lenders,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAGARD HOLDINGS MANAGER LP,<br>as the Administrative Agent</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. $100,000,000</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:95.52%;box-sizing:content-box;"></td>
    <td style="width:4.48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.	Definitions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.01.	Certain Defined Terms</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.02.	Accounting Terms and Principles</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.03.	Interpretation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.04.	Division</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.05.	Currency Generally</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.06.	Rates</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.	The Commitment and The Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01.	Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.02.	Borrowing Procedures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.03.	Funding of Borrowings</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.04.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.05.	Notes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.06.	Use of Proceeds</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.07.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.08.	Defaulting Lenders</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.09.	Benchmark Replacement Setting</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.10.	Inability to Determine Rates</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.11.	Illegality</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.	Payments of Principal and Interest, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.01.	Scheduled Repayments and Prepayments Generally; Application</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.02.	Interest</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.03.	Prepayments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04.	Commitment Termination</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.05.	Exit Fee</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.06.	Original Issue Discount</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.	Payments, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.01.	Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02.	Computations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03.	Set-Off</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.	Yield Protection, Taxes, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.01.	Additional Costs</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.02.	Compensation for Losses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.03.	Taxes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.04.	Mitigation Obligations; Replacement of Lenders</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:95.52%;box-sizing:content-box;"></td>
    <td style="width:4.48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.05.	Survival</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.	Conditions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.01.	Conditions to the Closing Date</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.02.	Conditions to the Borrowing of Tranche A-1 Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03.	Conditions to the Borrowing of Tranche A-2 Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.	Representations and Warranties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.01.	Power and Authority</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.02.	Authorization; Enforceability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.03.	Governmental and Other Approvals; No Conflicts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.04.	Financial Statements; Material Adverse Change</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.05.	Properties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.06.	No Actions or Proceedings</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.07.	Compliance with Laws and Agreements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.08.	Taxes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.09.	Full Disclosure</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.10.	Investment Company Act and Margin Stock Regulation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.11.	Solvency</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.12.	Subsidiaries</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.13.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.14.	Material Agreements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.15.	Restrictive Agreements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.16.	Real Property</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.17.	Pension Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.18.	Regulatory Approvals</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.19.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.20.	OFAC; Anti-Terrorism Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.21.	Anti-Corruption</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.22.	Priority of Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.23.	Royalty and Other Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.24.	Non-Competes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.25.	Reimbursement from Medical Reimbursement Programs</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.	Affirmative Covenants</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.01.	Financial Statements and Other Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.02.	Notices of Material Events</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.03.	Existence</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.04.	Payment of Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.05.	Insurance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:95.52%;box-sizing:content-box;"></td>
    <td style="width:4.48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.06.	Books and Records; Inspection Rights; Lender Calls</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.07.	Compliance with Laws and Other Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.08.	Maintenance of Properties, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.09.	Licenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.10.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.11.	Use of Proceeds</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.12.	Certain Obligations Respecting Subsidiaries; Further Assurances</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.13.	Termination of Non-Permitted Liens</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.14.	Board Materials</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.15.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.16.	Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.17.	ERISA Compliance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.18.	Cash Management</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.19.	Post-Closing Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.	Negative Covenants</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.01.	Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.02.	Liens</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.03.	Fundamental Changes and Acquisitions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.04.	Lines of Business</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05.	Investments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.06.	Restricted Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.07.	Payments of Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.08.	Change in Fiscal Year</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.09.	Sales of Assets, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.10.	Transactions with Affiliates</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.11.	Restrictive Agreements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.12.	Modifications and Terminations of Material Agreements and Organic Documents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.13.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.14.	Sales and Leasebacks</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.15.	Hazardous Material</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.16.	Accounting Changes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.17.	Compliance with ERISA</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.18.	Sanctions; Anti-Corruption Use of Proceeds</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.	Financial Covenant</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.01.	Minimum Liquidity</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:95.52%;box-sizing:content-box;"></td>
    <td style="width:4.48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.	Events of Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.01.	Events of Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.02.	Remedies</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.03.	Additional Remedies</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.04.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.05.	[Reserved]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.06.	Payment of Yield Protection Premium and Exit Fee</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 12.	The Administrative Agent</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.01.	Appointment and Duties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.02.	Binding Effect</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.03.	Use of Discretion</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.04.	Delegation of Rights and Duties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.05.	Reliance and Liability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.06.	Administrative Agent Individually</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.07.	Lender Credit Decision</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.08.	Expenses; Indemnities</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.09.	Resignation of the Administrative Agent</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.10.	Release of Collateral or Subsidiary Guarantors</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.11.	Additional Secured Parties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.12.	Agent May File Proofs of Claim</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.13.	Acknowledgements of Lenders</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.	Guaranty</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.01.	The Guaranty</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.02.	Obligations Unconditional</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.03.	Discharge Only Upon Payment in Full</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.04.	Additional Waivers; General Waivers</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.05.	Reinstatement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.06.	Subrogation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.07.	Remedies</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.08.	Instrument for the Payment of Money</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.09.	Continuing Guarantee</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.10.	Contribution with Respect to Guaranteed Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.11.	General Limitation on Guarantee Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 14.	Miscellaneous</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.01.	No Waiver</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.02.	Notices</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:95.52%;box-sizing:content-box;"></td>
    <td style="width:4.48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.03.	Expenses, Indemnification, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.04.	Amendments, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.05.	Successors and Assigns</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.06.	Survival</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.07.	Captions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.08.	Counterparts, Effectiveness, Electronic Execution</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.09.	Governing Law</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.10.	Jurisdiction, Service of Process and Venue</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.11.	Waiver of Jury Trial</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.12.	Waiver of Immunity</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.13.	Entire Agreement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.14.	Severability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.15.	No Fiduciary Relationship</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.16.	Confidentiality</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.17.	Interest Rate Limitation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.18.	Judgment Currency</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.19.	USA PATRIOT Act</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.20.	Acknowledgement and Consent to Bail-In of Affected Financial Institutions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.21.	Certain ERISA Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">v</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULES AND EXHIBITS</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1	-	Loans Schedule</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2	-	Products</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 3	-	Permitted Licenses</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4	-	Taletrectinib</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.05(b)	-	Certain Intellectual Property</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.06(c)	-	Collective Bargaining Agreements</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.08	-	Taxes</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.12	-	Information Regarding Subsidiaries</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.14	-	Material Agreements</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.15	-	Restrictive Agreements</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.16	-	Real Property Owned or Leased by Obligors</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.17	-	Pension Matters</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.18(c)	-	Adverse Findings</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.23	-	Royalties and Other Payments</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.26	-	Excluded Subsidiary Assets</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.01(b)	-	Existing Indebtedness</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.02(b)	-	Existing Liens</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.05(a)	-	Existing Investments</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.05(s)	-	Potential Investments</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.09(j)	-	Sale of Assets</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.10	-	Transactions with Affiliates</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.14	-	Existing Sales and Leasebacks</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A	-	Form of Note</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B	-	Form of Borrowing Notice</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C	-	Form of Guarantee Assumption Agreement</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-1	-	Form of U.S. Tax Compliance Certificate (For Foreign Lenders 	That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-2	-	Form of U.S. Tax Compliance Certificate (For Foreign Participants 	That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-3	-	Form of U.S. Tax Compliance Certificate (For Foreign Participants 	That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-4	-	Form of U.S. Tax Compliance Certificate (For Foreign Lenders 	That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit E	-	Form of Compliance Certificate</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit F	-	Form of Assignment and Assumption</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit G	-	Form of Landlord Consent</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vi</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit H	-	Form of Intercompany Subordination Agreement</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit I	-	Form of Solvency Certificate</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit J	-	Form of Funding Date Certificate</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CREDIT AGREEMENT AND GUARANTY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CREDIT AGREEMENT AND GUARANTY, dated as of March 3, 2025 (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), among </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), certain Subsidiaries of the Borrower that may be required to provide a Guaranty from time to time hereunder (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the lenders from time to time party hereto (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAGARD HOLDINGS MANAGER LP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as administrative agent for the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WITNESSETH:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Borrower has requested that the Lenders provide a senior secured term loan facility to the Borrower in an aggregate principal amount of $100,000,000, consisting of (a) a $50,000,000 Tranche A-1 Term Loan to be extended on the Tranche A-1 Funding Date and (b) a $50,000,000 Tranche A-2 Term Loan to be extended, at the Borrower&#x2019;s option, on the Tranche A-2 Funding Date; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Lenders are willing, on the terms and subject to the conditions set forth herein, to provide such senior secured term loan facility.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, the parties hereto agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As used herein, the following terms have the following respective meanings:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ABR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any day, a rate per annum equal to the highest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 0.50%, (c) Term SOFR for a one-month tenor in effect on such day plus 1.00% and (d) 5.00%. Any change in the ABR due to a change in the Prime Rate, the Federal Funds Effective Rate or Term SOFR shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Effective Rate or Term SOFR, respectively.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ABR Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Loan that bears interest based on the ABR.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ABR Term SOFR Determination Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning specified in the definition of &#x201c;Term SOFR&#x201d;.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Account Control Agreement Completion Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of amalgamation, consolidation, merger, purchase of assets, purchase of Equity Interests, or exclusive licensing or in-licensing of Intellectual Property or otherwise: (i) acquires all or substantially all of the assets of any other Person, (ii) acquires an entire business line, product, product line, unit or division of any other Person, (iii) with respect to any other Person that is managed or governed by a Board, acquires control of Equity Interests of such other Person representing more than fifty percent (50%) of the ordinary voting power (determined on a fully-diluted basis) for the election of directors of such Person&#x2019;s Board, or (iv) acquires control of more than fifty percent (50%) of the Equity Interests in any other Person (determined on a fully-diluted basis) that is not managed by a Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affected Financial Institution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any EEA Financial Institution or (b) any UK Financial Institution.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i)(x) an abbreviated new drug application (as defined in the FD&amp;C Act at 21 U.S.C. &#167; 355(j) and its implementing regulations) or any successor application or procedure and (y) any similar application or functional equivalent applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-Terrorism Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any laws relating to terrorism or money laundering, including, without limitation, (i) the Money Laundering Control Act of 1986 (e.g., 18 U.S.C. &#167;&#167; 1956 and 1957), (ii) the Bank Secrecy Act of 1970 (e.g., 31 U.S.C. &#167;&#167; 5311 &#x2013; 5330), as amended by the Patriot Act, (iii) the laws, regulations and Executive Orders administered by the United States Department of the Treasury&#x2019;s Office of Foreign Assets Control (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (iv) the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010 and implementing regulations by the United States Department of the Treasury, (v) any law prohibiting or directed against terrorist activities or the financing of terrorist activities (e.g., 18 U.S.C. &#167;&#167; 2339A and 2339B), or (vi) any similar laws enacted in the United States, United Kingdom, European Union</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any other jurisdictions in which the parties to this agreement operate, and all other present and future legal requirements of any Governmental Authority governing, addressing, relating to, or attempting to eliminate, terrorist acts and acts of war.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Availability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A-1 Availability Period or the Tranche A-2 Availability Period, as the context may require.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A-1 Commitment or the Tranche A-2 Commitment, as the context may require.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Commitment Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) with respect to the Tranche A-1 Commitment, the earlier to occur of (x) a CRL Event and receipt by Borrower of a notice of termination of the Commitments, which may be delivered by the Administrative Agent in its sole and absolute discretion, and (y) September 30, 2025 (as such date may be extended by the mutual agreement of the Administrative Agent and the Borrower, each in its sole and absolute discretion) and (ii) with respect to the Tranche A-2 Commitment, the earliest to occur of (x) any termination of the Tranche A-1 Commitment pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> immediately above, (y) the prepayment in full of the Tranche A-1 Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.03(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prior to the Tranche A-2 Funding Date and (z) June 30, 2026.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Funding Condition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A-1 Funding Condition and the Tranche A-2 Funding Condition, as the context may require.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Funding Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A-1 Funding Date and the Tranche A-2 Funding Date, as the context may require.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, all Laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Margin</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a rate of interest equal to 6.00% per annum.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Arm&#x2019;s Length Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any transaction, the terms of such transaction, taken as a whole, shall not be less favorable to the Borrower or any of its Subsidiaries than commercially reasonable terms that would be obtained in a transaction with a Person that is an unrelated third party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assignment and Assumption</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an assignment and assumption entered into by a Lender and an assignee of such Lender substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit F</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or such other form as agreed by the Administrative Agent.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Available Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date of determination, an amount equal to the sum of (i) the aggregate amount of net cash proceeds received by the Borrower in the immediately preceding 6-month period from any sale, after the Closing Date, of Equity Interests (other than Disqualified Equity Interests) of the Borrower, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">minus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ii) the aggregate amount of Investments, Restricted Payments and prepayments of Indebtedness previously made using the Available Amount.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Available Tenor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date of determination and with respect to the then-current Benchmark, as applicable, if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of &#x201c;Interest Period&#x201d; pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bail-In Action</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bail-In Legislation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time that is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bailee Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a bailee letter substantially in the form of Exhibit F to the Security Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bankruptcy Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Title 11 of the United States Code entitled &#x201c;Bankruptcy.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, initially, the Term SOFR Reference Rate; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then &#x201c;Benchmark&#x201d; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark Replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Benchmark Transition Event, the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower giving due consideration to (i) any selection or recommendation of a replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities at such time and (b) the related Benchmark Replacement Adjustment; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, if such Benchmark Replacement as so determined would be less than the Floor, such Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark Replacement Adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark Replacement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the earliest to occur of the following events with respect to the then-current Benchmark:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	in the case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Benchmark Transition Event,&#x201d; the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof); or</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	in the case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Benchmark Transition Event,&#x201d; the first date on which such Benchmark (or the published component used in the calculation thereof) has been or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) have been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and even if such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, if such Benchmark is a term rate, the &#x201c;Benchmark Replacement Date&#x201d; will be deemed to have occurred in the case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark Transition Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events with respect to the then-current Benchmark:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof);</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof); or</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, if such Benchmark is a term rate, a &#x201c;Benchmark Transition Event&#x201d; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark Transition Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in the case of a Benchmark Transition Event, the earlier of (a) the applicable Benchmark Replacement Date and (b) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benchmark Unavailability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Beneficial Ownership Certification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Beneficial Ownership Regulation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means 31 C.F.R. &#167; 1010.230.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benefit Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;employee benefit plan&#x201d; as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) which is (currently or hereafter), or within the prior six (6) years was, maintained or contributed to by any Obligor or Subsidiary thereof or to which any Obligor or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilar Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a biosimilar or interchangeable biosimilar application (as set forth in the Public Health Service Act at 42 U.S.C. &#167;262(k) and its implementing regulations), for a biologic product that is biosimilar to a reference product, or any successor application or procedure and any similar application, and all supplements and amendments that may be filed with respect to the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i)(x) a biologics license application (as set forth in the Public Health Service Act at 42 U.S.C. &#167; 262 and its implementing regulations) to introduce, or deliver for introduction, a biologic product, including vaccines into commerce in the U.S., or any successor application or procedure and (y) any similar application or functional equivalent relating to biologics licensing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, the board of directors or equivalent management or oversight body of such Person or any committee thereof authorized to act on behalf of such board (or equivalent body).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrower Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrowing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the borrowing of the Loans on each Applicable Funding Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrowing Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written notice substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bringdown Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each date on which a Loan is advanced pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any other date the representations and warranties under the Loan Documents are required to be made (other than the Closing Date).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.04.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a day (other than a Saturday or Sunday) on which commercial banks are not authorized or required to close in New York City or Toronto, Canada.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capital Lease Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal property, which obligations are required to be classified and accounted for as a finance lease on a balance sheet of such Person under GAAP, and for the purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Casualty Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the damage, destruction or condemnation, as the case may be, of property of the Borrower or any of its Subsidiaries in excess of [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cayman Guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Artemis Merger Sub II, Ltd., an exempted company incorporated with limited liability under the laws of the Cayman Islands.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cayman Security Document</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the equitable share mortgage among the Borrower and the Administrative Agent, granting a security interest in the Cayman Guarantor in favor of the Administrative Agent, for the benefit of the Secured Parties.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CFC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Subsidiary that is a &#x201c;controlled foreign corporation&#x201d; within the meaning of Section 957 of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CFC Holding Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Domestic Subsidiary that owns no material assets (directly or indirectly) other than Equity Interests and debt of one or more CFCs or Domestic Subsidiaries that are themselves CFC Holding Companies.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (and includes) any claim, demand, complaint, grievance, action, application, suit, cause of action, order, charge, indictment, prosecution, judgement or other similar process, whether in respect of assessments or reassessments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel, and all costs incurred in investigating or pursuing any of the foregoing or any proceeding relating to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Class A Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Borrower&#x2019;s Amended and Restated Certificate of Incorporation, dated as of February 10, 2021.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Class B Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Borrower&#x2019;s Amended and Restated Certificate of Incorporation, dated as of February 10, 2021.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the date on which the conditions precedent specified in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are satisfied (or waived in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986 and the rules and regulations promulgated thereunder from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any real, personal and mixed property (including Equity Interests), whether tangible or intangible, in which Liens are granted or purported to be granted to the Administrative Agent as security for the Obligations under any Loan Document on or after the Closing Date, including future acquired or created assets or property (or collectively, all such real, personal and mixed property, as the context may require); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for the avoidance of doubt, &#x201c;Collateral&#x201d; shall not include any Excluded Assets.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to each Lender, the obligation of such Lender to make Loans to the Borrower on each Applicable Funding Date in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the caption &#x201c;Applicable Commitment&#x201d;, as such Schedule may be</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Commitments on the date of this Agreement equals $100,000,000.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Competitor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) any competitor of the Borrower or any of its Subsidiaries primarily operating in the same line of business as the Borrower or any of its Subsidiaries and (ii) any of such competitor&#x2019;s Affiliates (other than any Person that is a bona fide debt fund primarily engaged in the making, purchasing, holding or other investing in commercial loans, notes, bonds or similar extensions of credit or securities in the Ordinary Course) that are either clearly identifiable as an Affiliate of any such competitor on the basis of such Person&#x2019;s name or identified by name in writing by the Borrower to the Administrative Agent from time to time. Notwithstanding anything to the contrary contained in this Agreement, (a) the Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor or enforce, compliance with the provisions hereof relating to Company Competitor and (b) the Borrower, the Subsidiary Guarantors and the Lenders acknowledge and agree that the Administrative Agent shall have no responsibility or obligation to determine whether any Lender or potential Lender is a Company Competitor and that the Administrative Agent shall have no liability with respect to any assignment or participation made to a Company Competitor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#x201c;ABR,&#x201d; the definition of &#x201c;Business Day,&#x201d; the definition of &#x201c;U.S. Government Securities Business Day,&#x201d; the definition of &#x201c;Interest Period&#x201d; or any similar or analogous definition (or the addition of a concept of &#x201c;interest period&#x201d;), timing and frequency of determining rates and making payments of interest, timing of Borrowing Notices or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and other technical, administrative or operational matters) that the Administrative Agent decides may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Connection Income Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contracts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any contract, license, lease, agreement, obligation, promise, undertaking, understanding, arrangement, document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case, whether written or oral, express or implied, and whether in respect of monetary or payment obligations, performance obligations or otherwise).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in respect of a particular Person, the possession by one or more other Persons, directly or indirectly, of the power to direct or cause the direction of the management or policies of such particular Person, whether through the ability to exercise voting power, by contract or otherwise. &#x201c;Controlling&#x201d; and &#x201c;Controlled&#x201d; have meanings correlative thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled Account</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.18(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Copyright</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all copyrights (including with respect to published and unpublished works of authorship, software, website and mobile content, data, databases and other compilations of information), copyright registrations and applications for copyright registrations, including all renewals, restorations, reversions and extensions thereof and all other rights whatsoever accruing thereunder or pertaining thereto throughout the world.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CRL Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Borrower has received from the FDA a complete response letter (as defined in 21 CFR 314.3) with respect to NDA 219713.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DEA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Drug Enforcement Administration.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Event of Default and any event that, upon the giving of notice, the lapse of time or both, would constitute an Event of Default.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Default Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.02(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Defaulting Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.08(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any Lender, as determined by the Administrative Agent, that (a) has failed to perform any of its funding obligations hereunder, including with respect to any Tranche A-1 Commitments or any Tranche A-2 Commitments, within two (2) Business Days of the date required to be funded by it hereunder, (b) has notified the Borrower or the Administrative Agent that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect, (c) has failed, within two (2) Business Days after written request by the Administrative Agent or the Borrower, to confirm in writing to the Administrative Agent or the Borrower that it will comply with its prospective funding obligations hereunder (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such Lender shall cease to be a Defaulting Lender pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon receipt of such written confirmation by the Administrative Agent or the Borrower), (d) has, or has a direct or indirect parent company that has, (i) become the subject of an Insolvency Proceeding, (ii) had a receiver, conservator, trustee, administrator, assignee for</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity, (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment or (iv) become the subject of a Bail-In Action; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any Equity Interests in that Lender or any direct or indirect parent company thereof by a Governmental Authority. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, and of the effective date of such status, shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.08(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) as of the date established therefor by the Administrative Agent in a written notice of such determination, which shall be delivered by the Administrative Agent to the Borrower and each Lender promptly following such determination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Acquisition Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any purchase price adjustments, royalty, earn-out, milestone payments, contingent or other deferred payment or payments of a similar nature (including any non-compete payments, consulting payments and any royalties payable and milestones based on sales) made in connection with any Permitted Acquisition or other acquisition or investment permitted under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Designated Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any country or territory to the extent that such country or territory is the subject of country- or territory-wide Sanctions.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disqualified Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any Equity Interest of such Person that, by its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (i) matures (excluding any maturity as the result of an optional redemption by the issuer thereof) or is mandatorily redeemable (other than solely for (x) Qualified Equity Interests and (y) cash in lieu of fractional shares), including pursuant to a sinking fund obligation or otherwise, (ii) is redeemable at the option of the holder thereof (other than solely for (x) Qualified Equity Interests and (y) cash in lieu of fractional shares), in whole or in part, (iii) requires scheduled payments of dividends or other distributions in cash (other than the payment of cash in lieu of redemption of fractional shares) or other securities that would constitute Disqualified Equity Interests, or (iv) is or becomes convertible into or exchangeable for (unless at the sole option of the issuer thereof) Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is [***] after the Maturity Date; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, any Equity Interests that would not constitute Disqualified Equity Interests but for provisions thereof giving holders thereof (or the holders of any security into or for which such Equity Interests are convertible, exchangeable or exercisable) the right to require the issuer thereof to redeem or repurchase such Equity Interests upon the occurrence of a change in control or fundamental change occurring prior</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the [***] after the Maturity Date shall not constitute Disqualified Equity Interests if such Equity Interests provide, to the satisfaction of the Administrative Agent in its reasonable discretion, that the issuer thereof will not be required to redeem or repurchase any such Equity Interests pursuant to such provisions prior to the payment in full of all Obligations (other than contingent indemnification obligations for which no claim has been asserted) under the Loan Documents; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, if such Equity Interests are issued pursuant to a plan for the benefit of employees of the Borrower or any Subsidiary or by any such plan to such employees, such Equity Interests shall not constitute Disqualified Equity Interests solely because such employee may deliver such Equity Interests to the Borrower and its Subsidiaries (or the Borrower or such Subsidiary withholds such Equity Interests) in satisfaction of any exercise price or tax withholding obligations with respect to such Equity Interests.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disqualified Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person designated by the Borrower as a &#x201c;Disqualified Lender&#x201d; by written notice delivered to the Administrative Agent on or prior to the date of this Agreement. Notwithstanding anything to the contrary contained in this Agreement, (a) the Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor or enforce, compliance with the provisions hereof relating to Disqualified Lenders and (b) the Borrower, the Subsidiary Guarantors and the Lenders acknowledge and agree that the Administrative Agent shall have no responsibility or obligation to determine whether any Lender or potential Lender is a Disqualified Lender and that the Administrative Agent shall have no liability with respect to any assignment or participation made to a Disqualified Lender.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Division</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">$</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means lawful money of the United States of America.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Domestic Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Subsidiary that is a corporation, limited liability company, partnership or similar business entity incorporated, formed or organized under the laws of the United States, any state of the United States or the District of Columbia.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EEA Financial Institution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any credit institution or investment firm established in any EEA Member Country that is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country that is a parent of an institution described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this definition, or (c) any financial institution established in an EEA Member Country that is a subsidiary of an institution described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this definition and is subject to consolidated supervision with its parent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EEA Member Country</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EEA Resolution Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eligible Transferee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means and includes (i) any commercial bank, (ii) any insurance company, (iii) any finance company, (iv) any financial institution, (v) any Person that is a bona fide debt fund primarily engaged in the making, purchasing, holding or other investing in commercial loans, notes, bonds or similar extensions of credit or securities in the Ordinary Course, (vi) with respect to any Lender, any of its Affiliates or such Lender&#x2019;s or Affiliate&#x2019;s managed funds or accounts, (vii) any Person that is a Sagard Lender and (viii) any other &#x201c;accredited investor&#x201d; (as defined in Regulation D of the Securities Act) that is principally in the business of managing investments or holding assets for investment purposes; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, an Eligible Transferee shall not include (x) any Company Competitor, Disqualified Lender or Defaulting Lender, or (y) any Person that primarily invests in distressed debt or other distressed financial assets; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (A) neither </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (x)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above shall apply retroactively to any Person that previously acquired an assignment or participation interest hereunder to the extent such Person was not a Company Competitor, Disqualified Lender, Defaulting Lender or a Person of the type described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (y)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above at the time of the applicable assignment or participation, as the case may be, and (B) with respect to both </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (x)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, the Administrative Agent shall not have any duty or obligation to carry out due diligence in order to identify or determine whether a Person would be excluded as an Eligible Transferee as a result of the application of either such proviso.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the European Medicines Agency.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Benefit Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of (a) an &#x201c;employee benefit plan&#x201d; (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA, (b) a &#x201c;plan&#x201d; as defined in and subject to Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such &#x201c;employee benefit plan&#x201d; or &#x201c;plan&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enhanced Liquidity Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date of determination (based on the most recent financial forecast presented to the Board, which shall be shared with the Administrative Agent and the Lenders), the aggregate amount of cash and Permitted Cash Equivalent Investments held by the Obligors sufficient to fund any payments (including Acquisition consideration, Deferred Acquisition Consideration and all similar payments be made in connection with the applicable Acquisition and all other Acquisitions consummated after the Closing Date and prior to such date and the Obligors&#x2019; operations for a period of not less than the lesser of (i) [***]months following the consummation of such Acquisition and (ii) the remaining period until the Maturity Date (it being understood that for purposes of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Enhanced Liquidity Amount shall</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include all amounts (including principal, interest, fees (including the Yield Protection Premium and the Exit Fee), expenses and indemnification obligations (other than inchoate indemnification obligations)) required for the repayment in full of the Obligations hereunder on the Maturity Date); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, for the avoidance of doubt and for all purposes hereunder, the Enhanced Liquidity Amount shall only be such amounts in excess of the Minimum Liquidity Amount.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Environmental Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any investigation, notice, notice of violation, claim, action, suit, proceeding, demand, information request, abatement order or other order or directive (conditional or otherwise), by any Governmental Authority or any other Person, arising (i) pursuant to or in connection with any actual or alleged violation of any Environmental Law; (ii) in connection with any Hazardous Material or any actual or alleged Hazardous Materials Activity; or (iii) in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural resources or the environment, arising out of a violation of Environmental Law or any Hazardous Materials Activity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Environmental Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all laws (including common law and any federal, state, provincial or local governmental law), rule, regulation, order, writ, judgment, notice, requirement, binding agreement, injunction or decree, whether U.S. or non-U.S., relating in any way to (i) environmental matters, including those relating to any Hazardous Materials Activity; (ii) the generation, use, storage, transportation or disposal of Hazardous Materials; or (iii) to the extent related to Hazardous Materials Activity, occupational safety and health, industrial hygiene, land use, natural resources or the protection of human, plant or animal health or welfare, in any manner applicable to the Borrower or any of its Subsidiaries or any Facility.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Environmental Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of any Obligor or any of its Subsidiaries directly or indirectly resulting from or based upon (i) violation of any Environmental Law, (ii) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (iii) exposure to any Hazardous Materials, (iv) the release or threatened release of any Hazardous Materials into the environment or (v) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person (for purposes of this defined term, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">issuer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), all shares of, interests or participations in, or other equivalents in respect of such issuer&#x2019;s capital or capital stock, including all membership interests, partnership interests or equivalent, whether now outstanding or issued after the Closing Date, and in each case, however designated and whether voting or non&#x1f;voting. Notwithstanding the foregoing, in no event shall any Indebtedness convertible or exchangeable into Equity Interests constitute &#x201c;Equity Interests&#x201d; hereunder.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equivalent Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount in the first currency determined by reference to the Exchange Rate at the time of determination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Employee Retirement Income Security Act of 1974.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ERISA Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or treated as a single employer, with any Obligor or Subsidiary thereof, within the meaning of Section 414(b) or (c) of the Code or, solely for purposes of Section 302 of ERISA and Sections 412 and 430 of the Code, is treated as a single employer under Section 414(m) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ERISA Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within thirty (30) days of the occurrence of such event; (ii) the applicability of the requirements of Section 4043(b) of ERISA with respect to a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph (9), (10), (11), (12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following thirty (30) days; (iii) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting in liability under Sections 4063 or 4064 of ERISA; (iv) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it is insolvent pursuant to Section 4245 of ERISA; (v) the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Title IV Plan or Multiemployer Plan; (vi) the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vii) the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Title IV Plan, or the failure to meet the minimum funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer Plan; (viii) the determination that any Title IV Plan is considered an at-risk plan or a plan in endangered to critical status within the meaning of Sections 430 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (ix) an event or condition which might reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan; (x) the imposition of any liability under Title IV of ERISA, other than</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Obligor or any ERISA Affiliate thereof; (xi) an application for a funding waiver under Section 303 of ERISA or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan; (xii) the occurrence of a non-exempt prohibited transaction under Sections 406 or 407 of ERISA for which any Obligor or any Subsidiary thereof could reasonably be expected to be directly or indirectly liable; (xiii) receipt from the IRS of notice of the failure of any Qualified Plan to qualify under Section 401(a) of the Code, or the failure of any trust forming part of any Qualified Plan to fail to qualify for exemption from taxation under Section 501(a) of the Code that is not corrected under the IRS&#x2019;s Employee Plans Compliance Resolution System (EPCRS); (xiv) the imposition of any lien (or the fulfillment of the conditions for the imposition of any lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including Section 303(k) of ERISA, or to Section 430(k) of the Code; or (xv) the establishment or amendment by any Obligor or any Subsidiary thereof of any &#x201c;welfare plan&#x201d;, as such term is defined in Section 3(1) of ERISA, that provides post-employment welfare benefits in a manner that would increase the liability of any Obligor, other than payment of premiums otherwise required by Section 4980B of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ERISA Funding Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the rules regarding minimum required contributions (including any installment payment thereof) to Title IV Plans, as set forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Deficiency Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Impacted Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Return Deficiency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Subrogation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EU Bail-In Legislation Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date, the rate at which any currency may be exchanged into another currency, as set forth on the relevant Bloomberg screen at or about 11:00 a.m. (Eastern time) on such date. In the event that such rate does not appear on the Bloomberg screen, the &#x201c;Exchange Rate&#x201d; shall be determined by reference to such other publicly available service for displaying exchange rates as may be reasonably designated by the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) deposit accounts exclusively used for payroll, payroll Taxes and other employee wage and benefit payments to or for the benefit of any Obligor&#x2019;s employees, (ii) zero balance accounts swept no less frequently than weekly to a Controlled Account (including any such account where payments pursuant to Medicaid, Medicare, TRICARE or other state or federal healthcare payor programs are deposited), (iii) accounts (including trust accounts) used exclusively for bona fide escrow purposes, insurance or fiduciary purposes, (iv) cash collateral for Permitted Liens, (v) collateral accounts in respect of any Revenue Interest Financing and (vi) any other deposit accounts established after the Closing Date only for so long as, in the case of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (vi)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the amounts of deposit therein do not exceed [***] in the aggregate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Asset</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Security Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of (i) AnBio Therapeutics (HK) Ltd., (ii) AnHeart Therapeutics (Hangzhou) Co., Ltd. and (iii) Baoquan Biomedical Technology (Shanghai) Co., Ltd., in each case so long as such Person does not own any Intellectual Property (and, for the avoidance of doubt, any data and information with respect thereto), Products or Product Authorizations, except Intellectual Property, Products and Product Authorizations (x) exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China and (y) until the expiration of the time period set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Intellectual Property (and, for the avoidance of doubt, any data and information with respect thereto), Products and Product Authorizations that cover the manufacture, use, sale, offer for sale or importation or other exploitation of Taletrectinib owned by AnHeart Therapeutics (Hangzhou) Co., Ltd. as of the Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each case, (x) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (y) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (1) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.04(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or (2) such Lender changes its lending office, except in each case to the extent that, pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, amounts with respect to such Taxes were payable either to such Lender&#x2019;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#x2019;s failure to comply with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iv) any withholding Taxes imposed under FATCA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exit Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Facility</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any real property (including all buildings, fixtures or other improvements located thereon) now, hereafter or heretofore owned, leased or operated by any Obligor or any of its Subsidiaries.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FATCA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules, guidance notes or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code or entered into in connection with the implementation of analogous provisions of non-U.S. law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FD&amp;C Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq. (or any successor thereto) and the rules, regulations and guidelines issued or promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means the Borrower has received Marketing Authorization of the Initial Taletrectinib Product from the FDA (a) indicated for the treatment of adult patients of ROS1 - positive non -small cell lung cancer (NSCLC) in first line or second line usage; (b) without a boxed warning in the labeling materials; (c) not subject to a &#x201c;Risk Evaluation and Mitigation Strategies&#x201d; (REMS); and (d) not approved pursuant to FDA&#x2019;s &#x201c;Accelerated Approval Program&#x201d; that requires confirmation of anticipated clinical benefit.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Funds Effective Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any day, the greater of (a) the rate calculated by the Federal Reserve Bank of New York based on such day&#x2019;s Federal funds transactions by depositary institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the Federal funds effective rate; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that (x) if such day is not a Business Day, the Federal Funds Effective Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the next succeeding Business Day, and (y) if no such rate is so published on such next succeeding Business Day, the Federal Funds Effective Rate for such day shall be the average rate charged to three (3) major banks on such day on such transactions as determined by the Administrative Agent and (b) 0%.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Reserve Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Governors of the Federal Reserve System of the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fee Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Fee Letter, dated as of the date of this Agreement, among the Borrower, the Lenders and the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Floor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a rate of interest equal to 4.00% per annum.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Lender that is not a U.S. Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Subsidiary that is not a Domestic Subsidiary.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Date Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a certificate substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit J</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means generally accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other statements by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All references to &#x201c;GAAP&#x201d; shall be to GAAP applied consistently with the principles used in the preparation of the financial statements delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governmental Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any consent, authorization, approval, order, license, franchise, permit, certification, accreditation, registration, clearance or exemption that is issued or granted by or from (or pursuant to any act of) any Governmental Authority, including any application or submission related to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governmental Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the government of the United States, any other nation or any political subdivision thereof, whether state, local or otherwise, and any agency, authority (including supranational authority), commission, instrumentality, regulatory body, court, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including each Patent Office, the FDA, the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DEA, the EMA, the Centers for Medicare and Medicaid Services, the Office of Inspector General of the Department of Health and Human Services and any other government authority in any jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of or by any Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">primary obligor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (ii) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (iv) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the term Guarantee shall not include (x) endorsements for collection or deposit and (y) guarantees of operating leases, in each case, in the Ordinary Course.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantee Assumption Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Guarantee Assumption Agreement substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by an entity that, pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is required to become a &#x201c;Subsidiary Guarantor.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guaranteed Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guaranty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Guaranty made by the Subsidiary Guarantors under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in favor of the Secured Parties (including any Guaranty assumed by an entity that is required to become a &#x201c;Subsidiary Guarantor&#x201d; pursuant to a Guarantee Assumption Agreement).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hazardous Material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any Governmental Authority or which may or would reasonably be expected to pose a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hazardous Materials Activity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, release, threatened release, discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, recycling, disposition or handling of any Hazardous Materials, and any investigation, monitoring, corrective action or response action with respect to any of the foregoing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all Laws and Product Authorizations applicable to the business, any Product or the Product Commercialization and Development Activities of any Obligor, whether U.S. or non-U.S., regulating the distribution, dispensing, importation, exportation, quality, manufacturing, marketing, labeling, promotion and provision of and payment for drugs, biological products, or healthcare products, items and services, including, without limitation, the FD&amp;C Act, the Public Health Service Act, the Social Security Act, the Federal Anti-Kickback Statute, the federal False Claims Act, the federal Physician Self-Referral Law (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stark Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the federal Physician Payment Sunshine Act, the Medicare Secondary Payer Law, the Prescription Drug Marketing Act, and all rules, regulations and guidance with respect to the coverage of prescription drugs pursuant to the Medicare and Medicaid programs, the TRICARE Program, programs administered by the Department of Veterans Affairs, and federal employee health benefit plans; and all rules, regulations and guidance promulgated under or pursuant to any of the foregoing, including any state and non-U.S. equivalents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hedging Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. Notwithstanding anything to the contrary in the foregoing, neither any Permitted Bond Hedge Transaction nor any Permitted Warrant Transaction shall be a Hedging Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Illegality Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Immaterial Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Subsidiary of the Borrower that does not own, license or hold any rights (whether by contract or otherwise) with respect to any Material Intellectual Property, Material Product Authorizations or Material Agreements and does not conduct any Product Commercialization and Development Activities with respect to Taletrectinib, in each case, other than such forgoing rights and Intellectual Property that are exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China and (i) individually constitutes or holds less than [***] percent ([***]%) of the Borrower&#x2019;s consolidated total assets or generates less than [***] percent ([***]%) of the Borrower&#x2019;s consolidated total revenue, and (ii) when taken together with all then existing Immaterial Subsidiaries, such Subsidiary and such Immaterial Subsidiaries, in the aggregate, would constitute or hold less than [***] percent ([***]%) of the Borrower&#x2019;s consolidated total assets or generate less than [***] percent ([***]%) of the Borrower&#x2019;s consolidated total revenue, in each case of the foregoing clauses (x) as of the last day of, or for, the most recently ended fiscal period for which financial statements were required to have been delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.01(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (y) for the avoidance of doubt, inclusive of the total assets and revenue of all Excluded Subsidiaries.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IND</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i)(x) an investigational new drug application (as defined in the FD&amp;C Act&#x2019;s implementing regulations at 21 CFR Part 312) that is required to be filed with the FDA before</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">beginning clinical testing in human subjects, or any successor application or procedure and (y) any similar application or functional equivalent relating to any investigational new drug application applicable to or required by any non-U.S. Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of any Person means, without duplication, (i) all obligations of such Person for borrowed money, (ii) all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (iii) all obligations of such Person upon which interest charges are customarily paid (excluding interest penalties for late payments under commercial contracts entered into in the Ordinary Course and, for the avoidance of doubt, which commercial contracts do not relate to obligations for borrowed money or purchase money indebtedness), (iv) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (v) all obligations of such Person in respect of the deferred purchase price of property or services (it being agreed that seller notes or earn-out obligations are addressed in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (xii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), (vi) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (vii) all Guarantees by such Person of Indebtedness of others, (viii) all Capital Lease Obligations of such Person, (ix) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (x) obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions (other than Permitted Warrant Transactions), (xi) all obligations, contingent or otherwise, of such Person in respect of bankers&#x2019; acceptances, (xii) all obligations in respect of any Deferred Acquisition Consideration, (xiii) any Disqualified Equity Interests of such Person, and (xiv) all other obligations required to be classified as indebtedness of such Person under GAAP; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, notwithstanding the foregoing, Indebtedness shall not include (A) accrued expenses, deferred rent, deferred Taxes, deferred compensation or customary obligations under employment agreements, or (B) accounts payable incurred in the Ordinary Course. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person&#x2019;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnified Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation of an Obligor and (ii) to the extent not otherwise described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Other Taxes.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Information Certificate delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initial Taletrectinib Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the definition of &#x201c;Taletrectinib&#x201d;.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insolvency Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization, restructuring, insolvency, liquidation, provisional liquidation, receivership, dissolution, winding-up or relief of debtors, or (ii) any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person&#x2019;s creditors generally or any substantial portion of such Person&#x2019;s creditors, in each case undertaken under U.S. federal, state or foreign law, including the Bankruptcy Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all intellectual property or proprietary rights anywhere in the world, including any rights in or to Patents, Trademarks, Copyrights, and Technical Information, in each case, whether U.S. or non U.S.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intercompany Subordination Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a subordination agreement to be executed and delivered by each Obligor and each of its Subsidiaries, pursuant to which all obligations in respect of any Indebtedness owing to any such Person by an Obligor shall be subordinated to the prior payment in full in cash of all Obligations, such agreement to be in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the period commencing on and including the Tranche A-1 Funding Date and ending on but excluding the immediately subsequent Payment Date and (b) subsequently, each period commencing on and excluding the last day of the previous Interest Period for such Loan and ending on but excluding the immediately subsequent Payment Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.02(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Invention</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any novel, inventive and useful art, apparatus, method, process, machine (including any article or device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture or composition of matter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any Person: (i) the acquisition (whether for cash, property, services or securities or otherwise) of any debt or Equity Interests, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person (including any &#x201c;short sale&#x201d; or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (ii) the making of any deposit with, or advance, loan, assumption of debt</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or other extension of credit to, or capital contribution in any other Person (including the purchase of property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not exceeding [***] days arising in connection with the sale of inventory or supplies by such Person in the Ordinary Course; (iii) the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person; or (iv) the consummation of an Acquisition. The amount of an Investment shall be the amount actually invested (which, in the case of any Investment constituting the contribution of an asset or property, shall be based on such Person&#x2019;s good faith estimate of the fair market value of such asset or property at the time such Investment is made), less the amount of cash received or returned for such Investment, without adjustment for subsequent increases or decreases in the value of such Investment or write-ups, write-downs or write-offs with respect thereto; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that in no event shall such amount be less than zero or increase any basket or amount pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above the fixed amount set forth therein. Notwithstanding anything to the contrary in the foregoing, the purchase of any Permitted Bond Hedge Transaction by the Borrower or any of its Subsidiaries and the performance of its obligations thereunder shall not be an Investment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Service.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Venture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a joint venture, partnership or other similar arrangement, in corporate, partnership or similar legal form with a Person other than Borrower or its Subsidiaries.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Landlord Consent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Landlord Consent substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit G.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all U.S. or non-U.S. federal, state, provincial, territorial, municipal or local statute, act, treaty, rule, guideline, regulation, ordinance, code or administrative or judicial precedent or authority, including any interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any mortgage, equitable mortgage, lien, license, pledge, hypothecation, charge, security interest, or other encumbrance of any kind or character whatsoever, whether or not filed, recorded or otherwise perfected under applicable Law, or any lease, title retention agreement, mortgage, restriction, easement, right-of-way, option or adverse claim of ownership or possession (including any conditional sale or other title retention agreement, any lease in the nature</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thereof, and any other encumbrance on title to real property, any option or other agreement to sell, or give a security interest in, such asset and any filing of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statutes of any jurisdiction)) or any preferential arrangement that has the practical effect of creating a security interest and (b) in the case of Equity Interests, any purchase option, call or similar right of a third party with respect to such Equity Interests.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each loan advanced by a Lender pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, this Agreement, the Notes, the Security Documents, the Fee Letter, any Guarantee Assumption Agreement, the Intercompany Subordination Agreement, the Permitted Intercreditor Agreement and any other subordination agreement, intercreditor agreement or other present or future document, instrument, agreement or certificate delivered to the Administrative Agent (for itself or for the benefit of any other Secured Party) in connection with this Agreement or any of the other Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Majority Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, Lenders having at such time in excess of [***] percent ([***]%) of the aggregate unused Commitments then in effect and the outstanding principal amount of the Loans at such time. The Commitments of any Defaulting Lender shall be disregarded in determining Majority Lenders at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mandatory Prepayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Margin Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means &#x201c;margin stock&#x201d; within the meaning of Regulations U and X.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a drug, pharmaceutical or biological product, the Regulatory Approvals required by Applicable Law to sell such product in a country or region, including, to the extent required by Applicable Law for the sale of such product, all pricing approvals and government reimbursement approvals.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; mean [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Environmental Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Environmental Liability that has had or could reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, any Indebtedness of any Obligor or Subsidiary thereof, the outstanding principal amount of which, individually or in the aggregate, exceeds [***] (or the Equivalent Amount in other currencies).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Intellectual Property, whether currently owned by (or purported to be owned by), or subject to a license, covenant not to sue or similar right to (or purported to be subject to a license, covenant not to sue or similar right to) the Borrower or any of its Subsidiaries, or acquired, developed, obtained by, or otherwise subject to a license, covenant not to sue or similar right to the Borrower or any of its Subsidiaries after the date hereof, in each case, the loss of which could reasonably be expected to result in (i) a Material Adverse Effect or (ii) a material adverse effect on Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Product Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all Product Authorizations, in each case, necessary to be held or maintained by, or for the benefit of, any Obligor or any of its Subsidiaries for any Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Subsidiary of the Borrower that is not an Immaterial Subsidiary.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means September 30, 2030.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Medicaid</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that government-sponsored entitlement program under Title XIX, P.L. 89-97 of the Social Security Act, which provides federal grants to states for medical assistance based on specific eligibility criteria, as set forth on Section 1396, et seq. of Title 42 of the United States Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Medicare</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that government-sponsored insurance program under Title XVIII, P.L. 89-97, of the Social Security Act, which provides for a health insurance system for eligible elderly and disabled individuals, as set forth at Section 1395, et seq. of Title 42 of the United States Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Minimum Liquidity Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mortgage Deliverables</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12(b)(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Multiemployer Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any multiemployer plan, as defined in Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any obligation or liability, contingent or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i)(x) a new drug application (set forth in the FD&amp;C Act at 21 U.S.C. &#167; 355(b) and its implementing regulations) or any successor application or procedure and (y) any similar application or functional equivalent relating to any new drug application applicable to or required by any non-U.S. country, jurisdiction or Governmental Authority, and (ii) all supplements and amendments that may be filed with respect to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (i) with respect to any Casualty Event experienced or suffered by any Obligor or any of its Subsidiaries, the amount of cash proceeds received from time to time by or on behalf of such Person in respect thereof (other than the proceeds of any business interruption insurance) after deducting therefrom only (w) reasonable out-of-pocket cash costs and expenses related thereto incurred by such Obligor or such Subsidiary in connection therewith, (x) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith, (y) reasonable reserves established for liabilities estimated to be payable in respect of such Casualty Event and deposited into escrow with a third party escrow agent on customary terms or set aside in a Controlled Account and (z) any amounts required to be used to prepay Permitted Indebtedness pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 9.01(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 9.01(l) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">secured by the assets subject to such Casualty Event (other than (A) Indebtedness owing to the Administrative Agent or any Lender under this Agreement or the other Loan Documents and (B) Indebtedness assumed by the purchaser of such asset); and (ii) with respect to any Asset Sale by any Obligor or any of its Subsidiaries, the amount of cash proceeds received from time to time by or on behalf of such Person in respect thereof after deducting therefrom only (w) reasonable out-of-pocket cash costs and expenses related thereto incurred by such Obligor or such Subsidiary in connection therewith, (x) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith, (y) reasonable reserves established for liabilities estimated to be payable in respect of such Asset Sale and deposited into escrow with a third party escrow agent on customary terms or set aside in a Controlled Account and (z) any amounts required to be used to prepay Permitted Indebtedness pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 9.01(j) and 9.01(l) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">secured by the assets subject to such Asset Sale (other than (A) Indebtedness owing to the Administrative Agent or any Lender under this Agreement or the other Loan Documents and (B) Indebtedness assumed by the purchaser of such asset); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, in each case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, costs and expenses shall only be deducted to the extent, that the amounts so deducted are (x) actually paid or payable to a Person that is not an Affiliate of any Obligor or any of its Subsidiaries and (y) properly attributable to such Casualty Event or Asset Sale, as the case may be; it being understood that &#x201c;Net Cash Proceeds&#x201d; shall include, without limitation, any cash received upon the sale or other disposition of any non-cash consideration received by any Obligor in any Casualty Event or Asset Sale.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Note</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a promissory note, in substantially the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hereto, executed and delivered by the Borrower to any Lender in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NY UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the UCC as in effect from time to time in New York.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties of every type and description owing by such Obligor to any Secured Party (including all Guaranteed Obligations) any other indemnitee hereunder or any participant, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument or for the payment of money, including, without duplication, (i) if such Obligor is the Borrower, all Loans, (ii) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a claim for post- filing or post-petition interest is allowed in any such proceeding, and (iii) all other fees, expenses (including fees, charges and disbursement of counsel), interest, Yield Protection Premium, Exit Fee, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obligors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the Borrower and the Subsidiary Guarantors and their respective successors and permitted assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the definition of &#x201c;Anti-Terrorism Laws.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ordinary Course</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means ordinary course of business or ordinary trade activities that are customary for similar businesses in the normal course of their ordinary operations and not while in financial distress.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organic Document</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any Person, such Person&#x2019;s formation documents, including, as applicable, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, memorandum and articles of association, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to such Person&#x2019;s Equity Interests, or any equivalent document of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Connection Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.04(b))</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Office</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the applicable patent office, including the United States Patent and Trademark Office and any comparable foreign patent office, for any Patents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all patents and patent applications, the Inventions and improvements described and claimed therein, the reissues, divisionals, continuations, renewals, extensions, reexaminations, substitutions and continuations in part thereof, and all rights whatsoever accruing thereunder or pertaining to the foregoing throughout the world.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patriot Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the last Business Day of each March, June, September and December of each year, commencing on the first such date to occur after the Tranche A-1 Funding Date, and the Maturity Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PBGC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Acquisition by the Borrower or any of its Subsidiaries, whether by purchase, merger or otherwise; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	immediately prior to, and immediately after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or could reasonably be expected to result therefrom;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	such Acquisition shall comply in all material respects with all applicable Laws and all applicable Governmental Approvals;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	in the case of any Acquisition of Equity Interests of another Person, after giving effect to such Acquisition, all Equity Interests of such other Person acquired by the Borrower or any of its Subsidiaries shall be owned, directly or indirectly, beneficially and of record, by the Borrower or any of its Subsidiaries, and, the Borrower shall cause such acquired Person to satisfy each of the actions set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as and when required by such Section;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	on a pro forma basis after giving effect to such Acquisition, the Borrower and its Subsidiaries shall be in compliance with the financial covenant set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	in the event that, on a pro forma basis after giving effect to such Acquisition, the Borrower and its Subsidiaries shall not have satisfied the Enhanced Liquidity Amount, to the extent that all or any portion of the purchase price (which for purposes hereof shall include reasonable estimates of (x) any Deferred Acquisition Consideration that could, by its terms, become due and payable prior to the date that is [***] days after the Maturity Date and (y) any forecasted research and development costs and similar expenditures in respect of such purchased assets) for any such Acquisition is paid in cash, the amount thereof shall not exceed [***] (or the Equivalent Amount in other currencies) in the aggregate with any other such Acquisitions from and after the Closing Date;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	to the extent that all or any portion of the purchase price for any such Acquisition is paid in Equity Interests, all such Equity Interests shall be Qualified Equity Interests;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	in the case of any such Acquisition that has a purchase price (which for purposes hereof shall include reasonable estimates of (x) any Deferred Acquisition Consideration that could, by its terms, become due and payable prior to the date that is [***] days after the Maturity Date and (y) any forecasted research and development costs and similar expenditures in respect of such purchased assets) in excess of [***] the Borrower shall provide to the Administrative Agent (i) at least [***] prior written notice of any such Acquisition, together with copies of all due diligence conducted by or on behalf of the Borrower or the applicable Subsidiary, as applicable, prior to such Acquisition and summaries or memos to the extent prepared and available, in each case subject to customary confidentiality restrictions, (ii) subject to customary confidentiality restrictions, a copy of the draft purchase agreement related to the proposed Acquisition (and any related documents reasonably requested by the Administrative Agent), (iii) financial statements of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Borrower and its Subsidiaries (as of the last day of the most recently ended fiscal quarter prior to the date of consummation of such Acquisition for which financial statements are required to be delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prepared on a Pro Forma Basis) (which for purposes hereof shall include reasonable estimates of (x) any Deferred Acquisition Consideration that could, by its terms, become due and payable prior to the date that is [***] days after the Maturity Date and (y) any forecasted research and development costs and similar expenditures in respect of such purchased assets), and (iv) subject to customary confidentiality restrictions, any other information reasonably requested (to the extent available), by the Administrative Agent and available to the Obligors; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	no Obligor or any of its Subsidiaries (including any acquired Person) shall, in connection with any such Acquisition, assume or remain liable with respect to (x) any Indebtedness of the related seller or the business, Person or assets acquired, except to the extent permitted pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (y) any Lien on any business, Person or assets acquired, except to the extent permitted pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (z) any other liabilities (including Tax, ERISA and environmental liabilities), except to the extent the assumption of such liability could not reasonably be expected to result in a Material Adverse Effect. Any other such Indebtedness, liabilities or Liens not permitted to be assumed, continued or otherwise supported by any Obligor or Subsidiary thereof hereunder shall be paid in full or released on the acquisition date as to the business, Persons or properties being so acquired on or before the consummation of such Acquisition.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Bond Hedge Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any call or capped call option (or substantively equivalent derivative transaction) relating to the Borrower&#x2019;s common stock (or other securities or property following a merger event, reclassification or other similar fundamental change of the Borrower, or adjustment with respect to the common stock of the Borrower) that is (A) purchased or otherwise entered into by the Borrower in connection with the issuance of any Permitted Convertible Debt, (B) settled in common stock of the Borrower (or such other securities or property), cash or a combination thereof (such amount of cash determined by reference to the price of the Borrower&#x2019;s common stock or such other securities or property), and cash in lieu of fractional shares of common stock of the Borrower and (C) on terms and conditions customary for bond hedge transactions in respect of transactions related to public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act) as reasonably determined by the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, (i) the purchase price for such Permitted Bond Hedge Transaction, less the proceeds received by the Borrower from the sale of any related Permitted Warrant Transaction (or in the case of capped calls, where such proceeds are not received but are reflected in a reduction of the premium), does not result in the incurrence of additional liability on the consolidated balance sheet of the Borrower (other than Indebtedness from the issuance of Permitted Convertible Debt in connection with such Permitted Bond Hedge Transaction) and (ii) the purchase price of any such Permitted Bond Hedge</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction shall not exceed, net of the proceeds of any Permitted Warrant Transaction entered into in connection therewith, [***]% of the proceeds obtained in the related Permitted Convertible Debt issuance.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Cash Equivalent Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) marketable direct obligations issued or unconditionally guaranteed by the United States or any member states of the European Union or any agency or any state thereof having maturities of not more than two (2) years from the date of acquisition, (ii) commercial paper maturing no more than three hundred sixty-five (365) days after the date of acquisition thereof and having the highest rating from either Standard &amp; Poor&#x2019;s Ratings Group or Moody&#x2019;s Investors Service, Inc., (iii) certificates of deposit maturing no more than two (2) years after issue that are issued by any bank organized under the Laws of the United States, or any state thereof, or the District of Columbia, or any U.S. branch of a foreign bank having, at the date of acquisition thereof, combined capital and surplus of not less than [***], (iv) any money market or similar funds that exclusively hold any of the foregoing, and (v) other short term liquid investments approved in writing by the Administrative Agent in its sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Convertible Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Indebtedness having a feature which entitles the holder in accordance with the terms thereof to convert or exchange all or a portion of such Indebtedness into Class A Common Stock of the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that (i) such Permitted Convertible Debt shall be unsecured, (ii) no Subsidiary of the Borrower shall guarantee Permitted Convertible Debt, (iii) Permitted Convertible Debt shall not include any financial maintenance covenants and shall only include covenants, defaults and conversion rights that are customary for public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act) as of the date of issuance, as determined by the Borrower in its good faith judgment, (iv) no Default or Event of Default shall have occurred and be continuing at the time of incurrence of such Permitted Convertible Debt or would result therefrom, (v) such Permitted Convertible Debt shall not require any scheduled amortization or have a scheduled maturity date, and shall not be subject to any mandatory repurchase or redemption (other than in connection with a customary change of control or &#x201c;fundamental change&#x201d; provision), in each case, earlier than [***] calendar days after the Maturity Date, (vi) such Permitted Convertible Debt shall bear interest at a rate per annum not to exceed such rate as is customary in the market at such time, as determined in the reasonable commercial judgment of a Responsible Officer of Borrower in good faith and (vii) the Borrower shall have delivered to the Administrative Agent a certificate of a Responsible Officer of the Borrower certifying as to the foregoing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Hedging Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Hedging Agreement entered into by any Obligor in such Obligor&#x2019;s Ordinary Course for the purpose of hedging currency risks or interest rate risks (and not for speculative purposes) and (x) with respect to hedging currency risks, in an aggregate notional amount for all such Hedging Agreements not in excess of [***] (or the Equivalent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount in other currencies) and (y), with respect to hedging interest rate risks, in an aggregate notional amount for all such Hedging Agreements not more than [***]%, of the aggregate principal amount of Loans outstanding at such time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Intercreditor Agreement, dated as of the Closing Date, by and among SAGARD HOLDINGS MANAGER LP, in its capacity as Administrative Agent hereunder, and SAGARD HEALTHCARE PARTNERS (DELAWARE) II LP, as Investor under the Royalty Financing Agreement, and acknowledged by the Obligors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) each license agreement listed on Schedule 3;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) any license agreement or covenant not to sue with respect to any Product exclusively outside the United States;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) any license or grant of rights to any Third Party (x) vendor or service provider (including contract research organizations, contract manufacturing organizations, clinical trial sites, distribution and channel partners, commercial vendors and other contractors for the exploitation of the Products) in order to provide services for the benefit of the Borrower or its Affiliates with respect to any Product or (y) wholesaler or distributor for the benefit of the Borrower or its Affiliates with respect to any Product, but to the extent that such license or grant of rights relates to rights to Taletrectinib in the United States, then such license or grant of rights must meet all of the following requirements: (i) such license or grant of rights is non-exclusive and entered into in the Ordinary Course; (ii) such license or grant of rights grants no rights to sell, offer to sell, have sold, market, promote or otherwise commercialize Taletrectinib in the United States, except for rights granted in the Ordinary Course, it being understood and agreed that notwithstanding any provision to the contrary, a license or grant of rights to a Person (other than the Borrower or an Affiliate of the Borrower) contract sales force or with respect to any type of promotion, co-promotion, marketing, co-marketing or similar arrangement with respect to the commercialization of Taletrectinib in the United States is not ordinary course and is not a permitted license; (iii) the Borrower or another Obligor retains the right to, and does, book the full amount of net sales of Taletrectinib in the United States; and (iv) such license or grant of rights is part of an Arm&#x2019;s Length Transaction, the terms of which do not provide for a sale or assignment to such Third Party of Intellectual Property or Governmental Approvals relating to Taletrectinib in the United States;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) any in-license agreement with respect to a Product acquired in connection with a Permitted Acquisition;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) any sponsored research or similar agreement providing for the development of a Product that does not grant the counterparty any right to sell, offer to sell, have sold, market, promote or otherwise commercialize Taletrectinib in the United States;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f) any intercompany licenses or grants of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, promotion, co-promotion, sales or distribution of Products among the Obligors or granted by any Subsidiary that is not an Obligor to an Obligor;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g) any license for the use of (or covenant not to sue with respect to) the Intellectual Property of the Borrower or any of its Subsidiaries or grants of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, promotion, co-promotion, distribution or importation of (i) any Product other than Taletrectinib, or (ii) Taletrectinib but solely with respect to Intellectual Property or rights exclusively outside the United States; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h) other licenses to which the Administrative Agent shall have consented to in writing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Liens permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Refinancing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Indebtedness permitted to be refinanced, extended, renewed or replaced hereunder, any refinancings, extensions, renewals and replacements of such Indebtedness; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such refinancing, extension, renewal or replacement shall not (i) increase the outstanding principal amount of the Indebtedness being refinanced, extended, renewed or replaced, except by an amount equal to accrued interest and a reasonable premium or other reasonable fee paid, and fees and expenses reasonably incurred in connection therewith, (ii) contain terms relating to outstanding principal amount, amortization, maturity, collateral security (if any) or subordination (if any), or other material terms that, taken as a whole, are less favorable in any material respect to the Obligors and their respective Subsidiaries or the Secured Parties than the terms of any agreement or instrument governing such existing Indebtedness, (iii) have an applicable interest rate which does not exceed the greater of (A) the rate of interest of the Indebtedness being replaced and (B) the then applicable market interest rate, (iv) contain any new requirement to grant any Lien or to give any Guarantee that was not an existing requirement of such Indebtedness and (v) after giving effect to such refinancing, extension, renewal or replacement, no Default or Event of Default shall have occurred or could reasonably be expected to occur as a result thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Permitted Warrant Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating to the Borrower&#x2019;s common stock (or other securities or property following a merger event, reclassification or other change of the common</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock of the Borrower) sold by the Borrower and with recourse to the Borrower only, substantially concurrently with any purchase by the Borrower of a Permitted Bond Hedge Transaction and settled in common stock of the Borrower, cash or a combination thereof (such amount of cash determined by reference to the price of the Borrower&#x2019;s common stock or such other securities or property), and cash in lieu of fractional shares of common stock of the Borrower, with a strike price higher than the strike price of the applicable Permitted Bond Hedge Transaction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any individual, corporation, company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepayment Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prime Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the rate of interest per annum last quoted by The Wall Street Journal as the &#x201c;Prime Rate&#x201d; in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &#x201c;bank prime loan&#x201d; rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent) or any similar release by the Federal Reserve Board (as determined by the Administrative Agent). Any change in the Prime Rate shall take effect at the opening of business on the day such change is publicly announced or quoted as being effective.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pro Forma Basis</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean, as of any date, that </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pro forma</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> effect will be given to the Transactions, any Acquisition, any issuance, incurrence, assumption or permanent repayment of Indebtedness (including Indebtedness issued, incurred or assumed as a result of, or to finance, any relevant transaction and for which any such pro forma calculation is being made), all sales, transfers and other dispositions or discontinuance of any subsidiary, line of business or division and any conversion of a Subsidiary Guarantor to Subsidiary or of a Subsidiary to a Subsidiary Guarantor, in each case that have occurred during the four consecutive fiscal quarter period of the Borrower being used to calculate such financial ratio (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reference Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), or subsequent to the end of the Reference Period but prior to such date or prior to or simultaneously with the event for which a determination under this definition is made (including any such event occurring at a person who became a Subsidiary after the commencement of the Reference Period), as if each such event occurred on the first day of the Reference Period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) those drug, pharmaceutical or biological products described on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 2 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attached hereto, and (ii) any current or future drug, pharmaceutical or biological product researched, developed, distributed, dispensed, imported, exported, labeled, promoted, manufactured, licensed, marketed, sold or otherwise commercialized by any Obligor or any of its</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries, including any such product in development or which may be developed. For clarity, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall include Taletrectinib.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all Governmental Approvals, whether U.S. or non-U.S. (including all applicable ANDAs, NDAs, BLAs, Biosimilar Applications, INDs, supplements, amendments, governmental price and reimbursement approvals and approvals granting regulatory exclusivity) of any Regulatory Authority, in each case, necessary to be held or maintained by, or for the benefit of, any Obligor or any of its Subsidiaries for the ownership, use or commercialization of any Product or for any Product Commercialization and Development Activities with respect thereto in any country or jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Commercialization and Development Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Product, any combination of research, development, testing, manufacture, formulation, use, sale, licensing, importation, exportation, shipping, storage, handling, design, labeling, marketing, promotion, supply, distribution, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing (including, without limitation, in respect of licensing, royalty or similar payments), or any similar or other activities the purpose of which is to commercially exploit such Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Related Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Product, all books, records, lists, ledgers, files, manuals, correspondence, reports, plans, drawings, data and other information of every kind (in any form or medium), and all techniques and other know-how, owned or possessed by the Obligors or any of their respective Subsidiaries that are necessary or useful for any Product Commercialization and Development Activities relating to such Product, including (i) brand materials and packaging, customer targeting and other marketing, promotion and sales materials and information, referral, customer, supplier and other contact lists and information, product, business, marketing and sales plans, research, studies and reports, sales, maintenance and production records, training materials and other marketing, sales and promotional information and (ii) clinical data, information included or supporting any Product Authorization, any regulatory filings, updates, notices and correspondence (including adverse event and other pharmacovigilance and other post-marketing reports and information, etc.), technical information, product development and operational data and records, and all other documents, records, files, data and other information, used in connection with the Product Commercialization and Development Activities for such Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prohibited Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the foregoing that is prohibited under any Law for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proportionate Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Lender, the percentage obtained by dividing (i) the sum of the Commitment (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (ii) the sum of the Commitments (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of all Lenders then in effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PTE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a prohibited transaction class exemption issued by the U.S. Department of Labor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Qualified Equity Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any Equity Interest of such Person that is not a Disqualified Equity Interest.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Qualified Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an employee pension benefit plan (as defined in Section 3(2) of ERISA) other than a Multiemployer Plan (i) that is or was at any time within the preceding five (5) years maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has within the preceding five (5) years ever made, or was within the preceding five (5) years ever obligated to make, contributions, and (ii) that is intended to be tax qualified under Section 401(a) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quarterly Lender Call Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.06.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Real Property Security Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Landlord Consents or Bailee Letters.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Administrative Agent, any Lender or any other recipient of any payment to be made by or on account of any Obligation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Referral Source</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.07(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Regulation T of the Board of Governors of the Federal Reserve System, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation U</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Regulation U of the Board of Governors of the Federal Reserve System, as amended.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Regulation X of the Board of Governors of the Federal Reserve System, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all regulatory approvals, registrations, certificates, authorizations, permits and supplements thereto, as well as associated materials (including the product dossier) pursuant to which a drug, pharmaceutical or biological product may be marketed, sold and distributed in a jurisdiction, issued by the appropriate Regulatory Authority, including approved NDAs and BLAs.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Governmental Authority, whether U.S. or non-U.S., that is concerned with or has regulatory or supervisory oversight with respect to any Product or any Product Commercialization and Development Activities relating to any Product, including the FDA and all equivalent Governmental Authorities, whether U.S. or non-U.S.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reinvestment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Relevant Governmental Body</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Federal Reserve Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board or the Federal Reserve Bank of New York, or any successor thereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repatriation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repatriated</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; have the meanings set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resignation Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resolution Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Responsible Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of any Person means each of the president, chief executive officer, chief financial officer, general counsel and similar officer of such Person (including in the case of any Foreign Subsidiary, directors).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any dividend or other distribution (whether in cash, Equity Interests or other property) with respect to any Equity Interests of any Obligor or any of its Subsidiaries, or any payment (whether in cash, Equity Interests or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such Equity Interests of any Obligor or any of its Subsidiaries or any option, warrant or other right to acquire any such Equity Interests of any Obligor or any of its Subsidiaries; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the issuance of, entry into (including any payments of premiums in connection therewith), performance of obligations under (including any payments of interest),</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and conversion, exercise, repurchase, redemption, settlement or early termination or cancellation of (whether in whole or in part and including by netting or set-off) (in each case, whether in cash, common stock of the Borrower or, following a merger event or other change of the common stock of Borrower, other securities or property), or the satisfaction of any condition that would permit or require any of the foregoing, any Permitted Convertible Debt, any Permitted Bond Hedge Transaction and any Permitted Warrant Transaction, including any payment or delivery in connection with a Permitted Warrant Transaction by (i) delivery of shares of the Borrower&#x2019;s common stock upon net share settlement thereof and any related purchase of such common stock required to be made in connection with such delivery, (ii) set-off or payment of an early termination payment or similar payment thereunder, in each case, in the Borrower&#x2019;s common stock upon any early termination thereof or (iii) in the event of cash settlement upon settlement, any payment of a cash settlement or equivalent amount, in each case, shall not constitute a Restricted Payment by the Borrower or any Subsidiary.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restrictive Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Contract or other arrangement that prohibits, restricts or imposes any condition upon (i) the ability of any Obligor or any of its Subsidiaries to create, incur or permit to exist any Lien upon any of its properties or assets (other than (x) customary provisions in Contracts (including without limitation leases and in-bound licenses of Intellectual Property) restricting the assignment thereof and (y) restrictions or conditions imposed by any Contract governing secured Permitted Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the extent that such restrictions or conditions apply only to the property or assets securing such Indebtedness), or (ii) the ability of any Obligor or any of its Subsidiaries to make Restricted Payments with respect to any of their respective Equity Interests or to make or repay loans or advances to any other Obligor or any of its Subsidiaries or such other Obligor or to Guarantee Indebtedness of any other Obligor or any of its Subsidiaries thereof or such other Obligor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the transactions contemplated by the Revenue Interest Financing Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Interest Financing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Revenue Interest Financing Agreement, dated as of the date hereof, by and between the Borrower and Sagard Healthcare Partners (Delaware) II LP, a Delaware limited partnership, as such agreement may be amended, restated, amended and restated, supplemented or otherwise modified from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sagard Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Lender that is an Affiliate, investor, co-investor, limited partner, managed fund or account of Sagard Healthcare Royalty Partners GP LLC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sanction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any international economic or financial sanction or trade embargo imposed, administered or enforced from time to time by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Member States, His Majesty&#x2019;s Treasury or any sanctions legislation extended to the Cayman Islands pursuant to any Order in Council of His Majesty&#x2019;s Privy Council in the United Kingdom or other relevant sanctions authority where the Borrower is located or conducts business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sanctioned Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, (i) any Person listed in any Sanctions-related list of designated Persons maintained by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, His Majesty&#x2019;s Treasury or other relevant sanctions authority, (ii) any Person organized or resident in a Designated Jurisdiction or (iii) any Person fifty percent (50%) or more owned or is controlled by any such Person or Persons described in the foregoing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Secured Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Lenders, the Administrative Agent and the Indemnified Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Act of 1933 and the rules and regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Security Agreement, delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, among the Obligors and the Administrative Agent, granting a security interest in the Obligors&#x2019; personal property in favor of the Administrative Agent, for the benefit of the Secured Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Security Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the Security Agreement, each Short-Form IP Security Agreement, each Real Property Security Document, the Cayman Security Document and each other security document, control agreement or financing statement required or recommended to perfect Liens in favor of the Secured Parties for purposes of securing the Obligations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-Form IP Security Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means short-form copyright, patent or trademark (as the case may be) security agreements, dated as of the Closing Date and substantially in the form of Exhibit C, D and E to the Security Agreement, entered into by one or more Obligors in favor of the Secured Parties, each in form and substance reasonably satisfactory to the Administrative Agent (and as amended, modified or replaced from time to time).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SOFR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SOFR Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SOFR Borrowing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to any Borrowing, the SOFR Loans comprising such Borrowing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SOFR Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Loan that bears interest at a rate based on Term SOFR, other than pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;ABR&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Solvent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to any Person as of any date of determination, that on such date (i) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (ii) the present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured in the ordinary course of business, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person&#x2019;s ability to pay such debts and liabilities as they mature in the ordinary course and (iv) such Person is not engaged in a business or transaction, and is not about to engage in a business or transaction, for which such Person&#x2019;s property would constitute an unreasonably small capital after giving due consideration to the prevailing practice in the industry in which such Person is engaged or is to engage. The amount of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specified Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means AnHeart Therapeutics (Hangzhou) Co., Ltd.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specified Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specified Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of the United States, United Kingdom, France, Germany, Ireland, Italy, Switzerland and, as to any pending European patent application in the European Patent Office or any other European Proprietary Rights, the European Union (and as to the European Union, excluding, for the avoidance of doubt, granted rights in its individual member states (other than France, Germany, Ireland, and Italy)).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">parent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) at any date, any corporation, limited liability company, partnership, association or other entity (i) of which securities or other ownership interests representing more than fifty percent (50%) of the equity or more than fifty percent (50%) of the ordinary voting power or, in the case of a partnership, more than fifty percent (50%) of the general partnership interests are, as of such date, owned, controlled or held, directly or indirectly, or (ii) that is, as of such date, otherwise Controlled, by the parent or one or more direct or indirect subsidiaries of the parent or by the parent and one or more direct or indirect subsidiaries of the parent. Unless otherwise specified, all references herein to a &#x201c;Subsidiary&#x201d; or to &#x201c;Subsidiaries&#x201d; shall refer to a Subsidiary or Subsidiaries of the Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each Subsidiary of the Borrower identified under the caption &#x201c;SUBSIDIARY GUARANTORS&#x201d; on the signature pages hereto and each Subsidiary of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Borrower that becomes a &#x201c;Subsidiary Guarantor&#x201d; after the date hereof pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.12(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taletrectinib</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any drug or pharmaceutical product (including any product in development or that may be developed) that contains taletrectinib, having the structure shown in Schedule 4, in each case in any dosage form, dosing regimen or strength, or any improvements or modifications thereto, and regardless of trade or brand name. For clarity, Taletrectinib shall include the product that is the subject of NDA 219713 that was submitted to the FDA on October 23, 2024, regardless of the trade or brand name of such product (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initial Taletrectinib Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taletrectinib Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the first commercial transfer or disposition for value of the Initial Taletrectinib Product for end use in the United States to a Third Party by Borrower or any of its Affiliates after FDA Approval. The following sales of the Initial Taletrectinib Product in the United States shall not constitute a &#x201c;Taletrectinib Sale&#x201d;: any distribution or other sale solely for so-called investigational new drug sales, clinical studies, compassionate or emergency use, named patient or single patient programs, expanded access or indigent programs, promotional samples, testing samples, donations or any similar instances where the Initial Taletrectinib Product is distributed at or below cost or supplied without charge.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Technical Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Product Related Information and, with respect to any Products or Product Commercialization and Development Activities, all related know-how, trade secrets and other proprietary or confidential information, any information of a scientific, technical, or business nature in any form or medium, Invention disclosures, all documented research, developmental, demonstration or engineering work, and all other technical data and information related thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term SOFR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	for any calculation with respect to a SOFR Loan, the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Periodic Term SOFR Determination Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that is two (2) U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day, and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	for any calculation with respect to an ABR Loan on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such day, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ABR Term SOFR Determination Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that is two (2) U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> however, that if as of 5:00 p.m. (New York City time) on any ABR Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such ABR Term SOFR Determination Day; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that if Term SOFR determined as provided above (including pursuant to the proviso under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above) shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term SOFR Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term SOFR Reference Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the forward-looking term rate based on SOFR.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person other than (a) the Borrower, (b) the Sagard Lender or (c) an Affiliate of either the Borrower or the Sagard Lender (as applicable).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Title IV Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any time within the preceding five (5) years maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has within the preceding five (5) years ever made, or was within</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the preceding five (5) years obligated to make, contributions, and (ii) that is or was subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all trade names, trademarks and service marks, logos and other indicia of origin, trademark and service mark registrations, and applications for trademark and service mark registrations, including (i) all renewals of trademark and service mark registrations and (ii) all rights whatsoever accruing thereunder or pertaining thereto throughout the world, together, in each case, with the goodwill associated therewith or symbolized thereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-1 Availability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period starting on the date of FDA Approval and ending on the Applicable Commitment Termination Date for the Tranche A-1 Commitment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-1 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to each Lender, the obligation of such Lender to make Tranche A-1 Term Loans to the Borrower on the Tranche A-1 Funding Date in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the caption &#x201c;Applicable Commitment&#x201d; for Tranche A-1 Term Loans, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Tranche A-1 Commitments on the date of this Agreement equals $50,000,000.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-1 Funding Condition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that (i) the Closing Date shall have occurred, (ii) FDA Approval shall have been received, (iii) a Borrowing Notice with respect to the Tranche A-1 Term Loans shall have been received by the Administrative Agent and (iv) each Obligor shall have instituted the policies and procedures required by the last sentence of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.07</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-1 Funding Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Tranche A-1 Commitment, the date on or prior to the expiration of the Tranche A-1 Availability Period on which all conditions precedent set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are satisfied or waived in accordance with the terms of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-1 Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.01(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-2 Availability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period starting on the Taletrectinib Sale and ending on the Applicable Commitment Termination Date for the Tranche A-2 Commitment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-2 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to each Lender, the obligation of such Lender to make Tranche A-2 Term Loans to the Borrower on the Tranche A-2 Funding Date in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the caption &#x201c;Applicable Commitment&#x201d; for Tranche A-2 Term Loans, as such Schedule may be amended from time to time pursuant to an</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment and Assumption or otherwise. The aggregate amount of Tranche A-2 Commitments on the date of this Agreement equals $50,000,000.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-2 Funding Condition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that (i) the Closing Date shall have occurred, (ii) the Taletrectinib Sale shall have occurred and (iii) a Borrowing Notice with respect to the Tranche A-2 Term Loans shall have been received by the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-2 Funding Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Tranche A-2 Commitment, the date on or prior to the expiration of the Tranche A-2 Availability Period on which all conditions precedent set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are satisfied or waived in accordance with the terms of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-2 Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.01(a)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the negotiation, preparation, execution, delivery and performance by each Obligor of this Agreement and the other Loan Documents to which such Obligor is (or is intended to be) a party, the making of the Loans hereunder, and all other transactions contemplated pursuant to this Agreement and the other Loan Documents, including the creation of the Liens pursuant to the Security Documents and (b) the payment of all fees and expenses incurred or paid by the Obligors in connection with the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any applicable jurisdictions, the Uniform Commercial Code as in effect in such jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">UK Financial Institution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any BRRD Undertaking (as such term is defined under the PRA Rulebook promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">UK Resolution Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unadjusted Benchmark Replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfunded Pension Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the excess, if any, of (a) the funding target as defined under Section 430(d) of the Code without regard to the special at-risk rules of Section 430(i) of the Code, over (b) the value of plan assets as defined under Section 430(g)(3)(A) of the Code determined as of the last day of each plan year, without regard to the averaging which may be</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allowed under Section 430(g)(3)(B) of the Code and reduced for any prefunding balance or funding standard carryover balance as defined and provided for in Section 430(f) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America, its fifty states and the District of Columbia.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Government Securities Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a &#x201c;United States Person&#x201d; within the meaning of Section 7701(a)(30) of the Code.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Tax Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(g)(ii)(B)(3)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Withholding Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the any Obligor and the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Write-Down and Conversion Powers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Yield Protection Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means with respect to any payment, termination, cancellation, redemption, repayment or prepayment (except for mandatory prepayments in connection with a Casualty Event) of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration or otherwise, or any distribution under a plan pursuant to the United States Bankruptcy Code (or the equivalent laws or regulations of any other jurisdiction), occurring (i) on or prior to the second anniversary of the funding of the Tranche A-1 Term Loans, an amount equal to the amount of interest that would have been paid on the principal amount of the Loans being so repaid or prepaid for the period from and including the date of such repayment or prepayment (excluding, for the avoidance of doubt, any interest on the Loans paid prior to such date) to but excluding the date that is the two (2) year anniversary of the funding of the Tranche</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-1 Term Loans, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">plus </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three percent (3%) of the principal amount of the Loans being so repaid or prepaid, (ii) at any time after the second anniversary of the funding of the Tranche A-1 Term Loans but on or prior to the third anniversary of the funding of the Tranche A-1 Term Loans, an amount equal to three percent (3%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid, (iii) at any time after the third anniversary of the funding of the Tranche A-1 Term Loans but on or prior to the fourth anniversary of the funding of the Tranche A-1 Term Loans, an amount equal to one percent (1%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid and (iv) if the prepayment is made after the fourth anniversary of the funding of the Tranche A-1 Term Loans, 0%.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Terms and Principles</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any definitions used in such calculations) shall be made, in accordance with GAAP. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Borrower and its Subsidiaries, in each case without duplication. If the Borrower requests an amendment to any provision hereof to eliminate the effect of (a) any change in GAAP or the application thereof or (b) the issuance of any new accounting rule or guidance or in the application thereof, in each case, occurring after the date of this Agreement, then the Lenders and Borrower agree that they will negotiate in good faith amendments to the provisions of this Agreement that are directly affected by such change or issuance with the intent of having the respective positions of the Lenders and Borrower after such change or issuance conform as nearly as possible to their respective positions as of the date of this Agreement and, until any such amendments have been agreed upon, (i) the provisions in this Agreement shall be calculated as if no such change or issuance has occurred and (ii) the Borrower shall provide to the Lenders a written reconciliation in form and substance reasonably satisfactory to the Lenders, between calculations of any baskets and other requirements hereunder before and after giving effect to such change or issuance.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the terms defined in this Agreement include the plural as well as the singular and vice versa;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	words importing gender include all genders;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	any reference to &#x201c;this Agreement&#x201d; refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	references to days, months and years refer to calendar days, months and years, respectively;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	all references herein to &#x201c;include&#x201d; or &#x201c;including&#x201d; shall be deemed to be followed by the words &#x201c;without limitation&#x201d;;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	the word &#x201c;from&#x201d; when used in connection with a period of time means &#x201c;from and including&#x201d; and the word &#x201c;until&#x201d; means &#x201c;to but not including&#x201d;;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	the words &#x201c;asset&#x201d; and &#x201c;property&#x201d; shall be construed to have the same meaning and effect and to refer broadly to any and all assets and properties, whether tangible or intangible, real or personal, including cash, securities, rights under contractual obligations and permits and any right or interest in any such assets or property;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	accounting terms not specifically defined herein (other than &#x201c;property&#x201d; and &#x201c;asset&#x201d;) shall be construed in accordance with GAAP, subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	the word &#x201c;will&#x201d; shall have the same meaning as the word &#x201c;shall&#x201d;;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	where any provision in this Agreement or any other Loan Document refers to an action to be taken by any Person, or an action which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or, to the knowledge of such Person, indirectly;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	references to any Lien granted or created hereunder or pursuant to any other Loan Document securing any Obligations shall deemed to be a Lien for the benefit of the Secured Parties; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	references to any Person shall include such Person and its successors and permitted transferees and assigns (including, in the case of any Governmental Authority, any successor Governmental Authority).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise expressly provided herein, references to organizational documents (including Organic Documents), agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents. Any definition or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reference to any Law shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any payment required to be made pursuant to the terms and conditions of any Loan Document falls due on a day which is not a Business Day (other than as described in the definition of &#x201c;Interest Period&#x201d;), then such required payment date shall be extended to the immediately following Business Day. For purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness of the Obligors and their Subsidiaries will be deemed to be equal to 100% of the outstanding principal amount thereof or payment obligations with respect thereto at the time of determination thereof, or with respect to any Hedging Agreements, the amount that would be payable if the agreement governing such Hedging Agreements were terminated on the date of termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Division</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#x2019;s laws) (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Division</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), if (a) any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its equity interests at such time.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currency Generally. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of determining compliance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with respect to the amount of any Indebtedness or Investment in a currency other than Dollars, no Default or Event of Default shall be deemed to have occurred solely as a result of changes in rates of currency exchange occurring after the time such Indebtedness or Investment is incurred, made or acquired (so long as such Indebtedness or Investment, at the time incurred, made or acquired, was permitted hereunder).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rates. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Administrative Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to ABR, the Term SOFR Reference Rate or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, ABR, the Term SOFR Reference Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions that affect the calculation of ABR, the Term SOFR Reference Rate, Term SOFR, any alternative, successor or replacement rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain ABR, the Term SOFR Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>The Commitment and The Loans</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	On the terms and subject to the conditions of this Agreement (including the satisfaction of the Applicable Funding Condition), each Lender agrees:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#x2019;s Tranche A-1 Commitment during the Tranche A-1 Availability Period in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-1 Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	to make Loans to the Borrower in a principal amount equal to the amount of such Lender&#x2019;s Tranche A-2 Commitment on a date specified by the Borrower during the Tranche A-2 Availability Period in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tranche A-2 Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	No amounts paid or prepaid with respect to any Loan may be reborrowed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Any term or provision hereof (or of any other Loan Document) to the contrary notwithstanding, Loans made to the Borrower will be denominated solely in Dollars and will be repayable solely in Dollars and no other currency.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowing Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At least [***] prior to any Applicable Funding Date (or such shorter period agreed by the Administrative Agent), the Borrower shall deliver to the Administrative Agent an irrevocable Borrowing Notice in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">signed by a Responsible Officer of the Borrower (which notice, if received by the Administrative Agent on a day that is not a Business Day or after 10:00 A.M. (Eastern time) on a Business Day, shall be deemed to have been delivered on the next Business Day). Each Borrowing Notice shall be for the full amount of each of the Applicable Commitments and no Borrowing Notice for less than such full amount shall be permitted. Notwithstanding anything herein to the contrary, the Borrower shall</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submit a Borrowing Notice with respect to the Tranche A-1 Term Loans promptly upon receipt of the FDA Approval.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding of Borrowings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Promptly following receipt of any written Borrowing Notice the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender&#x2019;s Loan to be made as part of the requested Borrowing. Each Lender shall make each Loan to be made by it hereunder on the proposed date thereof solely by wire transfer of immediately available funds, by 2:00 p.m. New York City time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the Lenders. Upon receipt of all funds the Administrative Agent will make such Loans available to the Borrower promptly by wire transfer of the amounts so received, in like funds, to an account designated by the Borrower in the applicable Borrowing Notice.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If requested by any Lender, the Loan of such Lender shall be evidenced by one or more Notes. The Borrower shall prepare, execute and deliver to the Lender such promissory note(s) substantially in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower shall use the proceeds of the Loans for (i) support of the launch activities and commercialization efforts for Taletrectinib and (ii) other working capital and general corporate purposes, including the payment of fees and expenses associated with this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defaulting Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waivers and Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Defaulting Lender&#x2019;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reallocation of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or otherwise, and including any amounts made available to the Administrative Agent by that Defaulting Lender pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), shall be applied at such time or times as may be</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determined by the Administrative Agent as follows: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">first</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the payment of any amounts owing by that Defaulting Lender to the Administrative Agent hereunder; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">second</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if so determined by the Administrative Agent and the Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of that Defaulting Lender to fund Loans under this Agreement (if any); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fourth</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against that Defaulting Lender as a result of that Defaulting Lender&#x2019;s breach of its obligations under this Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifth</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against that Defaulting Lender as a result of that Defaulting Lender&#x2019;s breach of its obligations under this Agreement; and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sixth</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to that Defaulting Lender or as otherwise directed by a court of competent jurisdiction; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, if (x) such payment is a payment of the principal amount of any Loans in respect of which that Defaulting Lender has not fully funded its appropriate share and (y) such Loans were made at a time when the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pro rata </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">basis prior to being applied to the payment of any Loans of that Defaulting Lender (which shall include, for the avoidance of doubt, any accrued but unpaid interest on the principal amount of the Loans being prepaid together with any breakage costs that may be owing pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any applicable Yield Protection Premium and the Exit Fee and other unpaid amounts then due and owing pursuant to this Agreement and the other Loan Documents). Any payments, prepayments, repayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.08(a)(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defaulting Lender Cure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Borrower and the Administrative Agent agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, that Lender will cease to be a Defaulting Lender; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender having been a Defaulting Lender.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Defaulting Lender shall be entitled to receive any upfront fee set forth in the Fee Letter for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any upfront fee that otherwise would have been required to have been paid to that Defaulting Lender).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement Setting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark Transition Event, the Administrative Agent and the Borrower may amend this Agreement to replace the then-current Benchmark with a Benchmark Replacement. Any such amendment with respect to a Benchmark Transition Event will become effective at 5:00 p.m. (New York City time) on the fifth (5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) Business Day after the Administrative Agent has posted such proposed amendment to all affected Lenders and the Borrower so long as the Administrative Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Majority Lenders. No replacement of a Benchmark with a Benchmark Replacement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will occur prior to the applicable Benchmark Transition Start Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices; Standards for Decisions and Determinations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent will promptly notify the Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Administrative Agent will notify the Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unavailability of Tenor of Benchmark</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the definition of &#x201c;Interest Period&#x201d; (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of &#x201c;Interest Period&#x201d; (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Unavailability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the Borrower&#x2019;s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrower may revoke any pending request for a SOFR Borrowing of, conversion to or continuation of SOFR Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to ABR Loans. During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of ABR based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of ABR.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inability to Determine Rates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if, on or prior to the first day of any Interest Period for any SOFR Loan:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) that &#x201c;Term SOFR&#x201d; cannot be determined pursuant to the definition thereof, or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the Majority Lenders determine that for any reason in connection with any request for a SOFR Loan or a conversion thereto or a continuation thereof that Term SOFR for any requested Interest Period with respect to a proposed SOFR Loan does not adequately and fairly reflect the cost to such Lenders of making and maintaining such Loan, and the Majority Lenders have provided notice of such determination to the Administrative Agent,</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">then, in each case, the Administrative Agent will promptly so notify the Borrower and each Lender.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon notice thereof by the Administrative Agent to the Borrower, any obligation of the Lenders to make SOFR Loans, and any right of the Borrower to continue SOFR Loans or to convert ABR Loans to SOFR Loans, shall be suspended (to the extent of the affected SOFR Loans or affected Interest Periods) until the Administrative Agent (with respect to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at the instruction of the Majority Lenders) revokes such notice. Upon receipt of such notice, (i) the Borrower may revoke any pending request for a borrowing of, conversion to or continuation of SOFR Loans (to the extent of the affected SOFR Loans or affected Interest Periods) or, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to ABR Loans in the amount specified therein and (ii) any outstanding affected SOFR Loans will be deemed to have been converted into ABR Loans at the end of the applicable Interest Period. Upon any such conversion, the Borrower shall also pay accrued interest on the amount so converted, together with any additional amounts required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) that &#x201c;Term SOFR&#x201d; cannot be determined pursuant to the definition thereof on any given day, the interest rate on ABR Loans shall be determined by the Administrative Agent without reference to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;ABR&#x201d; until the Administrative Agent revokes such determination.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Illegality</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable lending office to make, maintain or fund Loans whose interest is determined by reference to SOFR, the Term SOFR Reference Rate or Term SOFR, or to determine or charge interest based upon SOFR, the Term SOFR Reference Rate or Term SOFR, then, upon notice thereof by such Lender to the Borrower (through the Administrative Agent) (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Illegality Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (a) any obligation of the Lenders to make SOFR Loans, and any right of the Borrower to continue SOFR Loans or to convert ABR Loans to SOFR Loans, shall be suspended, and (b) the interest rate on which ABR Loans shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;ABR&#x201d;, in each case until each affected Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of an Illegality Notice, the Borrower shall, if necessary to avoid such illegality, upon demand from any Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all SOFR Loans to ABR Loans (the interest rate on which ABR Loans shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ABR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), on the last day of the Interest Period therefor, if all affected Lenders may lawfully continue to maintain such SOFR Loans to such day, or immediately, if any Lender may not lawfully continue to maintain such SOFR Loans to such day. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">amount so prepaid or converted, together with any additional amounts required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Payments of Principal and Interest, Etc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scheduled Repayments and Prepayments Generally; Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower hereby promises to pay to the Administrative Agent for the account of each Lender (as such amounts may in each case be reduced from time to time in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) on the Maturity Date, all outstanding Obligations in full (together with the Exit Fee, accrued and unpaid interest</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other accrued and unpaid charges thereon and all other obligations due and payable by the Borrower under this Agreement). Except as otherwise provided in this Agreement, each payment (including each repayment and prepayment) by the Borrower (other than fees payable pursuant to the Fee Letter) will be deemed to be made ratably in accordance with the Lenders&#x2019; Proportionate Shares and applied ratably among each tranche of the Loans. On any date occurring prior to the Maturity Date that payment or prepayment in full of the Loans hereunder occurs, the Borrower shall pay in full all outstanding Obligations, which shall include the Yield Protection Premium, if applicable, and the Exit Fee.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Generally</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Section, the outstanding principal amount of the Loans shall accrue interest from the date made to the date of repayment (whether by acceleration or otherwise and whether voluntary or mandatory) at a rate per annum equal to (i) Term SOFR for the Interest Period then in effect </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Applicable Margin or (ii) solely during and upon the occurrence of a Benchmark Transition Event, the ABR </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Applicable Margin (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Default Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the Interest Rate shall increase (i) automatically, in the case of any Event of Default under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.01(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.01(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) upon the request of the Majority Lenders, in the case of any other Event of Default, by [***] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">per annum </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the Interest Rate, as increased pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.02(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, being the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Default Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, with respect to the preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Majority Lenders may impose the Default Rate retroactively to the occurrence of such Event of Default. If any Obligation (including, without limitation, fees, costs and expenses payable hereunder) is not paid when due (giving effect to any applicable grace period) under any applicable Loan Document, the amount thereof shall accrue interest at the Default Rate.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Payment Dates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Accrued interest on the Loans shall be payable in arrears on each Payment Date applicable thereto in cash, and upon the payment or prepayment of the Loans (on the principal amount being so paid or prepaid) or in the event of any conversion of any SOFR Borrowing prior to the end of the Interest Period therefor; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that interest payable at the Default Rate shall also be payable in cash from time to time on demand by the Administrative Agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term SOFR Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the use or administration of Term SOFR, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Administrative Agent will promptly notify the Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Optional Prepayments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Subject to prior written notice pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below, the Borrower shall have the right to optionally prepay in whole, but not in part, the outstanding principal amount of the Loans (i.e., both the Tranche A-1 Term Loans and the Tranche A-2 Term Loans) on any Business Day for an amount equal to the sum of (A) the aggregate principal amount of the Loans being prepaid, (B) any accrued but unpaid interest on the principal amount of the Loans being prepaid together with any breakage costs that may be owing pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (C) any applicable Yield Protection Premium and (D) the Exit Fee and other unpaid amounts then due and owing pursuant to this Agreement and the other Loan Documents (such aggregate amount, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepayment Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	A notice of optional prepayment shall be effective only if received by the Administrative Agent not later than 2:00 p.m. (Eastern time) on a date not less than [***] (nor more than [***]) [***] prior to the proposed prepayment date; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that a notice of optional prepayment may state that such notice is conditional upon the effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness or the occurrence of some other identifiable event or condition, in which case such notice of prepayment may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified date of prepayment) if such condition is not satisfied. Each notice of optional prepayment shall specify the proposed prepayment date, the Prepayment Price, the principal amount to be prepaid, the applicable tranche or tranches to be prepaid (if a partial prepayment) and any conditions to prepayment (if applicable).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Prepayments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Prepayments for Casualty Events or Asset Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the occurrence of any Casualty Event or any Asset Sale pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for which the Net Cash Proceeds from such individual Casualty Event or Asset Sale exceeds [***], or which causes the aggregate total of Net Cash Proceeds from all such Casualty Events or Asset Sales to exceed [***], the Borrower shall make a mandatory prepayment of the Loans, together with any accrued but unpaid interest on any principal amount of the Loans being prepaid, Exit Fee and, solely with respect to an Asset Sale prepayment, any applicable Yield Protection Premium (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mandatory Prepayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which Mandatory Prepayment shall be in an amount equal to [***] percent ([***]%) of the Net Cash Proceeds received by the Borrower or any of its Subsidiaries with respect to such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event, as the case may be; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, so long as no Event of Default has occurred and is continuing or shall result therefrom, if, within [***] following the receipt of such Net Cash Proceeds a Responsible Officer of the Borrower delivers to the Administrative Agent a notice to the effect that the Borrower or the applicable Subsidiary intends to apply up to [***]of the Net Cash Proceeds from such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event, to reinvest in inventory or long-term assets of the Borrower or any of its Subsidiaries (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reinvestment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then up to [***]of such Net Cash Proceeds of such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event may be applied for such purpose in lieu of such mandatory prepayment to the extent such Net Cash Proceeds of such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event are actually applied for such purpose; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, if such Casualty Event or Asset Sale occurs with respect to any Obligor, such Reinvestment shall be made in the inventory or long-term assets of an Obligor; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, in the event that Net Cash Proceeds have not been so applied within [***] days following the receipt of such Net Cash Proceeds (such applicable period, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reinvestment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (or, if the Borrower or any of its Subsidiaries has entered into a binding commitment prior to the last day of such Reinvestment Period to reinvest such proceeds no later than [***] days following the last day of the Reinvestment Period, [***] days after the expiry of the Reinvestment Period), the Borrower shall no later than the end of such period make a Mandatory Prepayment in an aggregate amount equal to [***] percent ([***]%) of the unused balance of such Net Cash Proceeds received by any Obligor or any of its Subsidiaries with respect to such Asset Sale or insurance proceeds or condemnation awards in respect of such Casualty Event.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Prepayments for Debt Issuances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Immediately upon receipt by any Obligor or any of its Subsidiaries of proceeds from any issuance, incurrence or assumption of Indebtedness, other than Indebtedness permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on or after</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Tranche A-1 Funding Date, the Borrower shall prepay the Loans and other Obligations in an amount equal to [***]% of the cash proceeds received, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">plus </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accrued and unpaid interest on the principal amount of the Loans being prepaid</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> plus </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Yield Protection Premium, if applicable, and the Exit Fee.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower shall notify the Administrative Agent not later than 2:00 p.m. (New York City time) on a date not less than [***]  (or such shorter period agreed by the Administrative Agent) prior to the proposed prepayment date of any mandatory prepayments. Each notice of mandatory prepayment shall specify the proposed prepayment date, the amount of the Mandatory Prepayment, the principal amount to be prepaid and the subsection under which the prepayment is required. Notwithstanding anything in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the contrary, any Lender may elect, by written notice to the Administrative Agent no later than 2:00 p.m. (Eastern time), [***] prior to the mandatory prepayment date (or such later time as the Administrative Agent may agree), to decline all or any portion of any mandatory prepayment of its Loans pursuant to this</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Section 3.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Lender that fails to deliver such notice to the Administrative Agent in the time frame set forth above shall be deemed to have accepted its share of any mandatory prepayment. The aggregate amount of the prepayment that would have been applied to prepay Loans but was so declined may be retained by the Borrower and used for any general corporate purpose not prohibited by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yield Protection Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limiting the foregoing, whenever the Yield Protection Premium is in effect and payable pursuant to the terms hereof or any other Loan Document, such Yield Protection Premium shall be payable on each payment or prepayment (excluding mandatory prepayments in connection with a Casualty Event) of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All payment and prepayments shall be accompanied by accrued interest to the extent required by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any breakage costs that may be owing pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Exit Fee and, if applicable, the Yield Protection Premium.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Repatriation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding the foregoing terms of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the extent any or all of the Net Cash Proceeds of any Asset Sale by, or receipt of the Net Cash Proceeds of any Casualty Event by, a Subsidiary that is a CFC or CFC Holding Company otherwise giving rise to a prepayment pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is prohibited by any applicable local requirements of Law from being repatriated to the Borrower or any Subsidiary that is a Domestic Subsidiary including through the repayment of intercompany Indebtedness (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repatriation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;; with &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Repatriated</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; having a correlative meaning), the Borrower and its</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries shall take all commercially reasonable actions available under local Law to permit such Repatriation; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, if and to the extent any such Repatriation ceases to be prohibited, restricted or delayed by applicable local requirements of Law at any time following the date on which the applicable mandatory prepayment pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was otherwise required to be made, the Borrower shall promptly pay such previously prohibited, restricted or delayed amounts to the Lenders, which payment shall be applied in accordance with this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitment Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Applicable Commitment shall terminate automatically without further action upon the earliest of (i) the making by the Lenders of the Loans to which such Applicable Commitment relates on the Applicable Funding Date, (ii) the last day of the Applicable Availability Period and (iii) the acceleration of the Loans hereunder. The Borrower shall have the right at any time or from time to time to terminate in full (but not in part) all of the then outstanding Tranche A-2 Commitments; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Borrower shall give the Lender and the Administrative Agent at least [***] notice of each such termination. For the avoidance of doubt, the Borrower shall not have the right to voluntarily terminate the Tranche A-1 Commitments. Any notice of termination of the Tranche A-2 Commitments delivered pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.04 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may state that such notice is conditional upon the effectiveness of other credit facilities or the receipt of the proceeds from the issuance of other Indebtedness or the occurrence of some other identifiable event or condition, in which case such notice of termination may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified date of termination) if such condition is not satisfied. The termination of the Tranche A-2 Commitments shall be permanent. For the avoidance of doubt, if the Taletrectinib Sale is achieved within the Tranche A-2 Availability Period and the Borrower fails to submit a Borrowing Notice prior to the last day of the Tranche A-2 Availability Period, the Tranche A-2 Commitments shall automatically terminate without further action of any party hereto.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exit Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon any payment, termination, cancellation, distribution under a plan pursuant to the United States Bankruptcy Code (or any equivalent laws or regulations in any other jurisdiction) on account of the outstanding principal of, redemption, repayment or prepayment of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration or otherwise, including as a result of the commencement of any Insolvency Proceeding, the Borrower shall pay to each of the Lenders for its own account a fee equal to [***]% of the aggregate principal amount of such Loans to be paid or prepaid (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exit Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Exit Fee shall be earned, due and payable immediately upon any such payment, termination, cancellation, distribution, redemption, repayment or prepayment, and shall be in addition to any accrued and unpaid interest, reimbursement obligations, Yield Protection Premium or other amounts payable in connection therewith.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Original Issue Discount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower and the Lenders acknowledge that the Loans will be treated as issued with original issue discount for U.S. federal tax purposes, within the meaning</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Section 1273 of the Code, as set forth in the Fee Letter. The issue price, amount of original issue discount, issue date and yield to maturity for the Loans may be obtained by submitting a written request for such information to the Borrower care of Chief Financial Officer at [***] (which request shall also be sent via email to [***]).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Payments, Etc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments Generally</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any other Loan Document shall be made (i) in Dollars, in immediately available funds, without deduction, set off or counterclaim, to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, to the deposit account of the Administrative Agent designated by the Administrative Agent by notice to the Borrower, and (ii) not later than 2:00 p.m. (Eastern time) on the date on which such payment is due (each such payment made after such time on such due date may, in the Administrative Agent&#x2019;s discretion, be deemed to have been made on the next succeeding Business Day).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Application of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything herein to the contrary, following the occurrence and continuance of an Event of Default, all payments shall be applied as follows:</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">first</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the payment of that portion of the Obligations constituting unpaid fees, indemnities, expenses or other amounts (including fees and disbursements and other charges of counsel payable under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) payable to the Administrative Agent in its capacity as such;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">second</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the payment of that portion of the Obligations constituting unpaid fees, indemnities, costs, expenses and other amounts (other than principal and interest, but including fees and disbursements and other charges of counsel payable under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any Yield Protection Premium and any Exit Fees) payable to the Lenders arising under the Loan Documents, ratably among them in proportion to the respective amounts described in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (B) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payable to them;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(C)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans, ratably among the Lenders in proportion to the respective amounts described in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (C) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payable to them;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(D)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fourth</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the payment of that portion of the Obligations constituting unpaid principal of the Loans, ratably among the Lenders in proportion to the respective amounts described in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (D) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payable to them;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(E)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifth</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in reduction of any other Obligation then due and owing, ratably among the Administrative Agent and the Lenders based upon the respective aggregate amount of all such Obligations owing to them in accordance with the respective amounts thereof then due and payable; and</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(F)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sixth</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the balance, if any, after all Obligations have been indefeasibly paid in full, to the Borrower or such other Person as may be lawfully entitled to or directed by the Borrower to receive the remainder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Business Days</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the due date of any payment under this Agreement (whether in respect of principal, interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall continue to accrue and be payable for the period of such extension; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that if such next succeeding Business Day would fall after the Maturity Date, payment shall be made on the immediately preceding Business Day.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Computations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All computations of interest and fees hereunder shall be computed on the basis of a year of three hundred and sixty (360) days (or in the case of interest computed by reference to the ABR at times when the ABR is based on the Prime Rate, such interest shall be computed on the basis of a year of 365 days (or 366 days in a leap year)), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding principal amount of such Loan as of the applicable date of determination. The applicable ABR or Term SOFR shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest error.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Set-Off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Set-Off Generally</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the occurrence and during the continuance of any Event of Default, the Administrative Agent, each of the Lenders and each of their Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Administrative Agent, any Lender and any of their Affiliates to or for the credit or the account of any Obligor against any and all of the Obligations, whether or not such Person shall have made any demand and although such obligations may be unmatured; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, in the event that any Defaulting Lender shall</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.08</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. Any Person exercising rights of set off hereunder agrees promptly to notify the Borrower after any such set-off and application; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Administrative Agent, the Lenders and each of their Affiliates under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are in addition to other rights and remedies (including other rights of set-off) that such Persons may have.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Rights Not Required</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing contained in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.03(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall require the Administrative Agent, any Lender or any of their Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of any Obligor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments Set Aside. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any payment by or on behalf of any Obligor is made to the Administrative Agent or any Lender, or the Administrative Agent, any Lender or any Affiliate of the foregoing exercises its right of setoff pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, such Lender or such Affiliate in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any Insolvency Proceeding or otherwise, then:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Effective Rate from time to time in effect.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Yield Protection, Taxes, Etc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Law Generally</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If, on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), the adoption of any Law, or any change in any Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by the Administrative Agent or any of the Lenders (or its lending office) with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending office) or shall impose on a Lender (or its lending office) any other condition affecting the Loans or the Commitment, and the result of any of the foregoing is to increase the cost to such Lender of making or maintaining the Loans, or to reduce the amount of any sum received or receivable by such Lender under this Agreement or any other Loan Document, or subject any Lender to any Taxes on its Loan, Commitment or other obligations, or its deposits, reserves, other liabilities or capital (if any) attributable thereto by an amount reasonably deemed by such Lender in good faith to be material (other than (i) Indemnified Taxes, (ii) Taxes described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the definition of Excluded Taxes and (iii) Connection Income Taxes), then the Borrower shall pay to such Lender, within [***] of receipt of the certificate contemplated by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such additional amount or amounts as will compensate such Lender for such increased cost or reduction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Capital Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If a Lender shall have determined that, on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), the adoption of any Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender&#x2019;s obligations hereunder or the Loans to a level below that which a Lender (or its parent) could have achieved but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then the Borrower shall pay to such Lender, within [***] of receipt of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the certificate contemplated by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notification by Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Lender promptly will notify the Borrower of any event of which it has knowledge, occurring after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), which will entitle such Lender to compensation pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Before giving any such notice pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01(c) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such Lender shall designate a different lending office if such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such Lender. A certificate of such Lender claiming compensation under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, setting forth the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on the Borrower in the absence of manifest error. The Borrower shall not be required to compensate a Lender pursuant to the foregoing provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any increased costs incurred or reductions suffered more than six (6) months prior to the date that such Lender notifies the Borrower of the change in law giving rise to such increased costs or reductions and of such Lender&#x2019;s intention to claim compensation therefor (except that, if the change in law giving rise to such increased costs or reductions is retroactive, then the six-month period referred to above shall be extended to include the period of retroactive effect thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a change in Law for all purposes of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, regardless of the date enacted, adopted or issued.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation for Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of (a) the payment of any principal of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (b) the conversion of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default) or (c) the failure to borrow, convert, continue or prepay any SOFR Loan on the date specified in any notice delivered pursuant hereto, then, in any such event, the Borrower shall compensate each Lender for any loss, cost and expense attributable to such event, including any loss, cost or expense arising from the liquidation or redeployment of funds or from any fees payable. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive pursuant to this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within [***] days after receipt thereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For purposes of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the term &#x201c;applicable Law&#x201d; includes FATCA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments Free of Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any Taxes, except as required by any Law. If any Law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Laws and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding for Indemnified Taxes been made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Other Taxes by the Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable Laws, or at the option of the Administrative Agent or each Lender, timely reimburse it for the payment of any Other Taxes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evidence of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As soon as practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification by the Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower shall reimburse and indemnify each Recipient, within [***] days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification by the Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Lender shall severally indemnify the Administrative Agent, within [***] days after demand therefor, for (i) any Indemnified Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (ii) any Taxes attributable to such Lender&#x2019;s failure to comply with the provisions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> relating to the maintenance of a Participant Register, and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Status of Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by Law as reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two (2) sentences, the completion, execution and submission of such documentation (other than such documentation set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(g)(ii)(A), 5.03(g)(ii)(B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.03(g)(ii)(D)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) shall not be required if in such Lender&#x2019;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person:</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A)	any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 (or successor form) certifying that such Lender is exempt from U.S. federal backup withholding tax;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)	any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;interest&#x201d; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;business profits&#x201d; or &#x201c;other income&#x201d; article of such tax treaty;</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	executed copies of IRS Form W-8ECI (or successor form);</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-1 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the effect that such Foreign Lender is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, a &#x201c;10 percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Tax Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms); or</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY (or successor form), accompanied by IRS Form W-8ECI (or successor form), IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form), a U.S. Tax Compliance Certificate, substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-2 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IRS Form W-9 (or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successor form), and/or other certification documents from each beneficial owner, as applicable; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D-4 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on behalf of each such direct and indirect partner.</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(C)	any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Laws as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Laws to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(D)	if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#x2019;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (D)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#x201c;FATCA&#x201d; shall include any amendments made to FATCA after the date of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment of Certain Tax Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any party to this Agreement determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been indemnified pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(including by the payment of additional amounts pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	The parties hereto hereby agree that for U.S. federal and applicable state and local income Tax purposes the transactions contemplated by this Agreement will not be aggregated with the Revenue Interest Financing under Treas. Reg. Section 1.1275-2(c).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mitigation Obligations; Replacement of Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="docxtextref281"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	If the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then such Lender shall (at the request of the Borrower) use commercially reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) eliminate or reduce amounts payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	If any Lender requests compensation pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and such Lender has declined or is unable to designate a different lending office in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.04(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or if any Lender is a Defaulting Lender, then the Borrower may, at the Borrower&#x2019;s sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (other than such Lender&#x2019;s consent)), all of its interests, rights (other than its existing rights to payments pursuant to</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Section &#x200e;5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and obligations under this Agreement and the related Loan Documents to an Eligible Transferee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that: (i) the Borrower shall have provided all of the documentation and information in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (ii) such Lender shall have received payment of an amount equal to (A) the outstanding principal of its Loans, (B) accrued interest thereon, (C) accrued fees, (D) any Yield Protection Premium and any Exit Fees, as applicable and (E) all other amounts payable to it hereunder and under the other Loan Documents from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); (iii) in the case of any such assignment resulting from a claim for compensation under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or payments required to be made pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section &#x200e;5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such assignment will result in a reduction in such compensation or payments thereafter; and (iv) such assignment does not conflict with applicable Law. No Lender shall be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party&#x2019;s obligations under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Conditions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to the Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The occurrence of the Closing Date is subject to the prior or concurrent satisfaction or waiver of each of the conditions precedent set forth below in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> subject, in each case, to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received each Loan Document required to be executed by the appropriate Obligor on the Closing Date and delivered by each applicable Obligor in such number as reasonably requested by the Administrative Agent (which may be delivered by facsimile or other electronic means for the purposes of satisfying this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on the Closing Date) and such Loan Documents shall be in form and substance satisfactory to the Administrative Agent and the Lenders and their respective counsels.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretary&#x2019;s Certificate, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Administrative Agent shall have received from each Obligor (x) a copy of a good standing certificate in its jurisdiction of organization or incorporation and all other jurisdictions in which the nature of the business conducted by it makes such qualification necessary, dated a date reasonably close to the Closing Date, for each such Person and (y) a certificate, dated as of the Closing Date, duly executed and delivered by such Person&#x2019;s Responsible Officer, as to:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	resolutions of each such Person&#x2019;s Board then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the Transactions and, in relation to the Cayman Guarantor, a resolution of its shareholders authorizing the execution, delivery and performance of the Guaranty;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	the incumbency and signatures of Responsible Officers authorized to execute and deliver each Loan Document to be executed by such Person;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	the full force and validity of each Organic Document of such Person and copies thereof; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	in relation to the Cayman Guarantor, the full force and validity of its statutory registers (including as applicable its Register of Members, Register of Directors and Officers, and its Register of Mortgages and Charges);</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon which certificates shall be in form and substance reasonably satisfactory to the Administrative Agent and upon which the Administrative Agent and the Lenders may conclusively rely until they shall have received a further certificate of the Responsible Officer of any such Person cancelling or amending the prior certificate of such Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a fully completed Information Certificate in form and substance reasonably satisfactory to the Administrative Agent, dated as of the Closing Date, duly executed and delivered by a Responsible Officer of the Borrower. All documents and agreements required to be appended to the Information Certificate, shall be in form and substance reasonably satisfactory to the Administrative Agent, shall have been executed and delivered by the requisite parties and shall be in full force and effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Information, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Administrative Agent shall have received, or such information shall be publicly available on &#x201c;EDGAR,&#x201d; the (i) audited consolidated financial statements of the Borrower and its Subsidiaries for the fiscal year ended December 31, 2024 and (ii) consolidated financial statements of the Borrower and its Subsidiaries for the fiscal quarter and the 9-month period ended September 30, 2024.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solvency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a solvency certificate, substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, duly executed and delivered by the chief financial officer of the Borrower, dated as of the Closing Date, in form and substance reasonably satisfactory to the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received (i) the Security Agreement and the Cayman Security Document in form and substance reasonably acceptable to the Administrative Agent, dated as of the Closing Date, duly executed and delivered by each Obligor and (ii) all documents (including share certificates, transfers and stock transfer forms or certificates, notices, proxies or powers of attorney, directors letters of resignation and authorization, undertakings, deeds, letters, resolutions or any other instruments) required to be delivered or filed under the Security Documents and evidence satisfactory to it that arrangements have been made with respect to all registrations, notices or actions required under the Security Documents to be effected, given or made in order to establish a valid and perfected first priority security interest in the Collateral in accordance with the terms of the Security Documents, including:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	delivery of all certificates (in the case of Equity Interests that are certificated securities (as defined in the UCC)) evidencing the issued and outstanding capital securities owned by each Obligor that are required to be pledged and so delivered under the Security Agreement, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, in the case of Equity Interests that are uncertificated securities (as defined in the UCC), confirmation and evidence reasonably satisfactory to the Administrative Agent and the Lenders that the security interest required to be pledged therein under the Security Agreement has been transferred to and perfected by the Administrative Agent and the Lenders in accordance with Articles 8 and 9 of the NY UCC and all laws otherwise applicable to the perfection of the pledge of such Equity Interests;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	financing statements naming each Obligor as a debtor and the Administrative Agent as the secured party, or other similar instruments or documents, in each case suitable for filing, filed under the UCC (or equivalent law) of all jurisdictions as may be necessary or, in the opinion of the Administrative Agent, desirable to perfect the Liens of the Secured Parties pursuant to the Security Agreement;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	UCC-3 termination statements, if any, necessary to release all Liens and other rights of any Person in any collateral described in the Security Agreement previously granted by any Person;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	all applicable Short-Form IP Security Agreements required to be provided under the Security Agreement, each dated as of the Closing Date, duly executed and delivered by each applicable Obligor; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	the Intercompany Subordination Agreement or such other subordination agreement in form and substance reasonably satisfactory to the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lien Searches</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall be satisfied with Lien searches regarding the Borrower and the Subsidiary Guarantors made as of a date reasonably close to the Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinions of Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a duly executed legal opinion of counsel to the Obligors in each applicable jurisdiction of organization dated as of the Closing Date, in form and substance reasonably acceptable to the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fee Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received an executed counterpart of the Fee Letter, duly executed and delivered by the Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Fees, Expenses, Etc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Administrative Agent and each Lender shall have received for its own account, all fees, costs and expenses due and payable to it pursuant to the Fee Letter and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(and subject to the limitations and cap set forth therein), including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent&#x2019;s and the Lenders&#x2019; legal fees and expenses), in each case, (A) to the extent invoiced (or as to which a good faith estimate has been provided to the Borrower) at least one (1) Business Day prior to the Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Since December 31, 2024, no event, circumstance or change shall have occurred that has caused or could reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Change, both before and after giving effect to the Loans to be made on the Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Know Your Customer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received, as applicable, all documentation and other information required by bank regulatory authorities under applicable &#x201c;know your customer&#x201d; and Anti-Terrorism Laws, and a duly executed W-9 (or other applicable tax form) of the Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No event shall have occurred or be continuing that would constitute a Default or Event of Default.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The representations and warranties contained in this Agreement and in the other Loan Documents delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be true and correct in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the Closing Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Liquidity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received written evidence reasonably satisfactory to it that, as of the Closing Date, the Borrower is in compliance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There shall be no material pending or threatened (in writing) litigation or other proceedings (private or governmental) with respect to any Obligor or any such Subsidiaries (i) which pertain to the Transactions or (ii) individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect, except any such litigation or proceeding previously disclosed and acceptable to the Administrative Agent in its sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beneficial Ownership Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent requested by any Lender or the Administrative Agent, the Borrower shall have provided to such Lender and the Administrative Agent all documentation and other information so requested, including a duly executed W-9 of the Borrower (or such other applicable tax form), in connection with applicable &#x201c;know your customer&#x201d; and anti-money laundering rules and regulations, including the Patriot Act, and if the Borrower qualifies as a &#x201c;legal entity customer&#x201d; under the Beneficial Ownership Regulation, a Beneficial Ownership Certification, in each case prior to the Closing Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to the Borrowing of Tranche A-1 Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligation of each Lender to make the Tranche A-1 Terms Loans shall be subject to the delivery of a Borrowing Notice as required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.02, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the prior or concurrent satisfaction or waiver of each of the conditions precedent set forth below in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A-1 Funding Condition and Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Tranche A-1 Funding Condition shall have been satisfied and the Administrative Agent shall have received a Funding Date Certificate during the Tranche A-1 Availability Period, dated as of the Tranche A-1 Funding Date, duly executed and delivered by a Responsible Officer of the Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a Note to the extent requested by any Lender pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.05 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the Loans made on such Tranche A-1 Funding Date duly executed and delivered by a Responsible Officer of the Borrower.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solvency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a solvency certificate, substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, duly executed and delivered by the chief financial officer of the Borrower, dated as of the Tranche A-1 Funding Date, in form and substance reasonably satisfactory to the Administrative Agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fees, Expenses, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the Administrative Agent and each Lender shall have received for its own account (i) the upfront fee as set forth in the Fee Letter, which shall be paid by way of the Administrative Agent retaining such amount from the proceeds of the Loan and (ii) all fees, costs and expenses due and payable to it on or prior to the Tranche A-1 Funding Date pursuant to the Fee Letter and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent&#x2019;s and the Lenders&#x2019; legal fees and expenses) in each case, to the extent invoiced (or as to which a good faith estimate has been provided to the Borrower) at least one (1) Business Day prior to the Tranche A-1 Funding Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Since December 31, 2024, no event, circumstance or change shall have occurred that has caused or would reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Change, both before and after giving effect to the Loans to be made on the Tranche A-1 Funding Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No event shall have occurred or be continuing or would result from the making of the Loans on the Tranche A-1 Funding Date that would constitute a Default or Event of Default.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties; Updated Schedules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The representations and warranties contained in this Agreement and in the other Loan Documents delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be true and correct in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the Tranche A-1 Funding Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date. The Borrower shall have delivered to the Administrative Agent updated copies of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedules 7.06(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.17</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the extent required to satisfy the foregoing requirements set forth in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.02(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Liquidity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received written evidence reasonably satisfactory to it that, as of the Tranche A-1 Funding Date, the Borrower is in compliance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to the Borrowing of Tranche A-2 Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligation of each Lender to make the Tranche A-2 Terms Loans shall be subject to the delivery of a Borrowing Notice as required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the prior or concurrent satisfaction or waiver of each of the conditions precedent set forth below in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A-2 Funding Condition and Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Tranche A-2 Funding Condition shall have been satisfied and the Administrative Agent shall have received a Funding Date Certificate during the Tranche A-2 Availability Period, dated as of the Tranche A-2 Funding Date, duly executed and delivered by a Responsible Officer of the Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a Note to the extent requested by any Lender pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.05 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the Loans made on such Tranche A-2 Funding Date duly executed and delivered by a Responsible Officer of the Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solvency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received a solvency certificate, substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, duly executed and delivered by the chief financial officer of the Borrower, dated as of the Tranche A-2 Funding Date, in form and substance reasonably satisfactory to the Administrative Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fees, Expenses, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the Administrative Agent and each Lender shall have received for its own account (i) the upfront fee as set forth in the Fee Letter, which shall be paid by way of the Administrative Agent retaining such amount from the proceeds of the Loan and (ii) all fees, costs and expenses due and payable to it on or prior to the Tranche A-2 Funding Date pursuant to the Fee Letter and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent&#x2019;s and the Lenders&#x2019; legal fees and expenses) in each case, to the extent invoiced (or as to which a good faith estimate has been provided to the Borrower) at least one (1) Business Day prior to the Tranche A-2 Funding Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Since December 31, 2024, no event, circumstance or change shall have occurred that has caused or would reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Change, both before and after giving effect to the Loans to be made on the Tranche A-2 Funding Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No event shall have occurred or be continuing or would result from the making of the Loans on the Tranche A-2 Funding Date that would constitute a Default or Event of Default.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties; Updated Schedules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The representations and warranties contained in this Agreement and in the other Loan Documents delivered pursuant to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be true and correct in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the Tranche A-2 Funding Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date. The Borrower shall have delivered to the Administrative Agent updated copies of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedules 7.06(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.17 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the extent required to satisfy the foregoing requirements set forth in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.03(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Liquidity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall have received written evidence reasonably satisfactory to it that, as of the Tranche A-2 Funding Date, the Borrower is in compliance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Representations and Warranties</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Borrower and each other Obligor hereby jointly and severally represents and warrants to the Administrative Agent and each Lender on the Closing Date and each Bringdown Date, as set forth below:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Power and Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Obligor and each of its Subsidiaries (i) is duly organized or incorporated (as applicable) and validly existing under the laws of its jurisdiction of organization or incorporation, (ii) has all requisite corporate or other power, and has all Governmental Approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted, except to the extent that failure to have the same could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (iii) is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such qualification necessary except where failure so to qualify could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and (iv) has full power, authority and legal right to enter into and perform its obligations under each of the Loan Documents to which it is a party and, in the case of the Borrower, to borrow the Loans hereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorization; Enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Transaction to which an Obligor is a party (or to which it or any of its assets or properties is subject) are within such Obligor&#x2019;s corporate or other organizational powers and have been duly authorized by all necessary corporate or other organizational action including, if required, approval by all necessary holders of Equity Interests. This Agreement has been duly executed and delivered by each Obligor and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors&#x2019; rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental and Other Approvals; No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None of the execution, delivery and performance by each Obligor of the Loan Documents to which it is a party or the consummation by each Obligor of the Transactions (i) requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (x) such as have been obtained or made and are in full force and effect, (y) filings and recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents and (z) filings required under applicable securities laws, (ii) will violate (1) any Law, (2) any Organic Document of any Obligor or any of its Subsidiaries or (3) any order of any Governmental Authority, that in the case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)(1) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)(3)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect, (iii) will violate or result in a default under any Material Agreement binding upon any Obligor or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect or (iv) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of any Obligor or any of its Subsidiaries.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements; Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower has heretofore furnished to the Administrative Agent (who shall forward to the Lenders) consolidated financial statements required to be delivered pursuant to this Agreement. Such financial statements present fairly, in all material respects, the consolidated financial position and results of operations and cash flows of the Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP, subject (in the case of financial statements delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01(d)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to year-end audit adjustments and the absence of footnotes in the case of the statements of the type described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Since [***], no event, circumstance or change has occurred that has caused or could reasonably be expected to cause, individually or in the aggregate, a Material Adverse Change.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Properties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property Generally</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Obligor and each of its Subsidiaries has good and marketable fee simple title to, or valid leasehold interests in, or license to, all its real and personal property material to its business, including all properties and assets, whether tangible or intangible, necessary or required with respect to its Products or Product Commercialization and Development</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activities and all Material Intellectual Property, subject only to Permitted Liens and except for defects in title that (i) do not interfere in any material respect with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes and (ii) could not reasonably be expected to prevent or interfere with the ability of any Obligor or any of its Subsidiaries to conduct any Product Commercialization and Development Activities with respect to Taletrectinib in any material respect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Except as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.05(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A)	the Obligors are the sole and exclusive legal and beneficial owners of all right, title and interest in and to all Material Intellectual Property, in each case, that is owned or purported to be owned by such Obligor, free and clear of:</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	any Claims that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Taletrectinib, or</font></p>
  <p style="margin-left:20%;text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	any Liens other than Permitted Liens; and</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)	the Obligors own or have sufficient and valid rights to use all Material Intellectual Property required or necessary to conduct the businesses of the Borrower and its Subsidiaries as currently conducted and planned to be conducted, including the Product Commercialization and Development Activities with respect to Taletrectinib (other than Material Intellectual Property solely related to the Product Commercialization and Development Activities with respect to Taletrectinib exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China).</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	Without limiting </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.05(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and except as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.05(b)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A)	other than (1) customary restrictions in in-bound licenses of Material Intellectual Property and non-disclosure agreements, or (2) as would have been or is permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there are no judgments, licenses, covenants not to sue, grants, Liens (other than Permitted Liens), or other Claims, agreements or arrangements relating to any Material Intellectual Property, which materially restrict Borrower or any of its Subsidiaries with respect to its use, enforcement, or other exploitation of any Material Intellectual Property in connection with such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person&#x2019;s Product Commercialization and Development Activities with respect to Taletrectinib (other than such judgments, licenses, covenants not to sue, grants, Liens other Claims which restrict the use, enforcement, other exploitation of Material Intellectual Property solely related to the Product Commercialization and Development Activities with respect to Taletrectinib exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China);</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)	the operation and conduct of the business of the Borrower or any of its Subsidiaries as currently conducted or as proposed to be conducted, including the exploitation of Material Intellectual Property in such Person&#x2019;s Ordinary Course or in connection with the proposed commercialization of Taletrectinib (other than solely related to the exploitation of Intellectual Property in connection with the commercialization of Taletrectinib exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China) does not violate, infringe or constitute a misappropriation of any valid rights arising under any Intellectual Property of any other Person in any material respect;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(C)	(1) there are no pending Claims, or Claims threatened in writing, against Borrower or any of its Subsidiaries asserted by any other Person relating to any of such Person&#x2019;s Intellectual Property, including any Claims of adverse ownership, invalidity, infringement, misappropriation, or violation of such Person&#x2019;s Intellectual Property, in each case which are material in any respect; and (2) neither Borrower nor any of its Subsidiaries has received any notice from, or Claim by, any Person that the operation and conduct of the business of the Borrower or any of its Subsidiaries (including their exploitation of Material Intellectual Property), or any Product Commercialization and Development Activities with respect to Taletrectinib (other than Claims solely related to the Product Commercialization and development Activities with respect to Taletrectinib exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China), infringes upon, violates or constitutes a misappropriation of, any Intellectual Property of any other Person;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(D)	to the knowledge of the Obligors, no Material Intellectual Property is being infringed, violated or misappropriated by any other Person in any material respect, neither Borrower nor any of its Subsidiaries has put any other Person on notice of such actual or potential infringement, violation or misappropriation of any such Material Intellectual Property or initiated the enforcement of any Claim with respect to any such Material Intellectual Property;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(E)	to the knowledge of the Obligors, all current and former employees and contractors that have developed Material Intellectual Property for or on behalf</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Borrower or any of its Subsidiaries have executed written confidentiality and invention assignment Contracts with Borrower or such Subsidiary, as applicable, that irrevocably and presently assign to Borrower or such Subsidiary, as applicable, or its designee all rights of such employees and contractors in or to any such Material Intellectual Property, except as would vest initially in the Obligor or its Subsidiary by operation of Law;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(F)	Borrower and each of its Subsidiaries has taken reasonable precautions to protect the secrecy, confidentiality and value of its Material Intellectual Property consisting of trade secrets and confidential information; and</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(G)	(1) all maintenance fees, annuities, and the like due or payable on the Patents within the Material Intellectual Property have been timely paid or the failure to so pay was the result of an intentional decision by the applicable Obligor or licensor, and (2) all documents and instruments necessary to register or apply for or renew registration of all Patents, Trademarks and Copyrights within the Material Intellectual Property have been validly executed, delivered and filed in a timely manner with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, in each case, which would not reasonably be expected to result in (x) a Material Adverse Event or (y) a material adverse effect on Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	With respect to Material Intellectual Property consisting of Patents, except as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.05(b)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and without limiting the representations and warranties in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.05(b)(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.05(b)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A)	to the knowledge of the Obligors, each of the issued claims in such Patents is valid and enforceable, and, neither Borrower nor any of its Subsidiaries has received any notice asserting that any such Patent or any issued claims therein is invalid or unenforceable;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)	subsequent to the issuance of such Patents, neither Borrower nor any of its Subsidiaries or, to the knowledge of the Obligors, any of its predecessors-in-interest, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of the Inventions claimed in such Patents;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(C)	to the knowledge of the Obligors, (1) no allowable or allowed subject matter of such Patents is subject to any competing conception claims of allowable or allowed subject matter of any patent applications or patents of any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third party or has been the subject of any interference, re-examination, opposition, or any other post-grant proceedings, and (2) there is no basis for any such interference, re-examination, opposition, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, post grant review, or any other post-grant proceedings;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(D)	all maintenance fees, annuities, and the like due or payable on or with respect to any such Patents have been timely paid.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	None of the Obligors or any of their respective Subsidiaries is conducting any Product Commercialization and Development Activities with respect to any combination product, including any antibody drug conjugate, or any combination product that otherwise conjugates, combines, or otherwise contains Taletrectinib.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Actions or Proceedings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no litigation, investigation or proceeding pending or, to the knowledge of any Obligor threatened in writing, with respect to such Obligor or any such Subsidiaries by or before any Governmental Authority or arbitrator that, (i) individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or (ii) involves this Agreement or any other Loan Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except with respect to any matters that (either individually or in the aggregate) could not reasonably be expected to result in a Material Adverse Effect, no Obligor nor any of its Subsidiaries (i) has failed to comply with any Environmental Law in all material respects or to obtain, maintain or comply with any material permit, license or other approval required under any Environmental Law, (ii) has become subject to any Environmental Liability, (iii) has received any material Environmental Claim, or has knowledge that any is threatened, (iv) has entered into any agreement in which such Obligor or any Subsidiary has assumed or undertaken responsibility or obligations of any other person with respect to any Environmental Liability or (v) has knowledge of any basis for any other Environmental Liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Labor Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Obligor or any of its Subsidiaries has engaged in unfair labor practices as defined in 29 U.S.C. &#167; &#167;152(8) and 158 of the National Labor Relations Act and there are no pending or threatened in writing labor actions, disputes, grievances, arbitration proceedings, or similar Claims or actions involving the employees of any Obligor or any of its Subsidiaries, in each case, that could reasonably be expected to have a Material Adverse Effect. There are no strike or work stoppages in existence or threatened in writing against any Obligor and to the knowledge of such Obligor, no union organizing activity is taking place, in each case, that could reasonably be expected to have a Material Adverse Effect. Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.06(c) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">schedule may be updated on any Bringdown Date), there are no collective bargaining agreements covering employees of any Obligor or any of its Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Laws and Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Each Obligor is in compliance with all Laws and all Contracts binding upon it or its property, except where the failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Default has occurred and is continuing. The Obligors and their Subsidiaries are, and all Product Commercialization and Development Activities of such Persons are being conducted in compliance with all applicable Healthcare Laws (i) as of the Closing Date, in all material respects and (ii) as of the each Bringdown Date, except where the failure to do so could not reasonably be expected to result in a Material Adverse Effect or a material adverse effect on any Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	To the knowledge of the Obligors, any physician, other licensed healthcare professional, or any other Person who is in a position to refer patients or other business to the Borrower, any other Obligor or any Subsidiaries (collectively, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Referral Source</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) who has a direct ownership, investment, or financial interest in the Borrower, any other Obligor or any such Subsidiary paid fair market value for such ownership, investment or financial interest; any ownership or investment returns distributed to any Referral Source is in proportion to such Referral Source&#x2019;s ownership, investment or financial interest; and no preferential treatment or more favorable terms were or are offered to such Referral Source compared to investors or owners who are not in a position to refer patients or other business. No Obligor, nor any of its Subsidiaries, directly or indirectly, has or will guarantee a loan, make a payment toward a loan or otherwise subsidize a loan for any Referral Source including, without limitation, any loans related to financing the Referral Source&#x2019;s ownership, investment or financial interest in the Borrower, any other Obligor or any such Subsidiary, except to the extent such arrangement fully complies with an available exception or safe harbor to the Federal Anti-Kickback Statute, the Stark Law and all other applicable anti-kickback and self-referral laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Without limiting the generality of the foregoing:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Except where the failure to do so could not reasonably be expected to have any Material Adverse Effect or material adverse effect on any Product Commercialization and Development Activities with respect to Taletrectinib, to the knowledge of the Obligors, (a) each transaction with a Referral Source complies with the Federal Anti-Kickback Statute, the Stark Law and all other applicable anti-kickback and self-referral laws, whether U.S. or non-U.S.; (b) the transactions between the Borrower or any of its Subsidiaries and each Referral Source reflect fair market value, have commercially reasonable terms, and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were negotiated in an Arm&#x2019;s Length Transaction; and (c) the Borrower and its Subsidiaries do not obligate the Referral Source to purchase, use, recommend or arrange for the use of any products or services of any Obligor or any of its Subsidiaries; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	each Obligor and each of its Subsidiaries shall have implemented prior to the date that is one hundred and eighty (180) days following FDA Approval policies and procedures to monitor, collect, and report any payments or transfers of value to certain healthcare providers and teaching hospitals, in accordance, in all material respects, with industry standards and the Physician Payments Sunshine Act and their implementing regulations and state disclosure and transparency laws.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.08</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, each Obligor and its Subsidiaries has timely filed or caused to be filed all tax returns and reports required to have been filed and has paid or caused to be paid all taxes required to have been paid by it, except (a) taxes that are being contested in good faith by appropriate proceedings and for which such Obligor or such Subsidiary, as applicable, has set aside on its books adequate reserves with respect thereto in accordance with GAAP or (b) to the extent that the failure to do so would not reasonably be expected to have an Material Adverse Effect.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Full Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None of the reports, financial statements, certificates or other written information (other than projections, forward-looking information and information of a general economic or industry specific nature) furnished by or on behalf of the Obligors or any of their Subsidiaries to the Administrative Agent (on behalf of itself and the Lenders) in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished by or on behalf of the Obligors or any of their Subsidiaries, and Borrower&#x2019;s filings publicly available on &#x201c;EDGAR&#x201d;) contains when furnished any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not materially misleading; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time delivered, and it being understood that such projected financial information and all other forward looking information are not to be viewed as facts and are subject to significant uncertainties and contingencies, many of which are beyond the control of the Borrower or any of its Subsidiaries, including whether or not the Borrower will receive FDA Approval, and that actual results during the period or periods covered thereby may differ significantly from such projected results and that the differences may be material. Except as set forth in the Schedules to this Agreement, and made available to the Administrative Agent at least two (2) Business Days prior to the date of this Agreement, or as disclosed by the Borrower in writing to the Administrative Agent at least two (2) Business Days prior to the date of this Agreement, the Borrower has no knowledge of any fact or circumstance (other than general</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic or industry conditions) that could reasonably be expected to (a) have a Material Adverse Effect, or (b) materially and adversely affect Taletrectinib or the Product Commercialization and Development Activities with respect to Taletrectinib, including the receipt of Regulatory Approval and the proposed commercialization of Taletrectinib following receipt of Regulatory Approval.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Company Act and Margin Stock Regulation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Company Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Obligor is an &#x201c;investment company&#x201d; as defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Obligor is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the Loans will be used, whether immediately, incidentally or ultimately, to buy or carry any Margin Stock, to extend credit to others for the purpose of buying or carrying any Margin Stock, or in any way that is in violation of Regulation T, U or X.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solvency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Obligors, on a consolidated basis, are (a) on the Closing Date, immediately after giving effect to the consummation of the relevant Transactions, and (b) on each Applicable Funding Date, immediately after giving effect to the making of the relevant Loans, the use of proceeds thereof, and the consummation of the relevant Transactions, in each case, will be, Solvent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.12.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.12 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a complete and correct list of all direct and indirect Subsidiaries of the Borrower (as such schedule may be updated on any Bringdown Date). Each such Subsidiary is duly organized and validly existing under the jurisdiction of its organization shown in said </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the percentage ownership by each Obligor of each such Subsidiary thereof is as shown in said </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.14.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no Obligor nor any of its Subsidiaries is in material default or breach under any Material Agreement, nor does any Obligor have knowledge of (i) any Claim against it or any of its Subsidiaries for any material default or breach of any such Material Agreement or (ii) any material default or breach by any party to any such Material Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.15.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as of the Closing Date, no Obligor or any of its Subsidiaries is subject to any Restrictive Agreement, except (i) those permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) restrictions and conditions imposed by Law or by this Agreement, (iii) any stockholder agreement, shareholder agreement, charter, by-laws,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">memorandum and articles of association, or other organizational documents of an Obligor or any of its Subsidiaries as in effect on the date hereof and (iv) limitations associated with Permitted Liens.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.16.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Real Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.16 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">correctly sets forth all real property that is owned or leased by the Obligors (as such schedule may be updated on any Bringdown Date), indicating in each case whether the respective property is owned or leased, the identity of the owner and lessee (if applicable) and the location of the respective property. Except as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.16 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as such schedule may be updated on any Bringdown Date), no Obligor owns or leases (as tenant thereof) any real property as of the Closing Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.17.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pension Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.17 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sets forth (as such schedule may be updated on any Bringdown Date), a complete and correct list of, and that separately identifies, (i) all Title IV Plans, and (ii) all Multiemployer Plans. Each Qualified Plan, and each trust thereunder, has received a favorable determination or may rely upon an opinion letter for a prototype plan letter from the IRS and, as of the date of this Agreement, to the knowledge of the Obligors, nothing has occurred that would reasonably be expected to prevent, or cause the loss of, such qualification. Except for those that could not, in the aggregate, reasonably be expected to result in a Material Adverse Effect, (x) each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Laws, (y) there are no existing or pending (or to the knowledge of any Obligor, threatened) claims (other than routine claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which any Obligor or Subsidiary thereof incurs or otherwise has or could have an obligation or any liability or Claim and (z) no ERISA Event has occurred or is reasonably expected to occur. The Borrower and each of its ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. No Title IV Plan has any Unfunded Pension Liability.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.18.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Each Obligor and each of its Subsidiaries holds, either directly or through licensees and agents, all Product Authorizations necessary or required for the Borrower and each of its Subsidiaries to conduct, in all material respects, their respective operations and businesses as currently conducted and planned to be conducted, including its material Product Commercialization and Development Activities with respect to Taletrectinib as currently conducted and planned to be conducted.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	No Obligor nor its Subsidiaries has received any written notice from the FDA or any Governmental Authority that (i) it is considering suspending, revoking or materially limiting or delaying any Material Product Authorization or (ii) it is not likely to approve any applications</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made to such Governmental Authority with respect to any of the Products. To the knowledge of the Obligors, the Obligors and their Subsidiaries have made all required notices, registrations and reports (including field alerts or other reports of adverse drug experiences) and other filings with respect to Taletrectinib and its Product Commercialization and Development Activities with respect to Taletrectinib, in each case, which are material.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.18(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and without limiting the generality of any other representation or warranty made by any Obligor hereunder or under any other Loan Document: (i) no Obligor, nor any of its Subsidiaries nor, to the knowledge of any Obligor, any of their respective agents, suppliers, licensors or licensees have received any inspection reports, clinical holds, warning letters, untitled letters or notices or similar documents with respect to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib from any Regulatory Authority within the last [***] that asserts material lack of compliance with any applicable Healthcare Laws or Material Product Authorizations; (ii) no Obligor, nor any of its Subsidiaries nor, to the knowledge of any Obligor, any of their respective agents, suppliers, licensors or licensees have received any material notification from any Regulatory Authority within the last [***], asserting that Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib lacks a Material Product Authorization; (iii) to the knowledge of the Obligors there is no pending regulatory action, investigation or inquiry (other than non-material routine or periodic inspections or reviews) against any Obligor, any of its Subsidiaries or any of their respective suppliers, manufacturers, licensors or licensees with respect to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib, and, to the knowledge of any Obligor, there is no basis in fact for any material adverse regulatory action against such Obligor or any of its Subsidiaries or, to the knowledge of any Obligor, any of their respective suppliers, manufacturers, agents, licensors or licensees with respect to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib; and (iv) without limiting the foregoing, (A)(1) there have been no material product recalls, safety alerts, corrections, withdrawals, removals or the like conducted, undertaken or issued by any Obligor or any of its Subsidiaries, whether voluntary, at the request, demand or order of any Regulatory Authority or otherwise, with respect to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib within the last [***], (2) no such product recall, safety alert, correction, withdrawal, removal or the like has been requested, demanded or ordered by any Regulatory Authority with respect to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib within the last [***], and, to the knowledge of any Obligor, there is no basis in fact for the issuance of any such product recall, safety alert, correction, withdrawal, removal or the like with respect to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib, and (B) no criminal, injunctive, seizure, detention or civil penalty action has been commenced or threatened in writing by any Regulatory Authority within the last [***] with respect to Taletrectinib or any Product Commercialization and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Activities with respect to Taletrectinib, and there are no consent decrees (including plea agreements) that relate to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib, and, to the knowledge of each Obligor, there is no basis in fact for the commencement of any criminal injunctive, seizure, detention or civil penalty action by any Regulatory Authority relating to Taletrectinib or any Product Commercialization and Development Activities with respect to Taletrectinib or for the issuance of any consent decree. No Obligor nor any of its Subsidiaries, nor, to the knowledge of any Obligor, any of their respective agents, suppliers, licensees or licensors, is employing or utilizing the services of any individual, in connection with Product Commercialization and Development Activities with respect to Taletrectinib, who has been debarred from any federal healthcare program, which could reasonably be expect to have a Material Adverse Effect or a material adverse effect on the Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	None of the officers or directors, or to the knowledge of the Obligor or Subsidiary, employees or affiliates of the Obligor or Subsidiary or any agent or consultant has (x) made an untrue statement of material fact or fraudulent statement to any Governmental Authority or failed to disclose a material fact required to be disclosed to a Governmental Authority; or (y) committed an act, made a statement, or failed to make a statement that would provide a basis for the FDA to invoke its policy respecting &#x201c;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#x201d; set forth in 56 Fed. Reg. 46191 (September 10, 1991).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.19.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.20.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OFAC; Anti-Terrorism Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Neither the Borrower nor any of its Subsidiaries is in violation of any Anti-Terrorism Law or engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any applicable Anti-Terrorism Laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Neither the Borrower nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers, or employees (i) is currently the target of any Sanctions, (ii) is located, organized or residing in any Designated Jurisdiction in violation of Sanctions, or (iii) is or has been (within the previous five (5) years) engaged in any transaction with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing in any Designated Jurisdiction, in violation of Sanctions. No Loan, nor the proceeds from any Loan, has been or will be used, directly or, to the knowledge of the Borrower, indirectly, to lend, contribute or provide to, or has been or will be otherwise made available for the purpose of funding, any activity or business in any Designated Jurisdiction in violation of Sanctions or for the purpose of funding any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">violation of Sanctions, or in any other manner that will result in any violation by any party to this Agreement of Sanctions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.21.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Corruption</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither the Borrower nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers or employees, directly or indirectly, has (i) materially violated or is in material violation of any applicable anti-corruption Law, or (ii) made, offered to make, promised to make or authorized the payment or giving of, directly or indirectly, any Prohibited Payment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.22.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Priority of Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Obligations constitute unsubordinated obligations of the Obligors, and except for any obligations which have priority under applicable Law, rank at least pari passu in right of payment with all other unsubordinated Indebtedness of the Obligors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.23.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty and Other Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except for the Revenue Interest Financing or as set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.23 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as such schedule may be updated on any Bringdown Date), no Obligor, nor any of its Subsidiaries, is obligated to pay any royalty, milestone payment or any other contingent payment in respect of Taletrectinib.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.24.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Competes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither the Borrower, any other Obligor, nor any of their respective Subsidiaries, nor any of their respective directors, officers or employees, is subject to a non-compete agreement that prohibits or will interfere in any material respect with any of the Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.25.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement from Medical Reimbursement Programs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no investigation, audit, claim review, or other action pending with respect to any Obligor of which the Obligor has received written or oral notice or, to the knowledge of the Obligors, threatened in writing which could reasonably be expected to result in a revocation, suspension, termination, probation, restriction, limitation, or non-renewal of any provider number issued to any Obligor or result in the exclusion of any Obligor from Medicare or Medicaid, nor is there any action pending of which the Obligor has received written or oral notice or, to the knowledge of the Obligors, threatened in writing, pursuant to which any Governmental Authority seeks to impose material sanctions with respect to such Obligor&#x2019;s business that could reasonably be expected to have a Material Adverse Effect or a material adverse effect on any of the Product Commercialization and Development Activities with respect to Taletrectinib.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.26.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Subsidiary Assets</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.26 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a complete and correct list, as of the Closing Date, of all Intellectual Property, Product Authorizations (other than Product Authorizations exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China) and financial assets of the Excluded Subsidiaries that would otherwise constitute Collateral under this Agreement.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Affirmative Covenants</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other inchoate indemnification and expense reimbursement obligations for which no claim has been made) have been indefeasibly paid in full in cash:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements and Other Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower will furnish to the Administrative Agent:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	within forty-five (45) days after the end of the first three (3) fiscal quarters of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal quarter and (ii) the related consolidated statements of income, shareholders&#x2019; equity and cash flows of the Borrower and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such fiscal quarter, in each case prepared in all material respects in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with (iii) a certificate of a Responsible Officer of the Borrower stating that (x) such financial statements fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as at such date and (y) the results of operations of the Borrower and its Subsidiaries for the period ended on such date have been prepared in accordance with GAAP consistently applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed furnished on the date that such documents are publicly available on (A) &#x201c;EDGAR&#x201d; or the (B) Borrower&#x2019;s website (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nuvationbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Borrower shall give notice of any such posting pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the Administrative Agent (who shall then give notice of any such posting to the Lenders), in each case, with the related certificate separately delivered;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	within ninety (90) days after the end of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal year and (ii) the related consolidated statements of income, shareholders&#x2019; equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, in each case prepared in all material respects in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of KPMG LLP or another firm of independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any &#x201c;going concern&#x201d; or like qualification or exception or emphasis of matter of going concern footnote or any qualification or exception as to the scope of such audit, and in the case of such consolidated</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements, certified by a Responsible Officer of the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed furnished on the date that such documents are publicly available on (A) &#x201c;EDGAR&#x201d; or (B) the Borrower&#x2019;s website (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nuvationbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">);</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Borrower shall give notice of any such posting pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the Administrative Agent (who shall then give notice of any such posting to the Lenders); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any such report shall not be considered qualified due to the inclusion of a qualification, exception or an emphasis of matter paragraph in the audit opinion based on the impending maturity date of any Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within 15 months of the date of such report, the prospective breach of any financial covenant hereunder or liquidity issues due to ordinary course liabilities;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	together with the financial statements required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.01(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a compliance certificate signed by a Responsible Officer of the Borrower as of the end of the applicable accounting period (which delivery may be by electronic communication including email (but not fax) and shall be deemed to be an original, authentic counterpart thereof for all purposes) substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit E </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) including details of any issues that are material that are raised by auditors and any occurrence or existence of any event, circumstance, act or omission that would cause any representation or warranty contained in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.07</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Section 7.18 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be incorrect in any material respect (or in any respect if such representation or warranty is qualified by materiality or by reference to Material Adverse Effect or Material Adverse Change) if such representation or warranty were to be made at the time of delivery of a Compliance Certificate. For the avoidance of doubt, no representation or warranty contained in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.07</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.18 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is required to be, shall be or shall be deemed to be made in connection with a delivery of any Compliance Certificate;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	after being prepared by the Borrower and approved by its Board, and promptly following the Administrative Agent&#x2019;s request therefor, a consolidated budget for the Borrower and its Subsidiaries for the fiscal year to which such budget relates; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, for each fiscal year, on or before the [***]day following the beginning of such fiscal year, the Borrower shall prepare, and its Board shall approve such consolidated budget for such fiscal year, and the Borrower shall notify the Administrative Agent promptly after the Board has given such approval;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	copies of all press releases (other than any press release that is immaterial, routine or administrative in nature); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be deemed furnished on the date that such documents are publicly available on (i) &#x201c;EDGAR&#x201d; or (ii) the Borrower&#x2019;s website (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nuvationbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	within [***] after receipt thereof by an Obligor thereof, copies of each notice or other correspondence received from any securities regulator or exchange to the authority of which the Borrower may become subject from time to time concerning any investigation or possible</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigation or other inquiry by such agency regarding financial or other operational results of such Obligor, in each case, excluding any investigation or inquiry that is immaterial, routine or administrative in nature; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(f) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed furnished on the date that such documents are publicly available on (i) &#x201c;EDGAR&#x201d; or (ii) the Borrower&#x2019;s website (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nuvationbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of each Obligor and its Subsidiaries (other than any report or any communication that is immaterial, routine or administrative in nature), and copies of all annual, regular, periodic and special reports and registration statements which any Obligor or its Subsidiaries may file or be required to file with any securities regulator or exchange to the authority of which such Obligor or such Subsidiary, as applicable, may become subject from time to time; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(g) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed furnished on the date that such documents are publicly available on (i) &#x201c;EDGAR&#x201d; or (ii) the Borrower&#x2019;s website (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nuvationbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	the information regarding insurance maintained by the Borrower and its Subsidiaries as and when required under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	within [***] after the Borrower obtains knowledge of any Claim related to any Product or inventory involving more than [***] (or the Equivalent Amount in other currencies), written notice thereof from a Responsible Officer of the Borrower which notice shall include a statement setting forth details of such return, recovery, dispute or claim;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	as soon as possible and in any event within [***] after the end of each fiscal month (i) a certification from the chief financial officer (or other Responsible Officer in a similar financial role) that the Borrower has complied with the minimum liquidity requirement set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at all times during such fiscal month and (ii) upon the request of the Administrative Agent, the Borrower will provide reasonable back-up evidence with respect thereto; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the forgoing shall only be required if the Compliance Certificate last delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(c) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not include a certification that cash and Permitted Cash Equivalent Investments maintained in one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Administrative Agent and Liens permitted under Section 9.02(i) and (u), equals or exceeds [***]; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	together with the financial statements required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (i) a copy of any new Material Agreement entered during the fiscal period covered by such financial statements; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be deemed furnished on the date that such documents are publicly available on (x)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;EDGAR&#x201d; or (y) the Borrower&#x2019;s website (https://www.nuvationbio.com) and (ii) notice as to the creation, development or other acquisition (including any in-bound exclusive licenses) of any Material Intellectual Property by the Borrower or any Subsidiary after the Closing Date that is registered or becomes registered or the subject of an application for registration with any Governmental Authority; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	such other information respecting the businesses, financial performance, operations condition of the assets or liabilities of the Obligors (including with respect to the Collateral), taken as a whole, as the Administrative Agent may from time to time reasonably request.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices of Material Events</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower will furnish to the Administrative Agent written notice of the following (x) with respect to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below within [***] of and (y) with respect to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below, within [***], in each case, after a Responsible Officer of the Borrower first learns of or acquires knowledge (after reasonable due inquiry) with respect to:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the occurrence of any Default or Event of Default;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the occurrence of any event or any series of related events with respect to the property or assets of the Borrower or any of its Subsidiaries resulting in a Loss of [***] individually or [***] or more, in the aggregate (or the Equivalent Amount in other currencies);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	(i) any proposed acquisition of stock, assets or property by the Borrower or any of its Subsidiaries that could reasonably be expected to result in Material Environmental Liability, and (ii) any spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous Material by the Borrower or any of its Subsidiaries required to be reported to any Governmental Authority and that would reasonably be expected to result in Material Environmental Liability;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	the assertion of any Claim under any Environmental Law by any Person against, or with respect to the activities of, the Borrower or any of its Subsidiaries and any alleged liability or non-compliance with any Environmental Laws or any permits, licenses or authorizations issued pursuant to Environmental Laws, in each case, which could reasonably be expected to result in a Material Environmental Liability;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or affecting the Borrower or any of its Affiliates that would reasonably be expected to result in a Material Adverse Effect;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	(i) the intention of any ERISA Affiliate to file any notice of intent to terminate any Title IV Plan, a copy of such notice and (ii) the filing by any ERISA Affiliate of a request for a minimum funding waiver under Section 412 of the Code with respect to any Title IV Plan or Multiemployer Plan, in each case in writing and in reasonable detail (including a description of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of any notice filed with the PBGC or the IRS pertaining thereto);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	(i) the termination of any Material Agreement other than in accordance with its terms and not as a result of a breach or default, (ii) the receipt by the Borrower or any of its Subsidiaries of any notice of a material breach or default under any Material Agreement (and a copy thereof) asserting a default by such Obligor or any of its Subsidiaries where such alleged default would permit such counterparty to terminate such Material Agreement, or (iii) any material amendment to a Material Agreement that would be adverse in any material respect to the Lenders (and a copy thereof); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Borrower shall not be required to provide such notice if such documents become publicly available on (A) &#x201c;EDGAR&#x201d; or (B) the Borrower&#x2019;s website (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.nuvationbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) within the time period notice would otherwise be required pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	any material change in accounting policies or financial reporting practices by the Borrower or any of its Subsidiaries (other than as required under GAAP);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	any labor controversy resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor that could reasonably be expected to result in a Material Adverse Effect;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	any licensing agreement or arrangement entered into by the Borrower or any of its Subsidiaries in connection with any material Claim of violation, infringement or misappropriation (or alleged violation, infringement or misappropriation) of Intellectual Property by or against the Borrower or any of its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	any written notice or other written communication from the FDA that the FDA (i) will not approve, or will materially delay the approval of, any NDA submitted to the FDA with respect to Taletrectinib or (ii) intends to take any action to revoke, withdraw, suspend, cancel, materially limit, terminate or make any material adverse modification of any Marketing Authorization for Taletrectinib;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	any change to any Obligor&#x2019;s or any of its Subsidiaries&#x2019; ownership of any Controlled Account, by delivering the Administrative Agent a notice setting forth a complete and correct list of all such accounts as of the date of such change;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	any other development that results in, or could reasonably be expected to result in, a Material Adverse Effect; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	any written Claim by any Person that the conduct of any Obligor&#x2019;s (or any Subsidiary thereof) business, including the development, manufacture, use, sale or other</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialization of any Product, infringes any Intellectual Property of such Person, except to the extent any such Claim would not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each notice delivered under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be accompanied by a statement of a Responsible Officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. Nothing in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is intended to waive, consent to or otherwise permit any action or omission that is otherwise prohibited by this Agreement or any other Loan Document.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor shall, and shall cause each of its Material Subsidiaries to, preserve, renew and maintain in full force and effect its legal existence; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the foregoing shall not prohibit any merger, amalgamation, consolidation, liquidation or dissolution permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any Asset Sale permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will, and will cause each of its Subsidiaries to, pay and discharge its obligations, including (i) all material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, and all lawful claims for labor, materials and supplies which, if unpaid, might become a Lien upon any properties or assets of the Borrower or any of its Subsidiaries not constituting a Permitted Lien, except to the extent such Taxes, fees, assessments or governmental charges or levies or such claims are being contested in good faith by appropriate proceedings and are adequately reserved against in accordance with GAAP and (ii) all lawful claims which, if unpaid, would by law become a Lien upon its property not constituting a Permitted Lien.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Such Obligor will, and will cause each of its Subsidiaries to maintain, with financially sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses operating in the same or similar locations, including commercial property, liability (including product liability on or prior to the Taletrectinib Sale) and business interruption coverage.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Upon the request of the Administrative Agent, the Borrower shall furnish the Administrative Agent from time to time with (i) material information as to the insurance carried by it and, if so requested, copies of all such insurance policies and (ii) a certificate from the Borrower&#x2019;s insurance broker or other insurance specialist stating that all premiums then due on the policies relating to insurance on the Collateral have been paid and that such policies are in full force and effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Receipt of notice of termination or cancellation of any such insurance policies or reduction of coverages or amounts thereunder shall entitle the Secured Parties to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.05(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or otherwise to obtain similar insurance in place of such policies, in each case, the Borrower will be responsible for the reasonable and documented cost of such insurance (to be payable on demand). The amount of any such reasonable and documented expenses shall accrue interest at the Default Rate if not paid on demand and shall constitute &#x201c;Obligations.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Such Obligor shall cause each such policy of insurance (with respect to each such policy outstanding as of the Closing Date, within the time period set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to (i) name the Administrative Agent, on behalf of the Secured Parties, as an additional insured thereunder as its interests may appear, and (ii) in the case of each casualty insurance policy (including business interruption, if any) contain a lender loss payable clause or endorsement naming the Administrative Agent, on behalf of the Secured Parties, as loss payee thereunder and providing for at least [***] days&#x2019; prior written notice to the Administrative Agent ([***] days&#x2019; prior written notice in the event of cancellation for nonpayment) of any material modification or cancellation of such policy, and otherwise reasonably satisfactory in form and substance to the Administrative Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Books and Records; Inspection Rights; Lender Calls</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct (in all material respects) entries are made of all dealings and transactions in relation to its business and activities. Such Obligor will, and will cause each of its Subsidiaries to, permit any representatives designated by the Administrative Agent or the Lenders, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition (financial or otherwise) with its officers and independent accountants (so long as a representative of the Borrower is provided a reasonable opportunity to participate in any such discussion), during normal business hours (but not more often than once per calendar year in total for all such visits and inspections unless an Event of Default has occurred and is continuing) as the Administrative Agent or the Lenders may reasonably request; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that such representative shall use its commercially reasonable efforts to minimize disruption to the business and affairs of the Borrower as a result of any such visit, inspection, examination or discussion. Notwithstanding anything to the contrary contained herein or any other provision of the Loan Documents, no Obligor nor any of its Subsidiaries will be required to disclose or permit the inspection or discussion of, any document, information or other matter (i) that constitutes non-financial trade secrets or non-financial proprietary information, (ii) in respect of which disclosure to any Lender (or their respective representatives or contractors) is prohibited by any applicable Law or any binding confidentiality agreement with a third party (so long as such agreement is not entered into in contemplation of this Agreement) or (iii) that is subject to attorney-client or similar privilege, which could reasonably be expected to be lost or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">forfeited if disclosed to the Administrative Agent or any Lender. The Borrower shall pay all reasonable and documented costs of all such inspections.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the request of the Administrative Agent, on a date to be mutually agreed upon by the Borrower and the Administrative Agent (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quarterly Lender Call Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) following the end of each fiscal quarter, commencing with the delivery of information with respect to the fiscal quarter ending March 31, 2025, the Borrower will hold a conference call (at a time mutually agreed upon by the Borrower and the Administrative Agent but, in any event, no earlier than the Business Day following the delivery of applicable financial information pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 8.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above) with all Lenders who choose to attend such conference call, at which conference call shall be reviewed the financial results of the previous fiscal quarter.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Laws and Other Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will, and will cause each of its Subsidiaries to, (i) comply with all Laws (including Anti-Terrorism Laws, Sanctions and Environmental Laws) applicable to it and its business activities, (ii) comply with all Healthcare Laws and Governmental Approvals (including Product Authorizations) applicable to it and its business activities and (iii) maintain in full force and effect, remain in compliance with, and perform all obligations under all Material Agreement to which it is a party, except, in the case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above, where the failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Prior to the earlier of (x) the funding of the Tranche A-1 Term Loans and (y) the date that is [***] days after the Closing Date, each Obligor shall institute (if not already in effect) and thereafter maintain in effect and enforce policies and procedures reasonably designed to promote compliance by such Obligor, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Terrorism Laws and Sanctions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintenance of Properties, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such Obligor shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its assets and properties, including all assets and properties, whether tangible or intangible, relating to its Products or Product Commercialization and Development Activities, necessary or useful in the conduct of its business in good working order and condition in accordance with the general practice of other Persons of similar character and size, ordinary wear and tear and damage from casualty or condemnation excepted and except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor shall, and shall cause each of its Subsidiaries to, obtain and maintain all Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the consummation of the Transactions or the operation and conduct of its business and ownership of its properties (including its Product Commercialization and Development Activities), except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The proceeds of the Loans will be used only as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.06</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No part of the proceeds of the Loans will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board of Governors of the Federal Reserve System, including Regulations T, U and X.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.12.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Obligations Respecting Subsidiaries; Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiary Guarantors, etc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below and other than with respect to any Excluded Subsidiary, in the event that the Borrower or any of its Subsidiaries shall form or acquire any new Material Subsidiary or any Immaterial Subsidiary shall become a Material Subsidiary, the Borrower shall, within [***] calendar days in the case of a Domestic Subsidiary and within [***] calendar days in the case of a Foreign Subsidiary:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	cause such Subsidiary to become a &#x201c;Subsidiary Guarantor&#x201d; hereunder pursuant to a Guarantee Assumption Agreement (and in the case of any Foreign Subsidiary executing and delivering such applicable local law documents as shall be reasonably necessary or desirable) and a &#x201c;Grantor&#x201d; under the applicable Security Documents;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	take such action or cause such Subsidiary to take such action (including, but not limited to, executing and delivering the applicable Security Documents or acceding to or joining any existing Security Documents, delivering (where applicable) shares of stock together with undated transfer powers executed in blank, executing and delivering applicable control agreements, notices and other instruments required under the Security Documents, making any required filings or registrations and, in the case of any Foreign Subsidiary, executing and delivering such applicable local law surety documents or notices and making such notations as required under the Security Documents) as shall be reasonably necessary or desirable or reasonably requested by the Administrative Agent in order to create and perfect, in favor of the Administrative Agent, for the benefit of the Secured Parties, valid and enforceable first priority Liens (subject only to Permitted Liens), on substantially all of the personal property of such new Subsidiary as collateral security for the Obligations hereunder as and when required by the terms of the Security Documents; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents and the Intercompany Subordination Agreement;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	to the extent that the parent of such Subsidiary is not a party to the Security Agreement or other relevant Security Documents or has not otherwise pledged Equity Interests in its Subsidiaries in accordance with the terms of the applicable Security Documents and this Agreement, cause the parent (if possible) of such Subsidiary to execute</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and deliver a pledge agreement in favor of the Administrative Agent, for the benefit of the Secured Parties, in respect of all outstanding issued shares of such Subsidiary;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	deliver such proof of corporate action, incumbency of officers, legal opinions and other applicable documents as is consistent with those delivered by each Obligor pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or as the Administrative Agent shall reasonably request; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	cause each new Subsidiary to become a party to the Intercompany Subordination Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	such Obligor will take such action from time to time as shall reasonably be requested by the Administrative Agent to effectuate the purposes and objectives of this Agreement and the Security Documents; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	in the event that such Obligor acquires Intellectual Property during the term of this Agreement, then the provisions of this Agreement and the Security Documents shall and hereby does automatically apply thereto and any such Intellectual Property shall automatically constitute part of the Collateral under the Security Documents, without further action by any party, in each case from and after the date of such acquisition; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	without limiting the generality of the foregoing, each Obligor will, and will cause each Person that is required to be a Subsidiary Guarantor to, take such action from time to time (including, but not limited to, executing and delivering the applicable Security Documents or acceding to or joining any existing Security Documents, delivering (where applicable) shares of stock together with undated transfer powers executed in blank, executing and delivering applicable control agreements, notices and other instruments required under the Security Documents, making any required filings or registrations and, in the case of any Subsidiary organized or incorporated outside the United States, executing and delivering such applicable local law surety documents or notices and making such notations as required under the Security Documents) as shall be reasonably requested by the Administrative Agent to create, in favor of the Secured Parties, perfected first priority security interests and Liens in substantially all of the personal property (other than Excluded Assets) of such Obligor as collateral security for the Obligations as and when required by the terms of the applicable Security Documents; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, without limiting the right of the Administrative Agent to require a Lien or security interest in any newly acquired or created Subsidiary or asset,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the prior written request of the Borrower, the Borrower and the Administrative Agent shall consult, in good faith, as to whether the cost of obtaining a Lien or security interest thereon would be unreasonably excessive relative to the benefit thereof. Notwithstanding the foregoing, no Obligor will be required to make any filings or recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents in any Intellectual Property, other than filings or recordings to perfect or make enforceable any security interests in the Specified Jurisdictions (where applicable).</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	promptly (and in any event within [***]) following the acquisition by any Obligor following the Closing Date of any fee interest in real property having a value in excess of [***], such Obligor shall notify Administrative Agent of such fact and shall, if so requested by Administrative Agent, within [***] days following such request by Administrative Agent (or such longer period as agreed by Administrative Agent in its reasonable discretion), with respect to any such owned real property, deliver or cause to be delivered to Administrative Agent the following (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mortgage Deliverables</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;): (A) a mortgage or deed of trust, as applicable, in form and substance reasonably satisfactory to Administrative Agent, executed by the title holder thereof and recorded in the applicable jurisdiction, granting Administrative Agent, on behalf of the Lenders, a first priority Lien on the fee interest in such real property, (B) a lender&#x2019;s title insurance policy issued by a title insurer reasonably satisfactory to Administrative Agent in form and substance and in amounts reasonably satisfactory to Administrative Agent insuring Administrative Agent&#x2019;s, for itself and on behalf of the Lenders&#x2019;, first priority Lien in the fee interest in such real property, free and clear of all defects and encumbrances except Permitted Liens, (C) a current ALTA survey, certified to Administrative Agent, for itself and on behalf of the Lenders, by a licensed surveyor, in form and substance reasonably satisfactory to Administrative Agent, or survey affidavits sufficient to allow the issuer of the lender&#x2019;s title insurance policy to issue such policy without a survey exception, (D) a certificate, in form and substance reasonably acceptable to Administrative Agent, to Administrative Agent from a national certification agency acceptable to Administrative Agent, indicating whether such real property is located in a special flood hazard area and (E) legal opinions in form and substance reasonably acceptable to Administrative Agent from one or more law firms reasonably acceptable to Administrative Agent opining as to due execution, authority, noncircumvention, recordability, perfection and enforceability of such mortgage or deed of trust; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in the event that any Subsidiary that is not a Subsidiary Guarantor creates, develops, exclusively licenses, acquires or otherwise becomes the owner of any Intellectual Property (and, for the avoidance of doubt, all data and information with respect thereto), Products or Product Authorizations after the Closing Date, the Obligors shall cause such Subsidiary to assign, convey or transfer (and if</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assignment is not possible, exclusively license) all legal right, title and interest in such Intellectual Property (and, for the avoidance of doubt, all data and information with respect thereto), Products and Product Authorizations to an Obligor within ten (10) days</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the creation, development, licensing, acquisition or obtaining ownership thereof; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Intellectual Property (and related data and information), Product and Product Authorizations exclusive to the territorial jurisdiction of the Peoples&#x2019; Republic of China shall not be subject to the requirements of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this Section 8.12(b)(v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Certain Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, no Obligor shall be required to enter into (i) any mortgage, deed of trust or any similar agreement in respect to any fee interest real property having a fair market value of less than [***] or (ii) any leasehold interest, leasehold mortgage or any similar agreement in real property.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Non-Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that any Obligor shall become aware of, or be notified by the Administrative Agent or any Lender of the existence of, any outstanding Lien against any assets or property of such Obligor or any of its Subsidiaries, which Lien is not a Permitted Lien, such Obligor shall use its commercially reasonable efforts to promptly terminate or cause the termination of such Lien. This provision shall not limit any rights or remedies the Administrative Agent and Lenders have upon the occurrence and during the continuance of an Event of Default.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.14.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower shall deliver to the Administrative Agent (i) copies of any agenda and other written materials provided to the Board of the Borrower prior to any meeting of the Board on the same day such materials are furnished to the members of the Board or if the written materials are presented at a Board meeting, the date of such Board meeting and (ii) promptly upon presentation of any regular periodic materials to the Board of the Borrower reporting on the current, past or future financial performance and business and operations of the Borrower or any of its Subsidiaries (which shall include, among other things, development updates with respect to Taletrectinib, and updates with respect to material events relating to other Material Agreements), copies of such materials on the same day provided to the Board; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that any such material may be redacted by the Borrower to (A) exclude information relating to the Borrower&#x2019;s strategy regarding the Loans or performance or non-performance under the Loan Documents or to matters of conflict of interest to the Administrative Agent or any Lender, (B) exclude information that does not relate to Taletrectinib (other than scientific trade secrets with respect to Taletrectinib), or other information that constitutes non-financial trade secrets or non-financial proprietary information (in each case other than with respect to Taletrectinib), (C) exclude information relating Ordinary Course corporate governance, (D) exclude information relating that is subject to attorney-client or similar privilege, which could reasonably be expected to be lost or forfeited if disclosed to the Administrative Agent or any Lender or (E) protect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">individually identifiable health information (as defined under HIPAA) or other confidential information relating to healthcare patients; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such redactions are restricted so as to be only as extensive as is reasonably necessary in order to exclude information described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (A) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (E)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that documents required to be furnished pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.14 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be deemed furnished on the date that such documents are posted to the Borrower&#x2019;s board portal to which the Administrative Agent has been granted access.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.15.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.16.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> With respect to the Products and all Product Commercialization and Development Activities, such Obligor will, and will cause each of its Subsidiaries (to the extent applicable) to, (i) maintain in full force and effect all Material Product Authorizations, Material Agreements, Material Intellectual Property and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the business of Borrower and its Subsidiaries, except as would not reasonably be expected to have a Material Adverse Effect, (ii) maintain in full force and effect, and pay all costs and expenses relating to, such Regulatory Approvals, Material Agreements and Material Intellectual Property owned, used or controlled by such Obligor or any such Subsidiary that are used in or necessary for any related Product Commercialization and Development Activities, except as would not be reasonably expected to have a Material Adverse Effect, (iii) promptly after obtaining knowledge thereof, notify the Administrative Agent of any material violation, misappropriation or other infringement by any Person of such Obligor&#x2019;s or any such Subsidiaries&#x2019; Material Intellectual Property, and use commercially reasonable efforts to stop, curtail or abate such violation, misappropriation or infringement if determined appropriate by the Borrower in the exercise of its business judgment and (iv) except as set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, promptly after obtaining knowledge thereof, notify the Administrative Agent of any Claim by any Person that the conduct of the business of Borrower or any of its Subsidiaries, including in connection with any Product Commercialization and Development Activities, has violated, misappropriated or otherwise infringed any Intellectual Property of such Person, where such Claim could reasonably be expected to have a Material Adverse Effect. Each Obligor shall use commercially reasonable efforts to cause each new employee and contractor to execute and deliver a customary confidentiality, non&#x2011;disclosure and Intellectual Property assignment agreement that includes a waiver of moral rights to the extent permitted by Law and such agreements are customary in the applicable jurisdiction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.17.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor shall comply, and shall cause each of its Subsidiaries to comply, with the provisions of ERISA with respect to any Benefit Plans to which such Obligor or such Subsidiary is a party as an employer, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.18.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Management</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Such Obligor shall cause and maintain at all times after the Account Control Agreement Completion Date all deposit accounts, disbursement accounts, investment accounts (and other similar accounts) and lockboxes (other than Excluded Accounts) of the Obligors located within the U.S. to be subject to an account control agreement, in form and substance reasonably acceptable to the Administrative Agent (which, in any event, shall be consistent with the requirements of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) (each such deposit account, disbursement account, investment account (or similar account) and lockbox, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled Account</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); each such Controlled Account shall be a cash collateral account, with all cash, checks and other similar items of payment in such account securing payment of the Obligations, and each Obligor shall have granted a Lien to the Administrative Agent, for the benefit of the Secured Parties, over such Controlled Accounts; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	at any time after the occurrence and during the continuance of an Event of Default, at the request of the Administrative Agent, each Obligor shall cause all payments constituting proceeds of accounts to be directed into lockbox accounts under agreements in form and substance satisfactory to the Administrative Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.19.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Closing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Negative Covenants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made), have been indefeasibly paid in full in cash:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Obligations;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	(i) Indebtedness existing on the date hereof and, to the extent the outstanding principle amount as of the Closing Date exceeds [***], set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.01(b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) Permitted Refinancings thereof; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if such Indebtedness is intercompany Indebtedness, such Indebtedness shall be subject to the Intercompany Subordination Agreement;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money) incurred in the ordinary course of such Obligor&#x2019;s or such Subsidiary&#x2019;s business in accordance with customary terms and paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Indebtedness consisting of guarantees resulting from the endorsement of negotiable instruments for collection in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Indebtedness of an Obligor owing to any other Obligor, subject to the Intercompany Subordination Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Indebtedness of any Subsidiary that is not an Obligor owing to any Obligor (to the extent such Investment is permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or other Subsidiary that is not an Obligor;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Indebtedness of any Obligor owing to any Subsidiary that is not an Obligor, subject to the Intercompany Subordination Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Indebtedness owing by an Obligor to any Subsidiary that is not an Obligor shall not exceed [***] in the aggregate outstanding at any one time;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	[reserved];</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Guarantees by any Obligor of Permitted Indebtedness of any other Obligor;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Ordinary Course equipment and software financing and leasing (including Capital Lease Obligations and purchase money Indebtedness); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (i) if secured, the collateral therefor consists solely of the assets being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal amount of such Indebtedness does not exceed [***] (or the Equivalent Amount in other currencies) at any time;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Indebtedness under Permitted Hedging Agreements;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Indebtedness assumed pursuant to any Permitted Acquisition; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (i) no such Indebtedness (individually) shall exceed [***]% of the total purchase price paid in connection with such Permitted Acquisition, (ii) the aggregate outstanding principal amount of Indebtedness permitted pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(l) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not exceed [***] (or the Equivalent Amount in other currencies) at any time outstanding and (iii) no such Indebtedness was created or incurred in connection with, or in contemplation of, such Permitted Acquisition;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	[reserved];</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	Indebtedness pursuant to the Revenue Interest Financing;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	other Indebtedness in an aggregate outstanding principal amount not to exceed [***] (or the Equivalent Amount in other currencies);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Permitted Convertible Debt in an aggregate principal amount at any time outstanding not to exceed [***] </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and solely to the extent that, [***], additional amounts in excess of [***];</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	Indebtedness in respect of letters of credit, bank guarantees, bankers&#x2019; acceptances or similar instruments issued or created, or related to obligations or liabilities incurred, in the Ordinary Course, including in respect of workers compensation claims, health, disability or other employee benefits or property, leases, commercial contracts, Indebtedness permitted pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(s)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, casualty or liability insurance or self-insurance or other reimbursement-type obligations regarding workers compensation claims;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	Indebtedness arising in connection with the financing of insurance premiums in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	Indebtedness in respect of (i) performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and similar obligations in each case arising in the Ordinary Course and (ii) customary indemnification obligations to purchasers in connection with Asset Sales permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	Indebtedness in respect of netting services, overdraft protections, business credit cards, purchasing cards, payment processing, automatic clearinghouse arrangements, arrangements in respect of pooled deposit or sweep accounts, check endorsement guarantees, and otherwise in connection with deposit accounts or cash management services in each case in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	purchase price adjustments, indemnity payments and other Deferred Acquisition Consideration in connection with any Permitted Acquisition, in each case that are permitted pursuant to the definition of &#x201c;Permitted Acquisition&#x201d;; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	Permitted Refinancings of any items of Permitted Indebtedness under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any property now owned by it or such Subsidiary, except:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Liens securing the Obligations;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	(i) any Lien on any property or asset of such Obligor or any of its Subsidiaries existing on the date hereof and, to the extent any such Lien secures amounts or obligations in excess of [***], set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.02(b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) renewals and extensions thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (i) no such Lien (including any renewal or extension thereof) shall extend to any other property or asset of such Obligor or any of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and renewals, extensions and replacements thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien that do not increase the outstanding principal amount thereof (other than by an amount equal to unpaid interest and premiums thereon, including tender premium, and any customary underwriting discounts, fees, commissions and expenses associated with such extension, renewal or replacement);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Liens securing Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such Liens are restricted solely to the collateral described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Liens imposed by any Law arising in the Ordinary Course, related to carriers&#x2019;, warehousemen&#x2019;s, landlords&#x2019;, and mechanics&#x2019; liens, liens relating to leasehold improvements and other similar Liens arising in the Ordinary Course and which (x) do not in the aggregate materially detract from the value of the property subject thereto or materially impair the use thereof in the operations of the business of such Person, (y) are not in respect of Indebtedness for borrowed money or (z) are being contested in good faith by appropriate proceedings, which proceedings, diligently conducted, have the effect of preventing the forfeiture or sale of the property subject to such Liens and for which adequate reserves have been made if required in accordance with GAAP;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	pledges or deposits made in the Ordinary Course in connection with bids, contract leases, appeal bonds, workers&#x2019; compensation, unemployment insurance or other similar social security legislation;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Liens securing Taxes, assessments and other governmental charges, the payment of which is not past due or is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which adequate reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	servitudes, easements, rights of way, restrictions and other similar encumbrances on real property imposed by any Law and Liens consisting of zoning or building restrictions, easements, licenses, restrictions on the use of real property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors or any of their Subsidiaries; and</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	with respect to any real property, (i) such defects or encroachments as might be revealed by an up-to-date survey of such real property; (ii) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real property pursuant to all applicable Laws; and (iii) rights of expropriation, access or user or any similar right conferred or reserved by or in any Law, which, in the aggregate for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors or its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Bankers liens, rights of setoff and similar Liens incurred on deposits or other assets credited to any deposit or securities account made in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Liens securing Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (i) such Lien is not created in contemplation of or in connection with such Permitted Acquisition pursuant to which such Indebtedness was assumed, (ii) such Lien shall not apply to any other property or assets of the Borrower or any Subsidiary and (iii) such Lien shall secure only those obligations that it secured immediately prior to the consummation of such Permitted Acquisition and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Liens securing Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 9.01(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Any judgment Lien or Liens arising from decrees or attachments not constituting an Event of Default;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	Liens arising from precautionary UCC financing statement filings regarding operating leases of personal property and consignment arrangements entered into in the Ordinary Course in an Arm&#x2019;s Length Transaction;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	other Liens which secure obligations in an aggregate amount not to exceed [***] (or the Equivalent Amount in other currencies) at any time outstanding;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Liens securing Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(n) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and which are subject to the Permitted Intercreditor Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods and incurred in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	to the extent constituting a Lien, Permitted Licenses;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	Liens on cash and Permitted Cash Equivalent Investments securing obligations under Permitted Hedging Agreements;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	(i) Liens to secure payment of workers&#x2019; compensation, employment insurance, old age pensions, social security and other like obligations incurred in the Ordinary Course (other than Liens imposed by ERISA) and (ii) deposits in respect of letters of credit, bank guarantees or similar instruments issued for the account of any Obligor or any Subsidiary in the Ordinary Course supporting obligations of the type set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	to the extent constituting a Lien, customary cash escrow arrangements securing indemnification obligations associated with a Permitted Acquisition or any other Investment permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not to exceed [***] in the aggregate;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	Liens of a collection bank arising under Section 4-210 of the Uniform Commercial Code on items in the course of collection;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	Liens of sellers of goods to the Borrower and any of its Subsidiaries arising under Article 2 of the Uniform Commercial Code or similar provisions of applicable law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related expenses;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)	rights of first refusal, voting, redemption, transfer or other restrictions (including call provisions and buy-sell provisions) with respect to the Equity Interests of any Joint Venture or other Persons that are not Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x)	any Lien arising under conditional sale, title retention, consignment or similar arrangements for the sale of goods in the Ordinary Course; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such Lien attaches only to the goods subject to such sale, title retention, consignment or similar arrangement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)	(i) leases or subleases of real property entered into in the Ordinary Course, (ii) licenses, sublicenses, leases or subleases of personal property (other than Intellectual Property) granted to third parties in the Ordinary Course of business, in each case which do not interfere in any material respect with the operations of the business of any Obligor or any of its Subsidiaries and do not prohibit granting the Administrative Agent a security interest in any Obligor&#x2019;s personal property held at such location for the benefit of the Lenders and other Secured Parties, and (iii) retained interests of lessors or licensors or similar parties under any in-licenses.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that no Lien otherwise permitted under any of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall apply to any Material Intellectual Property, other than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fundamental Changes and Acquisitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, (i) enter into any transaction of merger, amalgamation or consolidation (or otherwise merge, amalgamate or consolidate), (ii) liquidate, provisionally liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), (iii) sell or issue any of its Disqualified Equity Interests, (iv) other than Permitted Acquisitions and any Acquisition permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, make any Acquisition or otherwise acquire any business or substantially all the property from, or Equity Interests of, or be a party to any Acquisition of, any Person or (v) sell, lease, transfer or otherwise dispose of all or substantially all of its property, except:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the merger, amalgamation or consolidation, liquidation or provisional liquidation of any (i) Subsidiary with or into any Obligor; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that with respect to any such transaction involving (x) the Borrower, the Borrower must be the surviving or successor entity of such transaction or (y) any other Obligor, an Obligor must be the surviving or successor entity of such transaction or the surviving Person shall concurrently therewith become an Obligor (unless such transaction involves more than one Obligor, then an Obligor must be the surviving or successor entity of such transaction) or (ii) any Subsidiary that is not an Obligor with or into any other Subsidiary that is not an Obligor;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the sale, lease, transfer or other disposition by (i) any Subsidiary of any or all of its property (upon voluntary liquidation, provisional liquidation, restructuring or otherwise) to any Obligor and (ii) any Subsidiary that is not an Obligor of any or all of its property (upon voluntary liquidation, provisional liquidation, restructuring or otherwise) to any other Subsidiary that is not an Obligor;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	the sale, transfer or other disposition of the Equity Interests of (i) any Subsidiary to any Obligor, (ii) any Subsidiary that is not an Obligor to any other Subsidiary that is not an Obligor;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	mergers, amalgamations or consolidations of any Subsidiary to effectuate an Asset Sales permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such merger, amalgamation or consolidation does not include the Borrower or the Borrower is the surviving entity from such merger, amalgamation or consolidation;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	in connection with any Permitted Acquisition or other Investment permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Borrower or any Subsidiary of the Borrower may merge or amalgamate into or consolidate with any other Person or permit any other Person to merge or amalgamate into or consolidate with it, so long as (i) the Person surviving such merger or amalgamation with any Subsidiary shall be a direct or indirect wholly-owned Subsidiary of the Borrower, (ii) in the case of any such merger or amalgamation to which the Borrower is a party, the Borrower is the surviving Person, and (iii) in the case of any such merger to which a Subsidiary Guarantor is a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">party, the surviving Person is such Subsidiary Guarantor or concurrently therewith becomes a Subsidiary Guarantor; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	any Subsidiary may dissolve, liquidate or wind up its affairs at any time, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, such dissolution, liquidation or winding up could not reasonably be expected to have a Material Adverse Effect and all of its assets and business are transferred to an Obligor or solely in the case of a Subsidiary that is not an Obligor, another Subsidiary that is not an Obligor prior to or concurrently with such dissolution, liquidation or winding up.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lines of Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, engage in any business other than the business engaged in on the date hereof by such Persons or a business reasonably related, incidental or complementary thereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding any Investments except:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Investments (but without giving effect to the cash return provision contained in the definition thereof) outstanding on the date hereof and identified in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.05(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any renewals, amendments and replacements thereof that do not increase the amount thereof of any such Investment, net of cash returns thereon, or require that any additional Investment be made (unless otherwise permitted hereunder);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	deposit accounts with banks (or similar deposit-taking institutions) and securities accounts maintained by the Obligors and their respective Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services in the Ordinary Course in an Arm&#x2019;s Length Transaction;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Investments in cash and Permitted Cash Equivalent Investments, which in the case of the Obligors shall be maintained after the Account Control Agreement Completion Date in Controlled Accounts (unless maintained in Excluded Accounts);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Investments by an Obligor (i) in another Obligor, (ii) in a non-Obligor Subsidiary (other than an Excluded Subsidiary), </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such amount shall not exceed, in any [***], [***], and (iii) in the Excluded Subsidiaries, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the amount of any such Investments shall not exceed (x) the amount necessary to fund ordinary course expenses of the Specified Subsidiary that are reasonably expected to become due and payable during the [***] month period immediately following such Investment (net of cash on hand and milestone and similar payments expected to be received during such period) and (y) [***] per fiscal year; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided, further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, notwithstanding anything herein to the contrary, no Investments (including with the proceeds of any sale, transfer, issuance or other disposition of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Interests of the Borrower or any Subsidiary thereof) in an Excluded Subsidiary are permitted under this Agreement other than pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Investments by a Subsidiary that is not an Obligor in the Borrower or any other Subsidiary (other than an Excluded Subsidiary);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Permitted Hedging Agreements;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	Investments consisting of prepaid expenses, deposits under commercial contracts for the purchase of assets, negotiable instruments held for collection or deposit, security deposits with utilities, landlords and other like Persons and deposits in connection with workers&#x2019; compensation and similar deposits, in each case, made in the Ordinary Course, and other deposits and cash collateral constituting Permitted Liens;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	employee, officer and director loans, travel advances and guarantees in accordance with the Borrower&#x2019;s usual and customary practices with respect thereto (if permitted by applicable Laws) and non-cash loans to employees, officers, or directors relating to the purchase of Equity Interests of the Borrower pursuant to employee stock purchase plans or agreements, which in the aggregate shall not exceed [***] outstanding at any time (or the Equivalent Amount in other currencies);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Investments (including debt obligations) received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	the increase in value of any Investment otherwise permitted pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	other Investments in an aggregate amount not to exceed [***] (or the Equivalent Amount in other currencies) in any fiscal year;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	Investments of any Person in existence at the time such Person becomes a Subsidiary; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such Investment was not made in connection with or anticipation of such Person becoming a Subsidiary and any modification, replacement, renewal or extension thereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	Investments permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (other than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thereof);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Permitted Acquisitions and earnest money deposits in connection with Permitted Acquisitions and Investments acquired as a result of a Permitted Acquisition to the extent that such Investments were not made in contemplation of or in connection with such Permitted Acquisition and were in existence prior to the date of such Permitted Acquisition;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Investments consisting of the non-cash portion of the sales consideration received by the Borrower or any of its Subsidiaries in connection with any Asset Sale permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	Investments in the Ordinary Course consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	to the extent constituting Investments, Guarantees of Indebtedness, which Guarantees are permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	Investments contemplated by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.05(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	to the extent constituting Investments, Investments in the form of Permitted Bond Hedge Transactions and Permitted Warrant Transactions, in each case, entered into in connection with Permitted Convertible Debt;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	Investments consisting of Permitted Liens; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	Investments (other than in any Excluded Subsidiary) made with the Available Amount.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, declare or make, directly or indirectly, any Restricted Payment; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the following Restricted Payments shall be permitted so long as no Event of Default has occurred and is continuing or could reasonably be expected to occur or result from such Restricted Payment:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	dividends with respect to the Borrower&#x2019;s Equity Interests payable solely in shares of its Qualified Equity Interests (or the equivalent thereof);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the Borrower&#x2019;s purchase, redemption, retirement, or other acquisition of shares of its Equity Interests with the Available Amount;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	(i) each Subsidiary that is an Obligor may make Restricted Payments to any other Obligor, and (ii) each Subsidiary that is not an Obligor may make (x) Restricted Payments to an Obligor and to another Subsidiary that is not an Obligor and (y) pro rata Restricted Payments to minority stockholders of any such Subsidiary;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	any purchase, redemption, retirement or other acquisition of Equity Interests of the Borrower held by consultants, officers, directors and employees or former consultants, officers, directors or employees (or their transferees, estates, or beneficiaries under their estates) of Borrower and its Subsidiaries not to exceed [***] (or the Equivalent Amount in other currencies)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in any fiscal year (it being agreed that, to the extent constituting an Investment permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the amount of any Indebtedness of such Persons owing to the Borrower or any Subsidiary forgiven in connection with such Restricted Payment shall be excluded from any determination pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the portion of such basket that is not used by the Borrower or its Subsidiaries in any fiscal year shall be carried-forward to the immediately succeeding fiscal year;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	cashless repurchases of Equity Interests deemed to occur upon exercises of options and warrants;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	cash payments made by the Borrower to redeem, purchase, repurchase or retire its obligations under options, warrants and other convertible securities issued by it in the nature of customary cash payments in lieu of fractional shares in accordance with the terms thereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Borrower may acquire (or withhold) its Equity Interests pursuant to any employee stock option or similar plan to pay withholding taxes for which Borrower is liable in respect of a current or former officer, director, employee, member of management or consultant upon such grant or award (or upon vesting or exercise thereof) and the Borrower may make deemed repurchases in connection with the exercise of stock options;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	any payment of interest, principal or fees in respect of any Indebtedness owed by any Obligor or any of its Subsidiaries to any holder of any Equity Interests of any Obligor or any of its Subsidiaries, in each case to the extent permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.07</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	so long as no Default or Event of Default has occurred and is continuing (or could reasonably be expected to occur after giving effect to such Restricted Payment), other Restricted Payments in an aggregate amount not to exceed [***] (or the Equivalent Amount in other currencies) in any fiscal year.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments of Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of any Indebtedness other than (i) payments of the Obligations; (ii) scheduled payments of other Indebtedness (including scheduled and required payments in respect of the Revenue Interest Financing) to the extent permitted pursuant to the terms, if any, of any applicable subordination or intercreditor agreement in respect of the Obligations; (iii) subject to the Intercompany Subordination Agreement, intercompany indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (iv) Indebtedness permitted to be incurred under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 9.01(b), (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (v) any prepayment, repurchase, redemption or similar action of the Permitted Convertible Debt using cash proceeds of any substantially simultaneous issuance of Permitted Convertible Debt (and any cash proceeds received pursuant to the exercise, early unwind or termination of any Permitted Bond Hedge Transaction in connection</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with such prepayment, repurchase, redemption or action); (vi) any cash prepayment, repurchase, redemption or similar action of the Permitted Convertible Debt with the Available Amount; (vii) the conversion to Equity Interests by holders of Permitted Convertible Debt in accordance with the terms of the indenture or other documentation governing such Permitted Convertible Debt, (viii) the exchange of existing Permitted Convertible Debt for the following (or any combination of the following): (1) new Permitted Convertible Debt (or the net cash proceeds from the issuance of such new Permitted Convertible Debt) to the extent such Indebtedness is permitted to be issued under the terms of this Agreement, (2) Class A Common Stock, (3) the cash proceeds, if any, received pursuant to the exercise, early unwind or termination of any Permitted Bond Hedge Transaction entered into in connection with such existing Permitted Convertible Debt, or (4) cash payment in respect of accrued and unpaid interest on such exchanged existing Permitted Convertible Debt; (ix) delivery of Class A Common Stock and cash in lieu of fractional shares or in respect of accrued and unpaid interest to any holder of Permitted Convertible Debt to induce such holder to convert Permitted Convertible Debt in accordance with the terms of the indenture governing such Permitted Convertible Debt; and (x) Permitted Refinancings of Indebtedness specifically permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Fiscal Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal year from that in effect on the date hereof without the prior written consent of Administrative Agent, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition to conform its fiscal year to that of the Borrower.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of Assets, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease or sublease (as lessor or sub-lessor), sale and leaseback, assign, convey, license or sub-license, transfer, or otherwise dispose of any of its businesses, assets or property of any kind, whether real, personal, or mixed and whether tangible or intangible, whether now owned or hereafter acquired (including accounts receivable and Equity Interests of Subsidiaries) (any thereof, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), except:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	sales, transfers and other dispositions of receivables in connection with the compromise, settlement or collection thereof in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	sales of inventory, including to end users (through wholesalers or other typical sales channels) or to distributors, in the Ordinary Course in an Arm&#x2019;s Length Transaction;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	the forgiveness, release or compromise of trade payables owed to any Obligor or Subsidiary in the Ordinary Course;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Permitted Licenses;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	transfers of assets, rights or property by (i) any Obligor to any other Obligor or (ii) any Subsidiary that is not an Obligor to an Obligor;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	dispositions (including by way of abandonment or cancellation) of any equipment and other tangible property that is obsolete or worn out or no longer used or useful in the Business disposed of in the Ordinary Course in an Arm&#x2019;s Length Transaction;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	dispositions resulting from Casualty Events (without giving effect to the Dollar exception set forth in the definition thereof);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	the unwinding of any Hedging Agreement permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.05 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to its terms;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	in connection with any transaction permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(other than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thereof)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Section</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Asset Sales identified in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	so long as no Default or Event of Default has occurred and is continuing (or could reasonably be expected to occur after giving effect to such Asset Sale), other Asset Sales (other than with respect to Material Intellectual Property) with a fair market value not in excess of [***] (or the Equivalent Amount in other currencies) in the aggregate in any fiscal year;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	other Asset Sales (other than with respect to Material Intellectual Property) not in excess of [***] (or the Equivalent Amount in other currencies) in the aggregate in any fiscal year in which any Obligor or any Subsidiary will receive cash proceeds in an amount equal to no less than [***] percent ([***]%) of the total consideration (fixed or contingent) paid or payable to such Obligor or Subsidiary;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	dispositions in the Ordinary Course of business consisting of the abandonment of Intellectual Property (other than Material Intellectual Property) which, in the reasonable good faith determination of Borrower, are not material to the conduct of the business of Borrower or any of its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	dispositions of cash and Permitted Cash Equivalents Investments in the Ordinary Course or otherwise in transactions permitted hereunder;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	the sale, transfer, issuance or other disposition of a </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de minimis </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">number of shares of the Equity Interests of a CFC in order to qualify members of the governing body of such CFC if required by applicable Law;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	to the extent constituting an Asset Sale, any Permitted Liens;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	the sale or transfer of any revenue and other proceeds pursuant to and in accordance with the Revenue Interest Financing and subject in all respects to the Intercreditor Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	to the extent constituting an Asset Sale, the waiver, amendment, cancellation or termination of any rights not prohibited pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any amendment, modification, restatement, cancellation, supplement, termination or waiver of any provision, of any Material Agreements not prohibited pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions with Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into or permit to exist any transaction to sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, unless such arrangement or transaction (i) is an Arm&#x2019;s Length Transaction, (ii) is of the kind which would be entered into by a prudent Person in the position of the Borrower with another Person that is not an Affiliate, (iii) is between or among (x) one or more Obligors, on the one hand, and, on the other hand, one or more Obligors, (y) one or more Subsidiaries of the Obligors that are not Obligors, on the one hand, and, on the other hand, one or more Subsidiaries of the Obligors that are not Obligors and (z) one or more Obligors or their Subsidiaries that are not Obligors, on the one hand, and, on the other hand, one or more Obligors or their Subsidiaries that are Obligors (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, with respect to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (z) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">only, the terms thereof are no less favorable than those that would be obtained in a comparable Arm&#x2019;s Length Transaction with a non-affiliated Person), (iv) is permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.06</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.07</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (v) constitutes customary compensation (including performance, discretionary, retention, relocation, transaction and other special bonuses and payment, severance payments and payments pursuant to employment agreements), other benefits (including retirement, health, stock option and other benefit plans, life insurance, disability insurance and other equity (or equity-linked) awards) and indemnification of, and other employment arrangements with, directors, officers, and employees of any Obligor or its Subsidiaries in the Ordinary Course, (vi) constitutes payment of customary fees, reimbursement of expenses, and payment of indemnification to officers and directors and customary payment of insurance premiums on behalf of officers and directors by the Obligors or their Subsidiaries, in each case, in the ordinary course of business, (vii) are the transactions set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or (viii) is a transaction (with any series of related transactions being aggregated for the purposes of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (viii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) including consideration of less than [***].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur or permit to exist any Restrictive Agreement other than (i) restrictions and conditions imposed by applicable Laws or by the Loan Documents, (ii) Restrictive Agreements listed on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) limitations associated with Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any document or instrument governing any Permitted Lien, (iv) any documentation governing Indebtedness referenced in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (l), (n)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (solely with respect to cash or Permitted Cash Equivalent Investments securing obligations permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in an amount not to exceed the amount permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(or any Permitted Refinancing thereof), (v) customary provisions in leases, Permitted Licenses and other Contracts restricting the assignment thereof or restricting the assignment, pledge, transfer or sublease or sublicense of the property leased, licensed or otherwise the subject thereof; (vi) any restrictions or conditions set forth in any agreement in effect at any time any Person becomes a Subsidiary (but not any modification or amendment expanding the scope of any such restriction or condition); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such agreement was not entered into in contemplation of such Person becoming a Subsidiary; (vii) restrictions or conditions in any Indebtedness permitted pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that is incurred or assumed by Subsidiaries that are not Obligors to the extent such restrictions or conditions are no more restrictive in any material respect than the restrictions and conditions in the Loan Documents; (viii) restrictions or conditions imposed by any agreement relating to purchase money Indebtedness and other secured Indebtedness or to leases and licenses permitted by this Agreement if such restrictions or conditions apply only to the property or assets securing such Indebtedness or the property leased or licensed; (ix) customary provisions in contracts for the disposition of any assets; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the restrictions in any such contract shall apply only to the assets or Subsidiary that is to be disposed of and such disposition is permitted hereunder; (x) customary provisions regarding confidentiality or restricting assignment, pledges or transfer of any Permitted License or any other agreement entered into in the Ordinary Course; (xi) customary restrictions or encumbrances in any agreement evidencing Permitted Convertible Debt that restricts the merger or consolidation of, or the sale of all or substantially all of the assets of, the Borrower or taken as a whole, are not more restrictive to the Obligors in any material respect than the comparable restrictions and encumbrances in the Loan Documents, taken as a whole (as reasonably determined by the a Responsible Officer of Borrower in good faith and as certified to by a certificate from such Responsible Officer delivered to the Administrative Agent); and (xii) restrictions or encumbrances in any agreement in effect at the time any Person becomes a Subsidiary, so long as (x) such agreement was not entered into in contemplation of such Person becoming a Subsidiary and (y) such restrictions or encumbrances do not extend beyond such Subsidiary or its assets.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.12.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modifications and Terminations of Material Agreements and Organic Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	waive, amend, terminate, replace or otherwise modify any term or provision of any Organic Document in any way or manner adverse to the interests of the Administrative Agent and the Lenders; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the avoidance of doubt, any waiver, amendment, termination, replacement or other modification of any provision related to the Class B Common Stock or the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">holders of Class B Common Stock shall be deemed adverse to the interests of the Administrative Agent and the Lenders; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	waive, amend, replace or otherwise modify any term or provision of any Material Agreement in a manner materially adverse to the rights and remedies the Administrative Agent and the Lenders hereunder; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	(x) take or omit to take any action that results in the termination of, or permits any other Person to terminate, any Material Agreement or any rights in or to Material Intellectual Property or (y) take any action that permits any Material Agreement or any rights in or to Material Intellectual Property to be terminated by any counterparty thereto prior to its stated date of expiration, in each case, except as would not be reasonably expected to have (x) a Material Adverse Effect or (y) a material adverse effect on Product Commercialization and Development Activities with respect to Taletrectinib; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	enter into, waive, terminate, replace or otherwise modify any Contract that involves or results in the disposition, assignment or licensing of any Material Intellectual Property, unless such agreement is (i) a Permitted License, (ii) permitted pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or (iii) approved in writing by the Majority Lenders.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outbound Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Obligor will, nor will it permit any of its Subsidiaries to, enter into or become or remain bound by any agreement under which an Obligor or any of its Subsidiaries grants any outbound license, covenant not to sue or other grant of rights under Material Intellectual Property relating to Taletrectinib, except for Permitted Licenses.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.14.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and Leasebacks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as disclosed on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 9.14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, except as otherwise consented to in writing by the Administrative Agent (such consent not to be unreasonably withheld), such Obligor will not, and will not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which such Person has sold or transferred or is to sell or transfer to any other Person and (ii) which such Obligor or Subsidiary intends to use for substantially the same purposes as property which has been or is to be sold or transferred.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.15.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hazardous Material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except as would not reasonably be expected to result in a Material Environmental Liability.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.16.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Such Obligor will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment or reporting practices, except as required or permitted by GAAP.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.17.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No ERISA Affiliate shall cause or suffer to exist (i) any event that could result in the imposition of a Lien with respect to any Title IV Plan or Multiemployer Plan or (ii) any other ERISA Event that could, in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Obligor or any of its Subsidiaries shall cause or suffer to exist any event that could result in the imposition of a Lien with respect to any Benefit Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.18.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions; Anti-Corruption Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Neither the Borrower or any of its Subsidiaries, or their respective directors, officers, employees, or agents shall (i) conduct any business or engage in any transaction or dealing with any Sanctioned Person in violation of Sanctions, including making or receiving any contribution of funds, goods or services to or for the benefit of any Sanctioned Person; (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to any Sanctions; or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any applicable Sanctions, the Patriot Act or any other Anti-Terrorism Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Borrower will not, directly or, to the knowledge of the Borrower, indirectly, use the proceeds of the Loans, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person, (i) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any applicable anti-corruption Law, or (ii)(A) for the purpose of funding any activities or business of or with any Sanctioned Person or any Designated Jurisdiction in violation of Sanctions or (B) in any other manner that would result in a violation of Sanctions by any party to this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, (i) the Borrower shall not, and shall not permit any of its Subsidiaries to (x) directly or indirectly transfer, by means of contribution, sale, sale and leaseback, assignment, lease or sublease, conveyance, license or sublicense, or other disposition of any kind or otherwise (including, for avoidance of doubt, in connection with a transaction permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as an Investment, Restricted Payment or Asset Sale), any Material Intellectual Property other than pursuant to Permitted Licenses or (y) permit any Person other than the Borrower or a Subsidiary Guarantor to license, own or hold any interest in such Material Intellectual Property other than pursuant to Permitted Licenses and (ii) except as permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12(b)(v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> no Material Intellectual Property shall be transferred, sold, sold and leaseback, assigned, leased or subleased, conveyed, licensed or sublicensed or otherwise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disposed of (including, for the avoidance of doubt, in connection with a transaction permitted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as an Investment, Restricted Payment or Asset Sale) to any Subsidiary other than a Subsidiary Guarantor (other than pursuant to Permitted Licenses).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Financial Covenant</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Liquidity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Obligors shall at all times maintain the Minimum Liquidity Amount in cash and/or Permitted Cash Equivalent Investments in, at all times after the Account Control Agreement Completion Date, one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Administrative Agent and Liens permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Events of Default</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the following events shall constitute an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Payment Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower shall fail to pay any principal of the Loan, when and as the same shall become due and payable, whether at the due date thereof, at a date fixed for prepayment thereof or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Payment Defaults</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Obligor shall fail to pay interest or any other Obligation (other than an amount referred to in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) when and as the same shall become due and payable, and such failure shall continue unremedied for a period of [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any representation or warranty made or deemed made by or on behalf of any Obligor or any of its Subsidiaries in or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, shall (i) have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Obligor shall fail to observe or perform any covenant, condition or agreement contained in (i) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.01(a), (b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and such failure shall continue</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unremedied for a period of [***] or (ii) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(solely as to the Borrower), </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.05(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.05(d),</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.18</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Obligor shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of [***] days after the earlier to occur of the date on which (i) a Responsible Officer of any Obligor becomes aware of such failure or (ii) written notice thereof shall have been given to any Obligor by the Administrative Agent or any Lender.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Default on Other Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Obligor or any of its Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect of any Material Indebtedness or the permitted Revenue Interest Financing, when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness or the permitted Revenue Interest Financing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Defaults on Other Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. (i) Any material breach of, or &#x201c;event of default&#x201d; or similar event under, any Contract governing any Material Indebtedness or similar event under the permitted Revenue Interest Financing shall occur and such breach or &#x201c;event of default&#x201d; or similar event shall continue unremedied, uncured or unwaived after the expiration of any grace or cure period thereunder, or (ii) any event or condition occurs (x) that results in any Material Indebtedness or the permitted Revenue Interest Financing becoming due prior to its scheduled maturity (including as a result of any change of control, fundamental change or similar event under any Material Indebtedness) or (y) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness or the permitted Revenue Interest Financing or any trustee or agent on its or their behalf to cause such Material Indebtedness or the permitted Revenue Interest Financing to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(g) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not apply to (x) secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Material Indebtedness, (y) Indebtedness which is convertible into Equity Interests (other than Disqualified Equity Interests) of the Borrower that converts to such Equity Interests (and nominal cash payments in respect of fractional shares and cash payments in respect of accrued and unpaid interest) in accordance with the express terms or conditions thereof (provided that Indebtedness in respect of Permitted Convertible Debt may only convert in Class A Common Stock) and (z) with respect to any Material Indebtedness consisting of Hedging Agreements, termination events or equivalent events pursuant to the terms of such Hedging Agreements and not as a result of any default thereunder by any Obligor or any Subsidiary.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insolvency, Bankruptcy, Etc.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Any Obligor or any of its Material Subsidiaries becomes insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits in writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	Any Obligor or any of its Material Subsidiaries commits an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a proposal (or files a notice of its intention to do so).</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	Any Obligor or any of its Material Subsidiaries institutes any proceeding seeking to adjudicate it an insolvent, or seeking liquidation, provisional liquidation, restructuring, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), or composition of it or its debts or any other relief, under any Law, whether U.S. or non-U.S., now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity, or files an answer admitting the material allegations of a petition filed against it in any such proceeding.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	Any Obligor or any of its Material Subsidiaries applies for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, provisional liquidator, restructuring officer, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	Any Obligor or any of its Material Subsidiaries takes any action, corporate or otherwise, to approve, effect, consent to or authorize any of the actions described in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or otherwise acts in furtherance thereof or fails to act in a timely and appropriate manner in defense thereof.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	Any petition is filed, application made or other proceeding instituted against or in respect of any Obligor or any of its Material Subsidiaries:</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A)	seeking to adjudicate it as insolvent;</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)	seeking a receiving order against it;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(C)	seeking liquidation, provisional liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts or any other relief under any Law, whether U.S. or non-U.S., now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity; or</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(D)	seeking the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, provisional liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property, and such petition, application or proceeding continues undismissed, or unstayed and in effect, for a period of [***] days after the institution thereof; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that if an order, decree or judgment is granted or entered (whether or not entered or subject to appeal) against such Obligor or such Subsidiary thereunder in the interim, such grace period will cease to apply; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if such Obligor or Material Subsidiary files an answer admitting the material allegations of a petition filed against it in any such proceeding, such grace period will cease to apply.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii)	Any other event occurs which, under the Laws of any applicable jurisdiction, has an effect equivalent to any of the events referred to in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Judgments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. One or more final judgments for the payment of money in an aggregate amount in excess of [***] (or the Equivalent Amount in other currencies) (to the extent not covered (other than to the extent of customary deductibles) by insurance pursuant to which the insurer has not denied coverage) shall be rendered against any Obligor or any of its Subsidiaries or any combination thereof and the same shall remain undischarged for a period of [***] calendar days during which execution shall not be effectively stayed or bonded pending appeal, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An ERISA Event shall have occurred that when taken together with all other ERISA Events that have occurred, could reasonably be expected to result in liability of the Borrower and its Subsidiaries in an aggregate amount in excess of [***] (or the Equivalent Amount in other currencies).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A Change of Control shall have occurred.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Matters, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of the following occurs after FDA Approval: (i) the FDA or any other Regulatory Authority initiates enforcement action against, or issues a warning letter, clinical hold, untitled letter, Official Action Indicated (OAI) status, or failure of a pre-approval inspection, with respect to, any Obligor, Taletrectinib or any manufacturing facilities for Taletrectinib that causes any Obligor to discontinue or withdraw, or could reasonably be expected to cause any Obligor to discontinue or withdraw, marketing or sales of Taletrectinib, or causes a delay in the manufacture or sale of Taletrectinib, which discountenance or delay extends for a period of more than [***] calendar days, (ii) except as permitted pursuant to the second sentence of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Revenue Interest Financing Agreement, any revocation, withdrawal, suspension, cancellation, material limitation, termination or material adverse modification of any Product Authorization issued by the FDA for Taletrectinib that is not reversed in full within [***] days of the first occurrence of such event, (iii) a recall of one or more batches of Taletrectinib in the United States (other than a total recall of Taletrectinib from the market in the United States) that results in or would reasonably be expected to result in a Material Adverse Effect or (iv) a total recall of Taletrectinib from the market in the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Security, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject in all respects to any applicable post-closing periods and certain other time periods and exceptions under the Loan Documents for any Obligor or Subsidiary to take perfection actions, if any of the following events occurs: (i) any Lien created by any of the Security Documents shall at any time (except as expressly permitted by the terms of any Loan Document) not constitute a valid and perfected Lien on a portion of the applicable Collateral having a value in excess of [***], in favor of the Secured Parties, free and clear of all other Liens (other than Permitted Liens) except due to the action or inaction of the Administrative Agent, (ii) except for expiration in accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) shall for whatever reason cease to be in full force and effect, (iii) any Obligor shall, directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability of any such Lien or any Loan Document or (iv) following the sale of Taletrectinib by any Obligor in the United States, any injunction, whether temporary or permanent, shall be rendered against any Obligor that prevents the Obligors from selling or manufacturing Taletrectinib or its commercially available successors in the United States for more than [***] calendar days and after the termination of such [***] day period the existence of such circumstance could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defaults Other Than Bankruptcy Defaults</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), and at any time thereafter during the continuance of such event, the Administrative Agent may, by notice to the Borrower, declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations, including any applicable Yield Protection Premium and the Exit Fee, shall become due and payable immediately (in the case of the Loans, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy Defaults</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In case of an Event of Default described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, including any applicable Yield Protection Premium and the Exit Fee, shall automatically become due and payable immediately (in the case of the Loans, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If an Event of Default has occurred and is continuing, if any Obligor shall be in default under a Material Agreement, the Administrative Agent shall have the right (but not the obligation) to cause the default or defaults under such Material Agreement to be remedied (including without limitation by paying any unpaid amount thereunder) and otherwise exercise any and all rights of such Obligor, as the case may be, thereunder, as may be necessary to prevent or cure any default. Without limiting the foregoing, upon any such default, each Obligor shall promptly execute, acknowledge and deliver to the Administrative Agent such instruments as may reasonably be required of such Obligor to permit the Administrative Agent to cure any default under the applicable Material Agreement or permit the Administrative Agent to take such other action required to enable the Administrative Agent to cure or remedy the matter in default and preserve the interests of the Administrative Agent. Any amounts paid by the Administrative Agent pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be payable in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall accrue interest at the Default Rate if not paid when due, and shall constitute &#x201c;Obligations.&#x201d; The Administrative Agent and the Lenders agree that in connection with any foreclosure or other exercise of rights under this Agreement or any other Loan Document with respect to Intellectual Property, the rights of the non-Affiliate licensees under Permitted Licenses will not be terminated, limited or otherwise adversely affected so long as no default exists under the Permitted License that would permit the licensor to terminate such Permitted License (commonly known as a non-disturbance); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Administrative Agent shall be entitled to exercise any rights of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligors under such licenses, including termination rights, upon the exercise of remedies during an Event of Default.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.04.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.05.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Yield Protection Premium and Exit Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything in this Agreement to the contrary, each of the Yield Protection Premium and Exit Fee shall automatically be due and payable at any time the Obligations become due and payable prior to the Maturity Date in accordance with the terms hereof (other than in connection with a prepayment due under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.03(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a result of a Casualty Event) as though such Indebtedness was voluntarily prepaid and shall constitute part of the Obligations, whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Borrower in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.02(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or automatically, in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.02(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), by operation of law or otherwise (including on account of any bankruptcy filing), in view of the impracticability and extreme difficulty of ascertaining the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders as a result thereof. Any Yield Protection Premium or Exit Fee or, if required, both the Yield Protection Premium and the Exit Fee payable pursuant to this Agreement shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, acceleration, redemption, repayment or prepayment and each Obligor agrees that such Yield Protection Premium or Exit Fee is reasonable under the circumstances currently existing. Each of the Yield Protection Premium and Exit Fee shall also become due and payable under this Agreement in the event the Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other means or the Obligations are reinstated pursuant to Section 1124 of the Bankruptcy Code. If either the Yield Protection Premium or Exit Fee (or both) becomes due and payable pursuant to this Agreement, such Yield Protection Premium or Exit Fee shall be deemed to be principal of the Loans and Obligations under this Agreement and interest shall accrue on the full principal amount of the Loans (including such Yield Protection Premium or Exit Fee) from and after the applicable triggering event. In the event the Yield Protection Premium is determined not to be due and payable by order of any court of competent jurisdiction, including by operation of the Bankruptcy Code, despite such a triggering event having occurred, each of the Yield Protection Premium and Exit Fee shall nonetheless constitute Obligations under this Agreement for all purposes hereunder. </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Obligor hereby waives the provisions of any present or future statute or law that prohibits or may prohibit the collection of the Yield Protection Premium and any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Obligors, the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrative Agent and the Lenders acknowledge and agree that any Yield Protection Premium and the Exit Fee due and payable in accordance with this Agreement shall not constitute unmatured interest, whether under Section 5.02(b)(3) of the Bankruptcy Code or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation. Each Obligor expressly agrees that (i) each of the Yield Protection Premium and Exit Fee is reasonable and is the product of an Arm&#x2019;s Length Transaction between sophisticated business people, ably represented by counsel, (ii) each of the Yield Protection Premium and Exit Fee shall be payable notwithstanding the then prevailing market rates at the time payment is made, (iii) there has been a course of conduct between the Lenders and the Obligors giving specific consideration in this transaction for such agreement to pay each of the Yield Protection Premium or Exit Fee, (iv) the Obligors shall not challenge or question, or support any other Person in challenging or questioning, the validity or enforceability of the Yield Protection Premium or Exit Fee or any similar or comparable prepayment fee under the circumstances described herein, and shall be estopped hereafter from claiming differently than as agreed to in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.06</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (v) their agreement to pay each of the Yield Protection Premium or Exit Fee is a material inducement to the Lenders to make the Loans, and (vi) each of the Yield Protection Premium and Exit Fee represents a good faith, reasonable estimate and calculation of the lost profits, losses or other damages of the Lenders and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such event. Each Obligor expressly acknowledges that its agreement to pay or guarantee the payment of the Yield Protection Premium or Exit Fee to the Lenders as herein described are individually and collectively a material inducement to holders to enter into this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>The Administrative Agent</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appointment and Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject in all cases to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appointment of the Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Lenders hereby irrevocably appoints Sagard Holdings Manager LP (together with any successor Administrative Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) as the Administrative Agent hereunder and authorizes the Administrative Agent to (i) execute and deliver the Loan Documents and accept delivery thereof on its behalf from any Obligor or any of its Subsidiaries, (ii) take such action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to the Administrative Agent under such Loan Documents and (iii) exercise such powers as are reasonably incidental thereto. Except as expressly set forth herein, the provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(other than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 12.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and solely to the extent expressly set forth therein) are solely for the benefit of the Administrative Agent and the Lenders, and no Obligor or any Affiliate thereof shall have rights as a third-party beneficiary of any such provisions.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duties as Collateral and Disbursing Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limiting the generality of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Administrative Agent shall have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (i) act as the disbursing and collecting agent for the Lenders with respect to all payments and collections arising in connection with the Loan Documents (including in any proceeding described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any other bankruptcy, insolvency or similar proceeding), and each Person making any payment in connection with any Loan Document to any Secured Party is hereby authorized to make such payment to the Administrative Agent, (ii) file and prove claims and file other documents necessary or desirable to allow the claims of the Secured Parties with respect to any Obligation in any proceeding described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any other bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise act on behalf of such Secured Party), (iii) act as collateral agent for each Secured Party for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iv) manage, supervise and otherwise deal with the Collateral, (v) take such other action as is necessary or desirable to maintain the perfection and priority of the Liens created or purported to be created by the Loan Documents, (vi) except as may be otherwise specified in any Loan Document, exercise all remedies given to the Administrative Agent and the other Secured Parties with respect to the Collateral, whether under the Loan Documents, applicable Laws or otherwise, (vii) enter into the Permitted Intercreditor Agreement, (viii) enter into non-disturbance agreements and similar agreements and (ix) execute any amendment, consent or waiver under the Loan Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Administrative Agent hereby appoints, authorizes and directs each Lender to act as collateral sub-agent for the Administrative Agent and the Lenders for purposes of the perfection of all Liens with respect to the Collateral, including any deposit account maintained by a Obligor with, and cash and Permitted Cash Equivalents Investments held by, such Lender, and may further authorize and direct the Lenders to take further actions as collateral sub-agents for purposes of enforcing such Liens or otherwise to transfer the Collateral subject thereto to the Administrative Agent, and each Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limited Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Lenders and the Obligors hereby each acknowledge and agree that the Administrative Agent (i) has undertaken its role hereunder purely as an accommodation to the parties hereto and the Transactions, (ii) is receiving no compensation for undertaking such role and (iii) subject only to the notice provisions set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, may resign from such role at any time for any reason or no reason whatsoever. Without limiting the foregoing, the parties hereto further acknowledge and agree that under the Loan Documents, the Administrative Agent (i) is acting solely on behalf of the Lenders (except to the limited extent provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), with duties that are entirely administrative in nature, notwithstanding the use of the defined term &#x201c;the Administrative Agent&#x201d;, the terms &#x201c;agent&#x201d;, &#x201c;administrative agent&#x201d; and &#x201c;collateral agent&#x201d; and similar terms in any Loan Document to refer to the Administrative Agent, which terms are used</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for title purposes only, (ii) is not assuming any duty or obligation under any Loan Document other than as expressly set forth therein or any role as agent, fiduciary or trustee of or for any Lender or any other Secured Party and (iii) shall have no implied functions, responsibilities, duties, obligations or other liabilities under any Loan Document (fiduciary or otherwise), in each case, regardless of whether a Default has occurred and is continuing, and each Lender hereby waives and agrees not to assert any claim against the Administrative Agent based on the roles, duties and legal relationships expressly disclaimed in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without in any way limiting the foregoing, the Administrative Agent shall not, except as expressly set forth in this Agreement and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Obligor or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Lender agrees that (i) any action taken by the Administrative Agent or the Majority Lenders (or, if expressly required hereby, a greater proportion of the Lenders) in accordance with the provisions of the Loan Documents, (ii) any action taken by the Administrative Agent in reliance upon the instructions of the Majority Lenders (or, where so required, such greater proportion) and (iii) the exercise by the Administrative Agent or the Majority Lenders (or, where so required, such greater proportion) of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Secured Parties.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Action without Instructions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent shall not be required to exercise any discretion or take, or to omit to take, any action, including with respect to enforcement or collection, except (subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below) any action it is required to take or omit to take (i) under any Loan Document or (ii) pursuant to written instructions from the Majority Lenders (or, where expressly required by the terms of this Agreement, a greater proportion of the Lenders).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right Not to Follow Certain Instructions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.03(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any other term or provision of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Administrative Agent shall not be required to take, or to omit to take, any action (i) unless, upon demand, the Administrative Agent receives an indemnification satisfactory to it from the Lenders (or, to the extent applicable and acceptable to the Administrative Agent, any other Secured Party) against all liabilities that, by reason of such action or omission, may be imposed on, incurred by or asserted against the Administrative Agent or any Related Party thereof or (ii) that is, in the opinion of the Administrative Agent, in its sole and absolute discretion, contrary to any Loan Document, Law or the best interests of the Administrative Agent or any of its Affiliates or Related Parties, including, for the avoidance of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doubt, any action that may be in violation of the automatic stay in connection with any Insolvency Proceeding.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delegation of Rights and Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent may, upon any term or condition it specifies, delegate or exercise any of its rights, powers and remedies under, and delegate or perform any of its duties or any other action with respect to, any Loan Document by or through any trustee, co-agent, employee, attorney-in-fact and any other Person (including any Secured Party). The Administrative Agent and any such Person may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. Any such Person and its Related Parties shall benefit from this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the extent provided by the Administrative Agent; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the exculpatory provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and of any such sub-agent, and shall apply to their respective activities in connection with their activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance and Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Administrative Agent may, without incurring any liability hereunder, (i) consult with any of its Related Parties and, whether or not selected by it, any other advisors, accountants and other experts (including advisors to, and accountants and experts engaged by, any Obligor) and (ii) rely and act upon any notice, request, certificate, consent, statement, instrument, document or other writing (including and electronic message, Internet or intranet website posting or other distribution), telephone message or conversation or oral conversation, in each case believed by it to be genuine and transmitted, signed or otherwise authenticated by the appropriate parties. In determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received written notice to the contrary from such Lender prior to the making of such Loan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Neither the Administrative Agent nor any of its Related Parties shall be liable for any action taken or omitted to be taken by any of them under or in connection with any Loan Document, and each Lender and the Borrower hereby waive and shall not assert (and the Borrower shall cause each other Obligor to waive and agree not to assert) any right, claim or cause of action based thereon, except to the extent of liabilities resulting primarily from the fraudulent conduct or behavior of the Administrative Agent or, as the case may be, such Related Party (each as determined in a final, non-appealable judgment or order by a court of competent jurisdiction) in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">connection with the duties expressly set forth herein. Without limiting the foregoing, the Administrative Agent:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	shall not be responsible or otherwise incur liability for any action or omission taken in reliance upon the instructions of, or with the consent of, the Majority Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or for the actions or omissions of any of its Related Parties selected with reasonable care (other than employees, officers and directors of the Administrative Agent, when acting on behalf of the Administrative Agent);</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	shall not be responsible to any Secured Party for the (a) validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or (b) due execution, legality, validity, enforceability, effectiveness, genuineness, sufficiency or value of, or the attachment, perfection or priority of any Lien created or purported to be created under or in connection with, any Loan Document;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	makes no warranty or representation, and shall not be responsible, to any Secured Party for, and shall not have any duty to ascertain or inquire into, any statement, document, information, certificate, report, representation or warranty made or furnished by or on behalf of any Related Party, in or in connection with any Loan Document or any transaction contemplated therein, whether or not transmitted by the Administrative Agent, including as to completeness, accuracy, scope or adequacy thereof, or for the scope, nature or results of any due diligence performed by the Administrative Agent in connection with the Loan Documents, including, for the avoidance of doubt, the satisfaction of any condition set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of this Agreement or elsewhere herein (other than to confirm receipt of items expressly required to be delivered to the Administrative Agent); and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	shall not have any duty to ascertain or to inquire as to the performance or observance of any provision of any Loan Document or whether any condition set forth in any Loan Document is satisfied or waived, including, without limiting the generality of the foregoing, as to the financial condition of any Obligor or as to the existence or continuation or possible occurrence or continuation of any Default or Event of Default and shall not be deemed to have notice or knowledge of such occurrence or continuation unless it has received a notice from the Borrower, any Lender describing such Default or Event of Default clearly labeled &#x201c;notice of default&#x201d; (in which case the Administrative Agent shall promptly give notice of such receipt to all Lenders);</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and, for each of the items set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above, each Lender and the Borrower hereby waives and agrees not to assert (and the Borrower shall cause each other Obligor to waive and agree not to assert) any right, claim or cause of action it might have against the Administrative Agent based thereon.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrative Agent Individually</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent and its Affiliates may make loans and other extensions of credit to, acquire stock and stock equivalents of, accept deposits from, act as the financial advisor for or in any other advisory capacity for, or engage in any kind of business with, any Obligor or Affiliate thereof as though it were not acting as the Administrative Agent and may receive separate fees and other payments therefor. To the extent the Administrative Agent or any of its Affiliates makes any Loan or otherwise becomes a Lender hereunder, it shall have and may exercise the same rights and powers hereunder and shall be subject to the same obligations and liabilities as any other Lender and the terms &#x201c;Lender&#x201d;, &#x201c;Majority Lender&#x201d;, and any similar terms shall, except where otherwise expressly provided in any Loan Document, include, without limitation, the Administrative Agent or such Affiliate, as the case may be, in its individual capacity as Lender or as one of the Majority Lenders, respectively.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender Credit Decision</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent, any Lender or any of their Related Parties or upon any document solely or in part because such document was transmitted by the Administrative Agent or any of its Related Parties, conducted its own independent investigation of the financial condition and affairs of each Obligor and has made and continues to make its own credit decisions in connection with entering into, and taking or not taking any action under, any Loan Document or with respect to any transaction contemplated in any Loan Document, in each case based on such documents and information as it shall deem appropriate.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses; Indemnities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Each Lender agrees to reimburse the Administrative Agent and each of its Related Parties (to the extent not reimbursed by any Obligor) promptly upon demand for such Lender&#x2019;s Proportionate Share of any costs and expenses (including fees, charges and disbursements of financial, legal and other advisors and Other Taxes paid in the name of, or on behalf of, any Obligor) that may be incurred by the Administrative Agent or any of its Related Parties in connection with the preparation, syndication, execution, delivery, administration, modification, consent, waiver or enforcement (whether through negotiations, through any work-out, bankruptcy, restructuring or other legal or other proceeding or otherwise) of, or legal advice in respect of its rights or responsibilities under, any Loan Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Each Lender further agrees to indemnify the Administrative Agent (or any sub-agent thereof) and any Related Party of the Administrative Agent (or any such sub-agent) (to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extent not indefeasibly paid by any Obligor), from and against such Lender&#x2019;s aggregate Proportionate Share of the liabilities (including taxes, interests and penalties imposed for not properly withholding or backup withholding on payments made to on or for the account of any Lender) that may be imposed on, incurred by or asserted against the Administrative Agent (or any sub-agent thereof) or any Related Parties of the Administrative Agent (or any such sub-agent) in any matter relating to or arising out of, in connection with or as a result of any Loan Document, any related document or any other act, event or transaction related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by the Administrative Agent (or any sub-agent thereof) or any Related Parties of the Administrative Agent (or any such sub-agent) under or with respect to any of the foregoing; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that no Lender shall be liable to the Administrative Agent (or any sub-agent thereof) or any Related Parties of the Administrative Agent (or any such sub-agent) to the extent such liability has resulted primarily from the gross negligence or willful misconduct of the Administrative Agent (or any sub-agent thereof) or, as the case may be, such Related Party of the Administrative Agent (or any sub-agent thereof), as determined by a court of competent jurisdiction in a final non-appealable judgment or order.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resignation of the Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	At any time upon not less than 30 days prior written notice, the Administrative Agent may resign as the &#x201c;the Administrative Agent&#x201d; hereunder, in whole or in part (in the sole and absolute discretion of the Administrative Agent). If the Administrative Agent delivers any such notice, the Majority Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be (i) a Lender holding at least thirty percent (30%) of the outstanding principal amount of the Loans or any Affiliate thereof or (ii) any other financial institution consented to by the Borrower (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the consent of the Borrower shall not be required to the extent an Event of Default has occurred and is continuing). If a successor Administrative Agent has not been appointed on or before the effectiveness of the resignation of the resigning Administrative Agent (or such earlier date as shall be agreed by the Majority Lenders) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resignation Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then the resigning Administrative Agent may (but shall not be obligated to), on behalf of the Lenders, appoint any Person reasonably chosen by it as the successor Administrative Agent, notwithstanding whether the Majority Lenders have appointed a successor or the Borrower has consented to such successor. Whether or not a successor has been appointed, such resignation shall become effective on the Resignation Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Effective from the Resignation Effective Date, (i) the resigning Administrative Agent shall be discharged from its duties and obligations under the Loan Documents to the extent set forth in the applicable resignation notice, (ii) the Majority Lenders shall assume and perform all of the duties of the Administrative Agent until a successor Administrative Agent shall have accepted a valid appointment hereunder, (iii) the resigning Administrative Agent and its Related</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties shall no longer have the benefit of any provision of any Loan Document other than with respect to (x) any actions taken or omitted to be taken while such resigning Administrative Agent was, or because the Administrative Agent had been, validly acting as the Administrative Agent under the Loan Documents or (y) any continuing duties such resigning Administrative Agent will continue to perform, and (iv) subject to its rights under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the resigning Administrative Agent shall take such action as may be reasonably necessary to assign to the successor Administrative Agent its rights as the Administrative Agent under the Loan Documents. Effective immediately upon its acceptance of a valid appointment as the Administrative Agent, a successor Administrative Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the resigning Administrative Agent under the Loan Documents.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release of Collateral or Subsidiary Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Lender hereby consents to the release and hereby directs the Administrative Agent to release, and the Administrative Agent hereby agrees, ((or, in the case of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.10(b))</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, release or subordinate) the following:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	any Subsidiary of the Borrower from its guaranty of any Obligation of any Obligor (i) if all of the Equity Interests in such Subsidiary owned by any Obligor or any of its Subsidiaries are disposed of in an Asset Sale permitted under the Loan Documents (including pursuant to a waiver or consent), to the extent that, after giving effect to such Asset Sale, such Subsidiary would not be required to guaranty any Obligations pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.12(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) upon (x) termination of the Commitments and (y) payment and satisfaction in full of all Loans and all other Obligations that the Administrative Agent has been notified in writing are then due and payable (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made); and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	any Lien held by the Administrative Agent for the benefit of the Secured Parties against (i) any Collateral that is disposed of by an Obligor in an Asset Sale permitted by the Loan Documents (including pursuant to a valid waiver or consent), (ii) any property subject to a Lien described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.02(c) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) all of the Collateral and all Obligors, upon (x) termination of the Commitments and (y) payment and satisfaction in full of all Loans and all other Obligations that the Administrative Agent has been notified in writing are then due and payable (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Lender hereby directs the Administrative Agent, and the Administrative Agent hereby agrees, upon receipt of reasonable advance notice from the Borrower, to execute and deliver or file such documents and to perform other actions reasonably necessary to release the guarantees and Liens when and as directed in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and deliver to the Borrower, at the expense of the Borrower, any portion of such Collateral so released pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that is in possession of the Administrative Agent. In addition, in connection with any Permitted Licenses,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each Lender hereby authorizes Administrative Agent to, and at the request of the Borrower, the Administrative Agent shall, negotiate and enter into a non-disturbance agreement and other similar agreements in form and substance reasonably satisfactory to Administrative Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing or anything to the contrary herein, (i) the release of any Obligor from its guaranty of any Obligations under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or otherwise hereunder shall only be permitted if any such permitted transaction or series of related transactions is not consummated for the primary purpose of effecting a release of such Obligor from its Obligations under the Loan Documents in accordance with the terms hereof, and (ii) the Administrative Agent may not effect a release of any Obligor that ceases to be an Obligor due solely to a disposition of Equity Interests in (or issuance of Equity Interests by) such Obligor, unless in the case of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the transaction related to such release is a disposition of Equity Interests for fair market value to an unaffiliated third party and for a bona fide primary business purpose.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Secured Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The benefit of the provisions of the Loan Documents directly relating to the Collateral or any Lien granted thereunder shall extend to and be available to any Secured Party that is not a Lender as long as, by accepting such benefits, such Secured Party agrees, as among the Administrative Agent and all other Secured Parties, that such Secured Party is bound by (and, if requested by the Administrative Agent, shall confirm such agreement in a writing in form and substance acceptable to the Administrative Agent) this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the decisions and actions of the Administrative Agent and the Majority Lenders (or, where expressly required by the terms of this Agreement, a greater proportion of the Lenders) to the same extent a Lender is bound; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, notwithstanding the foregoing, (i) such Secured Party shall be bound by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.08 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">only to the extent of liabilities, costs and expenses with respect to or otherwise relating to the Collateral held for the benefit of such Secured Party, in which case the obligations of such Secured Party thereunder shall not be limited by any concept of Proportionate Share or similar concept, (ii) each of the Administrative Agent and each Lender shall be entitled to act at its sole discretion, without regard to the interest of such Secured Party, regardless of whether any Obligation to such Secured Party thereafter remains outstanding, is deprived of the benefit of the Collateral, becomes unsecured or is otherwise affected or put in jeopardy thereby, and without any duty or liability to such Secured Party or any such Obligation and (iii) such Secured Party shall not have any right to be notified of, consent to, direct, require or be heard with respect to, any action taken or omitted in respect of the Collateral or under any Loan Document.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.12.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent May File Proofs of Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relating to any Obligor, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower or any other Obligor) shall be entitled and empowered (but not obligated) by intervention or such proceeding or otherwise:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) allowed in such judicial proceeding; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due to the Administrative Agent under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acknowledgements of Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	If the Administrative Agent notifies a Lender, or any Person who has received funds on behalf of a Lender (any such Lender or other recipient, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), that the Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) that any funds received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender or other Payment Recipient on its behalf) (any such funds, whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and demands the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative Agent and shall be segregated by the Payment Recipient and held in trust for the benefit of the Administrative Agent, and such Lender shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two Business Days thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">time to time in effect. A notice of the Administrative Agent to any Payment Recipient under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be conclusive, absent manifest error.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Without limiting immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, each Lender, or any Person who has received funds on behalf of a Lender, hereby further agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Lender or other such recipient otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part) in each case: (i)(A) in the case of immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (x)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an error shall be presumed to have been made (absent written confirmation from the Administrative Agent to the contrary) or (B) an error has been made (in the case of immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (z)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), in each case, with respect to such payment, prepayment or repayment; and (ii) such Lender shall (and shall cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within one Business Day of its knowledge of such error) notify the Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying the Administrative Agent pursuant to this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(b)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Each Lender hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender from any source, against any amount due to the Administrative Agent under immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or under the indemnification provisions of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	In the event that an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor by the Administrative Agent in accordance with immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, from any Lender that has received such Erroneous Payment (or portion thereof) (and/or from any Payment Recipient who received such Erroneous Payment (or portion thereof) on its respective behalf) (such unrecovered amount, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Return Deficiency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), upon the Administrative Agent&#x2019;s notice to such Lender at any time, (i) such Lender shall be deemed to have assigned its Loans (but not its Commitments) with respect to which such Erroneous Payment was made (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Impacted Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in an amount equal to the Erroneous Payment Return Deficiency (or such lesser amount as the Administrative Agent may specify) (such assignment of the Loans (but not Commitments) of the Erroneous Payment Impacted Loans, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Deficiency Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) at par plus any accrued and unpaid interest (with the assignment fee to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be waived by the Administrative Agent in such instance), and is hereby (together with the Borrower) deemed to execute and deliver an Assignment and Assumption with respect to such Erroneous Payment Deficiency Assignment, and such Lender shall deliver any Notes evidencing such Loans to the Borrower or the Administrative Agent, (ii) the Administrative Agent as the assignee Lender shall be deemed to acquire the Erroneous Payment Deficiency Assignment, (iii) upon such deemed acquisition, the Administrative Agent as the assignee Lender shall become a Lender, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning Lender shall cease to be a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this Agreement and its applicable Commitments which shall survive as to such assigning Lender and (iv) the Administrative Agent may reflect in the Register its ownership interest in the Loans subject to the Erroneous Payment Deficiency Assignment. The Administrative Agent may, in its discretion, sell any Loans acquired pursuant to an Erroneous Payment Deficiency Assignment and upon receipt of the proceeds of such sale, the Erroneous Payment Return Deficiency owing by the applicable Lender shall be reduced by the net proceeds of the sale of such Loan (or portion thereof), and the Administrative Agent shall retain all other rights, remedies and claims against such Lender (and/or against any recipient that receives funds on its respective behalf). For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender and such Commitments shall remain available in accordance with the terms of this Agreement. In addition, each party hereto agrees that, except to the extent that the Administrative Agent has sold a Loan (or portion thereof) acquired pursuant to an Erroneous Payment Deficiency Assignment, and irrespective of whether the Administrative Agent may be equitably subrogated, the Administrative Agent shall be contractually subrogated to all the rights and interests of the applicable Lender under the Loan Documents with respect to each Erroneous Payment Return Deficiency (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erroneous Payment Subrogation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The parties hereto agree that an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower or any other Obligor, except, in each case, to the extent such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower or any other Obligor for the purpose of making such Erroneous Payment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set&#x1f;off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including without limitation waiver of any defense based on &#x201c;discharge for value&#x201d; or any similar doctrine.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Each party&#x2019;s obligations, agreements and waivers under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.13(g) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Commitments and/or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Guaranty</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Guaranty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Subsidiary Guarantors hereby unconditionally jointly and severally guarantee to the Administrative Agent and the Lenders, and their successors and assigns, the full and punctual payment in full or performance (whether at stated maturity, by acceleration or otherwise) of the Obligations, including (i) principal of and interest on the Loans, (ii) all fees and other amounts and Obligations from time to time owing to the Administrative Agent and the Lenders by the Borrower and each other Obligor under this Agreement or under any other Loan Document, in each case strictly in accordance with the terms hereof and thereof and (iii) the punctual and faithful performance, keeping, observance and fulfillment by the Borrower and Subsidiary Guarantors of all the agreements, conditions, covenants and obligations of the Borrower and Subsidiary Guarantors contained in the Loan Documents (such obligations being herein collectively called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guaranteed Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Subsidiary Guarantors hereby further jointly and severally agree that if the Borrower or any other Obligor shall fail to pay any amount in full when due or perform any such obligation (whether at stated maturity, by acceleration or otherwise), the Subsidiary Guarantors will promptly pay the same or perform such obligation at the place and in the manner specified herein or in the relevant Loan Document, as the case may be, without any demand or notice whatsoever, and that in the case of any extension of time of payment or performance or renewal of any of the Guaranteed Obligations, the same will be promptly paid in full or performed when due (whether at extended maturity, by acceleration or otherwise) in accordance with the terms of such extension or renewal.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations Unconditional</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of the Subsidiary Guarantors under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall constitute a guaranty of payment and performance and not of collection and are absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the Guaranteed Obligations under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by all applicable Laws, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that the obligations of the Subsidiary Guarantors hereunder shall be absolute and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not alter or impair the liability of the Subsidiary Guarantors hereunder, which shall remain absolute and unconditional as described above:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	at any time or from time to time, without notice to the Subsidiary Guarantors, the time for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall be done or omitted;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be extended, modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	any lien or security interest granted to, or in favor of, the Secured Parties as security for any of the Guaranteed Obligations shall fail to be perfected or preserved;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	any modification or amendment of or supplement to this Agreement or any other Loan Document, including any such amendment which may increase the amount of, or the interest rates applicable to, any of the Guaranteed Obligations guaranteed hereby;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	any change in the corporate, partnership, limited liability company or other existence, structure or ownership of the Borrower, any Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations, or any Insolvency Proceeding or other similar proceeding affecting the Borrower, any Subsidiary Guarantor or any other guarantor of the Guaranteed Obligations, or any of their respective assets, or any resulting release or discharge of any obligation of the Borrower, any Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	the existence of any claim, setoff or other rights which any Subsidiary Guarantor may have at any time against the Borrower, any other Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations, the Administrative Agent, any Secured Party or any other Person, whether in connection herewith or in connection with any unrelated transactions; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, notwithstanding any other provisions in this Guaranty, nothing in this Guaranty shall prevent the assertion of any such claim by separate suit or compulsory counterclaim;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	the unenforceability or invalidity of the Guaranteed Obligations or any part thereof or the lack of genuineness, enforceability or validity of any agreement relating thereto or with respect to the Collateral, if any, securing the Guaranteed Obligations or any part thereof, or any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other invalidity or unenforceability relating to or against the Borrower, any Subsidiary Guarantor or any other guarantor of any of the Guaranteed Obligations, for any reason, related to this Agreement or any other Loan Document, or any provision of applicable Law, decree, order or regulation of any jurisdiction purporting to prohibit the payment of any of the Guaranteed Obligations by the Borrower, any Subsidiary Guarantor or any other guarantor of the Guaranteed Obligations;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	the disallowance, under any state or federal bankruptcy, insolvency or similar law, of all or any portion of the claims of the Secured Parties or the Administrative Agent for repayment of all or any part of the Guaranteed Obligations;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	the failure of any other guarantor to sign or become party to this Agreement or any amendment, change, or reaffirmation hereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	any release, surrender, compromise, settlement, waiver, subordination or modification, with or without consideration, of any Collateral securing the Guaranteed Obligations or any part thereof, any other guaranties with respect to the Guaranteed Obligations or any part thereof, or any other obligation of any person or entity with respect to the Guaranteed Obligations or any part thereof, or any nonperfection or invalidity of any direct or indirect security for the Guaranteed Obligations; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	any other act or omission to act or delay of any kind by the Borrower, such Subsidiary Guarantor, any other guarantor of the Guaranteed Obligations, the Administrative Agent, any Secured Party or any other Person or any other circumstance whatsoever which might, but for the provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, constitute a legal or equitable discharge of any Subsidiary Guarantor&#x2019;s obligations hereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Subsidiary Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Administrative Agent or any Lender exhaust any right, power or remedy or proceed against the Borrower or any other Subsidiary Guarantor under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discharge Only Upon Payment in Full</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to any prior release herefrom of any Subsidiary Guarantor by the Administrative Agent in accordance with (and pursuant to authority granted to the Administrative Agent under) the terms of this Agreement, each Subsidiary Guarantor&#x2019;s obligations hereunder shall remain in full force and effect until all of the Guaranteed Obligations shall have been indefeasibly paid in full in cash (other than inchoate indemnification and expense reimbursement obligations for which no claim has been made) and all other financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrangements among the Borrower or any Subsidiary Guarantor and the Secured Parties under or in connection with this Agreement and each other Loan Document shall have terminated (herein, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and until the prior and complete satisfaction of the Termination Conditions all of the rights and remedies under this Guaranty and the other Loan Documents shall survive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Waivers; General Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything herein to the contrary, each of the Subsidiary Guarantors hereby absolutely, unconditionally, knowingly, and expressly waives:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	any right it may have to revoke this Guaranty as to future indebtedness or notice of acceptance hereof;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	(A) notice of acceptance hereof; (B) notice of any other financial accommodations made or maintained under the Loan Documents or the creation or existence of any Guaranteed Obligations; (C) notice of the amount of the Guaranteed Obligations, subject, however, to each Subsidiary Guarantor&#x2019;s right to make inquiry of the Administrative Agent and the Secured Parties to ascertain the amount of the Guaranteed Obligations at any reasonable time; (D) notice of any adverse change in the financial condition of the Borrower or of any other fact that might increase such Subsidiary Guarantor&#x2019;s risk hereunder; (E) notice of presentment for payment, demand, protest, and notice thereof as to any instruments among the Loan Documents; (F) notice of any Event of Default; and (G) all other notices (except if such notice is specifically required to be given to such Subsidiary Guarantor under this Guaranty or under the other Loan Documents) and demands to which each Subsidiary Guarantor might otherwise be entitled;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	its right, if any, to require the Administrative Agent and the Secured Parties to institute suit against, or to exhaust any rights and remedies which the Administrative Agent and the Secured Parties now have or may hereafter have against, any other guarantor of the Guaranteed Obligations or any third party, or against any Collateral provided by such other guarantors or any third party; and each Subsidiary Guarantor further waives any defense arising by reason of any disability or other defense (other than the defense that the Guaranteed Obligations shall have been fully and finally performed and indefeasibly paid) of any other guarantor of the Guaranteed Obligations or by reason of the cessation from any cause whatsoever of the liability of any other guarantor of the Guaranteed Obligations in respect thereof;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	(A) any rights to assert against the Administrative Agent and the Secured Parties any defense (legal or equitable), set-off, counterclaim, or claim which such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiary Guarantor may now or at any time hereafter have against any other guarantor of the Guaranteed Obligations or any third party liable to the Administrative Agent and the Secured Parties; (B) any defense, set-off, counterclaim or claim, of any kind or nature, arising directly or indirectly from the present or future lack of perfection, sufficiency, validity or enforceability of the Guaranteed Obligations or any security therefor; (C) any defense such Subsidiary Guarantor has to performance hereunder, and any right such Subsidiary Guarantor has to be exonerated, arising by reason of: (1) the impairment or suspension of the Administrative Agent&#x2019;s and the Secured Parties&#x2019; rights or remedies against any other guarantor of the Guaranteed Obligations; (2) the alteration by the Administrative Agent and the Secured Parties of the Guaranteed Obligations; (3) any discharge of the obligations of any other guarantor of the Guaranteed Obligations to the Administrative Agent and the Secured Parties by operation of law as a result of the Administrative Agent&#x2019;s and the Secured Parties&#x2019; intervention or omission; or (4) the acceptance by the Administrative Agent and the Secured Parties of anything in partial satisfaction of the Guaranteed Obligations; and (D) the benefit of any statute of limitations affecting such Subsidiary Guarantor&#x2019;s liability hereunder or the enforcement thereof, and any act which shall defer or delay the operation of any statute of limitations applicable to the Guaranteed Obligations shall similarly operate to defer or delay the operation of such statute of limitations applicable to such Subsidiary Guarantor&#x2019;s liability hereunder; and</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	any defense arising by reason of or deriving from (A) any claim or defense based upon an election of remedies by the Administrative Agent and the other Secured Parties; or (B) any election by the Administrative Agent and the other Secured Parties under any provision of any state or federal bankruptcy, insolvency or similar law to limit the amount of, or any Collateral securing, its claim against the Subsidiary Guarantors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Subsidiary Guarantor irrevocably waives, to the fullest extent permitted by law, any notice not provided for herein.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reinstatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of the Subsidiary Guarantors under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of the Borrower in respect of the Guaranteed Obligations is at any time rescinded, annulled, avoided, set aside, invalidated, declared to be fraudulent or must be otherwise restored or repaid by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization, equitable cause or otherwise, and the Subsidiary Guarantors jointly and severally agree that they will indemnify the Secured Parties on demand for all reasonable costs and expenses (including fees of counsel) incurred by such Persons in connection with such rescission, repayment or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">145</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar payment under any state or federal bankruptcy, insolvency or similar law. The provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.05 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall survive termination of this Guaranty.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subrogation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Subsidiary Guarantors hereby jointly and severally agree that, until the prior and complete satisfaction of all Termination Conditions, they (i) shall have no right of subrogation with respect to the Guaranteed Obligations and (ii) waive any right to enforce any remedy which the Secured Parties or the Administrative Agent now have or may hereafter have against the Borrower, any endorser or any other guarantor of all or any part of the Guaranteed Obligations or any other Person, and each Subsidiary Guarantor waives any benefit of, and any right to participate in, any security or Collateral that may from time to time be given to the Secured Parties and the Administrative Agent to secure the payment or performance of all or any part of the Guaranteed Obligations or any other liability of the Borrower to the Secured Parties. Should any Subsidiary Guarantor have the right, notwithstanding the foregoing, to exercise its subrogation rights prior to complete satisfaction of the Termination Conditions, each Subsidiary Guarantor hereby expressly and irrevocably (A) subordinates any and all rights at law or in equity to subrogation, reimbursement, exoneration, contribution, indemnification or set-off that such Subsidiary Guarantor may have prior to the complete satisfaction of the Termination Conditions, and (B) waives any and all defenses available to a surety, guarantor or accommodation co-obligor until all Termination Conditions are satisfied in full. Each Subsidiary Guarantor acknowledges and agrees that this subordination is intended to benefit the Administrative Agent and the Secured Parties and shall not limit or otherwise affect such Subsidiary Guarantor&#x2019;s liability hereunder or the enforceability of this Guaranty, and that the Administrative Agent, the Secured Parties and their respective successors and assigns are intended third party beneficiaries of the waivers and agreements set forth in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.06</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Subsidiary Guarantors jointly and severally agree that, as between the Subsidiary Guarantors, on one hand, and the Administrative Agent and the Lenders, on the other hand, the obligations of the Borrower under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(and shall be deemed to have become automatically due and payable in the circumstances provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) for purposes of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notwithstanding any stay, injunction or other prohibition, including any such stay upon an Insolvency Proceeding, preventing such declaration (or such obligations from becoming automatically due and payable) as against the Borrower and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by the Borrower) shall forthwith become due and payable by the Subsidiary Guarantors for purposes of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Instrument for the Payment of Money</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Subsidiary Guarantor hereby acknowledges that the guarantee in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">constitutes an instrument for the payment of money, and consents and agrees that the Administrative Agent and the Lenders, at their sole option, in the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">146</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event of a dispute by such Subsidiary Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&amp;R &#167; 3213.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continuing Guarantee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The guarantee in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contribution with Respect to Guaranteed Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	To the extent that any Subsidiary Guarantor shall make a payment under this Guaranty (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantor Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) which, taking into account all other Guarantor Payments then previously or concurrently made by any other Subsidiary Guarantor, exceeds the amount which otherwise would have been paid by or attributable to such Subsidiary Guarantor if each Subsidiary Guarantor had paid the aggregate Guaranteed Obligations satisfied by such Guarantor Payment in the same proportion as such Subsidiary Guarantor&#x2019;s &#x201c;Allocable Amount&#x201d; (as defined below) (as determined immediately prior to such Guarantor Payment) bore to the aggregate Allocable Amounts of each of the Subsidiary Guarantors as determined immediately prior to the making of such Guarantor Payment, then, following the prior and complete satisfaction of the Termination Conditions, such Subsidiary Guarantor shall be entitled to receive contribution and indemnification payments from, and be reimbursed by, each other Subsidiary Guarantor for the amount of such excess, pro rata</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based upon their respective Allocable Amounts in effect immediately prior to such Guarantor Payment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	As of any date of determination, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Allocable Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of any Subsidiary Guarantor shall be equal to the maximum amount of the claim which could then be recovered from such Subsidiary Guarantor under this Agreement without rendering such claim voidable or avoidable under any state or federal bankruptcy, insolvency or similar law or other applicable Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is intended only to define the relative rights of the Subsidiary Guarantors, and nothing set forth in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is intended to or shall impair the obligations of the Subsidiary Guarantors, jointly and severally, to pay any amounts as and when the same shall become due and payable in accordance with the terms of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The parties hereto acknowledge that the rights of contribution and indemnification hereunder shall constitute assets of the Subsidiary Guarantor or Subsidiary Guarantors to which such contribution and indemnification is owing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The rights of the indemnifying Subsidiary Guarantors against other Subsidiary Guarantors under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.10 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be exercisable only upon the prior and complete satisfaction of the Termination Conditions.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">147</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Limitation on Guarantee Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In any action or proceeding involving any provincial, territorial or state corporate law, or any state or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of any Subsidiary Guarantor under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">would otherwise be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Subsidiary Guarantor, the Administrative Agent, any Lender or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Miscellaneous</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.01.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No failure on the part of the Administrative Agent or the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.02.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All notices, requests, instructions, directions and other communications provided for herein (including any modifications of, or waivers, requests or consents under, this Agreement) or in the other Loan Documents shall be given or made in writing (including by telecopy or email) delivered, if to the Borrower, another Obligor, the Administrative Agent or any Lender, to its address specified on the signature pages hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a written notice to the other parties. Except as otherwise provided in this Agreement or therein, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.03.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses, Indemnification, Etc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Obligor, jointly and severally, agrees to pay or reimburse within [***] of receipt of a reasonably detailed invoice (i) the Administrative Agent and the Lenders and their respective Affiliates for all of their reasonable and documented out of pocket costs and expenses (including the reasonable and documented out of pocket fees, expenses, charges and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">148</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disbursements of Sidley Austin LLP as primary counsel to Administrative Agent and the Lenders, and any local counsel (if necessary) and regulatory counsel for both of the Administrative Agent and the Lenders in each relevant material jurisdiction, and any sales, goods and services or other similar Taxes applicable thereto, and reasonable and documented printing, reproduction, document delivery, communication and travel costs) in connection with (x) the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Loans (exclusive of post-closing costs), (y) post-closing costs (including, without limitation, costs of the administration of this Agreement and the other Loan Documents) and (z) the negotiation or preparation of any modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, in the case of such expenses on the Closing Date, the amount of such expenses shall not exceed [***] and shall be without duplication of amounts paid on or prior to the Closing Date in connection with the Revenue Interest Financing and (ii) each of the Administrative Agent and the Lenders for all of their documented out of pocket costs and expenses (including the fees and expenses of any legal counsel) in connection with the enforcement, exercise or protection of their rights in connection with this Agreement and the other Loan Documents, including their rights under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or in connection with the Loans made hereunder, including such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans and in connection with any enforcement or collection proceedings resulting from the occurrence of an Event of Default.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Obligor, jointly and severally, hereby indemnifies the Administrative Agent (and any sub-agent thereof), the Lenders and their respective Affiliates, directors, officers, employees, attorneys, agents, advisors and controlling parties (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from and against, and agrees to hold them harmless against, any and all Claims and Losses of any kind including reasonable and documented out of pocket fees and disbursements of any counsel for each Indemnified Party (limited to one legal counsel in each relevant jurisdiction), that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to (i) this Agreement or any of the other Loan Documents or the Transactions, (ii) any use made or proposed to be made with the proceeds of the Loans, (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by any Obligor or any of its Subsidiaries, or (iv) any actual or prospective claim, investigation, litigation or proceeding relating to any of the foregoing, whether based on contract, tort, or any other theory, whether or not such investigation, litigation or proceeding is brought by any Obligor, any of its Subsidiaries, shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are satisfied or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is (i) found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party&#x2019;s bad faith, gross negligence or willful misconduct or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">149</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) is determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from a claim brought by any Obligor against an Indemnified Party for material breach in bad faith or reckless disregard of such Indemnified Party&#x2019;s obligations hereunder or under any other Loan Document. No Obligor shall assert any claim against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Loans. The Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties are each sometimes referred to in this Agreement as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrower Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. None of the Administrative Agent and the Lenders shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Loans. Notwithstanding the foregoing in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Obligors shall not be liable for any settlement of any proceeding effected without the Obligors&#x2019; consent (which consent shall not be unreasonably withheld, delayed or conditioned), but if settled with the Obligors&#x2019; written consent, or if there is a judgment against an Indemnified Party in any such proceeding, the Obligors shall indemnify and hold harmless each Indemnified Party to the extent and in the manner set forth above. The Obligors shall not, without the prior written consent of an Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed), effect any settlement of any pending or threatened proceeding against such Indemnified Party in respect of which indemnity could have been sought hereunder by such Indemnified Party unless (a) such settlement includes an unconditional release of such Indemnified Party from all liability or claims that are the subject matter of, or arise out of, such proceeding and (b) such settlement does not include any statement as to, or any admission of fault, culpability, wrongdoing or a failure to act by or on behalf of such Indemnified Party. This Section shall not apply with respect to (x) Taxes other than Taxes relating to a non-Tax Claim and (y) yield protection matters covered by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which shall be governed exclusively by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.04.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments, Etc. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise expressly provided in this Agreement, any provision of this Agreement and any other Loan Document may be modified or supplemented only by an instrument in writing signed by the Borrower, the Administrative Agent and the Majority Lenders; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	any such modification or supplement that is disproportionately adverse to any Lender as compared to other Lenders or subjects any Lender to any additional obligation shall not be effective without the consent of such affected Lender;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the consent of all of the Lenders shall be required to:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">150</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	amend, modify, discharge, terminate or waive any of the terms of this Agreement or any other Loan Document if such amendment, modification, discharge, termination or waiver would increase the amount of the Loans or Commitment, reduce the fees payable hereunder, reduce interest rates (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Majority Lenders may rescind an imposition of default interest hereunder) or other amounts payable with respect to the Loans (excluding mandatory prepayments), extend any date fixed for payment of principal (excluding mandatory prepayments) (it being understood that the waiver of any prepayment of Loans shall not constitute an extension of any date fixed for payment of principal), interest or other amounts payable relating to the Loans or extend the repayment dates of the Loans (excluding mandatory prepayments); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that a waiver of any condition precedent set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or of any Default or Event of Default or a mandatory reduction in Commitments is not considered an increase in Commitments of any Lender;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	amend, modify, discharge, terminate or waive any Security Document if the effect is to release all or substantially all of the Collateral subject thereto other than pursuant to the terms hereof or thereof;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	contractually subordinate the right of payment of the Obligations (including any guarantees thereof) or the Administrative Agent&#x2019;s Lien on all or substantially all of the Collateral, in each case, to any other Indebtedness or other obligations in a manner that adversely affects any Lender without the written consent of each such Lender; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that any Liens expressly permitted under this Agreement to be senior to the Obligations, any debtor-in-possession (or equivalent) financing or any use of Collateral in an insolvency proceeding, shall not be restricted by this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	amend or modify the definition of &#x201c;Proportionate Share&#x201d; or the pro-rata sharing provisions contained in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 3.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.01(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; or</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	amend this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.04 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or the definition of &#x201c;Majority Lenders&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary herein, (A) the Administrative Agent and the Borrower may amend or modify this Agreement and any other Loan Document to (1) cure any factual or typographical error, omission, defect or inconsistency therein, or (2) grant a new Lien for the benefit of the Lenders, extend an additional Lien over additional property for the benefit of the Lenders or join additional Persons as Obligors and (B) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">151</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.05.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the parties hereto or thereto and their respective successors and assigns permitted hereby or thereby, except that no Obligor may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Loan Documents (except in connection with an event expressly permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) without the prior written consent of the Administrative Agent and all of the Lenders. Any Lender may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Loan Documents (i) to an assignee in accordance with the provisions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) by way of participation in accordance with the provisions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right, remedy or claim under or by reason of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignments by Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Lender may at any time assign to one or more Eligible Transferees (or, if an Event of Default has occurred and is continuing under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.01(b), Section 11.01(d) (as it relates to a breach of Section 8.03, Section 8.16, Section 9 (other than Section 9.08 thereof) or Section 10), Section 11.01(f), Section 11.01(g), Section 11.01(h), Section 11.01(k), Section 11.01(m) and Section 11.01(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or the Borrower fails to perform or observe any term, covenant or agreement contained in the following sections and such default, if susceptible to cure, is not cured within the cure period applicable to such section (if any)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Specified Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to any Person that is not a Defaulting Lender) all or a portion of its rights and obligations under this Agreement (including all or a portion of the Loans at the time owing to it) and the other Loan Documents; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that no such assignment shall be made to any Obligor, any Affiliate of any Obligor, any employees or directors of any Obligor or any Affiliate of an Obligor at any time and no such assignment shall be made without the prior written consent of the Administrative Agent. The consent of the Borrower (such consent not to be unreasonably withheld, conditioned or delayed) shall be required unless (x) an Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has occurred and is continuing at the time of such assignment or (y) such assignment is to an Eligible Transferee described in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (vi) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition thereof; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within [***] after having received written notice thereof. Subject to the recording thereof by the Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">152</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and to receipt by the Administrative Agent of a processing and recordation fee in the amount of $3,500 (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment) from and after the date such Assignment and Assumption is recorded in the Register, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of the Lender under this Agreement and the other Loan Documents, and correspondingly the assigning Lender shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the Lender&#x2019;s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) and the other Loan Documents but shall continue to be entitled to the benefits of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any assignment or transfer by the Lender of rights or obligations under this Agreement that does not comply with this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If an assignee is not a Lender, the assignee shall provide the Administrative Agent with all &#x201c;know your customer&#x201d; documents requested by the Administrative Agent pursuant to anti-money laundering rules and regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments to Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Administrative Agent, the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to the Administrative Agent, the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made under this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at one of its offices in the United States a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior written notice. Notwithstanding anything to the contrary, any assignment of any Loan shall be effective only upon appropriate entries with respect thereto being made in the Register.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">153</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Lender may at any time, without the consent of, or notice to, the Borrower, sell participations to any Eligible Transferee or, if a Specified Event of Default has occurred and is continuing, to any Person that is not a Defaulting Lender (other than a natural person, a Defaulting Lender or any Obligor or any of its Affiliates or any employees or directors of any Obligor or any Affiliate of an Obligor) (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in all or a portion of the Lender&#x2019;s rights and/or obligations under this Agreement (including all or a portion of the Commitment and/or the Loans owing to it); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (i) such Lender&#x2019;s obligations under this Agreement and the other Loan Documents shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower shall continue to deal solely and directly with such Lender in connection therewith. Any agreement or instrument pursuant to which any Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce the Loan Documents and to approve any amendment, modification or waiver of any provision of the Loan Documents; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender&#x2019;s Commitment (it being understood and agreed that a waiver of any condition precedent set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.02 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or of any Default or Event of Default or a mandatory reduction in Commitments is not considered an increase of any Commitment), (ii) extend the date fixed for the payment of principal (excluding mandatory prepayments) of or interest on the Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to receive such interest (other than a waiver of default interest). Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Borrower agrees that each Participant shall be entitled to the benefits of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(subject to the requirements and limitations therein, including the requirements under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(g) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(it being understood that the documentation required under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.03(g) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such Participant (i) [reserved], (ii) agrees to be subject to the provisions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as if it were an assignee under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (iii) shall not be entitled to receive any greater payment under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in Law that occurs after the Participant acquired the applicable participation. To the extent permitted by Law, each Participant also shall be entitled to the benefits of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.03(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#x2019;s interest in the Loans or other obligations under the Loan Documents (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant&#x2019;s interest in any commitments, loans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">154</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Rights of Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the proviso to the third sentence of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(e) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above, a Participant shall not be entitled to receive any greater payment under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.01 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.03 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than such Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower&#x2019;s prior written consent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant of Security Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary contained herein, each Lender may at any time grant a security interest in, or otherwise pledge or assign as collateral (including, in the case of the following </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (B)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in connection with any exercise or enforcement of remedies), any of its rights under this Agreement and the other Loan Documents, whether now owned or hereafter acquired (including rights to payments of principal, interest or fees on the Loans), to (A) any federal reserve bank or (B) any holder of, or trustee or collateral agent for the benefit of the holders of, such Lender&#x2019;s Indebtedness or equity securities (including as a result of any exercise or enforcement of remedies in connection with any of the foregoing).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Additional Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable Proportionate Share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full Proportionate Share of all Loans. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">155</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.06.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of the Borrower under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 5.01</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.03</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.05</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.06</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.09</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.14 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the obligations of the Subsidiary Guarantors under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the repayment of the Obligations and the termination of the Commitments and, in the case of the Lenders&#x2019; assignment of any interest in the Commitments or the Loans hereunder, shall survive, in the case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that the Lenders may cease to be &#x201c;Lenders&#x201d; hereunder. In addition, each representation and warranty made, or deemed to be made by a Borrowing Notice, herein or pursuant hereto shall survive the making of such representation and warranty.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.07.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The table of contents and captions and Section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.08.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts, Effectiveness, Electronic Execution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. This Agreement shall become effective when counterparts hereof executed on behalf of the Obligors, the Administrative Agent and the Lender shall have been received by the Administrative Agent. The words &#x201c;execution,&#x201d; &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.09.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that Section 5-1401 of the New York General Obligations Law shall apply.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jurisdiction, Service of Process and Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Submission to Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party hereby irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or tort or otherwise, against such other party in any way relating to this Agreement or any Loan Document or the transactions relating hereto or thereto,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">156</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable Law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service of Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party hereby irrevocably and unconditionally consents to service of process in the manner provided for notices in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.02</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing in this Agreement will affect the right of any party hereto to service process in any other manner permitted by applicable Law. Each Foreign Subsidiary Guarantor hereby irrevocably and unconditionally appoints the Borrower, to receive for it and on its behalf, service of process which may be served in any suit, action or proceeding of the nature referred to in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. . Nothing in this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.10(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall affect the right of any Lender to serve process in any manner permitted by Law or limit the right of any Lender to bring proceedings against the Borrower in the courts of any jurisdiction or jurisdictions. To the extent that the Borrower has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, such Borrower irrevocably waives such immunity in respect of its obligations under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver of Venue, Etc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party hereto irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such party is or may be subject, by suit upon judgment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver of Jury Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.12.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver of Immunity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent that any Obligor may be or become entitled to claim for itself or its property or revenues any immunity on the ground of sovereignty or the like from</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">157</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity (whether or not claimed), such Obligor hereby irrevocably agrees not to claim and hereby irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan Documents.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof, including any confidentiality (or similar) agreements. EACH OBLIGOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH ADMINISTRATIVE AGENT OR THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.14.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof. Without limiting the foregoing provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by the Bankruptcy Code, or any other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect, as determined in good faith by the Administrative Agent, then such provisions shall be deemed to be in effect only to the extent not so limited.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.15.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Fiduciary Relationship</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Borrower acknowledges that the Administrative Agent and the Lenders have no fiduciary relationship with, or fiduciary duty to, the Borrower arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and the Borrower is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint venture among the parties.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.16.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent and each Lender agree to keep confidential, and not disclose to any Person all non-public information provided to them by or on behalf of any Obligor pursuant to this Agreement that is designated by such Obligor as confidential in accordance with its customary procedures for handling its own confidential information; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that nothing herein shall prevent the Administrative Agent or any Lender from disclosing any such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">158</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information (i) to the Administrative Agent, any other Lender, any Affiliate of a Lender or subject to an agreement to comply with the provisions of this Section, any Eligible Transferee or other assignee permitted under </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) subject to an agreement to comply with the provisions of this Section, to any actual or prospective direct or indirect counterparty to any Hedging Agreement (or any professional advisor to such counterparty) and their respective Related Parties, (iii) to its employees, officers, directors, representatives, agents, attorneys, accountants, trustees and other professional advisors (including those retained in connection with (x) the satisfaction or attempted satisfaction of any condition set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (y) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.04</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or those of any of its affiliates (collectively, its &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such information and instructed to keep such information confidential), (iv) upon the request or demand of any Governmental Authority or any Regulatory Authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (v) in response to any order of any court or other Governmental Authority or as may otherwise be required pursuant to any Law, (vi) if requested or required to do so in connection with any litigation or similar proceeding, (vii) that has been publicly disclosed (other than as a result of a disclosure in violation of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), (viii) to the National Association of Insurance Commissioners or any similar organization or any nationally recognized rating agency that requires access to information about a Lender&#x2019;s investment portfolio in connection with ratings issued with respect to such Lender, (ix) in connection with the exercise of any remedy hereunder or under any other Loan Document, (x) on a confidential basis to (A) any rating agency in connection with rating the Borrower or its Subsidiaries or the Loans or (B) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers of other market identifiers with respect to the Loans, (xi) to any current or prospective assignees, SPVs or participants, financing sources (including Persons that hold a security interest in any Lender&#x2019;s rights under this Agreement in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.05(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and to their respective Related Parties, in each case to the extent such assignees, SPVs, participants or financing sources agree to be bound by provisions the same as the provisions of this </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 14.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (and such Person may disclose information to their respective Related Parties in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above) or (xii) to any other party hereto; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, in the case of disclosure pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (iv), (v) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above, the Administrative Agent or applicable Lender, as applicable, shall promptly provide notice to the Borrower to the extent reasonable and not prohibited by Law or any applicable Governmental Authority.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.17.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Rate Limitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts that are treated as interest on such Loan under applicable Law (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">charges</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), shall exceed the maximum lawful rate (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maximum Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that may be contracted for, charged, taken, received or reserved by the Administrative Agent and the Lender holding such Loan in accordance with</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">159</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable Law, the rate of interest payable in respect of such Loan hereunder, together with all charges payable in respect thereof, shall be limited to the Maximum Rate. To the extent lawful, the interest and charges that would have been paid in respect of such Loan but were not paid as a result of the operation of this Section shall be cumulated and the interest and charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the amount collectible at the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Effective Rate for each day to the date of repayment, shall have been received by such Lender. Any amount collected by such Lender that exceeds the maximum amount collectible at the Maximum Rate shall be applied to the reduction of the principal balance of such Loan so that at no time shall the interest and charges paid or payable in respect of such Loan exceed the maximum amount collectible at the Maximum Rate.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.18.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Judgment Currency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in Dollars into another currency, the parties hereto agree, to the fullest extent permitted by Law, that the rate of exchange used shall be that at which, in accordance with normal banking procedures, the Administrative Agent could purchase Dollars with such other currency at the buying spot rate of exchange in the New York foreign exchange market on the Business Day immediately preceding that on which any such judgment, or any relevant part thereof, is given.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The obligations of the Obligors in respect of any sum due to the Administrative Agent hereunder and under the other Loan Documents shall, notwithstanding any judgment in a currency other than Dollars, be discharged only to the extent that on the Business Day following receipt by the Administrative Agent of any sum adjudged to be so due in such other currency the Administrative Agent may, in accordance with normal banking procedures, purchase Dollars with such other currency. If the amount of Dollars so purchased is less than the sum originally due to the Administrative Agent in Dollars, the Borrower agrees, to the fullest extent that it may effectively do so, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent against such loss. If the amount of Dollars so purchased exceeds the sum originally due to the Administrative Agent in Dollars, the Administrative Agent shall remit such excess to the Borrower.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.19.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USA PATRIOT Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrative Agent and the Lenders hereby notify the Obligors that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patriot Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), they are required to obtain, verify and record information that identifies the Obligors, which information includes the name and address of each Obligor and other information that will allow such Person to identify such Obligor in accordance with the Patriot Act.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">160</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.20.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acknowledgement and Consent to Bail-In of Affected Financial Institutions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the effects of any Bail-In Action on any such liability, including, if applicable:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	a reduction in full or in part or cancellation of any such liability;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.21.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain ERISA Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Each Person that becomes party hereto after the date hereof as a Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and its Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or Subsidiary Guarantors, that at least one of the following is and will be true:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	such Lender is not using &#x201c;plan assets&#x201d; (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Employee Benefit Plans with respect to such Lender&#x2019;s entrance into, participation in, administration of and performance of the Loans, the Notes or this Agreement;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	the transaction exemption set forth in one or more PTEs, including any amendments thereto, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">161</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender&#x2019;s entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	(A) such Lender is an investment fund managed by a &#x201c;Qualified Professional Asset Manager&#x201d; (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Notes and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender&#x2019;s entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement; or</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, unless either (1) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is true with respect to a Lender making the representation in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or (2) a Lender making the representation in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has provided another representation, warranty and covenant in accordance with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the immediately preceding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and its Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower, that none of the Administrative Agent or its Affiliates is a fiduciary with respect to the assets of such Lender involved in such Lender&#x2019;s entrance into, participation in, administration of and performance of the Loans, the Notes and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any other Loan Documents or any documents related hereto or thereto).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature Pages Follow]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">162</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BORROWER:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ David Hung, M.D.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: David Hung, M.D.<br>	Title:   President and Chief Executive Officer</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address for Notices:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation Bio Inc. <br>[***]</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a copy to:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley LLP</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3 Embarcadero Center, 20th Floor</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Francisco, CA 94111-4004</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn:	Mischi a Marca; Addison Pierce<br>Email:	gmamarca@cooley.com;<br>	afpierce@cooley.com</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature page to Credit Agreement and Guaranty]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUBSIDIARY GUARANTORS:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO OPERATING COMPANY LLC</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ David Hung, M.D.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name:  David Hung, M.D.<br>	Title:    Manager</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANHEART THERAPEUTICS LLC</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Stephen Dang<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: Stephen Dang<br>	Title:   Director</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address for Notices:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation Bio Inc. <br>[***]</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a copy to:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley LLP</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3 Embarcadero Center, 20th Floor</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Francisco, CA 94111-4004</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn:	Mischi a Marca; Addison Pierce<br>Email:	gmamarca@cooley.com;<br>	afpierce@cooley.com</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature page to Credit Agreement and Guaranty]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADMINISTRATIVE AGENT:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAGARD HOLDINGS MANAGER LP,<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by its general partner</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> SAGARD HOLDINGS MANAGER GP INC.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Adam Vigna<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: Adam Vigna  <br>	Title:   Chief Investment Officer</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address for Notices:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]With a copy (which shall not constitute notice) to:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sidley Austin LLP</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021 McKinney Avenue</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 2000</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dallas, TX 75201</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Angela Fontana</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: angela.fontana@sidley.com</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature page to Credit Agreement and Guaranty]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LENDERS:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAGARD HEALTHCARE PARTNERS (DELAWARE) LP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sagard Healthcare Royalty Partners GP LLC, its general partner</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Jason Sneah<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: Jason Sneah<br>	Title:   Manager</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Adam Vigna<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: Adam Vigna<br>	Title:   Chief Investment Officer</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address for Notices:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]With a copy (which shall not constitute notice) to:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sidley Austin LLP</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021 McKinney Avenue</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 2000</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dallas, TX 75201</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Angela Fontana</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: angela.fontana@sidley.com</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature page to Credit Agreement and Guaranty]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; 4900-8142-0056v.28&#34; &#34;&#34; 4900-8142-0056v.28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>nuvb-ex10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>
 <head>
  <title>EX-10.24</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x1f;CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#x201c;[***]&#x201d;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.24</font></p>
  <p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE INTEREST FINANCING AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by and between</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as the Company,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAGARD HEALTHCARE PARTNERS (DELAWARE) II LP,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as the Investor</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated March 3, 2025</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;" id="swtocupdatestarthere">&#160;</p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.38%;box-sizing:content-box;"></td>
    <td style="width:76.32%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Defined Terms</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rules of Construction</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounting Terms and Principles</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE II REVENUE INTEREST FINANCING</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase, Sale and Assignment.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment Amount</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Assumed Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Excluded Assets</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE III PAYMENTS ON ACCOUNT OF THE REVENUE INTEREST FINANCING</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on Account of the Revenue Interest Financing.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mode of Payment/Currency Exchange</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included Product Payment Reports and Record Retention</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audits.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.5.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Financial Accommodation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Organization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Conflicts.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ownership</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.5.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Governmental and Third Party Authorizations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.6.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Litigation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.7.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Solvency</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.8.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Brokers&#x2019; Fees</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.9.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance with Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.10.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intellectual Property Matters.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.11.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License Agreements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.12.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margin Stock</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.13.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material Contracts.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.14.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bankruptcy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.15.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office Locations; Names.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.16.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permitted Debt</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.17.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Statements; No Material Adverse Effect</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.18.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Default.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.19.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.20.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ERISA Compliance.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.21.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subsidiaries</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.22.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Perfection of Security Interests in the Collateral</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.23.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sanctions Concerns; Anti-Corruption Laws; PATRIOT Act.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.24.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Data Security; Data Privacy.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.25.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance of Included Products.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.38%;box-sizing:content-box;"></td>
    <td style="width:76.32%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.26.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Labor Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.27.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.28.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Full Disclosure</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE INVESTOR</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Organization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Conflicts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Governmental and Third Party Authorizations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.5.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Litigation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.6.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Brokers&#x2019; Fees</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.7.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Funds Available</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.8.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Access to Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE VI ARTICLE VI AFFIRMATIVE COVENANTS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collateral Matters; Guarantors.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Update Meetings</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notices.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Public Announcement.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.5.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Further Assurances.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.6.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IP Rights</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.7.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Existence</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.8.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercialization of the Included Products.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.9.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Statements.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.10.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.11.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of Obligations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.12.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maintenance of Properties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.13.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maintenance of Insurance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.14.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Books and Records</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.15.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Use of Proceeds</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.16.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ERISA Compliance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.17.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance with Contracts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.18.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance with Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.19.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws; Anti-Terrorism Laws.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.20.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Data Privacy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.21.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.22.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included Products</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.23.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 6.24.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RIFA Account(s)</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE VII NEGATIVE COVENANTS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liens</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional Protective Covenants</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE VIII CLOSING AND FUNDING</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.38%;box-sizing:content-box;"></td>
    <td style="width:76.32%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing Deliverables of the Company</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Funding</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE IX CONFIDENTIALITY</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Confidentiality; Permitted Use</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exceptions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permitted Disclosures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Return of Confidential Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE X INDEMNIFICATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indemnification by the Company</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indemnification by the Investor</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Procedures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Claims</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.5.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exclusive Remedies</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.6.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certain Limitations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE XI EVENTS OF DEFAULT AND REMEDIES</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Events of Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remedies Upon Event of Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE XII TERMINATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 12.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term and Termination Date</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 12.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effects of Termination</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:86.4pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-19.048%;padding-left:16%;font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE XIII MISCELLANEOUS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.1.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Survival</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.2.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Specific Performance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.3.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notices</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.4.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Successors and Assigns</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.5.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Independent Nature of Relationship</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.6.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entire Agreement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.7.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Governing Law.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.8.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Waiver of Jury Trial</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.9.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.10.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Counterparts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.11.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendments; No Waivers</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.12.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Third Party Rights</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.13.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Table of Contents and Headings</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:98.65pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2.267%;text-indent:-19.576%;padding-left:16%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 13.14.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intercreditor Agreement.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedules</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-1		Knowledge Persons</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-2		Taletrectinib Structure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-3		License Agreements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.8		Broker&#x2019;s Fees</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)	Included Product Patent Rights</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(h)	Included Product Patent Rights with Valid Claims for Initial Included Product</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(q)	Copyrights, Trademarks and Domain Names</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.13(a)	Material Contracts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.14		Bankruptcy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.16		Permitted Debt Facilities</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21		Subsidiaries</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.25(b)	Included Products and Product Registrations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 6.1(c)	Assigned Patents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.1		Existing Liens</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.2		Existing Indebtedness</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A	Form of Press Release</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B	Form of Intercreditor Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C	Form of Security Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D	Form of Guaranty</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE INTEREST FINANCING AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This REVENUE INTEREST FINANCING AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) dated as of March 3, 2025 is by and between Nuvation Bio Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Sagard Healthcare Partners (Delaware) II LP, a Delaware limited partnership (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Each of the Company and the Investor are referred to in this Agreement as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">W I T N E S E T H:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Company is developing Included Products for the purpose of commercializing such Included Products in the United States and wishes to obtain financing in respect thereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, to raise such financing, the Company desires to sell the Revenue Interest to the Investor in exchange for the Investor&#x2019;s payment of the Investment Amount on the terms and conditions set forth in this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Investor desires to purchase the Revenue Interest from the Company in exchange for payment of the Investment Amount on the terms and conditions set forth in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties set forth herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, intending to be legally bound, the parties hereto covenant and agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:4.852%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE I<br>DEFINED TERMS AND RULES OF CONSTRUCTION</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The following terms, as used herein, shall have the following respective meanings:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Abbreviated New Drug Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) an abbreviated new drug application (as set forth in the FDCA at 21 U.S.C. &#167; 355(j) and its implementing regulations, as amended), and (b) all supplements and amendments that may be filed with respect to any of the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any transaction, or any series of related transactions, by which any Person (for purposes of this definition, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquirer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) directly or indirectly, by means of amalgamation, merger, purchase of assets, purchase of Equity Interests, exclusive licensing or in-licensing of Intellectual Property or otherwise, (a) acquires all or substantially all of the assets of any other Person, (b) acquires an entire business line or unit or division of any other Person, (c) with respect to any other Person that is managed or governed by a Board, acquires control of Equity Interests of such other Person representing more than fifty percent (50%) of the ordinary voting power (determined on a fully diluted basis) for the election of directors of such Person&#x2019;s Board, or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) acquires control of more than fifty percent (50%) of the Equity Interests in any other Person (determined on a fully diluted basis) that is not managed by a Board.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the definition of &#x201c;Credit Agreement&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such Person. For purposes of this definition, &#x201c;control&#x201d; of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of securities entitled to elect the Board or management board, by contract or otherwise, and the terms &#x201c;controlled&#x201d; and &#x201c;controlling&#x201d; have meanings correlative to the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Net Revenues</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Calendar Year, the aggregate amount of Net Revenues in the United States for that Calendar Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Laws of any jurisdiction applicable to the Company or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Terrorism Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Laws relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, the Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) and any other enabling legislation or executive order relating thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, all Laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Tiered Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means for each Calendar Year, the percentage of Annual Net Revenues as set forth in the chart below:</font></p>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:11.204%;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:58.02%;box-sizing:content-box;"></td>
    <td style="width:41.98%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.2pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.413%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Annual Net Revenues</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.45pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.08%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.065%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Applicable Tiered Percentage</font></p></td>
   </tr>
   <tr style="height:31.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.75pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:1.067%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.315%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annual Net Revenues during a Calendar Year up to and including $600 million</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.7pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50%</font></p></td>
   </tr>
   <tr style="height:41.05pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.75pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:1.067%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.315%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annual Net Revenues during a Calendar Year greater than $600 million but less than $1 billion</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.45pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="margin-left:0.08%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.00%</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:11.204%;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:58.02%;box-sizing:content-box;"></td>
    <td style="width:41.98%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.2pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.413%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Annual Net Revenues</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.45pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.08%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.065%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Applicable Tiered Percentage</font></p></td>
   </tr>
   <tr style="height:26.65pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.75pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:1.067%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.315%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annual Net Revenues during a Calendar Year of $1 billion or more</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.45pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="margin-left:0.08%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00%</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.067%;text-indent:15.456%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assigned Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audited Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the audited consolidated balance sheets of the Company and its Subsidiaries for the fiscal years ended [***], and the related consolidated statements of income or operations and comprehensive loss, stockholders&#x2019; equity and cash flows for such fiscal years of the Company and its Subsidiaries then ended, including the notes thereto, audited by independent public accountants of recognized national standing and prepared in conformity with GAAP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;  means the occurrence of any of the following in respect of a Person: (a) such Person shall generally not, shall be unable to, or an admission in writing by such Person of its inability to, pay its debts as they come due or a general assignment by such Person for the benefit of creditors; (b) the filing of any petition by such Person seeking to adjudicate itself as bankrupt or insolvent, or seeking for itself any liquidation, winding-up, reorganization, arrangement, adjustment, protection, relief or composition of such Person or its debts under any Applicable Law relating to bankruptcy, insolvency, receivership, winding-up, liquidation, reorganization, examination, relief of debtors or other similar Applicable Law now or hereafter in effect, or seeking, consenting to or acquiescing in the entry of an order for relief in any case under any such Applicable Law, or the appointment of or taking possession by a receiver, trustee, custodian, liquidator, examiner, assignee, sequestrator or other similar official for such Person or for any substantial part of its property; (c) corporate or other entity action taken by such Person to authorize any of the actions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above; or (d) without the consent or acquiescence of such Person, the commencement of an action seeking entry of an order for relief or approval of a petition for relief or reorganization or any other petition seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or other similar relief under any present or future bankruptcy, insolvency or similar Applicable Law, or the filing of any such petition against such Person, or, without the consent or acquiescence of such Person, the commencement of an action seeking entry of an order appointing a trustee, custodian, receiver or liquidator of such Person or of all or any substantial part of the property of such Person, in each case where such petition or order shall remain unstayed or shall not have been stayed or dismissed within ninety (90) days from entry thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefit Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;employee benefit plan&#x201d; as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) which is (currently or hereafter), or within the prior six (6) years was, maintained or contributed to by any Company Party or Subsidiary thereof or to which any Company Party or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, the board of directors or equivalent management or oversight body of such Person or any committee thereof authorized to act on behalf of such board (or equivalent body).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, a collective reference to the businesses operated by the Company and its Subsidiaries at such time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City or Toronto, Canada are authorized or required by Applicable Law to remain closed.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for the first calendar quarter, the period beginning on the Closing Date and ending on the last day of the calendar quarter in which the Closing Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) for the first calendar year of the Payment Term, the period beginning on the Closing Date and ending on December 31 of such calendar year, (b) for each calendar year of the Payment Term thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31, and (c) for the last calendar year of the Payment Term, the period beginning on January 1 of the year in which this Agreement expires or terminates and ending on the effective date of expiration or termination of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Call Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Call Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Lease Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal property, which obligations are required to be classified and accounted for as a finance lease on a balance sheet of such Person under GAAP, and for the purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Confidentiality Agreement, dated as of [***], by and between Investor and the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***]</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (and includes) any claim, demand, complaint, grievance, action, application, suit, cause of action, order, charge, indictment, prosecution, judgement or other similar process, whether in respect of assessments or reassessments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel, and all costs incurred in investigating or pursuing any of the foregoing or any proceeding relating to any of the foregoing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class A Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Company&#x2019;s Amended and Restated Certificate of Incorporation, dated as of February 10, 2021.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class B Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Company&#x2019;s Amended and Restated Certificate of Incorporation, dated as of February 10, 2021.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has meaning set forth in the Security Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all activities with respect to the distribution, marketing, detailing, promotion, selling and securing of reimbursement of Included Products in the United States after Marketing Authorization for an Included Product in the United States has been obtained, which shall include, as applicable, post-launch marketing, promoting, detailing, marketing research, distributing, customer service, selling the Included Product, importing, exporting or transporting the Included Product for sale, and regulatory compliance with respect to the foregoing. When used as a verb, &#x201c;Commercialize&#x201d; means to engage in Commercialization.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercially Reasonable Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; [***]</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Competitor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any competitor of the Company or any of its Subsidiaries primarily operating in the same line of business as the Company or any of its Subsidiaries and (b) any of such competitor&#x2019;s Affiliates (other than any Person that is a bona fide debt fund primarily engaged in the making, purchasing, holding or other investing in commercial loans, notes, bonds or similar extensions of credit or securities in the ordinary course) that are either clearly identifiable as an Affiliate of any such competitor on the basis of such Person&#x2019;s name or identified by name in writing by the Company to the Investor from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnification Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.6(b).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnification Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the Company and the Guarantors.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparable Yield</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all technical and non-technical non-public information provided by either Party to the other (including, without limitation, the reports provided pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any notices or other information provided pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), either directly or indirectly, and including any materials prepared on the basis of such information, whether in graphic, written, electronic or oral form, and marked or identified at the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">time of disclosure as confidential, or which by its context would reasonably be deemed to be confidential, including without limitation information relating to a Party&#x2019;s technology, products and services, and any business, financial or customer information relating to a Party. The existence and terms of this Agreement shall be deemed the Confidential Information of both Parties. For clarity, this Agreement shall supersede the CDA and the CDA shall cease to be of any force and effect following the execution of this Agreement; provided, however, that all information falling within the definition of &#x201c;Confidential Information&#x201d; set forth in the CDA shall also be deemed Confidential Information disclosed pursuant to this Agreement, and the use and disclosure of such Confidential Information following the date of this Agreement shall be subject to the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any contract, agreement, commitment, government bid, instrument, license, sublicense, subcontract, real or personal property lease or sublease, letters of intent, memorandum of understanding, offer letter, note, indenture, mortgage, bond, letter of credit, guarantee, purchase order, or other legally binding business arrangement, whether written or oral, together with any amendments, restatements, supplements, waivers or other modifications thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to any Person, any obligation arising under any Contract.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Intellectual Property, that the applicable Person owns or has a license to such item or right and has the ability to grant to another party a license, sublicense, or rights of access and use under such item or right without violating the terms or conditions of any agreement or other arrangement between such Person and any Third Party in existence as of the time such party would be required to grant such license, sublicense, or rights of access and use. &#x201c;Controlling&#x201d; and &#x201c;Controlled&#x201d; have meanings correlative thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copyright License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any agreement, whether written or oral, providing for the grant of any right to use any Work under any Copyright.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) all proprietary rights afforded Works pursuant to Title 17 of the United States Code, including, without limitation, all rights in mask works, copyrights and original designs, and all proprietary rights afforded such Works by other countries for the full term thereof (and including all rights accruing by virtue of bilateral or international treaties and conventions thereto), whether registered or unregistered, including, but not limited to, all applications for registration, renewals, extensions, reversions or restorations thereof now or hereafter provided for by Law and all rights to make applications for registrations and recordations, regardless of the medium of fixation or means of expression, which are owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to; and (b) all copyright rights under the copyright Laws of the United States and all other countries for the full term thereof (and including all rights accruing by virtue of bilateral or international copyright treaties and conventions), whether registered or unregistered, including, but not limited to, all applications for registration, renewals, extensions, reversions or restorations of copyrights now or hereafter provided for by Law and all rights to make applications for copyright registrations and recordations, regardless of the medium of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fixation or means of expression, which are owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cover</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covering</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with reference to a Patent and a product, composition, article of manufacture, or method, that the manufacture, practice, use, offer for sale, sale or importation of the product, composition, article of manufacture or method, would infringe a Valid Claim of such Patent, and for purposes of determining such infringement, considering Valid Claims of pending patent applications as if they have already been issued, in the country in which such activity occurs without a license thereto (or ownership thereof).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Credit Agreement and Guaranty by and among the Company, as the borrower, certain Subsidiaries of the Company that may be required to provide guarantees from time to time thereunder, the lenders from time to time party thereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Sagard Holdings Manager LP, as administrative agent for the Lenders (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrative Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated March 3, 2025, and as the same may be amended, restated, amended and restated, supplemented, increased or otherwise modified from time to time in accordance herewith.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Agreement Security Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the &#x201c;Security Documents&#x201d; as defined in the Credit Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRL Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company has received from the FDA a complete response letter (as defined in 21 CFR 314.3) with respect to NDA 219713.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Daiichi Sankyo License Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the License Agreement, dated as of December 7, 2018, between Daiichi Sankyo Company, Limited and AnHeart Therapeutics LLC (previously AnHeart Therapeutics Inc.), as amended by First Amendment to License Agreement, dated as of August 17, 2020, which agreement was assigned by AnHeart Therapeutics LLC to the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Daiichi Sankyo Licensed Included Product Patent Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Included Product Patent Rights licensed or sublicensed by Daiichi Sankyo Company, Limited to the Company or any Company Party under the Daiichi Sankyo License Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DEA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Drug Enforcement Administration or any successor agency or authority thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debtor Relief Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, general equitable principles and principles of public policy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Acquisition Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any purchase price adjustments, royalty, earn-out, milestone payments, contingent or other deferred payment or payments of a similar nature (including any non-compete payments and consulting payments) made in connection with any acquisition or investment permitted under this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designated Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any country, territory or region which is the subject or target of sanctions which broadly prohibit dealings with that country or territory (currently includes Cuba, Iran, North Korea, Syria, and the Crimea, so-called Donetsk People&#x2019;s Republic, and so-called Luhansk People&#x2019;s Republic regions of Ukraine).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all activities related to research, development, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Drug Applications, regulatory affairs with respect to the foregoing and all other activities, in each case necessary or reasonably useful or otherwise requested or required by a Regulatory Agency as a condition or in support of obtaining or maintaining a Regulatory Approval in the United States. When used as a verb, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Develop</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means to engage in Development.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disposition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispose</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the sale, transfer, assignment, conveyance, out-license or out-sublicense, covenant not to sue, lease, sublease (as lessor or sub-lessor) or other disposition (including any Sale and Leaseback Transaction) of any property included in the Collateral or the Product Assets, by any Company Party, whether real, personal, or mixed and whether tangible or intangible, whether now owned or hereafter acquired (including accounts receivable), including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith, or forgiveness, release or compromise of any amount owed to any Company Party, in each case, in one transaction or a series of transactions, but excluding the following (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;): (a) the sale of inventory, including to end users (through wholesalers or other typical sales channels) or to distributors, in the ordinary course of business in an arm&#x2019;s-length transaction, provided that any such sale of finished Included Products in the United States is included in the calculation of Net Sales to the extent provided in the definition of Net Sales, or the sale, transfer or other disposition of the inventory for patient assistance programs or compassionate use in the ordinary course of business; (b) dispositions (including by way of abandonment or cancellation) in the ordinary course of business in an arm&#x2019;s-length transaction of any tangible property that is obsolete or worn out or no longer used or useful in the conduct of the Business of any Company Party; (c) any sale, lease, license, transfer or other disposition of property by one Company Party to another Company Party; (d) dispositions in the ordinary course of business consisting of the abandonment of IP Rights (other than any Orange Book Patent owned by any Company Party), including the abandonment of any Patent applications or specific claims thereunder that the Company reasonably and in good faith believes will not be allowed or granted, that (i) are not necessary or required for the conduct of the Business of any Company Party or the Development, Manufacture or Commercialization of the Included Products in the United States, and (ii) could not reasonably be expected to result in a Material Adverse Effect; (e) licenses, sublicenses, leases or subleases (other than relating to the IP Rights (except pursuant to Permitted Licenses)), in each</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">case granted to Third Parties in the ordinary course of business and not interfering with the Business of any Company Party or the Development, Manufacture or Commercialization of the Included Products in the United States; (f) any Involuntary Disposition (other than, for the avoidance of doubt, of any IP Rights (except pursuant to Permitted Licenses)); (g) Permitted Licenses and the transfer of any non-U.S. Governmental Licenses, including non-U.S. Product Registrations and non-U.S. Marketing Authorizations in connection with a Permitted License under subpart (b) of the definition of &#x201c;Permitted License&#x201d; provided such Permitted License does not include a transfer of or license to or right to use any U.S. Governmental Licenses, including U.S. Product Registrations and U.S. Marketing Authorizations; (h) sales, transfers and other dispositions of unpaid and overdue accounts receivable in connection with the compromise, settlement or collection thereof in the ordinary course of business and not as part of a financing transaction; (i) the forgiveness, release or compromise of any trade payables owed to any Company Party in the ordinary course of business; (j) the disposition of investment securities in the ordinary course and the disposition of cash and cash equivalents in the ordinary course for general corporate purposes, including Acquisitions and investments, or otherwise in transactions permitted hereunder; (k) to the extent constituting a Disposition, any Permitted Liens; and (l) waiver, amendment, cancellation or termination of any rights not prohibited pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any amendment, modification, restatement, cancellation, supplement, termination or waiver of any provision of any Material Contract not prohibited pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is understood and agreed that, notwithstanding anything to the contrary set forth in this definition, in no event shall a &#x201c;Permitted Transfer&#x201d; include any license of any Included Product or the license, transfer or pledge of any IP Rights within the United States, in each case, other than Permitted Licenses and Permitted Liens. For the further avoidance of doubt, the inclusion of specific categories of Permitted Transfers shall not create any implication that the applicable sale, transfer, assignment, conveyance, out- license or out-sublicense, lease, sublease (as lessor or sub-lessor) or other disposition of property that does not constitute Collateral or Product Assets is a Disposition within the meaning of this definition.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10(j).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disqualified Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any Equity Interest of such Person that, by its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (a) matures (excluding any maturity as the result of an optional redemption by the issuer thereof) or is mandatorily redeemable (other than solely for (i) Qualified Equity Interests and (ii) cash in lieu of fractional shares), including pursuant to a sinking fund obligation or otherwise, (b) is redeemable at the option of the holder thereof (other than solely for (i) Qualified Equity Interests and (ii) cash in lieu of fractional shares), in whole or in part, (c) requires scheduled payments of dividends or other distributions in cash (other than the payment of cash in lieu of redemption of fractional shares) or other securities that would constitute Disqualified Equity Interests, or (d) is or becomes convertible into or exchangeable for (unless at the sole option of the issuer thereof) Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is [***] days after the Maturity Date; provided, that, any Equity Interests that would not constitute Disqualified Equity Interests but for provisions thereof giving holders thereof (or the holders of any security into or for which such Equity Interests are convertible, exchangeable or exercisable) the right to require the issuer thereof to redeem or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">repurchase such Equity Interests upon the occurrence of a change in control or fundamental change occurring prior to the [***] day after the Maturity Date shall not constitute Disqualified Equity Interests if such Equity Interests provide, to the satisfaction of the Investor in its reasonable discretion, that the issuer thereof will not be required to redeem or repurchase any such Equity Interests pursuant to such provisions prior to the payment in full of all Obligations (other than contingent indemnification obligations for which no claim has been asserted) under the applicable Permitted Debt Facility Documents; provided, further, that, if such Equity Interests are issued pursuant to a plan for the benefit of employees of the Company or any Subsidiary or by any such plan to such employees, such Equity Interests shall not constitute Disqualified Equity Interests solely because such employee may deliver such Equity Interests to the Company and its Subsidiaries (or the Company or such Subsidiary withholds such Equity Interests) in satisfaction of any exercise price or tax withholding obligations with respect to such Equity Interests.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dollar</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or the sign &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means United States dollars.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Domain Names</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all domain names and URLs that are registered and/or owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a New Drug Application, a Supplemental Application, or an Abbreviated New Drug Application for any Included Product, as appropriate, in each case of the Company or any Subsidiary.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the European Medicines Agency or any successor agency or authority thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member, membership or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination. Notwithstanding the foregoing, in no event shall any Indebtedness convertible or exchangeable into Equity Interests constitute &#x201c;Equity Interests&#x201d; hereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equivalent Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount in the first currency determined by reference to the Exchange Rate at the time of determination.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Employee Retirement Income Security Act of 1974, as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any trade or business (whether or not incorporated) under common control with the Company within the meaning of Section 414(b) or (c) of the Internal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Code (and Sections 414(m) and (o) of the Internal Revenue Code for purposes of provisions relating to Section 412 of the Internal Revenue Code).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a Reportable Event with respect to a Pension Plan, (b) the withdrawal of the Company or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which such entity was a &#x201c;substantial employer&#x201d; as defined in Section 4001(a)(2) of ERISA or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA, (c) a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) by the Company or any ERISA Affiliate from a Multiemployer Plan, (d) the filing by the plan administrator of a notice of intent to terminate a Pension Plan or the treatment of a Pension Plan amendment as a termination under Sections 4041 of ERISA, (e) the institution by the PBGC of proceedings under Section 4042 of ERISA to terminate a Pension Plan, (f) the determination that any Multiemployer Plan is considered an at risk plan or a plan in endangered or critical status within the meaning of Section 432 of the Internal Revenue Code or Section 305 of ERISA or is insolvent, within the meaning of Section 4245 of ERISA, or has been terminated, within the meaning of Section 4041A of ERISA, (g) the determination that any Pension Plan is in at-risk status within the meaning of Section 303 of ERISA, or (h) the imposition of any liability pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA upon the Company or any ERISA Affiliate.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the events set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event of Material Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the occurrence of any of the events set forth in clauses (a), (e), (h)(i), (h)(ii), (j), (k), (l) and (m) of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (b) the Company fails to perform or observe any term, covenant or agreement contained in the following sections and such default, if susceptible to cure, is not cured within the cure period applicable to such section under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (IP Rights), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.7(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Existence), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Commercialization of the Included Products), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Liens), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Indebtedness), and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (except for clause (f) thereof) (Additional Protective Covenants).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date, the rate at which any currency may be exchanged into another currency, as set forth on the relevant Bloomberg screen at or about 11:00 a.m. (Eastern time) on such date. In the event that such rate does not appear on the Bloomberg screen, the &#x201c;Exchange Rate&#x201d; shall be determined by reference to such other publicly available service for displaying exchange rates as may be reasonably designated by the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Liabilities and Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the following payments by the Company or any Guarantor: (a) any interest pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (b) expense reimbursements pursuant to the Transaction Documents; (c) reimbursements pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (d) indemnification payments pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 10.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (e) indemnification payments pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in respect of Third Party Claims; and (f) indemnification payments in respect of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reimbursement of expenses incurred by the Investor Indemnified Parties (including attorney&#x2019;s fees) in enforcing their rights under the Transaction Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of (a) AnBio Therapeutics (HK) Ltd., (b) AnHeart Therapeutics (Hangzhou) Co., Ltd. and (c) Baoquan Biomedical Technology (Shanghai) Co., Ltd.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) Taxes imposed on or measured by the Investor&#x2019;s net income, however denominated, franchise (and similar) Taxes imposed in lieu of net income Taxes, and branch profits taxes (or any similar taxes), in each case, imposed by any jurisdiction as a result of the Investor being organized in or having its principal office in such jurisdiction, or as a result of any other present or former connection between the Investor and such jurisdiction other than any connections solely arising from executing, delivering, being a party to, engaging in any transactions pursuant to, performing its obligations under, receiving payments under, or enforcing this Agreement or any other Transaction Document, (b) Taxes attributable to the failure of the Investor to comply with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (c) any U.S. federal withholding Taxes imposed on amounts payable to or for the account of the Investor pursuant to a law in effect on the date on which the Investor acquires the Revenue Interest, and (d) any withholding Taxes imposed under FATCA.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATCA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to current Section 1471(b)(1) of the Internal Revenue Code (or any amended or successor version described above) and any fiscal or regulatory legislation, rules or official administrative guidance adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and that implement such Sections of the Internal Revenue Code.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.23(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration or any successor agency or authority thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company has received Marketing Authorization of the Initial Included Product from the FDA (a) indicated for the treatment of adult patients of ROS1 - positive, (b) without a boxed warning in the labeling materials, (c) not subject to &#x201c;Risk Evaluation and Mitigation Strategies&#x201d; (REMS), and (d) not approved pursuant to FDA&#x2019;s &#x201c;Accelerated Approval Program&#x201d; that requires confirmation of anticipated clinical benefit.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDCA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167; 301 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">et seq.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Audited Financial Statements and the Interim Financial Statements.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fundamental Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means those representations and warranties of the Company set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Organization), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (No Conflicts), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Authorization), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Ownership), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Intellectual Property Matters), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Material Contracts), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Bankruptcy), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.18</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (No Default), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.22</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Perfection of Security Interests in the Collateral), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Sanctions Concerns; Anti-Corruption Laws; PATRIOT Act), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.25</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Compliance of Included Products) and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.27</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Taxes).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means generally accepted accounting principles in effect as the standard financial accounting guidelines in the United States from time to time (consistently applied and on a basis consistent with the accounting policies, practices, procedures, valuation methods and principles used in preparing the Financial Statements), and any successor thereto; provided that if a transition in such generally accepted accounting principles would substantively change the recognition of revenue with respect to Net Revenues (defined as of the Closing Date) and its calculation as set forth in this Agreement, then the Parties shall mutually agree to amendments to this Agreement in order to cause the amount of Revenue Interest as determined after giving effect to such transition in generally accepted accounting principles to be substantially the same as the amount of Revenue Interest as determined under generally accepted accounting principles in effect as the standard financial accounting guidelines in the United States as of the Closing Date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generic Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to an Included Product in the United States, any product (other than those owned by the Company or any of its Subsidiaries) sold in the United States that is approved through an Abbreviated New Drug Application, or an application submitted under Section 505(b)(2) of the FDCA (21 U.S.C. &#167; 355(b)(2)), and (b) references any New Drug Application for such Included Product (or future functional equivalent owned or controlled by the Company or its Subsidiaries) and is listed in the FDA publication &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations&#x201d; (known as the Orange Book).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the government of the United States, any other nation or any political subdivision thereof, whether state, local or otherwise, and any agency, authority (including supranational authority), commission, instrumentality, regulatory body, court, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including each Patent Office, the FDA, the DEA, the EMA, and any other government authority in any jurisdiction.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all authorizations issuing from a Governmental Authority, including the FDA, DEA and EMA, based upon or as a result of applications to and requests for approval from a Governmental Authority for the right to manufacture, import, store, market, promote, advertise, offer for sale, sell, use and/or otherwise distribute an Included Product, which are owned by or licensed to the Company or any Subsidiary, acquired by the Company or any Subsidiary via assignment, purchase or otherwise or that the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guarantee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of or by any Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the &#x201c;primary obligor&#x201d;) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; provided that the term Guarantee shall not include (i) endorsements for collection or deposit and (ii) guarantees of operating leases, in each case, in the ordinary course of business.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) each Subsidiary that owns any portion of the Collateral or the Product Assets as of the Closing Date (other than AnHeart Therapeutics (Hangzhou) Co., Ltd.), and (b) any other Subsidiary of the Company that executes and delivers a Joinder Agreement pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guaranty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a customary guaranty, substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto, to be executed in favor of the Investor by each of the Guarantors, as amended or modified from time to time in accordance with the terms hereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. Notwithstanding anything to the contrary in the foregoing, neither any Permitted Bond Hedge Transaction nor any Permitted Warrant Transaction shall be a Hedging Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-License Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any pharmaceutical product Developed or Commercialized by the Company or its Subsidiaries (including any product in development or that may be developed) that contains taletrectinib, the structure of which is shown in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case in any dosage form, dosing regimen or strength, or any improvements or modifications thereto, and regardless of trade or brand name.  For clarity, Included Products shall include the product that is the subject of NDA 219713 that was submitted by the Company to the FDA on October 23, 2024, regardless of the trade or brand name of such product (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Included Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included Product Patent Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Patent Rights in each case which are owned or Controlled by, issued or licensed to, licensed by, or hereafter acquired or licensed by, the Company or its Affiliates, and in each such case, which are relating to the Development, Manufacture or Commercialization of any Included Products in the United States, including the Owned Included Product Patent Rights and the Licensed Included Product Patent Rights. For the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoidance of doubt, Included Product Patent Rights may include an international patent application filed under the Patent Cooperation Treaty (PCT). Included Product Patent Rights include, without limitation, the Patents listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Orange Book Patents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included Product Payment Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for each Calendar Quarter, an amount equal to the Applicable Tiered Percentage multiplied by the applicable portion of the Quarterly Net Revenues for such Calendar Quarter.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IND</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) (i) an investigational new drug application (as defined and provided for in FDA&#x2019;s implementing regulations, as amended) that is required to be filed with the FDA before beginning clinical testing in human subjects, or any successor application or procedure and (ii) any similar application or functional equivalent relating to any investigational new drug application applicable to or required by any non-U.S. Governmental Authority, and (b) all supplements and amendments that may be filed with respect to the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of any Person means, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid (excluding interest penalties for late payments under commercial contracts entered into in the ordinary course of business and, for the avoidance of doubt, which commercial contracts do not relate to obligations for borrowed money or purchase money indebtedness), (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of such Person in respect of the deferred purchase price of property or services (it being agreed that seller notes or earn-out obligations are addressed in clause (l)), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all Capital Lease Obligations of such Person, (i) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (j) obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions (other than Permitted Warrant Transactions), (k) all obligations, contingent or otherwise, of such Person in respect of bankers&#x2019; acceptances, (l) all obligations under any earn-out and guaranteed minimum milestone and Deferred Acquisition Consideration appearing on such Person&#x2019;s balance sheet in accordance with GAAP (but excluding any payments based on sales under any such license or other agreement), (m) any Disqualified Equity Interests of such Person, and (n) all other obligations required to be classified as indebtedness of such Person under GAAP; provided that, notwithstanding the foregoing, Indebtedness shall not include (i) accrued expenses, deferred rent, deferred Taxes, deferred compensation or customary obligations under employment agreements, or (ii) accounts payable incurred in the ordinary course of business. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person&#x2019;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Taxes imposed on or with respect to any payment made by or on account of any obligation of the Company under this Agreement, other than Excluded Taxes.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Included Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the definition of &#x201c;Included Product.&#x201d;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all intellectual property, including but not limited to all proprietary information, trade secrets, Know-How, utility models, confidential information, inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a Patent, including in pending patent applications) and improvements thereto, Patents, registered or unregistered Trademarks, trade names and service marks (including all goodwill associated therewith), registered and unregistered Copyrights and all applications thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany Patent Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany Subordination Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a subordination agreement executed and delivered by each Company Party and each of its Subsidiaries, pursuant to which all obligations in respect of any Indebtedness owing to any such Person by a Company Party shall be subordinated to the prior payment in full in cash of all Obligations, such agreement to be in form and substance reasonably satisfactory to the Investor (it being understood that a form not less favorable to the Investor than the intercompany subordination agreement delivered in connection with the Credit Agreement is satisfactory).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Intercreditor Agreement by and between the Investor and the Administrative Agent, and any other Permitted Debt Creditors initially pursuant to the Credit Agreement and acknowledged and agreed to by each Company Party named therein, dated as of the Closing Date in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as amended, amended and restated, supplement and otherwise modified from time to time in accordance with the terms thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the unaudited consolidated balance sheets of the Company and its Subsidiaries for [***], and the related consolidated statements of income or operation, stockholders&#x2019; equity and cash flows for such period of the Company and its Subsidiaries, including the notes thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Revenue Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Account</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means such account as designated by the Investor to the Company in writing from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Indemnification Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Indemnification Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Involuntary Disposition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Disposition resulting from the damage to or destruction of, or any condemnation of, any property of any Company Party.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all Intellectual Property, all Confidential Information, all Know-How, all Copyrights, all Domain Names, all Patent Rights (including, for the avoidance of doubt, the Included Product Patent Rights) and all Patent Term Extensions (and applications for Patent Term Extension) with respect thereto, all Proprietary Databases, all Proprietary Software, all Trademarks, all Trademark Licenses, all Trade Secrets, all Websites and all Website Agreements, and all License Agreements, in each case, which are owned or Controlled by, issued or licensed to, licensed by, or hereafter acquired or licensed by, the Company or its Affiliates as of the date hereof or during the Term, and in each such case, which are relating to any Included Products in the United States, including the Development, Manufacture or Commercialization of any Included Product in the United States.  The IP Rights include, but are not limited to, the items listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Internal Revenue Service.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joinder Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a joinder agreement, in form and substance satisfactory to the Investor, executed and delivered by each Subsidiary in accordance with the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Venture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a joint venture, partnership or other similar arrangement, in corporate, partnership or similar legal form with a Person other than Company or its Subsidiaries.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all non-public information, results and data of any type whatsoever, in any tangible or intangible form (and whether or not patentable), including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, skill, experience, data and results (including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical study data and results), analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Knowledge</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Company, (a) for purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Article IV</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the actual knowledge, after due inquiry, as of the date of this Agreement and the Closing Date, of any of the officers of the Company identified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (b) for all other purposes of this Agreement, the actual knowledge, after due inquiry, as of a specified time, of any of the officers of the Company identified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any successor to any such officer holding the same or substantially similar officer position at such time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all international, foreign, federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case, whether or not, having the force of law.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means December 31, 2042.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the definition of &#x201c;Credit Agreement&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Included Product Patent Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Included Product Patent Rights licensed or sublicensed by a Third Party to the Company or any of its Subsidiaries.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Included Product, any Third Party counterparty to a License Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any mortgage, lien, license, pledge, hypothecation, charge, security interest, or other encumbrance of any kind or character whatsoever, whether or not filed, recorded or otherwise perfected under Applicable Law, or any lease, title retention agreement, mortgage, restriction, easement, right-of-way, option or adverse claim of ownership or possession (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any other encumbrance on title to real property, any option or other agreement to sell, or give a security interest in, such asset and any filing of or agreement to give any financing statement under the UCC (or equivalent statutes of any jurisdiction)) or any preferential arrangement that has the practical effect of creating a security interest and (b) in the case of Equity Interests, any purchase option, call or similar right of a third party with respect to such Equity Interests.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any loss, assessment, award, cause of action, claim, charge, tax, cost, expense, fine, judgment, liability, obligation or penalty, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of any Included Product, or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance, and quality control.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to an Included Product, the Regulatory Approval required by Applicable Law to sell such Included Product in a country or region, including, to the extent required by Applicable Law for the sale of such Included Product, all pricing approvals and government reimbursement approvals.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Contract Counterparty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a counterparty to any Material Contract.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Contracts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any event or condition that constitutes an Event of Material Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Material Default.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning ascribed to such term in the Credit Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiemployer Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;employee benefit plan&#x201d; (as defined in Section 3(3) of ERISA) that is a &#x201c;multiemployer plan&#x201d; as defined in Section 4001(a)(3) of ERISA, to which the Company or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five (5) plan years, has made or been obligated to make contributions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Revenues</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, without duplication, the Net Sales and Other Product Payments.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, [***]</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Drug Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the FDCA at 21 U.S.C. &#167; 355(b) and its implementing regulations, as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all amounts, liabilities, obligations, covenants and duties of every type and description owing by the Company Parties to Investor and any other indemnitee hereunder, arising out of, under, or in connection with this Agreement or any other Transaction Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument or for the payment of money, including, without duplication (a) the payment of the Revenue Interest up to the Threshold, (b) the payment of the Put/Call Payment, (c) the payment of the True Up Payment, (d) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a claim for post- filing or post-petition interest is allowed in any such proceeding, and (e) all other fees, charges and expenses (including fees, charges and disbursement of counsel), interest, costs, indemnities and reimbursement of amounts paid and other sums chargeable to such Company Party under any Transaction Document.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ODD</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Orphan Drug Designation, as defined in 21 CFR 316.3(b)(11), as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Office of Foreign Assets Control of the United States Department of the Treasury.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orange Book</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the FDA publication &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; which identifies drug products approved by the FDA under the FDCA as well as patent and exclusivity information related to approved drug products, as may be amended from time to time.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orange Book Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the following Patents licensed by the Company that the Company intends to list in the Orange Book for the Initial Included Product: [***], and (b) the Patents owned or Controlled by, issued or licensed to, licensed by, or hereafter acquired or licensed by, the Company or its Subsidiaries listed in the Orange Book relating to any Included Product.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction), (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement, and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan Drug Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Orphan Drug Act amendments to the FDCA and all implementing regulations, as may be amended from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an intercreditor agreement, among the Investor, the Company and the Permitted Debt Creditors (or the representatives thereof) under clause (b) of the definition of &#x201c;Permitted Debt Facility&#x201d;, in a form substantially similar to the Intercreditor Agreement (and in any event not less favorable to the Investor) or otherwise reasonably satisfactory to the Investor, as amended, amended and restated, supplemented and otherwise modified from time to time in accordance with the terms thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Product Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, without duplication, (a) any partnership distributions, royalty payments, product supply payments (to the extent in excess of fully allocated costs of such supply of Included Product), upfront payments, earn-out payments, grant payments, milestone payments or any other payments or proceeds paid or payable to the Company or its Subsidiaries under or in respect of any License Agreement (other than: (i) payments for payment or reimbursement of expenses, including patent prosecution, defense, enforcement or maintenance expenses in respect of any intellectual property or IP Rights; (ii) up to the fair market value of payments received by Company for any debt and/or equity securities or instruments issued by Company; (iii) up to the fair market value of funds received as a reimbursement or prepayment of expenses for bona fide research and development activities of Included Products (including payments for FTEs, clinical development and manufacturing expenses); and (iv) currently unrecognized revenue from any cash payments received on or before the Closing Date under license agreements in effect as of the Closing Date); and (b) any damages awards, settlement amounts, product payments, ongoing royalties or other amounts paid or payable to the Company or its Subsidiaries relating to or resulting from the infringement, misappropriation or other violation by a Third Party of any IP Rights within the United States, net of any out-of-pocket costs and expenses incurred by the Company and its Subsidiaries in enforcing such IP Rights, in each case (a) and (b) above, to the extent such payments relate to the Development (for purposes of obtaining or maintain Regulatory Approvals in the United States), Manufacture (for purposes of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of Included Product for use in the United States), and/or Commercialization of Included Products in the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Out-License Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Owned Included Product Patent Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Included Product Patent Rights which are owned by the Company or its Subsidiaries.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Paragraph IV Certification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any certification filed pursuant to 21 U.S.C. &#167; 355(b)(2)(A)(iv), 21 U.S.C. &#167; 355(j)(2)(A)(vii)(IV), or any comparable Applicable Law (or any amendment or successor statute thereto) relating to any Included Product in any country or regulatory jurisdiction.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party(ies)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Office</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the applicable patent office, including the United States Patent and Trademark Office and any comparable foreign patent office, for any Patents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all Patents (whether established or registered or recorded in the United States or any other jurisdiction or international or multinational agency), together with any and all (a) rights and privileges arising under Applicable Law with respect to use of any Patents, (b) inventions and improvements described and claimed therein, (c)  income, fees, royalties, damages, claims and payments now or hereafter due and/or payable thereunder and with respect thereto including damages and payments for past, present or future infringements thereof, and (d) rights to sue for past, present or future infringements thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Term Extension</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means patent term extension applied for, or granted by the U.S. Patent and Trademark Office, pursuant to 35 U.S.C. &#167; 156 or any similar Applicable Law in other jurisdictions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all letters patent and patent applications (and all letters patent that issue therefrom or from an application claiming priority therefrom), and all patent term extensions, reissues, reexaminations, extensions, renewals, divisions, supplemental protection certificates, amendments, and continuations (including continuations-in-part and continuing prosecution applications) thereof, for the full term thereof, together with the right to claim the priority thereto and the right to sue for past infringement of any of the foregoing, in each case whether established or registered or recorded in the United States or any other jurisdiction or international or multinational agency.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the time period commencing on the Funding Date and expiring on the earlier of (a) the date upon which the Investor has received cash payments pursuant to the Transaction Documents (excluding Excluded Payments) totaling, in the aggregate, the Threshold, (b) the Quarterly Payment Date immediately following the Legal Maturity Date, and (c) the date when the Put/Call Payment is paid to the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PBGC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pension Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;employee pension benefit plan&#x201d; (as defined in Section 3(2) of ERISA), other than a Multiemployer Plan, that is maintained or is contributed to by the Company and any ERISA Affiliate and is either covered by Title IV of ERISA or is subject to minimum funding standards under Section 412 of the Internal Revenue Code.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means licenses, Governmental Licenses, certificates, accreditations, Regulatory Approvals, other authorizations, registrations, permits, consents, clearances and approvals required in connection with the conduct of the Business or to comply with any Applicable Laws, and those issued by state governments for the conduct of the Business.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Bond Hedge Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any call or capped call option (or substantively equivalent derivative transaction) relating to the Company&#x2019;s common stock (or other securities or property following a merger event, reclassification or other similar fundamental change of the Company, or adjustment with respect to the common stock of the Company) that is (a) purchased or otherwise entered into by the Company in connection with the issuance of any Permitted Convertible Notes, (b) settled in common stock of the Company (or such other securities or property), cash or a combination thereof (such amount of cash determined by reference to the price of the Company&#x2019;s common stock or such other securities or property), and cash in lieu of fractional shares of common stock of the Company and (c) on terms and conditions customary for bond hedge transactions in respect of transactions related to public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act) as reasonably determined by the Company; provided, that, the purchase of such Permitted Bond Hedge Transaction does not result in the incurrence of additional liability on the consolidated balance sheet of the Company (other than Indebtedness from the issuance of Permitted Convertible Notes in connection with such Permitted Bond Hedge Transaction) and (ii) the purchase price of any such Permitted Bond Hedge Transaction shall not exceed, net of the proceeds of any Permitted Warrant Transaction entered into in connection therewith, [***]% of the proceeds obtained in the related Permitted Convertible Notes issuance.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Convertible Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Indebtedness of the Company having a feature which entitles the holder in accordance with the terms thereof to convert or exchange all or a portion of such Indebtedness into, at the option of the Company, Class A Common Stock of the Company (or other securities or property following a merger event or other change of the Class A Common Stock of the Company), cash or any combination of cash and such Class A Common Stock (or such other securities or property) based on the market price of such Class A Common Stock (or such other securities or property); provided that: (i) such Permitted Convertible Notes shall be unsecured, (ii) such Permitted Convertible Notes shall not be guaranteed by any Subsidiary of the Company, (iii) such Permitted Convertible Notes shall not include any financial maintenance covenants and shall only include covenants, defaults and conversion rights that are customary for public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act) as of the date of issuance, as determined by the Company in its good faith judgment, (iv) no Default or Event of Default shall have occurred and be continuing at the time of incurrence of such Permitted Convertible Notes or would result therefrom, (v) such Permitted Convertible Notes shall not require any scheduled amortization or have a scheduled maturity date, and shall not be subject to any mandatory repurchase or redemption (other than in connection with a customary change of control or &#x201c;fundamental change&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provision), in each case, earlier than [***] calendar days after the Maturity Date, (vi) such Permitted Convertible Notes shall not bear interest at a rate per annum not to exceed such rate as is customary in the market at such time, as determined in the reasonable commercial judgment of a Responsible Officer of the Company in good faith and (vii) the Company shall have delivered to the Investor a certificate of a Responsible Officer of the Company certifying as to the foregoing clauses (i) through (vi).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the following Indebtedness of the Company and its Subsidiaries (which, for purposes of determining whether such Indebtedness exceeds any maximum amount provided in the applicable clause below, shall be calculated on a consolidated basis with respect to the Company and its Subsidiaries):</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Obligations;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	(i) Indebtedness existing on the date hereof and, to the extent in excess of [***], set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (ii) Permitted Refinancings thereof; provided that, if such Indebtedness is intercompany Indebtedness, such Indebtedness shall be subject to the Intercompany Subordination Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money) incurred in the ordinary course of such Company Party&#x2019;s or such Subsidiary&#x2019;s business in accordance with customary terms and paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Indebtedness consisting of guarantees resulting from the endorsement of negotiable instruments for collection in the ordinary course of business;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Indebtedness of any Company Party owing to any other Company Party, subject to the Intercompany Subordination Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Indebtedness of any Subsidiary that is not a Company Party owing to any Company Party (to the extent constituting a permitted investment under (x) if the Credit Agreement is outstanding, Section 9.05 of the Credit Agreement and (y) otherwise, any other Permitted Debt Facility then outstanding) or any other Subsidiary that is not a Company Party;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Indebtedness of any Company Party owing to any Subsidiary that is not a Company Party, subject to the Intercompany Subordination Agreement; provided any Indebtedness owing by any Company Party to any Subsidiary that is not a Company Party shall not exceed [***]in the aggregate outstanding at any one time;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	Guarantees by any Company Party of Permitted Debt of any other Company Party;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Ordinary course of business equipment and software financing and leasing (including Capital Lease Obligations and purchase money Indebtedness); provided that (i) if secured, the collateral therefor consists solely of the assets being financed, the products and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal amount of such Indebtedness does not exceed [***] (or the Equivalent Amount in other currencies) at any time;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Indebtedness under Permitted Hedging Agreements;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Indebtedness assumed pursuant to any Acquisition; provided that (i) no such Indebtedness (individually) shall exceed [***]% of the total purchase price paid in connection with such Acquisition, (ii) the aggregate outstanding principal amount of Indebtedness permitted pursuant to this clause (k) shall not exceed [***] (or the Equivalent Amount in other currencies) at any time outstanding and (iii) no such Indebtedness was created or incurred in connection with, or in contemplation of, such Acquisition;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Indebtedness pursuant to (i) any Permitted Debt Facility, and (ii) any Permitted Royalty Monetization;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	other Indebtedness in an aggregate outstanding principal amount not to exceed [***] (or the Equivalent Amount in other currencies);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	Permitted Convertible Notes in an aggregate principal amount at any time outstanding not to exceed [***] plus, and solely to the extent that, [***], unlimited;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Indebtedness in respect of letters of credit, bank guarantees, bankers&#x2019; acceptances or similar instruments issued or created, or related to obligations or liabilities incurred, in the ordinary course of business, including in respect of workers compensation claims, health, disability or other employee benefits or property, leases, commercial contracts, Indebtedness permitted pursuant to clause (i) of the clause (q) of this definition of &#x201c;Permitted Debt&#x201d;, casualty or liability insurance or self-insurance or other reimbursement-type obligations regarding workers compensation claims;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Indebtedness arising in connection with the financing of insurance premiums in the ordinary course;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	Indebtedness in respect of (i) performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and similar obligations in each case arising in the ordinary course and (ii) customary indemnification obligations to purchasers in connection with Dispositions not prohibited hereunder;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	Indebtedness in respect of netting services, overdraft protections, business credit cards, purchasing cards, payment processing, automatic clearinghouse arrangements, arrangements in respect of pooled deposit or sweep accounts, check endorsement guarantees, and otherwise in connection with deposit accounts or cash management services in each case in the ordinary course of business;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	purchase price adjustments, indemnity payments and other Deferred Acquisition Consideration in connection with any Acquisition; and</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	Permitted Refinancings of any items of Permitted Debt under clauses (a), (b), (g) and (i) of this definition of &#x201c;Permitted Debt&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Debt Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Debt Creditors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the lenders or noteholders, and any administrative agent, trustee, collateral agent, security agent, representative or similar agent under any Permitted Debt Facility.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Debt Facility</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) subject to entry into the Intercreditor Agreement, the secured credit facility provided under the Credit Agreement, including the funding of any commitments to extend credit thereunder after the Closing Date that are in existence on the Closing Date and (b) subject to the applicable Permitted Debt Creditors (or representative of the Permitted Debt Creditors) joining the Intercreditor Agreement or the entry into an Other Intercreditor Agreement, other secured Indebtedness in an outstanding principal amount not to exceed the Permitted Debt Cap.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Debt Facility Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the documents relating to a Permitted Debt Facility.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Hedging Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Hedging Agreement entered into by any Company Party in the ordinary course of business for the purpose of hedging currency risks or interest rate risks (and not for speculative purposes) and (x) with respect to hedging currency risks, in an aggregate amount for all such Hedging Agreements that is reasonably prudent given the Company&#x2019;s current financial condition and (y) with respect to hedging interest rate risks, in an aggregate notional amount for all such Hedging Agreements not more than [***], of the aggregate principal amount of loans outstanding at such time under any Permitted Debt Facility.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively,</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	each license agreement listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	any license agreement or covenant not to sue with respect to any Product exclusively outside the United States;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	any license or grant of rights to any Third Party (x) vendor or service provider (including contract research organizations, contract manufacturing organizations, clinical trial sites, distribution and channel partners, commercial vendors and other contractors for the exploitation of any Product) in order to provide services for the benefit of the Company or its Affiliates with respect to any Product or (y) wholesaler or distributor for the benefit of the Company or its Affiliates with respect to any Product, in each case ((x) and (y)), but to the extent that such license or grant of rights relates to rights to the Included Products in the United States, then such license or grant of rights must meet all of the following requirements: (i) such license or grant of rights is non-exclusive and entered into in the ordinary course; (ii) such license or grant of rights grants no rights to sell, offer to sell, have sold, market, promote or otherwise Commercialize the Included Product in the United States, except for rights granted in the ordinary course, it being understood and agreed that notwithstanding any provision to the contrary, a license</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or grant of rights to a Third Party contract sales force or with respect to any type of promotion, co-promotion, marketing, co-marketing or similar arrangement with respect to the Commercialization of the Included Products in the United States is not ordinary course and is not a Permitted License (unless otherwise permitted under clause (h) below); (iii) the Company or another Company Party retains the right to, and does, book the full amount of Net Sales of the Included Products in the United States; and (iv) such license or grant of rights is part of an arm&#x2019;s length transaction, the terms of which do not provide for a sale or assignment to such Third Party of IP Rights or Product Registrations relating to the Included Products in the United States;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	any in-license agreement with respect to a Product;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	any sponsored research or similar agreement providing for the Development of a Product that does not grant the counterparty any right to sell, offer to sell, have sold, market, promote or otherwise Commercialize any Included Product in the United States;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	any intercompany licenses or grants of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, promotion, co-promotion, sales or distribution of Products among the Company Parties or granted by any Subsidiary that is not a Company Party to a Company Party;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	any license for the use of (or covenant not to sue with respect to) the Intellectual Property of the Company or any of its Subsidiaries or grants of rights for development, manufacture, production, commercialization (including commercial sales to end users), marketing, promotion, co-promotion, distribution or importation of (i) any Product that is not an Included Product, or (ii) an Included Product but solely with respect to Intellectual Property or rights exclusively outside the United States; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	other licenses to which the Investor shall have consented to in writing.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Liens (i) securing the Obligations, (ii) created in favor of the Investor, for the benefit of the Investor, pursuant to the Transaction Documents, (iii) created in connection with the Credit Agreement and the Credit Agreement Security Agreement, and (iv) incurred by the Investor;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	any Lien on any property or asset of the Company or any of its Subsidiaries existing on the date hereof and, to the extent any such Lien secures amounts or obligations in excess of [***], set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 7.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and renewals and extensions thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien; provided that (i) no such Lien (including any renewal or extension thereof) shall extend to any other property or asset of the Company or any of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and renewals, extensions and replacements thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien that do not increase the outstanding principal amount thereof (other than by an amount equal to unpaid interest and premiums thereon, including tender premium, and any customary underwriting discounts, fees, commissions and expenses associated with such extension, renewal or replacement);</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Liens securing Indebtedness permitted under clause (i) of the definition of &#x201c;Permitted Debt&#x201d;; provided that such Liens are restricted solely to the collateral described in clause (i) of the definition of &#x201c;Permitted Debt&#x201d;;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Liens imposed by any Law arising in the ordinary course of business, related to carriers&#x2019;, warehousemen&#x2019;s, landlords&#x2019;, and mechanics&#x2019; liens, liens relating to leasehold improvements and other similar Liens arising in the ordinary course of business and which (x) do not in the aggregate materially detract from the value of the property subject thereto or materially impair the use thereof in the operations of the business of such Person, (y) are not in respect of Indebtedness for borrowed money or (z) are being contested in good faith by appropriate proceedings, which proceedings, diligently conducted, have the effect of preventing the forfeiture or sale of the property subject to such Liens and for which adequate reserves have been made if required in accordance with GAAP;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	pledges or deposits made in the ordinary course of business in connection with bids, contract leases, appeal bonds, workers&#x2019; compensation, unemployment insurance or other similar social security legislation;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Liens securing Taxes, assessments and other governmental charges, the payment of which is not past due or is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which adequate reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	servitudes, easements, rights of way, restrictions and other similar encumbrances on real property imposed by any Law and Liens consisting of zoning or building restrictions, easements, licenses, restrictions on the use of real property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Company Parties or any of their Subsidiaries; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	with respect to any real property, (i) such defects or encroachments as might be revealed by an up-to-date survey of such real property; (ii) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real property pursuant to all applicable Laws; and (iii) rights of expropriation, access or user or any similar right conferred or reserved by or in any Law, which, in the aggregate for clauses (i), (ii) and (iii), are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Company Parties or its Subsidiaries;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Bankers&#x2019; liens, rights of setoff and similar Liens incurred on deposits or other assets credited to any deposit or securities account made in the ordinary course of business;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Liens securing Indebtedness permitted under clause (k) of the definition of &#x201c;Permitted Debt&#x201d;; provided that (i) such Lien is not created in contemplation of or in connection with an acquisition permitted by any Permitted Debt Facility pursuant to which such Indebtedness was assumed, (ii) such Lien shall not apply to any other property or assets of the Company or any Subsidiary and (iii) such Lien shall secure only those obligations that it secured immediately prior</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the consummation of such acquisition and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Liens securing Indebtedness permitted under clauses (o), (p), (q) and (r) of the definition of &#x201c;Permitted Debt&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Any judgment Lien or Liens arising from decrees or attachments not constituting an Event of Default;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	Liens arising from precautionary UCC financing statement filings regarding operating leases of personal property and consignment arrangements entered into in the ordinary course in an arm&#x2019;s length transaction;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	other Liens which secure obligations in an aggregate amount not to exceed [***] (or the Equivalent Amount in other currencies) at any time outstanding;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Liens securing Indebtedness permitted under clause (l)(i) of the definition of &#x201c;Permitted Debt&#x201d; and which are subject to the Other Intercreditor Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods and incurred in the ordinary course;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	To the extent constituting a Lien, Permitted Licenses;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	Liens on cash and cash equivalent securing obligations under Permitted Hedging Agreements;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	(i) Liens to secure payment of workers&#x2019; compensation, employment insurance, old age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA) and (ii) deposits in respect of letters of credit, bank guarantees or similar instruments issued for the account of any Company Party or any Subsidiary in the ordinary course of business supporting obligations of the type set forth in clause (i) above;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	to the extent constituting a Lien, customary cash escrow arrangements securing indemnification obligations associated with an acquisition or any other investment not expressly prohibited by any Permitted Debt Facility not to exceed [***] in the aggregate;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	Liens of a collection bank arising under Section 4-210 of the UCC on items in the course of collection;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	Liens of sellers of goods to the Company and any of its Subsidiaries arising under Article 2 of the UCC or similar provisions of applicable law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related expenses;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)	rights of first refusal, voting, redemption, transfer or other restrictions (including call provisions and buy-sell provisions) with respect to the Equity Interests of any Joint Venture or other Persons that are not Subsidiaries;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x)	any Lien arising under conditional sale, title retention, consignment or similar arrangements for the sale of goods in the ordinary course of business; provided that such Lien attaches only to the goods subject to such sale, title retention, consignment or similar arrangement; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)	(i) leases or subleases of real property entered into in the Ordinary Course, (ii) licenses, sublicenses, leases or subleases of personal property (other than Intellectual Property) granted to third parties in the ordinary course of business, in each case which do not interfere in any material respect with the operations of the business of any Company Party or any of its Subsidiaries and do not prohibit granting the Investor a security interest in any Company Party&#x2019;s personal property held at such location for the benefit of the Investor and (iii) retained interests of lessors or licensors or similar parties under any in-licenses;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided that no Lien otherwise permitted under this definition of &#x201c;Permitted Lien&#x201d; shall apply to any IP Rights, other than clauses (a), (l), (o), (q) and (y)(iii) of this definition of &#x201c;Permitted Liens&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Refinancing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Permitted Debt that is permitted to be refinanced, extended, renewed or replaced hereunder, any refinancings, extensions, renewals and replacements of such Indebtedness; provided that: (a) such refinancing, extension, renewal or replacement shall not (i) increase the outstanding principal amount of the Indebtedness being refinanced, extended, renewed or replaced, except by an amount equal to accrued interest and a reasonable premium or other reasonable fee paid, and fees and expenses reasonably incurred in connection therewith, (ii) contain terms relating to outstanding principal amount, amortization, maturity, collateral security (if any) or subordination (if any), or other material terms that, taken as a whole, are less favorable in any material respect to the applicable Company Party and its respective Subsidiaries or the Investor than the terms of any agreement or instrument governing such Permitted Debt, (iii) have an applicable interest rate which does not exceed the greater of (A) the rate of interest of the Permitted Debt being replaced and (B) the then applicable market interest rate, (iv) have obligors or contingent obligors that were not obligors or contingent obligors (or that would not have been required to become obligors or contingent obligors) in respect of the Indebtedness being refinanced, extended, renewed or replaced, (v) be secured on terms less favorable, taken as a whole, to the Company than those contained in the documentation (including any intercreditor agreement) governing the Indebtedness being refinanced, extended, renewed or replaced (reasonably determined in good faith by the Company) and (vi) after giving effect to such refinancing, extension, renewal or replacement, no Default or Material Default shall have occurred or could reasonably be expected to occur as a result thereof; and (b) a joinder to the Intercreditor Agreement or an Other Intercreditor Agreement is executed in connection therewith.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Royalty Monetization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any monetization or financing transaction involving (a) the sale, transfer, option or collateralization of (i) any monetary payments (contingent or otherwise) payable to the Company or any Subsidiary by a counterparty under a license agreement (other than a License Agreement providing for the Commercialization of an Included</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product), or (ii) any product revenues (other than Net Sales or other revenues derived from the sale of Included Products in the United States), or (b) the provision of financing for the development, manufacture and/or commercialization of any product or product candidate (other than Included Products) in exchange for the future payment of royalties, milestones and other amounts (whether or not contingent), including but not limited to sales of royalty streams, royalty bonds and other royalty financings, synthetic royalty, development financings and revenue interest transactions (including but not limited to clinical trial funding arrangements), and hybrid monetization transactions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Warrant Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating to the Company&#x2019;s common stock (or other securities or property following a merger event, reclassification or other change of the common stock of the Company) sold by the Company and with recourse to the Company only, substantially concurrently with any purchase by the Company of a Permitted Bond Hedge Transaction and settled in common stock of the Company, cash or a combination thereof (such amount of cash determined by reference to the price of the Company&#x2019;s common stock or such other securities or property), and cash in lieu of fractional shares of common stock of the Company, with a strike price higher than the strike price of the applicable Permitted Bond Hedge Transaction.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any natural person, firm, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity, including public bodies, whether acting in an individual, fiduciary or other capacity.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.24(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prime Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the rate of interest per annum last quoted by The Wall Street Journal as the &#x201c;Prime Rate&#x201d; in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &#x201c;bank prime loan&#x201d; rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Investor) or any similar release by the Federal Reserve Board (as determined by the Investor). Any change in the Prime Rate shall take effect at the opening of business on the day such change is publicly announced or quoted as being effective.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any product or service developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by the Company or any Subsidiary, including, without limitation, the Included Products.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Assets</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Included Products in the United States, (a) all IP Rights, (b) each Material Contract related to any Included Product, (c) all Product Registrations, Regulatory Approvals, Marketing Authorizations, Regulatory Exclusivities and Regulatory Documentation related to any Included Product in the United States, (d) all inventory of Included Products and any raw materials and work-in-process relating thereto, whether within the United States or not, to the extent owned by the Company or its Subsidiaries and intended for sale in the United States, (e) all accounts receivables and payment intangibles arising out of sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of any Included Product in the United States or licenses of any IP Rights, (f) all other assets that are required or necessary for the Development, Manufacture or Commercialization of any Included Product in the United States and that are owned by, licensed to, or otherwise Controlled by the Company or any Subsidiary, and (g) all proceeds of any of the foregoing.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Registrations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to Included Products in the United States, (a) any approvals, clearances, registrations, licenses, listings, permits, INDs, New Drug Applications, ODDs, breakthrough therapy designations, fast track designations, clinical trial authorizations or Marketing Authorizations, including FDA drug listings, Marketing Authorization approvals and other national or regional marketing authorizations or permits, together with any supplements or amendments thereto, whether pending or issued, to the Company or any of its Subsidiaries by the relevant Governmental Authority related to the Development, Manufacture, or Commercialization of such Included Products over which such Governmental Authority has authority, (b) any rights that the Company or an Affiliate of the Company has in any Regulatory Approval under any agreement pursuant to which any such Regulatory Approval is held in the name of a third party and (c) pricing and reimbursement approval (if applicable or available) and all national drug code numbers (if any) assigned to the Included Products.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Databases</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any material non-public proprietary database or information repository that is owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Software</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any proprietary software (other than any software that is generally commercially available, off-the-shelf and/or open source) including, without limitation, the object code and source code forms of such software and all associated documentation, which is owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put Option Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put Option Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of any one of the following events:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	any Change of Control; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	any Event of Material Default or any Material Default to the extent relating to any of the events set forth in clauses(j), (k) or (l) of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	the Disposition or other form of divestment of any IP Rights (excluding, for the avoidance of doubt, any Permitted License or any Permitted Transfer).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put/Call Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an amount that equals:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	if the Put Option or Call Option is exercised on or before the second anniversary of the Closing Date, one hundred forty percent (140%) of the Investment Amount, less the aggregate of all of the payments received by the Investor pursuant to the Transaction Documents (excluding Excluded Payments) prior to such date;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	if the Put Option or Call Option is exercised after the second anniversary of the Closing Date and on or before August 1, 2031, one hundred sixty percent (160%) of the Investment Amount, less the aggregate of all of the payments received by the Investor pursuant to the Transaction Documents (excluding Excluded Payments) prior to such date;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	  if the Put Option or Call Option is exercised after August 1, 2031 and on or before August 1, 2034, one hundred seventy-five percent (175%) of the Investment Amount, less the aggregate of all of the payments received by the Investor pursuant to the Transaction Documents (excluding Excluded Payments) prior to such date; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	if, the Put Option or Call Option is exercised after August 1, 2034, two hundred percent (200%) of the Investment Amount, less the aggregate of all of the payments received by the Investor pursuant to the Transaction Documents (excluding Excluded Payments) prior to such date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, the Put/Call Payment shall be calculated as of the date of the payment of the Put/Call Payment.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualified Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any Equity Interest of such Person that is not a Disqualified Equity Interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Net Revenues</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Calendar Quarter during the Payment Term, the aggregate amount of Net Revenues in the United States for that Calendar Quarter.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Payment Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each February 1, May 1, August 1 and November 1 following the end of the first Calendar Quarter after the Funding Date (provided if any such date is not a Business Day, the Quarterly Payment Date shall be the next succeeding Business Day).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or other regulation of pharmaceuticals in any jurisdiction.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, all regulatory approvals, licenses, registrations, certificates, authorizations, permits and supplements thereto, as well as associated materials (including the product dossier) pursuant to which the Included Product may be marketed, sold and distributed in a jurisdiction, issued by the appropriate Regulatory Agency, including approved Drug Applications.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Documentation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all (a) applications (including all INDs, Drug Applications and other major regulatory filings), registrations, licenses, authorizations, and approvals, (b) correspondence and reports submitted to or received from Governmental Authorities (including minutes and official contact reports relating to any communications with any Governmental Authority) and all supporting documents with respect thereto, including all advertising and promotion documents, adverse event files, and complaint files, and (c) clinical data and any other data contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) relating to an Included Product.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Exclusivity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to an Included Product, any additional market protection, other than Patent protection or Patent-related exclusivity, granted by a Governmental Authority which confers an exclusive commercialization period either (a) during which the Company or any of its Subsidiaries, licensees or sublicensees has the exclusive right to Commercialize such Included Product (or products similar to such Included Product) in a given territory or for a given use, or (b) that prevents a third party from referencing the Regulatory Documentation for or relying on Regulatory Approval of such Included Product for the benefit of any Product Registration for a Generic Product without the prior written consent of the holder of the Product Registration for such Included Product, such that in each case ((a) and (b)), any unauthorized third party is prevented from marketing or selling a Generic Product of such Included Product during such period, including but not limited to new chemical entity exclusivity, orphan drug exclusivity, data exclusivity, pediatric exclusivity and the like.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a risk evaluation and mitigation strategy, to the extent required by the FDA pursuant to 21 U.S.C. &#167; 355-1.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reportable Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the events set forth in Section 4043(c) of ERISA, other than events for which the thirty (30)-day notice period has been waived.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsible Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the chief executive officer, president, chief financial officer, general counsel, and solely for purposes of the delivery of certificates pursuant to this Agreement, the secretary or any assistant secretary of the Company. Any document delivered hereunder that is signed by a Responsible Officer of the Company shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of the Company and such Responsible Officer shall be conclusively presumed to have acted on behalf of the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all of the Company&#x2019;s rights, title and interest in and to, free and clear of any and all Liens (except for any Lien contemplated under clauses (a), (c), (f), (i)  and (u) of the definition of &#x201c;Permitted Lien&#x201d;), that portion of the Annual Net Revenues of the Company in an amount equal to the Included Product Payment Amount for each Calendar Quarter during the Payment Term.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIFA Account</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any bank account into which payments made in respect of sales of the Included Products in the United States are remitted.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIFA Account Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to each RIFA Account, any agreement entered into by a RIFA Account Bank, the Investor and the Company pursuant to which,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">among other things, such RIFA Account shall be established and/or maintained, as applicable, and which agreement shall function as a control agreement in favor of the Investor with respect to such RIFA Account.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIFA Account Bank</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any bank or financial institution selected by the Company for purposes of establishing and/or maintaining a RIFA Account that is reasonably acceptable to the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIFA Account Trigger Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.24</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any recalls, field notifications, field alert reports, market withdrawals, warnings, &#x201c;dear health care provider&#x201d; letters, investigator notices, safety alerts, or any other notices of action issued or instigated by the Company, any Subsidiary, manufacturer or any Governmental Authority relating to an alleged lack of safety or regulatory compliance of the Included Products.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale and Leaseback Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Party or any Subsidiary, any arrangement, directly or indirectly, with any Person whereby the Party or such Subsidiary shall sell or transfer any property used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold or transferred.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanction(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any sanction administered or enforced by the United States government (including, without limitation, OFAC), the United Nations Security Council, the European Union, His Majesty&#x2019;s Treasury (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HMT</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or other relevant sanctions authority.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctioned Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any Person listed in any Sanctions-related list of designated persons maintained by the United States government (including, without limitation, OFAC), the United Nations Security Council, the European Union, HMT or other relevant sanctions authority, and (b) any Person fifty percent (50%) or greater owned or otherwise controlled by any such Person or Persons.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities and Exchange Commission or any successor agency or authority thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secured Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Credit Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the security agreement, dated as of the Closing Date, in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, executed in favor of the Investor by the Company and each of the Guarantors, as amended or modified from time to time in accordance with the terms hereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the Security Agreement, each Short- Form IP Security Agreement, and each other security document, control agreement or financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statement required or recommended to perfect Liens in favor of the Investor for purposes of securing the Obligations.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Set-off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any set-off, off-set, reduction or similar deduction.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-Form IP Security Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means short-form copyright, patent or trademark (as the case may be) security agreements, dated as of the Closing Date and substantially in the form of Exhibits B, C and D to the Security Agreement, entered into by one or more Company Parties in favor of the Investor, each in form and substance reasonably satisfactory to the Investor (and as amended, modified or replaced from time to time).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person (the &#x201c;parent&#x201d;) at any date, any corporation, limited liability company, partnership, association or other entity (a) of which securities or other ownership interests representing more than fifty percent (50%) of the equity or more than fifty percent (50%) of the ordinary voting power or, in the case of a partnership, more than fifty percent (50%) of the general partnership interests are, as of such date, owned, controlled or held, directly or indirectly, or (b) that is, as of such date, otherwise Controlled, by the parent or one or more direct or indirect subsidiaries of the parent or by the parent and one or more direct or indirect subsidiaries of the parent. Unless otherwise specified, all references herein to a &#x201c;Subsidiary&#x201d; or to &#x201c;Subsidiaries&#x201d; shall refer to a Subsidiary or Subsidiaries of the Company. As of the Closing Date, the Subsidiaries of the Company are set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an application submitted to an approved New Drug Application, or Abbreviated New Drug Application that proposes to make one or more changes to the authorized product.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any U.S. federal, state, local or non-U.S. tax, levy, impost, duty, assessment or withholding or other similar fee, deduction or charge, including all excise, sales, use, value added, transfer, stamp, documentary, filing, recordation and other fees imposed by any taxing authority (and interest, fines, penalties and additions related thereto).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person other than (a) the Company, (b) the Investor or (c) an Affiliate of either the Company or the Investor (as applicable).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any claim, action, suit or proceeding by a Third Party, excluding any lender, officer, directors, employee or agent or other representative of a Party, including any investigation by any Governmental Authority.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Threshold</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) one hundred sixty percent (160%) of the Investment Amount if the Investor has received payments pursuant to the Transaction Documents (excluding Excluded Payments) equal to such amount on or before August 1, 2031, (b) one hundred seventy-five percent (175%) of the Investment Amount if the Investor has received payments pursuant to the Transaction Documents (excluding Excluded Payments) equal to such amount on or before August 1, 2034, or (c) two hundred percent (200%) of the Investment Amount if the Investor has not received payments pursuant to the Transaction Documents (excluding Excluded Payments)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equal to one hundred seventy-five percent (175%) of the Investment Amount on or before August 1, 2034.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Secrets</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any data or information that is not commonly known by or available to the public, and which (a) derives economic value, actual or potential, from not being generally known to and not being readily ascertainable by proper means by other Persons who can obtain economic value from its disclosure or use, (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy, and (c) which are owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademark License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any agreement, written or oral, providing for the grant of any right to use any Trademark.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all statutory and common-law trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications to register in connection therewith, under the Laws of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, for the full term and all renewals thereof, which are owned by or licensed to the Company or any Subsidiary or with respect to which the Company or any Subsidiary is authorized or granted rights under or to.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this Agreement, the Intercreditor Agreement, the Security Documents, any Intercompany Subordination Agreement and any Joinder Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">True Up Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the amount equal to one hundred percent (100%) of the Investment Amount </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">less</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the aggregate amount of the payments received by the Investor pursuant to the Transaction Documents (excluding Excluded Payments) on or before February 1, 2043.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United States</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America, its 50 states, each territory and possession thereof and the District of Columbia.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Uniform Commercial Code as in effect from time to time in New York; provided that, if, with respect to any financing statement or by reason of any provisions of Applicable Law, the perfection or the effect of perfection or non-perfection of any security interest or any portion thereof granted hereunder or pursuant to the Security Agreement is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than New York, then &#x201c;UCC&#x201d; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valid Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (a) any claim of an issued and unexpired Patent, that shall not have been withdrawn, lapsed, abandoned, revoked, canceled or disclaimed, or held invalid or unenforceable by a court, Governmental Authority, national or regional patent office or other appropriate body that has competent jurisdiction in a decision being final and unappealable or unappealed within the time allowed for appeal; and (b) a claim of a pending Patent application that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is filed and being prosecuted in good faith and that has not been finally abandoned or finally rejected and which has been pending for no more than seven (7) years from its filing date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Website Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all agreements between the Company and/or any Subsidiary and any other Person pursuant to which such Person provides any services relating to the hosting, design, operation, management or maintenance of any Website, including without limitation, all agreements with any Person providing website hosting, database management or maintenance or disaster recovery services to the Company and/or any Subsidiary and all agreements with any domain name registrar, as all such agreements may be amended, supplemented or otherwise modified from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Websites</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all websites that the Company or any Subsidiary shall operate, manage or control through a Domain Name, whether on an exclusive basis or a nonexclusive basis, including, without limitation, all content, elements, data, information, materials, hypertext markup language (HTML), software and code, works of authorship, textual works, visual works, aural works, audiovisual works and functionality embodied in, published or available through each such website and all IP Rights in each of the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Work</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any work or subject matter that is subject to protection pursuant to Title 17 of the United States Code.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rules of Construction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless the context otherwise requires, in this Agreement:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	An accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The definitions of terms shall apply equally to the singular and plural forms of the terms defined.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The terms &#x201c;include&#x201d;, &#x201c;including&#x201d; and similar terms shall be construed as if followed by the phrase &#x201c;without limitation&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with the terms thereof (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth herein or in any of the other Transaction Documents) and include any annexes, exhibits and schedules attached thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	References to any Applicable Law shall include such Applicable Law as from time to time in effect, including any amendment, modification, codification, replacement or reenactment thereof or any substitution therefor.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	References to any Person shall be construed to include such Person&#x2019;s successors and permitted assigns (subject to any restrictions on assignment, transfer or delegation set forth herein or in any of the other Transaction Documents), and any reference to a Person in a particular capacity excludes such Person in other capacities.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	The word &#x201c;will&#x201d; shall be construed to have the same meaning and effect as the word &#x201c;shall&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	The words &#x201c;hereof&#x201d;, &#x201c;herein&#x201d;, &#x201c;hereunder&#x201d; and similar terms when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein are references to Articles and Sections of, and Exhibits to, this Agreement unless otherwise specified.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	In the computation of a period of time from a specified date to a later specified date, the word &#x201c;from&#x201d; means &#x201c;from and including&#x201d; and each of the words &#x201c;to&#x201d; and &#x201c;until&#x201d; means &#x201c;to but excluding&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Where any payment is to be made, any funds are to be applied or any calculation is to be made under this Agreement on a day that is not a Business Day, unless this Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with the terms thereof (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth herein or in any of the other Transaction Documents) and include any annexes, exhibits and schedules attached thereto.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Terms and Principles</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless otherwise specified, all accounting terms used in each Transaction Document shall be interpreted, and all accounting determinations and computations thereunder shall be made, in accordance with GAAP. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Company and its Subsidiaries, in each case without duplication. If Company requests an amendment to any provision hereof to eliminate the effect of (a) any change in GAAP or the application thereof or (b) the issuance of any new accounting rule or guidance or in the application thereof, in each case, occurring after the date of this Agreement, then Investor and the Company agree that they will negotiate in good faith amendments to the provisions of this Agreement that are directly affected by such change or issuance with the intent of having the respective positions of the Investor and the Company after such change or issuance conform as nearly as possible to their respective positions as of the date of this Agreement and, until any such amendments have been agreed upon, (i) the provisions in this Agreement shall be calculated as if no such change or issuance has occurred and (ii) the Company shall provide to the Investor a written reconciliation in form and substance reasonably</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory to the Investor, between calculations of any baskets and other requirements hereunder before and after giving effect to such change or issuance.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.507%;text-indent:-8.133%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:4.852%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE II<br>REVENUE INTEREST FINANCING</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase, Sale and Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	At the Closing and upon the terms and subject to the conditions of this Agreement (including satisfaction of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), the Company agrees to sell, transfer, assign and convey, and hereby sells, transfers, assigns and conveys, to the Investor, and the Investor shall purchase, acquire and accept, and hereby purchases, acquires and accepts, from the Company, free and clear of all Liens (except for any Lien contemplated under clauses (a), (c), (f), (i) and (u) of the definition of &#x201c;Permitted Lien&#x201d;), all of the Company&#x2019;s right, title and interests in and to the Revenue Interest. Immediately upon the Closing pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including the satisfaction of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), all of the Company&#x2019;s right, title and interest in and to the Revenue Interest shall terminate, and all such right, title and interest shall vest in the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Company hereby authorizes and consents to the Investor recording and filing, at the Company&#x2019;s sole cost and expense, one or more UCC financing statements (or equivalent instrument) and other financing statements in the appropriate filing offices under the UCC (and continuation statements with respect to such financing statements when applicable) and any other notices of security or notices of charge meeting the requirements of applicable law in such manner and in such jurisdictions as are necessary or appropriate to perfect the assignment to the Investors of the Revenue Interest and the Liens in the Collateral granted to the Investor under the Security Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the terms and subject to the conditions of this Agreement, and subject to the satisfaction of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the purchase price to be paid as consideration to the Company for the sale, transfer, assignment and conveyance of the Revenue Interest to the Investor is $150,000,000 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Investment Amount shall be non-creditable and non-refundable, and notwithstanding anything to the contrary herein, the Investment Amount shall not be subject to any withholding or offset or reduction for any Tax.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Assumed Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding any provision in this Agreement or in any other writing to the contrary, the Investor is not assuming any liability or obligation of the Company or any of the Company&#x2019;s Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter. All such liabilities and obligations shall be retained by and remain liabilities and obligations of the Company or the Company&#x2019;s Affiliates, as the case may be (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Liabilities and Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Assets</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor does not, pursuant to any of the Transaction Documents, purchase, acquire or accept any assets or contract rights of the Company, or any other assets of the Company, other than its rights with respect to the Revenue Interest and, to the extent provided in the Transaction Documents, the Collateral. As between the Parties, the Company has</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sole authority and responsibility for the research, development and Commercialization of Included Products.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE III<br>PAYMENTS ON ACCOUNT OF THE REVENUE INTEREST FINANCING</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments on Account of the Revenue Interest Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In consideration of the Investor paying the Investment Amount hereunder, the Company shall pay the Revenue Interest to the Investor as follows: On each Quarterly Payment Date following the Funding Date, the Company shall pay the Included Product Payment Amount to the Investor for such Quarterly Payment Date until the earlier of (i) date on which the Investor has received payments (excluding Excluded Payments) under the Transaction Documents equal to the Threshold, and (ii) the Quarterly Payment Date immediately following the Legal Maturity Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the occurrence and during the continuance of a Put Option Event following the Funding Date, the Investor shall have the right, but not the obligation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to require the Company to repurchase from the Investor all, but not less than all, of the Revenue Interest at a price equal to the Put/Call Payment. In the event that the Investor elects to exercise the Put Option, the Investor shall deliver written notice to the Company specifying the closing date for such repurchase (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Put Option Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which date shall be [***] days from the date of such notice; provided, however, in the event Company enters into an agreement that would constitute a Change of Control upon the closing of the transactions contemplated by such agreement, or otherwise publicly announces a Change of Control, then Company shall send to the Investor written notice of such potential Change of Control transaction within [***] days of entering into or otherwise publicly announcing such transaction, and the Investor shall have the right, but not the obligation, to exercise the Put Option by providing written notice to the Company within [***] days after receipt of such written notice from the Company of such potential Change of Control transaction, to require the Company to repurchase from Investor all, but not less than all, of the Revenue Interest at a price equal to the Put/Call Payment, which Put Option shall be contingent upon, and the Put Option Closing Date shall occur on, the closing of the Change of Control. If the Investor fails to provide notice exercising the Put Option in connection with a Change of Control within the [***] day period set forth above, Investor shall be deemed to have waived its right to exercise the Put Option for such Put Option Event.  On the Put Option Closing Date, the Company shall repurchase from the Investor the Revenue Interest by paying to the Investor the Put/Call Payment in cash, the payment of which shall be made by wire transfer of immediately available funds to the account designated by the Investor. Notwithstanding anything to the contrary contained herein, immediately upon the occurrence of a Bankruptcy Event, the Investor shall be deemed to have automatically and simultaneously elected to have the Company repurchase from the Investor the Revenue Interest for the Put/Call Payment in cash and the Put/Call Payment shall be immediately due and payable without any further action or notice by any party. For the avoidance of doubt, the Investor&#x2019;s election not to exercise the Put Option with respect to a given Put Option Event will not preclude the Investor from exercising the Put Option with respect to a continuing or subsequent Put Option Event.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Call Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall have the right, but not the obligation, at any time following the Funding Date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Call Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), exercisable upon [***] days&#x2019; prior written notice to Investor, to repurchase all, but not less than all, of the Revenue Interest from the Investor at a repurchase price equal to the Put/Call Payment. In order to exercise the Call Option, the Company shall deliver written notice to Investor of its election to so repurchase the Revenue Interest not less than [***] days prior to the proposed closing date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Call Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); provided, however, that such notice may state that it is conditioned upon the effectiveness of any financing transaction or one or more other events specified therein (including the occurrence of a Change of Control), in which case such notice may be revoked by the Company by written notice to the Investor if such condition is not satisfied. On the Call Closing Date, the Company shall repurchase from the Investor the Revenue Interest at a price equal to the Put/Call Payment, the payment of which shall be made by wire transfer of immediately available funds to the account designated by Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect of Put Option and Call Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the exercise of the Put Option, unless payment of the Put/Call Payment has been made when due, the Investor may, subject to the Intercreditor Agreement (or any Other Intercreditor Agreement), exercise all rights and remedies available to the Investor as a creditor hereunder and under the other Transaction Documents and applicable law (which exercise may be determined in its sole discretion and which such exercise shall not constitute an election of remedies), including enforcement of the Liens created thereby. For the avoidance of doubt, the Put/Call Payment shall be due and payable (in the case of an exercise of the Put Option as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or Call Option as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) at any time the Put Option or the Call Option is exercised or the Obligations are otherwise accelerated hereunder for any reason, whether due to acceleration pursuant to the terms of this Agreement, by operation of law or otherwise (including where bankruptcy filings or the exercise of any bankruptcy right or power, whether in any plan of reorganization or otherwise, results or would result in a payment, discharge, modification or other treatment of the Revenue Interest that would otherwise evade, avoid, or otherwise disappoint the expectations of the Investor in receiving the full benefit of their bargained-for Put/Call Payment). The Company and the Investor acknowledge and agree that none of the Put/Call Payment shall constitute unmatured interest, whether under Section 502(b)(2) of the United States Bankruptcy Code or otherwise, but instead is reasonably calculated to ensure that the Investor receives the benefit of its bargain under the terms of this Agreement. The Company acknowledges and agrees that the Investor shall be entitled to recover the full amount of the Put/Call Payment in each and every circumstance such amount is due pursuant to or in connection with this Agreement, including in the case of any Bankruptcy Event, so that the Investor shall receive the benefit of its bargain hereunder and otherwise receive full recovery as agreed under every possible circumstance, and, to the fullest extent permitted by maximum law, the Company hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise, other than the defense of payment in full. The Company acknowledges and agrees, and, to the fullest extent permitted by maximum law, waives any argument to the contrary, that payment of such amounts does not constitute a penalty or an otherwise unenforceable or invalid obligation. Any damages that the Investor may suffer or incur resulting from or arising in connection with any breach hereof or thereof by the Company shall constitute secured obligations owing to the Investors. The rights provided for herein are cumulative and are not exclusive of any other rights, powers, privileges or remedies provided by applicable law.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">True Up Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If, following the Funding Date, the Investor has not received payments pursuant to the Transaction Documents (excluding Excluded Payments) equal to one hundred percent (100%) of the Investment Amount on or before February 1, 2043, the Company shall repurchase from the Investor the Revenue Interest at a price equal to the True Up Payment, the payment of which shall be made on February 1, 2043 by wire transfer of immediately available funds to the account designated by the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest on Late Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All Revenue Interest, any Put/Call Payment, any True Up Payment and any other Obligations required to be paid but not timely paid to the Investor shall bear interest at a rate of [***] per annum, compounded monthly, from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Law; provided, that such interest shall always accrue on any underpayments. In addition, in the event that an Event of Material Default has occurred, and for so long it is occurring, interest shall accrue on the amount of the Put/Call Payment, at a rate of [***] per annum, compounded monthly, from the date such Event of Material Default occurred until the Put/Call Payment, if such payment becomes payable with respect to such Event of Material Default, is paid in full or, if less, the maximum interest rate permitted by Applicable Law. Any such overdue payment shall, when made, be accompanied by, and credited first to, all interest so accrued.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Account</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall deposit all amounts payable by the Company to the Investor under this Agreement into the Investor Account, unless otherwise instructed by the Investor.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mode of Payment/Currency Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All payments made by a Party hereunder shall be made by deposit of U.S. Dollars by wire transfer or ACH transfer in immediately available funds into the applicable account.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included Product Payment Reports and Record Retention</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Payment Term, the Company shall deliver to the Investor on or prior to each Quarterly Payment Date a written report of (a) the amount of gross sales and unit sales and the pricing of each Included Product sold in the United States during the applicable Calendar Quarter, (b) an itemized calculation of the Net Sales and Other Product Payments for such Calendar Quarter, and (c) a calculation of the amount of the Included Product Payment Amount due under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in respect of the applicable Calendar Quarter, showing the Applicable Tiered Percentage applied to the applicable Net Revenue, which report shall be certified as complete and accurate in all respects by a Responsible Officer. If information pertaining to the source of sales of any Included Product is not included in the quarterly reports delivered to the Investor under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company shall assist the Investor in obtaining such information. For three years after each sale of the Included Products made by the Company or any of its Subsidiaries, the Company shall keep (and shall ensure that its Affiliates shall keep) complete and accurate records of such sale in sufficient detail to confirm the accuracy of the applicable Included Product Payment Amount paid pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor shall treat all information that it receives under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as Confidential Information of the Company in accordance with the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Upon the written request of the Investor, and not more than once in each Calendar Year (so long as no Default or Event of Default has occurred and is continuing), the Company shall permit an independent certified public accounting firm of national prominence selected and, subject to Section 3.4(b) below, paid for by the Investor, and reasonably acceptable to the Company, to have access to and to review, during normal business hours and upon not less than thirty (30) days&#x2019; prior written notice, the relevant documents and records of the Company and its Subsidiaries as may reasonably be necessary to verify the accuracy and timeliness of the reports and payments (including calculation and payment of any Included Product Payment Amount) made by the Company under this Agreement. Such review may cover the records for sales or other dispositions of the Included Products sold in the United States and Net Revenues in any Calendar Year ending no earlier than the first day of the previous Calendar Year. The accounting firm shall be permitted to prepare and disclose to the Investor a written report stating only whether the Included Product Payment Amounts paid to the Investor hereunder and the reports provided by the Company relating to the Included Product Payment Amounts required hereunder are correct or incorrect and the specific details concerning any discrepancies. Notwithstanding the foregoing, after the occurrence and during the continuance of a Default or Event of Default, the Investor shall have the right, as often, at such times and with such prior notice, as the Investor shall determine, in its reasonable discretion, to have an independent certified public accounting firm of national prominence selected by the Investor review the relevant documents and records of the Company and its Subsidiaries.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	If such accounting firm reasonably concludes that any Included Product Payment Amount was owed and was not paid when due during such period pursuant to the provisions of this Agreement, the Company shall pay any undisputed late or unpaid Included Product Payment Amount within [***] days after the date the Investor delivers to the Company a notice including the accounting firm&#x2019;s written report and requesting such payment. If the amount of the underpayment as finally determined (exclusive of interest accrued thereon pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is [***] or more of the total amount actually owed for the period audited, then the Company shall in addition (A) reimburse the Investor for all reasonable costs and fees of the accounting firm related to such audit and (B) pay interest accrued on such amount of the underpayment at a rate of [***] per annum, compounded monthly, from the initial due date until paid in full or, if less, the maximum interest rate permitted by Applicable Law. In the event of overpayment, any amount of such overpayment shall be fully creditable against the Included Product Payment Amount payable for the immediately succeeding Calendar Quarter(s). If the overpayment is not fully applied prior to the final quarterly Included Product Payment Amount due hereunder, the Investors shall promptly refund an amount equal to any such remaining overpayment. The Investor shall (x) treat all information that it receives under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in accordance with the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (y) cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with the Company obligating such firm to retain all such information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for the Investor to enforce its rights under this Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Financial Accommodation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company hereby acknowledges, covenants and agrees that (a) this Agreement does not, and shall not, constitute a &#x201c;financial accommodation agreement&#x201d; pursuant to Section 365(c)(2) of the Bankruptcy Code, (b) it shall not take a position to the contrary in any court of competent jurisdiction including any bankruptcy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">court, and (c) it will not initiate, or assert in, any litigation or other legal proceeding that this Agreement does or may constitute a &#x201c;financial accommodation agreement&#x201d; under Section 365(c)(2) of the Bankruptcy Code.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV<br>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth in the disclosure schedules attached hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company hereby represents and warrants to the Investor as of the Closing Date and the Funding Date as follows:</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Company Party and its Subsidiaries is duly organized, validly existing and in good standing under the Laws of its jurisdiction of organization and has all powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business as now conducted. Each Company Party and its Subsidiaries is duly qualified to transact business and is in good standing in every jurisdiction in which such qualification or good standing is required by Applicable Law (except where the failure to be so qualified or in good standing could not reasonably be expected to result in a Material Adverse Effect).</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	None of the execution and delivery by any Company Party of any of the Transaction Documents to which it is party, the performance by any Company Party of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated hereby or thereby will: (i) contravene, conflict with, result in a breach, violation, cancellation or termination of, constitute a default (with or without notice or lapse of time, or both) under, require prepayment under, give any Person the right to exercise any remedy (including termination, cancellation or acceleration) or obtain any additional rights under, or accelerate the maturity or performance of or payment under, in any respect, (A) any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which any Company Party or any of their respective assets or properties may be subject or bound, (B) any term or provision of any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which a Company Party is a party or by which a Company Party or any of their respective assets or properties is bound or committed (other than a Material Contract), (C) any Material Contract, or (D) any term or provision of any of the organizational documents of any Company Party or its Subsidiaries, except in the case of clause (A) or (B) where any such event could not reasonably be expected to result in a Material Adverse Effect; or (ii) except as provided in any of the Transaction Documents to which it is party, result in or require the creation or imposition of any Lien on the Collateral.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	There does not exist any Lien on the Transaction Documents or the Revenue Interest (except for any Lien contemplated under clauses (a), (c), (f), (i) and (u) of the definition of &#x201c;Permitted Lien&#x201d;). There does not exist any Lien on any of the other Collateral (other than the Revenue Interest) or the Product Assets other than Permitted Liens.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Company Party has all powers and authority to execute and deliver, and perform its obligations under, the Transaction Documents to which it is party and to consummate the transactions contemplated hereby and thereby. The execution and delivery of each of the Transaction Documents to which any Company Party is party and the performance by each Company Party of its obligations hereunder and thereunder have been duly authorized by each Company Party. Each of the Transaction Documents to which any Company Party is party has been duly executed and delivered by each such Company Party. Each of the Transaction Documents to which any Company Party is party constitutes the legal, valid and binding obligation of such Company Party, enforceable against such Company Party in accordance with its respective terms, subject to applicable Debtor Relief Laws.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company Parties are the exclusive owners of the entire right, title (legal and equitable) and interest in, to, and under the Revenue Interest free and clear of all Liens (except for any Lien contemplated under clauses (a), (c), (f), (i) and (u) of the definition of &#x201c;Permitted Lien&#x201d;). The Company Parties are the exclusive owners of the entire right, title (legal and equitable) and interest in, to and under the other Collateral and the Product Assets, free and clear of all Liens, other than Permitted Liens. The Revenue Interest sold, assigned, transferred, conveyed and granted to the Investor on the Closing Date has not been pledged, sold, assigned, transferred, conveyed or granted by any Company Party to any other Person (except for any Lien contemplated under clauses (a), (c), (f), (i) and (u) of the definition of &#x201c;Permitted Lien&#x201d;). The other Collateral (other than the Revenue Interest) and the Product Assets have not been pledged, sold, assigned, transferred, conveyed or granted by any Company Party to any other Person (except for Permitted Liens). The Company Parties have the full right to sell, assign, transfer, convey and grant the Revenue Interest to the Investor. Upon the sale, assignment, transfer, conveyance and granting by the Company Parties of the Revenue Interest to the Investor, the Investor shall acquire good and marketable title to the Revenue Interest free and clear of all Liens (except for any Lien contemplated under clauses (a), (c), (f), (i) and (u) of the definition of &#x201c;Permitted Lien&#x201d;), and shall be the exclusive owner of the Revenue Interest. The Company Parties have not caused, and to the Knowledge of the Company no other Person has caused, the claims and rights of Investor created by any Transaction Document in and to the Revenue Interest to be subordinated to any creditor or any other Person. The Company Parties have not caused, and to the Knowledge of the Company no other Person has caused, the claims and rights of Investor created by any Transaction Document in and to the Collateral to be subordinated to any creditor or any other Person (other than the Liens granted in favor of the Secured Parties under the Credit Agreement Security Documents to the extent set forth in the Intercreditor Agreement).</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental and Third Party Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The execution and delivery by any Company Party of the Transaction Documents to which such Company Party is party, the performance by any Company Party of its obligations hereunder and thereunder and the consummation of any of the transactions contemplated hereunder and thereunder (including the sale, assignment, transfer, conveyance and granting of the Revenue Interest to the Investor) do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by or filing with any Governmental Authority or any other Person, except for applicable filings under U.S. securities laws, the filing of UCC financing statements and those previously obtained or made or to be obtained or made on the Closing Date.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no action, suit, arbitration proceeding, claim, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal, of which Company has received notice and including by or before a Governmental Authority) pending or, to the Knowledge of any Company Party, threatened by or against the Company or its Subsidiaries, at law or in equity, that (i) if adversely determined, could reasonably be expected to result in a in a Material Adverse Effect, or (ii) challenges or seeks to prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents to which any Company Party is party.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solvency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has determined that, and by virtue of each Company Party entering into the transactions contemplated by the Transaction Documents to which such Company Party is party and its authorization, execution and delivery of the Transaction Documents to which such Company Party is party, such Company Party&#x2019;s incurrence of any liability hereunder or thereunder or contemplated hereby or thereby is in its own best interests. Upon consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds therefrom, (a) the fair saleable value of the consolidated assets of the Company Parties will be greater than the sum of their debts, liabilities and other obligations, including known contingent liabilities, (b) the present fair saleable value of the consolidated assets of the Company Parties will be greater than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other obligations, including known contingent liabilities, as they become absolute and matured, (c) each Company Party will be able to realize upon its assets and pay its debts, liabilities and other obligations, including known contingent obligations, as they mature, (d) each Company Party will not have unreasonably small capital with which to engage in its business and will not be unable to pay its debts as they mature, (e) the Company Parties have not incurred, will not incur and do not have any present plans or intentions to incur debts or other obligations or liabilities beyond their ability to pay such debts or other obligations or liabilities as they become absolute and matured, (f) no Company Party will have become subject to any Bankruptcy Event and (g) no Company Party will have been rendered insolvent within the meaning of any Applicable Law. No step has been taken or is intended by any Company Party or, to its Knowledge, any other Person to make any Company Party subject to a Bankruptcy Event.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Brokers&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no Company Party has taken any action that would entitle any person or entity to any commission or broker&#x2019;s fee in connection with the transactions contemplated by this Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None of the Company or any of its Subsidiaries (a) has violated or is in violation of, or to the Knowledge of the Company, is under investigation by a Governmental Authority with respect to, or has been threatened to be charged with or been given notice of any violation of, any Applicable Law or any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority or (b) is subject to any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority, in each case, that could reasonably be expected to result in a material liability to the Company or any of its Subsidiaries. Each of the Company and each Subsidiary of the Company is in compliance with the requirements of all Applicable Laws except for any such event that,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sets forth an accurate and complete list of the Owned Included Product Patent Rights and the Licensed Included Product Patent Rights (other than any Licensed Included Product Patent Rights that (x) are non-exclusively licensed to any Company Party by a Third Party service provider in connection with services provided to the Company by such Third Party service provider, and (y) are not necessary to Commercialize the Included Products in the United States), in each case existing as of the Closing Date and the Funding Date (for the avoidance of doubt, the Company may update </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on or prior to the Funding Date by providing an updated copy to the Investor in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). For each Patent set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company has indicated: (i) the application number; (ii) the patent or registration number, if any; (iii) the country or other jurisdiction where the Patent Right was issued, registered, or filed; (iv) the scheduled expiration date of any issued Patent Right, including a notation if such scheduled expiration date includes a term extension or supplementary protection certificate; (v) the registered owner thereof; and (vi) for any Licensed Included Product Patent Right, the Company Party with rights thereto and the In-License Agreement pursuant to which such rights are granted.  The only Licensed Included Product Patent Rights that are necessary to Commercialize the Included Products in the United States are the Daiichi Sankyo Licensed Included Product Patent Rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Company (or the Company Party indicated on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is the sole and exclusive owner of the entire right, title and interest in each of the Owned Included Product Patent Rights. Other than Permitted Liens, the Owned Included Product Patent Rights are not subject to any encumbrance, Lien or claim of ownership by any Third Party, and to the Knowledge of the Company there are no facts that would preclude the Company from having unencumbered title to the Owned Included Product Patent Rights. No Company Party has received any written notice of any claim by any Third Party challenging the Company Parties&#x2019; ownership of the Owned Included Product Patent Rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	No issued Owned Included Product Patent Right or Daiichi Sankyo Licensed Included Product Patent Right has lapsed, expired or otherwise been terminated, and  no patent application comprising an Owned Included Product Patent Right or a Daiichi Sankyo Licensed Included Product Patent Right has lapsed, expired, been abandoned or otherwise been terminated, other than by operation of law or in the ordinary course of patent prosecution.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	There are no unpaid maintenance fees, annuities or other like payments that are overdue with respect to any of the Owned Included Product Patent Rights or Daiichi Sankyo Licensed Included Product Patent Rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	To the Knowledge of the Company, each of the Owned Included Product Patent Rights and Daiichi Sankyo Licensed Included Product Patent Rights correctly identifies each and every inventor of the claims thereof as determined in accordance with law of the United States. Each inventor of the Owned Included Product Patent Rights and the Daiichi Sankyo</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Included Product Patent Rights has executed an assignment assigning their entire right, title and interest in and to such Included Product Patent Rights and the inventions embodied, described and/or claimed therein, (i) with respect to Owned Included Product Patent Rights, to the Company or to an entity that has in turn executed an assignment assigning their entire right, title and interest in and to such Owned Included Product Patent Rights and the inventions embodied, described and/or claimed therein, to the Company, or (ii) with respect to the Daiichi Sankyo Licensed Included Product Patent Rights, to the licensor of such Daiichi Sankyo Licensed Included Product Patent Rights under the Daiichi Sankyo License Agreement or to an entity that has in turn executed an assignment assigning their entire right, title and interest in and to such Daiichi Sankyo Licensed Included Product Patent Rights and the inventions embodied, described and/or claimed therein, to such licensor, and in each case of (i) and (ii), each such assignment has been duly recorded at the United States Patent and Trademark Office. To the Knowledge of the Company, there is no Person who is or claims to be an inventor of any of the Included Product Patent Rights who is not a named inventor thereof. No Company Party has received from any Person who is not a named inventor of any of the Included Product Patent Rights written notice in which such Person claims to be an inventor of any of the Included Product Patent Rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	To the Knowledge of the Company, each of the issued Owned Included Product Patent Rights and issued Daiichi Sankyo Licensed Included Product Patent Rights and each of the claims thereof is valid, enforceable and subsisting, and each of the pending patent applications included in the Owned Included Product Patent Rights and the Daiichi Sankyo Licensed Included Product Patent Rights and each of the claims thereof will be valid, enforceable and subsisting upon issuance thereof. No Company Party has received any opinion of counsel that any of the Included Product Patent Rights or any claims thereof are invalid or unenforceable or, with respect to any pending patent applications, will be invalid or unenforceable upon issuance thereof. No Company Party has received notice of any claim by any Third Party challenging the validity or enforceability of any of the Included Product Patent Rights or any claims thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	To the Knowledge of the Company, each individual associated with the filing and prosecution of the Owned Included Product Patent Rights and Daiichi Sankyo Licensed Included Product Patent Rights has complied in all material respects with all applicable duties of candor and good faith in dealing with any Patent Office, including any duty to disclose to any Patent Office all information known by such individual to be material to patentability of each such Patent Right, in those jurisdictions where such duties exist.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	The Company has disclosed to the U.S. Patent and Trademark Office all patents, published patent applications, articles, abstracts, disclosures, sales, offers for sale or other prior art deemed material to patentability of any of the inventions claimed in the issued Owned Included Product Patent Rights, or that would otherwise reasonably be expected to materially adversely affect the validity or enforceability of any of the claims of such Owned Included Product Patent Rights.  All patents, published patent applications, articles, abstracts, disclosures, sales, offers for sale or other prior art deemed material to patentability of any of the inventions claimed in the Daiichi Sankyo Licensed Included Product Patent Rights or that would otherwise reasonably be expected to materially adversely affect the validity or enforceability of any of the claims of such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Daiichi Sankyo Licensed Included Product Patent Rights were disclosed to the U.S. Patent and Trademark Office.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	There is no pending or, to the Knowledge of the Company, threatened opposition, interference, reexamination, injunction, claim, suit, action, citation, summons, subpoena, hearing, inquiry, investigation (by the International Trade Commission or otherwise), complaint, arbitration, mediation, demand, decree or other dispute, disagreement, proceeding, claim, inter-partes review, post-grant review, or Paragraph IV Certification (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) challenging the legality, validity, enforceability, ownership or infringement of any of the Owned Included Product Patent Rights or Daiichi Sankyo Licensed Included Product Patent Rights or that could reasonably be expected to result in any Set-off against the payments due to the Investor under this Agreement. There are no Disputes by or with any Third Party against the Company or any of its Subsidiaries involving the Included Product Patent Rights, the Initial Included Product or any other Included Product currently being Developed by or on behalf of any Company Party. None of the Owned Included Product Patent Rights or to the Knowledge of the Company, the Daiichi Sankyo Licensed Included Product Patent Rights are subject to any outstanding injunction, judgment, order, decree, ruling, challenge, settlement or other disposition of a Dispute.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	There is no pending or, to the Knowledge of the Company, threatened, and no event has occurred or circumstance exists that (with or without notice or lapse of time, or both) would result in or serve as a basis for any, action, suit or proceeding, or any investigation or claim, and no Company Party has received any written notice of the foregoing, that claims that the manufacture, use, marketing, sale, offer for sale, importation or distribution in the United States of the Initial Included Product or any other Included Product currently being Developed by or on behalf of any Company Party infringes any Patent or other intellectual property rights of any other Person or constitutes misappropriation of any other Person&#x2019;s trade secrets or other intellectual property rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	To the Knowledge of the Company, none of the conception, development and reduction to practice of the inventions claimed in the Owned Included Product Patent Rights or the Daiichi Sankyo Licensed Included Product Patent Rights has constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	No Company Party has filed any disclaimer, other than a terminal disclaimer or in the ordinary course of patent prosecution, or made or permitted any other voluntary reduction in the scope of any Owned Included Product Patent Rights.  No Company Party nor any Third Party owner of the Daiichi Sankyo Licensed Included Product Patent Rights has filed any disclaimer, other than a terminal disclaimer or in the ordinary course of patent prosecution, or made or permitted any other voluntary reduction in the scope of any Daiichi Sankyo Licensed Included Product Patent Rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	To the Knowledge of the Company, no issued Third Party Patent has been, or is, or will be, infringed by any Company Party&#x2019;s proposed Commercialization in the United States of the Initial Included Product or any other Included Product currently being clinically Developed by or on behalf of any Company Party. To the Knowledge of the Company, no issued</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Patent would limit or prohibit in any material respect any Company Party&#x2019;s proposed Commercialization in the United States of the Initial Included Product or any other Included Product currently being clinically Developed by or on behalf of the Company as currently proposed. No Company Party has received any notice of any claim by any Third Party asserting that such Company Party&#x2019;s proposed Commercialization in the United States of the Initial Included Product or any other Included Product currently being Developed by or on behalf of such Company Party infringes or, upon Commercialization in the United States, could infringe such Third Party&#x2019;s Patents. No Company Party has received any opinion of counsel regarding infringement or non-infringement of any Third Party Patent by such Company Party&#x2019;s proposed Commercialization in the United States of the Initial Included Product or any other Included Product currently being Developed by or on behalf of such Company Party.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	To the Knowledge of the Company, there are no pending published patent applications owned by any Third Party, which the Company Parties do not have the right to use, which if issued, would limit or prohibit in any material respect the Company Parties&#x2019; Commercialization in the United States of the Initial Included Product or any other Included Product currently being Developed by or on behalf of the Company Parties.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	To the Knowledge of the Company, no Third Party is infringing any of the issued Owned Included Product Patent Rights or Daiichi Sankyo Licensed Included Product Patent Rights. No Company Party has provided written notice to any Third Party claiming that the Third Party is infringing any of the issued Owned Included Product Patent Rights or Daiichi Sankyo Licensed Included Product Patent Rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sets forth all Copyrights, Trademarks and Domain Names material to the Company Parties&#x2019; proposed Commercialization in the United States of the Initial Included Product (for the avoidance of doubt, the Company may update </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.10(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on or prior to the Funding Date by providing an updated copy to the Investor in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), including the name of the Company Party that owns each such Copyright, Trademark and Domain Name.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	The Owned Included Product Patent Rights and the Daiichi Sankyo Licensed Included Product Patent Rights constitute all of the Patent Rights necessary to Commercialize the Included Products in the United States following the Closing Date in accordance with the Company&#x2019;s plans.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.11.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 1.1-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sets forth an accurate and complete list of each partnership agreement, license agreement or similar agreement entered into by the Company or any of its Affiliates, pursuant to which (a) the Company or any Affiliate of the Company has granted a license or sublicense to any Third Party under any IP Rights to Develop, have Developed, Manufacture, have Manufactured, seek Regulatory Approval for, distribute, use, have used, import, sell, offer to sell, have sold or otherwise Commercialize an Included Product in the United States, other than agreements granting non-exclusive rights to Develop or Manufacture Included Products entered into in the ordinary course of business with vendors (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Out-License Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), or (b) a Third Party has granted a license or sublicense to the Company or any Affiliate of the Company under any IP Rights to Develop, have Developed,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture, have Manufactured, seek Regulatory Approval for, distribute, use, have used, import, sell, offer to sell, have sold or otherwise Commercialize an Included Product in the United States (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-License Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and all Out-License Agreements and In-License Agreements, together the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), other than In-License Agreements with any Third Party service provider or vendor (x) granting non-exclusive rights in connection with services provided to the Company by such Third Party service provider, and (y) granting rights with respect to IP Rights that are not necessary to Commercialize the Included Products in the United States. A true, correct and complete copy of each License Agreement, together with any amendment, supplement or modification, in each case existing as of the Closing Date, has been provided to the Investor. Each License Agreement is a valid and binding obligation of the Company and each counterparty thereto, and is enforceable against each counterparty thereto in accordance with its terms except as may be limited by applicable Debtor Relief Laws. Neither the Company nor the respective counterparty thereto has granted any written waiver under any provision of any License Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.12.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Company Party is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of buying or carrying margin stock, and no portion of the Investment Amount will be used, whether immediately, incidentally or ultimately, to buy or carry any margin stock, to extend credit to others for the purpose of buying or carrying any margin stock, or in any way that is in violation of Regulation T, U or X promulgated by the Board of Governors of the Federal Reserve System from time to time.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.13.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Contracts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.13(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto contains a list of the Material Contracts (for the avoidance of doubt, the Company may update </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.13(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on or prior to the Funding Date by providing an updated copy to the Investor in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). A true and complete copy of each Material Contract has been provided by the Company to the Investor.</font></p>
  <p style="text-indent:13.721%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:2.824%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Neither any Company Party nor, to the Knowledge of the Company, any Material Contract Counterparty is in breach or default of any Material Contract and to the Knowledge of the Company, no circumstances or grounds exist that would, upon the giving of notice, the passage of time or both, give rise (i) to a claim by any Company Party or any Material Contract Counterparty of a breach or default of any Material Contract, or (ii) to a right of rescission, early termination, revision, setoff, or any other rights, by any Person, in, to or under any Material Contract. No Company Party has received from, or delivered to, any Material Contract Counterparty, any notice alleging a breach or default under any Material Contract, which breach or default has not been cured.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Each Material Contract is a valid and binding obligation of the applicable Company Party and, to the Knowledge of the Company, of the applicable Material Contract Counterparty, enforceable against each of such Company Party and, to the Knowledge of the Company, each applicable Material Contract Counterparty in accordance with its terms, except as may be limited by applicable Debtor Relief Laws. No Company Party has received any notice from any Material Contract Counterparty or any other Person challenging the validity or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforceability of any Material Contract. Neither any Company Party, nor to the Knowledge of the Company, any other Person, has delivered or intends to deliver any notice to such Company Party or a Material Contract Counterparty challenging the validity or enforceability of any Material Contract.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	There are no settlements, covenants not to sue, consents, judgements, orders or similar obligations which: (i) restrict the rights of the Company or any of its Subsidiaries from the Development, Manufacture, or Commercialization of the Included Products in the United States, or (ii) permit any Third Parties to Develop, Manufacture or Commercialize the Included Products in the United States in any manner that would give rise to a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.14.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, neither any Company Party nor, to the Knowledge of the Company, any Material Contract Counterparty is contemplating or planning to commence any case, proceeding or other action relating to such Material Contract Counterparty&#x2019;s bankruptcy, insolvency, liquidation or dissolution or reorganization.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.15.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Office Locations; Names</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The chief place of business, the chief executive office and each office where each Company Party keeps its records regarding the Collateral are, as of the date hereof, each located at [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	No Company Party (or any predecessor by merger or otherwise) has, within the [***] period preceding the date hereof, had a name that differs from its name as of the date hereof.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.16.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no Indebtedness incurred by the Company or any of its Subsidiaries other than the Permitted Debt. Except as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there is no default or event of default (in each case, with or without notice or lapse of time, or both) under the Permitted Debt Facility Documents.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.17.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements; No Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Audited Financial Statements (a) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, (b) fairly present in all material respects the financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (c) show all material Indebtedness and other liabilities, direct or contingent, of the Company and its Subsidiaries as of the date thereof, including material liabilities for Taxes, commitments and Indebtedness to the extent required by GAAP. The Interim Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, (ii) fairly present in all material respects the financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, and (iii) show all material Indebtedness and other liabilities, direct or contingent, of the Company and its Subsidiaries as of the date thereof, including material liabilities for Taxes, material commitments and Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the extent required by GAAP, subject, in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this sentence, to the absence of footnotes and to normal year-end audit adjustments.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	From the date of the Audited Financial Statements to and including the Closing Date, there has been no Disposition by any Company Party, or any Involuntary Disposition, of any Collateral or Product Assets which is not reflected in the Financial Statements or in the notes thereto and has not otherwise been disclosed in writing to the Investor on or prior to the Closing Date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Since the date of the Audited Financial Statements, there has been no event or circumstance, either individually or in the aggregate, that has had or could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.18.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Neither the Company nor any Subsidiary is in default (with or without notice or lapse of time, or both) under or with respect to any Contractual Obligation that could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	No Change of Control, Default, Event of Default, Material Default or Event of Material Default has occurred and is continuing.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.19.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The properties of the Company and each of its Subsidiaries are insured with financially sound and reputable insurance companies which are not Affiliates of such Persons, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where the Company or the applicable Subsidiary operates.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.20.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (i) to the Knowledge of the Company, each Benefit Plan is in compliance with the applicable provisions of ERISA, the Internal Revenue Code and other federal or state Laws, and (ii) each Pension Plan that is intended to be a qualified plan under Section 401(a) of the Internal Revenue Code has received a favorable determination letter from the Internal Revenue Service to the effect that the form of such Benefit Plan is qualified under Section 401(a) of the Internal Revenue Code, an application for such a letter is currently being processed by the Internal Revenue Service or is entitled to rely on the opinion or advisory letter issued by the Internal Revenue Service to the sponsor of a preapproved plan document and, to the Knowledge of the Company, nothing has occurred that would prevent, or cause the loss of, such tax-qualified status.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	There are no pending or, to the Knowledge of the Company, threatened claims (other than routine claims for benefits in due course), actions or lawsuits, or action by any Governmental Authority, with respect to any Benefit Plan that could reasonably be expected to result in a Material Adverse Effect. The Company has not engaged in any prohibited transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or violation of the fiduciary responsibility rules with respect to any Benefit Plan, in any case, that could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Except as could not reasonably be expected to result in a Material Adverse Effect, (i) no ERISA Event has occurred with respect to any Pension Plan, (ii) the Company and each ERISA Affiliate has met all applicable requirements under the applicable pension funding rules in respect of each Pension Plan, and no waiver of the minimum funding standards under the applicable pension funding rules has been applied for or obtained, and (iii) neither the Company nor any ERISA Affiliate has incurred any liability to the PBGC other than for the payment of premiums due but not delinquent under Section 4007 of ERISA.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.21.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a complete and accurate list as of the date hereof of each Subsidiary of the Company, together with (a) such Subsidiary&#x2019;s jurisdiction of organization and (b) the percentage of Equity Interests in such Subsidiary owned by the Company. The Company does not have any Affiliates other than the Subsidiaries listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.22.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Perfection of Security Interests in the Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Security Documents create legal and valid security interests in, and Liens on, the Collateral and receivables purported to be covered thereby securing the payment and performance of the Obligations to the extent such security interests may be created pursuant to Article 9 of the UCC, which security interests and Liens will be, upon the timely and proper filings, deliveries, notations and other actions contemplated in the Security Documents, perfected security interests and Liens (to the extent that such security interests and Liens can be perfected by such filings, deliveries, notations and other actions), in each case, for the benefit of the Investor.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.23.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions Concerns; Anti-Corruption Laws; PATRIOT Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions Concerns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither the Company nor any Subsidiary, nor, to the Knowledge of the Company, any director, officer, employee, agent, Affiliate or representative of the Company or any Subsidiary, is an individual or entity that is, or is 50% or more owned or otherwise controlled by, any individual or entity that is (i) currently the subject or target of any Sanctions, (ii) included on OFAC&#x2019;s List of Specially Designated Nationals and Blocked Persons, HMT&#x2019;s Consolidated List of Financial Sanctions Targets and the Investment Ban List, or any similar list enforced by any other relevant sanctions authority or (iii) located, organized or resident in a Designated Jurisdiction.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither the Company nor, to the Knowledge of the Company, any of the Company&#x2019;s directors, officers, employees or agents, while acting on behalf of the Company, have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any &#x201c;foreign official&#x201d; (as such term is defined in the U.S. Foreign Corrupt Practices Act, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority or (iii) securing any improper advantage, in the case of (i), (ii) and (iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above in order to assist the Company or any of its Affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor, to the Knowledge of the Company, any of its directors, officers, employees or agents, while acting on behalf of the Company, have made or authorized any bribe, improper, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any applicable Law, rule or regulation. The Company further represents that it has maintained, and has caused each of its Subsidiaries to maintain, systems of internal controls (including accounting systems, purchasing systems and billing systems) to ensure compliance with all Anti-Corruption Laws. The Company and its Subsidiaries have conducted their business in compliance with all Anti- Corruption Laws, and have instituted and maintained policies and procedures designed to promote and ensure compliance with such laws.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PATRIOT Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent applicable, the Company and each Subsidiary is in compliance in all material respects with the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), as amended from time to time.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.24.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Security; Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	No Company Party has experienced any breach of its security resulting in unauthorized access by third parties of any Personal Information in its possession, custody, or control that could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	In connection with its collection, storage, transfer (including, without limitation, any transfer across national borders) and/or use of any personally identifiable information (as such term, or similar term, is defined under Applicable Laws) from any individuals, including, without limitation, any customers, prospective customers employees and/or other Third Parties (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), each Company Party is and has been, to the Knowledge of Company, in compliance in all material respects with (i) all Applicable Laws in all relevant jurisdictions, including (if applicable) the General Data Protection Regulation, (ii) such Company Party&#x2019;s privacy policies, and (iii) the relevant requirements of any contracts or codes of conduct to which such Company Party is a party, except in each case of (i)-(iii), for any such event that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. Each Company Party has commercially reasonable physical, technical, organizational and administrative security measures and policies in place designed to protect all Personal Information collected by it or on its behalf from and against unauthorized access, use and/or disclosure. Each Company Party is and has been, to the Knowledge of the Company, in compliance in all material respects with all Laws relating to data loss, theft and breach of security notification obligations, except for any such event that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.25.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance of Included Products</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	(i) The Company and its Subsidiaries possess all material Permits, including Governmental Licenses from the FDA, the DEA, the EMA and other Governmental Authorities required for the conduct of their business as currently conducted (including, for the avoidance of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doubt, the Development and proposed Commercialization of the Included Products in the United States), and all such Permits are in full force and effect;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	The Company and its Subsidiaries have not received any written communication from any Governmental Authority regarding any failure to materially comply with any Laws, including any terms or requirements of any Governmental License. To the Knowledge of the Company, there are no facts or circumstances that are reasonably likely to give rise to any revocation, withdrawal, suspension, cancellation, material limitation, termination, adverse modification or significant delay of any Governmental License required to continue to Develop or Commercialize as proposed the Included Products in the United States;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	None of the officers, directors, employees or, to the Knowledge of the Company, Affiliates of the Company or any Subsidiary or any agent or consultant involved in any Drug Application, has been convicted of any crime or engaged in any conduct for which debarment is authorized by 21 U.S.C. Section 335a nor, to the Knowledge of the Company, are any debarment proceedings or investigations pending or threatened against the Company or any Subsidiary or any of their respective officers, directors, employees or agents;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	None of the officers, directors, employees or, to the Knowledge of the Company, Affiliates of the Company or any Subsidiary or any agent or consultant involved in any Drug Application, has been convicted of any crime or engaged in any conduct for which debarment is authorized by 21 U.S.C. Section 335a nor, to the Knowledge of the Company, are any debarment proceedings or investigations pending or threatened against the Company or any Subsidiary or any of their respective officers, directors, employees or agents&#x37e;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	All preclinical studies and clinical trials conducted by or on behalf of the Company and its Subsidiaries that have been submitted to any Governmental Authority, including the FDA and its counterparts worldwide, in connection with any Product Registrations and request for a Regulatory Approval, are being or have been conducted in compliance in all material respects with the required experimental protocols and Applicable Laws;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	All Included Products have since [***] been manufactured, transported, stored and handled in all material respects in accordance with all Applicable Laws, including applicable current good manufacturing practices except where the failure to comply could not reasonably be expected to result in a Material Adverse Effect;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii)	Neither the Company nor any Subsidiary has received any written notice that any Governmental Authority, including without limitation the FDA, the DEA, the EMA, the Office of the Inspector General of the United States Department of Health and Human Services or the United States Department of Justice has commenced any investigation or threatened to initiate any action against the Company or a Subsidiary, or any action to enjoin the Company or a Subsidiary, its officers, directors, employees, agents and Affiliates, from conducting its business or for any material civil penalty, injunction, seizure or criminal action, in each case, that could reasonably be expected to result in a Material Adverse Effect or a material adverse effect on the Development or Commercialization of any Included Product in the United States;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(viii)	Neither the Company nor any Subsidiary has received from the FDA, the DEA, the EMA or other Governmental Authority at any time since [***], a Warning or Untitled Letter, Form FDA-483, request for regulatory meeting, or similar correspondence or notice alleging violations of Laws enforced by the FDA, the DEA, the EMA or any comparable correspondence from any other Governmental Authority with regard to any Included Product or the manufacture, processing, packaging or holding thereof, the subject of which communication is unresolved and if determined adversely to the Company or such Subsidiary could reasonably be expected to result in a Material Adverse Effect; and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ix)	Since [***], (A) there have been no Safety Notices, (B) to the Knowledge of the Company, there are no unresolved material product complaints with respect to any Included Product, and (C) to the Knowledge of the Company, there are no facts or circumstances that could reasonably be expected to result in (1) any material change to the &#x201c;Indications and Usage,&#x201d; &#x201c;Warnings and Precautions,&#x201d; and &#x201c;Contraindications&#x201d; sections as proposed in the draft Prescribing Information for the Initial Included Product initially submitted by the Company to the FDA on October 23, 2024 as part of NDA 219713 or a failure to obtain FDA Approval, (2) a termination or suspension of Development of Included Products, (3) the issuance of a Safety Notice by a U.S. Governmental Authority, or (4) the occurrence of a CRL Event.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	All of the Included Products that exist as of the date hereof are listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.25(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All of the Product Registrations that exist as of the date hereof are listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.25(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including with respect to each Product Registration (i) the Included Product to which such Product Registration relates, and (ii) the name of the Company Party that owns each such Product Registration.  Since [***], the operation of the Business of the Company and its Subsidiaries with respect to the Included Products, including the manufacture of the Initial Included Product, has been in material compliance with all Permits and Applicable Laws, including, without limitation, the FDCA.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Without limiting the generality of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.25(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.25(a)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, with respect to any Included Products being tested or manufactured by the Company and its Subsidiaries, as of the date hereof, to the Knowledge of the Company, neither the Company nor any Subsidiary has received any notice from any applicable Governmental Authority, including the FDA, the DEA and the EMA, that such Governmental Authority is conducting an investigation or review of (i) the Company and its Subsidiaries&#x2019; (or any third party contractors therefor) manufacturing facilities and processes for manufacturing such Included Products, in each case which have identified any material deficiencies or material violations of Laws or the Permits related to the manufacture of such Included Products, or (ii) any such Governmental License that could reasonably be expected to result in a revocation or withdrawal of such Governmental License, nor has any such Governmental Authority issued any order or recommendation stating that the development, testing or manufacturing of such Included Products by the Company and its Subsidiaries should cease.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Neither the Company nor any of its Subsidiaries has experienced any failures in the manufacturing of the Initial Included Product that could reasonably be expected to result in a material adverse effect on the Development or Commercialization of any Included</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product in the United States. The Company, its Affiliates and their respective manufacturers have not received any inspectional findings or audit findings by any Governmental Authority or third party that could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Except</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the ROS-1-positive solid tumors indication, the Company is not currently clinically developing the Initial Included Product for any indication that has not been granted an ODD by the FDA under the Orphan Drug Act and all implementing regulations, as amended. Based on the Company&#x2019;s ODD previously granted to the Initial Included Product for the treatment of ROS-1-positive, NTRK-positive, ALK-positive, LTK-positive, ACK-I-positive or DDR-1-positive non-small cell lung cancer (NSCLC), if the Initial Included Product receives marketing authorization from the FDA it will be eligible for the period of orphan drug exclusivity available under the Orphan Drug Act and all implementing regulations, as amended, notwithstanding that such period of orphan exclusivity has not been listed by FDA in the Orange Book for the Initial Included Product as of the date hereof.  Neither the Company nor any of its Subsidiaries is conducting any Development activities with respect to any combination product, including any antibody drug conjugate, or any combination product that otherwise conjugates, combines or otherwise contains the Included Product.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.26.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Labor Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There are no existing or, to the Knowledge of the Company, threatened strikes, lockouts or other labor Disputes involving the Company or any Subsidiary that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. Except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, hours worked by and payments of compensation made by the Company and its Subsidiaries to their respective employees are not in violation of the Fair Labor Standards Act or any other Applicable Law, rule or regulation dealing with such matters.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.27.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company and each of its Subsidiaries has (a) filed all Tax returns and reports required by to have been filed by it (including in its capacity as a withholding agent), (b) paid all Taxes required to be paid by it (including in its capacity as a withholding agent), and (c) provided adequate accruals, charges and reserves in accordance with GAAP in their applicable financial statements in respect of all Taxes not yet due and payable, except, in each case, (i) any such Taxes that are being diligently contested in good faith by appropriate proceedings and for which adequate reserves have been provided in accordance with GAAP or (ii) any failure that could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.28.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Full Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None of the reports, financial statements, certificates or other written information (other than projections, forward-looking information and information of a general economic or industry specific nature) furnished by or on behalf of the Company or any of its Subsidiaries to the Investor in connection with the negotiation of this Agreement and the other Transaction Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished by or on behalf of the Company, and the Company&#x2019;s filings publicly available on &#x201c;EDGAR&#x201d;) contains when furnished any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not materially misleading; provided that, with respect to projected financial information, the Company represents only that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such information was prepared in good faith based upon assumptions believed to be reasonable at the time delivered, and it being understood that such projected financial information and all other forward looking information are not to be viewed as facts and are subject to significant uncertainties and contingencies, many of which are beyond the control of the Company or any of its Subsidiaries, including whether or not the Company will receive FDA Approval, and that actual results during the period or periods covered thereby may differ significantly from such projected results and that the differences may be material.  Except as set forth in the Disclosure Schedules, as set forth in the Company&#x2019;s electronic data room maintained at Firmex.com and made available to the Investor at least two (2) Business Days prior to the date of this Agreement, or as disclosed by the Company in writing to the Investor at least two (2) Business Days prior to the date of this Agreement, the Company has no Knowledge of any fact or circumstance (other than general economic or industry conditions) that could reasonably be expected to (a) have a Material Adverse Effect, or (b) materially and adversely affect the Initial Included Product or the development and commercialization activities with respect to the Initial Included Product, including the receipt of Regulatory Approval and the proposed commercialization of the Initial Included Product following receipt of Regulatory Approval.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE V<br>REPRESENTATIONS AND WARRANTIES OF THE INVESTOR</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Investor hereby represents and warrants to the Company as of the Closing Date and the Funding Date as follows:</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investor is a Delaware limited partnership duly organized, validly existing and in good standing under the Laws of its state of formation, has all powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business as now conducted, and is treated as a partnership for U.S. federal (and applicable state and local) Tax purposes.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. None of the execution and delivery by the Investor of any of the Transaction Documents to which it is party, the performance by it of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated hereby or thereby will contravene, conflict with, result in a breach, violation, cancellation or termination of, constitute a default (with or without notice or lapse of time, or both) under, require prepayment under, give any Person the right to exercise any remedy (including termination, cancellation or acceleration) or obtain any additional rights under, or accelerate the maturity or performance of or payment under, in any respect, (i) any Applicable Law or any judgment, order, writ, decree, permit or license of any Governmental Authority to which such entity or any of its assets or properties may be subject or bound, (ii) any term or provision of any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which such entity is a party or by which such entity or any of its assets or properties is bound or committed or (iii) any term or provision of any of the organizational documents of such entity, except in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> where any such event would not result in a material adverse effect on the ability of such entity to consummate the transactions contemplated by the Transaction Documents.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor has all powers and authority to execute and deliver, and perform its obligations under, the Transaction Documents to which it is party and to consummate the transactions contemplated hereby and thereby. The execution and delivery of each of the Transaction Documents to which it is party, and the performance by it of its obligations hereunder and thereunder, have been duly authorized by it. Each of the Transaction Documents to which it is party has been duly executed and delivered by it. Each of the Transaction Documents to which it is a party constitutes the legal, valid and binding obligation of it, enforceable against it in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar Applicable Laws affecting creditors&#x2019; rights generally, general equitable principles and principles of public policy.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental and Third Party Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The execution and delivery by such entity of the Transaction Documents to which it is party, the performance by it of its obligations hereunder and thereunder and the consummation of any of the transactions contemplated hereunder and thereunder do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by or filing with any Governmental Authority or any other Person.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is no action, suit, arbitration proceeding, claim, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal and including by or before a Governmental Authority) pending or, to the knowledge of such entity, threatened by or against such entity, at law or in equity, that challenges or seeks to prevent or delay or which, if adversely determined, would prevent or delay the consummation of any of the transactions contemplated by any of the Transaction Documents to which it is party.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Brokers&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor has not taken any action that would entitle any person or entity to any commission or broker&#x2019;s fee in connection with the transactions contemplated by this Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funds Available</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of the date hereof, the Investor has sufficient funds on hand to satisfy its obligations to pay the Investment Amount due and payable on the Funding Date. It acknowledges and agrees that its obligations under this Agreement are not contingent on obtaining financing.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor acknowledges that it has (a) reviewed such documents and information relating to the Revenue Interest, the Collateral and the Included Products and (b) had the opportunity to ask such questions of, and to receive answers from, representatives of the Company, in each case, as it deemed necessary to make an informed decision to purchase, acquire and accept the Revenue Interest in accordance with the terms of this Agreement. The Investor has such knowledge, sophistication and experience in financial and business matters that it is capable of evaluating the risks and merits of purchasing, acquiring and accepting the Revenue Interest in accordance with the terms of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE VI<br>AFFIRMATIVE COVENANTS</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parties hereto covenant and agree as follows:</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Matters; Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	On or prior to the Closing Date, each of the Company and the Guarantors (if any) shall enter into the Security Agreement, pursuant to which the Company and the Guarantors (if any) shall grant to the Investor, a continuing security interest (with the priority provided for in the Intercreditor Agreement) in all of the Company&#x2019;s and the Guarantors&#x2019; (if any) respective right, title and interest in, to and under the Collateral, whether now or hereafter existing, and any and all &#x201c;proceeds&#x201d; thereof (as such term is defined in the UCC), in each case, for the benefit of the Investor as security for the prompt and complete payment and performance of the Obligations.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, each Guarantor shall enter into the Guaranty, pursuant to which each Guarantor shall guarantee the prompt performance of the Obligations. The Company shall cause any Subsidiary (other than an Excluded Subsidiary that is not so required under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) that may acquire or own any portion of the Collateral after the Closing Date to enter into a Joinder Agreement to become a party to this Agreement as a Company Party, the Guaranty as a Guarantor and the Security Agreement as a Grantor (as defined therein) within [***] days of such acquisition or ownership in the case of a Subsidiary incorporated, formed or organized under the laws of the United States, any state of the United States or the District of Columbia and within [***] days of such acquisition or ownership in the case of any other Subsidiary.  The Company shall cause any Subsidiary (other than an Excluded Subsidiary that is not so required under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) that may acquire or own any portion of the Product Assets after the Closing Date (but that does not otherwise own any Collateral) to enter into a Joinder Agreement to become a party to this Agreement as a Company Party and the Guaranty as a Guarantor within thirty (30) days of such acquisition or ownership.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Each of the Company and the Guarantors authorizes and consents to the Investor filing, including with the Secretary of State of the State of Delaware, at the Company&#x2019;s sole cost and expense, one or more UCC financing statements (or equivalent instrument) (and continuation statements with respect to such financing statements when applicable) or other instruments and notices, in such manner and in such jurisdictions, as in the Investor&#x2019;s determination may be necessary or appropriate to evidence the purchase, acquisition and acceptance by the Investor of the Revenue Interest hereunder and to perfect and maintain the perfection of the Investor&#x2019;s ownership in the Revenue Interest and the security interest in the Collateral granted by each of the Company and the Guarantors to the Investor pursuant to the Security Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	[***]</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Update Meetings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Payment Term, but subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Investor shall be entitled to a quarterly update call or meeting (at the Investor&#x2019;s election, in person, via teleconference or videoconference or at a location reasonably designated by the Company) to discuss (a) the reports delivered by the Company pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the Company&#x2019;s financial results and operations, (c) the progress of sales and product development and marketing efforts made by the Company, (d) the status and the historical and potential performance of the Included Products, (e) any material regulatory or Patent developments and/or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f) such other matters that the Investor reasonably deems appropriate. Any information disclosed by either Party during such update meetings or calls or provided to the Investor pursuant to its request shall be considered &#x201c;Confidential Information&#x201d; of the disclosing Party subject to the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding the foregoing, after the occurrence and during the continuance of a Default or an Event of Default, the Investor shall have the right, as reasonably often, at such reasonable times and with reasonable prior notice, to have additional update meetings at the Company&#x2019;s headquarters or inspect any records and operations of the Company and its Affiliates.  Notwithstanding anything to the contrary contained herein, no Company Party will be required to disclose or permit the inspection or discussion of, any document, information or other matter (i) that constitutes scientific trade secrets (it being understood and agreed that clinical data does not constitute scientific trade secrets), (ii) in respect of which disclosure to the Investor (or its respective representatives or contractors) is prohibited by any applicable Law or any binding confidentiality agreement with a third party (so long as such agreement is not entered into in contemplation of this Agreement), or (iii) that is subject to attorney-client or similar privilege, which could reasonably be expected to be lost or forfeited if disclosed to the Investor, provided that the Company shall enter into a common interest agreement with the Investor to permit disclosure under this clause (iii) to the extent applicable.  With respect to any confidentiality agreement with a Third Party entered into after the date of this Agreement relating to or that is expected to result in information or documentation that is required to be disclosed by the Investor to the Company under this Agreement, the Company shall use commercially reasonable efforts to include a provision that permits disclosure of such information and documentation to the Investor.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Promptly (and within no later than [***] Business Days) after receipt by the Company or any Subsidiary of notice of any action, suit, claim, demand, Dispute, investigation, arbitration or other legal proceeding (commenced or threatened) involving or related to any Included Product in the United States in excess of $[***], or the Company or any Subsidiary which owns any assets (including IP Rights) related to any Included Product in the United States, or the transactions contemplated by any Transaction Document, or to the Revenue Interest, the Company shall, subject to any confidentiality obligations to any Third Party, (i) inform the Investor in writing of the receipt of such notice and the substance thereof, and (ii) if such notice is in writing, furnish the Investor with a copy of such notice and any related materials with respect thereto reasonably requested by the Investor, and if such notice is not in writing, furnish to the Investor a written summary describing in reasonable detail the substance thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Promptly (and within no later than [***] Business Days) after receipt by the Company or any Subsidiary of any written notice, claim or demand challenging the legality, validity, enforceability or ownership of any IP Rights included in the Collateral or owned by the Company or any Subsidiary and relating to any Included Product that could reasonably be expected to adversely impact the Commercialization of Included Products in the United States (including, for the avoidance of doubt, any Paragraph IV Certification) or pursuant to which any Third Party commences or threatens any action, suit or other proceeding against the Company and relating to any Included Product or any Subsidiary which owns any assets (including IP Rights) related to any Included Product in the United States, the Company shall, subject to any confidentiality obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to any Third Party, (i) inform the Investor in writing of such receipt and (ii) furnish the Investor with a copy of such notice, claim or demand, or if such notice is not in writing, furnish to the Investor a written summary describing in reasonable detail the contents thereof, and an unredacted copy of all pleadings, briefs, certifications (including Paragraph IV Certifications), expert reports (including exhibits) and other documents reasonably requested by the Investor relating thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Company shall promptly (and in any event within [***] Business Days) provide Investor with copies of any material information, reports and notices if the contents of such information, report or notice could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Company shall provide the Investor with prompt (and within no later than (x) in the case of the following clauses (i) and (ii), [***] and (y) in the case of the following clauses (iii) and (iv), [***] Business Days) written notice after the Company has Knowledge of any of the following: (i) the occurrence of a Bankruptcy Event in respect of the Company or any Subsidiary or, to the extent it could reasonably be expected to result in a Material Adverse Effect, any Material Contract Counterparty to any Material Contract; (ii) the occurrence of any other Put Option Event (other than a Change of Control to the extent notice of such Change of Control has already been provided in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); (iii) any representation or warranty made by any Company Party in any of the Transaction Documents or in any certificate delivered to the Investor pursuant to this Agreement shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made; or (iv) any change, effect, event, occurrence, state of facts, development or condition with respect to the assets of the Company and its Subsidiaries, taken as a whole, that could reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	To the extent not addressed by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company shall promptly (and in any event within [***] Business Days) upon obtaining Knowledge thereof notify the Investor of the occurrence of a Default, Event of Default, or Material Default.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	The Company shall notify the Investor in writing not less than [***] Business Days prior to any change in, or amendment or alteration of, any Company Party&#x2019;s (i) legal name, (ii) form of legal entity or (iii) jurisdiction of organization.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	The Company shall notify the Investor of any ERISA Event promptly (and in any event, within [***] Business Days) following the Company becoming aware of such ERISA Event.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	The Company shall notify the Investor of the occurrence of any event of any material default or event of default (in each case, with or without notice or lapse of time, or both) related to any Permitted Debt Facility promptly following the Company obtaining Knowledge of such event of material default or event of default (and in any event, within [***] Business Days or within [***] Business Days if any Indebtedness under such Permitted Debt Facility has been accelerated).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	The Company shall promptly (and in any event, within [***] days) notify the Investor of (i) the termination of any Material Contract other than upon its scheduled</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination date; (ii) the receipt by any Company Party or any of its Affiliates from a Material Contract Counterparty asserting a default by the Company or any of its Subsidiaries under any Material Contract where such alleged default, if accurate, would permit such counterparty to terminate such Material Contract; (iii) the entering into of any new Material Contract by any Company Party or any Affiliate thereof; or (iv) any amendment to a Material Contract  (and a copy thereof shall be provided to the Investor).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	The Company shall notify the Investor within [***] Business Days of receipt any written notice or other written communications from the FDA that the FDA intends to revoke, withdraw, suspend, cancel, materially limit, terminate or make a materially adverse modification to any Marketing Authorization for any Included Product in the United States issued by the FDA.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Each notice pursuant to clauses (a) through (j) of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be accompanied by a statement of a Responsible Officer of the Company setting forth details of the occurrence referred to therein and stating what action the applicable Company Party has taken and proposes to take with respect thereto. Each notice pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3(d)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall describe with particularity any and all provisions of this Agreement and any other Transaction Document that have been breached.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Announcement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	As soon as reasonably practicable following the date hereof, one or both of the Parties shall issue a mutually agreed to press release substantially in the applicable form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as required by Applicable Law (including disclosure requirements of the SEC, the Nasdaq Stock Market or any other stock exchange on which securities issued by a Party or its Affiliates are traded) or for statements that are materially consistent with all or any portion of a previously approved public disclosure, neither Party shall make any other public announcement concerning this Agreement or the subject matter hereof without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed. In the event of a required public announcement, to the extent practicable under the circumstances, the Party making such announcement shall provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Parties shall coordinate in advance with each other in connection with the filing of this Agreement (including proposed redaction of certain provisions of this Agreement) with the SEC, the Nasdaq Stock Market or any other stock exchange on which securities issued by a Party or its Affiliate are traded, and each Party shall use reasonable efforts to seek confidential treatment for the terms of this Agreement proposed to be redacted by the other Party, if any. Other than such obligation, neither Party (nor its Affiliates) shall be obligated to consult with or obtain approval from the other Party with respect to any filings with the SEC, the Nasdaq Stock Market or any other stock exchange or Governmental Authority. For clarity, once a public announcement or other disclosure is made by a Party in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then no further consent or compliance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be required for any substantially similar disclosure thereafter.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Company shall promptly, upon the reasonable request of the Investor, at the Company&#x2019;s sole cost and expense: (i) execute, acknowledge and deliver, or cause the execution, acknowledgment and delivery of, and thereafter register, file or record, or cause to be registered, filed or recorded, in an appropriate governmental office, any document or instrument supplemental to or confirmatory of the Transaction Documents or otherwise deemed by the Investor reasonably necessary for the continued validity, perfection and priority of the Liens on the Collateral covered thereby subject to no other Liens except as permitted by the applicable Transaction Document, or obtain any consents or waivers as may be necessary in connection therewith; (ii) deliver or cause to be delivered to the Investor from time to time such other documentation, consents, authorizations, approvals and orders in form and substance reasonably satisfactory to the Investor as the Investor shall reasonably deem necessary to perfect or maintain the Liens on the Collateral pursuant to the Transaction Documents; and (iii) upon the exercise by the Investor of any power, right, privilege or remedy pursuant to any Transaction Document which requires any consent, approval, registration, qualification or authorization of any Governmental Authority, execute and deliver all applications, certifications, instruments and other documents and papers that the Investor may require. In addition, the Company shall promptly, at its sole cost and expense, execute and deliver to the Investor such further instruments and documents, and take such further action as the Investor may, at any time and from time to time, reasonably request in order to carry out the intent and purpose of this Agreement and the other Transaction Documents and to establish and protect the rights, interests and remedies created, or intended to be created, in favor of the Investors hereby and thereby.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Company and the Investor shall cooperate and provide assistance as reasonably requested by each of the Parties hereto, at the expense of the requesting Party (except as otherwise set forth herein), in connection with any litigation, arbitration, investigation or other proceeding (whether threatened, existing, initiated or contemplated prior to, on or after the date hereof) to which the requesting party, any of its Affiliates or controlling persons or any of their respective officers, directors, equityholders, controlling persons, managers, agents or employees is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such Persons have a direct or indirect interest, in each case relating to any Transaction Document, the transactions contemplated herein or therein or the Revenue Interest, but in all cases excluding any litigation brought by the Company (for itself or on behalf of any Company Indemnified Party) against the Investor or brought by the Investor (for itself or on behalf of any Investor Indemnified Party) against the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Each Party shall comply with all Applicable Laws with respect to the Transaction Documents and the Revenue Interest except where any non-compliance could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall, and shall cause its Affiliates to, use Commercially Reasonable Efforts to: (a) take any and all actions, and prepare, execute, deliver and file any and all agreements, documents and instruments, that are necessary to maintain the IP Rights in the United States, including by filing and prosecuting patent applications in the ordinary course, and payment of maintenance fees and annuities, (b) defend and enforce IP Rights in the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United States against infringement, interference, violation or unauthorized use by any other Person, and against any claims of invalidity or unenforceability (including by bringing any legal action for infringement or defending any claim or counterclaim of invalidity or action (including any reexamination, derivation proceeding, petition for post-grant review or inter-partes review before the US Patent Office) of any other Person or for declaratory judgment of non-infringement, invalidity or non-interference), (c) defend against any claim or action by any other Person that the manufacture, use, marketing, sale, offer for sale, importation or distribution of any of the Included Products in the United States as currently contemplated infringes on any Patent Right or other intellectual property rights of any other Person or constitutes misappropriation of any other Person&#x2019;s trade secrets or other intellectual property rights, and (d) obtain a patent listing in the Orange Book in respect of the Initial Included Product for at least one of U.S. Patent Nos. [***], and pursue a Patent Term Extension for U.S. Patent No. [***]. The Company shall not exercise or enforce its applicable rights in any manner that would result in a breach of this Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Company Party shall (a) preserve and maintain its existence (provided that any Guarantor may merge, dissolve or liquidate into another Company Party), (b) preserve and maintain its rights, franchises and privileges unless failure to do any of the foregoing could not reasonably be expected to result in a Material Adverse Effect, (c) qualify and remain qualified in good standing in each jurisdiction where the failure to preserve and maintain such qualifications could reasonably be expected to result in a Material Adverse Effect, and (d) comply in all material respects with its organizational documents.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization of the Included Products</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Company shall use Commercially Reasonable Efforts to obtain Marketing Authorization for the Included Products in the United States and Commercialize in the United States Included Products that have received Marketing Authorization in the United States. The Company shall prepare, execute, deliver and file any and all agreements, documents, instruments or other materials, and take any other actions, that are necessary to obtain and maintain Marketing Authorization in the United States for each Included Product and, when available in respect of each Included Product and where applicable, obtain and maintain Regulatory Exclusivity for such Included Product in the United States. The Company shall not (i) withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or abandonment of, a Drug Application for an Included Product that has been approved by the FDA in the United States, unless such withdrawal or abandonment is done for safety reasons or is otherwise required by Applicable Law, or (ii) take any action or fail to take any action that could reasonably be expected to result in the revocation of an ODD, Product Registration or similar item granted with respect to the Included Products in the United States, provided that the Company may, following reasonable consultation with the Investor, intentionally abandon an ODD or Marketing Authorization granted to a given Included Product in the United States if such abandonment is in connection with obtaining a Marketing Authorization for a different Included Product in the United States for formulation(s) or indication(s) in addition to or in lieu of the formulation(s) and indication(s) that were the subject of such abandoned ODD or Marketing Authorization so long as (x) the Company maintains a Marketing Authorization for an Included Product in the United States for the indication(s) that were the subject of such abandoned ODD or Marketing Authorization, and (y) there is no period of time as a result of such abandonment when the Included Product may not be</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sold for the indication(s) that were the subject of such abandoned ODD or Marketing Authorization.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Company shall, and shall cause its Subsidiaries to (i) maintain in full force and effect, and shall not terminate, any Material Contract (provided that the Company may terminate a Material Contract to enter into a replacement Material Contract if permitted under Section 7.3(b)), and (ii) use Commercially Reasonable Efforts to ensure a continuous supply of the Included Products sufficient to meet market demand in the United States. The Company shall, and shall cause its Subsidiaries to, use Commercially Reasonable Efforts to comply with all material terms and conditions of and fulfill all material obligations under each Material Contract (including, without limitation, each License Agreement) to which any of them is party. Upon the occurrence of a breach of any such Material Contract by any other party thereto which could reasonably be expected to result in a Material Adverse Effect, the Company shall use Commercially Reasonable Efforts to seek to enforce its (or its Subsidiary&#x2019;s) rights and remedies thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	To the extent not already filed publicly with the SEC, the Company shall deliver to the Investor, within ninety (90) days after the end of each fiscal year of the Company, consolidated balance sheets of the Company and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders&#x2019; equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in all material respects in accordance with GAAP, audited and accompanied by a report and opinion of an independent certified public accountant of nationally recognized standing and reasonably acceptable to the Investor, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any qualification or exception as to the scope of such audit; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	 The Company shall deliver to the Investor, within forty-five (45) days after the end of each of the first three (3) fiscal quarters of each fiscal year of the Company (or, if earlier, when required to be filed with the SEC), (i) to the extent not already filed publicly with the SEC, a consolidated balance sheet of the Company and its Subsidiaries as at the end of such fiscal quarter, and the related consolidated statements of income or operations, changes in stockholders&#x2019; equity and cash flows for such fiscal quarter and for the portion of the Company&#x2019;s fiscal year then ended, in each case, prepared in all material respects in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with (ii) a certificate of a Responsible Officer stating that (x) such financial statements fairly present in all material respects the financial condition of the Company and its Subsidiaries as at such date, and (y) the results of operations of the Company and its Subsidiaries for the period ended on such date have been prepared in accordance with GAAP consistently applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall deliver to the Investor, in form and detail reasonably satisfactory to the Investor, concurrently with the delivery of the financial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (or concurrently with the filing of such financial statements with the SEC), a certificate of a Responsible Officer of the Company listing the creation, development or other acquisition (including any in-bound exclusive licenses) by the Company or any Subsidiary of any IP Rights after the Closing Date that is registered or becomes registered or the subject of an application for registration with the United States Copyright Office or the United States Patent and Trademark Office.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents required to be delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Company posts such documents, or provides a link thereto on the Company&#x2019;s website, or (ii) on which such documents are posted on the Company&#x2019;s behalf on an internet or intranet website, if any, to which the Investor has access (whether a commercial, third-party website or whether sponsored by the Investor); provided that the Company shall notify the Investor of the posting of such documents and provide to the Investor by electronic mail electronic versions (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, soft copies) of such documents upon written request of the Investor.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.11.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Company Party shall pay and discharge all of their respective obligations and liabilities constituting (a) prior to the date on which penalties attach thereto, all material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Company Party, (b) as the same shall become due and payable, all lawful claims which, if unpaid, would by Law become a Lien upon any Collateral (other than a Permitted Lien), and (c) prior to the date on which such Indebtedness in excess of $10,000,000 shall become delinquent or in default, all such Indebtedness, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.12.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintenance of Properties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Company and its Subsidiaries shall maintain, preserve and protect all of its material properties and equipment necessary in the operation of its business in good working order and condition (ordinary wear and tear and casualty and condemnation events excepted) except where the failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and shall make all necessary repairs thereto and renewals and replacements thereof, except where the failure to do so could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.13.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintenance of Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as could not reasonably be expected to result in a Material Adverse Effect, each of the Company and its Subsidiaries shall maintain with financially sound and reputable insurance companies that are not Affiliates of the Company, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are customarily carried under similar circumstances by such other Persons.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.14.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Books and Records</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Company and its Subsidiaries shall maintain proper books of record and account, in which full, true and correct (in all material respects) entries in conformity with GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of the Company or such Subsidiary, as</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the case may be. Each of the Company and its Subsidiaries shall maintain such books of record and account in material conformity with all applicable requirements of any Governmental Authority having regulatory jurisdiction over the Company or such Subsidiary, as the case may be.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.15.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company and its Subsidiaries, taken as a whole, shall use substantially all of the Investment Amount (x) to support the Development and Commercialization of the Included Products, including the commercial launch of the Initial Included Product, and (y) for working capital, general corporate and administrative purposes. In no event, however, shall the Investment Amount be used to fund any activities of or business with any Person, or in any Designated Jurisdiction, that, at the time of such funding, is the subject of Sanctions, or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as Investor or otherwise) of Sanctions or otherwise in contravention of any Law or of any Transaction Document.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.16.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Company Party shall do each of the following: (a) maintain each Benefit Plan in compliance with the applicable provisions of ERISA, the Internal Revenue Code and other federal or state Law, (b) cause each Pension Plan that is qualified under Section 401(a) of the Internal Revenue Code to maintain such qualification, and (c) make all contributions required to be made by the Company and its Subsidiaries to any Pension Plan subject to Section 412 or Section 430 of the Internal Revenue Code, in each case, except as could not reasonably be expected to result a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.17.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Contracts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limitation of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, each of the Company and its Subsidiaries shall comply in all respects with each Contractual Obligation of such Person, except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.18.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limitation of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respects with all Applicable Laws (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary or required in connection with the conduct of the Company&#x2019;s and its Subsidiaries&#x2019; respective businesses, in each case, except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.19.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws; Anti-Terrorism Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Neither the Company, any of its Subsidiaries, nor any of their respective directors, officers, employees or agents shall, directly or indirectly, engage in any activity which would constitute a violation of the FCPA, make, offer, promise or authorize any payment or gift of any money or anything of value to or for the benefit of any &#x201c;foreign official&#x201d; (as such term is defined in the FCPA), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">act or decision of a foreign governmental authority or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its Affiliates in obtaining or retaining business for or with, or directing business to, any person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Neither the Company nor any of its Subsidiaries shall, nor shall the Company or any of its Subsidiaries permit any Affiliate controlled by the Company to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Sanctioned Person. Neither the Company nor any of its Subsidiaries shall, nor shall the Company or any of its Subsidiaries, permit any Affiliate controlled by the Company to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Sanctioned Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Sanctioned Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.20.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with its collection, storage, transfer (including, without limitation, any transfer across national borders) and/or use of any Personal Information, the Company shall, and shall cause its Subsidiaries to, take steps designed to maintain compliance in all material respects with, and shall maintain compliance in all material respects with (a) all Applicable Laws in all relevant jurisdictions, including (if applicable) the General Data Protection Regulation, (b) the Company&#x2019;s and its Subsidiaries&#x2019; privacy policies, and (c) the relevant requirements of any contracts or codes of conduct to which the Company&#x2019;s or any of its Subsidiaries is a party, except in each case of (a)-(c), for any such events that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. The Company shall maintain commercially reasonable physical, technical, organizational and administrative security measures and policies in place designed to protect all Personal Information collected by it or on its behalf from and against unauthorized access, use and/or disclosure. The Company shall, and shall cause its Subsidiaries to, take steps designed to maintain compliance in all material respects with all Applicable Laws, and shall maintain compliance in all material respects with all Applicable Laws, relating to data loss, theft and breach of security notification obligations, except for any such event that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Parties agree that for U.S. federal and applicable state and local income Tax purposes (i) the transactions contemplated by this Agreement are intended to constitute a debt instrument that is subject to U.S. Treasury Regulations under Section 1.1275-4(b) governing contingent payment debt instruments, (ii) the rights in respect of the Investment Amount constitute a debt instrument for U.S. federal and applicable state and local income tax purposes and (iii) the rights in respect of the Investment Amount or otherwise set forth in this Agreement will not be aggregated with any rights set forth in the Credit Agreement under Treas. Reg. Section 1.1275-2(c). Within 90 days after the date of this Agreement, the Company will prepare and deliver to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor a determination of the comparable yield and a projected payment schedule under Section 1.1275-4(b) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparable Yield</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Unless the Investor objects to the Comparable Yield within fifteen (15) days after receipt thereof, the Comparable Yield shall become final and binding on the Parties. If the Investor objects to the Comparable Yield within fifteen (15) days of receipt, then the Parties shall cooperate in good faith to agree on a revised Comparable Yield within twenty (20) days of the Investor&#x2019;s objection.  The Parties intend that the provisions of Treasury Regulation Section 1.1275-2(a)(1) would apply, subject to the exceptions in Treasury Regulation Section 1.1275-2(a)(2), to treat any non-contingent payments on the debt instrument and the projected amount of any contingent payments as first, a payment of any accrued and any unpaid original issue discount at such time and second, a payment of principal (including for purposes of the rules applicable to &#x201c;applicable high yield discount obligations.&#x201d;).  In accordance with Section 385(c) of the Code, the Parties agree not to take and to not cause or permit their Affiliates to take, any position that is inconsistent with the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on any U.S. federal, state or local income Tax return or for any other U.S. federal, state or local income Tax purpose, unless the Party that contemplates taking such an inconsistent position has been advised by national recognized counsel or accounting firm in writing that it is more likely than not that the inconsistent position is required by applicable Law or unless required by the good faith resolution of a Tax audit or other Tax proceeding.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	On or prior to the Closing Date, the Investor shall have delivered to the Company a valid, properly executed IRS Form W-9, IRS Form W-8IMY (with applicable certifications or attachments), IRS Form W-8BEN-E  or other applicable IRS withholding form, certifying that such Investor is (or payments to such Investor are) exempt from U.S. federal withholding tax with respect to any and all payments pursuant to this Agreement. The Investor will notify the Company reasonably in advance of any action or proposed action that would make any such form inaccurate and will replace the inaccurate form with an accurate one. The Company shall provide the Investor any reasonable assistance it may seek in obtaining an exemption or reduced rate from, or refund of, any U.S. federal withholding tax, if applicable.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Payments by or on account of any obligation of the Company under this Agreement shall be made without deduction or withholding for any Taxes, except as required by Applicable Law. If the Company is required by Law to deduct or withhold any Tax in respect of any amounts payable to an Investor pursuant to this agreement, (1) the Company shall make such deduction or withholding and timely pay such amount to the applicable Governmental Authority, (2) the Company shall provide such Investor with a receipt evidencing such payment or other evidence of such payment reasonably satisfactory to such Investor and (3) if the Tax deducted or withheld was an Indemnified Tax, the sum payable by the Company shall be increased so that after all required deductions and withholdings for Indemnified Taxes have been made (including deductions and withholdings applicable to additional sums payable under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), such Investor receives an amount equal to the sum it would have received had no such deductions or withholdings been made; provided, however, that (i) the Parties agree that no such deduction or withholding is intended on any payment hereunder if the Investor provides the withholding forms as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> claiming a complete exemption from such deduction or withholding and (ii) if the Company determines that any such deduction or withholding is required by Applicable Law, the Company will promptly notify the Investor if it becomes required to deduct or withhold any Tax in respect of any payment to the Investor pursuant to this Agreement and the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties will cooperate and use commercially reasonable efforts to reduce or mitigate any such obligation to deduct or withhold. For the avoidance of doubt, if any Tax deducted or withheld from payments to an Investor was not an Indemnified Tax, any such amounts so deducted and withheld and paid over to the applicable Governmental Authority shall be treated for all purposes of this Agreement as having been paid to (and received by) such Investor.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	If the Investor determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has received additional amounts pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, it shall pay to the Company an amount equal to such refund (but only to the extent of additional amounts paid under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of the Investor and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). The Company, upon the request of the Investor, shall repay to the Investor the amount paid over pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that the Investor is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in no event will the Investor be required to pay any amount to the Company pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(d) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment of which would place the Investor in a less favorable net after-Tax position than the Investor would have been in if the Tax for which the Company paid additional amounts and giving rise to such refund had not been deducted, withheld or otherwise imposed and the additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require the Investor to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the Company or any other Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Company shall reimburse and indemnify the Investor, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes payable or paid by the Investor or required to be withheld or deducted from a payment to the Investor and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Company by the Investor shall be conclusive absent manifest error.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Each Party&#x2019;s obligations under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall survive the termination of this Agreement, any assignment by the Investor and the payment, satisfaction or discharge of all obligations under this Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.22.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included Products</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the Development, Manufacture and Commercialization in the United States of each and any Included Product by the Company or any Subsidiary, the Company or such Subsidiary shall comply with all applicable Product Registrations, Marketing Authorizations, and Permits, except as could not individually or in the aggregate reasonably be expected to result in a material adverse effect on the Development, Manufacture or Commercialization in the United States of each and any Included Product.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.23.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company agrees to pay or reimburse within [***] Business Days of receipt of a reasonably detailed invoice the Investor and its Affiliates for all of their reasonable and documented out of pocket costs and expenses (including the reasonable and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">documented out of pocket fees, expenses, charges and disbursements of Sidley Austin LLP as primary counsel to the Investor and the fees of any other local counsel (if necessary), and any sales, goods and services or other similar Taxes applicable thereto, and reasonable and documented printing, reproduction, document delivery, communication and travel costs) in connection with the negotiation, preparation, execution and delivery of the Transaction Documents; provided, that the amount of such expenses (without duplication of any expenses reimbursed in connection with the Credit Agreement) together with any expenses reimbursed in connection with the Credit Agreement shall not exceed [***] (exclusive of post-closing costs).</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.24.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIFA Account(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Section 6.24 shall only apply to the extent that there is no Permitted Debt Facility or corresponding Intercreditor Agreement or Other Intercreditor Agreement in place pursuant to which the Permitted Debt Creditors have a first priority lien in the bank accounts of the Company and its Subsidiaries (the first date when such condition occurs, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIFA Account Trigger Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Within [***] Days following the RIFA Account Trigger Date, the Company, the Investor and each RIFA Account Bank shall enter into a RIFA Account Agreement in form and substance reasonably satisfactory to the Investor.  The Company shall direct, and shall use commercially reasonable efforts to cause, any Person making payments to the Company or its Subsidiaries in respect of the sale of the Included Products in the United States to remit such payments directly into a RIFA Account.  Any and all payments in respect of the sale of the Included Products in the United States received directly by the Company or its Subsidiaries shall be deposited into a RIFA Account within five (5) Business Days of the Company or its Subsidiary becoming aware of receipt of such payments.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE VII<br>NEGATIVE COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Term (unless otherwise specified below), no Company Party shall, nor shall it permit any Subsidiary to, directly or indirectly:</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Create, incur, assume or suffer to exist any Lien upon any Collateral, whether now owned or hereafter acquired, other than the Permitted Liens.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Create, incur, assume or suffer to exist any Indebtedness without the prior written consent of the Investor, except Permitted Debt, provided that the foregoing shall not apply at any time to the extent that, [***].</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Protective Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything herein to the contrary, without the prior written consent of the Investor:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	forgive, waive, cancel, release or compromise any amount owed to the Company or its Subsidiaries or its Affiliates and relating to the Revenue Interest outside the ordinary course of business;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	amend, modify, restate, supplement, waive any provision of, cancel or early terminate without entry into a replacement, any Material Contract, or grant any related consent thereunder, or agree to do any of the foregoing, including entering into any agreement with any Person under the provisions of such Material Contract, in each case, if such action would</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reasonably be expected to result in a Material Adverse Effect or a Material Default (other than a Material Default arising out of a breach of this Section 7.3(b));</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	(i) (A) assign, sell, transfer or license any of the IP Rights (other than Permitted Licenses and Liens which are subject to clause (B) below), or (B) otherwise encumber any of the IP Rights, except for Permitted Licenses and Permitted Liens, (ii) except as permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, permit any Subsidiary that is not a Company Party to own any portion of the Collateral or the Product Assets, or (iii) grant any Third Party the right to prosecute, enforce or defend IP Rights that Cover Included Products in the United States (other than to the Company&#x2019;s outside attorneys or other vendors working under the Company&#x2019;s direct supervision and control), other than pursuant to a Permitted License;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	create, incur, sell, issue, assume, enforce or suffer to exist any additional revenue interests (or similar economic equivalents) with respect to Net Revenues or the Included Products in the United States (for the avoidance of doubt, this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> does not prohibit the creation, incurrence, sale, issuance, assumption, enforcement or sufferance to exist any Permitted Royalty Monetization);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Dispose of any Collateral or any Product Assets, in each case, other than Permitted Transfers;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	change the fiscal year end without the prior written consent of the Investor (other than, in the case of any Subsidiary, to conform to the Company&#x2019;s fiscal year end); or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	settle any conversions of Permitted Convertible Notes in cash (other than cash in lieu of fractional shares).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE VIII<br>CLOSING AND FUNDING</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms of this Agreement, the closing of the transactions contemplated hereby (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and the date of the Closing, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall take place remotely via the exchange of documents and signatures, subject to the satisfaction of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or such other time and place as the Parties mutually agree.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Deliverables of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On the Closing Date, the Company shall deliver or cause to be delivered to the Investor the following:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Receipt by the Investor of executed counterparts (including by electronic means) of this Agreement, the Intercreditor Agreement, the Security Agreements and the Guaranty, executed by the parties thereto (in a manner reasonably acceptable to the Investor), in each case in form and substance satisfactory to the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization Documents, Resolutions, Etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Receipt by the Investor of the following (to the extent not previously provided to the Investor), each of which shall be originals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or electronic copies, in form and substance reasonably satisfactory to the Investor and its legal counsel:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	copies of the certificate of incorporation or organization, as appliable, of each Company Party certified to be true and complete as of a recent date by the appropriate Governmental Authority of the state or other jurisdiction of its incorporation or organization, where applicable, and the other Organization Documents, in each case certified by a secretary or assistant secretary (or, if such entity does not have a secretary or assistant secretary, a Responsible Officer) of such Company Party to be true and correct as of the Closing Date;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers of each Company Party evidencing (1) the identity, authority and capacity of each Responsible Officer thereof authorized to act as a Responsible Officer in connection with this Agreement and the other Transaction Documents to which such Company Party is a party, and (2) resolutions of the governing body of each Company Party authorizing and approving the execution, delivery and performance by such Company Party of this Agreement and the other Transaction Documents and the transactions contemplated herein and therein; and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	good standing certificates of each Company Party, and such other documents and certifications as the Investor may reasonably require to evidence that such Company Party is duly organized or formed, and is validly existing, in good standing and qualified to engage in business in its state of organization or formation.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinions of Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Receipt by the Investor of a written legal opinion of Cooley LLP, dated as of the Closing Date, addressed to the Investor, in form and substance reasonably acceptable to the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsible Officer&#x2019;s Closing Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Receipt by the Investor of a certificate of a Responsible Officer of each Company Party certifying that (i) the representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (other than the Fundamental Representations) are true and correct in all material respects on and as of the Closing Date (or, if made as of a specific date, as of such date); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, to the extent that any such representation or warranty is qualified by the term &#x201c;material&#x201d; or &#x201c;Material Adverse Effect,&#x201d; such representation or warranty (as so written, including the term &#x201c;material&#x201d; or &#x201c;Material Adverse Effect&#x201d;) are true and correct in all respects on and as of the Closing Date (or, if made as of a specific date, as of such date), (ii) the Fundamental Representations are true and correct in all respects on and as of the Closing Date (or, if made as of a specific date, as of such date), and (iii) no Bankruptcy Event with respect to Company or any of its Subsidiaries and no Change of Control, Default or Event of Default has occurred and its continuing, in each case on and as of the Closing Date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Perfection and Priority of Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Receipt by the Investor of the following:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	searches of UCC filings in the jurisdictions where a filing would need to be made in order to perfect the Investor&#x2019;s security interest in the Collateral, copies of the financing statements on file in such jurisdictions and evidence that no Liens exist on the Collateral other than Permitted Liens;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	UCC financing statements for each appropriate jurisdiction as is necessary to perfect the Investor&#x2019;s security interest in the Collateral&#x37e;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	searches of ownership of, and Liens on, the Included Product Patent Rights in the appropriate U.S. governmental offices; and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	a duly executed Perfection Certificate of the Company.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall provide written notice to the Investor within three (3) Business Days following the occurrence of FDA Approval together with documentation reasonably sufficient to evidence the occurrence of such event (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Subject to the satisfaction of the conditions set forth below in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, within ten (10) Business Days following the receipt of the Funding Notice by the Investor, the Investor shall deliver (or cause to be delivered) payment of the Investment Amount to the Company by electronic funds transfer or wire transfer of immediately available funds to one or more accounts specified in writing by the Company (such funding, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and the date of such payment, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); provided that the Investor shall have the right to, at its option, fund the Investment Amount on a net basis less any expenses owed by the Company in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Closing shall have occurred.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. FDA Approval shall have occurred and the Funding Notice shall have been received by the Investor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsible Officer&#x2019;s Funding Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Receipt by the Investor of a certificate of a Responsible Officer of each Company Party certifying that (i) the representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IV</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (other than the Fundamental Representations) are true and correct in all material respects on and as of the Funding Date (or, if made as of a specific date, as of such date); provided that, to the extent that any such representation or warranty is qualified by the term &#x201c;material&#x201d; or &#x201c;Material Adverse Effect,&#x201d; such representation or warranty (as so written, including the term &#x201c;material&#x201d; or &#x201c;Material Adverse Effect&#x201d;) are true and correct in all respects on and as of the Funding Date (or, if made as of a specific date, as of such date), (ii) the Fundamental Representations are true and correct in all respects on and as of the Funding Date (or, if made as of a specific date, as of such date), subject to any additions that the Company may make to the Disclosure Schedule with respect to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, provided that any such additions must be provided to the Investor at least three (3) Business Days prior to the Funding Date and must be reasonably satisfactory to the Investor, and (iii) no Bankruptcy Event with respect to the Company or any of its Subsidiaries and no Change of Control, Default, Event of Default, Material Default or Event of Material Default has occurred and is continuing, in each case on the Funding Date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Since the Closing Date, no event, circumstance or change shall have occurred that has caused or would reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Effect.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor shall have received for its own account all fees, costs and expenses due and payable to it on or prior to the Funding Date pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the extent invoiced (or as to which a good faith estimate has been provided to the Company) at least one (1) Business Day prior to the Funding Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX<br>CONFIDENTIALITY</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality; Permitted Use</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Payment Term and for a period of [***] thereafter, each Party shall maintain in strict confidence, and shall not disclose to any Third Party, all Confidential Information and materials disclosed or provided to it by the other Party, except as approved in writing in advance by the disclosing Party or in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and shall not use or reproduce the disclosing Party&#x2019;s Confidential Information for any purpose other than as required to carry out its obligations and exercise its rights pursuant to this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Party receiving such Confidential Information (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) agrees to institute measures to protect the Confidential Information in a manner consistent with the measures it uses to protect its own most sensitive proprietary and confidential information, which must not be less than a reasonable standard of care. Notwithstanding the foregoing, the Recipient may permit access to the disclosing Party&#x2019;s Confidential Information to those of its employees or authorized representatives having a need to know such information for the Purpose and who have signed confidentiality agreements or are otherwise bound by confidentiality obligations at least as restrictive as those contained herein. Each Party shall be responsible for the breach of this Agreement by its employees or authorized representatives. Each Party shall immediately notify the other Party upon discovery of any loss or unauthorized disclosure of the other Party&#x2019;s Confidential Information.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of confidentiality and non-use set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply to any portion of Confidential Information that the Recipient or its Affiliates can demonstrate was: (a) known to the general public at the time of its disclosure to the Recipient or its Affiliates, or thereafter became generally known to the general public, other than as a result of actions or omissions of the Recipient, its Affiliates, or anyone to whom the Recipient or its Affiliates disclosed such portion; (b) known by the Recipient or its Affiliates, prior to the date of disclosure by the disclosing Party without any obligation of confidentiality with respect to such information, as shown by the Recipient&#x2019;s written records; (c) disclosed to the Recipient or its Affiliates on an unrestricted basis from a source unrelated to the disclosing Party and not known by the Recipient or its Affiliates to be under a duty of confidentiality to the disclosing Party; or (d) independently developed by the Recipient or its Affiliates by personnel that did not use the Confidential Information of the disclosing Party in connection with such development, as shown by the Recipient&#x2019;s contemporaneous written records.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Disclosures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of confidentiality and non-use set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply to the extent that the receiving Party or its Affiliates:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	is required to disclose Confidential Information pursuant to: (i) an order of a court of competent jurisdiction; (ii) Applicable Laws; (iii) regulations or rules of a securities exchange; (iv) requirement of a Governmental Authority for purposes related to development or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization of an Included Product, or (v) the exercise by each Party of its rights granted to it under this Agreement or its retained rights or as required to perfect Investor&#x2019;s rights under the Transaction Documents;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	discloses such Confidential Information as reasonably necessary to prosecute or defend against litigation, including in response to a subpoena in a Third Party litigation;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	discloses such Confidential Information solely on a &#x201c;need to know basis&#x201d; to Affiliates, or potential or actual: acquirers, merger partners, licensees, permitted assignees, collaborators (including Licensees), subcontractors, investment bankers, limited partners, lenders, or other financial partners, and their respective directors, employees, contractors and agents;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	provides a copy of this Agreement or any of the other Transaction Documents to the extent requested by an authorized representative of a U.S. or foreign tax authority; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	discloses Confidential Information in response to a routine audit or examination by, or a blanket document request from, a Governmental Authority; provided that (A) such Third Party or person or entity in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> agrees to confidentiality and non-use obligations with respect thereto at least as stringent as those specified for in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and (B) in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the extent permitted by Applicable Law, the Recipient shall provide prior written notice thereof to the disclosing Party and provide the opportunity for the disclosing Party to review and comment on such required disclosure and request confidential treatment thereof or a protective order therefor; and provided, further, that the Recipient will use reasonable efforts to secure confidential treatment of such information and the Confidential Information disclosed shall be limited to that information which is legally required to be disclosed.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything set forth in this Agreement, prior to any foreclosure on the Collateral, the Investor shall not file any patent application based upon or using the Confidential Information of the Company provided hereunder.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall return or destroy, at the other Party&#x2019;s instruction, all Confidential Information of the other Party in its possession upon termination or expiration of this Agreement; provided, however, that each Party shall be entitled to retain one (1) copy of such Confidential Information of the other Party for legal archival purposes and/or as may be required by Applicable Law and neither Party shall be required to return, delete or destroy Confidential Information or any electronic files or any information prepared by such Party that have been backed-up or archived in the ordinary course of business consistent with past practice.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X<br>INDEMNIFICATION</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification by the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company agrees to indemnify and hold each of the Investor and their respective Affiliates and any and all of their respective partners,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directors, managers, members, officers, employees, agents and controlling persons (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) harmless from and against, and will pay to each Investor Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Investor Indemnified Party arising out of (a) any breach of any representation, warranty or certification made by the Company in any of the Transaction Documents or certificates given by the Company to the Investor in writing pursuant to this Agreement or any other Transaction Document, (b) any breach of or default (in each case, with or without notice or lapse of time, or both) under any covenant or agreement by the Company to the Investor pursuant to any Transaction Document, (c) any Excluded Liabilities and Obligations and (d) any fees, expenses, costs, liabilities or other amounts incurred or owed by the Company to any brokers, financial advisors or comparable other Persons retained or employed by it in connection with the transactions contemplated by this Agreement (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)&#x37e; provided, however, that the foregoing shall exclude any indemnification to any Investor Indemnified Party (i) that results from the bad faith, gross negligence or willful misconduct of such Investor Indemnified Party, (ii) to the extent resulting from acts or omissions of the Company based upon the written instructions from any Investor Indemnified Party, (iii) for any matter to the extent of, and in respect of, which any Company Indemnified Party would be entitled to indemnification under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification by the Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor jointly and severally agrees to indemnify and hold each of the Company, its Affiliates and any and all of their respective partners, directors, managers, members, officers, employees, agents and controlling Persons (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) harmless from and against, and will pay to each Company Indemnified Party the amount of, any and all Losses awarded against or incurred or suffered by such Company Indemnified Party arising out of (a) any breach of any representation, warranty or certification made by the Investor in any of the Transaction Documents or certificates given by the Investor in writing pursuant hereto or thereto, (b) any breach of or default (in each case, with or without notice or lapse of time, or both) under any covenant or agreement by the Investor pursuant to any Transaction Document and (c) any fees, expenses, costs, liabilities or other amounts incurred or owed by the Investor to any brokers, financial advisors or comparable other Persons retained or employed by it in connection with the transactions contemplated by this Agreement (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Indemnification Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)&#x37e; provided, however, that the foregoing shall exclude any indemnification to any Company Indemnified Party (i) that results from the bad faith, gross negligence or willful misconduct of such Company Indemnified Party, (ii) to the extent resulting from acts or omissions of the Investor based upon the written instructions from any Company Indemnified Party or (iii) for any matter to the extent of, and in respect of, which any Investor Indemnified Party would be entitled to indemnification under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any Third Party Claim shall be brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the indemnified party shall, promptly after receipt of notice of the commencement of any such Third Party Claim, notify the indemnifying party in writing of the commencement thereof, enclosing a copy of all papers served, if any; provided that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and only to the extent that, the indemnifying party is actually prejudiced by such omission. In the event that any Third Party Claim is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the indemnifying party will be entitled, at the indemnifying party&#x2019;s sole cost and expense, to participate therein. In any such Third Party Claim, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the sole cost and expense of such indemnified party unless (a) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (b) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to such indemnified party or (c) the named parties to any such Third Party Claim (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of counsel to the indemnifying party. It is agreed that the indemnifying party shall not, in connection with any Third Party Claim or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such indemnified parties. The indemnifying party shall not be liable for any settlement of any Third Party Claim effected without its written consent, but, if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any indemnifiable Loss by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or discharge of any pending or threatened Third Party Claim in respect of which any indemnified party is or would have been a party and indemnity would have been sought hereunder by such indemnified party, unless such settlement, compromise or discharge, as the case may be, (i) includes an unconditional written release of such indemnified party, in form and substance reasonably satisfactory to the indemnified party, from all liability on claims that are the subject matter of such claim or proceeding, (ii) does not include any statement as to an admission of fault, culpability or failure to act by or on behalf of any indemnified party and (iii) does not impose any continuing material obligation or restrictions on such indemnified party.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A claim by an indemnified party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for any matter not involving a Third Party Claim and in respect of which such indemnified party seeks indemnification hereunder may be made by delivering, in good faith, a written notice of demand to the indemnifying party, which notice shall contain (a) a description and the amount of any Losses incurred or suffered by the indemnified party (and the method of computation of such Losses), (b) a statement that the indemnified party is entitled to indemnification under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for such Losses and a reasonable explanation of the basis therefor, and (c) a demand for payment in the amount of such Losses. For all purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company shall be entitled to deliver such notice of demand to the Investor on behalf of the Company Indemnified Parties, and the Investor shall be entitled to deliver such notice of demand to the Company on behalf of the Investor Indemnified Parties. Within thirty (30) days after receipt by the indemnifying party of any such notice, the indemnifying party may deliver to the indemnified party that delivered the notice a written response in which the indemnifying party (a) agrees that the indemnified party is entitled to the full amount of the Losses claimed in the notice from the indemnified party; (b) agrees that the indemnified party is entitled to part, but not all, of the amount of the Losses claimed in the notice from the indemnified party; or (c) indicates that the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">indemnifying party disputes the entire amount of the Losses claimed in the notice from the indemnified party. If the indemnifying party and the indemnified party are unable to resolve any Dispute relating to any amount of the Losses claimed in the notice from the indemnified party within thirty (30) days after the delivery of the response to such notice from the indemnifying party, then the parties shall be entitled to resort to any legal remedy available to such party to resolve such Dispute that is provided for in this Agreement, subject to all the terms, conditions and limitations of this Agreement.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusive Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The indemnification afforded by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be the sole and exclusive remedy for any and all Losses awarded against or incurred or suffered by the Investor Indemnified Parties against the Company in connection with the Company Indemnification Obligations and the Company Indemnified Parties against the Investor in connection with the Investor Indemnification Obligations under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable, in each case other than any Company Indemnification Obligations or Investor Indemnification Obligations, as applicable, resulting from (a) the gross negligence, the bad faith or willful misconduct of the other Party, (b) acts or omissions based upon the written instructions from the other Party or (c) breach of confidentiality provisions in ARTICLE IX or the breach by the Investor of its obligations to pay the Investment Amount; provided that nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall alter or affect the rights of the either Party to specific performance by the other Party under the Transaction Documents or the rights of the Investor to exercise remedies under the Transaction Documents after an Event of Default or other rights of creditors under the UCC or any other Applicable Law.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Limitations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The indemnification afforded by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be subject to the following limitations:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Except for Losses arising from (x) a breach of confidentiality obligations under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (y) a Party&#x2019;s fraud, gross negligence or willful misconduct, no Party hereto shall be liable to the other for any lost profits, lost revenue, lost opportunity, indirect, consequential, punitive, special or incidental damages (and no claim for indemnification hereunder shall be asserted) under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to the other Party as a result of any breach or violation of any representation, warranty, covenant or agreement of such Party or its Affiliates (including under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in or pursuant to any Transaction Document. Notwithstanding the foregoing, the Investor shall be entitled to make indemnification claims, in accordance with the procedures set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for Losses that include any portion of payments in respect of the Revenue Interests or the Included Product Payment Amounts that the Investor was entitled to receive but did not receive timely or at all due to any indemnifiable events under any Transaction Document, and such portion of the payments in respect of the Revenue Interests or the Included Product Payment Amounts shall not be deemed lost profits, lost revenue, lost opportunity, indirect, consequential, punitive, special or incidental damages for any purpose of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	With respect to indemnification by the Company pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or Section 10.1</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#x2019;s maximum liability for any Loss suffered by an Investor Indemnified Party (other than any Loss resulting from a Third Party Claim) shall not exceed an amount (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnification Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) equal to [***]. Notwithstanding the foregoing, the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Indemnification Cap shall not apply to any Loss suffered by any Investor Indemnified Party in connection with a Third Party Claim.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	With respect to indemnification by the Investor pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Investor&#x2019;s maximum liability shall not exceed an amount (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Indemnification Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) equal to the excess (if any) of [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE XI<br>EVENTS OF DEFAULT AND REMEDIES</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any of the events set forth below shall constitute an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company fails to pay (i) the Included Product Payment Amount on any Quarterly Payment Date and such failure continues for more than [***] Business Days (or in the case of any underpayment discovered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, within the time period set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including the payment of any accrued interest thereon), (ii) pay when due the Put/Call Payment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (iii) pay when due the True Up Payment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (iv) pay any other amounts (not contested by the Company in good faith) within [***] Business Days of the date upon which the Company is notified in writing by the Investor that such amounts are due and payable hereunder;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company fails to perform or observe any term, covenant or agreement contained in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.7(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Existence), the last sentence of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and clause (i) in the first sentence of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Commercialization of the Included Products), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Financial Statements), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Anti-Corruption Laws; Anti-Terrorism Laws) and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE VII</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Negative Covenants), provided that in the case of any such default that is susceptible to cure and can be cured within [***] Business Days after the earlier of the date on which (i) a Responsible Officer of the Company has knowledge of such failure or (ii) written notice thereof shall have been given to the Company by the Investor, the Company shall have such [***]-Business-Day period to cure such default;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to Provide Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company fails to provide any notice with respect to any Put Option Event when required by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Defaults</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company fails to perform or observe any other covenant or agreement (not specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and contained in any Transaction Document on its part to be performed or observed, and such failure continues for [***] days after the earlier of the date on which (i) a Responsible Officer of the Company has knowledge of such default or (ii) written notice thereof shall have been given to the Company by the Investor;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insolvency Proceedings, Etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The occurrence of a Bankruptcy Event with respect to the Company or any of its Subsidiaries;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inability to Pay Debts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Attachment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company or any other Company Party becomes unable or admits in writing its inability or fails generally to pay its debts as they become due;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Judgments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There is entered against the Company or any Company Party one or more final judgments or orders for the payment of money in an aggregate amount exceeding [***] (or the Equivalent Amount in other currencies) (to the extent not covered (other than to the extent of customary deductibles) by independent third-party insurance as to which the insurer has not denied coverage) and, (i) enforcement proceedings are commenced by any creditor upon such judgment or order to attach or levy upon any assets of any Company Party to enforce any such judgment or (ii) such judgment shall remain undischarged for a period of [***] calendar days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. (i) With respect to any Indebtedness of the Company or any of its Subsidiaries (other than the Obligations hereunder) in excess of [***] (or its foreign currency equivalent), any other party to any agreement or instrument providing for such Indebtedness exercises the right to accelerate the maturity of any Indebtedness thereunder or to require a repurchase or prepayment of such Indebtedness, (ii) any Company Party (x) fails to pay when due beyond any grace period provided with respect thereto (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise) any Indebtedness (other than the Obligations hereunder) in excess of [***] (or its foreign currency equivalent) or (y) fails to perform or observe any covenant or agreement to be performed or observed by it contained in any agreement or in any instrument evidencing any of its Indebtedness (other than the Obligations hereunder) of [***] or more and, in each case, (1) such failure continues for [***] days without any waiver or forbearance of such failure by all applicable counterparties to any agreement or instrument providing for such Indebtedness, and (2) as a result of such failure, any other party to that agreement or instrument is entitled to exercise the right to accelerate the maturity of any Indebtedness thereunder; provided, that the dollar thresholds set forth above shall not apply to the Credit Agreement, or (iii) the occurrence of any &#x201c;fundamental change&#x201d;, &#x201c;change of control&#x201d;  or similar event under the terms of the Credit Agreement or any other Permitted Debt Facility Documents or any Permitted Convertible Notes, in each case in excess of [***] (or its foreign currency equivalent), and any other party to that agreement or instrument, as a result of such occurrence, is entitled to exercise the right to accelerate the maturity of any Indebtedness thereunder or to require a repurchase or prepayment of such Indebtedness;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or would result in liability of any Company Party under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of [***];</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Invalidity of Transaction Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any material provision of any Transaction Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder or satisfaction in full of all Obligations, ceases to be in full force and effect; or the Company or any Subsidiary contests in any manner the validity or enforceability of any Transaction Document; or any Company Party denies that it has any or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further liability or obligation under any Transaction Document, or purports to revoke, terminate or rescind any Transaction Document;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any security interest purported to be created by this Agreement or the Security Agreement shall cease to be in full force and effect, or shall cease to give the rights, powers and privileges purported to be created and granted hereunder or thereunder (including a perfected security interest in and Lien on substantially all of the Collateral (except as otherwise expressly provided herein and therein)) in favor of the Investor pursuant hereto or thereto (other than as a result of the failure by the Investor to take any action required to maintain the perfection of such security interests), or shall be asserted by any Company Party or any Subsidiary thereof not to be a valid, perfected (except as otherwise expressly provided in this Agreement or such Security Agreement) security interest in the Collateral with the priority provided for in the Intercreditor Agreement or the Other Intercreditor Agreement, as applicable;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiration or Termination of the Daiichi Sankyo License Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Daiichi Sankyo License Agreement (other than as the result of the replacement thereof) shall have expired or been early terminated;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as permitted pursuant to Section 6.8(a), any revocation, withdrawal, suspension, cancellation, material limitation, termination or material adverse modification of any Marketing Authorization for any Included Product issued by the FDA that is not reversed in full within [***] days of the first occurrence of such event; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Company or any other Company Party in or in connection with this Agreement or any Transaction Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with any Transaction Document or any amendment or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation, warranty or statement contains any materiality or Material Adverse Effect qualifier; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that such representation, warranty or statement does not otherwise contain any materiality or Material Adverse Effect qualifier.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies Upon Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any Event of Default occurs and is continuing, Investor may exercise on behalf of itself all rights and remedies available to it under the Transaction Documents and Applicable Law, including exercising its rights with respect to the Put Option pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement to the extent applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE XII<br>TERMINATION</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term and Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as provided in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, this Agreement shall commence on the date hereof and shall terminate upon the earliest of the following (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Prior to the Funding Date, the earliest to occur of the following:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	(A) the occurrence of a Bankruptcy Event with respect to the Company or any of its Subsidiaries, and (B) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	(A) the occurrence of a Change of Control, (B) written notice of termination by the Investor to the Company, and (C) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	(A) the occurrence of an Event of Default (other than a Bankruptcy Event with respect to the Company or any of its Subsidiaries or a Change of Control), (B) written notice of termination by the Investor to the Company, and (C) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	(A) written notice of termination by the Investor to the Company, which notice is provided after September 30, 2025 if FDA Approval has not occurred on or before September 30, 2025, and (B) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	 (A) written notice of termination by the Company to the Investor, which notice is provided after December 31, 2025 if FDA Approval has not occurred on or before December 31, 2025, and (B) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents); and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	(A) the occurrence of a CRL Event, (B) written notice of termination by the Investor to the Company following such occurrence, and (C) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Following the Funding Date, the earliest to occur of the following:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	(A) upon receipt by the Investor of aggregate payments under the Transaction Documents (excluding Excluded Payments) equal to the Threshold, and (B) payment and performance of all of the other Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	(A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, upon the occurrence of a Put Option Event and the payment of the Put/Call Payment, and (B) payment and performance of all of the other Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	(A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, payment of the Put/Call Payment, and (B) payment and performance of all of the other Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	(A) the occurrence of the Legal Maturity Date, provided that no True Up Payment is payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (B) payment and performance of all of the Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents); and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	(A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, payment of the True Up Payment, and (B) payment and performance of all of the other Obligations owed by the Company under this Agreement and the other Transaction Documents (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, neither the Investor nor the Company has any obligation to provide any written notice of termination under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effects of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	 In the event of the termination of this Agreement pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (i) each Transaction Document shall become void and have no effect without any liability on the part of any Party hereto or its Affiliates, directors, officers, stockholders, partners, managers or members other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Transaction Documents, including this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE IX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE X</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which shall survive any termination as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (ii) the Collateral and the Revenue Interest shall revert back to the Company, all Liens on the Collateral created by any Transaction Document shall automatically be released without the delivery of any instrument or performance of any act by any Person, and upon the Company&#x2019;s request, the Investor shall, at the expense of the Company, file a UCC-3 termination statement terminating the Lien on the Collateral.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	 In connection with any such termination and release, the Investor shall, at the expense of the Company, execute and deliver to and authorize the filing by any Company Party of all documents such Company Party shall reasonably request to evidence such termination and release.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Nothing contained in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall relieve any party from liability for any breach of this Agreement prior to the termination of the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE XIII<br>MISCELLANEOUS</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All representations, warranties and covenants made herein and in any other Transaction Document or any certificate delivered pursuant to this Agreement shall survive the execution and delivery of this Agreement, the Closing and the Funding.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Parties hereto acknowledges that the other Party hereto may not have adequate remedy at law if the other Party fails to perform any of its obligations under any of the Transaction Documents. In such event, each of the Parties hereto agrees that the other Party hereto shall have the right, in addition to any other rights it may have (whether at law or in equity), to seek specific performance of this Agreement without the necessity of posting a bond or proving the inadequacy of monetary damages as a remedy and to seek injunctive relief against any breach or threatened breach of the Transaction Documents. The Parties further agree not to assert that a remedy of specific performance is unenforceable, invalid, contrary to Applicable Law or inequitable for any reason.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All notices, consents, waivers and other communications hereunder shall be in writing and shall be effective (a) upon receipt when sent through the mails, registered or certified mail, return receipt requested, postage prepaid, with such receipt to be effective the date of delivery indicated on the return receipt, (b) upon receipt when sent by an overnight courier (costs prepaid and receipt requested), (c) on the date personally delivered to an authorized officer of the party to which sent or (d) on the date transmitted by electronic transmission with a confirmation of receipt, in all cases, with a copy emailed to the recipient at the applicable address, addressed to the recipient as follows:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if to the Company, to:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                        with required email copies to (which shall not constitute notice):</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                    Email: [***]; and gmamarca@cooley.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if to the Investor, to:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:13.333%;text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with required email copies to (which shall not constitute notice):</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy (which shall not constitute notice) to:</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sidley Austin LLP</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2850 Quarry Lake Drive, Suite 280</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Baltimore, MD 21209</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Asher M. Rubin; Adriana V. Tibbitts</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arubin@sidley.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">atibbitts@sidley.com</font></font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party hereto may, by notice given in accordance herewith to the other Party hereto, designate any further or different address to which subsequent notices, consents, waivers and other communications shall be sent.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns. Other than in connection with a Change of Control, the Company shall not be entitled to assign any of its obligations and rights under this Agreement without the prior written consent of the Investor. The Investor may assign any of its obligations and rights hereunder to any other Person (except to any Company Competitor or any Person that primarily invests in distressed debt or other distressed financial assets, provided, that the foregoing exception (x) shall not apply if a Material Default has occurred or is continuing, and (y) shall not apply retroactively to any Person that previously acquired an assignment hereunder to the extent that such Person was not a Company Competitor or a Person that primarily invests in distressed debt or other distressed financial assets at the time of the applicable assignment) without the consent of the Company provided that (a) such Investor shall cause such Person to become a party to the Intercreditor Agreement or Other Intercreditor Agreement, as applicable, in accordance with the terms thereof, (b) such Person agrees to be treated as an Investor for all purposes set forth herein (including </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), and (c) shall not be entitled to receive any greater payment under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.21(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> than the Investor would have been entitled to receive at the time of such assignment. Notwithstanding anything to the contrary contained herein, the Investor may at any time grant a security interest in, or otherwise pledge or assign as collateral (and in the case of the following clause (ii), to exercise or enforce remedies), any of its rights under this Agreement and the other Transaction Documents, whether now owned or hereafter acquired (including rights to payments of the Included Product Payment Amount, the Put/Call Payment, the True Up Payment and any interest thereon), to (i) any federal reserve bank or (ii) any holder of, or trustee or collateral agent for the benefit of the holders of, the Investor&#x2019;s Indebtedness or equity securities (including as a result of any exercise or enforcement of remedies in connection with any of the foregoing). The Investor shall give notice of any such assignment to the Company promptly after the occurrence thereof. The Company shall maintain a &#x201c;register&#x201d; at one of its offices in the United States for the recordation of the names and addresses of, and the amounts owing to, each Investor from time to time. Notwithstanding anything to the contrary contained in this Agreement, (i) no assignment of any interest of any Investor shall be effective until such assignment is recorded in the register and, consistent with the foregoing, the Company shall treat any Investor recorded in the register as an Investor under this Agreement, notwithstanding notice to the contrary and (ii) the Revenue Interest are registered obligations for U.S. federal income tax purposes and the right, title and interest of any Investor and its assignees in and to such Revenue Interest shall be transferable only upon notation of such transfer in the register. The register shall be available for inspection by the Company and the Investor at any reasonable time and from time to time upon reasonable prior written notice. Any purported assignment of rights or obligations in violation of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be void.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent Nature of Relationship</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The relationship between the Company and the Investor is solely that of lender and borrower, and neither the Company nor the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor has any fiduciary or other special relationship with any of the Investors and their Affiliates on the one hand, or the Company and its Affiliates on the other hand. Nothing contained herein or in any other Transaction Document shall be deemed to constitute the Company and the Investor as a partnership, an association, a joint venture or any other kind of entity or legal form. The Parties agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Authority.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement, together with the Exhibits hereto (which are incorporated herein by reference) and the other Transaction Documents, constitute the entire agreement between the Parties hereto with respect to the subject matter hereof and supersede all prior agreements, understandings and negotiations, both written and oral, between the Parties hereto with respect to the subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits hereto or the other Transaction Documents) has been made or relied upon by either Party hereto.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OR CHOICE OF FORUM OTHER THAN SECTIONS 5-1401 AND 5- 1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Each of the Parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the Supreme Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State court or, to the extent permitted by Applicable Law, in such federal court. Each of the Parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Applicable Law.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Each of the Parties hereto hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any court referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.7(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Parties hereto hereby irrevocably waives, to the fullest extent permitted by Applicable Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Each of the Parties hereto irrevocably consents to service of process in the manner provided for notices in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing in this Agreement will affect the right of any Party hereto to serve process in any other manner permitted by Applicable Law. Each of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hereto waives personal service of any summons, complaint or other process, which may be made by any other means permitted by New York law.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver of Jury Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 13.8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If one or more provisions of this Agreement are held to be invalid, illegal or unenforceable by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, which shall remain in full force and effect, and the Parties hereto shall replace such invalid, illegal or unenforceable provision with a new provision permitted by Applicable Law and having an economic effect as close as possible to the invalid, illegal or unenforceable provision. Any provision of this Agreement held invalid, illegal or unenforceable only in part or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid, illegal or unenforceable.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.10.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each Party hereto shall have received a counterpart hereof signed by the other Party hereto. Any counterpart may be executed by electronic transmission, and such electronic transmission shall be deemed an original.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.11.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments; No Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither this Agreement nor any term or provision hereof may be amended, supplemented, restated, waived, changed or modified except with the written consent of the Company and the Investor. No failure or delay by either Party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. No notice to or demand on either Party hereto in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.12.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Third Party Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Other than the Parties, no Person will have any legal or equitable right, remedy or claim under or with respect to this Agreement. This Agreement may be amended or terminated, and any provision of this Agreement may be waived, without the consent of any Person who is not a Party. The Company shall enforce any legal or equitable right, remedy or claim under or with respect to this Agreement for the benefit of the Company Indemnified Parties and the Investor shall enforce any legal or equitable right, remedy or claim under or with respect to this Agreement for the benefit of the Investor Indemnified Parties.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.13.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents and Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Table of Contents and headings of the Articles and Sections of this Agreement have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof.</font></p>
  <p style="margin-left:0.84%;text-indent:5.889%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.14.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Investor hereby acknowledges that it has received and reviewed the Intercreditor Agreement and agrees to be bound by the terms thereof. In addition, the Investor acknowledges and agrees that (i) the rights and remedies of the Investor hereunder and under the other Transaction Documents are subject to the Intercreditor Agreement and the Other Intercreditor Agreement and (ii) in the event of any conflict, the provisions of the Intercreditor Agreement or the Other Intercreditor Agreement, as applicable, shall control.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	In furtherance of the foregoing, notwithstanding anything to the contrary set forth herein or in any other Transaction Document, so long as the Credit Agreement or any Permitted Debt Facility Documents are in effect and any loans thereunder are outstanding, to the extent that any Company Party is required to give physical possession over, grant &#x201c;control&#x201d; of, or take any other action in respect of, any Collateral securing the First Lien Obligations (as such terms are defined in the Intercreditor Agreement or substantially similar terms under an Other Intercreditor Agreement, as applicable) with respect to the Investor under this Agreement or the other Transaction Documents, such requirement shall be satisfied if such action is taken with respect to the Administrative Agent or the Permitted Debt Creditors, as applicable. To the extent that any covenants, representations or warranties set forth in this Agreement or any other Transaction Document are untrue or incorrect solely as a result of the delivery to, or grant of possession or control to, the Administrative Agent or the Permitted Debt Creditors, as applicable, in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such covenant, representation or warranty shall not be deemed to be untrue or incorrect for purposes of this Agreement or such other Transaction Document.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[SIGNATURE PAGE FOLLOWS]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first written above.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ David Hung, M.D.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: David Hung, M.D.<br>	Title:	   President and Chief Executive Officer</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page to Revenue Interest Financing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first written above.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTOR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAGARD HEALTHCARE PARTNERS (DELAWARE) II LP</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: Sagard Healthcare Royalty Partners GP LLC, its general partner</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Jason Sneah<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: Jason Sneah<br>	Title:   Manager</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Adam Vigna<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Name: Adam Vigna<br>	Title:   Chief Investment Officer</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page to Revenue Interest Financing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A<br><br>Form of Press Release</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B<br><br>Form of Intercreditor Agreement</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT C<br><br>Form of Security Agreement</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT D<br><br>Form of Guaranty</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>nuvb-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVATION BIO INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of Subsidiaries</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.9%;box-sizing:content-box;"></td>
    <td style="width:1.18%;box-sizing:content-box;"></td>
    <td style="width:47.92%;box-sizing:content-box;"></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jurisdiction</font></p></td>
   </tr>
   <tr style="height:4.3pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AnBio Therapeutics (HK) Ltd.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AnHeart Therapeutics LLC</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AnHeart Therapeutics (Hangzhou) Co., Ltd.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">China</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Artemis Merger Sub II</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cayman Islands</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Baoquan Biomedical Technology (Shanghai) Co. Ltd.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">China</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nuvation Bio Operating Company LLC</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:4.3pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nuvation Bio Ireland Limited</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ireland</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nuvation Bio UK Limited</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RePharmation Ltd.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bermuda</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>nuvb-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-256910, No. 333-267110, No. 333-270614, No. 333-277646, and No 333-278804) on Forms S-8 and (No. 333-281255) on Form S-3 of our report dated March 6, 2025, with respect to the consolidated financial statements of Nuvation Bio Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">New York, New York</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">March 6, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">	</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>nuvb-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, David Hung, M.D., certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Nuvation Bio Inc; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.471%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:2.821%;box-sizing:content-box;"></td>
    <td style="width:41.708%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David Hung, M.D.</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David Hung, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>nuvb-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Philippe Sauvage, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Nuvation Bio Inc.; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:41.928%;box-sizing:content-box;"></td>
    <td style="width:10.542%;box-sizing:content-box;"></td>
    <td style="width:5.821%;box-sizing:content-box;"></td>
    <td style="width:41.708%;box-sizing:content-box;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 6, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Philippe Sauvage</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Philippe Sauvage</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>nuvb-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">David Hung, M.D., Chief Executive Officer of Nuvation Bio Inc. (the &#x201c;Company&#x201d;), and Philippe Sauvage, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, to which this Certification is attached as Exhibit 32.1 (the &#34;Annual Report&#34;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated: March 6, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITNESS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the undersigned have set their hands hereto as of the 6th day of March, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.9%;box-sizing:content-box;"></td>
    <td style="width:20.18%;box-sizing:content-box;"></td>
    <td style="width:39.92%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David Hung, M.D.</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Philippe Sauvage</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David Hung, M.D.</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">                        </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Philippe Sauvage</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Nuvation Bio Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date hereof), irrespective of any general incorporation language contained in such filing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.2
<SEQUENCE>9
<FILENAME>nuvb-ex97_2.htm
<DESCRIPTION>EX-97.2
<TEXT>
<html>
 <head>
  <title>EX-97.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 97.2</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UVATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021 E</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">QUITY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NCENTIVE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOPTED</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OARD</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IRECTORS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: J</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANUARY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 17, 2021</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PPROVED</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOCKHOLDERS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: F</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EBRUARY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 9, 2021</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 21, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. G</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENERAL</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Plan Purpose.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Available Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Plan provides for the grant of the following Awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock Options; (iii) SARs; (iv) Restricted Stock Awards; (v) RSU Awards; (vi) Performance Awards; and (vii) Other Awards.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Adoption Date; Effective Date. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan will come into existence on the Adoption Date, but no Award may be granted prior to the Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HARES</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UBJECT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LAN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Share Reserve. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to adjustment in accordance with Section 2(c) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 50,684,047 shares. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031, by the number of shares of Class A common stock equal to 4% of the total number of shares of Capital Stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31 of the preceding year; provided, however, that the Board may act prior to January 1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of a given year to provide that the increase for such year will be a lesser number of shares of Class A common stock.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Aggregate Incentive Stock Option Limit.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notwithstanding anything to the contrary in Section 2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 152,052,141 shares.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Share Reserve Operation.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Limit Applies to Common Stock Issued Pursuant to Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued, (2) the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than Common Stock), (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) Reversion of Previously Issued Shares of Common Stock to Share Reserve.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2) any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. E</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIGIBILITY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> L</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMITATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Eligible Award Recipients.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Specific Award Limitations.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Limitations on Incentive Stock Option Recipients.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Incentive Stock Options may be granted only to Employees of the Company or a &#x201c;parent corporation&#x201d; or &#x201c;subsidiary corporation&#x201d; thereof (as such terms are defined in Sections 424(e) and (f) of the Code).</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Incentive Stock Option $100,000 Limitation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i) the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (ii) the Option is not exercisable after the expiration of five years from the date of grant of such Option.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) Limitations on Nonstatutory Stock Options and SARs.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants unless the stock underlying such Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A or unless such Awards otherwise comply with the requirements of Section 409A.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) Limitations on Class B Common Stock Award Recipients.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> An Award representing the right to receive shares of the Company&#x2019;s Class B common stock may be granted only to a recipient who already beneficially own shares of Class B common stock at the time of grant.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Non-Employee Director Compensation Limit. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $750,000 in total value or (ii) in the event such Non-Employee Director is first appointed or elected to the Board during such calendar year, $1,000,000 in total value, in each case, calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes and excluding distributions from a deferred compensation program. Notwithstanding the foregoing, the Board shall have the authority to grant Awards and pay</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash fees with a total value in excess of these amounts to Non-Employee Directors who occupy Board leadership positions and in other circumstances deemed by the Board to be extraordinary.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PTIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PPRECIATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGHTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Term.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Exercise or Strike Price.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Exercise Procedure and Payment of Exercise Price for Options.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by cash or check, bank draft or money order payable to the Company;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to a &#x201c;cashless exercise&#x201d; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Option is a Nonstatutory Stock Option, by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exercise Procedure and Payment of Appreciation Distribution for SARs.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) Transferability.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Options and SARs may not be transferred to third party financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Restrictions on Transfer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#x2019;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Domestic Relations Orders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f) Vesting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#x2019;s Continuous Service.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g) Termination of Continuous Service for Cause.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service is terminated for Cause, the Participant&#x2019;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h) Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Subject to Section 4(i), if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#x2019;s Disability or death);</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months following the date of such termination if such termination is due to the Participant&#x2019;s Disability;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 months following the date of such termination if such termination is due to the Participant&#x2019;s death; or</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 months following the date of the Participant&#x2019;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Restrictions on Exercise; Extension of Exercisability. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i) the exercise of the Participant&#x2019;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#x2019;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions); provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j) Non-Exempt Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant&#x2019;s death or Disability, (ii) a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant&#x2019;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#x2019;s then current employment policies and guidelines). This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k) Whole Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WARDS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HAN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PTIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PPRECIATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGHTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Restricted Stock Awards and RSU Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Form of Award.</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Awards: To the extent consistent with the Company&#x2019;s Bylaws, at the Board&#x2019;s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company&#x2019;s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Awards: A RSU Award represents a Participant&#x2019;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#x2019;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Consideration.</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) services to the Company or an Affiliate, or (C) any other form of consideration as the Board may determine and permissible under Applicable Law.</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Awards: Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the Participant&#x2019;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#x2019;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) Vesting. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#x2019;s Continuous Service.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) Termination of Continuous Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (ii) any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) Dividends and Dividend Equivalents. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi) Settlement of RSU Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Other Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Other Awards may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DJUSTMENTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UPON</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HANGES</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OMMON</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THER</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORPORATE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> E</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VENTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Capitalization Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan, (ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 2(b), and (iii) the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this Section.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#x2019;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#x2019;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service; provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Corporate Transaction. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following provisions will apply to Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Awards May Be Assumed.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#x2019;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#x2019;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Awards Held by Current Participants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in which the Awards are not assumed in accordance with Section 6(c)(i). With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction or such later date as required to comply with Section 409A of the Code.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) Awards Held by Persons other than Current Participants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) Payment for Awards in Lieu of Exercise.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection with such exercise.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Appointment of Stockholder Representative.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#x2019;s behalf with respect to any escrow, indemnities and any contingent consideration.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) No Restriction on Right to Undertake Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMINISTRATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Administration by Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in subsection (c) below.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Powers of Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine from time to time: (1) which of the persons eligible under the Plan will be granted Awards; (2) when and how each Award will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To settle all controversies regarding the Plan and Awards granted under it.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(viii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To submit any amendment to the Plan for stockholder approval.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ix) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that, a Participant&#x2019;s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(xi) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction).</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(xii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1) the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2) the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A) a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B) cash and/or (C) other valuable consideration (as determined by the Board); or (3) any other action that is treated as a repricing under generally accepted accounting principles.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Delegation to Committee.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) General.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Rule 16b-3 Compliance.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under Rule 16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Effect of Board&#x2019;s Decision.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) Delegation to an Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AX</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITHHOLDING</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Withholding Authorization.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agree to make adequate provision for (including), any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Satisfaction of Withholding Obligation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a &#x201c;cashless exercise&#x201d; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board, or (vi) by such other method as may be set forth in the Award Agreement.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) No Obligation to Notify or Minimize Taxes; No Liability to Claims. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Withholding Indemnification. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#x2019;s and/or its Affiliate&#x2019;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. M</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ISCELLANEOUS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Source of Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Use of Proceeds from Sales of Common Stock. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Corporate Action Constituting Grant of Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Stockholder Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) No Employment or Other Service Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#x2019;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f) Change in Time Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event a Participant&#x2019;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g) Execution of Additional Documents.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#x2019;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator&#x2019;s request.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h) Electronic Delivery and Participation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any reference herein or in an Award Agreement to a &#x201c;written&#x201d; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#x2019;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Clawback/Recovery</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#x2019;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#x2019;s right to voluntary terminate employment upon a &#x201c;resignation for good reason,&#x201d; or for a &#x201c;constructive termination&#x201d; or any similar term under any plan of or agreement with the Company.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j) Securities Law Compliance. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k) Transfer or Assignment of Awards; Issued Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l) Effect on Other Employee Benefit Plans. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#x2019;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#x2019;s or any Affiliate&#x2019;s employee benefit plans.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m) Deferrals.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section 409A.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n) Section 409A. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award that constitutes &#x201c;deferred compensation&#x201d; under Section 409A is a &#x201c;specified employee&#x201d; for purposes of Section 409A, no distribution or payment of any amount that is due because of a &#x201c;separation from service&#x201d; (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#x2019;s &#x201c;separation from service&#x201d; or, if earlier, the date of the Participant&#x2019;s death, unless such distribution or payment can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o) Choice of Law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OVENANTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OMPANY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Compliance with Law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DDITIONAL</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ULES</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FOR</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WARDS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UBJECT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ECTION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 409A.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Application. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Non-Exempt Awards Subject to Non-Exempt Severance Arrangements.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Non-Exempt Award vests in the ordinary course during the Participant&#x2019;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the calendar year that includes the applicable vesting date, or (ii) the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day that follows the applicable vesting date.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#x2019;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day that follows the date of the Participant&#x2019;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant&#x2019;s Separation from Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Grant Notice as if they had vested in the ordinary course during the Participant&#x2019;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Treatment of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The provisions of this subsection (c) shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Vested Non-Exempt Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award. Upon the Section 409A Change in Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) Unvested Non-Exempt Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to subsection (e) of this Section.</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate Transaction.</font></p>
  <p style="text-indent:14.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section 409A Change in Control.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Treatment of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The following provisions of this subsection (d) shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Corporate Transaction.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award. Upon the Section 409A Change in Control the vesting and settlement of any Non-Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control pursuant to the preceding provision.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section 409A Change in Control. To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a &#x201c;separation from service&#x201d; such Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#x2019;s Separation From Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions in this subsection (e) for delivery of the shares in respect of the settlement of a RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EVERABILITY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERMINATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LAN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i) the Adoption Date, or (ii) the date the Plan is approved by the Company&#x2019;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EFINITIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used in the Plan, the following definitions apply to the capitalized terms indicated below:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquiring Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adoption Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the date the Plan is first approved by the Board or Compensation Committee.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance Award or any Other Award).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a Participant evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through electronic means, to a Participant along with the Grant Notice.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capital Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the shares of the Company&#x2019;s Class A common stock and the shares of the Company&#x2019;s Class B common stock.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalization Adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) the Participant&#x2019;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Participant&#x2019;s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Participant&#x2019;s failure to perform the Participant&#x2019;s assigned duties and responsibilities to the reasonable satisfaction of the Company which failure</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv) the Participant&#x2019;s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v) the Participant&#x2019;s material violation of any provision of any agreement(s) between the Participant and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#x2019;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#x2019;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change of</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#x2019;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subject Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the Acquiring Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Incumbent Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) respect to any</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), (iv) or (v) also constitutes a Section 409A Change in Control if required in order for the payment not to violate Section 409A of the Code.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Class A common stock and Class B common stock of the Company.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Panacea Acquisition Corp., a Delaware corporation, which following the Effective Date will be known as Nuvation Bio Inc.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Compensation Committee of the Board.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#x201c;Consultant&#x201d; for purposes of the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#x2019;s securities to such person.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuous Service</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that the Participant&#x2019;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#x2019;s service with the Company or an Affiliate, will not terminate a Participant&#x2019;s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#x2019;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#x2019;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#x2019;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#x201c;separation from service&#x201d; as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sale</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sale or other disposition of at least 50% of the outstanding securities of the Company;</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Corporate Transaction (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event described in clause (i), (ii), (iii), (iv) or (v) also constitutes a Section 409A Change in Control if required in order for the payment not to violate Section 409A of the Code.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a member of the Board.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">determine</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">determined</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means as determined by the Board or the Committee (or its designee) in its sole discretion.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the effective date of this Plan, which is the date of the closing of the transactions contemplated by the Agreement and Plan of Merger by and among Panacea Acquisition Corp., Panacea Merger Subsidiary Corp. and Nuvation Bio Inc., dated as of October 20, 2020, provided that this Plan is approved by the Company&#x2019;s stockholders prior to such date.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#x201c;Employee&#x201d; for purposes of the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company or the Affiliate of the Company that employs the Participant.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(z) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a corporation, partnership, limited liability company or other entity.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(aa) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(bb) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#x201c;Exchange Act Person&#x201d; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(cc) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows:</font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(dd) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governmental</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Body</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ee) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ff) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Incentive Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an option granted pursuant to Section 4 of the Plan that is intended to be, and qualifies as, an &#x201c;incentive stock option&#x201d; within the meaning of Section 422 of the Code.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(gg) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Materially Impair</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any amendment to the terms of the Award that materially adversely affects the Participant&#x2019;s rights under the Award. A Participant&#x2019;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#x2019;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#x2019;s rights under the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised, (ii) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iii) to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iv) to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section 409A; or (v) to comply with other Applicable Laws.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(hh) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation S-K</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a &#x201c;non-employee director&#x201d; for purposes of Rule 16b-3.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company or (ii) the terms of any Non-Exempt Severance Agreement.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(jj) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Exempt Director Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(kk) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Exempt Severance Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#x2019;s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ll) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonstatutory Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any option granted pursuant to Section 4 of the Plan that does not qualify as an Incentive Stock Option.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(mm) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(nn) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(oo) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided, including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(pp) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Optionholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(qq) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) that is not an Incentive Stock Options, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(rr) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a written or electronic agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ss) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Own,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Owned,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Owner,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means that a person or Entity will be deemed to &#x201c;Own,&#x201d; to have &#x201c;Owned,&#x201d; to be the &#x201c;Owner&#x201d; of, or to have acquired &#x201c;Ownership&#x201d; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(tt) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(uu) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Criteria</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or average stockholder&#x2019;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#x2019; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#x2019;s products; supply chain achievements; co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee whether or not listed herein.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ww) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Goals</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of items that are &#x201c;unusual&#x201d; in nature or occur &#x201c;infrequently&#x201d; as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of Common Stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company&#x2019;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(xx) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#x2019;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(yy) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this Panacea Acquisition Corp. 2021 Equity Incentive Plan, as it may be amended from time to time, which following the Effective Date shall be known as the Nuvation Bio Inc. 2021 Equity Incentive Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(zz) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#x2019;s other equity incentive programs.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(aaa) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Termination Exercise Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period following termination of a Participant&#x2019;s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(bbb) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ccc) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ddd) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(eee) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a written or electronic agreement between the Company and a holder of a RSU Award evidencing the terms and conditions of a RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(fff) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ggg) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 405</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 405 promulgated under the Securities Act.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(hhh) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Section 409A of the Code and the regulations and other guidance thereunder.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#x2019;s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(jjj) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(kkk) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the number of shares available for issuance under the Plan as set forth in Section 2(a).</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(lll) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SAR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 4.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(mmm) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SAR Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(nnn) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ooo) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ten Percent Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ppp) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company&#x2019;s policy permitting certain individuals to sell Company shares only during certain &#x201c;window&#x201d; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(qqq) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unvested Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(rrr) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vested Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img58233625_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 7X$ P# 2(  A$! Q$!_\0
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MYG]O9A_-2_\ !2_S/[9/^(C_ /89_P"B7_M4?^$+\)O_ )]U'_$1_P#L,_\
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M4?\ $1_^PS_T2_\ :H_\(7X3?_/NK^)NBC_5;*?Y*_\ X/E_D']O9A_-2_\
M!2_S/[9/^(C_ /89_P"B7_M4?^$+\)O_ )]U'_$1_P#L,_\ 1+_VJ/\ PA?A
M-_\ /NK^)NBC_5;*?Y*__@^7^0?V]F'\U+_P4O\ ,_MD_P"(C_\ 89_Z)?\
MM4?^$+\)O_GW4?\ $1_^PS_T2_\ :H_\(7X3?_/NK^)NBC_5;*?Y*_\ X/E_
MD']O9A_-2_\ !2_S/[9/^(C_ /89_P"B7_M4?^$+\)O_ )]U'_$1_P#L,_\
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M4?\ $1_^PS_T2_\ :H_\(7X3?_/NK^)NBC_5;*?Y*_\ X/E_D']O9A_-2_\
M!2_S/[9/^(C_ /89_P"B7_M4?^$+\)O_ )]U'_$1_P#L,_\ 1+_VJ/\ PA?A
M-_\ /NK^)NBC_5;*?Y*__@^7^0?V]F'\U+_P4O\ ,_MD_P"(C_\ 89_Z)?\
MM4?^$+\)O_GW4?\ $1_^PS_T2_\ :H_\(7X3?_/NK^)NBC_5;*?Y*_\ X/E_
MD']O9A_-2_\ !2_S/[9/^(C_ /89_P"B7_M4?^$+\)O_ )]U'_$1_P#L,_\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\ HE_[5'_A"_";_P"?=1_Q$?\
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M_"%^$W_S[J_B;HH_U6RG^2O_ .#Y?Y!_;V8?S4O_  4O\S^V3_B(_P#V&?\
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M_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\
MV&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI
M_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_
M^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^
MV3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOX
MFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\
MY]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U
M+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?
MA-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?
M^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^
M0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\
MVJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&
M?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_D
MK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\
ML,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_M
MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH
M_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]
MU'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_
M ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\
MS[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\
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M_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\
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M_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\
MV&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI
M_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_
M^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^
MV3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOX
MFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\
MY]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U
M+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?
MA-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?
M^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^
M0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\
MVJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&
M?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_D
MK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\
ML,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_M
MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH
M_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]
MU'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_
M ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\
MS[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\
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M_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\
M@^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]
M$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB
M/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5
MLI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$
M1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+
M_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_
MB;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_"
M;_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'
M\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X
M3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M
M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^
M7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O
M_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\
MV&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI
M_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_
M^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^
MV3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOX
MFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\
MY]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U
M+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\ VJ/_  A?
MA-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&?^B7_M4?
M^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\ @^7^
M0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\ L,_]$O\
MVJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_MD_XB/_V&
M?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_D
MK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]U'_$1_\
ML,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_ ,%+_,_M
MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH
M_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\ A"_";_Y]
MU'_$1_\ L,_]$O\ VJ/_  A?A-_\^ZOXFZ*/]5LI_DK_ /@^7^0?V]F'\U+_
M ,%+_,_MD_XB/_V&?^B7_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\
MS[J_B;HH_P!5LI_DK_\ @^7^0?V]F'\U+_P4O\S^V3_B(_\ V&?^B7_M4?\
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M_M4?^$+\)O\ Y]U'_$1_^PS_ -$O_:H_\(7X3?\ S[J_B;HH_P!5LI_DK_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /I_P#8B_Y/0_9$_P"SG_@%_P"K6\)U^[?_
M  <Q_P#)3/V4/^Q%^)__ *D'A.OPD_8B_P"3T/V1/^SG_@%_ZM;PG7[M_P#!
MS'_R4S]E#_L1?B?_ .I!X3KY_&?\E#E'_8/C?_34SV,-_P B;,?^OV'_ /3E
M,_F%HHHKZ \<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H6_X.2/^3S_ (/_ /9L/AC_ -6M\7Z_GIKDR/\ Y%. _P"O"_\ 2I'1FO\
MR,,5_P!?%_Z1$****]4\\**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_L9_X)M?\ *"#]I?\ [)Q^V9_ZKS7J_CFK^QG_ ()M?\H(/VE_
M^R<?MF?^J\UZO XB_P!TPO\ V,<)_P"E3/8R7_>:_P#V!U_S@?QS4445[YXX
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M &#XW_TU,]C#?\B;,?\ K]A__3E,_F%HHHKZ \<**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$4D,T:2(RBA6J::NG=/5-;-=S/;<**** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M',?_ "4S]E#_ +$7XG_^I!X3KY_&?\E#E'_8/C?_ $U,]C#?\B;,?^OV'_\
M3E,_F%HHHKZ \<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K] _P#@
ME5_RD1_9+_[*OIW_ *;-4K\_*_0/_@E5_P I$?V2_P#LJ^G?^FS5*Y<=_N6,
M_P"P7$?^F9G1A/\ >\+_ -A%'_TY$_1/_@Y(_P"3S_@__P!FP^&/_5K?%^OY
MZ:_H6_X.2/\ D\_X/_\ 9L/AC_U:WQ?K^>FN3(_^13@/^O"_]*D=&:_\C#%?
M]?%_Z1$****]4\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_J#_ ."*_P#P26\$?%/P
MKHG[8'[3OARR\6^$]3O+IO@W\)=>LH[OPYX@MM,N]2TC4?&?Q#T+5=.>WU[1
MIM0M]OA'07EETC4XK6?6-9M]2TZ[TRV;^8_1='U'Q#K.DZ!H]M]LU?7-3L-'
MTNT\Z"W^U:CJ=U%96-MY]U+!;0>?<SQ1>=<S0P1[M\TL<:LX_P!/3P3X2\)?
MLV_ 7PSX+T.-(/!7P/\ A7IVB61=X[,R:'\/_"\=NUY=SW$TB)=7EMI;WE_>
MWES*\EW//=WES-(\LS_,<3YA6PF&HX?#S<*N,E.+G%VFJ5/EYE&2:<7.4XQY
MEKRJ:3/<R/"4\16J5JT5*GAXQ:C+X74DVXMK:2A&,FT]+N+9^:/[=G_!9/\
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M>:,Y)--J7V&FUM?1,FGE\ZF!JXY5(*%*3BZ;3YG9P3:>WV_P\S^4NBOZP?\
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MG.$).+@Y1C)QDK2BVD^62Z-7LUW1\M)<LI134N637,M5*S:NGU3W7D?W*?\
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MX@T3Q%IMK#/_ &N\DTLFD7;_ +A$15WEQ\">*?"GBGP-XAU?PCXV\-:_X/\
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MKAUBL3B:>$H2ERTY3CS2F[VNH\T-&T[:MM1<N7E7,?P+T5_?S\=/V0_V)/\
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M5ZT82C3ITY2E5JRUC!.4K*VEY.S:5TK)MM=?X0J*_NZ\)_\ !=O_ ()T^/\
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M<U.S<)02NI1T3:>WDTT]4?R&T5_:AK7@S_@EW_P1CUWQ?\1?B9H]A\0?CO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_KQ3_P#2IA1117TYX@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ,I))7NTDWI>_0_##_@WE_Y/_N_^R#_$?_T\>"J_5K_@Y2_Y-B^ /_9>)O\
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MI=1<.N/M<5%VYY4H./?EC)J?G:\H7LNWD?G#_P 0WG[#O_15/VK?_"X^$/\
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MIZ--;IKHT?7O[(G[<W[1W[$?C.3Q9\#/&KV6FZB\9\5?#KQ&MYK7PS\;1QM
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M9],UJZTG5+75)OYK?^"]G_"'?\/+_@I_PL7[7_PK[_A3GP9_X3K^S_M'V_\
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M\8?'GQF\*:+\,[_Q-JNE:1\+/%'AC0M+UO5/$MOHMH=2\3V'BCP3XSM-2O\
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M_P#UGKX3UKEG_)49K_UXK?\ I["&>._Y$6 _Z^T__3>(/Z4O^#?;_E'II?\
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M7@<1?[IA?^QCA/\ TJ9[&2_[S7_[ Z_YP/XYJ***]\\<**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7Z!_P#!*K_E(C^R7_V5?3O_ $V:I7Y^5^@?_!*K_E(C^R7_ -E7T[_TV:I7
M+CO]RQG_ &"XC_TS,Z,)_O>%_P"PBC_Z<B?HG_P<D?\ )Y_P?_[-A\,?^K6^
M+]?STU_0M_P<D?\ )Y_P?_[-A\,?^K6^+]?STUR9'_R*<!_UX7_I4CHS7_D8
M8K_KXO\ TB(4445ZIYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5] _LU_M1?&_]DKXE
M:7\4_@9XXU/PEK]E- NK:8L\\_A7QGI,3.9O#?CCPYY\6G^)=!N4EEQ:WJ?:
M=-NVAUG0KS2=?L=.U6S^?J*F<(582IU(1G":<9PFE*,HO=2B[IKR94)RIRC.
M$I0G%IQE%M2BULTUJF?T\_#[_@YA^)>E^'[&T^*7[*?@KQMXGA2Y6_USP/\
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M&#6/ FB7%PJ8GEM?#^M_#_XC7]G#))\T,$WB:^>!/D>XN#^\K^7>BOJ<9E>
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M_9%\)^*/$B0PK?:KX,^,&L>!-$N+A4Q/+:^'];^'_P 1K^SADD^:&";Q-?/
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MF7*E9<T*<Y6_QSA*;^<CZU_;%_;8^/'[<OQ)L_B5\<M9TF2?1-)_L+PCX/\
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MK^PNOR[B;_D<8G_!A_\ TQ3/N<C_ .1=2_QU?_3DC\3O^#@#_E'=XC_[*O\
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M110 4444 %%%% !1110!]/\ [$7_ ">A^R)_V<_\ O\ U:WA.OW;_P"#F/\
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MH **** "BBB@ HHHH *_0/\ X)5?\I$?V2_^RKZ=_P"FS5*_/ROT#_X)5?\
M*1']DO\ [*OIW_ILU2N7'?[EC/\ L%Q'_IF9T83_ 'O"_P#811_].1/T3_X.
M2/\ D\_X/_\ 9L/AC_U:WQ?K^>FOZ%O^#DC_ )//^#__ &;#X8_]6M\7Z_GI
MKDR/_D4X#_KPO_2I'1FO_(PQ7_7Q?^D1"BBBO5//"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHU:\U3HTY5)M-\L5=V6[\DO/T/S!HKZ(_:G_ &8/BC^Q]\9_$GP+^+T>@?\
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M/H.GZGX:\+VTOBVYM]2FAM/-T/3;Z'43:ZA/;VS2Z;;QW4\,+LZ+Y_$&$P6
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M_!^IP6MYHVO^*-4\'_#2Q\0Z;?6-EJ5AK/AEOB=XD\'R>)M!U"QU"UGT_7]
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M'_K]A_\ TY3/YA:***^@/'"BBB@ HHHH **** "BBB@ K^K3_@V,_P";W/\
MNVS_ -[[7\I=?U:?\&QG_-[G_=MG_O?:\/B3_D2XW_N6_P#4N@>IDO\ R,\-
M_P!QO_4>J?8W_!7?_@J7^T#^P)\4/A+X)^#O@_X.>)=*\>> M4\4ZO<?$OP_
MXUUC4+;4++Q#/I,4.FR^%OB%X-MH;-K:)7DCNK2\G,Y++<)&1&/JG_@F!_P4
MHT'_ (*&?#_QG<WWA!/A]\5_AA?Z5;>.O"NGW-_JOAZ?2/$BZ@_ACQ-H&L7=
MG;XM]4DTC6K&ZT2ZFN-2TJ[TF266:>ROK"XE_"[_ (.6/^3@/V</^R.^(/\
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M32O)>?/+88O,\:HR5'"T91G5FDM)3@I3A&]HKWO:-MZ02U6R?\=Q_P""*?\
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M+-;U72KGPOH_A_2=(L_ASX-GBN;B?5Y5BA@75KO4KN2SM;6"!U87']3/P?\
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MP[?WTFBZ=K%CXH\.6VH3W>KZ1HFMK=W<%OH^JWVJW>G7>E7UM_;.K1HEX_\
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MDBCTBWM5?1++1H-/T.SDTNT6ZN]6O=1_6W_@V,_YO<_[ML_][[7RE_P<A_\
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MO:ZY:Z]HB^'?L=CX<E\5:EX=TP_\(RL.F6>BV7FW_@'_ ,'$_P <O''Q_P#
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M5:--.RO9'_!S+_R47]DS_L2OBK_Z??!E?S 5_3__ ,',O_)1?V3/^Q*^*O\
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M?AYH][XBTHZG%YB-<Z=?^,K;POHES9A9H[L:LMM=PM8R73+_ $1?\'%_[/\
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M<I:M;V<6!Y]W+!!N7S-PY<<[8'&-[+"XAOY49G1A/][PO_811_\ 3D3]"/\
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M $43]E[_ ,+SXG?_ #FJ/^(<7]NG_HHG[+W_ (7GQ._^<U1_;>4_]!^'_P#
MG_EY_GV8?V9F'_0)6_\  5_GY_GV9^ E%?OW_P 0XO[=/_11/V7O_"\^)W_S
MFJ/^(<7]NG_HHG[+W_A>?$[_ .<U1_;>4_\ 0?A__ G_ )>?Y]F']F9A_P!
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M_P 0XO[=/_11/V7O_"\^)W_SFJ/^(<7]NG_HHG[+W_A>?$[_ .<U1_;>4_\
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MAQ?VZ?\ HHG[+W_A>?$[_P"<U1_;>4_]!^'_ / G_EY_GV8?V9F'_0)6_P#
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MGX"45^_?_$.+^W3_ -%$_9>_\+SXG?\ SFJ/^(<7]NG_ **)^R]_X7GQ._\
MG-4?VWE/_0?A_P#P)_Y>?Y]F']F9A_T"5O\ P%?Y^?Y]F?@)17[]_P#$.+^W
M3_T43]E[_P +SXG?_.:H_P"(<7]NG_HHG[+W_A>?$[_YS5']MY3_ -!^'_\
M G_EY_GV8?V9F'_0)6_\!7^?G^?9GX"45^_?_$.+^W3_ -%$_9>_\+SXG?\
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M^(<7]NG_ **)^R]_X7GQ._\ G-4?VWE/_0?A_P#P)_Y>?Y]F']F9A_T"5O\
MP%?Y^?Y]F?@)17[]_P#$.+^W3_T43]E[_P +SXG?_.:H_P"(<7]NG_HHG[+W
M_A>?$[_YS5']MY3_ -!^'_\  G_EY_GV8?V9F'_0)6_\!7^?G^?9GX"45^_?
M_$.+^W3_ -%$_9>_\+SXG?\ SFJ/^(<7]NG_ **)^R]_X7GQ._\ G-4?VWE/
M_0?A_P#P)_Y>?Y]F']F9A_T"5O\ P%?Y^?Y]F?@)17[]_P#$.+^W3_T43]E[
M_P +SXG?_.:H_P"(<7]NG_HHG[+W_A>?$[_YS5']MY3_ -!^'_\  G_EY_GV
M8?V9F'_0)6_\!7^?G^?9GX"45^_?_$.+^W3_ -%$_9>_\+SXG?\ SFJ/^(<7
M]NG_ **)^R]_X7GQ._\ G-4?VWE/_0?A_P#P)_Y>?Y]F']F9A_T"5O\ P%?Y
M^?Y]F?@)17[]_P#$.+^W3_T43]E[_P +SXG?_.:H_P"(<7]NG_HHG[+W_A>?
M$[_YS5']MY3_ -!^'_\  G_EY_GV8?V9F'_0)6_\!7^?G^?9GX"45^_?_$.+
M^W3_ -%$_9>_\+SXG?\ SFJ/^(<7]NG_ **)^R]_X7GQ._\ G-4?VWE/_0?A
M_P#P)_Y>?Y]F']F9A_T"5O\ P%?Y^?Y]F?@)17[]_P#$.+^W3_T43]E[_P +
MSXG?_.:H_P"(<7]NG_HHG[+W_A>?$[_YS5']MY3_ -!^'_\  G_EY_GV8?V9
MF'_0)6_\!7^?G^?9GX"45^_?_$.+^W3_ -%$_9>_\+SXG?\ SFJ4?\&XG[=!
M(!^(O[+J@D L?'?Q/P 3U.WX,EL#J< G'0$\4O[;RG_H/H?^!/\ R\_ZLP_L
MS,/^@2M_X"O\_/\ /LS\ Z*_H E_X-P?VYH]NSXE_LLSYSGRO'7Q5&W&,;O/
M^"<.<Y.-N[H<XXS%_P 0XO[=/_11/V7O_"\^)W_SFJ/[;RG_ *#Z'_@3_P O
MZ^3'_9F8?] E7_P%?Y^?]69^ E%?OW_Q#B_MT_\ 11/V7O\ PO/B=_\ .:H_
MXAQ?VZ?^BB?LO?\ A>?$[_YS5/\ MO*?^@_#_P#@3_R\_P ^S%_9F8?] E;_
M ,!7^?G^?9GX"45^_?\ Q#B_MT_]%$_9>_\ "\^)W_SFJ/\ B'%_;I_Z*)^R
M]_X7GQ._^<U1_;>4_P#0?A__  )_Y>?Y]F']F9A_T"5O_ 5_GY_GV9^ E%?O
MW_Q#B_MT_P#11/V7O_"\^)W_ ,YJC_B'%_;I_P"BB?LO?^%Y\3O_ )S5']MY
M3_T'X?\ \"?^7G^?9A_9F8?] E;_ ,!7^?G^?9GX"45^_?\ Q#B_MT_]%$_9
M>_\ "\^)W_SFJ/\ B'%_;I_Z*)^R]_X7GQ._^<U1_;>4_P#0?A__  )_Y>?Y
M]F']F9A_T"5O_ 5_GY_GV9^ E%?OW_Q#B_MT_P#11/V7O_"\^)W_ ,YJC_B'
M%_;I_P"BB?LO?^%Y\3O_ )S5']MY3_T'X?\ \"?^7G^?9A_9F8?] E;_ ,!7
M^?G^?9GX"45^_?\ Q#B_MT_]%$_9>_\ "\^)W_SFJ/\ B'%_;I_Z*)^R]_X7
MGQ._^<U1_;>4_P#0?A__  )_Y>?Y]F']F9A_T"5O_ 5_GY_GV9^ E%?OW_Q#
MB_MT_P#11/V7O_"\^)W_ ,YJC_B'%_;I_P"BB?LO?^%Y\3O_ )S5']MY3_T'
MX?\ \"?^7G^?9A_9F8?] E;_ ,!7^?G^?9GX"45^_?\ Q#B_MT_]%$_9>_\
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M_P#11/V7O_"\^)W_ ,YJC_B'%_;I_P"BB?LO?^%Y\3O_ )S5']MY3_T'X?\
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M %7FO5^</_$.+^W3_P!%$_9>_P#"\^)W_P YJOW ^"/[)'Q,_8R_X)$?M0?
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MS;:E'F].AE6 J5:F$>,J2QD%)OV<4J47%V<?>BW.4+KG2G%O6UN65O\ ._\
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M'Q"\9:NX73_#?A'1;_7-5F3S8H9+J2VL(9FM=/MGGB:^U*[,&GV$3>?>W-O
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MN9;>&[BM]5T+6K6RU33IY;6XM[F.*\M89'MYX9E4QRHS?TX? C_@X\^(VO\
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M_L==?_\ 4 \7U]AF/_(OQW_8'BO_ $Q,^<P7^^83_L)H?^G8'^@+XX^(FB>
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MG:=:7-_J%_<P65C8V4$MU>7MY=2I!:VEI:P))/<W-S/(D,$$*/+-*Z1QHSL
M?TK\)?\ !'#_ (*4^-M!TKQ)H?[+NOPZ7K.FV&K6*^)?'?PF\$ZM]CU* 7-J
M+WP]XS\?:!X@TN\$1!NM-U33+/4K"0B&_M+:8^77Z+?\&W7P+\&>-_C?\>OC
MEXBL8=3\1_!#PIX'T#P-!>06EQ;:1JGQ;N/&D>J^*;,36DES;:]8Z'X"O?#U
MC>VMY;+%I/BOQ!;36]TUW!+9?HM_P58_X*Y_'G]A+X_> /A/\,?@YX"USPOJ
M?@BQ\:^(/%OQ+LO&5R/%7]H:W>6$V@^!9_#^N^&-/TB;P_:Z3,NJZM>MXO\
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MW</LMK*RM[B]O)H+2WGFC_1R+_@BM_P4WFT^/4T_9?U 6TL:2+%+\4O@?!J
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M\&^$K+2O">G:S>^)==T+POH&K>%+2SUOQ4FK:/J5O>ZQ'_6M_P %4E\#R?\
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M20N#^#'[6O\ P0>_:A_:0_:X^-7QKTGXJ? 3PQ\/?B?X]UKQ3IB:CK'Q#O\
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MI[0WUWTG_!2S_@K-_P .[_B!\-_ O_"@?^%O_P#"P?!VH>+/[4_X6I_PK_\
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M/P,K^?C_ (+>?\I0/VG/^Z+_ /K/7PGK^@?_ (-O/^3'?BI_V=;XX_\ 50_
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M7[5?C#X!_!#X?W?[5GQVT#3-5@_9QT?Q%XD\':C=6EMJ.MZ;K_B2"QT.+3O
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M>*;*Y98F;[!>Z-;WX5X6-L!<0&3]&_\ @W=_9#\.?$SXJ?$+]JKQWHR:I8_
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M?^"'B72_\$Q/V<#<2(\3W/QE>Q50 T-J/CQ\34>.0B-,N;U+R8$M*?+EC'F
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M,)+%+$[1RQ2Q^" \<D<B$.DB. R.I#*P#*00#7^7[7^G]_S;I_W17_W1J_S
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M'T^/PQ=_#;4;C04L=)DM;*32[--*DM%M=.>RM'LH ELUK;M$8D_CP_X-Y?\
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MOCM_Z7?"6OY9*_J;_P"#FS_D8?V-O^P-\=O_ $N^$M?RR5ZW#G_(FP7I7_\
M4JL<&=?\C/$_]P?_ %'I!1117MGEA1110 4444 %%%% !1110!]/_L1?\GH?
MLB?]G/\ P"_]6MX3K]V_^#F/_DIG[*'_ &(OQ/\ _4@\)U^$G[$7_)Z'[(G_
M &<_\ O_ %:WA.OW;_X.8_\ DIG[*'_8B_$__P!2#PG7S^,_Y*'*/^P?&_\
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M<2Y8'"4*:I3]K-0Y'RJ+3Y;5Y<\DFW%\LHW];/\ 1W_@VM_Y-B^/W_9>(?\
MU7WA6ORE_P"#AK_D_P#M/^R#_#C_ -/'C6OU:_X-K?\ DV+X_?\ 9>(?_5?>
M%:_*7_@X:_Y/_M/^R#_#C_T\>-:UP7_)68[_ *]U?_2*!&*_Y)_"_P"*G_Z5
M4/TM_P"#:'_DCO[4/_92_ G_ *BVJU^:7_!PU_R?_:?]D'^''_IX\:U^EO\
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M>:]\/]>UOP9=^!/&=CI&L/96B2>(O ?B+^U[&TU";3;19-1TF&]:QACD$(_
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MH&@NO++7+32_RO\ _!8&*6'_ (*2_M4I+')$Y\9>')0LB,C&*?X=^#IH9 K
M$QS0R1RQ.!MDB=)$)1E)_8O_ (-QOVK? >AZ1\5OV/\ Q3JNF:!XP\2^-Y/C
M#\,!J%\L$GCFXO?"FC^'/'7AO3(YK:&!M9\.:7X(\/>(+33HM0N]1UG2;WQ#
M?6NFV]GX5U.[F^F_^"F__!$K7?VPOCO#^T)\"OB)X.\">*_&O_"/:;\8-"^(
M)\1KHU['H&DVWA^U\:^%+O0=,U^4:\GA_2]%TF[\)7&GZ/HVJRV']LMXBT[4
M;G4/[0PP]>EE7$>82QLW2IXF%65.K*,G%^UJ4JT-4G[EHSAS*Z4X\KL[VVK4
MIX_)L&L-%5)T)4XS@FE+]W"5*2L[>]=QG9VO%\ROI?S#_@VA_P"2._M0_P#9
M2_ G_J+:K7YW?\'&'_)^'@W_ +-K\ ?^I[\5J_J)_82_96^"7["OPST3]FGP
M/XET?Q)\4+C1IO'_ ,2=?EMM*L/&7C>^^V6EA>>)]3TRP\V\TOPKIU[JL&A>
M"M,U.[O6T_25^R)J>LZE'KFJW7\NW_!QA_R?AX-_[-K\ ?\ J>_%:EE>(AB^
M)L1B:2E[*K2JNFY1<7*$84H*=G9I2Y')72=G9I.Z*QU&>'R2E1J6YZ<J2FDT
MU&3E*3C=:-QYK.VC:NFU9G]3'_!-'_DP#]D+_L@_@#_TSPU_*1_P3NCCE_X+
MMV"RQI(H^/?[84@61%=1)#X ^.\T,@# @/%*B2QN!N21%=2&4$?U;_\ !-'_
M ), _9"_[(/X _\ 3/#7\/FG?'^__9:_X*8^*/C_ &&GR:N/AI^U;\3M9U;1
MX9%AN=9\+W?CWQ1HWB_1K*XD98K6_P!6\*ZGK.G:?=SB2WM+VY@N;B"XABD@
MDC)Z4Z];B2C3^.M1Q-*&MO?J2Q$(Z]-6M0S"I&E3R2K/2-.=&I)]HPC0D_P3
M/Z9_^#CRRO+K]ACX<3VMI<W,&F_M2>!+W49H()9HK"SD^%WQHTY+N]DC1DM;
M9]0O[&Q2><QQ->7MI:AS/<PH_P#$K7^DA^T=\%_A#_P4B_8]U?P5I7BW3=1\
M%_%GPUIOBOX:?$?1B-:M-!\26@^W^%?%,-M8ZC8C41I.I*UGKNA2:A:23VYU
M?0[N6RN6D>#^?KX"_P#!MKX]@^(Z7O[2OQN\!W'PKTC5H;B/0_@^?%%YXO\
M&^E1MJ!:QU/5/%7AOP[I_@%Y6CTA[F33(O',TMO<ZK96MUIUQ;66KS[9!F^!
MP.7U*&+JNC5H5JLO9N$W.:ERV44HN\E/FBXOEY;7E:-VL\VR[%8K&0JX>"J4
MZM.$>=2BHP<;ZR;?PN+4DU?FU2N[)_CI_P $V_V&-8_;Y_:+L_A7_;EUX1\
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ML\9A6!;:6#Q9IR6CQW$LLDL-ZLT,"1P/<_EQ_P $_/VTO$O[!_[1>C_&S0]
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M*/\ _1UOCW_P6>"O_F7H_P"'NG_!1_\ Z.M\>_\ @L\%?_,O7YQ44?V?@/\
MH!P?_A-1_P#D/)?<'US%_P#05B?_  ?5_P#DO)?<?H[_ ,/=/^"C_P#T=;X]
M_P#!9X*_^9>C_A[I_P %'_\ HZWQ[_X+/!7_ ,R]?G%11_9^ _Z <'_X34?_
M )#R7W!]<Q?_ $%8G_P?5_\ DO)?<?H[_P /=/\ @H__ -'6^/?_  6>"O\
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M\%'_ /HZWQ[_ ."SP5_\R]?G%11_9^ _Z <'_P"$U'_Y#R7W!]<Q?_05B?\
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M,7_T%8G_ ,'U?_DO)?<?H[_P]T_X*/\ _1UOCW_P6>"O_F7H_P"'NG_!1_\
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M?_D/)?<'US%_]!6)_P#!]7_Y+R7W'Z._\/=/^"C_ /T=;X]_\%G@K_YEZ/\
MA[I_P4?_ .CK?'O_ (+/!7_S+U^<5%']GX#_ * <'_X34?\ Y#R7W!]<Q?\
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M?'O_ (+/!7_S+U^<5%']GX#_ * <'_X34?\ Y#R7W!]<Q?\ T%8G_P 'U?\
MY+R7W'Z._P##W3_@H_\ ]'6^/?\ P6>"O_F7H_X>Z?\ !1__ *.M\>_^"SP5
M_P#,O7YQ44?V?@/^@'!_^$U'_P"0\E]P?7,7_P!!6)_\'U?_ )+R7W'Z._\
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MFH__ "'DON#ZYB_^@K$_^#ZO_P EY+[C]'?^'NG_  4?_P"CK?'O_@L\%?\
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M*Q/_ (/J_P#R7DON/T=_X>Z?\%'_ /HZWQ[_ ."SP5_\R]'_  ]T_P""C_\
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M7W'Z._\ #W3_ (*/_P#1UOCW_P %G@K_ .9>C_A[I_P4?_Z.M\>_^"SP5_\
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M>Z?\%'_^CK?'O_@L\%?_ #+T?\/=/^"C_P#T=;X]_P#!9X*_^9>OSBHH_L_
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M *.M\>_^"SP5_P#,O1_P]T_X*/\ _1UOCW_P6>"O_F7K\XJ*/[/P'_0#@_\
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ML]?">OWN_P"#;7_DS[XT?]G*:W_ZJ_X75ZF:_P#)+8/_ +!\M_\ 35,X<O\
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ML?BL)A/K?"V)25ZF'Q57$T^]Z4*?M/-WHNHDN]CZ7$8CZOGM&[M&K0IT)_\
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MY7%[)JEF^E1G(Q=O>P'&+AI?G_C#_P"#AK_D_P#M/^R#_#C_ -/'C6OZ'?\
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M]"-YX_;XE'4I_%?AW45L=0UNVLD\%6"V-II'BCPO*&N[MKB]F'DI'^@WP/\
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M]:D=8W3E%2Y5-)KW9+5;K\YO^&R_^#=W_H3_ -E+_P 0/\3_ /T.]4/V]_\
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M%5^WW97EA^W/^V3!?6ES93R?M2?'N]2&[@EMI7L]2^*/BC4=.NTCF1':VO\
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M]W5FWZN=%GX\?\$"?^4B_@O_ +)I\4__ %'*_8?_ (.4O^38O@#_ -EXF_\
M5?>*J_'C_@@3_P I%_!?_9-/BG_ZCE?L/_P<I?\ )L7P!_[+Q-_ZK[Q56F/_
M .2KR[_KS3_+$DX7_D08S_K[+\Z!\I?\&S7_ "47]K/_ +$KX5?^GWQG7)?\
M'+'_ "<!^SA_V1WQ!_ZFMW7 ?\&YGQAT+P5^UG\2_A5KNIV6EO\ &7X42?\
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M(2LUS0G%2B[-)JZ:=FD^ZN?-3C*$Y0FK2A*49+1VE%M-75T[--:-KL?VO?\
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M3@JEEI>SG*:C%;W3;5K,_F/_ ."07_*2/]E7_L==?_\ 4 \7U_5I_P %Y?\
ME&Y\4O\ L=?A+_ZG^BU_*7_P2"_Y21_LJ_\ 8ZZ__P"H!XOK^]#]I+X)?#/]
MI'X+^./@/\61'_PB/Q2TJ7PSYJ7-E:ZO8:X0=3\/ZWX8DOXKBV/BGPUJNG6W
MB30EEM+Z#[=I"->Z??:>MW:ROB&M'#YYEE>:;A1IX>K-15Y<L,55E*RZNR=E
MI=Z76XLHI2K95C:,6E*I4K0BWMS2H4U&_9-M)OIYG^;C^SA)J4/[0_P&FT:W
MAN]7B^,_PNDTJUN&"P7.I1^.-#:QMYV:>V589KH11R,US;@(S$SQ#]XO^AC_
M ,%&I+2+]@K]L)KT1F$_LZ_%>-!)$9E^US>$-4BL"$"/B07[VQBEV@02A)B\
M8C,B_C1^Q5_P0,\5?L[_ +6OA;XS_%CXO>!/B'\-OA)JVG>,?AOI_AO1M:T_
MQ5XG\;Z7'!<Z)>^,-!UJQN]%\)V'A?7?^)UIQT3Q7XLOM2O=)TJ8RZ*99XX/
M;/\ @O\ ?M>>#?A?^RU??LOZ1K=G=_%OX^WGAK^T-"L-6GMM:\)_"SP[XCM?
M$VJ^*]2BL4E,5GXGUKPU8^!=/TS59+"#Q)IFI^+I[)[Z/PUJ=H5F>)HYOF^5
M4L#)UE2E"=2K",DHQE5A4FVI*+7LJ<'*5TK-\OQ)I5@:-7+LOQ]3%1]FYJ2A
M"4HMR:A*$5[KDO?G+E7=+F^&S,K_ (-N8[4?L4_%R5"GVU_VI/%L=P!(3(+6
M/X3_  9:S+P[R$0RRWPCD"*96$BEW\D!/P*_X+AV5Y:_\%._VCY[JTN;:#4K
M;X-7NG33P2PQ7]G'\!_AEISW=E)(BI=6R:A87UB\\!DB6\LKNU+B>VF1/T#_
M .#=3]K;P?X \;?%/]E/QUJNGZ#-\6;[1_'?PIU"_DM;*VU;QMI-H="\2^"W
MO9[A9+C6_$.BG0=2\*6"0)%*?#7B.U^TR:EJ6D6-U^B__!5K_@CIXA_;B^(V
M@_'7X)_$#PCX)^*%OX7TWP9XN\/?$-=8M?!OBK3M&OKF?1?$,&O>&M$\1:YH
MOB'3]/U"\TF^@ET/6=.UNPL?#T5N?#T^G:C=ZUI'$4\KXFQE3&2=*CBJ,E3J
MR4G"U3V%2,KI-\JE2E3;M:,EJTDV9RI3QV28:&&7M*E"I%SIIKFO!5(-6;6M
MJBFE>[BU;5V/AW_@V3_Y&']LG_L#? G_ -+OBU7FW_!RQ_R<!^SA_P!D=\0?
M^IK=U^^?_!/O]C+X&?\ !//P5IWP*T;Q?X?\4?'GXEV.H>/?&_B.[M],TSQG
MXZLO##:;I=W-HVBI+<ZW9?#3P/<ZW8Z?IEO=7=[8:?K7B2ZO9[J/6/%,L$GX
M&?\ !RQ_R<!^SA_V1WQ!_P"IK=UE@L53QO%+Q-%2]E4IU%3E*+BYQIX7V/.D
MTGRRE3DXWUMHTFFEIB:$\-D/L:EO:0E!S2:?+*>(53E;6EXJ23MI?9M6;]W_
M ."3'_!%WX,^-/@[X"_:C_:PT2Z^(&I_$2PMO%WPY^$5UJ<UCX*T7PK)J-M?
M^%O%/C"/0KN&[\6ZMXDL;"'5[/PW?:J?",/A;7_[,\6^&]8U>YEMM!^S/'OQ
MO_X( ?!#Q%<> /%?A?\ 8QGUS34)O8_#G[,UI\8[:SF@N;G2YK&^\6>!_A5X
MZTF'5K6YTV=+[2+K6QJMJVR[O+.-;^&>Y^R/^":/Q&\(?'?_ ()W?LVMX:U*
M=+;1/@?X6^"WB0V%QY6JZ)XF^&WA:S^'/B&,/+;@V5\T^D?VSIK26\B?8=0T
MV\B-W:S0SS_A1\+/^#;?QWIOQEBN/C=\>?A]J?[/6B7)U*XN/ UOXGT_XF>,
M;*RN+*7^Q=1T?6M)A\-^ +74K0ZE]OU^Q\9^-;G2UMK>.TTVY?4'O](Y_K%/
M%XW,7F^98S"?5ZDHT,/AY2A=1G.+A3CR5()Q48*SCSU'+G<W:3-O8SP^&P:R
M[!8>NZT(RJUJL5*SE&#4IOFC)J5Y.Z?+%*RCJD?T)_\ !0"2UE_8#_:ZEL0@
MLI/V8OB])9B.,PQBU?X>ZTUN(X2B&)!$4"1E$*+A2BXP/XP/^"(?_*4#]F/_
M +K1_P"L]?%BO[)OVW]>\+^*?^"<O[4/B3P3K.D^(_!VN_LG_%'5?"VO:%J,
M&KZ+K/A^^^&NK7&DZEI6J6TUQ;ZA87EC)!/:WD,\T=Q"Z2K(X;<?XB_^"4?Q
M0\+_  =_X*%?LR>._&6LVWA[PY;^+]=\,7^L7J3M9V4GQ"\">*_A[IS7;P6E
MZUO;3:GXIL[>>]FBCL["*9[V_O=.LK>XU"UZ,AA*62YW3C&3G*GB(1C9\SD\
M).*C9:\S>EDKWT,<UDEF65R;2BJE*3E?W4E7@V[]K:W[']'G_!R5_P F??!?
M_LY31/\ U5_Q1K\>/^#?.#39?^"A%E)?-"+JV^#'Q,GT82W!A=M29O#UM*MO
M&)(Q=S?V1<:JS6[+,%@6>Z\L-;+-%_3Q_P %5OV&_%?[>_[->F?"SX?^)/#7
MA?X@>$OB5X;^(?A:^\9WFK:?X4O6LM,U_P ,ZUI6N7NAZ%XFU2UAET+Q1J&H
MV$UEH=Y,^LZ9IMI*]K87=[<)_+!;?"OQ%_P14_X*(_LK^(?B[XA\.?$JXL/!
M=E\1_&S>!8]8@TK0O#?Q-D^*7P9\46>C76L:6FJ>(KKPYH]IJWB.QFDT'1)-
M:E-MI2VNE2,;]-,GK4<1D>)RVG47UV=/&<E!)\T_=YXV=N51E=1NY)7;6MK$
M9C2J4<UHXV<&L-&IAN:JVN6/O*+OUO&SE:VUGI>Y_7Q^V_\ %3]AWX4>!/"&
MK_MU:7\-]5\ ZGXM;3?!L7Q*^#FH?&?2X_%XT?4+II-/T33O _CJ32;_ /L6
M'45.JR6%FAMVEM/MA:<0R?GGX/\ V_O^"!OP]\2:5XS\ Q?L[^!_&&@SR7.A
M^*_!_P"Q9X[\->)-&N9;>:TEN-*UW1?@#9:IIT\MK<7%M)+9W4,CV\\T+,8Y
M75OMC]L+]F+X-_\ !4?]DS1_#6A?$2S70->O="^*7P<^+?AF,^(-.TS7K2QU
M/3;34Y=*CU#21K6F7NC:UKN@:WH%[>V-Q9SW;RR)9:]HMJ;7^=[1O^#:W]IN
M?Q5J-GXA^/\ \"-+\$13:DND^(=&M_B!KOBJ^@BN2FCR:CX-OO"_AS2-+FOK
M/$^I06WCO6$TJY)M;6XUF(?;#Y>6TLIGA9PQ^88W!UX3J1J4(5'"FX;7C#ZO
M4NW=QG!MRYHRO%*U^[&U,PC7C+"8/"XFE*,'"K*'--2\Y>VA9+1QE91LU[UT
MST#_ (+;?\%'_P!C[]K?]F7X;?"K]G?XH7GQ&\6:9\=M#^(.LHG@'XA^$M/T
MCP]H7P_^(WAR5[J]\>>%O"PN;R^U+QEIPL;72H]1/D6FHRWSV7EVBWLG_!*;
M_@MG\./@K\)O#O[-7[7']I:!X:^'EFNE_#/XO:#HFK>(X8O"[7ADM_"GCGP[
MH5MJ.N";PXMS+%H?B#P[INH+>Z!#:Z3J.C6VI:3_ &QXC^"?^"L'_!-[X7?\
M$\-,_9ETOP3\2_&/Q'\8?$_1OB3)\1KSQ-'X>TS3$O\ P2WP^BTS5O"GAC2+
M-M4\,Z-K<_BG7$&GZ[XD\73!M*2.WUN9[>\+_;'A_P#X-\K?XU?LQ? #XV?
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MHR3NI1;C)/NFK-/T/U-N?^"UG_!3FZL7TZ7]I^]6WD@6W:2V^%/P+L[\1J%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _JC_X-D?^0M^V?_V#O@!_Z4_&6OYTOVI/
M^3FOVB_^R[?%W_U8'B&OZ+?^#9'_ )"W[9__ &#O@!_Z4_&6OYTOVI/^3FOV
MB_\ LNWQ=_\ 5@>(:^>P/_)0YW_UZP'_ *CTSUL3_P BG+?^OF+_ /3K/":*
M**^A/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O[&3_ ,JVW_=&E_\
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MA'7YT?\ !5/_ )2(?M:?]E9U3_TWZ;7SU#_DI<=_V+J/_I=(]:K_ ,B;#?\
M895_](D?G]1117T)Y(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_8S_P
M3:_Y00?M+_\ 9./VS/\ U7FO5_'-7]C/_!-K_E!!^TO_ -DX_;,_]5YKU>!Q
M%_NF%_[&.$_]*F>QDO\ O-?_ + Z_P"<#^.:BBBO?/'"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -+1=:UCPWK&D^
M(O#NK:GH/B#0=3L-:T/7-%O[K2]8T76-+NHK[3-6TG4[&6"]T[4].O8(+RPO
M[.>&ZM+J&*XMY8Y8T<>T^/?VJ_VH?BIX;NO!GQ/_ &D?CW\1_!]]/:7-[X4\
M>_&'XA^,/#=Y<Z?<)=V%Q=:%XA\1:CI=Q/9744=S:2S6KR6UQ&DT+)(BL/!*
M*B5.G*492A"4H:QE*,7*+O>\6TVM==&M2E.<4XQE)1E\24FE+U2=G\PHHHJR
M3Z1UW]LG]K[Q3X=U7PAXF_:K_:1\1^$M=TFZT'6_"^N_'+XGZOX=UG0[ZV>R
MO=&U71-0\47&FZAI-Y9R26EUIUW;36=Q;.\$T+Q,4/'?#/\ :%^/OP6L]4T[
MX.?''XP?";3]<N8+W6K'X9_$OQIX#L]8O+6)X+6[U2U\+:WI4&H7-M!(\,$]
MVDTL,3O'&ZHQ!\?HK)4**BX*C24)-.4%3@HR:V;C:S:LK-K2Q;JU7)2=2HY)
M-*3G+F2>Z3O=)];'2^+_ !GXP^(7B+4?%_C[Q9XE\<>+=7^R?VMXH\7Z[JGB
M7Q%JGV"QMM+L/[1UO6KJ]U.]^Q:996>G6GVFYE^S6-I;6D.RW@BC3N_AG^T+
M\??@M9ZIIWP<^./Q@^$VGZY<P7NM6/PS^)?C3P'9ZQ>6L3P6MWJEKX6UO2H-
M0N;:"1X8)[M)I88G>.-U1B#X_15.G"4/9RA"4+)<CBG"T;67*U:RLK*VEE82
MG-2YE*2EJ^92:E=[NZ=]>NNIU'C3QQXT^)'B;5/&OQ$\7^*/'OC+7'MI-;\6
M^-/$&K>*?$VL26=E;:=:2:IKVN7=]JNH/:Z?9VEA;/=W<S065K;6L16""*-?
M6?V>OVJOVAOV4_$>H^*_V?/BKXE^&>K:S#8V^N1Z0UA?Z)X@ATR::XTQ/$/A
M?7K+5O#&O_V;+=7AT\ZQH]ZUDE_J,5J8HM0O4G^?J*)4J4Z;I3ITYTG%1=*4
M(RIN*M:+@TXN*LK*UE96V"-2<9^TC.<:B;:G&34TW>[YD^:[N[N]W=GZ#?&+
M_@JE^WY\?/ ?B+X9?%+]HK7-<\#>+;!-+\2:#I'@_P"&O@F/6=,6X2YDTV]O
MO G@OPUJDEA>,@@U.S%ZMMJUBTFFZG'=Z?++:O\ +/PS_:%^/OP6L]4T[X.?
M''XP?";3]<N8+W6K'X9_$OQIX#L]8O+6)X+6[U2U\+:WI4&H7-M!(\,$]VDT
ML,3O'&ZHQ!\?HK.&%PU*G*E3P]"G2D^:5.%&G"G*2M:4H1BHM^ZM6KZ+LBYU
MZ\YJ<ZU6<TK*<ZDY32UT4G)M+5Z)VU9TOB_QGXP^(7B+4?%_C[Q9XE\<>+=7
M^R?VMXH\7Z[JGB7Q%JGV"QMM+L/[1UO6KJ]U.]^Q:996>G6GVFYE^S6-I;6D
M.RW@BC3KO@Y\;OBS^SYXYL?B3\%O'WB+X<^-]/MKJQAU_P .7GV:>;3KX(+S
M3-0MI4GL-6TJZ:*"6XTO5+2\T^6>VM;A[9I[6WDC\LHK5TX2@Z<H0E3<>5TW
M%.#C:W*XM<KC;2UK6TL0I24E-2DII\RFFU)2O?F4D[WOK>][GZC7_P#P6E_X
M*:ZE8+IUQ^U#JD=NODXDL/AE\%-*OSY  3=JFE_#:SU-]V/WV^\;[0<F?S"2
M3^:OB7Q/XD\9Z[J?BGQAXAUSQ7XFUNY:]UGQ%XEU:_UW7=7O&54:[U/5]4N+
MK4+^Y9$1&GNKB64JBJ7PH PZ*RHX7"X9R>'PU"@Y64G1HTZ3DELI<D8WMTN7
M4KUZUO;5JM7EOR^TJ3J6OO;FD[7ZV/H7Q7^UQ^U=X[\-7W@OQQ^TY^T+XR\'
M:I;+9:EX3\5_&CXD>(?#6HV:J%6TOM"U?Q+>:7=VRJ JP7%K)$%  0 "OU-_
MX-Y?^3_[O_L@_P 1_P#T\>"J_"VOIW]D7]K7XK?L5?&;3?CA\'T\+W?B:RT3
M6O#=]H_C31[C6O#.NZ%KT,2WFFZI;:?J6B:U"D=Y:Z=JEM=:'KNC:@E[IMM%
M+=S:9-J&GWW/CL)[; 8O#8:%.G.M1G&*25.#FU9<W+'K9*]NU]#;"XCV>+P]
M>M*<HTJL)2;;G)14KNUWTU=D_P 3^K3_ (.(O&?C#X>_ ?\ 9L\9^ ?%?B7P
M/XPT'X_W5SH?BOP?KNJ>&O$FC7,OPV\86DMQI6NZ+=66J:=/+:W%Q;22V=U#
M(]O/-"S&.5U;^>B^_P""RW_!2_4=#/AZX_:E\01V#0F W%CX#^$FEZYL*NNX
M>)],\ 6GB59L.?\ 2%U87 8(PEW(A7)_;?\ ^"I7[1?[?'A3PCX*^,/A_P"$
MWAOP[X+\0GQ3I5E\-?#?B?1Y)]:;3=1TEKJ_N_%'C7QC=2H;'4YHOL]O-:VX
M:*"41B02M+^;=<&4Y3"A@*-#'X;"UJU*=62<Z=.OR*<W)<LIP;71NUM3JQ^8
M2JXNK5PE:O3IU(TTU&<Z7,XP47S1C)7VTOT+^JZKJFNZIJ6MZWJ5_K.M:S?W
MFJZOJ^JWEQJ&J:KJFH7$EW?ZEJ5_=R37=]?WUW-+=7EY=2RW%S<2R332/([,
M>U^%?Q;^)OP/\;Z/\1_A%XZ\3?#OQQH,PETWQ)X5U6YTJ_2,R1R3V%WY#B#4
M]'U 1+!JVAZI#>:-K-F9+#5;&\LII;=_.Z*]QQC*+A*,90:Y7!I.+C:W*XM6
M:MI9JUCRU*2DI*34D[J2;4D[WNFM4[ZWWN?I1XN_X+ ?\%(O&_A:^\':Y^U+
MXLAT;489K>ZE\->%?AMX)\0M#<1SQ2I#XP\%^"_#_BZTW)<2*#::Y R8B,95
MH(#'\D^ _P!I_P#:5^%=GK&G?##]H?XY?#C3_$.N7?B?7['P'\6O'WA"SUSQ
M)?Q6\%]XAUBV\/>(-.@U/7+V"UM8;O5KU)[^XBMK>.:X=(8POAM%8PP>$I1E
M"GA</3A)IRC"A2A&36SE&,4FUT;3:-98C$3:E.O6G**:C*56<G%/=)N3:3ZI
M%F]O;S4KR[U'4;NYO]0O[F>]OKZ]GENKR]O+J5Y[J[N[J=Y)[FYN9Y'FGGF=
MY9I7>21V=B3]R? G_@IK^W7^S7X-MOAY\'?VB?%/A_P38.YTGPUKNB>"OB'I
MF@PNL*M8^'(?B1X8\6GPWI0:'STT?0GT[2H[N>]O([-;O4+^:Y^$J*NK0H5X
M*G7HTJT$TU"K3A4@FMFHS35UT=M":=6K2ESTJE2G)IIRISE"5GNN:+3L^JN?
M2_[2/[8G[2G[7>I>'-5_:*^*FK?$JZ\()K*>%XKS2?#.@Z;H(\0MI;:X=+T;
MPGHF@Z1:/JAT72!>216(>9=.LT9MD"*.+^"G[0GQN_9Q\4OXS^!GQ1\9?##Q
M%/ EK?WGA36;BPMM9LHW:2+3_$.DDR:/XCTV*9OM,6G:[8:C8Q7:17<=NMS#
M%*GCE%"H4(TO81HTHT+./L53@J7*VVU[-+DLVVVK6;;>X.K5=3VKJ5'5NG[1
MSDZETK)\[?-=+1.^VA^J,G_!;#_@IW):BS;]IZY$02.,/'\)/@/%=;8BA4F^
MB^%R7I<[!YDAN#),"XF=P[AOA;XV?M&?';]I#Q#!XI^.OQ7\<?%'6;(7*:4_
MBW7;O4-/T&&]%K]MMO#6B;X]#\,V=Z]E:RWEEX?T[3;2ZN($N9X9)P9#XO16
M=+!8.A+GH83#49V:YJ5"E3E9[KFA"+L^NI53$XFK'EJXBO5C>_+4JU)QOWM*
M35S2T76M8\-ZQI/B+P[JVIZ#X@T'4[#6M#US1;^ZTO6-%UC2[J*^TS5M)U.Q
ME@O=.U/3KV""\L+^SGANK2ZABN+>6.6-''Z66O\ P6:_X*86>BKH$/[4FN/8
MI:Q6@GNOA]\'[[6C%##% CMXEO?A[<>(GNF2%&EO7U5KR>9I;F>XDN)YY9/S
M!HJJV&PV(<7B,/0KN%^5UJ5.JXWLWR\\9<MVDW:VR["IUZU&_L:U6ES?%[.I
M.'-;:_*U>WF>V6W[2G[0VG_$_P 3_&K2?CC\6=!^+OC-+R'Q5\2_#GQ \4^&
M_&VNVE]+8S7.G:CXCT+5-/U2;2G;2]+5-)-R-,@BTO3((+2*#3K..#B/'_Q)
M^(OQ7\1S^,/BEX^\:_$KQ=<VUK97/BGQ_P"*==\8^([BSL8_)L;2?6_$5_J.
MIRVUG#^ZM8)+IHK>/Y(41>*XJBM(TJ<6I1IPC)14%*,(IJ"M:":2:BK*T5HK
M*RT(<YM-.<FG)R:<FTY/>33=G)]7N%;GAKQ/XD\&:[IGBGP?XAUSPIXFT2Y6
M]T;Q%X:U:_T+7=(O%5D6[TS5]+N+74+"Y5'=%GM;B*4*[*'PQ!PZ*MI---)I
MJS3U33W375,E-IIIM-.Z:T::V:?1H]I^)/[27[1/QFT>R\._&#X^?&GXK>']
M-U--:T[0_B3\4_'/CK1[#6(K6ZL8]6LM,\4:[JEE:ZG'97U[9I?P01W26MY=
M6ZRB*XF1_'[*]O--O+34=.N[FPU"PN8+VQOK*>6UO+*\M94GM;NTNH'CGMKF
MVGC2:">%TEAE1)(W5U!%:BIC"$(\L(1A'7W8Q48Z[Z)):]2I2E)\TI2E+O)M
MO3;5MO0]_P#'7[6'[4WQ0\,W_@KXF?M*_'_XB>#=5>SDU3PEXZ^,GQ%\7>&=
M2DTZ]@U'3Y+_ $'7_$>H:5>/8ZA:VM_9O<6DC6M[;074!2>&.1? ***4*<*:
M<:<(4XMW:A%13=DKM125[)*^]DNP2G.;O.4INUKRDY.V]KMMVNWIYGT1J/[7
MO[66K^$;KX?ZM^U!^T1JG@.^T!_"E[X)U'XU_$J]\(WGA>2Q_LN3PW=>&[GQ
M-+HUQH$FF?\ $N?1YK)].:Q_T1K8V_[NO%O"WBOQ3X&\0Z1XN\$^)=?\'^+/
M#]Y'J.@^)_"VL:CX?\0Z)J$((BOM(UK2;FTU+3;R(,PCNK.YAG0,0KC)K HH
MC2IP4HQIPC&5^91A%*5U9\R22=UH[WT!U)R:<ISDX_"W)MQMJK-NZL]=#V;X
MD?M&_M"_&32[30_B_P#'CXS?%71;"_@U6QT?XD?%#QOXYTNSU2UM[ZSMM2M-
M/\3ZYJEI;W]O::IJ=K!>0PI<0V^HWT$<BQ7=PLF9\,?CI\;?@G)K,WP:^,7Q
M3^$DOB-+"/Q#+\,?B%XM\!2:]'I;7;:9'K+^%=7TIM433FU"_:P2^,ZV;7MV
M;<1FYF+^644O94N1T_9T_9O>GR1Y'JGK&W+ND]MTF/VE3FY^>?.MI\TN;:WQ
M7OMIOMH=CX[^(OQ!^*7B&?Q=\3?'7C+XC>*[J&&VNO$_COQ/K?B_Q#<V]MO^
MSP3ZUX@OM0U*:&#>_DQ27+)%O?8J[CFMX+\<>-/AOXFTOQK\._%_BCP%XRT-
M[F31/%O@OQ!JWA;Q-H\EY97.G7<FEZ]H=W8ZKI[W6GWEW87+VEW"T]E=7-K*
M6@GEC;EZ*KECR\G+'DY>7DLN7EM;EY;6Y;:6M:VA/-+FYN9\U^;FN^;FO>]]
M[WUO>]S]3;#_ (+6?\%.=-MDM;?]I^]DB3: U_\ "GX%ZK<G;&D8WWFJ?#&\
MNY,K&I8O.Q:0O*V99)';Y9^._P"VY^UE^TU8II'QS^/'C[Q_H*7IU%?#%[J,
M.D^$S??Z+Y=T_A/P[:Z/X<DFMFLX7LFDTMOL$IN);+R)+N[>?Y8HKGIX'!4I
MJI2P>%I5%M.GAZ,)KTE&"DODS:>*Q52+A4Q-><'HXSK5)1:[.,I-/[CU_P""
M_P ?_C5^SKXJ7QM\#_B;XO\ AEXE,:PW5]X6U:>R@U2V19@EGKNEL9=(\06$
M9GEDCL-;L-0LXYV%PD"SHDB_=<G_  6H_P""F\FF#26_:@U 6HM8[,2Q_"[X
M(1:GY,2)&KG6HOAHFLFZ*H#)?&_-[,Y>2:X>1W9ORUHIU<'A*\E.OA<-6FK)
M3JT*5222V2E.+>G3705/$XBE'EI5ZU.+NW&G5G"-WN[1DEKU/1OBI\7OBA\<
M?&6H_$'XO>/?%'Q%\9:H\YN=>\5ZO=:K=Q07%_>ZF=-TV.=S;:-HEM?:C?3:
M?H.D06.BZ6+J6'3;"T@(C&5\/OB'XZ^%'C/0/B)\-/%NO^!O'/A:]-_X>\5>
M&-3NM(UK2KEX)K2<VU[:21RB&\L;FZT_4+1R]IJ.FW=WIU]!<65U<02<=16Z
MA!0]FH15/EY.117)R6MR\MN7EMIRVM;2UC/FES<_-+GOS<]WS<R=U+FO>]];
MWO<_4:;_ (+2_P#!36?3HM+?]J'5%MH8([=)8?AE\%+;43'' ;=6EUBW^&T6
MKSSF,EI+J>^DN99\74LSW*K,/S(U75=4UW5-2UO6]2O]9UK6;^\U75]7U6\N
M-0U35=4U"XDN[_4M2O[N2:[OK^^NYI;J\O+J66XN;B62::1Y'9C0HK*CA<-A
M^;ZOAZ%#GMS^QHTZ7-:]N;DC'FM=VO>UV74KUZUO;5JM7EOR^TJ3GRWWMS-V
MO97MV/O/X+?\%/OV]?V??">G^!?A;^TIXUTOPAH\=M;Z)H'B73_"?Q(T_0-/
MLM-MM(L-%\.Q_$OP[XO;P_X=T_3[.WAT_P .:,]CH-@Z-<V>G074LTTDWQA_
MX*B_M^_'C0&\+_$C]IOQW<^'Y7@:[TOP?:>%OA=;:DENEZB6VK_\*N\/^#9-
M9L7^W2R7&GZJ]Y8W4\.GW%S;S3Z5I<EG\#45'U'!>T]K]3POM;\WM?J]+VG-
M_-S\G-?SO<KZUB>3V?UBO[.UN3VU3DMM;EYN6UM+6L%>T_#;]I+]HGX,Z/>^
M'?@_\?/C3\*?#^I:F^M:CH?PV^*?CGP+H]_K$MK:V,FK7NF>%]=TNRNM3DLK
M&RLWOYX)+I[6SM;=I3%;PHGBU%=$X0J+EG",X[\LXJ2NMG9IK0QC*4'>,I1?
M>+:?WJS-SQ+XG\2>,]=U/Q3XP\0ZYXK\3:W<M>ZSXB\2ZM?Z[KNKWC*J-=ZG
MJ^J7%UJ%_<LB(C3W5Q+*515+X4 >F_#;]I+]HGX,Z/>^'?@_\?/C3\*?#^I:
MF^M:CH?PV^*?CGP+H]_K$MK:V,FK7NF>%]=TNRNM3DLK&RLWOYX)+I[6SM;=
MI3%;PHGBU%*5.G**A*$)05K0E&+BK;6BTUITTTZ#4YQES1E*,M?>4FI:[ZIW
MUZ]S?\4^*_%/CGQ#J_B[QMXEU_QAXL\07DFHZ]XG\4ZQJ/B#Q#K>H3 "6^U?
M6M6N;O4M2O)0JB2ZO+F:=PH#.<"O1/@I^T)\;OV<?%+^,_@9\4?&7PP\13P)
M:W]YX4UFXL+;6;*-VDBT_P 0Z23)H_B/38IF^TQ:=KMAJ-C%=I%=QVZW,,4J
M>.442IPG!TY0A*FURNG**<''^5Q:<6O*U@4YQESQE*,T[J:DU)/OS)WOYWN?
MJC)_P6P_X*=R6HLV_:>N1$$CC#Q_"3X#Q76V(H5)OHOA<EZ7.P>9(;@R3 N)
MG<.X;X6^-G[1GQV_:0\0P>*?CK\5_''Q1UFR%RFE/XMUV[U#3]!AO1:_;;;P
MUHF^/0_#-G>O96LMY9>'].TVTNKB!+F>&2<&0^+T5C2P6#H2YZ&$PU&=FN:E
M0I4Y6>ZYH0B[/KJ:5,3B:L>6KB*]6-[\M2K4G&_>TI-7/I;]G[]L;]I_]E>7
M4S\ /C5XU^&]EK4AGU;0=,O;;4O">I7K-IY_M6]\'>(+75_"MQK:Q:796::Y
M)H[:O'IJ3:6EZNFW=Y:S_56O?\%G?^"F7B/3WTS4/VH]:M[:0L6DT'X=?!SP
MKJ +P36YV:MX8^'>CZK$!'.[*([U DZPW*!;FWMY8OR_HHJ8+!UI^TJX3"U:
MCWJ5,/2G/1)+WI0<M$DM]DAPQ6)IQY*>(KPA_)"K4C'_ ,!C)+\#8\0>(O$'
MBS6;_P 1>*M=UCQ-X@U687&J:[X@U.]UG6=2G6-(5GO]3U&>YO;R8111Q"2X
MGD<1QH@;:B@8]%%=*2222225DEHDELDNB1@VVVV[MZMO=ONPKZ\^ '[>_P"V
M)^R[IBZ%\#/C_P"._!7AF*26:V\'S3Z;XL\$V,]Q=3WMW<Z;X*\;:=XC\*:9
M<W]Y<S7.I7.GZ/;3ZE,X>_DN&1"OR'16=6E2K0<*U.G5@W=PJPC4@VMFXR35
MUZ%PJ5*4E.G.=.:VE"4H27I*+3_$_4;5/^"TO_!376(!;W?[4.J0QC.&TOX9
M?!30Y^7C?FYT3X;:?<GYHE S*<(9(QB.:57_ #J\=_$7X@_%+Q#/XN^)OCKQ
ME\1O%=U##;77B?QWXGUOQ?XAN;>VW_9X)]:\07VH:E-#!O?R8I+EDBWOL5=Q
MSQU%9T<)A<.V\/AL/0;5FZ-&G2;6]FX1BVK]&54Q%>LDJM>M52=TJE2<TGW2
ME)V9]]>!O^"HW[??PZ^&UQ\(_"_[2WC0> [C3[O2?[-\1:9X/\;:K::5>PO;
M3:9IGBSQKX;\0>+](T]+>1H+2STK7K.VT^$B.PCMD55'P+115TZ%"BYNC1I4
MG4:E4=.G"#J25[2FXI.35W9RN]7W%.K5J**J5*E105H*<Y24%II%2;45HM%9
M:+L%>]^!/VJ_VH?A;X=LO"'PR_:1^/GPZ\):;]I_L[POX$^,/Q#\(^';#[9?
M7FJ7?V+1/#_B+3],M?M6IZA?ZC<^1;1^??7UY=R[KBYFD?P2BKG3A47+4A"<
M;WM.*DKZZVDFKZO7S9,9S@[PE*#M:\9.+MO:Z:=KI:>1?U75=4UW5-2UO6]2
MO]9UK6;^\U75]7U6\N-0U35=4U"XDN[_ %+4K^[DFN[Z_OKN:6ZO+RZEEN+F
MXEDFFD>1V8]Q\-OC'\7?@UJ5]K/P@^*GQ'^%6KZG;)9:EJOPV\<>)_ VI:A9
MQNTD=I?7WAC5-+NKNVC=W=()Y9(D=V94!8D^<442A"4>248R@TDXRBG%I;+E
M:M965E82E)/F4FI)W4DVG?O=:W/2OB7\9_C#\:-0TW5OC%\5_B5\6-5T:SDT
M[2-3^)?CKQ1X[U#2M/FG-S+8Z;>^*=5U6YL;.6Y9KB2UM9(H'G8RLAD):NK^
M W[3?Q__ &8/$EQXL^ 7Q9\9?##5[[[/_:\?AW4R-#\1+96^I6VGQ>*_"M^E
M[X7\60:8FL:E+I4'B71]5ATN[NY;_3X[:^V7"^%45+I4I4W2E2INDU9TG"+I
MM7O9P:Y6KZVM:^I2J5%-5%.:J)W4U*2FG:UU)/F3MI>^Q^IMS_P6L_X*<W5B
M^G2_M/WJV\D"V[26WPI^!=G?B-0H#)JEI\,8-3BG(4;KF.[2Y8[F:4LS$_!G
MQA^//QG_ &@?$<7BWXV?$_QI\3_$-M;)966H>,=>OM8_LVS6*"(VFDVMQ*;+
M2;:46T,MS!IMM:Q75T'O+E);N669_):*SHX/"8>7-0PN&H2:LY4:%*G*SW5X
M1B[,NIB<157+5KUJL?Y:E6<U]TI-%_2M5U30M4TW6]$U*_T;6M&O[/5=(U?2
MKRXT_5-*U33[B.[L-2TV_M)(;NQO[&[ABNK.\M98KBVN(HYH9$D16'Z9:1_P
M6>_X*9:)I,6BV?[4>LS6<4)@2;5_AU\&_$&K%#&(RTNOZ]\.M2UV:;: 1<3:
MC).LF95D$I+G\OJ*=;#8;$<OUC#T*_+?E]M2IU>6]K\O/&5KV5[6O9=A4Z]>
MC?V-:K2YK<WLZDZ=[;7Y6KVZ7/9?C?\ M#?&W]I+Q;_PG/QT^)?BGXE^)DMH
M;*UO?$5\)+72[.&VM;46FB:-:1VNB:%;3)9P37D&C:=8Q7]\)=2ODN-0N;FZ
ME\Y\+>*_%/@;Q#I'B[P3XEU_P?XL\/WD>HZ#XG\+:QJ/A_Q#HFH0@B*^TC6M
M)N;34M-O(@S".ZL[F&= Q"N,FL"BM(TX0@J<80C34>54XQ2@HVMRJ*2BHVTL
ME:W0ASG*3G*4I3;NYN3<F^[DW>_G>Y^HFB?\%HO^"FGA_3;?2K#]J+5KBUM4
M"12ZW\-?@OXFU)@JJH-QK/B3X<:KJ]X^%!,EW?3NS%G9B[LS?.?QZ_;S_;"_
M:=T@>'?CC^T!X^\;>%R8'G\("\L?#/@V_FM+BWN[.YU;P?X/L?#_ (9UB\L;
MNU@N;"]U72KR[L;A&FM)H9))6?Y'HK"&!P5*:J4\'A:=1.ZJ0P]&$T^ZE&"D
MGYW-9XK%5(N$\37G!JSC.M4E%KLXN35O*QU'@OQQXT^&_B;2_&OP[\7^*/ 7
MC+0WN9-$\6^"_$&K>%O$VCR7EE<Z==R:7KVAW=CJNGO=:?>7=A<O:7<+3V5U
M<VLI:">6-NU^)?[0/QY^-%OIMI\8OC;\7?BQ::--)<Z1:_$OXD^,O'=OI5Q*
MC12SZ;#XIUK58[&:2-FCDEM5B=T9D9BI(/D5%;NG!R4W"#G%6C-Q3DEKHI-7
M2U>B?5F2G-1<%*2@W=Q4FHMZ:N-[-Z+==%V.H\%^./&GPW\3:7XU^'?B_P 4
M> O&6AO<R:)XM\%^(-6\+>)M'DO+*YTZ[DTO7M#N['5=/>ZT^\N["Y>TNX6G
MLKJYM92T$\L;=Q\3/VA?C[\:;/2].^,?QQ^,'Q9T_0[F>]T6Q^)GQ+\:>/+/
M1[RZB2"ZN]+M?%.MZK!I]S<P1I#//:)#+-$B1R.R* /'Z*'3IN:FX0<XJT9N
M,7.*UT4FKI:O9]7W!3FHN"E)0;NXJ346]-7&]F]%NNB[&EHNM:QX;UC2?$7A
MW5M3T'Q!H.IV&M:'KFBW]UI>L:+K&EW45]IFK:3J=C+!>Z=J>G7L$%Y87]G/
M#=6EU#%<6\L<L:./TOT[_@L]_P %,M+T:UT&V_:CUF6QLX5@BGU'X=?!O5]9
M=$D\T-=>(]6^'5[XAOIBW#7%[JEQ.\?[EY&A_=U^7U%9UL+AL1R_6,/0K\E^
M7VU*G5Y;[\O/&5K];6+IUZ]&_L:U6ES6YO9U)T[VVORM7MTN=I\1?B+XX^+?
MCCQ/\2OB5XGU;QEXZ\9:M<:WXE\2ZW<?:=1U34;G:#)(0J0V]O;PI%9Z?I]G
M%;Z?IFGV]KINFVMK86MM;1<7116T8QC%1BE&,4HQC%)1C%*R22T22T26B6B,
MVVVVVVVVVV[MMZMMO5MO5M[A7W3\%_\ @IC^W;^S[X4TWP-\*OVDO'&B^#]$
M\N/0_#NNVWAGQ]I6A6<%O8VMOI.A6OQ"T'Q4FBZ#:PZ=;K:>']+^R:):,][)
M;:?%)J6HO=?"U%9U:%&O'DKT:5:"=U&K3A4BGWY9IJ_G8JG5JTI<U*I4I2M;
MFISE"5NUXM.Q^EWC/_@L1_P4H\=Z)=>'];_:H\66-A>0S037'@SPG\-/ASK:
M).FQVM?$WP]\$^%_$EC,HYAN+'5;>XMW_>02QR?-7YP:KJNJ:[JFI:WK>I7^
MLZUK-_>:KJ^KZK>7&H:IJNJ:A<27=_J6I7]W)-=WU_?7<TMU>7EU++<7-Q+)
M--(\CLQH44J.&PV'36'P]"@I?$J-*G23]5",;_,JI6K5K.M6JU6MG4J3G;TY
MF[?(_27_ ()!?\I(_P!E7_L==?\ _4 \7U_6'_P70U75-"_X)X?$'6]$U*_T
M;6M&^(GP:U72-7TJ\N-/U32M4T_XCZ#=V&I:;?VDD-W8W]C=PQ75G>6LL5Q;
M7$4<T,B2(K#^'/X#?&SQU^SC\8?A_P#'#X:SZ9!XV^&_B"#Q!H8UK3H]6T>[
M989[._TO5K!WADGTS6-+N[[2K\V=U8:G#:WDMQI.I:9J<5IJ%M^A/[7G_!9/
M]JC]M#X/:E\#OB9X4^"'AGP3K&IZ/JNJM\//"GC/3=9O;G0=4L]8TM7O_%/Q
M$\81P0V]Y9(66TM+9IHY9HYGD'E&+PLRRO%8K-\NQM)4W0P_L55YIVDO9UYU
M96C9\UXR25GJ[IV6K]3!XZA0R[&8:;FJM9U'3Y8WC[]*$%>5]&I1;>FBLU?I
MQ>B?\%B_^"E/A_PM9^#[#]J?Q3<:386%OIL%WK?A#X8>)O%+V]M!%;QR7GCC
MQ)X'U;QKJ-^T<*-<:KJ'B"ZU2[G,MS=7DUS//+)^?GCWQ]XU^*/C'Q!\0?B+
MXIUOQIXV\5ZA)JGB+Q/XCU"XU/6-6OG1(A+=7ER[R%(+>*&TM+=-EM965O;V
M5G#!:6\$,?(T5[E+"X:A*4J&'H493TE*E1ITY25[VDX13>J3U;U1Y=2O7JI1
MJUJM6,?A52I.:CI;12;2TTTZ%FRO;S3;RTU'3KNYL-0L+F"]L;ZRGEM;RRO+
M65)[6[M+J!XY[:YMIXTF@GA=)89422-U=01^E?A__@L?_P %*_#/AO3O"NG?
MM3>)KG3-,L[2QMKKQ!X+^%GBWQ)+#9Q0PPOJ/C+Q5X$UGQ?J]XZ0(;O4=6UR
M]U"_E::>^N;B:XN))?S+HIUL-A\1RK$8>C74;N*K4J=7E;M=QYXRM>RO:U[+
ML%.O6HW]C6JTN:W-[.I.G>VU^5J]NESW74?VG_VCM3^+&I_':?XZ?%>U^,FK
M#4([OXEZ-X\\2>'_ !C'9ZI).]YI&G:UH6H:==Z/H#+<36\'A[2'L=#LK)EL
M++3[>RCCMTXCXC?%;XH_&'7H?%7Q;^)/C[XI>)[;3+?1;?Q'\1O&/B'QOKT&
MCVEQ=W=KI,.L>)M1U/4(M,MKJ_OKFWL$N%M8;B]NYHXEDN)F?@:*J-*E%QE&
MG3BXQ4(N,(IQ@MH1:2:BND5HNQ#J3DFG.;3ES-.3:<GO)IO63[O4]^_9_P#V
MIOVA/V6-?U7Q-^S]\5O%/PRU37;:TM->31)K2YTC7X-/DGFTY=>\.:Q::EX>
MUI]-DN[PZ;-JFEW<VG"^U!;*2!+^\6?W7XW_ /!3W]O+]HOPA=> ?BS^T?XN
MUCP;J*2P:QX>\-Z1X-^&^GZ_93VMU9W.E>)8_AIX:\(/XET2ZM[R9;O0]>?4
M='NG6VGN+&6>RLY(/@RBHEA<+.JJ\\-0G6C9QK2HTY54XVLU4<7-6LK6>EE8
MN.(KP@Z4:]:--WO3C4FH.^]X*2B[]=-3W*T_:?\ VE;#X?/\);']H?XY67PJ
MDT.]\,/\,[3XM>/K?X?/X;U))XM1\//X,A\0)X<;0[^.ZN8[W23IIL+I+B=)
M[>19I WAM%%:QA"'-R0C#F?-+EBH\TGNY62N_-ZD2E*5N:4I<JLN9MV797>B
M\EH?HS\,/^"MG_!1/X/^#])\!^!_VG/%*>&="MELM(M?%OA?X<_$C4+"QB>1
MK:P@\0?$?P;XL\1#3[*.3[+IU@VJM::;I\-IIEA#;:?96=M!\I?'O]HSXV?M
M0>.(?B/\>OB#JWQ'\:6VAVGAJTUK5K;2K(V.@6-]J>IVFCV&GZ)I^EZ78:?!
MJ.LZK>I;6=C!']IU"ZF(+RL3XG16-/"86E4=:EAL/3JROS5:=&G"I+FUE><8
MJ3N][O7J:3Q&(J05.=>M.FK6A.K.4%;:T7)Q5NEEIT/IW]GK]L_]J7]E1M13
M]G_XV^-?ASINKR75QJ?ANQNK36?!M]J%[%IMO<:U<^"/$UGK7A"3Q$UKH^FV
M4?B-M$_MZ"PM5L(-1BLI)8)/J?6_^"T7_!33Q!IMQI5_^U%JUO:W2%)9=$^&
MOP7\,ZDH964FWUGPW\.-*U>S?#$B2TOH'5@KJP=%9?R[HJ:F!P5:;J5<'A:M
M1V;J5,/2G-M;-RE!RTZ:CABL33CR4\17A!7M"%:I&*OO[L9):]=#N_B1\4/B
M-\8?%VI>/?BIXX\4?$+QEJ[EM0\2>+M:O]<U69/-EFCM8[F_FF:UT^V>>5;'
M3;00:?81-Y%E;6\"K&/J#X%_\%'OVWOV;?#UGX1^#O[1/C7PWX4TURVE^&-6
MM_#OCOP]I*&U-G]ET?1?B#HGBG3=)T]8B733=.MK;3X[K%\ELMZJW ^)**TJ
M8>A5IJE5H4:E*-DJ=2G"=-)*R2A*+BK+166B(C6JPFZD*M2%1WO.,Y1F[N[O
M)--W>KUW/T5^)?\ P5H_X*)_%KP[?^%?&7[4/C)=%U."&VO8?!VA> _AI>S0
MP7UMJ"(-9^&OA/PEK,6^XM8DN&AU"-KNR:XTVZ:;3KNZM9OSJHHIT</0P\7&
MA0HT(MW<:-.%*+>UVH1BF[:785*U6LU*K5J59)63J3E-I=DY-M(****U,PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#^EW_@VD_Y+E^TQ_P!DH\)?^I?)7]A=?QZ?\&TG_)<OVF/^R4>$O_4ODK^P
MNOR[B;_D<8G_  8?_P!,4S[G(_\ D74O\=7_ -.2/Q._X. /^4=WB/\ [*O\
M+_\ TYWU?PD5_=O_ ,' '_*.[Q'_ -E7^%__ *<[ZOX2*^JX2_Y%<_\ L+K?
M^FZ)X.?_ ._K_KQ3_P#2IA1117TYX@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#4Z-6K&*A77-3:DI.W+&6J6UU)/[[G!T445Z!R!1110 4444 %%%% !1110
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MV9M6PV(P_)[>E.E[1-PYU;FY;<UO-<RNG9JZN%%%%=1@%%%% !1110 4444
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M2ZUZZU&&UTRPTS6;WP_I<RW9O+KQ!8B!K>3R?[?RAU%2^O4^=M1OR5?9W?\
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MQ/H'A'1!>S&VLSJ_B35;31M-%W<!)3;VWVR]A\^81R&*+?($?;M/ZD_M;?\
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MOR[B;_D<8G_!A_\ TQ3/N<C_ .1=2_QU?_3DC\3O^#@#_E'=XC_[*O\ "_\
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M9_,+1117T!XX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!@WXS6.L6-A)H?Q$_9T\1>,=%?4=.BUJ+0]8;P--XQ\'>(+>TU"&Q>:_\
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M_P"K \0U_1;_ ,&R/_(6_;/_ .P=\ /_ $I^,M?SI?M2?\G-?M%_]EV^+O\
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M_1=1U72?$G[.GCF^LK"\O+;PWX6^(7C&TUK5[BUB\R#2M.G\;?#3P?X=BO\
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ML_WRC_L;X3\Y'KY1OC_^Q=B/S@?QS4445]">0%%%% !1110 4444 %?WL_\
M!!K_ )1N?"W_ +'7XM?^I_K5?P35_>S_ ,$&O^4;GPM_['7XM?\ J?ZU7R_%
MO_(LI_\ 892_]-5SW>'O]^J?]@U3_P!.43\A/^"C_P#P5C_;K_9G_;W^.7PK
M^%GQ>TRR^%_@34_"-OX>\":Q\-/AEK.G00ZW\+?"&M7J7.N7'A%?&EU_Q.]:
MO=5A:7Q1NCG,5J6;3(_L!_H0_P"";?[8K?MV_LI>&?C%KV@Z3H7C.VU76_A[
M\3M"TBXCO?#Z>,O#L5C+>W6E037-W?V&E>(M#U?1/$4&A:V6U#1X]9;2VNM<
ML;:R\1:S_+-_P56_8U_:V^,'_!1_X^Z]\,/V9_CMXW\,>,?$OPWLO#?C+0/A
M7XTO/ NIR-\,/A_HDMPGCD:,OA&VTVRU6"YL]5U>\UJWTK2)+2];5+VSCLKI
MX?Z9/^"2_P"Q_P"+?V*_V._#?PU^(]I9:;\4O%_BSQ'\4?B3H^G:O%KMEH?B
M/Q'#I6BZ=H::I:33Z7=WND>#?#'A6PUM]$FN-#_X2"#51I.H:S8B'7-2\7-J
M660R7+ITHX:&-E2PEW0]G&K.]!.M*LH6<O>LY3FG)5&E?WG?T\OJ8Z698R-1
MUI8:,\1;VO.X1:JVIJFY72TVC%J/)=VT1_,?\<?V=_"?[,?_  7,^#'PZ^'^
MGZ9HO@'4OVL_V5_'O@_P_I*30V?AS3/&WQ \ ZU>Z!#:2@Q6-II6ORZS:Z39
M6<TUG;Z&FEI!]E^;3[/^F'_@LOX8\2>,_P#@FY^T3X6\'^'M<\5^)M;N?@K9
M:-X=\-:3?Z[KNKWC?M!?"EUM-,TC2[>ZU"_N61'=8+6WEE*HS!,*2/YF_CG\
M?/"O[1__  78^%'Q#\ ^(;;Q3\/[/]KS]E+P/X,URP-E-IFHZ;X%\8_#3PUJ
MVH:/J%BOE:QH>K>+;'Q'K&B:QY]VFHZ3J-G/:7+Z>UFD?]B/[7W[1^A?LC_L
MV?%K]HGQ%I%SX@LOAMX=@O;'0+65K9]>\2Z[K&F>%/!NASWR6]X^EV&K^+M>
MT33M4UA;*^.C:;<W>JBPOOL?V29YI+$PK\-SE"57%0H82?LY-QG4K1J4I*G-
MM74Y32C-M:2;8L!&A.EG,8R5/#RJUX\Z2<84G"HG.*6CC&-Y12^RD?QZ> ?^
M#>O]O_QEX6M_$.NS? WX7:E<)</_ ,(7X^^(>L77BF!8IKB.#[1)\.O!?Q \
M*QO>Q0Q7=O$/%#2PPWEO%J"6-['>6EI^;/[6/[&GQ_\ V*_'MIX ^//@\Z%<
MZS92ZEX5\3:3<G6/!?C*PMC;I?S^&/$4<,,%]-I,UU;0:SI=Q%9ZSH[W=A)J
M6FVMOJ>F3WG[5_LB_P#!=7]K/XC?MK_#WPU\5Y?!U]\$OC7\4?"WP]3X<:-X
M0TJT;X:6WC/4H/"V@ZCX5\56R6OBS5)M.UK4M*U3Q)+XNU/Q2FI6,&K0:)IF
MD2W-A%9?KA_P7R^%GAKQS_P3S\<>.M5L;63Q!\%O&OPW\8^%M3,86_M)?$WC
M;0OAEK-A#=(OG?8-1TWQLUQ?6#R"RNKK2]+O)HI+O2]/D@]6.:9M@\RPF%S*
M&%=/&N$8?5U+]W*K)0BE*3NW3J.,9J7.G%MQG+1G \!E^)P6(Q&"E74\,I.7
MMFO?5.//)M)6M.";BX\K4E:45L?PM>&O#'B3QGKNF>%O!_A[7/%?B;6[E;+1
MO#OAK2;_ %W7=7O&5G6TTS2-+M[K4+^Y9$=U@M;>64JC,$PI(_9?X4_\$ O^
M"@OQ)T6;6/$.D_";X+.MPT5IH_Q6\?W+:UJ-N(;:5=0AM?AAX<^)D%E;R23S
M6RV^M76E:HLUE<O+IT=M)97%Y\T?\$M_VQ?AO^PY^T[+\:_BEX/\2^,?#<GP
MU\8>#8+7P=IV@ZEXFTK6-=N-$O+#5M+B\1:WX>L(-RZ1<:-J%TFJ1746D:QJ
M AAO [VDWUM\<_\ @X(_;E^(FO3S_""Z\%?L]>%H[FWFT[2-#\+>&?B/XB-N
MEA'!<VFN>)?B-X>UC2]26?4#/?Q3:1X0\-36\9M;)FG6"XGO?3QU3.9XCV&7
M4<-3I*G&4\7B9-Q<Y-_NX0C>2<4GS-TZB:>\';FX<+#+8T?:XRI6G4<Y1CAZ
M"2:BDO?E*5EJWI[\=MI6=O./CQ_P0L_;[^!OA:_\86WA7P1\:M(TB W>KV_P
M/\2:OXG\0V5FJ;I+FW\)>)O#'@WQ3K_E.5BDL_"VCZ[J2[FN?L1L8+FZ@_'2
MO]!K_@D-^VO\1OVY?V7M8^(?Q;L= MOB%X&^*/B#X;:SJ'ANTET[3O$MI9>'
MO"?BK2O$+:20UMI%Y);^*WT:\L;*YN+:6;1#JL:V2:FFGVG\K7[6OP"^%NG_
M /!9S7?@--I]KI7PG\<_M8?!RQ\2:7#<2:+IVG>'_C3JGP_\1^-K*SFLKJQ;
M0]*M3XUUJ&P&GW6GQ:/IZ01Z>]A#:P"'CRO-L74Q..P.8PI^WP5.=5SH)VE"
MFXJ:LVTV^>$H-<MTVI131T8_+\/"CA<5@YS]EB9QIJ%5ZQE--Q=[727+)23Y
MM;--HYK]E7_@CC^VQ^UIX,M_B+X5\+>%_AGX#U6UTJ_\+>)_C/JVM^$;;QKI
MFK+++#K'A73-'\,^*/$-_HB6BV]_%K=SHUEI.K6-_9W'AZ]UE6G\CV#XP?\
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M0\?>*M7T[6!\1?&%CH/@*ST;4M.\NZTW6-0\1VFF:BMQ:)974\MY:I-_:?\
ML??!C1OV(?V+/A5\*_&WB+0-)LO@O\-=2U_XF^*I]6DC\):3K-W<:S\1/BCK
MBZYK0LFA\*:;X@UCQ)>V^IZC#IL<.B01W,UEID2&SMO,S^EEU/"8"6$CAX8U
MNFVL+R1FX.E[TJD:37O>U4.24H\SES\KOS'=E-3&SQ&+6(E6EADIV=?F:4^?
M10E4^S[/FYHIV2Y6UL?Q8?#SP7^T7^R1_P %4/%'PP_8OTBR\;_&#X=?%;XL
M^$OAGX4OIDGT?Q9X+AT7Q1>3:-XH37=;\.6]S!!\.5FO]7%[K]L;#5]+_M#3
M=7EU#3].U)_KW_@K)\;/^"M7B?X'>#O#7[:WP-^'OP*^#.M?$*Q6";X2ZII>
MH:?XN\9:7H^LZCHN@^,+[1_C1\6)UMH;--4U[2=$U$Z1IVI:AH:ZQ##?W_AJ
M"?3^._X)\?%JS^/'_!=_1?C'I=S<W6A?$?XP?M4>*O#$M[9Q6%XOA#4_A!\:
M9/"%O=VD4, BN;/PP-)M)_-C^TO+ \EY)-=O--)^P7_!R'_R8[\*_P#LZWP/
M_P"JA^.=>KB,2X9SD^'K87#5:U3"8>53$5:<WB85&ZRER24XQ7+.#DN:G)J4
MI6M?3@HT5/+<QJTZ]>%.&(K*%&$HJC."5)KF3@Y/FC))\LXII)-/6_\ -C\)
M/^"3W[?_ ,=?AWX7^*_PL^ +^)_A_P"--/&J>&?$#_$_X,Z"NJZ>99(1<QZ9
MXE^(NC:S GG12Q$7>G6[B2.1"H9& ^!/$7A_6?"?B#7?"OB*PFTKQ!X:UC4_
M#^NZ7<&-I]-UG1KV?3M3L)VA>6)IK.]MI[>0Q221EXV*.ZX8_P!MW_!OC^T(
M?BI^QEJGP?U6_-UXE_9T\<7WAZ&&:[%W>#P!X\EO?%_@^[G+XNH($UM_'/A[
M3;>42P6^F^&K6WLK@00_8;#^?C_@N)^SV?@5^WS\0M<TVP-IX3^/.FZ;\:M#
M>*T$-I_;'B*2ZTSQ_ ;J+%O<ZE/X\T;7_$5ZFV&\@MO$FFR7<4OVF&_ONW Y
MMB*V;8S+,53HTW1YY8>5.,U*<8RBX\_/.:;G1G&HN6,$DI::JW-BLOHT\OPV
M-H3J3]IRJLIN+49.+3Y>6$6E&I&4'=RW7FW\<_LS_L(?M9?MA:?XIU;]G3X/
MZE\0M(\&7FGZ=XBUA_$G@GP=H]GJ6I0S7-MIEMJOCWQ-X7T_5M22UA%U?:?H
M]S?WFEVMSIUSJ<%I!JFFR77FO[07[.'QI_98^(<OPJ^/7@F;P#X]AT?3/$#:
M'+K?AKQ$CZ-K(G.G7]OJ_A'6=?T.ZAN&MKF)A;:G-);SV\]O<I#/%)&O]OG_
M  0W^!MQ\%_^"?/PWU+5=*?2?$7QKUWQ)\:=7BEN8;N6?3_$LMIHG@B^62">
MYAM[;5/AYX9\)ZS;V,<B-:_VG+]MMK759=1A7\KOV3? 7A+_ (*8?\%C/VE_
MVD/%UIIGB[X*? '6;>;PCI;ZM9>*/"WB>?PP\?PU^#]XL$^EW6E7_A7Q!8^#
M_$'Q4?3K&6WM4U_[$#?:[:SZE/J7/#/ZCQ>:<\*7]GY=3F_:04O;5*JJ0HTX
M<[JNFU5J>TY&J:T4;N^KVEE,%A\!RSJ?6\9*'NR<?9PIN$JDY<J@I_NX<G,G
M.]V].B_,[]F[_@BC^W?^TGX1L_'EAX+\+_"'PCK%K9WWAO5/C?KNI>#[[Q+8
MW5U>6[7^G^%-%\/^*O&MC811VL6H6]]XB\-Z'::YI&HZ;JWAB;7;"[6=?;/'
M'_!O)^WUX1T2[U?1=2^ GQ)NK6RO+M?#W@?X@^)+?6[Q[1(WCL;0^/O /@;1
MWO;X.ZV:RZO#;EX)%N;FV+V_G_N?_P %E?\ @IUXM_8>\-^"_A9\$1H(^.GQ
M5T;6-=7Q)JJZ9K3?##P;972Z19>)H_"5\+BWU'6?$6L#5+3PK<:_8W?AE9?"
M_B WNG:TUJUBGQ;_ ,$B/^"Q'[0/Q^_:&T;]FK]J37_#/C4_$#1_$3^ ?'\7
MAG1/!OB*'Q=H%A?^)AH&JV_A'3='\)7FG:KX?L-5M=.8:)I-ZFIZ?IEJMYJ-
MYJ9AGY8YEQ#6PD\TI4\'#"1YZD:$HSE5E1IWYIK6\HI1DV^>G*5I2A!1Y4;O
M!9/2Q$,#4GB95Y<L753BH*I.SC%Z63=TDE":C=*4N9,_E5\;>"?%WPW\7>(O
M 7CWP[JWA+QEX2U:[T/Q)X;URTEL=5T?5;&4Q7-G>6TH#(Z,-R.NZ&>%H[BW
MDE@ECD;^N?\ X($_L7_M"_L]ZC\5?BU\;/A2?!7A?XO_  S^%FK?"K7=1UWP
M3JNJZIIFHMK.OW ;1M$\0:KXH\)SS:1JVC3W^F^)M+T&_CD=;&]M$OK*YM;>
MI_P<;_LO:!K?PD^&G[6?A_1A#XU\#^++'X8?$"_L+2V0ZOX \5VNIW?AO5?$
M%X]Q'*Y\'^+M.M]"T5+>VFGG'Q#O!=R_9=-LU@]D_P""('_!0CXW_M>Z=XY^
M$?Q5T7X;VFB_L]_##X3:+X5UWPAH7B#2/$OB%4@U/PS+J'C"6_\ %>L:%<W]
MU:>'+2\F'AW0/#5@M_<7C6UA;V;VUE:F99C7S'('B:%.E&E-^SQ\9RDYTI0J
MTN546I)-3FXM\RDU3DE9.[2P6#I8/-U1JSJ.<5SX644E&HI0GS>TNFURQYE[
MK5YQ>MK)^5_\%P/^"?W[67[7OQB^#'BO]G'X1)\0=$\+_#G5]$\3Z@OCGX9>
M$&M-;N?$DMW;026_CCQEX8O;YWTU8"+JTM[JW2-(X'G5XQ$O\GWQ$^"?Q4^%
M/Q9UOX%>.?!>JZ7\6_#_ (BL_">H^!K%K+Q)J[>(]1^R?V;I.F-X8NM9LM=N
M=4_M"Q_LO^P[O48]2-W;"QDN#-&&_LG_ ."N_P#P5+_:!_8$^*'PE\$_!WP?
M\'/$NE>// 6J>*=7N/B7X?\ &NL:A;:A9>(9])BATV7PM\0O!MM#9M;1*\D=
MU:7DYG)9;A(R(Q_.E^S7_P %%H?"O_!22W_;Q_:*\%67B!/$%[XPO/&FA_#7
MPU:3WNBS:W\/;_P?HMW\.=,\7^+;6&QO=+GCT>TFN=8\5SW<GA^77HC>SWUZ
MDE=&0U<SAEL9/#X>KA:>%JSP<:<I1Q%:K&I)QIS<IRA%2?.DU!6]W?4SS:G@
M98UI5:L*\Z]*.)<HQ=&E3E"*<X)14FTN5M.;^U\O4_@Y_P $%/\ @H+\5](;
M6M;\-?#GX)6SIYMA:_&/QK<V.KZC%F(!ET7X?^'_ (B:KI+EGE7[-XDM-$NP
M+:5S;B*2T>Y7XT_\$%OV_P#X0>$]0\7:7H'PX^-EMI,=S=:EHGP6\5ZQK?BR
M'3;/3;G4;G4-/\,^,?"G@;5?$LBM;#3K;0?"<&O>+-3U*YMK?2?#]]&[S1^I
M_M#_ /!PG^V%\0/$>HK\ K7PI\ O!:[[;1T/AWP[\1/&DL46J/<0ZGJNJ>,M
M(U3PY'>W>FI;V-SI]EX::SM!)>-!<W%RUK?6W[U_\$8OVY_BW^V]\!?'^J_'
M*Y\.ZI\0_A=X[TWPI+XA\/Z&OAUO$?A^_P#"6CWNG:QKVE68&@Q^(KS6;;Q)
M-J$WAV#1](>*2U@M?#>CQ6T<E_EC,=Q%@:'U[$0P$:*E!3P\5.4X*;44I.[W
M;2;C5E:3VMH7A\+DV*JO"T98N51QDXUI.,8R<5=M)I;+I*FKKK?4_@IO;*\T
MV\N].U&TN;#4+"YGLKZQO8);6\LKRUE>"ZM+NUG2.>VN;:>-X9X)D26&5'CD
M174@?Z67[>'_ "8[^V9_V:E^T1_ZJ'QA7\4/_!;#X8>'?A?_ ,%%OC;;>%K2
MPTW2?&MMX*^(TFDZ;IEMI=II^M>*_">ES>)Y/+M&$-W<ZWXEM=7\3WU]Y%M-
M<7VN7/VE)[A);Z[_ +7OV\/^3'?VS/\ LU+]HC_U4/C"N;/ZZQ7^KN)BN55W
M*KRO>/M'@I.-^O*W:^SM=:&V4TG0_MBC)W=)1A=;/E6)2?E=*]MU>SU/\T2B
MBBON#Y<**** "BBB@ HHHH **** /Z&/^#;?_D\SXQ?]FQ^)/_5J_".OSH_X
M*I_\I$/VM/\ LK.J?^F_3:_1?_@VW_Y/,^,7_9L?B3_U:OPCK\Z/^"J?_*1#
M]K3_ +*SJG_IOTVOGJ'_ "4N._[%U'_TND>M5_Y$V&_[#*O_ *1(_/ZBBBOH
M3R3_ $D_V1O%5GX%_P""=/[,7C?4;>YO-/\ !W[%7P6\57UI9>5]LNK/P]\#
M/#6KW-O:>?)%!]IG@LWB@\Z6*+S63S)$3+#R#_@J7^Q[8?MR?L?>)M$\)65M
MJ_Q/\%V#_%/X(7\$;R7>I>(-.TU[R7PKI[G4M)M=GQ'T'S_"\#ZM/)I%EJFH
M:-KMY:O+HUK+!WG[/&E_VY_P2Z^!FB>?]E_MC]@;X9:7]I\KS_L_]H?L\:):
M>?Y/F0^=Y/G>9Y7FQ>9MV>8F=P^&O^""O[9$'QY_9?7X!^*M5AE^)O[-D-EX
M<L[:4HEWK/PBN,Q^!-6AAM](TVQ6'PVL<_@6YAAN]7U&.'1-'U;6[J.X\16H
ME_*(TZ].>+S/#.U3+\PBYK72%6I4Y)/9.'/!TYQ^TJMG[MS[Z4Z4X8?!5DN7
M%X22BW;65.%.\5_>Y9\\7T<+K6Q_'9^RQ_R<[^SE_P!EX^$/_JP?#U?V^_\
M!<__ )1F_'G_ +#/P>_]7)X$K\3?^"EW[$(_9N_X*9?L[_'+P3IMS'\*/VE/
MVC?A_P"++G8-7O;7PQ\7)OB7X?U7QYI%Q?W-M+8V-MXLNM0E\9>&M-_M5Y09
M_%.FZ5I>G:#X:LHA^V7_  7/_P"49OQY_P"PS\'O_5R>!*^@S'%4\;F'#>*I
M?!6JTI<K=W"7UFBIPE_>A).+Z-JZT:9Y.$P\\+@\YH5/BIPFK])1="HXS7E*
M+4EU5[/5,_!'_@V\_P"3XOBI_P!FI>./_5O? ROV2_X+C_MC?M'_ +'OPU^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^EW_@VD_Y+E^TQ_V2CPE_ZE\E?V%U_'I_P;2?\ER_:8_[)1X2
M_P#4ODK^PNOR[B;_ )'&)_P8?_TQ3/N<C_Y%U+_'5_\ 3DC\3O\ @X _Y1W>
M(_\ LJ_PO_\ 3G?5_"17]V__  < ?\H[O$?_ &5?X7_^G.^K^$BOJN$O^17/
M_L+K?^FZ)X.?_P"_K_KQ3_\ 2IA1117TYX@4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?3_[$7_)Z'[(G_9S_P  O_5K>$Z_
M=O\ X.8_^2F?LH?]B+\3_P#U(/"=?A)^Q%_R>A^R)_V<_P# +_U:WA.OW;_X
M.8_^2F?LH?\ 8B_$_P#]2#PG7S^,_P"2ARC_ +!\;_Z:F>QAO^1-F/\ U^P_
M_IRF?S"T445] >.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^@?\
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MZ+AV:NG:I:Z=T[8Q;>JU7EJ?K'_P0:_Y1N?"W_L=?BU_ZG^M5_*7_P %??\
ME)'^U5_V.N@?^H!X0K^J+_@@;K.CZE_P3H\":=IVJZ;?ZAX?^(/Q2T[7K&RO
MK6ZO-$U"[\6WNLVMCJ]K!+)/IMY<Z1J6G:K;VUZD,TVFZA97T:-:W4$LG\JG
M_!7*\M+_ /X*.?M475C=6U[;/XXT:-+BTGBN8'>#P+X4MYT6:%GC9X9XI8)5
M#$QS1R1.%=&45DR:XCSBZ:_WK\<73:^]:KNM0S/_ )$^6^E#\,/)/\3^Y_\
M;P_Y,=_;,_[-2_:(_P#50^,*_P T2O\ 2I_;EUK1[_\ 8-_:XU:QU;3+W2M;
M_9,^/=QHNIVE_:W.GZO;ZE\&_%USIT^EWL,KVU_#?VSI<64MI)*EU ZRP-)&
MP8_YJU5P>FL-C;JW[^"^:IZHGB/^-AO^O4__ $L_THOVS?\ E'Y^U=_V9S\=
M/_5*>*:_BW_X(A_\I0/V8_\ NM'_ *SU\6*_L\_;$U'3[W_@G?\ M1:G9WUG
M=Z;J'[&?QIN+#4+:Z@GL;ZWU#X)^)#83V=W$[P7,-\)X#9RPR.ER)HC"SB1,
M_P 6_P#P12U'3]+_ ."G/[,%SJ=]9Z=;2WGQ7TZ.XOKJ"T@DU#6/@5\3])TF
MQ26X>.-[S5-5O;+3-.M58SWNH7=K96R2W-Q%&_'D:?\ 8N?*SO['$+Y_5*FG
MJ=.:?\C+*?\ KY1_]/P/Z$_^#D/_ ),=^%?_ &=;X'_]5#\<Z]R_X(+7$$W_
M  3?^&L<,\,LEIX[^+%O=1QR)(]M.WCC4[I8+A58M#,UK<VURL<@5S!<03!?
M+EC9O!_^#D.YM_\ AB7X5VGGP_:_^&I_ ]S]E\U/M'V?_A4OQSB\_P G=YGD
M^9^[\W;LW_)NW<5^=G_! 3]O?P#\#]=\<_LI_&+Q)X>\#^$OB?XB_P"%@?#;
MQAK]RVE:6GQ*DTK1O#NM^$]<UN[NAH^FIXGT#0-$E\,W%_'IEO)K.BW6B2:E
M>ZKXA\/:;65/"U<3PK:E&4Y4,9/$.$4W*4(\T)V2U]V-1S=K^[%V1I.O"AGS
M]HU&-7#1I*3=DI2Y91N_[SARKSDC\X_^"PMM/:?\%)_VJ(KA/+D?Q=X7N57<
MCY@O/AOX+O+9\HS >9;SQ2;20Z;]DBI(K*/S3K^\K_@H=_P1K^%'[>OC[1_C
M1X>^)<WP0^*$VF:9I'C#Q+I?@;3O'6@_$+1-*LYK;0[[6-%A\2>"KQ_%>GV1
MT[2;3Q4WB.\67PMI6F:#/I<\&GZ5<Z=^;/[?O_!/[]A3_@GO_P $\_BMX6L]
M8\.>+/VI/B1<_#?_ (0'Q=\2+O1;KXK:U_8/Q9\+WOBA_ACX:A5I/!OAW3_!
M=WXALO%.I:!;0Q:C:2V6F>*M>U*ZGT&SKV\MS_!2P^782"K3Q4HX;"RHQIR_
M=N*A2G5E-I0]E%)U+QE*2BO>C'5KR\9E.)C6QF(DZ<:$76KQJ2FO?3<IQIQB
MO>]HVU"TE&-_A;T3]O\ ^"*W_!+3X)V_P+\$?M:_'OP-I'Q+^)/Q-6X\1_#S
MPSXXTJSUCPG\.?!UIJ6H:?X?UBV\-W9O=&USQ3XJBM8?%]MX@UBWNY- TVY\
M-P>'[+0=:L]:U#5?IWXL_P#!=7_@GS^S[XNU?X9^']/^*'Q"E\-ZSK>BZ[/\
M&?ASX>MO"NE:[HU\=/U2UCNO&WBOX<1:ONOHKF*'5O#EKK&C:@MI)=VFIW%E
M/8W-WU?_  1'_:G\#_'3]BCX9?#2/Q!X:A^*_P "=(N_A[XN\$6=Y':ZW#X;
M\/ZB8/!?BZ/0KO4+O5I]&U;PQ?Z!9ZAXAB1=&N?&%OK]E9K8^0NFVWR&?^#=
M3]F3PU\8=8^)_C'X]>*(?V<]-U:Y\3'X/W6E67ARZTG1+=X;[_A'?$/QNO?%
MMU<S>$K=X[FRO[V'PIH7BA_#TL<$?BZQUVW;Q//\_5GA:V9YBL]JXM.E4DL+
M0I*;A*//)1A!1C+E7)[-TG[D)WE.I4YG[WKTX8BG@L'_ &53P[]I"+KU9N/,
MFXQ;E)MKF?/SJHK2E"RC&%E[O[A?%7Q3I_CG]D_XD>-M)AO+?2O&'[/'C#Q3
MIEOJ,<$.H0:?X@^&VHZM90WT5M<7=M%>16UW&EU';W=U DZNL5Q-&%D;^27_
M (-O/^3XOBI_V:EXX_\ 5O? ROZIM6^)?PE^+?[%GQ(\;? S7M#\2?"JY^"G
MQ9T/PAJ?AQ?+T7[!X2\.>)_"DEEI]N8X7M;;3KK1I[&"VDA@>*&",&%%*BOY
M3?\ @W%U'3[+]NGXAVU[?6=I<ZQ^R]X\T[2;>ZNH+>?5-0B^)WP:U:2QTZ*5
MTDO;R/2M+U/4WM;999TT_3KZ]9!;6EQ)&\LBXY/Q!%PE!Q5-.$TU.'+[2\9)
MI-2C:TKI--.X8YJ689/+FC)2=1J47>,KJFTXM:-.]TUNFCZY_P"#G/\ YLC_
M .[D_P#W@5?REU_5=_P<X7-O+-^Q5;QSPR7%K_PT?]I@25'FM_.7X!O#Y\2L
M7B\U 7B\Q5\Q063(&:_E1KZKAO\ Y$N"_P"YC_U+KG@9U_R,\3_W!_\ 4>D%
M%%%>X>6%%%% ']4?_!LC_P A;]L__L'? #_TI^,M?SI?M2?\G-?M%_\ 9=OB
M[_ZL#Q#7]%O_  ;(_P#(6_;/_P"P=\ /_2GXRU_.E^U)_P G-?M%_P#9=OB[
M_P"K \0U\]@?^2ASO_KU@/\ U'IGK8G_ )%.6_\ 7S%_^G6>$T445]">2%%%
M% !1110 4444 ?T#_P#!MY_R?%\5/^S4O''_ *M[X&5_1;_P4O\ ^"C'_#NS
MP=\+O%G_  IW_A<'_"R?$VO>'?[/_P"%A?\ "OO[%_L32[74OMGVK_A!_&_]
MH_:?M/D?9_LUAY.SS//EW>6O\YG_  ;A7-O;?MQ?$_[1/#!Y_P"RQXUMH/.E
M2+SKB7XO? WRH(M[+YDTFUO+B3+O@[5.#7W=_P '+^K:4/AE^RYH1U/3QK;^
M._'VK)HQO;8:J^E1>']&LY-373_,^UMI\=W+%:O>B$VR7,L<#2"5U4_"YCAJ
M6+XHH8>O#VE&I2@IPYIQNHT*DE[T)1DK-)Z27GHSZG!UJF'R*K6I2Y*D*DN2
M5HRLW5A%Z23B[IM:I_>?+7Q@_P"#DSX^>)]);3_@I\ ?AW\)+V?"3Z[XO\4:
MM\6]2MHO+.7TBWAT7X<Z-;7GG!&675M+UZT%OYL)L&F>.ZA_GF^(/Q#\=?%?
MQGK_ ,1/B7XMU_QSXY\4WHO_ !#XJ\3ZG=:OK6JW*00VD!N;V[DDE,-G8VUK
MI^GVB%+33M-M+33K&"WLK6W@CXZBOK<)EV"P"E]4P\*+DDI23E.<DM4G4J2E
M-J^MN:U];7/G\1C,3BK?6*TJBB[J+Y8Q3VNH048IVTO:Y_I#?\$T?^3 /V0O
M^R#^ /\ TSPU_GX_M3_\G._M&_\ 9>/B]_ZL'Q#7]_/_  3!U[0]6_X)[?LG
M7^E:SI6IV.G?!;POI6H7FGZC9WEI8ZIH%J^F:[IMY<6TTD-K?Z+J5E>:?JUG
M.Z7&FWUI<VEY'#<02QI_ !^T_<07?[2O[0UU:SPW-K<_'+XM7%M<V\B307$$
MWC[Q!)#/!-&S1RPRQLLD<D;,DB,K*Q4@U\SPTFLRSFZ:_>-:KK[>MH>WG7^Y
M99_U[7_IFD?WS_\ !)S_ )1T?LG?]DT_]V/7:_B&UOX)^(?VD/\ @HEXV^!7
MA:<66L_%']K#X@^$DU5[87L.@Z?J'Q,U[^V_$MS9?:K)KVS\,Z''J/B"]LXK
MJ"XNK339H+9Q/)&#_;;_ ,$CM1T_4_\ @G+^RK+IM_9:A':^ +S3KF2QNH+M
M+?4-.\5^(;34+"=X))%AO;&[BEM;RUD*SVMQ')#/&DB,H_C$\%?'S3OV<_\
M@J'>?'R<6>I>&O!'[7'C[6-?E2&?5(YO ^L?$'Q'HOBR^TF+3KNW>[U.+PEK
M&JWOA]XYIK8ZM'I\T]MJ%H);*YSR3VL<=Q"Z*O63KNDFM'55;$.FFGWE;1[E
MYFH2PV3*H[4FJ2J-.UH.G1YW?RC=W/[(]"^"7_!/[_@E#^SO+XSUGPOX6\'^
M%_#::!IGB;XJ^(_"C>.?BKX^\3WDUO9Z:+[4M/T74O$6I:CJVKJ]_::!H5II
MWA'PRTNHZC8:5X<T.VO[BVY+]E#_ (+&?LN_MD?'6W^ /PF\(_&^R\3WNF>)
M]8L?$7C+PKX*T?PA>:=X6MWN[JYBN-.^(NM^(XOM]NHETV&[\,VTY$B)?Q:?
M('1/:_VP_P!ESX,_\%-OV6[+P-;?$BV;PQJ^K:7\2?A1\6O %]8>+]%T[Q5I
M.GZ[H6F>((K:PU6VTGQCH;:=K_B#1M6T5M6LQ/%>7/V74M)UJRLM1L?B+]CG
M_@GI^R%_P2C\9>&?'/Q3^.]MXZ^/OQA\1:?\'/ACX@\4V%GX&L$G\8ZA';PZ
M%X%^']MK?B:Z@U;6GCM[/Q%XNUOQ'JT,5I;VNF:1_P (TNL:G9>(O"I_4<1A
M,34QE7&XC-Y3J1I4;5)6=E:<GRM-1?,ZJG4BTH\L:>B<O5G];I8BA##0PU++
MHQ@YU+P6E]8K56<E90<8M-N\IZV7S1_P<O?\D=_9>_[*7X[_ /46TJOSQ_X)
MF?\ !;+7?V/O UK\"/CUX3\0_%+X+:"\TG@'5?"3Z5_PL3X?V]]?M>ZCX<AM
M];O](TGQ7X7,]S>ZAHUIJ.L:5JF@W4]QIL.K7>@2:5IGA[]#O^#E[_DCO[+W
M_92_'?\ ZBVE5E_#'_@AG^R#^U1^R#^S=\4_AUX[\8_"?XG>,/@)\,M=\7^(
MO#>MV_Q)\%ZK\0]<\#Z+J7BZ\\0^$=?OFOK74]/\3W%[;7>@^&/&/@^PTPQ7
M6ERZ9!<HDMK[F#JY;#A_!4LSA.5"M7Q$8SA&4O93C5J-3YH/VD'9M)PC)M-Q
M:<6T_+Q%/&RS?%5,#.,:M*E1<HRDE[2$J<$XVDN22O9M3<4FDT^9(_9CX?\
MQ;_86_X*:?"_6K#P]>?#7]H7P;8B"W\3^#?%?A]D\3^#[G4<O:3ZGX5\4:?I
MWBSPK-<W.G3C1?$UE:VEIJ5WH]U/X<UN].F23P_RF_'_ /8K\+?L%_\ !7;]
MDWP7X;N[^?X,>,OCQ^SI\4O!$VOK->'0?#5[\;=,TS7?"&HZQ/&T>LR>%;_0
M[T+-*TVHMX:O_#\VLM<W]W+>7G]'/_!.7_@E_P##S_@FY:?$CQ5-\6]0^)OC
M#Q[I^D:7K_B[6O#FD^ ?#>A^'="O]1O[6TTC1CK/B2]T][V?4(&UR\U'Q=?V
MU])IFF/:V.F>5*L_\R'_  6/_;>\._M$?MM^'O%OP%\71ZGX1_9VT/0/"G@?
MQWHR6LVF:SX[T'Q/J7BW7/&?AF^EM2^IZ3;ZW=:9HNDWSM=Z'JR>%5U[0C=:
M1K45_J&.21OF6,PN75Z];+)8>JG.JI1BI3IQ4)6<(I5%4;C%\D)SIJ;Y6HLU
MS-I8+#5\93I4\=&M!J--IR:C.\DFI-N/(DY+FG&,W%<UVC^U7]IO]H3PG^RK
M\#/'OQ_\=>'_ !KXH\(_#JVT6]UW1?AYI6FZWXMFL]:\3:+X8^UZ=IVL:UX=
MTR2VTF;6XM7UJ>\UFQBL-"L=2O\ ?*ULMO+^.'_$2'^P[_T2O]JW_P (?X0_
M_/SK[8_9&_:^_9T_X*E_LQ:]X6U?^QI?$7BCP%J/@G]H3X&W.I2:;XAT!]:T
ME-%\2WFCPPZC_;LG@C59M1:X\%>.])N_.MO/L[>>_P!(\::3JFF:7^6_B+_@
MV=^%]SXSMK[PE^U9X]T3X>)>63WGA?Q%\,_#WBCQG/I\=Z9-1M;;QYIGBCPA
MH=I>76GXM;*^E^'%[!87H-_/IVI0$:<OFX'#Y31>(P^=QQ&'Q5*H^5Q]KRN'
M*ERVI0F[\R<HS:Y)QE%J5D=F*JYA45&MECHUJ%2"O?DNI7?O7G*.EFDXWYHR
MBTXIG(?MH_\ !>K]EGX\_LL_&[X+?#/X5?']/&7Q1\#:GX(TN[\=:+\.O#?A
MG38_$'EV.H:M?ZEH'Q'\:ZJSZ7I\MU?6>GV^@R+JM[!!IT]_I$%S)JEI_)[7
M]+__  4]_P"";G[!7[!G[&L"^'/$.M:S^T]XC\:^'(? >M^-?'5Y<>-?%&C#
M4WE\81VGP^\.G3/"D'A#1]"687/B.[\+*-.U4Z'I=QXI;5M<TW3M5_F@K[7(
MH8".%J3RZ%>%"=>5Y8B_-4E",(\\+M_N^B=D^9336A\SFL\6Z\(8R=*56%*.
ME&UH*3<N6>B]_JU=JSBTVG<***_KH_9:_P""!O['/QO_ &:_@'\9/$_Q2_:+
MA\2_%/X0?#SQ_P"(;7PEXV^%L?ARPUWQ9X5TO6]7TW28=0^#FK7]K;:9J%[<
M:>;.^U34+RREMI+2ZO;F>%Y7[,?F6%RV%.IBG-1J2<(\D'-\R7,[VM;0Y\)@
MJ^-E.%!1;A%2ES24=&[:7WU/Z,O#'_)&?#W_ &3'2?\ U%;>O\N6O]4NP\/6
M6G^&;/PI#+=-IUCH5OX>BFE>)KUK*VT]--CEDD2!(#=&! [NMLD1E)98%3$8
M_E9_;T_X(;_LD_LO?LC?&GX]^!?BM\>/^$N^'&AZ+JNA0?$/Q5\--3\):A>7
M_B[P]H?]D:C9:/\ #+P?J<USK4.JRZ3HIL_$%K+%KM[ILWV;5EC;2+_XOAG,
M<-A*V)I5G-3QM;#4Z"C!R3ES58^];X5>K'H^NFA]+G>"KXBE0G347'#4Z\JO
M-)1LN6D]+[Z4Y=NG<_E:HHHK]#/CPHHHH **** "BBB@ K^QD_\ *MM_W1I?
M_6A17\<U?V,G_E6V_P"Z-+_ZT**^>S_?*/\ L;X3\Y'KY1OC_P#L78C\X'\<
MU%%%?0GD!1110 4444 %%%% !7][/_!!K_E&Y\+?^QU^+7_J?ZU7\$U?WH?\
M$%;RTG_X)Q_#>U@NK::YL?''Q4CO;>*>*2>S>?QUK%Q EU"C-);O- Z3Q+,J
M&2%UE0,C!C\OQ;_R+*?EC*5__!5=?F>[P]_OT_\ L&J?^G*1X!^VG_P7AD_9
M%_:5^*O[.</[+">/I?AM<^'[.+QI)\;6\,1ZO)X@\%^'O%J32>&E^$>OM9)9
M-KXL'A7Q#=-=+9FY$]J;@00?BC^V!_P7*_:V_:A\,^(OAQX4MM _9[^&GB":
MS2[L_AQJ/B"3XC:CHT5J%U#PYKWQ*FOK"2?1]8OFDEU*#PQX:\'OJ&DK#X;U
M5]2TBXUR'6_$?^"Q^HZ?JO\ P4I_:AO=+OK/4K-M?\"6ZW=A=07EL;BQ^$O@
M&QO8!/;O)$9K.]MKBSNH@^^WNH)K>94FB=%_,JNC*\FRR&&P6*^J0>(EAL/5
ME.I*K4_>RITYRFH5)RIQESZKE@N7:-EH8X[,L=*MB:'UB2I1K5J:C",(/D4Y
M147.$8S:Y='>3OUN?5O[!_\ R?%^QG_V=;^SO_ZM[P?7]L/_  6\_P"47_[3
MG_=%_P#UH7X3U_$E^Q!J.GZ/^VE^R%JVK7UGI>E:7^U#\ =1U/4]1NH++3].
MT^R^*_A.YO;Z^O;EXK:TL[2VBDN+JZN)(X+>"-Y972-&8?VS_P#!;^YMXO\
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M?A[IMIX7A#VDEE>ZUHW@'XBZWX>\0>(M&M[M3=KX=O[K4?".HI()&AN+;6M
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M:3J?B?[ 7_!'CX'_ + /BZ\^-WB'XDWGQ?\ BK8:-K&CZ1XT\2^&]$\$>$?
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MLW5M)U[Q#J]Y:Z[9:N?M%GJ5YI^IZ;?^7I-UI/K'["OP1_9"_8<N;_\ 8O\
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MQ=1_]+I'K5?^1-AO^PRK_P"D2/S^HHHKZ$\D_P!(;]EC_E&Q^SE_V8[\(?\
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MH^7_  22G3^?)*-S^G__ (-FO^2B_M9_]B5\*O\ T^^,Z]__ .#A+]H?X]?
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ME^.WAO55TNVG>.'-AI,5S'IFG11P6\%M86EM;6UM;6\44$?]BG_!;S_E%_\
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MSO;?4M2N;[R+*7[;/&2\THU<'C\;EF'CRT<PK82<(ZV=Y<T(Q6ND:U24;Z_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^@?_!*K
M_E(C^R7_ -E7T[_TV:I7Y^5^@?\ P2J_Y2(_LE_]E7T[_P!-FJ5RX[_<L9_V
M"XC_ -,S.C"?[WA?^PBC_P"G(GZ)_P#!R1_R>?\ !_\ [-A\,?\ JUOB_7\]
M-?T+?\')'_)Y_P '_P#LV'PQ_P"K6^+]?STUR9'_ ,BG ?\ 7A?^E2.C-?\
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M*** "BBB@ K^QG_@FU_R@@_:7_[)Q^V9_P"J\UZOXYJ_L9_X)M?\H(/VE_\
MLG'[9G_JO->KP.(O]TPO_8QPG_I4SV,E_P!YK_\ 8'7_ #@?QS4445[YXX44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?TN_\&TG_ "7+]IC_ +)1X2_]2^2O
M["Z_CT_X-I/^2Y?M,?\ 9*/"7_J7R5_877Y=Q-_R.,3_ (,/_P"F*9]SD?\
MR+J7^.K_ .G)'XG?\' '_*.[Q'_V5?X7_P#ISOJ_A(K^[?\ X. /^4=WB/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K] _^"57_*1']DO_ +*OIW_ILU2OS\K] _\
M@E5_RD1_9+_[*OIW_ILU2N7'?[EC/^P7$?\ IF9T83_>\+_V$4?_ $Y$_1/_
M (.2/^3S_@__ -FP^&/_ %:WQ?K^>FOZ%O\ @Y(_Y//^#_\ V;#X8_\ 5K?%
M^OYZ:Y,C_P"13@/^O"_]*D=&:_\ (PQ7_7Q?^D1"BBBO5//"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /ZH_^#9'_ )"W[9__ &#O@!_Z4_&6OYTOVI/^
M3FOVB_\ LNWQ=_\ 5@>(:_HM_P"#9'_D+?MG_P#8.^ '_I3\9:_G2_:D_P"3
MFOVB_P#LNWQ=_P#5@>(:^>P/_)0YW_UZP'_J/3/6Q/\ R*<M_P"OF+_].L\)
MHHHKZ$\D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_L9/_*MM_W1I?\
MUH45_'-7]C)_Y5MO^Z-+_P"M"BOGL_WRC_L;X3\Y'KY1OC_^Q=B/S@?QS444
M5]">0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>\?LL?\G._LY?]EX^$
M/_JP?#U>#U[Q^RQ_R<[^SE_V7CX0_P#JP?#U95_X%;_KU4_](D:4?XM+_KY#
M_P!*1_13_P '-W_(9_8R_P"P9\??_2KX.U_*]7]4/_!S=_R&?V,O^P9\??\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /Z7?\ @VD_Y+E^TQ_V2CPE_P"I?)7]A=?QZ?\ !M)_R7+]IC_L
ME'A+_P!2^2O["Z_+N)O^1QB?\&'_ /3%,^YR/_D74O\ '5_].2/Q._X. /\
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M^T?ZR9+_ -!O_EOB_P#Y0']BYG_T#?\ E;#_ /RT_E+HK^K3_B&,_P"KW/\
MS6S_ /'[1_Q#&?\ 5[G_ )K9_P#C]H_UDR7_ *#?_+?%_P#R@/[%S/\ Z!O_
M "MA_P#Y:?RET5_5I_Q#&?\ 5[G_ )K9_P#C]H_XAC/^KW/_ #6S_P#'[1_K
M)DO_ $&_^6^+_P#E ?V+F?\ T#?^5L/_ /+3^4NBOZM/^(8S_J]S_P UL_\
MQ^T?\0QG_5[G_FMG_P"/VC_63)?^@W_RWQ?_ ,H#^Q<S_P"@;_RMA_\ Y:?R
MET5_5I_Q#&?]7N?^:V?_ (_:/^(8S_J]S_S6S_\ '[1_K)DO_0;_ .6^+_\
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M;/\ \?M'^LF2_P#0;_Y;XO\ ^4!_8N9_] W_ )6P_P#\M/Y2Z*_JT_XAC/\
MJ]S_ ,UL_P#Q^T?\0QG_ %>Y_P":V?\ X_:/]9,E_P"@W_RWQ?\ \H#^Q<S_
M .@;_P K8?\ ^6G\I=%?U:?\0QG_ %>Y_P":V?\ X_:/^(8S_J]S_P UL_\
MQ^T?ZR9+_P!!O_EOB_\ Y0']BYG_ - W_E;#_P#RT_E+HK^K3_B&,_ZO<_\
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M(8S_ *O<_P#-;/\ \?M'_$,9_P!7N?\ FMG_ ./VC_63)?\ H-_\M\7_ /*
M_L7,_P#H&_\ *V'_ /EI_*717]6G_$,9_P!7N?\ FMG_ ./VC_B&,_ZO<_\
M-;/_ ,?M'^LF2_\ 0;_Y;XO_ .4!_8N9_P#0-_Y6P_\ \M/Y2Z*_JT_XAC/^
MKW/_ #6S_P#'[1_Q#&?]7N?^:V?_ (_:/]9,E_Z#?_+?%_\ R@/[%S/_ *!O
M_*V'_P#EI_*717]6G_$,9_U>Y_YK9_\ C]H_XAC/^KW/_-;/_P ?M'^LF2_]
M!O\ Y;XO_P"4!_8N9_\ 0-_Y6P__ ,M/Y2Z*_JT_XAC/^KW/_-;/_P ?M'_$
M,9_U>Y_YK9_^/VC_ %DR7_H-_P#+?%__ "@/[%S/_H&_\K8?_P"6G\]7[$7_
M ">A^R)_V<_\ O\ U:WA.OUO_P""[.N:CXDT?]B#6M6^*^D_&_4+WP+\;_M'
MQ0T/0+#PQI?B?[-\2=.M(OLNAZ9;VMC8_P!BP01^'I_(@3[3<:3->2;IKB1V
M^]?@C_P;J?\ "F_C1\(OB\/VP_\ A(S\*OB?X!^)'_"/?\,^?V1_;W_"#>*]
M)\3_ -C?VM_PN_4_[+_M3^R_L/\ :/\ 9NH?8O/^T_8;OROL\GTA^US_ ,$I
M?$O_  4-\'_L_:[XO^)OP^_9H\0_"W0OB'HNH>"_A9\,(/B%X$N/^$F\:-J-
MK<Z%=6WQ(\&P:;FQTVVN]3ACCU'[1K.I:B[2V[Q-&_CXG.LLJ9QEV*AB;X>A
M1Q4*M3V.(7)*I3E&"Y'24Y7;2O&,DNK2/2HY;C89;C,/*A:M5JT94X>THOFC
M"<')\RJ<JLD]')-]$S^&RBOZM/\ B&,_ZO<_\UL__'[1_P 0QG_5[G_FMG_X
M_:]C_63)?^@W_P M\7_\H/-_L7,_^@;_ ,K8?_Y:?RET5_5I_P 0QG_5[G_F
MMG_X_:/^(8S_ *O<_P#-;/\ \?M'^LF2_P#0;_Y;XO\ ^4!_8N9_] W_ )6P
M_P#\M/Y2Z*_JT_XAC/\ J]S_ ,UL_P#Q^T?\0QG_ %>Y_P":V?\ X_:/]9,E
M_P"@W_RWQ?\ \H#^Q<S_ .@;_P K8?\ ^6G\I=%?U:?\0QG_ %>Y_P":V?\
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MC_63)?\ H-_\M\7_ /* _L7,_P#H&_\ *V'_ /EI_*717]6G_$,9_P!7N?\
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MO_0;_P"6^+_^4!_8N9_] W_E;#__ "T_E+HK^K3_ (AC/^KW/_-;/_Q^T?\
M$,9_U>Y_YK9_^/VC_63)?^@W_P M\7_\H#^Q<S_Z!O\ RMA__EI_*717]6G_
M !#&?]7N?^:V?_C]H_XAC/\ J]S_ ,UL_P#Q^T?ZR9+_ -!O_EOB_P#Y0']B
MYG_T#?\ E;#_ /RT_E+HK^K3_B&,_P"KW/\ S6S_ /'[1_Q#&?\ 5[G_ )K9
M_P#C]H_UDR7_ *#?_+?%_P#R@/[%S/\ Z!O_ "MA_P#Y:?RET5_5I_Q#&?\
M5[G_ )K9_P#C]H_XAC/^KW/_ #6S_P#'[1_K)DO_ $&_^6^+_P#E ?V+F?\
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M5_5I_P 0QG_5[G_FMG_X_:/^(8S_ *O<_P#-;/\ \?M'^LF2_P#0;_Y;XO\
M^4!_8N9_] W_ )6P_P#\M/Y2Z*_JT_XAC/\ J]S_ ,UL_P#Q^T?\0QG_ %>Y
M_P":V?\ X_:/]9,E_P"@W_RWQ?\ \H#^Q<S_ .@;_P K8?\ ^6G\I=%?U:?\
M0QG_ %>Y_P":V?\ X_:/^(8S_J]S_P UL_\ Q^T?ZR9+_P!!O_EOB_\ Y0']
MBYG_ - W_E;#_P#RT_E+HK^K3_B&,_ZO<_\ -;/_ ,?M'_$,9_U>Y_YK9_\
MC]H_UDR7_H-_\M\7_P#* _L7,_\ H&_\K8?_ .6G\I=%?U:?\0QG_5[G_FMG
M_P"/VC_B&,_ZO<_\UL__ !^T?ZR9+_T&_P#EOB__ )0']BYG_P! W_E;#_\
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M/^KW/_-;/_Q^T?\ $,9_U>Y_YK9_^/VC_63)?^@W_P M\7_\H#^Q<S_Z!O\
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M+HK^K3_B&,_ZO<_\UL__ !^T?\0QG_5[G_FMG_X_:/\ 63)?^@W_ ,M\7_\
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MU:?\0QG_ %>Y_P":V?\ X_:/^(8S_J]S_P UL_\ Q^T?ZR9+_P!!O_EOB_\
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MV'_^6G\I=%?U:?\ $,9_U>Y_YK9_^/VC_B&,_P"KW/\ S6S_ /'[1_K)DO\
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M9_U>Y_YK9_\ C]H_XAC/^KW/_-;/_P ?M'^LF2_]!O\ Y;XO_P"4!_8N9_\
M0-_Y6P__ ,M/Y2Z*_JT_XAC/^KW/_-;/_P ?M'_$,9_U>Y_YK9_^/VC_ %DR
M7_H-_P#+?%__ "@/[%S/_H&_\K8?_P"6G\I=%?U:?\0QG_5[G_FMG_X_:/\
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MU:?\0QG_ %>Y_P":V?\ X_:/^(8S_J]S_P UL_\ Q^T?ZR9+_P!!O_EOB_\
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MHK^K3_B&,_ZO<_\ -;/_ ,?M'_$,9_U>Y_YK9_\ C]KU?]9,E_Z#?_+?%_\
MR@X/[%S/_H&_\K8?_P"6G\I=%?U:?\0QG_5[G_FMG_X_:/\ B&,_ZO<_\UL_
M_'[1_K)DO_0;_P"6^+_^4!_8N9_] W_E;#__ "T_E+HK^K3_ (AC/^KW/_-;
M/_Q^T?\ $,9_U>Y_YK9_^/VC_63)?^@W_P M\7_\H#^Q<S_Z!O\ RMA__EI_
M*717]6G_ !#&?]7N?^:V?_C]H_XAC/\ J]S_ ,UL_P#Q^T?ZR9+_ -!O_EOB
M_P#Y0']BYG_T#?\ E;#_ /RT_E+HK^K3_B&,_P"KW/\ S6S_ /'[1_Q#&?\
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M_P#+3^4NBOZM/^(8S_J]S_S6S_\ '[1_Q#&?]7N?^:V?_C]H_P!9,E_Z#?\
MRWQ?_P H#^Q<S_Z!O_*V'_\ EI_*717]6G_$,9_U>Y_YK9_^/VC_ (AC/^KW
M/_-;/_Q^T?ZR9+_T&_\ EOB__E ?V+F?_0-_Y6P__P M/Y2Z*_JT_P"(8S_J
M]S_S6S_\?M'_ !#&?]7N?^:V?_C]H_UDR7_H-_\ +?%__* _L7,_^@;_ ,K8
M?_Y:?RET5_5I_P 0QG_5[G_FMG_X_:/^(8S_ *O<_P#-;/\ \?M'^LF2_P#0
M;_Y;XO\ ^4!_8N9_] W_ )6P_P#\M/Y2Z*_JT_XAC/\ J]S_ ,UL_P#Q^T?\
M0QG_ %>Y_P":V?\ X_:/]9,E_P"@W_RWQ?\ \H#^Q<S_ .@;_P K8?\ ^6G\
MI=%?U:?\0QG_ %>Y_P":V?\ X_:/^(8S_J]S_P UL_\ Q^T?ZR9+_P!!O_EO
MB_\ Y0']BYG_ - W_E;#_P#RT_E+HK^K3_B&,_ZO<_\ -;/_ ,?M'_$,9_U>
MY_YK9_\ C]H_UDR7_H-_\M\7_P#* _L7,_\ H&_\K8?_ .6G\I=%?U:?\0QG
M_5[G_FMG_P"/VC_B&,_ZO<_\UL__ !^T?ZR9+_T&_P#EOB__ )0']BYG_P!
MW_E;#_\ RT_E+HK^K3_B&,_ZO<_\UL__ !^T?\0QG_5[G_FMG_X_:/\ 63)?
M^@W_ ,M\7_\ * _L7,_^@;_RMA__ ):?RET5_5I_Q#&?]7N?^:V?_C]H_P"(
M8S_J]S_S6S_\?M'^LF2_]!O_ );XO_Y0']BYG_T#?^5L/_\ +3^4NBOZM/\
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M^/VC_B&,_P"KW/\ S6S_ /'[1_K)DO\ T&_^6^+_ /E ?V+F?_0-_P"5L/\
M_+3^4NBOZM/^(8S_ *O<_P#-;/\ \?M'_$,9_P!7N?\ FMG_ ./VC_63)?\
MH-_\M\7_ /* _L7,_P#H&_\ *V'_ /EI_*717]6G_$,9_P!7N?\ FMG_ ./V
MC_B&,_ZO<_\ -;/_ ,?M'^LF2_\ 0;_Y;XO_ .4!_8N9_P#0-_Y6P_\ \M/Y
M2Z*_JT_XAC/^KW/_ #6S_P#'[1_Q#&?]7N?^:V?_ (_:/]9,E_Z#?_+?%_\
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M?^:V?_C]H_XAC/\ J]S_ ,UL_P#Q^T?ZR9+_ -!O_EOB_P#Y0']BYG_T#?\
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M_5[G_FMG_P"/VC_B&,_ZO<_\UL__ !^T?ZR9+_T&_P#EOB__ )0']BYG_P!
MW_E;#_\ RT_E+HK^K3_B&,_ZO<_\UL__ !^T?\0QG_5[G_FMG_X_:/\ 63)?
M^@W_ ,M\7_\ * _L7,_^@;_RMA__ ):?RET5_5I_Q#&?]7N?^:V?_C]H_P"(
M8S_J]S_S6S_\?M'^LF2_]!O_ );XO_Y0']BYG_T#?^5L/_\ +3^4NBOZM/\
MB&,_ZO<_\UL__'[1_P 0QG_5[G_FMG_X_:/]9,E_Z#?_ "WQ?_R@/[%S/_H&
M_P#*V'_^6G\I=%?U:?\ $,9_U>Y_YK9_^/VC_B&,_P"KW/\ S6S_ /'[1_K)
MDO\ T&_^6^+_ /E ?V+F?_0-_P"5L/\ _+3^4NBOZM/^(8S_ *O<_P#-;/\
M\?M'_$,9_P!7N?\ FMG_ ./VC_63)?\ H-_\M\7_ /* _L7,_P#H&_\ *V'_
M /EI_*717]6G_$,9_P!7N?\ FMG_ ./VC_B&,_ZO<_\ -;/_ ,?M'^LF2_\
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M^T?ZR9+_ -!O_EOB_P#Y0']BYG_T#?\ E;#_ /RT_E+HK^K3_B&,_P"KW/\
MS6S_ /'[1_Q#&?\ 5[G_ )K9_P#C]H_UDR7_ *#?_+?%_P#R@/[%S/\ Z!O_
M "MA_P#Y:?RET5_5I_Q#&?\ 5[G_ )K9_P#C]H_XAC/^KW/_ #6S_P#'[1_K
M)DO_ $&_^6^+_P#E ?V+F?\ T#?^5L/_ /+3^4NBOZM/^(8S_J]S_P UL_\
MQ^T?\0QG_5[G_FMG_P"/VC_63)?^@W_RWQ?_ ,H#^Q<S_P"@;_RMA_\ Y:?R
MET5_5I_Q#&?]7N?^:V?_ (_:/^(8S_J]S_S6S_\ '[1_K)DO_0;_ .6^+_\
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M;/\ \?M'^LF2_P#0;_Y;XO\ ^4!_8N9_] W_ )6P_P#\M/Y2Z*_JT_XAC/\
MJ]S_ ,UL_P#Q^T?\0QG_ %>Y_P":V?\ X_:/]9,E_P"@W_RWQ?\ \H#^Q<S_
M .@;_P K8?\ ^6G\I=%?U:?\0QG_ %>Y_P":V?\ X_:/^(8S_J]S_P UL_\
MQ^T?ZR9+_P!!O_EOB_\ Y0']BYG_ - W_E;#_P#RT_E+HK^K3_B&,_ZO<_\
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M(8S_ *O<_P#-;/\ \?M'_$,9_P!7N?\ FMG_ ./VC_63)?\ H-_\M\7_ /*
M_L7,_P#H&_\ *V'_ /EI_*717]6G_$,9_P!7N?\ FMG_ ./VC_B&,_ZO<_\
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MK)DO_0;_ .6^+_\ E ?V+F?_ $#?^5L/_P#+3^4NBOZM/^(8S_J]S_S6S_\
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M ./VC_B&,_ZO<_\ -;/_ ,?M'^LF2_\ 0;_Y;XO_ .4!_8N9_P#0-_Y6P_\
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M+HK^K3_B&,_ZO<_\UL__ !^T?\0QG_5[G_FMG_X_:/\ 63)?^@W_ ,M\7_\
M* _L7,_^@;_RMA__ ):?RET5_5I_Q#&?]7N?^:V?_C]H_P"(8S_J]S_S6S_\
M?M'^LF2_]!O_ );XO_Y0']BYG_T#?^5L/_\ +3^4NBOZM/\ B&,_ZO<_\UL_
M_'[1_P 0QG_5[G_FMG_X_:/]9,E_Z#?_ "WQ?_R@/[%S/_H&_P#*V'_^6G\I
M=%?U:?\ $,9_U>Y_YK9_^/VC_B&,_P"KW/\ S6S_ /'[1_K)DO\ T&_^6^+_
M /E ?V+F?_0-_P"5L/\ _+3^4NBOZM/^(8S_ *O<_P#-;/\ \?M'_$,9_P!7
MN?\ FMG_ ./VC_63)?\ H-_\M\7_ /* _L7,_P#H&_\ *V'_ /EI_*717]6G
M_$,9_P!7N?\ FMG_ ./VC_B&,_ZO<_\ -;/_ ,?M'^LF2_\ 0;_Y;XO_ .4!
M_8N9_P#0-_Y6P_\ \M/*/^#:3_DN7[3'_9*/"7_J7R5_877X]?\ !-'_ ()/
M?\.[O'/Q,\:?\+\_X7!_PL7PGI/AC^S?^%6?\*__ +'_ ++UAM5^W?;/^%C>
M-O[0\_=]G^S?9;'RL>;]HD_U=?L+7P6>XJAC,RK8C#5/:49QHJ,^6<+N-*$9
M>[4C&2M)-:Q5]U='U>54*N&P5.E7AR5(RJ-QYHRLI3;6L)2CJGT?J%%%%>0>
MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5X+^S%H>G>&_@=X(T72?A1JWP0T^R_X27[/\+]<UZ_\ $^J>&/M/B_7[
MN7[5KFISW-]??VU//)XA@\^=_LUOJT-G%MAMXT7WJOG[]EG4=%U7X#^!;_P[
MXS^)'Q!T>X_X2?['XO\ BY)=S?$/5_*\9>(8;C_A()+X"Z;[!=1SZ9I/FCC0
M[+353]V$H ^@:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[3XOU^[E^U:YJ<]S?7W]M3SR>(8//G?[-;ZM#9Q;8;>-%]ZKY^_99U'1=5^
M_@6_\.^,_B1\0='N/^$G^Q^+_BY)=S?$/5_*\9>(8;C_ (2"2^ NF^P74<^F
M:3YHXT.RTU4_=A* /H&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKP7^P]._X:@_X27_ (51JW]K_P#"A?[#_P"%X_V]?_V'_9W_  L+[?\ \*H_
MX1?S_P"R_P"UOM/_ !5_]O?9?M_V/_B7>?\ 9_W=>]5\_?VCHO\ PU3_ &3_
M ,)G\2/^$B_X9]_M'_A7OF7?_"H?[%_X6-]F_P"$S\G'V'_A9'V[_B1^9G[7
M_P (Q\N/)H ^@:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\:_9^U35=:^$7A+4M;^+.A?'+5+G^WOM7Q2\-:5H^B:)XH\GQ/K5O#
M]BTS0%72;;^Q+>*+P[<_9%'G7>D3W$^;F68GV6O&OV?M/UO2OA%X2L/$7@SX
M;_#W68/[>^V>$/A'':0_#W2/-\3ZU-;_ /"/QV)-JOV^UD@U35O*)SKE[J3/
M^\+T >RT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]%
M&Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\
MD7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=
M']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T
M[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUC
MT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O
M_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_
M^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:
MW_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[
M76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?
M].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\
MD7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;
M']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1
M?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?
MVM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O
M_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/1
M0!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__
M )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[
M71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?
M].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=
M8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T
M[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1
M?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?
MVM_T[_\ D7_[71_:W_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_
M^UUCT4 ;']K?].__ )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:
MW_3O_P"1?_M=8]% &Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__
M )%_^UT?VM_T[_\ D7_[76/10!L?VM_T[_\ D7_[71_:W_3O_P"1?_M=8]%
M&Q_:W_3O_P"1?_M=']K?].__ )%_^UUCT4 ;']K?].__ )%_^UT?VM_T[_\
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MPCDNX?B'I'F^,O#T-O\ \(_)8@W2_;[J2#3-6\H<Z'>ZDK_NR]?0- !1110
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M=1SZ9I/FCC0[+353]V$H ^@:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O!?[)T'_AJ#^W?^%6>)/^$H_P"%"_V3_P +M^VZI_PB']@_\+"^V?\
M"K/[/^V?V)_PDG]H?\5;]M^P?VI_9G[C[9]D_<U[U7S]_:.B_P##5/\ 9/\
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MKC\'3J.C.O"-7;E]ZT7;:4TG"+\I231\Q_\ !+C_ (*N?MU_M+_M^?!KX/\
MQC^,=CXF^%_Q D^*LFM^#;;X:?"W0+6!="^$WQ \::'#INMZ!X-TWQ7!'I>L
MZ!I@A-QX@NYKJTA>#4I;YII)6_L%K_/E_P""'W_*4/\ 9A_[K3_ZSS\6:_T&
MJ^D\6LNR_+.(\%0R[ X3 4)Y)AJLJ.#P]'#4I57CLRINK*G1A",JDH4Z<93:
M<I1A%-M11QY+5JUL+4E5J3J26(FE*I.4VE[.DTDY-M)-MI+2[?<*_C3_ .";
MG_!7;]O7XX_MO_!'X3?%SXOZ3XX^'/Q(\1:WH6N^%[KX8_#'0(;:W?PYK>JV
MEUI6K^#O"7ASQ'!>:9=:?;_8S=:S>VLL7F)J5K?E@R_V65_FT?\ !-KXH^ ?
M@G^V]^S_ /%?XH^([;PE\/\ P)XEUO7_ !5XBN[;4+V+3-,MO!?B9'D2PTFT
MO]5U&YFFDBMK+3=+L+W4M0O)X+*PM+F[GAA??PXRG!9IDW'/UC+<-F&*H99A
M_J#JX2GB<11Q%3"YPXO!N4)U:5:I4I4;.ARU)3A3M=QB+-*U2CB,NY:LZ4)5
MI>UM-PA*"G0O[2S2<4G+XM$F^[/])>BOY?\ Q=_P<S_#33_%TVG^"/V4O&7B
MCP1%JQMH_%'B'XIZ1X/\0W&C++ AU2+P?9>!_%]DMX\9NY8=*G\7PHPBM4FU
M*W:ZG^P_M=^Q%^WA\#_V]/AUJOCSX.S:]I][X5OM.T?QUX+\5V$-AXD\):OJ
M=B;ZSCN#9W-]INI:7J"PWJZ5K&G7LUO>G3[V.6.SN[:YM(?C<UX.XFR3!QQ^
M9Y37PN#DX)U_:8>M&FZC48*O'#UJL\.Y2DH15>-.\VH?$TCNHX["8B;IT:T9
MS5_=M*+=M7RN48J5EK[K>FNQ]I45^+&D_P#!>/\ 8HU#X[0? 34=!^/'A?69
M/B!/\-KCQIXC\"^%K;P-IWB*'5)=##ZD^G_$#4O&EIITFM1KIAN6\%M):RRK
M<ZA;V>G1W-[;_M/7F9EDV:Y.Z"S/ XC!/%4_;8?V\.55J:M>4))M/EYH\T;\
MT>:/,ES1OK2KT:_,Z-2-3D?++E=^5[V?]6T?9A17X^:'_P %M_V0O$G[4MG^
MR;H?ASXVZIXUU+XR/\$--\;Z;X6\#:I\,-2\5?\ "3R>$(-6L-;TSXDWOB*Z
M\(7FL(&MO$$/A1HSILB:O-;PZ8);J/\ 8.IS'*,SREX>.98*O@WBJ*Q&'5>/
M*ZM&6BG%7>E]&G9IZ-(=*O2K<SI5(U%"7++E=[2[/^K'F/QM^)MG\%/@S\7/
MC)J.E7.NZ?\ "7X8^/OB;?:)97$5I>:Q9^ _"NK>*KK2K2ZG22"VN=0@TI[2
M"XFCDBAEF221&12I_'?_ ()[?\%M=(_;I_:!A^ 5_P#LXZE\)=1U/PEXA\2:
M'XCM/BG:_$.RN+KPW%!>WFFZK83?#_P%/IEO-IINY;;4;.?69&OH;>SETZ*W
MN9-0M/TG_;S_ .3&OVSO^S4/VBO_ %4'C"OXWO\ @@)_RD;\$?\ 9-?BK_ZC
M35]UPKP[E&9\'<79KC<*ZN/RNC4G@:ZKXBG["5/"3K)^RI584:O--+F5:G45
ME:/*>?C,57HX[ T:<^6G6DE4CRQ?,G-1W:<E9/3E:\[G]Z%?@I^WA_P7&TS]
MB;]IGQ#^SL/V:;[XFKX5T?P=J>L>,3\6[?P66F\5Z)9^(FM=,\._\*W\6"[C
MT_3-1LE%S=:[I[7E^;JV-K:V\$5[<_O77\!G_!=__E)=\:/^Q8^$'_JK/"E<
M_AGD65<0\08C YOAGB\+3RK$XF-)5\1A[5H8G!TH3Y\-5HU'RPK5%RN?*VTW
M%M*U9MB:V%PT:E"?)-UH0;Y8R]UQFVK34EJXK6U^S/[N/A;X[L_BE\,OAU\3
M=.L;G2]/^(W@3PCX[L=,O9(I;S3K/Q=X?T_Q!:V-W+ 3!)<VD&H);SR0DQ/+
M&[1G817=U\[_ +(7_)IO[+__ &;O\%/_ %6OAFOHBOA<93A1Q>*HTU:%+$UZ
M<$VVU"%648IMW;LDM7J^IZ%-N5.$GO*$6_5Q3?XGA7[1_P"T?\)/V4?A)XE^
M-/QI\2Q>'/!WAR)8HHHECN==\3:[<QS/I/A+PEI+S02:WXGUN2"6.PL(Y88(
M8(;S5=5O--T+3=5U6Q_E1^)G_!RS^T/?>(]2?X-_ #X,>%_"(ND72+?XF3>.
M/'?B-[**)HY)]2O?"WBKX<Z9%=7TX2\2UM;":+2HF;36O-9=!JLGU1_P<TZO
MKT/PJ_93T&WOM1C\+ZE\0?B3J^L:;%),-)N]>T3PYX;L_#=]>Q+_ *.^HZ?I
M^O\ BJ#2Y)?WT5MJ>L+!\DMQ4/\ P;@^//V:[/X:?$KP#')X1TC]JC5_&^LZ
ME>-J2:?;>-O%_P *[70_#4^EV7AJ]N+A]0U+0?#^JVVLWNKZ-IR01VEW*-6N
M[2=<7L7ZSP]D61Y7P1/C',LEGQ'B:U>I3A@G6J4:&$P]+%3PLJE3V<*BBN:E
M*I5KU*5;EC*E3A&DG5G+QL3B,16S#ZC2Q"PL8Q3=3E4I3DX*:2NUTDDHJ4;V
M;=W9'8?\$\?^"\7C']I_X\^ /V=_C9\#O#6B>(/B5<W6D^'_ !Y\+-7U2UT>
MRUVSTN]U40:QX,\6WFLWL>DWMO876=3LO&5W>:=-'!!_8VJ1WDEU8?THU\WW
M_P"R!^S'J/Q@\#_'V;X)^!+;XP?#C[1_PB'CG2=*_L/4]/%SI&N:&RWEOHLN
MGZ9KR0:=XCU9;!/$-CJJ:9>2VNJ:<MKJFF:7>67TA7Y]Q'CLBS#%T,1D.55<
MGHRPL5B\).NZ]-8Q5:KE/#SE.3]BZ+HJW)17.IVHQ7O3]+"T\32A*.)K*O)3
M?)-147R<L;*227O*7-K>6C6O1%%%%?/'4>#_ +3_ ,>-(_9A_9_^*_Q]US0=
M2\4Z=\+_  E>>)'\.:3<VME>ZW=)+!9:;IJW]X'@T^WNM2O+2*^U$P7LFGV+
M7-Y!IVIW$$6GW/\ -W_Q$]?]60?^;*__ (@:_:C_ (*U?\HY/VLO^R:I_P"I
M+H%?RS?\&_WPD^%/QF_;(^)?A?XP?#+X>_%;PU8?LS>,M>L?#OQ)\%^&_'6A
M66NVOQ3^#.GVVM6FD>*--U33[?5K?3]4U.Q@U&&W2\AL]1O[:.98;RX23];X
M+R/AFOPEGO$.?954S.>5XR48PIXW&867L(8?"SY(+#XFA3<G.O)N512=DDFD
MCQ<PQ&+CC<-AL-65%5H*[=.$_><Y*[YXR=DHK16/O'_B)Z_ZL@_\V5__ ! U
M^[O[<?[:^D?L4_LP7/[1^J_#CQ#XVFEU+P?HNC> )M3M?!NH-J_BYQ+':>)=
M6N;+7F\.KI=E#?'4#:Z+K]TNIV\&G+9^3/-J%GVL'["?[$-M-#<VW[&_[*MO
M<6\L<]O<0?L\_".*:":)Q)%-#+'X062*6)U5XY$971U#*00#7YS?\'"'_*/+
M4O\ LLOPR_\ 0M>KR:;X/S_B'AK+\HX?Q&5X6OF4*.9PK9CB\0\91K5*"ITX
MRGB:DZ"@HUU*=&=.<E55I)QBX[/Z]AL+BZM?$PK3C2YJ+C2A'DE%2NVE"*E=
MN-E)->[MJT? W_$3U_U9!_YLK_\ B!KU'X7?\'+_ ,'-=UJWL?C!^S-X_P#A
MOHUQ<I VN>!_'VB?%1K**4*HO;[2]4\-?"^X%M!*Q:[33YM1O$M$>:SM+ZZ\
MNQD^5_\ @W4^ WP-^-W_  V'_P +H^#'PG^+O_",?\,^_P#"-_\ "S_AUX0\
M??\ "/?VU_PN_P#MC^P_^$KT?5O[)_M;^R=*_M/[!]G^W_V9I_VKS?L=MY?Z
MV?ML_P#!$[]D[X_?#3Q'/\$_AMX8^ OQHTK3=:U3P/J_PZTNR\-^$M;UV5X]
M0A\.^+_"=FUEH+Z+JDMN^E6=_IT>EW7A7[>M]:&[TZQ?0KWZO.L/X891G^)X
M<QW#^.P;HRPU.>:T,RQ]6G1>+PM#$QJNE5QM1J%-5XQJ-T:S7+*2IR6AQX>6
M;U\-#%4\33GS<S5&5*G%RY)R@US1IQU?*[>]'=*Z>WZ7_L[?M-? []JSX>V7
MQ.^ _P 0=$\>>&+EEM]02QF-OKWAG5-I:30O%_AR[$.M>%];C5?.73]9LK62
M\L9+;5M.-[I%]8W]S[Q7^>C_ ,$E_P!JKQI^R#^VO\/]-EDN].\&?%KQ=X?^
M"OQ@\-:AI<\LT=AK_B*WT;3M3FT]S!?V&M>"?$EU!J1D@C?4H;%-<TI;&\_M
M&:QG_P!"ZOA..>$GPEFT,-1K3Q& QE'ZS@:U3E]KR*7)4HUG%1A*K1E:\X)1
MG3G3GRP<G"/HY=C?KM%SE%1JTY<E2*VO:ZE%.[2DNC;:::N[7/R;_P""FG_!
M53PQ_P $Z+CX5Z"/A/<_&7QG\38?$6KMH$7CF/P!9^&O#'A]["S36+_5W\(^
M,YKNYUK5;][+2=-MM)2-XM)UJYO=1LFMK"VU/Q7_ ()X?\%LO#G[=GQ\E^ F
ML_ @_!36+[P5K_BCPEJ[?%.7XAQ^*-7\.3:=<:AX66PB^&7@P:9<_P#".3:S
MXCBU&XOYK5K?P]>69C%W<V:R_P ]W_!1GQKJ7[>W_!6?4/AMX4>YUS1H?B=X
M&_99\#C2+AI)(]*\-^(E\/\ BN_M-0N8+JQAT_\ X3?5O'GB2/5TLFT2STFX
M74YC?6<-QJ5YY!X\T_5?^"6?_!4J]GT2PUY= _9_^.MGXE\.Z9#K"#7/$?P/
M\3>5J]EH)U^&0V]Q?>*/A!XG?PUJMW,ODM?7VH6VKZ=$R7^E1_IF7^'O#U;A
MS#8"MA6^+\;P]B,XHU'B\5"=.<I0="$\,L3'#*-*IB</A)\V':ERU).7.E(\
MFKF>*CBIU8S_ -AIXJ-"2Y(--)>^U+EY[M1E->]U2M;0_P!#ZBL'PMXFT+QK
MX8\.>,O"^HQZOX9\6Z#I'B;P[JT,<\,.IZ%KVGV^JZ1J,45U%!=11WNGW=O<
MI'<P0SHLH6:*.0,@WJ_G^490E*$XN,HMQE&2<91E%V<9)V::::::335F?2II
MJZ=T]4ULUW"OX0_VH_\ @II^W)^VW^U=JGP__92^)7Q>\$^#M4\:WGA/X'?#
M;X,^,-1\":YXDTO1VU&VL-?\0:YX6U/1[W4M6\36,5SXEU:UU'7KOP_H44L5
ME;336NB0:I-_4Q_P4A_X*"?!+]AOP!H&C_%O1?B/KVJ?';0?B7X>\%V?P]T+
M0-7:WE\/:+H]KJVHZ]/XB\5>%+6QTZVN/&6@Q+]DN-0U"<W,KV^GRQVT[I_$
M-_P3G_:3\#?LA_ME?!W]H?XDZ5XLUOP5\/?^%A?VUI?@>QT?4O%%U_PEGPK\
M<>!]._LNRU[7?#6DS>3JWB6PN+W[7K=EY>G17<T'VFYCAM)_VOPPX?J++<]X
MBK9/#,,1# S7#]/%T8U*&+Q%*.,]M&BIMISEBL/0PKJ)1G3O4A":YY'@9OB4
MZV&PL:[I1=5?67"3C*$6Z?*Y-=%"<II:IV3:T1_8G_P2!\-?\%!O W@SXV^!
M_P!OBY\?WNK>'_%/@Q_AK>_$;Q7I7Q#UFXT_4O#MY/XE%E\0])UGQ-!XFTJ-
MH_#RB-O$VJMI.KG6+:9;.^EO8G_8JODW]C+]LCX6_MS?!^;XU?"+1_'&A>%[
M?Q?K?@FXTSXA:5HFC^(H-9T*TTJ^NF:U\/>(_%6EO936NM6,MK/#K$LC;Y$F
MA@EC9*_*S]IW_@X<_9<^#OB'4O"/P1\#>)_VE-7TF6"*Z\2Z5KVG^ /A?=R.
M8#<P:+XOO=+\4:_K$MBC7*375MX%71+JXA@73-9O[6Y>]MO@\5E'$7%'$&90
MPV01H9C&I3^O8# T8X3!X*K&G"BU)UJOL<-[:=.52U7$7G-U)*4[2:]&-?"X
M3#4G/$N5)Q?LZE23G4J1;<E91CS3Y4TO=CHK72/Z!:*_F+^&?_!S%\*-<\1Z
M;I_Q:_9>\;?#OPW=W3P7_B/P9\2=)^)UWI4+Q*+6]DT'4O!OPVDN[9;IB-22
MTU%[RTL$>ZL+75[SR]+?^CSX:_$KP'\8O ?A;XG_  P\4Z3XU\!>-=)@UOPS
MXFT2<SZ?J>GSEXR0)$BN;2\M+F*>PU32[^"UU31]4M;S2M5L[/4K.ZM8?-SK
MA?/N'?9/.,MK8.%=N-*JYT:]"<DFW!5\+5K454LG+V;J*IRIR4>5-FN'Q>&Q
M7-["K&HXZR5I1DEWY9J,K:VO:U]+W.XHK\F/$_\ P66_93\(_M:W7['>M^'/
MC):^/M/^(]A\,=3\;SZ#\/['X5Z7K-X]HESJ^H^(=4^)EAKUGX:T<W3-J^JS
M>%5>WAM+NY@M+FV2*:;XU\0?\'%?P7'[1NE_"3X=_ KQ/\0_A5?^.="\%CXS
MIXZM?#6HZA%J6L0:/?>)/#7PUU'P=<OJ6D123"[T./7/&OA;4=9L_+?4+/P[
M,Y@3KPW!/%6,L\/DN*E%X*&8*<Y4*-.6$J)NG5C4KU:=.4JB4G3I*3K5%&;A
M3:A*T3S#!PTEB()^T=.RYI/G5KJT8MV5U>7PJZNU<_HQHHKQS]H+XX>#_P!F
MSX+_ !$^.OCZUUZ^\'_#/P]-XCURQ\+V5GJ'B&]M8[BWM([31[/4=1TC3Y[Z
MYNKJ""%;[5=/M%9]]S>6\*O(OS=&C5Q%:EAZ$)5:U>K3HT:<5>52K5FH4X17
M64YR44N[1URDHQE*32C%.4F]DDKMOR25SV.BOQ:\(?\ !>;]A;Q1\)?B)\7=
M0'Q:\#Z?X"U;0_#]AX-\7^&?!P^('Q(U[7M-UO5+?3?AWH'ACX@^)[:_2PMM
M#E77-9\2:IX7\.:'/J.B0ZIK-LVK6?F?#6B?\'-OP]G\7067B/\ 9(\9:5X#
M:\B2Y\2:)\6M$U_Q=%IYEA$]U!X)OO WAK1KB\CA:XDBL9/']K!-+%#"^HP)
M.\]O]7A^ >,,4\2J.18N^$DHUE5EA\/:3A&HHTOK%:E]8DH3BW'#^U<6U&24
MM#BEF6!AR.6)A[ZO'E4Y:7M>7+%\JNG\7+??8_J*HKQ/]GG]H;X3_M2_"?PS
M\:/@OXFB\4>"/$\4RPS-#)9:KH^JV4GD:KX=\1:3/BZTC7M(N@8+VRG#)(C6
M^H:?<7VDWVGZA=_ GB?_ (++?LI^$?VM;K]CO6_#GQDM?'VG_$>P^&.I^-Y]
M!^']C\*]+UF\>T2YU?4?$.J?$RPUZS\-:.;IFU?59O"JO;PVEW<P6ES;)%--
MXF&R/-\9B,9A<-E^*JXG+Z=6KC:"IN-7"PHR4*KK4Y\LH.G-\LHM<R>EM&=$
M\10IQISG5@H57%4Y7O&;DKQY6KIW6J>UM3]9Z_#[_@HE_P %J?"O[!WQNM/@
M7I?P*OOC/XEB\'Z#XK\2Z@?B*WPYTSP_+XAGU=K+0T:?X>^,I=8OETJRTO6)
M;JS6/3EM];AM/M7]HV-_:0^'^(/^#BOX+C]HW2_A)\._@5XG^(?PJO\ QSH7
M@L?&=/'5KX:U'4(M2UB#1[[Q)X:^&NH^#KE]2TB*287>AQZYXU\+:CK-GY;Z
MA9^'9G,";/\ P5E^+'_!*'X;_M#^!--_;<_9A^*?QB^,%W\+-&\4Z-XE^&3W
M&EV<?@F?Q9XKT?1M-\32V7QN^%,6OW<.L>'->:WMM4TK7DM-.D2 7<5M=-9C
M[#(N$\1E^<X"CQ3PSFN/PV88'$XG"9?@:U%8NJZ2I/VM2%+'8:I1C151*K1K
M5\-6A*<'*$N65.7#B,;"KAZDL'BZ-.5.I"$ZM2,G"/,WHG*G-/FMI)1E%I.S
M5[K]I/V9OCOH7[3GP$^%OQ[\-Z)JWAO1OB?X7MO$=KH.N26<VIZ1(T]Q8WMC
M/<6$TUK=);W]G=):WD9A:\LQ!=36EC-+)90>Z5X)^RUJ7P9UG]G/X+ZM^SQH
MD7ASX(ZE\//#=[\,]"CTVZTE]+\+7-A'-96E[9WTD][_ &I&S2_VQ=WMU?WF
MI:J;S4;K4]3GNY-0N?SX_;;_ ."TW[+/[&OBS7?A8EEXG^-'QCT".!-6\(>
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M6OBN)-9T;PYX1\427NE:];:5H+ZAID^G^,=.A22[T/2KI+RVO8VM# D%Q/\
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MEG)?WQ35VN?A=<-J5TL\TFGW\!CN)?M>&N'*>%S7'8'BCA;.LRJT\L6+HX'
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M7&IZ]KVHF*>2WTW3;:>:.SM;[5+PVNDZ;J-_:?SN>-?^#FOP/INOZE9_#_\
M9'\2>+O#=OJ5_!I>N>*/C)I_@?4M2TR&8)IVHSZ!I_PT\<1:?<7T.Z:XT\ZW
M=BP/EQ"\NV9VBSR7A/B+B&G4JY1E=;%T:4G"==U*&&H>T23=.-?%U:%*=2*E
M%RIPG*<5*+E%*46W7QN%PK2KUHPDU=1M*<K=W&$922[-I)G]1U%?E+_P3_\
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MUS2]&MK:XU)-*\:Z;I^B7<6J64;W=S/::_X3T&QDLK:%[#5;[4+IM,M_5Q?
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MKFI*E5][95+.*>IR_P!K45C)T)2IQH1C_&YF[S2C>.BMHW)?+<_HK_X*/_\
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M",%)[OE25[=+]NFP4445YIJ%%%% 'X+_ /!P]_RC]U?_ ++-\+_Y:W7YV?\
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M -270*_FH_X-M?\ D^7XJ_\ 9J'CG_U;_P "J_I7_P""M7_*.3]K+_LFJ?\
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M_ANUTNZDMV\/S2);S0?G!_P;P_M$?#77?V3KW]GV[\::#8_%;P)\4/&-Y8^
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MV%W:V!N-7\9> M?\.Z; +Z^_T*R,MYJ4,?VN\_T6WW>=<?ND>OX&_P#@E?\
MM%^#/V//VZOAM\1?C*NH^'O!-JOC+X?^.M0?3+R?4?!O_"3:'J&APZM?Z.BI
MJ'V?0_$0TW_A)+>*WGU.RT5=6GLM-U#4[6VTVY^L\/:=3&<$\=X#"Q=?&5,-
M-T\-3]ZM4=7 5XTHPIJ\I2J3I3A325YS7+&\M#CS-J&/RZI-\L%-7D](JU2#
M=WLK)IOLM3_14K^ S_@N_P#\I+OC1_V+'P@_]59X4K^ZN]^,GPATWP'%\5-1
M^*OPWL/AA/#-<0?$>]\<^&+7P'-;V[7:7$\7B^?5(_#TD,#6%\LTJ:B4B:SN
MU=E-O,$_SWO^"CGQLT?]M/\ X*!?%OQY\&XK[Q#X=\<^,/!OP[^&"O##:7'B
MB+PSX=\-?#?2]3L$N4LYH;'QIKFDW&OZ)'K*VNHVNF:Y8VVJQ6-Q!-:VV'@W
MA,3#B+,L9.C4IX7#Y1B:%:O4A*%*G7GC,%*-&<Y)1C4Y:-:;BVG&-*;E:VM9
M[.#PM*FI)SG7C*,4TY.*A-.22U:O**OWDC^^']D+_DTW]E__ +-W^"G_ *K7
MPS7T17A.DRZ%^R_^S)IL_BZZW^&?V>/@19R^)[W25,V_0OA+\/XWUJZTU-3N
M+5I=VG^'[F6S74+NW+YC%W<0DR2+^.'[%?\ P7I\(_M:_M)>"?V>=8_9RUCX
M5M\1;O6=,\*^,8?B?!X\M_[4TS0]8UZSM==T./X>^$Y],CU:+2/[/ANK'4-9
MCM-3O;87:QZ:ESJ<'Y_3R+-L[6=9KEF"GBL!E]7$8G%UXU*$/949.M74E3JU
M85:S5*$IRA0A5G%)7BN:-_2>(HX?ZO1K5%"K5C"$(VD^:248VO&+4?>:2<FD
MWL]';]2_VU_V-/A9^W)\#];^#7Q,CETV<RC6O OCG3K6WN=?^'WC*UAEBT[Q
M#I<5PT4=[:/'++I^OZ'+<6T.NZ'=7EBMYIM\;#5]._AF_:N_X)=?MG_L4ZEJ
M/BCQ+X#UGQ-\/_#%RNKV?QL^%::GKGA;2;2UU.ZCTO6]<O-/@36/ 5RCV5I>
M&;7[?3[;3[J^TVWAU6>[GM]_]O?[1W_!07]F/]D[XM?"GX0?';QAJ'@K5_BW
MHWB#7=(\47.CSS>!O#=EH=U9V%H?&6NQR^=I/_"2:A<7EGHUQ9Z=JEA9OI&H
M3^*;SPW92Z3=:G]$+\6?@OXA^'-]\1D^)?POUSX1S6.S4_':^,O"FI_#F73=
M16WM]M]XG&I3^&7L;Y-2M(-MQ?&"Z6_MXL.+J)9/I>%N+.)N#\/A[9?5Q>1Y
ME4=6AA\51K1HUI.I*C5>7XF,6H5:DJ;A*G:K"4E&;H-S4I<F,P6$QTY?O8PQ
M%)<LI0E'FBK*252#>L4I)IZ-7MS:67\AO_!*G_@M)\6/AS\1/!O[/_[5'B?6
M?B?\(O&>IZ!X,\+>/-:E.H^./A9J]XVGZ!X?EOM5E9;KQ/X$>06]OK]OJDEW
MK^CI(=?TJ_NQ9WGA_6O[0J_S-OVB- ^''Q2_;,^)7A3]DW1H+SX=?$'XW77A
MGX(:'X?T[5[:SU*W\3^(X=(\-V7A[1[Z!M8MM/U/5+U%T32S91306=S:6=KI
MULB0V47][G[=W[97AK_@GC^S1:_%WQ!X<USXI7L.O^$_AKX2\.W7B6VT34_%
MWB74;#4+SSM>\67&EZLUFZ^'_#>OZYJ.HVWAW5[F[O+,0KIT45W+=V?O^)7#
M>$JYGPY6R/+WALRXDIU/:Y5&-/#M5XK".E.I2<H4<-6D\3.EB6W3I<]"524E
M)5IOFRG%35'%1Q%7GI85JU9MS7*^?F2=G*<?=4H;NTDEIRH^[:*_*7_@F=_P
M5,\,?\%&!\4=+A^$VI_![Q=\+X?#.HWFBW'B^/QYI6MZ+XGGURU@OM-U^'PM
MX2DAN=-N=%6+4M/OM'MSC4[&33KG4$CU#[%^K5?E&:97C\FQU;+LSP[PN-P_
M)[6BYTJG+[6G"K3:J49U*4U*G.,E*$Y+6S?,FE[-&M3KTXU:,E.G*_+))J]F
MT[J24DTTU9I,_.O_ (*U?\HY/VLO^R:I_P"I+H%?PP?L1_$W]L_X4_%;Q!XB
M_88TWXA:I\6KWX>ZKHOB*W^&WPDL/C-KJ?#JX\2>$[[5YKOPOJ'@OQU#8:2O
MB73O"*3Z\ND6\MK>26&GKJ,*:H]M>?W/_P#!6K_E')^UE_V35/\ U)= K^:C
M_@VU_P"3Y?BK_P!FH>.?_5O_  *K]FX QE/+_#WBK&U<'ALPIX?'U:D\%C(1
MJ8;$)83 +V=:$HSC*#O>SBU=+0\+,X.KF>"IJ<Z;G3BE4@[3C^\J:Q:M9G<?
M#']L'_@X+U+XD_#W3O%/@S]IR3PS?^./"=EXBCUK]B'PUH6C/H5UKVGP:NFK
M:VGP&TA]&TQM/DN%O]535M+;3K4RW:ZC9&$7,7ZX?\'"'_*/+4O^RR_#+_T+
M7J_<.OP\_P"#A#_E'EJ7_99?AE_Z%KU?+99G^%SWC#A*>&R'*<C6&S2A&<<J
MP].A'$NK6I-2KJG3IJ3I<C5-M-I3DKZG76PT\/@,:IXFMB.>DVG6DY.%HNZC
M=NRE>[]$? W_  ;"_P#-[_\ W;5_[WZOZO*_CL_X-U/CS\#?@C_PV'_PNCXS
M_"?X1?\ "3_\,^_\(W_PL_XB^$/ /_"0_P!B_P#"[_[8_L/_ (2O6-)_M;^R
M?[6TK^T_L'VC[!_:>G_:O*^V6WF?KG^VW_P6L_9)_9]^&_C&R^"WQ3\)?'CX
MZS:=_9O@CP[\.+\>*O!^GZKJ^GF2T\5^(?B!I=GJ?@.?1/#7G0WE]HFF:UJ>
MO:KJ2P>'AI]C&^LZOH/1Q[D6<9QQ_FM#+LNQ>)>(GED*=2%"J\.E_9>7TY5*
MF(Y?94Z5.3M5JSFH4[/G:L++<10H9;1E5JPARJLVG)<W\:HTE&_,VU:R2N[J
MVY_'_P#M'^7_ ,/&OCS_ ,(9_9_E?\-L?%'_ (13^R?L']E^7_PO77/["_LW
M;_Q*_P"S]OV7['M_T#[/Y>/]'K_0*_;'^/-I^S%^RW\<_CO<20QW7P[^'NM:
MGX>2YDMHX+SQIJ"1Z%X#TR5[M9( FK>--5T'3&W073$7>V*RO92EI-_$;_P2
M#_94\?\ [7'[;W@+Q[J.D7VJ?#GX/>.M+^,OQ>\9ZAIXNM%;5M%U*;Q1X7\-
M7C2M;6&H:OXZ\86%G:2:.)7F.@+XCUMM/OK#1KNTF_7S_@Y*_:8O="\)?!?]
ME#P]J2PGQRU]\6_B39(UD9I?#N@ZBNB_#NUDC>&:^2TU+Q):^+-0>6*6PC-U
MX5M8P=0#7"6/V7&.7T<]XLX*X4A.%>6785U,TDG?EPO+AZE6%5J_)4JX; 3E
M3A)\U\31;2C4BY<&!JRPV"Q^,:<55G:BGUG[RBUM=*=17:_DE;56/@__ (-\
M?@/=?&/]M3Q3\=_$Z2ZSIOP"\':EXF?4]3:[U&>Y^)OQ.;4O#'AR>^FG9HKB
M[ET/_A86N)>W\UQ=)JVE6E[:V\EW'_:.G?1W_!RE^SO_ &3XX^!'[4FBZ:$L
M_%VC:C\&O'=W::2;>V3Q#X9DN_%/@6\U358"8;[6?$&@ZEXLTVW6]CAOH](\
M"6L,%Q?V5H(-)^ /V7/^"(/[7G[67P/\&?'WP/XJ^!O@[P=X]769_#FE_$GQ
M-\0M&\4W&GZ-KFHZ VK3:;X?^%WBJQ@T[4[S2[JXT>5M5,M_IAMM22!+2\M9
M)>Y^,?\ P0!_;5^"_P *?B)\7-7\9_L[^*]&^&?@_7O'.N:!X+\9?$6[\57V
MA>&-/GU?6SH=GX@^$WAO2KZ^M-*M+R^CL9M9LY[Y;9[33UNM1FM;.X]G$XC(
MEQY2SN7&F!HUL)%Y*\CEA).T$JE"KA)8SZU&$9?7JL\1S+#J-.I&,)<T82D^
M>,,3_9TL.L!4E&;^L?6.=;WC)34.1MKV:4;<UVFVK;+^B3_@A9^T1_PO/]@?
MP/X9U34A>^+O@!K.J?!K64N=6-_J3^'M)6WUOX>WC64P%YINC6W@S6M,\'Z.
MK/<6,S^#=1BT^XB2TFTS3/V0K^)__@W/_:$E\ ?M7^-_@#J5Y<+H/[0/@*YN
M]&LHX[26)_B%\*H-2\4:;+(]PT=S:0-X#NOB)]I;3WD:[NK?24O;*XAMH+W2
MO[8*_&/$7)_[&XMS.E"/+A\;..9X9*Z7)C7*=5);*,,7'$TXI-I1@K6^%>_E
M=?V^"HMN\J:]C/UIV4;]VX.#;>K;/B;]M[]CC]F[]J[X>/J?Q^^&T7CZ_P#A
M+X5^(FM?#V[/BGQOX8F\.ZCK.AV=QJDT;^#/$OATZC%>S>&="EFM-7_M"SWZ
M; 5MUS+YG\,W_!*_X'_"[]I#]O/X$_!?XT>&/^$S^&GC/_A9_P#PDGAO^VO$
M7AW^TO\ A'?@U\0_%>C_ /$X\*:MH6OV?V/7]"TJ_P#] U6U^T?9?LMUY]E/
M<VTW^AI\5O\ DEWQ)_[$'QC_ .H[J-?P1_\ !#[_ )2A_LP_]UI_]9Y^+-?;
M>'6/QT>#N.U'&XN*R[*:]7+U'$5DL#4E@,UKRJ8-*:6%G*O&-:4Z'))U4JC;
MFDS@S2E3>.RUNG!NK72JODC>HE4H12J:>^E%N*4KI1=MC^A__@J1HOPW_P""
M;/\ P3!\9_"C]E'PW+\)-"^-7Q0TSX;>7IVN^*O$M_#)X_TG5=<\?W"ZWXPU
MKQ'K"2^(_ WP^U/PK/+<:@\=GIM_(FE"QOEL[B'\L_\ @@E^P#\&/VFM0^,W
MQQ^/_@W2/B/X5^'EQH_@#P+X(UZ2>X\/3^*]=L+G5?$WB77]'ADMH]2ET/0F
MT?3O#=MJ4E_I#7'B+6=4ETQ-;T'P]J=E^OW_  <)_#G7?'7_  3[?7]&LI;R
MV^$OQK^'?Q&\0F&>"-K30KC3/%_PU>]:WE!GOHH=5^(NDK/!9#S[>&1]3F*Z
M?I]\P_//_@V\_:.^'/A6/X[_ +/'B_Q5I/AKQ9XO\1^$?'GP_L]=U+2=*M_%
M=Q);_P#"(:UH>A2WMQ;7.I^)1<MX:>TT.V^UW5]:SSSV%L/L5^SWE.*S#_B%
M>?9CE^(Q-3-L1FTI9EC:=:K4S"4?;8&-:4\0I/$.2PDHN;E)N-&K6J:<\I$U
MH4_[8PU*K""H1HI4:;BE2ORU.5*-N7X[V26ZBNA[7_P7"_X)L_LU>$OV6=>_
M:B^"7PQ\$_!GQE\)-9\'P^)]+^'FCZ?X,\)^,?"/C+Q5H'@);>;P=H&DQZ"O
MB+1]>U[1-1L=3L(M!:;37\1#6)]9NFTB&VY7_@V?^,.LZAX/_:8^ NH2W$VA
M^%]>\%_%3PNICMF@LKWQA9ZGX7\80/<$+?1K=+X1\(7%E:!KBQ65-7N42QNK
MB=]3^H/^#@3]I_X;^!?V-_$'[."^)-#U+XJ_&[Q-X%M!X,M+R.[\0>'_  ?X
M.\5:'\2-0\7:M9V\X.BZ?+J/AG0-"TYM459M9DUV9M'LKV#3-7O](^2O^#9W
MX3>)K+2OVG/C??1/:^$]>N? OPS\/-):7 &KZSX>&M>)/$\\-W(L=MY.CVVN
M>&[?9;F[>>?4[@3FQ-E$M]G1K8S$^#^:U,ZJ5JTEF=)915QDISJRH+$Y<J?L
M)U+SG%57CX0=VHTE4@FJ<;)RC"&>48X>,8_NG[>,$E%2<*C?,EHGR^R;[NSW
M>OX<?\%-X;^Y_P""CG[5]EI9E%_J/QJ\1:9;)#.+9YWU-+;3VM3,TD4:Q7<=
MR]K.)9$A>&:1)SY+/7]4/[/G_!!#]C?X<?#CP/'\4M)\3>//CII2>$O$'B#X
MEZ5X^\5:18:7XUT;4+37-2M_!6@6;Z3X?E\+/?0MHUL?%GAC5M7NM#BCNF?3
M-8GDGA_EV_X**?\ *4#]HS_LXR3_ -.>E5_HL5V>(.>9ME7#_!&'RW'XG PQ
M>51JXF6%JSH5*SPV#RV-*$ZE-QFZ25>KS4K^SJ.2]I&2BDHRO#T:V)Q\JM.-
M1PK-04TI*//.JY-)W7-[L;2W5M&@K\Z_^"M7_*.3]K+_ +)JG_J2Z!7Z*5^=
M?_!6K_E')^UE_P!DU3_U)= K\?X<_P"2AR'_ +'.5_\ J=0/<Q7^[8C_ *\5
MO_3<C^0#_@C?^Q3\.OVV?VJ[OPO\7+F\E^''PN\#W/Q1\0>%=/DEMI_'LVG^
M)?#>@Z9X0O=2@DAN=)\/WMSKC7WB"\L)!JMQI^GMHVFR:=<:M_;NC_M?_P %
MPO\ @G7^S9X'_8]?X_? [X,>!/A+XK^"^O\ @?3=<N/AYHVE^#M.U[P#XJUZ
MW\%/!XAT728;.Q\1ZY!XH\1>&;F#Q'=V]UXG\A;N.[U&YL&E6'\G/^"$?[4'
MP=_9H_:[UT?&;Q'_ ,(=H_Q?^'<GPO\ #WBN_2"/POHWBB]\6>&M=TP^+M5F
MNH?[ T?4?[%DTJ/6Y()].L-1O+.76IM+T<7VK67[N?\ !P)^TI\/_ O[%GB#
M]G\>(-#U'XE?&[Q?X%TB/PC;WT%SX@T3POX-\2Z'\3M4\5ZA80W2S:;IZWGA
MKPWHD$M]$SWTGB:$V%K/%%>7NG?N/$N+XCAXH</X;#5<?'+Y5<O]C1INK'"5
M<'*<?[7FXPM2JN%)U?;RJ<TJ:5)2M%4D?/82&%>48J4U3=1*KS2=G-3M^X6M
MW&\K<J5D_>Z\Q\2?\&S?Q:UG[;^T_P# JZDO;CP^+7P5\6M"A-W)_9VD:R9;
MWP=XLD6Q=FB%[XBLAX+5[N!(I#!X7CANFN%%F+7\5?\ @IO#?W/_  4<_:OL
MM+,HO]1^-7B+3+9(9Q;/.^II;:>UJ9FDBC6*[CN7M9Q+(D+PS2).?)9Z_9;_
M (-FOAMK;^)_VHOB_+;M#X;MM!\"?#;3[IID":AK=]J&J>)]7MX;=8GD9M'L
M-/T22YFEGMD0:Y:)!%?,]P^G_D#_ ,%%/^4H'[1G_9QDG_ISTJO:R?V$/%#B
M]T%"ZR7!2K*.L?;^SR]SND[<S7*ZB5FYN3E[SDSGK\SRG \U_P"/44>CY;U+
M?K9]K=#^HG]GS_@@A^QO\./AQX'C^*6D^)O'GQTTI/"7B#Q!\2]*\?>*M(L-
M+\:Z-J%IKFI6_@K0+-])\/R^%GOH6T:V/BSPQJVKW6AQ1W3/IFL3R3P_C'_P
M<E?\GR_"K_LU#P-_ZM_XZU_;77\2G_!R5_R?+\*O^S4/ W_JW_CK7Y]X<9WF
MV=\;4:V:X_$XV<<%FDZ2KU93IT/;QHNI##TVW"A2?)"U*DH4URJT4[M^IFF'
MHX?+YQHTX4TYT4^5).7*VDYO>4M7[TKMWW/WH^!OQGNOV>/^")W@/XTZ;(\6
MN?#W]CJ+6O#$B6MO>JGC!_#L]AX.:>VNXY[62S7Q3>:0;XW-O<P1V7GRRVMR
MB-!)_+K_ ,$D/V3= _;U_;3O;/XWM<^*_ WA7P[XG^,_Q1M+O6;S3M1\=:@^
MN:9IMCI-S?6"_P!I2C6_%?B>UU77VM[G3)+C1['5X8]6M+ZYLX[G^E/PI\-M
M;^+G_!!;1O 'AJW:\\0ZQ^Q9#>:)8),D$NI:IX<T7_A)[+2X)9(I8A<:I<:-
M'I]NLWDPR3W,<<UY8Q.][;_ST_\ !!S]HWP%^S[^V[+:?$SQ#IOA7PO\8_A?
MXA^%UGX@UN^L=*T+2O%T_B#PKXM\-3:QJE\$CM+?4SX6U#PS9[[FVMY=8\0:
M8+AR$0K[?#SK4,A\3L5E7,LZCFN8QC.A_O5/#0E5E3E2</WL9Q4L;.DXN_M(
M)P7-$Y\5RRQ.40K6]@Z5)M2^!R?*FI7T:TIII]'9Z,_H[_;W_P""4?['/Q"_
M99^*<GP[^"/PU^#/Q$^'GP[UWQCX"\9_#?PKHW@JZ;6O ?AS6]6TS2/%LNA:
M7GQ!H/B ^;IOB:YU.TU/69H9K?5HKB;5M'TN2'^?G_@WG^+.N>"?V[9?AQ:L
MTWA[XT_"_P 8Z'K-F53RH=3\%VG_  GFA:T&RDHN+*#1=;T>)0TD+0>(KLRV
M[RI;W%K_ %1?\%&/VIOA1^SA^Q[\7/&'C#Q3HHO_ ![\,O&?A+X4Z#%J%K<7
M_P 0O%WBOPO=:5H%KH-K#<K<:EI$%QK%AJGB+5K 3P:/X<%QJLA?%M#<_P I
M_P#P;W_"OQ-XU_;XL_B#ID:1>&O@U\-/'/B'Q1?3QW!BDE\7:5+X!T+1+6:&
M*2)-6O[KQ#=:Q!%=O!#+I/AS7'25KB"&";AX6Q&.Q7AUQK+.:V)KX*-"LL!4
MQLZE1?6HX>3Y*-2JY2:CC%A.6*DX1KMV2FYFF,C2AFF7JA&,:CDG55-)>XY)
M7DEIK#VEWOR^5COO^#DK_D^7X5?]FH>!O_5O_'6OMW_@F-_P19_9H^+W[+OA
M'X]?M3Z1KWQ+\;_&S2-3\4Z#I^G^/O%'A_1?"7AC6Y;<^&M4SX:N-!U/4O&S
M1VUYJM_+K.J:SX?4:PEA/HMU<6!NW^(O^#DK_D^7X5?]FH>!O_5O_'6OZ?O^
M"8?_ "CY_9"_[(=X+_\ 2$UMGN<9EE'AGPA++,97P-3%.E2JU\-4E1K^RA2Q
M-7V<*T'&<(RG&#GRM.2BHM\KDG.'H4:^;8[VU.-103<8S2E&[Y%=Q=TVDW:^
MU[[V/Q"_X.&/A[X=^$?[*O[#'PI\(+>IX3^&.I:E\/?"Z:E=?;=13P[X+^''
MACPWHJW][Y<7VN]73=-MA=77E1_:)Q)+Y:;]H^A/^"%'PL\!?&W_ ()@_$WX
M3_%#P_%XJ^'_ ([^./Q*T'Q5X>FOM4TQ-4TN?PM\-)7@&I:)?:9K%A*LL,4T
M%YIFH6=];311S6US%*BN/,_^#F;_ )(]^RU_V4KQ]_ZB^CU]&?\ !NG_ ,F"
MZ_\ ]G$?$3_U$_AQ7#B*]=>$.7XF-:I'$K/IUU7C.4:T:ZS+&U%6C4BU.-15
M/?4TU)2]Y-/4TA&/]MUH<JY/JJCRV7+R^SI+EMM:VEMK:'\N?_!5#X'_  N_
M9O\ V\_CM\%_@OX8_P"$,^&G@S_A6'_"-^&_[:\1>(O[-_X2+X-?#SQ7K'_$
MX\5ZMKNOWGVS7]=U6_\ ]/U6Z^S_ &K[+:^1906UM#_:%^R5_P $R/V'?@-J
M7PH^/WPI^!T7A?XN:9X,L[[3_%TGQ$^+'B%[2\\8>"Y-&\1W$&B>*/'>M>'$
MEU+2];U6R+#1_P#18;Z867V8["O\C_\ P7(LKFU_X*??M(3SQ^7%J-K\&+VR
M;?&WG6T?P&^&.GO)M1V:/%Y87<.R41R'RO,"&*2-W_NC^!_Q \"^(_A-\#;K
M0O&'AK58?''PQ\-ZKX.-GK6G32>*-.TSPUHTFJ7FA0+<>?JD.E)=6W]JM9Q2
M_P!FM/$E\+=W53U<?YEFJX/X&G1Q^8)9CDO+F<J6*Q*6.=3*\NG56/E"I_M7
M.I8F4UB'/F3KRE>]1F>6TJ+QV8*5*D_95VZ*<(?N[5JJBZ::]RUHI<MK6C;H
M?Q8_\%\OV:I?@E^V[J/Q-TC1)=/\#?M(^'K7XA:?>PP[-)?Q]HZV_A[XF:7;
M2>5&6U1KZ+0_&^N(7NL3^/[:X6X1;H65G_23X9_X*!1O_P $@A^VW)JHG\;Z
M%\ YM+O[N%;>_>/X^Z?.GPFLWO[36RP2TU+XMR:=J<D&I)J$C:#J4-U#'K\<
M]JVI<M_P75_9CN?V@OV'?$?B[08(G\6_LZ:I+\9K61FN!+<>#=(T34[/XB::
MJP6EX'B7P_<+XF?>MJ%G\*VK2:A;6HNH[C^+:R_:@^(EK^R?XB_9&DOY)_AU
MK'QF\*_&&RCFFO9I=+O]&\->*M"UC1;-9=0:PM-(UR]U7P_KMS:VNF)-)J^@
M)=O>J)9H;CT\FR^EX@\)\,1KRA+%\-9MA\'CU-\TJN64_9QK4TI:\V(P<<(W
M.3:E4H5=)/W3*O5>68W%N*:ABJ,ITK;*J[N+TZ1J.>EM%)>I^IG_  ;]?L_3
M?&3]MV^^,6OV<FI^'OV>O!^J^-)[[4--?6+*Y^(OC9;OPGX-M;^[N6^S6>JB
MTN_&/C'1[ZX-S?+JO@Y+JPMQ<P-J>F?W,5^&7_!OY^SW'\)/V'8?BAJ-G;Q>
M*?VB_&FL^-Y;E9KIKR/P3X7GG\%^"]*O8)%CLH0MUI?BGQ19/:+/+-8^+X#>
M7K.D>GZ;^YM?F_B5F_\ :W%N8<DN;#Y;RY7ATK62PCDL1:VC3QD\2TUO#D[*
MWJY30]A@J5U:56]:7_;Z7+_Y34-.]S\Z_P#@K5_RCD_:R_[)JG_J2Z!7\9G_
M  2J_8AL/V]/VF;7X8>,M>O]&^%/@'PQJ_Q.^(::9J!L];U/2;74-"\/VWA_
MPRSV=_!::IXAUO5-#BU349;>!;7PUIVJS0WBZO!HMM<_V9_\%:O^4<G[67_9
M-4_]270*_G/_ .#:K_D[+XZ?]F[W?_JRO %?9<$8_%99X;<78[!5'1Q5#&U7
M1K))RI3J87+Z7M(7T4X1J.4):\LTI6=K'#F%.%7-<#3J+FA*$5*+VDE4J.S\
MFTKKJC]UM7_9$_9>_P""77P,_:C_ &FOV:?#FI_#CQAHG[-/BW3XWUCQ?XD\
M9:-J_BKP]I^HZOX+U*YL_&-QXE,&NZYXT;0=-N8[3[/X99#!&N@6L3WDDW\>
M7[!4W[(GBW]I^X\>?\%"_B/>:5\+M/L]=\=ZE;W?A[X@>*YOBK\2+W6;%[+P
M_P"(3\/=!UW7+72;I]2UGQ5KM[(MK#J4NC0Z'-(T.M7&S^[/_@H7\.M9^+'[
M#_[4O@+P[8)JFOZS\&/&EQHFF-/);-J&K:%IDGB+3K&WE0JHO;J[TF&"PCG>
M*SFO7@AOYH;*2XE3^'/_ ()6^&/V.O'_ .U/8?#C]MC0-$U?X9^/?"6L:#X3
MU'Q!XY\:_#[2] ^)PU'1K_PW<7WB#P;XD\,E+?6-.M->\.16^MW\>ER:KJ^E
MOYL=U'!'<=WA]C9XSAKC#,\PQ><8K,6Z=/%XO 5*5?/5@*.#O1^J5L4Y/VD4
M\5[-SE[J@W1:J0BUGF=-0Q>!HTH4(4M7"%1..'=24TGSQA;1VA>V]_>T;/T@
M_P""H?Q0_P""+WQH_9QU2_\ V2+WX<>#?VC/!^M^%M0\%Z5\*/V>OB%\(K3Q
MQH]UKUOI'BWPWXF>;X6^#_!,EI:>']9U#Q?;ZGJDL&N#4?"FFZ3INHFWO[G2
MM0^O?^#;'X@77C7X%_M4? CQ) FN>$/!GC+P7XFMM*UF"WU+29;'XQ>'?%.@
M^(=":SO%GCETF['PT%Q>Z5-$=-EEU:^F\AYM1U!I?OW4/^",O_!)?2= D\5Z
MK\ M#TSPO%90:E+XDU#X_P#QWLM CTZZ$1MK^36+GXPQZ<EE<">$P737(@E$
MT1CD82)GZK_8J_9]_8H^!G@OQ9/^Q'I_@(>"?&'B4#Q;KW@'XFZO\6K#4_$O
MAB!]._LR[\5:QXQ\;307&@1W<\;Z#!JEO#IMQ?7<SV$-U?7,LWSF;<5\/U>#
M<;D&6PXLQDWCL/B,+C\_6!JK UHU\/4G2CB<+7YJ<71I8A4:;HRFJF(JOG4&
ME'JH8/$QQU/$U7@J:]G*,Z>&]I'VD7&24N2<;-\SA=\UK1BK7W_A=O\ 3=0_
MX)O_ /!2J.UU.PO-1L?V9_VD--U**WO[6XTN]\3?#2Q\06NKZ1?QQ7$>I3V$
MWB_X::C9:GIMTJZLEN=6M;VUDU6%8I;G^K/_ (+N_M*Z?\,?V ;[PWX4UNTO
M-3_:9U[PYX"\/ZEI$UMJ-O=^!)(E\:^+-<L+Z*5["YT?5- TFR\-M>6[7C3V
MWC*WFL(P&_M*P_,__@Y2_9W_ +)\<? C]J31=-"6?B[1M1^#7CN[M-)-O;)X
MA\,R7?BGP+>:IJL!,-]K/B#0=2\6:;;K>QPWT>D>!+6&"XO[*T$&D_C=^UM^
MVSK_ .T[\"?V)?A#JTFI2S?LQ_"#7/!GB"]O([2WBU;Q)<^)9/#^B2VWV1%?
M4[?3_A+X(^&,3ZOJ)6_EU^]\30R0/(MQK.N?H&&RZ/'$O#_BIQC-X*56GG"O
M=^VP4*E:E*4&DO9_VGA9)QM[U/&0^*-F_,G5>7K,\$FUS\KH/^[4<8R2??V,
MUKWIO9G[R_\ !M5^SRUAX9^/G[4NL6#I/X@U#3?@GX%O)K2.%SI&C"P\8_$"
M>UN)=US=:?J>K7?@6S$EL(;%=0\,:A;R2WUW;/%I7X@_\%%/^4H'[1G_ &<9
M)_Z<]*K^X[_@GS^STO[+?[&_P#^#-Q8QV'B+0? MAK/CF)(9HY3\0?&,DWB[
MQM'</=!;RX-AXBUJ_P!)M9;M(94T[3[*V2TL+>W@L+7^''_@HI_RE _:,_[.
M,D_].>E5Y_!6<?VYQ]QAF$9<]&> J4,*UL\)A<5A\-AY);+VE.DJLDOMU)/5
MMLUQ]#ZOEV I6M)5%*:Z\\X2E*_HW;T21_4)_P '!GQUU[X3_L0:?X'\*Z__
M &/J_P =OB=I'@#7K6$(+[4OAQ8^'O$?B7Q=#!,]K-Y-K+JVF>$=(U3R)[.Y
MN+#6IK/S);*XOK>7\(/^"2_B#_@E+\+=%\9?$_\ ;Q\5^%M?^*ESK]SX=\"_
M"_QY\'?B3\4O!&@>#(=(L))_%][INA_#[Q=X+UK7_$6J:AJ.FVMMK2WL_AJT
M\/6^HV$=M?:P9K?]C?\ @Y%^'6L^(_V3?A)\0],L$N['X;?&>&W\17"SR)<:
M7I/C;PSJVF6]\;<E;>>REU[3=%TVXDW/>07>H:<+>%K6;4)K?\T/^"*O[.7_
M  3?_:L\'?$'X;?M0^ ?#FO_ +0>A^-8]3\''5?BS\4O >H^+?AYK>EZ-8V6
MG:'H?ACQYX7T/6M0\/\ BFUU87S:?;7&L-;^(=(CNX!#';SS\7#,LOPWA=7K
MUIYU2H5,RKO-*O#CPL<SC^_ITHJ4\191P_L%AE7=U4]E.U_8RFGIBU5GG$8Q
M6'<E2C[%8KG]E\+;LHZN7-SN/2Z[I'R+_P %:-=_X)T>-OB1\-OB#_P3[UG1
M([3Q#HGB?3_B]X&\(?#?QQ\-/!?A[6-'U#2KKPGXDT71/&'A#PG9VUWXKL]<
MUS2]2TSPI!_8>GP>#-+N3IVG7VJ7-QJG]$/@'P3K7_!03_@@QX6\.:K:W.N_
M$&7X%ZQ:^"IY],_MW7]0\>?LV^,=?\.^#!8-$[:@=9\8M\-;;PW=ZM;23:O=
M67B?4VNX-3>^OM/O?5?'W_!)'_@C=\*-*37?BE\)_ GPVT23SMFL^/OVF/C-
MX.TI_LRH]QLU#Q%\:M.M&\A)8VFQ,?*61&?:'4G]2/@I\./A9\(_A1X#^'?P
M1TC2=#^$WAOP_:P^ ]/T/5;O7=)&@7[2:M;WMGKM_J&K7VN)JLE_+JKZU=ZI
MJ-SJTM[)J$][=27#3/\ .<0\:997R7AS#Y-3XAJXK(LVIXW"9KG\,)*K4IX?
MVTWAWB<+6G&M*%2>%AR^R@HT,/3C4<YZRZL+@*T<1BIXAX90Q%!TYT<,Y\J<
MN5<W).*Y4TIO=WE)V26W\;7_  ;I?&N'P'^V7XN^$6I:AJD-A\>/A9J]CH^F
MVMR@TJ_\<?#B4^-M+N=5LI)8A++I_@F#XCKIU]"+FZLGO;FU2U-KJ=Y=V?E?
M_!;SXA>)/VA?^"D/Q#\#>%+:7Q':_!'P'H_P]T*STIS*\MIX0\&ZA\6?B-<_
M99(+0_;]#U?7O&-C?(AO+J\A\-PI:3W*?8;.+PGXKZ#<?\$Y/^"JE]-=Z;J-
MWX>^!G[2GA_XBZ-9W>H*=1USX4:IKVG>.=!ADU?3(I8I=1U/X>:U;6-[=0V4
MB1:LUW!?:,LL%YHR?=/_  0^\#+^U1_P47^./[1?CG3+&\LM'\-_%SXB:QHN
MKQ3>)(+[Q/\ 'O6=2\,W6CW]QJ5L]MJ-C<^&O%?CN#4;C4V-UJB*L+:?=07F
MHS6/Z?CJ6$RW-,P\2*<8UL)+A+#U,/%\MJV.Q$X1P\E.,G).IA887#M\KC&-
M:3YG=*/D4Y5*M&EE3;C/Z[)3[QIQ5Y:/32;G-:J[CZM_97_!M)\<K>^\"_M$
M?LX:CJ9&H>'O$VA_&3PII<L<CO<:5XETZV\'>-;BUN5B9(K;2=0\.^"O/LYY
MX0;GQ%]JL()GDU:6+\7-/@O?^"AG_!6V,6^GZ/J&D?&?]J*>_FL5B76=';X1
M^#M9EU#4&N%L9)+?74MOA+X1N;B_GAFMM/UJ>&XN3<:=8W;36W(_#+XH^./^
M"8_[5O[4O@8K-J&KV?P]_:2_9=U.\TQ;61KJ;6].O[/P#XMLIM0M[*=-)A\>
M>'_ 'C*YEMETG5I_#L%W!%&DUQ)ID_Z@_P#!M?\  VT\3?&_X\?M ZI;3.OP
MI\#Z!X"\+M-%<):-K_Q0O]2O=6U"RG%N(+C4-%\/>"9=,NX/M@-K9^,HI)K*
M9KNSN;7#,L-1X<GQMQM0<73S3)\N_LNK!JWUC&4_83DEH[5<6L#B9)IMIRDI
M)/EC5*<L4LOP$DTZ->JJT7_)3:DK^:A[2'JK6/[':***_ET^O/\ .P_8#N?[
M<_X*G_ +4+^"V>34/VGO[5EA$6ZWCNW\0:KJ"/#',TS)]FNPDUJS.\L+Q12"
M0R('K_1/K_.O_8\M+KX3_P#!5_X*^&_$MM<6NJ>&?VRK#X=ZI:7<,EI=6NN7
M/Q*N? KP7-M&MX]O<6^K7:I-;LSI'(C137,40>YC_P!%"OV+QCL\SR&I#6C/
M)8^RDG[K2Q%27N_]NR@[]4T>'D6E'$)_$L0[I[_!%:_-/\3_ #I_^"0__*2+
M]E#_ +'[4_\ U"O%-?O-_P ',W_)'OV6O^RE>/O_ %%]'K\&?^"0_P#RDB_9
M0_['[4__ %"O%-?O-_P<S?\ )'OV6O\ LI7C[_U%]'K[CB+_ ).MP;_V+:WY
M9N>?A?\ D2X[_K\O_=<^C/\ @W3_ .3!=?\ ^SB/B)_ZB?PXK^53]J3P=_PL
M/_@I?^T7X ^U?8?^$Y_;H^+O@[[=C/V/_A)OC[XAT7[5C9+G[/\ ;?.QY<GW
M/N/]T_U5_P#!NG_R8+K_ /V<1\1/_43^'%?S&_%;_E+Q\2?^TD'C'_UIS4:Y
MN&)RI<=^(M2#M.G2JS@[)VE"JY1=GH[-)V>A6,2>7Y4GJGRIKR<8W/ZZ/B'_
M ,$A_P!@SP]^R9X_^$OAKX'>&=+O].\">(=2T[XOW>GV.N_&J#Q5IOAV66'Q
M._Q#UBUNM9#W%_9)?W?AFQDT_P $I)/=6^D^&M)M)(8(/Y?_ /@@[XFFT'_@
MI9\'-+B,H3QIX5^+WAFX$98(T-I\,/$_C%1<;;B$&+[1X3@90\=TOGK"1;JX
M2ZMO[LOBM_R2[XD_]B#XQ_\ 4=U&OX(_^"'W_*4/]F'_ +K3_P"L\_%FOG>"
MLPQ^:<'>(O\ :.-Q6-<,LQ&(@\57J5Y1JU,MS&=2<95)2:YY4*3DDTKP5DM3
MJS"E3HXW*O94X4[UHQ?)%13C&K123226BE+SU/NC_@Y%^.NO>(/VB_A/^SW8
MZ_Y_@GX=_#'3O'^KZ!;A$CM_B/XVUOQ/8R3:D?LL<UQ=6G@G2/#D^G;KNYMK
M2V\07HMH[:XO-0\_U+]ASXE?\$%_@?\ LW>$/#'QM\0_#+XI_&?Q;X8TK6?B
M]K_Q,_9K^+OQ U'1?%^K:9YVK>$O!VIW_P (M;LO#ND>$)KZ?P_9:IX,N[!]
M>ETR+Q+<74U[/;/:_+?_  <5?#K6?#'[<'AOQ[/8)'H'Q-^#'A2XTO4XIY)5
MO-6\(ZGK?AW7+&>*4AK:]TZT30)Y([=#9R66IZ?,DSWLFH16_P"FW_!.S]@+
M_@D?^V)^S%\*?'*?!KPYXB^+-OX*T?3/C+H5C\<_CG::_I7Q#T*SLM+\7:CJ
M'A>T^*6GR:+I^NZOC7M+6VTV+1UT[6K"'39Y[<1.WL5ZN3X+PXX6EBZO$F'R
MZI&G.O4X7E@J51XV2JU*GU^IB'&U)8E5N3EDKUX1]K><*=L(JO4S7&*$<)*J
MFU%8Q5)+V:Y4O9J/VN7EO=?"WRZ-G\WGQ6^(GP0^ 7[?=W\7?V*_%>I^(?@E
M\/OC#X,^*/PFU0:9XCT&:+3HCX>\8ZUX+@TWQGIVC>(WT/P[K=QKWP_M$\36
M1GUWP]I<4FJ7&K0:C-?7O^DC7XV'_@ES_P $;/AS\2?!WAO4/AQ\+O#GQ1N?
M$&D3>#/!/BC]I+XGGQ)KNOP21:KI-EI_@7Q+\8YI?$[W(@2X&BR:+J=MJ=H'
MCN+*ZLY)8W_9.OS[C[B7+>(:7#ZP&&S>$LOP5;#U<;G-+#PQ6/I-8:-"JZF&
MK585Y*='$5*U11I0=6M)P@DVEZ>6X2KA7B?:2H-5:D91IT')PIOWG*-IQ3BK
M."BM6HQ5V%?@Q\3/V0/^"+/['OQ4\;_%;]I37/ FH>/OB)XXN?&Z^"_C)XSN
MOB%-H%WXDUZ^\631Z%\&O#UK<:C?^$+F^989M2\:>&/%ELFGPVVD7NN?9]8O
M[?6/VY\?^)YO!/@/QMXSMM)EUZX\(^$?$GB>WT*"=[6;6IM T:]U6+28;F.T
MOY+>749+1;..=+&\>)YA(MI<%1"_^>G^Q9X.\ ?MX?MXZ38_MF_%?6],TOXK
M:CXN\4>*_%MQXMTOP[JGB;Q7;:7<ZEH/A2+Q+XHM]4L],M-5NK:VT2QT^&-+
MO^RH+?PYX;FTZ]DTR:VO@')\1CL-Q#CY9QFF4Y5EV$I3S&.3R:Q^.BE7KQHT
M^5Z*G"C4;<H24W45-)QE5<5F5>-.>%I*A1KUJLVJ3KV]G3;<(N4K[W<DE9JU
MF][)_=/_  5M^*?_  21^,/P<\#:O^Q /AOX>^-_AGQ]96NI:1\,/@/XY^#6
MEZ[\-]4T77VUUM<@N_AQX$\(ZGJ&F^(+?PO/IFH7+W>O6UO)J%C9QO97EV]K
M^EG_  ;4>*[Z_P#V9_C_ .#)[JZFL?#/QML==L+:583;6;>+/!&BVEV+2;)N
MOW\GA6.6>U?%I#)BXME%Q>W[/\2?\%FOV//^";?[(/P/\(^%O@'X?T3PO^TW
MJ/CWP_#=:2GQ1^)?C;Q<_@&R\-ZC=>(]1\2>'-9\8:_X:\,KJ5YJ?A&^L[B_
MT;09]4%S(?"\<EC;ZG%;_4W_  ;2326WP4_:NN(;2XOYH/B%X'FBL;1K5+J]
MDB\)ZTZ6EL]]<V5DEQ<,HAA:\O+2U61U-Q<P0AY4^XSJ6 Q'A3B:F7SSRM@X
M9AAI82KQ$Z$L<^;,*$)3I5*/[IX5^TJ*C-.^M6+:2LO/P_M(YS%55AXS]E)3
MCA5)4U:E)I-2UY[)<R?E;H?C[^Q,_P -KW_@K[!=_M@-X>L]/?X[_'6[\86O
MQ72$:#)\69W\>#0[/Q@/$FGVUO'?0_$::RFM_P"W+72U'B:VTY+V.&0M92?K
MA_P<I:C\ 9_AW\#+$+X3NOVG;7Q^T4%S87%G)XSTKX*Q^%_$EWKNE^)(;2[%
MY!H=_P",M5\':EX7CUVRDC%S'XCG\.3VHNO$:W_X;?#>W\#?\%$OVZ/B9XA_
M:V^./AK]ERW^+%SX^\9W'C/7$T#2O#'AGQ!IL</_  C'@*>Z\3ZCX8TBTL],
MT2U&BVMWKNJV6JZP^B06UU?7?B35O.N?U8^!_P#P1M_X)PQ^)[/5?B1_P5"^
M$7QL\,P:G8)'X6^&WC'X/?#EM5NX)!--HFJZ]_PMKXH7LUKJ?FV5O<6VB0:%
MK4=I+.MAJMK>7=G?6/N9VLKR_B+(<\S7,,TP>-R;)\/"639=EN/QN%KRG&NI
M0P^84*4<+"'/.=*O"KR_6*5*BI2I+1\V']M5PN)P]&E1J0KXB35>K6ITYQLX
M.\J4I<[=DG%Q^&4F[2Z_H-_P0%_9N^%_AC]E7PW^TRGPHTSPO\:?B%'XZ\"W
MOQ"BU#Q[)J/B_P"&^E^-8I;)YM*\3>(M2\+Z>;O6] BCN+OP3HVB:;JEOX?T
M=KJ.;4+2\E?^8;_@IMI\VK_\%(/VJ-*MFB2XU/XZ:OI]N\[.L*37LUC;1-,T
M:2R+$KRJ9&2.1P@)5'.%/^B7X-\&^%/AYX4\/>!O WA[2?"?@_PGI-EH7AOP
MWH5E#I^D:-I&GPK!9V%A9P*D4,,,2@< N[EI96>5W=O\\S_@HI_RE _:,_[.
M,D_].>E5\]X;9O5SOC+BG-9NM;$X"O5H4Z]6=>=##O'498?#J<Y2M"C3Y81A
M%J$4N6"C&R.K-:$</@<'12C[E2,9.,5%2E[-J4K+K)W;;U>[;9_89X*_X(V?
ML#>$/@+JGP.N/@IX>\37GB'PQ_8FO_&3Q!IVG:I\97UM[,PR>,?#/C/5+34;
MCP/J\5Z1J5GIOA6'3O#4;QQ65]HNHZ>UU:W7\BG_  24U^Z^%_\ P4]_9PCM
M9FNQ_P +$\6_#RZ;RY(X[ZU\5^$/%_@>2>:UCO80%B?5(M3BCDN+B.UNK6WN
M##?&V6";_0WK_.G_ ."=?_*4#]G/_LXR/_TYZK7'X?YEF&;Y+XA1S/&XK'*>
M5.JUBJTZUJF(P>:PK2ASMJGSPI4XM0Y8J-.FDDH12TS*C2HXC+/94X4[5U'W
M(J.D:E%QO;>S;=W=W;UU/UT_X.5OC[XF/CCX!_LPZ?JES9>$K;P;=?&_Q3I,
M 9+?7]9UK7]?\$>#;C4)2I\X>&[;PMXQ^PVT+QQK)XBNKB^CN)(]+>S^S_\
M@CY_P3$_9>A_8_\ AG\:_C7\&?AY\8_BE\9K>[\?S7OQ'T'3O'FB>&_"E[/J
M.F^"_#6A^'O$%O=^&[>+_A'A'XBUBYDT5]7F\2Z[=6UWJ=]9>'/"ZZ7^=O\
MP<M?#G7=/_:,_9\^+DME+_PC/BSX*7?PYLM1$\$D!UWX>>.O$GB;4[*2VC'V
MJTE&G_$[2)XI[HB#44::.P#2:7J17]L/^"*O[1WPY^,?["_P7\!Z-XJTF7XC
M?"#PYJ'@/QEX*GU+24\4:=;^&-6\C2]<70K>X&HOX:OM%U?PZ+37'LDM9+VX
MFTZ:YEU&VN2T9M6Q>"\*.&YY+5K8>C6Q;>9UL'.<*DI2GCG45>K1:DJ;Q<8P
MGSO25.A2;2BHLHJG4SK%*NHRE&"]C&HDTK*G;E4M+\CNK=')]V?SM?\ !=K]
MA7X1_LA?&+X3^./@?HEKX,\!_'K1O&<T_@"QNIYM+\,^+OAW/X4AUZX\/6<]
MJ#I'AW7+#QEH-Y;:8-4U%;;68M?6S@TC1_[*TZ/]<?ASXQ^*_P"U/_P;W:_9
M^%;35]?^)N@?!3Q!\-9+6RBMCJ>O^&?@SXUCTNXM-+BME^T:S?WOP@\-QV#6
MOV9M>\0:U]JL84U/5+V"[O\ \V/^#B7]I_X;_&?XY?!7X._#GQ)H?C%?@+X9
M\;W?C#7O#MY'J>F67C#XFWWA;[5X1.JVT\MA>ZAX?T;P'HE]J2Z>)8=.N_$#
MZ3=WK:Q8ZGIFD?M]_P $P9_#?[$O_!*;X5?$/]HSQ-:?#WPH+'5/BCXBU;5]
M.U=8?#6B?%7QZP\"V]S:VME=:O>7>LV>N^%Y$2VTO?\ ;M=2Q@BN88$O[KMS
MG%8^' / F.S"E5QF?4<]P=?!T<1&K4Q>+A3KXZ>%I2C:5>JL1AH8%2T<ZKE1
M=Y5)1O&'A2>99C3I25/#2PTXSE!I0@Y1I*<KWY8\LG4:V4?>V29_+5_P2M^/
MW["OP+^*'C+_ (;B^!FF?%/P_P",;;PII?@CQMKW@W3?B=X<^%=Q;WVKV_BB
M]\1_#C5ENH=9T;6M/U;3K^XUS2-$\4>+- E\)P6GA[PW?OK]Y/9?UF_LA_LS
M?\$S/&/QAM/VS_V);GP6NOZ3I'B3PWK&E?"/Q']@\&6$WC)KJ.X/B?X574*W
MG@#5_LL%XF@:1!IG@ZP.DLES;Z)=V::?<Q>%?M&?\$K_ /@FW^W5X4UOX^_"
M7Q?X-^%^M>)KF&_OOC3\%_$FAW_PZU#6;]M"GED\7^"!JT'@F+6KNWN5?44T
MI_!7B2_USQ')K'B>[U75;A%D_FO_ ."5?CWQQ\ ?^"F?P=\+?#_Q58^)-+\1
M?%/4_@MXPG\/ZW<MX*^(7@?6+K4?#M[K$<EE>6UOKVD6+1VOQ \(FX>XMI-7
MT70;Y8+G:()NG,?JG'. S_-\GS+/\ES?!9;*&;Y-C*M99=5I4\--3PKIM^PA
M&M&A.*E"<+3_ -HQ&"IU*DIN:7/E]3#4*]+#5Z%2JO85Z:7M5)SBU._Q/E<D
M[-.ZM&-1I)'Z/?\ !P?^R+^SO\#[+X;?&OX6?#J+PI\3?CK\7OB5K?Q5\20^
M)O&>J)XJU74+*V\27UZ=#USQ%J?AS19;K7-3O]1G'AW2-(22:YD#(8ML:]S_
M ,$7O^";7[%G[67[(FK_ !0_: ^#'_"?^.K7XS>,_"<&N?\ "Q?BQX5\O0-)
M\/>"K[3[#^S/!7CKPYH[?9[K5]0E^U/I[7LOVC9/<R1Q0)%[%_P<QV5S)\$?
MV8M02/-G:_%3QE93S;XQLN;_ ,)6L]I'Y9<2MYL6G7K;T1HX_)VR.C21"3U/
M_@WB^('@72OV#/B/;:MXP\-:3/X)^/GBS4O%\>K:UIVEMX:TOQ!X3\!#0=5U
MK[?<6XT_2=:EL=1MM*U2Y,>GZA>Z7JMC:W,MYI>H06W#+-<XCX2X#&X?,LRC
MCHYI]7>+HXS%+%QH+&XFC3HNO3J*LJ2C[&E"GSJ"C[.G&-N5&BHT'G56G.E2
M=-T>90E3AR.7)"3ERM<O-\3;M?XFWN4_^#B[1-*\-?L ?!+PYH5E%INB:!^T
MW\-M$T?3H"YAL-*TKX*_&^QT^RA,KR2&*UM((8(S([N4C!=V;)/*_P#!M)_R
M;7^T-_V7'3__ % M KOO^#DK_DQKX5?]G7^!O_50?'6N!_X-I/\ DVO]H;_L
MN.G_ /J!:!7FTVY>#F)E)MR>=IMMMMMXZ@VVWJVWJV]6S3;/8I;>P_\ <3/Y
M_?VEM=\4_P#!0+_@J#XOT6WUB4-\7OVD;#X->!KW6&6Q@\/>!+#Q9:_#CPA+
M/:P6\T>G1:;X8L;76-5MK2SO+J?4GU.Z>/5]7O;B:^_M"F_X)3?\$^9_A1:?
M"%_V7/A8NC66BMHT/B^'PY86WQ7=WMKFW.LW?Q7MX8O'M_K0DNY;Q;N^UVYA
M2Y2V"6JVME9VT'\3FOW%[^QG_P %0KG6/&\$]O;_  )_;'M/%FN+$RWDNH^"
M]$^*=OXF-Y:216$KR)XB\%/'?64J:6E\D6HPR#3[:^7[+%_H-:=\=/@MJOPR
M;XT6/Q8^'4GPBCTRWUBY^)DOC+0+7P-8:;=16DT-WJGB:[OX-(TI"E_9>8NI
M75K) ]U!%.D<LBH?0\2\5F> PW!]+):^,PV5QRZG]4E@*E:E">(C##1PZYL.
MXJ<U0]E]7B];3JNFO?F9Y3"E4ECGB(PE6=:7M%446U%N3EI*[2<N;FZ:*^R.
M2_9=_9I^&W[(OP3\)_ 7X3C6G\%^#[CQ%=V-YXFN[#4?$FH77B?Q)JWB?4+G
M6M3T[2]'M]0N(KO5Y+"SF-A%)!I%EIM@S2BS61OXO_\ @X'T>'3/^"B?B*]B
M,9?Q#\)OA=K%P$MUA99H--U#0%$TBLQNY/L^AP$7#A&6$Q6H4I;([_VQ_ _X
M\_"7]I#P'!\3_@GXQMO'G@.ZUG7= M/$EEINMZ79W>I^&M2GTC6([2+7],TF
M\NK:WO[>6*#4H+:33=1B"7>FW=W9RQ3O_$!_P7PUR'5O^"D7Q)L(KF2=_#'@
M+X3Z'<1/,LJV4UQX)TWQ*MM"BS2&VC>W\0P7AA=+=FFNY;@0LDZ3S^;X5/'5
M..,PGCO;K&O+LQJ8_P"LPG'$.O/&8/VWMXU(J<*CKS3FI*+4M&E>QKG"IK+J
M:I\OLU4I*GR-./*H3Y>5IV:Y5HU?34_ME_8>UVX\4?L=_LL>)KM=EWXB_9O^
M!6NW2;D;9<:O\+O"^H3+NBAMXVVR7##=';P(<92&)<(OU17SO^R5X8U#P3^S
M+^S[X,U;3'T75?"/P/\ A'X8U/1Y;.?3I=)U#0/A_P"']*O=,DT^YM[2YL'L
M+FTDM7L[BUMI[5HC!+;PR(T:_1%?E68.$L?CI4[>SEC,2X6=UR.M-QLU=-<M
MK-=#V*2:I4T]U3@G?>ZBKW^84445QF@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/W[+.AZ+X<^ _@
M71O#OPV\5_"'1[/_ (2?['\._&]W=WOBCP]]H\9>(;NX_M.ZOGDNI?[6NIY]
M<LO-<[-/U.TC3$:(!] U\_?LLZKX7UOX#^!=3\&?$7QU\6?#5S_PD_\ 9OQ
M^)5QJ-UXUU_R?&7B&WO/[:N-5@MK^3^RK^*ZT33O/@39I.FV"1;H5C=@#Z!H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]C9/_P!"K+?_  APO_RH/K>+_P"@G$?^#JG_ ,D>Z_\ #47[3/\ T<5\=?\
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M@G$?^#JG_P D>Z_\-1?M,_\ 1Q7QU_\ #N>/_P#YH*/^&HOVF?\ HXKXZ_\
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M6_\ A#A?_E0?6\7_ -!.(_\ !U3_ .2/=?\ AJ+]IG_HXKXZ_P#AW/'_ /\
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M^QLG_P"A5EO_ (0X7_Y4'UO%_P#03B/_  =4_P#DCW7_ (:B_:9_Z.*^.O\
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M011PPQI&BJ/&**/[&R?_ *%66_\ A#A?_E0?6\7_ -!.(_\ !U3_ .2/=?\
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M_P#DCW7_ (:B_:9_Z.*^.O\ X=SQ_P#_ #04?\-1?M,_]'%?'7_P[GC_ /\
MF@KPJBC^QLG_ .A5EO\ X0X7_P"5!];Q?_03B/\ P=4_^2/=?^&HOVF?^CBO
MCK_X=SQ__P#-!1_PU%^TS_T<5\=?_#N>/_\ YH*\*HH_L;)_^A5EO_A#A?\
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M_P -1?M,_P#1Q7QU_P##N>/_ /YH*\*HH_L;)_\ H59;_P"$.%_^5!];Q?\
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M_P"2/=?^&HOVF?\ HXKXZ_\ AW/'_P#\T%'_  U%^TS_ -'%?'7_ ,.YX_\
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MIG_HXKXZ_P#AW/'_ /\ -!1_PU%^TS_T<5\=?_#N>/\ _P":"O"J*/[&R?\
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MO%_]!.(_\'5/_DCW7_AJ+]IG_HXKXZ_^'<\?_P#S04?\-1?M,_\ 1Q7QU_\
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MW/'_ /\ -!7A5%']C9/_ -"K+?\ PAPO_P J#ZWB_P#H)Q'_ (.J?_)'NO\
MPU%^TS_T<5\=?_#N>/\ _P":"C_AJ+]IG_HXKXZ_^'<\?_\ S05X511_8V3_
M /0JRW_PAPO_ ,J#ZWB_^@G$?^#JG_R1[K_PU%^TS_T<5\=?_#N>/_\ YH*/
M^&HOVF?^CBOCK_X=SQ__ /-!7A5%']C9/_T*LM_\(<+_ /*@^MXO_H)Q'_@Z
MI_\ )'NO_#47[3/_ $<5\=?_  [GC_\ ^:"C_AJ+]IG_ *.*^.O_ (=SQ_\
M_-!7A5%']C9/_P!"K+?_  APO_RH/K>+_P"@G$?^#JG_ ,D>Z_\ #47[3/\
MT<5\=?\ P[GC_P#^:"C_ (:B_:9_Z.*^.O\ X=SQ_P#_ #05X511_8V3_P#0
MJRW_ ,(<+_\ *@^MXO\ Z"<1_P"#JG_R1[K_ ,-1?M,_]'%?'7_P[GC_ /\
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M#QVD/\_NK?\ !MA^V9#>.FA?&3]F/4M/ ;R[K5O$?Q4T6\8B64+OL;/X2Z_
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M3(O$6BW>EZU?QW&GPZQH=\MTME=6NL6R07%O>??GA7_@VF_:=O/%$5IXW_:
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M=^'=)MY]7U>ZU/3=-/@U);;7+PZ9=:F+MII=$TK:+5?T.HKU\^X\XCXCP?\
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M&O[BXU)YM'T[2M/Q'!I]JL7T'_P36_X)P>%/^"=/P_\ '_AG3?B#<?%3Q?\
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M\*WZ:C?7EA8V_CGX:Z5JLUVFFQP:%Y/B"VTK1[Z6\%W=_P!E0/96HO.?U/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM_\ X3/[5_PK3[O]M_\ "&?V=_Q5/W_[+_MO^'[7S0!Z[1110 4444 %%%%
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M:/LMM_S[P?\ ?F/_ .)J>B@"#[+;?\^\'_?F/_XFC[+;?\^\'_?F/_XFIZ*
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MO!_WYC_^)H^RVW_/O!_WYC_^)J>B@"#[+;?\^\'_ 'YC_P#B:/LMM_S[P?\
M?F/_ .)J>B@"#[+;?\^\'_?F/_XFC[+;?\^\'_?F/_XFIZ* (/LMM_S[P?\
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M/_XFC[+;?\^\'_?F/_XFIZ* (/LMM_S[P?\ ?F/_ .)H^RVW_/O!_P!^8_\
MXFIZ* (/LMM_S[P?]^8__B:/LMM_S[P?]^8__B:GHH @^RVW_/O!_P!^8_\
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M***]4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHK^H/_@G)^RY\")_V/\
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M"=Y-1M'F<%*345)N]OYZZ***^J/,"BBB@ HHHH **** "BBB@ HHHH ****
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MX3U&.XFCB)\M)9X[6V2:15#RI;P*Y988POV-+A)U>#<3Q=]?45A\;'!_V?\
M5;N:E7P]#VGUKZPN5IU^;D^KRNHVYUS:<+QJ6/C@O9_%3<_:\^WNRE;DY=?A
MM?F7H?U!445^&7_!P]//%_P3FUJ.*:6*.Z^,?PN@N4CD=$N(%N=8N5AG52%F
MB6YM[>X$<@9!/!#*!YD2,OA9)EO]L9OEV5>V^K_7\71POM_9^U]C[::BZGLN
M>G[3E3OR>TAS;<T=SHQ%7V%"K6Y>;V<)3Y;\O-97M>SM?O9V[,_<VBOY8O\
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M)KT</3M[2O5IT:?,[1YZLXPCS.SLN:2N[.RULQ2DHQE)[13D[;V2NSWFBO\
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M+E4DTWE#,*$\)/&*-54J;:E%QC[2Z<59)3<=7)6][UL?NG17\%7P^_X*??\
M!=CXM>%]4\<?"KQ/\:?B9X+T._OM+UOQ?\/OV0/A;XS\+Z/J>F:=9:OJ6G:I
MK_ASX#:EI.GW^GZ3J6G:I?6=W=PW%IIU_97L\<=M=02R>T?L[_\ !Q'^U_\
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M;Q%E&[<GA4EN[1]Y>;_;,$O:/"8M4&[*LZ:Y=79:WY=7TY[]KL_OQHK\M_\
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M)],_X3'XIZ9H6B_9GOEU?4'CT=],WZ7JLVHZ=?P>'M1@_35X69A2A1HX_/\
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MW9O6[O+WK.S>A\2_\&O7_(E_MC_]C1\%/_33\2Z^L?\ @K=_P69D_8C\3?\
M#/7P,\+:3XN^/%_X5CUOQ)XI\22M+X5^%-OXAMI#X90:';D3^*/&%U:$>(DT
MZ_N-.T/2M.FT"ZO5\11ZQ<Z98?)W_!KU_P B7^V/_P!C1\%/_33\2Z_G3^//
MQF\.^(_^"@/Q:^.OQ#\"R_$?P7/^U3XQ\>Z[\+M4U]=%'BKP7IWQ-OM1@^'.
MH^)+;2-4-A8WGARTMO"EYJ5MH]U-'8>9+;P>=L=>Y<-8+/\ Q,XJKYCAWC<+
ME6'R_$+!*481Q>*JY=@XX>E4<JE-.%J=67)*4:4YJ"K35+GC/-XNIALIP<:4
MO9SK2JQ]I:_)"-6;DTK/75*Z3:5^57LU^BDO_!5W_@N!I7A#3?CMJ=_\28O@
MI>K;WMEXRU+]DWP3:?!_5K1_-M(S!X_7X2VD%Q:75S;7!$]CXQ1VNHIXH)TC
MB:W3^BO_ ())_P#!5O1O^"@?AC6OA]X_T>P\'?M)_#?0(-=\4Z5HXE_X1CQ[
MX26[L-'F\?\ A6&9YKG1S9:SJ.FZ;XH\-WD]S'IEWJ^BWFE:G?VFK36.A?D[
MK_\ P<N>$_%/@W6_AWXA_P"">^D:KX%\1^&-2\%ZYX3N?VC83H.I>$]7TJ;0
M]2\.W&G1_L]);G2+S1[B?39;)$2'['(T"JJ8 _.W_@@3<^*X/^"FGP@B\.V]
MU-H][X.^+]MX\EMXGDBM/"B?#3Q'>6=Q>NC*L%JWCFT\&6B2RAT-[=6D 423
M1NE9SPQ#,N&<_P 5FG!V7<)8W*</4QV65\NKY=-8JE0I5JTZ%?\ L^5ISY:2
MI3]O%*I.O3G02G3DD4,6Z6+PT*..JXVG6FJ=:-6-5<CDXQ4H^U2:5Y.2Y7HH
MM2NFK^;?\%4O^"AGQ?\ VX?BM;>$/B7X'\ >!]!_9U^(7QN\-_#ZP\)V'B>#
MQ(=(\2^)- TR>T\>ZGK_ (CU.RUK7--LOA_H<+W^B>'?!MK+?RZQ</HMO%<V
M=CIO>?L5?\%J/VH?V+OA%X2_9\^&?PS^!WC+P-HOB?5]7B/BSP[\0[OQSJDG
MBK76U75-.M]6T#XC:3H\,\LUQ+::1*OA.[:U+PM<6VILC)-^HW_!TA_S8S_W
M<U_[[Y7Z5?\ !O[_ ,HT_AK_ -E ^+?_ *F^HUMB\\R.CX:Y)F5;A;#XG+:N
M.GAZ62RQ\X4L/6AB,TI2Q4<4L+*<YU*E"M6<71BU+$R7M&X<TIAA\1+-<12C
MC)0JQIJ<JZIIN<7&@U!PYTDDI15[N_(M-;+US_@KO^W+\4OV /V:/!_QB^$/
MAKP!XH\5>)_C9X9^&4MG\2-/\1:IX?M-(UCP1\1O%=W?QV7ACQ-X2U*74DN/
M!=G:6S-K"VL<-Y<R2V\[K$%_GY^,_P#P<6_M+^(/V?OAIHOPUT[X<> /V@_$
M4WB36OB=X\\)>%)-0\,^#M%M/$FN:+X3\)^%?"/Q&U/Q[!+XGU+2].M/$WB+
M6=<GUC2K73]0TFTTJP:[O]0_L7]-?^#E[_DQ+X3_ /9VO@3_ -4[\>:^/_\
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M:C8:CX;OM'BEM]3MO%7CCQW;:M97]MJC)&EJ=%GLIX5G:XO(W-LO[+_M]_\
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M +3\/O?33ZE#IFH:;J6G3_8M1FGNK"^-[9_:[Z"""_NO[A?^",OPL\/?"O\
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MZVK)9F_\&Z7I/A7Q5JS:0]E;6RV4VK>#/#-W,L*0'3H+6*WN9/P+_P""G?\
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MXMMM-FFU&'0-?T#6M1T*Q\6Z;]OATR_N?$VDZGX5L;:P;5-&\._HK^VWX/\
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MT\9^,TTN]TS5]6@U;5],U/1O#OAW1M3TN?4I]+UR]O=<TF'2;:VUO^=70/\
M@JU_P7$^(&@/\8O C_$GQ%\*-)U&2/4]?\&?LE>$O$?PN$VG7T3W^DZGXSMO
MA3J[V@07=KIE_'%XMLM0MH);?;<VVH3"[D^8_P#@KSXNUKXN_P#!4#]HBUUB
M9+)--^(/AKX6Z.D*O<0:9HOA30?#WA2UGCBDDC>1[R:WNM>O(#,B'4=2O(X7
MA@,2Q_Z#7PL^&WA3X-_#7P'\*/ UE_9_@_X<^$M \&>'+5DM$F72?#NFV^F6
MDUX;&ULK274+J.V%UJ-S#:6ZW=_-<W1A1IF%&*IY!P'PWPY5Q'#N79_FN?X?
MZ[BJN9TX5H4::HX>M4I4?:4J\:3@L72HTW2C'F<)UJG.W%!!XG,<5BE#%5<-
M1PTO9PC2;BY/FE%.5G%N_LY2?,W:ZBK*Y^;_ /P2 _;Q^)7[?O[-WB;XB?%K
MPAH7AWQOX!^)>H?#G4=8\':?J6G>#_%L-KX9\,^(K/5+*UU34]6GT_Q!!!X@
M6W\2Z5!?3V$3G3=6L18VVMQZ-I7Y0_\ !2;_ (+Y?$7P#\6_%G[._P"Q?H.A
MVNH_#_Q9>>$O%/QGUZUT_P :/XA\2::\^EZIH'P_\(-;W.C1V.EZVK6G_"2:
MM<:W+KUW;26]AH&G64$6H:Q_0Q\>$\*?LX?LL?M0>/?ACX2T'P#)X7^$?QK^
M+]W%\/\ 0]%\)SZCXQT3X=:QK,_B:4:39V=M<^*+LZ%IZOK=ZDU[,]G9?:9Y
M([:,+_G;?L,_M+^$/V0/VD?!7[0GB[X,67QV/P^@U>]\+^#-1\6Q>#K.Q\7W
MEA)I^C>+FU&X\(>-[>:]\,+<W>HZ+#)H9ELM>72]=L+ZQU/1[*=8X(R')^(L
M;Q+Q%3R&.(PN"<?['X=G7IJA/%5:4ZKI5*M:5.AR*4(P@J\7AX*O*;IOV-.(
M9AB:^%IX3#/$.,ZE_;XI1?,H1DES)).5[-M\OO/EM?WFS].;W_@KG_P6I_9Y
MN?!OC;X^6_C>W\%:_JEC<Z-8_&W]EOPW\-/"OCNSLDCU&^T?2/$.D_#3X>ZC
M?0ZCIMS#)<W&@:V;^VM9+:\L[BV5R\W]87_!/#]O#P!_P4"^ =I\6/"M@WA?
MQ=H&I+X3^*?P_N;N.ZNO"'C*#3K/4)#8S_)/J?A/6[:[2^\+ZZ]O M]"E]IM
MQ'#K6B:S96?\N7[:W_!>KP_^V;^S9\1OV>M?_8MTWPV?&MIIS:'XQU#XX0^,
M9/!7B#2=5L]2T_Q-IFBR_!3P_)+J5LEO<62/:Z[I4QM;^[MWNGM;BYMKCWW_
M (-@;WQM'X[_ &L].M[:]?X<7?A+X8WNK7C6KOIT'C;3]8\40>'K:&];Y+>]
MN]"U/Q/+<6L!WW<%E:RW618V>/1XLX:IXC@['9SC^%\OX4SG*\12=.EEU7!/
M#XS"5:^'HOVBP,I4>9^WDHQJ+VRK4(N,E3K.*SP6+<<=3H4L95QM"M"7,ZL:
MG-3FHR>CJ)2M[JNU[O+*S3:N>]_\%9_^"XGQ _9\^+VK_LT?LD6^A6GB[P#/
M%:_%3XJ>)]%AU]-/\1S6CS/X*\'^'=5@_LF5]%AN+*XUKQ+JD>IP3ZF\NBV&
MEPQZ;<:CJ/Y\>"O^"RO_  4_^$.CV/B#]KOP1XL^(WP'^,FB:UX:T;7/'/P.
MTSX0IJ5GJEG%;WVM_"[QIX7\$>!O#OB;5='L9)[E-.O/[;TZ\CN9(;F;3R]K
MJ-C^>_[%FB6/[6__  4X^#K_ !(5]>L?BY^TK=?$?QK;ZHP4^(U?Q!JWQ,US
M3]7#+J7FP^()+&XL=5@$KR7,%[<V\>HVLDJZC#_H&?M9_"+X=?'+]G+XP?#G
MXI>%]-\6^$M6\!^);N73]1A5WL]4TK1[W4=&US2KH 3Z9KFBZE;V^H:3JEF\
M5W97<,<L4@&Y6,[CPKP0L@X?Q/#.#S6KC<+2KYKF-50680<ZGL95L)B)0=:%
M3V\:U2%.%:A3A3IPI1:YW4@8=XS,/K&)ABZE%0FXT:2O[-V2DE4C?E:Y7%-M
M2;;<NEG_  E?\$+_ /E*?^RY_P!UM_\ 6=/BY7^A]7^>#_P0O_Y2G_LN?]UM
M_P#6=/BY7^A]7@^-'_)4X#_L087_ -6.:G1D/^YU?^PF?_IJB%?YK/[-_P#R
ME1^ O_:0+X6_^M&:%7^E-7^71>_#/7OC3^U[=_!SPM=Z18>)_BS^TC/\,_#E
M]K\]Y:Z#9:]X\^)S^%M(N];NM.L-5U"VTBVU#5;>;4I['2]2O(;-)I+6PO)U
M2WD[O!^$*E/BZG4J*C3J9=A85*SCS*E"4<PC*HXWCS*G%N3C=72M=;F>>-QE
M@9*/,U5FU%:.33I-1OKN]-F?Z'7_  4/^+OP'^%/[(WQW7X]^*?">C^'_&'P
MF^(/AG2/#GB&:WN=3\:ZSJN@R:+IFB^&?#@\W5=>U$:WK6B*\FEVDJZ$;F#6
MM2NM+T^TFU*V_BK_ ."%WP^\5^.O^"EOP)U#PR^H6MG\.;+X@_$'Q?JFGPW<
MO]F^%+/P)KWAF9+U[5X1;Z?X@USQ3H/@^YFNIX[0_P#"1I!(EX\T>GWGC/[<
M?_!+_P#:D_X)_P!MX7UOXT:=X0U_P-XPU)M!T7XC_#/6M5\0^#3XF33Y-5_X
M1C4I]<\/>%M<T;6Y].MK^\TZWU;0K.#6;;2=:FT6YU&/1M3:U_J/_P"#>O5O
MV2-?_9F\52_ WX<_\(-\<O#6IZ+H/[1-YK_B.;QIXU\3W%W#J%WX.\4_\)!)
MH7AZQTOP1X@%GX@C\->#="TNRL= NM"U6WU-]?UQ+SQ=X@];ZI@N"N ,ZQ&4
MX^KQ+1S[GP<L?AJ=&E@<']8I5,$JM6B\17J4W#VDZ4VY57/$_5Z-2%!.[QYZ
MF89EAXUJ:PDL-:HJ<VY5*G+*-3E4N2*=[)I65H<\DY'S+_P<V_'?4=*\"_LY
M_LVZ5-<0V7C'7_$GQ=\8&*[BA2XM_!UM%X7\':=/;Q,UW=V=Q?>)O$VI3Q77
MV?3TOM%TFXACU"]MQ)I'KW_!MI^SUX2\)_LP_$+]H^?2XY_B+\6_B%JW@NWU
MVYM(S-IOPY\ 0Z8EKHNC7,]K]IM8M6\87NOZAXD>PO/L.M/I/A6"]MS>>%K>
M1/AG_@YXT?5(/CC^RYK\UC<1Z+J?PI\:Z/I^I,A%K=ZIH?B^TO=7L89.CW&G
MVGB'1+BY3&8X]3M&/^M&/UL_X-[=7LM2_P"";WA"RM7W3^'_ (J?%;2-27=$
MWEWL^NPZ]&@$<LCIG3M;L)-LZ0RDR%Q$8&AFE\K,?]C\&\ICA&X1Q^81^O2@
M_P"-S8O'U)*HT]4JF%P]-I]*4(M75C:DE4SVNYZNG2O33Z/DI)6^4YOYMG[?
M5_G+_P#!8/X%^%/V;/\ @H?\</"?PTL/^$9\):OJ'AGXH^&M)T\6MC:^';KQ
M]H&F^*=;L-!@TP6\&DZ+IWC"ZUU?#>F6MK81Z'HZ:=I=I"UM86]W<?Z-%?P
M?\' .IV%_P#\%+?B9:V=U%<7&B^ /A)IFJPQDE[&_E\#:9K,=K." %E?2]6T
MV] !(\B\A;.20.#P9K5H\38VA"4O8ULGKSK4TWR2E2Q6#5*I*.W-#VLX0DU=
M*K.*?ON^F>QB\)"32YHUXJ+ZJ\)W2>]G9-KR3Z']+O[6?B/QM^UM_P $/?$/
MCS2+*X\5>/OB=^RQ\)?B3X@LM'TR?[1>>(-+E\">-OB-'I^EV.G6[2-87.C>
M)3!#I^G16DRV@:Q1;)X9*_E#_P""2'[>/A3]@+]I;4OB'\0O#>J>(/A[X_\
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M4O<K3Y5):^[4>)2DN^CNC_.A_P""2'[>/A3]@+]I;4OB'\0O#>J>(/A[X_\
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MDL=5\6?%WXTZKILDEQX1L=!\$^#]1=F^S)?>(TU2_P#%_DHEPH^V66F6/AZ
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M7GMM(\.3V=KNLUGL\3/]H\>T'_@BI\%;;6_&,OB_XH_$^Y\+B_AG\$?V%?\
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MEN;A;71/ 6C&>.X\Z]2PAU%M?UD063ZE<Q)_/9^V3^W#\2?VJO&NM)#J^O\
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M\77GC_QWXU\>:A$8+_QMXM\1^+KZ W$MX8;SQ)K%YK-S$;N<":Z,<UZZ&XF
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MVDE\H%K_ %]KF)KN40AFG>[ECA!:-/YR?V/?&7CSX]_\%!_A!XT\;:[J&O\
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M_P!/FHU^)^//_)(9;_V4F#_]5><'V'!/_(UQ'_8OJ_\ J3A#]6_A)_RZ_P#
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MH3X,^)-W\,)?V4?C)XDU.'5Y]*LO%/@WP3KWB3X;:M''?W5A;:O:?$:RL/\
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M#2O"VN^*K;2+*+PI8ZG;HL.IOHFC:%I,&KWUN]U83^(6UC^R+[4-&73KV?\
M2ROS3.Z67T,XS.CE-7VV6T\;B(8*KS.:GAXU)*FXS>M2"CI"H[NI%*;;YKGK
M8=U94*,JRY:KIP=16M:;BN:ZZ.^ZZ/3H%%%%>6;!1110 5_GW?M_>+-:_P""
MC'_!736/AOX.U>.YT75?B]X/_9=^'>HC6)-9T32?#'A/7(_"6O>)=.U"WM[F
M#_A&;OQ-/XV^(R_V197=LMEK%Q/:+K,\C7NH_P!L?[<_[0*_LL_LB?M ?'F.
M=[;5O /P[U67PG,EO8W:IX^\126_A+X=BXM]2)LI;)_'6O\ AU+]9XKL?8FN
M"EAJ$@2QN/X>_P#@C+\;OV7/V>OVPKK]H+]K+XHW'@&R\#> /%S?#V^;PKXZ
M\9W&L_$7QH(?"M]/>IX+\)>,-1BM[?P1K'C/SYKM--:XU#4+%UU"5(KJRN_V
M/PPP6)P>7\3\48?"5L9BL'@:F7950P]&IB*M;&U(1KU(PI4X3E)QE]24G"$Y
M1I5:K:4.92\+-ZD9U<'@Y3C"%2HJM:4Y*,8TXOE3<I-+5>TT;5VHKKIT?_!:
M+X!7/['_ /P43UOQ=\--.B\%>&_B'%X0^/OPP?0](T_3M*\/:^+K[)XAM]*A
MM+<:0+C3?B'X9U;7UT\64#V5CK6D+=V<\-Q!?ZC_ &^?L>?M!V'[5?[,'P1_
M:#L8+"SE^)W@/2M:UW3=+F-QINC>,;,S:)XZT"PF>>YFDM- \9Z7KVBV[74I
MO?*L%^W1PW8FAC_E0_X+G_MD_L#?ML_"GX.>(_V>_C=9>-OC/\*O&FK:>VB2
M?#/XR>$KG4_AQXUTI7U]DUOQ=\/_  _H-Q/HOB/PYX6N;+3M0OTE2TU#79]+
MECGDN;34_LW_ (-H?VB#XG^"OQL_9EUB]:34OA9XOL?B3X.AFC56;P?\0X&L
M-=T^SDB;#V^A>+?#[:I<BZBCG%QXX00W-Y;@V^F=_%>7X[-O#C),US'!8S"9
MMP]..#QD,;AJ^&Q,L'*<<%[1PKPA4J*HXX"NZKBXIO$:WYV9X.K3HYIB*-*I
M"=#$KVE-TYQG!5$O:63BVE:]2-K_ ,OD>Z_\%BO^"KG[0/\ P3Y^)_P>\"?!
M?P3\'/$MCX]\!ZUXMUV]^*&A^-=;NX;NS\0MH]E:Z0OA3Q]X)AM+=(;>>:Z:
M\74I+B2:(1-:+;N+G\[?C#_P7;_;9_:.N/#/PQ_8 ^#.LGQ9I_@WP]J?Q#\8
M>"OA-K'Q:\;:SXN/ANQD\7OX(^'EUI_C73O"/P]TGQ--K5OI<WBC3_&&OZOI
M^GZ/J5UJ'A_=J>CW?*_\'.?_ "<1^S5_V1?Q!_ZG%]7[8_\ !"CX1?#KX=_\
M$Z_@WXS\)>%]-TOQA\8%\5>+/B5XH2%7UWQ=J^E^/_&7A[0AJ=^X,ITWP[H-
MC;:7H6DP>3ING1F_OHK8ZOK6N:CJ65/#\,Y!P)P[Q+BN'<+FN98BI4PU.%>4
MEAZV(JU<7/VV.@^>->%&AA)QITG3G!SG&\$[5:=.6+Q&98K"0Q,Z-&*C-N/Q
MQBHT_=IO1Q<I33;OHD]>DOP;_9-_X.%?VL?AI\3]-\,_MD+I'Q=^&]SX@@T;
MQOJH\"Z'X"^*G@"&.]GLM1U'1[+P5I?AKP[JCZ(TSW&K>%M<\*MJFJ?V5#IM
MCKN@7<EW<W/]0O\ P4*_:K\2?LJ?L0?%C]J3X1VG@KQMKOA#3?AQJ/@]/$1O
M]:\#ZW:>/OB3X&\&Q:G._AG6]%O-4TW^R/%LNK:=)I>NVD=Y)%:2+=M:R,'_
M )&_^#B7X9^'_A__ ,%"1KNA06]M-\7?@?\ #[XF>(8+:RALXQX@37/&_P .
M;F=O(.+NXOK#X>:=J%W>R)'-/=W4WG"1T,\WZU_M#>+-<\:_\&T>CZ[XBN_M
MVJ+\&/V;=!:Z*!9)K#PC^T7\*_"6CF=LEIKI='T2P2[NI"TUY<K+=SLTTSL=
M\]R'(,PGX?\ $. RO#9?AL_S?*L'F66T8\F&J1Q5:C*5-4J<:5**IJGBJ%2=
M*G2]O&<)N*:N3A\1B:2S/"U*TZL\-0K5*5:3O-.$79MMMN]X22;?*TU?4^0M
M%_X.3?C[J7P4U[2KGX,?##6/VF_%'C(^'OAXO@K0O&VF^ O"WAB33M&%OKNM
M>'M9\8>,M=\>>+]7UV]U+2?#OAO1M;T"QA:V34M8DN$@M=%\1_,&J_\ !:3_
M (*_?L\_$NQC^/LE[ILODVE]+\(/C7^SKX?^&=OJ&FM):2-=1+8>#? 7Q"B2
M\ABECBO8O$$EJGV^:2.%REH+?V+_ (-J_A%\.O'/[1OQL^(WB[POIOB#Q;\(
M_ ?A:[^'6H:I"MVGA;5/%NL:QIVL:YIEK*&@BUPZ;IJZ?9:IL-WI]I>ZE%:2
M1&]E:OU0_P"#D/X>>'?$G[#G@_Q]>VL0\3_#;XX>%O[ U01*]TFE>,=$\1:+
MXBT02L?W5AJDUOH.JW013))>>&],7*QB4-Z=>7!V4\9TN$:?".7UZ>/J4*>+
MQN*C&O4H8C&T(5,-#!0JPJNC0IPE2C4=*I1FYU)U%[U-RKX1^O5L!+&O&U8N
MDI.%.#<5*-.5I.HTUS2;YFKJ2LDMG:/Z=_L _MF^$OV[_P!FCPC\>?#6G)X=
MU>XO=2\)?$3P8+PZ@_@GXA>'A:MK.A_;O*A%W97NG:AHWBG0K@HMQ+X;\1Z,
MVH16FIF]LK;\%/&W_!P+\;/A3^W%\9?@M\1OA[\%(?V?O@]\8?CSX%O-0T7P
M]X\/Q6UO0_A1=^-],\-V6GZW>?$IO"*>+?&.K^&]'TJ*XN?"4.B0WNL[9H;.
MU1KR&;_@UW\2:M=>&?VS_",UQNT/0]=^ _B33K7#?N=6\5:?\6M,UFXR6*?Z
M39^#M!CP$5A]D^9G!0)^ _[3O@VR^(W_  5&_:%^'NHW=U8:?X[_ &^?BSX-
MO[ZR$37ME9>*/VA]?T2ZN[19TD@-U;07TDUN)HWB,J()$9,J>#(^#<AAQ?QI
MDV.PL<1@,!@J5?"<[G*I@Z6,I4L5'V,[\SJX>E75.$Y<\FZ:<N9MMZXC'XEX
M++Z].;C4JS<:EK)5)4Y<CYE;12E%MI66K6Q^H'[/7_!<?]O/XY?MW_ 3PU>>
M-/"OAKX,?%C]HOX9^ -0^#5AX!\$7^CZ=X(^('C[2O"5QIZ>-+OPZGQ$NM:T
MO2-;^U6^N1^)[&&XUNQM[N724TN2YT.;]_/^"J7_  52\+?\$[O"WAGP_P"'
M_#-E\1/CY\1+*YU3P?X/U2YNK/PUH'AJSNFL;GQEXRN;%H]0ET^74(YM-T31
M--FM+S7+RTU,G4],M],FFD_0_P"&?[/OP9^$/P[\'?"OP%\./!VB^"_ S^'K
MW0=+B\-Z& GB'PQ8Z?8Z5XRO&BT^);SQNBZ997,_BV6/^W+B^A%X][YX#C^
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MC3]M7]N+Q]\)?BW\4+GQ)XA\?>"](^'0\0ZQH"_%#QIJ5_J.L_$+7%\3>#/
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M%3''8F>5UZCJ-5Z%:%-58VYI1<H;]&]7%NVJM?6[.-_;#_X.%/VH/%FK>"-
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MYK'B#4II$M]0MM-T_P#;/1-"T3PSI5EH/AO1M*\/Z'IL1@T[1M$TZTTG2K"
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M_;%\?_LX?LX?#OX*>./#W@&;POX5N+_QUX0^(OB'Q/K/Q"U+2;#4==TK2/\
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MPI0Q$<RJU,5S*4\-*%7V-F]8I-*E[JWLE%ZJ%FDW_H8_%CXY?#;X,_!;Q?\
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MUF_O+BY2>W"VL$%DWG6\DNS4=RZ5Y%X]\EG<?W]?M'?LW?![]J_X3^(?@O\
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MW6W_ -:+^+E>9_\ !9;X)_\ !1OXPZ9^SVW_  3]\2_$S17\.7_Q/7XLZ?\
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M-5W^&_ ?Q,\(:S!>Z9<L\EM+::]X?U2T!626"X2!+JVFFMIHI7_E:_X-T_\
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M(WC*]N]$M;Y-233+>3Q_XP\4C2[66_BM[J[32EL3?RVEDU\;@6-H(8OVD_\
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MM+I8+J,_9[^WO+4O;M^0/_$-Q^P'_;_]L?\ "8?M,?V=]I\__A%?^%A^ _[
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MZGMTXU?8QC7<75<+5)0ORN3NFXW2=O5(_D*_X-X_V:?VC?@I^U#\:?$'QE^
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MMS_PA,MIIWQ!MKC4+M;+0O#ND>/C:0/>ZZV_]5_V8/V+_P!F;]C/1?%7A_\
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MTLHY'9+2U?4-0O[][>!8XFO;V[NBAGN9I'_TEO\ @IU^V%XU_8:_94UGX]>
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MQ)/)B0?5O[+?_!'S]A+]DSQ%IGCGP-\+KOQK\1]"U7^U_#_Q"^+.MS>-M?\
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M>GTW5?#.M:?'>WGAN6YNK&WU-] N=1EO-7MK2>ZU*[U.^^-_VE/V_P#]H?\
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M?/*G*$7:<Z<6DY7^)--)J]K'TE_P5E\=_P#"9?ME^+=)2/%O\./"?@OP);7
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M0C+F52;C",.6$H73NN4HHHK]+/G0HHHH **** "BBB@ HHHH **** "BBB@
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MW6C:IK0FL]9DL)-"U+0P+>VOEOHA_0_^T7_P3(_8?_:R^(G_  M?]H#X)?\
M"?\ C_\ L+3/#/\ ;_\ PLGXN^%?^))HTEW+IME_9?@KQ]X<T7_1GO[MOM/]
MG?:YO-Q/<2A(PGV5X'\%^&/AOX*\(?#OP3I,6@^#/ 7A?P_X+\(Z'!/=W,&B
M^&/"VDVFAZ!I,-S?W%W?7$6G:58VEG'/>W5S=RI")+FXFF9Y&_35QY'+.$,I
MR'AR689?F5"O+$9GCY4\/3A6E4=:I4IT)PK5JE2,JE2G'GJTJ,E1P].-O>:7
MD_V:ZV.K8G%*E5I2BHTJ=YMQMRI.2<8I646[)R3E-OU_G<\>_P#!M)^R+%X&
M\9R_#CXJ_M,R_$./PGXBD\!Q>)O&7PFO?#<GC--'O&\+Q^(;.S^#OA^\N]#?
M7!8KJUM:Z]HES/8&XB@U?3976\A_GZ_X(X_'RZ_9>_X*)_!^7Q&\N@:'\1=5
MU+]G[X@VNJ+=Z9-90^/[JUTO1H-45U0Z>NC_ !+T[P9J&JC5+<VMG;Z7=_;#
MI[1?VC8_Z*%?FGXK_P""/G_!.3QI\2=8^+NN?LW62_$#7?%4OC?4M:T+XF?&
M?PG:MXIFU :K+K%GX?\ "GQ&T7PUI<TNI#[?)#I>CV5JUVTD[6YDED9^C(_$
M64LNSW*N+JV9YMALTP;P^&JT88:M6PLYTZU*JVJU;"KE?/2JPE&4I0JT;J+Y
MVU&(RM*KAZV"C2HSHS4IJ3G&,TG%KX8SUT::LDU+5Z:_SW_\'.?_ "<1^S5_
MV1?Q!_ZG%]7J/_!(C_@M7^S[\!_V;[/]FO\ :GDN/AM!\'=-U>?X7^.?#OAK
MQ;XNL_'NDZMKNHZ_=^%-:TKP_8Z_J&C^-;75M9O9-,UB2*Q\'ZMH[K;:A<^'
M-1TB.7Q-Y=_P<Y_\G$?LU?\ 9%_$'_J<7U?:W[%G_!*+]CO]N;_@G#^R3XS^
M+'A+7_"_Q,B\)>*[.Y^*7PMUFT\*^--9TNQ^(WQ&T^RTOQ&-1TCQ#X7\2164
M<MBUCJ6N>&K_ %_3X=&TK2;'6+;0$O-(O?K9U.'H^&/"U/B2CCIX#$8ITJ=?
M+I06*P>)53,JL,1"-2].<'3IU:%2,H5+0K.4:;G&,H\=L2\WQCPDJ:J1IIN-
M6_).'+13B[6::;4D[K6-KV;/YWO^"E7[64__  4,_;7UWXB?#O1=?G\+7<7A
M+X0_!/P[?P,WB2^\/:7<2V^FK)8)//';7_B[QIKWB#Q#::1;[#8)XAMM-N#<
MW]O=WUW_ %(_\%$_@K)^SG_P0/\ %'P.NIEN-3^&?PL_9C\,Z]<HEI'%<^)K
M7XZ?!N7Q1=0)9%[=;>Y\13ZG/;[9KN0P21F>^OYS+>S_ %7^R%_P1U_8E_8S
M\7Z9\2? 'A/Q9X\^*.AK>KX?^(OQ;\2P^)]<\/\ V_SX[B?1='T/2?"O@?3M
M2%I-]@M]<@\)+KUI9))!:ZI#]NU1K_ _X+H?\HL/VH_^Z)?^M%_".O"QG%F6
M9QGG 619!A\10R;)<[R:,)XI1C5Q%6.,PM"E)04IR4:=)3;J5)*I6J5ZDITX
M<J<^BG@JU##YEB<3*,J^(P]>Z@VU&+ISDU>R5W*RLKJ*BK-WT_DH_P""0O\
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MWAVRUKQ--:-<Q6=MI.@:9=>-_'VH)<-I&E7-QKUQ;7*:7!;[?Z?]9_X-N/V
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M&AZ?X3\/ZI'INI:7X9@M_$4TFJ:QXLTJVU+5M3U'3M-LM)T:/3'O-?\ N?\
MX-A/^2-?M5?]E-^'_P#ZBNL5^LOP8_X)+?L(_!#X1?$'X->'_@U#XDT'XM^'
MU\+?%+Q)XUU[6=7\>^-M!BU6WUJUTRX\66%WI%[X8LK/4['2=0M[/P"GA&S&
MJ:)H^N26\NO6$6J5]"_LQ?L;?LV?L:^'_$_A?]FWX:Q?#?1/&6L6NO\ B6U'
MBKQOXNGU35;*R&G6<\FH^._$OB?4H(K:T#1PV5I>6]BCRSSK;"XN)Y9-\VXO
MX7_U0QO"618#-*%-XK#U,+BL6\/4^M*GB,/B,1B<7*-93I5JDZ<X4Z5*C.G[
M.-)OV-Y4J<T,#B_KT,;B*M&3Y)*<(<RY+QE&,(7C:44FFVY)WNO>^)_3M?A;
M_P '$7_*.G4_^RT?"_\ ]#UZOW2KQ7X__LZ_!G]J/X<WOPF^//@BU^('P_U#
M4+#5KG0+K5?$&B?\3/3#,=/O[?5?#&K:)K=E=6AGF\F:RU*W=?,;DU\'P]F-
M'*,\RK,\1"K4H8''8?$U845"565.E-2DJ<9SIP<VD^52G"+>CDEJ>EBJ4J^'
MK48M*52G*"<KV3:TO9-V[V3]#^'O_@B]_P %*?"7[!'Q$\7^%/C%X?E7X%_'
M2_T"W\3_ !$TO3]8U+7OA]XA\(0ZA'I.M+I6GK=MXC\+P6WB>XC\6:-I.FW'
MBFU@N].UG11J,ME_PC>O>M_\%PO^"HWPA_;8L_A/\&/V<=4UWQ#\+? /B#6O
M'OBWQ=J^B:SX9LO%7C)[*X\->%$T+0M=@TW6HK+P_H-]XGN9M0UO2;2[O&\5
MP6MM:Z>=.O\ [?\ TX^,O^"2G[!GC#]G?3_V8D^"D'ACX:Z#XGUSQMX3O/#W
MB7Q--XZ\(>,?$D-M:Z[XAT7QWXGU3Q)XBGGU6TL=.L]1TO7KS6_#M]::1H=O
M>:-/%H&B+I_RW\*?^#>W_@GE\-/%\?BS6-,^+GQ@BM;^VU'3O"?Q6\=Z7=>$
M+&XLYY;F".33/ GA+P%=ZY8>:T N=+\4:EKNF:C!9Q6FI6=Y:7&HP7WZU#C3
MP_KY_/B[$8#.Z&<4'.-'#15"K0Q?)2>&P^,G#VO)3Q?U9QA*#Q$:%*5-2C[:
MI%5I^*\!F4<,L%&KAY4)6<I/F4H7:E."?+=PY[M/EYI)M/E3Y5A?\&\_[/>M
M?![]AVY^(OB:UN++5_VAO'^H_$'2;6XM[:"2+P'I&G6/A7PG,VPR7DJZM<Z=
MX@\06DMU+%%)I6L:;):6,*/+?:E\!_\ !S!^RW96MQ\$OVP_#>ERQ7.IRR_
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MV:YG=7;@I;;^Y]Y_/M_P;"?\D:_:J_[*;\/_ /U%=8K^<_\ 9K^(7@GX!?\
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MUOXF>'3M$\4^']"U[6=4UC5'DLI;:/0M'L+9O[0U635+IQ:VNH]M_P &M_\
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M3BH*+23<HQE=RE)R25K*+NWHOX5?^#=/_E(>/^R%?$W_ -+O"5?J%_P<]_\
M)&OV5?\ LIOQ _\ 45T>OVB_9L_X)L?L3?LB>.;_ .)7[/7P.LO ?CG4?#]W
MX6N/$5QXW^)GC2[CT*_N[&^O;.PB\?\ C3Q59Z4]W<:=9BXO=+MK._FMXWLW
MNFLY[B"7TC]IW]C;]FS]LKP_X8\+_M)?#6+XD:)X-UBZU_PU:GQ5XW\(SZ7J
MM[9'3KR>/4? GB7PQJ4\5S:%8YK*[O+BQ=XH)VMC<6\$L>V/XZRG%<?99Q53
MPV8QR[!8>%&I1G2PRQLI1H8NDW"G'%RH-<V(C;FQ,6XQDW9VBYIY=6AEM7!N
M=)U:DG)24I^S2YH/5\BEM%[0>K7J?C[_ ,&T/_)B7Q8_[.U\=_\ JG?@-7]#
M]> _LX_LN_ ?]DCP)??#/]GCX?VOPX\$:EXCN?%VH:):ZWXG\0?;/$EYHVAZ
M!=ZO<:EXMUO7]7ENKC2/#>B6DV^_,;_85G:,W,US--[]7PW$V:4,ZS[-,UPT
M*M.ACL3*M2A74(UHP<8Q2J1ISJ04O=>D:DEYGHX2C*AAJ-&;BY4X*,G%MQ;5
M]FTG;U2/RA_X+6?M$2_L[?\ !/3XR7FF7MQ8>*OC"MA\!?"<]O':/BY^(T&H
M+XM$DETQ>U8?#'2/'DEE>6,,^H6VIQV,MH;)P=4L/Y:O^"./_!+OP!_P4.U7
MXV:W\9/$WQ!\)_#?X6Z?X4TK3;CX;ZOX=T;Q%K/C?Q7<ZG=QPFX\4>"O&NES
M:+HV@Z#>OJT*VMA?B^UOP\]I<3VXU"./^UO]IS]CS]G/]LCPSX<\'?M(?#O_
M (6-X<\)Z[)XF\/Z=_PEWCKPA_9^MRZ?<:7)>_;/ ?B?PO?W6ZPNIX/LU[=7
M-H/,\U;<3*DBZO[-?[*_P$_9!\ W_P ,/V=? $7PZ\#ZIXHU#QIJ.BQ^(O%O
MBA[SQ/JNFZ/H]]JT^K>-=?\ $FM/+-IGA_1K(0'4?LD,%A"MO;Q$R%_JLDXU
MP_#W"&.RG*XXZAQ#C\:L1/,8T\.L/1HQG1BHTJKK2K2FL/1E",9891C/$591
MGHF^/$8"6)QU.M6=.6%ITW%4FY<TI-2=Y+E4;<TD])ZJ,5;<_&/_ (AH?V$O
M^BL?M:_^%W\'?_G#5_++^UK\%O$O_!.G]O+Q;X%\&:AK37'P*^*/A7XA?!_Q
M+XC6)M4U#0(+C1OB%\--8U&]T:/2;+5-0L[673+'7=1T2'2+>;7],U:.WL=#
MN(9--L/]+FOA[]I3_@F[^Q3^U[XSTSXA_M"_ W3?'GC;2=#A\-VOB.V\8?$;
MP3J,NBVUS/=VMCJ;_#[QAX5CUI;.:ZN/L,^L1W]S91326]K-#;L8J[N%O$W,
M,!CJ[XFQ689QE>(PE6A*A&.'JU:=:4H.%2,*L\/"4)052E5BZJO&IS6;C9Y8
MS*:52G'ZI"E0K0FI*3<HIQ2::;2DTT[23L]5YMGTO\&OBEX<^-_PD^&?QB\(
MS)-X:^*'@7PMX[T79-Y[06/BC1K/6(K*X<Q6\BWNGF[:POX)[>VN;:]MKBVN
MK6VN(I8(_2J\S^#GP>^'?P!^&?A+X/?";0)?"WPZ\"V$^F>%?#\VN>(?$CZ5
M87&H7FIR6HUKQ7JVN:_>1+>7UR\(U#5;LVT+QVEL8K."W@B],K\PQ/U=XC$/
M">U6%=:K]6591598?VDO8^V4)3BJOL^7VBC.<5.ZC*2LWZ\.;ECSVY^6//RW
M<>:RYN5M)VO>UTG;=(_S@?\ @L+_ ,I+/VM?^R@:7_ZA'A6O]&'Q1X=T[Q?X
M9\1>$]85WTGQ1H6K^'=42,0-(VG:WI]QIMZL:W4%S;,[6US*%%Q;7$!8@302
MQ[HV^&/BU_P2O_8$^.GQ@U/X\?%;]G;0_%WQ1UO4M%U;6]<G\8?$K2]*US4-
M M;"RT^?6O!FA^--,\#ZNLEIIEG!JL&H^'+FWU^..4:]%J7VFZ\[]!*^XXMX
MKP6?99PE@\#1QE"OD&7RPV*J8B%&$)UWA\MI*6&=*O6E*G&>"G+FJQHR:E#W
M$^9+S\%@JF&JXV=24)1Q-12@HN3:BI57:=XI)M5$K)R6CU/\V+X1>)_'W_!+
M#_@HMX?UKQ]X8U*Y\1_LV?%+6-#\7:%+8P6.H^(_ WB#1=4\+:SJ>@6]]<26
M:-XQ^&7BR?Q#X*OY+V73YXM8T34X;^2RECNV_JX^,G_!PG^PIX9^"FN^,?@Y
MXG\2?$KXPS:7<0^$?A)J7P]\=^&9;?Q!<174>G77C/Q'JNCZ?X1M_#=A=1V]
MSK7_  C?BO6=9GLID@TJSFNGG>R_0O\ :R_X)W?LC_MJP6<WQY^%5CJ_BG2X
MGAT?X@^&[^_\(>/=.BD2"+R)/$.@SVCZ]8Q0P+'::3XKM]?T>Q+R7%CI]O=M
M]H'YG:1_P;8?L$:;>I=7OCW]J'Q! NW=IVK_ ! ^&\-E)MEBD)>30?@[HFH#
M>D;P-Y=_&!%-*R!9Q#-%]3CN*> ^+/[,S'BC#YQA<VR_#TJ&(IX&-*6$QT:<
MY573<O?J?5Y59U9J">%K4_;3IJM42C4..G@\QP7M:6#E0G0J2E.+J74Z;:4;
MVT7,DDK^_%\J;BF^4_ S_@B'^S1XX_:<_;Z\&?%O5[#7[[P)\#-?N?C+\1?&
ML4;V]HWC2 7U]X"T2;5FM9;%M8\0^.'L]8NM& 6\U'PQHGBB2V^S+;M=V_V%
M_P '.?\ R<1^S5_V1?Q!_P"IQ?5_6U\"/V?O@U^S)\.M,^$_P(^'^B?#?P#I
M5Q<WL&AZ-]MN)+O4KP1+>:OK>LZM=ZCKWB/6[J*WM;>YUOQ!JFIZM/:6=E:2
M7C6UE:Q0^.?M._L _LB_MDZKX:US]I'X/VOQ'UCP?I]QI/AW4_\ A,/B%X0O
M=.TRZN9+R>P^T> _%OA>2[M9+J1[CR;YKI%E;>@5@".1^(^%Q''&$XCQ.$Q=
M/*<OP>(P&$PE"-">+5&I2K156<)UJ5!5:E6KS5(1K<M.G&%.,ZKI\\]/[+G#
M+IX2$X.M5G&I.<G)0YE*#:3492LHQLFXW;;;2O9>!?\ !%[_ )1C?LH_]BOX
MU_\ 5K>/:_4*O./A%\(_AU\!_AMX1^$/PE\,6O@WX=>!-+_L?PKX:M+O4M0B
MTRP-S<7LJOJ&LWNI:OJ-U=7MW=7M[J&J:A>ZA?WMS<7=Y=3W$TDC>CU^:9QC
M*>89MFF84HSA2QV8XW&4H5%%5(4\3B:M>$:BC*45.,9I2492CS)VDU9GJT(.
ME1HTI-.5.E3@VKV;A!1;5TG9M:72=NAR'Q!C\6S> O&\7@">*U\=R^$/$L?@
MJYG%DT%OXM?1KU?#<\RZG#<::T4.LFRDD&H6\]D44B[AE@\Q&_SA/^"=OQ?^
M!'[/?[9O@SXA?M@> I?&?P[T&7Q=8>*-)\0^#+/QO=>'O&%WIU[9Z3XFU;P?
MXB1C?W_AKQ#LNKG=;SZYI%XK:OIMI/K.G6L+?Z55?D5^UA_P1+_8@_:Y^(NL
M?%GQ1I7Q"^%_Q!\3WR:IXPU[X,^)-#\.1>+]4$,L5QJFMZ#XH\)^-/#::KJ3
M/'=ZSJND:/I6I:SJ,']IZI=W>H7FIW-_]IP)Q1E.24,]RO.J>+A@L\PU.C+&
MY>E]:P[IPQ%-QO>,U&4,3*5.<.=TJL-:4XU9.'!F.#K8B6&K4'!U,/-R4*OP
M2NX._;1P5T[73T::5_PX_P""U'_!5C]E?]JKX%^#_P!F;]F-=<\::5H_C_P]
MXWU/X@OX<U;P%X0TJP\+^&M2TO2/#OAKPWXFT;2?$NI-.WB>]M;R2\T?PS9:
M)_PC\::<FNVFIPW%G]:_\&PG_)&OVJO^RF_#_P#]176*_4;X%?\ !'C]@[X$
M?"CX@?"2P^%5Q\1M-^*NE1:%\0O%WQ0UF36/B!K^BVTQN;73++Q+X=MO"A\&
M6]O=%;P/\/[/PG<W%];V-]>SW5YIFFSVGUC^S1^R+^SG^QYX2UGP1^SA\,=-
M^&OAWQ%K9\1:]#;ZQXF\2ZIK&K"TAL89]1\1^,];\1^([NWL[6 1:=ITVK/I
MNFF:\DT^TMI;^^>X[\VXLX7APCCN$LBPF;J$\90K4,;CY8>?UGDKT,17Q&(Y
M*D)4:DY4G2IT:6'Y'",*LG2G.=..=#!8MXVGC<1.A=4Y1E3IJ2Y+QE",8W34
MDD[N3E>]TKI)G^?YXO@\4_\ !-K_ (*97NI:UHFI>(IOV=?VD!XKLK+4[5_#
M5Y\0?A[:^*#K&E7]HUW;WT6E-X[\!W<-SIVI0Q:M9:=<:I'=6S:I#:J9_P"E
MO]L'_@X)_9)LOV==4A_9FO-7^+/QC^(OABXT2V\(>)_!?C/PCHWPT?7](2+4
MKOXA:EJMEHUCK5SHL=]=6<6D_#O7O$=IJNL6,D2^)+'1Y+?6[C]2_P!M'_@G
M%^RW^WE9^'&^.OA/54\5>$8I+/PW\1/!&K)X:\=:=HT]T+RZ\/2ZG)8ZGI^L
M:!-<F6X@TS7])U6'2;F\U&\T(Z5>ZIJ-Q=?,7[-/_!"_]@O]FCQIIOQ"LO#O
MCWXQ>+= U.VUGPQJ'QM\2Z-XDL?#6J6,]E=6%]IWAWPIX6\$>&;RZT^[LA=V
M-QK^C:S-:W,\L\,BR169M?2QO&'!7$&&R?,N(L%FU3/,GP\:4\)A)4H83,9T
MW&456K.SCAIU4ZUJ?L*U)U*E-_6(1ASY4\#F&%E7I86I16'KR<E.?,ZE)/1N
M*_G2T5^:,N5/W6]/Y4/^"&T$]K_P55_9BMKF&6WN;>7XXP7%O/&\,\$\/[._
MQ>CEAFBD"R12Q2*R21NJNCJ58!@17]W'[5OP*TO]IK]F[XU_ 754LMGQ0^'?
MB/PUI5UJ,UY;V6D^*9K)[KP;X@N);!)KH)X<\6VNB:]M2WO$D;31'/8WT#RV
M<_D'@'_@F]^Q3\+OVA+G]JCP!\#=-\,_':ZUOQAXC;QI9>,/B++:0:UX^L-8
MTSQ;?6'@R\\87/@/3&U>PU_6;5H=.\,6MM9QZA<?V=#:,5*_<%?+\;<7T.(L
M^RW.\KI8K!SP.7X.BEB52C4AC,-C,7B^>DZ-:JI4HRKTU3G)TYR<)-TX:7Z\
MOP4L+AJN'K.$U4JSE[CE9TYTX0M+FC%IOE=TKI)KWF?Y:OPY^-OQ._9]T7]H
MGX::#LTD_&SX=W'P2^(MK>HS7FE:=8?$#PKXGU7["L<OV=-6E7PEJ7@ZZ>Y2
M[MTT'Q1X@^S11:F=.U&Q_JU_X-H?V=SX8^"OQL_::UBR:/4OBGXOL?AMX.FF
MD5F7P?\ #R!K_7=0LXXEPEOKOBWQ VEW)NI9)S<>!T,-M9VY-QJ?ZC_$[_@C
MU_P3B^,7C[Q9\3_B%^S98:QXX\<Z_K'BGQ9K5A\2_C-X736_$7B#4[O6-:UB
MZTKPG\1=#T5+_4]3OKN]O)[?3H6FFF8M\H15^XO@Y\'/AG^S_P##/PE\'?@[
MX2L/ WPV\#6$^G>%_"^G3ZA=V^G6]WJ%YJU]))?:M>:AJVI7^I:MJ%_JNJ:I
MJM_?:GJFIWUYJ&H7ES>7,TS_ $W&'B1E>?9#7RW*\#C<'C<RKX.IFM6O3P\*
M52GAH0;A3JTL35JU7[2AAJ<'4I4DZ$)\R4I.+Y,#E5;#8F-6M4IU*=&,U1C%
MS;4IMZN,H**TE-NTF^9KHKK^0#_@YOL/'$?[3G[.^J:@EZ/AK>? >^L/";R6
M[+IS>.--^(/B.X^(26MT;=5FO4T#5?AB;^W%W,UM ^FR-;VHNUDN_KK]B/\
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MIJZC:ZC=V^O/]OLM.3Y$_P""LW_!<3X3_'3X+^*_V9/V2#XDUW1_B"EKIOQ
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MMI/]HZEKGB"XLEN$L)?$GBOQ#?:QXJ\1-IR7=VFF_P!MZU?C3DO+M+(0+=7
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M-EN9Y=F<<#GV+KSI8;+5AZBPV"K0J4UAO:U\7A9J5*G.,(3C&5U'F=GH:8O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O(O@/K?B3Q%\*?"NL^+O'GP^^)GB&\_MS^T/&_
MPLNH+WP'K?V?Q)K%K:?V%<VQ,$O]FV,%MI&J;#\FLV&H1M\Z-7KM>-?L_:'K
M?ASX1>$M%\1?#;PI\(M9L_[>^V?#SP1=6E[X7\/?:/$^M7=O_9=S8O):R_VM
M:SP:Y>^4[;-1U.[C?$B.  >RT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6?M7_"OO[,_XI_[5CR/^$C_=9\SBO7:\:_L/6_\ AH3_ (23_A6WA3_A'/\
MA37]A_\ "W_M5I_PG/\ ;?\ PF_V_P#X5M]BW_;O^$4^P_\ %3_:O+^R?VO^
MYW^=\M 'LM%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^:?[=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &1J<<CM"4CD<!7!V(SXY7KM!QGM
MGKSCH:R_(G_YX3_]^9?_ (BNKHH Q--BE2X9GBD1?)<9>-T&2\1 !8#)P"<#
MTK;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*DUGPQJ.J::FI6MO>V<]S8M<BZ@AN[:66)4GB9W?$'XJ_"_X2Z2FO?%3XD>
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M3II_A_PQI#W,5M-K?B+5I@8[+3[8R&3R8([O5M0,;VNC:9J>H-%9R_KQHO\
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M'^U3\??%-T(0)OB?XIT6Q\B.XB5M&\):A)X2T"26.ZN+J5;N31-#T^2^ E6
MWC3FUM[2V,-K#\+PKQ-CN)/$7B183-9XGAC+\KPZP.'I2I2PL\16A@(JNFJ?
M/+GG''SNY*I%RC"348.F>UF674<OR#+_ &N&5/,L1B*CK3FI*K&G!UFX6<K*
MT706W*U>25WS'S37Z-_\$^?V%YOVMO%.L>(O%^I7>A?!_P "W=I;>(9],>)=
M<\4:Y<1I=6_A72)9!(NF0+9$7NMZU)!<26MM+9V-A;/=:D=0TGXU^"OPA\6?
M'GXH^$/A)X';38_%'C.^N;+39]8FO+?2;1;'3;W6-0OM2GT^QU.]AL;#3-.O
M+RZDMM/NY4A@=E@<C%?UO_L)_LV:]^RO\ ['X9^++[PUJ7BRX\4^)/%'B*_\
M)2WMSHES=ZK/;V>GM!>ZEHN@:E>2Q:!I>CV]Q+?:<DL4T+6D$DME;6K5V^*G
M&O\ JQDE3"9;CJ5#/\=[".'IJTL3A\%6G6C6QU.#BXJWU>I0IU):PJS4X+F@
MFL>&LG_M'&1JXBC*>!H<[J2>E.I6@H.%&3O=_P 2,Y16\4T]&SXU^//[$G_!
M-_X>_#GXLV,&F:%H/Q-\!?"?Q3XWCTBR^-7B"X^(T*Z5X>N+C2M53P=X@\=7
M5G,^IZH^G0V"W?A^/2M0U*]LK&)%CNXX'_F9K]'_ /@H#^R/\9?@QXM\0?'#
MXI^+?A]KL'QD^*?BVZTFP\-Z_P"(M5\0VW]I7&H^((EO[?6/!_ANRBL-+TYK
M73?^);<3V]FYLK.WMHK0P[(_V5_^":'QK_:9\-P>/I=1TKX9?#S4$O!H?B'Q
M)97M]J7B*2U>"-+C1?#UN]I-<:--))<1)K-Q?6MM))97"VB7@&ZEPCC\NX<X
M9EGF=<<5\[P>/G0_V[,L1B*\,/BZ=*4,3@L JE3$8BM^^57]W2@Y-4G+D:C*
M09I0Q&89BL'@\FA@ZU!3O1P\*<)3I2DG3K5^6-.G#W''WI2LG+XM4?G)17[Q
MZ]_P0Z\0V^F7DOA?]H[1=8UE+2Y?3[#7OAC?>&],NKY(\V=M>:MI_CCQ5=6-
MI/+\ES>P:+J,UI'^]BL+UOW-?C7\8_@]X\^ WQ$\0_"_XDZ2ND>*?#L\2SI!
M.EYIVHV-W"EUINL:1?Q 1WNEZG9RQ75K-MBN(M[V=_;66I6MY96WUF0\:<,<
M3U:M#(\VHXVO1I^UJ4'2Q6%KJDI1@ZL:.,H8>K4IQE.$9U*<)0A*<%)ISC?S
M,;E&8Y=&,\9A9T83ERQGSTJD.:S:BYT9U(QDTFU&33:3:3LSS"BOT,T3_@F?
M^T%X@^ =C^T+I>L?#F[\,ZKX,'C;2?"5IJ7C34?B#JMG<1L^F:/INA:7X$OM
M.O/$6LN;>WTO38=;9)KJ\MK>:YMY&E6+W+Q9_P $C/&WPY_9_P#&?QC^(GQ?
MT'1/$_@GP9XF\8ZG\/M'\*RZ_8LFAZ;>ZA8Z.OC67Q-H\9U#4F@MK2Y>W\.7
M5I87%S(+.?6%@B-UC7X\X0P]6%&IGN$=:IF$LKA1I1Q&(JO'PE"$Z#IX>C5G
M%0G4IQG6E%4(2G!2JISC>H9)FM2+G'!5>2-!8ESDZ<(^P:;4^:<XIW2;C%-S
M:C)J+2=OR!HHKVC]G_X#^.?VDOBCH?PF^'HTV'7];MM6O6U376U2#P[HNGZ-
MIEUJ5UJ&O7^D:5K5WIUE(;>+3+:X_L^9)M8U'3-/&V6]B-?3XK%8?!8;$8S%
MUH8?"X6C4Q&(KU'RTZ5&E!SJ5)OI&$(MOKIHF]#SJ5*I6J0HTH.=2K.,*<(J
M\I3DU&,5YMM+\SQ>BOU#L_\ @DI^TY+\6[?X8W%]X!ETNVT'P_XF\3_$?1M5
MUJ]\(>'=.U_6-<TR+2476- \.:QKGB^*W\.W^J-H&EZ?):P65UHDNJZUI,6L
M6TP]G^+?_!%[XC^"O FK>*/AQ\5['XJ^(]'L9-0?P0? TOA'4-62#RGN+3P_
MJ#>+_$<&H:D(#<R6ME=6VG-?2016MO(;JZCB7Y&KXC<$4<1A,-4XBP/M<;&E
M*AR+$5:2C6M[)XBO2HSH8-34HS7URI0_=RC4=H-2?J1R#.)PJU(X"MRT7)3O
MR1E>'Q*$)34ZK333]E&>J<=TT?BK176^ /!FK?$?QWX*^'F@26,.N^//%OAO
MP9HLVIS36^FQ:MXHUFRT/3I-0N+>WNYX+&.\OH6NYH+6YFB@$CQV\SJL;?HW
MJW_!)#]I;1/'WP^\!W.O_##59_'8\0WT^L>&]4\87^E^$?#WA0Z&FMZ[XCN-
M7\$^'X43[1XCT>PTC2[&>[U76-0O-D%I'86FIZC8>WF?$>1Y-6I8?-<SPN!K
M5Z&(Q-*G7FXRJ4,+"=2O4BE%WC3A";?67*U%2E9')ALOQN+A*IAL/4K0A.%.
M4H)-1G4DHPB[M:R<DET5[MI'Y;U^Q_P)_P""07BOXN?!SPG\5_$7QJTCP!/X
MV\-6?B[0O#B>![CQ-''H.KV0U+0KK6-<;Q;X=2PDU#3Y;2^GBMM,U%;&VN5W
M2SSQR0#Y^_;=_8+3]C31/A[JEQ\7K/XA7GCW4-9L8=)7P</"=S9)H-I87&HW
ML)?Q=XBEU*SAEU/3[:25;:T$,EW!Y_E--!'+]=_&3X>_\%-OV8/V6+V?Q+^T
M1X%@^$'@CP_H7@M_"OA*ZM)O'&E^'=:OK/P;I>EZ=XDN_A=I&M/%IXU6TM(7
ML?&\E[I>FQQMISK#IT:V_P 3Q#Q/6S?+^':G!G%6495//,SJ8?#8K-,+7C4S
M"&'JQPE;#X##8S+<0Y58XNK2IR56A14I2A&&(AS>]Z^ RZ&$Q&/CF^68K$QP
M>'C4J4\-4@XT'4C[6%2M4I8BFE%THRDN6<VK/FIMK3\/;J*.WN;B"*Z@O8H9
MY8H[VU6Y2VNXXY&1+JW2]M[2\6"X51+$MW:6MRL;J)[>&4/&L%>I?!SX,?$?
MX]^.],^''PM\-W/B7Q/J4<]VT,;Q6MAI6EVGE_;M:US4[EX[+2=(LO-ACEO+
MN6,37=Q9Z;9I=:I?V%E<_L5X:_X(=^*KK2[>;QC^T1X?T+6FCC-UI_AKX<ZC
MXLTN&8KF5+?5]4\7^"[NYC1_ECEDT.T:5?F:&$_)7U&>\9\,<,5*5#.\XH8.
MO5@IPH>SQ&*Q+IMN*JSP^"H5ZM.G.2DHU)TX0FXR4&^627G8+*,QS&,IX/"3
MJPC)Q<^:G3IJ5DW%3K3A&4DFFXJ3DDU?=7_".BOT)_:S_P""<7QG_96T6?QW
M<ZGH/Q#^%L%Y:V5SXQT$R:7J.AS7TFGV=@OBCPMJ4CW&GKJFJWDMCIUQHFI>
M)K#_ $>(ZK>Z3=:A8V,WS7^SI^SO\0OVG_B5:_"_X;#1(=:ETG4]>OM3\2:A
M/INA:+HVE"%+C4-2GLK'5-2:*2]O-/TV"+3=*U&Z>\U&V+V\=FMU=VW;A.),
MBQ^4U,]PF:82ME-&%2I7QJJ<M.@J45.I'$1FHU:%6$91E*C6A"LE.'N>_"^-
M7+\;1Q4<%5PU6&*FXQA1:O*;F[1<&FXSBVFE.,G"ZE[WNNWA56["POM5OK+2
M]+LKO4M3U*[MK#3M.L+::\OK^^O)DM[2RLK2W22XNKNZN)(X+:V@CDFGFD2*
M)&=E4_J5X+_X)'?M"Z]\6]>^&_B/Q%X*\/\ A_PII>A:GK_Q(TH:_K_AZ4^)
M+35;C3M(\,VFH:3X6NM?UZTETQ1K^GS2:2FB65]I^H7%U)'J6D1:EY/\6_V'
M?B#\(/VM/A]^S9\-?'EMXW\<^*K+PWXG\)^+8+6?P"^B3SW.L7,U_J"0ZQK]
MUHLGA>/PU?Z\]YIFHZAJ#Z=;V]UIMI)J4L.GGSZ/&W"^+Q-3!8/.\%6Q<,LJ
M9M)+VSP]+ PHQKRQ&(Q*I?5Z,84IPJSI5*T*\:4O:>S4=3>>3YE2IQK5<'6A
M2EB(X5-\BG*M*;@J<*;ESR;DG%247!R7+S7T/I/XL?\ !(;7_A%\!O%_Q>US
MXY:7?^(?!'@>;Q9K?@K3O %R=*>^L+6.YU71M/\ &,_C".YN8(#]HBLM5G\(
M6C7IBB:;3;%9V\C\H_!7PW^(GQ*O;K3?ASX"\:>/]1L8%N;VP\%>%M<\57MG
M;.S(EQ=6NA6-_/;P.RLJRRQI&S*P#$@@?K#^W1X:_P""C/@;X7^%?!WQ^^-G
MA3XI>!_B1XJTOPA8>%/AOIMI)JVL>(-.:WUK0;'5EM?A7X(UO6VN+[3;>XT^
M%;W6)+G5[2"2>#[6UM)+^F'_  3B_8E\<_LA:7\4;SXD:[X4UGQ-\0KOPI%:
MP^#M2U?4M+TW1/#-OK,L:W,NL>'O#TPU2ZU#Q!>+<I##>VB6]C9-;72O+<JW
MYW#CW'\-\(XG.,[XAR3BC-<?C:O]@X?+HNAA:N&H5L)A\324Z> P567U1U:M
M:HZM%R24(+$57.\/>EDE#,,UIX3!X#&9;AJ%&/UVIB'SU(U)PJ5*<G&5>M%>
MU481BHS2=Y2]G%1U_EA\7>"?&?P_UJ7PWX\\)>)_!/B*""WNIM!\7:#JOAO6
MH;:[3S+6XETO6;2ROHX+F/\ >6\KP".9/GC9EYKF*_>'_@H_^PK\>?''Q#^-
MW[5,WB_X<-\-_#_AK3M5TSP[>^)/&4WBO3_#/@_PGI=C=Z?I^EMX-GT&SGOM
M3L]5UA;"W\01:>]]JMU=RW$5Q=W+'XUTO_@F'^T3J_P$A_:%L]9^&$GA:Y^&
MD_Q5M/#,6O\ B>\\;W?AN/09?$EO:6VFZ=X,O=%EUZ_TF-)+32E\0[Q<SQ6%
MW+:WPGMX?M\GX^X>QV399F6,S;+L+7QOU3#5Z,*TW3H9I7P].O4P"E.*E*='
MVG+*3]Q6NYZIOQ\7D>/HXO$8>CA<14A2]K4IS<8J4\-"I*$:[2=E&5KI;Z['
MYT45I:-I&I>(-7TK0-&M)+_6-<U*QTC2K&$H);W4M2NHK*QM(C(R1B2YNIXH
M4,CH@9P695R1]^_'O_@F?\>?V<_A-K'QA\?>*?A)<Z!H<N@V][H_AWQ%XKOO
M$C7/B#5;'1[:VMK>_P# ^E:1<2VES?K+>^7K7EK:V]U-:R77EHLGTF.SO*<M
MQ6 P./Q^'PV,S2JJ&7X:I-JKBJKG3IJ%*"3;O4JTX7=H\TDK[V\^C@\5B*5>
MM1H5*E+#1YZ]2*]VE&TI7DW;[,9.RN[+8_/"BBOJ7]EO]D+XK_M<^(/$^A?#
M*?PII<?@_2K+5->UWQGJNH:9HUHVJ7,MMI6G)_8^C^(-6GU#4_LFHSVPATE[
M*.#3+LWE[:RM9Q7?1C\PP65X.OC\QQ-+!X/#1C*OB:\N2E34IQIQYI=YU)PA
M%)-RG*,8IMI&="A6Q-6%"A3E5K5&U"G!7E)I.3LO**<F]DDV[)'RU17ZR_![
M_@D3\</B!XM\=:+XW\7>&OAYX9\#>(;SPHWBZTTS5_%4?BO6;.VTB]EN?!^D
MWG_"'R:IX;CMM4>WGUZ[OM.$6M6-YH8L9+ZRU5=-^,?BI^S#XS\#?M,^(/V8
M/!4D_P 5?&.G^(].\/:#-H.EG3IO$,NIZ+8:]%-)I\]_>P:*MA87S2:]+>:M
M+IFAQV&HWE]JB:=9SWJ>/@>+^&LRQF)P&!SC"XG$X/ _VEBE#VBH4,#:DW7J
M8N5..$48*M2=2/M_:4U*]2$5&3776RK,</1IUZV%J4Z=:M]7I7Y>>=;WK0C2
M4G5?-RRY7R<LFK1;;5_FBBOW!^'_ /P1)^(NLZ':WWQ(^-GAKP)K=Q%YLN@^
M'O!UWX]6Q+/\EO=:K-XF\'6SW"Q8-Q]BAO+6.;=%!=740%PWS;^UG_P3%^+G
M[,OABY^(FC^(M-^+'PWTN.$^(M<TK29_#OB#PR9KO[*EYJ_A>?4-91M$=IK)
M/[4TO6]2DMII;C^U+'3K&VBO[KSL%XB\%9AF,,JPF?X6KC:M7V-*#I8NG1K5
M6^6-.CC*N'IX.K.I)J-)4\1)UI-1I<[:3Z*V09Q0H2Q-7 U8T8QYY/FI2G"%
MKN4Z4:DJL5%:RYH+D2;E9)V_-"BOT+_9V_X)J?'C]ICX8Z=\6/ WB;X4Z+X;
MU74]8TNRM?&&O^++'69)-$O&L+NX:VT/P1XBLX[9KN.:* O?K</Y+N]O'&T3
MR?"?BSPUJG@SQ3XE\'ZXD<6M>$]?UGPUJ\<+M)#'JFA:C<Z7J"12.D;O&EW:
MS+&[1QLR@,R(25'T&"SS*,QQN.R[ X_#XG&Y9/V>/PU*3=7"S4YTW&JFDDU4
MA.#LW:2L[.QP5L%BL/1HUZU"I3HXF/-0J25HU(\JDG%WV<9)J]KIF!7UK^QQ
M^R5XH_:_^)M]X%T;7HO!NA:!X?NO$?BOQG=:)>Z[;Z1:+<0:?IFGVEA;W.F6
MM]K>L:C=1_8M.O=<T<2:58Z[J<%Q<-H[V5Q[/I?_  2__:%U3X#P_M"'Q)\(
MM.\(7'PPG^+<.C:IXKU^U\2GPI'X;E\66HFQX/E\+6>H:AHB17,"7WBBVL;1
MKF*/5]0TPQ7AM=[_ ()X?!#]M#Q@?'/Q+_96^)'A3X66>FS6O@W7]6\9WOGZ
M1XDO7@35FTR+PZW@OQ]8W]WH5M<V5V-1U;1+1K!=:6/1K^22YU6*'YW.^*\O
MJY!GN(R+B+)\+C,OE' _VAC)RE@\!CZM54H1KI4,0YSTJ>R4</B(.<5*5.=*
M,T=^#RRO#'8*GC<!BZM*NO;>PI)*K7H1CS2<'SPM'X>9NI3:B[*49-,\K_;@
M_8LE_8TU_P  Z,WQ'C^(\'CO1]:U..\'A)O"$NFRZ)>V5K-:O9GQ+XG2ZCF2
M_MY8KE;R!@RS1/; (DLOPS7U!^V+JWQWN_CWXNT']HWQK:>/?B9X%6S\(7NN
M:6EE#H8TRW1];T^VT&WL-#\-6UMI;'7;B_CA&A:;*+F^NI+FV2YDES]F_ +_
M ()!_'/XJ^'K#Q7\2/$NE?!/2=7M+._TK2=6T6Y\3^-7L[N,SI/JOAF'4M"M
M]!=K=H9%T[4];AUJ"1Y+;4]+TRX@>,UA>(L+P[PSE..XQXBR^OB<3AXU)9E0
MI\M+,)5FZ].6!PN&PU.K7IT\/5HQ<Z.#@W%1K5*=-U+!4P%3,,QQ5'*<!7A3
MISY5AYRO*ARI0DJU6I4E"#E4C-VG6:3O&,I*-S\DJ*_:?XN_\$6_BGX/\*7F
MO_"OXIZ-\6=9TY&N9_"-_P"%)/ &JZA:QQS-+'X?O)?%/BK3+_5 X@\FPU.Z
MT."XB:Y,>H?:H;:SOOSK_9K_ &6/B3^U'\2=<^%G@6\\,^'/$WASPSJWBK5C
MX]N]:T:RM;+1M:T3P_?64@TK0-?U)-434M?LHOLDFFQJBQW1GFA>$(_;EW&O
M"V:Y?C<UP&<X:M@<N2ECJTHU\//"0E?EG7P^)I4L33A-J2ISE14*CC)0E)QD
MECB,GS+"UZ.&KX2I"MB':C%.%156MXPG3E.G*4;KFBI7BFG)*Z/FRBOH3]I?
M]FGXA?LJ_$2#X:?$BZ\-ZAK-YX;TSQ78:CX3O]1U'1+_ $?5+O4M/AEMY]6T
MC0M0$L.H:/J5E<1W&F0;9K5VB::!XIG^@/V<O^":_P"T#^TU\-[;XJ>#-7^&
MGAKPKJ.JZII>CGQQK_B&QU#6%T>X^PW^HV5KX<\)>*$BT^+4XKS3%.H7%C>R
M7>GW3I9&S-K=W/9B>)<AP>5X?.L5FN$HY5BW26&QTZEJ->5:,I4XTG9RG*48
M3ERJ/,HPFY)*$FL:>78ZKB:F#IX:K/$TE)U**C[\%%I2<M;))RBKWLW)6O='
MY]T5TGC+PIK'@/Q?XK\#>(HHK?Q!X,\2:[X4UV"&3SH8=8\.ZI=:/J<44VU/
M-BCO;.=(Y-J[U4-M7.!]\_$S_@F!\?\ X2_!K7?C=XS\6_!RQ\,^'/#]EXAU
M+1QXK\21>)%CU&XLK2STN&*_\%6.A2ZW<W>H6MG:Z>-?#7M]-%I]C)<WT]O;
M3:XW/LFRZ670QN8X;#RS>I&CED9SUQM2;I*,:"BI<]W7HI/X?WL-?>1-'!8O
M$+$.C0J5%A8N6(<5I1BN9MSNU:W)/S]U]C\XJZ3P;X4UCQYXO\*>!O#L45QX
M@\9^)-"\*:%!-)Y,,VL>(M4M='TR*6;:_E127MY DDFUMBL6VMC!YNO;_P!F
M[X<?$;XK_'#X=^"?A'JVGZ!\2;O69M<\'ZYJ=_/I=GHVK^"],O\ QK'JC7]K
M8ZE<6T]A%X>FNK-HK&Y=KR*",1_/N';CL1'"8'&8J=:CAXX;"XC$2Q&(;6'H
M1HT9U'6KN/O*C247.JUKR1E;4RH0=6M1I*$ZCJ5:<%3IV]I-SFHJ$+Z<\K\L
M;Z<S1^@7[2/_  2HOOV<O@)XG^-.K?'G1==O?"<.@OJ/A5? .HZ797ESK>N:
M9H L=)\1IXGU>[NKA;S5(?LC77A>Q@N%5Y+Z72;9)KF'\CJ_5K_@H;+^WA\/
M="\#> _VHOCCX4^('A?Q[-JVL:5I'P]BTS2],EN_!DNEB4>)+73OAW\/+JZ$
M$OB*QNM.BO(-2T^6YB6Y0K>Z7"UOX_\ #+_@G1\;OBK^SY_PTGH'B7X96/@3
M_A'_ !OXD72M5U/QK+XQET[P#?Z_INLI;Z+H/@/7;:YOKFY\.:@NE65OJ<L]
MZ&M5*PRS^6OPO"^?5\!PY0S7B_BG*,S_ +3S2I0R[,L#35+ SC.+I4<#1Y,!
M@IU:T:^%QKE*>'Y[+D<Y>SN_:S+ PK9A/#95EN*PWU;#1G7P]>3E735I3K3Y
MJ]91@X5:*2C4MKS67-9? M%?LI\$_P#@C3\7O'_A.S\2_%;X@:;\%[_4_P!_
M9^$6\,?\)SXCM+!A)Y,VOI:>*/#VF:1?7.V&>/2H=1U*[M;6X":M_9FJP7.D
MP_%O[9'[&_C?]COQOHWA_P 0:S8^+_"GBZQO;_P5XUL+)M(765TAK*'7=/U#
M0IKW49M'U?1YM0T^2YMH]0U2QEL=4TRYMM3EGEO+/3_:R[C?A3-LVGDF79UA
M<7F<%5:H4HUW3J^P3E56'Q;HK!XIP@I5''#8BK)TX3J).%.<H\=?)LSPN%6,
MQ&#J4L.^6\YN"E'G=H^TI*;JTTVU&]2$5S.,7K))_'M6["POM5OK+2]+LKO4
MM3U*[MK#3M.L+::\OK^^O)DM[2RLK2W22XNKNZN)(X+:V@CDFGFD2*)&=E4U
M*^M_V#O \'Q#_;!^ 'ARYEGB@@\?6?BR4VX)DE7X?V5]X^^S,0CLL%V?#0M;
MF10CQVTTLB2PLHFC]S,\;#+<MS#,:BO3P&!Q>-FM=886A4KR6FNL:;VU['%A
MJ+Q&(H8>/Q5ZU*C'UJSC!?C(A^*_[#?[4_P0\#W7Q'^*'PIN?#/@NQN=-M+[
M65\5^!-<%E/J]Q'9Z>+S3_#GBC5]5M8[B[EAM//GL8X(KJ>"WGEBFGB1_DZO
MZ:O^"TOCPZ'^SY\/_ =KJJ6EYX]^)<-[>::#'Y^K^'/!VB:A=WZD.2WV2Q\0
MZOX2N9VB0,+G["K2I&[Q3_S*U\KX><1YKQ5PY3SK-J&"P];$8S%TZ$,#3Q%*
MC+#8>4:*FXXFOB9NHZ\*\92C5<&HQ2C&2DCT\]P&&RS,)83"SK5(4Z5*4W6E
M3E-5*B<VDZ<*:4>1P:3CS7;U::/K'X2?L-_M3_'3P=:?$#X6_"FY\2^#[^YO
M;2QUN;Q7X$\.P7L^G7<UA?"TM_%'BC1;VYCMKVWGM99X;9X!/#+$)2Z,!\N:
MGIM[H^I:AI&I0_9M1TJ^N]-O[?S(IO(O;&XDM;J'S8))8)?*GBD3S(99(GV[
MHY'0JQ_L#^!D5K^S3_P3W\'ZQ<Z1?Z=)X!_9YO\ XE:QH;IJ$&K1>(=4\.:C
M\1M?TZ:'4YA>V&J3>(]6OX9[6:2U@TV]E>WACL+*WCAM_P".ZN+@;B_,>*\P
MXJ5?#X.CE649FL#E56A2K1Q&(I^UQ:E/%5)XNM2E4C0I8:;5&C2@I5I6<DD;
M9SE6'RRAECA.M+$XK#.MBHU)0<*<N6E94HQIPDHN<JL??E)V@MG<*]$^%WPE
M^(_QK\7V?@3X6>$-7\:>*KZ)[A-,TJ.)5M;**6"";4M5U&\EM=+T32+>>ZM8
M+G5]8O;'3+::YMHI[N.2XA5_.Z_K*_X)4_!CPW\-_P!E;PKXWMK#3V\8_%YK
M[Q3XGUN"-WO+C3K75]4T[PMHKW4ZK*;32M*A^TFTB2*U@U;5-6>(7!E:\N>[
MC_C!<%Y"\RIX>&*QF(Q-/!8&A4<E1>(J4ZM5U<0X.,_8T:5&I.482C.I/V=)
M3IJ;JPQR/*O[7QOU>51TJ5.FZU:<;.?LXRC'EIW37/*4XI.2:BKR:E91?Y/Z
M=_P1D_:PO=/2]N?$GP3TBY>,NVD:CXO\62ZA&P0,(7ETGP!JFE&0L?+!CU.2
M+>"3*(\.?AO]H;]ESXS?LO:_IF@_%OPW!I2:^E_+X9UW3-2M=6T#Q)#I0T_^
MTY-*O;=EG#Z<^J6$=Y:ZA:6%] ;J!WM1#/!++]W?'3_@JK^UE8?&GQA8>"M6
MTCP!X2\'^.M9T>T\#7G@WP[JUQ=V'A[4TTM]-\5ZCKFE7.NI<WCZ7<R:HNC7
MVA7=I-JE_;6ES!]FT^2T^9OVQ_VVO%7[8\7PH;Q1X,T;P?>?#;1O$%M=_P!A
M:E=7NFZ[KOBB71'UC5[&SO[47^AV$D7A[3(;31KO6/$,MMY<LAU:9IF%>5PU
M6\3I9CEM7B&GP]7R3'T*M;%_4'.&,RQO"SK86+4I0C5G/$>RHS5&6.@H3G)U
M(\JF=.80X<6'Q$<!+'0QE"<8TO;I.EB;5(PJ/12<5&'/-<ZH-R27*[\I\244
M45^F'SH45Z[\"/@MXK_:&^*_A/X/>"+S0M/\3^,&UE=-O?$UW?6.AVXT+P]J
MWB:^>_NM-TW6+Z)?[-T6\6$6VFW3R7)AB*(CM*GJW[57[&GQ7_9!O_!=E\3-
M2\%ZQ%X\M-;NM"U'P3JFM:G8&3P[-ID6K65V==\.^&[N&[MEUG2Y\1VD]M)#
M>Q[+DRI-%%YE7.<JHYKA\DJXZA3S;%T)8K#8"4FL16P\%7<JM.-K.*6&KMZW
MM1J.UHLZ8X/$SPU3&1HSEA:4U3J5TO<A-\B49.]TVZE-;6O.*ZGR917VK^RU
M^P9\;/VM]"\4>)_AU?\ @30/#WA;5K;0;G5?'6M:QIL.HZS-9IJ%SI^EP>'_
M  YXGO7ETVQN-/N;Z6^M;"UV:G9I9W%Y,MY':?/WQM^#WBWX!?%+Q=\(O'+:
M7)XH\&7=E:ZE/HEU<WFD7<>I:38:YIU[IUS>6>G7<MI?:5J=E=PFZL+.Y5)@
MD]M#*K(LX?/,HQ69XK)</F&&K9K@:?ML7@:=3FKT*=Z2<YQ2LE%UZ,96;<)5
M(QDE)V">#Q5/#4L74H5(8:M+DI5I1M"<O>TB]W=0FUI9J+:NCRNOIC]D[]F3
MQ/\ M9?%J#X7>&M:T_PTEOH.I>*O$/B+4;::_AT;P]I=SIVGSW<.FV\MM)J5
MW+J6KZ78VUG]KLXWEO!)-=P0Q2./H7PC_P $P/C_ .+O@E9?'M/%OP<\/>"K
M_P "7'Q&CM_%'BOQ)I6KP>%X-'EUW[9?LG@JZ\/Z?YNFQ-<B6]U^"R@C(FO;
MRUMP\R4/^">7P?\ VJO'WC;QQXU_94^(7A#X;>)? VC:5H?B;7/%\^^RNM(\
M<2ZI<VNEC2I?!GCBSU6":Z\&O=2K>:04LKRSTV[AD2XCBEA\+-N*,NK9'Q!B
M,ES[*L/B\J@\+4QV+E.>"RW'UJGU?#K%\M&M=^W?)%1I5TZG*I4ZBO"7;A<M
MKPQF!IXS!8FI2Q+]K&C225;$4(1]I/V5YP^QJVYP:C=\T7JL_P#;B_88'[&)
M^');XLV/Q&/Q!_X240VG_"'W7A'4].'AK^Q?M%S]G7Q!XJL;JQE_MRUB\Z;4
M]/NOM&4MK&\A2[N+3Y9\-_ 7XY^,O#L7C#PA\%_BQXJ\)3I>R0>*?#?PZ\8:
MYX=F339I[;47BUO3-'NM,D2PN+:YM[UDNF%K-;SQ3F.2*15^Y_B%\!_VS?VK
M_P!K7Q)^SS\3_B?X0\:_%3X5>%)=3O-?U#4IM+^'&B^'+FW\.:RTVD0>&/!5
MFT$VHS^+] L[DP^#;;4);UK>SU,QVVE1-;?T5_"#X1>(O@U^RWX2^#WAQ?";
M>.O"?PIDT*"2.2ZT_P %WGQ%N=&NKG4=0GO+;0SJ8T34_&=[=W]_J[>'9=9N
M[>YN-4NM)GU.>:U?X7-O$;%\(Y#P_0QN8Y5Q-Q+C_8XC&UJ4_JN#_LW&^WQ&
M%QL%0PN%C&DZ$L+3IRE0I.I%5*TX+F5_;PN04LUQV.G1H8G+LNH<U.E&2]K5
M^L4?9PJTI<]6JW+G5632G+E;C%/1G\2M?LY^P-_P37^&O[3GP5NOBO\ %;Q%
M\2/#TE]XRUW1/"UGX)UCP?96FH>']%M='@?5[HZOX:\4W<=RWB%_$.EM:S+I
M\GE:7!=QPM;7$-Q<_$7[5O[%7Q3_ &/O^$"_X67K_P /]<_X6)_PE/\ 8O\
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MK1]&B^Q6EI#X]T/P+J_C%H$T>V!TVSMKK7-<O;F6UMMVF6T<\S@M;2/7[_\
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MH:S'X>\6>&'L_$VEZ=I&KWVE3Z5XST'P[K*2PZ;K^CW@F.G?99H;^%H)Y2)
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M0]=;O>S2)^'/=/MT/?\ E3T_])B?TYT445^.GNA1110 4444 %%%% !1110
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M6V2:15#RI;P*Y988PO\ :)\)O^25_#3_ +)_X-_]1S3:_BV_X.7O^3[?A/\
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M_P#!P;_P4$\?? +PSX#_ &5/@MXI\0>!?'7Q5T)O'WQ%\8>';M=*UFS^%_\
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MVNEWT>J>(DO]4T+7/%CO'X,\$^3=2G06D\1&3]5O^#83_DC7[57_ &4WX?\
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M(+C[(Q\F[U:>WG_TF*:OG2O[\X-_Y)#A7_LF\C_]5>%/P_-O^1KF?_8PQO\
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MU\*^!]+,21K((M*\.:??ZJES)%/.DTR>)=6UU$<F*2.U6VMYX(IX)4'[P_\
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MXU\:Z#=>)/%_BK3'EAU[P_X0NY[[0]*L-!O39M'IFJ>(+VTUB8ZWIFH0>(-
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M3_P40T7Q)J?P_P#$WQ4\0:-XMTO5Y-!U'PY_PK+X8Z9K]MK"R&S_ +.$6G^
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M<7#$BV=O'FO1:9';1*7SY]O'X!6>XD6((T=Y;()9'BDC@[<UP&#Q'BUP?D.
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MQ3!"&T/3KW4YFCL=&"Z7ILM\R0P6_GA6[L#X<9GC<7PS3SK%<'9=EV3SHXK
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MQ!8?"NSU"[6XLM*U&RBL-+T_P%9ZE>QZC<V-GJ%K;Q7MY%=-:1SRQN(J]/\
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MEK.Z\=>,_"_@VVO$M1?/:7'B?7+'1(;E+(W-F+MH)+Y95M3=VHN"@B-S!O\
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M>_$N&]O--!C\_5_#G@[1-0N[]2');[)8^(=7\)7,[1(&%S]A5I4C=XI_#O\
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M.4^_%8K"91D6387%8"./6(I/$.C.JZ*A-J-:<I-4ZO,U+%.*3LKIM;67WO\
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M9M-TW[-%J5[+(C6]E%:?VA<&**T:>+\N/^"3W['GBKQ1\3-*_:1\=Z#K.A>
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M2BTY6O6E\3F\UGQ!)I=H+99#<WEO'XHL-.N+:#S9H-5BNM.E5+RWFMXOVE^
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MM#6_^&A/[)_X3/X;_P#".?\ "FO[0_X5YYEI_P +>_MO_A-_LW_"9^3C[?\
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MUX^RC*2E&H]8YG0E@Y8RTE&+Y'3TY_:Z6AV=^9.^W*[O9H_I;K_.G_X*\?\
M*2+]J_\ ['[3/_4*\+5[C^SI_P $L?\ @I#\3?A5I_[;/P>U:UT'69;6/QS\
M/!/\3=:T/XW^/X-.ORUKK7A)K6QN;*.:6?3%O=,C\8^+?#-SK%M!9W.F07T-
MWIYN?S&^.7Q'^)GQ9^*WC'QW\99;V?XIZI>V6G^.Y]4TMM%UB;Q%X8TG3_"M
M]+KFE/%;M8Z_(VB*^O6YM;/;K#7N+*S!%K%^O>'W"6$R#/,SK8+B' 9VJ6"J
M9=CJ.'IJCB,%BWB<-54)TUB,2I4VJ%:#J<\&JL)4^1RC-0\3,\;/$X>C&IA:
MF';J*K3<GS1J4^22;4G&#3O*+M9Z-.^JO_J04445_,Y]8%%?Q7_\%O\ _@HO
M\6OB+^T5XQ_9(^#WC+7O#7P?^%TMAX,\9V/A*_U"RO/BG\2M]AJGB&'6I+:V
ML-2ETCPAK!M/"&F^&5:ZL+C7] UCQ#]JU2#5='ATGRG2O^"</_!5G]@[P'I_
M[:W@#4X?#NM:#9Q^.?'/@OP-XQU'Q'\1?#FC6K327LWQ2\#3Z*?"?C+2;:RU
M"]O?$>EZ=K'CE-*TF;5;_6[:PBLM3GM/U#">&W-E>6XW->(LNR;&YS",\JR[
M&4W?$.I"$Z$*M?V].5&<XU*?M%##U_8NK2IS_?3]DO(GFMJU6G1PM6O3H.U:
MK!_ D[2<8\KYDK.UY1YN5M>ZKGR;_P $Z_\ E*!^SG_V<9'_ .G/5:_T6*_S
MC_\ @F3J$VK_ /!2#]E?5;E8DN-3^.FD:A<) KK"DU[-?7,JPK(\LBQ*\K"-
M7DD<( &=SEC_ &%_\%@=>_;?TS]GOP9HW[#FD_$"\\9^+?B9I^A^.=5^%FER
M:AXZT7PDFAZSJ5L^GWULSW_AG2[W6[&Q@UCQ+916[VJ):Z9/K&GVNKS6VI?2
M>*672S/BOAO+EB<-@Y8G+(TGB<94]EAJ*6)Q,I3JU+.R2BU%?:FXQNN:ZY<G
MJJE@L55Y)S4:SER07-.7N4TDEWUU[*[/UEHK^(9O^"#/_!3CXQV.H_$'XJ^.
M?AA!XUOKB^U6^T;XM_&CQ;XQ\?ZKJ=]96FHWMS<:]X>\+?$'PU<ZCJ5[(VFW
M-W>^-%-QJEA//=7/]F&RU2Z\:_X)N?MM?M/_ +&G[8OP]_9\\?\ C?QJOPQN
M/C#IGP)^+7P:\6:O<>)=!\&W\GB*3X=WUUX?T^:76$\+ZMX&UZ>*^NV\$/:'
M7K?P_%HUX-6L!:6Z?//PWP>,P6/K9#Q;EN>8W+:#Q&)P5##NG%QC&<FJ.)AB
M\0JCG[.4*4O8QI3GRQG4I\UUT_VK.%2G'$X*MAZ=62A"I*5]6TKRBX0LE=-K
MF;2O9.UC^S;]MSXZ^)_V9OV4?CC\=_!>E:#K?BOX:^#)=>T#3/%$.H7'AZZU
M-]1T_3K<:Q;Z5J&DZE<V,+7WGSVUEJFG7%PL7DQWML7\Y/RF_P""0_\ P5A^
M/O[?/QC^*'PQ^,O@7X0>';+PA\,X_'FAZI\,M(\::)=&ZM_%.B^'[S3]6@\5
M>.?&L-[;W,.O07%K+9MI<EG)8RI*M\MZALO!/^"_7PN_;O\ $>I-\0OA/K/C
MV#]C+PG\!-+M_C-I'A_XM:1X4\(S>*O^%A>*I=8N/%GPYE\7:+JWCE9]'O/
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M*U+Q'=:WX%O_ (E>%[C7[@>$;_PJ-2U"/PQJ\>JZ9%::.DM^^GOI]O\ JO\
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M:\+?$7XH>,O'>BW<FB^ /$6M:7/'8^+-8U>&RN;/4[.VNH[JP6UN&,0BDE>
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MX$\,)\3O#/[._P -_"WPR^+GQ&\'>&M6\5:9J-AX%U+59+#PGK-E8ZA<Z_\
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M=6L ;.]OG?PDEGJ9@N;>"TTH744UG]__ +9WB[]J[]NK_@G9\!/BK_P3KO\
MQIX:^(/Q.\5> /'7B73O 7Q6T_X8^*-'\'+X0\<V7CGP8OC[6M8^'J7;>%OB
M7_8>BZJ=/O\ 3#KS:%/=6=O<Z4\D,W\3OPY\*_'+6_V@O"W@SX;77B2']HG4
M/B?:Z!X4O-(\96_A_P 5Q_%.37S9VL]CX\EUS3;73-:'B'+IXD?Q%:0QW?\
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MY)S1-2EA:V;8N.+J*G34%*,I5%3]]1H))2D[-\KE[N[2OT/PC\%?M#?MX?\
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MZ[IWA+Q=\3+_ ,1W=F;ZST_RM)L]9^$.@Z9/<^=>Q-LO-8L(O*61O.WA4?\
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MNT?X=VBZUIVJZ!X0\6WU]?6-]X,U+<VKZ1:37-OKLER+N"9;BVN/YE?VW/\
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MDH0I04Y+$9BZ5=X:AAJF)JQ@IU%"7*H1?*UKRS;TDKZ))N*NV[+^_.OYHO\
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MJTJ=.%24I<DXO,%AYTJ5.C/$5ZR4HTHOE:B]$Y.TW=V=DHM6C)MQ25_Z O\
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M-*A.I*WN*;@YJ.\GHEI#!3^KUZ%;%5:[KIIU)*S@G%1M"+E)):7M>U_.[?\
M-E_P;F_L^_'7X&>!?VIYOC7\'?B9\(6\5^+?A;'X:M/B=X)\1> ]3UL>']'\
M:-K%SIVD>*-/TO5+FPLCKNEQ-J,=F;"6XGDMK>YEN+2\BMZW_!QI\"/CA\</
M"/[*-M\%O@U\5OB_<^'/$?Q>G\0V_P +OAYXN\?SZ%!J>F?#V/39M9B\)Z/J
MTFEQ:A)97B64E\L"7;VERL!D:"4)_2M10N,\5_KC_K@\%AWB>=S^IJ=14/\
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MA'6O%/Q(O?@9X;\.V'@WP[;?VUK>HZWI;^&/MVF:9:Z<US_:5U%]ANRB6+W
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MW;QTEA<D)<VGAFQT:2:P\+7<T"R6\FOC6-9U*."[E?1TT+4[6TU8?G)^R?\
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M*Q5?&UZF)Q-3VM>KRN<W&$.;DA&$?=A&,%:$8Q2C%*R[A7]>W[,LFG_LX?\
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MO^"B?_#'?P_\5>!/^%.1?$3_ (2;QC)XM_M@>/?^$0GL_,T32='_ +-DMO\
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MZRT-H4UJ[\,1ZE;/K]KH[W%Q:0+JEQI2W<6GM/=VL*W;PF2XA0-(O[M?$_\
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M0?\ %.:/I4TND^'M0MMWG1:S<ZKX@EWN/LMCI\]M'>2_#/[$G[9=Y^QMXO\
M&7B.+X=:;\1;+QIX?LM%N[&;7Y?"VJV$VFZ@;VTN+#7%T;Q%"EE*)KE-3TV7
M1I&O94TV>*^L_L$D5Y\345O@N ^%<!DV,R'#Y53CEV8JFLP@ZV)^L8WV,_:4
MG7QD:T<4W2J7E24*L(TKR5*,(RDG%;.\SKXNEC:F*D\1AW)T&H4^2CS+EER4
MG!T_>6DFXMRLG)MI,^P_VS?VP/$G[8GC[0/%NK>&+7P1HGA3P_+H/A_PI9ZO
M+KR6OVK4[O4=0U2[U:;3=*>ZU+4$DT^RN6BL+.T^SZ/9&&UBE:X>7X\HHKZ'
M+<MP.48'#9;EN'CA<#A*?L\/0A*<XTX.4IM<]24ZDY2G*4Y3G.4Y2DY2DVVS
M@Q&(K8NM4Q&(J.K6JRYJDVHIR:22TBE%))))12222221L^'==OO"_B#0O$VE
MLBZGX=UG2]=TYI#,(UOM(O8-0M&<V\UO<!!<6\98P7$$P7)BFB?:Z_N5JO\
MP7$\07'A^_M=&_9STK3/$\VE3P:;K=_\4+G5M&L=9>V9+?4KKP[#X!TJ[O\
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M_P!/\5ZKXB\-1:C?1_#[XF)I]I%XJ3Q-+&9[K0H_$^LV<WC+2M9N)8=*FO\
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M]"A+*ZDL%.M5IQQ2JU'47O\ NPY):*$'RKFC)NVFK;LK+^HG]GK3M#TCX!?
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M2ON3?[R?R:M:OSX],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %9=__JW_ ,_Q&M2LN_\ ]6_^?XC0!_%;^UW/XCN?VA_B'-XM\4^
M/&OB!V\*_P!H>)OA>(!X%U/;X)\-I:_V&+9(X/\ 0K);;3]3V(O_ !.+34-V
M7W$_-M?0G[56B:AX<^/?CW1M5^%FE?!2_LV\,_:/AEHNO6/B;3/#/VCP=X>N
MHOLVN:;/<V5[_;,,\?B";R9W^S7&JRV<FV6WD1?GNO[\X-_Y)#A7_LF\C_\
M57A3\/S;_D:YG_V,,;_ZDU0HHHKZ0\\**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 5Y%YWB3_A?7V?_ (2OX??\(A_PJ'SO^$'Q!_PM3_A)/^$SV?\
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M%%%<Y04Y>I_W7_\ 0&IM*#@Y]B/S!']: $I#U7Z_T-+1CI['/Z$?UH ****
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MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7S]^RS;>$K3X#^!;?P+X:^)'A#PK'_PD_\ 9?AWXN0/;?$/3M_C
M+Q"]]_PD$$E[J#I]KU%KR^TG-Y-NT.YTUQY881)] UX+^S%KFG>)/@=X(UK2
M?BOJWQOT^]_X27[/\4-<T&_\,:IXG^S>+]?M)?M6AZG!;7UC_8L\$GAZ#SX$
M^TV^DPWD6Z&XC=@#WJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN2E_9<OHB1_PEC-C_J72/_<V?YU[?_$7/#S_ **#_P Q.>?_ #M./_5;/O\
MH!_\NL'_ /-!\HT5]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7
M-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\
M"?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\
MNL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$
M7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_
M .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_
M /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S
M_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-
M'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!
M\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/
M_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,
M5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45
M]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3G
MG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\
M]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\
M,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM
M#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?
M_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_
M /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;
M/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;
M_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-
M)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7-'_$7/#S_HH/_,3GG_SM#_5;/O\
MH!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\ "?;_ .7-'_#,5_\ ]#2?_"?;_P"7
M-'_$7/#S_HH/_,3GG_SM#_5;/O\ H!_\NL'_ /-!\L45]3_\,Q7_ /T-)_\
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MHKZG_P"&8K__ *&D_P#A/M_\N:/^&8K_ /Z&D_\ A/M_\N:/^(N>'G_10?\
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M\_\ G:'^JV??] /_ )=8/_YH/EBBOJ?_ (9BO_\ H:3_ .$^W_RYH_X9BO\
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M-%'(K(#_ (BYX>?]%!_YB<\_^=H?ZK9]_P! /_EU@_\ YH/FNBOJ?_AF*_\
M^AI/_A/M_P#+FC_AF*__ .AI/_A/M_\ +FC_ (BYX>?]%!_YB<\_^=H?ZK9]
M_P! /_EU@_\ YH/EBBOJ?_AF*_\ ^AI/_A/M_P#+FC_AF*__ .AI/_A/M_\
M+FC_ (BYX>?]%!_YB<\_^=H?ZK9]_P! /_EU@_\ YH/EBBOJ?_AF*_\ ^AI/
M_A/M_P#+FC_AF*__ .AI/_A/M_\ +FC_ (BYX>?]%!_YB<\_^=H?ZK9]_P!
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MFC_AF*__ .AI/_A/M_\ +FC_ (BYX>?]%!_YB<\_^=H?ZK9]_P! /_EU@_\
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MM_\ +FC_ (BYX>?]%!_YB<\_^=H?ZK9]_P! /_EU@_\ YH/EBBOJ?_AF*_\
M^AI/_A/M_P#+FC_AF*__ .AI/_A/M_\ +FC_ (BYX>?]%!_YB<\_^=H?ZK9]
M_P! /_EU@_\ YH/EBBOJ?_AF*_\ ^AI/_A/M_P#+FC_AF*__ .AI/_A/M_\
M+FC_ (BYX>?]%!_YB<\_^=H?ZK9]_P! /_EU@_\ YH/EBBOJ?_AF*_\ ^AI/
M_A/M_P#+FC_AF*__ .AI/_A/M_\ +FC_ (BYX>?]%!_YB<\_^=H?ZK9]_P!
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M^(N>'G_10?\ F)SS_P"=H?ZK9]_T _\ EU@__F@^6**^I_\ AF*__P"AI/\
MX3[?_+FC_AF*_P#^AI/_ (3[?_+FC_B+GAY_T4'_ )B<\_\ G:'^JV??] /_
M )=8/_YH/EBBOJ?_ (9BO_\ H:3_ .$^W_RYH_X9BO\ _H:3_P"$^W_RYH_X
MBYX>?]%!_P"8G//_ )VA_JMGW_0#_P"76#_^:#Y8HKZG_P"&8K__ *&D_P#A
M/M_\N:/^&8K_ /Z&D_\ A/M_\N:/^(N>'G_10?\ F)SS_P"=H?ZK9]_T _\
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M)/K:USFIYG@:U2-*G7YIS?+&/LZT;OM>5-)?-H_;&BOSE_X*%_\ !2OX,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_2C_ (5S#_S[C_OD?_$4?\*YA_Y]Q_WR/_B* /S7_P"%2G_GW/\ WR?\*/\
MA4I_Y]S_ -\G_"OTH_X5S#_S[C_OD?\ Q%'_  KF'_GW'_?(_P#B* /S7_X5
M*?\ GW/_ 'R?\*/^%2G_ )]S_P!\G_"OTH_X5S#_ ,^X_P"^1_\ $4?\*YA_
MY]Q_WR/_ (B@#\U_^%2G_GW/_?)_PH_X5*?^?<_]\G_"OTH_X5S#_P ^X_[Y
M'_Q%'_"N8?\ GW'_ 'R/_B* /S7_ .%2G_GW/_?)_P */^%2G_GW/_?)_P *
M_2C_ (5S#_S[C_OD?_$4?\*YA_Y]Q_WR/_B* /S7_P"%2G_GW/\ WR?\*/\
MA4I_Y]S_ -\G_"OTH_X5S#_S[C_OD?\ Q%'_  KF'_GW'_?(_P#B* /S7_X5
M*?\ GW/_ 'R?\*/^%2G_ )]S_P!\G_"OTH_X5S#_ ,^X_P"^1_\ $4?\*YA_
MY]Q_WR/_ (B@#\U_^%2G_GW/_?)_PH_X5*?^?<_]\G_"OTH_X5S#_P ^X_[Y
M'_Q%'_"N8?\ GW'_ 'R/_B* /S7_ .%2G_GW/_?)_P */^%2G_GW/_?)_P *
M_2C_ (5S#_S[C_OD?_$4?\*YA_Y]Q_WR/_B* /S7_P"%2G_GW/\ WR?\*/\
MA4I_Y]S_ -\G_"OTH_X5S#_S[C_OD?\ Q%'_  KF'_GW'_?(_P#B* /S7_X5
M*?\ GW/_ 'R?\*/^%2G_ )]S_P!\G_"OTH_X5S#_ ,^X_P"^1_\ $4?\*YA_
MY]Q_WR/_ (B@#\U_^%2G_GW/_?)_PH_X5*?^?<_]\G_"OTH_X5S#_P ^X_[Y
M'_Q%'_"N8?\ GW'_ 'R/_B* /S7_ .%2G_GW/_?)_P */^%2G_GW/_?)_P *
M_2C_ (5S#_S[C_OD?_$4?\*YA_Y]Q_WR/_B* /S7_P"%2G_GW/\ WR?\*/\
MA4I_Y]S_ -\G_"OTH_X5S#_S[C_OD?\ Q%'_  KF'_GW'_?(_P#B* /S7_X5
M*?\ GW/_ 'R?\*/^%2G_ )]S_P!\G_"OTH_X5S#_ ,^X_P"^1_\ $4?\*YA_
MY]Q_WR/_ (B@#\U_^%2G_GW/_?)_PH_X5*?^?<_]\G_"OTH_X5S#_P ^X_[Y
M'_Q%'_"N8?\ GW'_ 'R/_B* /S7_ .%2G_GW/_?)_P */^%2G_GW/_?)_P *
M_2C_ (5S#_S[C_OD?_$4?\*YA_Y]Q_WR/_B* /S7_P"%2G_GW/\ WR?\*/\
MA4I_Y]S_ -\G_"OTH_X5S#_S[C_OD?\ Q%'_  KF'_GW'_?(_P#B* /R/^+O
MPS\0:;\//$-[X8OO 6AZY#_9/V'5?B?/+9^!K7S-<TV*Y_MRYACDDC\^SDN+
M;3-J-OUB;3XSA6)'I'_"I3_S[G_OD_X5]C_'WX1WNN_"7Q9I6C_"G3/C+J-U
M_87V;X;:OKEAX9T_Q'Y'B71KF;[1K>I2VUE9?V/!#+KT7G3I]IGTN*TCW2W$
M:-[#_P *YA_Y]Q_WR/\ XB@#\U_^%2G_ )]S_P!\G_"C_A4I_P"?<_\ ?)_P
MK]*/^%<P_P#/N/\ OD?_ !%'_"N8?^?<?]\C_P"(H _-?_A4I_Y]S_WR?\*/
M^%2G_GW/_?)_PK]*/^%<P_\ /N/^^1_\11_PKF'_ )]Q_P!\C_XB@#\U_P#A
M4I_Y]S_WR?\ "C_A4I_Y]S_WR?\ "OTH_P"%<P_\^X_[Y'_Q%'_"N8?^?<?]
M\C_XB@#\U_\ A4I_Y]S_ -\G_"C_ (5*?^?<_P#?)_PK]*/^%<P_\^X_[Y'_
M ,11_P *YA_Y]Q_WR/\ XB@#\U_^%2G_ )]S_P!\G_"C_A4I_P"?<_\ ?)_P
MK]*/^%<P_P#/N/\ OD?_ !%'_"N8?^?<?]\C_P"(H _-?_A4I_Y]S_WR?\*/
M^%2G_GW/_?)_PK]*/^%<P_\ /N/^^1_\11_PKF'_ )]Q_P!\C_XB@#\U_P#A
M4I_Y]S_WR?\ "C_A4I_Y]S_WR?\ "OTH_P"%<P_\^X_[Y'_Q%'_"N8?^?<?]
M\C_XB@#\U_\ A4I_Y]S_ -\G_"C_ (5*?^?<_P#?)_PK]*/^%<P_\^X_[Y'_
M ,11_P *YA_Y]Q_WR/\ XB@#\U_^%2G_ )]S_P!\G_"C_A4I_P"?<_\ ?)_P
MK]*/^%<P_P#/N/\ OD?_ !%'_"N8?^?<?]\C_P"(H _-?_A4I_Y]S_WR?\*/
M^%2G_GW/_?)_PK]*/^%<P_\ /N/^^1_\11_PKF'_ )]Q_P!\C_XB@#\U_P#A
M4I_Y]S_WR?\ "C_A4I_Y]S_WR?\ "OTH_P"%<P_\^X_[Y'_Q%'_"N8?^?<?]
M\C_XB@#\U_\ A4I_Y]S_ -\G_"C_ (5*?^?<_P#?)_PK]*/^%<P_\^X_[Y'_
M ,11_P *YA_Y]Q_WR/\ XB@#\U_^%2G_ )]S_P!\G_"C_A4I_P"?<_\ ?)_P
MK]*/^%<P_P#/N/\ OD?_ !%'_"N8?^?<?]\C_P"(H _-?_A4I_Y]S_WR?\*/
M^%2G_GW/_?)_PK]*/^%<P_\ /N/^^1_\11_PKF'_ )]Q_P!\C_XB@#\U_P#A
M4I_Y]S_WR?\ "C_A4I_Y]S_WR?\ "OTH_P"%<P_\^X_[Y'_Q%'_"N8?^?<?]
M\C_XB@#\U_\ A4I_Y]S_ -\G_"C_ (5*?^?<_P#?)_PK]*/^%<P_\^X_[Y'_
M ,11_P *YA_Y]Q_WR/\ XB@#\U_^%2G_ )]S_P!\G_"C_A4I_P"?<_\ ?)_P
MK]*/^%<P_P#/N/\ OD?_ !%'_"N8?^?<?]\C_P"(H _-?_A4I_Y]S_WR?\*/
M^%2G_GW/_?)_PK]*/^%<P_\ /N/^^1_\11_PKF'_ )]Q_P!\C_XB@#\U_P#A
M4I_Y]S_WR?\ "C_A4I_Y]S_WR?\ "OTH_P"%<P_\^X_[Y'_Q%'_"N8?^?<?]
M\C_XB@#\L_&7PLU&U\(>*[G2GT&PU2W\-ZY/IM_XK=X/"]E?PZ7=26=WXDF1
M6>'0+:X6.;6)45FCTY+EU4D $\&_"S4;KPAX4N=5?0;_ %2X\-Z'/J5_X4=Y
M_"][?S:7:R7EWX;F=5>;0+FX:2;1Y756DTY[9V4$D#]&_B)\+I-0^'_CFPLO
M"%KXVO+WP=XFM+3P9>7MOI=GXNN;G1;V&#PQ=ZG=&*VTZVU^5TTJ>_N)8X+.
M*[>XFD2.-F!\//A=)I_P_P# UA>^$+7P3>67@[PS:7?@RSO;?5+/PC<VVBV4
M,_ABUU.U,MMJ-MH$J/I4%_;RR07D5HEQ#(\<BL0#X(_X5*?^?<_]\G_"C_A4
MI_Y]S_WR?\*_2C_A7,/_ #[C_OD?_$4?\*YA_P"?<?\ ?(_^(H _-?\ X5*?
M^?<_]\G_  H_X5*?^?<_]\G_  K]*/\ A7,/_/N/^^1_\11_PKF'_GW'_?(_
M^(H _-?_ (5*?^?<_P#?)_PH_P"%2G_GW/\ WR?\*_2C_A7,/_/N/^^1_P#$
M4?\ "N8?^?<?]\C_ .(H _-?_A4I_P"?<_\ ?)_PH_X5*?\ GW/_ 'R?\*_2
MC_A7,/\ S[C_ +Y'_P 11_PKF'_GW'_?(_\ B* /S7_X5*?^?<_]\G_"C_A4
MI_Y]S_WR?\*_2C_A7,/_ #[C_OD?_$4?\*YA_P"?<?\ ?(_^(H _-?\ X5*?
M^?<_]\G_  H_X5*?^?<_]\G_  K]*/\ A7,/_/N/^^1_\11_PKF'_GW'_?(_
M^(H _-?_ (5*?^?<_P#?)_PH_P"%2G_GW/\ WR?\*_2C_A7,/_/N/^^1_P#$
M4?\ "N8?^?<?]\C_ .(H _-?_A4I_P"?<_\ ?)_PH_X5*?\ GW/_ 'R?\*_2
MC_A7,/\ S[C_ +Y'_P 11_PKF'_GW'_?(_\ B* /S7_X5*?^?<_]\G_"C_A4
MI_Y]S_WR?\*_2C_A7,/_ #[C_OD?_$4?\*YA_P"?<?\ ?(_^(H _-?\ X5*?
M^?<_]\G_  H_X5*?^?<_]\G_  K]*/\ A7,/_/N/^^1_\11_PKF'_GW'_?(_
M^(H _-?_ (5*?^?<_P#?)_PH_P"%2G_GW/\ WR?\*_2C_A7,/_/N/^^1_P#$
M4?\ "N8?^?<?]\C_ .(H _-?_A4I_P"?<_\ ?)_PH_X5*?\ GW/_ 'R?\*_2
MC_A7,/\ S[C_ +Y'_P 11_PKF'_GW'_?(_\ B* /S7_X5*?^?<_]\G_"C_A4
MI_Y]S_WR?\*_2C_A7,/_ #[C_OD?_$4?\*YA_P"?<?\ ?(_^(H _-?\ X5*?
M^?<_]\G_  H_X5*?^?<_]\G_  K]*/\ A7,/_/N/^^1_\11_PKF'_GW'_?(_
M^(H _-?_ (5*?^?<_P#?)_PH_P"%2G_GW/\ WR?\*_2C_A7,/_/N/^^1_P#$
M4?\ "N8?^?<?]\C_ .(H _-?_A4I_P"?<_\ ?)_PH_X5*?\ GW/_ 'R?\*_2
MC_A7,/\ S[C_ +Y'_P 11_PKF'_GW'_?(_\ B* /S7_X5*?^?<_]\G_"C_A4
MI_Y]S_WR?\*_2C_A7,/_ #[C_OD?_$4?\*YA_P"?<?\ ?(_^(H _-?\ X5*?
M^?<_]\G_  H_X5*?^?<_]\G_  K]*/\ A7,/_/N/^^1_\11_PKF'_GW'_?(_
M^(H _-?_ (5*?^?<_P#?)_PH_P"%2G_GW/\ WR?\*_2C_A7,/_/N/^^1_P#$
M4?\ "N8?^?<?]\C_ .(H _-?_A4I_P"?<_\ ?)_PH_X5*?\ GW/_ 'R?\*_2
MC_A7,/\ S[C_ +Y'_P 11_PKF'_GW'_?(_\ B* /R/\ #/PS\07'Q#^)]EJ%
M]X"O-#L/^$+_ .$>TKP]/++XYT?[5H=Q+JW_  L.V:-8[7^T+Q4N?"7E/)Y^
MCK/(^U@!7I'_  J4_P#/N?\ OD_X5]C^"_A'>V?Q:^-6JW7PITSPKIVL?\*X
M_LOXDVVN6&H:A\5?[/\ #5U;7W]IZ);RR7OA_P#X0:=ET&R^WP6_]JP7#7=K
MYL2,X]A_X5S#_P ^X_[Y'_Q% 'YK_P#"I3_S[G_OD_X4?\*E/_/N?^^3_A7Z
M4?\ "N8?^?<?]\C_ .(H_P"%<P_\^X_[Y'_Q% 'YK_\ "I3_ ,^Y_P"^3_A1
M_P *E/\ S[G_ +Y/^%?I1_PKF'_GW'_?(_\ B*/^%<P_\^X_[Y'_ ,10!^:_
M_"I3_P ^Y_[Y/^%'_"I3_P ^Y_[Y/^%?I1_PKF'_ )]Q_P!\C_XBC_A7,/\
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MD_X5^E'_  KF'_GW'_?(_P#B*/\ A7,/_/N/^^1_\10!^:__  J4_P#/N?\
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M4_\ /N?^^3_A7Z4?\*YA_P"?<?\ ?(_^(H_X5S#_ ,^X_P"^1_\ $4 ?FO\
M\*E/_/N?^^3_ (4?\*E/_/N?^^3_ (5^E'_"N8?^?<?]\C_XBC_A7,/_ #[C
M_OD?_$4 ?FO_ ,*E/_/N?^^3_A1_PJ4_\^Y_[Y/^%?I1_P *YA_Y]Q_WR/\
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M?&;]@:32OB%J/QG\<^%_A#XI@US3M"T7_A76@16GQ6\*^.VTG7M;U'Q+IWB
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MN)AB\+0C!R<,+-TG4J1CJU:2<VVM%9ISEI%133/Z_/AK\2O ?QB\!^%OB?\
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M#_Q>\&GPUJ,EUJ6B?$CP\= U;2T#S7-]IOB>S.E:CIR0O=!I)KB&"YM$BDN
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M6SFMK+)2V3'^BC\&/^2<?#/_ +)_X1_]1O3J_@\_X+O_ /*2[XT?]BQ\(/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?OV68_#\/P'\"Q^
M%=,^*VCZ"O\ PD_V#3OC=&L7Q0M\^,O$+77_  DZ)/<*OG7AN)]%Q,^?#TND
MD[22B_0->&?LV:I9:S\%?!>I:=\6;_XY6=S_ ,)'Y/Q2U/2YM%O?%'D^+-=M
MY//TR=5EMO[$EB?P['O \Z'2([A<K*#0![G1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *U']F1?W?\ Q[_ZU;U% &#_ &9%_=_\>_\ K4?V9%_=_P#'O_K5O44 8/\
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M]W_Q[_ZU;U% &#_9D7]W_P >_P#K4?V9%_=_\>_^M6]10!@_V9%_=_\ 'O\
MZU']F1?W?_'O_K5O44 8/]F1?W?_ ![_ .M1_9D7]W_Q[_ZU;U% &#_9D7]W
M_P >_P#K4?V9%_=_\>_^M6]10!@_V9%_=_\ 'O\ ZU']F1?W?_'O_K5O44 8
M/]F1?W?_ ![_ .M1_9D7]W_Q[_ZU;U% &#_9D7]W_P >_P#K4?V9%_=_\>_^
MM6]10!@_V9%_=_\ 'O\ ZU']F1?W?_'O_K5O44 8/]F1?W?_ ![_ .M1_9D7
M]W_Q[_ZU;U% &#_9D7]W_P >_P#K4?V9%_=_\>_^M6]10!@_V9%_=_\ 'O\
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M ,>_^M6]10!@_P!F1?W?_'O_ *U']F1?W?\ Q[_ZU;U% &#_ &9%_=_\>_\
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M9D7]W_Q[_P"M6]10!@_V9%_=_P#'O_K4?V9%_=_\>_\ K5O44 8/]F1?W?\
MQ[_ZU']F1?W?_'O_ *U;U% &#_9D7]W_ ,>_^M1_9D7]W_Q[_P"M6]10!@_V
M9%_=_P#'O_K4?V9%_=_\>_\ K5O44 8/]F1?W?\ Q[_ZU']F1?W?_'O_ *U;
MU% &#_9D7]W_ ,>_^M1_9D7]W_Q[_P"M6]10!@_V9%_=_P#'O_K4?V9%_=_\
M>_\ K5O44 8/]F1?W?\ Q[_ZU']F1?W?_'O_ *U;U% &#_9D8_@_\>!_F*E7
M3XQV /Y__6_E6S10!0CM57HHX]/ICOP.W'-6T0+U'T']3[_YZ])** "BBB@
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MFUJ+QKX7AN?"7C'PGI.J:GJEE>Z#JVF6NJ3/?K#H6K+IJ7(EG2W_ *5?%O\
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MAZN-E5ARQK55*F^:,N:*E5=[1;:TDM))/RT/\Z?_ ()U_P#*4#]G/_LXR/\
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M5/VL*D?=J*,XW3TQ5'%4<QAC:%!XB+I\CBI*+4N5PU;NTM5).S6Z=MS]%_\
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MUWX>\0VB_%B"^TK6-*OH+[3+NTU.QL+DW-A<$6ZJO'U3_P %#_\ @F1\&?\
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MU%RSA2C&2NG:26JNFT[=TVNS"OXM/^"VW_!4S4OCGXM\3_L??!'4=3T?X/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\:_9^D\02_"+PE)XIU+X4ZOKS?V]]NU'X(2-+\+[C'B?
M6EM?^$8=X+9F\FS%O!K684QXABU8#< ';V6O$_V==-DTCX-^#M.E^$,'P&DM
M_P#A(=WPHMM=MO$T'A7S?%.N3C9K=G;VEM>_VX)1XD;R[>/[,^L-:/OD@9V
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MXV:W9V]I;7O]N"4>)&\NWC^S/K#6C[Y(&=O;* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#QK]H&3Q!%\(O%LGA;4OA3I&O+_8/V'4?C?(T7POM
M\^)]%6Z_X2=T@N67SK,W$&BXA?/B&720=H)=?9:\3_:*TV35_@WXQTZ+X0P?
M'F2X_P"$>V_"BYUVV\,P>*O*\4Z'.=^MWEO=VUE_88B/B1?,MY/M+Z.MHFR2
M=77VR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=5]GM_\ GA#_ -^D_P#B:/L]O_SPA_[])_\ $T <K175?9[?_GA#_P!^D_\
MB:/L]O\ \\(?^_2?_$T <K175?9[?_GA#_WZ3_XFC[/;_P#/"'_OTG_Q- '*
MT5U7V>W_ .>$/_?I/_B:/L]O_P \(?\ OTG_ ,30!RM%=5]GM_\ GA#_ -^D
M_P#B:/L]O_SPA_[])_\ $T <K175?9[?_GA#_P!^D_\ B:/L]O\ \\(?^_2?
M_$T <K175?9[?_GA#_WZ3_XFC[/;_P#/"'_OTG_Q- '*T5U7V>W_ .>$/_?I
M/_B:/L]O_P \(?\ OTG_ ,30!RM%=5]GM_\ GA#_ -^D_P#B:/L]O_SPA_[]
M)_\ $T <K175?9[?_GA#_P!^D_\ B:/L]O\ \\(?^_2?_$T <K175?9[?_GA
M#_WZ3_XFC[/;_P#/"'_OTG_Q- '*T5U7V>W_ .>$/_?I/_B:/L]O_P \(?\
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M;_\ /"'_ +])_P#$T <K175?9[?_ )X0_P#?I/\ XFC[/;_\\(?^_2?_ !-
M'*T5U7V>W_YX0_\ ?I/_ (FC[/;_ //"'_OTG_Q- '*T5U7V>W_YX0_]^D_^
M)H^SV_\ SPA_[])_\30!RM%=5]GM_P#GA#_WZ3_XFC[/;_\ /"'_ +])_P#$
MT <K175?9[?_ )X0_P#?I/\ XFC[/;_\\(?^_2?_ !- '*T5U7V>W_YX0_\
M?I/_ (FC[/;_ //"'_OTG_Q- '*T5U7V>W_YX0_]^D_^)H^SV_\ SPA_[])_
M\30!RM%=5]GM_P#GA#_WZ3_XFC[/;_\ /"'_ +])_P#$T <K175?9[?_ )X0
M_P#?I/\ XFC[/;_\\(?^_2?_ !- '*T5U7V>W_YX0_\ ?I/_ (FC[/;_ //"
M'_OTG_Q- '*T5U7V>W_YX0_]^D_^)H^SV_\ SPA_[])_\30!RM%=5]GM_P#G
MA#_WZ3_XFC[/;_\ /"'_ +])_P#$T <K175?9[?_ )X0_P#?I/\ XFC[/;_\
M\(?^_2?_ !- '*T5U7V>W_YX0_\ ?I/_ (FC[/;_ //"'_OTG_Q- '*T5U7V
M>W_YX0_]^D_^)H^SV_\ SPA_[])_\30!RM7M._X^D_W7_P#036Y]GM_^>$/_
M 'Z3_P")IRPPH=R11HPZ,J*IYZ\@ \T 24444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\_?LLQ^'X?@/X%C\*Z9\5M'T%?^$G^P:=\;HUB
M^*%OGQEXA:Z_X2=$GN%7SKPW$^BXF?/AZ722=I)1?H&O#/V;-:_X2+X*^"]8
M_P"%N?\ "]OMG_"1_P#%U?\ A&/^$-_X2K[/XLUVU_Y%O?)_9O\ 8?D?\(Y]
M\_;/['^W\?:L  ]SHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGS_\)=_8V6_LC_A)/,_MG^R]S?8/MOV3)\K- '<T444 %%%% !1110 4444
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M>X5?.O#<3Z+B9\^'I=))VDE%^@:\,_9LUK_A(O@KX+UC_A;G_"]OMG_"1_\
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M7_U%=_\ #0![G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-KN
MLQ:#I[:A-#).BRQ1>7$55R920#ER!@8Y[UQ/_"T-._Z!E[_W\@_^*K5^(O\
MR+<G_7Y:?^A/7@- 'M/_  M#3O\ H&7O_?R#_P"*H_X6AIW_ $#+W_OY!_\
M%5XM10![3_PM#3O^@9>_]_(/_BJ/^%H:=_T#+W_OY!_\57BU% 'M/_"T-._Z
M!E[_ -_(/_BJ/^%H:=_T#+W_ +^0?_%5XM10![3_ ,+0T[_H&7O_ '\@_P#B
MJ/\ A:&G?] R]_[^0?\ Q5>+44 >T_\ "T-._P"@9>_]_(/_ (JC_A:&G?\
M0,O?^_D'_P 57BU% 'M/_"T-._Z!E[_W\@_^*H_X6AIW_0,O?^_D'_Q5>+44
M >T_\+0T[_H&7O\ W\@_^*H_X6AIW_0,O?\ OY!_\57BU% 'M/\ PM#3O^@9
M>_\ ?R#_ .*H_P"%H:=_T#+W_OY!_P#%5XM10![3_P +0T[_ *!E[_W\@_\
MBJ/^%H:=_P! R]_[^0?_ !5>+44 >T_\+0T[_H&7O_?R#_XJC_A:&G?] R]_
M[^0?_%5XM10![3_PM#3O^@9>_P#?R#_XJC_A:&G?] R]_P"_D'_Q5>+44 >T
M_P#"T-._Z!E[_P!_(/\ XJC_ (6AIW_0,O?^_D'_ ,57BU% 'M/_  M#3O\
MH&7O_?R#_P"*H_X6AIW_ $#+W_OY!_\ %5XM10![3_PM#3O^@9>_]_(/_BJ/
M^%H:=_T#+W_OY!_\57BU% 'M/_"T-._Z!E[_ -_(/_BJ/^%H:=_T#+W_ +^0
M?_%5XM10![3_ ,+0T[_H&7O_ '\@_P#BJ/\ A:&G?] R]_[^0?\ Q5>+44 >
MT_\ "T-._P"@9>_]_(/_ (JC_A:&G?\ 0,O?^_D'_P 57BU% 'M/_"T-._Z!
ME[_W\@_^*H_X6AIW_0,O?^_D'_Q5>+44 >T_\+0T[_H&7O\ W\@_^*H_X6AI
MW_0,O?\ OY!_\57BU% 'M/\ PM#3O^@9>_\ ?R#_ .*H_P"%H:=_T#+W_OY!
M_P#%5XM10![3_P +0T[_ *!E[_W\@_\ BJ/^%H:=_P! R]_[^0?_ !5>+44
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M +^0?_%4?\+0T[_H&7O_ '\@_P#BJ\6HH ]I_P"%H:=_T#+W_OY!_P#%4?\
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M] R]_P"_D'_Q5'_"T-._Z!E[_P!_(/\ XJO%J* /:?\ A:&G?] R]_[^0?\
MQ5'_  M#3O\ H&7O_?R#_P"*KQ:B@#VG_A:&G?\ 0,O?^_D'_P 51_PM#3O^
M@9>_]_(/_BJ\6HH ]I_X6AIW_0,O?^_D'_Q5'_"T-._Z!E[_ -_(/_BJ\6HH
M ]I_X6AIW_0,O?\ OY!_\51_PM#3O^@9>_\ ?R#_ .*KQ:B@#VG_ (6AIW_0
M,O?^_D'_ ,51_P +0T[_ *!E[_W\@_\ BJ\6HH ]I_X6AIW_ $#+W_OY!_\
M%4?\+0T[_H&7O_?R#_XJO%J* /:?^%H:=_T#+W_OY!_\51_PM#3O^@9>_P#?
MR#_XJO%J* /:?^%H:=_T#+W_ +^0?_%4?\+0T[_H&7O_ '\@_P#BJ\6HH ]I
M_P"%H:=_T#+W_OY!_P#%4?\ "T-._P"@9>_]_(/_ (JO%J* /:?^%H:=_P!
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M_P"@K_Y(Z;_\AUR-% '7?\)WXK_Z"O\ Y(Z;_P#(='_"=^*_^@K_ .2.F_\
MR'7(T4 ==_PG?BO_ *"O_DCIO_R'1_PG?BO_ *"O_DCIO_R'7(T4 ==_PG?B
MO_H*_P#DCIO_ ,AT?\)WXK_Z"O\ Y(Z;_P#(=<C10!UW_"=^*_\ H*_^2.F_
M_(='_"=^*_\ H*_^2.F__(=<C10!UW_"=^*_^@K_ .2.F_\ R'1_PG?BO_H*
M_P#DCIO_ ,AUR-% '7?\)WXK_P"@K_Y(Z;_\AT?\)WXK_P"@K_Y(Z;_\AUR-
M% '7?\)WXK_Z"O\ Y(Z;_P#(='_"=^*_^@K_ .2.F_\ R'7(T4 ==_PG?BO_
M *"O_DCIO_R'1_PG?BO_ *"O_DCIO_R'7(T4 ==_PG?BO_H*_P#DCIO_ ,AT
M?\)WXK_Z"O\ Y(Z;_P#(=<C10!UW_"=^*_\ H*_^2.F__(='_"=^*_\ H*_^
M2.F__(=<C10!UW_"=^*_^@K_ .2.F_\ R'1_PG?BO_H*_P#DCIO_ ,AUR-%
M'7?\)WXK_P"@K_Y(Z;_\AT?\)WXK_P"@K_Y(Z;_\AUR-% '7?\)WXK_Z"O\
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M@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!UW_  G?BO\ Z"O_ )(Z;_\
M(='_  G?BO\ Z"O_ )(Z;_\ (=<C10!UW_"=^*_^@K_Y(Z;_ /(='_"=^*_^
M@K_Y(Z;_ /(=<C10!UW_  G?BO\ Z"O_ )(Z;_\ (='_  G?BO\ Z"O_ )(Z
M;_\ (=<C10!UW_"=^*_^@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!UW_
M  G?BO\ Z"O_ )(Z;_\ (='_  G?BO\ Z"O_ )(Z;_\ (=<C10!UW_"=^*_^
M@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!UW_  G?BO\ Z"O_ )(Z;_\
M(='_  G?BO\ Z"O_ )(Z;_\ (=<C10!UW_"=^*_^@K_Y(Z;_ /(='_"=^*_^
M@K_Y(Z;_ /(=<C10!UW_  G?BO\ Z"O_ )(Z;_\ (='_  G?BO\ Z"O_ )(Z
M;_\ (=<C10!UW_"=^*_^@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!UW_
M  G?BO\ Z"O_ )(Z;_\ (='_  G?BO\ Z"O_ )(Z;_\ (=<C10!UW_"=^*_^
M@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!UW_  G?BO\ Z"O_ )(Z;_\
M(='_  G?BO\ Z"O_ )(Z;_\ (=<C10!UW_"=^*_^@K_Y(Z;_ /(='_"=^*_^
M@K_Y(Z;_ /(=<C10!UW_  G?BO\ Z"O_ )(Z;_\ (='_  G?BO\ Z"O_ )(Z
M;_\ (=<C10!UW_"=^*_^@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!UW_
M  G?BO\ Z"O_ )(Z;_\ (='_  G?BO\ Z"O_ )(Z;_\ (=<C10!UW_"=^*_^
M@K_Y(Z;_ /(='_"=^*_^@K_Y(Z;_ /(=<C10!S_A;QE\2(OB1\5;C4-9^'K:
M)<_\(/\ \(_'X<TVQ7Q[%Y.@W":K_P +(D;3(TDWW91O!_ESW&S1A.K>2?D/
MIW_"=^*_^@K_ .2.F_\ R'7SKX.TK[)\5?C)J?\ PK7_ (1C^U_^%>?\7$_M
M_P#M'_A:'V#PY=6__("VC_A'?^$)W?V']YO[7^T?;/EV8KUR@#KO^$[\5_\
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M?_D.N1HH Z[_ (3OQ7_T%?\ R1TW_P"0Z/\ A._%?_05_P#)'3?_ )#KD:*
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M_P!!7_R1TW_Y#H_X3OQ7_P!!7_R1TW_Y#KD:* .N_P"$[\5_]!7_ ,D=-_\
MD.C_ (3OQ7_T%?\ R1TW_P"0ZY&B@#KO^$[\5_\ 05_\D=-_^0Z/^$[\5_\
M05_\D=-_^0ZY&B@#KO\ A._%?_05_P#)'3?_ )#H_P"$[\5_]!7_ ,D=-_\
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M^@9>_P#?R#_XJC_A:&G?] R]_P"_D'_Q5>+44 >T_P#"T-._Z!E[_P!_(/\
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MD'_Q5>+44 >T_P#"T-._Z!E[_P!_(/\ XJC_ (6AIW_0,O?^_D'_ ,57BU%
M'M/_  M#3O\ H&7O_?R#_P"*H_X6AIW_ $#+W_OY!_\ %5XM10![3_PM#3O^
M@9>_]_(/_BJ/^%H:=_T#+W_OY!_\57BU% 'M/_"T-._Z!E[_ -_(/_BJ/^%H
M:=_T#+W_ +^0?_%5XM10![3_ ,+0T[_H&7O_ '\@_P#BJ/\ A:&G?] R]_[^
M0?\ Q5>+44 >T_\ "T-._P"@9>_]_(/_ (JC_A:&G?\ 0,O?^_D'_P 57BU%
M 'M/_"T-._Z!E[_W\@_^*H_X6AIW_0,O?^_D'_Q5>+44 >T_\+0T[_H&7O\
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M_P"%H:=_T#+W_OY!_P#%5XM10![3_P +0T[_ *!E[_W\@_\ BJ/^%H:=_P!
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M*H_X6AIW_0,O?^_D'_Q5>+44 >T_\+0T[_H&7O\ W\@_^*H_X6AIW_0,O?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGW1]F_M/['S]GR0#URBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#S3X/R^(9OAUX=D\5V_@"UU]O[7^WP?"YI6\"QXUW4UM?["::>YE.Z
MR%L^I[IGQK#:@%VKA%]+KR/X$Z5_8GPJ\+:9_P *U_X5!]F_MS_BW?\ ;_\
MPE'_  CWG>(]8N/^0[M3[=_:WF_VY]T?9O[3^Q\_9\GUR@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \T^,$OB&'X=>(I/"EOX NM?7^R/L$'Q1
M:5? LF==TQ;K^W6AGMI1MLC<OIFV9,ZPNGAMRY1O2Z\C^.VE?VW\*O%.F?\
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MSIPMMSN<L:WQ M/M_@/QM8_\(U_PF?VSPCXDM/\ A#_[0_LG_A+/M&C7L/\
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MCO\ PA.[^P_O-_:_VC[9\NS%>N4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7FGP?E\0S?#KP[)XKM_ %KK[?VO]O@^%S2MX%CQKNIK:_V$TT]
MS*=UD+9]3W3/C6&U +M7"+Z77D?P)TK^Q/A5X6TS_A6O_"H/LW]N?\6[_M__
M (2C_A'O.\1ZQ<?\AW:GV[^UO-_MS[H^S?VG]CY^SY(!ZY1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \8_9ZDT63X/\ A!_#U_\ $74]';^W
M_L=]\6'63X@3X\4:V+C^WW6*!3Y5T)X=*Q$N-%CTT'<06/L]>4_!"^?4OA?X
M8O9/B7#\87F_MK/Q&@TBWT&+Q%Y?B'5H1LTFUGN8+3^R!&-";9,_GMIC7+;7
MF9%]6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9^[H ]6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /4/A?\ \A#5/^O.
M'_T?7M%>+_"__D(:I_UYP_\ H^O:* .%^(O_ "+<G_7Y:?\ H3UX#7OWQ%_Y
M%N3_ *_+3_T)Z\!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR_X,1ZU'\-?#:>(;#X=:9K"_P!L?;+'X3HT?P_@
MSK^JFW_L!&EG8>9:F";5<RMG6Y-2(V@A1ZA7D?P)T^TTOX5>%K"Q^'%Y\)+6
M#^W/*^'M_J,FJW?A_P WQ'K$S^;?S%I)_P"U9)'UN/<3Y4>I)"/EC H ]<HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPC_\$7C+_P";VC_AZ-^T#_T*GPC_ /!%XR_^;VC_ (@KQS_T#Y;_ .'&E_\
M(_U9^5S_ %OR;^?$?^")?YG]!WVQ/[Z_F/\ "C[8G]]?S'^%?SX_\/1OV@?^
MA4^$?_@B\9?_ #>T?\/1OV@?^A4^$?\ X(O&7_S>T?\ $%>.?^@?+?\ PXTO
M_D?ZL_*Y_K?DW\^(_P#!$O\ ,_H.^V)_?7\Q_A1]L3^^OYC_  K^?'_AZ-^T
M#_T*GPC_ /!%XR_^;VC_ (>C?M _]"I\(_\ P1>,O_F]H_X@KQS_ - ^6_\
MAQI?_(_U9^5S_6_)OY\1_P"")?YG]!WVQ/[Z_F/\*/MB?WU_,?X5_/C_ ,/1
MOV@?^A4^$?\ X(O&7_S>T?\ #T;]H'_H5/A'_P""+QE_\WM'_$%>.?\ H'RW
M_P .-+_Y'^K/RN?ZWY-_/B/_  1+_,_H.^V)_?7\Q_A1]L3^^OYC_"OY\?\
MAZ-^T#_T*GPC_P#!%XR_^;VC_AZ-^T#_ -"I\(__  1>,O\ YO:/^(*\<_\
M0/EO_AQI?_(_U9^5S_6_)OY\1_X(E_F?T'?;$_OK^8_PH^V)_?7\Q_A7\^/_
M  ]&_:!_Z%3X1_\ @B\9?_-[1_P]&_:!_P"A4^$?_@B\9?\ S>T?\05XY_Z!
M\M_\.-+_ .1_JS\KG^M^3?SXC_P1+_,_H.^V)_?7\Q_A1]L3^^OYC_"OY\?^
M'HW[0/\ T*GPC_\ !%XR_P#F]H_X>C?M _\ 0J?"/_P1>,O_ )O:/^(*\<_]
M ^6_^'&E_P#(_P!6?E<_UOR;^?$?^")?YG]!WVQ/[Z_F/\*/MB?WU_,?X5_/
MC_P]&_:!_P"A4^$?_@B\9?\ S>T?\/1OV@?^A4^$?_@B\9?_ #>T?\05XY_Z
M!\M_\.-+_P"1_JS\KG^M^3?SXC_P1+_,_H.^V)_?7\Q_A1]L3^^OYC_"OY\?
M^'HW[0/_ $*GPC_\$7C+_P";VC_AZ-^T#_T*GPC_ /!%XR_^;VC_ (@KQS_T
M#Y;_ .'&E_\ (_U9^5S_ %OR;^?$?^")?YG]!WVQ/[Z_F/\ "C[8G]]?S'^%
M?SX_\/1OV@?^A4^$?_@B\9?_ #>T?\/1OV@?^A4^$?\ X(O&7_S>T?\ $%>.
M?^@?+?\ PXTO_D?ZL_*Y_K?DW\^(_P#!$O\ ,_H.^V)_?7\Q_A1]L3^^OYC_
M  K^?'_AZ-^T#_T*GPC_ /!%XR_^;VC_ (>C?M _]"I\(_\ P1>,O_F]H_X@
MKQS_ - ^6_\ AQI?_(_U9^5S_6_)OY\1_P"")?YG]!WVQ/[Z_F/\*/MB?WU_
M,?X5_/C_ ,/1OV@?^A4^$?\ X(O&7_S>T?\ #T;]H'_H5/A'_P""+QE_\WM'
M_$%>.?\ H'RW_P .-+_Y'^K/RN?ZWY-_/B/_  1+_,_H.^V)_?7\Q_A1]L3^
M^OYC_"OY\?\ AZ-^T#_T*GPC_P#!%XR_^;VC_AZ-^T#_ -"I\(__  1>,O\
MYO:/^(*\<_\ 0/EO_AQI?_(_U9^5S_6_)OY\1_X(E_F?T'?;$_OK^8_PH^V)
M_?7\Q_A7\^/_  ]&_:!_Z%3X1_\ @B\9?_-[1_P]&_:!_P"A4^$?_@B\9?\
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M;VC_ (@KQS_T#Y;_ .'&E_\ (_U9^5S_ %OR;^?$?^")?YG]!WVQ/[Z_F/\
M"C[8G]]?S'^%?SX_\/1OV@?^A4^$?_@B\9?_ #>T?\/1OV@?^A4^$?\ X(O&
M7_S>T?\ $%>.?^@?+?\ PXTO_D?ZL_*Y_K?DW\^(_P#!$O\ ,_H.^V)_?7\Q
M_A1]L3^^OYC_  K^?'_AZ-^T#_T*GPC_ /!%XR_^;VC_ (>C?M _]"I\(_\
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M)_?7\Q_A1]L3^^OYC_"OY\?^'HW[0/\ T*GPC_\ !%XR_P#F]H_X>C?M _\
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M^A4^$?\ X(O&7_S>T?\ $%>.?^@?+?\ PXTO_D?ZL_*Y_K?DW\^(_P#!$O\
M,_H.^V)_?7\Q_A1]L3^^OYC_  K^?'_AZ-^T#_T*GPC_ /!%XR_^;VC_ (>C
M?M _]"I\(_\ P1>,O_F]H_X@KQS_ - ^6_\ AQI?_(_U9^5S_6_)OY\1_P""
M)?YG]!WVQ/[Z_F/\*/MB?WU_,?X5_/C_ ,/1OV@?^A4^$?\ X(O&7_S>T?\
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M^?$?^")?YG]!WVQ/[Z_F/\*/MB?WU_,?X5_/C_P]&_:!_P"A4^$?_@B\9?\
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MHW[0/_0J?"/_ ,$7C+_YO:/^(*\<_P#0/EO_ (<:7_R/]6?E<_UOR;^?$?\
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M^(_\$2_S/Z#OMB?WU_,?X4?;$_OK^8_PK^?'_AZ-^T#_ -"I\(__  1>,O\
MYO:/^'HW[0/_ $*GPC_\$7C+_P";VC_B"O'/_0/EO_AQI?\ R/\ 5GY7/];\
MF_GQ'_@B7^9_0=]L3^^OYC_"C[8G]]?S'^%?SX_\/1OV@?\ H5/A'_X(O&7_
M ,WM'_#T;]H'_H5/A'_X(O&7_P WM'_$%>.?^@?+?_#C2_\ D?ZL_*Y_K?DW
M\^(_\$2_S/Z#OMB?WU_,?X4?;$_OK^8_PK^?'_AZ-^T#_P!"I\(__!%XR_\
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M\(__  1>,O\ YO:/^'HW[0/_ $*GPC_\$7C+_P";VC_B"O'/_0/EO_AQI?\
MR/\ 5GY7/];\F_GQ'_@B7^9_0=]L3^^OYC_"C[8G]]?S'^%?SX_\/1OV@?\
MH5/A'_X(O&7_ ,WM'_#T;]H'_H5/A'_X(O&7_P WM'_$%>.?^@?+?_#C2_\
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MLH->N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E_P8CUJ/X:
M^&T\0V'PZTS6%_MC[98_"=&C^'\&=?U4V_\ 8"-+.P\RU,$VJYE;.MR:D1M!
M"CU"O(_@3I]II?PJ\+6%C\.+SX26L']N>5\/;_49-5N_#_F^(]8F?S;^8M)/
M_:LDCZW'N)\J/4DA'RQ@4 >N4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>7^7K7_"Z?-^P?#K_A'?\ A5WE_P!I[&_X6U_;7_"6;OL'F>;M_P"%
M=?8?](V>1N_X27YO-Q\E>H5Y'_9]I_POC^U?^%<7GV[_ (5'_9__  MW^T9/
ML'V3_A,OM/\ PKC^R<^3]L\[_BIO[1V^9Y/^C9V\4 >N4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'J'PO_ .0AJG_7G#_Z/KVBO%_A?_R$-4_Z\X?_
M $?7M% '"_$7_D6Y/^ORT_\ 0GKP&O?OB+_R+<G_ %^6G_H3UX#0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C'[
M/4FBR?!_P@_AZ_\ B+J>CM_;_P!COOBPZR?$"?'BC6Q<?V^ZQ0*?*NA/#I6(
MEQHL>F@[B"Q]GKRGX(:O?:[\+_#&JZE\1=.^+-[=?VUYWQ TG1K/0-/U_P C
MQ#JUM']GTBPAM[2T_LJ*&/1)?*B3SY]-DN9-TLSLP!ZM1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5:=\ ^@X_P ?Y8_6K-9]V<*2.N6H _DS
M^/\ +HTWQ;\5R>'[_P"(FIZ0PT+['??%=UD\?SX\-Z.L_P#;[K% K>7<B:'2
M\1+C18].'S$;CXW7N'[2&KWNO?&?QEJNH_$/3OBM>77_  C_ )WC[2M'L] L
M-?\ (\+Z);1_9])L(8+2T_LN*&/19?*B3SYM.DN7W2S.S>'U_?G!O_)(<*_]
MDWD?_JKPI^'YM_R-<S_[&&-_]2:H4445](>>%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]0^%__(0U3_KSA_\ 1]>T
M5XO\+_\ D(:I_P!></\ Z/KVB@#A?B+_ ,BW)_U^6G_H3UX#7OWQ%_Y%N3_K
M\M/_ $)Z\!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MVO#;;/$.A,.JZQIK#\+R$_TK]'_AS=L98!D]NY/0C QT^F><5^;OA_\ Y#NB
M_P#85T__ -*XJ_17X<?ZZ#_/9:_EWQ^_Y''#_P#V+<5_ZE(_2.!_]TQW_813
M_P#3;/T<^&DI*6_.1A?RY['].E?7F@MFWC'?"Y/\A_7_ /77QY\,?N0_1?ZU
M]@:!_J8_HO\ *OP$^X,_PE:>(8?B'\4;O4M)\ 6F@7G_  A'_"-ZIX=MY8_'
M6K_9]!GCUC_A8L[R-%<?V?>F.W\(^4D?E:.TZ2;V(->GUXSX&TBQL_BQ\:M5
M@^'6H^&KW6?^%<?;_B!<ZS>7NG_$O^S_  Q<VUK_ &9I$TSVFB?\(;$QT2]^
MQ10_VE/.MS<^9*@8>S4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7FGP?M/$-A\.O#MIXKTGP!H>OQ?VO]OTOX76\MKX%M?,UW4Y+7^PX)I)94
M\^R>VN-3W.V[6)M0=<*P ]+KQWX!:18Z%\)?">E:;\.M1^$UE:_V[Y/P_P!6
MUF\U_4- \_Q-K-S)]HU>_FN+N[_M66:36XO-E?R(-2CMH]L4**H![%1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5YI]D\0_\+B^W_P!D^ /^$4_X
M5I]D_MS[/+_PM/\ X2'_ (2GSO[)^U>9Y'_" ?V;_IGV?RO-_P"$B_>>9L^6
MO2Z\=_LBQ_X: _M[_A76H_VE_P *=_LC_A;?]LWG]D?8?^$U^V?\*Z_X1_SO
M[/\ [1\__BIO[9^S_;/LW^A>=Y'R4 >Q4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+4E'^:,*\(2:U6J5M14ZM.JG*E4A42T;ISC-)]FXMH****XRPHHK\LOV]_\
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M_P"$O^Q_\+%_X2#R?[0_L[[/_P 4S_8WVC[']I_TWR?.^>@#U:BBB@ HHHH
M**** "BBB@ HHHH **** "BN<\7>,?"/@#P[J?B_QWXI\.>"?"6BQPS:SXH\
M7:YIGAOP[I,-Q<P65O+J>MZS=66F6$<]Y<VUI#)=7,2RW-Q! A:66-&\$_X;
M;_8Q_P"CNOV8?_#^?"G_ .:RNJA@L9B8N>&PF*Q$%+E<Z&'JU8J22;BY4X22
ME:479N]I)VU1$JE.#M*<(MJZ4I1BVKVO9M:7T]3Z>HKYEA_;5_8VN)HK>W_:
MU_9EGN)Y$A@@A^//PLEFFFE8)%%%$GBIGDDD=E1(T4L[$*H)(%?3537PN*PO
M+]9PV(P_/?D]O1J4N?EMS<OM(QYN7FC>U[<RONAQG"=^2<9VM?EDI6OM>S=K
M].X4445SE!1110 4444 %%%% !1110 45R/C;X@^ OAGH;^)_B/XW\(?#_PU
M%.EK)XA\;>)=&\*:''<R0SW$=N^K:]>V%@D[P6US,D+7 D:&WGD"E(I&6+P'
M\1_AY\4]!7Q5\,?'G@SXC>%WN[G3T\2> _%&A^+]!:_L]GVNR76/#]]J&GM=
MVOFQ_:;87!F@\Q/-1=ZYU]A6]E[?V-7V'/[/VWLY^RY[7Y/:6Y.>VO+S7MT%
MS1YN7F7-:_+=<UN]M[>=K'9T445D,**** "BBB@ HHHH **** "BBO*?B'\=
M_@?\(KFRLOBQ\9?A3\,+S4H%NM.M/B'\1/"'@JYO[9I+B);BR@\2:QIDMU T
MMI=1+- DD9DMKA Q:&0+I2HUJ\U2H4JE:H[M4Z5.52;2U;4(*4G9:NRT$Y1B
MKR:BN[:2^]Z'JU%5-/U"PU:PLM5TJ]M-3TS4[2VU#3=2T^YAO+#4+"\A2YL[
MVRO+9Y+>[M+NWDCGMKF"22&>&1)8G='5C;J&FFTTTT[-/1IK=-=&AA1112 *
M*** "BBB@ HHHH **** "BOE+]L/]L/X7_L2?"_2/BQ\6-(\;ZWX>USQOI7@
M#3]/\ :5HNKZY)KFKZ+XBU^WDDM]?\1>%].BL(M.\+ZH]Q</J@E646\45O,T
MWR5?V._VTOA!^V[\/]<^(?PAM/&>E6/AKQ++X5UW1/'FBZ?HVO:?J*V-KJ5O
M(RZ+K7B/1+JTOK*[BGMI;'6[J6/:\=[!:3!8V])91F;RUYPL%7>5JM]7>-4;
MT%6NH\CDG=/F:C=I1YFHWN[&7MZ/M?8>TC[;EYO9W][EM>]O37O:[V3/K>BB
MBO--0HHHH **** "BBB@ HHHH ***^+/VS?V\/@O^PQH'@O7OB_IGC[6O^$_
MU'6--\.:5\/M#T?6=3GDT&'39]5N+EM?\1^%]*M+>UCU:Q(\W5/M$YE86]O+
MY4FWKP.!Q>98JC@<!AZF*Q==RC1H4H\U2HX0E4ERK32,(2G)MI*,6VTDR*E2
M%*$JE22A"-N:4G9*[25_5M+U9]IT5\U_LH?M3_#K]L7X16?QH^%^F>+]'\,W
MFO:WX<.F^.--TG2_$-MJ.@SQ178N+;0]=\2:68)DG@N+66VU>Y+PS*LRP7"2
MP1]G)^T/\ (O'4/PNE^.?P>C^)EQJ1T6W^'4GQ-\%)XZGUA998&TF'PBVMCQ
M!+J0G@GA-@FGM="6&6,Q;XW4.KE^.H8G$X2IA,1'$X.52.*HJE*<\.Z3M4]J
MH*7(H/24F^5=Q1JTY0A-3CR5$G"3:2ES?#:]KM]%N>PT445QF@4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /4/A?_R$-4_Z\X?_ $?7M%>+_"__ )"&J?\ 7G#_
M .CZ]HH X7XB_P#(MR?]?EI_Z$]> U[]\1?^1;D_Z_+3_P!">O : "BBB@ H
MHHH **** /E/]N+XVZ[^SI^R7\=OC)X6BW^*O!W@:Z'A68K9RQZ;XG\0WMCX
M5\.ZY-;:A:7MC?V_A_6=<L=<N=,N[:2#5+?3Y-.D,:W1E3^.?_@GU^R5>?\
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MUN;22*98+_3[NZL+R$.([JRN;BUG5X)I(V_G]_X-XKR[3]I;XWV"75PEC<_
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M#>A^&KO08_!MCK>H6NBZ?K>@ZSJ>N7-WXTTM-<O].T[4@?#GAS4K"*_AU/\
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M;R6=VD\"6AEB>UN%D56@E"_P&?LN>"?C]\4?BM:?"?\ 9PN]?LO'GQ2T;5/
M^ISZ#JMSH"#P1J1MKOQ:/$>NVA6?2_!_V"P5O%#))C4M(6XT1[?4DU1M)O\
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M^QAC?_4FJ%%%%?2'GA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/Y*O)_#]_X^7X?GI<_4"'_@W#A6:)KC]L:26W$B&>*']GY8)I(0P,J13O\
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M-*ZQQQJSNRJI(\A\%_M&_L]?$GQ WA/X=_'?X->/O%2?: _AGP7\4/!'BGQ
MAM([B:Z#:-H>N7^HK]FAM;J6XS;#R8[:X>3:L,A7^+_]B3X+?M8?MW?#R_\
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M"UM'UCQ)X2TC6=3:UM@SBWMVO;V<P0!V$,16,,P7)_S\_P!JS]E_Q_\ L?\
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M4-?^+TUAJVCW]KJ>F7T(T_P!&9;2_LI9[6YC$B/&9(974.C+G<I _*K]@O\
MX)[?%#_@HSXL^(GB"^^)R>"O#'A&:Q?QG\2/$FGZAX]\2ZOXG\0PZA<Z;86&
MC3ZYHD^N7<JZ=+<:WJ6I>)=/&G6TUK*G]HW-PEH> _;C_97_ &B_V*]:\-_
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MUIT[>9 1-'MC.^(B1<H=U?$O_!5[]L35?V/_ -F"]U7P1>SV'Q9^*.L+\/\
MX<ZC;1VDTGAN>6SGU+Q%XRDBOHIK>1=!T:UDM-/7RKB5?$6M:#,UM)917LL'
M\WG[$7_!,SXW_P#!1RW\;?''QM\7[KP9X5?Q/=Z/??$OQI8:O\3?&_C[QC#8
MV]]JTMM8:AXDT.]U6UTU+S3+?5?$FL>)($EO+MK'3!JUWI>LP:;\/PYP9@\?
MD]?B/B#-UDF24J[PU&I&A+$8C%5DXQDZ5.*E)P4W*$53IUZLYTZO[N$*<IOT
M,5CYTZ\<+AJ'UBNX\\ES*,81>W,WI>UF[N*2<=6W8_L\\!?%;X7?%2TN[_X8
M?$GP#\1['3_L9O[WP%XQ\.^,+2R&H1236!N[GP]J.HPVWVZ&&:6S\YT^TQ12
M20[T1B.^K^$3XV?"C]I'_@D)^U7X=G\'_$..ZO4L[?Q9X&\::5;S6'A_XC^#
MVNKK3;_2/&7@UM3OA#&\\-[I>N^&[W4;_P"R^9#J6C:PTDFFZM'_ $<_\%#_
M -M?Q9X0_P"";?A?]H?X'ZG+X4U_X^V'PQTW0-=TZZBOM5\$6/Q)\.W7B?6C
MIVH^5;?9O$6F:7INI>'(M4CM+?4M&U69K^T@TW5[&":RUS?@&6'Q?#_]BYG1
MS3*^):M.AE^/J0E0]E5DX<T<3!<TE%1E*HG&*JKV5:E4H0JTTJDT,R4H8GZQ
M2=&MA$Y5::?-=:V<'HM79;M:QDI-/3]$?&7[3G[-GPYU>70/B%^T+\#O FNP
M/+'-HOC+XL^ O#&KPR0.(YXY=-UO7[&\C>%R$E5X0T;D*X4G%>K>'/$OASQA
MHMAXD\)>(-$\4^'=5CDFTO7_  YJMAK>BZE%%/+;2RV&JZ9/=6-Y''<P36\C
MV\\BI/#+$Q$D;J/XF/\ @GY_P3 U3_@H-X4^(?Q)O?VB-"^'C>%_&4GA[5-*
ME\,7'Q(\>7^J7VFZ=KR^)-=TN7Q?X0.FZ%KQU+4+;2M<N-3O[C6M9T'Q';BU
M7^SI[@_N#_P2Q_X)_P#[1_[#7Q?^-FG_ !'\2Z%XC^$_BKP=X?\ ^$9U/PEX
MFOI- UCQ9!JPDFN[OP;J*65]INN:;I*SV<NIW.FR1&VN5M=/U:[BDN(XM.(^
M$.&LEP^84,/Q5[?/<KC1EB,MQ&!GAXXAU)4DZ>&JR:A*I&%55N6G4Q,O9Q:E
M&*;G%87'8O$2I2E@^7#UG+DJQJ*3BDG9SBM;-KENU#5Z7:L_W!KXD_X*%_LP
M>,OVO_V7?&7P1\!>,K#P7XEUG5?"^MV-QKD^JV_A;6V\-ZU;:LN@>*I-&MM0
MOUT>XG@AU"*:'2M6-IK.F:3?#3IWM4:/[;K\Q_\ @LA--!_P3=_:0>"62%VC
M^$T+/%(T;&&X^.?PRM[B(LA!,<]O++!-&3MEADDB<,CLI^0X;6(EQ#D4,+7C
MAL34S?+J5#$3HQQ$:%6KC*-.G6E0E*$:RIRDINFYPY^7E4X-\R[L5RK#8ASB
MYP5"JY14G%RBH2;BI*[C=*U[.U]GL>#_ /!*K_@F7\7/V&?&?Q0\<?%CQY\.
M?$=WXV\(Z/X6TO1OAY-XFU6WM_LNN3ZK?7^H:MXD\/\ A.2+RX[;3HK6UMM)
MNOM+WEZ9KBS73H/[4_;"OY7O^#=+5=4/C7]IS0SJ5^=%7PM\/-5&C_;+C^RQ
MJC:MXBLVU(:?YGV07[6B):M>"'[0;=5@,AB4*/#O^#A*:9OVR?A?;M+(;>+]
MF7PC-% 9&,,<T_Q3^,:3RI$3L229+>W2615#2+!"KDB) OZ'FO"^8<1^(F-R
M3,LZIRQ2P=&O/,J661IPE"E@</4ITXX&.,BHM1J*#D\5-MISUNH+RZ&,I87*
MX8BCAVH*;C[*59MW=247+VC@[W:O;D2Z>9_7!XZ^(WP]^%^BKXD^)?COP9\.
M_#KW:V":]XZ\4:)X2T5[YK2\OULEU37[[3[%KMK'3[^]6V$YF-I8WEP$\FVF
M=*_@'XH?#/XJZ5)KOPO^(G@7XD:'%(89=9\ ^+M \8:5',))H3%)J/A[4-1L
MTD$MM<1&-I@WF6\R8W12!?Y5?A9_P3D_:V_X*C>';#]J7X\?&SPW\-?#FM>%
MDT/X+Z(- O\ Q<Z>&?#$ATG2-,TSPK:Z_H]CX%\#2W$%_P"3J4^NZYXMU;4X
MM1U_6/#]\^K0ZYJOYW_!/QQ\<?\ @G-^VY'HL.I_V%XH\"_$&#X=_$G1O/EN
M_#?C+P;?:O90ZE9ZI:6$\BZEI.JZ3-:>(=#D_>WFF7ZZ3JUJD6IV,02<+X;9
M;CJ&8X+ <3X?&<2Y71E5Q>74L-/ZI3J0;C+#+$RDO:N-5*A4Q%'VD:-9J%6C
M%M7)YK6IRI5*F$E#"5I)0JN:YVG9J?*MKKWE&5G*.L9.Q_?I1117Y(>V?R8Z
M5_P0O_:H^.OQ5^)'Q ^-_P 4/"?PJTSQ1\1?'>J?VCJ%U=_%WXB:S:W6L:E>
M:5XCFT[3=6TW0IK+7A+9O$=4^(-MXAM;:2XEU31;2[MHK&Z_.S_@H'_P3N\?
M?L#>)?!%GKWC+2?B-X+^(UOX@?PGXRTK2+CP]</?>&+G3TU;2=<\/7&H:P=(
MOH[+6=%O[<Q:OJ-G>QWEU#:74TFEWNS^^&OX\?\ @O!^U1X:^,/QT\&_ CP7
M<QZAIG[/$?BBT\8:FEHT:S?$CQ3+HR:UHEO>//)]KM?"NFZ!IMC.T-K9B+7K
MW7K.=[X65J]M^]\ \:\6<0\2X7 U989Y12PM:6+PV'P=*G1PM"C0G##U(5FI
MXF,Y8EX>DHSQ$X2C)I06LE\WF67X+"X2=2/-[=SCR3G4;E.4I)R3CI!KDYG=
M1335[O9_HY_P;_\ QK\8>/OV>/BA\*?%&IWFL:=\&/&NB#P7<W\OG2Z3X7\=
M:9J%XOA:UE+>8=-TK6O#^L:G91S*SVO]OS6<,QL+>RM++X&_X+U_M4>)_%?Q
MWTW]EC0-9U;3_ 'PLT#P[KWCC1$F@M['Q)\1?%5A'XETVZO([.\GEU'3_#_@
M[5/#O]D1ZM%92VFL:GK\T6GO;_V=J=W^H_\ P0[_ &8/$7P(_9:U/XD>-;2\
MTKQ5^T/KNG^,K/0[OSX)=+^'FA6,^G>!9;ZPN;*W>UU37VO_ !!XI26&ZO+:
MZ\,:YX58BTOHK^W7^:;]LB./QA_P4@^/&FW5S;74&J?M3>(O#4TIAM[NW6"#
MQY_PC[6TUNA2&X^QQ0?8[JWD97D>"6*Y?SC*U=/#F$RK'^*'%&94(TJN&RNE
M5KT.2"E36/DL-A\5B(-7BVJRQSC))\TZBJPDFDW.*G6IY1@Z,N93K.,97>OL
MTY2A%]=8^SNKJR7*S]COAG_P;\>$_$_[/?AO7/&WQ@\?>$_V@O$GAJT\17.G
M+HVCCP#X1O\ 5]&COK/P?K?AF^TN+Q=>:CH=]/'8Z_K$?B?3/,DANX;7P_;O
M&DC_ )M_\$JOVC/'/[)_[;'A3X<>)-9O?#O@;XD^-?\ A3OQ<\(7UT#I,?B.
MYNK[PWX6U2\1&N;"RU7PIXZN+"*37D'^CZ%<>(+"2_MM,U*\N4_N3K_/W_:9
MBL? O_!1_P",TNEI-96&@_M>^*M8M8=/6&VDL43XJW&L>1ID=N+.&V2S=VAT
MV*,PBWBBMX_-!0RG'@?/LRXUH\6Y/GU98W#XK 2Q&'IRI4DL)*I.K!QP_+!-
M*G.>'J4.;F=*I0A.FXS<G)YAAJ6 E@J^&C[.4:JC)IOWTN5WE=]4I*6RDI-/
M1*W]2/\ P5S_ &1OVAOVQ_ OP-^''P+_ +..GV7Q)U+4_'\GB#Q<GAOPKI%A
M+H+6NB>)O$-B&N+_ %RVT>Y:_MX8]"T/Q%K]DVJ2/8Z4\%Q>RQ_EEK?_  ;N
M_%O3_AU<ZWH_[0W@G7_B?;:=?70\ 1^"-4TWPO?WMM%>R6>EZ;\1+[Q*ETTV
MHF*Q@CNM4\"Z39VUQ>3?:9DMK,7-S_6)7S!^V+^TYX2_9$_9_P#''QH\52QO
M<Z39/I/@O1WMY;MO$WC_ %:VND\*:!]GANK&5[6XO8&O-8E2\M7M-!L=5ODF
M#VRJWY]P[QKQ7@*&6</Y#+#P7UMQHTHX.E7K8VMBZ\I^SQ$ZRJOE<JBAS4%0
MG"G"-YKE<GZ>*R_!U)5<3B>9^XN:3J.,:<812O%1MK97M+F3;>FMC^#G]E?X
MR^-?V<OVC?A7\3O"5]J.D:QX6\<Z)!K6GQ%[<ZUX=N=6MK#Q9X1U:VE,8DL=
M=TB2]TF]MYO+EMWF6ZMI;34+2UN[?^Y;_@HK=7-I^PM^U9+:7$]K*_P2\<6K
MRV\TD$C6U]I4ME>V[/$RLT%W9W$]I=0DF.XMIYH)5>*1T;^+O]@C]FOQ5^V#
M^UA\/? T$%Y+X?B\2VWCWXL>(;=)+6+1/ FA:G!J_B6Y:\M+"\@TW5/$#B/P
MSX8>2R>S_P"$GUS2$N4AT];J>W_M+_X*&Z;>ZK^PU^U=:V$/GSQ? OXA:E(G
MF11;;+1M N]8U*;=-)&A^S:=8W5QY:L99O*\FWCEG>.)_P!"\3JN"EQ=P=3B
MZ7UZE7P\L<U:\</4S#"O"1J2[*4<9.,9V<83YK<LTWYF41J?4L<WS>SE&7L]
M]9*E-3:7_@"=NJMNC^/?_@G1_P $^O\ AOWQ+\3_  ]_PMS_ (5-_P *XT/P
M[K/VS_A O^$[_MG^W[_4K'[-]G_X33P;_9WV3^S_ #?.\^^\_P [9Y4/E[W_
M %8_XAPO^KR?_->?_P >5?B_^Q=^WC\7OV%M<\=Z_P#"3PY\-_$5Y\0M*T71
M]:B^(VD>)]7MK6VT*[OKVT?2T\,^,/",L,\DM_,MRUW->QO&L0BBA97=_P!?
M/@9_P<->,_\ A)K"S_:1^"WA*7PE<^;#J&O_  9&N:;K6E22W5K]FOHO#GC/
MQ1K]KJUM:V@O$O+(>(=-N+F62"XMKF(6[V5Y])Q93\3X9GC,1PUBJ7]D1IT)
M8;"QI934Q-XX>G]8Y8XS"SJS<JZJRC%UI2::5.-N6)R8)Y0Z4(XN$O;MRYIM
MUU"SD^6_LYJ*]VVO+9;R?4_IW\&>&K?P9X/\*>#[27S[3PIX:T+PU:S['B\Z
MWT+2[72X9?+EGNI(_,CM5?9)=7+IG:\\S R-TM8'A3Q3X?\ '/A;PUXU\)ZI
M;ZYX5\8:!HWBGPSK5GYGV36/#_B#3K;5M&U2U\Z.*;[/J&G7=M=P>;%')Y4R
M[XT;*C?K^7ZOM/:5/:J2J\\_:*:<9JIS/G4HM)J2E?F32:=TTCZ^-N5<MN6R
MY;.ZM;2SZJVS"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'J'PO_P"0AJG_ %YP_P#H^O:*
M\7^%_P#R$-4_Z\X?_1]>T4 <+\1?^1;D_P"ORT_]">O :]^^(O\ R+<G_7Y:
M?^A/7@- !1110 4444 %%%% !7A?QR_9F^ O[2F@IX;^./PN\+_$+38?^/.;
M5;>XM-:TT^3>0!M(\3:/<Z;XDT9UCO[PH^E:M9NDD[3(RS!9%^8_^"I/P3^,
MWQ]_8^\8^!O@.;^Z\?VGB;P1XOMM TO6QH%_XGL/"?B"VU>;2K*]EO=.LWO[
M"ZAL?$^F6U[=Q+-JGAZR-AG64TP5_.%X0_X*]_\ !2C]F)&\!?%;3[+Q7J-A
M')96NG?M)_#+Q-IWC#3!;/ DJ7%_I.I_#GQ3JUU!(DBS77BF[UN^#W4J7$[!
M+1;;[WAC@[-,\P7]IY!F^#HYIA<74I3P#Q53!X^C3C3I2I8JC6I.4^6JYU(W
M<:,(JC+DK5)\].GYV+QU'#U/8XFA.5&<$U5Y%4IR;;3A*+TT27\S?-K%*S?@
MG_!4#]A[1/V'OCMIGA?P7XEN?$'P[^(?A^;QEX+M=7+2>)?#5G%J<^F7_A[6
MKR.W@M-52SNX=^E:M (KBZL)8X=0M4O+62\O_P"CO]BG]K.]^%__  2(\%_M
M)_%RRFU>#X4>!/%FBZ6G]MQ177C6R\%^/=8^&WP]TO[??->OI%YJFHVFB^"M
M]TE[*MQ;?VG9Z?-!=V6F'^=VT^#O_!0?_@JC\9[#QUXE\,>+]?%_/8>%+CXD
M>)?#]YX.^#_P\T/33!]LLM-N'L[71;:'2H[M]:U+PYX7AU+Q-JE]?3Z@^FZA
MJFJ--<?U1?%_]AC2M9_X)S:]^P_\-]0CA?3/A9HFA>$]7U02VL.O>.O!NM:5
MX]L=5ULK=3_V5'XU\?:(+W7)+:2ZM-&76[R2SL+JSLX=-E_0N-\=@5E7!_#W
M$>8X7,,UI9M@:N>XG"U.>6&P$/:4,;*<Z:ISIU*E*M32<X0G6="I7=.,E%KR
M\OIU'6QV)PM*=*C*A4CAX35E*J^65-).Z:3BW9-J/,HW:/YY/AS\?/\ @K+_
M ,%//'WCN#X+?%C6_ GA[PF;'4M9L? 7C%/@SX,\ 6&NSZM+X9T5M<\/20>.
MM?GU.31]4M[*2_O?$VJ7"V-RVHW-OIL \CY7_P""B_[.7[7G[.WB7X8:;^UM
M\>/^%Z:QXGT/Q%?>#+__ (6A\3OB;_PCVFZ=?Z;!JUG]J^)>AZ)=:3]NNKFS
MF^SZ5'<6]U]G\RY=)(HE;'^ O[2'[7__  2W^*GCC2['P8/!NO\ B""UT?QW
M\-OC!X/U=_#_ (B;P_\ V@WA_5@+'4?#FK70T@:]?WWA_7/#/B2+2M3LM8^T
M"?5M(OX1+[5^TG\$O^"H7[9OA30_VLOB[\*/B)XNTJ\U&R\'^!?A_P"%_!6O
M_P#"0:1X>O["ZU3_ (2;PS\(M'TZ_P!=TSP3J<]A&;SQAJ4'VO7KN\T:Y%SJ
M.C/I=W!]M0HRRC/L'5HOA+*^$)48T\NJ488>CF&,Q%;"J/)3KM<LY^WYJDJE
M*IRU,+R\\JE251K@E)5\-.,OKM;'<S=2,G*5*G%33NX[I<MDDU=3O:R43^D+
M_@C5_P HV_V<?^ZO_P#J^?BC7\I_[5'_ "DY^,/_ &=]J_\ ZLQ*_KD_X)6?
M#GQW\)_V!OV?_ GQ*\*:WX(\9Z59?$*_U7PMXDLI=,U[28/$OQ9\>^*=&CU7
M3+@+=Z9>W.A:UIE[-IM]%;ZC8-<_9-1M;2^AN+:+^;']HC]C3]K'Q5_P4H^(
M^N^'OV<OC+JWACQ%^U+-XCT?QI:_#[Q(? 5UX?U7QQ;:U9ZXWCU]/3P;::2-
M-G2XO-1O-<M[332L\&HS6ES;7$,7P7!>.P5+C3Q KU<9A:5"M4SB=&M4Q%*%
M*K"6;59QG3J2FH3BX-24HMIQ:DG9IGHX^G4> RR*A-RBJ"E%1DW%^QBK225T
M[Z6?70_M6K^$3_@CE=6UG_P4@_9OEN[B"UB>?XJVJ2W$T<$;7-]\#_B7965N
MKRLJM/=WEQ!:6L()DN+F>&")7ED1&_N[K^"K]IK]F[]H;_@G%^U'=>-/"6@^
M,/#'AKP/\1AXH^!_Q=MM'O[KPCJFCKJ4M_X<TZ?7)#J.C7FHQZ85T/Q;X/UN
M^N+J]MS>6FL:?>:-J\4E]XWA8\/C,'QGD$L31P^-SS*:>&P2K248S?U?,\-4
M<=Y2=.6.HS<(1E-PYY*+4&;YQS0J8#$\DI4\/6<ZCBKV7-1FK]KJG)7=E>RO
MJ?UL?\%2YHH/^"?O[4#S2QPHW@"WA5Y76-3+<>)] @@B#.0#)//)'#"@.Z26
M1(T#.ZJ?P)_X-Y/^3H?C3_V02Z_]6'X&KF]1\7?\%+_^"P>BZ7X7U?PU:^$/
M@7X(TJZ\2:SK/A?P1KOA?X?^*O$GAK2;^]L[DW>LZIJM_P"/_B%JZW]II>D>
M$?#NM0>'+"YU#3-8N=%\.6C76OK]!?\ !"C]GSX]_"+]HWXN:Y\6/@A\7OAA
MHNI?!.YTK3M8^(?PU\9^"M+O]4;QUX-O%TVRU#Q+HNF6EU?M:6MS="S@FDN#
M;V\\XC\J&1E]JCEE/AKP^XLR7&YGEM;-JDHXNO@L+B85)895I86C1HR;Y74K
M2CA9U9PA&].,H<RM*,I82K/%YE@J].E55!>Y&I.#2GR\TI22UM%.:BFW9M.V
MS2^TO^"F_P#P2-'[7?BF;X[_  1\1:'X0^-L^F:?IWB_0_%;WL'A+XD0:):6
MFF:-J#ZQ86NHWOASQ5IFA6<6B13/INH:-KEG8Z%97?\ PCIL;S6;S\"+/XJ_
M\%&?^"67C73O &H:[XY^'6DQW>J:AHO@7Q/-_P )?\&_%]G;ZE>6VK:CX9TV
M[FO?#DMIJ-W<M<ZC?^&)=(UTM=Z=>7\UI=-8NOZ,_MF_ME?\%+_V)OVO/CCX
MJLH_$VL? +Q'XLTO4/!-M\0_!-]XJ^"4OAZ'2=$L-$L?#7B'3DTK_A%KJ*$1
MV'B+1?#/BG0+R_UV\NM5\1VE]X@OX-8E_._XS_M!?MS_ /!6GQEX'\*VWPMM
MO&$G@VYO(_#OA;X/>!=2TWPIX;O/$CZ)INJ:YXF\5>(=7UZ30K&ZDMM%COM6
M\8>,['PSI.^.7=IL=P[O[G"&$SZ&58##9[B.&\ZX+EE].L\1BZT*E3+X/#*=
M/"MUJ2I2>&J35%QKMJC135.O2Y(4%SXV>&=:K/#1Q>'QZJ-<L(M*H^=)S]V3
M:4TN9<OQ2U<7=R?]/FM?M&Z5^UC_ ,$I?C=\=],L+71I?&G[)G[0ZZ[X?M;Z
M34$\.^*-#^'OCG0?$6C_ &B>VL[EX[?5=-N);&2YM(9+G3)[&]C\ZWN8+B;^
M>;_@@U_R?:/^R,_$/_TL\+U_0KX(_9.\4? 7_@E3XZ_9?TJT_P"$L^)LO[,/
MQSTR_LM"MX)9]?\ BA\2_"?C;6;S0-*EA2 ZPEGXC\2KX1\/:C<I%=:EI6F:
M3)/%;,WV>'\7_P#@BA^R_P#M(?#/]L:]\:?$SX#?%[X;>$]/^$?C.PG\0?$/
MX>>*O VER7^J:EX:AL-/LKKQ5I>DQZE?W#1RR"QTXW5TEO#/=RPI:P33)\MD
MF(RC#\+>)>'P.*H0PD\5C8Y93J5XQJUL(X5885TXU)*K44X<D8-ISD[)^_='
M9B(UY8O*95(2<U"#K-1;49WBYW:5E9WOT730^.O^"TT=\G_!1CXX-=S1RV\N
MD_":33$0 -;V(^$?@B*2&8B*,M(VI1ZA< EYSY,\2^: !!#_ &F? VYTR\^"
MGP?O-%&W1KOX6_#^YTE3()BNF3^$](EL 9EFN5EQ:O$/,%Q.'^\)I0=[?@Y_
MP6__ & OB/\ %W4- _:K^"_AH^+=2\*>$+7P=\4O!GAO29KCQA?:/IFIZC?:
M)XZT^RL$EN/%3:7#JTVB^(((;=];TS0['1+R%+_0]-U!] _,#]G[_@IO_P %
M$/#/PHTO]D#X/Z+'XSUJPTI/#'@;6!\/O$_BOXV>"?#DRZ=8Z/HGAQ[;5O['
M&E:%!+!8^';GQ+X.UN?0M/U"VL;34(=/L/#\&E=N,RF7'?!7":R;&8&%?(:$
M,%F5+%8CV$<,H8;#X:K6K6A)QY/JT*ZYH_O*-9RIRE)<LLX5EEV88UUZ=1QQ
M,G4I2A'FY[SE-1CJKWYW%V>DHV:1X/\ \%4_^4@W[3W_ &/&G?\ J'^&J_HL
M_P""_K:FO[$?A86%W]FM7_:$\"+K<.XK]OTP>"_B6\5H (W#[-932;[:S0@"
MR+^86412_P ZOQB_X)L?MV^!M?\ #$GB'X&?%GXD>(OB-X<LO'FLZMX(\*^+
M/B6NCZUXEU34OMVA>.?$^B:?JMG9^-+66)+_ ,2)J5]B.;4/M'VV]MR;^7^T
M;]L_]FK3/VM_V;OB3\"[Z\L=(U'Q3IUG>>%/$-_9"]C\.>,?#^HVNM^'=5^5
M'N[:WDOK)=*UB;3RM])X?U+5[*+S$NY8)M^*<URK*\;X7UJ>887,,'DTJU#%
M8K"SA5BJ6'ADV%GB73IRJR@K4JE:$+RD_9N,)2:N1@J-:M3S>+ISI3KJ,H0F
MG%\TG7FH7:BGNHMZ)7NU;0_D5_X)U_LN?MQ?M%>#?B/=_LD_M0Q_!#1?"GB;
M2;?QEX8'QG^,OPSEU+5-7TJ272]>?3/AMX:UK2]0CGM-.NM/BO[^XBOPVFS6
MXA%O%$[_ &?\1?\ @C/_ ,%0?C!::98?%O\ :T^''Q2L=%N)[S1[+XB_'C]H
M7QO::3=W420W-UIEMXF^%VIPV%Q<0QI%//:I%+-$B1R,R* /@KP#K?\ P4%_
MX),_$[Q)J-KX"\1>"[?7V32?$=OXH\)ZCXG^#?Q-T_PC?-J,$]OKFGO;:5JZ
M:;!>730:SX=U_3/$NA:1XAU*W%[H_P#;%Y')])WO_!;_ /X*)_%>WGT'X;^"
M?AAHVLFWD@-]\*_A)XM\4Z]:RZ@\,%E=I8^+/%?Q"TP7,$Z-'IZ7&C2VD\UQ
M)'=6MZ1 D/TN:TN,<1FM3,^&:_"E;**_LZN%S&O3PTJU).C3IU?;8J%*I.?[
MQ5%"=*51NE*,96DG%<M&6!C15+%QQL:T;QG2BY\LGS)I1@VDM+732UNU]EG[
MN?LR_LH^*/V-?^"=7Q*^#7C?Q%H'B7QA'X)^.7BGQ#?>%7U&?PU;W>O^'M8^
MS6&C7FKZ;HVJ7UM;Z79V#SW5]I.G2M?RWD<=O]GBAEE_FS_X(G?\I$?A#_V+
MGQ5_]5IXHK^KKX7:I\</BC^P+I]Y\9/#FK6?QY\7_L]>)[#Q9X>O?#3^%?$-
M[XON_"^M:5;?VAX4,%DNB:_KQ%E?:AH]OI^E6EKJFH3V]EI&D6BP:9:?SB?\
M$A/V4OVG/AK^WA\/O%WQ&_9\^,OP_P#"?AOPY\3!K'BGQO\ #?Q;X4\.6TE]
MX*UK0K*&+7=>TFPTN^N+W5-1M(+.VT^ZNKBZC>2[@CDL[>YN(?B.'<P<\C\4
MI9GC<$\PQ5/'<\J=:E"GB<0\+F5.3PD6X.I2G5:C1Y(WE&4%:\DGZ.*I6Q&3
MJC3J>R@X63C)N$.:BU[1ZV:7Q7>Z?8_?G_@K9_RCN_:8_P"Q<\(?^K+\%5^(
MO_!NW_R7?]H+_LDFA_\ J8V=?N[_ ,%/O!WB[Q_^PA^T+X0\">%O$?C;Q;K6
M@>%H=&\+^$=#U/Q)XBU::W^(7A&]N(M,T31K6]U._D@L[:YNYH[6VE:*VMYY
MW"Q12.OY _\ !!_]GSX\_"'XQ?'76_BS\%OBM\+M(U+X::%I6F:A\1OA]XK\
M#VVJ:B?%,5VUGI<GB?2=+&I3PVUM+/<I9>>;6/RFN?*\^#S/.X>Q.'AX5\6X
M>>(HPKU,RYJ="56G&M4CR9.KPIN2G)7C)7C%J\6NC-,5";SC!249.*I:R46X
MK6MNTK+=;]T? 7_!<K_E(!XQ_P"R>?#+_P!1U:_I8\8_\HD/%/\ VCFUS_UF
M>ZK\'O\ @LK^RY^TK\2OVV/$7C;X;_ #XR_$7PCJG@3P%9V7B/P#\-?&'C/1
MY;O2M%2UU"U>^\-:/J<%O<6LY\MX+EX9202BLJEA_0KXK^'?C>X_X)J>)/A-
M;^&M2G^)$_[#6L?#N#P?#&DNL3>-Y?@'<^&HO#44*2-')J4FO,NEI&DI1[HA
M5D*D-7=Q'C,)/AOPQA#%8><\// NO"->E*5!0HX)3=:*DW3Y&FI<ZCRM-.S1
MGA*<UC,V;A-*2J<K<6E*\IM<KMK=--6W1_,M_P $&O\ D^T?]D9^(?\ Z6>%
MZ_I%_P""K5WIME_P3V_:<FU:2WBM7\&:-:1-=*KQ'4K_ ,;^%K'18U#*P%Q-
MK%S8Q6;8#)=O ZLC*'7^3KX(_L$?\%"]#L/$_P ?_AI\'OC)\-?&OP)U#PUX
MAT&RU;P;XK\%_$7Q%-?2:DEW-\-_#VNZ/:7WC6?1;>T#:_H5E9WD>IZ5J+Z6
M;;4Y[Q-&U#:_:?\ V_?VV?V[[#PY^S[XS\)6G_$OUS1+T_#+X3_#GQ-:^)?%
M7C#3(=1TW3K[6M*N-0\3^*+[49_^$@9?[ TXV'A^2_72KRW\/Q:A:VDX^JS[
MAG_6/C7+<^RW-LKK8+*JF7/-H1Q,'7P?U&M'&QT@YQFL31J15.;<(TY*7/?E
M=^/#8SZK@*N'JT*T:E95/8-Q:C4]HO9O5V:Y)+5*[>EMSZG_ .#>RTN'_;#^
M*E^L>;2V_9J\4VDTN]!LN+WXH_"*:UC\LL)&\V/3[MMZ(R)Y.)&1I(@_]AM?
MB_\ \$9_V%?&/[*'PE\6_$;XO:-!H?Q9^-A\/W(\-74$;Z]X%\!Z)!>7.C:'
MK,LD(GTGQ!KM_JUUJ_B70()F%G'9>&;/61%KVE7FGZ7^T%?DOB1FN$S?BW,,
M1@:L*^&HPP^#A7IRYJ=:6'HQC5G3DM)059U*<9Q;C-04X-QDF>UE5&=#!4XU
M$XSDY5'%JSBI/W4UNGRI-IV:;L]4%%%%?"'HA1110 4444 %%%% !7C'[/5[
MI6H_!_PA>:)XI\=>--+F_M_[+XF^)4ES+XUU+R_%&MQ3?VT]V!<-]CN$ET_3
MO,'&DVM@$^0+7L]>7_!C4-1U3X:^&[_5OB/I'Q;U"?\ MC[1\0M!T[3-*TKQ
M!Y6OZK#%]EL-&"Z;;_V5!''HD_V8#S;G39IIO](DE- 'J%%%% !1110 4444
M %%? '[9_P#P4B^ '[#&L>"?#OQ8TGXE^)-?\=Z;J>M:;I7PY\.Z'JTVGZ1I
MMU%8_P!H:M=^*/%7@_3(X[V]>>VL[?3[[4;X-97$E[:6=N]G-=?$G_$0C^QC
M_P!$R_:>_P#",^%/_P ^FOI,#PAQ-F6%I8W Y+C<3A*ZDZ->$(\E11G*G)QY
MI1;2G&2O:SLVFUJ<M3'82E-TZE>G"<;<T6W=72:O9/HT_P#AF?NU17Y=_!#_
M (+$_L*?&Z_M-%C^)6H_"KQ#?O;16>C?&/1/^$/CGEN9H[=83XHLKW7O MO-
M'/-#&T5WXKMY)!(9K99X(+J6#]1*\O,<IS/**JH9G@,7@*LDW".*H5*/M%&W
M-*E*<5&K%-I.5.4HIM*]S6E6HUX\U&I"HENX24K7V32=T_)V845^7O[4O_!6
M_P#9;_9)^+MY\%/B%I?Q5\1^--(M](NO$/\ P@'AWPKK&E^'(M=TO3=:TM=7
MN=;\<>&[I;BYTG5+;4/L=C8WUVEJ5FD@6.ZT]KS]%/A]XX\/?$[P%X(^)/A*
MXGN_"GQ"\(>&O''AB[NK6:QN;KP]XLT:RU[1;BXLKA4N+.>;3=0MI)K6=5FM
MY&:*55=& K%Y/FF!PF#Q^,P.(P^#S"*G@L15IN-/$0<%44J<NJE"49QNES0:
ME&\=0A7HU)U*4*D95*3M4@G=Q=[._H]'V>CU.NHK^5G]N_\ X+,?M&VO[0/C
M?X#?LBR:+X<T7P7XUD^'NG^,;'P?IWCKQWXY\7:9>66CZU;Z+I?B"T\1^&SI
MLGBNWU;0/#L=AX?U.]U_3FMM6M[R*?4;2UL?T)_X)1?M+_MO_&77OC?X#_;.
M\(>+M)U7P-I7P^UGPSK'C'X32?";6HCK[>(K74=-U#2X?#'AG3M0&J1:;8ZM
MITL>GVD]MY&I[!=V5U;QZ9])CN L[RW(EGV-J9=0HRH4,2L#/%269NAB*E"E
M"I]7]C[/W7B*;J0]O[2FFXS@JBY'R4\RP]7$_5J:JRDI2A[107L>:*;:YN;F
M^RTGRV>Z=G<_9VBOY6?V[_\ @LQ^T;:_M ^-_@-^R+)HOAS1?!?C63X>Z?XQ
ML?!^G>.O'?CGQ=IEY9:/K5OHNE^(+3Q'X;.FR>*[?5M \.QV'A_4[W7].:VU
M:WO(I]1M+6Q_0G_@E%^TO^V_\9=>^-_@/]L[PAXNTG5? VE?#[6?#.L>,?A-
M)\)M:B.OMXBM=1TW4-+A\,>&=.U :I%IMCJVG2QZ?:3VWD:GL%W975O'IACN
M L[RW(EGV-J9=0HRH4,2L#/%269NAB*E"E"I]7]C[/W7B*;J0]O[2FFXS@JB
MY&4\RP]7$_5J:JRDI2A[107L>:*;:YN;F^RTGRV>Z=G<_9VBBBOB3T HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -?P
M_P#\AW1?^PKI_P#Z5Q5^BOPX_P!=!_GLM?G5X?\ ^0[HO_85T_\ ]*XJ_17X
M<?ZZ#_/9:_EWQ^_Y''#_ /V+<5_ZE(_2.!_]TQW_ &$4_P#TVS]%?AC]R'Z+
M_6OL#0/]3']%_E7Q_P##'[D/T7^M?8&@?ZF/Z+_*OP$^X.3\!WNE3_%WXX6=
MIXI\=:MJEA_PK/\ M?PSK\ERW@KPG]J\+74NG_\ " )*/L\?]O6X;4/%7V4G
M?JT<)FP^*]KKROP?J&HW'Q(^*]A<_$?2/$VGZ=_P@G]F_#ZST[3+;5?AE]L\
M/W$UY_;-_:@:EJ7_  FDZKK>G?VJ3]CMK=X;'$#,*]4H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O&/V>KW2M1^#_ (0O-$\4^.O&FES?V_\
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M[_P<;-J8\._LE)%=[-&;6OC0U_8[B#<ZFEC\,1I-WL\LJWV*U?6X2QE0K]O
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M_'/C+5K?X;W6D^%?"VF76M>(-6BT'XO_  _\1:LNEZ381S7VHW%IHNDZC?\
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M=$UN&5[WXX>(;"ZD,D"QW)#R?#_3]3B8>)]9N!-#XDNX+CPKIB7);Q#J&@_
M/Q$_9$_;W\5^/O&GB7QO^R[^T[X@\8Z[XIU[5/%&MI\'?B;XDBU37;S4[F;5
M+VW\066AZK9:U:SW;2O::G8ZGJ%C>VQBN+.]N;:2*9_OO2OVI?\ @N]H.EZ;
MH>A^ ?VC]&T71K"STK1]'TK]ACPGIVEZ5I>G6\=GI^FZ;I]G^S_#:6-A8VD,
M-K9V=K#%;VMO%'!!&D2*H_IBAD4LBX863\)YUP]1S+,(WS?.L;F7L:T^:*TP
M*P]'%<J2J2I4)2E#ZM2O5@JF)KRKT_DY8GZQC/;XW#XJ5*D_W&'ITN9+5?Q'
M*4+ZI.2L^>32=H)1?]DM?P#_ +? NOA]_P %%OVAM3G>03Z3^T!J7C.-X8K:
M298=0UBS\7V7E0R32VTLB6M[ $2>15D8 7,=NS20Q_T)_P#!++XY?\%./B=\
M=O&^A_MH^'_BUIWPNLOA+JVK:#??$7]GW2?A#8CQ]#XQ\$V>EVNG:U8?#KP3
M-J=W<>';WQ5-)I;7-]'Y-J;MH(FMTD;YY_X+:_\ !/+XB>.?'-A^UC\#/!VN
M^.[K6-'AT7XT>&/#6FKJ6N:>_A32;2R\,>.-/TO3[=M6UNRF\/V3:%XBV)=W
M6CIH>@3Q1S:?>7C:3\?P'&AP?QCBLFS;,,MK1S+*U0AB\'B75P/MYSIXBC1E
MB*M*@HRG3A5IVE&*=:5*G%R<XG;F+ECL##$4:=6+HUN9TZD.6IRV<7)1BY72
M;B[IOW;O2S/Z7=,U*RUG3=/UC39OM.G:K8VFI6%QY<L/GV5];QW5K-Y-Q'%/
M%YL$L;^7-%'*F[;)&CAE'\$'CZ&T_:!_X*@^)+#PM)!<:9\4?VU[C1=#O;JT
MO9;.?2-<^,@TJSUF^L)[*"_BL)=.==6O[.YLDN+.S:>"YCWPR$^V^$?^"N/[
M?'@GX-VO[+NBR:.VN:9HR^"M#\<7_@WQ)>?'O0M,A$2V>EZ?=R:Z-(DU+3M'
MC_L?3]3U'P1?^(;73V6\CU'^VK>SU>V^Z?\ @C1_P32^).B_%#1_VLOC_P"$
M-3\$:/X+M+V7X1>!_%.F?8?$/B'Q-K6E&RA\<:QH>JV4D^G>'M"TC5+Z;PVM
MQ%8:Q=^*GTSQ!92V=GX?B.M>OD>23\-L%Q-F^<8[!^TQ&$G@LEHT*ZJ5<:[U
M)TJBIN$6O:U/J]DE+V4(UZE51IQC*6.(Q"S6I@Z-"G4M":J5Y2C:-/X>973>
MRYNJN^5)MO3^F7XA_$/P3\)_!/B7XC_$?Q+I?@_P/X/TN;6/$?B/6)C#8Z=8
MPE4!(19+BZN[JXDALM-TVRAN=2U74KFTTS3+2[U"[MK:7^'[]J;]I#X^?\%7
M?VH?#'A7X=^$=<GTMKNX\,?!;X2V5[)/#HVE232W6J>+_%4K7/\ 8=EKE_9Q
M+J?C7Q,QM=)T70]+LK":^ETS0$U"X_;S_@O+\,?VD/BOX!_9Y\-?!/X=?$[X
ME^#H?%/C_5/B)HGPV\-^(O%\MOKMMIGA6'X?7NM^'_#,%_>O:I:7/CQ+34[C
M3)K&PN7-N][9W.H6D-]^&?[.GAG_ (*F?LFZIXFUSX ?L]?M'^ ]:\86&GZ5
MK^L2?LCZCXNU2XTO3;B>\@TVSU#QS\)_$UWHUA-=SK=:E9Z+-I]OK%Q9Z5/J
M\=]+HVD-98^&V3X# Y+5XCHXS)ZO$6+AB*.6T,TQBPV&RZ-.M4PTY5O9JMB%
M4KJ+JR<:2G/#NE0ISHQKU:SK-:]6IB(X65.NL+!PE5E2I\\JK:C-<MW&-HW4
M5[UE.\FI.,8G]9G_  3U_86\(_L+?!H^$+2\L_$GQ.\9R:?K?Q;\=6EO+!!K
MNMV,-TFEZ'HRW*I>)X3\)1:AJ%GH*W:0W-[<7VKZ_<6>FW.N3Z99_>]?QT_\
M-=?\%\O^A3_:>_\ $)/#?_S@Z_=3]J"T_;)\>_\ !-GP?KOPMF\=:'^UM#\.
MO@5X_P#%^F^$KI_ GCR?Q186/A?6_BIH5EI%B^E0G4DN'UUK_P !*D::Q%9W
M?A>PTC4]0N+#0K[XGB+A?-8YK@\5G7$.0XS$9_F,</5QF%QTZ\,-.;IQ5;%*
M>&PT*&$I0E",>1\E*E!0C&,(Q1WX7&471G"AAL3"&&I<T83IJ+FEKRP:G)RF
M]W?63=[MMGZ36/ACPUIFFWFC:;X>T/3]'U#[1]OTFQTFPM--OOM=NEI=?;+&
M"WCM;G[3:QQVUQYT3^=;HD,FZ-54?QP?\%U_@K\(_A!^U#X$O/A;X8\+^!Y_
MB%\*K?Q1XR\*^$[&QT;39-<M_%?B/2(O%QT+3_*M=-N?$MK9BTO9;.QLK/5M
M0\/WNJR+=:W=:W>W&HG_  6T_P""CGPBL-1\!_$_PC\.[WQC9W>I:?>:S\5_
MA!XD\)>.]+O[>&"SN;*;0_#?B#X?^&K>[TBY'VEK:]\&O-#>7+Q:@D]KY%G%
M\\^#OV9/V\O^"F_QWC^(?C?P]XW-OXRU6SM/$'QE\;>&-4T#X<>#?#=M%/<K
M8^&HY[;3["\L-%L%DCTGPIX5,LLVH7MHVI36DVM7.LR?>\&<)YIP;FE;/<^S
M?+L)E-+"8B-2I2Q\JE+,.>"]FU&4*?/"G958<T76E4C3A3I2<FX^=CL;1QU&
M.&PU"K.NYQLG32E2L]=F[7^%V?*DVV]$?TL_\$6=4UC4O^"=GP6CU6"1(-*U
MCXHZ7HES+'=*U_H\7Q/\6723B:YDD2ZCM=1N]1TF&2T$=K!#IJ6 C$]G.S?J
MI7D7P$^"_A']G?X-?#CX)^!8?+\,_#GPO8>'K.X>WMK:ZUB]C#W6N>)-3AM$
MBM1K7BG7KG4_$FN26\4<4^L:K?3I&BR!1Z[7XIGN-HYEG>;YAAXN%#'9ECL7
M1C)6DJ6(Q-2K!R72;C).:V4FTM#W\-3E2P]"E*SE3HTX2MM>,%%V\KK3R"BB
MBO*-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ]0^%__ "$-4_Z\X?\ T?7M%>+_  O_ .0AJG_7
MG#_Z/KVB@#A?B+_R+<G_ %^6G_H3UX#7OWQ%_P"1;D_Z_+3_ -">O : "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR-_)E_P0_OM0M/\ @H-\/K>R60VVI^"/BA8ZN4$Y5=/C\':AJ433&)UC$?\
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MA9K7:A6J2Q690P]##1KTY>Y-QFO:/VEG[5J>MTG+W>1.6KN?R*_LL_%+X?\
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M2K&]U#QOKYC\5^&?%S:,)M5@T[PQ%I6I:=#=:GI.N2ZG]LLHK6WG\P_X*?\
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M  2Y_P"4?_[+W_9/&_\ 4BUROUSBW_DU_!7_ &$4?_47''BX/_D<8_\ P/\
M]*I'\8/PX\&>&OB-^WEX"^'OC/3?[9\'^//VNO"_@SQ7I'VR_P!._M7PUXH^
M,ECHFNZ;_:&E75CJEC]NTN^NK7[9IM[9W]MYOG6=U;W"1S)_6/XZ_P""(O\
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MO=0MK8O#<206\\G[V,?UF^$?VB?@IXY^"EO^T9X;^(>AW/P2N=#UCQ(OQ"U
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M (73_:/_  BW@7^P_P#A5WV+_A-?+MO^%E_VK_PEGG_\(MYN?MG_  @OV/\
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M>/I]4O+J:U,7GQ6]IID,VHW,[QK%!8Q27<K);HT@_O;HHK['C#BU\65\NKO
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M7DFL]0T]KVT"PW\%MJ%I=16=^(+.2^LEM[N?3].GFDL;?\)?B'_P<-:5X/\
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M8'_!<K_E(!XQ_P"R>?#+_P!1U:_KV_94_P"37OV;O^R"?![_ -5YX=K\7/\
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MX;2'PQ9^*;>_75F\3>#?"#P23/K=H;,6<=^LBQW!F>W*1K+^1_Q>_P""2_\
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M6Y)-II>]RW/Y7_\ @E?_ ,$[?V4_VZ?AO\0[WXF^/_B_X=^*W@#QBEI=>'/
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M6"7\>-*+YH1<O?32;+P&$KPP>.H58.%2JZL8W^&7/2<%*+_E;>C=O-'\V?\
MP;IS0K\3_P!IJW:6,7$O@/P!-% 9%$TD,'B'7DGE2(G>\<+W%NDLBJ5C:>%7
M(,J!OUN_X*^_M->/?V7?V/-2\1_#'5;SP[XX^(WCKP_\)M%\5:<D1U'PM'K^
MC>)_$>M:OIT\LB-I^I/X?\(ZKI6F:K:QS7^DZAJ=MJ.G?9;ZUM]1LOY][/\
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M-"T:+PSX7\7ZI<7VEZ7J>DZAJ,EWIUC816^JV*Q7L]Q(\$?1_M)_LK_ML?\
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MS;_D:YG_ -C#&_\ J35"BBBOI#SPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5XQ^SU>Z5J/P?\(7FB>*?'7C32YO[?\ LOB;XE27,OC74O+\4:W%-_;3W8%P
MWV.X273].\P<:3:V 3Y M>SUY?\ !C5M5USX:^&]4UOQUX<^)>J77]L?:O&W
MA.WMK3P_K7D:_JMO#_9]O:(EO'_9MO#%I-UY:C=>V%R[Y=F) /4**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O&/MNE?\-#_ -G?\)3XZ_MS_A2_
MVW_A"O,N?^%:?V5_PG'D?\)3Y6/L?_"=?;/^)3YF?M/]@?+CRJ]GKR_^UM5_
MX73_ &%_PG7AS^P_^%7?VM_PK/[/;?\ "6_VK_PEGV/_ (3K[7L^V?\ ".?8
M_P#BG_L^_P"S?VG^]V>;S0!ZA1110 4444 %%%% !1110 4444 %%%% !17R
M'^W!^UII7[%?P"UGXWZEX+U#X@RV>O>'_#6D^%;'6;;P['J&JZ_=.D;:CKUQ
M8:NVDZ?;6=M>W#W-MHFLW,ES':VBV*Q7,M[:?B'_ ,1'O_5FW_FPW_XC:^HR
M;@OB;B#"2QV498\7A8UIX=U7B\!AU[6G&$YQ4,5BJ%22C&I#WHP<&VTI.49)
M<=?'X3#35.O6Y)N*ER\E27NMM)MPA)*]GHW?R/Z>**_G\^"G_!P5\ _&WB#3
M-"^,GPA\:?!>WU6]BLAXHTKQ#8?$WPOHWG3K&E_XAEAT7P;XBM=,CB)DNI]'
M\-:]=P/M1;&6'S+F+]Z/#7B30?&7AS0/%_A;5;+7O#'BK1-*\2>'-<TV9;C3
MM9T'7+"#4](U6PN%^6>RU'3[JWO+69?EE@FC<<-7%G/#F=\/SIT\XRZO@G5Y
MO93FZ=6C5<;<T:>(H3JT)RBFG*,:CE%--I)IO2ABL/B4W0JQJ6W2NI*^UXR2
MDD^[5C;HK^2+_@GQ_P %4?VW?C-^V3\&_A?\4_BMI?C+P!\0=?UC1-:\-W/P
MY^'.AQ6\#^']8U.UN=,U7PGX6\/^((+O3KFQ@^R&YU>\MI(]Z:A;7Q8,/ZW:
MZ>)^%LQX3QM# YE5PE6KB,+'%TYX.I5JTU3E5JTN63K4,/-34J4KI0<;.+4G
M=I3A,92QM.56E&<8QFX-5%%.Z49:<LI*UI+KWT"BBBOFSJ"BBB@ HHHH ***
M* "BBB@ HHK\T?\ @H-_P4O^'O[!,?@S1=1\":Y\3_B'XZM-0UC2?"FGZJGA
M72;+P]ITK6<FK:SXKNM(UR.W>[U0K96.GZ;HVK7;)!?W=\-/BBT]=4[\LRS'
MYQC:.7Y;AIXO&5^;V5&#A%M0BYSE*=24*5.$81<I3J3C!):RU1G5JTZ%.56K
M-0A&UY.[M=I+1)MMMI))-GZ745_'_??\'"_[64FHI+IGPA_9VM-)$BE[*^T7
MXE:CJ+1"=V9$U2W^)>EVR2&V,<2RG2)%6=7N#"T;K:Q_KC_P3O\ ^"NO@K]M
M#Q<WP=\=>"H/A1\9I=/U#4_#5E8ZXVM>%/B!9Z1:/J.KPZ#->6ECJFD^(=,T
MZ*]U.;PY=+JZ3:)I>H:Q;ZW)]GN]/LOJLV\.>*\FP-7,<5@:<\+AX.IB)8;$
MT:\Z%./Q5*E.,E4=."UJ3IQJ*G%.<W&$7)<5'-,%7J*E"HU.3M!3A**DWLDW
MI=[).S;T5VTC]CZ***^&/1"BBB@ HK$\2>)?#G@[0=5\4^+_ !!HGA7PQH-E
M-J6N>(_$FJV&AZ#HVG6Z[KB_U75]3GM=/TZR@7YIKJ\N(8(EY>117"?#GX[_
M  /^,-SJEE\)/C+\*?BE>:)!;76M6GPY^(GA#QO<Z1;7DDL5I<:I!X9UC4Y;
M""ZEAFBMIKM(HYY(I4B9FC<#:.'KSI3KPH5IT*32J5HTYRI4V[)*=11<(-N4
M4E)IOF7=$N45)1<HJ3U46TI-=TKW?R/5J***Q*"BBB@ HHHH **_D?\ V3_^
M"I_[;_Q9_;H^%7PO\9_%G3KSX:>,/B])X6UCP39_#CX:Z?IYT*:;4+1+&UUJ
MV\)KXP@^S>7#<07)\2R7C3Q*+BXN(&E@D_K@KZ3B7A;,>%<3A<+F-7!U:F+P
ML<73>#J5JD(TW4G3Y*CK4*#512@[J,9PLTU-NZ7+A,92QD)SI1G%0FZ;]HHI
MMI)W7+*6EFMVGY!1117S9U!1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.C?V5?\ !+G_ )1__LO?]D\;_P!2+7*_CI^ /_*2;X*?]GP_#?\ ]7UHU=?
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M (H_MUI+!J6H;!\^J7EZ[?,S5Z77C'[/6DZ5H?P?\(:7HG@7Q'\--+M?[?\
MLO@GQ9<7-WX@T7S_ !1K=Q-_:%Q=N]Q)_:5Q-+JUKYC'997]LB815  /9Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^+/V^OV/M,_;<_9ZU7X.W'
MB/\ X1'Q!8Z_I?CCP+XCELUU#3]-\8Z%9ZKI]FNL6:[;J72-2TK7-8T>]FT^
M:*^L4U!=1@2^%H^EW_VG177@<;B<MQF&Q^#JNCBL)6A7H54HRY*E.2E%N,E*
M,XNUI0E%QG%N,DXMHBI3A5A.G47-"<7&47U3T>JU7DUJGJC^2?X5_L1_\%KO
MV,)/$OAG]F75+&;PGJFNZE<W%MX:\;_!;5O">LW4IM-/;Q;!X3^-4EM:Z9J>
MI:;X=T.-M172+3Q"FF_8M-N'6..^M8;NI_\ !+W_ (*G_ML^-M US]LOXGZ9
MX0TG1I]06*Z\8^+/#?C*;PQ8ZO=6K:U+X"^&OPFNI? EOJ&J?8]/ENK2/6?!
MEOJ-KI>G6]]JD?\ 9FFVL?\ 6717WDO$[.O:SQ=+*N&L/FE2+C+.*.3I9F[P
M]FY/$5*]2$FXZ-3I2@U[KCR^Z><LIP]E"5;%SHIZ4)5W['1WMRJ*:5U?25[Z
MWN>#_LS_ +//@3]E?X)^"/@;\.A>R^'/!EE=JVJ:H\4NL:_K.K:A=:QKVOZO
M-#''&][JNK7UU<+#$BVVG6AM=*L$ATZPM((O>***_/L1B*V+KUL5B:LZV(Q-
M6I7KUJCYIU:U6;G4J3?64YR<F^[/2C&,(QA!*,8148Q6RC%627DD@HHHK$H*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,O?N-]1_Z$:TZS+W[
MC?4?^A&@#^4O]IO2]<T7XW^-M,\2>$?!O@36K8^'?MOA7X?V\-KX1TKSO"FA
M7%O_ &1! !%']MM98-1O]@^;4[R]=OF8UX-7KOQWTK2]$^*OBG2]%\#^(?AO
MIEK_ &+]F\%^*[BXNM?T7SO#VDW$WV^>[9[B3^T;B675;7S&.VROK=$PBJ!Y
M%7]^<&_\DAPK_P!DWD?_ *J\*?A^;?\ (US/_L88W_U)JA1117TAYX4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_PLS[1<_P#")?V5_P )Q]L_X07[)O\ L?\ PD?VS_BH/M&S[3_9G[O?Y7%
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M7^F'_!=W_DPS4/\ LK?PY_\ 0M;K^>+_ ()P_P#!1[_AWW_PN7_BS7_"V_\
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MJ^]3A.-DL)B<7#&U,%BYPK-4_:0J1BHVT4K6C&-TU+JKIK1M,[;]M#_@LO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'J'PO\ ^0AJG_7G
M#_Z/KVBO%_A?_P A#5/^O.'_ -'U[10!POQ%_P"1;D_Z_+3_ -">O :]^^(O
M_(MR?]?EI_Z$]> T %%%% !1110 4444 %%%% !1110 4444 ?P>?\%?O"M[
MX4_X*'?M"177F20:]?\ @KQ5IET\ @6ZLM?^'?A.[D\E!-.6CL-1_M#2#.S(
M;B73I9_)@601)_<]X,\2V_C/P?X4\86D7D6GBOPUH7B6U@WO+Y-OKNEVNJ0Q
M>9+!:R2>7'=*F^2UMG?&YX(6)C7^6'_@X3^!!T'XJ?!W]HG2K0K8?$'PS>_#
MCQ9-'(IBC\3>"9VU3P_>7,;J)1=:WX<UNZL(F@DEM_LW@X"6&TG(EU']OO\
M@EG\6XOC'^PA^SYKC:C)J&K>%/"*_##7S/"L-U:ZC\-KF;PE:0W6R29)Y9]
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MFXT\13FHUHTW=\NZDE6.PF*J4<O5&DJD\-&+J1YZ<4I1C25KRG%--Q:]UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :_A__D.Z+_V%=/\
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M "BBB@ KQC^T?#__  T/_9/_  G'B[_A*O\ A2_]H_\ "MO/O?\ A _^$?\
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MBB@ HHHH **** "BBB@ KS3X/V&L:7\.O#MCK_@/PO\ #+5X/[7^U^!_!?\
M9_\ PC6B>;KNIS0?V;_92I8?\3*VDAU>\\A1_P 3"_NO-S-YA/I=>,?L]:3I
M6A_!_P (:7HG@7Q'\--+M?[?^R^"?%EQ<W?B#1?/\4:W<3?VA<7;O<2?VE<3
M2ZM:^8QV65_;(F$50 #V>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LR]^XWU'_H1K3K,O?N-]1_Z$: /Y2_VF[#6-,^-_C:QU[P+X8^&NK0'
MP[]K\%>#?[/_ .$;T7S/"FA30?V;_9:K8?\ $QMI(=6N_(4?Z??W7FYF\PGP
M:O7?COI6EZ)\5?%.EZ+X'\0_#?3+7^Q?LW@OQ7<7%UK^B^=X>TFXF^WSW;/<
M2?VC<2RZK:^8QVV5];HF$50/(J_OS@W_ ))#A7_LF\C_ /57A3\/S;_D:YG_
M -C#&_\ J35"BBBOI#SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH *\T^P:Q_PN+^U/^$#\+_\ "/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_CC4?\*RE_YX_P#CC4?\1XXO_P"A=PW_ .$>9_\ SW_J[\K'^I.5?]!&8?\
M@W#?_,A^<?\ P@7BS_H$M_X%V/\ \DT?\(%XL_Z!+?\ @78__)-?HY_PK*7_
M )X_^.-1_P *RE_YX_\ CC4?\1XXO_Z%W#?_ (1YG_\ /?\ J[\K'^I.5?\
M01F'_@W#?_,A^<?_  @7BS_H$M_X%V/_ ,DT?\(%XL_Z!+?^!=C_ /)-?HY_
MPK*7_GC_ ..-1_PK*7_GC_XXU'_$>.+_ /H7<-_^$>9__/?^KORL?ZDY5_T$
M9A_X-PW_ ,R'YQ_\(%XL_P"@2W_@78__ "31_P (%XL_Z!+?^!=C_P#)-?HY
M_P *RE_YX_\ CC4?\*RE_P">/_CC4?\ $>.+_P#H7<-_^$>9_P#SW_J[\K'^
MI.5?]!&8?^#<-_\ ,A^<?_"!>+/^@2W_ (%V/_R31_P@7BS_ *!+?^!=C_\
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M_P"@2W_@78__ "37Z.?\*RE_YX_^.-1_PK*7_GC_ ..-1_Q'CB__ *%W#?\
MX1YG_P#/?^KORL?ZDY5_T$9A_P"#<-_\R'YQ_P#"!>+/^@2W_@78_P#R31_P
M@7BS_H$M_P"!=C_\DU^CG_"LI?\ GC_XXU'_  K*7_GC_P".-1_Q'CB__H7<
M-_\ A'F?_P ]_P"KORL?ZDY5_P!!&8?^#<-_\R'YQ_\ "!>+/^@2W_@78_\
MR31_P@7BS_H$M_X%V/\ \DU^CG_"LI?^>/\ XXU'_"LI?^>/_CC4?\1XXO\
M^A=PW_X1YG_\]_ZN_*Q_J3E7_01F'_@W#?\ S(?G'_P@7BS_ *!+?^!=C_\
M)-'_  @7BS_H$M_X%V/_ ,DU^CG_  K*7_GC_P".-1_PK*7_ )X_^.-1_P 1
MXXO_ .A=PW_X1YG_ //?^KORL?ZDY5_T$9A_X-PW_P R'YQ_\(%XL_Z!+?\
M@78__)-'_"!>+/\ H$M_X%V/_P DU^CG_"LI?^>/_CC4?\*RE_YX_P#CC4?\
M1XXO_P"A=PW_ .$>9_\ SW_J[\K'^I.5?]!&8?\ @W#?_,A^<?\ P@7BS_H$
MM_X%V/\ \DT?\(%XL_Z!+?\ @78__)-?HY_PK*7_ )X_^.-1_P *RE_YX_\
MCC4?\1XXO_Z%W#?_ (1YG_\ /?\ J[\K'^I.5?\ 01F'_@W#?_,A^<?_  @7
MBS_H$M_X%V/_ ,DT?\(%XL_Z!+?^!=C_ /)-?HY_PK*7_GC_ ..-1_PK*7_G
MC_XXU'_$>.+_ /H7<-_^$>9__/?^KORL?ZDY5_T$9A_X-PW_ ,R'YQ_\(%XL
M_P"@2W_@78__ "31_P (%XL_Z!+?^!=C_P#)-?HY_P *RE_YX_\ CC4?\*RE
M_P">/_CC4?\ $>.+_P#H7<-_^$>9_P#SW_J[\K'^I.5?]!&8?^#<-_\ ,A^<
M?_"!>+/^@2W_ (%V/_R31_P@7BS_ *!+?^!=C_\ )-?HY_PK*7_GC_XXU'_"
MLI?^>/\ XXU'_$>.+_\ H7<-_P#A'F?_ ,]_ZN_*Q_J3E7_01F'_ (-PW_S(
M?F+XGTC4/!VAWWB3Q);MINBZ=]F^VWI9+L0_;+RWL+?_ $>Q:ZNI/,N[J"+]
MU ^SS-[[8U=UWO\ A O%G_0);_P+L?\ Y)K[D^)'@#5--\%ZS>Z9XGT#P+?0
M_P!G>1XJ\4"U70M+\S5;&*7[<VH,MF/MT,DFG6WG,,WEY;B/,NP'N/\ A64O
M_/'_ ,<:C_B/'%__ $+N&_\ PCS/_P">_P#5WY6/]2<J_P"@C,/_  ;AO_F0
M_./_ (0+Q9_T"6_\"['_ .2:/^$"\6?] EO_  +L?_DFOT<_X5E+_P \?_'&
MH_X5E+_SQ_\ '&H_XCQQ?_T+N&__  CS/_Y[_P!7?E8_U)RK_H(S#_P;AO\
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M['_Y)K]'/^%92_\ /'_QQJ/^%92_\\?_ !QJ/^(\<7_]"[AO_P (\S_^>_\
M5WY6/]2<J_Z",P_\&X;_ .9#\X_^$"\6?] EO_ NQ_\ DFC_ (0+Q9_T"6_\
M"['_ .2:_1S_ (5E+_SQ_P#'&H_X5E+_ ,\?_'&H_P"(\<7_ /0NX;_\(\S_
M /GO_5WY6/\ 4G*O^@C,/_!N&_\ F0_./_A O%G_ $"6_P# NQ_^2:/^$"\6
M?] EO_ NQ_\ DFOT<_X5E+_SQ_\ '&H_X5E+_P \?_'&H_XCQQ?_ -"[AO\
M\(\S_P#GO_5WY6/]2<J_Z",P_P#!N&_^9#\X_P#A O%G_0);_P "['_Y)H_X
M0+Q9_P! EO\ P+L?_DFOT<_X5E+_ ,\?_'&H_P"%92_\\?\ QQJ/^(\<7_\
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M_P! EO\ P+L?_DFC_A O%G_0);_P+L?_ ))K]'/^%92_\\?_ !QJ/^%92_\
M/'_QQJ/^(\<7_P#0NX;_ /"/,_\ Y[_U=^5C_4G*O^@C,/\ P;AO_F0_./\
MX0+Q9_T"6_\  NQ_^2:/^$"\6?\ 0);_ ,"['_Y)K]'/^%92_P#/'_QQJ/\
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M2:_1S_A64O\ SQ_\<:C_ (5E+_SQ_P#'&H_XCQQ?_P!"[AO_ ,(\S_\ GO\
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MO_5WY6/]2<J_Z",P_P#!N&_^9#\X_P#A O%G_0);_P "['_Y)H_X0+Q9_P!
MEO\ P+L?_DFOT<_X5E+_ ,\?_'&H_P"%92_\\?\ QQJ/^(\<7_\ 0NX;_P#"
M/,__ )[_ -7?E8_U)RK_ *",P_\ !N&_^9#\X_\ A O%G_0);_P+L?\ Y)H_
MX0+Q9_T"6_\  NQ_^2:_1S_A64O_ #Q_\<:C_A64O_/'_P <:C_B/'%__0NX
M;_\ "/,__GO_ %=^5C_4G*O^@C,/_!N&_P#F0_./_A O%G_0);_P+L?_ ))H
M_P"$"\6?] EO_ NQ_P#DFOT<_P"%92_\\?\ QQJ/^%92_P#/'_QQJ/\ B/'%
M_P#T+N&__"/,_P#Y[_U=^5C_ %)RK_H(S#_P;AO_ )D/SC_X0+Q9_P! EO\
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M_P#"/,__ )[_ -7?E8_U)RK_ *",P_\ !N&_^9#\X_\ A O%G_0);_P+L?\
MY)H_X0+Q9_T"6_\  NQ_^2:_1S_A64O_ #Q_\<:C_A64O_/'_P <:C_B/'%_
M_0NX;_\ "/,__GO_ %=^5C_4G*O^@C,/_!N&_P#F0_./_A O%G_0);_P+L?_
M ))H_P"$"\6?] EO_ NQ_P#DFOT<_P"%92_\\?\ QQJ/^%92_P#/'_QQJ/\
MB/'%_P#T+N&__"/,_P#Y[_U=^5C_ %)RK_H(S#_P;AO_ )D/SC_X0+Q9_P!
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M?:>* /2Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#U#X7_\A#5/^O.'
M_P!'U[17B_PO_P"0AJG_ %YP_P#H^O:* .%^(O\ R+<G_7Y:?^A/7@->_?$7
M_D6Y/^ORT_\ 0GKP&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O+_@QI.JZ'\-?#>EZWX%\.?#35+7^V/M7@GPG<
M6UWX?T7S]?U6XA_L^XM'>WD_M*WFBU:Z\MCMO;^Y1\.K >H5XQ^SUIWA_2?@
M_P"$-/\ "W@?Q=\.-!M_[?\ L/@SQW!>V_BO1O-\4:W-=?VK#J,UQ>)_:-Y)
M<:K8^=,^[3;ZS>/;$R*H![/1110 4444 %%%% !1110 4444 %%%% !1110
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M0!\G_P#"M8?^>(_[X'_Q-'_"M8?^>(_[X'_Q-?6']CQ?\\T_[Y/^%']CQ?\
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M'B_YYI_WR?\ "C^QXO\ GFG_ 'R?\* /D_\ X5K#_P \1_WP/_B:/^%:P_\
M/$?]\#_XFOK#^QXO^>:?]\G_  H_L>+_ )YI_P!\G_"@#Y/_ .%:P_\ /$?]
M\#_XFC_A6L/_ #Q'_? _^)KZP_L>+_GFG_?)_P */['B_P">:?\ ?)_PH ^3
M_P#A6L/_ #Q'_? _^)H_X5K#_P \1_WP/_B:^L/['B_YYI_WR?\ "C^QXO\
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M'B_YYI_WR?\ "C^QXO\ GFG_ 'R?\* /D_\ X5K#_P \1_WP/_B:/^%:P_\
M/$?]\#_XFOK#^QXO^>:?]\G_  H_L>+_ )YI_P!\G_"@#Y/_ .%:P_\ /$?]
M\#_XFC_A6L/_ #Q'_? _^)KZP_L>+_GFG_?)_P */['B_P">:?\ ?)_PH ^3
M_P#A6L/_ #Q'_? _^)H_X5K#_P \1_WP/_B:^L/['B_YYI_WR?\ "C^QXO\
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M^)H_X5K#_P \1_WP/_B:^L/['B_YYI_WR?\ "C^QXO\ GFG_ 'R?\* /D_\
MX5K#_P \1_WP/_B:/^%:P_\ /$?]\#_XFOK#^QXO^>:?]\G_  H_L>+_ )YI
M_P!\G_"@#Y/_ .%:P_\ /$?]\#_XFC_A6L/_ #Q'_? _^)KZP_L>+_GFG_?)
M_P */['B_P">:?\ ?)_PH ^3_P#A6L/_ #Q'_? _^)H_X5K#_P \1_WP/_B:
M^L/['B_YYI_WR?\ "C^QXO\ GFG_ 'R?\* /D_\ X5K#_P \1_WP/_B:/^%:
MP_\ /$?]\#_XFOK#^QXO^>:?]\G_  H_L>+_ )YI_P!\G_"@#Y/_ .%:P_\
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M^)H_X5K#_P \1_WP/_B:^L/['B_YYI_WR?\ "C^QXO\ GFG_ 'R?\* /D_\
MX5K#_P \1_WP/_B:/^%:P_\ /$?]\#_XFOK#^QXO^>:?]\G_  H_L>+_ )YI
M_P!\G_"@#Y/_ .%:P_\ /$?]\#_XFC_A6L/_ #Q'_? _^)KZP_L>+_GFG_?)
M_P */['B_P">:?\ ?)_PH ^3_P#A6L/_ #Q'_? _^)H_X5K#_P \1_WP/_B:
M^L/['B_YYI_WR?\ "C^QXO\ GFG_ 'R?\* /D_\ X5K#_P \1_WP/_B:/^%:
MP_\ /$?]\#_XFOK#^QXO^>:?]\G_  H_L>+_ )YI_P!\G_"@#Y/_ .%:P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7E_P8TG5=#^&OAO2];\"^'/AIJEK_ &Q]
MJ\$^$[BVN_#^B^?K^JW$/]GW%H[V\G]I6\T6K77EL=M[?W*/AU8#U"O&/V>M
M.\/Z3\'_  AI_A;P/XN^'&@V_P#;_P!A\&>.X+VW\5Z-YOBC6YKK^U8=1FN+
MQ/[1O)+C5;'SIGW:;?6;Q[8F15 /9Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O+_[)U7_A=/\ ;O\ P@OAS^P_^%7?V3_PLS[1;?\ "6_VK_PE
MGVS_ (07[)O^V?\ ".?8_P#BH/M&S[-_:?[K?YO%>H5XQ_9WA_\ X:'_ +6_
MX0?Q=_PE7_"E_P"SO^%D^1>_\('_ ,(__P )Q]I_X0?[3YW]G?\ "7?VC_Q/
MO(^S_;?[&_>>=Y'R4 >ST444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'J
M'PO_ .0AJG_7G#_Z/KVBO%_A?_R$-4_Z\X?_ $?7M% '"_$7_D6Y/^ORT_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ?\ &G44 -V+Z?J?\:-B^GZG_&G44 -V+Z?J?\:-B^GZG_&G44 -V+Z?J?\
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M !IU% !1110!XQX(U;2KSXP?''2[3QUXCU_5-'_X5I_:_@G4K>YC\/\ P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\8_M;2O^&A_["_X3KQ'_;G_  I?
M^UO^%9_9[G_A$O[*_P"$X^Q_\)U]KV?8_P#A(_MG_%/_ &??]I_LS]YL\KFO
M9Z\T_M77?^%Q?V'_ ,)AX+_X1G_A6G]J_P#" _:(?^%B?V[_ ,)3]C_X3#[)
MG[1_PA?]G_\ $E^T8\G^W/W>=] 'I=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEF_MI+LFX7[9</+J&G>8>=)NK I\A6@#V>BBB@ HHHH **** "BBB@ HHHH
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MDW5@4^0K7L] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y?\9])
MU77/AKXDTO1/ OASXEZI=?V/]E\$^++BVM/#^M>1K^E7$W]H7%VZ6\?]FV\,
MNK6OF,-U[86R)EV4'U"O&/VA;+2M1^#_ (OL];\+>.O&FES?V!]J\,_#6.YE
M\:ZEY?BC198?[%2T(N&^QW"1:AJ/EGC2;6_+_(&KV>@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110!ZA\+_\ D(:I_P!></\ Z/KVBO%_A?\ \A#5/^O.'_T?7M%
M'"_$7_D6Y/\ K\M/_0GKP&O?OB+_ ,BW)_U^6G_H3UX#0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7COP"U'1]6^
M$OA/4- ^(6N_%72+C^W?LGCWQ+:ZA9:WKWE>)M9@G^VVVJVUG?Q_V7<Q3:-;
M>?;1[[33H)(M\+QR-[%7E_P8O=5U'X:^&[S6_%/@7QIJDW]L?:O$WPUDMI?!
M6I>7K^JQ0_V*]H!;M]CMTBT_4?+'&K6M^'^<-0!ZA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!X[\ M1T?5OA+X3U#0/B%KOQ5TBX_MW
M[)X]\2VNH66MZ]Y7B;68)_MMMJMM9W\?]EW,4VC6WGVT>^TTZ"2+?"\<C>Q5
MY?\ !B]U74?AKX;O-;\4^!?&FJ3?VQ]J\3?#62VE\%:EY>OZK%#_ &*]H!;M
M]CMTBT_4?+'&K6M^'^<-7J% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X[\?=1T?2?A+XLU#7_ (A:[\*M(M_["^U^/?#5KJ%[K>@^;XFT:"#[
M%;:5;7E_)_:ES+#HUSY%M)LM-1GDEV0I)(OL5>7_ !GO=5T[X:^)+S1/%/@7
MP7JD/]C_ &7Q-\2I+:+P5IOF:_I44W]M/=@VZ_;+=Y=/T[S!SJUU8!/G*UZA
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ/<_%KXU:?9?$+7?$>KZ9_PKC^V_ 5_:ZA%HGPW^V^&KJ?3?[ N;FVBL+O\
MX3"V5]9U7^S;FZ\B[@2.\\B8K&?8J\O\*7NJS_$KXL6=WXI\"ZMI=A_P@O\
M9'AG0)+9O&OA/[5H%S+?_P#"?I$/M$?]O7 74/"OVHG?I,<QAPF:]0H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5?90-FK20B;+XKV>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\O\ @QI^HZ7\-?#=AJWPXTCX2:A!_;'VCX>Z#J.F:KI7A_S=?U6:+[+?Z,6T
MVX_M6"2/6Y_LQ/E7.I30S?Z1'**]0KQC]GJRTK3O@_X0L]$\+>.O!>EP_P!O
M_9?#/Q*CN8O&NF^9XHUN6;^VDNR;A?MEP\NH:=YAYTFZL"GR%: /9Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O+_[/U'_A=/\ :O\ PKC2/[)_
MX5=_9_\ PMW^T=,_M[^T?^$L^T_\*X_LG/\ ;/\ 9'V;_BIO[1V_V9]M_P!&
MS]KXKU"O&/L6E?\ #0_]H_\ "+>.O[<_X4O]B_X37R[G_A6G]E?\)QY__"+>
M;G['_P )U]L_XFWEX^T_V!\V?*H ]GHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#0*_\ )[3?_DROHJB@#YU_X03Q7_T"O_)[3?\ Y,H_X03Q7_T"O_)[3?\
MY,KZ*HH ^=?^$$\5_P#0*_\ )[3?_DRC_A!/%?\ T"O_ ">TW_Y,KZ*HH ^=
M?^$$\5_] K_R>TW_ .3*/^$$\5_] K_R>TW_ .3*^BJ* /G7_A!/%?\ T"O_
M ">TW_Y,H_X03Q7_ - K_P GM-_^3*^BJ* /G7_A!/%?_0*_\GM-_P#DRC_A
M!/%?_0*_\GM-_P#DROHJB@#X(_:,TG4O!_P:\8^(]?\ &VH_!_2-._X1[[7\
M1=)L1XDU#P[]K\5:'8P?9]%TI[N_O?[6N;J'0I?(MY/L\&IR7<NR&"1U]M_X
M03Q7_P! K_R>TW_Y,KK?CQ-XDM_A3XJF\(^*_A]X(\0I_8?]G^)_BF(&\!Z9
MN\2:.MW_ &Z+E)(#]ML6N=/TS>A_XG-WIY7#[2/7: /G7_A!/%?_ $"O_)[3
M?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03
MQ7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3
M?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ
M* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_
M] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3
M?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03
MQ7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3
M?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ
M* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_
M] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3
M?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03
MQ7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3
M?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ
M* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_
M] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3
M?_DRC_A!/%?_ $"O_)[3?_DROHJB@#X^^)GA?7M%^''Q UC4=1N?!>GZ3X(\
M5ZG?>,;/[+J=WX3L[#0;^ZNO$MKIMI/-=ZC<Z%!$^J06-K#+<7<MJMO#&\DB
MJ3X9^%]>UKX<?#_6-.U&Y\::?JW@CPIJ=CXQO/LNF7?BRSO]!L+JU\2W6FW<
M\-WIUSKL$J:I/8W4,5Q:2W36\T:21LH^DOB"^I1^ O&\FC:KX?T'6(_"'B5]
M*USQ:(SX5T;4DT:]:QU7Q,)5:(^'].NA%>:R)%:,Z=#<[U*Y%'P^?4I/ 7@B
M36=5\/Z]K$GA#PT^JZYX2$8\*ZSJ3Z-9-?:KX9$2K$/#^HW1EO-&$:K&-.FM
MMBA<"@#R3_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$
M$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O
M_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_
M (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O
M_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3
M*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$
M$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O
M_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_
M (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O
M_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3
M*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$
M$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O
M_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_
M (03Q7_T"O\ R>TW_P"3*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O
M_)[3?_DROHJB@#YU_P"$$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3
M*^BJ* /G7_A!/%?_ $"O_)[3?_DRC_A!/%?_ $"O_)[3?_DROHJB@#YU_P"$
M$\5_] K_ ,GM-_\ DRC_ (03Q7_T"O\ R>TW_P"3*^BJ* /@CP+I.I:I\9?C
MOX<LO&VH^*-7\+?\*P_MKX=7-B+#3_A=_;?A6\OM-_LS6KEXK#7O^$VMHWUV
M]_LVXNO[+GMUM+SR9G5#[;_P@GBO_H%?^3VF_P#R976^#9O$C_%;XS0ZGXK^
M'VK^'H/^%=_\(QX8\.B >//"/F^&[IM:_P"%C&-%G;^W[X1ZAX0^T.^-&BG$
M6U,BO7: /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH
M ^=?^$$\5_\ 0*_\GM-_^3*/^$$\5_\ 0*_\GM-_^3*^BJ* /G7_ (03Q7_T
M"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH ^=?^$$\5_\ 0*_\GM-_
M^3*/^$$\5_\ 0*_\GM-_^3*^BJ* /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%
M?_0*_P#)[3?_ ),KZ*HH ^=?^$$\5_\ 0*_\GM-_^3*/^$$\5_\ 0*_\GM-_
M^3*^BJ* /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH
M ^=?^$$\5_\ 0*_\GM-_^3*/^$$\5_\ 0*_\GM-_^3*^BJ* /G7_ (03Q7_T
M"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH ^=?^$$\5_\ 0*_\GM-_
M^3*/^$$\5_\ 0*_\GM-_^3*^BJ* /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%
M?_0*_P#)[3?_ ),KZ*HH ^=?^$$\5_\ 0*_\GM-_^3*/^$$\5_\ 0*_\GM-_
M^3*^BJ* /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH
M ^=?^$$\5_\ 0*_\GM-_^3*/^$$\5_\ 0*_\GM-_^3*^BJ* /G7_ (03Q7_T
M"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH ^=?^$$\5_\ 0*_\GM-_
M^3*/^$$\5_\ 0*_\GM-_^3*^BJ* /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%
M?_0*_P#)[3?_ ),KZ*HH ^=?^$$\5_\ 0*_\GM-_^3*/^$$\5_\ 0*_\GM-_
M^3*^BJ* /G7_ (03Q7_T"O\ R>TW_P"3*/\ A!/%?_0*_P#)[3?_ ),KZ*HH
M ^=?^$$\5_\ 0*_\GM-_^3*\2_9STG4O&'P:\'>(] \;:C\8-(U'_A(?LGQ%
MU:Q'AO4/$7V3Q5KEC/\ :-%U5[2_LO[)N;6;0HO/MX_M$&F1W<6^&>-V^]Z\
MB^ \WB2X^%/A6;Q=XK^'WC?Q"_\ ;G]H>)_A8(%\!ZGM\2:PMI_80MDC@'V*
MQ6VT_5-B#_B<VFH%LON) .2_X03Q7_T"O_)[3?\ Y,H_X03Q7_T"O_)[3?\
MY,KZ*HH ^=?^$$\5_P#0*_\ )[3?_DRC_A!/%?\ T"O_ ">TW_Y,KZ*HH ^=
M?^$$\5_] K_R>TW_ .3*/^$$\5_] K_R>TW_ .3*^BJ* /G7_A!/%?\ T"O_
M ">TW_Y,H_X03Q7_ - K_P GM-_^3*^BJ* /G7_A!/%?_0*_\GM-_P#DRC_A
M!/%?_0*_\GM-_P#DROHJB@#YU_X03Q7_ - K_P GM-_^3*/^$$\5_P#0*_\
M)[3?_DROHJB@#YU_X03Q7_T"O_)[3?\ Y,H_X03Q7_T"O_)[3?\ Y,KZ*HH
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MX03Q7_T"O_)[3?\ Y,H_X03Q7_T"O_)[3?\ Y,KZ*HH ^=?^$$\5_P#0*_\
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MA_X59)_T&T_\%[?_ "91_P *LD_Z#:?^"]O_ ),KU[ ]!^0HP/0?D* /(?\
MA5DG_0;3_P %[?\ R91_PJR3_H-I_P""]O\ Y,KU[ ]!^0HP/0?D* /(?^%6
M2?\ 0;3_ ,%[?_)E'_"K)/\ H-I_X+V_^3*]>P/0?D*,#T'Y"@#R'_A5DG_0
M;3_P7M_\F4?\*LD_Z#:?^"]O_DRO7L#T'Y"C ]!^0H \A_X59)_T&T_\%[?_
M "91_P *LD_Z#:?^"]O_ ),KU[ ]!^0HP/0?D* /(?\ A5DG_0;3_P %[?\
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M_0;3_P %[?\ R91_PJR3_H-I_P""]O\ Y,KU[ ]!^0HP/0?D* /(?^%62?\
M0;3_ ,%[?_)E'_"K)/\ H-I_X+V_^3*]>P/0?D*,#T'Y"@#R'_A5DG_0;3_P
M7M_\F4?\*LD_Z#:?^"]O_DRO7L#T'Y"C ]!^0H \A_X59)_T&T_\%[?_ "91
M_P *LD_Z#:?^"]O_ ),KU[ ]!^0HP/0?D* /(?\ A5DG_0;3_P %[?\ R91_
MPJR3_H-I_P""]O\ Y,KU[ ]!^0HP/0?D* /(?^%62?\ 0;3_ ,%[?_)E'_"K
M)/\ H-I_X+V_^3*]>P/0?D*,#T'Y"@#R'_A5DG_0;3_P7M_\F4?\*LD_Z#:?
M^"]O_DRO7L#T'Y"C ]!^0H \A_X59)_T&T_\%[?_ "91_P *LD_Z#:?^"]O_
M ),KU[ ]!^0HP/0?D* /(?\ A5DG_0;3_P %[?\ R91_PJR3_H-I_P""]O\
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M_H-I_P""]O\ Y,KU[ ]!^0HP/0?D* /(?^%62?\ 0;3_ ,%[?_)E'_"K)/\
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MA_X59)_T&T_\%[?_ "91_P *LD_Z#:?^"]O_ ),KU[ ]!^0HP/0?D* /(?\
MA5DG_0;3_P %[?\ R91_PJR3_H-I_P""]O\ Y,KU[ ]!^0HP/0?D* /(?^%6
M2?\ 0;3_ ,%[?_)E'_"K)/\ H-I_X+V_^3*]>P/0?D*,#T'Y"@#R'_A5DG_0
M;3_P7M_\F4?\*LD_Z#:?^"]O_DRO7L#T'Y"C ]!^0H \A_X59)_T&T_\%[?_
M "91_P *LD_Z#:?^"]O_ ),KU[ ]!^0HP/0?D* /(?\ A5DG_0;3_P %[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O!?V8M<T[Q)\#O!&M:3\5]6^-^GWO_  DOV?XH:YH-
M_P"&-4\3_9O%^OVDOVK0]3@MKZQ_L6>"3P]!Y\"?:;?28;R+=#<1NWO5>1?
M>^\5:E\*?"M[XUUOX8>(O$TW]N?VGK/P:N9KSX;7GE^)-8BLO^$;N;B*&:3[
M/I\=I:ZQOC79KT&J1KE55B >NT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >"_LQ:YIWB3X'>"-:TGXKZM\;]/O?^$E^S_%#7-!O_  QJ
MGB?[-XOU^TE^U:'J<%M?6/\ 8L\$GAZ#SX$^TV^DPWD6Z&XC=O>J\A^!%_XI
MU'X4^%;WQMKGPO\ $7B>;^W/[3UGX-74UY\-KSR_$FL167_"-W%Q%#-)]GT^
M.UM=8WQKLUZ#5(UW*JL?6C(H_P#KG'Y=Z )**KFX7L1_G\J3[0/;]/\ XJ@"
MS15;[0/;]/\ XJC[0/;]/_BJ +-%5OM ]OT_^*H^T#V_3_XJ@"S15;[0/;]/
M_BJ/M ]OT_\ BJ +-%5OM ]OT_\ BJ/M ]OT_P#BJ +-%5OM ]OT_P#BJ/M
M]OT_^*H LT56^T#V_3_XJC[0/;]/_BJ +-%5OM ]OT_^*H^T#V_3_P"*H LT
M56^T#V_3_P"*H^T#V_3_ .*H LT56^T#V_3_ .*H^T#V_3_XJ@"S15;[0/;]
M/_BJ/M ]OT_^*H LT56^T#V_3_XJC[0/;]/_ (J@"S15;[0/;]/_ (JC[0/;
M]/\ XJ@"S15;[0/;]/\ XJC[0/;]/_BJ +-%5OM ]OT_^*H^T#V_3_XJ@"S1
M5;[0/;]/_BJ/M ]OT_\ BJ +-%5OM ]OT_\ BJ/M ]OT_P#BJ +-%5OM ]OT
M_P#BJ/M ]OT_^*H LT56^T#V_3_XJC[0/;]/_BJ /#OVG=<T[PW\#O&^M:M\
M5]6^"&GV7_"-?:/BAH>@W_B?5/#'VGQ?H%I%]ET/3(+F^OO[:GGC\/3^1 _V
M:WU::\EVPV\CK[U7C/QXU;Q3IOPI\57O@G6_A?X=\3P_V'_9FL_&6YFL_AM9
M^9XDT>*]_P"$DN+=)IH_M&GR7=KH^R-M^O3Z6C85F8>N_:![?I_\50!9HJM]
MH'M^G_Q5'V@>WZ?_ !5 %FBJWV@>WZ?_ !5'V@>WZ?\ Q5 %FBJWV@>WZ?\
MQ5'V@>WZ?_%4 6:*K?:![?I_\51]H'M^G_Q5 %FBJWV@>WZ?_%4?:![?I_\
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MBBB@ HHHH **** "BBB@ HHHH **** /!?A]KFG7_P <?VA=%MOBOJWB[4-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/M;C_HVP?^'C_P#Q5U^$%%'_ !"/P\_Z)_\ \RV>?_/(/]:<^_Z#O_+7!_\
MS.?N_P#\/M;C_HVP?^'C_P#Q5T?\/M;C_HVP?^'C_P#Q5U^$%%'_ !"/P\_Z
M)_\ \RV>?_/(/]:<^_Z#O_+7!_\ S.?N_P#\/M;C_HVP?^'C_P#Q5T?\/M;C
M_HVP?^'C_P#Q5U^$%%'_ !"/P\_Z)_\ \RV>?_/(/]:<^_Z#O_+7!_\ S.?N
M_P#\/M;C_HVP?^'C_P#Q5T?\/M;C_HVP?^'C_P#Q5U^$%%'_ !"/P\_Z)_\
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MK3GW_0=_Y:X/_P"9S]W_ /A]K<?]&V#_ ,/'_P#BKH_X?:W'_1M@_P##Q_\
MXJZ_""BC_B$?AY_T3_\ YEL\_P#GD'^M.??]!W_EK@__ )G/W?\ ^'VMQ_T;
M8/\ P\?_ .*NC_A]K<?]&V#_ ,/'_P#BKK\(**/^(1^'G_1/_P#F6SS_ .>0
M?ZTY]_T'?^6N#_\ F<_=_P#X?:W'_1M@_P##Q_\ XJZ/^'VMQ_T;8/\ P\?_
M .*NOP@HH_XA'X>?]$__ .9;//\ YY!_K3GW_0=_Y:X/_P"9S]W_ /A]K<?]
M&V#_ ,/'_P#BKH_X?:W'_1M@_P##Q_\ XJZ_""BC_B$?AY_T3_\ YEL\_P#G
MD'^M.??]!W_EK@__ )G/W?\ ^'VMQ_T;8/\ P\?_ .*NC_A]K<?]&V#_ ,/'
M_P#BKK\(**/^(1^'G_1/_P#F6SS_ .>0?ZTY]_T'?^6N#_\ F<_=_P#X?:W'
M_1M@_P##Q_\ XJZ/^'VMQ_T;8/\ P\?_ .*NOP@HH_XA'X>?]$__ .9;//\
MYY!_K3GW_0=_Y:X/_P"9S]W_ /A]K<?]&V#_ ,/'_P#BKH_X?:W'_1M@_P##
MQ_\ XJZ_""BC_B$?AY_T3_\ YEL\_P#GD'^M.??]!W_EK@__ )G/W?\ ^'VM
MQ_T;8/\ P\?_ .*NC_A]K<?]&V#_ ,/'_P#BKK\(**/^(1^'G_1/_P#F6SS_
M .>0?ZTY]_T'?^6N#_\ F<_=_P#X?:W'_1M@_P##Q_\ XJZ/^'VMQ_T;8/\
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M9/CKK5S\*-)\(Z?K_P#PK'^S/BA::_8:AJGQ>_LKPM=VE[_:^AV]Q)?>'O\
MA )W7P]I_P#:$%O_ &M;W+7EIYL*,X]LKY^^'4?A]?CQ^T;)IVF?%:UUZ7_A
M4/\ PD>H^+HU7X7ZIL\&WRZ/_P *B<3R-)]ALR\'C_?#!L\0M;!?-'SCZ!H
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MVROG[R_#_P#PU3YW]F?%;_A*O^&??+_MCRU_X4?_ ,(__P +&W?V9YOG[_\
MA:W]I?Z5Y?V;;_PB'S>?G]W0!] T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5X9^S9JEEK/P5\%ZEIWQ9O_CE9W/_  D?D_%+4]+F
MT6]\4>3XLUVWD\_3)U66V_L26)_#L>\#SH=(CN%RLH->YUXU^S])X@E^$7A*
M3Q3J7PIU?7F_M[[=J/P0D:7X7W&/$^M+:_\ ",.\%LS>39BW@UK,*8\0Q:L!
MN #L >RT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#",.\%LS>39BW@UK,*8\0Q:L!N #L >RT444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !67?\ ^K?_ #_$:U*R[_\ U;_Y_B-
M'\3_ .U5ITFD_'OQ[I\OPD@^!;V[>&=WPKMM<MO$D/A;S?!WAZ<!-:M+>UM[
MW^VQ*/$3>7!']F?5VM'W/ SM\]U[?^T?%H$/QH\9Q^%]-^*>D:$K>'_L.G?&
MJ-(OB;;[O"VAM<_\)*B37"KYMX;B?1L3/GP_)I3'!)4>(5_?G!O_ "2'"O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\3_ &==-DTCX-^#M.E^$,'P&DM_
M^$AW?"BVUVV\30>%?-\4ZY.-FMV=O:6U[_;@E'B1O+MX_LSZPUH^^2!G;VRO
MG[]EF/P_#\!_ L?A73/BMH^@K_PD_P!@T[XW1K%\4+?/C+Q"UU_PDZ)/<*OG
M7AN)]%Q,^?#TNDD[22B@'T#1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5XG_ &;)_P -&_VO_P *A@\K_A2?]F_\+[_MVV^T^9_PG?VK_A4/_",_
M9_MGD;?^*S_MW[7]F\S_ (E_V?S?WM>V5\_>7X?_ .&J?._LSXK?\)5_PS[Y
M?]L>6O\ PH__ (1__A8V[^S/-\_?_P +6_M+_2O+^S;?^$0^;S\_NZ /H&BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2:PUE_PC:W%M:3#9I[6D>L;[>/.O)JA7>I5V /7J*** "BBB@ HHHH ****
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MPAXE31Y_&X<^"X=5;1KU=/E\7B..:0^%X[LPOKXCAE<Z2+L+&[84GP^358_
M7@B/79?"\^MIX0\-)K$_@@./!<VJKHUDNH2^$!)'#(/"\EV)GT 20Q.-)-H&
MC1LJ #KZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PSP%K7
MV[XU?'W1_P#A;G_"8_V'_P *K_XM5_PC']E?\*;_ +3\)WEU_P C)O;_ (2K
M_A8>S_A(_N)_8?V7[!\WF9KW.O(?!L/BE/BO\9I=6NOAA+X9F_X5W_PB5MX5
M68?$FT\OPW=+KW_"UF>VBA;S]0,<G@7R+BYVZ"+@2>2V$/KU !1110 4444
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M_9OL_P#PK#^R?W.W[7YW_"5\_9MG[V@#UZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*'2[K1FU7X@W7PU\[4/&EKX5URUCTV+Q'#;)%?R>'83<PZA9Q_9H;^6.R?\
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M"^ KC1+C0M1UOPDMLD5KK<.J1ZU=M/<:0^FVT>K?L_7^<)_P3#^-.L_L<_\
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M%FI:[+"\D5Q>VO@^V^&_Q#ELM'G9%GTF?4]<M-8NK*6-]5T#0KT2Z?%_2_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9=_\
MZM_\_P 1K4K+O_\ 5O\ Y_B- '\3'[4.B_\ "/?'7QUI'_"IO^%&_9&\-_\
M%K?^$F_X3'_A%_M'A#0+K'_"1[$_M'^VO/\ ^$B^Z/L?]K?8.?LN3X%7M_[1
M_P#PB?\ PN?QI_P@_P#PL7_A%MV@?V7_ ,+9W_\ "P/^16T3[;_;^_Y_^0C]
MK_LK=S_8O]FUXA7]^<&_\DAPK_V3>1_^JO"GX?FW_(US/_L88W_U)JA1117T
MAYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_"(_P!LX;^R/^$D\S^QO[4VM]@^V_:\'RL4?"^R_LWX:?#O3O\ A$?^%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDN9V2Z<,L=%S>,J8>4>5<KI<R::^)RYH05K>NO9'X3_\'+W_ "8E\)_^SM?
MG_JG?CS7B_\ P;"?\D:_:J_[*;\/_P#U%=8JM_P<)?M._LU_&G]C#X9>%O@Y
M^T+\#OBSXGL/VGO!FOWWASX9_%GP%X\UZRT&U^%/QJTZZUN[TCPMK^JZA;:1
M;:AJNEV,^I36Z6<-YJ5A:R3+/>6Z2>2?\&ZG[1?[/GP1^$_[2NG?&CX[?!OX
M1:AKOQ#\#WNAV'Q/^)_@GP#>ZS96GAK58+J[TJU\5ZYI,^HVMM/)'#<7%G'-
M%#+(D<CJ[*I_0Z&"QB\'\;AGA,2L0\UA)8=T*OMW'^TL)+F5+D]HURINZC:R
M;V1Y;J0_MR$^>')[&W-S+EO[&2MS7MOIN?U.?&WP)=_%+X,?%WX96%S;V=]\
M1?AAX^\"65W>32V]I:W?B[PIJWA^VN;JXAL]0F@MX)M026>:*POI8HE9X[.Y
M=1"_\4NG_P#!MU^W]>:5>ZA<^+/V:M)N[3[3Y&A:A\1/'$FJZGY%LD\7V*;2
MOA9J>B1_;)7:SMO[1UG3]ES&[7GV6T,=U)_9_P".?VC/@?\ #KX*WO[1GB?X
ME>&Q\#K#2]'UN7XF^'9[CQMX7N-%U_5].T/2-7TR\\%6_B!]8TN]U/5;"!+_
M $F&]M(XIFO)Y8K*"XN(N@^%OQE^$GQO\.0^+O@[\3/ OQ0\-3)"_P#;7@3Q
M3HWBBQ@:?S0EO>RZ/>79T^]62WN()["^6VO;:YMKJUN;>*XMIXH_@^'>*.).
M%,'C)990C#"8G%0AB*^)P52K2ABL/"SH*JW&G"JH5HNK2;=1*5-VC=-^EBL'
MA<;.FJTFYP@W&,*BBW";7O<NK:O'1K3??I_G6^/O"/[>G_!)GXZ:)H=YXE\6
M_!3QW8>9XQ\(ZIX3\16OB#X?>,M.NB^C7&MVEC(-1\(>+-/O%L!I^KZ)XJT*
M6ZCC@M+7Q!H=N/LD9_NP_P"";O[7C?MN_LC_  V^.&HZ4^C^,)8;CP;\1[-(
M([?39?B%X2CM;'Q/JN@11S3^3X?UZY>/7=(LY))+C2[745TBYFN9]/DNY_Y?
M/^#C/]I_X+?''XT_ CX9_";Q%X8\<:I\$_#'CN;Q[XR\)ZE;:SIAU/XC7/@R
M[TCP8-8LK5M/U&;PQI_A5]6N7TW6M6M+*[\77.E3Q:9K&GZM;R?MG_P;Z?#K
MQ/X!_P""=OA[4?$NGRZ?%\2_BEX^^(OAE9GM&>[\,7L'A[PO8:@%MKNYEBBO
M+OPGJ$L*7T5C=M"8YA:&TEM+N[_0^.^7-^ \CXCS; 4,!G]?$TJ;<*3H5:M&
MH\6N7EFW5E2K4:5/'4X5)3]DIOD<5.?-YF77H9EB,+1JRJ8:,'))RYDI+V>N
MB24HN3IMI+FLKWLC]O*_S6?V;_\ E*C\!?\ M(%\+?\ UHS0J_T'O'7[7G[)
MWPN\5:IX%^)G[4'[._P[\;Z']A_MOP=XZ^-?PU\(^*M'_M/3K/6--_M3P]K_
M (FT_5]/_M#2-0L-4L?M=G#]KTZ^L[Z#S+:YAE?_ #P?@#XM\*Z-_P %)_@I
MXZUCQ-X?TKP1I7[<7PW\6ZIXRU+6=-L?"NF^%;'X]:-K%[XFO_$-U<Q:19^'
M[/2(I=5NM9N+R/3;?3HY+Z:Y2V1I1S>%&%Q5/!<73J8:O3A7RB@Z$IT:D8UE
M*ECY1=*4HI5$U*+7(Y74HM:-7O.9P=3 I3BW&O+F2DGRVE2OS:Z?.Q_IC45X
MG\,OVEOV<OC7J]_X?^#7Q_\ @G\6]>TK36UG5-$^&7Q5\">/=7TW2%NK>R;5
M;_3?"NO:K>V>FK>W=I:-?7$,=J+JZM[<R^;-&C2_$[]I#]GCX):CIFC_ !G^
M/7P7^$>K:U92:EH^E_$[XH^!_ .HZMIT,[6LM_IEEXJUW2;F_LHKE6MY+JUB
ME@2=6A:02 J/QOZEC/;?5OJF)^L-<RP_L*OMN6W-S>RY/:6Y=;\MK:['N>TA
MR\_/#DVYN9<M]K<U[;Z;G\%'_!=#_E*?^U'_ -T2_P#6=/A'7]ZW[-__ ";O
M\!?^R+_"W_U!]"K_ #_/^"RWC_P)\4?^"DO[1_CKX9^-?"7Q$\$:Y_PJ#^Q/
M&/@7Q)HWB[PKK']F? ;X7:/J7]E^(= O=0TC4/[/U?3[_2[[[)>3?9-1L;RQ
MG\NYMIHD_N _90_:U_94\5?"W]GWX9^%_P!IK]GSQ)\1[KX6?#K0K7X?Z!\9
M_AQK'C>YUO3? ^E_VCHT'A33O$EQKTVJV'V.\^VZ='8-=VOV6Y\^&/R)=G[+
MX@X7%3X,X C##8B;PV4T/K"C1J2=#ERK+E+VR46Z7*XR4N?ELXR3M9GA99."
MQ^9-SBE*M+E;DK2O7J6Y7?6]U:U[W7<^ZZ***_$3Z **** "BBB@ HHHH **
M** "O#/V;-:_X2+X*^"]8_X6Y_PO;[9_PD?_ !=7_A&/^$-_X2K[/XLUVU_Y
M%O?)_9O]A^1_PCGWS]L_L?[?Q]JP/<Z\A^ \WBF?X4>%9?&MK\,++Q,_]N?V
MG;?!EIG^&T6WQ)K"V7_"-M<7-W,=^GK:2:QON),:\^J!=BA44 ]>HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ KPS^VO^,EO^$=_X6Y_S0S^VO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP5;6,-DMG9($OIYWN7:*.(Z?_!3;_@CQ#_P48^*W@#XI+^T-+\'+CP1\/?\
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M&G9I:--=T%%%%?#GH!1110 4444 %%%% !1110 5X9^S9HO_  COP5\%Z/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^S/[0^S_ &_^S-0^R^;]BN?*_H1_X.(O^4=.I_\ 9:/A?_Z'KU?G[_P:W_\
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M^"@OP_\ ^">GP4@^(7B/2)?&/CWQC?WGAWX4_#VWN_[/_P"$FU^TM4NM0O\
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M^+?!UK:Z=H"R:C%XW.N1W>FZ%X;:U>'R1I]S:7EN;'ZX_P""J_\ P57\/?\
M!.SP]X/\,^&?!]E\2?CK\2;+4-6\->&M6U";3O"WA;PMITQL9/%_B^2Q(U>^
M@OM7#Z9H&@:8^GOK+Z?K\\^OZ.NCQ1:GEB.#L\H9_3X;A1HXK,JL85:7U6O&
M>'J4)TW56(5>HJ2A15.,IRE5C3:2^&[BFX8[#SPSQ3E*%*+<9<\6I*2:CR\J
MYKN[27+???<_7VBOX.]-_P""KO\ P7 \>>%+WXR^";_XDZE\(]&N+L:OXO\
M!G[)O@GQ!\+K!M,N5EU*UU/QL_PEUVVL19I=6UG?B7Q1;W%I UN9)8;N4W,O
M[6_\$AO^"SMY^V1XG3]F_P#:,T[1]"_: GL=8UCP%XM\-6?]G>&?BEIVBV=Y
MK6MZ)/H:O,/#OC+0-"M+O64%G)+HGB#0]-U:Y6/0[_2H[77/8S?PUXARC 8G
M,95<LS"C@;O'4\LQ57$8C!QBKU)UZ57#4+1I+WJJA*<Z<+U)15*,YQPH9KA:
M]2%)*K2E4_ANK!1C-NUE%J<M7>RO9-Z)W:3_ *%Z**KW=W:6%K<W]_<V]E8V
M5O-=WEY=S1VUK:6EM&TUQ<W-Q,R0P6\$*/+--*Z1Q1HSNRJI(_/DFW9*[>B2
MW;['IEBBOXT_VP?^#@W]HSXC_%"Y^&?[!OAN+P7X9L]8U/PUH'C&Y\+:5\3O
MB1\4+X72VUAK?A_PIJ>BZOH/AZPN?*E;1M".E^*]5OX)8=0O[VTEN#H6G>'V
M7_!9W_@KO^ROX^\+']JSP[X@U/3-02ZU7_A7/QV_9^TCX(7_ (LT%E;3I9]$
MU/0OA]X UR&/3[U6EL]6M(-3LX=34P:G;:E:@Z?7Z70\*>**V&I5ISRK"XFO
M1E6HY9BL=*GF-2,8\UE2C0J4%)JUU/$1]FVE6=)J2CY,LYP<9N*5:<(R495H
M4[TDVTKW<E)I>47>WN\UU?\ N<HKY<_9J_:\^$'[4'[-?A_]J/P3JDNF?#_4
M= UO5_$MMK?E#6/ =]X3^UIXQT+Q/:V3W36]_P"'I;"ZF+0B2/5=);3]=TO[
M3I6K:=<7'\H_[0?_  7E_;C_ &A?C3?^!_V"?#>K^"O",UZVF^ M"T'X5:)\
M7?C-XT@LKF7.O:GHVJ^'O&NGV5SK,)AE_P"$:T+0KT:';LMHVMZM=*^I2^!D
MG!>>Y[C,?@Z%&C@Y95)PS&OF-26&P^#J*4X>RK2C3JU/:7IU'RPIS48TY2DX
MQLWTXC'X?#4Z524I3]LDZ4:2YI5$TG>*;BK>\MVKW25V?VMT5_(]^P5_P5J_
MX*.:?^U_\*OV5?VUO!%UJ_\ PMSQ5IOA>8_$WX2M\#?BEX/DU6SGN].U?3;'
M1/#/A#1[[3#'>6-U>Z;K'@NYN=3L5T\Z=KVC>?<75[^^'_!0_P#;P\ ?\$_?
M@'=_%CQ58-XH\7:_J3>$_A9\/[:[CM;KQ?XRGTZ\U",WT_SSZ9X3T2VM'OO%
M&NI;SK8PO8Z;;QS:UK>C65Y.:<'9UE>;8')W'#8[%9G"G4R^>75UB,/BH5)S
M@IPJ3C2E&,90FYSJPIQC"+J.7LTY#HXZA6HU*]YTX4FU456/+*#23LTG)-M2
M5DF[MVW/O&BOX4;'_@L#_P %GOVG/$FO:C^SAI_BF?3M+EFN+[PE^S]^S%HO
MQ6L/#MG=S@V,6IWFN^ ?BAX@A$"-';PW-]JD'VDL7D5W= G[0_\ !&/_ (*>
M?M)_ME>._BK\!_VF/"&@+XM^%W@>Q\86OCW1_#-]X*UNZ9_$L.CZAHGCOPVT
MSZ&FL7"ZWIT^ASZ!I7A2&'3M%U!+W2M2N[@ZC%ZN<>&^?9+EV)S'$8C*:\<%
M"G4QF%PN-G4QF%IU91A&=6E4P]*%KSC_  ZLW):P4D8T,UPU>K"E&%>+J-JG
M.=-*G-Q5VHM2;V[Q275H_H-HK^5__@I9_P %N/VF?A%^TM\2_P!DG]E/X9^&
M['6/ LVEZ!=^/M:\/ZC\0/'FJ:]_8EEXKUF]\&^$[6Z_X1NQT^UL;M=.5=?T
M7Q?+-8V>IZO)!IDUU;0Z/^<_C7_@JK_P7(_9_O-%\9_',?$SP+X5U'6;BSTW
M2_C/^R1X3^'?@WQ!?-:W-S_8%MK%U\*/!FO7<MI;*]Y';:5XJBU7R;,37-Q-
M MSYN^7>&'$6887"8KZSDV#>/H0Q."PV-Q\H8O$T:E.-6G.G2H8?$1]^$XOE
ME.,H-VJ*%B:N;X6E.<.6O4]G)QJ3ITTX0DGRM2E*47H]+I-/I?0_NXK^!C_@
MX*OKV/\ X*4^*Y8[RZCETWX9?"7^SI4N)5DL/+T)[U/L3JX:UV7DTUVGD&/;
M<RRSC$LC.?ZCO^"3W_!2<?\ !1;X1^,]6\3^#](\"_%WX2:OX>T7XB:)X;N[
MZ[\+:G;>*--O;OP[XO\ #L.J-<:GHNG:Y>Z'XIL%\.:CJFOW>E/H3._B#4TO
M(VB_EG_X.#?^4DOCC_LF7PG_ /496OH/##+,9D_'>899F-'V&,PF4XN%:FY1
MFDY5L!4A*,X.490J4JD*D)1=I0FGUL<V;UH5\NIUJ4N:$ZT'%V:V51--.S33
M337=']MW[)-[>ZG^RG^S+J6HW=UJ&HZA^SY\&+V_O[VXEN[V]O;OX<>&Y[J[
MN[J=Y)[FZN9Y))KBXFD>6:5WDD=G8D_0=? O@[XUZ=^SA_P3*^&_QXU70KWQ
M/8_"?]C3X9>-I?#FGW<&GW>N2:+\)/#MS;:5'J%S'/#IZ7UT(;>?4&MKUK&W
MDENX["_DA2SG_EXU'_@M!_P5^_:HUR]D_9;^&]]H>FZ99RQS:'^S[^SO?_&:
M\M4LKNQFN]2UW4?%GAWXH2&^B75]+T^[EM;+1=*AM;_3,:5!J%W'?7/R&6\&
MYMQ+BLVQ."G@,+@L)F%>C6QF88I8;#PJ2J3FJ:Y*=:JVHN+;5+D7-%<U[I=M
M7'T<)3H0J*I.I.E"484H<\FK)7U<5O\ WK^1_<#17\-OPK_X+W?\%%OV<_B?
M<^$OVLO#ME\4X-'U=+;QW\/OB-\--*^"7Q4\.P36=K,MCI4WA+PQX1A\/:G&
MCV^HQ+XO\#^(Q=6MY/"8H$NM/OM._I1_X*"?M]:_^S=^P1I?[8?[/WAWPUX]
MF\<#X1:EX$F\=6>N3^%K;PM\4!I^M6GB'7](\/:KH>K7:W'AZX6PLK.#Q)HJ
MVNM:QIU[/>WT-D^C:K.:\ Y_E..RK UHX/$?VU7AA\OQ>$Q7M,'6JS=.T74J
MPHU*=HU(34ITHQJ0;=%U'&23HYEAJU.M4BZD/81<JL)PM4C%7UY8N2>S6C=G
M\5CR/5O^"Z?['.A_M1:G^RAJOA+X_6OC?1_C=>_ 34?%W_"%^"9_A];>,M/\
M:2^ KR_^V6WQ+F\7S>'(=?AD7[;!X,EU*2T7[3%I#@JA_9VO\L?Q#\??&/B7
M]I+7/VH[_3?#47Q \0?'#4_C[>:/:6>J1^#HO&.J^/9_B)<:;;:?-K,^M)X:
M36IWM8;.7Q!-JBZ6%@?69+L&];^Q'_@D!_P5W_:._;__ &@?B'\(OC+\.O@Y
MX>T#PO\ !S5/B1IGB#X7Z%X[T2[BUC2_&O@CPPFC:O\ \)5X]\;V5S;ZG9>+
M;N]M?LXTRZADT67'VR*67[+];QIX:RR?+<-F>4TFJ&#P'M<Z]OC(SDL0G1CS
M8:$HQ<HN4ZC:B[64>57T?#@,V]O5E2KR]ZI4M0Y:;2Y==)--V>BU?G=V/S2_
M;'_X*_\ _!3;X8_MV_&#X/\ PTUW^P_#/@?XP^*?!?P_^#[?!_P3XLE\;^&M
M%\3:II_AG4I;V;P=+X_U?_A,])AM-1MQX=U_3Y5LYK:VLYWO(;O4+S^U2OY1
M/VI?^"\_[47P$_;A^)_[/6A?"KX!ZY\,?A_\6HO =M-JVC_$./QWJ6D1R:?:
MW-S/XCL_B+%X?@U*:>XGG@EC\%26MM"8K:2SNGC>YF_IG^-_QF\ _L\_"7Q]
M\:_BAJKZ-X#^''AZZ\1>(;V" W=XT$#1P6FGZ;9JT9O=7UC4;BSTC1[+S(A>
M:I?6EL98A*9%\3C+ XCZIPC2I\,Y?D]3&8%QP]3+*U+$U\XJ5:>7J$L1"CA<
M/5C7C*I!PA5EB:DIXJ<56DXN_3@*D>?&MXNK74*BYE6BX1H).I?E<IR7*[.[
M2@DH)\J31ZI17\1'Q9_X+X_\%"?VC_B&G@G]COP+:?#6WO-4OE\'^&O /PTA
M^-GQA\1V!FA^R1:U%XCT7QCHE[=QV\&\VWA7P+IAMGO[R&:^U01V-S!Q7AK_
M (+D?\%4/V;?B%:Z1^TOIR>,&B<WFK?#?XT_!71_@[XEETK[1>Z5-_9T_A'P
MC\/]8TQX]2T^_@@U&_TK6K:+5+"[M;FSNUMKBR7>'A+Q1*DI2K9-3Q;I.LLL
MJ9A+Z^XJ]ERPP\\-JTTI/$^S3NI35F0\ZP:D[1KN"ERNLJ7[N^G5R4]+WMR7
MMLGH?W645\T_LC_M5?#']LWX%>$OCU\*)=23P[XD6YL=1T;6K5K36O"WBC2S
M'#K_ (7U9,&VGO-(NW$8OM/FN=-U&V>WO["YEMKF,U_/!XJ_X.!/BY\*OV\/
MBK\$?BWX)^#FD?LU_"?XY_&?X<ZWX@\-^#/B)K'Q=O/#'PUUGQAH.@MIMR?B
M8/#%QXK\2ZGH.DV8DN/"UCH$%QJCF]?2=.BFU2T^5ROA//,WQ.9X+"81_7,H
MI5*F-PM67LZ\72G*G*C3IM.52NYQ<8TXZR=DF[J_96QN'H0HSG/W*[2ISBKQ
M::3YF]$HI.[;V5S^K6BOX>OC=_P6L_X*M_%*QUSXZ_ _P9KOP*_9HL-:O="T
M?Q/X6^!%C\0/"%JMGJ&HRV]IXR^+7Q&\%>,O#5[XS6QO]/LM<&B/X5TMFTRR
MEL/#6ERSZC)J/Z^_\$=O^"PNO_MKZWK?[/\ ^T+IVA:7\=]*TN]\4>#?%'A3
M2[C2O#_Q%\+Z<(SK=CJ.D"6[MM#\7>'?-COO,LYX-)\0:-/*UOIVE7NA7+ZU
M[.:>''$>5956S>M]0Q%'"ZXW#X/%/$8O I<OM/K,%2C2_<\R]LJ-:LZ4;U))
M4HRFL*.:X6M6C1C[6+G_  YU(*$*G;D;ES>]]GFC&[T6K2?]!%%%>5_'#XQ^
M"?V>_A#\1/C;\1KF]M?!/PR\*ZIXL\0-IEJM[JEQ::; 7CT[2;.2>UANM7U6
MZ:WTS2K>XN[.VFU"[MH[F\M+=I+F+X:E2J5ZM.C1A*I5K5(4J5."<IU*E22A
M"$(K64IR:C%+5MI(]%M13E)I**;;>R25VWY):GJE%?PY>,O^"W'_  5*_:D^
M*FO:9^QWX9USPIHJ7%QJ'A_X:?"/X*:+\=?&UCX;MXC''+XEU#6_ ?C6\U&X
M(1KS4-1TS0M!L([AFBM[:"UCV/\ H[_P2;_X*G_MJ_&;]J.3]CG]L7P=977B
M63PWXQUO_A*-?\"S_"7XH^&=7\(V<<UWI'B?PE8Z7HWAV]LIFL;RU%I#X3\+
MZMINJ3W<USJ5_;6\&DV_WV8>&G$.69=B,PQ%;*7+"87ZYB\OI8YSS##X>,>:
MI.I2=&-"2IJ_-[+$5%)IJDZC:3\VEFV%K58TH1KVG/DA5=.U*4MDD^;F5VU\
M4%;K9'[!?MV_\%"_@G_P3V\)^ _%_P :/#_Q,\2V7Q$\1:EX;T&P^&.A^&M:
MU.*ZTG35U2^O-17Q3XP\&6%O81Q2V\*M#J%U>27%Q&$LVA2XGA[O]B_]LOX4
M?MU_!D?'#X.Z=XUT;PPGBO7?!=[I'Q TC2=%\3:=KF@1:?<W45S;:%K_ (GT
M>6WN+'5M-O[2XL-<O4:"[6*X^S7L-U:0?Q;?\%G/V_\ XO\ [3GQV^(/[.'C
MCP9X \,>!?V8/C_\7?#'@*]T#3?$\'C+6[31-;N_!46J>+-2U?Q+?Z/?+J]A
MH<&M6J:-X;T.*!;]8UFOH42XE\U_8G_X+&?M-?L'?!Z\^"?PA\"_ GQ'X5OO
M&NM>.Y=0^)'AGX@:OX@75]=T[0],N[:.[\,?$_P?IHTV.WT"S>VA;27NDFEN
M6EO)D>*.'ZNGX4U\3PE@L3AZ2_UDKU85YJ>-BL)]2JRG.FK<C@JBH2HN2BVU
M/F7,UH<;SF,,;4A*3^JQBXJU-\_M%RIWUO924NFW0_T1J*_++_@HA^W;\3/V
M4?V$?#7[5'PT\$>#Y?'7BF]^$\47A/XCP^(-<T#0(_B#IW]K:I9W\6@:KX(U
MC4;W2H4ETZWF6]T=3=8O+BRVQM8/P7_!'C_@HE\7?^"A?PW^+_BCXP^$/AQX
M4UWX:^,/#_A^Q/PUL/$VEZ3J=EKNDWVIF6ZL/%'BCQ=>0W5JUJD(>'53%,&9
M_)B.%'YBN&<U>1XGB'V='^S<)B_J5>7MX>VC752E2LJ2;<H>TK0CS1;6K:]U
M7/6^MT?K$<+>7M9P]I%<KY7&S>_1V3=GVMOH?L517XD_\%EO^"F?QC_X)UZ9
M^SW%\&? _P ,_%>L_&2_^)\FKW_Q.L_%.K:9I&F?#JW\!*EGIVD>%?%'@ZZD
MO]7NO'D4S:C<ZV]O8V^CR6PTN[DU-;O3OKG_ ()E?M;>-?VV_P!D+P)\??B)
MX;\+^%O&>N:WXTT'7-.\%KJT'AB6?POXFU#2;:^TFQUS4M:U738KFQAM?/LK
MS6]8=;M+B>.]$,\=K;*MPWFE#(,)Q+4ITEE>-Q,L+0J*M!UG4A/$TVY45[T8
M>TPM:*;U]U.W+)-N.*HRQ,\(F_;4X*<EROE46H-6ELW:<7\WV/OVOS,_X+'Z
MIJ>C?\$TOVJ]0T?4;_2;^+PEX3ACOM-O+BQO(X;WXF>"+&\A2YM9(IDBN[*Y
MN+.YC5PD]K/-;RAXI71OY[OVUO\ @X)_:1\7_&76_ 7[#]UHO@KX:Z#XCU;P
MKX3\:KX*TGQSXV^+<K3P:1IWB2ST?QGHNKV&C:9J-_#+?>#M#A\.KKMS9ZA9
MMXC#7LS:'IWS?\>?^"J/[>>H?L[_ !R_8]_;V^&OB9M;^+7@_0U\*^)O&OPL
M'P/^(OAJ_P!*\;:'XN@O=3\*P^%_"6B^(_#.J66EC1D-GX?T>^L6-GJ:ZAJC
M)=V=]][D/AIQ)AL=D.:8E9?34<PR['5,LJ8IQS-82CC,/4Q%26'G15!^QI/G
MK4EB'4BFJ;A[5^S/-Q&;82=/$T8.J[TJM.-90O2<Y0DHI23YES2T4G%1TO?E
M]X^G?^#8J>=?V@OVF;99I5MIO@YX9GEMQ(X@EGM_&T$=O-)$#Y;RP1W5RD,C
M*7B2XG5"JS2!O[-Z_C#_ .#8S_DXC]I7_LB_A_\ ]3BQKUWX@?\ !P!^UK\!
MOVP/%/P4^.WP+^!FC?#GX>_%R_\ !7CFRT;3?B-!\0;3P?;:HUE'XBTKQ._C
MK7=!O[A](EL_%=C)#X"N+77=-DBL[.WM&OX=1M^OCCAG->).-\\IY33HUJN"
MR_+L15HU*].C5J0>$IQ7L8S:=67,E![1C*5-2E'GC?/+L71PF7X=UG**J5:L
M(R47))\[;YFOA5G?S2;2=F?UOT57M+NTO[6VO["YM[VQO;>&[L[RTFCN;6[M
M+F-9K>YMKB%GAGMYX726&:)WCEC=71F5@3_*_P# 3_@NU^T]^T9^W]X,_9S^
M&GPD^"VO? _Q[\>=0\(:!J4?AOXA1_%(?!>QUK4I[OQM>ZK9?$G6/"T>OZ+\
M/=-O/&>L>3X4FT)!87EMNMK$'5(/S?)N',TSVEF=; 4Z3I93AGBL=4KUHT(T
MJ7+5DDG/1S<:%62BVM*<FVK'JU\51P\J,:C?-7GR4U&+DY.\5LNB<HZ^>A_5
M1117'_$'Q_X-^%7@;Q;\2OB'K]EX6\#>!?#^J^*?%?B+4//:TTC0M%M);[4+
MR2*UBN+RZ>.WA<065C;75_?7!BL["UN;R>&"3PX0G4G"G3A*I4J2C"$(1<IS
MG)J,80C%.4I2DTHQ2;;:23;.AM)-MI))MMNR26K;;T22W9V%%?Q.?'W_ (."
M_P!M7X[>/9O!7[&'@6T^%6AWLK#PE:Z?X$LOB_\ &[7$TZU_M+5+B^M-6L?$
M_@X1/9:??7CZ5HW@:[GT;3&OWG\0ZDUO#J-KY?;_ /!:S_@KI^S+\0-)T_\
M:2M+K4IT_P")A??#3X]_L^:/\)=0U?1KR&.(/;_\(OX0^&/B>S\I"UWI.IQ/
M<VJ7[QR:A:ZQIRG3)/TREX3<45*,)3JY/A\54HNM#+*^/DL?*$4KVA3P]7#W
MN^5OZSR1EI.<=SR99U@U)I*O*"DHNK&FO9W?FY*?G\%VMD]#^[.BOD+]A_\
M;-^&/[=OP#T3XZ?#&#4M)B?4KGPIXW\(:PK/J?@7X@Z3IVDZEKOA2XU!;>WL
M];M[>RUO2=4TG7=.1+?5=$U;3;JYM-)U1]0T33/PD^.__!>3XT_ ;_@H/XT_
M9Z\8>#O@GI?[-WP[^--IX*\6^+?^$/\ B5KGQ0MO -E+8+XBUBSN=+^(L.B7
M?B(P/>SZ7'#X*EM(7:UMY[*\$4MQ/\MEO"6>YICLRRS#83EQ^54:M;&86M-4
MZL51J1IRITXVE[6I*<DJ<8751-.$FI1;[*N-P]&G2JSG>G6E&-.<5=/F5TV]
M.5):MNUM;ZH_J8HK^)?X\?\ !;3_ (*>_&MO&_Q9_97^'_B?X.?LS^!-4O(V
M\8^&O@59_$V'3=#,RV]A<_%SXB^,O"WCWP-HVM3LRRR6VAQ>&-/L'GBTOSM8
M>V;5M0_1_P#X([?\%G?'7[6WQ(_X9@_:?MO#?_"U]5T76M:^%GQ$\,Z-)H<7
MC]_#MG<Z]XB\)^)]!T_S]'T[Q/8^'+;5O$6DZSI%KH'AZ_T'P]J.G7MC;>((
M;"X\3>SF'AMQ)EV4U\VJK 5J>$A[3'8/"XIU\=@8**G4>)IQI*BO8TY*I5C2
MQ%64*=ZC7(I26%+-<)5K1HQ]I%S=J=2<.6G4;=DHMRYO>>D>:,4WINU?^DFB
MORB_X*L_\%-=$_X)V?"_PXV@>']/\;_'7XI_VW!\+_"NLB[;PKIUKX>;2UUS
MQAXY.F7VG:G_ &%IKZQ86VGZ/87^G:EXHU&:6TL-0L+33M9U33/P<TO]M7_@
MX4\9_"35/VQ?#6CW:_L[V-A<>*WM[+X3_ .'2'\*:?#;+>ZWH?A#7--F^.VO
M^#8X96UF;Q/I4FK6"Z?#J>KQZVNA:7?RV7)DW V;9QE]+-/K64Y7@L37>&P5
M;.,=]26/Q"DZ?LL&E2K2JSE4C*G!-04YPG&#DXRM=?,:%"JZ/)6K5(1YZD:%
M/VGLHV3YJGO1LDFF[7LFF[71_:!17\0NE_\ !RE^WGJ.IZ=I]O\ !C]EG5;B
M^O[.S@TO2_ 7QE;4]2FN;B."*PTY8_C?>NU_>.ZV]FJ65VYN)(PMK<$B)_ZJ
M/V\OVWOAI^P/\!M2^-/Q!M)_$>H7&KZ;X9\!_#W3;^/3M<\?>*=1E\QM+L+Z
M:TOK?2[+2='@U+Q#K>L7ML]K9:9IDMO!'>:S?Z/I6I9YOP-Q%DV+RO XK#4J
MN+SBI5I8"CA*\*\JM2BZ"FI?#&E%?6*;<ZCC345.<I1A"4DZ&8X7$0K5(3E&
M%!1E4E.+BDI*35M[OW6K*[O9).ZO]I45_"W>?\%HO^"OW[47C&__ .&9M"O]
M'MM,E82>!OV>_P!G:R^+LUG:WT=U/I0UZY\7^$OBOKK7YLM%U2X6ZM9-#L[]
M[;6;J'3(;2TCM=.[_P#9F_X.#_VOOA%\5;;PG^VEHEE\3O JZM9:-X[3_A -
M)^''QA\"?9]UI?ZEH^G:#9^%?#U]>VS3'4M6\+>(_#EO/J<MI#I^EZ[X426:
M63WJOA/Q13H5:D*N48C%4:2K5,LH8Z<\?%-747"6'AA^:2UC_M'+/:$I-I/G
M6=8-R2<:\82?*JTJ:5)OKJI.6G7W=.I_83\?_%WBOX?_  '^-GCSP'I$OB#Q
MQX)^$?Q(\7>#- A19)M;\5^&_!NLZSX=TB*-[>[1Y=2U>RL[*-&M;E6>8*UO
M,"8V_EB_X)/?\%4?^"A?[3O[>/@;X._&/QK%X[^%'B:+XDS>.M%A^$7@O08?
MA[#H?@#QKXC\/S1:_P"$/"NB:SHL2^+=(T+PU')XOU75TO$NQI<AFUF\ANQ_
M4KK?QAT*Z_9\U?X__#J\LO%GAJY^#>H?&'P+?R17]GIWB;0IO!,WC7PQ>207
M,-EJEK9:SI[6,S17%O:7\$%R4EA@N%9$_GD_X)@?\%NOVF/VS?VN/!O[//Q=
M^&GP+TCPWXRT'QKJ$6N?#C1O'^@:WI=[X4\)ZQXGB,@\3?$/QM8:A:WITM;*
M2!;6PEA$QN%NI"@@;FX8PE:?#G&$O]6LNS.6%PM15LPQU:E1QN3M8;$\U3"T
M:V&JU)U:/).ORTJN%J>TI*$I3O&,:QDXK%8'_:JM%3FN6G3BY4Z_OPM&<HSB
MDG?EO*,U9MJUM?Z?Z*_$#_@LS_P4Q^.'_!.R#]G-?@MX/^%/BFY^,4OQ:/B&
M7XHZ/XNUF#3H/AZGPT&FQZ-;^$_&O@J2*6^D\<WC7LU]<WR!+*V2"")GED/Y
MC_$W_@O;^UC\;_"OPD^$W[$7PA3Q3^T%KGPXTOQ'\:/$/@?X2>,?'U[I7C6(
M:?K'B#P[\&OAK=77BJ\/A_PW:6]UI7B?Q1XSL?%]O=KJ5]'X?AL4TG3?&.J>
M?E7 7$.<8' YGA*6%CE^/EB5'%U\3&E2PU/"U*U&M6QCY9.C252C.,6E.<W9
MQ@TVUK6S+"T*E2C-S=6GR^Y&#E*;FHRC&'\S:DGNDNK1_7O17\1'[+?_  7\
M_;+^$7QHTSPO^VK<1_$WX<MXB_L7XBVFI?#3PU\//BG\/[6<P6EQJ6B67@SP
M_P"#[*YN_#<RMJEYX;\1>'KJ]UJW-]I,.IZ1<W&GW^F_V"_%[]HOX5_!/X ^
M*?VE_&>M7$GPI\+>"K7QY+JNBV,NH7VLZ/JD5DWAZWT.PD-J;C4?$MUJ>E:;
MH\5[-I]K]MU*U_M*\TZT%Q=V_-Q!P9G?#F+P6$Q=*CB7F34<!7R^<\10Q55R
MA#V%)SI4:KK<U2E:$J47)5(.#DF[7AL?A\5"I.#E#V6M2-1*,H*S?,TG)<NC
MU3=K.]CW*BOXU=!_X*C?\%E_^"A'Q&\6V_[!GP_TSP1X-\)73LVE^%/"7PMU
M:'2-'O[G5[GP[!\0_B9\?EO_  A+XMOM.MY(O*T/_A#X-7;2'FTCPW$5O3/Y
M1J'_  7W_P""GO[/6L:Y\&_C/\//@9JWQ-\!:K/H/BV;XH_"_P 5:-XSBU.S
MB@CD34;/X=?$?P'X0>*Y55U*SOM%\/0:=J-M?QW^F3SZ3<6!7WH>%G$523H4
M\7D4\PITZ=7$Y5#-(RS'"4ZJ3A4Q-%4>2$)724HU9QDVN1R3N<SSC"I<SAB5
M2;:A6=%JE-K=0ES7;6[3BFK:H_N!HK\[O^"7'[67Q7_;7_9'\-?'[XP^#_"_
M@_Q1K_B_QOHEI!X)TCQ)HOA+6M$\,ZRVD6NM:);>*-<\2ZC+$+V#4=&O[F+7
M=0M&UC1]1AC:UFAGL;7]$:^"S# U\LQV+R_%*"Q."Q%7#5U3FJD%5HS<)J,X
MZ22DFKKYI/0]*E4C5IPJPORU(QG&ZL^62NKKIHPHHHKC+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^%=?\
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MX;\7Z7_:6I^(-;CU.^.IZ1(EQH>CZZ(KN#46L_-_I!_XAH?V$O\ HK'[6O\
MX7?P=_\ G#5_07%CX)R^.0\.9QF>=X2MPY@Z$\.LGIT(Q=6I"BHXG$.KAL3_
M +2WA_;Q46N3VTY/F=0^9P7]H57B<50HX><<54DI>W<FU%-^Y'EG#W$I\K;6
MO);2RO\ S*?\$K_V@8_V6_\ @H%\"?&<VM6\_@[6/&K_  F\::G9P79TK4/!
MWQ'=O!SZVT6HVVF:O%I6C:I?:+XU3S+.RU9(]"A6?3)I#/I%Q_5)_P '&/CC
M4_"?_!/2VT&PN;B"U^)WQ\^&G@?6XH/]5>Z9I^C^-OB3%;7G[Z+_ $=-9^'N
MD7BY2X_TNTM?W*_\?$'\MW_!5O\ 82T;]@#]I]?A7X'U+QEK_P +/%7@/PSX
M[^'NO^.9=(O_ !!<VUT+O0O$VF:IK'A[1O#VAW]_IOBS0]7N(X;70M)N;'0M
M3T".]M;AI8M7U3^B7]L/5M>_X*-_\$(/!?QI\.W=[KOQ \!Z+X$^)OC32=(L
M;W6+W6_&'PBNM3^&_P 88[N F35=,AMK2\\7?$**:>*_D_LO3K%I+BYTS4/[
M=&_$T,OQV?\ A[QGAY*>7XW&X/!5:]2'(HRE4=?+I5DDU"K"K+$QJN5E2E1B
MG)1A>,X1U:>&S/ 25JL*<ZD8IWNK*-51UU3CR.-M^;8\C_X-A_A9X>C\'?M0
M_&R:TBG\67GB;P;\+-.OY&5I]+\/:;I=QXMUFTM$%NC0Q:]J6JZ#-J+/=W*W
M+^&]+$=O9&UEEU";_@YK^$7PZMOA_P#L^_'&T\+Z;9_%*_\ 'FI_#C5O%MG"
MMMJ.M^#U\,:CKUCI6MO$%&J+H^I6)DT:>[$D^FQ7VI6UM(L%Y)&/S\_X(9_\
M%*?@I^Q)K_QB^&O[1=]J7A7X<?%AO#GB71_B-IVB:SXEM?"7BGPC8Z[:W.F>
M(/#_ (8TG6?%%]IOBVPU&RM].U+1K"_;1-7TF"&^TU],UR]UG0*/_!:;_@J-
MX#_;LU/PG\(?@-H-UJ7P6^$6NW7C!_B?K.EZSI.M>,_$=W:2^'%O-)T*_%G=
M>'O!%M:ZHL-N_B;2[7Q'JVJWEN9K+08K9+75<GD?$3\6I9JL+BUEB=.K+,/>
MA@Y8)Y;##?5U6NJ<YK$?NY81-U7*+KNE[-JH/ZQA?[%5'GI^UUC[+1U%4]JY
M<_+NERZ\^UGRIWT/V:_X-H?^3$OBQ_V=KX[_ /5._ :OYP/V\OA3XT_X)S_\
M%,?%&J^#--/AJU\*?%O1/VC/@/-$9Y]*G\%ZKXJ;QGX4M+"35K>>34M,\.:O
M8ZK\/=674H-0@N=0\+:U8W,FL6H>ZO?Z/_\ @VA_Y,2^+'_9VOCO_P!4[\!J
M\-_X.9?V=X]9^&?P&_:CTBSMQJ/@?Q+J/P=\:W*379OKOPYXQMKGQ-X+N)+=
ME>P33O#FOZ%XFLWGCDMKU[WQQ:QR1:A;JDFE>=E&;1P/BKQ!EN(M+!9]6KX"
MM3GK3E6C057#.2ND^=JKADFI7^LM65[K:O1=3)\+6C_$PT858M;J+=IV]-)O
M_!\CKO\ @X _:WTK6?V!/V>?#WP_NIAH'[96J>%?B/:O>.L-W?\ PI\*^'_#
MOQ(MK>>SLKJ>V:Z?Q+XI^&5_.XN[^QM6LI(HUN);BTOK7J?^#;;]G5/ 7[+7
MQ%_:)U:PBCUSX^^/'T;P[>-#,TK?#SX527^A026]Q.%CB%[X]U#QS;7\-@AB
MN!H6EO>7=U/:PVFE_P C/C#XP?%?]HCP_P#LS? VYB36(_@WX8N?@_\ "O1K
M$".\UBZ\<_$SQ%XJBEO9KN<0G5[NZ\4Z-X/MC')9Z;%H7A7P\'@2^_M34+__
M $LOV:_@MI'[.G[/_P '/@7H;)+8_"SX=^%O!KWL;.XU74](TJWAUS7'9XK<
MM/KVM_VAK-P5MK6/S[Z3RK2UBV6\?)QGA8\&<$8/A:E44L1FV;X[%8F<'_&P
M6%Q+G1E-;J<J:RN+OIS4:L=;.U8";QV85,9)>Y1H4X037PU)P2DD^R?MGZ27
M<_(_]L/_ (+!_L+_ +"/QB^('@_P+\);;XJ_M#7U[YGQ;U+X4Z)X)\*V*>)(
MK:TM)]%^)7Q2,#:MK7C&RM]-T>TU"QM-'\6/HPL4T?7+[2]8T9M&B_"7_@H;
M_P %O+#]OC]G'4?@#>?LI1?#6XG\7^%?&&E>-9/C8?&[Z+?^&[BY\SR?#X^$
MGA 3RZCI=_J6DF=M:B%K#?32^1<,%2O@#]FOXA>"?@%_P4"T#QU^V[X N/B/
MH'@3XN?$6V^/'@W6/#>G:Y=S^-)8/%_A[4-5U7PGK45A8:E<>$OB+>VOBN^T
M2ZM8&FET.6TBLOM)BM3^UO\ P6#_ ."LO['?Q^_9=E_97_9775/&\/B+Q5X:
MUW4?%MAX0UGX;>"/">G^&M6M_$SPZ=HGBGP_H6O:SJFL:H\EE+;1Z%H]A;-_
M:&JR:I=.+6UU'Z+!\*9;D&=<-T,+PUF?$&*G'!XJMQ1+,\71P6 G3GRSFJ5*
M^&G"C""K4L)B.15J$Z=&$Z\_:)<M3&U<3A\5*>*HX:"YX1P:I0E4JII65Y>^
MN9MQE.-^62;:BK'HO_!KGJ,\NE_MMZ2RQ"VLK_\ 9WU&)PKB=I]4M_C=;7"R
M,7,9B2/2+8PJL:.KO.7>16C6+\AO^"Z'_*4_]J/_ +HE_P"LZ?".OUJ_X-;_
M /F^;_NV7_WX.OR5_P""Z'_*4_\ :C_[HE_ZSI\(ZZ<F27C%Q7;3_A P[^;H
M\-M_>VV37_Y$>"_["9?A+%']X_[.GPX\$> /V<?A!\-?"GAG1=)\$Z3\*_"F
MDP>'K72]/@TNXMK_ ,/VL^KR7UA;VT-E>76O7M[?ZEK]Q-;%]9U/4=0O[_S[
MF]N))/\ /X_9T2V^'_\ P5V^$6D^$K*UT72='_X*!^&/!VDZ99));66F^';S
MX^V_A+^S+2*WEA,5M;Z'=R65O!N, B5(IHIK?S(9/]#[X3?\DK^&G_9/_!O_
M *CFFU_G@_";_E,+\-/^TE7@W_UJ'3:^/\,:DZO^O?M9SJ>URV=2KSR<O:3E
M_:'-.=W[TY<TKR=V^9ZZL[LU27]FV25JL4K*UDO962MLM%HC]??^#GOX@:U/
MX[_93^%8V0^'=+\)?$+X@2&-G\S4-:U[6=$\.0_:D8F,)H]CX;G^P-&%<MKF
MI"<R*+?R_P!;O^"#?PC\*?#;_@G'\)_$VAP;M?\ C)K/CGXB^-=2DM[2.:[U
M:+Q?K/@O2K.*2&%;EM/TKPWX3TBW@BO+F[87\FJWL#6L.H"QMOSZ_P"#F;]G
MO6M?^'_P!_:9T.UN+K3?A[JOB'X7^/&BM[:1+#3?&DFG:OX,U6>=3'>P6<&M
M:1KFCSM*+NS:^\0:3'$=.N)7&J>4?\$</^"Q_P"S+^SG^S+H?[,/[3VN:_\
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MSQ3=:YJU@^L:W?S/+=WL\-A96FGV,4DWV73K"VALM/@MK6-8A_/K_P '-/\
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MH&DZ?I&@16\W@Z^\#WOA]8[#3;'3;"-=.L]/AM6TZ#3FFTJ73UB5H(_XG_\
M@K[\4O\ @FY\7/B-X'\5?L%Z+-9Z_>?\)3>_&/7?#_@KQ#\/OAQXEN-5N=.U
M+0[K2O"_BRQT'5;;Q/:W]QXC37+JR\*Z+I5U;3Z>J3:D\$3VW]9O_!%3PSX^
M\+?\$T/V9[3XARZN-2U31?%WB;P[I^MVPBO-*\ ^)O'_ (IUOP#%#<&:::_T
MC5O"E[I?B?0+F<QFWT'7M-TRVABL=/M$'T?&F1Y=E63Y-Q7DN$S+AC'8G,8Q
MEE&)J5J-;#UU#$58XFC1E*53#3I2PZ<>65.G[&M2M2H3M2ERX#$5:U>O@L1.
MEBZ<*3:KQ491G%N"<')+EDFIZW3?-&5Y26J^2=/_ .#;3]@6RU-[^Y\;?M.:
MO:M*TBZ)J'Q"^'L6F1HUPDPA272OA'IFLF)(T:T4R:N\QMY79YFNA'<Q_M;\
M$O@5\(OV</AUHGPG^"'@/0_AU\/_  ^KG3_#^B)<N)+F81K=:GJVJ:A<7NM>
M(-<OA%$=1U_7]1U/6M1:.-[Z_N'16'K-%?F^9\1Y[G-.G1S3-<;C:-.7/"C6
MK2=)3MRJ;I1Y82FE=*<HN44Y)-<TK^I1PN'H-RHT:=.35G*,4I6WM?>U[-I.
MS:5]D%%%%>*= 4444 %%%% !1110 4444 %9=_\ ZM_\_P 1K4K+O_\ 5O\
MY_B- '\3_P"U5J,FK?'OQ[J$OQ;@^.CW#>&=WQ4MM#MO#</BGRO!WAZ %-%M
M+BZM[+^Q!$/#K>7/)]I?2&NWVO.R+\]U]%_M91Z]%^T#\0(_$^F_"S2-<5O"
M_P!NT_X*1M%\,K<MX+\.M;?\(RCS7#+YMH;>?6<S/GQ!+JK#:"%7YTK^_.#?
M^20X5_[)O(__ %5X4_#\V_Y&N9_]C#&_^I-4****^D//"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OMK]E[_ )%^_P#^QFNO_39H]?$M?;7[+W_(
MOW__ &,UU_Z;-'K\E\:_^2&Q'_8RR[_TY,^HX0_Y',/^P?$?^DH_6CX1?\N_
M^\O]*_1WP#_J8/JG\C7YQ?"+_EW_ -Y?Z5^CO@'_ %,'U3^1K^.3]8/H'3_]
M4/\ =']*V*Q]/_U0_P!T?TK8H **** "BBB@ HHHH **** "BBB@#B?B7<M9
M_#CX@7B>+X_A\]IX)\57*^/I;"+5(O!#0:%?RKXODTR:2&'48_#10:T]A+-%
M%>+9&WDD1)"P/AI<M>?#CX?WC^+X_B"]WX)\*W+>/HK"+2XO&[3Z%82MXOCT
MR&2:'3H_$I<ZTEA%-+%9K>BWCD=(PQD^(RZ@_P /?'::3;>%+W56\&^*%TRS
M\>*6\#W>H-HE\+*V\9JKQ%O"D]R8XO$2B2,G2'O '0G<#X<KJ"?#WP(FK6WA
M2RU5?!OA==3L_ :E? ]IJ"Z)8B]MO!BL\I7PI!<B2+PZIDD(TA+,%W(W$ [*
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \3\#:E)=?&3XZZ
M<WQ>@\91Z9_PK'R_A1'H5MI\_P &?MOA:[G?[1K<5Q)<^(/^%BE?^$DB^U6]
MM_926IM(/.C<N/;*\:\%1^(%^+OQMDU'3?A3:Z#)_P *V_X1S4?",;+\4-4V
M>&+M=7_X6\YGD63[%>%(/ &V&#9X>:Y#>:?G'LM !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGPIIMIX-BMO%B6:W#Z;X8U_3[+P_=:-XKOOLVFR^(=2OO#5T;2\31&UWV?\
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M-/U'3)(]8T/4;"QU:"ZM8?X[?^":_P"W3X0_X)^?&#Q/\:=9_9[LOCQXLO\
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MM'KJ6\AL;.2XL;N6UM'MO)O^"0G[>?AC_@GA^TGXWU7XSZ#XM?X<?$#P7?>
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M#1KC1M3T^74-4:]TK3=$U:*?6=#O?$&L6U_HWANTL;SQ/?:?=V>I2V_[G?\
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M_P!D_P"'7[/'[3/B37_A/XM^$-AK^B:;XK'@SQ7XS\)>,?#LWB2YUCP\;9/
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M?T'4+S49=!OK4:B][X4\5^$-&N=;T2%;/6FLK/4[*V2:^"Z9>?L+_P %=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M19V?O>Q53E5K.5D[7N<^*JNAAJ]5;PI3E'_%9J/RYFKGX2_\$&?A?<_M-?\
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M2_$/A[5+K67\.OK/AAE\3ZVVMLNG_,7_  <2?M"_'/X$?!/]GR'X)_%KQ_\
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MMU>&-(\/_'WP7<:CJGAEKA_!_COPSJ<WASQYX2^VR0/J$&DZU!'<6UWINHI
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MW2[=@HHHKS#8**** "BBB@ HHHH **** "BBB@ K+O\ _5O_ )_B-:E9=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K[:_9>_Y%^_\ ^QFNO_39H]?$M?;7[+W_
M "+]_P#]C-=?^FS1Z_)?&O\ Y(;$?]C++O\ TY,^HX0_Y',/^P?$?^DH_6CX
M1?\ +O\ [R_TK]'? /\ J8/JG\C7YQ?"+_EW_P!Y?Z5^CO@'_4P?5/Y&OXY/
MU@^@=/\ ]4/]T?TK8K'T_P#U0_W1_2MB@ HHHH **** "BBB@ HHHH ****
M.&^*%K!??#3XB65SX3G\?6UYX%\6VMQX%M;I[&Z\:07&@:A%+X3MKV,B2SG\
M1QNVCPW2$/;R7BS*0R"CX7VL%C\-/AW96WA.?P#;6?@7PE:V_@6ZNGOKKP7!
M;Z!I\47A.YO9"9+R?PY&BZ/-=.2]Q)9M,Q+.:K_%IM/3X5?$Q]7N?%=EI2?#
M[QFVIWG@-@GCBTT]?#FI&]N?!C,DJKXK@MA++X=8QR!=72S)1P-I/A*VGO\
M"KX9OI%SXKO=*?X?>#&TR\\>,'\<7>GMX<TTV5SXS94B5O%<]L8I?$3".,-J
M[WA"(#M !Z#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >&>
M M+LK7XU?'W4H/A-?^$+S5?^%5_;_BE<:I-=V7Q@^P^$[RWM?[/TQV,6D_\
M"OXF/AV[\D+]OFN5N),LH->YU\_?#J3P^WQX_:-CT[4_BM=:]%_PJ'_A(].\
M72*WPOTO?X-OFT?_ (5$@@C:/[=9AY_'^^:??XA6V*^4/D/T#0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<&BOI(<8<4T\*L%#/\TCAU!TXP6+J\\:=K<D:SDZT8)>[&,:B48^[%*.ARO
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M\&_M%_\ !,C]A_\ :R^(G_"U_P!H#X)?\)_X_P#["TSPS_;_ /PLGXN^%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K[:_9>_Y%^__ .QFNO\ TV:/7Q+7
MVU^R]_R+]_\ ]C-=?^FS1Z_)?&O_ )(;$?\ 8RR[_P!.3/J.$/\ D<P_[!\1
M_P"DH_6CX1?\N_\ O+_2OT=\ _ZF#ZI_(U^<7PB_Y=_]Y?Z5^CO@'_4P?5/Y
M&OXY/U@^@=/_ -4/]T?TK8K'T_\ U0_W1_2MB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4R_\^W_D,_X4 ?FE_P *VN/^?<_E_P#8T?\ "MKC_GW/Y?\ V-?I;_PJ9?\
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MY8J#Z=_PJ9?^?;_R&?\ "@#\TO\ A6UQ_P ^Y_+_ .QH_P"%;7'_ #[G\O\
M[&OTM_X5,O\ S[?^0S_A1_PJ9?\ GV_\AG_"@#\TO^%;7'_/N?R_^QH_X5M<
M?\^Y_+_[&OTM_P"%3+_S[?\ D,_X4?\ "IE_Y]O_ "&?\* /S2_X5M<?\^Y_
M+_[&C_A6UQ_S[G\O_L:_2W_A4R_\^W_D,_X4?\*F7_GV_P#(9_PH _-+_A6U
MQ_S[G\O_ +&C_A6UQ_S[G\O_ +&OTM_X5,O_ #[?^0S_ (4?\*F7_GV_\AG_
M  H _-+_ (5M<?\ /N?R_P#L:/\ A6UQ_P ^Y_+_ .QK]+?^%3+_ ,^W_D,_
MX4?\*F7_ )]O_(9_PH _-+_A6UQ_S[G\O_L:/^%;7'_/N?R_^QK]+?\ A4R_
M\^W_ )#/^%'_  J9?^?;_P AG_"@#\TO^%;7'_/N?R_^QH_X5M<?\^Y_+_[&
MOTM_X5,O_/M_Y#/^%'_"IE_Y]O\ R&?\* /S2_X5M<?\^Y_+_P"QH_X5M<?\
M^Y_+_P"QK]+?^%3+_P ^W_D,_P"%'_"IE_Y]O_(9_P * /S2_P"%;7'_ #[G
M\O\ [&C_ (5M<?\ /N?R_P#L:_2W_A4R_P#/M_Y#/^%'_"IE_P"?;_R&?\*
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M$J:5H?BTQCPKK.I/HUZMCI7B8RLL0\/ZC=&*SUDR,L8TZ:YWL%R:/A\FI1^
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M% !1110 4444 %%%% !1110 4444 %>)_P!N:C_PT;_PC7_"U])_LC_A2?\
M;G_"CO[ L/[<_M'_ (3O[!_PM?\ X2C[/_:?]D_9O^*0_L#[5]@^V?\ $Q^S
M_:/WE>V5Y%Y/B3_A?7VC_A%/A]_PB'_"H?)_X3C,'_"U/^$D_P"$SW_\(IMW
M_:O^%??V9_Q-\^7Y'_"1\;_,^6@#UVBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_GE'_WR?\*],\A?[J_K1Y"_W5_6@#S/_A%H?^>4?_?)_P */^$6A_YY1_\
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M'_GE'_WR?\*],\A?[J_K1Y"_W5_6@#S/_A%H?^>4?_?)_P */^$6A_YY1_\
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M'_GE'_WR?\*],\A?[J_K1Y"_W5_6@#S/_A%H?^>4?_?)_P */^$6A_YY1_\
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MO0!S%MI*18 4<=,#^O?'IW_#-;T-N$P !GT_3)_SS[9P;@11V_#M^F*?@#H
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M$[^)-4@:.^UQI@)FU2>Z,GSEJ /0:*** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"$7\_^R_[6^T_\5?\ V]]E^W_8_P#B7>?]G_=U[U7S]_:.B_\ #5/]D_\
M"9_$C_A(O^&??[1_X5[YEW_PJ'^Q?^%C?9O^$S\G'V'_ (61]N_XD?F9^U_\
M(Q\N/)H ^@:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\:_9^U35=:^$7A+4M;^+.A?'+5+G^WOM7Q2\-:5H^B:)XH\GQ/K5O#]BT
MS0%72;;^Q+>*+P[<_9%'G7>D3W$^;F68GV6O&OV?M/UO2OA%X2L/$7@SX;_#
MW68/[>^V>$/A'':0_#W2/-\3ZU-;_P#"/QV)-JOV^UD@U35O*)SKE[J3/^\+
MT >RT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >-?L_:I
MJNM?"+PEJ6M_%G0OCEJES_;WVKXI>&M*T?1-$\4>3XGUJWA^Q:9H"KI-M_8E
MO%%X=N?LBCSKO2)[B?-S+,3[+7C7[/VGZWI7PB\)6'B+P9\-_A[K,']O?;/"
M'PCCM(?A[I'F^)]:FM_^$?CL2;5?M]K)!JFK>43G7+W4F?\ >%Z]EH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7C7]J:K_P -"?V+_P +9T+^P_\ A37]J?\ "B_[*T?_
M (2;^U?^$W^R?\+9_MO;_P )!_87V3_BC_[*W?V/_:'^E[?MO->RUXU_9^M_
M\-"?VM_PAGPW_P"$<_X4U_9__"P_+M/^%O?VW_PF_P!I_P"$,\[/V_\ X5O]
MA_XGGEX^R?\ "3_-GSN* /9:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** /!?VG=)T'7/@=XWTOQ/\+/$GQKT.Z_X1K[=\,O"-[JFG^(?$OD>+]
MN+;^S[S1;RPU.'^QKR&W\07?V:[B\RQTJYBF\RW>6-_>J^?OVIM1T72O@/XZ
MO_$7C/XD?#[1[?\ X1C[9XO^$<EW#\0](\WQEX>AM_\ A'Y+$&Z7[?=20:9J
MWE#G0[W4E?\ =EZ^@: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#@OBK:6%_P#"_P")%CJOA74O'6EWO@+QA::EX)T::ZMM7\8V%SX>U&&\\*Z5
M<6,UO>P:EXAMWDTBQFL[B"ZBNKR)[>:*94=3X56EA8?"_P"&]CI7A74O NEV
M7@+P?::;X)UF:ZN=7\'6%MX>TZ&S\*ZK<7TUQ>SZEX>MTCTB^FO+B>ZENK.5
M[B:69G=H_BU<65G\*OB9=ZEK/B3PYIUK\/O&=QJ'B'P:TR>+]!LH/#FI2W6L
M^%7M\SIXDTN!9+[0VA!F75(+4Q_.%H^$MQ97GPJ^&=WINL^)/$>G77P^\&7&
MG^(?&33/XOUZRG\.:;+:ZSXJ>XQ._B35(&COM<:8"9M4GNC)\Y:@#T&BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%^'VDZ#9_'']H75-/^
M%GB3PGKFL?\ "IO^$A^)NIWNJ3^'OBU_9_A"]M])_P"$8L[N\FTRQ_X0.S9_
M#^M?V3:67VF^N8Y;_P"T7 60>]5\_?#K4=%N?CQ^T;86/C/XD:WK&F_\*A_M
MWPAXFDNV^'G@C[9X-OIM,_X5C',/LL7_  DMJKZGXT^QD[]<BMVN,2 5] T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@O[,6DZ#H?P.\$:7X
M8^%GB3X*:':_\)+]A^&7BZ]U34/$/AKS_%^OW%S_ &A>:U>7^IS?VS>37'B"
MT^TW<OEV.JVT4/EVZ11I[U7S]^RSJ.BZK\!_ M_X=\9_$CX@Z/<?\)/]C\7_
M !<DNYOB'J_E>,O$,-Q_PD$E\!=-]@NHY],TGS1QH=EIJI^["4 ?0-%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7@O\ 9.@_\-0?V[_PJSQ)_P )
M1_PH7^R?^%V_;=4_X1#^P?\ A87VS_A5G]G_ &S^Q/\ A)/[0_XJW[;]@_M3
M^S/W'VS[)^YKWJOG[^T=%_X:I_LG_A,_B1_PD7_#/O\ :/\ PKWS+O\ X5#_
M &+_ ,+&^S?\)GY./L/_  LC[=_Q(_,S]K_X1CY<>30!] T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \:_9^US6_$?PB\):UXB^)/A3XNZS>
M?V]]L^(?@BUM++POXA^S^)]:M+?^R[:Q2.UB_LFU@@T.]\I%WZCIEW(^9'<G
MV6O(O@/HGB3P[\*?"NC>+O ?P^^&?B&S_MS^T/!'PLM8++P'HGVCQ)K%U:?V
M%;6P$$7]I6,]MJ^J;!\^LW^H2-\[M7KM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!XU^T#KFM^'/A%XMUKP[\2?"GPBUFS_L'['\0_'%K:7OA?
MP]]H\3Z+:7']J6U\DEK+_:UK//H=EYJ-LU'4[21,2(A'LM>1?'C1/$GB+X4^
M*M&\(^ _A]\3/$-Y_8?]G^"/BG:P7O@/6_L_B31[J[_MVVN08)?[-L8+G5],
MWCY-9L-/D7YT6O7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C
M?B-?7NF?#WQWJ6F>)-)\&:CI_@WQ1?:?XPUZ**?0_"E[::)?7%IXDUJ"X5H)
MM)T*>./5-1BF5HI+.UF212A8$^'-]>ZG\/? FI:GXDTGQGJ.H>#?"]]J'C#0
M8HH-#\5WMWHEC<7?B31H+=5@ATG79Y)-4TZ*%5BCL[J%(U"!0'_$&RU+4O 7
MC?3M&T'P_P"*=8U#PAXELM*\,>+8HY_"OB/4KK1KV"QT'Q-!*#%-X?U>ZDBT
M_68I 8Y-.N+E'&TFCX?66I:;X"\$:=K.@^'_  MK&G^$/#5EJOACPE%'!X5\
M.:E:Z-907V@^&8(@(H?#^D74<NGZ-%&!''IUO;(@V@4 =?1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !15>YN[6SB,UW<06L(8*9;B5(8PS?=4O(RJ"V#@9R>U9_P#PD.@?]!O2
M?_!C:?\ QZ@#8HK'_P"$AT#_ *#>D_\ @QM/_CU'_"0Z!_T&])_\&-I_\>H
MV**Q_P#A(= _Z#>D_P#@QM/_ (]1_P )#H'_ $&])_\ !C:?_'J -BBL?_A(
M= _Z#>D_^#&T_P#CU'_"0Z!_T&])_P#!C:?_ !Z@#8HK'_X2'0/^@WI/_@QM
M/_CU'_"0Z!_T&])_\&-I_P#'J -BBL?_ (2'0/\ H-Z3_P"#&T_^/4?\)#H'
M_0;TG_P8VG_QZ@#8HK'_ .$AT#_H-Z3_ .#&T_\ CU'_  D.@?\ 0;TG_P &
M-I_\>H V**Q_^$AT#_H-Z3_X,;3_ ./4?\)#H'_0;TG_ ,&-I_\ 'J -BBL?
M_A(= _Z#>D_^#&T_^/4?\)#H'_0;TG_P8VG_ ,>H V**Q_\ A(= _P"@WI/_
M (,;3_X]1_PD.@?]!O2?_!C:?_'J -BBL?\ X2'0/^@WI/\ X,;3_P"/4?\
M"0Z!_P!!O2?_  8VG_QZ@#8HK'_X2'0/^@WI/_@QM/\ X]1_PD.@?]!O2?\
MP8VG_P >H V**Q_^$AT#_H-Z3_X,;3_X]1_PD.@?]!O2?_!C:?\ QZ@#8HK'
M_P"$AT#_ *#>D_\ @QM/_CU'_"0Z!_T&])_\&-I_\>H V**Q_P#A(= _Z#>D
M_P#@QM/_ (]1_P )#H'_ $&])_\ !C:?_'J -BBL?_A(= _Z#>D_^#&T_P#C
MU'_"0Z!_T&])_P#!C:?_ !Z@#8HK'_X2'0/^@WI/_@QM/_CU'_"0Z!_T&])_
M\&-I_P#'J -BBL?_ (2'0/\ H-Z3_P"#&T_^/4?\)#H'_0;TG_P8VG_QZ@#8
MHK'_ .$AT#_H-Z3_ .#&T_\ CU'_  D.@?\ 0;TG_P &-I_\>H V**Q_^$AT
M#_H-Z3_X,;3_ ./4?\)#H'_0;TG_ ,&-I_\ 'J -BBL?_A(= _Z#>D_^#&T_
M^/4?\)#H'_0;TG_P8VG_ ,>H V**Q_\ A(= _P"@WI/_ (,;3_X]1_PD.@?]
M!O2?_!C:?_'J -BBL?\ X2'0/^@WI/\ X,;3_P"/4?\ "0Z!_P!!O2?_  8V
MG_QZ@#8HK'_X2'0/^@WI/_@QM/\ X]1_PD.@?]!O2?\ P8VG_P >H V*^?OV
M6=#T7PY\!_ NC>'?AMXK^$.CV?\ PD_V/X=^-[N[O?%'A[[1XR\0W=Q_:=U?
M/)=2_P!K74\^N67FN=FGZG:1IB-$ ]I_X2'0/^@WI/\ X,;3_P"/5\V_LZ_$
M3P#'\#O -WX6^(WQ ^,.@WH\4FP\=^/;F?4/'6K_ &?QAKD5T/$<FLM8:DIT
M^\^T:/I'VFW3.C:99"'=;I$[@'U517G7_"S=!_Y]-7_\![+_ .3Z/^%FZ#_S
MZ:O_ . ]E_\ )] 'HM%>=?\ "S=!_P"?35__  'LO_D^C_A9N@_\^FK_ /@/
M9?\ R?0!Z+17G7_"S=!_Y]-7_P# >R_^3Z/^%FZ#_P ^FK_^ ]E_\GT >BT5
MYU_PLW0?^?35_P#P'LO_ )/H_P"%FZ#_ ,^FK_\ @/9?_)] 'HM%>=?\+-T'
M_GTU?_P'LO\ Y/H_X6;H/_/IJ_\ X#V7_P GT >BT5YU_P +-T'_ )]-7_\
M >R_^3Z/^%FZ#_SZ:O\ ^ ]E_P#)] 'HM%>=?\+-T'_GTU?_ ,![+_Y/H_X6
M;H/_ #Z:O_X#V7_R?0!Z+17G7_"S=!_Y]-7_ / >R_\ D^C_ (6;H/\ SZ:O
M_P" ]E_\GT >BT5YU_PLW0?^?35__ >R_P#D^C_A9N@_\^FK_P#@/9?_ "?0
M!Z+17G7_  LW0?\ GTU?_P ![+_Y/H_X6;H/_/IJ_P#X#V7_ ,GT >BT5YU_
MPLW0?^?35_\ P'LO_D^C_A9N@_\ /IJ__@/9?_)] 'HM%>=?\+-T'_GTU?\
M\![+_P"3Z/\ A9N@_P#/IJ__ (#V7_R?0!Z+17G7_"S=!_Y]-7_\![+_ .3Z
M/^%FZ#_SZ:O_ . ]E_\ )] 'HM%>=?\ "S=!_P"?35__  'LO_D^C_A9N@_\
M^FK_ /@/9?\ R?0!Z+17G7_"S=!_Y]-7_P# >R_^3Z/^%FZ#_P ^FK_^ ]E_
M\GT >BT5YU_PLW0?^?35_P#P'LO_ )/H_P"%FZ#_ ,^FK_\ @/9?_)] 'HM%
M>=?\+-T'_GTU?_P'LO\ Y/H_X6;H/_/IJ_\ X#V7_P GT >BT5YU_P +-T'_
M )]-7_\  >R_^3Z/^%FZ#_SZ:O\ ^ ]E_P#)] 'HM%>=?\+-T'_GTU?_ ,![
M+_Y/H_X6;H/_ #Z:O_X#V7_R?0!Z+17G7_"S=!_Y]-7_ / >R_\ D^C_ (6;
MH/\ SZ:O_P" ]E_\GT >BT5YU_PLW0?^?35__ >R_P#D^C_A9N@_\^FK_P#@
M/9?_ "?0!Z+17G7_  LW0?\ GTU?_P ![+_Y/H_X6;H/_/IJ_P#X#V7_ ,GT
M >BT5YU_PLW0?^?35_\ P'LO_D^C_A9N@_\ /IJ__@/9?_)] 'HM%>=?\+-T
M'_GTU?\ \![+_P"3Z/\ A9N@_P#/IJ__ (#V7_R?0!Z+17G7_"S=!_Y]-7_\
M![+_ .3Z/^%FZ#_SZ:O_ . ]E_\ )] 'HM%>=?\ "S=!_P"?35__  'LO_D^
MC_A9N@_\^FK_ /@/9?\ R?0!Z+17G7_"S=!_Y]-7_P# >R_^3Z/^%FZ#_P ^
MFK_^ ]E_\GT >BT5YU_PLW0?^?35_P#P'LO_ )/H_P"%FZ#_ ,^FK_\ @/9?
M_)] 'HM%>=?\+-T'_GTU?_P'LO\ Y/H_X6;H/_/IJ_\ X#V7_P GT >BT5YU
M_P +-T'_ )]-7_\  >R_^3Z/^%FZ#_SZ:O\ ^ ]E_P#)] 'HM%>=?\+-T'_G
MTU?_ ,![+_Y/H_X6;H/_ #Z:O_X#V7_R?0!Z+17G7_"S=!_Y]-7_ / >R_\
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M\::]M\6Z\MS_ &S=:E<V][+_ &7>"XT;3O.A39I6G6,<>Z)(V;W3_A9N@_\
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M/_/IJ_\ X#V7_P GT >BT5YU_P +-T'_ )]-7_\  >R_^3Z/^%FZ#_SZ:O\
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MIJ__ (#V7_R?0!Z+17G7_"S=!_Y]-7_\![+_ .3Z/^%FZ#_SZ:O_ . ]E_\
M)] 'HM%>=?\ "S=!_P"?35__  'LO_D^C_A9N@_\^FK_ /@/9?\ R?0!Z+17
MG7_"S=!_Y]-7_P# >R_^3Z/^%FZ#_P ^FK_^ ]E_\GT >BT5YU_PLW0?^?35
M_P#P'LO_ )/H_P"%FZ#_ ,^FK_\ @/9?_)] 'HM%>=?\+-T'_GTU?_P'LO\
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M_GTU?_P'LO\ Y/H_X6;H/_/IJ_\ X#V7_P GT >BT5YU_P +-T'_ )]-7_\
M >R_^3Z/^%FZ#_SZ:O\ ^ ]E_P#)] 'HM%>=?\+-T'_GTU?_ ,![+_Y/H_X6
M;H/_ #Z:O_X#V7_R?0!Z+17G7_"S=!_Y]-7_ / >R_\ D^C_ (6;H/\ SZ:O
M_P" ]E_\GT >BT5YU_PLW0?^?35__ >R_P#D^C_A9N@_\^FK_P#@/9?_ "?0
M!Z+17G7_  LW0?\ GTU?_P ![+_Y/H_X6;H/_/IJ_P#X#V7_ ,GT >BT5YU_
MPLW0?^?35_\ P'LO_D^C_A9N@_\ /IJ__@/9?_)] 'HM%>=?\+-T'_GTU?\
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M(?$,]U>1W,^N:U;F/4M6FN(XYY+^YN'F19&90 >_T5YU_P +-T'_ )]-7_\
M >R_^3Z/^%FZ#_SZ:O\ ^ ]E_P#)] 'HM%>=?\+-T'_GTU?_ ,![+_Y/H_X6
M;H/_ #Z:O_X#V7_R?0!Z+17G7_"S=!_Y]-7_ / >R_\ D^C_ (6;H/\ SZ:O
M_P" ]E_\GT >BT5YU_PLW0?^?35__ >R_P#D^C_A9N@_\^FK_P#@/9?_ "?0
M!Z+17G7_  LW0?\ GTU?_P ![+_Y/H_X6;H/_/IJ_P#X#V7_ ,GT >BT5YU_
MPLW0?^?35_\ P'LO_D^C_A9N@_\ /IJ__@/9?_)] 'HM%>=?\+-T'_GTU?\
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M_P"?35__  'LO_D^C_A9N@_\^FK_ /@/9?\ R?0!Z+17G7_"S=!_Y]-7_P#
M>R_^3Z/^%FZ#_P ^FK_^ ]E_\GT >BT5YU_PLW0?^?35_P#P'LO_ )/H_P"%
MFZ#_ ,^FK_\ @/9?_)] 'HM%>=?\+-T'_GTU?_P'LO\ Y/H_X6;H/_/IJ_\
MX#V7_P GT >BU\_?LLZ'HOASX#^!=&\._#;Q7\(='L_^$G^Q_#OQO=W=[XH\
M/?:/&7B&[N/[3NKYY+J7^UKJ>?7++S7.S3]3M(TQ&B =Y_PLW0?^?35__ >R
M_P#D^O"_V:OBEX#G^"?@N7PSXW^)_P 5=#;_ (2/[#X]^)$C7WC37MOBW7EN
M?[9NM2N;>]E_LN\%QHVG>="FS2M.L8X]T21LP!]<T5YU_P +-T'_ )]-7_\
M >R_^3Z/^%FZ#_SZ:O\ ^ ]E_P#)] 'HM%>=?\+-T'_GTU?_ ,![+_Y/H_X6
M;H/_ #Z:O_X#V7_R?0!Z+17G7_"S=!_Y]-7_ / >R_\ D^C_ (6;H/\ SZ:O
M_P" ]E_\GT >BT5YU_PLW0?^?35__ >R_P#D^C_A9N@_\^FK_P#@/9?_ "?0
M!Z+17G7_  LW0?\ GTU?_P ![+_Y/H_X6;H/_/IJ_P#X#V7_ ,GT >BT5YU_
MPLW0?^?35_\ P'LO_D^C_A9N@_\ /IJ__@/9?_)] 'HM%>=?\+-T'_GTU?\
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M?9U+T ?5%%8W_"0:#_T'-*_\&%E_\<H_X2#0?^@YI7_@PLO_ (Y0!LT5C?\
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M5_X,++_XY0!LT5C?\)!H/_0<TK_P867_ ,<H_P"$@T'_ *#FE?\ @PLO_CE
M&S16-_PD&@_]!S2O_!A9?_'*/^$@T'_H.:5_X,++_P".4 ;-%8W_  D&@_\
M0<TK_P &%E_\<H_X2#0?^@YI7_@PLO\ XY0!LT5C?\)!H/\ T'-*_P#!A9?_
M !RC_A(-!_Z#FE?^#"R_^.4 ;-%8W_"0:#_T'-*_\&%E_P#'*/\ A(-!_P"@
MYI7_ (,++_XY0!LT5C?\)!H/_0<TK_P867_QRC_A(-!_Z#FE?^#"R_\ CE &
MS16-_P )!H/_ $'-*_\ !A9?_'*/^$@T'_H.:5_X,++_ ..4 ;-%8W_"0:#_
M -!S2O\ P867_P <H_X2#0?^@YI7_@PLO_CE &S16-_PD&@_]!S2O_!A9?\
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M)!H/_0<TK_P867_QRC_A(-!_Z#FE?^#"R_\ CE &S16-_P )!H/_ $'-*_\
M!A9?_'*/^$@T'_H.:5_X,++_ ..4 ;-%8W_"0:#_ -!S2O\ P867_P <H_X2
M#0?^@YI7_@PLO_CE &S16-_PD&@_]!S2O_!A9?\ QRC_ (2#0?\ H.:5_P"#
M"R_^.4 ;-%8W_"0:#_T'-*_\&%E_\<H_X2#0?^@YI7_@PLO_ (Y0!LT5C?\
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M5_X,++_XY0!LT5C?\)!H/_0<TK_P867_ ,<H_P"$@T'_ *#FE?\ @PLO_CE
M&S16-_PD&@_]!S2O_!A9?_'*/^$@T'_H.:5_X,++_P".4 ;-%8W_  D&@_\
M0<TK_P &%E_\<H_X2#0?^@YI7_@PLO\ XY0!LT5C?\)!H/\ T'-*_P#!A9?_
M !RC_A(-!_Z#FE?^#"R_^.4 ;-%8W_"0:#_T'-*_\&%E_P#'*/\ A(-!_P"@
MYI7_ (,++_XY0!LT5C?\)!H/_0<TK_P867_QRC_A(-!_Z#FE?^#"R_\ CE &
MS16-_P )!H/_ $'-*_\ !A9?_'*/^$@T'_H.:5_X,++_ ..4 ;-%8W_"0:#_
M -!S2O\ P867_P <H_X2#0?^@YI7_@PLO_CE &S16-_PD&@_]!S2O_!A9?\
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M)!H/_0<TK_P867_QRC_A(-!_Z#FE?^#"R_\ CE &S16-_P )!H/_ $'-*_\
M!A9?_'*/^$@T'_H.:5_X,++_ ..4 ;-%8W_"0:#_ -!S2O\ P867_P <H_X2
M#0?^@YI7_@PLO_CE &S16-_PD&@_]!S2O_!A9?\ QRC_ (2#0?\ H.:5_P"#
M"R_^.4 ;-%8W_"0:#_T'-*_\&%E_\<H_X2#0?^@YI7_@PLO_ (Y0!LT5C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB+_R+<G_ %^6G_H3UX#7OWQ%_P"1;D_Z_+3_ -">O : "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\T^#]_K&J?#K
MP[?:_P"//"_Q-U>?^U_M?CCP7_9__"-:WY6NZG#!_9O]E,]A_P 2VVCATB\\
MAC_Q,+"Z\W$WF >EUY?\&-)U70_AKX;TO6_ OASX::I:_P!L?:O!/A.XMKOP
M_HOGZ_JMQ#_9]Q:.]O)_:5O-%JUUY;';>W]RCX=6  /4**** "BBB@ HHHH
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MFIZ_J/\ &CS4]?U'^-?"G_#PC]E+_HJK_P#A#?$?_P"8ZC_AX1^RE_T55_\
MPAOB/_\ ,=1_J;Q?_P!$KQ)_X8\T_P#F4/[6RK_H9Y?_ .%N&_\ EA]U^:GK
M^H_QH\U/7]1_C7PI_P /"/V4O^BJO_X0WQ'_ /F.H_X>$?LI?]%5?_PAOB/_
M /,=1_J;Q?\ ]$KQ)_X8\T_^90_M;*O^AGE__A;AO_EA]U^:GK^H_P :/-3U
M_4?XU\*?\/"/V4O^BJO_ .$-\1__ )CJ/^'A'[*7_157_P#"&^(__P QU'^I
MO%__ $2O$G_ACS3_ .90_M;*O^AGE_\ X6X;_P"6'W7YJ>OZC_&CS4]?U'^-
M?"G_  \(_92_Z*J__A#?$?\ ^8ZC_AX1^RE_T55__"&^(_\ \QU'^IO%_P#T
M2O$G_ACS3_YE#^ULJ_Z&>7_^%N&_^6'U#\8-4U;3/AUXBOO#_CSPO\,M7@_L
MG[)XW\9_V<?#6B>;KNF0S_VE_:KI8?\ $RM9)M(L_/8?Z??VOE9F\L'TKS4]
M?U'^-?F-\9/V\OV9M<^&_B/2]%US0/B3J=U_8_V;P5XL\'>/K;P_K7D:]I=Q
M-]OGN_""6Z?V=;PRZM:^8PW7MA;(F790?3O^'A'[*7_157_\(;XC_P#S'4?Z
MF\7_ /1*\2?^&/-/_F4/[6RK_H9Y?_X6X;_Y8?=?FIZ_J/\ &CS4]?U'^-?"
MG_#PC]E+_HJK_P#A#?$?_P"8ZC_AX1^RE_T55_\ PAOB/_\ ,=1_J;Q?_P!$
MKQ)_X8\T_P#F4/[6RK_H9Y?_ .%N&_\ EA]U^:GK^H_QH\U/7]1_C7PI_P /
M"/V4O^BJO_X0WQ'_ /F.H_X>$?LI?]%5?_PAOB/_ /,=1_J;Q?\ ]$KQ)_X8
M\T_^90_M;*O^AGE__A;AO_EA]U^:GK^H_P :/-3U_4?XU\*?\/"/V4O^BJO_
M .$-\1__ )CJ/^'A'[*7_157_P#"&^(__P QU'^IO%__ $2O$G_ACS3_ .90
M_M;*O^AGE_\ X6X;_P"6'W7YJ>OZC_&CS4]?U'^-?"G_  \(_92_Z*J__A#?
M$?\ ^8ZC_AX1^RE_T55__"&^(_\ \QU'^IO%_P#T2O$G_ACS3_YE#^ULJ_Z&
M>7_^%N&_^6'W7YJ>OZC_ !H\U/7]1_C7PI_P\(_92_Z*J_\ X0WQ'_\ F.H_
MX>$?LI?]%5?_ ,(;XC__ #'4?ZF\7_\ 1*\2?^&/-/\ YE#^ULJ_Z&>7_P#A
M;AO_ )8?=?FIZ_J/\:/-3U_4?XU\*?\ #PC]E+_HJK_^$-\1_P#YCJ/^'A'[
M*7_157_\(;XC_P#S'4?ZF\7_ /1*\2?^&/-/_F4/[6RK_H9Y?_X6X;_Y8?=?
MFIZ_J/\ &CS4]?U'^-?"G_#PC]E+_HJK_P#A#?$?_P"8ZC_AX1^RE_T55_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O-/@_?ZQJGPZ\.WVO\ CSPO\3=7G_M?[7XX\%_V?_PC
M6M^5KNIPP?V;_93/8?\ $MMHX=(O/(8_\3"PNO-Q-Y@'I=>7_!C2=5T/X:^&
M]+UOP+X<^&FJ6O\ ;'VKP3X3N+:[\/Z+Y^OZK<0_V?<6CO;R?VE;S1:M=>6Q
MVWM_<H^'5@ #U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS3[?
MK'_"XO[+_P"$\\+_ /"/_P#"M/M__"L?^)?_ ,)K_;'_  E/V?\ X3S[W]J_
M\(O]B_XI[[G]G_VM_%]IXKTNO+_[)U7_ (73_;O_  @OAS^P_P#A5W]D_P#"
MS/M%M_PEO]J_\)9]L_X07[)O^V?\(Y]C_P"*@^T;/LW]I_NM_F\4 >H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]O[E'PZL  >H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /4/A?_ ,A#5/\ KSA_]'U[
M17B_PO\ ^0AJG_7G#_Z/KVB@#A?B+_R+<G_7Y:?^A/7@->_?$7_D6Y/^ORT_
M]">O : "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\8_9ZLM*T[X/^$+/1/"WCKP7I</\ ;_V7PS\2H[F+QKIOF>*-
M;EF_MI+LFX7[9</+J&G>8>=)NK I\A6O9Z\=^ 6HZ/JWPE\)ZAH'Q"UWXJZ1
M<?V[]D\>^);74++6]>\KQ-K,$_VVVU6VL[^/^R[F*;1K;S[:/?::=!)%OA>.
M1@#V*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK#TZ[I^R]IS-0YN>RC*44^;ECO:^RT84445X!TA1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7WI\&9
M)YM#\,375[IFI7,NCZ1)<:CHI1M'OYWL(6EO=):,"-M,NI"T]@4 0VLD14;<
M5\%U]Z?!F*6#0_#$%QI$'A^>'1](BFT&UEAGM=$ECL(4DTBVGMB;>:#37#6<
M,L!,,D<*O$=C+7\W_2#_ .:1_P"Z_P#^\4_0.!?^9I_W(_\ NX?I7\+NEO\
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M-1@\>>#+6&_>R$GV9[V&VN)[>*Z:(SQP3S1)((Y'5L\KX2>9<*YUQ,L>J/\
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M[9;ZO8Q2OX?N[*]^V65[9ZT][H?+?\%8OVJ_"O[>/[2WPV\"_LYZ)K?CO3?
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M?37#!_:::)-J=O!J,NE+="PDOX(;MX#<1I(O\X?Q?_X+*_M,:1^VUXB_9?\
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M#5['2_#7B+Y3^+'_  5^_P""GHN_#'Q56U_X4E\*_&]S<7?P_P!/A^".FO\
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MP47^,_[>'_""6?Q+\.> ?"&A?#?4?%]]X:TGP#;>*[3[9_PEO]A1%_%4FO\
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M^EAL+BI8NHJM5TXPH1;C'E<')2GK:I.32<^=:.?+LK+^G[_@IS^W[XD_8O\
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MU:BHJ<!4KO&QC1Q&)Q6$]FW5JUXS45/E;7)[2[7O<C25FTY)II<S^:_VN/\
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MC3?#/A_5-'UK7H[+2M4M-8T6ZU6)M1BU#3M8A2PDTC5/Z._VCOV@?A[^R_\
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M:1;R?:-)OX8+NT_LN6%]&B\V)//ATZ.Y3=',C'QRO[\X-_Y)#A7_ +)O(_\
MU5X4_#\V_P"1KF?_ &,,;_ZDU0HHHKZ0\\**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[M
M^!T<$/AKP?#:V6I:;;1:!H4=OIVM!UUC3X(],MEBLM663]X-2M8PL%\'^<74
M<H;YLU\)5]W_  1GCNO#GA&YAU:;7X;C0=#GBUVXMY+2?6HYM-MY$U:>UF59
M;:;4E87DEO*JR0O,T;J&4@?S?](/_FD?^Z__ .\4_0.!?^9I_P!R/_NX?IA\
M+NEO]$_DM?:OAK_CVC_#^5?%7PNZ6_T3^2U]J^&O^/:/\/Y5_-Y^@'HMO]P?
M0?UJ>H+?[@^@_K4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M U:.VD;3K*]^/&G75V /*@O=4@^#]SI]LYSN\RZ@TC4Y8@%(*V<V2"%#>_\
M_!O3K&F3_LD?%S0(KR-]8TS]HS7M8O[ !_.MM,USX9_"^RTF\D)41F.^NO#V
MM0Q!79PVGS>8J*8R_P"WQE+ ^"\*F#_=SS'&U8XZ<+\THSS:KAI<[3]WVE#"
MX:A*^DJ3Y&GSW?S]E4SZ2J:JE3BZ:=K)JC&2M?>TISDK:IZ]#][*YSP[X.\(
M^$&\0/X3\+>'/"[^+/$>H>,?%+^'=#TS16\2^+M6AM+?5?%/B!M-M;8ZSXCU
M.WT^P@U#7-1-SJ=[#96D5S=2);0JG1U\<_\ !0?QQJ_PY_8E_:<\5Z%L&K6W
MPB\4Z193.SJUE)XIM1X5;4H&3G[7ID6M2:A9!@T37=K LR/"71OQS 8>KC<7
MA<!2J.$L?BL-A%J^1RK5H4Z;G&\5)0G-22;5FKIK<]VI*-.$ZC5_9PG/SM&+
M;L^ETC\0OVU_^"Z?C[2_B)XI^$_['N@^&/[&T+4I/#+?%SQ)I-QXEUK7M=L;
M\6][=> O#CW,6A0:2]U ^FZ?>^(=.\22:W:2R7UKIFF/-921_&NM?\%/?^"O
MGP8;1O$WQ;O_ !II'A_5!9MI<'Q7_9J\(^"O#>O+J,5S=Z>UIJ5K\-_!>H7@
MOK73M0FLSINMH+JVM;V:'S%MGDAO_P#!!OX4^%/B%^V7J_BKQ/:1ZC/\(_A9
MKGC;PI97%K9W5K'XKO->\.>%;+5IQ>07&V31].U[5;K37MEM[RVU@Z=J,%["
M;!H;K^JC]L;X;>#?BQ^RY\>/!GCG1;36M&NOA;XXU&W6YMK6>XTG7-&\-:GJ
M>@^(M(>[M[F*SUS0-5MK74])OO)D-M>6\;/'+$989/VW-\9PCP;F^ X8CPEE
MV:4E2P?]HYECJ=*OCI2Q347.C*M0J-34+5Y1A4I4G*I[*E"BH<S^?H0QN/HU
M,7]=JT9<T_94J;E&FE#6TE&2NKWBKJ3LKMRO8^7O^";?_!1WPQ^W=X.UO3]6
MT.#P3\:_ <$-UXW\):>M]/X=OM'O;I[;3?%/A34+MIY3IES*%L[_ $G4+J35
M-(U &-Y+VQN++4;GY-_X*F?\%3/CW^Q%\>_!?PG^$_@OX0Z_HNO_  AT3XAZ
MCJ/Q#T3QGJ^J+JFK^,_'GAIK*R;PUX\\(VD%A!:>$;:<">VN[B2XNYR9TB2.
M.OQS_P""'/B+5]$_X*!>"-,TVZ>WL_&'@#XG>'=?A5G"WVD6WAB?Q;#:R!64
M,B:[X7T6]"R!T\RSC8*'5'3U_P#X.$?^3S_AE_V;#X+_ /5K?&FG1X+R3!^)
MBRB>#IXC*<7E%7,Z."KRG4A0E-U*7LTW)3E"G6HU)4E.4G&$XQ;DXW!X_$5,
MI==3<:U.M&DZD;)RLXN_:[C)*6BNTW;4]R_:$_X*_?M@_'3Q)<>'?^"?_@3Q
M:/"'@G0+34/&'Q \*?!J\^)'B36M1M;:V?Q+K*Z)KGA[Q?IG@OX?6EW=1VFE
MKK>C-XADMO)U35M3TR74H]$T[(_8B_X+K>/M#\1:OX<_;;U7_A-/!]QH&L:C
MH?Q$\+^#-%TOQ9I?B#2+'5-6LO#^H>'?!^F:-HFL6WBZ2.T\+Z->0Z?H\>BZ
MS)I5UX@OX]#N=;UW2?V\_P""7'@OPQX*_8-_9QB\,Z-8:2?$W@*P\:>(9K.S
MM;:XUOQ/XE+WNJZSJL]M##)J-_(HMK".\O#-=1Z7I^FZ?YS6UA;(G\>/[5?A
M7P\__!17XW^$!I<$/AK4?VK_ !7I=UI%JTUG;?V=K/Q+G74+.W-K+#+902I>
M7"0I926XLXW6.R^SI%$L?3P]A.$>(:_$/"_^K.&PF&R>G55'-:<J<\XK/#XB
M>'JXB>+E1C4A5J5(QK4Z2G+#QBW1G2E2M$C%3QN&CA<7];G.>(<>:B[^PCS1
M4E%0YFFDGRMV4GNI)ZGW]\:_^"P'_!2+XA:;J?QE^#O@_5?@;^SS8ZW)H6F>
M*M$^$%GXZ\-K.;QX;73O%OQ1\?\ A'Q+X5NO%,CWMI:7%OH</ABW,J64$&D+
M.\\U]^JG_!)__@J+XE_;'U+Q1\%_C;INAV'QC\,Z%<>,M!\2^'+3^R-%\;^$
MK2^T[3=5MKO2);F:/3_%>A7FJV-P4TN3['K6BW5Q=1:9IC^']0N-2_2?XX?#
M+P!I?[)'Q?\ A5I?A+1-,^'6G? ;X@>&=.\(:;9I8:/I^B6G@C5H;2SL(+0P
MM9&T$<<UK=6TD5[;7<<=]#<)>HLX_D*_X(D74]O_ ,%#?A9##)LCOO"GQ3M;
MI=J-YL"?#[7KU8\LK,F+JSMI=T91SY>PL8WD1O,PU/AKBO@[BBMA.&L%DU;A
MZC4Q&!Q.'M+%SI4J%3$4OK.)Y(UJ]2<</4IUXUIUJ;]HI0:J14UM)XO!8[!Q
MJ8NIB(XJ2A4A*Z@I.48RY(7Y8I.:<>51>C35G8_H"_X*R_\ !0KXQ?L'P_ 5
M?A'X5^&GB2X^*LGQ/.N2_$;2O%&K0V$/@5?A\+!-)@\,^+_"+QR7C^,;MKR6
M\N+Q0MG;I##&7D<_FKXY_P""V?[67QNTCX=?#+]DGX0F[^,=QX3TW7/B7K_@
MOX?:[\0M1U#Q%'I]M?\ B+1OAO\ #2XB\676F>%O#TC7%IJFO^(IO%%YJ/SO
M8)HUI8PZOK7<_P#!Q[_S9M_W</\ ^\-K[$_X(0_"WP'X;_8VM_B?I/ARPM_'
MWQ&\:>,+;Q=XJ:(2ZQJ6F^%];GTC0='6[D#2VVCZ=!!)<PZ; T=L=0O+V_D1
M[BX9QC@,)PUD_AYDG%&.R##9KF4\7C,/3C6E*-'$8B>/S&E2GCHMRC6H4,-A
MFHTG3G&4XP3BFU5IU4GBZ^9XC!T\3.C24*<VXI<T8JG1<E3>CC*4Y[WT3?H_
MR2^"?_!</]L[X1_$!='_ &E;>Q^+/ANVUF.R\8:!K?@7P[\.?B)X<M1/:1ZA
M'H9\+:/X0TV'5K""*YEATWQ1HMTMU<SO:W-[81M!<V7],G[6'BGP_P".?V"/
MVE?&OA/5+?7/"OC#]D+XR>*?#.M6?F?9-8\/^(/@SXCU;1M4M?.CBF^SZAIU
MW;7<'FQ1R>5,N^-&RH_FV_X."O F@Z!^U3\,_&VEVT=IJGQ ^#ME_P ),(HU
M4:CJ7A3Q)K6D66KW$F2\M[)H<VEZ,^0J)9:%IZH-WF,WZC?LQZ_J?B3_ ((-
M>)=1U:?[1=6W[(_[7&@12?,-NF>%&^-'A;18/F9C_HVC:/86W4*?*RJHN$6^
M),LR;%97P7Q?E.68?*)YCFV!PN+P>$A&GAW.I.I-.-.G"G23H5<%7A&I"E3=
M6%6,JD6XQ45A*N(A7QV!K595U2HU)PJ3;<K)16K;;]Z-2+:;=FK)]_QQ_P""
M#7_)]H_[(S\0_P#TL\+U_1C_ ,%&/^"AOA;]@OP%X<O%\,)\0/BA\0IM5M/
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M*<7+E3M&5DYMR;45?ZH^'/\ P65_;X_9V^*VG^'/VP/#&J^*](2/3_\ A*O
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M3]"TV[6^EBC*7^GSI)IOT+_P;X?#?0O$?[2?Q9^)&J6L=WJGPT^%T%EX:,S
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MX6T.PU:^\4:9XV2QLUGO=0T!!JVNP>*KJ*W5/#%KIVG:K=>9I=SJEYH_RO\
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M2<J=*I.-%TTH>SVAF-:.4^W;YJ_M'0C-J[ONIM;.487WT<DG*^M[$W_!5_\
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M.9-;NS>"\COVD:.W,+VX219?Z<?VC?C+X@_:%_X(T>./C3XKT*P\-^)?B)\
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M- GN[2ST/2M:L=?U.>[U?7LVR3^([*/3M-T_RY;G5+J_\[3_ ,?=;_X*&?\
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MDG_:5_[*'X'_ /4;U6OZ-:_*?$G_ )+;/O\ K]A?_5?A#V<J_P"1?AO\,_\
MTY,_,/\ X+*_\HV_VCO^Z0?^KY^%U?C1_P &[?\ R7?]H+_LDFA_^IC9U^R_
M_!97_E&W^T=_W2#_ -7S\+J_D6_8R^*'[:OPN\6^,=2_8GTSXB:GXOU/P[:V
M7C./X=_"&P^+]_%X;CU.*>T?4-*O_!7C9-(M#J:Q*FH1V=D\LVVV-RX;RC]_
MP-EM3-_#+B3+:-?"X:IBLYK0A7QM65'"TW'#9)4O6JQIU90BU!Q35.5Y.*MK
M=>9F-54,VPE649S4*$6XTTI3=YXA6BFTF]>ZT/WA_P"#BK3?" ^'?[-6KW L
M(_'I\:>.--T@X@35+SP@NAZ3=>(@&\O[3<6&FZTWA<L#+Y%G<:JI$?F7Q:NJ
M_P"#=R+Q /@)\?Y[DZE_PBLGQ>T>+1EEFG;1QX@A\&:<_B8V-NSFVBU(Z=/X
M2&K311)//:KHJ7#R1V]LL7Y2G]BG_@J9_P % ?BKIWBGXV^#OB187\\8TJ\^
M('QZTD_"_P />#M!@NKFY>#3/!]QI6BZA;Z;]NNKB6WT3P-X+G$]Y>O>M:16
MC7FHP?UN?LB_LN>!?V//@9X5^"/@.YN]6M=&>[U;Q%XGU*&"VU/Q?XNUAHY=
M<\17MK;%X;)+AXK>QTO3DFNFTO0M/TK3);_4IK.34;KBXGQ>7</< X/@Y9I@
M\WS6IB56KO U57H8.FL9/&SM43O32DX4:<*BA5JJ=2JJ4(.RTP<*N*S*ICO8
MSH45"T?:+EE4?LU36G6ZO)M7BK*-V]3^#']DSXZ6G[-'[0_PR^.M[X<N/%T/
MPWU35-<3PS:ZE%HTNMW<OAS6=,L-/;5Y;/44TNWFOK^V%YJ T[49;.T$]Q#I
MU_-'':3?I3\0?^"L?_!5B.UT?XR20:I\+?A%XJU1KWPE-#\ -(7X7:]8K/$J
MZ-H_CGQQX1UO4-=M/]'EMY[G3?&!U)Y+B[,5Y;NMJMI\3_\ !-_P7X8^(7[<
MG[-GA+QEHUAXA\-:C\0H;K4M$U6SM=0TO4QHND:KKMK9ZEI]]#<6=]82WVFV
MPO+*Y@E@NK?S()%VR'']D_\ P4W\/:'XC_8-_:<@U[2;#5XM+^&.L^(=-2_M
M8KD6&N:$8=1T?5K,R*QMK_3KV".>UNH2DL;!E#;'D5OM>-<XR3 <4Y%@LPX<
MP6<XC,J.%PU3%8Y0K1PN"K8ZM0A'#8:M3JTG75:I5JSJOV<G&,*?,[J5+@P%
M#$5,'B*E/%5*$*4ISC"G>+G4C3A*3G.+4N7E48J.JNV^C4O%?^"77_!1J+]N
M3P+K_A_QSI6G>'/CK\-H;2?Q=9:';W</AKQ3X=U"9K?2_&&A0W,MU)IDIN4;
M3-?T.6^NQ:7ZV^I6,ZV&KQ:;I/SM_P %/_\ @JK\6?V4/BYI/[/'P(^'?AS5
MO&FL>"M-UR]\8>+;34]?>"_\77M_IN@Z?X.\*Z-J&G"\U6Q%@]TESK4VI6E[
MJ=[:61\.W%K93?VM^;?_  ;TZI=P_M<?%O14?%CJ'[.6OZI<INE!:[T?XF?"
MVTLGVB00G9#KE^"TD3RKY@$4D2-,LW[I?MN?MX_L@?L7>,] \0?$GPG:>/?V
MAI?"M['X3T_P=X8\*ZI\1]%\./\ ;UL8-:\8ZO/8WG@KPEK%_J6I111K?7-S
M=17.N7NF^'M6"7D<OY]FN1Y;DWB'B,!@^'*F?8:IA%BL'DM.M.%.&(KT(S<I
MSY9J.$HU%5DX55*E3A.-[JG&)Z='$5:^61J3Q2PTXSY*F(<4VXQE:R5U><DX
MZQLVT^[/Y\_%'_!1C_@L]X'T*T^*/C4_%/PA\-GDT.]CU[Q3^RMX3\/_  \O
M[74S:G2X#XKU7X3V8>R\1AXQ:S6GB2&YO!>9TF[A9[9H_P!J/^"5G_!3[7?V
MWKCQA\+OBKX5\/>'/B_X$\,V_BZ/5O"+7UOX>\;>%EU>WT/4]1&A:C/J%SX?
MU70[[5/#<.I)'K.H6&KS:X;O3[71(+;^SA^;7QU_X+W:%\9?A/\ %7X03_LB
M,FB_$OP!XK\#-JVJ?&R*XDTT^*/#]YI":PVBP_"4+-/HMY=KJ-G%!KEI/)-9
M6\T%_IUR4EM_E?\ X(5W\UG^WSH%O$L;)JGPO^)-A<&0,62&/3['4U:$JZA9
M#<:= A+K(ODO*H0.R2)]9F_#=/'\(Y[C,VX-ROA?,LMH5,7E]3+)X)NK3HTU
M6E[1X"5I-J$Z-2&)4DU452G"-2*DN*ABG3QN&A0Q];&4JLE"JJJJ>[*3Y=/:
M+1:J2<-K--M,_=7_ (*I?\%.;[]B6#PY\+?AAX?L-=^-OCWPS<>)[;4_$$9G
M\-^!O"=S=:QH.G^(9+"*>*;6]=N]=TJ_71M,G":0BZ1>W.K-<Q"#3;[\4;3_
M (*8_P#!8C2M TSXU:A'X[U#X0SQ'4;?7M6_9B\.VWPFUBPCM[F)Y1XWTWX<
MZ5-+8A[2ZNWN=.\9VY6>TG'VA;6&:V'U-_P7E_8[^*NL?$+0?VM?!.A:GXM^
M'T/@'3?!WQ(CT>UEU&_\!7OAB]UW4+7Q-JMI:0>?;^#-3TC48X)]89+BTT35
M=*NO[:OK*'6M%A?F/V0?^"]6L?#KPKX1^&/[27PK3Q5H/A;2]"\,:7\1_AI/
M!I7B.WT#1K+3])MF\1>"=5D_L77]4CMH)KF?4]#USPG;ND-O:1^'9)Y)K\\O
M#V49?#@[+,PR3A;)^+<=6<WG<,=4P_UVA--\]'#+$TJJHSIJT81@Z<_9J%:G
M2KRK<RO$UZKQU:EB,97P5.-OJ[IJ7LY+2TI\K7,GN[W5VXN4>6Q_05^PO^T3
MKO[5_P"RK\*/C]XG\/:3X6U_QY;^+5U70]!GO+C1[6[\)^/?%7@AY]/?4'EO
M8[?41X;74UM;F>ZELC>&S-Y>" 74WX._ML?\%Q?BF_Q-UKX2?L:Z3I>DZ3X9
M\6OX<3XGZEH]EXR\0?$'4M/N)]*N8/"?A>]M+[1K#P[J.K,8]'N9[?6-=UVU
MM]/OX!H37T^E+^N/QS^//P<NO^"9GQQ^,?[.$F@2?#G5?@=\1(/"$?@BPT[P
MY:^']>\<VNHZ)=O<Z':VD,.AZ]H7BKQ-/J_B72;FR@OSJT5^+I3=737#_P ?
M_P"PM^U-X0_8Z^-Z?&WQ-\%+3XWZII'AK5-+\&:3?>,E\&1>$O$>J7.GH_C*
MUO&\(>,1=ZI:Z)#J^B64+V,"6\>NW5]'.+RVM'B\O@CA? YC6XISVKP^\8\!
MC\3ALHX:Q52%*%*NYRKK"XF>+G"DY8:G4H8=O%1E""]K4=.K55.,=LPQE2E'
M!X>.*4%5IQE7Q<$Y-Q24>>"@F[3:E+W-7HKI79]YS_\ !5'_ (*R?LZ^)= U
M#]H33O%"Z3J%S;W$/A/XU_L]:-\+K?Q#I]I<YU"WTK4-)\!^ =9WW,*RVS7M
MK=7JV;A95@9HWCD_J1_8^_:N^'O[9?P1T+XT?#V*[TR*YN[GP]XM\+:E(D^I
M^"_&VEVUC<ZUX9O;N&.*WU!(+?4M.U/2]4@B@75-"U32M0FLM,N[FXTNR_EO
M_;@_X+%:#^VI^SWXB^!VK_LIV7@_4+_6_"_B3PMXZNOB^OC"?P7KWA[6K:XN
M-5TW0S\*O#1GO=5\,2^(_"$DRZU9-;:=XFOY?])56M)_N3_@W.N/$S>!_P!J
MBTNX+A?!L/BOX5W&@W+1N+2;Q-=:1XWC\6P03%C&]Q;:5:>"I+J-45XHKJS9
MV99HPG3QEPU2J<'U\]QO#6!X5SG+<91IO"Y=5P<L-C<)B*V'PZGR8&<Z'-S8
MCF2G;$0>&JMMTJD;Q@,6UCHX>GBZF,H5:<FIU8U%.G4C&4FKU$I6M'I[KYX_
M:3/Z3:^4_P!L#]D'X:?MJ?#;PY\+OBIJ/BC3?#WAOXC>&OB/;R>%+^ST^^O+
M_0;+6]&N=*O)KRPOQ_9VK>'_ !+KFGRO;+;WEG=7%IJ-O<;[+[/<?5E%?B6$
MQ>)P&)HXS!UIX?%8>:J4:U-VG3FKI2B[/75]'N>_.$*D)0J14H25I1>S79G\
MC_\ P7&_9Y^#?[-/@7]BGX=_!7P'H?@CP[;)^T UZVFVD?\ ;/B/4((/@7;G
M6_%FNR*VJ^)M<EB58Y-4UBZNKE(%BL[9H+&WMK6']2?^"$7_ "89I_\ V5OX
MC?\ H6B5\/?\''O_ #9M_P!W#_\ O#:^X?\ @A%_R89I_P#V5OXC?^A:)7['
MG%>OBO![)<1B:U7$5ZV<UYU:U:<JE6I.69YU>4ZDVY2D^KDVSP\/&,,\Q,81
M48QP\5&,4DDE2P^B2T2/I[_@J-_RC_\ VH?^R>+_ .I%H=?Q\_L%?MKZ[^P]
MXP^)WCOP?X%L?'OCGQU\.3\/O"%AK-S>1>']+U:]\3:%K4>L:U9:6T.L:[;P
M'1TM8_#^EWVCW.I27>%US3O)'G_V#?\ !4;_ )1__M0_]D\7_P!2+0Z_G%_X
M(+?"WP'\0?VO?%/B#QIX<L/$E_\ "[X4WWC3P,NJ1"YL]!\8_P#"8>$='L_$
M\%FX,$VL:38:CJ*Z-<7*S1Z7>78U>TBCUFQTK4+#IX!KX'#>'G%.(S+"2QV"
MHYA.I7P<:CI?6>7#9>Z=&52+3A"=7V:J25[0YGRS^"49E&I/,\%&E-4ZDJ:4
M9M7Y+SJ7DE9W:5[+O;5;K(\1_P#!63_@JW\&_%^@:S\6KB_\-V&NP0>(M"^'
M_P 4_P!GW0O!7AOQ+H(GA_?:;.?"?A/QSJ6A7)C:V?4M*\7B3;<2B#4HIQ!)
M#_37^P%^VGX9_;B^!%G\3=/TZT\,^-M"U.;PK\3/!%O?27H\.>)K6&*Z@N["
M6YBM[RX\.^(],N+;5]$NY(9(X9)-2T![_4-2\/ZG/7S-_P %P?A[H?B_]@'Q
M_P"*]1A@.K?"GQ?\-_%_AZZ:TAFN4NM;\;Z)\.]0M(;IBLUG!<Z7XUN;BX\H
MNMQ)8VL<L3826'\Q/^#=7Q/K$'Q._:3\&1W/_%/ZKX#\$^)[JS=0^-8T#Q!J
M>E6%S [$F#-EXEU**Z6,*+O%F9BWV*WV<F9X7(N*> ,;Q+@<CP.19ED^-6'J
M0R^G&C1K1C4PBJ0FJ=.E&JI8?&TJL9SA*K&M2Y554)S3NC/$8/,J>$J8BIB*
M5>GS)U6Y2BVIV:NVXVE3::347%W<;I-?U9U\6_MV_MI>"/V'O@G<_$WQ+9'Q
M'XHUN_;PQ\-_ ]O<I;7/BGQ9-87=]&;V;YYM/\,Z/;VK7GB/6D@F6SB>ST^!
M)=6U?2;2[^TJ_D6_X.'O&6KWW[2?P.^'LTKG0O#'P.;QEIL)E=HX]7\=^/?%
M>B:U*L!&R-YK/X<Z DDJDO,L$:. ((R?A>!<BP_$7$N!R[%W>#2K8G%1C)QE
M4HX:FY^Q4DU**JU/9TYRBU.-.4Y0:DDST<QQ$L+A*E6%N?W80;5TG.27-;K9
M7:OI=*^AYE9_\%4/^"M7[1'B#6K_ . 5CXDFL-.EEGO/"_P._9VTCXEV6@VE
MU,#9Q:C=:SX(^(VN1"%&2"*XO-2A^T%BSJSL@7];/^"2_P#P44_:!_:P\9_$
MKX+?M"^%M$7Q/\.?!UGXJMO&NE>'KSPCJ]RS>((=+OM'\:: TKZ.FJ3KK%A-
MH\VB:;X:BBL=(ODN],U"YG-_']9_\$GOAKX<^&G[ _[/]OX?@Q/XU\-3_$KQ
M)?.D:7.J>(_&M]<:G<SW)B"I)_9NG?V7X=L7VB0Z3HFGK.9)UEE?[QLO!7@W
M3O%.M>.=/\)>&;#QMXDL--TKQ%XPLM!TJU\4Z]I>C>8-'TW6O$$%I'JVJ6&E
M":8:;9WUW/;V/FR?98XM[9^@XIXCX;J?VUD6$X0RS!_5:]3"9=FF%C3H8R%;
M"8E4YUZ[A0A4JTZT:=1JG.K)Q4HQJ*HVY1YL)A<4OJ^(GCJT^>*G5HS;E3:G
M"ZC%.347%M:J.MM+=?Q^_P""E_\ P5JM?V,O$MC\'/A)X4T#Q_\ &N33;+7/
M$DGBUM3/@OP+I6IPFXT>UU.RT6_TG5M<U_6+8IJ":;:ZOI$&G:5-9WUQ>SO?
MP6J_BJ?^"F/_  6&U;PU-\7=,U;X@I\*Q+<W9\4:5^S)X)N_AI;VVFVTE_J-
MN/&-S\++^$6=K8VEU=W\LWB:2YM;.*YN7NX(X3)%\KV-C#^U1_P4LATSXAM)
M'IWQE_:[;3_%%O8%':W\/ZY\3FMKO1=-DO$F1([;0_\ B3:=/=PW8@BC@FN8
M+PQR0S?WSPZ+H]OH\7AZWTG38- @TU-%@T.&PM8M'AT>*U%C%I,6F)$ME'IL
M=DJV:6"0"U2U MUB$0"5]'FJX<\/<!D6#J<,Y=G^99AA%B\QQ69PIU5&W(I1
MPZK4<3"GS5)5(4U34%"G1BZGMIU'-<M'ZUF=3$5%BZN&HTJCITH4FXW[.5I1
M;T2<N:]W)\O*E8_ +_@FI_P63U?]H3X@:/\  ']I;2=#TCX@>*'6R^'7C[PE
MI=Y8Z1XKUH&YG?PYXGT9)[V#1-7N;94.CZKI_P!GT6]DMY;&\MM.O)+.34/N
MO_@J/^V1\2/V(?V?/"OQ6^%OA_P1XC\2^(OB]X>^'DMIX_L=>U+0[72]5\'^
M/?$MU>QVGAWQ#X8OY+]9_"-I:VY;55MXXKNX>2"9UC"_R/\ [2&A:;^S[_P4
M4^(NG?"J >&+#X:?M,1ZWX%L[-8X+?PS)I_C*Q\2:+8:5':):BVTW0;IX;31
MX(\36NGV=I"]Q-/&US)_15_P<(_\F8?#+_LY[P7_ .JI^--&<<+9#3XOX+Q.
M#P4*>4\3J->MED[^QA*%.C5DHP3_ '=.I3Q-'FI1DX1J0GR<L)**5#&8EX''
MQG4;KX1J,:J^)IR<5=M>\TX2]YJ[35[O4^/-5_X+E?M!?$7X)^ O!/P8^&>B
M:Y^UUXWUC7H/$O\ P@7P^\7:YX<\':*FLSZ9X3T[P9X+U35_%>J^*_'6O0-8
MWUQ/<76K^&]+BFM[0:=JNJ:G-8^'OG+X7?\ !9W]O/X&?&6VT7]JB34?'/A_
M1]6L[#XB?#+Q;\+O!WPO^(&A6,MN[7#:2NB>$?!=_IFOQ07UIJMM8^)K:YLM
M06UM;0G3;>_FU!?N_P#X-W/!?AA/A?\ M _$3^QK!_&=QX]T7P6/$$EG:OJE
MMX8M/#UCKC:-9W[0F]M;"^U6]6]U*SBN%M;^XT_2IKB%Y=.MG3XW_P"#A/2M
M.M/VL/A/JEK9P6^H:M\ M(74[J%!')?G3_'WCV"SDN@N%FG@MY#;+<.IG:VC
MM[9Y&@M;:.+V<!AN$JG%V9\$0X4P$L.Z>*JU,RK\M7&QKSHT\3*GAIRI>UPF
M'HTZKH8=4*T)Q]G"JY.<IN6-26-6!I9@\;4YDZ:5*-XTW%2Y+S7-:I.4ES2<
MHM.[25K6^@_VE_\ @L9^TQ\9_&_BWP-_P3C^'7B77/ W@>S;4=8^*VD?"37?
MB+XWU/3[8307/B>+PIJ&AZMI'@;P,]Q+BSD\8^%KK7+S['9WU]+X=:YOO#D?
M+_\ !/;_ (+5?&WQ%\:O!/P=_:NU'0_'/A?XE:[IW@W1OB-9>'- \(^)/"OB
MWQ#JD=CX<N=;M_#5IHGA74/"ES?7EMHVJN-%TN\T>VEM]?DU.YBTW4++5/U]
M_P""1WP\\$^!_P!@[X&ZIX3\-:7H>J>/] NO%_C74K.$_P!H>)O$ESK&IV3Z
MKJ][*TMS=S16-G:V-G$\OV:PLK>*TL8;>W18A_)=^VCI6G>"O^"C/QQM/"UG
M!HUIIO[2%_JUA:VJ!K:SOK[Q/:ZY<O;V\_FPQ0'4[NXGALD065M&ZVEK;PV<
M45NG-D&"X3S[$<1\(T>&\-AH91AZ]/#9Q4<*N;5JV&K/"5<36Q*IQJ0G+$<M
M>G2I5/J_+S4Y4N1J"K$U,;AHX7&RQ4YNO*+G02<:,8RBIJ$8W::Y;Q;:YKNZ
ME>[?]8'_  65_P"4;?[1W_=(/_5\_"ZOY4OV$OVZ/&7[$\'QGD^&7@6T\9_$
M[XOZ1X,\(^#)M6:ZN=&\.76G:KJ]Q<ZG<:!IRC4O%.IW#:A::?H>@V]YID$E
M[<F_O+RYBL!H>L_U6_\ !97_ )1M_M'?]T@_]7S\+J_$O_@WW^%O@/QC\>_B
M_P"/?%'ARPUSQ/\ "[P7X;N? =]J,0N4\-ZEXGU75;'5-8T^WE#01:P;#3UL
M;34MAN;&UN]0CM7C-Y*U<7!&)P&#\,N(\5F>">8X*AG<ZE7!<[IK$SC1R-X>
MG.::<:3Q/L76TDG24TZ=1-TY:9A"I/-L+"E4]E4EATE4M?D3EB.9I=9<O-R[
M>];5;KRK4O\ @K?_ ,%3?@5\0K)/C:]WI\GE6UY+\+/B]\!M#^'L%]IY>U=K
MB-;+PGX*\<Q)=112)'=Q:X]LOVV62.)MEJ(/ZDOV)OVK_"O[9O[/WA;XT>'+
M:#2=3N)[KPWX\\+0W,]Y_P (=X\T>&SGUG0#>3VMHUU ]GJ&EZYIEP(LS:+K
M.FR3%;EIXH_SH_X+]>!-!U_]CGPKXVN[:,>(OA_\8O#?]B:B(U:Y33?%>CZ]
MI.O:0)&/[JRU&6#1=2N=BEWNM TX96,2!OFO_@W)U_4[GP]^UKX6EGW:-H^M
M?!;7["V^;]UJ?B2Q^)^G:M/DL5_TBU\*:+'PBL/LWS,X*A.#/,'D?$7 $^*\
M#DN"R/'Y;C*>'Q%++Z<*5"M&6)H824'&G3I1FI+%T*\9S@ZM.4)4_:3C=RTP
MT\1A<R^I5,14Q%.K3<HNJVY1:A*=[MR:MR2C9.S33LGLWQ%_P6J_:*\-?MR>
M(OV=9OAE\%=0^&>@_M.ZY\$1<1:;XYL?'=UX<TWXEW?@"#5#XA?QQ?>'X=;>
M&&/4YI!X,DL&EWVR6,:,LR?K-_P4F_:L\>_L;_LRZA\9?AMH?A#Q!XKB\:^$
MO#%I9>.+36;_ ,/1VVNSW9O;FXLM!USPYJ5Q.EO9-':K'K%K''-,L\JW"1&W
ME_D-^)W_ "E4^(7_ &D$\6?^M&ZA7]*O_!=W_DPS4/\ LK?PY_\ 0M;KISOA
MS(\-G_AWAZ&6X>G0S6GAO[1I1Y^3%MRPEW53F[N7M)\SCRN2E:5TE:,/B\1/
M"YG.563E1<O92=KPTGMIY+1^O5GY\P?\%[/C+K_P,TG2/#7PP\"^(?VLO%OC
MS6=&L='\+>#_ !S+X$\-^!X;#1O[%U"'0+KQ;K6O^+?'6NZG=:Q;Z9INFZ[_
M &58Q:?'?:M9R[8=*UCY=LO^"P?_  4S^ 7Q1AL/C\DFIO:2V=_K7P@^+GP9
MT/X7ZB=#U%9)(Q:/H?A+P5XRTF2XLY?-T35K^;5K19X+2ZN[#6K-;RROOKO_
M (-U? ?A*]NOVF?B/?:)87OC/06^&GA;0->NK6WFO]!T76X/&]_K]II%R\1G
MLAKT^FZ3_:QBE_TJ+2-/BPB1S";7_P"#C'P]H:6/[*_BM-)L(_$MQ=_%;P]<
MZ[':Q1ZI=Z'9P^!]2L=)O+Q%6>\L-.O[[4;S3;6Y>6+3KC5-5EL5MWU34#<^
MS0I\(8;C:MP3#A+ 5J6*=5U\PQ/+7KTZU3+_ .TH4\)&=-RPN&HTO]GC[&K3
MJN=JO,Y1;JX2>.EE\<P>-J1<.7EI0O&+BJJI-S:=ISE+WGS1<;7CL[+^@C]G
MKXY>#/VE/@K\._CEX DN#X7^(F@)J]K:WL;QWVD:E:W5SI'B+P[J 9$CDU'P
MSXDT[5O#VH7%H9M/NKW3)[G3+J\T^6VNYOYB?BW_ ,%H?VYOC-\0O$'@']E#
MX9VOA:SL-<U72-#@\(_#R]^+WQ0U&)-4NK+3+K4+>^L_$/AU+JXMX(&CTVP\
M'RK%?-=QG4-3A-NL'ZL?\$,M8O\ 4_V ?"=E>3/+;^'?B/\ $O1]*1I)G%M8
M3ZXGB"2&-999$A1M3UW4K@QVR00F2=Y6B-Q+/--XE\;/^"S/[&G[*_BOQE\/
M/V=_@O;_ !*UBSUW4YO%>L_#B#P?\,_ACKOBF6\NKK5;B#Q9IFEZOJ'BJ_;6
M;O5)-4\10>$[O3+^[N)M1TO6M<CO9;FOB\DRNGE_$W$N5X/A+_6RO@<;4H9=
M#%UH0PF!H4L3B(*ICG6A]5J2JTW1C'VW(I3I5.1QO)KT,16E4PF$K5,;]2C4
MIQE5<(MSJ2E&#M347SI)\S?+>RDKW1^6;_\ !6?_ (*J_LY>--*A_: MM0GE
MO[#^T[;X??'CX!:5\,_[7T>22\T_^U-/7PUX4^&'BJ2!;N*X2VU"WU&XT]=1
MT_R9X+J**]LI_P"A&T_X*#0^/?\ @G3XV_;=^%_@NT_X27PYX'\3WS?#S7=1
MO]9T[PUXZT&^_L:YTW7-2TZPT"]U[0]'GGM?$5S)I\.@3ZUX>*1I>>'KBZ>[
MT_\ F<_X**?\%/++]OOP;\./#$GP"C^%>H_#OQ-JVO6OB$_$X^.I;VRUK2H]
M/U#1DL?^%?>#ELH[B>TTV^ENC=WA9M/AA%N@9I!^X/\ P;\7\UY^Q3X[MY5C
M5-+_ &D?&]A;E P9X9/AW\)=39IBSL&D%QJ,Z HL:^2D2E"ZO(_T_&618'#\
M,Y;Q#C^%<!DF:X/-<+#'Y9E]7#T\+BL&Z]2,J$YX%RPZ6)IQI2550G7H-RAS
M25T^3 8BI+%U<-3QE3$49T9.G6J*3G"IRQ]Y*K:7NMR7+?EEH[=OY4OVF/VA
M/&G[57QN\:_'KXA:9X7T;QAX\_X1O^U]-\&66JZ=X:MO^$7\):#X,T_^S;/6
M]:\1:I#YVE^';*>\^U:Q>>9?RW4L/V>W>&U@_HA_X)M_\%<OVC?VC/VE/@_^
MS1XZ^'OP<M/ VM^'?$^ERZ[X,T'QUIOB?2H_ WPYU[Q#I5_<7>L>/O$NCS0W
MEQX;M=*OHVT>T6275$EMKBW>..VG_*3_ (+*_P#*23]H[_ND'_JAOA=7]OGP
MQ_Y)M\/?^Q'\)_\ IAT^NSCW.,HI<)<,NKP[0KK-LDJ+*HRQDH?V ZN6X!T7
M0:P[>*^KJM124OJZFL-'FLJC4<LMH5WC<6HXJ4?8XA>V?(G]94:U3F4O?]SG
MY97MS6YWO;7\3O\ @J9_P5,^/?[$7Q[\%_"?X3^"_A#K^BZ_\(=$^(>HZC\0
M]$\9ZOJBZIJ_C/QYX::RLF\->//"-I!806GA&VG GMKNXDN+N<F=(DCCK];/
MV:OC1-\;_P!G'X2_'3Q#IVF^$[CQ]\.M$\:ZY80W[2:/HLUWIXN=3,5_?+ \
M>FP/'/.CWC%K6UPEQ<SF)[F3^6;_ (.$?^3S_AE_V;#X+_\ 5K?&FOTQ^(?C
M+5_ G_! ?3];T65X;R^_9L^&'@V9XY7A8Z1\1O&7A+X>Z_$70$LD^A>*-2AD
MB(V3QR-!(0DC$?*YEPQEM?A3@&>#PM'#9EGF8X3 8C&Q4W.H\8YTU*JG/EDH
MSY)+1-*+47%2E?NI8NK'&YDISE*EAZ4JL:;M9<B3LG:ZNKKY['QK^UA_P75^
M,?B?X@ZK\,OV+O#FB:3X>CUN]\*>'_B+J/AR;QMX[\>:K_:MUI&CZWX'\,ZC
M"=%TO3-=#V=SH>BZ]X5\1Z]?2RV1NX=.EEN=$KYDU'_@JE_P5K^!NH^&]9^,
M=UXAM-+UEK/5M%T?XR_LZ>'/ NA^+=,B+3/%97>D>!_A[K6H:5J,3*MQ=Z'K
MD%T(51[#4+-R\C^J_P#!OG\+_"WBC]H_XK_$W6K..^U[X5_#>TM_!HN((98]
M)U/Q[J5SI&JZ_:2NIGMM5A\/:9JGAZ&6%U1]*\3:W!,CF:(I_0S_ ,%'OAGX
M/^*/[$'[3&F^,=*M]2C\)?!_X@?$SPW<26UC->:+XP^'/A+6?%?A[5=,N+VT
MNVT^X-UIK:7?7-D+>^GT+4]8TR*[MX]0F>O>S/&\(<+\08/A*'"&6X_#KZC0
MQ^98RG2KX_VF.4'[2G4K4*DVX4ZM*M+EK4HRG*=*E"@H1D^6C3QV,PU3&O&U
M:4_WCITJ;<:5J?1J,DE=J45=.UDY.5VCG/\ @GK^WOX*_;P^%FI>(M-TB3PC
M\3/ ,FCZ9\5? ^ZXN[#2+_6X]2;0]<\/ZO+$B:AX;\3IHNKRZ?#.RZOI-WIN
MI:7J44\5M8:UK/YT_P#!0_\ X*W_ !\_9%_:ON?@?X#\&?!K4? VF^'O VKZ
MAK/C?P_XZUCQ&7\1V_V[5I8IO#OC[PW81V]K:NB6=L-&NK@20R2R3W/G);P_
MG1_P0&\4:OI'[:/B;PY:2I_9/B[X(^+H-7M9%=@TFB^(?"&K:;>0%)$"7=M+
M'<6R/()HOLFH7R>3YSPSP>=?\%RO^4@'C'_LGGPR_P#4=6EEW!628;Q(S#):
MN$ABLJGDL\RPF%Q$I5/J\JM7"PY5/F4IJE4]O&BYN4E2E",W4G%U).KC\1/*
MJ6(C-PK*NJ4YQLN;E4W>R5ES+E<DK*Z=K+0^P/VA?^"P7[9_QS\8^-[+]@?X
M?>*=-^$'P^,UW=?$'P_\&[OXF>-;[2=.CD:_\3>*XM7T/Q9X4\%>%KR.,W>G
MV5[X<MM7L;!?M6KZU'/<OIFE]Y_P38_X+-_%?XC_ !E\(? +]JZZT#Q)#\2]
M6M/#/@?XIZ7X=L_#FN6'CC5?*LO#WA[Q/I'ABUM?#U_I/BK51:Z+I5_I/A[2
MKK2/$&K02:O/=:!<27/A[]R_V'? ?A+X<_LA?LX>'O!NB6&A:9-\&?AOK]]'
M8VMO;/JGB'Q'X/T;6O$7B#4FMXH5N]8UW6+V[U+4[UT#W%U<.0$C6.-/XN?C
M9;V7PR_X*=^.E\"Z?9>&;3P9^V9/?>&--T:(Z9IVB/I?Q:BU#3[?2K;3WM1I
M=E8W$:"QM--:TAT^".*WT];6&"!(WD&'X5XHI\1<.8?AG"8!95@ZKP&:<T*F
M:59T93PZQ&)Q?LHU55E6C3K^R4JF'M*=*4)02YEB98S"2PF*EBYU'6G'VE'5
M44I)2<8PO;EY6XWLI[233V_OPHHHK\$/I#U#X7_\A#5/^O.'_P!'U[17B_PO
M_P"0AJG_ %YP_P#H^O:* .%^(O\ R+<G_7Y:?^A/7@->_?$7_D6Y/^ORT_\
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MBC1M4&M>'/#VBWVBZ_IGA32]8\16>K6$GA:T.G:G!INHV6HV6H)9W?\ 8_\
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MI>W<GAWXN?M=0Z39ZC(&N+R/P&OQ!ATJUO$2TQA[7P9I\<UO DPAMA%'#+J
MAB>_K^SG]E']D/X-_L9_#[5/AQ\&+#6X='USQ)-XKUS4_$VJIK?B#5M:FTO2
M]'\V[U%+2QB2UALM(M5M=.M+2UL+6:6]N8+:.>_NY)?._AA_P3;_ &)_@W\5
M-/\ C5\.?@=8:!\2])O]7U72_$,WC3XDZ]!IVHZY;7MIJ-Y9>'_$GC+5_#-M
M.T&HWB6;Q:,ATLRB32_L<D,+QX\.\4</<+8[B:MEU'-ZU/&8"."R*K5CA)UX
M25.3J5<?+GP\::J8J-&I'V%&JX4U*+IMQ2E6*P>*QE/"*HZ$73J>TQ$4YJ+U
M22IJT[VAS)\S5VUJDV?<=?YX_P :V\7?LH?MI_&!? &LOI'BKX2?&OXBV_@S
MQ#%8013V"P:[K-OH&MVVGW$#6<%Y%I=W:ZA:1^3<6,%T(FA^UVB1M+_>_P#'
M'XV?#S]G;X6^,/C!\4=:CT3P?X-TJXU&\<26HU'5KM(V_L_P]H%K>75E%J7B
M/7KP1:9H>F?:8/MNH7$,3S00^;/%_$3X \!_$G_@J[^WAKNIV_AJP\$1?$[Q
M,GC'XDW?@W2XSH?PV^'VE0:9I%[K,QG-K!J&MRV%K86;:A>?9Y_%WCC5#J%S
M!%+JERD/O>$7-@X<2YECX0IY!'+XPQN(KJ+H2K492G['DE%^VMAJM?VL(\UO
M:4J<HRE6IHY\[M-X2E2;>)=5NG&/Q*,K+FO?W??C&S?9NZ46??O_  0Y_8JU
M;XI?$W4/VSOBC::C<>$O &KZC:?#*;4[BY%UXS^*\S1R:SXNEGDG^UZGI'@Z
MTO+F&2YGC>TUCQAJR>3J$UWX1U[3V_K2K@?A9\,?!7P8^'7@WX5?#K1;?P_X
M)\!Z!8>'/#VEVZKF*RL(@C75[.JH]_JVIW)GU/6]6N=]]K.L7E]JNH33WUY<
M3R=]7Y[Q=Q)6XHSK$9C-2IX:*6'R_#O_ )A\%2<O91:3:52HY2K5K-KVM22B
M^2,$O3P6%C@Z$:2UD_>JR_FJ-+F?HK*,?)*^K85_GPZS\0H/ _\ P43U7XK?
M%[2+\VWA#]M*^^(7Q/T%=.L;[5/(\/\ QRE\2>-=(729?[.TV\O_ "[34[(:
M=+]@L;BX_P!&?[+ YV?Z#U?EK^T__P $@?V1OVJ/B5JGQ9\5+\1OA_XU\0_9
MI?%-]\*_$/AW1++Q/J%M"UO_ &QJVE>)?"'B_3TU>ZMQ;IJ%[I5OIKZC+:1W
MU\L^HW&H7E[[OAYQ/E7#N)S:GG%/$?5<TP*POUC#0]I5HN,I\T>7FC)0JPJR
M;G'FE&I3I^XXN4H\^9X2MBHT70<>>C4Y^6;M&5[:WL]8M+1V33>M[7_,_P#X
M*6_\%7? ?[07PHU[]F[]C6?Q!X[B\7Z'JNM?%GXD3>%]3\.Z+9_#+PYHVH>(
M/$WAW0-.\866C^(SJ,\&F^?XBUN_T73;"QT6UDTG07U[4_$/VC0/ O\ @WO^
M&@\0_M,?%KXH75D]S9?#7X2KHEG<-;.T&G>)/B'XCL(["Z%ZES&L%W+X=\*>
M+K&"TEM;A+RUN[^826\E@GG?OS\)?^"8G[&7P=^%WCGX3Z!\+7UG1OBAH:>&
M_B1XB\2^(]>N?'/C'0H]3@U:+2;KQ7I%]HM_X?TM;VSTZ:72_!?_  C&FWDV
MF6-Y?VEUJ$+7;^V_LY_LA_LZ?LF:=XHTO]GWX:67P^MO&M[IE_XIECU[Q9XF
MU'69]%@N[?2([K5_&6O>(M6%EID>H:BUAIL-[%IUI/J6I74%JESJ%Y+/ZE?C
M+AG <*YSPQP[@<TH_791A1QV,6&E4Q<:DZ"Q>(QM2G6@Z<IT(5,/0H4<,X*G
M&$YN$JM2G3PC@,75QE#%XJI1E[.[=.GSI0:3Y(4TXNZ4FIRE*=VVTDU%-_R[
M?\%__B1;>*?VNO!/P_L;B>6+X7?"'1;?58)'3R+7Q)XQUG6/$=RMO$H9@9?#
M;^$I9IY'5I69(EMXTMEGNOZ7/V OAPOPH_8L_9G\$^;)+/:_"/PIKVHF6.6)
MHM8\;6?_  F^MVJI/B98K/5_$5[:0^:D,C0P1L]O;,3;QX/QI_X)R?L8_M#_
M !(O?BY\8O@M;^,OB#J5OH]IJ&O/XY^)FAQWUOH-I#8:5'=Z+X9\::-H%Q]F
MLK:"T9I=+9[JWBCBNVG10*^U;6UMK&VM[*RMX+2SM((;6TM+6&.WMK6VMXUB
M@M[>")4B@@@B1(H88D6..-51%55 'AY_Q3@,QX5X:X=P%'&4GE,75Q\L1"A"
MC5Q;I.//AG2K59S@ZM?%RYJL*,E&<+QE)ODZ<-@ZE+&8O%5)0?MK1IJ+DY1A
M=:3O%).T8+1RU3U[_P &OQV>3]KK_@J7XPT:RU6/5K+XH_M5:=\-M)UF]4&T
M?PEIOC#3?AWHUZT=S]H,FF6?A/1K22W@DA>6;3[>*%;!976Q7^AS_@OIX5U;
MQ#^P[HNKZ;:7=S9^!?CSX!\5:_-;6KW$.GZ3>>&O'W@B&[U"9&5;&T?7?&.B
MV"74@='O[VRL@HDO(W7[2^'?_!-K]B3X4_%>R^-W@/X#Z/HGQ+TW6-4\0:9K
MDOBKX@ZU8:7K.L?:_M>H:9X5U_Q;JGA#3IX3>W#Z4;+08%T*7R9=$73Y+6U>
M'ZU\?> O!WQ2\%^)OAW\0?#^G^*O!7C'1[S0?$GA_5$=[/4],OHS'-"SPR0W
M-M/&=L]G?V4]MJ&G7L5O?Z?=6M[;6]Q'Z^;<>9?B,XX.Q>783&QR_A>C0IRH
M8J&'I5JEG0I8A48T:U:FD\-AZ4:4I3@O:+6$(J[PHY;5C0QU.K.G[7&2E)2@
MY.*WE#FYHQ?QRDY))Z;-O;^3C_@C9_P4%_9W_9)\!?&[P#\??$FI>#DU_P 0
MZ3XZ\(ZI9>%?$OBB'7;J'1CHNJ^'"OAG3]6N+#4L66F7&F3:E:6.CS+/?"\U
MFU>&".7X7_X*1?MP>(OVYOC!8^.K/1_$GAGX+^#XM5\+?"'PUX@%JT]LC#2;
MOQ7K>I/IWGZ7'XL\1M_PC][KVFV.I:LFC:=%X<TG^T]1AM+?4K[^BF+_ ((&
M?L.1^*#X@?6/CQ/I)O9KH>!Y?'WAL>%U@D1U331=P^ X?&OV*W9UDAD/B\ZB
MSQH)[^>,R))]B_$'_@F3^PK\3]-\$Z-XM_9Z\.?V1\.]$N/#W@_2O"_B+QWX
M TW2]-O+QM1OS+8^ ?%7AFUU;4M1U!Y+[4]<UJ+4=;U*\DENK[4;B>61V^D7
M'' . XEJ\38; YUC<?CX-8BI*GAE3R]?5HT6\'AZM:CS5\1R0A7G.O*,*<JO
ML:BC4E2GR_V?F53"+"3J8>G3IM<B3G>K[W-^\E&,K1C=N*44W)1YEHI+Y3_9
M$^!>MZ1_P1<U'X=^'M#NKKQQ\7_V8_CQXCL[&*QN8[_Q%KOQA\.>-[[P8L=E
M%+?S7$EWX?U?PII6GR6B;M2M+>RNX[**:Z: ?SE?\$N_VK/ 7[&/[50^(GQ;
MT;49?"&M>!O%'PXUZ_L=(.J:YX-GU;4]!U:#7[/2GEM[IYK:_P##46BZM';%
MM0BT35M7^S6EY<*ME/\ W:^&O#>@^#?#F@>$/"VE66@^&/"NB:5X;\.:'IL*
MV^G:-H.AV$&F:1I5A;K\L%EIVGVMO9VL*_+%!#&@X6OS&^/_ /P1M_8G_:!\
M5ZMXXO?#?C'X7>*-?O)]2U_4?A'XBT_P_:ZQJEW>37M]J5QH/B'0/%GANVO=
M0FGD-]-IFCV N6)G=3=O)</\]P]QME"EQ9@N(J.,>7\48O$8N5;"*,J^'EB)
MU7*$H\Z:C&$X.E*FJBA*GRNE.G+W>G$X"O\ [%4PLJ:J8.$8*-2_++E4;.]N
MMGS7LVG=--%+Q+_P6R_X)WZ%;Q3:7\6_$OC.23?OM/#7PJ^)-K<0;'@1?-;Q
MAX:\*6A\U9I)4\BZFPEK.)/+D:UCN?T!^"?QL\)_'3X,>"OCKX=L]=\->#/'
M7AK_ (2S3K?QQ;Z;HVLZ;HN^Y'VG6XK'5M7TJS0P6KWHF@U>\M#8R17/VG8Q
MV_EWX-_X(,?L)^&+R*YUM_C1\188[N*Y?3_&7Q"L+&SGAC7:^GRO\/O"O@2_
M%I.?GE>"^AOPW$-["GRU^O>F^"?"FC>"K#X<Z1H=EI7@?2O"UKX)TOPWIJR6
M.G:;X4L=)CT*RT.P6UDBEL[*STB**PM5MY8Y+>".,12(R*P^6S]<%TZ6&H\-
MRSRO6]OS8O%YF\,H+#J+2I4*5&G1YJCG+F<ITX**II)RYY./9AOK[E*6+6'C
M'EM"%'F;YKK63DY:))JR;NV]K(_A;_9:,O[4O_!4WX<>)K@W&J1_$#]J;4?C
M!=QWEDMZUYH^A>*M6^+%Y9WUBMF8!8OHVARVEY!]B@L;/3O-5HK.S@/D_P!Y
MM?%'P2_X)T_L9_LZ?$:#XL_!OX*V7@[X@6MEJ^GV6O'QG\1_$(L+7783;:HF
MG:3XJ\8:YH>GR7-J\MF+BRTV"YM[*>YLK66&UN;B&3[7KMX\XHP/$^-RZ>64
M,5AL!EV6T\'2I8R%&%7VBJ3E.2C0K5X*G[-4(1?M+MP;<8JR,\MP=3"4ZJK2
MA.I5JNI)P<G&UDDKRC%WOS-Z==V%?CU_P7-^(L_@?]@?Q)H%NR(WQ9^)/P[^
M'4DICNFFC@MKZ^^)4ZVTUM<VZ6KW$7PZ>TN)+N.[M9["XO+ VPGO(+FV_86O
MG;]HG]D_]G_]K#0_#OASX_\ P^C\?Z1X3U6YUOP_;GQ)XP\+S:;J5Y:&QNID
MO_!?B'P[J$T=Q:[4EM+JZGLW:.&8VYG@AD3Y_AS'8/+,]RK,L?"O4PN QM'%
MU(8:%.I7E+#R]K25.%6K0IM^VA3;YJL4HW?O-*+Z<53J5</6I4G%3J4Y03FV
MHI2TE=Q4G\+=K)ZV]3\1O^#=7X=S6/PY_:4^+,]HAM_$WC;P1\.],OW%@\D<
MW@;0M4\2Z[:6Q61M3MTF3XA^'9KT310V%X8-/^S27-Q8W2VGY-?\%;?&C?&7
M_@HQ\6M)T":>\B\/ZKX*^$6C+<$R!-4T#0M'TG6K2"&UBGECMX_&EYKT:11B
MYN)6WW'EI+/]CA_M&^!OP!^$'[-G@2'X:?!'P59> _!4.I7FL?V-9W^LZJT^
MK7\5K!>:C>ZIXAU+5]8U"]N(;*TADN;[4+B4Q6T,88)&JCY]U3_@FW^Q/K7Q
MGF_:#U;X'6&H?%JY\;P_$>Y\2W7C3XDRV-SXS@U&+5H]:N/"+>,O^$+G)U*&
M.]EL)?#KZ7/.&>>RDWON_0<M\0,KPW&>?\4XK"8^I''X)X3+:-*GAW4I*$<)
M3I/$QGB80IWI8."G*C4K.+G4M&=[GFU<MK3P&&P<)TTZ<U.LVY)2OSN7(U!M
M^]-VYE&]E=H^H/"FB^'_ (,?"?PWX=N-3\GPK\*/AWH^BSZS>)(OE>'_  +X
M:MK&34[J-&N95V:=I374Z(UQ(,,JM*V"W\0?_!/G2M7_ &DO^"G?PD\3:G=?
M:-1UKXW>)/COKVH:F(VFFN_"\^O?%FXFG21KQGO]0U;2X;>,Q/<20WUW'<?:
M(TA>]B_NIU_0='\4Z%K7ACQ#I]OJV@>(])U+0=<TJ\4O::GH^KV<VGZGI]T@
M*E[>]LKB>VG4,I:*5@""<U\D_ +_ ()[_L>?LP>-)_B)\$/@OI_@[QK/H]WH
M(\077BSX@>,;RTTR_D@DO8=,3QSXL\2VVD3W8MXX+B_TN"SU":R:>PDNFLKJ
MYMYO"X6XLP>0Y;Q5#$4L96S7/,']6P=>E3H2H49RIXN,ZF(G.M3J1O5Q,*CC
M3I55/V234=SHQF"GB:N#<90C1P\^><6Y*4DG3:44HM/2#6KC;F>Y\C_\%SO%
M.I^'_P!@+Q7I-@DC6OCCXD?#3PMK12U2X5-,M-;D\:Q/+,Q#6,9UCP?I*"ZC
M!=Y7CLB/+O)"/QI_X(R?MH?LL?LA67[0\_Q[\17_ (.\2^,X_ DWA?5X/"GB
M7Q6NMZ5X:A\6/>>&K >&-%U>?1K][_5[>YDDU5].TC5 ]C]HOH7TE#7]:/Q@
M^$?@'X\?#3Q?\(OBAH4/B3P)XXTL:5KVDRR20-(D5U;ZA87MG=0,D]EJFD:K
M96.L:1J%NRW&GZK86=[ PE@0C\D-+_X($_L/:?K::K=Z[\?-;L%V[O#6J>/?
M"T.B2;5C!WSZ+\/M(\1C>49F\OQ F&FD";%$*Q>MPSQ+PO2X/S'A?B!9IAXX
MO'_7)U<LA3E4Q$8RP=2FHSJ<T(5%/"1ISC5IRIRI*+4XR?[O'%X3&/'4L9AO
M8R<*7LTJS:47[Z>BU:M-M---.^CZ^_\ _!3J"^^-_P#P3&^-6K?#O2M6UA/%
M7@'X7_$K2=/.F7L>L'PKI7C_ .'OQ'U.YNM*2&6\M;C3O">F7^H7]M)$&LA:
MSBZ:)(99$_G:_P"".?[<GP8_8U^(OQ9L?CBM[HWA3XLZ)X.M;7Q]IOA^^\1W
M'A34_!^H:](MIJ%CI$=UKH\/ZW:>)KJXU&31M-U:\_M#0]%4Z=)$SW%M_:A_
M9FF_V;_8W]G6/]C_ &'^S/[)^R6_]F_V;]G^R?V=]A\O[+]A^R_Z-]D\K[/]
MG_<^7Y?RU^0OQ5_X(:_L+_$OQ!=^(=*TWXF?"-[ZX^U7.D?"KQ=I%AX?,K1A
M)%M-(\9^%?&]OI=O))^_^QZ3]AM()"4M8(+;$ QX4XHX=PV09UPKQ!1Q]/+,
MTQCQE+$X+DJ5Z3MA4J=1NS4J<L%AZE.<:-6$Y>TC5IJ#2;QN#Q4\3A\9AI4G
M5HPY)1J747\>JWT:J235TTK-.YJ>,O\ @N#_ ,$^O#%O)-HGQ \<_$61+1[E
M;7P;\,/%]C<33*ETZV$;?$&Q\"6HNY&MXHT>:YBL0]]:F2]2-+V2S^M/VL/C
M1IG@_P#8>^-7QJB75]&@N_@'K^L>'X+R."QURPUKQQX6.F^#K*^C$UU!8ZC'
MX@\0:/:7HCEO5LY_.,(O3$B3?'?PT_X(;?L(?#W5M*UC5=#^)'Q4FTB\%_%9
M_$OQM#<Z3>SQRI/:)JND^"]"\%6&IV=I+&I.FWD$NG:C$7M=:M-3M)9;=_U"
M^*WPJ\ ?&_X>^)_A5\4O#T?BKP#XRLH=/\2:!+J&K:4NHVMO?6NI6Z#4M"O]
M+U>RD@O[*TNH;C3]0M+F.6!&24<@^'F57@K"X[*)9%#.\3A</C(5LUK9B\+[
M2OAX5J$E2PE*G&C!S=.->[JQI1<I4XWMS./316/G3K?67AX3E!QHQI<]HR<9
M:S;<G:[CI'FT3?:_\A__  0-^'O_  E/[:.N>,YI/+M_AA\'_%FLP?Z-Y_GZ
MMXDU'0_!UK;><R>79@Z7K6N77G)*MS(;06T<4MO/>20?V95\O?LY_L8?LS?L
MF2>*9OV?OA=:> +GQJFEQ>);P^)/&?BN_P!1@T4WKZ;:K?\ C;Q'XDO+"T@D
MU"ZE>STV>SM;J9XYKN*>6WMWB^C]:T?3/$.CZMH&M6<>H:/KFFW^CZM83%Q#
M?:9J=K+97]G*8V201W-K/+#(8W1PKG:RM@A<<<1X;BGB">9X:&)HX-8;"X6A
M#$PI1Q$:=*+E4<J=*M4IW=:K6E!*O+FBXMRA?EB9?A98/#*E-PE4<YSDX.7*
MW*R5G**?PQBF^5>CZ_PB_LPQ7'[7/_!4SP#XAO+"UU>'XE_M1:U\8]6TJ:WM
M_P"R[GP[H?B;6OB]K6F2Z=XCO+I&T./PYH5Y9OHUY=7UT^DQG2[=;^\:""?^
MP'_@H=\2O^%2?L1?M-^-4?RKJ/X4>(O"VF7'VL63V>M?$-(OA[H5]#.;6\#7
M%AK'BFQO+:U:$+?7$$5BUQ9K<&[@I_ O_@G3^QG^S7XZM_B7\%_@K9>$/'5G
M97VGV/B*X\9_$?Q7=6%KJ=K-8Z@EA#XT\8>(K*QDO+*XGM+BXM+:&YDMII(6
ME\MBI]Z^.'P(^%/[2'P^U#X5_&CPK_PF?@+5;[2]2O\ 0?[<\2>'?/O=%O([
M_39O[4\*:QH6LQ?9KN))?+AU&.*;;Y=Q'+$2A]CBCB_*,]X@X=Q='"X^ED>2
MT\#2J8:M3PZQ=2G1Q?M<4J5.GBIT/WF'A1HT^:O#WH-R<4TEA@\#7PV&Q,)3
MIRQ%=U)*<92Y$Y0M#F;@I:2<I.T7H]+G\K'_  ;Z_#4>(_VI?B=\2[O3Y[JP
M^&?PANM/LKU8M16UTSQ3X]\1:38Z;)-=VSQZ>9[KPSH?C6UMM-U/SOMD<EU?
MV=LT^CFYM/.O^"\OA+6-!_;D'B*]M+A-*\<?"7P+JVB7K0@6ERND/K'AG4+:
M"X225);BSN]'\RZ@D%O=6\5[9R26PM;JRNKO^K3]G3]C_P#9R_9-M_%-K^S[
M\-;;X>Q^-?[$_P"$I:+Q'XQ\2W&L_P#"-OKDFA_:KOQCXA\0W:_V<WB/6A#Y
M$T64O3%+YD<%JD&)^UK^Q7\!?VT_!VE^$OC9X?U*YN/#4FI7'@OQCX:U5]$\
M8^"KO64L8M7N-!OGAOM+GCU2'3+"._TOQ!HVNZ'=O96-W-I;W^G:==6GK4O$
M7 KQ GQ++#XQ935P$,K5.I"E]<HX?V5*;J>RA7J4M,;"4W"%=MT)RDKU7[-X
M/*ZG]F+"*5/VZJ.M=.7LY2YFK<SBI?PVE=Q^)+IJ?DI\.?\ @MK^S)\*?V*O
MA;86D/B#Q3^T!X(^%_@WX>O\);?P_KNG:>_B;POX0M=$'B'4/&=[8Q^&[?P1
M<W^EQSS+INK:QXL@BOH;:'0;H17&H0_SP> _#_Q$_:=_;;\&>'?BZNJO\0OC
M1^T'X=M?B4=<T*2UOK&X\5^-+-_%TU[X7E?1S966BZ9<7\Z^'86TJWLM+LDT
MJQ6QMX8$B_KB_9^_X(U?L4_L^^,-,\>66@^-?BEXFT*XM+_P]=?%WQ#I7B"P
MT/5K"^%_::Q9Z%X<\-^$M"NM1MI4@6VEU?3=3AM?LT%Q:P0WHDNY/H7PC_P3
MO_8X\#_&N;]HKP]\&;9?C+/XH\0>-9?&FM^-OB3XKE;Q;XIN+^\UKQ$-%\5>
M,=:\-IJ]Q>:G>WMM>IHZS:7>RK>:4UE<P6\L79@>-N"^&ZN=SR# 9Q5Q.9T,
M14AF&(CAI2CBZKG.AAJ<)U:,L/@*%2?/.7)6Q%67*IQJ*C3DXJ9?C\4L-]9J
M4%&C*"=*+FDZ:Y5*3:C)2JM*R5XQ6MFN9GR'_P %T?B5'X'_ &$M;\+1Z@;2
M_P#BU\1? G@B&VAEA6YO+#3+ZX\?ZGE&1[D6")X-M[>]GMV@4/>6EE<SF#4&
MM+OY"_X-UOAO':^!?VD?B[-%.TNN>+/!OPWTZ=EN4MH8_"NCWWB?6HH6PMG<
M3W+>,= >X4M/<V<=K:E1:Q7S&\_<S]H7]EKX#_M5>&]'\(_'SP%'X^\/^']5
M;7-&L9/$7BWPVUAJKV[6CWL-[X/U[P_J!D:U>2W*R73QF&66/9MED#;?P(_9
M\^#W[,W@*+X8_ _P7;^!?!$6K:EKW]CP:KK^NRS:QJQA^WZA>:OXGU76]<OK
MB9+:UMU:]U*<6]I:VMG;"&TMH(8_D*'%. PW 6*X6H4,8LQQ^9+%XNNX45A'
M1C5P\TH5%7==U'#!X>#BZ$8VY_WC6DNZ6#J3S*&,E*#I4Z7)"-Y.:DU)7:<>
M5*\Y.ZDWMI?5>RT445\&>B%%%% !1110 4444 %%%% !69>_<;ZC_P!"-:=9
ME[]QOJ/_ $(T ?RE_M-RZY-\;_&TOB/Q#X-\5:TW_"._;=>^'XA'A&_V^%-"
M6W_L@0*D0^RV@@L[_8H_XF=O>[LMDGP:O;OVC-)O=#^,OC'2]1^'FG?"J\M?
M[ \[P#I6L6FO6&@^=X8T6XC^SZM833VEW_:D4R:S+Y4K^1-J,EM)MDA=1XC7
M]^<&_P#)(<*_]DWD?_JKPI^'YM_R-<S_ .QAC?\ U)JA1117TAYX4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML)KBTN_[5BFCUN7RI7\B?4I+:3;+"ZJ >K4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>:>;KO\ PN+R/^$B\%_\(S_PK3S?^$2Q#_PL3^W?^$IV
M?\)%G;Y__"%_V?\ \2W&_P G^W.=N_FO2Z\I_LB^_P"%X_V]_P *ZT[^S?\
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MXH\$>+].;2?$>@7<]Y;6^IZ>\L4YMY+C3KFSOH,30Q2I+:W4$T;QJR2*1FO
M/V=OV%_V5?V4-=\0^)_@#\*+?P'K_BG28-!US56\6^/?%EW=:/;WB:@FGP/X
MW\5>)!IUO)>Q07-TNF+9F]EM;,WAG%G:B'YC <986EPKQ3D^.I8NKFG$&/JX
MZ.(I0HO"J>(>&E6=>4Z\*T&YT:DDJ=&JGS13:U:ZZN G+&8.O3E"-'#4XTW&
M3ESVCS<O*E%Q>C2UE'9GY^?\%]O^3'M#_P"R]^ O_47^(%> _P#!NK_R2?\
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MUKSHMJ;4XIQ(P>&QU/#U<)6]@J2HU:=*47)R<ZCD[R=K<BYI?94MM&?S!?\
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ME;$2PT%AJL)*E34E:$90E)II23G+D244U!65G&[1^(7_  <>_P#-FW_=P_\
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MI5(*2JT[N*=2G&,I*#D=^-PRQ>'J4.;E<K.,K7491:DKKL[<K\FVM;'\[?\
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M/"'PSM=5TRSUZ*]+B>Y@U'Q-XC\7:=#;/"L%LNA_;+::<:I(L/J7@7_@@_\
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MS#XZM5H^QE0Q-53J.;ESQ@YN<U%*UI^].,7[T7HWR]/PH_X.$?\ D\_X9?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^5?S>?H!Z+;_ '!]!_6IZ@M_N#Z#^M3T %%%% !1110 4444 %%%% !1110
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MVO8_\- ?V#_PL74?[2_X4[_:_P#PJ3^QKS^R/L/_  FOV/\ X6+_ ,)!Y/\
M9_\ :/G_ /%,_P!C?:/MGV;_ $WR?(^>@#V*BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /AK]M7_@G[\$_V[K3X=6W
MQ?UOXC^'YOAA<>*9_#=_\.M<\/Z/=O%XQBT"/6[/4T\2>%/%MC=6\S^&-&F@
M:*RMKNWEMG$=UY-Q<12>R_LP_LV?#S]DOX-^'/@A\,)_$=[X5\-W6M7\6I>+
MM2M=5\1:G?Z]JMUJ]_>:G=:=INC:7YAFNOL\,6F:/IMI';6\ ^S-<&>XG^@*
M*]*IF^9U<MH9/4QM>>5X:K*O0P3G^XI592JSE.,;7NY5ZTK-M<U24DKNYDJ%
M*-65=4XJM./+*I;WG%**LWVM&*^2"BBBO--0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OE;]L#]C_ .%O[;'PMT[X2_%K4?&>D:!I
M'C/2?'FF:GX#U;2M(UZSU[2-*U[1(&6?6]!\2:7-:3:7XDU>UN;:ZTB?=YZ3
MP/!<P0S)]4T5T83%XG 8FCC,'6GA\5AZBJT*U-VG3G':47JK[IIIIIM--.Q,
MX0J0E"<5.$E:49*Z:[,^1/V./V*OA%^P_P" ?$7P^^$>H^-]:T_Q5XID\6ZU
MK'C_ %G2M8URYOSIEAI-O:QMH.@>&-'M["SM;!3;I!HT=T\MQ</=WET/LZV_
MUW113QF,Q688FMC,;7J8G%8B7/6KU9<U2I*RBG)^48J*22222222%3IPI0C3
MIQ4(15HQ6R6^GSU"OSU_;/\ ^":OP*_;G\3>"_%GQ:\6?%[P]J7@70M0\/:3
M;_#SQ1X;TO2[BQU'4%U*::]TWQ3X,\86R7ZSKL-]IB:;/=VX@M]2:]CL--%G
M^A5%:9?F..RK%0QN78FKA,534XPKT6E.,:D7":5TU:49.+33T8JM*G6@Z=6"
MG!M-QELVFFON:3/"OV;OV=?AM^RM\(O#GP5^%%G?V_A+PY/K%['=ZU/:7WB#
M5]1UW5KS5]0U/7]4M+#34U._:6[%E!</:1FVTJRTW3(52TL+:-/=:**PQ&(K
MXNO6Q6)JSKXC$59UJ]:I)RJ5:M23G4J3D]7*4FVWW948QA&,()1C%*,8I62B
ME9)+LEH%%%%8E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >H?"_P#Y"&J?]></_H^O:*\7^%__ "$-4_Z\X?\
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M)JU7B:&(ESUL-5<7+EC'F@VTG:*C'>+U2V<7K>[Z*BBBOSL],**** "BBB@
MHHHH **** "BBB@ HHHH **** "O-/@_=^(;_P"'7AV[\5ZMX US7Y?[7^WZ
MI\+KB6Z\"W7EZ[J<=K_8<\T<4K^19);6^I[D7;K$.H(N54$^EUY3\$-(OM"^
M%_AC2M2^'6G?":]M?[:\[X?Z3K-GK^GZ!Y_B'5KF/[/J]A-<6EW_ &K%-'K<
MOE2OY$^I26TFV6%U4 ]6HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBOG:7]K[]DR#6!X=G_:A_9VA
M\0->0Z<NA2_&SX:QZP=0N'2*WL!IC^)A>F\GDEBCAM1!Y\KR(B(S.H.]'#8G
M$\_U?#UZ_LTG/V-*I5Y$[V<^2,N5.SLW9.S[$RG"-N:48WT7-)*[[*[5SZ)H
MJ"UNK:^MK>]LKB"[L[N"&ZM+NUFCN+:ZMKB-98+BWGB9XIX)XG26&:)VCDC9
M71F5@3/6#33::LUHT]T^S*"BBB@ HJIJ&H6&DV%[JNJWMIIFF:9:7.H:EJ6H
M7,-G8:?86<+W-Y>WMY<O';VEI:6\<D]S<SR1PP0QO+*Z(C,/+? W[0/P%^)^
ML7GAWX:_&WX1?$/Q!I^[[?H7@;XD^#?%NL6.P7!?[9IF@:UJ%[;;1:71;SH$
MVBVN"<>3)MUA0KU*=2K3HU9TJ23JU(4YRITD]G4G&+C!/IS-7$Y132<DG+9-
MI-^BW?R/7:\^^*_Q.\*?!?X:^./BQXYN+NU\(?#[PUJOBKQ!-I]E-J-^-.TF
MV>YFCLK&#Y[F[G*K!;1%HHC-(AGGMX!)/'Z#7Y)_\%MOB/)X!_8#\?:7;WB6
M5[\4/&'@+X<6KE2TT\=QK)\8ZK9VS>=&L;W>@^#-6@N&>.Y#6+W<:PI)(EU;
M>AD67_VMG.598^90QV/PN&J.&DHT:M:$:TT[2LX4G.=[-+ENU8RQ%7V-"M5T
MO3ISFK[.2BW%;K=V6Z/3?V-O^"H/P!_;@^(7B3X:_"CPA\8_#VN^%_!ESXYO
M[OXA>&O"6EZ++I%KK>B:!+;6M_X9\=^+G&J->:_92PVEY;6B7%I%>S0SN;22
M.OT?K^93_@W4^'*IIW[2_P 7+A@S7-[X#^'.DJH@W1K90:UXF\0M*2C70$QO
M_# MQ')! Q@N3,EU(L#6?]-=>QQOE>6Y+Q)C\KRJ-6.%P<<-!^VJNM-UJF&I
M5JOON,7:,JO);6SB[.VBPR^M5KX2G6K-.<^9^ZE%<JDXQT3>Z5_GL%%%%?)'
M:%%%>+V7[2/[.^I>,5^'>G?'OX+ZA\0'NX-/3P+9?%+P-=>,7O[DP+;62^&(
M-=DUMKNX:ZME@MA8F:4W$ C1C-'NUI4*]=3=&C5K*E'GJ.E3G45."WG/DB^2
M/]Z5EYB<HQMS22N[*[2N^RON_)'M%%%9'B#7=*\+:#K?B;7;K[#H?AW2-2UW
M6;WR+FZ^QZ5I%G-J&HW7V:SAN+NX^SVEO--Y%K;SW,NSRX(9965&SC&4I*,4
MY2DU&,8IN4I-V226K;>B2U;T0]MS7HK^5'_@G?\ \%(_VY/VKOVX_AW\.?&7
MQ<LH/A7KEUXW\1^)?!.G_#;X;QV4'AW0/"&OZQ8Z';:[:^#H?%D,;ZM;Z19?
MVG/XDBN096EDFN69=.N?ZKJ^AXEX9QW"N-HY?F-;!U<16PE/&6P=2M5A3IU:
ME6E&%25;#T/WO-1FVH*<>7E:F[G+A,73QE.56E&<8QFZ?[Q13;2C)M*,I:6D
MM[.]]#R+Q%^T#\!?!_C.W^''BWXV_"+PO\0[O[#]E\!^(OB3X-T3QG<_VFGF
M:;]G\+ZGK5KKDW]H1_O+'R[%OM:?-!YB\UZ[7\N/BC_@A+^T)\2/VH?$_P 1
M_B-\9/A+JWPJ\9?%W7_&OB;4(-1^(<_Q(U7PMJ_B*\UN6Q'AZ[\.)IMIK-_:
MS)I,@/Q)NX](29[RWU75'LXK>Z_J.J^(<LR++898LGSO^V:V(PTJN8<N'=&E
MA*MJ7LX0E)MR<W*LI4Y>_25.+FVZB45A:V(JNM[?#^P49I4KRYG..MV[::>[
MJM'=JWNW917BOCK]I/\ 9U^%VM/X;^)GQ\^"OPZ\11QQS2:!XZ^*?@;PCK21
M300W,,KZ5X@UW3[Y8Y;:YM[B-V@"R03PRJ3'*C-VO@?XE?#GXG:8VM?#7Q_X
M)^(6C)Y._5O _BK0O%FF)]H5V@W7^@7^H6J^>L<C0YE'F+&Y3<%8CPIX3%0H
MQQ$\-B(4)V<*\Z-2-&2E\+C5<5"7-TM)WZ'2IP<G%3BY+>*DG)6WNKW5CM:*
M**YR@HKQ>R_:1_9WU+QBOP[T[X]_!?4/B ]W!IZ>!;+XI>!KKQB]_<F!;:R7
MPQ!KLFMM=W#75LL%L+$S2FX@$:,9H]V'^U+^TG\/_P!DSX)>,?C;\1;C=I7A
MNVBM]'T&WN8(-7\8^*M2<V^@>$M"2;>TVHZK=Y>>6*"Y72-&M=5\0WT2Z5H^
MH3P]E/+\=5Q&&PD,)B'B<9.G#"T94IPJ5Y5I*%)4E-1YE.4DE)>[K>]M2'4I
MQC.;G'D@FYRYDU%15W=K:RZ;GR%_P4P_X*&C]B/P9X5T/X>Z%H/C[X__ !'N
M)YO!_@O61J>H:;HOA;2'WZWXS\3Z-X>O+#6[G3I)$.B:!81:IH3:QJ!U:_L]
M1N+;PEK=D_G?_!)[]O;X_?MV6_QNUCXO^%?A;X8T+X;3> M,\-R?#KP[XMTJ
M35]7\3IXLNM;34;OQ+\0/%J,FC6>B:.T=M:V-J\C:V)7NR(1"WY37?PO^(FL
M?LL?MA_\%5_VI+2"R^+OQP\)KX9_9R\.:D%AM/"O@GXLS:7\.XO%/AO3+AK[
M48V;P)XE.@?"M[HQZKIGA+2-1\<75QJ4GB#2O%&G_IK_ ,$&OAJ?!O[#[>-+
MC3X(;OXN_%;QOXKM=3\O3C>W^@^'/[-^'=E:O<VKR7W]GZ=KGA#Q.]G8ZH89
M;:\O]5N[6V6TU**YN_U#-<DX?R?@?,53H8?&YQALTP>4ULXYG)?VK)4L=F&%
MP/O.#P^"PL?J?M+*56JL54Y*>C/'HXC$U\PI7E*G0E1J5HT-OW*;ITIU-+\U
M2;Y[=(\BNU='[4T445^1GMA1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-/@_=^(;_P"'7AV[
M\5ZMX US7Y?[7^WZI\+KB6Z\"W7EZ[J<=K_8<\T<4K^19);6^I[D7;K$.H(N
M54$^EUY3\$-(OM"^%_AC2M2^'6G?":]M?[:\[X?Z3K-GK^GZ!Y_B'5KF/[/J
M]A-<6EW_ &K%-'K<OE2OY$^I26TFV6%U4 ]6HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\T^U^(?^%Q?8/[6\ ?\(I_PK3[7_8?VB7_ (6G_P )
M#_PE/D_VM]E\OR/^$ _LW_0_M'F^;_PD7[OR]GS5Z77E/]D7W_"\?[>_X5UI
MW]F_\*I_LC_A;?\ ;-G_ &O]N_X2_P"V?\*Z_P"$?\[^T/[.^S_\5-_;/V?[
M']I_T+SO.^2@#U:BBB@ HHHH **** "BBB@ HHHH **** "BBOGNY_:X_92L
M]6@T&[_:<_9ZM==NKB*TM=%N?C1\-X-6N;N>Y:RAMH-.E\2K>37$UXK6D4,<
M+227*M BF4%!O1PV)Q'-]7P]>OR).?L:52KR)WLY<D9<J=G9NU[/LR93A&W-
M*,;Z+FDE=]E=JY]"45!:W5M?6UO>V5Q!=V=W!#=6EW:S1W%M=6UQ&LL%Q;SQ
M,\4\$\3I+#-$[1R1LKHS*P)_E(_X*6_\%-_VUOV>_P!M[XP?"3X1_%^V\*_#
MKP3_ ,*U_L3PR_PZ^&&O(/[=^%G@?Q;J_P!KU?Q'X-U?Q!<?;M8UW46;&KQ_
M9[>2."S^S")&'N<,\,9AQ7F%;+<OJX2A7H82IC9RQM2M2I>RI5L/0E%.CA\1
M/VCGB(-1<%'E4VYII*7/B\72P=*-6JIRC*:IKV:C)WE&4D_>E%6M%ZWOMH?U
M?45SG@[6+GQ#X1\+:_>I!%>:YX<T/6+N*U61+:.YU+3+6]G2W266>5($EG=8
M5EFFD6,*'ED8%ST=?/2BX2E![QDXNVUXMI_BCI3NDULTG]X4445(PHHKQ/Q9
M^TM^SCX"UP>&/'7[0'P3\%^)3.UJ/#WBSXJ^!/#FN&Z258&MAI.L:]9W_GK.
MZ0M#]G\Q966,J'8 ZT</7Q$G##T:M>:7,XT:<ZLE%;MQA&327>UB92C%7E*,
M5M>325^UVT?/'[:/_!13X#?L+3^!;#XMZ5\1_$.K_$&'6+O1=(^'7A_1-7N[
M?3=$>SAO-2U.Y\2^)_".E06[75]!:P06VI7FH/*7D>RCME\\_0/[-G[0/@G]
MJ;X*>"/CQ\.K+Q'IO@[Q['KTFD6'BZQT_3?$5JWASQ1K?A'4X=3LM*U77-.A
MD35] OQ";35KV&:V\B=909"B?S;?\'#VH6&K>.OV5=5TJ]M-3TS4_AYX\U#3
M=2T^YAO+#4+"\UCPQ<V=[97EL\EO=VEW;R1SVUS!))#/#(DL3NCJQ_7_ /X(
MU?\ *-O]G'_NK_\ ZOGXHU]_FW#.6X+P_P AXBI1Q"S/,,R>&Q+G5O2]E_PJ
M^["CRI0<7@Z.MW+X[WYM/.HXNK/,\3A6X^QI45.%H^]=JAO*^J_>2_#L?;&F
M_M%_L^:SXT'PWT?X[?!O5OB&9Q:CP%IOQ/\ !-]XT-R8XYA;CPM:ZY+KAG,,
ML4HA%CYACDC?;M=2?9*_E[^!G_!#/]HWX:?M4_#'XP^)?C+\)-:\"_#KXS^$
M/BC-?1:AX[U3XA>);;P?XSTSQ:MK?Z5J'@_3M'AUC76T]K:_U!_%M[':W%P]
M\$OR#;-_4)7@<2Y9D>65L'#(\[_MJG6PWM,345%T50K<UE!?XU[W([SIVM-M
MM'1A*V(K1F\1A_J[C.T(\W-S1M>_R>G9] HKQKQS^T;^SU\,-5FT+XE_'?X-
M?#S6[;[*+C1_'/Q0\$>$M5@-[;?;+(3:?K^N:?=Q?:[/_2[7?"OVBV_?Q;XO
MGKL/ _Q*^'/Q.TQM:^&OC_P3\0M&3R=^K>!_%6A>+-,3[0KM!NO] O\ 4+5?
M/6.1H<RCS%C<IN"L1X4L)BH48XB>&Q$*$[<M>5&I&C+FUCRU'%0?,FFK2=[Z
M'2IP<G%3BY*]XJ2<E;>ZO?3J=K117AWC+]IS]FSX<ZO+H'Q"_:%^!W@378'E
MCFT7QE\6? 7AC5X9('$<\<NFZWK]C>1O"Y"2J\(:-R%<*3BIHX>OB9<F'H5J
M\TKN%&G.K)+ORPC)V\[6"4HQ5Y2C%;7DTE?M=M'N-%8GASQ+X<\8:+8>)/"7
MB#1/%/AW58Y)M+U_PYJMAK>BZE%%/+;2RV&JZ9/=6-Y''<P36\CV\\BI/#+$
MQ$D;J-NLI1E"4H3BXRBW&49)QE&479QDG9IIIIII--692::NG=/5-;-=S$\1
M^)?#G@_1;_Q)XM\0:)X6\.Z5''-JFO\ B/5;#1-%TV*6>*VBEO\ 5=3GM;&S
MCDN9X;>-[B>-7GFBB4F21%/)_#KXQ?"/XP6FIW_PD^*?PX^*5CHMQ!9ZQ>_#
MKQQX9\;VFDW=U$\UM:ZG<^&=4U.&PN+B&-Y8(+IXI9HD>2-6121\U_\ !0O]
MF#QE^U_^R[XR^"/@+QE8>"_$NLZKX7UNQN-<GU6W\+:VWAO6K;5ET#Q5)HUM
MJ%^NCW$\$.H130Z5JQM-9TS2;X:=.]JC1_%7_!*K_@F7\7/V&?&?Q0\<?%CQ
MY\.?$=WXV\(Z/X6TO1OAY-XFU6WM_LNN3ZK?7^H:MXD\/^$Y(O+CMM.BM;6V
MTFZ^TO>7IFN+-=.@_M3Z3"Y9D=7AW'YEB,[6'SJAB%3PF3^PE)XFE?#KVCJ=
M.95*SO%\L%1]Z]VER3K8B.*ITH8?FP\HWG7YDN27O:6\K1TW?-IL?MA117 _
M$'XK?"[X2Z9;:U\5/B3X!^&>C7MP;.SU;X@^,?#O@S3+N[ 5C:VU_P"(]1TV
MUGN K*3!%*\H#*=N",_.TZ=2M.-*E3G5J3=H4Z<)3G)[VC"*<I.R;LDV=3:B
MFY-)+=MI)>K>AWU%<CX)^(/@+XF:&GB?X<>-_"'Q \-2SO:Q^(?!/B71O%>A
MR7,<,%Q);IJV@WM_8/.D%S;3/"MP9%AN()"H26-FZZE.$Z<Y4ZD)4YP;C.$X
MN$XR6ZE&23BUU328)II---/5-.Z:[IK<***Y7QAXZ\$?#S25U_Q_XR\*^!M"
M>[AT]-:\8>(=(\,Z2U_<I-);V2ZEK5Y96;7<\=O/)#;"8S2I!,R(RQN5(0G4
ME&%.$ISFU&,(1<I2D]E&,4VV^B2;8-I*[:26[>B7S.JHKPKP=^U'^S-\1-<M
M_#'P_P#VBO@5XZ\2W8W6GA[P=\7/ 'B?7+I?-B@W6^DZ)X@OK^8>?/!#F.W8
M>;-%']^1 WNM:5L/B,-)0Q%"M0FUS*%:E.E)Q>TE&<8MI][6%&49J\)1DN\6
MI+[TV%4=4U*RT;3=1UC4IOLVG:58W>I7]QY<LWD65C;R75U-Y-O'+/+Y4$4C
M^7#%)*^W;'&[E5.7XH\7^$_ ^D2Z_P"-?%'AWPAH4#K'/K7BC6]-\/Z1#(R2
M2+'+J6K7-I9QNR12NJO,K%(Y& (1B/$[OX[_  /^+OP_^)]E\)_C+\*?B?>:
M;X \776HVGP\^(GA#QK<V%LNB7$37%[!X;UC4Y;6!9;NUB::=(XQ)<VZ%@TT
M8;2AA*];EJ*A7EAU4A"I7A3FZ<.:48^]4Y7"+][3F>[6C"4XI\O-%2:;46U=
MV[*]W\CXV_9O_P""P?[+O[4?QV\-?L_?#CPO\:K+Q7XOD\4IX?U[Q7X5\'Z9
MX2O5\)^'-;\5WLS76G?$#6-?M8[W1O#]_/IPN_#L$K2F"WOHK&61E3]5Z_A+
M_P""-7_*23]G'_NK_P#ZH;XHU_=I7VOB/PYEO#&=X3 97&M'#U<IH8N:KU76
MFZT\7CJ$FI.,;1<,/3]U*RES-63LO/RK%5<7AYU*W*Y1K2@N6/*N50IR6EWK
M>3U"BBBO@#T@HHKY[U_]KC]E+PIJ<^B^*?VG/V>O#>LVW_'SI.O_ !H^&^CZ
MG;Y9E'GV&H^);:ZBRR.O[R)?F1AU4@;T,-B<3)QPV'KXB44G*-"E4JRBF[)M
M4XR:3>B;ZDRG"%G.48IZ)RDHW?97:/H2BL3PYXE\.>,-%L/$GA+Q!HGBGP[J
ML<DVEZ_X<U6PUO1=2BBGEMI9;#5=,GNK&\CCN8)K>1[>>14GAEB8B2-U&W6,
MHRA*4)Q<91;C*,DXRC*+LXR3LTTTTTTFFK,I--73NGJFMFNX450U75=+T'2]
M2US7-2L-&T71K"\U76-8U6\M].TO2M+TZWDO-0U+4M0O)(;2QL+&TAFNKR\N
MIHK>UMXI)YY$B1F'F/@;]H'X"_$_6+SP[\-?C;\(OB'X@T_=]OT+P-\2?!OB
MW6+'8+@O]LTS0-:U"]MMHM+HMYT";1;7!./)DVZ0P]>I3J5:=&K.E2LZM6%.
M<J=)/9U)QBXPOTYFB7**:BY14GLFTF_1;OY'KM%%<KXP\=>"/AYI*Z_X_P#&
M7A7P-H3W<.GIK7C#Q#I'AG26O[E)I+>R74M:O+*S:[GCMYY(;83&:5()F1&6
M-RL0A.I*,*<)3G-J,80BY2E)[*,8IMM]$DVQMI*[:26[>B7S.JHKQ[P!^T/\
M /BOJ<^B_"WXY_![XE:Q;1K-<Z3X ^)O@KQEJ=O"R3R++/8>'=;U&ZBC:.VN
M9%DDB52EO.P.V*0K[#5UJ%;#S=.O1JT*B2;IUJ<Z<TI*Z;C-1E9K5.UFM@C*
M,E>,E)=XM-?>KH**\B\??M _ 7X4WJ:;\4?C;\(OAMJ,GE^78>/OB3X-\'7L
MGFQ">+9:^(=:TZ=O,@(FCVQG?$1(N4.ZM_P%\5OA=\5+2[O_ (8?$GP#\1['
M3_L9O[WP%XQ\.^,+2R&H1236!N[GP]J.HPVWVZ&&:6S\YT^TQ1220[T1B+>$
MQ4:*Q,L-B(X=VM7=&HJ+NTE:JX\CNVDK2U;26K%SP<N53BY?R\RYONO?\#OJ
M**\B\??M _ 7X4WJ:;\4?C;\(OAMJ,GE^78>/OB3X-\'7LGFQ">+9:^(=:TZ
M=O,@(FCVQG?$1(N4.ZHHT:V(FJ="C5KU&FU3HTYU)M+=J,%*32ZNV@Y2C%7E
M)17>327WL\E_;$_;2^$'[$7P_P!#^(?Q>M/&>JV/B7Q+%X5T+1/ >BZ?K.O:
MAJ+6-UJ5Q(JZUK7AS1+6TL;*TEGN9;[6[663<D=E!=S%HUM?L>?MA_"_]MOX
M7ZO\6/A/I'C?1/#VA^-]5\ :AI_C_2M%TC7(]<TC1?#NOW$D=OH'B+Q1ITMA
M+IWBC2WM[A-4,K2FXBEMX6A^?\?_ /@O]XE\.>,/V7_V=_$GA+Q!HGBGP[JO
MQBU*;2]?\.:K8:WHNI11>#O$%M++8:KID]U8WD<=S!-;R/;SR*D\,L3$21NH
M]3_X-[O^3,/B;_V<]XT_]53\%J^_J<,9=2\/(<1RAB8YL\TEA9\]1JE"G'%5
M,.Z;H."Y9)0NW)\ZFY7=K17FK%U99F\*G'V*H\ZLO>;<8ROS7VUTM96^\_=J
MBBBOSL],**^>[G]KC]E*SU:#0;O]IS]GJUUVZN(K2UT6Y^-'PW@U:YNY[EK*
M&V@TZ7Q*MY-<37BM:10QPM))<JT"*904'OMK=6U];6][97$%W9W<$-U:7=K-
M'<6UU;7$:RP7%O/$SQ3P3Q.DL,T3M')&RNC,K G>MA<3AU%XC#UZ"G=P=:E4
MI*:6[BYQCS6NKVN3&<)7Y91E;?EDG;ULW8GHJIJ&H6&DV%[JNJWMIIFF:9:7
M.H:EJ6H7,-G8:?86<+W-Y>WMY<O';VEI:6\<D]S<SR1PP0QO+*Z(C,/GVT_;
M#_9'O]3CT6Q_:F_9RO=9EN'LXM)M/C?\,[C4Y+N,LLEK'80^)WNGN(V1P\"Q
M&52C!E!4X='"8K$*<L/AL17C3^.5&C4JJ%]5SN$9*.FNM@E.$;<TXQOMS22O
MZ7:N?1M?"W[:W_!07X*_L(0_#>7XO>'_ (E^(7^*,GBV/PY;_#G1/#6L36Z^
M"U\--K,VK-XE\8>$;>VC)\5Z2EF+:>]FG9K@M%$D.]ON*UNK:^MK>]LKB"[L
M[N"&ZM+NUFCN+:ZMKB-98+BWGB9XIX)XG26&:)VCDC971F5@3_,=_P ''O\
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M*C/1I^ZWHT]A*<)-J,HMK=*2;7JD[KYFE1116!04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZA\+_ /D(
M:I_UYP_^CZ]HKQ?X7_\ (0U3_KSA_P#1]>T4 <+\1?\ D6Y/^ORT_P#0GKP&
MO?OB+_R+<G_7Y:?^A/7@- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?QX?\'!GBO^U?VN_AKX5@N(Y;7PG\!-!GN(A;RQS6NM>(O''CRZO(I)
MY$1;F.31['P]<1>09(86EF0R^?Y\47](G_!._P (VG@G]AC]E+1K*;[1#>_
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MQ!9Z1#K^HF1(?[-OVV_^3,/VNO\ LV'X^?\ JJ?%E?R ?\%@_P!FGX.?LO\
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M.-A]K_MO_A'/%/E?8\^;Y']D2_:/]7YT'WZ_<O1_^#BW^UM7TK2O^&._L_\
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MG;]B^&OC#4//\S/F?VGXHL[;R?*V#9Y']D[_ #/,?S/M&W9'Y6Z3]E_^"/\
MI_\ 9G_!.3]FRV\[S_,TWXCZAO\ +\O;_:WQB^(>J^3MWR9^S_;?(\S</-\O
MS=D>_P M/J^)?WGA1P=5J:U89C[&#W?L?9YO%*ZV2C1HJWDKZHX\+IG6.BOA
M=%2?^*]!_G*1^E5%%%?CA[@4444 %%%% !1110 4444 %%%% !1110 4444
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MZC:2>#39A?RW+0W/]2OQ02T_9*_X)6^)='>*Z@N_AI^R-%X)@\^'?.?&^L>
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MU>?LA_#Z+X5_LL?L[_#V.WM[:?PM\&OAUIVJK:%C;S^(&\+:9=>)+^,M+/\
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MZ6%K>76TDTZW=-7D@;#02:DI%X\+?-&TQ0\J:_F_Z0?_ #2/_=?_ />*?H'
MO_,T_P"Y'_W</TO^%W2W^B?R6OM7PU_Q[1_A_*OBKX7=+?Z)_):^U?#7_'M'
M^'\J_F\_0#T6W^X/H/ZU/4%O]P?0?UJ>@ HHHH **** "BBB@ HHHH ****
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MC5?#VE3Z7J&I>+?%&DW*SP'3]2TS3+6'3-,U2%IKW2]7U[3-0LH!-:_;+/\
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M#1HI5*5.<HNG/5S?N>]973YE9-+EE**29^T/_!+'_@G_ /M'_L-?%_XV:?\
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MO"%Q=7&H^']0TJ]\8+X)URXN8=&FEBU>\\'WE[<^)_!^KZ8]RLE]8P&UDO\
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M'H,&HZO?7-QJ-_>Z/<:IJ^D1-=[A;:'9Z':PSRK$T5O^&O[>/['7_!1'X&?
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MVY7XMKIEY]KDM[J0Z_J%EJ^E6<DD\\S13W":[=6TBW"32S-<*LUJ9[GR5?\
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M"ZMHXK+4];L],BOJ_ CXU?\ !/+]OG_@G;K.H?&7P!K>MW'AKPW'J<LGQD^
M_B+7K.XTKPM;WNG2E_'&D0IIFNZ/I5^C6<NO:9>6^N>%%-E?0WVJ:EIEFM]<
M?LG_ ,$=?^"E7Q+_ &I=7\5_ +X^:CI>O?$+PKX4'C'P=XZ2WM='U7Q9X=TV
M\TG1-9T?6M-L+&VTF]UW29M2L=334[-K6^U2PN;Z6ZTZ9M*O-3D]3CBKGV;9
M#G&893GF59]PIB'AYU,+2PU&GC<IA0Q.'KQ5.I22J5'3G3A[?ZU/VT:-6I_L
MT8KGCCE\<-0Q-"E6P];#8R*DE-SDZ=9RA*.J>BNF^507+S)>\WH?OA1117\^
M'TP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;^$O@O\ MJ^ENHK1OA#\$O''B_4M29K>Y+%HO$WB;X@6"Q:8EA?7K306=M%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX$MO#GC1-0M(]%TVSO[S7--/B6;PI<:EI$=G<Q7L%OLNK>XM!/;R_P ]&O\
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M5\7OA1\6?B#XX^,_BS78=4\+:;X,\3^(?B;X:L=+L-.DT34?$?@'P_HUW>>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@NI_F?$%%?;_P#PJG2_^@%IW_@NM_\ XQ1_PJG2_P#H!:=_X+K?_P",4?\
M$?LH_P"B?S+_ ,*L+_\ (^O]/0_U'Q?_ $'8?_P74_S/B"BOM_\ X53I?_0"
MT[_P76__ ,8H_P"%4Z7_ - +3O\ P76__P 8H_XC]E'_ $3^9?\ A5A?_D?7
M^GH?ZCXO_H.P_P#X+J?YGQ!17V__ ,*ITO\ Z 6G?^"ZW_\ C%'_  JG2_\
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M3I?_ $ M._\ !=;_ /QBC_A5.E_] +3O_!=;_P#QBC_B/V4?]$_F7_A5A?\
MY'U_IZ'^H^+_ .@[#_\ @NI_F?$%%?;_ /PJG2_^@%IW_@NM_P#XQ1_PJG2_
M^@%IW_@NM_\ XQ1_Q'[*/^B?S+_PJPO_ ,CZ_P!/0_U'Q?\ T'8?_P %U/\
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M_@NI_F?$%%?;_P#PJG2_^@%IW_@NM_\ XQ1_PJG2_P#H!:=_X+K?_P",4?\
M$?LH_P"B?S+_ ,*L+_\ (^O]/0_U'Q?_ $'8?_P74_S/B"BOM_\ X53I?_0"
MT[_P76__ ,8H_P"%4Z7_ - +3O\ P76__P 8H_XC]E'_ $3^9?\ A5A?_D?7
M^GH?ZCXO_H.P_P#X+J?YGQ!17V__ ,*ITO\ Z 6G?^"ZW_\ C%'_  JG2_\
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M3I?_ $ M._\ !=;_ /QBC_A5.E_] +3O_!=;_P#QBC_B/V4?]$_F7_A5A?\
MY'U_IZ'^H^+_ .@[#_\ @NI_F?$%%?;_ /PJG2_^@%IW_@NM_P#XQ1_PJG2_
M^@%IW_@NM_\ XQ1_Q'[*/^B?S+_PJPO_ ,CZ_P!/0_U'Q?\ T'8?_P %U/\
M,^(**^W_ /A5.E_] +3O_!=;_P#QBC_A5.E_] +3O_!=;_\ QBC_ (C]E'_1
M/YE_X587_P"1]?Z>A_J/B_\ H.P__@NI_F?$%%?;_P#PJG2_^@%IW_@NM_\
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M7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M12W_ +H_[YH ^&/^%6_]._\ X[_]>C_A5O\ T[_^._\ UZ^Y_P#A%+?^Z/\
MOFC_ (12W_NC_OF@#X8_X5;_ -.__CO_ ->C_A5O_3O_ ..__7K[G_X12W_N
MC_OFC_A%+?\ NC_OF@#X8_X5;_T[_P#CO_UZ/^%6_P#3O_X[_P#7K[G_ .$4
MM_[H_P"^:/\ A%+?^Z/^^: /AC_A5O\ T[_^._\ UZ/^%6_]._\ X[_]>ON?
M_A%+?^Z/^^:/^$4M_P"Z/^^: /AC_A5O_3O_ ..__7H_X5;_ -.__CO_ ->O
MN?\ X12W_NC_ +YH_P"$4M_[H_[YH ^&/^%6_P#3O_X[_P#7H_X5;_T[_P#C
MO_UZ^Y_^$4M_[H_[YH_X12W_ +H_[YH ^&/^%6_]._\ X[_]>C_A5O\ T[_^
M._\ UZ^Y_P#A%+?^Z/\ OFC_ (12W_NC_OF@#X8_X5;_ -.__CO_ ->C_A5O
M_3O_ ..__7K[G_X12W_NC_OFC_A%+?\ NC_OF@#X8_X5;_T[_P#CO_UZ/^%6
M_P#3O_X[_P#7K[G_ .$4M_[H_P"^:/\ A%+?^Z/^^: /AC_A5O\ T[_^._\
MUZ/^%6_]._\ X[_]>ON?_A%+?^Z/^^:/^$4M_P"Z/^^: /AC_A5O_3O_ .._
M_7H_X5;_ -.__CO_ ->ON?\ X12W_NC_ +YH_P"$4M_[H_[YH ^&/^%6_P#3
MO_X[_P#7H_X5;_T[_P#CO_UZ^Y_^$4M_[H_[YH_X12W_ +H_[YH ^&/^%6_]
M._\ X[_]>C_A5O\ T[_^._\ UZ^Y_P#A%+?^Z/\ OFC_ (12W_NC_OF@#X8_
MX5;_ -.__CO_ ->C_A5O_3O_ ..__7K[G_X12W_NC_OFC_A%+?\ NC_OF@#\
MVOB?\+-;;P-K@\.?\(7:ZR?[,^QS_$-9!X/C_P")QIYN/[8\J*XD^:T\]-/V
MQ/\ \31K+.U<LO??\*M_Z=__ !W_ .O7TA\</ 4.K_"_Q/IZ_#?_ (6TUQ_8
MN/A\-<_X1D^(/*\0Z3.?^)YM?[%_90B_MO[I^T_V;]DX^T9'J_\ PBEO_='_
M 'S0!\,?\*M_Z=__ !W_ .O1_P *M_Z=_P#QW_Z]?<__  BEO_='_?-'_"*6
M_P#='_?- 'PQ_P *M_Z=_P#QW_Z]'_"K?^G?_P =_P#KU]S_ /"*6_\ ='_?
M-'_"*6_]T?\ ?- 'PQ_PJW_IW_\ '?\ Z]'_  JW_IW_ /'?_KU]S_\ "*6_
M]T?]\T?\(I;_ -T?]\T ?#'_  JW_IW_ /'?_KT?\*M_Z=__ !W_ .O7W/\
M\(I;_P!T?]\T?\(I;_W1_P!\T ?#'_"K?^G?_P =_P#KT?\ "K?^G?\ \=_^
MO7W/_P (I;_W1_WS1_PBEO\ W1_WS0!\,?\ "K?^G?\ \=_^O1_PJW_IW_\
M'?\ Z]?<_P#PBEO_ '1_WS1_PBEO_='_ 'S0!\,?\*M_Z=__ !W_ .O1_P *
MM_Z=_P#QW_Z]?<__  BEO_='_?-'_"*6_P#='_?- 'PQ_P *M_Z=_P#QW_Z]
M'_"K?^G?_P =_P#KU]S_ /"*6_\ ='_?-'_"*6_]T?\ ?- 'PQ_PJW_IW_\
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M_"*6_P#='_?- 'PQ_P *M_Z=_P#QW_Z]'_"K?^G?_P =_P#KU]S_ /"*6_\
M='_?-'_"*6_]T?\ ?- 'PQ_PJW_IW_\ '?\ Z]'_  JW_IW_ /'?_KU]S_\
M"*6_]T?]\T?\(I;_ -T?]\T ?#'_  JW_IW_ /'?_KT?\*M_Z=__ !W_ .O7
MW/\ \(I;_P!T?]\T?\(I;_W1_P!\T ?#'_"K?^G?_P =_P#KT?\ "K?^G?\
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M_P#VC_PM#[!X<NK?_D!;1_PCO_"$[O[#^\W]K_:/MGR[,5ZY0 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,O\ DG_"C[,O^2?\*M44 5?LR_Y)_P */LR_Y)_PJU10!5^S+_DG_"C[,O\
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M?\D_X5Y;\=M5_L3X5>*=3_X65_PJ#[-_8?\ Q<3^P/\ A*/^$>\[Q'H]O_R
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MC[,O^2?\*M44 5?LR_Y)_P */LR_Y)_PJU10!5^S+_DG_"C[,O\ DG_"K5%
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M_P!@?V=_PJ_[?X<NKC_D.[C_ ,)%_P )MM_MS[J_V1]G^Q_-OS7KE !1110
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M V?]1'=VH ]<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJD7A,N?"T6HMI=J;V/PT7>5SX?2Y,JZ,7DD<Z<+;<[G+&M\0+3[?X#\;6/\
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M_(_X0#^S?WF[[-YO_"1<>?L_=UZ77D?]E?\ %^/[<_X5K_S2/^RO^%P_V_\
M]3E]K_X5K_PBVW_N:/[?W_\ 4.V]Z /7**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH X;XE>#H_'W@K6O"4VL>+M!CU;^SMVK>!-7M-"\5VGV#5K#4Q_
M96JWT<MK:^>UF+:^\V-O/TV:\MDQ),C#N:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#"\4:.OB+PSXB\/O>:OIZ:[H6KZ.]_X?NXM/UZQ74]
M/N+)KS1+^=7@LM7MA.9M-NYD:*VO4AFD5D1@3POHZ^'?#/AWP^EYJ^H)H6A:
M1HZ7_B"[BU#7KY=,T^WLEO-;OX%2"]U>Y$ FU*[A18KF]>::-51U W:* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;0/!T>B^-?'_BU=
M8\77LGC7_A%?-TG6=7M+SPIHO_".:3-IB?\ "&Z5#&MUHW]HK*;GQ#]LDD_M
M#4DBN;?9&I6NYHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;']@^7]N_P"$NW?Z%_:_F_9/[&_T/R_.^:NYHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#U#X7_\A#5/^O.'_P!'U[17B_PO_P"0AJG_ %YP_P#H
M^O:* .%^(O\ R+<G_7Y:?^A/7@->_?$7_D6Y/^ORT_\ 0GKP&@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\
MH&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH
M/[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_
M /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!
MV_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z
M!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^R
MM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z
M** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =
MO_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8
M?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK
M2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC
M^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__
M !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!M
MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\
MH&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH
M/[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_
M /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!
MV_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z
M!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^R
MM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z
M** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =
MO_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8
M?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK
M2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC
M^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__
M !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!M
MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\
MH&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH
M/[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_
M /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!
MV_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z
M!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^R
MM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z
M** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =
MO_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8
M?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK
M2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC
M^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__
M !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!M
MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\
MH&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH
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MC_A66@_\_>K_ /@19?\ R!110 ?\*RT'_G[U?_P(LO\ Y H_X5EH/_/WJ_\
MX$67_P @444 '_"LM!_Y^]7_ / BR_\ D"C_ (5EH/\ S]ZO_P"!%E_\@444
M '_"LM!_Y^]7_P# BR_^0*/^%9:#_P _>K_^!%E_\@444 '_  K+0?\ G[U?
M_P "++_Y H_X5EH/_/WJ_P#X$67_ ,@444 '_"LM!_Y^]7_\"++_ .0*/^%9
M:#_S]ZO_ .!%E_\ (%%% !_PK+0?^?O5_P#P(LO_ ) H_P"%9:#_ ,_>K_\
M@19?_(%%% !_PK+0?^?O5_\ P(LO_D"C_A66@_\ /WJ__@19?_(%%% !_P *
MRT'_ )^]7_\  BR_^0*/^%9:#_S]ZO\ ^!%E_P#(%%% !_PK+0?^?O5__ BR
M_P#D"C_A66@_\_>K_P#@19?_ "!110 ?\*RT'_G[U?\ \"++_P"0*/\ A66@
M_P#/WJ__ ($67_R!110 ?\*RT'_G[U?_ ,"++_Y H_X5EH/_ #]ZO_X$67_R
M!110 ?\ "LM!_P"?O5__  (LO_D"C_A66@_\_>K_ /@19?\ R!110 ?\*RT'
M_G[U?_P(LO\ Y H_X5EH/_/WJ_\ X$67_P @444 '_"LM!_Y^]7_ / BR_\
MD"C_ (5EH/\ S]ZO_P"!%E_\@444 '_"LM!_Y^]7_P# BR_^0*/^%9:#_P _
M>K_^!%E_\@444 '_  K+0?\ G[U?_P "++_Y H_X5EH/_/WJ_P#X$67_ ,@4
M44 '_"LM!_Y^]7_\"++_ .0*/^%9:#_S]ZO_ .!%E_\ (%%% !_PK+0?^?O5
M_P#P(LO_ ) H_P"%9:#_ ,_>K_\ @19?_(%%% !_PK+0?^?O5_\ P(LO_D"C
M_A66@_\ /WJ__@19?_(%%% !_P *RT'_ )^]7_\  BR_^0*/^%9:#_S]ZO\
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M ($67_R!110 ?\*RT'_G[U?_ ,"++_Y H_X5EH/_ #]ZO_X$67_R!110 ?\
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M ) H_P"%9:#_ ,_>K_\ @19?_(%%% !_PK+0?^?O5_\ P(LO_D"C_A66@_\
M/WJ__@19?_(%%% !_P *RT'_ )^]7_\  BR_^0*/^%9:#_S]ZO\ ^!%E_P#(
M%%% !_PK+0?^?O5__ BR_P#D"C_A66@_\_>K_P#@19?_ "!110 ?\*RT'_G[
MU?\ \"++_P"0*/\ A66@_P#/WJ__ ($67_R!110 ?\*RT'_G[U?_ ,"++_Y
MH_X5EH/_ #]ZO_X$67_R!110 ?\ "LM!_P"?O5__  (LO_D"C_A66@_\_>K_
M /@19?\ R!110 ?\*RT'_G[U?_P(LO\ Y H_X5EH/_/WJ_\ X$67_P @444
M'_"LM!_Y^]7_ / BR_\ D"C_ (5EH/\ S]ZO_P"!%E_\@444 '_"LM!_Y^]7
M_P# BR_^0*/^%9:#_P _>K_^!%E_\@444 '_  K+0?\ G[U?_P "++_Y H_X
M5EH/_/WJ_P#X$67_ ,@444 '_"LM!_Y^]7_\"++_ .0*/^%9:#_S]ZO_ .!%
ME_\ (%%% !_PK+0?^?O5_P#P(LO_ ) H_P"%9:#_ ,_>K_\ @19?_(%%% !_
MPK+0?^?O5_\ P(LO_D"C_A66@_\ /WJ__@19?_(%%% !_P *RT'_ )^]7_\
M BR_^0*/^%9:#_S]ZO\ ^!%E_P#(%%% !_PK+0?^?O5__ BR_P#D"C_A66@_
M\_>K_P#@19?_ "!110 ?\*RT'_G[U?\ \"++_P"0*/\ A66@_P#/WJ__ ($6
M7_R!110 ?\*RT'_G[U?_ ,"++_Y H_X5EH/_ #]ZO_X$67_R!110 ?\ "LM!
M_P"?O5__  (LO_D"C_A66@_\_>K_ /@19?\ R!110 ?\*RT'_G[U?_P(LO\
MY H_X5EH/_/WJ_\ X$67_P @444 '_"LM!_Y^]7_ / BR_\ D"C_ (5EH/\
MS]ZO_P"!%E_\@444 '_"LM!_Y^]7_P# BR_^0*/^%9:#_P _>K_^!%E_\@44
M4 '_  K+0?\ G[U?_P "++_Y H_X5EH/_/WJ_P#X$67_ ,@444 '_"LM!_Y^
M]7_\"++_ .0*/^%9:#_S]ZO_ .!%E_\ (%%% !_PK+0?^?O5_P#P(LO_ ) H
M_P"%9:#_ ,_>K_\ @19?_(%%% !_PK+0?^?O5_\ P(LO_D"C_A66@_\ /WJ_
M_@19?_(%%% !_P *RT'_ )^]7_\  BR_^0*/^%9:#_S]ZO\ ^!%E_P#(%%%
M!_PK+0?^?O5__ BR_P#D"C_A66@_\_>K_P#@19?_ "!110 ?\*RT'_G[U?\
M\"++_P"0*UM(\$:+H\\EQ&+B\:2$PE-0%I<1("Z/O15M(BLF4 W;B-I88YR"
MB@#H/[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^
M =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!M
MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^R
MM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#Q
MNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_
M /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8
M?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_
M^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@
M _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__
M !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@
M';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_
M *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK
M2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;
MHHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^
M =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!M
MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^R
MM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#Q
MNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_
M /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8
M?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_
M^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@
M _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__
M !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@
M';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_
M *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK
M2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;
MHHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^
M =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!M
MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^R
MM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#Q
MNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_
M /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8
M?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_
M^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@
M _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__
M !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@
M';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_
M *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK
M2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;
MHHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^
M =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!M
MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^R
MM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#Q
MNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_
M /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8
M?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_
M^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@
M _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__
M !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@
M';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_
M *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK
M2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;
MHHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^
M =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8?^ =O_\ &Z/[*TO_ *!M
MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &Z** #^R
MM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@ _LK2_\ H&V'_@';_P#Q
MNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_
M /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@';__ !NBB@ _LK2_^@;8
M?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;HHH /[*TO_ *!MA_X!V_\ \;H_LK2_
M^@;8?^ =O_\ &Z** #^RM+_Z!MA_X!V__P ;H_LK2_\ H&V'_@';_P#QNBB@
M _LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;HHH /[*TO_H&V'_@';__
M !NC^RM+_P"@;8?^ =O_ /&Z** #^RM+_P"@;8?^ =O_ /&Z/[*TO_H&V'_@
J';__ !NBB@">"SM+8LUM:VUNS##-!!%$6 .0&,:J2 ><'(S5BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img58233625_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '1 ^0# 2(  A$! Q$!_\0
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M?Q17\ ]%'_$OG_57?^8#_P##0?Z]?]2O_P OO_O,_OXHK^ >BC_B7S_JKO\
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M_ /11_Q+Y_U5W_F _P#PT'^O7_4K_P#+[_[S/[^**_@'HH_XE\_ZJ[_S ?\
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M?Q17\ ]%'_$OG_57?^8#_P##0?Z]?]2O_P OO_O,_OXHK^ >BC_B7S_JKO\
MS ?_ (:#_7K_ *E?_E]_]YG]_%%?P#U[9\!/CS\0?V>_B'X?\=^!?$6K:5_9
MVIVLVM:3:7EPNE>(](\Z,:CI.L:8)X[+4K>[M59$2[1A!<);W4+Q7%O#+'AB
MO #$4\/6J83B>GB<3"G.5'#U<GEAJ=:I%-QIRKQS3$.DIOW>?V-3E;NXV+I<
M<TY5(1JY=*G3<DIU(XM5)0BW9R4'AJ?-9:VYXWM:Y_<912#D ^H%+7\['WH4
M444 %%>#?M.^/]9^&'P(^(GC;P]+]GUO2M,T^UTNY\M9#:7FNZ[I7AZ*\5'(
M4O:'5?M,9;(5XE;:^-I_FRU;6=7U^_N-5UW5-1UG4[N1YKK4=4O;B_O;F61F
M=Y)[JZDEGE=W9F9G<DL23R:^]X1X$K\4X7$XUYA# 8>AB'A8OZL\54J5HTZ=
M6:Y/;X>,(1A6I>]SR<G)KE7+=_SQXR_2 P/A)FV5Y''ANOQ#F689:LVJQ_M2
M&4X;"X*IBL3@\.U6_L_,IUZU6O@L4I4U0I1IPIQE[63J<L?ZQJ*_DGHKZ_\
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MR-)GO]3US44TZTU+6Q=26%I\I_M4(B_\$I?V,=JJO_%;:>?E4#F30/B@\AX
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M_J+_ -33_P L?_OP_@'HK^_BBC_B8/\ ZI'_ ,S_ /\ @4/]1?\ J:?^6/\
M]^'\ ]%?W\44?\3!_P#5(_\ F?\ _P "A_J+_P!33_RQ_P#OP_@'HK^_BBC_
M (F#_P"J1_\ ,_\ _@4/]1?^II_Y8_\ WX?P#T5_?Q11_P 3!_\ 5(_^9_\
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M_$P?_5(_^9__ / H?ZB_]33_ ,L?_OP_@'HK^_BBC_B8/_JD?_,__P#@4/\
M47_J:?\ EC_]^'\ ]%?W\44?\3!_]4C_ .9__P# H?ZB_P#4T_\ +'_[\/X!
MZ*_OXHH_XF#_ .J1_P#,_P#_ (%#_47_ *FG_EC_ /?A_ /7LWP(^!GC[]H#
MXB^'O '@7P_JNKRZIJ=I#J^HV=I.^G>'M(::,:CK&L:B();/2[2SMF=Q/>%4
MDG,%M$LL\\,,G]R5%88KZ0&(J8>M3PG#%/#8F=.<:->KG$L33HU)1:C4E0CE
M>'=50=I<BKT^:UG)(NGP-3C4A*KF4JE-23G".$5.4HIZQ4WB:BC=:7Y)6["#
M@ >@%+117\['WIPNGC_BYGBT[,9\"_#P;\YW8U_XGG9M_P"$8M,;,YS_ ,)G
MKV[?C_A&/"6W^U?&O=5PFGLA^)WBY05\P> _ATS#-GN"-X@^*(0D)XENM0"E
MED"FZ\'Z'9DJWV'Q+XJG&HZ7X-[N@#P3]I_P#K/Q.^ WQ%\%>'H3<ZWJFF:=
M=Z9:JZQM>7>@Z]I7B&.S1G!7S+S^RC;1J<;Y)50,A8.O\V6J:3JFAW]SI>M:
M;?Z1J=G*\-WIVIV=Q87UK-&Q1XKBTNHXIX9$965DDC5@P((R#7]9%%??<(\=
MUN%<+B<$\OAC\/7Q#Q45]9>%J4JTJ=.E4?/[#$QG"4*-*T>2+BXM\S4K+^>/
M&7Z/V"\6\WRO/(\25N'LQR_+5E-67]E0S;#XK!4\5B<9ATJ/]H99.A6I5\;B
MN:I[:K&I"I"/LX.GS2_DGHK^MBBOKO\ B,7_ %3O_F7_ /P6?C7_ !)3_P!7
M+_\ --__ !K/Y)Z*_K8HH_XC%_U3O_F7_P#P6'_$E/\ U<O_ ,TW_P#&L_DG
MHK^MBBC_ (C%_P!4[_YE_P#\%A_Q)3_U<O\ \TW_ /&L_DGHK^MBBC_B,7_5
M._\ F7__  6'_$E/_5R__--__&L_DGHK^MBBC_B,7_5._P#F7_\ P6'_ !)3
M_P!7+_\ --__ !K/Y)Z*_K8HH_XC%_U3O_F7_P#P6'_$E/\ U<O_ ,TW_P#&
ML_DGHK^MBBC_ (C%_P!4[_YE_P#\%A_Q)3_U<O\ \TW_ /&L_DGHK^MBBC_B
M,7_5._\ F7__  6'_$E/_5R__--__&L_DGHK^MBBC_B,7_5._P#F7_\ P6'_
M !)3_P!7+_\ --__ !K/Y)Z*_K8HH_XC%_U3O_F7_P#P6'_$E/\ U<O_ ,TW
M_P#&L_DGHK^MBBC_ (C%_P!4[_YE_P#\%A_Q)3_U<O\ \TW_ /&L_DGHK^MB
MBC_B,7_5._\ F7__  6'_$E/_5R__--__&L_DGHK^MBBC_B,7_5._P#F7_\
MP6'_ !)3_P!7+_\ --__ !K/Y)Z*_K8HH_XC%_U3O_F7_P#P6'_$E/\ U<O_
M ,TW_P#&L_DGHK^MBBC_ (C%_P!4[_YE_P#\%A_Q)3_U<O\ \TW_ /&L_DGH
MK^MBBC_B,7_5._\ F7__  6'_$E/_5R__--__&L_DGHK^MBBC_B,7_5._P#F
M7_\ P6'_ !)3_P!7+_\ --__ !K/Y)Z*_K8HH_XC%_U3O_F7_P#P6'_$E/\
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M6'_$E/\ U<O_ ,TW_P#&L_DGHK^MBBC_ (C%_P!4[_YE_P#\%A_Q)3_U<O\
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MM(UO2+F\TS4K.4JPCNK*ZF@?!VN<&N@H **** "BBB@ HHHH **** "BBB@
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M[[+9:_\ L*ZMI3Z,^DZM?V\'ABXL)O#-G+,M[9:/;WUO;7,/7?L\?\$V[_\
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MYN-4TW0-8O;6'3KD _AH_P""<O[!?[2'[7OPD_X)>>*/A_\ L1_!3]F3X=_
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M[=8\9SZ['XCNY=4T_7Y_$<FM:3*EK#I=_9VMC906^%^R=^P?XW_8=N?$]_\
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M#P3X9C\&^&=#U?P7KO\ P3MU'P5IUKI_AJ*+2Y'\/^'M(N-12-+C5)[V\47
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M4;"SU4ZHVI6T-V@!^1/[#W_!4'_@HKK_ .T9\<_@5\2OBEXX^(T'_# GQ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6'XG\2:+X.\-^(?%_B2]_L[P[X5T/5O$FO:A]GN[S[!HNAV%Q
MJ>J7OV2P@NKZZ^RV-K//]GLK:XNY]GE6\$TS)&VY7EGQT\-ZUXQ^"7QB\(>&
M[+^T?$7BKX6?$+PWH.G_ &BTL_M^M:YX2U?3-+LOM=_/:V-K]JOKJ"#[1>W-
MO:0;_-N)X85>10#YZ^#W_!1+]D+X]>*_AIX/^%GQ/UK7[_XTZ%K7B#X.:[J7
MPB^-7@_X>_%JU\,:%'XD\6:;\,OBKXU^'7AWX9>/O%7@W2/MLWC3P3X4\7:M
MXR\'7.A>*],\3Z#I6I^#_%-GH^A+_P %%O\ @GS!JTF@3?MU_L;PZ[#J+Z1+
MHLO[3OP3CU:+5H[DV4FER:<_C<7B:BEX#:/9-"+E;D& Q"4%*^)=/_9,_:!M
M?@3_ ,$-/"1\ >5XN_8ZU_\ 9ZG_ &B[-/%7@H3?#G2_!W[&GC?X3>-E744\
M2?8O%L-GX[U;2_#UQ;>!+SQ,=469=2L8K[1()M0B^VI?V8OC9)JTFHI_P46_
M;(@LWU%[U= B\$?\$^3I,-LUR9QI$<TW["DVNG3HXB+))9=:EU8VP#R:H]YF
M[(!X'^TO^U[^U/\ ![]L7]E/X0:!\#/A]I'[-/QH^./AWX+:_P#&;QUXP;7/
M'?C[7O$OPI^(OQ+N8OA%\/?!NK0+X,T3P&/ (T7Q)XP^+%^-1\0Z[J_]G>%/
MAO<:!I__  G%][M^U)XB_:/^&'A[XA?&?PK^T1^S3\(O@=\,OAYK/CGQ=;?%
M;]E'XG_&/Q1IMAX/TC4=<\4:N/%GA/\ ;-^!6E7-I+I]GG3-#C\#I>Q3QF!M
M6U*2ZB6#Y9_;YTW]H[Q]\>_V-;SX5?L;_'7XI^$?V6_VI-%^.7B_QYX:\=?L
MC:!X>\8^%9?@C\2_!MWI7P_TWXE_M/\ @+QO<^)=+\0_$'3K&]M?&7A#P5I$
MJZ3K=WIFM:C:)I,^K^F_MW?!_P",W[7O@[]FK]GC2/AUJFA? KXP_%?P=XQ_
M;6U'Q'K_ ,/TU'P9\$?AC;6OQ/E^!^J:=I'C/4K[6?$?Q?\ B+I7A/X=ZMJO
MPPNO&WAO3?#^G^-(=5UA_#NM6&I7H!/\!_'7_!0OX]?LI?LN_$F>[_9:^"WQ
M9^*'A#4_B/\ %_4/%_PC^+/CC0_#N@>(IGU?X1>%/!_P3T?X^>$-5M?$.K>"
M]7T:\^(NN>)OVB)QX-\0Z+?:1IG@[Q(OB=IO G=_\$Z_VI?%_P"V'^S#H/QF
M\<:#X1TOQ ?''Q0^'USK_P .+G4[SX6?$I?A=X^U[P#_ ,+3^%ESJ]QJ5ZWP
M^\=S:#/K7AVWDU[Q2-/AEDTW_A*=?>S?4I]7]L#0K+QE9^"/"'CO]@+3?V\_
MA)-<ZSXDU/P\W_#-'B;5_ 'Q%T6*QTSP;K,'PW_:I\7?#'X?ZCINJ^&O$7Q
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M?7)( [3&WBU'Q/J^E0R&Z?1M!\.WD^NZAXH[V@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P ))XB_Z#^M?^#2^_\ C]'_  DGB+_H/ZU_X-+[_P"/UBT5]=[*E_S[I_\
M@$?\O)?<>7S2_FE][_KHON-K_A)/$7_0?UK_ ,&E]_\ 'Z/^$D\1?]!_6O\
MP:7W_P ?K%HH]E2_Y]T__ (_Y>2^X.:7\TOO?]=%]QM?\))XB_Z#^M?^#2^_
M^/T?\))XB_Z#^M?^#2^_^/UBT4>RI?\ /NG_ . 1_P O)?<'-+^:7WO^NB^X
MVO\ A)/$7_0?UK_P:7W_ ,?H_P"$D\1?]!_6O_!I??\ Q^L6BCV5+_GW3_\
M (_Y>2^X.:7\TOO?]=%]QM?\))XB_P"@_K7_ (-+[_X_1_PDGB+_ *#^M?\
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M%--H-OH<DX1H3<1:?XGU?588S;/K.@^';.?0M0\4=M0 4444 %%%% !1110
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MDA_X"O\ +R7W!]8Q'_/^M_X-G_\ )&G_ &UK/_06U/\ \#[K_P".T?VUK/\
MT%M3_P# ^Z_^.UF44>SA_)#_ ,!7^7DON#ZQB/\ G_6_\&S_ /DC3_MK6?\
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M]RJ948QM>G%75U[L6FKV335TU=6NG:Z\A/$8A?\ +^M_X-G_ /)&G_;6L_\
M06U/_P #[K_X[1_;6L_]!;4__ ^Z_P#CM9E%+V</Y(?^ K_+R7W!]8Q'_/\
MK?\ @V?_ ,D:?]M:S_T%M3_\#[K_ ..T?VUK/_06U/\ \#[K_P".UF44>SA_
M)#_P%?Y>2^X/K&(_Y_UO_!L__DC3_MK6?^@MJ?\ X'W7_P =H_MK6?\ H+:G
M_P"!]U_\=K,HH]G#^2'_ ("O\O)?<'UC$?\ /^M_X-G_ /)&G_;6L_\ 06U/
M_P #[K_X[1_;6L_]!;4__ ^Z_P#CM9E%'LX?R0_\!7^7DON#ZQB/^?\ 6_\
M!L__ )(]6\!WMY>?VK]KN[JZ\O[#Y?VFXEG\O?\ ;-^SS7;;NVKNVXW;5SG
MQZ%7F?PZ_P"8Q_W#_P#V^KTRO"QB2Q-1)))<EDE9+]W'HC]#R&4IY7AI3E*4
MFZ]Y2;DW;$54KMMO1:!1117,>N%%%% !1110 4444 %%%% !1110!_$-^UA_
MR=-^TK_V7_XR?^K%\1UX!7O_ .UA_P G3?M*_P#9?_C)_P"K%\1UX!7^AV3?
M\B?*O^Q;@?\ U%I'X/B_][Q7_816_P#3D@K])O\ @G9\8?!GP:O/C5K/C ^(
M? I\0>%= \+^'_VBM%^'4'Q#L_@EK^H7>LRZ=_;5C<Z1J]O!:>,+BVB,-K+
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M?'/_  A?_":?V)_PDO\ Q3/@[Q'_ &E_PCG]K_V-_P C9X?UW[']C_MW5?\
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MBN.34I-I**?16LO2R2^Y(ZX1<8J+;DUU=[O[VW][84445)04444 %?6WAO\
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M5[)13DV[)NR2;T3;Z)LF<E"+DTW:RLK7;;44E=I:MI:M+NTCZ3HKY2_X0_\
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M\GT5Z=_PJCQ%_P _NB_^!-]_\KJ/^%4>(O\ G]T7_P ";[_Y75]1]>PG_/\
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M ";L/_DJCV]#_G]2_P#!D/\ ,/[.S#_H!QG_ (35_P#Y \_\2:%:>*?#NO\
MAG4)+F&P\1:+JNA7LUF\4=Y%::O8SZ?<R6LD\-Q"ERD-P[0/-;SQ+*%:2&5
M4;XKT_\ X)W? 2ST/P_X:O+WQ[KF@:+^S7?_ +*NI:7JVLZ#Y'B_X8W7B"/Q
M3I]SXFFTWPOIMY_PEOAO7TEU/PUKOA^YT!-*N+V^*6,BW<JM^BG_  AWB/\
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M*Z;_ (0[Q'_T#O\ R;L/_DJC_A#O$?\ T#O_ ";L/_DJCV]#_G]2_P#!D/\
M,/[.S#_H!QG_ (35_P#Y YFBNF_X0[Q'_P! [_R;L/\ Y*H_X0[Q'_T#O_)N
MP_\ DJCV]#_G]2_\&0_S#^SLP_Z <9_X35__ ) YFBNF_P"$.\1_] [_ ,F[
M#_Y*H_X0[Q'_ - [_P F[#_Y*H]O0_Y_4O\ P9#_ ##^SLP_Z <9_P"$U?\
M^0.F^'7_ #&/^X?_ .WU>F5PW@O1]2TG^TO[0MOL_P!H^Q^3^^@EW^5]J\S_
M %$LFW;YB?>VYW?+G!QW->+BY1EB*DHR4HODLXM-.T(IV:NG9Z>I]]D=.I1R
MS#TZM.=*I%UN:%2$H35Z]1J\9)25TTU=:IIK1A1117,>L%%%% !1110 4444
M %%%% !1110!_$-^UA_R=-^TK_V7_P",G_JQ?$=> 5[_ /M8?\G3?M*_]E_^
M,G_JQ?$=> 5_H=DW_(GRK_L6X'_U%I'X/B_][Q7_ &$5O_3D@HKZ&_90UM?#
M7[1/PI\0L_PTC&A^)#JP;XP:T?#?P\+:?IM_=*FN^(1IVKC0YY6B$>@:M)IE
M[#I_B1](NYX'ABDQ^Z<7QF_9YB_:1E\7:Y^T)X)UKXFZW\!-=L_A_KNM?$+X
M8ZUX&^"GB^[\1?:+CPSI7QML?AUJ_AR2XU&.4W&@ZQXR\(>+M2T#2K'5K.XM
M;BT\00:!>?.\2<68K(<9'"T,CKYI&66U<<JM"O4C+VL*LZ:P\Z5+!8KV=)1C
M[:MBZLX4Z=)2C"G6K^SH5>_+\LI8VDZD\9##-8B-'EG"+7+**ESJ4JU/FDV^
M6%*,6Y2LY2A#FG'\)/@)\#&^./\ PNG;XG'AC_A4'P!^(WQS.=%.L_\ "0K\
M/_[&SX8&-5TK^RCJW]K<:T?[2%C]G_Y!5YYO[OP&OWV^)/QL\ ZA\2_CH_B;
MQ=\!6\3ZC_P38^.'@V;XE> _CGX3^(MI\5O%VMZQHUGX9\-ZMK.E_#7X-: W
MQ3<:)JEXGA3P[X5:XO=,U73Y-.MHK.."PM/3M2^//P/M/V9[73?AKXK_ &?]
M>^#EI^S9=Z3J_P"S[X\^.W@KX?>+9/%=GX=N+O56M/ )^ _BWQ_XA^)LES;?
M8],O6^+.EZ;XD\0W37$6G+?26WB.7YV/'6=TJE.M/AS$XBGF%7 PI858RA3P
M^7J5"3Q'+F4<&Z>+J8J=JF$IXAX:,HQG"I4PDXND=[R;!RBX1Q].G*A&M*=1
MTIRG7:FE"^'=7FI1I*\:LJ?M&FTXQJIJ1_.AH6B:IXFUS1O#>AVIOM:\0:KI
MVB:19"6"W-YJFJW<-AI]J)[J6"UA-Q=W$,(EN9H8(R^^:6.-6<>RWG[._C+P
M_P")/BWX+^(/B'X=?"_QC\'/#5SXBUWPSX[\;:59ZCXDN8+6TO8O"?@.?1/[
M=TKQ7XOO[2]MY[#2+/48XYU9D:\CDC=%_:WX@?M+^'?!OA7X;^+O@M^TC^SQ
MH/P"\.:'\!H-!^!]EH&@:Q\:]"UJT\?^$HO'=\-*>!]7\/WEMX)?73K>LZ@E
M^)]/AU72;;P[#K.H6WBY#XW_ !M\,ZOXU_;2O]:_:2^"'CKPAXQ_9)\6:%\#
M]*\,>-O!DU[I<5["/,\#74UC!ITNK^,=2U\:GJ-IHHO_ !)K']GW%FRS0+,N
MGVL_Z]Y]B*U'V>0PPF$K0JPY9SS&IF$,51S#*:,J,XULGHX6%6&%Q]26(PZ]
MM33IUIT<QE+#>SKO^Q<%3C)2QLJM6,H/W8X=4)4YT,3-33ABYU90E4HI4ZEH
MR=X*=!*IS0_G8HK^F#3_ ([? _2] M+FR^/G[-\?[%</[.LVAW'[,[P^'IOB
M]=^.9=(2)XKSPM-ILGBF]U*X8RP75S)JL2W%V[+<:'<3RGQ0G!_"C]K/P7H&
MO?L*_!Z\^(_P:'P<\4_LNGPW^T$VM:IX(F32M5T7X=:S/H/AGQEXFN[SS_"]
MS9:Y:I86OAW4KNQ$]UX@U*UFL+B]OK1K?9>(6:3HXFK2X2Q$_J\<16E"IC<7
M0DJ.%P6-QV(H3]IDBMFE*G@O92P5)5Z#KXK"TX8^2J2G"/["PRE3C+-*:YW3
M@G&C2G[]6M1HTYQY<9KAI2K*:K2Y*BITZLG03BE+^=NBBBOU(^;/U]_X(K?\
MG3>/O^R >*?_ %8OPJK^GNOYA/\ @BM_R=-X^_[(!XI_]6+\*J_I[K^.?&O_
M )+G$?\ 8MR[_P!-S/UCA#_D30_[",1_Z4@HHHK\E/J#Y2_91_X]/VA/^SK?
MCE_Z?+*OJVOE+]E'_CT_:$_[.M^.7_I\LJ^K:WQ/\>IZK_TE&5#^%#T?YL*Y
MCQEXC_X1+PWJ7B'['_:']G_8_P#0_M'V3SOM=_:V/_'QY%SY?E_:?-_U#[]F
MSY=V]>GKS'XR?\DW\1_]P?\ ]/VET\+"-3%8:G-<T*F(HPG&[5XSJ1C)7335
MTVKIIKHTRYMJ$VM&HR:?FDVCS'_AHW_J3?\ RX?_ +QT?\-&_P#4F_\ EP__
M 'CKYCHK[3^Q<L_Z!O\ RMB/_EIY_P!8K?S_ /DL?_D3Z<_X:-_ZDW_RX?\
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ML7+/^@;_ ,K8C_Y:'UBM_/\ ^2Q_^1/IS_AHW_J3?_+A_P#O'1_PT;_U)O\
MY</_ -XZ^8Z*/[%RS_H&_P#*V(_^6A]8K?S_ /DL?_D3Z<_X:-_ZDW_RX?\
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M7]\=_P#HM?Q;_P##D>,?_ES1_P +^^.__1:_BW_X<CQC_P#+FOU/_B$.9?\
M0XP/_@BO_GZ_T]/Y*_XG.X8_Z(O/O_#AE_\ \CZ_T]/Z?:*_F"_X7]\=_P#H
MM?Q;_P##D>,?_ES1_P +^^.__1:_BW_X<CQC_P#+FC_B$.9?]#C _P#@BO\
MY^O]/0_XG.X8_P"B+S[_ ,.&7_\ R/K_ $]/Z?:*_F"_X7]\=_\ HM?Q;_\
M#D>,?_ES1_PO[X[_ /1:_BW_ .'(\8__ "YH_P"(0YE_T.,#_P""*_\ GZ_T
M]#_B<[AC_HB\^_\ #AE__P CZ_T]/Z?:*_F"_P"%_?'?_HM?Q;_\.1XQ_P#E
MS1_PO[X[_P#1:_BW_P"'(\8__+FC_B$.9?\ 0XP/_@BO_GZ_T]#_ (G.X8_Z
M(O/O_#AE_P#\CZ_T]/Z?:*_F"_X7]\=_^BU_%O\ \.1XQ_\ ES1_PO[X[_\
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M7R711_8.7_RU?_!K_P @_P"(C\3?\_<'_P"$D/\ Y(^M/^%\^$/^@;XD_P#
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M\/7OB75+KQ)JG[;7Q*T,V<-M;7MU=R#X-21:A;++#9Z1X=>XADT_[&\,Z?\
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M\.5OVIO^A^^ '_A4_$7_ .=51_PY6_:F_P"A^^ '_A4_$7_YU5=__$1^!O\
MHI<M_P# ZG_RLQ_U?SG_ *%V(_\  8__ "1^1MA?WVE7UEJFEWMWINIZ;=VU
M_IVHV%S-9WUA?6<R7%I>V5W;O'<6MW:W$<<]M<P21S031I+$ZNJL)=6U;5=?
MU74]=UW4]0UK6]:U"]U;6-8U:]N=1U75M5U&YDO-0U/4]0O))KN_U"_NYIKJ
M]O;J:6YNKF62>>2261F/ZV_\.5OVIO\ H?O@!_X5/Q%_^=51_P .5OVIO^A^
M^ '_ (5/Q%_^=54_\1%X$Y^?_6/*^?E<.?FGS\C:;CS>RORMI-QO:Z3M<?\
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MG)1=XMI/0_1^&<+B,'E4*.)I3HU57K2<)I*7+*2Y7HWH^@4445^;'T(4444
M%>8_&3_DF_B/_N#_ /I^TNO3J\Q^,G_)-_$?_<'_ /3]I==6!_WW!_\ 85A_
M_3T"*G\.I_@E_P"DL^%:***_1CR@HHHH **** "BBB@ HHHH **** "BBB@
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M'O@+\0O%NE>"_P!I;7?'WC7X:?%V+]D=?$NF^%?$O@3^RM1E\":+\-=7\/\
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M_LA^(_AOX-N?&^EVG@3XW6WPMU34KKXD^ _'O@J_\7:=X6U*QM8CIE[H]_\
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M%/1N*FVD]&UJ15FZ=.I-*[A"<TGLW&+=GZV/3O\ A=GP9_Z*Y\,?_"]\*_\
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M_P"%V?!G_HKGPQ_\+WPK_P#+:C_A=GP9_P"BN?#'_P +WPK_ /+:OYW:*/\
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MX,_]%<^&/_A>^%?_ );4?\+L^#/_ $5SX8_^%[X5_P#EM7\[M%'_ !#; _\
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M_P#HA,'_ .'2A_\ .(_93_A#?"'_ $*OAO\ \$>E_P#R+1_PAOA#_H5?#?\
MX(]+_P#D6OQKHH_U,K_]#JK_ .$L_P#YM#_B-V7_ /1"8/\ \.E#_P"<1^RG
M_"&^$/\ H5?#?_@CTO\ ^1:/^$-\(?\ 0J^&_P#P1Z7_ /(M?C711_J97_Z'
M57_PEG_\VA_Q&[+_ /HA,'_X=*'_ ,XC]E/^$-\(?]"KX;_\$>E__(M'_"&^
M$/\ H5?#?_@CTO\ ^1:_&NBC_4RO_P!#JK_X2S_^;0_XC=E__1"8/_PZ4/\
MYQ'[*?\ "&^$/^A5\-_^"/2__D6C_A#?"'_0J^&__!'I?_R+7XUT4?ZF5_\
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M]EA,'A)9=>E?$56I5'%RPWM6DL=1GSJ,L5%0>'48^SIU55JN3P[_ $+*<O\
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MS/%IV8SX%^'@WYSNQK_Q/.S;_P (Q:8V9SG_ (3/7MV_'_",>$MO]J^->ZH
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M5K=;^5NI]<45\C_\,!?L+_\ 1F_[+O\ X8;X8?\ S,4?\,!?L+_]&;_LN_\
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M_P##BOSN_P"'Q'[3/_0C? K_ ,)GQ_\ _/.H_P"'Q'[3/_0C? K_ ,)GQ_\
M_/.H_P!6?%C_ *#<O_\  LK_ /F+^K/RN?6\F_Y]U?NK?_+/ZL_*_P"B/_#N
M3_JL?_F/?_PXH_X=R?\ 58__ #'O_P"'%?G=_P /B/VF?^A&^!7_ (3/C_\
M^>=1_P /B/VF?^A&^!7_ (3/C_\ ^>=1_JSXL?\ 0;E__@65_P#S%_5GY7/K
M>3?\^ZOW5O\ Y9_5GY7_ $1_X=R?]5C_ /,>_P#X<4?\.Y/^JQ_^8]__  XK
M\[O^'Q'[3/\ T(WP*_\ "9\?_P#SSJ/^'Q'[3/\ T(WP*_\ "9\?_P#SSJ/]
M6?%C_H-R_P#\"RO_ .8OZL_*Y];R;_GW5^ZM_P#+/ZL_*_Z(_P##N3_JL?\
MYCW_ /#BC_AW)_U6/_S'O_X<5^=W_#XC]IG_ *$;X%?^$SX__P#GG4?\/B/V
MF?\ H1O@5_X3/C__ .>=1_JSXL?]!N7_ /@65_\ S%_5GY7/K>3?\^ZOW5O_
M )9_5GY7_1'_ (=R?]5C_P#,>_\ X<4?\.Y/^JQ_^8]__#BOSN_X?$?M,_\
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M[_#G_P":ZOZ(J*/^(M<1_P#0%DG_ (38_P#^>0?\2<^&7_0]X[_\.?#_ /\
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MJF'POLEB:\,OQTZ.'=>7)15>K&\*/MIQE"E[24?:24HPNTD?1?\ PR/\2/\
MH-^"/_!EKW_S-4?\,C_$C_H-^"/_  9:]_\ ,U7R]:_\%%OVD+W3-4UJR^'G
MPWN]'T-["/6M6M?"7CRXTS2)-5DFATQ-4OXO&[VNGOJ,UO<16"W<L+7DD$R6
MXD:)PN9_P\Q^._\ T*?PD_\ !#XQ_P#F]IK(/$*3DDLH;@U&:5:BW&3C&?+)
M)>Z^6<96>O*T]G%O.7B']&^$:4IOC*$:T'4HRG@<9&-6FJDZ+J4VVE."JTJM
M)S@W%5*=6%^:#2^M/^&1_B1_T&_!'_@RU[_YFJ/^&1_B1_T&_!'_ (,M>_\
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MK_Y^\7_^$F+\O[WK^/D?6G_#(_Q(_P"@WX(_\&6O?_,U1_PR/\2/^@WX(_\
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M\6W2S7'4,7[6$VY+_;J6)4+[T^1KW6@HHHKQ#[P**** "BBB@ HHHH ****
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M_H6HM837 LKO_1KDQ3?)7ZQ^$?VS?#MMJ/QQUFR^)7A6Q\?W_P"T"OB7X?\
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MW:ZW\13>K:// OAQKY86L#J*:7<RZTENVEG7H+>QD\.27/9T %%%% !1110
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MT5+;[9?W1ANH]+6#SY5M%CQD:IX)\9Z)HVG>(M:\(^)](\/ZQ]G_ +(UW5-
MU73]&U7[79IJ-K_9VIW=I#97WVG3Y$OK?[-/+YUFZ7,>Z!@Y[LIPN'RR%?"+
M&4:LIXFFH0YZ4:D71P&#PL*<J<>5*M.&%6(JQA"*<ZLY1@HM'@<89KF'%-;
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M *6O\9G_  R[^TS_ -&Z_'7_ ,-'X_\ _F?H_P"&7?VF?^C=?CK_ .&C\?\
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M1_PR[^TS_P!&Z_'7_P -'X__ /F?K^S.BC_B-F:?]"3+_P#PHQ'^7K_2U/[
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M>)/"#2'*Y3Q!I=HMY8QLZMF37-%TF! T6;ABY"@'Z%?\-9_LQ_\ 1P'P<_\
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M/X2_^6M?#$E]%W6,=\[5QSZC [^]49+Z+^Y&"?\ 87D=#VH ^]?^&L_V8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!  I6&$'@ =1&/3_ #VZ=41  BJH'8 #^0%.HH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **0D#J0/J<4WS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\
MGHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_
M +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #
MZ*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\
MGHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_
M +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #
MZ*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\
MGHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_
M +Z7_&CS(_\ GHG_ 'TO^- #Z*9YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^- #
MZCDABE7;)&C@]F53_,&E\R/_ )Z)_P!]+_C1YD?_ #T3_OI?\: .&\0?#KPQ
MXBA>.]TRUD+@@DPPYY&.#Y1-?%OQ2_85\">+)I=5TVR_LW6%5_L^JZ9+<:;J
ML!(&WR=0T];:Z4*51A&93$6C0LC; %_0OS(_^>B?]]+_ (T>9'_?3_OI?\:
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M2U/4K'1]-U#5]3N8[+3=*LKO4M0O)B1%:6-C!)=7=S*5#,(X+>*25RJD[4.
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M_H^CXW?]^]1_^;6C_AD3X]?]'T?&[_OWJ/\ \VM8O@W_ (*U?\$\O'WC#1?
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M:XS+(RHRY*T98_#X2IA4Z4VHU$ZJ<)>[*ST!RBG9R2?9M)_<7O\ AD3X]?\
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MZC_\VM'_  R)\>O^CZ/C=_W[U'_YM:^_J* /@'_AD3X]?]'T?&[_ +]ZC_\
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MB<5EM/!5<=1I-N\Y86GF."=5I<J>(A%2<E)1+ZVZ[_?>WY,^!/\ AD3X]?\
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ME:;+[^6C^Z_Y-'P#_P ,B?'K_H^CXW?]^]1_^;6C_AD3X]?]'T?&[_OWJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M26EK(SWFGS,7MK=B=T,97U<1XX<%8K%YE7Q?AW@L50QV9\,RA@Z6$RK X?\
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M@!X7E\>75I:^(?#VH>*->@N]:^)VMNLWB+XD7NHS:!K%A9:5JNHOH^BQ:9)
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M^11T[_L&V7\H*_7*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAN%=KG[<7[&WQ6^,WPU_9?\ !_[.>M?"O11^S1\5_A]\1-+\&_&)?%%O\/\
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M5TVQO)?7EPIX&JKAHQXJPSA@,+PMB<U3S7,)/,+0X@J\2X?+JBRJE"KBL7/
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MXPPN(S6>84<1/#4G@,.VZEVDDTDK.V[]V[^5V[7UM:W4M_M(?\%>KWPK\)_
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MC;X4LO%G@'Q!8ZM;3V]NVI::D\8U?P_?RP133Z3K>GDBYLKVU:3RV,D?V>Y
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M, ?$#_H8/%G_ (/9/_C% '[E45^&O_# 'Q _Z&#Q9_X/9/\ XQ1_PP!\0/\
MH8/%G_@]D_\ C% '[E45^&O_  P!\0/^A@\6?^#V3_XQ1_PP!\0/^A@\6?\
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M, ?$#_H8/%G_ (/9/_C% '[E45^&O_# 'Q _Z&#Q9_X/9/\ XQ1_PP!\0/\
MH8/%G_@]D_\ C% '[E45^&O_  P!\0/^A@\6?^#V3_XQ1_PP!\0/^A@\6?\
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MA[XJT'QIX:N+W3Y3;W]I!KOAO4-2TN:ZLIP8;NWCNFEMI08YD1QMKM_LUO\
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MG6=4L-+@A;6-3@T72%EFOKB".-M4UFZMM)TX.P-]J=S!86PENIHXFV_LUO\
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MVK7F@ZAK0&K:[:$Z38ZYI^H:->:D/]#M=6L;S3IYDO+::%/S0^!7_!/OX^?
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M(^',/Q,O-9UC0_A?X@TGPC!J^IV'A^_N-2TU-9T+P^\TVKZ5#I_[,?QD\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img58233625_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_2.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '> ]\# 2(  A$! Q$!_\0
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M2CSU90P^*E&G!R45*HUBFH1<FH\TK+F:5[M']2'_  ]&_84_Z+E_YC/XP_\
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MY?\ F,_C#_\ .^K^06BC_B W"'_0RXD_\+,K_P#G.'^NV:_] ^7_ /@K$_\
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M_P"8S^,/_P [ZOY!:*T_X@-PA_T,N)/_  LRO_YSD_Z[9K_T#Y?_ ."L3_\
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M%/\ HN7_ )C/XP__ #OJ_D%HKK_X@-PA_P!#+B3_ ,+,K_\ G.9?Z[9K_P!
M^7_^"L3_ /-9_7U_P]&_84_Z+E_YC/XP_P#SOJ/^'HW["G_1<O\ S&?QA_\
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MEQ)_X697_P#.</\ 7;-?^@?+_P#P5B?_ )K/Z^O^'HW["G_1<O\ S&?QA_\
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M%;6Y)=%^'VE%_! 7Q4XU)%D\*:C*/[>/AMF2:R7"M)/]F]ETS_@H/^Q]X?\
MC-\0OVIM#^"?QA3X^^(=)\1>'](TZ[U7PNWPYO[=9?[.\.>)=5D.MSZSX;\2
M:UX;TS0;+Q7;Z/8:WI6FO_:<6DIJ=Q-/K&H^CB<CXKAR8JE@N(EF"R3B+!8'
M$Y=C7A:M',\3QCF..RI8ZI]<H2J9?]1]E5G3J.MAE1E056EI#DPAC<LE^[E6
MP'L/KN!K5J>(HJI&>&IY3AJ.)]C%TIJ-?VRG!2BH5>=3<9+WK^:0?!ZS\(_\
M$Y?VLEUC6O%E]XF^%7[55U\-X(['Q[X\T_P-<QZ!K_PDTN[NY_AO:^)D\!:C
M=7%UJ&IW4.J:MX=U#5X&DLVCU /IU@]O^@?QD\.V7BW]O;]@GPSJ=[XDL-,U
MCX&^.8[Z;PGXN\5>!=;:.P\!>,=7@BMO$_@K6?#_ (ET^-K[3K1KE=/U:U%Y
M DEG=>=9SSP2?DA:?M>>&K[]C/\ :!^!7BK3?%-[\6?C3\>9/C#_ ,)!8Z=H
MX\%HFH:E\.=5U:._NIM>BUJUOYKOPGK+06UKH5]:@75@K7J[[@V_TKXE_P""
MB/P9UK]J[]EGXZ6WA7XG1^$?@A\./%'A'Q7IT^D>%5\1ZAJFO>#_ !1X=@E\
M/6<?C*33+O3X+O6K.:6?4M8TFY-LERR69ECBBG[LRR+BFO7S"M+"8RM74O$!
MX>M2E9*>8\)Y/A<OEA7SQ=.&)S*CB(8504%&M&4K0>ICA\;EL(4(*K2A!QR-
M5(26ML/FN)JUU5T:DZ>&E3=1R;O!I7>Q]=?LXZS\+/#/P'_X*/:7=_"N]U_3
MOAYX[^.-O\1DU+XF>+Y]1^,.BVUYX^N=/TV_UR^.H:QX5O;?PU$GAJZ\06-Y
MJNL:K/YGB/4;B?5I96?X3\5? C]G[XX_L,^(_P!HC]GOX17WPZ^)/PY^*-UI
MOC7PG8>,?'?Q!N'\+WVM"'3]'@;Q'?-#>KIV@^*_"FJOK>FZ);W$HT;5XKDL
M_P!L,//_  ,_;7^$O@_Q)^VAX?\ BAX:^)VI?!_]J[5_%=_;GP6WAL>-/"\&
MOZIXT# :7K6K0:!'J.HZ'XOB2]OH]6OHK"_T&QB2SUBTF:2'Z,_X)-^+]%D_
M:0_: \ ?#7P_XFD^ GBSP>_B*VB\:O97>M:''X7URUL/"\GB6XL)/[#74-4L
M/$FMP7MM8B:2::.VDMY9+/2;J88XO 9QPS'B;B"$<XP]; X[A_B"$IYGC(Y;
MF^!HX'+\-F^58F$\94HRK2J5<7"E"KA93H_5J%+"N%"&'IE4Z^$S)Y=@6\+.
M%:CCL TL/2^L86M*M6J87$TVJ,9J"C&DY.-1*?M)NI>;J2/DK_@H1\!_@]^S
M;<? 'X5^!M$:S^)]K\*[?Q#\:_$":MXAO[;Q/KVJ#3=+T^]AL-7UG5--T-O[
M5\/^+KX:;H<-C!%9:M8).+A([1T[3X2_ []G#X3?L7:=^UU^T+X UOXTZE\1
M_'=SX)^'/P[L?&?B'P#HUN=.OO$FGR2ZAKOAG9J4-W.W@[Q5J%Q>W']H6"VM
MEI6GVNFI>W%S<R_(W[8'Q?\ ^%Z_M)_%OXDV]TMWHVJ^*KK3/"\L4\LUL_A+
MPU'%X<\-7%L)<>2FHZ1I=KJL\4:I&+R^NI%!:1G;Z3^#?[67P&U']E?_ (9-
M_:E\$?$G5_"'ASQ;<>+/A[XN^$3^%SXIT&YO;W4M3G1K?Q?J%GID%[!?:[XC
MBCU$+J$-YI'B"YTV;2H)+1;Z\^OQ&"XCI<(\,T9U\YQN,>/R_%\3O!8RK2SB
MI@<4\3B\?A<+B8UZ.*A'#8NOAZ"AA<12K0P-"5&A*$(J*\J%;+Y9IF,XPPE&
ME["O2RWVU*$\+&M2]G2H5:M/V<Z4G4I0J3<JD)P=::G/FD[OVK]E_P"#/[#W
MQ]U3]K3Q]=?#SQWX;^#OPN^'W@+QQI6FZSXHUZ?Q+X#2UT?Q?JWQ(72)] UZ
MZ/B.SN$\,2#1G\1+K5]Y.UTLK:XD^S+8_9ZL?@5\6_AM_P % ?%/PI^'?COX
M,>%/"7[-:WFF^"],^-_Q1N;.^\0V/A;XQW<NJ^)SI_B;2;7QCI^H166E^9X7
M\76>N^'[+_B9V<%G)::E?&\\?^'?[6/[,_PFT7]L?P?\./AO\3_#/@_X[_!6
MQ^&OPYLKN]TCQ-J,'B*'P9XWT#4O$?CJ]U'Q+;'2;?5=7\4VU]+:>'3X@BM8
M8;LV=I"AM[!?)_V4?VF/ OP*^$_[7/@3Q9I'BS4M7^/GPDN? 7@^Y\.V6CW6
MG:9K$WAOQ]HRW/B674M=TFYM--%QXJL)&FTNTUBZ\F"[(LRZ0I/Y>,RC/\30
MXBKTGQ-_'X/IY'@L;FF)G*&$I_V'5S:<Z%/&5</5Q<94<0\;7J3K352&(E":
MG7Q,JW32Q6!ISP$)?V=\&;2QM6CAJ:3K2^NQPJC-T8U(TK3I^QA%1CRNFI*U
M.FH?I-\2/B3\ +#_ ();_L\^)M9_9J_M[X>:M\2M9T/PQ\,/^%R>-=+_ .$1
M\8Q77QPM;GQU_P )K:6#ZYK_ -KU'2_$>J?\(QJ%O'I<'_"4_88YC!H=@TFM
M\/O^"<'P\\%_#GX*?\)%^R]XJ_:1\6?$*PTO6?BOXLB^.%C\,;#X20:S9:7/
M+::#X?3Q3X8?Q<VCB[N#%:&*YEOI+&_N)M9A6YTW28_@_P "_M5?LY:_^QIX
M8_9:_: \&_&&YN?AQXTUWQKX(UGX8WGA3[%J.HWTWBW4-.CU^?Q%J%E<Z79)
M=>-]<T_4;/3]-U5Y;1+?4K6]M[UVMH.L\2?M??LK?M'_  K^$7AK]K3P+\=5
M^(OP>T5?#NG^,?@SJ'@DP>*]-2STJUGDUV'Q;>V,%D^LMI-I<:E!9:5<3VEV
MD\^E:I;07LME%XM3(N*,#];PF6T\_P %A*G%O$&*S#$4L7F>.JXC 8QXJID>
M*P<*/$66XNM&,IN693HXW#XBMB9X6MF,<>J-2D=D<;EM9T:N(>!K58Y7@:5"
M$Z6&HQIUZ2I1QE.LYX#$4HMJ-L.IT:E.%-58X=T'.,CZ-\ _\$[_ (!6'[5W
M[3'P:\<PZOKWP_\ #OP?TSQ_\/=2B\0:I;>(_!*>)IO+>[F.CW%I;ZMJWAN:
M'48M+MM>LM5T_4;&'3KS4],NY;N1#@?L7:7^SM\:OBQ\?F^#_P /OB/\&O '
MA[X W%L-!T?XY?%6PU#Q/KMIXL\0+#XMU[4?#OBS1;RXCU?PW<:'%=^"K^ZU
M7PQI>H07Z6\-^)?M\_SO^S;^V!^SM^SY\8?V@O$_AOX:?$3PU\+OB/\ #NU\
M&?#[PIIEYI_B[7M(O+2STZ"YU'Q+J/B3Q/II$>NZC;ZAKMVME?ZH-)GU'^R]
M/MY[&U@=?-OV#_VI_ /[+NN?%[4O'NB^+]9M_'_PWG\(Z,OA"RT6^FMM5:\\
M^.74TUG7M!2'3V1F#SVLMY<HZJ%LI Q9>[&9+Q;B,MXC]MB>(,9BH91PK2R>
M,\34P<<1B72P[SJK++\-C\1@UC8SHQ>):KXB%*O[:>&K2]K.I4PHXO*X8C+^
M6G@:5*6,S*6+:IQJNG2YY?5(K$5*$*SHM3DJ?N4W*'*JD5RJ,??_ -CS]G'P
M+\1OA!X8\3R?L-?%7]HO6-0\2:M9^,/&NI?&?2O@QX*L-)M=9FM5;X:02>,?
M#5QXWN--TV."'4(=0^P6<GB5=9TS_A(+6.QQ:_.__!1/]G7P+^S-^T1)X&^&
M_P#:$'A#7/!>@>---TK4KR?49M#;5+[6M(N]*BU&Z>2]OK5;K09;VVFO9);J
M.*]%K+/.;<3R>Y>&/VR_V8O''[,_P<^!7[2?@'XT7\OP4U:"\TVQ^%&H^&M/
M\(^/K/38[^#3++QI_:NMZ7J-M!-;7RQ:E_95H^J"\MGU/3M<LSJ-[8-\_?M]
M_M,^"?VK?C5HOQ+\!Z-XIT+2+'X<>'_"=U8^+K72;34AJVF:SXEU.[DMUT;6
M=;M9M.,>MV\5M<27-O<RO%,9;*W4)O\ 7R2'%CXTKU\;0S/#914EGU.M1JXG
M&XG+N18K#RRBK1GB<VQ6%<ZE&-65..7Y5E,<-3DZ-:6+G*3H\N,>5_V1"%&>
M&J8I+ RA*-.E3Q'-[*:Q<9QIX:G42C-Q3=?%8KVDESP5))<_Q#1117ZH?-!1
M110 5_?Q7\ ]?W\5_-_T@_\ FD?^Z_\ ^\4^_P"!=\T],%^>*"O ?VK_ /DU
MK]I3_L@/QC_]5WXCKWZO ?VK_P#DUK]I3_L@/QC_ /5=^(Z_ <F_Y'&5?]C+
M _\ J52/N<7_ +IBO^P>M_Z;D?Q"T445_H<?@X4444 ?MO\ \$9K7[;??M2V
M7VBUM/M?PZ\,VOVN^E^SV5K]HF\61?:+R?:_DVL._P RXEV-Y<2N^UMN#V]]
MX/G_ &,?^";OQ7\/^,?'NB_&B#X]ZO<Z'X$N?A5>:AXP^%?AM];LC:C4[;QA
M=6%G91PW":;<ZM/(MI9)>:U;6VGZ7!<W$=]JE?#G[!/[6GP[_99/QO/C_1/&
MFL_\+*\&:=X>T+_A#]/T.^^RW]E_;N^35_[:\1:!]GLW_M2#;+9_;YAY<N;;
MA-\GP!_:Y^'WA;]E/XZ?LL_&[1/&GB/PYXVCGU;X7WWABSTK5O\ A$_%5Q ;
MQ9-1CUKQ1X>^Q:1I_BG2?#GB.SBTE;MY[R;Q";NW<7H6;\6SSAW/<1Q/GN8T
M\)7Q&43S[@?&5L'2I4O;9GALNH1IXBM@L1)NI3GEN(Y*M>E35.6(HJK2]K!.
M[^NP6/P=/+<'AY580Q:P><TH592ER8>IB)IPA6II<LEB()QA.3:ISY9<KZ?I
MIH'_  33^%/@"/X2^"-;_9:\7_'Z7Q%IFFR_%SXX)\<K+X?VWP^U747\F]CT
M#X?1^,/#MYXDL-'GWW4ULNG/=PZ']F:UU+Q-KINM,3PWX1?\$_/@IIOQA_;#
M\%:WHFH?M :_\#T\,R?"WX/3>//^%;7_ (JL/%OAJ'QA8S:QXHTB^L9EO($O
M;#PN^I)]CT>SO(KZ\U#3S-J6G6NF^)_$?]KK]CG]J72?AMXF_:E^&OQWL?C#
MX#\.6'AG5=5^#.H>"1X;\::=IMU<WHM-5E\6:E!J>GZ9?7]W?ZC]DTZR35-(
MEUB_M;7Q!=HD-R_B?PX^*_[$NF>*_'^K:[\-/VA_A7#)XOL]6^$7BCX%_$A)
M_'G@_P ,6VG06%UX?U*Z\7Z]::?)+J]U;RZM>ZC&=1U"V;5[O2K&_AM-/M+B
MXX\'EO'7U',_[0S'B:GCZN&5/$4\-A:U;#K&0SFA6C7PF*?%?M?8UL'&MAIQ
MX>PF41A@*LJC@L70IPK[5L1DOM\-[##Y=*A&IS4W4J0C4]D\)*+A5IK+'#GA
M6Y)IX^KBG*O'E3]E.4H?4?P)_9<^ GQ:_;5\6_"?Q)^S_P#$?X3>%+?X%:KX
MBF^%WQ!\1^)%U#POX^M-=\/Z*=;\,>)=,UVUU;Q3X3$-[-<Z-?:GJ-S8ZM<R
MWKFV:RBLHXD\"? O]B[]J7X*_M+P? 7X5^./ /Q ^ /AX:[X5\?>(O'NM:U<
M?$JPATS7-0TR_P!;T.^O5\.>'[KQ!<>%M5L-2TBST:UBTJ"^TK4K/5?->_TS
M3?J/]E#]JG1_VL_^"AEWXR\-^%K_ ,,^&O"G[,>O>"]#.OOI]QXLUFVM/'?A
M75IM4\0W-@;B..9[K5IH+;3(]3U2ULTADO(KH7.J7J#XD'[:/[+OPD^#GQW\
M,_LO_"CXI^#_ (D?M#V+Z7XGN?&.I^'Y?"G@'3;W3M0TRYTSP%J.B:N^NRZ?
MH\.MZ_<>'5O],L;^+4]2BN[O49+/3-.TFVYU4XNQ>/J8*E#B/#YQA<NX+JT,
M-1SK$5\LRRO6Q^*>95,Y]MCN;%PQ678:IS+$1QO-*%2G7E/$^QJRMQRJE1A5
MF\!4PE6OF\:E26#A#$8F$*-)8>.$Y:+5)TL14C;D=%)-2@HTN>*ZGQW\$?V1
M?V+_ (9_ #_AH/X+^+OCO\2?C)HY\4>+I['XB^(/!%CX TI;319]1L] LO#M
M_IUKK]]I<NL165C8ZI<0IJUS::E>W>O:/:R:?8#W30O^"='[/]E^VN?AM>:5
MJ?B;X+_$']G;7OBGX+TF^\2:]::GX6U^'Q3X?T(1QZIH^HZ7J>I6FF6^H?;=
M+75[F]CGCU$6VJ)J$UA]JE^8M7_;%_91_:%^&WP6T/\ :[^'7QMU#Q]\%-/B
MT2TU[X2ZCX372_'FD16>F6MS;^*O[<U?0KS3XM<;2;*XU2'0X(M1L[M)[C1=
M>L(;V>R7NO"7_!3_ ,'R?MC7WQ\\<>"O&&G?#'1O@[JGPC^'W@_PG#HNK^(+
M"SG\1Z)KT.J:S'JNO:!I NM1EL;TZ@UA>R?8K=='TR%=26QDU&;;$8/C]X3%
M^P_UCAFRR_B59M6EF-2678K%5<9"60?ZNT5C9T\-.G1NU+"4,'R4%*GB'.K)
MIS3K9&JM/VBP$L*Z^7/"Q5"*KTJ<:+6.^OS]BI5%*?2M.JG-J5.T5<R-*^#G
M[%?[1/[.'[47B;X'_#'QG\-/&'[-6C6_B/3/&NO>./$/B6\^(.A1Z3KFJ6=_
MKN@7]Z?#VB7'B'_A%?$-I<Z5I%A')I##2=1BU$K<76D0^GZ)^R#^S[X>_9>^
M"GQ*M_V8_B/^TD/'_P -[7Q-\3_B3\-OBA?Q^,?AMK^IZ19:C-9:%\,M-U6R
MTKQ2-#U.^OM'EM6LM^EPZ"\FOR7-U).[_!G[+G[3'@7X(_!3]K[X;^*M(\6:
MCK?[0'P\TKPEX.N_#]EH]UI6F:E8Z-\1--EF\33:CKNE7=G8M-XOT]XY=+L=
M9G,=O>EK9&2!;CZ9_9S_ &TOV1OV:K:#QKX \"?M+:7\09O $.A>(/A?#XVT
M*\^ WB#QG]AT]+_QA<OJFMW7BB+4KZ]L L-XVEW%KI=A*T=AH*2+'M[\XRWB
MW"2S/#996XFQN&PN<X7$973GF.,J?VA0JY'@XXK#XC-H9K@\QPN'CF=3$U:#
MYL1E]'$4)4\1A/J[C">&$Q&5U8X>IB8Y=1JU,)4AB9*A1C]7G'&U73J4\++#
M5L/5J/#1IQFDH8B<)J5.K[2\EW7[+/[!WA/5OV7?#GQW\0?L_>)/VH/B!\1M
M;F70?AC!\6;'X,Z'X5\&V&J:QIG_  D-WXB?7M#N+VZU!=-:^\D3ZI)<"^T*
MRM])TR"+6=8?YJ_X*-_LI^"?V:_%_P ,]7^'VF:QX2\._%;PE<:S/\.-?U>W
M\1:GX!\0:(NDQ:UH_P#;UOJ>L#4[4MJ]JOF_VKK$(U.WU5K#6K[3)+*.UZ'P
ME^V=\#OB9^S\W[/?[7/@'XB7NC:#X^USQ]X#\6? VXT"RUG0;OQ#J?B/5I]-
M&D^+=5M=*AL])F\5:YINDPS-J^FKH5UI]A_9%M=:#9ZA<?&WQZU_]GS6=:\.
MVO[.G@/QMX.\+:-H(LM8U3XB>((M8\6^,=<:[FE?6=2LM/O+OP_HODVAM[6.
MTT$V]I,RRSO:PL56O5R+"<7+BS$XK-L5FM+"_P!H9N_JL:53$9-6RRK"^5PA
MB:F?/!T'A[4>3ZED%+,)5U7AC:]2E4E5CRXVKE;RRG3PM+#2J>PPJ]JYQABX
M8F$E]9;IQP7MIJI>=_:XZ6'4.25&$914'^CW[&'[#/A/QU^S3J7[0GB?X-:U
M^T=XMU_Q%?Z-\/\ X0Z;\4+?X3:.VC:-J0T?4]=UCQ9+J.B36]VFIVNKJ(DO
M[Z/[':6BPZ7<7%Y+-9?1=]^P1^R[X1_:'_9_L/&WPMUGP]X-_:&\">.-!D^$
M&M?$?6-0N/AM\7/#.G>'_%-C);>+_#'BUM2UVUN]'3Q'H1!UO6=$_M8V<P9F
MU'3[>U_/[X#?M=?!VV_9GU[]DS]ISP5\0/$7PW?Q!+XE\'>)_A7=>'XO&'AJ
M]N;W^U)+>.S\1W>G:5(;75Y+[4;2^N;B_CD75;S3KW2KBU2$CQ3QU\4OV?\
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MX]%NKRWMM*O]'FL]2<6LUEK5T9$F">1+X;\1?^"D^E67Q?\ V:M=^ _@/6M
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M ":[\0/^R^>)O_5>?"ZOR;QJ_P"2&Q/_ &,<N_\ 3LCZCA#_ )',/^P?$?\
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M/>$C>W</ASPF=4T2[.KZ@(3+:O;ZIJ8DB^4OV_/@A\-_@WI]KI?AC]E'X@_
MC5;7QY<Z7HWCZ7X@:K\2OAK\2/!<=CJ_DWCZKJ>JZB?#?C*\GM=/U.V\+1JL
M]MI7]I/>R%X8E&A\>?VDOV#_ (W_ !OL?C1XA^$W[0&NWGBUK>U^*VAZEKGA
MCP_IMM9:3X%3PMH&H>!1X>\227]UK%C>Z?HEU<Q:WJ>GZ5>PV4K/;*;B:UER
M_P!H[]M+X5^+OV9/#_[,'P;L/C5XDT.T\3Q>(=5\>_M%ZKX<USQK!;6=W>W]
MEH^B/X<O[^TBCBN+Q+2WNU.GK8:):RZ6EC=OJ=Q>6^>1X#B+ U^"*>'P?$4,
M+@\KRW+\XP&.QN,I8##5Z4:\<PS&G66<UJ5>,)1C1HY9B\OGAEA?JBRI89<Z
MHWC:V K0SF4ZV =2KB<17PE:C1I2KU83=)T*$H_5(R@VFY2Q-*LJCJNL\3[3
M1R_,.BBBOV<^1"BBB@ HHHH **** "BBB@ K]]?^"&W^M_:?_P"N7P8_]&?%
M2OP*K]]?^"&W^M_:?_ZY?!C_ -&?%2OS?Q<_Y-YQ#_W2?_5YEI[_  O_ ,CW
M >N(_P#42N?T!U^='_!1S]CKQ'^UG\.?"C> [[2[?XA?#;4=9U'P_8:S,+*P
MUW3O$%OIL6N:/_:?DS?V?>SMHNEW%A).(["6XMEAOKBTA<7=O^B]%?QWDN<8
M[(,TP><9=.-/&X&JZE&4X*=-\\)TJM.I!M<U.K1J5*51)QDX3ERRC*TE^L8S
M"4<=AJN$Q"<J-:*C-1?+)6DI1E%ZVE&48R3::NE=-71_(.__  2X_;J5V5?@
M>L@5F42)\3/A $< D!U$GCY'"L!N4.B/@C<JG(#?^'7/[=?_ $0W_P R9\'O
M_G@U_7U17ZQ_Q'GB_P#Z%W#?_A'F?_SX/F/]2<J_Z",P_P#!N&_^9#^07_AU
MS^W7_P!$-_\ ,F?![_YX-'_#KG]NO_HAO_F3/@]_\\&OZ^J*/^(\\7_]"WAO
M_P (\T_^? ?ZDY5_T$9A_P"#<-_\R'\@O_#KG]NO_HAO_F3/@]_\\&C_ (=<
M_MU_]$-_\R9\'O\ YX-?U]44?\1YXO\ ^A;PW_X1YI_\^ _U)RK_ *",P_\
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MMS8K,I6BHKFK8=VC%6C%7PND8K1):):(_D%_X=<_MU_]$-_\R9\'O_G@T?\
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M'7/[=?\ T0W_ ,R9\'O_ )X-'_#KG]NO_HAO_F3/@]_\\&OZ^J*O_B//%_\
MT+>&_P#PCS3_ .? O]2<J_Z",P_\&X;_ .9#^07_ (=<_MU_]$-_\R9\'O\
MYX-'_#KG]NO_ *(;_P"9,^#W_P \&OZ^J*/^(\\7_P#0MX;_ /"/-/\ Y\!_
MJ3E7_01F'_@W#?\ S(?R"_\ #KG]NO\ Z(;_ .9,^#W_ ,\&C_AUS^W7_P!$
M-_\ ,F?![_YX-?U]44?\1YXO_P"A;PW_ .$>:?\ SX#_ %)RK_H(S#_P;AO_
M )D/Y!?^'7/[=?\ T0W_ ,R9\'O_ )X-'_#KG]NO_HAO_F3/@]_\\&OZ^J*/
M^(\\7_\ 0MX;_P#"/-/_ )\!_J3E7_01F'_@W#?_ #(?R"_\.N?VZ_\ HAO_
M )DSX/?_ #P:/^'7/[=?_1#?_,F?![_YX-?U]44?\1YXO_Z%O#?_ (1YI_\
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MU]44?\1YXO\ ^A;PW_X1YI_\^ _U)RK_ *",P_\ !N&_^9#^3'P;_P $]O\
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M@?"?Q-X)T'4[;_A:NOW4V7^R#^Q[XR^*WB;_ ()=^'/VR?V=?'/CGP?\,/\
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MO[)_M/['IW]H_P!G?VC]C^W_ -GV'VSR?M'V.U\SR$_G@^/_ .S_  7/BO\
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MOQ%\ GQG\0O^"FWB3XDWOPC^+/P)^('A37M"NK7]GKP%X4U+PK\)_"FK^#O
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M%D_88\#7W[.,OPJ^*/C2VU3Q=XET+]LWXG6.F>']/TC2O%OACPAX\M]-\?\
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MSZA=:_X7O_!_A&.,^'O$4?A&QT;2[=%L]&U>.[46X_-OX,?\$B_VC]9\#_\
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M1110 4U_NG\/YBG4U_NG\/YB@!U%%% !17SI^TM_PT/_ ,(9I7_#./\ 9_\
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M?M\Z9-XD_:#_ &\/B[9_ YOCO\'_  !X]_9QTGQ]_P %"FM/#R?'3_@E5?\
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M:9;2WNI:IJFI7LL%GI^G:?9P37=]?7<T-M:6T,L\\L<4;N.#^#_QB^'?QZ\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN
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M_$_Q+\<;2QU7QSJ@*+'_ #]?LEZAX\UOPA_P25\+?&/P=X'^&GP(TO\ :_\
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M/UFTL-0M?B+]G_XQZ9_P5#G^/$EQ?:IJ'["^M? ;X*_"^7P/I6I7_ABZ\?\
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M_!GX<W_C[P39>$ !X2L_"/C&Z\-R^(?#=KX7  \.V^C:C90Z( !IJ6U?0-%
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M;_7O^$1^'WA?[78?\))XX\2?8/[&\)Z!]NLO[8UZ]L-.^UVWVGSDV_#&N?\
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M9F( !)KP3_@EK_R8W\&O^OGXD_\ JU?&U=L?^1;5_P"PRC_Z9K$OXX_X9?G
M_06BBBN$H^2?VZ?^35_BE_W)'_JQO"%?SNU_4I\6/AGH/QB\ :_\.?$UWJ]C
MH?B+^ROMMUH4]G:ZK%_9&M:=KMM]EGU"PU.T3?=Z7;QS^=8S[K9YDC\J5DFC
M^,O^'9WP(_Z&SXM_^#[P=_\ ,%7Z[P#QEDG#V3XG!9E/$QKU<SK8J"HX>56/
MLIX7!48MR35I<]"I>-M$D^I_&GTB/!+CKQ)XURO/.&,/EE7 83A;!936EC,Q
MIX2JL90S;.\944:4X2<J:HX_#M33LY.<;7CK^'%%?N/_ ,.SO@1_T-GQ;_\
M!]X._P#F"H_X=G? C_H;/BW_ .#[P=_\P5?<?\10X4_Y_8[_ ,(I_P#R7]6?
ME?\ !?\ B5'Q=_Z \A_\/=#_ .5?U9^5_P .**_<?_AV=\"/^AL^+?\ X/O!
MW_S!4?\ #L[X$?\ 0V?%O_P?>#O_ )@J/^(H<*?\_L=_X13_ /DOZL_*Y_Q*
MCXN_] >0_P#A[H?_ "K^K/RO^'%:>EZWK.B-?/HNKZGI#ZIIE]HFI-I=_=6#
M:CHVIQ>3J6D7S6DL1N],U"']U?6%P9+6[B_=SQ2)Q7[:?\.SO@1_T-GQ;_\
M!]X._P#F"H_X=G? C_H;/BW_ .#[P=_\P53+Q.X2G%QG4QDHO>,L#*47L]4Y
M-/7\O2^E/Z*OC#1G&I2PV2TJD'>-2GGU*$XMJUXSC34HNS:NGM===?QOT#XF
M_$CPKIC:)X7^(/C?PWHSW?\ :#:1H'BO7M'TQK_= WVUK#3K^VM#=[K6V;[2
M8C-NMX#OS%'MP[OQ-XDU"PN-*O\ Q!K=[I=WK=QXFNM-N]5O[FPN?$EW#]FN
M_$%Q9S7#V\VMW5O^XN-5DC:_FA_=27#)\M?M9_P[.^!'_0V?%O\ \'W@[_Y@
MJ/\ AV=\"/\ H;/BW_X/O!W_ ,P59+Q'X,C.52,:\:DY*<ZBRZTY36TY27O2
MDNDFVU9V>U^J?T8_&ZI0IX:I/+YX:C2="CAY\3.5"E1E;FHTZ4DZ<*3LN:G&
M*@^573LC\;?$OQ)^(OC.QMM,\8>/O&OBO3;*=;JST_Q+XJUW7;&TNDADMTN;
M:TU2_NH()U@EE@6:*-)%ADDB#!'92X?$WXD!?#RCX@^-POA&VFLO"BCQ9KP7
MPQ9W-@-*N+3P\!?XT6VGTL#39H--%M%+8 6;HUN!'7[(?\.SO@1_T-GQ;_\
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MAI=C>P6-X]Y8P065TUS!(;BTABMIB\,:(/V7_P"'9WP(_P"AL^+?_@^\'?\
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M#?0-'\!_#SQXG[-WQT\2>/SX;O[SXA^-=.\#WNKZ;:>%8U^(,-CX ?3=!_I
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M?PD_\.1X._\ ES1_PO[X$?\ 1:_A)_X<CP=_\N:_F"HH_P"(0Y;_ -#C'?\
M@BA_GZ_TM3_B<[B?_HB\A_\ #AF'_P CZ_TM?Z??^%_? C_HM?PD_P##D>#O
M_ES1_P +^^!'_1:_A)_X<CP=_P#+FOY@J*/^(0Y;_P!#C'?^"*'^?K_2U/\
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MI"%1P=2,)M<T8U'3IN<8M*;A#F3Y8V_KLHHHK,L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_=/X?S%.IK_=/X?S% #J
M*** /G3]I;_AH?\ X0S2O^&<?[/_ .$I_MZ'^V?M'_",?VA_8GV2Z_Y!_P#P
MF?\ Q3NS[9Y'VWS_ /3MGD_8>/M->]Z1_:W]DZ9_;W]G?VY_9UE_;/\ 9'VG
M^R?[6^S1?VC_ &9]L_TS^SOMGG?8OM?^D_9O*\_][OK0HKLJ8OVF#PV#^JX.
MG]6JXBI]:IT>7&8CV_L_W>)K\S]K2H\G[B'+'V?/4UES:>-ALF^K9WFF=_VK
MG.(_M3"Y?A?[(Q..]KDF7?V>L0OK&5X#V4?JF*QWM[YA5]K4^LNCA_=A[/WB
MOF_]K_\ :"L?V5OV9/C7^T#>:9)KUU\-/ NJ:OX:\,06]S=W7C'QY?&'0OAU
MX'LK2S9+RZU#QOX\U7PYX3T^VM&%U<7NLP0VV9G0'Z0KS'XJ_!KX;?&W2?#&
M@_%'PTOBK1O!WQ%\ ?%C0--FU77-,M+?Q[\+_$MCXP\":U>PZ)J>F+K4&@^)
MM,T_6$T+6_[1\/:A=65M_:NDWT421CC/9/YIOV<?&WBC]FSP'^V'^S#\)/%O
MQ9^'_C'XK?L,S_M?>%/BO^T%^S+^U)\&#KG[5OPO\"Z3X%_;MU7P)X:^,6@_
MLV^(=:\2>,OM/PK^*NCZI\./$L]GX&\8^--7\;ZIINL6^GWF@:C^YW[)=Q\9
M-0_8?^&FM_'+XA^%?B=XT\1_ ?PMXBB\4>%_ _BGP/++HFM?"W0[ZQM?%B>+
M_BM\7]6\6>-TN);VX\3>.EU_0[3Q1>W0O(?!^@NDR7/M_P 4_P!G7X,_&OQ)
M\//%WQ0\#VGBSQ!\*O\ A/8_!%[<ZIK]A%IUE\4?!>H?#WXA:-J6G:1JVGZ9
MXH\.^+O"&I7.DZUX:\5V>MZ!=-'8:D=-75M*TN^LSX,?L^_#+X _#"U^#?PV
M@\<1_#O3[9M/TO1?'?Q<^+GQ?O=&T?\ LFRT*V\.Z'XF^+WCGQUXKT3PMIFD
MZ=:6.B>%=)UNS\.:#$DIT72[![FY>8 _G]_9+_;9^)WPF_9)_P""97[-'PGA
M3PQJ.L?\$_O /QP\9?$V\_8U_:U_;F6TT2&YL? GAWP;HGP:_9)O?"WB/3;W
M5-734]7UKX@>,O'VC>'M LM-TS0[+P_XCU7Q5%<Z%]6?$3_@HU^T+;_L_?!_
MQA;>'_#'[/'[0'BGX"^.OB_XW^!?CS]CK]MO]JSXCV>J>!-:U#P@Z:W\'_@A
M8_"[QW^SY\&_%>OZ<FI>%?C9\;]1B:^T[43HZ?#V;4/#^OZE:_=]S_P3Y_92
M;P;\&/ ^B^!O&?@/3?V?/ S_  Q^$/B#X3_';X__  =^)?A+X;S1Z:MUX ;X
MP_"OXH>#OBSXA\&7TVC:/J&H^&?%7C76]&U+6-(TK6[^RN-8TVROH)O''[ G
M[,7Q'N?!^H^,_#OQ.U?6O!OPYN?A GB5?VDOVEM,\6^./A5>:H-:N_AQ\:_%
M^D?%VP\3_M!^";G5&N[N?PS\==6^(NCRMJ_B".2T:'Q'KT>H@'Q/IO\ P4*^
M-_B?4?V4_B;XEM_ ?[+7[+G[0/[/G[(_QAL_B;\0?V>/C/\ M%^$O%'CK]H6
MYLY?&'P:UCXZ_#3XK_"SX<_LH:CX7;Q/\-O!W@/QM\?O#.K^'OB3XH\>BZT&
MWN9O#=WX4U+U3_@FUJW[4_B#Q!^V'<_';XY>!/BIX6\+?M??';P#H.C:3\+/
MB+X7\0:%JV@7O@^2+_A'?$OC']HOXKZ=H7PIM=.N;JU\.?">R\)_:?#M[<S7
MZ^/M1@DDTU_H)?V /V8%L?A9H+^'/B?<>!_@QX8^$W@[X??">]_:4_:8OO@=
MI_A_X&PZ%%\*[77O@1>?%Z?X.>.KKPG+X8\.ZC%JWCOP/XEUC5=<T33/$&NW
M^J:Y9PZ@GJWP]_9K^$7PJ^)WQ/\ BY\/])\5^'/%?QDU:Y\1?$33(/BE\5;S
MX:ZWXIOK?0;34_&-G\%]2\:WOP=\->-M8M_#6CQZYXT\+>!-$\4ZYY%RVK:O
M>OJ6IM> 'YX?&']LS]K(^'?V[_CS\#(OV<]'^!__  3^UOQKX;\3?#3XL^#O
M'_B/XJ?'W5/@9\,M ^,WQLN=(^*GA+XO>$/!O[/MAJOAOQ+%X)^%JZ]\*_C?
M<-K&BMX^\8#3M&\1P>#M X/XD_MZ?MC:I<?MU^./@=I7[-VB_"K]BKX%?"W]
MH2W\/_%+P-\4?$WQ*^+6D^-?V<+;X_:Q\,VU/P]\5? /AOX;:O%:Z?KNF:5\
M1;G2?&]K;7>HZ1IVI?#62/2;_7=5^\_B1_P3Y_9+^+7Q \6?$CQS\.-?O]9^
M(M[X/U#XJ^&M'^,'QL\'_"7XSW7@/[)'X9?XY_ KP;\1= ^"GQO2VL-/T_0]
M2@^+/P_\96_B+PQI]AX4\1Q:MX;L[;2HO4]9_9@^!GB&3]HV75_ _P!KD_:U
M\*V/@G]H-O\ A)?&%O\ \+ \,:;X!O?AA9:9BU\00+X4\GP-J%YH?VWP2/#>
MH2>=_:<MW)K$<6H( ?E#\;?^"G7[0/\ PLKXO>%/V?/AU-(/@;\)?A%X[_X0
MF7]BO]MK]K'6_CSX]^+'PPL_C#8?##2/BI^S+IUC\-_V;K.+P_J>@>$+#QW\
M0['XH7.H>)];U/7+GP#IGASPA(GB7[3_ &S?VL/BS\"_V//!G[0?PL^'/AV/
MXF^-/'G[*7A:S^&7QP_X270+'1I/V@/C!\,OA]KGACQE=>'(CX@\+:_H-CXX
MOK";58M%U]O#>O68U"\\'^)X;&;PYJ'I?C#]A;]G'QCXBMO%W]C_ !3\ ^*8
M_!OA'P!J/B+X&?M)_M*_LYZUXL\(_#^WU"T\!Z3\0M2^ 7Q<^&MW\2O^$*M-
M6U>T\)W_ ,0)?$NI^'K35]7M=(O;2#5+^.X]D^*GP/\ AA\;/ ^F?#CXH^';
MCQ=X/TCQ3\._&UCIMWXC\4V5TOBGX4>,- \?> M8N=<TG6]/U_4+C1?%WAC1
M-9FCU#5+JVUN2S:U\00ZK8WE]:W(!^2_CW]K+_@HM\.Y/V[M%N-9_8J\3W7[
M!?PQT']H#6?&$/P;^.?A:W^./@/Q)\)]5^(EM\*M,^'3_M#>*Y/@SXNTJY^'
M7Q'M9_B_=?%#XS:-JT&L^"(8_@QH\FG:]>W_ #?QG_X*A?M!M\1?CEX>_9]^
M&5W?+^SY\/?@QXHA^'"_L4_MM?M4>(/VB/''Q2^#NA_'B?X;:+\:_P!F[3K/
MX4_LSB+POXK\)>!_#OBWXB:/\5IM1\7:OK7B37/!WAWPGX7MU\4_K=XB_9H^
M"7BN;]H"?7_!7V^7]J3P#IOPP^.[_P#"1^+;7_A.O VD>%O$W@O3M#VV6O6R
M^&/L_AKQAXCTW^T_!R^'M8F_M'[9/J$NH6EC=6OFWBW]A/\ 9O\ %WB./Q>F
MD?%?X?\ B@^$?"'@75==^!?[3'[37[.>I^+?#'P_L[O3O ME\0;KX!?%_P"&
MTGQ(NO!^FW]]IGAK6?'Q\2:WHNF7EUIVGZC!93R0, ?GQ^V%_P %/?B9\![W
M7O%/@9/!UUI/PLL/V?=;^)WP!O\ ]EO]K;XJ^/[:Q^+=SX(UCQ!X8^+'[47P
MY_L/]G7]B_XH:=X.\6W5UX8\!?%;0OBG?7]M:^$?&6M7.E:3\2-&T+3/I31_
MVJOC38_MO:M\$OC-J_@3X#?"_4_B#=^#?@-X2\5_LV_&37=4_:7T1?A';^*=
M.\0>!/VT].^+^F_LX^&?'=UXR@\97$W[/^M?"[5?BQ%X/^'FJ"*PN(==L_&&
ME>H_%/\ X)Q_L?\ QH\3>.?%/Q%^''BK5KGXH'PQ/\4/#VE?''X^^#_AW\3]
M6\%6&G:;X.\4_$GX5>#/BAX?^&7C_P <^%;?1?#\OAWQ]XN\(ZSXTT74?#'A
M35].UZWU7PKX=O=,]+_X9'^"4_QAT[XZ:Q:_$_Q;X]T/Q/J/C;PO:>/OV@_V
M@OB)\-/!/C'4]#UCPS/XI^'WP0\<_%#Q#\%?A]X@MO#GB+Q#H.D:OX*^'^@W
M^@:/X@UW3=#GTZSUC4H;D ^)_A+^WE\9?'/[.O\ P2]^+/B#PO\ #FP\5_MJ
M_M!V?PE^+>F6.B>*K71_#6AS?!G]IOXAW%QX"LKWQA=ZEHVNQ:]\%_#%EYOB
M;4O%5FFF7WB"W?33>7.GWNE<!\)?VXOVJ/%/[(5A^U=\5O&G[*/PWT_XJ>/K
MSX5_!_P?X?\ @9^TK\5?%MAKMA\5O%'PWAUFV\#?#SXA>(/B+^T7XX\2CPM?
MZAHW[._PP\)>!M1L=-AU'Q)J'QJFT71-76S^S?"'_!./]COP+X]\(?$GPU\+
M]=M?$?PY^(_C#XL?#"QO_C%\<->\#?";QO\ $&?Q?=>.;SX0_"[Q!\2-4^&?
MPGT3Q==>.O$=SXB\&?#KPCX9\%ZO<2Z1/>^'YI?#'AA]'Z_4OV'OV8M3^!_@
M[]G1_A[J>F_"OX=>-4^)'P\L_#GQ*^*OA/QKX \?Q^*==\9)XS\#?%OPOXWT
MCXN>$/$J:[XH\2%=8\.^.=-OAH^O:QX8$W_",ZC=Z/* ?B5\1?VL/CM^UC\.
M_P!FF2"Q^']K\;_@9_P6W\,?L\:!XL\4?!OXZ_ 'P+XGN--_9?\ B#\0?"_Q
M%\4?LZ_%;5-1^.?P^_LOP[\5=-@U[X7:]XS35/%&K>%KK^S/'?A'1O%VGZQX
M=]5^/WQU^-'C;XA?#?\ 9]^/Q^%NN?$3]FC_ (*N_P#!/>UB^(WP=\.>)O ?
M@SQ]X/\ BYH.K>//#-S-\-_&'CSXIZ_X&\3Z"PU31=<T^7XC^++#4XX=.US3
MKJRAU!M.MOT@NO\ @F;^Q5?_  ]U+X7ZE\)-8U7PKK'QR'[36IS:O\8_CEJW
MC*]_:$3X:6WPEC^,\_Q*U'XE77Q';XCP^$+.TN+?Q6/%8U:W\<V\/Q4@N8_B
MC&OC$=OX:_83_9<\*:'I.A:=\/-7U$:1\<O"_P"TH?$GB_XH_%SQ]\0]?^.'
M@J&&T\)?$#QS\4?'/CSQ%\2/B)J/A_3[6ST?2]/\>^*O$FAVVA6&G:"FE_V/
MIUE8P 'YL^'?^"H'[0WCKXJW>M?#_P"$'B?QG\']+_; U_\ 9IN_@QX4_88_
M;8\4?$"Y^'WA'XIWWP(\8_'=_P!MW2[=/V2="N/"GBW3]6^*FM?"R[\&ZE;Z
M=\/- O/ .L?%+1OB)=7=WX?^G?VS]3M]$_;E_P""5VLW:7$EKI'Q!_;'U.YC
MM(6N+J2WL/V-?B==3);6ZD-/</'$RPPJ0TLA5 <L*^EK3]BKX Z3\5-3^,7A
MFR^+7@7Q5KOCZ/XI>(M"^&W[2W[2WPS^$GB?XA,^GRZIXK\5? /X?_%SPW\"
M_%&J^*[G3+6]\?2>(/ASJ47Q$OWOM0\=1>(KW5-3GN_8?%WP=^''COQ_\)OB
MCXJ\._VKXZ^!NJ^+M:^%FN?VOKMC_P (OJ?COP?J7@'Q7<_V9INJ6>CZW_:O
MA+5]1TGR?$6GZO;V/VC[?IL5GJ<,%Y$ ?C;^RG_P4U_:=^/_ (C_ &>/&4/P
M2U_QO\*OVF]+\7:I!X#\(?L4_MH_"R;]G/2[[P=KGC_X0>)?&O[:WQ<M&_9B
M^//AO6K?0M-^'/C'4O 'A/X<:6GB_P ?:-XI\":UXN\*>&[BV\3^3_&/]K7X
MB?%7]BGXVZ1^UEIOP>UGXR^&-:_8@\8>+_V,?$_[-?[4/[-'B/X37OB/]L+X
M:^'9]5O/'NN?M(7%Y^T]\/\ PO\ $'1)[/X?_'/X$OX2^$7BWQ1\/WN=67Q#
MX?\ $=WX#MOU[^'O[#7[/7PFUR36?AE;?&CP'I__ !6*Z?\ #SPK^U5^U1HO
MP1\-P^.H]:37K7P7^S_8_&>'X'>!;&&7Q!J=_P"&+#P;\/="LO VKO9ZWX)@
M\/:OI6E7UEC0_P#!/;]E1] \<^'M?\'_ !!^(4/Q(C^&]KXNU[XO?M#_ +1W
MQH\>7VE?"+Q]#\4OAUX<T[XE?%GXL^,_B'X<\(^&_B% /%T7@_PUXHTCPMJ.
MLSWMQK&D:@-0OTN0#Y-^,/[9G[63>'OV[_CS\#(OV<]'^!__  3^UOQKX:\3
M?#3XL^#?'_B3XJ?'W5/@9\,] ^,WQLN=(^*GA+XO>$/!O[/MAJOAOQ+%X)^%
MJZ[\*OC?<OK&BMX^\7C3M&\1P>#M \R^)O\ P4"_;(N8/V^_B?\ !G1/V;]+
M^#G["WPL^&'QQ_X1?XD^"/BAX@^*7Q>\*^+?V6O!/[2?BKP%)KFB?%;P-X8^
M%NN:-IMWXKL])^($GAWXD0W<VH:)I-W\+H)/#5]K7C#]!/B1_P $^?V2_BU\
M0/%OQ(\<_#C7[_6?B+>>#]0^*OAK1OC!\;/!_P )?C/=> _LD?AE_CG\"O!O
MQ%\/_!3XWI;6&GZ?H>I0?%GX?^,K?Q%X8T^P\*>(XM6\-V=MI47I>O\ [*WP
M%\3VO[35GKG@/[=;?MC>'$\)?M'1_P#"4>,K;_A8OA^/X8I\&TT_?9^(K>3P
MAM^&\:>'/M7@1O#%Z<?VN;DZ\3JA /&/VVOVHOB!^S]^QM<_M&_"+PKX.\1^
M.+GQ5^R_I'A[PG\1[[6[+PI>6_QU_: ^#OPLU6PUG6?#"2ZOI,UOX?\ B+J3
M:?X@L=-UQ-%UF"QUBY\+^*;*SN/#>J?%GQT_X*%_M/\ [&D_[0_@#X\Z)\$O
MCA\1/!GP7_9V^*OP<\6? _X:?&+X>^&[[4OVB/VA5_9<L?"WQ$^$I\=_M(_$
MB_@\&?$.ZL?%BZIX U^^UGXA^%WN/"7AGPAI_CC[!!J'V[^W?^RE??M2?LAZ
MW^S)X+M_!$-KJOC/]FN];2OB/)J5UX,O? GP>_:%^$7Q.\6^'-96+1?%EYJG
M]L^!/ .MZ%IUC?Z7?6>L:K>V-CKEW9:;=WVJ6NQX<_8 _9.\.>#OBUX&E^&N
MK^-](^.FB:#X:^*FI_&+XJ_&+XZ^.?%7ASPE%,G@O0'^)OQH\?\ CWXCZ-HW
M@2ZN+G6O .E^'_%>DV7@3Q/<W/BOPC!HWB:YGU:0 _.#Q3_P4D_:X^'/PA_:
M;\1WGPOL/B-K'PI3]EG6?A'\8O&W[%W[9G["/P=\>W'QO_:!T#X+?$'X/^)/
MA_\ M)ZIXF^(-KXW\ Z=?V?B[3_B%X$\5^-O#%]I?CS1);WP=#J'@G5]!\6_
MM#\)[#XNZ;X&TBU^.?BSX<>-/B6/M$FOZ[\)_A]XG^&/@:3SIWDM+/2/"GC#
MXF_%S7X?[/MFCL[C4[WQG/\ VQ/"^I1:3H4=PNE6OA<7[#?[/DG@#QO\+_$4
M?QO^(_@7XAZI\.]:\2Z'\9?VL?VKOC?C4_A5XPM?'O@FY\.:G\7_ (U^-]8\
M$?8?%EAIVK:Q#X)U#P];^+O[,TNP\81:]INF6-G;_7= !1110 4444 %%%%
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MQ'IFB>%+;1;[PS?6WBK6/ 6M65]JC:[I]S+J.C6.H^%M8N+?4-(:6.W$4MW
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MK;XA^/U\.KJXU"R74;6_\/.-*O&U'3WLI+>>225+2>W^U017%M%.9(HWZ?\
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M4XJ$I*;C*G2J)R2LG^\A.S2[6$XIVNMMM6M[=O1'Y"_\.W/VD/\ I)+\?O\
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ME?;;K0I[.UU6+^R-:T[7;;[+/J%AJ=HF^[TNWCG\ZQGW6SS)'Y4K)-'\9?\
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MB./2X[,11;/U>_X=G? C_H;/BW_X/O!W_P P5'_#L[X$?]#9\6__  ?>#O\
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M/D"YMK>6+]G/^'9WP(_Z&SXM_P#@^\'?_,%1_P .SO@1_P!#9\6__!]X._\
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M-K/P^_:6^'\OP5\::/K+C2+G4M6TWQ1+X8_'_P#;#\+?MF_&CX&7'A_]I/\
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MO^?6*_\  *7_ ,O/] ZBO\_'_A]W_P %0/\ HYS_ ,PO^SW_ /.GH_X?=_\
M!4#_ *.<_P#,+_L]_P#SIZ/]4,R_Y_X'_P &XC_YF#_6+!?\^L5_X!2_^7G^
M@=17^?C_ ,/N_P#@J!_T<Y_YA?\ 9[_^=/1_P^[_ ."H'_1SG_F%_P!GO_YT
M]'^J&9?\_P# _P#@W$?_ #,'^L6"_P"?6*_\ I?_ "\_T#J*_P _'_A]W_P5
M _Z.<_\ ,+_L]_\ SIZ/^'W?_!4#_HYS_P PO^SW_P#.GH_U0S+_ )_X'_P;
MB/\ YF#_ %BP7_/K%?\ @%+_ .7G^@=17^?C_P /N_\ @J!_T<Y_YA?]GO\
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M3T?\/N_^"H'_ $<Y_P"87_9[_P#G3T?ZH9E_S_P/_@W$?_,P?ZQ8+_GUBO\
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M]W_P5 _Z.<_\PO\ L]__ #IZ/]4,R_Y_X'_P;B/_ )F#_6+!?\^L5_X!2_\
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M_P#@J!_T<Y_YA?\ 9[_^=/1_P^[_ ."H'_1SG_F%_P!GO_YT]'^J&9?\_P#
M_P#@W$?_ #,'^L6"_P"?6*_\ I?_ "\_T#J*_P _'_A]W_P5 _Z.<_\ ,+_L
M]_\ SIZ/^'W?_!4#_HYS_P PO^SW_P#.GH_U0S+_ )_X'_P;B/\ YF#_ %BP
M7_/K%?\ @%+_ .7G^@=17^?C_P /N_\ @J!_T<Y_YA?]GO\ ^=/1_P /N_\
M@J!_T<Y_YA?]GO\ ^=/1_JAF7_/_  /_ (-Q'_S,'^L6"_Y]8K_P"E_\O/\
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MZH9E_P _\#_X-Q'_ ,S!_K%@O^?6*_\  *7_ ,O/] ZBO\_'_A]W_P %0/\
MHYS_ ,PO^SW_ /.GH_X?=_\ !4#_ *.<_P#,+_L]_P#SIZ/]4,R_Y_X'_P &
MXC_YF#_6+!?\^L5_X!2_^7G^@=17^?C_ ,/N_P#@J!_T<Y_YA?\ 9[_^=/1_
MP^[_ ."H'_1SG_F%_P!GO_YT]'^J&9?\_P# _P#@W$?_ #,'^L6"_P"?6*_\
M I?_ "\_T#J*_P _'_A]W_P5 _Z.<_\ ,+_L]_\ SIZ/^'W?_!4#_HYS_P P
MO^SW_P#.GH_U0S+_ )_X'_P;B/\ YF#_ %BP7_/K%?\ @%+_ .7G^@=17^?C
M_P /N_\ @J!_T<Y_YA?]GO\ ^=/1_P /N_\ @J!_T<Y_YA?]GO\ ^=/1_JAF
M7_/_  /_ (-Q'_S,'^L6"_Y]8K_P"E_\O/\ 0.HK_/Q_X?=_\%0/^CG/_,+_
M +/?_P Z>C_A]W_P5 _Z.<_\PO\ L]__ #IZ/]4,R_Y_X'_P;B/_ )F#_6+!
M?\^L5_X!2_\ EY_H'45_GX_\/N_^"H'_ $<Y_P"87_9[_P#G3T?\/N_^"H'_
M $<Y_P"87_9[_P#G3T?ZH9E_S_P/_@W$?_,P?ZQ8+_GUBO\ P"E_\O/] ZBO
M\_'_ (?=_P#!4#_HYS_S"_[/?_SIZ/\ A]W_ ,%0/^CG/_,+_L]__.GH_P!4
M,R_Y_P"!_P#!N(_^9@_UBP7_ #ZQ7_@%+_Y>?Z!U%?Y^/_#[O_@J!_T<Y_YA
M?]GO_P"=/1_P^[_X*@?]'.?^87_9[_\ G3T?ZH9E_P _\#_X-Q'_ ,S!_K%@
MO^?6*_\  *7_ ,O/] ZBO\_'_A]W_P %0/\ HYS_ ,PO^SW_ /.GH_X?=_\
M!4#_ *.<_P#,+_L]_P#SIZ/]4,R_Y_X'_P &XC_YF#_6+!?\^L5_X!2_^7G^
M@=17^?C_ ,/N_P#@J!_T<Y_YA?\ 9[_^=/1_P^[_ ."H'_1SG_F%_P!GO_YT
M]'^J&9?\_P# _P#@W$?_ #,'^L6"_P"?6*_\ I?_ "\_T#J*_P _'_A]W_P5
M _Z.<_\ ,+_L]_\ SIZ/^'W?_!4#_HYS_P PO^SW_P#.GH_U0S+_ )_X'_P;
MB/\ YF#_ %BP7_/K%?\ @%+_ .7G^@=17^?C_P /N_\ @J!_T<Y_YA?]GO\
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M@5?REU_5I_P<Y_\ -D?_ '<G_P"\"K^4NOU3AO\ Y$N"_P"YG_U+KGP>=?\
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MC5-$\0ZC8G30VGZ7<CQ+#V6C_P#!(JSUN[\3:MH_QR\>^+/ MM\!?V5_VA?
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M?@U?_'C3K""Y\.:!,WB;XB>-]2^(]M-K32VC^'O"^HWUQ?V.E<+J/_!(;0?
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MM]^6[Y;^=K7"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGZU+I#:KHQU;1XH]1TB[LM2TVYO]-N[2^N/>OV@/VX4\)?%GXD^$_P!G;4?
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MNI0G1A[+V?,JLK\D(TVTJ-%2DX12M"4E%1;BN:4:C2OS,X*BBBO7//"BBB@
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MG2?"WASXJ7GA_3+ZS?Q"MKXBNK;PM-\?67[>/Q!N(/VAM#\>_"_X-?%CX?\
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MGQM\4OC)\9O%?PW_ &?O"OPC^ 'Q.A\2ZS\!+^/XX0ZI^T#XTE\!Z;X$\:_
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MDYHJ*:6<9X&%?GIJ7(FY<E:$:E*26L:>L:E2*E*T93LYJ'-9\S1[A^RWX-^
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M>B<84444 ?JI_P $2_\ E)[^S#_UV^,'_J@OBI7^@I7^?7_P1+_Y2>_LP_\
M7;XP?^J"^*E?Z"E?G/%__(RH?]@-+_U(Q)]EP[_N57_L*G_Z9H!1117RI[P4
MU_NG\/YBG4U_NG\/YB@!U%%% !1110 4444 ? _[</[(/[.W[5G_  K#_A?G
MP\_X3S_A _\ A-?^$3_XJWQSX7_LK_A*/^$2_MW_ )$SQ-X=^W?;O^$=T;_D
M)?;/LOV/_0_L_P!HNO/^!_\ AT)_P3M_Z-Z_\RS\<?\ YYE?L9\6_P#F7_\
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M_AT)_P $[?\ HWK_ ,RS\<?_ )YE?I111_:>9?\ 0QQW_A7B/_E@?4<%_P!
M>%_\)Z7_ ,@?FO\ \.A/^"=O_1O7_F6?CC_\\RC_ (="?\$[?^C>O_,L_''_
M .>97Z444?VGF7_0QQW_ (5XC_Y8'U'!?] >%_\ ">E_\@?FO_PZ$_X)V_\
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M/QQ_^>97Z444?VGF7_0QQW_A7B/_ )8'U'!?] >%_P#">E_\@?FO_P .A/\
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M+?:/^%N?\*O_ +7\S_BH?^$>_M?^R_E^T4?VGF7_ $,<=_X5XC_Y8'U'!?\
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M_P#1O7_F6?CC_P#/,K]***/[3S+_ *&.._\ "O$?_+ ^HX+_ * \+_X3TO\
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M<]:_X8^_X3'_ (73_P )]\&MO_"N_P#A1'_"P/\ A6?_  MSP5_PNS_A!O\
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M9#IUK%XP?QEX@O$U'6/%6HW:']IYE_T,<=_X5XC_ .6!]1P7_0'A?_">E_\
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M_P RS\<?_GF4?\.A/^"=O_1O7_F6?CC_ //,K]***/[3S+_H8X[_ ,*\1_\
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M+/QQ_P#GF4?\.A/^"=O_ $;U_P"99^./_P \ROTHHH_M/,O^ACCO_"O$?_+
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MC1ITZ46^9QIPC"+DTDY-123;22O:]DET04445D:!37^Z?P_F*=37^Z?P_F*
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MWQ[!H5SX>_?K_A16C?\ 0Y^/O_!AX>_^9BC_ (45HW_0Y^/O_!AX>_\ F8H
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MP\/?_,Q1_P **T;_ *'/Q]_X,/#W_P S% 'D]%>L?\**T;_H<_'W_@P\/?\
MS,4?\**T;_H<_'W_ (,/#W_S,4 >3T5ZQ_PHK1O^AS\??^##P]_\S%'_  HK
M1O\ H<_'W_@P\/?_ #,4 >3T5ZQ_PHK1O^AS\??^##P]_P#,Q1_PHK1O^AS\
M??\ @P\/?_,Q0!Y/17K'_"BM&_Z'/Q]_X,/#W_S,4?\ "BM&_P"AS\??^##P
M]_\ ,Q0!Y/17K'_"BM&_Z'/Q]_X,/#W_ ,S%'_"BM&_Z'/Q]_P"##P]_\S%
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M\2>)/@9-\$K_ /X3GX?OXA/BK0M'\1:-\?/@E\<] TV]\'Z]>^(K_P ->)?
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MY^/O_!AX>_\ F8H_X45HW_0Y^/O_  8>'O\ YF* /)Z*]8_X45HW_0Y^/O\
MP8>'O_F8H_X45HW_ $.?C[_P8>'O_F8H \GHKUC_ (45HW_0Y^/O_!AX>_\
MF8H_X45HW_0Y^/O_  8>'O\ YF* /)Z*]8_X45HW_0Y^/O\ P8>'O_F8H_X4
M5HW_ $.?C[_P8>'O_F8H \GHKUC_ (45HW_0Y^/O_!AX>_\ F8H_X45HW_0Y
M^/O_  8>'O\ YF* /)Z*]8_X45HW_0Y^/O\ P8>'O_F8H_X45HW_ $.?C[_P
M8>'O_F8H \GHKUC_ (45HW_0Y^/O_!AX>_\ F8H_X45HW_0Y^/O_  8>'O\
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MRU\0)XLU7Q?\6O!NO?"[3["X\0^&='U&[D\;^I?L _&/XLR?L-^.?VJOCO\
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MW_S+_P#W%?\ W&UXW0!;_P"$D^(W_12M?_\ !%X _P#F/H_X23XC?]%*U_\
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M1> /_F/H_P"$D^(W_12M?_\ !%X _P#F/JI10!;_ .$D^(W_ $4K7_\ P1>
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M_12M?_\ !%X _P#F/H_X23XC?]%*U_\ \$7@#_YCZJ44 6_^$D^(W_12M?\
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MVWOVC-7UOX8_':^LO@@W[(GQF_;1\9?L>^%OAS9>#O'UO^T#X7L]#^)/Q#^
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MBE:__P""+P!_\Q]5** +?_"2?$;_ **5K_\ X(O '_S'T?\ "2?$;_HI6O\
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M2M?_ /!%X _^8^JE% %O_A)/B-_T4K7_ /P1> /_ )CZ/^$D^(W_ $4K7_\
MP1> /_F/JI10!;_X23XC?]%*U_\ \$7@#_YCZ/\ A)/B-_T4K7__  1> /\
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M_$K0_%/C?Q!I,GB31_BGJN@>(=&UO7!JO@W[7-H$_AG^B'_A1>H?]%+\0_\
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M$U&PGT.+XB:'$'OHWN[O4+2WGT^^^'_V:/\ @G++^S_XO_9^\9S?%/PG>O\
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M1>H?]%+\0_\ @B\*_P#RJH_X47J'_12_$/\ X(O"O_RJH \ZHKT7_A1>H?\
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M2_$/_@B\*_\ RJH \ZHKT7_A1>H?]%+\0_\ @B\*_P#RJH_X47J'_12_$/\
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MEG_@H/I.L?L$Z!\?;_Q9K5W>?#K]HG]HSX\O^PI^T)??$+XMZ]X-'Q*\!_L
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MGZK_ &LGAV?1M3_9X_9R^./BWQ183Z%)J1O-3^'-_9>(=.M)+G1]>X'X)_\
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MUR+Q-::-\;/C]XVUSXJ^/?!NE^(+:22QU;PY\--1\3I\+O!]WIFS2V\'>"M
M33HULXX<_#6B_P#!%GX>:#X,^&FM67[0OQZN/VI/ '[3FC?MAWOQNU?XM_M"
M:W\'_$GQ]O?BUJ/Q)^*OB5?V+=5^/]W^SMX:TWXG^'_%/C_X731:!H=MXH\.
M>$?&-W=V_C#4_$27^JZP >L^*/\ @I(NM? 3Q5\?/ GPE^+?PV^%>E?'_P"!
M7P:\!?&[XD^!O@I\3O!7QNA^)_[8GA/]D_5;_P"'GPQ^'_[8O@[XO>&;2+Q!
MKK&\U/XXZ9\(?%/@#3]1M_$MU\*OB!X@\-ZQ\)+_ -:\2_\ !0/P?X%^+6K?
M##XA_ /]I'X>:-+X>^/VL_#+XN^,/#7PQTSX??'/5/V:=)EU[XH^%/AKH,7Q
M;NOC7IFJ+H6F>*?$'@CQ%\6OA#\+_AQ\2_#/A+4?%GP_\=>(_"VN^!-9\7_)
M>J?\$F?&OCK6?CYXO^(/QS^ WA;Q=\>/'_['GCWQ'!^R[^Q_JW[/OP_\2Z]^
MRM^V!X9_:RU/Q]\8O!FM_M._&/4_C#\=/B6?#$'PN3XQ7WC#PU>^$/"]W<75
MQX;\8D)I@X;0_P#@B9_9O[0]Y\=[_P"-GP?O=4CU/]M&ZM_&]C^R+ING_M2_
M$33OVQ?#OQ0T-M*_:4_:CO/C9K.O_&JS^!<?Q TO1O@[INB>"?A9X8T3P!X4
MM?!%UX:N4C\*ZUX* /NO]E?_ (*%> ?VJO&6@^"]-^"G[1'P8N?B!\!M'_::
M^"^K?'/PK\/_  ]IGQN^".HZQHN@:EXS\$6O@KXG_$#Q'X>E\+:IXL\$1>(O
M"WQ<T#X9>,X[3QUX5U?2?#VKZ-?SZA9^G_M7?M;^%/V3+#X)OK_PU^+_ ,6O
M$?[0OQNL_P!GKX6>!O@KH'A;7O%.M_$[5OA;\5?BMH=A?GQGXT\!>&_#V@:I
MI7PCU[1;GQAKWB+3O"OA+4M3TG7?'VK^$OAW9>+O'/A;XX^)7[$G[0/PQ^'O
MP5UG]EGXN,GQ[^"7[!R?\$^/AWXK;P!X'-GX<U+XB^//V8++4/VL=5TKXA^+
MM2\,W6C_  7T3X+ZG\0=4^#$NE>,M3\<V<LOAO0]4O-8@LK+6_M?]HC]G#_A
M??C7]D;QA_PF7_"*?\,K_M/0_M'_ -G?\([_ &[_ ,)WY/P ^/WP,_X0W[7_
M &YH_P#PC&[_ (7G_P )3_PD7V7Q#C_A%_[$_L,_VW_:^D '&>%_VW?A]XL_
M9)^,7[6D?@SX@>"])^!&C_M"2_%'X7?$NST#P]\1/ _B_P#9GN?&&G?$WP-X
MDD\-:_XV\&/?V&J>"]2BLO$7A+Q7XP\'ZSIESIVOZ!KVL:1>V]Q)^:,/_!1O
MX]_L\?$;]EGX5_M._%C]G]!=?L[?L[?$_P"/T?C#P'K&A?&3XU:A\6_"_P ?
MM<^.WQ(_9_;PAXXT#PUX1^%W[(=W\+O#6J^/=%/P8^,&L:GX/UZWTSQ1XG^'
M.LZIX;\6>)OT&O?V(XI?V4OVVOV:9_&=IXB@_; UC]LS6YM3O] ET2P\-1?M
M:MXTED\.7MM!JNOS:K:>%$\6MI]SK</V.76H;9[R/0]->4629?PI^&'B[]J'
MX.?L1^-OC=:>+/AMX;\!?#OP#\1?B1^RUXO\%7GASQ-<_M->#=/\(W'@B_\
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MR_C?\#_VM?@W\(/!/Q6_8Q\6S?$[XL_ ?P9HO[$*6'BK7OVZ/B!\(?B#KO\
M9/Q?_:/T+6K7XU^&=)\!>#_@MHUC\1/B#?:3?_L\?$7P?J7@3X+>)KW5OC-X
M9UCQ2=&\!_-GP[_X*T>,]8_:L^''PS\:_%C]B^PM?BC^V1\8_P!DF[_8=L5\
M4:'^WS\$M*\#7OQ:T7X<?'?QW=ZY\8KP>,/"_P 2;CX6:'XON/#47[,?PUT/
M0_ 7QI\&ZMH7Q8\:Q:!%>^//LWX]?L8_M,?M+W-AX&^+?[5?PHU#]G2\^(O[
M/OQ9\3^ /#_[)EYHWQ<TGQA\"]0^&7C672?@S\;KO]HS6='^''@;QA\6/AK_
M ,)N/^$Q^#_Q>^+G@_3/''C+PGX<^,T*1>"=:\%^@ZM^RW\<OBC^T9\-?BK^
MT!^T!\/?%GP=_9_^)7CCXK_ 7X'?";X">)OA/J$7C+7/#7BGX>^!=8^/?Q)\
M5_M"_&:#XP77PQ^'OC;Q5!HT'@KX?? [0]5^(&J1>/[_ $2--%\/>&-) ,/X
MV?M _&;0OVKM7^&_PDT:[\;Z5\#/V'/BK^TUXR^#.CIX>L_$7Q[^)7B[Q4_@
M[]FOX;:7XOUK2=3F\#6MS>_"KXUPW6H600ZKKNL^$I;PR:1X=U;3=6^1OV)/
MVSOVQ?VS[7XM^%OA[\;?V0/&%_X0^&OP1\1-^T+X8_8Y_:$\._#/X+?';Q7J
MWB:;XN_LA_%SX$^./VS+'Q]XL^,/@+P=IOAS5]:FTOXO?#'7_A7J'B>QTOXL
M?"[2M3O-!TK7/9?VH?V7]6^,'[5WQ1\*7=O\1O#WPV_;G_X)M?$K]D;QK\:?
MAGIL\FH_!_Q#\,O&_B?6O!PU77397=AX>O\ QEX9_:=^*FH^!KO4\:5>:O\
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M\,ZK^S+XB\/VGPJM/B3XF^'UGX(^,GPKMM5_4OX6_LQ>$OA5^R1X/_9#\/\
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MK]IOX'R?"#X*?M :-^SM>>(/%F@2_$;Q%K?PR\5?$VU\>?">S34&\7_"$P>
M_C=^SWX[\&VGQ#D?2M+\0>-O!/Q.T+Q;8>$X_$&B^'KO2=5U^U\2:$ ?)'PX
M_:<_;5^/G[%7AK]H7P3XL_8_^"&K>%&_:D;XM_%GXJ?#'XM_$CX0^-=&_9V^
M)WC#X<^#OB%\)_AOHGQV^$6M>$OA-\=/#G@O6/C/%XZ\7_'3QA+\-?";^'-
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M^SIHVM_M.WUS^SW\4]!T+XV?%30-/UOXCZQ^U!X3+:IX6U*]\#WI\,7=EXC
M/?\ ]KGXU^-/"/A?]ECPQ\(?&FEZ1XP_:@_:D^"7PCT7X@:5I6B>(;"/P2NF
M^)_CS\7+[PYINN1^(-%GN/%?P)^#7Q*\/>&=2NH]:A\/WWB+3O$R+J#:.BS?
M#OPR_P""AW[3?C;]NG_AF^XT[X*331?M"_'[X:>-_P!DM/A5\4_#7[37P._9
MS^%WA?7]3^&/[;7CGX\:M\6M3^%GC+X.?&S4Y/@W'X<L?#/P'T/2[B]^.Z^
M_!WQ%\=^-_@E\3;1_J?]K_X,W?ACPE^PIXI^&'@GQ-XPL?V./VL_@7XA@\,>
M%]*U+Q=XOA^&'B;P)X]_9(\6:Q:6-G%>:SK%E\/O!7QXNOB3XM%M#>7[^&?
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M^+/_ $-GAG_PB9?_ )IZ]0^+?_,O_P#<5_\ <;7C= &I_P )U\6?^AL\,_\
MA$R__-/1_P )U\6?^AL\,_\ A$R__-/7X]_M0_MI_$+X=?MNZ=^RUI'[5?[#
M7[)_A[4OV=?AK\5/#&L?M8_#[6_&_BCXJ?$+Q[\7/BK\.I_!'P_AMOVPOV7[
M&<Z98^"/#UU'I>GV/BW6[G4==9':&&>QA'KG@KXR_M>?M _$#XH>+/@;=_LZ
M>#O@)\'?CGXH^!">"_BOX$^)_B3XH?&W5O@]XOG\)?&KQ9IWQ8\+?$KPOX8^
M!6DQ>);;7_!?@+2;OX(?'ZXO[CP5)XUUC5K>P\:6WA/P@ ?I1_PG7Q9_Z&SP
MS_X1,O\ \T]'_"=?%G_H;/#/_A$R_P#S3U^*GB']M/\ :_@_9F\>?\%%=!LO
MV=D_9/\ !5OXU^)UA^SOK?@#XF']H#Q5^S7\.]:U+3=7^(;_ +0]O\7+7P%X
M7^(_B;P;H6K?%SP[\+S^S/XFTBPCGT;X3:C\1KO4+J\^)=CH_$;]N[XDZA)\
M5_B3X5_:'_8*_9$_9\^&OQ@\5?L^?#WQ)^VN^LSWW[2OQ;^'%C,_Q#M--\66
M7[0'P-T/X$>'=-\66.M^ =$%QX9^/GC?4[?POXE^)-UX(T[1[72/"VN@'[-?
M\)U\6?\ H;/#/_A$R_\ S3T?\)U\6?\ H;/#/_A$R_\ S3U\$?M?_';XN_#G
MP;^S9!\"-6^$FF>-/VB?VB/AG\&+?QA\0/"GB?XP_#WPWHOC?P?XY\67OB33
MO#G@[XD?!35O&.%\)6]MHLZ>-_#EI<6VH'49H7"I:'\^/$O_  4G_:)T:U\,
M^$?%_C?]DG]GN+1OC]^U[^SY\2_VWOBQ\-_B;XD_8VO_ !]^SC<^$E^'GA.'
M2+;X^?#8_ WQ!\:+/Q#XRLKVZ^)_[0GB30/ ?Q,^!_CWX+Z!J'Q6\;^(/#QL
M@#]_O^$Z^+/_ $-GAG_PB9?_ )IZ/^$Z^+/_ $-GAG_PB9?_ )IZ\/\ "GQ1
MU'7?B7XJ^%.L?#/XA>'-7\%_#[X;>-M4\?S:'/<?!'Q)J/Q N_&5A?>"OAM\
M2+I-*N?&?B?P'<^#);GQI97/A7P]/I.C>*? VI36ZR>(FLM/_-_PK^V]^T9K
M&M_"[X[7]E\$&_9$^-/[:?C/]CSPI\.;'P=X^M_V@?"UGH?Q*^(OP!\(_&C6
M_BU<_$JY\ >)HO&WQ?\ AF^M7GPHM/@?X4NO!WPX\>:8L_Q*\0>)?!FJ0^)@
M#]D/^$Z^+/\ T-GAG_PB9?\ YIZ/^$Z^+/\ T-GAG_PB9?\ YIZ^,?VJ?B?X
M[\-ZM^SK\'OA'KA\/_$[X_?'CPGX?.N1:1I.N3>%_@W\.1/\6/V@/$C6&O6>
MH:/ -1^&OA#4/A9HNLW]A?1Z+X\^*?@F\ALKJ[%O"W)?MF?'GX\? ;5/V;]0
M^&OA_P"$=U\.OB%^TS^SY\&_BAKGCF\\9:OXU&F?&7XO>%/AC-H?@'P;H$?A
MG0M+OUTKQ1?^+8_B?XA\>Z[;Z#J'A6S\(-\&/%MMXVF\9> 0#[[_ .$Z^+/_
M $-GAG_PB9?_ )IZ/^$Z^+/_ $-GAG_PB9?_ )IZRZ_/#X3_ /!2+X8_%OXB
M> ?!>G_!K]H?PAX4^*?Q@^.?[/GPZ^-?CCPK\/M,^$OB[XX?L]W?Q6'CSX<:
M7<Z3\3]<\?)>W.C?!3XC^(O"_BJ^^']G\//$%OX;U'PS;^,H_B%8:EX,L0#]
M(_\ A.OBS_T-GAG_ ,(F7_YIZ/\ A.OBS_T-GAG_ ,(F7_YIZ_*S]J;]JKXL
M_#+XP?'ZQ^&]]I/_  C/[+'["\'QY\9:%K>A6VK>%]7\?_'3XE>,?"?PK\6>
M.M1M19^*K#P3\$O"_P"SO\8O&WC#PYX7\2^$KOQ3X?\ $KSWNLV@T72[ZS\W
M^!G_  4MA^(_B7X%_"S7?BW^RM+XE\8?$SXD^'_$WQKL]:C\#?"'XP^%?#_Q
M$\1^ O@SH7[,/A#Q)\7/$6N^+OB]^T>EMIGBSP;X;\/?$+XM:!X6\!:!XE\8
MZGK6MQ>+OA!HWCH _9O_ (3KXL_]#9X9_P#")E_^:>C_ (3KXL_]#9X9_P#"
M)E_^:>OC']CWXG^.O'WASXU^$/B?KT?BOX@? 7]I?XR?!G6O%,>EZ3H;:_X>
MM-6L?B/\)KV[T;1++3]+L=7M_@E\2/AII>OR65I;VVK:]I^IZ[;V]K;ZK%:6
M_P!=4 :G_"=?%G_H;/#/_A$R_P#S3T?\)U\6?^AL\,_^$3+_ /-/6710!J?\
M)U\6?^AL\,_^$3+_ /-/1_PG7Q9_Z&SPS_X1,O\ \T]9=% &I_PG7Q9_Z&SP
MS_X1,O\ \T]'_"=?%G_H;/#/_A$R_P#S3UET4 :G_"=?%G_H;/#/_A$R_P#S
M3T?\)U\6?^AL\,_^$3+_ /-/6710!J?\)U\6?^AL\,_^$3+_ /-/1_PG7Q9_
MZ&SPS_X1,O\ \T]9=% &I_PG7Q9_Z&SPS_X1,O\ \T]'_"=?%G_H;/#/_A$R
M_P#S3UET4 :G_"=?%G_H;/#/_A$R_P#S3T?\)U\6?^AL\,_^$3+_ /-/6710
M!J?\)U\6?^AL\,_^$3+_ /-/1_PG7Q9_Z&SPS_X1,O\ \T]9=% &I_PG7Q9_
MZ&SPS_X1,O\ \T]'_"=?%G_H;/#/_A$R_P#S3UET4 :G_"=?%G_H;/#/_A$R
M_P#S3T?\)U\6?^AL\,_^$3+_ /-/6710!J?\)U\6?^AL\,_^$3+_ /-/1_PG
M7Q9_Z&SPS_X1,O\ \T]9=% &I_PG7Q9_Z&SPS_X1,O\ \T]'_"=?%G_H;/#/
M_A$R_P#S3UET4 :G_"=?%G_H;/#/_A$R_P#S3T?\)U\6?^AL\,_^$3+_ /-/
M6710!J?\)U\6?^AL\,_^$3+_ /-/1_PG7Q9_Z&SPS_X1,O\ \T]9=% &I_PG
M7Q9_Z&SPS_X1,O\ \T]'_"=?%G_H;/#/_A$R_P#S3UET4 :G_"=?%G_H;/#/
M_A$R_P#S3T?\)U\6?^AL\,_^$3+_ /-/677YC7?[;7Q(UW_@H%\,OV>/A]X<
M\!WW[-NIW7QC^&/CKXCZK9^)YO'6M?M ?"7P!;?$/Q;X;^'5U!JNF^$T\$?#
MFPUWP?X7\7>(I=-\7OK7Q(U'QY\/X6\(ZY\)=?\ [9 /U-_X3KXL_P#0V>&?
M_")E_P#FGH_X3KXL_P#0V>&?_")E_P#FGKX*_9E^.WQV^(GQ^_:[^$'QLT#X
M2^'E^!VJ_!N7P39?"R[\8Z\;?0OB?X+U7Q)):>*?&OBV/01XRU:-M.MKU-1T
MGX<?#JSTP:C/X>;2]>.DQ^*M9R-/^)_[0WQ,^/7[:?A#X/>*/ &FV'P)C_9W
M^"W@;1/B-X>N=4\&:)\5_&/A;3OC5\7OBMXK'A9M)\=^-CH_P@^+_P +$\(_
M"K3_ !MX!TGQ#K7A&]T;4/&G@N/QVWCSPD ?H9_PG7Q9_P"AL\,_^$3+_P#-
M/1_PG7Q9_P"AL\,_^$3+_P#-/7X6>)?^"DWQK^&7@7Q/X)\=Z;X%\6?&Y/V]
M-:_8@\"?&#X0?L[?M!_$3X7>*8M"^ MK^T'XN^+NG?LK?##QE\6OC]XM?X7V
M5MXO^#OBSX:>!?BAKOV_XJ>$;BYU'XC> O#2>,I?A[[7\,_VL_'/B#QC^P[X
M@G^-_@[XN>!/CY\0OVG_ -EWXEP^#_V>O&W[-NEZ7\>? 'AOQS\4_"+ZO\*O
MC5XJ^(7QS^$/CGX<:-^SI\7_ (3^-/A[XX\<^9KGB+Q+%KD_A?1KBPT>RM0#
M]:/^$Z^+/_0V>&?_  B9?_FGH_X3KXL_]#9X9_\ ")E_^:>OC']JGXG^._#>
MJ?L[_"#X1ZV?#_Q.^/WQW\)^'O[<BTC2==F\+_!WX=B;XK_'[Q(UAKMGJ&CP
M#4/AMX0O_A=HNLW]C>Q:-X[^*/@J[BL[JZ^SQ-R7[9OQY^/'P&U+]G'4?AIX
M?^$=W\._B!^TO^S]\'/BAKGCJ\\9:OXT&F?&3XN^%/AE+H?@+P;H$7AG0],O
MUTOQ/?\ BV/XG>(?'NN6^@:AX6L_"+?!GQ;;^-IO&/@( ^^_^$Z^+/\ T-GA
MG_PB9?\ YIZ/^$Z^+/\ T-GAG_PB9?\ YIZ^"/BO\=_CQX!_;._98^#MMH'P
MCA^ OQVN/BKH=]K,]WXRU_XNZEKW@;X2>(/B*EU:6\:>%?!OP[TC1=1T*TTM
MH9C\6[WQ[9:]<W0E^&,_AF*'Q7\,> O^"HOB[5OVF_ 'PZ\8?$_]D.QMOB1^
MUI\6?V6[K]C.R7Q)HW[<'P=TSP9=_%'2/A_\;/&EUK/Q8NAXK\-?$.?X::+X
MKG\/1_LY?#S1M&\$?%_PEJFB_$_QA'H<=YXV /W>_P"$Z^+/_0V>&?\ PB9?
M_FGH_P"$Z^+/_0V>&?\ PB9?_FGKX1^(/Q&^,GB7]KVS^ GPC\<>&_ MCX+_
M &4?&?Q?\67'BKP+'\0=$U?X@?$OQS;_  ]_9_GU[1+/Q!X)\33^$/!\WP^^
M,FO^)?#_ (8\?^!]6\:7$OA_3HO%6BVNEW[W?SYX#_:T^//PT^)W[8,/[3GQ
M,^!'Q.^!_P"R/\-OAO-XI\8? 3]FGXF_"KQ=J'Q[^(T=YXFM/@EX9T/Q#^U5
M^T@_CGQA9>!+KX;7%OX3T[3] \1^(O%7QQ^&N@: M]=2W=O. ?KC_P )U\6?
M^AL\,_\ A$R__-/1_P )U\6?^AL\,_\ A$R__-/7X?\ @;]M']K/4_@?I/QH
M^-6G_#KX=^*O@W_P4B\%_LS_ !W^&?PHL)-=\':M\+?BCXU\&?L_P:)?>*/&
M4VO^(;[5?A5X\^.WA#XA:KX_\$S>!T\6R?"V79X9TKPIXAU?PO-^UE &I_PG
M7Q9_Z&SPS_X1,O\ \T]'_"=?%G_H;/#/_A$R_P#S3UET4 :G_"=?%G_H;/#/
M_A$R_P#S3T?\)U\6?^AL\,_^$3+_ /-/6710!J?\)U\6?^AL\,_^$3+_ /-/
M1_PG7Q9_Z&SPS_X1,O\ \T]9=% &I_PG7Q9_Z&SPS_X1,O\ \T]'_"=?%G_H
M;/#/_A$R_P#S3UET4 :G_"=?%G_H;/#/_A$R_P#S3T?\)U\6?^AL\,_^$3+_
M /-/6710!J?\)U\6?^AL\,_^$3+_ /-/1_PG7Q9_Z&SPS_X1,O\ \T]> _M"
M?&G2_@#\*?$?Q&O-&N_%FLVSZ9X>\ ^ -*N8K77OB=\3O%NI6WASX=?#7P]-
M+#<1P:QXV\7:EI6A0ZA/;RV&B6]W=:_K!@T72M1NH/RW^ O[</[87Q\\%_LN
M?"NUN?V9/ G[4_Q>US]O:\^*'Q F^%WQ8\<_ SPKX&_8>_:7U']G*]E\$?"1
M?C;X#\;Z[KWQ U[7OAY):RZW\<]*M]"LXO%VMS:7J'F:3X?@ /W&_P"$Z^+/
M_0V>&?\ PB9?_FGH_P"$Z^+/_0V>&?\ PB9?_FGK\KH?VV_B%K7_  3.^(/[
M5L7A?PUI/QU\*>&OC1\.?^$:TRZO;CP)+^TC\*OBEXR_9O?^Q)]5M[K57^'^
ML_&SPH;[1(M2@OM87PG?6=O>"_U$2-/R_P"TE^U'\??V;/B=\"OAEHWQT_91
M^)7BOQ/J'[-G@>T_9F\5>'-5E_;3_:5M_&_Q&L/A_P#&/XY^$CX-^*?@;PE\
M*?"_@_0Y?$7C^[AM_P!G[XD?#[2=.^&WCK5?$?COP5H$[V?@H _7G_A.OBS_
M -#9X9_\(F7_ .:>C_A.OBS_ -#9X9_\(F7_ .:>OR$\"?MA_':;]L[Q7\'O
MC;XO\"_ [X:O\?O$_P )?@GX-\:_L*?M7Z%>?'S0[3X<#Q;X3NO ?[<WB'XP
MZ3^RSJ'CGQ#?6GBR_LO FC> =?\ $NM:%X \0VFDZ)]HE?6-)^K?V*/B?X\^
M)/P>UNQ^*NLGQ+\3_A%\9_CG\!_&WBEM/T;27\8W/PA^*OBGP?X9\<SZ7X>T
MS1-$TR^\>> K#PEXSU73-(T32=*TS5=>O;#2[,:;;6DTP!]G?\)U\6?^AL\,
M_P#A$R__ #3T?\)U\6?^AL\,_P#A$R__ #3U\0?LW_$SXG_'-_VGOB+9^*-.
MM?AX_P 9/&WPF_9GM-2\+6NHZ'IND_!2T7X8>,OB%JJZ;-X6\1>--/\ %_Q\
MT/XD7=E;#Q=:Z7JGP]T#PC/X4UC2UUJ[UBZ^:-)^-_[<FA_'KX\?!_Q-\9?V
M*O&V@?!7]EQ_BMXP^)?_  SE\8OV?_ _PK^)_C?5M0B^%6E>/O$FN?MA?':Q
MUGPSI?@KP?\ $#XG?$[1+:#P7K.G>&+?P"B>)M#L?'2^(]& /UV_X3KXL_\
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MYM&$8!]V?\)U\6?^AL\,_P#A$R__ #3T?\)U\6?^AL\,_P#A$R__ #3UET4
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M&O OPM_:*U[XA:Y\.M/_ &6/BS\0M3^*7QVL_%&N:SJS:+?Q>+-,\/\ PO\
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M\0>(+&RTP>&)/#UT ?KC_P )U\6?^AL\,_\ A$R__-/1_P )U\6?^AL\,_\
MA$R__-/7X@V7[47[=.N^'/ FA>+-=^ _A3Q/^VC^Q[\;/C?^S#JWPB^''BC^
MWOV=/BYX!\)^"?''A;X=_%.X^)?C_P"(?A?]H+0+[0?B)I\6I>._#_@CX+&?
M5/!>M64'@*SA\::1J/A']3/V??BQ8?'GX#?!7XXZ5;BTTSXQ_"?X>?%+3K02
M"86UCX^\):1XJM+<2K\LHA@U6.,2+P^W<.#0![E_PG7Q9_Z&SPS_ .$3+_\
M-/1_PG7Q9_Z&SPS_ .$3+_\ -/6710!J?\)U\6?^AL\,_P#A$R__ #3T?\)U
M\6?^AL\,_P#A$R__ #3UET4 >@>!_%GQ#U+Q3I5EK?B'0KW2YS>?:K6S\+2:
M=<RB/3[N6(1WAUZ\$)2>.*1B;:7>BM'A=^]?HBOFCP!_R-VD?6^_]-MY7TO0
M 4444 %-?[I_#^8IU-?[I_#^8H =1110 4444 %%%% 'C?Q;_P"9?_[BO_N-
MKQNOH#Q]X+UWQ=)I9TGQ%I.AQ:>EV)4U#PU=Z[)<2736Y#1RV_B?05MTC6W
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M9_\ ''A7X\_ NZ\"'XAVMV_C+5-#^).A_&O1]+^)]QJ_BC0+?3-!UJ_\&O\
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M_P##>ZG_ //&H X*BN]_X4SXR_Z'_P -?^&]U/\ ^>-1_P *9\9?]#_X:_\
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MSXR_Z'_PU_X;W4__ )XU'_"F?&7_ $/_ (:_\-[J?_SQJ ."HKO?^%,^,O\
MH?\ PU_X;W4__GC4?\*9\9?]#_X:_P##>ZG_ //&H X*BN]_X4SXR_Z'_P -
M?^&]U/\ ^>-1_P *9\9?]#_X:_\ #>ZG_P#/&H X*BN]_P"%,^,O^A_\-?\
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M'P/J,FO7XBGT>Z\*6Z/9R>6:K\#OCQ<?%;_@I1\,O@SXYUC]G+Q'^TZG[/\
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MOB)\%]?^(7PB^)?PD_: \0^._'.CV<O@NU\<_!O5?''A"Y^%7QL\%Z5<>(_
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MX1IXDURRDELY?$?B2?2PL.HZ-JT,7ZK_ /"F?&7_ $/_ (:_\-[J?_SQJ/\
MA3/C+_H?_#7_ (;W4_\ YXU '!45WO\ PIGQE_T/_AK_ ,-[J?\ \\:C_A3/
MC+_H?_#7_AO=3_\ GC4 <%17>_\ "F?&7_0_^&O_  WNI_\ SQJ/^%,^,O\
MH?\ PU_X;W4__GC4 <%17>_\*9\9?]#_ .&O_#>ZG_\ /&H_X4SXR_Z'_P -
M?^&]U/\ ^>-0!P5%=[_PIGQE_P!#_P"&O_#>ZG_\\:C_ (4SXR_Z'_PU_P"&
M]U/_ .>-0!P5%=[_ ,*9\9?]#_X:_P##>ZG_ //&H_X4SXR_Z'_PU_X;W4__
M )XU '!5^9O[3O[!?Q!^.'Q#^.WBSP3\:/A3X7\-?M._L]^$OV;/C%X8^,W[
M,S_'[5=+\!^$KWXG7-O+\%_$EM\;/A+8^!;J_D^*NM:U>Z1X_P#"GQD\'#QI
MI.@^*[?PQ"PU[3-?_6__ (4SXR_Z'_PU_P"&]U/_ .>-1_PIGQE_T/\ X:_\
M-[J?_P \:@#\I/%O['_[1E]^TK^SM\9/!/[2/P;T+X<?LT>#/$?PV\$?#KQI
M^S'X_P#'OQ!USP1\1-&^$>E_$W_A,_B_I_[6_@?2-5\8ZG/\*8KSP5XFT[X2
M:-IOA0:Y-#XC\+_$&6Q%W>=G\=/ ?BBR_;/_ &0?C9X=T;Q3>:5=?#S]I[]E
MOQQXA\(: VOW?@6T^,.G_"SXP^#?'GB 2:9K5CHOAC2/$W[-4OA5==U;3YM$
MM_%7Q \+Z?K EM-3$3?I1_PIGQE_T/\ X:_\-[J?_P \:C_A3/C+_H?_  U_
MX;W4_P#YXU 'XP^)_P#@G#\2/CYJ'CKQ)^U]^TCX1^(WC76/V8?$7[,/@3Q5
M\ ?V>[K]G:Y\-Z7XM\8^%/B'K'Q'\;VOBCXV_M 1_$CQUH_CGX=?#_Q'\/\
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M/%FH:7ILEK*E[X8UA;E#:_7?_"F?&7_0_P#AK_PWNI__ #QJ/^%,^,O^A_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW?BJ#X&>-O$?B;Q).UM;-XQ\::=IL-Q:ZSXBT2"7]F: "BBB@ HHHH ****
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M7[)>D_&._P#@-??$S58_B1H_Q5\+? [Q%!%\*_C#=>#/"?Q:\=Z7X<U?X?>
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M-;O-/TG2/L'4OVU_V:])^-L/[/EYX\U?_A8K>+](^'5[=V?PS^*VI?"SP_\
M$SQ#X;7Q=X=^%OB_X]Z;X(N_@1X*^*OB/P]/IE_X=^&/BWXD:+X\UU_$7A&Q
MTGP]>:AXR\*VFL 'VA_PM+XH?\\? 7_@M\0__+RC_A:7Q0_YX^ O_!;XA_\
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M =/_ ,+2^*'_ #Q\!?\ @M\0_P#R\H_X6E\4/^>/@+_P6^(?_EY7,44 =/\
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M/_R\H_X6E\4/^>/@+_P6^(?_ )>5S%% '3_\+2^*'_/'P%_X+?$/_P O*/\
MA:7Q0_YX^ O_  6^(?\ Y>5S%% '3_\ "TOBA_SQ\!?^"WQ#_P#+RC_A:7Q0
M_P">/@+_ ,%OB'_Y>5S%% '3_P#"TOBA_P \? 7_ (+?$/\ \O*/^%I?%#_G
MCX"_\%OB'_Y>5S%% '3_ /"TOBA_SQ\!?^"WQ#_\O*/^%I?%#_GCX"_\%OB'
M_P"7E<Q6?J^KZ3X?TG4]>U[4].T30]$TZ]U?6=9U>]MM-TG2-)TVVEO-1U/4
M]1O)8;.PTZPLX9KN]O;N:*VM;:*6>>6.*-W !V__  M+XH?\\? 7_@M\0_\
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M?\*I^)G_ $$_ O\ WQK_ /\ &Z /QP\:_L=_M*ZUK7QD^"NCW7P,E_9=^/\
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M]E^X/_"J?B9_T$_ O_?&O_\ QNC_ (53\3/^@GX%_P"^-?\ _C= 'X?>!_V
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M_P#QNC_A5/Q,_P"@GX%_[XU__P"-T <K175?\*I^)G_03\"_]\:__P#&Z/\
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M_P#\;H Y6BNJ_P"%4_$S_H)^!?\ OC7_ /XW1_PJGXF?]!/P+_WQK_\ \;H
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MC7__ (W1_P *I^)G_03\"_\ ?&O_ /QN@#E:*ZK_ (53\3/^@GX%_P"^-?\
M_C='_"J?B9_T$_ O_?&O_P#QN@#E:*ZK_A5/Q,_Z"?@7_OC7_P#XW1_PJGXF
M?]!/P+_WQK__ ,;H Y6BNJ_X53\3/^@GX%_[XU__ .-T?\*I^)G_ $$_ O\
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M;P'H^A>+O"FC?%C0_@O\/?%7@/79?%>G_%R.X3PQX?\ &>E\ O\ @I!^QO\
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M;K6[SXC> X?$?QQ\./V+/VZ/ WB;]CCXLZKXQ^%/CWQ]\#_%/[9?A'Q'X/\
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M\)W0LI_^$FOO!\$]M_PBMV =+'_P49_90N/ALOQ/L?$OQ:U;35\>^)/AC?>
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M_P"U=\<?@]K/C?X4?LR_LW1_$#X7?'3]H/X"_'GPW\5/VSOB#X(^%7ASQ#\
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M*+1]9M]1T2WNM8-A]ON/C;P#\$/V[O ?Q$_:0_:TTWP'^QO#^T%^T-KW[/\
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M5;AB[R26QC**%20,67S7_A<OQ%_Z$+P5_P"'!UW_ .=U7:_%O_F7_P#N*_\
MN-KQN@#K_P#A<OQ%_P"A"\%?^'!UW_YW5'_"Y?B+_P!"%X*_\.#KO_SNJ_*[
M]IS]MKXQ?!GXQ_$7X9?"C]G+P5\8])^"W[*^E?M:?%76/$O[0.H_"7Q4_@>^
M\7_%#PU<>%_A9X4C^!OQ%\-^-/&T-G\*=<U*SM_&_P 1_A+X;O+O4-)TNY\2
M:9!)>:M9U?''_!4W]F73/!_Q:O? 'B6;Q-X^^#WPR\+_ !/\<>'O%7P__:,T
M/X>_#O1_'/PF\(?&_P $?\+F^,'PP_9]^-^A_#.V\7_#CQKI.J>%KE-%\57G
MBS6;7Q!X1\'Z5XB\4^%/%>D:& ?JW_PN7XB_]"%X*_\ #@Z[_P#.ZH_X7+\1
M?^A"\%?^'!UW_P"=U7Q!XJ_;?_9F\%_%P?!+Q'X^UBS\9Q>+?"7P]U?5[;X8
M?%G5OA-X1^(_CZUTV]\#?#3X@?'W1_ U_P# GX<_$SQC;Z]X7?PQ\.O'?Q'\
M.^-==?QIX#ATS0KF;QWX/CUO?^"?[6WP(_:+\2^/_"WP:\3>)O&=[\+O$WC+
MP1X[UA/A5\6]!\#Z%XX^'OC/5/ /C/P.?B/XG\#:+\/M2\:Z!XBTFX:\\(Z1
MXGU#Q&WARZT;QK;Z9/X+\0Z!K^I 'V!_PN7XB_\ 0A>"O_#@Z[_\[JC_ (7+
M\1?^A"\%?^'!UW_YW5?C3\(O^"D_COQCXQ^$MS\3O@%\/?AS\#?CU\>_VN?V
M>/A=\0_#?[16J_$'XDVOB[]D?4/VA!XD\1?$_P"#FJ_ +X<Z?X2\!>)-!_9F
M^(VJQ^(_!GQ2^*$GA:^U#P1I7B33K6V\17>L:+LZ3_P4'^+9^'?PI_:C\5_L
MM:/X:_8E^,?B?X7:?X;^)D7QUN=3_:(\*^ _CGXJT?P1\(/C%\3?V<;GX,Z-
MX-\.^ /$&M^*?!FL^)K3PQ^T=XY\>^!/ /BRR\3Z[X*.IZ)XP\,>&@#]??\
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MK9ZMX2AU7P1XKT[20#[H_P"%R_$7_H0O!7_AP==_^=U1_P +E^(O_0A>"O\
MPX.N_P#SNJ_.CX3_ /!0;]GCX@_ 36/CEK7COP[I=CX#^"?PF^.GQ5M?!^F?
M&#Q9I/AWP9\:/!K^-?A]JW@A_%/P;^&7Q(^)^D>+]/MM0L/")T;X3:;XLUWQ
M!INH>$)O!>E^.+#4/"UGVWA?]N+]F'QE\6K_ ."OA_XB:A<>,;+5O'OAVWUB
M_P#AQ\4]#^$WB/Q5\*X)[GXG>"_ OQ[UWP3IOP+^(?CKX=P6&MR>./ _@3XC
M>(_%OA0>%/&XUW1K$^!O& T0 ^X?^%R_$7_H0O!7_AP==_\ G=4?\+E^(O\
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ML>&E\2_$OX"2_%7P;X4\+>)=&^(6L:@G@>^M-;N<CP=_P4S^#>L^$?!_Q/\
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ML_\ A5?B'_G\T;_P(OO_ )74?\*K\0_\_FC?^!%]_P#*Z@#\1=4_X)_?$)?
MO[:O@GPC<_#3POH_[0/C#]D#5?A)H+^*_&NLV7@KPK^SM\+/V=_ .M^'_%.N
MZCX/DUBXN4F^$&N0>&-0@@UVXUO3IM#U#7Y]&U"^U.TTVJ?V)?VB6UGQ/X3\
MSX+)\,[?_@ICX'_;L\&>,O\ A87CF3QUK'A.\^(D/Q$^)/@/Q/\ #W_A3T?A
M_P -^(O#MXEQIW@?4M*^)GBO3?&=M/#+KR^ Y;5_MG[B?\*K\0_\_FC?^!%]
M_P#*ZC_A5?B'_G\T;_P(OO\ Y74 ?@WXM_X)T^,KK]J_XG_$*X\%Z+\:/@=\
M;/VBOA#^T/K=OXD_X*#?MM?L\/\ #/7_  1I'P@T;4;8_LH?"CPGXV_9K_:+
MO/"NO_!S1OBIX&UCQ_JOPYO-<U*\TGX9>*C::'X&T3QM?6-7_8I_:U\2?L;_
M +2W[ 6I:A^SIIGP>\8_"#]ISP!\'_C-9>+?B7JGQ,\1ZA\7-=\2:S\+H/B;
M\,[CX;Z9X;^'UOX-M_%-SIGQ#\5Z!\3OB_J7CZZTV+7])\,^$)]5N=,L_P!W
M/^%5^(?^?S1O_ B^_P#E=1_PJOQ#_P _FC?^!%]_\KJ /P;^.G[#O[4?[1GC
M?QK\5?%8^ 7P_P#%7Q ^%W_!-;PEJGA+P]\3?B'XY\/Z)XA_8T_X*)>-_P!J
MWXE26'BS4O@AX&U'5M%\2_"[7=)L/ US<>$=*OKGQ\^H^'M?L-$\.V-MXVU/
MU/Q[^Q+\5?%/[4"?&O3_ !!\/H?"J_MQ_ 7]I@Z?>:KXCC\0?\()\+?V,_&O
M[._B#21:P>%+C3O^$MO/&OB.QU31[#^U?[&N/"T5W>WNO:?JR0Z)/^R/_"J_
M$/\ S^:-_P"!%]_\KJ/^%5^(?^?S1O\ P(OO_E=0!_.K\(?V7/VUOV:?@S^S
M-'\3M%^!WC;3_P#@G3\%_C-X@^&$7[/VH_%WXB?$O]HKXQ>*OA1K_P // '@
M2\^%NM_#[P':>"_"_AG3O&OB70=7U:U^*'C!_BGXAL?"WCZXT?X$Z0-1\.^'
M/T$^//P.^,W[0'P:_9DTC7KOX;Z+\5/A_P#'_P#8_P#CM\74L+SQ):>!GN_@
MS\2/!GQ"^*ND_#^233-?UNX2[ET;6;/P':Z^;<78;38=>US3@]S?Q_I-_P *
MK\0_\_FC?^!%]_\ *ZC_ (57XA_Y_-&_\"+[_P"5U 'Y[?!W]G;Q+X*\0?MV
M77BO5]$?1OVJ?VA[CXH^$'\.7NJ3:KH?@^]_9/\ V;O@)<6WB);O3=(CT_Q-
M'XG^$/BG5(+;1KW5[ :%>^'[P:S%J=SJ&EZ5\%_ 3]F?0_VM/V(_^"=?@[QO
MX%^#-QJ/[-G@_3_@;\=_%OB7PU8^(?C'\./$'P"T>R^!G[0'P7^!>O7_ (;N
M]3^&T_Q/^)_PGG\ _%KQII?BCPYXBM/AAHNI:/X>MKOQ-K_A_P 9>!/W]_X5
M7XA_Y_-&_P# B^_^5U'_  JOQ#_S^:-_X$7W_P KJ /Y?/BE^Q-XZ^ /P _;
M1\*:]I7PBT)_VP;#P)^R'\.V^#6K^([KQK\?O''QO_:.^(6C^'?C=\;K"X^'
M?@*S\'_$CPQX$^,>BZ)?Q:3K_P 4;+PKX'\ :]JUS\18?!_A[1=%T3^C<< #
MT KTS_A5?B'_ )_-&_\  B^_^5U'_"J_$/\ S^:-_P"!%]_\KJ /-**]+_X5
M7XA_Y_-&_P# B^_^5U'_  JOQ#_S^:-_X$7W_P KJ /-**]+_P"%5^(?^?S1
MO_ B^_\ E=1_PJOQ#_S^:-_X$7W_ ,KJ /-**]+_ .%5^(?^?S1O_ B^_P#E
M=1_PJOQ#_P _FC?^!%]_\KJ /-**]+_X57XA_P"?S1O_  (OO_E=1_PJOQ#_
M ,_FC?\ @1??_*Z@#S2BO2_^%5^(?^?S1O\ P(OO_E=1_P *K\0_\_FC?^!%
M]_\ *Z@#S2BO2_\ A5?B'_G\T;_P(OO_ )74?\*K\0_\_FC?^!%]_P#*Z@#S
M2BO2_P#A5?B'_G\T;_P(OO\ Y74?\*K\0_\ /YHW_@1??_*Z@#Y4^,?P.\%_
M'31M)T+QMK?Q@T2QT;4VU:SG^#G[0OQ]_9VUF:Z>UFLS%JWB/]G[XE_#'Q#K
MVF"&9W71=<U34=&2Z6&^2P6]MX+B.I\&?@#X%^ ]KKUGX(U[XUZY%XDN+"YU
M!_C-^TK^T9^T;=6\FFQW45NN@WW[0OQ4^*%[X5MY%NY3?VGA>XT>UU61+6;5
M(;R6RLWM_K;_ (57XA_Y_-&_\"+[_P"5U'_"J_$/_/YHW_@1??\ RNH \THK
MTO\ X57XA_Y_-&_\"+[_ .5U'_"J_$/_ #^:-_X$7W_RNH \THKTO_A5?B'_
M )_-&_\  B^_^5U'_"J_$/\ S^:-_P"!%]_\KJ /-**]+_X57XA_Y_-&_P#
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M^+?AM\2K'XA_ +PSJ=I\/A\&/'?AQ_">M>(+"Z^(\VIR:9<:=^^O_"J_$/\
MS^:-_P"!%]_\KJ/^%5^(?^?S1O\ P(OO_E=0!_.YXU_X)P?'>Y^ _@GX(V/P
MJ_8:^*WBVR\-_%'Q=H?[47Q UOXG_#WXW?LC_M2?M!_&?XD_&OXM_&C]F.YT
M3X3_ !.\4:CIOAOQIXS\(^*/A1IGA_XM_LU>-=.U_P"&UJ^K?$ )KNC7/P_^
MP_VW-%N_ WPM_9/^(FOZSJOB33?V;/VJOV<?%_Q"\57C>5>W7AS6!J_P!\3^
M/?$-O:.D4ECH@^+C>._$Y59+;2].TK4=::)HM+X_6#_A5?B'_G\T;_P(OO\
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M96&K>%/$'B/I]/\ VS_@+?II:OKGB/2]1U/Q-9^#&T/7/!'BS1]=TOQ7=_M
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M:3^ _ ^A_%73_#GC[Q)XE\,^$[+PO\1O!OQ&\$LVH7GAF"[U;W[P;^RC\#O
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MCQE!=>*]=L_"NZ]^&GCZUM?"_BF]^-_B#]FJ'P[XWNY?#XM_"FI/\?O#=_\
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M&?AKX&_$CXH^/M$\!:CI_A26WMM$U+X>>#?"X\*^ K31]!\.-I'@_2=)T^T
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M71?'DWQ$LM5\ >%/!4&I:[;JNEZ[H^CZ9X&NM0\&W07P(9=#'=>#?V4_@%X
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MCSQOKVC:AXG7PU\2O$^DV^KZQ:7FHKHD]GX=COH=#TK2+*P@U_\ 8N_93L]
MUB_\7>&]9728+'XBZAXZ\5^*_C9\89;_ ,2^'?'FC^ [+XG6?Q;\;ZW\1WUG
MX@>!]>\,?"3X>:+XD\._$K6O$'A >$/ N@^'YM,B\.Z5%8( 5M<_;Z_9M\.W
M'BVUU?Q!XNM)/"/BB;P9)-)\./'(T_Q'XDL_C(_[/VIZ=X-U<Z$-(\3_ -C_
M !?$/@G6;K3;^2RTS5;NU6\N(HI&D3H](_;4_9VU_P"*GC?X*Z'XRU/7?B9\
M/M#U[Q#X@\(>'O!?C3Q/K_\ 9OA+5? NA>,CI^A^&M!U?7+^[\(ZU\3? NEZ
M[8PZ9]KAO->>*UAO!H/B=M$K>+_V9?V5G\&^(]3\4Z;%H'@?6-+^*$_BCQ##
M\7OB#X+T:[T#XX?$R_\ C)\3EU/Q+I'CO18T\/>-/B'KM]K]Y;2:BFDPVU\N
M@Z9%9^&A!I"0:K\&?@!\.4\2>'O#/Q$U7X$ZCX_U'P;/J.EZ#\;_ !7X:L?+
M\0^/? 'A*&#P9X#U?QHWA'P5JOQ/\066A?#:+Q+X&\-:'XFU3Q3XRO5T/5#X
MX\5W5SJ0!RWQ=_;,7X1?'?Q[\-M9\'^&C\./@_\ LS:=^T_\5O'][XX\56WC
M>R\(:@?VA#)IO@#X8Z/\)/$>@^,;[2HOV?\ 4KK57\0_%?X?2FW\0VPT>RUB
M[T][2]N7'[0W[1%MJ/@?X>3?LY?#ZU^-_P 2-*\<>/?"_@R^_:&U2+P+8?";
MX=?\*\M/%OB#QE\1;7X$WVKZ-XZTWQ%\5/ _A9? 6@?#GQ?I5WJFK2WMEX]N
M/#VF:GK=IW_BSX#_ +/'C_XTZUXX\23:AJ?Q2O/ACX=^%GC3PE:?&GXDZ7X7
M\4_#"7_A;MWX5\/?$GX%:)X^L/AEXWTRZ'C?XPSZ+>^.O &M7EVDNMO:7LJ>
M&K3^R,X?L7_ <:=X:L!#\8?/\&7%]-X2\2']IW]IL^._#5IJGA>R\'ZGX?T3
MXBGXOGQ[IO@W4M'TS3+C4/ ]IXDB\'7WB/3--\976A2^,+"SUV$ \8^&_P"W
MWIOQ<U/P5?\ A+P?X*\*_#_4M:^%'@?QUK/QL^-&C_"WQQI/Q7^+7@SP+XYT
M_P"$_P ,/ R^%/%6B_&#QEX5TCXF>!8?%$4'Q!\&Z=?ZIXAM=)^'E]X^U-);
M1:_Q:_;ZO?A?\<OB'\'-.^"UU\3KCP1X8\0ZC8:-\.?'2Z[\:_$FOZ'^SQXQ
M_:&MUA^"H\'1O9_#S7;7PC#\*-)^(D7CC4II?C-XS\!>#)/"*1^)8=5@]5UK
M]E#]D7P!:^&_$NI^'K'X8^%? LWP7ATW3K/XL>/OAI\*3J'P4U;PY_PI"Y\5
M>!M*\=>'_AIXPUSP;J?AWP=I_AC4_&N@:YJ\J>'?">C/=7EIH>B65I[=KOP[
M^&FEV'Q>\1ZK+>>$;;XDZ6NH?%3Q?I_C[Q9X%O8].\.^$X?#BZY;>,-%\2:)
MJ7P_DT/PMID*CQ#X3U7PS=Z:+,ZS]OAU!'OZ .=^!/QRTOXS^$/#>NQCP]+J
MNNZ=XEU*XE^&^K>+/B/\-;$>&O&.H^#[W1A\5-0^'G@+2XO&EA>V(M_$OP[\
M0Z-X9^('A76H-<T35O#*OX=U&\'S%\,?^"A7A'5/V<?#/[3_ ,<M!\/?"/X<
M>-E\/:GH-YX5\4>.?BA%X>\-^(O">B^+TNOBAJ6I_!SX8Z9X/\0:1INM0_VM
MH?AVY\>Z=<?9;V3PQXE\2I97@MOH?]G?PG^SU;^&;;QG^SKXT7QWX+UBX\7N
MGB?P]\=_&OQF\)>(]8\2>,+WQ1XOUJ^U;5O'_C/1/$OBV7Q-<7D$_BC4)]1\
M3:5IZ+X4L]3L?#UI!H\/F#?\$\?V3[SX<Z3\*+GPO\2M6^'GA[2->\*^'O#^
MJ?M+_M,ZS%X<\):_X-;X:^(? ?A_4M1^,-WJ^@^ M0\&(?#-]X TG4+/P>;2
M%%;0UN8(Y4 +.L?MX?!BQU_P-HNC:7\1_%EIXQ_:8\?_ +*]]XCT'P'KS>'_
M  ;\0_A?X5^*'B3QWJ'B>^OK:R-OX5\-3?"3Q;INI:U:QW"16MI_PEL<<O@B
M2U\1W1\-?^"@?[,/QA7PI_PK#Q=K_CF?QG\1=-^&.B6OAKP-XNU><>(-6\$:
M-\3;2^U0V6DS0:'X8C^'6NV?B_4O$^L3V6CZ+9PZCHVM76G^+-,O_#UOS.H>
M$_\ @GW=7GC#XRZO\2OAG>S^!?C5IOB#X@_$C5OVFM9O;7PE\6O#OAGQUX)T
M[P7XW\27_P 4);+1=,T[P=\5O'GA,?!+Q!<V_@4>'/%^HZ)-X&;39X+:/Z#\
M"?LY?"#P#9?#F#POIGB>ZM/A9)/=_#63Q-\4_BE\06\+17W@M? +VVD7GCKQ
MKXFG.D-X1)TZVTF:>?2+>26;5K6SBUBXFU"0 \OT+]N7X)>,_@/\5/V@/ 8\
M:^)?#'PK\*6?BR]T6]\$^(_!GB3Q-9^(/A]H?Q)\!CPM9>-M/T"'4K'X@>'/
M%'AU_#?B 7">'A<ZF]OJVIZ;+I>LII]W4_VJK7X56FB:=^TKX6M?AUXXU=+_
M %FXTCX5ZCXX^.WA'0? =IK_ (/\,+X_\1^-+3X6> [SPYX>MM>\<Z%I&O3^
M(/"6DPZ/<1ZWJL%SJG@_P_J_BJU[CPU^RO\  +PE\-_%'PAT3X=6*?#?QIX!
M\,_"_P 4^%-3UCQ+K]AK7@3P?\/=-^%7AWP_=RZ_K6IWODV'@+1].T%KR*ZB
MU*^^S#5-0O;O699]1DYJ\_8Q^ .J1:'%KFD_$GQ,V@V^I6$-WXM_:!_:#\7:
MEK.C:OJO@O6M1\->,]5\2_%'5=3^('A"XU/X?^&+G_A#_'5WXB\+PB#5X(-(
MBM_%/BF'60# O/V[?V?;2\U73Q>_$"]O;/5H=$T.WT[X5?$*]/C^_F^(FJ?"
M4K\.9(?#S0^,[>V^).DS>%;^[T>6:VTZ2]T37K^6V\)Z_HFOW^#!_P %'/V0
M[C5O"F@Q_$YUUKQI\.Y/B5H.CW'AGQ+::T^C1_#'QA\99=(U+0[O2X-:T3Q7
M;_#/P!XR\4WWAW6=/L;[2HM"DTO5A8Z[J6BZ7J=_QC^P3\!O$JQOI%OXX\'7
MK?$3P[X_N-0T+XI_%A+RP71_BO<_&;5O#/@.5O'BM\)= \4^.+R>_P!:LOA:
MWA&UD@CTW3A:MI>B:+8:?W6@?L>?L^>%M/N-&\-^$O$6AZ%?_#?3_A/K'AW3
M/BG\6[/PWXD\&:7X2U3P+9Q^+?#D/CI=$\7>)QX6U>ZTRY^('B:PU;Q_?-!I
M.H7WB>YU/0=#O=. /*?BK_P44^ /PD\&ZCXK\06?Q+%\?@[\2?C1X1\'WGPY
M\4>&O%?Q T#X9>!_%7Q'U?2?"VE>*[#1;A]:O_!?@S7_ !#8+J,=CI\>GV,Z
M:C?V.HPRZ>G0V'[<OP?BUKQAH?BXZYX-U+P_J4]GI6BZIX9\;Q>)[^2V\#_L
MR>*&\.Z]HVI^#]'MO#_Q)U/5_P!JCX=Z%X;\ :;JWBFZ\06ET-4M-534K#QE
MX;\%]+XM_8E_9F\=>(I?$_BSX=WNL:A<^''\*WMC-\0OB=!X6U+1W^%'CCX'
M$:MX)L_&=OX,U;5%^$WQ)\<>"(O$&I:#=:_#I/B"Z:'4TO8+*[MH_$/[*O[+
MFDVNE^*/''AU&MO!GQD\%_M#1^*_B%\4?B#JKP?%[P-\/_"_PA\%^-?$OB7Q
MAXVO)]>ETGPGX3\&V-KI/BJ_U/P[=^*/#WA[QK=Z3=>/=-L/$40!D>'OV]/V
M8_%_A7]H?Q?X/\>MXJT[]E[P-J?Q)^+%OHFE7US?6'@K3H?B*\&N:0DL<%KJ
MT.LW/PF^(=CHMO%=Q7MY-X;DNI+:WTK5-#U'4\*R_;%U3P7KNN^$/VCOA-<?
M"_Q?!H_PL\1>$-(^&GB76?CW%XOL/C!XK\5>!O"_AL2Z-\/O!VI:9\1-*\5^
M%AIGBW18=&U?P5IT7B/P]J>A_$CQ-I@\1W7ASWWPC\ /A3X)\*^+? FAZ!JE
MQX$\;VFL:;KO@?Q-XU\=>./!:Z-X@FUN;5_#WA_PIXU\2^(/#_A#PQ?)XBU2
MR?PQX1T[0_#\>DO9:-#IL>D:1I%E8^6>%_V9_P!E?P/JVJ:390W&H^+/"6E?
M!GQEK4_CWXX?$[XD>/O#7A+X7ZUXUO?@E>ZKKGQ(^(GBCQCH_P /-%\2:?\
M$F_\-:9>:A;^"=6\00?$"^EL=2U1O$\S@$6C?MS_ +//B3PU)XS\-ZUXTU_P
M>GAGX9^(5\3:7\+OB+-I,VI?&71?ASXB^%/P^BFD\-12GXI>/M&^+OPRN_#O
MP[>%/$]R_C70[&6P@U&X>TBYZU_;Q^%%YXFBTJTTKQ9=Z-?:/:VVCO:^&?%4
MGCW5/BA%\9OB/\#_ !+\)XOAD_AN+78];\(^+_A?XK&MZT;Q]$@L-(UC6VG3
MPMIC>([GH/"_[&W[*Y\%6>F>"/#NKI\/==\(?"JQTNT\(_&KXOP^$M2TSX6>
M'_ >E?!_QUI":)\14TF;Q]X1\/\ PX^&P\(_&C3\_$NWA\&>$;ZU\:O-HNF7
M,$L/[*/[*L^J/X.L=%EB\9>%+/0_&4Z:3\8OB99?%'0(?$OQ1^)GQ&TGQU>>
M(]-\?P?$.PO/&_Q.U/XNWEUXUNM5CO\ QY/-X]\-:IJVMZ-%K>CQ@')7_P#P
M46_9>L3X5G7Q#XTO=(\5^%+;QHOB&U^&?CJ/1/#&@W'@B^^(\T_CRXO]#LKC
MP/<:3X+TZYUOQ!:>);33KCPXH2PUQ-/U1OL([WQY^U1X=TGP1X9\1?#;1XO'
M^O?$'XQ^-O@-\/=,UW6+CX>>%-2\?_#5_BA)\0;_ ,4^,[W0=?N/"OP_\(:5
M\%_B=KNH^,+3PKXEDU72/#*7/A'1?$QUS04U+PV#_@G%\/M&^)FM^,?"7B_5
M/#W@_6OA[)\,Y_A[+;:YKMI=^"!\%+KX,P> _$-_J_C*?2O%W@5WN$^)^M/X
MC\+7_P 5?$OQ*M;6]USXN7GA:VMO"<'N_AO]G7X#Q?"#X??LN-=S^(+#]G[0
M/AJFDG3O'^O^'?BQX6U'P_I%SI7ACQ_=>,? _B'0?B)X:\6^++:S\0OJ7BJU
MUG3-1\8PZGXOL]0O-4T_6-?MKH XW1OVY_A&FDV*^+-1TR\\41^%-&\2>(U^
M!MYXA_:!^&=A<^)OBGXK^"7@[P_H'Q7\*^#M(TSQ%X@\>_%?P9KO@'P-X9N]
M$\/>-M?\56=UH3^$K#5=,U>ST_L=(_;+^ FM6,%Y;^(M=M9)-=\+>%KG3-5\
M%^+-*U;3/%'BO]HJ^_90M_#^J:??Z1!-9ZCI7QYTR_\ !&M%\VEH+63Q!!=7
M?AEH]8>;2OV-?V=-%T#Q5X<T_P #ZLEEXULO#=KXEU"Z^)'Q1U'Q5J%UX/\
MC#\0_P!H#PQXCC\;ZCXTNO&6G>.-$^-7Q6\=_$NP^(.EZ]9>.8O%>L6^I?\
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M<?$K3O K?$F#Q7J7A"ZTOXD_$_X?ZKIWBY/V4+SX2_#+6=?OO .E1W03P?\
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MO?'?C"3XD:K%XZ\3?&[6;OP_#I'C'4O!FA>$?V</BC^UQ\"/CE\?O"6B^(O
MG@[PW\2(/'GQ/^'?P6L/#T]QJ/BK7+31M=CBTSPAXC\&Z-KOB/69O'_C3^S9
M^USX$T[XD^,_ OB*\\30RZQK>C6>FZ!\7/CEXDU3XB>"/'_[8G[.OB_P1%X[
M^%ECX>$'A;PO^S5^S-X3^)7P@UZR^%NK>//'_P 2_ &M>,-1T"VM_&7CG5=$
MO?IO]I7]L;QS\"O&WQ4T;1/ACX:\6>%/A;\,/V6?%FIZS?\ CR'PUK<OB/\
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MW/@[X!?'+2D\?>*?'VL>#?'WQ!\<?L3?LM_ G7)/#'Q!\<? U/$GQF^#U_\
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MO&W_  43^)'@WQU\,_@[J?PT^#^D?%GQK\8_&GPOU"WU'XO:T/!#P^!OB/\
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M:E$- N/BK\0YM-]3\#?!3XO_  J^*?C:X:VU?QO\*_'_ ,5/A3=> M-A^/\
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MM2U;Q)XFOM;N?#M_S/PD_P""A'QJ^+/B7]EI=0\%_!+X7^&_C-XX\!67B/\
MMKXA>(M6DU#PO\8/V5-$_:-^'^@>%-1O?"'AF!/BHDU]KWAY_#;QZA8^(&\/
M07FE7ZQZC?VVB2>&/^"EGQ8U&/X(R:M^SIX6NI_BC^S-\-/VH]4TSPS\;O"<
M&HIX2^+NE?%C6M!\)_#S2O'\?@;Q9\3O'/@G3_AEI\WCS1?!OA#67*>.=+?3
M3"UC91>)0#WK]H?X&?$O]HO]BM_AGX8^'?A30/B3XBU3P_XFT;P_\>_BQXP\
M3R> 7M/'*^*?M^H?$=_!7Q4\3OXP70!-I)TRQL+JQ\._VWJ'A72?$DWA[2+6
M74?;/C]\-_B=\:/@AXM\%6FF_#[1O&,'B_X9^+_"6D:GXL\0:OX$\:Q?"[XA
M?#_XI)X,^(NJ1^ ;+5-"\+?$6_\ "6J?#GQC%IOA?QJMIX,UB?5Q8>()KNX\
M*1? 7CG]O[XJP^')_%NE>)/V;9O!]]^PQ^TM^T98R_"7XN0>,O$VK_$#X+Z%
MH_BB/PO\-O$'B/P!J7A36+_P[INO:5:^,;;4_".NKI=K.?%-[HT=O/:>'SZ;
MJ/[='CZ]\07&D3>!]-\.:'-\>]&^'GA#6_#?C*"^\0:OHWA3_@H[X0_87\>)
MXST?Q+\.-1TC2;77)-?;Q7I]OX<U"]U6?1DNM,M_$/A36KBSUK3 #N_ _P"R
MS\7;K]H>^^.?Q%U#P=X3T7Q+\3O$/Q(\1_"OX5_$SXEW&@-JVF?"7X%?#+X=
MZQKNI)X8^'%G\4-?>Z^%&J:[XB_X2;PMHFB:3IMQX-\-6VE^*KCPQ+XFU#L/
MA)\"OB]X3_:[^-OQF\36'P_T+X:^.M#O=+\,Z?\ #+XD:_IEKK]XNI^%I]/\
M7?%3X(2?!C1]%UKXNW.FZ9?Z7J'Q@NOCAXIO+#0+#3?"N@>#;#3M9U>]M/*?
MV#/VU-<^.:W'@/XK^(OA;?\ BO3O"GPUU#0O&'A3QSIE]<^-O%WCO5?VBEU/
MX8ZOX?M_#7A;2=&^+W@SPG^SWJOC_P 4^!O#3:M>:1X3UM;ZZLXM.T.?7M6M
M^$OVO_%-[^WA\2_A%X^;Q1\,_@]X<^&&N_\ "*6'C[X/>.?!/AS5M>\)?$3P
M#X./Q+7XX>*/".E^ =:M?B%KWCN^\,>"O#7AGQOK>FW6B:)X3U??%XP\6ZKX
M8T  \]F_99_:MUWXP:G^T!XJ^''[*M]X]T7XIRW7@_P<OQO^)-W\-]>^"&B_
M!_\ :<^$GPZ\)ZM;?\,LZ9<^"?%_A6'XYW/B+Q%JTFG_ !:A\:7/Q,^,NA6]
MWX2\,:=\/-(L>ZU/]FKXV>#;S]@#X7>"_'?B74? GP[\#>"_A9^TGXAL]2U?
M38=:\-_ 2Q^'OQ%\#>*XD%VT0U/QE\1/AFGPQ\3Z++*K^*/AO\8/&\6L/JEG
MX>BL),']K7]IGQY\-?BM\5=%T'XVZ?\ #?Q'\+?@O\-/B'\!O@!<Z/X!GNOV
MQ/B#XM\3?$32=1\!/=>+?#FM>./$-EJ^L^'O _PRT72/@AJ7A'Q-X#\3>*$\
M4^--=US2O%7A;1--Y?Q=_P %,?'6A:9XI72O@5H5]K7@OXU-^S3XIN-?^*?A
MOP%X.\/?''1-!_:(\>>*-)U[Q?\ $*3PEH.B>$IOA[\)OA!K?A#Q#J>IVU[K
M\/[2_@.]CT7S--CT;Q( ><Z_^PE^W?%^RIK/PN\,_'X:Q\=_$,!N-8^)?C?]
MI;X@PV5KXXT_X(^(O"EA\3_ -[X6_9KL)/!&I^(?BY-X;\7>+?"GB+PG\48H
M=.BU7Q!X<\7:=\04M];NOJ'6/V4OCJGB_P /^-_#GQ!1_$,7[56M_%?Q!_PD
M'QG^+<_@JX^#EYXTBGTCP9+\-X=#FLM5U;0?!&I^(Y?#FA:'XD^'/AC1O'*V
M$VN:AXX\*ZQXGT74/-OCA_P4=\;?!KP9\</'NK_#/X9:1I7PQ\?^$OA?X4T3
MQ/\ %MK36/&/CG4OV-]!_;!\3:-J'B&S\-2_#+PY:Z;HNMR>$]+UZ;QY=:)J
MB:)K/B#3KW4]8E\)^ _%UKP9^U]\2K_]H!M.U3QAX-M/AM?Q_M"S:?H7Q*UO
MPQ\-O#EHFB^*O^"<FA?#JSO?'UEX-U_5H]<TF/\ :)^).G^&=)"7*^/?%OBO
M1O#&JWJ,?#NK^'0#J?CQ^S!^U+\3?COXX\8>%OB-9>$OA?XB^'OC3X?6$'A#
MX[?$;X=>-7T?Q1\+=&T2R,^FR_"7XF^'/#WBCP_\4K6^\6>'_&7AG4HM)TC1
M1&DOPXU?Q+KOBO6M6]9G_9Z^,/BCPC^RII'B[QSI>CZU\('U/5?B5+X#\8_$
M^PT36/$%MX$U;3/ TNG6UQJ-OJ/Q#TCPMXY?P[XCN-#^(5]8:#J[Z*NH2Z)
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M#5+'4=*\?>,)_$^O?\)1X6BL-%FN>*OB3^UCX?\ $?Q@\9_"OXZ>)?BI\+/
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MO&$OA)9H?"FO:WK%L_XY?LD?'GXF?M5>$?C+X<\:Z'I/AKP;K5_K_@WQ+?\
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M_#<M[XY1KYEOW\1W&I7.IW-]X#\/OV[/B9!XA\->&OBGI7P2DD\4_M>_M!?
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M'XSN+7PYX7\SQ:;I/$=UXCO^*?V&_A-XM^ /PP_9RU+Q#\1(/!'PG^!GB?\
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M6>IZWX\E/B'QA>^.7DO/^%=>(+;3M=O_ -JGQ]^US.;?0/%OPZ\0^%=4L/\
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I*** "BBB@ HHHH **** "BBB@ HHHH *:_W3^'\Q3J:_W3^'\Q0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img58233625_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ G # 2(  A$! Q$!_\0
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M]U/R_P"G?E^+[G[%_P##[']I3_HEOP._\!/'O_S8T?\ #[']I3_HEOP._P#
M3Q[_ /-C7XZ44?\ $->!/^B:R_[\3_\ +_ZN_*Q_K#G7_0QK_=3\O^G?E^+[
MG[%_\/L?VE/^B6_ [_P$\>__ #8T?\/L?VE/^B6_ [_P$\>__-C7XZ44?\0U
MX$_Z)K+_ +\3_P#+_P"KORL?ZPYU_P!#&O\ =3\O^G?E^+[G[%_\/L?VE/\
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M$?A::^B=:[Z']F#X5?%7X9_L_? _PK;_ !K^&_P[3]HW]I36-6@^*EKH=O\
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M)US1?'=OX8U?PS#XIO/#.D^&/$UAK-GYJ:?J-I86:Z-J'VI[N6\%BMG-Z_\
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M7_@. \O^H+R_%]S]&_\ AYM\:O\ H1/A=_X#^+/_ )I*/^'FWQJ_Z$3X7?\
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M?MS_ /1(=)_\.9\.?_FDK^NZBC_B._&'_0#P[_X1YA_\]?ZN_*Q_J5E7_/\
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M[ZCS)-:PX0P%-*,,9FD(QESI0Q-&*4[<KFE'#)*3C>+DM;-J]C^5/6?V"?\
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MY^#M>M=*GO!MNI[&'4/%DR0SSI^[>8 R^5^Y5UB^2O.O^'5W[<__ $2'2?\
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M_P#"X\&?_+JC_A@W]J;_ *)YIW_A<>#/_EU7]#-%'_$6>)/^@7)O_";&?_/
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M*BRNI?+&:+]F;]OF#PS'X*A;Q%%X/BM/L$7AA/BQX<&AQV/G+.+--/\ [?\
M)6W69$EBB50L+*##Y8R#^[%%8_\ $3,XY81_LGASEIRA*G'^SJ_+3E37+3E!
M?7;0E"/NPE&SC'2+2T.M?17X+52M6_UQ\3?;8FG6HXBK_K+E_M,12Q$U5Q%*
MO4_L+GJT\157M*\*CE&M4M.HI25W^%>J?LV?M_:Y>G4=:G\2ZM?MH>I^&6N]
M1^+/AV[F;P[K0C76-$+3:^P_L[55BB74;< "\$48G+^6FVO>_LQ?MZZEX;3P
M;J)\17WA*/3X-)C\-7GQ8\.W&B+IEK/:W-K8#3Y?$#0?9K:>QLI;="I,+6L
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M?_T.>O\ 2U_GF_X8-_:F_P"B>:=_X7'@S_Y=4?\ #!O[4W_1/-._\+CP9_\
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M"JTN?V8+O6],.LM>:1=>'/A'XUL;WPMIFOV5M/?^'-?M+[5;*_\ M$,U>I_
MG]B+]E?]F>/QQ#\#/@]H7P^A^(V@:%X3\8PZ=JGB?48M4\*>%SXD_P"$8\+0
M1:]KFJIHWAKPW'XO\1VWA_0-#73=)T2QU26PTRSM;*&UMX #XOT'_@LI\!O$
M'PWU?XD+\(OC7X2M;'PE\ OB/H^B_%;5OV=O@]=>+OA=^TC:^-)?AI\0/#WB
M+XF?'SPSX!&FWM[\/O%6FW7AW6_%^C>.?-L8;O3_  MJ&G7<=V.<^*'_  42
M^+FE_$G]@[QAX"T#POIW[-'[5WCWX>>!O%%]XQ\'1^+M%\+)X^U3Q;H,<MU^
MU3\'?C/XX^"FE>/KO7M)\-Z+\.?A]I'A[QUI/C?4M=:WU#Q_X>>2W6#]&_AQ
M^RI^SO\ "2>VN/AY\)_"WAV2S^%OPS^"ML(XKS488?A=\'&\1O\ #'P>MOK%
MYJ%N;#P>WB[Q&=+N&B;46_M:Y%W>W($0CR?%?[''[,OCGXL>#OC=XM^$/AS7
M?B/X ?2)_".J7MQK1T32-0\._P!H_P#".:T/!$6J1^!;WQ%X:.KZD?#?B34O
M#5YKWA]KN5M'U&R;:5 /DO\ X)W_ +6OQM^.'B7XN?"[]JMK;P#^T3X(T_1?
M&=U\ IOV>?&GP;O_  7\./$/C#X@>&?#'C#2?'7B/XI_$?1/CAX2\5MX4^R6
M?BWPS9>#H]*UG1]9L+_1VDN8%M/U,KY,\%? _P#9#_8?T/XH?%C0M%\"? [0
MM<@L=6^*?Q-\9^,+Z.WBT?0GO/[&L=7\;?$/Q#J+Z%X0T"75;]?#WA>UU33O
M"VB3:G=)HVDVDM]*LOH6H_M-_LYZ/XE^%W@W5OCM\(M+\6_&W3=/UGX/>&=1
M^(?A6RUWXG:3K$'VG1]1\"Z5<ZI'>^)[+6(<OI%QI$-U%JA5TL&N)$=5 /<:
M*** "BBB@ HHHH **** "BBB@"M>?\>EU_U[3^W_ "R>L_PX,>'M!'IHVECJ
M#TL8.XX/U'![5H7O_'G=_P#7M/VS_P LG[=_I6;X:&/#F@ \$:)I0P!M'%C
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MG@GQ!=ZUX9^)_@2_\(^&_"7C'Q!XS\2SZU/IVG>&I+W1-=AT[WO]K;_@H_\
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MW7/^$XTGPDVJZH/'&D>&KNWUO2[>WU;5W;Q5J?CG0]+L;FUN_=/%_P#P62^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\Q?\
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M[;]U\0;K]HSXB^+_ (,6?P]TS3/#%UX*\8^%?AE\,-3N(/@9XC\,>+]$\?\
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M0\*Z79?&^.]U?PM<W_BW4IM)LKJ#7-^FSRW.GV;/"W[!?[;VL^&?B9\.]?\
MVA/&FB^'E\:_!/QW\.O$OQ3^//[2_P 1/$-Q>W/[-_A?P_\ 'O2X_$7P1_:,
M^!'Q"T[3+KXZ1>(M;T_P]XB\7ZSX$ACEEU#PEX2T>*ZM9K;]V** /Q%\5?L\
M_M1:M^VO^SWXE\;?LW:=\4/@?^R+\)IH_A)\0/#/Q8\%Z3)\3?VA_&?P0N/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG4_._LO4M--JEG[1^SCIG[2?ASQMXG\/_&*;4/$W@Q- :Z\&^,=0U"!+I?\
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M=_K_ $M3^W\5_P ^</\ =4_^6>O]+7_1J_X?/_\ !+__ */!^'?_ (*?'?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '\//_!R[_P GQ?"+_LU_PW_ZM#XH5_.[7]$7_!R[_P GQ?"+_LU_PW_Z
MM#XH5_.[7]D\ _\ )'</_P#8!'_TY4/A<R_W_$_]?/\ VV(4445]><(4444
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MD^AIW_#V+]DC_G^^(_\ X0&H?_)-?1:_L3?LE(JJO[/GPO55 50/#-I@*!@
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M+&"=Q&+&#@L.&^HZ]:T;WFSNQ_T[3^__ "R>L[PT"/#F@ C!&BZ4",8P18P
MC X&/3MTH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\"_:NU2ZT/\ 9;_:4UNQ$1O='^ /QCU2S$Z&6 W6G_#OQ'=VXFC#(9(O-A3S
M$#H73<H92<CWVOG#]L;_ )-$_:H_[-P^.'_JL?%%=N6_\C' ?]AN%_\ 3],B
MI_#J?X)?^DL_SC[3]L_XQM:6I-OX(R;>$G_BG+KJ8U)_YC-6/^&SOC%_S[^"
M/_"=NO\ Y<U\BV7_ !YVG_7M!_Z*2K-?W9+=^K_,_.CZQ_X;.^,7_/OX(_\
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MMXFN?#=[\.OBI\7-!/[+_P )[GQKJ7A#PA9>&;?5=<\1W$CZA9ZJS6/V/?\
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M-_\ $T ;%%8__"0:-_T$;?\ [Z;_ .)H_P"$@T;_ *"-O_WTW_Q- &Q16/\
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M*U'4-,EN[)X9Y-/O[RR>1K:ZGC?3_P"$@T;_ *"-O_WTW_Q- '\_^L_M7?\
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MP+K8TZ*VGTCP_J]A8>(]<F\9:/'KF@VVGZ+I]_%K-SD232VTMI# DDEP[6X
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M4U.:WL+")B"9+FZFCBC4$DDX4_Q-W'_! S_@J'):SQI\$_!1=[>5%!^-/PT
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MQ35+C5(=6U'6-8\%:QJ>MZI-<ZG#=RW%S/X/:4+9SV%Q#<ZO=+#?)H\*Z)(
M86F_%3]OG3/B3'X*\7_#CX<R:=-\'?B]XXLO%6D^&/$$'@$^/K2UTV;X5^!O
M%/C^7QQ>Z9X4M[+49=7TOQ#>+8ZMJGB6QL;/7+/2O#=K>S_8M#2+_P#X*47M
MIX%U?7M'^!^DWMG/X5U?QEX4TFU)AU6"V\(ZQ:^,?",NL7/C?5Q:R:YXHO\
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MZ=4EU*"&1->\.V6CZ=I=YJL<1$FMZ]8V.FSV^GZU+<VEC91SV21: T>FA+H
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M^SO?7>KZEX3/CFP^W:AI_P#PB&EKX(G_ .$LBM)AXZOHO$-S=^.3'+;W5G/
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M3Z7K=I9G7O&,45]H>C_#>XT1H]3UB\U&XT62ZU>?PWI'B6ZN?^$6M_1O!_\
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@HXY""Z),883*JL%D,49<$HN)*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img58233625_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_4.jpg
M_]C_X  02D9)1@ ! @$ \ #P  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )Z!A@# 2(  A$! Q$!_\0
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M_P"B4_$[_OYH'_R91_P^S^!O_1*?B=_W\T#_ .3*_FKHH_X@SP'_ - &-_\
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M*G_#[/X&_P#1*?B=_P!_- _^3*/^'V?P-_Z)3\3O^_F@?_)E?S5T4?\ $&>
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M .@#&_\ ARQ?_P L_J[\K'^MV=_\_P"A_P"$U/\ KO\ TM?Z5/\ A]G\#?\
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MP^S^!O\ T2GXG?\ ?S0/_DRC_A]G\#?^B4_$[_OYH'_R97\U=%'_ !!G@/\
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MC_6[._\ G_0_\)J?]=_Z6O\ 2I_P^S^!O_1*?B=_W\T#_P"3*/\ A]G\#?\
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M_H?^$U/^N_\ 2U_I4_X?9_ W_HE/Q._[^:!_\F4?\/L_@;_T2GXG?]_- _\
MDROYJZ*/^(,\!_\ 0!C?_#EB_P#Y9_5WY6/];L[_ .?]#_PFI_UW_I:_TJ?\
M/L_@;_T2GXG?]_- _P#DRC_A]G\#?^B4_$[_ +^:!_\ )E?S5T4?\09X#_Z
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M$58I2G"A12<U3B]'4FW&G!RO&+FIR4E%Q?YIXM^(4/#+@G,>*%@XX_&0K8;
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MBO\ PNQ'_P D9_\ $U'C'_T.<I_\,&7?_*S]K/\ AYO\+/\ H0O''_?6D_\
MR31_P\W^%G_0A>./^^M)_P#DFOQ3HH_XAEPE_P! N*_\+L1_\D'_ !-1XQ_]
M#G*?_#!EW_RL_:S_ (>;_"S_ *$+QQ_WUI/_ ,DT?\/-_A9_T(7CC_OK2?\
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M]]:3_P#)-'_#S?X6?]"%XX_[ZTG_ .2:_%.BC_B&7"7_ $"XK_PNQ'_R0?\
M$U'C'_T.<I_\,&7?_*S]K/\ AYO\+/\ H0O''_?6D_\ R31_P\W^%G_0A>./
M^^M)_P#DFOQ3HH_XAEPE_P! N*_\+L1_\D'_ !-1XQ_]#G*?_#!EW_RL_:S_
M (>;_"S_ *$+QQ_WUI/_ ,DT?\/-_A9_T(7CC_OK2?\ Y)K\4Z*/^(9<)?\
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MZTG_ .2:_%.BC_B&7"7_ $"XK_PNQ'_R0?\ $U'C'_T.<I_\,&7?_*S]K/\
MAYO\+/\ H0O''_?6D_\ R31_P\W^%G_0A>./^^M)_P#DFOQ3HH_XAEPE_P!
MN*_\+L1_\D'_ !-1XQ_]#G*?_#!EW_RL_:S_ (>;_"S_ *$+QQ_WUI/_ ,DT
M?\/-_A9_T(7CC_OK2?\ Y)K\4Z*/^(9<)?\ 0+BO_"[$?_)!_P 34>,?_0YR
MG_PP9=_\K/VL_P"'F_PL_P"A"\<?]]:3_P#)-'_#S?X6?]"%XX_[ZTG_ .2:
M_%.BC_B&7"7_ $"XK_PNQ'_R0?\ $U'C'_T.<I_\,&7?_*S]K/\ AYO\+/\
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M.U/3[@-%(([FTN421 \;I-#( T4\$D<\$DD,B.W[^_\ !;5_^+6_LUR2.?\
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MBBBNDS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK[X_X)@?\GR_!'_NH'_JM?%M? ]??'_!,#_D^7X(_P#=0/\ U6OBVOG.,/\
MDDN*/^R>SG_U78D]#*?^1KEG_8PP7_J32/[ ****_@(_< KE+KQSX4LO&>D?
M#RZUJVA\9Z]H6J^)M(T%DG-W?:%HEU8V6JZC$ZQ&W$-E=:E8PRK),DI:Y0I&
MZABO5UXQK&J7D7QZ\$Z.FM^*8;&[^'7C*^F\/VOP_2_\'WUQ:ZSX>BAU+5?B
M8;1Y/#NMV23R0Z7X46]A7Q!:W-[?M!,=*#Q@'L]%%% !7X+?\%%_^3BF_P"Q
M$\+_ /H_5Z_>FOP6_P""B_\ R<4W_8B>%_\ T?J]?I'A9_R5#_[%N+_]+PY_
M,'TN/^33P_[*G)?_ $SF!\(4445_2!_F,%%%% !1110 4444 %%%% !1110
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M45^W'QX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB%XKN-"O$AEM=2.@?#WP9KJV<BW,4T \V6QC5))(9!%($EVDH!6)_P $]?\
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MXJZ9\)/CA/=^/YKK4H;V*PU^SNO%,L-Q8>-M/AN9+26[L+CS$TJ[N-'N6O\
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M6HET?QUHHMYE-K]D6Z;3M2DLS^]N7UC5+G8R0RLON3>$I<#<,\3Y+EL\!F'
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[X_P""8'_)\OP1_P"Z@?\
MJM?%M? ]??'_  3 _P"3Y?@C_P!U _\ 5:^+:^<XP_Y)+BC_ +)[.?\ U78D
M]#*?^1KEG_8PP7_J32/[ ****_@(_< KQS5[/6W^.O@N^AT[XB2>'X?A[XPM
M[[5=/\9Z=9_"ZVU*;5_#[V5GXD\!R7*ZKK?BZY@CN9/#WB*VM);/1M/AU:SN
M9HI-0A5_8Z\&US2M/E_:/^'^LR:;\-I-3M/A=X[L;?5=1\3ZE;?%:VM+K7?"
M\MQ9^&?",:_V5JO@ZXD@BD\2:U<L+S3-1BT>VM@8KV8@ ]YHHHH *_!;_@HO
M_P G%-_V(GA?_P!'ZO7[TU^"W_!1?_DXIO\ L1/"_P#Z/U>OTCPL_P"2H?\
MV+<7_P"EX<_F#Z7'_)IX?]E3DO\ Z9S ^$****_I _S&"BBB@ HHHH ****
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M>JI8O=+(6*R)Y)8.*7XT3#]GC]@_PE\-XE_L_P 4^/M*TS0=1CQ'8:G'<>(
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M,7PKG.*ED="LL+PUP;0IRQ&'6"I4ZL5C/;\^&HPE"NJZQ='$SZG]E'XS^/\
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M*** "BBB@ HHHH **** "BBB@ HHHH _=;_@FQ_R;UJ7_93/%7_IN\/44?\
M!-C_ )-ZU+_LIGBK_P!-WAZBOY-XS_Y*G/?^QA6_0_V$\#_^31^'O_9,Y?\
M^D,M_P#!3W_DQ?X\?]@[P9_ZL?P?7\?U?VR?M@_"'5?CQ^S3\7?A5H+A-?\
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M_I8_RY"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^8-.P,8QQTQVQZ444"LKMV5WN^KMM?T&".,'(1 1T(50?S S2A57.U57/)P
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MP?V!DW_0MPO_ (+]//R1^2'_  Y>_9+_ .AD^./_ (6_AS_YAZ/^'+W[)?\
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M_@OT\_)'Y(?\.7OV2_\ H9/CC_X6_AS_ .8>C_AR]^R7_P!#)\<?_"W\.?\
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M_P!#)\<?_"W\.?\ S#U^M]%'_$1../\ HI\V_P#"C_[7R7W!_8&3?]"W"_\
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M_P#0R?''_P +?PY_\P]?K?11_P 1$XX_Z*?-O_"C_P"U\E]P?V!DW_0MPO\
MX+]//R1^2'_#E[]DO_H9/CC_ .%OX<_^8>C_ (<O?LE_]#)\<?\ PM_#G_S#
MU^M]%'_$1../^BGS;_PH_P#M?)?<']@9-_T+<+_X+]//R1^2'_#E[]DO_H9/
MCC_X6_AS_P"8>C_AR]^R7_T,GQQ_\+?PY_\ ,/7ZWT4?\1$XX_Z*?-O_  H_
M^U\E]P?V!DW_ $+<+_X+]//R1^2'_#E[]DO_ *&3XX_^%OX<_P#F'H_X<O?L
ME_\ 0R?''_PM_#G_ ,P]?K?11_Q$3CC_ **?-O\ PH_^U\E]P?V!DW_0MPO_
M (+]//R1^2'_  Y>_9+_ .AD^./_ (6_AS_YAZ/^'+W[)?\ T,GQQ_\ "W\.
M?_,/7ZWT4?\ $1../^BGS;_PH_\ M?)?<']@9-_T+<+_ ."_3S\D?DA_PY>_
M9+_Z&3XX_P#A;^'/_F'H_P"'+W[)?_0R?''_ ,+?PY_\P]?K?11_Q$3CC_HI
M\V_\*/\ [7R7W!_8&3?]"W"_^"_3S\D?DA_PY>_9+_Z&3XX_^%OX<_\ F'H_
MX<O?LE_]#)\<?_"W\.?_ ##U^M]%'_$1../^BGS;_P */_M?)?<']@9-_P!"
MW"_^"_3S\D?DA_PY>_9+_P"AD^./_A;^'/\ YAZ/^'+W[)?_ $,GQQ_\+?PY
M_P#,/7ZWT4?\1$XX_P"BGS;_ ,*/_M?)?<']@9-_T+<+_P""_3S\D?DA_P .
M7OV2_P#H9/CC_P"%OX<_^8>C_AR]^R7_ -#)\<?_  M_#G_S#U^M]%'_ !$3
MCC_HI\V_\*/_ +7R7W!_8&3?]"W"_P#@OT\_)'Y(?\.7OV2_^AD^./\ X6_A
MS_YAZ/\ AR]^R7_T,GQQ_P#"W\.?_,/7ZWT4?\1$XX_Z*?-O_"C_ .U\E]P?
MV!DW_0MPO_@OT\_)'Y(?\.7OV2_^AD^./_A;^'/_ )AZ/^'+W[)?_0R?''_P
MM_#G_P P]?K?11_Q$3CC_HI\V_\ "C_[7R7W!_8&3?\ 0MPO_@OT\_)'Y:>%
MO^"/G['GAW58]1U&U^)?C6WC4C^QO%?C=?[*=CG;)(/#6C^&]19D.&"_VB(F
MVA9(W0LK?I)X-\%>$?AWX:TOP=X%\.:/X3\+:) ;?2M!T*Q@T[3;&)G:5Q#;
M6Z(@>65WFGE;=+/,[S3.\CLQZ>BO%S;B//L]5..<9OC\QA2?-2I8K$U*E&G*
MSCSPHN7LHS<6XN:@IN.CDUH=>%R_!8+F>$PM##N2M*5*G&,I):J+G;F<4U=1
M;M?6UPHHHKQ3L"O'-7MM:;XZ^"[N&Q^)SZ#%\/?&$-]J&F^(](M_A'!J,NK^
M'VLK;Q3X6FF&N:EXTGA2X?PSJ]G ^GZ=IL6M6]Y(DUW;AO8Z\)US2["7]HOP
M#K$FA>#)]2M/AAXZL;?Q'>>-;RS\>6%K=:YX8EN-+T3P CBPUSP[?2013ZSX
MDGC:XT6\M=.LH6":C(" >[4444 %9NL:-I/B'3+W1==TVQUC2-2@>UO],U*U
MAO;&\MY!AX;BVN$DAE1A_"Z'! 88(!&E13C*491E&3C*+4HRBVI1DG=2BU9I
MII--.Z>J(J4Z=:G.E5A"K2J0E3J4ZD8SIU(33C.$X23C.$HMQE&2:DFTTTSX
M:\2_\$\OV<?$%]]MLM.\6>$D;>9+#POXD:*P=W=G:00ZW9:Y)#R=J16TT%O&
M@5(X548KG?\ AVI^S]_T&OBC_P"%/HO_ ,RU?H/17T<.,.**<(PCGN9<L59<
MV)G-V7>4^:3V6LFWHNR/S*OX*^$V)K5*]7P^X7]I4ESS]EEE&A#F=KN-*@J=
M*"T6D(15];7;O^?'_#M3]G[_ *#7Q1_\*?1?_F6H_P"':G[/W_0:^*/_ (4^
MB_\ S+5^@]%7_KGQ5_T/<Q_\'/\ R\E]QE_Q [PC_P"C?\-_^$*\O[_DC\^/
M^':G[/W_ $&OBC_X4^B__,M1_P .U/V?O^@U\4?_  I]%_\ F6K]!Z*/]<^*
MO^A[F/\ X.?^7DON#_B!WA'_ -&_X;_\(5Y?W_)'Y\?\.U/V?O\ H-?%'_PI
M]%_^9:C_ (=J?L_?]!KXH_\ A3Z+_P#,M7Z#T4?ZY\5?]#W,?_!S_P O)?<'
M_$#O"/\ Z-_PW_X0KR_O^2/SX_X=J?L_?]!KXH_^%/HO_P RU'_#M3]G[_H-
M?%'_ ,*?1?\ YEJ_0>BC_7/BK_H>YC_X.?\ EY+[@_X@=X1_]&_X;_\ "%>7
M]_R1^?'_  [4_9^_Z#7Q1_\ "GT7_P"9:C_AVI^S]_T&OBC_ .%/HO\ \RU?
MH/11_KGQ5_T/<Q_\'/\ R\E]P?\ $#O"/_HW_#?_ (0KR_O^2/SX_P"':G[/
MW_0:^*/_ (4^B_\ S+4?\.U/V?O^@U\4?_"GT7_YEJ_0>BC_ %SXJ_Z'N8_^
M#G_EY+[@_P"('>$?_1O^&_\ PA7E_?\ )'Y\?\.U/V?O^@U\4?\ PI]%_P#F
M6H_X=J?L_?\ 0:^*/_A3Z+_\RU?H/11_KGQ5_P!#W,?_  <_\O)?<'_$#O"/
M_HW_  W_ .$*\O[_ )(_/C_AVI^S]_T&OBC_ .%/HO\ \RU'_#M3]G[_ *#7
MQ1_\*?1?_F6K]!Z*/]<^*O\ H>YC_P"#G_EY+[@_X@=X1_\ 1O\ AO\ \(5Y
M?W_)'Y\?\.U/V?O^@U\4?_"GT7_YEJ/^':G[/W_0:^*/_A3Z+_\ ,M7Z#T4?
MZY\5?]#W,?\ P<_\O)?<'_$#O"/_ *-_PW_X0KR_O^2/SX_X=J?L_?\ 0:^*
M/_A3Z+_\RU'_  [4_9^_Z#7Q1_\ "GT7_P"9:OT'HH_USXJ_Z'N8_P#@Y_Y>
M2^X/^('>$?\ T;_AO_PA7E_?\D?GQ_P[4_9^_P"@U\4?_"GT7_YEJ/\ AVI^
MS]_T&OBC_P"%/HO_ ,RU?H/11_KGQ5_T/<Q_\'/_ "\E]P?\0.\(_P#HW_#?
M_A"O+^_Y(_/C_AVI^S]_T&OBC_X4^B__ #+4?\.U/V?O^@U\4?\ PI]%_P#F
M6K]!Z*/]<^*O^A[F/_@Y_P"7DON#_B!WA'_T;_AO_P (5Y?W_)'Y\?\ #M3]
MG[_H-?%'_P *?1?_ )EJ/^':G[/W_0:^*/\ X4^B_P#S+5^@]%'^N?%7_0]S
M'_P<_P#+R7W!_P 0.\(_^C?\-_\ A"O+^_Y(_/C_ (=J?L_?]!KXH_\ A3Z+
M_P#,M1_P[4_9^_Z#7Q1_\*?1?_F6K]!Z*/\ 7/BK_H>YC_X.?^7DON#_ (@=
MX1_]&_X;_P#"%>7]_P D?GQ_P[4_9^_Z#7Q1_P#"GT7_ .9:C_AVI^S]_P!!
MKXH_^%/HO_S+5^@]%'^N?%7_ $/<Q_\ !S_R\E]P?\0.\(_^C?\ #?\ X0KR
M_O\ DC\^/^':G[/W_0:^*/\ X4^B_P#S+4?\.U/V?O\ H-?%'_PI]%_^9:OT
M'HH_USXJ_P"A[F/_ (.?^7DON#_B!WA'_P!&_P"&_P#PA7E_?\D?GQ_P[4_9
M^_Z#7Q1_\*?1?_F6H_X=J?L_?]!KXH_^%/HO_P RU?H/11_KGQ5_T/<Q_P#!
MS_R\E]P?\0.\(_\ HW_#?_A"O+^_Y(_/C_AVI^S]_P!!KXH_^%/HO_S+4?\
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MT?\ "DO^"V/_ $4+Q=_X=[X7T?\ $.,!_P!'%X"_\/#\O^G7F_N\P_U@K_\
M0@SO_P )'Y>?F_N\S^CBBOYQ_P#A27_!;'_HH7B[_P .]\+Z/^%)?\%L?^BA
M>+O_  [WPOH_XAQ@/^CB\!?^'A^7_3KS?W>8?ZP5_P#H09W_ .$C\O/S?W>9
M_1Q17\X__"DO^"V/_10O%W_AWOA?1_PI+_@MC_T4+Q=_X=[X7T?\0XP'_1Q>
M O\ P\/R_P"G7F_N\P_U@K_]"#.__"1^7GYO[O,_HXHK^<?_ (4E_P %L?\
MHH7B[_P[WPOH_P"%)?\ !;'_ **%XN_\.]\+Z/\ B'& _P"CB\!?^'A^7_3K
MS?W>8?ZP5_\ H09W_P"$C\O/S?W>9_1Q17\X_P#PI+_@MC_T4+Q=_P"'>^%]
M'_"DO^"V/_10O%W_ (=[X7T?\0XP'_1Q> O_  \/R_Z=>;^[S#_6"O\ ]"#.
M_P#PD?EY^;^[S/Z.**_G'_X4E_P6Q_Z*%XN_\.]\+Z/^%)?\%L?^BA>+O_#O
M?"^C_B'& _Z.+P%_X>'Y?].O-_=YA_K!7_Z$&=_^$C\O/S?W>9_1Q17\X_\
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M+_@MC_T4+Q=_X=[X7T?\*2_X+8_]%"\7?^'>^%]'_$.,!_T<7@+_ ,/#\O\
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MCB\!?^'A^7_3KS?W>8?ZP5_^A!G?_A(_+S\W]WF?T<45_./_ ,*2_P""V/\
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M_+_IUYO[O,/]8*__ $(,[_\ "1^7GYO[O,_HXHK^<?\ X4E_P6Q_Z*%XN_\
M#O?"^C_A27_!;'_HH7B[_P .]\+Z/^(<8#_HXO 7_AX?E_TZ\W]WF'^L%?\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
MH;_$/_APO M'_"L?^"FW_0W^(?\ PX7@6C_4K"?]%GPC_P"')_\ ROS_ #[,
M/^(Z9S_T8[QD_P#$87_S1_5GY7_9>BOQH_X5C_P4V_Z&_P 0_P#APO M'_"L
M?^"FW_0W^(?_  X7@6C_ %*PG_19\(_^')__ "OS_/LP_P"(Z9S_ -&.\9/_
M !&%_P#-']6?E?\ 9>BOQH_X5C_P4V_Z&_Q#_P"'"\"T?\*Q_P""FW_0W^(?
M_#A>!:/]2L)_T6?"/_AR?_ROS_/LP_XCIG/_ $8[QD_\1A?_ #1_5GY7_9>B
MOQH_X5C_ ,%-O^AO\0_^'"\"T?\ "L?^"FW_ $-_B'_PX7@6C_4K"?\ 19\(
M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
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M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
MH;_$/_APO M'_"L?^"FW_0W^(?\ PX7@6C_4K"?]%GPC_P"')_\ ROS_ #[,
M/^(Z9S_T8[QD_P#$87_S1_5GY7_9>BOQH_X5C_P4V_Z&_P 0_P#APO M'_"L
M?^"FW_0W^(?_  X7@6C_ %*PG_19\(_^')__ "OS_/LP_P"(Z9S_ -&.\9/_
M !&%_P#-']6?E?\ 9>BOQH_X5C_P4V_Z&_Q#_P"'"\"T?\*Q_P""FW_0W^(?
M_#A>!:/]2L)_T6?"/_AR?_ROS_/LP_XCIG/_ $8[QD_\1A?_ #1_5GY7_9>B
MOQH_X5C_ ,%-O^AO\0_^'"\"T?\ "L?^"FW_ $-_B'_PX7@6C_4K"?\ 19\(
M_P#AR?\ \K\_S[,/^(Z9S_T8[QD_\1A?_-']6?E?]EZ*_&C_ (5C_P %-O\
MH;_$/_APO M'_"L?^"FW_0W^(?\ PX7@6C_4K"?]%GPC_P"')_\ ROS_ #[,
M/^(Z9S_T8[QD_P#$87_S1_5GY7_9>BOQH_X5C_P4V_Z&_P 0_P#APO M'_"L
M?^"FW_0W^(?_  X7@6C_ %*PG_19\(_^')__ "OS_/LP_P"(Z9S_ -&.\9/_
M !&%_P#-']6?E?\ 9>BOQH_X5C_P4V_Z&_Q#_P"'"\"U!??%O]O']F@V&N_%
M739?%_@UYH_[1DU@Z1X@L%#N85M[GQ/X;_?Z%=R9=[07)\B641M-%-&IC87
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M:O'LOQ"^)LOCOX3^)/%'B1=2U/48OMGB2:UU'^R8;V_$$MS!I:2BT1[>TL+
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M]GOP;+X[^+'BJS\,:")UL[(R)-=ZCK&HR1M)#IFC:;:)+=ZC>S*C$)#'Y4*
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MJR7:,P6OTF!# ,I#*P!5@0001D$$<$$<@C@BOYE/VQ+WXE_M.^"/"_ASP?\
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MRF#X5KXW"T,5'.>'*$:\.=4<5F]&AB*?O<O+6HR@Y4YIZN+;=K/J?KV>>+N
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M;?)Q,GBG4=8^!$7PMTK]A3QDL-_X+M;'3?&EIIUO/.^KS:;"UKXUMKM?#/\
M:,T\]YY>K1.-1,DD#K:F9K8F,K)N$<NJY9A<RQ]#&XE9AC\5A:=&.8Y=E4\N
MPN%KO#U*^(^O<KQ.*C.,F\/17*E&TN5M7?&_C-Q/@^*\TX7X>Q^0Y=+ASAS*
M<VQ&,J\,\3<6TN)<WS7 4\QP^7Y;_J_[195E56A5I1AF..;J3G53I.I",W']
M@O#OB+0_%NAZ9XD\-:I9ZUH.LVD5_I>J6$RSVEY:S#*2Q..00<I)&X26&57A
MF2.5'1<+XDZ5XGUWP#XPT;P7J:Z-XKU3P_J=CH&J//):K8ZG<VTD5M<?:H8Y
MIK4H[?+<PQ/-;L1-$ID1:^1?^"?/AGQ_X/\ @]X@T#Q[X?\ $7AF6T\=ZE-H
M6E^(]/N--F32[O2M'N)Y;&WN55OL<VK/J,I91L:Z:YY+;J^\*^*S3"T\FSK%
M8;#5Z6-I8#&)X>NU"I3KPA*-6DZD8N5.=XN,:L4W"34DO=/W?A+-\1QQP+E.
M:YIE^*R/%<09*UF. C*OA<5@*]>G4PN*6'G4C#$T&IJ=7"5)Q5:G"5*<O?5S
M\;/'G_!.B[\._#+Q5X\U7XKWVO\ CGP]X?U?Q3J5O<Z:)-$OWTJVFU74H4O[
MN>XULW$]M!.8;N:0F6]*--$J.[+TW_!,CQ[XIU.?XB^ [_4[S4/"^C:5H6OZ
M-:WL\MS_ &->:C>7UI=VUF\TKFWL[U(%N/LD:B(7,,\RX:5Q73?MS?M(37JR
M?LX?"LSZYXK\3W-MI'C"31EEN;RW2ZEB:W\(:6;1PTFLZI((TU5%W+::>TEM
M.5:XF6+Z/_8^_9U/P"^'CKKJ6\GC_P 7O:ZIXLE@,4T>F^5"5T_P[:W2 B6#
M2HY9/M$D3M;W&H374T)DB\J5_P!&S/.,PJ<#8E\3U:=?'9UBJ-3(L-.A0I5Z
M&%I5*-2IBU3I4Z;I8=PC4A1DX\SC4@E)TZZM_,?"W!7#>&\?\JAX48/$X'(>
M!LJQN&\0,UHYAF&,R_'YKBL/B\/A\GGB<7B,2L7F$:E2A5QM.-3V:JX>M*5.
M%? -R^N****_(C^T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#\>O^"=O_)=OCY_V"O\ W=-4
MHH_X)V_\EV^/G_8*_P#=TU2BON?$7_DJ,3_V!97_ .J_#GX!]&7_ )--EO\
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MCGO&5&51Z056ODF 5&FY/13JN$U3C>\W%J*;T/V4HHHKX,_H0**** "BBB@
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MQZ_X?B_"_P#Z(#\3O_"@\(?_ "51_P /Q?A?_P!$!^)W_A0>$/\ Y*K]A?\
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M]?Z>A]2XB_Z'>'_\-M+R_O\ D_O\C\>O^'XOPO\ ^B _$[_PH/"'_P E4?\
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MB+_H=X?_ ,-M+R_O^3^_R/QZ_P"'XOPO_P"B _$[_P *#PA_\E4?\/Q?A?\
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M'A#_ .2J_87_ (5%\)_^B8?#S_PBO#?_ ,K*/^%1?"?_ *)A\//_  BO#?\
M\K*/[=\-/^B#S+_Q)\9_\K]?Z>A]2XB_Z'>'_P##;2\O[_D_O\C\>O\ A^+\
M+_\ H@/Q._\ "@\(?_)5'_#\7X7_ /1 ?B=_X4'A#_Y*K]A?^%1?"?\ Z)A\
M//\ PBO#?_RLH_X5%\)_^B8?#S_PBO#?_P K*/[=\-/^B#S+_P 2?&?_ "OU
M_IZ'U+B+_H=X?_PVTO+^_P"3^_R/QZ_X?B_"_P#Z(#\3O_"@\(?_ "51_P /
MQ?A?_P!$!^)W_A0>$/\ Y*K]A?\ A47PG_Z)A\//_"*\-_\ RLH_X5%\)_\
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MZ'>'_P##;2\O[_D_O\C\>O\ A^+\+_\ H@/Q._\ "@\(?_)5'_#\7X7_ /1
M?B=_X4'A#_Y*K]A?^%1?"?\ Z)A\//\ PBO#?_RLH_X5%\)_^B8?#S_PBO#?
M_P K*/[=\-/^B#S+_P 2?&?_ "OU_IZ'U+B+_H=X?_PVTO+^_P"3^_R/QZ_X
M?B_"_P#Z(#\3O_"@\(?_ "51_P /Q?A?_P!$!^)W_A0>$/\ Y*K]A?\ A47P
MG_Z)A\//_"*\-_\ RLH_X5%\)_\ HF'P\_\ "*\-_P#RLH_MWPT_Z(/,O_$G
MQG_ROU_IZ'U+B+_H=X?_ ,-M+R_O^3^_R/QZ_P"'XOPO_P"B _$[_P *#PA_
M\E4?\/Q?A?\ ]$!^)W_A0>$/_DJOV%_X5%\)_P#HF'P\_P#"*\-__*RC_A47
MPG_Z)A\//_"*\-__ "LH_MWPT_Z(/,O_ !)\9_\ *_7^GH?4N(O^AWA__#;2
M\O[_ )/[_(_'K_A^+\+_ /H@/Q._\*#PA_\ )5'_  _%^%__ $0'XG?^%!X0
M_P#DJOV%_P"%1?"?_HF'P\_\(KPW_P#*RC_A47PG_P"B8?#S_P (KPW_ /*R
MC^W?#3_H@\R_\2?&?_*_7^GH?4N(O^AWA_\ PVTO+^_Y/[_(_'K_ (?B_"__
M *(#\3O_  H/"'_R51_P_%^%_P#T0'XG?^%!X0_^2J_87_A47PG_ .B8?#S_
M ,(KPW_\K*/^%1?"?_HF'P\_\(KPW_\ *RC^W?#3_H@\R_\ $GQG_P K]?Z>
MA]2XB_Z'>'_\-M+R_O\ D_O\C\>O^'XOPO\ ^B _$[_PH/"'_P E4?\ #\7X
M7_\ 1 ?B=_X4'A#_ .2J_87_ (5%\)_^B8?#S_PBO#?_ ,K*/^%1?"?_ *)A
M\//_  BO#?\ \K*/[=\-/^B#S+_Q)\9_\K]?Z>A]2XB_Z'>'_P##;2\O[_D_
MO\C\>O\ A^+\+_\ H@/Q._\ "@\(?_)5'_#\7X7_ /1 ?B=_X4'A#_Y*K]A?
M^%1?"?\ Z)A\//\ PBO#?_RLH_X5%\)_^B8?#S_PBO#?_P K*/[=\-/^B#S+
M_P 2?&?_ "OU_IZ'U+B+_H=X?_PVTO+^_P"3^_R/QZ_X?B_"_P#Z(#\3O_"@
M\(?_ "51_P /Q?A?_P!$!^)W_A0>$/\ Y*K]A?\ A47PG_Z)A\//_"*\-_\
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M[=\-/^B#S+_Q)\9_\K]?Z>A]2XB_Z'>'_P##;2\O[_D_O\C\>O\ A^+\+_\
MH@/Q._\ "@\(?_)5'_#\7X7_ /1 ?B=_X4'A#_Y*K]A?^%1?"?\ Z)A\//\
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M?^%!X0_^2J_87_A47PG_ .B8?#S_ ,(KPW_\K*/^%1?"?_HF'P\_\(KPW_\
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MHG@7_HDOCC_P;^'/_DBOT6_X5YX _P"A&\'_ /A,Z+_\A4?\*\\ ?]"-X/\
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M_?Y'YT_\/1/ O_1)?''_ (-_#G_R11_P]$\"_P#1)?''_@W\.?\ R17Z+?\
M"O/ '_0C>#__  F=%_\ D*C_ (5YX _Z$;P?_P"$SHO_ ,A4?VMP/_T26-_\
M/N)_^0#_ %.\?/\ H\>1?^*_ROR_Z?>3^_R/SI_X>B>!?^B2^./_  ;^'/\
MY(H_X>B>!?\ HDOCC_P;^'/_ )(K]%O^%>> /^A&\'_^$SHO_P A4?\ "O/
M'_0C>#__  F=%_\ D*C^UN!_^B2QO_A]Q/\ \@'^IWCY_P!'CR+_ ,5_E?E_
MT^\G]_D?G3_P]$\"_P#1)?''_@W\.?\ R11_P]$\"_\ 1)?''_@W\.?_ "17
MZ+?\*\\ ?]"-X/\ _"9T7_Y"H_X5YX _Z$;P?_X3.B__ "%1_:W _P#T26-_
M\/N)_P#D _U.\?/^CQY%_P"*_P K\O\ I]Y/[_(_.G_AZ)X%_P"B2^./_!OX
M<_\ DBC_ (>B>!?^B2^./_!OX<_^2*_1;_A7G@#_ *$;P?\ ^$SHO_R%1_PK
MSP!_T(W@_P#\)G1?_D*C^UN!_P#HDL;_ .'W$_\ R ?ZG>/G_1X\B_\ %?Y7
MY?\ 3[R?W^1^=/\ P]$\"_\ 1)?''_@W\.?_ "11_P /1/ O_1)?''_@W\.?
M_)%?HM_PKSP!_P!"-X/_ /"9T7_Y"H_X5YX _P"A&\'_ /A,Z+_\A4?VMP/_
M -$EC?\ P^XG_P"0#_4[Q\_Z/'D7_BO\K\O^GWD_O\C\Z?\ AZ)X%_Z)+XX_
M\&_AS_Y(H_X>B>!?^B2^./\ P;^'/_DBOT6_X5YX _Z$;P?_ .$SHO\ \A4?
M\*\\ ?\ 0C>#_P#PF=%_^0J/[6X'_P"B2QO_ (?<3_\ (!_J=X^?]'CR+_Q7
M^5^7_3[R?W^1^=/_  ]$\"_]$E\<?^#?PY_\D4?\/1/ O_1)?''_ (-_#G_R
M17Z+?\*\\ ?]"-X/_P#"9T7_ .0J/^%>> /^A&\'_P#A,Z+_ /(5']K<#_\
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M_P D5^BW_"O/ '_0C>#_ /PF=%_^0J/^%>> /^A&\'_^$SHO_P A4?VMP/\
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MHG@7_HDOCC_P;^'/_DBC_AZ)X%_Z)+XX_P#!OX<_^2*_1;_A7G@#_H1O!_\
MX3.B_P#R%1_PKSP!_P!"-X/_ /"9T7_Y"H_M;@?_ *)+&_\ A]Q/_P @'^IW
MCY_T>/(O_%?Y7Y?]/O)_?Y'YT_\ #T3P+_T27QQ_X-_#G_R11_P]$\"_]$E\
M<?\ @W\.?_)%?HM_PKSP!_T(W@__ ,)G1?\ Y"H_X5YX _Z$;P?_ .$SHO\
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M_P!'CR+_ ,5_E?E_T^\G]_D?G3_P]$\"_P#1)?''_@W\.?\ R11_P]$\"_\
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M2HXJ4JE6M6J-)U<1B:TZF(Q%5I>TKU:D[1YK(HHHKB/="BBB@ HHHH ****
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MU(VD)\)PPB\41:B8EN'\9.A?PTUFNG*P&L," >X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "B@D $D@ #))X  ZDGL!5>UO+2^B$]E=6]Y
M691-:SQ7$193AE$D3.A93PPW9!Z@4 6**** "BJUK>6E]&TME=6UY$LC1-+:
MSQ7$:RH 6C9XF=1(H92R$AE# D#(JS0 4444 %%5K6]L[U9'LKNUNTBD,4K6
MMQ%<+'*H!:.1HG<)( 02C$, 02.:LT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*^!_Q,^+&G7QT^U\':%XLBCO?%=Q'876IW#?#R[U*&QTSXE6ME8V5S/J%]X
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MX1F.UFTWS$_MHAP#VZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0_'$Q1Z4]X6M--UW3AXB\+QW&IVJI?6CZ]H(#[I[4K^Y/[:OP<_X*)?%'6_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M \.>'OV^OV'_ !%_9?Q#UWP=!:V'@SXT> +O59M)TWXE>&-+MH;*.TEL[_\
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M-85N;JWTBSLX;BX6%%B$TJ/((U5 VU0  )X[\=^#/AAX,\4?$7XB^*="\$^
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M/BWXI\0RZOHOAFSBE-^C:18:4)KBVGU;Q+X>TE+O5;8 _J$HKX4NOVWOA_\
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M-.G^(?"NM:;XAT._$$KP3FSU;2+F\L+KR9XY(9?(N'\N6-XWPZLH_ #]H/\
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M,D9W4 =)14<TT-O#+<7$L<$$$;S3SS.L4,,,2EY)99'*I''&BL[N[!44%F(
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M\^+'[4_BF\^'<UC9Z[:ZU::%XQ6U1=0\;:5$+*WM E]+8W,"H+G3KG3[@(R
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M,FJZNEJVEWO]5%% 'X3?\%?O^":?Q:_:^^&O_!.CX>_LPV_@?2=%_8^_;0^
M/Q=U[1O%VOW6APVGP>^&&DW_ (?NK;P]<)I^I?VEK&E:?)8_9M,N#;/?Q12;
M+L3J$E^LO^"O_P"RY\5?VT_^";?[57[+OP0@\/7/Q4^+_@SP]H/@^'Q7K1\.
M^'WO=/\ B%X/\17AU+619W_V*--*T6_>%C:2B:Y6&W)B$QE3])Z* /@3Q?\
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M3Z_:U_:P/[5WQ4_X6/\ LK_M8?LZ_ ;6?VF]1TGX::WJNM2:5\#X=1DN5NO
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MB.WU;4/ VN:C:6^G^*+'39[FVAOKS1I[NVM9IXX)I4F+1J ?"7[%/PI\(_\
M!)G_ (.'M=_X)\_LY:KXWL/V0OVROV0KSXS^%O@AK/C/Q)XG\+_!_P")G@Z?
M6]4EU#0Y?$U]K.J7<-QIOP^\9VEI=WVI/J"6GC---O[S4DT?3'A^8/B9_P $
MBO\ @G[J/_!RA\/_ -E&[^">NR_ CQ[_ ,$[_$O[0?BKP:/C?\?(KS4?BW>?
M%SXCZ?<>)HO&</Q.C\=Z9:/9Z=9Q#POI?B:R\*1M$TT>B))+*S_I_P#&C]GW
MX[:Q_P '1G[('[0^E?!WXE:C\ _"?[#/C[POXF^-%IX.UR?X7Z#XGOM*^.-E
M9^&]5\;QV;>'K+Q!<W.M:-'#HMQ?IJ4HU2RECMGAF$@\E_X*0:E\=?V*_P#@
MO+^S'_P4E3]D[]HS]I/]F'4/V(=;_9E\::E^S'\.-7^+'C7P1XJ'C[Q[XCDN
M]3\+:3"BPQNGBKPP^F1ZAJ>F1ZU;OK8L+MKK1Y;:8 _IR^#GPA^'WP!^%G@+
MX+?"C0YO#7PV^&7AK3?"'@K0+C6]?\23Z3X?TB$06%E-KWBG5-:\1ZO+%$,/
M?ZUJVH:C<-F2YNI9"6/\Q/\ P6VM?#?QV_X*N_\ !*_]BK]KKXB>*_ ?_!.S
MXN^&_BYXO^('AV+Q;J?PT^&_QF^-WAG3M?\ ^$/^'OC[X@:9J?AU[>%TM_#]
MC9:6VNI=SOXG;2M'AL=7\4V6J6_],_P)^*<OQO\ @[\.?B[/\._B-\)9/B'X
M6TWQ3_PK;XN^'O\ A$OB9X.34XS-%HOC;PR;F[?0M?@B*->:7-.UQ9M(L-RL
M4ZR1)_'_ /\ !=;P[XU^)/\ P6%_9K^'_P ._P!EKX1_\%3M>UK]BSXD>&[_
M /8-\8>(K[PG>_!W2;OQOIGB*\^/^L^,Q<:1X;\!2^($TV#P_P"%_$FL>)M*
MU5KB&;2;.%+O5?#-Q< 'D/C3_@F/_P $V/!?_!PE^Q7^RC^S/X/E\4? WQC\
M"?BK\5OVBO@-X(^.'Q7U/P;\%/&?@/1?$WB#X8>/X=7\(_$R/Q%X-U3Q%XDT
M7P[%J?A/Q+J\WAJ]@OK"2/1&?Q?9M%^EO[3/_*V+_P $Y?\ M''\9/\ TN_:
M7KYN_8U_:K^'/_!'OQG\*?"G[1__  0PO/\ @EWX$_:R^)^C_!Q_VF_ ?Q?\
M%?M$:#%XRU2W$WAKPWX^\0Z=KWC+Q_H_ANZOX!>0:;>>)HK2.SM-;\1Z3X>U
M:30M9:'[H_:%^!'QLUO_ (.9OV"?V@M&^$OQ$U7X$^#OV"?BUX+\6_&+3O".
MM7GPU\,>+[^\_: :Q\,:_P",H+-]"TC7KU?$&A&RTJ^O8+V[&K6+6T,JRY4
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M;G5M"73M%UNT35I-<UVVT[2OH7Q[^S]\<[C_ (.>?@7^T3;?"+XAW7P$L/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY]UZWT-
MOVFOAW=3Q?"H^(8_A1X_BL)M4UK4X?C*FF2:_P"%&OH_">@1H=)OO SSI:GQ
M3J-TXO;+5%T.&V4Q7,Q'T%7AVM:@L?[0O@33#KTD#W'PT\;W8\-CX7RZG%J"
MV^M^&HSJK?%X1F'PJ]@91 O@EY%?Q.+HZFJ,-%)4 ]QHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_ ?]N'_ ()A?MI:I^W7<_\ !3/_ ()O
M?M/_  M^$W[1NI?L^VGP \9_"S]H7X=WOC'X3>/_  UH^NVNMZ1L\1Z%)<:Y
MX-E:6V@%_<0>'->N#+9VT]C-9++>P7/[\44 ?S13?\$J_P#@IA^WO\2/V?O%
M'_!7S]JG]GC4_@C^SK\8=+^..@?LG_LD?#[Q%:^$?'?Q!\,QQQ^%=1^('Q*\
M<PZ)K][IFDP3ZS8#3+;P\\S:=K^MV]M?V$E\;E/Z7:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKKV@77]AZC/X>OFL+6.W:)J^A_\ @Y3^/GQ \0_!S]GS_@EG^SS=73_M$?\
M!33XM:%\*3'IRSS3>'?@CHVMZ1=?$;Q#K*V,<NI67AN5Y]/3Q#J5K'+##X-T
MOQH-0C;3_M /[[_LT?L_^ /V5/V?O@Y^S?\ "ZR-EX!^"OP]\,_#WPVLD5O%
M=WMIX=TV"SGUK4UM8X;=]9\07R76NZW<0Q1I=:OJ-[<A%\W  /<**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_5SJ
M'_"\?!HCD^)PTP_#_P 7FXBTT67_  J-KL:MH'V=_%)=#J'_  FBQ^:/#(@=
M;;^S3K)G4OY1'L%>-ZOI]Q)\=O!6IKX>\27%M;?#SQC:2>)[?QE;6?A73I;C
M6/#TD>DZGX#:X6[UK6-06%[C3O$45M)#HUO:7=G)+&VHHK@'LE%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX@T?P5IEKK$=IXHLO$<,D>G&34)=/N8[6TA-[)=S&2>3^SO]BCX'?'+]G?\
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M3X)Z5\?_ -E7XDV7Q%^']_>2:1J6;*^T7Q'X2\36MM;7.H^%/&/AK5H+75=
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MS/<:C<?VBSZS%;Q7N@:E:2)+:_CY\)?VB_VN?V"/^"Q_[*W[&?C/_@H-K/\
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MK&UO="O-#GMK.)Y[A1^N-?FGX$\-3_L=?\$AM&T#X2ZK<6>H_LZ_\$^[BY\
MZYJ,%O?W-MKOP^^ 5SJVAZO>6TR&VO)(]8T^"]EMYXVBGP8I@ZLY;^>K_@E5
MH?\ P6F_X*W?L+?"OXV^/?\ @I5XD_9,\!^'=%^)'A#X<>)OA9X*\+^,OC7^
MT'X]L/&?B!)/BE\;]?U>+3]+T;P9X9GDB\ Z%X#\-VMMJ>KV7AFXUZZU#2+B
M>VNM5 /[0:*_GT_X(._MG_M??M"?"']LOX$_M=:QI'Q7_:&_8(_:/\8_LWS?
M$^SMK3P[)\88/#=C=KH&LZU;06EC9VM]?W>E3_\ $[>W@FU'3;^QOM3A34$O
M))<T?MO_ /!PUCG_ ((A?!TGN1_P4+^!0'X ZGG'UH _H=K^;GQS_P ' _CW
MQ'XA^(=W^Q/_ ,$H?VY_VU?@G\,M4\0^'M;_ &@/"GAB^^'G@7Q'KWA35[K1
M_$$/PYL=8\(>(=:\;:=8SVV\S6UM8ZV$9C=>';2.)I#^A_["O[07_!33XP>-
M?&VC?MT?\$^?!/[('@O2O"]MJ?@GQGX5_:@^'/QRG\4^)VU:UM;GPQ=^'?!L
MMU?:3$NE37.JIK=W-#:*UE]@$4TUVCP_;OQ;^*OPG_9D^#7COXP_$[7-%^'/
MP@^$/A#5_%_BW6Y+=;32O#_AO0[:2[NFMK"QAWS3RD"VT[2]/MI;W4M1N+;3
M["VGO+J&&0 ^-O\ @F!_P4_^ '_!5/\ 9_G^-WP2M]=\*:UX5UQ?!OQ9^$WC
M)K!?&WPO\;)917LFD:NEA/)'?:1?(T\GAWQ"L-E'K=O:79:PT^^LK_3K/\P?
MBW_P<%_&;P_^TO\ M+_L]_L[?\$C/VOOVO+#]F'XI7?PF\:?$SX,ZA<:QH+^
M([2PMK_9=V&B?#;Q.=!DNHIWFLK*_P!4DNKBRC2\*QB4Q1^;?\&L/PN^(=[\
M(?VZ_P!N#Q1X(C^&O@#]OO\ :X\5?&#X*^"VM+[3Y[?X?Z5K/C&1=9L[*YT^
MPM5\,WNJ^++W1?#=Y9AEU&#PU=W:Q163Z>\_C?P7_:2_;>_X)L?MM?\ !4UK
M#_@DA^V]^U+X&_:7_;,N_BUX+^)/P@\*R0^%)?!UEX6L= CO-*NKG1=3A\0R
MWTD<EU:_9;BTMVC40R7,<P=4 /WD_P""<7[=OQI_;@\._$[5OC3^P)^TC^PA
MJO@#6]!TS1M$_:"TZ\M3\0;#6K"\NI]5\+76H>&/"-S.-$N+/[)JT*Z7/;P&
M\L'34))9IK:V\!_85_;L^/?C#_@HW_P41_X)R?M5MX2U#QS\ -0\+?'+]F[Q
M?X/\.'P[;^,?V6OB-%IR:59>)+=;ZZMKGQ7X'O-:\*6.K:K:*J:GJ>OZQ:O'
M;_V"B2>V?\$VO^"LW[,'_!3O0_B/'\&[3XB_#?XK_!C5[;1/C'\ /C=X9M_!
M7Q?^'=U>S7MMI][JF@VVJ:Q97FBZA<Z;J%K#J.G:C/)97EI)I^NV>CZDT=F_
MY,?M_MJG[/O_  <N_P#!(;XZ:6L,NF?M2_ OXR_LL^(-.MWN;%IG\(2>(]8.
MK:LUK/&FL"!OBKX8?3K6^BE@MKC08)B&>&W:  _JCHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O']6
M;5O^%X^#4BD^)XT4_#_Q>UW%IMMI;?")K\:OH M'\4W<J'6(O&JQ&<>&8;1Q
M8RZ8=::Z!E2#'L%>,:QI4DOQY\%:P/#FI7$5I\.O&5BWBF/QK]CTG3'NM8\/
M2KI%UX \]?[<O-1$!N+;Q']GD_L6.SFL_-3^T=K 'L]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\:W_!(_
M]C#]DC]J[_@I;_P7^US]I#]G?X0?'/6OAQ_P4+8>"-1^)?@S1?%]UX574_&7
MQONM2CT=M5M[D645[?:)I\MW&BA+B;3X1,K^0%7^RFN7T#P1X+\*ZCXDU?PO
MX1\,>'-6\8ZD-9\7:IH.@:5I&H^*=7 E U7Q%>Z?:6]SK>H@338O=2EN;G]]
M*?-S*^X S;'PIH'PW\"7OA_X7^$/#?A'3-$T?59?#?A7PGH.E^'M M;[[/<7
M,$%EHNCVMGIULMS?%6D2"VC$LDC,X+,2?\__ /X)C:C_ ,$;_CO\ _C3^UQ_
MP6\^+.@?&/\ ;[M_BY\5M+^+?PZ_:6\>^,I?%_A*STK6XX/#?A+X:? ?3]4L
M&BO;^339]+T[2="T&2_M]32X\+6UKI]I81VH_P!#JOF;5_V+OV0]?^,]C^T7
MKG[,/P%UCX]::CK8_&'4OA1X)O?B-;&0SL\T7BVXT6361<EKJX879NS=*TTC
M+,&8F@#^6G_@U_C\-P?L1_\ !7-/!WA+5OA_X-_X;%^/L_A'P+X@TZXT;7?!
M?A*X^#OA^?PUX7UK2+QWN])U30-$>RTO4--NW:YL+NTFM;AC-"]??_\ P:G,
MK_\ !%']G-E8,I^(7[1Y!4@@AOCW\0&!!'&""&'J"#WK^@O1?!?@[PX_B*3P
M]X3\-:#)XOU>[U_Q9)HVA:7I;^)]=OXTAO\ 6O$+6-K VM:M>Q1QQ7>HZD;F
M\N8T5)IG50 _PKX0\)^!=&@\.>"?"_AWP=X>M9KNXM=!\+:+IOA_1K:XO[J6
M]OIX-+TFVM+&&:]O9Y[N[DC@5[BYFEGE+RR.Q /Y2O\ @NC\0O!O[/G_  6.
M_P""$'[2OQGUR#X>_ ;X?^+?VAM)\<?%;7H+J'P9X4U#6M&\,0Z7;Z[K$4,M
MOI[W7G-< 3E2EC;7U^P^RV-W+#_3'^SQ^TU\ ?VL_A^_Q6_9L^+'@_XS?#=/
M$.K^%?\ A-/ NH_VMX?D\0:#]F_M?3(+]8XXKB:Q^V6OG/ 9(")D,<K@G'1?
M&'X(?!O]H3P1J'PU^.WPL\ ?&'X?:JT<FH^#/B3X3T3QEX;NY823%-+I&O65
M]9^?%EA'.L2S(KNJN%=@=GX;_#'X<_!SP7H7PX^$W@3PC\-? 'ABT6Q\.^"_
M OA[2O"WAC1+126\C3-$T6UL].LXV8EW$-NADD9I)"SL6(!P/[1G[3O[/_[(
MWPVG^,'[2WQ7\(_!GX96VLZ5X>F\9^-;]]/T==<UMYDTG2EECAGEEO;\V]P8
M((H79D@FD(6.)V7^./X,?\%2O^">6@?\'*W[7G[66L_M<?"'3OV<?&W_  3^
M\#_#?PE\7KC5[\>#_$'CW3];^ D][X3T^^337D?6+6V\.:[<2PR01QJFE7:"
M4SHL3?VU^,/ _@OXAZ'-X9\?>$/#'CCPW<S07%QX?\7Z!I7B319[BU?S+6>;
M2]9M+VQDFMI/WEO*\!DA?YXV5N:\A/[(O[*)!!_9D_9]P>#_ ,6:^'7_ ,SE
M 'DGQ^_X*%?LV? #]B/7_P#@H)?>)-2^)/[.&D^"-%\?:1XF^%>F-XIN?&'A
M_P 2W]AI?AV[\.6[RZ?#);ZI?ZG91?;=0N;"RLHI7N+ZX@BB<CZ _9\^./@;
M]IGX%_"']H?X92ZI-\//C;\.?"'Q1\%2:WI[Z5K#>&?&VAV6OZ/_ &IIKR2M
M8Z@ME?0K=VOFRB&<.BRR* [=K-X!\"W'@X_#NX\%^$Y_ !TN/0_^$&E\.Z/)
MX/\ [%A5%ATC_A&7LSHO]EQ+&BQV'V+[+&$0)$ JXW-*TG2M!TS3]$T/3-/T
M;1M)L[?3M*TC2K.VT[3-,T^SB6"TL=/L+..&UL[.U@1(;>VMHHX((D6.)%10
M  ?SD?\ !V$0/^"+GQTR0,_$GX&@9..3\1M) '/<G@#N2 .2*[3P1_P<)_\
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MJ\3Z1.EW#?I+::UK&BW=^KI>V\%TI:=ML\22###- '\A?@/P/^VK_P %,_\
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MIX8\$>&/#W@[PW8-<-8>'_"VBZ;X?T2R:[N);NZ:TTK2;:TL+9KFZFFN9S#
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M_P#MX?$'PWJ%VT%C=Z79:;<7?A[X.V=_8SQ/8ZA*DUO9"VUB[LY?%VLZ)'X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%>3_&_XS>"?@!\,O$_Q4^(%\;/P_P"&K/S?(A,9U#6-2G/E:9H6D02/
M&+K5-5NV2VM80P5=SW$[1VT$\L?X+Q?M+_\ !2G]NC6-;N_V;](NOAI\---O
M;F"TN=#N=-\-V4$MJQ,=EJ?Q%UN)[S5]?:WG3[;8Z*L.E12H%-I!+&6D^OX<
MX,S'B+#XG,%B<ORC)\'-4L5G&<8E83 PK-1DL/3GRSE6K\LHR<(1Y8J45.<9
M3IJ?E9AF^'P%2G0]G7Q6+K+FIX3"T_:UG!.W/)72A"Z:NW=V=HM1DU_2!17\
MXO\ PS=_P6>_Z*[XJ_\ #\:/_P#(U'_#-W_!9[_HKOBK_P /QH__ ,C5]#_Q
M#O*_^CB\$?\ AQE_\AZ_T].#^WL3_P!"#.>G_,.O+S\W]S/Z.J*_G%_X9N_X
M+/?]%=\5?^'XT?\ ^1J/^&;O^"SW_17?%7_A^-'_ /D:C_B'>5_]'%X(_P##
MC+_Y#U_IZ']O8G_H09ST_P"8=>7GYO[F?T=45_.+_P ,W?\ !9[_ **[XJ_\
M/QH__P C4?\ #-W_  6>_P"BN^*O_#\:/_\ (U'_ !#O*_\ HXO!'_AQE_\
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M0]?Z>A_;V)_Z$&<]/^8=>7GYO[F?T=45_.+_ ,,W?\%GO^BN^*O_  _&C_\
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M@SGI_P PZ\O/S?W,_HZHK^<7_AF[_@L]_P!%=\5?^'XT?_Y&H_X9N_X+/?\
M17?%7_A^-'_^1J/^(=Y7_P!'%X(_\.,O_D/7^GH?V]B?^A!G/3_F'7EY^;^Y
MG]'5%?SB_P##-W_!9[_HKOBK_P /QH__ ,C4?\,W?\%GO^BN^*O_  _&C_\
MR-1_Q#O*_P#HXO!'_AQE_P#(>O\ 3T/[>Q/_ $(,YZ?\PZ\O/S?W,_HZHK^<
M7_AF[_@L]_T5WQ5_X?C1_P#Y&H_X9N_X+/?]%=\5?^'XT?\ ^1J/^(=Y7_T<
M7@C_ ,.,O_D/7^GH?V]B?^A!G/3_ )AUY>?F_N9_1U17\XO_  S=_P %GO\
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M/_#C+_Y#U_IZ']O8G_H09ST_YAUY>?F_N9_1U17\XO\ PS=_P6>_Z*[XJ_\
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M>7GYO[F?T=45_.+_ ,,W?\%GO^BN^*O_  _&C_\ R-1_PS=_P6>_Z*[XJ_\
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M .0]?Z>A_;V)_P"A!G/3_F'7EY^;^YG]'5%?SB_\,W?\%GO^BN^*O_#\:/\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOSB_:0_P""NO\
MP39_9"^*>I_!+]I+]KKX7_";XK:+IFCZQJ_@CQ"WB.XUG3=.\062:EHMQ>KH
MV@ZI;6QU'3I8;ZW@EN%N#:3P3M$L4\3. ?H[17QO^RG_ ,%"?V*/VXAXF7]D
MW]I+X9?'"Z\&K:2>*-+\'ZQ+_;NB6]]D6E[>Z!JUKIFMIIT[@PIJ2V#V N/]
M&:Y%P1'7V10 4444 %%<[XL\7^$_ 7AW5/%_CKQ1X=\%^$]$ACN-:\4>+-;T
MWPYX=TBWEGBM8I]4UK6+FSTVPADN9X+>.6[N8D>>:*%6,DB*VW;7-M>VUO>6
M=Q!=V=W!%<VMU;2QSVUS;3QK+!<6\\3/%-!-$Z212QLT<D;*Z,RL"0">BJ6I
M:EIVCZ??:OJ]_9:5I6EV=SJ&I:GJ5U!8Z?IUA9PO<7=]?7MU)%;6EG:V\<D]
MS<W$L<,$*/+*ZHK,/P[\;?\ !R5_P1J\"?%C1_A%J/[8OAG6-4U2ZFLKOQCX
M3\+^,O$_PQ\.W<$]Q;R1>(?'^D:%<:#9J);9A]IM9[ZS"20R-<+'(KT ?NC1
M7-^#O&7A/XA^%/#OCOP'XDT3QCX+\7:-I_B'POXJ\-ZE::SH'B#0]5MH[S3=
M6TC5+"6>SO["]MI8Y[>YMY9(I(V!5JZ2@ HJ.66."*2>9UCAAC>661SM2..-
M2[NQ/ 5%!9B>@!-?CU?_ /!P)_P1JTV_O-,O/^"@'P2CO-/O+BPNDC/C*YA2
MYM9GMYUCN[7PK-:7$:RQL%N+>>6WE4"2*5XF5R ?L317SK^S7^US^S)^V)X+
MF^(?[+_QQ^'/QP\'VET;'4=6\ >(K/6'TB\\ZZ@CM=<TQ6CU;0KB=[*[-I#K
M%A927D=O+-:K-"ADKZ*H **** "BN&^)WQ(\&?!WX<^._BS\1=:A\.> ?AKX
M1\0^.O&>OW$<TT.C^&/"VE76M:WJ4D-O'+<3+::=9W$WDP1232E!'$CNRJ?"
M/V*OVU/@)_P4!^ /A[]I?]FK7=<\1_"?Q/K7B;0-(U7Q%X9U?PCJ<VI>$=8N
M=!UN.31=;@M[^&*#4;6:*&9X_+N$7S(B5- 'UA1110 4444 %%%% !1110 4
M444 %%?GW^RG_P %$_A;^U[^TS^V_P#LT_#7P9XYL-3_ &$?'_A3X8_$WQWX
MA'ARW\*>)_&?B>+Q,9=-\%VUEKE]XBGAT*\\(:]I^J7NLZ/I$#7-K&;(W44Z
M25^@E !1110 4444 %%?GU\=?^"B?PQ^!/[<G[(O[!>K>!?B#XJ^*'[7VB_$
M;Q%X8\2>%HO#EQX2\ :)\-]+N-3U'4O'PO==L]?L[/5?LT]GI5QI>C:E#)=1
MLDSQ!6(ZJ;_@H/\ LU0_MTVW_!.===\5W/[4-Q\+/^%RR>&[3P1XAN?"]CX!
M\J>4:KJ7C6*T;P_8R,84@6VN+I)&NKNQM!FXNX8V /MNBBB@ HHHH **** "
MBBB@ HKXK_;L_P""@7[,O_!.'X0Z1\</VJ/%FL^$_ 6O>.=&^'>D3^'?"NM^
M,M8OO%&N6.JZE96L&A^'[:[U!K=;+1;^:YO/*\BWV1([>9/"C_9MK<QWEK;7
M<(<174$-S$)$:.01SQK*@DC<!XWVL-R, R-E6 (- $]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@I_P6V\6ZC<P?
ML^?"JVN[JTT_7==UOQ'J*QR,+6ZN8VT_P_I$D\(.R6;3)-1O;FV+J=AGDP1N
M-?M)\(?AKH/P>^&/@?X9^&K.ULM(\&^'-,T6)+2(0Q7%U;6Z?VCJ+IEB;C4]
M0:ZU"Y=F9GN+F1B>:_"[_@M-_P E7_9B_P"O?5/_ %*M!K^ABOT_BF4J'AYX
M<8:E)PH8E\2XVO36D:N)IYA1I4ZTU]J<*=6I"#=W&$G%63/G,M2GGW$%22O.
MG_9U&$GO&G+#RE*"[*4H1DTMVKO4****_,#Z,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **P
M]:\3>&_#26TGB+Q!HF@1WDOD6CZUJMAI:74_!\FV:^N(!/+@@^7$6?!SC%:Y
MGA$/V@S1"W\L2^>9$$/E%=PD\W.SRRI#!]VTJ<YQS5.$U&,W"2C-M0DXM1FX
MNTE%VM)IM)I-V;LQ<T;M75UJU=72>S:W5_,EHKRNV^.?P5O/%#>"+3XN?#2Y
M\9)-);-X5@\<>&I?$*W$2>9) ='34VOQ-&GSO%Y'F*O)45ZI6E;#XC#N"Q%"
MM0=2"J4U6I3I.=-[3@IQCS0?24;Q?1DPJ0J7Y)PGRMQER24N62WB[-V:ZIZA
M17G?C7XO?"GX;36=O\0_B7X"\#7&H;_L,'B[Q;H/AV:\$85G-M%JU_:23!0Z
M$F-6 #+ZBNUTO5=+UNPM=5T74K#5],O8DGL]1TR[M[^QNX)%#QS6UW:R2P3Q
M.C!D>.1E92""0:)X;$4Z5.O4H5H4*UU2K3I3C2JN.DE3J.*A.ST?*W;J"J4Y
M2E",X.<+<T%*+E&^W-%.\;]+I%^BJUY>V>G6MQ?:A=VUC96L3375Y>3Q6MK;
M0H,O-<7$[I##$@Y:21U11R2*R_#WBCPUXML6U/PKXAT/Q+IJ3O;/?Z!JMCK%
MDES&JM);M<Z?/<0K.BNC/$SB15=&*@,I,*G4<)5%";IQDHRJ*,G",I7<8RG;
ME4FD[)N[L[%<T;J-US--J-U=I;M+=I=6;M%%%0,**** "BJM[?66G6\EYJ%Y
M:V%I%M\VZO;B*UMX]S!%\R>=XXDW.P5=S#+$*,D@5C0^,/"5P_EV_BGPY/(>
MB0ZWIDKG)P/E2Z8\GCIUJXTZDTY0ISDEHW&$I)/31M)I;K[T)RBG9R2>]FTG
M;OJ='14;31+"UP9%,*Q&8RJ=R>4%WF12N=R[/F!7.1TSD5\\_!+]K#X _M%Z
MIXCT;X.>/[;QCJ/A.UL[W7;>'1_$&EFSL[^YN;2TN ^M:5IT<Z37%G<1 0-)
M(A0&1$5T9MZ.!QN(P^*Q=#"8FMA<"J3QN)I4*M2AA%7FZ=%XFM"+IT/;33A2
M]K*/M))QC=IHSE6HPG3I3JTH5*W-[&G*I&,ZO(N:?LX-J53E33ERI\J=W9'T
M51117*:A1110 4444 %%%% !13))(XD>65TCCC4L\DC*B(JC)9W8A54#DDD
M#DFO+K;XY_!6\\4-X(M/BY\-+GQBDSV[>%8/''AJ;Q"MQ$N^2 Z1'J;7XF1>
M7B\C>HZJ*VI8;$5U4="A6K*E!U*KI4IU%3@MYU'",E""ZRE9+JR)U*<.7GG"
M',^6//*,>:7\L;M7?DKL]4HHHK$L**** "BBB@ HHHH **** "BBB@ HHHH
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M-0T3XC(ATW0/#EG)+%%K/A>X=;K7;VXTZ^@4QZ7*0AGO-%%% !1110 4444
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MSE(H[O7/'&JWHTKPG8:7;6]]K>JZM'IFAZ;#?3&SCD .P_X)8_\ !8?X]_\
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M3-5L)-1T_4/B;\1M9;5M U;3V:46NE:KHUC\:].UBUOC&]Q-=>$DB1/]&26
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MZ,*6,SK,<HC*CEV%R_$4:<XRG*GB,53I*;G2YW+GA3G!RYTVKVY7:I(_-O\
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M4"M(SV:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#QG]HCX#^ /VH?@;\5/V>/BI%K,_PY^,?@O6O 7C2'P]K
M%SX?UN;P]K]LUIJ,6F:U: W.FW4D#,B7,(9D!(VL"08_V<OV??A=^RG\"_A;
M^SG\%M#D\.?"WX/>#]*\$^"])N+N74;V'2-)A\M+C4]3G_TG5-7OYVFO]6U2
MY)N=1U&YN;R=C+,YKVJB@#"\4^%_#OC?PSXB\%^,-$TSQ+X2\7:%J_ACQ1X<
MUJSAU#1]?\.Z_I]QI6M:+JUA<*]O>Z;JNFW=S8WUI.CPW-K/+#*K([ _A_\
M"/\ X-P?^"6GP?\ %F@^(--^&7Q*\;^&O"'B36_&?@CX/?%/XQ>-?B!\#O!7
MC'6Y1(WBOP[\*];O9/"\.OZ8BB#3-0O[74)(XEC:[%Y<0PSQ_N[10!\!_!W_
M ()I_LM? ?\ 8C\5_P#!/WX:Z-XWT7]GOQOH'Q,\/^)HI/'_ (AN_'^HQ?%V
M?5;GQOJ9\?RW']NV^M:A)K%W]FU&VDBDL56!+9$6$ _1/[,_[.GPM_9(^ WP
MM_9N^"ND7FA_"WX/^%++P?X-T[4=0FU?4X]+LFEE,^J:K<@7&I:G>W4]Q>7]
M],%>YNIY9"JA@H]SHH _+C]N;_@CU^Q7_P %!_BG\,_CE\<] ^(^@?&?X3:#
M?>%O"/Q3^#/Q-\2_"7QU%X<O+N>_BT;4/$'A>:&\O;/2KR^U>XT8LT=QIK:[
MK<=O.L&J743_ 'M\$O@_X+_9^^$'PT^"'PZAU6#P-\*/!7A[P'X6&NZO>^(-
M>ET?PWIL&FVEWKNOZE)+J.N:Y>I!]LUC6+Z62\U/4I[F]N7::=S7J-% 'Y,_
M\%#/^"+'[$'_  4\^(7PZ^)W[5&C_%#4_%?PK\*W?@[P=/X%^)VM^"+*PTF]
MUN;7[B22QTZ*6&34GU&;<=13RKEH8;:%V=+6#R_B31O^#5G_ ()1:)K.DZY;
MZ7^TQ<7>CZKI^KVT5[^TCXYFM9KK3;R&^@6ZC01220M- @E5)8W9"P61&(<?
MT@T4 ?"O[='_  3B_93_ ."C/PS^'?P@_:G\&:SXP\ ?##XC:#\3_#&AZ)XL
MUSPJI\0>'])U70(+/5;G1KF"YU/0[[1-;U/3-2TV:4&:"Y\V">VNXH;F/[<T
MO3+#1=,T[1M*M8K+2])L;33--LH01#:6%A;QVMG:Q!BS"*WMXHXHPS,0J#))
MYJ]10!^>/_!0_P#X)@?LJ_\ !4#P3\.O '[56E^.]4\/?"WQ;?>-O"4?@3QU
MJO@>Z@U_4-*.CSW%[<::DHOHTLS_ *,DT>^UFW202)YDH?X!^%O_  ; _P#!
M'WX:^*K7Q;JOP)\9_&2[L(RNGZ3\<?BWXY^(/AJS<RQS>:F@3:CIVG7+>9$I
M:+4(KRVE!9)H)$.VOZ#** ,/PSX8\->"O#^C^$_!OA[0_"7A7P]86^E:!X9\
M,Z38:#X?T/3+1!':Z;H^C:5;VFG:986T8"6]G96T%O"@"QQJHQ7XS_$G_@W^
M_P"">WCGXW?$K]H#PA9_'_\ 9T^('QBDFN?B:/V6_P!H/XB? ;P[XRO[R]N=
M2U/4-8\/^!]0LK&2;5]1NY]0U.VA$.FW%]))>"PCN9IY9?VTHH _/3X._P#!
M+/\ 8G^"7[(/Q!_89\,?"B;7/V>/BYJ7B;7OBUX=\<^+/%/B[7OB9XF\8#1U
MU_Q3XP\6ZGJK:_>^(;R/P[X>C34K2\L7M?[#TV2U6&>!I9/C/P'_ ,&ZG_!-
M[P?XA^%&J>)=._:'^-WA?X(ZK;ZW\,?A#\?OVC_B9\5_@IX5U.P@,.ES6/PN
M\0ZHWA?[/I8\M[;2WM&TB;R8X-0L+VSWVS_NO10!\:_&K]@O]F_]H+]HC]EO
M]IWXI^%]6\0?$;]CF^\4ZM\"K!?$%_9^!?#VN>*K&SLIM?U'P7;E='UC6M#;
M3=-U#PO?W4?F:#J>FV-[9XEMHMOXY_\ !=WXJ?\ !&S4OB#\!O@9_P %6K3X
MZ> =1\&>'KGXZ_!']H?X:>%/BO'H_@Z^USQ'<>$]3\&V'Q%^$-AXC\0:5XHU
MJ\\%:=KM]HM[X9.G16VB^&]5CURQU)K&&;^E:N<\5>#_  CXZT>?P[XW\+>'
M/&/A^Y=)+G0O%6B:9XAT>X>,,(WGTS5[6\LI70.X1I(&*AV"D!CD _A%_9]_
M9W_8]_;A_P""A'[!?A7_ ()3?"KXI_$7]C;]FGXOW_[8?[<G[8'Q^\,_%2.[
M^,_Q.M8TM_@SX>F^*7QGT*Q^(_C3Q+X3BM?$MGHOAZVM=)\-W$'B"?5$CNDT
M2\UI?[&?C!^PG^SO\=OVH_V:/VPOB/X?UW5OC3^R3;>.K?X+:A;>)M3T[P]H
MLGQ#L(=-\07NK>';1X[/7;Q;6$+ISWQ:*SD=I?)ED2%HOK+1]%T?P[I=CH?A
M_2=-T+1=,@2UTW2-'L+73-+T^UCSLMK'3[**"TM($R=D,$,<:Y.%&:TJ /CO
M]KS]A3]GK]N2'X(6'[1&A:_XIT3X _&GPI\>_!GAJP\2:AHWAO5?'?@QY'T1
M/'&BVN;+QAX<3S9H[OP]JT<EC=Q3SQ2@QS2JWV)110!\0?MY?\$\/V7/^"D7
MPGT3X/?M2>#M4\1^'_"GC+2_'_@S7?"_B/4_!WC7P7XMTN.>U35O#/BC2'2]
MT][S3[J[TW4;9UGM+RUG#O +VTT^[M/CGPC_ ,$!_P#@G'X/T.RL;;P-\2]?
M\5K\<OAC^T!XB^+GC/XM^+_%_P 9O'GC+X.WYU/X=Z)XY^).O7-[XAUWP!X?
MOE@NH_!/GVNC7=U9:;>WL5Q?:;87-O\ M+10!\@_'']ASX!?M$_M!_LP?M,?
M%+2?$6L_$G]D/6O%WB+X,PP>)+VT\(V&N>,]*ATC4]5\0>%%633/$%_9V]O!
M-HEW>*MQI%Y$MS:2)(#FK^V[^P?^SS_P4*^&'A+X.?M,:+XC\1?#[P=\5?"/
MQAT_1/#OBC4?"OV_Q;X*MM9L]&BUFZTLK<W^B-;:_J45[I9DB2Y\V.02Q300
MR)]D44 ?*'[:?[$W[.?_  4"^ WB#]G#]J#P,OCGX::]J&F:Y%#;WUQH^O\
MAOQ+HK3G2/%/A/7[(K?:#X@T^*ZO;2*_M6/G:=J&I:9>17.G:A>6LWYF1?\
M!M__ ,$OI_A]\0/ GB?P-\7_ (A:A\1M"\)>#M2^*/Q'^-_CGQO\8/#WP_\
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MX&O+&76;^VL+.WTU-3D\K4+C3HH+&_N;RUL[**V_6NB@#X&_8:_X)F?L=_\
M!.[1_%EI^S1\-)=(\5?$*^GU'XC?%;QIKVJ^/_B_\0;F;4+C4POBWXA^)9[S
M7=0LX;NX>:+3(9K33//5+R6SEO\ ?=/V7P1_80_9W_9^_:2_:>_:S^'V@:__
M ,+P_:YOO"5W\7_%/B+Q-J7B%)+;P7:75IHFB^%+'4&>'PMH*K=":ZTK3B+>
MYFM-.+!8]/M(HOL>B@#XWOOV#_V>-3_;DT;_ (*(7VA:_<?M,>'_ ('/^SUH
MVNOXDOQX8L/AU+KFLZ_-##X44#3SK<UYKVIPOK$C/.+*X-LB(,LWV1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?SS_\%IO^
M2K_LQ?\ 7OJG_J5:#7]#%?ST?\%IU8?%3]F*0J1'Y&JKYA!";E\4:"Q7=]W(
M7YB,Y"\GCFOZ%@0P#*0RL 58$$$$9!!'!!'((X(K]-XN_P"2#\,?^P;BC_U:
M84^=RO\ Y'?$?_7S+?\ U&J"T445^9'T04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_$.+Q;/X \
M<P> 9H+?QW-X/\31>"I[DVZVT'BV31;U/#DUPUVDEJL$6L&S>4W,<EN(U8S(
MT>Y3V%%72G[*I3J\L)^SG"?)4CSTY\DE+EJ0TYH2M:<;KFBVNHI+FC*-W'F3
M5XNTE=6O%]&MT^CU/Y>O'/[-W_!2C]M#XA_#_2_C_P""+C1+3PO ='?Q=KEG
MX5\->%M+TJXO[:77]5DMO#-S-+JVIWB1 VT5K8;YXXEAMDMXS(&_37_@I3\(
M/C_XN_9T^'GPA_9S\/:KXD\-6VJ:9HOCO1-%U&VL]<O_  QX>T:&W\-64PN;
MNPAOM$-Y:^=K5N9=LES;:67ADB,BU^J%%?H6*\2,QQ.8\/8R&3Y%A,)PS5KU
M\MR?"82K2RU5\2^:I5G26(<^>-11JT?9SIJE5C[2*<I2<O!I</8>G0Q]*6+Q
MM:KF,:<,1BJM6,L0X4](P4_9I--7C/FC)S@^5NR5OY<O@+X#_P""I?[-.C:I
MH/P@^"5_X?L-<OUU+6);OP?\-=7U74[F-/*@6\UG4+R?4YK:TC+K9VC7/V>U
M\V4PQJTLA;]8OV=- _:G_:,^!7QT^&_[</AB#PROB^$^%_"SII.B:7J3:7J.
MD7'V[49=/\/WQM)X])U8:;>::TTL$EU-'<P3LT*#;^E=%3GWB%7SU5*TN'.'
M,OS2IB<-BUG>!P=:&;4Z^%JTJM.<,54Q%1\S=*,).<9_N[P5K)IX'(88)QBL
MPS"OAHTZE)X.M5C+"RA5@XR3I1A%)+FE)*+7O.[OK?\ FT^%/PQ_X*;?L)ZC
M\0?AW\(?A=9?%+PIXGN5O+37;6VL_$/AQ+V%)[*T\4:%;S^(- O-'UJZLTB;
M4])U6VNK%GCM3=VMPZ)*?LK_ ()P_L2_%/X3>,_''[27[0\T</Q7^(%MJ=MI
M_A[[7!J&HZ;;>)M2M_$'B77O$=[92&P37=<U".WA_LJU64:3#;3J]SYEW);Q
M?L#13S?Q)S7-L#F.%_LS)<OQ6=4\/2SO-,!A*E+'YG2PT8QA3K3G7J4Z<)\J
M]JJ-.'/%N%XP;BUA.'L-A:V'J?6<97IX.526#PU>K&='#2J;R@HTXRDU=\KG
M)V=GNKGXJ_MF^)O^"D'C'Q%\:O@UX ^!NB^)/@5XKTV[\*:+XATZPL9=8U#P
MSK6BV\-_=#4+SQ5;^1JJW$]]#\^FK% 8XRL+=3\U?L@>'O\ @I7^S!;V/PZ\
M)?L\01^!/%/Q*TCQ#XNOO%%GIE[>V5IJ+:!H6O7-O>67BRT\B"UT+3!<Q+]E
MN)([F-Y ) _E'^C^BKPOB&\+DCR"/"G#%3 U(4'B5/#X[FQ>*P]*%*&.Q"CC
ME"6*?(JCFHQCSMM12LDJF0^UQBQKS3,HUHNHJ?+4HVI4ZDW)T87HMJFK\J3;
M]W=MZA1117YP?0!1110!\"?\%+?A7\0OC'^RKXB\%_#'PO?>,?%<WB[P/J<&
MA:;):1WMQ9:9KT%Q?RP?;;BU@<VT&9G0S*QC5RH8C:>K_P""?'PU\<?"+]DG
MX5> OB-H,_ACQAI"^++C5="NIK:>ZT]=8\:^(=8L8[E[.:>W$[Z??VLLL<<T
MGE-(8V;>K ?:%%?0RXCQ<N%Z?"KHX;ZE3SF6=K$)5?K3Q$L(\)[)R]I['V"A
M)SM[+VG/]OET.!9?2692S/GJ>VEA/J;IWC[+D]JJO/;EY^>Z2^/EM]F^I6O(
MWFL[J*,9DEMIXT!. 7>)E4$G@9) R>E?B3_P2>_9G^.WP'^(?QTU+XN_#K5O
M!&GZWH'AK2=$O=1N=,G@UB[T_7]?N;LZ>;"]NWDMX[>>"43RI"KK-'M!)(7]
MOZ*,LXCQ>5Y+Q!D=&CAJF&XBAE\,75JJJZ]%9=B)XBB\.X5(4TYRJ2C4]K3J
M)QMRJ+U'B<!2Q.+P.,G.I&I@'7E2A%QY)O$0C"7M+Q<GRJ*<>64==[K0_#']
MHS]F#X]^*_\ @IW\+OC1X<^'&JZQ\+;/6_@_?:CXSM+O2_[-TNV\+K-#K;:C
M%->Q7T#V;#<$2UF::-D>+=NP%_;J_93_ &CM*_:T\%_MB?L]>$(?BG=V,_A*
M[O/"1:TEO=&\1>$=/?2+1IM*O+[3AJ/AW4]*C25[JROHKW3]4$K,D>ZSF?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"EC,'B&X0K*EI2JTZB:4*L8^[:34;:W=W%_5/_#6_P"RS_T<9\$?_#G^#?\
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M&?!'_P .?X-_^7%'_#6_[+/_ $<9\$?_  Y_@W_Y<5^:W_#D#X&?]%D^+O\
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M_EQ1_P -;_LL_P#1QGP1_P##G^#?_EQ7YK?\.0/@9_T63XN_^ W@/_YEJ/\
MAR!\#/\ HLGQ=_\  ;P'_P#,M1_8_A3_ -%AG_\ X9)>7_3KS?W>8?6^)O\
MH58'_P +%_\ )^O]+7]*?^&M_P!EG_HXSX(_^'/\&_\ RXH_X:W_ &6?^CC/
M@C_X<_P;_P#+BOS6_P"'('P,_P"BR?%W_P !O ?_ ,RU'_#D#X&?]%D^+O\
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M\*?^BPS_ /\ #)+R_P"G7F_N\P^M\3?]"K _^%B_^3]?Z6OZ4_\ #6_[+/\
MT<9\$?\ PY_@W_Y<4?\ #6_[+/\ T<9\$?\ PY_@W_Y<5^:W_#D#X&?]%D^+
MO_@-X#_^9:C_ (<@? S_ *+)\7?_  &\!_\ S+4?V/X4_P#189__ .&27E_T
MZ\W]WF'UOB;_ *%6!_\ "Q?_ "?K_2U_2G_AK?\ 99_Z.,^"/_AS_!O_ ,N*
M/^&M_P!EG_HXSX(_^'/\&_\ RXK\UO\ AR!\#/\ HLGQ=_\  ;P'_P#,M1_P
MY ^!G_19/B[_ . W@/\ ^9:C^Q_"G_HL,_\ _#)+R_Z=>;^[S#ZWQ-_T*L#_
M .%B_P#D_7^EK^E/_#6_[+/_ $<9\$?_  Y_@W_Y<4?\-;_LL_\ 1QGP1_\
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M\-;_ ++/_1QGP1_\.?X-_P#EQ7YK?\.0/@9_T63XN_\ @-X#_P#F6H_X<@?
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MM_PY ^!G_19/B[_X#> __F6H_P"'('P,_P"BR?%W_P !O ?_ ,RU']C^%/\
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M_P#\,DO+_IUYO[O,/K?$W_0JP/\ X6+_ .3]?Z6OZ4_\-;_LL_\ 1QGP1_\
M#G^#?_EQ1_PUO^RS_P!'&?!'_P .?X-_^7%?FM_PY ^!G_19/B[_ . W@/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHFI16-B\,%IJ&EVE[:)!<1^80#^M&BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\,UNQTU_VB/ >HR:1X%EU6W^&/CB
MVMM;O?$EW;_$2SLY]<\,O<6&@^%4<66I^&+N2.*77-8F1KC3;ZWTRWB94O)
M?<Z\-UN^TY/VA_ >GR:MX%BU2?X9>.+FVT6^\.W=Q\1+RT@UOPTEQ?Z!XH1#
M9:;X8M))88M<TF:19]1OKC3+B)62T<@ ]RHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 445Y[KGQ;^%WAGQ]X/^%7B+XB>"]#^)GQ!M-6O_ O@#5O$ND6'C#Q
MA9:% ]SK5UX;\/75W%JFLP:7;Q2SWTMA;3K;112R2E4BD*@'H5%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?V=?&'PZ^&OB?Q]\0O'?Q6^)W@'PY\4?#_PG^"WP;^)/Q>^)%GX!\7>'=/\
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MXBZ1HFH^(=,L!+$^H/IB3W%I;O\ ;9;<6*2W,?\ .'\1OB;^V1XQ_P"#H?\
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MW_!0W_@H5^SY_P $U?V=?$7[0?Q]UMS'$9-%^''PXT66";Q[\8?B#<P.VB>
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M%Q!+)^&OP$_X*J_M-?M6>)OB)H?_  2#_P""6OP_\;_LF_#[Q5XT\$ZO\?\
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M7B[6_C%\3;2]U7PC\&?@U\.?&'QG^*]YX?T^&ZFN?$UWX%^'^EZSKFF>'O\
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M _B2VL=<T^PU*;3[U-/U'[/+8W$MM/;>>EY!/;Q_B+_P:9Z5IWCG]D+]K?\
M:@\8P/XB_:%^-W[>?QM_X6U\2O$'VR_\;:ZVC:#X#UG3-)UC6M1FGEN8[#4?
M&7B/5 ;3R(FN=?NHK@2RVRF/B_B-X4\,_ 7_ (.UOV=-2^"5GH-AJ'[3_P"Q
M=XS/[1GA7P[HEOID5FFC:9XN.D^.==&ER0Q7>L^()? 7@ZU;5;^U5V32(D=[
MB>X:6@#]>OB]_P %OO\ @G3\#/&7[0?PV^(_Q?UK2?B7^SA\1? WPG\6_#:R
M\ >+=:\>^,_B!\0]-_M?P[X=^$'A32--O-9^*5V--#7>KOX4M;V#0X?*DU62
MU2ZLVN.?^%O_  7K_P""7_Q2^$_Q_P#B_'^T'_PKK1OV8[[3=.^,/A/XQ>#O
M%/PP^)V@WNNRM9>'K73?AOXHTVS\6>);O7]:CG\.:;8>'].U&_\ ^$@MWTR\
MM;2:2V,_Y2?\$O/@[\+O''_!QM_P7'^*7C'P+X>\3?$'X-Z[\#!\*_%&M6,>
MH:AX"E\?^$+ZP\87WAG[3YD&F:KKFG^'M)T^XU>"%=3BT^"XL;:ZAM;^_BN<
MCQO^S)\#?&?_  =S>']3\:?#CPSXLW_L(V/QZM-/US3(+O2;+XN>$=0C\&:!
MXY.EN#87^NZ9I-O%/8W6HVUS]CU>*UUNW5-7LK2]A /VA_8^_P""TG[!O[;G
MQRU3]FKX1>-?B%X<^.VG>&3XPM_AA\9?A'X^^#WBK7O#T5J]_>:AX>T_QOH^
MF/JHL--5-4NX8BMP-+E348(I[19IHNN_;+_X*X?L2_L*_$SP=\$?C7XY\8ZO
M\</'>E6_B'P[\&/A!\,/'7Q@^)USX9O)-6M[/Q-/X4\"Z+JM];:)>7FAZK96
MMW)A[BZL;B.*%EBD=?QX_P""O.B:1X6_X+Z_\&_7C_PWIMIH7C?QQXN_:!\$
M>,O%6E1+8ZWXI\(:#:>!!HOAO7KZWV3:GH^ECQKXL%E9W;2Q0KX@U)5 6?"_
M:/[;_P#P4XG^"G[;%C^QY^PW^PZ_[:?_  4)U[X:^%/&_C^[MM7\(_#7P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"6'[>/P@_;F^+G_  4=_P""0GQP^"7P]^*O[2/A+PSX6_:.^ /[17AB_O\
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M3O&6NZ5>:WI.@RP>)="UU[N]TO3[JRO+N-X-(EMD2"YC9)9XY3O2-HW^XZ*
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MK+J=G#'<:K?+#NLK"![>SBU#4]>OM2_;FB@#\C?V-?\ @FSXN_9?_P""BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5! - '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7C.L:G/%\>?!.DKKNNP6UU\.O&5Y)X=@\#)>^'+^6VUCP]''J=
M_P#$,PL^@ZI8K,T%CX9$Z+KD%S<WIC<Z8"OLU>/:O'JI^.?@R6*R^*3Z,OP^
M\7I=ZAIFLZ1#\'H+YM7\/FUMO%>@S3#6[WQO/$)W\+ZC9P/86>F1:W#=R)+<
MVZL >PT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]
M3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ
M#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR
M?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z
M*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:
M,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@"
M>BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/Y
MFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H
M GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3
M^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F
M: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?
M4_F:,GU/YF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/
MYF@">BH,GU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,
MGU/YFC)]3^9H GHJ#)]3^9HR?4_F: )Z*@R?4_F:,GU/YF@">BH,GU/YFC)]
M3^9H GK)ET+2)]:L_$<MC"^MV%A=Z79ZB=_GV]A?2P3W=JF'$?ESRVL#ON0M
MF)=K 9!OY/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%0
M9/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3
MZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/1
M4&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1
MD^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3
MT5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,
MT9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S-
M$]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?
MS-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S
M0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3Z
MG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_
M,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D
M^I_,T9/J?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J
M?S- $]%09/J?S-&3ZG\S0!/14&3ZG\S1D^I_,T 3T5!D^I_,T9/J?S- $]%0
69/J?S-&3ZG\S0!/14&3ZG\S10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img58233625_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_5.jpg
M_]C_X  02D9)1@ ! 0$ \ #P  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *S!A@# 2(  A$! Q$!_\0
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ML/X=_P#/?4__   >C_AL/X=_\]]3_P# !Z^&J*/[#PGG]_\ P ^N5?(^Y?\
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M?4__   >C_AL/X=_\]]3_P# !Z^&J*/[#PGG]_\ P ^N5?(^Y?\ AL/X=_\
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M / !Z/\ AL/X=_\ /?4__ !Z^&J*/[#PGG]__ #ZY5\C[E_X;#^'?_/?4_\
MP >C_AL/X=_\]]3_ / !Z^&J*/[#PGG]_P#P ^N5?(^Y?^&P_AW_ ,]]3_\
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ML/X=_P#/?4__   >OAJBC^P\)Y_?_P  /KE7R/N7_AL/X=_\]]3_ / !Z/\
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M?4__   >OAJBC^P\)Y_?_P  /KE7R/N7_AL/X=_\]]3_ / !Z/\ AL/X=_\
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M >OAJBC^P\)Y_?\ \ /KE7R/N7_AL/X=_P#/?4__   >C_AL/X=_\]]3_P#
M!Z^&J*/[#PGG]_\ P ^N5?(^Y?\ AL/X=_\ /?4__ !Z/^&P_AW_ ,]]3_\
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M?_P ^N5?(^Y?^&P_AW_SWU/_ , 'H_X;#^'?_/?4_P#P >OAJBC^P\)Y_?\
M\ /KE7R/N7_AL/X=_P#/?4__   >C_AL/X=_\]]3_P# !Z^&J*/[#PGG]_\
MP ^N5?(^Y?\ AL/X=_\ /?4__ !Z/^&P_AW_ ,]]3_\  !Z^&J*/[#PGG]__
M   ^N5?(^Y?^&P_AW_SWU/\ \ 'H_P"&P_AW_P ]]3_\ 'KX:HH_L/">?W_\
M /KE7R/N7_AL/X=_\]]3_P# !Z/^&P_AW_SWU/\ \ 'KX:HH_L/">?W_ / #
MZY5\C[E_X;#^'?\ SWU/_P  'H_X;#^'?_/?4_\ P >OAJBC^P\)Y_?_ , /
MKE7R/N7_ (;#^'?_ #WU/_P >C_AL/X=_P#/?4__   >OAJBC^P\)Y_?_P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"X^SF&47&<>3L._/IMQG-2W6FWMC'ONK*ZM8\XWSP.BY],D"E=#*U%=5\+_
M<GQ.\;67AR*]33Y+E))/M#Q[PH12Q^7(ST]:D^+'P]?X5^-9_#TM^FHO'#'.
M)UC\O(<'C;DXQ@]ZR]M3]K[&_O6O;R*Y9<O/T.1HJ6WM9[R0QVT$MS)C.R&,
MNV/7 %%S:SV4@CN;>:VD(R$FC9&QZX(K6ZV)(J**]2^"?P*G^,\>KR1:S%I*
M:>T:'= 92Y<$_P!X8 Q^M95JT*$'4J.R148N;Y8[GEM%6M8T]M'UB_TZ21))
M+.>2W=TZ$HQ4D>W%%OI5]>1"6WL+NXB/22&W=U_,#%:<RM<DJT4K*59E8%74
MX96&"#Z$4B_O'")\[DX"KR2?3%4(**DN;6>RDV7,$MM)C.R:,HV/7!%27&G7
MEG")KBSN;>$G DFA=%/XD8I70RO12*P;H<U:M]+OKR+S;>QNKB+_ )Z0P.Z_
MF!BAM+<"M12.?+W;N"N00>",=J];\5?L^W'A;X1V?CI]<AN(KB*WF-D+<J5$
MQ4 ;]W)&X=O6LJE:G2<5-V<G9>I482E=KH>2T4*=V /F+' QSD^E6+K3;RQ4
M/<V5U;(QP&G@= ?Q(K6Y)7HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^K?V&?^/7QG_UT
MM/\ T&6BC]AG_CU\9_\ 72T_]!EHK\VS;_?:GR_)'T.%_@Q_KJ87[;W_ ".7
MAG_KPE_]&"OF^OI#]M[_ )'+PS_UX2_^C!7S?7VN5_[G3]/U9X^)_C2"BBBO
M4.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"&07 4MCW&,^N*]T^-7CS0/@I':>(DT2"^\1WBFRM%4"/]V#N?+ <#D=!DG
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MN6AA6-VFA9#N4;P1N5L<=>"*\1NKO]H*]\+ZO?:E=W6FZ7;VLDEP;R."&1D
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M^;/(Q/\ &D%%%%>L<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^'+1)#*D^I-,EP6! )WC"@'YN2#P/>O(?BQ\;+Q?C-JOB#P3JC64'E16GVJ
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M3J24IQ3:\C%2E%63-G7_ !IKWBK4+:^UC5[K4KRU $$]P^6C ;<,'''/-/\
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M_?J6C_AB/Q/_ -#)I/\ WZEK['HH_MK&?S+[D'U.EV/CC_AB/Q/_ -#)I/\
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M3_WZEK['HH_MK&?S+[D'U.EV/CC_ (8C\3_]#)I/_?J6C_AB/Q/_ -#)I/\
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M_?J6C_AB/Q/_ -#)I/\ WZEK['HH_MK&?S+[D'U.EV/CC_AB/Q/_ -#)I/\
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M3_WZEK['HH_MK&?S+[D'U.EV/CC_ (8C\3_]#)I/_?J6C_AB/Q/_ -#)I/\
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M_?J6C_AB/Q/_ -#)I/\ WZEK['HH_MK&?S+[D'U.EV/CC_AB/Q/_ -#)I/\
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M3_WZEK['HH_MK&?S+[D'U.EV/CC_ (8C\3_]#)I/_?J6C_AB/Q/_ -#)I/\
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M1?\ QVC_ (;H^'G_ #Z:Y_X#1?\ QVO<?^$.T#_H!Z;_ . D?^%'_"':!_T
M]-_\!(_\*.?#_P C^_\ X >QS'_G]'_P'_@GAW_#='P\_P"?37/_  &B_P#C
MM'_#='P\_P"?37/_  &B_P#CM>X_\(=H'_0#TW_P$C_PH_X0[0/^@'IO_@)'
M_A1SX?\ D?W_ / #V.8_\_H_^ _\$\._X;H^'G_/IKG_ (#1?_':/^&Z/AY_
MSZ:Y_P" T7_QVO<?^$.T#_H!Z;_X"1_X4?\ "':!_P! /3?_  $C_P *.?#_
M ,C^_P#X >QS'_G]'_P'_@GAW_#='P\_Y]-<_P# :+_X[1_PW1\//^?37/\
MP&B_^.U[C_PAV@?] /3?_ 2/_"C_ (0[0/\ H!Z;_P" D?\ A1SX?^1_?_P
M]CF/_/Z/_@/_  3P[_ANCX>?\^FN?^ T7_QVC_ANCX>?\^FN?^ T7_QVO<?^
M$.T#_H!Z;_X"1_X4?\(=H'_0#TW_ ,!(_P#"CGP_\C^__@![',?^?T?_  '_
M ()X=_PW1\//^?37/_ :+_X[1_PW1\//^?37/_ :+_X[7N/_  AV@?\ 0#TW
M_P !(_\ "C_A#M _Z >F_P#@)'_A1SX?^1_?_P  /8YC_P _H_\ @/\ P3P[
M_ANCX>?\^FN?^ T7_P =H_X;H^'G_/IKG_@-%_\ ':]Q_P"$.T#_ * >F_\
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M@?\ 0#TW_P !(_\ "C_A#M _Z >F_P#@)'_A1SX?^1_?_P  /8YC_P _H_\
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M (#1?_':/^&Z/AY_SZ:Y_P" T7_QVO<?^$.T#_H!Z;_X"1_X4?\ "':!_P!
M/3?_  $C_P *.?#_ ,C^_P#X >QS'_G]'_P'_@GAW_#='P\_Y]-<_P# :+_X
M[1_PW1\//^?37/\ P&B_^.U[C_PAV@?] /3?_ 2/_"C_ (0[0/\ H!Z;_P"
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MT?\ P'_@GAW_  W1\//^?37/_ :+_P".T?\ #='P\_Y]-<_\!HO_ ([7N/\
MPAV@?] /3?\ P$C_ ,*/^$.T#_H!Z;_X"1_X4<^'_D?W_P# #V.8_P#/Z/\
MX#_P3P[_ (;H^'G_ #Z:Y_X#1?\ QVC_ (;H^'G_ #Z:Y_X#1?\ QVO<?^$.
MT#_H!Z;_ . D?^%'_"':!_T ]-_\!(_\*.?#_P C^_\ X >QS'_G]'_P'_@G
MAW_#='P\_P"?37/_  &B_P#CM'_#='P\_P"?37/_  &B_P#CM>X_\(=H'_0#
MTW_P$C_PH_X0[0/^@'IO_@)'_A1SX?\ D?W_ / #V.8_\_H_^ _\$\._X;H^
M'G_/IKG_ (#1?_':/^&Z/AY_SZ:Y_P" T7_QVO<?^$.T#_H!Z;_X"1_X4?\
M"':!_P! /3?_  $C_P *.?#_ ,C^_P#X >QS'_G]'_P'_@GAW_#='P\_Y]-<
M_P# :+_X[1_PW1\//^?37/\ P&B_^.U[C_PAV@?] /3?_ 2/_"C_ (0[0/\
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M%_\ ':]Q_P"$.T#_ * >F_\ @)'_ (4?\(=H'_0#TW_P$C_PHY\/_(_O_P"
M'L<Q_P"?T?\ P'_@GAW_  W1\//^?37/_ :+_P".T?\ #='P\_Y]-<_\!HO_
M ([7N/\ PAV@?] /3?\ P$C_ ,*/^$.T#_H!Z;_X"1_X4<^'_D?W_P# #V.8
M_P#/Z/\ X#_P3P[_ (;H^'G_ #Z:Y_X#1?\ QVC_ (;H^'G_ #Z:Y_X#1?\
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MY_X#1?\ QVO<?^$.T#_H!Z;_ . D?^%'_"':!_T ]-_\!(_\*.?#_P C^_\
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M$C_PHY\/_(_O_P" 'L<Q_P"?T?\ P'_@GAW_  W1\//^?37/_ :+_P".T?\
M#='P\_Y]-<_\!HO_ ([7N/\ PAV@?] /3?\ P$C_ ,*/^$.T#_H!Z;_X"1_X
M4<^'_D?W_P# #V.8_P#/Z/\ X#_P3P[_ (;H^'G_ #Z:Y_X#1?\ QVC_ (;H
M^'G_ #Z:Y_X#1?\ QVO<?^$.T#_H!Z;_ . D?^%'_"':!_T ]-_\!(_\*.?#
M_P C^_\ X >QS'_G]'_P'_@GAW_#='P\_P"?37/_  &B_P#CM'_#='P\_P"?
M37/_  &B_P#CM>X_\(=H'_0#TW_P$C_PH_X0[0/^@'IO_@)'_A1SX?\ D?W_
M / #V.8_\_H_^ _\$\._X;H^'G_/IKG_ (#1?_':/^&Z/AY_SZ:Y_P" T7_Q
MVO<?^$.T#_H!Z;_X"1_X4?\ "':!_P! /3?_  $C_P *.?#_ ,C^_P#X >QS
M'_G]'_P'_@GAW_#='P\_Y]-<_P# :+_X[1_PW1\//^?37/\ P&B_^.U[C_PA
MV@?] /3?_ 2/_"C_ (0[0/\ H!Z;_P" D?\ A1SX?^1_?_P ]CF/_/Z/_@/_
M  3P[_ANCX>?\^FN?^ T7_QVC_ANCX>?\^FN?^ T7_QVO<?^$.T#_H!Z;_X"
M1_X4?\(=H'_0#TW_ ,!(_P#"CGP_\C^__@![',?^?T?_  '_ ()X=_PW1\//
M^?37/_ :+_X[1_PW1\//^?37/_ :+_X[7N/_  AV@?\ 0#TW_P !(_\ "C_A
M#M _Z >F_P#@)'_A1SX?^1_?_P  /8YC_P _H_\ @/\ P3P[_ANCX>?\^FN?
M^ T7_P =H_X;H^'G_/IKG_@-%_\ ':]Q_P"$.T#_ * >F_\ @)'_ (4?\(=H
M'_0#TW_P$C_PHY\/_(_O_P" 'L<Q_P"?T?\ P'_@GAW_  W1\//^?37/_ :+
M_P".T?\ #='P\_Y]-<_\!HO_ ([7N/\ PAV@?] /3?\ P$C_ ,*/^$.T#_H!
MZ;_X"1_X4<^'_D?W_P# #V.8_P#/Z/\ X#_P3P[_ (;H^'G_ #Z:Y_X#1?\
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M  '_ ()X=_PW1\//^?37/_ :+_X[1_PW1\//^?37/_ :+_X[7N/_  AV@?\
M0#TW_P !(_\ "C_A#M _Z >F_P#@)'_A1SX?^1_?_P  /8YC_P _H_\ @/\
MP3P[_ANCX>?\^FN?^ T7_P =H_X;H^'G_/IKG_@-%_\ ':]Q_P"$.T#_ * >
MF_\ @)'_ (4?\(=H'_0#TW_P$C_PHY\/_(_O_P" 'L<Q_P"?T?\ P'_@GAW_
M  W1\//^?37/_ :+_P".T?\ #='P\_Y]-<_\!HO_ ([7N/\ PAV@?] /3?\
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MW1\//^?37/\ P&B_^.U[C_PAV@?] /3?_ 2/_"C_ (0[0/\ H!Z;_P" D?\
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M.T#_ * >F_\ @)'_ (4?\(=H'_0#TW_P$C_PHY\/_(_O_P" 'L<Q_P"?T?\
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M_P! /3?_  $C_P *.?#_ ,C^_P#X >QS'_G]'_P'_@GAW_#='P\_Y]-<_P#
M:+_X[1_PW1\//^?37/\ P&B_^.U[C_PAV@?] /3?_ 2/_"C_ (0[0/\ H!Z;
M_P" D?\ A1SX?^1_?_P ]CF/_/Z/_@/_  3P[_ANCX>?\^FN?^ T7_QVC_AN
MCX>?\^FN?^ T7_QVO<?^$.T#_H!Z;_X"1_X4?\(=H'_0#TW_ ,!(_P#"CGP_
M\C^__@![',?^?T?_  '_ ()X=_PW1\//^?37/_ :+_X[1_PW1\//^?37/_ :
M+_X[7N/_  AV@?\ 0#TW_P !(_\ "C_A#M _Z >F_P#@)'_A1SX?^1_?_P
M/8YC_P _H_\ @/\ P3P[_ANCX>?\^FN?^ T7_P =H_X;H^'G_/IKG_@-%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+_P"T'_R<Y\(?
M^NT?_I0*^H*^7_V@_P#DYSX0_P#7:/\ ]*!79A?XGR?Y'BYM_NZ_Q1_]*1]0
M4445QGM!1110 4444 %%%% !7R]\#_\ D[;XJ?\ 7.3_ -'15]0U\O? _P#Y
M.V^*G_7.3_T=%790^"IZ?JCQ<?\ Q\-_B_1GU#1117&>T%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHKYK\:?M^_#'P?XH?14.IZYY) FO=+A1X$) ) +."V,\[0>>*]NM?B1X;N_
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MAF8Z9J"LT0N(]D@VNR,",GD,IKJ*YI1<).,E9HT335T%%%%2,**** "BBB@
MHHHH **** "BBB@ HHI&8*"2< =S0 M%8U]XMTO3R5>Y$CC^&(;JRW^)&GJV
M!#.5_O8'^-9NI!;L[(8/$5%>,&=;17+0_$;29,[_ #HO]Y,_R-:VG^)--U+
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M,]H**** "BBB@ HHHH **** "BBD9@O4@?6@!:*9YR?WU_.G9STYH 6BBB@
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M2<I>[=O9F7^U7\0[CXK?L:^ O%5W EM>:AJ4+SQQYV"18YU8KGL2I(^M<_\
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M=3QDXJJ]6E"E5C[52<I)K?:XH1DY1?+:RL?.O[#?_)#_ (V_]>/_ +:S5O\
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M/5I8R,M)G3T5%;W$=U&'B8,IJ6N<]%.^J"BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%)G'7BF^:G]]?SH ?12!@W(.12T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2A&.<#:W!_G7T(_B#3(\AM0M@>F/-7_&O>PE3FIV;V/R7B#!.EB^>G'22O\
M/J:%%58=4L[C'EW4,A]%D!JU7<?*N+CHT%%%%,D**** "BBB@ HHHH ****
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M'ZC=;B:\K$55-Z'WV38"6%C:3NV9-RVYC5:I)6W&HZ\P^XBK(****"@HHHH
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M7AU]K;22,\DC2.>K,V363/K?^U7K4\N7VF?.U<ZDG[B2/?6^+&AJK'_2,@<
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MXE30[79&0UW(/D7^Z/[QJ9245=FM*E.M-4X*[92\9>*AIL+6EL_^DL/G8?\
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M_1I&J_\ @W;_ .,T?\-H_M.?]&D:K_X-V_\ C- 'W3'(DRAXV5U/1E.13J_
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MNH?N\;JQ+RZ+L>:C:Y)'6JTCEJ<86)J5')#&;-)116YSA1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<^$_#.H-?Z1X7T72KYOO7-CI\,,I_P"!*H-=#13NR'",FFUJ@HHHI%A1110
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MY.\G=GUL(1IQ48*R04445)84444 %%%% !1110 4444 %%%% !1110 4444
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M):L]/^"/AC[#IDVL3+B6Z^2'/:,'D_B?Y5Z?45K:Q6-K%;P((X8E"(J]  ,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD_R/%S;_ '=?XH_^E(^H****XSV@HHHH **** "BBB@ KY>^!_\ R=M\5/\
MKG)_Z.BKZAKY>^!__)VWQ4_ZYR?^CHJ[*'P5/3]4>+C_ ./AO\7Z,^H:***X
MSV@HHHH **** "BBB@ I",\$9%+10!2N-%L+HYEM(F/KM -4I/"&EN<_9RO^
MZY_QK:HJU.2V9C*C2E\45]QA#P7I@/\ JY#_ ,#-31>%=+BZ6JM_OL3_ %K7
MHI^TGW)6'HK:"^X@M[&WM?\ 4P1Q?[J@5/114;FZ2BK(****0PHHHH ****
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M@#ZQHKS7X,_M(?#;]H&QFN? 7BVQU]H$5Y[6,F.X@!Z%XG =1GC.,9[UZ50
M4444 %%%% !117GOQN^/'A#]GGPG;^)O&]W<Z?HDMW'9&[M[22X6.1P2I<1@
ME5^4_,>,X'<4 >A45!9WUOJ%E!>6TR3VLT:RQS(V5=&&0P/H0<UP/P=^/W@O
MX]P>(+GP3J,NKV6B:@VF75Y]EDC@:=1EA&[*!( "#E<C##U% 'HM%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 A 8$$9%9=[X6T?4,_:-,M9?<Q '\ZU:*32>Z-(
M5)TW>#:]#E9OA?X9FSG3%3_<D<?UJ%?A/X87&=/9OK,_^-=A16?L:?\ *CL6
M88Q*RK2_\"9SEO\ #OPW:X*:1;DCO("_\S6Y:V-M8ILMK>*!?2- H_2IZ*J,
M8QV1SU,16K?Q)M^K;"BBBK.<**** "BBB@ HHHH **** "OE_P#:#_Y.<^$/
M_7:/_P!*!7U!7R_^T'_R<Y\(?^NT?_I0*[,+_$^3_(\7-O\ =U_BC_Z4CZ@H
MHHKC/:"BBB@ HHHH **** "OE[X'_P#)VWQ4_P"N<G_HZ*OJ&OE[X'_\G;?%
M3_KG)_Z.BKLH?!4]/U1XN/\ X^&_Q?HSZAHHHKC/:"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR[]J;_DV7XM?]BGJO_I)
M+7J->7?M3?\ )LOQ:_[%/5?_ $DEH \P_P""<VF6>H?L/?#&*ZM(+F*2RN5=
M)HU=6'VR?@@CFO$?%'A6R_9'_P""CWPZE\#Q1:)X2^*EO+9:OH=LNVW%PI($
MB1CA/G:)ACH6DZ U[/\ \$Z?$.E:7^Q%\,3>ZG9V@CL[DOY]PB;?],GZY/%>
M,>(?%&G_ +7W_!1[X>CP3=1ZQX0^%=I)?ZIKEHP>V>Y8DK'&XX;YQ$O!.=LA
M'W: /2?VCOVW/%OP7_::TWX5>'O L/C6XUKP['>:19V\C174^HR3RQJCR$[$
M@5(F=B5R,'D"M[Q-\?OC3\*OV5_B!\0/B+X(\.:)XR\/LLEA8V5VUS974#&$
M;VVR%E(,CJ1N'*9Z&N(\4JK?\%=/!Q*@E?AU(02.A\ZY&1^!/YUZI_P4-LY[
M[]B_XJ1V\332+IBR%4&3M6:-F/T"@D^PH ]7\!^-KOQ7\'O#WBZY@AAO]1T*
MWU22"+/E+)) LA5<G.T$XY.<5XO^S=^UY+\1_P!DW5/C-X\L['18M+.H27<.
ME!]GE6Q( 0.Q)=L8 SR2.E7_ (8_'#P%H/[%OA'Q7J/BO3;/0(/"UO;27<TZ
M@"9+=8WB"]3('!78!G/&*^4_V<]2TRS_ ."0OC^YU2RN-1T]XM80V]MD2%GE
MVQMG!P%=E8GL%)H [_Q!^UY^T_=?!FZ^,?A_X3>#[7X?_9CJ5M::EJ$T^J&Q
MZBX94=%(V_-@<XYP17TO^RE\2/&_Q>^#NE^,/'%KX;M;C6 MYIX\,S320FT>
M-"OF>9RLH8NK*"0-M?&?@"#]H/QQ^S7H?PAM?$OPK_X1;4=#@T[_ (2U-9:6
M\@T^2)1Y1MQUE5#Y><=NN>:^_O@]\-;#X._"WPMX)TR>2ZL="T^*QCN)0 \N
MQ<%R!P"QR<>] "?&#X6Z+\:OAGXB\$^((1+I>LVC6[G&6B;JDB_[2,%8>ZBO
MR]TWXU?%.Q^%\O[%P@OD^+']M_\ "-PZRJ_NAH)4R-,')S@1 @'_ )Y'@@BO
MTU^/'QDT7X _";Q'X[UYLV.DVQD6!6 >YF)VQ0K_ +3N57VSGH*_-BX_9L^)
M$OP(3]K/[7>/\<?[8_X3,V@WX&D8P+01]@(OWF,?ZOY,4 ?IC\&OA/HGP.^&
M/A[P/X>B\O2]'ME@5V #S/U>5\?Q.Q9C[FNTK@?@3\9-#^/OPI\/>.?#\JO8
MZK;AWAW M;S#B6%_]I'!7\,]#7?4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5ZU_+9RWDL\:2D 'RU=CL& .!Z"O2:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KY+U#_@EO^SYJ>I7M]-X;U037D[W$PCUNZ169V+-P
M'X&2:^M** /./@Y^SK\./@!87%KX"\)V'A[[3_Q\7$*EYY@.@>5R78#L"<#T
MJSXX^!OA#XB?$#P5XTUS3Y+GQ!X/EFFT>X2X=%A:4*'W(IVO]Q?O XQ7?44
M)7S;=?\ !.K]G^]\;R>)Y? -N;F6;[1)IZW4RV#R<_,;8/Y9Y).,8]J^DZ*
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M?_)SGPA_Z[1_^E KLPO\3Y/\CQ<V_P!W7^*/_I2/J"BBBN,]H**** "BBB@
MHHHH *^7O@?_ ,G;?%3_ *YR?^CHJ^H:^7O@?_R=M\5/^N<G_HZ*NRA\%3T_
M5'BX_P#CX;_%^C/J&BBBN,]H**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OE_P#:#_Y.<^$/_7:/_P!*!7U!7R_^
MT'_R<Y\(?^NT?_I0*[,+_$^3_(\7-O\ =U_BC_Z4CZ@HHHKC/:"BBB@ HHHH
M **** "OE[X'_P#)VWQ4_P"N<G_HZ*OJ&OE[X'_\G;?%3_KG)_Z.BKLH?!4]
M/U1XN/\ X^&_Q?HSZAHHHKC/:"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;4O^?:^]A]2Q?_04_P#P&/\ D?+W_#4GQ(_Z)#J'_?%S_P#&:/\ AJ3XD?\
M1(=0_P"^+G_XS7U#11[:E_S[7WL/J6+_ .@I_P#@,?\ (^7O^&I/B1_T2'4/
M^^+G_P",T?\ #4GQ(_Z)#J'_ 'Q<_P#QFOJ&BCVU+_GVOO8?4L7_ -!3_P#
M8_Y'R]_PU)\2/^B0ZA_WQ<__ !FC_AJ3XD?]$AU#_OBY_P#C-?4-%'MJ7_/M
M?>P^I8O_ *"G_P" Q_R/E[_AJ3XD?]$AU#_OBY_^,T?\-2?$C_HD.H?]\7/_
M ,9KZAHH]M2_Y]K[V'U+%_\ 04__  &/^1\O?\-2?$C_ *)#J'_?%S_\9H_X
M:D^)'_1(=0_[XN?_ (S7U#11[:E_S[7WL/J6+_Z"G_X#'_(^7O\ AJ3XD?\
M1(=0_P"^+G_XS1_PU)\2/^B0ZA_WQ<__ !FOJ&BCVU+_ )]K[V'U+%_]!3_\
M!C_D?+W_  U)\2/^B0ZA_P!\7/\ \9H_X:D^)'_1(=0_[XN?_C-?4-%'MJ7_
M #[7WL/J6+_Z"G_X#'_(^7O^&I/B1_T2'4/^^+G_ .,T?\-2?$C_ *)#J'_?
M%S_\9KZAHH]M2_Y]K[V'U+%_]!3_ / 8_P"1\O?\-2?$C_HD.H?]\7/_ ,9H
M_P"&I/B1_P!$AU#_ +XN?_C-?4-%'MJ7_/M?>P^I8O\ Z"G_ . Q_P CY>_X
M:D^)'_1(=0_[XN?_ (S1_P -2?$C_HD.H?\ ?%S_ /&:^H:*/;4O^?:^]A]2
MQ?\ T%/_ ,!C_D?+W_#4GQ(_Z)#J'_?%S_\ &:/^&I/B1_T2'4/^^+G_ .,U
M]0T4>VI?\^U][#ZEB_\ H*?_ (#'_(^7O^&I/B1_T2'4/^^+G_XS1_PU)\2/
M^B0ZA_WQ<_\ QFOJ&BCVU+_GVOO8?4L7_P!!3_\  8_Y'R]_PU)\2/\ HD.H
M?]\7/_QFC_AJ3XD?]$AU#_OBY_\ C-?4-%'MJ7_/M?>P^I8O_H*?_@,?\CY>
M_P"&I/B1_P!$AU#_ +XN?_C-'_#4GQ(_Z)#J'_?%S_\ &:^H:*/;4O\ GVOO
M8?4L7_T%/_P&/^1\O?\ #4GQ(_Z)#J'_ 'Q<_P#QFC_AJ3XD?]$AU#_OBY_^
M,U]0T4>VI?\ /M?>P^I8O_H*?_@,?\CY>_X:D^)'_1(=0_[XN?\ XS1_PU)\
M2/\ HD.H?]\7/_QFOJ&BCVU+_GVOO8?4L7_T%/\ \!C_ )'R]_PU)\2/^B0Z
MA_WQ<_\ QFC_ (:D^)'_ $2'4/\ OBY_^,U]0T4>VI?\^U][#ZEB_P#H*?\
MX#'_ "/E[_AJ3XD?]$AU#_OBY_\ C-'_  U)\2/^B0ZA_P!\7/\ \9KZAHH]
MM2_Y]K[V'U+%_P#04_\ P&/^1\O?\-2?$C_HD.H?]\7/_P 9H_X:D^)'_1(=
M0_[XN?\ XS7U#11[:E_S[7WL/J6+_P"@I_\ @,?\CY>_X:D^)'_1(=0_[XN?
M_C-'_#4GQ(_Z)#J'_?%S_P#&:^H:*/;4O^?:^]A]2Q?_ $%/_P !C_D?+W_#
M4GQ(_P"B0ZA_WQ<__&:/^&I/B1_T2'4/^^+G_P",U]0T4>VI?\^U][#ZEB_^
M@I_^ Q_R/E[_ (:D^)'_ $2'4/\ OBY_^,T?\-2?$C_HD.H?]\7/_P 9KZAH
MH]M2_P"?:^]A]2Q?_04__ 8_Y'R]_P -2?$C_HD.H?\ ?%S_ /&:/^&I/B1_
MT2'4/^^+G_XS7U#11[:E_P ^U][#ZEB_^@I_^ Q_R/E[_AJ3XD?]$AU#_OBY
M_P#C-'_#4GQ(_P"B0ZA_WQ<__&:^H:*/;4O^?:^]A]2Q?_04_P#P&/\ D?+W
M_#4GQ(_Z)#J'_?%S_P#&:/\ AJ3XD?\ 1(=0_P"^+G_XS7U#11[:E_S[7WL/
MJ6+_ .@I_P#@,?\ (^7O^&I/B1_T2'4/^^+G_P",T?\ #4GQ(_Z)#J'_ 'Q<
M_P#QFOJ&BCVU+_GVOO8?4L7_ -!3_P# 8_Y'R]_PU)\2/^B0ZA_WQ<__ !FC
M_AJ3XD?]$AU#_OBY_P#C-?4-%'MJ7_/M?>P^I8O_ *"G_P" Q_R/E[_AJ3XD
M?]$AU#_OBY_^,T?\-2?$C_HD.H?]\7/_ ,9KZAHH]M2_Y]K[V'U+%_\ 04__
M  &/^1\O?\-2?$C_ *)#J'_?%S_\9H_X:D^)'_1(=0_[XN?_ (S7U#11[:E_
MS[7WL/J6+_Z"G_X#'_(^7O\ AJ3XD?\ 1(=0_P"^+G_XS1_PU)\2/^B0ZA_W
MQ<__ !FOJ&BCVU+_ )]K[V'U+%_]!3_\!C_D?+W_  U)\2/^B0ZA_P!\7/\
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M?4L7_P!!3_\  8_Y'R]_PU)\2/\ HD.H?]\7/_QFC_AJ3XD?]$AU#_OBY_\
MC-?4-%'MJ7_/M?>P^I8O_H*?_@,?\CY>_P"&I/B1_P!$AU#_ +XN?_C-'_#4
MGQ(_Z)#J'_?%S_\ &:^H:*/;4O\ GVOO8?4L7_T%/_P&/^1\O?\ #4GQ(_Z)
M#J'_ 'Q<_P#QFC_AJ3XD?]$AU#_OBY_^,U]0T4>VI?\ /M?>P^I8O_H*?_@,
M?\CY>_X:D^)'_1(=0_[XN?\ XS1_PU)\2/\ HD.H?]\7/_QFOJ&BCVU+_GVO
MO8?4L7_T%/\ \!C_ )'R]_PU)\2/^B0ZA_WQ<_\ QFC_ (:D^)'_ $2'4/\
MOBY_^,U]0T4>VI?\^U][#ZEB_P#H*?\ X#'_ "/E[_AJ3XD?]$AU#_OBY_\
MC-'_  U)\2/^B0ZA_P!\7/\ \9KZAHH]M2_Y]K[V'U+%_P#04_\ P&/^1\O?
M\-2?$C_HD.H?]\7/_P 9H_X:D^)'_1(=0_[XN?\ XS7U#11[:E_S[7WL/J6+
M_P"@I_\ @,?\CY>_X:D^)'_1(=0_[XN?_C-'_#4GQ(_Z)#J'_?%S_P#&:^H:
M*/;4O^?:^]A]2Q?_ $%/_P !C_D?+W_#4GQ(_P"B0ZA_WQ<__&:/^&I/B1_T
M2'4/^^+G_P",U]0T4>VI?\^U][#ZEB_^@I_^ Q_R/E[_ (:D^)'_ $2'4/\
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M)\2/^B0ZA_WQ<_\ QFOJ&BCVU+_GVOO8?4L7_P!!3_\  8_Y'R]_PU)\2/\
MHD.H?]\7/_QFC_AJ3XD?]$AU#_OBY_\ C-?4-%'MJ7_/M?>P^I8O_H*?_@,?
M\CY>_P"&I/B1_P!$AU#_ +XN?_C-'_#4GQ(_Z)#J'_?%S_\ &:^H:*/;4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRE&*O)V-"BN6D^)6@QNR_:9'V]UB.#]#4"?%/0F'S/,A]X\_RK;V%7^5G/\
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M;2X#+<RB->P[GV KSW7/B!=719+4_9(?4??/X]OPKG=:UZXU*8S7,OF/C [
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MVRJ&(INM15IK\?\ @GRE1117UY^<A1110 4444 %%%% !1110 4444 %%%%
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ME+245)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF&"2@.[ SBG:U\4/#?A_Q]X?\%7E^P\3Z]%+/8V$,+R,T40)>1RH(C7@X9R
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MC7G&.R;_ #"BBBMCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH <'(I_G'UJ*BE8"1I#ZTS-)118 HH
MHI@%%%% !2-]VEHH 93NU-IW85)0=Q2TG<4M3T-4%%%%2:(*2EI.U0SJ@!I,
MFE-%<U0]K!_$)DT+]ZBE7[U>15/T3+^A<AK1@K/AK1AZ5\OBC]'P'0G6G=C3
M5IW:O&D?20!>M.IJ]:=63.E!3CPM-I6^[4LT0E.3K3:<M2S6(^BBBI-0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 -:E]*4TE2RD+2=J6D[5/0U%
MHHHJ6:1W"D[4M%0SJ@(>E!H-!KEJ;'N8'XAM.7[PI*6/[PKR*Q^C9>MB]!VK
M0AJA!VK0BKY;%'Z-@5H3"E[4@Z4O:O'D?11%6G4U:=6;.A!2M24K5+-$)2K_
M %I*7^&I-$244"BI-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH"@>PKU<!'64S\_XLQ"4*>'777]%^H^BBBO8/S@**** "BBB@ HHHH ****
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MS0QW$;1RQK(C=5=00?PJO'I-E#GR[.WCW<';$HS^E<KP':1[\>+-/>HZ^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M117GGLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXO\ CGX\?!^#QSXV\/:=X:35[F2;1K.Q:0NUAP(Y)=Y/S,0Q&, KM.!FO<*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (4'+X]6Y>Z\MSMF"%O[-,W3F0+&>V\!\]:_3#]M[X[:K\"_@C=S^%[2XO\
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MP-<![E8F\L<W(P6QCJ0.O<>M?;E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img58233625_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_6.jpg
M_]C_X  02D9)1@ ! 0$ \ #P  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *Q!A@# 2(  A$! Q$!_\0
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M<6C_ /0J:E_X$14?\-Q:/_T*FI?^!$5?(M%']CX+^3\6'UNMW/KK_AN+1_\
MH5-2_P# B*C_ (;BT?\ Z%34O_ B*OD6BC^Q\%_)^+#ZW6[GUU_PW%H__0J:
ME_X$14?\-Q:/_P!"IJ7_ ($15\BT4?V/@OY/Q8?6ZW<^NO\ AN+1_P#H5-2_
M\"(J/^&XM'_Z%34O_ B*OD6BC^Q\%_)^+#ZW6[GUU_PW%H__ $*FI?\ @1%1
M_P -Q:/_ -"IJ7_@1%7R+11_8^"_D_%A];K=SZZ_X;BT?_H5-2_\"(J/^&XM
M'_Z%34O_  (BKY%HH_L?!?R?BP^MUNY]=?\ #<6C_P#0J:E_X$14?\-Q:/\
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M/_T*FI?^!$5'_#<6C_\ 0J:E_P"!$5?(M%']CX+^3\6'UNMW/KK_ (;BT?\
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M5-2_\"(J/^&XM'_Z%34O_ B*OD6BC^Q\%_)^+#ZW6[GUU_PW%H__ $*FI?\
M@1%1_P -Q:/_ -"IJ7_@1%7R+11_8^"_D_%A];K=SZZ_X;BT?_H5-2_\"(J/
M^&XM'_Z%34O_  (BKY%HH_L?!?R?BP^MUNY]=?\ #<6C_P#0J:E_X$14?\-Q
M:/\ ]"IJ7_@1%7R+11_8^"_D_%A];K=SZZ_X;BT?_H5-2_\  B*C_AN+1_\
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M99S8NV^-!U;:P&X=SCH!7)>#_A!XE\=^&=4UW1K:&YLM/9EEC\P^<[!0VU$
M.XX(QZFKCBZ$X>TC-6V)=*:?*UJ<717ND'['7C>;0_MOVK2TO?+W_P!FM*WF
M@XSL+8VAOQQ[UY#I/A35]<\2Q^'[*PEEUF29K<6A&UE=<[@V>@&#DGIBG3Q5
M"MS.G-.VX2ISC;F6YDT5[W)^QEXT33S*NIZ/)>;-_P!B$KAB?3<5Q^/2O,O
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MEMY'Q.9$4X+ 'ZT+(K=&!_&OMG0?$47PZ_9;T;Q':Z197MU;V,+>5.@"N6D
M)) SGDFL'X;_ !@\(_'?4T\*^*_!UA:W]PC-;R(H>.0@9*JV R-@$C!YP>:S
M_M*;4YJE>,6TW==/(KZNKI.6K\CY;\+^&=0\9:]::-I4<<NH73%88Y9!&K$
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M3_K^E_\ 15?(M?6Y/_N4/G^9Y>+_ (S"BBBO:.,**** "BBB@ HHHH ****
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MF$M<+<P[#_K(VPO)SPIK&A#$5,12J3C+1.]TDD[;*W3U+J.$:<HQ:Z=3T/\
M;>UF^M[7PSID5U+%87)FEF@1L+(R;-I;UQDXJ7XH7D]_^QKHMS<RO<7#0V),
MLAW,2'49)/?%>:_M+?&'0/BU<: ^A+>!;%9A*;J'R_O[<8Y.?NFK/BOXT>'=
M<_9UTSP1 MX-:MX[9)-\&(OW;@MA\^@]*='"U(T,,N36,KORU>XI5(N=1WT:
M/3/CQ-/X/_9E\-:=I+O9V\RV=M,T!V;D,19@<?WF'/XU\X?#NZN=?\9^#_#^
MH7EQ=:-_:T&VQEE8Q)N=0Q"YXR..*]G\#_''P1XP^%]MX*^)"3PBTC6*.\5'
M=75/]6X* LK@8'3!Q[XKA?B3XI^'VAZ;HNF_#>UG:]L+U;^37+E")'91\J98
M!B,X)& O%;82-2C&6'E3?,V_>MIKUN15<9-5%+2RT/=/VF-%\,>)-8T>T\2?
M$.3PFD,#30Z>MNTBRL6QYN0>HQ@>GXUPWQ[^(W@[7O@GIGA[3O%,?B;6K&:W
M"W'E,LD@12K2-D8&0>>>2:O>(/BQ\)/CAHNGMXW^W:#J]FI >!7)!.-P1T5@
MRD@'##(KRGXN7WPP31;+2_ -C=2W:3>;<:K=;\NFW&SY^3S@\  8]ZY\'AY)
MTJ=6,TX/LN5?.VS]32M->]*+5G]_W'OW[37C35?"?P>\/6VE7,EDVJ-%;33P
ML5D$8A+%5(Y&< 9'.*^.M0U*[U>\>[OKJ:]NG #37#EW;  &2>>  *]K^/?Q
MJ\/?$SP3X9TG1UO%N]/E62?[3#L7 B*<')SR:\+KT\KH.C0]^-I7?J<^(GSS
MT=T?7O[#\L;>%?%$0(\U;^-CSSM,0 _4&OE+Q':S6/B/5[:X0QW$-[,DB-U#
M"1LBNR^"GQ>N_@_XH>_6%KW3;I!%>6BD NH.592?XE.?J"17K_BS7?V?_B-J
MAU_4[R_TW49B'N(H(IHC*1_?"JRY/<@@G'6L/WF#Q=2HX.49VV5[-%^[5I1C
M=)KN>7?LR'_B^'AOZS?^B7K=_;!_Y+&__8/@_FU$/Q6\#:'\9/"^M^']$N-*
M\,:/;O;.(XAYTY97'F%<Y)&X#YB2<5V_B[XM? SQUXA76]<T;6-0OUC6++0R
M*A5<X!42!3U-3.56.+CB?92MRVT6NXXJ+I.GS*]S>_9#ADT7X1^)-6O"(["2
MZEFC:0X79'$H=OID'\C7FW[('A74M<^),WB&WD>STS38W%P4/RRM(#MA]Q_$
M?3:/6F?%;]I:/Q+X3;PEX0T;_A'] 9/)=FVK(\8/W%5>$4]^23GMS5O3?CMX
M;\!_ T^%O":7O_"27,6+F\FMQ&@ED_UL@;)S@95?H#VK!T<2X59<EI56E;LN
M[+YZ=XJ^D?Q9[7\<H!\8/@KJTGA74&NUM+AI'CMSQ<>0Y$D1]>A8>I5:^$E8
M,H(Y!YKV?]G'XY6_PEO-1L=9^T2Z!>() D">8T4XXR%ST9>#_NK7GGQ%O-!U
M+QKJMYX96:/1;F7SH8[B/RVC+#+KMR> V<>U=N7T:F#G/#M7CNG^GJ8UYQJI
M5.O5'T1^PUM\GQD?X]]KCZ8EKY?U@EM8U$GJ;J8G_OMJ]X_8O\3)IGQ U31I
M9-JZI9[HEXP9(CG'UVLWY&O+?C%X=D\*?%'Q-ISQB)5O9)HE P/+D.]"/P8?
ME3H>YF%9/[2BU\M!3UH0?:Y](?LU_P#)MOB;_KI?_P#HD5\T?"/P;%\0/B%H
M&@7#F.UNYOWY'4QHI=U'N0I'XUZI\'_CIX;\!_!W6O#.I)?-JETUTT7D0!HS
MYD85<MGCGK7@^FWUUI-S#<V5S-9W<7W)[>0HZ'&.&'(XHP]&K&IB'\/,]'^H
MZDXN-/K;<^S/BE\-_&WBWXH>$6TS3+6#P;X=N+=X%%TB$X92[[.O"J% ]CZU
MS?[9W@76=4ET[Q/;6\;Z-I=F8KJ8R@,C/* N%ZGJ.E>#^&/BOXDTSQ-I-Y?^
M)=;N+"WNXI;B'[=*^^-7!9=I;!R >#79_M&?&RR^*&HZ:OAZ]U*+2H[=H[JU
MN-T4<C[PRDH&PV,=3TKBI8/$T<116CC%/6S^=]=V:RJTYTY]V,_94^'P\9_$
MN+4;F/?IVAJ+M\C*M,3B)?P(+?\  :3]JKQ]_P )E\3IK"WEWZ?HBFT3!^4S
M9S*WYX7_ (#70_"'X[^$OA/\*KS3[2"^E\5W0EF=C;CRC,05C!?/W5 7MZU\
M]S32W$TDTSM+-(Q>21CDLQ.23]37?1I3JXR=>HK*.D?U9C*48TE"+U>K/KOQ
M-_R958_]@^V_]&K7@7P!TVYU3XS>$X[4$O%>"X?':- 68GVQQ^->N>%_CS\.
M;CX.Z5X+\56FJSI#;)!=100G:Q5L@AU8'&0#3=,^/_PO^%]C,W@+PA=2:G,A
M0SW:^6?;=(S,Y'L/3\:\^E[>C3K452;<G*W;7S-Y<DI0FY*R2]3'_;8U"&X^
M(6D6L91I;;3,R[3\REI&(!_ 9_&NW_:$S)^R_P"$))26EQIQRW7)@.:^9=:U
MC5_B?XT:[OI#<ZKJ]TD0V#(4LP554?W5!  ]J^B/VS=:BTW0_"/A6)RTD>;J
M0#@;$3RTR/<EORJY4'2GA,/U5V_EN2I\RJS[GRQ1117TIYX4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!]0?L-_P#(2\8_]<K7^<M%'[#?
M_(2\8_\ 7*U_G+17YQG'^^S^7Y(^@PG\%&Y^W#&S>%_"S@?*M_("?3,1Q7R'
M7Z/_ !>^&MK\5O!-UHD\@M[C(FM;DC/E3+G:2.X.2#[$U\+>)O@KXX\*:A):
M7GAN_GVMA9[*!IXI!ZJR _K@U]#DN*I?5_8N5I*YP8NG+GYTM&<316__ ,*^
M\5?]"QK7_@NF_P#B:/\ A7WBK_H6-:_\%TW_ ,37T7M8?S(X.678P**W_P#A
M7WBK_H6-:_\ !=-_\31_PK[Q5_T+&M?^"Z;_ .)H]K#^9!RR[&!16_\ \*^\
M5?\ 0L:U_P""Z;_XFC_A7WBK_H6-:_\ !=-_\31[6'\R#EEV,"BM_P#X5]XJ
M_P"A8UK_ ,%TW_Q-'_"OO%7_ $+&M?\ @NF_^)H]K#^9!RR[&!16_P#\*^\5
M?]"QK7_@NF_^)H_X5]XJ_P"A8UK_ ,%TW_Q-'M8?S(.678P**W_^%?>*O^A8
MUK_P73?_ !-'_"OO%7_0L:U_X+IO_B:/:P_F0<LNQ@45O_\ "OO%7_0L:U_X
M+IO_ (FC_A7WBK_H6-:_\%TW_P 31[6'\R#EEV,"BM__ (5]XJ_Z%C6O_!=-
M_P#$T?\ "OO%7_0L:U_X+IO_ (FCVL/YD'++L8%%;_\ PK[Q5_T+&M?^"Z;_
M .)H_P"%?>*O^A8UK_P73?\ Q-'M8?S(.678P**W_P#A7WBK_H6-:_\ !=-_
M\31_PK[Q5_T+&M?^"Z;_ .)H]K#^9!RR[&!16_\ \*^\5?\ 0L:U_P""Z;_X
MFC_A7WBK_H6-:_\ !=-_\31[6'\R#EEV,"BM_P#X5]XJ_P"A8UK_ ,%TW_Q-
M'_"OO%7_ $+&M?\ @NF_^)H]K#^9!RR[&!16_P#\*^\5?]"QK7_@NF_^)H_X
M5]XJ_P"A8UK_ ,%TW_Q-'M8?S(.678P**W_^%?>*O^A8UK_P73?_ !-'_"OO
M%7_0L:U_X+IO_B:/:P_F0<LNQ@45O_\ "OO%7_0L:U_X+IO_ (FC_A7WBK_H
M6-:_\%TW_P 31[6'\R#EEV,"BM__ (5]XJ_Z%C6O_!=-_P#$T?\ "OO%7_0L
M:U_X+IO_ (FCVL/YD'++L8%%;_\ PK[Q5_T+&M?^"Z;_ .)H_P"%?>*O^A8U
MK_P73?\ Q-'M8?S(.678P**W_P#A7WBK_H6-:_\ !=-_\31_PK[Q5_T+&M?^
M"Z;_ .)H]K#^9!RR[&!16_\ \*^\5?\ 0L:U_P""Z;_XFC_A7WBK_H6-:_\
M!=-_\31[6'\R#EEV,"BM_P#X5]XJ_P"A8UK_ ,%TW_Q-'_"OO%7_ $+&M?\
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M&M?^"Z;_ .)H_P"%?>*O^A8UK_P73?\ Q-90]C3;<&E?5^I3YY6OT,"BM_\
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M $+&M?\ @NF_^)H_X5]XJ_Z%C6O_  73?_$T>UA_,@Y9=C HK?\ ^%?>*O\
MH6-:_P#!=-_\31_PK[Q5_P!"QK7_ (+IO_B:/:P_F0<LNQ@45O\ _"OO%7_0
ML:U_X+IO_B:/^%?>*O\ H6-:_P#!=-_\31[6'\R#EEV,"BM__A7WBK_H6-:_
M\%TW_P 31_PK[Q5_T+&M?^"Z;_XFCVL/YD'++L8%%;__  K[Q5_T+&M?^"Z;
M_P")H_X5]XJ_Z%C6O_!=-_\ $T>UA_,@Y9=C HK?_P"%?>*O^A8UK_P73?\
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M (FCVL/YD'++L8%%;_\ PK[Q5_T+&M?^"Z;_ .)H_P"%?>*O^A8UK_P73?\
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MBM__ (5]XJ_Z%C6O_!=-_P#$UH:'\'_&WB*^CM+/POJ8D8@;[BV:"-?=F<
M5+K4XJ[DOO'RR>R/<_V&XV^V^,9,?)LM5S[YE.**]J^!?PEC^$?@_P"P22I<
MZK=/Y][<1YVE\8"KG^%1P/7D]Z*_-LQK1Q&*G4AM_DK'T&'@Z=-1>YZ/1117
MG'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGV&E7+J]PMO!O/FR[255F9SA03@ 9KU^@ HJMJ3%=/N2I((C8@CZ5.GW%^E
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#O&%<!B.<@G-=O'9:Q\'_C/X%T>#Q7KGB+0O%27MM<VNO77VIH)X81*DT3D
MKG# KT] *PM4^!?C3Q1X?\3^)[L:?IOCO4M=L->L]+6;?;VXL@%@MWE Y9EW
M[G P"PQQ76Z3X?\ &OQ&^*7AGQ/XJ\/6_A#2O#$-PUK9"^CO)[NZG3RV8LGR
MK&J9Q_$2: /:**** "BJFE?\>2_[S_\ H1JW0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 444V218HV=V"(HRS,<  =S0 ZB
MOFCXV_\ !1+X'? [[1:W_BV+Q%K4.1_97AT"\EW8^ZSJ?+0_[S ^U?(FJ?\
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M_>?_ -"-7*IZ5_QXK_O/_P"A&KE !1110 4444 %%%% !1110 4444 %%%%
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MASX%_#;4O%FKRDI!>:G"[;CTW):PY=ADC[S+[BN1C_94_;$_;&9;GXM>-V\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'>:M?!4?R ?+B1<D*">2<G)/% 'K%%%% !1110 4444 %%%% !1110 4444
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MJ>_:@#Z"HKE?AG\0+7XE^$;76[6%K8NS136[')BD7[RY[CH0?0BNJH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *>E?\>*_[S_^A&KE4]*_X\5_WG_]"-7* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBO&/VKOVB]#_9Q^#_ (BU^[UG3+/Q&MA,=%TZ]F'F7EUL/EJL>=S#=C.!
M@#J10![/7BG[17[87PP_9ATMI?&.O(=79-]OH-AB:^GXXQ&#\BG^\Y5?>OPL
MTO\ ;"^.W_":3ZW8_$WQ.^N:BS1-MO7='+\;5A.47K\H51M.,8P*_3#]F_\
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MGYC<N,I 3U$8/?\ VCR?:O7* (K6UAL;>.WMXD@@B4(D<:A551T  Z"I:**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJG_(-
MN?\ KFW\JL1_ZM?I5?5/^0;<_P#7-OY58C_U:_2@!U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GI7_'BO\ O/\
M^A&KE4]*_P"/%?\ >?\ ]"-7* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKB_BI\9O!/P3\.OKGC
MCQ+8>'=/7.QKR4!Y2/X8T'S2-[*": .TKA/BY\<O GP)\.OK7CKQ-8^'[+!,
M:W$F9IR/X8HAEY#[*#7Y]?$[_@J)X_\ CAXBD\#_ +,W@74+^^ERG]N7=H)I
M]O3S$AY2)?\ ;E)'J!5WX2?\$IO$?Q*\0CQO^TIXVOO$.L7!\Q]%LKQI7/7Y
M)KD] /[D0 '9J ,WXC?\%-/B=^T)XBG\$?LR^!-0DFDRC:[=6PFN54Y'F*AS
M% O^W*3]%-;/P<_X).ZIXU\0#QM^T;XSOO%>NW+"671[6\>3)SG;-='YB!_=
MCP!V;%?H)\._A?X2^$GAV'0?!OA[3_#FDQ=+:PA$88_WG/5V_P!IB2?6NHH
M^>_!G[ 7P%^'_CZW\8Z'\/K.UUJU=9;;S)YIH+>1>DB1.Y0,#R#C@\C!KZ$H
MHH **** "BBB@ HHHH *YOQU\0=$^'6CMJ.LW0A0\10K\TLS?W47O_(=ZXKX
MP?M :5\-UDTZQ"ZMXB(P+5#\D)/0R$?^@CD^U>?>!/@;KWQ0UA?%OQ(N)FCE
MPT6FL=CNO4!@/]6G^R.3WQ0!DL_C;]J35]J[M!\%PR\]2G'Y>;)_XZO\_HKP
M%\.]$^'&CK8:-:B+=@S7#\RSM_>=N_TZ#M6]8V-MI=G#:6<$=M:PJ$CAB4*J
M*.@ %6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y_QMXT
MM? NC+J%U9ZAJ)DF6WAM-+M6N)YI&SM55'T/)( [D4 =!17 ^ ?C-HOCS4-9
MTS['J7A[6M'1);[2]<@$$\43@E)>&92A /S GIS7.Z?^U!X6OKC3IFTW7K3P
M[J5T+.R\37.GE--N)"Q50)-VX*S# 9E"GL: /8**\S\7?'O1_"_B+4=%MM%U
M_P 2WFEQ)-J?]A6'VA+%7&Y?,)8?,5&[:NYL<XJ?5OCSX6L/#/AO6;%KSQ /
M$G&D6.D6YFN;S"[GVH2-H0#YBQ 7H>: /1:*XWX=?%32/B2-3AL[>^TS5-+E
M6&_TG5;?R+JV9EW+N7)!5AR&!(..M=E0!5U3_D&W/_7-OY58C_U:_2J^J?\
M(-N?^N;?RJQ'_JU^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKBOB?
M\:O OP7T<ZGXX\5:9X:M,93[=.%DD]DC&7<^R@FOA#XK?\%@K35-4/ASX&^
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MK,OVKQ!#J$<L9AS\QBC'[POCH&51DC) YK]P(88[>%(HHUBBC4*B( %4#@
M=!3Z *NEZ?%I.FVEC!GR+6%(8\]=JJ%'Z"K5%% !13)IH[>%Y976*)%+.[D!
M5 ZDD]!7S1\2/C-K/Q4UH^"_AVDLD4Q*7&HQDJ9%Z-M;^"/U;J>@]P#<^,'[
M0$\>H-X1\"JVHZ]._D/=VXWB)CP4C_O/ZGHOUZ:OP6_9_A\%R+KWB-EU/Q-*
M?,!<^8EL3R2"?O/ZM^7J=_X/_!'2OA9IXE(2_P!>E7$]\5Z9ZI&#]U?U/?TK
MTJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"GI7_ !XK_O/_ .A&KE4]*_X\5_WG_P#0C5R@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBOEC_@H)^V)>?LA_#/2KW1-,M]3\4:]<R6NGB\R;> (H:25P""V-R +
MD9+=<#! /J>N2^)7Q8\'?!WP[+KOC7Q'I_AO2T_Y;WTP0N?[J+]YV_V5!/M7
MY+^!O^"L/[0OQ"TYO!GAWPAI'B'QWJ4NVPO].L)'EC7&6 MPQ1B,9WMA5&=P
M/4>J?#/_ ()?_$/XZ>(X?''[37CO4+Z\EP_]AVEUYUP%Z^6\O^KA7_8B!'H1
M0!8^*O\ P50\7_%KQ$W@C]FGP-J&M:I.2BZW>69EEQ_?BM_NHO\ MS' [J*;
M\+/^"6/C/XP>(D\;_M+^.=0U?4YB';1+.\,TV.NR2X^[&O\ L0C [,*_0;X4
M_!?P1\$?#J:'X'\-6/AW3U WK:Q_O)B/XI)#EI&]V)-=K0!R'PR^$?@WX,^'
M(]"\$^'-/\.:8G)AL80ID/\ >D?[SM_M,2:Z^BB@ HHHH **** "BBB@ HHK
MB_B+\7/#OPSL]^JW>^\9<Q6$&&FD_#^$>YP* )?$7Q<\'^%-772]5UZUL[XX
MS"Q+%,]-Q (7\<5X[\1/V@-5\9ZM_P (G\-8)KJYF)1]2B7YB._EY^ZH[R'\
M/6OGW4--USQ;J]SJT.D:C=?VI=231.D#R!RS$X# 8..GX5]F_ KX<I\/? ME
M'<V45OKERGFWTB@%RQ)*H6_V00,#C(- &#\'_P!G?3_ SQZQKC)K'B-CYGF/
M\T=NQZ[<_>;_ &SSZ8KV2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K&\8>,-(\!>&[W7==O8[#3+--\LTGZ*HZLQ/  Y).*V:YKQ
M[\./#GQ/T>+2_$^F+JMA%.MRD+R.@61<[6RC Y&3WH \7M_!^OZ[X5^*WQ(U
M>S?3-9\3:#+::7I(_P!;9V,<,AB$F/\ ELY8NP'W<@=16/\ $34M-U+]A_PU
M!830L]]8:/:6,,1&Z6X$L'R(!U8%6.!SP:]M\&_!7P;\/]6DU/0M)DL[V2)H
M&DDO;B<%"02-LDC#J!SC-5]%^ /P^\.^)4U_3O"UE:ZI'*T\4B[RD,C?>>.,
ML41CD\JH/- ''_ ?4+33?%OQJCO9HK>ZM_%,MU<-,P4K;M;Q&-V)_AVAL$\=
M:\A_9YVZ?XR^#4UU^[L[W2/$(T]I>%9GO_,39GN8N1CJ#Z5])^,O@;X$^(&L
MC5M?\.6VH:@8Q"\Y9XS*@Z))L8"11Z/D5I>+/A?X5\<:'::/K6AVMYIUFRM:
MP@&+[.5&%,3(04P./E(XH \[\ O'??M4?%"ZM'6:VATG2[2>2,Y5;A?.8H3T
MW!67(ZC(KVVL'P9X$T#X>Z1_9GAW2X-*LC(TK1P@DR.>KNQ)9F/JQ)K>H JZ
MI_R#;G_KFW\JL1_ZM?I5?5/^0;<_]<V_E5B/_5K]* '4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 445QGQ>^+WA;X%^ -4\8^,-233-%L$RS'F29S]V*->KNQX"C] "0
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MLB+W)KYMAM?%G[5'B3SYS)HO@JTEPJ@Y7CL/^>DN._1<_F 2>)O&?BC]I;Q
M_A[PM%)IOA:%A]HN)<J'7/WI2/TC'7O[>_?#CX8Z+\,=%6QTN'=,X!N+R0#S
M9V]2>P]%' K6\)^$=*\$Z+#I6CVB6EI$.B\L[=V8]68^IK8H **** "BBB@
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M[I>EVFBZ?!8V%O':6<"!(H8EVJBCL!4MK;I9VL-O&,1Q(J+] ,"I: "BBB@
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MFKJ/V6?^"7,&GZV/B)\?K\^.O&]U+]J.D7$YN+:&0_Q7#D_Z0X]/N#&/FX-
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M %%%% !1110 4444 %%%% !1110 45'<7$5G;RSSRI#!$I>221@JHH&223T
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M_P"N;?RJQ'_JU^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,%1M&\":G)X$^#-HGQ!\?3R&T%Y;(9[*UF/ 5 G-Q)G^%?E!')/*UP'[/\
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M>/PW\4?VA)%FUB<^&O#+G<L)5HT9?:/.Z0^[D"O:?AW\$/"_PWC22RL_M>I
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M&QD]D1>KN>@502>U 'D_[1G[<_PG_9?UJQT7QCJUU+KEU&)QINE6WVB:*(G
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MF)./;-='110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/8UV=85*<J<W":LT7&2DDT%%%%9E!1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44V2188V=V5$4;F9C@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_(-N?\ KFW\JL1_ZM?I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8C*N8BQ8A>%YX'-?86CS+<:392I:26"20(PM9D"/""H.QE'0CH1[4 7****
M"BBB@ HHHH **** *>E?\>*_[S_^A&KE4]*_X\5_WG_]"-7* "BBB@ HHHH
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M>3?-/+]6]/88%=:..!P*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^;_#]Q\0T^+'Q.3X?Z=X?AT-=4B^UIXBFE$C7QMX
MS)+&L0W!'4QXW<?*2O4BO<O!3>)GT-3XMCTJ+6/,;<NCM(T&S/RX,@W9QUKY
MW^(#?"C3_B5XDO=0\;^.=$\07$JQZ@FCF]2+*+A5!CA*E5!XY.,FO9_@??:!
MJ7@&WN?#6NZQXDTB2:0QZAKCRO/(<\@-*JL5!X'&* ._HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/.Z0_P 3^W1?Y>^T 9?ACP[9>$]"L]*L(8X;>VC5/W:!=Q  +$#N>I-:E%%
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M#PGHVN+H]]X@L;;4F(7[/)* 03T#'HI^I%<YX^_:#\(> _,A>]_M745_Y<[
MAR#_ +3?=7\3GVKXH^PZEXDU266WM+O4;B\G=E9(F=I7+9[=^:^N_A3^S?X=
M\+Z587VM:>NI:ZT:R2K=$/% Y&2JI]WCIDYZ4 <%)XV^*_QR8Q>'K%O#>@R'
M:;I6,8*^\Q&YOH@KLO O[*?A_0Y%O/$<\GB/4"=S))E8-W^[G+_\"/X5[@B+
M&JHBA548"J, "G4 06=C;Z;:QVUI!';6\8PD4*!54>@ Z5/110 4444 %%%%
M !6/XN\6:9X'\/W>LZQ<K:V-LNYF/)8]E4=V)X JYJVK6>@Z9=:CJ%Q':65M
M&99II3A44=2:^2+JZUW]KKXB"TMC/IG@72I-S-C&!_>/8RN.@_A'Z^AA,+[=
MN=1VA'=_HO-F%6IR:1UD]A_AO0=;_:S^(#Z_K:RZ?X+TV3RXK=6ZC.?*4]W/
M!=^W0=J^N;&QM]+LH+.TA2VM8$$<4,:X5% P !Z54\.^'=/\)Z+::3I5LEI8
M6J".*)!P!ZGU)ZD]R:TJ6+Q7UB2C!6A'9?UU"E3]FKO5O<****X#<**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *H:IJ]KIT;))>VEM<LA,2W4H0$]B><XSZ5?KB_'GPG\#^.K
MA-3\5^'=.U::S@*+<7L6XQQ@EB,^G4T >7>*9OBQXT\-ZIH%WK?PUTVSU.WD
MM)KN">XFDBC=2K,J,0I;!.,\9KW/PWI<>A^'=*TV*=KJ*SM8K=)W.6D"(%#$
M]R<9_&OD!M%\.W&@S>-;;]GC19_ARD;7(NS=(NH26@)S<BWQC&T%]A;)'>OL
M'P])83:!IKZ4$72VMHFM!&,*(2@V8'IMQ0!H4444 >5>*/@&GC"XU"+4/'/B
MYM#OW9KC14U!%@96.6B#>7Y@C/3:'Z<5H>+_ ('Z+XDFT"[TZ]U'PGJNA6YL
MK#4-#E6*2.V( ,!#*RLF%'!!P1D5Z+10!YC!^SQX2'@'5?"MTM]J$6JW/VZ^
MU2YN2U]/=;@RW!E !#J57;@ #& ,58\%?!.P\*^*!XDU#7=:\6Z]';&SMK[7
M+A)#:PDY98U1%4%B!EL;CCK7HU% !1110!3TK_CQ7_>?_P!"-7*IZ5_QXK_O
M/_Z$:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9^
MN>(-+\+Z;)J&LZE9Z381_?NKZ=(8E^K,0!^=<1\3?VBOAQ\(/ R^+O%'B[3+
M+0I59K6>*=9FO"/X8%3)E/\ NY]\4 >CU\X_M/?MY_"[]EVWFM-9U+^W?%FW
M,7AO2762YR>AE/W85]VY]%-?&?CK]NCXZ?MJ^);KP-^SCX7U#P[H&[R[KQ V
M$NA&3C=)/_J[52.RDN>Q[5[=^R__ ,$JO!7PMNH?%'Q.N4^)/C5G\]DNU+:?
M!+G.0C\SMG^*3@_W1UH ^=X[/]J#_@I]>*]TW_"L_@](^=N'BMID]AQ)>-[G
M$>?[M?>'[,O[#7PO_9<L8IO#^DC5?$^S$_B35%62[8D $1\8B7V0#KR37T##
M"EO$D42+'&BA51!@*!P !V%/H **** "BBB@ ILDBQ1L[L$11EF8X 'J:K:M
MJUGH>FW%_J%S'9V=NA>6:5L*H%?,7BWXA>)OVB->D\+^#(I;+PZIQ=74F4\Q
M<_>E/\*^B#EN_L ;/Q0^/&I>,-6_X0[X<))>74Y,4VHVXY/8B(_PJ.\A_#UK
MMO@Q\!=/^&L*ZC?E-2\1RC+W+#*09ZK'G]6/)]JZ/X7_  FT7X6:2;?3T\^]
ME ^TW\H'F2D=O]E?11^M=M0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !112,P5<L0!ZF@!:*\ \<?
MM@:#X3\5W&CVFCW6L0VDAAN+R&944,#A@@(.[![Y'0UZ+8?''P)J&EVM^/$^
MG6\=Q&)!'<7"I(F1T92<@CH17;/!8BG%2E!V>QBJU.3:3V.ZHKSZ;]H#X=6^
M0WB_3"1_=EW?R%49_P!ICX:6_7Q1 _\ US@E;^25"PN(>U-_<Q^UI_S(]/HK
MQZX_:Q^&T.=NKW$W_7.RE_JHK.F_;&^'L/W6U27_ '++_%A6JP&*?_+I_<3[
M>E_,CW*BOGRX_;7\$19\JPU>7ZPQK_-ZSI?VX_#><0>'=4E/^U)$O_LQK599
MC'_R[9/UFE_,?2E%?$/Q:_:JUOQQ#:VGAY;SPO9*"T[1S#SIV[#>H&U1Z#J3
M7I_[(?Q-\0^,(]<TC6[N;5(K!8Y8+RX.Z1=Q(,;-WZ9&>>M;5<JKT<.Z]2RM
MTZD1Q4)SY(GT?1117BG8%%%% !1110 4444 %8/C7QKIGP_T%]9UAKB/3XY$
M222WMWG,>XXW%4!.T=SC@5O5@>./'&C?#OPY<:WKURUKI\)5"R1/*[,QPJJB
M@LQ)., 4 >+:#)XBN/$GB/7/@YXG\'^)]"\0W U"YLM4N)/,LKHQJCNIBR=K
M!4)1P"#7J/P@\ W7P[\(&QU*_CU36;R\N-2U&[AC\N.2XFD+OL7LHR /85X1
MXJTF;XV7QOO!_P &)=(NVYB\7:Y<-HDR>DBK"?.?'7YN..:]X^#OA/Q+X)\!
MV6D^+/$;>*M9B9R^H,I'RDY5,GEMHXW'DT =M1110 4444 %%%% !1110!5U
M3_D&W/\ US;^56(_]6OTJOJG_(-N?^N;?RJQ'_JU^E #J*** "BBB@ HHHH
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M'O#7PI;>'74M-+7.N =?];$40'ZEJ^G=)L7TS2;*SDN9;V2WA2)KF<YDE*J
M7;W.,GZT 6Z*** "BBB@ HHHH **** *>E?\>*_[S_\ H1JY5/2O^/%?]Y__
M $(U<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\[?VV/^
M"ANI1^(O^%-? $2>(O'^H3?8+G5],7SOLDAX,-MCAIASN?[L>#W!*@'SI_P6
M7^*S^)OCAX?\'Z?XCBO]'T/2P]UI=K,66VOGD??YH''F>6(L#JH)Z9-<I_P3
M?_8CL_VJM6U37/'9U9? ?A\I%;P0.8X[ZX<EGB$G554 %MF"=XY%?<W[%O\
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MBBBO).H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*ZN%M;:69E9EC0N512S$
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MU!*G_IFO1!].?>O1+>RM[1G,$$4)D.7,:!=Q]3CK4]% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 4]*_X\5_WG_]"-7*IZ5_QXK_ +S_ /H1JY0 4444 %%%% !1110
M4444 %%%% !1110 5SOQ"^(7AWX5^#]2\4>*]6M]%T+3X_,N+NY;"CT4#JS$
M\!1DDD "OC3]IS_@J]X2_9_^*UYX%TOPE>>,;S2I1#JMW'>+:Q028RT<>48R
M,N0#G: <C)Q7S=I6E?%C_@K=\4_[1U1KCP3\$=#NB(X8B612.JH2 )[EE/+D
M;8P>G.& )?'GQ%^*O_!5SXH2>#/ 45SX2^#&D3JUY>W(*HXSQ-<X/[R0CE(
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MPWIUHPZ2" ,__?39/ZUU=%<=7&8BM_$FW\S:-*G#X8B#C@<"EHHKC-0HHHH
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MKV**-(8TCC18XT 5448"@= !Z4^BO)JUZM=WJR;]3JC",/A5@HHHK L****
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MY+R,XTG)\]75]NB"BBBO(.L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KP7XR7WB33_CS\/Y?"NF6.KZM_96I@6VH7
M9MHMFZ#<VX*W(XXQW->]52FT:PN-5MM3ELX9-0MHWBANF0&2-'P756Z@':N?
MH* /*6\5?'':<> _"I/;_B?R?_&:];TZ2YDT^V>]BC@O&B4S11/O1'P-RAL#
M(!SSBK%% !1110 4444 %%%% !1110!3TK_CQ7_>?_T(U<JGI7_'BO\ O/\
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MA.WSBOK+X9?"SX1?LB>#QI/AZUTWPQ;, 9[J>0/>7C#^*1S\\A]N@[ "N?\
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MA\.=%VF32IM5<?Q7]PSC_OE<+^E>PT5C4S+%U-'4:]-/R+CAZ4?LG":U\#?
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ML/A?K][#!KOB.UT%]2GN9YKRQDGE FSYQ,B2*H( .-N00*U%\-O\%?C;\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5=4_Y!MS_ -<V
M_E5B/_5K]*KZI_R#;G_KFW\JL1_ZM?I0 ZBBB@ HHHH **** "BBB@ HHHH
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#99&'GQNFD]V<\G\\5T]%%>%*<JCYIN[.U)15D%%%%0,**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !T%5-*_X\5_WG_]"-7*TQ&(GB9\\SERW+:&5T?8T=>K;W84445RGK!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 45$]U!',L+S1K*WW8V8!C]!4M KI[!1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH IZ5_QXK_ +S_ /H1JY5/2O\ CQ7_ 'G_ /0C5R@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 1E#*58 J1@@]#7DOCWX"V>KS-J?AN4:-JJG
MS!&A*Q.W7(QRA]QQ[5ZW16]&M4H2YH.QP8S X?'T_9XB-UT[KT?0\(\,_&C6
M?!>H+H?CNSF4KPM]M^?'JV.'7_:7GZU[9I>JV>M6,5Y87,=W:R#*2Q-N4U3\
M3>%-*\7:>UGJMFEU%_"6&&0^JMU!KQ/4_ /BWX.WTNJ>%;J34](SNEMF7<0O
M^V@^]_O+S7=RT,7\/N3_  ?^1X'/C\GTJ7K4>_VX^O\ ,O/<^@Z*\J\._M$>
M&]0TEI]4:32[V/ >WV-)O/JA Y'UP17>^&/%NE>,=/-YI-VMU"K;7P"&1O1@
M>17%4P]6E?GBT>YALRP>,LJ%52;5[7U^[<V****YST@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NJ?\@VY_ZY
MM_*K$?\ JU^E5]3YTZYQS^[;^56$^XOTH =17E/Q1_:@^''PCFDLM9\0)=ZV
MH^70]'B:^OV/IY,0)7ZOM'O7S#X^_;4^+?CEI;3X?^$].^'NFM\JZSXJD%Y?
MD?WDM(B8T/L[M]* /N/Q!XBTKPII4^IZWJ=GI&FP#=+>7TZPQ(/4NQ %?&WQ
M>_X*M?"_P?=3:/\ #ZPU+XK>(A\J1:+$R68;'&9BI+#W1&'O7S-KGP6N_B;J
MR:M\3/%'B3XFZDI#+'J<[1V<1_Z9V\>%0<G@<5W/A[P GANS6UT/0;+1;8<;
M842(?CMY/XUVT<'7K_!'3N]%^)YU?,L'AOXU6*^:N<'X@\:_$K]KKQ19:M\9
MO#.GZ+X4T3?/HOAN%,*9Y-JF2;+%WPJ\!L#G[O6K%S\%?A\NM6VMOX4TM+RU
M&(S' %CSV)C'R,1V)'%>L:+X;EM[GSKZ:*? ^6)/N@^I]:Z[PW9Z?;^(;6_N
MO#\?B!;4,WV)E)1B1@,P .0#ZC%>I'*91:=25UV7^;/F*O%F#C75*FFX_P W
M1?+=G)>"/A_XM^(TRIX;T:1[<':;Z<!((Q_OGY?P&37T1X!_8YTC3Y([[QAJ
M$FOWG4VL+,EN#Z$_>?\ 0>U:5M^T-J%E"D,?@QX(8QM6.,NJJ/0#9Q4W_#2U
MTOW_  I./^VQ'_LE;3^MQCR8:FH1\FK_ #>YT1SW*V^:K5;?G&7Y6/9]'T33
M_#UA'9:996^GVD8PL-O&$4?@*O5X9_PT\J_?\,7 _P"W@#_V6E'[4=I_%X<N
M5_[>5_\ B:\IX#%-W<?Q7^9U?ZQY4O\ E]^$O\CW*BO$%_:BTW^+0;L?]MD-
M2K^U%H_\6C7P^CH?ZU/U#$_R?D6N(LJ?_+Y?<_\ (]JHKQD?M0:#@YTO4 ?K
M'_\ %5YW)^T!XM;6S>I<PI:;\BP\I3'LS]TG[V<=\UI3RW$3O=6]3FQ'%&6T
M.7EGSW_E6WK>Q]545X0_[1VJZD0ND>$I9B>A9WD_]!7^M(?''Q;UO'V+PZM@
MK="UMM_61JCZA67QVCZM&O\ K%@I?P%*I_ABW^=CWBD9@HRQ 'J:\('A3XPZ
MV?\ 2M;73E;^[<*F/^_:YI5_9Z\0:HV[6/%\DN?O!/,D_P#0F'\J?U6E'XZR
M^5V']K8NI_ P4W_B:C^=SV*^\5:+IF?M>K65OCJ)+A ?RS7C/CK]HNZL==>U
M\.0VES90$!KJ;+B8]]N",#MFM?3_ -F+0(<&\U*_NS_L;(Q_(_SJ'7_V9=-N
MKB)](U.;3H@ )(IU\[/N#D$'VKHH+ TY^_)R^6AYN/EG^(HVH4U3UZ23E]^B
M-SP]^T!X8U#2;>;4[K^S+\C$MN8W<*WLP'(/6M5?C;X*;_F.Q#ZQ2#_V6JVF
M_ ?P=9Z?!;SZ8+Z:-</<S2.'D/<G! 'X5*WP+\$M_P P95^DTG_Q582^HN3M
MS?@=]-9_&$5+V3=NO-?YVT^[0LK\9O!3?\S!;#ZAQ_2GK\8/!C?\S%9CZL1_
M2LUO@)X*;_F%NOTN)/\ &HF_9]\%M_RXW"_2ZD_QJ;8+O+\"^;/?Y:7WR-M?
MBQX/?IXBL/\ O[4R_$[PF_3Q#I__ '_6N:;]G?P:W2VO%^ET]1-^SCX/;HE\
MOTN3_A3Y<%_-+[D'M,\6].G]\O\ ([!?B'X8?IK^G?\ @2O^-8?C+XS>'_"F
MFI/!<Q:Q<2-MCM[.96/N6(SM%8[?LV^$6Z-J"_\ ;P/_ (FL'Q7^S1:+IV_P
MW=RK>JV3%?2 HZ^@(7@UI3IX)S7--V\T<V)Q&>QHR<*,+^3N_DFM3I?"/Q^\
M.^(+>8ZDZZ#/%CY+F0,K@]U8#GZ8K0N_CIX*M<_\3@3G_IC#(WZ[:X;P+^SB
MBI+-XK<2,<"*UM)B OJ688S]!7>VGP1\%6F,:)'*1WFD=OYFG6C@8S=G)^EK
M?B1@ZG$%6A%SC"+_ +U[_-+1&#=_M*>%(,^5%J%P?]F$*#^;5D3?M06+Y%GX
M?NYSVWS*O\@:]/L_A_X9L,>1H.GH1W^S*3^9%:]OIMI9X\BUAA_ZYQA?Y"LO
M:82.U-OU?^1V?5<YJ?%B8Q](7_-GB'_"_?%6H?\ (-\&NX/3*2R?R45E>*O%
M7Q/\4:!>VUQX>ELM.DCS,T%NROL')&2V<>N!TKZ-HIQQ=*#3A17XLBID^+KP
M<*^,DT^R2/BSP';:_+XFMG\,QR'58<LIC  48YWYXQ[&O7?[0^-<?6UA?_@$
M']#7N,-K#;LYBACB+G+%% S]:EK6MF/M97]FOGJ<>"X:>$IN"Q,UK]E\J^[7
M4\(_M[XSQ]=,B;_MC$?Y-2?\)5\8X^NB1O\ ]NZG^3U[Q16'UR/_ #ZC]QW_
M -BU.F,J_P#@2_R/!O\ A./B_'U\-HW_ &Z?X24[_A87Q93[WA0-_P!NC?\
MQ=>[T4?6X?\ /J(?V/76V,J?>O\ (\(_X6A\4(_O^#\_]NLG_P 52_\ "WOB
M/']_P7G_ +=9O\:]VHH^M4NM%?B/^R<6ML;/[H_Y'P[KVI:E?:_=7FI23IJC
M2EG\S<LD;9X '5<=A7NG@[]HW28]+L[/78KR.^AC6.6Y5 ZNP&-Q .1GZ5Z]
M<>'M+O+]+Z?3K6:\3[MQ)"K./3YB,U5UCP7H.OJ1J&D6=T3_ !/"-W_?76NN
MKCJ&(C&-2GMV9Y&#R''Y=4G5PV(3<OYD[/UUW*.C?$[PMKV!9ZY:,Y_Y9ROY
M;?DV#73)(LBAD8,IZ%3D5Y=K/[.?A34MS6HNM,<]/)EW(/\ @+9_G7,M\!_%
M7AMC)X;\5LH7I&[/"3[<$K^E<OL<+4^"I;U7ZH]7ZYFV'_CX937>$OT>I[S1
M7@O_  D7Q>\(\7FFKK,"]6$2RY'UC(/YBK6G_M,1VT@AUWP_<V4H^\86SC_@
M+A3^M)X"J]:=I>C*CQ!@XOEQ"E2?]Z+7XZH]PHKQ?Q%^TQI=J(!HNGS:B6&9
M&N"80GMT.3^E=!HOQ\\)ZAI,5U>WO]F739#VDJL[*1Z%1R/>LY8/$1BI.#.J
MGGF6U*CIQK*Z^2^]Z/[STBBO,[K]H?P;;YVW-U<?]<K9L?F<5CW7[3WA^/(M
M]-U"<_[6Q!_Z$:(X+$2V@Q3SS+*>]>/R=_R/9**\*D_:8N+KC3_"T\Q[;IBW
M_H*&FK\9O'^I?\@_P80#T)MYG_PK3^SZ_P!I)>K1S?ZQY?+2G)R](R?Z'N]%
M>#_\)+\9-2/[G1X[,'^]!&N/^^VH_P"$?^,VI'][JD=FI_NS1KC_ +Y4FCZE
M;XJD5\Q?VYS?P\-5E_V[;\V>Q^)?$^F^$=*DU'5+@6ULI"YP268]%4#J363X
M+^)V@^/))HM+N'^T1#<UO.A1]O3<!W'TKQOQ5\'/B#J&EM<ZAJZZZ\)WK9_:
M'=O<KN &<5C^"?@OXRU"XENHS)X;>(82:X9HW8GJ %YQ[UU1P>&]DY2JJ_X?
M=N>34SK-/KD80PCY'T:U?SV7]=SZGHKP@_#?XJV'_'OXL$X'0&[D/_H2TBZ5
M\:;#E;V*Z ]9(6_FHKE^J0?PU8_D>M_;-:/\3!U%Z)/\F>\45X/_ ,)%\9K'
M_6Z3'<@>D,3?^@M2_P#"UOB98?\ 'WX.\P?WA:2C]0QH^HS?PRB_F'^L%"/\
M2E4CZP?_  3W>BO!)/VAO$=G&_VOP@T+!3\[>:JCW.5Z?C7GMC\9O%UKK2:C
M)J\UP-^Y[63'D,N>5"] ,=QS6T,LKS3;LOG_ )')7XKP%%Q4>:5]]+6^^WX'
MU[17BD?[46D''F:->IZ[70_U%68_VGO#;??T_4D^BQG_ -GKG^HXE?8/17$&
M5R_Y?K\?\CV*BO*(_P!I3PD_WH]03ZP _P FJS'^T5X.?K/>)_O6K?TJ/J>(
M_D9LL[RV6V(C]YZ=17G<?Q]\%R==2D3_ 'K=Q_2K4?QO\$R?\QV-?]Z*0?\
MLM0\+77V']S-XYK@);5X?^!+_,[JBN.C^,'@R3[OB"T_X$6'\Q7GOC;]HYM-
MUIK3P]:VM_:18WW<S,5D/4A,$<#UJZ>#KU9<JB_GH88G.L!A:?M)U4UY.[_
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MI]J_^]"I_I5:3PEH<GW]&T]O]ZUC/]*UJ*GGDMF:.C3EO%?<<_)\/_#,WW]
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M,>1J]A-_N7*'^M</<?L[^#9\[;>[@_ZYW+?US63=?LP^'9,^1J.H0'_:*/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17
M'_%;XC0?"WP?+K4EE+J=T\\5G9:? P5[JYE<)'&">F2>3V )KE?#?Q6\5:?\
M0=(\)>//#=AH]SKD$TVEWVDWQN89'B4-)#(&12KA3G(R#B@#UJBBB@"GI7_'
MBO\ O/\ ^A&KE4]*_P"/%?\ >?\ ]"-7* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAN%L'AT_?DV_.WY'@Y^'OQ:A_P!7XJ63ZWC?U2C_ (1?XR6_W-:CE_[>$/\
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M_P!FW?\ T%;C_OB/_P")H_LV[_Z"MQ_WQ'_\36E10!F_V;=_]!6X_P"^(_\
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MH_LV[_Z"MQ_WQ'_\36E10!F_V;=_]!6X_P"^(_\ XFC^S;O_ *"MQ_WQ'_\
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MS;O_ *"MQ_WQ'_\ $UI44 9O]FW?_05N/^^(_P#XFC^S;O\ Z"MQ_P!\1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5Y7K/[.'A;6O$NL:TU]X@LI]
M8F6>_M]/UB>W@N&"!/F1&'\*@5ZI10!Q.I?!OPCJ'P_A\%KI*V.@6Y1[>&QD
M:%[>16WK+&ZG<'#?-NSG.<YS3/!?P=T#P-XCN]?LI-2O-:O+5;.YOM2OY;J6
M9%;<NXN3R.@QCBNYHH \:_9R^&USX.?QUKVHZ.=#U#Q)KUQ=K9,RLT5LK$1
MD$CYLN^,\>97LM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !24M% !7'_%CX>_\+2\#WGAE]3E
MTJUO9(A=20QAVDA616>+DC <+M)[ FNPHH C@ACM88X8D$<4:A$51@  8 %2
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M._\ [71_PE/Q5_Z$71__  =__:Z]/HH \P_X2GXJ_P#0BZ/_ .#O_P"UT?\
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M@.JAL$CTH O5GZYX@TOPQISZAK&I6>DV"$*]U?3I#$I)P 68@#)KX D^$_\
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MSVVGM*/.D51EB%ZX [^U+>>,M"L/$ECX>N-6M(M<OD>2VT]I1YTBJ,LP7K@
M'GVKRKXF:MX7T/XS> +A[S2K#4?MMR^HR-+&DH!M&6,RG.0.@&[UXJ'XFZMX
M7T3XZ_#FY:\TJQOA<WKZC,TL:2 &R*Q&5LY / 7=Z\4 >O>)_%&G^$-,74-2
MD:*V:XAM@R(6.^618T&!ZLPJ;2=<M-;-Z+1I&-G</:R^9$R8D7&<;@-PY^\,
M@^M<)^T%^\^'L&T;LZSI9^49_P"7Z&O(O'WCR^TN=[;5-3U'^PI_&>H6MW#!
M?&UD>!+96CB2;(**'(;:",X(S0!]445\M6NKVVB_#/P5HMWK%UJ<^K37L\E]
M_P )5)#:(5.\0SWJY8NJL@"+C+*W'%2> [O6OB5IOPGL=:U[6$AU'3]8-^]G
M=R0270AG18@\BA6X&/FX8_B: /J&LKP_XFL/$RZ@;"1I!87LMA/N0KB:,@.!
MGJ.>M?->C^+]1USP?\+;3Q7XCU&P\/WUWK%MJ>J"Z:U>5K>:1+2.6X7!7*H3
MG(WE.3Z^G?LV20S>$_$<EM>7.I6K^(K]H;R\!$LZ;QM=L@$DCO@9ZT >MT45
MYGXPT?XE77B"XDT+6+"VTH[?)B= &7CG.5.3G/>M:=-5'9R2]3CQ6(>&@IJG
M*?E&S?XM'I><<G@57L]3L]0W_9;N"Y\LX?R9 ^T^^#Q7AOBSPW\6)/#M\MYJ
MD%]:^7^]M[,?O77N%PH/X9KSSX7Z%XLN/$#MX9$EA<HC"6XF4K$H_NOD8)ST
M&,UZ<,!&5.4_:K3[OF?+U^(:M'$TZ"PL_>[[_):I_>CZ^K$\4>--"\%Q6,FN
MZK:Z5'?7*6=L]TX02S-G:@/J<&O-?^$>^,'_ $']._(?_$5C_%_PO=^(=-^%
MFA>+_)U2:\\0-!>M"N$96M+G!''!'!!QU -<%2BJ:NII^A]!A<=+$S<)49P\
MY))?@V>TZEXHTG1YKF&]OX;:6VLWU"99&P4MT.&E/^R/6FR>+-'ATO3M2?48
M%L-2:%+2X+?+.TN/*"GONR,?6OG329-?UC4_&?@[4XKB^\5:+X*N](:8J?\
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M4D:&:)NZLI';VH ](I" PP1D5Y__ ,- ?#K_ *&_3?\ OX?\*/\ AH#X=?\
M0WZ;_P!_#_A0!Z!TX%+7GW_#0'PZ_P"AOTW_ +^'_"C_ (: ^'7_ $-^F_\
M?P_X4 =^T:OM+*&*G(R,X/K39H([A=LL:RKG.UU!%<%_PT!\.O\ H;]-_P"_
MA_PH_P"&@/AU_P!#?IO_ '\/^% '?^6F<[5SC;G';TI%A1-NU%7:,# Z#TK@
M?^&@/AU_T-^F_P#?P_X4?\- ?#K_ *&_3?\ OX?\* .\6VA1658D4,=S *.3
MZFE:WBDD61HD:1?NN5!(^AK@O^&@/AU_T-^F_P#?P_X4?\- ?#K_ *&_3?\
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MFP)L7:.BXX&.E))!'-M,D:R%3E=R@X/J*X+_ (: ^'7_ $-^F_\ ?P_X4?\
M#0'PZ_Z&_3?^_A_PH []T612KJ&4]0PR*=7GW_#0'PZ_Z&_3?^_A_P */^&@
M/AU_T-^F_P#?P_X4 =S)I]K-(7>VA=SU9HP2:D^SQ>=YWE)YN,>9M&['IFN"
M_P"&@/AU_P!#?IO_ '\/^%'_  T!\.O^AOTW_OX?\* .YDL+::0O);0R.>K,
M@)-$FGVLSEY+:&1VZLT8)-<-_P - ?#K_H;]-_[^'_"C_AH#X=?]#?IO_?P_
MX4 =^R*RX901Z$5RWC+X=6/C*ZTV]-]J&CZEIS2-;WVES"*10X =3E64A@!G
M([5D_P##0'PZ_P"AOTW_ +^'_"C_ (: ^'7_ $-^F_\ ?P_X4 ;O@SP!I7@?
M1'TRR6:YCEN9+R>>]?S99YW.7D<D?>)] !70B-%((101G''3/6N!_P"&@/AU
M_P!#?IO_ '\/^%'_  T!\.O^AOTW_OX?\* .]:WB>/RVB1H^NPJ,>O2GJH7.
M !DY.!7G_P#PT!\.O^AOTW_OX?\ "C_AH#X=?]#?IO\ W\/^% 'H-%>??\-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC^P-+_Z!MI_WX7_"K]% %#^P-+_Z!MI_WX7_  H_L#2_^@;:?]^%_P *OT4
M4/[ TO\ Z!MI_P!^%_PH_L#2_P#H&VG_ 'X7_"K]% %#^P-+_P"@;:?]^%_P
MH_L#2_\ H&VG_?A?\*OT4 4/[ TO_H&VG_?A?\*/[ TO_H&VG_?A?\*OT4 4
M/[ TO_H&VG_?A?\ "C^P-+_Z!MI_WX7_  J_10!0_L#2_P#H&VG_ 'X7_"C^
MP-+_ .@;:?\ ?A?\*OT4 4/[ TO_ *!MI_WX7_"C^P-+_P"@;:?]^%_PJ_10
M!0_L#2_^@;:?]^%_PH_L#2_^@;:?]^%_PJ_10!0_L#2_^@;:?]^%_P */[ T
MO_H&VG_?A?\ "K]% %#^P-+_ .@;:?\ ?A?\*/[ TO\ Z!MI_P!^%_PJ_10!
M0_L#2_\ H&VG_?A?\*/[ TO_ *!MI_WX7_"K]% %#^P-+_Z!MI_WX7_"C^P-
M+_Z!MI_WX7_"K]% %#^P-+_Z!MI_WX7_  H_L#2_^@;:?]^%_P *OT4 4/[
MTO\ Z!MI_P!^%_PH_L#2_P#H&VG_ 'X7_"K]% %#^P-+_P"@;:?]^%_PH_L#
M2_\ H&VG_?A?\*OT4 4/[!TP<C3K0'_K@O\ A5Y5"J%48 X %+10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img58233625_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_7.jpg
M_]C_X  02D9)1@ ! @$ \ #P  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +=!A4# 2(  A$! Q$!_\0
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M]#'%?^#/^!Y?GW9^L7_#Y+]JS_H"?#'_ ,$U[_\ )%'_  ^2_:L_Z GPQ_\
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M_!#_ /D_ZN_*Q_;V<?\ 0QQ7_@S_ ('E^?=GZQ?\/DOVK/\ H"?#'_P37O\
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M (,_X'E^?=GZQ?\ #Y+]JS_H"?#'_P $U[_\D4?\/DOVK/\ H"?#'_P37O\
M\D5^3M%'_$/."/\ HF,I_P#!#_\ D_ZN_*Q_;V<?]#'%?^#/^!Y?GW9^L7_#
MY+]JS_H"?#'_ ,$U[_\ )%'_  ^2_:L_Z GPQ_\ !->__)%?D[11_P 0\X(_
MZ)C*?_!#_P#D_P"KORL?V]G'_0QQ7_@S_@>7Y]V?K%_P^2_:L_Z GPQ_\$U[
M_P#)%'_#Y+]JS_H"?#'_ ,$U[_\ )%?D[11_Q#S@C_HF,I_\$/\ ^3_J[\K'
M]O9Q_P!#'%?^#/\ @>7Y]V?K%_P^2_:L_P"@)\,?_!->_P#R11_P^2_:L_Z
MGPQ_\$U[_P#)%?D[11_Q#S@C_HF,I_\ !#_^3_J[\K']O9Q_T,<5_P"#/^!Y
M?GW9^L7_  ^2_:L_Z GPQ_\ !->__)%'_#Y+]JS_ * GPQ_\$U[_ /)%?D[1
M1_Q#S@C_ *)C*?\ P0__ )/^KORL?V]G'_0QQ7_@S_@>7Y]V?K%_P^2_:L_Z
M GPQ_P#!->__ "11_P /DOVK/^@)\,?_  37O_R17Y.T4?\ $/."/^B8RG_P
M0_\ Y/\ J[\K']O9Q_T,<5_X,_X'E^?=GZQ?\/DOVK/^@)\,?_!->_\ R11_
MP^2_:L_Z GPQ_P#!->__ "17Y.T4?\0\X(_Z)C*?_!#_ /D_ZN_*Q_;V<?\
M0QQ7_@S_ ('E^?=GZQ?\/DOVK/\ H"?#'_P37O\ \D4?\/DOVK/^@)\,?_!-
M>_\ R17Y.T4?\0\X(_Z)C*?_  0__D_ZN_*Q_;V<?]#'%?\ @S_@>7Y]V?K%
M_P /DOVK/^@)\,?_  37O_R11_P^2_:L_P"@)\,?_!->_P#R17Y.T4?\0\X(
M_P"B8RG_ ,$/_P"3_J[\K']O9Q_T,<5_X,_X'E^?=GZQ?\/DOVK/^@)\,?\
MP37O_P D4?\ #Y+]JS_H"?#'_P $U[_\D5^3M%'_ !#S@C_HF,I_\$/_ .3_
M *N_*Q_;V<?]#'%?^#/^!Y?GW9^L7_#Y+]JS_H"?#'_P37O_ ,D4?\/DOVK/
M^@)\,?\ P37O_P D5^3M%'_$/."/^B8RG_P0_P#Y/^KORL?V]G'_ $,<5_X,
M_P"!Y?GW9^L7_#Y+]JS_ * GPQ_\$U[_ /)%'_#Y+]JS_H"?#'_P37O_ ,D5
M^3M%'_$/."/^B8RG_P $/_Y/^KORL?V]G'_0QQ7_ (,_X'E^?=GZQ?\ #Y+]
MJS_H"?#'_P $U[_\D4?\/DOVK/\ H"?#'_P37O\ \D5^3M%'_$/."/\ HF,I
M_P#!#_\ D_ZN_*Q_;V<?]#'%?^#/^!Y?GW9^L7_#Y+]JS_H"?#'_ ,$U[_\
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M]#'%?^#/^!Y?GW9^L7_#Y+]JS_H"?#'_ ,$U[_\ )%'_  ^2_:L_Z GPQ_\
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M_!#_ /D_ZN_*Q_;V<?\ 0QQ7_@S_ ('E^?=GZQ?\/DOVK/\ H"?#'_P37O\
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M (,_X'E^?=GZQ?\ #Y+]JS_H"?#'_P $U[_\D4?\/DOVK/\ H"?#'_P37O\
M\D5^3M%'_$/."/\ HF,I_P#!#_\ D_ZN_*Q_;V<?]#'%?^#/^!Y?GW9^L7_#
MY+]JS_H"?#'_ ,$U[_\ )%'_  ^2_:L_Z GPQ_\ !->__)%?D[11_P 0\X(_
MZ)C*?_!#_P#D_P"KORL?V]G'_0QQ7_@S_@>7Y]V?K%_P^2_:L_Z GPQ_\$U[
M_P#)%'_#Y+]JS_H"?#'_ ,$U[_\ )%?D[11_Q#S@C_HF,I_\$/\ ^3_J[\K'
M]O9Q_P!#'%?^#/\ @>7Y]V?K%_P^2_:L_P"@)\,?_!->_P#R11_P^2_:L_Z
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MP^2_:L_Z GPQ_P#!->__ "17Y.T4?\0\X(_Z)C*?_!#_ /D_ZN_*Q_;V<?\
M0QQ7_@S_ ('E^?=GZQ?\/DOVK/\ H"?#'_P37O\ \D4?\/DOVK/^@)\,?_!-
M>_\ R17Y.T4?\0\X(_Z)C*?_  0__D_ZN_*Q_;V<?]#'%?\ @S_@>7Y]V?K%
M_P /DOVK/^@)\,?_  37O_R11_P^2_:L_P"@)\,?_!->_P#R17Y.T4?\0\X(
M_P"B8RG_ ,$/_P"3_J[\K']O9Q_T,<5_X,_X'E^?=GZQ?\/DOVK/^@)\,?\
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M_P#!#_\ D_ZN_*Q_;V<?]#'%?^#/^!Y?GW9^L7_#Y+]JS_H"?#'_ ,$U[_\
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M]#'%?^#/^!Y?GW9^L7_#Y+]JS_H"?#'_ ,$U[_\ )%'_  ^2_:L_Z GPQ_\
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M_!#_ /D_ZN_*Q_;V<?\ 0QQ7_@S_ ('E^?=GZQ?\/DOVK/\ H"?#'_P37O\
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M (,_X'E^?=GZQ?\ #Y+]JS_H"?#'_P $U[_\D4?\/DOVK/\ H"?#'_P37O\
M\D5^3M%'_$/."/\ HF,I_P#!#_\ D_ZN_*Q_;V<?]#'%?^#/^!Y?GW9^L7_#
MY+]JS_H"?#'_ ,$U[_\ )%'_  ^2_:L_Z GPQ_\ !->__)%?D[11_P 0\X(_
MZ)C*?_!#_P#D_P"KORL?V]G'_0QQ7_@S_@>7Y]V?K%_P^2_:L_Z GPQ_\$U[
M_P#)%'_#Y+]JS_H"?#'_ ,$U[_\ )%?D[11_Q#S@C_HF,I_\$/\ ^3_J[\K'
M]O9Q_P!#'%?^#/\ @>7Y]V?K%_P^2_:L_P"@)\,?_!->_P#R11_P^2_:L_Z
MGPQ_\$U[_P#)%?D[11_Q#S@C_HF,I_\ !#_^3_J[\K']O9Q_T,<5_P"#/^!Y
M?GW9^L7_  ^2_:L_Z GPQ_\ !->__)%'_#Y+]JS_ * GPQ_\$U[_ /)%?D[1
M1_Q#S@C_ *)C*?\ P0__ )/^KORL?V]G'_0QQ7_@S_@>7Y]V?K%_P^2_:L_Z
M GPQ_P#!->__ "11_P /DOVK/^@)\,?_  37O_R17Y.T4?\ $/."/^B8RG_P
M0_\ Y/\ J[\K']O9Q_T,<5_X,_X'E^?=GZR)_P %D_VJU92V@_#!U!!*'1[\
M!@.H)6Y# 'U!!]"*^^_V//\ @K+HOQF\8:9\,/CCX:T?X>>+/$%Q'9>%?$^A
M7=R_A#6=2DVI!HVH1ZG--=Z/J=T0[6]U)</874SI:QQV[#<W\T%(;NYT_&HV
M<K07NG.FHV5PG#V][8.MW:3H>SP7$,<J'LR UYN:^%?!>9X*MA*&38;+<14@
MUA\;@E.C6P]:WN5.53]G5@I6YZ=6,HRBY).$G&4>C"\2YOAJT*L\75Q%.+3J
M4:SC.%2'VHW:YH2:VE%IIZNZNG_?S17G7P@U74-=^$OPNUO5KE[S5-9^'7@G
M5=2O)<>9=:AJ'AK3+N\N9,<;Y[B:25\<;F-%?Q17I2H5JU"33E1JU*4FKV<J
M<W!M7ULVKJ^MC]@A-3A":T4XQFD]TI)-7^\_&?\ X+D_\B?^SA_V.?C_ /\
M4<TBOYY*_H;_ ."Y/_(G_LX?]CGX_P#_ %'-(K^>2O[.\'_^3?Y+_P!?<T_]
M6N-/R+BK_D>XWTPW_J)0"BBBOTT^>"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#\-;EK;SO%W@*^N=4MM)MKV.)[#4M7AEM+<0Z1?M,L5IJME+?6.XQFYGMQ/
M9/77%O#3S/\ L=9U@7F3KO"K#*KJ\4K7PJJV]B\2FU'ZNJGMN9\G)S:'+_9>
M8_5_K?U2M]7Y/:>TY?\ EW_S\Y;\_L^OM.7DMK>VI\*T45]-_LT?LC_&3]JW
M7M3TGX8:58PZ5H*(?$/C#Q#//8>%]&GF3S;73IKNWMKNYN=6O(@TMO865I<2
M)&JS7AM;>6*9_7QV/P6686MCLPQ5'!X/#Q4JV(Q%2-.E33:BKRDTKRDU&$5>
M4Y-1BG)I/EHT*V(JPHT*<ZM6;M"G3BY2D]W9+HE=MO1)-MI)L^9**_2_X\_\
M$L_C[\"?AWKOQ.NM=\%>,/#OA>T2_P#$%KH5UJ46LV=DT\4$EY;VE[IT$%W;
M6IE62Y*W23)$"Z0N%;;G_ +_ ()>_M#?'SP#X=^)VGZEX(\'^$/%=K_:&@/X
MAU.^EUG4=*<D6NJQZ?IFG7L$5E?*/-M1<WL-V8\-+;19&? 7''"3RYYLL^R_
M^SUB7@WB75DE]:5/VOL%3<56=7V7[Q15-MP]Y76IVO)LT6(^J_4:_P!8]G[7
MV?*OX7-R>TYK\G(I>ZWS6YM-]#\X**_0_P#:0_X)H_'S]F[P#J?Q0UG4/!_B
M_P $:!]E;Q'?>'=0NHM2T.WN[E+./4+S3]3L[)9M/%U/:6[26-Q=72S7*;K4
M1*TH\F_9N_8N^+_[5'ASQ]XG^&-YX/AL_AU=6EEK-GXCU+4K+4K^[OM+GU:V
M@T:"PTG4HKEWMX#$!<S6NZYDCC7(+.O51XKX<Q&55,[HYQ@IY51K0P];&JK:
MC1KSG2A"C6NE*E4E*O12C.,7:K"7PR3><\LS"&)C@Y82LL3*#J0H\CYYP2DW
M.-KJ44HRNXMJ\9+=-'R317ZR>#_^".O[3GB7PK:Z_J^N_#[P?JM_:1W=MX7U
MG4-5FU*T$L8=;;6IK#2KFULKM&.V6*UEOECXS)OW(OYK^._AEXX^&WQ#USX5
M^+- O+3QWX?UM= N]"M$.HW%UJ$QC-@-+^Q^=_:,>JQ3VUQIQM@[SQW,2-&D
MXDB2LKXHX>SO$8K"Y5F^"QV(P47/$T\/54G"FI*#JIM*-2E&;495:3G3C*45
M*2<HW6)RW'8.%.IBL+6H0K.U.4XV4I6NHO=QDUJHR2DTG9:.W!T5^LG@C_@C
MK^TWXH\-V6O:]KG@'P1?:C8PWL/AG5[_ %*[UFP::/>+/6CI^FW%C9W<9(6:
M.TN[Y8R2"^]64?#_ ,5?V7?C+\(OC1:? /7_  V-9^(NL2:6/#-AX6F_M6U\
M56^M2O!IU]H\K);S+:2W$-S#/)J4%@UD;2ZFO%@MHC-667\7<,YKBL1@\NSO
M+\7B<+3J5J].E7C:%&BTJM95)<M.I2I73J5*<YPA%J4I*.I5?*LQPU.G5KX.
MO2IU91A"4H/6<_A@XJ\HRE;W8R2;>B5SY[HK]9])_P""/OQ\GM])M_$7Q'^$
M/A;Q7KMM+=:7X/O=>OKC5KB.WA6>ZC18M-S<S6*L!?\ ]G)?6]MR_P!H=,$_
M OQI_9Z^*'P!^)8^%/Q&T>&Q\2W#V)TFYLIVN=%U^SU*Z%G9:EH]^\<)N+*:
MZW0,TL,$T,L<J30QNC**RSBSAO.,3/"99G&"QF)ITYUG2I5'S2HTY<E2K2<X
MQC6IPDFIU*+J1B]V@Q&69AA*<:N)PE:C3DU%2E%64I).,9<K;A)IIJ,[-]$>
M)45^G5I_P27_ &IIO%_A/PO/)X%^P^)]"O/$-UXKL-6U6ZT'PQ9V@M=EGK4L
M^C6DSZM?RW<<.GV6FQ7PE9)YI98;6&2<?%?[0?P1\1_LZ?%OQ-\'_%FI:5J^
MN^&(-%N;K4-%>=].N(==TFUUFS\HW,-O,)$M;N)+A'B 28.JE@ QO+>*.'\W
MQ7U+*\VP>.Q7U:6,='#5?:26&A66'E5DTN6/+5E&+C)J=I1ER\DHR<XC+L=A
M:?ML3A:U&G[14>>I'E7M)0]HHJ^K;A=W2MHU>Z:7C!( ))  &23P !U)/8"O
M4_ ?P.^-'Q1@N;KX<?"GQYXVM+1%DN+O0/#U[<VB1NGF)(MS(L,,\;Q_.LEN
M\R,.C5];_P#!-;]F71OVD_V@4B\9VDEY\/?AOI/_  F'B.Q:WD>R\07R7=O9
MZ)X;N;I2(X([B\N$U&\MWW->Z98WEN@3>94_2?\ ;%_X*?W?[.WQ"D^!'[./
M@;P/.GPY,>C^*=2US3[M/#.G7L4*AO"?AO0=!N]#^RR:*Q\N_NVG-JL^;:VM
M"BFY?YS/>+\SI9]'A;A?)Z6<9Q#!QQ^.JXO%/"9?EV'FTJ:KSC'GJ5:JE"T(
M3AR^UI-.H_:1AWX+*L//!/,LQQ<L)A'6="C"E257$8B:^+V:;Y8QB[WE*,OA
ME?E]UO\ GGU[P]X@\*ZG<Z)XHT/5_#FL6;LESIFMZ?<Z;>0LI*MF&ZCC+H&#
M+YL1DB+*P#D@XD7POXK=5=/"/B]T8!D=/"OB%T=6&59'732KJP(*LI*L"""0
M0:^^_P!LK]N'PG^U]\(/ MMK_P +X?"?QP\(^()QJ'B73&CNM$O_  C)82"X
MMK&^E*:G;K>ZFZ7 T2\%]'8>0\\.H,UY,@_;C]MC]J7XB?LH_L\_"/QI\-]+
M\*:IJVNW7ASP_>0^+;+4KVQCLF\,"[,EO%I>J:5,MQYD**&>9XPA8>7G!KES
M#C3B#+UPU@JW"U*.=\08S,\#+ U\WA1PU&IERP\HUZ6,I87%1K8?%4ZSJ4W*
M%.5/EY9*;]XTP^48&N\QJQS*4L'@:.'K*O#"N52<:_,G"=*56FX5*4H\LDFT
M[IJRT/Y0+[2-9TN)9]6T/7-(@=Q%'/JVBZII<$DK<K$D]_:6\3RL 2L:N7(!
M(4@&H[/3M3U*1X=+TO5-5FB3S)8=*TV^U.>*+<$\V6&PM[B6*(N0@DD14+D(
M&W$"OZ/OV1OV[O"7[<6K:K^SS^TY\+O LVMZUIU]J/A>6"S,_A?7D@MC#J6E
M0V>M7=[JFB^)K:UFEO-,O],U![FYM1>&!K":P$ES\+P:G'_P3!_X*#7VDZ5=
MW>H_"C6+;2HM5L//6^U1?A;XTNI)+&"[FDA@>YU7PGJEE+>VB(8?M:6%I'<W
M+B6=WVPG&N:U<7G&1XSAMX/B?+LLEFV!RU9E#$8+.,+&48VPN84\*N2K*4N2
M,9X9KVGN2E!PJ<DU<HPT:6$QE',%6RW$8B.&K8CZO*G6PE1J_P"]P\JCNDO>
M;51>[[R33BY?E)<VMW93O:WUI=V%U%M\VTO[6XL;N+<H9?-M;J.&XBWJ0R>9
M&NY2&7(.:L'2=86R&IMHNM+I14,-6;1]27261G\M775&M18%&EQ$K"X*M*1&
MI+D+7]%7_!0O]A6__:$^,?P4^*_PJMA=6'Q0U30O!OQ2U?3I/,L[+0DMX[C2
M/&SW4#7;!9=!AET6*XMK1[6":+3KBX9S<LQX?_@JW\:-!^$7PH^'_P"Q5\,D
MM;/3KK0-#O/&5O"+=9=/\&^'9K<^&-)N;=+"* W7B+6;#^W+J^M)[>99M&)F
M@9-2)KEROQ)HYY5X5PF4Y<L5C\]6(JYKA98SV?\ 8&&P,N3&U<1-8>;JR4XU
M%A*<X89XE>R]ZFZ\(FN)X?G@XYE5Q5?V=#!\D<+55+F^O5*RYJ,::]HN1.+B
MZLDZGLVY?$H29_/]7US^R1^QO\1?VP?$7BK1O!6LZ'X6TOP;IUG>Z[XF\0P7
MEWI]O=:I+*FE:5':6#)=2W5^EK?3I(A,4,5E+YHRZ5\C=*_HJ_98AM/V<?\
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MK?\ "'P^&[SQ+;075@;E&U 7J:#:7*2DR@(!.R,4)5.#FOYN/V:O&F@?#?\
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M;\1WNDS:-%/HNBO%=67AOP[IEXMOJ5IMO[2";5M3N[=!?0;[: .ES<RG]%O
M_P 1/%?PF_X).6GQ&\#7L.F^+?"?P0EU/0=0N+5+V*ROOM@MDN?LLA6.5X4G
M=X0YVK*$<JP7:?Y8&&58#J00/Q%?N!<_MG_L_7'_  3(U#X IXLND^+%S\,9
M?!,?A.72;M;HZP-35A.;@!K,:9)'$9DNS/O,3HQ@#'8//XLX(P^7Y;PCE&39
M;B\PPD>,L#C<WE4A/'UL1&O>.,QN9S4+3A.FE"M.4(48P2ARQC9&^5YQ.OB,
MUQ6,Q%*A5>3UJ.%46J$*;IV=&CAHN5U)2;E"*E*;=W=M:<]_P2[\8^.OVA?V
ML[;6_C7X\\5?$C4?A!\,O%OB7X?R^*=22_.B:MXCUC1M UB>W'D1;C>66J7$
MKA@Q2XCAFCV&%0/G_P#X*=?%GXF7O[8'Q"L7\8>*='T_P%;Z-I?A'3=,US5=
M)L-+L[:V745O(+6RNK:*22_OP+^XGG6;SI  I$/[NOFS]E3]H36?V8?C9X6^
M*VF6DFJV%@;C2O%&A).]O_;?AG4XS!J-J'4@&ZM0RZAIHD#0C4;6V:9'C#*?
MV)^*_BS_ ()1?M7^,_#7QQ^)'Q8O/!_BI[73D\3^%;^36=#O/$=CI40AL-'\
M6Z?;:5JRP_9HE\GS-!U.TN+B$A);A^175FF&GPSQ]'/ZF08[,<@K\./+<%#)
M,K^O?V;BXXCZQ6H_4J$4L/'%/VTW6C&$9U,7-2DTZ\HYX:I',,C>!CC:-#&P
MS!8BM]<Q/L/K%%TU3C4]M4;=1TER1Y+MQC2C9:4[^J?MTQI\5/\ @EWX5\;^
M-9YI?%-EX7^%'C2VOKME6]U#Q1<V-II=W=2,%!D;4[;5M0U&6--JR$K(01$N
M.>\/^,?V7O\ @I1^SQ\-_@WXL^)-W\)?BCX+BTE+7PQ8:Q;Z+=IXCTO1?[,F
MO-,T6_>VTWQQH4M@)IH(-KQV%_+%(RQW=M%O^%/^"AO[=7@'X^>"_!OP&^ V
MCZAIWPL\#7EE>SZSJEH=-_M.[\.6,^A^&M+T+3S+-+'H&F:?)/,+N[D9M1%S
M:K]EMVLF:7L- ^&G_!)'QU:>$/'#_'+QE\%M3M;#0KC6/A]/J%]$\>N:6+>:
M_N;EM2\/>*-05;^]B=R+'7%A>([K:"U#K&ORV"X=Q&7<,9;6S+"\3Y1F:X@S
MK.\BJ9)E<LSKY!#$T\-2I83,,#3<W[/&TZ?M(TG3BDHRIU:M%2E"IZ-;'TZ^
M98B&'J9;BL,\!@\)C8XS$_5H8UTI3E*K0KSM[U&4K<U];J48S=I1^9_VP?V7
MOC=^R1XW\!V7BOXBZSXQ\(ZM-?:9\-/&5EKNMVE[;Z7::NE[?>';R)[P76G7
M\<-[;7VHPVDSZ9.]YMM6:&-47]0?^"MVKZQIO[+'[.5QIFLZSI=S<>+O#ZW%
MSI>KZCIMS<*WP\U&1DN+BQN;>:=&D D9)7=6D <@L :^'O\ @IS^VA\/?VG-
M:^'/A/X0F^U#PO\ #*?6]4E\6ZC:26<6MZ[JRV=I'#IEM*[7$VDV=KIEK<I?
MR"WEN9[J>$P*(%=OOAOVK_\ @GE^U9\ /AMX<_:9\2V/AO4_!\>F7=SX'UO4
M/%&G:KI_B31-%?1);VQU#PU!&FHZ=J-M/<_8RTR[UFVR01S0I*>_&SXD^J^&
MO$F>9!F&*Q668S-Y9SA<JRR-3&QIXE<F!JU,OI."ISQ%*'MJR?LZ<*LI<ZI3
MJ1IO&C'+_:<09=@L=0I4L12PGU2IB<0XT7*FXRK1C7DGS1IR?)!^]*4=N91<
MC\V/V./V8_VF/VAOAYX\;PS\9;[X/_ --?&I^.-6U76]2M;3Q/K^FV<#:A?6
MZ64D=_/=:7IRV[7>LWM_#II,#VTTCW$# ?LW_P $[_A1\+_A6_Q+M?AK^UHG
M[2::Y%X;NM:TY-=L-<3PI<V27L4%U"]MJVISV\6HBYGC"R^2LHB1B&=./A7]
MD/\ ;*_91L/A#\5_V5?BGJFH?#KX7:OXA^(2_#_Q%?6NH+!-\/\ Q3>37EM9
MZOJ4#ZE=V/B:SN;F06,<EK=1W%O'";J8LCI)Z%^RS^T!_P $XOV,O%'B;P/\
M-_B;XJ\5VWB[2H-:\1?&+Q'$]YH[3:9+!;Z+X+TY=.T72=\T<=UJ=_<RIH\
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MI-RYI:Q3?V7\-/ G@?PM^P1\8? _A3X[1_M*>$-)\(?$X6'B^XO=-UF.P?\
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MC+XD^)+[QE\0/$VK^,?%FIQ64&H>(==N!=ZI>PZ;:16.GQ7$ZI&'2SLX8K:
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M6#48=+U&8+-';)K'C+Q!=7NL-9:;.$NFT2TMH()TED-O+;W#F4?%'['WQO\
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MJ;A%)-)))ZN[_G'BR8HR>OEIGZ[1FI*0   #@ 8 ] *6OV,^32LDNRL%%%%
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JM]_QY7G
M_7K<?^B7JU56^_X\KS_KUN/_ $2]5#XX_P"*/YH4MGZ/\C^ZWX$_\D0^#?\
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M !K]>L^S_K_AU]Y\L/HIGF1_\]$_[Z7_ !H\R/\ YZ)_WTO^-%GV?]?\.OO
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MTO\ C1YD?_/1/^^E_P :+/L_Z_X=?> ^BF>9'_ST3_OI?\:/,C_YZ)_WTO\
MC19]G_7_  Z^\!]%,\R/_GHG_?2_XT>9'_ST3_OI?\:+/L_Z_P"'7W@/HIGF
M1_\ /1/^^E_QH\R/_GHG_?2_XT6?9_U_PZ^\!]%,\R/_ )Z)_P!]+_C1YD?_
M #T3_OI?\:+/L_Z_X=?> ^BF>9'_ ,]$_P"^E_QH\R/_ )Z)_P!]+_C19]G_
M %_PZ^\!]%,\R/\ YZ)_WTO^-'F1_P#/1/\ OI?\:+/L_P"O^'7W@/HIGF1_
M\]$_[Z7_ !H\R/\ YZ)_WTO^-%GV?]?\.OO ?13/,C_YZ)_WTO\ C1YD?_/1
M/^^E_P :+/L_Z_X=?> ^BF>9'_ST3_OI?\:/,C_YZ)_WTO\ C19]G_7_  Z^
M\!]%,\R/_GHG_?2_XT>9'_ST3_OI?\:+/L_Z_P"'7W@/HIGF1_\ /1/^^E_Q
MH\R/_GHG_?2_XT6?9_U_PZ^\!]%,\R/_ )Z)_P!]+_C1YD?_ #T3_OI?\:+/
ML_Z_X=?> ^BF>9'_ ,]$_P"^E_QH\R/_ )Z)_P!]+_C19]G_ %_PZ^\!]%,\
MR/\ YZ)_WTO^-'F1_P#/1/\ OI?\:+/L_P"O^'7W@/HIGF1_\]$_[Z7_ !H\
MR/\ YZ)_WTO^-%GV?]?\.OO ?13/,C_YZ)_WTO\ C1YD?_/1/^^E_P :+/L_
MZ_X=?> ^BF>9'_ST3_OI?\:/,C_YZ)_WTO\ C19]G_7_  Z^\!]%,\R/_GHG
M_?2_XT>9'_ST3_OI?\:+/L_Z_P"'7W@/HIGF1_\ /1/^^E_QH\R/_GHG_?2_
MXT6?9_U_PZ^\!]%,\R/_ )Z)_P!]+_C1YD?_ #T3_OI?\:+/L_Z_X=?> ^BF
M>9'_ ,]$_P"^E_QH\R/_ )Z)_P!]+_C19]G_ %_PZ^\!]%,\R/\ YZ)_WTO^
M-'F1_P#/1/\ OI?\:+/L_P"O^'7W@/HIGF1_\]$_[Z7_ !H\R/\ YZ)_WTO^
M-%GV?]?\.OO ?13/,C_YZ)_WTO\ C1YD?_/1/^^E_P :+/L_Z_X=?> ^BF>9
M'_ST3_OI?\:/,C_YZ)_WTO\ C19]G_7_  Z^\!]%,\R/_GHG_?2_XT>9'_ST
M3_OI?\:+/L_Z_P"'7W@/HIGF1_\ /1/^^E_QH\R/_GHG_?2_XT6?9_U_PZ^\
M!]%,\R/_ )Z)_P!]+_C1YD?_ #T3_OI?\:+/L_Z_X=?> ^BF>9'_ ,]$_P"^
ME_QH\R/_ )Z)_P!]+_C19]G_ %_PZ^\!]%,\R/\ YZ)_WTO^-'F1_P#/1/\
MOI?\:+/L_P"O^'7W@/HIGF1_\]$_[Z7_ !H\R/\ YZ)_WTO^-%GV?]?\.OO
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MTO\ C1YD?_/1/^^E_P :+/L_Z_X=?> ^BF>9'_ST3_OI?\:/,C_YZ)_WTO\
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M9>(_^A_G?_AUQW_R_P E]P?V=E__ $ X/_PFH?\ R!\A?\,#_L=_]$!\#?\
M?K5/_EE1_P ,#_L=_P#1 ? W_?K5/_EE7U[11_K+Q'_T/\[_ /#KCO\ Y?Y+
M[@_L[+_^@'!_^$U#_P"0/D+_ (8'_8[_ .B ^!O^_6J?_+*C_A@?]CO_ *(#
MX&_[]:I_\LJ^O:*/]9>(_P#H?YW_ .'7'?\ R_R7W!_9V7_] .#_ /":A_\
M('R%_P ,#_L=_P#1 ? W_?K5/_EE1_PP/^QW_P!$!\#?]^M4_P#EE7U[11_K
M+Q'_ -#_ #O_ ,.N._\ E_DON#^SLO\ ^@'!_P#A-0_^0/D+_A@?]CO_ *(#
MX&_[]:I_\LJ/^&!_V._^B ^!O^_6J?\ RRKZ]HH_UEXC_P"A_G?_ (=<=_\
M+_)?<']G9?\ ] .#_P#":A_\@?(7_# _['?_ $0'P-_WZU3_ .65'_# _P"Q
MW_T0'P-_WZU3_P"65?7M%'^LO$?_ $/\[_\ #KCO_E_DON#^SLO_ .@'!_\
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MBC_67B/_ *'^=_\ AUQW_P O\E]P?V=E_P#T X/_ ,)J'_R!\A?\,#_L=_\
M1 ? W_?K5/\ Y94?\,#_ +'?_1 ? W_?K5/_ )95]>T4?ZR\1_\ 0_SO_P .
MN._^7^2^X/[.R_\ Z <'_P"$U#_Y ^0O^&!_V._^B ^!O^_6J?\ RRH_X8'_
M &._^B ^!O\ OUJG_P LJ^O:*/\ 67B/_H?YW_X=<=_\O\E]P?V=E_\ T X/
M_P )J'_R!\A?\,#_ +'?_1 ? W_?K5/_ )94?\,#_L=_]$!\#?\ ?K5/_EE7
MU[11_K+Q'_T/\[_\.N._^7^2^X/[.R__ * <'_X34/\ Y ^0O^&!_P!CO_H@
M/@;_ +]:I_\ +*C_ (8'_8[_ .B ^!O^_6J?_+*OKVBC_67B/_H?YW_X=<=_
M\O\ )?<']G9?_P! .#_\)J'_ ,@?(7_# _['?_1 ? W_ 'ZU3_Y94?\ # _[
M'?\ T0'P-_WZU3_Y95]>T4?ZR\1_]#_._P#PZX[_ .7^2^X/[.R__H!P?_A-
M0_\ D#Y"_P"&!_V._P#H@/@;_OUJG_RRH_X8'_8[_P"B ^!O^_6J?_+*OKVB
MC_67B/\ Z'^=_P#AUQW_ ,O\E]P?V=E__0#@_P#PFH?_ "!\A?\ # _['?\
MT0'P-_WZU3_Y94?\,#_L=_\ 1 ? W_?K5/\ Y95]>T4?ZR\1_P#0_P [_P##
MKCO_ )?Y+[@_L[+_ /H!P?\ X34/_D#Y"_X8'_8[_P"B ^!O^_6J?_+*C_A@
M?]CO_H@/@;_OUJG_ ,LJ^O:*/]9>(_\ H?YW_P"'7'?_ "_R7W!_9V7_ /0#
M@_\ PFH?_('R%_PP/^QW_P!$!\#?]^M4_P#EE1_PP/\ L=_]$!\#?]^M4_\
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MI_\ +*OKVBC_ %EXC_Z'^=_^'7'?_+_)?<']G9?_ - .#_\ ":A_\@?(7_#
M_P"QW_T0'P-_WZU3_P"65'_# _['?_1 ? W_ 'ZU3_Y95]>T4?ZR\1_]#_._
M_#KCO_E_DON#^SLO_P"@'!_^$U#_ .0/D+_A@?\ 8[_Z(#X&_P"_6J?_ "RH
M_P"&!_V._P#H@/@;_OUJG_RRKZ]HH_UEXC_Z'^=_^'7'?_+_ "7W!_9V7_\
M0#@__":A_P#('R%_PP/^QW_T0'P-_P!^M4_^65'_  P/^QW_ -$!\#?]^M4_
M^65?7M%'^LO$?_0_SO\ \.N._P#E_DON#^SLO_Z <'_X34/_ ) ^0O\ A@?]
MCO\ Z(#X&_[]:I_\LJ/^&!_V._\ H@/@;_OUJG_RRKZ]HH_UEXC_ .A_G?\
MX=<=_P#+_)?<']G9?_T X/\ \)J'_P @?(7_  P/^QW_ -$!\#?]^M4_^65'
M_# _['?_ $0'P-_WZU3_ .65?7M%'^LO$?\ T/\ ._\ PZX[_P"7^2^X/[.R
M_P#Z <'_ .$U#_Y ^0O^&!_V._\ H@/@;_OUJG_RRH_X8'_8[_Z(#X&_[]:I
M_P#+*OKVBC_67B/_ *'^=_\ AUQW_P O\E]P?V=E_P#T X/_ ,)J'_R!\A?\
M,#_L=_\ 1 ? W_?K5/\ Y94?\,#_ +'?_1 ? W_?K5/_ )95]>T4?ZR\1_\
M0_SO_P .N._^7^2^X/[.R_\ Z <'_P"$U#_Y ^0O^&!_V._^B ^!O^_6J?\
MRRH_X8'_ &._^B ^!O\ OUJG_P LJ^O:*/\ 67B/_H?YW_X=<=_\O\E]P?V=
ME_\ T X/_P )J'_R!\A?\,#_ +'?_1 ? W_?K5/_ )94?\,#_L=_]$!\#?\
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M?_+*OKVBC_67B/\ Z'^=_P#AUQW_ ,O\E]P?V=E__0#@_P#PFH?_ "!\A?\
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M]$!\#?\ ?K5/_EE7U[11_K+Q'_T/\[_\.N._^7^2^X/[.R__ * <'_X34/\
MY ^0O^&!_P!CO_H@/@;_ +]:I_\ +*C_ (8'_8[_ .B ^!O^_6J?_+*OKVBC
M_67B/_H?YW_X=<=_\O\ )?<']G9?_P! .#_\)J'_ ,@?(7_# _['?_1 ? W_
M 'ZU3_Y94?\ # _['?\ T0'P-_WZU3_Y95]>T4?ZR\1_]#_._P#PZX[_ .7^
M2^X/[.R__H!P?_A-0_\ D#Y"_P"&!_V._P#H@/@;_OUJG_RRH_X8'_8[_P"B
M ^!O^_6J?_+*OKVBC_67B/\ Z'^=_P#AUQW_ ,O\E]P?V=E__0#@_P#PFH?_
M "!\A?\ # _['?\ T0'P-_WZU3_Y94?\,#_L=_\ 1 ? W_?K5/\ Y95]>T4?
MZR\1_P#0_P [_P##KCO_ )?Y+[@_L[+_ /H!P?\ X34/_D#Y"_X8'_8[_P"B
M ^!O^_6J?_+*C_A@?]CO_H@/@;_OUJG_ ,LJ^O:*/]9>(_\ H?YW_P"'7'?_
M "_R7W!_9V7_ /0#@_\ PFH?_('R%_PP/^QW_P!$!\#?]^M4_P#EE1_PP/\
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M1_K+Q'_T/\[_ /#KCO\ Y?Y+[@_L[+_^@'!_^$U#_P"0/D+_ (8'_8[_ .B
M^!O^_6J?_+*C_A@?]CO_ *(#X&_[]:I_\LJ^O:*/]9>(_P#H?YW_ .'7'?\
MR_R7W!_9V7_] .#_ /":A_\ ('R%_P ,#_L=_P#1 ? W_?K5/_EE1_PP/^QW
M_P!$!\#?]^M4_P#EE7U[11_K+Q'_ -#_ #O_ ,.N._\ E_DON#^SLO\ ^@'!
M_P#A-0_^0/D+_A@?]CO_ *(#X&_[]:I_\LJ/^&!_V._^B ^!O^_6J?\ RRKZ
M]HH_UEXC_P"A_G?_ (=<=_\ +_)?<']G9?\ ] .#_P#":A_\@?(7_# _['?_
M $0'P-_WZU3_ .65'_# _P"QW_T0'P-_WZU3_P"65?7M%'^LO$?_ $/\[_\
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M -$!\#?]^M4_^65'_# _['?_ $0'P-_WZU3_ .65?7M%'^LO$?\ T/\ ._\
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MC3IMKLW"*;"BBBO/-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8@  =22<  =R:4$$9!R#R".A'K0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>M&T_P"/2U_Z]X?_ $6M %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEY_;M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8WB+_D ZQ_V#KO\ ]$O6C:?\>EK_
M ->\/_HM:SO$7_(!UC_L'7?_ *)>M&T_X]+7_KWA_P#1:T 6**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_$C5KZ]^*'CYHK]@T/B#2=6\ W%Q%!&CVH3)< \@_:)_X.O_ -HO]I[QO>?
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M+/6-=@F@T;2YYM-BNXM-TBSM(;::24H[;@1^N  4!5 "@      #   X  X
M' %+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &-XB_Y .L?]@Z[_ /1+UHVG
M_'I:_P#7O#_Z+6L[Q%_R =8_[!UW_P"B7K1M/^/2U_Z]X?\ T6M %BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **_*?]N/_@M9_P $XO\ @GU97L/QY_:&
M\-WOCFUA$T'PD^&4MM\0OB=>XU)])FC'A_1KO[+I<MG>Q2K?1:_JFD26L44D
MTB;%!/\ +-\3/^#DO_@JQ_P4?\4ZA\(_^"./[$WB;PMI3K<!_BKJ_AFV^)GC
M6.+2KLP:I<'4]<M;/X0>$K.>QU'2;F2QU*VUCQ%ITDGF6NH84E@#^X+X\_M*
M_L__ ++O@B\^)'[1/QC^'7P8\#V4L=O+XC^(GBO1_"^GRWD\<LEKIUD^J75N
M]_J=Z()4L=-LDN+V]E7R;6"65E0_R7_MC_\ !X1\"=(UT?"?_@G%\!/'G[67
MQ*UB[L='T'QAXAT?7?!W@2ZU353=:?#:>'_"ZZ?/\1O%&KVNJMIXMK1_#^CZ
M3JR3JEIJLI?*?/'P(_X-1OVL_P!K3QS:_'/_ (+'_MO>.O'/BBXWI??#_P $
M>,M1^(OBN2WT^_ADTG3K[XJ>,!>:3IOA^>P>\MY=$\+>&H)M)62.#2=7@2-)
M5_K-_8Q_X)@?L)?L :%%I'[+'[.G@+X>ZE]EDL[_ ,=SZ?\ \)+\3M;MI)Q<
MM!KGQ'\1MJ7B_4[=)QO@M+C5C9VN2MK;PHQ4@'\:>E_\$ZO^#D+_ (+;W^G>
M)/VZOC3J7[&/[.&J3V&K_P#"O-6^V_#[S+$R#0-:T[1?@-X4NW\7QZQ-H4MY
M>QQ?%B]TO1=0=U=KQIY"@_?[]@C_ (-B_P#@F7^Q+_8'BKQ%X!N?VI/C%H[Z
M=?'XB?'&"TU+1+36])U.\O['5O"WPUMS+X9T!UBGMK6YAOY?$7VH644LDPWF
M-?Z)Z* ,[2-'TGP_IEEHN@Z7IVB:-IMNEIIVDZ18VVFZ9I]K&,1VUE86<4-K
M:V\8X2&"*.-!]U16C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8WB+_D ZQ_V#KO_P!$O6C:?\>EK_U[P_\ HM:SO$7_ " =8_[!UW_Z)>M&
MT_X]+7_KWA_]%K0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBOC7]K?_@H-^QK^POX3F\7_
M +4G[0'P]^%=L8[\:9H>KZW;7'B_Q%?6&FR:JVC^'?"=B]QKFJZM<V:!K2UA
MLP)FDBS(BN' !]E5S'C/QMX-^'/AG5_&OQ!\6>&_ W@[P_:/?Z]XK\7ZYIGA
MOPYHMC'CS+S5=;UBYL]-T^V3(#3W5S%&"0"V2*_B2_:8_P"#M7XE_'7QK<_
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M=XB_Y .L?]@Z[_\ 1+UHVG_'I:_]>\/_ *+6@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHKC_ ![\0O 7PK\*:MX[^)OC3PK\/?!6@PI/
MK7BWQKK^E>&/#FE12RI!"U_K.LW5EI]J9YY([>W66X5Y[B6."%7FD1& .PK)
MUS7M#\,Z7=ZYXDUG2?#^BV$9FO\ 5]<U&STG2[*$=9;O4+^:WM+:,=Y)ID4=
MS7\D'[?7_!VY^RY\*-6O?@O_ ,$^/A]XB_;6^.^L.OAWPIXCTW3-;TSX0Q^+
M=7M9+?18-(M(+0?$'XGWUGKKV]E>>&]!T7PY!J[$1:)XKN5F2<?ESH7_  34
M_P"#@/\ X+UZM9?$+_@H'\:M3_8]_9:UB5=0T?X6:A87OAZ";1+OR]=TH:!^
MSWX>U&PEU>*WN9#9VVM_&OQ,/%^B3IF.VO+1$0@'[/?\%"O^#KC]A']EEM4^
M'O[+@N?VT_CF)GTNPT_X>7$\'PJTO59[&[:RDU/Q[':W$?B(0:Q%;Z7J.B>$
M8;W4T>9V2>,1@O\ B_!\!_\ @XJ_X.&)8?$'QE\67'[#W[$7BN1?$GAKP]>P
M:MX#\(:GX9OV;Q-X.?3/!.F36OC_ .+(CMKB&QT[Q?XDE2U!57NYX8V2(?U*
M?\$\O^"!'_!.'_@G+'IOB+X;?"&W^*?QDM+>..?XX?&Y-/\ '?C6*YCO;;4H
MKKPQIMS8P^$/ US9WULAT_5/"GA[3?$<-H39W>O7\32%_P!J: /Y[O\ @G;_
M ,&U/_!.']@>30O&FH>!7_:8^.>C7-KJ<'Q8^-UE8:U'H^KV&I'4].U'P;X%
M5)/"WA:\TZ0K;PZE!;76K7%O$@O;Z9RQK^@NVMK>SMX;2T@AM;6VBC@M[:VB
M2"WMX(E"10PPQ*L<44:*$CCC5410%4  "IJ* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OCMI?A#7/@C\8
M=%^(.JRZ#X"U?X7>/M,\:ZY!GS]'\)WWA75;;Q%JD.U7;S=/TB6[NX\(Q+Q#
M"D\5^)G[(?\ P4!^(OPK_9W^&?PW\)_\$^_VPOC+X#\$:(/#7PY^+WPJ^&>G
MP^#OBA\/=)GEM/"/CJVM=7U#1[NTU+Q%H\=O?ZS +:6W.J274]M=W$4RN/W3
M^)/AJR\9?#OQYX0U+P_%XLT[Q3X-\3^';_PM/J<FBP>)+/6M%O=-N=!FUB)6
METF+5X;E[!]2C5I+%;@W2 M$!7XZ_ 'Q?_P5"^ 7PM\-_!VR_8X\#>,/#'P^
MAE\->!-4U?XR:7:Z]!X%TZ1H/"^E>();#3[>QU+5M)TM8+"?5;6TM$OT@CGE
M@$[2NX!^F?[,GQX\1_M"^ M3\:>)_@%\8_V=;_3_ !1J'AV+P3\;M$L=!\5Z
MA:V-CIMY'XDLK.POM0ADT.^DU"6RM+AIED>ZTZ]1HU6-2WT97S[^S?XV^//C
MSP/J.K_M#?"71?@WXT@\2W^GZ?X8T+Q5'XNM+SPY#9:;-9:U)J4<<2Q3W5Y/
MJ%L]GM)C2S23/[W ^@J "BBB@ HHHH **** "BBB@ HHHH QO$7_ " =8_[!
MUW_Z)>M&T_X]+7_KWA_]%K6=XB_Y .L?]@Z[_P#1+UHVG_'I:_\ 7O#_ .BU
MH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6=*\6?$30+;7[=IM2TO2-,>&X^$7P7CM]2T[26OM \->&O$-GJ$;>>/LES;
MR 'U7^VU_P '=G@.7Q,/@5_P2O\ @-XM_:J^+.OWC>'-&^(/B'PUXCL/!XUC
M4H+O3;!_!?@6QM&\;^-]3LM>:P>&&_L-#\/ZI:2"2VU*[C?;7Q_X$_X(<_\
M!:O_ (++>*]+^-/_  5N_:8\3?L]_"/4Y7U73/@P72X\8:=I&K1OJT.F^&O@
MSI-S%X/^'L>GZY9:='<V/C^XC\1:<&^UVVFW<D8S_8M^Q%_P3!_8<_X)W^&V
MT+]E3X!^$/ &J7=D+#7?B!=02>)/B=XF@,L-S)#K_P 0=??4/$][8O>PK>QZ
M.NH0Z+97!SI^G6L:I&OWW0!^6'[ _P#P1D_X)\_\$Y-*LS^S[\#M#N/B!"A%
M]\9/B%%:^-/BIJ$AO(M00IXFU*T']CP6=Y$LFFP:':Z=]AC'E)+)EW?]3Z**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO%/C?\ M(?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI_QZ6O\ U[P_^BUK.\1?\@'6/^P==_\ HEZT;3_CTM?^O>'_ -%K0!8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **J7]_8:7:3Z
MAJ=[::=86J>9<WM_<PVEI;QY"[Y[FX>.&%-S!=TCJN2!G)%?B7^VA_P</_\
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MJ_I]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@[P[X@EU"T\W5K3Q=XSU>_UKXBZQ>'59&E_M?0]=\,2744*>;"OF,H_M>HH
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MBM=KIC:A]G%\ULK7 M3*809 HK\IBW_!<+<V(O\ @G0%WOL!?XZ%@FX[ Q
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M7ZV_\%C%.L_!W]FCP1I9%YXN\4?MM_LXW7AWP_;;9M7U>V\,^*)]8\03Z;9
MB6ZCTC2U-YJ+1@K;6A,TA"@&OM/XF?L;? #XI_LXVW[*VM^#DTKX1:1HFC:-
MX3TSPU<R:1J?@E_#30S>&]8\*ZFBRR:=K&AW=O#>6=R\=Q#),C)>VUU;3302
M>4_"[_@GI\,_ 'Q7\&?&?Q?\4OCS\>_&WPTT-]#^&4OQR\>67BS2_A\)[/\
MLV\UKPUI6F>'O#]K#XEO], TV_\ $%ZM[J=Y: )/.[_/0!]]4444 8WB+_D
MZQ_V#KO_ -$O6C:?\>EK_P!>\/\ Z+6L[Q%_R =8_P"P==_^B7K1M/\ CTM?
M^O>'_P!%K0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(-0AM+K3QXVDT7,/AZZOK"]M]1M=/N)'U"73Y!="U$;*6\B_:$_X.8?^"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\%_M%_L,C]H+XB-\0S^TI^T-\*Q_8.FZ(WA;X:^-/[#\,+_9DEW(=36Q,
M+[+Z[%UMNY=V)!!&>,&OQD\?ZK^PC\.O'$W@'5?^"G/[9FN:K9:B-)U?5?!&
MN>+/&_A/0M05VCNK;7/%GAK0-1T+2WT]U9-1^TWJ"Q966X*,I _HS^/^B^+/
M$OP)^-'AWP$]Q'XYU[X4_$+1O!KVEP+2Z7Q3JGA+5[+0&MKIGC6VG&JSVIBN
M#(@ADVR%U"Y'Y"_L)?ML_P#!/3X-?LE^"OA/\0/'OPV^#'Q"\#^#[3PW^T#\
M/?'WA]_#?BIO'NF6K:9XNOO&>G7&C>?XCN=9O8KJ[.IW@O;C4[.Z2694\TPJ
M ?HK^Q#X+^'WA#X)PW/PO_:"\5?M+>"O&'B+4_%6C_$GQ9XNM_&ETZW%O8:7
M/HUAJUL L5AIT^E2-]@D5)[6]N+P3(KN0/L&OR,_X)8MX;US5_VP_B)\$-$_
MX1G]DKX@?'J/5?@-I(T.X\/66IWECX2T;3?B)XU\,Z;<PPF/P7XMUVWMKSPU
M+ ([:2T@=8K6T,3P)^N= !1110 4444 %%%% !1110 4444 8WB+_D ZQ_V#
MKO\ ]$O6C:?\>EK_ ->\/_HM:SO$7_(!UC_L'7?_ *)>M&T_X]+7_KWA_P#1
M:T 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2>)M.8W,J7MW;6O@J. RAX8I-C^;7]Q@ 4!5 55 "J    ,  #@ #@ < 4M
M'Y7?LF_\$4?^"8_[%UOI<WP7_9/^&\GBO3M"30+GXA_$'35^(WCC6K5)TN6N
MM5U3Q6-0L1J4DT4327FEZ7ICD1*%507W_J;%%%;Q10011PP0QI%##$BQQ111
MJ$CBBC0*D<<:*$1$ 55 50  *DHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEYK2?VCJ'C.:XMM2MHC$8H(].MK=RK)+)*HA&X2@[PML]_G]_;R_X<_06/\
M:5\ /]^#7(O]ZQ5L?]\3-6A%^T5\-7'SWFJ1>S:5=,?_ !Q6_P @^V?CW_AV
MI9?]'3_M(_\ A1>'O_E#1_P[4L_^CI_VD?\ PHO#W_RAH%[O][[U_EZ_T]/L
MG_AH7X7]]7OA]='U#C\H33Q^T)\+3UUN[7ZZ/J?_ ++;&OC^'_@G'!!]S]J'
M]H-_^NVJ>%YNV.=_A\Y_QYK5A_X)]M!C9^TO\;GQ_P ]AX*FS]=_ALY_'/KU
MH#W?[WWK_+U_K;ZM'[07PJ/_ #,$X^NCZO\ _(1J4?'WX6'_ )F-A]=+U0?S
MM :^8HOV$KJ'[G[1WQ9;_KKI/P^E/0#DOX7)/^3UYJT/V';X?\W$_$\_70/A
MR?\ W5: ]W^]^'_ /II?CM\+VZ>)4'^]8Z@O\[45*GQP^&#]/%%N/]^VO$_5
MK<#OZU\R#]B+4%Z?M#_$H_[WAKX:M_/PI4B_L3ZBO_-POQ%/U\+?#,_^ZG0'
MN_WOP/J./XQ?#67&/%FFKGIYC21_^AQC'XXJ\GQ2^'<GW?&.@CG'SW\4?_H9
M6OE9/V*[M?O?'KX@/]?#'PW7/K]WPJ*L+^QA(/O?'#QZX]#X<^'HS_WSX9%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM-:\(^';S6?%=XT32&9KJ+XC6IN)QYLL'11_6\JJJJJJ%50%55 "JH& J@8
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M^S/\''L[OPC\+]%GUG3[A[FS\1>)0_B7Q!;2.,8AU/5C<311H,^7'$$5,X4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]9/(L5FN894Q\^Z34GW02D\!X(N!WXY]4T3X"_#+12S?V%_:LC%"'UF>2_\
M*9#G="C;$CW'!("G@ =,Y!>ZNK?RM?YWO^'^9Y9?_M,7VJ-<VG@CP3?:C<*N
M8+FY%Q>%%W >9<:9IT+3!3T.+Q0I/+<8-,R_M*>-W*+%'X4T^\@;YB+73H%C
M*CY1)_IFL02/GY67#@YR1CCZULM,TW3E":?86=DH01@6MM#!\BXPA,:*2H(!
MP2>1GK5Z@=TMHKYW?_ /D:Q_9KU?5I;:[\;^.+W4'4 7%O ;B]G"@8"0ZGJ,
MSLN.!EK-AC/':O4M#^ 7PTT7R7;1I=7N8)!(EUJUW-.Y93D;X8#;6DBYZJ]N
MRL.&!'%>ST4"YGW?RT_(S[#2=*TJ-HM+TS3]-B8Y:.PL[:SC8^K);QQJ3[D&
MM"BB@0445%)/!"T:2S11/,VR%9)$1I7X^2-6(+MR/E4$\CCF@"6BF2RQ0QM+
M-)'%$@R\DKK'&@R!EG<A5&2!DD<D"OE[XJ?MH_LT_!U;B/Q?\4M EU2TN_L5
MSX?\-S'Q/X@M[C8[XN=)T7[7<VD0V;&N+I8;='95>1<D@ ^I**_%#Q=_P5A\
M1^,M2A\+_LV? KQ!XLUB^^V6EO>Z^D]S/)<8"VESI.C>'TOS=[01+):ZE=63
MX9%*_>!XL_!__@I]^U5%]H^(7C0?!CP=J]B$DT6YN'\*0,+6:0+'>^$=#:X\
M3VE]+N8_:;FYBCG18G8*I4T ?KA\3/VF/@+\'DE_X6)\4_"7A^Y@N&M)M,.H
MKJ>LPW2IO\BXT?2$O]3M'8$!3=6L$9)P7'./SH\?_P#!77P9+??\(Y\"_A3X
MP^(NOWBWEI82ZM$=+#WZ&5+6>PT'2DUG5M=LG"I<^7%+IMS+"Q3;"P+#H?AO
M_P $C/@QHTZZQ\5O&7C'XH:[-]BN;G==G0[ 7D:QM=P3S0O<ZEK-C+*'1#J-
MPD[0$>9AB0/T7^'_ ,$?A%\*K1+'X=_#GPEX1MXYVN8_[(T:TAG2=P5:5+MT
MDNU8@D<3@8)P.3D _&_[1_P5/_:IA>.-(_@AX+UJQ20.!_P@5HR02*P$%R%U
MCXC6=Y,R\1L;>%R,2.B<CU7P!_P2-\+3ZB_B/X\?%CQ9\1-;N6M;JXMM'8Z7
M%-<[FDO8-6UG59-9U36H)B502QC2KC(=]^6 '[&T4 >#?"_]F#X!?!N*)?AW
M\+/"FB74%PUW#JTU@-9UV&X=!&\EOKNMOJ.K6H=1S#:WD, ).V)<XKWFBB@
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M3%EIITZ6ZEU0"X75FOSJ@N$7]T+=;4K\Q>OH>@ HHHH **** "BBB@ HHHH
M**** ,;Q%_R =8_[!UW_ .B7K1M/^/2U_P"O>'_T6M9WB+_D ZQ_V#KO_P!$
MO6C:?\>EK_U[P_\ HM: +%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>?\ Q6^*7@/X
M(_#3QY\7_BAXAL_"?P[^&?A/7O''C7Q)?^8UKHOAKPUIMQJVL:A)'"DEQ/\
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MA@H+\5<D_P""</[8'Q UR;5_BW^U:6&H1(+Z7P_KWC6XNFW %X'TE8=!T(A
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M1/.8T56GEWRL!\SGFNOHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#]?Z*** ,;Q%_P @'6/^P==_^B7K1M/^/2U_Z]X?_1:UG>(O^0#K'_8.N_\
MT2]:-I_QZ6O_ %[P_P#HM: +%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45R7C7Q_X$^&NA7'BGXC>-?"7@#PS:$"[
M\1>-?$FC>%="M259P+C5]=O;#3X241V DN%.U6;HI(_*[]H3_@O;_P $COV9
M]1CT7XB?MM?"?6=<N=(EUFRTOX43ZS\:!>6\;,BV_P#;7PKTKQ;X9T^_G=2D
M-GK&N:;*WWF"1@N #]?J*_C$_: _X/2_V*?"NEW5G^S1^S=\>OC?XUCUN#3[
M*W\<OX9^$O@S5-.:0QRZA8:Y8:C\0_%#W$C%%LM/N/!%I)<,P#RPY%?)Z?\
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MXTTR>U_L+7O'.J7.I^&CI\MSY;ZAKO@_X=Z9=>)[5;A%D2QA_MVT+W"[))0
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MFO+MSG&V*&)<.1U.& 'K7F^J_M1>";78NE:9K6KNV,H\<6F$$G&T"Y+LQ''
M49/ SWZ72/V=OAEIGF?:-.OM;W@;1J^H2R+%CJ8A9+8D9[[RXYXQ7HNG> ?!
M6DQ)#8>%M#B2,J4+Z=;W,BE>%(FNDFFR.Q\S.>>M >[YO[E_F?G=X_\ B!X@
M\9^)+O5;N?4]-MDF5M)TB2>:'^R[4 &W_=KY2_:'4"26=4"SN?,7@Y/JWA&Q
M^.OQ(T/3Y[#Q;<6/AZW>XTQ+Z74'M+NX6(J99+E((Q<:G&/,\N*>24Y"-$I
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MA@<G[Q8MT&< 8[555%"JH55 "JH"JH'0 #  '8 8I:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&\1?\ (!UC
M_L'7?_HEZT;3_CTM?^O>'_T6M9WB+_D ZQ_V#KO_ -$O6C:?\>EK_P!>\/\
MZ+6@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%>5>*?CM\$/ UX=.\;?&3X5>#]0 8FQ\4_$/PCX?O $^^3:ZMK%I.
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M-_2?A59#67M1\1?#/PAURYU4^2V'TY-,_:"\6W^ARH!C?J$7APH22ZR*A"@
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M?:K?4;IE/<(\NHXXZ!BHX[#.* LOYE]S?]?U\OS4'P?_ ."L4*[]3^.SZ0F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M76IV=JEU822KCR;MY)+>.0#SHBAW+YK^S%_P2W\5:SXWFU#]HA_"Y\!:997
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3*R@J8[2^@T^!@/O'>QW ]ADUB0?&G_@K#XB_P!%?PWX6\'+*!F;Q%X9\/\
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MX$K^W;/U%X9\9?LW>!(&M_!'P&\&Z'$5VA([+PP 1U RRW#*/H^?PKHA\?\
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MJU&3M&K2;[*I%O\ !EJBD#*W*L&'J"#_ "I:DU"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI=>BJ9_A1K-I^93XG3X ]LUZ#H'[?W[.>LF/9^WOXZ\,[B/^1JT/Q[I/E_\
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M:TVLS])KFY_X*=VV<3BYQ_SZZ3\.WS]/,LHC^8'K61_PDO\ P4]ADP='UFX
MZXT'X9^6>>Q62-CD>PQQWK\GHO\ @@Y_P4FT:^>?P[^WKX=BC!'E3WOQ%_:
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MC5D]MY5,9)M^K>WI?P&/XP_\$6;9&DE_;B2^**6$?GZLTDA ^XB0?#N,LS=
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MLWXCIQO_ *I8JL^L:.;9,WTT3KXS#Q[ZW6OD>U1?\%DO^"9,D:N?VO/AS$6
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M%GBX)K_G0Q:I:Z;9S:BGAY+B-989]>FA(2SC=&#&.+[3<QCF6W0%2W\7</\
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M+&[GT_\ X2'P1XBTKQ-HXOK98VN+)M0TBZN[9;J!98VEMVD$L8="R ,,]?\
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M_P!&COK2!9(VEF174D ^NJ*** ,;Q%_R =8_[!UW_P"B7K1M/^/2U_Z]X?\
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M]?\ 9(X1)^B2\A87*<LP,90P6 P>"A-6G'"86AAHS6GQ*A3IJ6RWW>KU2/\
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MX_L13SG\*LK_ ,'.'PES^]_9,^*40[G_ (3_ ,)MC_RE+V_7CWK]O7_X)_\
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M(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\ B: .6_X3[P;_ -#%IW_?QO\
MXBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\ OTG_ ,31]GM_^>$/_?I/_B:
M.6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%IW_?QO\ XBNI^SV__/"'_OTG
M_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW_?QO_B*/^$^\&_\ 0Q:=_P!_
M&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\ WZ3_ .)H Y;_ (3[P;_T,6G?
M]_&_^(H_X3[P;_T,6G?]_&_^(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\
MB: .6_X3[P;_ -#%IW_?QO\ XBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\
MOTG_ ,31]GM_^>$/_?I/_B: .6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%
MIW_?QO\ XBNI^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW
M_?QO_B*/^$^\&_\ 0Q:=_P!_&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\
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M(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\ B: .6_X3[P;_ -#%IW_?QO\
MXBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\ OTG_ ,31]GM_^>$/_?I/_B:
M.6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%IW_?QO\ XBNI^SV__/"'_OTG
M_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW_?QO_B*/^$^\&_\ 0Q:=_P!_
M&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\ WZ3_ .)H Y;_ (3[P;_T,6G?
M]_&_^(H_X3[P;_T,6G?]_&_^(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\
MB: .6_X3[P;_ -#%IW_?QO\ XBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\
MOTG_ ,31]GM_^>$/_?I/_B: .6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%
MIW_?QO\ XBNI^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW
M_?QO_B*/^$^\&_\ 0Q:=_P!_&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\
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M(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\ B: .6_X3[P;_ -#%IW_?QO\
MXBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\ OTG_ ,31]GM_^>$/_?I/_B:
M.6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%IW_?QO\ XBNI^SV__/"'_OTG
M_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW_?QO_B*/^$^\&_\ 0Q:=_P!_
M&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\ WZ3_ .)H Y;_ (3[P;_T,6G?
M]_&_^(H_X3[P;_T,6G?]_&_^(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\
MB: .6_X3[P;_ -#%IW_?QO\ XBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\
MOTG_ ,31]GM_^>$/_?I/_B: .6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%
MIW_?QO\ XBNI^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW
M_?QO_B*/^$^\&_\ 0Q:=_P!_&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\
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M(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\ B: .6_X3[P;_ -#%IW_?QO\
MXBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\ OTG_ ,31]GM_^>$/_?I/_B:
M.6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%IW_?QO\ XBNI^SV__/"'_OTG
M_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW_?QO_B*/^$^\&_\ 0Q:=_P!_
M&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\ WZ3_ .)H Y;_ (3[P;_T,6G?
M]_&_^(H_X3[P;_T,6G?]_&_^(KJ?L]O_ ,\(?^_2?_$T?9[?_GA#_P!^D_\
MB: .6_X3[P;_ -#%IW_?QO\ XBC_ (3[P;_T,6G?]_&_^(KJ?L]O_P \(?\
MOTG_ ,31]GM_^>$/_?I/_B: .6_X3[P;_P!#%IW_ '\;_P"(H_X3[P;_ -#%
MIW_?QO\ XBNI^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XF@#EO^$^\&_]#%IW
M_?QO_B*/^$^\&_\ 0Q:=_P!_&_\ B*ZG[/;_ //"'_OTG_Q-'V>W_P">$/\
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M#_WZ3_XFC[/;CI!#_P!^D_\ B: )J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MKC?&GQ%\ ?#?3XM6^(7C?PEX&TRXD>*WO_%WB+2?#MI<S1JK20VT^K7=I'<2
MHKJSQ0L[JK!BH!!JWX2\:^#O'NDQZ_X&\5^'/&.ARN8X]7\+ZWINO::TJA6:
M'[;I=S=6XF0,OF0F021Y =%/% '3T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%<IXI\>>!_ \=I-XU\9>%/!\-^\D5C+XI\1:1X?CO9(@K2QVDF
MK7EHMR\2NC2)"79 RE@ PSSNE_&SX-:WJ-EH^B_%OX8ZOJVI7,=GIVEZ7X]\
M*W^HZA=S';#:V5E::K+<W5S*>(X((I)9#PJDT >FT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%8.M^*O"_AJ32X?$?B30?#\NN7T>EZ+%K>L:?I
M4FKZG,R)%IVEI?W$#:A?2O)&L=I:":X=I$58R64'>H **YM/&?@^7Q+-X,C\
M5^&I/&%O;"]G\*)KNEOXE@LS'',+N;0ENCJD=L8IH91.]JL1CEC</M=2>DH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **\^\:_%GX6_#9K9/B'\2/ G
M@:2\4/9P^+O%FA>'9[M"YC#VL&K7]I-<IY@9"\*.H96!(VG'3>'?$OASQ?I%
MKK_A37]%\3:%?!FLM9\/ZI9:QI5V$8I)]GU#3Y[BUF\MU9)!'*Q1U9& 8$
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MPSXAMK"73O$EV+?4+1]+L["0_P!I%Y%2:)HFS^A'BCPA\.O^"I/PJ^"?Q:\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1VLWF;7  /VRHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BOFSXI?M,>&_ 'B^#X9^&?"GC#XM?%.6S
MM-2NO WP^TZ&_NO#^E:@SQZ?JWB[5KRXM-'\,Z?>R*!;-J-VEU<1$3P6LD)5
MVXW_ (7?^T^W*?L>:[L/*;_BS\-4?:>5WH=6)1L8W*22IR.U 'V+17QU_P +
MN_:A_P"C/-;_ /#M_#7_ .6U'_"[OVH?^C/-;_\ #M_#7_Y;4 ?8M%?'7_"[
MOVH?^C/-;_\ #M_#7_Y;4?\ "[OVH?\ HSS6_P#P[?PU_P#EM0!]BT5\=?\
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MV+17QU_PN[]J'_HSS6__  [?PU_^6U'_  N[]J'_ *,\UO\ \.W\-?\ Y;4
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M6U 'V+17QU_PN[]J'_HSS6__  [?PU_^6U'_  N[]J'_ *,\UO\ \.W\-?\
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M_#7_ .6U 'V+17QU_P +N_:A_P"C/-;_ /#M_#7_ .6U'_"[OVH?^C/-;_\
M#M_#7_Y;4 ?8M%?'7_"[OVH?^C/-;_\ #M_#7_Y;4?\ "[OVH?\ HSS6_P#P
M[?PU_P#EM0!]BT5\=?\ "[OVH?\ HSS6_P#P[?PU_P#EM1_PN[]J'_HSS6__
M  [?PU_^6U 'V+17QU_PN[]J'_HSS6__  [?PU_^6U'_  N[]J'_ *,\UO\
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M?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\
M1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_
M]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM
M_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:
MW_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#A
MV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=
MOX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK
M_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:_
M_+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+
M:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@
M#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[
M%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%H
MKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKX
MZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_
MX7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7
M=^U#_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^
MU#_T9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#
M_P!&>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T
M9YK?_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&
M>:W_ .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?
M_AV_AK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_
M .';^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_
MAK_\MJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';
M^&O_ ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\
MMJ/^%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_
M ,MJ/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^
M%W?M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ
M/^%W?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M
M0_\ 1GFM_P#AV_AK_P#+:@#[%HKXZ_X7=^U#_P!&>:W_ .';^&O_ ,MJ/^%W
M?M0_]&>:W_X=OX:__+:@#[%HKXZ_X7=^U#_T9YK?_AV_AK_\MJ/^%W?M0_\
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MHHH **** "BBB@ HHHH **** "BBL?7_ !%X?\*:1=Z_XIUW1_#6@Z?Y!O\
M6]?U.RT;2+(75S#96QN]2U&>VL[;[1>7%O:0>=,GFW,\,$>Z65$8 V**9')'
M+&DL3I+%*BR1R1LKQR1NH9'1U)5T=2&5E)5E(()!I] !1110 4444 %%%8%U
MXK\+6/B+2O"%[XET"S\6:[9WVHZ'X7NM9TZW\1:SI^EA#J=]I6BS7*:EJ-GI
MPDC-]=6EM-!:!T-P\>Y<@&_1110 4444 %%%% !1110 4444 %%%% !1110
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M++;V%E&[7-Y.RPV\4DA"T ;E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!XK^T1\-=!^*_P;\?>$=>M(IO.\.:IJ.BWC92XT7Q'I5G-J&@ZW8W"8
MFMKO3-3M[:Z22%D9U1X6)CD<%O[-WBK7/''P$^$7BWQ-/%=>(->\!>';_6+J
M")8(KG4)+");F=(5^6,32(TFT< L:](\9?\ (H>*O^Q;US_TUW5>+?LA_P#)
ML7P-_P"R=>'O_244 ?1M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/X1\5> 5N+_3_P"T-(\8^%Y9K2PO;/5[6VTW4=%U=+?4HQ?6U_;QSV<A>/\
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MS;WNH:9>0P:9>:'=+%J!O+E&@22))C#K_LO?M;_%?X^Z)I?Q-\4?L[_\*X^
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M9VT;P-XOFGTY].\1ZIX1\-WEGXEL[.""]EU&&72+J1(;AKVRM8I&8&VDG7+
M DG_ ."B'@>W_94^%_[29^&_CJ?7?B]XTT[X6>"O@I!_9H\<:A\5[[Q+JWAA
M_ \]]+,FBV$]I=:#K%Y<ZE>7$5I#963M)MG98#I_#3]L3XBQ_&GP?\!?VG?V
M>]5^ /C'XI:7XBU?X3>(;/QKX=^(G@+QA+X:*3:IX0N/$/A]@FA^-K;36_M6
M+2KY/*U.S#-82NZ;'^8=1_95_:'U+]E7X0)X2T/2]*^+WP$_;(\;_M(V'P\\
M67UG9Q_$'PU!\5/BA>IX4MO$-K_:^G^'-2\6^$/%Z7^B:O=VE]%9W#VL-[;V
MDDLDMKW7A/PM^TS^V#^T3\ _C/\ &OX"R?LM_"W]F6^\9>(]$\&^*?&>B^-/
MB7X_^)?B#2H=!L[^)_#,)T'1/ NDZ6\\N^YEGUC5KT@1)8PHX(!]F?M1_M):
M+^S+X"T;Q-=>%M=\?>+?&WC7P[\-/AI\/?#1MX=7\:>/?%4TL>DZ2-1O2NG:
M)IL,%M>:AJ^N:F\=CIMA:2R2%YG@AE_,"R^)'Q8^(/\ P5:_9 @^-GP&U/X'
M>,_"?P#_ &B(@DOBC0/&WA7Q/8:U8Z=<I>>$O%&A,8I_[*CLXK?Q!9W207%G
M=WELFUXV#G[G_;R^#WQ=^)/@[X2>./@38Z+KOQ._9_\ C1X9^,FD^#_$&HC2
MK#QQH^A:;K5AXC\(VFHO;7=MI^OZUINHM;:!?WL)LK34&5[DI&QD3Y7\(>&O
MVO/CI^WI^S=^T=\6/V<D^"/PH\*?!CXR>$HM&F\;:+XN\9>&M2\66$$$Z>/[
MC3&M=/MKK5[ZWLU\-V.@6NI11627=QJ6H+*\<2 'J?B+]OSXJZV?B9XV_9\_
M9.\6?&KX#?!S7?%.@>+?BB/'/A3P?<>,KOP/#)_PF,WPD\,:U,-0\7Z9H5_;
MWNEC5V:VLM4O;"[6P+QQK(]OQ7_P4>TG6O#_ .R])^SI\,[SXO>+OVMO!_B;
MQU\,M'\0>*=$^&>B6NA>#+6UG\2Q:]XB\2NEI#K-I/<FQL](M1+<ZA-;W$MM
MO@C#-X/X#\%?MG_LB^"/&O['_P *OV;=,^,G@#QAXE^+5U\%OCI;_%'2O#&B
M> O#?Q$U'7-7M+?XU:3J6B76M#6?#]_J=Q(+KPI9ZI;:O;/90)#;3+,5V/%G
M[,WB'X*_L8?LY_LW>*OV3(?VZ%\!^'&TOQ%KGA7QMHWPX\8>$?&\^J/KL>O>
M$+K5(+;6=+TZ;4+Z^@N_$?A_Q-I&IV5O96XETR\BU![:$ ^L?C-^V'KOP1^'
MOP?E\5_!K4E^/?QP\3GP+X'^"2>-_":VY\56UG+?ZO-JWQ'EN4\)6'AK1=.B
M.IWFKR3@R6SQ000M=2%4@_9R_;,O?BI\7/$W[.?Q:^'5E\)/COX;^'^E?%2'
MPWH_Q!\+?$SP[XE\ ZIKE]X>?6]'\0^%;B:.TFTG5K:UL=3TO58K>\5[^VN;
M<2VTFY?A[Q+^P[^TY+^S[^R%>_$:R\$_M._$7]F#XE_$7QKXN^#OQ)UR/Q);
M?$;X<^,[75=.TKP!8^/_ !1I-Y87WBSP/H<FDVFEZSK_ (?FL]>NK%HY9;'S
M%N&^U/V-_#-I<7>O^.Y_V ? G[&5Z]D=!TV[@?X;M\1]>LWFM+O4;+5+3P!X
M8M(-,\.O<PVTUH)/%&HG4+FR\Z;3+0PP2. =?^U9^UA>_LV>(?@?X6T?X5>)
M/BUXD^.OB7Q7X,\*>'O"U[966H-XFT7PV=<TB"YN-19+&QTK4)E:VU/6;R1+
M71K8&\GWHNP^5^//VW/B;X(G^%OPF?\ 9^LM0_:P^(7@[Q%X]UGX.M\7/!.E
M^%O 'A#P_K<VBIXAU[XF:E-;Z%>VNM3+"FDV.F+-?S73SVKQH]I(6[C]IOX8
M^/O&G[2'["_C+PKX:O=:\,?#'XF_$?6/'VKVTUC'!X9TK6?A[-I6F7U['<W4
M%Q-#=ZCBS1;&&[E65E,D:19D'SU^V?\ LR>*KK]IOP;^U[I'[/'@_P#:^\,:
M!\%-3^#WB[X">(&\,P>)(7?Q>OB70?&_@;_A-+#4?#&K:I;RZEJ-AJ.FWK:/
M<0Z<))[74)VE:&( [?3?^"F?P\T[X*_M!?$?XD^ _$'A#QY^S+XJT+P!\2_A
M=H^L:%XTEN_&WC*.R'@"P\*>,=#N9/#6K:7XTN]0M+>TU22Y@CT4R3?VVEL;
M67=G>"?VV?VF+O\ :M^&O[+_ ,4_V3-/^'&I?$/PCK_Q)378/B_X8\4P:7\/
MO#MX-+U/4V_LM/)O=;M-5N-.M9M MG-VUO>?;XB;>)R/FK]JW0I-'_X)_?%&
M*']DCX5?LEZO\6/B%\&O#>C?#?2KCX?7L_CZ\U?QSHVGZ?I7Q"U/0=#\$^'O
M 6JS1O/IT'B?_A(=6G\'07#:W8:Q#=6J6[ZOP!UCP=^S=^U3\'_"?Q!^#FI:
MO\5OVAM)\2>"/ _Q0;]K/6/VKO%?@+PQH5BGBM_#]QI/B'PUH>H>!OAKJDYG
MD/B;3YY[>ZU18+34);D-;[0"_P#!_P#:[^'G[.G[*GQ,^+'PV^#7Q)UK2Y?V
M[/B)\,M7\#7GC[4OB#XP\0>+_$/CVST;7-:\)WFN/)+;VVI7;QOX<\%0/'9:
M<Q6RM=B2$UZ[J'_!0OXU>'/BGIGP&\5?L5^/+#XU_$SPW/XV^!?@W2OB#X*U
MJP\1>$+.\;3]9U'XC>);.X;2OAO-X7E\FYUY-1:YB$5W;VMH\EV6!^:?!O[*
M7[0NG_LM:GX)O?AEJ]KXM7_@I[-\;XM#>_T,W=Q\*I/C!HVNKXR@DCU1[0V
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M[V^F^&=%GU6QLH9BZXU&\U2WN+"\G?RPPBM(EBCC<AY))0-A^D/^&$_V6O\
MHF,?_A3>+_\ Y?5U9Q+PQCCZJH4\]G"T+O*)898'FY8\RI?7VJ_-HW-J]+G;
M]F[;>1P53^E=/A_"/'8C@"E6YZRC'C6GF<N(72]I>F\7_J]'Z@H6NJ*G;%^S
M2^L^^TUSWQ&^/_PY^-G[+/[4.J_#'7[Z\D\,?!CXEQ:@TEEJ6A:EIMU=> ?$
M=QI]Q&MS';747F_99I+6Z@(*R0,T;JZ9'Y5_\$O_ (C^,/@9\.=#_9C^*7B7
M6_$.A_M$?LW7'[3G[-OB[6-2O-3NI9M7\,W5_P#%OX:SW]S-<7EM?>%-;F36
M=);4+I9M1L+^=]/3R;7 _7[QS^SSX0\$?LW?M ?#[X)^!XK+5O'?PN^(FG6>
ME65U/<ZCX@\0ZGX,UG2]&L&U+6KV65C)=726ME'<WL=G:M<R,#"LLKGX<US]
MBWXK>./^"<?[+WA?0;$?#_\ :_\ V8OAOX3\4?"A]8N+"4>'?B9I'A)M$USP
MEJ[(^IZ%/8^)=,FO/#VH2SQZC9P--#=PNC0+,OY]F+R]XVN\JCBXY?S1^K+'
M.D\4H\D>?VSH_NKNISN*A=*#BFVTV_Z1X9CQ)'(\OCQ?4R>KQ&J=3^TYY!#%
MPRAU77JNBL%''-XODCAG1C4=:SE75648Q@XQ7QWX(UO76_X)B_\ !*B^;7]?
M>_U#]LOX4VVHZ@VN:JVH:E:R>//C"LEKJ5^UX;O4+61(HDDMKR:>"1(HD>-E
MBC"_IQ_P51OK_3_V6]-N-.O[_3;G_A?_ .SG%]ITV^NM/N3#-\8/"L<T)N+.
M:"8P3QLT4\)<Q3Q,T4J/&S*?EWP3^Q!\>?$O_!,/]E/X1BUL/AO^T9^S[\0/
M"OQOT/PEXKOHSH%QXM\'^/O%VN6O@[Q7JNC-JSVFE:MHOB.6.\O-+>\F@E,4
M:NP,C#O_ !C9_M@_MU:G\//A-\3OV9)/V7O@_P" _BQX*\??&7Q1XL^(7AWQ
MI>_$NS^'^HKX@TGPM\*M.\-6B7EK9ZIXGT[3[JX\2ZY=6#V.F(L9TVZFE:-N
M(]T]"\"W.L? K_@II\4/ 5]J.LW7PZ_:^^$^A_%OP)9W5Z8_#?A3XD?"M(O"
M?Q!T/2X+NYE>?5?%FE7&D>*[J.R$:H4N', 7+&U^S!J-W\6/VO/VQOVG]6UL
M0?#KP3=Z)^RG\+9H?%OVCPCJ%GX"D@\2?$WQ%)I3W"Z?8ZJ_C+4-,T8:FR!Y
MHM.N+2*8QQR*;O\ P4R^#?QK\9_#'X=_&?\ 9<\-VWB7]IO]FGQXWCWX7:;-
M<6Z7&J:7KFBWOAKQMX<L+34[JUT*_O-:TZXTZ2.'6IHK9?[,+QW$4VU9/9/V
M5OV9M&^&_P"R3\/O@;\5/#OAKQG>7N@S:W\5--USP[IMWI'B3QOXNU.X\6>*
M9=:T:\.IV%]<Q:UJ+VTLLSW23/8Q2QL$$:H >S?$[1]?^*W@'5?#7PI^+B_#
MS5=1N[.RO?'OA2WT?Q-K&C:69%DU:WT5;B66QL-<O+)O)L-2G6232WE6^AAD
MECC!_/W_ ()-:&_A7P9^UAX2'B'Q7XGM?"_[9/Q<T>RU?QKXAU#Q/XBNX8;3
MPY++<:AJVI2R2RSW5U-<7<RQ+#;+-/)Y,$:';7VUK7A?PY^S+\*/'.L_LY?L
MY>']6U2U3_A((_A-\)]-\(_#F\\=:RJVE@5@N%LK'1#JPL8XU2ZU/;NMK18/
M/4+&M?G#_P $Y-:_:H\!?$+XN>"OBM^Q=\2OAIX5^-WQS^(_QH;XDZWXV\!7
M^B^#;7Q#I5@^G^'-1TK1]2OM4U.^DNM)6S6\M%A@WWJ2O$D<3 @'RC\"_#O[
M(_PRTS4IOV[?A)\9_"/Q%U_]IKXGV&F_%;XA^&_C'8?#@0WOC^\N?A_:S^/[
M/4!X2L=/@TN.P6 W4EO9VC%K>X8#.[]6O^"@GP<\0?&CX!^,;BT^,?C3P'\-
MO!WPQ^*7CCQ;X5^'5W%HFI?%.\T?P-J6J>"],U#QU9R?VSHOA;3=6MDUC4K'
M1"K>(_*M+.YN([-7W_/7[2FN_ML_M7>!OBW^R':?L;6OPKT?XA:=>^"O$/QY
M\8?&'P_XF^'-KX+U&ZCAU'7?!MAHFAV'BG6/$\FE[I]&L=0TK28=-U/RWNI9
MUMR6]E_:GO/C#\%_V9?#?[/?P._9R^(/[2J^(_@AXD^"EUK_ (:\4^%- F\%
M1:;\/++P7H6O^(XO%-Y;OJW]M->2W)BT^X\U7TZZ$TJ>="Y .X_9(M/&/C#_
M ()_? VR\->,I_"GCCQ%^S_X:M](\=7=C'XFN=!US4/#Z);^()-.U28Q:O/8
MW$@NEM[Z<QW$D:K,Y4G/S/\ \$_OAQ<_!S]K;]N_X7S?$'XA?$L^'IO@)J>H
M^+OB1XEO?$7B'Q!XH\4_#:W\0^+-?F$SBQTI=8UV_O+R+2=*MK>PTV!XK*V0
MPP1X]&_8A\=?M#>"/V.F\+?$+]D?XA>"O'W[/'PXT/PSX4\$ZEXP\%7>I?'"
M_P!"\,23'_A%+S3;VZT[P_\ ;-0MHM*C77;G;'<W22LY@1FKY_\ V5O''[6L
M/[:_QK^(WCW]A#XK?#GP+^T[JGPOM+KQ-K/CWX=:C9_"VU^'GP]/AZYU+7X-
M*U2XO=:@U6_T^)8(]+M89;=KZ(.'2.1Z /U!_:3^/_@O]EWX)^//CEX_2_N?
M#G@;3([IM-TJ-)=4UO5M0O+?2?#^@:<)GC@2]UW7+[3])MI[F2.UMY;M9[F1
M((Y&'X^?M!_&;XV_$W]I?_@FKIWQH_9A\0?!!)?VI+3Q=X-UZ;QEX6\=Z)J&
MEWO@G5XH]!UFY\/N\WAWQO:Q2"ZN]-N4%N;;<()Y)%D5/TQ_;W_9X\4_M2?L
ML_$CX.>!M8TO0_&FL-X9U[PI>ZXLAT:37_!GBG1_%NFZ?JCQPW+V]CJMQHRZ
M=/=BUNA:)=?:3:SB+RV^$O%^F_MJ_M+_ !:_8C\8^-/V5#\%O!?[/W[1&F:M
MXUAO_B)X=\8^)]3">%M4T;4O%^GVNE+IUEIW@"S=XGL[J234-=U.6Y2$Z79)
M$TK 'U#XK_;4^)WB/QO\1_#/[+'[-.N?M"^'O@EKJ>&?BKXW_P"$Y\,^ ]'/
MBNVLY-3USP/\.X=><W?CCQ/H>GBT74FLHX],M=5U.QTE[AKEI-O%7W_!33P[
MXD^"G[/GQ)^#7POU3QMXR_:.\<>(OACX5\ >)?%OAKP+%X2^(7@ZRU&Z\7>&
M_&_BC5[DZ/9W6BW.DWVEA;&2Y.H:@D<5GO$@-><^#] _:\_8<\:_&OP-\)/V
M9H_VE?AI\>/CEXK^,'@/QEHOQ)T+P?/\//$'Q#BT>/7[#XIZ9KUB;EO#MAJE
MK'>6^I>');VY.E6UT@M6N9(UCYWPU^R)XM_9S_89\,_!'Q_^R]X?_;>O=6\9
M_$'Q]\2O"NB^,='\.ZSX1\1_%#Q%?^(+M_AE?^)='@N+]]!O-6>PA\0V>N>$
M==M;*W.I6KO(/( !]J_$?]K?Q%\#_@)X<^)OQF^"NM^'OBAXN\;Z)\,O"WP8
M\.>+?#/BFY\0^.O$\]ROA^RM/&UI/%X9T_1KJPL[S5=0US59[:TT:SL[I;W_
M $A8HI>8^!_[:/BGQ;\;='_9V^.OPBTWX/?$[Q?X*\2_$#P$= ^*G@KXH>'/
M%NB>%=2L[+6M.BN_"]U)>Z7KVEVM['J-U;:C:QVT]HDLEI<2%"@^)U_88_:B
M\3?LB>$-$\>P^$?B+\0?AG^U"/C_ /##X&?%_P 5ZG\0-%L/@AY,MM9_LV^+
M/'NL6UV-;UW3]%O[J"S\3:I8:II>GZK;6EH%GT^/[17US^R#X9AU7QC>>+[[
M_@FQ\/\ ]CR?0;"ZL-.\8SW'PJD\?WFHWD9M]0L=$LO 7A1)HO#=U:/)%+J\
MWB:RDO%;[.^BF-G9 #Z#_:H_:-/[,_A'P'XJ3P%XC^)$_C?XM>$/A59^&/"4
M:S^(I[_QC:ZVVGSZ;:/A+IX[W2X(KA7>.*VLY[F_GD2"TD->->-/VQ_B-\+/
M 'P^C^)?[/SZ/^T3\7O'&L^#OAK\"-)^*'@K5$U2VTO3YM9F\5:Y\06N;?PQ
MH'A[2=(AENO$%S=2,]G)$EO"LTEW;@^N_M-^"/%GC34OV99O"NB7.M1>"_VI
M/A]XW\4O;26L8T7PGI7A7X@6.I:W<BZN(#);6EWJVG021VHGNF>[C,=NZ+(R
M?/\ ^WI^S#XH^+GBSX ?'#P9\-? /QQU3]G_ %CQK<Z[\#OB5-:0>'?B1X-\
M8>&9].U>PTR74M-U;1T\9:?=6MA>>$VUFS_LP:JL+W<T42,Q *_AS_@HOI/A
M[1OCO;_M%?#&_P#A+XZ_9\^$T7QL\4Z#X9\6^&OBGHOB7X?7=W=:?;:GX1\0
M>%;J6WN+Z/588='O])U!+6ZL[RXBG<FRECFKS.Q_X*%_M('XP_LU?#3Q'^Q_
M9>$;']JN6YUCX7ZCJ'QH\(:CJ!\$:/I>E>*/$VJ:U:Z:DD%CKNA^$-6@U8Z$
M9FFU"Z233K)Y)EY\B^++66A?L4_M<>-]3_8+^'_[%$.J?"N7PAI=U-I_PR\0
M^+_&MYJNIVUG+X<\4>&/!'AS3M,T_P (7=U-;P0:KJWC"2TQ=3:E/!H[V27-
M<3\'KCPC^R=\1?V9/&WQ6^!-YK?B'XEZKX<^"7PKOM#_ &PM=_:>U[X2R>-]
M!(OE^'?PHU;0HETOX>VKZ#;V'BOQ)HWB'5SX1T&"%I=5O=.C<W0!ZYX9_:R^
M&G[/ME_P5!^+O@OX4^.+S7?A#^U!INE?$:PUGXC:EXEMOB!XFU+1/#]M'J?@
MC3=4::V\#:=]BOHK>'PQIL<=E)?QF95WSEJ]8US_ (*,?%#P%XP\!>$?B;^Q
MI\3/#6J?M 6.J#]F30--\7^$->\4_$#Q)HUOHU_?>%/&^EVEP$^&-[#HFKR>
M(=0U'7I6T[0M-TN_AU)S>*D9^3O%W[)/[1FH> O^"L.DV?PNUB?4/CM^UEX,
M^(GP@MEU#00_COP?IL'A#[=K&EL^JJEK';MIUZC0:L^GW+- VR)@R%OO#]K;
MX0_$SQ[^US_P3E\?>#O".HZ]X.^$/Q.^,6M?$S7[2XTZ*T\(:5XA^&2Z+HM[
MJ,5W>VUY<1:CJ@-E$NFVU]*LGS31QQ?O* .@^$'[;<NKP?M$Z3^T=\,[G]GC
MQS^S+H-EXW^(.@WGB?1_&=A??#K4]&U+7K/QOX9U+0R3J>CPVNF75C>2K"H7
M589+6(L1A?!--_X*?Z]INF?#GXL?$S]GN3P1^S5\7?$?@7PWX*^(]G\6? /B
MKQK8GXDW"V?@O6O%?PPT:]E\06&EZO=364=S%9_:K_18[^&;48!'#<%.H^('
M[*_Q#^+7[1G[>27EE+X5\ ?'[]D?P)\%_"/C^Y-I>6DGB2;3_&5EJ[0:;#=?
M;Y(] .J6<UX+B&VCF,J1V[S9<IX5^S?\$/%?@8_##X(_$#_@E=\$M1\4?#71
MO!^D^)_VE9-4^$G_  @OB2?P[::?&_CSP]=R> ;WQM>^*KF>WCU8Z1?:1IMQ
M#JXF UF+RDN  ?3OC#]MCXR7'[0/QE_9R^!G[+FL_%[Q?\)].\%:S<^)+CQU
MX>\$^!HM.\56<]T\.MZ[KI"VFM$P[-'T>U2>YU&%+N])BM[*8GZ;_98_:.\*
M_M6?!?PY\8_"6DZUX>M]5N]:T'7/#7B"W\G5?#7B_P *:I<Z!XM\/3RH/L^H
M)I&NV-[96^K61:QU2WBCOK1O)G4#RGX!_#'QYX2_:X_;=\?>(?#MUIG@WXGO
M\ )? FO2SV4EKXB'A7PIXQT[Q$MK%!<RWD#Z3>7]E#<"]MK8.;J-K<SJ)"F/
M_P $X/A'\0_@E^SOJ?@;XG>')_#'B9?C;\=/$$=A/<V5V+G0O$OQ+U_6M U6
MWFL;BYB:UU72[NWO+=9&CN$CE"W$$,@9  ?,W_!7[X1^,->^ GCWXS3_ !H\
M?Z)X.^%>@^ 9_"7PA\'WI\+:%J'Q#U7XL^%-(O/'/C77M+EBUOQ-!9>&]4GT
MG1?"TTL&CV<]Q=ZG+Y]Q)&L?ZW^$V9O"OAEF9F9O#^C,S.Q9F8Z=;$LS,2S,
M3R68DDDDDDU^6/\ P5,UK]I'Q_\ "OQQ^S-\%_V2/B'\7].^(7ACP7JW_"V/
M#OB[P3I7AW0=6T;XB:9XAN_#EYH>OZCI^K75ZMAX7A<W4$BVN-9MBI=K>9#]
MY?LT>._B#\0_A'H&N_$[X+^)O@+XLM9+K0;CX?>+=<T+Q#J\-IH9CL+/6FU'
MPY-/IIM=;BB^VVD"RM<01,$N/WF: /?*Y'Q]XY\+_#'P/XN^(WC;4X]%\'^!
M?#>L^+?%&KRI)+'IF@Z!83ZGJM\\<*O+(MM96TTI2-&=]NU%+$"NNK#\3^&?
M#_C3PYKOA#Q7I%AX@\,>)](U'0/$&AZI;I=:;J^C:M:RV.I:;?6T@*3VMY:3
MRP3QL,-&[#@\UOAGAUB<.\9&M+"*O2>*CAY0CB)8=5(^WC0E44J<:SI<RI2G
M&4%/E<DXW0'X\#_@OY_P32897XG^/R#T8?!OXC$,,\,I_L+!5A\RL.&4@C@U
MYY\6?^#A?]ACPW\.O%>M?"34?&_Q/^)-EICGP=X&OO /C#P=IVN:S-+%!;IJ
M?B76])@L-+TRS65]0U"4LUU-:6DMM812WL]NA^@3_P $._\ @F$2Q_X9HM1N
M9FPOQ'^+"J"S%B%5?' 55!.%10%5<*H"@"O-/C#_ ,$$?V ?&OPU\6^&?A9\
M-IO@W\0M4TWR_"GQ)T[Q5X]\43>&-6AN(;B&ZF\/>(_%UYI.K6-RL+V.H6<\
M<<KV-U.;2YM+M8+F/^D<MK_1._M' ?6,'XRK#_7,+[9YE5X9EERI>VI^T>/6
M65/[2>#4.?ZRLO7UUT5-87]^X&?[W_IW_P"3?J?GO^R]_P '(CZY\1+O1_VM
M?A;X>\ _#?4(-2O-/\:?#+_A)_%.J>';U51]/T;4?#KVDEYJVFRX>$:I9*+V
M*1S+<VS0@8_1;_A_W_P33_Z*=\0/_#-_$;_Y15^=_P"R=_P;DOX;^)S>(OVN
M/'WA7XA?#71OMT-E\/?!'_"1:5)XRE=-EA?ZYKT=UINH:'96[ SS:5ILDUU.
M[)'_ &G$J,S?J;_PXZ_X)A?]&T6W_AR?BS_\W-?4\?S^B)#/K9?0X[K4G@\.
MZCX J8".11JWG=?\91..,>,]GR/$/#<V#^!)_6%B$3'VUM>3_MZ]_P /UU/9
MOV9/^"D/[)_[;ES\1?"G[/GCC6?$'B3P/X3?Q%KVE:YX0\2>$;R#1;YI-.M]
M3M%UZPLC>6POV2UDEM2_DSLJM@D5^3G_  2?^)7C?]G;4_A9:?$CQ1XA\2?!
MC]N[Q!\4!X#UC6]5OM9C\!_M!?#GQWXF\-WG@UC=SW=UI^E>.?!&BZ5?V&I7
MLT%@^L:2NE649N9WS^RO[/'[!'[*G[']OX]O/V;_ (0Z9X"UKQWHXTW7M2CU
MCQ'XAU;4K2SAE:RTN/4O%6LZS=V6G"Z9;A["SGMK.:["74\3S(LB_&GP)_8A
M\:>-O^"9/A7]GOXHZ%J'PQ^-'A#QEXZ^)GPZN;^XTZ;4? 7Q1T+XM^,/&OPN
M\5-)83ZOI4]NS7>GS7-O.NHV\FE:E<175B\P\E/YDXOEPA//L5+@6EQ!2X:]
MGAE@X<3SP$\X]JL/3^MO$/+5]45-XKVKP\82E)4>3GESW2U7-;WK7\KV_'4^
M!1KOB$?\$E/VM[\^(?$7]IVW_!0GQI96^I'7M8_M2ULT_:8\!P+8VVH&]^VV
MUDD#O;K90SQVR0.\"Q")V0_L9_P4OO+VQ_X)T?M,7MA>WNGWT'P>:6"^T^\N
M;&^MY?M>C_O;>]M)8;J"7!(\R*5'P2-V"<_"_P"SI^PA^T'\0_\ @F3\<OV<
M?CW;CX6?'7XC?'?XD?%*WO1=:;?:;=>*H?&_A_QIH&OR2:4][!'X;\6>)?#[
MW4J0)!>6^D7Y>.SLY5CMH_3OBG)^WI^UU\-]4_8Z\9_LN:/\#]-\0CPYX9^-
M'[1%]\1M'\4?#76?!&F:G8/XP?X0^%[&U@\87VK>*K>S\OP[%XA;2CH<%T\V
MH37$EL5;YD9M:9=ZY\#?VS/V/_B?>:QKEY\.?VM?V;="^ GB6SO=7^S^&?#/
MQ5\"^&;+QYX&\33QWMRXOM>\9Z4FL^$XE@B2XEEM[4NTK2,P]0\/3ZQ\:?\
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MTJ_LH;BU@FN]3F^R2-<(Z$;9%7Q3X?\ Q%_;+U+]OQ/VDM>_X)X?&+PIX/\
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M/CSXL>&+_P ._$GP?\5_#?B+PA\.(8+SQ;9QW?A&ZFO;'Q1H^G3?VG)I%S:
M7UBKS6$LQBE1?FK5O^"H?QWN-&^ GQ!\(_L>?:/A3^U/XZ\.^ _@'XB\1?&'
MPAINM^)]1\4F\?P_<^(]$MQ<'PA!K-GI]U?6RZE,S6J-!:W;+<N16_X-CL],
M\ _';XA:[_P3?\ _L5V/@CX*_$QU^*,UA\)_$_C2/5G\,:A"T'ASPAX'\(-+
MK_AJ6U>::^N=1U[3(;_R4TR\T66UNIY[?X!^"DOA/]EWX.?LS_M.?&3X#_\
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M$2JK70E/ECX3^ '[+7C+]G3PMX'_ &8O&W_!,OX,?M(:IX5&J:?9_M.W5_\
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M **** "J.J?\@W4?^O&[_P#2>2KU1S1+/#+ _P!R:*2)_P#=D4HWZ$T ?/\
M^R?_ ,FV?!3_ +)[X?\ _21:^A*^!OV6_B?8?"P:A^RK\7M>M]!^(7PUO]7M
M_!E]KPAT72_B#\-WOYKOPSK/AB[N#':WC:?IMS;Z=J-C]H>_MY8 \B$.PC^Y
MAK6CD C5M,((!!%_:D$'D$$2X((Z&@#3HK-_MG1_^@KIO_@=:_\ QVC^V='_
M .@KIO\ X'6O_P =H TJ*S?[9T?_ *"NF_\ @=:__':/[9T?_H*Z;_X'6O\
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MO]LZ/_T%=-_\#K7_ ..T?VSH_P#T%=-_\#K7_P".T :5%9O]LZ/_ -!73?\
MP.M?_CM']LZ/_P!!73?_  .M?_CM &E16;_;.C_]!73?_ ZU_P#CM']LZ/\
M]!73?_ ZU_\ CM &E16;_;.C_P#05TW_ ,#K7_X[1_;.C_\ 05TW_P #K7_X
M[0!I45F_VSH__05TW_P.M?\ X[1_;.C_ /05TW_P.M?_ ([0!I45F_VSH_\
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M .@KIO\ X'6O_P =H_MG1_\ H*Z;_P"!UK_\=H TJ*S?[9T?_H*Z;_X'6O\
M\=H_MG1_^@KIO_@=:_\ QV@#2HK-_MG1_P#H*Z;_ .!UK_\ ':/[9T?_ *"N
MF_\ @=:__': -*BLW^V='_Z"NF_^!UK_ /':/[9T?_H*Z;_X'6O_ ,=H TJ*
MS?[9T?\ Z"NF_P#@=:__ !VC^V='_P"@KIO_ ('6O_QV@#2HK-_MG1_^@KIO
M_@=:_P#QVC^V='_Z"NF_^!UK_P#': -*BLW^V='_ .@KIO\ X'6O_P =H_MG
M1_\ H*Z;_P"!UK_\=H TJ*S?[9T?_H*Z;_X'6O\ \=H_MG1_^@KIO_@=:_\
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MMG1_^@KIO_@=:_\ QV@#2HK-_MG1_P#H*Z;_ .!UK_\ ':/[9T?_ *"NF_\
M@=:__': -*BLW^V='_Z"NF_^!UK_ /':/[9T?_H*Z;_X'6O_ ,=H TJ*S?[9
MT?\ Z"NF_P#@=:__ !VC^V='_P"@KIO_ ('6O_QV@#2HK-_MG1_^@KIO_@=:
M_P#QVC^V='_Z"NF_^!UK_P#': -*BLW^V='_ .@KIO\ X'6O_P =H_MG1_\
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M .@KIO\ X'6O_P =H_MG1_\ H*Z;_P"!UK_\=H TJ*S?[9T?_H*Z;_X'6O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\(?C-\5? '[)W_!6
M'XE?&_\ ;+OI-#^!'Q8_8Y^&7P__ &<OB3JWP_U_Q=X+\.^(O OC_P 7:U\6
M/A?-?>&M"\0W&D>+=5N->TOQO&=0L+9-9T2\AL[74)WTK[$G[O44 ?SU:O\
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MP!<_&+Q9X\\-?#R6'X8?M W/B7XC77CKP_#J'Q26XNO#6N'[*BV^E:/IP?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img58233625_8.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_8.gif
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M8,0LM-2C'W7_]N")3A)Y X5TTGX Z0?<=I$#KQ_J[D>D_ EP?P#L'^O^5[8
M^@]_83+@ @OH0 )"D(+$ZI_ME/2\,#7M&*P8 0 41SX2EM"$)T1A"E6X0A::
M#Q<X0E;)_'>C;@DO>2*3WXZ&=,,<"FF'NI,AD7X8NR#JL'Y S"$-F8=#HQF1
M6$ALHA)UQ\222;%X3?3A$8F81";R\'3NDUCOPIBC0YF@93X;B/E8N$8VMM&-
M;X1C'.7_R"$U L!\ZAM4%4V%P0XV*HA*6V+TO'9%_3'0BX5\H@T5F,@;1I"1
M&LR=(:?HR$ &#Y!3%"38".DHASUOCX2\7?^.(8M>+&Z.IT1E*E6Y2E:VTI5,
M4:,P6N"-($VRD%*LEO("-+WX>0V,QN+EL:9F-*2=JI=@^^4NY27,K!$SF"=K
MYNJ>F;1A2G.9T/R:,Z])S6@"<YN73&8Q03<_D25S9&.,'P>+!L1[U=&.KX1G
M/.4Y3WK6TYZ1<^>%2/ ^=7JN<,:T808-53VCE<UXU)N8$7^'4/D95)<$A5;S
M(.K)APZPH0J=F$4+BM&&:C2BQ!M9'BFZT(D&SHB#>Z2CZ+<H_Z+]AZ3W,X$(
M68, "2Q@ 13@0 0"X LY[+2G//5I4($ZU)\65:A&)>I1E9I4IB+5J4M]:E.A
M.E6I5C6J5Z4J5JV:5:YNU:M:[6D .$"!=BQ  NYD$TUMBE.=?K6K8'UK7-TZ
M5[C25:YUQ>M=]6I7OAI5K&0U*UI1I-:;YG2O>>WK816;6,8BUK&+?6QCY?K7
MLIX53H1E*V0U*UG.1M:SF_UL9T&[5\H&]IXL;-7")D8XDY)LD#I$7D=E2])B
M)=-U8_2-;4^'VVR&E+9)TRWM>!O<WTZ(N*L%;D:%Z[_C-K2VRIW4,8T'O2T.
ME(C=3%0P$' A-0IV,PFX:0#$.U[REM?7O.=%;WK5NU[VMM>][X5O?.4[7_K6
MU[[WY< "$N!=$8&7 O<%<( %/& "%]C !T:P6/7+7P_Y-\$/AG"$)3QA"L]7
MI^3-[WY3Y. *=]C#'P9QB-][X?%FF,&GK5QWT\@YXDG2DI#LYS_YJ< 9[Y#&
M(VV@_C J4-OMV)*L\_$M<<QC(._VQ[D+<@1KG&-_/@^C,@8=)%&:J'06=,KU
MD,4(WPD:!"R  R(&<YC%/&8/Y_?$]NGRE\F\9C:WV<WP-;.(TOQF.M?9SFR.
M\XCF?&<^]]G/$<XSBO_%-XUFK&^)UKU=<&DX3C+%UK4<!*/G/@K 2%/7D#ZJ
M]*(!R,!,=Y&/XQSBI#G=1U%CFM3J-'6H45V@3CLWBH;TH_ZT^,>"RG:W-HH&
M*?.Y&0280,U_!G:PA6W?#(>HU[\>=K*5O>SR%KM#QV9VM*4];&=["-K3QG:V
MZUQM05-.Q=MMP2TD:N55.Y2@!Y70]%S\R4:N^\H]5K*Y61IOA<Y[AO)^WXWK
MG>](!@[>]]ZW.I&W;T;Z>Y"T@S+H.$I.&Q+.-RW0T)G%0E-D:]OB%Q<S!53V
M; E4'.,?!SF%-2[Q]% \Y"='>81'3L>.I]SE+Q_PRKM=N31=@!6E4U*5;W?_
M;S&*L];T"JFF#TE&26-2454.(R21;O1%+7V3Z2[ZTYO915M.W=7MMOK/L=YN
M*??;UDU79+G5W1M2IE$S"/ XS-6^]O=R( $;0CO;Y3YW]KJ=/G&G>][U7N*W
MUP?O>P>\W.T^\\?!+.((X!PMA]YB*Z?32)>$]*.6I>Z5MA;A3C:<P:-L^?<]
M&?/V]CSG/V^CD%6^;*$_?>;-C6C3$XWTGW^?WF ]QG,Z^M*XW'30GW>H8)@C
M+>8C^54D0.+ %Q_F')! ?89O?.:_'/GR67[SI7_RY\\G^M/'_L6K3WC)[6.?
MJ-KTIF4;49U7RK?,A-2A3/9H6),>4:,Z.)7?7\L$5XYS_?#7)&OO3_](J1^D
M\7>__?.A^D,: 10B O2_?OJY^ZLF^_DC=.LZ'),06> NRY"'!<B^#,2X!0B^
MU[A #03!;.- ]_C $#3!:!O!]RC!$V3!84M![O^[&5?A+@38)^"(NGYB/"1C
MGI#A(-P*OQ:#)"*KNO:+'LD[LK 30B0\PJU+0B9<PB!<0BK#'>N*-0-*(+S1
MO]@)'5SR$1)@E;) @$UHP3$4-@KHP)D20S)4PSYKAS-$C3!<PSB\LS9T#SB4
MPSMT,SJ$09O1D(*8AA' $:TC.E>;GMJ3-'Y3LI0R0)P#PD53G;%#HD>$G>19
M1$C<(DEL1!S"Q"*</QVQ1$H$J4^\0>9YF&+9/*^[,=M1MX4B0"!TA5;9,C=L
M"@2@@+#"PUL<,PZ0Q=.@15O$Q5\,,5U4CUX$QF(,QETL#6(TQF6L,&'<0YOA
MKEYH =@2OX+SOT,#*-'_^;3XP31(NQ'-Z[S@ 4?8*Y1Q%+UO7#UR1,>%2SUD
M,<=V])QW-#W<84?78[5YNT:0PC]R.SU0NSUVXZB1^C0=T81>T!ZOZ#)F5$B1
M0\;12,B%A,@'>\'R>,B(M$@#FTCSJ,B+Y,@ R\AG+)@UV8<38 4;1#=^9*F3
MU"/;NZ[ENL=[VRWW<:D;B\F7I$GADDFN$R!&'"B8Q$F;1,6?C#*?')6<)$J4
M>BGARJBDZY%C(C=^?$JH@Z(9RC4$((<*W#*M\(>.Y$J/7(^M[,JPI*\%0 ^P
M%,NSA"^R3 ^S1,NV7"^U!$F"69-NB#@2F$)>&KA:HK*""THR$<)&6A+Y@<1]
M6'0B?]Q)O9P\F@Q,HQG,*!%,Q41,P[RMR/2YR<RBQ,1!GFLX\?.G)CO$*3*]
MSM1&IZD'$D@3KY  MU3-]4H^]$C-U81-\VI-\GC-V+1-\9K-\JC-VXS-W(S_
M2X&1AY- @ 1H@5MKO&/1H/,#HFO1/5<+NO.#3H^*H1B2SE%<()>T-%Q*RMD2
MHNV$2FKDSN@4*=6S3I6BE\Z9IO%#J+]$Q-<K*&XLI@*I#EP@AWW RJQ(@+3C
MS;;TS=?(S_VTS?Y<C?\$T-XT#P(MT-44T-_DE>^X2L33QNA),M[B$2A+Q?8,
MQ_;9R7UTG<Y9/2+ST"3K4'OCT"\B40MRSR'[L1 U,N31N2ML*0/:J(?2,=7S
M(-X2'HE9J7*,AF!@BQ;QCH.,"EI,4-@T0XK\KR)5S2-U#2)5TB5M2%Y+TB=M
M2R9ET'Y9DPO9APT(D.94+D0[40=\3%!#G4)T2J_C_XW&I#WW$Z/;8E.&P\[X
MG$[C)-,YC=,SO;KC=#1#U%#-],X68\<LNCI*X<D_TCT:*T5O< 6K_$*LV$TJ
M/<N8HDU(=4M);8U'I=2PM%37P-1,Y<I-O5)^B;@&$!:DY$PBK)=XL[PTK<+4
ML3=R2ZGKK#%%+++17$X=M-66#%-:Q56!PSV!9!O%A#0>XR/U"SN%4]5-^31)
MP3<;>Y;MDBFL0( 0\-2S=,8FU<]JC<AK58V_TU:NY-;5\-9OY<AP#=5<F4%7
M>#Q.VM "W+PPXDO0E$ @:<P9XE/;ZU-!/"0RQ5$OLBU\W:9^U9U_)<42U=%Q
M$[4+%53 X4E)ZB%]118/K2P74RD5TR$!!)B&?> 3JNA4<HU(N&P-$_#8K@39
MU!#9D>7*DE6-DT59CE39<_^E%>"SHUYX,BMDJ$1ZF(+#3$\9J7_T'<#I)0L5
MDGR4O]G+O4816B(A6C9EV*,EG 2*FD/%0G9M,6.-)%G3R>+"QD^+U7A=U[EI
M5BYJ 7>H0"%U"@1MV6WM.]9 V[1=2',MC;9U6X6$6].0V[E=QKJ%65GA+M5B
MN 2TH$G$$3!R/*%S3L&52BL:&1Y4H#S=4ZT-J<%TW()%+MF27'VE7.IBW'Y]
M-2 CJ:^5O#]%M$&,2F(Q':_[.F:MD.V"11>1BH[%VV)\V=. W=C]Q=D=C=JU
M75S$7=+0W=W%P][=6SP!/@0@U2YJ3UL-4\;=.LS]Q_9K/%]]( 9B)(6RQTEB
M7L[_J]XK"T@3K=7\ =9T)#C52Z15M,94>]6^>55W,R9*\5 ?\L:()9J%,P,T
MT1##BXHI!5YCY  M2PTGW5]C#(%NU=\ !L8!%M<"-F!<1.#AK15RR-B%V3GH
MLK_J8K? ]4$#1#CGP99?M2X?',+43<[0I=HV5=VD[&"6S,Y,>C'S[+I ;;2E
M++\X-<3-13J&4\ZI](V+?2>S78I>6.!E7-O42( @-L8ACELC/N(!5>)B1&('
M)MZUF 9PFYWRVS?IJC_KY19Y25&=0]Z@S,$IND:A/46A^:<+;AVHFSR!*CVZ
M.>,KJQTU1M:(C3S1(YM:318 7.& \]YRP^-X35XK>E,.(FH!<[C*5X&*WVUB
M%A3>T&#91;[#!S!92,9%25Y92KY%2X;_XEBYD*M\H3$10(KZH],=5,1-U:+$
M8!2^NL>S,>5T7JI%1(854U/&VJ85W6;5.GW\L4,U&Q;.I*_%8]1M2NB:1.K"
M+4'!A>W"6(TEB:908$P>0PY@C6>&9A:D@-2@YFH^P6M6C6S6YA#DYDW6DQE$
M %;HM!]LX?7;W!:V58);7T@,J<I;7';V&M6Y(AG+7G/KWN>\YVZL50D4X=!D
MW\-15>F:4;GY8 E*UO5=X8A]M8%\M\')L@N9#)>!)>+[YA9\8M(HXHQ6PXT&
MC8[V:#($Z= 0Z9'6:''.$^ [ 7>@$5/6T:YC,NK%&^;EXW[;68 59@:4'3 U
MW 5TX\'Y1$ZD_SJ@]B"A+F;EX4[J*B9V_$YC#CMT#DI_ME<7ODE5;M7JV"^K
MI,OL:8IX0.DQ7%#1..FP#L&Q]HRR-FL01.O/4.NUSL"V5FDW468$< 6PV;U*
MNMZ>I>53QEILF6,YW;%U.F'11%$9%=2%:N-L/&PIX^.<3MS+TZ@WG4D<Q-S"
M1)W'-LP=32A]2^$4M;S(YHUH4)E.C@I%ANO :V3/P,#49NO3:&W7UD"Y[HS8
MENWLH^VY'JRX.('MDH5!45[[8^'!QB+G+&4NLK4U-3)+_(^8KB[,ID3C5&XM
MAL"?;=<,_NN5;"#G/J>E,V%0E-'NG:&ES4Y>9E7)OJ'Z:P%E?IF#L!YHI+#M
MVY:^<(9M^<Z^U=:,^+9OYL/OS=#O_2Z^_M;_[1-IE:N$ABYE-3]"VNW-P4#<
MUZOAW,7[9SAN/^K6(J9CZ'&<E%/\:9]E2F6I432ETU/=3(>^)/+,/X[26:S5
M(#7]06*%<'-@[]-<"G0 \/GNYAMO/OH>#6_6\;GC<=+P\1]GNR ?\#8)SI=!
M ', 1';#\#YNJ)PDS4<[90O^3H_RZ3UBK125M7-*5@':0J4D'CS%QB]"(/S+
M)"&K0G@ED]/]D>Q=7%9\*>A\5U3.55=^SAD.D&2&UC7QX:$8<B(_/M6@5D$'
MO 8FC4(W]+U#]-)0]$7/NT8_\C9A"V6&!A/8'S3.$NBU-/RKM[W.XSH=W0\-
M;QRD;LT]Z,K$V2F;_UKI/>B ,T+T1L7.F;R4Y+?+;'&HM*6:]5.:[*7Z6^H+
M9=$T)@$9-VVGR%9(?[D(4(UD5_:4DV;3</9G1[EH/XUII_:0L_9)?Y,9;(#?
M;L7/F:0'G)\;,^ACIO#?&7<6%SH(XN6G#'-^U=ITA*)K;-A4)Y5#XU-$:?6%
M>]^E/,E?-_'Y:UCH]D3$758QI]P=D05H8&_L40J,SG:84XV)G[O3L/B+1XV,
MESOVD-E8-#N0%_F/)_F0+_F1-_F41_F5/_F65WF79_F7E_F8IWF8M_F9O_F:
MQ_F9[XD+F>+M2H#1;F>OL4?ES$?X;5'$#N_/1)H2S^LPUCQ[@V?[ 5S_03[?
M5/^487IRQ]WR+V]'0(:\=\MPT!9FQF/*;)Q>4V^4:&@&]CZ)/Q<*CE^[M,!X
MN:=XT[![M4N-O+_[\XC2<__]>XU5Y@2(D%6\&IZU:GL&;W+7[JS]'ZLUHC.M
M#O*F(2\^,O95LJ'!%$.-ZGU'\S=7HG^/W'N,2@_6X,QNU^2><WH>M6 '3(>[
M'UQP> 20!S6"^Y_ =KZ7MK\7"]U/N;KW_9/;^^ 7?HIL"9>OP.1_)^5G_N5W
M_N:'_N>7_NBG_NFW_NK'_NO7_NSG_NWW_NX'_^]7>95 QI\?SKLNT3$)&;P,
M4XNR\!RD_(/MY3*/:5Y%<<W7RP!$8QW"TSL&B'KUHM4[1G"@IH$"#S)<J% 3
M08@.&TIL&)$@QGH5$V94V-#C0H,3!QY[>!%DQ9$I)9I4Z/)D-(X<7\YL:1&D
M0XW_%#&Z<H< 03=Y (82+6KT*-*D1@,P;>KT*=2H4J=2K6KU*M:L6K=R[>KU
M*]BP8L4J+6OV+-JT:H?*&>OV+=RX<N?2K6L7[MJ\>O>B;7OW+^# @@<3+IR5
M+^+$B?T:;NSX,>3(DA53KLP7P5',F(=NU@R@,^?/H46#)CW:LVC3J5&#+LTZ
MM.O5L$_+5MV:=NS<N'?+UMV;]^W?PH,3GSU\M&WC1C>GQ;Q/WD]H)A;6C.F1
MI768&U]Z-%A=94:1(#MFC$G^.G>$.6^R3ZA0/'E-(C%6QSZ3X?V2Y=UGK\^]
M_'@RT8231??]=]]W!5XWGWKT-=C2>.N9!-]_!#[H4H06_P+8H'PP10C@,:ST
M\A,YF)'3C65G2;8BBRVZ^&)6S*4X8XHPVG@CCCD&)@>-/5*F(Y!!"CDD5CSZ
M>"1B1"JY)),X&HDDE#/*^)EG/Y&F69587DGEEE9JZ2678'J999AADBGFEV9V
M>2:;:[KY99MPOJFFG'72>>>8<^9IYYYHJO:G7M.<B( Y";#R433ZZ332ANRI
M9Q-"B=X4Z84'240A>CM1ZF%VX!&8H$/8D:1I@?$A2B" %^DWDT0I9912=QWA
M1*F&%<+ZZJ0@IJKH@S>EQ*"HB:Y$WWFMXLIHAA =4Y&B*<G20 - D1/E44U:
M>RVVA4U++;=F9?LMN.&ZU2VYU?^*>RZZZ5)5+KM%J?LNO.BV.V]1,FJV00>:
MV& #.!]X4, X!7CP <#]CF.PP (3/'#!'P3,\,$.*]SPPP1'7#'%$U^L,<(0
M=VSQQQE[+/'(&&]<,L<D@ZRRR"N;'/+)+J?\,LLQMWRSS3F'[($-16C203PG
M[//3- A U\VVJ0UU@EHE_M2++ RF.M*#]E'HX'F9*JI@I^:%1.O4%9X4((%2
M;S?U0=U]FEZQYQUT-=C(_C<??P@>FRN&7L/Z**XBW0JA=B!Y5V'<M6($WZH'
MDIUHWA]2EW<+"9 X[;9)(QE!O)EKSB2*]):[.>BAZ^AYMZ*;?GJ+I).+.NNM
M&Z:ZYYA5;:#)OP40;#ONN1< ,,$?]+[[[K?O/L[OP!.O.^_('R]\\LPO#WSS
MT#]O?/'#5Q\]]<I?/[WUVGOO_/;A?R^]^."/G[WYZ9.?>^_@U/Z!)B3\-/F?
M4_^6I5F)"21@1DC&ABKLJ1K%D:T)I&JFDE#8&@4X@3 K5A-9EN'8MD $92B!
M]KG;HCHEJ@H6Y"3!X@YV".B_['@';PHTH8%Z]< /6LIM@_L;",O#()1$Z&P(
M#% TS.".$4GK<Z[[(1#I8CG8(2F(1CPB68A81"0RL8F'42*4G"C%*48%BE&:
M$@EZQ[S;":]Z6\Q=P)B'.S%>;XS0,R/TRJA&Y*$1>&LD(QO?>$8YIC&.=H0C
M'N=X1SWFL8Y]=.,>]1@\-Q+O _*;GYCT,B@$],(=+:@4LM"VJ!IR+8*;6@]_
M.$20&<;$(%CCFPHWZ<&Q=0V!%/20"BV4*<<M3D"29(C_U/['2@>]YW#789S7
MM!:15>['<1BLI  AQ9ZM$3"4J]P@??1'(N1$B0-4?*84AVC%&4&SFDCTQ31[
M9,UM!A&;V=0F-\/).F]^\T@(V( -;!<P0+)/=\4+8QT':3% SE.> */G/>VY
M3C/N\W?]Q-T_Z\E/? 8TGP/5)T$3BM"%'K2A_E2H0P$*T8<RE*)FY.(]BR<Q
M&QP2D552FE*$,C_]>2U5WVG0LGKI*%>)$)4 9"!&<&FKL,TJ@3#EX E_9=.7
M0JJ!+@0<W"@IH0O*$I8A=-0N<^DVJDD2F201%:Q<A1)2J5*I,L';5#L825=J
MI!F2 U/IQ"E6T96S1[X8*UHU_U=6RYPUK6Y]UUI3U-:WTE5<<:V,C#H #CVN
M\P/ .&,8_QJ\08 #GGT]HT3KN,]!+C:Q@&RL0!G+U\DJEK*/M:QD*ZO9RVXV
MLYS]K&=#ZUC11G:TCO7K'(&!4>AI@E >!:E9D#92=T2C;5\C954+%TRW&4A2
M'?D;HGI+':S53:5,[1!U*.34"-KR;LC%;:8R*<KU).Z$:P.F,0<DJ0P.]W%E
MRZU+/+F@4E;00,,Z[N%*BLE5?B@:"6CD_.H5I;K2%USVN^M>ZJM?:ST)O_G=
M+X"5U%___C? !@;2@ F\EVZDTX^#9)]JV;E.>++3 X.HWC@NK+L,8UC#PN/P
MACUL//@1#X_$ #,QB#^,XA5WN,4A=K&*83QB&9>8QB>V<8IG_&+=:?BB#QX>
M0#]@ _U!X[4?3<JT?J*_!!CWEC7LSMZ(I=58<M=3!=QN4D=XW5@Z*H951BIW
MB8O*#];*E\+=+@NE.CA5B0U2;3Y65EU*3"=+5;W6(4ENQZ;3-S-UDIR:J59'
M50_]10LUW#HPHG.DX,4DNM$O6K1>&./H24<&TGN1-*4S_3I+ZP6=]!2L[2(<
MSWCV<Q"'->CO"FM/59N1U:D^+,%<C3M9QQK6!:#UK6V-ZUWKNM>K]G6K@?WJ
M7Q,[V,4>MK&3C6R0-1:R[@2>#4S0BV84^2?RV/]'6IR& /V!\I/:-1Q7Z<P0
M&69-O3A-;GS2P]Y7AOFDZ>:MX +WR4XAA),3Z2UR)8BV<"_5/@^9)>$\!-S'
MX<>7]^X5ES/(*WG?$)<(VIJKW$/H^,+V2)J^N&'NR^FR8+SC@MEX6CPN\K^
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M'$#N4 %D)2^ YQ0&G/RC O44"E,,P@!W8@AHQ8)03Q^..&0"%T:2.))0*@N
M4$FLA+:);75P<:G#H&C&9E*"Z0  HBPD)7!HR,8&+2ESZVHDB[J$SG[,+R-3
MHP#/69?H,:WD&%R*+#?J1K3N+9'(R1BB1XIUC5872I 5+T&5>!O"+M/L[^H.
M+:7.:7 7(@)S,@^/+9LU,YGL>!U1[0R13E""Z?2$$W'E^69B'82O1E\) *(3
M;/M35K!+E18@>X)I=E!#_-8G=Q+08ZM"+S3G8UO#=R;V-A-0<I3_T6=E3VJ!
M;UQ%=)@2$'Z]\UT1,!<CF+*0[7][8G^[K7_3BP #N!VM4RJ&K7W&%A43^-\
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M9BTVAD-3G:%[?5T:G$?#<B PHI\/-9#M5$J'@^.YO=6;E$8S+,J;A;>SN2^
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M)@CIT:1)!# G/J0I<J',G0D*YOP)-"C0G42+&CV*%"$Y>07&%6A:8)#3 A^
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M9T^#R965%B&G(:4G/\E(.SXFMVAQ67%->\H"I#&YKM3M*XDF#@HH@Y9>3?_
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MKCW =_#AQ8\G7][\>?3IU:]GW][]>_CQY<^G7[]^=_SY]>_?GF#\ OX$LF]
M @LT\$ $$U1P00,#=/#! /T3#\#\&+3P0@PSU'!##MV#\$,0LY,P/ KWDZ-#
M%%-4<4466_PN1!@='!&\$K7K!CL$D&*HIZ-J4NF#GE@"LJ*;9H))*(6 VJDD
MB'B<B$D=*S+_*:0CC>RHRJ(R:A)+G4Z:DB@NN:P(*"!_?/(EEXQJ:!PR)_)@
M(8H2DHJJJJ3K12N#N-(J 5P$<&XQW^Q";%"].N-MT+2"\PRPUA)U32WDV&H4
M.N$$C30P2?NJ5-/-#IVKMDT=;>Q0Z$P+=;+B4%65,]Y,ZS0T4EG=#+79B&--
MU%$Y#92P6CDE%+C:1CL54@EP<:>9KKI!(,8 773V66BCE=:\99FU-K\92>1O
M6FZ[]?;;!:\5%[]L:<0/7'3357?=\\9U5\3R:NR.77KKM5?:=]TM]SMY"<(.
M(:*.NFDC+9&BDDB5"BXJ28>4M%+@)]4,^$N&C8KSS*!JRDG+G)Y"_SC@ K2,
M":@V@]HH(8<;7OC@E!ZZ^.(U$>9X8")5+F IFC&^TJ.+%Z+@9ZHD$&:ZK0!
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MQTQ"$9S1$B8;N9@'@EG+YVT)23$CDI*$Y!!<]I)Y3PG?0A2&2XAATYBZ#";
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MM1":!,C%95F6]X1/1Z5+/154"0%0_F"V?Q5+<(-4[AC820W0@XW&A%58> D
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M)0F@4&&;/4R?E0@:WK(553Y8)8I(A]%],UZ/X1CE0R9T0O]EV[K':@)O?RL
M:/Z?!)^Y9O S;3UDLYU2<V:TZFHU@DJH4/'-P8GK40N1$6@4M?7UNZTI?18.
M6$%Q[0#*)G52OKUG]Y/COC[)@,[>K?-BHF-DFO+F OYG7'F<]@QNQ9UR_4
MV7X/>:&YH?H6"G'W>!D]%JGW=\\<TJ;ML)26.N>*?6^/>&?M;S'M_Q@]/[\0
M?6<=0!=!@,\.>=\\^&!MX3Z/"5[X%FEX\JCW%D'XQWMXB(^6!K/FS5D'@TTK
MRTOY"6GW?W>6B*86T'YY"^'XP9-S'&EE7=+Y8A:G*52X35TXH#:>HI51U(5O
M6Z8(\2:2$V9T+O0262T>)1P9@TO_:GWC/=<".<TL765&F,?,;I.+"*1MAZG0
M0\,=+GE0Z9FS3;JV(1UZP#)-OU:1#7:-\7Y&Q$1914B!$7*(<%(KRD2#WP/V
MM+5@Z^PX 98*L,4N9/GE8K+(3DLQ*7*U:W*>+FO%SH""K[.36^1X&C1&"\E6
M%GFP#H9V%PC^%B5' &'X(BK7._FH$=[6<S2?%B5W<O1@>0ZI_3?'G-)_>-SG
MEM1?_2YJ?8'P/'@'L0G1BN,VZ6[1?8<7>9!_%MA/_MDG^%W,<SXE-FSP;=2O
M%ML_C]_?D!+1^ N$?HI_%BQ'@ 5@-B@J(_(?CWCHV/.(?Z,1 "HB_G*C]X$(
M?_3W?H"8_Q=@(,&"!@\B3*AP(<.!O@! C"AQ(L6*%B]BS*@1 8 /!3P6*  ,
M),B/(4N&'$0RI$F4+%>N--GAPL0.)EFR'!=R T5G'X!IG+@!6($.&#=LN-E2
MI%*<)W,^+>DRZM.E'T<6/6KS)LB9%D]LV!JSP ::$<,6T+G4Z$6D'M3^1"DU
M*M:7)[%Z!%E79-ZF%"@H6[! @H0$"1 @CH@8 33#$J+5BZ8I<CW*FB!CKIQ9
M\V7*T3 ?@URO,V32E3V'GBQZ\^K1F5F[CMWZ->7(QTR+OAPZ<K2@&$_4EFQ;
M=>W.GH,;ATUY=_#(N$E(!(X:>6O3QV5?KT[;^FS+I3,GYPPY]?_WV+MW8R;>
M^GCW\.5ITS[.W7OSR!*$'49 3AZ ;K[_6]20@ ,2N- \A\D1@"\&<031 @46
MM(!B$%)8(8'S1)2 A1M6B"%$&G(8HH@+^0>@B2>BZ-N(*PIX( ()+EA0@P \
M6*&$$"' HHX#)A 1-CL"&8"' ( 8I)$#/I2BDDNB&..1%MX(0(XZSBAECQ#]
MJ!"1"1IT)99/CCADD6"&Z&669 *9))-KLID1EV@6.$U$"S@I8I0.1B3 0H<M
M ,)!$B7P)IP4"A#1H!R*>2B0;3*Z)#DX I 657:1A%=:X.@4EU-C*454I068
M51-5'PP"S@>A2I046_\E5< )0;6Z*:4W5O4E*TQ-P8533*A:=,%=(8W#:T5;
M2>I5K[^&]*I&L:Z4JU-<26J7KM"ZE&D!?[6S0#Z$)6 .8O^/*H98 NL(H)ES
MS0F7WC'.M<8<NN=VEZZYGJF&6SVIO9L9>O7"VR][]5$DW6G1;##"1<"YQ^Z]
MG_6+'F?T@0??N[6=]K#$__8;GV0.RWNQ9.F=._%[S,'V&FG\TLO>NMU!/*^\
M]8$<,<?F"E=/8;VXHU\WC_+7:$6*/AGEF 5."#2+4=9H-(%(*TTFN#Y#O6;3
M0 IM8=%3<R@!C@)AW1#370<9M=@I@HW0U2MB,R$V#2+ -81R2.1/V0I]/7="
M6DOIMMT#CMWWB7L/Y&72(_HB.#9U(U2G087B"+A!(+#M^$&(2ZX0W'YC/A$Y
MW<CS 3@J35N2L\ V95==M5IEET7_':"DUCBKBLH3@%O]=T%?<UVE5TF6E@X7
M[[J77H!OOE;E&^LL:41\2;7C+ND@UDXUZ5-J/<O27M>>LXE@$L1CV&(X[HR
M.0D((\%H*HN6;W:DW5;>S/;:2W-EX;7L,G8P_\L=<10AD%UERE*$!-MA&6O4
M@YK5M(\^NR'. B46L=A,!SX)]%_"S$6_\3B09J8QH&E(9K\!TB<YG;%7 C7&
MKY+);SD/A(P$<)$?_60.(I6C4-4H-*,9"BA*.!R(#G=HM1@",4 ^S&&&*G3#
M(2:DB#OL(1*)%L0G D!093NBCOPAI3=%[H<.PB$3<:C$)A8$BF($7)3B 22.
M)(UR!/+2_Y1FV* $*,YQ703C0,3HM_V,8QR8:HJGGH6ZN<0D5]1+G? JTJI:
MZ418$-D)@(A7R.%-BW2R2MU/)E4M:6'R(_\AED?^<Q+99823CPR*(S\R" ^$
M!)716DHE9T4M5E*+ NU@!3H>((%U)* 7WX,(.19CF'A$$#L?P]]\/+8RYW@P
M71W,8,SLI2_0Q.R#!H1,P"96#^A4,QH>] P)>M&+B9P  2-0S3%3)IH15.D$
MO2"!.6T#+P/FJYO1Z45]XM>+$P!0G>RYH,7\9;+UK6::YIJ9^OQ7P&3NTV'R
M&=EU"N.]G0& /T\3&QT5(C@I>NV+(5J;# <B@1DE8' (&8QB0/]THR+)P4M"
M# !'B42WQ.!H: 1)FTL]"M*#I#0C!_FH1 HSQ"K9,7,53<A%(51#$;64(#S]
MD$@GAS<K\?!#!+E31=H8@#DI9*E20D!367JEJ3Z5JSA5Z<\,HE4 ^'2':@JJ
MW\BHT2.]U8D=%5!2;9JAKIH5I ^J:P!RBI&9OO&E,T* 3 ="TR)IM;!4Y9]!
M%@!3*^$5:&ME:UOM)@<J/LE+<1S04^$XH,O.-1YZ9<@"XE'2J-:TCA@9DS :
MEQ#'#K:P+)6J76E;$+]>9*=52FO9* NUS77D([C[@*90]Q3>;>IS@+0>2$ )
M %#&BB^,C$BH3E"]K$1D*T3!B7.CVP'_YT+D>,6=Y'65HA/026L<Z.V+I;K+
MDN\*)2_ <"ZQC)5=D<C.D;"#R 9*XM[W@A< -O&('J%%2 -3;R][D0M+_A*8
MP73OA1'9'&,,LXX4$C VG5'HRV9#G(7B+YH:SO (TS?,EG4,P[>IIGE>8S"*
MC$"8E3'!BS%"SW:*!H 5.8$ CZ-C /28,MB$",*B\4V+]'B8K2%!B7Q#SQ(?
M$'\&E9]VVDGE?EK9A.NI<HK!<YS=./1;4HKA4!&"60*Q[4PA&E( '%N1R )U
M3GB30!AU.I!Y-$A/9KY(4Z&!(VQ8\<T&T4B$+I( -4MNHKX=VV8K>N8!I7E%
M;'8S1>!L$9*B_Y4@9*6(,&+D)8RV^2((0/20'A1G*2&:T%,U-*(!=[E%4W1O
MD0:3&@=TIPL9BM(3B>QBMV8H@JA:2'E.R*FW:! _HSK0E>Y21CI-D&+3J+>P
M[ENCE5;K,[K6B'F2:YM/;>DWFQ8 Z^#2IB=B1F!#Y-P'@7:?_ZSL70_:SJBM
MR*&E/6TVD8,<JI24IJI"J=-!!9$@R=1VQP+*"SC7WR$)U0:.#(!2<E<B8G%*
MPI^UWZ& 0RFW&Q4E@;7'6GGDXY&<[B(IGJJ75!PGHOI 6;;+$O >DBP2J=[%
M7^(Z9/%;5RYW"<@+_I*18&M[N,P9 I0ECVGT<GP" &9I%"9B#\=+F/_J,8Y!
M':8>@FKSRO]Z3XC)R?5L6KD>/P: =#HV9(V<(,61.?M%Z+D9&+_&X1#Y7T9,
M(+_.C!WM*D,.O=H#&]UD['PETT0#S3F9?8K,-5@/6;Q0=C.B/ZK)?>- F0O2
M6ML2B*9$TAN';L15C#2UUX)^]F.WBIC!1007DYO(8>!=D"NUWB)TEE'I%R/6
M>9L^0YQWG.3O[;/*6SZN#=%\ G8/)1R)WMB%#DK2/OI8V]\^ .&VZK,G4OII
M_ E/%^'\+G&TF#1*I/O%WZ'OH;8WXAM_1Y^VD)=D.U+D@W[/&Z%]E6R/>HBH
MOK&L!ZI(80_MV2M5]T%?C8!6AE1)JQG-JY6>7Z/LC6:A240(PX9(1(%X7O)%
MF_XQWU35GNW%VP4NGP&ZGJ9]R/\QR :>WJJ%"TBEGZ),U@*:"+@85_006"95
MQ?/X&_4TS\)%1"_ 3B0='%"<1<#I8$3XT1"6W"K)W,RYQ(*%Q'>A"L)1RZK8
MA+%LA;4X!;*5'/7\EQ$J#TN@"K%4#\Q9#ZI Q<M-1+\U!>H@%\@IG"4]A2Q1
M@+:T4"[_[5+X5%@"F _&S :':="[S(<>$D?"E$??51U]7$?+%).YL%AW[$:-
M241VL%U0O,M_R ^,K4MG."( B%U0()3<_4?9:="66= >.M.4$6+B2<PT3=T#
M?9G'^(_-%,;W/(JB10WPS1L"5)M"N,.OK<B5@-2/Z!H 5A_R>150O9^#<$F=
MS%&HX8@P1HDP!@#;*-&MK1XR*@B#N%:6+(#[[0TMNB"3V"(S2DDN)L0NSM6(
M^&*& ..,0&,T*L9>Q1XO%L3TO4F=9)&,W!5+#<29>=X[[J/P(0V,8*.4&!8/
M<:/=?&.;[(TY @"<W*-13> :0<J'K&-$M..=U-LVLI[B!*1#_WQ@-4J),UKD
M0-Z4.#;D6.%(/8H@1(S;5!W&W"0DH]B-FASDBEQ;0X 4J!'51(I;@NB:N@VC
ME-")]!DC02R(+["-0&*@!]ZB2$($-$HC;5'C4BZ 4@[CE&AC31Y*3 *(G$C)
M">0*@^'<<)&.*K726 Q<2Z0*$(97M'12=L'.Q)&.1'2A4M!E&^[7K'P*J&"$
M36AA=CVA*8D<2-RE)&%AI*@<=>T<,)!A$7H$> &#J6@2=>'E1$22<76<SI$E
M3@Q22 2="7!/ C2#F$745C7 +RF'D@5B- 74*PZ>*]9,O)23NG2,0+'+,67=
M"D%0-L%3S51$+ZQ&-$1B4  'R'@B1O\@$S5-Q#@M1R;F755I!G.P6#UD8G10
MQ\ XW<QX&-]M3&VJSW<<$WK@)G9VI_ULD"B>3 HY5 ,4';29'_ -EH4D97X
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MS+6L639&]/7>&+FN,>7:0-_W,?FC$42,EGD8X^-<53G;&L07/[7B?F!&)#E
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MM_F+DBEYP'Y1]ZRL91NB"K/8BK_O__OICDK!C0,<+@!H H2$!.X0(-@' "&
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M&K#9^AE7F!RA487V\80OU%$*\B#=12 2XX,XMR 2 &N]5B;L[;*'"YHT$MV
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M<I/9.$C*F$E0M8.>)&F[J)-5=3$HPHIA%8W@26?8T6F=\SG?"(YY&8]N>9<
MD)[VR)XGD8[N68;M")\E,9_Q:)\@P7@-  NP85H0>)!$IEIUH7_^*)!B=Y%/
M-$4-B&SO1&VH28>LA5IZXH=YY!@;#SE:#"AN?')% @A;AT)#=D-L=8%$5H1N
M9F$#%M@.%( Y*REO8"$L'/@]Q?6!U@6=_]4Z+L6;-6J=//I(>/1ZKQ=ZOK=<
M3DERN'APWZ5(M,>"F,=)"W>$,")QK>>"D"8CTI.3J.AR/&H_3%IYQY)5(<,B
MJS0<^S-@T82?ZZB?\:FFXKB7=^FF:\JF(B&?<GJ%^@E+?SDL_)B(HTE/$;E_
M9=%$(Z:AB$*H"=BAH_4:#YEMD -V_^>HW!1.@KF8IDD8>>=B@(J:B2)0D_@!
MG"EX>]BH;&$#'" .(<"B+BI&"<"-*__#-6:$ ,(E ,%'2K H@OUR4FOD@DI9
MG*\8EK&HJ]45G+!H.G<&4IEG9TF(BMW14V[D++H9I$%)2MQ9E,WY>6W6.MZ9
MA!Q3K27S7+II<OI5DV5&I*LSGL.A,L<' %19)LIWIV6XGG$*KVI(IQ!&KUYH
MK_>)KU]8GV])2\C1"S: 1/#'3>>FAX6H8_Y(@'\Q14#TIY%E60U+F83RD%E'
MD@^XAXOJ. 5JD.9T@*@E1')WFIUQ@.HD69+5C_U(;HXR#B<9 KRA*U362N7Y
MC>2P#\71#.X@DR0#>:='BX%V2D5)7U&ZG6J$E(MVDT5+(DL;9EK*G#YUE-J1
M@LY(<N4J@@S_-Z1-.5Y<2B+]MJ.=]X)0F4=!BAWC:J7QE5*,-$I%BSMC%B)3
M""SM"B?\2H;Z&A)C6+?2=[=YJ[?+!Z?LV;=^RW3V>4#RL \GT W%T0NN\ %S
MJ&16]Y$J5E!45UDL*T6$TG^5F)GXI[#FIK#KQI!AAX"0>W9IPXE^DE"D:1=-
MEF2A(A>08AA_PT3P9#CF)W:#< KGL**AZ \2L X)4'S%<6 AL64)P!PKDHM'
M154IEYQ;:WI%NG Y"7EF29L[2$@T=9MS5HS')5U^=)/8F9U/F4JY1XMT)J7H
MLV;PH8N39H/?<GFLAZP_JYW9ZX0"5AS^8U8:-KC=)Z\JH5L/@#G1_\>_UP>X
M;TG W7>W$X' W&>?9J5E,#D<FG"9'0IM"W@H(VHJKPNAB7. )P:9VN:QH2M;
M#GJYW-:Q@]>A![EUU":!1[9.$K5BD8C!A=J I,4X4P>I-F ,, NS+;JJK>JJ
M8-%+)R"CO2";'J-RLOB<1ZJCV9EO!->;2-N]6#N_Z_M5/!A3LU.35:P>5IQI
M:$M>5SMPQP@BB&2"+J@M!H>E!C>-^?9?3[Q)Q_6EX[O&GX0RG4,PLU0T#'Q]
M_IL2/'=7?2Q]_@J?@SQ]"MR>A_RW;+HCH".K$NQ_2K:HA#FH:8=:^H09_6?!
ME0NZE;BQ59=B ]7)=Y=B$$N0?EC"H_LUF-I<P;*[N1GIH(ACHJYQ"QS@P[W!
M"D"<>+ D$HJ;'.M JYA&C4,KC,_+K#B%JZA49BOGE=3I1E@YC+68O-I+E)W'
M2#"HM"879K##Q0+SMOZEHZ>3>]>[DZ[7S=#[G47:>].*'G5F4U6&'/+P%;*D
M,Z*VR$NW<\B487:*S[!VM_WLSZIFP',9T )-:@Z\>,=AO G "G0BPY'33XP%
MHOX8T8O9N2/+4!HMPHR)P29[*BG;*!R:-[>+;0AU@",+8W?APK$QH -H?CR&
MFH%XHG?B 867*S#;#LJPJFCI.?\A00XRBD;"T('>?)/.:R]!:Y83%Y1FW)71
MR+2I5+;XI96U^;/""E:M$Z[4:J1)G:3PH5_7T;9<+:1^-L7=K"[5S&_*>]9B
MZV;,J=;)W$:V(V $]C3O>M XI\\YTX5X_7-WV]= E\B [=?ZN2-ON+C#@0L2
MT $>$*J@]5D?&J&9\8![8IIDT[J8^W\'JMFJF\(?N<D>JJB7ZU!W6!MTE](U
MO(BO"\HIIH<3F"J?Z,,5I<N_\:(911+&2ZO"9VD6<W%H;5*W>DGS U5G5M8B
M6#&1)K60!GI93,;+>6=[],S+N,VQ6-7_%LY0N%]/S6A:+,U6Y<7,ZXI?VZU(
M+:7E6]W_9.8/Z5H<.&O8.G/7@[UJ>CU"&0;?\3UJ''"W]GW?'#8/B;S?_'UA
M^7VW.(O8PA4<LF #F7B[D4&B?4)LK]72TH;"C9B0'/VY"WEMGVRZ?0-#(5G1
M&,ZAJ^M# 4E_E,TI!"OA$OMWY]=9_P@.-A#;,:NJZ%#;\7;;(C%@.>L.BHV;
M4LR+ ;<QZ$LQ/4M[[%RE8*7$V?N"<UR49#UR*S<R$/)FOW."T'I>IT3'(I?4
MPMV]8%VUQEU57JS$/PJFRQJU7H6*ZBM@5=@R%!#@JC;@2K+/%&8,<$YJ<DZG
M '[G"D8!B6SG?,YA><Z>.Q)U%,'0P>&["Z --M#H'@"JH(JR_Y .JA[0V) N
M69=>Z99^Z9R>LHX[Z9"(LIC^Z9(^#J4.Z07PZ)(^J)\.B9 >ZI,N6:K.Z1\0
MD*8>ZXY[ZJ=N3IV>ZY(.Z[4![(X+[+J.ZZ(^Z[C>ZZ<>ZL7>[+W^[*R.Z9(.
MJG4'Z1[0Z+>@#5[D1;T!BKI%93<NM_V3X\&EV^EUE--\FTRIK<(WEL Z@MX=
MW-P9>E3+U2\X<=0ESNDE:*Z#UG'&>>9UWA>"9]%]Q35EC>(MM%=]Q<48Q<6Z
MQ2THK$P<:$F]2C2+ "\)%L0;)ZP0Z!OFYPA$YP_6#@;M\6G5#G?;#B9_82"?
M\B6_\M6$\@H\#;\,R<<K 9F#.36^"?_;P*(L&K.\88% 7XY '[-$#_2X'/1%
M3P&YTO1,K_3<[O1.7_1"3_5&__183P$^?/17K_6\P>U8[_2X3/1'G_19__1C
M#_5*3_9/;X%;K_1P[_5*;_93S_9M?_=<S_5X?_=+S_3B@-,^3P&L$(K@SEO(
M\9([4L\@,0TW$L$RJ:S7(GGO&QZ*]/"^&.7-:U1&/?!1'H(^>^ZNHY1 7K;S
MRYR"QO!6#7%'M2PAV,;'/,RJN/F7+UUH7*LXBJWKO%U%VM, 4-=$LP P'V$R
M/^=[36' '_P)M@!W>_S('UC*K\#,W_QZ]?QT*A8Q"L$VOP[!@?.8PPKHL FL
M (J!'_BR(&5FW=X.XH#^XW_^AM?M0/_SZ__SYK_^[A_XVE#_3/_S]Q_XYS__
M $&A'06!! <>+(B0@BR#"1TBA/C0H<2(%0M2O*C0(L:!'!M&E'B18<:/%-N=
M9*6LW0*6+"6\E)! )@*:"   Z";O_^9. #II-I 9KUZTH<>(#JV'%.E1HM$T
M(=7$=&E2ITVG+GUJM>I5J5.C3B7ZE:C1K%3!<C4[5NO3H6R;9BW+%>Y9JV+-
MTD4K-=HQL&[CJL6*U6B]KTJU&D[;%K%5Q&T9'R[*="[DQU0G-]:;V+'EP6^;
M\G4:V#-5T(7#UI,@( $T!/O(3;M)CN=LVK5MSY800/=NWKU]_P8>7/APXL6-
M'T>>7/ERYLV=/X?N?,%MZK-[^ZJ>7?MVVB:B?P<?7OQX\N7-GP<_G?MZ]NW7
M+T ?7_Y\^O7MWS^NWOU^_OT!>,<O0 $')+!  _/Q+T$%M]L'@)H0,"<!81*
M28('6&(%'?^65AJ(E4U.4H85"CP<\<.33D3QPQ W"1'%=DQ$<<453X011 ]E
M])#&=F;$4<4;<]Q11!*![/!#"A9 <1L>242RQ"!]]-'%&A<(T<D93[+R1Q:!
M1-)&&$UL\<0C7;SRQ2>?[/',DS9QLIUMT-32Q1*/5&8!#5MRZ:5U9(*FF9H
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M"I);.:GP(FDY/\H1.>6R*.)+P[4PP[8 G#7+H_#C"8DJR9C\PL5XOF/02=I
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MFSB!$QC)[]*5" :  ZX'0#4!RYW94K&_]<NY\UJGC,-""BY/G=M/,]O@V=@
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MN]HCW: CUC;6"SEPXVB@/>+5>T(QWVAS =?N2[<WY+YNS:)F;!LM7;BVR4H
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M]EL?N3JRF,.QA8!'4Y;[K 8=MOQ&7"H[#2Z^)3J:B0DYG?-(TMH"NH[$B&8
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MB\_,2+LS&;F(O]%Q.(VHB9MI$#H]7M8I#9>60[*%QN:,937U%4()C$"=V &
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M/>MF!_O9OZYVK[-][&EO>]G1+O>UNWWN<$\[T\&==' +?;:RA=4ZPO(J$W"
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M.<*O%0(0<5NY9Z_(^(VO8\0_D?L5>(R[8^%<M,G.BT6J^$GKBP1BCEG@2&Y
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M)2TAV^R./GO9QW8V/Z'-;.HX>Y(*0E4R;1DD<*)II&*,T";W:1Y,EJB35Q/
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MWBA6W@"VG")D*0<V55B2X8C-Y9:M2UX-'BFRC%*0G@@RX?ZUYY*)3E'IKPS
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MLM,N+@V[:P.:)55-'\3AGO09)X&:L\DHG]ZHZ02W_7ICL-<$[FH+WGE$%\X
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M*ZVZ@? G95H)&TJ5(A8M'O8)[6/1W5OB_E2LUK1F_TRM:^J@<B+1,"6O'"G
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MSBG.KW(E0*L^$9R&J$6NV5DGH<$R=Z=&A@:++72'\N;H9-/*-*U8$A3Z*%:
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MUBK!6 TNQMHU\I:V-!FI'@P4<J%GC,U<2(UP04>TS@2F1H"F<LHL%B2=%>.
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MZ H5[\#FUC4N@M9FT^G&^,$G>[Z>>^J3F]SG[WDE: ;1A?+&<#5& F##%!D
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MGE]^"$*Y? \Q96FW7#*G<FS##S2;J1_/-<B9YZP0Y 8D(6HN*&V(JX<$<)$
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MD/LU,(J.Z\B6]B='35=]//E$,124<X: M[&2[5 Y=20 =]8I=5-F2RIR :1
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M,$D_Q*MC?-9D@OXYQZO5LG8^F(8V+IQK<S,]V?MP,B'MK%--R*G=Y7*0G2X
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M]EBF2)L66:."HC>!""88R:2BU.FH#)#D9<BWDMZ+;+VX1MI$+V6%$3@"IP3
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M+,FYT&32*"*)?"N/6\E>2_(XRHXQ,Y@8L0]"#%+):HPR-0(HES[, Y(1%-(
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MX)=Y=P"!F^<&#4@G\?@('5M"+PP =9"E5@((80GB"9 @((%!@P0/OC*@KUH
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M$WKB>$B9@^D4^QIW[N[I4[_Z;900:$33 )XT: &L",&TS>K6;*N5VFFM*^J
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M54^JK-N^K?N< P6$  6(@S&T#Q?H0X.LV?#E9@959]V!$8(:W()B9L[A3U"
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M&:[(Z"GK013BJ\XA:1 EPB[JGA[,?V%KQL3KD^6-LE1C-ZU<K_I8?G%%F2P
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M>WY5A[X46]D!?NR]QSP@@HDIL?A>;5+6*IM&U.4GQ8(P;$$U%<7T];/OWC7
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M5$.U/7S9NJ/WF7\G>W63 L"Y>WOA>YTD*SZ7\52]W=D;IL@'FJ:AN*K!%TQ
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MX_N\"'"_U7LD_5NN^KN#V<N^WCN^:Y96RXNIL1C W9N\U L-L3B=/NJ_S6O
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M-G4L5G&98VQF,I]9S6EF\XME_.98!4J^.39J5Q=2T.<B@!P.OO*^ON,+KTB
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M8RNZW01N'70$3O$F[VP4SO)&;ZO=E2"$/$?&$+5V3TW3ZZ9,V%GQ$T+HA5Z
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MN"WV%!6Y8MUDU;@U(FONL>YR]6ZW'Z:D5CQM323/-!=9-*>__P(<L, #+Y:
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MET@B1D@ )WZ.)78$*T*,!+C/J%5:&R' *G;&!RX,!882E^BB74P$*9Z.)P*
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MC$_57AG-H,ST90W^Y>X$9JS8H& 6)F'>QS\FYM)(QQ5UD0]V!S ]#0Y*(?9
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M=N@Q/6[JS0YR-IU*]$69K34M4-UL<[SO19R 0D3R1<BQ4FGM$H7CK:#H)BQ
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M,<@<O51RR"*M]!%)&4GJ$$<TTU01QQ639+)*#BFX<X&L,DK *W+L0@ :C22
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MER*!48Y>:9)8%F"5C/.1*#5IN\M]$T2E^U"8FG0G9?1N'0EP_T>?R($ =R9
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M%NWL\T3K9&/310+E=17&_Z2]2>CG<^JW72)ME//K%Q/MP;/)%#_.<M[M\2Z
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M?/M6ZUB04U4^UFOT;F2U<S/?1;F3;DJ[@C-[7OD5:&C%J%4>7OV0W+0/!0K
MCCU[MFS:P&;GIAW; V_8M0L BTV\5\,-Q LX[)!\0T'>!3H41/X!'##G!R_$
MEDZ0^6SL Y-'G\Z;.\(+%P@F-Z]0._0/NXFG3P@>>6SP *"SMR\</\$3PA6
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M#RLD']^8T1QM-*24=)'&0%I'F;%6LP63F+^2M%"+QG:SVY/ ",RT#Q2B<*C
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M#TI;LQ\<C^,P(->(%N6I0@P+'RUD$204O0%""#JK#B\,$.7X0L93,W13C>\
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M3=/=&M0RIR<^/<U,ICJYDZO0E2 SHNI,N=R-R$S_MMTO\DZ4BE9* 2/0<5<
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M]N4W"I/8D-Y7X$?J55IFM&;T.1?V06<Z,N97."8]CIO, $"]%03P:%RY<61
M=B1XVI=" O^/1DJD_8CG>$8@_TDD\9!8?,47@W&G^93D1T($[E2D>K:71[;.
M/^[C>=;;I\AGN[7G@Q7 L"C# J"<RFT,#R* .21 /)@$3<KDC>W$P_ DN"!A
M8DP,2S2ACJU$E*EA$%F%/)39A_;+F-5$%^H0#85A4F@55+YH#RG%%6J+7Q!&
MMF2+$LXD$B;1S'GH88CEQ4B ,+@#RY'#9 CE6S:IDSYI6SWF;/Q(1B2%.2
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MU9UD(EG5*L6V'76I3]TRY[9ZR.):[JMO'5#DY?K7^83-=:MY!.\F3B'G;,F
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MM"-JD=2B=GW95U"ZUFN=$&RIZ7WAMPGEMYKHMW[_D?!^RVGLI*63*-1L?W>
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M),$(6JGW:M?JK\]^^^ZS+X'6\L]/_V'^O-]6_/7OSW__B>*?O_X)<(!9NQ\
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MUJ\;BO%SN$&(0WZ8.(I[DF=  L?S3K^3/>;MMH8EC@\_D/\1#AFXVY:3V#X
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M1(8\R(4T2(642(N4%GNSM3 :J9*B)9G;Q2>9"SYQ$5C4!UE\0Y5<R:Q)#02
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MESE9Z=:Z!FYVAOUG^PTKY?9"H(FZCS4Z*UNZ' 7# #[@U\="V _]JQR.Q&B
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M;H>-X8LAPJC>BFO#W>+<(.YM]O_>\*E]MMGX"5[WVH-KV(5^-8ZX=X41%D[
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M,!X$0.,O,SH1@"9TH5G&$I&,@^TJ::FV1QI.;&XSY=A6V2+:GI) 9P,N@KH
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MDTG_W=W"2=3N\1&[Z4/3X)L)ZIX--5_ #)Y4(-Y'H4NV&%5G3=-A/F::*-9
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M.UYN\"XG-'+)"R%B8=IG5OH&Q31F9I1KT7+-[N(!+>P0/J+G>)BE6YJA<!)
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M]9[ILM_ N2]CE8;,F0  TX/B&Y_G&8;@^WJ_>4X _S-4#YR?K;=7 1Q7$=/
M">7;:A6@CV0?*!.]+QS#=:LJ>,FDEMB8-P,_@>/D@G0"0Z0IWBRB[MB5?D^-
M4\XV@$<^@N(U!H,AE*[V7-./PC17T+2%960$RD#T=(XC6EFD-O0JJ!M!KT)#
MJ9@^)ZF5]#.9N>A)G=(T#V+O$CE'8X1)CU0"4R0I2(F8'P]'2]"9,XPSP?/W
M%-LHZH>)8*J82UPC:D,H0&-#%+7OA)0TE ,K)NG_IAI-)T.!O\XV<FK_VM0N
M?J\['S@O:K,:)ADUT"4_AN9G?\< 0^]=-FXJ7D4-Z5/\BGB9C&G*H^*92&\I
MSTXT7Q@OQKRENJ]1U8HT,G=DL^O,XC#"1:D4 X&IPTF0 ZM1-L;#DX[I93_I
MUA,&</C.=,+E>(B4AV^I(*STG(@CQ\W#B0ABBPD9+^3K/$(/@NN17E*O0QDC
M @#G@4%'R-_EH7K=J%$316[XTR4PUP<8[?).RT5I(1,YRA6Y-08Q(V(]P_O=
MW_]#0BRMN7@5$TT<A;ZYC8((7(3,\IO)=WS]6;ZW%[]O4 L8)<*QE[5P<-Y.
M:%??V56]=WG=.YNC!%E["%3^'>53GHB MK?U1J23,I5$A&A#D&ZC.'"\4-E3
MEZS>5GQ.-B,:]]!V>R#DJZ77PEP\[>>CA69Z96[9QF!B!UWRPG-LY_U2]*D?
M1'Z%%B.R1V1M?M71>L <1Z*=&'\L3'#^2PZKFM!:7@ ^;'VV]6W*G+=B40-'
MIA\EUG3SD6)FQNY*ZK<8IJ@W+BG'3,YZ^V?RJZU@9A'[$!R[.B3U@1%5^D'H
M=J-PX<I:9C#>!4)>PA%E%K<_+:UM:G"X/F9WK6Q=LF3_!2UTDF4>\SX"SQ .
M<2TIP'[L@NL,V^YG?12Y16>G.\S0((3#4!9;B 7-7'*X2&;X=&(WR9#V,1+J
MF_'/B$;H)4"^,%=;0F!SF>PEH(4+U@BS*^VMJS3J:]_6-HQEU^$6MD)@!V+\
MHT-H67_LSG]B>0;%UF?M>G%9M)5<CV7O.P<@X@E8)VQ@00D)!!@4()"A  D.
M(:YK6# >0847]>D#P+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;/F2P0X
M$ZR30*!G3UH^@S8)VB6HT:,$@/Y$NK1G4:8$AA(04E0JU)Y#J1JUZI/K4:U8
MKS9EJK3L6+%'NWC=BE0I6@)/_Z6N->K6YU.?2JVJO>KV+E&Z;X]ZK1L6*5?"
M<+M>K5K8Z=RZ?A4C3)  )P( E\G9W,RYL^?/H$.+'DVZM&F/!O1!;-C0H6N(
MPM:YCI=@-42'L1VV+OA086Z+ G(+=\U0=FV%Q74'ETU[]6S9RA6^2JWN^'(!
M"33J4P<Q003MM75BGZ O=02% K_KJY8<>0CD EYI?"_,7>IJZERO2]#.@ $-
M!5G7GP%<)(2<?&=0<%L\FY17H$ "_88=;++E=IT N" 78870"72<0!V.D!R$
MZ+7G(6S160?<BAJ6")R+S+4G#$*3:73:::E1Z!MT-+HFX6T'H<><<0VAJ&*,
M%UHX9/]$Q+$F'D,?EKA@1)11H%UT\8Q01FKZ).!A>=M!A- Z Z8F4'=@^@*<
ME_N%<%Q_^KQB')SZA(#D"%;^)R*$>&KTRH7R&: @0\)8&6>)US7DI7(6L@:?
MH[\AB1US;$;76XO Q:9B;JMIJB.44UIDG8\=+I?=1C>:MEZ,+!;I(I30\=9J
M11,BVAJHLVFXWT2FZN@HHM=UQ^)#BTIG'H>X:1>!<1%PV6-PY&F4GT/JI7/<
MM>\U%*TX4(+)78DCB).:G+,E0)X!YU Z(#:.RE<-MPI]V.BE)#HYI:6\ <EK
M:_%PVJ1#UCF7JW)1OFAA;@FQ5JK _*":ZL,01RSQQ!17'-/_93CUDL",@5WU
M6,=OS2544(B))7)C1D7F%%I#=2'$6R6[57)4*.-UE%EBJ2Q6R5SI+!?(4,WL
M&%0NUXR4SD('IG-@3=Q5U&26 3"-Q517;?756&>M]4GE4<;KU]9=A.*E%]6Z
M[T 8Q79FL;^2>!M!%ZUM$:UEDWC1KK(.E!!! FE0GCN+KB8.%^6] CA$XJ9&
MP:(A:.2?/NV(%T^>^BS^4$&$6^>X@7ARN3C? JA3WB<Z"92AZ/J8\5!#X%FG
M3C5<1+#W0!'2_JK<Q,Z-*;&\.@2Z0BC>S1N5O1>_=N[Q@EA0V5(NU%#<+3Y4
MWM8Q=;VHHPCY3FMK"+7=//1?T[V]_Y2R[KU\D'5?BN%"P>D-_**)RUXV1+Y4
M4U[D%P5J^$5<V)_:! 9""#;\ T#K-.X\M/%%>60GD!%H@(#%@HCH#&"&6X6N
M/&6XG@ V9Z +&N \8[*;19[G*.49Y&LF=!2OG,.KY94N=V4[6Y$,1");^6Z&
MT<M0"*FDF^E1#R8:V5B+A/<^C+C-=KY#3N^R%SYZ+41L&GS5:W2RO-ZL9E$5
M2IOV!. W VRLAN)XH $ >*8\&: =#FE<>?SS.8:8,7+.R9Q#-M>0=H )CNB9
M( .1Z+]FG$^/5%0('9>8,&*][VZV@R(25X@\*"6R1%@T(0S/]T3>0,]YO3D3
MDS"YG_;Q2O\79_BA*$=)RE*:<B6600!E>.*5M:AL9BI;BU229A>2,45E2TM:
MS$)&%J#1$FA T\HL6=:4I?U%:49;#%_.TK%7 C-ESU3,R*XB 6%4!B?3V(<\
M3LG-;GKSF^#LC$9JV!Q<M6T_SI'0\(+C''XM23@\*B2)1F6BY,RK7K$26 (>
M%P%U^**? 9B.?[!A'6N""3\!]=.65 .P?=Y''?WTVWK>5QX-?,A<_N%"AAJB
M'FXY23T4:$B?UA.>X&!C/<NRU(;:@Z1B16I$I(J@$^O5FT9%B5 \NE"KF.0K
M@+%J2-=*33A',M$U3216/^W5=>"IU.O%J"*E&A&2_(5/Y:SI61#_8I4^U3'0
M6P1 '5]53WG$4<@$+%0?L1/K)JCS/N\\C@L!Z*=&JI'2!$Q''Q&@R%K70U9*
M@=2*#&E6Y5YDQXFJ+3[E\44A)02KQB9*BGG+E*2&LSL?95)7N-)7<L8$R>SY
M2D7Q6I!Q;#14D9AI1[DJYV4G5,A$16E3)6(J]I0H)'NBTT4S0A2E6L4JAV[G
MJV'E C_\8U'T4.9QU?CJ!/ZW4%H=]S[_5$>T]($P!^DD/,M%JVH%"R]3&:I+
M$'*'?+:SJ 1\%SZ,S9<&(32\E=H+.QLZSE1%BUI7V9"FT6EI]GR#G(W*2$SM
M2X#]2DO@ AOXP";!6$YJ,\UG"NTN>F&+_\UH%DW M&69: %*9'Z&89H53<*P
MM"4TDS*RO423EE8Y63.ER<P1M[B7QGRQ-%.<S&=N>&74I(PY<-*1?2#XQT .
MLI!'TS5%&I)W*;RO[7J$Q8,$<+U;W&\3NU>B3F+/?"V:TD3$ 2;M>+D\$]"8
M]BCP..V,T5SZ*&#OR,PEQXT1C0*9( !=P^8SFL]_^!L>GE\8@M1DL*8/!.\A
M053#@UB2T#:$K][:J440:9%]M6-?^JB<9+R]KX:L>I1!&H(+TB(XB!$IB#!4
M2*O76'5@M^$O$DT(O?#LRT#,.[24%C6"YXW:?6+CHG_:;#\W1RY#O4F &.=Z
MOW;8#XYL$L:Y[KKCN R"*-![BY!8BR4 /.\);7LF%I<-X&SDB%&(NHUL\Q!]
MM^,AR82P(70,*8G#[$D2T1YR6[2)167:)40B,P2=#W\,:A9:\GU,#!*2JYRO
M3::OANX&WJTOF4[U#?J&6R3.MK_\Y3"7E"!D[K)& "B?.<>-S1I/<^3B#&:7
MFE$9A>QU.W0(/__(#B/"3DT !=#G#]9F?$V4M'I#A<3>7/+6G!P?NO7FZ$4Z
MNIJN4G>0 LY#^PYXR%"/NM3_J883P#WDF"(NC%5^B?4*2W-I(A.94F(L8YA]
MQ9BQ9'$O@78RKA/3ZV\_<=#B?LN4R;(I,JLQV7TR&6@@8!H((,?4ID[XPAM^
MR!,%V+,6-*]$(>M$M9WGLZ0:6^;PW+:;1)AS>OH;_NSZ\_^37<(ZSY\M$7!Q
MV3$ NV8S@G8L-/0;8]98KX,+M_[GBN"1]\:=8WNRWL:A&J@53HG#V"MVYS:^
M*I62<)/%K#*)JI==T_,JKQQA&0=%DFU\=X3*;^I*"K/N9&UMT28JXT/_L:X!
MK84$MOF$W?91WY<W1D&OK,C9=#)F6*YY*,/=<GE'_^9! ;QA3>,"++[%*:>B
M#YH4_QRIAPV')0Q<I0_:<'W AUGMA"R,U3[E@GR*QU\"4WVI]7XO11%3]4[H
M82')45(KDAO IBB>]FGL<1V!PTX=*'G4=T2R)2-(51ST!"&2$S"U<B\9B"NT
MTWJ@MVMI)GKF1!FN]SBO$#FI%WPD,@*E5V:O\'(<M1X4@!R3T2P$LB;@D3<)
M$(%;>$4%F%N]AUE/0E.\181,I2DUI#ZT\2+.=T_MDRE7U%N*\BG;DP M2!P=
MV"T.<WB$6(B&J!*IU  :PQ,7!DP_LW<WTV%,(1=:P&)]T75I831N1V$3-HE'
MDXG3%&,J9F&DF!@XYA5^$1DX@S.2V#10P14<1G>$$6$5)O\5D!@8,],=4<,1
MVW2(OOB+P$@U081""I$AM3<E^#8PDI1PG41(J78B\A1:LY-P4S1"4P0\CG0V
M!$$9W-B-E$%."U%[WA@@&Q-(5N:--)1^X$8;\=*-"K%M -1$W'A#W%@1X<&-
MUV9EC19Q9V-( K-P;M->/ 2([/=D578F3J8?>1,CET13ED0K+VA@H(9H8E)(
MO2,WZ9,W B B!.-9CI2,N:8<M?9$.#1# &:2@=16Z.B-OD&'ZOB-[=ADQK62
MET49#X<=-LF.\#AS'L*-M^*3AD095"@1 <(OM[-I),F%,GE)B220B%2-N=*/
M_6A%Z9AP]=9>@5,Z C:(!Q9$5/;_C$I$-]CX;K@F=/OX?)UE2)E61,CG:K]B
M9/4V&2OY9,:SC>[8DPG D;U#A2R90MQ((^75C0*QDSX7(=Q8>P9ADTI9CTZ$
M=&@#:9JV$(R&:50)8):2*TQDE(A238^I2")D1 _7([PRDAO$E<%XFJ@I=2>0
M$U=G,KCD8@XF8226=7 7%"\C&$>A!:.8,BA6FTQ32Y'8B36V,[Z)&+^4%[ )
M80V6,VLW=KYI&&6'=STQ&<U@&=H$ -V0FMJYG=PI$X9E*Z/B*-3V4C683^;$
M6IRU@+=U4>[U?L0!A 7G(>=VE(ZV4XRU@ID6#YP%(UPX?'@H5<(@6/E10C4U
MGR]%GN#X_R(QPGN/YWC&!1VZL8,\")A[>&^U(B'I"%/NQ9\K J'6N";<AV"I
MH4ZR 6R:I7FZ<AS0)Q'82(3W0B(H");0B'FJ55\16DX"$V^ A2M1=2L;^B(;
M>"$]54X+&*#4H:(8,7Q1<GP[HDG;(QO)-RFIU8%V"!R R2CYZ2\'JE_$-Q%'
M<H?N::4%52JG$F2@ABB1 E4GV* :FG[7IQQ']1PC4C <0J0E]1Q+BHWK%SV0
M\E1/A7Z/Q7Y8PI\M,H+(X5;;D4FM=9[CIJ@40D^YI4G',:2H%7E0 FQO>%O^
M@GY6JE1'2:/"!UK"IT)EVIVF>JK=A #[@!,-D)<\01BWN)RX.?]ANXEA'P.;
MA;&):D=A&E9WS2F<)O.*L1IWM>HQON2)M>DSSQF<P*H8<3$6PQH4W>%WFM$1
MU8JJV)JMW=EO+^2E U=NBDH\'K))K>&942:39 ..O$-OH(*NOT-$[D-^'929
ML*)"&@BA#H$+24:OI$9P%*!R6(9)$-<[RJB6HA*0R'$^-!4W%DDK.Z1)N&.P
MVEAJ0Y<^!\<^Z6>2&M@^$K!O7=DEAR:3E$8E$8MPK](]"U-2;S-K5&8\ DMH
M5,1H'@HL,<1I%ADAB ::]^(\Q3.E-06:2(0X*@=QRY-5E 1#1DFP[$8^H D=
M361NI=:R\P8B'<2.<6@W"0DW/UF1E:;_/"J$M:5IIEW"62,;E11KH9Y$0I=C
ML/QUM!2Q2!I)<%1Y29B*/+A#L!?Y+ZN62&!K="W:251"C?IA$2&P9^2V@-_Z
MD$!KLH)[&R9:+'G+C,,SLE?F@^"CL*]"1$\[N,5!&^ Z<)OFL=HZNJ1;,99Q
M;[3YB751JVC7=:N+8<;9,;8(8K,:F[\IG< YFRN&B7O'8:][%L^J=<.)B8T(
M3$XSNX>!B\L*G4TA,E 3-9=1NM([O8?GE8EVG]27'!RI,,S7N0*7GH'HI$B"
M+/Y53HVRH*:&3UG5+]C84VBZ6YFD-F&:@A\8J IQ"Q$@5K*S>4WR?I W@F]J
MM62Z&I,551JJW7QO.JKH.X!)Q2+"4D\^YX'K"AQ_"%@&99H$EG@?"*,0>F[X
M>E7PQ2'%HJ*=Y&2=0BE@*2'.5U#4URCGFZ>0!U.1:7Q+-97_*5_7 K$GJ! 0
MA3IXM51CR:>K=:$>'!W%IX'L!5E<:D_I9&66R:(D["(% W#=:\3 0J( $Y$&
MUC!VRJ(YN(=4G*,Z];XSU: WI:7G%HT*#(@V2J=26GY@FFCC=E- <L)KW"_,
M 5'ZZR3,%QXONL/_^*8!PJ2=1U\Q;*@%"G[C.ZCSM"0TZ#U%A\>JQE[HM"@8
MJL74F\F:_VP3?W>Z'+.\K+B\)L9+M9MA: &)?C$8'E.)CBB)R/H62X/*H,AB
ML5B\LCEW%>86+2.)3W&)S\EAW5&=TR /V;G)QGS,&=PEO%.T<,K,<KN 8R)K
M\#%KMA:TK>6YMQ:'Z;-%%:J6 7LK5'93X%JSB@8E^98W3,>U7/A=)5?-M--J
M]$HP\K:W^S%#KM)^E[).28:2AK2,QA4]3GEER%-O)?EPD"L,F%Q:H*:RCX:0
M$+<Z OO'O\._BM=:N2:5&K1XNW,\29:2A#2XFXM)Y<K1_:E!!+M# W$.O59R
MU7=OW3H\+U20E<;,_OR43&2WUJRW/$2A39=$& M%^]JT:OLORO^C#_P@MA9-
ML0J9T^P(NF +/3@$.I*4(3(D:3E[5.S8LB-DL3@4:IN9L*R6D$LMF3.WTS8D
M#KT&07P;/5K=<]7,N"VJU2X]L#7DEBUM0^]*M>S#F3V=<TC9/ XWU+:6T,A<
MV(8]$O)0=<U@$<S+B9]HK+2[G'X18C@6G1.FJR\6JZ+(3'?GJZ782LKDG&ZG
MF\MKBJ68NY-MV9!MFVFG=L4*G#/#=7V'$^0@#_(P>(>=V[I]-23UA_2U*0WZ
M7D>T(;GU*:L5PYW:I;7B?#LE'AQ(*/RKHIK%+S<5(8;<(?5,*LMM*BC9#MGU
M"I93W:5V+8%<6RBZ4E U*G[<7]@8,,/_\2*2L\8<V[U;_2%PH]V5(BHTRB8J
M*"07%:('EB,!4]WJ<Z>>&Z%1[))0FHZ><H-.%%H^!9X$G+#8G7[\VYX7RE^B
M8L/,P1ODC2O#P8+UQ1_1 MXNE< $:L>>:LZELE)4JAOKS;W,5T[V/:%D?+Y+
M=8'D)"G(_1OI79$=4JK\5@V[$J'CQVC^*<+<J\+[7;]'I-P0DG#JU**.9+5.
M]*7<(WXNB:4;[H,YVD)(,MW[00'1,@&6T]0'CL5O:^/<^ZB,:FJ<"N$["\(Y
MF%X4[>(RO+Y21=Z3NMP?3AL OMN";MBJNIJJQ& GHYR[>IRDO+S#A,N.K;ND
M#-JO>,K$^4RM_Q2MS2IBK^UUG<Z)Q:KHS-GHD7[+0F%,$H 0NP@ O3CHKO[J
MJJ+,219E1PFE6E0V CFCQ[-#7NIN:!NYU/:VY3:'_IBAE_+<RI.WS%/0_9R4
M)1MQV-R-%4GEQ%@\#GO-1S:Q@?O/GI65EQ<1IF,[%/&6A0:5:OOLU+A?KK+-
M%_%TG^9%3=>M,]CMOR-%XXZ4. RG\":-N4;3DLD^HW8V<7ED[,BP).O6G)O=
M[7O001Q]E\4K+ GL3%?)XHXH5#U$N9[3.7>E]1F6:JF1T7QJ!!T]8YVXOK.H
M\(Q%">'NGR9HN^&UDR+-V*.XY([7:DN4'OA";/PVF-9 '=^4 T>:,/^_0N'1
MY:")7]8.+"84)*TACH+YSN@<29&TMR("))?V\97$)-7<.[47UMP,+%^O1:%B
ML?H\R:,:2%(FUM6&P;#>]J5[NJV9N[OK8K!ZVK(:K)M>V<HDF[$Z%\+TV)F=
M]\5$-'@/,C2&J[-9%ZL8G+H<8Z/LV:R(V81OZD0Q%TZ#RTJ!$.Y0G9BA3<7L
M]J ?^C.A$8#*Y!<BKT1J*[;^(H8LJJHE64E>PXC,O5$L$2I8](_EXB_E;A0_
M+,ZG'_6T4\'&&@W>-FY,>:E_3]!1^UB.6B.XAC6LIUSZ>ZFF(2A*X>#7YSG,
MYMA!V.%D6$3BO_3;HB0(^W <(YLRX4B,6HS_IN8\Z.73;"'K7>._#_NFIGGR
M!%2I)L:E#[@ (4"8 (+Q!"20(+#@NH((!1B$Z-"@,(;Q*@I,&(_BPX4'*R98
M%T]B00$)-SYD.- B1X,C5\8;P9*A (8."29TN-'DQ82X2$*<*2PA2H@$2QJ-
MJ$\? *9-G3Z%&E7J5*I5K3[55\TH2)L<?UX4F'+F48,+)8+L6);CQ@1 C\K,
M&3+GUJ%E@=HLZE7M1KL($Y DR1<M0;X');0]JI/PT:$473K$VQ&EUY2 3TYD
MF-%HX:)E3Q9^B/=B7K<H'=:=K-GNS+MUU[%M?)'SPKR'#RN]FEOW;MZ]??\&
M'ESX<.+%C1]'GIPJ_P+F"!(\ET! ^G3IM*A3MW[]>A/MW:5SQ^Z]R_7L!,![
M)S!>>A<AVL]_5W\]_O;OZ.>C3X^?^GOW^OGK!Q"\\@ D4+SV"D3P/P2[*T]
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M 9X$+7[_0M+L$":6U:VF<D91S>S"!ZC4H.]DU#N?8_P4P"!]+B/2\TH#_Y(
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MB67Z[#L(;1%@X9_Q)EU_ZNB/41A M12//71VD_-;\767&IES<E:L'*AL>9A
M>[A-;Q*?P/26&U=<![I/7N):GY5:Q[O-:><?,9/! O2AS781Q"5>X;OVTSJ
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M0H$'"31)Z##APH4/)S*D:''@1840+4J4^)!@1H0>$S8)%T]  F@($ #8!P#
MM)<R9]*L:?,FSIPZ=_+LZ?,GT*!"AQ(M:O0HTJ1*ES+=J4]?@G4G!> 2("&!
M@'7"!$P]*2'KUI,GMVKE*L!J@GAEI9HMF]4KVJE5N3Q-<)7MU+,AJNG3@!7E
M5:MASVH]69CP5K-7I]X=K%B X[=M[9I-O%:88<QH)8/=O$X WZ>B]87FEC<>
MUJ_J-(A^%>!K7JII(:.]?-;P2<J!Q=[N;#9KU,R]VV[]2MS_[%2\G(439DRV
M.-;DP]?FEJ#/0-/L1.O>Y2WU,^??RLMV%V\W:F+4;N%V/BF.K]_@QP70K29>
M[.S%LY53+BM\<6]2]3?8>9(I!^!WFOG656\,KO/>:*&%1D%QOYVU&FGZ<!/
M"'GMEAI7Z+45#VJ2[<<@9[ )1MA9%BHF'V]7!:;B;[CU)L%@7N4W&W+SW9@
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MY44\BPD2D19M0L1$W D))5W6I5V.2NM-B3,QR'?Q%9*4'&+X)>(MC1]%1FV
MDAD@$EFE!9]<":!$C(!,SEJ0U4*-CCYT"6>(PVKP135H@!^*U'[\!5=@0R@-
M6 *0835$ %F5'E>T7* \WGUPQ4*U V@>G?#QTT\Y$E?XPI6X!M=91VCLS%,$
MRE2$@ ;_7-D\;55@RMXOX9/O>1)).8:8M)F&E8V(+&#P#=U?2@S[><8VD<4?
M>08RD=AO*,IF@)+1*=5)[%\>\<5()AEE#EX!%B)]!"< 7:;W@85FVM=E#M[.
M/1_#^$_2"=<X&4!J7DG2B<7^V4AFV$AH%)*%1$7W]8B(6 50S=.%7 D7#!Z
M3-Y";8]HB$-5?$5C6B%_[8AR .9U!9/G$9-Z%(=E:$IR*(BG?%OKJ0<[R1%@
M@87'H$C(R4?5;=]VOE0;B0C82  HX5Q7+&8\\(F?)&?$5%V#OD70",WFC%?6
M.-4K/&EJB@."P-Y9"*AI%BB0K>9?" -0&4 [I)(<X0;IH8GF.EW'X$T&,"6
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MB<S:*!2^!#7H.1\)3DV&B"VL]$4<FC+)>W*3 ..TA3H'VHAA#( -\L@':R/
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M5*CNZ(0$%"(@-:"T:<*M-"$2+)@@:M)V%!,HQ$74:-*E.QTJC,E0IT2:%T=
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M&*A"=0 "=))R%$CF+D<30GBC5XHQ3J7$+&!E$.3&<)DT0JB&<?J&'"UC )^
M;#Z!*I\#=H'!BUY7;KJR.31$1NTG;@1923D7=JD1,"PD6SX$(*?!:SS7<OM8
M'UC3<B\"?U!73]H23OTX1OMRBUZ'*GND;/&(;080=,OQ3R*$C15).M3G>P1Y
M22U211BR&U-1&@<6?_06+NR(31P#6KG8<R'R,2.)-=2F=$R43:T!CM/Q?SIQ
M"T]$*U5IC*K13=2G2%JTD]/(D>X(('O_9(N51&VS-$1<T1 XR8I[R9>,U@W.
M P G("1-P79NUPY[2(EM$CZ,F)AU%W>#IV5\.$!Z\IAUYSZ)5XE:<GAEEF9?
M!HI^Z#]]%YG9<WA#13^1F)G8HV>$H R0(BEH46@(0 [D $%UV)>WB9NY&1R3
ML0 ]%&/S9"YAB%R-E8MGHUD?\UC!5UP1IE;D45[AM55A2# REC/\!6*^,VT,
MUI)!^6*S='K:DH&1!D=<51:&-6$9-CL=]EV8PV( EHP)N)YH<U>;TUBP9V-P
M-#02H ^O@&23\0!O)8;NN38UR%T2T5]$9#K**6#WF7K5\E['M2JZ@S X*).5
MI8,/J'Q@4S+!_ZDVL>5*>&41RG$YNK<XMS)7,IE(%T=9.Y$QF(4S#=DJ[4=6
ML=6 1%AZO!*#7UAC+_9@/",!!L %B<:;WH=/TWF<85A@L5)9)"@\NH6$W;4J
MZ94T&O1B7GB#"X.$V^>%TN5<"4,W%/.=2"-_HA67D=5P13I^.K-J)<EBJ7)#
M2MB>S"E<#<.B3LHV2DI$_?57_56='G8J/QJDNBFH@\I0M&DIW4 ."- +>+@
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M],1)BC$^-L/2=<%(_TB=41B%,B>]4]C=T_J$:U.=*22%&,9]#5:"7IC$H94
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MSW[MW_Z@60G.-QK/#^^*?4"%"X%S>-_C(#@#@4=V#CC<[[\$%27X!I#\>(^
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M<U( NNJE6#9G,!NH[]HIG;JG839EX0HI\DIJ(1NNJ")G5YK ]J8GT%HT.%.
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MNJ +?'R]IVG9Q;;9I?Q&;-")ABVTAFCT3"BV09;^^#G%6 HUXS7(<*[X@_X
MV3)*W+ UP[\ G:=0*BP=(XP74%@D) -*PRW\F.O819:+2-$WP\%=\,,3KZYG
M*<NMXX;1@VC"W<;3Z2(@<'('P@@YTBTH(R3$6D44KUK&LMC'4":*1QF*4,@0
M.=4WGN,[WN.!U L#R<FKN(K@YGAYC &:-U">TC7R [5'(L"!:I^ +2DI8-9B
ME<6/&@"XMQ\1]W,UD^!XB (R8+#$@=(XJ%PT*2 D)%8?T0);'I?JZC$F=\C@
M*N;9 MK('"?.K-+V_NQ/V.PJIAXT#6P;"<)F;PL[ZWTL?",@\YWLV2D#A*I_
M6.4< Z !O-LPP5MOVUT14W<6?3,ANJ5N/)(JXGXNSP*;J:@>A94MK.[C'Q_R
M(U_R)W\Z$9;R+Q_S,U_S-SB?\X6D(SH?]$-?]$>?]$N?5R34]%-?]5>?]5O?
M]5\?]F-?]F>?]FO?]F\?]W-?]W>?]WO?]W\?^#*#7_B'G_B+W_B/'_F37_F7
DG_F;W_F?'_JC7_JGG_JKW_JO'_NS7_NWG_N[W_N_7_D# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img58233625_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img58233625_9.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $W PP# 2(  A$! Q$!_\0
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M#_\ )U?S >7'_P \T_[Y7_"CRX_^>:?]\K_A7V/_ !"'+?\ H<8[_P $4/\
M/U_I:_BO_$YW%/\ T1>0?^'#,?\ Y$_I_P#^%^_ _P#Z*Y\.?_"PT'_Y.H_X
M7[\#_P#HKGPY_P#"PT'_ .3J_F \N/\ YYI_WRO^%'EQ_P#/-/\ OE?\*/\
MB$.6_P#0XQW_ ((H?Y^O]+4_XG.XI_Z(O(/_  X9C_\ (G]/_P#POWX'_P#1
M7/AS_P"%AH/_ ,G4?\+]^!__ $5SX<_^%AH/_P G5_,!Y<?_ #S3_OE?\*/+
MC_YYI_WRO^%'_$(<M_Z'&._\$4/\_7^EJ?\ $YW%/_1%Y!_X<,Q_^1/Z?_\
MA?OP/_Z*Y\.?_"PT'_Y.H_X7[\#_ /HKGPY_\+#0?_DZOY@/+C_YYI_WRO\
MA1Y<?_/-/^^5_P */^(0Y;_T.,=_X(H?Y^O]+4_XG.XI_P"B+R#_ ,.&8_\
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MZ'&._P#!%#_/U_I:G_$YW%/_ $1>0?\ APS'_P"1/ZB8_C?\&YK.[U"+XI>
M)+&PEM(+V\3Q7HC6UI-?F8645Q,+PQPR79MYQ;J[*9C#((PQ1L5?^%^_ _\
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MW%/_ $1>0?\ APS'_P"1/Z?_ /A?OP/_ .BN?#G_ ,+#0?\ Y.H_X7[\#_\
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MFG_?*_X4?\0ARW_H<8[_ ,$4/\_7^EJ?\3G<4_\ 1%Y!_P"'#,?_ )$_I_\
M^%^_ _\ Z*Y\.?\ PL-!_P#DZC_A?OP/_P"BN?#G_P +#0?_ ).K^8#RX_\
MGFG_ 'RO^%'EQ_\ /-/^^5_PH_XA#EO_ $.,=_X(H?Y^O]+4_P")SN*?^B+R
M#_PX9C_\B?T__P#"_?@?_P!%<^'/_A8:#_\ )U'_  OWX'_]%<^'/_A8:#_\
MG5_,!Y<?_/-/^^5_PH\N/_GFG_?*_P"%'_$(<M_Z'&._\$4/\_7^EJ?\3G<4
M_P#1%Y!_X<,Q_P#D3^G_ /X7[\#_ /HKGPY_\+#0?_DZC_A?OP/_ .BN?#G_
M ,+#0?\ Y.K^8#RX_P#GFG_?*_X4>7'_ ,\T_P"^5_PH_P"(0Y;_ -#C'?\
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M (6U:ZGGU99+#PK -.M]3M;6.WU/PUI=LLMZWFM;'PGPA^SG^T=<_LZ? _\
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M ,+? T?@S2=)O-/C_MNZU6X\>:W+=B"Z34;*7PQ*L&G7EN]U<6GUSXR_:O\
MV:?A]\*?"_QR\9?'3X8:#\(?'":4_@KXAW?B_2)/#'C$:W;27NE+X4U&VN9T
M\1RWME#/>Q0Z.+V865M=W;HEO:7,D7PUX8\'>/OC+^W)^Q!^TMJO[/\ \1?
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M5\7VOP_M?B,?'.@P>$8_'-[J":5;>$-0UFYO(;32/$CZA)%:/HVK/97\,LT
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MJRHJ?#<:CA3EB%0DZD*<G6I55&+@H3G^(U%?MS_PSA^R)_T2;6__  I]?_\
MF@H_X9P_9$_Z)-K?_A3Z_P#_ #04?\1*R?\ Z%N=_P#A/@?+_J8^?X>MJ_XE
M:XX_Z*3@7_PY9[_]#GFOO/Q&HK]N?^&</V1/^B3:W_X4^O\ _P T%'_#.'[(
MG_1)M;_\*?7_ /YH*/\ B)63_P#0MSO_ ,)\#Y?]3'S_  ];'_$K7''_ $4G
M O\ X<L]_P#H<\U]Y^(U%?MS_P ,X?LB?]$FUO\ \*?7_P#YH*/^&</V1/\
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M9/\ ]"W._P#PGP/E_P!3'S_#UL?\2M<<?]%)P+_X<L]_^ASS7WGXC45^W/\
MPSA^R)_T2;6__"GU_P#^:"C_ (9P_9$_Z)-K?_A3Z_\ _-!1_P 1*R?_ *%N
M=_\ A/@?+_J8^?X>MC_B5KCC_HI.!?\ PY9[_P#0YYK[SYE_X)D?\EE\?_\
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MP-J-EJ=[JMKHFHZSX=>_N;.^GD?VSX!_M?\ [;VH>#/V(OVC_B=\7?AIXO\
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M?8P1VME86T%G9VL*[(;:UM8D@MX(E'"QPPHD:*/NJH':OF?X\?&_XU_"S7M
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MOV>HK\8?^&J_VJ_^AJ\+_P#A":=_\<H_X:K_ &J_^AJ\+_\ A":=_P#'*/\
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M5:WB)DM.GB\'/$86<L#Q':O0CC\;A958<N1MJ,<3AZ]%J:A+FI2?+R.,Y?V
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M1DO$G(KQ:DKX#B7=--?\R+O^O9G[2>&?V4/B)XU\6^!?VB;33+'P5XF74?\
M@GCXF\%:9XCUGQ3H7B_X8>!/@SX#E\/?M*_#>Y\.269L?#U_XJL]4OO#=SH,
M$#V7C6&VC3Q#>006.EO#\T6W_!+#X]V_P@N_@L/%?PN/P[D^$=EX_M?!0U;6
M18P_MU'1XOA9J?C9KT>'Q$WPW?X76L7C"WOVLVUD_%JZN=2?2D"1W]?GD?\
M@K'_ ,%&CR?B)\.2?4_!_P /_P#QVC_A[%_P49_Z*)\.?_#/>'__ ([6/)P
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M$U7SY'%<M'#TJM::3YG&G)0C.=H/^L6BOX__ /A[%_P49_Z*)\.?_#/>'_\
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M\1Z\%?\ HY.1?^$/$O\ \XO/\^S/[ **_C__ .'L7_!1G_HHGPY_\,]X?_\
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MUKQ'\/OB?H7QATW3/$K?$7PWX=F\,_"._P#&GA'0FN]'T1M2\2S6]]JUS/\
MZ1!;)<_1W[0GP?\ VX/VK_V9O%'ASQWX!_9Z^&7Q/\+?%G]FGXM_"CX?Z#\5
MO&?C/P]XGU7X!_%WPA\6?%.E^-_B9<?#;PZ_AVP\?S^%8M!\*'2/ 6L7'A6&
M0ZCKMQK+W!M+']6J* /R-^)W['GB;XQ^-_VPOB;^TG;^ /A]\+/VB_\ @GM\
M.O@AXRL]+\97OBF7X:>-?!FK?&?Q5XQUI=:O/"WABWOM"\#1>,M!USP_XO\
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MJNK#C-B?W5_[Y'^%&Q/[J_\ ?(_PIGGV_P#S\VW_ ($0?_'*//M_^?FV_P#
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MRCS[?_GYMO\ P(A_^.5A]7K_ //BM_X+G_\ (^:^\^6^KXK_ )\8C_P74_\
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MQ)>WTUU>3@'TY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:BY%2K894)54JDKJM0E6DY1DH1G"$82J.$T?E]_PP+\'_P#H2M/_ /!GK_\
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M  9Z_P#_ "VH_P"&!?@__P!"5I__ (,]?_\ EM7Z(44?\33_ $D/^C[>+_\
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MB-#;R:CXGL].N6")K*I)YMM*T6)5D"[BR!7 8?;E>D>$O^1"^,/_ &!?!/\
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M65QGY?\ 4Z\OQ?<\W^W\W_Z&&,_\*:_E_?\ +\NVOYW_ /# OP?_ .A*T_\
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M\*>(?_GY_5WY6X?K%'_H!PO_ ('C?_FOU_I:^D?\(5X1_P"BQ>"?_!'X^_\
MF7H_X0KPC_T6+P3_ ."/Q]_\R]>;T4?VE@/^B<RC_P *>(?_ )^?U=^5CZQ1
M_P"@'"_^!XW_ .:_7^EKZ1_PA7A'_HL7@G_P1^/O_F7H_P"$*\(_]%B\$_\
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M_!'X^_\ F7KS>BO'_M+ ?]$YE'_A3Q#_ //S^KORMR_6*/\ T X7_P #QO\
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MOH?Q!N$O3J]A!##:L(4OKA-/GNK*WGN;>QO;BQ6"6YM(9WCB=ND3,T,?S/\
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MPM#8KIC=?_P4R\$2_$;]NS_@GKX37]G'X=?M7Q3?"G]MC46^#/Q7\5Z1X/\
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MVFG:=86\MW?:A?W,-G96=I ADGN;NZN'C@M[>&-6DEFFD2.-%+NP4$U_-O\
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M\-C>*O\ HDGP-_\ "8\5_P#S;T?\-C>*O^B2? W_ ,)CQ7_\V]'_ !"3,O\
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M /V9/V>K*33?$OQ6T(^-M6^$VJ_%WPMI>E:#XR\=Z1%X)2SN1H'C_P ;:O\
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M-$\/>)_#MOX3N;#Q7XC\;Z^MI:?##PW\(7\9:]JEL\MMK5A9:N]O:/?\3?\
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M//BUX8O/&OA#QGHOBK6O!?CWQ1J4VHZ[X0UC5K[0)#!80VUC;1:?9I"_5_\
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MG1['0/#&J:W.OAC2-/TZRTF"V\.:='%I>B2SV.G6]K9QZGJ&FV5OJ6LR0VT
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M$8K"X;^TZ6$S##^(45[G_P ,R?M!?]$F\3_]_M"_^7%'_#,G[07_ $2;Q/\
M]_M"_P#EQ7B?V7F?_0MS#_PBQ/\ \J/TO_7C@C_HL^$?_$FR3_YN/#**]S_X
M9D_:"_Z)-XG_ ._VA?\ RXH_X9D_:"_Z)-XG_P"_VA?_ "XH_LO,_P#H6YA_
MX18G_P"5!_KQP1_T6?"/_B39)_\ -QX97N'PY_Y)#^TC_P!BS\+_ /U:6C4_
M_AF3]H+_ *)-XG_[_:%_\N*]B\!?L[_'.S^%G[0%A=?##Q'!>:OX=^'$.F6[
MRZ+YE[+9_$G2;RZCA*ZLR!H+2.2X?S&C'EH0I9\(>[+LMS*.(J.678]+ZCF:
MN\'B4KRRW%QBM:6\I-12W;:2U9\UQ9QKP74RK"1I\8\)SDN*>!:CC#B3)9-0
MI<<\.5:LVHXYM0I4H3J5)?#"G"4Y-1BVOBJBO<_^&9/V@O\ HDWB?_O]H7_R
MXH_X9D_:"_Z)-XG_ ._VA?\ RXKA_LO,_P#H6YA_X18G_P"5'TO^O'!'_19\
M(_\ B39)_P#-QX917N?_  S)^T%_T2;Q/_W^T+_Y<4?\,R?M!?\ 1)O$_P#W
M^T+_ .7%']EYG_T+<P_\(L3_ /*@_P!>."/^BSX1_P#$FR3_ .;CPROI']FR
M6X;6_%FDP>!I_%J^)--\+Z%<:YIL_@--?^'-I/XTT>ZO?%NC0?$30_$/A^82
MV-K<Z/JTTUA!'::7>SR76I6$3K-6#_PS)^T%_P!$F\3_ /?[0O\ Y<4Q_P!F
M#X_2@"3X1>)) IW .^@. V,9 ;6" <<9'..*Z<'A,TPF)IXA99F4O9\UXQPE
M:$FIPE3DE.IA:\8-QD[2]E*4=X.$U&<?'X@XAX&S[)\;E,^-^#*2Q:P[52MQ
M#EE>C"IAL7A\92G4H83/<LK5X1JX>#=#Z[2HUOX>*AB<+*MA:WK?C[X,_"W1
M_A'XQ\<Z-XH/BOQ_I/C'Q'I=E96GB31+:Q\2?#NW^(M_H&E?'^RT&QM]]OH^
MLB!?"\?@:SG+6T\\7C>%QX>D@B;XTKW#_AF'X_;MW_"H_$FX-O#;]!W!]NS?
MG^V,[MGR[LYV_+G'%/\ ^&9/V@O^B3>)_P#O]H7_ ,N*TQV%QN*J4IT<BQF#
MC3H0I2A3PF*FJLXN3E6E*5",G.?,E+F<Y/E3<VVSDX:S[AG(\+C</F/BGP[Q
M%4Q.9XG'8?$XW/\ (<//!86O3H0I991I4LTJ4(X;"RI5)T50IX:E'V\H0P].
M,(W\,HKW/_AF3]H+_HDWB?\ [_:%_P#+BC_AF3]H+_HDWB?_ +_:%_\ +BN+
M^R\S_P"A;F'_ (18G_Y4?1_Z\<$?]%GPC_XDV2?_ #<>&45[G_PS)^T%_P!$
MF\3_ /?[0O\ Y<4?\,R?M!?]$F\3_P#?[0O_ )<4?V7F?_0MS#_PBQ/_ ,J#
M_7C@C_HL^$?_ !)LD_\ FX_1/_@BU_R<+\5O^R,G_P!3?PW7]*5?SY?\$B_A
M%\3OA[\=OB9JOCCP3K'AG3;WX2G3[2\U%]-:*XOO^$Q\/W/V:,6=_=2>9Y$,
MLN714VH?GW8!_H-K^GO"ZC6H<(X6G7I5:-18O'-TZU.=*:3KMIN$XQDDUJFU
MJM4?X;?3OS'+LU^D1GN,RO,,#F>$EPYPG".+R[&8?'864Z>348U(1Q&%J5:,
MITY)QG%3<H23C))Z!1117Z(?QP%?-/[8NA?M#>)_V8OC-H/[*/B+3_"G[0FI
M^#Y[?X9Z[J-QI]DEKJWVVRDU""PU'5]-UC2-(U[4M!35M,\-:WJ^EW^E:)XB
MO-+U;4K66QLIU/TM10!_.E\._P!B7X\W>N_MI>+OC!^RG\8?B5X"^-GP@_98
M\&>&/A?\9_VWO#WCSX^>)=>^$OQ!\>^*/$7B/3_C%9>)KS2/AIXJ\#:EK>@>
M-OAII6C^,=*\-Q:UIR7>F>*?"NH7]W9:5U^O?LV?MLZY^SUX&C^)?PN^-_Q4
M^.G@3XI?'+6OV:/B?X2_:N^$O@/]K#]EKP!XETK1]%^'.A_$_P"*<L6E_#+X
MUGQ#:)K=I\5 K^.+*]\.VWAC3-:\/_$K5;6?6;;]_J* /Q8\(?#']OO]G/XL
M^-_C+>_!+P/^V-X__:2_90_9A\"?%;6O#/Q#\#_"BQ\%_M$_ CPKXUT'Q7_:
M>F>/9-+CO_@9\0-5\=3^(HI_!4.I>(]$O+77%3P#<IJMDD7G_P  ?V//VL/^
M"?\ XF^!/B?X:_"KP[^UD=._8&^'/[)OC:PT3XE>%_A;<?#_ .)7PU^)7CWX
MFVFOZ3=_$,6D5Y\%_$=U\3M3T&^CT2._\;:);^#O#]_!X.UO[4;.R_>>B@#\
M/_BI^SA^WG;^,_V_/B=\(+*/PIXE^/OBO]@?5-,_X5U\2_"?AWQIXW^'WPH\
M"Z9X<_:;\%?"OQOXML+FQ^&WC2ZM6UGP]X"\9^.M$TF&0O'J5O)I4LL.I6/S
MWIG[!_[7E[\&/V\[J+X4^*-)\8?%G]J/]C/]H'X.?#_XN_M.:5\9OB5XY\-?
MLXQ? ^^\3^&_&/QIU/5=8LM*\6ZQ+\-]:T_P]:ZYJ^H^&?#TDNBZ/:^(KSP_
M9IK*?TB44 ?@#\;OV1?VB/&7[27Q8_:+OO@%^T'XQ\)_M6? ?X.^$_%GPD^#
M7[;VD?L]^)OA)XJ^&^E^-O#^M^ OBH-&\=Z#X#^*/@?Q/I'B^&\@\2>%?$?B
MF\\.ZHGBBPMO#>J6.LPZA)WUS^S)^TQ^SGX_^,2?L[_LT^%/BG\.?VAOV*OV
M<_V=/#.FZY\;=#TG_AG3Q)^S_P"!_B+\/].\*^/=?\:6\GBCXB?"F[T3QW8Z
M@FO^#]+U[Q9?:YI&NOJ7AJ+^WHM4@_:G5_$&@: =*77=<TC16UW5[3P_HBZO
MJ5EIIUC7[])Y+'0]*%Y/"=0U>]CM;F2TTVT\Z]N4MYVA@=8I"O(>&OBW\.O&
M'Q ^)GPK\->)[35?'_P<_P"$,'Q+\-PVNHQ77A3_ (6%HD_B/P;]LN;FS@T^
MZ_MS1+:>_M_[-N[WR(XS'>?9IRL1 /DGX#_LJZE-_P $SOAE^QC\<=,M--U>
MY_9$T/\ 9_\ B7IMC=V6KVNEZC<_#./P5KXT^_L9;BPO/[-N9)I]/O+2>6(R
M003P2G"O7XY#_@G5_P % /&/PJ\'^*_&/A+PAH_[1WQ^U+7?V1?VPKJT^(?A
MNZ71_P!B/5/!'P@^%,7CC3M:M[R2R\4ZQ9Z9\"Y_'VF^#[$W&N0WOQO\4V-S
M ^H6MZ8OZB:\W^*OQ=^'/P1\*P>-_BGXHM/"'A:Y\5>"/!$&L7MKJ-W!)XJ^
M)'B_1? 7@G1Q#I=E?W0FU_Q=XBT71;>9H!:6\]_'/?7%K9QSW$0!^1'[4G["
M/QT^*&M_\%.;'X:^&?#.F^'OV@OV-/V6OA#\ Y-0\3:;INFZUXT^"VJ?&75=
M:\)7]O UUJ/A73HK?Q!X5TBSUK5+%=-?^UC-"T\.FWPB^DO!WPR^._Q!_;C_
M &>OVK?''P:N/A/X:T+]BOXY_"3QIX:\1>._ 'C#Q1X*^(OBSXU?"'Q#X:T*
M:[\%ZQK&FZXFM^%?!.L:U-KGAVZN]*LU$&FZC<P:A.MK7Z6T4 ?"_P#P39^"
M7Q&_9U_8S^%/P?\ BSHMGX=\>^%M8^+]UK&CV&KZ9KMI9VOBOXW?$?QEX?\
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M04\.7J>'M&U_Q)J.B'Q%H<'BP^'?"T%I<^)->L_#$URFK7FDZ+;7L-Q>74<
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MW^>?\\O_  )D?DQ?\\H_^^%_PH\F+_GE'_WPO^%244679?U_PR^X.>?\TO\
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M&="TK5=4^&FM7.NZ1I40N[W2[Y_#OBOR'][^/_Q>^(/P#U+]N3P7^SW^U_\
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MHLNCZ?9:8"+*U@A2/5?@[\)-=;Q6^M_"[X>:P_CR/PC#XX;5?!?AS4#XRA\
M7/VSP)#XJ-WILW_"0Q>"[O\ TGPK'JWVM/#]Q^^TE;23YJ /YW?VEOB_\1OV
M?Q_P4-^'G[/_ .UQ\8_B_P##O1/^":VB?M)6WQ#\2_%Z/XI>)_@K\=]2^)'B
M#PMH5QX/^(E@H?PK9_%3P-;7'BVU\&6DT&AZ8_AG^VO"6DZ-HNJK:M[OX!\
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MV*T?E+)A2^P'^*O_ (:[_8\_Z%W]J+_P)^$'_P CU_8A_P %;_\ E&]^UO\
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MQQ^48G-:.0T,WGA,#GN46]KC\;# 1XK_ (:[_8\_Z%W]J+_P)^$'_P CT?\
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MBL%6P^)J_KA_PUW^QY_T+O[47_@3\(/_ )'H_P"&N_V//^A=_:B_\"?A!_\
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M?_*_ZN_*WZX?\-=_L>?]"[^U%_X$_"#_ .1Z/^&N_P!CS_H7?VHO_ GX0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /SF_P""N! _X)O?M;DD ?\
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M@::\&>2-.&,Q.9XS+O8)1CB<1C\1AK5:N(G*?3/^"A7[5:V'B6R\9?%/Q/\
M%1M8^$'C;X,^';KXE^(?$?B:;X<Z!\1++2-"\6Z[X&236+>WT_Q=JGA'2[CP
M:VNZA#J<T?A[6=5M5C\V:&>#R3X?_M6?M*_"GP%K?PM^&OQU^*?@7X=^(FU%
M]8\&^%_&FN:/H%W)J]J+'5I!865W%%:R:I9@6VHR68MWOH0([II5XKV;_AJK
M]O'^VAX;_P"$N^)G_"1&P_M0:#_P@.F_VT=,P3_:(TO_ (1+[<;# )^UB#[/
M@$^9BKFM_M0?MV>&O!OA7X@:_P#$CQ#I'A3QQ)J*>$;^_L_ -O=^((M)O;W3
M-1O].T1],&NS:/:ZGIVH:8^M_P!FKH[:G976GQWSWD$D"W+&UJC]O+/^+93P
MM&O"6(66+VM&A5E0I8A5:ZX@53V<V\/1J>UFTTL/1E[JI07/0X7R_!4_[,H^
M$GT?*.&X@S#*\11RB7'$W@<QS/ 4<RQ^43R_*JGA#+"2Q6'IT\YS/!+ 8:-1
M5'F^9TTZU3'XB7SCX5_:%^./@>#X>6WA#XK>./#EO\)-5\5:[\,8M(U^^LT\
M!ZUXXM4LO%VK>%A%*O\ 8VH^(+:..+4KRR\J>?8C^8)%5QR6O_$GQ]XIT'P/
MX7\1^,/$&M^'_AI9:IIWP_TG4M3N;NT\'V&M:Q-X@U6RT!)78Z=:WNMW$^J3
M06[+']MFEG15>1B?H#_ANS]K/_HLVN?^"?PG_P#,_1_PW9^UG_T6;7/_  3^
M$_\ YGZ\V5?+YTW1GGF?RHN,8.E++:$J;A%8:,8.#X@Y7&,<'A(QC:R6$PR2
M2HT^3[6EE?&%#&+,:'A;X24<PC7JXJ..I<;9I3QD<37J9U5K8A8J'@_&NJ]:
MKQ'Q#4JUE/VE2IGV=3G)RS3'.O6F_;I_;'N/&7AGXAW7[2_QEN_''@SPWJ/A
M#PIXIO/'6MW>M>'_  YK#V<FKZ5I5[<W,LMG#JKZ=I[:E)$5N+\V-F;J:7[-
M#LQ-:_;%_:I\1>&_'_@_6_V@OBQJ/A;XJ:K=:W\1M G\::R-+\9ZI?Q:?!J%
MWK]G'<I%?-J4.DZ;'J<<B^3J2V5N+Z.XV"ND_P"&[/VL_P#HLVN?^"?PG_\
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MSQ'X_P!--]IGP3^'>G?"G3Y]1LM4FDM[J$>-/%9BT!7FMXW,302M<][\0O\
M@J?^TM#XB_9-UG2?AS\)/V??@Y\>?@U\+OB-J?C_ /:7T'XPGPOJ_P 0_%_B
M%=*\8? [3?'O@NP3P_\ #+Q3X9L@EUINJ?$JRAL=5?4=-:9;6.=$>%X%^(<:
M> J5\OP6%_M&&-G1IXC'THUE]2HUL0Z:HTXU*F)JXBA0K5Z%+ QQ<X4:<ZV*
M6&I0E.+YX_ET[Z?U^%S^@"BD!! ((((!!!R"#R""."".01UI:_'B@HHHH **
M** /SG_X*W_\HWOVM_\ LF)_]2/0:_B__P""5WQS\ _ CXJ?'?6/'?Q!\-?#
M>7QI^S)X\\ ^"M;\8:M\6_#OAF[\;:OXI\":CI.E:SXG^!EM/\4O#5C<VNCZ
MA--K7A*6QU.V6VV07L3S!)/[8/\ @J+H,'B?]@#]J'0+GQ'X=\(P:I\._LTG
MB3Q;<W]GX<TD'Q!HCBXU6YTO3=8U"*W8H(5:UTR\D,TL2^5M9G7^ [_AF#P[
M_P!':_LH?^%;\4O_ )S]?RCXXULPR_CSAG.,OHX6M5P&1J4:>*KT:=.4IXW,
M:;4X3Q%"I*/+4=G%\O-9-NSB_P#H#_999?P=Q?\ 1,\;_#CB_,L^RS \5>*=
M2G7Q6095F>-QU&A1X8X*Q-.KA\5A<GS;!T*WUG!1BX5Z;JJFW*$8.5.JOU'_
M &T?VP_V-OB7H'C<6]QK?[0.C^(OVX?$WQF\0?#S3]=\2?".YUN'6_V8_A]X
M%O\ QCX6\6W/@+4GLO VG_$71-4T[PQ::UHA\::QHNGV\_B*"&>\DU*;Z9\"
M_P#!0/\ 9H\$?LZ_LQZ#X:^-_@F;Q)\/;W]EZ?3/ WCS3?C'>6&C:M\/_$'C
MR?Q3X?\ B5X<TWP#>>!_ GASX<Z9XLMY]#^./P>&O?%3XD:[H'A_7/&6@:BL
M+6"?@_\ \,P>'?\ H[7]E#_PK?BE_P#.?H_X9@\._P#1VO[*'_A6_%+_ .<_
M7Y?1XSXLHYCC\SAE^0QQ&84)49\M7#1=+GJ*HYTJT<R6*FU)1=.&(KUZ-)N?
MLJ<5B,5'$?W7F'T:OH]YGP9PCP-BN+O%FKDW"&9T,RPL:N!SRM','A\&\%3P
M^.RZKP5+(Z,:E"<X8O%91E65YACHO#/%XRM5RG(*N4?O]X._X*,?L%^%OVM/
MA3XTU+XA?$?_ (33P+\+O@U\&+G]H^WL/$7QI\-77ABQ\:>,O&_Q9TO6O&OQ
M/;P-\7=7&J6VK^%_ *_%9OAO=^+&\*V7B+3].\,P6EY9LOE?A#_@H5^SUX&_
M9H\/^%CXY\#>*]<TK7_A?X0^%/@+5C\8)O#&D:5X&_:MNOB[%\6OCG\%W\&2
M?#'PCXJM_#<4T_B?Q;\+?&OC[QCXUM=7M-%CL+1;.XB/XJ_\,P>'?^CM?V4/
M_"M^*7_SGZ/^&8/#O_1VO[*'_A6_%+_YS]=#X\XQM4Y,!D%-U*>:4DZ=3#QY
M8YK'!PK/D_M-TI5:4,'05&NZ?MGRP56=6$(07D+Z)_T;G+!?6.+?%W&T\)B^
M!,<Z>-P6<UW5K\ 5L^Q.60^LO@:..I8''8CB3,ZF8973Q:RY/$UYY;A<OKXB
MM7G_ $.G_@I/^S=-\4_!^BQ_&SPS9V>F?#>5OBS\:+GXJ?M07?B47>H?M(0?
M&FT\ _!OXRQ?!I/BQXQTSPW803VFI^!O&G@OP5X*U_P_JL7P[L?$=GIND2WD
MWXD?MH?MX7G[2DGCCP'X>\%>&M$^%9^,7BWQA\/;]]/OK;Q/I_@J;Q]\5/%O
MA'1%TMM6N_#7AFY5/BKK0\37/AS3;*]\1"T\/VNLW=['X>LV;QG_ (9@\._]
M':_LH?\ A6_%+_YS]'_#,'AW_H[7]E#_ ,*WXI?_ #GZ\W/>*^,,^PDL%7IY
M9A:%3GA66#KX&G*K0E3I4XX:3GC*G+1BH*;5-0E.I4G*4FI**^S\*_ 'Z-_A
M/Q#1XGRG$\<9YFN$^K5\OGQ'E/%>,HX#-J.+Q6,J9W0I87AK!NIF->>+5!3Q
M<\30P^$P^%HT*,)TW5G\H45]7_\ #,'AW_H[7]E#_P *WXI?_.?H_P"&8/#O
M_1VO[*'_ (5OQ2_^<_7P?]BYA_S[P_\ X78#_P":?-?>?UC_ ,1,X/\ ^@O-
M_P#Q%.+/_G'YK[SY0HKZO_X9@\._]':_LH?^%;\4O_G/T?\ #,'AW_H[7]E#
M_P *WXI?_.?H_L7,/^?>'_\ "[ ?_-/FOO#_ (B9P?\ ]!>;_P#B*<6?_./S
M7WGRA17U?_PS!X=_Z.U_90_\*WXI?_.?H_X9@\._]':_LH?^%;\4O_G/T?V+
MF'_/O#_^%V _^:?-?>'_ !$S@_\ Z"\W_P#$4XL_^<?FOO/E"BOJ_P#X9@\.
M_P#1VO[*'_A6_%+_ .<_1_PS!X=_Z.U_90_\*WXI?_.?H_L7,/\ GWA__"[
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MKW4]4U_1=%U\IJFDV\FN>(]:U#Q/J6LMIEYK%K%+^>W_  S!X=_Z.U_90_\
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M*OA:U/XH-'RA17U?_P ,P>'?^CM?V4/_  K?BE_\Y^C_ (9@\._]':_LH?\
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M ,1,X/\ ^@O-_P#Q%.+/_G'YK[SY0HKZO_X9@\._]':_LH?^%;\4O_G/T?\
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M_.?H_L7,/^?>'_\ "[ ?_-/FOO#_ (B9P?\ ]!>;_P#B*<6?_./S7WG[(_\
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MYM&U46\J:/JUA:W>G:Q,JV^F7-U<21Q-Z.7<2>,-7+\#F^4YAQU6RG*(PR3
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M"4]UX2M[?QU%H>GVMQ>W-MX+EU^]EM8)KBTMKB**1U]VTC]K;]G?Q!JW[/\
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MPE\5['X31:QK'Q*L-.F\'>"-,\5:Q>K?^$#XDOX&\0VB"/3&N998BU#X\_\
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M3P],Y5IJW:UO1.Z6W_!?5[W_ "9^+_[)7Q7\<?MR?M!_&ZU\%>']6\ >,_\
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M_P ,>7?_ #/Y?GW8?\3@?2M_Z22\<O\ Q:/&?_SX\OS[L_'3_APO_P $R?\
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M; =,D5AW'[=/Q_CW;;OP7QG&?"TAZ8_ZB_O4?V/X8J[_ -3,BT_ZI[*^EO\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_'9^V_\
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M*-7 Y3A<57A2P]&M@Z#H5_K_ ,4? ?X4Z1\1O&'@>RTC24LM!\)_$C7M+O\
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M_P#$_P 4M0O?$RW7A&W\<P^!_$XTNTL6.@7OPUTG6;1/#?CN]6[22;6--O\
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M\#95G659'2I9Q6D_:3<\'@YQO/+Z/+&3P\ZKDVY-SC4>'U6%YO9IJ4I4Z?\
M<7@EP_Q1P_PFJ'$F)J1ABJE/%95D]>+>(R?"5(S<H5IR]^E+%S:K+ 6M@N5\
MSCB*^(HT2BBBOLC]C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG@G7;'Q/X2\06JMQ'J?A_P 0:98:OIEP/FM[VTAF7E!7444 ?GU^T)_P3>^
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MXEU;2?#GAGPYH^@:AXBM]4NO#EEH.D1:#+IW]G6AB^KJ* / +O\ 95_9QO\
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MS^-]-\57DT_BO2_&-YJ'B?3M:M=<U&_OKCZ8HH \)T[]F3X#:9JFE:]#\,]
MNO$&B:7::+IWB/6&U'7_ !)'IECX=\<^$;.UN/$.N7VHZS?K;>&/B7X]T&*2
M_OKJ9=+\5:M:"3RIPJ9WC7]DW]G#XBV_PYL_&WP>\&^(;3X2:$OA7X=VM[8S
M+;^&/"8&@+-X1M8;:X@CN_"5^GA;PY%JWA?4EO=!UB'1--AU73[R*TB1?H>B
M@#PVR_9G^ &G'438_"/P/;#5]8\/:_J:Q:+;B._UGPI\2?%/Q@\-ZA=1D&.6
M?1OB?XW\7>-['<I2+7O$.J7>P_:76N"T?]AC]D30=.O])TSX ?#R'3]4M[ZR
MOH)]+EOC<:=J'@SQ)\.I]*,U_<W4\>CP^ ?%_B;P9IVCQ2IIFD>&-8N]$TJT
MLM/9+=/J^B@#X"^.W_!//X5_&KXK^#OC!9>)_%GPL\6>&=1EU:[U'X>IHVG:
MM?ZS->^!)I?%&E:_<:?/J_AGQC/I7P[\-^%;G7["XG2X\*VO]DRZ:<FX/U+X
M'^"'PQ^'_A'P%X+T?PM8:AI?PSGNK_P;>^)XD\3Z]H^MZC/?7>K>)+77-:2\
MU&W\0ZO>:IJ=UJ&JVDUO/(^H7447DVL@MU]8HH \:^*/[/GP?^-.M_#_ ,1_
M$[P9;^*]9^%?B >*_A[>W.K>(+ ^%O$JJL::[I\&D:MI]LVJ1P"6TBO+J&XF
MBL;O4+"-TL]2U""Y@F_9P^!<_BCPAXUD^&'A4^*O ?B?QEXT\*ZXMD\=[IGB
MKX@Z@^K^+]=D:.94U/4-9U9EU1Y=62^%GJ4%G?:<MI=6-G+![910!Y%;_ +X
M+6VOWGBF+X8^#O[?U"[^(=]J&IRZ+:W$U_=?%JV\-6?Q,DO4N%EANAXXM/!W
MA>V\21SQ21:G!HEA%.C1Q;3PMM^Q[^SE9Z%X7\.6GPY6UTSP1KMUXB\&-;^+
M/'$.J>$KV^TS3]'OK+PUK\?B9=>T/PY>Z;I&D6UYX0TS4K7PG=#2M,DGT62;
M3[.2'Z7HH \R\2_!GX5^,?$C^,/%'@/PYKOBB2W\!VCZYJ-@D^HM;?"_QM<?
M$CX>PFX8AMGA#QW=7/BK0Q_RYZS,]VF7.*\EU/\ 8C_92UC5?&.N:A\$/!TV
ML>/+RZU'Q)J:)J=M>R:C?>,K3XB7NHZ-<6NHP2>%=0O?'UE#XVO+[PJVBW=U
MXK:Y\03S2:K>WEU/]3T4 ?-\_P"R!^S+=WVK:A>_!;P1J$VO6L%IK$&HZ?+J
M.FZA';_#N_\ A()[G1[VXN-)>_N/AIJ5WX)U#5!9#4M3\/O#8:C=W4=I:>0W
M1_V/_P!F70M O/#.G_!GP9_9.I^'?&?A/5UO[2YUC4-<\._$/4_"NK^-=+U[
M6]8NK[6]=@\17W@7P8U^^L:A>SFV\*^'["&6*PTFRMH?I*B@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \FT/XGW.K?&GX@_!^Y\'ZGI2>"/ GPX\>6
M'B^?4M*NM+\56/Q U;Q_HK6ECI]G-+J.ESZ#?^ +V&Z.KI;/?_:XY;*!K:'[
M1-\?P_\ !1[X;Z//K*?$;PAXD\!6US\;/BG\$OAU>7%IXDU2V\9ZO\*_$FL^
M$=2U^_N#X/TVRTCP[JVOZ7::?9ZQX:O/'NB6%SK>F6&MZOINKRMIB^D>$-=_
M9<\=_M=_&/0O#'AFRO\ ]H;X>Z#X&MOBCXTBU'3H;F--)MM'\1>$O",MC_PE
M2^)KO_A'].\6:3KRRQ^#QX/M7\0RP?V[-KMYJ>GUX5XV_:"_X)CZ]96C?$=O
M \K_  F^)OQJT^WT35/ASXNU?4?"/CW1=8\8^-OBU?2Z1X<\.ZNRV>MZMX \
M3>-IM1N(Y]&\1:UX?COK5[GQ1I<%O: 'K!_X*+?LW6^F:?J%_J?B^(_\(KK7
MC'Q:MEX(\3:A:?#O1/#'A_7?%/B2]\<WR:;#'X>@TOP_X?NM;C&H1P7NHZ-J
M&@:C86,T.OZ:)]+5O^"@G[.VC>#?@OXSN[CXAF'X]S^++?X?>'(?AGXO?QC*
MW@?4(-$\4S:[X<;3DO- L=*\17VC^'Y-4U QZ7/J&N:3<6MY/I%Q)J</):#\
M1?\ @G%JVHZOHV@W/P6GUOQ1J7A;P5K.A1^%I(=>\1:OX[^'NF_#'0O#-SH=
MQHL6JZMJ$WPT\):9X.U?3!9W%QX:\-Z%#I_B6+2+>T*K8\<>+?V4?!'_  B.
MD:CX#;5-+^!=K\/-=\%Z\;JY\WPE<?&/Q?K&EVNC0W^N:Y;>)Y8(=*\):W\0
M_'6C:JMUI-MX%\-6^L:C9W@MM(M0 :?C7_@H1\%_ ?@?X,^+O$6@_$;1=2^/
MWPW\3_$;X:>#==\-1:?XBD@\.>$)/&,6@^,%M=0U2S\':IKMDL5CHUUJ-Q-H
MEUJ4Z6PU3?P=GXP?M:>)?A=X\\.^!M-^"&J^-G\=^&/#M]X#U;3O'?A[3;6Z
M\7>)O&'A/P=IF@>.(+FRN)OA_P"';Z^\6(ND>,KXZFVO7V@^)-,TCPY=3Z:D
MEURVKV?_  3FO/\ A ]'UI_@+>Q_"_2?%F@^ K&^O]/N[7POHJ>(&\%^*=$L
M4DN)+8V.G>(+^71/[+NC/%H\UQ<#3K>SA,\@O:EX:_X)]_&+QSK6JZA%\&_&
MWCWXB:3H/P]UF1=5%QJOB;3?"FOQ6?A/1Y+6VO8UFF\.>(;6.;PK?00)?:3=
M9U/1+R!+A[J4 X'4_P#@H=J=O'!)I7[.WBG6(]=\!^$OB/X0N%\>^$[.QO\
MP_J/@'QQ\1O&6G>)]1DAEL/"7B[P[X=^'7BJ[\,^&C<:S-XYM+>RU1;KPYI-
MV][;?5OQ$^.5YX-A^"NJ:!X#OO&GA_XO>,/"?AA[BUUW3M'\0:%;>,A:2:?J
MNG>%;R"?4/%3Z5I]Q>^)?%%A9S6 \/\ @WP]XF\175ZZ:2+.Z^0[FW_X)5SW
M?BF*XM_@*QUOXO>"OAYXGM?)N5T>X^,.C:9=^$? ^B/9HHT6WUM]*\-:GX T
MVZLH8;/6+71M8^'SW5\MIJ6AIU>H_$S_ ()T_%/P3\,/CAK7B+X>ZIX8^']Q
MK'BKX5^*=;A\6>'==\*W?CR?2-2U:30](U.VT?Q?I]SXJ?4M# T272DEU2WO
MM-T^UTZ6UN;>V< ]C^+7[67ACX.>/[OX?^)O"^M3ZB/#_AWQCH]S8W^D!=>\
M&RP^/K_XB^(+*WN[FVEC@^%.D> 9]2\3PSLOG+XD\*P6LRMJK/;^9Z+_ ,%(
M/V=_$VC:+XH\/#X@7GA74K2UFO-?O/ 'BC3;73]7O]&^(.I:?X&@CFTV2;5?
MB-=WOPYUK2%\*62GR[I[7S-266[TZVU#I=4^(/["GQ'\/^*?'.JZ[\'O'>D?
ML^:;XF^!OB77[B*W\3:E\/\ 3OB/;:!X;\3?#I9/L][KI'CQ;#0/#UQI>FI=
MS>*-0L(M'@%]J=G/;1>8:AXT_P""8/P_\%Z]X$U?4O@)X=\&>&]3LM"\0:!J
M]DJ0VNJ^)O#_ (ZL?,NTO[22^O;E=#U/XDVFOZ^'N3X=E3QI#XBU+2]1TO6E
MLP#U"\_;\_9]T_POKOB6\E^(4$WAC4#H7B+PL_PX\4?\)?HGBN+2K[5K_P (
MZGHWV+_1-=T>+3+^#6S-<KI.D26L]Q?ZK!ID3WZV_B3^W;\!?A7XVG^'GBBY
M\7S^+$^%6F_&"UT[P[X5NO$L.H>%M4US2] @MK?4=&GN].M=8AN-8LM0O8=6
MNM-T^S\/_:?$=QJ::'9W5_%\^>)'_P""9=GIWAWQ'K'@WX81?#R[^"=QI\OQ
M7-A=:?X7\._#>?QXO@/3_#?B76TFMM:T^^\6^+K[Q7I$UUJ=NE]<IX?\:67B
MC58(8[FVNK_BCQG_ ,$QO'GQ+U;P9JME\,?$OCJT\#VGPVU][+0-7TKP_I_P
MUTSQ@OP_GT.Y\9_9]$\ R:#HWB30SX1U?3M-U^[U06>CR^');&ZTNR?3XP#U
M#7O^"BW[.7AG5=%T?6Y/B'97?B'QA\2_ ^D(/ .L75Q<:Y\*[%+[Q"\NE69N
M-<L=(U-3/#X2US4-*M=)\5&V>[T>[N-,N=.O[WNM"_;7^!'B23XC2Z-JGB6\
MT7X8>$X/&NN^*!X5U6/PYJ_AVZU[4_#UMJ/@J_EC27QO8SWFE33)JGAFUU+1
M_LMQ9%M16YN4MA\QZ1K_ /P2W_X2#0=:MX/A+X)UVZ\7O=^ O&7B2QF\'76L
M>+/''@FP?^U/#-YXI6TN+B"P\+6^DZ9IDNK646@>'"-(TG0HK4WEA!<]5X.U
M#]@3PC9?#;P5X:\.^&+SPA\4/V>/!'PC\(^*=0TW4-1T[Q1\([_4(? 7PU^&
M<$>I(VN7Z_$%=%\1:U9II^C)::YIO@C7_%VNW_E6%K?N =YX]_X**_LU_#A_
M%Z>)+_QX/^$,U!M$O?[/^'OB2]FUKQ+#\1O&?PQO?#/A"Q2V34?%VLZ9KO@#
MQ7?ZHF@6=]96&A::M]<WR3WMC9W/IGP9_:K\"?'?XA^//!'@30_&!TKP1X5\
M,>*K;QSKVA7?A_P[XTM?$?BCQ_X1E_X0^/5$M]2U*ST76OAWK.GZEJ5Q:6<2
MZ@LEDD6ZV>1_D;PQ;?\ !/KQ FE^&_"W[/6H7&E2^(?BW\)?#FLV'@#6K32;
M2X^"$EW\8O$4_A;Q4-4@DTBP\:ZBEWXR\)^)-"OK*]^)]QYNNRW-]IV[4!Q_
MAC]LW_@GOX \27OQ$\+_  QUKPIXQ\=_#GQ;^T!XAUO3_#/ANTU#4="\'7OQ
M \,:WJ&N:C#XU;2KK0X+Z/QHT_CB.\NO@EI.I^)3JFO^/]'UCQ5!<WP!^@WP
M ^.=Q\;;3XDIJG@75?AWK_PS^)6K?#S6/#NM7DEQ?S+::3HFOZ1KPM[W2M"U
M2SL]=T;7[&\LA>:3'9WL6=1\/:IXB\-W>D^(-2^=[G_@H_\ "/3[354N?A]\
M:]6\0Z3>ZKIK^'?!G@"Z\4G4-5LOB3JGP]L- T?Q +G3/#.H>)]4MM+E\:KH
M":M'>6?A83RSDZC MA-F> ?V@_V-/A-X8^%'BGX7^#-1T/3_ (UZ<WB^2'PG
MX?CN=4\&^&/%6I?#;1[KQI\6;=-<FETK0(]5\3_"WP]I][#+X@F;3=1T+_A#
M+:\\%V=Q?6?,W/QA_82U/Q/\.OA)K_P<_L+4/V@KCXS_ &:P\4^ -*\*BQG^
M'?BGQSX)^(^H>*;?4M6L-?L7CUS2/$[:CJFAZ=JLGABTU+3=;\8W'A*UUW2+
MRZ /0X_^"EG[,EY#XBN-'E^*/B"W\*ZO\1M.UFXT'X3>-=1MXK#X5_V#;>+O
M%%K<1::(=1\+PZYXET;PMIVI6$ES+JOB:\CTJRM)'*R-I0_\%"_@7J7C/PS\
M.-%MO&MQX^\2VOA"_7PQK'ANZ\.WFCP>(OBOHWP@UW3->DU#,>C^+/ OB75S
M+XD\*:C]FU)["RN+K2CJ%NT,\GFNB_$3]B.RU[Q-X4T?X'ZVUEJGQ*T[X;1Z
MI%\.IM5\#^*9OC/\8='^%/B#Q-X1NO[3OM/LOAE<?&CP=H6@>--8BL]!TNZ\
M1:3HVLVFGZQ:7NE:M?<9X*^._P#P3^\6>+?#GQ6T/X)/:^)?$?C+6O#-[XUE
M\'>%'?P4-#^)W@G/C[XC'2O%FHCP%IVK?%OQAX.M[:[\1V5A\06U5;?4=<\.
MZ?X;T)]3L0#VWP;_ ,%!OAUXB^,?B[X+:_X-\7>#?$GACXI>-_AK9W&H&QU2
M#Q/;>'/&'A7P'X9\;Z%;Z0]Q=3^%_&WBS6_$/A^&:1$N/#>L>!]<L_$$5J+C
M39KJ;4O^"E/[*^FZ5X:UE_$?BRYL_$NN>$=!5;3P/K\E[H=UX[GV^%)_$>G2
MV\-]IEIK%@R>(+>06]Q,/#,B^(9($TI9;F/3N/"W[(_QC^+WBWX.Z]\"-(U;
MQ(/AUK'C.V\9:IX*TD^&?'G@3XB_$'PUXT\:WO@SQOI-]<:A<V]U\4M+\,:]
MKANAHAU+Q58)K&@2:Q_9NJ7MIC>!/AI^R7\6M<^*'@.7]E!/">H? _Q'\*XM
M:M?%/@#PS86NK7O@KP1/I/PHG\-7OA'7]>CUNT\/?#JVT^RTO0]0DL[W3_"V
ML^'[/4="BMM3M[>@!WAS_@HE\'M9@%WJ_@[XN^$$9-&U*?2M>\ ZK+XF\/>#
M=1O]7TW4/B7XUTG1EU2Q\,_#C1+C3+::]\3KK6J(+'6=+NY+2#S9(HX/&?\
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MPY=:ZANO%'BH>%M'3Q=I\1"ZG=:A9JNFI=ZA$ <SX>_X*9_"[Q'HG@W4=/\
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M ;U]?T/^%&]?7]#_ (444 &]?7]#_A1O7U_0_P"%%% !O7U_0_X4;U]?T/\
MA110 ;U]?T/^%&]?7]#_ (444 &]?7]#_A1O7U_0_P"%%% !O7U_0_X4;U]?
MT/\ A110 ;U]?T/^%&]?7]#_ (444 &]?7]#_A1O7U_0_P"%%% !O7U_0_X4
L;U]?T/\ A110 ;U]?T/^%&]?7]#_ (444 &]?7]#_A1O7U_0_P"%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>nuvb-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-06T17:09:39.0565+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://nuvationbio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:nuvb="http://nuvationbio.com/20241231" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet" id="ConsolidatedBalanceSheet">
        <link:definition>100010 - Statement - Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails2" id="DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Aggregate Lease Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals" id="ConsolidatedBalanceSheetParentheticals">
        <link:definition>100030 - Statement - Consolidated Balance Sheet (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals" id="StatementConsolidatedStatementOfStockholdersEquityParentheticals">
        <link:definition>100060 - Statement - Consolidated Statement of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows" id="ConsolidatedStatementOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DescriptionOfOrganizationAndBusinessOperations" id="DescriptionOfOrganizationAndBusinessOperations">
        <link:definition>995467 - Disclosure - Description of Organization and Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatements" id="RestatementOfPreviouslyIssuedFinancialStatements">
        <link:definition>995477 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995487 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition" id="DisclosureAcquisition">
        <link:definition>995497 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMerger" id="DisclosureMerger">
        <link:definition>995507 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale">
        <link:definition>995517 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="DisclosureCollaborationAndLicenseAgreements">
        <link:definition>995527 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing" id="DisclosureBorrowing">
        <link:definition>995537 - Disclosure - Borrowing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>995547 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1" id="DisclosureAccruedExpenses1">
        <link:definition>995557 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOffering" id="InitialPublicOffering">
        <link:definition>995567 - Disclosure - Initial Public Offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacement" id="PrivatePlacement">
        <link:definition>995577 - Disclosure - Private Placement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995587 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995597 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStock" id="DisclosureRedeemableSeriesAConvertiblePreferredStock">
        <link:definition>995607 - Disclosure - Redeemable Series A Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>995617 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995627 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1" id="DisclosureAccumulatedOtherComprehensiveLossIncome1">
        <link:definition>995637 - Disclosure - Accumulated Other Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>995647 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlan" id="Disclosure401kPlan">
        <link:definition>995657 - Disclosure - 401(K) plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/Warrants" id="Warrants">
        <link:definition>995667 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTax" id="IncomeTax">
        <link:definition>995677 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>995687 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995697 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>995707 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>995717 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" id="RestatementOfPreviouslyIssuedFinancialStatementsTables">
        <link:definition>995727 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995737 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables" id="DisclosureAcquisitionTables">
        <link:definition>995747 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerTables" id="DisclosureMergerTables">
        <link:definition>995757 - Disclosure - Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables">
        <link:definition>995767 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" id="DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>995777 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>995787 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>995797 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995807 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995817 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables" id="DisclosureAccumulatedOtherComprehensiveLossIncomeTables">
        <link:definition>995827 - Disclosure - Accumulated Other Comprehensive (loss) Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995837 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>995847 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables" id="IncomeTaxTables">
        <link:definition>995857 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringTables" id="DisclosureRestructuringTables">
        <link:definition>995867 - Disclosure - RESTRUCTURING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails">
        <link:definition>995877 - Disclosure - Description of Organization and Business Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995887 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails" id="DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails">
        <link:definition>995897 - Disclosure - Significant Accounting Policies - Schedule of Concentration of Credit Risk Net Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails" id="DisclosureAcquisitionAdditionalInformationDetails">
        <link:definition>995907 - Disclosure - Acquisition (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails" id="DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails">
        <link:definition>995917 - Disclosure - Acquisition - Schedule of Final Allocable Purchase Price Consists (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails" id="DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails">
        <link:definition>995927 - Disclosure - Acquisition - Schedule of Final Allocable Purchase Price Consists (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails" id="DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails">
        <link:definition>995937 - Disclosure - Merger - Schedule of Net Proceed from Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails" id="DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails">
        <link:definition>995947 - Disclosure - Merger - Summary of Number of Shares of Common Stock Outstanding on Business Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails" id="DisclosureMergerAdditionalInformationDetails">
        <link:definition>995957 - Disclosure - Merger - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe">
        <link:definition>995967 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Marketable securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur">
        <link:definition>995977 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995987 - Disclosure - Fair Value Measurements and Marketable Securities (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails">
        <link:definition>995997 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Net Realized Gain (Loss) on Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails">
        <link:definition>996007 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale - Schedule of Marketable Securities with Continuous Unrealized Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails" id="DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails">
        <link:definition>996017 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule Of Available for sale Securities Maturity on Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails" id="DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails">
        <link:definition>996027 - Disclosure - Collaboration and License Agreements - Schedule of revenue recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>996037 - Disclosure - Collaboration and License Agreements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails" id="DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails">
        <link:definition>996047 - Disclosure - Collaboration and License Agreements - Schedule Of Contract Assets And Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails" id="DisclosureBorrowingAdditionalInformationDetails">
        <link:definition>996057 - Disclosure - Borrowing (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>996067 - Disclosure - Property and Equipment - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>996077 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>996087 - Disclosure - ACCRUED EXPENSES - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails" id="InitialPublicOfferingDetails">
        <link:definition>996097 - Disclosure - Initial Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails" id="PrivatePlacementDetails">
        <link:definition>996107 - Disclosure - Private Placement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <link:definition>996117 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>996127 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails" id="DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails">
        <link:definition>996137 - Disclosure - Leases - Schedule of Aggregate Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails" id="DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails">
        <link:definition>996147 - Disclosure - Leases - Schedule of Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails" id="DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>996157 - Disclosure - Redeemable Series A Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>996167 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails" id="DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails">
        <link:definition>996177 - Disclosure - Net Loss Per Share - Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails" id="DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>996187 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Changes in Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>996197 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
        <link:definition>996207 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>996217 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails" id="DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails">
        <link:definition>996227 - Disclosure - Stock-Based Compensation - Summary of Grant-date Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>996237 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails" id="Disclosure401kPlanAdditionalInformationDetails">
        <link:definition>996247 - Disclosure - 401(K) PLAN - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails" id="WarrantsAdditionalInformationDetails">
        <link:definition>996257 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails" id="DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails">
        <link:definition>996267 - Disclosure - Warrants - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails" id="DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails">
        <link:definition>996277 - Disclosure - Warrants - Schedule of Fair Values for Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsParentheticalDetails" id="DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsParentheticalDetails">
        <link:definition>996287 - Disclosure - Warrants - Schedule of Fair Values for Outstanding Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails" id="DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails">
        <link:definition>996297 - Disclosure - Warrants - Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails" id="DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails">
        <link:definition>996307 - Disclosure - Income Tax - Summary Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails" id="IncomeTaxSummaryOfNetDeferredTaxAssetsDetails">
        <link:definition>996317 - Disclosure - Income Tax - Summary of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails" id="DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails">
        <link:definition>996327 - Disclosure - Income Taxe - Summary of Net Deferred Tax Assets (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails" id="IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails">
        <link:definition>996337 - Disclosure - Income Tax - Summary of Reconciliation of the Federal Income Tax Rate to the Company's Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails" id="IncomeTaxAdditionalInformationDetails">
        <link:definition>996347 - Disclosure - Income Tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails">
        <link:definition>996357 - Disclosure - Income Tax - Summary of unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails" id="DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails">
        <link:definition>996367 - Disclosure - RESTRUCTURING - Summary of accrued restructuring costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" id="DisclosureRestructuringAdditionalInformationDetails">
        <link:definition>996377 - Disclosure - RESTRUCTURING (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>996387 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>996397 - Disclosure - Subsequent Event (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet" xlink:href="nuvb-20241231.xsd#ConsolidatedBalanceSheet" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails2" xlink:href="nuvb-20241231.xsd#DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="nuvb-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows" xlink:href="nuvb-20241231.xsd#ConsolidatedStatementOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails" xlink:href="nuvb-20241231.xsd#DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails" xlink:href="nuvb-20241231.xsd#DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails" xlink:href="nuvb-20241231.xsd#DisclosurePropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails" xlink:href="nuvb-20241231.xsd#DisclosureAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails" xlink:href="nuvb-20241231.xsd#DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:href="nuvb-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails" xlink:href="nuvb-20241231.xsd#IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/CoverPage" xlink:href="nuvb-20241231.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals" xlink:href="nuvb-20241231.xsd#ConsolidatedBalanceSheetParentheticals" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="nuvb-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals" xlink:href="nuvb-20241231.xsd#StatementConsolidatedStatementOfStockholdersEquityParentheticals" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="nuvb-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DescriptionOfOrganizationAndBusinessOperations" xlink:href="nuvb-20241231.xsd#DescriptionOfOrganizationAndBusinessOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:href="nuvb-20241231.xsd#RestatementOfPreviouslyIssuedFinancialStatements" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="nuvb-20241231.xsd#DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition" xlink:href="nuvb-20241231.xsd#DisclosureAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMerger" xlink:href="nuvb-20241231.xsd#DisclosureMerger" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="nuvb-20241231.xsd#DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing" xlink:href="nuvb-20241231.xsd#DisclosureBorrowing" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="nuvb-20241231.xsd#DisclosurePropertyAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1" xlink:href="nuvb-20241231.xsd#DisclosureAccruedExpenses1" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOffering" xlink:href="nuvb-20241231.xsd#InitialPublicOffering" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacement" xlink:href="nuvb-20241231.xsd#PrivatePlacement" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactions" xlink:href="nuvb-20241231.xsd#RelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases" xlink:href="nuvb-20241231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStock" xlink:href="nuvb-20241231.xsd#DisclosureRedeemableSeriesAConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/StockholdersEquity" xlink:href="nuvb-20241231.xsd#StockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="nuvb-20241231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1" xlink:href="nuvb-20241231.xsd#DisclosureAccumulatedOtherComprehensiveLossIncome1" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlan" xlink:href="nuvb-20241231.xsd#Disclosure401kPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/Warrants" xlink:href="nuvb-20241231.xsd#Warrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTax" xlink:href="nuvb-20241231.xsd#IncomeTax" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuring" xlink:href="nuvb-20241231.xsd#DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="nuvb-20241231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="nuvb-20241231.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="nuvb-20241231.xsd#DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:href="nuvb-20241231.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nuvb-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables" xlink:href="nuvb-20241231.xsd#DisclosureAcquisitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerTables" xlink:href="nuvb-20241231.xsd#DisclosureMergerTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="nuvb-20241231.xsd#DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="nuvb-20241231.xsd#DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="nuvb-20241231.xsd#DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:href="nuvb-20241231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="nuvb-20241231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables" xlink:href="nuvb-20241231.xsd#DisclosureAccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables" xlink:href="nuvb-20241231.xsd#DisclosureWarrantsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables" xlink:href="nuvb-20241231.xsd#IncomeTaxTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringTables" xlink:href="nuvb-20241231.xsd#DisclosureRestructuringTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails" xlink:href="nuvb-20241231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureAcquisitionAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails" xlink:href="nuvb-20241231.xsd#DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails" xlink:href="nuvb-20241231.xsd#DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureMergerAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails" xlink:href="nuvb-20241231.xsd#DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails" xlink:href="nuvb-20241231.xsd#DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails" xlink:href="nuvb-20241231.xsd#DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureBorrowingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails" xlink:href="nuvb-20241231.xsd#InitialPublicOfferingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails" xlink:href="nuvb-20241231.xsd#PrivatePlacementDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails" xlink:href="nuvb-20241231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails" xlink:href="nuvb-20241231.xsd#DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails" xlink:href="nuvb-20241231.xsd#DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="nuvb-20241231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#Disclosure401kPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#WarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails" xlink:href="nuvb-20241231.xsd#DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails" xlink:href="nuvb-20241231.xsd#DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsParentheticalDetails" xlink:href="nuvb-20241231.xsd#DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails" xlink:href="nuvb-20241231.xsd#DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails" xlink:href="nuvb-20241231.xsd#DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails" xlink:href="nuvb-20241231.xsd#IncomeTaxSummaryOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails" xlink:href="nuvb-20241231.xsd#DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#IncomeTaxAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails" xlink:href="nuvb-20241231.xsd#DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails" xlink:href="nuvb-20241231.xsd#DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureRestructuringAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="nuvb-20241231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TotalFinancialAssets" xlink:label="nuvb_TotalFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NewYorkCityMember" xlink:label="nuvb_NewYorkCityMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OutstandingAtDecember312020AfterAdjustment" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LesseeOperatingLeaseExpirationYear" xlink:label="nuvb_LesseeOperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" xlink:label="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicOfferingDetailsLineItems" xlink:label="nuvb_InitialPublicOfferingDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OtherThanUnitedStateMember" xlink:label="nuvb_OtherThanUnitedStateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToPIPEFinancing" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingLineItems" xlink:label="us-gaap_SubordinatedBorrowingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" xlink:label="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesUponBusinessCombination" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" xlink:label="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossAbstract" xlink:label="us-gaap_MarketableSecuritiesGainLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionWithServiceConditionsMember" xlink:label="nuvb_OptionWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ReceivedNonRefundableUpfrontCashPayment" xlink:label="nuvb_ReceivedNonRefundableUpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock" xlink:label="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareOutstandingPriorToBusinessCombination" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CommonStockRedemptionPricePerShare" xlink:label="nuvb_CommonStockRedemptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TaxCreditCarryforwardsExpiration" xlink:label="nuvb_TaxCreditCarryforwardsExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketRiskBenefitChangeInFairValueGainLoss" xlink:label="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MarketableSecuritiesMember" xlink:label="nuvb_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SanFranciscoMember" xlink:label="nuvb_SanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:label="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAndSecurityAgreementMember" xlink:label="nuvb_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ClassACommonSharesSubjectToRepurchaseMember" xlink:label="nuvb_ClassACommonSharesSubjectToRepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashAtBankAndCashHeldInTrustAccount" xlink:label="nuvb_CashAtBankAndCashHeldInTrustAccount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PACoInvestmentsLLCMember" xlink:label="nuvb_PACoInvestmentsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" xlink:label="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfSharesRelatedToMerger" xlink:label="nuvb_ConversionOfSharesRelatedToMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassACommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AmortizationOfPremiumOnMarketableSecurities" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RelatedPartyTransactionsDetailsTable" xlink:label="nuvb_RelatedPartyTransactionsDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedemptionOfSharePriorToBusinessCombination" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsIssued" xlink:label="nuvb_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderSharesMember" xlink:label="nuvb_FounderSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:label="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IntangibleAssetsNetOfAmortization" xlink:label="nuvb_IntangibleAssetsNetOfAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" xlink:label="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ServicesFees" xlink:label="nuvb_ServicesFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SaleOfUnderwritingDiscountsShares" xlink:label="nuvb_SaleOfUnderwritingDiscountsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NonCashLeaseExpense" xlink:label="nuvb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LongTermBorroing" xlink:label="nuvb_LongTermBorroing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingsAbstract" xlink:label="us-gaap_SubordinatedBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SagardHealthcarePartnersMember" xlink:label="nuvb_SagardHealthcarePartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromBusinessCombinationNet" xlink:label="nuvb_ProceedsFromBusinessCombinationNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EmployeeStockPurchasePlanMember" xlink:label="nuvb_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_USApprovalMember" xlink:label="nuvb_USApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShortTermWorkingCapital" xlink:label="nuvb_ShortTermWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockholdersEquityDetailsTable" xlink:label="nuvb_StockholdersEquityDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PercentageOfLongLivedAssets" xlink:label="nuvb_PercentageOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockholdersEquityDetailsLineItems" xlink:label="nuvb_StockholdersEquityDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesBasedStockOptionGrantedVestingPercentage" xlink:label="nuvb_SharesBasedStockOptionGrantedVestingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InnoventMember" xlink:label="nuvb_InnoventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingTable" xlink:label="us-gaap_SubordinatedBorrowingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" xlink:label="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationPricePerShare" xlink:label="nuvb_BusinessCombinationPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantDisclosureAbstract" xlink:label="nuvb_WarrantDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BorrowingTwoThousandsAndTwentyTwoMember" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToForwardPurchase" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantDisclosureTextBlock" xlink:label="nuvb_WarrantDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicDisclosureOfferingTextBlock" xlink:label="nuvb_InitialPublicDisclosureOfferingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TransactionCostsRelatedToAnheartAcquisition" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InterestReceivableOnMarketableSecuritiesCurrent" xlink:label="nuvb_InterestReceivableOnMarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderSharesConversion" xlink:label="nuvb_FounderSharesConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfEquitySecuritiesSold" xlink:label="nuvb_NumberOfEquitySecuritiesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ContractWithCustomerAssets" xlink:label="nuvb_ContractWithCustomerAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" xlink:label="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationTrueUp" xlink:label="nuvb_BusinessCombinationTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SubjecttopossibleredemptionPerShare" xlink:label="nuvb_SubjecttopossibleredemptionPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InternalRevenueCode59Member" xlink:label="nuvb_InternalRevenueCode59Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate" xlink:label="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesValue" xlink:label="nuvb_IssuanceOfSharesValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BorrowingTwoThousandsAndTwentyMember" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CustomerBMember" xlink:label="nuvb_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CollaborationAndLicenseAgreementsTextblock" xlink:label="nuvb_CollaborationAndLicenseAgreementsTextblock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesExchangedInRecapitalization" xlink:label="nuvb_SharesExchangedInRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeaseLiabilityRecognized" xlink:label="nuvb_OperatingLeaseLiabilityRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WorkingCapitalLoans" xlink:label="nuvb_WorkingCapitalLoans"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" xlink:label="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MergerAgreementMember" xlink:label="nuvb_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDisclosureAbstract" xlink:label="nuvb_PrivatePlacementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:label="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeaseAdditionalTerm" xlink:label="nuvb_LeaseAdditionalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LiquidityPolicyTextBlock" xlink:label="nuvb_LiquidityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FinancialAssets" xlink:label="nuvb_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeaseSecurityDepositNoncurrent" xlink:label="nuvb_LeaseSecurityDepositNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="nuvb_CashAndCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PriorEffectOfBusinessCombinationTransactionMember" xlink:label="nuvb_PriorEffectOfBusinessCombinationTransactionMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfFounderShares" xlink:label="nuvb_ConversionOfFounderShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PanaceaMember" xlink:label="nuvb_PanaceaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SponsorMember" xlink:label="nuvb_SponsorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SaleOfPrivatePlacementShares" xlink:label="nuvb_SaleOfPrivatePlacementShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" xlink:label="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" xlink:label="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForRsusVestedShare" xlink:label="nuvb_IssuanceOfCommonStockForRsusVestedShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FoodAndDrugAdministrationApprovalMember" xlink:label="nuvb_FoodAndDrugAdministrationApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedeemableWarrantsMember" xlink:label="nuvb_RedeemableWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" xlink:label="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AdditionalPurchaseUnits" xlink:label="nuvb_AdditionalPurchaseUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsIssuedDuringThePeriod" xlink:label="nuvb_WarrantsIssuedDuringThePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicDisclosureOfferingAbstract" xlink:label="nuvb_InitialPublicDisclosureOfferingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AssumedShareBasedAwardsMember" xlink:label="nuvb_AssumedShareBasedAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrencyTranslationAdjustmentValue" xlink:label="nuvb_CurrencyTranslationAdjustmentValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PanaceaEquityAtEffectiveTime" xlink:label="nuvb_PanaceaEquityAtEffectiveTime"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDetailsTable" xlink:label="nuvb_PrivatePlacementDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FairValueOfWarrantsTradingPrice" xlink:label="nuvb_FairValueOfWarrantsTradingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:label="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EstimatedFairValueWarrantPerShare" xlink:label="nuvb_EstimatedFairValueWarrantPerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShortTermBorrowingsDrawnDown" xlink:label="nuvb_ShortTermBorrowingsDrawnDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockConversionRatio" xlink:label="nuvb_StockConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription" xlink:label="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfMilestones" xlink:label="nuvb_NumberOfMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_HoldingOfOutstandingPreferredStock" xlink:label="nuvb_HoldingOfOutstandingPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NkMember" xlink:label="nuvb_NkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SubjectToPossibleRedemptionShares" xlink:label="nuvb_SubjectToPossibleRedemptionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ReductionToAdditionalPaidInCapital" xlink:label="nuvb_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock" xlink:label="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationWarrants" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OrphanDrugTaxCreditCarryforwardMember" xlink:label="nuvb_OrphanDrugTaxCreditCarryforwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CollaborationAndLicenceAgreementAbstract" xlink:label="nuvb_CollaborationAndLicenceAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingNameDomain" xlink:label="us-gaap_SubordinatedBorrowingNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" xlink:label="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MaximumSaleOfCommonStockPricePerShare" xlink:label="nuvb_MaximumSaleOfCommonStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RealizedLossOnMarketableSecurities" xlink:label="nuvb_RealizedLossOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" xlink:label="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EmergingGrowthPolicyTextBlock" xlink:label="nuvb_EmergingGrowthPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAgreementsWithChinaMerchantsBankMember" xlink:label="nuvb_LoanAgreementsWithChinaMerchantsBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantLiability" xlink:label="nuvb_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingAxis" xlink:label="us-gaap_SubordinatedBorrowingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassBCommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RevenueRecognizedUponMilestonePaymenyts" xlink:label="nuvb_RevenueRecognizedUponMilestonePaymenyts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CustomerAMember" xlink:label="nuvb_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LicenseRevenueMember" xlink:label="nuvb_LicenseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDetailsLineItems" xlink:label="nuvb_PrivatePlacementDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DescriptionOfPublicWarrant" xlink:label="nuvb_DescriptionOfPublicWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAgreementsWithBankOfHangzhouMember" xlink:label="nuvb_LoanAgreementsWithBankOfHangzhouMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RevenueRecognitionPolicyPolicyTextBlock" xlink:label="nuvb_RevenueRecognitionPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConcentrationRiskThresholdPercentage" xlink:label="nuvb_ConcentrationRiskThresholdPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AllocablePurchasePrice" xlink:label="nuvb_AllocablePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicOfferingDetailsTable" xlink:label="nuvb_InitialPublicOfferingDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderMember" xlink:label="nuvb_FounderMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:label="nuvb_RelatedPartyTransactionsDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConvertiblePreferredStocksMember" xlink:label="nuvb_ConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsPolicyTextBlock" xlink:label="nuvb_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDisclosureTextBlock" xlink:label="nuvb_PrivatePlacementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeasesPolicyTextBlock" xlink:label="nuvb_LeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BankLoans" xlink:label="srt_BankLoans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ClassAAndClassBCommonStockMember" xlink:label="nuvb_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" xlink:label="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OwedMilestonePayments" xlink:label="nuvb_OwedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" xlink:label="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLossCarryforwardsExpiration" xlink:label="nuvb_OperatingLossCarryforwardsExpiration"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MilestonesRequirePayments" xlink:label="nuvb_MilestonesRequirePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InternalRevenueCode174Member" xlink:label="nuvb_InternalRevenueCode174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredTaxAssetsLeaseLiability" xlink:label="nuvb_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to Common Stock related to the AnHeart acquisition, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TotalFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TotalFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total financial assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TotalFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total financial assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NewYorkCityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York, New York</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NewYorkCityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New York City [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NewYorkCityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New York City.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of share option outstanding, 2020 after adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at December 31, 2020 after adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding at December 31, 2020 after adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding at December 31, 2020 after adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Values for Outstanding Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shares of Nuvation Bio outstanding immediately following the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Common Shares Outstanding After Business Combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Shares Outstanding After Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LesseeOperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LesseeOperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LesseeOperatingLeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Including Additional Paid in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Capitalized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Equity Level1 To Level2 or Level3 Transfers Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Equity Level1 To Level2 or Level3 Transfers Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Equity Level1 To Level2 or Level3 Transfers Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicOfferingDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Public Offering Details Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicOfferingDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering (Details) [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OtherThanUnitedStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Than United State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OtherThanUnitedStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Than United State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OtherThanUnitedStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than U.S. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Sources and Uses of Funds Related to Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued pursuant to the PIPE financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Pursuant To P I P E Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued pursuant to the PIPE financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowing [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Futures Minimum Payment Due In Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Futures Minimum Payment Due In Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of shares upon Business Combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Shares Upon Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Issuance of shares upoon Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion adjustment related to the Merge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, conversion adjustment related to business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Conversion adjustment related to Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains (losses) on available-for-sale securities were as follows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Gain (Loss) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionWithServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options with Service Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionWithServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option with Service Conditions Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionWithServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option with Service Conditions Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Combination Common Stock Shares Outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Common Stock Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common stock of Panacea</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Japan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ReceivedNonRefundableUpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Received NonRefundable Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ReceivedNonRefundableUpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Received NonRefundable Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ReceivedNonRefundableUpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received a non-refundable upfront cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance and exchange of common stock, net of issuance cost upon the Merger (see Note 3), shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance and exchange of common stock, net of issuance cost upon business combination transaction, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payment Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payment for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Series A Convertible Preferred Stock Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for information about redeemable series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Panacea shares outstanding prior to Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share outstanding prior to business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Outstanding Prior To Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities with Continuous Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CommonStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Redemption Price Per Share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CommonStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Redemption Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CommonStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock redemption price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Number of Shares of Common Stock Outstanding on Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization of preferred stock due to business combination transaction, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization Of Preferred Stock Due To Business Combination Transaction Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TaxCreditCarryforwardsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforwards Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TaxCreditCarryforwardsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TaxCreditCarryforwardsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Fair Value, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Risk Benefit, Change in Fair Value, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of share option, Forfeited or canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share option, Forfeited or canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basic And Diluted Net Loss Per Share Class A And Class B Nonredeemable Common Stockin Doll</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per share, Class A and Class B non-redeemable common stock (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss/Basic and Diluted&#160;Non-Redeemable&#160;Class&#160;A and B Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and additional paid in capital, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Warrant Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Francisco, California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">San Francisco [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">San Francisco.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForCreditLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance for Credit Loss [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period Share Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and Warrants Issued During Period Share Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock and Warrants Issued During Period Share Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock related to the AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Convertible Preferred Stock related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Convertible Preferred Stock related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized contract cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Capitalized Contract Cost, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net unrealized losses on equities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average shares outstanding of non-redeemable common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding of Class A and Class B non-redeemable common stock (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-Redeemable&#160;Class&#160;A and B Common Stock, Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ClassACommonSharesSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A Common Shares Subject to Repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ClassACommonSharesSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A Common Shares Subject to Repurchase [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashAtBankAndCashHeldInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash at bank and cash held in trust account.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashAtBankAndCashHeldInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash At Bank And Cash Held In Trust Account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashAtBankAndCashHeldInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Panacea cash at bank and cash held in a trust account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets held in the Trust Account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with customer liability revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Machinery and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Realized Gain (Loss) on Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Realized Gain (Loss) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PACoInvestmentsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">P A Co Investments L L C Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PACoInvestmentsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PACoInvestmentsLLCMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PACoInvestmentsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PA Co-Investments LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred financing costs in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred financing costs in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred financing costs in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Convertible, Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest receivable on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest and Dividends Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Interest and Dividends Receivable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options assumed for acquisition of AnHeart</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of replacement awards related to the AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Replacement Awards Related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Replacement Awards Related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfSharesRelatedToMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of shares related to merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfSharesRelatedToMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Shares Related To Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfSharesRelatedToMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Panacea shares as a result of merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Old Nuvation Class A common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Old Nuvation Class A common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Old Nuvation Class A common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium and discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Premium On Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of premium on marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net amortization on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Final Allocable Purchase Price Consists</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RelatedPartyTransactionsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transactions Details Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RelatedPartyTransactionsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of share option outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of share option outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: redemption of Panacea shares prior to the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redemption of share prior to business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redemption Of Share Prior To Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restatement of previously issued financials statements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restatement Of Previously Issued Financials Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restatement of Previously Issued Financials Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UNITED STATES [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder Shares Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FounderSharesMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of common stock for in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RoyaltyExpense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state net operating loss carryovers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issuable under share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issuable Under Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issuable under the plan (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment,net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net of accumulated depreciation of $874 and $666, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, acquired and retired, at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Retired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payment Due In Four Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IntangibleAssetsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net of accumulated amortization of $448</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IntangibleAssetsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net of Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IntangibleAssetsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible Assets Net of Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and additional paid in capital, par value (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Decreased Subject to Repurchase Under Stock Restriction Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares decreased subject to repurchase under stock restriction agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Decreased Subject to Repurchase Under Stock Restriction Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Description of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Description of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ServicesFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of services fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ServicesFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ServicesFees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ServicesFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">services fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SaleOfUnderwritingDiscountsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Underwriting Discounts Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SaleOfUnderwritingDiscountsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SaleOfUnderwritingDiscountsShares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SaleOfUnderwritingDiscountsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of underwriting discounts, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued consultant fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net realized losses on equities sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Realized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net realized losses on equities sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LongTermBorroing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Borroing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LongTermBorroing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-Term Borroing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LongTermBorroing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Calculation of Basic and Diluted Net Income (loss) Per Common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and benefit costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedules Of Concentration Of Risk By Risk Factor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowings Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government and government agency securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SagardHealthcarePartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sagard Healthcare Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SagardHealthcarePartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sagard Healthcare Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SagardHealthcarePartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sagard Healthcare Partners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromBusinessCombinationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromBusinessCombinationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from business combination net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromBusinessCombinationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Business Combination Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price (in Dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_USApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_USApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_USApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShortTermWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term working capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShortTermWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Working Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShortTermWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-Term Working Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strike price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockholdersEquityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders Equity Details Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockholdersEquityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of share option, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share option, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share option exercisable, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PercentageOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Long Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PercentageOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Long Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PercentageOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AnheartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AnHeart [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AnheartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AnHeart [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AnheartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AnHeart [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">True-up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation True Up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation True Up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockholdersEquityDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders Equity Details Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockholdersEquityDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity (Details) [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares based option granted expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesBasedStockOptionGrantedVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Based Stock Option Granted Vesting Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesBasedStockOptionGrantedVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Based Stock Option Granted Vesting Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesBasedStockOptionGrantedVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Based Stock Option Granted Vesting Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InnoventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innovent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InnoventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innovent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InnoventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innovent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowing [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current and deferred federal tax expense benefit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current and Deferred Federal Tax Expense Benefit [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionsWithServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options with Service Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionsWithServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options with Service Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionsWithServiceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options with Service Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Non-vested at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Non-vested at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Acquisition Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Acquisition Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exceeded Fair Value of the Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Combination Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BusinessCombinationPricePerShare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination price per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and additional paid in capital, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to the AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock Related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax Provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payment Due In Three Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of underwriter fees and other offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Underwriter Fees And Other Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of underwriter fees and other offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development capitalized expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Revenue Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowing Two Thousands And Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowing Two Thousands And Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowing in 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding line of credit balance net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued pursuant to the Forward Purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Pursuant To Forward Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued pursuant to the Forward Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized losses from sales of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash acquired from AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, frequency of commitment fee payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Commitment Fee Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicDisclosureOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicDisclosureOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InitialPublicDisclosureOfferingTextBlock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicDisclosureOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INITIAL PUBLIC OFFERING</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELATED PARTY TRANSACTIONS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction costs related to AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs related to AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs related to AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InterestReceivableOnMarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest receivable on marketable securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InterestReceivableOnMarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable On Marketable Securities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InterestReceivableOnMarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderSharesConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder Shares Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderSharesConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder share conversion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderSharesConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder Shares Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfEquitySecuritiesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equity securities sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfEquitySecuritiesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Equity Securities Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfEquitySecuritiesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Equity Securities Sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ContractWithCustomerAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ContractWithCustomerAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract With Customer Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ContractWithCustomerAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Operating Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Flow, Noncash Operating Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Combination True</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">True-up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Business Combination True Up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Other Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Other Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recent Accounting Pronouncement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization of preferred stock due to business combination transaction, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization Of Preferred Stock Due To Business Combination Transaction Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due With in one year, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options assumed for acquisition of AnHeart</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SubjecttopossibleredemptionPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subject to possible redemption value of per shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SubjecttopossibleredemptionPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SubjectToPossibleRedemption Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SubjecttopossibleredemptionPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subject to possible redemption, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of share option, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share option, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InternalRevenueCode59Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRC 59 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InternalRevenueCode59Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Code 59 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InternalRevenueCode59Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal Revenue Code 59 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of common stock for in-process research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during the period, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Redeemed or Called During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock redeemed during the period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in value of common stock subject to redemption (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Warrants member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition of Private Warrants Liability Upon Closing Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of private warrants liability upon closing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowing Two Thousands And Twenty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowing Two Thousands And Twenty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowing in 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Realized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net realized losses on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share option, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CollaborationAndLicenseAgreementsTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CollaborationAndLicenseAgreementsTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements [TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CollaborationAndLicenseAgreementsTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration And License Agreements TextBlock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesExchangedInRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares exchanged in recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesExchangedInRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Exchanged In Recapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SharesExchangedInRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Exchanged In Recapitalization, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeaseLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liability recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeaseLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeaseLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WorkingCapitalLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working Capital Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WorkingCapitalLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WorkingCapitalLoans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WorkingCapitalLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of Private Warrants liability recognized in earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Fair Value of Private Warrants Liability Recognized in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of private warrants liability recognized in earnings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of Private Warrants liability recognized in earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Grant-date Fair Value of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Future Minimum Lease Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payment For Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Future Minimum Rental Payment For Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeaseAdditionalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease additional term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeaseAdditionalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Additional Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeaseAdditionalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease additional term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Per share price (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 Months or Greater, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class of warrant or right, exercise price of warrants or rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant price per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-Sale Securities, Debt Maturities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity Policy Text Block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeaseSecurityDepositNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease security deposit noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeaseSecurityDepositNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Security Deposit Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeaseSecurityDepositNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross decreases - prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross decreases - prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of the Federal Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Secured Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and marketable securities .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Condensed Financial Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net of accumulated amortization of $448</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PriorEffectOfBusinessCombinationTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior effect of business combination transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PriorEffectOfBusinessCombinationTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Effect Of Business Combination Transaction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PriorEffectOfBusinessCombinationTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Effect Of Business Combination Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Founder shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Founder Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Founder shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Panacea member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Panacea [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Panacea [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Securities outstanding excluded from calculation of weighted average shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class B Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ownership percentage of outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExchangeTradedFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Traded Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsor Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SponsorMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SaleOfPrivatePlacementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Private Placement Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SaleOfPrivatePlacementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SaleOfPrivatePlacementShares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SaleOfPrivatePlacementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of private placement, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed interest rate on borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowing, Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Preferred Stocks Related To The Acquisition Of AnHeart( Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart( Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Of Convertible Preferred Stocks Related To The Acquisition Of AnHeart( Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Replacement Awards Related To The AnHeart Acquisition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Replacement Awards Related To The AnHeart Acquisition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Of Replacement Awards Related To The AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units RSU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock in shares (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock in shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Combination, Conversion of Redeemable Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Conversion Of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Old Nuvation Redeemable Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Redeemed or Called During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock redeemed or called during period, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in value of common stock subject to redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition Related Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition-related Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquisition Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from PIPE investment and forward purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From P I P E Investment And Forward Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from PIPE investment and forward purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination, Control Obtained Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Control Obtained Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to common stockholders due to exercised right to redeem shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Common Stockholders Due To Exercised Right To Redeem Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment to Panacea Class A common stockholders who exercised their right to redeem their shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of accrued restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForRsusVestedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock for RSUs Vested, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForRsusVestedShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock for RSUs Vested, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FoodAndDrugAdministrationApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Food And Drug Administration Approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FoodAndDrugAdministrationApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Food And Drug Administration Approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FoodAndDrugAdministrationApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FDA Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Contract Assets And Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedeemableWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedeemableWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RedeemableWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares based weighted average grant-date fair value of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of NonRefundable Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of NonRefundable Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred tax assets attributable to taxable temporary differences from research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net of accumulated depreciation of $874 and $666, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Marketable Securities Available for Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to Common Stock related to the AnHeart acquisition, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net of allowance for credit loss of $nil</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AdditionalPurchaseUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Purchase Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AdditionalPurchaseUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AdditionalPurchaseUnits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AdditionalPurchaseUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional purchase units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsIssuedDuringThePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsIssuedDuringThePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued During The Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsIssuedDuringThePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Realized gains from sales of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization of common stock due to business combination transaction, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization Of Common Stock Due To Business Combination Transaction Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock terms of conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Terms of Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during the period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares based option granted vest period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicDisclosureOfferingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Public Disclosure Offering Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicDisclosureOfferingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Disclosure Offering [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AssumedShareBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assumed Share Based Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AssumedShareBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assumed Share Based Awards Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AssumedShareBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumed Share Based Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrencyTranslationAdjustmentValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Currency Translation Adjustment Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrencyTranslationAdjustmentValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Currency Translation Adjustment Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrencyTranslationAdjustmentValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaEquityAtEffectiveTime_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Panacea Equity at Effective Time, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaEquityAtEffectiveTime_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Panacea equity at Effective Time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaEquityAtEffectiveTime_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Panacea equity at effective time.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PanaceaEquityAtEffectiveTime_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Panacea Equity at Effective Time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Details Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FairValueOfWarrantsTradingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants, Trading Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FairValueOfWarrantsTradingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Warrants, Trading Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FairValueOfWarrantsTradingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value O fWarrants Trading Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Organization and Business Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Short-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Short-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of short term borroing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risks and Uncertainties [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Intrinsic Value, Outstanding at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for purchase under ESPP, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for purchase under ESPP, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock for purchase under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payment Due In Five Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EstimatedFairValueWarrantPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Warrant Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EstimatedFairValueWarrantPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated Fair Value Warrant Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EstimatedFairValueWarrantPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value Warrant Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShortTermBorrowingsDrawnDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term borrowings drawn down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShortTermBorrowingsDrawnDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Borrowings Drawn Down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ShortTermBorrowingsDrawnDown_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-Term Borrowings Drawn Down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross Profit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payment Due Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_StockConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Performance Obligation Satisfied over Time, Method Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, performance obligation satisfied over time, method used, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NumberOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StandbyLettersOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Standby Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StandbyLettersOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Standby Letters of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_HoldingOfOutstandingPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Holding of Outstanding Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_HoldingOfOutstandingPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Holding of Outstanding Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_HoldingOfOutstandingPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Holding of Outstanding Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases - prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Date of Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_NkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and additional paid in capital, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of common stock issued to common stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restatement of previously issued financials statements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restatement Of Previously Issued Financials Statements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SubjectToPossibleRedemptionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subject To Possible Redemption Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SubjectToPossibleRedemptionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SubjectToPossibleRedemptionShares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SubjectToPossibleRedemptionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subject to possible redemption, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Outstanding at December, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to additional paid in-capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction to additional paid in-capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction to additional paid in-capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income, Noncontrolling Interest [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OrphanDrugTaxCreditCarryforwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan Drug Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OrphanDrugTaxCreditCarryforwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OrphanDrugTaxCreditCarryforwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Tax Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CollaborationAndLicenceAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration and Licence Agreement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CollaborationAndLicenceAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and Licence Agreement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowing, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ForwardPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forward Purchase Warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ForwardPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forward Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ForwardPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forward Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock For AnHeart Acquisition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock For AnHeart Acquisition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Of Common Stock For AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Accumulated Other Comprehensive (loss) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Available for sale Securities Classified By Contractual Maturity Date Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Classified By Contractual Maturity Date Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available for sale Securities Maturity On Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MaximumSaleOfCommonStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum sale of common stock price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MaximumSaleOfCommonStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MaximumSaleOfCommonStockPricePerShare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MaximumSaleOfCommonStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RealizedLossOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Realized loss On Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RealizedLossOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized loss On Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RealizedLossOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount reclassified for realized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases - current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options with Service Market And Performance Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options With Service Market and Performance Condition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options with service market and performance condition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConsiderationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consideration Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConsiderationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConsiderationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Issuance of Common Stock Under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Common Stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term borrowings outstanding balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Average Outstanding Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EmergingGrowthPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Policy Text Block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EmergingGrowthPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EmergingGrowthPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAgreementsWithChinaMerchantsBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreements With China Merchants Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAgreementsWithChinaMerchantsBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Agreements With China Merchants Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAgreementsWithChinaMerchantsBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreements With China Merchants Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrants liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue From Contract With Customer Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowing [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Service Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Service Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issued Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in Liabilities Classified in Level 3 of Fair Value Hierarchy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in liabilities classified in Level 3 of fair value hierarchy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Old Nuvation Class B common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Old Nuvation Class B common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Old Nuvation Class B common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of the significant inputs to the Monte Carlo Simulation for the fair value of the Public Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RevenueRecognizedUponMilestonePaymenyts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognized Upon Milestone Paymenyts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RevenueRecognizedUponMilestonePaymenyts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Recognized Upon Milestone Paymenyts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RevenueRecognizedUponMilestonePaymenyts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of assets and businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net gains (losses) on equity securities were as follows:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Realized Gain (Loss) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs to Fulfill a Contract with a Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CertificateOfDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificate of deposits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CertificateOfDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Certificate of deposits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year through five years, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(K) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less than 12 Months, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 Months, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for purchase under ESPP, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for purchase under ESPP, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for purchase under ESPP, (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Non-Voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Details Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement (Details) [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment advisory fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to Common Stock related to the AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DescriptionOfPublicWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of public warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DescriptionOfPublicWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DescriptionOfPublicWarrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DescriptionOfPublicWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of public warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summaryof Significant Accounting Policies Details Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock outstanding or issuable, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAgreementsWithBankOfHangzhouMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreements With Bank of Hangzhou [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAgreementsWithBankOfHangzhouMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Agreements With Bank of Hangzhou [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LoanAgreementsWithBankOfHangzhouMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreements With Bank Of Hangzhou [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ACCRUED EXPENSES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Security Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants related to the AnHeart acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Warrants Related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Warrants Related to the AnHeart Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Short-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Functional Currency and Foreign Currency Translations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss, net of taxes:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RevenueRecognitionPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RevenueRecognitionPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Recognition Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RevenueRecognitionPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConcentrationRiskThresholdPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Threshold Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConcentrationRiskThresholdPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration Risk Threshold Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConcentrationRiskThresholdPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Threshold Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options with Service, Market, and Performance Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments on borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Termination [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract termination costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax expense - federal and state</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Federal, State and Local, Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amount reclassified for realized gains included in gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount reclassified for realized loss (gain) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited or canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited or canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in unrealized (loss) gain on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized (loss) gain on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 Months, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AllocablePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total allocable purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AllocablePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocable Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_AllocablePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allocable Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair values of outstanding warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicOfferingDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Public Offering Details Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InitialPublicOfferingDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000,Class B 60,000,000) shares authorized as of December 31, 2024 and December 31, 2023, respectively, 337,837,872 (Class A 336,837,872, Class B 1,000,000) and 219,046,219 (Class A 218,046,219, Class B 1,000,000) shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_FounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RelatedPartyTransactionsDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transactions Details Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_RelatedPartyTransactionsDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions (Details) [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stocks [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Preferred Stocks [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable securities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock for AnHeart acquisition (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock for AnHeart acquisition (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock for AnHeart acquisition (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 17)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public and Private Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">12 Months or Greater, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PrivatePlacementDisclosureTextBlock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_PrivatePlacementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PRIVATE PLACEMENT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payment Due Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Commodity Contract Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Acquired IPR&amp;D, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Acquired IPR&amp;D, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_LeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summaryof Significant Accounting Policies Details Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies (Details) [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BankLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broker-Dealer, Bank Loan, Short-Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BankLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term bank loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum Annual Contributions Per Employee, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A And Class B Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A and Class B common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A and Class B Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance and exchange of common stock, net of issuance cost upon the Merger (see Note 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance and exchange of common stock, net of issuance cost upon business combination transaction, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current and deferred state and local tax expense benefit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current and Deferred State and Local Tax Expense Benefit [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OwedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Owed Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OwedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Owed Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OwedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company is owed in milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based By Weighted Average Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBasedCompensationArrangementByShareBasedByWeightedAveragePeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based By Weighted Average Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLossCarryforwardsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses carried forward expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLossCarryforwardsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_OperatingLossCarryforwardsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MilestonesRequirePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestones Require Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MilestonesRequirePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestones Require Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_MilestonesRequirePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones require payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss (gain) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss (gain) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total losses on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InternalRevenueCode174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Code 174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InternalRevenueCode174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal Revenue Code 174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_InternalRevenueCode174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRC 174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvb_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_TotalFinancialAssets" xlink:to="nuvb_TotalFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NewYorkCityMember" xlink:to="nuvb_NewYorkCityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OutstandingAtDecember312020AfterAdjustment" xlink:to="nuvb_OutstandingAtDecember312020AfterAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:to="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LesseeOperatingLeaseExpirationYear" xlink:to="nuvb_LesseeOperatingLeaseExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" xlink:to="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="nuvb_InitialPublicOfferingDetailsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OtherThanUnitedStateMember" xlink:to="nuvb_OtherThanUnitedStateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SharesIssuedPursuantToPIPEFinancing" xlink:to="nuvb_SharesIssuedPursuantToPIPEFinancing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_SubordinatedBorrowingLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" xlink:to="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfSharesUponBusinessCombination" xlink:to="nuvb_IssuanceOfSharesUponBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" xlink:to="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OptionWithServiceConditionsMember" xlink:to="nuvb_OptionWithServiceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:to="nuvb_BusinessCombinationCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ReceivedNonRefundableUpfrontCashPayment" xlink:to="nuvb_ReceivedNonRefundableUpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" xlink:to="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock" xlink:to="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ShareOutstandingPriorToBusinessCombination" xlink:to="nuvb_ShareOutstandingPriorToBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CommonStockRedemptionPricePerShare" xlink:to="nuvb_CommonStockRedemptionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_TaxCreditCarryforwardsExpiration" xlink:to="nuvb_TaxCreditCarryforwardsExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss" xlink:to="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" xlink:to="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_MarketableSecuritiesMember" xlink:to="nuvb_MarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:to="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SanFranciscoMember" xlink:to="nuvb_SanFranciscoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_AllowanceForCreditLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:to="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" xlink:to="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LoanAndSecurityAgreementMember" xlink:to="nuvb_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" xlink:to="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ClassACommonSharesSubjectToRepurchaseMember" xlink:to="nuvb_ClassACommonSharesSubjectToRepurchaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CashAtBankAndCashHeldInTrustAccount" xlink:to="nuvb_CashAtBankAndCashHeldInTrustAccount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:to="us-gaap_ScheduleOfRealizedGainLossTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PACoInvestmentsLLCMember" xlink:to="nuvb_PACoInvestmentsLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" xlink:to="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" xlink:to="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConversionOfSharesRelatedToMerger" xlink:to="nuvb_ConversionOfSharesRelatedToMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConversionOfOldNuvationClassACommonStock" xlink:to="nuvb_ConversionOfOldNuvationClassACommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_AmortizationOfPremiumOnMarketableSecurities" xlink:to="nuvb_AmortizationOfPremiumOnMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RelatedPartyTransactionsDetailsTable" xlink:to="nuvb_RelatedPartyTransactionsDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RedemptionOfSharePriorToBusinessCombination" xlink:to="nuvb_RedemptionOfSharePriorToBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" xlink:to="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WarrantsIssued" xlink:to="nuvb_WarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FounderSharesMember" xlink:to="nuvb_FounderSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:to="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IntangibleAssetsNetOfAmortization" xlink:to="nuvb_IntangibleAssetsNetOfAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" xlink:to="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ServicesFees" xlink:to="nuvb_ServicesFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SaleOfUnderwritingDiscountsShares" xlink:to="nuvb_SaleOfUnderwritingDiscountsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NonCashLeaseExpense" xlink:to="nuvb_NonCashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LongTermBorroing" xlink:to="nuvb_LongTermBorroing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:to="us-gaap_SubordinatedBorrowingsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_SubordinatedBorrowingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SagardHealthcarePartnersMember" xlink:to="nuvb_SagardHealthcarePartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ProceedsFromBusinessCombinationNet" xlink:to="nuvb_ProceedsFromBusinessCombinationNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EmployeeStockPurchasePlanMember" xlink:to="nuvb_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_USApprovalMember" xlink:to="nuvb_USApprovalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ShortTermWorkingCapital" xlink:to="nuvb_ShortTermWorkingCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_StockholdersEquityDetailsTable" xlink:to="nuvb_StockholdersEquityDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PercentageOfLongLivedAssets" xlink:to="nuvb_PercentageOfLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_AnheartMember" xlink:to="nuvb_AnheartMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="nuvb_StockholdersEquityDetailsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SharesBasedStockOptionGrantedVestingPercentage" xlink:to="nuvb_SharesBasedStockOptionGrantedVestingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InnoventMember" xlink:to="nuvb_InnoventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="us-gaap_SubordinatedBorrowingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" xlink:to="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OptionsWithServiceConditionsMember" xlink:to="nuvb_OptionsWithServiceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BusinessCombinationPricePerShare" xlink:to="nuvb_BusinessCombinationPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" xlink:to="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" xlink:to="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WarrantDisclosureAbstract" xlink:to="nuvb_WarrantDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PrivatePlacementWarrantsMember" xlink:to="nuvb_PrivatePlacementWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BorrowingTwoThousandsAndTwentyTwoMember" xlink:to="nuvb_BorrowingTwoThousandsAndTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SharesIssuedPursuantToForwardPurchase" xlink:to="nuvb_SharesIssuedPursuantToForwardPurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalBondsMember" xlink:to="us-gaap_MunicipalBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WarrantDisclosureTextBlock" xlink:to="nuvb_WarrantDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InitialPublicDisclosureOfferingTextBlock" xlink:to="nuvb_InitialPublicDisclosureOfferingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_TransactionCostsRelatedToAnheartAcquisition" xlink:to="nuvb_TransactionCostsRelatedToAnheartAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InterestReceivableOnMarketableSecuritiesCurrent" xlink:to="nuvb_InterestReceivableOnMarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FounderSharesConversion" xlink:to="nuvb_FounderSharesConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NumberOfEquitySecuritiesSold" xlink:to="nuvb_NumberOfEquitySecuritiesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ContractWithCustomerAssets" xlink:to="nuvb_ContractWithCustomerAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" xlink:to="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BusinessCombinationTrueUp" xlink:to="nuvb_BusinessCombinationTrueUp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfOtherComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_AcquiredInProcessResearchAndDevelopment" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SubjecttopossibleredemptionPerShare" xlink:to="nuvb_SubjecttopossibleredemptionPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InternalRevenueCode59Member" xlink:to="nuvb_InternalRevenueCode59Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PublicWarrantsMember" xlink:to="nuvb_PublicWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate" xlink:to="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfSharesValue" xlink:to="nuvb_IssuanceOfSharesValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BorrowingTwoThousandsAndTwentyMember" xlink:to="nuvb_BorrowingTwoThousandsAndTwentyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CustomerBMember" xlink:to="nuvb_CustomerBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CollaborationAndLicenseAgreementsTextblock" xlink:to="nuvb_CollaborationAndLicenseAgreementsTextblock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SharesExchangedInRecapitalization" xlink:to="nuvb_SharesExchangedInRecapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeaseLiabilityRecognized" xlink:to="nuvb_OperatingLeaseLiabilityRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WorkingCapitalLoans" xlink:to="nuvb_WorkingCapitalLoans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" xlink:to="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_MergerAgreementMember" xlink:to="nuvb_MergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PrivatePlacementDisclosureAbstract" xlink:to="nuvb_PrivatePlacementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:to="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LeaseAdditionalTerm" xlink:to="nuvb_LeaseAdditionalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LiquidityPolicyTextBlock" xlink:to="nuvb_LiquidityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FinancialAssets" xlink:to="nuvb_FinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LeaseSecurityDepositNoncurrent" xlink:to="nuvb_LeaseSecurityDepositNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="nuvb_CashAndCashEquivalentsAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PriorEffectOfBusinessCombinationTransactionMember" xlink:to="nuvb_PriorEffectOfBusinessCombinationTransactionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConversionOfFounderShares" xlink:to="nuvb_ConversionOfFounderShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PanaceaMember" xlink:to="nuvb_PanaceaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeTradedFundsMember" xlink:to="us-gaap_ExchangeTradedFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SponsorMember" xlink:to="nuvb_SponsorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SaleOfPrivatePlacementShares" xlink:to="nuvb_SaleOfPrivatePlacementShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" xlink:to="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" xlink:to="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" xlink:to="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionRelatedCostsMember" xlink:to="us-gaap_AcquisitionRelatedCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" xlink:to="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationControlObtainedDescription" xlink:to="us-gaap_BusinessCombinationControlObtainedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" xlink:to="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfCommonStockForRsusVestedShare" xlink:to="nuvb_IssuanceOfCommonStockForRsusVestedShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FoodAndDrugAdministrationApprovalMember" xlink:to="nuvb_FoodAndDrugAdministrationApprovalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RedeemableWarrantsMember" xlink:to="nuvb_RedeemableWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" xlink:to="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_AdditionalPurchaseUnits" xlink:to="nuvb_AdditionalPurchaseUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WarrantsIssuedDuringThePeriod" xlink:to="nuvb_WarrantsIssuedDuringThePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionFeatures" xlink:to="us-gaap_CommonStockConversionFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InitialPublicDisclosureOfferingAbstract" xlink:to="nuvb_InitialPublicDisclosureOfferingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_AssumedShareBasedAwardsMember" xlink:to="nuvb_AssumedShareBasedAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CurrencyTranslationAdjustmentValue" xlink:to="nuvb_CurrencyTranslationAdjustmentValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PanaceaEquityAtEffectiveTime" xlink:to="nuvb_PanaceaEquityAtEffectiveTime_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="nuvb_PrivatePlacementDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FairValueOfWarrantsTradingPrice" xlink:to="nuvb_FairValueOfWarrantsTradingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" xlink:to="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EstimatedFairValueWarrantPerShare" xlink:to="nuvb_EstimatedFairValueWarrantPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ShortTermBorrowingsDrawnDown" xlink:to="nuvb_ShortTermBorrowingsDrawnDown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_StockConversionRatio" xlink:to="nuvb_StockConversionRatio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription" xlink:to="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NumberOfMilestones" xlink:to="nuvb_NumberOfMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandbyLettersOfCreditMember" xlink:to="us-gaap_StandbyLettersOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_HoldingOfOutstandingPreferredStock" xlink:to="nuvb_HoldingOfOutstandingPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_NkMember" xlink:to="nuvb_NkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock" xlink:to="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SubjectToPossibleRedemptionShares" xlink:to="nuvb_SubjectToPossibleRedemptionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ReductionToAdditionalPaidInCapital" xlink:to="nuvb_ReductionToAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock" xlink:to="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EffectiveIncomeTaxRateReconciliationWarrants" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OrphanDrugTaxCreditCarryforwardMember" xlink:to="nuvb_OrphanDrugTaxCreditCarryforwardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CollaborationAndLicenceAgreementAbstract" xlink:to="nuvb_CollaborationAndLicenceAgreementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingNameDomain" xlink:to="us-gaap_SubordinatedBorrowingNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ForwardPurchaseWarrantsMember" xlink:to="nuvb_ForwardPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" xlink:to="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" xlink:to="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_MaximumSaleOfCommonStockPricePerShare" xlink:to="nuvb_MaximumSaleOfCommonStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RealizedLossOnMarketableSecurities" xlink:to="nuvb_RealizedLossOnMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" xlink:to="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConsiderationWarrantsMember" xlink:to="nuvb_ConsiderationWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:to="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EmergingGrowthPolicyTextBlock" xlink:to="nuvb_EmergingGrowthPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LoanAgreementsWithChinaMerchantsBankMember" xlink:to="nuvb_LoanAgreementsWithChinaMerchantsBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WarrantLiability" xlink:to="nuvb_WarrantLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingAxis" xlink:to="us-gaap_SubordinatedBorrowingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" xlink:to="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConversionOfOldNuvationClassBCommonStock" xlink:to="nuvb_ConversionOfOldNuvationClassBCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RevenueRecognizedUponMilestonePaymenyts" xlink:to="nuvb_RevenueRecognizedUponMilestonePaymenyts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CustomerAMember" xlink:to="nuvb_CustomerAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CertificateOfDepositsMember" xlink:to="nuvb_CertificateOfDepositsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LicenseRevenueMember" xlink:to="nuvb_LicenseRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" xlink:to="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="nuvb_PrivatePlacementDetailsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_DescriptionOfPublicWarrant" xlink:to="nuvb_DescriptionOfPublicWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LoanAgreementsWithBankOfHangzhouMember" xlink:to="nuvb_LoanAgreementsWithBankOfHangzhouMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" xlink:to="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RevenueRecognitionPolicyPolicyTextBlock" xlink:to="nuvb_RevenueRecognitionPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" xlink:to="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConcentrationRiskThresholdPercentage" xlink:to="nuvb_ConcentrationRiskThresholdPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_AllocablePurchasePrice" xlink:to="nuvb_AllocablePurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InitialPublicOfferingDetailsTable" xlink:to="nuvb_InitialPublicOfferingDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_FounderMember" xlink:to="nuvb_FounderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_RelatedPartyTransactionsDetailsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ConvertiblePreferredStocksMember" xlink:to="nuvb_ConvertiblePreferredStocksMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" xlink:to="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_WarrantsPolicyTextBlock" xlink:to="nuvb_WarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_PrivatePlacementDisclosureTextBlock" xlink:to="nuvb_PrivatePlacementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_LeasesPolicyTextBlock" xlink:to="nuvb_LeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BankLoans" xlink:to="srt_BankLoans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_ClassAAndClassBCommonStockMember" xlink:to="nuvb_ClassAAndClassBCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" xlink:to="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" xlink:to="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OwedMilestonePayments" xlink:to="nuvb_OwedMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" xlink:to="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_OperatingLossCarryforwardsExpiration" xlink:to="nuvb_OperatingLossCarryforwardsExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_MilestonesRequirePayments" xlink:to="nuvb_MilestonesRequirePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_InternalRevenueCode174Member" xlink:to="nuvb_InternalRevenueCode174Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvb_DeferredTaxAssetsLeaseLiability" xlink:to="nuvb_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedeemableWarrantsMember" xlink:label="nuvb_RedeemableWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_RedeemableWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantLiability" xlink:label="nuvb_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeaseSecurityDepositNoncurrent" xlink:label="nuvb_LeaseSecurityDepositNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InterestReceivableOnMarketableSecuritiesCurrent" xlink:label="nuvb_InterestReceivableOnMarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nuvb_WarrantLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="nuvb_LeaseSecurityDepositNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="nuvb_InterestReceivableOnMarketableSecuritiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IntangibleAssetsNetOfAmortization" xlink:label="nuvb_IntangibleAssetsNetOfAmortization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SubjectToPossibleRedemptionShares" xlink:label="nuvb_SubjectToPossibleRedemptionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SubjecttopossibleredemptionPerShare" xlink:label="nuvb_SubjecttopossibleredemptionPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IntangibleAssetsNetOfAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_SubjectToPossibleRedemptionShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_SubjecttopossibleredemptionPerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_8"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PriorEffectOfBusinessCombinationTransactionMember" xlink:label="nuvb_PriorEffectOfBusinessCombinationTransactionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConvertiblePreferredStocksMember" xlink:label="nuvb_ConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesExchangedInRecapitalization" xlink:label="nuvb_SharesExchangedInRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForRsusVestedShare" xlink:label="nuvb_IssuanceOfCommonStockForRsusVestedShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrencyTranslationAdjustmentValue" xlink:label="nuvb_CurrencyTranslationAdjustmentValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_28"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_29"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="nuvb_PriorEffectOfBusinessCombinationTransactionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvb_ConvertiblePreferredStocksMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_SharesExchangedInRecapitalization" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForRsusVestedShare" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_CurrencyTranslationAdjustmentValue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SaleOfUnderwritingDiscountsShares" xlink:label="nuvb_SaleOfUnderwritingDiscountsShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SaleOfPrivatePlacementShares" xlink:label="nuvb_SaleOfPrivatePlacementShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesValue" xlink:label="nuvb_IssuanceOfSharesValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_SaleOfUnderwritingDiscountsShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_SaleOfPrivatePlacementShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_IssuanceOfSharesValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" xlink:label="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TransactionCostsRelatedToAnheartAcquisition" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NonCashLeaseExpense" xlink:label="nuvb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AmortizationOfPremiumOnMarketableSecurities" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeaseLiabilityRecognized" xlink:label="nuvb_OperatingLeaseLiabilityRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" xlink:label="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="nuvb_TransactionCostsRelatedToAnheartAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nuvb_NonCashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nuvb_AmortizationOfPremiumOnMarketableSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_OperatingLeaseLiabilityRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DescriptionOfOrganizationAndBusinessOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" xlink:to="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMerger" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CollaborationAndLicenceAgreementAbstract" xlink:label="nuvb_CollaborationAndLicenceAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CollaborationAndLicenseAgreementsTextblock" xlink:label="nuvb_CollaborationAndLicenseAgreementsTextblock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CollaborationAndLicenceAgreementAbstract" xlink:to="nuvb_CollaborationAndLicenseAgreementsTextblock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingsAbstract" xlink:label="us-gaap_SubordinatedBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingsDisclosureTextBlock" xlink:label="us-gaap_SubordinatedBorrowingsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_SubordinatedBorrowingsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOffering" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicDisclosureOfferingAbstract" xlink:label="nuvb_InitialPublicDisclosureOfferingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicDisclosureOfferingTextBlock" xlink:label="nuvb_InitialPublicDisclosureOfferingTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicDisclosureOfferingAbstract" xlink:to="nuvb_InitialPublicDisclosureOfferingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDisclosureAbstract" xlink:label="nuvb_PrivatePlacementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDisclosureTextBlock" xlink:label="nuvb_PrivatePlacementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDisclosureAbstract" xlink:to="nuvb_PrivatePlacementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock" xlink:label="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock" xlink:label="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantDisclosureAbstract" xlink:label="nuvb_WarrantDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantDisclosureTextBlock" xlink:label="nuvb_WarrantDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_WarrantDisclosureAbstract" xlink:to="nuvb_WarrantDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTax" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LiquidityPolicyTextBlock" xlink:label="nuvb_LiquidityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EmergingGrowthPolicyTextBlock" xlink:label="nuvb_EmergingGrowthPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsPolicyTextBlock" xlink:label="nuvb_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RevenueRecognitionPolicyPolicyTextBlock" xlink:label="nuvb_RevenueRecognitionPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeasesPolicyTextBlock" xlink:label="nuvb_LeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_LiquidityPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_EmergingGrowthPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_WarrantsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_RevenueRecognitionPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_LeasesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" xlink:label="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" xlink:label="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfRealizedGainLossTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CollaborationAndLicenceAgreementAbstract" xlink:label="nuvb_CollaborationAndLicenceAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CollaborationAndLicenceAgreementAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CollaborationAndLicenceAgreementAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:label="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantDisclosureAbstract" xlink:label="nuvb_WarrantDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_WarrantDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_WarrantDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_WarrantDisclosureAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MergerAgreementMember" xlink:label="nuvb_MergerAgreementMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConcentrationRiskThresholdPercentage" xlink:label="nuvb_ConcentrationRiskThresholdPercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OtherThanUnitedStateMember" xlink:label="nuvb_OtherThanUnitedStateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="nuvb_CashAndCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FairValueOfWarrantsTradingPrice" xlink:label="nuvb_FairValueOfWarrantsTradingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PercentageOfLongLivedAssets" xlink:label="nuvb_PercentageOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_AnheartMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_ConcentrationRiskThresholdPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ConsiderationWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nuvb_OtherThanUnitedStateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_CashAndCashEquivalentsAndMarketableSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_FairValueOfWarrantsTradingPrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_PercentageOfLongLivedAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CustomerAMember" xlink:label="nuvb_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CustomerBMember" xlink:label="nuvb_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="nuvb_CustomerAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="nuvb_CustomerBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_AnheartMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AllocablePurchasePrice" xlink:label="nuvb_AllocablePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AssumedShareBasedAwardsMember" xlink:label="nuvb_AssumedShareBasedAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_AllocablePurchasePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_ConsiderationWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_AssumedShareBasedAwardsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AcquisitionRelatedCostsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:label="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EstimatedFairValueWarrantPerShare" xlink:label="nuvb_EstimatedFairValueWarrantPerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_EstimatedFairValueWarrantPerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashAtBankAndCashHeldInTrustAccount" xlink:label="nuvb_CashAtBankAndCashHeldInTrustAccount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" xlink:label="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" xlink:label="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromBusinessCombinationNet" xlink:label="nuvb_ProceedsFromBusinessCombinationNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PanaceaEquityAtEffectiveTime" xlink:label="nuvb_PanaceaEquityAtEffectiveTime"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_CashAtBankAndCashHeldInTrustAccount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_ProceedsFromBusinessCombinationNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="nuvb_PanaceaEquityAtEffectiveTime" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareOutstandingPriorToBusinessCombination" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedemptionOfSharePriorToBusinessCombination" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfSharesRelatedToMerger" xlink:label="nuvb_ConversionOfSharesRelatedToMerger"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToPIPEFinancing" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToForwardPurchase" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesUponBusinessCombination" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassACommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassBCommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfFounderShares" xlink:label="nuvb_ConversionOfFounderShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ShareOutstandingPriorToBusinessCombination" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_RedemptionOfSharePriorToBusinessCombination" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfSharesRelatedToMerger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_BusinessCombinationCommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_SharesIssuedPursuantToPIPEFinancing" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_SharesIssuedPursuantToForwardPurchase" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_IssuanceOfSharesUponBusinessCombination" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfOldNuvationClassACommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfOldNuvationClassBCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfFounderShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PanaceaMember" xlink:label="nuvb_PanaceaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CommonStockRedemptionPricePerShare" xlink:label="nuvb_CommonStockRedemptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsIssuedDuringThePeriod" xlink:label="nuvb_WarrantsIssuedDuringThePeriod"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockConversionRatio" xlink:label="nuvb_StockConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderSharesConversion" xlink:label="nuvb_FounderSharesConversion"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_PanaceaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_CommonStockRedemptionPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_WarrantsIssuedDuringThePeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_StockConversionRatio" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_FounderSharesConversion" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AccretionExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FinancialAssets" xlink:label="nuvb_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TotalFinancialAssets" xlink:label="nuvb_TotalFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="nuvb_FinancialAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_FinancialAssets" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_FinancialAssets" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_FinancialAssets" xlink:to="nuvb_TotalFinancialAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ExchangeTradedFundsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:label="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MarketableSecuritiesMember" xlink:label="nuvb_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvb_MarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ExchangeTradedFundsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfEquitySecuritiesSold" xlink:label="nuvb_NumberOfEquitySecuritiesSold"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="nuvb_NumberOfEquitySecuritiesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossAbstract" xlink:label="us-gaap_MarketableSecuritiesGainLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesGainLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesGainLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesGainLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ExchangeTradedFundsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossAbstract" xlink:label="us-gaap_AllowanceForCreditLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForCreditLossAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LicenseRevenueMember" xlink:label="nuvb_LicenseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_LicenseRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RevenueRecognizedUponMilestonePaymenyts" xlink:label="nuvb_RevenueRecognizedUponMilestonePaymenyts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InnoventMember" xlink:label="nuvb_InnoventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CollaborationAndLicenceAgreementAbstract" xlink:label="nuvb_CollaborationAndLicenceAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NkMember" xlink:label="nuvb_NkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription" xlink:label="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ContractWithCustomerAssets" xlink:label="nuvb_ContractWithCustomerAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MilestonesRequirePayments" xlink:label="nuvb_MilestonesRequirePayments"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfMilestones" xlink:label="nuvb_NumberOfMilestones"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" xlink:label="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ReceivedNonRefundableUpfrontCashPayment" xlink:label="nuvb_ReceivedNonRefundableUpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OwedMilestonePayments" xlink:label="nuvb_OwedMilestonePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RevenueRecognizedUponMilestonePaymenyts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nuvb_InnoventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_AnheartMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CollaborationAndLicenceAgreementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nuvb_NkMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_ContractWithCustomerAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_MilestonesRequirePayments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_NumberOfMilestones" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_ReceivedNonRefundableUpfrontCashPayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_OwedMilestonePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingLineItems" xlink:label="us-gaap_SubordinatedBorrowingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAgreementsWithBankOfHangzhouMember" xlink:label="nuvb_LoanAgreementsWithBankOfHangzhouMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingsAbstract" xlink:label="us-gaap_SubordinatedBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingTable" xlink:label="us-gaap_SubordinatedBorrowingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingAxis" xlink:label="us-gaap_SubordinatedBorrowingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingNameDomain" xlink:label="us-gaap_SubordinatedBorrowingNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BorrowingTwoThousandsAndTwentyMember" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShortTermBorrowingsDrawnDown" xlink:label="nuvb_ShortTermBorrowingsDrawnDown"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAgreementsWithChinaMerchantsBankMember" xlink:label="nuvb_LoanAgreementsWithChinaMerchantsBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BorrowingTwoThousandsAndTwentyTwoMember" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAndSecurityAgreementMember" xlink:label="nuvb_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BankLoans" xlink:label="srt_BankLoans"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LongTermBorroing" xlink:label="nuvb_LongTermBorroing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShortTermWorkingCapital" xlink:label="nuvb_ShortTermWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvb_LoanAgreementsWithBankOfHangzhouMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingsAbstract" xlink:to="us-gaap_SubordinatedBorrowingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="us-gaap_SubordinatedBorrowingAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingNameDomain" xlink:to="nuvb_BorrowingTwoThousandsAndTwentyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingAxis" xlink:to="us-gaap_SubordinatedBorrowingNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="nuvb_ShortTermBorrowingsDrawnDown" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvb_LoanAgreementsWithChinaMerchantsBankMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingNameDomain" xlink:to="nuvb_BorrowingTwoThousandsAndTwentyTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvb_LoanAndSecurityAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="us-gaap_SubordinatedBorrowingLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="srt_BankLoans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="nuvb_LongTermBorroing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="nuvb_ShortTermWorkingCapital" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicOfferingDetailsLineItems" xlink:label="nuvb_InitialPublicOfferingDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicDisclosureOfferingAbstract" xlink:label="nuvb_InitialPublicDisclosureOfferingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicOfferingDetailsTable" xlink:label="nuvb_InitialPublicOfferingDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AdditionalPurchaseUnits" xlink:label="nuvb_AdditionalPurchaseUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DescriptionOfPublicWarrant" xlink:label="nuvb_DescriptionOfPublicWarrant"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicDisclosureOfferingAbstract" xlink:to="nuvb_InitialPublicOfferingDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicOfferingDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="nuvb_AdditionalPurchaseUnits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicOfferingDetailsTable" xlink:to="nuvb_InitialPublicOfferingDetailsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="nuvb_DescriptionOfPublicWarrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PACoInvestmentsLLCMember" xlink:label="nuvb_PACoInvestmentsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDisclosureAbstract" xlink:label="nuvb_PrivatePlacementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDetailsTable" xlink:label="nuvb_PrivatePlacementDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDetailsLineItems" xlink:label="nuvb_PrivatePlacementDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SponsorMember" xlink:label="nuvb_SponsorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nuvb_PACoInvestmentsLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDisclosureAbstract" xlink:to="nuvb_PrivatePlacementDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nuvb_SponsorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="nuvb_PrivatePlacementDetailsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderSharesMember" xlink:label="nuvb_FounderSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RelatedPartyTransactionsDetailsTable" xlink:label="nuvb_RelatedPartyTransactionsDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:label="nuvb_RelatedPartyTransactionsDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MaximumSaleOfCommonStockPricePerShare" xlink:label="nuvb_MaximumSaleOfCommonStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ServicesFees" xlink:label="nuvb_ServicesFees"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WorkingCapitalLoans" xlink:label="nuvb_WorkingCapitalLoans"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationPricePerShare" xlink:label="nuvb_BusinessCombinationPricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nuvb_FounderSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="nuvb_RelatedPartyTransactionsDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsTable" xlink:to="nuvb_RelatedPartyTransactionsDetailsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_MaximumSaleOfCommonStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_ServicesFees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_WorkingCapitalLoans" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_BusinessCombinationPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NewYorkCityMember" xlink:label="nuvb_NewYorkCityMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeaseAdditionalTerm" xlink:label="nuvb_LeaseAdditionalTerm"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SanFranciscoMember" xlink:label="nuvb_SanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LesseeOperatingLeaseExpirationYear" xlink:label="nuvb_LesseeOperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nuvb_NewYorkCityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nuvb_LeaseAdditionalTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nuvb_SanFranciscoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nuvb_LesseeOperatingLeaseExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" xlink:label="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_HoldingOfOutstandingPreferredStock" xlink:label="nuvb_HoldingOfOutstandingPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ReductionToAdditionalPaidInCapital" xlink:label="nuvb_ReductionToAdditionalPaidInCapital"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_HoldingOfOutstandingPreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_ReductionToAdditionalPaidInCapital" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderMember" xlink:label="nuvb_FounderMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockholdersEquityDetailsTable" xlink:label="nuvb_StockholdersEquityDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockholdersEquityDetailsLineItems" xlink:label="nuvb_StockholdersEquityDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesExchangedInRecapitalization" xlink:label="nuvb_SharesExchangedInRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ClassAAndClassBCommonStockMember" xlink:label="nuvb_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" xlink:label="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="nuvb_FounderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="nuvb_SharesExchangedInRecapitalization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="nuvb_StockholdersEquityDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsTable" xlink:to="nuvb_StockholdersEquityDetailsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_ClassAAndClassBCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_BusinessCombinationControlObtainedDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ClassACommonSharesSubjectToRepurchaseMember" xlink:label="nuvb_ClassACommonSharesSubjectToRepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nuvb_ClassACommonSharesSubjectToRepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RealizedLossOnMarketableSecurities" xlink:label="nuvb_RealizedLossOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrencyTranslationAdjustmentValue" xlink:label="nuvb_CurrencyTranslationAdjustmentValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="nuvb_RealizedLossOnMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="nuvb_CurrencyTranslationAdjustmentValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:label="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EmployeeStockPurchasePlanMember" xlink:label="nuvb_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionWithServiceConditionsMember" xlink:label="nuvb_OptionWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" xlink:label="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" xlink:label="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesBasedStockOptionGrantedVestingPercentage" xlink:label="nuvb_SharesBasedStockOptionGrantedVestingPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvb_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionWithServiceConditionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_SharesBasedStockOptionGrantedVestingPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" xlink:label="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OutstandingAtDecember312020AfterAdjustment" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_OutstandingAtDecember312020AfterAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketRiskBenefitChangeInFairValueGainLoss" xlink:label="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" xlink:label="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ConsiderationWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ConsiderationWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsIssued" xlink:label="nuvb_WarrantsIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="nuvb_WarrantsIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate" xlink:label="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" xlink:label="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" xlink:label="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" xlink:label="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" xlink:label="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredTaxAssetsLeaseLiability" xlink:label="nuvb_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nuvb_DeferredTaxAssetsLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InternalRevenueCode59Member" xlink:label="nuvb_InternalRevenueCode59Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InternalRevenueCode174Member" xlink:label="nuvb_InternalRevenueCode174Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nuvb_InternalRevenueCode59Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nuvb_InternalRevenueCode174Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationWarrants" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationTrueUp" xlink:label="nuvb_BusinessCombinationTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_BusinessCombinationTrueUp" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OrphanDrugTaxCreditCarryforwardMember" xlink:label="nuvb_OrphanDrugTaxCreditCarryforwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLossCarryforwardsExpiration" xlink:label="nuvb_OperatingLossCarryforwardsExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TaxCreditCarryforwardsExpiration" xlink:label="nuvb_TaxCreditCarryforwardsExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nuvb_OrphanDrugTaxCreditCarryforwardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="nuvb_OperatingLossCarryforwardsExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="nuvb_TaxCreditCarryforwardsExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_StandbyLettersOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_USApprovalMember" xlink:label="nuvb_USApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SagardHealthcarePartnersMember" xlink:label="nuvb_SagardHealthcarePartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FoodAndDrugAdministrationApprovalMember" xlink:label="nuvb_FoodAndDrugAdministrationApprovalMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RoyaltyExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_USApprovalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SecuredDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_SagardHealthcarePartnersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_FoodAndDrugAdministrationApprovalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedeemableWarrantsMember" xlink:label="nuvb_RedeemableWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_RedeemableWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IntangibleAssetsNetOfAmortization" xlink:label="nuvb_IntangibleAssetsNetOfAmortization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SubjectToPossibleRedemptionShares" xlink:label="nuvb_SubjectToPossibleRedemptionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SubjecttopossibleredemptionPerShare" xlink:label="nuvb_SubjecttopossibleredemptionPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IntangibleAssetsNetOfAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_SubjectToPossibleRedemptionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_SubjecttopossibleredemptionPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" xlink:label="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" xlink:label="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PriorEffectOfBusinessCombinationTransactionMember" xlink:label="nuvb_PriorEffectOfBusinessCombinationTransactionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" xlink:label="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConvertiblePreferredStocksMember" xlink:label="nuvb_ConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesExchangedInRecapitalization" xlink:label="nuvb_SharesExchangedInRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" xlink:label="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" xlink:label="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" xlink:label="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" xlink:label="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockForRsusVestedShare" xlink:label="nuvb_IssuanceOfCommonStockForRsusVestedShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CurrencyTranslationAdjustmentValue" xlink:label="nuvb_CurrencyTranslationAdjustmentValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="nuvb_PriorEffectOfBusinessCombinationTransactionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvb_ConvertiblePreferredStocksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_SharesExchangedInRecapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_IssuanceOfCommonStockForRsusVestedShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_CurrencyTranslationAdjustmentValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SaleOfUnderwritingDiscountsShares" xlink:label="nuvb_SaleOfUnderwritingDiscountsShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SaleOfPrivatePlacementShares" xlink:label="nuvb_SaleOfPrivatePlacementShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesValue" xlink:label="nuvb_IssuanceOfSharesValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_SaleOfUnderwritingDiscountsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_SaleOfPrivatePlacementShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_IssuanceOfSharesValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" xlink:label="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TransactionCostsRelatedToAnheartAcquisition" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NonCashLeaseExpense" xlink:label="nuvb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" xlink:label="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AmortizationOfPremiumOnMarketableSecurities" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeaseLiabilityRecognized" xlink:label="nuvb_OperatingLeaseLiabilityRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" xlink:label="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="nuvb_TransactionCostsRelatedToAnheartAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nuvb_NonCashLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nuvb_AmortizationOfPremiumOnMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nuvb_OperatingLeaseLiabilityRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MergerAgreementMember" xlink:label="nuvb_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_MergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConcentrationRiskThresholdPercentage" xlink:label="nuvb_ConcentrationRiskThresholdPercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OtherThanUnitedStateMember" xlink:label="nuvb_OtherThanUnitedStateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="nuvb_CashAndCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FairValueOfWarrantsTradingPrice" xlink:label="nuvb_FairValueOfWarrantsTradingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PercentageOfLongLivedAssets" xlink:label="nuvb_PercentageOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_AnheartMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_ConcentrationRiskThresholdPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ConsiderationWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nuvb_OtherThanUnitedStateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_CashAndCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_FairValueOfWarrantsTradingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nuvb_PercentageOfLongLivedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CustomerAMember" xlink:label="nuvb_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CustomerBMember" xlink:label="nuvb_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="nuvb_CustomerAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="nuvb_CustomerBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_AnheartMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AllocablePurchasePrice" xlink:label="nuvb_AllocablePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AssumedShareBasedAwardsMember" xlink:label="nuvb_AssumedShareBasedAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_AllocablePurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_ConsiderationWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_AssumedShareBasedAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AcquisitionRelatedCostsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" xlink:label="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EstimatedFairValueWarrantPerShare" xlink:label="nuvb_EstimatedFairValueWarrantPerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_EstimatedFairValueWarrantPerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareOutstandingPriorToBusinessCombination" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedemptionOfSharePriorToBusinessCombination" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfSharesRelatedToMerger" xlink:label="nuvb_ConversionOfSharesRelatedToMerger"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToPIPEFinancing" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToForwardPurchase" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesUponBusinessCombination" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassACommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassBCommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfFounderShares" xlink:label="nuvb_ConversionOfFounderShares"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ShareOutstandingPriorToBusinessCombination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_RedemptionOfSharePriorToBusinessCombination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfSharesRelatedToMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_BusinessCombinationCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_SharesIssuedPursuantToPIPEFinancing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_SharesIssuedPursuantToForwardPurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_IssuanceOfSharesUponBusinessCombination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfOldNuvationClassACommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfOldNuvationClassBCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_ConversionOfFounderShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PanaceaMember" xlink:label="nuvb_PanaceaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CommonStockRedemptionPricePerShare" xlink:label="nuvb_CommonStockRedemptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantsIssuedDuringThePeriod" xlink:label="nuvb_WarrantsIssuedDuringThePeriod"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockConversionRatio" xlink:label="nuvb_StockConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderSharesConversion" xlink:label="nuvb_FounderSharesConversion"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_PanaceaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_CommonStockRedemptionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_WarrantsIssuedDuringThePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_StockConversionRatio" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_FounderSharesConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AccretionExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FinancialAssets" xlink:label="nuvb_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TotalFinancialAssets" xlink:label="nuvb_TotalFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="nuvb_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_FinancialAssets" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_FinancialAssets" xlink:to="us-gaap_MarketableSecuritiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_FinancialAssets" xlink:to="nuvb_TotalFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ExchangeTradedFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:label="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MarketableSecuritiesMember" xlink:label="nuvb_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvb_MarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ExchangeTradedFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeTradedFundsMember" xlink:label="us-gaap_ExchangeTradedFundsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ExchangeTradedFundsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CertificateOfDepositsMember" xlink:label="nuvb_CertificateOfDepositsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_CertificateOfDepositsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LicenseRevenueMember" xlink:label="nuvb_LicenseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_LicenseRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RevenueRecognizedUponMilestonePaymenyts" xlink:label="nuvb_RevenueRecognizedUponMilestonePaymenyts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InnoventMember" xlink:label="nuvb_InnoventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AnheartMember" xlink:label="nuvb_AnheartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NkMember" xlink:label="nuvb_NkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription" xlink:label="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ContractWithCustomerAssets" xlink:label="nuvb_ContractWithCustomerAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MilestonesRequirePayments" xlink:label="nuvb_MilestonesRequirePayments"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfMilestones" xlink:label="nuvb_NumberOfMilestones"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" xlink:label="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ReceivedNonRefundableUpfrontCashPayment" xlink:label="nuvb_ReceivedNonRefundableUpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OwedMilestonePayments" xlink:label="nuvb_OwedMilestonePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RevenueRecognizedUponMilestonePaymenyts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nuvb_InnoventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nuvb_AnheartMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nuvb_NkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_ContractWithCustomerAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_MilestonesRequirePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_NumberOfMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_ReceivedNonRefundableUpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_OwedMilestonePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ResearchAndDevelopmentServiceRevenueMember" xlink:label="nuvb_ResearchAndDevelopmentServiceRevenueMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nuvb_ResearchAndDevelopmentServiceRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingLineItems" xlink:label="us-gaap_SubordinatedBorrowingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingTable" xlink:label="us-gaap_SubordinatedBorrowingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAgreementsWithBankOfHangzhouMember" xlink:label="nuvb_LoanAgreementsWithBankOfHangzhouMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingAxis" xlink:label="us-gaap_SubordinatedBorrowingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingNameDomain" xlink:label="us-gaap_SubordinatedBorrowingNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BorrowingTwoThousandsAndTwentyMember" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingNameDomain" xlink:label="us-gaap_SubordinatedBorrowingNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShortTermBorrowingsDrawnDown" xlink:label="nuvb_ShortTermBorrowingsDrawnDown"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAgreementsWithChinaMerchantsBankMember" xlink:label="nuvb_LoanAgreementsWithChinaMerchantsBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BorrowingTwoThousandsAndTwentyTwoMember" xlink:label="nuvb_BorrowingTwoThousandsAndTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LoanAndSecurityAgreementMember" xlink:label="nuvb_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BankLoans" xlink:label="srt_BankLoans"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LongTermBorroing" xlink:label="nuvb_LongTermBorroing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShortTermWorkingCapital" xlink:label="nuvb_ShortTermWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_SubordinatedBorrowingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvb_LoanAgreementsWithBankOfHangzhouMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="us-gaap_SubordinatedBorrowingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingNameDomain" xlink:to="nuvb_BorrowingTwoThousandsAndTwentyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubordinatedBorrowingAxis" xlink:to="us-gaap_SubordinatedBorrowingNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubordinatedBorrowingAxis" xlink:to="us-gaap_SubordinatedBorrowingNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="nuvb_ShortTermBorrowingsDrawnDown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvb_LoanAgreementsWithChinaMerchantsBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingNameDomain" xlink:to="nuvb_BorrowingTwoThousandsAndTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nuvb_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubordinatedBorrowingTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="srt_BankLoans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="nuvb_LongTermBorroing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="nuvb_ShortTermWorkingCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubordinatedBorrowingLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicOfferingDetailsLineItems" xlink:label="nuvb_InitialPublicOfferingDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InitialPublicOfferingDetailsTable" xlink:label="nuvb_InitialPublicOfferingDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AdditionalPurchaseUnits" xlink:label="nuvb_AdditionalPurchaseUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_DescriptionOfPublicWarrant" xlink:label="nuvb_DescriptionOfPublicWarrant"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="nuvb_InitialPublicOfferingDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_InitialPublicOfferingDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="nuvb_AdditionalPurchaseUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_InitialPublicOfferingDetailsLineItems" xlink:to="nuvb_DescriptionOfPublicWarrant" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDetailsLineItems" xlink:label="nuvb_PrivatePlacementDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementDetailsTable" xlink:label="nuvb_PrivatePlacementDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PACoInvestmentsLLCMember" xlink:label="nuvb_PACoInvestmentsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SponsorMember" xlink:label="nuvb_SponsorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="nuvb_PrivatePlacementDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nuvb_PACoInvestmentsLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nuvb_SponsorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_PrivatePlacementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:label="nuvb_RelatedPartyTransactionsDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RelatedPartyTransactionsDetailsTable" xlink:label="nuvb_RelatedPartyTransactionsDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderSharesMember" xlink:label="nuvb_FounderSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_MaximumSaleOfCommonStockPricePerShare" xlink:label="nuvb_MaximumSaleOfCommonStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ServicesFees" xlink:label="nuvb_ServicesFees"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WorkingCapitalLoans" xlink:label="nuvb_WorkingCapitalLoans"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationPricePerShare" xlink:label="nuvb_BusinessCombinationPricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_RelatedPartyTransactionsDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nuvb_FounderSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_MaximumSaleOfCommonStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_ServicesFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_WorkingCapitalLoans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_RelatedPartyTransactionsDetailsLineItems" xlink:to="nuvb_BusinessCombinationPricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NewYorkCityMember" xlink:label="nuvb_NewYorkCityMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeaseAdditionalTerm" xlink:label="nuvb_LeaseAdditionalTerm"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SanFranciscoMember" xlink:label="nuvb_SanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LesseeOperatingLeaseExpirationYear" xlink:label="nuvb_LesseeOperatingLeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nuvb_NewYorkCityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nuvb_LeaseAdditionalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nuvb_SanFranciscoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nuvb_LesseeOperatingLeaseExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_HoldingOfOutstandingPreferredStock" xlink:label="nuvb_HoldingOfOutstandingPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ReductionToAdditionalPaidInCapital" xlink:label="nuvb_ReductionToAdditionalPaidInCapital"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_HoldingOfOutstandingPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvb_ReductionToAdditionalPaidInCapital" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockholdersEquityDetailsLineItems" xlink:label="nuvb_StockholdersEquityDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_StockholdersEquityDetailsTable" xlink:label="nuvb_StockholdersEquityDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FounderMember" xlink:label="nuvb_FounderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesExchangedInRecapitalization" xlink:label="nuvb_SharesExchangedInRecapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ClassAAndClassBCommonStockMember" xlink:label="nuvb_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" xlink:label="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="nuvb_StockholdersEquityDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="nuvb_FounderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="nuvb_SharesExchangedInRecapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nuvb_StockholdersEquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvb_ClassAAndClassBCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_BusinessCombinationControlObtainedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvb_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ClassACommonSharesSubjectToRepurchaseMember" xlink:label="nuvb_ClassACommonSharesSubjectToRepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nuvb_ClassACommonSharesSubjectToRepurchaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" xlink:label="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionWithServiceConditionsMember" xlink:label="nuvb_OptionWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EmployeeStockPurchasePlanMember" xlink:label="nuvb_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" xlink:label="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" xlink:label="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesBasedStockOptionGrantedVestingPercentage" xlink:label="nuvb_SharesBasedStockOptionGrantedVestingPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionWithServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvb_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_SharesBasedStockOptionGrantedVestingPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" xlink:label="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OutstandingAtDecember312020AfterAdjustment" xlink:label="nuvb_OutstandingAtDecember312020AfterAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nuvb_OutstandingAtDecember312020AfterAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OptionsWithServiceConditionsMember" xlink:label="nuvb_OptionsWithServiceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvb_OptionsWithServiceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketRiskBenefitChangeInFairValueGainLoss" xlink:label="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" xlink:label="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_MarketRiskBenefitChangeInFairValueGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ConsiderationWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PublicWarrantsMember" xlink:label="nuvb_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PrivatePlacementWarrantsMember" xlink:label="nuvb_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ForwardPurchaseWarrantsMember" xlink:label="nuvb_ForwardPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConsiderationWarrantsMember" xlink:label="nuvb_ConsiderationWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PublicWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_PrivatePlacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ForwardPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nuvb_ConsiderationWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InternalRevenueCode59Member" xlink:label="nuvb_InternalRevenueCode59Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InternalRevenueCode174Member" xlink:label="nuvb_InternalRevenueCode174Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nuvb_InternalRevenueCode59Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nuvb_InternalRevenueCode174Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OrphanDrugTaxCreditCarryforwardMember" xlink:label="nuvb_OrphanDrugTaxCreditCarryforwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLossCarryforwardsExpiration" xlink:label="nuvb_OperatingLossCarryforwardsExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TaxCreditCarryforwardsExpiration" xlink:label="nuvb_TaxCreditCarryforwardsExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nuvb_OrphanDrugTaxCreditCarryforwardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="nuvb_OperatingLossCarryforwardsExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="nuvb_TaxCreditCarryforwardsExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_StandbyLettersOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_USApprovalMember" xlink:label="nuvb_USApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SagardHealthcarePartnersMember" xlink:label="nuvb_SagardHealthcarePartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_FoodAndDrugAdministrationApprovalMember" xlink:label="nuvb_FoodAndDrugAdministrationApprovalMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_USApprovalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_SagardHealthcarePartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvb_FoodAndDrugAdministrationApprovalMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nuvb_WarrantLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="nuvb_LeaseSecurityDepositNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="nuvb_InterestReceivableOnMarketableSecuritiesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_WarrantLiability" xlink:label="nuvb_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_LeaseSecurityDepositNoncurrent" xlink:label="nuvb_LeaseSecurityDepositNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_InterestReceivableOnMarketableSecuritiesCurrent" xlink:label="nuvb_InterestReceivableOnMarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ProfessionalFees" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="6" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="nuvb_TransactionCostsRelatedToAnheartAcquisition" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nuvb_AcquiredInProcessResearchAndDevelopment" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nuvb_NonCashLeaseExpense" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nuvb_AmortizationOfPremiumOnMarketableSecurities" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" order="17" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="20" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TransactionCostsRelatedToAnheartAcquisition" xlink:label="nuvb_TransactionCostsRelatedToAnheartAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AcquiredInProcessResearchAndDevelopment" xlink:label="nuvb_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NonCashLeaseExpense" xlink:label="nuvb_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_AmortizationOfPremiumOnMarketableSecurities" xlink:label="nuvb_AmortizationOfPremiumOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_ProceedsFromBusinessCombinationNet" xlink:to="nuvb_CashAtBankAndCashHeldInTrustAccount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_ProceedsFromBusinessCombinationNet" xlink:to="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_ProceedsFromBusinessCombinationNet" xlink:to="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_ProceedsFromBusinessCombinationNet" xlink:to="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromBusinessCombinationNet" xlink:label="nuvb_ProceedsFromBusinessCombinationNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_CashAtBankAndCashHeldInTrustAccount" xlink:label="nuvb_CashAtBankAndCashHeldInTrustAccount"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" xlink:label="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" xlink:label="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" xlink:label="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:to="nuvb_IssuanceOfSharesUponBusinessCombination" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_IssuanceOfSharesUponBusinessCombination" xlink:to="nuvb_BusinessCombinationCommonStockSharesOutstanding" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:to="nuvb_ShareOutstandingPriorToBusinessCombination" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:to="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_IssuanceOfSharesUponBusinessCombination" xlink:to="nuvb_SharesIssuedPursuantToPIPEFinancing" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:to="nuvb_RedemptionOfSharePriorToBusinessCombination" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:to="nuvb_ConversionOfOldNuvationClassACommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_IssuanceOfSharesUponBusinessCombination" xlink:to="nuvb_SharesIssuedPursuantToForwardPurchase" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:to="nuvb_ConversionOfSharesRelatedToMerger" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:to="nuvb_ConversionOfOldNuvationClassBCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:to="nuvb_ConversionOfFounderShares" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" xlink:label="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_IssuanceOfSharesUponBusinessCombination" xlink:label="nuvb_IssuanceOfSharesUponBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationCommonStockSharesOutstanding" xlink:label="nuvb_BusinessCombinationCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ShareOutstandingPriorToBusinessCombination" xlink:label="nuvb_ShareOutstandingPriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" xlink:label="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToPIPEFinancing" xlink:label="nuvb_SharesIssuedPursuantToPIPEFinancing"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_RedemptionOfSharePriorToBusinessCombination" xlink:label="nuvb_RedemptionOfSharePriorToBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassACommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassACommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_SharesIssuedPursuantToForwardPurchase" xlink:label="nuvb_SharesIssuedPursuantToForwardPurchase"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfSharesRelatedToMerger" xlink:label="nuvb_ConversionOfSharesRelatedToMerger"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfOldNuvationClassBCommonStock" xlink:label="nuvb_ConversionOfOldNuvationClassBCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_ConversionOfFounderShares" xlink:label="nuvb_ConversionOfFounderShares"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_TotalFinancialAssets" xlink:to="us-gaap_MarketableSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_TotalFinancialAssets" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_TotalFinancialAssets" xlink:label="nuvb_TotalFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:to="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDue" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" xlink:label="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:label="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationWarrants" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationWarrants" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="nuvb-20241231.xsd#nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" xlink:label="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nuvb_OptionsWithServiceMarketAndPerformanceConditionMember" name="OptionsWithServiceMarketAndPerformanceConditionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_PanaceaEquityAtEffectiveTime" name="PanaceaEquityAtEffectiveTime" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_InitialPublicDisclosureOfferingTextBlock" name="InitialPublicDisclosureOfferingTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ServicesFees" name="ServicesFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_ConversionOfFounderShares" name="ConversionOfFounderShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CashAndCashEquivalentsAndMarketableSecurities" name="CashAndCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_RealizedLossOnMarketableSecurities" name="RealizedLossOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_SponsorMember" name="SponsorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_SubjectToPossibleRedemptionShares" name="SubjectToPossibleRedemptionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_InitialPublicOfferingDetailsLineItems" name="InitialPublicOfferingDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate" name="RecognitionOfPrivateWarrantsLiabilityUponClosingDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_ConversionOfSharesRelatedToMerger" name="ConversionOfSharesRelatedToMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_RevenueRecognitionPolicyPolicyTextBlock" name="RevenueRecognitionPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_USApprovalMember" name="USApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears" name="OperatingLeasesFuturesMinimumPaymentDueInTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" name="BusinessCombinationConversionOfRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_BusinessCombinationCommonStockSharesOutstanding" name="BusinessCombinationCommonStockSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ContractWithCustomerAssets" name="ContractWithCustomerAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_PrivatePlacementDisclosureTextBlock" name="PrivatePlacementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition" name="IssuanceOfWarrantsRelatedToTheAnheartAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_OperatingLossCarryforwardsExpiration" name="OperatingLossCarryforwardsExpiration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_FounderSharesConversion" name="FounderSharesConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_StockholdersEquityDetailsTable" name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_PrivatePlacementDisclosureAbstract" name="PrivatePlacementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" name="IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_EffectiveIncomeTaxRateReconciliationWarrants" name="EffectiveIncomeTaxRateReconciliationWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" name="RestatementOfPreviouslyIssuedFinancialsStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_InterestReceivableOnMarketableSecuritiesCurrent" name="InterestReceivableOnMarketableSecuritiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_ReductionToAdditionalPaidInCapital" name="ReductionToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_StockConversionRatio" name="StockConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_AllocablePurchasePrice" name="AllocablePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_SummaryofSignificantAccountingPoliciesDetailsTable" name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_DescriptionOfPublicWarrant" name="DescriptionOfPublicWarrant" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IntangibleAssetsNetOfAmortization" name="IntangibleAssetsNetOfAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_CashAtBankAndCashHeldInTrustAccount" name="CashAtBankAndCashHeldInTrustAccount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_RedemptionOfSharePriorToBusinessCombination" name="RedemptionOfSharePriorToBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems" name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_SanFranciscoMember" name="SanFranciscoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" name="Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement" name="NumberOfSharesIssuableUnderShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_SharesIssuedPursuantToPIPEFinancing" name="SharesIssuedPursuantToPIPEFinancing" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_RevenueRecognizedUponMilestonePaymenyts" name="RevenueRecognizedUponMilestonePaymenyts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_BorrowingTwoThousandsAndTwentyTwoMember" name="BorrowingTwoThousandsAndTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_FoodAndDrugAdministrationApprovalMember" name="FoodAndDrugAdministrationApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_SaleOfUnderwritingDiscountsShares" name="SaleOfUnderwritingDiscountsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" name="IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" name="RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_IssuanceOfCommonStockForRsusVestedShare" name="IssuanceOfCommonStockForRsusVestedShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" name="IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_FounderMember" name="FounderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_BusinessCombinationTrueUp" name="BusinessCombinationTrueUp" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_FounderSharesMember" name="FounderSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract" name="CashFlowNoncashOperatingActivitiesDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_EstimatedFairValueWarrantPerShare" name="EstimatedFairValueWarrantPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ShareOutstandingPriorToBusinessCombination" name="ShareOutstandingPriorToBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_OperatingLeaseLiabilityRecognized" name="OperatingLeaseLiabilityRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" name="IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_LongTermBorroing" name="LongTermBorroing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_TaxCreditCarryforwardsExpiration" name="TaxCreditCarryforwardsExpiration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_WarrantDisclosureTextBlock" name="WarrantDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CurrencyTranslationAdjustmentValue" name="CurrencyTranslationAdjustmentValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_NewYorkCityMember" name="NewYorkCityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_CollaborationAndLicenceAgreementAbstract" name="CollaborationAndLicenceAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent" name="OperatingLeasesFutureMinimumPaymentDueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_RelatedPartyTransactionsDetailsLineItems" name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_IssuanceOfSharesValue" name="IssuanceOfSharesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_WarrantDisclosureAbstract" name="WarrantDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_ForwardPurchaseWarrantsMember" name="ForwardPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_IssuanceOfSharesUponBusinessCombination" name="IssuanceOfSharesUponBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ConvertiblePreferredStocksMember" name="ConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_SagardHealthcarePartnersMember" name="SagardHealthcarePartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_LoanAgreementsWithChinaMerchantsBankMember" name="LoanAgreementsWithChinaMerchantsBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_WarrantLiability" name="WarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" name="IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_OutstandingAtDecember312020AfterAdjustment" name="OutstandingAtDecember312020AfterAdjustment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_OwedMilestonePayments" name="OwedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_ClassAAndClassBCommonStockMember" name="ClassAAndClassBCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" name="IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp" name="ProceedsFromIssuanceOfCommonStockUnderEspp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_SubjecttopossibleredemptionPerShare" name="SubjecttopossibleredemptionPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CustomerBMember" name="CustomerBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_SharesExchangedInRecapitalization" name="SharesExchangedInRecapitalization" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_NumberOfEquitySecuritiesSold" name="NumberOfEquitySecuritiesSold" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_SharesIssuedPursuantToForwardPurchase" name="SharesIssuedPursuantToForwardPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ConsiderationWarrantsMember" name="ConsiderationWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears" name="OperatingLeasesFutureMinimumPaymentDueInThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" name="RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" name="IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition" name="IssuanceOfCommonStockRelatedToTheAnheartAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_PercentageOfLongLivedAssets" name="PercentageOfLongLivedAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ReceivedNonRefundableUpfrontCashPayment" name="ReceivedNonRefundableUpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_InitialPublicOfferingDetailsTable" name="InitialPublicOfferingDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_WorkingCapitalLoans" name="WorkingCapitalLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_ClassACommonSharesSubjectToRepurchaseMember" name="ClassACommonSharesSubjectToRepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_NumberOfMilestones" name="NumberOfMilestones" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract" name="CurrentAndDeferredFederalTaxExpenseBenefitAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_PrivatePlacementDetailsTable" name="PrivatePlacementDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_LeaseSecurityDepositNoncurrent" name="LeaseSecurityDepositNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" name="FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter" name="OperatingLeasesFutureMinimumPaymentDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_ConversionOfOldNuvationClassACommonStock" name="ConversionOfOldNuvationClassACommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_MergerAgreementMember" name="MergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts" name="PaymentOfUnderwriterFeesAndOtherOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_HoldingOfOutstandingPreferredStock" name="HoldingOfOutstandingPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue" name="IssuanceOfCommonStockForPurchaseUnderEsppValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_LicenseRevenueMember" name="LicenseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" name="ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears" name="OperatingLeasesFutureMinimumPaymentDueInFiveYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_LoanAgreementsWithBankOfHangzhouMember" name="LoanAgreementsWithBankOfHangzhouMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" name="RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination" name="NumberOfCommonSharesOutstandingAfterBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_LeaseAdditionalTerm" name="LeaseAdditionalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CollaborationAndLicenseAgreementsTextblock" name="CollaborationAndLicenseAgreementsTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_AssumedShareBasedAwardsMember" name="AssumedShareBasedAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" name="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_PublicWarrantsMember" name="PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares" name="IssuanceOfCommonStockForAnheartAcquisitionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_WarrantsIssuedDuringThePeriod" name="WarrantsIssuedDuringThePeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_AmortizationOfPremiumOnMarketableSecurities" name="AmortizationOfPremiumOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue" name="IssuanceOfCommonStockForAnheartAcquisitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_FairValueOfWarrantsTradingPrice" name="FairValueOfWarrantsTradingPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" name="WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ConversionOfOldNuvationClassBCommonStock" name="ConversionOfOldNuvationClassBCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_PriorEffectOfBusinessCombinationTransactionMember" name="PriorEffectOfBusinessCombinationTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_FinancialAssets" name="FinancialAssets" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_ShortTermWorkingCapital" name="ShortTermWorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_OptionWithServiceConditionsMember" name="OptionWithServiceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_OperatingLeasesFutureMinimumPaymentDue" name="OperatingLeasesFutureMinimumPaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_ShortTermBorrowingsDrawnDown" name="ShortTermBorrowingsDrawnDown" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_TotalFinancialAssets" name="TotalFinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_LesseeOperatingLeaseExpirationYear" name="LesseeOperatingLeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_InitialPublicDisclosureOfferingAbstract" name="InitialPublicDisclosureOfferingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_OrphanDrugTaxCreditCarryforwardMember" name="OrphanDrugTaxCreditCarryforwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_InternalRevenueCode174Member" name="InternalRevenueCode174Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" name="EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_NkMember" name="NkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_EmergingGrowthPolicyTextBlock" name="EmergingGrowthPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_BusinessCombinationPricePerShare" name="BusinessCombinationPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" name="NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_RepaymentsOfNonRefundableUpfrontCashPayment" name="RepaymentsOfNonRefundableUpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" name="CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_StockholdersEquityDetailsLineItems" name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_InnoventMember" name="InnoventMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_OtherThanUnitedStateMember" name="OtherThanUnitedStateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" name="DeferredFinancingCostsInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_PrivatePlacementDetailsLineItems" name="PrivatePlacementDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_RedeemableWarrantsMember" name="RedeemableWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" name="ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" name="PaymentToCommonStockholdersDueToExercisedRightToRedeemShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock" name="RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_SaleOfPrivatePlacementShares" name="SaleOfPrivatePlacementShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_AnheartMember" name="AnheartMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_InternalRevenueCode59Member" name="InternalRevenueCode59Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_TransactionCostsRelatedToAnheartAcquisition" name="TransactionCostsRelatedToAnheartAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears" name="OperatingLeasesFutureMinimumPaymentDueInFourYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvb_BorrowingTwoThousandsAndTwentyMember" name="BorrowingTwoThousandsAndTwentyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_EffectiveIncomeTaxRateReconciliationTrueUp" name="EffectiveIncomeTaxRateReconciliationTrueUp" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_PanaceaMember" name="PanaceaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_ProceedsFromBusinessCombinationNet" name="ProceedsFromBusinessCombinationNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_ResearchAndDevelopmentServiceRevenueMember" name="ResearchAndDevelopmentServiceRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" name="ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_AdditionalPurchaseUnits" name="AdditionalPurchaseUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock" name="RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ConcentrationRiskThresholdPercentage" name="ConcentrationRiskThresholdPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvb_OptionsWithServiceConditionsMember" name="OptionsWithServiceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_PACoInvestmentsLLCMember" name="PACoInvestmentsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_CertificateOfDepositsMember" name="CertificateOfDepositsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CustomerAMember" name="CustomerAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_RelatedPartyTransactionsDetailsTable" name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_SharesBasedStockOptionGrantedVestingPercentage" name="SharesBasedStockOptionGrantedVestingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" name="EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" name="ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_CommonStockRedemptionPricePerShare" name="CommonStockRedemptionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" name="BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares" name="IssuanceOfCommonStockForPurchaseUnderEsppShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_MaximumSaleOfCommonStockPricePerShare" name="MaximumSaleOfCommonStockPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvb_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvb_MilestonesRequirePayments" name="MilestonesRequirePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525756928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NUVATION BIO INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001811063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1500 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text"> Suite 1401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">208-6102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-0862255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text"> Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,742,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain portions of the registrant's definitive proxy statement relating to the Company's Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NUVB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,678,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nuvb_RedeemableWarrantsMember', window );">Redeemable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to Purchase Class A Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NUVB.WS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nuvb_RedeemableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nuvb_RedeemableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530886480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,723<span></span>
</td>
<td class="nump">$ 42,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net of allowance for credit loss of $nil</a></td>
<td class="nump">12,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,271<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">466,969<span></span>
</td>
<td class="nump">568,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_InterestReceivableOnMarketableSecuritiesCurrent', window );">Interest receivable on marketable securities</a></td>
<td class="nump">3,570<span></span>
</td>
<td class="nump">3,702<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">526,255<span></span>
</td>
<td class="nump">616,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $874 and $666, respectively</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization of $448</a></td>
<td class="nump">4,622<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LeaseSecurityDepositNoncurrent', window );">Lease security deposit</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,402<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">6,616<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">540,626<span></span>
</td>
<td class="nump">621,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,348<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, current portion</a></td>
<td class="nump">11,117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">6,283<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">32,833<span></span>
</td>
<td class="nump">9,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">58,244<span></span>
</td>
<td class="nump">13,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">15,572<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">76,838<span></span>
</td>
<td class="nump">16,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000,Class B 60,000,000) shares authorized as of December 31, 2024 and December 31, 2023, respectively, 337,837,872 (Class A 336,837,872, Class B 1,000,000) and 219,046,219 (Class A 218,046,219, Class B 1,000,000) shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">1,373,958<span></span>
</td>
<td class="nump">947,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(910,743)<span></span>
</td>
<td class="num">(342,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">463,788<span></span>
</td>
<td class="nump">605,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 540,626<span></span>
</td>
<td class="nump">$ 621,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_InterestReceivableOnMarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest receivable on marketable securities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_InterestReceivableOnMarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_LeaseSecurityDepositNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease security deposit noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_LeaseSecurityDepositNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530072192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation of $874 and $666, respectively</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IntangibleAssetsNetOfAmortization', window );">Intangible assets, net of accumulated amortization of $448</a></td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock and additional paid in capital, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock and additional paid in capital, shares issued</a></td>
<td class="nump">337,837,872<span></span>
</td>
<td class="nump">219,046,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid in capital, shares outstanding</a></td>
<td class="nump">337,837,872<span></span>
</td>
<td class="nump">219,046,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock and additional paid in capital, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid in capital, shares authorized</a></td>
<td class="nump">1,060,000,000<span></span>
</td>
<td class="nump">1,060,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock and additional paid in capital, shares issued</a></td>
<td class="nump">336,837,872<span></span>
</td>
<td class="nump">218,046,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid in capital, shares outstanding</a></td>
<td class="nump">336,837,872<span></span>
</td>
<td class="nump">218,046,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Shares [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid in capital, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock and additional paid in capital, shares issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid in capital, shares outstanding</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Shares [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid in capital, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IntangibleAssetsNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Net of Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IntangibleAssetsNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530735536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 7,873<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">7,078<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit, Total</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">99,119<span></span>
</td>
<td class="nump">71,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">425,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">69,233<span></span>
</td>
<td class="nump">28,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">593,422<span></span>
</td>
<td class="nump">99,822<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(592,627)<span></span>
</td>
<td class="num">(99,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">27,062<span></span>
</td>
<td class="nump">24,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(341)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Investment advisory fees</a></td>
<td class="num">(976)<span></span>
</td>
<td class="num">(949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants liability</a></td>
<td class="num">(936)<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Realized loss on marketable securities</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">24,688<span></span>
</td>
<td class="nump">24,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(567,939)<span></span>
</td>
<td class="num">(75,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (567,939)<span></span>
</td>
<td class="num">$ (75,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">268,772<span></span>
</td>
<td class="nump">218,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">268,772<span></span>
</td>
<td class="nump">218,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (567,939)<span></span>
</td>
<td class="num">$ (75,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit', window );">Currency translation adjustment</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesUnrealizedGainLoss', window );">Change in unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (567,547)<span></span>
</td>
<td class="num">$ (70,095)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from translating foreign currency financial statements into the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526156976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Class A [Member]</div></th>
<th class="th"><div>Class A Shares [Member]</div></th>
<th class="th"><div>Common Stock Including Additional Paid in Capital [Member]</div></th>
<th class="th">
<div>Common Stock Including Additional Paid in Capital [Member] </div>
<div>Class A Shares [Member]</div>
</th>
<th class="th">
<div>Common Stock Including Additional Paid in Capital [Member] </div>
<div>Class B Shares [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th">
<div>Convertible Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 655,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 927,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (267,002)<span></span>
</td>
<td class="num">$ (5,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,632,699<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue', window );">Issuance of common stock for purchase under ESPP</a></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares', window );">Issuance of common stock for purchase under ESPP, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">19,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(75,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CurrencyTranslationAdjustmentValue', window );">Currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">5,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">605,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342,804)<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,046,219<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,646,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue', window );">Issuance Of Common Stock For AnHeart Acquisition</a></td>
<td class="nump">89,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares', window );">Issuance of Common Stock for AnHeart acquisition (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,646,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue', window );">Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares', window );">Issuance Of Convertible Preferred Stocks Related To The Acquisition Of AnHeart( Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock to Common Stock related to the AnHeart acquisition, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(851,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock to Common Stock related to the AnHeart acquisition, Value</a></td>
<td class="nump">274,938<span></span>
</td>
<td class="num">$ (274,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue', window );">Issuance Of Replacement Awards Related To The AnHeart Acquisition</a></td>
<td class="nump">24,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue', window );">Issuance of common stock for purchase under ESPP</a></td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares', window );">Issuance of common stock for purchase under ESPP, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockForRsusVestedShare', window );">Issuance of Common Stock for RSUs Vested, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,167,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">32,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(567,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(567,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CurrencyTranslationAdjustmentValue', window );">Currency translation adjustment</a></td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 463,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,373,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (910,743)<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,837,872<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CurrencyTranslationAdjustmentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency Translation Adjustment Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CurrencyTranslationAdjustmentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for AnHeart acquisition (Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock For AnHeart Acquisition Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for purchase under ESPP, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for purchase under ESPP, value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfCommonStockForRsusVestedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for RSUs Vested, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfCommonStockForRsusVestedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart( Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Replacement Awards Related To The AnHeart Acquisition Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530738800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (567,939)<span></span>
</td>
<td class="num">$ (75,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">32,275<span></span>
</td>
<td class="nump">19,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">936<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AmortizationOfPremiumOnMarketableSecurities', window );">Amortization of premium and discounts on marketable securities</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(12,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Realized loss on marketable securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of property and equipment</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">425,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(12,722)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,010)<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable', window );">Interest receivable on marketable securities</a></td>
<td class="nump">132<span></span>
</td>
<td class="num">(1,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Lease security deposit</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(6,029)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,654)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities', window );">Contract liabilities</a></td>
<td class="nump">3,942<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">6,838<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(130,413)<span></span>
</td>
<td class="num">(67,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from AnHeart acquisition</a></td>
<td class="nump">19,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TransactionCostsRelatedToAnheartAcquisition', window );">Transaction costs related to AnHeart acquisition</a></td>
<td class="num">(7,434)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(339,645)<span></span>
</td>
<td class="num">(703,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">450,082<span></span>
</td>
<td class="nump">712,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">122,703<span></span>
</td>
<td class="nump">8,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">12,609<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments on borrowings</a></td>
<td class="num">(17,163)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp', window );">Proceeds from issuance of common stock under ESPP</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="nump">4,458<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(6,926)<span></span>
</td>
<td class="num">(58,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">42,649<span></span>
</td>
<td class="nump">101,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">35,723<span></span>
</td>
<td class="nump">42,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for tax</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition', window );">Issuance of common stock related to the AnHeart acquisition</a></td>
<td class="nump">89,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition', window );">Issuance of convertible preferred stock related to the AnHeart acquisition</a></td>
<td class="nump">274,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition', window );">Issuance of warrants related to the AnHeart acquisition</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition', window );">Issuance of replacement awards related to the AnHeart acquisition</a></td>
<td class="nump">24,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_OperatingLeaseLiabilityRecognized', window );">Operating lease liability recognized</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_AmortizationOfPremiumOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_AmortizationOfPremiumOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock Related to the AnHeart Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Convertible Preferred Stock related to the AnHeart Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Replacement Awards Related to the AnHeart Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrants Related to the AnHeart Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_OperatingLeaseLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_OperatingLeaseLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock Under ESPP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_TransactionCostsRelatedToAnheartAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to AnHeart acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_TransactionCostsRelatedToAnheartAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the assets (liabilities) created through trading commodity-based derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522818768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (567,939)<span></span>
</td>
<td class="num">$ (75,802)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526495168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530738960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768524831056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bersecurity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property and confidential information that is proprietary, strategic or competitive in nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee, together with our information security function and third-party service providers  help identify, assess, and manage the Company&#8217;s cybersecurity threats and risks. Additionally they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods including, for example using automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#8217;s risk profile, evaluating threats reported to us, conducting internal and/or external audits,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting threat assessments for internal and external threats, third party threat assessments, conducting vulnerability assessments to identify vulnerabilities, and using external intelligence feeds.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: cybersecurity-related policies and procedures (including incident response plans and policies, a vulnerability management policy, disaster recovery/business continuity plans), incident detection and response, periodic risk assessments, implementation of security standards/certifications, encryption of data, network security and system monitoring controls (including technology solutions such as antivirus, firewalls and monitoring tools), awareness training for all employees, security measures, asset management, tracking and disposal, penetration testing, cybersecurity insurance coverage, and a dedicated cybersecurity staff.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into the Company&#8217;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#8217;s enterprise risk management program; (2) security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk, and (4) we have a cybersecurity incident response plan to identify, assess, respond to, and inform escalating levels of management based on the nature and severity of such incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party service providers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example Professional services firms, including legal counsel, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers (including SIEM tools and 24/7 managed detection and response), penetration testing firms, and dark web monitoring services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business,  such as application providers, hosting companies, and contract research organizations. We have a vendor management program to manage cybersecurity risks associated with our use of these providers.  The program includes a risk assessment for each vendor, a security questionnaire, review of the vendor's written security program, review of security assessments and other reports. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendor management process</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affect</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company and how they may do so, see the section titled &#8220;Risk Factors&#8221; in Item 1A of this Annual Report on Form 10-K, including the risk factor titled &#8220;&#8212;Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or experience security breaches or other unauthorized or improper access.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for oversight of the Company&#8217;s cybersecurity risk.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure, Operations and Cyber Security</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> who has  fifteen years of experience in the industry and oversees the Company&#8217;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.</span></span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#8217;s overall risk management strategy,</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#8217;s cybersecurity program.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div></div><div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and policies include </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting to the audit committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the board of directors for certain cybersecurity incidents.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors and audit committee receive periodic reports concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into the Company&#8217;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#8217;s enterprise risk management program; (2) security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk, and (4) we have a cybersecurity incident response plan to identify, assess, respond to, and inform escalating levels of management based on the nature and severity of such incidents.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for oversight of the Company&#8217;s cybersecurity risk.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure, Operations and Cyber Security</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> who has  fifteen years of experience in the industry and oversees the Company&#8217;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.</span></span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#8217;s overall risk management strategy,</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#8217;s cybersecurity program.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and policies include </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting to the audit committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the board of directors for certain cybersecurity incidents.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors and audit committee receive periodic reports concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for oversight of the Company&#8217;s cybersecurity risk.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure, Operations and Cyber Security</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#8217;s overall risk management strategy,</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#8217;s cybersecurity program.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and policies include </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting to the audit committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the board of directors for certain cybersecurity incidents.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors and audit committee receive periodic reports concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#8217;s overall risk management strategy,</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Director Infrastructure, Operations and Cyber Security</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> who has  fifteen years of experience in the industry and oversees the Company&#8217;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and policies include </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting to the audit committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the board of directors for certain cybersecurity incidents.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors and audit committee receive periodic reports concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628755328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Organization and Business Operations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation Bio Inc. and subsidiaries (&#8220;Nuvation Bio&#8221;), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2021, (the &#8220;Closing Date&#8221;), Nuvation Bio Inc., a Delaware corporation (&#8220;Legacy Nuvation Bio&#8221;), Panacea Acquisition Corp. (&#8220;Panacea&#8221;), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (&#8220;Merger Sub&#8221;) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (&#8220;Merger Agreement&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the &#8220;Merger&#8221;) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the &#8220;Company&#8221; or &#8220;Nuvation Bio&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024 (the "Acquisition Date"), the Company completed its acquisition of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands (&#8220;AnHeart&#8221;), pursuant to that certain Agreement and Plan of Merger (the "AnHeart Merger Agreement"), by and among the Company, AnHeart, Artemis Merger Sub I, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company, and Artemis Merger Sub II, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768633630000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 2. SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">a.	Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">b.	Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the balances of the Company and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">c.	Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company has an accumulated deficit of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">910.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and net cash used in operating activities was approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2024. Management expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. The Company believes that its existing cash, cash equivalents, and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that these consolidated financial statements are issued. The Company&#8217;s research and development activities can be costly, and the timing and outcomes are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the progress of the Company&#8217;s research and development activities and the level of financial resources available.</span></p></div><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">d.	Significant Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company&#8217;s products, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except in China where taletrectinib is being commercialized by our partner Innovent, there can be no assurance that the Company&#8217;s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and vendors and obtaining and protecting intellectual property.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.	Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">f.	Functional Currency and Foreign Currency Translations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's reporting currency is the U.S. dollar ("USD"). The functional currency of the Company's subsidiaries incorporated in People Republic of China ("PRC") is Renminbi ("RMB"). The functional currency of the Company and its subsidiaries incorporated outside the PRC is USD. Transactions denominated in currencies other than the functional currencies are re-measured into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are re-measured at the balance sheet date exchange rate. The resulting exchange differences are included in the net loss of the statements of operations and comprehensive loss. Assets and liabilities of the Company with functional currency other than USD are translated into USD at fiscal year-end exchange rates. Equity amounts are translated at historical exchange rates. Income and expense items are translated at average exchange rates during the fiscal year. Translation adjustments arising from these are reported as foreign currency translation adjustments and are shown as a component of other comprehensive income (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">g.	Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts, a money market mutual fund and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk.</span></p></div><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">h.	Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt securities have been classified as available-for-sale which may be sold before maturity as they are not classified as trading securities or as held-to-maturity securities. Marketable debt securities classified as available-for-sale are carried at fair value with unrealized gains or losses reported in other comprehensive income (loss). Exchange traded funds are equity securities, which are reported as marketable securities with readily determinable fair values, are also carried at fair value with unrealized gains and losses included in other (expense) income, net. Realized gains and losses on both debt and equity securities are included in other (expense) income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For securities in an unrealized loss position, management considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. Management also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If management determines there is any other than temporary impairment, the entire difference between amortized cost and fair value is recognized as impairment through earnings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to credit losses primarily through its available-for-sale investments. The Company assesses whether its available-for sale investments are impaired at each reporting period. Unrealized losses or impairments resulting from the amortized cost basis of any available-for-sale debt security exceeding its fair value are evaluated for identification of credit losses and non-credit related losses. Any credit losses are charged to earnings against the allowance for credit losses of the debt security, limited to the difference between the fair value and the amortized cost basis of the debt security. Any difference between the fair value of the debt security and the amortized cost basis, less the allowance for expected credit losses, are reported in other comprehensive income (loss). Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for expected credit losses subject to the total allowance previously recognized. The Company&#8217;s expected loss allowance methodology for the debt securities includes reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. As of December 31, 2024, the Company has not recognized an allowance for expected credit losses related to available-for-sale investments as the Company has not identified any unrealized losses for these investments attributable to credit factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income includes amortization and accretion of purchase premium and discount. Premiums and discounts on debt securities are amortized on the effective-interest method. Gains and losses on sales are recorded on the settlement date and determined using the specific identification method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.	Acquisition of assets and businesses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in GAAP, no goodwill is recognized and acquired in-process research and development is expensed in acquired in-process research and development expenses. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">j.	Concentration of Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of credit risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of customers</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customers represent more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div><div><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.528%;box-sizing:content-box;"></td>
          <td style="width:1.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.437%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.837%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,725</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customer represents more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's balances of accounts receivable as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.38%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,610</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">k.	</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets of generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for computers and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for furniture and equipment. The cost of leasehold improvements is amortized on the straight-line method over the lesser of the estimated asset life or remaining term of the lease. Maintenance costs are expensed as incurred, while major betterments are capitalized.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">l.	Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and an impairment assessment may be performed on the recoverability or the carrying amounts. If an impairment occurs, the loss is measured by comparing the fair value of the asset to its carrying amount.</span></p></div><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">m.	Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787,472</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase common stock outstanding, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,791,639</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Public Warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Private Placement Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">833,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Forward Purchase Warrants (as defined below). Each whole warrant entitles the registered holder to purchase one share of our Class A common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the consideration for AnHeart, the Company issued warrants collectively exercisable for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A Common Stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Consideration Warrants&#8221;). The fair value of the Consideration Warrants was determined to approximate the public warrant trading price as of closing of the Acquisition, yielding a fair value of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stockholder </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants. Accordingly, the Company classified the Consideration Warrants as liabilities, consistent with the classification of the Company&#8217;s Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer based on the stockholder approval from the 2024 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) on September 3, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated Public Warrants, Private Placement Warrants, Consideration Warrants, and Forward Purchase Warrants (the &#8220;Warrants&#8221;) under ASC 815-40, Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders&#8217; equity. Specifically, the settlement value of the Warrants is dependent, in part, on the holder of the Warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on our Common Stock, the Warrants fail the indexation guidance in ASC 815-40, which would preclude classification in stockholders&#8217; equity. Additionally, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#8217;s Common Stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Because not all of the Company&#8217;s stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Warrants do not meet the conditions to be classified in equity. Since the Warrants meet the definition of a derivative under ASC 815, the Company recorded these Warrants as liabilities on the balance sheet at fair value upon the closing of the Merger, with subsequent changes in their respective fair values recognized in the consolidated statement of operations and comprehensive loss at each reporting date. The fair value of Consideration, Public, and Forward Purchase Warrants was determined using the closing price of the publicly traded warrants on the NYSE market.  The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (see Note 4).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">n.	Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies ASC Topic 606, "Revenue from Contracts with Customers" ("ASC 606") to account for its revenue transactions.  Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the five-step model. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.  Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.  Accounts receivable represent amounts invoiced and revenues recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment.</span></p></div><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">o.	Collaborative Arrangement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the FASB issued Topic 808, "Collaborative Arrangements" ("ASC 808"): Clarifying the Interaction between ASC 808 and ASC 606. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard for all periods presented. The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. The Company assessed and determined that none of the collaboration agreements entered into during the periods presented were within the scope of ASC 808, as all of the agreements did not involve active participation by both parties in a joint research activity, and therefore did not qualify as collaborative arrangements under ASC 808.  The Company has determined that all the elements of the above collaborations are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. The Company recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.  The Company's collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from the portion of the transaction price allocated to the license at a point in time, when the license is transferred to the customer and the customer is able to benefit from the license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs based on the use of an input method.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A customer's right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or a discount. Optional future services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. The optional future services do not include a material right to be accounted for as performance obligations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's collaboration agreements include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company's collaboration agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company receives payments from its customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until the Company performs its obligations under the arrangement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a complete discussion of accounting for revenue, see Note 5, "Collaboration and License Agreements."</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p.	Costs to Fulfill a Contract with a Customer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not capitalized any costs for the years ended December 31, 2024 and 2023.  The Company is required to capitalize costs incurred to fulfill customer contracts. These costs are required to be amortized to expense on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates, compared to previously being expensed as incurred. Elements of the costs primarily include (i) payroll and other related costs of personnel related directly to the contract activities; (ii) costs related to pre-clinical testing and clinical trials such as payments to contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"), investigators, and clinical trial sites that conduct the contract activities; (iv) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses; and (v) other research and development costs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">q.	Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in operating lease right-of-use, or ROU assets; current operating lease liabilities; and non-current operating lease liabilities on its balance sheets. The Company currently does not have any finance leases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#8217;s leases generally do not provide an implicit rate. The incremental borrowing rate is reevaluated upon a lease modification. The operating lease ROU asset also includes any initial direct costs and prepaid lease payments made less any lease incentives. The Company considered information available at the adoption date of  Topic 842, "Leases" ("ASC 842") to determine the incremental borrowing rate for leases in existence as of this date. The incremental borrowing rate used was the weighted average rate between secured and unsecured lending arrangement.  Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the option will be exercised. Variable payments included in the lease agreement are expensed as incurred. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company elected to apply each of the practical expedients described in ASC 842-10-65-1(f) which allow companies not to reassess: (i) whether any expired or existing agreements contain leases, (ii) the classification of any expired or existing leases, and (iii) the capitalization of initial direct costs for any existing leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term operating leases. A short-term operating lease is a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.  The Company also elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.</span></p></div><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">r.	Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s operations are focused on oncology development activities. Substantially all revenues were derived from customers located in China and Japan. For the year ended December 31, 2024, the revenues derived from customers located in China and Japan were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation's Chief Executive Officer is the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM utilizes the Company&#8217;s strategic product development roadmaps and financial models, as a key input to resource allocation. The CODM is regularly provided with actual, budgeted and forecasted expense information to make decisions on resource</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocation and assess performance of the business and monitor budget versus actual results using income from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant expenses within income from operations, as well as within net income, include cost of revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss. Other segment items within net income include interest income, interest expense, investment advisory fees, change in fair value of warrant liability, realized loss on marketable securities and other expense, net, and income tax expense.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-lived assets consist primarily of property, plant and equipment, net. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of long-lived assets were in the U.S. As of December 31, 2024, no individual country other than the U.S. accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more of these assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">s.	Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred in connection with research and development activities are expensed as incurred. These costs include fees paid to consultants, vendors and various entities that perform certain research and testing on behalf of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new product compound, as well as pre-commercial milestone payments, are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new product compound did not also include processes or activities that would constitute a "business" as defined under U.S. GAAP, and the product candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval which meet the capitalization criteria would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. If the conditions enabling capitalization of development costs as an asset have not yet been met, all development expenditures are recognized in profit or loss when incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">t.	Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes compensation cost for grants of employee stock options using a fair-value measurement method, that is recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the fair value of stock-based awards that are based only on a service condition using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, volatility, dividend yield, and expected life of the options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the fair value of stock-based awards that are based on both a service condition and achievement of the first to occur of a market or performance condition using a Monte Carlo simulation.</span></p></div><div><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">u.	Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. The difference between the financial statement and tax basis of assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the years in which they are expected to affect taxable income. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of the tax provision. Returns for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years beginning with those filed for the period ended December 31, 2018 are open to federal and state tax examination.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">v.	Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07&#8212;Segment Reporting (Topic 280):  Topic 280 "Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted ASU 2023-07 effective December 31, 2024. The adoption of the guidance did not have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements. See Note 2(r) for further information on Nuvation's segment reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09 &#8211; Income Taxes (Topic 740): "Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. This guidance is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522806336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 3. ACQUISITION</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024, the Company completed the acquisition of AnHeart. Pursuant to the terms of the AnHeart Merger Agreement, at the effective time of the First Merger (as defined in the Merger Agreement) (the &#8220;First Effective Time&#8221;), the Company issued to AnHeart securityholders (i) approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A Non-Voting Convertible Preferred Stock of the Company, and (iii) the Consideration Warrants. The shares of our Series A Non-Voting Convertible Preferred Stock were automatically convertible into an aggregate of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,120,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock upon the approval of such conversion by the Company&#8217;s stockholders in accordance with the rules of the New York Stock Exchange. Since the preferred stock was not mandatorily redeemable and the exception for a deemed liquidation event was not met, all of the outstanding convertible preferred stock was classified as mezzanine equity in the balance sheet at the Acquisition Date. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 3, 2024, the Company held its Annual Meeting at which the Company&#8217;s stockholders approved for the purpose of complying with the listing rules of the New York Stock Exchange, the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,120,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock issued in April 2024. Additionally, the Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting. The conversion of the Convertible Preferred Stock into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,120,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock was completed and those shares were issued and outstanding as of September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the First Effective Time, (i) each option to purchase shares of Ordinary Shares (as defined in the Merger Agreement) of AnHeart (an &#8220;AnHeart Option&#8221;) held by a Continuing Company Service Provider (as defined in the Merger Agreement), whether or not vested, was assumed and converted into an option to purchase Class A Common Stock (each such option, an &#8220;Assumed Option&#8221;), and (ii) each restricted stock unit reflecting the right to receive Ordinary Shares of AnHeart (an &#8220;AnHeart RSU&#8221;) held by a Continuing Company Service Provider (as defined in the Merger Agreement) was assumed and became a restricted stock unit with respect to a number of shares of Class A Common Stock (each such restricted stock unit, an &#8220;Assumed RSU&#8221;). Each Assumed Option and Assumed RSU is subject to the same terms and conditions (including vesting and exercise schedule) as were applicable to the corresponding AnHeart Option or AnHeart RSU immediately prior to the First Effective Time, subject to limited exceptions set forth in the Merger Agreement. Any other AnHeart Option and AnHeart RSU that remained unexercised and outstanding as of immediately prior to the First Effective Time was canceled without payment. From and after the Effective Time:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of shares of Class A Common Stock subject to each Assumed Option was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart Option immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio (as defined in the Merger Agreement) and rounding down to the nearest whole number of shares;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the per-share exercise price for Class A Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per-share exercise price of each AnHeart Option, as in effect immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio and rounding up to the nearest whole cent; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of shares of Class A Common Stock subject to each Assumed RSU was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart RSU immediately prior to the First Effective Time, by (B) 1.7551 and rounding down to the nearest whole number of shares.</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The final allocable purchase price consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"></td>
        <td style="width:10.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A Common Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Non-Voting Convertible Preferred Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assumed share-based awards </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocable purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">____________________________</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of the Acquisition Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at as-converted value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued at the estimated fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2641</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp; Assumed RSUs) attributable to precombination services.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the transaction as an asset acquisition since the lead asset, taletrectinib, represented substantially all of the fair value of the gross assets acquired, which excludes cash acquired. At the Acquisition Date, we recorded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million charge representing an acquired in-process research and development asset with no alternative future use in acquired in-process research and development expenses, of which the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of assets acquired primarily consisting of cash and liabilities assumed were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628889360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 3. ACQUISITION</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024, the Company completed the acquisition of AnHeart. Pursuant to the terms of the AnHeart Merger Agreement, at the effective time of the First Merger (as defined in the Merger Agreement) (the &#8220;First Effective Time&#8221;), the Company issued to AnHeart securityholders (i) approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series A Non-Voting Convertible Preferred Stock of the Company, and (iii) the Consideration Warrants. The shares of our Series A Non-Voting Convertible Preferred Stock were automatically convertible into an aggregate of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,120,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock upon the approval of such conversion by the Company&#8217;s stockholders in accordance with the rules of the New York Stock Exchange. Since the preferred stock was not mandatorily redeemable and the exception for a deemed liquidation event was not met, all of the outstanding convertible preferred stock was classified as mezzanine equity in the balance sheet at the Acquisition Date. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 3, 2024, the Company held its Annual Meeting at which the Company&#8217;s stockholders approved for the purpose of complying with the listing rules of the New York Stock Exchange, the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,120,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock issued in April 2024. Additionally, the Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting. The conversion of the Convertible Preferred Stock into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,120,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock was completed and those shares were issued and outstanding as of September 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the First Effective Time, (i) each option to purchase shares of Ordinary Shares (as defined in the Merger Agreement) of AnHeart (an &#8220;AnHeart Option&#8221;) held by a Continuing Company Service Provider (as defined in the Merger Agreement), whether or not vested, was assumed and converted into an option to purchase Class A Common Stock (each such option, an &#8220;Assumed Option&#8221;), and (ii) each restricted stock unit reflecting the right to receive Ordinary Shares of AnHeart (an &#8220;AnHeart RSU&#8221;) held by a Continuing Company Service Provider (as defined in the Merger Agreement) was assumed and became a restricted stock unit with respect to a number of shares of Class A Common Stock (each such restricted stock unit, an &#8220;Assumed RSU&#8221;). Each Assumed Option and Assumed RSU is subject to the same terms and conditions (including vesting and exercise schedule) as were applicable to the corresponding AnHeart Option or AnHeart RSU immediately prior to the First Effective Time, subject to limited exceptions set forth in the Merger Agreement. Any other AnHeart Option and AnHeart RSU that remained unexercised and outstanding as of immediately prior to the First Effective Time was canceled without payment. From and after the Effective Time:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of shares of Class A Common Stock subject to each Assumed Option was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart Option immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio (as defined in the Merger Agreement) and rounding down to the nearest whole number of shares;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the per-share exercise price for Class A Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per-share exercise price of each AnHeart Option, as in effect immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio and rounding up to the nearest whole cent; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of shares of Class A Common Stock subject to each Assumed RSU was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart RSU immediately prior to the First Effective Time, by (B) 1.7551 and rounding down to the nearest whole number of shares.</span></div></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The final allocable purchase price consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"></td>
        <td style="width:10.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A Common Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Non-Voting Convertible Preferred Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assumed share-based awards </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocable purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">____________________________</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of the Acquisition Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at as-converted value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued at the estimated fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2641</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp; Assumed RSUs) attributable to precombination services.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the transaction as an asset acquisition since the lead asset, taletrectinib, represented substantially all of the fair value of the gross assets acquired, which excludes cash acquired. At the Acquisition Date, we recorded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million charge representing an acquired in-process research and development asset with no alternative future use in acquired in-process research and development expenses, of which the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of assets acquired primarily consisting of cash and liabilities assumed were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628843232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available-for-Sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Marketable Securities Available for Sale</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 4. FAIR VALUE MEASUREMENTS AND MARKETABLE SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8212; Unobservable inputs that reflect the Company&#8217;s estimates of the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following table presents information about the Company&#8217;s marketable securities and the Warrant liability as of December 31, 2024 and 2023, measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company&#8217;s Warrant liabilities are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">included </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">within the Level 1 and Level 3 fair value hierarchy.  The fair value of the Consideration, Public and Forward Purchase Warrants is determined using the closing price of the warrants on the NYSE market. The fair value of the Private Placement Warrants is determined using the Black-Scholes option pricing formula. The primary unobservable input utilized in determining the fair value of the Private Warrants is the expected volatility. The expected volatility was estimated considering observable Public Warrant pricing, the Company's own historical volatility and the volatility of guideline public companies.  </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have not been any transfers between the levels during the periods.</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets:</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,053</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,509</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,628</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,628</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,585</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,585</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets:</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">595,073</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">574,499</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">338</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consist primarily of U.S. government and government agency, certificate of deposits, commercial paper, corporate bond and municipal securities ("Debt Securities"). Based on the Company&#8217;s intentions regarding its marketable securities, all Debt Securities are classified as available-for-sale and are carried at fair value based on the price that would be received upon sale of the security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides the amortized cost, aggregate fair value, and unrealized gains (losses) of marketable securities as of December 31, 2024 and December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.438%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,628</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,891</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478,482</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.447%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,987</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,508</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,509</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,171</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,609</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,628</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">452,813</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,791</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,585</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,384</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,012</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">594,892</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,193</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,012</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">595,073</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the activity related to the net gains (losses) on marketable securities included in other income (expense) on the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized gains (losses) on available-for-sale securities were as follows:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized gains from sales of available-for-sale securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized losses from sales of available-for-sale securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized losses on marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables provide marketable securities with continuous unrealized losses for less than 12 months and 12 months or greater and the related fair values as of December 31, 2024 and 2023 were as follows:</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:34.412%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,021</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,099</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,923</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,010</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:31.295%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 Months</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,101</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,101</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199,552</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">694</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,313</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,844</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,484</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">246</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236,190</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,245</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">284</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">287,435</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,011</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity information based on fair value of the available-for-sale securities is as follows as of December 31, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.58%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Within one year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After one year<br/>through five years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,065</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384,029</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,940</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628793392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CollaborationAndLicenceAgreementAbstract', window );"><strong>Collaboration and Licence Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CollaborationAndLicenseAgreementsTextblock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 5. COLLABORATION AND LICENSE AGREEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into collaborative arrangements for the research and development, and commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license and in-license compound to other parties. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost reimbursement arrangements and royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-Licensing Arrangements with Daiichi Sankyo Company Ltd. ("DS")</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments and royalty payments. All upfront and development milestones were expensed in research and development expense as incurred. We have reached </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestones in 2024, which require payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to DS under the arrangement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Out-Licensing Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's revenue related to its out-licensing collaborative agreements consist of upfront license fees and research and development services revenue from its collaboration agreements with Innovent Biologics Co. Ltd. ("Innovent") and Nippon Kayaku Co., Ltd. ("NK") for </span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taletrectinib </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("AB-106").</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total revenue recognized for the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.14%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.919999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,086</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no revenue for 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with NewG Lab</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2020, AnHeart entered into an agreement with NewG Lab. under which they will grant a sub-licensable, royalty-bearing, exclusive right and license to NewG Lab to develop and commercialize AB-106 in Korea (the " NewG Lab Territory"), with NewG Lab responsible for funding ongoing clinical trials of AB-106, regulatory submissions after development and for commercialization upon regulatory approvals. They also granted NewG Lab the option to obtain the same aforementioned rights to AB-106 in Malaysia (the "NewG Lab Option").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During July 2024, the Company terminated the agreement with NewG Lab.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement with Innovent</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, AnHeart entered into an agreement with Innovent, granting Innovent a sub-licensable, royalty-bearing, exclusive right and license to commercialize AB-106 in the People's Republic of China and Taiwan (the "Innovent Territory"). AnHeart is responsible for funding ongoing clinical trials of AB-106, regulatory submissions after development with Innovent responsible for commercialization upon regulatory approvals. They also granted Innovent the option to obtain a license to commercialize AB-329 once they provide proof of concept behind the compound in a region in the Innovent Territory (the "Innovent Option"). Under the agreement, AnHeart received a non-refundable upfront cash payment, is owed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for achievement of certain regulatory approval milestones,  and is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of additional regulatory milestones, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of commercial milestones, and tiered percentage royalties ranging from mid-teen to low-twenties on annual net sales of taletrectinib in the Innovent Territory subject to certain adjustments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AnHeart determined that the license represents a single performance obligation. The research and development services represent a material promise and were determined to be a separate performance obligation at the outset of the agreement as the promise is distinct and has standalone value to Innovent. They concluded that, at the inception of the agreement, the Innovent Option did not constitute a material right as it does not represent a discount to the fair value of the exclusive license that Innovent would not have received without entering into the agreement and is therefore not considered a distinct performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfied the license performance obligation at a point in time when the license was delivered and the transfer of know-how completed. The portion of the transaction price allocated to the research and development services was deferred and is being recognized as research and development service revenue using an input method. Estimated costs to complete are reassessed on a periodic basis and any updates to the revenue earned are recognized on a prospective basis. The China NMPA approvals for first and second line indications of ROS1+ NSCLC represent achievement of two regulatory milestones. As such, the Company is owed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments under the agreement, of which the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of license revenue at a point in time and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the milestone payments is deferred and recognized as research and development service revenue using an input method. For the year ended December 31, 2024, the Company recognized license revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and research and development service revenue of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million under the Innovent agreement.  As of December 31, 2024, the accounts receivable of Innovent was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration and License Agreement with NK</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, AnHeart entered into an agreement with NK, granting NK a sub-licensable, royalty-bearing, exclusive right and license to commercialize AB-106 in Japan (the "NK Territory"). AnHeart is responsible for funding ongoing clinical trials of AB-106 in the NK Territory, with NK responsible for funding regulatory submissions in the NK Territory. The Company also granted NK a sub-licensable, royalty-bearing, exclusive right and license to research, develop and commercialize any new indications of AB-106 in the NK Territory ("NK New Indication Right"). Under the agreement, AnHeart received a non-refundable upfront cash payment and is eligible to receive $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of a regulatory milestone, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of commercial milestones, and a lower-mid double digit percentage royalty on net sales of taletrectinib in the NK Territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AnHeart determined that the license represents a single performance obligation. The research and development services represent a material promise and were determined to be a separate performance obligation at the outset of the agreement as the promise is distinct and has standalone value to NK. They concluded that, at the inception of the agreement, the NK New Indication Right did not constitute a material right.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion of the transaction price allocated to the research and development services was deferred and is being recognized as research and development service revenue using an input method. Estimated costs to complete are reassessed on a periodic basis and any updates to the revenue earned are recognized on a prospective basis. The Company recognized research and development service revenue of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2024. As of December 31, 2024, the accounts receivable of NK was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract assets and contract liabilities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the Company satisfies its performance obligations by providing services to a customer before the customer pays consideration and before payment is due, the Company recognizes its rights to consideration as a contract asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any contract assets as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When a customer pays consideration before the Company provide services, the Company records its obligation as a contract liability. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to recognize all of this balance as revenue as research and development services are provided over the next 4 years.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract liabilities of the Company as of December 31, 2024 is listed in the table below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue in 2024 that was included in the contract liability balance recorded upon the acquisition of AnHeart.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The balance of contract liabilities as of December 31, 2024 represents the transaction price allocated to the remaining performance obligations. The contract liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is expected to be recognized within one year and the rest in the following three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs incurred to fulfill customer contracts were capitalized and amortized to cost of revenue on a systematic basis that is consistent with the transfer of research and development services to the customer to which the asset relates. For the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion of costs incurred to fulfill customer contracts were capitalized and expensed in the same period. There were no balances related to the costs incurred to fulfill customer contracts as of December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CollaborationAndLicenceAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and Licence Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CollaborationAndLicenceAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CollaborationAndLicenseAgreementsTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreements TextBlock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CollaborationAndLicenseAgreementsTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523338512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingsAbstract', window );"><strong>Subordinated Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingsDisclosureTextBlock', window );">Borrowing</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 6. BORROWING</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2020, AnHeart entered into loan agreements with Bank of Hangzhou to obtain short-term borrowings to supplement its working capital. As of December 31, 2024, the outstanding balance net of repayments was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For the year ended December 31, 2024, the Company had drawn down $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and repaid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The fixed interest rate of these borrowings is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, AnHeart entered into loan agreements with China Merchants Bank to obtain short-term borrowings to supplement its working capital. As of December 31, 2024, the outstanding balance was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company repaid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. The fixed interest rate of these borrowings was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 4, 2023, AnHeart entered into a Loan and Security Agreement ("2023 SSVB Agreement") with Shanghai Pudong Development Bank in Silicon Valley for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million RMB or equivalent in optional currency USD term loans ("SSVB Loan"). The SSVB Loan consists of a short-term working capital loan of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million RMB and a long-term loan of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million RMB, which matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 4, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 4, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, at which time all outstanding balances are due. Draws on the line of credit for the short-term loans are payable on the maturity date of the SSVB Loan. Draws on the line of credit for the long-term loans are payable in equal instalments monthly over the shorter of 24 months or from the date the draw took place till the SSVB loan matures. Outstanding balances will bear interest at a fixed rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. As of December 31, 2024, the outstanding line of credit balance net of repayments was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. For the year ended December 31, 2024, the Company repaid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC's uniform net capital rule, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478878/942-470-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523347392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 7. PROPERTY AND EQUIPMENT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">553</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,460</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,383</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">874</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">666</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">586</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense related to property and equipment was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 20223, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523953984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 8. ACCRUED EXPENSES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued consultant fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,243</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,917</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,818</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,349</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">827</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">679</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,833</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,793</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522855344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 9. LEASES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located in New York, New York, where we lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,900</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space under a lease that terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an option for us to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which is not reasonably assured of exercise, and in San Francisco, where we lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,418</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space that terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also occupy office space located in Burlington, Massachusetts, where we lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,235</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space under a lease that terminates in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as a total of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,735</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square meters of office space in the People&#8217;s Republic of China, in the cities of Beijing, Guangzhou, Hangzhou and Shanghai, under leases that terminate in 2026 through 2027.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively. Expense related to variable leases was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t significant for the years ended December 31, 2024 and 2023.  Operating cash flows for the year ended December 31, 2024 and 2023 included</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the future minimum lease analysis of the Company's operating lease liabilities showing the aggregate lease payments as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,767</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,775</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,632</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average incremental borrowing rate used to determine the operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The Company's weighted average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.63</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> y</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ears as of December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525117568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 10. STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Founder owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding Class B common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Restriction Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Merger, the shares subject to the &#8220;Stock Restriction Agreement&#8221; between the Company and the Founder was adjusted based on the Exchange Ratio. The number of shares, as adjusted, subject to repurchase per the terms of the Stock Restriction Agreement is reduced each month by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,101,240</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class A common shares and no common shares will be subject to repurchase by June 2022. As of December 31, 2024, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Common Stock subject to the repurchase option.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Class A and Class B common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one vote per share on all matters</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, except that the holders of Class A common stock do not participate in the election of the directors who are elected exclusively by the holders of Class B common stock. Holders of Class A and Class B common stock vote together as a single class on all matters, except that (i) the holders of Class B common stock have the right, voting as a separate class, to elect and remove without cause three directors plus at least 50% of any directors in excess of seven, and (ii) the approval of the holders of a majority of Class B common stock, voting as a separate class, is required for approval by the stockholders of any acquisition (whether by merger, sale of shares or sale of assets) or liquidation. There are no cumulative voting rights.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conversion</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of Class B common stock will automatically convert into one share of Class A common stock upon transfer to a non-authorized holder. In addition, the Class B common stock is subject to a &#8220;sunset&#8221; provision under which all outstanding shares of Class B common stock will automatically convert into an equal number of shares of Class A common stock if ownership of shares of Class A and Class B common stock held by our President and Chief executive Officer, David Hung, M.D., falls below an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,188,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares or if Dr. Hung dies, becomes disabled or ceases to be our Chief Executive Officer, unless he is terminated from such position by us without cause.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628879936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 11. NET LOSS PER SHARE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic loss per share is computed by dividing net loss by the weighted-average number of shares of Class A and Class B common stock outstanding, but excluding shares of common stock subject to repurchase for the period. The number of common stock shares subject to repurchase was determined prospectively from the date of the Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restriction Agreement described in Note 10. Diluted loss per share reflects the potential dilution that could occur if the stock options to issue common stock were exercised. The Company had a net loss in all periods presented thus the dilutive net loss per common share is the same as the basic net loss per common share as the effect of any options or conversions is anti-dilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The earnings per share amounts are the same for the different classes of common stock because the holders of each class are legally entitled to equal per share distributions whether through dividends or liquidation.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities outstanding at December 31, 2024 and 2023 have been excluded from the calculation of weighted average shares outstanding:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,681,182</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787,462</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock options</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,729,709</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,649,239</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,420,131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522811472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 12. ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a rollforward of the changes in accumulated other comprehensive (loss) income for the years ended December 31, 2024 and 2023, which is all attributable to unrealized gains (losses) on available-for-sale securities. All amounts are net of tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at beginning of period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amount reclassified for realized loss on marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency translation adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for tabular information relating to Other Comprehensive Income (OCI) as is applicable to noncontrolling interests. This text block may also include OCI relative to the filing entity, the aforementioned noncontrolling interest OCI, as well as OCI on a consolidated basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628924608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 13. STOCK-BASED COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The 2021 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2019, the Company adopted the 2019 Equity Incentive Plan or (&#8220;2019 Plan&#8221;), which provided for the grant of options, stock appreciation rights, restricted stock, and other stock awards.  In January 2021, our board of directors adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan was approved by our stockholders in February 2021 and became effective immediately upon the Closing Date of the Merger.  Shares available for future issuance under the 2019 Plan were canceled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The 2021 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), within the meaning of Section 422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorized Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The maximum number of shares of Class A common stock that may be issued under the 2021 Plan was initially set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,684,047</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31 of the preceding year, or (2) a lesser number of shares of Class A common stock determined by our board of directors prior to the date of the increase</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares of Class A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock that may be issued on the exercise of ISOs under the 2021 Plan is three times the number of shares available for issuance upon the 2021 Plan becoming effective or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,052,141</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, our board of directors adopted the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by our stockholders in February 2021 and became effective immediately upon the Closing Date of the Merger.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Reserve.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The maximum number of shares of Class A common stock that may be issued under the 2021 ESPP was initially set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,750,354</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Class A common stock reserved for issuance under the 2021 ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31st of the preceding calendar year or such lesser number of shares of Class A common stock as determined by our board of directors.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Shares subject to purchase rights granted under the 2021 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the 2021 ESPP.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock-based compensation expense included in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,450</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,797</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,825</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,275</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,513</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Options with Service Conditions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted with only service conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity with service condition only for employees and members of the Company&#8217;s Board of Directors for the year ended December 31, 2024 is as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Issuable<br/>Pursuant to<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic<br/>Value (in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,834,045</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.51</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options assumed for acquisition of AnHeart</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,742,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,175,083</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,750,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,192,263</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,808,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.72</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,475</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,245,561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.43</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All unvested options as of December 31, 2024 are expected to vest.  The weighted average grant-date fair value of stock options outstanding on December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.57</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share, respectively. Total</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unrecognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensation costs related to non-vested stock options at December 31, 2024 was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and is expected to be recognized within future operating results over a weighted-average period of</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ears.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock options granted with only service conditions during the years ended December 31, 2024 and 2023, the inputs in the Black-Scholes option-pricing model to determine the fair value is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.287%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:14.857%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:14.857%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.61</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.94</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.63</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.74</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company estimated its expected stock volatility based on the blended average of its historical volatility and of publicly traded set of peer companies.  The expected term of the Company&#8217;s options has been determined utilizing the &#8220;simplified&#8221; method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Dividend yield is based on the expectation that the Company will not pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Options with Service, Market, and Performance Conditions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted with combined service, market, and performance conditions will vest based on achievement of various service conditions and either a market-based or performance-based goals in three tranches with multiple categories such as the Company&#8217;s market capitalization, and clinical and regulatory milestones. The market-based and performance-based goals period ends in October 2030. The explicit service periods are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for tranche 1, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for tranche 2, and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for tranche 3. Upon the vesting requirement, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options will vest for each of tranche 1 and 2, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the options granted for tranche 3 will vest. The Company recognizes the fair value of the options within each tranche over the longer of their explicit service period or derived service period. The achievement of the performance condition was not deemed probable on the date of grant. As of December 31, 2024, the performance condition was not deemed probable.  The expense recognized is based on the fair value of the market condition for the years ended December 31, 2024 and 2023. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity with combined service, market, and performance conditions for employees for the year ended December 31, 2024 is as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Issuable<br/>Pursuant to<br/>Stock Options</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic<br/>Value (in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,815,194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.31</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,042</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,921,152</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.74</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748,375</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.91</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value of stock options outstanding on December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. Total unrecognized compensation costs related to non-vested stock options at December 31, 2024 was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion and is expected to be recognized within future operating results over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the stock options granted with combined service, market, and performance conditions was based on a Monte Carlo simulation with an embedded Black-Sholes pricing model. For the years ended December 31, 2024 and 2023, the fair value was computed using the following assumptions:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.3%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:14.86%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.61</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.94</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.17</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.30</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The determination of expected volatility, risk- free rate, and dividend yield was the same approach as used for the above stock options granted with service only conditions. The expected term period represents the time used as an input in the embedded Black-Sholes pricing model which is based on the midpoint between the vest and expiration dates for each tranche.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity for the restricted stock units assumed in the AnHeart acquisition for the year ended December 31, 2024.</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"></td>
        <td style="width:9.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs assumed for the acquisition of AnHeart</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,201,694</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">618,340</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or canceled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,420,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value of stock options outstanding on December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Total unrecognized compensation costs related to non-vested stock options at December 31, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and is expected to be recognized within future operating results over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522823616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">401(K) Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 14. 401(K) PLAN</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sponsors a 401(k) plan (the &#8220;Plan&#8221;) covering substantially all employees of the Company. The Plan allows employees to contribute tax deferred salary deductions into the Plan under the provisions of Section 401(k) of the Internal Revenue Code. Matching contributions are made by the Company up to a maximum amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employee contributions, subject to certain limitations as defined in the Plan. The Company made matching contributions o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628837888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_WarrantDisclosureAbstract', window );"><strong>Warrant Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_WarrantDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 15. WARRANTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787,472</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase Common Stock outstanding, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,791,639</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Public Warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Private Placement Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">833,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Forward Purchase Warrants. Each whole warrant entitles the registered holder to purchase one share of our Class A Common Stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A Common Stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Acquisition, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consideration Warrants. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, there were an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,681,182</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the Consideration Warrants, Public Warrants, Private Warrants and Forward Purchase Warrants do not meet the conditions to be classified in equity.  The warrants were recorded at fair value with subsequent changes in fair value reflected in earnings (see Note 4). The change in fair value resulted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million during the year ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of Consideration, Public and Forward Purchase Warrants is determined using the closing price of the warrants on the NYSE market and the related Warrant liability is included in Level 1 fair value measurements. The Company utilizes the Black-Scholes option pricing formula to determine the fair value of the Private Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liability for the Private Warrants is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The annualized volatility of the Warrant was based on a calibration to the publicly traded warrant price as of the valuation date. The risk-free interest rate was estimated using linear interpolation assuming a term consistent with the time until the warrants expire, and yield information was based on U.S. Treasury Constant Maturities.  The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned warrant liabilities are not subject to qualified hedge accounting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Levels 1, 2 or 3 during the period ended December 31, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides quantitative assumptions regarding Level 3 fair value measurements:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:62.04%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Strike price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137.5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined the following fair values for the outstanding Warrants (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Public Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,102</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forward Purchase Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">665</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,053</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following presents changes in liabilities classified in Level 3 of the fair value hierarchy for the year ended December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Private Warrants liability recognized in earnings</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_WarrantDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_WarrantDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_WarrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_WarrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768635223616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 16. INCOME TAXES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not record a provision or benefit for income taxes for the years ended December 31, 2024 and 2023. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the net deferred tax asset as of December 31, 2024 and 2023 are as follows:</span></span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,698</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,290</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,379</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,133</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs*</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,294</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,156</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,172</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,307</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,116</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,124</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,035</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,589</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,412</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">853</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">931</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,591</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,444</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">931</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,481</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">24.8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 59(e) and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">70.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 174.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate for the years ended December 31, 2024 and 2023 are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal tax benefit</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.06</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.84</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.65</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.33</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.05</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">True-up</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.42</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.66</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.26</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal net operating loss carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The federal net operating losses have an unlimited carryover period and state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal research and development tax credit carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and state research and development tax credit carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The federal resea</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rch and development tax credits begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and state research and development tax credits have an unlimited carryover period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal orphan drug tax credit carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The federal orphan drug tax credits begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the federal and state net operating losses may be subject to change of ownership limitations provided by the Internal Revenue Code and similar state provisions. An annual loss limitation may result in the expiration or reduced utilization of the net operating losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage-point cumulative change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of AnHeart Therapeutics, Inc.'s previous mergers with AnHeart Hangzhou in March 2019 and AnHeart Ltd (Cayman) in September 2021, we are subject to the Section 382 limitation. Our utilization of these pre-merger NOL and tax credit carryforwards is limited to the amount of income that the related entity contributes to our consolidated taxable income.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company maintained a full valuation allowance on its net deferred tax assets. The valuation allowance was determined in accordance with the provisions of ASC 740, Accounting for Income Taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. The Company&#8217;s history of cumulative losses, along with expected future U.S. losses required that a full valuation allowance be recorded against all net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.	</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company&#8217;s total amount of unrecognized tax benefits was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llion, none of which would impact the Company&#8217;s effective tax rate, if recognized. The Company does not anticipate that the amount of unrecognized tax benefit will significantly increase within the next 12 months.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the activity related to the unrecognized tax benefits were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,068</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross increases - current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross decreases - prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to taxation in the United States and various state jurisdictions. All tax years remain subject to examination for U.S. federal and state purposes. All net operating losses generated to date are subject to adjustment for U.S. federal and state purposes. The Company is not currently under examination in federal or state jurisdictions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523386656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="notes" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 17. COMMITMENTS AND CONTINGE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NCIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases its office space under non-cancellable operating lease agreements. The leases also require the Company to pay real estate taxes and other operational expenses associated with the leased location and is included in rent expense. The effect of graduating rents, net of the rent credits, is being amortized over the life of the lease so as to result in equal monthly rent expense over the lease term. Deferred rent liability reported in the accompanying consolidated balance sheets represents the cumulative excess of straight-line rental costs over the actual rental payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has standby letters of credit with banks in the aggregate amount of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million which serve as security for the New York and San Francisco spaces operating leases. The standby letters of credit automatically renew </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annually</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party, for which management believes the ultimate outcome would have a material adverse effect on the Company&#8217;s financial position.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522820544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE 18. SUBSEQUENT EVENT</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, the Company announced the closing of a non-dilutive financing of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Sagard. The financing is comprised of a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million synthetic royalty and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of senior secured debt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">synthetic royalty and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of debt will be funded conditioned upon FDA&#8217;s approval of taletrectinib on or prior to September 30, 2025. The transaction will support the U.S. launch of taletrectinib,  and general corporate purposes.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526161776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">a.	Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">b.	Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the balances of the Company and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">c.	Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company has an accumulated deficit of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">910.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and net cash used in operating activities was approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2024. Management expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. The Company believes that its existing cash, cash equivalents, and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that these consolidated financial statements are issued. The Company&#8217;s research and development activities can be costly, and the timing and outcomes are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the progress of the Company&#8217;s research and development activities and the level of financial resources available.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">Significant Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">d.	Significant Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company&#8217;s products, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except in China where taletrectinib is being commercialized by our partner Innovent, there can be no assurance that the Company&#8217;s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and vendors and obtaining and protecting intellectual property.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.	Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency and Foreign Currency Translations</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">f.	Functional Currency and Foreign Currency Translations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's reporting currency is the U.S. dollar ("USD"). The functional currency of the Company's subsidiaries incorporated in People Republic of China ("PRC") is Renminbi ("RMB"). The functional currency of the Company and its subsidiaries incorporated outside the PRC is USD. Transactions denominated in currencies other than the functional currencies are re-measured into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are re-measured at the balance sheet date exchange rate. The resulting exchange differences are included in the net loss of the statements of operations and comprehensive loss. Assets and liabilities of the Company with functional currency other than USD are translated into USD at fiscal year-end exchange rates. Equity amounts are translated at historical exchange rates. Income and expense items are translated at average exchange rates during the fiscal year. Translation adjustments arising from these are reported as foreign currency translation adjustments and are shown as a component of other comprehensive income (loss).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">g.	Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts, a money market mutual fund and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">h.	Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt securities have been classified as available-for-sale which may be sold before maturity as they are not classified as trading securities or as held-to-maturity securities. Marketable debt securities classified as available-for-sale are carried at fair value with unrealized gains or losses reported in other comprehensive income (loss). Exchange traded funds are equity securities, which are reported as marketable securities with readily determinable fair values, are also carried at fair value with unrealized gains and losses included in other (expense) income, net. Realized gains and losses on both debt and equity securities are included in other (expense) income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For securities in an unrealized loss position, management considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. Management also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If management determines there is any other than temporary impairment, the entire difference between amortized cost and fair value is recognized as impairment through earnings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is exposed to credit losses primarily through its available-for-sale investments. The Company assesses whether its available-for sale investments are impaired at each reporting period. Unrealized losses or impairments resulting from the amortized cost basis of any available-for-sale debt security exceeding its fair value are evaluated for identification of credit losses and non-credit related losses. Any credit losses are charged to earnings against the allowance for credit losses of the debt security, limited to the difference between the fair value and the amortized cost basis of the debt security. Any difference between the fair value of the debt security and the amortized cost basis, less the allowance for expected credit losses, are reported in other comprehensive income (loss). Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for expected credit losses subject to the total allowance previously recognized. The Company&#8217;s expected loss allowance methodology for the debt securities includes reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. As of December 31, 2024, the Company has not recognized an allowance for expected credit losses related to available-for-sale investments as the Company has not identified any unrealized losses for these investments attributable to credit factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income includes amortization and accretion of purchase premium and discount. Premiums and discounts on debt securities are amortized on the effective-interest method. Gains and losses on sales are recorded on the settlement date and determined using the specific identification method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisition of assets and businesses</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.	Acquisition of assets and businesses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in GAAP, no goodwill is recognized and acquired in-process research and development is expensed in acquired in-process research and development expenses. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">j.	Concentration of Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of credit risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of customers</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customers represent more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.528%;box-sizing:content-box;"></td>
          <td style="width:1.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.437%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.837%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,725</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customer represents more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's balances of accounts receivable as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.38%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,610</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">k.	</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets of generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for computers and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for furniture and equipment. The cost of leasehold improvements is amortized on the straight-line method over the lesser of the estimated asset life or remaining term of the lease. Maintenance costs are expensed as incurred, while major betterments are capitalized.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">l.	Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and an impairment assessment may be performed on the recoverability or the carrying amounts. If an impairment occurs, the loss is measured by comparing the fair value of the asset to its carrying amount.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">m.	Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787,472</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase common stock outstanding, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,791,639</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Public Warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Private Placement Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">833,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Forward Purchase Warrants (as defined below). Each whole warrant entitles the registered holder to purchase one share of our Class A common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the consideration for AnHeart, the Company issued warrants collectively exercisable for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A Common Stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Consideration Warrants&#8221;). The fair value of the Consideration Warrants was determined to approximate the public warrant trading price as of closing of the Acquisition, yielding a fair value of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stockholder </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval and otherwise have terms identical to those of the Company&#8217;s outstanding Public Warrants. Accordingly, the Company classified the Consideration Warrants as liabilities, consistent with the classification of the Company&#8217;s Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer based on the stockholder approval from the 2024 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) on September 3, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated Public Warrants, Private Placement Warrants, Consideration Warrants, and Forward Purchase Warrants (the &#8220;Warrants&#8221;) under ASC 815-40, Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders&#8217; equity. Specifically, the settlement value of the Warrants is dependent, in part, on the holder of the Warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on our Common Stock, the Warrants fail the indexation guidance in ASC 815-40, which would preclude classification in stockholders&#8217; equity. Additionally, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#8217;s Common Stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Because not all of the Company&#8217;s stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Warrants do not meet the conditions to be classified in equity. Since the Warrants meet the definition of a derivative under ASC 815, the Company recorded these Warrants as liabilities on the balance sheet at fair value upon the closing of the Merger, with subsequent changes in their respective fair values recognized in the consolidated statement of operations and comprehensive loss at each reporting date. The fair value of Consideration, Public, and Forward Purchase Warrants was determined using the closing price of the publicly traded warrants on the NYSE market.  The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (see Note 4).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_RevenueRecognitionPolicyPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">n.	Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies ASC Topic 606, "Revenue from Contracts with Customers" ("ASC 606") to account for its revenue transactions.  Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the five-step model. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.  Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.  Accounts receivable represent amounts invoiced and revenues recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangement</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">o.	Collaborative Arrangement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, the FASB issued Topic 808, "Collaborative Arrangements" ("ASC 808"): Clarifying the Interaction between ASC 808 and ASC 606. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard for all periods presented. The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. The Company assessed and determined that none of the collaboration agreements entered into during the periods presented were within the scope of ASC 808, as all of the agreements did not involve active participation by both parties in a joint research activity, and therefore did not qualify as collaborative arrangements under ASC 808.  The Company has determined that all the elements of the above collaborations are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. The Company recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.  The Company's collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from the portion of the transaction price allocated to the license at a point in time, when the license is transferred to the customer and the customer is able to benefit from the license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs based on the use of an input method.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A customer's right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or a discount. Optional future services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. The optional future services do not include a material right to be accounted for as performance obligations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's collaboration agreements include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company's collaboration agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company receives payments from its customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until the Company performs its obligations under the arrangement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a complete discussion of accounting for revenue, see Note 5, "Collaboration and License Agreements."</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Costs to Fulfill a Contract with a Customer</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">p.	Costs to Fulfill a Contract with a Customer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not capitalized any costs for the years ended December 31, 2024 and 2023.  The Company is required to capitalize costs incurred to fulfill customer contracts. These costs are required to be amortized to expense on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates, compared to previously being expensed as incurred. Elements of the costs primarily include (i) payroll and other related costs of personnel related directly to the contract activities; (ii) costs related to pre-clinical testing and clinical trials such as payments to contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"), investigators, and clinical trial sites that conduct the contract activities; (iv) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses; and (v) other research and development costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">q.	Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in operating lease right-of-use, or ROU assets; current operating lease liabilities; and non-current operating lease liabilities on its balance sheets. The Company currently does not have any finance leases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#8217;s leases generally do not provide an implicit rate. The incremental borrowing rate is reevaluated upon a lease modification. The operating lease ROU asset also includes any initial direct costs and prepaid lease payments made less any lease incentives. The Company considered information available at the adoption date of  Topic 842, "Leases" ("ASC 842") to determine the incremental borrowing rate for leases in existence as of this date. The incremental borrowing rate used was the weighted average rate between secured and unsecured lending arrangement.  Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the option will be exercised. Variable payments included in the lease agreement are expensed as incurred. Lease expense is recognized on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company elected to apply each of the practical expedients described in ASC 842-10-65-1(f) which allow companies not to reassess: (i) whether any expired or existing agreements contain leases, (ii) the classification of any expired or existing leases, and (iii) the capitalization of initial direct costs for any existing leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term operating leases. A short-term operating lease is a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.  The Company also elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">r.	Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s operations are focused on oncology development activities. Substantially all revenues were derived from customers located in China and Japan. For the year ended December 31, 2024, the revenues derived from customers located in China and Japan were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvation's Chief Executive Officer is the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM utilizes the Company&#8217;s strategic product development roadmaps and financial models, as a key input to resource allocation. The CODM is regularly provided with actual, budgeted and forecasted expense information to make decisions on resource</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocation and assess performance of the business and monitor budget versus actual results using income from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant expenses within income from operations, as well as within net income, include cost of revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss. Other segment items within net income include interest income, interest expense, investment advisory fees, change in fair value of warrant liability, realized loss on marketable securities and other expense, net, and income tax expense.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-lived assets consist primarily of property, plant and equipment, net. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of long-lived assets were in the U.S. As of December 31, 2024, no individual country other than the U.S. accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or more of these assets.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">s.	Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred in connection with research and development activities are expensed as incurred. These costs include fees paid to consultants, vendors and various entities that perform certain research and testing on behalf of the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new product compound, as well as pre-commercial milestone payments, are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new product compound did not also include processes or activities that would constitute a "business" as defined under U.S. GAAP, and the product candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval which meet the capitalization criteria would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. If the conditions enabling capitalization of development costs as an asset have not yet been met, all development expenditures are recognized in profit or loss when incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">t.	Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes compensation cost for grants of employee stock options using a fair-value measurement method, that is recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the fair value of stock-based awards that are based only on a service condition using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, volatility, dividend yield, and expected life of the options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines the fair value of stock-based awards that are based on both a service condition and achievement of the first to occur of a market or performance condition using a Monte Carlo simulation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">u.	Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. The difference between the financial statement and tax basis of assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the years in which they are expected to affect taxable income. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of the tax provision. Returns for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years beginning with those filed for the period ended December 31, 2018 are open to federal and state tax examination.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncement</a></td>
<td class="text"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">v.	Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07&#8212;Segment Reporting (Topic 280):  Topic 280 "Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted ASU 2023-07 effective December 31, 2024. The adoption of the guidance did not have a material effect on the Company&#8217;s unaudited condensed consolidated financial statements. See Note 2(r) for further information on Nuvation's segment reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09 &#8211; Income Taxes (Topic 740): "Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. This guidance is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_RevenueRecognitionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_RevenueRecognitionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628901856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules Of Concentration Of Risk By Risk Factor</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customers represent more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.528%;box-sizing:content-box;"></td>
          <td style="width:1.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.437%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.837%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,725</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below customer represents more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company's balances of accounts receivable as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.38%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,610</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">k.	</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628851888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Final Allocable Purchase Price Consists</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The final allocable purchase price consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"></td>
        <td style="width:10.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A Common Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,297</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Non-Voting Convertible Preferred Stock </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assumed share-based awards </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total allocable purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">____________________________</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of the Acquisition Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at as-converted value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)     </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued at the estimated fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2641</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp; Assumed RSUs) attributable to precombination services.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522835984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available-for-Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Marketable securities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have not been any transfers between the levels during the periods.</span><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets:</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,053</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.121%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.189%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,509</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,935</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,628</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,628</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,585</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,585</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets:</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">595,073</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">574,499</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">338</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides the amortized cost, aggregate fair value, and unrealized gains (losses) of marketable securities as of December 31, 2024 and December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.438%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.904%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.684000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,628</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,891</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478,482</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.447%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.687999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,574</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,987</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,988</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">947</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,508</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,509</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,171</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,609</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,628</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">452,813</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,095</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,791</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,585</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,384</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,012</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568,564</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">594,892</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,193</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,012</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">595,073</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock', window );">Schedule of Net Realized Gain (Loss) on Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the activity related to the net gains (losses) on marketable securities included in other income (expense) on the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized gains (losses) on available-for-sale securities were as follows:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized gains from sales of available-for-sale securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized losses from sales of available-for-sale securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net realized losses on marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule Of Available for sale Securities Maturity On Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity information based on fair value of the available-for-sale securities is as follows as of December 31, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.58%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.74%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Within one year</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After one year<br/>through five years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,227</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,295</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,875</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355,170</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,865</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,065</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,930</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384,029</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,940</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466,969</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Marketable Securities with Continuous Unrealized Losses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables provide marketable securities with continuous unrealized losses for less than 12 months and 12 months or greater and the related fair values as of December 31, 2024 and 2023 were as follows:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:34.412%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.219%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.712%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,021</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,099</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,659</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,923</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,010</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:31.295%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.279%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.172%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 Months</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,101</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,101</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government and government agency securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199,552</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">694</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,761</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,313</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,844</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,484</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">246</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236,190</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,245</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">284</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">287,435</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,011</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Available for sale Securities Classified By Contractual Maturity Date Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628923872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CollaborationAndLicenceAgreementAbstract', window );"><strong>Collaboration and Licence Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of revenue recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes total revenue recognized for the years ended December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.14%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.919999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,086</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,873</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule Of Contract Assets And Contract Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contract liabilities of the Company as of December 31, 2024 is listed in the table below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development service revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,689</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue in 2024 that was included in the contract liability balance recorded upon the acquisition of AnHeart.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CollaborationAndLicenceAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and Licence Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CollaborationAndLicenceAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768635121920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computers</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">553</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,460</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,383</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">874</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">666</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">586</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768638177936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued consultant fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,243</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,917</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,818</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,349</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">827</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other taxes</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">679</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,833</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,793</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523368064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Commitments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the future minimum lease analysis of the Company's operating lease liabilities showing the aggregate lease payments as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,767</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">837</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,775</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,632</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522865232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following securities outstanding at December 31, 2024 and 2023 have been excluded from the calculation of weighted average shares outstanding:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,681,182</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787,462</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock options</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,729,709</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,649,239</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,420,131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530932304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (loss) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive (loss) Income</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a rollforward of the changes in accumulated other comprehensive (loss) income for the years ended December 31, 2024 and 2023, which is all attributable to unrealized gains (losses) on available-for-sale securities. All amounts are net of tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at beginning of period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,526</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amount reclassified for realized loss on marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency translation adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768529575552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock-based compensation expense included in the Company&#8217;s Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,450</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,797</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,825</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,275</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,513</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity for the restricted stock units assumed in the AnHeart acquisition for the year ended December 31, 2024.</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.92%;box-sizing:content-box;"></td>
        <td style="width:9.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs assumed for the acquisition of AnHeart</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,201,694</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">618,340</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or canceled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,420,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Options with Service, Market, and Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity with combined service, market, and performance conditions for employees for the year ended December 31, 2024 is as follows:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Issuable<br/>Pursuant to<br/>Stock Options</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic<br/>Value (in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,815,194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.31</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,042</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,921,152</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.74</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748,375</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.91</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Grant-date Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the stock options granted with combined service, market, and performance conditions was based on a Monte Carlo simulation with an embedded Black-Sholes pricing model. For the years ended December 31, 2024 and 2023, the fair value was computed using the following assumptions:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.3%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:14.86%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.61</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.94</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.27</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.17</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.30</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember', window );">Options with Service Conditions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity with service condition only for employees and members of the Company&#8217;s Board of Directors for the year ended December 31, 2024 is as follows:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares Issuable<br/>Pursuant to<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic<br/>Value (in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,834,045</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.51</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options assumed for acquisition of AnHeart</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,742,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,175,083</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,750,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,192,263</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,808,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.72</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,475</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,245,561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.43</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Grant-date Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock options granted with only service conditions during the years ended December 31, 2024 and 2023, the inputs in the Black-Scholes option-pricing model to determine the fair value is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.287%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:14.857%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:14.857%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.08</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.61</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.94</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.63</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.74</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.47</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523951920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_WarrantDisclosureAbstract', window );"><strong>Warrant Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides quantitative assumptions regarding Level 3 fair value measurements:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:62.04%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Strike price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137.5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Fair Values for Outstanding Warrants</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined the following fair values for the outstanding Warrants (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Public Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,102</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forward Purchase Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consideration Warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">665</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,053</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following presents changes in liabilities classified in Level 3 of the fair value hierarchy for the year ended December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of Private Warrants liability recognized in earnings</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_WarrantDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_WarrantDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768637548608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax Provision</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the net deferred tax asset as of December 31, 2024 and 2023 are as follows:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,698</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,290</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,379</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,133</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs*</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,294</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,156</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,172</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,307</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,116</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,124</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,035</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,589</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,412</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">853</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">931</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,591</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,444</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">931</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,145</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,481</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">24.8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 59(e) and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">70.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 174.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of the Federal Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate for the years ended December 31, 2024 and 2023 are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes, net of federal tax benefit</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.06</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.84</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.65</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.33</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.05</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">True-up</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.42</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other items</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.66</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.26</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the activity related to the unrecognized tax benefits were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,068</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross increases - current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross decreases - prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526288704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (910,743)<span></span>
</td>
<td class="num">$ (342,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (130,413)<span></span>
</td>
<td class="num">(67,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
<td class="text">the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#8217;s Common Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 502,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">5,787,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,402<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember', window );">AnHeart [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue From Contract With Customer Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue From Contract With Customer Including Assessed Tax</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue From Contract With Customer Including Assessed Tax</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_PercentageOfLongLivedAssets', window );">Percentage of long-lived assets</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nuvb_OtherThanUnitedStateMember', window );">Other than U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_PercentageOfLongLivedAssets', window );">Percentage of long-lived assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">5,787,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue Net [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ConcentrationRiskThresholdPercentage', window );">Concentration Risk Threshold Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ConcentrationRiskThresholdPercentage', window );">Concentration Risk Threshold Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">4,791,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">162,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember', window );">Forward Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember', window );">Consideration Warrants [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">2,893,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_FairValueOfWarrantsTradingPrice', window );">Fair Value O fWarrants Trading Price</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_FairValueOfWarrantsTradingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants, Trading Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_FairValueOfWarrantsTradingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_PercentageOfLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Long Lived Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_PercentageOfLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summaryof Significant Accounting Policies Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nuvb_OtherThanUnitedStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nuvb_OtherThanUnitedStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530287680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Concentration of Credit Risk Net Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=nuvb_CustomerAMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue From Contract With Customer Including Assessed Tax</a></td>
<td class="nump">5,148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=nuvb_CustomerBMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue From Contract With Customer Including Assessed Tax</a></td>
<td class="nump">2,725<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="nump">$ 12,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=nuvb_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=nuvb_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=nuvb_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=nuvb_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530840816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 03, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember', window );">AnHeart [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired', window );">Research and development asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,646,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of preferred stock to Common Stock related to the AnHeart acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,120,200<span></span>
</td>
<td class="nump">85,120,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | AnHeart [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">27,646,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | AnHeart [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">851,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | AnHeart [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of preferred stock to Common Stock related to the AnHeart acquisition</a></td>
<td class="nump">85,120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530583920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Schedule of Final Allocable Purchase Price Consists (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AllocablePurchasePrice', window );">Total allocable purchase price</a></td>
<td class="nump">$ 397,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AllocablePurchasePrice', window );">Total allocable purchase price</a></td>
<td class="nump">89,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AllocablePurchasePrice', window );">Total allocable purchase price</a></td>
<td class="nump">274,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nuvb_ConsiderationWarrantsMember', window );">Consideration Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AllocablePurchasePrice', window );">Total allocable purchase price</a></td>
<td class="nump">764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nuvb_AssumedShareBasedAwardsMember', window );">Assumed Share Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AllocablePurchasePrice', window );">Total allocable purchase price</a></td>
<td class="nump">24,818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_AcquisitionRelatedCostsMember', window );">Acquisition Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_AllocablePurchasePrice', window );">Total allocable purchase price</a></td>
<td class="nump">$ 7,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of the Acquisition Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at as-converted value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued at the estimated fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2641</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp; Assumed RSUs) attributable to precombination services.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_AllocablePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocable Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_AllocablePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nuvb_ConsiderationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nuvb_ConsiderationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nuvb_AssumedShareBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nuvb_AssumedShareBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522869952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Schedule of Final Allocable Purchase Price Consists (Parenthetical) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued Price Per Share</a></td>
<td class="nump">$ 3.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants', window );">Stock and Warrants Issued During Period Share Preferred Stock and Warrants | shares</a></td>
<td class="nump">2,893,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_EstimatedFairValueWarrantPerShare', window );">Estimated Fair Value Warrant Per Share</a></td>
<td class="nump">$ 0.2641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="nump">27,646,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued Price Per Share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="nump">851,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued Price Per Share</a></td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_EstimatedFairValueWarrantPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Warrant Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_EstimatedFairValueWarrantPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and Warrants Issued During Period Share Preferred Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768636168864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued Price Per Share</a></td>
<td class="nump">$ 3.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period, shares | shares</a></td>
<td class="nump">27,646,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued Price Per Share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525685696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Marketable securities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 11,549<span></span>
</td>
<td class="nump">$ 26,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">466,969<span></span>
</td>
<td class="nump">568,564<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TotalFinancialAssets', window );">Total financial assets</a></td>
<td class="nump">478,518<span></span>
</td>
<td class="nump">595,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrants</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">20,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TotalFinancialAssets', window );">Total financial assets</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">20,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrants</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">466,969<span></span>
</td>
<td class="nump">568,564<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TotalFinancialAssets', window );">Total financial assets</a></td>
<td class="nump">466,969<span></span>
</td>
<td class="nump">574,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TotalFinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrants</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">355,170<span></span>
</td>
<td class="nump">453,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">355,170<span></span>
</td>
<td class="nump">453,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">80,930<span></span>
</td>
<td class="nump">81,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">80,930<span></span>
</td>
<td class="nump">81,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">18,227<span></span>
</td>
<td class="nump">23,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">18,227<span></span>
</td>
<td class="nump">23,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember', window );">Certificate of deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">12,642<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember', window );">Certificate of deposits [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember', window );">Certificate of deposits [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">12,642<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember', window );">Certificate of deposits [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">20,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">20,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_TotalFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total financial assets:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_TotalFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768531256720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 478,482<span></span>
</td>
<td class="nump">$ 594,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">478,518<span></span>
</td>
<td class="nump">595,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">26,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">26,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency securities [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">20,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">20,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember', window );">Marketable securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">466,933<span></span>
</td>
<td class="nump">568,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">466,969<span></span>
</td>
<td class="nump">568,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember', window );">Marketable securities [Member] | U.S. government and government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">355,214<span></span>
</td>
<td class="nump">452,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">355,170<span></span>
</td>
<td class="nump">453,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember', window );">Marketable securities [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">80,891<span></span>
</td>
<td class="nump">81,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">80,930<span></span>
</td>
<td class="nump">81,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember', window );">Marketable securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,200<span></span>
</td>
<td class="nump">23,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">18,227<span></span>
</td>
<td class="nump">23,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember', window );">Marketable securities [Member] | Certificate of deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,628<span></span>
</td>
<td class="nump">10,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 12,642<span></span>
</td>
<td class="nump">$ 10,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvb_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526151504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Net Realized Gain (Loss) on Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossAbstract', window );"><strong>Realized gains (losses) on available-for-sale securities were as follows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains from sales of available-for-sale securities</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses from sales of available-for-sale securities</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract', window );"><strong>Net gains (losses) on equity securities were as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Net realized losses on marketable securities</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (139)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526542640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available-for-Sale - Schedule of Marketable Securities with Continuous Unrealized Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 131,923<span></span>
</td>
<td class="nump">$ 236,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">55,010<span></span>
</td>
<td class="nump">51,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Unrealized Losses</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</a></td>
<td class="nump">186,933<span></span>
</td>
<td class="nump">287,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">(560)<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember', window );">Certificate of deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">111,021<span></span>
</td>
<td class="nump">199,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">45,099<span></span>
</td>
<td class="nump">24,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Unrealized Losses</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</a></td>
<td class="nump">156,120<span></span>
</td>
<td class="nump">224,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">20,659<span></span>
</td>
<td class="nump">21,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">9,911<span></span>
</td>
<td class="nump">26,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Unrealized Losses</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</a></td>
<td class="nump">30,570<span></span>
</td>
<td class="nump">48,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (274)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525646192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities Available For Sale - Schedule Of Available for sale Securities Maturity on Fair Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-Sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due With in one year, Amortized Cost</a></td>
<td class="nump">$ 384,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">82,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">466,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-Sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due With in one year, Amortized Cost</a></td>
<td class="nump">52,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">28,065<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">80,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-Sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due With in one year, Amortized Cost</a></td>
<td class="nump">300,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">54,875<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">355,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-Sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due With in one year, Amortized Cost</a></td>
<td class="nump">18,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">18,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember', window );">Certificate of deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-Sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due With in one year, Amortized Cost</a></td>
<td class="nump">12,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">$ 12,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvb_CertificateOfDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768635244944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of revenue recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 7,873<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvb_LicenseRevenueMember', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember', window );">Research and development service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvb_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvb_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525254208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,873<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,119<span></span>
</td>
<td class="nump">71,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,722<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription', window );">Revenue, performance obligation satisfied over time, method used, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company expects to recognize all of this balance as revenue as research and development services are provided over the next 4 years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ContractWithCustomerAssets', window );">Contract Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_MilestonesRequirePayments', window );">Milestones require payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_NumberOfMilestones', window );">Number of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">two<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nuvb_InnoventMember', window );">Innovent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_RepaymentsOfNonRefundableUpfrontCashPayment', window );">Repayments of NonRefundable Upfront Cash Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ReceivedNonRefundableUpfrontCashPayment', window );">Received a non-refundable upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Achievement of commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nuvb_NkMember', window );">Nk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ReceivedNonRefundableUpfrontCashPayment', window );">Received a non-refundable upfront cash payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Achievement of commercial milestones</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember', window );">AnHeart [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember', window );">Research and development service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember', window );">Research and development service revenue | Innovent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_OwedMilestonePayments', window );">Company is owed in milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember', window );">Research and development service revenue | Nk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member] | Innovent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ContractWithCustomerAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ContractWithCustomerAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_MilestonesRequirePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones Require Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_MilestonesRequirePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_OwedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Owed Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_OwedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ReceivedNonRefundableUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received NonRefundable Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ReceivedNonRefundableUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_RepaymentsOfNonRefundableUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of NonRefundable Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_RepaymentsOfNonRefundableUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nuvb_InnoventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nuvb_InnoventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nuvb_NkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nuvb_NkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nuvb_AnheartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526893552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule Of Contract Assets And Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="nump">$ 11,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember', window );">Research and development service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="nump">$ 26,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nuvb_ResearchAndDevelopmentServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526120320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 04, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nuvb_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short term borroing</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Fixed interest rate on borrowings</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_BankLoans', window );">Short term bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LongTermBorroing', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ShortTermWorkingCapital', window );">Short term working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Outstanding line of credit balance net</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Loan And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Long term debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  04,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Loan And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Long term debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyMember', window );">Borrowing in 2020 [Member] | Loan Agreements With Bank Of Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-term borrowings outstanding balance</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ShortTermBorrowingsDrawnDown', window );">Short term borrowings drawn down</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short term borroing</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyMember', window );">Borrowing in 2020 [Member] | Loan Agreements With China Merchants Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short term borroing</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Fixed interest rate on borrowings</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyMember', window );">Borrowing in 2020 [Member] | Maximum [Member] | Loan Agreements With Bank Of Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Fixed interest rate on borrowings</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyMember', window );">Borrowing in 2020 [Member] | Minimum [Member] | Loan Agreements With Bank Of Hangzhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Fixed interest rate on borrowings</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyTwoMember', window );">Borrowing in 2022 [Member] | Loan Agreements With China Merchants Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingLineItems', window );"><strong>Subordinated Borrowing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-term borrowings outstanding balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_LongTermBorroing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Borroing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_LongTermBorroing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ShortTermBorrowingsDrawnDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Borrowings Drawn Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ShortTermBorrowingsDrawnDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ShortTermWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ShortTermWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_BankLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term bank loan secured by broker-dealer customer's security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_BankLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nuvb_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nuvb_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nuvb_LoanAgreementsWithBankOfHangzhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nuvb_LoanAgreementsWithBankOfHangzhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nuvb_LoanAgreementsWithChinaMerchantsBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nuvb_LoanAgreementsWithChinaMerchantsBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingAxis=nuvb_BorrowingTwoThousandsAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530569264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,460<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(874)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment,net</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523408336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526098944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued consultant fees</a></td>
<td class="nump">$ 16,243<span></span>
</td>
<td class="nump">$ 4,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Accrued employee compensation</a></td>
<td class="nump">14,818<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued other taxes</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued other</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities, Total</a></td>
<td class="nump">$ 32,833<span></span>
</td>
<td class="nump">$ 9,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628789632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
<td class="text">the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#8217;s Common Stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768524049616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | $</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease Expense | $</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating leases | $</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nuvb_NewYorkCityMember', window );">New York City [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LeaseAdditionalTerm', window );">Lease additional term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LesseeOperatingLeaseExpirationYear', window );">Operating lease expiration year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nuvb_SanFranciscoMember', window );">San Francisco, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="nump">19,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LesseeOperatingLeaseExpirationYear', window );">Operating lease expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | ft&#178;</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_LesseeOperatingLeaseExpirationYear', window );">Operating lease expiration year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space | m&#178;</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_LeaseAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease additional term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_LeaseAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_LesseeOperatingLeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_LesseeOperatingLeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nuvb_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nuvb_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nuvb_SanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nuvb_SanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530798768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Aggregate Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530932128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">337,837,872<span></span>
</td>
<td class="nump">219,046,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">337,837,872<span></span>
</td>
<td class="nump">219,046,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">336,837,872<span></span>
</td>
<td class="nump">218,046,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">336,837,872<span></span>
</td>
<td class="nump">218,046,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement', window );">Number of Shares Decreased Subject to Repurchase Under Stock Restriction Agreement</a></td>
<td class="nump">1,101,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock Repurchased During Period, Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage of outstanding shares</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment Ownership Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nuvb_ClassAAndClassBCommonStockMember', window );">Class A And Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationControlObtainedDescription', window );">Business Combination, Control Obtained Description</a></td>
<td class="text">Holders of Class A and Class B common stock are entitled to one vote per share on all matters, except that the holders of Class A common stock do not participate in the election of the directors who are elected exclusively by the holders of Class B common stock. Holders of Class A and Class B common stock vote together as a single class on all matters, except that (i) the holders of Class B common stock have the right, voting as a separate class, to elect and remove without cause three directors plus at least 50% of any directors in excess of seven, and (ii) the approval of the holders of a majority of Class B common stock, voting as a separate class, is required for approval by the stockholders of any acquisition (whether by merger, sale of shares or sale of assets) or liquidation. There are no cumulative voting rights.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred Stock, Convertible, Shares Issuable</a></td>
<td class="nump">43,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">one vote per share on all matters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares decreased subject to repurchase under stock restriction agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationControlObtainedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of how the entity obtained control of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationControlObtainedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nuvb_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nuvb_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nuvb_ClassAAndClassBCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nuvb_ClassAAndClassBCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526145760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities outstanding excluded from calculation of weighted average shares outstanding</a></td>
<td class="nump">8,681,182<span></span>
</td>
<td class="nump">5,787,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities outstanding excluded from calculation of weighted average shares outstanding</a></td>
<td class="nump">57,729,709<span></span>
</td>
<td class="nump">30,649,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities outstanding excluded from calculation of weighted average shares outstanding</a></td>
<td class="nump">1,420,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768524955664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income - Schedule of Changes in Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at beginning of period</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="num">$ (5,526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss)</a></td>
<td class="num">(157)<span></span>
</td>
<td class="nump">5,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_RealizedLossOnMarketableSecurities', window );">Amount reclassified for realized loss on marketable securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CurrencyTranslationAdjustmentValue', window );">Currency translation adjustment</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance at end of period</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CurrencyTranslationAdjustmentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency Translation Adjustment Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CurrencyTranslationAdjustmentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_RealizedLossOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized loss On Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_RealizedLossOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530617264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Shares based weighted average grant-date fair value of stock options</a></td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (1) 4.0% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31 of the preceding year, or (2) a lesser number of shares of Class A common stock determined by our board of directors prior to the date of the increase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Number of common stock outstanding or issuable, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvb_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">The number of shares of Class A common stock reserved for issuance under the 2021 ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by 1.0% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31st of the preceding calendar year or such lesser number of shares of Class A common stock as determined by our board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Number of common stock outstanding or issuable, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based option granted vest period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Shares based option granted expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Maximum [Member] | 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement', window );">Number of common shares issuable under the plan (in shares)</a></td>
<td class="nump">50,684,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">152,052,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Maximum [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement', window );">Number of common shares issuable under the plan (in shares)</a></td>
<td class="nump">4,750,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based option granted vest period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SharesBasedStockOptionGrantedVestingPercentage', window );">Shares Based Stock Option Granted Vesting Percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based option granted vest period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SharesBasedStockOptionGrantedVestingPercentage', window );">Shares Based Stock Option Granted Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based option granted vest period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_SharesBasedStockOptionGrantedVestingPercentage', window );">Shares Based Stock Option Granted Vesting Percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceMarketAndPerformanceConditionMember', window );">Options with Service Market And Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Shares based weighted average grant-date fair value of stock options</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod', window );">Share Based Compensation Arrangement By Share Based By Weighted Average Period</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Shares based weighted average grant-date fair value of stock options</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod', window );">Share Based Compensation Arrangement By Share Based By Weighted Average Period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember', window );">Options with Service Conditions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="nump">$ 48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod', window );">Share Based Compensation Arrangement By Share Based By Weighted Average Period</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable under share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedByWeightedAveragePeriod</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_SharesBasedStockOptionGrantedVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Based Stock Option Granted Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_SharesBasedStockOptionGrantedVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceMarketAndPerformanceConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceMarketAndPerformanceConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525294016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 32,275<span></span>
</td>
<td class="nump">$ 19,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">16,450<span></span>
</td>
<td class="nump">8,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 15,825<span></span>
</td>
<td class="nump">$ 10,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526600832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember', window );">Options with Service Conditions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share option outstanding, Beginning balance | shares</a></td>
<td class="nump">26,834,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Options assumed for acquisition of AnHeart | shares</a></td>
<td class="nump">13,742,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share option, Granted | shares</a></td>
<td class="nump">20,175,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share option, Forfeited or canceled | shares</a></td>
<td class="num">(1,750,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share option, Exercised | shares</a></td>
<td class="num">(5,192,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share option outstanding, Ending balance | shares</a></td>
<td class="nump">53,808,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share option exercisable, Ending balance | shares</a></td>
<td class="nump">24,245,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 3.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options assumed for acquisition of AnHeart | $ / shares</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">4.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">0.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2021 | $ / shares</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding at December, 2021</a></td>
<td class="text">7 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021</a></td>
<td class="text">6 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at December 31, 2021 | $</a></td>
<td class="nump">$ 32,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2021 | $</a></td>
<td class="nump">$ 18,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Options with Service, Market, and Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share option outstanding, Beginning balance | shares</a></td>
<td class="nump">3,815,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share option, Granted | shares</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share option, Forfeited or canceled | shares</a></td>
<td class="num">(144,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share option outstanding, Ending balance | shares</a></td>
<td class="nump">3,921,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share option exercisable, Ending balance | shares</a></td>
<td class="nump">748,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 6.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">3.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">6.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2021 | $ / shares</a></td>
<td class="nump">$ 6.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding at December, 2021</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021</a></td>
<td class="text">5 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at December 31, 2021 | $</a></td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2021 | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530938848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Grant-date Fair Value of Stock Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember', window );">Options with Service Conditions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember', window );">Options with Service Conditions [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.74%<span></span>
</td>
<td class="nump">4.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember', window );">Options with Service Conditions [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.63%<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Options with Service, Market, and Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Options with Service, Market, and Performance Conditions | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Options with Service, Market, and Performance Conditions | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">6 years 5 months 26 days<span></span>
</td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nuvb_OptionsWithServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530822480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units RSU [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested at December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Options assumed for acquisition of AnHeart</a></td>
<td class="nump">2,201,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="num">(618,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited or canceled</a></td>
<td class="num">(163,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested at December 31, 2024</a></td>
<td class="nump">1,420,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628952000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) PLAN - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum Annual Contributions Per Employee, Amount</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526061200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">5,787,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitChangeInFairValueGainLoss', window );">Change in Fair Value, Gain (Loss) | $</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription', window );">Fair Value Equity Level1 To Level2 or Level3 Transfers Description</a></td>
<td class="text">no<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 3.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">4,791,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">162,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember', window );">Forward Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">833,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">5,787,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Aggregate warrants outstanding</a></td>
<td class="nump">8,681,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Consideration Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">2,893,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Equity Level1 To Level2 or Level3 Transfers Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitChangeInFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from (increase) decrease in fair value of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Excludes change attributable to instrument-specific credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480112/944-40-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitChangeInFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628910960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of Warrants</a></td>
<td class="nump">$ 936<span></span>
</td>
<td class="num">$ (497)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Strike price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">137.50%<span></span>
</td>
<td class="nump">82.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525009952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Schedule of Fair Values for Outstanding Warrants (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair values of outstanding warrants</a></td>
<td class="nump">$ 2,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair values of outstanding warrants</a></td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair values of outstanding warrants</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember', window );">Forward Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair values of outstanding warrants</a></td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember', window );">Consideration Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair values of outstanding warrants</a></td>
<td class="nump">$ 665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_ForwardPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nuvb_ConsiderationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526051984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy', window );">Beginning balance</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings', window );">Change in fair value of Private Warrants liability recognized in earnings</a></td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy', window );">Ending balance</a></td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of private warrants liability recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in liabilities classified in Level 3 of fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523371552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>State</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current and deferred state and local tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768530354000">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Summary of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax asset</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 107,698<span></span>
</td>
<td class="nump">$ 29,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,379<span></span>
</td>
<td class="nump">13,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">97,294<span></span>
</td>
<td class="nump">49,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,172<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_DeferredTaxAssetsLeaseLiability', window );">Lease Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">930<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">242,589<span></span>
</td>
<td class="nump">101,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(853)<span></span>
</td>
<td class="num">(931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,591)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,444)<span></span>
</td>
<td class="num">(931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(238,145)<span></span>
</td>
<td class="num">(100,481)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">24.8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 59(e) and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">70.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 174.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525269680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxe - Summary of Net Deferred Tax Assets (Parenthetical) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nuvb_InternalRevenueCode59Member', window );">IRC 59 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalized expenditures</a></td>
<td class="nump">$ 24.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nuvb_InternalRevenueCode174Member', window );">IRC 174 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalized expenditures</a></td>
<td class="nump">$ 70.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nuvb_InternalRevenueCode59Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nuvb_InternalRevenueCode59Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nuvb_InternalRevenueCode174Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nuvb_InternalRevenueCode174Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768525196512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Reconciliation of the Federal Income Tax Rate to the Company's Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="nump">5.06%<span></span>
</td>
<td class="nump">4.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent', window );">Acquired IPR&amp;D</a></td>
<td class="num">(19.65%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock based compensation</a></td>
<td class="num">(0.31%)<span></span>
</td>
<td class="num">(1.33%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Tax credits</a></td>
<td class="nump">0.72%<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_EffectiveIncomeTaxRateReconciliationTrueUp', window );">True-up</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="num">(3.42%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent', window );">Acquisition</a></td>
<td class="nump">10.25%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in rate</a></td>
<td class="nump">6.49%<span></span>
</td>
<td class="num">(4.41%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other items</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(24.26%)<span></span>
</td>
<td class="num">(19.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Acquired IPR&amp;D, Other, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Acquisition Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_EffectiveIncomeTaxRateReconciliationTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation True Up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_EffectiveIncomeTaxRateReconciliationTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768526141680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_OperatingLossCarryforwardsExpiration', window );">Net operating losses carried forward expiration year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TaxCreditCarryforwardsExpiration', window );">Tax Credit Carryforwards Expiration</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 7,391<span></span>
</td>
<td class="nump">$ 5,629<span></span>
</td>
<td class="nump">$ 5,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=nuvb_OrphanDrugTaxCreditCarryforwardMember', window );">Orphan Drug Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and state net operating loss carryovers</a></td>
<td class="nump">270,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and state net operating loss carryovers</a></td>
<td class="nump">194,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Orphan Drug Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvb_TaxCreditCarryforwardsExpiration', window );">Tax Credit Carryforwards Expiration</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_OperatingLossCarryforwardsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_OperatingLossCarryforwardsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvb_TaxCreditCarryforwardsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforwards expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvb_TaxCreditCarryforwardsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=nuvb_OrphanDrugTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=nuvb_OrphanDrugTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768522792176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of unrecognized tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Beginning Balance</a></td>
<td class="nump">$ 5,629<span></span>
</td>
<td class="nump">$ 5,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases - current year tax positions</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases - prior year tax positions</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">$ 7,391<span></span>
</td>
<td class="nump">$ 5,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768628891744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - Standby Letter of Credit [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Letter of Credit, Amount</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment', window );">Line of credit facility, frequency of commitment fee payment</a></td>
<td class="text">annually<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of when the fee for available but unused credit capacity is required to be paid (for example, annually, quarterly, or monthly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45768523947936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Additional Information) (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">RoyaltyExpense</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_SagardHealthcarePartnersMember', window );">Sagard Healthcare Partners</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">250.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvb_FoodAndDrugAdministrationApprovalMember', window );">FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvb_SagardHealthcarePartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvb_SagardHealthcarePartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvb_FoodAndDrugAdministrationApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvb_FoodAndDrugAdministrationApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX/LI8W+]1IV@>@;.U?\ 4$L#!!0    ( +F)9EJ:,8<CLP8  &D;   8
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M56B[5MF3IN1O\@][;_MX;T[FCJ+55Z?20+1#$71<?[ILZ#G>GOYTE&T=K1)
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M CP6><FO)QLAMI>S&4\VI,#\@FY)*?]9459@(2_9>L:WC."T;E3D,^0XP:S
M63F97]7W[MC\BE8BSTIRQP"OB@*SIQN2T_WU!$X.-[YDZXU0-V;SJRU>DWLB
MOFWOF+R:=5[2K" ESV@)&%E=3S[ RX6+5(/:XN^,[/G1;Z!"65+ZH"YNT^N)
MHQ21G"1"N<#R:T<6),^5)ZGC1^MTTCU3-3S^??#^J0Y>!K/$G"QH_CU+Q>9Z
M$DU 2E:XRL47NO^=M 'YRE]"<UY_@GUKZTQ 4G%!B[:Q5%!D9?.-']N..&H
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MTSC?_TN>#\<J$[+<Y46Z.027+=A$2?TS_'8X$2<!5#T3P X!K!7 S#,!ZB%
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M2R(5V+1*ZX3*NGTVR8583>S,=DC[[^='R&@5T#3M"[&O[SGWG(M]XY;Q)U$
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MX??DT\=W;R_>OKY,LD7R,K.%3>IU\@GW5;49,=*7K0%F6M6[?58=$)9575D
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M)P)$HLC6:WP-#\T+!( -C$->V4,,E)H7+$,O.]AWC$F3$B)Q[1B9OQ$&=$J
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M1@,4G4[U[L%S X^7_O[U!!X?+-K5I;%B6.VR/X H6A( *T5!/P!!Z,4$!-I
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M'XE16@Y!:MZ ;XE:Q]@<$MD5:*Q@%0-%<O72:2J5Q1*E)6Z6"X1VK&9#N5T
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M:T[N<L>U.5THY/W91!? "@K6JF#G2_]&JU*=')0>&T0@>L4[B!GAKUE$WC=
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M9UQ*\%T4*YV"AL@I99H%6Q@DY4/Q= 1<N2+:FIV4(XV .Y;-LS&)*H)Q98R
M4L]'-10X:B]7C7V/0;T,=12;5%0+=@;%)H)+C!_W,D0NGWIC+C#9)-3-_MM0
M.3J;0E$<;8E;0_=V@Z>0>LL[]0U(/.8F T+2D"=VNC'@P;WOO*028ZB>VN/
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MM(6\;3(*%"N8AF%+X]2#P&CYT,7PJIIE.NF$!5+>-5RD\AEV'6U*>PN5(='
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MF_1)"$@]UQC$4Z[^^$,6B!*AL)F_;V)E)C.&(A3P.NPZF42@**A E\U4"CR
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M-XU#2;JT]Y#"A<8-+/^J^$H#A^C.D9+5D_6]M>-[&$?5OWM-Y]KKC$S)-$S
MR4SB*&*Y%=6S:&4;L:^:45'WFB][.M<2ZQ;3R(TUS@61+FQJN1'G$S(Z$K10
MBBJ\6[1OVV/+0[9@F5IY0L)UX_B@/Q2YSC*F.NAPHU::AIZLE0O?O<)I+Z&;
M7)H@07[.*:FZ59DI@V<8'6Y4<?:4&5(C 8V,-*]\!3)73H7+HV<(57>E*IQR
M$:&RNAQXJ'^!G1F)=8:A*UU!3SX,D] (S9&BQ)QZ(%/R;#*8\B<P(T:\8[(6
M]6>+^B)!NZ[SUS%](:#0I%6(+NK6/4>9(I=\K55G3-J3[BO8@P7=8<F9SEB!
M]FC0M+^=*[\7XF#4/VIVZF^Z]=[O?(O(J2NA+RYT2 ;#PV>)=K3]J#,-WS)6
MT\,7H?<@AD9\96J.I0.4DUXX634/WI3\96-FO#<Y_UP@%I2E"7@_-\8W#[1!
M^ZGK_+]02P,$%     @ N8EF6E.3:WPK"P  XB(  !D   !X;"]W;W)K<VAE
M971S+W-H965T,34N>&ULU5I;;QLW%G[7KR#4HAL#$WNNDL9-#-B)TP8;9P,[
M3E$L]H&:H20V<U%(CA7WU^\Y)&>&DD9JG2T*[(LTY)"'Y_+Q?(>47FQJ\5FN
M&%/D:UE4\N5XI=3Z_.Q,9BM64GE:KUD%;Q:U**F"IEB>R;5@-->3RN(L]/W)
M64EY-;YXH?L^B(L7=:,*7K$/@LBF+*EXO&)%O7DY#L9MQRU?KA1VG%V\6-,E
MNV/J?OU!0.NLDY+SDE62UQ41;/%R?!F<7\4X7@_XQ-E&.L\$+9G7]6=LO,U?
MCGU4B!4L4RB!PM<#>\6* @6!&E^LS'&W)$YTGUOI;[3M8,N<2O:J+G[AN5J]
M',_&)&<+VA3JMM[\S*P]"<K+ZD+J3[(Q8R?IF&2-5'5I)X,&):_,-_UJ_>!,
MF/D')H1V0JCU-@MI+5]312]>B'I#!(X&:?B@3=6S03E>85#NE("W'.:IBS>4
M"_*)%@TC-XS*1C#PN)*$5CFYH>(S4W1>,'+'LD9PQ9DDEP^4%]CY'"#Q_(X6
M[,69 DU0WEEF5[TRJX8'5@U"<E-7:B7)=96S?%O &9C0V1&V=ER%1R6^9MDI
MB0*/A'X8'Y$7=7Z)M+SHC_WRFLNLJ-$UDOS[<BZ5 "C]9\AH(S(>%HG;ZURN
M:<9>CF'_2"8>V/CBA^^"B?_C$87C3N'XF/3_)9 $ DD.!?+HJL,VO?_7QVL2
MGY(WEV]OR:?+=_?7Y.;Z\N[^]OKF^OW'.W+Y_C6YN;S]Y_7'RZMWU^3N^M7]
M[=N/;Z_OR,<5(Z_J<DVK1[(6]0//0<^\\S^I%V3!*UIEG!:$2LFL@7UGP>F<
M%\9 M:**4)B642$XRPDT%^BF!^TFW,PY@<R@8-6UX!DS,S9U4^1DSB#G9 Q2
M1DZ:-8R2X"!4@%9F90).6U.>$U43@$0E%TP0VBGP2'B%8VN1,U$\FB'4I*(Y
M4QO&*MC'&!>0(A3/.%B-YBBM3]G'D.14,?!FKWGI!KBDCZAL5H!6?(%F;AE&
MR[H!&:"X;.:_82Y\0.5@< T.4S!PP]5*#^75N@&!8$_G):KUA<GP7C+7Y:ZC
M&\FKI1:QJ M(\Z8E&",%>V"%/"?O\)L$Y(?O9F$0_DC>FJ4P.$U%\]\@T8$F
M7YH:OW0LI/:?SMG63U+C%"!1@;?Z^$/?7M"5@Z,5E<81-BQ@'LU _A%7&VW#
M76UYE15-SG;41*4D+V$KB4/^V;/$&Y#1&[8O<,=&7G4NZ3!>U<HNXK6!K,$Z
M@2.JG>6Z2?4<MVR7 [2;6FSW0'[&3]DI2E4,]K@B IP$)CQR!OL$TLD#MIC*
M3D^TY2V,VD4 _WH7P>(5HKR W; 0=8F+9+40];P6&HCS1U<ANSD@(A3?X$A6
M6#P*:QN$KI+DF1VZ)<QH<=(&,^J">5\YB[BZ0CF M8(+'CUG^J,D8#8OT6R[
M%]!-3;E&;>SLH;UL,DDC<1WM^W:;[#OY="OWY:ASO99VVUDMM_;U'"/!*U.6
MZ?JF3>>>!2HNQA$&FTI[T2SA[%#M 9VV*XUN1]8<ZK=!1Y0]E<B>2C#L./H7
M2+1@N8,=JCT&[,S*.02L96@] QXBK]U^N]D9M< ,W$#J!F7!=@XH,_C*89LH
M9K:U,V7%F: B6SVV0>HSF&+9JN)?&CNI]7.C0,O?F<[A.0-X0X4%AC79RI&[
M%9K.$;NF:C<(UB8)DU:YB56;_5#[%HY#>ML(.4Y86'6A"(9MI&WQR(=F7O!,
M2X/*=$-%#ETP'^#1J@7AE+U%N9.AD4KQV1">76#3SK+@>O_KW;4-]2&=/L"F
MAB"0#P6PO\Z=?[CT%0S]_/PN6]4%;B2]>[IM@>!K"@M2Z,0C G##[E[M0P:^
M;5?IV.>@EJYNV,^^KF&K@Y2'&G-*OP,'7H!W^@0 "<\& Q=UM+-!:6%AS?)<
MN/W#[,45AZI>Z$SO+-)N(:<+;%@VL!06761MY&=:%(!-JPMX6]$'D_SG6%$@
MJ-MB1'9U!LHU3$SR1K3>6H,-=2Y/1WN[<_2Q5J!="]N6#BUT1\_>HLBZD:"S
M/!F]V:G(SD>OJ%P1]J4!WQ>86\Y'4.VSQS9'+AJ81[XG0> E<>H^M#FZ>QK9
M5_:K?=^^O1G*1K ^@R2\T$D"G9BS-6 >@A^$WB3N:7V[.8(HE4QH0]84G$."
MF1>&TW[X5G-T?WIW2I;U Q.5AC\&T&TN694]NDDR2A(OF/J=O)TVK"_6FKS(
MO$8'S7POC?KAV\U1/)EXZ:1WR4[;AG"W6CX'U\;3F9<$,]?O[>3>[V^&*NKS
M4;>/OB>AYR<1"O'29#MV:;P'J>AO@E3H>\DT=A_V(?7DP,5>.IOUCG9;>T%+
MXQXPSO,HG'B)G[9J)1#*Y)M1[ -L)CTLMYK[* :.G82]^MO-;W!&$L%Z2>^.
M[?8^B@%CLW[X=G.43 "+D[A[O=,^@N(D33Q_&KFAAD\O3I^&XDAC.(IF6U )
M$C(8%)/\I;($Q0N=I/^4#SV2#<?3PYR^%3+L<9VH!99-I>O*PE7GV?@UFROG
M4#^&@O?*+1-WRQ8LXBM3M@JVA-*AK1('"SLHN(J"[*QACM3]<1/8D6[=">F3
M,NK\EY^]<;35[O%0.6MO#>S9%US^NR9MJ<"8Y1*-5FZE8&K*IA*,FKIB23F>
M*:!,DDR>X*H':MXCE>U>^CL?(-G+3KO[?O6?].I.QSNM!^FO=W9SY5/)=B\A
M=B]'PRS;OOT&LH5$$\3[\C3O#O.M[Y,]ROTVJ@UAY3B:D&<DGOGDI*7;(9J=
MI0$8F<)0/=(PK6'8*(),@T*2";ZR1#DR+!K/0IV))O#9CNCX=8 #_]Z('Z;
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M3<9$F']4F(:JU_I?#/-:J;K4CRM&<R9P +Q?U+5J&[A ][>6B_\"4$L#!!0
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M67JH^69!+V/4;@*-+Y2RFP^W0/?6GOP%4$L#!!0    ( +F)9EIF88.$$ ,
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M7CB^#3;YFMD\9>=_I=&W2H>'PVX LNQWDP;EM$89;$'I#^C2FI!Y&IF4TW6
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M#G;@1HG^ 8TYS)E-U *;4ID' N4US^8*'-(OZ$=.XQ1(R=8:H_LD4V;*=*,
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MM>J^6;P$6\;K\]@&E$5\S/#UPTX$L#^QF+7-BQA8?D\=_P]02P,$%     @
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M]'9^_32EX+/YG(+?TO(4'G*$I1+4";C,P+*%0/"@TAI@H&F+^LR:Z=15@[1
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MG-4L2^ZLMK)>:BKD+JMRV0J#EO2PU<,VCSOUZMA)9GXB"H%TS8%'!;C:TA!
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M4]>FX,>5DH#,M #S"V/J[H4.Z#]\?/$?4$L#!!0    ( +F)9EJBZ&P-(@,
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MLM2R_+2@?P1J9T#G,Z7L9N$<;/\ZPS]02P,$%     @ N8EF6O=%#!2-+@
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M,'XI_NA@;>UI#([S0X$)N=')%>T>.),YK$WCN%,: 62?X081I[M#5]*>0'0
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MN=FQ:+-RF;S]AEHJ2N3K/> 3L#4#> */3-N@X5D5:^"\ C-D]Z#]P*D7_R.
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M;IE,3L<_!(X?YP4%"#3MHC7-(87CWNU!N2[)-0AOV+;I#NPF0BDJGB0 SP$
M=5)[3/S@:'W$#PX=J0: PV)_N4_!W#=&SX(0'22[^IWT?)TF<^Q O&:LU[VX
M@)]/%DVETEC1E0_9[X"E+7&DC8*@[^JB\\8P'ZJU@"[R61@9L!C<<]%V3+]
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MK<&<\O_.8\'WU59F(_80]T:X^SKV29LG](8K[E.LB<QH22$";L3]!\*K@F\
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M['J@RDE9;HQ<N^DTEX;$N65*?RZHK /9%U*:_<82U']7PW]02P,$%     @
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M&S*;AW0^'>Q <W JGY2\_:*L0T'RSZ M]WYA0X+64)R-Z9#0:1;.T]G .UF
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ML$?F<$OEW[:\T-RN1:E+66B9B=3NI W\E7=?\(^$2&+XVJ"\"<-ZP)\-OHN
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M?%_'*614=V0. G=64F74X%2M?9TKH(ESRK@?!L' SR@3WG3LUF[4="P+PYF
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M"29B7B0O='=R?\;[F5,1EYVIK&F1R]*8Q@\%T\Q406;B LF;#MG7 G[C.LU
MK=VCH3%>(4QYL]:K];LT*Z_C%_/R4;NF:LT$%AI6Z!ITAJBS*A^*<F)D[B[G
M2!J\ZMTPQ;<5E#7 _9649CNQ >K7>OH'4$L#!!0    ( +F)9EJRHO/*P0(
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MCB4-:#3>@;XOM79;PR?8C?S97U!+ P04    " "YB69:SK'E2+("  "V!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q]E&MOVC 4AK_S*ZRLFEH)
M-==R&T0"2K5*ZX3*NDV:]L$D)\2J8V>V4^B_WW$"&:LH7X@OYSQ^C\U[QENI
MGG4.8,BNX$)/G-R8<N2Z.LFAH/I:EB!P)Y.JH :G:N/J4@%-ZZ2"NX'G]=R"
M,N'$XWIMJ>*QK QG I:*Z*HHJ'J= 9?;B>,[AX5'MLF-77#C<4DWL +S5"X5
MSMR6DK("A&92$ 79Q)GZHUEDX^N [PRV^FA,;"5K*9_MY#Z=.)X5!!P28PD4
M/R\P!\XM"&7\V3.=]DB;>#P^T._JVK&6-=4PE_P'2TT^<08.22&C%3>/<OL9
M]O7<6%XBN:Y_R;:)C3R'))4VLM@GHX*"B>9+=_M[.$H8O)<0[!."6G=S4*WR
MEAH:CY7<$F6CD68'=:EU-HICPC[*RBC<99AGXNE\_OBTN"6+G\O%U]5B12Z_
MT34'?35V#>)MD)OL4;,&%;R#\@/R((7)-5F(%-+_ 2[J:L4%!W&SX"SQ%I)K
M$OI=$GA!=(87ML6&-2]\K]@D416DY NC:\:98:"[9%XI!<*07].U-@K_);]/
ME=Z H]-@ZYR1+FD"$P>MH4&]@!-__.#WO$]G9$>M[.@</5ZA$].* Y$9.90
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MIL9BZM933YPN0[DOM:/F$88%=6LTWH'6UUJ[W<1OT/;_^6]02P,$%     @
MN8EF6N!P!+?4 @  )P8  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
MC55;;]HP%'[G5QRE4K5)47/E6D "VFF3U@V5;GV8]F#""8GJV)GM0/?O=YP
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M<G]F$E?DVNV<#R(P=5>N)TZO0R=<:D=]-0P+>LC0> /:7VGM=A,?H'D:I_\
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M=V]R:W-H965T<R]S:&5E=#0Q+GAM;*U6;6_;-A#^KE]QT):A 3+KQ2]I,MM
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MZ<:N/W/Z14+M%I ]4\H>!FZ#]J=K^A]02P,$%     @ N8EF6B.Q8NIZ!0
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M%TK  )EOQZ;AC&3(7@".**2TX1A,XQNH\;LG* !']%)ZZ!@LY!L8\NTTY+@
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M'*L:R-\GE(K5B1J@^EIS\']02P,$%     @ N8EF6JMPT_=K P  1@X  !D
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M9SJ-<R7@- 8Y-9Z$/XM8QB:DUV@.+(F*A"&^0I_BC"9HDB0\I$O8NB]$N(&
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MN#PN@S@X3;QGN\+8B3!=[.D.GL'\M5\K'(6-2LY*$)I)011LE\%M?+.*1];
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M3@O]JH$P#OK_GG-U7I@$[3N9_@)02P,$%     @ N8EF6KHT0)/K"0  35\
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M_:<^9B1;O5615?M_V>LQUENPU:ZJB\WQX*8%FS0__)_\<;P2G0-X,'* ?SS
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M3!MX1A+QC.QS2N3%HC>:#(1Q&8W0C 2:D3C-C(THEC,VN+ISG\T!*Q)@11+
MBB2%%2HU\_5J@!5U.:S@$JX)*VM840 KB@I6%"FL4*F9:0.L*")84=.P@H:8
M[0-847\.5BPG9'!UY[Z:@U\4\(LBX!=%RB]4:F;&P"_J<G[!)9P3=N 7U5F"
M0L4OBI1?J-3,M(%?%!&_*#M^&0H;YQ<%_*(NY!=\L@57=^ZS.?A% ;\H GY1
MI/Q"I6:NNP)^"2_G%US">=&5-;^$P"\A%;^$I/Q"I6:F#?P2$O%+.,TO:(C9
M/N"7<(I?-AM=[E]X^IQL=8D.)+B6<\_,02LAT$J(TXI#09(B"Y6:F38@2TBT
M*#;LDP:/?#\\+\I^F"^4/_*(* 0D"?'5,J.%:7G3CLL[=]H<H!)VUM[BBV\=
M:I5V]>T<"W5"X)X0YQ[[6NVOM.T-GEB(V3Y@D7!B6<UDC>)W?[B\<V?-@2D1
M8$I$M8HG(H45*C4S;>":B&@53S2P:'=@/!T(0\;3"$ DPD%DNE;QFPA<WKG3
MYEC*&P'U1/@J(8=:)44>*C4S;4">"&4+AUH-)L=3-,1L'[!)-#&=HLLZ?4Q7
M[9UN\<C6>EM4:8T_ <0EG3MHCB5$$4!/1#4/$Y'B#96:F3;@340T#Q/U)UBX
MKP+_O#8'PCP>JI'Z[.P',C$/,U&?EFB*G\6Y[^:8CXF @2)\/L:A9$EIATK-
MW(4%:"?&)V6L2S:>7L>$AICM RR))[81L2U5G%#QLSCO)3/'7$P,"!13[5L2
MD\(.E9J9-L!.3+1O2=S?E&1H=!T*&Q]=8Z"3&*<3ZY+%014_BW/?S3%;$P,1
MQ?A6*0XE2\I!5&IFVL!!,3[Y8U^R_1U1>J,K%F*V#X EG@"6(M??CUM LH^[
MJ;?4<#7GOIEC4B8&"(H)=D^)21&'2LW,N+/EVN6[I\3]Q=)#6RH-A&%;*GG=
MC=(F@&2\)"VQ=.(,[ONHS;*1FM?92<W#'SE9;AY'BCAD<F=9^YVL)R9Z;/;Z
M\0;6:P_M #80A]9K9S,U;X)*+.IU8D\J_ SN/3?'Y SW.ONW>03OS[R)D&4]
M!^!PK[,9G'?Y.S1O&NCF5&C,6?,ZF[9Y$RAB4:<XD$Z<P;W'YIBLX5YGOS@/
M?QIE6:>T6\91R9UEW=DTSIN8_+&JTX.&1.L4BSDT;]G9ZKS=:+XIOZ<TKUBF
M'YMCO*OVH6MYV+K]\*4NMOO=SQ^*NBXV^X_/.EGKL@UH?O]8%/7;EW9#]=,.
M^K?_!U!+ P04    " "YB69:BA_S>40'   3,P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6R]6VUOVS80_BN$5PP=4,?BFRQUB8$T6;<!"Q T2_>A
MV ?9IFVALNE*<M(.^_&C9,64Q!?+%><OB64?CW='ZKF'=]+E,T\_9RO&<O!U
MG6RRJ\$JS[=O1Z-LMF+K*+O@6[81ORQXNHYR<9DN1]DV9=&\'+1.1LCS_-$Z
MBC>#R67YW7TZN>2[/(DW[#X%V6Z]CM)O[UC"GZ\&</#RQ8=XN<J++T:3RVVT
M9 \L?]S>I^)J=- RC]=LD\5\ U*VN!I<P[<WOE<,*"4^QNPYJWT&A2M3SC\7
M%[_/KP9>81%+V"PO5$3BWQ.[84E2:!)V?*F4#@YS%@/KGU^TOR^=%\Y,HXS=
M\.2O>)ZOK@;! ,S9(MHE^0?^_!NK'**%OAE/LO(O>*YDO0&8[;*<KZO!PH)U
MO-G_C[Y6@:@-@,0P %4#4-<!N!J 2T?WEI5NW49Y-+E,^3-("VFAK?A0QJ8<
M+;R)-\4R/N2I^#46X_+)^RA.P<<HV3%PQZ)LES*Q1GD&HLT<W$7I9Y9'TX2!
M!S;;I7$>LPQ</T5Q4GXIX@@>(O%A"![$]IKOQ$>^ #<\R]^ Z^4R9<LH%V)R
MBD+KXT9LMR3^A\W!KV*;9<60(S,-Q78=9L5,KV^%6)QD/XDY'Q]NP>M7/X%7
M(-Z /U=\EPGUV>4H%V$IG!O-JA"\VX< &4)PRV87 ,,W 'F(:(;?=!^.F\-'
M8C$.*X(.*X)*?=BH;YK7HO"F%88BX.*[-4_S,H9%M,&GZVF6I^*6^%OG_GX^
MHI^OP(FWV3::L:N! (*,I4]L,/GQ!^A[/^N"X4A9(S3X$!ILTSYI>JUS=3^>
MEN,+!'N:D'%  G0Y>JH[H8K1D 2A%&N81P[F$:MY[9VM,W"OP6_,[+>L4V4@
M#+'>-GJPC7:U[0^>94QK'%4F'E+?:UFG$8(>-(3./YCG6\V3&*&SRU>F%*M*
M8="R3!6C(?7&ALB-#Z:-K:;=1-D*_/)E%S^).Z^ QD]W;#UEJ?96LZHZ]59S
MI*SA=7#P.C@S"@4N0^-(62,TX2$T84\4"C4W,"5A:[NJ4LBG7J#?K="3"=WK
MC4*5BOK<[=M<(P(-IM6X!NP/0I4.JVTVD:9M,NM":^8Z@D#5X&-+JA$KUC0T
M&"?S'K0GOL>+APNPY$\LW13TK.11]<LEV\R^@4Q2IQ>, O^"D_#+;L>I=ZDK
M;<VHR70,R9DQ#%H)P,GA<:2M&1[)"*"=$AS',;N"D]U5F0,)@['AWI#, =JI
M0R>\LZHXV1&5:)B@49(,:&<9W:#1*;VHM'5!4<D:H#7S'D-1IQR@TM;:3Z;\
M*;,[M*?W&YYN>5H<7*=<G">_'TJMTYSLK"-MS2.I)!7(._>AU,IB3CZ5.M+6
M#(\D-LA.;(Y#J5W!R>ZJ!"@D!B1%M<*#G0)U05*[BI/]4/F2 8*0Y$KH"%?J
M@J1V'2>[@3N[(<D+LA<3[$AJ'WRR_6K%P;R=)+] =GYQQS?L6U7: ^]W?;#4
M/M/)[CK2UHR+)"S(/S>6.J4WKK0UPR.9$+(SH0Y8JA(7W6%,(X8\.B:&?2TY
M#K)SG$XPJ7*3]B'6*M(T37(79.<NW;!/+3PHMME$FJ5;22&PO2YA!S2L*3=H
MUE0C9EE3+!,XMB?P6@-"<XK6&NPTH;O2UG1?9GY\[IX#=LH37&EKAJ?6=NC=
M=U 9 /']$./V_E7EJ!_@P+2!)5W _7L/N$OS02,$H:DS@B49P [Z#[A3 T(G
M9>Y 8)F7<9\>!-8T(<0*^PI":;H0?D!]TPK+O(CM>=$.48)1?7>14.NNTU*#
M*VW-T,F,C<_=S,!.*QFNM#7#(UD#[MO0P"H?P)0B2-J;7Y4C% 70T((CDCR0
M_DT-HG(#@I7>JH9G>"$UV"?Y W'0V2#JJ7U(@C:\Z:3&V!1!F>))G_X&40_B
M8H'A6#%.E2,4P[$I@#+%$GN*/8INIK*<UANGIWM7VIJ1J3U4<.XN!G%:/'"E
MK1D>22Q(WRX&4?E"X 4A;&]MC1@<AX;*/I&T@O3O3Q!-1P&VF85&R#=4NXED
M%<1!WX&H)^FABEL:(60ZF1&9NTF?C@)1#]&!%V+%-HT8I($)M63F)/;,V0&U
MUFN6SN(H ??1EJ5VV'+:,7"EK?FXD<S8]-P= ^JT8^!*6S,\DC#0OAT#JO(
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M\8.#9#;9A(?)=/<F2 9R90>K(I$H<EUVR/JTGMWG=F0=G$]QII<C^ FF_"#
MUK\RZ>>0(*1W-L"09#EDRXT6:SNGED+CU+/+%+]+0!H#?)X(H7<;<T']I3/Y
M!U!+ P04    " "YB69:9:WQ_ X&   M)0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6S%FFUOHS@0Q[^*E5N==J5F@VT@T&LC=5/M@]1*U6:[]^)T
M+USB-*B <\9IMO?ISR8L#F!\FX2V;]H ,\-_!MOSB\/9AO&'?$FI #_2),O/
M!TLA5J>C41XM:4KR]VQ%,WEEP7A*A#SD]Z-\Q2F9%TYI,D*.XX]2$F>#R5EQ
M[H9/SMA:)'%&;SC(UVE*^-,'FK#-^0 .?I[X&M\OA3HQFIRMR#V=47&[NN'R
M:%1%F<<IS?*898#3Q?G@ IY.74<Y%!;?8[K)=SX#E<H=8P_JX,O\?. H132A
MD5 AB/SW2*<T250DJ>.?,NB@NJ=RW/W\,_K'(GF9S!W)Z90E?\9SL3P?! ,P
MIPNR3L17MOE,RX0\%2]B25[\!9O2UAF :)T+EI;.4D$:9]O_Y$=9B!T'Z'8X
MH-(!_:H#+AUPD>A669'6)1%D<L;9!G!E+:.I#T5M"F^939RIQS@37%Z-I9^8
M?"0Q!]])LJ;@FI)\S:E\1B('))N#:\(?J"!W"04S&JUY+&*:@XM'$B?JY% .
MHN&,R*M#,)/#:[Z6']FBPVT3BR68LDS$V9JM<W";R5&7Q/_2.;AB>2XMWEY*
MKSC)W\EXM[-+\/;-._ &Q!GXMI0.4E!^-A(R925\%)7I?=BFASK2NZ31>X#A
M"4 .<@WNTU]WQW7WD2QT56U451L5\7!GO#NQ4Y03\)DF\Z%@PVLBU+FG$W"1
MR)E%LH@"65XPY70>BZ)"X*\K&0U\$33-_S958GMKUWQKM1R<YBL2T?.!G.\Y
MY8]T,/G]-^@[?YCJTE.P6I5P525LBSZYHC);L209@ A<RR&SE)72 ]64^S:@
M5P14*]?C!&(8JF?VN)M5VPQA'X9.95;3ZU9ZW?WUML:W2?8VKK^C9^ABV!!M
M,!JCL5FR5TGVK)(KH4 .LD]2J:#\_VKLM71XG@.=AEJ#%42N9Y;K5W+] ^3^
M4HG]=O4@"ANB#48H<,V:QY7FL55S:ZZW%\Y6"N"&Y;%J;R?@&Q,D,24T;FF%
M@1_BYE!OFZ%@[.*.!Q%4207/F=1%%*W3=2(?W_:2)<V@_4@\OSG8#$;0@="<
M8UCE&%ISG%(NXD4<296JG<WI2NF7Z^\U3>\H-ZZ]UHC[KKT]!:LE#QT-!,[K
M]:CRWCT5JJ]H]4KMH!/LNT^5$6O3TFU.78.1)V>X>51#S1[0VK2/:%-EX%U!
MS9EH,!FB#L6: Z =! [I4F5(JU:;25VJ1@!H9X C.A1L-_B68IM)7;$F &A'
M@.?J3[!- (8A;L"$[B&N,0':.>'EVA-L(T/KH9FHHB-##1703A53EJ:41S%)
MP U946[M2O98>Z^V/46K9Z[) P:OV)>LV+-WI7J*5J^4YA=H!YA#^E*O %-&
MVQWYH>0R\]A'FDR0M9\?T<#L@??^;NRT)W;'TH4T3" [3!S2Z^PA]TZKC1T=
M30;M['?8F>.(MFB/O'=R-H2I)Z?Q!-GQY+DZJ/VV>V?>IAW+9-3 @^S \W*M
MUBYD[W(8ME.Z)J]F*61GJ=L9^,:+[=.G8N?T$WND/%,[J=;^;(^Z=V8]1:O7
M0+,7\E]Q;]/*?7M7JJ=H]4IIAD-VACN@/R/#K@^$#FKN%9KLPM#S.K@3:?I"
M]HV?(WJO89,&AT%3N,'*#SNVX)!&(61'H8.Z:IM>7,\)FWN&!C/DCOV.A15K
MRL%VRCFB96(#F 2HH=MDA(,.U1I?L!U?GJL7XC:40,^'J/EERV"'Y-=.V+&T
M8TTPV$XP+]?GL&$+Q0U:B1JLQKAC?N.=GUSL+#-E?,6XVO)L)&QM8/:@^R[+
M?46KET 3#79?KX'A7B&FKVCU2FG<P7;<.>0'.L.ND.-[S4759 8#MZ,/8 TG
MV+XQ='C[PH9=G-:/+28CU+6F:D[ =DXXI'GA-@"$(6QB@L$*^6[7+UY84P*V
M4\(QO<L  .ZXJ=M@A%R_0[:F!&RGA&=K7FU$P(XW;BWI!N (<-?X<35)N':2
M>+G650KQ:N#13--DA,;-,3?:>9=%O4AT3?A]G.4@H0OIYKP?2W^^?3=G>R#8
MJGB]Y8X)P=+BXY*2.>7*0%Y?,"9^'J@W9JHWI";_ 5!+ P04    " "YB69:
M1JO+X^T#  "6$@  &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6R]F%%O
MHS@0Q[^*Q:U.NU(;L!,(Z261VD2KNX?HJLUV]V%U#PX9@E7 G&V2[7WZLPD%
M*@)=54U>&AN8F?\,,_H53P]</,H(0*&?29S*F14IE=W8M@PB2*@<\ Q2?2?D
M(J%*;\7.EID NBV,DM@FCN/9"66I-9\6U^[%?,IS%;,4[@62>9)0\70',3_,
M+&P]7_C"=I$R%^SY-*,[6(-ZR.Z%WMF5ERU+()6,ITA .+-N\<T=<8U!\<0W
M!@?96".3RH;S1[/Y:SNS'*,(8@B4<4'USQX6$,?&D];Q;^G4JF(:P^;ZV?OG
M(GF=S(9*6/#X.]NJ:&;Y%MI"2/-8?>&'/Z%,J! 8\%@6?]&A?-:Q4)!+Q9/2
M6"M(6'K\I3_+0C0,".DP(*4!*70? Q4JEU31^53P Q+F:>W-+(I4"VLMCJ7F
MK:R5T'>9ME/SSY0)](W&.: 54)D+T"57$M%TBU94/(*BFQC0&H)<,,5 HML]
M97%Q49<%K:E>7*.U[I9MKI=_AXT'=-,@25^:KZ@RRR>D7TDC^,>ECL1B^0E]
M0"Q%7R.>2ZU!3FVELS1:[:#,Z.Z8$>G(: G!  WQ%2(.&:&']1)]_/#II1M;
M%ZFJ%*DJ10J_PPZ_55K7.JWK]<NTKM 2-NHY.9/GC]N-5$(WW3^G4CB&&IT.
M92;Q1F8T@)FE1TV"V(,U__TW[#E_]"0RK!(9]GF?+W6YOS,5F3KS%- 34'&%
M;A,N%/L/MFC!I3JE^>C5+;R:8=_/A_[((9.IO3^A9E2I&;VJAH8*1*4%J4CP
M?!>A4,]K<47^BKQC&*\ASR>3D7-:G5NI<WO5?>6*QK\2W6U%'WG>Q.LHCE>%
M]WK#+[C(N* *T(;K84 _5I!L0)QLJ5Y/;VRI<:5S?+G9&)\A$;]*Q#_+;/BM
MU^\2WW-/O_U))69RF=&8M-01W^E2AYT:'<[[#$?IY\5L.I-AQVSB!KMPKX"'
MP7J =GP/(C74*J#5W.X@#9Z0K.'3-S_]L=[8=[BF"[X@7O Y^()KP.#S$*9T
MV^R3H:,)T]6I-6/PA2"#VY1Q1_ZX2V"-&?Q.G,%MT Q=%X^[9JDF#7X--4D"
M(F T1O<TTY7JG95SP ;7M,$7Q T^!V]P#1Q\'N+@-G*P3\BXHP]JYN +00>W
MJ=/1I*0F#GDGXI V<7JJ0VKBD'[B+$ '#EE@_B7CH?[\R[ADJA\L_2[?V&"D
M\=ERR>^6<X"%U& AYP$+:8,%$V]$.MJAY@JY$%=(FRM=PU(SA;P34TH_[BO5
ML1NG#.;$9D7%CJ42Q1!J.V<PU@[$\1#DN%$\*PX>-EPIGA3+".@6A'E WP\Y
M5\\;<Y91'47-_P=02P,$%     @ N8EF6C+V;!G\ @  0@L  !D   !X;"]W
M;W)K<VAE971S+W-H965T-30N>&ULM59=;]HP%/TK5E9-K;0U'T"@'40J=-,J
MM5)5UNUAVH-)+DG4Q,YL![K]^ET[(04&V5K1%Q([/B?G'-^8.UQR\2 3 $4>
M\XS)D94H59S;M@P3R*D\Y04P?#+G(J<*AR*V92& 1@:49[;G.+Z=TY19P=#,
MW8I@R$N5I0QN!9%EGE/Q:PP97XXLUUI-W*5QHO2$'0P+&L,4U'UQ*W!D-RQ1
MF@.3*6=$P'QD7;CG$]?1 +/B:PI+N79/M)49YP]Z<!6-+$<K@@Q"I2DH7A8P
M@2S33*CC9TUJ->_4P/7[%?LG8Q[-S*B$"<^^I9%*1M; (A',:9FI.[[\#+6A
MGN8+>2;-+UG6:QV+A*54/*_!J"!/676ECW40:P#7WP/P:H"W#>CN 71J0,<8
MK9096Y=4T6 H^)((O1K9](W)QJ#13<KT-DZ5P*<IXE2 ]C,ZXX)6H;*(7*<A
M[A*0BU@ X(8I2=Z3*99/5&9 ^!PW;P&L!+R&/&;I;XC(\24HFF;R!)?>3R_)
M\=$).2(I(U\27DIDE4-;H5K]3CNLE8TK9=X>9:Y';CA3B20?6031)H&--ANO
MWLKKV&MEO(3PE'3<=\1SO.X.09/_AW=:Y'2:Z#N&K[./+Y4TQI#C*GM,]JY.
M]OLU+B57"G+Y8U=P%6]W-Z_^\,]E04,86?AE2Q +L(*W;US?^;#+]('(-B+H
M-A%TV]B#VO NCQ6P9X#Z+%H$_4$?8U^L:_][D=.LV!#4:P3U6@6MBE_L%]9*
M\-SP#T2VX=5OO/JO5'_^(2,X$-E&!/TF@OY+ZZ\"^FNEY3D#?ZO^6ME?J'W0
M:!_\0[L$*L+$'-H1&LEXH8]KHE^$9=Q6PZW,S]W  Y%MA'#6A'#V2C5\=L@(
M#D2V$8'K//V%.R^MXAJY?D+V\!S=*N-V_N?JM]>ZD1Q$;)HT24)>,E7]63>S
M32-X8=J?K?FQ;A!-E_-$4W67-U3$*9,D@SE2.J=]-"BJAJT:*%Z8GF?&%790
MYC;!)A>$7H#/YYRKU4"_H&F;@S]02P,$%     @ N8EF6DA#5DFD!@  ?"L
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M&A$<$JX'J/^O&)/["^V@.G [^Q]02P,$%     @ N8EF6O^!*3), @  $P4
M !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULM53O3]LP$/U73AF:0.K(
M#T+'6!JIM)J8Q+2*PO;93:Z-A6-GMM/ ?[^S$Z)N [[M2^*S[Y[?>_8YZY1^
M,!6BA<=:2#,+*FN;RS T184U,Z>J04DK6Z5K9BG4N] T&EGIBVH1)E$T#6O&
M99!G?FZE\TRU5G")*PVFK6NFGZY0J&X6Q,'SQ"W?5=9-A'G6L!VNT=XW*TU1
M.**4O$9IN)*@<3L+YO'E5>KR?<(/CITY&(-3LE'JP05?RUD0.4(HL+ .@=%O
MCPL4P@$1C5\#9C!NZ0H/Q\_H7[QVTK)A!A=*_.2EK6;!10 E;EDK[*WJKG'0
M<^[P"B6,_T(WY$8!%*VQJAZ*B4'-9?]GCX,/!P5)\DI!,A0DGG>_D6>Y9);E
MF58=:)=-:&[@I?IJ(L>E.Y2UU;3*J<[FI$:PC=*L]TB6<,,+\AQAOM.(9+\U
M\ '6=!G*5B!\W\)"2:O)39@;@[0ZIZ)Q[H:S#1?<<C1PO$3+N# G< 1<PEVE
M6D,[F"RTQ-SM'Q8#RZN>9?(*RR46IW 63R")DA3NUTLX/CKY$R8DX:/Z9%2?
M>-ST5?4#[8[;"A;>;M234<73!.Z49>(EQCWRN4=V5W^?QW$<15FX?X'0V4CH
M[$U"MVB0Z:+R)U'BGIJF<6< !O6>#H;Z8(^RQ9<(O8GLFOO2-*S 64#=Z^ P
MR-^_BZ?1YS>,3$?>Z7\S,OW'R&0ZO?CTEY'AP1UWS\4WIG=<&A"XI;KH]",!
MZ+X%^\"JQE_[C;)$Q@\K>K50NP1:WRIEGP/72>,[F/\&4$L#!!0    ( +F)
M9EJ4VA'K=04  /TB   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;+6:
M76^C.!2&_XK%CE8=:2> 2=*DFT3JQXZFTD13-9J=B]%>.. $5+"SQFG:T?[X
MM8%@2(G;4'/3A@^_]GO,,8^-)SO*'M(08PZ>DIBD4ROD?'-AVZD?X@2E/;K!
M1%Q9498@+@[9VDXW#*,@*Y3$-G2<H9V@B%BS27;NCLTF=,OCB. [!M)MDB#V
M?(5CNIM:KK4_<1^M0RY/V+/)!JWQ O/OFSLFCNQ2)8@23-*($L#P:FI=NA?7
M7E\6R.[X.\*[M/(;2"M+2A_DP6TPM1S9(AQCGTL))/X]XFL<QU))M./?0M0J
MZY0%J[_WZI\S\\+,$J7XFL8_HH"'4VMD@0"OT#;F]W3W!1>&!E+/IW&:_06[
MXE[' OXVY30I"HL6)!')_Z.G(A"5 N[P2 %8%(!O+> 5!;S,:-ZRS-8-XF@V
M870'F+Q;J,D?66RRTL)-1&0W+C@35R-1CL^N*!,E(K(&9Y=!$,G0HAC<DOP!
M$4<?P=D-YBB*TX_@$_B^N %G'SZ"#R B8![%L;@CG=A<M$3JV7Y1ZU5>*SQ2
MJPO!G!(>IN O$N"@+F"+!I4^X-['%=0JWF"_!SSW#P =V&]HT+6^^.6&]8#3
MSXI[FN9X95B]3*]_1.\K101<D@ LL+]E$7\&EVN&L7C^.?@YQ\D2LW^:PJ95
ME2E]D6Z0CZ>6R-D4LT=LS7[_S1TZ?S99-B16"T"_#$ _4_>.!&"Q75(61 1Q
M' #UD/W\*NX#MQPG::/_ODG_AL1J_@>E_X'V ;C'&_0LNSL%= 72D#(..&8)
M6,I8B% TN<\EQYFD''\?9V[O?&(_5DUIJVUI:EB:&FI-?8Z>1&]&1!C!*0=,
M="X00_%RW[V-(T$NZ<***Z?G].'@P)BVZI;&SDMCYUICBTK_(/( 8I&^35ZT
M*J<^GKG8H!*7OE/&I&9C5-H8O3+JB!3+7 1XR9L,:,N?:B 7&U8,P",&QJ6!
M\5O[0;[]Y8CAHTW$4=QD1JMUJIGQB]XX9L9UU+O5T=KYMN4I1R20/N0U.13X
M#(O7K'C,8D1\# AN[*=">%Q+FL.A0%][RY1Q*^3@:MW-T5.4;)/R?0;^ VU?
M>_J:3NU*4VKUN$ 5%]C%JZ]0-14#0VKU&"C\<5_CG^I()("5YX]#((+2:-XH
M^+S2N SV,MJ3N#?0&5:XXVII8C:/B+%D, I!IM3J<5$8Y XZ209#F%/$H MH
M<A4UN7IL.CD9#*%085[?N'HR]'6&%4VY>IQ2_2QFB4+5>9D6^TQ(P8^(A^!*
M4M>W%?B"R/I72+?Z!#&*8:;4ZK%2R.:..DD0HR1G2JT> T5][ANP[Y.:'F5S
M"4 K]%3@4F,D<FW7K;#2H#<\9"5#L%A?G% D"/4DN#B8 .8. X9V! 1TUSC9
M*"1KQESXPIF^YK;.% 5"/06VFN@6FJ]:ZP+DH (YJ(6D%L/8=2@2&<PQ\T,D
M3V;#FFXHT[?@U#0VI5:/EX(^Z'4QE$&C[&=*K1X#Q8%0SX'MTJ'_8K8'>Z/#
M9.@"Y* ".:A?T&JU]E-H'B[^>.-#;UT &E2 !O4,I$WTH]/<]R",OD$G/_-=
MK)U!A7OPO).\-XIQIM3J,5 8!_5+;^W28]2\-NH<KHWJ*V]K3O$9U/.9/C^.
MS7S?E1]&U_9,J=4_!2GX\YPN\L,S!';%QZ N,-%3F.CI,;%5?A2:+UX?A^FA
MK[NM-\6)WFF<",USHKX%)S\+77"B5_DVV@DG>F8_CG;!B9[B1$_/B>^:\A;:
MU8\5SF%*&*5%N[+!(,%LG>V[2(%/MX3G>PW*L^7>CLML1X.M;L\WALP16T<D
M!3%>B:).[URX8/E>B_R TTVV76%).:=)]C/$*,!,WB"NKRCE^P-90;GC9?8_
M4$L#!!0    ( +F)9EJ<B^6V4P,  (0.   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;+5776^;,!3]*Q:;IDYJRV<([1*D+5VU2IL4K=WV4.W!)3>-
M5<#,-DF[7[]KH!02QIJ)OB2VN?=PSO4!KB<;+N[D"D"1^R1.Y=18*96=FJ:,
M5I!0><PS2/'*DHN$*IR*6U-F NBB2$IBT[$LWTPH2XUP4JS-13CAN8I9"G-!
M9)XD5#Q\@)AOIH9M/"Y\9;<KI1?,<)+16[@$]2V;"YR9-<J")9!*QE,B8#DU
MWMNG,]O3"47$=P8;V1@3+>6&\SL]N5A,#4LS@A@BI2$H_JUA!G&LD9#'KPK4
MJ.^I$YOC1_3S0CR*N:$29CS^P19J-34"@RQ@2?-8?>6;3U )&FF\B,>R^"6;
M,M:W#!+E4O&D2D8&"4O+?WI?%:*1@$*[$YPJP7EN@ELEN(70DEDAZXPJ&DX$
MWQ"AHQ%-#XK:%-FHAJ5Z&R^5P*L,\U0X%^@(H1X(31?DXZ^<9;A'BAR1@S-0
ME,7R+8Z_79Z1@]=OR6O"4G*UXKG$:#DQ%1+0,&94W>Q#>3/G+S<[@^B8N/8A
M<2S'ZTB?/3_=;:>;*+O6[M3:G0+/_8?V0S*/*8INE^#Z,X:3"P6)_-DEM<3V
MNK'UTW<J,QK!U,#'2X)8@Q&^>67[UKLNX0.!M<K@UF5P^]##*ZYH3+*F$>"Q
M"EW"2[11@:;?$NO0]GQK8JZ;@CJ"W,"M@UI$O9JHUTOT,TB)SWV4)WE,%2SP
M<<5R1(R6+P3D31,N%/M=+'11+_']!JNC8.QM4>\(\GV_F_JHIC[Z[QH?IM!9
MY]$.CU'@;W'=C1G;XVZJ?DW5[Z4ZXTF6*Q"27'^!Y 9$I_M[,?9U_T!@+;GC
M6N[X!5\"XR'+,!!8JPQ!789@T)= L&,\WSG9,N=NC!<$W>8\J6F>]-(\ST7*
M5"Z@8'C.[O6XWZF]@/MNT4!@+>VV]?2MME[0JQ7X0)48"JU=BD;;8@_JUPJN
M9<9QL&78CJ#1Z"\?+?NIR[![O][XV<(V<\7C!;E(D/ :-,=^S_8C[KU5+]%=
MV$_MA>V^I&M[FY>]2S$06KL43PV,W=_![.U:;Z>-<AN&K#1U!'G.EFO-QA%!
MG\^^4''+4DEB6&*6=3S&=%$>><J)XEEQ:KCA"L\@Q7"%QT00.@"O+SE7CQ-]
M$*D/GN$?4$L#!!0    ( +F)9EH<EO4X; (  -$%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4Y+GAM;*U474_;,!3]*U:&)I 829/2(=9&Z@<3/"!5=&P/
MTQ[<Y+:Q<.Q@.PWLU^_:3K/"2K>'O23V];TGYYSXWF$CU8,N  QY*KG0HZ P
MIKH,0YT54%)])BL0>+*2JJ0&MVH=ZDH!S5U1R<,XB@9A29D(TJ&+S54ZE+7A
M3,!<$5V7)57/$^"R&06]8!NX8^O"V$"8#BNZA@68^VJN<!=V*#DK06@F!5&P
M&@7CWN6T;_-=PE<&C=Y9$ZMD*>6#W=SDHR"RA(!#9BP"Q=<&IL"Y!4(:CRUF
MT'W2%NZNM^B?G7;4LJ0:II)_8[DI1L%%0')8T9J;.]E<0ZOGW.)EDFOW)$V;
M&P4DJ[6195N,#$HF_)L^M3[L%/0&;Q3$;4'\NJ#_1D'2%B1.J&?F9,VHH>E0
MR88HFXUH=N&\<=6HA@G[%Q=&X2G#.I/.%5X(99X)%3FY>JQ9A;_(D ]DG.?,
M&DTYN1'^MEC;CV=@*./Z!%/N%S-R?'1"C@@3Y$LA:XT@>A@:Y&71PZSE,/$<
MXC<X]&)R*X4I-+D2.>0O 4(4U*F*MZHF\4'$&61G).F=DCB*^WL(3?^]/#E
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M9IVK?@*N&?[&(%O'@9M;XO&-QY+W);H0P/<+:VEOA 3M!A[] 5!+ P04
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MAR7^($":#;B^%4*_!*9I#;^<] ]02P,$%     @ N8EF6F1A!ZL[!@  TQP
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MCYL850A8HHV"AVLC78%>:BOCV'(FD(-K4U,.TR<CV1[ :PF6ILBUFZ*\>^]
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MG:L>,E)5ZZPF1J[*[C.7!GM9.<SP;P.4-<#O"RG-=F(W:/Y?XK]02P,$%
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M%'Y']+\B>;@[^NTSFV+>.#ZSU^^3WQW]Q3);\3K:JOQV99J"-=3.LQ.P')E
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M(:DZQKE@\BV1>6(T%S1XNIA((T(TI8FL#HZUOQ=HGI\LHDMT-.KZ68T!G<Y
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MQ<V:=A"9/86>GL>],VG<*&6DRFC'0E5J(94'XX3K&3B@-QI4W#S;K.SEB=J
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M"2,+<!8O%+?J: W6E5<A5G9SGXZ\P"I"AHFV%,3\;7""C%DFH^/ODM2K[K3
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M:49QE-; /)\+H?<;>T$UW(__ 5!+ P04    " "YB69:@6-4\O@"   I#
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MZ<G27B9ZE@=A-NCG"\[59F'&R_K70?@74$L#!!0    ( +F)9EK("ZAFJP(
M "$&   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;(55;6_3,!#^*Z<P
MH4V"I4U?QD8;:5V90&*H6AG[@/C@)I?$FF,7VTDW?CUG)PT%NNY+XY>[YYX[
M/W>=;)1^, 6BA<=22#,-"FO7%V%HD@)+9D[5&B7=9$J7S-)6YZ%9:V2I=RI%
M&/5ZX[!D7 ;QQ)\M=#Q1E15<XD*#J<J2Z:<9"K69!OU@>W#+\\*Z@S">K%F.
M2[1WZX6F7=BAI+Q$:;B2H#&;!I?]B]G8V7N#;QPW9F<-+I.54@]N\RF=!CU'
M" 4FUB$P^M1XA4(X(*+QL\4,NI#.<7>]1;_VN5,N*V;P2HE[GMIB&KP+(,6,
M5<+>JLU';/,9.;Q$">-_8=/:]@)(*F-5V3H3@Y++YLL>VSKL.$31,PY1ZQ!Y
MWDT@SW+.+(LG6FU .VM"<PN?JO<F<ERZ1UE:3;><_&Q\S[1FTAIX"\OF74!E
M<%4PF:,!+D%PMN*"6T[;1#!C>,8Q=3>?L48! V=O"X2,<0TU$Q5"P5$SG11/
M<#Q'R[@P)W#D7+X6JC),IF826B+O*(1)2W36$(V>(=J/X$9)6QCX(%-,_P8(
M*>LN]6B;^BPZB#C'Y!0&_3<0]:(AW"WG<'QT<@!WT)5TX'$'+Y64$@6O<@-?
ME$68<Y,(92J-\/UR9:PF2?[85XD&?[@?W[7IA5FS!*<!]:%!76,0OW[5'_?>
M'V _[-@/#Z'',\RYE%SF)';!9(+["#80(P_AVKZ.^Z-)6.\).^K"C@Z&;13G
M-+*C(U+60O.:4>VZHF[U^$0C(5&YY+\:-2+3CO5>936AQSMTS\[WTQUW=,<'
MZ9(&7RC1^+\2G0__B1GNM&V).O?#B;I,5=(V'=R==O/OLFG[/^;-\+QAFIZ-
MJH,9N?9.SRBP;@92L[%J[8? 2ED:*7Y9T Q'[0SH/E.DT';C G3_"O%O4$L#
M!!0    ( +F)9EJ/*@E/20(  *$%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<W+GAM;*U4VV[;, S]%4$KAA;8XFN3(;,--,F&]:% T+3;LV(SL5!;\B0Y
MR?Y^NCBN6R3!'O9BBQ3/$8]$,MES\2)+ (4.=<5DBDNEFJGGR;R$FL@1;X#I
MG0T7-5':%%M/-@)(84%UY86^/_9J0AG.$NM;BBSAK:HH@Z5 LJUK(O[,H.+[
M% ?XZ'BDVU(9AY<E#=G""M1SLQ3:\GJ6@M; ).4,"=BD^"Z8SF,3;P-^4MC+
MP1H9)6O.7XQQ7Z38-PE!!;DR#$3_=C"'JC)$.HW?'2?NCS3 X?K(_MUJUUK6
M1,*<5[]HH<H4?\&H@ UI*_7(]S^@TW-K^')>2?M%>Q<[F6"4MU+QN@/K#&K*
MW)\<NGL8 (+Q&4#8 <+W@/@,(.H D17J,K.R%D21+!%\CX2)UFQF8>_&HK4:
MRLPKKI30NU3C5';/<EX#>B(']!FMW%.B@7,I^([:)[M>@"*TDC<Z\'FU0-=7
M-^@*48:>2MY*P@J9>$IG9'B]O#M]YDX/SYP>A.B!,U5*](T54+PE\+247D]X
MU#,++S(N(!^A*/B$0C^,3R0T_W=X="&=J+_>R/)%9_A6BB@X=2\.%I^&F=:=
MRH;DD&+=FQ+$#G#V\4,P]K^>TO2?R-XHC'N%\27V[+5 ]$C1Y6 K1Y$#G"P'
MQW5KN<R V65^XNV&6BY%N 2]0;77(+9V"$B4\Y8I5RB]MY\S=[:]WOEG>OZX
M<?%*XX;7 Q%;RB2J8*,I_=%$YR/<0'"&XHWMJ357ND/MLM0S%(0)T/L;SM71
M, ?T4SG["U!+ P04    " "YB69: #,^%V8$  "B#P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970W."YX;6RM5UUOZS8,_2N"5PSML,:6O]TE =H$PPK<NQ5M
M[]W#L ?55A*CMI5)<M/NUU_*=AW'EHT^M ^-+9'4(2GSD/,#X\]B1ZE$KWE6
MB(6QDW)_99HBWM&<B!G;TP)V-HSG1,(KWYIBSRE)*J4\,VW+\LV<I(6QG%=K
M=WPY9Z7,TH+><23*/"?\[89F[+ PL/&^<)]N=U(MF,OYGFSI Y7?]G<<WLS6
M2I+FM! I*Q"GFX5QC:_6.%0*E<3WE!Y$YQDI5YX8>U8OM\G"L!0BFM%8*A,$
M?E[HBF:9L@0X_FN,&NV92K'[_&[]]\IY<.:)"+IBV=]I(G<+(S100C>DS.0]
M._Q!&X<\92]FF:C^HT,C:QDH+H5D>:,,"/*TJ'_):Q.(C@)V1A3L1L'N*[@C
M"DZCX'Q4P6T4W"HRM2M5'-9$DN6<LP/B2AJLJ8<JF)4VN)\6*N\/DL-N"GIR
M>5O$+*?HD;RB2_10)Q^Q#?H3KMR:;BCG-*EVKX6@4J#S-94DS<0%B'][6*/S
MLPMTAM("/>Y8*4B1B+DI 9>R;L8-AE6-P1[!L*;Q##GX5V1;MJM17W]<W3E5
M-R$:;4CL-B1V9<\9M=>X+<%MHMS6N53;</4VU-=Z)?8DI@L#/D=!^0LUEC__
MA'WK-YV#GV3LQ%VG==>9LKY4F88RPHE,BRW*F! H)IR_04TY$)[H?*\->I5!
M55A>EM@*_"B<FR]=KX9B=F1'5BMU M=MX;J3<.\A (3'.P1W#3[P%ZA<>ZA#
MLLI6#&E+I?8*UE;]+N;(":(>9(V4@QU'#]EK(7N3D%=DGTJ2I?_#G>)C\&,F
MM,!OIFW_@__5>>L-_(@".W)[W@ZEW A[OMY;O_76GT3T(%G\?*EJ<0).Y4!0
M@J@2KX/IZ\(=V#V80ZG L0(]RJ!%&4RBO(YC7@+")U:4VOL2#&.#L=]#-A3"
MV';UR,(663B)[ N%T*$O*7E*LU2^Z;"%P^PZ5@_:4 9;CJ>'%K70HDEH?\D=
MY3I T>"P/IRAA../I!!;1^ZR)O$\,OBL%,OWZK6>@ZP!!-NUO;!? C1RV,(N
MMD?0=I@6?YQ7LB:_*1576K3X,_GELZR=>GXD5#Q)8,NJFU1=10DW>Y11&R/=
MP%^&GM-/CT8J<O!(<HXDB*=9</1J-WHGYSE>A/NPAF(C1(>/3(>GJ4YSO3O7
M1@MVR%^7+OSUP6K$QF-XI#D\S47?25:2NIO/8)X@14RU((>T<VD[(7:]/DR-
M(+8L-QQ#>J0H/,U1JN?Y:-GP!UU,O[9-BIPB5/1TNG*D!3S-"\#TZ)=N*U%U
M#!HWH!N/LS*A8J+9Z)BAKT#1T#65(*V^T3-DN[,09HTL4ZDLBX1R='N_0EYT
M3B\J4V<HL&:N1@0'[DQ7,<S.@))3OJT&/>@S65G(NE-M5]MA\J::N0;KP=4*
MHJC;"6&GFC_-XQ'U]/J5\&U:")31#1QGS0)(%:\'POI%LGTU(CTQ"0-7];B#
M(9IR)0#[&\;D^XLZH!W+ES\ 4$L#!!0    ( +F)9EJ./W =D (   T'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;+65;6_:,!#'O\HIJZ96VD@(
M =H.(K6@:97:#<&ZO:CVPB078LVQ,]L\=)]^YX1&; ,F38(7Q ]W?__.9Y\'
M:Z6_FQS1PJ80T@R]W-KRVO=-DF/!3$N5*&DF4[I@EKIZX9M2(TLKIT+X81#T
M_()QZ<6#:FRBXX%:6L$E3C2895$P_7R+0JV'7MM[&9CR16[=@!\/2K; &=K'
M<J*IYS<J*2]0&JXD:,R&WDW[^K;O["N#+QS79J<-+I*Y4M]=YRX=>H$#0H&)
M=0J,/BL<H1!.B#!^;#6]9DGGN-M^47]?Q4ZQS)G!D1)?>6KSH7?I08H96PH[
M5>L/N(VGZ_02)4SU#^NM;>!!LC16%5MG(BBXK+]LL]V''8<P/. 0;AW"BKM>
MJ*(<,\OB@59KT,Z:U%RC"K7R)C@N75)F5M,L)S\;W\E$%0B?V0;A+<SJU(#*
MX",=B#%FJ#6F;AINC$%KX'S"-$J;H^4)$Q=P/D;+N# 7< 9<P@,7@G;;#'Q+
M=&X-/]F2W-8DX0&2,28MZ+3?0!B$$3S.QG!^=O&[C$_!-1&&381AI1L=BG Z
M@NX5/#U@,4?];1_840%W+:Y-R1(<>G3N#>H5>O'K5^U>\.X(7J?!ZU3JG0-X
MGTK4S'*Y@'ME#(R8UL]TU]9,IP:>[LD:[BP69B]XYP3@40,>'=W7*2DRG>3
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M(J:N5'/1BFY<C7M=CHN?&=?'Z)91N1'H5YI TA9PE1.U)_CHR34V*D807Z#
M_PEA#X<=$UJ\W#SH,(]>;HX-W@3U>PD*O>"[[P4$^O2[>HIN).3BGR[4I538
M+:4CQZ78DAAFC@H- O@>G/F//_A#[Y<N3#;%(DMB+81AC3 TJ<__4%%3Q4>N
M%C%=HXP)H5#&A/,4$J16]X'P!,'C-N7E,G\"PKOHFD?!7C#NPFBTZHO1DE@+
MXZ#&.# ZJ$/#@H.*#&BAX#U5Y-3&K=%U43.+*FJ3+FI&J[[4+(FUJ UK:D.C
M@P^40\S6-/U/+3:I$"Z!PBJ5G:&RE!H44OH?]7X^"B;^U-V?HCGO-!CB2;M3
MU-')&X[K3BU71K4K(Z,K?_+MAE 4\=T:G2R&3[>0+X%W!B2C8-^ 9%,LLB36
M CFN08[MQ?2Q380VQ2)+8BV$DQKAY#7!J M@*30\V0J3B>=]LZF,H_4%8TFL
M!<;WFD3.,Z*YET2"<5>:!?JN*:MJD2VU-KR3+-BWMS4K+5L<;:I%MM3:'''#
M$1L7X7M(5,*5(544(%$L2'J6A14YV!/; ^^N&_#9QL4C+SC;NN:9].9F2:W-
MK<GV?6,FW">N54HM/N>!S3Q>;SK_1Q[O-XF\;\ZQCZO*&-QL)MP+JVJ1+;4V
MOB:!]P<6@YO-%'QA52VRI=;FV*3TOCFGMQ'<AF>;UY^$'<'-.)/>W"RIM;DU
M]8-O+B#Z!+?160'C!QW1S6I-8$NMC:>I"GQCQGP6W= 7](J2RSQ([WUKM6*P
MI=8&W-0,_L1B_+-9$BRLJD6VU-K?5YL* YLKC%=^"?J.*O9"W(7.;-87G2VU
M$IU[\L$]![XN#BY4[&<[*LMO[_7=^G#DJC@2<)ONY<G*+>'KE J4P4J9>A<C
M%?MX>5A1-B3;%I_OETQ*EA>7&R J9.@.ZOF*,7ELZ 'J(Z/Y5U!+ P04
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M3*H)8):9FM' =8"Z3QF3ZXU^0#OUH[]02P,$%     @ N8EF6MZY8IF$ @
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M]CVX\SX*5^^I</W_R^$?4$L#!!0    ( +F)9EJ7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ N8EF6G(/4*)/!@
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MQBLC6OD7)I. V"8?M#'ZT74$"(2I(R!VA\OQ7=+BQCL?L@O7%S;^ Y .TT9
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MJ'?Y3KV'\?-0AUO/UQJO_YU4CY=SZ^WRU^77SLG=>\4YW%<,SW\!4$L#!!0
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MGY[SV?)7@9M?4$L! A0#%     @ N8EF6@=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "YB69:AM7?
M4.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "YB69:F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +F)9EKLEH'"3PL   ]'
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "YB69:FC&'([,&  !I&P  &               @(&2$P
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ N8EF6AMR88],
M!   /Q0  !@              ("!>QH  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( +F)9EKUD"M2)@8  ,\9   8              "
M@?T>  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "YB69:
M9@I-)H()  #?8   &               @(%9)0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ N8EF6KC8D.JQ"   &RD  !@
M     ("!$2\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M +F)9EJYE.8I30(  *4%   8              " @?@W  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " "YB69:+'5HOD,"  "*!@  &
M            @(%[.@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ N8EF6L?&A)80 @  W 0  !@              ("!]#P  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( +F)9EJ/,UBKX0P  -U#
M   9              " @3H_  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ N8EF6BYNVX[^!   Z@P  !D              ("!4DP
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "YB69:8> -
MV4TI  #6A0  &0              @(&'40  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( +F)9EJ>JS)620D  /L:   9
M  " @0M[  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
MN8EF6DP&G*1+"0  ]AH  !D              ("!BX0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " "YB69:4Y-K?"L+  #B(@  &0
M            @($-C@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( +F)9EJ_EI*YYPL  %TH   9              " @6^9  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ N8EF6M'E<RM\!
M=PL  !D              ("!C:4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " "YB69:9F&#A! #  "T!@  &0              @(%
MJ@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +F)9EKT
M(.1VK (  +H%   9              " @8>M  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ N8EF6J.R!A6V!   $PL  !D
M     ("!:K   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +F)9EJBZ&P-(@,  ,L&   9              "
M@9+0  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ N8EF
M6CADMZ*:!P  ZA(  !D              ("!Z],  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " "YB69:EL3R!LH)  "S&0  &0
M        @(&\VP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( +F)9EHCW]@E: 0  (H)   9              " @;WE  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ N8EF6I3)-6__ @  @08
M !D              ("!7.H  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " "YB69:]T4,%(TN  !.GP  &0              @(&2[0
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +F)9EJ_Y'QY
M_0(  +H&   9              " @58< 0!X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ N8EF6F1"X3B* P  FP<  !D
M ("!BA\! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "Y
MB69:?3J0?@D(   +&P  &0              @(%+(P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +F)9EJP%,OY-0,  +D'   9
M          " @8LK 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#
M%     @ N8EF6K*B\\K! @  _@4  !D              ("!]RX! 'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "YB69:SK'E2+("  "V
M!0  &0              @('O,0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;%!+ 0(4 Q0    ( +F)9EHY'G2.O0(   L&   9              " @=@T
M 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ N8EF6N!P
M!+?4 @  )P8  !D              ("!S#<! 'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q02P$"% ,4    " "YB69:J7A(?TD#   F!P  &0
M    @('7.@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M +F)9EKH#*%3W08  /H5   9              " @5<^ 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ N8EF6KVSSG'? P  @ D  !D
M             ("!:T4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " "YB69:([%BZGH%   7#0  &0              @(&!20$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( +F)9EH2047@? @
M +DY   9              " @3)/ 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ N8EF6JMPT_=K P  1@X  !D              ("!
MY5<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "YB69:
M,;_V("8%   !)P  &0              @(&'6P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( +F)9EH41[XJDP0  .D1   9
M      " @>1@ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ N8EF6I@GZ^!@ P  /PL  !D              ("!KF4! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "YB69:"NUZ3J,"   S!P
M&0              @(%%:0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( +F)9EJZ-$"3ZPD  $U?   9              " @1]L 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ N8EF6HH?\WE$
M!P  $S,  !D              ("!078! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " "YB69:34Z@^00#  #U"   &0
M@(&\?0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +F)
M9EIEK?'\#@8  "TE   9              " @?>  0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ N8EF6D:KR^/M P  EA(  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( +F)9EJ<B^6V4P,  (0.   9
M  " @9V= 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
MN8EF6AR6]3AL @  T04  !D              ("!)Z$! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " "YB69:Z#5&_LH"   X"   &0
M            @('*HP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( +F)9EK1Y6,VAP(  (T%   9              " @<NF 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ N8EF6I.LQONT!
MZ1@  !D              ("!B:D! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    " "YB69:UF%D)HD"  !^!@  &0              @(%T
MK@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( +F)9EID
M80>K.P8  -,<   9              " @32Q 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ N8EF6NI=(T1A P  D@T  !D
M     ("!IK<! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +F)9EJ :I@9204  .,>   9              "
M@0;1 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ N8EF
M6G3E[^#^ @  HP<  !D              ("!AM8! 'AL+W=O<FMS:&5E=',O
M<VAE970W,2YX;6Q02P$"% ,4    " "YB69:<.AJ9)4"  "W!@  &0
M        @(&[V0$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0
M   ( +F)9EKA,,$,+P0  "\2   9              " @8?< 0!X;"]W;W)K
M<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ N8EF6E&^O["0 P  Z L
M !D              ("![> ! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q0
M2P$"% ,4    " "YB69:@6-4\O@"   I#   &0              @(&TY $
M>&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( +F)9EK("ZAF
MJP(  "$&   9              " @>/G 0!X;"]W;W)K<VAE971S+W-H965T
M-S8N>&UL4$L! A0#%     @ N8EF6H\J"4]) @  H04  !D
M ("!Q>H! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " "Y
MB69: #,^%V8$  "B#P  &0              @(%%[0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( +F)9EJ./W =D (   T'   9
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M970X,RYX;6Q02P$"% ,4    " "YB69:ELAR!;<"  #&"   &0
M    @($, P( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    (
M +F)9EI64!1W2 ,  ,P4   -              "  ?H% @!X;"]S='EL97,N
M>&UL4$L! A0#%     @ N8EF6I>*NQS     $P(   L              ( !
M;0D" %]R96QS+RYR96QS4$L! A0#%     @ N8EF6G(/4*)/!@  ##<   \
M             ( !5@H" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +F)
M9EJ3,;S]@ (  ),Q   :              "  =(0 @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +F)9EKW,"8&)P(  #(P   3
M          "  8H3 @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !< %P
*.QD  .(5 @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheet (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals</Role>
      <ShortName>Consolidated Balance Sheet (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Description of Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>Description of Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureMerger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available-for-Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Borrowing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing</Role>
      <ShortName>Borrowing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995557 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Accumulated Other Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995657 - Disclosure - 401(K) plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlan</Role>
      <ShortName>401(K) plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available-for-Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995797 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Accumulated Other Comprehensive (loss) Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive (loss) Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/Warrants</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/IncomeTax</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Significant Accounting Policies - Schedule of Concentration of Credit Risk Net Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Concentration of Credit Risk Net Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Acquisition (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Acquisition (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Acquisition - Schedule of Final Allocable Purchase Price Consists (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails</Role>
      <ShortName>Acquisition - Schedule of Final Allocable Purchase Price Consists (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Acquisition - Schedule of Final Allocable Purchase Price Consists (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails</Role>
      <ShortName>Acquisition - Schedule of Final Allocable Purchase Price Consists (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Merger - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails</Role>
      <ShortName>Merger - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Marketable securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Marketable securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Net Realized Gain (Loss) on Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Net Realized Gain (Loss) on Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale - Schedule of Marketable Securities with Continuous Unrealized Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available-for-Sale - Schedule of Marketable Securities with Continuous Unrealized Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule Of Available for sale Securities Maturity on Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities Available For Sale - Schedule Of Available for sale Securities Maturity on Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Collaboration and License Agreements - Schedule of revenue recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of revenue recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Collaboration and License Agreements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Collaboration and License Agreements - Schedule Of Contract Assets And Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule Of Contract Assets And Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Borrowing (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails</Role>
      <ShortName>Borrowing (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Property and Equipment - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996077 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996087 - Disclosure - ACCRUED EXPENSES - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996117 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996127 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996137 - Disclosure - Leases - Schedule of Aggregate Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Aggregate Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996167 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996177 - Disclosure - Net Loss Per Share - Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996187 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Changes in Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income - Schedule of Changes in Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996197 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996207 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996217 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996227 - Disclosure - Stock-Based Compensation - Summary of Grant-date Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Grant-date Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996237 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996247 - Disclosure - 401(K) PLAN - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails</Role>
      <ShortName>401(K) PLAN - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996257 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996267 - Disclosure - Warrants - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails</Role>
      <ShortName>Warrants - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996277 - Disclosure - Warrants - Schedule of Fair Values for Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails</Role>
      <ShortName>Warrants - Schedule of Fair Values for Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996297 - Disclosure - Warrants - Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails</Role>
      <ShortName>Warrants - Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996307 - Disclosure - Income Tax - Summary Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails</Role>
      <ShortName>Income Tax - Summary Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996317 - Disclosure - Income Tax - Summary of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Tax - Summary of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996327 - Disclosure - Income Taxe - Summary of Net Deferred Tax Assets (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails</Role>
      <ShortName>Income Taxe - Summary of Net Deferred Tax Assets (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996337 - Disclosure - Income Tax - Summary of Reconciliation of the Federal Income Tax Rate to the Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails</Role>
      <ShortName>Income Tax - Summary of Reconciliation of the Federal Income Tax Rate to the Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996347 - Disclosure - Income Tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails</Role>
      <ShortName>Income Tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996357 - Disclosure - Income Tax - Summary of unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Tax - Summary of unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996387 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="nuvb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996397 - Disclosure - Subsequent Event (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="nuvb-20241231.htm">nuvb-20241231.htm</File>
    <File>nuvb-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img58233625_0.jpg</File>
    <File>img58233625_1.jpg</File>
    <File>img58233625_2.jpg</File>
    <File>img58233625_3.jpg</File>
    <File>img58233625_4.jpg</File>
    <File>img58233625_5.jpg</File>
    <File>img58233625_6.jpg</File>
    <File>img58233625_7.jpg</File>
    <File>img58233625_8.gif</File>
    <File>img58233625_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="816">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nuvb-20241231.htm": {
   "nsprefix": "nuvb",
   "nsuri": "http://nuvationbio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "nuvb-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "nuvb-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 342,
   "keyCustom": 64,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 44,
   "memberCustom": 35,
   "hidden": {
    "total": 5,
    "http://fasb.org/us-gaap/2024": 2,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 236,
   "entityCount": 1,
   "segmentCount": 81,
   "elementCount": 900,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 816,
    "http://xbrl.sec.gov/dei/2024": 44,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
     "longName": "100010 - Statement - Consolidated Balance Sheet",
     "shortName": "Consolidated Balance Sheet",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
     "longName": "100030 - Statement - Consolidated Balance Sheet (Parentheticals)",
     "shortName": "Consolidated Balance Sheet (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "nuvb:IntangibleAssetsNetOfAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_6f054bef-1755-4a9e-b507-73b2cd109b47",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6f054bef-1755-4a9e-b507-73b2cd109b47",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_6f054bef-1755-4a9e-b507-73b2cd109b47",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6f054bef-1755-4a9e-b507-73b2cd109b47",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DescriptionOfOrganizationAndBusinessOperations",
     "longName": "995467 - Disclosure - Description of Organization and Business Operations",
     "shortName": "Description of Organization and Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies",
     "longName": "995487 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition",
     "longName": "995497 - Disclosure - Acquisition",
     "shortName": "Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMerger",
     "longName": "995507 - Disclosure - Merger",
     "shortName": "Merger",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale",
     "longName": "995517 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale",
     "shortName": "Fair Value Measurements and Marketable Securities Available-for-Sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements",
     "longName": "995527 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:CollaborationAndLicenseAgreementsTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:CollaborationAndLicenseAgreementsTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing",
     "longName": "995537 - Disclosure - Borrowing",
     "shortName": "Borrowing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SubordinatedBorrowingsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SubordinatedBorrowingsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment",
     "longName": "995547 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1",
     "longName": "995557 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases",
     "longName": "995597 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/StockholdersEquity",
     "longName": "995617 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995627 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1",
     "longName": "995637 - Disclosure - Accumulated Other Comprehensive (Loss) Income",
     "shortName": "Accumulated Other Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1",
     "longName": "995647 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlan",
     "longName": "995657 - Disclosure - 401(K) plan",
     "shortName": "401(K) plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/Warrants",
     "longName": "995667 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:WarrantDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:WarrantDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/IncomeTax",
     "longName": "995677 - Disclosure - Income Tax",
     "shortName": "Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995697 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent",
     "longName": "995707 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "995717 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995737 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables",
     "longName": "995747 - Disclosure - Acquisition (Tables)",
     "shortName": "Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables",
     "longName": "995767 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale (Tables)",
     "shortName": "Fair Value Measurements and Marketable Securities Available-for-Sale (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables",
     "longName": "995777 - Disclosure - Collaboration and License Agreements (Tables)",
     "shortName": "Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "longName": "995787 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables",
     "longName": "995797 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995807 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995817 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables",
     "longName": "995827 - Disclosure - Accumulated Other Comprehensive (loss) Income (Tables)",
     "shortName": "Accumulated Other Comprehensive (loss) Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995837 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables",
     "longName": "995847 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables",
     "longName": "995857 - Disclosure - Income Tax (Tables)",
     "shortName": "Income Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995887 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "nuvb:CashAndCashEquivalentsAndMarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "nuvb:LiquidityPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails",
     "longName": "995897 - Disclosure - Significant Accounting Policies - Schedule of Concentration of Credit Risk Net Revenue (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Concentration of Credit Risk Net Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_da21c4c3-938d-42bc-bc80-ba4f2ce5c849",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
     "longName": "995907 - Disclosure - Acquisition (Additional Information) (Details)",
     "shortName": "Acquisition (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_0f03a15b-3abb-4776-a53a-0c003dafb17a",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0f03a15b-3abb-4776-a53a-0c003dafb17a",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
     "longName": "995917 - Disclosure - Acquisition - Schedule of Final Allocable Purchase Price Consists (Details)",
     "shortName": "Acquisition - Schedule of Final Allocable Purchase Price Consists (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:AllocablePurchasePrice",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:AllocablePurchasePrice",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
     "longName": "995927 - Disclosure - Acquisition - Schedule of Final Allocable Purchase Price Consists (Parenthetical) (Details)",
     "shortName": "Acquisition - Schedule of Final Allocable Purchase Price Consists (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
     "longName": "995957 - Disclosure - Merger - Additional Information (Details)",
     "shortName": "Merger - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
     "longName": "995967 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Marketable securities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Marketable securities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
     "longName": "995977 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale (Details)",
     "shortName": "Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails",
     "longName": "995997 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Net Realized Gain (Loss) on Marketable Securities (Details)",
     "shortName": "Fair Value Measurements and Marketable Securities Available For Sale - Schedule of Net Realized Gain (Loss) on Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails",
     "longName": "996007 - Disclosure - Fair Value Measurements and Marketable Securities Available-for-Sale - Schedule of Marketable Securities with Continuous Unrealized Losses (Details)",
     "shortName": "Fair Value Measurements and Marketable Securities Available-for-Sale - Schedule of Marketable Securities with Continuous Unrealized Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
     "longName": "996017 - Disclosure - Fair Value Measurements and Marketable Securities Available For Sale - Schedule Of Available for sale Securities Maturity on Fair Value (Details)",
     "shortName": "Fair Value Measurements and Marketable Securities Available For Sale - Schedule Of Available for sale Securities Maturity on Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nuvb:ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nuvb:ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails",
     "longName": "996027 - Disclosure - Collaboration and License Agreements - Schedule of revenue recognized (Details)",
     "shortName": "Collaboration and License Agreements - Schedule of revenue recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59e21847-16f9-4084-92e3-35afa293d947",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "longName": "996037 - Disclosure - Collaboration and License Agreements (Additional Information) (Details)",
     "shortName": "Collaboration and License Agreements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails",
     "longName": "996047 - Disclosure - Collaboration and License Agreements - Schedule Of Contract Assets And Contract Liabilities (Details)",
     "shortName": "Collaboration and License Agreements - Schedule Of Contract Assets And Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails",
     "longName": "996057 - Disclosure - Borrowing (Additional Information) (Details)",
     "shortName": "Borrowing (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_26117e6c-01c9-4aec-ab24-63bd5f5810f8",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_26117e6c-01c9-4aec-ab24-63bd5f5810f8",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails",
     "longName": "996067 - Disclosure - Property and Equipment - (Details)",
     "shortName": "Property and Equipment - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "longName": "996077 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails",
     "longName": "996087 - Disclosure - ACCRUED EXPENSES - (Details)",
     "shortName": "ACCRUED EXPENSES - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails",
     "longName": "996117 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SaleOfStockDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "996127 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails",
     "longName": "996137 - Disclosure - Leases - Schedule of Aggregate Lease Payments (Details)",
     "shortName": "Leases - Schedule of Aggregate Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "996167 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a5a3ec93-d622-45c2-8770-84e991a7b996",
      "name": "nuvb:NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails",
     "longName": "996177 - Disclosure - Net Loss Per Share - Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding (Details)",
     "shortName": "Net Loss Per Share - Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_e555de18-2b2c-49fe-b7c4-7fc47b8d8119",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e555de18-2b2c-49fe-b7c4-7fc47b8d8119",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails",
     "longName": "996187 - Disclosure - Accumulated Other Comprehensive Income - Schedule of Changes in Accumulated Other Comprehensive Income (Details)",
     "shortName": "Accumulated Other Comprehensive Income - Schedule of Changes in Accumulated Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_2a8fdeac-e96f-4090-9037-5d3af26c4059",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "996197 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
     "longName": "996207 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "996217 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_0c652882-855e-465e-8c03-230c6f70279d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c652882-855e-465e-8c03-230c6f70279d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
     "longName": "996227 - Disclosure - Stock-Based Compensation - Summary of Grant-date Fair Value of Stock Options Granted (Details)",
     "shortName": "Stock-Based Compensation - Summary of Grant-date Fair Value of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "longName": "996237 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_b98b6295-0101-48a0-af40-21586c6ade2e",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b98b6295-0101-48a0-af40-21586c6ade2e",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails",
     "longName": "996247 - Disclosure - 401(K) PLAN - Additional Information (Details)",
     "shortName": "401(K) PLAN - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails",
     "longName": "996257 - Disclosure - Warrants - Additional Information (Details)",
     "shortName": "Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "nuvb:WarrantsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:MarketRiskBenefitChangeInFairValueGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails",
     "longName": "996267 - Disclosure - Warrants - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements (Details)",
     "shortName": "Warrants - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
     "longName": "996277 - Disclosure - Warrants - Schedule of Fair Values for Outstanding Warrants (Details)",
     "shortName": "Warrants - Schedule of Fair Values for Outstanding Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails",
     "longName": "996297 - Disclosure - Warrants - Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy (Details)",
     "shortName": "Warrants - Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_2a8fdeac-e96f-4090-9037-5d3af26c4059",
      "name": "nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2a8fdeac-e96f-4090-9037-5d3af26c4059",
      "name": "nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails",
     "longName": "996307 - Disclosure - Income Tax - Summary Income Tax Provision (Details)",
     "shortName": "Income Tax - Summary Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R78": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails",
     "longName": "996317 - Disclosure - Income Tax - Summary of Net Deferred Tax Assets (Details)",
     "shortName": "Income Tax - Summary of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails",
     "longName": "996327 - Disclosure - Income Taxe - Summary of Net Deferred Tax Assets (Parenthetical) (Details)",
     "shortName": "Income Taxe - Summary of Net Deferred Tax Assets (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_f4d88de7-a689-43dc-94ed-786f211f10b1",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4d88de7-a689-43dc-94ed-786f211f10b1",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails",
     "longName": "996337 - Disclosure - Income Tax - Summary of Reconciliation of the Federal Income Tax Rate to the Company's Effective Tax Rate (Details)",
     "shortName": "Income Tax - Summary of Reconciliation of the Federal Income Tax Rate to the Company's Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails",
     "longName": "996347 - Disclosure - Income Tax - Additional Information (Details)",
     "shortName": "Income Tax - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:OperatingLossCarryforwardsExpiration",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "nuvb:OperatingLossCarryforwardsExpiration",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails",
     "longName": "996357 - Disclosure - Income Tax - Summary of unrecognized tax benefits (Details)",
     "shortName": "Income Tax - Summary of unrecognized tax benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_2a8fdeac-e96f-4090-9037-5d3af26c4059",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ea97e0-ebd5-40bc-be56-aa30eff45d81",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "996387 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_39d9ef20-3367-48ef-9bd5-5cb516f43747",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_39d9ef20-3367-48ef-9bd5-5cb516f43747",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "longName": "996397 - Disclosure - Subsequent Event (Additional Information) (Details)",
     "shortName": "Subsequent Event (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_0b0d4681-373d-40ee-a05b-cf4167b76104",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b0d4681-373d-40ee-a05b-cf4167b76104",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvb-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpenses1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66",
      "r70",
      "r1160"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r905"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total",
        "terseLabel": "Accounts receivable, net of allowance for credit loss of $nil",
        "verboseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r837",
      "r925",
      "r1207",
      "r1208"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion Expense",
        "label": "Accretion Expense",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r1119"
     ]
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation",
        "label": "Accrued Employee Benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r129"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued Liabilities, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued consultant fees",
        "label": "Accrued Professional Fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $874 and $666, respectively",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r201",
      "r689"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r82",
      "r207",
      "r684",
      "r719",
      "r723"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r10",
      "r21",
      "r534",
      "r537",
      "r597",
      "r714",
      "r715",
      "r1071",
      "r1072",
      "r1073",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "nuvb_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired In-Process Research and Development",
        "documentation": "Acquired in-process research and development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquisitionRelatedCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquisitionRelatedCostsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition Related Costs [Member]",
        "label": "Acquisition-related Costs [Member]",
        "verboseLabel": "Acquisition Costs [Member]",
        "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1177",
      "r1244"
     ]
    },
    "nuvb_AdditionalPurchaseUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "AdditionalPurchaseUnits",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Purchase Units",
        "label": "AdditionalPurchaseUnits",
        "terseLabel": "Additional purchase units"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in Paid in Capital",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r111",
      "r114"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r434"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r975",
      "r1008"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r978",
      "r1011"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1003",
      "r1012",
      "r1016",
      "r1024"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "nuvb_AllocablePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "AllocablePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total allocable purchase price",
        "label": "Allocable Purchase Price",
        "documentation": "Allocable Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r475"
     ]
    },
    "us-gaap_AllowanceForCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r289",
      "r330",
      "r333",
      "r334",
      "r1208"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_AmortizationOfPremiumOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "AmortizationOfPremiumOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premium and discounts on marketable securities",
        "label": "Amortization Of Premium On Marketable Securities",
        "documentation": "Amortization of premium on marketable securities.",
        "terseLabel": "Net amortization on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_AnheartMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "AnheartMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AnHeart [Member]",
        "label": "AnHeart [Member]",
        "documentation": "AnHeart [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Securities outstanding excluded from calculation of weighted average shares outstanding",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Purchase of common stock (in Shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisition of assets and businesses",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r142",
      "r203",
      "r232",
      "r264",
      "r268",
      "r281",
      "r282",
      "r325",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r529",
      "r531",
      "r568",
      "r680",
      "r781",
      "r863",
      "r864",
      "r905",
      "r932",
      "r1126",
      "r1127",
      "r1194"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r209",
      "r232",
      "r325",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r529",
      "r531",
      "r568",
      "r905",
      "r1126",
      "r1127",
      "r1194"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_AssumedShareBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "AssumedShareBasedAwardsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumed Share Based Awards [Member]",
        "documentation": "Assumed Share Based Awards Member",
        "terseLabel": "Assumed Share Based Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r961"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r961"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r961"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Opinion",
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r338",
      "r679"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, Amortized Cost",
        "terseLabel": "Total, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1203"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due With in one year, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value",
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r338",
      "r546",
      "r672",
      "r894",
      "r897",
      "r1099",
      "r1181",
      "r1182",
      "r1183"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "srt_BankLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BankLoans",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Broker-Dealer, Bank Loan, Short-Term",
        "terseLabel": "Short term bank loan",
        "documentation": "Amount of short-term bank loan secured by broker-dealer customer's security."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "nuvb_BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic And Diluted Net Loss Per Share Class A And Class B Nonredeemable Common Stockin Doll",
        "label": "BasicAndDilutedNetLossPerShareClassAAndClassBNonredeemableCommonStockinDoll",
        "terseLabel": "Basic and diluted net loss per share, Class A and Class B non-redeemable common stock (in Dollars per share)",
        "verboseLabel": "Loss/Basic and Diluted\u00a0Non-Redeemable\u00a0Class\u00a0A and B Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_BorrowingTwoThousandsAndTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BorrowingTwoThousandsAndTwentyMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing Two Thousands And Twenty [Member]",
        "documentation": "Borrowing Two Thousands And Twenty [Member]",
        "terseLabel": "Borrowing in 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_BorrowingTwoThousandsAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BorrowingTwoThousandsAndTwentyTwoMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing Two Thousands And Twenty Two [Member]",
        "documentation": "Borrowing Two Thousands And Twenty Two [Member]",
        "terseLabel": "Borrowing in 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r524",
      "r887",
      "r888"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r524",
      "r887",
      "r888"
     ]
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement Date",
        "label": "Business Acquisition, Date of Acquisition Agreement",
        "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Public per share (in Dollars per share)",
        "verboseLabel": "Per share price (in Dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_BusinessCombinationCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BusinessCombinationCommonStockSharesOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Common Stock Shares Outstanding.",
        "label": "Business Combination Common Stock Shares Outstanding",
        "totalLabel": "Common stock of Panacea"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationControlObtainedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationControlObtainedDescription",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Control Obtained Description",
        "label": "Business Combination, Control Obtained Description",
        "documentation": "This element represents a description of how the entity obtained control of the acquired entity."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "nuvb_BusinessCombinationConversionOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BusinessCombinationConversionOfRedeemableConvertiblePreferredStock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Conversion of Redeemable Convertible Preferred Stock.",
        "label": "Business Combination Conversion Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Conversion of Old Nuvation Redeemable Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisition",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMerger"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger",
        "terseLabel": "Acquisition",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r525"
     ]
    },
    "nuvb_BusinessCombinationPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BusinessCombinationPricePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Price Per Share",
        "label": "BusinessCombinationPricePerShare",
        "terseLabel": "Business combination price per share (in Dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total",
        "terseLabel": "Assets acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expense",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities",
        "documentation": "The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "nuvb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Warrant Liability.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_BusinessCombinationTrueUp": {
     "xbrltype": "pureItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "BusinessCombinationTrueUp",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination True",
        "terseLabel": "True-up",
        "label": "Effective Income Tax Business Combination True Up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost",
        "label": "Capitalized Contract Cost, Net",
        "totalLabel": "Capitalized Contract Cost, Net, Total",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired from AnHeart acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CashAndCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CashAndCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and marketable securities .",
        "label": "Cash And Cash Equivalents And Marketable Securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r199",
      "r855"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "nuvb_CashAtBankAndCashHeldInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CashAtBankAndCashHeldInTrustAccount",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash at bank and cash held in trust account.",
        "label": "Cash At Bank And Cash Held In Trust Account",
        "terseLabel": "Panacea cash at bank and cash held in a trust account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r97",
      "r228"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "terseLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r97"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1206"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "nuvb_CashFlowNoncashOperatingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CashFlowNoncashOperatingActivitiesDisclosureAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Operating Activities Disclosure [Abstract]",
        "documentation": "Cash Flow, Noncash Operating Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CertificateOfDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CertificateOfDepositsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificate of deposits [Member]",
        "documentation": "Certificate of deposits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of Private Warrants liability recognized in earnings",
        "label": "Change in Fair Value of Private Warrants Liability Recognized in Earnings",
        "documentation": "Change in fair value of private warrants liability recognized in earnings.",
        "terseLabel": "Change in fair value of Private Warrants liability recognized in earnings"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "nuvb_ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Changes in Liabilities Classified in Level 3 of Fair Value Hierarchy",
        "documentation": "Changes in liabilities classified in Level 3 of fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ClassAAndClassBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ClassAAndClassBCommonStockMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A And Class B Common Stock [Member]",
        "documentation": "Class A and Class B common stock.",
        "label": "Class A and Class B Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ClassACommonSharesSubjectToRepurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ClassACommonSharesSubjectToRepurchaseMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Common Shares Subject to Repurchase.",
        "label": "Class A Common Shares Subject to Repurchase [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r204",
      "r205",
      "r206",
      "r232",
      "r254",
      "r255",
      "r257",
      "r259",
      "r266",
      "r267",
      "r325",
      "r376",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r388",
      "r389",
      "r392",
      "r395",
      "r403",
      "r568",
      "r734",
      "r735",
      "r736",
      "r737",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r768",
      "r790",
      "r811",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r1048",
      "r1080",
      "r1090"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class of warrant or right, exercise price of warrants or rights",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant price per share (in Dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock outstanding",
        "terseLabel": "Warrants to purchase common stock outstanding",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "nuvb_CollaborationAndLicenceAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CollaborationAndLicenceAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration and Licence Agreement [Abstract]",
        "documentation": "Collaboration and Licence Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CollaborationAndLicenseAgreementsTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CollaborationAndLicenseAgreementsTextblock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaboration And License Agreements [TextBlock]",
        "documentation": "Collaboration And License Agreements TextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangement",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r375",
      "r926",
      "r927",
      "r928",
      "r929"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 17)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r133",
      "r682",
      "r767"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r367",
      "r368",
      "r839",
      "r1116",
      "r1120"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A Shares [Member]",
        "terseLabel": "Class A Common Stock [Member]",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class B Shares [Member]",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockConversionFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConversionFeatures",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock terms of conversion",
        "label": "Common Stock, Terms of Conversion",
        "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r404"
     ]
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Additional Paid-in Capital [Member]",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and additional paid in capital, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "nuvb_CommonStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CommonStockRedemptionPricePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Redemption Price Per Share.",
        "label": "Common Stock Redemption Price Per Share",
        "terseLabel": "Common stock redemption price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and additional paid in capital, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r768"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares issued",
        "terseLabel": "Common stock and additional paid in capital, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding",
        "terseLabel": "Common stock and additional paid in capital, shares outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r768",
      "r787",
      "r1244",
      "r1245"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value",
        "verboseLabel": "Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000,Class B 60,000,000) shares authorized as of December 31, 2024 and December 31, 2023, respectively, 337,837,872 (Class A 336,837,872, Class B 1,000,000) and 219,046,219 (Class A 218,046,219, Class B 1,000,000) shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r683",
      "r905"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Voting Rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r213",
      "r215",
      "r221",
      "r674",
      "r695",
      "r696"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r58",
      "r59",
      "r287",
      "r838"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r58",
      "r59",
      "r287",
      "r725",
      "r838"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r58",
      "r59",
      "r287",
      "r838",
      "r1054"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r151"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "nuvb_ConcentrationRiskThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConcentrationRiskThresholdPercentage",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Threshold Percentage",
        "documentation": "Concentration Risk Threshold Percentage",
        "terseLabel": "Concentration Risk Threshold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r58",
      "r59",
      "r287",
      "r838"
     ]
    },
    "nuvb_ConsiderationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConsiderationWarrantsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration Warrants [Member]",
        "documentation": "Consideration Warrants [Member]",
        "terseLabel": "Consideration Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r857"
     ]
    },
    "us-gaap_ContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractTerminationMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Termination [Member]",
        "terseLabel": "Contract termination costs",
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": [
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule Of Contract Assets And Contract Liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "nuvb_ContractWithCustomerAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ContractWithCustomerAssets",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Assets",
        "documentation": "Contract With Customer Assets",
        "terseLabel": "Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "terseLabel": "Contract Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r419"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities, current portion",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r419"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r419"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer liability revenue recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "nuvb_ConversionOfFounderShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConversionOfFounderShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Founder shares.",
        "label": "Conversion Of Founder Shares",
        "terseLabel": "Conversion of Founder shares"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ConversionOfOldNuvationClassACommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConversionOfOldNuvationClassACommonStock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Old Nuvation Class A common stock",
        "label": "Conversion of Old Nuvation Class A common stock",
        "documentation": "Conversion of Old Nuvation Class A common stock"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ConversionOfOldNuvationClassBCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConversionOfOldNuvationClassBCommonStock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Old Nuvation Class B common stock",
        "label": "Conversion of Old Nuvation Class B common stock",
        "documentation": "Conversion of Old Nuvation Class B common stock"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ConversionOfSharesRelatedToMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConversionOfSharesRelatedToMerger",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of shares related to merger.",
        "label": "Conversion Of Shares Related To Merger",
        "terseLabel": "Conversion of Panacea shares as a result of merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock to Common Stock related to the AnHeart acquisition, Value",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of preferred stock to Common Stock related to the AnHeart acquisition, Share",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]",
        "verboseLabel": "Series A Non-Voting Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r392",
      "r926",
      "r927",
      "r928",
      "r929"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Conversion of preferred stock to Common Stock related to the AnHeart acquisition",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r44",
      "r75",
      "r113",
      "r398"
     ]
    },
    "nuvb_ConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ConvertiblePreferredStocksMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock [Member]",
        "label": "Convertible Preferred Stocks [Member]",
        "documentation": "Convertible Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r886",
      "r894",
      "r906",
      "r920",
      "r1237"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r639"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CurrencyTranslationAdjustmentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CurrencyTranslationAdjustmentValue",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency Translation Adjustment Value",
        "documentation": "Currency Translation Adjustment Value",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CurrentAndDeferredFederalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CurrentAndDeferredFederalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current and deferred federal tax expense benefit.",
        "label": "Current and Deferred Federal Tax Expense Benefit [Abstract]",
        "terseLabel": "Federal"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CurrentAndDeferredStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current and deferred state and local tax expense benefit.",
        "label": "Current and Deferred State and Local Tax Expense Benefit [Abstract]",
        "terseLabel": "State"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense - federal and state",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Current Federal, State and Local, Tax Expense (Benefit), Total",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1083",
      "r1171"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1083",
      "r1171"
     ]
    },
    "nuvb_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]",
        "documentation": "Customer A [Member]",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]",
        "documentation": "Customer B [Member]",
        "terseLabel": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r287"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1039"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1032"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1034"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1034"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1033"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r342",
      "r867"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Greater, Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r342"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 Months, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r342",
      "r867"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 Months, Unrealized Losses",
        "terseLabel": "Less than 12 Months, Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r342"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Realized gains from sales of available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized losses from sales of available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amount reclassified for realized gains included in gain (loss) on marketable securities",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total",
        "terseLabel": "Amount reclassified for realized loss (gain) on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1101",
      "r1102"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r340",
      "r867"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r341"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities with Continuous Unrealized Losses",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r867",
      "r1114"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_DebtSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Unrealized Gain (Loss), Total",
        "label": "Debt Securities, Unrealized Gain (Loss)",
        "negatedLabel": "Change in unrealized (loss) gain on available-for-sale securities",
        "terseLabel": "Change in unrealized (loss) gain on available-for-sale securities",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Financing Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1170",
      "r1171"
     ]
    },
    "nuvb_DeferredFinancingCostsInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "DeferredFinancingCostsInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred financing costs in accounts payable and accrued expenses",
        "label": "Deferred financing costs in accounts payable and accrued expenses",
        "documentation": "Deferred financing costs in accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax benefit",
        "terseLabel": "Deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r160",
      "r1083"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r130",
      "r502"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1170",
      "r1171"
     ]
    },
    "nuvb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Amount of deferred tax assets attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Research and development capitalized expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "nuvb_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "verboseLabel": "Change in valuation allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain on marketable securities",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Annual Contributions Per Employee, Amount",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Annual Contributions Per Employee, Percent",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/Disclosure401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "401(K) Plan",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r124",
      "r125",
      "r210",
      "r856"
     ]
    },
    "nuvb_DescriptionOfPublicWarrant": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "DescriptionOfPublicWarrant",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of public warrant.",
        "label": "DescriptionOfPublicWarrant",
        "terseLabel": "Description of public warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of revenue recognized",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r436",
      "r467",
      "r468",
      "r470",
      "r890"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r961"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r961",
      "r1004"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information:",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net loss per share attributable to common stockholders, basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r254",
      "r257",
      "r258",
      "r259",
      "r263",
      "r522",
      "r527",
      "r543",
      "r544",
      "r675",
      "r697",
      "r858"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r246",
      "r254",
      "r257",
      "r258",
      "r259",
      "r263",
      "r522",
      "r527",
      "r543",
      "r544",
      "r675",
      "r697",
      "r858"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r260",
      "r261",
      "r262"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Income tax provision",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r893"
     ]
    },
    "nuvb_EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Acquired IPR&amp;D, Other, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Acquired IPR&amp;D, Other, Percent",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Acquisition Rate, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Acquisition Rate, Percent",
        "terseLabel": "Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal statutory rate",
        "terseLabel": "Federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r484",
      "r512",
      "r893"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r893",
      "r1084",
      "r1161"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in rate",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r893",
      "r1084",
      "r1161"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r1084",
      "r1161"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r1084",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r893",
      "r1084",
      "r1161"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r1084",
      "r1161",
      "r1163"
     ]
    },
    "nuvb_EffectiveIncomeTaxRateReconciliationTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTrueUp",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "True-up",
        "label": "Effective Income Tax Rate Reconciliation True Up",
        "documentation": "Effective Income Tax Rate Reconciliation True Up"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_EffectiveIncomeTaxRateReconciliationWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationWarrants",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxSummaryOfReconciliationOfTheFederalIncomeTaxRateToTheCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Effective Income Tax Rate Reconciliation Warrants",
        "documentation": "Effective Income Tax Rate Reconciliation Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_EmergingGrowthPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EmergingGrowthPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Growth Policy Text Block.",
        "label": "Emerging Growth Policy [Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and benefit costs",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r194",
      "r217",
      "r218",
      "r219",
      "r234",
      "r235",
      "r236",
      "r238",
      "r244",
      "r247",
      "r249",
      "r265",
      "r326",
      "r329",
      "r352",
      "r406",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r526",
      "r527",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r542",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r583",
      "r597",
      "r693",
      "r714",
      "r715",
      "r716",
      "r743",
      "r811"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r518",
      "r1049",
      "r1050",
      "r1051",
      "r1172",
      "r1173",
      "r1174",
      "r1175"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ownership percentage of outstanding shares",
        "terseLabel": "Equity Method Investment Ownership Percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Equity Securities, FV-NI, Gain (Loss), Total",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r1111"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedGainLossAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net gains (losses) on equity securities were as follows:",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net realized losses on equities sold",
        "label": "Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Net realized losses on equities sold",
        "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net unrealized losses on equities",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r975",
      "r1008"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r972",
      "r1005"
     ]
    },
    "nuvb_EstimatedFairValueWarrantPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "EstimatedFairValueWarrantPerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Fair Value Warrant Per Share",
        "documentation": "Estimated Fair Value Warrant Per Share",
        "terseLabel": "Estimated Fair Value Warrant Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExchangeTradedFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExchangeTradedFundsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Traded Funds [Member]",
        "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of Warrants",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrants liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of the significant inputs to the Monte Carlo Simulation for the fair value of the Public Warrants",
        "verboseLabel": "Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549",
      "r897"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable securities Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r561",
      "r895"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r561",
      "r895"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r559",
      "r560",
      "r562",
      "r610",
      "r611",
      "r612",
      "r874",
      "r875",
      "r884",
      "r885",
      "r886",
      "r894",
      "r897"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Marketable Securities Available for Sale",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r557",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r671",
      "r894",
      "r898"
     ]
    },
    "nuvb_FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Equity Level1 To Level2 or Level3 Transfers Description",
        "label": "Fair Value Equity Level1 To Level2 or Level3 Transfers Description",
        "terseLabel": "Fair Value Equity Level1 To Level2 or Level3 Transfers Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r422",
      "r427",
      "r547",
      "r560",
      "r610",
      "r884",
      "r885",
      "r886",
      "r894"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r422",
      "r427",
      "r547",
      "r548",
      "r560",
      "r611",
      "r874",
      "r875",
      "r884",
      "r885",
      "r886",
      "r894"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r547",
      "r548",
      "r549",
      "r550",
      "r560",
      "r612",
      "r874",
      "r875",
      "r884",
      "r885",
      "r886",
      "r894",
      "r897"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in liabilities classified in Level 3 of the fair value hierarchy",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r559",
      "r560",
      "r562",
      "r610",
      "r611",
      "r612",
      "r874",
      "r875",
      "r884",
      "r885",
      "r886",
      "r894",
      "r897"
     ]
    },
    "nuvb_FairValueOfWarrantsTradingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FairValueOfWarrantsTradingPrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Warrants, Trading Price",
        "documentation": "Fair Value of Warrants, Trading Price",
        "terseLabel": "Fair Value O fWarrants Trading Price"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_FinancialAssets": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FinancialAssets",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets",
        "documentation": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r331",
      "r332",
      "r335",
      "r336",
      "r337",
      "r339",
      "r343",
      "r344",
      "r386",
      "r401",
      "r539",
      "r567",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r694",
      "r867",
      "r894",
      "r895",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r906",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1178",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Finite-Lived Intangible Assets, Net, Total",
        "terseLabel": "Intangible assets, net of accumulated amortization of $448",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r1115"
     ]
    },
    "nuvb_FoodAndDrugAdministrationApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FoodAndDrugAdministrationApprovalMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Food And Drug Administration Approval [Member]",
        "documentation": "Food And Drug Administration Approval [Member]",
        "terseLabel": "FDA Approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional Currency and Foreign Currency Translations",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "nuvb_ForwardPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ForwardPurchaseWarrantsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward Purchase Warrants member.",
        "label": "Forward Purchase Warrants [Member]",
        "terseLabel": "Forward Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_FounderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FounderMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder.",
        "label": "Founder [Member]",
        "terseLabel": "Founder"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_FounderSharesConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FounderSharesConversion",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder Shares Conversion",
        "documentation": "Founder share conversion.",
        "label": "Founder Shares Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder Shares Member",
        "label": "FounderSharesMember",
        "terseLabel": "Founder Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Furniture and Equipment [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Net loss on disposal of property and equipment",
        "negatedLabel": "Net loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r792"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross Profit, Total",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r87",
      "r141",
      "r232",
      "r325",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r568",
      "r860",
      "r863",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1126"
     ]
    },
    "nuvb_HoldingOfOutstandingPreferredStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "HoldingOfOutstandingPreferredStock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Holding of Outstanding Preferred Stock",
        "label": "Holding of Outstanding Preferred Stock",
        "documentation": "Holding of Outstanding Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r961"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r106"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r136",
      "r141",
      "r676",
      "r691",
      "r860",
      "r863",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r359",
      "r552",
      "r556",
      "r561",
      "r711",
      "r713",
      "r795",
      "r851",
      "r896",
      "r1210"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r359",
      "r552",
      "r556",
      "r561",
      "r711",
      "r713",
      "r795",
      "r851",
      "r896",
      "r1210"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r484",
      "r485",
      "r495",
      "r507",
      "r893",
      "r1167"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r484",
      "r485",
      "r495",
      "r507",
      "r893",
      "r1167"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r1167"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r1167"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r479",
      "r484",
      "r492",
      "r493",
      "r494",
      "r499",
      "r506",
      "r513",
      "r515",
      "r516",
      "r517",
      "r739",
      "r893"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Provision for income taxes",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r161",
      "r248",
      "r249",
      "r264",
      "r272",
      "r282",
      "r483",
      "r484",
      "r514",
      "r701",
      "r893"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r481",
      "r482",
      "r499",
      "r500",
      "r505",
      "r509",
      "r733"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for tax",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r99",
      "r1079",
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInCommodityContractAssetsAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Commodity Contract Assets and Liabilities",
        "terseLabel": "Contract liabilities",
        "negatedLabel": "Contract liabilities",
        "documentation": "The increase (decrease) during the reporting period in the assets (liabilities) created through trading commodity-based derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestAndDividendsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest receivable on marketable securities",
        "terseLabel": "Interest receivable on marketable securities",
        "label": "Increase (Decrease) in Interest and Dividends Receivable",
        "totalLabel": "Increase (Decrease) in Interest and Dividends Receivable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "terseLabel": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Lease security deposit",
        "documentation": "The increase (decrease) during the reporting period in security deposits."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1003",
      "r1012",
      "r1016",
      "r1024"
     ]
    },
    "nuvb_InitialPublicDisclosureOfferingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InitialPublicDisclosureOfferingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Disclosure Offering Abstract",
        "label": "Initial Public Disclosure Offering [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_InitialPublicDisclosureOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InitialPublicDisclosureOfferingTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of initial public offering.",
        "label": "InitialPublicDisclosureOfferingTextBlock",
        "terseLabel": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_InitialPublicOfferingDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InitialPublicOfferingDetailsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering Details Line Items",
        "label": "Initial Public Offering (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_InitialPublicOfferingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InitialPublicOfferingDetailsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering Details Table",
        "label": "Initial Public Offering (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_InnoventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InnoventMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Innovent [Member]",
        "documentation": "Innovent [Member]",
        "terseLabel": "Innovent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1028"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1028"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1028"
     ]
    },
    "nuvb_IntangibleAssetsNetOfAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IntangibleAssetsNetOfAmortization",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net of accumulated amortization of $448",
        "label": "Intangible Assets Net of Amortization",
        "documentation": "Intangible Assets Net of Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r1076"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r225",
      "r226"
     ]
    },
    "nuvb_InterestReceivableOnMarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InterestReceivableOnMarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest receivable on marketable securities current.",
        "label": "Interest Receivable On Marketable Securities Current",
        "terseLabel": "Interest receivable on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_InternalRevenueCode174Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InternalRevenueCode174Member",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Revenue Code 174 [Member]",
        "documentation": "Internal Revenue Code 174 [Member]",
        "terseLabel": "IRC 174 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_InternalRevenueCode59Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "InternalRevenueCode59Member",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IRC 59 [Member]",
        "label": "Internal Revenue Code 59 [Member]",
        "documentation": "Internal Revenue Code 59 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r729",
      "r730",
      "r731",
      "r732",
      "r821",
      "r822"
     ]
    },
    "nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance and exchange of common stock, net of issuance cost upon the Merger (see Note 3), shares",
        "documentation": "Issuance and exchange of common stock, net of issuance cost upon business combination transaction, shares.",
        "label": "Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Shares"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance and exchange of common stock, net of issuance cost upon the Merger (see Note 3)",
        "documentation": "Issuance and exchange of common stock, net of issuance cost upon business combination transaction, value.",
        "label": "Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Value"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfCommonStockForAnheartAcquisitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfCommonStockForAnheartAcquisitionShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for AnHeart acquisition (Shares)",
        "documentation": "Issuance of Common Stock for AnHeart acquisition (Shares)",
        "terseLabel": "Issuance of Common Stock for AnHeart acquisition (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfCommonStockForAnheartAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfCommonStockForAnheartAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock For AnHeart Acquisition Value",
        "documentation": "Issuance Of Common Stock For AnHeart Acquisition Value",
        "terseLabel": "Issuance Of Common Stock For AnHeart Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfCommonStockForPurchaseUnderEsppShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfCommonStockForPurchaseUnderEsppShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for purchase under ESPP, shares",
        "documentation": "Issuance of common stock for purchase under ESPP, shares",
        "terseLabel": "Issuance of common stock for purchase under ESPP, (shares)"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfCommonStockForPurchaseUnderEsppValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfCommonStockForPurchaseUnderEsppValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for purchase under ESPP, value",
        "documentation": "Issuance of common stock for purchase under ESPP, value",
        "terseLabel": "Proceeds from issuance of common stock under ESPP",
        "negatedLabel": "Proceeds from issuance of common stock under ESPP",
        "verboseLabel": "Issuance of common stock for purchase under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfCommonStockForRsusVestedShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfCommonStockForRsusVestedShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for RSUs Vested, Share",
        "documentation": "Issuance of Common Stock for RSUs Vested, Share"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfCommonStockRelatedToTheAnheartAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfCommonStockRelatedToTheAnheartAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock related to the AnHeart acquisition",
        "label": "Issuance of Common Stock Related to the AnHeart Acquisition",
        "documentation": "Issuance of Common Stock Related to the AnHeart Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock related to the AnHeart acquisition",
        "label": "Issuance of Convertible Preferred Stock related to the AnHeart Acquisition",
        "documentation": "Issuance of Convertible Preferred Stock related to the AnHeart Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Convertible Preferred Stocks Related To The Acquisition Of AnHeart( Shares)",
        "documentation": "Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart( Shares)",
        "terseLabel": "Issuance Of Convertible Preferred Stocks Related To The Acquisition Of AnHeart( Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart Value",
        "documentation": "Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart Value",
        "terseLabel": "Issuance of Convertible Preferred Stocks Related to The Acquisition of AnHeart"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of replacement awards related to the AnHeart acquisition",
        "label": "Issuance of Replacement Awards Related to the AnHeart Acquisition",
        "documentation": "Issuance of Replacement Awards Related to the AnHeart Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Replacement Awards Related To The AnHeart Acquisition Value",
        "documentation": "Issuance Of Replacement Awards Related To The AnHeart Acquisition Value",
        "terseLabel": "Issuance Of Replacement Awards Related To The AnHeart Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfSharesUponBusinessCombination": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfSharesUponBusinessCombination",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares upon Business Combination.",
        "label": "Issuance Of Shares Upon Business Combination",
        "totalLabel": "Issuance of shares upoon Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfSharesValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, value",
        "documentation": "Issuance of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_IssuanceOfWarrantsRelatedToTheAnheartAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "IssuanceOfWarrantsRelatedToTheAnheartAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants related to the AnHeart acquisition",
        "label": "Issuance of Warrants Related to the AnHeart Acquisition",
        "documentation": "Issuance of Warrants Related to the AnHeart Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "JP",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LeaseAdditionalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LeaseAdditionalTerm",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease additional term",
        "label": "Lease Additional Term",
        "documentation": "Lease additional term."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LeaseSecurityDepositNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LeaseSecurityDepositNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease security deposit noncurrent.",
        "label": "Lease Security Deposit Noncurrent",
        "terseLabel": "Lease security deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r594"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LeasesPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Leases [Policy Text Block]",
        "documentation": "Leases policy text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r595"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease existence of option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "nuvb_LesseeOperatingLeaseExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LesseeOperatingLeaseExpirationYear",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expiration year",
        "label": "Lessee Operating Lease Expiration Year",
        "documentation": "Lessee operating lease expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Commitments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r65",
      "r66",
      "r67",
      "r69",
      "r70",
      "r71",
      "r74",
      "r232",
      "r325",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r530",
      "r531",
      "r532",
      "r568",
      "r766",
      "r859",
      "r932",
      "r1126",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r134",
      "r686",
      "r905",
      "r1082",
      "r1112",
      "r1186"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r198",
      "r232",
      "r325",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r530",
      "r531",
      "r532",
      "r568",
      "r905",
      "r1126",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License [Member]",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "nuvb_LicenseRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LicenseRevenueMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue [Member]",
        "documentation": "License Revenue [Member]",
        "terseLabel": "License revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit, Amount",
        "label": "Long-Term Line of Credit",
        "totalLabel": "Long-term Line of Credit, Total",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r1205"
     ]
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityFrequencyOfCommitmentFeePayment",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, frequency of commitment fee payment",
        "label": "Line of Credit Facility, Frequency of Commitment Fee Payment",
        "documentation": "Description of when the fee for available but unused credit capacity is required to be paid (for example, annually, quarterly, or monthly)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r68"
     ]
    },
    "nuvb_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Policy Text Block.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LoanAgreementsWithBankOfHangzhouMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LoanAgreementsWithBankOfHangzhouMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreements With Bank of Hangzhou [Member]",
        "documentation": "Loan Agreements With Bank of Hangzhou [Member]",
        "terseLabel": "Loan Agreements With Bank Of Hangzhou [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LoanAgreementsWithChinaMerchantsBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LoanAgreementsWithChinaMerchantsBankMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreements With China Merchants Bank [Member]",
        "documentation": "Loan Agreements With China Merchants Bank [Member]",
        "terseLabel": "Loan Agreements With China Merchants Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan and Security Agreement [Member]",
        "documentation": "Loan and Security Agreement [Member]",
        "terseLabel": "Loan And Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_LongTermBorroing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "LongTermBorroing",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Borroing",
        "documentation": "Long-Term Borroing",
        "terseLabel": "Long term debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term debt maturity date",
        "label": "Long-Term Debt, Maturity Date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1182",
      "r1183"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of commercial milestones",
        "label": "Long-Term Purchase Commitment, Amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r374",
      "r476",
      "r724",
      "r873",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r374",
      "r476",
      "r873",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r374",
      "r476",
      "r873",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r374",
      "r476",
      "r724",
      "r873",
      "r1121",
      "r1122"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MA",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitChangeInFairValueGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketRiskBenefitChangeInFairValueGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value, Gain (Loss)",
        "label": "Market Risk Benefit, Change in Fair Value, Gain (Loss)",
        "documentation": "Amount of gain (loss) from (increase) decrease in fair value of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Excludes change attributable to instrument-specific credit risk."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable Securities, Total",
        "label": "Marketable Securities",
        "terseLabel": "Assets held in the Trust Account",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r1067"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities:",
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "totalLabel": "Marketable Securities, Current, Total",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss (gain) on marketable securities",
        "terseLabel": "Net loss (gain) on marketable securities",
        "label": "Marketable Securities, Gain (Loss)",
        "totalLabel": "Total losses on marketable securities",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesGainLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesGainLossAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains (losses) on available-for-sale securities were as follows",
        "label": "Marketable Security, Gain (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfNetRealizedGainLossOnMarketableSecuritiesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Gain (Loss)",
        "negatedLabel": "Realized loss on marketable securities",
        "verboseLabel": "Realized loss on marketable securities",
        "totalLabel": "Net realized losses on marketable securities",
        "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities [Member]",
        "documentation": "Marketable securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "totalLabel": "Marketable Securities, Unrealized Gain (Loss), Total",
        "terseLabel": "Unrealized gain (loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r167",
      "r169",
      "r170",
      "r172",
      "r192",
      "r193",
      "r370",
      "r371",
      "r372",
      "r373",
      "r431",
      "r476",
      "r550",
      "r638",
      "r710",
      "r712",
      "r724",
      "r758",
      "r759",
      "r819",
      "r823",
      "r825",
      "r826",
      "r828",
      "r849",
      "r850",
      "r866",
      "r876",
      "r889",
      "r897",
      "r898",
      "r902",
      "r903",
      "r916",
      "r1128",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "nuvb_MaximumSaleOfCommonStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "MaximumSaleOfCommonStockPricePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum sale of common stock price per share.",
        "label": "MaximumSaleOfCommonStockPricePerShare",
        "terseLabel": "Common stock price per share (in Dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "nuvb_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger agreement member.",
        "label": "Merger Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_MilestonesRequirePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "MilestonesRequirePayments",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestones Require Payments",
        "documentation": "Milestones Require Payments",
        "terseLabel": "Milestones require payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r167",
      "r169",
      "r170",
      "r172",
      "r192",
      "r193",
      "r370",
      "r371",
      "r372",
      "r373",
      "r431",
      "r476",
      "r550",
      "r638",
      "r710",
      "r712",
      "r724",
      "r758",
      "r759",
      "r819",
      "r823",
      "r825",
      "r826",
      "r828",
      "r849",
      "r850",
      "r866",
      "r876",
      "r889",
      "r897",
      "r898",
      "r902",
      "r916",
      "r1128",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flow from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flow from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r100",
      "r137",
      "r196",
      "r211",
      "r214",
      "r219",
      "r232",
      "r237",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r248",
      "r249",
      "r256",
      "r325",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r522",
      "r527",
      "r544",
      "r568",
      "r692",
      "r789",
      "r809",
      "r810",
      "r930",
      "r1126"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recent Accounting Pronouncement",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NewYorkCityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NewYorkCityMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York, New York",
        "label": "New York City [Member]",
        "documentation": "New York City."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NkMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nk [Member]",
        "label": "NK [Member]",
        "documentation": "NK [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash lease expense",
        "label": "Non Cash Lease Expense",
        "documentation": "Non-cash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1003",
      "r1012"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activity:",
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Non-cash investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NumberOfCommonSharesOutstandingAfterBusinessCombination": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NumberOfCommonSharesOutstandingAfterBusinessCombination",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shares of Nuvation Bio outstanding immediately following the Merger",
        "documentation": "Number of Common Shares Outstanding After Business Combination.",
        "label": "Number Of Common Shares Outstanding After Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NumberOfEquitySecuritiesSold": {
     "xbrltype": "integerItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NumberOfEquitySecuritiesSold",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity securities sold",
        "label": "Number of Equity Securities Sold",
        "documentation": "Number of Equity Securities Sold."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NumberOfMilestones": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NumberOfMilestones",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Milestones",
        "documentation": "Number Of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Decreased Subject to Repurchase Under Stock Restriction Agreement",
        "documentation": "Number of shares decreased subject to repurchase under stock restriction agreement",
        "label": "Number of Shares Decreased Subject to Repurchase Under Stock Restriction Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_NumberOfSharesIssuableUnderShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "NumberOfSharesIssuableUnderShareBasedPaymentArrangement",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable under share based payment arrangement.",
        "label": "Number Of Shares Issuable Under Share Based Payment Arrangement",
        "terseLabel": "Number of common shares issuable under the plan (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r860",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r904"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash lease expense",
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1190"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfAggregateLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "nuvb_OperatingLeaseLiabilityRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeaseLiabilityRecognized",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability recognized",
        "documentation": "Operating lease liability recognized",
        "terseLabel": "Operating lease liability recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average incremental borrowing rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r904"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r904"
     ]
    },
    "nuvb_OperatingLeasesFutureMinimumPaymentDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentDue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Operating Leases Future Minimum Payment Due",
        "documentation": "Amount of required minimum rental payment for leases having an initial or remaining non-cancelable letter-terms in excess of one year."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OperatingLeasesFutureMinimumPaymentDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentDueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2021",
        "label": "Operating Leases Future Minimum Payment Due Current",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OperatingLeasesFutureMinimumPaymentDueInFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentDueInFiveYears",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Operating Leases Future Minimum Payment Due In Five Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OperatingLeasesFutureMinimumPaymentDueInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentDueInFourYears",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "Operating Leases Future Minimum Payment Due In Four Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OperatingLeasesFutureMinimumPaymentDueInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentDueInThreeYears",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2023",
        "label": "Operating Leases Future Minimum Payment Due In Three Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OperatingLeasesFutureMinimumPaymentDueThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPaymentDueThereafter",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "Operating Leases Future Minimum Payment Due Thereafter",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim period are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OperatingLeasesFuturesMinimumPaymentDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLeasesFuturesMinimumPaymentDueInTwoYears",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2022",
        "label": "Operating Leases Futures Minimum Payment Due In Two Years",
        "documentation": "Operating Leases Futures Minimum Payment Due In Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryovers",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "nuvb_OperatingLossCarryforwardsExpiration": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpiration",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses carried forward expiration year",
        "label": "Operating Loss Carryforwards, Expiration",
        "documentation": "Operating loss carryforwards expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxeSummaryOfNetDeferredTaxAssetsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "nuvb_OptionWithServiceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OptionWithServiceConditionsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options with Service Conditions",
        "label": "Option with Service Conditions Member",
        "documentation": "Option with Service Conditions Member"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OptionsWithServiceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OptionsWithServiceConditionsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options with Service Conditions [Member]",
        "documentation": "Options with Service Conditions [Member]",
        "terseLabel": "Options with Service Conditions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_OptionsWithServiceMarketAndPerformanceConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OptionsWithServiceMarketAndPerformanceConditionMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options with Service Market And Performance Conditions",
        "label": "Options With Service Market and Performance Condition [Member]",
        "documentation": "Options with service market and performance condition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Organization and Business Operations",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r122",
      "r726",
      "r727"
     ]
    },
    "nuvb_OrphanDrugTaxCreditCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OrphanDrugTaxCreditCarryforwardMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug Tax Credit Carryforward [Member]",
        "label": "Orphan Drug Tax Credit Carryforward [Member]",
        "terseLabel": "Orphan Drug Tax Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Noncurrent",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r17",
      "r212",
      "r215",
      "r220",
      "r244",
      "r571",
      "r572",
      "r577",
      "r673",
      "r693",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss, net of taxes:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeNoncontrollingInterestTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "Other Comprehensive Income, Noncontrolling Interest [Text Block]",
        "documentation": "The entire disclosure for tabular information relating to Other Comprehensive Income (OCI) as is applicable to noncontrolling interests. This text block may also include OCI relative to the filing entity, the aforementioned noncontrolling interest OCI, as well as OCI on a consolidated basis."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "terseLabel": "Other expense",
        "negatedLabel": "Other expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "nuvb_OtherThanUnitedStateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OtherThanUnitedStateMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Than United State [Member]",
        "documentation": "Other Than United State [Member]",
        "terseLabel": "Other than U.S. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r977",
      "r1010"
     ]
    },
    "nuvb_OutstandingAtDecember312020AfterAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OutstandingAtDecember312020AfterAdjustment",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of share option outstanding, 2020 after adjustment",
        "terseLabel": "Outstanding at December 31, 2020 after adjustment",
        "label": "Outstanding at December 31, 2020 after adjustment",
        "documentation": "Outstanding at December 31, 2020 after adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "nuvb_OwedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "OwedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owed Milestone Payments",
        "documentation": "Owed Milestone Payments",
        "terseLabel": "Company is owed in milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PACoInvestmentsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PACoInvestmentsLLCMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "P A Co Investments L L C Member",
        "label": "PACoInvestmentsLLCMember",
        "terseLabel": "PA Co-Investments LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PanaceaEquityAtEffectiveTime": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PanaceaEquityAtEffectiveTime",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Panacea Equity at Effective Time, Total",
        "terseLabel": "Panacea equity at Effective Time",
        "documentation": "Panacea equity at effective time.",
        "label": "Panacea Equity at Effective Time"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PanaceaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PanaceaMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Panacea member.",
        "label": "Panacea [Member]",
        "terseLabel": "Panacea [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "nuvb_PaymentOfUnderwriterFeesAndOtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PaymentOfUnderwriterFeesAndOtherOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of underwriter fees and other offering costs.",
        "label": "Payment Of Underwriter Fees And Other Offering Costs",
        "negatedLabel": "Payment of underwriter fees and other offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PaymentToCommonStockholdersDueToExercisedRightToRedeemShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PaymentToCommonStockholdersDueToExercisedRightToRedeemShares",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to common stockholders due to exercised right to redeem shares.",
        "label": "Payment To Common Stockholders Due To Exercised Right To Redeem Shares",
        "negatedLabel": "Payment to Panacea Class A common stockholders who exercised their right to redeem their shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Cash payments",
        "negatedLabel": "Cash payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r1077"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments on borrowings",
        "label": "Payments of Financing Costs",
        "totalLabel": "Payments of Financing Costs, Total",
        "negatedLabel": "Payments on borrowings",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "terseLabel": "Net cash consideration",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "terseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Machinery and Equipment",
        "documentation": "The cash outflow for acquisition of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "terseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "nuvb_PercentageOfLongLivedAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PercentageOfLongLivedAssets",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Long Lived Assets",
        "documentation": "Percentage Of Long Lived Assets",
        "terseLabel": "Percentage of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options with Service, Market, and Performance Conditions",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_PreferredClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredClassAMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Class A [Member]",
        "terseLabel": "Preferred Class A [Member]",
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredClassBMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Class B [Member]",
        "label": "Preferred Class B [Member]",
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Convertible, Shares Issuable",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeded Fair Value of the Common Stock",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r392",
      "r405"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "verboseLabel": "Preferred stock, par value (in Dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r388"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r768"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r388"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r768",
      "r787",
      "r1244",
      "r1245"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "nuvb_PriorEffectOfBusinessCombinationTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PriorEffectOfBusinessCombinationTransactionMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior effect of business combination transaction.",
        "label": "Prior Effect Of Business Combination Transaction [Member]",
        "terseLabel": "Prior Effect Of Business Combination Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PrivatePlacementDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PrivatePlacementDetailsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Details Line Items",
        "label": "Private Placement (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PrivatePlacementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PrivatePlacementDetailsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Details Table",
        "label": "Private Placement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PrivatePlacementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PrivatePlacementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Disclosure Abstract",
        "label": "Private Placement Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PrivatePlacementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PrivatePlacementDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of private placement.",
        "label": "PrivatePlacementDisclosureTextBlock",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Unit [Member]",
        "verboseLabel": "Private Placement Warrant [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Warrants member.",
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ProceedsFromBusinessCombinationNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ProceedsFromBusinessCombinationNet",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net proceeds",
        "documentation": "Proceeds from business combination net.",
        "label": "Proceeds From Business Combination Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value of common stock issued to common stockholder",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "nuvb_ProceedsFromIssuanceOfCommonStockUnderEspp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEspp",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock under ESPP",
        "documentation": "Proceeds from Issuance of Common Stock Under ESPP",
        "terseLabel": "Proceeds from issuance of Common Stock under ESPP",
        "negatedLabel": "Proceeds from issuance of common stock under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerScheduleOfNetProceedFromBusinessCombinationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from PIPE investment and forward purchase agreement.",
        "label": "Proceeds From P I P E Investment And Forward Purchase Agreement",
        "terseLabel": "Proceeds from PIPE investment and forward purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfOtherPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Other Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Short-Term Debt",
        "totalLabel": "Proceeds from borrowings",
        "terseLabel": "Proceeds from borrowings",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r15"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r190",
      "r284",
      "r639",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r853",
      "r877",
      "r915",
      "r916",
      "r917",
      "r919",
      "r921",
      "r1065",
      "r1123",
      "r1124",
      "r1131",
      "r1209",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1238",
      "r1239"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r190",
      "r284",
      "r639",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r853",
      "r877",
      "r915",
      "r916",
      "r917",
      "r919",
      "r921",
      "r1065",
      "r1123",
      "r1124",
      "r1131",
      "r1209",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1238",
      "r1239"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment advisory fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r930",
      "r1242",
      "r1243"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r594"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r152",
      "r155",
      "r159"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "totalLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r200",
      "r690"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment,net",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $874 and $666, respectively",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r594",
      "r678",
      "r690",
      "r905"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r152",
      "r155",
      "r688"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r594"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Warrants member",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r167",
      "r169",
      "r170",
      "r172",
      "r192",
      "r193",
      "r370",
      "r371",
      "r372",
      "r373",
      "r421",
      "r431",
      "r462",
      "r463",
      "r464",
      "r476",
      "r550",
      "r613",
      "r622",
      "r638",
      "r710",
      "r712",
      "r724",
      "r758",
      "r759",
      "r819",
      "r823",
      "r825",
      "r826",
      "r828",
      "r849",
      "r850",
      "r866",
      "r876",
      "r889",
      "r897",
      "r898",
      "r902",
      "r903",
      "r916",
      "r924",
      "r1117",
      "r1128",
      "r1182",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r167",
      "r169",
      "r170",
      "r172",
      "r192",
      "r193",
      "r370",
      "r371",
      "r372",
      "r373",
      "r421",
      "r431",
      "r462",
      "r463",
      "r464",
      "r476",
      "r550",
      "r613",
      "r622",
      "r638",
      "r710",
      "r712",
      "r724",
      "r758",
      "r759",
      "r819",
      "r823",
      "r825",
      "r826",
      "r828",
      "r849",
      "r850",
      "r866",
      "r876",
      "r889",
      "r897",
      "r898",
      "r902",
      "r903",
      "r916",
      "r924",
      "r1117",
      "r1128",
      "r1182",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "nuvb_RealizedLossOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RealizedLossOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeScheduleOfChangesInAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Realized loss On Marketable Securities",
        "label": "Realized loss On Marketable Securities",
        "terseLabel": "Amount reclassified for realized loss on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ReceivedNonRefundableUpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ReceivedNonRefundableUpfrontCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Received NonRefundable Upfront Cash Payment",
        "documentation": "Received NonRefundable Upfront Cash Payment",
        "terseLabel": "Received a non-refundable upfront cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RecognitionOfPrivateWarrantsLiabilityUponClosingDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RecognitionOfPrivateWarrantsLiabilityUponClosingDate",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInLiabilitiesClassifiedInLevel3OfTheFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of Private Warrants Liability Upon Closing Date",
        "documentation": "Recognition of private warrants liability upon closing date."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r972",
      "r1005"
     ]
    },
    "nuvb_RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RedeemableSeriesAConvertiblePreferredStockDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Series A Convertible Preferred Stock",
        "label": "Redeemable Series A Convertible Preferred Stock Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about redeemable series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RedeemableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RedeemableWarrantsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Warrants [Member]",
        "documentation": "Redeemable Warrants [Member]",
        "terseLabel": "Redeemable Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RedemptionOfSharePriorToBusinessCombination": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RedemptionOfSharePriorToBusinessCombination",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: redemption of Panacea shares prior to the Merger",
        "documentation": "Redemption of share prior to business combination.",
        "label": "Redemption Of Share Prior To Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ReductionToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ReductionToAdditionalPaidInCapital",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction to additional paid in-capital",
        "label": "Reduction to additional paid in-capital",
        "documentation": "Reduction to additional paid in-capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r428",
      "r601",
      "r602",
      "r681",
      "r687",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r786",
      "r788",
      "r818"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Principal amount",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r601"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602",
      "r1193"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r428",
      "r601",
      "r602",
      "r681",
      "r687",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r786",
      "r788",
      "r818",
      "r1193"
     ]
    },
    "nuvb_RelatedPartyTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transactions Details Line Items",
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transactions Details Table",
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r740",
      "r741",
      "r742",
      "r793",
      "r794",
      "r795",
      "r815",
      "r817"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding line of credit balance net",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r1081"
     ]
    },
    "nuvb_RepaymentsOfNonRefundableUpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RepaymentsOfNonRefundableUpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of NonRefundable Upfront Cash Payment",
        "documentation": "Repayments of NonRefundable Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-Term Debt",
        "totalLabel": "Repayments of Short-Term Debt, Total",
        "terseLabel": "Repayments of short term borroing",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Capitalized Cost",
        "terseLabel": "Research and development asset",
        "documentation": "Amount of asset recognized from cost for research and development asset acquired in transaction other than business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r851",
      "r863",
      "r1202"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "nuvb_ResearchAndDevelopmentServiceRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ResearchAndDevelopmentServiceRevenueMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Service Revenue [Member]",
        "documentation": "Research and Development Service Revenue [Member]",
        "terseLabel": "Research and development service revenue"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r195",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r263",
      "r327",
      "r328",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r527",
      "r541",
      "r542",
      "r543",
      "r544",
      "r579",
      "r581",
      "r596",
      "r597",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r728",
      "r1097"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r974",
      "r1007"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1014"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r195",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r263",
      "r327",
      "r328",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r527",
      "r541",
      "r542",
      "r543",
      "r544",
      "r579",
      "r581",
      "r596",
      "r597",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r728",
      "r1097"
     ]
    },
    "nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RestatementOfPreviouslyIssuedFinancialsStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restatement of previously issued financials statements.",
        "label": "Restatement Of Previously Issued Financials Statements [Abstract]",
        "terseLabel": "Restatement of Previously Issued Financials Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RestatementOfPreviouslyIssuedFinancialsStatementsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restatement of previously issued financials statements.",
        "label": "Restatement Of Previously Issued Financials Statements [Text Block]",
        "terseLabel": "RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units RSU [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r358",
      "r361",
      "r366"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "totalLabel": "Total restructuring costs",
        "terseLabel": "Total restructuring costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r362",
      "r363",
      "r1118"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r363",
      "r364"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs",
        "totalLabel": "Balance at December 31, 2022",
        "terseLabel": "Restructuring Costs",
        "verboseLabel": "Balance at December 31, 2022",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r114",
      "r685",
      "r718",
      "r723",
      "r738",
      "r769",
      "r905"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r234",
      "r235",
      "r236",
      "r238",
      "r244",
      "r247",
      "r249",
      "r326",
      "r329",
      "r352",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r526",
      "r527",
      "r533",
      "r535",
      "r536",
      "r538",
      "r542",
      "r580",
      "r583",
      "r714",
      "r716",
      "r743",
      "r1244"
     ]
    },
    "nuvb_RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RetroactiveApplicationOfRecapitalizationOfCommonStockDueToBusinessCombinationTransactionShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization of common stock due to business combination transaction, shares.",
        "label": "Retroactive Application Of Recapitalization Of Common Stock Due To Business Combination Transaction Shares"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization of preferred stock due to business combination transaction, shares.",
        "label": "Retroactive Application Of Recapitalization Of Preferred Stock Due To Business Combination Transaction Shares"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization of preferred stock due to business combination transaction, value.",
        "label": "Retroactive Application Of Recapitalization Of Preferred Stock Due To Business Combination Transaction Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfRevenueRecognizedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r264",
      "r269",
      "r270",
      "r280",
      "r282",
      "r284",
      "r285",
      "r287",
      "r417",
      "r418",
      "r639"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue From Contract With Customer Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r264",
      "r269",
      "r270",
      "r280",
      "r282",
      "r284",
      "r285",
      "r287",
      "r417",
      "r418",
      "r639"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs to Fulfill a Contract with a Customer",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r852"
     ]
    },
    "us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Performance Obligation Satisfied over Time, Method Used, Description",
        "terseLabel": "Revenue, performance obligation satisfied over time, method used, description",
        "documentation": "Description of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "nuvb_RevenueRecognitionPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RevenueRecognitionPolicyPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition Policy [Policy Text Block]",
        "documentation": "Revenue Recognition Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_RevenueRecognizedUponMilestonePaymenyts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "RevenueRecognizedUponMilestonePaymenyts",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognized Upon Milestone Paymenyts",
        "documentation": "Revenue Recognized Upon Milestone Paymenyts",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset recognized",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r904"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "RoyaltyExpense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "nuvb_SagardHealthcarePartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SagardHealthcarePartnersMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sagard Healthcare Partners [Member]",
        "documentation": "Sagard Healthcare Partners [Member]",
        "terseLabel": "Sagard Healthcare Partners"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SaleOfPrivatePlacementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SaleOfPrivatePlacementShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Private Placement Shares",
        "label": "SaleOfPrivatePlacementShares",
        "terseLabel": "Sale of private placement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Aggregate amount",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Purchase price (in Dollars)",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Sale of Stock, Description of Transaction",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r57",
      "r123"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock in shares (in Shares)",
        "verboseLabel": "Sale of stock in shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strike price",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Price per share (in Dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SaleOfUnderwritingDiscountsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SaleOfUnderwritingDiscountsShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Underwriting Discounts Shares",
        "label": "SaleOfUnderwritingDiscountsShares",
        "terseLabel": "Sale of underwriting discounts, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue Net [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r1053"
     ]
    },
    "nuvb_SanFranciscoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SanFranciscoMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Francisco, California [Member]",
        "label": "San Francisco [Member]",
        "documentation": "San Francisco."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued expenses",
        "label": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive (loss) Income",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1187",
      "r1189"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Securities Outstanding Excluded from Calculation of Weighted Average Shares Outstanding",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "nuvb_ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Available for sale Securities Classified By Contractual Maturity Date Table Text Block",
        "label": "Schedule Of Available For Sale Securities Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Schedule Of Available for sale Securities Maturity On Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost, Aggregate Fair Value and Unrealized Gains of Marketable Securities Available-for-sale",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Shares of Common Stock Outstanding on Merger",
        "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]",
        "documentation": "Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r524"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Final Allocable Purchase Price Consists",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Income Tax Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table Text Block]",
        "terseLabel": "Summary of Condensed Financial Statements",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1085"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Calculation of Basic and Diluted Net Income (loss) Per Common share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of the Federal Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r893",
      "r1161"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r518",
      "r1049",
      "r1050",
      "r1051",
      "r1172",
      "r1173",
      "r1174",
      "r1175"
     ]
    },
    "nuvb_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Future Minimum Lease Commitments",
        "label": "Schedule of Future Minimum Rental Payment For Operating Leases [Table Text Block]",
        "documentation": "Schedule of Future Minimum Rental Payment For Operating Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r594"
     ]
    },
    "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRealizedGainLossTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Realized Gain (Loss) on Marketable Securities",
        "label": "Schedule of Realized Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sources and Uses of Funds Related to Merger",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of accrued restructuring costs",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r107",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r435",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Units Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r116"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Grant-date Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Values for Outstanding Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r892"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules Of Concentration Of Risk By Risk Factor",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r58",
      "r126"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt",
        "terseLabel": "Secured Debt",
        "totalLabel": "Secured Debt, Total",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r1205"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r168",
      "r171",
      "r173",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r285",
      "r286",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r755",
      "r756",
      "r757",
      "r820",
      "r824",
      "r827",
      "r829",
      "r836",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r854",
      "r878",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r918",
      "r924",
      "r1131",
      "r1209",
      "r1211",
      "r1212",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1238",
      "r1239"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r283",
      "r285",
      "r861",
      "r862",
      "r865"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative [Member]",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069",
      "r1129"
     ]
    },
    "nuvb_ServicesFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ServicesFees",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of services fees.",
        "label": "ServicesFees",
        "terseLabel": "services fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares based option granted vest period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "nuvb_ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConversionAdjustmentRelatedToBusinessCombination",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion adjustment related to the Merge",
        "documentation": "Share-based compensation arrangement by share-based payment award, conversion adjustment related to business combination.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Conversion adjustment related to Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r435",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share option exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share option, Expired",
        "terseLabel": "Number of share option, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share option, Forfeited or canceled",
        "terseLabel": "Number of share option, Forfeited or canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share option, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Outstanding at December 31, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of share option outstanding, Ending balance",
        "periodStartLabel": "Number of share option outstanding, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options assumed for acquisition of AnHeart",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r440",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474"
     ]
    },
    "nuvb_ShareOutstandingPriorToBusinessCombination": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ShareOutstandingPriorToBusinessCombination",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Panacea shares outstanding prior to Merger",
        "documentation": "Share outstanding prior to business combination.",
        "label": "Share Outstanding Prior To Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares based option granted expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfGrantdateFairValueOfStockOptionsGrantedDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable at December 31, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Non-vested at December 31, 2024",
        "periodStartLabel": "Non-vested at December 31, 2023",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "terseLabel": "Forfeited or canceled",
        "negatedLabel": "Forfeited or canceled",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Outstanding at December, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested",
        "negatedLabel": "Vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares based weighted average grant-date fair value of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock outstanding or issuable, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based By Weighted Average Period",
        "documentation": "ShareBasedCompensationArrangementByShareBasedByWeightedAveragePeriod",
        "terseLabel": "Share Based Compensation Arrangement By Share Based By Weighted Average Period"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SharesBasedStockOptionGrantedVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SharesBasedStockOptionGrantedVestingPercentage",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Based Stock Option Granted Vesting Percentage",
        "documentation": "Shares Based Stock Option Granted Vesting Percentage",
        "terseLabel": "Shares Based Stock Option Granted Vesting Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SharesExchangedInRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SharesExchangedInRecapitalization",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares exchanged in recapitalization",
        "label": "Shares Exchanged In Recapitalization",
        "documentation": "Shares Exchanged In Recapitalization, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Shares, Issued, Ending Balance",
        "periodStartLabel": "Shares, Issued, Beginning Balance",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issued Price Per Share",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SharesIssuedPursuantToForwardPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SharesIssuedPursuantToForwardPurchase",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to the Forward Purchase.",
        "label": "Shares Issued Pursuant To Forward Purchase",
        "terseLabel": "Shares issued pursuant to the Forward Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SharesIssuedPursuantToPIPEFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SharesIssuedPursuantToPIPEFinancing",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued pursuant to the PIPE financing.",
        "label": "Shares Issued Pursuant To P I P E Financing",
        "terseLabel": "Shares issued pursuant to the PIPE financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Debt, Total",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term borrowings",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r128",
      "r905",
      "r1204"
     ]
    },
    "nuvb_ShortTermBorrowingsDrawnDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ShortTermBorrowingsDrawnDown",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term borrowings drawn down",
        "label": "Short-Term Borrowings Drawn Down",
        "documentation": "Short-Term Borrowings Drawn Down"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_ShortTermWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "ShortTermWorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term working capital",
        "label": "Short-Term Working Capital",
        "documentation": "Short-Term Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShorttermDebtAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShorttermDebtAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term borrowings outstanding balance",
        "label": "Short-Term Debt, Average Outstanding Amount",
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r796"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r229"
     ]
    },
    "nuvb_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SponsorMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor Member",
        "label": "SponsorMember",
        "terseLabel": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StandbyLettersOfCreditMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Letter of Credit [Member]",
        "label": "Standby Letters of Credit [Member]",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r1125",
      "r1240",
      "r1241"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerSummaryOfNumberOfSharesOfCommonStockOutstandingOnBusinessMergerDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://nuvationbio.com/20241231/taxonomy/role/WarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r204",
      "r205",
      "r206",
      "r232",
      "r254",
      "r255",
      "r257",
      "r259",
      "r266",
      "r267",
      "r325",
      "r376",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r388",
      "r389",
      "r392",
      "r395",
      "r403",
      "r568",
      "r734",
      "r735",
      "r736",
      "r737",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r768",
      "r790",
      "r811",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r1048",
      "r1080",
      "r1090"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r78",
      "r79",
      "r194",
      "r217",
      "r218",
      "r219",
      "r234",
      "r235",
      "r236",
      "r238",
      "r244",
      "r247",
      "r249",
      "r265",
      "r326",
      "r329",
      "r352",
      "r406",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r526",
      "r527",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r542",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r583",
      "r597",
      "r693",
      "r714",
      "r715",
      "r716",
      "r743",
      "r811"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r168",
      "r171",
      "r173",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r285",
      "r286",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r755",
      "r756",
      "r757",
      "r820",
      "r824",
      "r827",
      "r829",
      "r836",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r854",
      "r878",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r918",
      "r924",
      "r1131",
      "r1209",
      "r1211",
      "r1212",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1238",
      "r1239"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r265",
      "r583",
      "r639",
      "r729",
      "r754",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r768",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r791",
      "r792",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r811",
      "r925"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals",
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfContractAssetsAndContractLiabilitiesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRedeemableSeriesAConvertiblePreferredStockAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r265",
      "r288",
      "r583",
      "r639",
      "r729",
      "r754",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r768",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r788",
      "r791",
      "r792",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r811",
      "r925"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r976",
      "r1009"
     ]
    },
    "nuvb_StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and Warrants Issued During Period Share Preferred Stock and Warrants",
        "documentation": "Stock and Warrants Issued During Period Share Preferred Stock and Warrants",
        "terseLabel": "Stock and Warrants Issued During Period Share Preferred Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Exercise of warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_StockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "StockConversionRatio",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Conversion Ratio",
        "label": "Stock Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of common stock for in-process research and development",
        "terseLabel": "Issuance of common stock for in-process research and development",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options assumed for acquisition of AnHeart",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r114"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureAcquisitionScheduleOfFinalAllocablePurchasePriceConsistsParentheticalDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, shares",
        "verboseLabel": "Stock issued during the period, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r114",
      "r734",
      "r811",
      "r831"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share option, Exercised",
        "verboseLabel": "Exercise of stock options, shares",
        "terseLabel": "Number of share option, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r114",
      "r446"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "negatedLabel": "Issuance of common stock for in-process research and development expense",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Stock issued during the period, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r114",
      "r743",
      "r811",
      "r831",
      "r931"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r78",
      "r79",
      "r114"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Redeemed or Called During Period, Shares",
        "terseLabel": "Stock redeemed during the period, shares",
        "verboseLabel": "Change in value of common stock subject to redemption (in Shares)",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Redeemed or Called During Period, Value",
        "terseLabel": "Stock redeemed or called during period, value",
        "verboseLabel": "Change in value of common stock subject to redemption",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchased During Period, Shares",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r114",
      "r737",
      "r811",
      "r833"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet",
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r103",
      "r770",
      "r787",
      "r812",
      "r813",
      "r905",
      "r932",
      "r1082",
      "r1112",
      "r1186",
      "r1244"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_StockholdersEquityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "StockholdersEquityDetailsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity Details Line Items",
        "label": "Stockholders' Equity (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity Details Table",
        "label": "Stockholders' Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "verboseLabel": "Redeemable Series A Convertible Preferred Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r231",
      "r387",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r402",
      "r406",
      "r540",
      "r814",
      "r816",
      "r835"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "nuvb_SubjectToPossibleRedemptionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SubjectToPossibleRedemptionShares",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subject To Possible Redemption Shares",
        "label": "SubjectToPossibleRedemptionShares",
        "terseLabel": "Subject to possible redemption, shares"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SubjecttopossibleredemptionPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SubjecttopossibleredemptionPerShare",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subject to possible redemption value of per shares.",
        "label": "SubjectToPossibleRedemption Per Share",
        "terseLabel": "Subject to possible redemption, per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubordinatedBorrowingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subordinated Borrowing [Axis]",
        "documentation": "Information by name of borrowing under subordinated debt agreement."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingInterestRate",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate on borrowings",
        "label": "Subordinated Borrowing, Interest Rate",
        "documentation": "Stated interest rate of the subordinated debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubordinatedBorrowingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subordinated Borrowing [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubordinatedBorrowingNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subordinated Borrowing, Name [Domain]",
        "documentation": "Name of the borrowing under subordinated debt agreements, including exchange memberships contributed for the use of the Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubordinatedBorrowingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subordinated Borrowing [Table]",
        "documentation": "Disclosure of information about borrowing under subordinated debt agreement that qualifies as available in computing net capital under U.S. Securities and Exchange Commission's (SEC) uniform net capital rule. Includes, but is not limited to, restrictive covenant, collateral, interest rate, due date, and amount due by date and owed in total."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_SubordinatedBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subordinated Borrowings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubordinatedBorrowingsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingsDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing",
        "label": "Subordinated Borrowings Disclosure [Text Block]",
        "documentation": "The entire disclosure for borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC's uniform net capital rule, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r606"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/InitialPublicOfferingDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summaryof Significant Accounting Policies Details Line Items",
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationOfCreditRiskNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summaryof Significant Accounting Policies Details Table",
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "nuvb_TaxCreditCarryforwardsExpiration": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "TaxCreditCarryforwardsExpiration",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforwards Expiration",
        "label": "Tax Credit Carryforwards Expiration",
        "documentation": "Tax credit carryforwards expiration."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1192"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_TotalFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "TotalFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Total financial assets:",
        "documentation": "Total financial assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_TransactionCostsRelatedToAnheartAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "TransactionCostsRelatedToAnheartAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs related to AnHeart acquisition",
        "documentation": "Transaction costs related to AnHeart acquisition",
        "terseLabel": "Transaction costs related to AnHeart acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r386",
      "r401",
      "r539",
      "r567",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r694",
      "r894",
      "r895",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r906",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1178",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit)",
        "terseLabel": "Currency translation adjustment",
        "negatedLabel": "Currency translation adjustment",
        "documentation": "Amount of income tax expense (benefit) from translating foreign currency financial statements into the reporting currency."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r82",
      "r1188"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, acquired and retired, at cost",
        "label": "Treasury Stock, Shares, Retired",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r114"
     ]
    },
    "nuvb_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Equity Incentive Plan [Member]",
        "documentation": "2021 Equity Incentive Plan.",
        "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureBorrowingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureRestructuringSummaryOfAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r363",
      "r364"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_USApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "USApprovalMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. approval [Member]",
        "documentation": "U.S. approval [Member]",
        "terseLabel": "U.S. approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfAvailableForSaleSecuritiesMaturityOnFairValueDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfCostAggregateFairValueAndUnrealizedGainsOfMarketableSecur",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableForSaleScheduleOfMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDe",
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAvailableforsaleScheduleOfMarketableSecuritiesWithContinuousUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and government agency securities [Member]",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r884",
      "r906",
      "r920",
      "r1237"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails",
      "http://nuvationbio.com/20241231/taxonomy/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r496",
      "r892"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross decreases - prior year tax positions",
        "terseLabel": "Gross decreases - prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r892"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increases - current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r892"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increases - prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r892"
     ]
    },
    "us-gaap_UnusualRisksAndUncertaintiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnusualRisksAndUncertaintiesTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Risks and Uncertainties",
        "label": "Unusual Risks and Uncertainties [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r148",
      "r149",
      "r153",
      "r154"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureIncomeTaxSummaryIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in Valuation Allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease Expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r904"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "nuvb_WarrantDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WarrantDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant disclosure.",
        "label": "Warrant Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_WarrantDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WarrantDisclosureTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "documentation": "Warrant disclosure.",
        "label": "Warrant Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability",
        "documentation": "Warrant liability.",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesOutstandingExcludedFromCalculationOfWeightedAverageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923",
      "r926",
      "r927",
      "r928",
      "r929"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair values of outstanding warrants",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1182",
      "r1183"
     ]
    },
    "nuvb_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureWarrantsScheduleOfFairValuesForOutstandingWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "label": "Warrants Issued",
        "documentation": "Warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_WarrantsIssuedDuringThePeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WarrantsIssuedDuringThePeriod",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued during the period.",
        "label": "Warrants Issued During The Period",
        "terseLabel": "Warrants issued during the period"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "terseLabel": "Public and Private Warrants",
        "documentation": "Warrants policy text block.",
        "label": "Warrants Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r259"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r259"
     ]
    },
    "nuvb_WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average shares outstanding of non-redeemable common stock.",
        "label": "WeightedAverageSharesOutstandingOfClassAAndClassBNonredeemableCommonStock",
        "terseLabel": "Weighted average shares outstanding of Class A and Class B non-redeemable common stock (in Shares)",
        "verboseLabel": "Non-Redeemable\u00a0Class\u00a0A and B Common Stock, Basic and Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "nuvb_WorkingCapitalLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nuvationbio.com/20241231",
     "localname": "WorkingCapitalLoans",
     "crdr": "credit",
     "presentation": [
      "http://nuvationbio.com/20241231/taxonomy/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital Loans",
        "label": "WorkingCapitalLoans",
        "terseLabel": "Working capital loans"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "12",
   "Subparagraph": "(f)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 3.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478878/942-470-45-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480112/944-40-45-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Rule 15c3-1",
   "Number": "240",
   "Section": "15c3-1",
   "Publisher": "SEC"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0000950170-25-034903-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-034903-xbrl.zip
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MB^G*3-309X5,8=<'>IWYN=8][F03G3C ^K3R5EAVE/QW ?$+V5' ?_0AOR[
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MRY)P]I7@8OU,K$_6?*VZT/S*VWFN%FA299<Z^Y5YPD<$F$+Z[#M[&=<Y0(7
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M\A"D)?W$<J-:SD."8MF4QX>K:,+,H/'%O1B!9@]C>NCB)#_BE @SOEN6Q<^
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MDN]K(5!"TIZ]RSI;=3HU+2W-O2F96 XY3)I=J'I$F^N&U2[&R3 -W2#Q?,,
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M:?RZL%E.8)?%XR:WKVCI<9^;_:?##WVWK:VSL-%#G,5)\2>Q+$\8U6;G+1#
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M)"0GOA_.N>L]]ZYSUKUGW?OAG@_/AX25O?:S]^__*SS/_F_5'!UI:Q,F?K5
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MW2[; -QGIBP/G*=OAWYH-N"K/=R6/WN7I#!RI.:A$/21T(M(I\A@D0;)EIH
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MF:>OKA[*B?7IC[2RF7Q>G$'A5,W@$@1@X 5Q$G!F4IY$>7'$NDT2_R*QQY^
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MW9132/\G:32_;$!-E;!RAN 0]<P)9TC/=?KF%I6Z*.A[Y]Q5K1;EZPXOV?V
M[+Z293IM.>8@C3/,S2K.#\R("%8!2FD"96##DU.-D" A]@(M-X 4RZ;[S'_
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MALK)^$,O@>II*;9R4JL?\V<'1'<$)[0U3&\VI4;,?D1W4T+9A69(.2I]OWK
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MHS\\I!%Q;(&NG+)Z.[O__G]A[[VCFMK>=M%L&RHB @(*2K8B(C5;:5(D6]V
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ME( ]8,S+URD';H>W0N<1<AB@>SPWC:%[>N/J7^F2";L:I.(%$-+&-((!71-
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MX652RZ^;?R5S\?N=P].>?Y)22=YSXYGH(!U@!LBN?:?#$E%$(+E=$VP<'W&
MUV_\5:6#%_%Q"C0_?7E^4)[V<<G5*>&=K&X8E)FR)*-PSM(PLB\\9]IM+-@/
MU[%./'EP/*1/N0RA3M^H?J?IQ)Y,Z#;4'W"(2C[W%>WO>=#F8?U""[9Z/.+>
MC7R]BSMUV1IMF<?>5I1VVSEXJ;E[#-CYN >YJ%4LL\S^%%:=OZ%,&P$D04%^
M!.M"3YT"NLH*5MB..;'Y?!56*D4<XAOD0KM"DJDW_FN>=@*#1I$D._O.]N5=
M.*YXJ. /TYOB ] &O34TYP;_G=UR(/\#?&^K)Y,QB-RTNS91L[Y&3-V_HI=>
M_*VL: H<H3@U3SPF3*31K%M:7C,WT69NQ-ID6'4#>'^1E(]:)?$/K@H@>QW!
M><YN[.^@$W-5.&<[$2)H0@__<"NKNI"UFU&2RN Y=4S,6I-*O6TQAIVU&%17
M^Z&O6$MAFKR:0N/.I47Y<];D4(E&ZE7%5WEE8M-\?=PTGNF2N@<W ZWU)S*O
M]N)_@1D=9Q%^K$79ATFGY+#32Y<5U$# TX_^?2'=GG4RAE^7XY5DI,Q MNER
MG)@-<@XIN35FNLD5OHA QF35QI>&T-9]=_(8^?(21H>EYP*ES-]ET!J+K0:?
MCJ9E^IPM&/%3Q8Y;KYRYS0SWW.OQ)-!A7/4)K,]6;6HT)S'[C&M))374*:]Z
M[$7J#^U^'(ML!9$_EB* #L7%W<F-2:QHRJP!:,YP"9!TS*S<0HCW,P00<>3R
M0';HT-6H<*&LV8O1'8EZ'U9[Z<5V%LLUJ@Z-S V@UH#ZHG/76$YK/"::_6C$
MKZ9DS%B"^WL;T[J-[45$'FL]SKJ*,#>M*#_SBE?N-,QUIXN++<NY-#0GWP9D
M4;FYAL0TM3R][PA>-M84"^5<YP_,:MJH!(AB0T SALZ175[*?[ $D+BMWT[M
MBK3U/#NQ?=-M.@_L$LK+2M1&$O_@6^;.! /%E:I@5WW0+,[YI0BK"\3_AKC?
M6&7@CE6?" Y(N/%'5>C!,WI5=,0:YW.2K!FBI25EE/=R7B1='[ ?W'QQ%P4C
M?BJTB[JS'I7Q:;V%[;".CLK<7.IS&K_P@G)X[+M^^56N6^(#RSIV1HT $J#%
M73E7D,B16OR_[2[][[9X,N0?T+\W06/: %,&>W*HN_!2>^F19=AGSX,W#J\V
M1W?6$.N#'F95!7C)B.##U(_XH[0>+/0:W@Q,7GOU.I9O?R_X%GR6269+F D@
MUG_P]@OE9AK\TU>^4.-/O0+O""".I.X=?@2:8_7#%0ME,R DE6D*.YHIVXV*
M;E<%]5]B@H0B8M\W((X:4].%D 0IIN-*X]\$$'G,UZZ@CZY(3.0;8[7Z="LT
M5&J9U6U$8KH11YT"B3DF)^P0WX73Y B#/P/_9@/WW.#"C)6!KSDUXN?ZZZC'
M_0]GNGG*A:@,V;Q0.OO"?385H<,[&_$\9?=Q)_GX,H2X[8.,D2=I0]7.%561
M_+;GX $3'$\ Z;I()B%X1Q%3D0*(Z& "C?NY5 ")#P3\\3OG\$(#)(N7(G_O
M=RKFD3($D \XJ "R"UA8_,[V$F??NR6 _)Y)9DKS<0#^'FZ7#8H,L [#UD<$
M$!,IMH<P<[\RA&)4OQS..(&:)O 3E=?:A%9HL6N#'V0/^"W OT'C!) W^._A
M_*AGP+U[T&\'A,/[!;7XX_)S2M*<[?]DL(7\4]V\9F"I -=' SVPU@+(HHX9
M>]9. +D, MP# D@V?G$J[B>VG]A^8ON)[?\@;!_VH)C^XNO]9]<%$$D!Q//9
M^2?A[09@>9B7_O0GK%3NL3<#ZVVF6@.*<*:_\OJ' [L9L+7F-Y*[Q4]R$1V0
M+?GV0[$=*Q=^Z;TA?I3<N(G?$7\I@/P%WX2R/?[C5K@%OM?<R?]QS A.@(H
M\@\7SM\C@/0-?EWKYCU_!GQ0"N#N!?#"(>#_S'#:H'&O)G&"!9"A/WC99&8K
M**3I =]4,$Z6O2QT' D<&$ /9QD*("_&H-/A")Z(4.(QE?D>PA%#IY['\78Y
M"K]>I^_?^5'_-3:S^6_)[-9/;#^Q_<3V$]O_Z=A*A%=[ /='J;T7$MESCGI
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M4F4LE/*/V+A>CWT@D:.!)C<,/*=S# .>X"%S0_YPNF(]VAU^@P6E7++L"C5
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M?Q]K,*9='7.8TF4LS3)^'E*$=G7H XWY7WX)\@P[\3 ^0-W?+T3,>'TWU=?
M;Z:D\,ZE[LRQUDV<!]#1 ]W$*8@)(/5HI@B?0):NV,GG/8+?'XP10$A>'?)
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MOO0 MUOP-Q_^$N1Q$\#S".KZ;C"A^Q6(L)J0[X.+8[V"0M@V!7HWQFL:*WP
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M/8/#C^_5E<S]5NI?5O:R*/S!VF!4 ]-^DL<U%1 I 2D#*<B_X+M,0SC'Z!^
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MW=+:0<./%UH2[#+",@_J^S@>$ 9A<JDJ:L"=]@K0LU=%9<)4BQTD-5_=1)
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MJ!1$K<?O [)!%;1+UYO62MI70.H3DM68K9N56]_71I)NM3JA$VLZH1'<'V"
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MCF@H!TJ.BL\3M*+,W?/ADD[B-@VSY[*J5H-?SRF_']ET-56:^[DH]]ZT=$\
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M"F@L\W+C.45;AC(0ZQG8WBS)AYA2$[0,XZT08*=T*YTO]]II9>O95!C$H!+
M00Q'_P=\\P_\.>H;$J W!MK.YD'M_#J0+H#E!%BL55)_'MTJAI.H]4.OG)UX
M<7>S-G0$L (F<3^QWY;6">WH9]_UQF.:N?QJTJW=R_L293RDR!#[< E7;OK2
M^O#(]+?]$=*:"G<3^''@__![+H\Q@+I>#(4$L3:6 RD^\W\WEF?[?W#7[A59
M./K]LS<HQR(_H&0@Q\<BGWQU":OX!#<^J'SK:DV[@IXO?#2X93D*4[DUR_84
MYSA;S$N_-0F0F])[$(C9QONM-V!LS(D=WTR5GM,W1-%H.S?=1^IUB=HLQX)
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M*F^<Y.!XC]1D0)I\H[A;KQ#'.L])?=N/W.YSO(Y2[A<-WX\DRZBTNE_(2[6
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M*ED8<(\J%]&5_37_03$JAG (-T5Z0)?4_+-ZT+?^5 D.+3-(4&!FB-J54ZO
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MW#^GCC\.,'[JJG!7W\C(D,@CHWE:JQNNZFUIBLY+LC>WSPMQ-/.U^L,Z\66
MM[4'9+4T;F,VQG_D.>_.W*L<,8X2^R0KA=@%?@D6Q"&9 SUVWKV>3?LOR0.;
MPFO?8!8&G0^2C&C2M2D0\MRYV3E4$.Z &*%>I,[/8R_\AU$):N(/N31G%Z,'
M^6+=/=ZQ^3(H8U,SB![5<I7XB1NJ,=8QWHD!UC&HPCH4R>:;R1K7*+^@X=LM
M+6*;O(^(VZ'#:A>G6EXNP-Z1*8+3/!?4X'GLF^*9%XM>M\3\H[S82+XJ3G>
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M51!0Z40$;&B4+J46(&! ^IZ4(D*((=)'"$FI]&U)JW21)O0!!0+2IN@+$)$
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M3 >ONS\A(SBW5_\<N!Q'YI] 2[U?_KR("0RUC:-&#WTON7U9H^>$\O$TF),
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M5 '3\?,.\_6?^>9]R=)M=;,PIWZR>['R]LCKY[#6:F*AA6V.03K)ZJA+]G:
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MBNKE:[+$EBJJ.[OP)JW-[U4FM C;-:0-$ZN>1]M_ZXF3ZX&X;VR& %12Q='
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M%9OJ<;6 TW3K&B.Q*$9NFC%X843!UNYW7=XIN'N,_G3>U-?X-+?:;0^9UJE
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MN^+'/S3"00=@7RFM<^BC2/IH?2P2<P%MP7(BQ6(4_+M4'R-#\Q64?HM3L!W
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M=Q9?V,!@I6%RVW)IK?1.TT5+6]'9U;TR&HRR36E\,T$@&HFV1]L/# @Y6:L
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M+54WRJ<WQKC2:WQ1<=;N@LB&:#5F%-LPF-!AM#!C_%,Q$&F;4&3ZAED7RQ"
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M_"!L[<0#=0^<23I?5(@@^^1MY6!\#:02USC_1B/'@FHJ/\2LZ+G1'=E2T,(
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MC19>60#O;,-M'<>0'L^>9G_.CKSB_XS[#ZE5_1SLL>UQJ@KCN<2(,-N.!WW
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MQSM]G':?"&9,>B>:=NEG=PE ![K,DA+I.EXHW3!]DT8_)'+B]--VEX(5\:;
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M",LMU+P%QCM'!=%81_76O$B)S%&^# TG-0D4B8X#@7(P,R7V!+@C#'.JEN>
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ML%%SM]'?2GGC36J9U "_(#AACA_OQ'!@!.D:+!S7720&3:6EOFYOE,RY_>8
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MR.NX<O^:M=W^%I5+)ZVAP-M4\7-BG*2/1;7.Z%C%*(XX"T56)__RTGM0)17
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M&2$1O7UP@<X_V J)XO1:FZEB&28@S):7)#5:#44+K2YP+XI@I01P\UJ9H#&
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MO8LRO1&<@HA+_]<P7/]B8^.J\]H3;L3':EPOG&MF"#G$?"R4(PUR9D2P+3U
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M0%=&VPOMZ%JGB7L+ZO,?PS_O/]0,W^7S;K%>'MS+%<&:DXS.UI/9Z+ %DF%
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MO2DE6_P0MZIWPVG/^+$#1@_Z-GS6^K/+1)I4EO*Y4G"2=WXV!6BD[<58W1Q
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M#I/:L!J2L!N+ ",?5#[XX#*F0\IJAI1H^IFV6FI'1]V%9N&!0>U4>G'S.]0
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M=%/+\RKAZ)C'N?KK'6.^J9Z]-HY51&_<[\(%(VEP@<9,IFI&("7]Y^32-:W
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M.J<3R,>:J7N#@HGO!B?B10>."HNL#X!I;D!.I_I.%):7/[K^Y'K&,KW-LX,
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MNB;"JZDSC+ XD?A4SG]Z>JI?FHPGG1NT;.Q6>2F*HX;+@*:;O$3PSIS4FK1
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MAW-+'-$< ZVS?6KFL5^4:YZ6*^[&*YYDSR?4&H6*F:N[HHT\V(\$?VFEJ6=
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M7U#0P]B:GGD, DCW4U;."M/OR,^KN.%&?U:&9.?VR8[9%$WY$?^"=9"B1,?
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M>T2'*D0ZM9CWZ]7Y'/SL)AG;^.+(?_^,F0O7(J=FZEWC&+/YB#IS2L?,'_C
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MZ_G/]NT'@Y;.>?:R\O:Z5>D35V5,M^_MPHV>_TEB&@CV,V:);>OC9KP?X $
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M;^]E6^U3/SZ1,ZRF L-KJ TN_:\HGQC@&5=!80:O5@RI]2-MIR\H;FNC\XB
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M?> 8^^+:'G8H)P;?)AW""S,&MW])GX=.AN#14(;I\P!=/G.,/C)@IFON$EN
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M>-1Y7UG-'&N1=[^U8#JO@$\Q-5,080KJ"(6&2P!W_;AWMJ^=3<%O9E\@Q=:
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M<A*AW+ZS"LE@6H^PU"I9M^EJF;G5GJ3<@RC4)<K"N3FO%EA, )9_0T_8\'E
MKOH\L_<!/;S"R20&7<F95G_V\ *G@+HG3TN1:SZH)$E*T<!Q;<ZT#5_A]4EQ
M0M<@]MR"9R+9VZ3[L+K][32T%,@TI%&/&/G%]\H'2QIJU\1-*\7#&[&/WLU#
MX7X57F <W2 PTX-UB8AW3R@Y:DYE_M8D$H&:GR\6&TO4I.14CD\I\_.JSW;H
MZ#L+F;%M!%\ZJ6N+B9@>N;17W,6XFQT\;8)2C$+OH @W"7] @%]]7C+EV6/'
M(#Y.'F$ +U['OBS?+F=_A\D]V D,L:">UK[_-;-%O:9P_;I7GLJ/?Z109*5-
M=0,UM]5$&VCIV5Z]TTN-XM??VS8QL6QN9TX,5^HXCQT'2) )D1Y <R M:I=,
MB U,%K#;H".OJ%R:\8+-.(07Y_I[!.,@<2RPHHN33<$#Y<L3:/N+W_]Z\%;N
M2*6@PT.@]Z)A_-"[D!6IFX&W?NO(K"4^ZJAXD5Q;PMSL^]+%>U'7A!G:E.Y@
MF;HZT6$W4ZYY45%VO*LWO70B4Y4\;+X+"7;QT)"F<<JEDB[TY7^7C!J""/[
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M[&D5#Z9\E)508%K]HEFJ2BQ:9O-\X^=!/[T:"B9&8/TFD#8+9V"?M(_OH%3
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MD)LB4+=IHRM]7??()<0=P7CF4%@G"1*G%M8.M:-'1Z#N4$YG,'9M,C[VN5;
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MK<D92"3/W>O6NSC^^\36]J]M\9U-;/"X:F/&J93PF\0-"=])#"#EP1(V88P
MM4P#)).A<%2G:AIL1X=U[41I1<?^2N>/;;N0)PBD+S)WSFRZ2(P6CW9<G9Y9
M/[P?FI[1A .:?CN?)S->*359/%X5$-S>,K5"=SK$$T96.B0?W63Q:5^*&*Y3
M7& J\Q6[O?Q &:]%>AJ8)WQ=#QL\\#')4Y,V#I?BZB_-:?#7G"@SRZ%]R9*<
M)J5MW/V<[;4Q.H;.L'!V?,#.E*U9PK"Y6SF+V..H[1CTF#"SNP3IA+W B%7J
M< HM^2N,1VI$1UGO DN>?N$]1@!UC2:3I%:&UT7T=/!,M>GK-)'Z8@///,!/
M;)$;WYG8/2$WY=U6?LQN8@L"]>;T56)-%/KVY.6ZQHDV#QJS,T]Q0FGORVJT
M6=,X2I\\I&'7'D64J,@>?%U9T-R6KN3VOK4E]U>[2<2;K[P*R-O#W"NW)>U3
M5MZWO-=Z_>2 ]Z*-H&8HWL,A3>9NU)4;W;TX[H>1<SKW57%:(Q8)8RD-3BVR
M;G*/%![)=II"^36X=J\6D-(*9L73LFWCY_2IQ8P]<=F:KTPV]TO.XV[2:_Y$
M2R$C%F6V=,L!AWGH2:^F4$@B6G>X&#ZO:D(-ZE=R;?O<(>DY?V5,64?16_62
MN9KS+5OZM;)BH,9T:N4%%TJ-$:XG4+;Q_ND.[TH;-.DPR=98,.<R58&B8#1&
M),-AZ6;M#WJ?.8T>N'(_+;/Q^9&'IKVU=N6:QNC1ABQ3THVXMA6FOK/+H,V,
M46!HQ3'(3M66%K*(B5J@/0WN.09Q>1(NH2Y1AF>4.4C2Q-&=#I,1NGU4T#R/
M^'+B]W>3#;F64,"QFF5 V\ZG@/F\KGLQ@L^YZ"_.'(/X-\0=34X8Z;UQ#>1M
MVH2P!.K9W-),3Y;=4:%..%.$/2U^K;4264,^Z+ITK_LO9'3W_%DH%\J8%GX0
M&5C#NVX)APD^H>X=7=$U'G0<93D6\T"%-FP$-BV];%JTY^<0N\CJ<(>%=7\8
M_PTQ].E+29VKT^=]CS)/6]X@+OIYV;6I2G&0,J!]F=DD/2R>@M-[%?EUW,SA
M=H[7>(D9\HDI_Q.J<>!E3U-\(!Q.,)%3KBK"F*29ZZ.1H:[ZP@]_^L]F'WP,
MVEA@'8,$JHP'"<<@FV/0*I (P@C &M#Q!4#8$B1A#\./NDVW)3I+#K5!&)#H
M>;66UC:.B.(X\7@&VX))P1J?#BPP7G-0]2:/E=KID@V;VKZ8"1"=FT,#2!"'
M$=0].K8WM"^Z0PI909E,1LZ#F>!NL#AI;AK =DL:OFS0=DRF:B.^FI1R:D'U
MV^S[];M6OF-[,_92'Y]$ B\QZ*>^K)2+"L>@/^8-?VS_D@/0WL<@*:=A=N^%
MA2.C<@Y9";^\^O+_82_4_W>S75/9,F3^!&0S_FZ@5W/6+%<+2YT6';&]=W09
M=4_C97+<)WS-O.-@F'^1W1>5&):ZE+?\AR_.&T*#R/OP"OCF18N&Y.7OS1U^
M&5\UN;\7>\<E\9^(9GA5A=RM,M'"2QGGN!E'RD^6R9GY&0N7?;)IRUI.R%HC
MDF]<(-&Z7.%:^'+_9YV:O1LWGJ4^RRD\@Q.>6[[:XD*5^;ZOC\Y'D\ T4\3P
MM 39Y17][@)EEB!(K6%YXX"[QR"3>/+'#A'Q^UK5R34;#S=MQ>.08STWLMU;
M1EQ'$RP=2 IS7AG/E1->_IKYC5'7?VNV(H:F<+._%B'Q(MTAS=K=4"#ZB'HM
M_8&67;FJ@HRD>T5QJJEF(UY![$7/[PHZ>LJ9M96%8M_\Q["M"M_P\L]R+FTQ
M4N'%N:\Y3'$S)___GE#_AXD<*6 Z%3'NA!<=TD>95>C+* / :)$?#$3TN=RB
MZ\]55RSMG%K34\H8NT<[6J3UY&$+,<1[A7/Z)5^NX8HV147!O]]4F]O_> Q"
MM&9N34XZ! _0D\^[:FK(VC?>XG<4X:*L_;[^,%_VKG^%@YH7RAJLZ"9NY36T
M-K-L3&ILURE1J,A^E'<^_8&%'TYK-&<\RSPB(2BIJME,H?A@W>U[64&[PI+N
M3I2:2@)$9!_\R_1Z:'"$"EL:N7% =$!'O2N.=27'UPA[U:^IAVHY=GG[9#E7
MITL7B8=V^OZBX/E73'[LSP7?J\*5N*OQW&JYMRT"RRS+U\UF]W(?&/CD4$M4
M)9;3&UJ"=-;[4OQ?I*0DX$2D&YH=G08.ITD;1Q?,8:,[+"$>AC[@MHCY\S"8
M*DJW[-*[.(GR6'J@!A'Q/,3&JP[R,'VCYW\:$U_AU=HT=;Y'S<C0BJJ%NX=0
M'!<$''D0(_D;+>@4_7*2%\2'QC^SR>:686JQ/V-^0GG34LF?L)1VQ^YG0$UG
MEP&=/T9'R1NW+JKEGE1$6JF@\/,Y0TN'*Z<K%0IG/(,?(K3,(LIFBPG@Z2?;
M6TOCC^M9E.28=(XXK/GK#Y1&TM [N[.]2<[9'FET^0R)GVY/,40JY$UX[&UP
M!N:54^I7$BH,7AJ-Q1>UY^\)_>T:/>B:U/M8^.E$Q>=<E#+OV&J9LZP_\>+\
M))]@UE.S\96WJR(R0]O82%5.67J-6OL_=XNBVS"=E_5.L"! .QU*R8SIN K(
M_(.^';T(.057SQ#7B%=%J)Q#^ESR[SFL(LYXB88:E+B&%#LO=!4CPVPCS)@(
MD3^=YN;NP'7'S[G YV4$5E^C)?IOG=T1,<-Y7>!^6"9OE6-M7%?AD,MM15D9
M?[1J4WGE*\.T5;V2>?V"UINHFU%\:85<4ZEQ::E^<0G2MXUP0=0+3>X'N++O
M_/KH-$RG]1[_2[; 49EEYS&(FR6Q2/AY?5X,0) E5 36T*=&5)/YU@FTU T-
M#HV-R?K&-!I15&4JA%LL=64M1)\WN&&BRA" [_;?$+QJCD9,3DO"+^[(#M8C
M73?(KJ_)<H_6/U<NR:>M3R;KZL'OS:$^^^4XC/0:33\QT#A+0[89B(PG&KEN
M#*25_#+N+JMMW+]1N9T5;LDM6]!N^?I?[5C]IQ%*(8",S%8S[0KFRS'HP[PN
M4$B#DA=B6*:4=12,,N?F""0NFDITDPK6&/-2$WOM?)1)J,BZ[=AZRU6VV,C>
MG"6T:915=?-P?@OQM'+,*]7)])N31\\7L[,#:RO(-B74HVXW^.^>9-IH"7=*
MA4UZZ.S0.%S6X$)(R0!..>2NNK&9R?C S?+FCFO(4.O+AM,CZ2'CI4640C'B
M^8/0)G,'JF?1(7AP6:25DFAI-LFY*R7$@Y'?:?.I%9LM'64X(&C2U=_[[3HI
M*M\OV+U@9I8G[([?J4QO59L;OREY1]9^J.-!!H<@7L)L3\O=%4R[=-OXQK,2
M&5%9HZ)9B8@TQ_B1]_T]>&1CY?"-HFRCW:LDTVNI1FNC05[,Z2+F2Q%FR:(O
M<,6GB0(["9ATNUP%?O1"/8.)"=SA]<SZU$2^12NX%-AVJWPCRQM/93R_5N]+
M-QZ8L<Y\T)QGJN?(1-@I;>.:0M[>X<G7/B#0[CE^H1:%0QA9^)8V"9W7*FA^
M$]<GWU_]DN<^"Q;"BSV:$0@V;;0,29$WF'=HSH ,>U#ZHO<V/B6\C[I(*Y-_
MMCSH']N5==,OJ.)LAQ6.ITJ>4TPRV\4T&X:#=&[D#<@C0%39,@7*]3@;KPUZ
MX'AJ(QUNI"L.O4=3CSM48+P^>HV6^7'FX#GP!X) Y>\I$E^DQU%RE';9?HWH
M-N?"J[VG.D:WK][/X&FU#^JL\#PHX\/A/M':WO6[AA5[B;)@G9@7! &,)W^,
MEF$7-$K\;,M.K)KW[L#'W@63$=7LQ[&!_.>0$1;NG@%50F9"]Y65EWFO'MPB
MP;-0HJ2._)+U PS<1&T0X5[[2<[M7=W <C02E\SX;.<>'?<LU]XZU3SR][1T
M?0TQRS1WKM(!)94K=D_NW^#GDE<[+VUEU1XMQ4@JA,N6XH*^DI;QXZFFSJK#
M<@6$ D(4F':?\-.=M],F="QE)WX?(O0QSZ?0G494DKCW.6 U#.''X%&R[ D]
M'1/("U>JGJ0>@_"KHZI"X=YJ;; O6:C&T:' IB4,<,6V<W-(WAWPI4=0;*/Q
M/::?H4MAOCQ GW&&OO>\U60+7^*BX]^"[C^#&Z27NQQOA1=N3;GJ<:*)'>Q5
M/A$E33X&-= %X[!2/88JO2:\A?4I*3@J[I?]E42Q:_C$L=\.;+E6?; -A^VJ
MU$"CJ:+R4/O!5Q 9->^\DEU__3 8]2?::8K,U@1=RAR T6^.0:.=ZQH:)A1W
M]A#]*GNZ8?H$^%+=Y)YC/[6RNGAL^S&^M>EG!I%XR)-MDHUHU0XA(_L([%["
M.UAWS<RI3>N)AG8/*$VF"\JWP5^XR=:94'P\*>V-8&II[XWHW"8SPZHT-[.*
M!.;AP5H%S@AQZ:3L8B\!YW;65(H]/'/!+YYR-O-DFB)3Y#6Y;)DO48O6)]>2
MYF59Y?O'6KEQH()9U6B)<9J,S3-4;43ZR)+%AR6%1QTX*+^%'>[VG9&ZA$+9
MA>S<_M[KYOAE.35AO \)RST"&WL"H^FK3+^S-[JX((C6["]]G:,?>+YV4?9)
MBO\YJQ23TT"XSK?N^A7#EX&RSI0K CH^9U?I2XSUHX3BHR24/[E*<JQW!#E#
MG-=^-XGWY?U?Y+UG5%/;U__+.1XK0A0$I)\C2H=8*%+SLP!"#)$NH41%Q8 0
M$9  (3F*]':D*E4Z 4.D2TN$4(X@-10))20(2),$(6PAA'^\SW/?W6>,9_S?
MWA?[33*RL]9><\WY^:Z]YIINKBA2T<K.?4/K?)&6'?=&GU,-B,"I>C9R:46T
MZJZ?;V91.]=I2,<^\8CR3[(B1R7B<M:%1(=TCPL@>5L)%?-$I</N+T@RY],0
MY/ZB@J694W-J'T92S\Y)LHH?AIS^KO!Y8]6H@Z5FQ[W@9Y=F^#Y/*3O5H^_4
MR+NO(VB)LUE.*,7C0^[=;*=94">%+M71QX2_)(N,M#B4N80EPMR_GTBG@Z/6
MP)41[Z1V^%4!0[=1Z>]83E=T&*C&1/JWB<FINMHR"B'WKWVA%_I>Y(/ -592
M#,YT+[\V0<F.C7QN#)U#BS^2D:+"KG4@S,H!3_,1W>9F6; 8;$X+9#-RQMM%
MGH@Q/O='KT936ZG;D;E+.S^[3[/'KL7FO^CS]SJ-]54.6!INMRN-[F1EET].
MA-XT%4T\0SP]LN":IG$UQV#ZZ:>I^?8'!HF&V2MWW]<0S#-3BQUM2ZW2"CF(
M8A3M939NY,[7<7N<J@#E-DNS_WO1SX+?DU?S:]G1*R\^!-R.!RV_QX3(YD#L
MQK&6K*PLW1$F>R!*YW6A%")_&,<H@5? ]?(#2U"2CI+C_^@T[!173$TY+W%F
MD(B-N:H/K@V'8[KG*BQ X6V#A.B.\<R4!$.=@D6#IVU6_BCPLQ/QY=:PJR=3
MYT^WJ@Y51%=81YPV3//JUUEJ<S:PMAYR\CE;N96:&>\PE6E9LWA,@^O"??$K
MM0V3-#O0KBB+M6,SNGKAT9<P(/-FCAZ)64&*TE<03\:+HLY#@RMG)KS2^3J<
M.Z&M%]O5P.1NOU*7R0&?@[VF^8^'SL  FOO#:QV-*N+,<M:&<8#?EQ ),@GA
M%:D"4@\,5K)+MZ\*>.1@V6[9A<U.'C6'=5D&S%6O/G2S/555ZR;=+\=VW5Q6
M,_^N;UMLT&V>Z9VY BW*;#3#U6'VA?A'/8+9#*YKRUX!#\YI[[4<#6!$[AQ.
M# 1'-9'^9M+F:L9T>V':U]DVG'#,#J9X-+*XW.SM%U<S)E>FLMKGW1I1@G1&
M@V.QVKJKQ;/:J\"=,9O%"]&+<[/N_(/$#'0UQ5\2^''I@KZST1DA+U\)C8>4
MO!T<0+]])/F]@=XW=>E]J(DR]?;H9LMY+)+ZFD>YV/>DL5AZ?L+,ZP.6*FV;
MK@(RC_"Z\++TH*:9C/L$O5CW<)2#AZ/=2S6#?K^XID;'NU?)BB)V(KI(B2,C
M^5872VW]7TY:TK/G/]4VIED[24A^38:1LE1)2T%4_*]J+'_K[3ADX[2!8DZ4
MT]C8<!_Z.T\_:)8BNF3+T*KUQFOEYA  HTZI)PC8LW/I_4?KH#%$8N9EY<;F
M-!F!+S6!H!F 2E"40-WA#P/>+'BXZ5FO7%7V>'3+7>_94C8C5F=2M<6BE.'V
MK8G;?*A4M*98MS*O'+4@<HPU]EV\ .5_>PIZ?TEWP]UP B-M$6LLG[.0>C%>
MU$A<TUV]L#B"^T$.IGX[-O9B<KRZ(?I5SX64.**,S;.ZGYGP9@EJ<"5(Q-C!
M2V=4W<^6T(O(+CY2GS857#=:-"*7EU:)<QQR)[*1LZ0.)/T 2_05F\:,#-=N
M9L%<L!LU%QJ&-V'*$P5NUSH4_AQY@Y#7N$Y[.20<UWC-TN0S-_-AWD$NJ0RU
M$\;X/DX% V>0U%X\:(+2!8\CZXQB'0ROF>R1J*JU$!" OQE4_;<K*CUH1GW0
M&%:V0O NBTN/<LNR9B^1J\\K 4'6.?>#MC IB1COB'/6Z7ZOU3'E50YJL]]L
M"3&=5ED^ZM7%5A?M"0W2JOVUA"[?B_93V?<SM)$I#PTR4]^G&A Z/_34SLL$
MI";#.JU@_I;*6?&G,F$&SCIX@TVG35E.-_\(9;9/I:V)$6UZE&?'\?+.E'R#
MK]".X&@%F""Z$4GPJMP%Z)$ZBL@WLFR8P@*397-P9,>QU+?HIUVW3&-3W,8N
M5VTO23=O4K9[1IF=1HJ+^CL ?A1S&XARXK@ 07RQU,2-.=L:6FV"F,E9[QGY
M9XVCCC"K#:.4,LWS+H^VLT;GDX]\[=7B'(CP=RT\W\_^F1)Y0,U^YH$A\!AF
M^,',H<XB-[;8,"VLQEJ'7%GAWW?9_(>U.D=:TC.R\U;;"+44>>KK^V4)M1Y=
M5S'_VJE4CW\SGRX^J0X*\<)ZFH6A=SWYO9:[9[!.P^33*AVG397JBV?#E+IL
M5TX  1AWZ.'1P+R3*"6+IN&H:&,K6XS'H,>(Y+.1$WW>!!?%ZJ[\^QE?8W<>
M-U]H6_@BI_T@8VRG2UC:2I<]VIJ#<!].)?6"/=U/+;=S0^Q+I8,L<J*IH^UC
MA"B2J-5($=-6;BA/,WTE4RQ5\=W]\=<VR #<OWGOP9T,.MVRKD^!U?V1<7QS
MVLI$WQ%X3J*[35L8,YV_KQFK%;2/$5EA5FW8PF!A+X1YUF-:I\@8"?UD11CW
M$<5@FRE.=&F9G!DE*_,>MXY>OV\96NJ%^V-X<SOCSF^TFXUL99*_W+V;53%U
MP:?SCR@?-Z9N2.\+Q;@J45]_>O STD-M#E5;P7P?H,XJC?)1+G0/F%LEC-0T
M%RT;#CD^+4F)PU4>CJIQ;4\F71,M-$>T%Z.ZD@F+!U4&5+EY8*6Q81\=_,5-
MIZ5]H;5?1YI]3^*:#]:"8Q1.<C9GM($@%D2"#AAJ7>IPO. ,4*^.H76TX,XU
MXNY+94T6T3J['[ FE5!=GJ.I0IZU?^EM$7T;,3A!9>%@F+9%[H-LLPR;OJ?Q
M%F-/ K.9TDV!:M82:F1$;;E=Q6EK\5*M<X5QP[=2F:J??G[Y+*GT6W2NK 1\
M8NP%K/+1I\N?W"_&%TRYWJ]#3/N<+<HTD]C1%31N8.\-7PHW3)'9VE-BK766
MY#/11P#3.9?PCT- ^CIU9R ^,+1Y,LQTLL=-:W6K@@1ZI)<45K;B_ZVI/B,4
M50Z)/),)3=#;X4_O@ #UPVV*$[VS*AT#43-' >'"-F:?.?SHLF%#4JTL6@Q3
MT;'R0+>K7(MG8#+*B-D*"UP-%/[@HWM7+P-=9J'C^,_MF6D4=X@QX<KXF<SB
M5?FY7C;5N73L3?;[)&G;5F,3_;_SH5]ZFAPJFCA$::N3+SU4[RY"Z0[%L%&[
MI_$AC@[1P?=K/&U?/EDF52<8V&<T9#?.'6(>/'PHQ:=V66VCW79^O@;_NM;&
M+,QFX?]9R9((O4G3U?*VI6WZR,+)HW5AB!W:S>%:XL7AT#VHW0AI,7&L&TY;
M]?%(7^;N<)=O$XE:6@7)H3%?$T][!,O;\^=_57QCFZUYNPV]Y1Q>DY[;I1R>
M8M"#ZV=^ T*:?/,K40]9PD>)C Y3K5&?]<T;NL*6+C8UE,%:-RF7:I_ZH/09
MK7N>5<@<EK;&OQ@G$/QDSAPS@ML/!5V]D//8\2]J1MX7YI)YX+G3_F;6A3;%
ML!YU_[A4-./O'LY$]OQQ^<-VR3/#/EVGEAB^P9_*2E;73DWE9-D\\V3J2NQI
M H7\(UELF<4;37%M2 F<]K=,SHN['J&LF!995L(9H^2\;VN!Q4NFI]@17P<U
M7U_2-&P1,Y13*CR>]PD?3JGN^_YF%X]1XC[D3&7JD<DR0*'WOM#1RPU584Y7
M.?J1/)623YS?^3TNLHV/75'\<^S^=*[^T)14F)[65691 \7[FH__W ,%)79]
M<&3?!>EGVK7SJ0^ [ 'I2&)DQ=6F-N:=1<=: ];22.RS\*_9Q=)6QD-6EN3/
M3J"%VX8?$)C86U I]UR9A!OV+V>71Y)MPFL6XH*:FBR+5J=SR*(%E+=P0(-!
M!?V==\Q4A*=&,U7@:0*_BB5VF9X!7FE]UL\595M$MEP@>;E+L1<C KW#?&="
M]V3:>S9V87'VX[P+6E^=8$\B.;4_WR3?*H$O?F_U%6=9N3HG#_:7W5F9+6-I
MW%.S*XY.53'0-'&V23-3#:V\F*TBX5,LK5)N<.DF.?CA18S!: 2*EF!@94^S
M<1\^YJ673BBBC0?0ED\Y!;$;VC/1B7QEGB';M.:=&7--J<O=B)T4H>N&0]V)
ME ?!.*!HG;TSN[?3O0OJJ\Q*$#/0T+,-9Z_(?$3<4SKNO>W)W=R+A=S;%YH8
MX+ISP#$\,%-Z$QG#@3-]E-H0.8R.//&^2N^=UN^M'H?>#G_+[*\I>V08CWK;
M35QN2JC/8%8XZ>T$[ O=R[IQ;#Q]PA.+3/_J7&^1S'KT\'3\,[R[SGGOPU=S
M$/:-%;;Y:WX.ZN.%J]^Z NVR">:U3.M+V6\+4M)F-]Z9ZPO'=]GE' MX<MZ_
M?+G?)I5X%)Z>[7%T!F8^M/#$-L7&UI?+#_E6$+M3^/E_WBGV?WGMG=S+HGR]
MP5[<W2'Q\W1E>-])0XH3S?SK2:)X2OF^T-(/F_]%LC.1=W9?* ,)'-XD#:[_
ML2_478O\7KIAQ>, EOM"VA0V: F9/R/X2=(CRC3\:QHO'?<V-/"_\YD'JG;#
M>5S=_/_O%7#LWEY4P;X0U7Y?J%UPKV.3G7CV*SS5=%_HKN 3QJX;@_?GOM 7
M"KN*S/CU]:H1GRJ8/LA)"JML%YG!I:PF3:UOX!"_-H+RIX;PS'(\4_97$C2+
M MR@,//P#1#FK;#D=?X)_"H2N,WXKP3IM3S!W5^2UA@<Z%[*YUTDUV*]/ABB
M*Q1VX']>4^9Q\6V!^-FB?2%!<+NW"W_.. YY2));(A\%BN>X'*D$G@>QEZDH
M"M38#;4<+6BMC&&N0%W@LH_HVQ&VC$[ZUD#T\1KM5V$5DX*.R3@:Y2@+5^T1
M5KXZ:^M'^]_4L_N;"Q6/#33P=+>+.':KV"K0RYYH&+#<?R+^S]%1 WV5TV8&
MEBJ12B?APN:!RXQDR:98:UB/E9J97HH/F7BV<K(:DF^H ;0*I(J@:VV>^T*/
MT3'X^H8V4@2D#M159AS,)K'J2\/8/W9-T0+R/<R3HP<E8"WNZD! 6T=TP8<Q
M(*H,<60[%QQW@_V%EN68.(/A7=%DT;D;8_W#Z+5CS9B\B!IM\:ZACPMV[:,$
MI(B<@_H'@U'"5?MYVV(5!:^1\S\<_E)'YVKG)*?*^%B>?-EEVT5+L[)"F?N*
MV-O8PLZN/^JQZC.1WS'1$1@F^?'R_\I\-=A(ONB%45V32_RC6R7=)<OZ.R%>
M%$6RPE)(IK.[*T*YL 3&Q$<[B:/&5_YX%==[U%?+QS.Y?];2]X?+%0US]],3
MN ?[0N%W2W/(QW C8[]VK4MU@G\?D&A\]?DDW(]I8FX44QB=IW4NU\CE?J;9
MK8WBEF/SZ:?;]Q*TQ0(Q^N*=#*3-;>SC)_B)?2&'YLPTK D(M45ZI^V8@_.%
M5_0LZRVZTI^T>-T&9EOS.F$#]!]KWWL<O\Z/,^M^9N3O7?F_S/0!G/^7F3[]
M\6;(NU>)ONYH3X%/X;6,.=6MKN&XSU8'IN@:/P5^+_Q.(,QZD<E8\R]V7=;?
MEG'/8#%>7D)E/M[.$/N"HGDAD!WF(P_?UR2;-]2F[Q%]$%PH9BZTT,?7\^)I
MC\D]ZW&XV->D*/_/N)L<C=-LVT+%=^6F5'KY%Z_+J7M)=<1_616JNFN>09*T
MFNIL9:65VR&!/PU,"E*^+BPT:,Y+K2/T 73UE&I!+#OQOX]784/H_MQ_ (]=
M9=XI3D,W) XQ37[%1!]>JK;T\=HX/X*%LS12,2T0ILCO,ZJ^OF#=@9->9S1D
MK\?2;[\K\,YQL?5V4[0>01,#\Z_6J[?*Z2FDKMR[(/&7>8*,WU."(]%2]6KV
MF;K48N6"Y.DJ*YN7#]1T3W<:6,$FSJ9-H@N@_@Q5TNP :X GL<(_=G<W"(M$
M1U)J)-833.660KAU9>[  :;41RTCOL:$#E&&<:LU$G\2^Y^:&H&SZ'9LJAX2
M"QT0ASX@8(+:4HQ!>)6HQZS:6LF]0Q1]GIS(KO"D&]9#@*C1>%1SWE$ I15(
M$G,'!EBXN%TX(-9](];$ELZ"BR_EL5_S[&@Z6E*K ]@F\EO.M_42]/"6<YV\
M(1\$\CJ/RVS1_*QV-4$.AZ=./$/%EI1&]E3=GG$ULU N/.UFOI%ALM0051I3
MVD^4[M\)5IP\532O?ONQ ^+\LYQ'=MM.+NLEF71KT<DB?&"JTYSBBWTAKP%I
M_A<(^_IZ(K(6$E\KP<Y(W%J?4.*2:+KC0ZS&JJ% K="/,\> -*8SSX%ID>SX
M(0HV^EWG"OZK)G$OABAO=^W% D?G]?IW?"X<T-=P'EW=%T*O06_4C 9JP%00
M@/0<=TRGV7NE3&?-N;;/KIVV1"1,F*F[(.OSC(?[[OD6I-*AFLG_\0AZ:&H.
M>EXEL5&IULWR>]_.PKBW8DVP8F^K3G8X4-4,>RZ7L?XD%#'/'5773:U%IUT*
M7CB9\%C^,LT_\N*%5"__IQ_47-+9?D'3R)F$EH'O,[&JI)<F)PHH"21 S8DG
M0>(?TV>K<-> "C::"8EF,//^QH(JOST!+GT,@@@;'V3M)DD#3R$BWS*&@<1%
M!$?E!9AG6892 #>%.XW]9:HXHO.C"$5_2;\ND]H08C 2M37'9B X4M%\>4"X
MPQ0\C'^/=29AP.WT\5@=R'LD"O]EYLRHCI'L&MJ2_WGT7)XMC5)3I_;],;^M
M;$!WJS2%&]IX_T.B!02:\Z3>XY_YGZ8>\<07.7+KH*ULS?.CBXYUET/5=8G1
M\02[%QE:&(TA@GO>Q>3%R:P44'QQ3(5[VN416VIONJ^?35Q0:MCXL^TX(-6M
MKIZ[]NNXZ<)W_^\K%@XDAE+;L#K/MG-Z_PO;D+_V(?/%O.F5F4W]&058&% Q
M"__-:R?]GW$G26CY%Q19?;RV8K)/E^2CO2:Y,R.M!1LE=G[(Z(N\CD32 K6,
MG&GO=!,4^+T.PX$N&FY0Z*C.9!FX=@UJ37YA5*$A,'+G<_4MU2WUZ1IQ+A7!
M]U^PCBIE2BOH.T+:\#RYHZQ>='0>V];$B>I^FM+$,2^<I41"CIO*69:@ALG$
M<QG1E;*W.4883VA=7?)2YU!6E^,&K'BR4VX.,0*^%XJNM]2PW,O'=5*.UC&>
M(ZLAJQ/L\$Y'D@=K/8IRT%0.\.\R#&5\\8HKQ?0,4&7\,0W6#2,!K?2PK?0\
MEH&ND9%PA8'OGYD]PD'0YL][Y>CZ < .E/QD7?3AOI ;P?AA,'1RX(!M]I\$
MFX"[+G1;+_=AFZBZ8FF#*P3#*E2W&1@B$I^K)!&;OSH<J>!:7N S/5UAHA6$
MTO4<'EO;G#YE@Q0+$8# +*/.H@-]$JNX]QK_:#T.=V+W,.]<GC#N !8))##Q
M:U#'5AJ$>89M066<Q&1=YP]56Q+IWZF[T)OUNP_*!PZXNOQ\=;1 6SZ0.I2K
MW"IG8A1JM84:*OV\IA!2$Z_T>76UL:AR=;6NYE11H;3EVJFO:ZW)S28+L?M"
M)FY2?&'*OM#!Z\-U/A ;\EZ!#D7,>6+:S,__[0KRD.GA*T7+0^9/N8B7,_)
MX%OO*OIG4V>DU5AM[R!D9+J#H8OW0U:5KD&8X$EQ+AIX(/!5[1#/>KCTHVCR
MN<$SS35-']AY"0'UAOA8WB5,?4;#P&,ZCGA\>.E3J*;3-D)B+*7<%2&@ET=G
M/58O%_[]@RQ.97*<7[)OQ^LIORM3_W*L;KD]S4'J<GM# _5NL93MA:R2.>G.
M#4M]J?O D^!T15FU]F2"=+OQ5-VI>U/HAW.]!M/*PT$U3A8CIYQ^_";HU["
M7A+Y7_!5C.[U<(8H13!LL>D4D19]%BA\?0YYX@SF,',@;CTPP7>[*U=I\-5W
M[18\$R*1!761%?E]"N&R9%EZ*/T[%[K0JCSHS.?C/KF;<B"=Z D[[@.@<,[[
M2QU$FF>YEV=Z'+/;24^5?)89(!,5P_-@SU%Q9\;7[])6_VJHJHI==QCQ74SL
M[SFBI65[Y6#MA?;HN/D%.=VDWJ>NI28=#NW0H]E-<<+6:5;5'32NZW@@4_U$
ML<0YR;G5%8=GWF_,IK50K*71#D>J&<S^;4H62M74&ZMEV>!=,7-AHW%37H)W
M%'OO5SUI :59WP$Z.7 K=D9W,_CX-T-D$M;/LP#C= 6XQ':QH]6*")N-!=Z8
MK:INYNA3*6) ^G(OE*;98!E<Z=U4)^#S/S*DZ"\[[Z=3\)#9* ;;#A2+;SCT
MG!/$[%X#D0"\"T!AMQJ#65H@Q##/I!A ;'<I'!R[EV<Q&BB[!KZJ1]?,C(IJ
ML?#PW"/Y%7_+E(@%QVT^\B'>_]VL;OL'2>1#N%*/2LX]K_DZ=FWAU4 "4X/E
M=4_MVLG+5R]EJ\]^:^L2)YP>>5)AZO;@W9FOC64//SPV"[QZLD+ZTR>S_O.W
M4F)]BD:^?A\>7D*:-5?MS@GX&2?HL1-DMA9?9T%%TN>Z]H5^P]]75/C"@[#1
M;:_?LBEQNI/( QB5;D-*/#;T[EUMTES,%/8*^V&K0DPAQM0EA:E?15M]NI,4
M$4@Y4=\86NQ5[]B$?TYUO?3&S]$4<[QAF9VC:<S1K6"5VJ8K)*CVG+#V+[6J
M_5EJ^"K^KV-/4UN7G*^*IX;X89IN&WH5NS_,3E4Z?791S:A5/-4A&59/7VL6
M") []DX;>($+%>B1%T4X>EZ=TQJJ BNYET]602F*8V4)6&V.?NPJ?86Y^+?Q
MN7>/9"@1ZP$O7\#.[#(7HXP53PUZV7AM=!+:2(@55/784"UC=0(W>FY\FL)V
M0TX&<>/WXL@GL"='\)Z@TRCR[QRI#G@T@I]%PN3.M>.D.<\(DBE,!H@:*II1
MZHP9@'(.1VFM;0D3KT/+IF!OIY:=JVI@IKOP&%+R]E 'V]0O@O48?&R$F-%[
MOLLN J&;CVAN>VJ=X]5"(VCJ>'>GZZBKG8M"O]%V.$L+OG8^W_@L)U;70=V'
M8-9E.KS4Z7Q.7]XUK77=1;$IP(GMP-[E'_N5W_ %J&.&V74K'FN!<TI9GB\V
MC7;7P"X</'5]X@ 3'<\#%RZ'/,QY4+&,>$8@ ?ZS>L5%2]L[N!0"BEZ\E3,]
MI2^9&;B7MLKI]@G\HSK48G5=(#9.\L<%H@W[)/?T'A&K^!9[ETU^@P\N /HO
M&RO=95/F%)X3E@;\/ +J.=\XWW)%H'M&MRS</*A- ^&:OMK*=7KGE_F*KSQ?
M[2WSQ3A:EYTP6'>+UT[4TK7S&,TPIUB8QL:'>T]>>SU)^5;N$#$3YY]K,';R
MPX]K)ZTNT@/5NE/67R[0G<8^Y4WZ2'3S3 5>+QRG#LBV(\7("MY<=S6V?F(+
MI!A3VIY[AL;;JAW=U/(:UE@SW;A<6=#04A>LM7#%)&VKCKB7\#&]GS]&WSCZ
M-DD@+M5!:Y[EN,Y]H2I\)SR>?&I$9Q(4<U$[838I DG/1(VN?>4PXK94WVE]
M'VXW\S%E"7R,(OP$T'4Z,(%N1L4\H<^X>$$-EYSVA7)GJU<=C2Y0'P2@ZN([
M[RW-YEN5I\IIC)03$-7S3TMEGOJ,^NJ7GO[T*?3=YJ+CJ27KVDSND_"RKYE!
ML:[CB(EIG\H&MX%!*PT>]U>1C(,S LO-0>'^'*PS\>=&Q77L*.>\0V70NR,7
M@6ML8:OP#D.'XE4IF<@H/4()5B7.EG9OE*B4V0[=,[U->C<\.X6XD7&RB[J[
MPY9*P$(X&A]GC@-Q3(W.$:S&W/I1(*B++#TBD1](%L!&;&VH29!YBU-#.NN0
M2XX>G_YD$*ZCJ7@!>D;BV8Z"VFPVXZ7C,><T5XD0S**[3OD=K_&*(]8O2N:/
M59)EC\^IF9>G:A85%9K8Q5EH@\[G)W!CDPE2\+1/]C8P@GO?TWY4T6AN.3W(
M\%?:Z'^^&T!D@.V/#!$L))C%B"9?8@OP3J-40R^?A98!XBS8I*A5A[\RF?0?
MSN-H39W)!RZAP8L>)CT'(Z6+SY[U[>W@7=PKP'NN)P0%<14/D0VQ<D!#6/%D
MW4RI)[N7A7[1$AI4BCB;/MC:MT>)"&QU]#8*S-P85LYD*B7<;ZJ_VE8:K<]1
M$UCR =R(@C;0NNOKO2]T8-SEURD6=W<-ED(.1VXJ@CXVZ#4]&$]H,6/V:70J
MZ')@\RUKY!\(<6_'W!.)G,+8?GDP]82\LE!39"'!6[&:PH8Q@#.'.Q2_%'*C
M .BN)9 QUQ_!:EX#M^'T:3Q_]B*4G<9_J>.#[,1)^\C":0$,<7!TW212>HEK
MAYR>\O)W73*5@(:NZ</SX&Z.^F"II=.51WLVR%)MGM)=H9H*J*P[ZG/5[^HO
M6XZ61C\I/&ZF:;S<]5V<8$4\:$N$>U@G(#BENY_,_'_>^JSAV#F2?TVTW*;0
M5F?%(5#,KR7;=3BT:$XY>>&I#:69MG.Y(%;CA__H_T]3&&-_BM?^S[N<!!=I
MH9<O^G L,%1Q CEKGO*@?-DQQ+&!T^\@H"^7E8HPB).;49O"GRVT<?N:6/OZ
M$<FN]3WUSV[=JG4?]GB_G?M9(="8X2C/7.27:ZSXIWV:573^F(+QBXFSKZ:U
M9M$O\0>T$:<E8FX7>&?%Q87+W;TU8#S\:L%JE>&A+>8W^\7/O[L"+L?V!N_4
M-%G5ENTZQ>YT\0;1$WON8][;&8/,VY-SN<(3:W"Z80O?<F/CZ<_UO@U(?KDJ
MJ1<.:,+7+#EQW.M[L2UF')=9Q\82P(,E/Y!D+#*["Q);EA%-8SGK:,@_Y7X/
M,]^^.1RXZW.-^F/9]EJ)\!]AZ!MCFO?J6IH#WDNU]W-IBQ<_D\D^KV>K/U\J
ME3,W$H<*FSL4JP['K\"N7B2HMC^]E;"N<MK:$9Y^\1F\O.[V4+'MN_5>:^VG
M\TX^9NZ?]-(8T-KF6ESQ$/+C8CL#4,_@24G-97#7>6IP.9X+T+8O=(3"]>2=
M9; K\/<I+RDG($QY_B1_D-_%GQ8H=/BL(VGOU9[@*M\7>HA_%);WZ[33S*@)
M+*/*]:<;.@HRV\A@.X F:*Q3(8IK$@<SXK4?@^]D=4!$<+H\\2&^.) 60*HU
M*5XCOF%[1N+DO$/.K61Y?ZG=@]O1 BN\M6S/;&>Z5_CXF&: O]'8<=%SZK6$
M!6.3Z$[;*./W ?['X6.97A>A$V,?;>,-"E5KE_NS?53)]S,]TVM:-*RLT]7/
M^_84$:XE;]>,Z9X+]0Y("3'1QC\;<>IA5 6MH68AD][<8#9\[8# L\)':C5
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MW@D&$QRS&4 KH#UH.%FW&),^;EYS$"T2?^M?):KZ[&>-'O_'[I[/67+4\SW
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MY'+HO3&W[#$+<. #1=%4&HO=;2"\B*\K7;5FE0(6[3M"4OQ!V1E9'JIL>D%
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M:TG>-1"VOYB5>\%=D5G85-> %IK"FG.MD0-*7E/PQ8,1MX)%ZV2;7 5F6-@
M,^<X# W0_K+,K&LP$"_$P&85NI,U-";X)B>'^:>P9FR7R,K)=J[ 8%UO)H.W
M"JZ%\E-DUZJJ=H0BH),-8!5LGP\*+#8NE;#]XJ(Y/&"2?J*\XJ7[4&[ 2\R/
M+QWI-4!Y-*[?/O@-H3;]3$'AS.&.X(\C&*/1TKLFC-:2[/BTM>V<Q,UI&R^]
M<!#Z3!# -7C /271L#O6& 'D[0@AV#'1+0I(+3)K791W8?N5L>8<;#^(NDZ.
M1R7D#!P-J,_[@ZT2'V*C=DQ']]<87[OV>OZ3VZ@B>QW+W]M<'.[+%FF5R290
M=X04L-=F5Z$?^.J0PUB=69*T?Y/F2-]83-$HUJ "3-H1JN.9_J+#RLU* N2"
MBDMA'$USY%J5=M(J@;'^YJD(E[0FRS_0"]129P1",/L:6AO:%H64,L@S ?I^
MT:!2"'7U293B*?8T*;Q"OOFCS/2(-USTL'^>0KW]07_=OJ,=H]8)B_^$<PE?
MN_DB-""!.2984N Y:,(*3@Y$V #1 BNQ!S1@F5**%@!B289*HK&U5H-PK![<
MQ/1D/2,<I;,8'! &>%A(208T&/SBNV7_N(GK??:S6K$K./-6AB]/[TE/I6\Z
M&\0J^CR),M3I_$QU+8WI[):URC"T)]2G^W@DEJ[ZV5B\Z/F17DQ-HK+RGQ1[
ME&@5^X^$%#MDF'_-5Z7U:(G6CZFUW&X=7L<K;5T"&[APWMU=ODVDU)1V4YZT
M[0/0R7I]D%F_%;R **52(,CILR/&YYEX84S6[%IDJ27+>D+[T#).?OA,!L\)
MJ\K,T2=XT>\6-K//:"M->6J2HZ8)/(DQ_J'RN77PG.?,<2R$G=.!%Q=\R#*)
MI5$M%@4JU$!M&N-A# MZ"-7@T953,0E#LQ!'P-8J-,^DW,/_N=4[U&!]L6*K
MU*B,;:9A@L?V*:![UB5+H-'M)W$BV'TC#KU^-/%Q^=G2Z+I*HCFJ-UQ3A::#
M/0)$C45B+P=K/K4)D:3F:9(']5;+T9A4_6REO*XMX<Q^_-<4_H$1=K@ ;M^I
M\*3&VA'BQN'("M"9?W*9?W8[LTT%O+G&H',M;-C>Y"J+8DRX.87<$FH-WU:9
M$X_AJ9<&&,@T2 3(9/JY/!TA'67-W1C&030_OGO-C0:G7]]S0AR9OQ1MH& F
M5:P<ER?MC(GM4']5_D!#7UN,E?^1RWC<593>OY6QS*RY]"!4>3-@HYR>+N=9
M$:2FV5!,'#CHU;RH.3*X[8-OAU-FWRB>$21G+'_ ]#C[%[45TCY]!BR?&XC-
M]HO$*N5CEFU'-V&B21=F;(;) ]++V;F$&)XET\3VNNZ$O+R)_B1C.?B_[/K6
MXH_*Q2/9WL>P.?R#I!VA?7+@CA#7#O<?OLYOU9=[E7<)?)0//F#N&TB8!Z*R
M.I(@-,43IMITO@)F+U\2<:SK%IN4A+T]=C0NZ*YNDHXSN:F6;CJM9Z2:"<_5
M7__(D]@1BDSF&T_QKFS7&6L#MM.AAL(K/X$)JX;,S[ S1$A2F]KE4LQ$IVRT
M"4O>MPF(YUUJ<'.!U)VG,UBH\OR\T>F!+>)VE.D>$,TQVX[DB_%4V._\#?<U
M/#.5^LC")X9YGT*%BQX:Z/0^1VYE-]",4B01***4DL7@IB;"G;Y&"J4&!@8R
MM[4.5&O639F.: 1>U-$@J'Z\*!S#/E:US_#W-#XQ6M/Y5V%LLF=1Y7N[U[YK
M%2_QY=39-(<N)Y13$M*5B+C0V:%WXAX8$'2BZ7ZX2SI:.2B5DX)_VS(P3^E$
M / !4.W[JB5+G6C <0#_F98B/_F7_!DGS!,?-KT(OCM'+)#-4O$8-K87K!6(
M^[3GL9;N3"]HQ^,_CRRR3FO*8.8IA!P P9.%\0_AN>>Q#GA1W @.DM"]?DLK
MPR">+\6[ UXKP8JRUPB% 7MM1R0VX*0#&+,/6RG1FUZ.%K_K A$T12EV\O-,
M1OFP/)51(:*MOI'%,N"=T..>P T<]<+^M?U"0$>B9MV*AX'6E>S0J*XHE2B*
MWTRTP7+ QSMHGGSQHJDTVZ6*8?8%#M=,9S1$&NN$7>AXKF HXD9<N\T3V=UZ
M(Y!M<PWH;&&>">@S!_+W7P,03F X4Q3>_NLEF(@[;<.R%IFZC?) OPK=$3J@
M_23K1H+%^_<CV+)]Y-_O(QR0<IBK*'G<BQ=?ZWX: AVWL.=[[[^.;CT4?W'2
MQE/JIX>#W;=B->+[.\]#/3B!YB-(VP"'RM[C,SV=-Q7.-=+[ED8[N^Q;+ZK%
M)Y(M?WPQU+1PY;VS&FW;$5I0 B3G#**@_OBG F^+NX@Y-6\J"^;/3DG2MCQE
MY=M&2I,<!L^T#*Z'71-#;WC][;4HN_*BRN:1K]$5C]/),[V4?P5)?$X[GB&[
MJC"W^[B1((X[LHC_@P<IP\+?Q?"ENY_A3EFSK=TH )D4FP]&,)=M$"Y@6B7&
MV\2L4VXS.:$X8(NV(Q0=LJUXK)JD_=(?4*N#U$"!JPKF$8[\@P^X&IZ3&I9G
M7" RNO-'*BN.Z:8D"U)F2,Z=4]/F%UK)Z3"C_0?H=4ERUXZ[T<'J;8*Q"!,?
M1P <\=&*>]AM:2@2"*7AZUU>%((Y?[?%JVYLAUUM!.N@=74VMM.W4XV2M%W)
M[KK;MI-E!C(&!D<J.]?>J=" F,-?G6L5H>UW, 8)U-NI @VPZ1G/UGT+)O:D
M?[]2/'PK-L/8^)+?F:'7CH/>_&@#V;@DC7?%QW_ CN2K5FJY6P47#:7RG;ZN
MI7D80?(ILI39.@+@BI=&4CG_ O@8,O0)OK:OOZ[)-J8"$\;!OF7+=C27*S>%
MT4,B8*R&SO7]F'<FMSK#9&H2X-\'C<V8"^2#H]^^W_@<$H4A$BD/\;/)!,!Y
MVYJS-=3B Q3.*::]P> YT2#RC0>F $X2<4>,@^$LV+_7-O,B(U@3@?I(\K$0
M4?S?HV2%0]VT)O0$DZZ]AK4I6L))U]2_#70T!]872*L- J-\"+4C5&.P:L'4
M]*-F:Q4S7U+\M!/VSUQIHA,1UK5X<<Q>CV&>B4D2(?W4VR: 4UJ"S"YY$G;G
MK>="=EY.Z9*<9WU6IGXMC8?"M[?(?2LLV@UZW7 1U6EYM"1/'BS,7Y:HJNUJ
M\ AM;4MB77_SXE3VQ>_71EI,BB=CJU-9>Y1;'FBH/Q!M ="'L$:T%NE.S*2!
MZ.P%8Y>_<SV5[\JJ$PV=%M78R4I'RATKX](7Z956#0W.4HV%#F+2FN=Z,54R
MT(,'64LW3\5A:Y.L?Y3K%TS>^C3L$*1E7$_.1A)WA(H(H+HX3SKFBF!!/EKP
ME@<,GK08%&'_WB[$G40*=^+D@9G8_C=YH@ ^TM&N=8C>A=.QT?IU8V337R\0
M<6-X RT&AID/;S1NJFZTWN?\\ASR&0HDDBG?7?_>'8N";P\V/>DOSD[XD,)6
MZ40<TLTUO[YI@F\GO'-]UF(!O+<I15S]M65;.F>$CC)L9OPI^[#)EQ>,J>^U
MJW\*CVC09SSK6(.]%"PGDJG6:)N6X-K90?T3O&[>?F=CP!*/;I-96#S4VBEW
M)X%I(TP59,F\BT6I!B_6SS8TC9%.ZIQ6L'!H29:-WGNTFQ^)$#&5QSC.SE 1
M>WCG +TL#CZ2?P*T_AOPB]%TUSSJ.X0U*IE8S$SSEI>'JUN&BI2M1HT6/A M
M;IJ:Z7L0XF/^*NI8Q2/A/<",F'/GO34OPK=&/F3Y?45C[D67*+F 9$6RE5-$
ML1J[:+8FI(P>4JCH=W"TO'_2[C+KP0D753-I5U$+46V_ T-!6K!L>UN7X"!^
MOP.VC[&DUO-=0+^\HWLY;#"#B^/W39\%X]BH#CG9&"QZ%A+W.(:::^$&/"24
M(Z?%V7?UVXX# [%5F];J7HZ.(Z5TWN4_%4_"\4<7[1 P'\E< Y<:&7W&Y&/]
MC-]FNU.,!/?@M\"HBM,H,KA^01SC(O,92U!QGOLCIK84SV^,&+(C) >-Q5J6
MM&QYE[_!0H%(^.3"X/CB8P:YE'<FF]S5H-4:%JC<&OVDU/VR3'X5W@RB*-E!
MJ(U9J>':87XQ4Y[5080^,O'/\')\[2D:L"-D-HA5,2V<4Y!DCM94#;"0YFE^
M?H$/6 FU^<BEK:DEFW"=+U\B2AXIU2=J_Y[ 4:%UE&?0V^(,BW9$G4I"VV%W
M[$.H^)N1=:SV;)\%K09CV-]-^Y5Y%+EED)!C_QZ(25K]U@IT3$XM&6I<\+\#
MUWP4TOJP8ZO;<7"EU&TV,4:%I8$^RI8VCKZ8J'6PFPN)\?/.SC=V]G"L6'2J
M]'!:N*]ZY:^G)-F8IR35)O0X/?;.L6S0 W-#I_-B?_%VF^JUG^?,+1^<2<M8
MF<"V_9PG;W\;H.?,@.H$GDPIYU$C@$YJ,X6#TS/M'OSR6P\*W7B!VYD\ X#>
MT694^^[ZIOPJY#I;+ V@,]<*(\0*2R:IRGU=3X@Y7)2[)DEC33.CMV^7LXRA
M:'$A?/O?;7L86#> &(E!T!C[B]HDP5* _VW-J%*@Q3VBA@-VS\<'?L#*01B\
MOMEZ7629A/YCYDH6([#SWK+'V5I?/UXCCC$#>)/$^5\HM7Z=Z"_+B.V$D!E1
M@AP#V9</=MN!3/'$VX!KK&ZNRX #G6=3XO^.)P7P4I=</J*#;Z>@JA<=Y>'<
MYK"F<'A"#BHE8K<)#AH;"!&H"<K$<)JQR3_A!5HSD]:(F-'JK1!%??IFBM1E
MYK(_&OZUH;7Y,QDJV1N,VC,3MB^CJL%=1A^S@:F-+F==-%)X/0<BM)DWOJMW
M.H0L^H[<@XDG=CB38@JV"S[T.#TB-*0F!FC?K;1+2,PP[%<WEM'L5K"-TO#U
M##ST.4NG4N[U\+="E<*R=.):)7GM1T^??G7X#$^:P!>)8^_E8,'62GX?Y-TU
M@45BK0L-2)-HL/@\E4&?,3J,?6(T10=4;^<KC/S#_YBQX1:D4:U'.KKT8ND>
MK+RE23,ZZ_#CP*[",CX6H\X741>L$"AH5C@.1G*: 8L$4R6L,/BQ .4M-T@>
M.,$3HYL>*2GVJW"GH2.(/"UV:11/8E:0[G*<!U=NY\WK+@^LMAK^,'IUJC$'
MIHTJ&^>'\VG9RBFKN^/#+H*&.T)'I3>7(0F$.N)8)UYN8BE1"DQ"=,HU=/8]
M@(U0M8J_45D'-8(T0MW^)"E_DFW09R_IO[-J2H0N'.>Z\TZ#H>Q>SGVP'?C.
MRHK:F)$!K5T 2%S0/'WSF//T@--07?B4A?F8;N6;/[?N-!8LN7"VHM,JW%M<
M'[K>Z]9PV-/HUC_7T7+DG1BD$^@7UZM,ZA@B97_3<Y+Q$3;,ZW)^^S+N\F@4
M#"TW<LI6NLPQRO!>L4SCU/5C88F?3&OBHK6*I0^^'RPBK4REICHKX5P:/1T#
M+>LGF]QW^XD! JGX;85?:=P1"FW8$7*GL^;Q^9OX/''>$0K?@<#5PD\%[@B-
MAH"-B(4(;_$DR ^G6>C*Y:@=H9'D@)#;T+50_,I9_%9 K.OOJMV*T1\9D'\I
MG.?:492MP6QI?+$>/NO:.M4D? ZV&AX&/.@8>WPM)HZOP1_2X>D \QR*R7QU
MI"\)\Y/U (1?;QY=JUL6=;6K'](DB[I,!UJ%*V@[M$3WG4T=[?@1:OW(J 7R
M3,V1M12JIJ:[Y#ONYE0U]ZG\BOTG);5D@Y0+I3)?YT)#B*&->9A)WR>I*3K.
M=X9=DFT,;<RWUC:^$!8$V+E/'&P&($S82A)["F<"EG8\AL;P?( <@?J$I(AA
MHE'AN;"NIO[*-Q\+%K.UH[$7C:=<O8?-&XC^\3^0#U.KGP7],TI6)VK#ZG(<
MZOEJ BF+FA%O<9TC@:KH#[EF5.TRCR^\2^_ 2+8P;:N$(#I)^=(F50N<;66^
M2MU<]99 EX*1GFS;R%GNJ^K2Y,\[0AWFSZ]GI>@^COB>R)_$ ]8[0HPT_L$=
MH4!F!'K./)<IBO\P_==PSN5!G!)/9Y0L\+>ZX"O=WWH(T%Q/=7- ' /W'"0W
M;BRCN'V[I4E5LZ.!=;D!@3+?[5/,AQEC6RF"+/!X$_U%";']JL59^\-,C$ 4
ML/>!T=*"!6B=S3<*ZU(+<@XA.>E%+?,"C6A0X+EE/N9QMS5@$;N/$*L$C$6&
M:&KU=/_=])D,C[#9W [6-O9BB<.77FH=FCV\+)$^M\36/,$E"&O@Y'+EW$Y
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MY=QG%\3CY;ZD_0RGB;GG^4L]W)S8ETJL :X7R@_^5%06F/_0@GAF=U-Y@Y%
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M'/'*TCV:*_JZI^NRUOD!$SA*U7HUJWDAH4M+@'N/AT>AWR'-YT$=$&';4O?
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M:\LMQ?+H-JA"W">P$-KW"!:"^&(H0_;0ABR[AJF?W*)5RHGMII[FGF($4Q/
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MP]2,&1Q- EU5],^O**I5JG0W':&Y6T_!)(]]5&K Z@XX'OLOB"=S0" *9S'
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MJ^1& _!'/_#'P,@V#6PP]1CBJU=5_/"3!DMV@C=5#*T^=4?OQPIA8O-4HHA
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MP>]7Z:(,FZ85RE>%O<1]R)MT#)W"#4&TQ0KJ& KNG#BAN BKK62_WR7AV#-
M*Z1L<'Q$CZDDL#Q2;@I\5"3F5U>$U8"=UHJPU,PF2V3"P<&0NN#L!FKMUYWF
MPTT_QOW$E!U&41&-[,A=QS14%LS\Z)*/6^ 5%,] 71/L,2$:1PU;^JM>FLR/
M7KAJ_&TGR-7/QF;,G9)?;(54+NS/R[]$N2?5$JJR:VMK8NY:[VWBL8&.%59
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MW$^#M2$CPUG9*I=44P\O%X4'V*77/!:[T;EKQQ6ZI8=]@OY]R'/<L-XC%4E
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M/D@JHE]18#/L?A>]7#G^?,*"4Q^'@X7R4TT[/DFXT0]__DRG+UKUN8JS(_K
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M7..Y 6"^FP!>![CR_\+!*4#JC"OT,'H:6CU0I=LO"P2[0@XOZ#TJR/<L'\?
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M*M_BJRLJ@IUV(F9:M@!?$FC+=/.36(8$H5>%(30)@9+.2=Y/%$ P$-YR#QZ
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MOG#BRLLCB;:X2^SD'@!XF)>A?3CL>_Z!P(NZ\'0B,OM7&R%77]#U\@HZJL]
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M>A+JQ;A,5Z0T;]^G_U8.N4VU@:&5!<!;_5"ZVW%53_F6-S_^X;3!(&F?<\N
MAP)-C%LF<U8.!E:WIQY9>?NK=<].0_0C($MB*4D 2F#*#N=I@T'%&<N5_5U#
MA;6N[H[L^V(W#(3/_3YQ\(7/W;G[]^@Z$03T>ZX[1/UQ=$@T^7+O8B1X3-?J
MN/M$CCD ;!';\2)E8-GC)H!LK=F7+.LEWU)-,X*J,-1+V7I =40/1E8Z%?.H
M82*FP=,MZO/':@_ZRQ$RKC_:I"*VQO.;SL6<"+;*W&OC[<ET3S[MKQW/]\5>
MD[^-%W ^XTJ\^^;Y5BC27:^VU#T7(1KL*Y3!4X**PBT6U=X;\[6'$R13D!9<
MUG$?->UK@3Y+5'-L6J.-!"&%LGS&POKYC"4/R9R&_O@+>U1JP#F[]Z,?2->:
MH(E3Q/I1R7$7"09\S!E^G?8$ S&P:G\T8JAX)3LQUW]6*#L%HEWU[4>+JU4$
MM7]\W4,VZ/E:C)N2HJ(O6$BCB'B%[2]L[;(H8"4?\!ZPJTHU'0 *&6@P+F0,
M0;GUW/@R.%(Q5F(#V$P#_E@[/?WRS26AR4_'+@EQM^@QAN;/6Q7%K?")%/]7
M-FI\+XK?2.4)<F3_/\C%_/W9U>NL8P=*HB,M"]C4VNF/*@PE_N)+-WGE@GH4
M1(79O6US/SW2QN=52UN-ETB.[*WR$3TG/ZRKW=,J^A+0X=C$ZZOK&"&\=DY6
M5?E2N3_J=Y9S=?83 *V1.[]B\^]I+M1/[ I8V9Q>2@)<V-XD*\?WRK=3]U)(
M8V*#1(.*.KK+ X(:7.#;73IT4%2-<C3E'^F.KJIX=XIR4H4%XPZ'Z_QJJO1+
MNN"4U?^UDBZ?W1D]$8\;/V-IFDU 3_SV:Q:\(O,FV&.@5[)P\'@WG9X])*K0
M/1WQL[5'U40S#.2M3;V4AAYLS[">4BAOFR)/5TP]_\H?^;+@[E* >_[@LOK_
M#D#T"J]ZPE-:KFW\9G,!-D!)#MF+=>"4LQ\FK<H9#%6N\3I-UM;A\S9=*NL&
MNP(RRUV*<I.\FJ)B(4YRO"(6(4.?9\LT'2M_=N;0HPKE+>P@;5B5D!9K +SW
MRCEQQ$-72D0E*1[@[($E?>H^#LME] YF&)S2>XL.7+7R!7;,\+&UGZ/^4?;%
M30-Q2NP@W@9TDR^2"$]M]5+QF5:0ZNIZ?\'>2I.?=N_7@&".^6':UVXZ)\6#
MY$-(H%PPI!N1X<(!WG>I,XEG+)26(ZL8HVF,<E5?=6P&;DE\&B*[<L9R^10[
M(&Z>/F\7S+E5A#G_I5'5].BMGQ@ QU7HRCS'%_$3]UA3)O<R,=%M-"(R1#3>
MX!9$D_D1G;XR\J@Y_@DE?+L!]%#"N#6F-(!\-, 9V[5'+7I9?!1)<SI-Q3X#
M?.G&\<<)G9;U\ON+7B]TM;Q/SN9;M(HB<XB">T&6,6![&TXPSJ/LAWM'\V%Y
MKFT[93=_,"7Q.\SDQ+[S<SB[Q!:_N;24KP<.HL1V\\!3(S+[4TBXK^7EEBN&
M @_:(K0=&D2=K!O,I[(U6V#&Z=8N&-+>F)? >DN-S387#H^X(@UX6ESCI-R\
M#ZY<'IB5S@$9;6W)O,/JZ/_Y/\V-_W/5=Y^Q' 4SH:D$A,]YE=1!#QDF?P-2
ML42 )64\@UHQ%.V;T"L*7B;9I"AFGXO7%LP%JNBR+9I:EK !=C'JP##G$AS+
MUIF 7<N?0>A2P$3I#W]W6,9@&Q^,'[<]?\;B=PHRIG(,006W147I,#(JPUU_
M%0S=@=Z @$"1OF3HC2A1OL^[08#67=0KI0KF2%=\(-?$F!W6!A_X-/M>,S>9
M]_1G'_; [ 7J-#=*C%E+09)^MC-@88 3@2?0(ZEJ.V/>[REE/';&+/]?+]Z=
MY98??<H\<9-B_! 12G:_=4%7=GK$1<LQ[QC_QGH,X)W;?4D:&@4T_LV0XM\5
MSCUZDUW]?2]&HRO4TTC]J[7>LYXG*[/#8NEB+3\R?*BS_0!NZ42&BP$LZJUY
M;5L2"7M#;*?4D#RR=4#4!?#X'2_!N<<TX'Y6T\YIX#1AG$B_D?Y */69W2?)
MPM4G^9;LUT9< R8_3 ]IUROJ.;Z=$<H_+97#AV^.U8S<0QCXB'JXM;7ANJ[V
M\*<[2:8XW=H>RN^IK)&5UL(5V5K8NYAWRGO_^,RL!@0 LT0%?QWQ8(Z6\>&9
M-S>%U,>;$/?/C7(*X*J>*@HQ-@C[WA71&E@#$KWM)1HK1?L9J)9AN>C@WIN\
MU1_H,,!/>+>^)PQS'8'>!I". &C-T\L %@"E@'Z.VQ/.6-U>=>8D7 C@U^!B
M=N["Z4L;0T7)"8%AOA7F2J](NUS+5FT]&F.1O TIR:TPH?Y[H;274P_ZIS$Y
MINNJ_%&"&&NL&@EZ-=3SHMOH %WA>DPI.40KTUE71#.USJ:L=5_(T=?)MD9+
M!F$?5F/!71J=_W1660YH]"9$0Z57ZF=$P!<%$9T7")-TV\P&WOJJB@F>>4CM
MO=S,1P*(AHE=<9H\?9>L3/2EA5 B!X.%_<M$\!A+U!*XVVHV?)G=;<NY5\QD
M$N-0[\^7X>M;O^4^LZ5PK(].6*P_1AQ81DI^>M7*:=;V<CD#2K&$Q]=4Q"T"
M^=^"W-39E5>DWE#E[S<14.5M13&!40PWL;];FR?^F$2T(6K!D4RNMI@,5]]V
M#4H 7_D3C^J2."A$\+05ZX^:^]'?+GJ9;DHUW.A?XNV<V4,/3ZY3AN,AEG^X
ME^[PM?T((UJ2E]E![<Z<GI(E'(JEF32:U0O);HTSEH".CB(@<8(N[IQ;"\[%
MG=/9,)Q[V:8>C"(#!W6]I-UG&M_A"98]#J;X/3V?1J")XKMT4-01S)*LLK!E
M)V'K?Z#>D#+WF#U8;IBJO<^V"KYPARHF;-W[NZ I)T:)6Z[OD6]J1+7#P#/>
M1SORAHBKX9M#R1<$TY </JGU"(&8$8)I2_RGZHW72V(5,B[@>BS1:="IMN;
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M]P98:<_O:Y9^&,Z;G;"'MC2)(+9XX%;%^.DMQOZW 7J/M\TZ$]NY!N4@:*I
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M391.^PT]D\BD3[4.>7>_N WQ5#NLY:VF>(Z\[,X4,:_YB 8/.['*&YLQ\1'
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MO#L\&P9!$1-VCXM!18LB>4^J4OJ.3J+.4=.$XE-03K59C1P0?)J[R^2EB*5
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M1UI7#A 9Q2S+R#S4]J'G].B+P:RO/PT=_V5>UW)64KR_GS7^34[+O'+M1D]
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M$4)RA4Y-:9RI<9)#NINVHH6YI6L/\FL[]((P)>]+1@+'PPVF\(\(G'ON?/G
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MY %B)]U2Q;JHXXE>8$AM?]7YI=*;>D8#-:[C=\4YSYH12HF-Z9[=/P^8[9$
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M9R$"9=H*<O#K'SOVX5<;.#V1>+:A^.(7!&GX.TXJGZFRT"!&G"SN,I>01#%
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M@.L>MH*I#TYT7F7;,]1?;'_;*1:^'AX:)3<=W!:W@_RWT*BF@)&NM'1^;1Z
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M=0@IWO"K, V6<\S5=E1 81Y_Q'6"SC#MIDJ26$9K1USBP>KQG4K3AK(5?A^
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MP*L8#9D.V-L^Y88B]20M%O#UBB74U[61MX/=?ZMO*^#N[13]B^=-O1':H\O
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M .+<XOJSH:/#$@).ECA<3"F#_?S3,T@VY4FAG%G[+L)8;K<?*?_I ?KV0OO
M[37TS>C\]P\K'E2,5TI8"77<LPSSNQ9SSN&L-DXL1:^O"MZJ9M9/<==Z[E K
ML<B'0;QXGPDWK\<*6Y5>M0()!&'UN_3P;A(MFP35!HBA+P$!\+&,V Z'I>B
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MVT^I?0DW"$W'W6Y=N3^IYOR@\869;*GO(F8&PG<<'U^[>\A;USE4T7XT@Y-
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MY'DAF#L)0&CT/7PJ(K'(D]"SP(!0G+!\ON7W/U)>AZP]7++2,Q91FBRXR\+
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M9_>3HKU4E#@]YB3;@HZQZA"RTF?8QBP?PX6/XCG:^\8EYK,XOG1MGF"[ 6?
M#AX0Z4Z9G0,F[6\[G;7QY"V\@F&[9A&A=%)06TOM Q_6S=]O_BK@M27<[$;V
M;62(%!R,Z 6)]J?*0JX[NSDNR^9G47>,&]:N[[YRNO2L:O*2487^*VW> %G\
M(D*C,*IRKIX@E$2.UW0-[QSBL!044L[@2QO73!\YO*G^3]KS;=_I4H@G8E"N
M=,>-]P"W03B^$/SJ!+NG=!V%H8Z?@OY2X>1$.=C4??/R@XD@H-W95_,K!EYD
M10YB"MO/V.DJ*G?_Q^@K+Y7C[%4D]I6"OX<_W-T[\.Z<(7SWL'L^?$X!.,\P
MZ9J_V/*&XGC&>VZSZ96%.K%^/H$%3CVE<#6AI9R@8L<Y^]6)-Q08')J3/B.Y
MUC'XP^+/U&D]V1IYZN[7?-X/M!I''9<H;-8"_/B5\X4<4X\]F;D4GX\6->9^
M*]TVGAW6XH(24G_F<O*:<9CP6T0^=BDW24F'&WS[V+HI=ACP-!MJ7U)7F2R'
M*])]OCV5VGD*(F1VE>CPHQ#04:9*QM'50AJ."X@WK\MBB0B3*$Z#.<5# 5>S
MD0KXK/29I@Q<X>2T_4GEH'H&W4AUAJM+/#DO^%_-] 4X"W;;838PT=$N(IOV
M_87R4]"OCL$&2?-=HG(,R?3R=BI*)=!OO@Y6@Y)=)QVALXLZ)\0<9D/9I<7%
M$-/]#J]W)3@!J<SV4Q"EO&=.C=&3B'8SBW'F CQIL',O*3;1-$^?KMWMFJ81
M;6_%4A]$8:(L[ **-F0=AL!=:!TK#RRX7M-2.^I%?:<H'F<7+#\==W=M"LSU
M[*[CL2R)ME.BK?#$7]$REUVAAURZ'ZS9M3.,#=B<OV4%MS4MEDW7C*-G>O$K
MX*Z\N)"K?#ZVU(3[I.+EB)%-Y].(D(*3]&7.ZG*OUQ[JP<-O*TY!T_$' N#J
M6."- VT@N=.5P<;B-N<H9MX\=+XVMD>EXC9@>,>3G. 'M'+A<D%TO<*SW:*Q
MO6,<WDVA GG3I#G>+"-8G<Z_B$EHT>)/T+Y)A]%ZXEHD-)U[V>+._ECO%EJ.
M?@%1@V\2^.,=1E6"L'<?5374-=:W/F]R0:BV,$Q=4V1X0Y>!2#KX8.#D;)\1
M,.[0(5T>EA2@UTWDU>%%63B9[L+&5&7PQ&@AI6A%3^:]"CSED:@ W3K[@5J^
M;OP>NU8J9[@GX1(2.C=D>6<:;JY:OV=+#Z?RQ[1QA/:'<@/WJ5WT;-1Z!_KR
M\V^?4NXIXD]!Y^>"]1N'*RO]1!X&]7M>67-]-,9T#PI H\OKH]W(7IM;7JHF
M6,D0TT LC.J#O%8=+/XW_>2*EVNZMSKWXDF2N# TC54>SAKH/@XVX!<^K\<>
MF0#7Y.X8+99Y6K"F;X754'1#(]G_MACPGEP=SHOMKUF[,;9J8$(9/^H"NU_&
M%P[9E+]9MGX^\K'1(<%R&-.)#1T,_3)/AZ"CB/CE=@=<W"F(MT6?(4X:@:'Z
MG8:U%=P7<ES;#VRRHJ/W')Q$V<:WDG!4W/79GC=S-]%<JYZ(NZL[@5!'?N\.
M\@37C"-3_]B&U06[?@IRW0;^(%+=UD]!G/M#@!V&GG8*>G8*ZF O ^(MCY68
M8C!ZTBD(CO9 (P%;DHXAYA1T235Z,K3W8%NYMV67-?"#=)"\:G+PQ_ M0/WX
M'%,Z\\$H(3'(,GYACW@-?R)N%M5O.>$WQ(4ZFG\*1+KGP_T7X#:9 0%-Q3$+
MPWL.)KV;G=["P@IZEJY7CL+]4.G=?M*OBZR3J([CLA_(R"N2_.#(%&,KZ1 /
MC4KC=+&T0&\K^+?LM%>II81*-]+4(_</M)(EE'M_1$<30=H*6I;JFZ/SLFMV
M+NV'2NKXSL_\GW> 5JH3^ N&3T<*$"=-!#1%_;4P'Q.J2J^,1I?V(A0+@_*!
MH,ZFW'=%3FO<DUWGTS+KU6Q>0P(D/G)16K;%';INZ',%_@BE N=8%W$,K2[*
M>4P,2S[8<X1Y?I$##K,<9VJY4>^%BL^M3@04*CISN':Z=N>*5+>1'Z4,JL)5
M)L9]]UL,U*#=V-\^[Q!5T![)4P$]F)J 3AQ@VZ;>/.KWGL"AZG>6\: PCY).
M5'+0#[(.=@8OA<$HTZVYV%<'B:*U!?*9Y44S+0@.5IZ[:N')Q-1W;3CIWJ#$
M\RG_(#WEKW0\?]W3PIBP3LUK3['.D1YX&2I#IE<SD5HV[HC+4>=$[?S[0DE$
M 0.5<)T.>*0>WBN$- 5O-CQ\G?##(KO6_.3[LZU&6&O>KK6O,S<],U8[D!;"
MUI[+.;RM>@HZ8P*KVF&\@E [[Q:!P_C(+8HRIRQN>,78J1[B[2VO5E=5D:EN
MJ8>\7E.L!2N$T8UPOZ([W([= !.;P#M(^F)'J IC=J"1</S0:=E8E+TF\<?Q
MDPL]&TW%"1NJTEL1 =E%57%?IZ6;U?W;B%POXF_]L_MJMJ3WQU2H$K\IS]+W
M<FBB8%^DX)N@7IN*TA%/5:^@^NO9CN]OJ$_<>>^H0+&+VRLU-B<L7AJ0Z869
M=-\8&;]?%W0#P]1</CC#\V?A4] 'Y87#4Y"V$%7G]] OL#I^DLC5]<Y<14"8
M9H='"+0<3Q,Y/4+Y&,WVT]N3A_PVN1<G6O2#D$C.^8:&K-F;=1$JNRVOY1[K
M!N@NY(/K<9W@*7 G\8JV')UH!"!Q'BS9;TQ#&N=U*&INU&'<:V]3C?U$W90^
M,)"8&=WB0,TN%_8T6 /S=$F0\T5FA"*:D.G%+7?AE+#>+725TJ8;#4S9IDHV
M+IKQH4Q,Z+A8;3G:SQ;QTC/GTU78RQ4AB][GU"?S6(S>'"MJ(H[>J"N7:.U.
M]4:7"[^D$AJ%"MO;$$%FG>!8'7$7%)JMJ^%K<E39<XVLZG!?9\VH.UTT69?4
M[Z4?;'W'C=,*2L<.>$<2\BR>OGYU+$'Z>?Z)WZO*#/7;29H?'1Q9W;Z5>4+)
M=M1/A?V"4M*[)*N1=#*QQS-DZ(SD <GZ30(MA-.0(9I*5]M;?;N5[5:^VF/!
M()+NLS]%B#R<TRJW:1GVFQ>"-PVFO_G6EZ@055H\!:,TWIYUT+O;@EC1)7"V
M)[-[$.F63NX+0Y'XQPK:2HN<\<1+OM-8L$'\ADW&W\"A'ET1M\CWETK0G[[3
M6@BLCV-K8P9YVO^#YXU=#05/\8GM4]#F\C$$,5^3_"4*>$?5 G-Z."N,M;A3
MY]F -Z0N37]<Z8JM;=9':"ZV1&%#4[(ZS[GSV3<5A6<T"GI3VH7_=?OUV#L?
MGJ%+:6@NGX_:@!Q[!W#E?#":_\]5UWQ#U<2W[T@C72,=0Y<NT!LJY.);/5AS
M%=,1X@_7%'>\=]]LQ%\R?['O([M/U9,KUU1$V?ZV9II6)HL-,O93Q%Y\HW]K
M.A=K#_OYM?D4%/:,-4-^2NB<_[4R5W709K3G%'29<"GIVL?-NBK&P ")'L%1
M+3)HH]K?)!<,HQ$O ,0O;SO;1!A#D=I&"T-<9_%F=,59[AO![.HZ%TEM6]+>
M=\"9/'B@43@YYYC\:_FF9\&FQDDM<.^,HBH8M:C*D:'%"9+9!?5P9*7GGPUD
M%O\T*MJ$'*QU3F)D9GX@'Y7:F2L9WODN<. 9I+ N[],,E-(5(@\I<S3R?$$L
M M.?@O^C<_[DTRGH!?+&^L3;)]#H>)8(2KP3?:U-")5J2DCQ?#.W;GA&0/R:
M"N$..(J2[[S )+RT8';U;L'!Z RDV,.<<@KR6(6Z#>#8&>SQ@(]6_]TYS7_>
M?%7C5"^_+.#8(UEJ/QKQ<74TQTAVLN59N1"OG+E='(1:;EDL9?,1(66J//7\
MGHU+>.>9=O$2*WPE[[CFPO .2TO_F-("M_B^G/"">JOLH84Q]VL/4]U>MK!@
M7AKN+ #3S^1I,&?>')#:E2L]AMU+9'\T.BZT='3T(\9Z5Q*%Q7KF)3YO;"6V
MY,Z13&NB:"S6$J6/$KAX0$R<K^'<Y#^^MY*E&\.Z&ZR!:3\2)9;IQ!9ZF-!@
M%X D2HBU@@3Q^$IQ1ZC8!+0O4/Z,ZQ6Z=J85OOI/2,X6JNU>9.6?';,A(,K)
M'SIY=*%:N_83X+V %@)HTI_9^AMS';1@Y_1Y^W][\5@,*1Q2_1@5/D.9[MQB
M_$.'[..8?,<]41"'!762L)/UKY35.27&4OWGFPF-ZH>:[M%,A;*9,*BUOA R
M04$^+F;1'W&R].+1L>[HBQLN[T<8/%(+&U?!YRW/Q_8O)WYE\*[2W.(^+YJ(
M0&_G:?I1#=A3.:,=QU]:6^3X77UYWS9'3Y;4?[-K:;S,)M'#;_S&?0WCK&*M
MO@3AK#2)>UICV7AW=FF84W*[\=$IB$2LLMUTIQ&CU8A\OKH1 >JZG-O!ZE+Q
MFZKK.(%@G9&L19*YG5J)'PH?XM"5H;D^;52<UUQW[LEN)5667/W5Z5QPIHM+
M2-F\/?RM4_I<8>F:K3]9R#_'Q5/UQ_[)_O=>)-S-#>Z5XNCD-.MH=(./_,WP
MUNB F#ZW<DTIJ^T4],JA%;S R>0YIIE%[:T;74C]%"P\W,;Q,L,_U>FK"X%Q
M/C>9WFSVZ]+!DDFC9X7\OFIC0\K1&B([WL'>QKVI,;/_ V."?TG[7B+U5:T,
M:8$A,"<VH%-$OIOC457\P+KC:5K>98$*^71[JV[+[VE+JQ3>>QF95S)E24O7
M:^4-9/WR#'^).IC(EW[0%TQXD>I3:*U1,I(^8FSK/9''3&?J "&+X+C<.]_:
MP$S=;Y7!)HN<W#/]\,\O,U(H#^[OT:&.L)E?O-'><#>D2&MZX<#8[JQC^V^W
M'\C7],5$3$QAZ.N8:1PK!LEZ/A0^SZ0CIHD+B;GG=,1/2OR&!!WA1@$N]'5J
M46N09]EC<;D"(+ES@N(>K?(C@FN$O56/=.BL$"G(:P4U#*XQ+ER,0W\; J1A
MS.N&-/>-0H99ARY'J  *]D5SAI+\5QXC.F8[V.]L"HO'TU;D_1 IHYH1TW#:
M]I7W%($]X?6</V9(_BGL_;SU6>IQ:W>^>RL)>5LK*A=W:$O\I]<[?3&#)!R;
MZU&MVUPV#AU)QI,6J[X50UQ8E;3B2Z;6LEN?:(,5S=+]$FDFJ@-RBS)ZZU<3
M5:,.0O<L$WA^Y @E6?@<9'H8R][9^@#TTX8 *?[-[ 7D92"SNTT&4#_)I&+8
M +0]PRQF7Q>P0U_&H6OQ2IRK$YIUN) #!:T>];>1\U,JQR;QR363%"=GQ\!0
M:VS+:)/!/-?$&G\7)R!GNRG'L*7.)X8*(73X /7/*W/:]#DL%>)N3E^.UH8C
ML:3\]8P4^%$%-/BHOE/$W2S*84 G*%LJ9?%)TQ1')Y:[1R/IY2E(Q?<^CS5#
ML3X?\'E0C;&<T'Y0!C^23"R:/H_(T;,>]Z)6C59XDNZ6YF[MH#QI5_J*C*[S
MG;L54LSQ3*,2Y>AD>IOT?5*67I8KZ*9<N7("51DKL^HTN1;;62BA50AOE^YJ
M5/CP_<7M?G&+M#=E[YN^I<'P1R/1NO@W>%>(9;'I*G8KN]DFA!,.W#Q69+X]
MR<<X@B_HB*R)WHTG(;S\FJEEJ" 2Q3HA\WD\PF"<:5V^\M;Q**)/Z/FH)TYR
M3.=KLJ]G9)/*Y_GN4]"4WD'8R4<%%1&]1752_#S;ZIQD8W/-,$&"W*)$@Z@M
M'?1)+^=VA^AU0)=:W8OG\-R"FZ_V9;"*R$]A.T$"E6+5K4'HU=T%6%@PVUE"
M>WR2P>3,0PVN=<P[C#'UJ/$P80^RRY3J=ISNM?T<K<<O+3:?N:IE4E>6ZX8W
M"5+U=3;TGBA^JP9"U)9)&OK&63SL!'3,KK%ZN1#TKU484/!3>G2LXH,X>\A
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M\K!3E3;YZ>P/@2Z&>C>:Q_??SZT\6&+Q^B-,7C^J)X]9[4CP?>P\RGN.YAE
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MW5:X[_I-&RR6#<DN]\7J:S7^]M]-UA)O:XU9@PE^I>JCCU>%5Y8618NG<N\
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M<*IJRK'H8R^EGKP^6Q@6KEMK^&4H//0&X+K ^=<\6\M]AAS-(,]--:GUC$E
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MVRK>,6:9Z#Z]W]2SQ;D[28YTGSQI9P4)??OT:YST_VEMH:S!832U#$T@4J\
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M__HY<L\)C\=7$>JJJNKJ:ZIKZJ-&!@='!#:QG@H*^7:>FU@LU2J*'77S49S
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ME+-ED4,6$?EA6,@15>,)/:E9F=HWX0O'(?F&B? 2YX]K-A,Z'5#^?80/:=J
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M4"+\*MA:+H#KB32L\;E)F)P<ND%$%J<;:(8+FQAES[(@C. R3H4Q9OH84'P
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MV]9[=\RM+%S3(N2^?]_#VN#\6-ZKI$[<3GE-',F*S1>"+C4.F _F\09HZ!M
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M$(9^J4C%G<6JO\E>[^&(:)O,#"EM[V^![E?FW%S);A]^?!LTOCVS$6D)_YY
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M1VDV=X=M&LI,21$7.1"<674@63XYJ&8ND$SXL3P6V-;>LX< $AF:M*UNS E
MM@\NRCE4!X M@9S2L[E=98P<\\//J@-'4=ZQ5X3]$&BC4$,@^6:\TF1X:PUN
M<KO#4.[N%Y805VYK_>DWD;49UO/)3G54".LVLR4%XS]4=8FGM&QRDO&ED:K2
MU"%FPSRSV .=:(?$T$[K?#YQ +HYU;1A2UOK8B ?-$O68KV"BP+<QV>^O)TU
MDU>S%#BC?.+[MVO<W(2N4)>3S@4^*3VVXE?6;34UJ^*'J#O[7T\/<N$BWDVE
MZ@[M5<[='\LKF9>#7(X;\J; Z0/<P-I[C0*'3$O,56CGK-N1=\%O$_TZ]A_'
MLSPG[1.=)!1M;W)^,"#=,$ UL@]&-KH)E#,A_85EOW$$RE'5IN-U[2(XCA5)
M%W[$$V4Q=;NUK8WQ)7\>)H#L/#?"L7IPSZYIP\R!.5C_OB/(E+P>*&7:I[YN
MB $N)??#?@N@_+Z-CV^@N*["3W%\:64BJ"S2]:1]QW&^3V0*[ZC4&;N]]IB9
M&1:9QN/OP$X@"MSS)H6K.EBX*D3M [0N1C3.QC-N#LRX79:R&UT87Q-WD6,Z
MH5O9-'Z/("SU@?<;XTLF+?WJ';<:@A0,,$5+5P+)UN_KD<F61$+.)-NF[214
M[G/'1$?3$[0O4U(D99)W95(!((ADO@#B*=,_@8<FYP?J^NA*;-M\GS"L38UF
MJNF:_X;,A;:@_C+%9>YFOGI&<U^M_&&320<JSP>>>L639-++Z#QL<$@FXOYZ
M6>+EG675M$<OEB=ZG?OZ3[?EW7'KCE"THTE8<(OR=;W+T:XU/QY=X7C+'H)=
MJ6&2\I"TG]:/B]-ST$R<C*UCWC>'-+OOH=X_[?])@T]@.*)K77;H:]RT3OE5
MF<S$SN1(NNRP%-IL$O>,FKZAMY]%B/(I1[J0?.^:OV,\2*?N^>2XN?;A+ .5
M I[)G,9(8A!P0*5E  9&WRVV!\SHL2X?P$?;3]&JK= "5(KPY]AR,UJM48],
MX@AI!W]&1Z4R<)^ 2U>?]I\PEHB]8"+7-#;78]$ZMJ4K;$AW)_+^;0]A3/7)
M'^<F<\P9R=2^9GPMJH4?R!IC*3W#QWM\56>0Y():Q+P ]>MB4R3;(-WE79Y5
MV!^WA1")] N2:B'ZC\7V*KB)?'H @]$(+M;X5*4--2BXIQM^ AWDB^?<GM2U
M$5U4U_XSH<L]0P:[]6C'!WUO4N0D<I=5P)-.M_RT3WA>E$<F].?K/:L(S!;\
M^(_R_ONG=/2?].>LJV<\ WRT\M]N:V65W!SIGBI0%EVU2,0@-!$I\2\3NCZ;
M.HDENHM'X>QZ=[3Q>.KR=S>]0Y,5JW;88_D7?YI_J9!0?1"6K+KPJ'7-V?.C
M!O-Y[>EOO(1?RVQ=-M-<UV0V6-U)<U/' HAKC8,R1C.?*)*<H_=(?WXZFN;<
M\NY=RQ4+IT_:GT^9>-;5,L&<4S$TRSZXE"O'%,#4H#[&E#VB'#$VP'J@'+K4
M7J#\A)!R(33]- Z4!NUPAI^<"0A%O=I$;>K4HCVF5V6X?86%M=\2&WWK2;RN
ME0,0PRTD4R8RL?,PX#]/*.EKZE0 L#0/.;A]8T2I59"QU/QT/U9]/D#C7!9Y
M\6<?E,I&*L3(C4LY%Q31>H(U:LO?-Q7RCC3.?VW*GIZAB60JOFU.N,TL[/,8
M.K(U*:L0B7D!./1$'S>\#XL\BNQO;IPD9(MA:S/7SI.'U!=F:XX4/<_U1+FJ
M"OTVG^3O(IN$-?!#6\KLW:H71XR'/R\5..0@ELRJS\4ZC7;Y.=YQ+U0W/Y9O
M\'>Y"KRY:39.J\<BTTHQ:>B;EO5SK,2%CHX 4M7'*9VHM3N+=+6^CUIM;<Y[
M2[QC:NPXW@A<\ "$B/6A%G[82JVEPD50EMVE$LU,R:=HZ7GU:#WF@UJ$?LIF
MW?EQ8SOJ-3]N?I.<?\\(] ^IRB]"Q5%TUU=M4G<[&GE'^/6*1N*/<BRX;]!!
M$G-8^@$H;4Z->3BU8FT_HUFL8RM9/4(HR+)/9J)AIH^5[D$\!2RO/BAJ(6,S
M*T..NU\CY'<TQ2_=YGAS&W%,7,8!*%"3#.\C=R;4I,>*T?I;7P9*#5@0XTD6
MH^L11L3C@.@U;S^KO]X6.S$V$_Z^)T-#D9P"_,M@+LG'RL:&.6*+IVL.0'?
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M=9(Z*M-:\L@A?$Y-A4D*[ PH)>XXL4&2**5-\"ZV> 1MF\M%?MH328Z3'[Q
M3GO8TDC%B"Y%NZ4 ]8IA6T8]IW#.(V04J4#>NKEMQZ0-'P,S^UY?N= #^"7%
MZQ<>=]BQ04=Q&_Z;F9/ML&_@]L_<3<#3=))_BQV1M\V4OST8D3?BRUA%7_<S
M&?ZRG*V(@Q';\&&1TKN%;Q1:\?6OD;%5[15QK?L]XX\.54G8,>3?:'^\*,7?
M80>_TMZ*+8$'3,L.&GC[S#MW7@SY0YW01<7F!E-^]%J;6@7[WZI!8%[9<+AA
M2;J]P0Z>:7I>TN?B_#+ZWH^TCW8Z92+?5TN[VQMGZ.*,ZNA@!;G!2F\(PK'\
MT)#S'QZ[MU_*2OI$@R@D_/+OD(%,=\><;%+$.T:2K2?V>/:%.Y$^O]^T!';&
M#>T_F13ZV&[5/I(NTF$7I\3CA0I+T[)I8\QU: -_BWX*>@W=0(7=0&J1LY]&
MV!K4[RA\HJ0[8IU" X,2(S%IP[LF^R%D!4>VCZ[.ST'/32WEC33@).)49KI]
M*][#UB/?\_T[3 SSR]S/KB$*;5D(/[9M_QE/YA(S]1FS9[-GQ=8OP67';F:<
MW_0*X\]5"2I1/M[XAZ6[;<_;:FU3>;O2J8:V=[<Q3@K8^>QC,TD@*B5]$,Z8
M=-03Y8[77("8754C'^&0WW\M)-HN#;&ILY6 !EQZG.1R_;[R&FT'2?2PUL],
M_4BM%-CP\G*T&D<H>O=J)HPV=9)(\F.+,5,'Z?G,!PETN>0J!7)>%1X6G9*L
M S2KM(C$A)EECV&X=J!GYH;\USL7^*+T&0FT0S6_FXYC3E\9Q(\*;L1HXPG>
MXS ?E2&$IM2=86W;Z66G]J!4\0GD8E-K[JE#HY((1Q .-Y'/RN^B2@DG :=)
MMGLB(BN1_XU$GNLIY4?Z%OU@=M+-=;AD0FXN+@FI?[7&U6_H>P.74),WK=+X
ML3'6]-;PNV%V_H[)R.?9>F$B4!H_+MROYP\1%+G=35Q4-5J9#R/"F?%3RX\?
M/S;IIQ,E)I?CE) GQ@*)?L?[8#%SF5%H'=9$"F-Q2%N?5;9>1Z&HG,5<8/?F
M*_6@0;.]^>KX>/KBGTT]K:X=B'E7F9XLT%Z2=$5JN\,>?J(6A3UC(_$HT_3:
MQ;=++O[#?JC>ATK /A[JM6OYTW8'NL.=-V\#!IV7&>&C2H'F X/E)G6PJS[>
MIXOC-(0TJ/@;.I3K5."_*GK"!$3#G$.'\OQ6)>T>J\@%%X2RP:)+5R"W/DR=
M+4OWYIU,_"6ZQ"G.Z]+H""YMONSI'=>V7U4WJ0A1ZKCJIS;9]'89$Y4J'KP;
MF]E)3?F'=QB_,9)?S/>UV0$*E7F'AUP?COGT;*;JQRK2;'*<&92= FORH]%_
M XSD8F<6]TE&H\/*C=?/.<QS<DY>6W=CD #'43:C7I1\A]QU\8R(3"@]3B6Q
M_V+7%R%G#7V>-=%WW?-EXQ"B=R3[W @O4/;"^CR&KY&2]0\ODI--_,&U,!%/
M43S*=7LZG^>(;GD]7]?"Z_TXH?;X0;P*KV%L[/0SLSX"O2+[7"IPQB+[,W?2
MC3TMK])[GX=2E&6MRG4Y!0[5.I;8%*J<JOBSMC1$7WAI1O*>=]2?O^[P_1'V
MUX_[RWYOM9RDK^VHCV>9$VOSF67EJG:-2Z4E8#%S2U)Z(-S[!"X%<"[..&X2
M2LY>+7B'=N4=R2%,HC2ZF%+,'D2)!S]".YP@ZU'/:\@TL"W]%CYW:G0C4XKV
MUX@>W-^WQ,JPH.P]9.F*>0E&=<5*(./9[>9S;O<5T(PEJL8I03[#286;@9SC
M';O8<]>X"V^J4'F^B#/J1W.(8RA864%Z=>B'E"\ZCU[0_N3\QRY<H(_J;HT4
M?50F_U$W=X;5GRZP]8^2R$5H&<3>A0F/QFLTN>3)Q!"4.B'KXP0_72 !J=5[
M!U=KK:^X;P0.U_/H<KA.7 +@Y%P:QK1=>& 4[1$:0D_?E_[P =CSB9OX7XL3
MW;/2A6R+9TI644'Q'HIJ2@D-!I_N\A2U0N)N/.GXUC%/,<T;[BV4%;M>H'XF
MZ&9Y5O?TZ<J?':<*(I[D#CFY!%[]V3KM'KA1R6V#9Q)=(ZZ<$=P,6<9;?W&J
M/%1Q!ST8B:B(B:B*=+#9I5J#9M_,'*0H[YC'?2E4X F+L0CJL[A+*$\POW8.
M>9K<Z/E,8( I+8BAF3S8TC"83+'C;B6O=8X^E\V16Y;=)K3792VP[\XD4.6H
MLR50TCJ]/VVK#<@E=H+DT$;<K_E$ZXA9\$&^D_L;RV^_"<?[[]@6*/9WFO@E
M)MCQOA9IWKFA\TR9YR4WG%P29K:;V9I;GN+7,*!%Q6/2L!:+6=3[Q',!F).(
M.9[T:#KU81_4CHLH3UZH;TSPMD.R>NNWS>I3M*J+OZY-N,0OG GG(30\IVA
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MPK8,ZZ.S4P5.91,_OJ8_VK*-B/2/Y#(XD88F65A-"\KF";D_.MI%];L!NQE
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MXL:8=N1C1&?IGDC#G@@7 E54$-]$\S&SIMXN6CK &)ZV_$2?_AG!+I16>'+
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M*N()P1$6F\5UJ+NT"S\0CK^^=HS'PA8G-%JQ4K-.DH^.C,^.A(3"HY>5LZ0
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M0,SBG,FULO$I+[8DA;XAEF3I14Z&_V\<%37L"SY-N6UHTCFBHSSKO[>UK,O
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M0GSQFBXSP> YLC9X95X==$1KS$?/-'[ -PI:O'ST(6O:HT;/UFO5[RS>K6*
M_CK2HK!JTZW6)2[$W+76<Z!XV$P LBS @O3-+=>]H>H=<9(D*SKG/S]9G>OB
M: :A%.G^^KV]51#B/5>Z-?A4::""$\S[-VX+N (^A0+UQ@==8&GV9UW?]6)[
M9Z+U80TK,V$DND"=B4\2+&BOZ6])7>#-(=^]ZZN[92GJH[/K6V?&#$EIKRF
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M62'[0L[!QW4)0D4LN*6S;\-R#FP3-[5=JB@+^9)HPR=#>"8^_*H(PM(!OKB
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M%PMF?$U 5O]B/F YT4_WA59&/0D_? C?LP5A<&-5.E(@IVY2T\&>KWURF.[
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MB*C&GLC[.8S8GDA#1..>R'36TBZ_7XBF0% 6EB0\.S0.>Y1)MC=!O:#LCS$
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MAPT0!A(G5S*N[*?=D0T)/,!+A_?INW)VX!-&/"E-P:$.KI.@']LT^DQ@@7$
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MV3MVDT3R7#G7/ T/^/=E9_\3.7O"/M0H W4T]&?#D-9$"$,K;?D5;_8%>.^
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M,T*=4I0/6>4KGZPE&_Z>)BQ\Q[",FMQJ)Q@#?Q%IC3Q7^].E(*\C9!6[W_>
M4 R$/[+;0SCN@DVY'EC2[MVFBA4EZ3V1))05 -^P!I9\I[6WOC;2(VN(Q<!.
MFCYW3T04I/3*:WA:AAC&:;>D;5/$[<KF/GS\JM"8E^BY,R!019<+COQZ0B,#
MS'L#'P:^]$..KYN9;/@Q"Q2Z?4],F9T!=)D%+4FU95-Q??UM1!]H_%9DDZE[
M22+&<DE">E5);6;+YUC/^+:/J[;JO/+_W;RUB@!?_X_JFNW_;#$_1ZQ@\ 1,
M+\[.V465Z%3ZH!%HK+*<<K"]?[G)-=CA4O6YY1BCS*G\Z*P;T9',2=C<Y;6
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ME[UG-?XKSC;2Z5MQ*'%\\/#Y3PTKG4<,E>LC6>X.&G))#Y)E+^T[ZE7N>*M
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MXZH,,?^2ENR09^A$\^?9+B3]!GB^ V.\ILODAT)72?,>3LU3^^N=3VSGSA#
M8U,D+"9K3(SL#$;V/*R!,'%]S2!C<\^9D"+2U?N??T78E>PL[_-:4_U\K32I
MV\'E *BA"L9<$:.WJ./FO)9DW0#+TVYK2:HLJ<C7FK]6F5H>@_F(5ZBU*_Q1
MDN/_C2),4HY)D2.,CS_]__X_J'+*<7(F-2BJ!M8Q[)1C<YEURL'[#P]5D9%)
M)KHHK@+2MO4?K.PE=7%,K/CSG&3V0 3=VQ*IOV5_8X(-2U>/H_4F_?)W9H%6
MV(UHZ"\B>%0G^]!3L4]QD01-][>B"PWLB<)T0?T6H%67^%5XV+_,(OQW+?;-
M*98% WGENWW]">;QU$IS5SU[H/"*/H '=36J<MDL95?YTQ?C48K&R:]NTH\G
M 823[' )=C4-0_G5S$H/!AP+>R /9*JLC03V$TOYK8TX_ANBWQ-8 I+/FDZR
MA1A_DJ.O.LR;17.;TR)6!X/@]/44%X.?O?>88.N9<EHA_-["<%=[?6ED?'R'
MZ3VC<,FGDQ\-G%BE92GT^@R)H1\2!.3SE1G>;]JMJW6$!7=8&[,Z_UO5DDRC
MUX7='<NB>+G%']TN)?":5XJBV]&-=M-'G=+&F:V65_E7B4#,9=GZ#G2XGL_<
M,=>Q!K(;W+CW%^DW?5%:)H2I)M0'U>?U#4-#7>4@2:,4G;5/3D?4+5.RWSZ)
M^5#?5'2D;.$+TA.\9!AY=1SCY% S0_))H>[N_3S#J?*3=RS#8VO$<_JE_O'K
MT  X8O-5H7%V.=QG\N! $<+C7:@19Y\WC]"-:VH*=NTXA/A.$U2>-_UE6N4#
M>G%9&8](]8X.+VOYL<1#Z2C7'/ J> 6RXBKT8-<=U  )J=CQ@^J)/A C1!&$
M3>@]-JL#(D'E9D-!QI_\5)V-86_=WQ/?V]'O81/>#6UO_ "F=^;<NCVJ_4A#
M(:B?V%FQ5EO[PQ351+I$6JF#THHH)KW^";SLT4\P3MKA![80#3JCW*7$=>.!
M)TNGW''CWA876K57[(G#>/60SU'\E,2\$-JO]H5RZ'VU-YWGMMB<N2&,'_C\
M[<&+G1./?B_<6I7*?T7O,A8!>W<)SIG>\]!YW/Y7=NRW:W^R+UJ["OA?;;G$
MZUHKTV2XHSB+!W8Z=I!UG ]\1J>PLA??5JE AYH%!,1>EN4EOM0NTL-<)B?H
MY5V/<Q,X>"E)=,]QK_VNXYT%\NUJ;CTD[?"=R;G$"1K@C5>TH97B:Z'1%VC<
MU<V"\XFQ'>>AP>B%S:.7'U\KZ3_$0UQ]='?QYQ^5NAR403Y_/THN7-T1^>,U
MI2F6CR%U0B!F?M[KCU:GYP[V/#&0A97*?0HYLUT;8?ZK%VAI;%%R>5?VLYD[
M,2]HF2FE.Z&ME(F/PZ@_KZ=+:Q6]NWL=86(4Q7.$[1V1Z0LXT<?Q) ZKF2GR
MQ?7HM@#\1[2M"O$(93/M@C$@YJ)N5LTZD)<1*JW@VW_&ZM#5)17A#7<?VWZ@
M+QEG9TR0)J>77WU3HIZ53;15%OR5!6PP^'!23WK)(Q#]V?7!! )4\]U\98^'
M"3$I>D(;C/USYK=V7[3HPD#;M(;@M.B3B>?M4QIN@D4"^P1/D7O05V7"E&1[
M*28[17%J).@+M_7K7L]6/W%A9^X;J/I>RLJZ'#E1O?)D,ZO$=-@F!Z,S58S1
M&;8I1LMK_JH33OE</:TFG)*!]ZG_AM7,"GIE"N4ORS*5%J[(,I7* GAT741V
M.Q_XQY+.=]RDA=DP!3Q6]0B_P?T@G//P$H,[HY1VV(ZF4%NJB5"T1&JW2!].
M.J-$&I^[U4T8.$I=, T3A>X%UTL,BLC57BM/^/$TE;> 6E]\M7MV3'&0[^V8
M!MW.(XEP<Q9[LSIT:QK]4)X*:[RF+T<^W!GQ[C9!V+NE#9![@?WVC/<]#\F]
MF*O/0E96+Q/7+AO;M&$N1F0 #_TCF^8@$[+=R\PS7,!)),Z+%]%QE+T^<U22
MB'V!OQO69^E"(^T;_AT\X=N$U.M01R1%DOXJ$0L-TZHS\=78U].P/7X^FV4H
M%^\6=\JA%P*2Y0M(,.J?NCMUOT;#;.02,#1@VGL&^ZA1ULY8H_QF]Y9E-<9J
M_I&9:5M %K&LD*PR&MAJNVEU":C&J$OS,0ZPB?L%#O!3W3$I=,:K3^;DC:*:
M(TXY6(*) UH 8?5Q/BC@"AY%$7]=N<70+/U?&]V+$9;488CSN2<EXI5Z0.)?
M8")MF\F[(3NZL@FS/0PG(W8![(10H[R$Q2\.EOFT6:T#=J*.K7R6&PD#5Z+E
M-Z,%ZFDNC:2$?>15[]);Q*FUF;6ZR9 "58+IE ;V90AZ6M4OU 5LVWK\6-<X
MGU\S:]Z1$RI%S/JQM3:LJ(^*T8;\WC\QN*9CH21S+^&JPV5W28@ T(I+MW3&
M)P#G>N;-BQ>"^\:*^K39>_/'ZO_@A(J_.6S:E*?TF^'EI^T6M:X&NDZHV'D)
MRQOS@FV MN3#UO BK]W9;?Q9P"(G#,01ZK2]7E1F]&]T9)(*@J\<&BW^"0%;
MT9QHM# '3Q!Q-AZ87JJ%:%_$8*)'IBUY&U_CNS:STS@R.\MI&AKIX15YH5D$
MXT5?8'/JK>QX?7"5.I,M4F*I[GOZB\Y*U^\S!O)T*AQF%MNKB-W(GZG?8CBY
MIM? FQ[8V$_65A"+S-]W98EIAFM]@;3W^YZ4(%F_K%W%(%>U[S1!]6?"G4]J
MZ!).I3?=<377<#K'IEH)-O48W?R<*GD%D18%L]Q_VB7[?O4%C%RK4UNS/2FL
MVG@X\ZQ9P75R]IOUA$5ME,K7->R![';FL2V\G?&$66EPY^Q,FNB:!=@-/F98
M_]+UKJY\BT8Z=^*#:30M@^N1'HR"]F& FC0/15[4G91$S_RUN/  W9][LD,\
MY6@%T(Z6YQJVQ;U8BOX9@/E2^^C!D\P5U??AOTXY0"?H4P[.2SOB]CH_2?7-
MZYF2MV9_2AN%T242$<K]VI]?Z-1RXP9ZBKW'ND3Y0#P*^^]8VJ TT;A%]2\>
MUL8:X2*Q17'R \)KOQB>>1.YUS2\JU4LS03D!\KBT'1MS=I6HI]68%>U?*L6
M@[33>^P!DVB2Z'.1@(APPJVZ#:Z2&Y6%NEUO%6YR;IURR#Z;*MT\HU#=_B_V
M] LSH2,P7Q'14<WYR)+[3S--FV(&8 5.A]93!@<G>8 5P@R BRW&]*"0!@$<
MS*(^[,JBJ"6-G;V*O+BT<930BMW0??EB<OA!F!%=YEU%M^8[3S<!=(//W_!8
MW3=I(\%>%]C/?[)O3K@(L\]3$(-2W0$,265SY1$_VG6T4Z?N9\>AH2GLM<<^
MD8Z61(P.B%&/%2%GESP9]KGG^&GLIY+!O2:#TMLG'KSH,+E'SZIS6SWDM'^@
M^;,2%5)3[%--SRXZ>ODZLOME%\>"@\L0Q3\>(!Q:8J$L&REJ==UPA<3EX Q1
MNJ_1V+A4CH$3^O,%7V4[*W?8+/6BET?]KS58B<63/^0= K*B+]/#DDXY7NXQ
MY61?(Z#5W]M<45%TOE6AV-#VD__)MG22]Y<OP6^'M*Z3Q;\]=PS5V=:_0M&,
M"?^H>7TS_]/0':<-S5E%?R@M- IVS,OR8_H?Z[(_E=YDMM/U_J";)(7X<VX8
MR%BH+/1<W\AW:BSMQ'O/.HDUO6.(>8 ^[1]O>1-/3&Q>4XN \?BUUACVQ;Q(
M[7)_D<1SSSMNYWHQQX1&ZC3N%QN;9_90UO2-G"WOU*P;C66(%_O8Q0L/P*M#
M9 T<!H*^NOZL3Y[5WQ(JI+Y7;U RTJ;(K\K9595;JE/X*W,V30=4+*K]H"[$
MUM*40P":M)#-Z(-\/G[$M*;*[2MK]7OULP&MDP?CUT:K32JW0%V<Y ZMZA&\
MCX%8D*?W'C']U7&/C7GH@_C=0C?4L3B=>)P>U LD,G_V0VA@2$Q3EW@XBY>6
M2,UHI3;PB[OF4G&95YC@WI'['8JAI#X1X^95,5-J4WJM=*Q_0GGD;(*PU/&Y
M+YW]F&^9+'XP8Y+FM?.:ZI\0A#"@[:6I2UQ#G.5/(_%3#A&9="_LTI:!?,<D
MROKNAI,XEC /=@([G=DEVXXH/^A>19[#@E6=.7_A*<?/F"ZK.,3M?W$TM@TX
M^4?-X_LY= $UHKU*([>WN9 CY;N[9")^>"?!MBA7QZ:F]8NT.D5  J1!K?'5
M?Z5PTT^F^#VJW=9K^QUPDG&7D5VY^>@L0K[99^6(9M[+[-C;DA UT$0\/OFG
MZPX,PA<MLV51 T]U\$P1=G?\?6*?2_R*=)1>;^DM<JECOODG8F.A-<Q'NC!\
MO7#+9FJWD<OCV52H*&F"P)0]RR/\R%Z)^O&_&DGQ*'Z$))7$RP1">%W@^;T1
MA)AWG_Q"HV1\+<>$&UWN_;28T5#E>1@%U5C+;5QK7-CZ[=MB+:',>RU&[XG-
M#\V4$Y 6!9&M.U3^MT? ,T<7C8=N-.8+VK+=45..^,W)-8;KF%:,J7:+V;,<
MY^?D7VDJGFG=U"7=]!?T>^OK)59+D48VJW;\A-&/VP?3ZH70BO$YY$(O^VK@
M"F'>G"+)$F/:K/@+?C\R(.$VG#)3-4XY)&2R,1!\Y>M(& [:YI=<P?3O$SFH
MR7+9G*%9A".Q/C**,##O!1&7_K%_\N=-2MC_]5@'CIHSP#022P$EP30X' 1P
MSH)(T_NPT:ML3BM!N*Z%A6?;5$V-4B.?^!O"AM#1>_//^[_V]CE+=']:SX3R
M[%@823=-4EDU91W5KA(!>!5QU#6DUW"EG0V?TLMR$*^K0V8ML:PNL \[@-:E
MQ7E8JA2EB<D=R_?8K@/O;^1%%HR(-TCXE2?;3O.O6EY%U5GN9E=2J2L+06$=
MK:A[65FI$'+Z,DNP@?'BB6.-@1@BM+7EYH+ 4BR-/<SW0\UE]CK+9$K*N<5(
MNPDA>3^]_X(_$W/L'?W9X/9)G?Y_O:V%?%P%8S_,2\3KZX9PG>]Y-4]FQON6
MKC]KG=*P<-H"Y9M-%&X]FYHW%W6,<PI%$^T++5(&+Y4P"G8-=,OJ*<O<VJ!X
M^O*\XPONYMGR*V1T4A]U"Y0K;)L:;V?&;8T6 O)DV>3JV%IWN,D-V  [D-=?
MA.=*X*@PP\]-:(60C4=7_92U?ZH7%Z:"3$T5-\E0,$.2P7/*$5/L#6B ]!HQ
M]>@>W4NR=*$X]0<FP"E]L1KF[9"13O^GB>!.TO2!K^2S2=;#6N^VJ-%R&"AH
MV=%Y;E,SZ)'_7G]_(_FRP]'LH#]3Z?/LV)MW+%ZF;^V&",<LXD$5G.!*K\2B
MH5W2L_H:;M5%!%ZFZI-)(IQECH'[GHW "QM!S.Z#=)]#J_HI#5OROJBOL3+
M*9'V*F6<CX+Z;?5^X:]=1<70NK>%DWTS&"7+VVX*[B]^89+R1 0DA8#!G::5
MB_*V.=6ZB-TU&ZK2?-X-85UXJ9GM"K;'K 0 $PFT3]>P[N]RJ"A#]95C-(@
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MJ5_8*ESL_])F7*#=5I\!;C__:XMF0JW%T0#4V;^BE;XW"1[5OEN!\#INO=D
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M"JDOV-Y5!-$D%H!2JC#H]O/6ZA7[6D4>8^%07>W"EE#[. 7+&GE[VZ^M4YY
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M=O)KBRB=8#DJV]C:0MN*W35EMD(Z.)?I)W,ZC*J_!N#_W+E%"T>)F;%3W4N
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M)+/$=1DMP#Z]A[D0S1(F4HIJF]R"DD(A[5E+V/]P0"K=K3<C2U:+KW3]RH_
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M:SG7 @[O/AO1..:18ZMML@EI-^> KN)(5QG^!Z]^5%*A\=X%2VI\%M2=DTX
MI$\L^]M?UFD5I;^VB*9IWFL(8>I_^2W@JRYN!Z51:5D$['3J)>NY.7U<WX]<
MP804097FV2_)W,7Q@0,2+:%).#\J8"JS=/! X87G/O3(G6X!H07@I$4<O#Y
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MW_#4>N>/FH+O/<)%YNS&MK-<+3W+HTI99[@^,9,-09H:62HM8?X*^ GE.X%
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M9[SB<KJRC]Q9DDJ/DY**2$SOJ63_2RDN'WL5=-;'6K_'GK%Q73Z"ZJN,ZN:
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MZ6]9J>+2\<1,YEZ&6T8=,YV'AMNL9:HC17M.(Y<ZP?6Y?Z%YD%/"QO$];&'
MB,8DDN5C/>&/4N_2CSZE;!@X:Z56;9W[V>V/:KB_X]%C2<R>,_8.W8[=9A:G
MG:O#3!35L_TR*V6$&^Q>E$PX_E:0ZV&BGM3@>;:\TL9,Z=OH+\5)2A=3P$*
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MMLR3CVE$VSIF5&J5BSML&N,Y<7]+;2MJ%"$WNX- U!3-ZI^^06B$\AL>1@D
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M@7C% 8>&&.E]TK1NQ0I2;%+*O" *-OBEUW"HP9_I?FL,JIT^)Z:TF\OF%>6
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M:9X0PHRYXW :AWJQ%*56A%>KT,R*>+42%!!4,OVP:NXG02!1RX7P#O$?XV(
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M40Z/_F;"B5+9DH_2_Q3ATE085WJZ] O]G'QE?6[$J"DCSY6JC)^9)"31#4@
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M],CS.OEKUI.OA<NC]<U0 ($'=5S?4\%CQ@T/PV![EI2V:(34V'V#0DA#BP-
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M@I4Y0RD]*<.A]UOK/7]\W_?766>=[YSO_8,%K'L!]WW=U_4;UL-]/9W37*3
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ML7&ZWN.=S_ T4]LS^DL(,ECAPU:4&*1'Y*(V,IA)O=2926_@KGJ5X6)BUR[
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MS&4CV)#&*_/=@!\WFK] -U<2C<\I98D4K>_'PN8$%X%)]G=RUN&9&;3Y48;
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M7H[>YU3E5$J+/N+NJLH/H9ZIN+MC]JY>>MZ\YLAS364WUQ,O%Z2U>PZYMUY
MZ\<&J.I%1I@72VHT6@SZJ([ "O-0*=1MI3A46SA/62"_P3=(XLL)BTABT%\/
M\;_E<]*80$>?NNY+WIUB1?B>\MXYC>+IB7=@<$,RQ07CV]3:W)H\>.KEG]^<
M(R=_PI0^U'NV\R<5PDD/43W'T5V!Q%6MO6BC#,BCP.[9Y3"T;;D5V]RV,>%:
MJ(ZY9\]YI*WVY^C'MJ'E"31&P<>GVE?/NSO0'6UJ*AC-RX4^ ;SODC+3%@0!
M#UA'8O>*AF\LFY"3>G9@":-X+PH#TZ#_RRC%;L$^NE_]+/>1?%">8Y]:IW Q
M/BQ+6IM>]K*M'7/9#%FE&AVM$:W;RK(0]:&XU[' 25'-CC+^@K BUCAX B+'
MGC171R/$H#Z((M"\X-,QSY(&E =:U=489-91G)(I%H1+Z\96!IGOZ4QS'F58
MC]=OZ=U;-FRCM&5RWZ.IMX3&$NE52.@^C__AA0]RK1/5S!R(LJ+S>&-[+YS,
M0.4UE:Y"0L4RARF)]U[<NQZ90ID9%GAN;@KQ'MV>VSG6.G>HJT ,<F;H&IX.
MUPNVG"#LBY7P83<91KH\F64P%7L>CP/.E>#/9BY]'-^")H;B%OJ*S2A-#_QQ
MJP:S\GWF4MR )-),G=.>Z(CQ>LJ5&LM_AD[,UJ=Q#/Z:]HJMS%F</J@5=YY2
M;^::RCYPV]V)?+WGXAE747.60WB EFVYE$.YC;MS.F=I[&G5F$.1K7P\^D)_
M0V(O#8)H[J:I.I#\5'SHCA\JUA0WM$-/EMXNHMN;5D$C(=FP)I;@.('[12*'
M&")%JB"'"H1DQ:.X]PG_(D6_40%4E_J/O[")+%@\,S'H;\@4X<,%,4@>N[U/
M#*J('!=*4K ;<Z<>^Z.+ XS\L]+#[TT#P=S,K4G\7<Z, _"5VWJC,R<L,Q5?
M:.KY:4HZ&PX=3#F9^U#U TJ*T$V%[#-7B9T@'H %PA-9Q_!P-C4))F/^"]X(
MR'@F.-;%#<(E(=HGS8\-/@N6HX7S',2@_KO$%T!27_N)8$299):4O GE;TSU
M?+WL-+6K ]^D%HQ[H#\+H@'7!58<2FY5WQ#Z,]Z*.U?"SI)#3,^^]L/K-BS\
M%+*Y,T4SK"BO?%^FDEATS\GE 9\I?3(1-\XA7$@#:"??XI+BFN^TRB7WL;]$
M/.CUTW!+0. >VR::))YR"8KV8"1X66MJ#9M<J+KJ"GF)L)G%W'\U69XP<*/F
M2(^KL.SWA9/S8TMMVCI&8R&;3K8V6/GODN2*"\3;_(,6@U2I:/@!5+!*>&4R
MWIH[TQVQO3<C-/R 26(SFKTA%R0&S>2@6^CG7^/:G9:WP_)K0!$/=-H^A<M)
MA8M>A=F'_L;3S_6O!T(]Z%M">:?DX<I@E5,EZ.HE=VX2+GT"D9#.8'K_=C)C
MX?P5@V0U->GW9> %0K\$&*W73-&<P4)L$D0]=C<0]ZIB00CVY)&(A_ 03A\I
M^&6^LKG*"$5^H4AM_7BCTI>0M#ZTXM#,T,&9:WYV*;!*UA2<[]\NS*3>DB0#
MI#E7#$JM$P17X4T9^&O,AA3=S26##E4AJM_<B ?-"@\,V[E4V=:F$O+D.?!L
MQ891'^*C4[.C<P2ZCM$->)G]AI74F_KT4H&??^\E*\*!6)VS57'E9DU'$"]P
M40IG[Y6;75\9^XA^Z4CKOKEHI:A0[9+]J%2I--*IS[%R*P@(L%48^U!SJ>^K
MK;/]%4M46=G[1P7?G$8[8UL;YJDBF6\2,Z3*HPIS4 FH[0P]0I0B<$E2T3])
MREO#8B=4-!K5L/:3\AH4VM,Z+M!A8P]Z 4[PN*J%,AO*A0"]!\N'@H-YUMT)
MOI16HP]3K\O><.V/T66F2XN.M\YS)\W> (3DH(5FO/OXV:;!<Q?#W:=\=43;
MY7=TV0>O&YX9-\S0[@IQ< TVJF^H#TZJ2^FI#CL^;.AV^..G])CQHQ4;ERS#
M$3Z+#$(C:JUJ1Q5PYQL+LP503A:3P;_-9:7@C7<NX*5&\);LV>B%@9XAB/=(
M^"R$'9 0)D193I R+/K<MA/S:]!1"9U]F:65*&1WI%_DSQ.39_L,'-+X+!J6
MZ<?_ QBJGP50$N&WMIMKQVE-N6/P9&MEXZ# "*B;AZL%MR 4ZSXF$D/KO)?4
ME2?)]E=9-JUCAO;G^V.L@L.:$[\ZOFC)]B_X,GM2= ?&.8+:EO@IP81$QD/&
MORT*Y/-%^[K+8U]1U0R)F<94TL_4HX8RPTD%K/MAF -X74+2'Y];5?C-[+6K
M7U'9V["48@/16*ZN@6G&*36C8-5H?WNWZ(G<>@S&K#/T;<=?FM;G!_S?NV?T
M?5)4PUNI[M&M/&I;A-@*NE3M0/;2/'U5.8?R\2+SS#9Y4)OF^O;1<WK-@\K]
MCH[QU=%1F/YSJ5[O&Y\61MW)]RDD^J$)7&?4%'.1GPB4[)P#TCC]3[B+'&R/
M&"2W)%)\B4W)"I@G[L<->'8P[FQ =05RG S?;3U3QY=T0]5N=D>-[.^?32HJ
MZZ\<Y_9E)1M$WB%'MQ'FRWR,A?DDUA2#(T"18LGSIL,_ PWLX>00,^6RX/R_
M?5A <U]5Y6]XY7"NJ+_'KRZHX",QQ1!^<'9J6:0Z&(@.W]L<\QS-_"W"G1?[
MAP0F+:CS\2;P-6=>1!^*!)9(]#0WHBPE9F&0/&YV=YYU#*V,:'U@6!1NL*,C
M7Q\8]2F9T&JFI[<Q%3M>Y^&-5M>)<QQK6(?6!HP>CT=/H@IC)4P5%T0-VIF]
M_0:L+@@7%N,-V=^A&(VQ<-B^]P(;7E=S<*59.G2]EJ07\(H 7FW8P#S;Q\^3
M!]+L'VQ;!7X:(VU=T?GF'PD#C8G>#)7T'ZFMKE<Y8@((]MS1L_'32"]1N5?_
MXG'!W;B*<L3YHDOT\O2/3M]T)W5]R?C7)F,^>Q4?/5UP*+N=:RQM5#HL;1QM
M6396+DNFKPDB?ISNX*I3%U" MO4KH85UEKNW*?M3+D]GH%AGS""BX*C!T*X9
M]F*RX!Q&4]CK]K7,Q*J.0U0 L#23 J_'Q[O(DZCKR/BVKONH=11PB2!RD.=+
M MADV$!8QL:@1AH$\F*02/HEUUHD_6U>& KG*KZK7, FSUW8^84WV8>29T[/
M!!=TEF<-^;/7P/;-7_4HY]BF=GF%-[Q/R-3LK*Q=O1M:MX)H>S%:2A<1),CP
M6+([FC<E+U* KVQB9O["!ZI4B+DZ8.W*?=H>"?@0#Y5,E% G""UZ&QI/\5>X
M!@5>+72[T)]'SP?9A&7M+D4<.:FL/K/P-O\HQQQ\N0Y1H7SJE3_YR[)']>.H
MKT5(>M^06YYZ@@EY0:4M_7H5P^&@[=.;)@\K/EZD%?E/I4:Z7C?SK?2I\QC_
MPRG5\5M5O:NVC27S;$?$+*G!/Y8FDN9Q:32JBH1A'Q+W=!W"M9S,IQ'D"0$L
M19RJYRSXZ8@GKOA;7]1O^2V?-1]8=C*&Z"P/N&P?>8B\1E%6FC2:E+,T(W3/
MU;+D80$;QP1((%A8%<U&*7C ,LWW">Q(C*+2'4P>L8%P"T>E&8/#,;(CC'6R
M_4^_MUO(%KT=^16S>(U3P)FETN/X[H",_PY4-(S:WP5:$IULYR40:6!9:-)-
MGN%ZH5)6:*T85#FW?-C'IKP[@J"8N83U/CR+#6FQ2FF/5-4E0 @A<."7C00Q
M*%@,8IKVHTB01$*@#.'!/1R?<;6PM^L0"3C?=:&%PK/*+^\N"U+7LG> IOH<
M2)3)B&7V]RPZMV19RMZMJ2^I]9[S02VWWBL.V;]PAZ@]W/;L4H76](?I+F.Y
MK)[)8E5YGS.4N^0 *R#*Y<Q$UL39K4<?M9T<#M/HZ8^0]*\'NCKQ1K*C"2LC
ME?M#4Y_Z?O>^6!5-ST[[\.A.[993CKM9LTBV5YB_AM?@.G/<UU#UTW.5*;'Z
M*]]0!_%@S7%R7V<93%8@$_%SP:>:<B^#A[3GE2D" G\6XN2'O:M.O,OE3*CJ
M3"VV3^BY<U=$,G$21K(05E+7TP@K9H)3#>LU?#2@S!Z>+IR']&#_*E9H,V;"
M>C;V!(J433J0=OY:R>'1./N!9('SY?A6YA/&.MZ58UKDWAN!"'/_9M0>TU^E
M5_24>.O!'M0 :D8"R(ZEL=-$LE0&%7V:@,Z LTOQO[9PG7!)W4WX4V3>\]2O
MW2*Y$8K<XN>YXZCDXD-&;LS,)':G/JH)%5A0VU)0@YH5MGRB?V(Y-'D9]W^_
M=7''G'-LX:B9D93:@[YYKJNFA;QG_Z-SCZ4>E"W=_#Q>Y0!<UWE$;'9TC7S*
M?#1S6P=:^^6]D5*\0K5SE?28UV@6A>W,M"MPT-[YRD!^83(U-C7X3P"]*M&(
M&,1U(":CI,(T#^/2^E'-F41(PAIS:E9O(W43?F#)1Y/;4CRJZ_RFYCF09,6X
M@^#,2:^O3LS/,J\8CAWJ%8-Z-P2'&?S*)F$*#,/:!7SCR >90[CJM>T;/;#T
M$W:F4QLDR '<,R1.<XQ\^9*1CY#877R!CK_ B2' E8RW<]!=ZF.8,*%^3.#4
M,T+)1M(F$B7[V40KZ<ZMMKS!7^D&LTKOD*V9=E68L([3=S ?7N)\'RBWX7ZW
M>L)Y<(1YM>]$QK4KP(]33#_.H$,$:L(7%/_G>#_ F_,X=K? ;[+>;:._U6@;
M-"&07MA9"OC+&XA#C.@UD#HR('TYR)1/U$D#Y'UP,I3*,!PZO^A.Z9H\^06
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M7EA/COP)N6-79VW#,/N==9C4IM?W5JE"1F>E81\KYH'GGEY^5*K6-''[:.7
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M.L9V6G!W(0;Z*_Q@V863-Y"#X/N"*_HE6 /&N=%/#RY^$CTW5\.;<N$]J%V
M.[N21I!=ZCK$A3X(0T+!.!0MZOH]S;S<<H_?-!XH1I85+"]S++HX.S>ZVMK'
MPDV7ZL-E;=?71<N<3ZBFX;;*4Z^!4$WVT[CS-<43@Z''C,Q;;KH5(5Q.O&A[
MXH<>*7^7\S$WTCGCHF.NAV.IPXU<3Y>H/VZ^"%_A-!ZAV&LF92"<*U5L^IWP
M7)?W11V61N\?>96M9UM_WR!TZ^#/[:CAQ"!^Y0O@[LZ=0)53#=SA@:[#$P80
MZ67S7WC#&;$0=)14+_OYYTF1:EL73RH.;\/.SMON+T(WX.[IQ(2(+NO;N[O3
M64.9RQ<UVD0M9#"@ 14<1MF,G.3YU'!E+!AF4,5'*H^Z3HZ9PP0132,:C/IX
M*Z;(WG=QX4#4/4\O:?99;\-_'S@:6%TZ<NT)4,C_D1^19HJ\Z('B$Q(?#!4X
MT$7@97/=<4-,M#> XFR AV.X0L/98*>N<6B(V?$:X"Z;RK6*SWY?WED97\H=
M2#98.9(Y=&+%AE&'(3W\OE7VXPHJI.769'+!AH2UL^P9_Z+.K]CP('WV03R;
MO%]F=+'FAS\?NNAQ@*Z-L;I,'U X><*60=OX-/W)NG?\^>TVB%RSCR(<;'N$
M4F76?R[CVJ5+MD4F%REZI\?N9J<O6OIJC]U-%VF=?CKV!Y!^(E?EB?>Q@$ZM
M_:SV#H<)^S?R.3;+CUXB.I GAY>U^&>$1()OUOUB&=XM,:A1G3A_?)YX!/<(
MK+0R]Q-06"- O!@3V+&3(0ZBMQT\M\8%B*K]GO[[:N]Y77%[J[ '"^_&1%R8
ML@B/"=5E]02L:7"$%]@; D6I!586^3FTGD38+9IC*5!0-4CT7>10U7MTL8JP
M)'PV2"1KHMI1J..)+2<WY9E>J\?JZ7UH"Z0'/];0.T,((7*O#T\A5B0V=,=L
MF;IW"YHL*4?Y<**"P&K<_/1*P7A6TDGNQ)/RY>V-. &8G48]N&3T=7F[<Z*R
M8JFRNTJOY24N;+#NNC>)_KG ;32(VENY)LV.@0Q N"ZL3'49WH'S[P/5H4*J
M2!- >;4^B,3<)EI/2@J^+MAFK"3QDY)GW<>\-^MAF;@G_@E3-JI[;P03::F/
MHYY:]E_PS(->ZB$$]!'0G** M'XVVQR.-DZ.G2%.#V2KCU8.'IG),[)M=M5,
M? 7UWR_/S_KF^/%#Y:F<I@_?,!$1(1M5PH_6.R&Q0\J09@W1I!M1?E.&^""I
MATE-P9!S"#?]JUES@07FI;4HG/J@U3A45_\V\/?>'$)Y]_SMP*V9C-NS)*"N
MX.H1,4@:QG48/@!D+6P(%*C\/RBCF\_"9:C,"Y; 4(TGT]M2MBN_#"?3VX1'
M\A0R(J*Z/,DO&/C+N(<#IP;K;'I5PA^*Z%UD-Z$CT" 1,0Q!&)E'>LTU7F#U
MQ$2PW_XW]MX]'LIU[Q^_6U:II!&AB%DEJ80.#N4P4UD2DDH(,:M43C$=G UW
M2SE$FE7"BIA*DL0DIT(F,PZ5),=A1L:,D)C,D'$S]]SSN^V]?\_W6?N[G^_S
M?3VO]G?O_3S^^/":N6>NZW-=U^?P?M_SN:Y[XD':-%Y9"G"W"O*22U][M+\K
MS6BD:RX79L<6-06LCLJ(\=/4L!L^*O_0]\NG1K'1W*,DT11K YO./:\MB]@X
M.YRDQ.,T4E:.;/L<BC/R4"1@/FO*"3Z^BP@>*N02%GV>](MXPM2+>L(*[("]
M\NT"\K_,!J?=]CU]'SKY<:K @A O<UM 7/2)M,<\W3P[F-QR[FN<G/P6;3^C
M<Z62K(B@M5<KKRG=%6[/3\@WV>LDR4A>NB+4,-\:>[WNA!/)E-'.L+=]T-%Q
MZV/_)ZXW&'EC8^Z[G-#F#22^%)!=ZWK\8S2=)C\<8R'TY9097!HGNI/\/[%M
M!!4#![-O!H0ZIYBDBWX;2[#Y:9)$C]GX*4B(@8R;&OHP;5+ >YP5:=UI[G!W
M)(,2CVC[9ALSMY1I''G?$*!3.]Z?:4> ;*86!!O:^=^M/Y_C=^.X7\IV5U;9
M+8YOQMK2BJ\4?I)X<YB<J 5:,$"X1%$() 858!091/!N6+J]H_$]+F:5[[)I
MG+K0HNSV\[(D1WOC;SPIL/_Y\XIXE[;AFG:U+V^^WA2Q9URKYVY1H73_9Z%A
M>0:*VGNZAFOO#Q[1B)B8YCF1KSXHV5I@/@'98N)9UU.5W_:J7@U0:BCY6?#X
M/?%P+SL/(S]T?-?M<_H&L1=)7W9M6'L&[QX;\3PB=<!T<]G2D?9KQ[V.'#R4
M;WM4\F2S]<='.3L_6FP[>O[HQ55>/H?"$BI)US?;ZMFE,IR_MG7:F!E5AO1*
M5%%UKE?+@0,&/9A^3CT68^G[Q"=;!J*=F2W/]X[88$?$A(GIE;EIE +VS,&S
M*'EK/L/8^\S_46X:]TQ':6/I=;M=X\.7)[V0Q07B76 MBLG\6F1)>Z  \2%(
MEI$A!?BR]Z N"X?:1B>H1&CW*H*<%*WI'^&9['4ZSR<"&V<>SHW"N'68XWF9
M'L<(QI2 \T^,: E!"5_[%1J)*"7I%-T0Z\&X3-$^0<58J%!Q([(.-FNM68AR
M+^>JBX^.6>4Y\#0,Z)[R;21MV00^W]E?"D#64X.9^\N%*DGAI\,MQN/*NK<$
M:Q@<4F4%%Z*+8D33D +]+!";ES#E82GRE=PU7Q'%]6>/%!F2EY%\VV%++I_
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M/Y\J7\:$UW].Z=T\PXSC1:DJX4@6^C</MMD:?##B4DK.E,T]P+J6L' 4*ZC
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M['"M.9X,*;"8*2I2%YN(0T$1012'Z48Z1=>P!BM)^%*Q["58R6ON$_!:BI>
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MP6_*4N"-AHD4^.WS7[\Q>N/^?$/S#?W#&AI]%RT/-?&L\AC@<G<HW16*-*[
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M-DL!+,<7>=\"TZ-KKV_S;/&T%N@X(>RYGW@=$!476$\*H-,9"-;7(:]0AD9
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MC\+6*WBQY5^2,1.= KJ1I"#NS]DX77+O\EPVSI%MJL=B^#@4!?S8/?>)O\
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M PZ,<^ZC^FEU5;'C<] ^<!S_X&AFA%DH<W2LM@6?[*'94,"F,F#[ )2>2T^
MHXGOL 4U!WMU>5A^X#5VY5J$]T6FY7X!J-,1.IN'TAEE# =;4A%=]IKINE9%
M,U>9 A"FX\SR;R6!\9[C_+-A9B3I$P>+'CI='"E,_;T[O=[; &P?:YC+>"P
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MVR.X\]GSF9[QY<YMEU]9(H[H-BN9C"0_H 9:9D+LLY-?/BJ:KB&W8Y8MV6\
MPRHDDI>'NH(\-:1KHQ"M@4EPWS/>IG"/<4'3W3R'6ESYE]^.?&V:3GFPN;W>
M3R,BXM"3YF'(C@CZW/R#ZUO\JT(3NPZ=?0&5)3Z 4+5)<W$]B'CBH1"W:T;,
MK*1@,U41^OIB<LC4*F?S&-5I>6P])(1A>1"X2K.HCYHQ-UH)+S W]= HSBAZ
M\AG[?/<I8@G7G7N@3_]WX7PXA7&Z^-"F=LL$=U'>/[HV;X"Q#3\/CH<5[ P0
MP0[IH'!- B#Q?[2T\$?:W5!?MAS&SK8W<X)G9_I"-+'RB 4!B']0OF(E$]?
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MW5$\5Y_*(@]O/+"+\<]5G>RN.B8 28)KO=8B.;?1G?8=*L@_6<1DOLK*%4<
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M#_=1& UIH.C*^H7+Q[["%EW/6F5 OFP-BK((0.GE#ZP,XD2MIYED:L]0=$B
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ME2SOU*C?B_U6[*Q1_&71.<!_9LS'3;FXP$2^I*'5I/5<XB5\M-X?_U%=5AV
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M!S>*WD-L>Z).(F\#7HQ!JA3_8!!=Q,7/J_MI:4JPV.1F)U1"96-_?F29+U8
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M:0B[@?'^?<<+=RPD+!C\$O'[BM<?J/<&-?WYS#[JP-\M%RLZ%8[)YUX)G@E
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MP%+B@I."B;,Y85CMHF'G9FXB=Y)4[\1?&L8Y#M[H,K.\%R:"@H!:3*G]4&O
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M@"WEY*^IG"D+. E49DL^B\;$1%UP25=SE)\P/9H7TTDI'ZMZ8-:3MOJMNJF
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M.ZX095UW$CH:1!1L5I[>"NJ)J/;5\\Q2;$U9P$U>YPI.LW2X$PB)2JX01@?
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MPXR"DAEWEYEK<VKO+<_*29%R<>+8]@\X(6W$2PF]\2B^:L6+,RTH76-EVO.
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M(X)FH[!:?@S#:G\-T"#O]R!^W*\U+'@VPP(+W<%QA0R! 2JT"SM18 _T=/!
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M*['RPNI8FQA]\\7#<R,^]UQ^!/Y[-2PD)$3^PV7T*Y@-;/XUCH_/-!K+!A/
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M0*&9H1UT<E:)HY):LZ1PYW'US'"D4M10\BOT5/IX$7?M,!)E+[PH6CA]-N1
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M_"_K82_7)/$4P@%"4/!G,O<BF] [".^/DC8_"-BS\WM:94GL+>2H7CI:M0-
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M\D=954LA_HHZGY*#PJ+; GLS)L]<1*T(&>1<$J%>BB<=.Q>+K9AO&=7IU/#
M.2;V"K'A&58/.Z*O11>=!"Q7*-&)E,<,679[4VM,>06)]]?L*5LGI7[F%>JI
MW.N$:LZYC(/PL^_)S2'WAU1:NQ'QQO?#SOS(')A!\FA@$H6&.5)56BL[OTK+
M5EL=,BUW6; ATQB7[1>S@JJS^41M,WH$9F9AG<X*@V83)WV9N12AF033=%'!
M.9P]C;7*VR.<@W2NP)P#3M)MU+%R3ODP.NW>.EY+ZOVTD:YU@^;SMK%S1ZW$
M5[:@=" &'2DMY>;6JW?06S!O+BT0:OH&PSZZ</:.=!KQS@$E:"8\?E=$#-%S
M5(BIVH6*G,)8]82_V<T)+SCXEO#(%T N)0^:'*2C8VIVMS7..4?!;*;V5\J/
M ;N<'X(^[C@=<. _%8AB$?-P%II-F3-,"0<=^8RUZ"-+370AZ\I>>"PU=9YJ
M'LW[L?YG2,6LO[%==5GOJX#FRZHM(S]8S;+0VUU[",3#5EQU +8C0>@R(P1!
M1'"J-%XD<6E6%U#F"'U+H;.:(^XRHA^#89'9I>'ILH?-:3P3!ED,?6,IXE]T
MPC<9X^MYL3/TV?Q:RV^3 3HU=SD(T7^9(2VJ8IL_Q>YW(+%*!A+I,E;+<$CM
MH["5L:H%2X=')S2&)]?';K3_769GLUJ3AWU*)9[NRWI1YH!X0F3)N%#MSEK;
M#)F@8,NLD\O@2:%JX6<1_(>E5SS% %%.$+T?K\D6_"/0H(4YL0D]8#&/+@9
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M6:EO*O"]?]3=^L!7 D]1**M.9+ \A!<#=T/X!KA+Q%[XH]Q.E7'R7 E45I>
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MWRLC/,-=$5'9DD6KPTWII?[;D&0<G/%KL^-J*6JUX(0'4ISO -^ '5,G^['
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MY.Q<YQT A*;:.\ZO89F:E (?PCGJL;XC@I,\#2"U.*;!*M^#7;;)+0XN\6]
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M:<W=\V=1'H7B0O2X%]H=E@7ST?+?S-"*+E,]W4%MW6ECKO&D$[E: (@#NPE
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M4V)_5CQ^D8IDP>&R7U!5:+IT*Y+UGO\9X]VE:@QX+PWP[YR:4%"3AX>QEJR
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M8@%F[^D)1Z+RY&T#PJ./L^ )%K8J#] 13(7$YYRL.V]-IO,"J,_Z>"^$-Y>
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M% FUKWUM77ZH1<RZ]G?,DP5B8QFE$OXC^[':\\=EL\XQO8,0<BTN"C>Z"VK
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M8N;]PI%'D/K)Q[R#+"B--;"([R E+NB,+[(/I.)4>5I U")>:FV"*D^].[-
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M6A>B @*4U/+SHTSR'W:%H)6JYOY:$:UOB#]?)1!]*^S@.]#$Q2"P!_$/BO6
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M[-V([71!=&7]F2D62G+V'G)%;1O* -CX#&N;]+]2A%_Y'CQ3Z& /B3;4_A#
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M.UI=7N%%R!L#HKN0E)O1V+7L?P7:U2X:)M9/_>+S>A?RN4-V%U*B)>@WN=
MR(^[ /D__-J#%$#9=[DA[)H*<1>R[&RSHP+,\X*@BU6T13O<+N2+OL )?+9#
M[$*&Z\LV[1@].TNP00_R AU*_1(@>)2MUH5=L83=F<-N_QG"B[+:A8P\Y$F
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MC=_JJ6/!3\W#76#F5<\B4!5D]3//%1:^6#@K=N"3=B%[^!>G5S*0APPO<Y5
M0FC^==]@DB-&%XQEB,E.+TO24N 2A.Z2 S'!B>9.!]4),5ZDHJ8[!7EW"'=>
M9^GL\6*L#J2MMD>C/A4.ESAJ+BI;3U69!A]W/CV59FF):O68.;H@H2!UH>2:
MM9.I68CI-E9^K#@_KO/_,2'J2P'FP?A">(X_UX'7:"B!T6#ANW+U?C"("88:
M)@Q?]S9M[&%#F>6=T$]%V7=KX+(NWE/M/O,'#?L7.@+V?6"I9B8:F*JKJY]&
M_96Z,T<N9+H*;-WN6'3[5ZU'P=[W@,JN$8&ME][0G#$9^5*\>O?-F-$%_>+N
M1]5F9DV$OJANR^X;@03IKAM^V>PXI=J4$.>JC R?)_A_+(PD?GC>_=\[H8C?
MN4\$AO\=+3]'7-\SOQ$ISA_4VT[0A,:TZM&X>YC8DXZ8VY0ABK064F@U9$?J
MQ;DA ^C3.=1;:M+ ]_8[I/Z-N,WBC0<.459J64Y(%XZNCMCBR9N.%!'\/E5?
MYVL:_HZ7RG#Y;^&OC714C1PO^GZ8O)B0LT!6=<E]1XY]&YW@X9I?1%2WKR6H
M-"&]NLT_^$U6K0S22R_D-[L_^O\!Y?EOIU"CAE*[D']O"C0Q^2IV\VFX$9K:
MO@OY>= ;O[4HQD\F>[TY+,74X,8_QM(6B/RHK3FM#;HX]HM3*I^J!MM4)/_V
M7Q=MG$_F"_]D6<YWT2F#D1'23G2D83P0S[B=E(K*//JVJH:%2_Z5@5Y\-2P&
M+V)7=Q _:2@9_UZ29H7P<7NJ.7DGZ0ZQLFZDPH.?A743J#+Z(9@[<J+L?<97
MK X"O#ZW[FY[;,8XS*XSXN+(659FG.4L\X+OT";(-2&OE!1I9#C*Z?JZI3A\
M222F@E,"DZKUD=);Y!XW9K]J:;HCGR$F#AH;&]4Y'+WBR]B(R1/ZI)H;5?6Q
M._3AYF>%QK^8.@VA>1?>Q*:<V(6T"#LY^<CZA*NHH-54UT_'C \/CY\0\!E?
MTKS]F[JZYPIWWCP_^/)LS(F7[DE:UD8V=P^L&:!;W[:=@GJDC978M2$NEF:\
M1$='M8UE5\TTOLX[4^+W;6K\3^ [;3U09*!ZK-L[I97;_ ,.%,A=TX>^FMS@
M2A2P4<#VNI7B6F(QVH?Y'>2+O6@,Z= G2^Q"_@+/TAG]>0W%<)0P?695($./
MK&TM::IIPYN]==89R=KG:ANR9H>_[HMS:+WZJ\+SG$8D7K3UM'?$8? 2$&@+
MKKY=LI,*>T*<7TU^(8D_S-4M6;%-?96%V'_.58PUL_&BYL!O&=>>\#4.QS>X
MAVI.R?+4X6:VJ\ QOM E-^T2@1O=RRO2['N2J*X%390A18E=\H@^WYS1.WL^
M_>6YX$17H\O'$S]?4+!(.KX+L=G^E<69_+F.L0M9JY['QVC3#W#5F**/-6*R
MA@=9_IU91K4%K-O(8\MA9M^(*.845")9T1K8&O:QZ G;,8[9T$P\^K5;\Y/_
MPXI-=[7"EE??Y.;,93N 67V=MJ^AD8,7KSK]A;KG*611NLPH=;\TYF-%PI6G
M&5),[G98Y;@K!?[0-9K-"ZIT2%*W+PU2MB!LA:7PYI_[EGVXD16?D-&<\C@G
M==DGN$% S]N<L![D1.KOK:<QGBQ#RBY$*.('0ZMQAGL+D(H+%GYJ[%)-:7T]
M!VS1HQY4QXPU^_LS]=]DF><>SG3S+[M)?C>\):H\I%X3/V,WEWP,V]:%%5W#
M(-7Q#(V)[&[#LX!F8+,/,]>'J?V2@3V*$#)[])P)W3\)PCO'?_.(5BM*TN5Z
M[OU[4-6R_/:,ZSP 91_FY37K<VPBQO$'(O: 30YCFF+"X)0U2Z[GA9;HT:M0
M@=MJXPNQ-)+(-3-Z<-(X.R1LAAJ#O(6SRI#M'$;>E7D]LJ51)2R,7Z+RA68X
M>R/Z\(>Q;L@CF)L@'(A_3Q=N1@ W[0"CV?1R$/$'_)K@2^C$-_LRJ+]Y-TK%
M;7W^EC_:C/B!3AETI(QQ'71BM?0/;3ZH'BFJBK<?+8I8"Q$"]E_O_*R:"HW^
M^$-H@N<-M7Q3*5'B5I5UM9%\(,:2=)LB Y;8=(^4G6@8\$O?!_65-CTUW!K$
M>IVA>,A*W#2HI$=4.MSD:M= \YNT1:_Z^C9E7YW[#81"1_,A7B3O%1;UJR(B
MA=;^5&->JFW&<F>[([..%J9>0EBU_6>9KP 08X- 7_5@J @:;U[;-*KVD%*F
MXG(3T>Q1/:HE+%PF>J/#8H2\$<29<BK!9M#!J\9\!(R1R<L6>RZ0S#X8%%D@
MM>:FZ1*N%24<:_ LXK*+7KA8]"EERD?&O<H62CUKX&7QP]KO<)/S9?N^OOXZ
MX'?D1J/!I1<>.B(LC,"6#QS<A7Q8Y%X6T'TW ,DG^2=JX83NIZ%#NOY\8(7+
M67%[!ZK> KZ7CI2L!5S]4_O\D>PX4TO"NHNBNOV/^L#O%?=8KW!Q']XZFBCU
M/K*"&_4+I<3[?)C*HCUI:81^VN >7>1;[$(X&M@) W_>'4HO7ROBL%>61BQU
M[BU>B*O#-).'LP[@,-<Y#T#H+5J-G#^B9JS&Q=]HK%5G^8E,T<NRY1!@VG[%
MT97@'G MXRUQMDV+L% XXC1]\]QE/9U?2:[^UTI-2?B_8=]3_)_CV1B8J&"0
MGGJ-T=Z3>K19AA:^)H@3(V9%69U?US7'2XBE/M;_?CP:]#AH;(2-(E8[UVAZ
MLL/GR: B8DV7M>=FRZ=@Y(3_7$6LQ$(T[_F*Z[Y?J>1Q.PO_C)Z],_F]SQ[P
MP^?/=F&]W9-\A$O.O2Y?..QV-W6Z1X<U(X"6@[R76XC/PNRWD>VMHJS##2$,
MIU4S>69RVRY$RJ4[8V<F!L^CA,M59(<6._[F&<!$'/#)TLP8H3L9>RHL-"[+
MK&6Y9F0U2P;L0C#!W.9=2%L/;((ZB:P22V=#UY/?<9]P0C+9V'6--7H-YC3_
M \>5ODE^QROC>'+T!W8AQAQC-G&"&LIN_$D51L=K8\QB>E7F ZXV[_<PEA:J
MQYAYIR\/YXHH/'16L;)QYN7@WP7=SY^7[BY;M/0^?,VA6Q(WINBJR1!*(YAU
MWXV+][9*.(E4JVA9+5MI"*JMXS7S_H9Y\8S9)%YJQ#', Q;D&<:M')65A)N/
MIKS3\RT3>-ZPKFU<</R4TZU0WWS*.!(1[U*;-.!9^US.3"WJ2>IUK40RZ]=F
MU=@N)/4'+P.V1EJ"[HCV8\V@P'7_NEU(AU _>Q 4@&XTC76 H\)#<-'8!VCX
M1P$2_Q!X>03'F&^(?<JC;V+/4O\A/^.? JN9@_$1$(#^/COQ,6U^?S5315\#
M5W=*AF5@*$Q[RSKWEM^]8Q=7H>4K)"JT]IMB9C&\'+4LI=M@-LU+WK_PZJ&V
M&[/"Y@;AY'EQ\SR9=),/MV..1MM[EJH_]E/6?/<NMW#*^5W1M\V'C)ZQG)(O
M8X4$W:E<0CGQ'-!?2&DN&L_RGN"GIG-UL&T/L0MG85+4->=?&6!+1]JW-K#
MOU0 J;$C"T-M<,VH IO\P27WXB?CV[ U=AV[D(19>8"Z;A?*[-N%)&9HNT(S
M.^L,M5GKY$ZJ^+7$;SBW$,90*),#$P<KZ'<3-:5K-FNBM9I2W1Z>K;I?YR4B
M3CZ,MMN7XEF?X J->WQRI?#[1Z,#47V7K,N89Z29CP*#%P[:EBB8'LZ*(O2F
MI)MZ+_>V9;DKW[LX% 6@<_1LW-7#WJ7=FXRB*?NIV#VAI;GF4JG0"2N^63C;
M;Q=2=0@(%XSY(L[GYR<:=BX^[SR ;=>8;&*G\RHB+CIC;H.I#'PT5*[U'#H$
M#L24E#BW5:#I?P!UB5JYBMT1!BS/%ZKRXY1Z?_6'-=2C1F\^3Z&N9'](H3F/
M?O-5VZB)WUBB_B<1OXLP7^K/*V*3J_Q^W/PBOQ0O:;?@H'/DP6OMD,3V!<JX
MC&Y% *X@ODSF$1IW.\.PE&WM8Z+[*='(U75L9"&GP0VE[O(T[K/WU81K2F/)
M^@4W+*.<O V&B7(>$H59"[8MPTU#T__9.7/V/+(SA'N$QK?\;6Z#HX@_AMV2
M\^9/^RP9W-N%I%0E\V(![,[+1-TJC6TE+&T'OV-VY:> ]D6^,)1M*\ \!O>Q
M' \FJ,UOQ!B> 5QFNRJ3A+.I,7D*\38<]Q=_4#-XY:T*]A/.SK,QT>4/@YI\
M%&'W&^[L0H($ )ZQ"Y'\QK_";X=5+\9NP:?B>8$W 4)/1XL?$S"E/7;AZHR1
MN=(>U\8^QO/Q 4_?+NV8$ZZ!&4RGU_X.&YZ^QNLO\-DP(, P_3A]']73Y=$K
M+D^?F1RG6=SVS-%*LIJAU?R*\.$OUFWH];_AOQ>H=9RX_\3*^QD/SS^XCX0H
MY7=&*%>^?M+#H$Y*]82IE?3* 8@Y0<_//FCODE57IW#2.I/UN4U1^=I)!\-^
M>)5WM*M&2E@H(E4^KKC-&[9V,2^!P68NR/1V>Y_"K:![;%L+X^W0667A.V/Y
M!+^<Z1I"R&(PC'L(7W]<H(H,PI_]9ZF 7%$ UI06A,"YR@USX7,"! 6%G2A\
M&L<_BG]JJL-GCJ<R0 O6C_=?BT=#XF!UCO#]A.*'4,.2T+#U'U?L"+2$B$%'
M\_2W7"@0DYF/ENK$BFHV(?]CQ4^Q*U-*)^+T$&87<MPGY!C6R]FE:=J$1PC0
M;*207_5XI/.JSHM;0\0\_[]2+^1XF#_Y,^=/7AW,DV0WM][S8A?"$&?M2Z(2
MP/GWK?(9_<&B,#-64K1GZ3+;I]RA8JHD*!%N2M-*/,7V-?0BEUO==;F]MU4R
MF4#G$8V"YP+J<^JD8WKF5AJOEBMXV;VUN="70M!5,JK_8'HEGD(X9-0=X'?9
M7"U?V2K:WCS7J/]05[?%4ZNA%8JKF7=>,=^$+\'OQ *.&Y_;$4=!3[;'F.H#
M(*^D8L5.1W)6AD5M\W5J#^L?+1I!^$NV,6")EDZ.RUEYA"(PY&8B16)8S>!&
MEO_GFBF<_7PK)>8;48#R+0+10N1/&6I_TAJ<TF!&O&:(*M[&W[6O:'9G#HJ"
MO?XB]BO;MB02?$XCAGJH@@ HM+XM?9J,R%@9ON;9EK&36)%)=*)[O]R%/$#5
M5NY"'(+L9N&=:ZN3@U)P94:Y(<I2_?+ A2_+#_P MA]"W++ECDG]TNBRJ6AX
MA4'K\J(J4<SCD&W70%S8W?20M:"0.N4XE O2Q'5G=C'R5_A;]> SF ?V><1!
M4!98<NUC#.YW<"GSSBKH4J\DK^K5O@TN]YGDDS4O]<C.KC12ML;:.XZJU>9Z
M^0:5[<69OZMYKH'.C^-RQ%^0XLE.$K%E>I\3S!S35\>+?Q)M*0X-HR4ZXU8Y
M.=G?!DTO)<B?N'ZA6]PBP;;WDJU)Z+GG<1?*3?]?UW\_MG 2MZ [XB2]__O7
M&[$%#7;V\%:_U#PVL6;P*-JXK77O."D9%S'%0.+8P"1H;/JC6>FML],NY/YU
MB+@Q>\KAKU%_MEBV57/+DY^O:)%V%=R0X9J68TQR7%"+U'O^&="_R'$7<H^7
MW1:A4E_?2-M$ZG=,FG72_?/6\YB(==E8CS%?3+?^0S)IZ&+<FU );,0C?V[*
M20'^W9\U%GBZ9B4PPG<7(N\\R.\^0>>9E HF^],SB__EVO'_09<,_W^3N5*O
M67#KS(P4O[T1RT_O0N93#\-HU_GA:EAUD"<8KR3!LY5^@F&T?+ECO&<7TNA.
M73N+YV=[+I$[H UB0UC2TV=OL"7)2]3>5MC_LJ,SIS@MS3\V3)E"O, >#X8+
M"#VH<7M("PO>@+TS<'@[U0%-,$#Q\&\&_4MW(>T!C_Z&!^Y"#BY,G<]FX*_B
M%>$9]Y.%S,*>HHE_;^8J#S(W>D0M1P2(\TG+S)TO@6=3$RDJ\:\-8*P]'%@[
MS98-!1*F>K_.3O'%G9[X*CIPE(FYX9K^VHL0&N73?VMFN/_3W %9D]]+PS("
ML'[8=N@<%;S]/W=NGK+16,8]K(!IM5L)".]-/BVY!MLNQ</O0HZ1JQ<_\*=Y
M7W5H@M?!WO\?6T!35. YF/P?6T!L!%=UL,99\*@"+WT7<JAG"L;8QSDO,"?!
M+6-!:\6&0]7KL E\$WTAX(]3@_]S;/>9W;S[;OBA1K"++7ODSQ'-/GCN3<M1
MBO"KAVN:'.&KKE^_L]G?%^;K:FIJZI),OOEYIES]*T8GP^[6;3=P@8QM>T)U
M\Q7KV8X02O*/S_J6ZHF]%D4]N@G=LVP7 ?EGZF?O=D;,8E=&A%;+NU W\>O!
MGG,-XXL#,<P9C^H'#8AFK.^OW79=D,PYRQ^"'N;+M$RP>N+X$F#9GP O,7HT
M(R1K_4.E3WRR4)N>F=];+M)]'RWZHYU5%W&ZHF)\,CO1T$E@R0;7X&:C0;ZW
M=R%WQM8T@DA.IBV-(\%F&I:4O!Z+D6!9Z2^4EG?4JL8DE6S]*?U7A+I&2GV<
M[OIBTAU"XKG;%CNT&.ZQE !SJ2N=#UXEW"R+(9E'JZK+U%P82%.V6K0O36PO
M+"*J>P>EIVLIV^C.ZW<9=_4'BMP^'.1^^Y)IP./ '.=4U-1+;Y*'IV)+(<G'
MAY\!$S,\ RHR>YYCM%A01D]L$/4$&MHMXZS7@S,P+OCXH'+TX0/5J+]7Y;I(
M,Z3.0 =O1]\U[<F,]!(GE^6L7$+16U2@KY0',A4*&"%P6''^27Y[WE$*F$CP
MEI$%R=UY:JR>YYNYMDJD8&'_W\!G004%,V;N 2)7)JY7(">]^?(CDG\PM^^,
M:_)LI45DHDRIY5L_!T*>O<WPE,YSB>E4M1&1U!&/*7AAKC9&-"U\*Z4H%M"O
MT&?1,1-HN6!BOW5Q2\$V6J8Z^5RI5=2"7-#C.%^55=^@UMKI"_EQW_N?_UH"
M[4X&U3>XKQZ\W85X^#,&^=$DVE<L]XC*7');<@(6&(<"=:WBF(M@R:\]1.X%
M/&A,9=Q''VC/N\IOX],$.NX#C\3[50;;,+44Z[$+\<9Z+.,G86[?#:=XN>YL
MO,Y:!A^YC.-*A?#_O')7,$_K@,5=R(WQU9], 7EX]"O?!I5!QP(-6&8_MGU*
MT*! )0K]X'M#N:>10++ XO<)&A_DW9G5Y(_Q!;(R:H3_ENK&[]^%9 [68O/Y
M/]KK10:O &7:;?>'2@QZ:WWY_3+V<6C'Y GWRZ5C#3YC9;=S]>\2;5J]*[^:
MM 6:FFI\9:5?&![P&JT8)L@8_DAS'J]9O6VXDI"]G>-[?VUKF&98(>@9,Z*;
MOI?Z8.,HY@@8"=QLFT1T].LP?>L2-C4D0,0-G7=+R$F^2'Q["LKQ6VK18&"@
M!^%#,:KQ"]NQI2CS5+:[0G<FJE06GFAE/:Y!X#D(6CP$TCM=U7FXX&OR+BWA
M?3 <["0F<"Y96#4%(3^!?H(4 85[H/?4#'Y 7OJT:M'NQ^@'USU7"<U/_&LV
M!:[QHY)C%3&*K$%R)?3GMZ,T9_8P9@DA6@EA2=% \ES=L^A=2!RT@^V84[O=
M>GK,?^MV395,#"'T<*Y;('-#:L8>C;U5/;0IJY+=9 :%#WND8\E84#%SC13"
MD>/W"1C2]0J7"3HX]HV"/(&YWCSBR3'/X%]BG:LT"44536N1"C,E'0VS?0A>
MCV;@1\([BK0FUY+0S*2KD\'?J6*/G>-A73T2G9:=(^2U19=[ 9I>[17JWL'*
M/\QZ-2]NH>9:R%>B%M&6N7>N_UO><KL6]:+3[<U\]-V KQ9?(E,3-8<3TW,(
M4I;CC8X?S@_#X@4=HW:2]W!/\:HB]G$18"I3&"N,EFIS/3L>/'C,9]MVF_82
M->E+C3*X13H[@7I2-YG+ZZSZ(-&2AR^:</66V@Z\[NGN$Q"L>9>Z 8VCSC$'
M<1FGE+)ZVJC5T'B,R=SGK9M^>>=H$0K+KL=IQ&').\=7+-"6(VVMRM5.=0DS
M\,.O87&,V^).YR:C1 -U/N]"\JB?1^:*<!PC_BARGZ$0F,?>A2  6G(SRJ<(
M';-JFJ?B8A&DKP_O1]KBS!KSAOG"/IPR43WF^ #31__5F_HLW?NQ+P^25^+Y
M0F("UKS"^\= GB/$M6X! P"G-NIA@^N ?UO(["4@.9Y[J5 P!]I1 88X@Y ?
MJ#PE5E*QEMAQL+W#)G*PL@%[S$>/L%5C69BA\V3]=Z6="-U=B!6ALT%=]L6[
M$]P.V5=N *AJX$4KP;7_!6P%4!@B9L8W:D^U.%9WVJ0Y'R^];EFX\$':P>9+
M7VOSN_2%Z!+S=#VK7!-=(]/@\R5M]>I>O<K*XN9L1)9MDV//YA7V+=X[PR/\
M2:CP/3 7R-_YOL<#'825 O5=X#[^$FA%I'UGA_DXR==/G42@M-:J/,U?E922
MTO,KN_^Q1%4F/8-4A&J5YZ"P;>983\3G5-MJP#]II"OO"OBZ%/1#'D6U[@6T
M\>Z! 2A/S>I)KVH0_RNKQQ7X)U5*]JI384+[3FOUOL3<@0)>M($EZN4*,HH*
M^$-?$&IYQ @M\(XT)M%_SH!_]I_?9TTRVW<A1S!213?N_QY\\P)":N",FJ_*
M7A0;X2?<$\CQX+CS>_#O#L1%*"TC*8CU:/+RI,I2GE0-\'D8@V*=AQU$"W>R
M0 ^*KV5'1/SQR9 7&&/R5"+BOBOT4W!,I)-DUM/$'ERP<6-SI"6W3I,Q"V7P
MM3L7'!(-:+)IRL+'(ML]6(E_/O5.7[Y-."D;DD \.#@YPGZ9IFQR(SLM?5&>
M5A#7R7P,CA<NC9#[/U@&NY1T&5&4MDPHO6LCIM_Z[D?X8#N-91#LG$O0"3$+
M?K=/O$<]50"%"P^#KY).=K$_,(:Q#,MXAV^GK2[54IYZSZI4G[SAU'=&I096
M!:M,7E\'%-E,8*"Z#*/41--,/@:::?Z81^)F-=[A$"P8;C]184WOZ?<^]^#B
MI<G9Q&(XT?5ILN70ECXQ1NOY-;\^(VIC7#L5BD71$V# 3:P4?Q!ZC"^#,<#-
M#>):SUP'-NR3&?@7F ,< \P?GYKMQ)(VD\4& ^;N[4+$-0=C)*6R\EU6_UG.
MV.'X\)52!AUB?#XWP\,<X66O6G\5PA9!YVW?XC5\&?JKH2%NI!MYP.!I/G+J
M5J6)?U#C4SH.@WCHEV'UJCFVY@@P/25&D:^L%5%3WY!HS;S$.'7J(]I)M__=
M29U<H%;_ E%Y<_GKXYX+\UXC4=X#SJ^6QZVB2I0K6\0>+-M:3^7,34/55/W.
M9UR.EGG5;'@Y]TG^C(3YYI>9E!9-T@-:5WCWSOD*+!Q;N\$]+C^'7;O"Z%>>
M[_D^"Y8Q#\3.ZQ@>!9T8L20LX_Q8T.>*B+Y@IJAI> 9'$8?1\;_<[R]94H+9
M(6VUC&7$>I;TNY5B/?EFZ$#^X2O 4]H+DF^S$T<)S+P%9,^4NJY&G 3K"""Q
MTY:]GR%1X8O1* 'WM.WXSGRF7/ZSUA)L[96LMZ[5>]Z]'@)=W.!*>;9'7!W"
M^CV%=[:>>]>2W)YW&0R>\\'CPG(B/XY4;":*F;K(NHZLJ\OOOT#6I$O<+)NF
M+Z=0ITAOQX+6;WNY5XT'3?C!3%KW<$T%HWTV8APFRH4!!7:@+E P=R#^6P'.
M)+FC57O(UV#?O%=P\MH3J-?0+L1+3OV.;%=ME;<4;5QO#[J@NW9R%_)"2UCX
MD!9RW^0,(G\"?E5=@I%0%UWUD'[QW\ DA0P?W,Z CG0ZC?2PZ'+4.<86QO#\
M<^_XM.4&FVC[TE$5CG>-%<$D_=*KQOK>326FEYN$] 6K:/ONK9EUEOEED!3<
MR_SI<<J^+E1C%AE)E\1(LV@,W/,(#8Q!<Q,5\$RNT7\:?KU^5).3J\YU^G/X
MIEK+>O2D:NWV$[M'S@[3I:])>3XA*0-?OPW--61_+V,W"%YV@C^ K\;&4\1P
M6+$:46/V<U;WLX#BY5GE^ ['+Q%2@'\,I<70^MFF"E[:=2EK-*PU/^5G"88O
M/:S5HF^6(:U:0>XN$_V*1VUZKDL&;7P6XQ]J8YWOF)LEEZ".<$^"5K#H5KG5
MV3,MD7?'-_M]NL+&J#%!<O><ZM=\U[YM-5T+[[I+1\7M/+8W*3'VW-=5X"A]
MUO]+&?_09WKEGS#98+P,?V96W0GY.]K_>N9=H"<Z6$,$W(5T96&3N($ER!X9
M,Z8- ,-AC,,-D]_:B]ZTJ!^A'".VE:]*.=YT=IY='G>L2"W^>5*N75<;96S(
M%'&5TOSX_6&UE)-8Q@+ZPEB>VRLM[W^B[=W25$P#WCH)HS^5&"FGYIJF1LM8
M6M+E$LFW[1]J*MY.#/MD6>988)JNGIP^P*I.\RQ/JS$YMW".MDX38"9X-9+A
M^:+9@K",E-B%>)*/8RX#8^L?/WF?4@$VDM?Y"MK)XG4S/J$!;Z%[0.6=;S,"
M;A2,R3CF[#(IL!>"XY2W%?8-;5.:H2$)NO>TGOB$$7C[<#@+%L5%$"9]7*&L
M_?$A$OS,LF4[EBH[L];NT15CU<O=[X&;\ON3C$S$A[#_X$'E P*>-Y<.E8R0
M0(=TPBIYB\^YNBQRAZO\NW?^8AA-4&,>$34+96D\WSK>ZGO/+*)WF]$39: 2
M7.*U'>\>6+2"]TIVO&@22*R;(LGL?<?3VH5$8@TOK,RJ\-(C3F.TQLXU-=2!
M")8E@'Z"^I;GY 0[#*Z:4EB_#3TD%7IRSCJA\^E=>A^9Q^2:?X#1A4?BDREF
M 63)1QDVIZ2)G1/FB"Q@;>G>?'3/@G1I5R!'+_U:KH&93F+.ZL1H[HENBU2"
MY964NU%+'P8>V4\.2@+IJT-=2M<'<L,,,AKM'F%BC3W.CU5DS121.#W(XWS!
MW ,0&Q-4=A68/2<62Y73A(JC&^<9=%RPO^ARWE%<)VU2*DHKW,7\9_"%"@H8
MI#7"-0X.(;C&>KQ+ZNC,\LM]5'?L.@FU(U ^)UK'\ZGJ;>Z5#<'!<>_OE<VQ
ME"64NEME"HO'$Y3;K5<N6$=:1::=HVDZIK2,F)T/EU :*3ME^D_"?-#T_=3X
M %09L:#:9&)YFDOD56/G\I"5T3UKF:Q\7]DYC78Z3J:G Q_IJL>RB^(&S)&%
MO/*.L]032T%H>T@8/QU;#D::U56/&L ?TF1$:QR76=?8;PT);H;%#UJ>LW=\
M_\ J0@'S\!;3/O8*+^WK\/WZN&6^%J@\;$NQ#37/QI8H)%7+[K,].^M[ZNN.
M2O=[ZYK0F=<2</(W+%=J#U_H4"$J#RI@^_?(T3)5KF"J7?A^<+NTZUZJHU?8
M^3ZY$&/@<&YQ_WE9E]$%_N!8LYE:>E-/$<K',U^ ;%K\MZ3/J)PZ[I%L]K'1
M=8V>]0:6BGE*][DJ&E<+@!HU)WV?_3[/,?^TU'H!?'/#9"]VHGK9SI'^W$!G
MW_!,3XDQEIGHZ*3BM6Z@4>K*7^_X_#%$# S)^9IC'-MIDQ0@ _1>?-5+\1XO
MVVI6+;8(L)DFR* ;>NUCS^782J9V.9H2\ /,MXAC66[+;FY[EZXV_HBROM=P
MOG"C[_Z,9IK=-EUAK(:?YY4?QX\P3..&\&H$ME]%_QU[GRZ'Y"H)8(("3<(?
MU12KN<[DZ72TRE<!]&CNF7*CA37@:R6SH8:$': Q9^=MWPUK^O[I=:5[YTF9
MIDRG79@O^7G$H,"XD/0HV+'F\+<"V4I]OR&).5/'TBYS>^O%5_R$0?JRX*:4
MT2WX%%Q%AR61@K9JDQF+R1I&*/<'YZ-F%9KCC&HMBDQ$?DP[8*_IR2W&P#PW
MILIL&WF5K<=7\$>;]>>2XUMU$0G0PP]2CH\&+V]\H<TE.]3\^+8YH]-YR=%[
M,B-[/O'LL*_I8,>L3E5U=4VJ#>X&38:')>!Q>!'87!*];N#MG(#A1NK!.I+W
M<,V!T589ED=RM.%)5 ;^]PAYA];80(T7?C6Y\/>V.WZOWX#=:H9>%:K-=N5+
M63IQ?U'J8CY_!BM4)(?\O_#HV@S7PXSINGTG_6[F/:@)T,7XT)@YK2V.KS#7
MO&/K/PP18Y-D<O6_CT:2<.DP-\NLQ#]M;*PR%[W< SZ75@>Q3GBK:X6Z1Y8=
M)UPH2MW.T9V:T2S$7PZ[_CCE/\J*^0Y&(84,Q3'7>2^;KQ/0&W?! A:1(4%\
M8: ;_G9I1ZTG2O/IY>UN'4??M-ES8Q2H^')88M/,#'C3^0YCJ,;EL7W&K&*C
M4W!#%'7.F'NTB3T&.G .<SW 2)88L_L9:T^GGD:\H;397(L>C?$UG3'C9(VS
M3NURE:5),MEB1\&R=MN7GX7-3GV]HBI5IP/U2MDK670^Q8M:X ^JT-;(P#&F
MU-H4*YZ=R,+][3[&U\1H@#:^!:!L=T=GA/I(T5!0'U)2>-5'5]-,!5D)C)-/
M2D6<HRF^6 W3+ER:3&BS5^ZLY.\5O*B,0/@//H-1_'OPL;/"X,\Y?Q"!T6+0
MHT).*0YMTD&39G>&?^5J[+R&$ K^E#VX#XSLJ-L^\6Z4+%#:P<'77O]H'O%[
MD*0DO\80:M:"BE:_OG=Q(@<(6J'@;^04<\+ "F?YQWWTNBAWXXEF/=/RXKXL
M+?6\E ST0AQ_K.-[;[(^?*6_Y'&W5%[ZTREZ]NOEC^7C+5);+@"./0=JL8AL
M6Q9R/92AKR$[P=4&C''\<V!\Y\ZIIGQ4;9[NR&G0Q;UDI?5T);^_DA:L]CN;
MOW%GI&!T,X (9GWK%E"X[EDV!S%J95$UPDUF:PLX0W[$(*QV%]().XJY!-HP
MR/&N)UG&,<W2P?-]:6 \@RZ$LI6:%$UJ> M&_*SA4$70\UT_FVI&#8P+8M7(
M!94_W!I1OGG8ZFE5%['NY+^1!W<A#\B@8O*Z&] TAX^2!XR?E0L<*6P29A]Y
MR\RS4X^#1:U"10QL# M"M4G,7*3S>$5A_<N[OP47?_SGYDE;]JI$LT4G=="8
M*SOS*V$@2X??C^O&[U!:A>TZ%KC7.GX2#[.*0J.)25&/FXV^HVFD$Z.$F$S5
MY0X)H8CA7-.XRPOII28*-=,MVTLV7?>\F(].A#;ZCB>6?>^J^5J>'8DAJ<R0
MI(@W=Q)Y)5C41@R^"MHNBIQ'=-UGR=%B@EK@=X;^&N;*$ZZ7@?$.8UM-Y.H)
MU(X'98O_DF"LF)9I5^WLO3.0[BY'R5E2G_P.A\/)EWCQ5']8)*S.%C??$LB0
M3&0)_X'$A=4F$M"19F!LOI>>87X/LKJE>9A<+H8SL&#VZWWMG4,U)C8=&/VK
MY7FXK@C;HDVK<!OZJXQX"/9+AY881P5[&+NIYM=Z78 ,@; O%KPRZIH[:+0+
M*1I\H348Q<BI(N,<,H^9V846R5XFQA 4;$<EE.X].N[L(@$-_<Y4-O14^:&Y
MX7&/&%]>;6IOU+?F:=(+SYQ]_*5$Y0?2[%XZR0=905Q17*?M0O:=!Y4X0I/+
M,K!XU6!_.8P5RS!%:T.$JPFLL=DZEDLWK7U55V?/TOR8#;7 U\2  )\RI^7,
M_3U6S6/^F_$<^+5K\S4M3=7<'5#GUS$;C!R+F/P0H\7RGTM^$7$8A%N-GJV,
M[&$;7DUFJN6EGUQ_5%8,9M^@ ';16_JBAN>=8#6M+_@*#=&*]2]]/>!_^&&%
M=R$H4;M.:"V5>[R@.\O ,6F"KQHQ+./?M@L1H@]49C]5;,^(4!GA2Z%O?V<$
M98<OG:T=P6@143L9)=?29/[VA*_?< A66LA;6=RI @MV(7M?\N(P3P$=_G$Z
M+N(HZ,FH)1&\$CT8&O&NTD,D6:9M.LFHRL<WL+-5_I^.4N[U))]B]LJ.71Q%
MMEB]9C6^Z=KY^3_J^8.CFAN$;F 7LN=1A<-+1GWJH5?S5YQ71<J8 ?5_&CGZ
MJR3,P_,(>N)E0EIG<"56*3F>N$[K\A+;D@O$M25#1W1.A[23N(&"Z=T"'%Y5
M:4 \8J)H+2?'R=Q$>S+-.C2_Z0/V A9 _'Q;+YB3B?S!3,GO/=>:=R&GWF0=
M8KSTB/'RH([F*=U+%S[W\M^$BA1YB> S:?]<)Z\,L@7^\GE5Q "TDMKE"5YC
MZ;1#92@;$EUOEEW/9F!_!^W:=7:449,?'YO<LQ1,<[XAD$:[#$LU>)RM#W]U
M)F_6ZUP.7%8!JX@4L)-#-53P@N+:8)&SIG\ $>,U7*Z(AFMJ:.74U7ZO^7-9
MMN8AJ_(&JT#B=)52;_*L&'A5A1V:V04]9"@5,1QV.%FANP!H<LU^'V% K8X/
M[)C#RO8=SY,;I82*&#_(?HN>G%23;!M'UWICCV"*GJ^NP]4R1P+R]BCV7_T1
M\_CC@DV&F&SJH*AID$_X@9/6E2=PT8\S57,*; /80N+5P2K79X=0W_]2IA5D
M,%?O+K#35G]0+OQ0-Y+!["#AY[],32C2;#@= )&)BS34PEP%_+O\<5D%JX9"
MK%D<BBDFYGUYTODS0BOQLUO5U][O5RL>?EOW-"%IJ!4EN@H7*R1D")W@RG.0
M@AEH(P P^N<ZYI-<()5I&\U"=.6IM0!YN4Q.(>A9 "HZ5WY:H_CP+'L[S&D>
M++%.,2$7>Y\0\65$246.ZE?Y.ZW#E/UI1L53W\ ?_(._L1@8'XX.^&/.D!@N
MNPK=V^RU4QOI-=Q;I?',4.':-XK0];U=*1:>\TY0:6?7OOO,"[#:FB]-E+JL
MKRJY<""SFY:%YQZ/Y OYA/H63:_894&[R4FV>2>'*ICOX/'K\G.T:$*\:=W8
M0'9A;P;3[  #$7.?MJ55UV+OR!SG?_]A_R1EU0Z;\.&J\.\@,1:0[NM4S<1=
ML.T<+9-)RG48*N-P]ZZ8BU<MON\FA24IN5K_O%=.UXB0OU2R92!G>I)JWV5Z
MR8(R_[%ELN3\!L'X!&D&'\C) Y_.^\HR[?YN%F?)=I04&S-V(5#P9H>K]J>"
ML7*Z^9C[4+--@8-/XSWO,$S"AGNQ0CI7./3!MPV?Q^>>O8X[&K920EQFRYA%
M9Z03'!Q160]>HWR)RXU^>%_1W!B\FZ>0D\.$@\/4N2?LC(P,5L\^2HUXC\B1
M[I>W7KPHO0I-H!^1!\T ++.NR^0-O+A5!J/-HG4>\BTTN9_$A.T'D=8LV;:S
M?WS0+^PK>C5Q)C@]_45B^K_RWRF(U1/I<-%#$3N-1!Q120FQG:Z+NF%IJFRY
M72"E8J1#RNBIC+"?-0NO;,ZR=52IS:AU\0UDP*;T^4*5'"U^=QAW%R)&83%A
ML3#)]8+:3 LP?,[KX:W6$W">#F(\J*'9LV)5ZHE>1.PI4N&*+6WR:6WNJ99R
MD[WCM"O+DN-2=V?KOOIE"@#R).J*2[X/LNI4 ?%S;M.W(&J2[6379*JJ6ZV#
M"U?A$P-SP^.E"34YJ.3D+673D9L_H9P]&/%4]C:O85-.?MZ55/PKCN=4&7,P
MGBI-]AQ],!*,E9I8SO.K+D$]W_B3(]>?#Y([ZR9M$TM:XP,*79?##A-*7+QT
MPH(7$B.->7;\3S# =./S-G.QC2S.O09@WV_$4(6YKHVW2S3^YH;.)8NA6L5I
MFTB)B^']YY\&N@P'->7>[)39F_7<R*,,U;C06E_I%2+US]*GSTA"] QQK2')
MC+%QP*ZORIGSVZL'/S,4Q6ZTPBX2XLDW8D1M<Y9U1PIN'HLQSRH12K4FF).\
M/B4H**<K*DBCK<N^HI?&.MU*+=^:'DM##3]*(%BE*WHJW;!]@@H\GYKJ_4&%
M_&L+!CIU8"YY/1-@(U\@]VVM-KVJZ:O?I!\'X9W:XY/(Q&:IDH$4,Y0'TU=R
MG&-9]TQ+&%V(AX]I]AM;?Z(8/6?+P6P:FD:TX.$:$KQJ@:X@8'^CNN&/@1KM
M2$G,%9939Q@U*4CN9F?87V#@&[25;6W52 WO>E"W7N&L(HL:)1(X/?V3^B#N
M@T9/IK_*-*5U:2^]C\85=V=VDX$1]C;HG^\(A[$5N_J/==%%N&8^0DY]BY/.
M2R&&RD/G)P*C$R9 <GNC2+6+TX=]:WH!HV>C%^.8S/;M53IX-94/IZYQ=B'W
M4YUW(:/=W]]%G%IXA3CRJ/G:B[RSK19)[^T^/EJ=+$6_N*%9J70WU\MX-JB,
ML;!QH:LW%:?3\G%&=:#F^P=F?H',9NGMM):IME8O5U,-/Z_^7P<^)NUYAKQB
MV!R%6HU?$Y &M.E@>X0$R[B+_B)"'8!%8S 8:>)*%A2G*?#_RZT7A\JU>/*W
M0!RS>(%E$*88CX2/DBH>?*J1D^WR??#ZZ>V57I5$;;.;>]B_JM9/<R5Y1:T*
M2]"#F%!@W@F4GD?*>-MF*3ZK\&NV\9C'[P<CD:WU/KZPCA##,V9B[7I)R60?
MNZ,.D^B(0\VZ 43OK*B-(L,RSX@=EU;2 AVX(Z"+GFMMY?R^7T4SO33BL"(8
M-58X4[%+@66>O\R2,JEFA41C+N4OMRK3FC6*EF5THK:R45Q]U1\.2Y4KM)U:
M(@'I/>0=0A/,,^#SY-1^[A%!-U]Q#P.(M2&.+\8)# !*95NDVAJ?TJ,Q#@R2
MRKK(("-#T&@-0F+&:\=C,C10],J=L2V5?VO$KNADZ)FBV'92=C3;%&^=B!B+
M=NZ^G ?2/8?<'DWD]W^?M"_ZT3M&/-';*G7LI%JP\2&A#;$U+[N2?0?'WRPZ
MII1PEC[<**PB)WSTLGR;*.#[0E4XCEZ<[^V Q?BT:>L&PO&-WN%XGYDP F\9
M7=?5>@*0BM':D$&/N YS+S%@(JB0,-H+@^LDERXWPK*,3939M9GU]>FURBX1
MBQ*#E($N]T17XUO^BWW,9.Y)(X#X!TMN(!M(9H>P<)UD,<=I5R=LNQF3?@JU
M"Q&1O2OY_=Q=)$I/@1C5>F;6A(ADAJYGVV7?&F52."JN*-NZP&F'B?!="%=2
MOBM/B87C'ML_U36I1?H2ADVD()ZUGF9UVHJ[&*,\&#./?>2>3'M?ZM0ZAS-'
M2%.CU=XZK8)S9K?-M"\53\_*.H73!9\N,N(!""5R]X)U6-'MR-,@XT R)9XN
M,^UJ4C2%'C$#[7S?H.\LB2IT]5['2OW-'/]K?.-<GJ[',).FT*0S0FAWO'F@
M[XON87@DP[DG+K"Y3CP/(9:%]1CN77)7^:MX.(!M&LRZFJ,<S)Q>==2[JF)I
M?CF8?/CC;45Q*VG$ 5S92;UTZ,-54_$2)5=V@KQV_F922X0B4;T%B8/-,? 3
MYJM&[_!=U -8KVO'.BV-SXQID@^CL(<-K/(G>A73[\%%L59@[!QGW52G]DC?
MN;I3LL-9NE\R9MPRKEI^Q7Z&352SGP&(=3/ J@UZRE#. 9UL!H0DN],*AU4-
M7-R)RZUG*?Z'T05.0!+Q,-&#X-WX-5<DMFQ)BGD,5>;:H57W4J]7)/H86,8C
M&.@#B!XJ8*TACKXY)Q:)46-2HPR50-:O$E@[=I&8:^<;#228*NNFL$-+NQ!Q
MM1H4YE#YA,\1T-.&U9RGVOPNM2VL%;^O]K4!@E% 7!Z:<+K.$XQ^F\46\C"_
M P^8.?#%^8-92*Z*OPA8U]EHUP85F4#IA%44&,;GH\>1DNC%'@NC4A^[K"*B
MUF#L9J)45U8$L=0[I"YD&-M^\VF Q*ACZN3,S=4 G8./N![M]2*I!UYY_"0>
M&V]GRI_TQ?H;[WE&-MU:HA&5DQH[W5;L\M=12C>BT1P[?<688W*Q/M)VXI;I
MCE?O#.@03SE8ETA]ZU53=W4H[JNM2FYR3^454.<$O+8:V>X;;@&0VP;WHY/9
M,6-!#6?B%COU'M2YSV%CMLV_[@DX_)+9U*_3F?65I)!"Z>T+])^K+)@>/*Y"
M]-X>IXF%^LYC#U/GF-@8F<$7FAQH'*PZ),%@'V,U._/Y-A)([E338%X;?WVL
M.W_RN]FQNT!F!ZVQSBE#_B[<Y?JW]?*7WQ[Z4IQ:LGRXD0*!<)T7TRH>,11"
MES*\@GD,9*2S]G08_HXW 72><V5)'[2ZHW5BMYID$Q&=KF=HFJ]<9Z_=,),R
MTC/#X4A;AS1JBO#(L2TES2_CFF8'+*HY4+ZPFJ#1+5X>1HVCN8JMR6RCXPS%
M0",F/;J1&L5DG<J>4SO?T6XHQ?*,QK@P?<7:A/?.'ONT6;]I1-O,]7<:VEBC
MJ)S8O)UI_A3C/>*]K48P\EVR[C70>N^YB=87SWCP*N>IZ2O,\1^9B20)D2>7
MC^<>#%>^&A<DMV";XZ$5^8CHB$F-8D@/Z);^I/RI63E4=OMX2KK1S8FNV5SM
MG[D+4FH%BOZH$(F@$124BO_O.-#QHX%CA'$7@*[6,K06D<35866S'4 \F?O@
M'9BB29<%OXV+FF)C)HGQWQ:>^ZP[W06ZB-W]AE,.-2D[FT6EM/^+N_<.:K(-
M]_SSOA941*1+$6P(2(F%HK38  $A M)+1$1*!$1  @3R*B5T?$% 08@*(4"$
M4!(Z1 CE502D2Z@)"M(D00B/I&T\L[N_.;/GS,[LG/WMV?WCGH')\.1Y[ESE
M\PWW=5U*(CX!5[_=SUX%OSDW<$9@R\TP:9VHWR4]@Y#=0=C" 'E*Y&R<\6E$
MP&-7HFYXC#IQI$6/WN 14L?<\Q%P[:B=H"84?KCG;DL3_[@0,6O#\>&VD;^=
M@BB15\GFOT</G:^E!8HF"*<B\H^7O5AXKC9W_IM#@HIFCT/ORMB;Q!SIBCV)
MA4>QMB/XKMLXY=4"I\9'I]YF=7L5W#PD<;C,)JO,,><6WLH^U5O16\M>DZ#Z
M??M;U*P=.Y);+$A82KMYO9 ]AD',>;IF;N(66 AQP&BOE0>E0U<_!DM7+V$J
M)6M#]RT]6\IQJ<2_61J^L=-&OG-:+Y+T_.QDQ$]B<;<8;^\@:HX(JU[ ,U0Z
M!3 -UN2I(8),/AL&"/VE3=@%I\K$VM&AZ2U7=^X7O)L1W?-=SC%C*T#KY\U!
M8JNU<&N0XQB)*VP]?$&DHNM]VP@1[@XE_-=>OKJ"^_N79KYM,3*./TD"J_3F
MIL>(QHQ!Y(V/3W,"!G%,6%R,) )J-OZ (\_%16.7\OB@Q#"N [W'*@L6K;D6
M)CRM9(&&MK8$:,W:5B7P0;=X REV[F9F<NFY$7,,\D'&@E[L3V/E 45CR$0$
ML>SVSG/ZHJNP=;K[15K9<'Z:CJ.8J_12E)^5JFGXMMOM^<'4+GK9?"GM+&]@
M>\3.8]!/MM'>.@#?;'J6?,:%-,:"F'%4!)@LC30D,^U)Z#34?8@TX-.>V:(6
M3(>*<BR'6MP)U*13=<Y88XE61E#<NX6$W5&-T&SZ@/&5H .GY"O=7%%7"_]@
MKL>VJ2' %(B8L1(B%LIT?-KB532Q,B//W)OS@Q59^#+Z2*9L]NET^7R_>8/7
M+56M3R=O#1/N-E2-: 8$!51JSO,\(7/-D!J]]]#8&''@ C.<)D09$$9JCI+6
MI?T+=S-%T9Q=M&F)CD*),8WQJ_DNPUM^VIKB'=T?QYVJHW5='1J)R9)M]:WA
M+>F6+VSOLYMY^S3IEFM>+ GF7DR W-04H#>?T0D57:K;'K_@XMRKW)-@*$S_
M?@=>.FR7.=3O.B!YHW;*=6GU<_.415/8R)OBYO&D!E1"M>'QO^@S\AUW'_TS
M(+ME:"TLEHA/3 D,\_T86'*"Y"/;4:&Z\?'5Z*5A_+I=W/R]JA>OW,Z1SCHU
M=M3>YA:?,3VC.V@QENH5.M*$+R$&7*CC$B%S-7P0B'QO71ZN=,!0C^8>,I_1
MI73(\!:0;\58:"P&HMJ-94<LIE/(A^ Q.GE'(QD(O%6FP?&R)7UHO$Z4^]GI
M >^RY1R7'_E1;W&]&%&(("(_I>;-8%*4:@E=HGNT[_%!/J+H0E4&IG.KR>T*
M<:8^R9$F5G6*](_ZG_Y7KI\]W,=*VD/XBN&(6[7)3<?,\A0;N6^QC!$9(2L@
M-@1GPCPO<GX6BJ$3JZ6(L3:QG;H4:!U3W%RWWCA;BDYU-Z.K1UU\=\2?#[I;
ME[L.!BYZ+,XA"]6 DWN3^*!]+;/$W6>!)X8A6G]K6-'A$/2*'[:/Y@H]@BW^
MDJ:E(]R[0A"NK-@%XZ:%7=(XE0)]V=4S;!8+F.W!>".5DCY<4*#(I/7R&ET3
MCV=TV:2>N2KE8WSSJ(%G3$6?2?M(0']*A44^JQ:YJ#)>33H[6CW8:8L[$!;]
MZF'_*^70*=M6L_6?['%2]E"0R1LVF'T$U6[!VQ4S)1 6 AZ30/C0Z]$ZJ%V^
MNHHG1WHZ W9UY%F1?A24^HN4J TM,'K2.![W"JF+']DW'<ON&#8G%DY4ZO8?
MYPH3_B$#)V&K6XP>VOAJ"F-XWOIOQK@E([=K('5&[!GG"E-#INUL:Q-3,8TF
MP,JFR?;Q9RZ(9M?1.<8.W%@Q0-UU[#6CH"[I]0KU>1TU[K'M$DO_@!.OR?&K
MFPWZ8]5+EG?LAS*ZWYV'B*0[\PKN-^S+5VBPJLX^:_%7[FKTX[:W83K3*OLM
MS@9T&,\<LL<E8&V;8\ML#P2T7\3*LC];:;=^DVXDUF0/-3EZ2]IX_#'TOSI9
M_#_3BD3_Z_IJ@@P XX..B]CQ6FA\T.#6FN0?'1P3/NCO0.@.A\@'?2YLV=O*
M_E<EV-K_7OW\'QQ%5#NL13V*!@54P]?V2XV_//5[<O/3%OL2=\,_]S35C/..
M M8_H,J[AW/2*3:\ST,'5_\)5![&8CX\N2>FLFTT-R ^"0RT\R29\<4>)KAD
MCLX;1,Z8R#HX*ZARZ7%3\;F(S';XJ4*W<(O\KZ2Z\.[%I]*G=7A.J#D:Y(G0
M%:",$<Y*&JHX\ 5YA=&W3LF0ME)(OIO1.;._@ 05G7'K7E:6<9E%ZS3C]^7M
M5ZYGZ\7^E2-O_D^N#;=-<)/.'->4>:75XVQC>%KIAU+_&4E&,N?L^"?&.SV'
MI@P*_&6+LI_(V(?3YM\PEX=#K<S!-P>,MD@<F=RWPK]^5+SAHM/NU7J YMQF
MLA;3]SZOR5O3]'+V+/-<#C%Q-]%_>3LO<-PN-MG"3U'QCRB%WG.O-UEI#AFO
M(EYEYX]..'".SJ WSK&C41]OQ$!0$S%9?)"UOC?J,4:"_#4?>94/JE;JPNQX
MCJ@S+>?'.8>WS0$:VPIH9B5DL3)'D#I>\S E*K#HP+B*5*T;_3&G'@4/06&7
M9C2"$B,?G(U^*^\E@ET;B"<8=VD\C:C0V0VM)?](:"Z:1*"OC84*CQ>J&X58
MC(1&-0:X:#>F3]H2\SZ&UT?<+3Q5<** *ITC6^3\9VZRR1[1E]T<LZP%0$L8
MFWNW\$2)S5\LYSAC0E+1ZAFV1HUATCC60@>F*U>S4'3FV;;= K$HNF95$VET
M,[2<DNU0CK7Z:>HVN%"^_N,#B6EF[KQ2AV:T"W*X(-H]SXSIAVP[\D%;UY V
MA*5YGK Z'Z0Z*8#K'\]0R[\ =YA>3#>&8>)NP#+C%G,DV%<Q5-UM^@'@$.1(
MFDK'+MI-10D]6X#0H7B,<;>MB*X$.!4JB_?@EF9.-#>><_5]7!$>)5*;5'''
M.> ;]P*W&N5S! 4/FB#3S5:W(2E?&7+(*QD=[4A7Z;@VY0#%(&'$+,5#IS[D
M35O%&Q%3 WR&2)>G]C7'JGL)R^:9 <PSD'!IIJE97O#ZP44G!7A%CO?L%[);
M9XNN%J9FIR0DJ8L."7&(4Q]AA9ZYBFK"&C^>\OMIKNW]M)VN^JVAQ<@"2?+G
M>F4J,,(7W^PSFTE]9?\U;Q0?N)JQB..)#/%!F5EL:S[H2P9CA0^"SIPBR JT
M:!SJZT^>+&JB"@#S00[UW7G</H'!A@K8\OPF^8NH#5!0*9JJQP=)ZQ 261Z*
M0ZD81IPK(&$YN-GZ9_35M5L"!<UX#GQ<OT5N:AXYFL=8KG-@NG97B1B;.TVE
M"_$.2 D^ASPTBP%TT6 I*<QE:+RCHCS@AT5>RKT&.2C3<VN64@P4=?%.QSI8
M,IE"[0,^IS+H*RF7'E"'F!83E/-NQ_^>5XP_!*9]1Q2DTF6]IAY%-NS[C$M%
MW(0OE%8=\=?=::*TV'J,O9I[5:J,T^L8*0S:E<S[)UW*KC7,[B6EL#"%^A$F
MD7NZSTCY6^-F^+]9@0R/!">@_J4"V9QN!;,4"$PT$O*[!-EUG+06=(LX%.HN
M83(4H[<4OE-"P"_G_G3]LM3DD>\59/3C3:G'@ BVH/B"FYN5PKEFPC:,?8$C
M1N3FM^WB7 #D/>GR&"DJ4H^Q_/T<(GD=FF+>,,H'#0>!"W]8Z<KCOZ_6FR.^
M/]/\UM]I\FE(UXEW&!CGB=#1787GF4') 7P0O%&[&24.Y'LP=\L]F/W#T2;?
M&NT\&KAUY)WWB,2\[JO<(1?ECY,?$'G1R=/:]\-J28>.60<>HL<<?7]_*L!1
M^Y.'Z/Y"AW=5]CD2LA[V:@Z="^(AM[][+O?GIQF:7"H=2],+[VW*M$_ON%MN
MTSLJ9U',&$PI4XP,MK!)4X9_#+;2DVX=XX-.LN2[9QDVX"\P&B^!=WR<[#_[
M9)LEUI^S%C2'4?2=E="AG*08MF=1E ZI,&%)WG\IMR1OVRR! Q3Z]K1D:6SK
M#O9RHGBS*%)0$FKN+8ID7%#&T6>@$Q<^!\P/MQU!2C*T=>%EB%HG8KY]8Z;\
M9(&!98)#D!B"[#2BR"3F1X2)KC8_KAK,%#"U7!1LBE>WA&($&F>)4(U); ]_
M_?C$R;9)2T ^H&BZ6KS;U7MMMJOBD>2G$TXC\OMU/S(_6IZR.CB+)U<O<B14
M6'>XJ6 (394AC7Z'Z*7'MH<\F)5L.S[CO*)X>K@"O#I') \CP3XX)S\/149K
M'"WHUI1?DQGG5*ZN?L&/+#R0Y3#LHHY85^MK@<SE)G[:>/#8L_/EI]+;;^+L
MJT@/$?Z*@^KU:PP@W,KZHXY_%_U,E,$PUOI F/()DL+ 69LBCP(-Y3W*:AO]
M.BKJJ 3;UOI4V)FVFL!_MB!?H*S()FX.'R3@P%C('I*W(#_&%5%BY*(MNP?N
M5VF;=<]HC!!:[.GY-A&[Q_>7=Q7Y[_3UQWJ5_^H*(O:=Z?;U)-:==7;E@R0%
M_F@%^P6!3'CQ/LX\X8->3XWO"(W/@5<'!)ZH,4SV067P08>,+T+6]*+FY5$)
M/+78+CE4O 1MMZ)"ODW>IP\L2\N!PYBDR(U3_IE2#3DB>UP>_T%W]=QP+&CG
M..?>8;2$.QITLQ50AVF-C"5/IHZ#BHQM8>"*B;YD>4<RJ^&C>92?W5.[(:NK
M#L/R3_&7ON%%H7DYTH_S%Y]^C?.^EMWF9_)AH\-JHV23N@;;7B8GK .:&9QB
M,_HV-P5S@+SE@O @-\IQ#+AUY+G46[PO&*)2BK$1>.VH"B4_0\H9<;\#=E I
M#DX''M 8X_&;L$.7/^!%DPJE(XJ;HK7H.[;44/^4<)&WQW4SPB(6 )_";VY&
MG4=2'P<E[Y1(E]@G4JX2JCKI8)<2E3VVA[]V#%;8>$CZ&_OLV=/K<VK*;E*7
M,M;E660==VD!?S70<#"CZ8V-7L1']0A-<,B6RK]1F?P+SOK$K8!XN[NR[+EX
M0UELS#"D]@=N7@3*B@86:6EZ'7FH[B"T7J'RB*%E!&.Q2\X>@WY'5 \2-R]W
M7\F-+/Y[J8YZ4[H&-H ZX=P5N'VH&M/$DP/.#-,(% ((>:FJM6'D'?*/.<(!
MX$RO3<N-M\UD(J,RWO.-J\>TV;[#/<%A(D^A^M=WFVND5J?]Y?@32T"U-P7#
MY19J\5?8=\Q]]I;A_?53=;.0?[A^"+C;VI*W8. 7.#QOE>=N_J?%B:@X(LEY
MXB8^ .0ISF!P+GI)Y'L%3_P(@YU)4#IJ*9O+UCBD(EF-6M.!WTXSN1KO9W,K
M595CH>4Q.E&_-Z6SY9ZJ+2Z!TEV;K7>@9?3X(<NKYQP6GM\F1#R8Z6TCOU!B
MF HDL@<(\&0_1-AU8<0YP7."R%HH52=0[P8&&1*(Q4XJ.*X%LF?Z1]SG"9>^
M=RO;33$%4EU3LTVD)S\<7).,;V1/)O,$8,=Q VR84=;D49X$TAJ(8EXS'R(X
M6HWJ0-$QVHS9-.*:G@U"?.D!>!VI4^;_>"R\(D##41@>K!'RXI3Y]?MZ#I!^
M*.=:/!_D*("?O)]\T/Q'LA-YK@!5M1M2I1(;<Q)PCE$W9WK,TV62B!F'+<N4
M=H.?> Z]&=PL"_VN80=5U&3&SIBK3[FY62*H\35K9]_G^-^-6-S!B-4J'J++
M#NCW7EC^DCJ4HR0<5Y2KT7S4-,WE8:>U_1F+-I7]IF>?JXV5J5]B]XNEVCWX
M^G')JZKL5D5"JFJC]2/\FM]'\X;BS%25T\/!EH'U0ST+.(Z">X6)$ 4U@:9T
MTTTPMYGDS@!_@ROGW]EUO?YN+%N=1YL[C\ZT=&0JB)F<;S_QOC[K9._^ANN8
MI5G@6 \:3(1\L2(9M%Y:K>!X,8OH,HF;S3G$O(FP*'E7T0. J97I)>Q32?(-
M$D387]^\N3YS63++,K,=YYJBME8A8'4^:(ZL)*O)"6([(RQIQIB0:&5<NRA:
M+KJ.$!#\:.'C9+>2F**2S+(H;D+STQ@SNJA#9.YD./(.L:TU1X?4D.YJ=,&J
M$+J$8XD#1B$,"98QM[!-:EG7;JEI',V3_[Z#3B).XLTU D-G98#&2D._^=_5
M#G=J38S0R8;7\-2;/NFR7S.E<Q#'LF<D6WZU$#H*C_26+R7V!=?VE!K)=S32
MF<%E4J./[IYU6?.O7XY/\)B\U&WOTI&F8\W%^3^L_=6!FXKV,9%TG.]I^+<4
MBM2\4NU8$8WK*C#$.!U18<1\UZS8IGS&&A]4!0STA,Q,(0C.&RTV%90P+EZW
M2*1U7J#*/<R"L4Z_/I=,ZW;WG9P6+]*K'<_E'!DEN8?0" E;5D$]'@I ;KD[
MZD$TOGM&HKZ.R."1OL)W*EH@$RQ68@Z3#[H_29'."OM6.AWE^6@]]_ZI7;_[
ML(+^;UCJY[=_Z(V@OIL25_[;3W]!!(DX?2?A23G'GFG%!R48PND#B7D* K D
M>S(STN^W-C"MJ[\AHLP3%MFV 5>/@)78QAL&:5J]_4F/E\9T4Q2_9\NV)+<.
ML)Z/AKD'S3NF;EG!>Q05@;_+IE$=1BR,',)V9F;\\E@+1M@WA\%]*GS=$L$'
MU5;04RR:-CX'ME8WA/?62M"RN;_:R1LW'A*X61%*O'(&CO:KGI,6 F$?\4)M
MG2ZU,9':1!?^GY;$_W\L.(#B76L"<^,%T,Y53R:;Q"B@*F,Y+!?.LH!D.>A0
M&/O $A^TXR@5D\RYR >Y"_U:)7&:Y[<YZ1=1O*X& M?";$E!E+>4+O""9-1.
M .8M^7_H"ON[^WG&%/H[>:SM_6?(2,\F[!OL+\S#1S&[1I"0$&;X? (&)_ F
M*JNYA _JJ!6X5T9[WJ?M&H3C>]0#!FF$:L8Y7C5PP%D@R_:;Y+7AZ4I5?9#\
MLFL2TQ&/_L)15SYRE/#^]1AQ8_6E\!A]Q@(9^UT ,D]1]Q J5O5U&9U*HGP0
MT1 2'(P27$"G\X:6%HIVIL%^E!A$NO!+]]8_S]:NFD1B_T/W]?_)8*'>#2$B
M(7R0B"@WZW>)< J9=H8/B@=SB_B@ Y,#K8)'%>6)\4& M7'?[]<G6C"KZX E
MF8BB7UOD%JV1O\PV;R S"EL+6\AL5WO!GPYS!8EU_S@:4B4P$4<4'-51RS:J
MYRB3J61&3G0&3X) 6F7[<$[^[BJ;C%IE\_JX./9T89#V'\O_WTY'CJ\NL8T1
M65T,SE6FS'M,;"0?E%&QF+XLJ@"''324* ?:A%^4Y"RH)R(MH]\,5)@8.DH,
M&(8H+_^39:51WO[UL?$'$[A%J_\AVS<N%;(66N*AY=;YSQ696;%675LI@UM7
M@U,K^J34#?#%JV-]L/(?@G>]=_:_-0ID%O&$F_F@T[*EJ G7W[W*W\##?F$$
MM'P .,GPFE?BZ* YFNMQL(/&9U =EP3[I,(36P><%?]@X-(A52B2X+D?"9[;
M"]4!+5[&3*"HF(E('U;&%V1&G< BG+BX/K8R.9<+BIE&U5R'U)'?&ZP_%0=8
MT(2!$#I&!'@[VZ5&RV9&MNNA%QL>$_.O!J HIQ<,>J,:Z>(EM?YCPQ%VV0W7
MHR*04-[^7L%=S?\^R!8SR7%UB@&[<9R: 8&W[9.9/)W[?A!Q8E; 7'%BG(<!
MO%[_0DWF@UP850SX5#P3,.5Q;:GCQG;%1/+DUL'ZI(TIF82)2K.#T6[&$;!S
M\4B= [>K'^875[\,<!Y)URH >UKI:ZOC9!U3J2D9ZHO)N7\[[G<H@9L=7BKS
MG#?OMLV*M?#H+[?\N\UGW4)31SIG>W!R'?8'4@UP9U0._:#0T)0@$.=B]8AQ
M-WBU9<_<^B' >&C3CVDN\E=S'8-5@+L6PCIR/T\=<DEI==#RU,-5LSM1RZJ$
M3^6WRUP>E3D4+X]DORJ__0IW23O3VC;KT6-SY<>;Y@\RG)4EG]N:/\@T!U\G
M0IY  &4?3K$\RY,/JIX7:/H12">)FX)J-T-][23[$]@GC<%\T- Y6"&JAL Y
MO&W"?8GRY8/^0 I,*^'9J&$ CF,X%I;F<X/APSG3#!69<?\04>S?Y)"[%TLG
M - MX)3E'Z4]1FP7P&60="V0.9EVS%I1=!Q%A<QM<[1%WV.2R7L@M!."[;;D
M20?%ZJ#V"0*?%?=O;BLWB8L7S>*^X:9Q<8+8Z1>A%+6*H=8I!D&)/6-DA_ET
ME0\7"C5IJP-:W8:F0KN@H&K[&7DILPG]2]EN)O:K^%LXET!);UD]ZU<CA%XA
MM=.Y&;FT<Y)G+^;I^&V,E)VI%%N,:WQ>VBTV=C[8,1/N4-%< \F& GK-/"B$
M'L3-%TV#;,&1TH1= C.I1CHP9;JA@"HL@W-R?MKG]F>D$&.V*T81\*'UZ?_8
MB6J%=,3()@]<@8H!.1UCB("U._F=N34S0,WRC36]#P&Z^9XZ"]@@+-6=O"GS
M^W^UOX=^76,+<>XR';NZ@2V5+M<,<:3V:(Q"UYN,!.$YIP?'1UML:*(24+QY
M3,PQH&O]5!KG9)"/5![5N=3U0TD4^ERQCX ?GF:BVH\+\M6D3+<@S#>WB0$#
MUX$P9O*V1=T0Q]./WAQ@@1(29'VVC%7L3<88+JK4[S!LF2<_MKFFW]][I:6M
M;DAGTI(K/F"Y'TOU\+.S?!=]5%&;A@(2&][1G=J09*G,X?>>M7H)G>V>Y_R&
MGG_]/O[FP.=4VO[!L&S91XVJY*D1O/(_C"-=.5?1RN4]AY?[,PR5#'7,0]0N
MUA5@>_O*89\R#;WF!S@2%-Y^$_8EWH<8;2"MS-*3KNFR2".G:+5)<,R9X&Z,
MC#]U( UY+_1*"6 ;).)+/L2Y]D8@=KH,[:**H(_SP+&!F_DF+3DK+NFS5Y*]
M G[9"391AP]Z_A?"@/=AL7.6:^;2]E6@*.=FP9).P,*D(Q=OK *<O,TX_<+C
M/L.GO=6R*SP2D^Q]5K\=7H; =;;),.+:Y*H2EHH*U]E@R]'U+6'?XMJZEL&%
M!O>K A_\4L3;MTU#?9ED)9.!+6\FQ8DY3:K[F]XJW\X3#OK3!;CG6]=V.CM@
MGC?-E!0$".VV4_J!B?=J['R*$7X_MB2DRTYV[7[D9]>ODK1QD(P&,"H5W;(9
MX@NR.0?(H]5'\HXT>MY>&2JSR!$],-EY-?5-F)V$GKZ37\BUB=)^"9S,P=.G
M*U6$/"[*.5G<+C<K//=<DIJ26F#.T3*?*%6W\._?T5'9FNT1@;,DN,4<KTI>
M#UE1)R.^4(?)BU=!A^UODP5J;1H8VRF;K9:=CYON8U_WSF$.%^](5\/I1G96
M(YL#Y\%_()Z$_0I-<WZ@LZ\[O[PW(.1?NN$YD.<*84*0N_CUO8@4FFC7)9TT
M@QY]%K9H@%'4)9>358J8[##'^;HXE.CX@A\4U[>.$M6^-:-(EJ6^=>)+*O:,
MK7KJ%G3MCT?D2B6&C2AP4B\)XK^>R@-SW_ D.##&.MHP8-X)"0ZJ $[V4'4K
MA!*\LRB*8D,<Y8 R9Z#G<D"(757$ T-(L9G6BQF1MF2SS!_,L'T>RJ0F()<6
MSI&G,-NV.Q]3YJ$]D'@/>4:JGO2CZ?J.[RWN\S"Q9=V4DZW<M!J@EJ((&M:&
M)]%OK*UNF<,\DL<LT2WY9BVN.M5M"W.?>M"/#EQ4Z,8<I5<!]G'Q-R<3F$?T
M1]\8(AE,IQ>T"LFB(W2YT&5:U3#>5I(F2_>6.L_<K'9Z>;MXX[L%<LVFJ[OX
M[J@..&R@.7BPV\Y<EYHPO@V.TR=TB5*]>/O4F%F4O%5'8_5QXZ,3 -J"L;;&
MJ@@+>^<_LQ>X- _9A[2KS_FQO+'C7-+(*$GS+/.5.Y0EE,5*D^^@2F?X>06?
M*M428")J+MMX#S<MY@PRC*E'"9H\:?99:Q,L!IR&DQ-V"$G(\'DP>L>^/DT[
MP&(HJD!LBW  *.H82PJN1$3.WVXB*AYOUK5S\[59HB++\,NZ#I$9K-^#+\,I
MA+_(0D@EACJ-E_85:<2X_T0/O1JZ9O]V9'&$3B[\P78GC[O/I5/Y(!NF5D7I
M<EYWTP>_(.^P4O_P$F%U5\?T,4@[BHKBB7 _(V'T5G@WI%:T2U.%MI;3B,\?
M9C3W-%ECPVC1?\H/Z,._,F93M1U'=/+=]<?F>ZW E)V,!))N\HQ/6HN)Y.-G
M5[0?\D%R]\)@TM\NI@:"$Q@O%^#)GS;>]>[#V^'CRA)#YT:^Q0<B(CYX?K</
M3BMMZ!6[&O9&Z?Y7YL6#5W>R?>UPR86*J:IC6+OLLE)<O='SS(5,*_:'C0\F
MS9/K(E&\_?*" -'$(,7ZMZD 2D6(D)N.Y^JP!&0(,%[LI/[N@EN-SL(;YMV9
MJ8OU]0VORIZ)'92P,/VG('<%.J$^-[!*8(33@M&LJ\.<(Y@#+=Z5_AZGW%'O
M>7ID(*L(D>],"J:UFOY0DE_V.,4,Z"[/"^A&GTYE/5O)<O9SK--C5;NZ3.=_
M0RV@!! 1&PF!7UIW@!SF>' +B*T&O<](8VD5'(OQH.OO1=6D.]@T#/J8[]17
M<[61[+<@J02W9Y BR!=UE@7J"X$5.12S?PI!,SX.:Z=KHKI<,(F>GZ%H#0%1
M)A:.F1-7CNILN=_W\L-AWSUFSDQYO!M?55Q[M\D\/^'*&9<RU-0HL\71M;R[
MG))?E.OU+K=0EI.3TYPMB-RV"S)F5-O2LD<A5M"97 W%&K2#:,'80H2[AL)M
M97_\1,A//7F31QWBM=:.0U3UMHS59<[O:<U5J':3U]RTMJ,]C'$:)V0ZYK.2
MM.&%\OKX,)$T10QCGA(N$O*VCWE@P5FR!U5)B<Q]B+A@9I(WLB(7W5U!\+$:
MH@]R3':8L&<0QJT!X-2/ C:"X\@([WK1IN_!41UMN<!@#=.F?^2J4$H-(W#^
M>8]?T@7Y-->23/)FUC^M#&W^\@/IB)^<?5>S7.5Q.<^O/@.:.;9$X(7$>5PY
MN+W?,<E?/\)>R<_E+<M^Y2K6/WB!,E0!%;6N\!O,MKS4?38XST(*$JY6X#3[
MKD7'),ZQ0MT$?H0DO:8BHW>D3'6FK[EBK$RIOX<C4<0*!':Q+W/,1V,T>5]F
MB; .V)](/<9 TKWF4>1QIM(\. ZIQI29UTOQV=#!-Q!.,)42-_D@L4G$>?.@
MH@:F64H_V/!:A,XXFF,4Q2W)8]72""L_KW.K('<US_3<8,PF\$'^D E7JV'M
M22O(]<^A1R7F@SH,#.2%Y2]Z5@UMIIVTK&)J/V;5Y=0QV[UQ2ZQ;9@</]XBT
MMIQ)3H0<A- 5P#LM&,ZX *T5[4]!&($*ZMI6P6PO<\V&OP\RK[$A&A+F^^YX
MW\"ATG+W'TS/SU:.BAC3/4Z5O:PZBPNVACRYB)=5L-9+/T?TO86N;9]3O=>8
M,?JPVO],H%C.W@V\??>6_X>?%I^?!F.M7YW\>F=IX>+%BW:]2XWF,V'*B=@^
MO2%6V5L+EJ5U78" RW$6JF_)PL:)G ;F;/LZ<+J'(Z7_,?KNL#-#KS-#%HB9
M^7D3JL#18TH CO2Q6$_<K-,UM9&UFPY-);6OKZAWP8O,YX-$@%C*X[]79!P]
MY*2WY? >O9P<WCAL]QP7#?$W1\HR4//^B)G%]K/ M>X922"%9K#B?J'30V%T
M/<!S=$T3_/5SF % S!#WW3[7$[7+958(8]$\I'--A##)ZY59$>T6!?12Z%WD
MQ!+,G%X/.($Z&_]C(8]N!*%C,<D<6?SWX ]&'U*LTK<[J)!.5]1A+*F!N,LN
M3^1/5W1F6+0QI/;4>&$]6T.0',E%%,6SGUN\V/8<*&,@5;MU+T_$I$V:<XXT
MIJ4M*@[UCLG5K6L[R<0E;:X)V:)$IR;?5ZWH*^;3Y-77KAI\J%AK,<,IXPI0
MW/V47[/"#)*"220R.*5OPYGF Q6AO'@E8O$B+TSY?M%^*[!/U.V2I>X$B?TJ
M]OWO\FQ>_KSXROB"K&JW<ZCJ7<GAPC-2)]X.+0]%;OHU6ON/9=R.R8F9<N&U
M,D_R]L.8L&[]RGP_3[J2#*_?0YI9UXCUV^"#7OO54[-S$PRM*JD3YL$A!D8E
MKP8B<]I_5/KD'!%S<$TJN(GYW=X#DQAJ!&:1@)=OEUU(\0EX>M"3R#X"^@%8
MZVU=PSA8>T 6N.! KA[*O ^MGZ4NZ=8W$7.DNRT'5ELAMB,.>VN&@W#UO"9#
M+YK2(4  \L9J#)64S7^V"/L1DY2\Q3BD39&53E^+?CT::5[B[DN=>:G9]9PU
M_LP,5>(Q1?V@@^UK_62IAE!)MC>7^64%O.2#]C(YD42F1S%&R%@7>8(I]&1F
MP2\T)2,I$^AMYZF3B%GWGCG[.Q1*,WS20U/8^9<W7*S*76:6!OTA/E97M-/
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M :C7@#YX/V"Z,=-QY,'U&04_+_C$MX:1=;+9?.'Q-X?V%+T8+-IZ0$D]^S)
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M4-2Z1;NG8$F.)[>0&"U+GE_@@RZ/QIQ"9-FE+-PR3%.Q 4)HEJX9SQNY"Z2
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MC%UR6N/]^=-O63V>YZ1J5G4.A/XJ'V8I,!>?UBO+7O78+'Z[=CHG;38L]+Y
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M7,6S^3&O[6-B& ,O=TO#1-<<F!\$]0;X0Z-5ZGF9,/BS,> ?],\LW-?N1W=
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M-GCRX76.\TAGE'EQ3L/*E8-1CGFZP&= LL'MGQY,C*$LC;]B85D&SI>L>3+
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MI0[* "@#S,&MM_<4J0<_$P:(]3DM5V/8;=-K2LMCNC11:_D;7Z*2NPQH6^J
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M?L6V-J6;&16Z?'?B4*J-D?23OO[54T+CYST7&ST(_X>]]XYJ:OO^1?,]>D1
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M.ENQO@XQ(58,(EM2B$0"TZVP1WF@#E-=[%/R<ERP?ZB\_"9&VFI!+;BE2H8
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M-/;,F<7! "\]A;#-CH:\' YMS"1@,EYS 0^H"73@$L'U!NOAC('YWH](:5=
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M O%H22"$UA9V<U)/&*&E_QG!<>LR9%:4VRC@2GR;O2K<(]/^'*O4!;2J3O%
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M7HD :M&,N<J,KU+&#/):JFO#W LMDO^@AN:VJAM?E?KX2*B#AM%^L46Q+&=
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M>HTKI3JV@@=CDXGSTS!RJ<UD\7-JZ<8!%@S52'JW?5C/1A[2A8Q]//ZRXFG
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M0R)QP#O ,+M'*J]8P77[1EKBZI6<8-K88MBC=(^MMV$K$14\4)BNT](66UR
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M.H2R^$RB_9[94HZZ?\GFV%>/7%9%KNA1U//.O>+!KM!)B.3;[BJRF<1V5==
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MHK1/^YME:#,NA$H<-E<B^.=?&"W'R[^/*#%K))!"B_!F-ZKQFCV.WGTN&Y2
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MQ\@$(,>515L!RZRQ/PY$DD#+H)/P&&.:.+(3G+9XF8W)8ZOV4RLYS6NEQQU
M#(GTKINR/T[!JI2HE*GC-))@3E.Z>OFK_;.>QE#9=*QX@C%/D<">7SX0&72:
M&UX^\H2-'5 YSZ8][)%'<2D8:<"',2:_N+ 9ZS&S9ZF8Z\R6NW^'9U6MVY')
M+W@43NN;S8\/7ZE(X-^O @H<)^M5FR:L<2&XFT73%=FL>4E/W<$5U$=]N=0
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MQ>U#]A<&QB12!P<7/[W8H5]I#JWJ&7$O,74T*O0?O5&<]KU1(<G;);+!Q>U
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MS>58GFR+0+2=;3?D"VRR(+V%VZ^)<^44:/?[5JP4X+-DE=TO<0S:4%I6/8R
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MH21)AN>(3OQ1/P<BX;"L18NB7EA3ROUP2YF0V.87K+Q&W)(]./U 1)'4/]F
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MOX<SMW8[$Q+T$+;3!B6QCG^T3T<[^#ATO&J=0-I,&3A<8N4NDWERN<M.KQ&
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M^(2Q] %0C&RQ)8'R!(%_E;U$TTK'0E\@:4-5M8ALC=R6D47?BTF-N%!$ Z+
M20\5!7G9Q7[E]RC$W\12@NJ#/WRCXJC:*9*<P[G>D:Z_M)RPC87E]@"\._./
M&M?N&Q?D$;(5UK)$:&B!WE64OQ-$7IM5R7S>RCRJ7"[F7EWHZ570V5H4GCL?
M[Z-)2Z]?I+"1):7F;; U4EE#CUXM40@*B;/6$F?=Q;N3@%G4WPUG(I32U$?U
M,D_5E]:0O\Y9A4X:_(<&]%/XY5!NJ1#4IB$$U2ZQ'U)\*0S1Y']VHGDML%W
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M'&@J8Z)WX85>=E+DC#=S5%/PP.)4_#"L87OM'<\@%"H1I7,1T@MM'$Z/Q!U
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MO4[B["ONR?DTX[B__%6 7.'4O! $F.!=2@8$XF;,@=!\S6POP(;C[-1Z5J?
M]OA8Y*Z/[V]UZ0U%Q?JS$K8-+^XO7'M@;:>^B]E]*5J:9CK;"0H6]%F8 UX\
M R#$M: '(MNI  R_]37H&A;GZ^8PI9+8RSC%T+W=,@&8NBU#,_2^F;J",H3;
MLO'=N=]R^L(1!B\L7WX.6&3/SB"NQ9OCNCIAWY_ ]HJ"S5F@7@BJ'/"REA6S
M!+_EWWK-U\YD(LYVS<N%!M5_(@?<OEUU'6'%BLL_H\T<1QVI<+3/0Z<7VU4&
M: ^Y?3@MY4W#O#OUB%PUEJCN:!^.)7\<C9Z*%7EX79R-$'3@D* 'KQ2)IZF[
M[C9@C9@=R#[H?FP4$[)_:<YX:C/@;.PXX,?"B\-;2B339WK3;I' KX @V-@J
M&1I5BJGCK=)N=QX;)Y*-(E$&LE=0T=-"4# >N' A>-00OT<P ]GGUB/M_\=(
MU' Z72RH8:9J26;I-'PPFD5)+/GCJ>&,Z.]+6R?'XULRV>/5DHF";W&/!02(
M"S6<B=/QV'4"OOTJ6MXM@MZ"S:BP3%;QG)GN0'-V,IYQA/Q;%B?%IB6[5Z!6
M^*-O3HI-RBHW)249IBKVWKN5]W+)0J?9!QV)1,LC3+853$:Z7EH)TKC$!;I
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MS$MJQ4$ELV<44YA5_7?[[NC=AY,-=['U=IW><VOOWM,IS3W8JYR;)7L!-.=
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MU+5$&^^(0$T$\.QK!H"!UFH'"S(]T$N7@-[\N07+@LH(C  ;=P 7L]O(H*@
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M%KI\52"G8L5B+V?R:>VB;]2J\;G0^..\HU,"N?%UE)&9CR8JEJJF-[)A6/[
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MG<3R&HK+WG$G9'NIU*^1+7DT,IAE-S)+MOH?WO:8U390!XG-Y_NXGJ8PO;6
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MI3."/@RW)XXJ9VY 7)2;6[IX0=C%/.KI.D86H!:^N4\3*&/'%-/GM9GR78Q
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M9%Y1.J&KL0,18\C[ER?--RXM9MKC*#^+QWS"RAX*(.'))2<^<V#817=[V*%
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M;C*U.<5W,10WGH\/*"'T!MG0@!QMQ<@L9:N0/7YC0=(X*':64RL;G-YH+,&
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MH,!+@HY*0(B2.3'NH38-E4640*#;IVNM,'VJ>=&#3)FO!/\JG _G*24OX:"
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MG^G7KYXH=Y(U2=\= )XQEO^*I&>SC@T>B.\F(MS?("%0:5UF2TK5X*J7*S+
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M6@M;F5J[/'^]1'G;/-NYD-TK=?M&])^!H '0)#/T34ZG>%E18$=HR<)>:^5
M'D+ED(=?>K20#X7F%P9Y24>T&\@^-8D(I@Y'BXP1,7TM,9JLG)6HK1$%ZWR*
M^RGM1ZQHJOH9MRUGB;MKEE&>YLZMW5-O&BRC]0WP;YN:6^)V:E2^T.';06#W
M+:FSCU6.):_F&G4+";L+NF<[K27AR_5L\IT\QM>:&MN?FS_9F*R5<_LWX?Z2
ML>N 9L;,Z(259^ASH#R2W/^K2P7@0'N,/4)H!A_Q&7WX3-]E"QMP3Z>1P>?]
MO10_'?$]UL.&$02WI!\3RI=L&''4'?2)EMKRY9ZJC;T13 !2;%=K@57:T9H(
MNH$7,*B5J; _L=3,_ 82C:FV]2JGU"MD!Q<(KT^DY]BEC6J>+ P8T6)(0+#2
MD5H/W\+O[;QM>S1372-6CT+&\P@;W3IGKX,Y=<07Z\$= K1&K[VBJ*>72,Q^
MMTF.-(V%2 #%8F2@3UD^@_PF632A<VG57=Q7.#BT3T*B51(0,+G0YR4]C0M]
M)4R>@-UX@L-;\LBR*B<'N9(&?DO:3J(&ZE+\$@S5J8 4'F_N!$:=+">K2[']
M&1+%E"("/^G]9*=;5E(S0 @>U<,53'*.!:FNO9V%=6HBZ_U;=20*"B70E9Z<
MFBC<C+[* J;O%>=&UZI#4WIOB0=9&>F0>+T"HFQ'T)::]Q@O-\ K:V2CY964
M[E2#C,/CB1:XEE E_5:"06S7 6C#3W["*D0MG05;0;%%H4P%3K'QS0" 7/=9
MQ+FW=/-^3VMU$9-@BB5,FFTQC?5.ZF\%0&;)DPAU"N!" %=XO*P3T7\VTBSN
M86%@D5%B_HVZ1U'/#U 46"\I"7BA4Q*+,&!A5W#G$'_0S9,#'S=/=^I2,M06
M'">#1/SE6_<HF>0+VWB!T!*SM],W'K5,?9_[L 39?SZK,7AKO]E9$#%XL_^A
M$H7AP@Y2$#?3HIJ+@L6]6J[D0G25;3%N:)!#/&2HU<H,=*>%DO-D0JOZKMIY
MC/7YG* 'Z5>E6O:#E*XM;,[/5K, U"R6K@SW]!YE[+S'EOXYW*$)0F/2S\.4
MK'Z,?9\^4TH^O+INI;8%1:4 A6(NPZL7'E7#TL9$/7$Y,(' 0Q,/&^ \J8'$
M%JEEZG"2PWZR ^EI[]OK\0QE%]PVK?LZ^_ZL3'_WS?'O6(L3+>T3;(/&,0OZ
M;B*E<'');7'333*IF8.T;9A2;QYQ=B%,K%HJ$LRJ</:2_9U6F;V6Q]+&-&^8
M201_J3:KO%[NZ(TFNX&J9](:US)<K2PCKG_TCNVU+ZP^:Z0X8E"MJ!ZVGSJO
MWI3JM-%A6$1%OB?$DYJ3B.#SB$NLA16L[N 1W[G.!RW(!6/9J7IM%>$;[=%?
M=)F2^?KU:5&5T$(=M&\$3(Q96)E1#3G(:#IY?ND*Z J!TM)TQ'=R,>9]9 DA
MI,X53F2^I.\4&TWI"L/MS5A)*[>_"^B5N>1M!]8C[M QG@P3MT6II;4H@HBG
M5ZV-8FOG/\=5A+Z?,/7.#Y:+RK&OME09"6Y3UGZTKJ\%!=F&!"A-,>W6*FOT
M>C7"KHKK2@VH62M=J?5^^F,^K&JR^EH=6K$>"@OR]8.VHFFUD_:K@#EGYA4.
M+S4\W#WKR8(R(UF>%7!]3V]5_E1#]S#M]63#",I/K"J-##(TI0H&12T%4(9'
M$ZWNDH@MSA)RHA/:,C2+]3N?M'*J/*^5I##6F2$LP*$-7&*?W#J(2^R^R$/3
MAZ27D(-%W?/@C9R"1)-H\JXPQ%D:F6*H7IUS_'X86'#SP*G"6S HJ#/E6@:G
M)I5<XO/2<0#I/S7X<#V+F8J;]4VI8P14/"FW?7B14_/:SN*6O;62O$2V66J>
MO,V<\E,'&NQQJ9QEF$?+:M-F'1+8?8V7TX* ?QF%.+5-A8Y)Q4S*G6LJDO.*
M(Q.28XZU3P0:/X9]C^CTI&/ZW:B/;IHPL8_75TVOGO-$;>'F-+FG]@[%8@:.
M^$2T<.G LYT:U PD)2GIX50IO36]$TG%FKMTT">@D3H=Y*70C4+C)/[$3G6M
M]H$XBL#(]<UH\-UIA19\IL3DM<D=W^ZV+L[]LJYT9ZE@,UU!>_[4L1#ESP'-
MJV98I8>/\P+LLVYL3.=&^#F)9E#MM.451]5L"[-S<WJE+LK>KB8*6FA:6:B_
M,'95"*443[E!M":LC!Q?VIJ*[_FY_LSX7PH(J;("7,%FSC^A:3\ZIPQAA]:L
MLD73:WX6LS&7$4:M;_W^Y6MJ+I%FF9.7'EB>/CX@:>=R6F$TT?9OX)M(E8V;
MG=[]4A<-G[[TV+^%3L*(GPG-O_[,X4UVNC=HY(-#J5AVO%+;@ #Y_FH)_VF[
MH!"B7>Y"!R(E1&=G$>M[_:"ER&^$=/R([Q%R[HB/&<62##G41:C3Q:2=>S@6
MPWW/W783?GB"/1F7&=*L@?'M3E>==]70@_SR:B]@LNIJOLQGNTT9%?A%UXV6
M?(F;"_/$G[X,%:[@S*^^2ZS]OE9]'NJN8&W08S^LGUT694$9DJ;OZ%.W7I:"
M?%L HIVB# 5PW&CA[:",SDAZ8ZQ[=6E32TMCYL3$['YDZEI/\'5DP4,-O3H)
MV,L'?3[7-Q]NFHO:V8@[MBQYW"W*A3IV/*^VM8 6@D!*%C_L!1)KI>ZBS]AE
M:/LK''\G46@V$YR9NN%JH((5&MW]O,<][7<H$]/GE@K'D/F)"UU@BMUGY&-4
M&D#XAP_EB$^.")5_/:,;9UZ,#=T]![?PM)O?9,H^1)Y@A1!S IBS39"#M,6-
M%_.N[M'O&#+DP;^YZG! 'T$P1@%N<X\Q^#?;NW*H@E70NWRE(>W!1)B[9/;M
M<;]8VY<[JFJEK81)''99AJ9IAV^>:MXJ<C^TA+[L<%-)DWRUIL=V&Z1J?*ZS
MUM:ST*N9WK3NE-4=L9F;>K9663WL%G!.N8@E9G79+$\Q2C^4?"82<ZI?L>/K
M#M8O!KO4W0K\O=.;%\K(R!Z@H176:[-0K>O0E&W8T-[5V1Y'+!'BH6C+)4FK
MV#53>.B"$AM)IPX:7\X>MG'4<!VJVIH]2!O8ANWNHD]?B<G@#H+I-K"Y**;$
M6X8A@(\M&>Z-A7]P09*O,5"I81"$%576W*99F>DFLJ5K:\(4_'WF:5"!Q:1J
M':T>9K&\*1 1)MC\B8,WC=3;4:(8#I^BZ['7;_9[ Y2+SWQ.^2!^^Z(O(+ F
M[)VOU%"4LP%(">'VRKZ'#+&9MR^U$)V92+<+V!PKJ AJW@_LV(GQBYD'TT&P
MS_O,KPPM+V-6+?F(3P)N3@G8:-$W6N]#)>COH,A98E#]QR\92#]W5BS)]5.G
M#3DPDO)A5+-B?G.^-7'G1T>T%!%-K)8O*:HPQ80 &PELX2*F-"<7T"^Y#*!;
M$Q@^?5XW/FG#SH#A&&HBIHPUZ/B6/MHA-(?/ -QI&$?<)MN<]4]ZT#*"'FC%
ML&( HC(7U&Z(NEO*#"] LZ8CE:_V==XYVWW;03.]]S;B8>G%&\':XGJ3:=9:
M95.Y5) 6%@2R=U=T@9U.#(MN*@5-![;JGGB^_"W2=?APAO#JF^1VS^$)[A"P
MH9B4IBTTU[JR4T1?MV=T=1?[40)=.RVI61>@DDQ]AP+1N8U/F\M !C 5KZIN
M)2FI'A*"@4@ZZ>CNV[IYD!86QWQ\Y0GBA_>0/1I'?-Z$^0[*,;8]ZR==;7;0
M"UCPY]MQ#.,:3X359(&B8EW+A,#OA] .V#'X.E$_FO1YQ59,U&/>TC!X]7C;
M8_Y=997"VS/!9Y_L2:W-O0XY\R\S3(,Q2,G706M+]=N7*#DZKIZ0NFO86$4=
M/E7KIJ02JJ@?D%,.FK#>+,+P6QEY3MV.L.\(V@B+'K6;?-\MV$C7;B7J(33*
M@,0%FS,F*RZ=%\(Q[F!6(%OFY+_= )NS'ANZC,5YKZ\999<F*B=Q5TKFU][C
M\7W/^G:PK)1?" ;X"\'P5+_(*KI/X)UIW:J][1!$!_[#O0P/L#E]UVT'6GVY
M!2;#!C(PJ6]:7\B[ ^4-[20$[E]V!S>-7FO+V2],G50=:WI=$E;C^ZI$\\0-
MJY*KGV>R'2M>%^:Y= R$I.6^\[NV+@=QK?>+J$TDSMHZ5DU6E=+W3+U4K*[L
M@^8\%?Q\0V-"-@ET$)*E,$"@1[T'_/Z#-#=,/$CZVU@F0/)@+$F$U%=RF[Z;
MJC ;!G>3]7-C2&8:RE.00BQ"OV1[32.GQ@CI-G7CJF6@_O*'#Q-C]R<"ZV*H
MK&#Z^OLCOE,(?C(P$2B(T*YD =_'\(_?0!CP>"]$XS_Y^DXYF+XKL2<BOA1N
M[E!,NBF'MH2V]BF\P49]F*S%S@YW<VW-:R9UK?_QJWR=0G3Z1XW/[;98>V%I
ME]>.D=_+D^M6E?%4:S3HKG; ![LP9<7JD:%WNL\]%"<J=ZWS](Q=>NGQ#Q<?
M9J>[@W2E*K*=&UN2UE"TVB.^X\6<?X_X@DC"<ZQ=RF@*5>@,&]0\\:19DI5!
M;^W3,99AZ*#+(;-FE-YA-_S,=Z 8W-DU2N]+V]N6*;RZH,?6>4C!,9LT6TNH
MK.H-P*$@+TDJ'?'YXCX?Z^M69 SVM+"R*&!95A,Q<&7KB.\"PHIA]@J[.5,B
MCG)NF(4U&^D,$^5DZ.%)@;0P66?S3_6X(/E/.]H2^G(E_WKUR(#E=S>LQ.>X
M#7XX5>Y@1/WMU<PSJ*GBB';C(6UYT/7%/#$*UO27W\TU4S?;D% :)P,8&'5H
M[3CR'#NR4$@*F-T#&G*O('N4"'\)I0$D?P"R@.>!?AGJ?4"Q'T@15U:',T.L
MQ(!5C7$-6+[<T)[X3=;$@5[_@HH%]APDO3+J-&/.[/U1.&R78M52'ACV9%<T
M)M9SW@T\O_@9O."^_'EY8002X1=^-ERG]7F!1K.NQ*S.G@K1J)/>T:]UJWSP
M1M!_-C_TR8@YGU/0^*CQEC@YX-/PLNTO\O;;?_LHT-E$B>(W725RVG[:=R4P
M)X9 9CKQXECQP,L6KR_^*J@,VGL:_W#MQXR5_,<?D1U=X!!&$O6(CWW>G><E
MC/6^?>Y-/!V3U7T*VCY:;=Q0C_IG^<9DIU'99FNKU=-]&4,%*D"0M=OK)8<O
M!$W8^ZQPA(CYP4.!HB;''[N3\(-T4>XI>9[Z#UGB5%F%05$6C"(Y4 R^DZ\R
M(CU,A:4V9PG#@R8=6[LLAP/MMGJ71>FX6 00-QR4PM2:1%AAMMR.Y]/6/?SW
M H2)T9(T<?%M9/U%N[<$.RYIQ!@[M/W.N-6Y:&Y^>6PA)"K(&AQ>,/^L*BI_
M]1-Q4\\8"?D18+C?]5,<U_4S<#AJ*\KK8$?\)ZV*9SS*R+]4W:GH09I\%7?T
MP'1]P'(L&45O43>TT<W@*A;K[%).SR0EHQFRI%C^3/Z_Z_W>S=Z9QCW!T/L*
M/7^P<SR\7,:N[5T WO7'R9Q^Z4,_5_N>&@Q7\"HJ]R1K:+\=Q2O4HAW'7\M:
M!.Z>7E:OT2U6#HN(1NLYK"+&U^/]AM48:]9C(P%^F_..B>_0 9'7:_GGFT=\
M;+HF\#(P'7_C2>\J=TM(!']QX#7=\S]G]D" HN,-5G(TQOU,\:3WA-^.^%;R
M@&^!VR,,<R)!VO@TXEA:#TK44$$"+Y2$L%+H(Z0;*T:K&IJ4;AI+SYR5=D[O
MOL1*NAL!"U4%VTVF[VUDCYV5S)&!7,Y-X?_J*$;_F>D=7YY"]-;X_%$-<$'(
M+[TTJ=^YW%S<)O_IE[X)C%YOYVUEZXMX'[UOH\'XBDE[M,6S>(SUZU6KY=>8
M4Q\>A%O3 W4E0XLGK3>,DU7&8E002JP(!I&\FVHLQG:B=R5E&,NQ)GJ-=/NX
M%Z8J.A/'')L2ORT\^$<NVGAME#OO#CTTL!R&%JET0&NAM?Y^L?ZK&2Z1XN(C
MUF@+[<M.N>L66*4!M'[NJJ(#QD[$+IZLAU>T%K&PS77+?91CI>4.JBRTTIJT
M\M3Z#L&46_E/+K)/,)!LF5]WE+@,]61M63\SACKM,OW0NJNM$ H[#3>AJ,?A
M$$">WTQ\R"\,&\N*N0 G]=LM+%2D! H$+%^?5IN7>@A->[5S=G+XP/WP&@\%
M\4*-S><LZZD5#HI[P<U?FDN ,6U$X(<>A"Z&>9]@S-A("^I09[?OH*]5TBTF
M^7%#PSND("O&2(:8#7;MJ1ZNZ*Y>\QIB!HK3J&V8Y"9#Y1Z?O3JB>,*X18*'
ME?F9URVKS"&MK;E^4)2? 2B$[?;Z.QWN9L_,_6H7?\17>-/9F0M>/>)K?1*!
M&@#&H<X>\?D+)<:HL@P8:;U.<K=9@=2B4UJ[8G"P+>I!<^M4($U;P,AMX/YN
M<]$(T&D2]GW)W>;M=&B7O06A8>I[E_7 V(/)756<:NDKH-@VSY86COA8"C1<
MZI79=88D3;9JPW;)B,BZLD?1C1?MW;OWJ?GN!_<N(!F=E'&B+JB7+ >0[(]\
M;.K<$?6,#MSM%\]W[;N]9F6!/XO3&ECQGRTP<G.)G$BX;=5_9\IV^FYMNH^D
MTQGMBS['5_T'IIT%DNJIRE.0J=S0M%Q[B!>SFP9V-\!Z%3:]3.N)$<WJ:6 ;
MP,YM2,:<R"*>7FFAEZ!]SU6_6619A9:6HLZ1-N:SEQ8V]>_-Z^D'3N<=>! C
M'D_<"6VZEGV2;<488\O@>4K_QD!F7&-X_8N2X5Z$V(/G22#Z$=][DG#S.T,)
M.ZDG=IN]NHS!.#:4J@(5M("Z%W54T1#>QV<F UH_;8AN/+^YH1/IMS,B?B$H
MZO67/:QAD^; 7^ADD#-3'",U VE!VPFV60<'>>#E)?5"K,Q ULYA3Z=4JFIX
M1UIE19059<XKM%M_V# P4,'X[%&YLN##$T-T?BO.*[5N/O]9X*E07G:"((71
MXQ0&,#,T.MR5]4^%OWY28J"A#PX^25R^/L[VKMVZ>F\:;V6(G6F9?^9&LH+"
MO$_4]!P'6W/'2$VM/:0Y*+GR%1VY8AYWQ$<^P0HKWY3NKL7 P[DB0F(LU/;^
M >U[87XMD$E(#R.<WVJ*KF%"KG_#3*TF"BY[-C_MD]"@.3CII2]H]T^4 ,1?
M^3"TE!_*J86J4#7$_<?$KTWV6>199%=N-<^'>41LSZ\UO26;9>B@SSB0Y>5,
M%7LULF-G7VCEK+;;Y#,))M]JF;_FZ^IP^Y$M29EJQHKPO3L,''$LI;"LMT2>
MEYB/^(0A)=)3;$^F"XW<A.IKMTGN-* *G28%.,W,K$UM_0M_/NG5A<\+_&%E
MS360E0_EC,WY_)H )Q0S]+S[4D$/\ER8D!RKME].AL$?%T8 (#RFJ0QD:B6]
M(#4T_!/"E,S15Y$%_D'')06&8:^OVTW^<-\]R_(SG\&K&CA/-1=Q[-;O%ZJ<
M EK[UP_V+=ZE"W]8#GEYQ.?7JX&Y>*O?\8$#-<C-V<X^U/M1J>G01*JM;:PM
MR'SZYO+X#%.LJS8\Y$O&SG[^S%JT+W2WOHXUR^01H]B8F/^ &RK?45 B,2.$
M4U=8(?7P28N&3VQ0%4J&#6*D'R3F83R'D!!?*<9^.L)>HEAD^;[?RXT7<T8+
M@WP=$3/S2P\/</TQBI\0PF2D"'RRWRW=#9AH>/D-5$Z1(8?5"A<U07_5/UD<
M4@N53O\TWV\TU>"RP2R0O&4>>'SVW OQ1*5KRAD$+^U#$X0@O8"F2K>G -\C
M93>]%"<,+S. Q":6'WBJ4[)VL!1>,C$00=MQ\U2P*QFV:\H$Z\QKE2S83FJK
MJCQHAF88.$[BOF]UU(+:,*FU+ZG5SB.,MH_F^-J[4IV^ 7D:+_%):?$*\LI[
MN9L?\L0XN?(&40VQD,"R6+350(*>V0=K,4KNY8\[$\UVH-M!$YMSW.>$QJP>
MC@*3\E_'RABRHGD,ZW=(R3FZ9#\R8Y9[8]90@'S<4_<>/;PW4--^RC"<JBIZ
MUS-HWRG."C_1*8C>; _*@(6%5-\M0'I/UF'5ERV-=)#?<;@/I,\%W%.<0Z68
M'I)H&#"-= 9OD[JLR9@^XDOX87-J/@ E_N.(CQ_^CR$0#=4M-%HNUTW"=FJO
M /A-,0&M N7HN( ^&X06UL1EHJ]WV/Y= L&A=IMM0JE3$'TL=6HULV/XUJ)(
MJ<F6<&[ ARY7A>2JJ?7;VLJA]*F?%3^_;%C8P5ZYQZGT3/7:5=/>16/=7D^L
M0M!B6/$RB_V02/\<T!,Q6].8R$@_ZBY-AA>!?O4AB.&.EUSJ8H1VGV" >[(D
M @XR=FIQ6^!CAI80LHOVPO!&:5NA)>X,O,"$@?I':VTO>\VL@+@L/N[W+IN[
MX[Y1ORJ1!7V/D#OBBT,05DH(9Q"6?A1/'PL6CE%I9;Q%>UZH, "0]F_/2HRO
M%;Z?O6=*5X]C_Q98.]]_6?+DL"MWO+$M]]0.;4<U) CYU!]7D205;,7+.B;
MD:M)#T*I)])JQZ2?MUZ#WM8?C_7:]I%.,3/>MLM,4GF_LL@I)]J&=.W^IXX4
M+O.L=6WF8,?Y_W&Q' "%% :NY)+>\O=GI1UD#:*2 4T#!11 :B0AY0;;LY:5
M:B/+=IBLP\/.?UXRB3A76@-WOL^80:UP3#Z6+%^-@D:\L?*MOE>Y8-O2WA*>
M0C!1Q 'X7ZY=B+;(>RJU_?@DUD7?,> OAC9]6MD^QRY//Z=<S^+I,PMKD2#5
MBOEVLSVT=8UMM;6X2+C%T_0)Z./<'%#]U@/<*#B1Q_]M6 J#/6.IW1=9"_0M
M)B+M#U8Q634&)@:/ZFM"/&"-XZX7XT9;E0_^_=1ISI!TIJ]^K($I9)_:U4I+
M5L5H++J;BM'O7 .7.]C^NI-X5D/LK<OVXW/Y:F?RU4HDQ<%"9QVU,.(VPF?L
MXZ%WS-#WJQSL,FJLW";RIC;L?MWZP.CRPV_WWGH::= _] LT39>D-0)CD2P]
M70JIGR#!)2UKL%RI@B%VR$3 :;;VR@F6.3F#=C(%XDL%)"V+,]33$/?R;3\$
M[OP8<>_?+QS-B\9:B9"&*_WUS?X=?=*<=@=<PSW#>4%868P"QK9+X.H0?[%N
M4PYKP0+H%C0U \E$,?838Y2W(G,-O@_CA)<0@,GNRU^=#YP:M ^Z."T)@?2!
MY2'5>$F!"L^-)WYM'!RGGK""0C82:%V8C08$@A5RKH%B=&Y(:^P<^PZ=L\V]
MR&#&H06=!+T"KX_UZ?Q1U'4]*GG'_E#=#3\=>J@]'9:6H39/?##EUP5\J8GL
MP1/>.K3_W6F3C,1K=[W-/WTN1RB+*]52,G0J'?1;-G6E[P"7%VI;^*R]<+02
M8CRBW9X<#ZXCP\<N]3_EFN1-C;1E)=1^F;IJ?KY1L5<LY(*B7?S65+79TVJE
MZ5P%K^FK4@/XR)T*E5;K,H;?WWU$\92Z*N_@%S@U?XYWJ[(%K0I];0)D[*GV
MTT=&;TN2_88E]/Y *!FX\H9[EJZ[[5G'&N[C2B'GXX@MX*;]U!^65A;$_A!_
M?><^ 0.< &O25B+_X"0.[;[A%IT-+]EU[FBB=Z/1_OFWH&[3J$0U+ [;O/N]
MC#'[C^$%AD&OW&4Z?Q]0X&N,%MTF]?L<C^BPP'V%82VU95OZH8>N-%Q=$#7[
M@N.C^^NQ5F7NT)>E[:W9*LD/\XS_Y.3P0-GK([Y&_FU79H;)BGFOE2:(D<&I
MG0M BB LPZ.H0LD%^=F,8%\8)3#2_1W;J-)+^;VVK&3O Q;RWM27YN;VJ="%
MVN'0=P#8[$@P2>H!Y<ECUQOM)6IY9\OBJSX-/%RUUF-;N5KDHI-KMV4R;BO9
MQI<.&0=%6*.KWQWJA:U^ON"M-.WH(:_\;2WW4A'F5,5$[-HT+F)Y<Z9Q9A89
M#Q0AK"S!6 JX+(1E"(X5:9.).G6C_ND(&9A($ YU1PF:**6*Y;M[,PQZ@")A
M+,.-\ORO"X,X 47Y]D(9 RA4D::J&E/,><$[9=817X/Z=B"E"T@!$,=.L-(&
M4*):OD=\*9)]P-0#MK$RX^0_*O-+KHO+_D[207EDTND-_;PE_)=QRQH75H"L
MF>)0ZNCFC,(K><Z=LLZ+YI+!QNJG;YQ3,/JXY>TGY&>7RW $X#%!SF>FU6G0
MNY:@@;JU2MQH\=SD10D14<?+B>47,*%3DNV'_8$2[:XJH0UY]5\CG5.:K?R(
MD3]RW?*3*((JMI]^%.L_HPAP5)R:"XFVC2_[&!^NM#>U%9X^^^QJ_+^Y84]N
MLL)7 &Q1?J8XYZ6QHCO[,>L"78+X_HA/Y,FV-E9GL,]O$"R&^%-K"WB^-S L
M=%(+)@4G]<D!)N4[FB*>F(XDYL'" KV#P[PA6A+ASC<M][O$OSSXJ,%RTTO7
MD91)(WHS7GSI)W]]"+4M3TU R_UIJAR2KC*8;Y>EZC+D9N?4%+[L4#WZX/5&
M;TCE[FD+X=PWW\/C"X/4-@PJ6SRS\H !@,]I3$].TW:GC/>A)4(%SRK@)VYA
M@W9[)H"IB!"RS-(YL(AII0E.OKM\Q4:4!7Y0,NMH)7D?VJ$R7%ND)#_Y!'.H
M5S*O)#G9?8)]D@4ZU&+?^F1\CBU$]RSXFQ=%O7\HA2*%7$E0Z2;3X+H 9[<6
M3'A4'2O)=OH'QXOYC?LMPK=K^H?E(4%]" _*GYF?/]7U/%7AI<_F7QN^DP.4
M]8+QJLWQ]V.B;KR8_FAMU2[_PL@GC&T[7N;UI8HE4,ON;0^'ZIK,&LP))\M\
M1[$K-7H;Y<7O"L?]EYH]7]!A-$E>POT/)^F(#ZK.8_#X7]0H%DQ'L8[X#@7^
MI(\QC_C8-U!IOWHGI5S/D%]L#RQ@@F,[H\DCDIP+NSL+-. <"5HTTK<O$I^N
ML(ID7Q2@V,C$C"+?(M_C8L&_S^R_!QS'$\3]22<[;242@JM__LL2[2$)X23?
M$P1\9^IA.^HRQ/F!XM*ED1JWI:Z9<MP"_*Z,Y1+H^^SL#7S6QIG.6<IZSU@"
M20YQNA9QBS6X A-BWZ-+M#&?;<9<8*C^VS6YWC997];]MB-+4+8?3<M;U!B#
M1/EI=RUUIOYI?^FQ(.T+ I3\_O$K-07-VO216XLH8>GF9YNLPKRJ3[%QE>CX
M4J]GI69HF0&TO+BUX?>5UV5X#U;ZC0#;/K/L!&D\9:IFX,RMG/88=EEN14F-
M<^!<$^L_/'ARGSN&HM\72@4<-[2IXRZ0SG,O9F4TP8=M8P%GV$ZL=0KPGT(>
M(I5%N[M<SPDF=V3H]A_QG7MB" JGJ&18;*X[%JY[,"Z^K4=! S$N_@.#KCFV
MK";NF5;Z/O?T+'V=,A:GQ0L0LQG7&6;9[>#42ZQ:#$3NZ@P[A+Y[=R90^PN8
MQV%[):ECYY<"G+OEL[]]"/1:L,NQF<&3A ;1$&-)PN2/HD..NTL^ 3WVJVMF
MZQ$?W89TW@L]DT-1GS=X3U='=5C36_M@ISSG0&L?'J4;EFBS(%3!/Z)?G8H5
M4N,(W#OF492RI[$/FSODGN)A]N/?6<?J%^#E7/&QY&Y-5II-V^1.<X8)%96\
MPDA$H3U<KB:],KQ<MB$G3E>KF9V4JM\!DJ_0NYM;]B7HQ8J0A@N4HA_^\'^(
M;1XD492)$87]K);F:YE4H_QTN/H#&N@G%75[FGD>;<&=.)?C>%6Q^H/C^HAT
MB>:PAGWI64WB7Y"V.4.[9V%N5CH[Y1\7\5:6YE'RXH^[1+FGQLA@ %R3>[KV
M\*8_0;B,@)_Y0M]-PR_=&G1LFJ)I6P+XX>44W32VY<I+]7.UP3?VA2W)@>X6
M71/7$A>L&UL_J347ZW^8<(\2FU(GV%25$80_,AH_-MT@:A3K3>0#95('/N3*
MDJU=:O;J-OKG=1^$K-I!;KO1/)N^*DXZ5-M5%&5CK,6F2G:SE75C@F9;_RA+
M58G_]/]59?]_4^G_\PT/ +\&?IDC^-D<JK5G<=_(7<)MQ!!.$%:H0DDV5"&6
MPFIKVINW^1%<4?935A1EJ_8P2N]ZE"# LY&A3JQ]N:NVA#A45=YW9E3&-IVZ
MJ#I:>S+MXG_(MN4'W-^P9R[Z$/>*FGVS,L2YAJ;ZN4JX8HL&K_ &XBO3X6,I
MEMSH=XBR*=3*J[Y?0P"!WQZ")8#;-$3XKZZ3*]H ^K-]]LN"7N2A ?AWY&8Q
M:\]+]HCO)!%ATM+%LCJT0RA$VW#4B2AA0V'&N5GS;(@8IVB@6[J;OL3$^,'D
M>U+!RZQCUOBI2GPSZ!(O./T9OB^"'2T2\Z+RB(PZ<BCE5R.B)CQ=@5M-RM)F
MAFU89Z6_2)]^W50C[I3A)4X/W;I3NPL?@>)W??X!65YIWT@*_CF 46';\KC7
M?SM]B5N$ %%417OE9&<[72F!UK.F=%+"=T_[/J]+,^H>@[X57POETP_RL=5+
M_SDFAN<A_;;VMJ=U3HK%?U][^&MXVW5)MCB.*TM8(:5V"_-(UV]'? (%7 E8
M"AM( =*$6&X$>CTOE0/?-M>.:&XC'_&^ J.B:.KX:-S8H?G\$\,L]0_?KI/6
MU-T/ WG2?$((0"ZT$B4!?&S1%4^5E5UBEFQ B[[G>IRQ' F>UD\2Z8QIG7WF
M]ID%<&6X9%EZ0LVGZX.TOOXJOTYD2Y9Z0O<;HE.YGB9_=D=+12*LR*3SZVR_
MEU1':1</E#A80/?E=+^W9Y5]KW>U<^Y->JVA37,:QO:NMN)D?$5.+I5_U#=^
MY&;;DQ/*07;%<#/+.3/1&>MGP=;6RA+3.E-%+4-=0JE '\X9<!:!;@O[VZG0
MLY@'?[.0 01^>,W.S.V'TIG%Y 16!HRJ?KXSA%.R2:*U@Q.QVBH)+[!K+7NT
MN/N)LM,<GCGTC"&_F1%\P8=*A// '^+C6S;<4\&_:F,9L^^%A </O6,FI4\,
M)L3(=Z?4?P6>ZA:'2F#YDPU/0W!WY\W>4<?$2\,*+!G6#6^&:E@P,SHU,5J3
M&,EM"*N_IQUM-C!Y]R///4J.^+YDQ'P@,.UC+B$W5<IGR]/'GMXFI!JJQP]#
MS87CAS8H;S.[;H=,E%R'__FH5ME1- "M_S1!.F9"M=HAP]I9L>J#JSW1H32'
MLNZDIEE/-G;"RI_04WRGEM&J$)2"+4EJ1OZWUA]#0WBQ7O'8?1S@#/<JPHWA
MP&1R95F!*S@1UJPSM.AS*&NMF;[V(KS&J'#9XV2J3!JSQ5WFSPJ<_%*?ANG9
MB?9[1WQ$(;:H"5= FY=8MEFBE+%8%'V$9[MM0+(BJ[6>_:OU5A%7DI^MLOOV
MB"^09? ^1I3;RQW@F98[%=G,*>*>SZ()T8 T=Z3!H<TV88X1G4;31>S2L$=\
M)Z(Y]<"5\A8=0--L/.($;$4H:5F-X2$,.>([;2QB2D%)(7BT+RHX6HA]I5N$
MX=5TRIUT40T%SY_<..!/1%PFU\I"P1H!;HD959XNK!A9R0^C;+VQO?I;'X.G
MJ^QZ'[U\'=GG,#C=3_:D!V<  S8^H=W@R5-/TZ?$W4++T'ZW>W5?=)V=%30Y
M9O':5_EELMT#A_+3[$ATA(6RZO5)!+:EQ0JEC^RYAN"O_77++S:3.Q2I\P*F
MVM<.[%=1E_-JO/\ONB6'3OUSJC.B>M%&JV%(Y%Y+B5RV=D:LT9=O1,S"_8+P
MYVO=W3SQIR"T:[Z"Z;:62_:VJ8K;; C=AIR4$BJ9^2AO?0(+[HLY5^A*O>LV
M;UL/MW&--U&3?9,H\[=A;?(0IY'WQU=X)JK8:7-X;8[$G20TJ\:[P0;!LBPW
MV#DXD+PX/N\Y1D?U1&*GBYGE$?5+QT+$@.?9#UHDG/;F(8WFNO&=.K/M<J51
MQA@*\+S_O!R)+5G$/4VBD.9Q9/-$8V.V&'UZ-Y6KC1!J;)O  T_ZZ\<TU,%Q
M%"#1R-D^E>*IT-ON&=\J3&+%]43B5WDQ\$9S5+3ZH:77!%Y(V.VSYU( LUTB
MH29*&TY2JJ4$G0EE.*#S[88#OMA<+(2'I_4YPY.<M-UM#PBM"6?56V?RIC:K
M]04=/1C#6X.*5:_E:;Y.>@G68\5W-6R;,G!CPR/&GC3?(%^?;2#K*B"M$\C+
M'M<QVP2=?ZK=22@A.+A/3GCV4JJ_UQ:(P9_T7]A[\[ FLFUMO&Q;41&C(*"@
M1$5%94BK#,J0:-.(BAA'4!#2BL@0(8T(! F4$R @1D6A!2$J C++K$R1,+7:
M&.8(""%!D2E080@%22I?T?><[_2]OW/O[[OWXWS=YSS\L9ZG"$G5N]?>>ZUW
M[;7V+IH;WT37TKK9H^?>E]Q7VW0GU$]YVFS-NAQI?JBYASX4&YQ_/^BI[10"
M5NB@84P6'C76UWTL>TC!Y2:P?QK-&M[)%U#AZSU[7[9V[!6"E2.K*ST6/DIU
M[\+>.'&]9W^SKD^<MKP59CG54WKY=)>HTKI%UZ?#**=9OXXR$2.ZAO9L+'XU
M?=' %;\A)J3$-QB)]-'=-MID+234O)9H\0)565<R( =+<@;(PG4+ OC?=FT/
M9YUUV=68(I2[V2A(<(X6[1)$FXS<YI.6[4HH4NS%Z+W_$E%Q8=4 7&JXW;:2
M==N-GU8\&NE_.,/YX(E-QTY\3EFP[?'CYL2C!XU&6!=>[>=M#;!+4]YZ_/:F
M9:=W&RUZT;5U'SOV;;J)=EO!!?; %2:;C,B_-63@),IRHJM6VY>_+FHH7UJ9
MOJI[NXF[ F3[1G7%H\_;GQ3'B+<%;O]AH&G!M;.%8_/M?WZ&M!"ZX[DKRO5I
MCM*(H'FT(]*G&\OB^%PZ3?L%G%C%4476-M&TS%JB,_GQ08,L6Z\^M7WQS_M%
MAK9!2T',F?[,!3=U_5.LR.!/DT9&QQVL);O1,;SO2S/HQH:UB;6,):ZJJJKM
MM9$$-PQ&LJ#1L<F:')>3#MM0EM*6YN<7-BVUV\Y\E<>$!DZ;+Z>&)&U<\C[-
M4?Y:VAD_F'@C@53]>IS<G+3%V=^1(!^6O<^3ZF=\^HZBWD]QM\_TO3V;?N+F
MXW-?5M6<23^1^R%MVRL=HVWW?=*//W;:^""CW[HMO>3 [FH#WZCBU\A5QKSU
MS;K( HE*4<OMS+0**([WJW$<<5=Q?,&B4FSB)E[LE_.//#<9::^_[Z7SS.77
MZY8*KZ;K7/J-3X:$)KG%;GXHUW:Y#DO,;<P?I!BZ(75G4SHLW5SDXKTW<I3\
M#:%:;)QI;MWFSM%?AD_?"0XRL7//="\XEHORN<:"C!0M;;OAUG).4,;DAM=.
M*R?RCS&?O3QJH?QHK\7*(_/^GCAJB8T'8^EA> 78Q*ZE7+N?H#XASX7W!S4(
MS<WK=4RW)\&,H:ZM'-T-8KW09/OVCQ]EP+F*;X,T&+]<PS=Y/:_SU^O/VN@K
M>C>*NRK";VL*6@G;O*\IUJK$+(-CL0*VP$R]NR6_%53(D+ 5R8IM(,O(PTNG
MR5(4B;>RRG2B13(=&2?N_921!ICYAF]Y\LT_@^2.R( 6YA2B:?<P!D10G\,6
MJ@$(:@;<,RE'A-A:IL:@<7:UF7:/@[2'ZB+ *EUV6%A;:>P25L[N'L'858L\
M,-;7V]^]%ZNMTH0D78<6B^(BM]F_-;+RTBQB^XS'"/R=^)%&HEMPJ'./F2J/
M$5IJ)4\],6!'J.APRT#6M$V5+X8^M8+0G8Y/!_1SI,]85O:9)%23#HSC,YK$
M>V2/?%"0 ??-@\&A.#3DF[ -)F#JF)_)CV3 QTIU&9!J\'WXENSGIM!L[A3\
M;^TJ+&0ZCTRIHGH<NE L YHNT$F*G Y2[J0D8E(&B'8Z@/UYEMEO:62T%>HH
MZ732*9$!AP]-WUDN ^[]2AC"HI\]3YQ(Y*E*T'^4,AN9EK3Y2#(F#=0D/28M
M8G[A2K\@#Z=-NK$3WP4>GU)#=A-.X:\UH=V&F;0<SPRO_=OEWXT^^$&;N&?Z
MP67X=>Z^0=KYT-JN^&Z47-K!O0A+P::V(L8P5EE:I:%=UCB<&,TYE@\-Y61E
M>Y_U7GG7T?R":&R?\)=WQ) 8CG%*)3UT.OYKN,#4W^\%K,4JXCCN?OGRQL$<
M87Q=5_!9+T+X4'[)*7Y!DX>IA4YD>L='>XLU*C]U;2K=_MPK+0Q95Y'6296O
M$;4KQP1/F'GVL#0VW;!LHE&4ZKK+S$_&[2NC$W.%M.VY!W#!P\/MJPS@Q,O^
M^JEZ#:=/7<>$UKL7EG\#6126./,"=]H70:$A3UKUN=_^ ,$X8LO9AHS$9IW2
M]4MOCUKP JP*8A6^V;JVRVR;R0\7+GQ[=UGY+$\9C!)D^/H%5W(>'GSV26+;
M2'-(Z<-"&6 >7K7=544M*!4*%=NR.'Y^S/;I+V6E?EWK40:(7"8M[Y<![4J?
MP/,='0;Q*0_E<[$7LS= 'O3P3$2;=J&L)9\8HH)?S41Y(4I.%T7G\>S=GL%1
M6=*82K^C9"Y4D.5H$S(HQAUQ%= 4/ENJWGM25G5IY-RJ*X+9W>[+!_.R7K^
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M<N^/LH)('4#;,ZN?"J=NQXKL9G>1J(;I(CA^LK5\!=7J6"O:.-*: BN&8*2
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M@ L=E2I1/E]>= :<O302<T&K6;L.C_E(5B-59B_[.(C,AYB5NHX8 5@ 8RO
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MGB,TZ\3:C>W,4 _=?)/^+(-.O2WFUGJ)S[^GOSA5JYA/]Z8HUL@OWP)3_-Q
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MI%,IE5<2(ORD.<\&VGV9?B*3?DE$ITUO>\^[DA"J4R,(;R$.W0\:J;X/#O\
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M\75$33'E$3_2\S2S\/[_XN[-HYK*OG715%DVB$@IG=*E%*454.D4 BD;0$!
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M^N25ADL$F:R%W4\VN?<&0G,]K#6ZPLT;O"SUW/H_/6X]AM.O^Z8?;*^@HHK
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M^K-.)ED,:<=PFR9'%' LNJ$ET<7+4/P@MMOM=$]XJVU/C\B-A9J12H2L:U2
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MV98H5\R;G<9[@?&8^1)%#^/:<E9F,2+<&YSJ"(;FBVF]X;HOVZ)GD3WC_ ,
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M&/1%TR"IQ*<S6MW27VLQB(L3>L+L 6SF/4I+YZ?4X#_LYM7<A]P-F,*0:JH
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M)T]2/;&>E'@_<GKZ6/KYR&/G;\>=N6^<=&W,1L+A=^ 0CBO3.LM9)7L3DHW
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MDN6P? " __%^M-S\"GRLLM#/7*6/!M7SL_,++FH9&A[BJ%*YXLF],^\KR<=
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M$*Y[/=Y//4ERUCQE$_PK1I,[7D-<C7"KA-NH#NMO2L)/T&B(LQXHY>689;\
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MO*VN(EBBNND0H2=(A6>3P*:#T3YZ8 DTBB'4XGZR&'B.L"$BJP!_:-.$ ?E
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MP'((K![7'UCH/HRQ';5RKS8L*'>N0RCOS\WWF57FI22I959%EX;I:[<^R?\
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MD;F$RT,T-9H(,L6'3"S?_!UX/A)R.)2_#<U<+_,]WCQA&!6HDPXU8QKFH/=
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M$Q%-I%24([BLSIBD.1IEE")>,U!4^ZRMF=)1"#Z-++F($BF/_4)YP).CM%9
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M>+TG5T<Q[B]F#,;?K2,B8J^JG(^XL7L&.Z&NP]T#9>+^SF)">VERXP:;@Q(
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MWG5JMBAIA"[7L6*_)0U6G\S#.7_VA\C,O?A5+  2X26'>L,&#1P2J9UQJ%:
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MH^_$HK2S$6UR@8L]$L"$CD^:G:^+=WEC]L*'](K\'^]WEZ\KL%YOP3 5 >$
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M=)8-]M&(>T))X?,OR#(H0B<]W#NI4$JWZE,!6@6(# IDF1<6+$A]=%TDG^6
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M2E;Q!8M10VA+39U487/3F7Z8KDR^NIO#G7YO4N/ JC]/96;J%.K,/&WJ?EB
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M5+2BQHX)I^3O07)*=M%RI:-%8>\'.%DN44WQ["^-C=[;<T$8T B&;;H>1U8
MX#O[^7U</NB%@)BH-CPSCO+/(GA0.2JULX$NE_=UZ\+I,A6N?]YN%G-,FG%>
MUS(!5SEG.N($6Y<''T1I6W(LB3-YAFWNLA\Y#0F7-2?4VMVOU/0'5\!.+C/<
MD^=$018CI%L'B\+KRSR*CY3(^>5MCG.Y!KY8KQ3U5>Q[5OXY9A-VS$E*,N;:
M5] P<JC-:[1$2G/!\XS+D03;>??FV,.V%99U\"%$[E)WA]G5TG*M627?"](G
MR827^;IUOU@X^U=C&5HXD=*.&Q!IJ9%RW3'S$-[OOM("W&AUQF,\P1+?>0J
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M9(S:Z@)'YGUM@*KQP?<=:)/^P9)"^[EW7E%Z'FKU#:7U!(NW@@KD_!M("W+
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M><98CJLXD+UIGE -=W'NI!EX_2\T'QHO5UP[A.N@?V7<&PWH[IXPR*L2.7Y
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M%XBA>)I7GBB8;^1@TN#Q!MBV*RF%L5FY9P^6:BF8N#ZY_VT9FXK!X<[]VGZ
M:NY_7U=JF%H:'U/G'(X8C>PL[JCX;[J@3NU780&CDK=?E!'[I>':?%Y7<"V,
MT03F'S?VY1CG1!MP_!O9EMS*_ '%HD+#25% )(+*'G$D$#Y!<<$UCLIK4_8L
M>]5U5$M>S>RT[PR4QO":\_>RN=0UD2[8"UL8IL.XDK^KQ_/.\!:LR5)F+AR_
MPB8Z=%?LB/FEF%@F1)GN/4"1RP?2KQ=-A,4Z$-R?>T)5-+)]1W[\[.AH>_.F
MI;-T4WJ.#9*=;PN6?4[[P"9R3,+#4CQO.I,?\.(1#:$7L@IM?3_=Q[G+'@^E
MH9:>S,^\J@0;G^]UI?;EHR_VX22^D\OX#=R.APX?.=GVU00H_2=$/93$]@5]
MWC_,W%[.)@R# )('Q]7;C#&%T(*D"8W?<!*7JAS^B]8TQ);*"&5GT2,!:FW=
M%H;E]FE3=^#A#9ON9C9(%!(XZT$F'>/?_[U-A"_?Q4Y*C:CVA >R#,I/\&WD
MRH,>1$N+ V:]'9D<=<J%Q+1QFCUMN2=,M3?^4//U?7G<I>Y7GG;J'7[:X!_2
MHGCL%P@IW)V7L=_AD]P<$M$NO93@0SH)_\/@74  ]=Z7H@&F6U&3[L(A645=
M;[.FHXC!6H5V)*U\2B0O!.6BU;5U4 3APX"(%=W-JIZL)9TNW30L5P!0BP&M
M-N%=EUFESG:EWIRS15/A^;9I"7Y[',ILK'*JH"V;IR"5:.I)^;Y?#K&I3,]E
MSYF'L>GP.-</A0J?^LA3DYC][:>OOW/:H=KT'<[Q&LMWJO6[?!(OD4>=) \K
M?'7!I!6;NK:_K-Z2,)M]IQ?N6M+E/#$RL<R$\$\:LK4I\47E;&-N]D@TOE5$
M*O?7D)*(V!J?RZHS7W'8.3(>D%L"^K\%6G5U[8JEX!UA4W\3B;3MA%*M/CML
M-NDHE,NA[HKM;1!%&)?T ;D/&<200NP1O$9XU"&,)WL40LNT6]ES/7-R'/R3
M'WER\$!*DEH/)^8%% %Z#<]V'MTN!3MSY!HKC4IBJGO1 Z^ABM?'&VIUQQ?[
MRX,$JD!KG[\"9RO-<&L?0+L\RG=D6LJLQ,:#,\PM<=[7D>C5'3>^_;[9PHVJ
MU9'!0XV-)__YK_=.SK-KUI !Z=^M3/:0;N-EUHH56S+K$#% [.T_*4D*[-@\
MOF5B!1UDY&7L,X/XBVV<VV4[<"=3? >2$5[\/EFU=1BZ5))]CI6K^.&BAW3?
M2Y]#[W-T2,<X"H>2O&O?O_8=7U08<G4S"77Q1(VY?75'FU[($91Z1[XDX!]3
M1_L'E9*CT5IOOM0ZX$9YFD28G\6-=[R14)O-TKQE?>X; -. [+V!#-^XZ@Z8
M,'6=U  T"RR., :\F!LN[Q5%Z=>]_#9S31=&R?=2FZ"[&C_KK8&W^CW]TM[$
M+LJ+C)1:PB0$OQZJ&^;]W@A- 4 -@ ]718#:($CVCR-TV9*4I.-LXPQEU:(/
M0X'&_Z2G1(-E;((,-UC4O=YIZ8=1GRXM522$66;BGIELGI*?O+H=P?V]]1,I
M'$0VK@XGLJ.87R*!]SO#/$M7()\U/85P6ECCZ1M2\-#]C0@LE#FMG8(Z9RAE
MUKL3D6XP>UO'8(I8<ND*MU\2O4.CE"FREY]$*WOTS8'9PDP6_A!LP@7:L9QN
M;H/VA*$.-V-\]::SI3QNC,UWT+:5-"<741/?YD+4_56,9!N@++F#)B3)0?6W
M[FDV?2V8],K, M7,_BNNIU.PF@:K=>$70RY^*L"8O(\J#'UG:UMJ:*U34I&]
M0[W19:7O92OQ[7*M255Q)Q+IY:5^IU)EZY>MZ*E$>;A7]!EL.05C@I\(]R,2
M.\>Z_I#Z2=%U89U]S-E/)J.VL@S";L'\3[*YV8FOUW:"4PVZ RGN\<24,CF"
MZ4/,_I*:J5 C[V2OV5VQP%VQ /5^W"*([86<9LQ+;R 3V0F]Y7\L=G'2\MGO
M(XZO>1=3<%?)*'S:?%<;)ZP\?=[B)'LV+Y,@T*!*0",$6<U 6IBU+4TW KP1
M_32@^-.4Y'M!$2 B[+W:@I2NQ'I'[%<4D@I)Z5MB;F)&>Y3@JQ^^;NA4/!G<
M5TX!'T;\E2 96XBZTTS#$ A$L[#U5\2F&QLN-8"V: !705K/(:#D!N?>G"*G
ME8J#7&GC/2P&4;=D/&%T'>]D/Y\9NK\_'$;V!['ST@WQ;S)4#NC$S()=1H.R
MEJ#@:%YG6WT#[M)SCF.ZJ_X*)U41<>U[9H+W(/A^Q<D+E GRH+1I'N-A5,H2
M^EZ0[?GE!SGB(;U172I0G0MOWS'=]@V"0E^V_U)55VOQ& >_*2&^+/J"9%]C
MI/IK Q#> ;C%%K7E&;29[RP20$E:7^/#AHBS:$%KJB$0G2A/+HY]ZM=[((1_
M'0,/!\M^G33"74)OI1MN*'(UIQI4+NZ*^81*^OC E& )VMIP79V-4VD3HZ,3
M"AL;N##<@N>KUM9D]1NOD@\\/9.F\#0PU]#UNMNMO=N_#D>]</VH[TLVP.ZS
MA?/][CDV97>@%?/#CX_5MW>_-+G]8?3!XE+H1MGB0=M415>7#LR!OBV\E@U)
MNSN,]O?K+.T/A@?/O?[G_W-]=WS\;:V9;\I>[U'GR"?SO7"M7-*T"(CIKX_.
M\P0=F]4MC*G_[;M!&@G;*^>=1@5Q#%JZ9XMF'-&3!?PCHV ".%6H,$H$IWO'
M]L&F(1MX,Z8POWYJ;2?IT3*0[MZ>M[[3G3(I5XRD-]JKM((+M7_)K#K[V+1X
M^KGN&:_YOYE8]H!0<EP$^O+CED%;!_@>;&+.Q]HHMG2_?/QPYKJNTR)*6@QX
M_W[::I+X&<<"ZPYS55HQ@#-+X#P[,7"YQ'MBLT'WGD%)*W)F-7EU@KY#9[WG
MSDEVFK6=)782.M+,LF%86 9=<V/S5*&_YGR9!KPZS37D2\X+92_/QVM?3+KO
MI5\<_!Y_Q$WC44.=J?VW.@+ZA#/>#C7\=+S"&6UHX?7 1//!^PEX0(BUS!6<
MA%'A#?I:I;VMWFR86HE?&*P2^)TW;OR6@N;R/-FU) NV>+^RL6<)TYK2B=/W
M4U'_I(L>-P3OAV.O-W4T\:[M' ]O6HVWS-!1;R&0BM[VH&]'54.;KD,3P@Q'
MB()7P"\1)\X*\GI @/^F8[(+4+G R-FL]_U:)"=*(^!_NDX'UL2M',-G;0^K
MA.SL;X\(4VXO^F8H\KKFUWX^NWZX7&?'LZ/8J7'=0DMT3U+(V\C,I%.=G,.%
MU?R;@-7/25!H^ZB%++SSQAOVK\)*B3-TJ(H^&Y^S\:,S3DVP*_;Y1_D;^N73
MFK"]<I__@?%/B9Y-3=@'D=C>T*=XIZ=VA7&2>3?:? :5(-G"<\V3!C)QLHNX
M10*]/,W\_"O DEQVJK55;O@NW3HCNMOG,JFYJR/;?90H;O1M6ECZ<CE)(1C^
MLWSA_LQEG1A/6I&&[NN:D8HLK.U+Z,#T,-U8J>](RG(:=63I2=R,LK4&^&P:
MR)A,VR%HI'&AQ(--2P45<EN;6.W5:=O[A67%M@.W.9VL="H^LYQM(YW!D$.X
M,'/ -X!\CBKWQ@3"A14A#7=6>EJU0M?(-3_S?:W8W1TUU-^*O T-F[=WW_+L
M;NSI[AJ++K##NH\=XW[RM^9_%$7LM"44GVS9A-EPQ/$O S_K?>$1?8K+O;MB
M<H#V38ZYBN)XEXM\.M^N!I[7ZRTH75Q,3U^/@1R9GF9 _14GHM6[1Z)+;9?,
MNOTGYKXI)9Y9=A[3V15K/T'P4UFP+B9/*CJ46#RR*#F;;9%NF%K?84XW;ZGN
M]SOK=YX%TS28TGE1_^4-7 I+SP\?4<BTY4,G2?/)NV)O)H@L'DF&/L>_QUYZ
M$8N,1)A+O +6R&M,2<]-#=1MC+<-%@!Y<!#N1R2*)*,M=!*>S[>F>J\PAN(0
M<\=9#4I]B^;VSX)=SS\W5XG-J/4O^/9?/]K6('3@Z>W;6KF^>8<KQ:^X8-QE
MG&OJOCXK:_N@HA7SYOD3\PKG:A6M"VX^MLX._,T)DB'#U$'7ZP$#P]P5X\NZ
M<'_V"-J(I:I"V?!TEI0^]PYPO<$GI".\D25E2G,<0_AQC"E%WGP&^ZG?7_DS
MOBOTF('T:*6U",F09S=^<CMBB,)FUG%:C/01GQ!%\(;(^UHR7['3U_VPP"9+
M9,, (@=&C9]MJ5!OGB8RTOC:T"I PX&8=C7*(+:ER.+TB+G?&;\JN=S6XLF)
M"];GFG+C+#YS0'R98*X:!]+'V,N7F[#8\[LO&BY)94VQ-0.ARYS5H"*/(,S4
M%(6=,%@@=@W5W\EDR*WXJW+<&Y%!@4%0"PP+!_'NAL&T+\K%9$WLRUL%I5H>
M3%+A2P,)S+Q4R,&N\T'SC'2A5!.*3"X[^0:ULRIY0 _?0#1[I]8UMHDG7KKR
M\];8%CY&U\YY#!]AJ&SMU-71T]/1UM%6Y#&<<9&F1F7G');_KXG_\'^%)Z//
M"IO7U17;3/6(UYV)H3'+IL]G'-1'*9-Y(AOFO(1V0-^@I2RQ/Q^Z=KZY/T#+
MI6;1!A_UPM#I&]9*3U,K,JL@X-=+5#/4:(-OM/9].FF"Q';E503&F7>(4R/H
M.],.C:3V5$,)VMM&Q-7'-YL[8==R;ZC+S4G1 E#:FB<V5&\\HR]MXRJ+?NR*
MQ1>RE\G2P%G&NB,[@E5=SL&*G/Z:U!Z6?SX2N]H!R;C+P5!*XZ7,G"9U\6&&
M2H-@:2"_WYN4%H8),52B-,,)=TR]"FS0@MP;M^'"!3PX]V+E'Y0'[T(6H\\7
M_&EBX7/RY.F<U .N,3XI9Q<49;%4&M?UW'6;(:,Q4NQQO&X37]E7BV)+J'V/
MCF^HC)Y!M>#\WI^/72H@-(_2>\JIXGQY#Y:.4%_0M4TZV'FJ%;!F#S,9CUYE
MG=M\[7*VL7H&X5BVA#1=@NN!U4%';C_:7&<V9]9OZ.@L)MMEGPAOL,23IJ:9
M/\HEA'\@C@-!%J7[\^/F0:D68NPB-&:ZY&XNP_T30A>]0F^#WMN,"&L(SG=I
M[42M?M.>'N]J?P9K3GA(,Z20S(%AH40E[PCB"M"(141PRM^6FD& XH8U-E#I
M.0DVAW(T#036?H].7>OI8*-;G\RS$24]0X?RIY7WK,?J8WU]?0;-F_[;%8MQ
MHLPX_3,$1Z8VF7?DZA4\\%7--8+714/[>\Y_(M-B_ES-/=.]TI$M:S9^J[2N
M]UPU.DKB<:VUS!.*6X$2Q>''V,ER'9.J#;V0@;G6,TT=(VMUK=]%\E=< 7Y5
MQ- II*"(DUXKL;$J\NR>=@Z2C.+B9(F4HOB[N 5MR[36N9/$KO8;J+FI;3.D
M./R?:5W*B/G&;:VWS]8+!E)%&JQ:1/A5PG>[8G\@@X:E^?N!+982([5'E7VX
M=4$2JYL$W@MOINQ8YA@,'X>7\:AR/Z-F ) UYVRM?(;.V8F&']"%L1]8,\,1
M0J+J.CV'4C_Q"7D=*=MS#&$$+,R'!3+QU'+Q$*$IVZ)+=U>,P+?$D56G[72K
M5J*"8R,N=;7\I"<*2BG02V65&#]O"-WVM1WL>8F:\ I,!.2_P)_S/,>62;0N
M-]X5P'D"LAVO]V@!OV]FI8BA#YJQ8Y6GE:E-^)P6$6;5ZB1(2U,A8%TX84^9
MT<YA'C*6X%R+NFEP@1_DZRXO7]3_\F6I[6?42-B0VV*M_!.*2X%&>JT][7[!
MG3IP;%F/S E'9?-PJ9$2[(&^^W5T8N6!;ES,II6'LW/W.(K!2 (A>R&6@>79
M2 6$.-N1Z8_FJ [T: +IK.=\W=>AII!_P-%YTM/F3T.-I7"A^4#'=S*JNR=S
M7TLIM^2%[@^?;EL%O8TOB7\>($J_X8MB+?X'_T8+F['^8AZ4?G[&407'T6=Q
MB^^'54;?"$<8SR=*>XP;/FS_#ZI^!-91G'+HUIDS+]1DNON4HI/7-D!3V4*)
M6-YIX;LYXV:@A#W9*SPU;J$*?1C;HJCQI"N25;(K=B34^Y!B=8G1TWJ+O-OA
M*$AZ_99AF.G2ZL<M9T7MU?-3<Q!/3[^IE9\_6XI5?O&LDOXK;R9M!&/@$%O!
MJR3E <[_!GMC.\HJF,^',_E0)C2Z$Q<@:1=F/[K5ZZ_*7IS]$/OOYZGZEI_-
M,]/[6]*N90;]M;UP^[O%D?<7L1H?'M2=&/(MUPOM46?U8%U &=1>CT+-D:JZ
M6Q6*KJOF^H1E6\<B[*)[NM'WRES\8[PMX<UJ-^3AR9>K+Z$];NH:4+L7#8D%
M15@??\8S!CLBEISZ"7D7F5TN$U3D2.1? ]HZ#KDOF;C+C@A!<)B#4:R-6HFS
M3;@A1![&MONB:I49) ;+/'O!AX[8]_MH*H0-Y$@2#221=,)[-2\VF,U@:L.,
M.^X?/C6*L.;LH<1^8V ^\.P7M]*[P$SMSL<G3UN\GQ";L3\%#T/601Y;[DN2
M%PZ72QLXIEJ*(]2A\^5_P&.V):)Q!T>_NXU]B%IM_6E:5A$3BX6U[E2WUOG-
M^L_:JQ6CJM$),<WO6[W<Z7-S"CWQP+0(9BN")[MB(:0,&M\+>,=V'^RW/*)7
M3RBU^.FOH@_D,9E(6,4570)A++K\($"^^FE;0A?GK*T?F5 ]'!49M(]8.-;L
M/>U#!E46159[6>=%'=;]\">P\]R;X;-3J'6<3:.Z+*,=)=*XC;49:%OSMHL?
M92^50MO>U6"<S4?CQM^Z%_G8[7-P'5MXMZ&N82@.-1DNK#$Q^SCDK[7F$?QJ
M&#B[*T9^T2.;U+<KUBR?HN>])WI73/)'N8*?[ILGUE*3E)(21L9/H_I/KZ^K
M<?.!!CN?VLKOQQ)J[KX(U[M6'E(,M+/SJ*2#GT5JZB_"5FZY8OV6GKFN](9?
M%,>.)=OE[5WRO#(BRUA%<SRX_'*JAD]&/?A$P]:/ ZK%&T43/Q5OGEL*$A?L
MBQ98D&W>-(T2L-KV^C=INKH$@;$];:.B^0UM78=I!S/3UC:[DSLW.CHZ=W&^
MI27Y(C-98?3<TZ.RUHO2&Z+9W@L1Y(IBG)?9HPTTXQPY+B+9DM45B1UD@8X/
ML(<IPA.CA# ?BCS.H*._90>2R9=A?<41E>.Y=\>V:^^5T<UF;PW6Q#G-S$'>
MQ6+V<W+=BN\B'#.&3V>E7,R2+:$P3V'<4["3E#'<WGSG/()G6<A8ZB\-*^/'
MS@[ZN6_=L7;B)\U2V5W89V$U[ZS^=$I\^*79,4:C 24HY!DE?2:)D6#/^9%Q
M;$EJ?'&. 5+,_ZOWP_:&&<"1:B%'"^J>7-\"AX41QCCA3U^'QC[PL0XTA:31
M*N0V_PZZ0([:.XI4F%.#6=*WA <+D?O0&S-ERD [S^]JU=3JA?UM77EO89S]
MREH3G&,TA03(?BAG*.)_-T^W'+4^U/%/F@8)O[[,=1+\*Y02]B.EB8[IH/TZ
MAFW1B5&4?#C>=XQO7U?=RI+R\2ZQ&_V!--IRLK-3>#:AI'MF/"QZS<[.1](+
MW=V>3#?9VOQ2_%&H@.PUVA4+0#Y&RAKLBN5 #B>)>X: COTH$4#<1OE7C7,L
MU-8^0>FY[6$)T)HY+SB24G9AG*\?9G:Y9DZ]A%IY>O3#:WOP^H.KD@-YASG6
MTO=;S#*Q06-1\6.<YP?FF[2(@2FE<!N7_%H/D!["'%KWO&:D%G3;"IMJ>*XC
MC*KIKBV>U>_2IY6;XF=:1CMZ?.GUMHU6**V[XD.YOD=8:'[P3(P0OBNF.$UE
M-*5O8#B/$'_4]SQEX5/*%85GI@%]RGG/R\>YDOL[ZZ>_*LZVE$?N\>J-DRN.
MA=5X6W^9\>R-/A.2-!GRE$":VQ4; .642UL&1Z3V_ GT<JR]\ZZQD8^CL3E6
M'$I1I=-XPZB1<)C-?02+BPF20[,NQ;.O5X?$!]/_YH571!YR-#CRJYDJ(JP]
M;Y''D/-84FM:9^TT$$KN/8IPX%R #[#L&8^CVSZFLZ>9W,+]+ZK\U_1/#-4K
MIK7JIN)22T+ERX/+J7,7QP]71.UU7BW6E.YFRAL=/FGW(I!Y,&[O X"LE-'P
M^JLM\81MTL SIR3ZYU"BH%YU* )J^[)2T[TZ%[%)@]NZEL"+W3HB\RB5VGHP
MQNS/!27CJ4ZT7")/A!83018Q(@LB$R,];<;*J:Z,9(+%0G=R,&1-HEGVTY@%
MRZSO!@]@%GI%<1H\?TP5W'3TV]()O>"<#<,\A=!W7U9E_ !K?]KTSFB#.#.8
M#-J'4 !BYAFID,,$'Z0TH/$V?E]ZNODE]'3=DK;V@63#\?75FI\[+9@'P6/;
MW=[+B=SF>G](:$<*C>'OZZB1""GCQ!YS9SU9._I\R+9,4?/V-[[9KMASA*P&
M.$@N'^I:LZ@U7D_G$M5>_U+=VVTN)W?1]&@5,?]GW>"O.H/V\M=-3Q#/>G"I
MR/+#S9R#TGM$3'1M&Y+%D"=D?P]C2D_;\ECR%!'%K"EMN/S'%DVM)L)FP>]T
M] MD,V%Z<%=,C^;2I!A-^KNQK6U7S K9]'8Y>$?:8Q&_82F*U"/!4U)H7J8W
MAEHN"Z9$I L-.=)3:([]SS[2$2#V6A/'HB),TF=7[%XHW2,3<9HEN&28@(T,
M1Z5N%D94]U3J5L5.#EI41M;X^_-Z5"(MW,AM+^EED8Y'MWUI_WM#\B1?I;N]
M7M#\;EV,NG +>[ I/'*I(-0%LWFQW=;\5]FQ%BT#/W&5>$.37W<W3OC3YX8]
M"82']L:X#>2'73% ,X(O&_L629#ORTG@A@MR@CGBN2Q.4GK=&D0N2<V>F>A(
M[M M)X,/A]#3,\SMF;-['#BI17DL_9KA_27+0+8/:21Z6E)9;L)>XW)B@@M'
MFFX@_;]=L<<)0D7I(T(:2*[GG)_7I:%B,B0%^]IKQK"9H!B;:7$:R.TSDZR(
M+SY?+_\ B.TKTVM,'O7Q2>DB=I*>VT2H)\<Q2)82R/GGY8W%O8S4.1/ \15"
M-S'8"JBHP*0)U>#9E![5R09$U(+RP4L.4MZZ9]>H\=>YV4BF0#?BWH\5]"A?
M?E?L0'])G-&+P#@D-*;FRF3$!JFY?#V=9YKT#A6;94":^LE$%Y/7(A3G5HJ%
MFD67$JAE9\=B7OSPU-OXD;%)1)Z S9T93RUZH5)10TPKD5KWCJG:*4+'[*OS
M795_-KSJL:!WXNW]ABCR2;-'0^<$#YU23SX\?QOM(J^8_ZH1_B3,-N;5ROOH
MTR[25U)/ZB=C%!S"CV&=2\U5_Z&.]]^BLNJ<BIL[HU>^H_?G?TDU8&T6H%ZB
M-6=;1NVO&_,[D;U(H9H/',/M8#N2>4J9B]G,V#YE.89;LK7CF4E*V?F)F+RC
M,[@NVQ./BLD13,V[9=;NA2_.^,!'IX([A,66?X/3)=F57!W!"[[,TCL=+ND
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M)"!D?D)),K7BT$U-ZZ.*T:\7G=Z7:HUKSDY@O6_9=K6_9LU4)'F^2)+S-+^
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M5?LR:=A4-J2^F:[%%!1C6W- !U;</P9%L&[5Z;(QQ/FYK=]0KMDD[MW75^>
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M/RF)%)ZVOQA$ZE8"6S#"AKX3I4 ')U?DCS!-WYJ_]Y^R6=5L^#7>DM["9VY
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MQ=;F=GCC#,4DDF]@KO7+2^-;UF/=XC<ZM=</5&CW\0=WPJ(''\X$>AOR6\9
MH5>:3E@EE<3%_";4:QB\'&_[T5 \2LNYU4&M'J7O/DAO?UKX?JS$S/KAP^#W
MW[=DD0]5_"+3E>M\?A[E@(YM8_N^,KF,6W,2S0&5@S^.[8=Q0$?W.* TR:\<
MT'H[P,L!66/C!?>/'^C]*2Y6@U_/KP+BNC@@4-0Y5P",8%BF'8NN\J^D422!
MFLTUD\8VBQOJ *2'K<"X,%+YO3V1-[MH1.CSW #R'NH4[<NHX0\*!.NC&HVH
M!S^9!U",D0X*/0>C,HWXP("*:C&E]!7H7P:#S>M'E2I0Q+H(2!4&ZX"Z-&U/
M3%H?BAA_^/M@J?'EK7S,[UK+JP-7V\*?TK+LK@X/T,<>".2*OJ*OB<E1_>3L
M%DO$;[]W[V<FT&S\OU@J3]J+'_4/"[@MEJ[EX%]4F-.>M13J&,CCBMJ,7*;V
M,L7*.2 IW%XZMW=Q\UB6\:X+TY#A79*,G<^ET*U6T-<1IJ.[SH033"YL/2NW
M2%P\_22(<9C:U;(^T>"8X<@GL=O^%$/Y^.OEWXU74FQ&;K<1FQI?H+)Z,(@#
M7U8N\2X'-,D![<&_,HVH0_]"P 7T8R]H@P[3KHRC30S99*BU9E&I\Q2OF',A
MD5$2'V'TWE"BO>I[(GE\E5?=3^:U:\)REDG7_]1BNO\:=J:F7]RQ*RPEXK0*
MX4;7*SG/:J<PX^2K'V+$E:X,9S]#]N>DV71UAE 3DAZ4%9<,'3V>?KNFX@/&
MQ;KT!.W!RU?YBGTC@;9+_LS2RG<C#Q[WC-<V;ZND<(/FPY^(7LT3CW8C $2:
MZFG_AU-N,WWS&SY4>-<DTR1 ':S;[7E](JY-N0HPJMIRD/O>$(X2='-ZY_91
M535 RO55(S?L)A79/(H'>NPI#S4@93XU^GBOB1405/QC:FP\GS9TJB/?ST.&
MK!&>E"2O 3[5YM)0\/[$3O:/RDH-1>S9E3DQ0IB&F&E(N87-^'4#6B_M/':>
MDOJMV)SZ*$^/5?A/XUG#BR.7&$12[9V!,W_3W\@"YII%BS/GO*ZZ_WV[V%E_
M2 ET\_(!=ZYL6$^P]_#?OF#Y5Q%'F,H5DYBD[H;__/(N,& )4.L*(,Z10%96
M2=G(>_7?S(S1NV\NKNY"N*CL0N<Y=V*&!F]K=V.]$_0435+<9H"!DB[OPB1_
M*4L=74AV\J4^(.^-+FK89J2+OGSZKLS692(M0&]N[/+(C:6J"OUJ<27?\I]-
MP<U]#UM=YU["LP:9BB8C)LPJ;,=#XN(%R:O<$ VC#W!3<@R_-KUGQTU3#U8V
M<?UIA"0'-!9&G=K&<BF7;LG5\(6]UPP2\Q8P2;\WW>.AE6E90[XW06,T=N%X
MW=S\]D,,>,7"R[''@%[2N!;".^:FU4 04NK3&VN9D\?79@_?&&8JY_L21.A[
M.%3A#TEQ<LCL<4-RQ6A1\9N"%:$'*_OW</[/JLW_5V7TMS:?'>1>G;TUJ/+_
M([B*_-]S*Z.7&U [#8PN;$-Q=##-,$@V1B6*%[@>)4',//NMN]"5"P3N462=
M?V+5TZQ3NQ\BA4,'0J5[2B32]UXL?<KR6CG3O0_[?^)B IX#JMM:?T%7W"/0
M[5.?L+6!OS%/!XR)D8ZDQW.X,/T4&HYW5:#G/P_XV[4&H\" MZ/_/)=#6UR;
M=_?=+YFLN$<<V50)F=4,AT<3^+CV%(R]@W@FJ3O,#'N .T=0<O?5>M22D4ZE
M)'&UN0%/%:G7DQ]?(N\=&-+Q3YCB65.&URX3,O%N_EF"4R7IV")W [(Q!W3#
M)+$)IDZ]CY.CB>IT*_P^IPSGS3#+A>K?G6_VW+@W;3[5;33^:L&L4K>F5%<#
MIT=4_X!9U>[?I=>\74B80U<MFAU,8M&- X&^385%$OQ,$K9##PW>0 %RCNN3
M9;]A/NP18+IX5=+DS=)O2$ 3H7D[8O;%[SS$F]K/VPN4QD==7X999[$=G;#M
M>Y!3Q/7E-N$_FPH+%E')OL0/D'4LE?(\;B]MF'#BAQ#LO'%E,+Z;]FP\PETE
MUZ]RUJDA5P7O.?^&::CZ;]V&T3_W,N:V>TE"/R=7CZR.IQXKBYI$Y' C^D$J
M\TT<2?5 9XLK6JNEP(@[/I'NYMS+E$C^2*UV<O*T%U?VQ^"]T:XX?@?_5Z5V
MI1OR1A;&@C*EEH\"[?*KLSM&.[Q?KZ)E3S;WVR;%L"$/%=^H5\K>FW+K"TF#
MR6#G_Z/0K3F@O]B]+HU)4><B?#^P/P/FC,LNJ5W;3&/R#LO'<8PI1@N_KB"A
M<:PZ?^6JOU9+;\RNF*+</]R\*![?:;]5L8$J<YK]I%Z1"BA!F.=XJ<L;;Q;@
ML5%G -G@TE483Y2@"R;K-].T[,<O-J2)@4IN,\'RQ70OYJ67UOB?I,ZJD?:/
MI>E'!Y6N[*O42@_%UP,:UQ7^0MY#KE  *<BZUX$^^QNQ!M^#!T>@Z'[C*G6P
M9%>H(FU6<C]2N$?_;"2\PT,D?$5=^<Z,;EBHA9?OA.ZC<I\RWU^J1VS<5FI-
MQ0.)[XE'L?,)L _+'43!;T#GEC$0P\#:D%4#-*X+]=)^)894NI+V XL\0_W"
M_$)EXY@25-P1/]V=H#Y_KS1SAGL5\9T["1TDL?DFF/T\@#4SK3]_/RFY5FE9
M.'J0."[>WA_WX=W[T8^T<KO.GIR@5[^7A2UK26-V_L%?SE'[EWDT%-C;$3L/
M)F,O'S9[)FNX6F^3J=Z<?LM8C7BY)C05&I:>AO*1JQ3FTMH1)"!1P>1GQ;1Q
M)_ND1-N>[J_NRE /8""R:.9;Y:O]@-3$?/).*J]4A?@ 9BHS&JI!'0P?:GY^
M<M[=S2_VLB3N')G]YPR.C[C:],9G^JI,;591B*+S47P/G^9"QYQ.NL7[IQ 1
M#/@V.:!-)_22=)VPJGXC]9"25X9Y$M-H_E?*X"LD4F)H%X^(P]$1X/BYT_3>
M]7 JY2^DBV8<'E-+,^E6%F:?^;:+=/V-;U//.SN"5C;OTM>BL\8JNPN%_CQC
M$NE%E9=<=7T25 S0]K_Y-3[:GAWTH4>(X99$\/Q7?N?(]]NKM3U2R%,%6U39
M/^L)_A+47C (/RQBT^5>^/U#:?]&Z[[VNH:V]\-WWU^21J*??2?,ZDEM5.8:
MSX1,?OG$]N6 O!%Q>8I<#KF?^E3_+T;1'I[6#+7' Y=O,ZJ*0K%[N1;L\Q&*
M=$(VJO)W2UZ]\E3DNP%JXU/<[0_A0_6*LR;>/DBO4*F&EON4'S#$YU2F&(E^
MZ59 E"Z;O%]4R$@BE42<HWM3WOA_&$+QKA T@*>2QQR)#U2$J:./0GT#*F[_
MYY\Q3YF]<8', 16O4KISYK3G+I6D6UD_%[A(,N0]T5%E%(_G05>+)[A<M7I*
M\LPY^\LG[B7*M^>AR^D\P?'T&89:<,!6G]""6&,K*BMTM;#=&=$%9@JQ!WHT
MB70K;'P:D!LX<7.T38!.^$6=;/ZWFQ?0A1WS:T'_]-L6N2BL&4T[&O?\Q;*S
MRE-*T49C7F7@^#@'-+T;\>; (:J+6#NT\88ZJVH(3%//;^U"P.H;5(0H)MPZ
M\P:C)(8]3J_?T;V'YX&CT"64"H7,Q_JMGA6^>)F![R-I=O4UA'IZ$V_"@S9%
MG!))S*#HOO)]Z?N"/L97<_WY*VUB[#U>R<K):W]YYJG]L\<RW2RGC5PG/?+&
M4S:9%*[PT#K'1_3%4H"Q6YEI=UUN5>'4<-5=?,#$HCY7-XYBN08IC*G)>JU2
MA_^7?:*=#$7@,8=^_ET-G*?BXFHQ$FTZI3/.,RL-XY+RC$3?\OG?ZY4RHUOU
M,N,ARB;=C9E7ZF<_9R"F&LDN1%HCD[^<;6-ZH,T!S2*XVL_',"868O\ETHT0
MWPKF8<_7"1=28#3A[EDODY=S6Z3]T![8&4PP@CX>4S9M=C?.*8XT)TP/C0[9
MN+-WY5$W./$=XUAFP*7N2+\2UU6'\8D/+.]YU6]J>Z: )X-HRRIHXZ7[F'S5
MO[8ZP>730"A"J'U![%MEO>KYRIDH&<)PFUHI\/Q7IZ1DR]@_HQJ\.C)?0_@T
MS</Y3*Q'-D3G^MF;)PGM0=AC=W_["'@[*Y_B@(3U+PPP0DI>+Y19E\LF=GE6
MBSP^5R*:+F_W7.Q4]=G UI3;M[\OGB_K,\COI#OM<R&F^BSIAF=9IUFZAK2O
ML=6K+#]3G8$7TN=&!=-S H>!& [H.-<!#69C9TD<T!8?_BL<N/B+6;!,_<5*
MA9R#[5XAXAN)OI1O!WL/694!4%GO@QM,S48@&ORD2B,)SZ.'2>OQ$&X=7F0<
M<0EQ(7=@YXG\F(?[R$A3]12E6>?9F1D74Q6<C]9_,HW/C7;@_S-EI;W.=SN=
M,@$M0N5Y1.I?_Z/&TU0VMLRC>%S!MNN>_;M2"\?T,+L&S1PW'P-^2[6Z*>NE
M]9+HTE/]A*O]I]-=S/@3'^XEFJD[E&=F4%H?EVJ5C81C+V#I'HC?^B,<T%T?
MZC([ _..Z*^OS10>)W#)N>-LE#C&G'05,0MD&K!>$'W@\2TRV<73D2U;3CCJ
M,G?<CF#*."#CIQWG9BBS_EDRN663*PT92JI%8T4?A+[.-;&_M!W %X;^;#)!
M6<7,4 Z(5VTAKA,,6#!1K*023/@!BBUTO!O"A^W"F867*BEQ@3?B\D+ X5L<
MD$GX=-I>ZH?(,H26 /S"K<Y(S_FM$T#H1TE^>N,3Z,5BDW> >8>^^%?F96JD
MZ/FJP(OD"#UJ^[4)XV'U3U6J/LUM>7I\U_JGQF1:FYN:T^^ H=O]0Y<?+8FC
MGN59=&#<CIYR"SXMC(_M&L^0R3U!1=J1C'%*OE]R']?+GK042BLU3OL>6K]S
MK21S\,[5G^5RNDY-7_BM'P:;!:Q)+9S+<B_<7<4*0>@FW!6DE;J\[LEPI0F]
M8,2:LQ2IH3T6$%)&UD22^L:U+1?L24QTAP#RE[[$:#T?Q/0#<6)K)SP;)8"<
M0D_]>. ^UX%&E\QH9H<=L1GPV<31'<& _#().S72V:+Z$?&OJ#LEGLU=AKHT
M):\SX%TLI,GXCGFEK2MY8;3.0K27)"KY+D-X'Q67'^V>86%NS]#,1F%+5[7V
MA(0>WWN9%3R+Q-;"(!S0?!*EVH?KCR56*?R!=5OQ"!ZF"4UQLAY^%M\).^N;
MI9*"1PK;#&ELXH/> N6=>6KDD('IWS+.J$Q20XMRT=AG8S;2<31P5[%URP<P
MYTY[%RM9'QRAPACJC 13H1X7AJ/D?)%48H(H!Y2T6^EJQ\ G[3C5RVF$!^AB
M!9S=5D*C).JX?+XS\$,9>C9/N%[T^8LBY-D;,O7>0@4(\\0%E;_*<STQ[8N_
MQ^[_8J7;?YQ+OO+*G_Q,SEQ8OEDUP"-6%/H:+9J8[F=;L"%GE9;K^Y#TUQLE
M*%U_ BP.(_IGI&5;-,M)HQY=RVZK:BX(<[%Q2&)^XH"BT=CO:6PR<<^*">:
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MI2$CY\*04MM!&^L0/P7CME7?I5#V:9-WR#0U.>1\(0I70LQVX[B1(@G9;7Q
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M'*S>V_B/75<FH\ZZ2RE/478Z[B]+P^0K'T\6ZT^,3+>S?-E&G#-< ;I/]F:
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M;/1D:&)U/OW/C,W_DZ9]87?#9 +YS0JW^G]<_07*YP-R&/#P&3HVPX=1G+J
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M"(<*&->GM;3C>!^*%0RO_5PAC^QSELS'KF>]4^W[ST:!+_!0GJ+:.NB3A:D
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MMX^<;#3D> M/ EJ&'G2/SA^RR(N*E7::]6I_4S]63"/\5X9%>WM@89<K,>+
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MQG@N2*YQ].9=[&;*H+NC9JKZ!!&;,']UF0P_*LRU9:8B3^J0V^2EM!D-NQW
MCIY%.\FE^F(NS?TGN\Q%WR4#&NTUS!/L)P"""?F3^Z9^!ND$(.:3P)U2\EH3
MQNKN&F_*+(O/=H5:#!YV1NN3FA,,XG87H+'=M/PG#OOH\FAP'A_T_ 7FZQ;O
M%&:J&M#D@QQ(/=G<!NYS03B#IV[TDFL@:]\(J%&V#W"(CA%#8>?YH%B-UFMT
M=P1-^B\D!UHQ._?Y\LR*;KL"]D__('<;]VX^B"@"C(G?K>L-2CNKSY77E*4
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M@KN]P83P"I_B,2;$<3J4DSFUR_TY&72%?-C*G@\ZR]']V;L'IX0Y@V4^)K_
MUV]0D?-S+^>C\[.Z(;\5#B.=U<_%S*XL=4;IL+0^A.S>3IC,COW,L83[!"ZV
MIKI^GH('/JLYF1[%!V$Z--'.RDF0>^"I,*?,;U7405HGZH[YEM:W<TRIEDI
M1O4>(SC$_E$!<\6YZ*R]ZX.__2>H_?>E_HDZ);!'MTSL&]9S]N.1UESR?0"Q
M(')C<.O*(@8.% Q,?]AL$,DS90NP_,HGS!6&[!/3;P%I;!COL.#"!=&(Z;@*
M>=B'-!C<TIJ+VXL1.%#?-!?/2J3+5WQES"E%#;+GSGWZ8CBGV3\E4+WJQH1X
M3#C-])!]&=[IH7&/:-A:9!Y2HJK!7,NW(EQUY96AQIL)?55:B!T6(%SC!:7L
MV=^2<%R(;?S_2H>2"^"ZL:=JF$.</_+DJX'$$M]5KL#EP(F':SA_/C<^/]'?
MR]Y3JRO="GBY!7?*J"OX4))6GUHXM?J>]]N*5#:NDR ,^\PQ;05(" A[*8,E
MQ =9I9FWL YET(WN2V\]4A)6 $_9F.PI1/RUY35JX[GY7@3T])N$]9^__Q\?
MCN_)I,E7 <:G>=T8XJ%$M8GY.5>T-&L@!6<!5WO\Q=DO2F6XRO!"R4I*:]E9
M\%H.-V#.%O7QA-:3)*&,, <Y/34UUN=/2D(YQ#L>2C%2(A7%AK><;!*)XXP+
M.$3%KFN*C=];9=WZ,Q?(MTOFOF(TYTAD!HY%X@F!]RTH^Y>B!K+[UW',)YB3
ME/GDF%E)YOCJ]TR8I';<<]<YU%*/3,;7ANO[IGDAY+:1L^-?ZYGLYS17"W^'
MB,.ANN-$@QRR@$IPQ&R[,+5S:[UT;'*>.K>H5;@,2.P8@H_ZY?V:W*F[9QQ;
MUE>*>+P<"(\ZR5K$T>W;)[2;\%6>S:/;T\F_+/MC0C34I'R]HC5+  KOR/Z^
M1M0(MGZP&RIV;5\3#1WA'4?MTN:B%5ERO4D;Z- %3.SD1', (4PZ5GETVS^"
MQHZM J(U=DX2A>.J/)W4'ST<M=F4K6CMDR0.KA;-,6^"IRT6/)H*W'GCX(97
MN?0<HZLB=7Y74%ET<@\CV+(Z;N4*Q:= -*ZP8_AFFMM 0G"$OTC*V(YL-ZDM
M]8O+"F;4B?/$M=/I987R.Y:&(V7*P]XJVJWOU\UEK[H[_>W.@]3&X>SGW</6
M07@3U1,,%7/X1Y5</4ZN?FA--=ZC1+Q!A0@WLREC1.;*J-ZL;,KXH3#7HAF6
MH<CYE,,3^08,+DPS?!:RWOE#[<9"8;'9NC'UL+@HZ>JVYA-3 ,0URR/G]B0^
MQ.E!U@"Q@75_I:$YB5MYZ</]K+TC;;?JVL8(16-\D!IF/D]>8?)G-X .BZC#
M$#9^9265XS=A> #OX1>L4Q%>UDMG$5#GG!+M<@V[R6UC!PF7(MBS*2N64N5R
M\C-*T#4(^S(W/DJ4UP4YMM$JRFP*]8?:LM1[WI2C-GKRSC2:[1"D5EW\8S__
MFSO_MU?M2$C.%?7M;)-X;]E;.#QW.'N%MQZ1L\P'O<)2#X6]&P148I-#*TYF
MW8']QIMZS+DU>N855>_?ZH8L>E)6\G87L5X?\6?F$_9D)GU@)F2Z(M#OG][3
M84Q&."?@='_MNO(@^GJ,:RP;Y;:@5%"V?]OD+4L\/X;P#.\1$GH7E=#8_B3W
MF^:34)N*J\7M*M%N2F#5T.+PNUWF;/_2,BMM";OFS5)GH\R^F\DK?!!/B,CB
M8:86V&< $EWDG"W6G(5)]O>/$@.4U@>VX9,LA(>1M-13_&S.TTH-/-$(W/&D
M776R_L?VCBYS9MG:$JF=DD24A5"0@.[JO!2!#GN%/<X'^>9\5T[LQ![EG(F8
MCY2B*9)N;[0&+^B,?FV,'AW4O7RM"+":LXZ(:W__!R(7:?':PX2-]P]<FF.Z
M)%/+H50?=B:3M+;,+-]$G@!NS O2 N><PS*->UW=PI)%[@%+-[Q!5O!!/MVX
M+V;(TGX:=AM\ +ZX++*(I?_&RFA+L3"R_-K"+8$]8V.94"B@D-P-.^3RV=4=
MM00%Y!8B872I0AQ47 1*W^B:$4%#*OQB;>IC>BPM+)FYZQ7%*(Q)VR8C5';P
M,&!J$F-VO^W30D=A#/;8XV/"RG";0;TM.?/L%P5M^-,'S]J=Q^DUF<XXA=NZ
MI0:FJSP\D5B'4Y9_8WF_3B6#IV;L;MF"6_]8:9M65S?YQL(^9%QAKX)W1.""
M?V(>@1,A3&LD-;5O'MR!6.5":0J8XUISL;##AF)%?JF4?]$W6.H-Q++OF1A)
MXF0S G%-J9F*'Q_(P93A,W-IL-\4T[-2G&>5XT(M-NR ;WS0;_>YA9 'L.?#
M4:,PT7;MY2AUX&]FTE?61F((\@#<A?!B1_37[^TG=?6)O4EHR0571H#!G)@E
MK<7U?&BNU2SR&&##'OFH^D. 50PSM539@3#>83!SU8R%81 J@%Z[8Y-@(>-C
M0&^WO)S8^[@/=,WC?AY@YB^9#U(GD#K#:$WZH$0773;1(+HUK[LK=3JQ5(%+
M%W##]YRHH2@A0="(<71UZMG&.@!- B)L*%TT!>-FV8PQ0EUS7)/EW2TEV\:D
MER@-QH<3G:HG @ICEJQ2]UV'6HW*RRGTVR_R>/ZY"XT1\7K!?S?>CY'/^_7M
M8XF:L7)/^&3FU?N+"W%[GXJE%0_3O'8J;SVURC6S"O6VB1H0TLP6?%3U2,*G
M2T%IY3.F5N8!QH,IRO)V]2W8II-$Q0>558-+P;PCKH@%B("+"$4*=$""\>7F
M\1W\$Z-@>E@O)LYE-N51P^WF=*H5\:S'+/[9#9]"5-16#T]Q* 17]VS62&]Z
M16KV=,.S6>'/AMBA.4"/0+]<DKNOA3Y'NML?'+$P&$>MN_0\!.%],)&&%57[
MT\#]ETMDUM7&RZ:_';W7<+QM+%%_BDEF!I H,"*PP4X%*/KA&&8R8-&!%0DI
MDQFZVL('O: XC1E:$XJDZ<N69'88YX]9&42%2>UK#XR?\R>2PYPG*H!G\+./
M%L<\N1=#BHU#&R!*9:<A+^9$T4?F)5]=]4P=F."M?%SMS7Y[\:28-2YAH:=@
M\B[<(Z*4H*Y0G?? ]21>7?_;X8<>&IZE-B\<P#&7]8JMQ+[A+/M$E2T5\)(?
MU"82$CS6(E.3"%*9\&9GA6]*/VI0B3/D<*KYAKO[^"E814O$E=U=WN$T)AT*
MXKV+^F5<0VWDXRX]]J5A!$M^^8!4-FI=.V6>H;+Y#?UZ0K=E"'VJ:#"@3/$]
M0KH^I<1,(<(5N3C)MM;',4(%\M4&B*3GY#B%QAGZ[)L#R0N6.TECCCZF]<S%
M:'KR<;0GN<9"W9R]8F%T5M72. )AI,+>7-%)16E-17-(ZB*#.ZJL:^J0!P1
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MM*:U+ZSGL;C)9F]^6R#5U]>37IFM!_BDZMV+T<UTO&GBR8E$3?.$5 52Z(#
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MZ99*!,C%5O.[7C4"9GV+ ;*9:+6X*5X06DP%>H;W!77_P#5@^9ZP4>GU(D#
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M=VY/9(UHA1S8H=F>?4C\%#O-!O\PDTN!K4=-2O^\%EM01LUX..^6E2:2>?0
M'G\SV"JBU<]MQFO&SDO)BE2-._+C^M$@QQ=7E5F/W&?HCK#14P\T<DLD3+G2
M4Y#)G:D<,C89:ZS9!F5,U<&6N4)O28K;)JK.0QNR4ENP)1C+K7SJ+T#Z2I!
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M&_*YT&\<B7(J=$KP"!HPCKA!(>.6MT%(A[D#8T<&[87&MABM':>+ W$#?;7
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M8]EA*@_0-RX*8AXT[\Z8YJ^5Y4IDOS20V.<]^/5E*JR6_#A0^LJ0^80I[/[
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M>$?/N=TG/Z[8/NJ=U&TULK6^4.Z%U_+29Q0O6 RUSH\*!UQ$W820MQ)5@J.
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MRX[NJXLN1E(110&L,VRX</,U]F=<%'P#X9"'H23H\PKOT;X8_Z 7O8YC26S
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M(7GHEEQF;\JV/GNC,ZQ1(V[(Z9"8)_O#13 X8N0^O(3:0KT/ER.<!&,8;75
M-$:BU!E#;XY_SD31I/'B#-R&7%*^,0-KP?32!?D6N<R$X>H[T9WGN>T6VS>Z
M>JR_1Q&<M'8*W*K1.,8_ELIN/%RJ?FW>R;1'_;J;>C3ED..F]&L[EP\4W@]/
M3^I,+._H16W<7%%ULOS4(>MX]7L6R0ZM0S6]S=SI^#H,J*-:%Q\C@NVJE>7#
MRD S=CE#KFE/C5B+4)/H\!H,&)G=!O9:=Q12I+;VM[@% *1 '+*+['63E-P1
M:,?%^E/LZ\_.:W:>?1Q"Y4O;TE4;1; P3%'3>$2M9J!$$V:K@5D^'L-)>:#)
M/SUZ1GZI88#3KK, _[G?GO9U8B#=;B7IGI,3,Z6]15)02*GCG3YUWX3S1EC9
M;FRET=A%UU<XR"Z5E8\X>H42\_W%U/NJ[@+?DYC^[!S[5UZ.T>;OA^*NCA05
M-\]_S+PD2 M/4;>+KEFBO@&)S33^SBRA>"'O'%Y2\ SOPCO+7\<V?6!PC4UN
M4M+J$FHR'>(;%#=/7>RNE<:VY2&B];"2R(85F>K>5.U(N@#%DB=%+@[NT9F6
MD-QZ&AN2M["\P+QN8%<.19HB"'WO!O:^+4=LTH*_'0!B_+$A@I]&6X:EV#^7
MD/!7,V9J!R6_!@?;@_<PDNXKG[99]?3T#BNQ#5,*F/&NN)!K/A[Y1BKSD'?J
MHCKI?+,LQXTI](K(\+F9O8VNM^(,9(_7X*[9J6\^8E6J&MYD4O"8A!S(9G:^
MI.^V2DNI]OFHGNAY*5-N-TIR<VM5XJC2C9G9F=I AUY\82XCS6S0E%\(U"E2
M1_X4P79,&ZH%^G')X#(]%/G60>SNL+,1/>!NM24)S<Q4XR"C=!9(T2W-^A%I
MM[CE#CJ1I2?UI"@3[U^<]5ZL<;Y6(?N'1[+$<=*B",:7"QLA-L-C:9MKUS>P
M8^@!\;5JSH'8%H)Z=>]-0WB@K2,G@I3KX*FOE(%U]??+F9!UB'BN];TB^GSC
MU,WV?29'B]5:"?/6Z./*\7X74#+73I*D3<+-*W8RZ8=/I-_JNC63X4EH,D.X
M?QL*3G*[/&Q;H-%O:TU2'$UNC]@:>/*#N9[FN*WI*7,.OJ<??TBE&!V FX,+
M-Q'9)(9;O51?SU(#5:9Z/4,$BQ#N[Q(> 4<QI>S9AP:(/!#3J&I2T<Y7SAGT
ME).7+?%RR^\_YQ^4[2GNB?/2&OZ^2W9FX^//(1[?2Z!NO=-+O4D3PVN 9J/D
MOKEQAH%#RCWA@:]3PX9A](=_X$T+S'(:Z!_!VX[$;2!:\1@JI7%8O#C3R\HR
MY'Q7Z1"ROGYL(0/9*'^C-9=97@5,A<J,?7R@:OL@WT=;6:?NNJOC;I0,2KO1
MN+NN*\[=*G&B%?GDO9IEQ0=SLTO6:6$6B;3)O&NRLGJ>1LGIU^1?XRD[8BS-
M'+WL\LZDH1R)3?!&.*@YRQKB(.E+4<)UDV@XZ.:6#Y(M>O@2#$M4@P@FJ4?G
MJ-J4=FOY2RHWRFLP'2(?Z.$D^VE.]DY#'DO*2+9EYC/7;Y$4[.EWWS*HIM21
M*,1KG6;DO5HM3AM+@]-9Y]#2$%.(J]O.-UP]'U.6^:4OL#C$$M,H*T^,KD85
MNLM]2%U=[%0";&96*85[%#@P!\J*2%,.@F\]A]U9V6@LHGU19L&>!+](3G#Q
M=8J)8"N<B?R4(_?GI6?.#$]4M(^W+BNBOOGQX_@23^N76>:V<2I6-N-.I;[]
M)C7Z8.SE"Y=>T/H/F3XR'N@E+'PE.G</6*$H]Z+5R)^E+OY;"]G^,\NB% 3C
M<]NZ$5.?X0(XNAVMPZ8*?Y$G"8*@GLB:&E!;'PY"B+K_*W%QV4,$>W8F4#)D
MJ1&S+/M-!"-_1 K$I]ZZPYY'J_V'%?(N0696NPN(H&]@+T8V.A\SQ;!$L*(^
M_A7C>,:&W1R3,F]$>;MKAFG:;;<T\\;"#%E+W8SL)*4VM"E;];)P$+Q,]T(*
M95%\+1&L5 3S!IH:A6]%L/L8X7:X:F-P$Y7_>SFB#RC&DZ<1U81.P1/N9\/V
MWW_L)UK_0S]#_"3D0WD7(=;2HR=TX'%<K+_!%[$Y1\[P&7F=Z-I#2*D^OE'G
M[7!A$T\EI>G2%7[HS_@SV:LIW"/7)Z9/?']+LX":3-[R)-NJ_9N>8&\@@AY9
M3XU"2)5B=F,Y> 2X2,9J%(26,[@E[/*&U-_(C$[2E/S#%$]O%JZ45_#.*LS-
M!4?_TV#PP8G!B78SI7>9NIB=G+:WM(@_@G(_TLOO:AUY@^O'*](G#I]BR:;7
M2(UU#E"S?!%[BJM)*N_G\I\H&5(NE&M\G%ONCE"5VG4Y4TK<5%+]C]@479=3
MMK[1P=D=P<.T=7$CTU8:NV,:6W;_(MUX'=L;ZZP?UV17H!^M5;C'W,[+XS9!
MQAJ3D[D?-*)7?//!T2U_6C=_U>@9L_T1L]Y13?GA6P(>E>F$/]01IN"N?T7!
M17[U 'VU(RO 8@T&C.\W%>Q83A'*7 .6X1@FLU68!0'PQ&DI"",F@2=LB@P7
MBAOJ&3K"WQT"A!*%(AC8!&?GWZ:NK/.@@=I0'!W="302/B FB)^H[ ()$>S=
MB@B&-!*80BSSRQTX!,A=(M@QQF8-R&_!R_H8 :QTEB_G*()QHA'T2TQ@X:=.
M*ML9)X(UJXE@48)$H!WQ!*#;0<3MT:(P,W)E-:-Y.HT02N0)W1IWH@9%L'^L
MO3ZO ])X(PD8J:*)8+'6(I@T#Y+U'#@J@M6_U!'!E*<$9Z06X9#(<WT 7\Z6
MWQ:E1H:>_5?5A]OF0$I+6$$INS\52J2RA,I<2-RO0E?HMRL8H6GO2C!\TE!'
M&/8:,D:;M$S<9HW!K:[H_4<--I,L(+5E,Z!6G *$1TSYIM-9P@?\C] OKZG\
M>/+" J(+CQ&(78/,<4;.&^Y]OGK6T+^N7\8J!6*Q6J>A9NR!^N%Z_#]VV 3P
M J2N;(7@:J2*^!U_SCB4^F_4_@_]QX$7QZ^HSNOPU>LA^#.D=GX1P:PYP()B
MY&K-B$_@O6@>\&_4_0_=QT"XPA>0WS'@90A%OX4"I&?_TGDX&]><9\UY_KLX
M3Z<(MK-6T4,?>5=OZ-RBUPGZ'.1.O[DUL>AIH3<]E+R+2&^/Y099<(GE3WY.
M68I\C".TMR5%+TC]ES=\;=2LC9HUYUESGO^RSJ,QVW9/]B(I K]7<Z1[I!0C
M-0&XAC6N]ZZ1+&;>&;Z@/Q!QM:K:AV5I%E A=^_JKD4#:A1AEWM/IBQ'Z]L?
M3$-%1Z34U DMQD&V(/=YU4]UN5\_"DIORDMSZ3GW>3ZE&T*SSWT;U\$8X_>P
MOR: +O6H,#M#%3DT_,N,:513@L<H9@>SK"/NQI6YFU1*@*!Z8#OAD^J<F2':
M=&SX $>XXR%01"A(8=R"]P,#AIU3,AZ7N53T2J2.:HE%2K_ QNGKX'SSX#'F
MR1#E@H10W$ OR7$*@1KC^B0&A<:7URR7?^?F]PQ\'N\'MES34*3B*O1=X+?=
M7EF&9M I"+=S#P/W$O8"ZLLQ=.$?[)?P?7"_DPHCOLAR=,W)49E%JS#Q\RZC
M"8.=E2*8P9TF@E/HOL&_[6%\\6P7YN,*<<KFR[_[S*'_AR(6&[C_C SA,-XG
M9(]45-E*(Y%=B"C7J3:/IDHM2F;*O9%WXVN8;G^#Z-<*:!C5:C<J=W2'S8M]
M.I-9'5\W0!X0JO-O="+HKD ]4O (&C3S0BT:5XP;L+H3KASTG1P5&KV)YQ_
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MXB*CJ;OU$*OO"F(!+*1X]5]QCRK(@EB+T;220E4Y-+YEV_\Z8GC?:>IKX3R
M%62QB-J?4*]^+/M">[ )F&VM[*F&XL!7M+>R53RHIEJI\%:-0%D#;%4J1+JN
MZ79^_1!@+^'6M70![-ES48)R*X;I#['3V^1I),1..Q%_O91ZRCL!L5-'ZNJB
M'W,$76F^VO2E$_ NP#/T#<^Q5?B5ES5-&P!<QJ>7]_Y8<HKV^ Y&"N7D$K@
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M^V\^?-:L8KC3#=0Z?:E[F;:1A< 8^F/:?UCVKQD6^[]DV?\P[/^QBPLL5UJ
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MW\?X]S'^?8S_Z3$<7<>L/ ^=N1)XY<KIBO3'6H$G]WFX+?!8M/*O=5]8YQ0
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M"@FQ<B-X1JZ!6R[="[L7./.GK>3JU"7?%,#0#R__?8^Y5B,6Z!7C40D//X=
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M#*- GP3C+I3YX;<7R"7,HJ:UTDMP :0L'OD@-X!9')$72+V!-9'Z8O6[1PZ
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M>V":X^\R00%SNA>D"MK9B!AFK* &= WEL%DHBC9LTL)8059!. Y,HDUKE2F
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M*#DAH)L5LA+R4+ WA/,9G)%;?/,93,2N"*O+:L&D^:,0S18ZR-9=13&"SN:
M'4)F&D6?%"G(HC<<YX\:3E>2>INQJZ"_RT48Y1/?_$U[;? /QGT8<5+WH/QO
M3DC]0]AK++FYS.&!LR1"W@9./IW /'9ZU"%QD6K2/5(\TC\-.Q2\*<*EM0I#
M-Y/4\H<M-GP^O^\:QWBQJ= /)SXB>Q!.683T634;(_*"SZ1ZL?6@ @@J0<RL
MMX \8V_P5EQA*5/:\JQ@9U&@GYV-@QBCS0X2-?HZ@;.MM=<Q-D<B[.Y%F*YF
M5AW>V+=!$DH83A&=R:[*3OY#0\\EFO%<H_L_; #MI9J?QK>-6+ZY'Z+>:36U
M>5?=E6_"#6^,LWRR/':]LLG.'SL[=8V$GL9(_.5]"D"9=8XPC!<LN0[N%(AO
M2BRDP;!(P(OE_OFIOCZIN;I+'Y;X0Y@61B)+X_MIV Z<:ZZK4N5W:KX*>&5H
M!YFD8LT(:?8<Z^],6:X GS"GNX2!T(C6N7I*7]X&6;Y\-2E:J--&72;O1E?B
M6S#7><N;#,*P>Z#_QMZ;AC65]7NB44M1 2,@H"#D+150$>+ H(!)*26(5$!
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M RZW!F,R]X_.5;+C9G?F8H?[:[E?Q3$F%&;WE)C[;P5DB^PX"0M,OD$GZ%N
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M6]NCKK?%0ILZ][976#RN,ZDDV6MC\#^L/>;HIRP+?8[$6&077)QU:]1_G+-
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MO]T:]'MK>L=KWX,O4<'(DFOHI8V*(6\*'D7/M[-K4=O!:,DVR #T%W(3R(9
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M%W01Q&.*F_"/&/\O5ZM>TKO0LY4B2$FP1C56[&.F-J@;*S*5@05);T?U_XY
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M<.HL5%[]BT65 Q&7@1N5O'.82&6X)!A3C<F7&ZT3(!R'X,H>.!T'DC<%*$W
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M]X66@ZR+(4BF5:R8GB%D@N'Z8*)&'2#!_?W#KP BOI9^@"T\&>/4%=E$;Q?
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M+=(!RH\T]+(R\JZ90\K@ PN;7?/ET;[07&) J:=]2=%$@YNSK-9TZVM[@]H
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MMWZ<Y%4[89Q+EN([ N%0R8AJU/!:S+GU3B5:H2?[+PUC03+_EE %4$ICD!Y
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M-Z6!M] ?2<(T2:[X*YWW00<19"""F#NG*(;Z<H(,$63H_%\B",-0F2\@%K]
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M1,4UR?%R2M2'HCF%C5MZ(44;(<%6'DWA; ?]-^?";%<^79LF5:<YBB"QDT"
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MF@FW]>?UYT.!MM:A $6M/&DKO"]BAX>[=?-L2LQA;)Y3!/10%R@14["RNX*
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MHW)-<>LAJ/<Y)]?$CNXGZKNOI:MA3K(\1!!N$97=NYU?.B(P8%/E@":G5\#
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M$%QCO_XJX7+U)H&YX)1U;O/F4<=W4MF*I$/IU74RV5=.57S78+YXV6+'U;V
M_/"L**'*ZD<%-UA0:J(V,0^KEX_G^U:[]TV3E $-2EX4@^81;#9F<@J#IXE
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M"6ZL6>F-RHO*R,$Q/^/77<2SK"(" 8'F_(N90@)$Z,T0@0YH_&@50@[QKHE
M VEL<4+=BX>(_^]#R3\92>,X.EX.-F<@COF;EV2AE["&3YJ.0I\4@?"AT0L,
M?OU6_2IY+N,_'O^4")00A*-[BY$1*9[%KN@P')4%0^*W#G7LQ#'/SXA PO"1
M?S(13#1Q P$($>B!#X[?)7#=O+$U92T&S(* 3M[T7??]BAN$ &%J B<8OX<L
M//)S'](O(E"U.$A/-D0@:C)_67QF6O0P;$T5*_%378O?X?^H_!\8G;#BZ7G^
MF2P";1-#8#-%[,CK];9\812=1\"M]B_TBZW%,/8R?*L&MYF!XQN6")7?BD".
M&2+063&3$V0W)T4@<**@'#=G!LC^O',J?F=SUO8?C<(:0"P!+[W&"7=FB^=5
M7NQ,\&*X 9]'V' 2@;[BZ7BQ^??_14$K$;ARO(4Q06)')<76;SIB7V9'5]&;
M&\[+1!&H%T: :0C%.8?Z&K8@'M4W8Q&(S<KX#S/K/!O&-U'E/A6!BI2FG872
M)C 1:+; _)]L6_6L'L&NK^+QRCF+ XX0.])/_,+XL4R:%+,E!^<4[2PX]"^
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MK&$\#+I!C9DZ=^-B8G@&-[*'$L+Q'^H+'#D;/2H=8"5HR3EARAO^@IJ\(VX
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MNI&2??8.(Z3;5I'&,)OAI2^M'1VMK_ZJN>?NYGY9\T>?ZH[D4Y,?X^Q0TQG
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MB@I'I6+:RGW_@6\?7$);4U:DW,K3AUS%ZD_)MM)%"?]<J,CW8R?$P]#[M\]
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M7Z4/46V&:[14\Q:X0N["'2)12ZLXA_6-Y<*,-WA$A\_CX\2ZBX>!^6)TZV?
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M*1OC-W9PRH,:A=MA(*V6[U_\:2$B,?5\C\^OLEM)SX6CA9+L6CSG/FX_WP%
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M_%QLKJ@9)!/@!XH7;<[@H+:(WP!O;@C'.=$?>E2<69*Q>Z<GK5@J!.(=(6@
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M=[H;+5^%V31%9D^K#\6?M8_S<TGR"FH[J:3TJ"5=JI?C.:%8Q1JIOCFSA:@
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M>-<'*E@6.S$A[NX04+ =CT21/3*4Z9G4I'41(DX844?>9]R7!G:B5CPK75;
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M2@#"MY 12R;YS"*50J7<@.L<D V7@*K[T#H22'P3$_4S]Z-"(,Y5J"[>JNG
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M8*-IJ'5SZEUN[&&5L@E04>:Y*.HD\>9;8O%>X,5/IE4916*7GBO8?7#ST<L
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M8$9\V;5_\9G='TL\O#]B/[XN+6-=(^4+,=O((U@9YE[R__Y+0O%YM)ZN*K8
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M67W^8AP\_E!3JFO*JK3X=^15P=CBH=6A*1%V/3/(A.#OW;B>@]KI-9MS<(A
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M9[01?P%O'O/26^P"#0J#1C&VP/!]\1% CR-B(JLA^AJ>='S];?4[IJ'X]VN
M60M&'3>^$]+S*6>T(+=-\Q1)=OQCBP)FQ?LL3&WM^W[#4(]1C=EGI6(>GS>?
MMW:!I 3)KGE!'3W"E39L D59#"\4&T/7W\Q(#D(5?"07*8KL:PP%'5OK7)3I
MJBA%L56_8H"6:G4UD$,K"L@,9[_/&YPSG@^3&)R_-KS(;9EB<Y'+Q_BT$;:(
M"%C%"]"R1.0$LIFVZW_OKO#!@&$/^+28<:G/QAC%+[)?*D"MM/P YW3U;\_&
MH=J!B7KJ5%#JY.G/O9)M8CE@Y<$R-M9<JID>HXY@$\*LLCRAR#SQ&2#V^424
MGW-DA+J72TN8NX6Z7-XA&QS^D.4D_:1*;=V-\,TTZB(OI.ZX41&11L)2B?I.
M>\+\V4:Q<ND*NA\VTU5%I<4M%0VL=)SH:96^U[UW-?K#,LZJ2;>TL]V5?K1:
ME6]5\\A+\NZVT;,I2!UV*1FMNS6V&#DM%I(_8I4H@4$[N)(^1+54$B50AB%/
M.@FYK)TD;L \-QT^78$\2I?>G W:WAF6XJV[6<*)KI 6$4MZ1W<:D'6V'CQ2
M4ZKNJ:+E-6"TT&=56,+U'JM]'C[1B*X)?R Y2&G69EA@UCPEO>-H*'[M\GC@
MN 7(8R/WDLX/FE"H]90/8RJ_]Y)P!%P)%.C_OA&4BJM!2,W4YX]7"2A*@>XQ
M\S5=U9_=W7!WOLL$ZRR9Y$JZ6%6,6 L] 64KA)] - ?!B8?:*KAL(5(J@")C
M(?L:<FE]^^6C_M 5(IT]I*[$?,RP]M?OM\-KE?B'U?ZPT^/(O[YS[QU946Q8
M!TH]:G238@?!V (Z[#N<C]D*I2.DB&'HO41DRP_WFJ0<#2"],O/.#&K_9ZV/
MXUU+45J3/0YX%WQ8[8D3YR<G4:9_$4N]P[&RS2-A6CGX\VJ/KN&^N5T[ /S-
MU^_7^?AFB!CS[,8KX#]1L(=I^V"*:8&.0NP'WW>G!(=L$_*WG)V.L#3A,8QN
M#=F]JBL)*NOYAA:%@36,9O0C+' 9/9KZ@5)-;^6ID4(!%PY#X[NW$N0H0";4
M8Q.EXBW@40+D;K$N% 7FB1X 3N59/F;)-:P]8V+K01/$'A[>U!P9\^<[X-N_
MJU;48+SF6#+U^MH1<<!ZQ1+!OWT#5DW.6SL7F(,"VILW8"-L :\5DX#>96&S
MAA?KKA=-052!!G('WGYBW:Z%M4LB'W\+M8MH9P7>*N1GG^<\GBT>=C=(3WW#
M[2F97# X0BGPTIO0^= D)5' SJ$?\J2K@R"W,S0.=HY!1<'[67P4TGA%CH07
M6:HC(-NZKYY?NWFCK* Q$\Z/%XV5)\]/!(TL3B#8,E%W^OF,#QNP1PBX@07&
M5SM+X('=1C(&_!^5B<\7VJLEX&7O:&Z[T"\<+,V/SSQM$#0DD#YT(UGMZH5[
MIVDIC2>?77^7>2IE=ZQ/<@_^S]O5%<]K+%CR<2W .$*OLW**O:3+SWU4&%,8
M+8HH\V1IZ!N:-NH)WT+OK*7CFR^_N&!?CKTWU#0?M1@YV[14_V,F"YV6O54T
M)4H"&6*%AF;WE?E"T%_T',I8.R?V!'K:X%P]_F&)136(:*'$J%L_RJ>UA8TC
M^L0Z0?D&A?<;O0H#; 1>9UQZYY&U?V2&Y=Y=5<XH9*:L;,!J_G=_KH<F.06=
M!88G,MB+6\5600]/DC_3]UL@@?96K.;X\MUG9$5(V<JC1Q%?@7_R:O1[9BI7
M]5_JM<A.-8)Q@T$@'I_EYC@O0A,A.U'(>HYXVYOOZNT/4-M)ZH!S&=\N^]Y*
MRVKA(Z8J\1 [DQ:[:.'H(Y<AB&S:NF+]>6[A;B1=?CI]:#6L"95M4%W?E+27
M&P@/#MIGU42E,=7%IZ&REXC=I"N U$/R8<AS?#30FDU& >4Q0DW8C.D-IVJ6
M.3JNU$3SS'QMB44G(504A-IB_.J8XL7__FM<:TW1ZB8V1)]TNSVI72AWN_HG
MZ8\?29>,+G;7GC3^5/&E6.D-_W9$&.(HD<2 KU.I+7]6J)H_G>GM.,8_D79"
M\?5,QU-U>ZP+P6GMR%A-V=C*T-3/+7Q,G/NZI' #MN/ .T!EOGG-4WQC/9OB
M1QL))* _H/<%28QG5=R[%EM9JEZX>T/9D850BHR>_1GWNOIADIZ MF.:K$VW
M;GI/:U$O*$/'AJHV=JFX)2YK2';U ]'-6-E-"T;;34QL9FDT>H#.6*WO**4!
M$I9_AAZW2DDFJXL1X--:EW'#(;':!!P^K0Q.CTL-A1,75*#'A29CDI)(@5V
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M$X,FK-D8Z6GG.K(Z"&]%2(^5TT K>V6!L,U\>>Y.H,JXTL!RI)V'_84$Z%9
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M%GAV%.Z#-HEH=ZY)) @>?=-G^\**IQ,03^R2& QFY,7<DCM64*[@B+03B;^
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MVR5RCLVN)#\$/01"<AV(.P%=7Z$V.ZJ)Q]\-WWPC=,2WOYC]0=IQV;5!\[_
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M'A_^>U]"$ID*.<FV*(=4QJQUX19B.P5/2>&N817829V DQ-),D?2(<@\6-)
MT,!!KR#<>>!]@027LC*59CV.]+)[[O)D6F_8-F[OPW:Z=-8PUKK3T>HU;CJ.
M.0+ZJ[>4_0K&VM[PA#^8--)ZX)I<%D2\_+9XR_7(#+O-HL.LHT:6F_4=X[R'
M'(Y**OW-S-[E!- >)W>^E#_AV%:*W/6QH^]B%^/+'-@E7<6$/4^J&MB/%RG-
M6&C_<+.*YC4D$2S 143AT6EY2X)DT@T)=PU4*KY"<GA)2)S8.="HA:_R\Q5
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MCG_C%(3&$FZTAF*>=Z<MTOBE4ANH(+0,V@Z_(WB)G!M[1CK4(W?4;'_.L6B
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M$A&940S%8WM(F)B2T'N0NAB;\@5U0VRH4CE:7GMIU6? &U)OMG>H7.M+??6
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MW\-/];TWPUGQLR5I_)#N/IHQI=F5LYF(D7Q8A563TX$%R7(;(?5G;Y+#H(]
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MP4^I#88\#D.?[FLW(<<5$K8%[P_<8B0=8( EY&#DFW35%FU@M%AA42;C$\L
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M<:ZME9%/]Y^%&VG-!ALC5L9O._S-/*]ZDKZJ)Z;W[(!O(/K@?5)_=#=W8W*
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M@\0)&XORW"&WEQCQUV-J;'$V<6Z;&V%UNY=S9S!R#]0?^?(J98<NJ'\:\/K
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M63G)T_@VPQ+RLDC=:2.UENMV#7!;4:@XG+N)'M]-QP .<'@FUD\E70X<1V)
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M-E$KS+2^&U%K9V=TY6NQ8G$@']S"JCI7V1M>1/KTT?N7<$FE$4L)G(PZR1K
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M*LL5N7:+SWI;:G8SAB 72<6P_U0+EQ5SK&[>#XC)]_"IS+&2*;52O*?Q_?M
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M.2S,'9:'"D]?A,1#;&.CSG_4LR[Q(*?@D^Y/!!^/6'I:[EL<KN[[5H""_]S
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M@8]T3;23IMKX!M B+2.>)EX]9UGJ'J'J_64"NI^M7:]N1#V']-Q:<YK:GM9
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M96C!9S<"G>2-VS-^H\I.^EPE51_':B&/G*G$2$SXJ+DT3DQ&&U(<*Y14N0E
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M)C8_#S.S4AL7$1FI_==\*]_@OMOT);24#1)2]7=M8BJ">]4ZR1!M#:=AO6;
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MFQ8N8JI(%27U!H#TCRG#:0(FPP@%':_E'\"T+O[\;-.-RT2UAB40V0ZBC9F
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M5M( AB=,>NQ/U25\"'@UR*N\Q5%KW +WC'A 44D1V!$K8>3M^P(9_DA/@Y^
ML9SZE><"R5$IU3Y_PS]2560\KAJN*Z"I,EO6XLRF%:<[")&/@;5BSQI>"!PC
M +2HY*;AN41\K98+9:6=&+,:YG+KH\0GVMBZM9&R//&+ WN%S3V+4P.,)B"9
M"-8U&I%XJP#!2:D'["K+*Z/R#BO@U5CD>!,O6 8G!"A$(>$VS8D/S,8X<HG#
M!JRA"+P>T+Q?CE)-N(']255&$.7!!BLAVJQ7XC[S.V"+*1^<$00)?I[<&7N+
M6#TQDZH (QWI(:98M18^748[#F7.L$3H6W1;4&4VD,^XI6 P4U*C/F0G-<$)
M#E=@A]00"KHAU0DHLXIMM*!Y LOAJ"9?Y3O"U1A&E?=VB@=S!5UE&C&$HR2:
M -<?Z<3KXK;07]-U8;8"[']-$S)?37.&NH2$]L3OQ%N )D">2_+'RK+HVVC.
MLDSI=E#2CK."V+%S=#VKEB<-2B(O^(J0LA+V<H.3!!2M;?7;C$R[;0\J<EU%
M<E0: T;-5()Z0O;L:DC)!3(JY[-OXE;UT4C"4WN:]RYN'TQB1[S<Z1 4:Q_;
MXCL7'[$52WQ+W!;2N+YGFX<R:>Z1_79_\T=T'E%)ZL[G?9AN]S<JA[X4Y-)'
M,*L*%91H #^CL9M[ B3>MN#](G6$.$E5F!0#SV+V!W^JGRMX7HY2:PCD SJ3
MB\?H)GT1S)]7(#ZTO2%O>M%?2C\OJZ>O'84YR/(1R=]H.V%U,$@XGK,X.%/Z
ME!HM(+P:=3X$$9(:L1\F*R8'7@N 9<SEBCR'N]K,2WTGG<FA07Q)RHO.*.[
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M=&AH[)UG#$O$IWJJ-7;''!UT*^]KQ$M-RQMZOT0 NKZPNE=M8TT]=-[=EU!
M'1=W-%V]YZ6Z+@.W[44U^*FGM>2D_3G9PFU.,&?HFX!>Q X&M' VM+5P5"GL
M]0I42$@'AHB=A*B"MXL$G/A!W/I:,+VV97LT87"^$S?G"!YH3RZ;M=VCDF*Y
M//2[/NU@)"7/\<G> HO+G3^?K0,T&4AMA-BA-$3-F<\>CN+K<;M0TDL*QHJC
M#Q#XQ%M9MP TS4=4C+UI9#WX':]',X*6&NT!.Q>2*1$8-*EQ3W?$G'[MS1UE
MWV4.8Y(C3M6ERNH9B5:=3- )4*5%RAX# 5W#7>)%>$BRCV8KJT?V2'\#.<W
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M^3.>?5>-Q:GVZB?:3YZ\G'V"GOUU/BO755C>9JV&1>N0P\F_3?D32=JJSI;
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MOD+LQCJ,O!QGE U\'K(YB?ADA>@PH1]PV_K:XQNUOB8(YP4:24Q]18GGP1S
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MA2=3#A#23*E'):J$K(ECK%G60>*U/G*$-6AFUF(-PTRH$"T!_P XN+=\=DZ
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MG#^D<':+3G@9":]A,0 C 8WS+Q%:%NFCT&^0K$)XUFGCFQA@ER3+G9:*V%S
M12#J>YNL@7F1\EI(G,HISDA1>M!:1+QS1-X/14;8^O"^-4GR("I+](1+/"34
M532?C' "<*TXE<X7D<NG$68 /'4!I0?>"O+A+I>-I](P]V:"X:S^V*%^.X](
MCNSDP&SNE\]3#64/QZGQ6QUO_#J6-838 2IQ87L U&VYNYBJ#,:WL;5^X&>0
M%-B6(6>/DBG$'O!VG# *AMH"%@VU(.#L=\R!)I\88>=O!OC.6^JJO8J@7:YI
M'J@S ?&[,>U?T7*M'#1X 8!+-23)E:*U@KVF"NR[5"@[<GXTP,VPZ-U+0IQP
MGLM>_UUWHA[.RX9^-XQF]8?W.CL*.W>JF/3%>NSL[@@/WW9_>&HP.OG^)@\R
MOTN0QQG34ZC^UX'.6N/\<C#X$,D:7!*M&4'V.JSB<#\C(2ZH/Z>Y"+J2\E^C
M[]'? 5SRGX,,CZ/N "IIUP"CT*O5,.NVH!(.G4*L84DQ7A1%ZCL_]#7JY%^D
MMO^N%/I?DWKP]HHI.?+14^7_><U0L)FD0SQY!QD^KS%%VBUAL-@)&VLKU>&H
M&F LJ4Q:ZM)<G_\#<[+?WMB48QY/N+@RXT[*L74S;-D\T71@^=N]E\/8!L_'
MU1BOE4KWP=@92Q^/AI_/$^<<##/I/KDQ_^H=X$9#"W%VUV]Z<;?V_!BQB! ^
MB.W:D%:65)Q90:G<;+H/OR8A6NGG7_8_%;ULTQIY<VBWC'6Y6FQ^DT"<W\,+
M>YM\G/+Q&J,NXV4R5/O1U^Y*O?26[O:7]UL&JMQ%&>9M#\KTJDH$7TI>>L5T
MTPZ E0!6R&P;,^,:0GEP=>LT.DZ9>!Q0YF4J>11<&++K<"?#Y-82R^P,9Y6J
M8&Y)Y*U+,V<B$*9]=BL7[2QQ,E<N/VG@(5-:G9.PU4U_81J<5*BJR(X0.J3G
M5C+8$2B^F7".>I<F#P=*FU\3"KA2EG/M -Y:^?VMAOJ\/P-:'0Q-V<(@[QG/
M9+61Y[GFUIH8;6U#:GW;[;J/MY)HHVK2T__UO %+%VY;+AB;B7V224;R&*"\
MF9J*V%7;O[BB+9Q(43C*]TB@'.J62-A.P,Z_D)K,VDU G>G!#WB0FTDNO7*4
M8"Y\UMO1B4*A5=-GM.&\-5P;FH5+6-RVVBFJ\1P]P4P:U0"JB[,3)[39X7,A
MTKDUK!44L[16GN*:+EK?^;,'GTD^N5+-@H/*7/3Z601LBJ0OV6V(+^>,Z2[_
MXE6*9^9L?1M[%\A03#VSH)[*+*H30N\@;,''S]9*?ZV/?"N4=VN2A[M-AB!4
M""CID1XKEBYX"YY)-6K"10E0&B!6Q,R"SB%E%_TP^?9S[2ETLL[$]%0Y>&F>
M4Z0.4-,7-\72C*8-GV<^'[ZES$-GDQF3LU% ?/N:!K$C1FDC;&E&GZ"79$S
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M>H':.F?;FL^<:R\>)7B.GGDS6#J@V#A^A'_%4:LS%!<JL*8,.38\Y :T[PK
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M@#%D\?SZ$<+OZX3FR$U@VPSW.DCAWF#I0: :H]_YF0^<MD,P%5'HWWM^A[N
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MX(QH?]<#B2HS2H0_N#&144ZUK^UVCJV"Y]FMOA'^"D_X\F7AQ&4)P1]D2$?
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MW[\D5SQQJ[QZ^> 7OXI+O9M[V6[%OE<[3X_S2H_?N)M;[/W @I!]) UOZ.R
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M_A"Q_,7J+*MB[\#N@F7VYSIK1BR946L>I5HWXUW^I]-2U*C$>\AU_^4WU@L
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M?UPD)0\&MATJ80WAD[[KH\:1SW"1RF*6""'=HN7=+-$#H!KY;;-J.$D>+,6
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ML+! 2*3C@YB#9%D%3 ]^2M'SZW%>,U:IP,!K@\ W[4#U2#/+8&+^C[!  W@
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M%&79^[DVHYCL]*I6)M4(;,W)$X=[MAX/+2%2;@S-\*Y&E Z/G=)L(0ZFR9Y
MA,F$TW)?ZG&H=+((%!#@,LD$-P'05&"06+K.J&&V$@T_D5YB#!J.@,-FYP??
M_M\3TO%BK-1(0E])UR*.FSA,3H/LEL E/1<B/T5A5H9A3$JZ(KT"+J@ZP22%
M'EVV"\32J6LA"S91:W:0J*O8"=,EZ#3,\BUDU3;JI?X&;3"O38U:$0S%]6>0
M<2L4MI F)]U'Q&B)TVOM#W2"S+C)#<;@1 O.& QD7K:]O7LZZ6L.VWQ5'(;9
MPSH]/9#F V.$TP-=*O/Q&'(+*RG0GI""06]1[$20B'E301*B,>WB_.@V#PE>
M@^H/LM)GZ&D%*R K4I,EM#8@B-VTDT=.I#-)YJOT@);M3X9&OUVC;:2Z*BMP
MNVA]>!TDP^ZO>0X#)(@E#%88"MB8ZK;K8JX^U12> #7?-EF\X@'GU*AD_ HJ
M%C)JQ50S6\-]CB#@))=CV2R#R$_VTPG\N5N\HY!;I8C$G.2:P>YNT!5&!26Z
MEX:G1L%=$G(R41MAU0)ZN^CB:TA/A@BH&U5(A^^6GH'3P6AVP280$^\<)T0X
M0ZY.I82[_',G*&@S=X9+F; I9UY+V\>UW^X';3W\@NV38;;K%*^JHK#']-!+
MY9IZY$[G5:V^:A0Z"ILPG]/B%70,K'H._47C^3W@L]KP&7YUMYA R&]P:#B8
MC;_U77&@A[8Q@.I.3@;A?1^ZQ8+6H-:@XW509P/>8,UKNO@62:([")-D>LH<
MY\V%8TZ&^>!WWQZWVU '$I@UA1 B(2P5IZ YSFY DG2C,)'70ESA' &YM^.<
M(2,./3F7GC0C]]^-\>0I8L7,E2%7^ :)^0]+<I3TTI,GWB[X42T2P%::4FT)
M,[4NII^-@+.Y!<1H5F)E;_N1GLACQ9OK*Q/QX71]ZI[7<)P(DQHM6.@<! VI
M4>%#MD/XL_G+)"T%-KQ9<FIN?TL':\GX\?EH=N?"[V^=VEMM3,4;>X<$2:I\
M9?7LKC@]V1?$/;XDA]#+&ZMN0YJR]IZIH)J$*MO'=<^4Z32+@(/9?>,NA$L0
MIV.YE8OGVJ.:6ZS'2(1/Y4*=3,C'!V[]OWA[\Z@FTJ]=%$5%1(C,,J85!!GC
M0$ A)*TTH"*B(+.01E0F(2)3Q)"HR"RD%0$%(8T,D3$BHPB)D 1:49E!@A*2
MJ,@D50JQ)"&<]'?O.7_<^]V[?F>MN^X?[UI9E4I5O6_M_>SG2>W:FU>$R K<
M#'J]$'R5F."SCD*1(A?B$'>[1 5/X:NB*995?(8Z018B@3%,TD;QF6JH?N9D
M<R>X7/(;%%/E"*JL+37#]!SY9A\]/$J6WA,"@ 1>;XZ8!!3QR9D==FLU MK-
M=EI6,RVE<$9(?Q&\+K.53A4PY.8"-X !_<)+1=6^7U>Y0MKMYB3GX]\)CM0Y
MH1 3*B(6J9=0MVO>E2%:2UZ3  \L)T$*9NG_YN-H.0 N6)#13>/@7,#X*KD;
MXETB-0D'HV"T]FCYQ9)<1 D&.L+':DLX7$T+'>%YZ >O,YQ[=)BH"_6Z W*W
M);IA8?QU&7CHE E@U,Q?VH:/XD^R)&X@6=@,98#>0A-HLIPXYH?K6@P1(%*1
MM/?)/?J(M3L$-Q%2,H)I=$Z7J 9"9&$W%,&;6/'OUY^G-*6P9Q;M 6D(E()
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MVB8H'@[[ 'ZJ_PVJ#>\+PHR:>V6/>:,EZ_.],A9F/E_5^M4<&$ TZG]ZS=+
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MJR(SU;KBI%/TK7_F!%=^65CN9E<_3T4H%URI/"BKF^2V@.^UI)D[!3_JR5&
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M"R.)OV>$"HPSYS%JXI-0U316Q1^"L[D*<;"=4-38+UK3VP3F@0@-OTMM?-Q
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M#PN)LG8.2G6;#!1:39MOYD90)?@-IE& YV9*HC.)S.#N\[^@^0=>A::[IWU
M3*KFOF92OF\BU5 G6/]9R^$A**GC<^BKK#.C%0=GO#5&JSUSX^Z/D=SKK,8+
M9V*"C.]'7 O_PIY[)^RWZ-L6H;MEA#T<MM?'RVBXBV_(^[%Q*L-IDO_D1-QN
MXQU0"-_0C>WN6N+R4//]2AHE!)X18#8BP53@F4:W^;:_B>H$?6+T-L@),\'
MJF=FBC0"]H''LQZ%R@Z,1[^ ]6U,OE>YD*_MG_50(^]X\[\F?:9.PI7_Z_+(
M#NO&J8DDBR,5 >]"XXI3*C%V=XMJ0@N:TVJGVHNK2O!QN@VAE2%M,]D)ZV]%
MEB^L)2QG]^W51/W4VMR2AYP<_,\&PD-RDA?F$7:AZM>BPW9!88U&'WY-TJZY
M;[[LEN.6.-&0>6'%7OPO5\C#]1RUA$HE,B+V'.,(YP11A_=\[+J\^ZY9G=^>
MI/R6JK2/;,&"H^<<NG:\+K7=^!YYILR7U?VP#/EG#34+K59OB^53=AND7QYI
M8FWHW:NK*NL:B<9MGYO9V^0OB\F[Q\]2<AXA'0NZ4'FX 5-[[G2I:7&+"N<O
M;8;FZ[<#][U .(>;&J"?PAYO:5OR#:(FKDQ[ >,/^#IJ[)GUP^;^%SYM'!I?
M,J=N" W0'=D_L6'AF5FCZ?;*)%>W94]US.*W_ZR8&D*W.I[F&F'@AJ\R;QB^
MLOIE5V5G6U9/H>-78=Q88::V=Y4WEGQ^#%U201T+%81Z_%4U6I9571-HA,U8
M'"@V:_12-W[^NZ.+Q0+GMR<.'M45!Y\0+]'$=KJX/U<T).%0KC#!Q&W(8OE:
M1VC<S%,Y; L\U30:N17"=.& ;/RM&=<:8CEERYRU?F_:2O=GA^@6:\E49@9Q
MA;C;_\COG[4QF0R'1\1X3K'Z<!/RV1SJQ!U,,^B<\F;)0#9ZYZ>QB^-?$\6>
M_;43S;A+H_R[L]>+(D.^+'^.\,5?&T+\IXVXJ\G[ 7OC@*Y<XYQ*L6],>Y9M
M_8]ERU4N#^<]19&.NN,Y\VY%UGD?$^=/N89VJ02EK1TGKF1R;*\?TTKF!!9K
M,+<(C]AZNS&->$^C\7SP'":U>M:''VE^A%B].Q.-?E:'44NM<-N9%':/]EZ=
MQ5&(C;R"%K;T&K<;%5 #M+@T#Y.VQ$BS'[%$&K3@J)@;X83WJ-_'IVCY4?%1
M!H6UIRM=9!$O#X8,6V ?VQJ(,:%Y,]NAX)( R2EH#!"Z 2[M@@0_C@9K6VWC
MXO(>@1:HE'X U O@VG&[$9LQ90&_3\TZY6/;7DL<'I_2HM<=OF\R_<Y4MOJ?
M]4.NM\7MN:I[U%QXXF*HM7O,?FNK(/V#'_;^HJ]U)GK!_2%BXLBQ#T56AF,U
MUJ\_U(Z=GGS)V++VT_NF2 O#\;XCKIS725N_1CYT37^X-W3\%7ZDRJ4<H9K"
MN;!X\OT-3TUW>&J9\7-;E<,;"?C;6#BRAX* BB=ZF)9@<$9MXQ[$-A\H&S=F
M48B#A];J#F)NRS[YI=9>O/=;T]W 'T[X5*0/O]*:_7(H^=6 @=.Y=@Q&6L$\
M$K(FH@FBQTE6E=#]+A-E'UOG6I(=E%!%9'D^>]+0,N(UZ =R>I/A64WG/C76
MG&LL%&>P5.VDGXJ8X_$]WH=8KO^9K'U<@;AJ&F;^9'5NO-NU!+/PM22MKWA_
M5T;F?D.C\1B#T#,[W"-<W-^[1#@?NO$&5\*BOMD;87*D#WQNVZ*5U=/[(\>S
M[\2#H%?-1]7Q7A4!T4]^?(0IR/K%Y8"'GG;8+G7?)R6[3T4@/S_[(JQ_&JQ1
M5D;48S/5 7JBQ3L7-L>:=:N)H$Q$"I!)?+#1VEL4\*B>&#'=.[-K?,5<!14=
M?Z\LI#^^ROGQY+O!WPK:WR/;&-,]*$O0F[IZ:5SB7XNMX78&AI;Y;$H>?\5V
M&KZBGM>+&8K.LE9V-C@]M,3^,SRZZ,"K/I>6&Y?O[[ETHRQ8^O _0TKU(X'2
M>GYYM6M9@'K.C8#]'SX7'W+HV1%1?NA:;MRSG L;K3RJK)Q/V?9_[LZD# WV
MU@YG/GFSY(7SVVB<7GOM0W?TW(?H(*VQJHW)K^;<*_+YH<-%<9]+G%22RQPS
M:KPG3VV-^-^R"-<IW;_RL=^E=^6P+B,Y[#-NC)8KP?W3'/S_='/PSDO2AS)$
M'S@%GU(O!S>#?VD<ZK\RX=:D<%J1I2A$?A>7$+^^8H^0:.[@^_K 0D;@<].7
MSRQ]?A>/J8\D]UQ\0N8N-"W\NC:N70]777HO7'[2]#VA:<NTH,(]SW9H,>C-
MYR^_Y!L-Y 4T7-FT1_=9[8A245"?FK/'6C'^9A3Q<(*R9/?#8U66CH_';3]_
MVN5J'Z7[Z#M.#MNH!' [B@B< *5Q20*/-9W=2=-BJ/+Z";[0'K$[64&<9&N%
MF)U(JB^?^%K#52,A6ULA93XRK2UHK)QED,*P.=X B$5Y$ 79B=,.6>O+.C#K
M-M;(W>7$IRK - WOXC83>JBW\G41TE(Y+,C4TD=:TTA]L[[#>V8;]"_T1;H"
ME\VX#%MOL4/8C#94&"]4AD]^$UAVT--FM"!E.6S#5ZCS[Q6&U@:W5R2NPCL5
MY]])G$$O.M\9>T81SY"8 H,=Q? 7LL:_VU8Z"3!+>!!_'GHD)DK\H9-BFY=_
MD(>9"N#?CI*]H@(T81C)]!F03Z7+[!8!4N00*R25L1X,6[55KPRE[25A>7Y%
MQ[IFK,?,":FZ6N#C^C*^#6$'=,>1*M9=V&[YDS3='*=P%PW?EOL?26P S>0"
MN":E$X4Z!"FQ*<]B[RC*Z[_0309+ZX$O'#3"O$[SW 1YH\3_!4-::1L+*G4B
M=J)#5GZ \IQ8*A"%PX2_0)W(6DTXYC=JZQX%3VY4_I-2M6:X_GL--'B\4+Q/
M8BC-1U]!O(D5Q8VCM!>8^E""@/+&@$-;KRE* #%+[-HPFAK99BI##IO\QIFB
M=G%UB'!^<^M'HK>H>>1KOYX'J%]\Z_#4; KY"+&WNUB7">X\X^XJ?2?]';5Q
M#MU@N;0*1/$,4@[%]]OP<6R%)" Z^GM=SOTD.5T;*E*E=-D+BL[X/"@K] 2]
M4P^.2NQKL/NYJ+*J=[^<RI^RIJ5R-\GVDGQ'R=IAM!T,ZYD#;=!)4,T%>@I\
M/SC..%GQ)H2U(SI!TQ^0W1/8M)N<'8N6(KNC0JUCTV*2AY=(V.#:^3ARF5US
M:W#@]I;RT+@D6L7_M\?:_]_]OQ?M&XW^]QK^FSK_R^L4- +P)TS'B_Z09K'X
M>2Q^(=. TO5<#DNBRF'*+)D:&GHLTX58XF"9*ASR0 ,*-/[YG8_>10E6W+I<
MZQ5/39;0>''L6NP4N3]81)D5RA *4[WQ)SFL1%$0_D**[>2P+Q7T/SJ CS:(
MI+*,$N\MVC$WO@=ZQ918+"VX9']T?72BYI5*C</<V-*G_'OI U>?.WYACU:D
MYLQ__G+B5&'&;.+EV@]>R-"#*^IUWWQI<SKV%!I5@EJ1;;TEAV&L%+H,)XJ7
MPV:QF'\7],<M) ?)86@ #5DJU-Q?/8A%#659PD46L!4G82@(><%$(J'POU$
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MM3M^*+O"RCVZ_8W+4==,N[;0XSEENU8;4-'C?^_XEZFMVR)HW[[(03=$:P;
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M/@':IOD]^"RQO,X4,?._;]SEZK'O_W%N]'8TKXC60&?3IDR$E/1E&;+YQ0V
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M%]RH;E\W#1XT00JN#O5=?O"Z%#1(B_A:\>+IR%>M)L*VT!;MNRU!W]$@5]0
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M]/N'YF\(%M[;3#_U5#OWS5Z8AX>@_&;HM+:*KFR=K2R+*_ =V(2[-?#.,>Q
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MI8WA^09R;AB^^[7!DY2<-*]ZJ4D9U:)C_;<'338XJ^62Y:KQ%;F<GJTI^:4
M.DTDH\CI]^"EY.,><F%"D4\/9R;*<QL8D2XBWC7PYVB%.5'=OM ,X9A2[BK>
M@[M8:?V1^A3C?"1NA"_65NXB2Z8V.$F;.GE*UA]DNH6E*!,]8S^K["!9HO:C
M>X5!4T<%U:+TQ2][ZBX5EH+"ADN:E@=X^(X'V$163%=5H701*XT3.'?H1&WZ
MFY'!21]H/_U,V-")5]]1O?Y.OS#=U-MNI1TV]_HK,CE OO9E$0OKS3W$V92@
M;-3[ L&*<C2*.V#X^-*F^NV3<.^](,/LNU^EO1I F,1*($XT)Y-/I56L]*0-
M=X&[02=0M_9I#4="0[;>RV\Z%OU.CWP1$04"<=O1R:+RT@1WN?0FR$=+SXD6
M)[CSQ*-PX!T/*RWGQ*R:KY-:Z7&,Y=U?T@@)0*RTF2P\Y4QUKBU*;Y9)%%6S
MSE-AVL(G\M6,3982TI]41XRER[G#4&50)K%!)UD8(;31RR@%-$/T"TEOE]LR
MG87#R.)X9)'<%YAU_":! S'-(ADE/8A /+-:)W$AN_GW!]4R-[)$]".Y'M\'
M,12ZJ\SI];OTSP4M&Y&Y4)S67CB"/AK,3C;N5+D/9&"/36?!!AW];'KC=U$)
M$YK<7_V9&5R?7XG]G3#]9F/ W0MH*XUN)X0^ZD@R>BEWY["EQ-2MB7#8$>1C
M#YN@>=72LWS&Z(KOV[F; $_?JTK=' 5BCN/>I@(LW!BR(OV(^3/A9D/1/;W@
MS,"[;?W;@#$%%<R#LEZ13L*C*)15;U<"CF[!\AM]CJ+\--]#;.7&@2=FGZEU
M0"5GK;0:=8LD>W(1]E2&3YARJQ]@;N+^'6WC>^]PY\ >@(>]UM4JG^QX-;:E
M.[E\EU3O*M-I/8A]5=__\+"R.RF4KE^1BU*0'>?/S$ZZ<KCM5*KT/]W9_S_Q
MLFWD8SND.5;: ODL\N<3$Q+247B%6*K?PUU* 1!961X7C&D_ ]^3-%S0K)T%
M$O4;+YLW@4@]D<*WYR#FD&%R;K??H\TZME+J$L]=*5$C3FM]6?9Q1;- ACXU
M:"OFE66EK20\S)%DKV@=0*XNTS(5B8724_ZQQFOF$/A=7&I<A<68(' $5Y)S
M/73(3)@+8E#[HSIQ&A)/[]N*(J-7<'8(L-'3L^3^7>22Q,ETJD68[1P!BJ3U
M*"HORIJC;'5C*EG.B?,_6!Y;2JRT6*8#V1D]:VI[VFJ)!_P1X.OI,^!M6%#S
MU):G"T0+M""B5:UP()<(;7<F&IU5$9XR2?U2W [M>;C8Q/97B*LE='@+0 R\
MN<-UK@_+&I.O^6&=XW;THB3DF5L45IO).1FKD_7GFUHP :47SD%.R\ 5_*$I
MO6.-E1:3NU7?VOPH6HMJ,[@+A$<_[JD:6T#^R%T"-ND0NI#=P)V%%8G1<GXZ
M<X[(;7C.6HFE]DY"@3HK.52PJZN!&X7QC'UX.L4]::OASRWW!+*;W?+-0EL4
M,?)UK?.$TA;&M"XY?9BQ$11B++VZ6=9G0&4JR!UF]20]\?@,""JHGF*>AC<8
M)&["N:EV2J72O3;+#Z)'QC$8:4\]5ZM;J?$NF!Y8).1:"H944 Z_]G<9X5RN
M"QJUTLQ+XWQPA:ZBE'"F),COQ<)2)6,)WII!K4<V5/.1E5;UXC2^P:3%#^:D
MH#],W=96D=[ I1@4JLX/;8##\*]J8R)K_*N85Z5NT)>LF0E\C,<Z*_T>:=QP
ME%)Z(_S*6HEH/NS;G>P9O@-?44;5N-.(R+V[&!L\-VX\J6)'7*K4AQZ#/*+Z
MA0]5$2^J4U/*$S5*[7#XQ'?\Z)!OA#(W44L=Y60$E-,32DQB4&W>3JS%\IL5
M-K!G#Z4'QIZQ0G!9@W0^;-_%B40MFY63@]F4K!0WK\+4E(D,8'UX(:*S@N.#
M>VP#=N9 80A:J\KQ<?OL9'GJM^H6[GMR_ O;Y@OD<^9"RO%J)O2L+,[1D^98
M8KGE.^Y\LI]/1[Z4.(!\76T:](5%0'E"*#?YT4Y4EK:&:;K8(_=Y8ACK/^$M
MI8K?4^XU9*7-DZJDTPD[3(W6IG$"$%WB<>(3S2_1&X&8?Y7Y/3T7#KLC9)O.
M@$@#<V&BG-NC.#BFF3",-4;R786R2 7NE<,BW%8\+*6@>^]-4!C5]6HLV9X?
MCI4V27,8<["3P_F]]-0RC5#4&=8U1U[WP&MI!%4] F)%+]<WT4IS/DRN( [Q
MQ8QU8$PGU>2HH?NW$[3V*RQ7B /F;?"F3F*Y;1KIDU"&8#6O#2)I65S=A%(K
MEG,$,T&,02 F74887&SW>;U@OM!V=YT<=T^\,C$:A!7KZ4ID.AR)!S5?F0[-
M(3X!$^80XA@PZJ'9-\N*1[X3A@?BX>=*L8DF!5V;>&)6<7F<YF;U3=@5DRB%
MG, C)<-N$7#TN^XEEZ2^ES;6/&U@'@P+7$#[JU?XC]I:J=&%DLEL4P"@JO5#
M "EWR]_#94K!M"@M8"K=3*\'XB=[\Y(+S?1YPK6/=]RKZ28"CMP:DNES!<&'
MMGXJ5A6YY^^X'SSJK))[)IZNV&,Y&AV,#^KR3R'QS'3(B;0APNYWL8AI>&23
MNSJ=$^8@N1T=%]'E+Y)]W98;]&&O[T2>.;"WJO#\K/)KPZ:\M;Y/(IX^-;W3
M2MLQ[4_$S!:F&X):%G(WBEJIU".)$K J=E1KWDIX=\KMX1@\5:OFBQ78QV;Z
MPB%H+HS$XORM;=6R3+;"1F0C:I-6OBC!Q"WD:@I_'O/G>^7X\=V(".SP(^PA
M[_L?<'IF4NJV5SR/R?Q1&URB_T7ZO38/29#E66F+N$O@) PYFXSD0@S*N4CU
M"C%I!R"U@.KHMJ@0;+V9SSO-GR6: Y8:F<Y4/^SN-,1=$M!JJJ^6-F]!<[?N
MZ-)AQ@)E/V6$9QBPW<58K^DR%JMB:>BFOX$*W,9T'QRZ3KB >^9MX.%NX'T5
M/L)/DWMTPEM+XJ"Y]<PC6*D.42(91<Y8S^5#!DGV!O7M>(6=;>[=:D$V=TUO
M-=TU.C$'?1[T@3DE#)Q$0[>BW90-*.E .PEZJNZA3*S<UKDT4S.@;JJ-6%RT
MF/RE4[\N1""PKSGOU7<HYKW@>1^?+\MN/S:?/CBQL]=*TQ47N5FDE$<09)]@
MYT&'^0MA)C7@EZU9?$\K+;%U(:D.H4(A03I>2KI#>M<2K-PP*WN&/XM8L(D3
M>WL8FD7XH3)'XD0[YUT=E+;[Q$1V4J&]%UJ:5A]0_&M\G:BPI'>3>1_2N 6*
MXV6.X#Q3#L9NH6OD2EWM:=)5]%B["(E)9:+JT56WB*\LEZ&O*<Z)]L'RSQ#)
M^-)F9E6I^A#=M!^O*<8B6Z+]NOT$;L3&VO:=!M9H[M260<$=,!UW&FF<')#*
M'HY(C\,K+5DB-OR!Y0(4J\U0++32XED:L2D1SU=J^U[0^V(,L>FDC5"I"VQ-
ME[\OY#<D'L=>T9G;20[8CP]^!I)O$:%8RV7HG"_D0KCC*4VMYZ(9% ]*UE1!
MSB!/W2QW:--AD@=" SG'HI,R:I70S 2IN]P_GG^_M>GO<J<M:.NS0J4/%D25
M0&7UN**AO?@YO+Z3"+Z[!W;B:6(B,5.ZGFXOC%1-B!Q^L%QW:RQ:VL5AWWQ)
MKL!,,MU/XXA=PBG;T0H#WT5I#A%I*;\;HC<*FC7AU( YR#RY-\%F+._U\T'V
M8OG46QHZ2A?#@2=U?Q_SVSS29\!Z<O&C35I7&<>MI*DF LDD5I7'1SMUC%[O
MY 3$+M.>#&^!*OE-DJQH)OC=G$@<!N>OL3*]0!]>V!01I R8/1RQL>(XLY&?
MIJ4<'O:ZJ<Y4<OS:<$'%G9U@K*4-_A2DWQS:4)U9=DT8VQS-[$@VKE:K=A<T
ML?NZ_A)UIC:7^E--J>!@(#9OA3TM?X/#<<24"A0E\+(NDI$P8-=%!'^CG5<?
M0)D#9R#=WBU? I8JOZ<8MYL3B]P2LAM-[+!AS1G&ZOINT6+A8'AW4F1I)4;)
ME5/5+RO@78+7^<8)BE:;P&;<A.0$ZZ7]D0U3)D,AEE;&9L"QN)>:>8]B8=T5
MQD;N/)!^E=@*<LK@+W&DA3E7U$TZX[U&NPI@IX1LO\"X#Y)CS9N$&U2:7E-R
MGF)M]O4$QI*\Q!1SN:G5<GZ)I4KNQFY\+C"E 2/&;M!<5.T4MCS6)<L:W![A
MHQO]:\2RE\>X[W:)V(0MZ$N^&1GG_N)T?-G0F"X%RS#^6AD5,5)[HN4?6-^6
M%TQ72">MU7J\F8D%J;3] E,;[J:$%L#^;5Q7^ 38SY"9?>/D\RPE]9XWA^N,
MZNRO1<O45\E?3AQ48*\$V>0B?.:8LC6[DWQ<,#'Z!QRFR[IC_'!/XB4#_PMZ
M6GVP&2;"<9XQ#$]1%5PJIBC8SY*+4.Q8JV.-]DCG4V*/-4/4)%H![ P!?/6
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MZ0X"S%N$B0TB?T9 U:/\O6W)46'$)IQO.@JBT%MO6N<-/-;G^C.9T: XL.I
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M6C[$U'-RJ(7P7-N5SVP7FP7&T?$%/?M R<@,PK[=T0PV+^N]^B-1GG$L3^0
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M712 KE&)X%DE%0K2<'DFRLBF*?2/XRP?>@ZU^.Z%..)X-5&/2PN1.5:XZ:I
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M7U,I^M+0N+ATT=-AY)C2K_T4'/<^UIP:LIV9**#",%^&3'L!EWHC,P!FU.7
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M5QW%UL!R\(2,TAY'ZZ*'OR,<&V/PEW\'/9_:KO!6(_R^RJ30K-(%X  1N8Z
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M<HY_V?\E:]8? ]02V1ST*3-^.17R2#;.XAYB43\QL/NQN#U$5?=9A74;K1-
MM",2U(5LL,(B;Z-_G@)BP.X@J=-&!A1P)E&?@>](]E9R4785\+-4V2XGM+^6
M^X,+1ROZ!Q]E2W(7_%Y[8_F5QWFOO\I92L^U?:OD(8% 2DY_8TP8"<;8DR@V
M:"&WOC'!&CBG?Y&M-%JK<E&L-IEG"]0WJ%B9,:%E VC"!--%GNM!X8T^R/6R
M'RYA]GC,UX<L?8B_.*3;V= Q6ABB?F0_J/OS=&#L<]!&2\993BC6T#7.^L.T
MS=XTT=8L3!RPCNB,M7TSHDHRS/ ?]I0#J0;5P_:'T82A*D:_3%*Z +4FI'\Y
M&3$\"HUXIY(/*?8X:[HVJFLT);9INX%O#?H"V7 /K$00]Q331?)RG;QE=KUX
MQ42!T#E4Q'5QE\&9MA=WQCN!) *R:.^1?<A>QHA%6$YVT2M?\::1(2VR:?&B
M 'P@3\5HM[FB:).N\;'\ RCW>+W0%!@5#BZ44<GM;U5Y8UZJ_"#'C)7KNN64
MUSA+#A/7$08[PL=9.2JB_Q5*D1/EO%::..\@*IAY<2QJG#50N!8JA6JEPY&$
MR7()I%FYB!_9)?8A/=6<TS)/L3>R\1GE3OHUQGAJ#&QDQU/Q7+"RI=3E <'/
M/Q;X90JLQH*WXY$INP=V/VH?+5B\O/;B1FJUO[[\TG^ )NLJ9$<)9BD@9):-
M0$IX6I)!5 IA;C',"$:SXI?9+AR3%Z@<]A-CN<;Z^DXS=Z91/@798Y/99P5O
M<=9O.=14>SER%RE15R=O[?;UB<#^>/S RB!/&4,B[S<S5R8N:\:8=2L1.%.\
M=N6*(66@3<;SIG4J%CT5F0_VXE('\!4H:?9433TF=!$EQ(,"G)/_:&>,N,94
MG8:G23XD%I;*R_M?%F^58$_"FT*\KF<*O455.QX\^.-"DXK@RSV!H+6438P8
MM V>NVS?T)YT9^DGMFK>',2AP-@6@T1V*!=.U'1:!<Y[9B.QY&_C+#RGOAQ4
M87 F;QFUF91(*7?,%F"495)'K[<E&&'V*X'K:*%G<QHADHWVT+-T9U4O4:*'
M]G[!'V>5!D-_GKR=<8TWQB]4;++^5:0U&0IK5UP'$"9LC/,TI@W;EKV[7G)C
MR^U7D!NU/9GTLYPE:T,S<JI/+,_;=VN+$3VE_*"S>O1R0$3/M09P!&]8%V-5
M%W=+5ORJ2H%[RTT](QS[Y@Q_+$$KS(+M%6L('6YHEIUSTU-K;=]3"635WAX*
M)?;C'@4DNVE;>!4X:BD!<_:7 YYI6_N\N^36W'<>\NI##XY^KN?G*];PM((.
M 8CB??R?^Z@6 &$J3(NZT.;OR"(;FV;B5IU^<YSUIO4*^ZQR>J^XW4#<Y:UZ
MI?(.MBU )Q?H<DH]P#IL!%+W^[1__3HB!YFT+Z0%SN_>GO1HH("[Z<I+F9O8
M+_E1M31'Z2OJ:RW]J ?Q8>S^I$%]UB/3%KRMRAN2T1#=!!%G -\22ZBH0'2$
M#PZJ^H26B[9[RA>,/>(\1S'&L.9(&!-?1+OK>E78"@7#4T?IF6R0W* BBFSE
M\<SOF;3[:Q2;W0YCR[0YJBCT3R@R4<,RH57P%@;)S*NO*\=9.J]3<%!/(QU$
M)%"S_'#..05<]FH[2+><MYVE)F&?4(SCGU9:A<.311&X=%A.\O$*NC#)U%:]
M:NASC^CXE81A9&>1>';['>XZK!.O#L/2"D:.C6SN'V?QWW2V*N(F*N8I>Q:"
MM+1RY%B.(>9QYA?UMIN(P,3.UK;00;8K_J2D59ZE\D'VX:A#\DFA1F ?0WF2
M%;H\L=M@O"N1.OR.W\)8\$_ +G86D^W\QDO%#!A,6EYH]?LWTY'^>2\G_=%F
M98,P34S\>>MF9 ?)SZHSV!V2U4:/I)$E>%UE#C>J/%Z$MGCTNQ$_^\ZRR92^
M0R=_DZ)3&OIE(85*7\J9J)<>:XN]\8V%S0;E$04[\@T[(MOV\%[<&7NO;#AS
M];'AO4+,>7J^^3UW[9.E 0W_!F,B_@TW&F_\GW'^;SG.JC<+4>,EZ(.W'+VG
MD:U%)<J5X(WQL>!,? BH)YV', TCV TC";C!7E32 KE?'DW_XUB*O0:M#>S)
M5$(O[P.E>2<)%7+]KX@^-C6C;B.CD2HGT!:N>/K+-WI^#_Q^N/FCE'&ME@.V
M"H:+.E1SE5QDLZU,.169N/%%^QB=7)F/.!C17J'6X)A:N&@ D^6\1@*,20K8
ME(%:?@#U!V8X5/1O\<\?J8/L7GV<W(,O81S:]-CRWG_^6BQO-$L](7>5L0*:
MH9P!!O;8OE=$6+=6#H^SR!Y,,O*)8?IA>J$H7!WZ*S,BS@SQ3^,L=RY<D92'
MHW:#]3+78VQGL2YT]YT'%X!Z0T.[-Z[*4J16]@WI*H8\G*SN[XDP@#Q@G8HD
MUX)H E*O@N8RCD]GCWQNNR .[$6VVXH5 F+ LAN4E5/<=K\N9!+C$'(@5V0-
M6829SZ%?C[/R>#SP3UAC<*!VDJ,]>=P#0E*'C9T5*I)NZ45]@F?4IMO::LCE
MZ+NTX4I<-95*LN51DVX(1!?P0D,VFBC3%]'3[:WKD 3?J4I"KDX?9^67^@,!
MZ8GY7L2V3/WQ%<_O+A$4<G*<-;)^3#:=Y[W%!+N#;SJQ@6:G'4,:I1]YO.KZ
MH=(EW6@2$T/O%8D\NW9Z%NC3R!Z,LPKH-:*^<"_A::4',J5=:4_K?M?=2JI_
MDQPJ96*,X>;/;%>I%&?9OJKXR*M[#OV-<4/PJ;=#&0F;VT<'.0RJW[+%6]6/
M?LJ;8'G^?[+\"B%1N1'L97;1L\G,1H)!#5%ERFBIU[![.UM1K[K+Z5K#5/&\
MERH7RGU&J$J")JE.7PJ%LY8'.[DZLF<ERLL.O>NN2@AZ<@U4JCN'4VT+WS-M
MJ/N@Q<H1=\-NRC#ZB<HK2*J/M:01+:KAE^^4-P]@*9&6]> BGJ38A0M\J-4_
M@%0RU#(DJ+/5(1\5;\V^I3\4>KW"N,8U<#K-*/;HCY^OP]DSD4_S_X75^9IV
MVHKIE=1FP$C&,5RHY9\KM2,CFM'3,A?J  D;I4VR;,-D;@2A? =[#,7[DIS3
M7,];E!!DXZ@4\OP+D!\E!AK%*\AE7I_[NA"<IFKO*+*[PO.<\)BH<^-3Q>H*
M.G^<]:<<+/\37+'$?S. $$V\VSCK3-Y+)K.1A7=>*=F@U^KW!;6XATJX]K*G
M2 ^?H:*M,+6["TDW%GJVAG[OP@U=QEO3SN,A&V7-]=$[M >.W!!Y[NE,N+0F
M?%O[7Y0_$L)A-C%(LPR()WB!P[.HG3V*O:26@91ZC32/=B"%+5#O0 MO,3#<
MH38V@//718_#NWENU-9.Q0GC8VC2SS)GL!][+:FD/E45J'DN!)QY;*-Y^;ZG
M7^OACO=#4W:C;A;:Q/L2S"'>; />1.<7H(?\$M:/L^CI 00'-Q>,2KV RE3?
MT@!A$<WR+ 82D)762'#?T%(\U@+GR=QO'TN^'-YLF!*LDQ1!GL'I<G:R:A9R
MPB27//+,_:SF3HQH<S^[[_#%_O=;[+_NC$Y_3R1IVAYG?C]#.&5#FNK]?,=<
M=_?_^8'^GJ"5]3[&^"-+KH&5$>!FBJE;BAD*]X,"X^58K+Y5>-;P ;47D\]I
MP:1N(#"U(:358(>@Q$#KBHVT.RG+#]ITVQ"7$8JWQ2@V#?]RU%O[QPNBA';8
M=8=^<I+?+'>A?X)KLU]+2366H.'K^V+KR1ZMSHG:9[O&@T1%F'#D"!DJR(M?
M# 152# 9,K(&D\\:C.Z?VX6$$<4T>RX(Q\=9DD5DPCG%3%R7QTC5W^IPM*!_
M]8EQUI$_+^B_U\9^=*!8&Z,Z QN+(3?TH#![+$TPB^?WLG\Z*=5<=MS1$V0+
M^4P!*JUKV;DQDA'/&X=Z3AZ4?/7N8#:L$18*,VY$).Q+.#$U_]TO1Y9TB?^C
MX^=DZIBM1!PD[N7-X4'/E*&)8K;M6_HCM/DB.<[*I6>(3)8XE<1REO@2A.TF
M0C0S,89(=CT"#5@*![LD/X'SIR7%5)M$XRPCI$%S46?%K@Q\$Q*,%WJ]TS:U
M&67/9.^7)$_XKN(VF2]O(;*'6%Y-IELN$O("Y0?44H"ED@.-\ S%:L*5;T?M
M?$0ZEQS!D^4Y-!M(R>OL@G<]6=1>PHI]V^\//;?$>P(V86[E?<B?)O)1I)BD
M,^-B1=U#VM+]A-]:,'%[Y'.5Y>^,W39CI65"ZV<4 BY:=R-'P5ZBK361Y_.J
M.+Z:A''[@D!Z4A\2SO>\DYF&)=M",%N]^K(0=Y;=TL<D%\]J3RY>V)!37O6\
M+P)]]^8]8_2-Y["-$*K'636Z1G.6RHX;>/0$>H7R!QF88-+S0\7??K/EUE"X
M^N2:ZR5'Y(?>/%GS8X]7Z^/4R>^4U4<#-;__?"BD?N6F(.G\HW@_R_8=%R5T
MC'4;F8KXDU5;']BN*F%*0-:WIB28JIGT:MLBV'B_FU,7N'(3$&!KPK$[E::P
MJ@:T436#=@*1V 09=/3@BZ35R>*YQ NZ_HJHH/'DZYJD(U?HS#_OT+_)3L3.
M&BQ^PEL)-I&.IH%60P'J2D'D2A,\,A,EC*+.'6 ?(=L&YA/_TH:#+=AJQ4+C
MXPR_1B]#"U3(^_ '\M-+T>\*1)6M8C]0(G_E]>LUL??3V]5!,%L4$=YA!&KC
M.&M82AZT-I7.:5?XX#=H.^JP+5?UM5S_VQN,<4(+$,\>>CZR !01%RRG2/8Y
MZFAY;QLC*.=2WL^0(YBC+%O@S?6L^$(D;43=@W9.E!E <TXJ+Z;=.K1#=%33
M[U$T%O)>ROGW*+ZM $UB2V0.^T$D 5L>$=+,M^.LN7NHKYXIUS"[[@(??#AQ
MBGLQJ&,2!X?.BA<CVX"*.)S",56J_Z%T34XK#0!Y>"NAR^&*9!#7';.MZFS:
M7>_E6Y=Z553*2,]0F9WR _DI-+G0?RM1G\7=?I7RMGVCVB?+AN_W-#.D *ZW
M4I!G')"U.,A%TL^?I@X]#DM$MMMG<GV("YB7Z,(7][^)78U$X)O>WKW[*G15
M]0S!K?<]%_3_"B;_+R:/77^46+?23:B+^!,D'(S@NLE4(HC"4"=QIZK&D*4Z
MJ#L;/QL\L:Z$M2/1D024)1?[?]'71@@TEPS>/-?GP.,5S<]_U%V7?HW!MV;9
M'.Y<;M*UE[R >D*S+'ADI< F?%\-=XT4#J/6SP3B#E5-?2M_,MT!3WW+D4 U
M$9F,NNIK@IP52=85$^V*5"ZINLG(I^W*F8.H&XJM!*I*NINV[P@6S'YUE%J2
M_Z8I?E&GTC51+\R>^C"(YT>H-'.^WO!B(('L;!0OOF^K&6=]!166^K0KHDY4
MQ"%<6Z7J@&JN2-+L99<\)IY2"]25U#(FMPR^HE.;KB?O#N7D!$G=Q$]V@%VI
M+V+Y)9_6D]$:MN/@N\9+G5$S0P;_S73^[>E@=AY# =_#KCS>(=^)<LL9UHT@
M @\I3)7V2C2"&O9I[B["WI+^R';Y#A)2 >I;>;. Y#8203;(\WFKZ*<SJ8UD
MM]0DDPC85 23J?PS@BD,<QYX)CO[K<A[#R_XQ#$^UW:-F1W[G%[6.,[22W<#
M.?F!SE)L*X,/F;,,#N@^*3N2V&_TJ",DS!N<Q$XBE?9D98YB"UX@=XA'M@-#
M==^6Z[*"?BZH(B6X;PWIVJ;6JGG3B58I)G0 AZWAGY)\,_O]ICPP,.)$7&A%
M/92+Q/]!.]XG2,$9R%GI_X(Z >3R=3<3NX\+^M"I08NCC='J"V7*F\([\3[[
M<4G^,5G^\?IW\=DW$XLW4T[?J&.[@F)?'%6?/]1_WKJ56@G*R"*C_!S/ UG,
MB!=.MMZ@<7*,)8X_Q'6YZ'0DG"S87$](\H.<!&O)*<J+&-^)^@M8F):"1TAV
MY)@B>H3<O3>23GY]Z7Z%.2<X^V%X\JCA_2;TVZ),*TSWB9ULI6(/Q(6(&-EO
M#1,=C6<T+X?GPZ2Z6\1P NFXHRN5[9CTR#D;D[,.E=H1+P9&[AR33P;69GUJ
M3G7&[61ZZ0^@$A/,2JXO#OZ%-XEX?;'\D!>4JRC7H 1?=[;?]QE\T,G3:#_B
M3=2KT2GP5^8<,33Q- NJY0]C)IW^ _T;O#3;J;585NM9P-U@A/4UEL.^@>""
M;]9@<IG4+='K)RD6Q[A'C3CX:4H@=]?MO:]B.,-%[SE/U4B1$?4\Y('>]V]9
MLU)=+)-2$=90NEOEH)PGDFXE.#G!WB/Q9G4\EY!+X8.Z7-Z"=N[*E*-WAJ#G
M2O93<>@A@6OPB^7>3P[1NN9^EZ[*[-$MZYN?5;P>A@]<YD0!M74+LI?Q9#O)
MW^FG C;B341M( P6IY\DGFKX-#V;&,N=_XQK7_EJ!RB(R=@Q42\JA-1)N0DX
MZIKT@#<S]-L8:7:0]PNO8> =V;U<.?*^,+.YWO8M+TC\$\].6,!; VHRK'L,
M8JWJ?D*+*@N]#S7+<M":7W69O 6'S'B@G7KWW^.0#<H'X *Y""XP>''755#!
M!%MM\];$SR1T3?"DI&VO)MK7HI-/Q'^8;VZ&$?I?D+W!DCY1G3Y!<-JU05$/
M355.0Y:!?6EKKBSH?S76V._0S@T^D3;G+[[\NA=)-5_4WC^XMW3WQ#US_["=
M^%_(&[.H2>,LO^/G1Y7CK,Z47S,X\?X8FL-;^C1X)"SZ,7GI](V^O8K6] !T
M\BNO8V,SGZ0$/UX6?5\TL/W<"^UEQ49+2,#O(RN^_R7]P/LU^A CZVWW>0OW
MT+WW::UA*FTO@O!5]495%C1="2-[5*19^U+I+.HW82$M[#SEQR"%5V]=C3#V
M/=I4 )U[5Z0ND$YZ52]SU>8S.B^\J7].%[*%T#6/F JJD[5+/,X/C+/L8&,5
M;*<,3%35YC3@_ \8W$D^8.51*,EI;$N/B[ DV&[79:3CR+N#E0D5HN-\B=(#
M[35]2H:<I1<F=T;>B$^&/N#Y#/KR0(DQQ7$K;R'Y64D*UO=#ZKK,<=841]LW
M<"*J']O>0=EA\AS#_2D]64%MN@]  68_<L"$>E";B,J1%*L;M;:&/'[A)NC!
MHQL%3B -8Q<RVL@+='1KU;X^/0KWFXD&"#Z8:Z[;$]U4RJWOH0+WKZJX<R+B
MG.I+0]]U[6>V&V)?9&&/TJV76@6JK4?ZQ-U>6W[+MNZAVZ$:3@N_P.!$':A,
M+$)=50F&.=0VX$]XQ@")E?.@T-3@N9GT+2 %1EDA,RF9&]?_RC^)-@T]EUB>
M;1+.$ERQ[Q:O'&>=J1"K:3L0C?'/%IM;!!XOP,I6+[C%,'-OKRC"@MK*E?,F
M2KQ)T(21?8K5I%G#,)F3R![SSQ-_1'WXE&</_A&!"<^&&EK@#T1AD6 _7M4
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M-N-C= J0K.T9G<>^ V-)R+9Q5BGO R;1A+GH'R<BJ$!./O1&VR@ @223?IP
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ML =BU +;?BHOC$TP+*#6+SY>G-,40SS0/DR,77PD^7I4@/NA"LX13/78V](
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MH1<X@Q6-GTJ!^Y(LUWK1>#\'G9=3YPUJ$WZ?K87O/"DBHJR6/Q/%E+=D<7<
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M[,L=.>,QYS?9KBM=GG->JD^*4]HC(GMJ"@JNU;X5Z'@1NO;JORCV>BRM#5Z
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M:#R4'CO+=H8/2UJ/!YU2.M.=\AE-=J2OI0)4$PY[28:^^7WQ&QA@[&R3Y>\
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M>>$\<6C+1&1N4P0F<'WFOM#^N8%:(\Q5O5HB9F; R:EQDO7K<QG8IYJ//OV
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MDCN-81$N3LKZU4$IF>_R^?LNFP[V'*NH;G'SSMOROO"SKSJ6/UOT!^I-Q0?
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M2U\,RH;WWMQ\I[:X/"^@^UT8=4?G5Y]/4N+X_1#ZOI%) 4F:W8(DK?Q3@ED
M.Y63W^*<,Z4 (7PV]?K@E]/OV+TPV<K3_B5*X/EV'P@[A([9@4,UYJ/.(1PV
MMH\CK@GLCPO\>"&/ZMI)3M+U0W8$-%O!"@.?-K5U:.AD?RQ0:.4+[.@C10=S
MX,4H?]I(G7Q9IUBC7RPH;2Q93!P,.F'N>9M IWE.4C*2_WG9W.7_WE/0-O[4
M.;7!25/BWAU0.:A&JL)'?R,R0O'><ZQ#R?9)38@:6YU_)A?)NO3&</4Y0B._
M@FV@H=R\9-,<,J(7]C&F+3]('"LWAJU5*F:3R5@H(_O1<*%PJ8/*]FE]W>4-
M1X);?GYGS4*.[$\6V[VCOXG]254/G()9&/21.C-CD3Q@Z&VDH%YEI&6SV9H*
ML.< _,U9:-K!@^1^(CP;WEF^R; '_^7V$]?R)+3AR, D17G6S_4SU\*OK17"
M&2,/X)3']A"2)[I!1XKI7'<X+D]]FEYW8P#X*N/+!)(]8HUG05'R]P$+.BI7
MD^[&V<O2*V@'MN"O2KU[+AU[U790@G<K9B?*M8[U\''4)<*,9%X>0O6+R6"B
M,(NUV9D\ MH3<2?T[<NAH%IQ8A+/M8I8:>%TZN+/:N-OZ3=6_OQ%_-:D)"<&
M7FY.MOYES(_-%FQ";U^\)2C:3A04^32V%@PL?@RN&)%L7=1M<:R/&.9 RI;B
MY1KZY\0*<?J[EJWR+X%M8E I7Y2A,M?^"EIVU):TTWL&!E2W95:Q<$;":<79
M&BOO6Y")><<VTJ(7/&VK8;K#*> MQBL?DLTVO@S&Q&?#FW^8:C4P[DXLTRL9
M\TZ4V]/$D5;,AURQ[JJ'=)KDN[/=1XI74-Y2L[CX#FFZPDT6@/=S'[?;/@4K
MD1P&+I4U>&FX<UE<[\&,7LRDSF%3R67UQ+/F*[>&/:*].MF?D&%GWS;)9W?S
M8Z.@O5W5%2?'!FO;65!%0BT]W,*VJX)O:J3Y WYX21&"T[31+GA9-ML-5!DS
MS8]8/D226O>FR/#$MHH'N<H7Q*^S>;8+%X8>OR?0JD_*/7O(C<:H+W2&_>#/
M/ATW\)I)2L&)H1J7V+")\%!K+G+$ZK6K+3DLN"EZZ5FN:T+TXF[_%A\@)<X.
M?GV*Y4PL>XN]5SV#PO'N7O$1W)0-!^.MV/9;=T$5FI();[PU7+(8'+Z3</KO
M0H<.>,/A.P.Z5MUK255LDVGNB\UE($:E&\R*J<,]\O#FGK<J9)YP>9QG=V$Z
M"6%1H1K=OKP8S'NYYO+I\8L;I0D3Q5VZ6[=ON58AB:?67;J3$!BQU>,CAT)"
M/Q9F$&?IEZP6S@7RYDG*]K"01KVK;&\\]OI<K_G//&BA? .(,9_$0\X]OQ!S
M^#A\<;B$112D+]&U_*/^6'&LX'U$3FU5S1-9WIP6L]%:PB2GBH\I=X \=5X:
MX:.B>Q$GT^]M-4"+$24SIE30S,BK F'D;NQO[^+]&;,/"@J@=&A![[8,=: N
ME7,<S8AK#FZ(W)RQ4T](1H<LP? ^8M".60LC$^S1K][ WPR^@+G\0X0(VW=%
M*N!N!O'$;+D/O$1N3Q&HB1[?07Z:R\BASRO4[+M:=W:U; 7S_+C>]>"SRI?@
MS%"AF^KOBBJG42D^T*^,J+V.)C*^>HBK&4[L)2!ADJ(9V$!$:?("[6M/+%<Q
M'$F_9"B7/)#,P_PB[/^%JOEB>/VMB)&P>PFV];W"C_:_UETA9EKK,BNJ\=ER
M-UOWU+&:>).('DB4C=XM%\1B)5+4ZQD4(MI&1%=A#%$T_4E/C<)9D**E,_+V
M$1ND9UG'[\5';'^(,A:\KE>?+BDTF.;_O/]9$COS7OS)Z&4=-<]\MPTC1_3G
MV<O & XI];1DZ<S7)6YR(D90.;*Y7;;6R&OU!C'1>,\EK '9C'/S83_CAO F
M+I4_SI\#;\>;KY3:$5=95U^8X>_<A0_F^E^_$]\6=9.0KK</T!QO+9*[^*@@
M+WA3'HHHH46;^/C%$"0/J@XO6/U+25BLT@[^H;A/NFTIO U<",Q]%_8],C>N
M,/%:/'LNP2ZZ'QE:-NQIR_U+0GOT\-Y(%7N%]>\P@PC4#DQOL['!\M >F3O.
M:;Q*OVMA#>EI<,#-%Z0;",<Q;61/HHS/PSNW]R8F<T3MP]%T</':&H6QI6C#
MNE7DBIOD%YG,BOO^%2MY9ZB%K# [M5Q,I&2L9J\Z #+,ISK?L&)PMM:<1=B3
M*',N_'TBK[$.F3U).4*EV)[;(""5PGX@/0U_^C7?F_RJT\O\ ZY0/>6*)O29
MY,P;U%R;$RA'_2*Q-1?+P-=4MQ%ZG='4#X6#*(PO'IA/%"I3?1OLW#\+=L>8
MF1'AZ?+ETMP 9EXXXL[:1#BKV!2<GUUA(A>B=^Q4LS>B"!V?I.0EARZJE"'7
MP&XT-0%Q8VW&0KWM$?#1V99GK/66]7:H\1^3SWW]ZQ#D=D(ZCW2W4U;6GMIH
M9B]TC'I^(!@?)'V1G(F!#)1/![$1X *&B$^_FWBOI.;(F7AT9IE@I+%D*4&_
MA?=K!P+;Y_/=XR*TN?M>Q7:U"1?8'_ZY?"EXCRF4-XG")G'!0" 8PI[%8&(U
M,UT_#XE/##5GA^W63-S^(3FT=3'@&?AJ<2Z;W<Z:>6?(MN#R0/\W77*Z(%!I
M5,JG5[>_8[BNNV"P^FSM'*.P%35@$'7F]+W?9BUE'3)+YH U2&9$H";_V(+:
M+E;(G;AZ]EVT")K?4M9_(.YT6G,YYKU]UIL>Y4_:+1VQ735%II6]89VWZNNS
M^N3)!'_L;OF0IRBO1N$*+^Q)9F0RG'H;$5P.<XQAR&YPG& T_2 PFP/VPPMQ
M\1Y\S5U([-44S:COA..-IVI:%\'KJXJ4$[>*R(!Z4%B95OIUAKP(G:2,B@P*
MESZAYKUG:SKI<Y/<"!(/_6?5QB_(@UTGO$^/H'9)\27+.]9)V>JH.#_&VHT^
M"P[MJ YY&Z#/,D]LQD9Z:$*?^JY^S:J4\N+42<J+$8-'!3:+Q2E_30_L"=C+
M<;Q][ZJV65'@62LV+L??:X(DYV7N@6J)RS#D5@FO)[:-J#S-%<=77DPA&-N(
ML.[:2[Q2P9^^@]>C8P[;.K]B,[H@0_F^R_6!8^OO1I)^^'?Y%A:9T&9SW3!N
M:JXXIE6>?,]>9JVM@5Z4?MLE_QSD,L^&]RIFC_M:4[_N9?OH **T*^2?I :_
M]>?J_\-3UG)$<0JF6V^2JXA0U".?2-K=3FXV>"][BU*S; $C\X%H(_$17EML
M0-RUV--\:$\'^R,.:H64<M]]G;#775 PLK5CC0+]K(WE<T^P5DWWQR69?K)D
M],N:/_+[?,UI/)#\N<'!>S3:]PGQM,4IC\4_6E?RR1/KS0J(=[,[X-M$,G2)
M9U,G$L<[P/[H];K3]\,OT[ULW03CW#OGJ,!&FYTQ9M4<*U<J*'(/ 7-C+[GB
M6EQ$=?1<PB=S!;ZEU)#(:1X()JCI?C(_ML(X27'[><C3Z:P]:J+"E24+<G\U
M8=R<ZI81L7/<Q(9?3.<J8)HA\FF.;"'>BBI$Y,IIOR0)^QDSCF+XGOJ;B/L[
M+MCN)PN^V[_Y/ND-"LL."O@JVUI"(I(S %-#_[+N,?[3,X/)!51IHE>U5UN7
M[^OIZ)F19TG=T>U85 :8S>^CE_R*3/7C^H9-#V'GH*T9MH5$H1KQ'H$6R1>0
M?FG+=^$A:O[<UQ,G+Q$,]21E$;D!4GMT+\.W5R67@YAM3ZW%MH"XD^]/KRQ.
M2SR.29WC'R2D7 W,E&V^!2J1H]P7G69D>9.>UP:?*I<X1,1%'#L_\!'XA>A7
MB^_$TVE$=+H1F?N:[7\Q&ERZ"ZD15Y"B87MU)B=258IY_1K/E3^\Y5VN]? P
MLWT(O]J*GP0<5#H:>IBX-](8[=9M6Q)&6!K7V180Q^[B>@Y0I=XCM^$UHLSQ
MUEQV$%[94 D'\[VB>5=/7N*53]53F)=\AQ^0.-O?^K4>BQ8O[(\:JHV>DQ%*
M*;UN&Y X\ED!]*KR35AK7;\@!N5D!SQF+39P<^AK\?&:]\VF;%V@4IPII+7#
M83[I,A:\$>-[ 6.D**R]>M:[5!=A<.B&D/T]_OD^6^L*S*=W(DTAR&$G_+Q\
M[1-"DE,=%B Z\\>.^ZPHN_:S.?;*MO*(+UJT[^7SY/A OI%+%0C?AS_J"D>9
MFK^%/:N?D<O-DOM>J(IWO9)T=R)*._J+Y0O8']_^)/DN2/D61\[ @52EQ!-<
MW$\X%9"<VZ^#9HI&5<89H 'O5T?\'S2]:UP3U]K^CU5!1(@<HR!)/:(BI%:0
M%D*B(B)23*T5%"2IM<HA8AXKR ACHB($B)!:GTJ+6R(B("*DRJEB2" 'V*U;
MPSD:A#"37>4H,UL.:\,D_.+S__Q?Y$6223*Y9ZWKOK[)NM<]J*B&RC[M2A$+
M^5Y="F1KCY0GG9AZL>_E2ZY@]<[JNX]F?J ^5HR/46?6-#"6]=99W.B*$29I
MBF7/+?8$8CQ,Q=Z$O;^-R7FBGR'?X,4:!A4OOXT&NZ-M_49MFSWUB*([-<+R
M*E>(VZY_EP4?2ZV!$B?JJKYS\&H1-(8I62*!.Y\*>X$(FQSX_#WP3DG9@O\/
MJ"!GPXGW"&:>#ZE5L)SQ:6)1O) (JP('#"JY3T\J9SEQ BLNRT@^@=I%W'%Y
M$_E=GSZ[ZCXH5ZG8H3C+O-RB.;Y8A9B_F0W;-_0RG$9B#!/)V"PB?VJCL<EL
MLW"V=)X*.<]<PZ4%*9Q58!L<V-3%\ 2+U9/SGQ%'.HFUQA?,=@:S[^\BFMT
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M@'!NGV')P/G[Q.:GF$)='8N\$];E9RCE%,Q<.1]A[@[\%WL-=DLQU >X'U?
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M3!V VEO,:SOXZR"N1KZMH1:W&V5OK>]+>1'6]MDHGU;;0_./9![53=1<_F+
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M2>H_#C$C,>OJFD0+%F7<,UCFVRW^IOIGF*"-8V_6Q5SXI0PJUEKHQ%X46IG
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M)7[M'OXI*G+>:&ZW\2W?7=%'@%.G44FN!C*@#D5RMO4S;6VBW7.PX?G6U=\
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M=;(ONX>:W6#V'"5'Q<OA4@#OW"DTBH<T%_P)#/C1-VU<;](UZ8YP&.C$Q2?
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M,]!O9- GI:ZPD\D\W!H-%J'#]$L9@IQ /1U:CP;^E]@",B^:V$5'+[""BKB
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MG)[1%\OC3<]B+(7Q'.2:#+&*G*&X_=WDY6Q7B>I':DSS(Z%\U%$UW"2:^\#
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MQX6U_(#GOX5PGYVO3K)X>8OST"[BX(+_RO+87\N&>A&Q6IHG7-A%).W(L6\
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M.L2\,C%6GY<&[!U/QBK6]IY]&W4H(&B?_5]9P1H#7>$(MK(7=I(YKY#KB+7
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M[_(UU'\RV/+9HDNXE6SB:33AA)J.0<@YO)T<QGZT7&B*0(P_=KQ7S8FY;,0
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M/OC'&!&.)*Q78&9<G&5VS^='T%YU+$3KX$\X\D<Y 0%]:&NJ"3*(H\K) ,A
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M)(;[G;;]O;XIN](@R[5V:^/AE3.EN @;SW.>!:GW[L:^+WSVX./=W,^?/-S
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M^NN= HUI_-*',$FR\[9(13]"9AD)#4ZWV"V""?F;@7<G.^;;'K\9^#+$^V:
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M(W26:?H(B4EL4Z3;AZE)L$Z1Z14A_3<#X! N60^5\;JC=C[-Z<!;$^X"I;E
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M.'57#U1-9I; )]9L<74X^Q<H&+[\O6W9$CG[CS5GFLE!7@=$\5=>5KQW7O7
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M>)U 4 TZU2Z70K)+AVUTVIXUV3WUPR[=RN?8BMBI[?&_6\(TLJ'W\-K\Q_9
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MAN<>F@Q!N-355&'WI$W?&Y3$/TF3*)XC_/3*%C'_8L$OJ%=C,ZY\Z#TMO7H
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M;W%%;23D/?]_FO^3\??X'F($P7YJ4"DBM1#&/*_$ZT[_4LS(K#A;LD$*J31
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MM1-.PLK=-MU+>LUZ+MB417*,6:WT< O+I[RR99_BG^^_K +H>\\=^#%2SCY
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M^.YM, IP1B:PX V$9[C9YCPEP:;\8O % 0JF' <Z;RF? CP3^<X(X?U*K0W
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MI^!5='38T$Q<B*_,F>+7_I2'.S%6O^M9FY.SZ =[Q5(J[0 H[<&_$\[?AS!
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MJ.WV7:SB?7\],16VX\#;IIH_]TS8^QRH<T^)V4'2GH[)63'ZJ=UL8N'SBA&
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M>A6G,-/H;=K!-8OV94\:[EM+_M_9?* )N%UWW/ 0H1>@G^(VZ$+<V,J:72]
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M16A'CE@'U_]1@5=J/<X;W3&D^]/[^6+XSX/\]5-;2:-36;7'8Y3_94<[3W\
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MGUO%SKS*/([?0N] <$;:G0('4+N7?'3)$+U<S;> ZI1#@ZYFYDUD9$ U2 D
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M&%#"DH<B1+U8>*<O]QIZK(:\8@1DDBGC60;;/G1W\/)$W63;R=B$B?R=O(6
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MN!Z#(S:R=?AO(IH+)4FXCY6/>O9S65#8F>&H_1> /)V%] Q06J?$G8%G\:E
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MK()EVAQ+ZT([B&</C',&4-:Q^V:8\4KX9G*1;W;E$6/WUN=&?U]#:*$#,Y5
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M3SI^.7PZV#P[Z_^[>0JS\O[_ %!+ P04    " "YB69:[SK8&($; @#\V@(
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M)?$+\/?C%$)X\:?U<P$@(^IX^RT9,)I)G)O6^L]W;"*UN4!_D&)(C":D+C)
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MI,S_I&7TGS9!Y75>+1(K\PEZ>BV)#!C(DB(#LJ 6$>; ^8-C$O0+&=#O!EV
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M;I[RPDS(Z[:_P:;2I(Y6N3'(<KS.2RMM>;H4==B8(Q9L,_9!TBKZ.OV0#N2
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M,?M":6XFUA8BV2KTYICZI*YZPM9DC!O-T;IN%H=IC74%FJ%$US@S,5=;.J1
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MA;:W6[%97+1/[)%Q-T6=6&]D\;5)+T;[LR7F=]%,"4E5W25DKEF4P)8H2ON
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M&AD[&AXEQYG&H,R_UG%Q.A18/VD+4/T2D&B6;P,SO6@@N[,NY0N7"]?7,9#
M^\.92B?#>]+9-GX;<+Z") _L7I>D-E3#J[R$>$558#Y.&S+&C=7+()] !HJ3
M] ?GUQ<<.-A"Z]8_5CX1&3:"B?P=&$&+&4P"^:8G.ES&V0%ICT99/T5>'2>"
MW$K=T4-31%#QXLYLAQWMTYQ]U0<L]2$BPW^+EL[:N-2D(@N?X<;\!%34LP@K
MF /@#K#N5TJ-NG(JHQ'A%>:<O5EEY/PF5C1/+V^4TSYABZ-XU-O#Y9+"G/P5
M4.N@A_<U6OZY&[R_#3[!D/H<0'3.JB6B+9(FW&5*E0JVA=O">RF+A<;,R@??
MU2Q=M-+'C :IL-?(A:FDTS^JOE7W^G(JME-U0@\X[\/X%L^=_I)(>W:-:$2
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MOJ&;YI8^LMG?S$$:2%6>J-[6*GBF$<-?H'U=AD1S817*2ECYI,Y.Z,3XLBY
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MH8B^\U>9T/'6?TY].5<EOOY]FPRX[G">009L.A/6*+4L972_XTM(7-UG F3
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M<OG<CCAE*P3!K?U,W^- HP<]<KG5S3X98E^%J]Y,!!)47DD!O>)ZC5&F(-E
MS]DRG>PT=(+SN*E)XOJ]-(N]13W[QK*B[*24.X.\U9_:HW5U&))*7LHUI' _
M_<7T]"[<S>-L+A%SSAVH$6HYK6"H=*G(2PN,;)Y^Y23=;6P0%"QY7\?Z@\7*
MK:7>OU(>PKF&_(P37,0&R_ME0:9I^;&B)8M>OU/ TG ;\XJQ9INTK<DR&M-
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MZ>>7F_TN2I%+QA%7C_+5X?" >S3V.LD&EJD>\Z$[2HI!V0V)JN9K[H^9XQK
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M]#V7J=QU/L7UAH)(S-G>>O4-:4NA;/L[OSB)^8N&+=:A>0-U'C=#-/++*=&
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M_&U&5*"*)9EV?SW1U@#^7A)5&;HA0 :5Z?G#'M_O2],E D%X<7:[6 4+]QB
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MU4&=LK_\&UY^,$V-V7\M-;NX:NKOF>:$3:GKO98F;$IN6VFR1$RW$^V'1S"
M+W'(7/@7A!5I4_L>S$[;('+U29(.;VH"Z +S-N[URVNZP"%A.I1\FE0J=GM,
MQK8,?'@(-"9\>?:X7SW\L$GJ/@-X+6N-WT3C;KI7AG-/;#F+=Q5?Q9S^%8"_
MB7@S%K0C:F:0A[^)_!?OVT@>A$UZ80NQ%I@7Y&$8:W1W%"VOF_%H^$!HF>^I
M2,UQ=<_$/5O_T5H!_-V/TX05Y?KKS8.0*?5#MX$'/MAIVDW:2GSP;&JM;)M$
M7N1H$76CBJ$<C/G4.W$4BO,Z[9@]]:)*9%_5K=/Q1B>?<ZX_][)IWL,?1,B
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M)$<&=H\2UD%G^-SX>B]0IHW3691$6<\CKIH:V05&W3!=$?G\0_TN?IK1E,]
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M:UC*MN^U,C^E4YCF?[8/N['2<>88_&WTJQ0%F>*%&$E.!.,:OHK;RE(A*SM
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M>7/]D0+.C@J((K8%])(W]DXP!(44QOC[3-1LIE95(%N(5?;:W_@@M;.O5,>
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M<DOPYL7>\\I6;_:92KI[R3I?1[I=Q^E1UGG$JZ+["R]\WM&YH_VBP 9NT?^
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MIF\^MV;F,\*?B? &4C*@*N>;B56/E" UR4;'AI\):.CK*?Z8&F*HY!V=%@P
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M] ?&-)Z>K,V/B1 ;[^GKJ<%7\RR"Q%/GFK9O_5<)9OGAISP3(GH#F 7% IK
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M%KMML"]$D!8N D?]'@\K;6_\X]$G# X)#.V>');_LYE@E>!::97/*/N2QWE
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M4EW86(*L-CP"HBYZ[H*$G*5HM]+J.W$!YU7A OC%4/"XY6A>>#.0,K@*6I&
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M;,8]N$WI#5Z&;<BL:J]\G/!(XNFO6K@,6_^DXRM)^;8^EE%[XF6(I^R407.
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M%#J9BH!#+H+4]EU4E1UC6)<6WWL?R!?&3/024O*CO0<L.D??/H;LC]%)5W*
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M7E8)%;5%OHWGF5OTOV&LJSSM"@7R.K'&Q*ZR<%]<VK;7*@F!<;MO )AEF#:
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MW#Q(A$U>ZV#=0!>R95<(4?( I0 MMA*W0:EQ8@UY/W<"5X 1;RZ9:7ZZ%67
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M=I'/2U\2E/AS:M ^^9LQS95.0O$@QTWH<4<")/"5X.M#?=U7-B2O,W\]\FK
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M<I*_4D(5H'8(J2/1712Z<,DW96:3=*V5RLWGI\:T>ZGHC7A%?LAMB1-O+LU
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M R$]0_^=V^K.R#6IMR\CN31R5QTMRDIIRYW?,J(VIJ^96T]8!QESS3>_"3
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M%J;4E./C^,NP&9Y0D7D]>>104%SQ<!A-AV@ V8< 00X>0<^.Y?@-*V$OS'[
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MW7X3_2*0ZE8Y-ZL-#?_?-73.SV4X8'CH5?BX,T(@J_$4C[,&\O@UQ3XSHLW
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MQ9J'2B<FUP,!6POI.$*[>,AZ#P\YR1?V0OT@J3M_#99J$L%6A+QZG'J+3)L
M]R025]MY[M7-)J8,;PTE)$;^]MRQWWZLN+^3?GJ;>BV@Z5?[88+A>CVF;%%?
M$N=E'X6X7E%Z'C&!$%Y$C]=UD'91<1R<$A93/]:-V.$A1DM*]P$^+\J#FECE
M#_<!_9^>EHJ/UA1Q@H/\D,E5D25!GB>CJZE]7G&HLZ@0.&1@L3*_4[27L!.B
M@WR.VPN2R)M ; 7<&209VZD98&2IC4.5UT&D8 -O;DM)*W#P$5^U)DYQ0!'O
M*3S5,IWN.[0-NW'<R\NC[W7P:LBS-=B S#H+12<(LE@\'B=V!Z:%SV7;CY8R
M69E5(DWQGY+7U)V<+$U2AQ7-I(&>3$4=JP21TET*H6.<'\4M6HX]0Z-#GP3[
M'CM:.24O_>?%&"/N'Z;ZE@5FW&9[2[^V%.6 RM+M,;(E3XN/0S756B>Y XR!
M"6<>KF<@4:HZMKA4:(AF2D]@Q]B[C0_D[RF3BT3L#,X6'P?DLF?"V#[F>3Y:
M3,='>]W-^BP^RP^1MM*#Z-!QLCW4RT$H2S^3 31[ HV1%-@>QB^VTS1'J/(
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M)O4Y9Z!=R9)#5T86IX,HRR&7OQ44.EUJ;J86IM>=H 2_O'^$ZKH^587-L#T
M8-+-7<RZ:+O NPF5D&^W]M[1-]QA\U@2HT5*#BO%>II4W;Q#P<64S;:$?.W/
M6"[Y"7QA#1B95NJ\127)#EWFW+\@(+WRCC686J#M/B9Q#^$<2$^D[N>YX'J(
M6R ;$,U7SR#N(VP'W-,CFT]G\.C;Q8:CB[< JI7T2>H^IH6BR/O4&9X':][G
MNOTV4+HP^#MB@UA+IF)!TC[,AC78'_\;U8DB:OR<LAPD!= U?R*4K5&\P!*9
MBT@.%9->=8-W8]VF>U:?@N(FQ&3CZNB+@S51PA!'UIF2FJL/C!^I[8 /HNI0
M\S- D_ ,I"1[#X4,2WP"28I$.'2YKT.JQ&S0.A6"<<URK@WR,YO-KWJOKI%;
M'A-IT_U=LM3A\V,V^I;!B[BL\)?W42:H4!RD,S:__CA$'BH'!OAYO38;>;8/
M0#+W6'PL%[=%[ J9@99== 5"I'H2TF2:GN8X;&W'C7Y!;:L;HB ;8C)VUSF%
ME36V5O7BK#I>>Y]>@\40=JT_G9H0<>49Z#C$]A<C-P#+SBPY?$P[44UC@1+#
M4[KGC6#<NZT14CK52IF][/QJ+O_[K)VPW]>#ENO<C[Y<]$/XG17T9>R5[/ >
MHX"+ ]"!WGD[V1ZMH01@CA<EN%0LOC@L=@<HG4W$[4"$5 XJK((.?&2<;1O]
M,;:@F]U[(=7CUC#Y4D'8L.O'YL";C0D30Z-P),]%4ZHD,_*X2X'YGQY7>\V0
MZKN[I[)>SZRVU;O3Z[,R_1ORYURHB:MR+1F;+I]5=/E-X:I>QH2BW*/=28@A
M)94- $4P*',JO/6FI)QBU#:IEGB?I$*\YPW$:$=LL]4)1"F+C[[X660T9FU0
MWJ6-&(KT_DW1QFW:L3ENVO7S8KT+SI5I87PLR"Y?D7Q,05#-2_R!:C)O,V4X
M,,T%FN<:4ON<AVZ'F/<?^[CC]+%<-360-<'JVEVWI4K RSS,,-OQRO3L#\JE
MWQ%%LD-9@T$'Y>?7Y[7\#J 9%!AQQ!.3N8R&$XS!D)4,JA[B@77D:TA[5HET
M<2@SRZ9;T).?G?9SZ)\U6+'NX&)#0<1?9XINO9!N@+S68)O;93J)(&I K\>Z
M6RCMY#WB6ZUOTZO))>(PJ(E/3K;5J LW"H^N>.[R:H85V1?]2#^P80O%N%0N
M.U#7OI'^_./AC7"&[6Y@+(Z**H;0'33MSV(]+@;NX37C*9](,"L9#[1%?%[J
M.[U3YD)M,TJ]6$$LOX3Z&WIMA3GU:L!SQ;W!Q:K0 'A(JK1>%1*#G^9'=5%8
M&SO52(@U6  Z&;&[)'^:%RB1$9= 5#)Y _4DWU#4-UGH[#ILD06'$!=K:[)#
M,)=:R1>'!2]VS#2I#YW%&^DTYT?[2>IE>FYCNUUV@T8RZR/%86KA78CQ  9B
MZ\$Q5$!66GY>2L-BFH\6.)!F[<H3Q/ "4J@WS"/'Q*Y\N-KLO4KL"FT_-8M!
MT\ZP,'3N4V^0,IBW&CP"'I0^YJ-D]MS10@9<%N6A)*YC!<_[I# )^LHEQ5E5
MT9J 7BZ\=Y&%X@5TD^**5(?G]QV9"?<0FX#;7TVIBVQSK9L:AZ8&ZU.H3SC#
M1LC;*Y.HA3:5#2"EAS*.%.(DS^F!61,X82%4SHWUZD+LI/L6+*K,LG][H]ZE
M+B3* <)F7J7F2?T&B5/'W>\1L;Z>GR==F)%P1?97IQ^!5D4%OC$!*2$O)_^7
MI?05JI"I[>UAVC[Q9FB/[ //>FB&H^744:3=#,T!3K)=!W'1J>!/Z7;:F+53
M&-<&W=&(V$G<,8[/ZM)P3[6H') +8@F$:3'<Q^4.(2\AW-6LZS7#^3U[Z*7!
MT]97.3+HA.:<R R:)="49.W+%>6=-8E J@;F!R1'Q"2E'\F89EK$>/7I>V]\
MYYB]V4 K[J_=WS9"#A(R*8 TOB+DRH3^D-BQ/M,ASI5@ )6#ZL)CDGPBDBT=
M)S4=$CP 10R4JDZK3$6L1LV;(#/N#$V?$/#Y#5$'8G;1E%/'NAKO(9.JJB+(
M2E_L> K+IS-GS)W[@T@UY'3$6_+\(C@I+);DHVXCDZ6(L4A<!JK6I2FS2JH8
MK#9U<'AI$1Y82[!_F^0"RBU4<2>=,@>\J5X>IV8&")Z&)[1*__5[M#^05CNX
M)$.M%N_,)*[DD,OG>F_330W,B SMSK'S0TLBCU^UK%YT;:JB\QGE0[>.V._%
M/D[84V4 @Q:%5$D"*H RF8V(4T/4.R90H/+3T$:PO).L+=[#K83O"M:P3%S&
M:$%'O\7NM Y[R?K1UZ.]%WTL<$%L4^FDE_'%=4#E>:_Y:_8?EQQ@!#M1-*G#
M&N4W .FK=\8J<U8$9SD"URXB BA/KZ<C(#-O@)Z\C)+'CW40C8?X12,6N&U0
M\9F(-N;4+W1+*S-2,^": &D<L!U0G'2Q76#RR3*?UR'38\XS(OSS_)L0JA*(
MQ(">XC\A7]'O^#3>=+K4&*)WK\'V4*/YR/BF:5<HZB5^FG>A+3R&IQ75KHV@
M>9@4 V@RMMC[Z[6@IJ::ZYB@1O5C:[#Z^HOR[U%[23<'[F/JT0)YT1$B$Z%2
M3]Z)1>TBW;+!=D\=@,RV:>NVU0,9B<U\&P,M'=<1@AW7X9KYP [,Q.1DQ[&4
M*'QE6(G/Z:9CV;KW?U $K2)YZ8 ,^RB)VKN@$Z+S@30=4)VQ*$^X"F3U:*%.
M XNI%HBM$GHW;6OCZ.VEP(:"*J.J?FGR*$M:JKJ0>RO%A##^;5>W^8[WY%LR
M&#U,9)%J+.?7+>0W2(D'GV (GP.FT#2WK.U54/ZWBY/LZX&K:[!$L?/+^NDS
M(/KALNA $PN>; Y54T(.T!M\IX-8B:5E/@[AY<'JN75$?P<9E,JBC@YD.10+
M;FPO.@18RDXNV3.I*T2QTV?[,.VPV EB\\F:XAO "D/VSU@KQZ92\8GUSMUS
M?6WH]JDM+62'IIJ1)9R24WFA\^EW],_ES=(/;?F?I:!LPR<($9+L]6P.EJOP
M[AC*#Y-!VAY!TB;L&!/KE^-MISNMVG/M_<I_-O[E&:B1F?5:7B,WBX>$:WIY
M]<.[U-2/!+=$2NK=+UY/@K?^BY4YU/A0.N?9/?^G',P6*.VBY(WM0;$^%/UZ
M1H.21),3HR651&-\*R>N<"MHH61YH04*"*N<A"+K\:'\LYD%6%Q0Z#>5F]^I
MR6S:E8ORO9AZRKR.R$HZ2MJ)\LM*86L03E1ABW0EF;:&]F QY^&]@!0+8_B9
M(7%,X*K1*K&X>B87OM=G7P,31[ IQHR/3QV),ZS4F])MRO^A0.M^F0KK!@\E
M1:#4H2@?("]EJ<\;RR >'HQ$;X>2'&GH8WUNGY=;]RSU>YVG)JN:>K+'KW_Q
M_++O)FV/]Y]F^6('R%)VO#]('28T!6B.87ODLZT&P1ETB^>0--AB)P#9,9""
MVD.(Y-,?V"J!(]^'OGKA*T]#EZJ"=^%OS%G9EYPM_3J;N_JXY$XGTI8%ZE 6
M2F7N']-.@0Z.S=>(3A![;$]*XFW5(&Q7"WI^#08:VD'=W$6-:U/X)E<ZF-L0
M @Z->;T%)?.T(W^5E:I5A9?/-:EIN+V 97H?&!HXGSJ\T4]SKQ):JN E4L.2
MWQY+D $T<XRF,6O%GB_F4N!>@5:'$G#B:Y0U6*?339M,>C2O#[&+P1-Y]7G?
MP!<-=+NO^!QH&J:R]2U.;!#M;[C:@'@9<5&>#^_ 0?LH8N5?G)7U>KV]%C:'
M9*1N0$NL[1P.I*)94?S%+EQFOKPL7#TA,#%J0,I! 3V>53UII5/C'WS]1_7>
M+!B_*6EL*AIB:1;@#V7]Q$PN2A6NBC1('>=TH( HD0NDCFD%DSKZW::O0D&@
M&7<Z/7(@B;2+H(LL;6RF,\W7ZQCOX4/)9UMH-<R&HWY16KWCD<Z*L?;GLCMG
M%OS>2?;(/+(EZ@\ZI(>8CQ')0^Q>A*IT.Q33*]67 ;SZ!0UX*M%"' J1^?!T
MDBK.VB"CU$7]H;'8BV]\2OBCEQ$V%2B,DOGRAE3]LM9-7[ZBMWHQY#\A-$D<
M-@DZR.XE9[%59#PA2PV/X%&2J*[@F"MS&9?I X="P/)>\G::.N&/UGIJVB4:
M)KEH,]!87#X.Q8UUW7L8< G4>U;G@'T]ZSH5_*>#=G%,5*2E($<F>/?Y/IE\
M!B09)-\U6 H"(3TL'5B#*<CN=0,^7OB8:0WGKA>EA19$6OLH-P$4QH 2J=.8
M2U; .W4VR@QVD&#,A<R%13]6)]$-ZE9%%5'AKS!?!\SC<>WN)""$+%8VQ<:Z
M=PJMH@3ZS\6[1PD!AS(6UV#^;1N%+Z#64NFGQ\'*P8-SEAHXL<&[2'YQAAIO
MX4BVYU.7CY-D \WWC:<'I?_]CQ<V(,2[QH1FDBK;+>*]$K*8!,Q= C#WZ0&Q
M&/M1Z6\? /=NC;%.U$XQ@@9(B_(=4@"U5JYBFF&&VL&A1[=#=10L\U/S]F=+
MCU<S/ZW!;@U .@'S]B($(624%(23@Z)D9 ;-0K@-A2QIRL"GGM1-V2.^"V5P
MVW9IGIWW8UH;\N!:&+;+2X?H@!/U+<U-&0W*_FDWY>;5X#;U]-?_@PEYTDW4
MQ!PG0. D<B&.3VW^O R"T\)&S"8[,+YKE9V"7(XQ+$1Q%S)"7N #S@)3&<?Z
M$-MG1H5J=[&12L]"].8;<REA9FGX'-MKDM<H3BKB;9/ 3V1G)[H*D>V@*B!+
MF&QE^-.*W4V?J..MP=)IF_!]W:.;IT8_;09#*SG8OCV1!2*LXLE8"XL3UE6G
M^!=2%35%!7U>)P]7T3U_/H<_H-^467G O$S%-BT,BJ\%B<P)YGEG0/<NPYEE
M1#);E1I$"::A(#JX^4?(*;ZK(H^=3-0K^N4];,1M?1?]DKD_GWG^UPA2KT[&
M5F.90LPFTDWX!%M(E)30@Q99 USA@W6C!B35.*I>%$CJMCT 'BOEJ61/=MS-
M<\L_F,9UUK(K0B@&&C2=PE897C@P]0/K<ORMQY+HS$N1=BH,FA()X9(B"]3D
M8T<97TK&!'I*>@5'90KX8$!D$\B:@[+%^#\8W.&6'W64_FVV*A?-?U7U1U."
M[]!J=*QY'SF3!_;U64ZH7/I=[O_C"S& $JL52,_1YV7>S&>U7%KJJ42R5Q4O
MD3J"1I*ZT1.IITJ<O@57_MAQ*A2C$FCD'O7U/>9)^C?DH4SLJMJF(]M*3-_*
M>>RPVW1KA].FG>]UX@R7IDS68-EP!D*TF9<E\;R)+ORX!OL6U45:_F6\!AL.
MCAO\_Y= <IW4=9SJA;IO'2Y_WS^.W1N.1W4-X@UB'H<V?L8WNJ@M6Y^P8'B7
MY%9N\NRHBW;YYT^OY)'T]X,+KN.7W,\1/Y9:4=^2ZYX=^G#9>FGZ@YZ)YU_,
M_%T-Y9K5@8TMJ<[YIAE?HA^[I]7GC%#4!ZN8/Y=1>92]TGXV<#EKTIZ'8$C6
M<P?B3,R=T8KM$5'@W>8 +D8)[^4\5(T4E(XM7S.FFH6;MS26X_\O]MXTJHFM
M:Q>-VP81,2J=@! 5%14Q-C1*D]AL0$2,B@*"D*V(-!$C A(EI%2D%[(5!04A
M(M(),=(KA$1(@*V(-*$14-)M19I(12&6I#O%^_=[?]SSGN_<>\\9FS'6&+"
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M9?YP09QE&3YDQ#A!UGOD>O[+FLP]HO=0[NG?L#C*$O)\R%WN +DZ&()93;-
M?/7-,4R^@W]@/X,^4GYV5PFAOH7G5A):ESX/$_A.LMKI4Y@HP6:SG_>%T9N[
M=ZYB1B\155WXF;1CU2'(81EZ>S-GX<VW <F)E?24--M5_8S4$Q\+7->/G:HQ
MU_V[,/?PQHB<M_>7OL\T6'B]V%.O['C^L7YZ2B3?:K-M].+CEZLRV#8I;[X.
MO+B.^-?7(L3\ZXC5"(U];DYZOS;/S//?4S9"2)8.-%W9'HI=:09.JQ%(\IEP
MH'!L9 5OFTKO]/C1<17*S9BM0QIRN](W#:SRY6QX1UG=97FQH+)O>JPFIN'!
MN<QF?5P 0[\_LNP7!4,R.T7=-U#,HV-60SW-8NXELJN?/>=:;-](E?#-'STS
MR/B-0CQWEC[KV^Z8>-NI/%7XTO)BM=@JR'N)P)3WOW#4SC_MOZGYKZ6'].^D
M=%$6]J&<0-VAM#H.WMAG'X,_P=LG7=?:+_8!/V:,C:! 0?BB?"'AS;J4L)@3
MD3N]\;YCE\P6UO\1RV(:G^ZM_DN-"%8C$"''\0IKJM<K&)8-[7ZVQ[JB#%5;
M3Y_RG6"M2O\RP<&8W8934XA*NR[3VX.;[?>7;=;LO7H'V=\NA&U[';_\1U5B
M_VG_K8U)\&;U\<3LF]5?:W"K6Y[@P*E66Z]LQZP;%X@44[_QY0134S<W28S(
M8J@V_S&4W;]YV[HNQ8Z%'SV'/M^;S9T&#\V>PZ$J!VY/&%TI,&^C+ABO&#.U
MRG*KA:+%%O:Y%SO;+GE#2]Y_$WN#TYE#E#KP\_-,,5YJ\C'<W29-1)K\G+J_
MJJ[W@C\IQ^/$G_,'2_X7"L?]W]HL?L%9^N8O\BFH&!R5S14/,_W*1[+6DR9>
M#[FDL2_&\\A!A:0#+3X#B9%3!F-_^I$Q*9;H%IMK[I_I["2KFA35K%E1J'3$
MVR$Z:XOLW88+:H1[E.(9T,1E?[^*!?<1Y5@O-:*'GQ Y3UXJ#P::?E<C HB0
M>6>"%4J7TD\S5MB#%0Y^EN],-<&/F=<&DIE7Q:7EQ,@R;6?T0I)6\[6+=:(I
M79LL3%TA$)*+<JEW6SSUQ]TQT2F/Z&35&SQX"@^91TLJI-$GH86@N9C.Y1M;
MT:VMP\$JD1>'FDQ;Y$ L#^$'Y!Q[^1(<N2'%-_LC&Z6&+WAGC3(+B 4N5Z."
MBMJ7Y5MIG5>1I%AHBX&D0KZ>\A9E#)Q/0W%IE=OH\C#*B!JQ?)IF',RO[&R"
MF1+K-[ NE6(^QC*V]<'4B#Y=1JZ Z*;M0I@[;HMB:P7O]!N7)8>7?>S([X@(
M"'2L32MYHR$@2G#2*5D]U*Y&+(3)RLW-Y./* IC$YMQ5O6:AX7]-D=K&3R.3
M=Y(#P" NWY!\$NQO$-*QN'X' Y&A@[F0ODSL7M<52<B\Z>;N,^&Q8GABH%\?
MMQ2WX\_YLWT0S/P6+E12U8CSU-LJ TA3^E-,3,"L).^34IL!8\7%;F2ZQ]$N
MAS7\91B30U)2@T^O Q ;9'"S.C7-]FW>P>I8C]/5?3.K'M^?GK"@/T;= 8(
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M6JF::!O(SDV_$RVDS0_QW]TS0S!V2]O&.?8@M-,\Y<(W^MGL!75YQFXE/J1
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M=]Z[W_G?,5X;Y[P[WF E,V/,O=::^<TU?VOO.4>2'?P4?@&XK::DJ@00$!
MJ,L'@)\!G@%$A(1_/R\;\>63Y#H)"3$QR0U2TFO7*6Y04)#?(">_>8OZ]LU;
M5+?(R6_3W::Z0T-+2TM!2<] 1\- 34-+\[<1 J++.<0D9"0D9#0WR6_2_-]N
M^%: ZCIAY34&(@)V@)"*@(B* -\!L $  0G!OS7@?VL$A)<8KY%>)[M!?CD
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M(.W3_<,O"I&'J6EUZ5TTCA4J;1Q.8E>\%VS)P^\>XQK,D0;NZ7OP#3P/)9.
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M;U$ZZQM:(+[3V@VS5%3-TGH([H'/(Q UQFLG;_1$W%UPJT+=EX:PE_WXWNV
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M5 W[N"T\0!D2$M0X\4$K4N@T6KC*77DDMO'G(0W-'YPU^KW>VX2SU$?.?ZK
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M 9PZ48"YAVX_\,-#MYWS#( #W=7Z:0*+(P(Z5.ZC3@R'/G"\W6?IS?0&FDM
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M9:<A#(36B.B?_2_JBV]$CASP^'^7W?<B;88&@S&_^7=A&RN5([RQY#SZ9,/
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M<&9OL2 C2&V15N@Y@,%\I?C,A[+.HS*<_VD=T69Q^'Y_V0W%P8S-=8)EW^L
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MDVZ=J0GFVWA#0Z'DYLN$;5I-L^-[[A7]S*CC?^4X*E0\O#4A?^) 3HZ^:^<
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M=QU<R.'W<&_1A$8<.-U=<2ZKMERO/NAUC6UK4_25D-NSDJXA@:)T,:G C7,
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MT*$5X.-U0N'MB0\XD?,63F@C" YZ\V9;0^ E+^'-.[V#/&S?8[(ZY93;B#4
MMSY.*^PW1$!)G9&1K*2G2C.VMI<*1_*G)CHJ.!A$V[DOG#&2-J@:PW_"=7JM
M["R1<-7=ZQO=<2KF03FUP:2-0HWVG(?!]XT,3K+XQH6D2T9USUECC^DWS>;0
M0:"BZ1#"U2D&=OQTQCK;[$&B-1-24L[R49%R\G>=YO0*=*P79H5SHQG[I/G
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M,ZGTM6/$/NVVT0W<<$(82C"\<(K_N,O5!)FS3SMK^M@I;=L.7O!MR;G(=WT
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MS5..89("FWQ$=IW3CE',5"HL8]T@,FV/ZEM&)F'X,!>UGQW@+\O&1B&EX6^
M'*-$2=C!4?Q67>[/RLR&2I$AB.3/E^6UMT!;W2*GK9[T0:?6V>MK.? %@\-
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M!3=>T6C*VXN(*;52V6J"9;2O2)FSKD:!!7;/RF_DRUKZC__.*JW_9W^9RS6
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M(@+^+]B'_V?_NW;]^_\ 4$L#!!0    ( +F)9EKU 4Z_'1X! !:" 0 1
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MG3E=@%P<<7=A<9S@AY4#3@F72,_\+#[3= NZPT]!W992:4^NW&!55;^.S[$
M^ZK2S="8?8'8[)8[ =.?=A1I)\^&J;M7KOANV4W9?BWMS&8QL?"HD_3'"4WP
M?Y4A;T R/Y0^7K/"ZQ%;G[RI17?T+JC+4EQ+OJ\A$W)_<_!F]J"N>Q4H1=>]
M-M;4_QM(@GZ"X.R@V6%6*+J8RHTNW'0I-UO^Y",\+$,$>.>N3V;/EFLG/6CB
M*J7A[B11WS-JN;$J-(,%=*6R);H'.OGD[VD#^)');U;U +TP1H!VS3OG8<4[
M:+YIS$,K*U-'=5?[BAAUX8:4/@#U([S0(:7OC ,*:K+QJ17SSS^O3IA.IH?1
M[?I/[V^M9E&@I5.ZF#\G)R<C./HN Y*O'JF\_)8I3'EW36*CJ&2?CK:QO.W'
MKOHVWVNOPBFM\:2QD:\J.F-JQFM^N51=L?RQHYQZ V </7.3^=F#*ZTJY%SS
M40;-@Z"O=Z9G6FQN:L>._0,RM0!I*PN)%O)^.J8>?/R\SR3%QR"6T)?UK5SJ
M\546K&*M$T98G./;WV[(G%$ZV12)7^-<G?TIM+RF7H%"!I]-[,#21=[+]* O
MEJ]5SA+I-LI*G</H)&.2B3_&FTX/N':DYO-\"6:^DEK)K&9_#[;=TZ96SC=9
MLIPU&Y3L'<'A"\Q+V;SKD'W-Q[*RU"U$"K*?N@>'1J-9\^>T ^I=\I4I:9HI
M>Q/P.*E&0GO7HB 'S%E-GYTLA5VDO,9[@MH4=]]-7K _$"-83R?!(V0BXF@.
MG:BJ ]I30@Q=56%-?#^ZAV&T:KVN!^'X\><Y+RG\DRZG+1#G2%!:EZ("' -=
M^4+WYJR>>A&CZ74]S\A$@^@BP3N[ZS_5 A.?6!DHO<57&/3AVM+0>T$!DEA;
M^ 97;$?3ZAEF,I-K%"WT_6:6H*CB,WY%C^B6&.>W>:>20W7/[8A:BOW;&?3K
M<W^>?D]VT[VV:=]4C>)8:&V!!^\GY+N-7T.-ZBBC50OG5I]%_IJ*&$?) /3<
MUP*UX?[8N1?IM>;N$PCSN#-\W$>*26?@[FWPBC%FJ)D.#B+3TZR->HB,8W_]
MU:[W_%-4(M)WO%2PQ;Z%H5>B1+2W&0O82A#NCO;B3) SRKC3IA'=H2'UW- R
MS7S;DP'(X0_;OY!,VQ1TKW/8T]*_"@XXP"1=TL"1_8^TPQ3)RB?>O!F0S8N1
MS+:-=.>L4J[)E$V76K,PWG>;R&%Z=V+>%\O^!O8+,ER6X4072A8:;UG/W1[9
MS!PTZD\8^K;9Z^OD05YU?-?3F@.>N?0SSB3%Y6G-*QU?I^IA2*ID=('R';%=
M^N2?=V,!+*DFA*M$YA1@$FB9TD0,_1A$ AVVG\7GYKGO>X?^Q$*]@M@VX_(@
MDC2KAT10(+_JT_T.ZKEZ)E)QNUML=1S-?:CWJZ4T2'UX4%(.RD&CIF'JZ/W
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MX9O\@T:Q$_^5?SHA2V91W"'+-&Y^KSN_I[ ^ZL$7/A7/CL[6*ZCX,)[RTK.
M\40BNW/4LK4 T]<LVSQ1U6\?U47LENW\WFLK)8X6)PC#("/7!1CR.RW#Z\;<
M^H7R6NT_HMRE>>+NY?RSJN9BIO6S,">G KF!O!9SQ7J!^.)JDDRGI=I648>L
MU\9 D*VDC]C-A*O ^7X6+,PWTV*W]*'&BAIDXA=8HH3,8%$WL*^U/AX6<WA=
M6Q1\B[.%M;@6%7IE9H6RZ?21E?I0%2ON"+,M=6FPE?Y2V#IS.SB*6'HOW>B^
MN>UU9?;C.X.OSRI4RG/K93;WOQ[OO*P?9ES>JO[[W&FE["O5S2S5Z083:[W,
M:XGX/F;G[&=XB?MC1WR%BT/I_3#C>@SB(/4((PX"NX6!;Q.&,81Y#FITF*G*
M]=Z;O;>0_OXX'O;=>+<HU[$K:7WRP+.T-.J%3=_F1MY!.>+WRP4*)ZFR?5>F
MT\% O]46@*\J,ABE#XR1?YBGFK,WDAMG$TDO>GRWO_VN)6/\:(0\Q%W]2G$W
M5;7+[8-_5HC71P$LH(K_Y3&]0>23+\37$]^P #_B5L7VJ>Q-)STO&?:&@_N3
M?A>0W:.O*E<'FZ"HOVD$'#)1"N5 ZRM%-+=V&+*9%Q$1*S"%EW\Q]3-RG&^C
M"^S'&SKM!Q""*E:?&,7*ZTK%@@R*G!/;D@\"1.*M8ZQMGD?E;'\+DBGKD\[[
M6"RM;Q3C?X$4R9 B+A!8>AP>G[NP!RO-3+,F-;=<Z/OYA/K,P288>'E6NM:"
MXPPD]_(]'0QB='&S_?B,^N&4;E4"H48F)5&H9>D5JZ^6UW!D"G-5<8, VT2#
MK?MF[['0>N.@WE2S] +*;*T@1EZ9,,.I)#+C='OU5\^+*$D<M2Z_"Z"^B2:-
M[JJ=RF>WOK)KRSY,6)$[\K6>=Z.\YM!?PZ=1P?>6D>8,^BN(%JV&!82%PJ&&
M"(NIT )3"Y/JOM(FOGJ6OD?M7#$GJ1>AJVX'! $(S7:1'0:V.V.GN31YW3 !
M4H:^T.-CV3M3OB 7T[/[VK-F2;-7_=KMND,QUG2"+LB1X_R7.5S+.B4LGY3H
MSACVMU98Q5:P@ _6B.&/I0G.@ZZ[K'(:M?%*][@^/5BF])9Y@P5X*>SQ(8="
MR*6Z+1F2%V&,/14.=L:_*0QU'KV4C?JQ297)O8N(2]W;K"52*@H:;8D_B4C/
M6K(:^JQ6\K=0LE>N?WI%KL<Q-E%]5^>/H>(T!%72! .Z/2QSKC2=/SD"\3J;
M\PIF6LOV<%G #XA;C==7UGG=TWGTQ YY[\>5/L]].)'GZN 6"1S_-LFH(:B;
MO*C:L?GW9924X^_+J"<[E3)\#VDVVJ3JG&MBN6 VT[;X8ANWW@G ]4DL4[V$
M/?QFFI3G1"SI:Y.@H*U3]+7GQ(-N'#R^ZW=MBVKP.%]2"_NU;E9BQM+T4_-\
M.ZL6IK4YFLO*$I.A/1=N;1BF"7D[J*DC[(5[_P\+$6.;9"7F<D"ZJ[PG82X"
M''KFANL\O@U;J)WU(GY<R?'3ZUZX$IDT1R,P,NAV'8H4X3UOHLDY!QNDS[,6
M2R^/]O;.TB.IR++J^F6$'(:C&9(SZ1!V-PL6R52B&C!2XR+> 0M@1^_E[&4U
MY^:4\'*[60Q<I]0_.(\\/J/5M<P>H-55!OPS"U2Z(L<">C2[@&=]TQ?]RNP_
ME] ?FF[66/-2<'J5T193]]4^QBI!,?06FM8E:-[J6 "ECVG)NQ&<!L<"@5Y7
M[N">VA7M2TP*%J!LU%-]5@^\^JP(_KJQB@7$M-TH3L>U_[[]^#\WQ4EX*LH=
M"["-Y?*M+J-IOUGEK:JJRXZ$*:M =7/#BW-C=4Y8@",[ "T"-]B,A$\_:W#N
M+^U8,,_AR WSOH@Q/WQ'*"P2QY?:A)I=F6VQKP,1%OM[3=:J00Y%*)ZN]"YE
M?D%"B:'I[7:[.3_V%N</8)>*0]V!&N@B7OI9YXG+*Z3ZA.U8$#FJZ)HH3>+7
M_$GLUI%H6^GP1-0Q)+B9:S+H'OKM"$L'<])0?JP\[&.XG^;3RI)G!DEB[^-$
MWG<16*+X$)7M+9081M_$]LOOBVG72OF.BL,4IW(KQ*(>W1Q-T;\Q#YO@[)%5
M&>\Z^!:<COE#)+GX0QEMI?>5.!&E]\+2"R)!->]FT1]VN0J+#^IWL8#J[H_5
M?%DQ-"82\Z.F.S4CUTDV[])(!3?=0\\K_,]6?P%7,7E2'X%V5N1[_@D7EPE@
MAP7"1!DG4=I$#)P;:-J+<( H$J%?);>;(<0OPU.*E9F[^4D2BF5#M),W:(O)
M$D.(Y9%EG&O=W;%2W=XPH_ F&2<N-MKQW-@Y_WWGV'3>,(7;@NZ9ZHJ3_<\S
M-%J,<@OK&@)J2JKV+^>G]&+\-@:#7"!64^RMP&K[L+QNEU6Y6 :+2KT]VPJ7
MOPI%W('M)3Z9:/I5S/1G7[?V9EXXY8'(RB].J\DRZ"%7IKQ%Y'SI/*[4K?3,
M1ZV,,JUTHXZIW?L7-JODP$[#Q%U9K>NTZ(]5HW?FJ)7&-TA4 D-?U6FS@GP@
M'4LL56"F.1.U!E<(E[J;VP/\A*<EFC0S]/,SK'4YE!I%'CG/1=<W_-5-!T^U
M?Q3P[,A(#'J5MUS9ODX90>N$#\G-_3C@&ON^]"91.O:$Z]L&3NLPJ[*6%UP0
MR7YKIZ&VH^7C\,J<=R1G5>775._(1WWYI#9W;<*(V*IS$.W=0&+,?2</5 C+
MWHZ\$2LDWN$-1[)(R_W$ 0)O=&YF[$AFDV'!1T4!- ]J<(65UA<6<"VD-Z[]
MQ<4E^5D*#(_ 3H^DALB</>]VAJ].#F.;!DQS87HCZ+I-]T/! YC/G,5-$<;5
M( NOA';:IE\$NI*"R],"M=X;II'A]NXE\);&%8+ K^J/M Y&?UW=B3BP#/"K
MOU)G6DH_/2_C7$WIAA+YMBSO^6HKC4.KZCF2N6IJDN_:&.<$*09V)^1(;R5&
ME</!:PSOUU%*'LOL+/T*L<U<D,$X*;MDJ< U AS>WYEK=TA:K?=4R1EXY(I2
MJJMKSV;&84H3W@%=2V+?KJ-6&,I1[2:-J9H9JB#ZS=65 <A&F'V7>N\6^WE/
MD2)1 YPA!,,%C,Y#M<&2UJ%"L(.MJOBGK2?'Y;U=XS'N77SQ<,HN2C(0,RJO
M6"K"YM>$/%4 F7"EXK.K4?!4\,SP@%5H'.7/T@--#-.T[F291+V;%U!T9>#8
MJ9Q_C^W81XK%MW<8IWR8KM14'WG&S=.?[/0F<:>RP9M#U#Q>O;CSS.$+"(R@
MAZRV1#,/%7^;S]O,>/LS*5.<MV15@DSE$7?\U,W\>7=L):V#C6>"]8DV>9.P
M2J>?SD#GST D=,,*B.JZTIB4-RBRV/96U1K-3Z_.RR%CS/D-L.%FO;6WV$@9
MC 70MZSHH%J/#N\F[&DT1>^?QS^)7<9+\B(*>;$5MYQZ)B+MUP_8'EOL#SRM
MR2R0D(TTW$KQ8.\*$I\&K]@YP]IV:Y,;OOS*P!]]WH/XYJT3''KCG)7O%\H&
M'M"A* K'3ZTI7;V0YUO^$+_%9EMB^"1=/LV' (^324%MQR*Y>A4:S <U1_UZ
MV3!9;:*>OJ/X+(3AR[%Q3O#7WMY>OHG5'VA)U.!RH,.*\E9PDROW&'^M&D?R
MK$6HRMA76MQO27;<K,*/V#4V"DU+?D!MU+OF"Z\:YDI3S(+RRS^\6))/_'6)
M<2@$<8Z<LO(M#T>>'E!V:JU>B]F-B(G;BU )GS#BGQYUE[X#5Q!,) .)06;N
MI&]262*Y5+K>MA'<Q;RJ/*6,6R(-8D<YF,)K(TK.E,L3&*B6JE2>^(AEZPTF
M$'?WB;T_92P36];N@E*"I%$^JPJ41F;C 4''XD"'"'_647PF&<9UHRQ^";^Q
MTL/:09YJK^*K*BF#>TQ/#+[;06>P@ [__$)$T*7FX./5G3-R69/#F#'Z$UM*
M-L:MNEZ,P4X+L6>C"= )&L5@3WM2BN37@C1NWC:'>%0%59]L[1\AB#1N)%9K
MB?/CY=GK$$VW4V-TUV(G\1HGY/.TZC<TJ!H.[8X-Z*)//F<PI2C9E"GMN?40
M0AI.\EP*M[YU7VU-8BZZ;;+0L+8R+NZ6D-G!.>-8(6/7G6%[=S 5R*Y,'6'3
MP5PW 1608/2ZM1IEG&_KJ'NGJ"@=#L"+2SKUV>\G;\Z"TW3(5BYE"*[NKAYJ
M9NA;QV?#ZJA?OO,^7M)S3I]&F\!)SCMH4'W&1Q(*IE:G$6--7Y^^&]SM^?U@
M?PTHN61C#OZ=!4EU"&:Q'*W>8[*%+Y:ZWV\K;8B0W$#9\G7IE(UV/_/<++A=
M].IGT^<=\;7^ANJ#49^?*Z^]W!YR!V1,M_XR6YEN4_#0:=&.QC.-NA1(-)LW
M4\O.>LOQ["1Y5VQ) KC?&FA3B+9#I?CEU:5HU7VZT75I3U3&9? IVE,WT-#9
MX2>I6BH/JQ5LG(38OCS=%-D.%BU3O1IP3KO.5!3T!:^X1<DK!Q8K>]%EH*T%
M<JJC!WCP8UJU.;_=#:++T* N5:E:SE\?LSS6N#Q5%XB*F;##AU7L>P 9%3E]
M0SO9Y!#B/OYY(Q57YLDAG?>M 5$/B95G1X[KA\12U]!2'$]6M=C4A3DU9YA.
MQAWCU:\?@K1^=);XIAE/W"6[V_@K<U5XC;QZW9Z)K4XB546%;WMG/.8ASWT7
M2D4]5R.'Z9::ZY(Q7Z.V<]ZPTM7F>-;N1X/L_1?+TSTFW99\.T>$F%%+:D1*
M<&*;%8V+'5CP_L<E?ONG:6XD6 #W0 *%#-[TCK%L9BE<K%7V>1YWQ(%;DVZ)
MA1*_)!;PQLCQ8#8%I]E+1R0]-&3>*/)]ACDKL/CYYS1ME63(IK>A;K&08VZ)
M]Z4;^LL^%G"V(85)J@:=P%V[UO10Y2L\ D^86JI>)?**&KPXM+\$D =0MF?%
M60+&,;=F?5DZO2\S?E.IDX^9M6DT5)6L4910NAN*@^.6;C4S/A$8#@%Q^DD6
M<S"B]Y)FW+=MO>V[ G!,QKVVBTXG'\SG\7E/#Q2^TTYXKFYR#^CB%YZ]>G3+
MR;M]N/E*_DN8C,VF6E$H@M=Y$80G#B1#\RU#B5&A+TR\^G]H-=V+\VEXZ/TH
MD!;T+;..K?K8[;VBP([4$B,W8KB#LLI\D/FH,F2(4H3ST]M@,CB5!\0CLQJ"
M"%BCV^J@C-1%09[[E7P;_TJ8#&WOH*HENNO)/Y_UAF3(F*3:6IOP-$;?Y:(Y
M>FR#%Q&39^!ZZ4>-&6VFF6CB0S@8RWX8L\C/Q0)<:AH246NN-W!_$\^=XM:Q
M4Y:XK)+S:.!\7'Q\ART-U#F\8[F&:%^S"FT60A%I:5<NPE 5/;F1::"G3,$T
MJBWRA;L*$T;#5U^%^\\_KP<J!QA+Z1E[,9=O)-Q0[39+>N$JN'W9B%RWO^+^
M0(.2GPN%!!8: 1W8+R3!#%A RP_PCNP$L*IKZ2,0%_1P]>I9WR=Y_5[(BHF^
MC</VE?([(*ZBC"_P-YA<0HC,-T'@\1,_#SGIZE#_*CV5(I7EWZ&MT*PPF8G^
MG.=4C3'5FKT9QPEQ]WH;'T R]#$*T]=+.U;F:/.)LBJK6<AOYK#/I00;)3#/
MD9X" @N;5Y0[E@YKY/K+=MUA7CP@N9P]>MC<(^7T2B9O_HS*AL<B9W3 #D@,
MAAWA\'N)PE>ETXVPU!II)=U/;-SBPV38[I"I?<>HT&*83E;T!4S#=,&SO)]4
M/R9%=))MPZ_ !.TS$L2&.M&((=?7F"C=2!6);<4O$N0 'L;7!5#ZKS=SF2NY
M7=GX"I0QO).HXFD"LS"U90U$G0C-#J]5M[29_5+I-C'[6L4WKT'0$.%HC\<2
MLFXK_!NH9,+.BGEHC'Z$2G)>!5)43U9YUXSDZ@UEFH>\\ [\;7O*#^1=R7M?
M2O:TT&Q^(T%[NJ!GT2";][75ZQMER]EX77,@2-.MR-;PYCI92^8[9-R_3S,H
MIOHD\]&>E0&P&W)S"\8DS^F6#U*I2GLV(= #5F1<^*P>PQ Y0F]^KB=R5L;9
M:=K=:H'7+B4K%+[O5ET\J/0]SL5TA?%7TV-E!QYSH<$JJC#=]&/G2@+3?+;/
M;\\>:GYUJLFL%2DE'GJ>:ULR;(327!9P5K[^"M57JHY%:ZX26WJ=W%$.2UQ_
M;'RI>D+I898%"&)"1;>#R<^@1*B^-OSRK_-F1<\K":,,VJ%$,9+::)(FJ[6(
M SJ7U5@II;$F4I\BQRGZNU\S2,U$VL)B":=Z=<26QNK=/EBQ2D (?0_[=:?/
M,LP,1FODC22/YYNP #X*)H,T)C*BE=23C=#.J6P]U][>$]/A-*V4"Y:BB6SI
M,I@?*V2_-'O>UV9MJCYG@<S<V-1\3C$@*8D03!6*FO98 U*AF>%NG:7:IE/W
M)MSD39Q%>Q!^>NK4?50:%7@?AD3BW%/7WP3)HA@T41=^:V9J9USC;E4M'.N!
M:5M7SS>82!NSGUH&.G<K"OB6]7>S4U4/^CPW,>P[?HFX->V\S%&F=M!3]F6E
MZ%6YXEC19_V07U7316+(^ +M9$G_U"R69D%M1&BG[B[AQ,S.5+D???)0ZY>'
M,O:OY,J[68/I#BVE!:3VS7+$.U.5G&V5@NI/:,&\%R*O L*-<_2.U1YS0/4Z
MEG%0J9<MR!_-VK?0['"?T//#!C!WT**B&@<@06$V!0(O1;S(>>[[FG:RE ^=
MO#Z>F% HXXT>3MS^'G4>=_O?-C'^[^Q_V T1LO(,ZF$_5CX [B&WL  5YHO]
MD^M1?^C$42N883W @E;7"A#P7IE6!^<OL[2^>@;N)4-87;^%8 &JJI99__B.
MA2_P/!6\:O4UR6JE?S0KRU-7.:@(U/,O[-W@[ ,KK-#)UV*87X+@4Y(S<(Q5
ME4#!>PS';@-_,^'8640-E3UR8T(^+<=PZ]PAWWVZVE?J=Q:K4PLYYKZ)<T/%
MT)2(DK@VTG-QN6'YCJT/U!3AT $.7I2:/O0JM5&;.O1BB?VN;G#_D?</W;8>
MP#+)19,%VQN'JD*M/OF:\5_7NMMZ&87ONM3ESF2 L].&%F#DIPA]3>-]0_BB
M.:EQT+I9?%SG\ENQN*0CV%$<FL@9L<I.N:?(7,MV+][Z2K)>G*IYR^[B=H+4
MPWW*,EFCH68J!!;POND68FJNP_1^Z77MA^Q:QZD'*GX=L52&TO;<++_V2-=\
M.C2!;""=.L2#D.G;CSE#>Q(\9U;6\#:[G@NK[FB4D:^6/ZQ:8]/65!Q&A] 9
MR'HWN&Z!KPP?5%)V"C +T5JQ9)'64YL*Y :0Z:3HBJYQB^) TN1C;D3T.-!A
M)HA&=8VE?=FD6D;"K;PV54A^(=/P;$@JQD$:*H):0/2W9=$WL^PDARPB@;2F
M\OJ$OH!(XYAG>*Y7!>GN,T:9:'I42=!M5-&:,68 ,VE2:CK3ON7WU"ZI%B]T
M9V<Q9=+9\/>59+H=[61R) 3VF*Z^5AMJ4X>JIFS-B^@XR-,NSF+P.]XW.@%!
MJ_RRI!99O+=\3J%$0,_) S=]%V?3"0GZF,?3*=3FC!/K@IL",5?VA<SG;T\M
M&-_52^T>NK](D?M5$MC)'I,#9]]O^>8LNF-X.?;$^G7^T'8PI.Y';U_FUV&-
MT)6E.'$KF%6K[%)XF>=7M'Q-(7,O76RK,7RNYC,O0[!2W\_6,IHGJ#/XM!Y*
M-0<EUVGH7[+CYDPK)=Q.2B# A'][]_?:7>:0)60D"@QO;Z]-!I.C)3Q3ILVK
MSHL,?"CH,KY^S0*D4V1E@%(F>24DF/60Z=/:MDG7X"<3R/(&5\UD6$[>=9QG
MH3S0'4'T[&O21OD$9ZV]98R.6CW:W?+A2A:C,SL-1MSI]AXLMG,P+KOTZ?%,
M54$/SIW/.E^[ (P[BPU6L]-K^9'P09 V=Z0I9G7/H"YN6=.-,M4BV&6CGI&K
MVC<SJT@[=T_R,B/-ST=RFL^#E&HTZ5P0S(MTLLY'T&W=+]88WBAM=N J$G+
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M@V=T917/O:9QOJR8ZT0RKKP=NB?2*%9)F8*'A[\9+'EPV.2"2.P*DK%@Z/)
M2:G!I[*OXVWH,G+%)#K[5*#\B5]I$[YZZ13'X<@,>F0RH3I7L8!H&+@=3#'[
M6GTEP\:T>D+P[)?A$+[/T\HO<S_?F],1J@N_4X+)&D[&-(N@A-:T/U+-H#CU
M$-X9JPIJ>[(64RE<2M0.D50K60%XC&3!A^LOIX'9(%Z$6VL8RFE53=Q/7M<K
M=W:7WG\S+;?AHA?9VSQB>GN=Z!9WGXH2)[X.T3<T)P+X<5^1R[=[Y?SCF3>"
MTW'$U&IF]^31IV$NFG V\VR 7E]/T$M")>A+Z%V4ZLI!@ $J>HW]H^DAA#N"
ML)R\+,LZS[SA5]M<:]-%Q<%]@Z_I*TK2 /M?0<$DO#6YG9Y7";DAG*^(+U_L
MG#/L/*+X5_X]]9_0<$DWZISYPJI\UQI%?H9MZO5 (9]_XE.+Q00K^T:T?FW2
M+D"_0T5G^T9W2@7=EZQAMNN[*.*H#5=_VMDA@O?!$G#XG% =^K8IV9A_*X&8
M?&"'1?QM.(GM2U$&[O>)7=JEO@SOK5&Q#HC&#L6'$T%WU&WR45&DI#*WIDJY
M)#6)OC"KD,R^]3G5S>3!C8LHN,%O!X7(ZX!<H+YO=V"EFVG?31S/.5@"O&HN
MI ;9YI]9M'))JD@SEF !A+XG'5E5Y%A ^S7UEEDS?"&O.PRX<G>*:_3!E43G
M?!>X\CM_,/5')HL><YI/?.^ZVY:H,8PW*Z'SRA&9KX/V].DO#[WZ"<\%RT#U
MNYKT]:WQ#A]C!Z@J5 ;6_5_XN[4NT:(9)INH2GQ5VM@9RE)6EE"J7G*$#9HR
M=E920R9K#A>^GYH-REM9M_&^3BIRH/I;O9O%X02U'\O<SEC U$ZR#Y)6R1_Q
MIQC"K<J.S=<H$&%O&>/>W1KT1LPZLQ-AQ% ,JJ&=_EL?JX3H[A]4#Y;]\D+F
MA_A:4^>.R@#*WOZ&:C_B(WV!8EC3IO4%=V"X&YF#TM9^:5K\G"XYK4X+_%57
M@?.RUN_1QE>?P[?"I&3N%JZ)*U@ ,UH%E;>218,J;I_"W!YK$B%O-YTEW3[B
M;FS(D*]YU7M<\OIK-X+:$0_VMP<*%*4:H?V$KH9O5E;FVO_]L^O?3-\V_E5L
MQ@P'3[_8'0"1QTU1-3NBYF[D!#6*%2YW0%^+$8CN,)V089^U9,4]MIBY*MD%
M50&/A!4GCQ\4WEQ&>_T=[+1W<0J>O1$RH$N#:!'(U2MC@OD?LG9YGP2:5#,C
M?*:"%;]?U[6XE;(@Y2U8-*(?@VE]*PW#RK++Q2YNMP)>-=M"JB'\C 1X&:4)
MPF+%5]28>5F&@]B5:ZN^,2[X4N2I/E/S&,Q-5HQER[9<_7V]NB'^;6+.9B5H
M!,@""\#/O\Y6%'4Z9Q-"+'6X<+] 3&0;\'MIUI=)=HEZ,[4E/:-IXTA:/]D[
MZT;3C"-I&Z\_G6;=?IW).27@!69P[K\C)IC)LC_U\QX71R7 (EI2\R4% "_F
M$V6YX[_P>(B_K+@(W".YA:FO/2ZFP@**K?*,)H'K+!Y8@/G<A<%'+& 2.A;,
M^F\_NOQG,*O(I=KI@T%$^#0R&6$4AI9:7=!O;: ,=].*+<U,% D>T"$?Z^OO
M/Y2YRX:[;%,65'E=AP4L?]='<1N#/V01Y+A1@YXU)^Z++9EP9S9XQGA?Z/(0
M#=0A-_2;M?&^7&>!E^/]"8M7O!%$W1:J+Z;E78HUA 0%^,]PHUT:^7OY<P3X
M8[0'9G_+DUVOXISZH&FZU[HCP8Z0V1QUA%1T<(I%35.65N:9#55T*_U"I<L=
MW"<$TFOO:C4N+>NQ !P4:3L60";/F8^R:8.9,TN&%:ANF)G,Q? *JG-GJG,E
M_'5(C/PO<2%0X,/(&UUO80$CL>9%_D9H7^C?*[7^?V^%TB&LNJ HWJ4VMU K
MVC(T+9)Y.O+^>,&59-X/)W6F$)C.V^W&>28F;:([ME0)RB]!YC?JO@W- 0\L
M:E].8]5?)2SE?1A[+[+D(.F++5\OQ^&0&CXO^[,1HD6OS2R&%B>A<"M<?ACX
M#JI?<R27M/[->MI 0R)D)4ST "7(=U*+H3F:BT9.7(!D\FK;((06G@T&+A*F
M8EV@K<&.=)\8@,?8+[$5!C35<&N#R^H>D%[>I!"%!1C'-\T>N.0Z.]N#UH\^
M)?)G6?2FGWXC ]Z4 ]R8":U57!NA2("6G&@R*>[34/(K;#NH.YU/_KDQ8PMI
MZC_DBX<@7UR7 ]_8FV5%6TJY 5"6'G4[U.J5&SOO'7!(G@.WB@FA8\/A-XH0
M1 ,/56=V"$$+Y*%>#S/:CA\D2R8NS) /_1?JWC.LR6_;%WT1 14!D5ZC H*"
MHE2E!5$$1 R@="0J2F^*- D$Z2 0 04!(2!56D":%!,ZTD0Z!&F)])900B"%
MPW^M>\]>:^U[[K/.*F?O\V%^2_+DF>\8OS+&F/,-&$M\& # O @0^G$+ GA6
M=GQ]Y^%%.&CEZJ9;@V;3#-O'.=?1XPC[Z1U4Z?:WB]VWRL,[[E74E'T)\VYS
M=3[=(<BA;0(P;!<]^-^+H8?WZ3=JP#N]F/?F")HE[2+Z$"+/3"#WYZ>[BG7H
M)8'O@.6_XQ3QOW\5UN5]MO_D6&,9GN7%%AM6[*JPJ\Q^^EJV49*=;2-P,L'A
M2&N"C%%%_5%M 3O;(&!9#]7+,<%(VB6"VOKX$*\Q%0Y?1ZIZM6Y7#JEIYPDG
MCN.K Z,S[6&_@YB]D;A2,U(<K;3!G_(2II4\X[.ZZ^Z!YDN)>86*9'! CQ^[
MYN/3L>ZJ0]N19!1> SO3.PZ <D3( ? 4SISV\)*9&?'9IBP)%6D7<]Q>'?:U
M@UH1*1K-H6Z>^),QAG;XS!]!. *[52XZ8Z?C<;)1-8<V/'>YIQ[_Y:2&@^L7
M.9;='$KOZC54R>(_OCT7EJ!$'&8#3 ]UFKL_@,&WP:?@M&/#77\7'?SK%UJ/
M5G (P+D@5HP]J&J)UT<?#Q=H/7$ V"[)7XACZ="/VC.G#;FYD[2!@(<%3KQU
M!C&[-:-7QBT:P_7<+HMS=@C&%??< T3ST$RT'/A,L8T H31+,A1]TC&6*-:V
M!1['H:.5_8^^(QQ]'.B?U/>T.:/'N77[T)*#JCBHW-F&(2;$J6S)%FC8"UWQ
MX-9F0HNXWTR;BZ[?A(CXNS#ZTAH41N\]?(3PY@-@' ZY,6O Z>8U8I L>F:H
M7'&[X=$LX:@3O.ZU3JD#X^9Y//UX"47_$"$,(UI] H]'LR(YK;O]GI-*M*98
MJAV%*Q3ZDW^EB*=GGI;_WL>S7TZ1"FP)!&AI5(XL\2G1 46DZ$TW]FS<]4NA
M7QI^)[E?0$IPZF&5PKX;0A2WT__R9,(+S"FTA .<[66(?]&O->^C-YQ!<C^F
MHC%#!"G&)/(@<6!T%CRV=JY<):/D9;A):&>Y6(RPFVW(T&] G<V2+$_\U(<;
MCAVC"#EBTU.@&F/HG8OC+46/GGKHB$43I/O8? =)&:/YQ)-*O'6F:4>A]M4)
M,^]C"L1#3S)<'I>\%'."M!%T*$Q^D^\[PSWA?B+S)3 >T'>6[B@^<2G)A!<O
M(-P,*W_/_,H?R^0_J8FB9>0FVR$9EKI2"UOARZ/_+8P0+O *]2D!V0AG6#X4
M8AE%HN^SQU'W>RJ^ZW1SZPU/EC<C/C<>#6)#"?GB;Y"?SP;<; T\/^Q:^9 #
M$MGMZ>]-,58$]20V,HHG $=3J;ED)#$"ET_ED<3!IMGI?#>\9E&A*K!N$NWV
MW!WQ @ZN2<ZACW:J'OY/M[M&0(1JS$PIB+N6HO.:?LS!YR'Z*3]-LNX9>+V=
M ].WGTCPGYD.13.2.2"$B!"%@NT2T=Y7[$\SM)B7G@66KL69TY@! /#$5,!7
M^V90X_Z-5WSMFWG//GV$@A?^R)QTXF+H2:A9" -=# E225SY$RF;]6%XX$X7
M&H1P*^D<MP<>H2E<?C[RD[J-?(T2#V3S/V]@@S2"/]5"P^&G+@5*D&^/6E6%
ME;RIT%:L%_Z0 VVH75<Y%7"LM/#_9FQJL"65TCYM@\<[9@Z R"K*-_N[%43!
ML;LO'ZJ0'L_;/'31L"SV^]7B+?\Z2"5>4[3/Y@)%.W ,>A)L)W(IEQC7$&'V
M=-H]<^R)\Q(9SQFR>8&^]1[ZBBHS< "XR,9-$U(A)6-4 Z+J2NH;!8/JG4EA
MC) IUSL;C)2)T+VK,2=H5VAIAXB8N'\^+8 O5N.ZTR95B^C:SW??,>'NAEW"
MJ>-;Z6C_<)92CP;;DU*,WZN@<=#*#2JWOW%MOX: HQSU.OG)C\=?AQKFPT3D
M@\_7,[Z,$'D2ZB\<Y[R,&G>G'__C"B=_ROF*XF:T.C''U[/0Z2VB8J(S[NXI
MX<*9;;M?DTT\.]7O<\8=+%W1R+SQB242[Z)8^,B(1)S4NY<FA[)A]>+D7^?Q
M [[DZGVOG!JS^SKNKB>2$RS,+Q;&Y20.H-V)"QVNGKA[95-<9->C \<#+;S$
MA1Z.9EV$[%<>[L764C2P%G@E\"?6)^ANZKVXHB)R+!HBP;ZX-K8]I6-Z2(:>
M*]%XM"B5<9CJ5\3!"[OS-15G$>F[/<XND%R6"'H.'P,A<KT/ )8#P'Y2=A;;
M\7E9V\N=$_GAU]<N38@1O_H!@%5#.NUT =$C(T)"OFMK.-TS45KBSPM,3$0
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M-:4;O-NMT5!\BP1JG0KB>$6"AM,9*\B>LT*7> ?9^V.W>F,$<L%^??C!L1/
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MX#7X'+SQ!LJ- &X",U/5'P1(:D>L.8'QI$6_061 [R"A[25%C1=$3O"2&'=
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M"K$:D^MNJ%(K%X_;V1)1)-HKT["Y.72ZO?KD+^*$99.0OLS@M5NQW,]2/A
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M9V(?R2@I-E]4@8WNO_^EI&08.P!1#=46_3UB'Z;F-[LA?%.FCKW<N5!<\G1
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M*7S86,S^#!Z*'B+'$KGTR,]FTV+M39,Y\[M/GH#[J45\DMH!9\ZCGY.M" >
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MQ*_L['K7,]G^9%JF6T&59BU(UA4?[.U\G.^E'6F^S5+7D>,Y5Y48L'>R!)I
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M!6Y5=N'YXBKCFH5?8^^7^=V[:4J<H*T2[6_0)EHB5)Y8A*F5H<<M^]GC'K&
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M&=N&GL2(=P\&;>VZ8<2UJJA?-?2H*>IV?J&O4X!"\_!,+<;$;B^MY$\G+?G
M)$*QFET;%M,S .UMU0O5'EH9^8\9=DDD' IB9CT!F9$+=G[M>:5M20B2>5P=
MOZVX3I^ ..Z8.,JD$1^2GOIB:JU(<KF]=(JVIE5'T+,7936&&@:1YFG!,%RT
M>(SSUS%&S+/OUU[:7B).]&^GE";M_YCP87>ZI:6#%"GM>\GR$FK)N:<^.BM
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MKQNPS-=H\-!FAI7=_M0]@;>56:%G=01_?Y37D6 ^C:/1;#6I"VJ#MZ2Z5TY
M^L+%=5FR5??7MHQ'RA6EZ5YD/XLDS^RLF]^2UNA^\E+9\004H(.?PM(@JTFO
MZH2+TCS8:Z>Z<GZJ0>X:RG-N0C.%_) 7$4'/1W,4ZYH+SXN0%VJC5F :VD:L
M?7<X*A4>(%V$;'^,',:C<U,03@3/4W89$0''%!J&)% ,3?S?S\&^11_K(N&6
MY\(%>*P$JT,\U%G/:0-T2:%[!:_S=6:_)Q]8/C*]3+K9HLKV6O5?-SES>MQI
MMU3S8=80)EMQY]7EU"V7K;OF%9?<M>2(3WPVW.[SY"J>F@39'/!ODX>%%LU7
MCA8-$69Y@DL6(A_>US=]@Z^FS7O#"'+W]WH&A.[4HNE,[B(1&U7Z%)?5U OC
MTE$7K33=2Q >, 98(M>S-.D1-P8V?AX/KX;CU^3_K!CZKTOB]> E0J4<:%;'
MN=%-!1-6=<8U,V+;&?(M=,RN[T"HGSO C:ZM@VS2R^I!$CTNH>-0EYM!ZU;=
MUG*JD)]"-<\C[5M!YQ; <O>.-*;&V:B.;Q#U?,92+Y)C*6!T+>I)]63?4)FU
M/*\DE?1^.G*A-#RB7XWV0<Q]"*U/[US93B32 16BLI#;57OM!/1)"KTEHG(U
M4W-U9$DP0K[+)C=_X^J B'#A"@JXMM-,EB#$ (!N%WX6[L."*XF?_%0Z\TSK
MAZ- <,:74JSDTX@?+"E!5? #W:XTL(3TU,\&'EQ=7\X7U.?JJM*/[/<[KYJ$
MIB.YFOD:K:CK@&1\>5L:K7--A;<,O6?$L\OQHG8W?Y\-G;A/1;V%86-XJWZ/
ME^E@F7(14, B([C;?6X  2Y*Z-0Y:73:+X5K']AU*?JY%$6DP98/"Z7?U80U
M4;J)M6[#1,!IF8)+"*517+3<:2*JXPY0\'0Z#[4H\_2UWWK68Z7Z^LWUIH'L
M= 7*<1_^5@?-^?M"[CN@JW-2]J.S?J7QAV,%T<==/+76/&69!Q;*?FBC,47C
MA;3)7/T$-=PBJY4/8PAA6NOJ57VGL==@]_K@\2B8P?[M/W)8"9FC-]4.#L"M
MUFP=J&KAI@N,'6)=V&AZ^H@^:6*^2=HD%6V^M7O"-DNU^D@PH^MPX)?2\5A3
M2]-$X%1;@B96@NMGW4J($/*>JJ![]/V5E/:T@RC*X+SK 4H%T,4YG+*9"\Y-
M@II! TW1]VM'+$!]LM5$4<K/A8VQ^KK9$DFV^=6W[%FC!\C%AO %C>Z]T5'"
MZE^5TRL;_Q)*]N\'!PM/F!4:IBB2( FM=>:1J$*DN<T;0QM.BTFQY/3I*;]J
MP<@[T^.-.C<JX/01KZ=>QO=S2=-;S5ZW3Z2*D?+BU+%/YRM,2T]GON' [N4X
MZ3@/H8N=HHCL(O%)!XWRFHE21,O&T'L2W,)W52_M//)B_,5#?85W+[3T/]<W
M_HM9J->0,$58)H*Y[3!I)_@ KG1)O5Q%N.-@OX=-.^_@'?)9;J57-5$/V:*!
MYJ7T87=4AA:A/,"6I+_Z\#*_5N%"5,5324Y:@%-BG=;@"-J*+#L!;=&?<B96
M_+G<<&7IC00?6L"SJ;]L<$CP4H49@W?J2%JL(,50*U[)GPZTJ2R';'GF98A'
M=C#CY@AO<3.$RD)CCD] 2+';3_6'!/SM=IN[E"HCJG&K#6/P)N8$=+8@H'(
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M"R OL5&L(2*:!-%),DL];\_W90I2&J2"F6S*0CJE>DH1I9B,R8&91ITS8U.
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MI* @JO_9$ZV;?Q]"S@HV,TM=1M9D7?"4:&LN*RB'E6!C6B>UX40H$6M_\BB
MBC=<T;;)Y!ZVI\M"G.^[0@VMY/:DX-YJ^O3'.8\V(5]EWZY Q._0_ T3J5G+
M]2.D/#.ASR',+&WM8<GAA(E4V$-UB:2QEC5_4RONLO R_>(N34^?.1(0?5RW
M!,'4$(7N$ZO;9EJV1ZW7G!F[89%2L%*,5@A[=?1Q@&C:IF']B'74!NR9'4='
M7-8<QRD?(SF-+7=A8668)Z'$Z4'(D3ED*1O1VS*) ZN2@'/O8%LINZQZA[$0
M<]%=&\*G#V65PR0 B%H2/?O#4O)TF':P17/FM$=?<EOESZDDS- H00@T 9U]
M.*R7'E=F VMB=3W4TT!VP(:S\!\3-KB*9WA(P'MTT,PR# 4RF"I;0OY I]W7
M2Y8)2\EUOUMPA7&R(>&5-;.L.X=&D?-I3?Z>EIHF?_TSBNA*?JA=T7*9S_PM
M'/0+#CUY$T%O+8X6Z%&I9.ZMV[@=KU')9M?63#6J3//TJ-Z0X8WZG%B5W+J
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M2*O8W@OZO]J[SJ FNVT=1 4I!I$B-0H(2)<J+8 H14 Z2!?I1 A%>@E%4$I
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MT[01[8\5]'+%?=%ZR@13BK\VNHUV]F1NI.M@CD^Z"O>:JD4G3QSW/3C7Z93
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ML&<6P4V>VC:0>]:1\^A96+Y-;R@BLZ4Y/E:D"1%3$J2N()&_^E*2?[/)+V1
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M3MIULA."X;L&,Y=<]FUD_+CR>\.8QQ*Z<D^+#-:UL^PM$7;C^7<?>.64R*C
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MN>F^$VJN.YTGS]R6JWC0P3(D]/5BTTI#&.Q:SF-6;Y4T/[H+I^KGR^(^V8R
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MDX5OC_5C:8!B<+-BSWZTL,I9 9 3>H><<JI[_U2#S#B\_J"YI;.Q\XM*ONS
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MY4.G[-, ZB=8W7YLIQ$B8JCPFBJ8FXQVB)5V>&*KRAO0I?>L0?]ESF!RY_W
ML"I5>*Z&4>FDO/R'R "XCJ]\%^:]?K](W>\!&B ZE ;8<\'#L+XD#'&CJ0#M
M(MXM24 UGCQLT=2>3U9PE)=S6L%B5[[9V9--31<5HGP9=<35F[\X=?6E)\"]
MK!HZ8>PNK=2::YNM6E?T,4VOE[+E^G";#<FK?$Y5V[<(*A+V"'Z94M$2"6E'
M/<$LT<UU*[."IT+,W:GZS!'<32]]G)GU[G"8?#PI9<^\2=]8:?S@3J&\1F-6
M]3YWUOK$V17*M=9)&L -%%/8$/?)-$GD^GG91H@&YQJ<#]T&XUU>]Z[)T=]@
MFL.JBS#W7E/ZRB"&]+KZ?8G!ZQ&)_I3,"^^1$E['YP$B\RF"Q.S>?6QQ_PD-
M$-_$HN/T)4)&F8SIY3\Z73;!#VMX'^[LLW2-]589^^$6]M9U([\P!0<LCJD#
M1@_X-VD [YISQ_J4?.[+#23[T!>W6[ VL4#>%;LM&N#JIAVS\L,<^1_=P%OO
M1!_]:X1G,18^*FJU:8U[_#Z@' &G)X+]J7/@IL'=NE,'ZF=^.6$)HJ%'8:-Z
M;..RI..D"B0@K%Q5 ,;K<,PM+#JMVU]U&RLDTL>-?MGZ: [GO?;/UL$0<]H+
M3O+2'4RG3L_"BDZ?;;*PF(B"?*P8:[_&2P56K*EDOPL1_!1CG:+)N:_#JCN<
MJ136FUF&?UXR4R9UM*E!N>(=-; F/8O4=?7)?UR/L$?).<IP=J4\NFMB8%*R
M)VG0<5=Z^DVGVRK.LNT78C%_Q6%O\.F>QF"W'W@JJ)]K^N,YP=N+MZ+E'4Q\
M8YTXE 7TER\.4T'3WV8>W3B0FF7N#=QN.$X,>6ISX %TY>/]O!&Z+O:NT"?K
MC)<Z/N%UJD,#](A!PPC#F'%C\">@ !$9Z]OWCD^B8T9+LG*0J#"YBT+9+@UQ
M;9203@*+V"I-@S@_)]P:N+I#,4VK1_:\3UZT?=J24F__M4TQ-I]A'#*7#5X>
M9E1J;BD[W=H@K'^'>\=9D_Y-+N1C-*HJS101/3+9IT@.@0BZ-,#Q79@@;$$Q
MEP8P9;,9+R18F!X#65/01_,]Z),8C\ OYR-3!GFPQH(;Y@>-??MAW$?O*4H?
MO+KIVB=OS@KWXK=7)BP3?][;;_ TN-@T5O[>; \GNO)X^;GT)1T%D#Y5ZCPC
MJ/1$8NY@Z/>^FGAL%[QK79%=0*QJFP; PCA4)@,"=GA5=G1(VHI/&NKBAAN:
M8\6^.>BCW7XO;?Q[S =7%,"L2+J%;)B(X 6G%?M?K7 H(FQNC;BF@&U)7PWK
MS7/+]=*3N87]\BL,/7V8TJ<V'35" _PH=V-[!D7^QM@@_YVID<(39=)^GN4_
M^I'I+HOVXJ[AS.G8_/)+D2S*>W4 )-3S3>1:< #;-LM1* ^%8WJ=E(^D?EEM
MA.T6KM]%N1*RDRAAZV?NGS0=R7JU#G,SU?)0*YQ'=)68@Z/]T/J,O,HWYGD>
M?9M,Y@Z;5&I_86/-;M:I>L04N)'2+"SUGQI<0R> ZM?)IE#2R5RY>Q#"5B%O
MVDYB;*%C-@=7PW_BX%?F$W)#;U5S3Q>4114C%X>74B*(5P=\XX+FU8*:T9RJ
M("&R'ND)*4C I$'U*&>IRIS/>[V[Z4UCYZ.-@\M-HY^K>6/Y;'#)^ESN2V_J
M- 1]KC+E?7MZ-WZXSG94VY QUE6?P:2)%68KI\=>'^#W#^+N>*:CIXD3J<54
M*=8N<DA(<\;+JM?%G_XYQ+R<[P#WW?Y)06Y[X+/CK;NZTJH,$J6%TZ8Q,/<%
MD%O: BMIC.SKQ8C!&25T@X+1GSQ1#+(X5@ZH=F08DX6@ GY9I:,C[$P4R\ [
M*J]R&H+8=':2.%_W83,!7;XD#>)\[*'#ZP+QJ4Y3?*6\FV64U]**E[UX4(Z"
MA%G[1G%] ?U\^O-/\2Z\*)%X$,%BXMRLZN]VK7=I?N_/M@?WP?BA8D3%N%+"
M_2_[4R>K_=C?L3Z'(?+R(UHD&F !4NEXIR=(XN!10!,/NW2NDLAGTZ]TI-G.
MLS0HI%P7+Z1\V@=BI'BQ9 *5IP*:%2LA_"G1#V1!'#^L47)OYN>_8'+OC0C$
MFC8OR/DM+CD8%D".F:\R$7V">I^Z,T<X)B$*9B:4.X>SY(RE<07N8(5BF>!L
M@[E&V?8O68:)3[+K*^-?/4G?- AM:I"KN9KS[1<&+VU*)\@MR7)W.M/SS(DW
M8<!RIDUAJVQ(?)]':MIDYPU4&_7C!!G7U.6%.=FUN(_Z8=^-*-ZY_G2 ^%2G
M C*?80_6US*/2;]KO2E-5Y7(*_C-:H(^V,&:^#M)2W7-EV6QN:@FN ,\15%%
MV'WZ<:N !K!N3YV2>O?OKAW@77[0/\K%6C:'LNL3G.?E*T@%[M00;097;A%^
M9N/WV1875[S@&4[DG=[VQA;@D\NJRR(/=) LMJSIO\)L0DK_<7,H__=J39[*
M1"J,8+IHNLBQEI:@Q56R0-$\]U$\O<!;D:#KA2S+]O?7387Y4.*$T@;MY<8,
MK_;:2>"$1']!0W77\AAENI-#5_!^2P0B9GT)PQ=3PP\5Z-> 8EC@+DH:A2A7
M"T04,@6#D]2T?:EU?%:MBO=[%RN<+&V.5&>HJ'^2F*TX9CDD959I<MQM9Q[S
M6)<_X*Q PK"QW+*2?ABAZV,/'$_*,F@S-"1NV'B##YE(G\_>12@&'Y!LR=JG
MMRF,+81E:A0.O$NOY5Q)CK)(P_S.5J->FRQJG-J(G+WC]6KEYHQ/H,"8I_+@
M<-;-X-^^GCM@DA\9M3Y!EJQ&G6I#W1J:T.2B(O*MWX9??E8%GGK].$*Y])JS
M@#]E3WO^38\R#^LP8E'[R2/ETA S^]F.OJ;?=-&=1"#'$"W6-]NJH"SD+B)3
M+YKQT%O1Z(N60@$GD2=>2\(7%5YPN76VJ?),<YRJ\;VUT*;@EZSL?**TZU1Q
M@YV8GOG5>EB/)GKM0P;E#C&NCX6'5$ANP^^Y]Q1(3,HI'K*$#816M^&/ ]+8
MMH(NTB$=A@*UOV%]"LL@V3S^)C?21EJ[(F<,/\3X'><[L:SG*5[=^$HVN@#F
MR7;C;*V'@TT5^VF *A%L< ZATHE+5@\IOJ/');J#*_\2,\?/.45JG"F<U%$;
M\MS\FBAO'2-G(ASRE,C19WZ2-EO>,Y!7S*"WK6 6,5Y2>GXXV(BP4ZF"]7"E
M/^H&0<UCG9L]@$(]OIHDN[7Y;[&NPD6N^H##&R]>>>V DD/1% X.7,OY 0J=
M".-23>-9A@826I+D5,>"=.$BO#L1_%']W*'"^6=I_E=B(,]/+']MD79*M[D%
M)#UNS.!B-X8"7&NRT6Y@[)WSN64Y]:-^B="L(VXO4@3(48BSAIZ3$X_L?R#P
MT-3*,IBW9RCSF[J'/L_JIJIOP8<'<!] $-O?M8\/CF=/GU$,"#7G +!>ZZQ]
M-73+3\'!IOT1XLT=7_9]O'/^&WOO =54UZZ+1E%1$1!!.D0%046(!41IL2%@
MA(@H58B(2(F(?H!$"(F"="&?H/ !0I0J-=*E!@A%141:D""I-IJL*(0E:3?>
MN^_9_QC_O^\XY^SR[S.NC/%F!)B9:ZYW/N_SOL_*7',-HUL\+!41PW3.W+<W
MW![#GON#UR_&ITEIWD^XF"^T>!&NU?TA,MNGO%WW94UKW[T:^C6'=1<.3%-S
M(UP/C[^N-BGW_J)V^-2%"UB31[;G"VY[9 R^=8O5).MVO8ONKW[QV"H@03CE
MJWG\7L#K\CB]Q]O/&>ZVLG$H^G#1SS<R;X ?A:,9\E&8Y:,YE!7#Y7@K38PR
M]?LXQ1U78F97.K,2RR<T8N+/12NC(X_HQBK3>FFFMW5J+QO9$F_ 2XG20Q*&
MC3X0F(A9=0=KR1W/V,DZ5-(M:\^>?!"=S\2V)7^40_]\\2C)1J<LT_>4K_6:
MVN=KRG9!TM[<*(/HID'6<%%#Y#XUB>[U@X*ZT&@1E$&_.(6&;V[59\'DIQ7=
M/81I"'L;MEPYK#MK^#LU7+$GJ"3@\\+I]D>.?WE:6*?MWR=5FU)S7\XE$XRB
M'+&&^JSM=4-TG74(TY^[P7 MO=_M4)CSL$3MLH]S19'!J[<.>U[W:Q*W>B@F
M#(9H7AS->;W_= 7-\>*2UJ[AZ*0AO=(7UKK#=OKE+:*;[%=)!R)^!A"KAK+3
M_H1 I.ZL@RRNSB#[6-D;Z+88K%5R/-KUSU[X4L; ]SWZ(HSX@/^:67[!F2^R
M(,%GJ1PQY&3;>:O#8D@2/%NI 4?X#F]FW(5_/VDE*\E3>\#;$M672K"&KL9_
M3,!JB"$U%X ?8HBCEG:2&&(6 OVIZD.>.[A5#"GYC%N.%T/"GXHA7@'X:06X
M-IS9M$TB"K7XAQ]KRJN!?'W-36"(K93^DU=,/U*@"#.[LBS!0JJHO[EOWAQ0
M6Q1#UAV3'>Q&06;B>_+DZ[+>X&F3E_;->D'CCO=KFKKW9-MH50S'77@1??BY
M!;M?D!1(NU7 $IY;/CZ^R)^2N3CBES'N.+04&1 J=.AE;U#?[=U4V^3Z.27M
M9-A472\?<?+;O?VB1L#%N/,R:"J?Z5@IG?*Z^O#[R\ W!*U+];'G-<^-,RJ?
M0P./-^H&>F32G$IEZ&8BSQXPL"XDXJ_$GK+#SQP?[<G 5IW_.E)T."1H4$7.
M3X.1X1AY(%=I\ #\YU?B\K 8DJ)]!?]C"+Y0)(:H"R,&:T5DUC@=^WQE=]Z_
M_MWBI1CR)1_/0(B,W7CX<8$9OR/JW^AB+Q\^*]**8EHE^65!!8M(_C2^E_"O
M+96CB$MBB%P[ +4^^(8@BM 7+I(Y-O^C9;+5H$0<Q:,P\OE9GVW$$$M%T0J*
M6_ _6EH3_81X"JE5>NC,#QTQ)"]1#(F"@4/_VC3_7TY ZFOQ[0=BR.!),:0]
M4^#_MXW])L00%#"[L&K1Z6_.ZV];U\Z)(20P;/G.;R?\=L)O)_QVPF\G_#=S
M JD![A,\&=*+JJ86<)R'L/K%F&5*GEGMR(@30">53_D/>01FGT^7,71_RY.Q
MM-W.-YQ:*OKTM,8 4TO1>5,9H-[8_0]/P.3+YRQG*;..\?Z0,WOW_Z5Y.KHR
M/J=4=7!B--8]R.'A].B]I^<V/_9UN)F69G\0>TBO7:YNOVI@ZJ/ H!<.>PS+
M2]0,[$X;'F[(#BC.:F%[.@QZ</433-K,SXBZJZGU;4XN#4.B2;U"X[K1!;TV
M]-;1G7%T1%VTW91/UCSK<HY+OV=]\K\Q?55?CQW??,_ITSV?]5.OD1F[3YD^
MS'F86WG;KLEN9O+Z@O)D4(MGPU3:Z07/+78[/Z8A\O^Q!\O^!07;__E3?$A@
M_LPU0'O[N[ HE]-FWW(*9]5OE4;F)T\;#\[[&_.?50W<';T<_=ECYPO_1]JA
MC5F/3.4-8Q10WK@):,/"??@U ])J2CD&;@=&L8@0]QF9(@SZU-CU,$R5B>79
M3BUZ4=AMPXR_8K>\?MO[MK?GVBVW]7H91Q);'JBP8?]PV#]NJIU");W9IU:E
MLZF,\_TEV_L.:3>U0<UG6RG;TVQ/_M-!Y^S[.\^=_^1XZO4!6[IJV>)7%XK3
M,\Z)+=/-BZ,^_+[3%T=_%O4/^B/HCN<<6UKL"?\X4+T>_4ND_B:*WVSYVPF_
MG?"_YH2_5<2E@G_I "TR683/#? /@<N\?)!0@-'IS+:<HL:-\T@<N-+M@[+R
ME':H&T<TG+'@>&%S5 ,Z^ #]]>O=]J/I_1K7UA?F7;MJ*I/!*N=PQTI9S_\Z
M?;TM8NS*TXVAS*:<H&]3E>O+7_\1N-_!7C_TV6CW^=B-^QZ=KK_RU$'!_O6Y
MC$3=9O0M7E)+D.Z$D"#8((:D;0>"1:]<*(/"DZ$1!LW V[O>+*0LB.^BG7T0
M2I;USW:X6UQ!^GQZKS%:)LKLS6E0XZ,R;R@>*SN0?C?;0+#0,Y:"==:K@[UR
M47"O,*KX&7C^(2=L:**\ZLN"<3[K]$-MH&1]2Q"F1S\X^]!LKV@';A NU;[W
MY0^!->C")&VEV[[\/N.>FAC87->KJ]"K-S9_CN&4I7-_C>VG%LS0T8U/7&H<
M$?))W<R9LO=GK+&&_M/J[R/&=EU V/B>>UA@4H:T&9(KVA-VF>7\>$_GPL8_
M[[.%/KHC?,*?9-9=,<2'O++-:IT80G8O$4/V/A-#XJ2%J6+(USN@AD@82!34
MD$C^)">A+QN^ OV"!\/Z\-_%D)W+FHR)";P0PA1#@.QX,60;-E8,V23/UQ)#
MAE8!IL*5,?A/7QO!/OA<N!AR4KJ#L3Q[7@SY]"@JTAHZ"U,00]Z)(>9B"*5*
M\I+Y$_8"7ELCAJRLZA1#6";RHJ,_942J4)[D?_E2S&#^4AG^^VL"> G_?D&4
M('^7O$ M%4/Z]ZSPDN!4+PEFGXHD!XF_*'F!?4?=P/OYBB&+4C%B2%<@5'#W
MN\K?CP(*=(@AU0SA9J@4GE'I)(9D7%B:5\)7M$HBY(1@01)Z+Q9$J(_M3-';
M?HDKI*7%D'NC\)]2'V%_-PCXW_NP?):V2PQQPQ!$\3\9(JV;# 'Y552G,#=3
M<M9R\F+(AF?X[](O47\WAO-XBI2H#[]X%"LKAN#JD2(WE_$Z1U$-%RJ4_T$6
MF''(/_%I_!B^.4P,>:()%2F>%4,^RO_/SV+!WTVB-.\62@PY>A@NT'LJAKR$
M;O^[$3C^_:RBO(9L5OJ[\8OPMY+)GY4<Y9,(\4U^;HXLNG,##]J?$$/^M#K^
M]R,H^+LI;6_+)RQE)D@:X7,E$S\N.4R_(/,#]#>R?B/K-[)^(^LWLGXCZS>R
M?B/K-[)^(^LWLGXCZS>R?B/K-[)^(^LWLGXCZS>R?B/K-[)^(^LWLGXCZS>R
M_J>0I6/-7ROJ>]>O.218#>QYI5B1<$8]'?+RV+D+2\JGU#3+RW=_[4@UF(9M
M /4[Z6M&5$X!+K&M<);E+B6?$C#<]OG0_)6TPVE;LS$5V^Y>-[)X-J3.QA\(
MWVCZLB][^FO5&:^@; Y+'3,WN*]W)+G5.[F7?7-?\HAK;[U=CZ5R::AG2H#W
MC5&-1YJ6&P]$F)Y.,0NJ&NC:_3P_R6#0=..N_#N_[;^QD<+# [S1(5%1(<&^
MOGYK&DW#,T-L@M#HH-7&Z1\N?CCS2FGS"?6ZM'Z#BIOYM2UKUXPE?;'P9D%E
M04F8YND"\/NA.5'A73C8NR6D+)AYLB4@;=SYW5+YD3JAD\,+=,"E%ZZPO55Z
MC0\IQN?6/&BPK8R&6'AT0>N_S)$Y8DC"2GP7;"T6 WJS"8EF/L;A.(6A5K=B
MKYFX\[V@X1HGC:!3K&-[@^I^?BO9F ;/;-B],:*O6SY!M!IT8B6+(>K8T]SX
M>*PLRWY_2!0))%ZH&S9^[W$E;>]Q]C=7JD=\ZFXO W]L?^+)ZY<3>8?@LG!F
M*7D-;C4&9B>\;[5%-$C>A%5C,FA^9X4%(A7)^:16@R%% 5Y;N=:9,0+S\HD!
MKO+,PH41ZT>C[L> HMP>$B^U\>:.BYZZ[XZ%7B]\L26R;UZMP!]5%R[8*LT+
M%>:VZTQ3FR7]+,3 U[:Z\4]]P,#.)WB!(;W:IJ,F-R5.0[(M]URB9B=ASG0>
M*BFT-FO='6[!QGR.\XOM@"-PFP6WP?W<98J$FA\*5,$<)B/1?7V:?R$9R&OT
M*Q7FV1KMK'\0;.AS\_85+'CE)-^S=8=G"QNFYFP1WPVG,7A70'M.I2*+V$U,
M)6\2;.4P-O=O4G>)K1=#E*8;S"IJ/M08-D_UZ$X:#YJ_.952;[=WC!WVU_[$
M&.(;<G*>"C ^]VNW3'M0BTV\YP4=PFE^):K#)92<FH%77(1+3U,C] @<Y&:L
MR;!#+=/0R67HVCFM(]_JE.(\(F_/5QH6/KIJ&*+[[8D:F9D-K85WHFA0WE;X
M5MQ!@14P2!#IX,9=R(H"7RZ^%Z<W?,V$L<4KT&PAV0+!>OET**S2B_:=;UTW
M5-<OXYT_^=YNDUGHZTWK=5)5.1!A82NU+@AN2^Q666G(\GDRZ=I0$E))1]$F
M Y17 BF\N%&_T>)'>]G5KG#<^!]G&MA0>M8A[!@;M5X,"21/D#G4:A(&SV3T
MDN*)"F&,36\!= 0\#FOC&U4Z86&_XS6[+^+BE,?QH>?9W]Z:)[LF$MYD8=\W
MBB&'M3=QQY-$!C@*^?GR7!-'?O.L60EE,!$.G)W"\\YR:P9*/S345@B401>.
MK'^ E2IYC&K=W&*W8RBTQ9QU4\=0^- ^Z(\:C^H$T1TQI/-,^Q:!L?!Q*&%"
MFI< [F22906&8"+0SRL$S8$^F]%6^8+I/+4X,:2#H;1TD 53Q$1V[YN^E<&8
MI&Z9KC[5\&X&:4:YL?!'EUU2\QT<P]%:">)H^Z9,YN#:"VLR+D,@8;J/(=)_
M!!Q;<T4SYJ7.4^TZR/_=Y+?]EYE+EN JF SO@L="-XOT/3 VW5:638#^O3"&
MD@=HVO6\8D4,2=0;6ORY<'G8>,PW+!7=E^AM*JM9CM:PI%COZ?8)/I-_!YX-
MG4#S!D"7?.PIKLM\$-]9L$]8(O#FG\>L#"UZF@T>$^:T!I2"&DQ]"J8D?%BD
M@3WP:'R99+QZ@\"3W>-8BLEQ)!RHF3Q5W<^#SB,K9_"KR&C\!$6T<3N:.:@)
M$IGA"2+9&<;Z=F.H'.CA-&X1 $A*+.X6"IL1O[)(WS#"3O?(T,@-_,$_V+WG
M@9U> C<H;\?W*OC5KT_D*<%K,&FSHHT*_-L8.*?QUZ_+%'CMPIP04&1G4AJY
MX]TDZ4"ZG*3J^L%6Z6DY-)+1U[5B52U;5;8-R(U);CO^C?W!.M1H!]I%E7*;
M,$?D^[['=4!KNT2]4%7<9FQ(&_@3..'*_7+/2GM:6QUT81.V@'B.5E4EV]+/
M$XQDR\IW9UO6-3L0BS%E7]RBJ1?(;7&>1F]L(O]X77,/^=4K"2*ZOH1Z/\OY
MM6$5?[/H%5RI"+ BL<E)J-K&^0#]^0(NG/DE=M@2B4KMZW.GEI=A!CMI)MTV
MK\E-0%!J+:^EY4X-XJ9VSJT_"]/63LT2-7'F_@S@?+"B:!!?*X;,_6"BDEXQ
MR>NQ?P#Z??!4N&)K%,#I)LHODN)I*A2UCU3!D4+77_MT!/EGB]K8N0$?AZ^,
M[$USJ4DZ>&MDC1.1GK0+DI^T2TJC&_5]]1@?W]V\4"(M1"S/NQ\B<F>#Q! O
MR6Q\K:]84,"_E)9T]#R,(4J,&*H30P@(U,JOV[^L*R&N^?]/+[_M?]DXK5%<
MQ0[HQE:#4O +&Y]JH0/,=KKO11M5LQ<T08(-0(RK>S$5?8H6UU1%=PW(B';9
M<?C>\B[?/RMNQOVA=.>6R<\128Y<(X9$E^-ZH, 9_"8PN!M:G]FC C04<>QT
M)<@W[\C3&/HF<.%*]QRZU7B6%NC>0& EKTX?*)A6_' TN[C(@LIKJ#0.:/MX
MZ1%(XM^2Y(8/1 "Y,-$<=:(37R,BL F3-NS8UEE?1?#H!XP.:V?]BM> 3[A/
M&&<J_$P3M1[Q7C=%MTY;&?!J*0R\^=)JL*JO^5 Z."T95";66/(Z@>]T$AR3
M9.ZU<N L?R/6?\1B;9@R$2!V6*F!D<!X[W?]>..@ Q[]?*@D3&+5,XI( L=4
MQ@6^S\69]B._MBA  GT)P8Y&E5>B]VONOX,O8<SI2WJ3%3Z$,PO$D/4?P0'^
M+BRB@3L8MRAT#I+I7MDI?$Q326E5K.Q>4SWMM1\HXHJ&AJ[#KN7)(AP>=5/=
M8V.[0]P]3[^RN"&L174C!6J2T:[Y+JP00WR%^KQB80'>'Q77;@CNE^C2E&:;
M.U@9X$<G?'-H):*K_?!XE854)5BU?)'K5<H<N#H\XO9N,=*M/G;8V&XI&:TQ
MX.!3]L'#_5!V0V,F<;(>HN1H_>\R'TRRZ*A9GS"F2B)'$=24$D&$NQ@RW@I?
M,42;2^)V%14^IR71I?E>DK*$,SPN:F-)Q#/ZJ/(_>]OZ_^.L+"*NH&1:6856
M51[E5QP0X5OT]FEIH'OLFT/.ZE&QCV$W;T=&W?Z#ZT%S=Y_LTUTV/?A*<]\)
MC7Z#,H-] BEA&YSYB0SJ0>?,: NQ0>V[!OBGL9>&G<[60V7;5PF3NZF'S$;-
M[*M*BVB8 K;N^&;,0=N1L."&R4F\_U>7=L/6D4\JJQ=LMAR]?$/^ZXYV%6&U
M&,(LPE=+S\FS<HA;<*/$.M@=G.;%G;%+HBSFA(EK&"$A;Z?GD7Q$.5(&5+1#
MD[>@,[^.;%-NR-CT1>Z/-===P"XJGEG" &["!,J3Y]J 8('B%QY^%.XCADST
M=:NL>R7:-5$ATGY@ 6-KJ&6\_M(-AV+]2GK"L8D[BRB4"L%F(".S[)A.=U6T
MHHXI#5\]*% 3 CT"1!"W5K0QDG\*Y/,JP>HJKPE,<D^[-$ GLV4UNM3SBFZ6
MS(_5$34$MF,D$FX7YF<^^=([,,9NK%7JYDTEA0+:O5<WY+<)\_',63&$!N/E
M<=N^=,B#.O%SOAQR(LYX[,O88HH\&Y5B 7T&4KI-%5U1G>$ELW1ET..)3+GJ
MWB79=2..D>5X+2^*"8%V^5;MCTM'?J!6XSM;)$+%91#< T^JL()): Q%OK:@
M*# %*G^VMU6#3D6S[\ OO>Y&#RJ)H.U<:*Y\EUDH(#@ *!-]RCUSCH0:<&Z7
M^?=?4ZB@8^[[\''"7 D9X"?Z>0C@#%120EP=C";+X63 4^91AV0J33NL5(87
MU>I+AH-P/3Y1;$^'X:DPE%+@NTF5E'K"9OJ,>V'[E4K#R;I4#X:_U'=SGJJ$
M"#4E@SI$9A+_=)N!KX7[D>701(5M2=]VBXP$YU)A"2B%8H)CXTC^J.'>I91;
M&YX,U35]'KG<DFP_O'=^>T.VW6GSZVMP+R!*:\^NO@.1_$A!((<A<A#-58A_
M'\'\)IK_*B.]QD\21#)NO_;-EN ARLV+POW"BP.F%E*#O!6/ >FLAPV,S>WZ
M7IQS47K^??&+:'+-]!\3])X]#&O23/;)C&IKW6&]'DF^W\M0A#,_DL$]?0(E
M?(]9?!<<U"',V;.#90(<&E>)]LR(U!K +(XK>[CJC7I1Y^A2OP?\GO:6VKP^
MQ^'K5ZI'*^L)"@'#=I_=9U3/N4KQH\$?_-.B03&D9B$:9J6+&X*KBK2PJH#E
MP^K)?C8\(<]@2  KZ;]M\<<K=(F;56G8]>65W*_1YZM'KJ6Q>;P+WX,N93B?
MA[_"SQ/$$.E[V W#)D, 4;2A!U#L(]9G=E=>_M9G\P[KS=:">@+A=XWJ[<]/
M!0 T#+YKMF20J]&CWE951L,TU.'EOZXX5*27N0?69+[&<@$=D>RI7UD9C=2D
M"4(D+NL33=+-N(-)1J9%ORY,K,'T.X+)[";#13YX93AT=B$I;Y]*MD,.Z^><
M]G>ZIV(773TZ:.>55%E]E[LZ=BXK \+[>.9?T.>9<ZN>6A?B^J&U)7?:M6=0
MOFEOQ9"^$$D5 *0)'*CSA8\OUJE_Z<8K-!2QA0Y3^AK,NA=C*;E5IVF37??/
MW\&K1Z $BN4BN>.2(4TRINFZPN9VXQE4-6&.58;T+I=4W*UC[9, _TWU 5DI
M]Y$ZU!VZ4@M>I:_"_BGB=J0F2AD6VJ9R-MP%W9MW/&:9SULOAL1<EO!]%KX:
MQI-.:K5F:A!IZ1SEU)4P+IC([96Q1YRLHR[F.GP7]3D#C12/$%A<J+1K24-]
M4YP(I1#US,UZ;[KL9Q-1XM<GF^9U;(:Q\&(W_V:YS!+_[$,YUS.R;Z47NDX&
M-%\EHE6[;U&=E6^>0*.#55G;HW=QCBV?=TY1.KO*^C_.UIDFD#]*5>#?FRW\
MVFS"GX;O*R()(R43ED^M;;460[9I^8@ZQ_$K.V=/C8@L#?&S=*A0N6[5Y7_V
MCAG_K<V @Z(Q1!ME^>JB+I%B3H\84J\_OPI89GE6IPH"LK5)E9,7,>1N%ZKZ
MM>QR?Y$6D)O\ 9U=51ER]6ZEH7?MZJMI>U\FL3JD)RZ\P0SVTF7!$%8NJI>\
M&>O&(DMAS"D\ IZ$(?6L?,YBD>7\&_9SWK2.A;5=_CQH/S*?OLUXV67_J0V0
M!EL2&\'[2X+7>MQ.01BW<K #"NK*ST5Q2"E>YN/?2H#!N'9]S$(7[2TI/.S9
M;+-]JQ>4:F$ E!QS:6IL':F?"$Z?$YF3U6\59F.#=B9Y].\8CP/-1>L/2BIZ
M2:1'-X*9=J!$VZZ](:P2V %^K)Y/W]%4E+3W*'N\U;YPFKZM]N%,=G"L2/6K
MJ3)95J3R80(9Y"W[-J?LV*U/5Q[NS-DR_$YZUF;^AX2(_/"=YGC?$VS8.M$@
MJ0HW 5=>)#>Z3M($9G_ZH]97U/<;/'MZJ)G18^\UP1HUGF8=M \NQUJ]:PWQ
M-="]F>@2FJ+"\0!_B.0DHBCZFP45M_%=%?D2<@+>+1MRC59(!/X4R+^KMY0Z
MFS;>';%5,A\)8;M@.!/!R>_SS(:&:BZ4,B]]&AC[_G*(09&GK<6?DPAHE& S
M7+2A1$)=*_92*! %Z-MPQ9"> 66#W3D<5.^N2D$4YR,U_8297GD9>,O3?4,H
M>>V)2AO#J9ZWCUB16E:]NXT>GRSQ#^'OU[Q)T;Q!4;=6LGW0H^1?JGDS/]:6
M8[W*4>'H>>M5%XY*"H0G\A_)/&W)5%F3O8EWQZED!?@UI J&S*."I-N&U/*J
M )%^VD(7:@/#=>RIW9):L+&&[*D?/>U&;?5CV9^_3WI26UTN-Q>\_C'3KJWG
MW(B<\6 U=I'C\.L$!G[,X'MD>8$:,-C9(.=;!Y#O6I@48ER.)[&>1M,1Y+DI
MY>'75,0$J[X1D3/M$]GR=--5=H#;L2K>?UYV[>6J".Z$$?C2GF+(U\Q*#22X
M6"^&D##X17=J^+_-1W?V_K,OU/VW-*]CW'+>75"+?Q@#.P>F<'^PQRD+,?1U
MPUO43*!*@A-<9P(K2'OBNKZ'OZEGX+CSZWGCN>?=#S9H?32_8"<-?2T_+\F"
MTM&X-UZK1A=$ZJ(.O+2%'Q^%/6L:@QC!VCT+H W>:U>Q*EA7:Y05*4?<=*@&
MY/24ZJ[/S#;\%E]H71C(9K^W+BT\4-$MQ5=/.YFH[>:IDV0<H)MV:OV#_-5O
MO\T=+]L3_>;-T;,;=%>A[A$;PP6:P9*@:A/&;A^MLW3A7&CL$T.2,BY/[0 ]
M^>;MN=QU*_KDZK:FFB8J-F"KL(0RH(],8H_M70HE]*@3$D)+K_M,L?H3I4Z@
M!EKQU9+>.B441/9?DDB43+9$"LQ9\@^AMU10\U:-Y[B!3MZFO)W3F<BF&.:7
M.*)(<?[R-[X]]3J\5N#(;@H*C?(R./S:H=K<$C<GZD(!:+A T8!WA'B&ZT+
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M@Z"1RWP6<U >)Z&PFKY.6#Q1"8^61=J-7<WA(*-%VB?PG)^+]DJT0%-M_1=
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M2M>Q-9K3;TPR?U;UU-D9(G01/A;!P1(VK!=/&V024][>O5F%A8#IK$E+Q7/
M_*.QV+8O=RRBF/,'>ZR48RXT-K>V7>6NRS*8:3#+'3U@'71+IS%#P]7J$L/'
MI1OZG-RQ$$^6;EW%D4524!IZPB(LGJO2VYBW$^SDCI\=K;-$.G,S[^M4U]0U
M//\+@W-;G-=! J*D!N7FZ_&;WAHZWUZ0HY+WETPN_J/EBZM2_C^N[/S_[LYN
MD,\K%9+)/LCW.107JUW"9W!_4JP8LGZ>,Q)FZ$ YR55),F9QH I]A;VZK75
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MXX;F%I0-U'=%5_56C;'5?(G+V6=VE<)/ )YL E],D7N79P9D<FWY YV&@(D
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M3;86FW:5-7AR?&_G")##5<: @#+NF6GL1PHU)N,28%7LG6N42C?7)SF?%L3
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MB9$/ZOZ' LPJCH,V/VK]OK!=1:2M$H%C->_*QAL@4:YZ/0.4'WWA05M!X1&
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MY\2VVB-M([&_+_V\Q,5:@<.^NLA(,A!+)RL=OW!!\+N.(-#)2_]W/:6(CJA
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M8;L6>]Q[?!/WYW7V_',44;W+"%8ZN1!=0:;<*M^'J&^>:IC9.SQK&?;,J2T
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M<8(HEOP%?+]HZ<%&>Q3K!G<>?I@+797?G)U')8<* R'$+J[&>*1/Z.&HRW"
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M]T.*5M91U=74ZXL1>1>6Y448!?_IPU-R &VN$(T!<1ZG3+#=D?2AB^-^_HC
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M"BQG"_*>$8KUA0MZQ.5"$DN4&8(D69HWQ!BJT=ZYL;3B\NFWTIILU'^6FK"
M2Y:'>>]( 0VE9SWQ*47Y=/U[15\-S=N$+8RMQZI?-ES(2VWT3!;0W)#1&0X
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M#W-X*:TP)W>M0Y=+4A:!1&+OXP0B/0D*5G1MHJGF/7-9AI'"&Z4XF:4^8ZP
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MLK2W$KF8.-KV"T;.)=0F/PV3VL8<!8K-;S<NZT2"Y6X=)'T1N/KX'*4R,"'
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MR:B;N>9N]2X9%>WW3K^]5;"=J&TO<?9G5K"GIXRUBIBB)/C3)QP@BE[$SM$
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M FW:+J%^.&E:E=F&]PSF94'XV,;,!D>@D/T-Y;44(T*_PV"PN8 (TD9<RL(
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M1T%G2-W!U0/LBMC'.I753.G610I)6S4<!.QL&6;HX1)(>$;@W$+_M/,HY_$
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M;H*""E%-NEH>H&24L%LGD"7]M]C'?-*M" SERUV !DC-0-RX=Y0%BO]F_ 8
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M[<"M!T5D4 7OBIKLSB/;7F4WVMFPHR;+-47F1U\&E?2*SNR8FJ* !BC6"2Z
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M%*9YQSBD=0(GF'2T;6_ 2@)3^L,3MQA6GVD]UU.JZOVDUJCZB45JP'V)4]?
MOH]Q6!)2ESQ]M'.PF^$"[K[@XWO'B%I5<L^KL.3>PMG>6]ZV92<K59IOO5 Q
MO875L'P5?4VO5RO%1L6R1PD1-3LS*DW7IYJW<@''$!<'4![0: -L-$NYH+W
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M<Y6'%D28;P_0T&%2KU5D&7\?%+WPE<!KUJ'B+5FT)02EX(OTH R&]KU(&M\
MRLU?V@LB6'$R94J0'ZEDJ95\PEP"@Y$V! 0X"[A(5D>TSEJ$K%_AXTA>I0TT
M:=H\C2ZOF:TLPHN[(47@VP0IS/?( ZM)],^6]N3Z<C>G"6I>_]P2=6VPFZ>X
MI'WXBRBPRXM"_?4I(97P =W<>&O,UZ?@].1!EN[*C#:BM8ILC[C?(9W2AXB'
M)+ T=GE7ZZ&@/R=YZ(?/DI]-"!0QAX7[I*JAZ2-"-EC 'C;F_6'S3EI#);#F
M0(JP (D?HH2+ZLF0G@0VB]UAJ#<[ ?2\/[R;'G\&,Q%RUERHW,?7)=<+3(2&
M^&6Z&7[R%JY(='O%Q!+;-+Z/0CIC_#<U\%VE'JEV:FKT$(\P<89(B6;\(E2:
MAHTRUY:$"<2^O 2R]-QKR5]K9IM U(Z/9-Y;(-,;P><P/];<D4Z0PYG\&U0\
M/[T1DU ;2EI.+87P9Z5CEI2;&,:EG!+=^V<_^B!QBWJ G= XC&5)G/Q6TYWK
M])<.NO[@*Z&,VU<\FI-.+M\]'BI4!EJS@UNSG^>?6'^&\-/D?=#<8 :O+$_U
MHC_!M>T9KGX*).D&(HV(%R\NT[[9>I U^YAZ&Z^ISDE@J+<L=<TYVL);5%9M
M"5EJ!@_]L__+87.^X3]7=D]\T)^1-.X53\/.R11J7YQU![];#+4QJ]N%VYR*
MH2A'8#!:(./ZF>#F$%?  -,I8EUH7]O"I=YY[MNC_CE0&"N\>"0M-@(7></G
MJ03FU'#_V[WB<\/%9SR[YDTD,,"^ZU,V<9+[4-&W+$4FMN\7%%D;:HW[F<G_
M9X-+!6@-+XD2PS@J,/G\GI,5=K3F7>7@'5?UDX]QU7V?[0P.CAS9WGVG+P2F
MH&S]=7;C$ZV_>I]\'>J_=>+NHC-%Y6MJ$&-ORS,-Q2PL.?[G'E\/:[G21P-Z
MS[Z"+(MG"5X]I2<[!_(T_GQ:=JK =,^?YWE&^YKTXCX2#G-_C 3=;N'=/LVC
M*4Y\MYOM+TBY<O"TD:7F.OV(2Y<'B*?WUEA<"IBWH@R3.8D(P F=0*U!18.6
M7'9[H/F)6B@+R!BU&8RE6%E?"<R]1.A@->RNZP]\X6G'&CS7?J5@)MQZ+''T
MP\JUT)7(;U33E)+:<=N[!NPZU5__K/_-EM+VE<!8JR#O]G!V?,@2"&\AQX/?
M^2/]/6WQVEEY?D_'/:9&[IZ\GCVX=3#P&)G>B@NZ*_MD;0=!'!2#&%H16K9M
MQ*R=L#K.,["+_6,/%SI?<,.XT:FY)QLA,S<H#]_63#"P/IZU4<LCO*6?U?/(
MOX]VYI2)_[G\G%,(EU3O@N>7_;VUE36CDGS/]>0]N_+U8=NIAP&G5(J<FR]4
M$9&#.U3=5 Z<S4NDG;F5O"]&FTG/6YVPIZP3?ESJ#6'_HR%,EK(M.)*-!&.%
MRC.<MCHQ%9C@+<RE<L;T>=B'\[=7T$E6A[FB@\L>U=VF'5>BZ_I&G1,^"/X*
MIG?Y*N_?<;+422Q'XR+A1,-^\E7\"+8IW)GZ@B"!<5WF?('))HT+&=9)V<_Q
MKPD1O,4?!/<6C9L5!E<?N OT(_9DNVO:.XP>#;;J?<8RPT@5;)-#@Z+P(A@:
M+3A$Q$.67/FR.+&1Z ^T'UI.&/@6\J=YN(\$B \#7Q^J:W@Q\Z?4S<\\+A#5
M9['Y3VU_=@9KY3]V;]WUXT3L-^8V:%*J651&><S94<Z"C+B+JB%6$W=B-Y ,
M1H0>T!2/24%M3N2FE143$AN!3O/[5OJ<$HWI!:>!D*TY0]<<CRTXQ2!G1^N,
M@_"[JI/P*C4PQ#N3<[8P;\*CB:.#]A_79Q+.K-);+;.+L_H,["-,K]M9M89B
MM:UZ<)IH0_.Y'(]9V'9;YRQA#_S<YS73^M7;-Q^%/=A_],OF\ >646=%V6PQ
MP4::8U(DL/@7F]S%R@M26]'=2B.SI4:!MT>:'@5-S,4#_NQED DE3).Z\!*8
ME=1',>VE'K2''T'^Q86+5C!BW7N'\1"&H2F!V:A)#0Y9^B,N[U_0] L%UDPA
M$"L625.LLMVP--U,/D0O3TF%$>PKDXL"\**-;F$B(5Z\D_*O6*6T6;X$]K,9
M(5BD"AT1OC426/9F"8R=+\7U6Y/V+]>)_F_ :JF5TC3:M8&\T$L&32)_4_Y-
M^3?EWY1_4_Y-^3?EWY1_4_Y-^3?EWY1_4_Y-^3?EWY1_4_X_A_)%<#)J+%6]
M12/"N"+WU9,*U[B+:[Y,V\-<SOV_KIA2.9K\^+]REWWU/W'O\C]$J7D;59&X
M"F!C$IVAZ FR+$'S]-LGO!HF&!9'IVX:\>C4*+)7H*]4C>6'*>765K;*6[Y^
M<_7%Y@#V0P:.LZ ]=6!&O![$QEIYYWSX=FB)+#\3?K/^)?VU:@:B>BK,W)EW
M;6/#-=VCN^ZNZL&HK.KK^7>N-O*@)1#O<LAKVOW-DX@^7(P,B_3#UAN90+3-
M)Y LAW?*];;[ZY;<]:M!*M6:Q,N&'OEP"<:RFD\'*SF#-:^&_5:0K<P8BX:2
M0H]V7YI_.)9"U">_FE8/UGHS,NSJ%E#Q><SC R%YP\ZGKG"Y_&Z9E__6B[]D
MP4Y@(+F%)F^)=CQ'&=:/F?2>J7 #M_%RVM3Y@)4__XY7RRHH$+4HO,*>^G&B
M?,1-ME0KW_;2>Q^9\'MR^IF8K1 *J]3)^4OHPBVTNH*_@?0%<G&U[E":O/&V
M8/EW]-VU%OFA;7MS_CC#+U),OO09-70^_-3_^GCYOZ,,!9:U4J.9"AG#J!W"
MDX#>_7S&6?XMJ*XU0SW6M^[8M_W\-P%#_!0/VK.M\LW).:GW=?S;';EL)2BX
M=<6VE,EU)-N"9M'$K<555/ATFEM;:JAB@CT_T@:3S1O$&PX\/;JM^-S DWN7
MC\!&<]\))# UR,5A<+%LXS1)%Q!G\:Q#KD4JLY97!C/]2V9D-SPIB-0_]?9=
ML@1V]M+#@\\U>L<O/]@KOUFQO/O?M@)PE6VP6!?TC6:H%]B70NTMM3(/%T]>
M.UDP:.50/#6BEJY2(>/'2SD[8!08J&2O9KXG:;_OAJ]'Y8)B.=0$[$;Q[M80
M<Q8SSDL.['=V5Y@AV+5J(.,:VG;M]C;'Y8^/5;UY7+3A;]X!W4W-S?<L/^AW
M,H+ %"Z"I9_H@(ECJJ 0D-(/D9J[/EJ=P&*)M1B,^+$)UY*2$,]C@SS"QCCP
M5T];CXSS,>Y]U5&_VO$DGK51NP? +WN)&]&EP=[UA22IB?LN]"[)7S<H"O)^
M=:G#NN#SQ@\?=C_PU]E]:?U?)JMH_ZOK(R>THSAE\J1/". "DY*.5F$<+H!&
MN9.S3L!/[M!](H)#4<T/9\<4-^PAGHK!:'R&5MA':FUH[XOLN=_SN\<6+C.B
M#5_$;JA(O:(^R^0FP?DA$MB#0O$ >E6#UJ=12)^ST$*]+X%M0IGXH3?=,5:M
MB3%$[;(O])P2FX.[D],^:?BT%08$YCWM.RU[[:+&B6K*A@Z75M1^NBB:R<EG
MJY#T"!*8'5B0/KLL\"8> D(ZI>5 2[VY=BAAT1H^$<:JME!QP\?E @-)2^.)
M!?#UY'S;8JS;A[*[X6E!U4-7Z_5F,<%%I%Y$C<R<M>"6OY<*B(Y%R05(KTBX
M#H!S#=LI0F0DEZ)$R)7 FLR7PV,?25/B5&V^V4HT+099ZIOH&%UFR'WW+F/L
MN8--ZEGXI_ ]N??D_DUAI3Y1-ELO0(G[G#4VI8,_N78/&_9.B=7K:AL 45E"
M\;>Z1/NZ^N0]-R?IFS\?^6M9T4;)_FE3FNE$@M 54)_U%Q@26&*Y0JY(CT^$
M]G+1L4P%YI4NA1'"*$\OCJ'ZLDO[.0\Q(M-BW*[W0+C7[&VEU]' 8H+Z::6
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MJW?JM\/9FCC+/2V88'VSX8IH.&^HL6OX9PM;@\R)&E\-M,7BS6)!'!<OU)7
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M4;8$QOF#*B_<FS/M).[>V<>+C0_9^P*G:6VTC.V^@U$8L=W\<WM,H/GY<L8
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M5/:F$C\BR=E=?T)F./!EPJ'9;[CX*Z+NQVM8=D(5=YYOTF)7'%H5!1._;S"
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M%BS%YVE,+ ZT$\O:X008X2YL GD#Z2#I/7HS:HL?>G/#86(@)('A06-/$/\
M2;<^B(X;^9I=^)*PSU/G>'^5X?E)Y^J3&7M#5/QN?!VYIFAWKT3@>63=W?65
M8!_W8]1KMM_02@E[E#XU,C(72*^;>9:7!4-NR=CB9G[MHR9NV[:HSG#1W>0J
M()C;'F=J6>)]$?AL/*U>NJLVV[+S1+^CT?YK?B4WN;%_WU@]O]DX^U)*YQKG
M&7*Z4#E3*O42($\)[*BG@P2V-H,JS<YE.VM%A2&F@\/%0E-?O=C>KWG',Z8O
M]$_2E6!&]G*7$SAM\ODR>W^N>Q*UAA(H@47+ 'GB:!]M"6PDHTM;.+V6=)ER
MSDLO3& 48%CZIA)4R"=I/>46N*2-._<'S@UWR!_=@M_G:]OB?^O:D1-;\S[Z
M[;T=PNP2KYIQ$-@*D3[G1])>/KJ@%&O;;W_^Q*FG;U)W8]86;G_2I)/1V]M@
M130;#-'7TNURKE,/3_K;.31W\A2S.GI>+VC; 7IO<WG.TQ,7'/\VMURW+>,:
M&892W>5'X>89O]Y'KPC(>'OW$FQCLD[#\8V3WW8H7E *?;5%M2B?N 7"Y4P[
M9U1G<I_M;"C_ X,S&,J('K$]*'I_7#TLN/':(RXO]!']]KHG<K4/5D74'V:N
M^2G32I)[)Y(J<KP$]H@M@S* ,EMH_#M2I:(.C$A@)R$7;CWY E ?FR3>!8WT
M>CHO8\&JP?@07W*1_XI6;DEUTF6CW"ABW]8)'VX%^B9[.).;/BNU$VN71.4Z
M$#YR H=>"Y6@- G9,XTCDPDA75L@?/-*=A:(;@2G7<;E^ZHR$P5SNV;,WGP2
M,4]7U3Z5SRPQZ[VT,SGL,?.U\#+D(C@N_DBM(E/0-_##$]R2LCD9+C)1 H-;
M'> L/&*NF1-BO#D+6J,SV7+X"H)3&WKCDI;S&N[HE&[56P+CXDM<9;MI)T/?
M*"MH8]QPHZC @'Q#:FGX2%&N"5*1]'$%PRK!M%FH-[= 3D B!FRE/$+M]6!/
M,97I@=YM3M"HRX]%Y+JI;"\*[9*7O]N)YT%AN^FA(T]J!TJ_98R,;$_I02F2
M1M!*=BV8^]2-TDGRM[0%]W+8R1D&M6%-3&U<@RF076?(+^>R917N$"+::M4H
M!^H 9IS549J;8TC.U,WK?[ZV5^C-+W?\RH/ZQ');)XQYS,0)3LWL"E6%M$7<
M-;X+1#X4[R%,7(+J./!8BZS)."O5 K(_H<,10$03G2+6TTJI\).5_I2(V]5I
MX=D%@=8-U%T)1?JA5'I[TT*\EX4TF0B5F4Y 3729J:<E%]X>:-XJ@2GA==Z]
MB4'*$4@=W.QW^1WD<+VZ!/=[(0[/#'02,<D_G+,O[E;;W$M)OB;ZT^HNH,RC
MMCFBL=)*'D'4%U7?H28QM81W0:=&JAJ7')-QIH SA^1MH@46H:-(>VW!-:R1
MAB+:,(2[4->_5GM']^30Y?H^\EUM"OZ@9CAL!==&!<Y[6I=(8-XB!XYYTX(R
M,;)25,Y \[2"&T.UMPTLEL OO-$P2E$04EYW%%OX#[I=3[?\C(Q?<IU4&[%.
MID82K2#>V<]MTI&P;B.TQ,.H2#,2YV:40(70+.!G0><',\I:,*MK6K RHT)4
M-T.Y:.K6#$H#O%C3$K]+_'' %SP.1V7F$FX/PN=PF3/ZF6VRM+5/ZK!;A6O
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M>N[ET;V0IWF:R)VA-S5_^MRV/)FS)WH])WF;N3NX+_?W=74X)9N]3TCLDV4
M6'5V#9GQA+H!LLM@S&"!%&. E7+60L[-\VC3/H5CB,28V3-;4V)@S\C48N:9
M([6&G"SRE@K.G>O2&3G"F$=,SX%U7 23THQ-681M8IF$E86I8?^>N!RW?J+^
M6K5.<WE8ATU.0&"8X/8Q/YUO;3+!U]Z$6V5$=^1[%Q)'[DC:!-T1X]:3A4(@
MFW@U8:M0,MN6$,O#K&-45544]O'JS<L #G?!BET2.<@WT WXI;["0']_Y<\#
M?>U6K-M;B8G'E R%;I>8GH5>IVK'+&<;*]RZ+0!.)LOJ"?Z:ORPYQK'X@\Q
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M'H_VGYI'(2S0+D*DD*XP%&LA79&'9E">TYO^[4 7E[86PC7EJ>S9W;L95<S
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M<;6H._+LDWJ/ _BI--]+O<;)S9M-?P X&0^DI:'W$CDBW,QJX/"L+ X<S %
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MWX^PR(IW3UN>9Y\LLVD(U>(FLIOE%N2^/>0^T[5@5A%%5!D@;N?!DRGK%>X
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M6;XI<=7;S?/+KVJ1RH$HV:"R0.4XB8'_9"07.N;P8H4;HN'I; O@!%+,T)W
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M56>=/R*5A01P+?15-1%19]X ')XF1NMSZ %_=!*(.%7;P 2JRAX'3JZ?NGZ
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MFMQ/J+)UJ-E/<8[^+YX8___P0BP._7]02P,$%     @ N8EF6I-* B^,4P,
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MVF)Z_W=$KK8LW]9\X.01?*=I"?%^!J!E=E4FR30I#-@0>G0H%0@ZTB0[2^:
ML\8E&^1"!;=^_R[X@C"(2^:W,')3*GN")1N7<J4F<P>#@5/E2.-G+8<S*>!6
M;"@7+2'C$!]S82G%<QGS:-747\>'?#_$,JM#20&%5,NC7^$W7OP#7@T!*.$5
M7>=V,%S'A(;2759W=T<7@V[XAG#X.,^%2-'')0=X;8)W=:"78#E2.D536.W7
M4N[T3J379;U$?V/(9JL57$+23MAP!H?8*0D49$,W4Q$X4/C#-V80:40D6K'3
M-U5238:D;8@',.LTB.7%:,L" HUH!C<B1GBR)B)T>%D%>J?E?/K@#P;7)787
MA6PF>B@8A\(XC,2H-?!2*?HBA;TF)TDX$'BS2DL%:.TS-4/%4UJW2_]&Z$9Z
MM'=8!0 REVM#51!_1D71 E]M>&CQ<V@Y-%314GT5 8 .(5Y ]CEG]A"0LE0V
M!W3:6'5#=5^/964F54I@Q"(@)S&L-H]4)"IYYH5*EWW%^) 0&9&]LF^5U5A*
MYGOH)4-YF&X:V27^(&<.]WK-EF]MUHFJJ$J<]GGH<@N^4#1(IG?"!UF0\H$)
MT2XT&7B@Y$L0T2;/-#7/:$X+LXCUQB(-%XBJ5%@1ATHQ%"8L&6[0IH+M9H@2
M.954695.LI GES 6N%U%TS(;UI'\PCZM5SA@PC%717ORU6\<=%T&(6QE]C6*
M!"V5<I:Q\B*91'QQ5!"NL#-".'@J86KH4HDB"%%T8 ,J?600< F6R@B7!55P
MB\B0SHB2',-'6[=1L96-5K^9F9JYF1C2?@)G5W'BEX;DEP @ 2%P/G:H#4W5
M6[< ,?FT7IZI<B<U)J7BER8@#M,& N+@>7N7:2#@6 6C#KI8BC1U$*:Y+.KP
MFS51-^XF#A*'$&P')J %2-9F1;BY+RP9 KR9;EJY;MC2@(2%$.]'<QP4)^OU
M*X/7<9RYGNS9GK<$7V5V']SEGO19G_;I5I_C'RSXF??9G_[YG[DS0L17'@]0
M/B8@)%VDCP"ZH S:H#,C?_EU3O-Q)T_5CJ3IH$@8FJ$:NBABXRD#6AZPHD_G
MN*$D6J(F"B*)=)/G$2[4J [/>:(P&J,RZB!GHPYD91^X$ +6V&'D.:,^^J-
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M?>;-C6C3$XWTGW^?WF ]QG,Z^M*XW'30GW>H8)@C+>8C^54D0.+ %Q_F')!
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MP3$4-@KHP)D20S)4PSYKAS-$C3!<PSB\LS9T#SB4PSMT,SJ$09O1D(*8AA'
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MZ'&<E%/\:9]E2F6I432ETU/=3(>^)/+,/X[26:S5(#7]06*%<'-@[]-<"G0
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MH0Y=IWSC+;^^6GGVF>;E\-+SES<$MVL9.ICS_]<ZZ.:W/_J)K&#/$1E[6G9
M^200& C$CP*]PT 'ZJ>!"WQ@!2-XP0<:*&/ZRQP@_CSPK^,T<#\;W%]WDC/
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M#L',+#."CHRF:2K_JHG@#!&]3F\.X@S#K!++!,G6LL[$ALOF3@_M"/#.)$;
MB WWSE>%1NMV]8OH1"4JU3/]2".)T2=V<]NZLT(#25:08D5[ E@2U'F$45K
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M@@][S,WL<N_"!J7JD@];6?&B+'8Q4U:_*$(JM88&RUJ#-EL+E#23KQB[B[I
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M1_TRX5+PDI=["]VQ^[[RF22U6Z35@V2)<C=ZIX8N\R@E'D_&LQDT?Q2?>;2
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M%X=21Y@B!E$[H46/B5,X1A3. YBU(G7 XY?"$HBGPF6F!HK'B)BT8HJ+.1.
MEIF2"5AS:)=)1A3;UV72YY9%$7IR@ XFP4.4F7=RL [8YY@58XK46)ISDGAK
MB8VB=YBAQIM>-Y>?>9=O69NQ222YJ1&[68O7%S%X,FG#69QRLABT=HYJI%RS
M]E@>2("]QHYJ46UH@8# M8!\1#+\IQ9< S7#1ESS%US>UA7 ('_@_U"0"-$+
M&X 78-,:^?<4]$D5[IB/#3ALI@2!#"E*9-%N*M-<KL:!Z4@T9L,*M$26P=$I
MTQ <#<!=\A1S$E8Z6[B$.4@X4!AQ*@I,3UEQ4/F#4?B"(N>2)9)Q+OE?"W(,
ML[,</@H[]M%-+N>"1OBB$<>B,>B$/UDZ+FJ#!E:#'?=>1UIA^55S)*A+762*
MASD0K,!CE3<3Z& HE(EJ')$KFRA4TNEW.R$2BQB*::H16Q*:TWF9I/F=LT*)
M1-6<".%6/A*7F->:)C&+Q2*FEG@CR[D\J'EIW\AE<IH1=&IX:8:*>)JG<K*G
M?(H4\>!GD.JG8I>:1F2;B5J(L*AT1%&HLYLI=%FEE_729X-)E\8SG$UVJ73B
MC5ODI44W:(P* *GZG*%J=8&I(WWJG(.BE[X:B]L)J+)(J0.1J0.3=Y9:JR:Q
MI0[A->DV-NCV&!XI;JW!:Y@E65<Q;2BS2$@C$)V$%?LG@8&A2:(Q1Z;$H,=&
M2)$$@$>C6]H:G^(6;!!: *T5;FE!7%-!2A.Y?ND6:V-TH0E)-&3A;F8S7?+6
M-O_U%C?"01Q6J"(!]U\]*7$L%SGCQ2%^$W#M097[=953Z1WK=1TMYW T>J4"
MEW(9&Z-@*7,$HAP--CA7684T6"$JRZ0TRTQ(";0SFC@-)Z5.:+3TX6\ UH*+
M,X+6=0(=LU@(%793(IGQD#:^D&J#D@#F<!,"D"4B$0\@JBQ>"Q2X@ !<>Q/"
M$(J& IV,1F_R8[6E=G@U]A-;6V1D6RQ+LK:@F9V&.:UT8HJ2B0!XJR.#(@QH
M.[8*(4)A*R.#.XA%LK7R,[AR^Q/2J!&D=[A%%K?VTRM,Q6=OV[4-U+DY1HA'
M<:LVA$-_JYG26A'T1KAX"+H^UY;7$K81@P#;*!*#(@#_17:[E/MASZ@H9;J[
MDBN;'+2V6HNXRM*[6X(M3):["W"X#T%OLOEEJ:NZJ\MSGCH05MN8.F*W""$/
M(S"[_5.[RMN9.9&Y\O.Z0%44DZ*[O%N\K/=A"S"\-S&Y@[JJ:X(MW<MSUGN]
M O$QY"">:R0V/I.MY/EJU[I'Q;8S)Z!<U?88M^6/%LDRQ$5*:1094X$8,6/!
M1L,6%2%M!7NO9/,8#C@T7;' ^JA^WF87=I2!Q(6@7R,9YOA* TQ^K+&M(= .
M%$!+-F>2+2$/^R W=%->)C*$ Z8B1GPXZF6S1[HX1KR"._BD6 E/N'.R3FI@
M/UJC2QN#[6&S"M)/96@<T$0Z_V4\LUZ,HQ"7QB&BQ5YX8,>D<ESYE,:A8%48
M.COZ<EL,(!_JI>LRJZ3F"Y%R0[SB))D:+AI5R+ZK*J0"$XVL(XRL*L]*R(E\
MR&>R$&@6)>&BR8ZR*8?6Q__;=U\V:H]"RHD,)Y)<,&L"R(-<*J?B$WX6*8T7
MR&ORRI$R97NZRJ16:HX<N* LK.%(R:7,R6\2RXLLR+ "R;J\4Y-LRA.3S H$
MR9D<S;E[)Z:"RJKFRT9QS0FUR<<,)XW\K)+L$["XS<,\R[OLS*O\R,J,S.HL
M=:^<+K.:K-F\&-:J@*Y$2/A<1AXY-F.$%8/@6'Y$P0FZ&8G1 N^8PMD6&/+G
M%&[42?_!$*%_E*#K!Y#X^1"=)-"-X=#%U0&$46P72EIZE!%H$6T*J* 3/!H3
M&5OFZI"5,6QL5#*Z5L"2\6J#  ZG] $?P*&TE&$WQV$I>;8)(+[G(;,RN(2>
M<TQ?:,7M-&#\M)079\<'YU]9"+,\^[(R2:5">8-+BE\RJK-NK-4]>Y-C>')<
MC)0^J(3QA'!)&95@'5Z,D]9\4W/NX#L@ZA!1JSX1(,][S==][=<*E<VF^]>#
M3=B%S=>!312G:]B+S=B-?2N(C;V.+=F33=F/#=D'18].L8%SY'ZQ1G[IUGY.
MP; .6#54,0XF 7[P)VP,.<'()M /",,BC)%J$: :(4A%4:#_8>,4>V02AP1_
MPQ5:[VD6+<S"K8V0UH:!5T%(R(T6'@#3A.2P'CH<P;%8Y""B"+!==%,?QB%-
M[F4B;?S5X($?2UB$ ;9R58S5DD.D3>PA(_O55RS'34JT<;Q>(H+&)%)@[J%P
M][VB5(S&7,R#)_<A+!C%\V0A;7P[[(W414N4X#V"NZ%+GUPGE4WA%6[AI'K9
MTWCA&\[A%(Z<V=SA(2[BCOWA@3WB)X[B?EWBE]H; \&.-!Q'8N%<]ZI&ZUG;
MP?;:(#ROE/'!#1J?+MS0/)ZOJ''2OP7"EB$9O)T1?$&/'^#/2GYL/CY(AB%_
M%6C;$ZUL!)N/"9FMJU' ,2-'R>48\^=  9NP /FP-K=$W> [Q+^4E$Z<H_1D
M(4(834]-AA:G<<UDU>WUYE\I8$Y)34>LU02W3OI-DT?ZLUJIA>[TDE!,37:\
M.DHM<-"43?/];SSYA=A1L@\WLSB[.RLR'"\BHEZ4EBENZJ<^9A*>6+,WX:CN
MZJ]^5K7*ZHD)Z[5NZS9TJ;,N)XI]Z[WNZZF'F+I^%!TS#LI],C M;J_D 1MX
M[&?4&AU VDN.%L"0X_Q)W"T=T9>11M$^T/6XG]B.Y7_T&$H^-"[,,MS^$ [,
M,JP1VD:^%SS#%[#%-! 9[J&EK@QY,NP>%>=9?L;>K1H*%3NM-C9'@O^VBP"]
ME  JB,7H=:5&NG(U&Z4I%W)%JM;]/:4"EN#G#5 A=Z-#F4[>Q(-/S>E!:I/R
MK94?N]TU:K)_PT]2R" .3Q\4#V%;2*,1;[%\7O$OR/%,:W,PTAMXO3Z_+O1#
M#]C?V23$&JE$K_1+;YG%>?1)P>M,+_4HGNNPV8E3C_5*[_16KQ&+9<\RO* &
MVC7@0*%<P6X*N#.]0#4$>GYYL0$F?$?+#4A9OMH ,!I@<P&?\6UT;QEX46X"
MZI[AGO?$#4IE-!=4<T='PXXQ,UKGBA?P'M'H"AGXGJ"?$>\(\:]U+_D=&-H'
MO)'D6?94838\[ ^W8;=B&R/"(0SZAN@^.\?_R^1>W)VB'3M,)#N35JSH[H2B
M.C@@"H=R ]>26\UQ:HP@\V4=G=-,77ARE.[62SR%$$+>XI3I%9+G6<CQO0^T
MY&WS8>R%30NBB^4;B9CUX^_KJIY6+T4CY4S^ZT_9_DN*Z*_-["__J.[^W0?_
M5S__^7_B];]J]P\0  0.)'@"P+@/!1062,APH<*$$0N,@SA18D-@#24ZY/C0
MX\.&'Q4"$QD2I$B/)C^J_$AR(<N3*&6*=#FS(T>*-F/JK#ER9LZ5*"^^=*B1
MHU&0X 9A_*!T(\-S%-HM6"!A78($"+0.1$ . ;0$ B34TQ2MGMFSFLZN-8LV
MVK&U9>NE=1O7K-RW_W7SDFV[UN_=OGC5]C5[3._<P'79\OW[US#BQXVC#9;+
M>"]@QV<)(QY\]ECEMIU#HY6,M][CR9@5NX6[.?7:R*M%\XWM%^]CRGH_+V8-
MVB_=Q<'SSK9,UC/;P9\+'\;\-_GJ>A*P:D4@3R Y@MFU;^>N/<!W\.'%CR=?
MWOQY].G5KV??WOU[^/'ESZ=?OWYW_/GU[]^>8/P"_@2R;T ""S3P0 035'!!
M P-T\,$ _1,/P/P8M/!"##/4<$,.W8/P0Q"SDS \"O>3HT,44U1Q119;_"Y$
M&!T<$;P2M>L&.P208JBGHVI2Z8.>6 *RHIMF@DDHA8#:J22(>)R(21TK,O\I
MI".-[*C*HC)J$DN=3IJ2*"ZYK @H(']\\B67C&IH'#(G\F ABA*2BJJJI.M%
M*X.XTBH!7 1P;C'?[$)L4+TZXVW0M(+S#+#6$G5-+>38:A0ZX02--#!)^ZI4
MT\T.G:NV31UM[%#H3 MULN)0594SWDSK-#126=T,M=F(8TW443D-E+!:.244
MN-I&.Q52"7!QIYFNND$@Q@!==/99:*.5UKQEF;4VOQE)Y&]:;KOU]ML%KQ47
MOVQIQ ]<=--5=]WSQG57Q/)J[(Y=>NNU5]IWW2WW.WD)P@XAHHZZ:2,MD:*2
M2)4*+BI)AY2T4N GU0SX2X:-BO/,H&K*2<N<GD+_.. "M(P)J#:#VB@AAQM>
M^."4'KKXXC41YGA@(E4N8"F:,;[2HXL7HN!GJB009KJM $#@1@2:<2>!L7A#
M;2Y7D6ON-4\%>Q4X3WV5[-?B;H.UK4EEW3HQ1(6E]3C,K&;L-D5U)9M17S%#
M33G+[JJTM,9\,_7KV: [+#A7H[ZLZ[AC%2YJO"E]"SA7CY$N 6BVPBY?[^ZU
M_'+,+ZR6<G'W-;?"S$,7??3X?.'\7<_YY8YTUEMW?3S33^_\O'ZS>_UVW$./
M77884P^@QLEO1*KDA7>B.$HIB^QXXI6+/W/(CG):'J>=7QH$2I!/OM+'+,%,
M/F?M:S8I38V?G-Y+\;_G'1FB0<#I>:5!4M:H_7'<_UC@Z3TN:ARIIJHS 7=0
M_V<@7MD3TV E*L.0;6M/.URN" 4IU7!F.;!9U=0N]2>^V<TULC(4W#J(M0T6
M+H2YV9IH3"@HYOQ*A"H\'*@65S@,/O!M8HN&6SZ(J]"<C6^)NJ -';4WQMDP
M;HV*#M&\,D#9<2!W2V3BNK8C!U\$ (I2C.(4IPB" ' @.PL( #:^X\4N?E&,
M74Q =LX11C2JIW8#B6(3W?A&?#VQBG.D8AVQJ$6"<!&,>QSC'LM(D#/R<3W]
M:B,<#7E(%<FQCE:DXQVWB$9!1O*/ PGD&-78G4(B4I.;M!!!&+G(1F;QD9'L
MXQ<G*9!*IC$]\L+.!S:F(XRHCRD0"]E0!B:R':'L9O\LP:7'3$(1G-$2)ANY
MF >"6<OG;0E),2.2DH3D$%SVDGE/"=]"%(9+B&'3F+H,)L#:))'Z%:],$W&?
M*[,9$I$QTR';?$D(@.8/JR3@3D4# #E.\)4$C*!I(^3:JFC%&K@!*FT;!*&H
M7A/!"CK&;RIT8=0$9RG28&J"=WNAK4XCEX?^38$1I.!I)(H;"[K&,* 9J=/(
MIK<9O@6"9>N;0?OIP,,@#H8QC6CBHB.=!B!@'T;CG8 X^5.@&FAS W$/!1XY
MC^\@-0!*96I2W9$=#D0 /$IESQJ#>E6LRF=U[3%J'I>:5+!^5:SS>"I!HCI5
M]]0HJVMEJWJV4]2CAK6I8RW_ZT#.&M:JOK6M>^4K> @"5Z_.5;!.A:I4\3K(
MZQCM?,.K'L485B2-\ AYY(39_63)D3?M"$W)BXA+E$01^YDI)A)CWL0\Z[R/
M1?9CDAVM,#<K,-)*SWZE;1)$I)>]]=$VEU+24F@GTK^@#2TK1\/.3JG3C'CX
M::*H:M73M/8UR83MN2_U80H5RK7&:90RQ=D:3 W:*]H@]$^Q6BY<>%A0Z*JJ
M;^LM3749TT/CK"IK#'RNL'CEPNYR:F[ ZDNP!B68CFX0B$5,0$[MR5/>]57!
M;!VJ3]D3@NQ(P#V]R X%ZM.O!6<XJ+NS77L@3! )MX?"!+$P?2BD811SDL-$
M]7"$_R=<X0MW.,4SAB.'W?/A@828/2,>2(GG Z!E45-DTD2GQX!IL,?:$K+.
MDZ;YK@<RFK$,F2+I&< @]KZ8I-.:U2Q2Q*PTSM0&3&3'9%EG5?)9SD(S9L-S
M2OK N<OJY6Q,5XH*G23P.*U,SFA:,0=6QI+1W_C*H84#8FW*0C<ALO!6$33-
MH.,+4:?!M#,D-9R !9JJ2S>0,(\*\%P.M2L6CJULU*U4;'"S*4/EC3FB:4UE
M,!I$ES8:;%%SK@I7RE$\T[.G-.:U&[>3R?1T=2!<;,\I >!C^7# V"?J=;-?
M)P?N !L]PA8(L=EC;&3'AP)E=':W70=M[4C[/-0&@+77@__M^BB;(.+V=KOO
M]5>N/K+8,*:/.,J(@)*5V9JX7=-LJ2>3@TV)>[6M2#DU:^:@U"S-4C;8]9;7
M6=,Z#WK: W/SGAEG:B9IMI.EI<21Q!"'>^E\+BOX8KM\I''^S'\2B$<"D-45
M@4QCSPA(0')CZ)P=IO>!J":O76(#ZI#N_&J\RMK8#KWJ5YTPA=;U8:N<7M$2
M)GJA8!/T93YH7^X62KP158L)"2/=47.TAD4/E=!%A=*T_%RCT1D:LDZPCVHU
M^%V&=7?=[R5WP [$'^Y!MWRVK5>[!YY>6V4/N?<^;Q+/YQR3%'SCV07X]1B>
M[_36MK$!X'C,HPO>A<_.X:]->?A-+%X@0=:?:'V)/F+">2A%_E[&KRSEG9$V
ML@Q7V$@:DMDEB]9D#\%F1["I/^8-W+1KOB4XG\QZ(V_\)J]463=GKS."N;XA
M4J'  O(1SP#_%DT>U $+TT;]0U&7_6W@!7K6!=4X\9N_4EX#_]ICN.A,<Q0X
M;EDHVCO:\^%<&J,S3-6DM:O2H+LZO"B5JKNTPY@4L#- F1(UFK*-0B&PR+&.
M>MJUS*O :8$\]3@'>?L\@@B!^.  'JL<"QQ!9R&\]=! KT*\@?! ^." !I Q
M$HS!%<' ]$#!89N\#OS $/0D&>S!%%FW]K#!:L/!%?S %XRY[?LF[X$>[_$R
MS8*39DJ)-'FMA&NM]($R9[J?B4LX9B(^*X0MU,.M'@DSB),]U!+#)2F -WFX
M)&L]X<NX^LG"E(@?RSK##U"Y!3"!.Y,G/"$(N&N L(@'^VJIZ0HH_R!R+P+,
M+QQ*'-^HH.V:C%:[%(OZ(0NZ(  KQ)+BNN5XQ+ CE4-SH$;\OIGR"_JB(4\;
M.D]LFUH+*+0X1 GZ+A2Z(>UZ/XOB%=)X''.@#KFC'"7R05_,D%WLJ0=)'1#X
MNW/Y163L)&%D%M\Q1AA,1F@\D&6,$6)T1AJ,1FRDCQ6;1OYH1F,CAVX @ ^
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MHU%MRYD'@A#MP"MMR 47UD8 UZZ/:M$QVCDEW!Z=SP: T YIVJYM;UD WT:
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MN6;P,VT]9+.=4G-FM.IJ-8)*J%#QS<&)ZU$+D1%H%+7U];NM*7T6#EA!<>T
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MWY 2T?@+A'Z*?Q8L1X %8#8H*B/R'X]XZ-CSB'^C$0 J(OYRH_>!"'_T]WZ
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M*DU;DK/ -F577;5:99=%_QV@I-8XJXK*$X!;_7=!7W-=I5=)EI8.%^^ZEUZ
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M.,6C4'@DHC)EL(-''="_-'[(L%>.C2U6,B#SF9^__Q:4&R7;-%I2*K:4V[:
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M:]J\C@].UL!LG[/<F8<N'HZ#'F92U#K+B&]X:9K=Z*17&?[MZ''1 ]]Q7/-
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M@4*75$983@(B8JEI8J8GIC08IDM-]87D$"9A(F*8YJLE5M!-"0-)+^EAZ-0
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MDH'BO"0BO1J@9BQ2)4;.Y"Y):.96(H%T*?G8OB#7:_]5L$?#:T_SXC :  %
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MF/#BO7B!@3N<-C'@P)[KWM7;.*Y:R(PO@[XLVO+GR9X_IP6GMFU<U*55YZ5
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M8%ZUPACN"88LK N>SN+#4K6P;62[BZ0ZXSC=I,:(.6S4VA9C W%08!N[DH
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M+T ?7_Y\^O7MWS^NWOU^_OT!>,<O0 $')+!  _/Q+T$%M]L'@)H0,"<!81*
M28('6&(%'?^65AJ(E4U.4H85"CP<\<.33D3QPQ W"1'%=DQ$<<453X011 ]E
M])#&=F;$4<4;<]Q11!*![/!#"A9 <1L>242RQ"!]]-'%&A<(T<D93[+R1Q:!
M1-)&&$UL\<0C7;SRQ2>?[/',DS9QLIUMT-32Q1*/5&8!#5MRZ:5U9(*FF9H
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M"I);.:GP(FDY/\H1.>6R*.)+P[4PP[8 G#7+H_#C"8DJR9C\PL5XOF/02=I
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MFSB!$QC)[]*5" :  ZX'0#4!RYW94K&_]<NY\UJGC,-""BY/G=M/,]O@V=@
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MN]HCW: CUC;6"SEPXVB@/>+5>T(QWVAS =?N2[<WY+YNS:)F;!LM7;BVR4H
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M]EL?N3JRF,.QA8!'4Y;[K 8=MOQ&7"H[#2Z^)3J:B0DYG?-(TMH"NH[$B&8
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MB\_,2+LS&;F(O]%Q.(VHB9MI$#H]7M8I#9>60[*%QN:,937U%4()C$"=V &
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M/>MF!_O9OZYVK[-][&EO>]G1+O>UNWWN<$\[T\&==' +?;:RA=4ZPO(J$W"
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M.<*O%0(0<5NY9Z_(^(VO8\0_D?L5>(R[8^%<M,G.BT6J^$GKBP1BCEG@2&Y
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M)2TAV^R./GO9QW8V/Z'-;.HX>Y(*0E4R;1DD<*)II&*,T";W:1Y,EJB35Q/
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MWBA6W@"VG")D*0<V55B2X8C-Y9:M2UX-'BFRC%*0G@@RX?ZUYY*)3E'IKPS
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MLM,N+@V[:P.:)55-'\3AGO09)X&:L\DHG]ZHZ02W_7ICL-<$[FH+WGE$%\X
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M!)W,^1YK/[#X_&@RA4G%"MO22L0A/NV6P5W'"/O7#.L1@NTG1@:=.'#_H>@
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MA"?ILSP84E5FTI+'DW_T!R>8-D#O)U;^IVQHA3\L*7\S(FP+I'ZJ=FO;DY)
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M<4XQ?= G?$1&3VD!;X^91.DX F$72L5D=VSG0<VT'M*Q%:<D#I^B3#]QFOI
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MH\.J+@99-9LR5<'4FG@0I*5EC+W5RL(YR0)[<%/:>>'5_V,H %S(6P@38>*
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M$_2"7+5"$/(K--AN *.(, EP^)2(CDM$UX:_L1-PCDRG2P[!T=EE6P<&(0+
M]PGF]Q% 8>N@ 3"W"5.6HU$M +:E2\G%9+PE42Q-J\48K&U(L601C]K89X/6
M>,'.7G\5+JZY* W**.&2KTP[C9+D^(75JID($ ($Q$L@02 N 1(2"%@G+*'
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MLEJQ%Q52M%*Q)(*8FG/(F.82E#F<&K')D1:SNW@ )%)S0\51K)$1&=9"OHK
MM"QYK7"I%=8B- +CG%S9G&:Y1%!!P%<[ UT8B"+[E%C,G >+%OAZPS:S1%DA
M,F4YEE,D+6S!'#23+<:#LJ_I+G$P"'? &D<+&H+X,RW!L&WAM'8AES9!%,-(
M&8&8+;$)I:FAE\>0%VR $CS1$VQ1,/G"M&8A+VJ$Q4Y#,HW)Q&7I.F?4NLBS
M1_>Z-(XA&6O9(]G3ART,&H])G,NQ1(;I,]4RR/>*FEE!13-4I%M@0:\$LT5<
M))<(()HZ2QN#H9>)8$;2HS$_E!:%:12R@Y79ZJXT*3(M$4?+F8A&.[2)H"5L
ME*UU&0C7^R_3BD<F\\18T2.,49I>U#(>B1I+-#!2\Y5?A)@XTA)6M$*G?$JH
M_U0-!Y0-:(@=OJI!</- :6/"9\./:MM 8T.?!^G*\^C*VS">Y\&?Y;# _$BW
MK#R.(63"8\.JZODUY3E"(2S"ZO"V=9L?_EA+7E..]MA*^?E [LFV7U-! 9D>
M".DUPXH&#V$L*8Q*RJQ,R\1"@*NG>?*@^5,,'X$X.MH]#!*MBQ.,:EJIFP(\
M132UF3*]6:*B@9&(B-"M5W"'P5"^CJ$("M"BA4"(5X(\">H<F:.B.4$\+DF<
M]2N_X?0NC=B)!'@< 2 QG[ XO@C @TL5_R-(1[*DZCRU^PL\MQN]FN/,T%L:
M2K,_>THX4U.(J],W@"2]G3J2EB*DA&.5A NO3LRFB?^CNHM+.>RT/\: ( F@
MSXQ1"J9 )W;RIX: (GGBQJFH/L& NI6SJ#9!"B'#)N<<NHQ;H-@:3AN"S@R%
M%OK\B=)CO[\0.%4Y.#/JS$#:3()840H*H_*$N*+#.3WDBX>*/7ZKB:0[.-<S
MM>L4%P%EO8B N<Z4'$NR)XF;HQ(R+Q$+/G04NK-HH$4;R7;H)BC:J;7PBK"0
M*+)X( JZI);8!(D*HL/0"]P4,HR@L[*8N4\HN'APSF12/%7QL'-B&8DS(_%K
M3=(KC%,+38M3IF7*/7>JSVEJ3\M,5$55U&Z(C=D@FA74*_*0-V43K![<G0G,
MP;>"P>N)U&_[P24$U> A3"7_U,M/S:KF8([TN1U? XZ_>M6SE#847-5SFTOI
M"=6Q,A^_9%4D[%6MNBKVD1T@I-2X') "X0T/><(0651F;=8$K*P9$2 >#9="
MO+1?28R;E*54RIC1RA;H*L2E)#N'^T(48T@ JQLT&PDV,8 ZB0BLT8=NC*UG
MG#%?R9-'I,?36D:_<2Y]"(%J'9HGXM%5:1AV@8@6TP=F*<>_T=:E_+0>4TB!
M;#/D*[WV:K #BZ "M8BA;+.(3,-N;96?;,I6LY&'+;@4]96%/%EL@16']):)
M]!9PE4UM$;T7?8A*C#1+02-CR1-_%8;D0I12'$F1F(AUM;"/52V%(8OB--K5
M&X@(_[,1Q3&4BI$2<AD40 G8S-(6#;L9%9T*;U$C6PG$-(22)"VR+,F<1 H5
MD]5&!ENR:U%)@A!95ZL))#$P.)02H<Q$XQ+1NYW'T3N:)]O%!E,OB  :6-$6
M,+19M]$<@@B<@!$(J6U7FR6(/#$UH]" !A.U9JB)VIP:+@"PD1"&3!&'QC"(
M$;@7'LV2<GR8B0C8@(386S2R1 &5-X0ZGD&SW$3;0*0OC2W$O#7;%(TZEIE0
M9RU>XU5 V*"ULY$ O;2=;=.06$W!$KQ+M"H0";P>=WNJYW4.=N.J9I,/<8LW
M(Q1,KJ)+P-HJ=S-"MYPV[A&WL@PWN\0J[0'6ZX&JM_S>N/]D'W+;7AS$5.0!
MS+S\MN285/B%#OB0 (60S!$Y7@9NX*$Z( 3*S$A2J>'%V][[%"![O32L/:%C
M.[7#(],B46CAV[]82@D@)GA=*!)U/X'P)Q7%(8L2(_);328S4(."%*;P)@L:
M)1O:*9"S*(2(2=@$B</;(1RUH*'CT]"EBVY:I \^43P2P$5".P*,XHQEK8?[
M3T6J)PF0VRKCT1"F8)F")A#"*8>;NGQ2V?TKNY0JNQ\S)SU4#(43)8C2"*>;
M/)' .X0;N3I>/'WPB5<1(Q[1X^1"O^N4B2'J8=FDI9<@XI":"W$0'4!FV#_J
M*1&S8]L;HR!.G)L:._E;H[0+.A/_%50%V[TP.B>0:(D$3%U47*<P?:;:PX73
MK-+.26/M*^,H 8F8 %)J';LP[4Q:FH 3C0@YC8?HJSL1%@"!*B&C>%-*"N($
MT#G$*Z@KK;J!\"=E6@D;2I4B%BT>]@GM8]'=6^+^5*S6M&;_3*UKZJ!R(M$P
M):\<*<!.S%,07E,==6!\SF>C(H>D&HAI2\+Z)1ZTI X2=#;K-<+9@;>NV@]=
M]4 8-&BOO,I+Q<!BQ3:%WH];2^C%#-9Q0YZR^N>(9K8)X51AU=2YU.A+?:I+
M-:M9_6CV25;_F4Q]GFF:)AW,E%8^1-(&2\5/[%:;[3%>\6DEVT2TE:\W)CO.
M4LDA612!_X7GFCB#0\,P>HFOXM2'0TL8G7"5(\O</*G78FP<2'DN*)$NC.R1
MOG$85@F<M;EDL,.5T/K$OO7"I%PD4JG%I9S(@UP6;.5:I8D6S^HQF=DWD]B1
M:S65J"E#HD/%T-4Q9MG:K\463?QEGRY*40RRL+9:.Q%=G@BQ!"@#GK"PG02;
M5X"6D#S# M6M"" (,^@NPB;L3%G8'_%#?NSJV&:\GC';,/NR+6,X(F$_42DG
M-PRSAI6E4-F8?.3'4VRR;YD(+V8UB1FP\ K;Y686S/DN44.PH!W;G=3'I>SK
M(E-A+>.^&>O'OF%77RE:/907\Q82:/3)]$)MVM M1TO;3**5R_^^F!H+)6A,
MXUKTF4T1M<;!E>'N+Z=)QT52O'ORQ3:S%KS88P/,$M&I:0F?<-5!@&Y  '?H
M!<@@WPNTU8NN2[,20L9D7U3UZ/?]\+ T5<32M:4Z5>C%J@EDJ[/$2KR:7K:B
MGQC'R[N2*Y(.C^>E-^^I0?-5\?\88!.O7G6+#U^+\<ADK 6F<"B/<M6XZ0 "
M8XRB9+H&$BBC.H^I3@YJ%_;;:A6%92O>IO!TN"T/@<JUT<'PA?4KKA]VB3$*
MBAN.%JCP*+MH(H9(Y+Q#(GB%.5/BB3>INNICEK. /(@(9@2]OR@#/DRV(T-B
M8HD8KF6*'(CTH. +T\WL)E=6T?D*.E7HQCJ#&N,MQB9+ IT\O2,LMM%[)&==
MTCQK#F1)$O.E/&*G*+S$-@BH^#N#F+E19[*S^&,MWRX-$@AQ@/,3%O2%VHE&
M1EEA./3A2H!7&O2(X',U0>$K!<\O)[CYC!*B&= 2QLZ:._.1B"WT5$TZLCBT
M2Z1["G>0F4_86V62] @K?N5N?QGZTN)7%[%T%SG;TSTJ)M&0@*"E,U#F="1F
M_R+=&G6^. L;2@H2,QS $(>/*PGT*S2_N2,(71H@>I.PJ.- =Y,P?Z9'&C,^
MVQ(8E<UITA6C9K]%CSAQM^8= U(Y[KSHH@M$E7*=W_]YUI"':>!G!!@8&I0V
M^#"W\Z7?6B56O41R5)6=(11!7)6J%>Q!_@4W]RT?'E2KK=S!N7+>YT!,;NMZ
M7\,0J])?"U%I@ ;6[E5ZP9J04D5"HB^>M_JJD+:/)K2WF.9YO=_[SJBLRY+6
M1J%']!KJ-BO\Q69<?53%4%(295HR=@Q75/'6H349C2RQ^LL4?9"%9BG.<4R,
M=]WL2SE$DP!M8'DBJVV8,@"4X#( T*X7@U&:A$'M&\GO9I%]GTX93&1KBL1;
MW/WTZ7;L_[Z]\R0R<'6MH+2FT7H,*L,Z?:!'C= 9X38O+S1YF#GJ)0MOA,RG
MF;UNU@JSQJ\7<@D2*K$7=<'_W%>16JO^,4&L+3>!&*FMAF/"$2[@PX)A"E_A
M5W_E&(/!$79:<X 0("!!! /ZU F(MRY! GT.!0J0D'#@NHGQ)@JKB%&CQHL"
M,@H4!O%C19$10U9,4%'A1HLG)\*4D$"B1)@@9[8$F5"C1)PE(3;4!V HT:)&
MCR)-JG0ITZ9&#<;+B%/@18]2+ZZDF%!D/)P7)8+\.K JR)IB+ZJ<*+/F3)QI
M/7:56'6A6:\E4TXP2-*MN D.7[EM9\!@B(0)*.@;;% <3F$4#%831W4@%WU5
M&^J5VLYA9+@$#49@>3.QO@14$Z@#+7<@9--P!4I<>9=J2HVX)K\6.+7J3JT7
M=8:E__VQ]]R!=5G&U6UV7?+<<)FO#.IT.O7JUJ]CSZY]._?NWK^##R]^O-)N
MY,@AZ,500KUH]=K#U^1^_OOYQ^#3AX]?$_[Z_=W+YU]^T1P#('W1!&@?@NWQ
MYYY^" Y8H(#O_7=,@ _ZEV!]%CHHWWT&^B?A? $62**#$5YXH'_]!:@A@?0U
MN-^#,9XX(8@I]O<?C3G6N&"-&O(H(H\3MO=A? ^Z)R&&]>#XGXP]KGB@BSQ*
M@$L""&!)GI9;<MFEEU^"&::86S+$D#D)C#F=0Z;1A)M:*HFTFDR\,1=1 EAY
ME-57:<&FDEAWVBE 1>MP):A(=0KZ&T8A&?J:1P*I\U< ZO_X$H$Z 53CD 'M
MX!9!8@:\$H$OF>JSR6!F3": IP9-$,&DI$9@F@!<#!:KG>(,ID\[,@EZ#FD,
MP0:I0YS.*<ZO<B5 JSX1G(:H1:[962>AP3)WIT:&!HLM=(?RYNADT\HTK5@2
M%/HH5H N]*U'-2UT6:*P)99FF(FM%Y$PO/&:+[2(8F62L[RYE"ZA7;ED9[_8
MK@LMKP<C6M.][PH*43R:1N#JI>IHD*D!$S3CIT"?5F.I!OSH,T$9@S&T)VG+
MJA-!96M.E-@$'B<[V,RQ.?8IH!Z%H#.@LX(VF;$&M250G7A"=/1(7\7Y[KB[
MO?D:N>I.-.UPX<8);=5-[RFQ2PO_@[OSN^MD*J^8,"?,;K=4/WKM"#']_)+$
M;+IFFM+B"C!"PG1R:S3 MV$+TU>D53RIR)K.G.VG+(]<\JH)W(:6Q@>)JH%#
MI0F:0*:)7S2"!JRR*:RNT%XT=&E6?VZ K82:;G??!=,)*+D)3UN[0EV=ZW1,
M:L&$=YTF33;GNW&O];/K1F<MK4C .V2V\\]#'[WTTU-?G3P 8(F :_@9Z>"3
M3-)7XGXG?M@DE#^.^/V,3KX8XXP@,CB@C4+*?WZ4];E?XY XVE^DBCYRSTDL
M&I)^/#2@'2DH0R_"D/[:QR ;/8D_WTL0C234(OMY[T0(I%_^F#0^!L:G1DH"
M8#UD<J7L_V$OA=5;(0M;Z,(7PA"&^JB&6WZCD>!<IB:]<0M;>@*6GEQ+&&MI
MR0Y78T/!O44XR,E*G^YRD5<8Y'*DTI2N2 *4O%PNBNW8C#X*$ZZ!8'&&4D2(
M8?R"N=]\9H9]$LRRMA*=Q$1F+VR, *_ J!>H63$L*?&66;PFQ)9TZV>/BAA+
MK%@<B^Q18C?4$V[HHASC](:0(4F 06*X'34F9R20S&1P\'C$+X+EAJL1CL>"
M4T3AO TY5 F.3HY8E1$@)HJ<T=1@L)& 0@U$,+)TB"W]\HJ.Y%(QE_N+9 82
M*0-PP2:F<D@(H"6+H*FD+7-,&!:M*(!G'L0T&3GB<$[RJ&UF!?^/C#),*%%"
M'"5:LSA]7$X>Y;:N2"I$:P!KY4>D8\E+5B,EPO.*T=!I1;ELLVHVJ5:;1".;
MG,"S(CJ\X4F\DA:HN7(ANI2B&$G&#PW(*BX)V$RN+H=17UI3&*;JJ#Y(]HIV
MK&15&'782+OXQL5$<@1L1$C6N+$F9,UQE,D!"4^9:!5&KLU:(1GE3J8"$1P"
MDS91621,K @XM!34FR]QE$+M><^K8C6K6MWJ=+)WIIF "$I"8M&!."0@_EWP
M2! :(0B7),(.J2A^$$P@D&X$I;J:M:Q2\M\#V;>C$ (VK?]3(&![-"48Q35)
M8262AAH4H\,"EJV)O1]BV0<^^(AH2CC_XE]A,936*3VP@2441@+,D:5I<#6U
MJETM:UL[GC7YA$X XTC6HA8LX04*7X+,J. "9;6JK>M0)K%*JHJW-@&D3IB*
MB4 [ZB66@43 +[5BB#HRU5R7$,2,B2E#<_OED)DABE#'NM,Q;;6U[]YR(L=L
M+DTT5S)T]>TU ].6< ,5&_GB+FG^ZA? SH*P0/'.:OX=6[ENVY;@OE.\0G$M
M4F &KHC<AE<-ZZ;R(+8V/ G2;\'C[=ZP)3SY N]@!P.N0'"EW$^UBB'UG1,%
M"F*SYN("O2-N,6DV%@%W0"XBJ]J$2>:TJIEYQ!>)81; (E5%JVU.89[2E7-(
MK+=@H67$^3J)_[2\U5L!9XY.IQ$ X*X6NK]E3GBU*U1XIPK@B1F P4I94YZD
MC"[X3@:/U4(:\H8S7Q#WULPS85J?!BF6Y#59'!K;I3ZP$8&.18LKAUG5QC;!
MD,T%+R$TSI7)4B:L3:72,#\FK4 T!BRQ5'=T5DERU6Z1F.M:#<M7?MV(PRNU
M;PV7G'@SEWTU.6#E,:QSWZPSUHY*L+*I.=C"'C:QET(.[&$IQQ.B8/WNQZ,.
MDK#91*J?8U4$6@!"J4CK.Z!;&>C8"&X[M&2-4K7/VFW%>C!]\E.?C[[=;,[6
M%823Y:N\ZT$_N7)[W=F.]H[0BC\"#C9\V-;1>TP(#2Q-8Q_7*S;#&__N\(=W
MZ:9C69IN2J+3A+9%A^SLJ1)G<Q,Y-12J7C.H&\FI2*.5*>4J-V58>J)RM&AS
M-C!/.<7+)#B1T'P@I#F'0B=>ID+"O"==OB4P(YJJX[X:4*:,)\BINA<= @R2
MK6Q,.,'22./D>+@_>>2=K#KL&>HIQU!K#)0GOM0=WH5XAB2.77PS-ZC+_"0]
M>>X[NVE"E:^<D7M1N97*%.*$C("T>.\DL$R9\G/EBN?IM#G + T3QA^4IW(K
MYSIYE_6!$B?NJL2*1<*2<3/?A)$X1.1$',KT8'F=V&HD.R M?O2LZ(2=[RS.
M()&J1-=$)UW/A8WGS]D;J=P=[Y8>?=X&?QM!8(U=^) L/6^CPWA8)H8+,Z&G
MXYE/=,,,9#VR$YQL('I[5>:$J<6Y27&B*9&WV6F(X"\YK?N8?JF^FEVIASC]
MZV___^=E#QKK*:#\$I19P%K6OEG0 2U68_7? 8Z;88G;LP4<?\1;LXG6_NS5
M9!'(7"U;9<$5]T3(N5T69%W68I5(!,+/_SR671&6 ?%?!Q+@D-P;!I&5DFA;
M_YB@@YA0,R# L0W%/MS?#O)@#SH<S+#+'\G=PVS-?Z5*\L2:2XR8U(A-<05.
M\?P7?F4+GT'=T6'?T<@*;E5A?WG-U]0:SDB2W"7 T!A ,SP,OW@-$_%3'74-
M&M861R1,HKE3X'A$E_6:FW1%[81.32 +&DI9X!0AE9&9?_4$L*E>:>Q7GU65
M&$:+GP5/$K:7P609Q*A%W_01&C85;KW)W8A<DP4,TM"9_XAEBQ_VUNP5#%%=
M1,^@C-A,F80!#WT]5Q("3"3R#43TVFHXTN,M3*I4C=9@6</0C=),C1'^%J/@
MC>ZTA8+](.:(6:'@4JV1V)[0VC'NSBCAS935"7R)V"].17TI89\T55-IF9QH
MS4O@HNQD&!_R%LZT65,9&:KHUDA AQ5VX2XVXL0%HJK!FNZ8G+\46!5.33R*
M&)SDEH$)5$$6C8 IC$@8H@\ZY$-")'5T [)ICVE,FP15%@*QV[^AVUU1&[M)
M%@2U%838B $ZV\ MX+R1Y$>*5@6>3XJ4X$A:5DH&H+VII !AX(8L"&2EU4RV
M9+T-UK/AY%R-$$:&EHM\FUPYB?^$] 0TD$,W(%Q$2N544F7U&,2<\--5C,32
MY=%L]%$K=82>'-1S4%T-L1W($=+6<5SI$54DP1Y/X)[) 1'JM8D5M07@' <O
M9A(4Z4,9>(32554?X40YT>41\L0F":$>N81B/I</<=GKI471G:4X4LO5-0<P
MS9TX=J-&S)^:J=%DF%(_+I_1F9(Z.B8\C5-H<I)/I=W<]1P]>=XH<9Q/8%\X
M'A%7P"4J7@O:A>,CG5P"8!&S?)P?^90119(>49TD)>?5/*;)X49R;IS'%941
M 1,/\>)IC))LSN-<))$MGD8E-=Q5^M,I:50Y_:7&K5U/9:4CT=I+:%V>B=Q7
MZETAL5+_1X!E.YU2;*93))E3)LF%[O73(.$"8CC$.6@2[US&$I%$(2V')TDG
M=2YH4M5>6))>.N6B<)R39_#A)HU%=,1#@];%?UJ3SBU859KHB=K?L6%)QPC1
M92%)]XCD8JG@^WP@C Z)_0 )!0F(9/W53UJ;6/7( '+D@^35!P)@1HX@915I
MD%R(2?8D3&+6B"3I6*W@?(R@^<3@CJZD31)6EH;0DLZ@"AH)9"'@4/YD"5D)
MEI##PJ%HF[KI:LE! ,BIG+80O1BA;$G5'*Y-;9'CN=3>/NZ.R!FA+F88_!F&
MLX2+0A3*U @CU&0C%?Y,HKZ);569H52$.+0,J6Q*Z+P+F37-_X%5(MR@(6YA
M(G%)DJF"HSU*:H+>HYWAW+8@3$+B$G_Q&O+\UB[*1/,4F\0I#2""HL=L32VZ
MF2A6:C/6*L%8#2[&VC7REK8T&:D>#!1RH6>,S5Q(C7!!1[3.!*9&@*9RRBP6
M))T5XX!YBS?B"Z/0V1?]BY?U%F[Q!K!*&)B%S25"U9=1&%?DB1#13:>5Z*X:
M@/:1V*0B*H75H7W%35#U:M^(RV"F2J7^3A16ZQ3^%X#.FAC2W9F1TSKF:=@T
M"O*\$PA8BL;82GNIXV]YRRQJ#>!4;&[,&CI66:,2JZ+,%Y5-:KQ"#*ERB]WD
MJZCFJVY)0+R\:= *;6NA1[()1(5DD/]1HL^TZ=6-NFB[.2U;B=M=[0>5]B2
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MZ[1."WT61=PZ;S**;UYT]R'SA;:4SZ:D9;5ZS+A45S<I)6GTRJY(\_\RU+,
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M[R3J^2Q<)O!@S*141C?6I"_> !#S"5.R#!,@U@D3L"X!P7@"$JQ#B%"@/GT
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M?9;CBX=H( &)2R@--QC'-WF'3@"*P/0$@MOT]<< $9")GF7R+AN*XS\$W+-
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M"BES1*1D#(1H$F1JMX8O[14XV0-_U]%^\9-L:69OKP,_D].."0!HV:1H%"!
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MPJ#&!K )UJ:G%_F<[<>"P;9GY])#SS<=QYML#L=OR1,D6_D>FN8>(3 =UP!
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M4HY@2>=1%-OVO+^"IZ;.I*RRJI!Q+-A+"R[8J MYN*\J'8TIIH.J+-LC,X9
MG+!HC[,# +:CJLK3BOV#*,SKG??1/X-XO]U#/.-8IF(I)'U(D-*SL/IA"H<Z
MJNZ0"0Q9*L0H/0.8/<U"#XF@ ,DS#(8+#.C@I .9OM3HJE3B/IMP*:.P)0@)
M)Z?@B7=2D!-$C+O0AV8"E@1(I)7PI70SJB)\O^=CC?4K'<=3/K,0$)6J#I+
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M-?>XW^_PU;/!QEWU1U_YGWR0U5M-_T][T)6ST94!]EKUF([N: ,Z1!;Y0 @
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MQ&EKH.6N46ZA',+_&"^:Z:2%,!A=J_)]EUDFXYN.+(O-86P-K.&.[/^$;)G
M8+].*LA XK1^87K!*]'%,@T.D31/@+M5<]LE+PR6&:'D+KV6"7MU+"M[BK=F
MV"'&64+)83JC\C4KHRAZ(4D\F2J'8I,5(D$8;):E8)L:B3I.";-NC(@Y&*TH
MBQ'Z%Y.)](DI[(4%6<6]<R%&*IP)JM]$M"-'M507#KHE<?=!%A/7;._D*%^M
MWT,^[8M>9&Z(K1T?C_W]!P!>3U>?7_3(VJKQ+!_O+ +:L?U=&_M98 5B)-)&
M8%R)-5AK9'@,UNV\GTR^&O#T!P9.*4\T@&B0PS3L@SRT[51/-F5/!B1__TC[
M2,0F &@HT:9%Z$_%=9P+99XZC:^]D1Y2UB7>O*?[.HS=N>7O\F5#T>?I+N_Y
MTG9/T5$0S:;MNH4-9YXZ]J8K>67Y-I[LIN=)X"4/?E,991!J:9YHQAUOUD70
MW=$(+("0L%N<ML,%'V5?YC"#_EQU4? 60K?(-%3ARAL+[]'G=K;MYB')R5L<
M"??>U1SKVLPR\=%8 B=[3M-ZAI)KKQEQ*H0A)9T/ER8L=V=*_&[\\M3\.F52
M,F5M"] ]$9U/)( T@X"[;7?*U=LQT1X'=_=\ZQV$V6KV<M-SWR\=N<@)"SCF
M,E'>D6\+Z]T%:W3@_EQ:(O@1SNX-R^H7/67@^O_VB5B37O+,#/>EBLLXD?<E
M<)9E?CK>8RHS>*H>36'C3V"W1%>VEF\Y9DA(58]&D5QU.T357!\DK.G'3>(L
MT+8H>JAU( OR?B"I\"0M^1ED'N^51BX6CL8.3;IQ'Y=?^O$5B>ZU7S7' Z*Q
M>Y#H M+L?.Q?=91.!5)/8.-&:R#/;O2&-BA#3C8("5VI!W(YJ(<Z85QV +2/
M5+3#IGACK&C*0<\A+2:L,BLU-A>CF[99.C)KB^F-K!:TI(T<)QMA,D?7*QML
M [7I:AWOI,%6"6O+P##[@#GBGYY7"5_*P:K9KI97=2&$W$3[$\Y0+0M[JC:+
M/I@!NYTZ@F&[3F?+W'C_JL6Z1+SFXC%K3$MKX1!Y+*]7(2F'[LK5H0ZNV0Y2
M"CGC-[WL6"=W'+;^*D<16B(BH[FV-#!CTA*^2&\9#(X$#BWFEW7E%T8CC7AM
MBD5H2CR0#;FWVR=4@PH5C">C( %3W;S=ZT-GZL80HQ/R%KZ6628G#1B6-N3-
M8(X4(\V[?"IN7*;::JR>F/#6\VC*NK0S%#1[S(EX8W'YJXF[H+[S#-(Y:Y!!
M[*8<5\@LEVEQ*D$,R\B+.MF7O60[CO;]RE4O@!29'P$R#UE[U5=?\4RV\5]3
MQV&W==:Z?5L78+$5Q_O];-7RQ]O[*/#<>5PK&]1"K>+7I-)BL5:G6GT,.F]4
M_Z2:"[83YXY=FUISJ(89*,,AHVT"] +D3 , H(_9IWY4DWK[M -$L*>!TVYB
M@KUQ+^@&WV\L'RLWB5X+'91!J\4D1CF.=[@BAKA#VQS]KM#&%K=HS_Z!BO!R
MGAC&%5]]<\R3XRXWB2791;AO?A'GQB]M\N;ORYL75H1$4 "[R<0M5'#L_OAG
M=[@%_]0T865[E;;KVAM&"RR*,]X"KPM "(@G0-@Z 00-'AQ84.&Z!!(4,B0H
M$"*NA@T?"L@H,./ C0R%133(<*'!@0(@)ACHT2#$D@(=2LA(,J3"@Q<3F#P(
MD21'B#9A"CQ(LJ/0ER<E]A3*<^1%E#8E(HUYTV.$:O\4 &35NI5K5Z]?P885
M.Y9K.WV^C":$JG.E4)(C#>9$*,#BT8Q%"Q:--U5@5 $)3YY4F&"IT;\[$0>=
MJ1,HRZ P-P8>JI-AT9L%]W)<EWEOY+@FX:8=S#:NQY],+PH6G-+E7(DQ-UJ<
M/%<U1)=L.686JO%GVZ>[.?\^:?FM1G57R297OIQY<^?/H4>7/IUZ=>O7L6=7
M3@X .03?>R5X*&'!@G84-$6KIU[]>O?NT[L_QEX3?/7QV^>OAW\_^_[UUJOO
M/O\"="\_ 0'4ST#YHL$/0?[\RV^^! LD4#_]^(L/P04;//"] 3^TC\+V%HR/
M0P/YX]!!%$>L\,0(X5M01A#_9SRQOO7F0[!!$6L,$48+CVF1/O],M% 3"C8I
M3X*4S/D. 0#DD4>[*:FLTLHKL<Q2RRVQ#,#++[E,+@%]N"#L))?,1*RMS81B
M4RW);%HG)(<:.TC.OU1"*"2D?#OSKYIDNO-.F=J$D\UX"&N-390(LXG0@02%
MM"U"VVP34&$@72K/2/\LU-$\UVQKI9Q""G1-P@#S]-/--MM4LH$HQ?1..T^:
M==9/ \54J(<D([0U0@?-23"+@)USKX&XT*>7,+7LA<Q&805N)U?M!%1:JM3\
M"U94C>U44D_OK#73<*N%=$_$6NN4T44E56E6WX22K;";9#(73IZTK9;15P^3
MEMQ@H'_:ES>;X#27WH>$752"-4O5;#4\PQ5V-UO'72C?;6NMZ:DSTPS6L'<9
M_6FS9)=EMMEJRC1,@FYK;916:6$]5UR@A+L83Z HC593-X_-=UIMW2TU3TT5
M%?JWE3\]R2)!A?Z68U9'5>U:V6(F>*)_?9-S9G*W595-F8#M$Z5SR6WMZ;P8
MC1-5R:;*]2:/9]78U+2Y)@A994W.6^^]^>[;[[__IY.G&R?%6[(\\R@PHT 6
M+_RO<1A1A-S"%UV<W,,?'YS\1 -SK%Q' ".?4,4)(RR2P@\W9"_(#BDD7446
M*]1$] M33U!V&$VG<<?=7Z<==05S]U''U1<?LD?=\=O1Q1 9CT8<=%A9()\E
MQ8/FN^ZZ@7(:P+GOWOOOP0^?JR_!])Z;:A9@C:K0$$U5KIJ$:>TMI59JB3;1
MZI_+-<HT-<PTWJ!%F80$["AZ<HC.Q#:;H,3#+[L9RD\:R*]=03 A<MD-0W#C
MEH3$KS "[$QO'/@2D(#&)AVQS*00DB8',N:# QL,FD!(FQ-R9 %D$M]TL(&^
MI&R0+T#)$[XP8IO%:/"%_R%T(4BLQAB9'49JG-E(44Z8JO5!!C4924E)"DC%
M^_5$-23DX )W\\.U:/$Q(U199#@"%+\T$&R@PE9>?G5!_-UO8"7)4T<RF!DN
MV@\AB*HA%VY('6[H8P&9V4@8>0*V=,4).'$!(J2&*)6T1)*''Y'B!.MXDPN&
MYI 3.8T+6W@0-"*J-XP!Y41T$Y01+L:23A'A;&JUJ_RULGT,Q%D(64@: 8S@
M,8\R2M!*4\H'6LTV;MG84RKBPW3IQB U?$4@H1E-:4Z3FM'ACCS(X1T$B&<\
MAZ. -J+!GF@0;YR6<]Q^<%0B!0&)=\PC$H9^=(S@^<AQY)3GX\X9N1"E:$:S
MX_\1ZWYD.PF]TW;]#.?IX)E/$ 6T/1I"G8T>-R$(44A#EV,</0,JHHK^)Y\"
M6N<Y:4<!"K1#23(1CY.>5$V5KI2E+>V;+\@7@.^%0!\12%30KJ4U6OEI9OSR
M&*(V)C&:^4M4ZOK7RRSU%)!MRVVAFIC1W(2P5AFLB#RKV<ZHZB:A_:IKA]K4
MVCX5IY#,:8ETN5E4BVJIF0D+K$R;5]G(>DM2:M*7<\L84O]B%5FX5"QFJ*FF
MHL6QN05,B" $64T.Q:Y.*:QC+7.JG7)C5+(U;%TLJ<FVOJ9"IQT$%Q)KE=6\
M!=J)(7-HJ^D86,5J3(:I-:F[ 992C44MS%XV7U9UX-7_* L4-K',9HOZ%ZER
MNJ=$[48=^M@K7\42@FJ4087$$JIDI%J0N/K,3^O2U:Y 1B[#^ 23JX5(9BL;
MWE[AE&,8PYD);P7)C*'I5CN[KMAXFC8$>NI,NO+MN:XZJ[EURI?JTIC8ZE5;
M;'4-*6ESV[0V.ZO.8I9MIM%5<<6!7 E/F,(5ML[@OB.>>!B.I"(]Z(P$5#O>
M'<AU#'+<YV)7XHR.<Y\L'O$\1RRD%@5H=I_;78KH<U'-\0['E>.H11/D.H8&
M67(/FL^0=UQ0BUZ(G)2#<856)U%\_LB<]2"=CC*7('%L(TD+> #U$H#2K%S3
MPF4V\YE7&E,0?,]9A+R6%E4#_S^3R"53^IMK4%"S24H2D<X$V^ R69BG':9)
M, TT#'%BJ#+$#&V'9+Q7$8TH2D 3K#CY@Z\F/[+,*:)1)*Z=",SFG"X"XOG3
M(\P?+XE85)#X0Q_Z2 ":V[P F@T';$6<R1&;DF=;#@66J18.<9IR3##*+]"]
MP8M!J&9650J0TTP]#+!I,Q5;-AHS[AIF_?8X6D3I)I:-W$AKW A&.U_DLH?D
M#!<'!D<C*J6$Q-XNG(\F:0FT^M5H!D"LU4W$2EM-U>SCM+HMO<EE=W<R/S03
MPGZ=Z%!>Y(J,8=_].,,8=Z?%D.DBX5R&N#\SI:HRH\8,(E-H-IT@3)+T>TI4
M>!A"#O]*9.#&]G14Y"+&Q\S5Y#O11S5&8&^=[YSG@>P&=\@A#R<UPQTY\0=Y
M%C#2<X03Q?A<D)!'E*,J#[G'1<HR0^])9)".Z$;EE'&5C_?DA69=1(W#*(XP
M!Z*-0MUT+?X0Z<BNNHDN.<AS)YX[?X?0K:MG=G=G,=KU*;D6'6FDT?NR1A+0
MI.L!(*4]=_SC(5^EF,KT>WY5A[X46]D!?NR]QSP@@HDIL?A>;5+6*IM&U.4G
MQ8(P;$$U%<7T];/OWC7 =<N8:8"+M6DQ[5^TW:]'#+8U23'VKF@-V7!3I=_P
MAM96Y\H9\M-*3&QQ:C<@T$<(=&Z&:D2 OW]:5&YK7]YKZ:S_UD&E[F(1RULV
M=791;WYJ]Q/C&TKUMXET^Z_=C"HVG;XM@;>??K@_;[<TB?R,!H1&H/CN2ERH
M1:=NQ;G\A;=.@I=F+[6^"U"@15]B2#9([C>LSPQXSO)V8VGPB]:$JE\4:[6^
MQ=-T*P4?$ /?C[ VQ0)KZ[K:Z'_$BFW(1OSD*XD&HVO&IE>2JJ@FY:9 :VF&
M)E] B&/BI,%:T*KL);7HY)CHSY-F\&.<"N%2<+6^QA>J@0,B[PO!, RQ0TJX
MPDG"HYO*8QN4 3T"9*$8I.E^;'DLRNK\:: 0!.HF)WAR+ \QIPT!I.U4QP\3
MRG<"T9P$;Z$ ,75J!^_XSG+F;L8^_XIV.F=SBDQX!+'LN&['LHS&2D<.WR[P
MG&>DT,'+ED0FFL%ZGJ3QQ' 56;$5M6+RP <!;BX$I$4BDHW/3"G?"$)]%"B"
M1JZ8I ;B;L*$F*+90@V6.JD'CZDHXD@SWBU_X"W^YD@@>$D(Q6V- ".7L/"-
M."LU^H*%'"4B6$\C L,RPG&64..*G&)E2"B2! X7Q,$ ]*$!=$X6KZ]^W,B*
MTLTDD(C;0.,NC$V8J@L(VP+F0&B(WF*&L,C:B*+\](A]'(EH^J4PNNB\%BDS
M4,-/V,WDWH*!(M+;/HG?"*;/Q(U?E&+?PLA^"I+<GD*,HD4O0BZ3# D7*.#F
MS('G[)$#1ETIB&I&+RXK(3A.X@;&';EKWYH1)CT#D[X1D0Y)?3;2E&CM,DCH
M(7<1)\JOU]Y-?U(NL!YN]#*.:N8,C/9-;.@G51BHF'IP*A@BAD8%,"SHSIQ(
M,8(R >)Q'EWQ+O'_,B\%ASM02CSB!^DV0:0HX!- AT FRD$ZD: N<<6P[$4V
ML1))Q!'5"1(?ZL7>0^KHJ48:RC#M\'C0;D-ZC*&ZKC$3BG$0LT!Z;#UT!T<
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M#_V)$8E72%I3#RND04(@64=J64TJS!" '+I!2E21E-$YG:TCIC!7?!I 435
M1<.2; <.D"4BW%30(TW6&3L68/,G;6\)) .7J68V51R25;8K(9.P,71IB"*9
M96'BXR2I)8-CW-;RVC3IF-#-7=UU*I*R)YY(Y +7;)Y6?]0HL6A& JP/;QZO
M%Q05&]C1:25-6O#H,>2E@&CN,YI-(C<Z@7J(GE&NX-2QVGY"99FH,/8D8J,%
M;K$8'(\03D#)W"Q(?8228(&JY,8HX!PCX&3H3)WQW4"Z@$YR*QOC)U>ZWB#/
MI0T IFU)I+TU;-V6:2=V)2[_.N,R R+K!&8R28&23:X_K5]8SEJ.,%9J=JX(
M=E[XA>;X+3(R0EX +BCJ(D)]XXL,&RO;NK2DK=?:U6+(UFA_,2F=,2]>0J7I
M39U-^[2O)#@18!\D%0',H>BZ*1]8P70%,P(F1,I"U72T>3)Q>^IX53]N5W2$
MU^M E5CY, X/,<1TQ^N.6W=6UTA>).MRN9F!U7H';U/WSD?@3J/<\# 3\\?4
M;GJ_.W=R4S?!V:2>]7JX [79N[V5XUK#9P0&B0M"0(4:%)#=ZO0.8T9=.(3S
M):Z&\/P E;$R+U T23\#C,#0E6X V?ZJ4&I\Z6R<<[LT-/6$5*H-5$YJL'$Q
M;SSET>^F]N]+'1R2YC2&QRM +\/ 0F",2P;R$N 5R$0<D'B*]S?V:)"V*D5:
MWA3]]O1CA(II5JNU%%S4\$J)P2:+S=6&T;2U#*M;P+68PF_WXD4][Q--]OME
M4E  CZIHJMA.:;RK$HQ_;_A*\_1/. "4T3KR>@'&N4 <<J^Q%CR*1X4GQ/S\
M:D:]7G1N:)RQCFE(>3ADI%,?RT^(?NW-[,H[S;/]L!,H!Z([N[& E>9;@64!
M#TD$8X\%\UGVJ/R38G2M@E0)0[C"#V7%J^$5TMR]43W5_Y>CC$$WPU(9Z1#G
M'"@@!#Y!FZ.WG&[Y56_]=E*,<I*9$T_,UWDUQ7X]QX ]QH;]QGQ9O&L51E[U
M/3RQ556$H&09F(O'ZC#15$.U/7S9NJ/WF7\G>W63 L"Y>WOA>YTD*SZ7\52]
MW=D;IL@'FJ:AN*K!%TQ @/8ZWZQ1*D:%:J(6NXQH7 LR-*[J%ADBV8Y6BQIM
M+NHB(:BF;FU6@@@^XG92RC6(SJRMHF&)X"_2HPUWSJ6JB.!%*4;IS^3U7NFE
MJ[%+'Q,@'XI+']3!A+]PWF_.%PKIBY=)+S8/XM$6*A4-'U."+4C2;5<NEXA(
MY7$/7S3^4>PGT=2M,CZ/7&EZ'/\G N8HHVW#E8]&\N@K^XW<$F0S2"E1B(Z"
M$2-5#AQ1""E<_N;48=W#$ '401Y!X %60H\4HAJEC=V"8RJA4S%(5C004HIP
MO*WW491:I>.%;5Q=SHY,%J][PB\,252TL2 UC8_$B%P;LB3=@BWGY2=#*?-W
M.-0([1^E5&2%HRDJNH$>X.5]@=7=_?5A?RM2L=4;X P-ISS:81,NE0(BX,-<
MC#*Q>T62MW6'#+<GT[<W\YP>D?AO&\F^3C6']<E^6?C_P]8Y!]E+$[L#"C.'
M&:*@U]H+T>JH?56/FT..S R,8=9W\[Q]\SNZ87O6._;EGY3969K$H=5J2M8"
MO&Y@C]'_ 4) / $)!*P;*$""@(42"B)<EU"@06$1(4J,!W$=Q8L2$S34R+#@
M08D)$XPLN1!APX$'$R!$6%)E09(#:TY<.'*=R8$2A-E<F5*@1Y$\70K4R1'F
MRXDGE]HLV93A0@$;+1I<^O'A1H4V0<8SN9%GT) @#Y952?4JSJ<-VT70![<=
M@+ETZ]J]BS>OWKU\^_K-*\Z /@-E%B!MN) BR*F()7JE.79I6:)3%ZO\RK(K
M3(D*.:IU_)3EQH@R$X<$VK$A8H5<I?+<RAFLVIR**;8N2O*D0L6E21=4?3.J
M5JF=.2YN+'IV5Y&VC28O&_;WSJF9#<X,'F_3V[A_NWO_#C[\_]P0!@07=O@9
M,O7@%"5731X4..['(U]ZO)G58'SG"97.;L_<6B3AHAQG4Q&X5%+K(1?13<_Y
M)"!H#+5W$FDHH9;@9",-E9-CMCEX&DD1J?:;A"A!5EI7S:F7'$L)N 67/G*)
M1V.--MZ(8XXZ[LACCS[^"&20W2$ P D(')E DA(LN4 ^K+1# 93G4!!!--'4
MH\F56FI23SW1'+/EE5Z.*::679:9)9EC>JD)F&>N&0V79<*YIIIDRDFGFV*R
M^::9<UZ9YI=HPNEFEL>,>:B?:=H9)Z!_>JDGEVKZR:>C;M(9)Z29TLEFI)7B
M^6>;=WKZZ)B+9FIFH*#V^2:CJ]:CY_^=<&H2 07GB$,!*Q0LP.L"2XZ0@#O-
M'$E.L4(>BVRRRB[+;+/./@LMD">$ %<U7*A#P2:^7@011FFUQI$P%K5VGT#B
M'B745YV)E9:WZ3;HKK<UE1O/N4,]16!$Y_J7$D3B8J939[MU"Y%)*97;'E56
M$52<OQD%=2ZZZ'J[D\,$V831?=Z>FZ^Z"DMT+E?"M'9N=#J)96^W$^N+U%<!
MHY<4QT%Y;)L)4*K#18P1$!EMSW@A8$:U7-PB3CN^JEQ49_NZ9-6^!*\\T,BI
M.5=P<2>:"Q%75>.D,8<@!WQQ29W=IW&W]%K\DLH?;R;O0B/,'%;80A47+]CJ
MPNPRP^5*M2__UNAJK*_"&ZM\=F0D]6U3Q$@G->[!K!D>SY+^;').!%Q4HT\U
M9O#L<^=U 2T87.H4[8\$3V<,G(*)G4S5N@;V;2_):J\=MNNM?]SO0O?U39/*
MX*Z-7L1#C3WPWP276[QGZO6^M]4N(]QXOV2#RU9D?2MDE-[K&HP8\E-MY/3@
M#.<><=KH1CQR/IM0<$O.F6_N>?SRST]__?9'2PY=\@"P#P!'(M ,=RB)2;R*
M$@4H((YSA*!*CCI3 V<%*3L%:E*).M,$4<4F13$*3*IJ8*DP*"@O/1!-C]*$
M-RBE*CI-\%1K,M2C,#A!$<)J3J:B5 :Q9*9)R;!1:HHA#7FHPQRF_TJ(%\23
M#VN(1 _BL(=A6J*9P!2-"(2  E.,DC)ZM:3N_8]SW<C?_;X(QC"*<8QDE%\O
M0O"*:L5HC6O$'!O?B#DWJK&-,9+C'-4H1SO>T8UZS%P=_<A&/OYQCWBD(R#]
M*,@X#I*.<=3%&>+(QVKH,8^ 3&0E#WG'2V*2D'TLI"8+J<A%5BN/@GSC'#L9
M2+B\0AR]*".S$B".-+:QCY;\8S5T$<I!HM*4H:2D(4?IR5^>TI"ES"0ECVG+
M12(SE9^T8S&%F;E2]A*3OB0F(@]IR6<^LXZYY.4G,\E,N$R  @EP9;,2@$8X
MZE*4ZX3F-9,)SV)6TYG8O*0VO=E-8%;SG?^2U"0IP[E+:6(SD?<,9S!%N<]_
M^M.>UASF.SE93W&*HYSFK*A%+XK1C/Z%2%M,DD<D\( '\&H3[2CI 2E@##-8
MZ4R'PE00G>BI)')J2S/M%$U_6*<07M""B(*@$#&%)T;I4*BHNJE+A<I3H^*T
MA(/Z85"%&*F?XI2HK'+IE1(E*:EV*59(M2$1;V&&*5412D;C518]"HW_ 8 <
MW=B?1M\*U[C*=:X]:D [.'"+"91','P=3(SZJ@]^^/6-H?-K80?[5[@ UI2*
M7>-A'<M8R$H6L9&E;&4OVU@V/A:SF\7L9!?+V,)NMJ^=U6QE16O9TR)VM(,U
MP 1 8(9VM)*N/VJ#  7,D%?W)=:SY7%LZ#I;6,&F=K>[!2UA*5O:WYKRL*6U
M[&-1ZUG>9K:QS8WN<:D[7.)RUKJMQ:YV02M8OG)! ^J(@&QI&R2[1D =K]#M
M=;V[W.*^E[O$9:YII8O=Y@*7OMGM;V*5Z]_WVO>YQU6N?OEKVNJ&5KLQXL)K
M8SM;]$IXPA3_KG!?NCB7:?C/?T?J!0(&"%)>L4(941+'%$.0T@@$ZJ;'.-6K
ME$C$H?[TJ#]-4ZQX.*>=WM!/%00A45O<U*3*M*HN9*F8TI0E%&K5QR\-\E%7
M&"I9D=")2X0R2^\D55!965,UW5.6/F$&6YTT2F5=0.F6E"1W-$"M)["PF]\,
MYSC+><YTKK.=[XSG/.MYSWSNLY__#.A Z\BM'/V?1S\J@7STJJ3MF!(5*< !
M,U3IQ:V:\9PNI4$E3LK*+_1IERH%ZDT#5<I8!340<6S3G"Y*ATBFE%()-<(A
M8Y""F>YJC[&$94S=^DNB=G6H9]WI5DO92F;@@*U"( Y<E70;6$1S_Y(:L.8C
M;1@ ;O6BH*^-[6QK>]O<[K:WOPWN<(M[W.0NM[DE7&@D>32+O5K -M8GI4>C
MV QF^ 253]U!),9PJ"Z44P59E4(86U"K-W0557>ZU$KK6E$Y;/(,*WWKG?K0
M4/K.L1)=G.D;MXJ%KGZJJ6#M\$ !6==RBD:QIV0,$Y^4T;UZP%F?_3\,S\6M
MYZZYS6^.\YSK?.<\[[G/?P[TH L]HSS3\!8_G*2$$%#$)A7S%#E@# 5R( 0A
MH)654(UI5J%JA3+6,L$?Q54MA7VFE-X35*DJZU]7^HBF9B+9J[ID)-+XX34E
M%*+$?E./^WBJ<<HZ49-LI0@4.P10=WH"5_F^JV8[.P'1)I(7\]>-H4L>Y[X(
M@!PJ+X?):W[SG.^\YS\/^M"+?O3BR5^Z$6 .:*R;W;Q"QR9&/.8I)M#$QC V
MU#D@#@Z<P]BUS_V4IEY[W ,_]R@F/J11;'L.V'[WOH?T[Y_O?-Y#W?>VK[TQ
M0H#RXNL^^LW?OO>C#^G:.W_\WM_]\:^/4MTKG_S05_X4T8_^]4,=Q4\//OEM
M_W3S7W__XJ@]\]5O?+T'?/D7?@%8?\L7?M(':;>W>\)7?\27<L.W??#G??+W
M? BH?.)G#,8 ?B<V9BS7;EG4$!YU=!@6>:2'@G\F!P' @BR8@B\(@S$H@S-(
M@S5H@S?_Z"R$]C_-<&@BV"OHP"N,!B4GA6RX4H0*E&S"AX3&AFS(AGZ$=V).
M2'A4U'_(MH0)A&Q35X7$MX5<2'7(1D5-F'MCV(1,B'M49(9;B'L*A(8J-X53
MJ(77ARM3%WU@>&)FB(9A6(5*^(9:F(5(:(59B(5Y&(542'@F9H3R9BM:R(9W
M.(9TR'ST=X>$6(:&:(18:(91R(2"J'Y4EWM4*(=RB(6?6(:(>"NXXF@&!"7M
MYBM9!"S!,BQ'T@V.-W-S86TXB(MPU8(LZ NYZ(N_"(S!*(S#2(S%:&>1ES_[
M, WR<'0]F$7^8 *]P@KH0&8&=$!3)%8'="L>Z'2&-R6'YVA5_[2-CX9 WUA%
MYYB(5$A%X:B-CY:-XS@EW_B.Y8A V$B.]HB/UWB-;JB/Y:AR['B/^GAXN")F
MCO:-".2.^GB.8G9X">F&V<B-*I>0BGB*V$B0]CA[!9F0]JB-#6F0!:ER!*F(
M'FB1"LF0582*JEA2K-B*+Y< 'O8_QF*,,TE&N^B"-(F3.:F3.\F3/>F3/\E6
M:]51SLAZ[2:$C*:*8V:-2GE 0[B4!Z1LB,>44ZF43DF5']B45TF55BF56LF5
M3ZF559F5(OF4VA"69PF6:,F47ZF6;(F077F5\2:62IF*6$E6[; )RL *),62
M(CB"P6(.6U0DMDAMA?F3AXDL-AD B/_)F(WIF(\)F9$IF8"V/_+ 5N30C!ZE
M=.P6C:PXC:^G#$=I4J*)E*4IFF1VEZ2IFJ.YFD=9C:U)FJAIFK IFZP)FZ=I
MF[/9#J%YFZU9F[T9F\#IFL#YF[A)4L-YE,<IFB,VC=/(DB;@EX>V9@U@) C0
M9D0B#R<XF=M)(XK)G=\)GN$IGN-)GN59(Y!'%^1@=)FY>EGD<B+%DO$IGRRY
MER*F+>C "NV6GPM0G_@IC0O@G_PI8O\)H/LYG_RI+0AJGPNJH >JGP4ZH +:
MH(M&H/D9H/79H!B*H0SJGP&*GPE:9A#*BAYJH09ZH?,9HAF:H#^(H1^ZH!BZ
MH@-:HA'*H@$DVFY V)?Y$)VX<&@(T'A&LE;I:9Y#2A<VV8M$BJ1)JJ1+RJ1-
M_RJ#UB8/V8F9[+ENF[DD(?4 ^:!H#GJ@6]HD#NJE7"JF\^FE6YJEO5*F8SJF
M8;JF:<HK;HJF8*JF<TJG<-IN8>JF6\JF=!J?(A52?IE%!'%H,/D_;>9%;>6D
MY%EYNYBHC>JHCPJID2JIV)8_^W-T"  -YG!H2F*E@/J,2P*=( 6=[PE2(NAR
M?DFJIVJJI7JEI9JJK%JJ.BH!K1BJL*JJ?PJKG^IRH=J*OD*J[NFJN2JKP/JK
MK>JIJ\JJJGJLGGJKP6JL?MF2J1JJHPJLSJJJ+2DYRYJM$G!FK]JJWJJMGCH4
MFYH E[I6D8>=D[J=WJFN[>JN[PJO\2JO/7.H<\%1'/_V/VO&>.1:$,,3KDNR
M#O_JJ0%[K 0+L =K.@*KL N[L 1KL.'ZL PKL1.KK0;KL!A!L1D[L'X9L1!+
M(G^YJ9<J;3QSBX8YKS[)KB>KLBO+LBWKLB=K;8XW#?L@LN7*KS=[: 0A# FP
ML_PJJ 7Q-A[5LSF;)$/+LT6+M#A+KC_;KTGGLTU+M$K;KSUKM$SKM$<;M4K2
MK_$0M%9[:#LK %W;M5LKM5 KJ#]+M45[,5!;MFU+$&^KM$.KLS?KM5A[LR*+
M ,PXF)Q3BR^KDXO*BWXKN(-+N(5KN-S9/\O817C[81_6#*H70+V@M +4MI6+
MLY1KN9FKN9.;9ILKM0'DN?PLRH.A>[.4"[JDB[J8N[EJ]I*I%XN,RS\ @*AV
ML3_:>;C"F+*WJ[N[R[N]Z[O_HB</&A:[7G1ZC-MX6Q281P)M_Y.\KYMZJ)=6
MR1N8F>JCT7LDTJN\S'LDL8B]U[N]V8MZVAN^ )2]U#N^YSN^KQMM:Y:\C>N^
M,-F]T=:^_^-AT^D.UVN]X_N\"'"_U7LD_5NN^KN#V<N^WCN^:Y96RXNIL1C
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M8 $)M-P2Y0468'FGIZ46.VRRHRY[;+/31GOML]M6VVVFJ>; :JRUYI)KKSD
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M9&5B4':./<92EK,L7A_'* %8TE*7NYRE+2N(2UX&4YAQ]&4JC1F:CWQ1'@@
MV&KL,Z40:0Z!TZ1F-:$4G76QQ8=;) @"NC&-_!U3G"=Q%F(2\,)AIE.=,N1
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MU5K,CI$M69(]69--691=695M699]69>-69B=69FM69J]69O-69P]V4N-H)8
M)^BLQP0P0U1K4_\T,>2L0Z652J;UPS7U,MII2!O=TE^AR(((_U)XB=@SF5BF
MZ-@(PUBO5;#-"-L%"P^[&;!*1=M(U52V35NWI=2VA=NW7=NY'8VXI5NYS5N\
MW5N[K5N>Y=N_[5N]%5S 55O"/=PF-%R>]=F5&$]E2X"B-3<':0O'Y*:D/4(2
M%;FJ#5C_H]Q6\5Q6 5TU[)!\)=W*<3_1K5?3W1S4K9#@BZBOJ[-X?8O:3$,5
M99=P$X@1, <$U5J)70Q NPJR+2^P'5[O&EOC_2[NBJ!:;%[6)-F!@][GC5[G
M'#OGK5[JG=[KW5[IQ=[IU=[NY5[J%5_P'=_P/5_S3=_R75_K15_VS=[V35_O
M1=O%70D565?K@ ;7G)-QNTHS33_;O;%*<63/RVU:)^E+;\P0+_55935:_4S:
M6Q6(!WC89/+=,$E$K "!Y,VNS-#@#<:NS?#@#Z:M[=@6!-B #M $&[ !</@
M#RB <2@ #_@ &&[A<;!A&99A&I[A&OZ &.;A&_9A'>[A'Z;A("YB(A[B(U9B
M' ;B)C;B)TYB)Q;B*4;B):YB)J9B*-9B*=YB*X[B*_;B+/YB+@[C+CYC,T[C
M*/8 &R@"3>B >#@!_/6P9?+*)KS_XY*X3&4S@:/-W :^RR1)0'I]E>/4F($E
M9!$KY,HZY%E19,M5V,B-DE84Y%L1(A=55DY98(,0@6M%@!/@4^6S8!]I/N$=
M81+&#%.N+>1-9=<R6P#8 $UXX0*@X5FN95LN !BFX0_095S&95K&Y7'@Y5X.
MYEO.Y6(FYE\VYF1&YEY6YF9FYF$69F"69F>.YF.F9FB>YFO>YF7&9F_FYF?^
MYFX&9VL>9W,.9UO697"0Y0_0!!((4G*XS,1-B8&SC@0 /#8%Y#F5C=\;-YES
M."%0/Q?DL1Y"$C4ETS,]: >.SZ=5$&I5N'PV5O.[K!Y]$%JEC>82MX;8A :H
MS(X(95'^_Y%&Y#RK8.561F631JU53NF\RKZ0( %=3F9:_F5IEFE;CN%DKN6<
MIF:=;N:>;F:>#NIB_NE>%NJ='FJC]NFD!FJD;NJC?FJE=NJHAFJFINJBENJH
M]N6B#N8/>.<@'=F0 &F/4!&Q<P<$*$]&UM'.D;]DW:9B[2@IT=5+EMH8I=&I
M?=$9+="(4,R[?DRYENBVCF3_U(*3) @\Z.009<*0!A*N70J6SJO@O8S'ANR5
MGFRVBNSLVP ;F.48ONITOF5AQFFFUFHCONK2)FT8-NW41NW.[NG6YN77KN78
M/FW75NW97NW:9FW;WFW=[NW<_FW8YFW@EFWA#F[?-NZ>GNG4%O]F(;8!K\;:
M2L.\D1@9Z^B%>Z9=B"A"8B6N,_5C*[K=!&X== 1.\2;O;!3.\D9OJ]V5((0\
M1\80M79/3=/KIDS86?$30NB%7H @S!/KQ;Z1QE8*RYZKXAWPGJIL ]^IMP.)
M#@"'J.[L#P &G\9I"??E00 'T89PGR9NIFYMK?9P#K]J$*?M#W]P$^_P$Q?Q
M%"]Q%&]Q%7=Q%G]Q&8]Q&@_Q&B=Q&P_Q"%=J8%#N9M8$!.!=Z!:,/&9->S82
M2^[C&R-@5+E7% VNV*5O TX2PL;N!L8]O33HB:"Q;UG*&3WL3HYGQ?YO'CF[
M4D[PG2(ME$;S-$=P-F\I-?>,;MCLJM94ZG3N<<_N;-'V; \8!&D>!S^_94#_
M\T#_Y4$7]$(?YD0'YD6'X48_=$-_=$DG=$I']$J/]$M7]$QG]$UW]$Z'=$VW
M]%L.].2V<V#6Z7&P@02 AD[N_]V2*)1]\#!S6"5\/LSU_NX_W%&&P#WX>[E6
M_)BNDE92 7:"$797(7:$,G:H[>,"]E\;%)@Y9#@L=U>!"(<$$/($)?/VP."K
M&.DW;ZG,\/9O9ZG-$/=QSZ?/T&S3KO!9QO/1'NW7'@0-QVU>QG#4MO>>QO=Z
MUW :UO=:]O=^Y_<" /B!%WB"/WB#3_A[5_A\9_A]7WB(;_B(?WB)KWB*AV(0
M'W%![V4;,(%>: 9H&'*09A&AA=S^DX@=2V#]P/+HD%,-27E<+P@A\$0$;A I
M(;<#O'F-P7D%T?G*XOF%O>^/ Z)V)59Y115*SFNW():EM/95=W5M+_-%*>ES
M=ZD"K_]Z=.=8K"=WQWG.S1;J8J;IGU;N&ZYE=X]A0-=F1U?[M#?FM7?[MB?F
MMY?[N*?ENF=TMA^$O-][N-?[ON=[NO?[P =\NQ?\PB=\O/][Q1_\Q3]\M<=S
MYE9M7(9\H/X 8>@%=VB&>HSGP-"=9=HSZS;Y"T'8B+Y!@W9RKSJD_$C*P=*+
MBI[RY5R24K/Y]MMU$B50W)7!PALU8>D4@1" :X<@;;7"J*^1 $^*K>=ZR4Y^
M?7)SYE<GS["!9=[PT:9I=Y]IO9?[S\;E%_;Q[K?S[[?E\*?E\>?^[2__'/;^
M\U]_]6]_\&?_]W=_\8?_^9=_\J?_^[=_\Y=_HH9P@ #VH0#_08+C" XLF+
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MT;/).9.:K:^@CX(5"; EK7/I,*,;+5K+*.Q**YXT:!+&S@5T2922IC2G-[,
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MG+]L"7B&)^B0YT_2179Z8"I"IQQ<Y7P*QY:6$)=X:<:!J4]VC *Z3V=TY5Y
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ME_1T",6YG.?SARTZ6^;G<>O%=.8YR][VG\\NGY,>"]*%/Z0.-$IE3NL%=PJ
M^T0ZG8.@H NW>I>:6Z)QQ-CBIFTZ,#(Z7DRGH=^S9\QY9N2ZG(JZ1I#ZFP?
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MG 0K'5>V;%1H9IR7.5_&U51I20$_Z4+M*Z$N@&D_IXZ\ZQ/;@LF ?;;^BC:
M6I)M'9<<X=2VR 2X=;O^.5DPT=)?69]-6Y@H8KN=E9ND_53E=>K;BVKV;I-[
M>,Q_E2(?^9BM5:S21?IK[KIO[-D_L156S+YQ4J;)E08',/RYW8X#C;2Z:/,/
MP-R@^TDZ!"SS;ZOQ4M).O.V^N]"ED#[XH( "..SPPQ [',=#8$3L$$4./TRQ
MQ!--NJ #%#>X0*3_&#\P$404=3SQ1!([]& 0'CO<@"051]1QQP)\%#+'(YM<
M$LEQH#S1PRJM_- #%D><4DLC=?0QR!R]5'+((JWT$4D92>H01S335!''%9-D
MLDH.*;AS@:PR2L K<NQ" !J-)(#HHH<F*O0@BPZUJ**'&BWH48<B+4@@(1"]
M-%%,$5UT4DT]I:BA3T4E--1+2UV4@%!19?3252%2=2!7#1VHH8D6+?6B)G"E
MU5*,-&H @7T \!,D#(T]%MEDE5V6V68O-$8<"LZ1UEF6PJHP//-$<HJJ:P,H
M+"RW:H.J*_Z2JBL_["![2S3@=O/6)VT=] E<H@0@:;1Q78,W 'F)8HPZ___2
M[7>E@;&UK%ID^3V8,VT!X%9 ?1.[BJC4WA-)F+?0E5 D@[LC*9Z\D-KXXW4%
M+GG;<M?]EZ\!]^7.801$5A<E!!9FN+*$D[T9Y]Y(6H?G .YMF=YW Q 7*W(E
M!B!CI?S9C6*7V0I::I&H_I9HEDT&6.N4BU[Y)ZX)?MDQATD29N:P5;*YY\YT
M_NXC!-Q,\\PFZ9:S3B3Q/J&D&-.\X (MQ;2RQ+L'=Q))OD7:($DRZ78<[[I#
M!.;)PPF_4G+*N\P12A8_1%/(+!U?$L<.:5Q<\RM3MY+(D>R^T<BY5S1R=B=/
MI'P<"MIA)4\)XDF@&:^Z^;.J=09U:%%;)2VT(O]8$7VTBTX).'351J6?7B)$
M<;6^H%VSQYXB2C6]/OQ<8RUT(N[!UY[\BE!57R%-927H>O)'I=^@^._''_F!
M)!B!3P@@!SFZ$9+AO0V!"53@ AG80 =>J&V=<1C$C*,VYAC%7U_K& 6G8Y3/
M@"TI)6E:4K25KJ!44&@$\LO*2FB4$[*E:P#P6%+D<#(,%BR"EWG@3G+8,!5&
MABI5>QC28,.UX,R+AA$KR@<WZ)07"F<N2HP.T>2@M'A)48H,REH& Q:AP:P$
MB3UTX@Z'(D;'5)$\2/'%"+B&Q@L6A8M'=$H)B;@8%);GAT"\HQ;7Y48H5BV,
M6?2)=!3#12?N)R5AM&.#(LWXEB>2<28?V5#>8M<D.5W2DHU+4@?Z%J7'#0EP
M)-F WT3$20 $K@ =:)U=G&&D59Z$<:D<2>",9,H3=$B5L^Q Y!0' %*6:7$%
MB!,H3W=*QE42<[B<Y>76A"-3HC*7(H%1CEYIDE@68)6,\Y$H-6F[RWT31*7[
M4)B:="=E]&X="7#_1Y_(@0!W)D 8QQN5]];W/$C1"E/S<P@]4R6J6F4*G^@C
M"#^9U[]9=<^@_?040957/D?M3U2RFI_THI?/\SD4HLTCU/?N61#?-6.=W2!6
M2"!94I.>%*4I56E+&OF6H8TD:'[L8-+,A9Z':9 M^3(*A%9"H:-8\2B$B4E>
M9*I3_X@L-=:R8!,Y(["%I:VEEWGD2ED2U;E,,#2[R8N!CC*/NJ"-IG\Q&$^S
MX[.1Z/0H9)V0$+U5EWA<S"5OO:)KH)JS;@45*'FMJU672E67\#6$:41*/(R8
MQZ7=-*Q?,5A2*>-2P]J4);1Q6%M!!M>6R'5L;-GK3EFB2+'D];.;!:Q?_U4B
M++L X),ITAR5O'2C3+*V0R6Y)HDF5TJ5H-)*:RHF2?Q6@)7$\I4[TNU);%0E
M4XKD2<6\Y8HZL-M.:JESO=S :F4YDEW&UG7.K1&*?LM=ZX:3FWJS9.HF1TF]
MX0@<M$W1G=JQ@ =((".]* P"S)$  <@3HP'EW_(8LD__WH^?^DQ>0"-%/GH2
MU%08Q96K*BH^CEX$5?I$<#W[:Q']Z9,@G+((KA9R*X1B:B'D2]]#+[*K"3]D
M3^X<X+!(VV(7OQC&,::):%O*1*\AQ8J&M*EE]RB9F(PP*8],@&AE4C$E:HLV
M,F5I7V>8%!L"MD(R1@F-6XK5P%[PD8M-XW*\2/\4LZT$R%?^(U*^7-;#]N61
M@RGS6GU"V#U:)C6>A3)UI)P2*C<2J#?DCXXM6R"4I*O(;[$Q8LD<DP-Q+<U
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M_U7\5FBC^'GBYBN*O[12GW[+%V+L;[C"HT)5NC/J7^@K%/W_1'A"";(G/IW
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MQ/7HN]!9#J%%(%GYZ!M16_9>D\!;<5L\]L5QS:.V6>.N_2K#:!'J-KEY$$I
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MDO"GB0AC&\F)-6Y%D' V&0FUC$ VSN0M7#S4JSG< AB_<+R3<@LB'Z1.=*S
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M..UJ@CH\"%!&*73U3P(0 >?MBUI6Y6B]5N<ZB_M<0/ITB,@6J74-E?]35X;
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M6&V3(?*\S 72=%#,"%10W6R?^5!%.U__00^B AE6.XPEC"@&:1\G0$ #HOC
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MS$\N#;3+&O45_W*C=5 P8;.@O_9,L6 S[>8X*=N/&+8\'[GM'B$;(NWZ=CC
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M523>>(4$X[0B(\UE<]A:-0I>I#T)+-J6L^G:M;'B:HF:9?A>7$8)7-)C80)
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M81,");H!> @1@#R(#40DO%@08Q<"$1^60&CPH,&-&#&&/-A$R\"%(!&*Z C
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MIHM]["J:4S.NVD6NDBQ[RD:)S%B^=D^7^[E2X?&-"?H\GQ. F/\UMVU7<$P
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M#AWT[425-K"U_9$3"ZZYU8K +<2>12#!F^BOZ3"X733Q[5N!\P67PF8*"&K
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MY/6R7^G3J%Z*J4EG1I&SFC29S-QG1Q[BOJN"-K2B'?_M7! P'@1 XR\S.A&
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MY[Y4-JR0B0NM<LW6T 1*/<M^BJS2,N^_(/6N>O_+3"Q) !>6)(X^:697%J&
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M>43AI*D.?UG$/%D<#Z:#.HB#]$E33%#6\<44I="40V C%Z@+9&5)._1@!$0
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MI\JU0\DUB4.\0E;UR0B(K@;_*/GY<B_ +05CJDMT#IWP \0Z 1($#!20@*"
M> H+"A,HP"%#B +C(93(<&&"BOKT ?#X$61(D2-)EC1Y$B5(?=4*2EPX4>$Z
MBPD=QJ-XLR'%EC$3/'P9+Z+%F 47+O1)]"C,EQ,M+B2XM"=&=Z\,Z!.'$6$[
M?56O$E4HC(*ZE?HTA$@@;B6%H@S!BN7XRI=#C0<GK$Q -$$"#=72J5,886Q5
MCAS%+>2V4EC+!%KU^05*MVK.@@G2'GP*<^[EM0:QZK08T>9G@9I;+K6IT*+,
MRY=A)CPMU*OI@@2%2:#<,65NW;MYC^3(T+7.KP+E$F1=5+7+A\491CV]U/;0
MY\[OA,(6@ NC2Z2<(T(<F(#"6\D5ZQK0<-=E G4:!H,XR$4?E]@/(\!?&2'$
M1;=^V:)-&P^P:@9;29=JQ+$-K6I\P2N!":J:2Z9VJO(KL80 XP*AF4 ;:D/4
M7!N*IP\3DN@RZF@BJ"GI-,())Z42^XDBH9"[K;<:;;P1QQQUW)'''GW\$<@@
MA?_$D1P $$  F@1&D(" )@AX$DHHNXB2RB>GK)( 6K"LTLDMH]0RRBZ]M!)+
M,)LDX$HHS1SSS#:Q%!-*)]-D<TXXT:1R3EKF9#/*/>/,DT\L <732S^W[$*(
M)^T,E$H[UX3SRB[79)10/B>E$DPYJ5Q'F 3,.1* (H<<E=1233T5U5157955
M(#F:*[98">(TMKM^\LJR@M99:U==;Q7F5J<N<@I8AGHU=C-:C?55U\0$4D?
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MC[5&*8%NJ1,\T<O70JHU+EM1H"YYJ0COB(8U[B8L 8 Q@+3R@AY_782]>1.
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MQRYX(GGX0RX0U)JJ$].6LB":$T"!402OZ)J2"3Q'$"=X93SD[T.&IL3@KN1
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M/HS-EP8A-+R5V@L[&SK.5$6+6E?9D*;1:6GV?(.<C<I(3.U+@/U*2^ "&_C
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M:HH#@L#>60BH:18HD*WF7P@#4!E .Z22'.$&Z:&)YCI=Q^!-!C E@$*EYDF
MP)-BPV>:A3S]SZ_QTF 8YY55@R^(%5)IRDYMY\Z12=RE7MD!5.)P"MO=I:5>
M_ZIQT8L$NHK";((39>4,KJ 1'9R[->59QA8+FJJJNJ6WN)8,,DL3O*"VK!93
MGJI9&AP)>LM2XA84<6!N'<L#M$NKD$,$8JJQ'BNRY@1W.!/%3,^%E5C]S&,
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M*\NPPNQ N00@"ZS.*)H0NO$JE,VEP53KT,,/00Q1Q!%)+-'$$U%,4?]%$!$
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MH_^,FGU7Z]]4'>?+M;;UK7%=D!:]"!J \0=:U:K #N)UV';*7X\:.U@0\DB
M2;+KF9KM0<<Z<("$[2L%GQTG*!U6KEMBDK<-Z-<2(A9/<0(3!QDH;F4OP!\I
M28 Y7C2-?0" '-W(];WQG6]]E^@H*HT)&:DC&ZQJ+:M<>613H=H5G5 @ASSU
MUT>QEJ&JV-&@>KM*'.=XDZ985!N?@0M0HYE:W'0$/--ZJBGM,Y@W+E$K7E1I
M2G#91$@J32[8T59/0&Z2MF$C-$O!2@*,>91JA& T-GUD,U5Y(2M#!SYF?&7
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M<\HJ&8M:^Y"Z81. DW@+(;GA)R+ %T+35HR:K[E 6>1Q6N@P<^=KJVE65KB
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M&*A"=0 "=))R%$CF+D<30GBC5XHQ3J7$+&!E$.3&<)DT0JB&<?J&'"UC )^
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M2MB>S"E<#<.B3LHV2DI$_?57_56='G8J/QJDNBFH@\I0M&DIW4 ."- +>+@
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M],1)BC$^-L/2=<%(_TB=41B%,B>]4]C=T_J$:U.=*22%&,9]#5:"7IC$H94
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MSW[MW_Z@60G.-QK/#^^*?4"%"X%S>-_C(#@#@4=V#CC<[[\$%27X!I#\>(^
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M<U( NNJE6#9G,!NH[]HIG;JG839EX0HI\DIJ(1NNJ")G5YK ]J8GT%HT.%.
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M6U%F!JCJZ292QV0@'[\<AHS"PO!3,N.XV?V3I)$RL'ZDHZ)UESV<S>T)-[A
M+!TCZO$[O[6WBA>VK+Y3-"@!MQ+8>"!V^PV)=9LNA:ORLV22V5/? YG$B!4L
MT<&M5OC#F:M"9PFNV LN_:+(GQ0H+#LYB%?70U:HF#(LD(GI:A-2C_YFY:S(
MK&^$.N$<W5A5,109!&0BVTQ(EO86B:VO/[S8"]TJ)#F"L*>";/N+0=ZS...1
M:('U,N%'4$CJ+*+]3H+I0:%U[-02%.;$(!:"8,)^UY[X"81^H.(44_ V,0-R
M"(35.J"HQH*XOK@/12[$RT%T(AB,?(M"<O$:#\\BE#\!D5WTVII)BJ@0&L(E
MB(*4V"*A:!GT^7 [W3N8?T:E(JB4QAJER4-ID!*;IRT%6_C)#!S]5J_4!+(F
MB4313JZ7D>RQY89O@: I![<V0<J'CF]CX]YV^;)<B<I"_L*(1< "1_)=IH_1
M >7@4EFS>@DD)'8\8S/S!QN2E.5/3*%<Z$ZT':)IJ(N-J5542(>L_O!,(9+4
MG_!ZUTYWOA.>\93G/.E93WO>_Q.?,0*=Y^!",TYUQ"!Z,AM)@.60D?Q&(Z]9
MW_,J2:S^^)-JIX'(J,P$JL+@;2Z&2U!!RSB4@IJQ*F)ZI)8&E:_V<1,NESP'
M5WBQC2II#E!O EA"3)HKA;Z%29P:9>@BAQ%L5!)4'S7B$8V#$8!!T)MED6-,
M!XG&O7"  8P9#5LZHS6'Z$DCK.(@G@0*J@^6BGHY RJS:(,;@)61>E+Y20$S
MI<8686XL6;7A6'_CFM&,Z"P]2]=%CGK2L4!TJ*#JJC6]1\M=UG0H#V1<2](#
M+:A09BX#.R6\HL+%8!Z+ BLE2$M?&BB)91-;U"N>0_5&F*;&$5N(F<A,'TL>
M=^556?][71:RD.HUP%(D#\M3%6WI!-0RXFVD@ I:Z.*TU-NF* \:@(KF-* !
MMW *:LO,FU/51MVA8F@X-9DI7#(PT3)-]*)TG55JTW9:UPI3(5"-SS5%"(#C
M]L=PZ$WARH*U'5SQA"N".V^UT,(Y&29@N_W:[FD5U"5M<J6CW20N-Z'*NHZ6
MKIRH$JO!XFO:?%X8PQG6\(8YW&$/?QC$+9+8^]PSH )?I2.)PD8>F%8LFOZ&
MH4))4%*(N*?Z(,U*%W&-UY244;WQ$C+8!"%1"3M!D3H2R?J3 PG9JT(68:"Y
M28DROQ;+%T3N;RA7&52-)2>S%,]D'EUD*U-G7"\)Z60\%KG_R@/FRL_RHNQ8
M>[Q(1Z!!(JA\U8)CV2I1V:J16A6Y=+&424?S4)8ICGC,Z4EK2'^,HK\\E@%+
MY@X':C.<Y)9!0D%4DFRMC,LT>\T@WOD.^^BKD @$LFS6,3261ZWHLS 6)K_9
ME;NNB*=$S5J2(\9)E&G27"KW#*1,C6A"OG7>-2J$S2-)]HJ6NC)VWNN\U-Q>
ML F;&$^K+=0XKJ:U]3<>1CI'2<$%VFZ$=B[QQ="G&%!&7S:QR9^D)QW2A=N(
MU#Q;_R+3L%[=TV:XG2)QZ3C'8Q%TJJ>)TJ9J+1W6R Y/:?QL4@.@':CV)#!_
M*:KQH)"4/NO>_8#:(HR=^6=SZ??7_]CUY8=SAS*8&?(P0_=-BJ )K Q0P2[?
MO)DX!3J<148V=4+<<Y__'.A!%_K0B>YA.70<JB#;%,E[ZI.!5"E4&.HN3BX"
ME=_\!6^M7<A& +ARJ!2:5);!6[=@#9=BHYPM%H%N8>*TEC'UQ7Q))NE;$.N3
M$6V2?]4:CVI64_"6& 3%9:F[0LYN=9G<=D$N-\@LS7UREH]%ZP#@1:,!'Z:T
M^V_K)-D(5%HB033"UL(6/E1CQF,"A_4T)%PU8-/S-!.8$]LI;A=6Q,3KD$\B
MP-Z[M31DD[(@:&GDLJ^>">;\NYU#%<:MQS\0+_IN>9, E?GTK?RQ+A\SB:>M
MZ3HG]D8T(/\3V/H$]P-U2$%;Z63N>%_X10;1:))2)SW_&C(RP5#A[M9Q46%@
M[PP9#E,<:^#0=NDLVB1,4J[J-L/'[BY_Y*BYNNPMH ( YH]Y]&@@[NSY1B3Z
MD&CZ*!#;KL\G"@,J&",#0>2W?*N2Q$WEKD)N.N[[."_^*F);'K!:L,'R N>3
M?H8D^J(CH*PV1@3_].<JO(*,FH2__FXW*BJDP(Y]Q*[V+&A/.J_*,*+!J$Z/
M^"GR)N]XRH4'O::2N(B?XL0BA@/X(&,\RJ]X].NU[,2_KJY)+,P!:XX( T^M
M3 (#NLHB\.5. D7M.*/XO.8+M6U9WJA)H,IYGE#V0(7V#";K#%#_/[ZOZ!K1
M$1\1$B-1$B=1Z#R&0DP"9*Q*(V10K1A X9( 4S!/\UY-0)YH)$;LB4*EZV8N
M@A"J2WK,YAH-F=C)$FZM>7AB=6SO#GV(J4:J>)HH4?I'FBB"S3;#ZJ[$\]RB
M5W!)2F(HC]ZBZRCF+*@B'09(S-!M%IUG&4]$&451,QJ ;JR%C\;"\_P&<0*I
M<KJO_M#"'4Y.6QRO@]ABS%3'&T$%+?9BX&IC%YD,;I[MI^+J'AO/Z>BB4DZ*
M$VW)]G3J'H\)<4Q$)Z8Q))R#'ITBWA2B&P5DB')IU/1MXEIQ7^;(K?CQY%)Q
M."I' L)'DL[Q2WH%?G!)^/#C' /)LN"B_QA;XAC/J$ZH K08[1;-XB-=,OV8
MYRR&L1-[DH?VXC^2R6@>HB4'Z1Q9K(LF$@ JLBUZ<@.)$BB#\B)+LHN^K1?E
M[D\.A:H Q%_0HCAB\L;$QWX$A"I=0MZ&XB-U2%0XQI H9#P8ZBPDH"D!X"*Q
MD6C8[A6["(7&,>0,CEHN#RU2)!5MD0(JIU8LT3EF$B/BC4)TJS',DO#Z"XDD
M2 ?UAQ5Q$3.O,"_)S&OZ4K5HD0;SRI?P(RF=B5KRZ$3Z1P"7LN/*D4+P,>=\
M@BABTB89D1)_$SB#4SB'DSB+TSB/$SGK"<Z2TTBLJN(<CSFC4SJGDSJKLT66
M[L/"!TY SCJ[TP@[OQ,\PU,\QYF3/,O3/(]D.<^31L;L5!I#/=\3/N-3/F/'
M.34,CIIM/O-3/_>3/_O3/_\30/DS/0.4Y4@,KZJ)0!-401<T.NLSP]Y1,Q"4
M02>40BO40B\40S-40U=D0!GTF.P#&S=41$>41.6)RSZL-0VS1%>415O415\4
M1F-41F>41FO41F\41W-41W>41WO41W\42(-42(>42(O42(\429-15$F7E$F;
MU$F?%$JC5$JGE$JKU$JO%$NS5$NWE$N[U$N_%$S#5$S'E$S+U$S/%$W35$W7
ME$W;U$W?%$[C5$[GE$[KU$[O%$_S5$_WE$_[U$___Y1).^(@[XD]7T?7O+10
M3\0@*.U%$O5V'!50(U52)Y52*]52W8ENL))24 *JNF8D?LI.+@LN,,>9K"Y$
M4^3H[@U)2+521+7)=@2N9.2GNI!/8 >/Z#(A.A4M0(Y"SLSJ;K-%?C4T'1%2
M,>*X$H)5R1(ZB014<Y%%BO52HU5:IY5:J]5:401P%H98#HT$N5.&'*XK1@[#
M$BQ%H-5%.M1W+BM.-.(SCR0(/S-XO&4\E''8K,Y5K<LG&+41S?5X"FEP0D)"
M^/5&5,,XH&-%!/9:$U9A%Y9A&S9--<(BUBM,3.[%L&;$"M'13D+B3@(_[>E0
M5^E48P1=8]/^Y*L%D>0"_=T%IF[KD AR/,Q'18?-$!\18;$3(0%J69$D),LU
M9!W69W\6:(-6:)54(]"D79-E6Y$EP2Q"*#KB:#7#+3"E(YI!4J:Q,0ZR+KA,
M+#RF:LY,,LV#;OHB6WW'<RCE+/25(V=K6,5"(^".0AC5;*U6*$'.; /@8^?%
MY9Y/*</D)_EV;Q7S";6&K0S"8$5K-X)29OM-6%$'+=K5$M/+(QQ3*1@1;.5V
M;/=M;VEF 2J'<?-*%2_Q\TZB/O]B4$JB<;VG;V/%-WGH:5OQ1'@H;0D%+=#V
M5T-Q=H<6=W-7=W>7=___,RL@!R6(Y:QRSL*.;EM88CO CBGRH S"9'F^17,T
M,*<(XNAVXNMX820TL,AFE2!(M336(D-:-N\L) ^YXP=AJ9*8EB! I_D  *J,
MHV,6+ X) JJ2 H_49+HF1"@2ZF1O0R:B4"DXY5LN:VKD2W SL4G2B@&6!W%Y
MD0%T(5>;!&<E(^4$X_O"T&B28E\T6$*\5R>R"@!\XRH >(+_PV[&XEM6$D3(
MSE\$IB=8:.':Z"T2\_P<XN) ) _@P2;D4<A"=JF@UV@N;^^BXC8D;<M<LW>3
M6(F7F(F;.!*S(MM,PBF2UF+M;]$"9GW8K#26:B[<KFC?Y63S@S]BD>*<I#;_
MH$L6FP)+,'(S"JP9(<-;(0G4@*IXSB<WM6]#M*:J<M/ )(1H+BL("^-$+<Q[
M>O-BTMB'- )_"0<G<+!D$Z0LID\I4.QWRM<GT-C%I*(O)+EX9 :&"$)Q &!C
M[ 8O_-78U-<>&YF[\J)FW.=CZW);/!E*V'@E/8?QXLN)<UF7=YF7>QE3+R(D
MIZ;UUKB*+>2*L>/LK&FI.F*1+4(C"@,[1W!$\(8+U<8B8,J\RCC5EBVH,(AM
MR/55M>-[4.)/P'E>-H2%CZ<T: 95[DLSF.V"9B:!=_9XKB*M<!ES4]>=DR4C
MI(8V:F)ZP5B@Q7DLM N5+@+QHB*=A86C0H<7=(,Q_V.8?@^7!O_K6*PE#R X
M(=SF1+YE-A5BH;M9C1-BV>K7R+CRSWQ9I5>:I5O:I7&$/=17BZ&36QV2VBRZ
M#.@(PE(+T796:[L2J/>W_F2,#XLZI5/-F&:XM_@$P>Z8J/Z"CP(2A3Y6G7@I
M T N)+SC<E.4A@'7)) 2#1D-7Y'H1':*4[@:MA@OD\6).^PH,(Y', C:M=!:
M5Z:GL@2H:CZ&VJ)X0BCD2N2ET>:B<D;13DQY0NX-<D[JI,N2+6(2-E\:LB-;
MLB?[I3OC+M(C^\0/V$Q"5?<+(D3.,J)Z1'Z5Y+R-!*=Y"^OO->2ZNN#F09+:
M^WKKJ!,L;D$$JE-K6LQ9;U(BMI]WJX62:=9>A"GJ,"%L5BV+0X'):]CR-K@1
MXX-0!3=NZ[8"FK6WADG<+!I-EB,S;J^O+ST!.S,?NVJ\[P7SKKP3^YW1:/^2
M:9\IV[W?&[[C_UMWHVM!J-BU$5+!)!!$.F@C).:9=P-,O'*$OM:HC8T@7SMT
M*@A\2G:^.@+YJH^LQ_IN]28/%$[G#,*F084J'-2KG4^@6]%@#+>S?2CT.%".
M2(N0^A6NK;G '?1$=ZHXRN6H/Q<KOSM1J#+RX,S/8I?$L!&2JTN50.51IDB^
MB]S(CQS))S4]DG(VA5=I.X[].'2&^F3N_JF23(M_W4N"3[MG_F(T 6"AJYL@
MKV1:,.>J>%$@>WO\C,U!4]8>:15NVN'#,\);<P)A\6/'@2Q76(=ZDAE%_L3A
MQHRX)^2CHT*6.06PJOM#8BBA&\[*!8J;\S=6\N>[A6J/Z0VE:F)D"?]%N?6\
M(R!=0,Q\J HXR4O=U$\=U=DT3E+7OK7YDQLC+6N):,Y,Y2)9*9\- 9[MI\$M
MJ'U0=8FZH M\?+VG:=G%MMFE_$9LT(F&+;2&:/1,*+9!EO[X.<58"C7C-<AP
MKOB#_@#9,DK<L#7#OP"=IU J+!TCC!=06"0D TK#+?R8Z]A%EHM(T3?#P5WP
MPQ.OKF<IRZWCAM&#:,+=QM/I(B!P<@?""#G2+2@C),1:112O6L:RV,=0)HI'
M&8I0R! YU3>>XSO>XX'4"P/)R:NXBN#F>'F, 9HW4)[2-?(#M4<BP(%JGX M
M*2E@UF*5Q8\: +BW'Q'W<S63X'B( C)@L,2!TCBH7#0I("0D5A_1 EL>E^KJ
M,29WR. JYMD"VL@<)\ZLTO;^[$_8["JF'C0-;!L)PF9O"SOK?2Q\(R#SG>S9
M*0.$JG]8Y1P#H &\VS#!6V_;71%3=Q9],R&ZI6X\DBKB?B[/ INIJ!Z%E2VL
M[N,?'_(C7_(G?SH1EO(O'_,S7_,W.)_SA:0C.A_T0U_T1Y_T2Y]7)-3T4U_U
M5Y_U6]_U7Q_V8U_V9Y_V:]_V;Q_W<U_W=Y_W>]_W?Q_X,H-?^(>?^(O?^(\?
M^9-?^9>?^9O?^9\?^J-?^J>?^JO?^J\?^[-?^[>?^[O?^[]?^0," #M02P,$
M%     @ N8EF6O>>\1W3% ( 2$L" !$   !I;6<U.#(S,S8R-5\Y+FIP9^R[
M>5!3:;\N&D4;E2$R*PA1$5$1$)D4D;0B(B)&0$% B(K(D(8T"A(A)HK(#&D'
M0%&(3"(B1&22*0M(@%8:D5E R-2*3+*60%B2Z:[>^]3Y=IWN/[YS=]VZ5?>>
M4*$J[WKS6^_S&Y^'!-E'&1>U_OA1IZ.H%2M7H$C(#THVBK)'K?AO/OXR\M^U
ML4+6C%)9L\):3E%NQ5;42I45<BHK9&P4!H5:L?H_-Z#^QV/%2KE5JW^27[-V
MG0*RH7H]:N4*.;F5J^16KUZU"KEZ [F.6J6R6G6+V:&?U%POR&\-5]][ZV[>
M&OW#%2T:;CW@-O.+5V+7KM/4VK!1VV"[X8Z=NRPLK:SW[;>Q/^)PU/&8TW'W
MTV<\/,]Z>?M?"K@<&!0<<C4B\EH4Z7KT[;@[\0F)2<GW[C_(R,QZ^"@[OZ"P
MZ%GQ\Y(7KRNKJFMJW]35M[+8;>T=O[]]U]O7/S X]'%XA,<7_/GYR\37R2GH
M^_S"HG )_K'\%ZX5*+G_"?T?<:D@N%:N6B6W2OXO7"M61OVU0675ZBUF/ZD>
M<I6_$*ZV=>^M->J'[^95M*S5-W<#-2Y>Z5FGN<V"9P#]!>T_D/U[P&+_;R'[
MG\#^A6L$A40/"9Z<"@J+DDIWY">C_I]X_C$8F://&@GX5LT(N69C12L^'&:Z
MZ')R2L=(88?<KHWEY=_T]IU/-=^5=7<@:L_&MQI?."# E)>A>L[!5V6H.^FW
M9:BW RSIQ_.8X2S!ALWKR=M_R/]&Y5_P'P$>TTRP/[[0EUJ1?93[+62E.'XJ
MH)'&]J_8X'6JW7E=WM&<_>VNIW<,? D+FQPO3<O,=%K"9C5>@>;W@?2DO4]H
M)CQQI571PS]_[0K$ZR2WG2HY65@!?](I6/,A)24V7=/\"_%Q]A6?;52<# 4"
ME'\=*OZO0_536R4P1H9RN,KKEFIJHV4H0\_Y%9\[9"C;/ND//%C029->+Y9\
M!WAX?QEJ?8*Q#)77?D"&6G5*AL+B)PDP0WPR2AVQJ?4;E<<RDZ'^Q$W*4%*M
MN689:MF(KDP%7WV@_K"AP7A 3H;Z6D[>+T.UL@XA^Z:DYVW?R% 3V52.D53]
M>K@,U6TA0S$]Q3MDJ$3[3!GJ@T!7AHK=0:4S%JJQ_*MOBJ6)C<B1E3?29*BM
M_UTTCN+#FVJE"1OFQ"KV8@FUJ$2&4LMIPRXX_(F!?_V#^D-MF8H8%8%8:?($
MBR[>;8&1GBSX&RS@(?H_@_<.V:QWCCK?A9W+D*'68?GK/P,+^SJHW&3,Q+3$
M& <_^;93ALHWW2Q#L>(11_Y.[Y.AQ*:<6S+4@J?=)AF*=^&I#/4]$O-W3 /B
MYO_JG.\"&2HW6(8B,V#7?PA(")4]$8Z3J%R7EVXRQTB/2.F(;8H8\41^'3@A
M0RDH(>;O/_\;-L87N7_Y)@LCGL>)/E-;:7#<?J)$V8P#;TU B@WE["XU/)!,
M_9KR.Q;D/40.;+@@0R%&E[A4B49W A8^&X05YSC^ S#JGO_BGO\2=RI[2R?U
M:WBZ#-6BCNT>6O:F0_L_N<M01_R0'$E01")W%_O\H=1:K)/]?NY4"C_KYK:*
M5YF]"J-LR"]Q</ ^_M&=!YYJ"JQ->WT?7V^K;]CYD+4YU>QH&_Z?$BY"?& 3
M%7QN9T29W0]A6E^*2]^;-%Y('ROM_->)-+H=6W^I+SMQ6B\TS1F=F+9J8)W>
M=](YDRUOIPN86UUK@XJ;YCBIRQ<@*QUTA@?MIS_=KL?C/3?N:Z2<S]COWE5Y
MHNZP\=%O)AO6G Z=[G)SOD3[[Y:#48%TB[*/#&6?&B5=DR>E +U#M__?B$*Q
M#/4/I\;^/;E*?]S\KTGZ7ZKO?P72+T,EO>?3E[=^1XOW7<:*DR18Q/#_6L&N
M?X.&_T/^7RGZKP+$0&NN<)8W^0.@ WI^49I9_/_KUO2X.YZN;$E-SC5[!>(2
MGO7N7G0YW'FV7W7:*^:YQ5?C"&.3Z;/ O:A7%?U$!>.<)^T;RF;*#;)][[X(
MN,6X7"FY*XZ)*B=X*S(-X-!B7*$?2>YD;6-_9,YE!>.KI^"<X,@H;A?VQ&FP
MOU:X-)+M[;0I,WLV/>W@$]K:^F/\C #& 0T>H'S^Q;MTHT1(/:0UU4RUV,;B
M>H9V1D%"W,S]^IS &7X&QWSD;>7D7D8AD@?#7S0SK7>"G48=%XP$I9^K(/5P
MF!.P^YK.JOG=1W7?A:TS+[J56F%^I4K#,BSL<KX,%47]M_I:<P-V.*;#>L0N
MY_I/E=P5?-W+K/;LS 3NVNKIAXV!Y2-B[$"UL4X;]J.PJY!Z<;S;/ZJ08VO5
M65;6-M9X.$C__#$_'3;G)[$7#Y.@MP;.*W<H' VRPS;>&SK<-_B9@T_&ONHL
M&1Z?R@ZO/O*J<L#BZQUAMO>4TS?C[;5O@O3321\?B*UY]0/ZQ^FJGAE>0Z0@
M]]//=[Y_?>9QZM:9+\!PQ<Z3UL\^'WUY^DG)6P6U!3J$E4\H26'#^*R>UIYF
M>_.RQ$PCLXCGYU_8-ATMN]YVW,+@EZ'=C_/.L%2T26(#+[?3I;U/@'S.OUN8
MLU627.86/.S,XZ2^_"6BH>L /S"IJEOAJY5F[5Y<V?#8=%1]1GK2<T)TB/=E
MUK'!2SW5URU&V=G<3X>*NW>FK4BU?@X7"_="C#L1DBBW!NBG[,%E7&(UH/RQ
MJ?MV8_@%S3K3^$9KTR3+L:/C 3VFS):B#MWJS_%I-ZYC/BY.SGPS*2M_VL?+
M_&(;0J*V]H<<?0#G M4YQ_L?Z!_.<(HY<=#A>)5V\<;O[YZ,UF<P-'8E+TR^
M=ZY56$B'KFZ,+TEEP>Y9G0K.Z-BV]TTG*$9HEPN5F\S;N*6'^($. \6)><&'
M3S_H+7%+6_N=;Z:^\XRDY=\IDQQ?<RZ573KFS,K4+HX5'^(=(&J<<R$4$"@[
MP*'$W0N$$FYO6&1-^LZ9JK3#7SYS3E9GDGK;>V?_H#(#?"YE!HWRJ;< #5O=
MHJ#E;P!7]\KHD2$+7QU\Q<#YOL]-KYS1ZS\5Y=)T)6U58=G7"JY'6C;53V8=
M/="6_?V=5>+!_EW(?>UT([<XA.\>.UXC1&:X?Y/'YWW>64#(/;=B-Y,]5QYX
M5]WKE;HOGX8?O*J&:*TS>UD7KC-KS\A0H45QJ<$7IO?SLUY]8;E%5)S>=;B,
MU%?D9JD6][G3#O^U\M]K=5<;\6!/HPX/HT3P[IRJ=TRV3"/X]5J:KB:E_*QM
M5>RO'/_*T:HZ@/F-\#AM<P@Q\NE;J[R 9\XF9<7C"AN^A<Z6ZV',_DN_]UBP
MW?'.S$)2ICBGXT8_>)P\C78PW.4>,?'N<UA02;O32>NXVM3L =!?FO4I./.B
MII9N<YTR1F5FS\>$HUZY5F>VX+02BI/S9OV5 X\7/A\LWN]:TNE!MS8^YO#U
MO]M8??XVYB 9ZO][=.G_#.I_=U"?IFR 'X%S[4.UVE&WQ>$\G'J(9B806O_Z
M0^2L]9GZVLIY-W2UR^J,/WH=B1/.F_P(SW%F/=9AY]'A^$0Z>.*2 ]PI^/[B
M!97GI?+;TTW4UC-Y4#-CM%Y<FK+7YMR!)X/OO@Z5)!6?3-=[4>IA%C=:YG2:
MD*E4ZM!@TM0]#<C#HHU\SU7GX5),%N_U'T<-=1_R#.):SY1ZI_K'LM_%;2_V
MVEGGXICM5&J8_\'(VFLP@HX.]HZO*Y_R\+9+*_+NC"D)B4[[PR/3RNJWG=?#
M3,("+R7ON.NX>^:G7W\Z>S.B-!V^S<6CQ2X@/K%Q-?]YF"&(!'%AHB]R6^4;
M@G-U4F%ZT)?JNE/M.BDQB?FY6I?N8?=:JK;M#A 0Z4^?UR]X;#^S)2$R^,5\
MD8;-J_PO&5[N<4_\;>XFF,<%["AQVC9R<N+KFQ_^%VZU=QL7)3 >LM8F9:Y,
M-RG\RB/X^Q\E*CBK>3_9=;HHH<37_4[(@\G^')LPMU2#;?F+C?OY>#0,.+R"
M,'>J<ZS9VLK%*H]Q PN/WQ!_,=7W).4\K;N5:SV\R]8-%>6XU6:?IYO\/2DB
MEC95R5##6<*K,$]D/\748T*7'X/./&(:TY!#\C_15-L7B5[O0S+_F3D4T#.S
MJ/#F2_7K-_V:OX\Z1(8K5OA4Q7HF.[@E5,!G0* 5D+=5*83E6BHX)@F%EG]6
M.)>,21I<Z^N ADSAMZGO?SJLNH*SF#?;JD/:XK#N;FOR&T8NEIM/1S<2(7^A
MDN05<R/9$ER<2+';#"\)K\!U/-QJV/\DX0@ R2=% JM#A-IV=R\-S8]Z*92*
MAO-J;L]ZKF\.N'OD7OZ]U@IGI4TGM^[;/U!R)RTD1<FM4?]DU=>=U<<C+VP\
MOJ=DA]=[L_O'70H#,G#F)1F?!\RS-YRP(MIJ:EY_AEGA_4Q_M?V>C VVOKL-
MHE\5>Y3KY42Y682<C@O<%6+B&3;73D&JL>5G,=XZG>P/ H*AF8%2\@9(>E>T
MFY0@; 1]G]V&<"R\9J.9@'Y'JLJL[+5U*N[D'S2R!]N&XL07GDUKUR2%ZMU_
M&;0W>"3G69'!MT<OQW*L3]7$(F;1(T/"9I@#$H["?044EMVFW@B,GG@3R&FC
MQ2V?X<SZ\[P6B1N<!3K&<C[@4+QE$Z"PN0K\I9:R:;"X?RXR)B7-CX.K1\)8
MJ53&S@JVQ3^FRV,#NC<Y0-Z"-OIK&6JF4F0O[:*L!B1)% OR=DGQ5DE>X^$A
M4XC542M5>E4#K^#AXIF;(%R;:;*V)+>(VZUU#N[S&+#%!4?QJ.M8!03,QRPY
MUP:@5F3:QP&=Z E^RK E%W/';P6V8F+6%\0(-.DB&S$6!-H 7?*Y&Y1I7GH)
MG[;F*U.O&MI^G[?4SS0G+3F\K@>@'4R@%\O3 VM20L.+#]D<'K1RTLS=<U#N
M$W )/TH4WI<4VVTCS;=*-TN29^S42&B>81L-0UX/ET#*^)' %JE-'<AATU:0
MJ,<&OU7-ZK34>]ZL>CRG-JGU'4ZQ?Y7@=?M,W^!/#75UF3V9;_E9DYP43@UQ
M)@^4]V*"$^W B!;/NA51]L&9T<I%SX,H%E N+6]*F(U/*ASP[[$,7ACM?#BG
M=JPQ%.UI^N(AM?)E;^MU8GEHP:E9O@SURI.%3L0J+F)&L_$8$LX=?$E5D:&X
M3S&Z=H:PRJ+Y9<=D.PSI?BN@\+(*HQD,^-?7ZY\8,%D(]5"X<,V8L2K3_'I-
MA6EF-QC8AI0<06\ETCT+*1]KEPUG<@2,D>0E-N>5_ QB,<C83M>+;-<?6:8W
MQ[:S@&4H)7H<V4D^W?80K\YB+@$!\/DG#CMWZZM&H'>!.F,4!>G=/]B8Z;G^
M)N6UV$'"D*$"&''1M7<B,$GT*OE6ZFJ"GTU?H^E+DJ'SD)B0[X4G 4Y0>3U3
M&WQ6PDNYW+!W>N1:0_G>2:'6B/>8C].6>>TSMY>J-1BS::)=X^*@^\)K59*G
M4K5SY%]3W.H_<'BI=I8]^+9 MJ:5H1L3'#EKW#-/=O$OCF]J C^YV=4%$S95
M?@J&.M13@8?45YP9)RB0BYW=*-KB!%UML6(:U,)*,M2J^V 6 O8&9'.DM[I+
M@87=T"?0S"@E)?"0(59-*)D8R'1&KVNVF+YQ<G#PP T<R]OW=6?T.,$'LQ9,
MF)D0.9Z3OJ<C(XM+K\^:J1,TZ? 36HFCGBR\#ME3Y,MQYF)AMR6[#2!MUKJ$
M?&V @H4]VP>9.[,ZO#EMV,3Q]6]P"M9QAF!.5O+F(;%+V:1T"U #?LL)OQ&Q
M8KE4A(S@EF,RU"5@!,NF8LBF7&I2O16]1/K>;P>4FR88A Y*<PK.(J/2C'L
MAW9AB'&5_0&-,3K4A,PEYF;I[Z&!7F]ZR\_W6^2<'OOH,]Q&C+I:S$>/UG(#
M$ZF!W2ETA(T$XI,Y*^WVMH"9N@<MVP8H>X/&5X(>:=3GG(\^(RT"ND[7,\(L
M-\9HVJB.&)'F[/K!)+0Z,WX?,H/W;R<D4DV9YI0_@"J QER/G-43&T!7%F^&
M4P+X^#1LE9 N\B ;PK=#;W!##_"BVKH33H50*Z]5/R<;?1 'EDYK9W_EJ-DZ
M!X.<=HH*_3 $Q.+B9K=9#65+!B82&./[ZS#)V-<<MFDJO;)[ME, K"4CMXV-
M@^F""?;<,(=7W))FURE\0QT&#C=!H;0[S)W6:3.-EEQ 4;RI!IS1SLSC.5GJ
M7KLN]N%[AEJ^M+3NLSU(#4<_25XA<A701@G"8S!>8 9R^/A9'9#8#*PO@- )
M8H,8[IPJ272H=['I #MW9V^$+^'GODB% YW/M_?U>?8U.N1]"AY:CO4^ZUM>
M5EP897>CWU4/8 -52S,0=RYE7 N6X]-3$0(2@4FSLX@=%""5KEB-50_.9)H.
MZ@,BO/!\;:]>N(U+J21^(6AP:*5.VH4R$\\3R;-YOYG^6=P!##OS@91&2QEJ
M=5_6"=@HBD%*$3Z 0\%1%E6N'*@4'[ KADZ1B$(<V!%/K1!C8R))KW]HF[*=
M"2(=GQM^H5;C?6R5KAO!L9W1(Y0=,$%T&#84-L!7^9SA(9Y61QFZG:-2S1@F
MNDA>5--T)CEKR6=$&+(/[ E.MR[KW>>;8J:TOS#X!" 9J\0\(#8&N8.V!WFK
MP7AZ\2?X/COZIUN:!?F$Z.T%5DUKY*<-V^DCUESKF<^%D_5S'?04)@IV*"#(
M>4M_[V^\P7>Q9EV++H"CCF>=&SS?]ZR_^ XQ[&7$<X.FF /^!OUWGY_=DNEQ
M),S02U(-7*(IDQIX2S<7YT;,><II DQRMO4=\2%0Q!K)2JOR.>C,7C9-$SB1
MM9X/.QQ\MZ9,?+X\A><?/5C&WXB[7VC\9W.[K:&P!3;@(PE=C1.K^;==HRLG
MI).50(* T09L@D6G&U[W1BKI-].#)/3&R#R2*7M)N/SDW>2U7#.@=];"N<MN
M\)N0Y9D]^,WLEXM:KI1+Y N25*;!.#E<4D?91/8$Z;,3 F(<OL:P'8LF+;4N
MT5]?*Q+MK6VEJ<%Z^!7D_6!95AQSUQ1'LTH+O@UVLNF*EIS5GQP(S[VG/WR5
M8QD5$/S6:D9/39UZOT)D#-T6SDM2I2C2N&D\L!$(QL?AE1NI.WNRI$@EJ< -
MN!IHE3LI]16X6#3X6*TK/(!:_N('4OW7?L.'9'XV^25TXE;OT8593V$JK))'
MNLJGI2S24NQ6]Y%-06>V*^S,_])TG3%\Z!G9!K(8I&#ZMWYH](GXOF8AU&6&
M[,EK**IJV+DSP:>/'F;BWST? VG*4*<0GBQ#C<8(\.Q94\&U6I&BV.RO>B,;
M0=UM-]RY\:6B_>?@R_-\QV8.FM)M8YJPB-< : P+QHB?LPPE+S[22SZ@Q48D
M@GB?EK=?G<G#0;TU 54-0V4FDOO"8OB0R/VC&&EIL072]TPY28;=3K('("EG
M'H ]!;6M]"2F:G^C/ &L8V+P)!_NR0R^L_%5MZ'&,\](-!Q\AW?#D<=(-.YK
MV<E[_$A\Q"0BILO:+<6EKJFIKQGK:8$?O=UB$]@&C :VR% ;3<E:X&T>,)/
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M?$^I.K)Y/MCQ[RM"J:$T*1?A9"W[$7>YD&4HM \&0E\!EFW\M&4H'E'C!W5
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M.JSH])0,M5:&"L#'1Y.]&V6H310C,D%20U%!N&8=B.4&,-J(JIWY4C9V_2*
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M3BI@XO>*[<"Y.U6>$"-6K06+GEV$Q;XEY%]K!FP/"'0/ZV[5.1/J_:5G3OH
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MSPS',!GU-X91='DCX+YP)@X_H[?HQMBE^(UA(TUG 7J(J4]KJ6Q6/T2X5F"
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M^7'KO3-/_(A^UE#Y?A?JTXN:)>2-F6@4L6=0+KR.;N;';U?W)\6APR&7A+L
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M:&^__/LJ#&(/CZ!%WP+G0Q1YNN*Q[5Y;UG=OF*\I>D1#N@00-H593L;>\K<
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M/^*>88.EZ&4!5.?6:Z;LALZRH]6&F\J2FP-_C8QX0K?\?JG<0Y;=*'S3+C\
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MA$=#CQ!#Z+,PN@M6N(E X]^]A#FLL8,6 I3:IB09HL]1<.R2RX&A[QMV)$)
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MV_-3FO:CO_^DSN108[G,$[GW>0JG9)\J[DUY5WQ][].<%P>E%.WF$CW[[>[
M;B?KM9^]_\Y@@:SX]Y+1N^2_W64$_M9@%C/EZ761NC(H;@F?W65WD<10:JIQ
M<H E=RRNL_+9/*B'@!)#+)\Q'4[<0TOB8ZJQ"HB^[G0/P\$U/.&#:C3\$/NX
MI\LI^J-<^G1+9IWH:7/Z5';^E)E[X92>2C*6'<F4!V!4> 2:?A,ZYK:E"NRC
MP469RJR\IE-A+5/[@2[:]&Z4*L-Z/MV'SC,+C6:? 3JI7<7U])BOXKGX3RQC
M&OQ)0,=F<( JO^/B\&DK^AU=U0'USI#Q#E6G/5OI,HDF4XX%*X\2MB[4=HBN
MG?:1]ZXPF--RS?NK0L\8B)DQ\6V9NDB_FTSC@(XLN2C]GW<M . I=5G'X?.L
M#=T-B;_AXTN&T1P5YA U"(TNJ2-EQ8:HRL:IO+ZIJSC?LP^A<W7,8SMF=/X5
M+KDY;BT-4.LQ9,PAW2/LJ>G:L[A@O'<#)5JN#P6F2B3P6 X&2CFVZ,H.!CH'
M66?P7?:>-+88TO Q^K'U_5%]0_W[%)A861>WS!JL;)3>SGYDSQ:!F_9PKG,)
M<A%A%7!CS]SZRET=!Q3=^79Z4?O^J]DX*SIEA34CI4>V&8B!!(50IY^=8UZB
M^T9!]KU=;)CU<KGP?D<WX;4Q?L+NU),PJI)2:<.%!NU(0PLQ>[O=Y>4'#Y4?
M./'LRMZC?E:KFR87?JS?',!I2$C@]&#>=X;N^7Q?_<:%@Q^[ N]F191;J&^9
M!-W3;WTW47@7>2#K!./%$#"WPSN!^HL5S0&YZ5SXU@ZMYDZ'?#D"*A1VF>D!
MQ-&3N [!E\K' <6ZZ+!>A?$@.:"6,6QLF#!*EF&#>8N,E,#PMU*3#AG>\U6_
M4C)%IBJCX:F?*DOETJ.9AK/H56O&<ZIF I<TBW7/ "=?H\[0Y5O _*A@;EIN
M(37)#FLQNL*+O=Z/B6"PNFIX'IAQ""[^O28[S@3=1LF2RZ:M&AKTNRR;FU@V
M-SBYP?I43XC0O[P&-SW^3LI'.L(:*4P3W**T5&_-2+^SH0,E4$GG-*PR%N;V
M[))JH/)5[Y#+=E/!MR.D@PML,J[/6C@/2@3]W-)V3I\J*ID:0XP%1A#K@L8B
M6%\N/K)Y].)D2DCVA[*HWZ^6<;-)L2]./IT@]*'RI@GZ(@=49]:J.B8.'JUC
M\W[8D6?Z @E4: (%PZN[G]T%%6F28L*2J*U)Y$M=^#9XM'AQ;N@,6AAP(S?4
MEA2[(%S$&3SD$7R-B4NSW6;)AHE7*-2FGC1X[\0@=C-IS&,6LZI!1Y/!])OX
M)V IB"\WYRFU_="95RX763BBF'\%BJ^W!GS04WM%= I*UXQF"R.3/OHO.VPE
M,42I"4/#R05>#3?"S@0'+I[%V/0Q#=%E[3J-S: P^@@RDYQ5@2U9R'(AO5ER
MZ([S+ISV%M>/+',++EF\J,T,LO2TS<J-(/YPMG-8OCDRU5DXX:POI!W_*,CL
M[KHRL4A%I:18MT@E/BLASONHO5Z)29'RY >OFXL401.??<S:4WJ!4FD_1=;'
MR0&, [)9!]_ Q*]/VO[JZU5&([)[QO!L7KY9TFCG+)BL^J3.A9<5 [T%CG8@
M.K0W*ZNU#>LJ,J2?TS&SWPE4LP-F'B&XA6V/YTTB?"'.7ITMQQ:2.:!F,V_A
MMM_WJ=@E15>*)PQ#VU&^K,*P$V&]\$,DQ'2LKL#SYNG=$#A#@GU C%ZW59C:
MWB1$EXOQ9P09#!+-*U"/AU"&]!_3-)UU/9KES*L-EL#&&J\0,7;]4^8V;CJ1
M>%E&]_2K.R#P@(\PD#1C!@ZC9&IC5A [QP';K5?5 Q $@V?+EB&Z>H6QAYMK
M^*>U_=Y-:F;[D.[LXTAH,YH7)3QC4U]+]YDJS:(D[>. XHA^-$]"@O6&C]RH
MR"C!)W!3PDQA@ .Z-SV>22-,KPSL0 $H+:C9-PHMRM3?<66/D:K6VGP3JIA*
MTHIT4O3&VNCS9G%V'1;E!(30=RPH^VI3:;C;XS<&OJ)YE\17?T:4HQQ5JMQ#
M9:?BL&3L]5TLGN%K32=Z;U'.,L_KUA7JT9P-39J&:[C*QKC$WK "OK#MW)I>
MC"VS7U0]1VH8"%AN-#8E-)&>3:[ZJ&CP*=R7331^*V+6@=G%[H77D)YQ0/>O
MZQYB#Z*%*MC22-46:5GI72Q,C3W)XP,/8+QCB7@$/7B6T,Z0B]NYLM"P.8OD
MFV5]B[^'<J,==ISY%JU<@SO%?P (WL ?7'0YG3$#) [P;>'IF-8>,?0G:Y*[
MB>!,7>MA_IF>V/LD5\S87" T.@OSY*RNC->8690M%\!76F5JN16<)Z#=J+.X
MJ67O_%^4II/<F.KZ3@[UZUST,0HYN/H1>O<M_N/DY:U58(X!W7)@I09>#U-;
MUMW-*M15Z-RYYLD^0?==6=N1AZX*,/;0N(+YM]>983<R^,@N_!2FF6A$V'$4
MI&Y070(N -3Z"CH[BVF 11?"A.A35>[^ CNV.O0@-B^.\5P?\*5?WHIA%9ZD
M=R4UHQ-(E6;MOC%C=Q.*/ ^^GB3O6(9UA*E2HA*9JO?N$C\,KMX!.NE;(8=M
MR7D'&QL'9?M05ZA2O@;]OOC"%(\'_ NF[PB-0=?HW<EOO=DRP^IX_@4'DYK,
MAHHZW))(EFERL7V+FO)4?@F\R]?#W>?XB0Z=+WTM3YC=2K_Z&)JK."Y=BV2W
MR,^8IO.WJ#'(,YHK!#H_#=W:J#?S<R4SG^G=KWN*W8N68D)GP:)8,@<DYNB,
MG&W>FN9K$@9,(*H\SW'WB>>29OF%ICIIA]T#60J>YT?AH5RXWR?$,$R < %Y
M[UU6 <2=<?HCEOJMQ4PDK/T=$,=UX4<T$'O+9DCB7FR1_DWP4:01V_/K!^4C
MSRO, HMZ%#L@32;5NM\RW_(L7WLH\S:E95'FX:D.R>3*@&3)_8:&%M;):9$V
M%GJ[#\B(!X8=8?[%JB)Y^8Z8V3.*<QEU;5/[645,*)0IB)]-6GTZ,RG?3#KL
M"KBJDGNDV=VI*-W*0>+N^P%=00[$H29!9!LX1ASRV#8:8B3/N)\:1&5=ZRF!
MRVX[C#YLVL\B0N^;A;L( 'T,^*P9&1,'%=(5X3H!"%"U\]>2BPR0OJ..P%2[
M/)_!Q$_SUW0)VM,I9/!^KVW-1)1UX*QO%/BHCX;)(R7'R8?-LVW2DL^;*[UL
ML[9*I'$:C94\&V+Z:.CT0=(]54#A<&($PZPE#THGM<(%@9-<X@0GD"2A5'<4
MC)6A;O8D[SC +=!'W6,#$.,9_$&D"FV@/4^.2ZA20+^4I8OW 92)FV;,QNQ,
M]N5<0Y=& D.XE8!YQ_X"K8&OAO@P"K8D^\)TF39 *,.VF4L\ABOX66B\)0!O
MQO#BV-+M=+=VZ3UT=#-:G,P30;QRI+',*T^5_BVZ!A.MG9&+TZ.]U6>*#^=Z
ME"R\0SQV;QD[>P)<G6:N#Q+ZCP/U:\<&W?&!:<L!5;ER0!L-GTE\$-59G9!/
M';0[O<7/)H#JYNVH< V$>T3AJX!0HQ#'N%17]8=DV71Z2O>>PS0U=2/)O9=_
M0'W0/F9"3L#O72%':=DFFM>'50+,>(R#C[S".TY,>OZ,U^ [P,S>";G\@>_5
MK5-76UV)=:%+V+!=/+^>0VNAL5;N3<>8AT!'8/2>V(_;7X&)7?!VZ/5$P2ZU
M"O6__9VJM3_.:3S(T:JL2@^^>[3%I1BJ9BUK:@<1D5/,6:#)&CD-Q&=]BTM2
M,F'G?R3I^1YO2GXI:78<\(VE2EYT3I[U(+^L:Q&;4E-J0WOJ\1N>SR;WD]TO
MA7M$(9VZPT,+R@Z&F"%$311*C+_W\#-MAS?X^1R1NF;\2(F6+)W,&!6BXRV4
M,[6=HEH>V/EU@$:L)WSP,1B_/:E?[-"J#;$0L^PZLCJ/J@)Z:&N)3+0O@C]6
MP[WQ?>404Z_,P>N%H6P&?F^8W'OC1F,]X^7@H:C(-PT)'@,U/GGZSW=7-GTY
M 3BR)>1;?NUA"T,_EE=^3@(,B-89DC]XF/*2B?QF>D;0>VBAY&1ZYHRKY ^(
M&NV=ULPZUVRT:9UXOAC+/.4DT+K^"5+KY)T9>M4.I7NL^)B&VON^LJAFHS1Z
MC7>SV(U0XKD4+$^D=?T4.#E$=.]*Z#@K$VJ$-1Z!#)#AMZFFJ5AV[7SIA0A-
M4:-CQI&VVL7] 8/X#M]'8YB"AV%][$NA>G\-N=$Y('*(LR'YL7J3>&4#@>Y5
M *.&)&@OW_A [QJT\++@VF?7*4>7&Y2+M7[V';)MG4^UWU\NQ:X*S *$>@CL
M"&;FN@80T&DB01XCAAVI$H]Z%C"N+.V\?XSR*=-'S:S04/H5I#(BSY@Q?S[W
MZF=C</<T< \CN#K) ?%B9ERFLDE4<8;-Q+8'6S ^K(9$'V&?X9YA1=JCZ:;%
MM<T>K<'M%5"J5K?.MFT(M>>HS*PJ$*UU;38V4EM%N/K]P]DSO9'2><H/W05J
MY7*/7U5?QD\U6R&LPM.- KY)D6@OH<8\'JQJ:C-!W]HQ;MW:JRK\5BF"K#AT
M6G@OEJ'?=J$AS1+NO\0!":.,RX"SR ,C2,OKO<6-_8'*=\WX :].PR&4V=N%
M1YC;_6M,8_3]]AVC[V/@5\77?1SF9S5M70)6NJ<\0;__;H'.@39 #_:A*+X[
M+LC^5169:D"-[O+C\O7XGP\=D- V6_/1\4A>BJ@O3X*,HV/@;6%L3CMO%>@]
MQ I,'YGB&NTW,+HFM_I)PAS0NJ^+]&6RZ<DO6(-:UU9[ Y6 !_3FWMR@W)Y1
MUQ(CBP1QV\\^XGXE-@28P<5YG 7.?MVZ[))Q+'ZE9OLF3?YQ?6:DAH>10!'"
M[Y'GI)9JV+FZ;<)W^>YOWDKUG^]_M_!=_*PT#P7N^0JC^V0 "6Z6VV,YH%]U
M!6P)B5;X!DQW/P=$/4\CL7V6X]@GY=PY(/W]>AS0DV^Z\,TSZ^B@5QBF!7[Q
M,@=TI4F4 Z+99Z$WU'YODC"09OL%_0^Q&#(O:L:2%E)0A[E2SZT5S1SOXX".
MIE[@GO:<BZH?_3&JVVF_2!^^0&GI:-CT]F$ZUW(?^\+54_D8:$^U;LZ;)C<.
M*+*-8<LZ9O:4!-Q XCF@[,=0:A71F@.ZECKCRQ:45N* YJ>2@/!7F2PA,7[V
MGIQ?Z$%L%VN*BWQ"9=NF'%"O;P0'!&3<Q; ._6*'OMJ8$UX'_]/"#B?0\-LR
MF#UH^DL&G .ZN(%ND?E"6GC]-YHN^:V37:3K^WV='RB"]P>QGZ-4N2:I6IT#
M6O#XO;/ ^PWP+UF,('3%%?#@@ J8UBY^+B%4_!BIA0+='Z:R;$(GS0P^7)26
M!_2]A7-<I!C:(\XJN,!9JRSCA>PVY;/OQN)D+YH(T0M-U.>M<K2#PXS_7,[F
MTEUIH7F-!_62(J')K;V?2_M2T_Q#8,3U2_@N/G>3'V\IYJC/%[Z%E]<'NY]5
M8'=R0(7%KI;"$?GQ]#[KOQD"GZLJL,)W_>):;9I=_=\W*#_XFK,8:JS]"7M)
M0</>!MO1:6**-C6'G__]*EYD&3M&_N,T4P["Y9"NQG_L4SCSZHU.=NRA* YH
M5S>*M&0YSUY30_]S?K *^)?<UOJC;%EH+B(\@0$F]+.@!S Z)?8)3R\&,-6"
M)/*K_T/V]^THLE-[[GE$\K._?QG D99>K<.'>K!O\2^C5I-H&2!\,_QIN'0X
MTJ/U#CA?6JM5]7_8?X?HY/\M_3>7)\PJ)CA[4"EM7+&&D@54-,SVV*-TWO>V
MZ$HSG!ZUF0D"8]/D;<RXJZZZVP/2Z(^ZT2=(9G:\$>KC1=ML]!\%\K;\Q!S.
M\31UNO+"40 VC'7/J?N[;)C<Y O ^G:,A*7264.B(9\[XP[NJ+!31C[_RI-.
M5"-#$6ENBW,C36&*7V;!Y4.?WQ%ITAT5$J@--C:;JGKQ]1#<^XBCI67F>-X1
M()O6L]O0'1SE41EQ%F7F0_N[=?+9U,%-)1^Y';V+=;$_WC@MBCZ^6Q#D&X+5
M#G^_+LQLN>-0SP'Q>;>FCAW6M#(1=.D?&Z:-K9L,UXRJ^ 1J8EJ#PC2,5Z_@
MUI15"@>5-7:6.W J/M]]'CDX=;F>]1\W/E7'54;_"E(H6,.G6G7\49''DL3G
M!NEIBT-%DHJX/,B%HN@M/@%8;[!ED;;UL'2\]T":+&]OT7&K^->_X#CPJ-_&
MV_#3II?PD:4Y;@JEZ.4P[Y5!C[^QHCQDIPHU\]@<!R^8 ZRL8"T(&)V-F5I:
M6MO9O6/[_GGKU@/OGPX7I#R,JQB=ZEFLC%2(YCD'^X\#E[NPY]]ES!I[(''R
MQ@C9I\LP1E#+ #)CH'4=P9;*A-<0,RTU\1ZED?5#Q2G#" W8M<=C&KC.'N_Y
M#I_"IE=%W?<WCU>H+_JLW0UGGOXG-/JCZCXJAV:U<YH&$GXL$0EO;POB++5+
MV561-Q,.Z05>B+ED6W3 (,<;UI#W.0=Q21NA[\C*1!MAFWRHY8T+9M.TE7X7
MEGJ:W*_W[E-^1N<MPGXJSOFFVX>FXX!Q!\9!^D9#SF.W*:1[!;IZ;75%O^A+
MY<0RI4E&I"[YRH41F+=/F9=F_YBAK[L7_=,#'P?8R=A]<579LQYQ<A@K] KI
MH!ZB8A(@F5,"LD.EMW0T[0:9_HC#4=&;2KUCY.FBH=9<XJ.M-VWL[K&./>HB
M- -5^*ZZU61:A)AO.&F/D. 31[*N$@ACBO*CC*6R)4ZW2L2BFXL!46(@G*ND
M;-\'S:&I6CVFCVW4D8)Q"J8$(R?W].;BTTM-4V\R'GYS7 J8-3Y2"IL[8FFU
MJ&_I95+Z(DE97WWE!MJ=U/]&Q2+1@_K&_ZM_YO9XUI3+Y_/AE[*IN<%NG:)!
MI?VV@SNU_'&Z)Z.]^CH* 1O:N#5]*YNZMSKT GOXL$3SXSO]3O*1&Z(#&J&Z
MZV;]^.\RB,T:[P_9N(<W<FV6%N^\<O]([TG4P!QHKY"+V9^YMV$S82O;+TBY
M<-UIS&[I8O7HQ+C]'F1MSX'8V:ZZ)*O:P?[NK:D!<X*=[VK*?)/:O\.:8J<]
MK1?*(O$JJI^E4*?**X=6LW>\^ 3.F)866=]9*K3,-4IY9D$X$S)8#U:RY()0
MW;;E)4O,%B;2:>,7*X<#&O[2DR7=5Z=BCR[3=.@@X#]L^?CH+@V&J2#K+ ?7
M""44PR2[(?5<W^M#&@KW*MA]:-%H];_5<48_KKT?O*^,4\T[L)=>^\K7U>,P
MLWHJ-.9K*N_.6MS4F4%"J+%#4PU]LW7X W9IS"/F9$8S:X5HZ(,KPF[%#.(P
M-K[5UW^*7/Q)1[MV%) 183+U=9%J2B6 \1_J8^$?$C'F)-@FN$5D>F=TV+08
M"ML;!7\IL!04_LP0C/LLZ>[@EWM]^"U% ]E=[JV=C#,WPJPT;%LU><\WB>L&
MEZ:8Q54;%&E@+YM%WOLZX&6R+/.U*& .7><&I./);KZN^S*C5JG5_43OUR/J
MXD[)':ZO@5_W(TD%#ON(/_X/YMX\J(FU6Q^-&Q45(0(R"U&95(2H@"A"HAL1
M$1$%F8=L1&2(B A(A) H0\(@L)U@"T)4)I$A*I-"3(0 V8H(,D5!"$F<&"+=
MRM"23G+CJ7/.[Y[S?>?6=V[5K;K_4:&KWW[7L]:SGB?=G>7UTHA1(G2)""[\
MWGY&NZ5PTR>]19HV(S8976P_?L=$KJ'PAX#F(LVB#=$+]NJ!_;#SRK)W?]84
MSG^CE_H$1+;45!L5IG2\?:E&_1MR^T>=U<\P%+M&MGRY3-H!Y2_RT6TQ500]
M1\!32OT(D3MC1B6E.)!9S)<XB![1='<^NQK!=9<4.W1^"HBZF:\048-%Q-QR
MM+-7L>ZN:N-_V3J03OQ^T]AIQ>7S)VX&WS)&AZ;<FT_<2K]X9VM_]E6U3P*.
M]'5>N8HO)9UX",]O+_76N_GIH16AV2J*VU._5L7YBGO>4O.*&2%.CY+N'-@2
MM_Y."/K,76E=*]1<-0XY"5#4TX^:&EJ@/,&864=+6>'I4Z.''[MX/J/YY;DV
M/,W_+AV9[AC)' @=\C(;'!@?/4K1:%8X97J-^R^*0ZY*L%SH?W["=D%U[C79
M['-$G1W\07@GJ%CW+\8QVS(MB^/TGNPN0?7N;P-5+_4\KAH:%/*>#$PZ9<2-
MG66S5[><C^.3MK^6O'M5-M4H0QCU^MT*,TV^4^AUU1WWOQ$VY'\F;%#_.V%S
MC74V;_V6;J()I%FZIULN2/X(&S#E*)0HH\#5ENBE+;M0L.*OV9U5;D5B1AOI
M%:OLQ]L0NQU1<S*$OZ6;E$*4(3"OERYF_<S[E3*FE>W_OY:__U,4\OZ9U?@G
MON(O<J=<V+'F]/ADJ?'M2AG" 4.FG2&]_F?OH, &,D2*)S%AF+D-CH*R[T\%
MK8+B^1EQL^G4D[D_VD8PC9616FKR??G?'4DNG(IRZ_#K0(<]N5C0G3N^E3B7
MPQ!E_<UC6$MX$P;._E3&GA>AM\ ]9P./7,J/\AQN3R*'&/OKV&:935OMF+]T
MO[@\T1G'O^!'NQ%#3K7#39C$>[-+]E;=&!1L6+%V=VB0K^;NIN "!B;*.61'
M5HD)4UW!W5-#AS/2R1?<V]=YQ#E@R_TLR=V?E^G[H%:@\@5/'Z-%/ !9@C:'
M;^"@!-"E;4F&N&(7==_QP93MP<)FBIU;Q8<(VS<T@ZK2,9^IEJ0QGS%7M?$(
M;GYS_J>TIA^=VZKS#M9A.5(,D-?.6P$5"%!Y\0^(]A.SJR*\;7D9\56BV6@U
M]K&&XZ&WSC:,XL<.+9PY<[AVID&\KWJZ.W-S4T-3B<!'\ =2 Z*)#4AO6#IV
M'N(]$$^ 9E>[K2.T+AP%HYISF,N@M*F1;[2'!*V@IO[@MZG&7;>KWC<U5WSP
M'7G7^"U'L.QAA$U!X;EB<DR8\:=;C)=?KI/;;&6(TU6DK0%$'S(UL372FZ9>
M"HU=FO  M018>*L+*^=XK\9'LM8YT@HY-/+:6W,].B/[09M*O;SNK$I4\)_!
MY2<(UVXS#NA&XLOORH'?+S]AWCJ"EH#5<1"JMKAREZB"T45IG"7&3R S64@[
M/!\)N9:[D'\K8E$-;(%H*G,3+L]@[.]"\A65/'Z.DU3=WC/W&I\NLO<TJC^$
MQP+'L>]=]D/)$[Q,/WH>PR7Z/KP?-,TD&O+12-.VV1PMW/KX:%7"MM5U<$0E
M,G4W#1D&-<O-W*KDJVJ1F"T,%N!92Z%6-#:5/@@\$)8<8O^WHK, _8Z^< '$
M799B8"NNG7)LP@1O)%80@-,B647@!32-46<!';6?N?+P_%]H4>-?]+E50Z0-
M! >I,1/U;,"J/>[EZ@83>0J(,%] 4SXW'6-.T.N@J1!CPLC)?)S&.W)8Y,*2
M5VL=A/-4W0Z,M<54$++9NOEY GWU$_6,IF;&X\&Y9'?.\?J6E*VUWPSC5C)C
MH68QD?0*M1S%W@'OA^[9V9#,@.4XS3C)OO:@9= MT-!K@*1Q=/-6T*:SQ8E-
M4X2J/0#LY=4%8; Q<U=#7X/#=IM'M4*72EYY(RN3UQPV4PU<Y_ _WQ/0LAY-
M/8:]@#B>*F,9'N"V8^R@EP^A;'YC@VYR9V]'=K(Z'Y4.1]?XP?;-V9X#1)X>
M[MT(%.Z2%'VVI2C@[T=]BKM8P#'6^]UN%)()A'L((3N"C!^!U Y]!0$W@Q$K
M7P&[GN@(EL@0@LJTLU%6])7$0WG"B]5")5I6"_FJG4[IY((M.FT^Q[*SR2-<
MUYRU@+GS**)9*[]9_\PUL3K\6S]L.<%2&ILDV8&AK,M2:X+_ J6OD9Z!U9)S
MA0.(AP. DT@\GZ8^Q30'*Z]:]ZZ+?!3AE6N^$9@7P4S='8>R3?Y\K5/TYQ-)
M PD5/FXAJ?A&O 0J\2>@,, 1&_9SKA'PIDK-H53!F6(D!ZTX@B]!-8+-U,U
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MGIVRX $<#V1[ 4=EB'5S. W(U&48]EN:38^:,1D\W=+7H*S@.FCG6C,5Y,@
M3*D-(MTO'>Z1)S!_%GI$/CS+Z9"G4"^LX;$0!0V)MT"Q"W5@#)C0AE/!VY90
M^;=AM!"M !]J&:Z#HP0Y;B<&B/(60,6> <S+N5T]20&VL2_#\$#!$3 @&SUR
MMC+7K!@SOPGQB1$O+_-'T*5*HB;T%DA=(()<^4++V&(7B.K4#(D>P([0>[!9
M,)3/FLA3(\RR6WB<;)'6[V!E;GR/!4>0UXE</IG(2@T%Z_TY%T.&2US=\:V'
M76MH_M*WO,?-+\@CE6URC;("##L(XF!#\AJ[T+O$_5!2-" 6.'6@TK68VF!T
MNM7T<TNV;A?M(;P;-$V?WVE#K:6?B=+<>ZZ,>K35!UTCI'P?&2=(+_[Z.>85
MJH!C;SN-@E,GG\D)8Y/7"4"DJ !06O"%,LL(W>QQ&Z R UZ&[>!E^"FFP\%R
MI?!B?',3$)T#ZPM[4+]SS>>C--F=A>8U%@6)I$J3HJH([^-6TLD:TACO27XJ
M2)6N]ZH&3PV/<B:%]F;\VL%L/F[#!TC)!2JJ&_4+_,I:&T_/OLC4H?&/44%#
MSQ0I>P:C, 1'A JJL[/%2D;].?.2XH8)@]N V816*CF,KCPUK@FX99#,"7EN
MP_'OB0X)E\!4H5LG+E<7MAGP]7UGSRP6N&63+,#<UO+)S7K:IUVUW%A-_:6M
MUZ?FS36GOG^.(+CI2#M9]94=ROZ";\T"NL*'*=L"CIL>C(2RP=UQH%M6#84E
MF'W_!J?2 V2[9YF9GQDWWV1G;9IN96F=^V?^;MN)AN Z_ZG-GS^Z=(Z1VPZQ
M0ORQ^D0WZ)P,H9W.R9:N:;ZZ"6H,J8 4!"1Z,/!=_$(4V3)\34!?%Q&TYCFP
M4$ /E#2-P>;\GXTX$7W#H=,WVB[J+CGLS.O AO.@K31V]%H2A]6(%"F);?&)
M3EEVL6(K/\(VLC;!4" O5XP)T9(I=U/43+M]^) '!&&;P9Y^DC[TP[4OWDTI
M,K&D]2[^_@CW\)"Z6V'2/O'?9Z/Y^Y%5)%-2%ZJ^N4ONF7):"CI0"A^FO6D-
M3E=(^K -U+B=M 7TNBT7S::I4HWI0DX& UGQ>V%0?9A!QM(Q.CVR8!<N'%_)
MF]K,_V/PW+F[*:N$_5"UV)"X'!JH(QX&41W1*WOKY+U0DQ76@UL( #\-!AF!
M%C>M\U(2O]4^Q!?2T@U3CPS53 R$T3R&XY72P95%^I49P>K;CT_%=*X_7*(E
MMZ!M!UEALQK$S9(RV!O "KA71KMD"(2\96 UK/W)5X-4(<X$?>TD2;OHZ-"L
MW4X0Y=WO=B4*)@MZ4Y<82]9+;"$Y?4DQ>[NUSTQ=[9Q9T2A_ _)CB;7D.9S,
MS],F#;6L;Z;]9F?#YUV6[Y,<W(N"PCA,JU0!#=YLFULI=B-P.H(V@ $8P^@U
M$2._AE*Z[)RT3::SRP?L4!$)*H\?^MM<-:8>M2GP.Z_8!#O+D0B3PZ0!>PM0
M>@36"P,SG!K$>5&B!'D*HQS8*"VI!;2!P..[79[K?FYX$ H6FN%6$GB_-X#H
MRW7;H\/R H!A^HHARG/#2R/W [J?C8Y\8YWN??]ML8.T%;3FL@,-_/-TI+VV
MV)E*@;EA[^!FH';QA?+*Q4ZMEC!V&G#'YAJ4V'VX.5J'0'G7&U+I'ZD6L?AX
MLO?B69'YIM1/!/+$0W)]10%8O\" G, U; &6W6.X@*4>8H'T#A&.']WYW*'-
M>\FJ9+V;&M3J_VRPH9?J$3&N,V!G9FA=GCY<]= %F3OWKAQT2RD;@NWUQM&C
M0F%T^Q>HBL]*.4]H>O-#$)U-^J5_M*V0RCY^D0F??_ KJ+5?@S8P06++\^*;
M2QJY^4N\3*OD?<?$I$I\;(U;S,[^J-E3CUG7!Q4^^\H0$W=03SY*ET.^$P?*
M8>\F&2)]$X9)4H66NA=2H$]A8#9_X;8@6RG0-!!HIDAWCA+WYPE<*U.LE379
MKF_+ 1<H/WI-SKXC_?=<C7&N3_*1K@!U)E2\&UJ!6>8XT4L9+ME 70@=(B;4
MP0;9QX:)O[/>^2UVB-2]^XAD^K1[;[5KC- UJ;.I<*$^O@X?9%D4-&2M'W:B
ME7ONW,=A8_P &\]J<KN,T2$Z2A[$S5[%JI)TPTD*D&HLH'CT\0!L74X\SL5L
M>S_-TK/"5UFY(0DT=I-4_=DC$)<!1]-KRRO92&5X$UD'/U)>WQU5Z^,;.1L=
MO@B[_IN^O,E 3<Q2#?9PI9OPPRVXSCS(A=9F:TUOC[XJ]Y%T<R8JTJR,>& P
M/H^BZW0YFFD(N1T&-"O =U"O#QB6'N>*9GM[C!RH'AMYF72F_O(Y?U(GMOXC
M2J^6%:Z7AX1:?<'/18+:,,ZXP0##"703)&1B-A"<!,B,ANKGR !P,96D/LVT
M&,3H$3RZ;$NN/9BZJ(X?T:)LCP[./CEDT".J&(PV+AJ>1Z?P5.+)5Z7JDKO1
M<UM-H-H),K7$$O+ETU5SO+VRS)#+"3)$($#-)'J6->5H3(4W7XBTY5PA6L85
MYHS3,*6GFY K;@TQM JN]7:[BH_#JU)FA9XWX/U/;%#U+':O"NP-=6SN9QRP
M(ZE R8)>I6FI);"8:52B;W+8NBC*C8W1XL;[U#+L36H?.&ED4I(.UX4UID3O
MAJZ)2=*7K-5SLPJ1)590Y?;=O'72#>_@4WV&P.QEJ1$DD';S#4JC\;%XT*G+
M#Y=BAQ*8N_&_L ?T/[J@K]HE1?"?KUQ=RF@N7-H[)SJT[[A*@KN\GL^37B92
MTTG:A$.C;09FP%!!F\A#4')OPCRD#:7)-(/4NW1#:5VSVE,&=E C/[M7%W+H
M2D1G-=)70(N=NC='<EOYRB%>S#ZC'3X.42%1FK0S?[)^#>\^)^U*G'W!NT*K
MOU@+7.P73W!GQD!%!Z@(B&W[ 15UJ3#5Y!:L\7D(;J"XD<+-;:W]*DJB1UZ+
M##+@SIN['1RVFKY2,=5DDW^<O3;Y2R8KBO8^NYV$E7L.<P<!49>63=H<3E(&
ML=13 #F=$24<6\-CHU3I'_NE!E!1)VD'@*7 #GSD,BB6XW?5PX_@$ !V/>.+
MT!WN#OLFO;V/MUE=DWCL1YG $9),*8)( #]5=J*U)PWV]F$,V7Q'0+-43JTH
M+<PVHA:(SK);7K"H6Q:T&BRI BJ[#-8] \D4\WB][M$Q[%%0:6IU>0 .YUS^
M_/;SEA_/7038%]'I-$W2*BA[(0Z<I10%0%@!:SF:79S4?B%RZ8/B<2#R75N%
M#!'B6NL_M1/_*:AKW"R"CFV0\LY?&4FJ,KKN1+YMW0MM,YW1X^=I3&-40%.1
MTMUPW0(*(TD0G5ZR9<B:MA82NP+>Z21CZ%C4(667%P9;H<P$_A[&"CY+.ZCI
M!FE<%_C6*'#1]^A2=5S/7-\T'/+\,;Z$QZ8U]\Z4"U@4DAS.^T075E$[>2TQ
MN!Q2X%RTH:E@MDX&88$O.=;\,A8%MKD$%'D"K@6=>^-QZT>G1\SE4K/63N_\
MN/' _+Y]DG4\WY=?Y![/7[R<U(U=%4V,)?/SJ DMKWGK2 8V;6-1&$-(*.\6
MHAK26LN OTG*D!]7X)U)](CFH]+/^'??#@70%.% G%(!(6?LCJ#_;_]6/GIF
MDW@/4;N1:T5?$X[9-TRTK(74W2&_DE70+;! L-A)1WS%KFU,2]&7;UD3P':P
M]*#*=JD^T#A67EY!,RFNB#@>U2_ZH[_TEM7@[HJ;9. XZQU -.1B]DYA=<X2
M;8#1=IJZ%3JU9->070@?IP]9^@$V';/JD7X6-^X1]G&"E$#O]+D\7<C28[ .
M=KK;V H5L$="BWPBAW7I(Y1;L?I";#L6.![]7JNK+Z+_*TM3=UAX NKE8]__
M$*,Z#99#-R;(:I-D+3OR_4 H^X6!AER0,B(F) H=)9IYG$+S.P52)1"9,5>+
M9AML<8[:_#:^NCM[]/ 91"WP0[IZ46Q%W-%G%\A'KYU$J9\C;A+,4N26W5;^
M1V\>5@^.Y[NM^?6"0-["N<8).G5<'RSH4(YU!@RN[2YYY#/"HIA;B1Q<ZQL:
M&@;H45%_'':JB<#6:[4EJW>@$'8G*B O@C7K?2K_VW.@>:)Q%"_=^!?!HPUC
M#"RFP^8U$99MNRL6EN "/]-4HGUX"S5C\^"\MN[+;QM;<@534[ZMZ-5P,!0C
MI*%@#[FUP:H[U!*$$^6S:0V\+%WKYY1J78*'!]A+-003*%:CQ>Z?VY4-Q,=9
MP.!"8<=PXK%[Y)@*/YR/OM>^K>BHTH*!_QQ>^6\#+(5YT!8;^#95I"Q#G%HO
M0RS%#>!_UDBNSM'61DIMH#\+<XL &2( 2@\%8CN;>0I6J,SOX3($0/DEP0P9
M_9L'HF9K[5QB\/SD(U+]-8$7I@\/P$ZVD[$\!YU;1G&.J %O4>]=?-!6R77,
M/D(2NS"JZW'M%'-U(==UP/RH6<RE\_'F]AT[]3+_2-MY\(SDXX.G'C_"$#+$
M5J1X!TR^=L09R.NHRUF\]K'/UXVH8=NF2*LE*0JR.MT%-05Z#A8=(9/\[T]_
M_'YK3:/A:]!GJ-SG1.T:SZJJ;0UA6TXNQ&O8YM[I_U2P-#2G7GTMA+$2-*74
M6^QX1?#0*HH9BS_$W&?9%HS?MO-OPJFHWA6X7=T[M3\T:P+S._;F&N2:K0+_
MVO;T]8:=?T7>LF]$]YF E>V]Z:S?&(X/27TT9:9Z)%G=S@E$"7HIUO1EQ)U0
M I#GE^W.*. CKSBEP3RM\*6&&_#V1WW6U5Q0N:?W,H:+CQ6XB9)W[7/9_>-^
MW46Y#I4AGC2PFBK3XGB:^)9SQ65%O-3S#A.U-NTENFXIB2T!1!30./ !*NW*
M-S"MSW,6)^24'!#HVQ'.?1^>FGA=R+R'&HWV0U)O+/P!20SL6&E!1GEKUIU-
M7G8^R]E3+S[F>XJS4I_:81V3*_)@DE:%H%;!A]=]6[&\<-7OVM=?/!C>D:#F
M$O/2Z,Y';OO)GEC;;.750(_?X*.G-2M-[L3L.1KH5T\X/)SC(\![L/OBQ[=Y
MAKC?_U1)R3E\+%K)/7[J%6Z(@%D^<75M_9UCZETS!KYYO4\PVU[&#%TXMI$_
MLU)AS=,LIJ>W@K=Q=\PE)GY#W=X5VUN:D*L]!3&^8P$FID@*A9S*_J03OPWW
M*&@E@&H+/)(408SAR[M8H:)H)_HR4^L=?+2?85I!7,$$J%?BGH<(4+FUC2S]
M48)W9\$%HM%U\5$@M#G-@I&@2.4>!\V9F0LAY;[LAU,K/\+B"62Z#*$<CTXA
M*S:B# @)?#T"UDG24#/086#??QK(S:R%N!,;%@O\MI/,0%L,RR;+*;V1M;YG
M)2VF\M+N$Q&)VT9[5*Y%A42.W&31:$ WS:!I.QFHA!T^E9[S^<&79/'&/:7<
M$;T/B.1),K^ 9/^3@H-.&FS^<>Q  0;U8Y590XH,,2)^AKOYXQ78W_(PS*>E
MA$-+>VQ^@LV]/WNL=>GU0RY[.-=0!S4S?F3^XU?C[*I5;TNVN3-"*6G)-\ =
M3%U JOSY&+4?:5)1OV%TVVO^#'C;<^_'AO,Z0?C\H5>$"PV$@6F=(.]#>VN=
M@6]KGI_E*+'G)B]XL;\0"O/TD0R,->P(L-K,Z(ICTTQUX- M,+H+I82Q(7@(
MW-(Q*[!7YEBKFHIJI\=W 9SVZIY$W.J E^63-L<)WM[9'DV#<3<9W,9 W?>B
M>)&=VT-C4?/'N<@3JJL_G-!P5@@WWJ^S9G57S)W3P@K\!Z'D+PSV8.LIR%%P
MF&LDRIE;'E!2J52S[,8'H0E-AEC[4GR _-8$Q$JD?:R?,3ALD8M-C]DAMZV<
MOGO.Z!"GJ?BI8[OBSL]%#E7[[?'###=M]B%PZ=9'[H0&Q4<>NJ/OC)LO65;)
MG_WMT]!Y0"A=_[I^.[Y@(?<41-W6?KSZ2$EH4<AW6%/1HK;D#'I9_J?U/[+>
MG_&FY-OH9+ _$8B:*DTVJFZKJ0LD'<<D&FQI*EHA0QPLZI A%L6_RQ"?.E'
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M3],)[$QUE:L,L?P-%"K6AF,&S*W&@KXL'.R3JVQYGTV,RAG+I^/+IVRP:X6
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M!_X:6WDU'IO%6D<RA)Z@]7!0G9LJE.A#M.?3J2W6O=2&0/4V-:CERV'02B3
MJD7Z\2CP3DWSBE+PQX*6I((86TX:U90ST:%KR39=;E=PP%'><MC.EQ'&S]Y4
M0[BQ$ /=JR(4".9O#01&JM;=0%+C\!GGSM*MU5<T,;]%S4585'H=$(> 9@(Z
MNS=U'/4$].[HU9"3*;!0*LA;0[#H]APBO5W T]9#7W"/@.:T!A]ISXH.RFP
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M5W2VD7A#K\G3L.*/!=WQY-'4 TQ)"6WB4\$5.^^PJCP*%[-LH&&8"_^:OUC
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M>_ZNZ<A$7_5-1'=.;G)I\->W#_#U?+&XBL/QMX*9/!.^DZ (+@.J,@DK,VC
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MU9/P;#K8F!Q<X3&'S=K8%G-U+""Y0% LU,'/(.1I8IL]4VT)HH!-0A6P@!L
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MDMMD/_!#6\"+S$6<"3,&N96T->1KAWQC3C@K* *9(LV27MT=S0F.EG/-/UA
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MS[#';+U,T$RX%D-4Q@:RU"9784#N6H_ZKE\O(4COQ)9]Z_'X,-L@=GI2:.G
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MH4$F-G_*-6?[)I-5L7WH"O*#;#<3U('2#=^"B!*,^ #Y &CN!,"6'G+7-PA
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M[4!*&K>S$=P:L'0'\@&+!V] #^Y !B?Y/3#0E>>X YE#(/,&.7#MDB><=9.
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MS!\Z@DQ=_7F:P5HT"I??@21=Y:YN*Y&6B@6>.)RNQX_XCJ.>1$?SL\8W+N]
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M/--RM(#6&O\R5CFA?'IR,1;E??[&-&RDYF9C;Z'=#N1UC<&O'ZIQ+D0V =3
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MAWKOX>U4C"IWBH6G;^,V$KCQ>51D1C@;#3^,;M2QL(HGHM,$'=:4&<.VD[M
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MGY*X<Q?OW&ZP,.[@3.9\C0_G"[MMZ2,Q,#"*:]75^E-@ 'P/@G>Q1W+?@$Y
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M)04F)O#PS5>2V1+H#\:#/'TV-1R:2J J--_#(&?Z<&='?]1HRC<HMKM27;.
M2*]MRYYI=YF-N[@O2&5?[[;?66X%:Q9UUQNF#>U-*C0N>V1=G=OSRD7CFC/Q
MI9^94[MIRX?+%?M[GE&^%6S8667,?D< :\K*9@ G!BS.2A8=H8[^73Y24N"0
M8'+:)'8M3V(&F%"UD;L[ZR6=S/#[==L]).I5@]8,X%)^[5O\!0X,5(N<E@;5
M(P"J [A<BF9VC5.D+?RYI"X%TGVL!,\>$+K?N'V^"RF]A)6\4(V"250;S+<I
MS63JTSWI"TSP=_ 1?Q\@]F+_]^XWN>[IE\%U@1%M!CNY<%B6FSB:^ ?X6%;
MJ#SE 8P19O<+U&8OSR>=3>/#AVKU,-)BU;+ZOZ9W 0@J4A;MU:W@\MXA+K#Z
MV\^ZYR>[7O?.*1_;;GTYSI<%$2Q'?A_SMX9X%18N39"I2 F3M7DQP,L0ID@
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M"V:2VE^QJF((Q'F43*$]K]<7RJD.UF_7-3P-R$-#=0/.3;OVAGZ#U&EA)_9
M=?@U,/L1;Q19W_2CCHJ,P1TF&2^'060Y'K0>[BO. ?IMX"K^(.SHG&_.8Y/N
M;.KTOK? $%P6Z7@U+<K#OQB6P?KKU? MS5?(V7>7Y 7^V#RR9%9Y*3@@(.)@
M8U,.P\W%*O["6M7==/2)--*FA<C;P7\36EJR3;HP YRK'%._"SD'9"E*%XP)
M>O^>79=*%Q;FML7G6%*:PU BO//&F74#?N]I?MY!Z2A;Q9<4XTI;I6;_2%=1
MUVM"K=^G'2)GULH;&H8;\QQ_J?)+@VPZW!\W06[?W5F39 SU4'%)/#A'?=2V
M!R[Z8Y%(;OP2 E>>\,N1"8M=&33%-,D62I/?C>CJ0(LM4BZ6?]2Y?SM3QHX7
M$E(-J"=PI%(H>$$ZD%*Z[*[<PGV+Y2\?4F?6[F(/9%'O#6U#)]:A<7RA);=J
ME+9>J5L:LJILO\&33#%QG[-H:TEP3#=13JIU&=Z/7ZTCW-"RDF7Z7YPG(HZ2
ME#X]4I#W/KI0OR7TXAQ<-*4O"*VMKCG1O?G P)SN0U//H3$<FW+NWVAP?IX:
M*)0F9_1SY9J=VODRY[56J(Y[7D/ S^$:X.,\?$*V^W>S6?ADON,7C#2UWVR>
M_&$ .(%/W /=MZ9=;+.XE+, 26DJ5!TLM0WX9_;CB2IPHOXP3;%W#W34Q9D;
MYSFR4:&K*^7^$:71#ZG; W$D\:QBQG@,?#Z?),8DQ-7CA2%/R$+P^7]F0<#'
MMY/H 8I1#4-Y<4VJ\/0[P#^\A$+PL]1(RHF,"ON\&<KX]=Y-K2A^N_*EV-S2
MI^3WZ(]=S"+[5'KV^,L'QN^VSQ@P@);G23<B$(I>DIV-S$]9G;>+>YK'C@<,
MA92DE/SU9MDHI$;_H??QMNVAN9B4/="T[*<]$'013B'7SG&D#B,!#7@7<D*@
M$U>[T\X5)4JR== [5 T*.&56 >BEIO"I9*J*'I$IDPU-L+7ZHJL_<Q8)\H6I
M#JN21SD>;]!U#O$6;8%3W;8!DKW'KVPO4G"3LG2!F#T0"C^92W^,UOMSD"2%
MN<!/1)@ISGYF3DF)/U:E,8]"\ZIJ+G772"AF<%,'YU;R,&&LS=[#-?X!L"S(
MLS=9Q;_\<&XGW_09NPPP&?W+5S2IG$/:K&K)N\&::$WYNK0'*-D[0<^55A4A
M58MR'VTK[3Q4DXJL1#V")O(:VG)4SGLCP#>_._O-5**NKN?,,9 .;7N@$U@H
M[R-2FO.0_0C[!:=8R=];KLL'%3W^W(* 8A:6H4(N\U=1]I\#7!7&D[<O-@QZ
M#FV<"+"]WM#Z94,DW/U8YJRR3N5BYB>7TAEMNRU(.WY"D?6<(?/T]]MY=@QH
MG+%!-?8C"<1]]1.5(<M 9W7DB@.(3IPXYDA>>!R$I[ZCRS.J)S$O^&Z'#HJ5
MB)^@T7:T'FTV_3QDZAG']$QZ]R)4I*H0<JI0%IQ[12NZ/*'K,T)43)*F(F9E
ML;J2_V;S\XD^K8]L TLZ-;[R!S=6RZ.\H#PJG$R7QSXTVSK&/LMK1S+XXMAO
M8]*6AEM#S/<.'%V""!X#9JBXE$(=)F1-F;J1I"+/M,1WH@Z@\9<S'  OQN.>
MZU]"YN)@!T=A<QZOO@*&5Y-7;S7GH)I6PNSMP_XBF/)7%P$(TT3AK KN:V1G
MH=H[9A.E>D("I\3K1M:EE_FLA?M[OT8WT:P:F/"NNXKO^@_F?8Y[[8H.[V@I
M[DEH2K<M(=GWR^V!S!OZ &2[NRC#A$3PGB<+HKT[9/+&&MZ@<YT:&*28$C1V
MSIZI4K5\HKQZ)<CW7,Y3Y*IS?H_BBD+E4&_48V:QZ\ I4]6E.I12,'%'@_:@
M23'[^WEY;Z<3+D_G3WU[IN5Q^H*=DFYXP<+[KW8*Y_O</=RS,?<E$X.)+ZP[
M["G44]^;LUWU3]H67TX[<U)M-'^PJ7QF4GVZ@8O)AZN2_3<F!>@[71E3"%81
MD#(/%US.(\3RU/ED4 >FR>N;%1D)-+;[QS=<(:,;)PF\8ML.&AN8Q'%_&.:%
MIO47#-[@J;:E*TM,YO<6,M5LBE\"GFQ1SEW&P-HE]G[,M5&L(OKR\ ?R/MQ\
MH=$>Z$-U8NZM%9+X<SXI42GR*)Z^4CKA>_JBJ]]R$-(M'2FQ?,O5EQW8<$!G
M8>8&LI[W=1!I>*4K4)WB)776^?;9-]23]P!BIAY+KLO=\>9],^0?Y1<^G=^V
M<DR\4R.M8>67&?M0U.IV"2(O-3\Y</<G1\%_TVPSP(N!9#WG9OU^Y'L&H],,
MF,VC%'A?>/OXE/\7310ZOP=*Y."*'(%PY]I1>)VQA:<7 ;WY61GUYV#HOT2M
M-Z*VE)V,0_V%N95FOJC'.O_^W?,SH0,':!BN692Z8WO=]8$XQBIUK:KF(9\-
MZ@+5;!], !#U#[J<,I40QQ-#Z_6H2/!ZOOQ4/F'1$S_>M;-[OX3@Z&X.B:<2
M-P.]HWWVG<O@.^;R+CZ&HUZY2E)F7JNCXL16>.J,2+\ *E3<[_&)%[@JP*VA
MW.?'=@YCO3+47[?HU;E*;Q'[EA?#NCJ6W'KK]A"O)&D!4Z3="X")O\L8P99E
M?9MP[9&V@$>P3(;[-+2]'K!A] >S:(PH=$W=[%"NAZR\?:&"!,'A]"Y+1OJ,
M?+RJP -YS3R$6X"_CM')RI!1-JG0;&N+.<>ZQFTDJC*]>4+RI1PP &:@Z.,4
M,G#2/87*/LE30V_1W+/FUUSFXSX!BKRC.LZ43JS":'W^C$77U.'$:FB2\1E?
MZHN4J15Q1[?3_F_NU:,,N(0]T'PVOOY;%N\SZ1 7#]57CFPO/,_-ADGPNLB-
M&2D;1#,"^O$"(H$L3/2<;PN#*OGF!9;I*Z0WA8<63P(I?]8T#=]M&PVHOQUC
MF3?7^]*<]^QDM2&424FI_=1L^>"$< +=09M"71K/OBESKCXX[[U(%O3?LZGW
M ZY5>1F!);/F-RL:2?LOA&JW'MD2D18)TQ-.J2HY!;M>/]:RZULYY?Q@9B-R
M:6J"YT7VQP,GO-=,R["#\'I>.2.7SRD3>9J8_=PW''D&G8*B#AS"CL#DN'AM
MXS.>\_A#OH4"&>U(R9]P*8PQLW(GS1A<TO[:91;]:+HC7";<.33K]:F4B3KD
M()Z"$ 8?X)P'</-%BE>-(?-X(;3CU9W-E4HY!B_.X_6O@+>(0_5361J3Y_)_
M559^)_[QU?P@XEA:I)_6=Z"\\^9.ZMETR,<M/T>Y0>H/$R43D6L2YU?0J;C1
MS:_DDQ2:GIQ]S]W39[ML>FN)*HK3\^_0I\;28 \0C2]+9%Z]FG9#E>8AW?3)
MVTM2UJ88>;/GG/L ?!Z:,2?,\68$T[#9#RL!@9Y=\T%C1(GSRN/XM(>1!,7R
MR %-'81Y<_W(@Z^NSA]H_A;/[_T26I_J R_(<LXC>8)9>Z"K%IUD  W3PFVY
M(6M"'.+R@GK$O+/+:,$%"2?['TJ5:4J5W[^ Y2/OI?2%V[>+C$TU,],,+GS&
M)+W9NF$UGD5>*1"@X]-49+Z_)^93^,7JZKP2X72/\8!R3A!.;I%SX:_N^V>+
MK@AKAVD(/J,SZK5HLXJB"12BZ?4;Y<67LS5TKU_38@[SE*#\K/UQ#_1*G8;D
M&$.DR;^JBO_+6#W1\KL'?6+4!_Q/LZ >GMSF!L_[=Q?Z=1PM")9-_IGI?@%'
M&Z3#>9@(;-0D\/OYEBP_A]S; PU*,*$\%7#R'&?<^C^M#C_<I'"=L'G$KNI[
MSSV02$3X'DCO_^M&/Q^EA5M6(S[: W45=^,XP.\1_V^S/OD?DW['ER(?=NWW
M0$/FZ.][H!2SU#W0+^;W7SO>=,)_;(_9?V\9?S%'V4_@2^G4#,Z9[W.< ?X%
M//9 DD]^5NZ!7F<R^2Q/)D-^#[1%[]U:'^A! $%DCJ0&+S$W"<=@8/BC+[1D
M_(>-?'>IF'=L9S]N4)D" 3Q[R;_P_V\W<XT#RR[\TJA.S^7I_*8BBSVYBS/X
M=#R#B@-.(+CB4 F^^)T'^&/WAT+^RXCM&C3C7%D_R/?0Q7@XHR<7MP7G7R*!
M8R4PU,3+M.B!<IR-O?=  QG0@5:X,IS:P=>>-_&[Q]WYU8W2SN2/GK?RWU9N
MRJL,(.&K(-]%X2(X:H8N?R$X_E7 0 &X!,55RTU' O7H@3T07N5WMW=K7QS#
M% )HA*7-S\FB!1# )9H<Y@S]I45'7E.2M@NMNO.C%Y'$L/7/H"[?)>9V@</O
M-R9T.C?E*[_^TA.F>]2U@G3UX@7(?SNO/'=?T-71\P.QYP.M2P2LGGEE?E^S
M+5VQ*H^5I$R="?6[_6:H-KC@VW86*B]A:'S9++X\M3)A]RHP?KG1(S%>3]D^
M-ZG PZI43UKDA.P^$2O-A_TCY>/I @>BV[LK'4Y5G),%7[*8'(IU^-^A8H@=
MAC-L,J82J,@U22:.2HA%D51ZJ'R5W!$@>\42T?YH;D7P;M[]EV&O-K=#ISV"
M3^>MN'[Z(T73.@S3#+LDP)$.9K7]O7\J@R)9$,*0HB@'\^-#? \$?XF-0$I2
M510E$SM&YBO*IZCE8Y21[]2*DI[".+,;@3J3[[<N3=;G.]=7#7(CLN_@?-P?
M9GG)+T@N&]*$VKV=[-T*[HRB%#B7XKQB^Q@A9R:\G,474[4T#>;?=NCEI8[0
M"&K-^-G_Q-)_&C'F_*E>837]7;6Z!XHOB/G;6/#TV@;MP-P>:'RJ\1]^W!=A
M1S>E1=]@#!?9I,//(*V%N[\VS.\2CP?V1F]6XT6]8,CQN9E<6QUNT0@)^GH\
M42&,6=<IVT"N)I/(=_APB^,7PQ?PGU>)%GN@A!@:7X(;C.#^RSJZ60!AV**F
M2F_FD("0('1/] EY#JXID==0(\"1*F<5/7TW/@<^\Q>:X4H>8(=D##6F<M0S
M6^:)! )G. +A1N:#][PFKNN2+P9I7BT.X_.6O]BXR&'F%NP9?Q!A/MT[BUM*
M0N?N@< "72B>_YO_M):W__Z(-1T[; -RWOD@H-H4XZ7$G^S&SQU(>CV$80V>
MLKE\P!T 5XD90S0V>5-T9F4Q6$B]Z= WKB&UK[RR<G /Y+!U7O,^'+%B-;1[
M$WC:5L_$9\P%;LMNX_0F<?^'$-TZCYO_!UGO_VPF8MZS5=E85>, 8TSOWPT7
MF3U04_6:\+%]ZYRCP5_1]I=ZWO$F^.#*]E<RC'LT';V)PHMYN2-G> WK S""
M.-?DMTOPDA>7Z5#(Q8"V5>C*SIS[_YZ2*QS)@;B,JK/C6)'5C%_2)?P$^:EI
M<Z'A#K>1=_'?/_VK!=AKC,["V9;&R#U0H;_/=YZLN5O0??-AK/*G%KXHS6C:
M#@L:H2,(H5I;4>H<Z^%(=$]/AC]NQ(SP<Q+Z/X:D\]^\2;*2VBWGU0X3JX=4
M FAKF'>Y !O:(+"&8[[ZT] 5<*CF"E==].9%1P6/*[>M.GZ'R?4&BOR[BZ),
M(EUPP;U;&]5XATXDP0":LJQ#J^[M5KD8Z4+2B4 MSA1D_(^S<,\26/-@QO_9
M6H4Y\]D('<5>/'_ AK4'6AT;039 NA)<ZWE* KP/5@*\ K#[7%J 4@K%_**N
MR+^/491?2'OR\ESNXAP21DB!6$Z9-W/5B4ZU:[0=9=@ +P97&;E*_]\K0V0(
MOGZNZ[;I<3JE65/P<_P,%H\Z_SEXMD87[D=.>9K52*>HJK0(L_= (W\^QFT/
M1&+@U+<-@!X?W)TXK<T]$ $YUK:]^1!V(4H_B-RU>P,@K:%BNDCGHUKIX]F\
MJ!E.W?^,CRK:*JL%Z!4/R%61D5/F&"^>_XS@Q"80JE<=#2&-R.ZEC]/!5%V]
M<<HC)3J/%@/GM?1_*Y2O!/2.3>V!-A'?48ALP^E=$DE,8_G4S_:.F='=&^@!
MPB90V3W0A.F/P%D^)__/?CE'9TT":[(S+0ST+L O[;\>"-Q\ZA@.:4+T #L!
MK0RD?#=&Y]ARQFX*>P3G"=RMXCNH+P6Q2Z@EY?"=@N,[Y1?';(B^[!E/KM\U
M1\^OD:')KC[L\,^RA+DH153D_^X5&3KK%[>(IJ8S%WWZ_&+'(PBW+SV*E)T&
MYT@ILM(S+J*,A7NJ8]4O\*-I'#N7'N5OF(-&*@-ZJOPMBM1<1JWCG'?&.SJY
MYTC/SKNP$:\3,L#9];\P5G39AM;%E%XFZ<<V_'\D*,3+..!D]9J.2M@<6B F
M':-\K ?.4MP#7:C0R@!.0=?@\AU(#$R)KM'^"(_<3=^F$[Z,H?91'Z"P(A_U
M]T!OP[6BR,U<_YE"41QA<<A"%.?[,V/W3U\.2?UAY-I<HNS 0E,++/7_DF6_
M-_.3:BFR03]B$L?8(. .?HK$382/C[ ?>ZN@@%-[H#5G?!A_6]MA>$;,)P0/
MS\8Y?W)$"E')A[Y-(WGF?64_$;^BX!"]KFKV-=+?SR.WN*JDO]?G>FF&,J2R
M4)H!%]E*'O_?XPGC9LB1AK+J,\*@/ 4& KG?<E@>LG4:EW:OGZ]Z';A5Q1H*
M"128T8'Y4\T;>Z K8-S6LN,GF)290WL$#+]MY05S=\=GA$78X7QS,_11 S_3
M=J\M^T]WPK2C6IEGR8B>/C;^?^? T?PJ$/T..[X$<S.C9ECQ]CW?Y>.T:\UE
M5H#_!Y$WY&R6JL_W:J(SZ@G&91Z-NH7&__G%^,R))]7NOK:'DR-"+.TM_=9G
ME>U[@HAUT>L'O'%J<(_FG%%=V.3AD!6TJ5%]V4#LV1M")==M0\N#%AP4])L+
M'$R<KND]\^U>_GSC['>'+/O6"[Z_SS%67'1/4\";0U^[*QCX#1.T37%'T:T3
MMVR?>:[Y&[F:V[\M.?CK[0VIM^:FYF_,EWB3_Q<4;&M0O;O@^SD^#-T8)H3:
MW19 @PJADT=<G=S;GQ7.WKNH^[/?ZO--5]\64GZ0RKC-<.#0Q7R+Y[,7)!6=
MVH1("\;[/CQ*]18#4R.N6=ND%F=^KTTM5BOPDM>^:).:G9<9H+^>CT!.^7#/
MD++EDO5KY'"OR6FC2PX$H1%_&Z9MJI]-^8W7MY='"#;RO;'+G\7.IM*^>LF&
M3#WFJ+.U^+,]MP>ZAYH@=V./,?= /W88;'M&1K*Q-36!@:V+>H->[,:>2J;_
MF64W'$JH3Q_H;)DM\T6I^AE9QG8O'/%\/RV8>/UXIBFJU><5*4/WT^97O+"2
MC-U?'5[OS]\(CI<]D% 21^D.5>^WL2Z^=CKZV?<-\S>S"(<P[)5NU^#NPN.+
M#>_Q&>_K$M\/)S+U3T^X7HOJNM --^E?I;X+R592%VI.]T)*II29B9IJWC[U
MJ3SMI+J<6KW0R5>M&=E"0"M/Z!C[3V":Y<Q-P?E ,^!B^FS1*ST0,$>2-2>2
M9C^Z4?_RHMUH:)3>GTWCH19J7H9A*A"CLK&J@()$;PN()IVK_+VZWE\5R9?K
MM#:P/6,@Z6< M!.F/%[/;M-P_=+0*NQF>WWT9RO@/K5C-5*_.E%:WU;;VO24
M^KZQ.?GZ_:1)M6LVIH^;9?0.Y'I'P#SRO)C]M5_%?'/I>B)5P;>I+^X$3;08
MU* %^\M.FLE?ECZ]F97ZS.[:E*\CXO906(!)9 3^XT(9,YQ% RK9>KPI,ABK
M@;D+#.,8M1LLJ7&RCS DD2Q!%&";H!VZ'0I/,7ZR!.F(.)C\$$D.2$%:S$4C
MI8WUWB)]SP#YUG4Q70K*!1(-\46^;_O(/@L86;8&N@J1AF>8X@7<L5]:>$6O
M.#<!<SI?8RJHQ\VU;T3WO^; %9 =7'"/<T_"3^X!GGC8(/'VK.;0L1J&2CF-
M+.?L-ZO5-%1?#A9W\K,&,L\$0WX&SX,!#?(/2T;U%2"72DY UAEVX 26R'(<
MG3< A!9:F$1]7PFGGF6$5=3JEE#3W+]='P\H<D^2)PSK+$8/?C73R%XPE=2H
MG.)]AAS0;MB(P9ZL!SRH+KBCV &L\@A'G6%KE_QQ;(-*CM]^*006\<N#Q[OT
M3_MZ1_[C<JG$*E.[;^QIK(C@??A@-C'\7X:6'B5HUE2D6H"?EQW]AN,5X]Y[
MZL;6O"" :.^1^U+*8M)<NPL52I3&*D6N&<G=O!HT010U6D?[CG3?#<H._A;8
MW]H06&UA;ECM)CFZ&OQK80C^ #=EZ\C8 \7 1'W@2OK@)PZX>BA'&L(O_L?>
M<K"(?1SC^"UJ-04??]1QE2]"NI\0+/Y9GA5M97HGK:\/7Z]A0E(>-"C[\:XG
MDD:@]Y]^<^]A?>268.&<D^\8\':^ "$W970ADY&2/&7>9[($"8JF=)$/D22P
M?><>.Z0^J <GNJL/_H0J<ZR9A$Z$M M@/VPY>+>VCF&8R!%G5-\D,0W&2E[Y
MM7R3J7&?T^53-6PK6P+[$:L!!-/PL=CCP#[&M"L00$<D/E[LJI9$7[G]Y6[;
M4 ,\":O^7M9Y)^W3UXL#OC0=FSN68T6>)A65BKW[LZ.=/+$NO]]^"N-1W$]]
MP<H#GIWPVI[VERY_ A<\(DHX9X>J.,J$-D*L?O\5F^8Q5,B:@?3MMK3/-9&1
MY1:^Z''[M;+96>0OG'_+^SP$'$S+B*_IV_P::B7^4OL<&))'JW%"[9:TOTA3
MZB[5/+\'*O.L<:P(K5F[591$\7KT[QM:T*\ .8]3WK<?2O1T40FNM74[+V<:
M6NVG35$&V(#MNG7LGV@7%H5;M@?RATMB_T4*FZWY4N<F1C'>['W+Y(;P#*S&
M<J$0@'OSE6,&I&BD&B %7)<:9?#BQ49BN=0 A>'+^5V%:D/UW76M;/7OW\R#
MO0("#K)"2":\*61#TX>-1%P]_$=D //M5@]. >?STI-U>Y1\9R-Y"A5OK-+X
M-SJ8?HU0"B!HE8L):P_J4RK!MP8QRE'%_K/'AN -LLA-[6WUXRS6@0>V+%3W
M'N@=^(<+4Z,=(LI30N^P_ !;VL!!SA_OC! 4DP,NC*^RC;.B0\Z7M):=]3?A
MTW>'OF?;.]4O!WK5YMU2RQ%XV$(<H$%_7)3M!$]'LARX)6IMC'-9# KK-N!
MAPH!AM2UC'BOE,XZH+?S89K659)"WZ,3+_RI8(&ED_@)!07G^C%GRD!X(%/M
MO6PN.H::]H"2AX'^U?YMPK@Z\4S]V52<*&,W^G/MC\F'4)'N](<Q%%I=:@\[
M6/Q)>Q K(&?A4;S+DT\/GW-.*! 9F3:ES?<R1YO0,Z6LAL*T22>W<K^9%WQ=
M>T@%Z*&A_L+5$2B]8#&,/Y#$V*)!,K"G..<!2^J&) <&A#)V>N8DB+C*59F6
MOUKX*=:?*6G+V* @CJRZJ[H9N=U R0+)7H/ZR#K+_8ZGB:FF )6*FUYDS8S
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M;=<J[+^?9_^=FOG[*E=ZJ&D5]FUDZB3 EO\R!G3)H26JO:3P.[%&#I3+J6/
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MEI0."9][JOCQAO?E;>=D\82]JS!F83H.08"8C4BX\K(<?NNKO(5)/Q">1;<
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M2(Y/<Y4F\0KJP\:E!5;E^-&AP''9'I[4MDC8358ZE\LB<O)Z"Y[UNU/0K-+
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MO4L ;L:0RI>PM]9@[^!("G5%M.*!MIF,4+5O,U5NL<&FRC:TLT1FII9-.2F
M85XYS1]D)E9.52E=0H-!3=YE?G=,N^Z8RN0#V^L%;&%HG1I%3XI,J>DCR'21
M-DFE \8FTESEK+0@>X@4%E5J8NH)-QB@7F]&; 60R31*@?\8/"H&FZ0D*]HH
MC1AD,E'/&FU?044&5(-KO9^.N.>,D]U4&[V6+<<$/LF\;!"9;GU-Z59%=3EY
MN0; B,VGF3$CKQ<@3X;>6.> )*$$3S+<E+^3_X?_I_/HH[NAY+,&Y_PB0[I>
MJ<N6!;(4B^ETW8FAGVPR_!L3Y;TO1APIVR/R-W;BDFDWAW$IXLTTVQ&<L0PZ
MVKSD/M]<<)T2 [JY <UOJDP*GIJZ-7EOJ C7)R'[!,53)?:W,<;T=PQ#7GL:
M0B-[X2)NPSA20^D"5%E%2)LP,* MJ:HR?IB[%E>DW,>6^(CTI/.C\W4X.,VA
MMFNRY@W\XH/WBSB@MEJ^[.1R*FW B\]_HD6]KMIH#L3[W0H<5^E"=?*U5SIX
M^^<JX]\Z5*@9>S$QQF2%X-Z-,8>DKAW9EUX [9(,_9'SM3F+C1.5$2D'8_*L
MI]W.HOMV9\)_L-E)FEX8X!4$U0%B>4LC*]4AF34RM):J*Y7/SR31 N7PK1->
MM!/573SV)BK3K=,,8*>AW4NIUP. Z6)=_M.@,8QA]Y=N\LLKM2_O6-:5$XP[
M,+M4]2H+<._](H8$1:V2-BX@]6TS_/&UW9C-$J>96R(KHG$+*PR8219Z8+(K
MQJ/><:FSOAW"JS)M0)1HGVJC77G&_+FT<L[49=*0-$#U4;A,ZH$*A73X-.<V
M^E".3[I(CZ8/S52,(=2EUW)[JB;!R!,82IJFZQ+[VS):TJ+9VUH4*V8- E9R
MR$L<G&B<_T@^<7S2)GZ%_O[;^-"%5[#YH60"/ZR>FRK@WJEQ<D#I.Y=2ASRK
M.\E5D]&DJ7@)8D?W?)WV@-KO$3&'P,C'U_H-,YY16Y>1A!J@WW\P G^U,+X@
M2&)8X4W&N+U'3*@! 3 X#]HL&?*?*MT[;9978=L@R[<J#6F5T(BV"WI81E5&
M7(0( 4#^GX&V\:RU$TO%Q<E)!521HM/TP"K,I_=@@8!LUY<UC3,%4%-;ES4#
M^8FJ(U2#!49/93'@"K[YS$]#6P(C#;$6<HK:.<,C\(0DY670I^F&S  \K0PR
M!;*R;U8-]IT.O4G"-KY!_-/5;-^;OZYKKMSIQM3S&F0*^[DAKW+,82AI%7:%
MH!^1<VNE("0'IT=DZ"KU:P7P1K=XRU488G05MCGFS04<8F!@  H@JK9*T7Z<
MC],"MN1WR/U+#WK7DX@)^4 \ *\1:=#[Q5KB<-R6494F4)S-0A\?(8<-M]P5
MH9WE%%/JY3FG<^UO\P_Q@/G/:>->?82(I<OLE(,[04JR>4^T1;?[H-!X.O?F
M-<K!2.\O)9#%,H'F",V.</O=ZO,UEPT+*,O')OKM$LM(M9@#0.\+9)IYMTU;
MZ+Q)>8*%JTC00[,G%U'9$L1^X _$GCO_D#UG3PB[K^U../[TD=! CDM;A?V"
MTJ;FUL<MY V;FBPP0'%Z#=D>!UU!,PK<AJW"FA@Z<_ML3*\WJ/8"R]:<F\$<
M2.MB6I<DJS]L8>5]4L+"&^1I(*NNT#<BYT)V07W?N^4+ZF+!UEA.<-,,Z4>@
MFX9\15-'J)37OA%R:_11F?<8>8-7".O0#C1R"94@R<:/FW"W4$NI_BXX(R*X
M69#76W"UO*185K!9ZZA\!MK/;IC1&\W7Z8Y6*U1V3<]"I:)20Q+7-L2,;D_Z
M-<%%XH.QE(H,J8P3G?.4*34#SUZ1[H&:AM^03HB?IWW%]:+M8S&%E-^R+V;8
MKC@W8/FL>O@.4K]6,AI;HO1X& A>*"CWI]Z07((HW' -W\Z:*;.+/6JQY1M$
M*N,09Z'XILXQ8U'&<&K6S+);4]S[^^4#8PY7%I:\"V/)$J+(3#TJ,LVY9TIH
M^70""9L?Q#<PMM&<W'00X_]LL*D?SH"_S8E-K:F;R%U7FWZ^*]K43$+0F9I;
M\;KXBM^I8)\'F$HSZ529SC[Q/:4U ;) 25H_8A#41'D/ISXC_JW8&.TOYVJ[
M@YVS;KQN)0G$,]82<UAI0A<Y8[,?M:6Q-FBWL)-FH<A R-SQT]/_4#3'$6:\
M3K)5#5(OHIUX2*LSR':EI@:UEJ VJQ<!WK\J78"53B,5C>/;>(.MXYR&H8T8
MXS'10:A2\9?-C:Z0VGR&#O5'.[X1A.6,1HTW?_4%,PMOO CX^:"W[&M:-W:X
MA+#F5X1Z/;"Z2E\0FT3S%.BL+*;6B)E+_WI08R5!.R&?*IH_ O6Z Q7"!W4+
MY6KK33KU"F=,$D0^MGLHK^N("36?EQ641-C9J4CV36S(8EWZ\)3#EXFF#N4I
MP#X#K3."7!ON<5_!,.VC/NUJ##H,9C<1MGT\'48B1Y6/B79+E<YRDR$]-T5E
MG*G!A=?,GX&\YFS%OL:X@ RW!L96QO!?()75,"&'KZ6N2[!LQFK$L/6PC29Y
M%B>K@?:[(CAD=A:TOQ6#TYG8#$D"NY1^Q1_[QEZ2^A$<.6,3Y.-YYQA//(7;
M?))"JG)Y]NE60C8(7W@)70>^-LKV 7DS3,Q^B.T-Y(8[)(" O>0-I<DN6W40
MU,VD^1"'=705[RY%J.QJ &-^HY7_F1H?=\OZVS'^K:\^9VF[TI!-2,!SYDX<
MHR\48"2+=D-=YPA(HLRX5^FK,NBE60U7FKVMK579=F-V*8/5T>-S]DMI&X!6
MG%JVIRA/6[."H^+M^)K)Z>3U:I-8>_(]Q&H< LZS3&0M"2-K /9%2LK$L'A]
M/\FA-7 5UN3;7A5(@"(M>]+&>.Z(B1/@ID7\5MEK1:O53S/..3?1YK&E$L[9
M_N#Q.60&%G!';L:DVB4J5F%]71=9 1WH! 79^JS5'&'RRX?*&<Q.UY&)UFJK
M!V/]@<6#_V+U/@MK>N@M*]5(Y1[]OH&@ =>CA[2>TO:N",5AC'N"$F8!U<<7
MC,RKFA#K"-U NI-)DTH3M+\[HQ:KR3*XM$III< 91:16^)[<6LLJAA[T6^G[
MEW[)/\[EF1XFGP>#6O9]G18/%PS!;*8<))=ZYF;2XTYG<>1_T=RO+(HW"CV_
MN2&X)=1T N"=TKM@)^7K4=D*EV3:_BHH]VW.EA?F7UX4]I5_JF+'QX:%8A]1
M+11BI8'^ADIKM'89[8B(^39H6U?,&?!/;_Q43W:RT#2A$*IK[ _Z&QVE6"\A
M&5]Y-[P*T^][-VQE=%D:.<G+W=MI2]C4-VCQ"(F35R)5&UZ44/T;V08V.AKR
MK>(DC ZQW^6VT$6M=36\22A-YY'T=*N04T# A_%:W!Y\MQ1A\_)%I_ PA6SW
M1MX.G?-JJ*TU/D>"%P7 8BZJAAB;;%=A&UL4N/70]9:]),KV@5%\;_K(C/8$
M4I<7Z-C03V#2@D<(IM3^?FE0M99')]I6SDU>A>D=M)HV"X^><FZF&R=L))]K
M_F?<-/"[HQC:+WV[7^DD%V^ANDBPVX0QQ:1:!P0W"LE4F9!(Y6."H/)*=9E+
M!.R'3\<W$$M).=Q$'B-9M8>P?4RPQ_Y%N*%=P_2X\IW3H\JO><H3*P78X5R5
M'G@F&?0?RS_>2_, ^A<EAHBM4)C<9!5F,*HR!X::5V'&RD/ GPZ&W& BA?*D
M50'7&Q<;S1VS(O/26^/;X*= 2OK[DNA2WF.%>-E+S<XOL9-=<F)-:P9\N.5V
MQ9<.&^TA[=%OF"R*_P\_M>)SN?>@S2J,WQI]L+FN;"*NJE"AG1YE*A,GQ-OV
MOG":6S8]@8YM(=3V\.]:=--<BY3'ZL"6!G?+9HP)D-2>(714I.]3.M-B",G]
MC":=>&^U!HHQM9,M-AFJ-@/ON>1GU&19EU>-0U!Z =1U6?3Z#D.GK;A=0E 3
MV(F8%2U)_PV^ MNGCG>=O<SJQT$M-:9F"MS=F!6ODZ#UHQ\=EM!(0[NQ/]Z_
MI91J$M!)(PV;'FU4.3V:&X"O@3C- L.DFYP))-%-NH2!]VDL1!O*8(D>4$@!
MJ5-I+:61%*@U0Q/I3E.K,&8,/ 7_<EQEY>;7Z_MS/[WJ0]]8-C[T4ZRAP6A<
M3')&%,4VZ67#[V1LL+C/N)%H&09HRZ<$X?D&(/9V-*3H_.R;7:\ZFK,PTJ@R
M%:9/88(X)20CHUE<%*6L<MCUU^</-+3'\,$UL-GU# I;<S2YGY*J,NA6(=0&
MUBB-+-J-]GE([5)M7H6ET4U!0B-J4S_-MOHU('MHSDFQ (UI.Z%'95#L)=?H
MB;P@1^Q&WX'1U&?4VO?_;.(:,.K=&6'N6!^V1*3%AU)!4J/=+'5MU6-UO-X*
M5(6(,LJ(.G(()&!^%X/LB3PX-9='"$K#ZH\%':P%O@4-R$B8;0*^J+,HKXBJ
M6#([N?(G-JP=3F5X (]^]&]HRR#/Y4:1+G@%8=);,Y 0XM(QSV8N1=X/'NZ;
M\W<_=;R)M:#9_(?MP'Z-=S%J'6I7QJ7>(:7&.%U=NAD1@7TQ,]GR;&QVS$BL
M2=L<'<]>3_5Z^W!TH=? EZA/#7G[@.@)'?C?V TCN]Z?9AK<"\+3Y6U$<O/K
MPM-%Q.?$I4=".V^P><WGG%CE%OL%:B^EHL+F)'C4]R%>U&$CUL8% Y(F2NB(
MCH]7MF1_Y9C,1)CS?ALJ#*+G'P8^MS2ZAL6[83?ZCY^<GBXB^7?SO\8@H?WB
M27&1C&A,5JK+YI>>F'3W$#SK+"49L5_UL09(SI;GXK;W0],3KLOV"_?RX5*E
M10))H6-TJ6N*6YR ">S/RW^,_OUM_L0PI4][X3H4HV!MAMHE2&VT+5E!T9O
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MQ= 9N%;$XF(__78A5)+@,\DW;NKWYPF4Q<OM6U42\<OV#'0P/#-FYB["F$W
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M+NFR*QZN\(F<CQ$B9 ?J6G"BAS/1+CMLX4;&KLN;!^DM0]6FTY65I%B"IM#
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M1UST=5/,?&0MX,$2)I;)PR6*#%]V11+.'>$R%:^ J;?\SF@UEX6_^%A_O3#
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MV@#B(52@X$TG[?#3DQ3KNF=0M;M;5&GX_5&O@ 06GN_OW]IVX(MV8@)%LX9
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M/=U\[O_PNVC; I7:;VA3-@K%$EYURL*(_K_C39-WJ#R6&/4UJ&N!VHE4BV!
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M07))7ED*BI/WUJ:Z(C?NY>'1L#[)N3-GY@?L\+K[2=[_[OHV/UAIR:"*L![
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MX$'[+C=3%#BY^@'GZ;H+*-(,XGA6QAG#2NWNWON'"1%&<LN!^CQ@(5_LOQA
M59/(#!A)RHB<>I<M<).@X)X?O4)P'[3Q@6*[E;E(HXG,%+ ]2@,:FE)B%-5.
MEYQE?_O77N,-3W/'OU15?6D(?P-#^_3-J\K0[ 4C >_$C)F<#GUOK-,?P5S(
MCBKO6%':]M<P[V-MM"5N#TA?6)(<>]WC&00:- E48@DL)6Q6,5G1VRWT'Z;[
MR3V%S(+@1G:[#1$+[D[S+"3Q/M*H6= L]385J0^]_.Z+:JY(X<'V3AJC(-D
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M+ZMTM#&&E/K;)^SF%9)W8J>NV]T<\^ 8.619?+$IDGR9I9*SAGM#?(K8>JX
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MBQ^VJS=(Y6T,TKL[/=6S;(/RE5U]K%KZM03ZYGP>6)?]E5.723^NJTD[S0B
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M0Q]^ZDY(G;Y]451/C8B+31V:=C'5OP$;]!@E^W0(,TMS$5EF)P>P.C5]01C
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MI+T&ZK:_O-$!\S@DPT$[)GG:WJ*;"_@&CZY*(@%]P^T?SN]M7-A;N'(;HPO
M/^W4"L$WMMMH$&,(_I(".EL(5&[F#[W22'++*/!DK9:."R,-5W]8W!W_/><C
M&.KP=(%FVPS=.GUE869DUJ<0N[#?,'TQH_0/%Y[:%[W\%GUC&%"WHPKS^8BQ
MC3I-P$T W9*ZQBKMQ9C95$,=#8XZ)L!80.X"EG#%S(FI</<9P Z>,0;GHNEN
M6&#RSE?('U&!UX".P+--#3(!8M(,T*Q'K_'P,#?HZP[^Y:=1-$355R]VX$8T
M5]%CCC$?H5N+ ;KN3CS(O>":O(&KNXBL!T3MMOA&@]"]?.Z'C/+42:U#=XKR
MBC$]QE#(!/7UI MG8HV< <[A;(15UQ3G!%WN 2"PK]YO[6TM_EXW'_UH-H_'
ML_ *V#BS0-,DM&BRX(5G2X31"PSMX$@_YM$\,---+X\F0)3.>YH3JX49@AYX
M";]5;=WYCAB,&*&W!NMT@#$ZM),.$?=QIG C<((/X*N.3\Y2K\YOR6V@9@,U
M2X.:OR^*W"+3%S!>N\@/AC>:=I(OQ,!.0_-@WQ?D["Z\-)K'7AJ/X8_HC]!Z
MJ#X=@ 3@*S!BTZ!=5OQQW4POSLUA^W@:,XD9/8=%F/I_[+UK<]O(LB7Z_?X*
M1-_=$W8<2MN2Y5=[YD;(DFSK;-OR2'+W.?-E B2+%-H@P T0DMF__N;*S'J!
MH"2[;5FR,1-Q=ILB@4(A*Y\K5\8'BUTA'"J;&=23QD=+<G>2@Q^) AD;VG'D
M1>A+?-)PLZS@9(3_=9C['.CY#W)\9;6J]Q(SF2!U$@8@T#5X;.Q:ZL,2NP<X
M^:.TJ>%#YHUX<Z5X%9ZBHL9BZT65:<XQ7H;5XXUFCDB0Z(/Z# ]"FM;P("V&
MN]2]\NB5QS=7'G+P-1VZWEBSM8=]I7!I1,I#XI_P3,7',?!QX'<78B-+KB1P
M/<>>![HY*C D^4@KAVJ##S[_?%QRSK5M?;NL-RXY-".4*JPASDU_D/J#=",.
M?PXC!+N&1.20'&A7&L0_*?3DSGPZ9O0:]0B(Q4O')- D"5&QRA>E1M&0:G9Q
M,\UJC#/XS4V^X!,J5@5VOV5ZQ#G.9G.4J(J&3FW9V(Q8N!R)'\1Z^<HLNQ=<
MZHHO"[U KR_KG=W^F-W@,6.C1+&7Q;X@H0<JU:4>-5\%IZ/889%<V1'"O%\U
MTPW\'XR"_[.9PJ#0<R]0QD-VL2E@ 8T<O2SX<5'BL"_,Z*R@O9@N!S;^56.*
M2CN\9CYC-BPFU]:ZU[I.MEZZ2/:)@_ 6V2S#?G7&G\^-5'+M/1G(8G?#U.$Y
MQ;ZTK]3RN,,M8<^4"]**W9'G+X=UB9SI-8[VCXL-OE)Z6]#U!S%V_>^5 +_V
M^=GJ@<(_"E"XMZN]7?UZT&O-52<+U(T%GL,F%=%94=/A&S"2!#^IFUFFLW2]
M^\D6#?&;]31%$ <1$LV5R #D0I16;R8O)8L-;W:@ #*V@R:M\@SI<#(3=G'U
MHAE;Z,JHM6(.#,GN#CV*\)Q-7G!-BYOKN&19M:_8^[/]N;N)Y"T$UQ1,Y-:J
M6O@4B+AMUY%:3:K@HI,TR^5<SNC0+CA7 H#X0AQE@Z.;CI;6C08]>#T10DLN
MG\[G.7T![FJ8$6H69Z444/L#TA^0FTA0,IIX;>BB)0<8@.JC!$@N:RD1V< !
M+^M! N[6RH6,DM_@(!(A(,5W#!DUG(6!_:"_HZ9GSK.RJ?-EHK!\KH%P*:!F
M(&^=224$"!']M8,4*50XN(AV#V3<YH& 5A(H.(CR$'Y%KB*"\*\J9QE%G_VY
MZ\_=31DF3::3%UC6%G9>,T8 WE\Z2Z<X<'EF19CD+T,MT&22]T#5<(&N"NTQ
MZBX0<+:"[1BW#:RD+QA H0T*P47\;3-R2BM&IELW4(XWP(B\2EM^9+B7++(_
M1OTQNHEC=):2'9&2550P Z!EY3C8)"+$.$]''_DD% 8UMU2CL8K<-#H,]!]U
M610FMTE[.ADCPP6 2XITJ[94[92MW'<5_S15BLXA!A%--:F)I@+:V#P=@L\"
MS2K]D>J/U T<*8"THTA)D^." Y.^.YP@"?TY@&+WS_E]=).!S<"S:8K/)CYR
MQT/Q8K: '1TN=@\YY]^+?B_ZWUST&8:8,63C"JQ&MZ^%W@VSM(A28!;#/O*R
MF#+2(K@FSDJ-A'POWKUXWTAQ=UV+KNW7#AJ_JV@T"WLC@O,%G(%'<)Z9-%^<
MC:2SO)Q(NWF:"_4!3 .9#SX4&6T\.@F6R3Q=VJ;+$6TS!3]5[6JW>EC(='#Q
M,E_:#G7YUX#1%V9,"Q>OC/M$PU5,JK092Z_M$#C"/+U JSDMR6A4HA_Q !Q:
MD2E&2_U(+A-UF,ZK[!P9/+Z7';B%;P>]W,'=W5_TA//F2E\SSCV@B:0_L,NP
M>,CE=_VB&RW*[35+3K6(PUL"H*X.Z#SG7 >_(H[ Y(D<XG/%GL\-O:8^Q]CK
MG1O1.R\IABDO;(I"VB"2W1& N9G-AN\6KPT]J,,@LI"[\M>26\FGE;3:ZW<]
MP4,'L8JDX.EDE$L#P^R/H? (",Z$#/3>65:DFTG"##DA KFNFKG#(*OI]G>B
M_:=(D<-'C,PK['-X_HF!(ZT@W3ABE<LHDV%66+X '-VTR(S>N*P5=<8_! PM
MIQM+%A6A84;'0"@7'-E)GZSL#_"-A(05T)-,2T&VG+L",TF&**.'R/.9F65,
MST([]A$-5B4%?.AT8M.$T\]9]QA1%A;>4!X[]_P)0L/!7O:Z$EW@L+1*=3ZA
MZ9P>E^X/C&$.95.!GRB;*-='_) C0X)LGY.ATCH""L;8/GZ&PCS9:U?E@WM/
MNUR8JC^B_1&]B2.JP$BVG#:?Z'L (;BC="X9?7MP-%)==[0YP W.E3#VQ.V#
MF;0:1:V* ]3!&Q3K^!_O/OR^L?5H:TO^Z^GCI^Y@B@O=$7NLQM;]*>I/T0VU
MZUCV*1M[N>93\RF34IO/RMM&&PJ+Z>OH- --4?SWV*FE"U+L!2@**G^6OTO$
MODTQMMI5Q[Q__5GHS\(-G@6?A9"LZ,"=B $4]0+Y30ZW"NXK#9O-$:.H+)?:
M3+\P.>B\0$*"IDR#K)!T9%Z2615O,&@&$- ^XZI&=!%N1?BL>\FC&&XZP&'W
MBP8,I2K3L>^'$]ACF(H!T8E#L0@7'!8N\)+^>/;'\T:2N3%?8.B]:1]TK2UK
M]1G.,21T4:5C)LNI#%*S4LO+"K#8UDS31+Y76=>9A4PQ0Z6K_P'\")<QP'>9
MF1#:I8O5Z[O$+D6%7#Z95Q(.E@(1R\L>;M6?EIN'6RE>GO-_2)4WV<(&/&S,
MX,^I+6-SQ(;%\TMV&Q9[F%R.X7)H?U/X2K>B^.NZ,6-W-UM(EV/E3)]ERVT;
MR(#;04C5SDD<^:0UA3X,&S"TNIW1ZS?%M#][_=F[@;-W&EDF',.LR!8P!$EN
MIG*"1L8@.<_TAF8J^7$A#!1ZY E. J-*(E.BV!+'^IJ<9V7N^'BSRUU KM;;
M3ADXD$HH;0^2[Z:14 P?%V::6I=O1GLG%0 ]R3:8L^G&OJWS1VGKC*?4]VV=
M?5MG;]IZT_;+_W?8:5Z08!?&#[4:4E+64&QNBIA'S&.+I>43K62VX.5 R);<
MBVQ: 7P*_VP.SE2;T.]]N5[@;Q1"M@*W<'6B,(W-"6M)W]%=\2RU,EV!>Q*Q
M2%;XX*7-U&,'Z_BN+XR9$:26F6=C,\M&6(@.' JK78-6/3A(#/JQ(K[<K(5<
MN6'#P1[?.?1=N8I]<48GD:%54ICVV^$Q)FYT!PYR7(,+.37KY-XO>V^/ZE_N
M#_S7Z5R;M")'=.6;Q_)-X/&@&/P#]6>_/_LW<_:U3F4#GK&!-:MM!TO0:%D9
MCISVJ\WD=:,I#U_Q_6B6(3@K0(L*>'-\GM46)HIZV8*/QL!>E6FZ2CJZB"$]
M/[FSEOUQZ(_##:0U3#(FV=M@B:+55(UP+6L6 +7;LA#JTN0LK0,K)DC  C&N
M0AK/2_Z?>7EA&[]PB;VSS$R2@T]FU'"W]!%*5!AC(YD*IJ*R-',A1:HB(\/S
MF!63O&$2R%;2([.C)P03G=KA==Z8I8D.L6%#+?.HUARP;SL*]JL<@V\_*^62
MG,A7&'639&/D ZK%_\TN&9#]?<?(O-^]U5-NCD^3PUN]P!L6+4G5L&!99_;6
MBI:,,]G\6_,]OODB7[03P+=RE5]GV-/WUN=?T;\MDI=F6#5H!-]ZP#-OMP;)
MO6#\ZUY>,G?Y/OF=.B.%XK%WS;DD>UYD97)8C#8'9#+W39Y>\,"_LIHK$"RY
MI]=Y8Z9H*PI_Z"_W/BWH6=.H06*/+K+I?J[?\#^!/VQ_]M94:!DX:89U-L[P
M+/CQVB6QNZW]5O K2N"ARXM"N>[U$N0GV.O;1?C[V'6(&S^;<84?NQ8Z%.PY
MP.6WPW+I?>].*V,<UNU]GG('A5XX)>=I*OB",?_F:+0H,8YX6U[-@_9*W-7L
M>C9[^8ZM,H84L*,GA%0\5L . FMO(@0F@,VC:\4-_K&B@+?6(<K)16HI?E@0
MJK*9GNE :+Z)?\DD/>+M"HL=+:SC>MK8UG6GNJG.LW-V4C&B[3KB&QQG6803
ME^1(LDCA*1]TWE;\X3%/PRI2F0,9?>%($F,%6&_1XK-DO1"=TRNOP;^(M(]<
MR@YG*MUTTRX]T@M_.U,/#53HD# WKW.D[SHZ!<(:M<=AW6X<QS%H/JVJ5&>3
MSIN*7B1&5 -AY2K G;\=DB05#)#B.Q8\& C/\M]HECGA[[B!H3*^EHO+RQGY
M &[0];L/O[\(ISX''V_^<>(&0J,Z8-&)G!_UIDW&N6_)8"*%834RA!C>59UL
M\86#F7$R!369,@^8AK"J1*RVYO/+$WPET W'<DPZ#Y$;F>0OTPOMBD>R2]N4
M)\_XE>V(.O@E] R@I) 49L6ENL:.XA/EDG8V6N+ET[I-L\A&=?)F,8;7 H0[
MV6C\<J37HI>JWH(9!T+)C<MZ:/;2)3U6<EB3 1_7SBP'79KBI<PC^X-1T@JO
MN-0/T$?65;?-%!Y]*)@HYS#8?1CXIM+=:H'.M-#L' Z^ZE.+'W6) 8H6AF]W
MK>D[+JH_>YTC&CMLJXR#K<PTJ\F%@HL#S"N@W]C251NN!&P\7,W7H)B0M.(I
MF,D1?^(NP\4G.\U"/D!J.N7ZD1O'*CI94(V7_A8V2291D 2$M:(;3"[<? C,
MM_K\R9PV=$^.SK&)YN)[A?!?N/X^J%\!_B+D39-I7@[3/!EFY1SMOG1GF#[E
MMH)Z7:2CC[E,0IH9JQS)S@!=NR!].S,+'M"F(Y=&@L8EXQ/P7(&PP*"746#N
M..TRQZ*CGS'!8#FPES)@5\#(VP^VGN*27#_@Y+]QR?_2)O_WT_-LS%6U0?)V
M<W^3PW9WE;=FG)WKQ$87=.3J"WC(<7N.AWL@-&C7R7\ML-#_\?]N/=EYKG0$
M>?I7.2<=-$SN8?2&M+K@(>OD-,W_,D61RO?)).<FM:/Q<-M_;.UL/J2MSW,H
M1HRGPU_>3^A=5QKGV-0&?^8R"K(ECWO;M"+4F(548>RIH,/3F6/#H%4+[-RS
M&6(?9^!LSWC<GNW2'T0-]=&(/VG3#S]QR8#HTQ;BHKMG,1B0:*5L07N-!A$&
MJ=N4$*T)+IQ;41EW_-/WTG $C1ZM>@86TEF98["Z4;K%;,9C982?0T >XB4"
M5,^E+W:=,M\.C9*<]"'G2R_<?!K:XM?C=^\:?O=AC]_]4?"[/[ON1]*&;;W/
MKI3AT"[-POSV=_S6;UUIZG$X7[BM/P(.YSL$13@S[(%D[.MZIT/=D-_^5CGY
M&WAW.L% F_V^EN_$GA'\(DQ12),S>@_D2R&5IH"D">X[8G=1I[]FP37A%YD4
MZT?\,*0OT+HYC)F4HX9!@'9I%V<(;!;\?P%]&AJ>[RYC8^F&Y$8BRA'2X.Z[
MM<;G"?NJ]<C<,, %"/!!P#:;AS.2\(.13((6)Q';43)-&V) "NC(<BAPJZ.7
M$DP'H9_HQL<@@2837B+7L1(HEF-\=+-?>B!BKP!O@P(\+.@8L#/9%0?Z0/%V
M>0U_H&=&(MRN5?,$:C!VR(PE-Z^ZE83IHFEFA25S1B52]!VC<KX'S+&XL6AF
MK$J" %*S1S(?5-: J)/9$"P2D[Z75F-6JD@^V>3&R=&>RVPLN/R2:1XHS>N2
MGS6[_$4%PTC#)Q8=QPI%(ED?#3,=+&E@R[VWP?]G9&>Q^G+-_OY>O5H\[M56
MK[:^G]IZW:":-:)S0K\,J%5ODY;Z#>=7QU;Q*7-]#8GE7'%)9)S/!9WX7>EG
MD'YVZ6.PM!#2X<#J2*BBP;^"L</(>=4H/9WS9L!%T2:CK&BXL,>I75$G=.-A
MD^46OMWD#$QG_V]2HFI5^^$H3% 1TG?[8CYG$9G*TQ3G&3F8DO03[VYNRGEN
MH%:!\>&K,+_9I"G$/1M"G=7SK)+!1@%1**E9^&!\Z2NAY"T]<GF<_W<J5=]=
M2W0%^I8Y>2'SSP"OJ^A&=3=/5C+/YJP>?_O\(M\79XJ^RKY=]=Z^(-F0S:9)
M78W(5LVFCYYN/WSX>/O1_WVP^>=\^@L8^#H_CY3GX^V=^:?GFIK;?KA-__CE
MGW^S"/$#"2CZP6;@K$['YV"AZG"U!FU>4)3.$9ZE^4 #LD$B;3!Y0L[,>4EQ
M9+VLX5RDJIK(WAO]SP)[86-%=%=O5&7-@3$^3+:<,W-\=+(5%)'.LB%S5P$2
ME4TTEI50D58]*2N%JY*:=G/MZ0Y,P\-0,5SO/\C-*C:DVC R4,D-4ZJ")22Y
M]\N[D[TW>[_<WTP.BP"JNKW#+'(IN74-;U'=#,F7J^T,4$$%8/?W47'9E9F@
M$5CXW?ZN]QI+#R5X6992891?CNDU<>MX]..7P8_M<V)L0#!\JL7=>IWM<"]<
M]H4?/;D'O9.DTX)$(AO=!ZRA2/;-R,QX*[8'NAVX-BV+O.J1F5NH\#M\ +1*
MK2\E3=Y7IAY5F7"P\S-^J.E"+XU)=D?10[[?__ RV"/.020Z:)6U(CW ?S:T
MN.V'O(A'_)*8^+TEH#Y9X?(-G=N1CC'W*-Z4O!2Y<IN#B49DS3&D@B*%<*M0
MK]4)?L+6&PQUB(9A8KH?.P]C+X?)8ED!M&B2C_0 '#.H?*-)^/1?A]PD+(12
M= FA*XWFHEG6>UMI1C=1P958!!+TA"\R"6_H@B?-7V=E<S_9*S<9FN0VW7YY
M)6:X#:JI1T&LH%]1@;+5V)929D=2TVX;/ O2^1$>U!E'U0.;5[-)R:XL&MQ-
MEFL69!NMCH7+0OV7>971&:F67<3P$8T \H;IK Y2>QY;WE6;#GK[V\Y0'\;^
MQ&'LUSY:)R'3>2K'8M#R<(858*YS.@!HB5D,U$:Q*K:^";(V#??A9IB:(./$
MQ^9L.:[@W4#1>_]F=KC_VCDXFTFP!J_T#5GW)I6;>/S3>T:K;_/XA.5U;#W.
M/3)3?$NZ2D;[X]OO^@11?[*^U<GR8P.8(3VK*-1HF:G]_;UDPE/"4SU3G/&8
M&D&9IR3"8Y#)<+(7:=12\JY+^QV8*##1H"2EG0O3JKQ _SWJA!4\,>_1U24H
M-3DI7&^ZL09KCYR<M:U_?L9IZ[P5^XN!7ZBS9,>6"I0+:I+-AG4$%"6X!U_W
MH*#G7C0>T/=/^N8IV6R3GR_UT[D)RFP28I!7GJ=(;B%3=<;9.&;=80*JGMWP
M!T%'[?3HJ!\%'=4;X*]H@,\SRX/^VUDV)O?JZYCDNVB+U2C*8"LV0'/\Q_:&
M)<1UKNGK@^/M#9>,"1(@V+9ZH0FS03+;.WZ_-PARARF3T..;]BMLWIC.MYEM
MD(W+F#(Q*6&7N2XDJ3>;!3KVY=6^@-G[IS?BGSY]_)0[Y3&D%OT?)0]]WG9"
M^6)_V\KD1I#(EO P1JYCZ,BLU"OP.)5/% 1NH$N?40#ND@>G':EM0;W+/^OP
M4KQ@+2DROSU=?<=?['A_Q\>16CI4-Q:_0,:=]MG,:^>]VAE>FI$)F:+0>E!A
MK9I1!%-A4L[1J-84#BLU:2I.?8;)&J:6\B0#X@M;7]2-BI_H.."11UH)$Q9M
ML]_>A'8H3(HRX[CV RCQE5S*NMY_@\WJ.Y9SOCD_S GG(*;+GL3F#F5ZZ0C7
M"U3C!0V98TQM!VR3"_)1Y%D;"7:ET8W!1UR3N[SAK=WPPSJ#,\/"91PAL0+,
MTRE/OX6N$>/K<.RU"EV/8^_=B9_+G7CA 3LRV-V.O ; .RN#"3"N8U5LOA9H
M+&_PX#,Z]**)H+W3W$OY-Y?R8S( XSRR(=> 'W0"#IA%W)B/N(96-RHS;2A@
M+"U4EAS9NB]6]'+][>5ZER548>3D+4W+J)FEW6WO9Q^WZNXK9?3?NF<IL_1K
M*-8K[E[ O[F OQ'" 3O=8$Q[ 'BO#%/MYA<(&O^#OH:N!B_+#M\)Y/ T!J"3
M"#OC(*_9R!2U"3N^+-)%1K+04C@S WA)/TV\/S(WB;I26652&8EKLU$K'X8J
M]6A$$J9X#R_V\;B46?HIF]'ZV+P@/^=XYBU4J\]B=;.>*G#L;F:Q;@ZN__VJ
ME[=^<,#WZ%@/8Z+?!/=[Z)+]*M-]ZG/]GGWE3@-^ :ZF\&4@__U=B]\'KN:F
MT?A_$XP/B/VUH/6]4$9">0!.EJ5)4?$NI0</R72,1!<V-&VCDP0&V@<J=##S
MB[.H?WZC\JZXWT99A;F;CO8_Z$,AP01^-#&T!Y:''0V$$*]/_ G=8?O751D2
MH6&PMD@1>528")_<>P,Z _0@@HGMR?/D_X"?V'_RC$3KPQR"_?!1?-W"7"#/
M$S_*FH8(OK&"W0231V\E'>MY0;L@$+0#.Z@>#E7#-WU$-Y4C0O< 3JXV%A>
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MK<"ZH<A>.U48QMRZ4G4M<,W5BVTF+H40[DKTY4#I1_N$7+=C._K'XR>?FS<
MRC.;#>FV+NBVDW;%M6E-JI-I!1QZQZ'Z-1,+< %UO2Z?\.1KY1.V'CRZ?D*A
MG4J@6!Z"OY(]0(A/PLBC 9F9:9:--Q:<U2\!_MM87""R ;0))Z1H> */32YT
M!<'=4G!E'L+^Q!G1ZR4E5D6H3T($20@&6:[;H[5AMOL!!]OU9T?;EX@!2E4:
M(P4;?)U8JS. [W@TBFO\^FVP5W='>PA;%Y=*DQ?,Z]V=18J.W0;'_VM\:)\&
MR!92S_OL+(#BI$%@MRX?\..$I[<Y>.R!57<-6/6T!U;UP*H[&#9]ZQP=)TDU
MF;HND6H-=F '^M3>+9:9&&O]4,*K+XV"WV5S>#?_2I?IQP:!^2".S-_]2P-'
MI<SG>6D^L@M"SG?_NG[0',3*]+//C9+AC\!]/6MHXT+L'GR>_TSQBN[%"^N*
M@NEINF[<%4MVW;]8!G?6L\.S)%OSI60]0:2DB8N6&VESGYO)^U9 '>ZKO&L7
M/:?)/W;B@G04*5\>R_YC^ZK0,^T,7EWL^O!OA*[<K4=VCB)3TGX-<K9K2^%T
MX:NCT_ E2X04[ML5L5$4+DI49D.Q5/_-HV>SD>#R5J1!)#N5H?9Q>H)>[\AX
M@!_M0DI!<'WF"W3ATF5WRJ]9O\?Z/G?_.N.R:$/)E:=_?VXL%EYB$_^ZXBXL
M53;T^![Q%MM/+51@_KM&[]>,W,.R\:5AXX\3UGWSJJ.<$*C!RW;I&B[/NW_=
M#2_GVQ2$_DY/YG<8OWZ23LA0HU0X_"V9'>Z_[J>O?\:6R9!%Y+7R06L">SR@
M%QX=-VRP=;+[2X>%M]R.65&8R$A!)K;S52;RAK3^4W(-9BD2P?NO4?E=&.@?
M9$-DY.6"^VRK,C=6K8VR!:QL.D):%B,LT%)?E\G'HKPH4+$03#S]KJ(0>9E'
MW\49_U=EAK7]*6E"\L_2?/F75?VT/>>FLIV(65WBAJP^2G(7G^T\>DZ;NRBG
M>4/[0)]O)F_IOTBAX GT6C!VPZ*L9F)A@NMU7<&Z<62*2N#RZ=20!"3;&V?+
M<46/X+]X;WOC]2M,I!B-FID=O@!^#/HXR4TZ9B7)NPPMBB''.GBK&?%\!0P"
MYZD>[I6,3)[3E= Y4HY 91R]'C/GZZ!-8+RLU==CCH2W:/&/^PRP 3/9"WFM
M9'3I'8A=EQ-)3NYB.3?^9>'3XZV'VZ^3>V_A&XY3-]5[^X'2%>P9T"GER0L6
M1":Y03=P5B\J%YE^*)@# IW!9F66^J+->4!WW8A7JL(57P934QYL/=U R1(;
M2^8M'LO^;("AF L9^,DY\WNMN>V#'?I"@4EG_&?R73G'?\N0,7W\O%XQPG%D
M/.XP+TN>"K.U]5QTXC E=YC>J(V$7[QXX8;4T)N>&4MC G]$E65M%:4_9! \
M>S#<><"\5O9_<$C3,:TT8^(4/?%UJ+IG\S2#U\4'GR+G\F)A@U/+5:(:@M1[
M+=6BX0CR;_CJO+J L>R3*6 N)POR2\?X!3GG'$URJ3"UQUY./3_.AF0L*6;$
M>1JB<D9;#BU1F=*.MT>)3>?OX1'HFW2O23:L*/)"R1YJFA2-6@&9>+6@:'6:
MJPH3FO7@T0?T(-,I3CMO8[JPNZRW$*5#%YR5.,]RQW%&@1T&9V<ZO*9+\?RH
MV)LO'92G8WNB87B]THCI5=QP(QYW_I#^_X/'C^_' ZK]4.H!\]=LF)H<'!'$
ME2G5X2'OFE&]$S(PI3RF$V0XXG-)5HDS<AC:559R>EJH.9_.>^^N)#0_@L'C
M9*$IR&]@!X(YALIBPW]"VJ:9UQYB)R-$,6!OQ-Y6.JRMU17UA VK4%F7:T@P
M]F<SGLKZ.*K+R&6B=SM%7LD.Z>/8&D!HGB@EZ0'Q!=Q8LHO6P-%C^X==_M &
MQ^_ >+3A!OM9[7V\^^[(J>\)SPBS#RE^*S\]OK4!'JDI$QJI^Q!>8^/-JU?1
M=>(-DVOIVFO16I@8$>T';>3;X\.$9 -QKV%:+$&.,[[Z/*U'<-JROWSV=IS5
MB%PU&X0=8X.U$9LJSJS1%3A9)5VA-5S<< X;K!U]=6P0*[,:Y?.6(D8F#Y7"
M=_O=SB>[59Y-KZ-6VC'6C/"M+7'>YM:OZ\7_X</-A[]>)M47G)B?YQ3]N>OK
MI4M2!16Y$;]QK\#*MW T4SU6.R269/I'2[@1DO!<]Q/6#4(AD)N:$T6<\Y(+
M/4PHF)J2%U-0*&4/*\LN9UFAZ&IN+<D*?J+X2NO]@)]8?F8IA3?-3(GZH#>8
MB W*%^D\SLL9,B@2(J9C1+^:C:3X:/>@OB_B("]H:V,;4D-_7 8$NCO;FX]_
MO<_@/%);W+2>XJW ;D 2[,O=/=A,WI5.:$@L'R6@?Z/_(%GC !<)]PT+67(L
M?I7!R%4L<T_([?"7>_]CNGB^_>!776#]D83BC+SRBJ)@J.54JB26C ]0]:;*
M%@TJ%CE9=E*C]%_5XHPTZQ3_+71\@X2^/,:N#.BDU6<#TL:CC^B1+"15.090
MCFZVF9Q@FQ+(H6OJ%_TMMK-.<0!JG3!$0@Y\>8;$-&=,N6"2I#.@P' (]C?8
M[8]U-@1$/ W4L-BMU\O^L$[O]6*^W9<?3@[W#]X=OD@.=H_?_/?&R>GNJX-D
M?_=T-SEY??3'P7[R^O#5ZX-C/[[P>/?TX"0Y?;W[+OG]Z'C7_OSP7?+FZ(^-
M5\>[^P?D#!Z]VSAX1]_9.WSWZCX/0L1U[)^#/^T?OJ0U'&C8\NK-X=';W1YW
M=,=Q1\]ZW-%/A#OZ2@JQ<P#APS4#"!]>-8!P^\F6#B#\T33[%Z8S'/WI?M )
M\#Y/A;0I*HL45ANS[WB[W<&M\?;.=GKS5*FCIJI<S9;I>)$JT'3(-L7(Y5#)
M4I>(337#8<+\AJM]2\5]X.KMXB'-S])JEHY*<I(,MPJA(A45'Y#5(V=+WY9X
M^HQN\3!Z&<NM!0->C:.%($>3=I"[(1 8D4.+_Z[,E+:FD,A'^@N"I?,,[+1*
M9^B'KH-\;LOE91B110_X;ZT)PQA9T>*?]<RS0J96.^ZGVF#';2KI$XE$+9FD
MU2?%,O S?S$[AUY9;"\+W&]<LFY/K?MK/OK?+VV['"->ISU@$9OS,CDB\0/U
MWO?9PD[3M;/&=.U<:;H>[=RHZ;H[@G 9DUAOGBP,]@0TO9; ]T$G$/8&J;7N
M!2!0SL_?OQ;;5E@'B)&M\ZJ<GRUS(*1&B=@$VTZ;-%R/#E"N5TF/(^9J/UEE
M%@P+<QW^UU^N+43<+N-RVPO>-[XC'71?5TF+G"54Q[\MV5<:M>LZE/#GT7L]
MOGXW;N?=?#ONHZOHO2[OYMWY#$3T+6<'NU4GND^3W?$TV=:#/D_V$^7)?AS3
M>1U;>0O(":Y<HJ,FB/!5GTU,T'+^.KD1;\-KZWW KMKN]03Y>D2-;9;6*Z@D
M L%9TUUTY>)N-6EC=*SHJMBBD+:Q[CR!7T396,>X_IL@;+SRW="ROA%CXU6W
M[CNGO@I?XW?0T+V"OBG"1I>L HID'7GCU1F!SKQ8C8/,\MH4CH!QR8)^5N;C
M%@'CU^18O'K!ZI[(U;!$Z?)87:BAA=XF>,R5PO<=.O!LW0&:$QF$_?T]%%47
MI MO>>?==_&U)N2=C)65@':LE!VKV>(/FRQ?,!QZ-L_+)?L565TW1@&*K+EG
M.%>S,C>C!DD=E#_YT-)ISS9TO.1%"J3:F.]@/F72*0%(G)9-0?.W(4>F7H Q
M=6;0));5Z@V,I-L+KW.NKY+;2*H4?618,S>T\_A6^E1:749G9B;=60S@HY6S
MX9]D=EAS5@B"4,"60[ DX(&RA;2?\R7_2Z%Q])__+<5+E'?IYT >TL_. *>G
M-Y8;)D1$$HN+K^I:;EH1E V5PJEZFL8Q(O*]Q2M"_XOMA0OX#^NFFM ?N$^.
M-F<V)&5J :>*WM8"<B6X<_:GD*+CKA6>2@R$GGU8>8VUCCK6:FP.CMN<5E1U
MOSP!=->F=1%ICYMD4]CVH0$J?6SFY O65IJD7XW,_>VR[+=)D]YXIFO_^,.K
M#?R?9._HW7]^>,48PMWC@V3_X.3PU;N#_>3T*'EQ^([^]X\CQ@0>'!^\.TU.
M=X]?'9R>)">';S^\.=U]=W#TX>3-?W_^5GYQNNFK[.-5[_&;2M'W??2[_N2=
ME?U':RK[CZX&I3W^04%IUWJ'_S++ (HS-(69(#41.@*"%3*_W>:&FJ#00DN8
M;>1D]S?(OL*]YF60_?^EE;Q'VAK.WO;37^/:2LO5ZRRC<,K_.;_2#=RQ_@V5
M+B3]5UZ^?P9XED]^O572L+/YY!&%-$\?[SS;?OADY\GVHU^?7Y356(H5OWTT
M9DY+S=T&:6&#]^F2C4%>_NGV]F.7F \J''+CK0</?FU=];:<B5-Q<9U_EGAG
M-YOQU,,Z0CAP>28Y)S^H*1PIA3I-S[VDQK6D7F)[B?UJ$GL$7HJR2@Y_MP[\
M\GDO=[W<?6NY>T&JKVX'K8B\NZ+47B)[B?SF$OE:,AXL@,I]DIOG$,JKI:^'
MZ-P-B,Y6#]'Y42 ZO>[O=?_7:YW.T#\N'DANZEJ'ZG $![! T4S2T0)):D:^
M(\4]+,?+#4[NTV7^;(#9#?K/8]5RBWDNOWU1[=V'WS>V'FUM_9;L)J<VQD5F
M?S_FY/HC&Z.>\0$EB+TS,W,\0;L !3 >87=\GC*5PDD)V)@0T-SNPMR-B[+=
M[@&GX13EINU5&])61YL_X&(4&)E\AB*=VHIT<B'O@NMQH_!=Z'>8\J>92\5(
MVBJ4M*V<.&+&U+ZMFM^6)5CY@RL]0(PG=JT,:0$W(?A,,+\IFV7"F60[$5$$
M5Z16;0&$'0N3:II\3\IC_O$N75;(9C>ORAKTB:P-H!2Q@US/NE4%]%MPM-^3
M$VL[]\;I(N5#:E]J?RY7"N8^7<Y%4J%$"2%V[D" B\:VZHZ%5\B)I=96.5"!
M$77DABW6P^3>FW=[Z7NPK0KA2F'A86'!=>!O.J;S5#!'(TZ')V:):1D#@D(A
M3?U=NXTWDZ,)("A&N!*AXOWI0RL&2)"JKF.;YH#RC;,Q(UCT!O%=E1&,7J\B
MV^RJ>[:N6RSTD3PSR;'YE J0$S)=) ?'__'/]\?_$:O9ZXCVZ<Z3_5"RV[(\
M2MEXK4IQ!5(XIO!4],$Z.6V9&$G8JYD!N9+XB=;4,#)73X9E$U/9_6&MQF?Z
M([OB]1T<'_Z^>WKX^T%R])(^^^-P_^#-?R<?3@[VD[W7!V^/DMU7!^].!\G)
MA_?OCP].3@Y.DO?'1R>GNZ<'3#WTXOA@]^0TV=M]MW=PG+PZ/OKC]#4(B_[K
MX-W1J^/=EZ<GWVV_.^O+C]?4EQ]_>7WYL[3)#R1+NZ[)$:-@TTNM6J?-;*D1
M?(N1U NV*FW2#!D>Y%08,ZHUL-:9.LJL9"[5,=HUN?UT0\#0XJ JO!G>*&/Z
M5]? M[Y* ]&+^VC& +S^]*KH"QW8PW>G!\=O#T]/ 4_:/SHY?/<*6LF]\S<'
MN_LG0#.=?" %=,C0I@]OCXY)W[P^?'%X>GCT+GE)__SCX.!?;;73IX?O7'IX
MNT\/_RCIX>]L])^L,?I/.HW^P\#H/WOX@X+*O@G3V7=,-O"NWUY?Z;!(WO*,
MO^T'VSO<E<*,K&8<=+_:,0CL*RDOTS^WE><LC+$Y4)*/N7^27@G2&/ERA4],
M4.'@U97)$8,V\QE\LDG&0V_ !<&\YOPJA1<,!!+VC;LFRQ6NM,X<'CE7)<AA
MSY'FRY?!"$'PKV%^DN#;T8)<V4Y@QU++USTHR--:-*17GNQPZ?>?],W3"K[B
M^5(_Q004F61(U_JP>;*9O-S?39@1GU[*0'EMS#PC#8SQ.9K 0 &!7<.1F>,_
MMC<*,V7%[;C77Q\<;V\XXG4,TH'S2EL61<>#9+9W_'YOX#>!I U3,O!-^Q5^
M9-B%HIEM5!BCP[-B2B1!:77J#ML;4WRUY[ES\*Z9$#E@]@?7<-"[K43_W-J!
M)#*\BXS)J+E+0;L*<G+$/=.;3WZ!08_IZD@F+TKK\M8@798^D.!@#[PK/"T!
M59KX\8*V697VE/L(0?=O&<7P %_@[7Y5.WA[E*AS:&\%T=I5QO/IYC2;=!A/
M_?PRKK5'=\EX?H<.-PC"T\=/?TM>')RNGRYW1QZFS[9VOES2_LF+_>T A8QQ
M>*UN.Q8 -_YNX(<[O3C>W\$5/IHEX_ \A0=^(6L4_>Y'J[$GH+11IO93\/AK
M/"ZES#MF.\5CC#9Q QX! VO%-R7C4#?#C7')K>DDM/M; YV%%@Y)<A/[9"@;
M3U:F>V;#1D?3E9^R$?LBN"UMS:470>E_I)0.0P/<-MF^5"O0MEBS&>]?+?P*
M9[3PLM+]<'ANDIPS+-W>7=(U00_?@!-)/(N&AT8@(80^1S:5LG2I1:)*0N)(
M6^BJKWB]MBZ:9Q\!4*C*V9 '3\Q-D:5M(]BG)>Y<6N)AGY;XX=(2/ZF).I@9
M+'5*<:,.L]3Y=S4ZL$GGC18\*]6'#:'B5$, =0WUZ^S,O5<9$@+1W,W#2+OC
M*@"9Z%Q6>DBZ%FG88N%&L]K9H A%%B8E[UA*![!QX> _*-AF*B&)Z+^1XSZ,
M5I7F%5^F/9^*K42!YN?5-9[9.BD/4F__TEF#>QZMTFD4=*+6BCE12W'?$EW8
M/G3>&X^Z">L-%R2D=&EF;9U*!,X_=7W?MEQ/RV=*2SL>;= RL/(R[4O\C+=!
M2Z$8GU]#)N3L=,'ADD-]> _TE6C?!4^F6^>**7[7L0CO&^E#L?V. ! !X[F8
M< V:9=CD)$]G,R7)Y!&3MK9#%\(]N8F>=U0N)<"E(GI=G:\(M6]IKF>>'WH3
M9L(-^5B@(+.JKA?$P$0,@(H?+W93[@98XE8&:S? /M)0(.:2)"?D84'2F3AF
M^[GZ]C?T_OJ [&L&9#*:O!U_11$:'=/,F3R?E 3K6ICAE FQ,!$SC";;&CS"
M]&9>'RL<?T%<"YJ U0+'3:*V6>U:(4/^MA#0):E'O[8%&+,QKE:6(U8'M+EM
M@R2D7JM:)] XR:L,$\'H 3T%DH?!0=/QV' >9"DATT"T'K.2U,S4DK>C+5+)
M(3D?IX_UFZ*E00',:VO]T-&= &B6UJL;-E"FO$O,+S:BT_X.5K6Y4$*W(C+)
MINN=8<[QFKL?U*W73RAI/7O60D'(4$ &0?RPU?[/.GR')\EN\O;H^" Y.7AS
ML,?((TBKEO"/CC]_EWX<#76X]^@!2%@;X2VR>\80N*[S$PO?S[QS_\__'%9(
M-,L.=.:QGZTI C^[$OFU\TSSV+?A25?"V1]*EWPI]+UKGCB.1]^C\GFUZ6VN
M34M!><$C0>W6AK/"V_7(J$3-+M;U2L0\]D/)9)D<M6L2+(>Q^V;DQJZL7>/P
M6@L;D?D'6:N#S)=Y.D\KX9>.5QT7: ==I5VM_IZ^>[$W"!1UW,TB0>KJG4WQ
M%RG[!;W L5F].U_Z;L2(/^_)V6VFM"8/ZP#];L.2KM.E-=^2%H(L%3<TS9=,
M(1U0.D-&%+7!S3OT3+E4/CB# F>RZRCZN5TD_J& Z12V0/@WDY<E0 !2J$?<
MHNL8).^:<_G5BPQ'<I2A>*_\I?:@!1/X5HX5(H=H64*.O?ZH\3SP6/BUP6Q%
M32#-1%NDS,/PP!EN"^YBF\A:'6)&FR&+U EW76/P"I(K)!?G/KUIGV<N%=BP
M#PV]+OSV<.."8IJS;)Z4<Y2CFD+"$+K(1+AGXYB@8R,<9(7^!TDT64+XI/0K
MB1%70M/0 T0 J5Q&2=DLZ#Z:K+6JY%;KC[[Z=>>J7SM]]>N'JW[=RJ#A[R!8
MKFF\%X9-;$-*_7U5@EEX^;TP-[W[]25L:4T5C8QI1B-@.<9F;H3.*LF1PE17
M04C=%0C+@R.&,JF,BSO"^&PG:'#U2DI;ZIDPM-3[]S(*)%-C*R,HSI%FE!%G
M<!/4L _X5G,.:-CVDYFV0S.D$1Z>#@_U+>A:(R8Z<O,I%"P[IUN1$EU:3GK0
M>F(=&ELL2EM^TX_%9PSNHD\?7DI[G=P1F.L1T'O<:L?A9Y?\/Z007G'1H#;F
MHX@ "^W*B[9FD*NTF#K*M HJ8 H*.]<1!PA:].LL9;-TL4"8"Z+V1H)JDKF9
M(3$6$GBTW&'JB_^D7A8@%\]JF<;#T49YQ1$)"-+E?%D"^ QC"NFIS@K4)/A?
MN$HA"^2X6KS?F7\:I:_PFB%?!K@Q7<L0$"_2%@B**KME6 TB^S$/QZDYH&OM
M\]4* NZ^#D%$J1@ ['"H3G^P;O/!VF41=MFFAUL##>T7*<7R'''H%"063^ )
M[3 A06-FQ@6IB9$Y02@'D8QQ):MS, HKZ]:4$S=FD^M3M5FY2>>9]4>60^-P
MS2NGELMZY630.KZ>7DD!_?A2O(C:KT(YI1-FVAU[L^7/,VRQ5S@(?/,PQHV.
MSJ7G1MLH0KW%6ZJW+@4VP_]R*9..?=/I"@Y4JE/T^!?;#QX^Y ;A!SO;R3UA
MOW \-'(=9"N#X::<R  +AH*1O/I)S],LMQ0Z_!7I]>$+E#J]29_FTD%)O4[X
MSOL! Q$/,5RG).QD-Z#?KC>NVPX+[U(!/":W0[-<X^1'R^W/_37._2,]]UL_
M\;GO#WYK0UYJ6AA,*79<T>7''[;^2P^MG;'#7V@H@@W3SP&17+7F1*_S%'ZX
ML_I,S^K#[W-6^]/AS*+O<?I&9\(69*XI]#^PA=IYH%*_\Q-;J/X(QK3]1CB/
MW%3OA:7)I4LFE?EWD]GAL4%!$@D5&=P'L55H/Z#S:-:7<8M<K>Y,UI!-8I0C
M'=<Z$ZQJ2A\.!1:?AEF4. E#CSX>!+-WPQ0*(T99ZO37D%0[WKS28;B)'+^1
M@$/+(D>S0GU65@N0 &0EGM.6M\/;IC+*F/7%<"E06MNK'LZ01NF9"5FY/=ZM
M$9TQW!SB%,(@.BUN2+H;MTQ/_G)_=Z-=XL5##<+LT"BMD6.B73(D7+R9W-<1
M'6A_A/T<TM?I8G2V\4?Z"=0&NR.&SD*#TA=3MY\\-YI>$M887G#L''QF2EA]
M_;3<$2?&F"-3=I:G/=J%J!H1+JT)Q(VGN=.3- L[?SA0*_+V^)[M+1N:90G:
M";K00M@$MG9T-+P#/2 3Q\^@NRC;FN:;R1%$ 'A?J\!G)3\88X"B'2U65R\+
M5#H*AA[,D-+GY3G]&.C/,A3=^,ULN)OIGVT!@N>' T)D!%4LI!.16^>?T);[
M ^D+1CM:F>&\9#CF7'9XY1WR:]M,WMM3ZA9;KUH!NNQ!@^1_.WTIX6IDZM:8
M#"^SSJXSEKQ]!C:3/[@MA_%;<I4RRJO&.UL++^6RM88+!J33_9=L,R-[UM06
ML)YAJ'4R;5*,*S:BJ.1-BZ''#]*&Q*5B]$;[K>!PZ#'Z</+^]&@@7"L\W%O!
M+"@G,6.*[0Z@A0GZ"[HL> K24DT^QJ[S[&11A&.>"XZ!W.Y#/K.FF IS<^LJ
MM\L2]Z9XM1:YJ-*Q 0V@^')JX*+A\C X)>J2%Y;/ADW2-.,^M["<4'"OVLF"
M#WQ'X5$036A.K SK0;D]G:91Q:-DXX*0JZ$L;4UQI=AA>+8LESKDA%V >2:1
M<?)"$=Y1_:CED,\KQHC!,G-9%<=K,\$:KRI/92A[SM1*<PFV(H=".O!I?R=(
M8Z$]A?ON[:CMVA]!B\<:,&0N'995*EI6"'&,U:!TA)H<):!;=I+Z@W2=HCZL
MEMA5*R,0>0F$7)6[F9=R>KI+YHNSK!KS;_G\'+(C"["FF#NKO9F-@DPOD(CB
M#"_EIQOXJ7,"+EBGJY.-R?;P$7*.6YL8 %B&3W2;9:_'X]TY/-ZC'H_W$^'Q
M?APU+WW]@NA0();6PAA'/3) <5O-K-2#K+5A'R;D\//X'P_B<I4T\33:VM^6
MY&%&K,KF[A/6TK&&IB>5:2T-SQCBJ4(.IHT+:/,_^2P49DGJ@,>B9#/:.+9+
M3>]CW&;A.STS:[!O'OR$Q,$P*]M^L]!G,M<#VIM+>N4%DK?,]M2(X^\A0]ZY
M8!=4TFIE?FZT.^03A7O3-!\D-;.8@[=<0D.NQ-(-) 4@(*7 44;(D%8N5J7@
M^&.4%1"T5<<##A*Z*XX6>>6)\DT>TZ^3EY*;4'Z#8[[@L;\@3ETG8'93F2KO
M5$/B-T?JOHV*Z7BA)\U\GO?PXKND)?YPX:\BN!3%*R?44P"P.2A*5(@U068I
M427?'2,KZ+^ 0+81?,6,<YP-XM*/Y<O+BD:9'_!W#FN"X,5E>,-A>%I"7H>R
ME+:@8$84/X7]AY8$(BCF)#*+X;WBY,,7K)^Q+:./Y&8.A*R75.""*PA,15A;
MOL!KPT8M##M8KWOP;!*F2&T"&<&?> ]F',U!TT0AJ!S$25E:\EP)\AQ8/!6:
M#^.&4" 4!>=$(R]DN$0>>L:-7ZJI"Z/U&+F4/!HB6JP=8K9.6 8)O!:))]D0
MD<=1%H7)E>A(QOD@[<*!,%]]4HXPTZ*I^-W0QM=&2SXU?3@R=:+A<A2L7BY%
M?15\14FT-$&:('5%KT0V68YJA![=?7\H<AYXEG*&4"T7AW;U%PS=3NU,P+Q$
MT(5L><V6Q:?&7*NC7Y>^7[9%2!"BZ/*9JZLX.R@,F9N) TU+4G+]";6(.'O0
M</5ZY?)2[;$C 67[-G2!8>9E[^V1[^3,7*J'$T0DM\%C8FVZ,:,S+=PG)AV=
M7:DEI09B:Q-S;M9(F%:.5IG.S$59?0SSD)+;E=H-UB=E N\":@D11Y)3EH7!
M<A&:_!MO4SM')YW;+A4D^L>?M/4;P^6&_F<R3(&OQ\3;L6WM",\PM(RB$F1A
M4=XTSU<6=5DC2+!BT>V\,FR]Q] ':5[4HU//)HL]\9N_9M=EI5@8\\UB0UTC
M;8;8B@?Z6'1(M$/<-BTONJRFY(O_I0@.U$2S:M3,P+4.77>15JBS;#+--KT:
M-1^VY_ARJ; T@U$9_<+(HCF? FV//6"ZN29?9'.G L0Z5>F%"QE%S-+QN&+1
MY2?U/$QS<!8)^7Z) (*>FH$RI*3N1ECY<SK]>VW00>_MWRU#[M5^9=@(A[/$
M0OTJ]23G:-H<4[FFCPC?'\ +Y1%A@KSI<$('HE_;::BU.JET7B.#0D,>.>$8
ML*6QP9HF1M0=>?#B2\:*I<A(!":[66RX%I48+*/RO=)C$J%;7(<D:'CJ+(6Z
M'9MZ1)X]8!=#4!8$A=%TSI?4G,1I>-G?DN.CDZU5@GQ-5B31EY,C6O<;30;N
M.KNG:8H!@/EFOG )P;1F?O/#HBBY?Y)WSC]#^XE])A*/M7=&OGWO$:_B0B-A
M"P4S$KQ!C ,9-ED^UBC)>ARMB$I(4G*$0\%9BD^C/7\NBL1[(_&2SE^.N_?"
M,<D"NZCYN$V4A83MLFW$Y=!N7LZU_]$AAL*?!/?O6'(<U+%W)B$S[5HYRT8K
MB!Z Z:8ENQ(I1Y_,<=LP13, 3:[,N"JAG(7HW81;[2;,S2+K'80[IM<8#AFG
M_WD,1%0C "5V+6:/0W#Z/IU[\OG_DE919L]&M,Y!AX BX^;F!1NND1<2"160
MBP*\T<QH#<P=5<1-WC8_XQ%V43XKQ@ -(G>&LT,9*Q=6L*X6P2,\<C.>FI6(
MT2WPW'CHK&CT"6)E'\V$C\)Q_@Q)41\@:HP4XN^4MN&JS7;5%PKE1H!>T8JS
M@H1FT2@N?XK J1"?C4+R419AJ>;-,,<,5\9#9>? +Y'>-\R%%P>3=G0*&Q;[
MG<&ZCG!6[38''*"2>*\0A$XU%K=97'_%*+Z<K501.ETP94(7ZBVV;[O%\K)0
M5CP?1=9,FMQGB%9N8FQ8CG=H; ;CPM\L["P ^U2,*V5;QF74WDM:S1OJINH^
MU68J4J$N12S^@XYBI'6FQ'40ATA?B'V?,<UUD'FCE?S93"4ZJ3W'M2;]1:(<
MAQB@X$H!S8?70A%M\=.WO,1X?XMQQ ^#Y!P#6[MO^7=T %^6'F87:?O_8\B)
MI @H'PV2%Q6F#>0;;Y> )9_\N\F&PV2/?[AT4_=>O#VQ0_<&R4&>)6\RGFO]
MEA[GXR!Y!R[(!>G=]]&*:KI.-2\5NVFO9;_L+_A^0OM!@=BQX<P@?;=UG0&%
M(*--BVVS_')\WD[2HIQDR2M3_+6<^?F$\K$;4(BM.2Y'9RLGK0=UW3E0U^,>
MU/7#@;I^4CMW./%-()T3%1SE)W(\_Y&\.]E[L\=NI*TG<S4VRO (\M::SW2*
M*40+?QO8MW F@.A>-^_@O]+\8UEE,C]V(#K3_?&X_"M?TIT^VC_SL",Q#?R%
MW6:Z6%:E_-F.->#T5,#*&8T'L"5VG-"I:3&#2H\JZ%=S^L#=Y2\TG:4S?MR[
M$<OWXMTMWK/#_==;25Y>H,N'7O4TS^@6*P(>$':L$>\3G@WKQ?AW<CJ*;*J2
MF-P[IW_K%>YO)A0"B),F]^\4R)6A'?)=62$2T\?9U.3NAIB 8^_0R^0MELDC
MY9%0$N-:![E %9Z5U0P=DW;N-6>QU?7645=<2D4:<CF7PK0++S7.TRX,<F%7
MKZ9'(+.31;U3?G#\'\D,'.FT*IGD%@SPBGG6*7[-<XV" .@5KOA6>($<BN_[
M<]%HU,.GGW'2(0@**"!(EW#&8[Z=R.M_E>4F'=/_GOQKD/QG6M2U:;OL&D%P
MZ&$=_L#1AUD1Y!_[Z=Q!#+=*^IPXC"JDVW:E6@3HD,$SZ %%(%5?BUY;2N9L
M__15^ W$"QVXY#5/+'*VUVUVJ!*<_"C:0IBU'[II:-@A2$IATDJ@*%TH*RG0
M#VOS[T:ZI%L9#$O@T'EG:R"EJ=?GVC7N+-*9*R4%6+"BH5L 22)DF)O)"1(3
M_AEY?WPD['=>#LJ*7",0/H.KG$@\! $1U)6/A@49GO)HN?!$V1&[#D#@\EXS
M"F+I,>H9G[*4PZP^2W()Q\B%9"#2BU3 CF[&5.Q@M1C2VR<I)$?7680&HP.1
M@1TQRA$;D?I<83S*P2D8:7<'.M3.%5R4@Z[CS.KG;5G-S\J3)5WA:%ZDX-DG
M74&Q\*?L(_0!:28LY< -<9:$P!)HTQ>E.4,&T ""31:9].MLD.P.A^0/#."<
M0D.-RB$N^;*<DO06G+#1D82U:K$79K%(5],.QZ2>/D;?YZ=V*_G4TEP+EPI*
M<=!T(G5KT[73.D2;\LNAPRY%<I=8#KJUO9-2E.LT?72?-<HL_DXF3>1.>WG$
M*_=NW)M3V$I!<4V.%_M 2Y*3238D*Y7UG#\=N/;EJAJV+JI@S?28:MH?6+QJ
M]1M0EJW\I[;;L)T/@!?T^J=PJ($)R_A< G'A$*P6>2SH5AY5JAE\5O!KT^F#
M2#@=^EES_-Q[' F*:U/"GSKLG!T2&@,\7#3*G'_<3[V)C.)4^!'(=HW^W62V
MY<0B&J],_(ZS=%J0S'.]PQ6<I+<)3<ZX$I,+,#[9;Y;H0@:5%3I754@S=!XB
MI@>Z(ZWE9:[=\.C $_T*@_FJ?*GZULN!U*IK;L Z-SJQ/<30!)<;"!1\1/M8
M\0A[,8^7%$M85TM6."JPZ*@57H)U)H(;R8JB D93BZ",JB8+>'#LV_UW0V=O
MDIFH$J9E_%16$\"OH[6LR@T]OVW@-T5%3R<)\.&?QD+R>9_;LA9X,]S_AHZU
M=K50>XBP'@%G,@S(8R?HX@.+2&)WJM=F'348Q-IHADJ%&4B*:I4'[DN-K=5:
MX.>^+('K:AV52ZII<16.9VJF$SE3MI= 4-8Z^7)B+N2O.8"B[/'@2(WM-R$J
MJ,J4K''!C)UIQSD^YA]!.RHK%)00T]BT:X&N>2(@4-!@CY]$VBY73A6^H7AU
MI4OADUBERKS#5&E=08&/$WUC):LJ+8];=1G<(/HM+;:V,U1'VH=O%5_[942'
MT]7115,'W.A"8+5N+]C?L91IJ!5H]PTN(DQ)'\W2W98GF$I#G88$MO_#TAG
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M=.-8P884PV6;]LW]_&XDYG\XY?R%8VM9V>Q#,/=7QSC?D6?HJR\K,T%CHM"
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MO$<4F]'O[_WR:N_]+_=7*XU:M8UNOF%;J='+7](6KJ9B0G;7*/=BP(Z@3\U
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M];/9]B\D?@]^\_65B,PS  RR/*[2B[;4;"8'YX;[+5G).%14A".J@K[_V'!
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M2JMZMJFKJT+QB[N&Z=T<ZA"!S>C33W;NH[9SF_)]<; DTL-P<)2GT?*K"[>
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M!>D!QO#P@]F8:.(V1EJ.W)ZF8X>9ND%>,% +U Z$]J7-,K[Y+0ZO83(O;N#
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M9JLN)%4"?1&3QI=0_G87QCO)EX2Q'8:LAKW?"]:Y6 IMM;C0&N95L[=TM1<
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M39B8+* 2P(\K=E1=**[HYR;!5 3V-]1B\ W.UBU0\U88H)519O%^XD,;;\2
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M+R[_:@GAP+<*1]&7&Z!?7RX+XRWVTD[1H\LWFI^]CFDV]M6R" ;H48@ASZ]
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M0?U7O2*MXD8"$-B]-G3>#?[.GA67<-1V *J=4DW%Z9S738/<4A8)TM0 Q3[
M99U%7.*"8;'PI86N  /CT"2F4L=$DV+:UP@F5(0=-F[:\0-\$%:_RV(<6["\
MXVQSS_>#V=6SCO/<BD"/)_E1+E,5ZSHZ@D%0F@Z UK]P3XFFM41>C3#9\"*_
MRR&7QI/1844^DJN0=D[2W9Y<+1'S.VP7';;''(QC[/1W'5U#3H^#]Z+1=#I9
M7"J++>/*E>DVBE+.QLP4ZNZE;*Q,J4^V9:?MOVOZY)#&K6R1"O9NE+Q\P8I6
M5SFC*$RVT74@^)J=\CTE>3:F'6+@2=(2' ^2LGVO&;*!D'&Y&C34<2$)=I;7
M17A:;:(-:8186I-.GE+:JLF>23YH)7UI80@3GF/"<_R*>([/)CS'A.=XA-X#
M=X8ZWYE]Q*3UR;O/0OP 7SDZRI9/%7_YN/^1J1OA3@GVA6/[E#J5TO(@IV?:
MSL:G!MHH"LE]F\\)IW5@X>4']WZRR:<\** E;TI+8P"H<.P2.ZZJXBK7#J%*
M@"B+8E1(<]*NG%B[?^UU.I3,OC79?R0L$5]9/C0O>%$VBWX+T\&+F;OJT[2H
M1=O#O%1F"4()I4?<_?G>.)O"R+A*[8@00L2=65RFIE&2_XQ>P94UJ\M9 O#L
M>Y!+8@8=*<6M5+#&C!/!>8HK=_U_3BEK(N:?MOA#J$JL:%TSR$T)V_<Q%^@/
M=,M?K%9ELY5#22)^C:&O1U+J]XK%AZC"7(L>HH&TRO%GY/<X)\@AJ&10F]E-
M3G<-S<K2AV0E1Z1'':[KH$!G%F006XN%T6O(R-JB8.9I$:,IK$?42$NB;;G*
M0=01^PM]PB=2*#'768=MSP(<TRZ?=OEOO<N/GLU<@$YKSFG=\0]?!AL47NUI
M.14_QE2<-(6'#/NHIH4AF_6[5W3%;NT3OQXY/V(MD9MSX&O_;720'U(@ AU7
M2+-HP:WVPS+Z@-X2$"KZ4P1!&MR8/V2(G[IG#4,FET6[:,HYJDF,@$@).NZ4
M2OG#H4U_)G[RW<-GK*<(_/ 5W-,WB;A$A78/YEL<^>%[0=_#6]BCY .., 3W
MFFE]1:C*M/&[/2PJI/T?-D@')N=FE'[>ELLR;X16,T/H OLH#4" "K53HF#R
M+WZS[72TTC7%L-/J^\U77ZRD2E\Y8KB!HANRI_5&!1VF53FMRM]^53([B_>X
M?99A6H'3"OS-5Z B1#9E(3[I="1/2^_!CN2.J\LL-R<.8=1N\.BF:35.J_$W
M7XU<M[1U:(G :>5-*^\W7WD[T0L692!M:7Y?2.\-^+>B"&1(CHN(GR2;F61D
MJA)-B_6!XVBSE0EWD#2#6$_WW<KH4[J_,*ET4WMB<-< 3))T$#KI:"XX\S>$
MYD!X$+36G+FVD2A/&0 OU0@8$"U?RWXBI[^=2)AG.79-A=I^,K?:S.,Q0,E<
M2X4RO <3:8^"-,,NG0-UKZ1#J5T;>)-Y;4+W5Z%4]$XMB8G@=P4(&*Z]KL2*
M-G'-;#'[6JN2@8MJ3&[,J="&!<GK%LVMQNW1FQ#X>(DX7]:[+I'*=GQ$CG>2
MC@]IW-7&&*Z8](M.V'[L+KS,6=V[3'7Z!@U9AS)K<];K;FI1J5K3_M_L9T9J
M$4"W15LVQ>WO]8"*:TF344M11UZY5:2%U4>K>S8R[AG1RK6UC842\1@!2A>E
M@IG S&G&V7N*)CMBA5L/(L,CQR\=?EK)DR=JZ(E 40#E!"B.KNHAX'<R+*EA
M>1%15:Y=,938N50KAN$ .GT<XST"X1!KY(%; 6;IT5BRVZ*@YCU 5W([APX1
MTMVJ*ZL^5[2(<L2!>Y<6DN&F GZ,&[M%%&DK(@C;8@GW0>!7UO U;#$]G(SA
M\)]H]50V6%IZ*I'KIV=9[#.OXYSY5GGTH9?TAO,F %W0$@)<VX+1%B:U-#4R
M38U,OV(CT^=3(]/4R/0(3[-?RW!_$A#\Q0?T ;>X("X-1@_%S_9MP+E$K*SB
M;>D>@RN:V)#QI$3,L,I%3VB8*8_RH'O%X>DYG'2\31H=*7]27,13,GI:EP^
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MBI:'("B-;2:X\:3_;;RA/TO_.(Y4CRO$O43''WQ<$N=7G-R[WO8OF=R)U/.
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MX!Y2CI\$C2 FH*81]B=U(U=M+G6\7+G)DP([5=+F,"+_44'\?:,(/W5-^L3
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M#3T4<\TFZKS_]P*773+^[Q<RDV02Q%>_L_='DW^EE5RM:2 ),\SKQR&XNW^
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MOT1H6!S&RF:')K?&6:WY2H9_K:M\\V853JJ, -,?S@UQ79RF1=H_J+0[A G
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M#/!:W(YV0>@[TE=']X:L-S\/)HI)07/WS#/OE$P\F^16REAB]<$T1-W;O4^
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M$,)G3E0\EX3P^\Y:5'%9*YA)]\3R>$7XWSTRC?'!T1)6=$RA[,_3+08!VGP
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M] '/%AS-R1%Q)09:*Q]&TNJY05N;_,!'0O*>A(I _388WJNV$#,L8,H2!"&
MK3(*B Y0O-QI1&'D[H[+>GL&:= NX@'1C40]'WY_EF:.CUMU_[/0_@D6T\S)
M:-.F^,^)S!I1S\7J=9S*$H5*A<T@RF-:H90! [@% /!GC@LXA(%WT-MS)7S
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MS\JDSR-JOO_,(-#?@@[Z=* 6]]J.EU3'>1E''/\07N$3<30W--J$IM>O7K!
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M/2<X<?(VB9"&:V,C(,H*0Q6"_12"(AJYG9  /7[QC-?O\MI9Y H1M_(PM-V
M_#_&"3=()13HDY ,N>50:0DT LB6(>9#:% *Z$V_F$-8# 6,33C'R2(PHI4!
M39D!8>*H(N["/\ [# (2MH(115<8*$6NAN(DPO-U"I28/*A1]DP*SUI\V_.
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ME*,-DE6\PTG%M-9NNSWCV"C$I>P7Q;:1R@.=AT4]%)].M>]>9O4E85U?1M[
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M*(F1@LRMZ2IQ#<K83KHIV\VPAT7=,*ZSIA])WV()!)6,$ .7!&\9<3C%T32
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MQ0+,S:/_S'%1YITE/S.3YM^R/[ @A3XZI-#7"U)H00I]A*XW]_9]_BC->&M
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M9R(J-JL?:&&KSQ;JH 40],L"@OZR ((60-!':-=HINL7CWY\]>+U#_3OAX]
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M31Z&$E510:V/'G&2O@QG'T)$_0YG]?YGD!'9,>6K_"GU_0[E$B44GNIGICP
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M("F'F6152<4Z+H"V/"-UJN4E,<]MCD26K;R=AI55+L>SRS":8+N;+Y,1\9+
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M*&&,T F1,7]7-3E.2E6F-)]!J4V3W93J])*+?<>Y6-,A,ZSKE+?P/M4:1<V
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M+I8LSQ@:E1%B])KEW=U:[&<GFZ<M3G 5!R=+T3*B-,53,5 -JC3ZO"028%A
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MOS!%%@_\@5G!?HCFZ599M[QRT87#B7X,Q1\6 IH&BS!\<O0X\W)DB4@?ZKE
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MG:_;(PCT5?*Y L_J"_XA5_ XS9 5%P72H:]=O^/6S93#E5+QF1=1FBH?G&0
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M7!)+<@7->@IS.*_DY.M;78DG*810>G:?+?8\&)_A72@L7*.E50XBO1ZX[DR
MW'A5&99:EG@!(SDY^2C,HB]AMB5^ 1@89>'"@<JAR@8>!Y8J5>.#]G@2E#TP
MBV=<7BA*)0!VYD1H]":6:VT?D*T:B,N'XN$][Z9XF=)+-ES+&'/_%\<;3%W;
M>4L7 RX+" D1;X ?,]"Y"U5*K C.I-3)KL8F[LS ]^(CSQ["&VOEC**%Q>U.
M'34.O.(<!A_$NB%Q<G!]CE87E>)1/+/B+WV#7E(.4=J$;3PV)'<?3P0!C97Q
M=72IV$8..R ;Y$N461^]",7X"/=<PY!W2@+W6%1JC[((.:ZJF@QA1=BYV5Q.
M]$;+>NSJ;,I]7%5<>Z+_B2?-3=LI9)'L>15?"/]7^#G^"I$[%H;K(F$"$_?*
M\G8$0:_PY/>K;\*FPI]HD/P?U:8P+WF@S)H.*QE':IHGJZD;#V$Z?8'>.[N
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M&#MH8A [U'&-CL%/*7^XSJU+6MRTZZAY&$<HKQJ_4O2FA*&["2V):S!FD:'
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M\5R)1.$9 S_)^XQI)]@F^DJ;)QEXX\KT!4:V).^6IH8*88HTXQ=,&K/(V8?
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MJL[KFW0L\OG?^JK?Q2W,$, /]?BE-GP &663N'M150A#G+E>0A==.%XO!#W
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M2%"B9$LBI3-5TTDHX."<YSS[RB*BGI;*$#\[GS$=;YXU* *"3('H# X&/_"
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M S-W)2\Y@Q/U@)SL;Z8Y=X5;C,%DHPXN>LPHY6I)JR*.\.8YQW/I ,Z$4W2
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M*191)YXRO> \0[&]6T2#$XL:FCC/)MU83:-LXH,+'CWO!ST%)P&C4,:@(S-
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MC[)%E5:.C(=C<@G*=@OZ(PSMZQ)I$\]_;8Y&MO.I'(]<@ULMU33X@U<:_'2
MCPJ;9='^;3>='8WA/S[Y?,M9 )^NGA=!$2J<"XI.G,NH3'I94=",:^#YM>(>
M;%A8)JZ>F8HH9 8X<B;MTD9'ISH0;*TP&]$ZC:F*:GBRMT=U41&L2<.EBG+Y
M'7B4$]O-TL,WFRV]W[FT^R!-H%UW0.H<+6.:N%/T98&#Z/6P,@FVC566J@ME
M@FWR,[JMEG^;18OEGW#<%T8#EG_7,<+EWZT';ODO["5<_K6:%DVV\BL.3%W9
MR5>,$:X\6>(H\I6?X\Y5"T0OFL^B_R(PS]5Y).61,C<-G7]4+5&E@-T1#0(I
M>5IAU0_^630![QQK#1-YQ[F;&"YGTG!,F:LHJ(N6R!7C!*4CZ5GT@M18KO$O
M)2/I:#X=/5M:/N=T$88-&KD4&+E$N$2[D0(, < 2M=A9+29]IH]QWO91V/6I
M!_S*;O""L">A&< ;+AV&;MMV-K.;E!E\ID\QM;>HJF8VUT/XHIH#RH"V*X#5
M^[N"[I$LW'H<Z30A8[#@BTTNOW$/2?P>H4O %R7CKS2\R>.+@[@"9[H/3\ND
M$3,6X1/'L[QF<WT])D=&/-$4 OXL4ZT9^D5EE-2R)0S&36V*@S) 1W9$A[(!
MP2G]^52W+\#_Q+%NP;O0C.*1\3E=@WL,L9"_/:L4UYRVU[R6'YG!Q.W1ST;[
M(&8TD6B <^M4*Y2[F.B609E0@B"A77@57T,:5TTA"&=O[6.$034'I1^^2!7"
M0O5I&23(MW1,@9"PCKY0E9*=AH:;:.8)$5=)C4"K53RE8C$]8\)$%$Q0@PN^
MX.*Y;4@.!&2Q8B6^L89XVG@._XI-"&L[D74%U_OMMGW.;NF[6C"H0$2&BQ&:
M#;88PP3=7[Q?YUZ+>9HS<V)R,"U:9;<=/*:%.BX2M*Z^J>QE!7P!UXZ6 D!/
MTXQJI^54?%CW(S*]CF9AZLIQVD_*S6J6+S=<78+K!0UU4A-?G:?6#S!3R3FM
M2 XDY[$2 5)@5WEL<RO[T\/%D:<W,0^& !8[C5!UNT"Z_'>3E@ON_BMX2(,U
M0T)] _.K>3NI$/E4":$9;)$*>8V646F05?&^\39@8_!.B8D"?--M3GU/(9I;
M:I@^BM_.I;O .:KJ\NE8)IL&R!'WHX";QF8I=J+.T+-T#G+B/"O&P'7&:3&?
M1D!DL0(2B64B'6641O&7C*1D8?-.S[$]D,*IV_E,U:!Z*HY)%SF>\GR!BKR(
M"GS53 'EX9U(F'D!?T6NA9P!*VF3%+DA"Q5*XYD4*+P2;H0P/-8C\.(I,.F5
M9B!E&+R.@ $&?VNP]<*O_==];CVK5_D55&S.BPTI*98V@4/Y,#D2]!9LGP3*
M;BMJCVJJ/E!2-N=5\/_7N-'__(_AT3Z+%"#9Z,]B'I7I.'B1%Y>2#(F'K()/
M4?:GRO.(GW\98J>'1#JBX6>?#_?[>P#Z+$/V6T4L(3Y,  %*WN0+D6?\F\BR
MEP*20X(5SE4M<;0R @?[YAH]A9J/5 BCUJ@-[)D;IS1T<*IF6"JQ"+$OE,8,
M%P0AG;O]BQ'KK5\!)QLLD6Y*ZGW!HZ-G,^Q6 E3QI]$ZYDU9-<K"M08Z4@"+
M"W@J(>R >X8]%=BY7.^(&U?9#=*T8QPNSCL09*IF*#5F!0CT)M-:,4TQO.#)
MCU$LTY3US!.JC:?F+&D$UV!:>%BUS5PGW?]VY7 ](1?,IKF!D9@\.F/E=%ZF
M&68([L/E@[+!3FW\ZVG^-X6&!:@3L"%B>E7PCSH!FGLF?WOVDK.19P4PNBBY
M0(TU66*@JQPL1)Z@:HJPY.DXQ'X^V!JHQ/DV;+V#F:QP<F<&C+.\P&9M//6S
M1PB*'0\H)DO_FB.X><P?;?WC^[,AJCOI&%OJHPT04U\ZM.A,EW!1^((:V;1F
M96#>I<:I1.O\?T X>8_))L:F.5F#5(?G+ $,OYV]^L>K9R_[R,?L@? \8X5<
M#)2SK-$V8WMU RW^#*U$]LLE\#=*F!P%V%HB4ST0.L$\O2@X':M)@ 1_"CY]
M_'SVJ?<.7Y$V.TBR\NL[G.8N<@O?6"SO$!OBC7'^T3DF:L(NWI<@W/+@-?*R
MUP0D!N9X06#ZW#]#H[!@R41/G2: 951&1@]J/OSV]:EAPAL#F4]O.TEH:"0R
MF%QZ2OR",1S=[8?1<N'NML+M AE.G3V_/N6>ZP@CP_=_BZ2U%,J\F)O.((Y6
M*Z=Z]MNO'TZ?;704[/%$,X'US>)X<E5'J"RGL7O2?O"+MH+F19'1N CC]L&O
MZ,MUKU1??:L1.QI;U.@0+H8X E\-5^>W[N6WY7MIX8,T(#4@ ZQZ']<%]JDG
MUK#!\3L1&O4+E=*=DIU3R#_1N)BC,0.D3=XSE?/:=G YD7&]* N4I<$7N#X2
MSIJL];D^_<\[?2X'K&O@:>0C$46XC!5PU:95Y%RK89I"/O! D@68GV2#M? .
MBXHZH%]U@+H3E%&"+/FV^'1[,!.0 82H5!9EEH#06$W+M%I*4**!0L>ME_C)
MA>+E,=0'VF:.%T'^L]=1FH)&BFW8OBR*/F+NYJL536V7TZR.-O7W"/#?:QO;
MK&TX;JB5.V:]85E32.<*0_?:)UHMF46AJ+%&-5XUCEBEM0@D>H%&QH+Z)1:@
M\P AE0O1W;$Q(.BZ"U=CUO,[<8P..>!).RJIPI %4)>6KQ5H%-'KTU%2U&0R
MD#(]Q2V6Z!+  'G6%30'C!D=_]#.0%G"E\YD$TJ,^)DPHX=?K'Y"WQO"=P6'
M[ TB>NH(_98@U7[_Z  8]/'A_LEH[VC_:'3PP\\8 N.4CI^^*#6'K68&0)+^
M07"Z C"8O0!RX]"D+SAY(/SAX6#PP]*JVT):9]&DH;&1K&U&3!CAD@X]+BG0
M!"1 Q?ZAF)+$2K4<Q;DW34T^Q*J(4QH:!A@]722 ^XJ$[A#4H-F[UW\;HJ:[
M].4./3>R^BM*V575%XD:8R&X9$\^;HBEG?3C<[AV+8?K9.!SN!Y+#I<76=]1
M9%VD54H>M,5/TS0!!OI]A-@N2J_S+(4W*%!E#%F48F3H4#M-S*WH<+8&>J@E
M65&5(XI(L.A./6+<<W*"C3BVO:-6,\38/[FEG*ENE[8!A9EM1O[[*3"/'BB%
M8"?),:X779YXO+[WC<4RG_^W-SP8#I%,*#\G+:MZV7Q"8Z9'%@V\^*^&A@"^
M>/;Z]2MTTW+G=-2[J.TW*8)4.7F.-(*M9P,T_C$\C.2"@0_RQ:&+C9[I!^XF
MKM#[AC^NU?R,*Z,JLA0(KYD5U-2]<+T4,H DD?GF8(&I2J>;@!F&TM]QGM"Z
M;S"X73<VZO0C//D)C$.572SDUSGV1J>1K["6<71E$>8+8#QFVLPP]C['F;LS
M8!+G97$)2W-36]K4'/]EU#-99"^>_>W-QU'OV4O7+8-(6M7B(@[=O\21YDT]
MG/E.:1QX/L[@TCYEG:/WZN.'5]JQ%5K  2[&>'9:CS]!8$+U)6]FSLH%CCF!
M$QEG]8>/[]%7[=F59U?WP:Z.#X_9-/WE]:CGA&O81&U'(H%JBEF1P%<D*07N
MMXQZ4IJ= ?+^\N;3LY>.V2JI.?2?5?#+Q]?[_>"T<ME(E.<%9KHDU!X*X_O"
MK9!Q8<P(@*3F)O4GT'L6GX^K#4R:DGRKKB9"8YFQM51DYS(;]C+7X02>\VW"
M&/@6,^(64 (XG3U;16E&.BIKNF-/J%Z?N>DZ(G[BZ2U27/[:R<#[/]X+Y]G<
M'3JXSS!0---Q,F8UFO'HX!Z9&Y)+K$PD5SO)KHKU4?RJ'5K>)(ZLM3UL0B;C
MS%"=XJ85;QJ<F07 .ROB%!NQPS=T&/2]=JR_*G)2N^A47F7PM/00M+2:KO:6
M4M5 Y_V >FY"3FZ)[JM)\,9DO+WGC#=$;;?78T@4 7A9I+DDH+V:1BEF6NM(
M\2^Z@<MKT\ E.#6CJ#+L/HM1\3KX)?H3+"3I]-=:4D99H4W$8^11)NE^,)Z6
M/"W=!RVYV1M+4HGR_!AA=?K!AVF:I8!BP5D$Y'*N-!HOS_AD.GMK"A6$SCQ2
M>Z1^8*2F/*A*]PZ+@M]>G^JD)G3S:",/B_7$3..Q=QODYFR0YO2"LA:B\[P
MV,<OJ0+G-1@CCC#3.S&Y161SP@^TZG)R4>*DX$D1%><M1B3ZXC+E.8J4</2Y
M@J^\551*ZJ9\?7C]^:U-^F*7'R4HP#.ZKN;O#6Q\M,<](OL;A&$](7M"_F9"
M_GN44W-2;DS:D85G/"D/FSM'*42.3VE=[IPG&T\V]T VOT9E/!6B65+I="UA
M$E V"$5D**B#^>M)FK%=)"6FW".AF:.$?#XZ&/0'P4Q*;,A-<1;AE$&.S]I7
MTHI"HF5:\:#=*'@^;+U;+7(@(Z2OLEA$&4@S^S(),7AAT'I!Y=A"G=JAXRE4
M.0/*==(ZO7NS-</2ZMV^CJ\S*R[%BFF,C^*_S*7JFFKC0E-J.REBBG ZE=0H
M*+),5\38T9:8,\"%N8C"Z$@C ES.$K4YGV[0H)U:VJX?,ZG\YI<:6PY@>P78
MTQCDQ%03#89$L%:7B)9.5JL,XP8-SP;%LK5%@ 71DR)#%X=35"A%]+;J+,A5
M?8F=_7GE/#K7@P?L8Z06FGWA@^;@NC5"&$Q36@X^7A5YCIF'9<234'7?8 G>
M7J0$#$ZVX%\CI\3B HO;YU3.;4NP;>,+KJD&^:OR1KG=>6E>@\D-I^\661:-
M"UDT.B^5[M$!Z\#7*F9YP-]R;*] *>4X1KMJ'W'Y;K$/($U2UYL@!DGY*?:#
MJ*2;#U+)(6,:UU7B+3B]/"3;!,>V V6EMLV$ @Y;-:9C!A4["DI*EW2&J9JH
M$MDE=69N):U(8K(=)"%L%ZR+"_SD.RKUUN&K#SR;0IJ4OGCVX=V'-UCI8AD^
MH7\N_6Y(YW%&L7C>T]ED&ZZCH>L!4@-A5DG:D(H N7"&/19U<=</9E 4MD1_
MHS87]WC.QWZH!3H.[HWC9M8P]B=JDL8I:;[/3X:#_I$6I_W@;!U+<_9"F^3R
M&)T43_-][<8[KEW88C>)F"1Y:F*!"UY![?PM4(F+.+6J]!*)M";4QU,T7%WB
MYT+55JUB1(4G- &YJJ[@U ""F@B4V]A0YYB"6QQQ<P: P5;5E/B>EKN>#SWT
M^="/)1]ZJZ?P?6_$18<CU4T#WT1N20FPW# &,]!(Z1*>#?\FT@5U70PT9Y0$
MQSW7,-.&.C!D)  KE_\BXS>+TX@%65TMZ>=KA%*1GQ>D*3LJ.$D/7WWE73%W
M1AKB5>PN/V0=?,FP^_G_>!>AQ\N[QDOI'%.J<[05"BQH=4)=J]CZLT=*CY1W
MC92L(R@VYF0>IG3.\OCG\>_.\<_8]US[;YVP+;]%9[69FDR*LO9LTJ/I/:*I
M=5X9F\;$O6VG"I#G.7RE0Z8C.GN$]0A[UPCK1HPPAI-I1%WFLSJ7O<5FV2RZ
M-M![HV#" \9^[[!U#L4!K+N:7-3FC]2%M-.C;CPS'7J7&S1RW3R9.L?@7@1_
MP<3J."X:9$KGH6-28!.1KSWQQH<FKYF;MTG:=9I738D6<FBZ"[/_WC8!IWP;
MX_G1^0O PRCO1@Y).Y?8E6R=PB6ZAR&!AKQ&V%ZUU1O; 1"&X:2EJ(XU<DR-
M&*[CQM*;TPTXX2$I M5EY_W@,[R4<1?W&FZ7G4W(?DT]>0NBK:BA9M88V>.)
MJ.@66[I?#K^IE:BA$]N3RZ26GPP<'2M4%,L+@W,4$CDG2-FGYA&&BJF?685Q
MXG%M@WW4XHAOQ4Q^Y2BXBRQFM$([^BE)5_(Z7105K^@5!7RP9^Q#4W$*(O8I
MG^C2O"8WC=_'W)EZY?X(3MS!?TS-]V,IW0?$6B"& FPI>TMA>^Z<P$+]>,NE
MX/[54:S07).)J;MS:4L>-;O2MU5415UYP_N,$KB&"FNJH\G$]%#7;:.P]!=O
MO:(Y#I=*=Q>WL+"JJQ,19Z!AN%W/W-6X8<&\=#OV(J2].\WG/G<FJ&!_]3(A
M#"$?JNR&@H4T\#>C3N35-* :2MR?;=Y&#!^H&UN0![6*ISD5$85VI@43087I
M<PAA<PEN?ZT.9QHF[3F[(,S5L7ON.T_C.WC( CPHK=8GT04<W>DFS_7@^(1@
M"5(1'L0$V%]Q@/V,AQUCT@%WNUW0Z0G62QA9Z>NREYP"XL?2G]=2"N@)F.>$
M21#<D%/!M18SNB49Y,%L!\1\V<Q-D@#^=%$@TZ1]R-")& >AU$OS K@%KQEY
M_#FG[O1G-0&1QASHWG[]X!<95"+U+GD#B(S]5=<-SE@6+/J:6JV-F05*MT$<
MU,)9FDB'YT0S,Y0D^$WMWD\L\T?DGRJBK71B.#I"5JXPPH;6G)FILV%P&R Q
MY9)\+L)2FW>=*BAYW1T%('%65)('N*,Y@O1E7+V]+SS<=1^A2@#JH/&\M3F4
M3O'4T(;YEL%(R>@QA O_WLQQ#@4W5Z7\Y?75!2P_YICJCU"UY6Y[ YU__XF2
MFXV,Y ]KK<5T:,TBN,CIZ@>H7:GD7L1%.2]('P%U9EX H?E)Y"TBP=HF^'O.
MF6&=\^5N#K"'XR'? J];#M?XR'+]P:=:;QGWQ>@V9J!P!O927J*K>&FOSCJ=
M=-V, ,!12BXU72;H/>K[XPR)^*2[6G%2Y17[T'EKV'(U<5ON5IQ:A;-^C%KB
M_+G5ZQ?9/E;GTC.D;(HRJ>?1M#Y)'2[XBR1]<(Q:GI# USF:\V@A8WA8#:8^
M178^DS3$,&I6"VYN!*S=P-@=K03WC+9IKEK?JM!J2V=C, (5)XVY&Z=D41$J
M^JWMZD+LJ7&9&J6AE+DOVPHXAKV"C5A6MDD<S1I!;P&9%B8=VXY]PZ7+".=;
M?9[WVJC*:CGE%)/9$V/&%-6$ZY=:8S1>J/YY'PUQ2>@5.^DEZQ2TZWEMU..D
M0=,0O0^@S D:LY? H0DJC^<$28NU_2# @D3\%;]02\(D\!PL:>(>.R:1<EU>
M<RB&;\<Y+K51CB<^S^$"#;!@GVF1V+8W9(FOW[/^F-/ >=)D$[@2E3S8L%<_
M>NJNU ='[#D]>X(W8AEZ3K8>7JTPI;:D1:+ZW#<?]KDS+'21C>L%F'\[%3?6
MH=ACE[.1&D5Y'N6BQE9:O<W1\D*?M(^S>_R]ASA[9:8=D[$B5I1K6$D@*6ZU
M!":];AZEB?;,$T8[4=!R$P3V51N[4;4Q\E4;CZ5JPXL/+SZ^&YZ)::P]2V!.
M)X63R+!4I2@S6%FTN#DQ4A7@<[4\UMZ+TCZ;9\5"*9VW8Q!6YRMH7VP595%)
M&0!CE:M)*CXM*C7OL8\,';WP+L\:_Z[Y6X_'5)<"-_21\YCV-9:[KKQV?&5.
MCVCX<2&SV]G4PN%YE00.] CW[D84Q@$I[CCCWD2_G[3!+DS32]UDGS5;FGHA
M?]7#4X,ZTND!"B ]X_2,B6V/( Y)- <K[AU@!M+SJ;$'+O>#8/;85'I<-?/0
M2B*SUFJ4M?5;6#CX6Y$[D0)3AF7\N@"7\P)A2!%CV1I\;&R<P.2+E+P4#7!\
MK>')SQOT^"#0&I\MF;"<,(6 Y@BN\X.D/O!;-?IQ!3%,JU!-DKQQ7CR#G>K5
MX3%SE*A4%M*FCE)",==6O\,#_U(4+]*C[+ _,([X1<<OEL:[9?7N*+V\ #P&
M?37GZ)' #V#F,R\Z"5]2O=;>A$U\+&S!J^E16.![BE!<("U9AH7;J0#S*C=%
M64<M66H/LYIU106TW7\R%$>135P2+2&P:8@7K$0N>==C=9[F8C/S>DLYP$0R
M&GFQ]XQMN<,%Q/@'[!9G7C1'MOF"735OE(Q2U1FK:IBNV2-OTRS5\]<I663]
M9/MN(,"R. 0()Z7H3*G5K-1V4F.B.,S"F6=)4UK&Z/!;E@8;)"HR%>O 4,1!
MUTND5AIH7YLD*I.3VLI#Y2C6<E39[3F#H9ZU '@Z>22W#&S\U6E_<MIN?^)#
M&]=";*EAC&&5TL>)+"G==LKHLT0Z(0[KT4%)^251:':E3B?565'6)FO7[6N
M*86*6LAB\K,6N593MJY R9/GB4&F79@DSO-73.Z\6:D??.C>MGNRF^K?P=NE
M$[N+E4H&.%/6I)*\\HD#)5(A,&,^3N?()CJR,QW10:PJI55,,ZBRR4P++>+
MG'#,>N79FU=A\-L_S]Z$MB0 S>!9VLRJ[MH 1\TR90)+&+'VKCQCNBXOE,#Y
M+L>!,L$+X44OX8I4[1E2!Z12@900P\M6+[EXBOD59$Y$:6G3R2\I\Z*5(1%2
MU[X2%3:0Z;G,,L/\DZB:4M$&O&T22%+3I:WU(N^!1H&E%>HY6O5W*)0;!)K7
MA2[%$CD'+L _Z68MN62.DYI"&;;,%9X,'6T:=U]-#37:^C^QI4WPAO*"5WJX
M$;3A7_;N-9.TRQ&_Q5QI6])(OP5LWYW_?*^VE_?6]=+?GKT]JHD 0!679,0R
M>VUFV.[S3S+Z:S)B]?4:+YWF*=0G4G6SE.7DGJT ]/V!=B7.AS 0"*_&0BCH
MVHZVXV'P\5X6+8"4^!'^TLF@/_A!/TZ(/J_43Y6:1VA#:YA0W1N_]@R_#I\W
M\6!GQK-^7QZ"IY)VN.!HOS_<_\$-U<HI.5;[XYK7AOV3V[QU\U=&\*7AB?-_
MQW?PV?_[8UTN U$BV\> ,^,H_G)>8EIY3VAY0O_73<M.E(=C[/A#!_S;L?4!
MAM O%!B%.$F7<1S^LI):@8%V^8E10%[=JJCZ;6/E=7(+*/%VGRZ@ "7Q+__U
M;/3L>P#-9&KH5)YY+7.2M03K!&L'"#K ?/R=H/QM:3HKVN5&UX J]CH-^RZQ
M^(H+838TV-O>*[DSU+^"91,MK_+L&" UB9\XS[Y;$A$;RO/T+>/IU[$'2[MW
M"4;Z^N-0(AXY[&[.7+5"?'L^ZAJ.(.*Z>=-W8K:N<7:@$X#EVX,K[-4'8<4;
MW>4_Q*E2WIH#;P+OI\Z6-X->7NPF[.X93-\)R;:#%7]78AZ%@^-#CX0/8!MX
M\?4PXFMM4:G.OO1R;??DVBT]23O*=.X4#;_=*?=89.-!>'1\M#V(?+4';D=1
M^:'-/_K(?0E06P&ZTQ+T$T9SO7C<6?$XZH^0K21%@T'D;1.0;53='+#/'UA2
MW@"JCU!6'H7'1WO;A-5/1EH^5,; ]^'4PP?AU++^7U[!R^,R_4M817G5 P,P
MG6Q_0.#I0?(^0E1/#ZH>DM^1(\,_,<=NTUSG>VTY<L>YB+[7S\[U^FEK:K[7
MSP[W^GGJ=4N?IJI4P6548<F^SC!/<ZI!":HTE]D73ID_%@B<YG]3V 9 :I%M
M^]8*9U4DP;\;^*LJ\5',N7LZ]4&WK;,SPY=\O>_&!1)SK$:AHK6 N&927.:Z
M"-U.LS)UJ>,%3F.(]1 L''Q3E(NUU1'W"=5MJH;8N/B!IFY<4?WP3;4.!_O]
MX]N4#_3W[J7483CL']U/484_T;:=:$LK4&Z?B_/X,LX?P#[_7I!ZP 3F0U^4
M<M=%*5UUW[X@Q;.'76 /]U/?\$B)_YWNV?;C0Q9 /#Y2]LK8UE^1Y[:^0GCK
M^+&O!/:LP+,"SPJ8%=PF\\JS L\*/"MX7*S@Q6O%9MI+SQ"\);<;G.>.*8+&
MP!9-%>5)=:=4L27@W"E&_O2XA'?#;"7D/)UZ;/-TNOV0\W3JL<W3Z5W;*[ZK
MX3U54K]?R?+\:4M8Z@Z74/N&ACO#53WL/+%Z8MUFA/.P\\3JB75'$.Z1P\[W
MBMH]"V==MT7?/FJ'VD=M"^QVIS74%K/G[TK>)R?A<'CR1-'QGJG6\[RGB&2>
MYVT;SSL:AJ-CS_,\S_,\S_.\)\+S1D?A\=[@B:+CPT9;O>_BH7P7I]@SJJ3>
M4+UY6<2JJM8.D-X.SN/EW$[!;C>5J4<HWO9'!^'@R,NW74)#S^MV"G:[B62/
MD-?]YW\<CX8CCX:[A(:>U^T4['83R1XAK_-ZG<^Y>'I^B[^J7)511BZ**(&G
MTJHNJ77Z=C :+\W\3,O[14,_TU)?P.%).-I[V$%=CW^HI6>IGJ4^=C3T+-7$
M1H_# \]2=QF7MP50GJ4^:33T+-7X;0;AT>"^W39/C:4^=$K*Z#Y=.Z/'X=JA
MT>L=PZ&\R-Q9D;G=T]AW3&@^[2'L!R=[X?YHM$WH_"@EI^>LGK,^?D3TG+55
MYWCL&>MNX_.V ,HSUB>.B)ZQ.IX>4%D/']C5\Q0XJW;VP#]Q'+*?8GYMLY+7
MMKC'#S6_67,7.[,\E;&!"4XO?SXZZA\'\,TL+?)@4I1!/57! I8(U,I4T0 G
M7 5Q,9M'6()5%_C#7C_ 0>IZU> RJH)YF0+$X"!!TBA\+H(/'?0'YD/FZ30/
MYJJLBCQ76:]4650K[&E5U560E.F%RG&3N*4("[^J%">MXSSVT_QOL,<Z@(]=
MJBS#?U9U$7_IC>EDN$<X;42/(R0*6*,,QBI7 *Z*?GH^Z.]W;BB:%<"S_HST
MMZ*J A!DL.QE47X!&,6*%QBM6:">IF72 R#5"SF+/AF (L[2'!EB4)<I_*]<
M"X,^RE1=JKB&)\;PY4FE:CQ_HNS:IMBM4N5%&BL^2U(VYP$@2C.)XKHIT0T9
MX0Q[>+K):CP$0@16Q[\@.#],<;UA,"MR DTT7P  FV2!S_[V^7][QX?'_9N/
ML?\6WO1=!U'</6,RE8CO;"6B9U8W8U;O\^ 4>$46G#!O"9>Q=CWEAT#W\&",
M6D."_&4?&,S0D&,\!2#@ W,DF)SP'LX;W:!\E.B^#B[3>AKDP,(R4.YR2MD,
M)@T0F0H:X1<W652SX7LFKMT3_&[&[&DK8]93TTUSC-<)__U!_^A&PC_<1/I;
MF3\\[N_=2.;?@/R?#_?ZH\[%*Q"C+!;A[KZH5E .WMOK'W;OJ2PF0+KP,\!P
MHNC90?^@\]DBCANX\7CA+CQ<\W"FSMT5A[=5.JYXNXZ^RNK=&@F\#Q0,;+$I
M2X7;3N$6XYK5F+W^2?<A26<RJ--Q-RF@WGD9+2ME5G.!#=FU734FS:NF!  :
MU/3\\#I92;?Q+@<"5,$+88$O0UB]]GRP'9"?HCJ=9<4E:;MH6P>B!B *4WY$
M4EP2RA9-*7B>"F0%'U_^M*50O3\XKG@N$ P,SHYLCJBI"^W$P=WA\G >?+R7
M18NBD4?X2R>#_N '_3@@2A;-*_53I4"V@#C08&$O#[WV;#DMY@*$PCC-TGKQ
MDWZ_(]^%OW:PWS\Z&.+WOB*4<&MR3(#\UY^?_;CFO6%_='R+MV[QRK!_/!@-
M[/_=9@U_OL=]OL<QS?)1#_#Q@[9NT[K^T$\@OLMYJ_\$I;P*WJQ8='X>L6</
MN\ >_!R^+<2V1PTYKVEM_15Y5OIPK-1K6NO*3@>C?:]5>5;@68%G!8/1;>K/
M/2OPK,"S@L?%"EY-H_S\-GV^/#/P5MP#<)V[I887[S!!LFBJ*$^JEYZ);Q<3
MWT$N(5_XRRMX?5RF?PD!LZI>I<ITLOTZA0>MIW1/Z8_ ./"0\W3JZ73[L>U1
M0^[V[:/NUN2Y;;>H]7F5.V3PO+\VO?0A^>P.E]7?,Z-]P/+NG6>U'G:>6#VQ
M;C/">=AY8O7$NB,(]\AAYP<<;979L]%MOD,T5%4MAH[O)+9#G<2V!79MA-P<
M:,^W ]NV@RM_WSD:1^'@\+Y[+&X+.MXSU7J>]Q21S/.\K>-Y^^'A</A$T='S
M/,_S/,][>CPOW#_P+&]WY_9XC\4W>"PD)+L=S,6+LIV"W6[J2X]0@KW8VW^J
M NRVZM1MDN\]Q_,<SW.\K>!X__D?QZ/AR*/A+J&AYW4[!;O=1+)'R.N\=O=]
MM#N?6;&+?HH+5=4\D2"Y2*NB7% S\>U@-EZB[13LO$3;%HEV<G3X1''0^RL\
MQ_,<[PERO/V3)XJ#GN-YCN<YWM/C>*.C)XJ"#^RT\,D5#^VTX)YW-'HL2LO@
M(LH:A?.6+J.RC/(ZR-*(A_=L!_/Q$FZG8.<EW+9(N),][\7P.KWG>)[C/1&.
MMW_R5'7ZW41!S^=V"G:[B62/D,^]&(;[>[>98/ 8L-#G7#QQ]\5'!1_Z4R5!
M5E154.0R29YG'ZNX*=,Z]1D87L)Y";?+$NZI-K;PK@O/\#S#>X(,;\\G8'B.
MYSF>YWA/A.,-GVP"QO= 09]WL7N."QXVX#M:[)[PNN7XS!WE+7>*AM\^B?2Q
M", 7P\%]J_RWGD7JS0+/63UG]9QU-SCKPW3?V"7FNO7(O"V \CSU2:.AYZE>
M6WUZ62FC^W3NC+;>N7.[T9*?BCK*@J)SP&08Y*KV,G5G9>JH/T)FE!0-)AUM
MFU3=G1;>MX;J(Q2P.-K@^'B;T'KKA.S6JXO; BC/83V']1RV@\,.1H-M0FO/
M83V'W1)4]!S6<]AOYK"'AUZ!?8C,G_4.H:[[_ 8OT9WPZ>&#\&E9_R^OX.5Q
MF?XEK**\ZE6J3"?WP<@])+=O[/G3@ZJ'I(?DMD'24[K'3P_)IP!)3^D>/[<4
MDMK*@G]B8P'ZU^WQ,=EO7_6Y;X #'C=)+X(XBZH*<>E<]<34QOW @K!7?$"V
M^B<%[[_^U-O[>9*IK[TD+55<IT7^$]!X,\M_3M)JGD6+G_"O*QC7/P#TPKWI
M) ?XSW\U59U.%GJ3]&)/Y<G/\Z)*:>5295&=7JB?Q\57A B>TK@#OFYHWE\+
MQ/:=V4J49<?-;7PJW_L:3_9;J SW(_^+USDUW@(Y4IIG:0X;JZ.R_BEJZN+G
M]A\ V/PSWSYY"J()'/>G*+N,%M7/SWXT>-+)<_!6'<18NN#O>X_W2GAW1W?V
MNLR9W=28_?[!WMX/5^3'#$<W0N<6)(3BM@69WZ_/G,%? 1TKE03C1?!\T#\*
MX&,9(%,P*<H 7@P6*BH#P&!XY+6*U6P,:^T-PV T&.V#WC&;1R7\J2[PA[U@
M7J8 &-AO0,C(?P$0Z.]@K]Q4CR26+4W*8@;_KN?_5-A!]_FH?V"V8A=-&H4+
M3@'W81LU+MF4BV"1JBR!UR85' D.$@7/A_U]\[[[<3Q2O&G;WA!7&O3W.E<R
MQQ"(PL-YPB\,.U\HW*JU_I*,V(3#?@-*?M>LK>^-H/](_]VD"<'[531/,=OK
MHZJ*IHQA003JAPQV#1?T?J[*"%E=M0YZ-Z+QPT=#XF^9A&(U1^@ DI=%<SY=
M)=@P *@&A0%C,(TN5#!6"D@AS2-8('&H#2@)R:6*,D77D%95@\_@59R!@@B;
M/87'U425R .JNHB_T(- UK,BYQ]"W%?6H#0S^\)5?U7E.>P,'\?__/#NPYO
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MK!69F\1I<Y?T4 ,<]H\.ON^BJ!*7P0@8V37+HO&FR&L#G*9@P)#Z8! O+VJ
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MZ39,#[(S8S.L*D)-I?W@E/:9I5]4MM"+B'K1VC%&1PO02UP.5\4I6R=Q&,3
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MU=TG@=.JX!BB#%&&*-/BD.3E-/DNVDE$##J%(7H0/8@>!#K;:!0@Z+P^^95
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MXPK-(#18HE181\(N&W>B0D-?-=\&[^IF4\L@ARFH<@??@=$TDD1J=U"8?ZD
M"B40POT(7Y1>28_?L5Z(@ @?)(!.<8%X<LJ'"([$ ]DPOTM2H%+0:C[<=8VS
ME9B@=2.DZ7F+0X]Y 5-J5T>!X"4I,)X8&CX;YH4WR#TV2H;Y$7!>\J%XC>MT
ME?IRF%V/#3)^E/$!0V!?'N,W @+NHPPP0R_*1T?5U7/.^HMG&VK7-?#ACT@/
M'$<Y(2#WXX<W[Y^XS>U:UO)W@21<X5V&WG6>?=FKQA9.0"JEJQY,N.'2V1E$
MJ1E*P6OPFY_?:&^>HMK.DVA&X2V&G=:O8^VN6<GWA8;P^Q_'W\XNUCN0)4[1
M/VZ? F<7VYK\V?8G?W[R^I.?6U+H1^I,ZVK4[6!)WJ+.7=32C BS,<)09L_:
MZ?P)H-V1])6E_IUD314_)^-[LYMW3\GR<72T&<(LV)-XW9[V#9+J??9>^L3N
MHT#Z=1C?=J2OW4\3=EH]O=(K(XY-!GG9_J!)Q?HP8\>89?MR?I?$UU:,U%TB
M$+FA=H-2>RCP5X/E/Y+^) Y;S<-$*:(4R<4-R<7+E&<BYE($-I[<13R43A^Y
M/Q2!N!=A&/D\73H;;#/!2&NFS]JC)2[^/+V2+CY+Q]^^75R=G_ZKU3$&%.LR
MU;F.^7?2@*=9$DL/=TF&,?5!!$8#1JG7\5]E3P*,.>DE#R+8WVN$E13AP7!-
M$F&(S+31(;Z]O(MZ$3Q%NF;#>W;+.^)3CJ\O8F?ZG2)-(!SV, SZ@:?X13;T
M@%[Y,*]2 V#C3G_4N /3 ?Q</"@9YFV.)P$B2WZ/91E*Z5LN3\91 '?@!>68
M_Q*,^7@DZQ_"'G^4@R@M0I P,F+8CS\$43;HL=$1?CLCT;LFR'0<5F74P9\E
M%U;C$S?*/ ;0GV21>'+*,8#\GC<C%LHQBH"%A73"L_2;W"CB\K5)OG6OH*I8
M$QH!%JC\%]?SKK:=RSE%HJ*.G.4L+>-@)K\ :A<?%\LOC&B1-'+$>@]LE)4Q
M(4T^F%#G8ED;G#&UPNM=R%=R,ZPY<':.0Z):KH,*Y\;XP 1C D7\(885)BD*
M<2E/AR)'0^JQ!Y"B$H.II#$? 5?!6_W".@+V+&(A\8,H;MX?LSX(<A ]?O&8
M+.<L*-)-$HD+>XI7C6SP6O$52.TR=!'D.Q_KGTY#]6#08BPRG,0%/D.QF(_@
M!442&*JA3O4BS#$3Z2=BM* +1(1E$:Y9Y9I/Y%WA$(I,":7*CBF?@@/-Q*2*
M9#9X6)TG+H(J\Z1XK2!G72DKPY$"O>,R,C2OTN$ZRZ2^=:1;# 3%1#81NYDQ
M4*/5DF2S:Y+-TZ$-92@N+'1T+G)Z@D1\!N3&Q);B1O$$P 4CJ7HVU@0#S8UY
M9^$(!X,?^IBDE/;%G_""_([ESX]/Y,'%HVIP97I=E KV&7-1K=!%XMSX+\S+
M'96L"0P!H\=<;='WJ(B'#8#I,?[U/DKS(2^HGH2[$49ZH/;F<['5*P11CZ.D
M,8):)&R7@=*%M5H&2(=)#_Y"!B[$338IB*:"L4NA50J>:M,66UMD=&9"6F%A
M@6 W&*YE#HZMQ2T+FVOAJ&5547X8MEP^.15VE[CO98',VFHAR<H"P<6SMZE6
MUW!>$)/L+.<=GN6<#=<;<G;80W5=8>]U'-BNBQ#M\V@^[_L])*;Y%N4]8AAB
MF"7.!W/BES8&_NW4&<QBP4C7[Z5/QW^<?9)^_?W\%PI&:LJJ-'G(UI)-LW]L
M<W+'HK3?*"KX,6$IX+ZE3_!VG YO7P0R\?*C*(?1^DN=DD:Q'PU8[VG*;FR^
M3Q>?7]MFV?7C_V?#JM>HUUZ,W;:S!KL8<W5@F5&MBH@APNP 80ZIM<_^&72(
M RY_/?MR=GEY*ET?__['\2^GA ,(!SR+ ]#"_QS%#$Q2L$C)PE^OA?\D9<G"
M)PN_Q6NPE>CAJ5A&LO#;H#R),$2877;YUT&95=AN;?3NGS6'(.#KQ?7IM?3U
M^+??S_]YNGE;X$GR2G\/Q?\4?0\)_<=EIS3MYI_SM6Y6*QJR;\>6[+'O)\,B
MC+(T9<G2)$MSVWR]FJ7Y-<E@>%_9]V'\[X7-S$-U4[6AQA;1IXU;E[S(+6"_
M]1N09^?2R>]GY#PFY_%S1[(B83*9F]%-=B#9@>VW Z-8.AE&Y&AL@Z EPA!A
M=MG1N'_Z':W!JXN/IU??I(]=Z>/Q_SO]>G%UVI'^>44AQF0=/D>T+YBT?A8'
M?,!%/JY$YB*9BRUAX-7,Q:O$@ZD+6<C^XOTDY2 +4XI$;84D)L(08<A\;),!
M@.;C;V=?I8]?SDY^.SV__G;\^3/9C60WDE>1S,1]-A-_B_K2QU[D?^=QEK,P
M)/NP#1*7"$.$(?NP38I>V(?'WWZ]^M>Y=-J5/A]_^7AZ]0M9B&0ADH5(%N)>
M6X@LOTM'L9!ZK.?Q])9LQ#;(7"(,$89LQ#:I^L81]-?CZU^/OU"%*S(2R4@D
M(W'_C<3RM/DKR^Y8CVH>M4?H$F&(,&0EMDG7HY7X9U<Z/O_VZ\7YOZ0_3J_.
M+\[)1B0;D6Q$LA'WV49$H1?G=TD\DOZ ZY-XC<TU7RDM=-V=6F8R2'&ZU!9P
M]]H"VM06\#5VWOIZ!;VL+V!;Y.ZZ&?GL_-/I_Y6^74B?S\Z/ST_.CK](U]^.
MOYU^/3W_=KWEKE);Y V<[FXVDW+,%5I"/7O/J^+$9I<\L<C+&U#-1\CB&=4-
M8@7'K+,9+F;27<K#G]_\O>A1=Y.$-S"8FU2TFN,I#VX&0Z\7^3?,]V^PQ>+3
MXB$,YQ-7O#7@?H(M&T&T#V&R*2J3$C4NX<DKVV.&$^E05_58I4LQUF:)I<\P
MY'JWL,5]+1.+L&0?GKDR=<TB29VT.<2>W"AP^2QOO.*JMG6_S^[OYXTMSDD2
MB^TJ&MR.J_%>8\=;T1[SZ#5;7;W&%E->=X/MBM?SE4SO6C'Y#<:[\5@/:P7>
M9'><Y]M411/;X6,Q*ND:1Y5A_U=049^XS_L>3R5=%=X>0W0"@E]TTD>[H8\,
MVI'/[\BL4@!H.B8#7NRLUFS-L7["/7E1C:_HEWR2].']=SS.L'74ER3+I+!H
M BZ-.$LS231QIIV\\SMYTY[VG=[)L(7[8O<6O<P!_\$GB?_]!GN?YZ.6;N5K
M'.)=TH-'9__U=T=3[0_2J1@PZ=\]V;46[=HE]:_/LKN;L)<\9"W=M2<P0.DS
M#I T[5[N69OV[-P]&R<YSV[RY&9B\X:5'Z78QMO<M.<X0"E/I&<=/;05=V,K
M.AM_0W$8!3SS"K/150K)H)",+33\6/,![LNVRKI'H^YY;$CS-,;HFKK^TVL=
MOAQ,N(@4!3^_>?GI\7:#2ZY.+R^NODD7GR4,,[D\A7_.OTE7I[^<77\[O3K]
M)%W^CM6WI..3DXO?S[^=G?\B?3Z[^OJ2K;SQ.4G+!\4\RY4_X(=2$[0E[NU;
M(M!ETTTDP"1^^#%A:2!\1&7<<O9RF;S&=5MAX5;>Q2U;M?/AO0 RTL<HD<YB
MOWNTKTPLGKQ\([&+010C?>#_R,F+@[6%R6?M O46"^KFTAV[YQ(;!A'2!PD&
MBBCIP]A&&!S4Q.)2>;0L9<4A+DB'&684 B0;>ED41"R-8%AOBT403WSWK..Y
M(X8@S!=XX<3;LPDW63)Y3N5/G%/UDBSK2-D<_W?AL.\4]Z"G+9SC:8/?XL+=
MUJD%8C4DX:60WF+H'N*">]X;%6.>&&OMM6B,^ET7*"0EPQ3&+CATP?LDF%B&
M45PABU)\6Q1+K->3^G!!BI?"UP,82U8\;_R(RAI$<C4688$U&$\Z&_8*>D?X
M8Y+F^-%"-(0!PRSA^SZ>/3Q$^9WT>_>Z*]WR&![8ZXV0Y_@ "<#&<6F#HA]@
MCV==DG 3N_8CRZ*"WJ6L.V01]NT.=L<"NXBEO.+I 5Q<QN!.[8U23&2PN6)
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M>LR/XF%?#I)<+J]X\W]TLV-CK,#DA/_/GN^LUQ0T)([WA&E('+=+'/N*I?!
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M$6]>6^L=TU:VJJM7+RI[P)N39#[)?)+YFY3YBN:%7 -P%02N(1N:;<LL,$+
M9UPQ#0=^=ZV7 +*MRGQ;V6Z\\A[+_*T>06D;PG#:?F"X;TG.>A1,UW*]O:,;
MGYR@+]:YGJX!,@*X!  )=*[O^XB90MG4'.;H-K=UPUM+-M &8C9,S>IHIDEN
MSS;M'!*WK:11NYGF8,0M"WT_-+@J!ZK+92-T=)DYIB-S4P\473<"AZ_ES&D3
MXM92K8ZATRG3+IPRK0F0["+BN$R3 4QT)')YL,K?H ]?C$M@^/ZP/^RQG ?
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MDND[Q58DTVN9KKNA[09A(%LA!R1E>DQV;!;*3%%-BQNJYO*9#FDOS/%95_R
MU=&M[<8/[+%,7_U\:QZ7KHJ^6G>^-4EH.>.^'#W*=U$ N.WH\TVH*IIM&%SF
M9L!EP[9=V!F.+6N.KBF!9C&?.=.K-?,0SS=\AYM@(XF*48'KR+#? CG0?=MU
M#-?BIKOA.,%^/\K[\$<FL3@0NQ]NXK$/NU=Z>Y[D7%+M=S7;S/VQX/8[7%,
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M\KXX\@:CM/,R($XRZ')G,+):>122TE3)P/,_5D[OEMP3I@B*E+*,UB8BPTQ
MQIC$190I6+QNY"6#;)+R/\#=+0RBM<HH@.)]4^4[ALG*1^N%ID@GDC&9&H<T
MXQAAQVW(J3#19"4;%LZ&2 1%2H>,R<(63(X."4,QY<91S=@*)M\8$#O?9'8+
ME'\]>?-#U>3GE-_";F(S8M\!9T-S6HPY0'./H!E2XAZ:"'!X#>71JZ?V<'O^
M>-_YMB^.^\(YQHT5R&>$1SPFA:PU%&%+@O'!$R%6<G$9C%;4YE?FWR/.4LJL
MP1DRD4IEE&4>K^;BS\#])C^>_+?OU46DRKDYW3,">&HT/WI  S !^ XPP0XS
M0=264DTCPC%ZQ#G.6D XB:2CB880F2#V+A,P*ZD2VF>MP H3>(6<%!;IK":B
MB\E9Q5^>"<1 4 D\ #P /  \L/65&1NT)JF@,:$"<1,\<I$HQ"T1G#ACF5Y=
MIPPR,9<\4BS%C,N.Y^2<"$2P4E%0I[%XN<J,%&* U;X!\D9Z>Y<#@Z"W]Y&A
M]_9+K/VPB=4DY<\OQ[9.SHN3/GI@-- C=/)"&1:,M'$C0>B!5X&1^FJD_<A?
M00MVK 53])@X9Y 7*6M!;B0R(H6R:&\%I\9:S^YJ01TEQ\H*Y'PB^3TR:T%%
M/$K2&1*)L=*H>[7@4=/,8G@SJ_/%?HCU<!+F#57M+X_GZ?$R;P[?::TZ>O_N
MNVVM8B )K-_W*<H F'MHHGZ[3"^Z\6!3$S@5M'B"%T'.F'-&;"F3R6,DM+&(
M.^V0T9'DG+'MUW%!,[6RKLNCTI+HG&<RCCC5'#DG(R)6.:Q9="2L[G.Z/V?\
MIQW-XO=3QJ<O+S E(&GL49A!TMA#$_7;97K![Y T[I93 0[UT$3]=AG (7 J
MP"' H4V[S)XJU2PJE38A(A.S2.42>^1HPBCXX*B)Q"D65_:%4^YB9!0I;%SI
MB7/(*8Y1DH*R&"SU.(!2W>8P@P&7+]4$5T*B#+0L37!^<G8V&2]ZX;)75^>S
MVI_:)N90"+&NWIY\^  \"@TZ_4H\P$A@) @]\"HPTA8;:3_26E"/':M'&YD/
M*2ID?%FSC,0@+0-'.#K*DH_:KTZP>4QOW'AVX5XM4^3C]+I-D%NY^&Y2?UAD
MQ[^6Y/AM<WY^LFB!>V97'#%J8##LG>I3? $D]]!$_7896%@ I]I-IP)HVA,O
MVK%L,5 N4L0226$#XL&[G#=R@:RFP3JG4S3X.5UQC\L6VZ6'CE89J&"0+O8H
MP"!=[*&)^NTRO6!V2!=WRZD AWIHHGZ[#. 0.!7@$.#0IEUF3S6JI=Y8'00R
M1GC$R[*&]1:7SKA@0N0IJ97=_H_IAP.-NET!!N/@7JH3K@T"Y++[EV:1L_,X
M;FQQ4F!*:+OI5VH!1@(C0>B!5X&1MMA(^Y&^;EX?0IT*G*K']@ <VG*7 1P"
MI]I-IP)HVA,OVK$2.N=!B!@D<H0IQ),VR$;)$:6"4!J4C_19;5[++>6'X5^S
M9GJ6+Z7Y-#G,UB_78$<?[# <C5_;\^'4CMHM 6U-\?6-DN+'^,=LV.1;/XGU
MQ=#'^5[TC]%//H_;3^FR[D[,0! HO?<I,"'-[*&)^NTRO<@((,W<+:<"'.JA
MB?KM,H!#X%2 0X!#FW:9/=6V4BG&.(LHJK)Y75J/-/$&815=<@'SF#H9EP;:
M=K<#$P:LO51;V?LXK4:3!@X5A5Z6GJ4@8"0P$H0>>!48:8N-M!_IZN9U)-2S
MP*EZ; _ H2UW&< A<*K=="J )O B@"9PJDW; W!HRUVF'TM^#P6BJX?U<*/^
MN+3G1I<8L5:,"B*0TXG-3V0R 3NDC8_2$Q6(I7>7&*WUW!"ED$I,(A[+=&TL
M-1*:>T:\E-C1NTN,[^/T:.PG9_&72=,\?#VPR4\F_^T["X-*##2F>[8P>-LY
M'NX'?P7H!^C?">B'%!2<JL?V !S:<I>!%/1%4M!$N;0L<I22M(ACDI"+$B-/
M>2*>2<Z-Z:++#5+07J>@,/OLI9K4CJ>GL6ZGGM7Q-(Z;X46L/MLAS#[K=^>,
MRWX=ZZN?'(CS:=5,1L-0+?UBUTSZTF:<(PIF8$@(8 C@OOH=!# $\$OEU'T,
MV7X[U?<M!N6]]3KF!D&PWZX)> =X!W@'>+<OKMD+QP,(W'D_ PC<M&,"!$+*
M!W@'> =XM^>N"7@'>-=CO-NQ^4S,)"X-IT@&%Q$/G"'KK$*42JT]9HH(?K=S
MA1,=L>4)49+_X,XY9(7RR,08<%+!2.7N=JZT"_:O;Z[77S>RO(_3X_3)?NEH
MQI(8**PVVL8"L ^P#[#? Z<"V/\*[ NI1))<(,RQ0MP;C*S5%*E(I/'2.^-6
M]LP\I6$18'\G8!^F[W70V/CGW&!N,@J/B-^?[:B<?#RHWD0?SURL*T8&%<64
M 3_WC)^W,[9W?/%FVTM(X%2;M@?@T):[#. 0.!7@$.#0IEUF3VL-!F-#=% H
M41$0)R8@;15'CGMB+$]<>7&WUH Y]U@1@70@Y4@\;I".,2&'C>>*2A_)2JVA
M'>_?',^FS=2.B^UO%1::]K<W*PI'[]]]IZ1 B1Y@+@>4F#W;%MGO0 +L[:&)
M^NTR>XJ]2H12T0V(89FQ5XB(G%48:>UYQ,9H%O5=[/6"&4&313HC,^(^4F0Y
M<8CR$$W4&7P-7C_VDD$V2OD?(.\6AA'TXX(7 1C?381MY,DRBR23$7&L+3+<
M4N2I"8Y;+@R6=\'8:1^=\@FQR"7B+&4PQI%EG R<<64L*_T9=\!X.O&_GTY&
M(=;-VS]FP^EE1TMLAJN!X@(0>0MC"1 9O*COB+SS<Z*TB8QP*A"F5B N14ZR
M/1,Y)R?.4FV#D.DN T29I&*.(4I<RJQA=68-X9#0020OHB/&=LD #QL6Q3@=
M:,SWC I@8"G41X  =B@EUXP$%6W;NTP0ISPAS;U&5%@>@I:<R; "R$8YYU)
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M\9(@MYN6WDWJ#XOL^->2'+]MSL]/%M/6OCF [>C]N^^I1J8'1N_;A.1^QQ=
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M&(=S1_L450#$/311OUT&%A# J7;3J0":P(L FL"I-FT/P*$M=QG (7 JP"'
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MQ PM-/W*9,!(8"0(/? J,-(6&ZG_Z6R_70;*8N!4@$. 0YMV&< A<*K=="J
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MZ:3J%OCO[:."PGLO"^\@&S<D&S_4\=P.P_*$LWG!?5(VJU5^5M?Y18M*?#\
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MQ )U.L9HG3///EK[9J7W:($YQ^EUBS@G!7!^+7CSMCD_[_ID;4X5L/T61R4
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M7-J>Q:6>F&Y[%HY@4>AZ42AA3%-@!E%:YH/+H)"-7"!M!6,DN!1=)Z=2'2V
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MEQ=Q_3W+ZVB+,;.SLWDS0+;:-+M9,R^+-G,F/3N?MPKD(,G/^S 'TZ*3H-S
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M,7-]!:##; NC6J /=N-LY@'F;^#).;UIXTWP@K,*1&AC++_-9]\M,1P^5F<
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MV4>N4=\21%OPZ5QP^\#T3&V1MY-L59?>:Y7!BQKOL1RW=^F.6+WMFSM N=T
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MSG[W<[B-G8LQ+V2+Q>!A $ U3C='Y+.8%G08Y<YA#=39#!"KN@K=_3LV@[$
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M<.X0"U>YQ*%J9G+0<I158=O@=U_T<FIL#]>7;(&>/2^>IF,<@$.IEEBCL>F
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M;7,S6IQ[/%*&1P /3-6CMU!&+6>GJ>4@C@16O@F7MKHZVU\X-61'7)&:.BY
M[/1VT_#%Y#N[]J=@X3(S L(.$;.J]"?0PNJUFXW;CQ5TQG2?R39975==9\86
MGK&%[NQMI_[Y0,@5E:RNIZMTO5_'57RVN' 8Y;>KI@^[^VPT]W']7$W#+%<W
MN1'(8J!"?QY>AFEZ:^S2.K*!3?ED_^T=+<!L)\ *[I"5-5+'F-CO"J  W\%N
M>OLQ>D^W!+AVV943&;2>#6&4/M]RUT;ZF7V3 @^W#&62/D=$9%YEFSB83H#5
M:HT#[X(7G;?HA>W!K4UK?MNNP2A]__ODY$,_+7#[:/HZY;X9XHZ&BJ[]+]JU
MKCX5WLA-!8P=,XY7;86J>V+FWCMI^<068($OK3_!%<NLV]TM(DUQ@T&+JI']
M1,1V#1_]<ZV6+K"UO5![)N=*K79E)O<#./IN&)/J;#/V  S_RE1$#*G"0R%T
MGQ;?]5A$<)T[ ,!>]'IAAZ4,HS_8:)!*WR%:=).3D8,A?'"PZ%86]58AJL'9
MI4OF->5?>'*7:F7;<)P;AP)0QOA!@^_P,8#V5DU3A8T@:YQ1@!G&Z+^PT\L[
M!OW(=:\AY9'(RXC0+)-@<88<]/T0[,A2,49E# H\OY<DVC. PX]8D80L#KB!
M@;CM/ TZV+NNB.8#F/6MU[_N5?]:S;_[N*K%'ZY7W_@ O/S=VW&OZ^PH1N"R
M7E[DS,.\2W5^L:@O%8Z> ACWE4LV/L",,Y-89^:X>,+V/)[U71RF'&+(G^W"
M#6QC(5TB0%_D-W::=AS3-)? G@%=GX=1+U@C_#^S!F=)O:T;K3;85=?WS\A:
MTZFR+Q_ 35M>[%KI] _W78;[<58@,\S#7M.[OBC;%+1.?-_MB&SM80T@[DX>
M':/+8<C6(.=&3;=_7#!XST=Q5IN^HP9%23?1S([/M5+<U)6:B<AG%7R\,554
M.Z:0@1K#3-%*U_=X6+=-=+'X;=SLS05V4X+W=@;$>'S<N*LW=N<F9D!!'S=H
M3*7.IQKCX-;W;[QN6!!X6:F%M%I6CVUC/< 1HD>\AT(\BR>[$,\H<--6V^83
M5=.N>HY@S0V'3QOS:S9QF 6_X!Z"UZQ9U#A\;VUG6=^E?"C,19PD)2,R202A
M3"56\TDBGNBRX#K+[M3QH]-\WIE(TV_LR]=5#-UD>;YBZ Y:T7K^G3V: ,[&
M-PW9QR9< ,.6D@Y14]6.Q(LKK\<*SRY(VRLX5JZX-E>.SX^*1HW)U0UZ8U\F
MU:*C.M&N"JGG],Z6Q4?0-C<6JK#52::7H^-70[_$[1Z,8AP9'[(ZVU&,O FJ
MW5%U_*X=MNH*FV2E81>FM+ZK@[<L;^NUUB\ S[NJ;[UOS]/)?VRY7&.ETSSX
MJ8/7*(:]YQ5VP,?YQ;H+0-EY"\-BQV#:!]+AG(>&*&!!6_4.;EZPS_;+#>N[
M4[D2XGK4<&W;>S-6$MT< WB?B>+;K6V4*=OT<]=E!B>(5&<X;-2JT*MV)R)U
MA?YX_)],,P:3WS'L=?0Y-Y"H=IBVLBD/\/0")5D[<Y+/])\8VB"8$^R;.BBC
MG0C5:?9&N3>!'C?SQ(0'31VO@=-B8:<Q;8Q4W+L5?-)LQSI00/\);&.,;NKK
M9R- JVGC[]594Z]/45@+L,-/C9OGF@P(SP,/JTIOTOF%37@HG*YJ0;6WV>*3
M$OW5JJGXVO4!V<>0)N-P-]Y@1QX"CG1)J?"//]1R9EL4#/3+5?=#M71/6/YH
M:=BX9]MNGMI$C/0-60S5&3;0=OT0AC$"]H6H:B(APCO6RQ%'-^S4COYL9X.F
M.A[!AMY*L'CZ7B>;'/W":&>FU*!V!O!@AMCAS<O)R DY)2+;#V<\8=M K=OW
M//C5B@L$P"'AE4_*]TGY3Y64G_JD_&\\*?\^,^.?*B/_ZRWQYZ ?H70[)&9B
MC0RN 'PF,NC:T:"YHZM%;_[T+O"=[1VBPN@-]84R975:R3XWVZA+3EMFW62
M&^4,WVN\KBRHS'5:$%5B5EXI).$AU@3GLE ED$*8;W5"N(W7"A9RTK?+_]#4
M2_BK[9[4WJ3_S1.ZI9#$CMHQ]0G3I5!O"(83"*9'\-B&VOW"] %F>/P=C'M#
MQUBG;5NTO#WY^".H\^T:R'P$R(]F@#$ZM'^_,,D8V%GQ]Q>OS),DS(U!$/_0
M-1/JNSX%+VU;QK@(7WW?]6B$?P0OWIVCEJ_Z%N'V$>,-Z-[R4]6*18U&5?O"
M>4' >(*%M,ZOXVH2,%/BW$RML'=W?C,W],L,K>A?[JHR3%ON+D6^,_35\@S]
M '+T+O@4K]>KR3S2KK"CJS1!TPAG;J\KV;L1C$5FTD?@\SBCQ*W8\M$QR_T_
M#'YH+H,^3=H5+_<;N^Z1=&;9MIW TC?&O$ ?V&JUV0/5_(Z'^_'W[O!&J]W*
MVK8/]R_M.N%W6^TR@]PT\'X*M'WCONJ:]9*M9>5FA4J;Y'2M7W$.>.$FCL0O
MFU=V+O>Z,=GCX\)N^-^H.+X[JWX"ZJ.[:PPC/F@VT!_Z'C;08TH9F".,?@C&
M,8".QG.*-+Y%V,.M4X*VHQJZ=*^KJ'?L+I@%[842AA*Q@=7(J6!\Y,B:T VQ
MQ';Z0PGCQ.& *9OW2;+7T]\_E76L#(Y@YWUT'N*+&@]C1#=].M[ZPA)$Z_BO
M=6<::D-4AT7N<DV-V-<-8GU7.RIV*U1QE.A0ARD1,@5;HB@E*47"">!N6N9E
M"/K1O701_-'E# ('X4Y[')#HID'!FRSVIJ;(O=J;CZ%.W:R;R/O?W@3)/#AY
M_?___N[CN]_>O?^[]VJ/>K,O@Q/0%A9!.>YF-[2L[MK7[.]Q,P\^K)MVS6P^
MJ/%SFN[-3IYVG7!^4<TI\.&3T9BTU<C#B\QI59WWR1IO36J >^CE**O6Q=\V
M7_<J>(F77<<7^_2;_LT(GZX#S'2'3A# RKN%NGK12_2?8^<^;/!KG,5?3&(+
ML+C#+]K*XA2$F2H)*TK@1Q$'MD###"S#-"D*'8:)H%N-HN RXU%)\E!Q0M.8
M$9;E@H0BS7,FBTQHM97$B5DA[PP(?S*C;#X8@6)R.UO8L?EI6L+5FM_&E5OA
M=7W-\EE&LUF<I@==P178G2$"OT8'>'""2'8.9V*@Y%H]'S[NZ!B$&,@K0@4/
M":4YP]*KC.09%R$5.>715LDICZ44D0Z)2')XL(@2PG0$_]2 ?SI328+#<IX
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M8.<@M;_5#GT[#$=?UNJ]?@U,YODB]A)0TK#9J<ROVF#@ZR@@[$WU>J47]>=
MXTBI^L+<C92 #:Z!(8-X#MX9]6%I9\-T$W:K=BQ9I@S["% U"L,(>'1.TKP
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M/YH(),ALK:5<N95B_A(?I4B]!R9<+>8W%*SW":B06NJ8:6(;S+UBP+,G-H0
MW%DY=5]YC@: /5&$U<TY0J[;G6N6P*?$0.4LB:*6";6RXI05(3E9!U1*!T(H
M#Y8% T[G(&*,7"=T@]&0$(6[+:?N*\_1H+"57DN;+5!=_%J1!"]NL' %BID7
M+$2F;NEIU=XYK@0H[B0(I5CYNHY0?E,V\UR<YPVB,+K!'5CWQVK^;5;SC\]&
MXSJHQX^&$9?U.\ND.,P>A]D_CXTY#S'$+,!K&^KF@PH*T4J0GHO(3*J)@Y4-
M"[E+LGP"BAD%(GI;CG:U*<\SHDN I<4V8R)#>]+L/B0Z\#'V"/8(]GNI7@CV
M5WE@RE3@*H#W)7@2-)$"]M)#"$QYF;TTJV ?DLHDLO(E4L%>JX+S5M0Y1,3[
M1$44>65WVL,.O1#H$>@1Z+NG7@CTET#O6$S:*04V5*^^CN1TUC#(TF7CN7%6
MK&Q150C 1>$(>)$8B()C8*.,0%7*VFJJ&-T@T*-7?V#6B&"/8(]@OY5&BFA5
MSC1#9D'.=Y0UB5.0WG,2@S6.QY5)S9(Q;;P%3DC=?)PD\-Q:,#Q2+FAT.FVP
MFPV]^CU)NF"S1?<)!ZD9J;E3ZH74?$7-6B7+A88L;&TT3P%,YJ8.\8["\L 3
M6VF\8,[DF%R 5&B]9F1([7'4("-WF:D@B-QF'":5Z4DED)_WU1P1[1'M$>VW
M@?;2".,,*:#M:GI%U;4T5J<U&19]2B);L[KJ)CC+BE%0=9%.T+K#@RRX3S0E
MI!!&\DQ@((9 CT"/0(] WQ&@MY10X;@"*8FL;GT!>IXTL.0,MR2Q*%> /E/O
MO&4&RH=JODKG+&? 2/19,RV8X>C6(]HCVB/:=T"]$.VO2F1#%-9% I(S4EQT
M5IM/N &9+#5*9N;URO830EAK G>@:=T]TV0/AI6C5:*RQ 4VI71DF[ =.-!W
MHJFEO<H&$BSM>3O=UO)I+F8_&L0OL/=WHZD;-+D_=,-VZPHWF:3IY"62^7Z0
M.3MA%47B:%8P<Y=T?EU+'R_$_]HUK]\NP:-A]ARS<\D8H%PE$#I&,+Q0==*,
M!))=SG9E-XPO2<\,9Q_]RQ9D?EQ@S.L68M85Q%G9(YIWC-MO*-4AL#LB/R(_
M(O\!(;_*,63I-1#E*8B8+-2::1"6.YV8)H;;YZ1J-HW\C/2D[MKJ'0(_ C\"
M/P)_EX&?*$N-I!*LJ(7/TGOP/CC@EA7X9HXYN3H#[ M2-QMW^;7H"6L1^1'Y
M$?D1^1'Y'U^=Q;75S$60LGCNPK#B\B?G0! 6D@E!N[2RZ=.7I''6C/S=S^$<
M(.C?E<6YNS/F-DU=:SIG7S,W.Z.<X^;AHI[UT[^\8"^>+:!N4$/W%0GEA :'
M!H<&USDYH<&A(J'!H<&AP>V;(AV!G)Y7,8EQ]TXJ)B^7MII!W_G^H"U2?E+!
M)&(J8BIB:A?EA :'BH0&AP:'!K=OBH1R0H-#@T.#VWV8CH,CM[=;U_^Z\=@-
MI[A-%U:R827;SL%X&Y5L+A%"280HDZC-*PF,8Q*R"M%'*9V(*S7,3YDJ^7T:
M]S^Z:?]C^M'UQ__C!K/T:[[ZX\\7*X#G:RIMYA([&;&L&<D R0#)X LVM1=&
MA[8-D1D"PLL(UB@-5%&==$J<K98U/V7HY+;)@!LD R0#) ,D R2#Q[>UUXT=
MLY5@0[ @M*/@$\F0153<6!V+_-8QF'*S9("M+\@%R 7(!<@%S^$"P2GQR7*@
MR4<0V5!PTN<2&$1C HE6"K..L95;#@QHU_:$/$ N6,[YE)_K2-*_ME*O)^@/
M9^Y"[+'_<>DAES,IXD1R_M4]Z13*RN]/?/1_S2;3?CY_JDU=W<]]UW^\+/]^
M.;>UF5P.;JV&->E/ILW9N.CMN%RA&>7F]Y.W)\W[4=&TX6DYN''#>.W7]VD8
MSGM-J)J8BRY.4STJIK/1I#^=E ]&IZ=IW-9?GKFS-*Y_&9^-QO6+?E1.5D]X
M6NPL],_*=Y9NY^L7WR<_;98FRWYSTGSG)BDV!3&F'U+S9G1:A'G>.ESZU:3I
MM\]77O2D&:?W;ERMH"EWT9S>]KR]Q@T&S8UK-&Z<FC!PDTEYFG(E5_[RT?4'
M]5@H5@Z3 @#M/;=?=.-Q^ZUIDPN2-!\KE#1^^1Z+,$,J/Y6O?!K-!K'QJ=Q<
M2 5G8C,[*]]JSUAD5K]]<7?G)PL][X*V-,M&UQK0',U^F94WVP^+,27:JI!M
M@""J4QY4 B>(JFLU5K)(Z]91-\';\.2L3@0*WDL0Q(?B_)>CG>,DY2QD-/0F
M>+\-'U*<#0IBOUZ\F!]'X[=N>0;Q;ZE<)Q0,;\W^7?W.NW+5[P:C\.\732HH
M?E:M?SR[N*,"$"F^GC[V,?Y)7SP51-3!8,B[HJYY-!B,/E4KFQO7V7CTL1_+
M":LNN]-1P80_4JWSF$R+M;U_7ZVRV/V5K?1:4YH-QZD\8_WJ>]<OUOOU8#29
MI,DWU2QNM=UJE^6S[XLAG?HT;CCM-8PPT9[NYE_YM6KOI[VW)Y/>'6]M>^_I
M%MZ\9KX+4KR#+ NG5IN?8V)U2MXGN/ FZMV7R[]H06'Q8'^T(OW\$OBK/$B?
M(?8+VM7SE9,/9J?#5[$_.1NX\Y?UTQ57Y4069Z4^R:)6H_QZ(<'%([4'0AK&
M5RW%U#./TZ!UW(J;\[G*K\KDTN/Y_$BWYD&1W_.2K]SR+ECFC] E]J#FFN[-
M=6VA61\NBW,NI-L?#OK#<F-3-YZ^=+/IZ-7U#\I[G_]YKHAMA8[+1?@OW>"3
M.Y^\>O'MI<K>YD>W"K:DHS=T[2DJM1T<^;(U@_FU'W)8GP4B2^#0.@3+V+&(
MYZ)@+K,,SJO"H((%,,0XH)**0JHY92G_R58H^%&'\>NP\P5/_>*NVWTL]2_"
MC M2FM_ =4RL[ZYU&0O2C687FCP7+"7DA'RUB,B*50[<V22]G*0S5YWBI5*S
MI=*UC_U)?QZ3OEP<<4=-VOPB0IP(;KY:UMZ+ESE7WV_O.9:>L"<>^,3#R(DR
M@ES]\]3SX.-V\''-B25BNT]XR(=M4WD>J*,U]Y;1/K[;=97D'EP-.R'T2VJ>
M%W]JUS471]_N%9HUT?7M'N%N%OE16@\V(%!U>P?"%XKNX2VH.B/<S39=KP3F
MFU;:Q^S5U!G9[[+[ 5&[6Z\+I;7VMC$$[:>!]NO%@NV?_?C;O[X93::(V@@#
MG946PL!F8.#WJVS,WVHV!D$ 0:"STD(0V#@(_-SF8A$%4*\/1+:HK:BM^X'"
MM3RU:>M34:%Q_0R]0/29NYCUZ(SH-@O&7_]4*WI'LXD;QLDWJ(\'-E'YUO=S
MQW2F+W@Y^S.4Z8V;?&C2?V;]CVY0_O*$&<F;4_$];[U;LW]\J^"ZT26VOUR/
M\D/#1</=0\5#^:'AHN'NH>(=B_Q0%U$7NR(_U$74Q0[(;S<CNI?$N[QOUC/&
M=#_H4"W/[N[^#EN/&QY1/CR_:,MN<GD]3ZT->-[DG./Q91\GP>>-A'EFDO5
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M0O(D0N9$%9"7#(Q*#CPEBD@G=%@=RKM-8L $$)HN)H"0+) L.D 6QC%.4G!
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M*'5A(\X#VR7];"+I1'N$(OWL?]II7X "R0O)JVLZN8W$%%<N.ZDA&!I!>)/
M)6I 9V\ISS)QNE)4O0YJV7!BJJYM285K6YW,3*VA0VI-B:AC"HPPA-R.D;,3
M5JT\CF8%[7;)PT]U$O]KUX1\NP2/AI))5H)P)<$I'T!03<$'ER"I0*)R0J;5
MX:S,F1R3"Y"LJO4EEH E7(.,A8R9"H)(VY6TDQ4]T[F5Q1LZ=PCDC,2 Q(#$
M<$#$D&,4BOD,E+($0M>IW<[FNC>/3]8RF?E*W],&B&'K6:C=CQY"KD"N0*Y
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M5US6R&O4V2K8DH[>T+6GJ-113EF]!@XMB2YCQZ+N(PKF,LO@O%(@! M@B'%
M)15.D)RRE/_D+^X:U?R0#KZXZ[J/);L]&!7+Q8F@3QV >L*HW>KL5'VBGWRS
M^(SXC/B,^(Q=>\8MS0Y=I?H'EP%."/V2E8#%G]K4VN+H@QOW@=)ZQB+=':MT
M7RBZAVNK.R/<S8XI7(G/-ZVTCZD%[HSL#V'B,Z(VHO:N4?N.Z?P(VD\#[9^7
MUVC_WJ[*(FPC#G166H@#F\&!2^NO.9F_S7,R" 0(!)V5UD.U%OLJN<V:^;O1
MU U0"]%FT6;19CLI2UPGP=>%TNH*Q&)\M*@RJN5H;2$B1D5H_IV5%IK_9LS_
MJCBY^;DM<$440!3HK+00!= )."B%1O-'\]^]^:,3@"BP/])"%$ GX* 4^KB4
M& %B7P$"W03,[Z"?@E[=7G0O=$9TF\7DKW\:-M,/H]G$#>/DRT=>[JM0.[C5
M\'-WU)H+\QE#R;_@Y>S/*/(W]=%S>?AIJJ,R8FI;^Y_J>3QOPF97!+Q+ZGK.
MT,:NR&][0UTWIG4'.,CUCIG@4B6OO0%*,@$A2 83D@<?*-?:1N<LN3G"B=JD
MD]4,0J .!+4.O"(,&,O6!<^BR.[+1CB]&2TF MT^S*DVF]3QJY3-:\W7M2^)
M6,.N6(=CMSN ."2)8U4V)(G](8FL7$XF<'#:J#HH2($A=5J0TYI8:@W/NGLD
M\3J$V>FL'0KW]+VL<O]SBO!'&H^JS1I&V2ND#*0,I RD#*2,^[9O,,[ES"QP
MS3T(PA-X8Q40:80-L;")L+NGC 55_#K^>31\G\;($<@1R!'[K&S($?O#$51R
M8V508$4(((*48$3F4.*+I+T+BIG0/8[ L (IHU/"0LI RC@:RLA&2J(%J&P9
M"!\%>.H-$!*"LR)KKO/F*>-VHL"D!%)!]XP2V0'9H1.*N(UDMI4Q)ATJ)Q1V
MH"2"H90"3U1Q(Y/@@NZ*'3!LV!^N>%J!VJ(<& O4UFGIOY^\/6G>CXH$AG6W
MW7;KIN5?WZ=A.%_:8JH[L(NAX-[)#YW-SG.\S4ER91+DD'V) &LM@K0<1,J&
M)6J4D^DFQ\O 2'0I +.Z?--G BX'#BP[)F)DCC&S%P5KQ9GI$4:1\P_!9)$?
M]DY^^ZML!\@/7S]G^\9G,!#G3'%-.!A&$@AG,EA)-'BOJ8V.)1-E]QAH+?'G
M"B%Q:Y",GK]8]-3&,F0E9"5DI4ZQTNV<X9-7*@@&49F"_R)%,-X6]@A<"$<S
MBW:E'&[[G+&><K@5DA"R1ZQ%GC@$BT5ZV#OY[:^R'2 ]["IHH2;+RD"%/6*A
M'98SF,0S!$U5S#)'SD7W"&@S08MAR$48LR I(2DA*=U#&9'1:+..H P+(*2,
MX'4.D).A7FE!7=H"96RTUHY*U:.,(!V@86*]'>K?(>C?040K1GG*%$W )*]3
M:9P%XYP'K90PA6""I'Y7U+.9F*0\%K+0!H,2G#G7G9*^-Z/QV6A<)\[YT3!B
MQ=X^N@MK'=J,#L43Q7F +L?M#H%,UBAC-3A-/0@;##CN S@1C?6))6E7' )A
M@M A61 EC 7!!*^C[00D2Z2S-$MEY%Y4_3'24[(3^;,U#PQ'N^^*L)"&4!V1
MACH0^7)*A.3*0Y!*@0@L@96>@-4ZRIBY<5YUC^@V5%S8B4;H?>(\S.4A^2'Y
M(?EM9E&69UO8A$$)N1B(+ O-2)&!F!PCM8P0P7=/31NJ8;0]2SO1=[5/=+07
M9M\582$+H3HB"W4@!/.4D""$@!!M(2Z6,MBD:5UZI,H2YJAGW>.Y#:4E-7(>
MAF!(?DA^2'X=",$842;J%$&G1*!68(+SB8,J5[3"*LKURL3<]5/31DLR.>E)
MW8E:F'UBG;VP[@[;+O(/:BCR3P>"+Q,M)50%4%+7/C7!P"E'0#K!$U>24AYW
MQ7 ;ZD9#LMMUB+7+>8_ML_:'L=SB_$*;K!:]$'05ZOQBRU>_$.7Q!'L8+N\6
M9=@)JS 31[."O)US6/9K\/.3)7N OLL=FUCZ7,ZG.# B%(B<%#BJ"=@HBI/
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MV[K!(%<G*?J<BHC3Y[/YZRA"N8MV%E]JVC=8XJ)Q*MK^OVG.$^/DPH=R@ML
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MPYB)(QRY$X0%XT4C%W=W<VB/PMEZ6ZA-#S.SRZX86LNAB%TB$,U$[^ T94D
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M2IQ@O8>.*MVB?8)#U050C@?H)%6)$6(0K;JVXQ"1C9JCI(2C*IAHPIHDDWL
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MS&Y^ZQR\)Z04NEV\%CIXN9(R5U]6-9N=.N_4^=W;M2M!O:*>(^](IO/E!)F
M!2*8TXA!+<O0"*QM[8YMTQ'O.MP]7%=VVL/X'AH8W"GE9?E&ZR<7$RJH81)%
MF_.0I!*U6<6$2M9Q0HAOY"%M[6D]GLF55:[JM9/;@6P'LG< 66>)IS0"R$IP
M5:3@"&"2(6\UU22%)&BCB<W6[LWC68>B)XX 9#F16EOA$):&P$0%@BP3 3&7
MC'!>,=_LG+*UY_)X)G<+D.TVF=KC@[SJ?^F'. R=0NP48DN"B"HHPZ*6B+@
MKHR)$H$.E0@GJZQ+B@C9R!+9FGEJWR&D^7K:9P!I,R%>MZG0X<&CQP,!WB]A
MAJ*@'4/<48\,V-N(2AFTP3[QV&B8:IW+Y/8.R: \>+_9,#-1@0LLL5-@J#_4
MIL)CQX.--$0K=N .)$0W-L4^GJ9^%8=.EBT[O"@B/-I9U72Y/UGJYUHW_;O,
M^"DJ-R"SYN0V>S"Z54._>=/64:K./NW#:>,,)<MGYAY_<,#YU WZ?G!13,8V
MGUO&2?5UC./"5P_3C^6,X">N1*3AJ,GE$__O_Z4I4<_+14?"4UL6+L;A92O
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MEFE*9$R*K*4U,ZR=4-0CYZ//+;%PK@LH$1=4TF!QD'+G@8A];+HPE)P0T;5
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M-[:I+"GN+.(-A&NOYGXY8BOFX?#9O?$W NW=)0/O/_Q^&?!>K- M1;I':1X
M[PY6%V)P=/-7B$'GB8'P1">E U*"*\2ED,CQG+(BC,)&\637,^$E$51P(A"C
M(I<\U00Y8C60"1D(BTI$[->(08Z-O@'(B>'5= R#_:U9Q&_-^XM+Z+FCJ5]+
M2Z$G%),3>8<*I$4/C\*A+Q;_/LK_]S;5ICL 6ZSYT<U?L>:=M^;.*QH]>.LQ
M&HDXE0)I#!Z\,BXZJ4CR=KT8^3;6?-LLU9F;W\!1_6;8DH"_CT=U<?&[J*K%
MQ3]6@_^/)HK6'0@N]O[HYJ_8^P[9^Q\.5"LJ,HN=4Q+80=Y,S:U$1CN.C J8
M6D5P(FN;J;=F%/=8./C'O5<-UD()DN@3]HT2S4\0$K:M?/ACB2@\-H+Q\VB<
M8C_G$XS&E;=#'P>%;QPEW]@R?:PPDGUEXQ7.<C_.8@F0%D\M\CKOU7)>(BVM
M0H)12CWW$9.UDF.'X"R+9(?9YP6D[I3&$,E.Z"Y:E^X5:;Z=*OETJ<YN8BDE
M&_(NV9"\T)BCIS&T1S.ZA-$T[[TL1.;>1.8.$_H(J<PU/8!-%-$;@:QW!$B#
M9<@%;I'22MC$#7-RK:65B$D*KQ6B*1='DI(@JY)#(@H=%=8R)MK)K,IU8G'"
M*3XA; <](/:L_9TC%_M>GSFBW7'7S#XYB(7[5C&)(]XM]]AG\W#[EA_[S);9
MW -2=Z%$U<[\K7V4=&EW>V;G#*3,?HIMI2B4*RQ5R?;'U>=<Z"QGJ:\6E!I-
M)_7$#K.XY?)-:WY=4ZOJ+YNB4G=XE ?@E2$&C)ER2&-A<]%-@QS%&#'"8XB$
M<\D[M.CVG[.W]:)]64UNSRMX58N*="L\\_</KW+9F7%SX47M.7R7TG.L]XUP
M5A=DN%=]'$WL !Y['/WHTQ NGXW4Y13#AWI25^,XL$U5LU$UO(Q(K,KTIOC$
ML<@QBS[(7 .6<I$7CUV6:*<1>$#2.*:LH&MRO(U_]/KL?#"ZB/%#6T-N<W;:
MP@EJ)+ANWM#R[R_AE;P=3?X9823SEW95<A?R*I?E%8F;:B7V1*?EM8+S!_FU
MY9)V_7JIW-ZH<KEBUD*(<ZF^_K!*T\ET# !\'G/Q.T!;<!VG Y#H$6! 91<
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M'L99_Y'+8#%@T&--3[HB78\A0:DXB,4J%*OPN*V"MR):RC'"UC+$%?5(&R[
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M;01,KX)C^Z/P3;F$*[@(%J^:C*KX];P_;K*7[RF,"PF:V>S%IAY'G+4<)(8
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MIC3$]K9PUL".9[=OSJOS)7K5B^Q##Z=P4K-R<7GY9CQ Q::#2=;R?/VX4 S
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M>Y5_&?=S]"CD/IV7;'ZXL<]=@J<#><JCG.6JKT6$UH*3LWC09CPVGBL:! $
MI@"PTDND@TJ(&^=4",HSM8;'6W6-F[JZ0=_)Z\^97U\7QJEF :T87DQN.[Y_
MD8>*_G0U:-*$?'2O^O#[3Q]>__^_OW[[L7K]#_BW.#&7D_1NWBV<-7WUQ"KB
M@-4%[\0WS8#!F1R =K5UH&T3, C]P;3Q+6<*V/XV/<\ <00>!&94JH UPL+E
MJK;1(:=-0([QZ'22S.JU*DF)&!F#,\@%!5X'2PYI&PFBA#&/M5!)Q#4MSU0U
MAE?1[<J!H +W<+==B#EM3]FF?;"?['C6;?125L!BY*A&-E6A%:HC$!K!DK22
M6J24!MKM4D F@=N)'<',1.%%6A,:['#@4A/$% M@&F)$%F0.^<2)5$Y)@M>H
M^OO1A1U,+EZWT:,=R0TY'KFI+X: .>!\ <=I9J+QZXY 0*(T&H,@(*$8H(KA
M&!FJ$\*2,.4!.@! K@J(B$$PX2W"E($5]Y0A8U/,T,*D")[R\ "HTK3I/ [I
MZ-*@<D0U#G-ME;I])3#G;M+KTA"KV])AL/&VKG.:Q*>(5ON[?K?2GOG/ABM]
M?8;8\S2(7X$*C&,C+[E9Z_1L^#STZ_.!O7B6?UU+INB)_K 9['R_(7R<$:/Y
MJ)L3$;@CS^><_EG3VQ?HQG(+T$6.[-=;YKS>.*M[ZU*S<V\1=4G$&%F1L<:U
M6DC6Z2*+=S:[_6%>>T#U!/S%ME/PZ@_PWMNO6T%L,GAM@LE_9@=?[$4]:_>Z
M+)&KF3U9P)9D](JL;2-2=W(0'BC?I[WW30[<O3)_=I$[L9R.<0</^[8>[./Q
MQC(_[I)2'RT)XTHDZ0-&UNC,N$&R+)8,>>#:# >K=4I729A17#L'GJ!HW,&0
M,-(1*)P+'-.8&,=ZK:S"[DG8\3!TX#V9Z%1?X'..2Z9ITSP7C@P-N,+?TW,X
M[N=7+Q:1.GM^/AY]SHE<J9K [$P:UC#LNQS: P;5UJB;C*H/\7PRZ\&+V\A$
MZSU.QG98SUYU<^-Z>IZ7RML,NIQX-K#3H3]=N\%)U<ANF\N6E[O'<-I*6MH=
MDL@*2RHL:3N61!^>)?W[7]TH7/SM?_S[7T\G9X.__5]02P,$%     @ N8EF
M6NU$[#RR^P$ H&L> !$   !N=79B+3(P,C0Q,C,Q+GAS9.R]>7?KN+4G^G]_
M"KSJ7N]6K6?7&2K#K;R;VTN>*L[UL?QLGTJGL]ZJ18N0Q!1%*B!I'^73-S8&
M$B3!&22H$W7?U+$D8&,&]OC;__$_O^Q\](I)Y(7!'[_Y\/W[;Q .5J'K!9L_
M?O/YZ7SQ='E[^\W__,__]A__U_DYNKJYO4?W^ TM5K'WBJ^\:.6'44(P^O;I
MTW?H?UT\WJ&GU1;O''05KI(=#F)TCK9QO/_#NW=O;V_?NVLOB$(_B6EST?>K
M</<.G9\+XI<$._ ]NG)BC/[P\?W'WYZ__^'\_>^>/_S^#^]__,,//W[__K>_
M^^W_\_[]']Z_5ZJ%^P/Q-ML8?;OZ#D$MVG808-_'!W3C!4ZP\AP?/<E6S]!M
ML/H>+7P?/4*U"#WB")-7['[/B7Z)W#]$?!"Q0S8XOG=V.-H[*_S';\10@N25
M=?7%"]D@:*N_^?#QAP_?(">.B?>2Q/@F)+LKO'82/_[C-TGPC\3QO;6'73J_
M/H:)R150?J8+$D1_H"V\M&B.%UZ%21"30UK^RPOQOX_PZOM-^/I._,@JR0IN
M3,[CPQY':158'%8M))MW].=W\#/4^0AKD#6%5^YYE+SHFQ(_YIJBWU46SA6D
MTY[KS=L/K"\?W[__\.Y_?;KCVTH6]KW@5WW?:?D?WL'/+TZ$T_%B3]\)^D.^
M$_1'-\Z7%51_^X[_J!;U:OI -WI,]U[:A]6A8B+H#_D9"Y+=1UT7/KY_A[_$
M.(B\%Q^?0S%,V+Z(SC_"P>75(Y+U?^U$+ZPR_3+71A3OB;XW\$NN:!*=;QQG
M7Z8I?LC/7VEAQ#)^^/''']^Q7[_YS_^&$#MDWFX?DACQLW87KMA8:F84/IW+
M:3V'K\X_?*1[\WM*[!L4E$YIS9J\&]8)N;]Z=2+=G'T[(7<BM/[;JG:U6[=5
MBU'=#2(_G,.'VK:U]T^_#J1[DOW5ONEL+_=K5UY1\F)KWW+N)NS6>.G,OL-^
M',&GVN;+1[W?F.6-"'^T'V]ZC_8<JWJ7\/&*;]J-.7<5M>Y"TYO'/D>M#K;N
MQ>QYV,1K ']T.&3R#3&PT;ML\B$S3JO^\&[E^*O$9\7./WROOT6CPC-8JJ5T
MP F",&8_P%?RR_W>"]8A_X9^!S?P'TCHXV>Z9 C^^/QXV\AMO8N=+V$0[@[O
MH,:[RY"RS0_.AC[P'GW9LX^R&=F0BRG3Z[$N?7@/_X^RQ IWS"HBJ/D?[XKE
M"Y22"+O+X#_9WWM"N=: #_6.?B$JBR(U%96YZU0OZU9E-?&EG%G3\PV2@^=2
MX<"]<'QXQI^V&,=R^BM^;5B-#[ :3W0:<;H<&2$D*"%&ZK0\=<N3R8)WF#(W
M$?#K;N+CY7JQV1"\H?/)?GAP#C#3T16.'<^//O+EZUV[87D_LL.6B:GGB-.'
M11=-H'"-TD;XST@V@[X5#5'!\K3\?4[G@T/H/&QQ[-&11?5GM5"V86E_:']R
MT;=YTM^=UK)N+=-)56<T_3):KI=[*7@N O<RW-$9VH)8^HKOPD@L\E B#:O_
MF]K5S]J!TYVUA)S 1;FV$#1VV@Z#ML-3'*Y^W8:^BTET_8_$BP\MMX"F8L.R
M_[;#LJO4_PUQ^J>5[K_2NO727>^#J33L@=^UVP-56^#T&/1^V)5%O'2B[8T?
MOFF>=&VIAC7]??LU!9J($3TM7#N&_/+P0O<_7B6$;O]'+_KUDQ-0<1,F]"FF
M+R/>'.@3_!/(H0'76.=9\L[U:Q;[QQ]_^YO?_K[(E.=:0- $RMHX0[*5,_9^
M9PV=-D#M!L#1BGA[*$FY+;)Q N^?K!Y=K(LD\@(<11EK)!:]6YV&A?Y=::$5
M^HPS4UI@:RO;4'BVTR+7+?(CCK+K]H'@5R],(O]P&T4)=E/K9\88\67N7*MA
MH7]?6FBE!5CHK W$&U$MLVDSIZ5N=Z$_>9O 6U/N)8@7*V9?\8+- WTN5QZ.
MBK=W?>&&A?WWTL(JY%!&#TF"IR5LMX2+%65&(]:5XH*I/S4LSX^EY5$JGY:B
MW5)\PF2#27$5Q+?U"_#;]Z4%X/5.<]]N[F\<C_SL^ F=;@<^LV> \AJ?'/(K
MCIT7'S]QKI!>+8M7Q_/AJW5((L<OL:F#:#6L\X?2.D-KB#6'U/88%Y.UB+(F
M4=KF.6WT_(FV>MHE+068T*<3%Q+)B=YY*QQ$>+$A6.5JNE1H6.^/91%%)<E6
M61!%&=73>K9;SXN0D/"-L@W%=<M^:%B?'TKKDU8]+4*[17@@(96Q8A#=03&V
MAQU<7 ]MF8:E^4UI:205=FI2.J=U:LLIK@@5F*Z_[.&VB3Z4V<7"[PWK4]:^
M+"XO'S]?7Z'K__5P??]T_71:F;J5N87&'?\A>:$2SW*]QB2]R/0_-:Q'64DB
MR"!.!TE"IV6I6Y8'XM%R^,%W5CB[RDK?-BQ&69$A**"4Q&D9ZO51/JCL'QQZ
MWS\3)XB<E:)>K/RU85G*:@A!"3%22*5U6I\N;CIZ]YNF]2CK'7B]T]RWF_M'
M[%*1@8ND!,31RS!XI2P2./8_$$SO>P)VM'#U:W%].M2L7\/?E547&6W$B:,%
M4LBCE#ZWJYX6N]Z67N44T<7G 1:JK'LX>3;T/WKW. :7GP=,GK8.*2F1BC\W
MK$U93T ),)\B1$D@1N.T,JT%G627L&=]&6\Q*?F$W0:4#M8)0.WJ-:QE6:>@
M4$:,=,%W[%N@_AWB]$_+W-)X!9<7Q#\QIS\ZDZQZ:56KBC4L8EG[P B=7P E
MI)(ZK5>[]?K-^P^_4N&G9*9*OV]8D;*^@=;\]K^^0WM:^;0(=8OP%X=0P4:J
MM]-/#1->5BC(FJ?9KE?LP#7^['R1RASYL6&^RSH#7A71NJ<9;RL013%)5G%"
M-%:!_(\-JZ%3%2C53PO2UN2VVWFQ-*%2*1"\/'"@<S"I*]JP6&4]@D),..LK
MY$Z+UY+%2EXB_(^$CO[Z56/5*?Y<OTB_+RL*,@*(43BMBP&_K5[^6RW]N'ZO
MT2'4^W&A;^5?)_]XHPZ8SZ!?Z^F&*>HVK'59)]'+&1-]RYL[K7^]GB_9[1QR
M6*YKSZFZZIUJ-*QU66<AJ+/HEZ8C?EK@C@JJU+=27<^Z @W+5]96*"1.Z]/+
MD5._-+G?&E:EK+'@M4\+,J%WIWX9#5!L6/RR]L2$I^=IZYAV^=3OC[;5&C9!
M6:73QOWSM,@&7!#UZUI3LF$IR_H@O3OB:?&&^256<42Z0@U+IHEJ*7@HGA:K
ME[./?HURO]4OS;^7=4$"3^>T((/<$/0KHR_4L$1E54_9)>&T7./X)E1>@ATJ
M-RQO6;O3Z*7@*UX*IY4WXJZ@7^C:L@WKJM'D5#@NG):PXQ)*\[=^T0J_-BQ3
M66,CZY^6I9N575V-XI<-BU!6T&06]],R##&]ZX^(KDC#$I75*(_73\^/GR^?
M:6?O?SJM4L=5Z@;,LG!=UFO'OPW6(=FQ;P6497%Q#5)NV!-EK4H/.!A@>-(^
M(*43&5;G:4\9,$=WV4+]"37LF,[P(Z?=,<WNR/!Y+\-@16>(GT[ZD6 Z_8#@
M1:7.1_R*@P3WV36]&FC8366]4O-N4E&"<SUA7["^<+PR$+)%=TY[;8!EM<N]
MT[9:_;[XL:S4REEA]1?*=Z=5'K#*V?$&UQ-_X?OA"AC"AX2LMH#S3;P5!@Q(
M+TK!OFM6OQ>YAEU1UJ.INR)_,[!64=HLDNTBUC"2+9^VS%1;)@?Q:GC_:&DW
M;":=UF[P9LIUY'0?]?07R=:>/N$/)%QA[-Z0<"=EC\MP]T)7A D?%3NI/Z&&
M;5-6"@I/E/R. =Y#-(C6M,5,;E+;/&V0GAM$^NO=)[L73)9K9D*)@#/=[>C=
M 6K:91)#9C%(F[@,Y.SSZO5[Q@SMAFU45EIFVRAS%^1=8(Z#K!.<Y85N<%4T
M4CJ"Z)?I)I/>4:?MU6=[=6%X6]1HV J5OFTGP=FJU]M-2,!/+'M#=*4%07<1
MIVTL@T?X&12S%P[E"Z[,P"(:[$[#AC3J;X=HOQ'SM\L_D$JU**LF^X^<6&V4
M[OET$(B-XG0&[)R!RS"*T]1,*4E*YG- L.-[_\3N3XX71*7M.<X9Z-^=AC-0
M5HR/< :@]V=*IBNE":":C0&Q012.3:5W:\2\6T_G8\3ST8%!,$:W8<>6%?/=
M=^Q)L3:OVY;IT[-K#!R3EH&.A(F]9ZX7#3NUK/0?X6[ERG_E^I30,)27J-C\
MIST^72Q)/1O[%R_>\C#S)$RB[!V$%32[V0UVIW;7_^Y]V:1A)(JEDJM6JKW1
M_J-L "ICP8=PVOMV[O?2+YD@Y\0L\](R2%L:]8[OU9.&'6\4H5][SR_72@%Z
M)!!C?97JLO-PZRN-G[:[Z=BO;"<)BSN5U\-- '=,Q;XU0;)A _9+&5"X4HGP
M("!IZZ?M8WS[=!&HAA%KV#)E\TZ[,,.3X#3]30,<#7%6\8*R,"G0$7QQYSDO
MGE\G&(W42L/F*AM]NMY'2^;RQ)I'O$-H(2"9V'=*GTY;KW<.E"ZW4;M*#1NC
M; )*R9ZNEE%CFRM6M:YHPUJ6K2<5T<WGIQ4TL8)=#FOG^@UKK<M-4;'6)U/N
M*#'NE8YDVE(-RUE6H9>BW$^'=DA.GMQJU99H6*FR"EE0*V;H.2U7OUP]N96J
M^K%^D3Z4-9ZES#VGY1F6PR>W3$V%&I:KK*ZKSNAS6K=^<!]=F)46-1I6M*S_
M$M @)W;$[+(J>G3IS,%^>' .3(2O7>&VE1L6NZRY2A=;56=FWB;L9R1;.2W]
MT*6_26+P!Z6]VR4[]J."G-UR![2BT; 1REHF[4;@32'1EM@-*M;W:4.,ED*L
MRS-@B&K#IBEKH#JF'CN]*>;"?$OYR#I%?G>KW; ORMHL7::ST^(;6_P"P%B&
M3)T:M968C^LO*S]Q>4S393;TY?HOV-ML*>N^H,?5V6 1PI)5K-@[TS;>L/7*
MRC4-:EH>73LS_*N!,;*C/!!+Z2K4D9U%HK<RTD8E<-K$)K'9.#"08F#;.L$&
M1[=!BUK5ZKYQVVO8JAK%80,"G$!'*OB#\YXA+VA;_[0SC6#'=7Y?NU%HV#T:
M$(PJG+G3.SON1LA>/.W/PI[0:6=T(UF_53YJ$O]4;Q7U9:PJ)9H_[9\Q]L^2
MP6@M5K'W2IGD ;M&3ZAAKU0D*6ZW5Q!O$LDV3QO$\ ;Y"1 J735J+;?6$?N]
MTGG2+/&&C516([?;2*R5<[<0V5;881$2G3GM,,,[C$%$>JM8:(<^TTX/NXI:
M$&S821T0=7,[*6M9[!UH^W0W#4X@W(7O;56G8?W+JFF1>/CA;G%_8FX'KJ^$
M/6Y>U58E&]:RK#%.89=/"VD:)SO37OQ_"?WLP62 CB*=VD>\<0@HJ^[P*_9_
MT 8%51SL4=IHV#S5";$+*A&U*[FME'8&L=Z@'RJ#BTZ;;O"F2Y<ZN@F)HAF5
M)5OOK+:$&K9/635<L7VR/1&Q^#!5JYNAQ)\VR-@;I WXGR&J#5NGK*H=M'5.
M@'^&MI(4,E+MO!+*<ND[4>2M/>S2K]G;LUP_;S/A]D\>)@Y9;:ODFG$::=AH
M9:VNNM$RV491^OM*],XJ[0[\(M\X6IYN-K2&O?G*GKJM[-9I[W7=>VF*"[$:
MZ><'$KYZ4;4HU+YB_1[YH:S.5;)F9+M$^3)MX;3<'9.;9+B..+X2KBOT:QY%
M5W!,[U*E88G+6ECM$@O$$MD*^U4$^)T6NN^YQK4+V(8G&4*J86.4M:K9QL M
M=\:)^S!S)0"R0+"B3Z_P8(%W'[OT8?73LH].C)]#^@-H*9W@$%VOUQ@4D/+'
MABO$9!,-.ZNL9:VZ<O*=DMR%Z)=:"UI'<<A^%KW[MPBE_<O*G+9@MRW8K*MK
M5[1A2Y05K[DM<5+7C<-1+M< M21Q0^CW%SB@G:U4F'2NW[#LM5G9<C=!HK2#
MZ/#0BVCIM D&96]+%U)$I.9^!/S/JJW0DTK#AFC* 9?;$PYO#!&U-;0*3VDS
MANZ*;O[_;2LVK'U9:5K(_W<"FC"&89-&T0B\&+IT..B:PZTOF89]4-: JE$_
MCH"329LZL0?F'#:2EPC_(Z&COW[MB%S1I6K#^FO<35/BB%'_E[\*X#_@!\,6
MP0]^+4VI0U90\Q'35Y+_J6Z,+R_$_SXDFW=>$+]SO=T[4>:=X_O?H"^,PI;@
M=5KA[>WM^[32Q_?O?\M(N/$Y_/W]E\C][TK-F';WC]]$WF[OXV_>&>H9_1L\
MR\/@G,Z=D_AQSWY6TAF[U^'.\8+AG<Z1&:?/K(GS'8;4+GT[K*,Q2F^WE"A9
M)2_X/)VDGGVNH32DY] PCG;.]S@AX1[^82V_HS?..AW%F^=B<AXX@*G59M)]
M0M*Z0/Q<?*"C^?#OYQ\^G'_\P,:DI]M[.)&Z$O0U^2'M1 1<.=QGYUZ,=^4!
M1.4EH+65Z_/\P_>\RWI*]5V6_>WY $)ZM-#WP!'4O7!\)UCAIRW&A2N&$GLY
MEQ185YOJC=KIGE'Z'YL&-93NJ(-^HF\T\YI1IS[],EJNE:S3@9N+2(*XO*:Q
M&R(_V69-N[9<7SK1]L8/WQK'V+;^1)MW0$*]MOMX<!/33H6AU'$=9\=HJQ--
MF.TT5:WG>"8=/:IE&9#(:=IE&=S1HUJ6[AE?IEV-OOT[JD7HEY9AVH48TL>)
M%J,6;[?M;+4@,M%PJI!'VXZDOOX<A9F19!G+0VZ'T]5WY%VHCSH!(WNYU,_/
M)(V/+ >^8O+@;!K9T%)!*[J4G"=8)R&UF8I=E4,9SVJPFJ&:I,6AZKK5;55-
MT9_H7KX\4$E8Y/X]/'K1KY^<@!XCZ.M33&BO-_#H_P3'*X =VOY.[DMYW('C
M:$6\/;_]EF3C!-X_63W:%2GM9_JOQL'VHC;J ,%1(=UK#P2_>F$2^8?;**)<
MSXT',^TY?G8.FX;8E]Y$V_?)VP3>FAZ<(*:<79@PD_D#/79@-&^_5UN1F8S#
MI;="Q.RF7=C:4J5)%7I=57''()&*K)0CRY2%5J:Z]IM2+W6XY]N2FFAH:=*>
M]D,H5;$HFP\3RNU*XQ]ZR^$?)I+&O'*RBV8IJJ;2J-TM9GQHZFE5^9$9#GV^
M@V;&HK[>I'J)KIJ&B3O9'GVZ_4"ZTQQ9+.LN8%J1'RMQ>MM/?47%Z>[L:L!5
MZ!=7!76[RSM1G$HVT )I=1A7 X&)AB$AG]KWNUACU([*>/JF[A7+3:-V;:TB
MG?Q&5^()NES:FFJ3B0R5CO!=A(5&(E/=#GE?[@ZW@K[B'!0>AA4?DRI NBJ:
MGH%U,:Z^RE,=E^-)P67KUJ#=,/O0FEZ=U6XL+:I.JMKJVFM=K2-0<W4=IKFV
MYJ+RZCH#'0E:U"EU'5DS#3OZI>X72$WU214,77NNJV5'K.W:\]KJ\Q)Q>VRG
M[F2M"KM=1]B&RD0#DO)BUR'HZTTC;;;K:T5Q&Y)GU\FMJ3Q1][N9W.N#>]N.
MVGR;<Q 6S<S-X";F,!6JGWM F;B8"/^X2X+I",!YA;E<4WF_AZOQ:$U/+\&9
MV3,="4X_3,61U*-=6_A^N(++[B$AJRVXTA+*ZH-_EQ?U<%8UU-#,IT4/[#?V
M'-6U.JG6P,Q):4]KCAH&(U-@NL4Y3E1!/5(?#?<7+]YRQ7D2)E$6?P4"R%01
M2>8[.A<E4#8D\>8^IHALG:?68&-SF1XS9]I(,W.9DAP'1]FW5<R!885]"[Y0
M ,['W$0]VI_:)\_,_NE$SJ+>U<QH^U*>WI6N=5Q2<]U)'>M:]KNAFA4WNY9=
M;UE]4IVXF=/1GM;LG/7,3(#9]J945^><]PRIHWK1M6-9R8SV*<NLH(]<?UGY
MB<OA6RXS"*GE^B_8VVSI65[0178V6&"89!4[SYF5;LW!$F0B)[T9XY'!GEBU
M-QD\Q+UH6QU\Q[3EPV:C5V,SFIZ*K-PF)Z6VB7E,1=?\TX:FIU^S\YBR-@F5
M#4U3^Z8F=@4W<\UVH3:)"_F0876A,;$'@]FTL5W](,9HW=H$MDZ!VG^6.C8Q
MVZD89G\SV][4DV0VC67G.1NC^8FFL$,VQK;3TIGDQ(!,M9D(6WIR=2$V]4KV
MR;_7>6W[-S+-:@]A+3H1L71.FW-<]3VN;2G;<%_LD->IEX=C9_HV)L&4%KDC
M2?M1AZ9LT8,:L!.M:$C/UIUHO^$6\U+\R(<7,'!*]\YYP2TRLD Z"+4:)+7X
M\?S#Q_,/OV/CTE$;H[O/8>SX9OM<)CE*QP&.S7#'2R3K.^Y#T3OZER@-353V
M_@?> RB84O=BJ)"2R;>*O\0X<+&K) I*&PY7N:+@0QB'FB0D:?:/M1.]L)XD
MT?G&<?;LC+[#?AS);]BQ8K,AOOA%\=5XQ0N0!CC>7<'M-P6J8./XXS>=J[^S
M-< T4)9./KZE?T850]$4--+I"*^^WX2O[U8'E_>7_I%UDW[XI00[>!$ZQ%VN
MKSS*Q5#BT?*5_@ZVJF>Z7RY\!>!$C*$O%6NK<H5?XLQ8]R?LNW&X$_C3X"[[
M!O"*5&KG+N5@ZVM:OB$4K4T#MWM'S!K)[=T[.#;"'([=#Y7'KJF>M2%19IR
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M*%5IS%[[ZKDX</N@9C>0F4C=?!G2":]0S)9_MPD3H684N6L&B- 7MZ=J<$@
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M2AE[,"V0P!W?<3B\U!FJ%B^ZIL8<(OG*0%#LQSP69:47?0]"QZ?"*>-RC@I
M4&['YLV-'<K1@;D.OV(_9(IRP577/M!M:EIV,TFMQ+7/D;ZL:>4'E[><#7TY
MP!)_!ZPE]TW7:CUJBD\:)/H(6UJ[#XJ_F@9'X@!CU?Q8OH!I*:F%H/U,$OQY
MKQ68VM>>&*WNQ@N>XEU\34A(*(=-,!-J*G1%+2I9.^ -SD$51[VIEL7@-BIA
M^OP9<?^>\-"[FR1@,^WXS/\<@E<HK\_4 JM#6XV)"<I3\;5W%8;=MK6L@WTQ
M+R7(&4E;\=/#WVJ=.I$X/JCU+"-Y<[9E(_3MA=_$M ..[Q\6[!7 [I(\4MF
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M/&%I);/17'-\_[5JY(#JPE8S[6 .(5CG7EXJ9JW#MP%/WB:3N('W@>HR73&
MQFHV!T29T#0#QATT N)(M6&NKH:]C:1CN0L_'E^<D Z%&78,O&4 T5;,#3)!
M@_. @0,M '_9,7FM0X!OJF4_3\UR7>5[VSYW6B.%>43],6@[UM?*+ J5SFT=
MR5CG[%*'3X5':V#KM%6L#41R"XIB^ZXA-T9M%=,03D*"Z^9%V*FJ143#-\KQ
M +PJH!N0,*!_<E>WB+.1_+]-.HO.9":UJ8NT59?TSR5Y#M^*8F]=29O\:K)+
MF$ZQZLZMU;:TKV\9W:[A[2D4LN\QS4*%+CH$<%U8G^<6(<$\^C)%UJI7C70D
M-57.@,3U* TI)6@.>;'$L8(KM4<G,=".=07M34ARO'6#,K94W*+BE:>J!)=!
MJ;B_JLZ@4UG<,#_SB&,2<I^QQ7Y/W^74HK+B -S>/\4W^4"/JP0_AUK-3NJO
MH(O1G:;-.0J+34QLJZIV50F-T>ECQ(TWN:'0:1/RJ-:*H2]C74R[I-.UP5$[
MAKJADCVNM.#OG)GIE5N+?@*KLQ<L Q:EM]@!,N<_0454Z7IA@+"MU_QYZQ%N
M]T^3A=*#?.O2O>>MQ4V7HH.U?;J[$[7(&>>#I!I88VWAN;G9M,9 5X*D.;Y&
M4?\^!NS'J'V:M9A"O^2^U+7@37THV72*2;VJ\V$*3'AG+J"EY8Y:N,L,HCH#
M5,:0Z_6BBF B#OA,N4/(Y=P#K[$S>=.!A\G+W^DNC<-]&+$6Z6[$W!!2APG2
MIIJ]VY1>-SA:Y'GX>A?%FAKVO)JX(W .P[IC:K>&ND?[WF4 U2FBU$BOF*ZE
M,7S+ \<7OH27H8M_^V,=<&UU\9DX-Q=>=G@%0"M?C1G8FXP]I&UI.,Z>N"98
MZMHJ]F2I3$7Z'"Y<#IX*SI$>9=A$+C3)N<$7A!S E6D'*P&:$Q?C'4A,^;NS
M2KX:I[%)[3@\"NW&#YWJ@$BUS-RR5K$M>(_?V"^5V*NMZLYR: ;R<=70L>S:
M74R,UJ3<:ZIE,;8U-?E+\.GZV[.F@MUMR&\E,&I<.KZO2^Q6M_E:U#:-/\/N
MIA:H,[IR-@W1\ A$6?1<D]U97]RJYR>]9C3;.' ;$QNWK#QQ_BN V=0\@;F?
M)^J24-0>/GQ\>?;B$K*QMHA=>(*@Z)R_B"6_4X<QVZZN<5O=*MP$GC2-,=VI
MO!C2H*#/^S"XI&PM[83&O-B?SFB@C_QZK306Z@O:UT@]09HUO#G07?!3^ JB
M(.UD%1\PC-8<G$7+F<K:NXG6U)T4-*TO8MH8N6G:I#6,5E0F8RS(#?VNN*?J
MRQK/;\*#1O6N3MHB1ZS5XE)&JFEZ#ID\'%.6,/)6=<_")$U;-UZG<6"IV80]
M>VN.=I>ZM398L]M2F6=$5I]8+(OX?QJ BY\<+X#83@YM1^\^9OIZWCK!,][M
M0^*0P^UN[WBDS@70 .&CO2=8-KCTI/Y$JF'BQFC)Z&L4Q7O"IPS^4CQLZ*=?
M/BV*/C7B6^.0!CYM(.1J?K"6>"N6#61#,$X-DB\:,V?7VJ. ALKX8/<V*/JQ
M:2UWC97LZ]3Y]?P).Z C=Y?012KAT@--]ZD7?0["%W!/@\-_&^R3.&]2OSBP
MZLSIN3:^?+3F; 8?Z<.#ZNZ(ADJC0K2G0I^0#/]9TM2VK&01>B*(0E_F>6GE
M55=;Q=ZCE-!=#H" \?6K4-[4GI[J\J8!1T/R*WBF\DOJ+G0"+=*,KICI=X)=
MF;=!>G%4*S&RK7D;2*1>[>,QD.2L0%15!D*UGL# ^.N8!=GVQE =T(CA[? )
MDPTFZ3M?+:#J"XX,*]\.JJ)%+=-,2[JFN<0:C[1Q, 2SQ;T)22$)1^UV,4?7
M\%A9&YF9&\(J=%W7%9M3&&RC#WY]G9FB;'-HH21,*(='%,!LZ9+WX>,G6F(;
M+0F$Q-2DZ#3:B#U&AN<>$\_.DCR"[TW.)S?],1*_1E5P#/UH61LZ"^-98Y*A
M5X+N8'WC@3K< S481,AP68YV(]+_5,LM&6UB7GNDRO30LI)5AM=S/8<<., "
M8R9JD#6JRUN,FX_!$$@EN%?/Q>[%X7,$W.$MRWN< YQJL)GT(#3[X)^&(7<F
M8YHW8.E!P5>L5FBL+VL:7E?>.=6 GL4BL](LU^?ZG278LO#BY>E=REBIJ2H;
MIIO^GUN= ;(/)<LH7+0+[:'4:ZN,P;A+AY$KO =NK=))ITT-:Q,-;*?4&]"Y
M$Y[_D8S! FM7XL,5#_N&LF8A$?8_YTL:FU*Q($9(ST"!T2Y.JY.ZH@=)B]$R
M*U![PZM7&1V3E9BI_TO%8S^(E+45D:(1!.(SV>@^C'&C/J=K;8L;SJ?D-C_1
M^X)0/B)P%^[."QC8!QR9>CMWR\HC(,-JO.X"5\=3:/6\G0A,"F2@YN\-7)@]
M-V7R4E^J>@5<;S+V3(UTS\3XCNX8*N;$3K"!&$;.TE;#$3=4,J_0#8D$@:X'
M'ZE-'=J1B/ET 2+SQG*=2\FA-Z57%38]M_0)6&&G9MYR!2QJ,/>4Q_*D:X%
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MJ^KG<,0&[9D< ,, 5SST$L_[*F'VL^>W8G[EOE1FP+8.U(*VRU)NI)'109\
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M<(K=-&Y&@A&R-P^_O%);/JP^%MT"$6*EB!1G*, Q?.G)TH#IQ1TY,NA>]"U
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MC!$1@R?3#5YTHL2Z#U=[2M)(P\1/)I&8'9X_GY$)-]?H.12NP9^<U=8+,#E
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M3#D,FG!'4#J.GA?>VR,<0<D4(;L_KOIS&Y(8(@[^$I)?(6"%(XP.2TU%2?+
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M=O!YAED-;"E-\;W@.0'8VB8!BF2H+<)LU8R2#4-#8C;=[!M87*ME4L1DD93
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M$,TW]$M4EM%\6;-S0J@$NLL\9?_,>5TU,"(D<["_QNSL3Q79T),KV9"EA7-
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MLLV*I> F+^QCO^,"U."2,]8A/@8B!L&9JT2O#_]QR'-,1<M:W)@#KEZMRFP
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MW*H?41PQY84J=NP*B-4O%-'0@0!HI3()"D'YW\70!4^&6^JW""+@>3U1T86
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M$CE,KRQUO9UH.YE1S<4FH:GWIPX/ ]&\^BVIEI=U6>4K6B"1#=O\Y2*[P57
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M7$W\=\:5E7=6S>Y-7FA2I9@6U^5Z[?(\["KO0S(R@VJ)J2+7C_?W(][+?L#
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M>J]SD)X.?]"XK?Y<$GPDP,N<&HX\-Y$_A4#>5D#;16WIE[8::.^EI5VB2;>
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MCT6??_S\:;A8VKWF)>%:B.Q;*.NNF2)!HN^7_<\KYF:Q Z<I8&M)045KX96
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M]5LI2*&*DQ[KIY+^=\U47;^ /N?J?"6/<(%!66XZ0V/MM@U(?I-=52_@N1%
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M<3K>T(<PT]P>Z6>QZ KK#+2_.T6B.B<0D/<]CA-SMGDQ>^N5QL5UR&P7"57
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M'ZV*QQH-RM[H<B$0@S';8QBUFIF)>7>P2>V3AJVJBDJ!]+$.IIPQ*(03I]B
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MXK?W;^(7FQ0 !4HUT]9+"JLJJM5EU7N?#$QC2G@4".=7&VLS5%N;5$%7P:!
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M8<TW6XM!A7L0;H@J]%+EV)4#HT"UN@9ON]4$X]M3[2\-B[?>'#@0'S:N]DC
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M(K7VY[S)$6*MMZ=GSF[Q#0@KC]F2:K(@1XBX/PF?A"HX/"C=',*4N2\-4>K
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M(2@V7AY:[1*D\@]*2[S/L-%,6-P* C,AZJ5L,XK:!K,0!\,H"B:E%69Q;5U
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M;^N]%[FO#GU]/P0[^EF/\\R?PCYJKV$6CQ"OHO)<Q?6C9"ZY=&:TA7BU#:6
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MP1.)Z.,J)6]D$^X"K]+@-%:H"VKQD)=U#S_)#9 SZ\S55KZ%)UX3W*(#@.W
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MO:/!Q6UA([Z".6<-__A0(.,90"BVWG>:6T9R%6/@?O;2KY :\>LN-6OX$J<
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M8&\3: ?.1]A5H300OAR9%H>$VO<%N)WG3$;2__)?/WQ%8F(5E+DTJ+,1SBU
M/S@9+.\00QR\@#Q,,3F<@>;$3&56,!<M!CMX.0+<*RQ\*]!>T3E6Y4.K."Z\
MJ/W'#%ZK^E+"?_H@IH:,%:SL)%I6AZ30@I5J83LX\XC[T>:Z2NANU@5^%B"Z
MIN3I? 33R[!?O!0;B#.27)&79>M=!=@Z?4'M(1EY2_3QQM@O<4O,9 '6#+O
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MX[C1H-P.BL0=1]%4?$NT,%T'.O]A&V^2N+..XV,:.T"T@X .9/YD"W%=T)K
MG7<)S[N_/4$\957H_R7,OG[V8N^]?'X3@I6#=^1W_I1\@!3=+*#DQ4+XO?]\
M3S[^Y)^"LAL'_,>Y"0?\X5?9;5'Z0URTE)+N(^I!)3U^.'X=4T#>)%X:K'=W
MD.'X</%L#;>5X>>3(7W?P$]^%0%18!6C "(K-\QS -;I:_'FUS]!QGI,X@RE
M+"&7P7C0QZYO*6D/&/(%Y/VD]KW2BX"MY"G(X&D@/T>6(0TE@'\)=Z=2<<&#
MX3^W\-L>E/(RI*#F0Q:A":6_OZ,S#1XB[WTD"GJ+F *OV@\\D-)LAJC7S1I4
M?])*RKCTAI!6,@7H2X)LN?,FI6"C3S9_;MM]F 8;#QJH]_$[_-V(^TQ>PCQH
MFZ0,76;KM+E76?LJR7,ND15- 7X^AH9!0&%2B9;0QT;'6?H(PBZ_J/WG/I8O
M"2]K#@4Y2$,OBDXKG  (@G7Z KP,VK=OT>DI_ JBTS;ICWH![R&RI^)<_$(H
M^(YY.D$YNFD>9AW>?#F=B"_K*IU((D;5QRS2#\\'JX+'7/8!\Q>)QQE?P!$U
M_$FPBJM>Z@Z7=ZYUJ J'&G*-7N"M<K1+U86N*RK2+K, YX1,68^0 !U>Y&V9
M)VX5.*!D$-_WWSC:0T77[5?N$IH3?I4Q!)&#NB+$J1+HK0.8)_:,\4K-=#E!
M^PA=#)/A'YT3IJ:F08IWUM&B8EW$)^ORG1/ZIJ'($;YE1^OVS-.H9M9I"H=3
ML4X5+G!':Y+TTZZ$RWQ..'2#=C4C?X(:DPG->1D/OJ.9[^9%&<'Q[V(&+FY9
M\]9O/(S]YIF2;-LQ#^"1NR&O4-N$\G!N3N<A5<L*7.@]\,_T'L=3L+"Q5P%?
M_3T("F2*<J'(:&"0LG?5KV\!BNX/QR@Y ? *TH_0!Q2((KP-7'A\+I@J>Q'A
M!M.T2*?^[YE#X>BS+PD ;@WJ":@@Z-D[@/H%IG&7<<RGS#UO#5)<EQA7IY]]
M[HBM_BO6E-'&MG]&:>MAK=ZFNV,6$AWWJ5^A;/>*2%&%APY)TFYC5]4<G3!G
M%^>'HQ=6_N8Q_M@O8;ZO6/-M$@>E8D>\H**SK#J\-N&U<8Q:3Y44FV7%H?S=
MZ(.\X"-6(:M-D.<V2E53Z##/RNNKDNQEO^)<BH]ZO;W3!$"=XNMH?L54^%6N
M-<\=WQ=H&IW.4C3=T6K\"3W>2M0K^2\?78IC1Q!7:8+V8*Y13JW&H/A+L:I]
M)IVG]KH'Y&@^BEG9+6)JS!VQ%PH183O'T625Z0GT$G/*T?P+LUQ V@QS,=)R
M!S(_#8^EXKQ.W[VXZGH);_=-D4'\95G5Z@4QPZ"\O5[4ZG=V!W(OC,S%9>IM
MMGKG\B(NS"D6^ 4(^X/\N/636,A$<!EC !/V=X=>@-JU?K%Z3P&^XS^(GR5K
M$9N 97BU::.MVG[9'(OMK.;/4^Q<_0S2=Y V)T[WIY('S@_!+->^&QX\$0Y/
MENRBC-1FNU) 09)%D"SCM1D](\QN.?'*09P^.]LL 9&93V/;4=BLU7@0\@UR
MY#2/&GI8<P0?+)>?2H3(>O+L,I9>P_<89]]#\[)\C"*,WS=)%/JHAZ@&VXBB
MXKP6AX.7GI(=<T/5MVFVT"4K*5;9I'9!,GW&KF),V;M-8A^@)O_8T8"R1$\W
M(/;W$("O#*N .\TB@.I],957[K2Y 60^S^8V\K*L>>]KG>(7/%@T1QUO%PCL
M8V',L(?$D%==CKI:,\R!461Y<@#I8'/,7$/>+-/$A7V^(C35'FB0E- ;\GA'
M*S;:AP/-):?2WJBZ.7%R/D5FV@<6]WJ+S)PG6)K$8I;F+=#@3V>PX _GKO>?
M0/*>>L<]U!DC MFQQTZ[Y=*WUMX$$??LL>YMV;S>Y(P#O'I*DN[X[@XP*;..
M10[2AAWP!!=QM+EH7<T0VGH 0V;1Q]NC@'(%+VN&/6!<HD=?S&@HMW)3O$6A
M7[^R3+^<Q'%J.TXBCTAZJKI.EC^T.D^6O_CU]KFWN]8?K.+!#L50T?M4V0OX
M '&!'BIB\COR6&-;?P'EPY[W7AJ'\3O$J5\<"OQ^\1W8A7[8?V9&8J(QH!X*
MN*<<O5>$7LGZCO[%+I!C3%#-+M+P ^)H4[\8+< XV#,,L)#_W5!8"/R#N9+"
MZA7I%^ #B+"W"#!/G#K<& "4ET\)[W%10))80#%1/R0IRI_;%*F_]S+ IVGV
M! ,D_>650M+P#XJ1-=11X/!LGT2HJ@7]Q7LGAD&$YJG?:P9IJ?PF_UA9PU67
M6M;OU:+T393)"5DDH\22/MJHTE![&=O)FEN(M<SS\U:^ T&%X,U430B0L4#9
MB/Z##+4/N(,8OV!-?CF=0!I2"]CG#(.\=%=$3^&.EITI,M.T[[L;)GDNT 6
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M3#J"LFGGDU ;+X;:ED=7%KH#K$*H0^\I6919V?+5G.-2K*)9T5D&C8S*62F
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M752,COW2R2]AOK]-XCR,BZ3HR5#$X7*X6+:472QE%_:5753RF$:]FZ1Z" E
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MX#G:]P(^0%P U#WN/487S7A$+\R\ZJ%&N/EF@]RP'6^:N=@<>6?, !QKBEI
MLC1O 0%_.@, ?_AUDR9!X>?KM+QTI+?DJ,-,;/3,'P Y/L0>Z]Z6+WY<A^(P
MK%A&17ET3R%QG+&[5FWC <H.E$6(]!'<;J3(\@3J9O??_:@(H.1 />/@_P7T
M5U/&K*3X"%Y !I5P?P_/_ Z]4IX<$>^NCI][,!*SW?7H"LJ*CMN6R8[=]5;P
MN#7" 8?K. (\J=7NQ="[T<J?H2D+291&Y26S=YM!%_>L"^A;/7+HD8S-:! )
MT(S@BJ,$IZ,>-KF;(B.%9VDKKH(@+(%XC'=)>L #35N)KSDTUM'V>'8A8: Q
M[;39"\OVZPU2KE/VS/TOQR3^'$8 WO,8;+P3_/(I[R-3:NIBG]IGGUIH84QE
M$.)JB(V7YB?L0X2"#;$O5NHH>X[B(WB,X^2#EO)'&F$,E3=%!EEHEJW\WXJP
MKC>!_X1R@HE._CS%*%W%>TB7#(QV!]A&FXQ$;M8,V\ 8?\7,OQ=-(EGZJ=!&
M+UZP:<&N-%=FKF5WC&+&\_R5SG.:OQFD"I*XOO]^1 BAGC]KCKDL9-]/"FB:
M0%T4A/@)I&= S1DGCC5]-S<@Q;94[(/U6Q26IOHK_-]L%X)@_0'2;7B 9)KO
MD^!+AJ)RF9^&1T:3.@4+&TR('_*6I]!["R-H3 _L#@H")!>Q$]@QL"G/%2=\
MK'R,C,38&*/-H=@[AGE9'EUO#^6/T)D$8X)BY#8&,V1(6 DN#6<R;NF#54NN
M LFF]>[\0:(,&XY2;I >*PC7N^<D?@&[(@X0S_YRW*7P8-#KJ!4.R!:I^'3E
M.T?B!02C=BTVU9QBE<3O6Y >-@54!;P,H$2W,,=YL <D6VFZ%F^:XB-8?P-!
MSQ]%OE;D@<Y&0>F^T+:'O^]\=#S(P09:SM=I-2JN.NAK;Q#'.H1(N6,:Q/3=
MCXX#+^RC;!#0<Q9:#;]0M8J 5[$;^&62BR/X8+V^K!(A;F2)"*=*D .2#B='
M"-T0CG>W30P"_,31) @YY7%)#V$47/3\SHZ"/4Y_.+N\;09; 4/D,@_'R[Q$
M^0 SAF S#A32 %.C<+PZ38P.* $8QXO,I&3A11$<Q_MRBB%*-JKC^.O""I"B
M!P=_MP4'W.B2#NC_80OT(L$I'0CXR18$\.)?6C1(NUS2I#B;%K"ML2#EPWI:
M\&&-)BT7+-2""^NT27Y\40L>K-$L6='+69:4G-L/U!*PU #@V/H7M4Z$>X0L
MM296UYK,*"5J*4*YJB*4)<'#VE"NM>;TDMEA2?QE5ID=%L1L[5(B;Y(T3;ZA
MF**5]<<%U&^#,$9Q@&:G7/V0/<F<KDC:%U-OI$\P!\0^2?,<6I&HI>#J Z3>
M.U@7>99[,8Y,LS)5Q>::*W=)4_1*5?V<TS.\"^??M )0[#;SLJNH;BB5>/'9
M D3R^L:+OZYW_X1;^'V?%(P64V(S)]6D7Q#BB%ON_W72;7WVOH>'XD#=6/?O
M=C$<1H4E?;RY)XS@VNM=ZTXQMD\>>UWL1%-1K\@UI9CCY[_9R3G,ET$3K]VS
M=V#7^_-F*98K9_WC6[*%TB"#,AL1Y/8;I,,37:H(S9L7ZG7UBL3J$W+@-]_,
M[E+O6WR7?.OOE#]>N]IQNX<(^@Q0J '^!JD2,JH'=?:T<A[:8$PYW_G[I#<.
M_G+LI3M/-5B>?8Y4-F2*K +*C:./UT''R!OBET_$U$3)H5WZ#+M8VV,,S2^0
MY2_PMS+,K3-OTBN(KCY",4FU./]-.164D5(,/P2??.Z],<;K1EM-_G%3?\H!
M4X?K$E>_).E7B* J(8<IJ7I#K>!/R',$_U.^$"7 G[KCW8V&"+G>.I$1AG_+
M9I^P2)1$'AEB?C+'\3+2QCWWQQ7T5CF*)HHA6D<1>FXDFX$4CYMPG=Q<EC&7
M CBF[ZJ3YB][BQS!#:M<5!=RW"@=Y0>E!RZUFFET^(DC,-):R8L Z<B!CM0A
MAKZF1C:*>=RL1HH0F^1&*;@"HXU$1_#!8HTJ$:+W]DR9_BZL@0OX2AW'A7JM
MF^ZL=115/,V[Z]BU&4C%FG=/[-H,^>0RM>53M[G$6HN_@N&1=QP72K@E(R1@
M,WHTF>T4X\WUFGPU'L]NC,7U6GUAG/2"-:Z7WLNIF\. D>M5]M)W@1Z%<KW8
M?J3ET0][N5YU?Y%*\=0-HKF8*;])$RA,H0(0!_>_%2$N@#"='U_O:1-!NZV]
ML<'!] *6 A/-92XT9:O473*SYD6G&P.0NJ]/:9))GU@YR3Y@;DY(363DZXK,
MM \LM#5F=J#(3(,EP(=C ?739E/,Y&/::),ODA2' K<%NP/'%/AA5:9TC$!5
M!;\Z0/D;_HY_3ST*"KS*EC>&H(<BA<(02BNXG8?P._H7.[^<,<&^NT=_68(Y
MQ5QF%O RL$^BX/%P3)./T@?!?CB),</95")Q+:5C7 NK 5;'?/B:]3CT\)0(
MJY$B%!B4T"R$$-.6W#9C1]QI)ZDH"V&IC5R;L73)Q1KJ<-UF!Q0=R?%@R3@^
MHT[EFBOZV-3$TLAL#AU,+[BTM6:T 25L(F$JBNXXRQ[1VEZT*=ZBT%_O=B -
MX_<+?634!YWIGZ(YOR0F*JZ%8'V4Y,L2G&3.1><AK>,U3_RO=:_-U[T'.=MC
MEA4@>(Q;<56:FTYF"2L ]0[PGZ)/+PM,- ;4XV;--$+/?S=9O9:%0>BEIQ8B
MV:T+*.,5W^1SFYRZC>87>$V)G(8VU!A2"8\JX"NW24.?YDUGSU&,W%;S=FC3
M8+[W"T[6(#[HR!CMG*M$7J:UWA;CRA9'[;AQ2!DGHQQ%D;R<:J.H)0BLAE\T
MCYPM,FC$0<.7S2CA^HCDU,Y>4A,-CXY:\!<P5ZJX=]1.O8RE<A0(1_/_+B /
MEL+BCMD.CP^. YO(\X&"K!:*<D?Y"M-8Y\Y1K(!2OD<UT9GC)^V3L0USQ*P?
MXR#\"(/"BRCMN,CCS&X55:#@Q[Y0%O8^/&Z3^SA'Z8.TIMFR*\P;/ LZF,W1
M2]*_VTR7"66PN3R?R,NR"K/,$R ,-)F<=$ABO*,5+R^I/]!@JYCS*X5,3!,&
MJI9>J]OD,?X &7[4)7MZNJ6WK:*.O6*7G[K70-JWB@4"=;P5Y-PNCKHYM?_"
M@$EB 2N E+RS=@E;FV,OM+9@1T@,24KG3-T!-J 9F[<;D&(<\5':'6X# +<0
MHR$TI[$"6;^*!G<H12DBB[CI=Q>U3!NSGVTFVNPWY#>>81J2=:&?M(WC"$YH
MC6IT(&4^C6U&Q1YHYI7CR* ;7KT4PX&EXSC@=)WJS#:I]HG5L"_1IY$HX5E#
MG1M!N#<VHT L "?B3R8^+C=$F<W($*,'>=.R6TT\Y"^.X(35[$LU4IS7*J0U
M\JO*][@@P'#N4-"UP&T.ZJOEL@Q-WF8D:+XL/>^&S8D-FH3NM DO4V5Y7$@6
M0CXCFS,^]!"+C+QV)P.$!I6>3!#.UP84VGV(6G"N8K<UY[O4#!&A>3;XB*T)
MW%,.X"$I()674HI<0T\=ML0#KS>1X$8TD>#&.+',(/[-41_6<K%)@366&BKW
M \4J >TDY$K!1YVI6(Y5C[Z47R[Y#S?(+#'1BIR*%OK*AXXRD<.064%U4@)(
M/R 6LP< B%IGY^^*O]WM$TEZZXXZ3/6+DU5Z/R2N-]3H,43M'#A4R9WC9DJ
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M6'CI@&IO!]31QUNY[UMO9Y55=:K)B/H=>U%VC1T!Y]2[8[J>:JQB]#&7I7P
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MDXYY/4>44(B#:<0['C>5)PV&.\"=P.6Y4*H^SW.VWO\MX,\A5$[##] *9[Z
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M=\4$^02\#&#+'+6T!<<D"_/G)/9[LN-'RZ$3XRXM9KK.]R"%W.:8@CTR4S]
MV>$7I3E!PEWOMMYW9Z ?PVE)H]P#EP39N0$MHNV&U3I(U5RFNTG!T0N#*K %
MSQZ3-=GFM!U8,19<]_KY)<SWMT66PRN;-D?L&LATC?<!.5H@[7Z X#'.O?@]
MA *U'-X6JW^V'$#.364>)N&^V@XN][Y^]M*O4,&'9UF)7(+I;3N08O>4PH1=
M Y9^0UN<ED"I?W$"+L+YG1^@!EE^UN77L0CIV@ZUL!L%M6EG>,=LAY-!M9UK
M^8)@6.^^9*5H:>#[JQQ\TZ3*=8'J9<E5?S2\N1Y1$?=8CS%8JDLS#P8%NH.!
M!IMA]T,-Q"T/AAFL9Q4SR0;%JYQI-@#$W[L5VV3?1L) <]0M%JP@D[S07'.,
MD1*3('-(\F!S_>N9<0<B",PI!GO \:,*1' $)AJ5"=18 54\T&8HSET?.OH[
M.R*/,7Y+>\Y[YB7MCC6GSI!\\F1]AC!2\:GSO.E#&N#,,$D1<JYR&JU(K6(,
M7 &?,1% _CR#PDO -TR18?R9QI_%83N *>Q?8*K)2C:FRY<($F>2G:?$O56B
MLXV!QW2&$4%BS;"-Z[$AX4PR!PS9(4N&@3A6L3(@[44=:@>R2YA4%V@^4YIB
M0!EOR648N$8%[D)_SC"#NI<C/74*];EM"=YO=N[LO'I_3\$[U-/P'^KG0ZK&
M)3_:D&+]!"!. 87Y-!LNR V_6'._Q %$"S)IH)G[W8=#Z]>)'<F;O 0SE%EC
MLYHF\O%) MSW_(E.MQ- .KW*0TM=RQ(N3'.?\$9;QWE?<\A;$6&UJUB:7V;K
M704)_"OV3+7,9&0@V\" S^;Z _Q]Z3PK4,U2L_,;L$O2RJR'UCS([K]#-1YR
MDC#VTA.N"T3:%E+NDPA^X;U6;YB<Z?Q=9S@RA#+I;K_7 :H-:(V$<B#63-T!
M%.3MXR$!IY%H'$$2P>G5=YL-JJRK_07_AM8O;I-7Q'X)TC9Y <<D1:15JLS^
M"2Y4T=<-B,$N)*+FCU;BIKGE%0"TYP'H/?&=(8-/*;P%FS39A41^]P(ABPM0
M7Y.^^P-*YZ@(T+,K4)S#_PO:^<FV@T[DY0R6?R8&5^AX8N'($#".E".,$I'5
MD/9<$L!VDHB@K*0S<^LAE!1TJ!'$V87U)4Z!%X6_@^"3%\8==<]V6F8*,>S'
M6_F_%6&*?/10 " SBRS2G(&8(\O0,T[KW:<D"<[=#4#VFD2!.\0L*+,ZF'#D
M]*1X+X(-$BS>_0-HR>0?G3E!EF[Y"K"PY;S1YDQ%B=31/GAABM/#SG;&>E<E
MI62D%'T[SUE2[/3DL".%"$+$+$K%M@,K1<6D>%BM0C16$W:K;/=>O 4':#TC
MC?MPA.2/O6_.Y/5+X06#W)[1IX*_25[L:1S $UA2/2>RSB^:]Z,/U1>:#[TU
MTMBVN13>VSQ]O$$")OAS*80W'&D.\R3SM(_MSAB3B;\\@3],_*7.,-MG_E)'
M+Q%<%2N;YUQ]38?&MYIQ!M/KF0YJXO;9<XR!0K#L>QMOCS"(\1'><LHYR*]D
M7+80':%,&4.:85C'$^5FM-'&ML]W7!+AX$Y3G'\H['3L[%9JJD$5@.YAI&@
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M(GA1+L*/V#<L%H]U0X5V,RB+Y!>U856OCI4['KL&G9$ULF"W?*#M/CGPWQ'
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M,,Z+F(+BS',O@*)9Q @4;5XY%HC6&M:9&HW?MFGS_ +\)/:AM>25[8W@[A\
M%!)>U(Q%3PMO$_@']-:5%Y^R\NUA>%+5'RVP1)I4^'IKG=VCMPG#N$#]JLLC
M3&)R:0MQ=A=%J[S"SVONY04DOU-GL/66RG280@A"O1R>X#6-6A$#Z\V7RU"$
M6840)=5/%VY>[LKG)$'JNQ2OUT]"SPGB>(6/F]DU;\=9;N!,>,.(SQ#>?T?O
M8,()50BU3U:VFD(37;OS*W[CK"%'\"%#1_"7MY 1A7F&^5"#F;_97L2KF52V
M:0&^'!MT_'V6A"(GK[(0_1/]L<]6_C%+[,A<H]N]%[_# ?>QYZ-6D#V-\*>K
M1U"9;]&\CMK2!!=MN2:>NZIC+QQ4]N)#-9 EI%&4?$.-I,]HL[(<31Y7_7IF
M\04L U+25)2 7FYEJ]%"MPM'XX.ZI&(OTF5FW="C=-%Z5A\RV7(;?<#$Y:Q&
M@*1M-I[TI;YCX#Y07DV7GV_U<0],J-$'VE_)P)'5=L^X ZMFFV*]! OE L8[
M7,UJ,J29(*.ID;*@U4@8FAFCP1\L937@4C;$Q20A\A7A"%CU5_0_;U"8E;_^
M__X$,?#?WO$8QKL$_:KZ11PG.5X!_P[]"D2X$\U_A$$3J\,& FJX\ K2C] '
M98<:J"3"B[Q+T@/:'[0I GS!/P/TRM ?_B/V#O $1TXNCS_(TS^B?V7_'20'
M+XP?H5&YA3__X3^RXBW+0ZBOPSF?TJ0X_L\?$#F$_UW9G?C?1_S6_;9<JBCM
M'+BO,,+]$_[G#WF*TB4\N%(*;V3U\Y_HB-AX\.8"K^P1M<K/L;OP &IXV6-*
ML,K='9(8Y!XT-\8#%<;H19Z<!=/.B["VB.>^>1'"]O_\P<=2D07K8PS/PXLV
MQ5L4^N>TROIYX2WXGM]$^)&,$F[Q\?VCS>L_:3[=$A,,D"OZS%!!40U6]W>*
MCT]\U_+GQW@PI(2,,: -9E:^(V/Z:-";*I!EU IL^:[-78%(:X,_5KTEU'ZC
MJ36^.<Z+U[$/-_A-]O(U]O;[!^0^8LWIRTVRA6\%X(U-]NTF=N06PS4&1$8Z
M=-]?CU#*)FE7^/9^::50W7Y+MONDR+PX@.2W_0;_>%K'H!2@4'6"/T/QB7IF
M=&&3GV<E^*_%V[^AAK!--I .D4?F_$!:EU\+#%3*FX3OJ*@24:L"58H3U%@!
MVEY&U"#H@SM YFB,X1-$&OU[')8Y7YL4\M(<U/*B*9]!#U7>0I4(@82MR)H)
MC9GK$%L2>!%NJ(Y0!MHG>E_ !X@+T#K%30*)]_]U=ZV_C>-&_$_J[5Z+HD51
MP'EU V3MP/'U<!\5B;:%M45#LI/U_?6=(2F^1$F4'\FH7S8+<4B9(CG/WPR/
M\M^&CAQ-3E9%_NUELMN5'-0%EQDWGY-DM@TSNWZ@W."WR2[?2[5@SBJ6E"DJ
M27>P;!LN*C5AS3S-L"XUVFB4JQ,@\;438'!'*A^EG\5=XHI:^9DN,1(])AF<
M5=?ER1T?HZL;O9ECF!U)T?EU>ZCV?,O*^O) +?5:*<A(^5Z^H!07T+53T6+<
M/PT1&$5*5OR9Z\=K)4TK*8LUFQ1KX%U[*]:A5=O!_<@L?C__,\P=#!-QZ>)2
MWC)<@1S,]7L]0=!%:T]^A?+@L]?=\8\9EES/JK69'DL2S'/--_!S*VDJ*PMK
M@0,Z;K(.JA-LL&S_SS6TE^GA55AR5_/1MS*8B1JCGQ492G+&IN$D<[:K?_E$
MG*"AK&CP "/B2</ %/++#.OCRZB=#&E_]OD&0P/Q6_@0'0KL+>>':G.4?FY]
M,W'U4A-5_JDX8P!ZAZ78,^"Y>UA#!F<=Q@@[>G4*<NV(&MB-BJT2X1T7N"]>
M+/@DDP'79/.<Y-ECH8Q5LPWZ*<GP@]YY"WEF!/,<W^/(ND:;/;<=B(3//M<(
M TBQ[_.A3-=8E*[,4RVOVUK'LT(-7XI;?:C5Y>*3C>8HJJQAOGS)5T6^S%.L
M"9ZFH$FB>BP\@N8^3%<Y.Z$G887MCE5IF>^4"UPX_Y64-8O>3O'A,B<BY@$[
M9H6N&;E#IPP$J5T&WA(S?82CV<TBG+R_28H?*JC\C6U 5"S*0U7O32?RW$<Z
M'L9EHG J;@&LEY<+'G!?6;(UO@M!$W((_VE$^4[M34ZY?$F*AQ*UX2KE7M0]
MT$(R'"(V'T($L]3"NPO6NA*DK\=*D[P>97H4RQ)0E9(5D[]&3_HB8]FK7,_P
ML_?[](!+6$<EA?W\BG>3UAX?D3"@@A@3,]_ZPYS<G>#)UU. 7WPHT9& >(3'
MYWME&!KO?10IO1FZ$=H_68:Q]^_Y!JQ!D$)RE8Y["T,424Y&GD6$LWA9\G>$
M;!J 3:41-O#097;1Y"0YX /GB!ZZ*P^K2;;-BQP["MAU,,P=34YRLGA;W&PI
M.,\[>C"*%;H\4?)6'M2HGY#>T3W9L2DN1CW;/:I&&=%!G[-]R1/A\83M"WJ7
MS-+ ,E8U<"&I@4EVC!GK<H5TU07(KBI)&Y_T^N\9T4<W^\L*9C_P<EX=JO^"
MV& 2@-S<CCWDE,]C*UK!/5+F+($9+,^7RY8N.2*][Z6"B+[ <1Z2%"O!(RJ3
M'EN1'#4!-3>K$\D-+H7;1')!T*GRL.'O>/<*_%?'W"?(@^5-L:U!T=/ZTO/"
MW<,[M\@)]-7GRF7XK)901_WZ"0.A/M'RV7,4/\*"0/5[GH;TH,<A6VXF,-97
M&&X8)!RIRM B]H:&_D\>:$2?[8ECUF&Y%0:JY9EH/J?B9>^?DZYGT .SZJ<C
M![%R,_+JB?A/+\J4+I'AHGY@!^*QB\*7+&2 CA+:D!Z%K:6*@^G,?<>ZBZ$D
MPS5ZHSE3]OX'+W_<@K1PM;]  TW=CV-/KKQ21?:4I[ Z;+(JF71E^/I>-#VY
M ,S ZP4Z,A':.XU'-"C)_0P2^VAY2%KC</'TY!;>Z#'2&&MQX#F-9%A0_THV
M!(9_9CL(R*W5@]0]:EQ2+<]]T[J3B"2C]?<91GXZ+*]H<GIF5[NSS5W%?CJ2
M"_F2K&#O?6/)9K].$8P!'+%@9>7']+NI2$[MB2>%EN2B!,_M&C;:=X;G#)X@
M",>=YI >)*>L>$<#.-A\/A[1?@F_=XN,/'O $<E5R^\UV=^Q5&SC7[]\_>7K
M+Q.\8L:8+5I9'-"#G&4Z>V>9!T4PP(661C*KV0\XW"15-4$$(?[GQHJ.>4*I
MEXXD&ZM/*/SP^Y^I*!+GA  %5K0FPC3R%GW"TNS#L;0KO(">!O-<\I2QK'HH
M^3884150A_MJIT-60WJ0.30118)D#9D]WZD:,J6&HOIQD2C2*T1&+L'ZZDSJ
M&X\7^(])'GUYC.I#F3T6/D["A=AU$M([BC4:4F:5FERJ%[[13M]N&GM.>;%G
M*_;IONLPV-&S:KN1D0UB>DL'NF*59^JZ@+ AWTE"\K2=<C_F$$^BVW,\-D=
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MBW/V#7,-CFF!]1[596"KNS)Y+^[X>]'8QT&:\<QUP>'TM3";<!N5N?7B$9Z
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M>!1%XZY5ADSBF>,9S/'6,\<F,4>OBUFLDLO(1):(8P7[%*Y7PB=M/).:![X
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MF\4B;WRY[?/)MB9P/9X)GL@$;\'NSJ.(L&VC),V-MZP].[Q8=N NE3.5<DL
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M$W<3,G&!(ZQET;SX1L,S;W=]AN$F'0][E'F+:>F-98A&GP>>&S:,&\"8N!C
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MI[Z^=3)[:Y0(_8*2VOU4UV*JOD[&U\DT=:Z^3L;7R31DI3R,O#=H'S!HN7P
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M6^)[C)4$44ZVX4P& 9SW*=Z4"$+X-C Z.W0<VG-Y?WO>NH__\>)A'M/ P/I
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MMM%&T_=#%!:S9Z.YD)X\&\S>JZ:@+#Y=IXPW7WLPC&JH9&$X/OQR:Q39]Q-
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M9#N0$PG>I89#A9'V[:"Z.(^0A*&$7;B:*I'2[,$J#3OG2OTY3B@>:EC]"@[
M0W7_"X\H2$71]T7B8!^Q*2,3/TPHL=UH8=!$L&&F?!5WE:OJ \S1L)PAQ=+9
M4,/+H?*/1E,^B"@VW+":9#:IR-O&18.T#(X3+4=QD<TSV+$%_!^VBGP6E .R
M$B5WL70,>N/=@84\H'U -R$2S$!1M0/AM]BCEGS>XBQ.DVA&M8J711NX-N.S
MC"58C<Y[:*C6,%5F)C.LS<H,:&FJ7LF:T,&#P R*"J :M3B^/F-]ZS-Z:Y2
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MY;E[D[C[!!W4S>5L1A7&_'$,$J-CG#WJJS$Y]KO[>R4[+*F"#L7B;P13TK8
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M5@VP_G\92IFMF1*RV2:%Q\!);/HH<JR^SU,T:%)QC/@C3Z34PM"9*JK81+@
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MML&WOALOLG:&NUUP$.B_O;"#(@O#1YSZ&#B+ )<]0#,KV_O@W@''*1P. K)
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M/]O!FHX_B X0<%;PO'9(BD1H*,%?$FV9)2';Z9=&CNP[G$V[]'I3>N$18G3
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M33V(ID8,:L2@3K6M$8,:,:@3>5.1N/C3=T3/"A%L)(()FE$KW1M;SNQ@.,=
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M(M+D&S ZAP;FPKG37]M0WC4%JUW82/)*A1=2FF7;2?F0SJ(FLSC73J3<K,'
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MS>-=/%-N1T#9Z*5TSN006^*6 CL:L+W&8-,#>90=];[.A"MHF 2G^X>6F+Z
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MW@QS3CC@,A;4XK_N6%D4)*,??8.#&=+L[YVA9?J0T$M=W,J]GEX VST\R+O
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M&#FBU.RV'(  0!&WEY2IJ&R*OT:@G%!YLS9W&;E!$(]"?/#/G&O ]'I34"V
M-GW91D8F2/UE!6/B>").TH0M\8FKKI::!P/K@V$UWF7"8]F 3;RUJ2I;AY (
M;>;(@+D"[(C&$?NZ1OB$A7(_V2F4JFG, $>F/=*W[SB9B##Z(8S^<> P>J\L
M,BB]%&^\B2'I7V^$96!J$B5B@(Z[D2A?R'XZ>?3D\7T1,CW_SJLX8#?GNM8M
M_-U0&4^&,\)+OP:5UUZHHKH>+7_;M9@J.53%UE"5:B08K;"$;0$6"&8_X3=H
M7=RVMF&F3]0)/*62R_V]U 6>/7C$][ET+Q%+POWYU/OSW/0S>-8UFHR*YS!&
M)@,W;[5%"OB8IEOC,&9G3%R<78 E=$%%#0<'RRZ\^.UI,GO&#,VFT!278E#D
MG.R+!NQ_[@AY"@4ILPLE^6CR23%1#GZF1 *F<AI"95"!S3R?#]/O^\HXF?3Z
M^;Q7NDF_9 -:9,!0&K0&$D"?V-FO@2EN)'W$%H?3PEP)5ESY%9.N*G#W-#*@
M!,K&'C:3S-ZX3+0I/)L"C(HSKX^YN=/\0*X-'#LGNRJQ#G[%+.)7-W!A,V5O
M:RKQ3W]]^##9G*Q/DMF+K(%?EQ16X-N*J_3H&WAAT1<8ISLKL>2NJI7WR[G\
MK1?RM3WCO2G@4V.<]Q/CO-D-\H%W+M@UAG? ZY.'&#!XFN4XLQF#G5@'Z_5E
MK>"SR2I;Z@*^H[@' R&_+5N];/%2J;QQU9ZZ:6PY"3_K%9SF1:MR?D,]AHK#
MP!%_6./)URM-%YRD&VHW])0M.VW8=_PIPH,&:T'</-A6*-]EI%AL;=>1 _1
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M56==WA7RIHW !UL""*#CEN$9XO:Y; CXAJ&_Z:1]5=L6[)-26H_N97S/(20
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M$MIV= TM>V4(I"HQ&]S5B.F=X,T3TL63"JZC(!*TE;LN5)DMB2F(,OU\ ['
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MA0<I\&*\Z^R#,I"U/<-R(5PD@"^V7!V+T?[.-C>5;W/RCKZ,7(\2# ;C6B&
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MS*[,Z=KC:#.P+Q8Q>E)?10W PD@C1\_#?)Y3I\.ZZGTOX.NNKP*938G()N!
MIOP!5(.][G=\$_C<%R?)NZK 'E"KR?5[A8NN@P,<6/U\:F$1M%D6>,%J03J\
M"@$6[+='X );)@)$!H8S9U8#ZV2O@7LO[B6?,2W#)6D2XU7BJK*S-73OP;R
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M/1Z_ 4@B]8@TR?2^[EOE01]:HWD)A_=0/04]$Q9E5>B\'R,+&!@1"$AI.8+
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M?]^HFC"6DNP8";'M1M:&\D6<O#Y1)OR2PNU\@6)D1>0UV\*;DK]U&7RZK5!
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M./2RW#WOO#GH'P_1O8*\.!<4):$M[&>>865@CB!?UG@]."_5&^^MF UR!^_
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M.(55A AP/:JL G4F >GQ4R D'U1+H6@D]&_T>H.T^+HE<GR*[3,&$EG"%4)
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M39\.H!%\?[5 HS%EYR=CV/_PH?:[G):WC&2.@9D*^J_HZ=)@P['Z[ PI9:W
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MPVSRBHJP*<&P)"1J,?,6V&S['EQ=KM\$O\-DR[ S+R(5F^Z;P!7<>MUTU"[
MAW3C3MC3L.DMF18'/P=7R4 OX:/+LJG,2<WNS,F[-/D=?_5_XSEL? Y[%/@Y
M["T*T-3Y+BQCX3(CI51OC Y5UU0E$]^18D-*:4+TFYIZCH7(KK&$7/]D71)W
MO%0Q2Y(([SML-@ZH CV9"IGJ>Q?)KJ4_E_0X0MR=VXK@7P8V/S=Z](8IV<</
M)<.1NOAU8UHHK=BLK.KB#=[>IWP7NY0F/ $B+&RR<A^'OG)OB8;Q]E?OVU/$
M]#YZ'!3Y/SH S%^@>B6 B9;(C*JR8VUC6,#";\30-_G#@Z*-$1-:4R"Y&:7H
M@X0X_,:$1R6B(>C00I(3 @2^A"5>P*<D=V& *?0>?PQMV15EKLU52<@T^K'@
MR2[PF6"J.L0#G\[<"6GJV-UAJUI,<F>(:C!44LN=CQ?'X_/<X,I>0ZYH%P?F
M-J-&(;Q,E)P=;_C?!+[A__,-EQ@4_XJ'M?'8?1OXV-F43IBTQ:=>D?7HVY"Z
M\VC=2@ZK&%1Y(<3!J%[;TJ9LU2*G,X@)"XN& +6VB)F2B!Z<D;AZX0H25#,2
M8V5_ #]KV </O)L )>G<,'T[(W)[S5V6.ZFQ;?N=)K'<<\MH]L9F[[O S1[L
M6'U;YH+?/1W+5YZ0Y?LNI.Y,]Y*"UT>)79;=6/-V=@K9&M$2X148W&8)WMXH
M[(8]?E+9!</W?5C#1R:[U7VNJ0$LFH5R,H+?1XY$-.2["<*>]8C)E&-*X0(Z
M$K<Q>T%WD;5J^G$.'_>8IUSN[A.)8DB=$]'U)XRN_^&$X)-W" H;FWH238WH
M^HBN#[6M$5T?T?6!C%1$U]]^1VS4IFG!!QDV4F/>EWDEU'U=U^2E%.@;0A$W
MGX@1)TN!@?&J8YS0C*)RENS>U!)+1HQEK"X7CNY&9UX&7"-"S;\V_NBK4M61
M-FT2N_H^^-A51HIKI#(7DA_Z(/#8AA.;^CXH3(4@**H=1OHZ"?5E1 "!#)$R
MU)9K\JIF&APD'+",!8;.YB.Q%*Q!B,=6(MBPH"R##F40%Q7=8-3+O-CTG1@E
M1NA11U*%<OUDI<!0=DJ!L5HY?&8+@P^HY/1LD6.3AYY^?#2L.?C1D\:-GU[5
MG9D#/ _A[EG=:\P&A][\63T?EXW;TGA;"ET0]S4<)G#)_I;!X:(-+)<2=,^Y
M1N&'H(R"LQU]M'TXC!9TZ(PZ9*1B;#)O'"NJJJ D,>R%[\H>'OKROY/7569
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M*%WY2)=9UBAS(FD]SDWXJZDN=66-UY'0(.$W\TGGYU"7-4PN^TB2B!2I29X
MFN95Z/)EQ9#Z8YDM2Y;8:S7F Q?QOQ?8V30ZR0N<B_XLYL(L9P*YLX>NXKH,
MC\3?97;G.Y^OD+*1.#[Q]ANDS?6EI(4 F)URBPWFG^M"BC=$73:N/Z?'>1;*
ME&)=94B*IU<L,H=MADVRDMM9TO3##\17)CYB>E_%I,'X_TLDKU,%U;%Y+\!*
ML]#MO]?X,#2 LD._TN,0#UGC0U;HE.DS% -AG;0^\F4ND8(WSRJ9*=T OH'S
MAC\^>/CM0^?_'GU^M/&=K23.%O=>'*V3@4@)V(E42=N/*T4,6V SK"^T#+J0
M:V9KIEQ&RZN)/\X'.$2T$ACM'/+:IK6<[+ID=*^1'Q,=(S)DR/M#\A5,]NO$
M%M C=70G="$O1UYI-R**3+FU5)7@V:XVU*CF.Y>$!-_///_V^4X^XNUB ?U,
M ?T_?&SLK%:!]0^P"EDHPN',"[/<GNR1KU7./+\B[VJ]X6INF>DZE(>>34D1
M/:R61$T6.A$,G9PU\=1\R7RWCNAMM;/*Q4R>G3GETJ-)YJTM@WSEAR+G;%6^
M1S<&(6VTG3";M)R):"6$M+M$H-,) YU"AB5\39"8V-2OL:D1Z!2!3J&V-0*=
M(M ID)&*0*?/ '1"/0:4S<!,P!Y_9NR?6CD=[8IT#Y)WUV8Q/!B#58<<>6&7
M2C0B""$A 0+VP3KTF=:BS=",A.+.K$>^*E6%^B*J=</G^D(,YTL"HFB'-06<
MX=DH=;%PL@9: N@:YUQD[SX/SZE'G6,D2HP01W3S1VY^OKAWZA7%/T(C0O+*
M.=.!,[49>AN;P+4L4B0" 2*CH!<:ZQ29N,05*23W.U[94GMK*H==63!;>3RC
M)_83!54L)"4]6.5<4Z[NNF2>)PWF1 MU+)/$R$J%]HN#G2(I9B.?9+*\R%%9
M\VV@\4:<+@=K@C%P'52%+L'.E[PQ?# @F I5+>43$0YBP6C4\8&!S%H'6'K8
M,$G'?(9X) 7"N$;2IBN\O4+KCJ%@SC__]K>__4L4C;J.++()EE99_AX[?Y+C
MM5$JS-S]W<H;8RH7FW8X%-8]Y4A8^#/%= 6.M$[!?TP/I]*[O#:S&3;NSS0;
M< P[-[D_.R)/I3;S.JB#9.@I?FF2\JWM!<Z.IZ/<-R7#\:2P\Q+Q8-?NV\2
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MNFQ95D3>$%/$XQ1QOKCG(QU]9*&3=S4NR<F< F21!+4^@NZP$$%NF+H,NM/
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M%^760)>:,;]8BO9$2.,T?&.>"LPPB'H\H1GS0*I>N,E0#A,F:54RVR Z=!P
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MK**Z8VA^QX(>LG QDX.$D=J@\DMI%:9/1X'9PH!6$5:Z[FD]=R@: FLL,S4
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M(0II$TJP;,#XNG#DI,.LF%K!(^@=UFN3H5?3@8#4 S2XI(^HO\N,X)D#<R1
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MPHG$QDF!L/]/ZDJL6,45ZF3>$)M >BTI5L\ML>B/0T_FX[*^5%WO?<@L9AS
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MY\^DE "GD%NAT)NA$SXX8VV3Y1<2'NC Y8%IQU[R)?Q<>V+)L(5>NT^YY6X
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M!4-)E!HP871*;T*!@6/RO*D02,7Q6HP58F!YU;3]A1ZU J$&I1M'C,HR<^Q
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MU9#2>B4K_0W?]:JHG&(!8=)1V*;."N$@YUH18@M7,*[L18]EU0W;0KG.+8/
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M12[;DXQD$C@4TE[757?%.TZPCQAV^%RPD6:W+ZH#_BZ%#5*7Y@"GPN=;(C3
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MM"_,AG(Y<9TL@:S6QB8_5#R.$AL)\7+O#>7XI-18M\T0\#?-K=W3J]P*9\6
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M]FG.L(HB[T4/[K@@)4$EL!8Q3MZ5%B05WVSJ?(UUW^OJQGP_EZ/TT%'IZK.
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M0+^7W,?<+QPD9B-K&L5Q3#V?&N.%V3BZ; \V-KE-5D!!O'0XJY6PTB43&W^
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MCXZN@X8=/@0WTR##!08&5EA1899/&IXLEC#/PS]X=UH')BDL*"^13RE2R%L
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M/]A$")%R#K<O:-,ZQ:+->M0CR1 #IU ($0#JZQ-K;)M:XR.U)'!EDQ50+O;
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M#]9$EXW" 5'D6)@)L>H2<].ZKT9\@.< 7T[ES-;&:&T+^8Y5)E^"N"H"2JE
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M(U9P=RF=Q2):I?_+KV).]P"Z,!/@(A5SV$ZZGJ->EJ$IMRQ<:AUGCV OQ"7
MJJ1(IZ8YKJ*R4:&PR/,DF$=@->TA&^-6D@0I,,O7W3Q2/R[(5RT26MCC9:Z6
MSQ][K6/O>\>/O?,\>)DF58R@YPGN5BD*4M1=4DQ$CF<:^<;O5_EM)I*%JH2Y
M)S-?2:BJ51[,]9@+:\Q,ZP002_U]4FU Z,,ZG+.-K>KHBMZ&6.WRC$)#766_
MSDQL;@7W?%4C4!<:&&6I:$R)T]CH-:Y@ DWT,#\MR2G,(34A-(H._@/(=L"=
M(:R\Y:7Y;=_:]JZWY#JI>Z;N;?:=NQFK#!G2S69ICAR2-6^;-A0(<9*6<983
MTS:8$)=R$P%)-1JHJR?K:B;/7;E[@;B0RN1TJ0\==4LX2>&<MHE!;?B%YLMN
MHRHI_@B'-'%+6IVVU:^CLO;B'3QS&/2+I=#+B2RVA#),D*T1;)IK.= ,ZQ(@
M-'B[:MY-C\O3P7T@'=R*"S^80)JLI'6A6HG?JS<Z6G$LBC:'K5.C];"9'L-F
M7$YR?TT "S_4KW&H'C;C83.NCM7#9CQLQI&5\K"9ST$%9%S/@W2@ JS=<5NK
M1D]0 RSX9#B?IUG*/$&1\CD@',U9:O1]K40[8%'RY3K;JD"5Z,JB<**"GC&2
M<Y=">!H9_:$YCK"BUQAGEY^83%*?VKU!OU['BN1#*0M2&#[1 G+L(XHW%>$:
MY,6(J< N9^BK40R3_VUU2-FJ'[\6R0)<5Q/=.& ?5]YL+I#2&+I0)/(M".+5
M;-*R':BP8UHH4 >\ (:=I<A<4C@1ATX; 6(:0@XSWPKX/)=R'@O(U]![8NK&
M[CYV U=%"PZIRMU?K,06_AGC:T3X^::0"D ([@^@<HZM$91VRY/--820H,.3
MRK0T@[T'?PZX$\DF+>>F*!3P(<LUPLIJWZB:?N80"4J!.2H(]_2$5<:IELVX
MF =2PGHQ=<=/#X^<2OT.*#N1F[:)S+@0J:-%;@?Y<AEMV6P;XK>J[=!?->GX
MJ%_2C3S8XP>,MJ%P7%H(U;9I(+7/)IAA<T\&IT%J5V>[*(R-9?>WU_F2="T'
M&"%)DY;4[1'9E#"+"U:&T.R M2BQZGHT5^@.8Y' MJ+^7?&&0N(8:V]=9]]O
M !K\9D"5Z)34^F\%<!/D<U\R1R$(&;66@<-$OL6PD@)8,$($OIV(195!6GYK
M?;>N"NA>Q9@"S.?5"^:ADA-?CR/]7._86'-;N6,P5F3S)X5Y8*0>&*KVGM0$
M1/57&I9E'J>Z&\MX)6<=(_;8M!2/$OEXF(F;@2(R :2".DW1RF\QN]!IM&=6
MJ'6HIEZ!E87)3;&)J96'8! //%Z>I.E<+8%(J-Z3?R*O3')(X'<<:$@P4R,/
M5. &PW. ]X>C&L12LS%03D7:)BKW(C6SQ7&)W;>XMPW:J[;8KH*;-,^L+C=]
M0O,X=2(.:'&,1_% V56[4*VZC751WZTBS7\&;=$6\GOHD$:0'[##8LY*L\25
M8(D!5Q$RDEE:9@:)=.6YJ!;! "B2%MV&"@?DII_G6=HIJ_1$>7U90J^F)FH8
M=[!RF [2/P?=V7KLAUC$J3D$"\#!;*U.48AVP]1C-UE*B'8@C*BN86=1F>*H
M#X8#NG-MCG8.J9[J9U6F:>I2T6B,+/\X>$%VZ,G;J_&E[F/S0FZNJ&HNZ>ZG
MPQU@,B/5 769KP!2P#0T='/J%HGNAB+<*]Y+,Y9&/4_ANRX -[XKS!3))FI
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M,=#HS*II9UA5+]-4'09#B,C6!MFZB.2 XAYE+?!QS]G14XU[Q0AG(9(J-H(
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M)1VCI51A"EKBTE +B$E.Q'(E]]R>- ]WC,4?9WE9WG?2; OX(^>K\R+2_86
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M2IT\HC28'VHOANHSZSZS[NI8?6;=9]8=62F?6?\RKO[3(\==_:&AMM<T[2?
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M:_NA]F*H'BGCD3*NCM4C93Q2QI&5^L)(F0[7Z%'X0?=P1M+539[=8.Q"-Y"
MGF3@^BRD)PP<!-QW2WL>1T^.'^3P['O&.L\S*'E5!5_-9QT_>?;3!SX,BNAT
MZ?Z-L-M0S(%5 0FR\2$_/'GZ[*-<N"?7.5 IMQRUU&;7_<MC"91U\L&$#TGG
M0,>/1H@*R2!K(L5+CT(1Z<#5_]->_:7MU0]16-Z0L-P5T0*&_.!WJH]200=@
M[7[!;W6?9U K*:+)T*^=B#@M&=4P$]=1-C>D&$S\D0?HHK8$4M3$D<M^60[O
M*X!R""?4Z>2+RCUW\5,E2<TBM;*:/2D%[_6#&;Q@D5>+Z^!@,="K45\,BJ2?
MZC8],ZAXU?"KQIR&NY[*#Y6Z:/=S"J'??F^/G+]*I?@D\?VTR@W'O"G1;O>_
M!" "YW>VC.RC[(SJ' 80 )AOY&"Z+5+L,303FUM@^=F5.,%Z<TB<E/+$Q;+Y
M0JC&L$F-#ZA7Z>%/SV(.]88IS4RUP@IYD>(:'1P[WI@2]);NZN!62Q(^TKJY
M/IR>5#6AD6,36F)ZL0WS4>?V$J%+?-+8RL7YUK2.SCBTTWDZ\!/\V2886D^J
MEC^:=^E^!V/?.D?5-/6-6\O@5?6G?:NPYD[-JX*,"8_I^5*8'H;NK"S(SJX.
M2?670"\_F*=)%2,:J*L-)B%2FDXS1:'(0/_K?3*[G>8.J"DUQ]!M85LM5 E3
MO(\CJPM,'.Z"$NN^M(G^H.!F@"Q[M*3PS\$7=DC<RLC_ZTJ^$W7VOHR@D.LE
MHLW^_7GGY*,#_$>?+\#O,25]PY0\[5'2\!$E@/U0>S%4CRGQF!)7Q^HQ)1Y3
MXLA*?6%,R6.M:QJ?!^_&T_/1U57P[O5H,KIXV<F(CETGX@CYS!O.*-%/)%6V
M!3<SKE2'CT1D4MX*:GNJPQ\4Z-N*2+KY:5&JOAR0]=KLH?>V4XW/CS[7VGS,
M<?W9HV$O+B:3BW>CR;TJD![I')V__7TX'5^<!R_&%\'X_,1!>?H+U9XC,_!7
MJ;H7VU\^M"H81Y0 (2Y:R+]@< R.;\B^IY])F+\KOPM.HYLT"5Y70%KPYO#T
M\&^SXN\N!<._.8^6XI?.U_P&::!_"8+@LA E\O12F?MU*N;!"(\*"#=>S.=I
M+.X%,GD<<CID?F0(@Y_G&SDYY1?6^9_6A_V4^KWBF/:+- _&J_@P $G[U[??
M?KLS@/K(9N@==I@+XGP-M%2NR<W7??@Y*Q0G@,K>!F=GEWY"<$*>!:/E+"KB
M2![C>7""\75H/R#WSLLLOQ_B\1%,TU6T"EY"7C,MXSP,3H;!S\^/CX^?/#\Z
M>NZGB [KS6;URS=OH&M1*O7N&Q"J7P-YA*>06;],11$+.*-&RRC-?OEFL8R6
M<,G_Q+@E#^-\^2L:2]%\C==:7S@VPX]<=_L,J<^0/CS'#VL%$;*30B3IQHJ:
M@2?$;#3;?_<H8/Z(DA]^J+T8JL^G^GRJJV/U^52?3W5DI?["&GTWP[:?/1EU
M]?;%U?AT/)S\$;QZ.YP,SZ<7DRO7(G)_6237SM3!V2?_.G\5G%R\N1R>_Q&<
MG9VXEQ#XNCU@EU,B/G7WV5)W=^3N%-N 8VKKZ]Z*?OANJJ'A^>O1<#(-IJ_E
M>74Y>CL=GUSYH\H?57T_JJXV8GTM5O(H6"T</:::KVA.J%.,;G_IG)W?A"YO
M0@^A\1 :#Z'IH5)Q5B@\A,9#:#R$YO,<UE\,0N-!%!Y$X4*6[!%E//U0>S%4
M#Z+P( I7Q^I!%!Y$X<A*>1#%EP91#$_?C,_'5U/ !_P^"H:O1N=37P&]Q]\<
MOAI.3H/7%V>GX_-75\&;X;F<LTEP=AFZ%MG';M>E;DL!C ,KDVAV<G:#7=/[
MZM*7F_L<1.\3@<,D6@:_@^/MFK+@-*!YP2"HIP&IK'QL6F'XNG*?%+MWL G2
M7W;>YT ^.[X.RNLHR[!YL;RVW*2;:B/@3SEW Y\;\KDAMKG2!')#0XCOKGR*
M2,_+TZ.GQ\&;^!_I:@73<R-6E?!30R)3R2<%3^5#_83@A)Q*11N583#]9_#C
M]T^/COVTJ-R8_ ?8@,%PM1!9%+R4WT72/O/S R]!.<$@PKDYG-/<_$^)"MDG
M 'T"T)&XX=>4*O)#_1J'ZA. /@'HZEA] M G !U9*9\ _-(IE[/1^>GHB]=-
M]VJ*5%)J-#R;OCX93D;!Y7 R/9>S%AR<CLZ&[^1'@\"$I5RP[D.77B;PPK4O
MC?5170(_/:!Z$15)\%I$V>8ZAO;9DWPK_[W%]MHK4920C#T[.PD_=7;YDTN=
M@V+W=6<07,[.]3%=_%L$"/VKE8BN'<T7-][0I(O_$EH#+W^/%J[@P0H>K/"I
M N,>K."^J>&L]'BP@@<K>+""!RM\CC/;@Q4^)5C! >O/D]Y[N(:':SRFW*H?
M:B^&ZN$:'J[AZE@]7,--N,;?OIOER?;O_^=OWUUOEMG?_S]02P,$%     @
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M]^WO7%];CM$Y)I@@,"\9='N<TD6-[:ML_A+ 0HHQ[$@"\W<I8TM,"NJ38:?
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MP::OEJ A*T2I;7QK7L,7KE:NHYD!+C)&!NQN597(5G7_]EV.#\P <F*:)*$
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M%A\ ^]-\/T%_FK];8O>5GN:GJ@1L6&\QE-X/M0CB'D]T_,=V@SF!Q&)-LC_
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M,H4. ;4QG)@[MA+V>Y6BIOJ76BE20A &_U*=?6":$KO17YB5$(<8(TPY;2?
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M5G#HB0'V_HL0*XO5ITWM23:H3W0XC.^@P<\*265M@%NE;KW-SJ^LC>I ?OB
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M#O8#X@ 1AJ;A9H%A:&%ZZ?L3>T;9!C;OEAN:.I'PO#*14)R/0';'@;?/1X5
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M!Q%[;HMS62A*1[K&7\);H8#A"OYT>2//PI=<Y3?T3B2@NP>"Y+[-ZR#@.\;
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MCCB\PBE@C-;2OY74B'#F#DA.9=?;F@HOEE4FPG<(S<28C:'?!):"3!M,(X[
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M1;H61Z;PR)HQZ^/0^=A0L W@D,.W5SMH/<X'PO!UVZA(RG6'W3C[VX=??E[
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MS3)_:"1[B =X)&P#55ZV,@R8DPF+_)TW7 JL5)WS54>VM#0PP>3JO(:A@W'
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M0"4\T6GL]0)QZ):):)\Q7 A:"O^/M+^;9;[N\G87]Z:X5PA/L"^Y'0S:ULT
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MK 1X/&B=;1:9IH-!M?AWO0DJ!L+QV=\5JS7M& :&;5#\@QKL)2QM7 %^\<)
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M,CU@K%^5(?0[/K=-3.$IZ$<[)%MB1&M0@:$T-!RPM!R)<4A+HTS(*SM B3]
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M+1SALILITV5HL![S.L]$)+!6E':RAL/=FOC2OQ#5T'Q(O _)[</C.B4B=K=
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MUT+-S5,S*^R-*0ET>&<BZ"%*.3+?87RS3;NQY\+2>)I@P_<#+FU+[=IA@8$
M_N\22=]1%L2U%Q0'RFU#(V2[.O$'V@!@R:K?_/S+N=_%:=L<DMU&ZC(P#S=9
M"]$)1B-++M41BU;QCQ9_T@WG'_]@,R5S=O8AV=DGT\K.^N6-,45NIS 7I\_Z
M\_3)F,:4.9<M4SY))J))1R-#>A2#% ?6COJ%FVY^)%"2PTP@I:;<$8Z.Y^]M
ME=5IME)WPZ?980.Y7&B/%@:D0J1^"=M!L^/LG*DYL=*Y!E:I>GWO82(C+0UG
M,DCD,Y ;[[7!!X4_'!XD(9QGXI>MN\Q;RL"6,C'1N3>F6AN[ON$YVJJW=$/V
MG%%-33(8]JXM)P+*KI&A--=(]P.&BLGK:_UEYCT?NWHO,X.9WB+N/*Y@!+"2
MDU !GX3;JL86B[HMV'P-012K4X<G 1N)Y1K5!\*O7WO<F&&O")G+@=L5#GE^
MOA1OIFY17@^./JN:; 7VXR<]^Z_GYZJ(,' F]] BA^=)92 .+.<X@.$#$1K>
MXAJ[9IG,E3IHP3C+S;LBG.;,'9N<PR[W7U1,H\(!S\%[/ F'AZ+4?6/DCEK!
M]K TWC54+O:AC[,(=51CZ[5+[2#4&CR@1#/;S &;.3%UO'>PA'F>G)>PF"MD
MH3LKFNS1>5DA>2$^%9:>GT=OSMZ_O7K]/CH;&3/'G)N9NH!>;PJ.:GY%QR&4
MXP?PEW)%#W_.1(#P#]Q>RIU!L )S-[@T#)&""JE%(G2"0PQ;_KU@P%5XT!EF
M%&\H=<,XD5AP"]\]_M^LLXU,SQ3'^-QVM/55X$#0?L-W?^BLE,%S4 K"+7!?
M* 'R8!D9*Q%EW[MD[3*EE :3\_K%V;D+W5Z*9N&[K1'(XX6I8>71?OR*IFJ2
M\T[W<UZN/B MM4(9__4O[]V)SA%"D6>LFJ=G];I8[$Q\3W=:*Z^'K[O[,PPL
M'FH;I!2<2)&LT+:G6E 7F2J3FUMT;6I[A42+ZT+,#0,@3(VQAJ;\+N#%DWHO
MITZ]!_\W+Z"=K> 0[F)*5G!HTYV$'3S2YH6?N26IMK"VQK!VUI#@*F00:_+^
M41AKQ93.Z S?)/FZ=S',L"@ACB(&]2\DJT% 6(D\F[C24$XZJWFAR8K\'TEV
MVQQV%5UG:VNU-C!(:G(90P5?0$36&E&<&_"F\3A^XA6,>&5@N?##@M'AS]/G
MT0GR'!*NRE0;-*4I'%ZX@./7TW>GT0LY6B9*] :[5C+4#3S#^@D"KS>,_CO!
M8_2B4UH(+\[?G(UIXNL+6BPH4J+AWY:(.U_!EF&UR/1]6DHH0L[!S*.,YIHG
M1N=@H0$>D%$_H?UP#;.J0("0K""Y0L*[*;P8@I9:S*3^('9W9>_ [K%87U6T
M_J$#<#8C[N\&784;;IUB7!G?%0LW,(23ZFS]FTKL(U_[L+*!G<_F&<B_V$B<
MGJ2X9\+R[W%*P/#( ]G*UIBFS(S^FC#ZZ]L1 X9F]-?\@ <><$9_37#9?:7H
MKV0)/@'NZ_3BR9FH:]:[WL<=[I5,\3A"MXAB2V7T#VT@5! ,%H99Q9DW4O\G
M*N>\I63!9XAP\"Z_2$!#<<M D+*L,BQVJ,N$O5!+\O8@>B&U;.>N23P31Q^R
MU8=ELOK@E&[:(D_NUFWNXW;6)$%.0RN=/W:8Y=K\"W@3 8J/?$&'6((P-B:8
M$A]^W?(OP^KXNJTD32)IKEKR20S_VL U?203?D9-*0<:9N&-Z6%Q5._JQFP(
M8Y!IEXTDMC!C97ESD,.V)?I4/21&IWP%%_0^$]GH//<^HPXR0PVZO98P!)@-
M1??A& R2L]*K1X+:=B5TMYEKD1UJ/[/7BCH7TY&C-0>&H&D;:8MWHTN1R2J3
MUEMJ@$KA@3 2Q:035PDQ8BX%Q+'G@2FVP":3.2LUA)N<4C ^UJ)/]#XHH3J#
M$P?&VX(_>TPBWIS=RQ-M&SI_?7?FE[^BD_?8ZA==75VA27G3+D^CEZ?1D\<_
M//KN^^A$U@JLJA)70?0:=H,E6+>GW\?1T\>/GV BP4O4<+]DMN%&/_CO7&]]
M2+UU8J*'%TF36.S \XC^?%-EM\G(5!!GRSW$5=05B4)/!$'NL%D7*^N2^4Z)
MA70P_AU=A@Q[L'T_;H6-Q@P?1#W6;6+Y01C?CLXI\< 3Y(8F/IP#SPXA50W'
M$AT?L6VDS-LGSLW< /%%RTM7N(T4A=@BVBWPI:RP7+IBCD3$SU "D_I4UZ;R
MW,W8LE?EV29CN Y'$O;'R:K"ENM"2IP11\DUI3W_!=YSR^E0%\-0<93*A=DZ
M$R(8-VN"$D/L"QOS!U[1@6'Y9X$C#]>ES2HL M>>5L#^1V(N&(J%P(.D#18K
MV?9C+T*29^/0))0H/M&QO45(UQ2K&T.K>4R&WU8[XB%=PJRV 1@VG P'QC9P
M?8B;A04/"E["&:='V0*ZC^+V9QZ<8.VY@8SD_L44!'N471;"%EZJ;VT<*E6$
MOGZ[*U!N>7>VP9'?38,7L;<6= [)JB1#G*R8UG15IFS6):+#T1-(8U\_GB#S
M6V9B%2D4'[4G59!'=!\,X2,L IZ(Z3;1]A_#GO*9FK=.H\O^?*%(W6J'YSMW
M"1-M;W8U5L%@$IG53<'_]$'Y@E=-4FR2JIN*L2]V0]W J2@ZI6!5(U>X1=;D
M[,2L#=6I8"8-;J=B5ABVD5$AJ^0=5G(R8O?@;JX3C)^'=O"8S+%8+Z&DA1L<
M')BC%E*0!7K(8L*O:/7XVL4I+@)D\* 0:<TX7N>LV'%%*L6U4J5X@O=V&HY@
MKLT1T@,BI(FI(CO"+IR65PH*$V+I<6%B9K=X($K"K?S>S*9$+J$58WW(8%L/
M"&E>9BM3(#6@Y9AZ<2%\6A>7\H_+OYQYD/=!/AN\OM6O4/"%[LEL=_TT:^*3
M0[EDK._(ZTF2VS)+9>J.::+.@(0) Q*^&W$->P8DS ]XX %G0,($E]U7"DA(
MRW;9B#,!44U>;EVW8U5N25[DW,:RVCAN>^4Z;JI%[19$4T?Z&-AY1S$D^#S*
MMXS^CK [1^L6OJ#V 2Y<4:SS_!@?\^GCK\6_S#*B4SRB;,Y1IK*6PD]1& 9.
M0PF)MK!DH)K1'*8^1,Q"4J6*35TG68XE;X(7L->:,Z,U_(=C;_@5%]P]7 'F
M=.%="YZBGR8:\G)MC?,0.Z3'*[FV:29/9$6 %/@3+^+.LP^8/X6'N,:42H6-
M/L*F4YG;<B6I,7R>M$KN,#%3M[60S\2($5Z97!-HGCRL2_EZO+ QXG@I>-^4
MJ9=9P.3S=4$?%,0(D^P.#8?SV.%.A<>?[EH6*Y[07YX&_7:[<(]?H_-ZZTF1
M??,*?J*3SV&:/*"3#V\Z(I<54L\?;&733P@S):4MS \EU!!U6^:WCA;THFJO
M-8',,\\R(\%1MQF%;9J8K;#B3OUK ;6HAH$8T7%N-C7+I**M(*M]^-5R%SU]
M0ET9YZ>6O^C9L^^28R%C%1.!N/,3XL:@Q1 5+.PYLSWUCC?69X75?.11@VAC
M6TD7<B_A/>]3X&J?8UV</O[NGIDYL<5Q.Z^->6TT]?___WU\]H.9=XY@<<#:
M. -_%JZR@EB.^IWJ!OPAJ=C8#QMT'FHOL;;<2?UE$ \[[/&)0MRM" +6[7*#
MSEZJ;LT^7NM0,_'%Q9D]/2%!3845N#JZ*ZL\A:<T4H<)B_Y4UA'=P[?F6FI5
MRKV!?@O,52Z;:.D16>#/B, =G2N<[LPZ#[]Q3^&&Y*& ->LK,3A%GAO+8.6J
ME$[I3J5UGKWA[,UX^O:=1GH_->DB_M>?_O2G_^9W!:=OT0-OJ:V4 !S,K,,8
M$,':WL#_R\6@#KY!_&*U*JNT ^D-WU406[BO)$L=79=EZMT0JQEHGZ@4\9Q@
MCA?22!SSF:IT\XSJS*CL:+6[4''#BUU%YXZ#NJ/L6A^0L[]PPO]XS5VI-K-!
M4Q/N4=$4RLCD1TT0A:&EU.:!?S5)3H8QC?ZUA7%2+8M:99D.'?QO^.)6QH$'
M++0NV/4[FSW,2=A0&F+,D'Y4(O;;XP,$;!GJ1_$AA.3_>VG)PO8<E%'X?LA!
M$"X/,;?6KXLYYR#6G1"!"#30<I.TD%.ON2ZL57:;Y>CEP+#2V_U[6RC"S&3_
M@\L7W3^P]%G!#<+T74CS]+G @#P4]MXTNA<Y%YE??@JM$YD'K2)=^WI43#Z7
MKR94OOI^Q!6/N7PU/^!<OOIC+;M^^>JK]3<_T>&\!UUCL=E[*B;BFE)+DQ<G
M@3<4_2VIM&/W5]5+>TEB:#%2VVSPBH^^_?%9'$3-E8N9-\8TA+CQL.L0+K%8
M1$I]KO"->,D0.4$T#I>S#:J44R-DI,_3=?!1.?$% \>2=YV+V>K1P1$1V0(L
M)&E"HN?WB&/LQ9&Q:M#1 \.4^9!<:XZ@S#5I@5PS<4BTMI;L7%CHRE!3 .Z=
MTX*4YEA;!3_\A/VXW)+[>YYOE_#Z,WB1S_$6Y@@Q2"=_7'SSSE\P)V<+J?&Y
MI%!11N^2M8%9]8IF.;+G_7R$@&50*_0F@O7CMS(1*0F /<'#<BO=B2MP^/.'
MWL*A<N7QT^ODR:(3*;&BN-R+=HA<%:DL P[&?JVQ*<=2;^G/Q#SQ;]Z /83-
MFZ#/]I?XA?Z:1>,S=VK[J]HHR9]7@I3 )JW  \"3UQ"N+7$1^T!T!1)>42C;
M3S])C$NJSS;'&1+/Z[-C,A.9%+7[]!EVGS[]ENX)_!5\.Z_@)T^?_/3#DV<<
MTWFI(&97H).X/.7)4QAMO[;+MD$KPRS6[L5] _!=.,DS[IM ]4M%^2;AG";R
M1"8\VY?@0.JH;_E$H@YC3W7^]B5KQ\SPW*&N-<QJ[D6MT/(S'_=K,N#JG;XF
MP7<P$&/"YYY&WEL9+B7,;^:?\F:ZJ51_.V21IX&WQ9+2 PNLT_$U>"Q%<UZ;
M&9^I2#8]WE]N):*)4=[!%*'[V7OBTR@*G LRG5M3!3BVGVT6\HBB6W<\!DU*
MM\;F.;C.# UO=EZ-.BN\+7Z \\0BZ?J%K7O;4WFS/-\O-_7U;A>KQ3=_\T=,
M7^(UEP*(PW$]+5OC]46=)(N3D1%'XOR=]'".;3R196Q8OKKO_' )'FQOPVQ7
M?DVWZV0/&<1X>&<^1H[]$\N"DNBP60BO&'PTXL&F/2S9N50"595D3U(CJ_T2
M%K'-=ZISE;G-X*4)G>U]HZ<=U]&)/+ACPW!]U&55<Q@)@=*B4^.&?Z$X8<!?
M55.W6/ N+?OMX%;E=5CS1LV46<*H(,-NMR)D2U@A]T?&I4W[Q4#&22([W:EX
MFT]U;G2VQ7TWR(RY"]=_.PB5?7"ESZ%^E3*/<;_V5H8N0XH'-">'[\:?*G4K
M0\=L?TPK1[7=E"];-]*HC+=."\@%DC&M24E]A2]R[U =LUZC^H;&: 5CM)]U
MZ>O=_=/#Z>,AVKTA0AS)*EBX=>\-'DQX/'@N?^;"]*BVL[D./MTZ^ \C+IW.
M=?#Y 0\\X%P'G^"R^TK;. _AR +&W;C+*2WA3]@"X/GEU;[&PHPADDQ9M,X*
MVZ600*#5N$]$$FJ/DTSQ@8MX1D;=]^RT:U8F/4M.S.*;2T)"3RG;\JFIH2]R
M,UJJ?/OZW:,GC]@(W\KC1TV[P5#=%4=#7MZ,Q; ]6A7I!LEW&OAIAF)O8* @
M67<-[0+ADU/>^+I*"B:ZCEY?7'A@#R$X)+QSM47I;>Z06C6V13M#N7)<IG@K
MCKJ\]ME[3Z.?DYHK+M[S.?(XO.@6\R!E6\.SZ>W89/F!9\,?- AOUEIJ.-!Q
M].K]VW_W_CQ[Z?_U\GWPW?F_/[IR[PC.?G'QUG]K\*8?U1M\:NSLC?(6'IG:
M?*OHY-6[\Y?G*!I[3Z0F-A'YVJL/AK-"TA+FM5KK^(-A%*W>R("%R#!G9860
MP)"5*8NTT[M)\=V8CW#!.KLEC-$M!)64Y_H\[Y$$<S'O@3B$U"8B*+?0NQO_
M1H+9)N4WF&7TA(7<%B$2?B[+#_>7]P<3B*?100W*H3B\FYS;A9P&N+=QIFPH
M,[HJ-TLM\&^U%!-VL\,TSI9ENN,W Y?Z>\L,;PXQU3V%%*H:3UF2#ZIC^3GG
MT$+M243O#Q:69@ZXAR3GOY\6!]S+!/QV]&C I1D7XQMZD [$1/5X3DP>D>7W
MNE7JILH^X,Q'N=*R;=S,CW)Z]HNLWK:L=(*-O+H;[F]C?1@%XV^E^N0F,FK0
MD5ZQ8Z[]FZX:1S=E6U$OY@?55TU5L41H53>(1&*K0X(IQR2!^;6%7K]'1ERQ
MP]^5.:%M+(&C>*J^PVTCJ5+28;0MQ?0^S^X50P&7)\DMP(#VG U/_=G(/<3(
M_3 M(_<^^6C&9]SZVAG[\OPGR0)B6X1PHY<%3X/R0&UEVYZQ_]4C6EP2,M$!
M6?E0YMOU-'B$V7Z58!(;/3WD0<:%H9AGZJE#^<?E E9_9J_NDSK"A9:&O_WT
M"Q#^9K5 _P7,&B&DX?S47[A:5<Q\OKI!H6A]XMI4MV:PB?>7L[,W8A#!9GAE
MVK45G\8*F+ "985UR; :89\/#='.-%':&C5^K'G"3;W=AK\3OU#(9[!L0%SK
M3C-8TI;84BK?6<$=Q.L$[WQ)5>6JW%;46NGS,. M."X(.SIV'-R[MD.X;VC\
MNJ9%H;H,R.^QO\RV]B&V]L=IV=H72*UV83FYQV5U?0H9,9OQH&$ >V,J8>?V
M@B7;'1YH/902,":T_/YNE#(??G('GLJC' )2MH?N('*0O+\)3RU@KPA>65%N
MLI5(:L/4!+<3K13>$&I4P, N4,NMR.J;^WD\#D2O-CV"@!)>Z5W.#<)$FNL2
M&[ZM2P91[QD8 V.)^PCC2./P'AD9I,'[HERUXC2B8'$.'A]N&NC8<S:!HW3]
M"U4SF+J,84%UNY6$@CPD7< ?MKH\>AAB>Y^]W!$FIM',;MLE[!:YG_2 LVD7
MPN7%+V=OK6J#BYGO;G"/M7<1P%8V66TG%=Z/_6(M*LXE053@-=#/PH/I-_ N
M3%U3W(%,>!^82L+;PFC\LL(J-^=8KM%G#UL^>)1Y$X%O=]$=1E@LU(X[GD>T
M!S>>FP1WG^=N3^'(IYO(D#F/[6QV)7GO*,Q'>L*#99%S,#4F&S$7_B=<^/]Q
MQ+7BN? _/^"!!YP+_Q-<=OW"?S^"^2K"%8I[?;_LCOHQD6RH'^92&:_=HA-<
MU^UFR^#=)7B'YM9F%#SY(H&I4I>[]2%C23%*>$V>#7BP9>J7DPX[)K9LQ6ZE
M>.O1H+<NN4F^-\1:HZ-72VLMG:=R;>'HS7F$NRT6]]!5M(!I)M6]9C0S\OJR
M=R[1/>4,=J4XJRHP>+1/'_11W1AZ-N[4#TY )4$I)'::3]E/3JAZU3)G&H3T
M=90RCM2O&U;R+TQ/LV]/[N@2O=A=!)X\:NMY@P$>']4F.^]'KV"O3'4Y.MJ0
MYXIG6QKKH)Y&7F*\-E3&14U  9[:Z#/2AC<N0?9^V8L$#(I3564!81:I.%4E
MW*RGVPRW]B*K-N;CZ4IDJBC[[>*%;D %!X ?C;18=R5U]=J^KPNPRBAY5E9Z
M$!4B>^$55_IJU;GJ-TC LV!8FK'XU&>_NG\IKL&&A1=.)'$TXX<;05Q\,++%
M^BEM+RCN?0P8!_.AE/(Z4,+ /-=RX8<T+'&FU L)8Y4/UHBEAIQV2.I7/23S
M@3+OX;:[L$>$EN.6(0A]]DH;O]I&]_Z-W(?Q7I=Y7MYQ>?[0M8[",CWZX?3)
MM\_^MXUD:-?[_O3[[W_X4MO>;XLW[MBA69;Y%\I]G;U]?W7^\C+ZZ_]95O_W
M[>6;MY?O+E^]/WM_]?K5N^CLU47TM[.W;\]>O;^Z?!>]?A&]_]?+Z.K57R_?
MO7_]]ICQ_J)#.S*/XKUOQF1+\7('N!1@MT:0CTUBV7**ZZD%>XES_8)3*[QZ
M7K0,.^$/:UD2]9_GI/2Q2>GO3I],*R?]VM.Z'%.RZ=1+O&)M[ *BJSMF%]@0
MF!8!JK!QUC?9%KPO*L;0DZ#_"U8Z2^$CBXS@E#*[VA9<Y4!;W!HG6MF-;/9>
MEH[:RY!&NKQ# "[MEJZ947WE7(3A8G3\6$)N#:MP!4X#.5D^#(W@1H5;L(EL
M+K76VO9IQL5!?;&\$PGN"IOHFYVZT P^]@D]R3NY<VS.$B34C.YCEST)!A6+
M:L1^LC8I.2@G<J-:-=2T+,8%JR1?4/5UVU:X <^@@8?8C*?3LAFD0%^L81Z,
M3 DS*&*9CV;5VF!6HN.=1@C6NHB;+@<-5V@L849&&@,BB"S!'MF)@OF",EM=
M\#1KN:J-?%:-%'B6.UO=L?]DW83-)G!6&W<[]YZ&HE9N4;Z%D((,#+TC\KOC
MH/K,BKNQ0Q.%>CIT6I]@:<WFJLF:%I<\MAPG>+(3<NFE6Q<)&J07O$0$V98%
MHC$Y03$'K,J;!5M=:\4X$T+H*?V&U("(681$DMG[I\(-LIU\1*>^-B(3M#'I
MSH=5!(H_W2="@>1<J$865&!B>BERC%(.LS"DQVO5>C?^<48Z1YM6>R7\UT_0
MW*CS,')Z"7H<&B+$8VG*XN]M>JUQ+1V.P6L,H[V"D%.W%1I<Z;$>DBIRS1PA
MSPMBCYMN=B2I(?"G$J1L(9G+*%@J/WQU\#RQ0T?@.,M!MYFR;B6>U#BR3MLP
MF6T[D0EBR(W_T>;MU.!6A,%:ULB3VX7#@3"$P;0*AY_&"933;>X^[8'A+/2$
M+%^R$48SAH/<]\2ZWD/-\-15=]?^W?@RZK3H145]2N9_E2>H,3XVUA(6$[!0
M(]8$O_-4!([NSDZ6F;+*^!.));_81IM[S+/L,H/;2=<UFNNH$ZJC_C3BTMM<
M1YT?<*ZC_K&6W3%UU#F ?C:M /K,3P6-R8EB\+U++A_(>TDTMFHE!R0!-N>5
M)"YB>1HO$I:HZ&&1-J>G'^!\24 L66W\-S_7GHP N'G:8O#0%( M.PVE ;H/
M[\"<]LYD/!Q&G3*9H89AAJU.GW1_CKF23BMO*_6?_C=<(G&L:)(8X![)W%QC
MI9QRL'2I92:ZB%YDAZ,3*_\]0QE$(REKAO#Y3%9F6Z-(QSCV405>7G*9%!^J
M=MNLB&B.&,8+_'=E_" MCC:XYF&<VXU/Y-\A[I1B*-X_!.%IAN1OEB1.4@52
MP<WA&K:8^X\V:^@DVRHK5MDVMX1P]D\8!$;5POJ"_[^;4Z8/L/C?3LOB!QD:
MG ?OB66#R7.#[6!D&=4#=G.Y"_,LGS&#>JSIM :XFSSU,C.']XG!LZ:EI PX
M1RF)K9KR4XG% MDDEB3K0IX!0O5#6%\YVH'8*N>5L>J\<0^F(U[FG"ZC[IVP
MYWZV%M?BR>G2V8@\P(A\-RTC\JJ,7F;*;3HZ,U$99E2QPG]UBWM\4BTSG=RN
M;R_&C%<&*V)E&;!Q_5)A%';U;6F*).Z3N?),=Z>)3A3&1^*$L54?A.NF\ ]9
M5[?4EJ=(GN"\3$0B@,9<"L5:3N#%N$2>5ZQZ#*_"A2?\;/OO/_@PL"#_Z_7?
M\^G5\0E^A>@TK@M@-R4Z$SO53KQ!1:'BFENO:F,^U-QIP@E/;B9*Z,QD<8DR
MQ6&[G-9.+,G1WI&?;$^%6NK!&\%LLQY@LR9&H@$VZ^>JA)\ZK_F%&6/'>1#T
M$B(X^6"D.+ARQ$Z\9@SKAM&W6RY3EI57)Q#V&6QQ$\NUI$'P^NJ,V==1>$]5
MP8>@SBOG 2MG8LP,",:#5ZWPZ7&MF+,]'//=A52W:R8G;Z(U/0^\B1O)YR!'
M2KW>]9Q]W,T2'Z5!Y=^S3=D6/=8!+=GYR,73Z KQ^78+EL05KAGA'AA,2_5:
M=Z6QP78D4'V0,0/$],Z-$\7UO @?L @GUK)_ML(68YR2GD#:N)9BL'D%TU[F
MNN5)82D$)'Y"5]-!%+H-]UR!<3T3;]%!;/$JX#O"=;3Q ;$UE.W2*+Q/@$_T
M)4ML29 ^^"TR"[2%[I/U![X9TMD4I8)8$[[:@@/;(>6?.8:V4&?RWKLB05WZ
M$7AT&($4UW0ZT#">*%^!P<3&BI$=:(#:"AQM.L%*DP I(8&VS>"8#"4M:3/'
M3&6_=V3 YZ!QL&\/PJ!R>X/PU97KR'*D]G@YU[E%659%>@IKDWW[&=/,D+%<
M1^8VR=O$:NA46?V!W](&SMQ(4I*>G:(T?GJ%T/+SZ[&_=0C&M(RZO>US4\>#
MFCJNL*OC[,6+J[=_.7M_]=?+Z/SU7R]?G;UZ_V[&NDP6Z_+]XQ'#(V:LR_R
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MMLL1NE,)9(5RB)C>MXIQOOE$'@QIK/$ZM<I*&T000P]OYX-%K%BJ[4Z.^\Z
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M(5D<1;)VB9PI.S!PS[X\(]$4,)F E#808#<F^SD#928,E'DV8FS%#)29'_#
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M8U0BPM)6*=2!N#+V+&F,/B'R;*)E4F?8;U#7H=HTJ8YTUAN6#&%]5DP;23[
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M%$>W,$;5F,'N",N4OM*NDF_ZSOM4)P]5&4-51L>J,BB#[YH&!91H,?P-PE)
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MS 7MV>W@W3S$N_FI7][-%'9@8G'B=<F"QY-0(="*+SE,;L)JTX]7P3K(#,!
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ME-R*DP7,WD]P;]R7;Y1+E>[=TG9XJ)O'>R7CU?MY##O7"^60R>HT9=$*WN4
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M<-R8E)"/4<0#.!,XA//\FMKS^I-+<B8"=_&<^S+-J)A,C[AAS_A3S!.>96!
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M+PL*R!CN#%+A= ?2,YF74Z:9FPNY6SD?A$MHIIFG648A>9EFN_:KY&*=K8(
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MRLK9P*9>//W^#'60/-._O5-+'3W*@6N!\"^#FTV[?]ON[VY^!L/_$-IOXPZ
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M5L?O88.H_'V4E& A\R;)]4;D$.P')15ZWIX?[(HWO6ZISQG3^PY-&0.4Q2U
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MYRXT.A/FP2903-X"O4'D&G+D(VV\@_G=<71%_2@'E][+B]F7'#H<@E]8=6:
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MUK*S'U@FFC?@>V#=(5 #&@P:[):*_G53,;\[ -^.OIC_]7_]=G7]Z_F;D=?
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M[[@:@I]/TO\CI/_S<4G_:U\X>6E*WYUKIS;QFRV[A5O;$H%7KTA $<-TKFR
M+[$E&)U-V)+4R 2/VJ<E'=J[<,+<C1YS]V+$@*T)<S=-\$O W$U(*%3!R:<C
MH>@2@[)Y30JB*!]+J+8/$)5\ B!*VIM1BOS3P5'^ZS K^V!G<BKK>7Q\"F.
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M6K]1+U_-"!! -^Y HGTVB..NZSW.@*<6^1D< CMNL2=.@9:GMW(,D /;";W
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MRG3]^S]^>S>_6^2__P]02P$"% ,4    " "YB69:8HI3#$1P#@";YA$ $0
M            @ $     :6UG-3@R,S,V,C5?,"YJ<&=02P$"% ,4    " "Y
MB69:]?\-PCD\ @ 2BP( $0              @ %S< X :6UG-3@R,S,V,C5?
M,2YJ<&=02P$"% ,4    " "YB69:5EM0<:U7 P [^0, $0
M@ ';K!  :6UG-3@R,S,V,C5?,BYJ<&=02P$"% ,4    " "YB69:)UX(3WFX
M  #IS   $0              @ &W!!0 :6UG-3@R,S,V,C5?,RYJ<&=02P$"
M% ,4    " "YB69:[SK8&($; @#\V@( $0              @ %?O10 :6UG
M-3@R,S,V,C5?-"YJ<&=02P$"% ,4    " "YB69:@E>AILP$ 0!4@0$ $0
M            @ $/V18 :6UG-3@R,S,V,C5?-2YJ<&=02P$"% ,4    " "Y
MB69:]0%.OQT> 0 6@@$ $0              @ $*WA< :6UG-3@R,S,V,C5?
M-BYJ<&=02P$"% ,4    " "YB69:&ZG[!=+& 0"&=P( $0
M@ %6_!@ :6UG-3@R,S,V,C5?-RYJ<&=02P$"% ,4    " "YB69:DTH"+XQ3
M P!&4P, $0              @ %7PQH :6UG-3@R,S,V,C5?."YG:6902P$"
M% ,4    " "YB69:]Y[Q'=,4 @!(2P( $0              @ $2%QX :6UG
M-3@R,S,V,C5?.2YJ<&=02P$"% ,4    " "YB69:N'FV5+&M! #C/S8 $0
M            @ $4+"  ;G5V8BTR,#(T,3(S,2YH=&U02P$"% ,4    " "Y
MB69:[43L/++[ 0"@:QX $0              @ 'TV20 ;G5V8BTR,#(T,3(S
M,2YX<V102P$"% ,4    " "YB69:6?MZM,!^ @!K&AP $
M@ '5U28 ;G5V8BUE>#$P7S(S+FAT;5!+ 0(4 Q0    ( +F)9EIJP8+T!I4!
M /V<#P 0              "  <-4*0!N=79B+65X,3!?,C0N:'1M4$L! A0#
M%     @ N8EF6D\ACE\X!   DC@   \              ( !]^DJ &YU=F(M
M97@R,5\Q+FAT;5!+ 0(4 Q0    ( +F)9EI?2! I_@(  &42   /
M      "  5SN*@!N=79B+65X,C-?,2YH=&U02P$"% ,4    " "YB69:@H3
MJ4X(   M/P  #P              @ &'\2H ;G5V8BUE>#,Q7S$N:'1M4$L!
M A0#%     @ N8EF6JT:B,AB"   '$    \              ( ! OHJ &YU
M=F(M97@S,5\R+FAT;5!+ 0(4 Q0    ( +F)9EJUU_@T]@8  !DU   /
M          "  9$"*P!N=79B+65X,S)?,2YH=&U02P$"% ,4    " "YB69:
MD'&]E4>#  "#C00 #P              @ &T"2L ;G5V8BUE>#DW7S(N:'1M
64$L%!@     4 !0 W@0  "B-*P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>nuvb-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nuvb="http://nuvationbio.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nuvb-20241231.xsd" xlink:type="simple"/>
    <context id="C_80f9920f-001e-4ee0-bc41-726bea9c2be2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8480017c-198b-4473-b4ab-8b7816a14484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_85891461-e727-4c8a-a45e-24ce144694c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_86eee26d-a7c8-4971-a02e-0c536e6bb91b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:NkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b229bac-622e-41dd-87db-5a7e8d379dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:SanFranciscoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c1b26be-f804-4b3f-992e-e5e76af52068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d9345df-39ad-447f-a1af-a822c985ade5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8e6407a5-bcf1-4464-971c-f6b91e19a697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e8cdc8e-8210-4b4d-9cd5-f1a28755b54e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8fd6169f-7ab5-46a7-a6cc-3a2bc4eb6868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_926d281c-c192-41fa-9469-55fc53c364ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_933286c8-e34a-49bc-beba-8abcc047b16c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_93ac93d0-60a9-4a06-90a6-fd3ede540eb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:ConsiderationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_942a2b2b-70da-4457-a462-954c54372c8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_943111d4-1cca-4ec9-9b87-c18a3c9909ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:ForwardPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_952278b9-3008-410e-b399-83d1341da7e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9748bbba-55ba-4df0-8e3a-bd402ef3408d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:FoodAndDrugAdministrationApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9a955a31-b3a1-4541-96dc-cc575ee9a1d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9bfa5b92-b29a-404b-9eb6-c8b1699ee7f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9c555376-54aa-4690-a07a-8995c5f1de8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a1fa561b-037b-48f9-b6e6-35db1b21440b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a2bdff39-def8-4415-a8b5-6832e22064e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a4328f73-2497-4e2b-ab79-aaa0f3d84e59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a5a3ec93-d622-45c2-8770-84e991a7b996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7fd337a-9497-4d90-be00-2699c0401c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a8df6974-75d8-4cdd-aa79-237e8cd65e90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a9328880-f63c-496f-99d3-ea644af60276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithChinaMerchantsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_aac49177-7f36-4ea5-b068-584c31c660b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_abb8df07-b97c-4a48-aefb-b20f734b97a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_abba69cb-6d7c-456b-a9e7-8c60b7df5832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aca3d405-cc0e-4215-b0e3-ff17e649ad8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithChinaMerchantsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_acea1f01-0d21-43fb-b399-83953ae01873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_acf04de5-17e7-45a9-89d8-b6eb52400fba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nuvb:InternalRevenueCode174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b05136ff-fb6b-4102-a36c-cf37b5c03746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b09ceff4-bb66-4ef2-9cdf-6517cbd7196b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1434390-9c27-4f94-8077-b738947d29fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b15e2718-f40d-4bdc-b3db-1dc125497868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b2ddc1f0-c371-4813-af10-cf895f6e3373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="C_b3414614-96e7-4ae2-b1f7-055df470e8ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:NkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3a3ed53-7933-4dff-be9b-82cf2713934b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4189f91-e001-4361-b114-dc6380eac776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b432f621-66c8-4177-856f-0710048eeb24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b5db802e-98fe-4d8f-8ce3-efda58046123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b5f38a77-58df-4c07-a7ce-d20e2e695546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b5fad4a0-b4e2-4fff-9d5d-16ef79716219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b647e270-1e2a-41ed-99c4-b1fdac51fdee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b68630d3-6944-4401-9af4-dc2436cb5eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b6964028-a1f5-4562-8dd6-ab7b2f917574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b7745198-d60e-4f1b-a9f3-33740d640e7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b84b1da0-aedf-4620-881d-35579afeb08f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:AssumedShareBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b84cd312-fd39-4b1d-8699-fda7c967c8b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b8ceb7cf-3e46-43f2-a0e3-ded43479a354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b98b6295-0101-48a0-af40-21586c6ade2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c3e4516b-f8d6-469d-9172-f8b2294ea29b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c53952fa-847c-4ce2-a41b-24de9e826c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c5581c71-90c7-436b-aaba-8f1f78e6dc28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c671dc80-de5d-4aa6-a09f-d6f224165348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:RedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c982e94f-abaf-48a7-a575-7a406ffb1b30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_ca424ba3-3e9c-4fc8-943e-50b54d3eb6a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce6f0d2b-c086-4763-b947-870bbe14d4f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cfda41d6-83a3-4e48-ba69-343cbe55f56b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-09</instant>
        </period>
    </context>
    <context id="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4d1928d-1758-446a-9b41-e8b4d12651af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:ClassAAndClassBCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d630f863-0d98-4a3a-a20e-783e2c04a4e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d7bd32b5-b034-49be-9ebf-85bf65031ef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d83e520c-196f-42be-bff1-f66d4956ab03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da21c4c3-938d-42bc-bc80-ba4f2ce5c849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da7ecdf1-4156-4924-8c2b-91c1bbf48649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e2513bc6-e23a-4295-b2e3-1e55986d0108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e48fcc9a-b0c1-44cf-86db-3afdf6eb9d8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e555de18-2b2c-49fe-b7c4-7fc47b8d8119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e59de91c-61ea-4944-9861-5e3a0c84322c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e6904180-de0a-402e-a43d-2eb3649975e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceMarketAndPerformanceConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e6f673b3-21bf-40a8-945b-58d5fc5eb19a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e720fa47-bca7-4ca0-8f9f-5310a1a2429a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e781b479-dd2a-4691-8eb1-89cc93788c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e97bbbfd-29be-4b48-8399-0c877e55e63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eab07c10-f6ec-4739-8ac1-c72a472fe56e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb8419be-c990-483e-98aa-581ed2dfd11f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ed2589a9-11fc-46c5-a588-1f840166c29f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ed404de3-f206-47f2-9ddc-6680cc0e8957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_efe682e8-6905-4a59-a9b1-a74dcdb4a136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f04153c5-2436-41de-9120-dcd4ef68be2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f196edb9-bd73-43fb-8ae1-2133c0857f5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:SagardHealthcarePartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f1bab928-2d56-4296-a932-20dbf7274283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f24bee32-709b-4a1b-b740-f6523eda2c0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f3542591-19a8-4b91-a21e-e2ed9f8b23a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="C_f4520a62-400d-4bbb-bc6f-dfcca29c01bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f4d88de7-a689-43dc-94ed-786f211f10b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nuvb:InternalRevenueCode59Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f54ce4b1-75d3-4c3a-841f-2d8ce4cc5489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f600fe9a-155a-446b-92c8-a7fc4ddd37e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f64c1371-e223-4a9e-939d-999f45e6fda0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f65e2027-f5ac-4490-8e99-bc62d9e131dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6d0b85e-30b4-4e3d-90ba-0b428c795f3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f73a9537-952a-476b-a1b9-94ceb77e4027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f77ce2c2-1105-4078-a520-6f9949541a3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f9007fb3-c6d1-4f58-99a8-9b1c076139b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f9dc1391-a88d-47a7-b7e3-f1a434ed0445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceMarketAndPerformanceConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fd25faa1-dc18-456c-8ff2-cfd565b81886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fdd8837c-b00d-4e16-b06b-aaf29e21f38f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe9e98bb-bd80-487d-b08c-3e44af1635e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_feb7f3f7-75e8-4c18-a40f-52dbffc94964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_02eea57f-659f-4ea9-a9be-e8bf4cf97e78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_044c0715-8d17-4f49-8eef-b09c4726ce1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_07229a6d-6da2-40c2-88a0-037159cfa57e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0727c878-248f-4686-86bc-a4597d7f4e1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07f313fd-524b-46d2-99aa-b951b4324490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">nuvb:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0b0d4681-373d-40ee-a05b-cf4167b76104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0c652882-855e-465e-8c03-230c6f70279d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0dded1bb-24a8-4a81-9bbe-145757df1e2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0ec4baa0-50bf-4ee8-bab3-3ce9c13fadb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0f03a15b-3abb-4776-a53a-0c003dafb17a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_101e91ce-9660-46bb-af18-7822809f659f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_10ac330b-db11-468f-b855-d1877a78ce3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_11048d21-d2dd-4d6a-8603-844e4ce4caa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_123f4631-c9de-4408-9fbf-82e1d9db0a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:NkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_12761058-5ed6-4b90-92ad-003f0933b78a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_12b28d30-7841-4345-96a7-0f6603d08fb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1632c343-8902-43c4-8df1-34be8034ddec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_16f76ae8-82d8-4ad7-884d-2c31f5e8ddc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17baa364-63a5-4662-be7d-3a569f3f9131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b58aa7a-19df-4858-9619-311b52c1a5ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1fe9b1fa-5c06-41bc-904a-8d55067e5f76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_23995f85-8e92-4f98-835d-389f59c1c8ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceMarketAndPerformanceConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_23c3ae60-037a-4b82-a8ea-fb789a61b20b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_24401d38-47d2-484c-ba0b-f6174eb508ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_26a84641-0351-4435-853e-2d9c28676213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_27aec131-424f-4703-abb2-81c1cfb32c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_28c85cf7-f7fc-4376-b2ea-94cb2e1e8f60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_292c1c1e-5581-4c9b-8157-24e0d07be12b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2a8fdeac-e96f-4090-9037-5d3af26c4059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2da576e1-d49e-45c4-bfa3-24d20530d615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2fa726a6-4678-4715-b671-32d7fc4b3458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2fcaddbe-59b4-4dd8-acff-d235bcf3608a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_308b572c-bcec-40d0-86b6-45262da0d663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_30c42ef8-e350-413e-8d4a-0cb11d19dd8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_30e55683-04d9-41a0-bd33-67d960b1716c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">nuvb:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_331fb293-9d15-4ccd-b119-469a710b3daa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3321395a-631d-476b-8f7d-c59b5665b1b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvb:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_34e78618-c534-4284-bb6e-1a7b083eb1da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_36730653-ff82-4c63-a01f-ca2dd3b496b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_3757f3f2-4eb9-4da5-87da-348aee145967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="C_38dfcba2-bd95-458c-a352-b4df776e9ce0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39922b23-3d3c-4025-8814-7b066e6e395d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39d9ef20-3367-48ef-9bd5-5cb516f43747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3a62758c-8331-43c7-b65a-8ceaebefba74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b40daf5-2951-4982-9dc4-35739b254bf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="C_3c8db28e-2317-426a-ae9d-38906384d4dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3cb6dc20-b571-4ae0-9e67-6ab4aff1d9d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3cba4440-12d3-4ee9-9032-9e8572c8aa7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3d24e6c8-77cc-422b-ba78-255de1017179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:OtherThanUnitedStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3e12a88b-ec80-4a4c-95d8-aee1b5d352ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_412486e3-9ba5-40f0-bf1b-da7b97f1b931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_418e0a4f-214f-4bbb-a57c-9eed0f7d967b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_418fbc05-c30f-4227-9cfe-1386e01c9955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_42013ae0-ddac-4812-88ab-b99d2d7149ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44998c3a-718b-48fb-8220-6e156a09eee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44d82460-2e05-4f7c-9c55-b545075fb034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4681f739-9c28-49fc-bde8-0490bae0f771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_474282e8-2bd8-473d-b449-c1749a573ed7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:SanFranciscoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_484ef476-4e04-4c47-b500-750696fee41c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nuvb:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4b3274d8-aece-4320-b574-aac0c61b61d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4b9f43a9-9d6b-48e7-8cc3-ca1f86613de6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:ClassAAndClassBCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4d5e27ff-5781-4fd0-ad66-8f80196d9597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4e84c14b-26d4-4b95-88a1-d3d37077db29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4f00ab19-70eb-452a-a67c-0c577ad86cfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nuvb:AnheartMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="C_529b7cca-f4b7-4116-a505-7babb7b8fa92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_532ddbb7-20a6-413d-b66d-5c3445bb8db6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54b6680f-d764-4c4f-bd20-7ff2e11edc6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_54d22bf6-7851-4a61-9f26-acc23b794faa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nuvb:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_55955901-09db-418b-89e5-7cba4fc0a390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5634f3f1-5114-4a3c-9c5e-9f28b9b642a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nuvb:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_573fc90e-3384-4e88-bebb-411d7823adc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57ac3f3b-9cda-4711-b678-dd10a4a451ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5915e704-6a60-4fe4-b048-5cb37f86d627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubordinatedBorrowingAxis">nuvb:BorrowingTwoThousandsAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nuvb:LoanAgreementsWithBankOfHangzhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_59e21847-16f9-4084-92e3-35afa293d947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5bade152-78d3-45ae-93eb-5920249b2833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5c1f1a22-82b1-4d98-9857-c486ab81f376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5ed535ca-023f-4c23-9afe-8ae365dc24de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_5ef65c87-2f51-4661-a7fb-5e58e7086ef2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_60d2085a-baaf-4b22-8edb-e7cc340aab3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nuvb:ResearchAndDevelopmentServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_60d86b53-364b-4bb8-a244-c7731ef29c6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_612babb2-a261-40cd-b2ca-5ceb1ce31e71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_61525415-3259-4e81-b1a8-a96d13e75e0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_62336d85-1efb-4a6d-a379-5fc3378a8347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63c9b400-5728-40d4-a6f1-9117ecc729d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nuvb:InnoventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_64371941-b776-4c3c-ab99-a54d91207dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvb:CertificateOfDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_643df37d-2f04-4154-b398-b0bb4de05827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_66e37e69-8ac7-4c73-be34-2b5741857629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_673b8d54-13ef-4cf8-98c1-1882bd894e37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_68c26585-4b66-4439-9588-4c1bd035ebe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_694fe0ae-e3fc-4dfc-a41f-7d05ec59e408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69989213-f1c9-4257-8e6c-cc9e8660ba6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvb:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6a5444ea-1b3c-444f-8c39-856c8ccbdd74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6d9872a7-adc1-43ff-8f43-9e26797a3c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6ed882e8-da6b-4efe-bc8b-354008a8cc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nuvb:OptionsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6f054bef-1755-4a9e-b507-73b2cd109b47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6f4cfee1-80ef-4add-9e23-106b99b62a74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nuvb:ConsiderationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_70942f4b-acda-4d74-b1c9-cadcea492b15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-03</instant>
        </period>
    </context>
    <context id="C_70f4ad29-01fb-4717-94fc-a3ad777c8950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_71aaefa0-51ea-4664-bacf-7f5628476895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_77f61e72-e151-4de9-96f4-7091dc97bbc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7950894a-1811-4b80-ae40-787e405417b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nuvb:ConsiderationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_79e5ffa3-86c1-447a-bb2e-bece04e75439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001811063</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="U_sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_c256e67e-65b1-456e-8082-26044c0f9ea9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_1b365542-d97d-4178-852e-c4076abbdd7e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_be77b654-62d0-41a4-837f-fb3f4c1fd6cc">0001811063</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      id="F_f102744e-e5de-4779-9087-28320d26aca8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      id="F_bc4c8e53-d632-4d98-8fdd-d3c798496e59"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_a189c457-4057-42a0-8d13-77a284c68f72">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_312f2c6a-fc96-4cef-80c4-ebd9da92827d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_efe4dceb-03d1-413b-b754-9a8d2dcb7b6f">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d9cf69fa-fc41-41af-9514-6c63c6792881">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_fb1bf9cf-9a91-45ed-ae4d-ba21240da868">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_1a3878f3-9fec-4f6b-a6a0-e35fc398230f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_6dac8b3a-b7b9-4523-9048-b8aba6feb8d8">001-39351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_3d6d78b5-e616-4bde-9f00-e2d0fbb988e7">NUVATION BIO INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9d03e33b-f3c9-47e3-b807-cbd09d9e5d7b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b126628c-38e2-41c4-962b-318d1b62c6c9">85-0862255</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_58b94f6a-602a-4f92-b4cd-3be7ca134411">1500 Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_1b6d7c00-e6c2-46d9-a407-571151db0d81"> Suite 1401</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_afebbdcd-784f-4123-b4cc-def161680bce">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9ab5b006-cb6a-456c-b3ee-3e4bb17cae6c">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_5d5435db-a414-4187-ab96-c7b541b5627c">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_3cf2a0a1-ac1f-46a0-b85d-4f4c9b831e4f">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_32e620bc-edf7-4179-a8d1-e1faaf566fd0">208-6102</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      id="F_1715e657-fc10-462a-823b-b91f4275ba84">Class A Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816"
      id="F_9b8a8bd8-b653-4ecb-9dca-3152674f8ae7">Warrants to Purchase Class A Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      id="F_c5f0a450-f0e1-4f86-a1d9-cf471225e895">NUVB</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816"
      id="F_2e605851-1881-4a2c-9083-2e7b286e2200">NUVB.WS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      id="F_56a8db6d-0a27-4648-8090-3fbf2f75938c">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="C_c94e94bf-ab4d-4346-a7fa-f3e93887a816"
      id="F_2dd03639-78df-43c2-ba0c-4bd19399d0b1">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9a22469f-1a27-499f-951d-1d2a4c3e953c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_895fc282-4886-41dd-af22-0285ba11189e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_07bef960-3c02-48e4-9cc0-68acaae5813d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_369af07d-2631-4ffa-8318-391882853891">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_ecf1d241-af16-447a-8fa1-61049dd58e45">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_a2765452-d793-453a-bd1a-55614719afc4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_68c53109-34ad-49fe-9994-93d74413e138">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_eb494c83-0257-45b1-a8a9-6ee65fe6d508">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b6ec9839-cc52-48e1-b7eb-837debf014ee">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d95b60dc-3e57-4efb-a0fb-0c24a0e69a13">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_a4328f73-2497-4e2b-ab79-aaa0f3d84e59"
      decimals="-3"
      id="F_7970eb9e-8248-4aa4-a3fb-84ae4f1fce25"
      unitRef="U_USD">522742050000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_36730653-ff82-4c63-a01f-ca2dd3b496b8"
      decimals="INF"
      id="F_61c7ca43-37d0-49ad-b956-f875652dcd7e"
      unitRef="U_shares">337678855</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_11048d21-d2dd-4d6a-8603-844e4ce4caa3"
      decimals="INF"
      id="F_c215fe31-abc2-4c3f-8300-bc3c6383b13f"
      unitRef="U_shares">1000000</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9756ec20-3544-40c8-8f90-0e8f435f8fb8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain portions of the registrant's definitive proxy statement relating to the Company's Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_ce117189-0836-44cb-8e9c-4bac9608af83">&lt;p id="cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;bersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property and confidential information that is proprietary, strategic or competitive in nature.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee, together with our information security function and third-party service providers  help identify, assess, and manage the Company&#x2019;s cybersecurity threats and risks. Additionally they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#x2019;s risk profile using various methods including, for example using automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#x2019;s risk profile, evaluating threats reported to us, conducting internal and/or external audits,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;conducting threat assessments for internal and external threats, third party threat assessments, conducting vulnerability assessments to identify vulnerabilities, and using external intelligence feeds.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: cybersecurity-related policies and procedures (including incident response plans and policies, a vulnerability management policy, disaster recovery/business continuity plans), incident detection and response, periodic risk assessments, implementation of security standards/certifications, encryption of data, network security and system monitoring controls (including technology solutions such as antivirus, firewalls and monitoring tools), awareness training for all employees, security measures, asset management, tracking and disposal, penetration testing, cybersecurity insurance coverage, and a dedicated cybersecurity staff.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our assessment and management of material risks from cybersecurity threats are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into the Company&#x2019;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#x2019;s enterprise risk management program; (2) security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk, and (4) we have a cybersecurity incident response plan to identify, assess, respond to, and inform escalating levels of management based on the nature and severity of such incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party service providers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example Professional services firms, including legal counsel, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers (including SIEM tools and 24/7 managed detection and response), penetration testing firms, and dark web monitoring services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers to perform a variety of functions throughout our business,  such as application providers, hosting companies, and contract research organizations. We have a vendor management program to manage cybersecurity risks associated with our use of these providers.  The program includes a risk assessment for each vendor, a security questionnaire, review of the vendor's written security program, review of security assessments and other reports. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vendor management process&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the risks from cybersecurity threats that may &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affect&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company and how they may do so, see the section titled &#x201c;Risk Factors&#x201d; in Item 1A of this Annual Report on Form 10-K, including the risk factor titled &#x201c;&#x2014;Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or experience security breaches or other unauthorized or improper access.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for oversight of the Company&#x2019;s cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure, Operations and Cyber Security&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; who has  fifteen years of experience in the industry and oversees the Company&#x2019;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy,&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#x2019;s cybersecurity program.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and policies include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reporting to the audit committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors and audit committee receive periodic reports concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_4f46447b-1b56-4282-8b26-0e0ed3abcb41">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our assessment and management of material risks from cybersecurity threats are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into the Company&#x2019;s overall risk management processes. For example, (1) cybersecurity risk is addressed as a component of the Company&#x2019;s enterprise risk management program; (2) security management works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk, and (4) we have a cybersecurity incident response plan to identify, assess, respond to, and inform escalating levels of management based on the nature and severity of such incidents.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_ba83c675-0623-4d90-976b-65fda94f46c1">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_5148af86-a983-4a51-ac01-4640f7751850">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_60798e41-7935-409a-a7c0-73ebacc773e8">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_03618b92-aa4b-48a5-9916-d831e898beb7">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_00d3a543-f5ed-4640-b9b6-7fa5d92f0285">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for oversight of the Company&#x2019;s cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure, Operations and Cyber Security&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; who has  fifteen years of experience in the industry and oversees the Company&#x2019;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy,&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#x2019;s cybersecurity program.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and policies include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reporting to the audit committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors and audit committee receive periodic reports concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_37f2f9dd-31df-4a5f-94b8-353ad397c52f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for oversight of the Company&#x2019;s cybersecurity risk.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_dd5561ee-14e4-4c88-b829-969b00dc7027">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure, Operations and Cyber Security&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_a64b5aab-2c69-41aa-8fa3-f44639d038a6">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure, Operations and Cyber Security&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; who has  fifteen years of experience in the industry and oversees the Company&#x2019;s infrastructure, operations and cyber security, and our Vice President of Legal, who has expertise in legal, compliance and privacy matters.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_61ddaf5a-9acf-4f21-92e0-67c543ca564e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy,&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, reviewing security assessments and other security-related reports, and retaining assessors, consultants, auditors, or third parties in connection with the company&#x2019;s cybersecurity program.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and policies include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reporting to the audit committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors and audit committee receive periodic reports concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_4c9980b3-4910-4071-a021-5dfa75131cba">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Senior Director Infrastructure&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, Operations and Cyber Security is responsible for integrating cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy,&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_f7b9d1b8-dc19-4e8a-a765-b0135919220e">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_1e63d364-05e1-42cb-9974-c60c572c2154">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity incident response processes and policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Senior Director Infrastructure, Operations and Cyber Security, who works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and policies include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reporting to the audit committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors and audit committee receive periodic reports concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The  board of directors and audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9b7c172f-96a7-43db-bb1b-09b7a509cf1d">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorOpinionTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_f16a4597-5ab1-492b-88d0-fa9f801392c3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47"
      id="F_b0264d1c-acbb-4e5a-916f-281a909c40f7">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47"
      id="F_13fd8bad-3cc8-429f-8bce-1624c9e57321">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47"
      id="F_bd0f1e48-df28-4d27-8239-0528f4f55e94">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47"
      id="F_d0b9b147-ff31-4b12-a7d3-da4e5f558b58">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_6f054bef-1755-4a9e-b507-73b2cd109b47"
      id="F_a6c6d5b2-4c9a-44af-964c-9e60a30a78d4">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_64fc9965-089e-4f67-b7e0-be0deb59b3b0">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d3c726f2-b27b-4d01-bad9-b5e0e1af2b66">New York, NY</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_f0e088e6-9517-422d-87b3-467dd361d0be">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_9a75e01e-e5e7-4b8b-815c-28e5dbd65ef0"
      unitRef="U_USD">35723000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_c060ed18-c7f5-4edc-8a5d-0ad9a6dc395f"
      unitRef="U_USD">42649000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_203b54c4-bb50-4cfa-9a6a-6bb3487089ad"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_214bca7c-7308-47a2-b90a-a1404991a9ca"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_29ddd845-9187-41b2-b482-dd3c9d3ca03c"
      unitRef="U_USD">12722000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_8c5ddb8c-088f-48d3-b728-aca6d350a8d3"
      unitRef="U_USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_36832755-9324-41de-85da-9ffe082fe221"
      unitRef="U_USD">7271000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_fef66559-de6d-4e29-a260-05e8ef7ced4f"
      unitRef="U_USD">1519000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_1ac7e1d3-23bc-4c89-9919-c02a80f23f93"
      unitRef="U_USD">466969000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_a698cffa-dff8-4b4b-a747-8e939b6d1137"
      unitRef="U_USD">568564000</us-gaap:MarketableSecuritiesCurrent>
    <nuvb:InterestReceivableOnMarketableSecuritiesCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_d8d91337-f52a-40f8-93bb-3721baa6fb61"
      unitRef="U_USD">3570000</nuvb:InterestReceivableOnMarketableSecuritiesCurrent>
    <nuvb:InterestReceivableOnMarketableSecuritiesCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_02bfe2ac-dd94-4277-ad4f-dfe0548ad496"
      unitRef="U_USD">3702000</nuvb:InterestReceivableOnMarketableSecuritiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b328679c-9864-4ccc-917f-528a837e734b"
      unitRef="U_USD">526255000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_afccf4e1-d19e-4f83-a858-e53d0334d8e7"
      unitRef="U_USD">616434000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_ceb89de5-d717-4a24-a784-ede3e17daa02"
      unitRef="U_USD">874000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_9afd19e6-46e3-4b71-b268-503c79f2ee94"
      unitRef="U_USD">666000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_a57df3d8-9cf4-4f77-8170-b40c72c29ef0"
      unitRef="U_USD">586000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_86fb8170-dfe3-47f3-b6f4-6e047385ff9a"
      unitRef="U_USD">717000</us-gaap:PropertyPlantAndEquipmentNet>
    <nuvb:IntangibleAssetsNetOfAmortization
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_793b7257-6433-4354-b411-3c682e6d2aa1"
      unitRef="U_USD">448000</nuvb:IntangibleAssetsNetOfAmortization>
    <nuvb:IntangibleAssetsNetOfAmortization
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_bd96a65f-48c9-4f03-9b23-787f224dccee"
      unitRef="U_USD">448000</nuvb:IntangibleAssetsNetOfAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_48112ab6-2d2f-4051-85e9-7d146ba405c8"
      unitRef="U_USD">4622000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_c93798f9-1ca4-4500-80ec-089405f44c47"
      unitRef="U_USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <nuvb:LeaseSecurityDepositNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_6c10e6b1-91ce-40a2-9fb2-c7755215b5b9"
      unitRef="U_USD">145000</nuvb:LeaseSecurityDepositNoncurrent>
    <nuvb:LeaseSecurityDepositNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_ee961c56-bbbe-4224-ae44-049b71b3c595"
      unitRef="U_USD">141000</nuvb:LeaseSecurityDepositNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_9afabb97-7dec-45df-8b8d-7a9a1e0e4774"
      unitRef="U_USD">2402000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_10b6670f-ce8d-40a0-beef-b7532f89a23e"
      unitRef="U_USD">3605000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_095115e3-60e6-45da-b019-b60dfaf68263"
      unitRef="U_USD">6616000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_5ba5bcf2-2919-49b6-9d12-03ea6b479962"
      unitRef="U_USD">587000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_899828c3-edf9-4af5-88d1-07cd69e7741b"
      unitRef="U_USD">540626000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_bb111c47-ad3c-4dfb-b512-eeb3fa8e4a19"
      unitRef="U_USD">621484000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_75d761a2-a6f3-4630-a133-6628e838810f"
      unitRef="U_USD">6348000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_d6727c53-a187-480c-a18e-97fe3681ca6d"
      unitRef="U_USD">2209000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_df6013b4-9869-44b3-8a48-f036ad98b94c"
      unitRef="U_USD">1663000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_85e5a31f-90f8-4d3d-809b-21d8b622f20f"
      unitRef="U_USD">1972000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_271dec5d-71d9-45da-b770-d582f18fef17"
      unitRef="U_USD">11117000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_d1f72370-5a4e-45d9-822f-3a9da5bded49"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_85dc515a-3b6e-4f53-90cf-bc60a09c4536"
      unitRef="U_USD">6283000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_1a611ad6-63bd-450f-850c-5e0a09031d49"
      unitRef="U_USD">0</us-gaap:ShortTermBorrowings>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_2f977a52-f632-410f-84f4-dcf9abf18006"
      unitRef="U_USD">32833000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_57cf257f-0da6-4dee-baab-b2dcc4fb2ba8"
      unitRef="U_USD">9793000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_2d82400b-9e26-457c-bd73-714a3161303f"
      unitRef="U_USD">58244000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_60b64d5e-5c2f-430a-a11b-4ea47bf1e22b"
      unitRef="U_USD">13974000</us-gaap:LiabilitiesCurrent>
    <nuvb:WarrantLiability
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_1a753672-e0e0-4d64-a9fa-4f7543a06d42"
      unitRef="U_USD">2053000</nuvb:WarrantLiability>
    <nuvb:WarrantLiability
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_b88a3ff0-02b7-4f28-99d9-6e02571daa14"
      unitRef="U_USD">353000</nuvb:WarrantLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_2454e258-3e5a-46e6-9f06-ada98f9c1f77"
      unitRef="U_USD">15572000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_00ee1b51-b7d8-463f-9604-bc2d49b22634"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_60097fd9-dcf3-45cb-9301-acc1b8dc5cc1"
      unitRef="U_USD">969000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_09dd33e5-eb05-4fe4-8c38-2339968832f6"
      unitRef="U_USD">2035000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b2ced7da-eeb3-494d-b4b8-d24373a00689"
      unitRef="U_USD">76838000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_39f79dfd-6fef-45ba-87af-a0156e4129ec"
      unitRef="U_USD">16362000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_292c1c1e-5581-4c9b-8157-24e0d07be12b"
      decimals="4"
      id="F_de690f6c-ce18-44b5-8078-0fb211c49912"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3e12a88b-ec80-4a4c-95d8-aee1b5d352ca"
      decimals="4"
      id="F_5ded1d5a-72d5-482e-8d39-f8b7093aee27"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="4"
      id="F_427cabee-839f-434a-888c-7d5a133d5a5d"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="4"
      id="F_18475f50-30c4-49d1-9d34-9ed07ff586e9"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_292c1c1e-5581-4c9b-8157-24e0d07be12b"
      decimals="0"
      id="F_9a6e893e-7f91-4153-818d-d779d55f1092"
      unitRef="U_shares">1060000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3e12a88b-ec80-4a4c-95d8-aee1b5d352ca"
      decimals="0"
      id="F_b6c07015-d11f-4010-9e26-ad925a1339ec"
      unitRef="U_shares">1060000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4d5e27ff-5781-4fd0-ad66-8f80196d9597"
      decimals="0"
      id="F_f69a0e01-811a-418b-bff8-ae75a866daeb"
      unitRef="U_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6f4cfee1-80ef-4add-9e23-106b99b62a74"
      decimals="0"
      id="F_b0576026-90ba-4d0b-a11e-9f43af540baf"
      unitRef="U_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_23c3ae60-037a-4b82-a8ea-fb789a61b20b"
      decimals="0"
      id="F_10a02a33-4e5e-4df9-8562-4c3f52deeebb"
      unitRef="U_shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e59de91c-61ea-4944-9861-5e3a0c84322c"
      decimals="0"
      id="F_a875cf9b-4c23-4385-b4f9-b06766c91dbd"
      unitRef="U_shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="0"
      id="F_63023b1e-5a0a-4f42-9c6e-0d2cbfd2b72a"
      unitRef="U_shares">337837872</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="0"
      id="F_6b2b60c8-b3a0-4685-95d0-ca5edc331397"
      unitRef="U_shares">337837872</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f"
      decimals="0"
      id="F_f3a641bc-50e7-4ae1-96ae-174e682a8da4"
      unitRef="U_shares">336837872</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f"
      decimals="0"
      id="F_e977b119-1442-42b2-bbc6-ea86bce1bd7e"
      unitRef="U_shares">336837872</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_10ac330b-db11-468f-b855-d1877a78ce3f"
      decimals="0"
      id="F_bc0f4499-62dd-4e6c-88fc-ef0736ca01a6"
      unitRef="U_shares">1000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_10ac330b-db11-468f-b855-d1877a78ce3f"
      decimals="0"
      id="F_92b46357-f8fa-4e7e-8fe5-86352ccf4ddc"
      unitRef="U_shares">1000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="0"
      id="F_9b4df941-37b6-4d37-b536-1bdf9595bf8b"
      unitRef="U_shares">219046219</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="0"
      id="F_9e60de2e-95fd-44aa-b269-d96d80f26da4"
      unitRef="U_shares">219046219</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e781b479-dd2a-4691-8eb1-89cc93788c93"
      decimals="0"
      id="F_1e131096-d3f1-45ea-b87e-1c75d44dfa91"
      unitRef="U_shares">218046219</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e781b479-dd2a-4691-8eb1-89cc93788c93"
      decimals="0"
      id="F_f62d2b12-161d-4916-9ee1-f016996db1cc"
      unitRef="U_shares">218046219</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_42013ae0-ddac-4812-88ab-b99d2d7149ae"
      decimals="0"
      id="F_5e3bc3f4-d165-4915-9322-ad1630e2bd24"
      unitRef="U_shares">1000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_42013ae0-ddac-4812-88ab-b99d2d7149ae"
      decimals="0"
      id="F_b3c91d59-f452-4b92-a112-8a97affa2b25"
      unitRef="U_shares">1000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_45607dfa-64ba-431e-96be-5c6349672a23"
      unitRef="U_USD">1373958000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_198d38d7-2062-4c6f-9520-f2dcc74495ea"
      unitRef="U_USD">947745000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_c040b0ce-39bb-4768-adb5-b7bf6212465c"
      unitRef="U_USD">-910743000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_fe8009dd-c6e6-4f38-ac91-c32e91cf9b97"
      unitRef="U_USD">-342804000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_2e02311b-f0a5-4a0e-a298-e47dada460c8"
      unitRef="U_USD">573000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_b3a3e57f-bebd-4cdd-ac20-6a51bff4b03f"
      unitRef="U_USD">181000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_9ff89139-5514-47cc-915b-cbbcd154e003"
      unitRef="U_USD">463788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_f1dd74e5-edce-434e-999b-5526a3b551a5"
      unitRef="U_USD">605122000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_202bd83c-9ad3-4f92-a1e7-9f5f924b3636"
      unitRef="U_USD">540626000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_0ba53ac0-29ba-4e1f-961b-edbab74b2297"
      unitRef="U_USD">621484000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_3380096a-5030-471b-ba6b-8586b8b09ba5"
      unitRef="U_USD">7873000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_1eeb20e0-1c7a-403e-938e-3c6c430fa8b0"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_21fae73b-974f-41d6-8e8a-636bb84141f6"
      unitRef="U_USD">7078000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_fb286dd9-6201-4c9f-bcc2-0b4ad9dd974a"
      unitRef="U_USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_ff2eb0d5-f4c5-49e5-ab0b-ddd22acadfc3"
      unitRef="U_USD">795000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_5189a3bb-48ea-445f-bd49-0f97e898709a"
      unitRef="U_USD">0</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_9655db7d-6594-434f-aabc-0bc46769c67a"
      unitRef="U_USD">99119000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_f2aa4cf1-fb93-4ed9-8b02-3d77e816e79e"
      unitRef="U_USD">71289000</us-gaap:ResearchAndDevelopmentExpense>
    <nuvb:AcquiredInProcessResearchAndDevelopment
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_6ac2e149-4bfd-4370-a0cd-6475a14374d3"
      unitRef="U_USD">425070000</nuvb:AcquiredInProcessResearchAndDevelopment>
    <nuvb:AcquiredInProcessResearchAndDevelopment
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_3b5868e4-4fc9-4c5f-b368-09203388d607"
      unitRef="U_USD">0</nuvb:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_fec8a879-c288-4cee-b077-3cb4938899a6"
      unitRef="U_USD">69233000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_e87e2112-bbb9-499a-9e60-c8d5fd77b1d2"
      unitRef="U_USD">28533000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_72907b3b-6af2-4461-a190-5f786f309fd2"
      unitRef="U_USD">593422000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_4606dcaa-0352-49cf-8f05-0ffd5ea2aa0a"
      unitRef="U_USD">99822000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_2fb47511-4722-447b-9e33-3761f2f6f791"
      unitRef="U_USD">-592627000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_195168e2-6f4a-4d03-a207-7cca3371d9bd"
      unitRef="U_USD">-99822000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_b92a0af4-795a-47d7-b971-e90f9e52d4e1"
      unitRef="U_USD">27062000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_9a62af4a-5df5-4e5a-b670-160729c1a2e3"
      unitRef="U_USD">24611000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_4d968458-667d-4c2e-ad4e-8128549bac75"
      unitRef="U_USD">341000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_51e22113-bdb2-459c-a4cc-d628396029f4"
      unitRef="U_USD">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:ProfessionalFees
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_536d3c5e-34ae-4a80-bced-aaaf94e5ca4f"
      unitRef="U_USD">976000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_21392e47-974f-4af3-b1db-49e093ffaf96"
      unitRef="U_USD">949000</us-gaap:ProfessionalFees>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_eb4cf92e-113d-4d04-8862-42292e802456"
      unitRef="U_USD">936000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_abefb52b-8e54-4acc-bd58-4224cf779336"
      unitRef="U_USD">-497000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_68359078-5979-40b9-86c5-9038e7f3bcf7"
      unitRef="U_USD">-12000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_ebe6ad12-dac5-485e-a6d2-05df693ebd1d"
      unitRef="U_USD">-139000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_cccb2330-97a1-4336-95c4-dd5bffe0842d"
      unitRef="U_USD">109000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_3561a946-74bb-4c6a-8319-629d3b1c841f"
      unitRef="U_USD">0</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_9d063fb7-00c8-41a1-b42e-3bc2b3e3f636"
      unitRef="U_USD">24688000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_a6b78800-cfe4-4b97-804e-0e79a7180f49"
      unitRef="U_USD">24020000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_048f83b2-2b13-4aae-9cbc-d2ec87b1e139"
      unitRef="U_USD">-567939000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_b6a95e8c-9e5e-4221-8376-0a69ecbb83d5"
      unitRef="U_USD">-75802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_86a26cbc-1f4d-49c8-93db-a18e6fe9ad71"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_c63328c7-ceb8-483e-8fc7-de8192aa06f0"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_9e1e3924-f296-4c5c-b49e-86241d07eea2"
      unitRef="U_USD">-567939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_bfe429d0-eea5-4b38-ac88-0a5a491f0326"
      unitRef="U_USD">-75802000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="2"
      id="F_b4cfa408-36cd-490a-9dcf-dcbf73126dc8"
      unitRef="U_USDollarShare">-2.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="2"
      id="F_fa4a351f-e22b-41aa-b1ca-5113bc170380"
      unitRef="U_USDollarShare">-2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="2"
      id="F_b189d66d-e658-4f84-b6c8-1d298cd472a7"
      unitRef="U_USDollarShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="2"
      id="F_a543c521-716d-4fc5-b6a5-de18f78d15d5"
      unitRef="U_USDollarShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="INF"
      id="F_7a31ed06-4ce1-4be9-9c8b-8a540bacb95f"
      unitRef="U_shares">268772</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="INF"
      id="F_5b78cecd-eaaa-4951-ad55-97e09abc65ec"
      unitRef="U_shares">268772</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="INF"
      id="F_256a23a6-cd22-47f3-993f-2b8d5826bdd5"
      unitRef="U_shares">218880</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="INF"
      id="F_cf3e6df8-e011-46c0-b559-496cfbaaab01"
      unitRef="U_shares">218880</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_4da3d2b8-6d20-41bc-ab90-2ef8280911f3"
      unitRef="U_USD">-567939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_41a455ac-7b91-44ef-a195-c4f5464f2ee1"
      unitRef="U_USD">-75802000</us-gaap:NetIncomeLoss>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_9b116014-d788-415f-bbd5-397e93436cae"
      unitRef="U_USD">-537000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_4cff63d2-c90c-48be-8ef3-e81b8bcb7eea"
      unitRef="U_USD">0</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_a4cced9f-03be-4bbe-b2c0-1ca22baabf18"
      unitRef="U_USD">-145000</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_3f7b8f19-2364-4cef-8193-86c325fa1eb5"
      unitRef="U_USD">5707000</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_49230a78-a2a9-4d10-ac8f-df9a4979f518"
      unitRef="U_USD">-567547000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_88ecd2d9-cb82-4e98-b060-d5b3277a7a61"
      unitRef="U_USD">-70095000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_1b58aa7a-19df-4858-9619-311b52c1a5ca"
      decimals="0"
      id="F_745f9a34-fdda-4acf-b1d9-06ecb34a495d"
      unitRef="U_shares">217632699</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_f64c1371-e223-4a9e-939d-999f45e6fda0"
      decimals="0"
      id="F_d978bc6d-41cf-4b90-a87c-df78276d487c"
      unitRef="U_shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5bade152-78d3-45ae-93eb-5920249b2833"
      decimals="-3"
      id="F_7ceac582-8f1f-429b-8340-0b4ad495181d"
      unitRef="U_USD">927604000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6d9872a7-adc1-43ff-8f43-9e26797a3c00"
      decimals="-3"
      id="F_5bb349a5-c181-4ef7-aa92-0a1d9cdc155c"
      unitRef="U_USD">-267002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3a62758c-8331-43c7-b65a-8ceaebefba74"
      decimals="-3"
      id="F_e8a2282e-0eec-4402-85b6-6b2f2dde351a"
      unitRef="U_USD">-5526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053"
      decimals="-3"
      id="F_ad881f02-8125-49dc-be17-4a1541b9a38d"
      unitRef="U_USD">655076000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8e6407a5-bcf1-4464-971c-f6b91e19a697"
      decimals="INF"
      id="F_fec01bb9-c5f5-4496-95fd-8f1a5429aac3"
      unitRef="U_shares">215614</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_34e78618-c534-4284-bb6e-1a7b083eb1da"
      decimals="-3"
      id="F_0a236fc0-589a-4b8b-98e1-8f9e267bd837"
      unitRef="U_USD">375000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_1da789de-9e8b-460c-b2f0-dcdb29e1b73e"
      unitRef="U_USD">375000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <nuvb:IssuanceOfCommonStockForPurchaseUnderEsppShares
      contextRef="C_8e6407a5-bcf1-4464-971c-f6b91e19a697"
      decimals="INF"
      id="F_ae3cdfe7-9c34-4e19-86d4-0eb23fce8c1d"
      unitRef="U_shares">197906</nuvb:IssuanceOfCommonStockForPurchaseUnderEsppShares>
    <nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue
      contextRef="C_34e78618-c534-4284-bb6e-1a7b083eb1da"
      decimals="-3"
      id="F_d245fe06-65ad-4dcb-9c45-a82dabb8fe90"
      unitRef="U_USD">253000</nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue>
    <nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_a2c9a8d5-995c-4c34-aca0-460d9de4ff73"
      unitRef="U_USD">253000</nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_34e78618-c534-4284-bb6e-1a7b083eb1da"
      decimals="-3"
      id="F_44d55ed6-b137-4f89-ae64-225122d7ce20"
      unitRef="U_USD">19513000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_6773343e-e7f1-46ac-81c9-07ebfbd04efe"
      unitRef="U_USD">19513000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_aac49177-7f36-4ea5-b068-584c31c660b2"
      decimals="-3"
      id="F_08732515-b8f3-460c-9d0b-89ce6c17d1a2"
      unitRef="U_USD">-75802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_f246a3e4-ff6a-401f-be60-c24f1c364499"
      unitRef="U_USD">-75802000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_418e0a4f-214f-4bbb-a57c-9eed0f7d967b"
      decimals="-3"
      id="F_39f46942-6dbe-4d43-aba7-22688c037154"
      unitRef="U_USD">5707000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_5675f645-0407-4c90-aa82-7e169c6cb9b2"
      unitRef="U_USD">5707000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_044c0715-8d17-4f49-8eef-b09c4726ce1d"
      decimals="INF"
      id="F_900918d7-f25d-419d-8a74-b4c19a4f47c5"
      unitRef="U_shares">218046219</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_c53952fa-847c-4ce2-a41b-24de9e826c90"
      decimals="INF"
      id="F_75de169d-306d-455e-ba70-88c4e09983e8"
      unitRef="U_shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b8ceb7cf-3e46-43f2-a0e3-ded43479a354"
      decimals="-3"
      id="F_9ae4fa3a-636e-408a-94a2-c29db4a45906"
      unitRef="U_USD">947745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e6f673b3-21bf-40a8-945b-58d5fc5eb19a"
      decimals="-3"
      id="F_89e31425-02a5-465a-8c35-ba1ba28ad56f"
      unitRef="U_USD">-342804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e97bbbfd-29be-4b48-8399-0c877e55e63f"
      decimals="-3"
      id="F_831d7eac-9ee1-424f-84c8-25a4dd86436d"
      unitRef="U_USD">181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_c074f6d3-fdd6-47a1-bbe3-7eab310df87c"
      unitRef="U_USD">605122000</us-gaap:StockholdersEquity>
    <nuvb:IssuanceOfCommonStockForAnheartAcquisitionShares
      contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03"
      decimals="0"
      id="F_0ba8d5bc-0f8d-406f-86e5-c2c2d07ad393"
      unitRef="U_shares">27646255</nuvb:IssuanceOfCommonStockForAnheartAcquisitionShares>
    <nuvb:IssuanceOfCommonStockForAnheartAcquisitionValue
      contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"
      decimals="-3"
      id="F_891b916a-145b-4bb1-ac87-f21ff9273650"
      unitRef="U_USD">89297000</nuvb:IssuanceOfCommonStockForAnheartAcquisitionValue>
    <nuvb:IssuanceOfCommonStockForAnheartAcquisitionValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_4f2c384f-5b21-4283-ab74-b5ba83903d23"
      unitRef="U_USD">89297000</nuvb:IssuanceOfCommonStockForAnheartAcquisitionValue>
    <nuvb:IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares
      contextRef="C_484ef476-4e04-4c47-b500-750696fee41c"
      decimals="0"
      id="F_c9dcc7d3-28e1-4092-8783-1e7efdf9917f"
      unitRef="U_shares">851202</nuvb:IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartShares>
    <nuvb:IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue
      contextRef="C_eab07c10-f6ec-4739-8ac1-c72a472fe56e"
      decimals="-3"
      id="F_6876c8aa-ca00-4292-8bd0-90629fa1afbf"
      unitRef="U_USD">274938000</nuvb:IssuanceOfConvertiblePreferredStocksRelatedToTheAcquisitionOfAnheartValue>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_484ef476-4e04-4c47-b500-750696fee41c"
      decimals="0"
      id="F_68173b07-849d-44ee-821b-e27eaab839ca"
      unitRef="U_shares">-851202</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_eab07c10-f6ec-4739-8ac1-c72a472fe56e"
      decimals="-3"
      id="F_4224408b-42e9-454f-affb-4c9727c39e63"
      unitRef="U_USD">-274938000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03"
      decimals="0"
      id="F_f7309687-c144-4bb6-b4f8-241f4d4fd649"
      unitRef="U_shares">85120200</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"
      decimals="-3"
      id="F_751c9d01-9773-4bf5-978f-2be6b8c4297e"
      unitRef="U_USD">274938000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_92f2c451-3a54-4d7e-abb7-2c4a44d208e3"
      unitRef="U_USD">274938000</us-gaap:ConversionOfStockAmountConverted1>
    <nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue
      contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"
      decimals="-3"
      id="F_16c8d5cc-04c1-4171-8645-6e8c12ba58d8"
      unitRef="U_USD">24818000</nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue>
    <nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_1cb89fd8-51e9-4c17-875b-d3804b175630"
      unitRef="U_USD">24818000</nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisitionValue>
    <nuvb:IssuanceOfCommonStockForPurchaseUnderEsppShares
      contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03"
      decimals="INF"
      id="F_3ad9e691-a9b4-422f-ab67-7676983baac2"
      unitRef="U_shares">238982</nuvb:IssuanceOfCommonStockForPurchaseUnderEsppShares>
    <nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue
      contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"
      decimals="-3"
      id="F_cb387bf4-6437-405d-ab39-cbfde724d1db"
      unitRef="U_USD">427000</nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue>
    <nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_39d29d46-40f1-45b4-a826-2aaafb80dbdb"
      unitRef="U_USD">427000</nuvb:IssuanceOfCommonStockForPurchaseUnderEsppValue>
    <nuvb:IssuanceOfCommonStockForRsusVestedShare
      contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03"
      decimals="0"
      id="F_56fb691d-4484-4bc6-a76c-1f186c266463"
      unitRef="U_shares">618340</nuvb:IssuanceOfCommonStockForRsusVestedShare>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_86fcf68a-e1be-42a7-be3e-df1a3f615e03"
      decimals="INF"
      id="F_51633e4f-a2da-4456-ac88-40f3e496e42f"
      unitRef="U_shares">5167876</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"
      decimals="-3"
      id="F_cfbf4a48-856a-40d2-82be-c50dcdf7088b"
      unitRef="U_USD">4458000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_3f651544-b0ba-4931-b66c-c245920ccf16"
      unitRef="U_USD">4458000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_dfd16fa9-dd5e-4416-8c0b-ff7e2da8e53d"
      decimals="-3"
      id="F_b0351f57-b5e6-41ea-b449-b232b537593d"
      unitRef="U_USD">32275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_09f443ef-16fc-4015-b7c6-48683b354065"
      unitRef="U_USD">32275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_4e84c14b-26d4-4b95-88a1-d3d37077db29"
      decimals="-3"
      id="F_d144fd30-801c-4754-a39c-6d63ff211e91"
      unitRef="U_USD">-567939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_b7febf5e-9677-420f-b1fe-7aa35a429173"
      unitRef="U_USD">-567939000</us-gaap:NetIncomeLoss>
    <nuvb:CurrencyTranslationAdjustmentValue
      contextRef="C_e720fa47-bca7-4ca0-8f9f-5310a1a2429a"
      decimals="-3"
      id="F_bf4e42d6-95d8-42e9-b9f2-3c17734c2595"
      unitRef="U_USD">537000</nuvb:CurrencyTranslationAdjustmentValue>
    <nuvb:CurrencyTranslationAdjustmentValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_fb989c7a-b11e-4497-8de1-efbfed68b5f7"
      unitRef="U_USD">537000</nuvb:CurrencyTranslationAdjustmentValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e720fa47-bca7-4ca0-8f9f-5310a1a2429a"
      decimals="-3"
      id="F_68722e6a-ace9-4a09-83f9-5e14a9144e93"
      unitRef="U_USD">-145000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_6f21e8d0-684f-4b43-9e7a-5b2ea8d79166"
      unitRef="U_USD">-145000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_643df37d-2f04-4154-b398-b0bb4de05827"
      decimals="INF"
      id="F_0f6a31f2-9294-4cac-8670-787dd4591ba6"
      unitRef="U_shares">336837872</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_9bfa5b92-b29a-404b-9eb6-c8b1699ee7f0"
      decimals="INF"
      id="F_dfd9bc7b-808b-4599-a1ca-cdc059cef2d4"
      unitRef="U_shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e2513bc6-e23a-4295-b2e3-1e55986d0108"
      decimals="-3"
      id="F_21b2755b-63ce-426f-9a6a-4637e70ff6d7"
      unitRef="U_USD">1373958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_55955901-09db-418b-89e5-7cba4fc0a390"
      decimals="-3"
      id="F_3cc5b567-8357-49b0-aa42-b1d86b073031"
      unitRef="U_USD">-910743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ed404de3-f206-47f2-9ddc-6680cc0e8957"
      decimals="-3"
      id="F_84e5d39a-5302-4f06-8918-886cb6c34230"
      unitRef="U_USD">573000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_c7d28e09-378a-4d99-a320-134aa908c3b0"
      unitRef="U_USD">463788000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_64ad2d8a-dbaa-4c5c-ac27-eed85417ac07"
      unitRef="U_USD">-567939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_b1149169-a4ef-441c-803b-888823b133ab"
      unitRef="U_USD">-75802000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_73a36ab4-df61-4f85-b091-1410b8a0fdab"
      unitRef="U_USD">32275000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_fcc3d59c-65f1-4c16-b4c9-3cd7f437985c"
      unitRef="U_USD">19513000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_c092b8ad-79a6-4935-974c-41191db23e38"
      unitRef="U_USD">683000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_ed21e01b-e8f7-4ed9-8a13-66a788e8c21c"
      unitRef="U_USD">222000</us-gaap:DepreciationAndAmortization>
    <nuvb:NonCashLeaseExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_60886d93-a302-468c-a694-544dd5546cef"
      unitRef="U_USD">-172000</nuvb:NonCashLeaseExpense>
    <nuvb:NonCashLeaseExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_a4ea2a20-feed-4a9a-a469-96beab23c45d"
      unitRef="U_USD">-67000</nuvb:NonCashLeaseExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_e12a12f6-8fd6-4bc9-846c-73eec8bae6e0"
      unitRef="U_USD">936000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_cafa1b5d-ae53-413d-921b-181ee1d65fa4"
      unitRef="U_USD">-497000</us-gaap:FairValueAdjustmentOfWarrants>
    <nuvb:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_f2ae5e8e-9514-46c0-b43d-d99096024139"
      unitRef="U_USD">9000000</nuvb:AmortizationOfPremiumOnMarketableSecurities>
    <nuvb:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_283c6391-8487-4a29-a6be-da76eb0fca48"
      unitRef="U_USD">12057000</nuvb:AmortizationOfPremiumOnMarketableSecurities>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_81c7ce58-deb5-429d-839c-0286a4fe5a92"
      unitRef="U_USD">-12000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_4b0c27ba-470e-4b80-8980-ef2549906a0d"
      unitRef="U_USD">-139000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_4b4777b1-0b48-463d-b2d4-cc88617dacd4"
      unitRef="U_USD">-229000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_2ad00928-a406-4437-990f-9a20f7ca2d1e"
      unitRef="U_USD">-10000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <nuvb:AcquiredInProcessResearchAndDevelopment
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_4f7a8cb2-e952-4ed5-8e98-6ac281077be0"
      unitRef="U_USD">425070000</nuvb:AcquiredInProcessResearchAndDevelopment>
    <nuvb:AcquiredInProcessResearchAndDevelopment
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_24ff2bef-29f9-4bad-82e4-75b88d4d5cdb"
      unitRef="U_USD">0</nuvb:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_b814552b-d12c-4c45-9ead-c6a05539ed3f"
      unitRef="U_USD">12722000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_e58f6b8a-f2c2-4708-b514-3043f9f8bc60"
      unitRef="U_USD">-0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_92ada797-a0ec-4c1d-9a97-fdbb9b31575e"
      unitRef="U_USD">3010000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_1a4bd80d-2739-405f-9363-afff9172957f"
      unitRef="U_USD">-2300000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_fc3d7d64-b6a0-40b2-a303-f794496fb9f1"
      unitRef="U_USD">-132000</us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable>
    <us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_e5a6e4a6-033c-42bc-954b-1e3bf9740126"
      unitRef="U_USD">1217000</us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_b1756d72-354c-4459-b9ab-83bb1ac681b8"
      unitRef="U_USD">-4000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_4d899c36-dc67-4a61-b31c-f6e9687f9e46"
      unitRef="U_USD">-3000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_9d92391c-7b50-456c-b1c7-16fccb0301e4"
      unitRef="U_USD">6029000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_28ed75b0-154c-420c-991f-498cdbacec94"
      unitRef="U_USD">587000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_acbb6e39-c033-4ce8-90b7-feb97767ef57"
      unitRef="U_USD">-1654000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_1cd3f10d-1c91-49bf-8b81-a03bb9c68be6"
      unitRef="U_USD">70000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_3a57edb9-2c3f-4cb5-8dde-ff90badf2565"
      unitRef="U_USD">-3942000</us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_2c422fac-b380-4a2c-95ac-0d50d9dab826"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_13c2b5cb-7d8e-42fc-88b4-5a9bd7b30bcb"
      unitRef="U_USD">6838000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_f28459cc-1741-4d5e-baaf-085f8f5ffcc3"
      unitRef="U_USD">-23000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_e5b47a7b-2279-4142-b188-e37efb705d18"
      unitRef="U_USD">-130413000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_18fae18a-87cd-4b01-9a81-b745347fde8b"
      unitRef="U_USD">-67999000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_34b9d61b-e009-4115-9c16-25b1d446c2db"
      unitRef="U_USD">19862000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_662dfbf4-5608-4192-b58c-41e7128effbe"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <nuvb:TransactionCostsRelatedToAnheartAcquisition
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_38a0e12f-ae43-4941-a901-84cebab85760"
      unitRef="U_USD">-7434000</nuvb:TransactionCostsRelatedToAnheartAcquisition>
    <nuvb:TransactionCostsRelatedToAnheartAcquisition
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_e09f0112-e2bc-411c-8ca4-dbce9193e456"
      unitRef="U_USD">0</nuvb:TransactionCostsRelatedToAnheartAcquisition>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_446468b4-a2d2-45c6-bec9-1d9c767b4cc4"
      unitRef="U_USD">339645000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_01ea83c6-cbe7-4cc6-ba60-caf001c5aea1"
      unitRef="U_USD">703373000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_a4ffc699-5f8a-437a-b29c-482fd35f838b"
      unitRef="U_USD">450082000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_f75c4a48-9b9d-4efe-87a3-bf6ad986ad20"
      unitRef="U_USD">712349000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_629efb39-eaee-41ed-9999-fbb9050d2422"
      unitRef="U_USD">162000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_dfbdce12-59fc-4f45-afec-3b0442215950"
      unitRef="U_USD">69000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_dada74b9-420f-4870-821e-518f9107a7cf"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_a0b1e189-ab12-4126-ab56-e15b87b9f850"
      unitRef="U_USD">14000</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_a3103b1a-1308-417a-b276-0c77f32319ed"
      unitRef="U_USD">122703000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_edc8ac25-4fa7-4426-a5b0-3617ad11d52e"
      unitRef="U_USD">8921000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_e7958876-6d45-4d2a-a128-b953f1771b04"
      unitRef="U_USD">12609000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_10969d6e-47e6-4cab-8f52-f7453994b42f"
      unitRef="U_USD">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_f5a062e4-9ab0-4259-9dea-6672674c5270"
      unitRef="U_USD">17163000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_2e347e77-4034-47e5-8310-50d2141c0c72"
      unitRef="U_USD">0</us-gaap:PaymentsOfFinancingCosts>
    <nuvb:ProceedsFromIssuanceOfCommonStockUnderEspp
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_7f171f8d-5c32-450c-b8d9-3d2b8eeeabb9"
      unitRef="U_USD">-427000</nuvb:ProceedsFromIssuanceOfCommonStockUnderEspp>
    <nuvb:ProceedsFromIssuanceOfCommonStockUnderEspp
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_5abafe5a-45d6-4c70-8366-439fddce1329"
      unitRef="U_USD">-253000</nuvb:ProceedsFromIssuanceOfCommonStockUnderEspp>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_ac2c305c-cbd4-476d-bbc9-10c53d4345ee"
      unitRef="U_USD">4458000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_52ef267c-2ac8-4fb2-a215-47e5f8cab4c9"
      unitRef="U_USD">375000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_0fa84458-0330-427a-9b96-1ca4a14a6815"
      unitRef="U_USD">331000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_0caf983f-b8ef-4ae3-8b9b-49db821b245e"
      unitRef="U_USD">628000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_04ea3e4d-ba77-46b7-8a74-639e73fce073"
      unitRef="U_USD">453000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_09b099ef-1633-4aa0-a1b6-0e738310851f"
      unitRef="U_USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_72c6b950-8376-4f60-ada5-a52f3375228b"
      unitRef="U_USD">-6926000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_d09fc5e1-4b94-4bbe-8ab4-2f568ccea5e2"
      unitRef="U_USD">-58450000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_4c5f3f76-4b58-4ca8-b5ec-7f02c7fd10ef"
      unitRef="U_USD">42649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053"
      decimals="-3"
      id="F_77bd5038-df20-42ca-bf08-e09602a19eec"
      unitRef="U_USD">101099000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b7d4eb03-42af-461c-9025-41e83c6564df"
      unitRef="U_USD">35723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_8c4c9b25-1dad-43d7-84b1-73575f3f4c95"
      unitRef="U_USD">42649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_f002fd39-2230-46d7-ae45-8a5331dbfebe"
      unitRef="U_USD">341000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_3ae0766b-cc20-4b8e-8bbe-e96b4cbcabf4"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_1e9bb180-7d90-43b9-a513-0abf3830e27f"
      unitRef="U_USD">373000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_5aafc20b-57a7-45da-acb5-acc0e838e786"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_a7d700a3-553b-4188-a323-d498599d7fcd"
      unitRef="U_USD">620000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_70cd8c47-ab33-4fba-a3c8-4b81f0272df1"
      unitRef="U_USD">1216000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nuvb:OperatingLeaseLiabilityRecognized
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_58f52a1b-c70b-4729-b115-ba3b16371880"
      unitRef="U_USD">608000</nuvb:OperatingLeaseLiabilityRecognized>
    <nuvb:OperatingLeaseLiabilityRecognized
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_aa977e16-7831-4777-8b3a-dd37dc095e67"
      unitRef="U_USD">1216000</nuvb:OperatingLeaseLiabilityRecognized>
    <nuvb:IssuanceOfCommonStockRelatedToTheAnheartAcquisition
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_b60f400d-90bf-411c-a976-3e12d30aa2a3"
      unitRef="U_USD">89297000</nuvb:IssuanceOfCommonStockRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfCommonStockRelatedToTheAnheartAcquisition
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_99a7976c-6a72-47f6-bf8f-6477cc97ca21"
      unitRef="U_USD">0</nuvb:IssuanceOfCommonStockRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_d8f44f02-b5d8-43a8-a723-d685e8039451"
      unitRef="U_USD">274938000</nuvb:IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_64af6838-e5e5-48b4-a9bb-6753f2b86d01"
      unitRef="U_USD">0</nuvb:IssuanceOfConvertiblePreferredStockRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfWarrantsRelatedToTheAnheartAcquisition
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_40493f91-7c92-40d7-a2b1-49449f8f07b2"
      unitRef="U_USD">764000</nuvb:IssuanceOfWarrantsRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfWarrantsRelatedToTheAnheartAcquisition
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_52627db7-18bb-42e5-92b1-dda4c361346e"
      unitRef="U_USD">0</nuvb:IssuanceOfWarrantsRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_3924d147-3ebf-4d49-9f0d-33b71c4124ac"
      unitRef="U_USD">24818000</nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition>
    <nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_f86ca094-9283-4153-9181-a66a3a7c1363"
      unitRef="U_USD">0</nuvb:IssuanceOfReplacementAwardsRelatedToTheAnheartAcquisition>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_57e95ae1-65e8-4be9-bfbb-7cfe683a5f7e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nuvation Bio Inc. and subsidiaries (&#x201c;Nuvation Bio&#x201d;), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 10, 2021, (the &#x201c;Closing Date&#x201d;), Nuvation Bio Inc., a Delaware corporation (&#x201c;Legacy Nuvation Bio&#x201d;), Panacea Acquisition Corp. (&#x201c;Panacea&#x201d;), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (&#x201c;Merger Sub&#x201d;) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (&#x201c;Merger Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the &#x201c;Merger&#x201d;) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the &#x201c;Company&#x201d; or &#x201c;Nuvation Bio&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 9, 2024 (the "Acquisition Date"), the Company completed its acquisition of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands (&#x201c;AnHeart&#x201d;), pursuant to that certain Agreement and Plan of Merger (the "AnHeart Merger Agreement"), by and among the Company, AnHeart, Artemis Merger Sub I, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company, and Artemis Merger Sub II, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_f0420a8a-6b99-436e-b403-4b35d93dfbba">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 2. SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;a.	Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;b.	Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the balances of the Company and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;c.	Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company has an accumulated deficit of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;910.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and net cash used in operating activities was approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million for the year ended December 31, 2024. Management expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;502.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million. The Company believes that its existing cash, cash equivalents, and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that these consolidated financial statements are issued. The Company&#x2019;s research and development activities can be costly, and the timing and outcomes are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the progress of the Company&#x2019;s research and development activities and the level of financial resources available.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;d.	Significant Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;trial activities of the Company&#x2019;s products, the Company&#x2019;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company&#x2019;s products, the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#x2019;s ability to raise capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Except in China where taletrectinib is being commercialized by our partner Innovent, there can be no assurance that the Company&#x2019;s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and vendors and obtaining and protecting intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;e.	Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;f.	Functional Currency and Foreign Currency Translations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's reporting currency is the U.S. dollar ("USD"). The functional currency of the Company's subsidiaries incorporated in People Republic of China ("PRC") is Renminbi ("RMB"). The functional currency of the Company and its subsidiaries incorporated outside the PRC is USD. Transactions denominated in currencies other than the functional currencies are re-measured into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are re-measured at the balance sheet date exchange rate. The resulting exchange differences are included in the net loss of the statements of operations and comprehensive loss. Assets and liabilities of the Company with functional currency other than USD are translated into USD at fiscal year-end exchange rates. Equity amounts are translated at historical exchange rates. Income and expense items are translated at average exchange rates during the fiscal year. Translation adjustments arising from these are reported as foreign currency translation adjustments and are shown as a component of other comprehensive income (loss).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;g.	Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts, a money market mutual fund and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;h.	Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Debt securities have been classified as available-for-sale which may be sold before maturity as they are not classified as trading securities or as held-to-maturity securities. Marketable debt securities classified as available-for-sale are carried at fair value with unrealized gains or losses reported in other comprehensive income (loss). Exchange traded funds are equity securities, which are reported as marketable securities with readily determinable fair values, are also carried at fair value with unrealized gains and losses included in other (expense) income, net. Realized gains and losses on both debt and equity securities are included in other (expense) income, net.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For securities in an unrealized loss position, management considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. Management also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If management determines there is any other than temporary impairment, the entire difference between amortized cost and fair value is recognized as impairment through earnings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to credit losses primarily through its available-for-sale investments. The Company assesses whether its available-for sale investments are impaired at each reporting period. Unrealized losses or impairments resulting from the amortized cost basis of any available-for-sale debt security exceeding its fair value are evaluated for identification of credit losses and non-credit related losses. Any credit losses are charged to earnings against the allowance for credit losses of the debt security, limited to the difference between the fair value and the amortized cost basis of the debt security. Any difference between the fair value of the debt security and the amortized cost basis, less the allowance for expected credit losses, are reported in other comprehensive income (loss). Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for expected credit losses subject to the total allowance previously recognized. The Company&#x2019;s expected loss allowance methodology for the debt securities includes reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. As of December 31, 2024, the Company has not recognized an allowance for expected credit losses related to available-for-sale investments as the Company has not identified any unrealized losses for these investments attributable to credit factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest income includes amortization and accretion of purchase premium and discount. Premiums and discounts on debt securities are amortized on the effective-interest method. Gains and losses on sales are recorded on the settlement date and determined using the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;i.	Acquisition of assets and businesses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in GAAP, no goodwill is recognized and acquired in-process research and development is expensed in acquired in-process research and development expenses. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;j.	Concentration of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of customers&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Below customers represent more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.528%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.437%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.837%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Below customer represents more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's balances of accounts receivable as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;k.	&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets of generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for computers and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for furniture and equipment. The cost of leasehold improvements is amortized on the straight-line method over the lesser of the estimated asset life or remaining term of the lease. Maintenance costs are expensed as incurred, while major betterments are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;l.	Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and an impairment assessment may be performed on the recoverability or the carrying amounts. If an impairment occurs, the loss is measured by comparing the fair value of the asset to its carrying amount.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;m.	Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the Merger, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787,472&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants to purchase common stock outstanding, consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,791,639&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Public Warrants, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Private Placement Warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;833,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Forward Purchase Warrants (as defined below). Each whole warrant entitles the registered holder to purchase one share of our Class A common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the consideration for AnHeart, the Company issued warrants collectively exercisable for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,893,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A Common Stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;Consideration Warrants&#x201d;). The fair value of the Consideration Warrants was determined to approximate the public warrant trading price as of closing of the Acquisition, yielding a fair value of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;stockholder &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approval and otherwise have terms identical to those of the Company&#x2019;s outstanding Public Warrants. Accordingly, the Company classified the Consideration Warrants as liabilities, consistent with the classification of the Company&#x2019;s Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer based on the stockholder approval from the 2024 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;) on September 3, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluated Public Warrants, Private Placement Warrants, Consideration Warrants, and Forward Purchase Warrants (the &#x201c;Warrants&#x201d;) under ASC 815-40, Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders&#x2019; equity. Specifically, the settlement value of the Warrants is dependent, in part, on the holder of the Warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on our Common Stock, the Warrants fail the indexation guidance in ASC 815-40, which would preclude classification in stockholders&#x2019; equity. Additionally, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#x2019;s Common Stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Because not all of the Company&#x2019;s stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Warrants do not meet the conditions to be classified in equity. Since the Warrants meet the definition of a derivative under ASC 815, the Company recorded these Warrants as liabilities on the balance sheet at fair value upon the closing of the Merger, with subsequent changes in their respective fair values recognized in the consolidated statement of operations and comprehensive loss at each reporting date. The fair value of Consideration, Public, and Forward Purchase Warrants was determined using the closing price of the publicly traded warrants on the NYSE market.  The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (see Note 4).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;n.	Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies ASC Topic 606, "Revenue from Contracts with Customers" ("ASC 606") to account for its revenue transactions.  Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the five-step model. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.  Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.  Accounts receivable represent amounts invoiced and revenues recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;o.	Collaborative Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2018, the FASB issued Topic 808, "Collaborative Arrangements" ("ASC 808"): Clarifying the Interaction between ASC 808 and ASC 606. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard for all periods presented. The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. The Company assessed and determined that none of the collaboration agreements entered into during the periods presented were within the scope of ASC 808, as all of the agreements did not involve active participation by both parties in a joint research activity, and therefore did not qualify as collaborative arrangements under ASC 808.  The Company has determined that all the elements of the above collaborations are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. The Company recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.  The Company's collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If a license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from the portion of the transaction price allocated to the license at a point in time, when the license is transferred to the customer and the customer is able to benefit from the license.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development services&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs based on the use of an input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Customer options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A customer's right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or a discount. Optional future services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. The optional future services do not include a material right to be accounted for as performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's collaboration agreements include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company's collaboration agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company receives payments from its customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until the Company performs its obligations under the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a complete discussion of accounting for revenue, see Note 5, "Collaboration and License Agreements."&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;p.	Costs to Fulfill a Contract with a Customer&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not capitalized any costs for the years ended December 31, 2024 and 2023.  The Company is required to capitalize costs incurred to fulfill customer contracts. These costs are required to be amortized to expense on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates, compared to previously being expensed as incurred. Elements of the costs primarily include (i) payroll and other related costs of personnel related directly to the contract activities; (ii) costs related to pre-clinical testing and clinical trials such as payments to contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"), investigators, and clinical trial sites that conduct the contract activities; (iv) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses; and (v) other research and development costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;q.	Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in operating lease right-of-use, or ROU assets; current operating lease liabilities; and non-current operating lease liabilities on its balance sheets. The Company currently does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#x2019;s leases generally do not provide an implicit rate. The incremental borrowing rate is reevaluated upon a lease modification. The operating lease ROU asset also includes any initial direct costs and prepaid lease payments made less any lease incentives. The Company considered information available at the adoption date of  Topic 842, "Leases" ("ASC 842") to determine the incremental borrowing rate for leases in existence as of this date. The incremental borrowing rate used was the weighted average rate between secured and unsecured lending arrangement.  Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the option will be exercised. Variable payments included in the lease agreement are expensed as incurred. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company elected to apply each of the practical expedients described in ASC 842-10-65-1(f) which allow companies not to reassess: (i) whether any expired or existing agreements contain leases, (ii) the classification of any expired or existing leases, and (iii) the capitalization of initial direct costs for any existing leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term operating leases. A short-term operating lease is a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.  The Company also elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;r.	Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s operations are focused on oncology development activities. Substantially all revenues were derived from customers located in China and Japan. For the year ended December 31, 2024, the revenues derived from customers located in China and Japan were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nuvation's Chief Executive Officer is the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The CODM utilizes the Company&#x2019;s strategic product development roadmaps and financial models, as a key input to resource allocation. The CODM is regularly provided with actual, budgeted and forecasted expense information to make decisions on resource&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;allocation and assess performance of the business and monitor budget versus actual results using income from operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant expenses within income from operations, as well as within net income, include cost of revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss. Other segment items within net income include interest income, interest expense, investment advisory fees, change in fair value of warrant liability, realized loss on marketable securities and other expense, net, and income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-lived assets consist primarily of property, plant and equipment, net. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of long-lived assets were in the U.S. As of December 31, 2024, no individual country other than the U.S. accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% or more of these assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;s.	Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs incurred in connection with research and development activities are expensed as incurred. These costs include fees paid to consultants, vendors and various entities that perform certain research and testing on behalf of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new product compound, as well as pre-commercial milestone payments, are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new product compound did not also include processes or activities that would constitute a "business" as defined under U.S. GAAP, and the product candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval which meet the capitalization criteria would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. If the conditions enabling capitalization of development costs as an asset have not yet been met, all development expenditures are recognized in profit or loss when incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;t.	Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes compensation cost for grants of employee stock options using a fair-value measurement method, that is recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines the fair value of stock-based awards that are based only on a service condition using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, volatility, dividend yield, and expected life of the options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines the fair value of stock-based awards that are based on both a service condition and achievement of the first to occur of a market or performance condition using a Monte Carlo simulation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;u.	Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. The difference between the financial statement and tax basis of assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the years in which they are expected to affect taxable income. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of the tax provision. Returns for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;tax &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years beginning with those filed for the period ended December 31, 2018 are open to federal and state tax examination.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;v.	Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07&#x2014;Segment Reporting (Topic 280):  Topic 280 "Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted ASU 2023-07 effective December 31, 2024. The adoption of the guidance did not have a material effect on the Company&#x2019;s unaudited condensed consolidated financial statements. See Note 2(r) for further information on Nuvation's segment reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x2013; Income Taxes (Topic 740): "Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. This guidance is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_390356ad-a767-4e9e-a225-7e796900f36e">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;a.	Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_913a551e-982e-435a-a334-e1e2e2e36dac">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;b.	Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the balances of the Company and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <nuvb:LiquidityPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_c65a11b9-c97d-4da7-b04f-57ae21c77ab4">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;c.	Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company has an accumulated deficit of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;910.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and net cash used in operating activities was approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million for the year ended December 31, 2024. Management expects to continue to incur operating losses and negative cash flows from operations for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;502.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million. The Company believes that its existing cash, cash equivalents, and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that these consolidated financial statements are issued. The Company&#x2019;s research and development activities can be costly, and the timing and outcomes are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the progress of the Company&#x2019;s research and development activities and the level of financial resources available.&lt;/span&gt;&lt;/p&gt;</nuvb:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-5"
      id="F_c9f90a8e-061e-498e-aa12-da4508433718"
      unitRef="U_USD">-910700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_12704dee-aaa6-46f2-b95c-3bce15c26733"
      unitRef="U_USD">-130400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <nuvb:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-5"
      id="F_17f55eeb-405f-4a2a-ac93-2073c56142e8"
      unitRef="U_USD">502700000</nuvb:CashAndCashEquivalentsAndMarketableSecurities>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_264fcbbf-7357-4246-b257-a1d833b5848d">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;d.	Significant Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;trial activities of the Company&#x2019;s products, the Company&#x2019;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company&#x2019;s products, the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#x2019;s ability to raise capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Except in China where taletrectinib is being commercialized by our partner Innovent, there can be no assurance that the Company&#x2019;s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and vendors and obtaining and protecting intellectual property.&lt;/span&gt;&lt;/p&gt;</us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_7a332efa-08c8-40e6-8226-bee55abe234e">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;e.	Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_fd7107f3-85b7-44f4-b006-648a5953069f">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;f.	Functional Currency and Foreign Currency Translations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's reporting currency is the U.S. dollar ("USD"). The functional currency of the Company's subsidiaries incorporated in People Republic of China ("PRC") is Renminbi ("RMB"). The functional currency of the Company and its subsidiaries incorporated outside the PRC is USD. Transactions denominated in currencies other than the functional currencies are re-measured into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Foreign currency denominated financial assets and liabilities are re-measured at the balance sheet date exchange rate. The resulting exchange differences are included in the net loss of the statements of operations and comprehensive loss. Assets and liabilities of the Company with functional currency other than USD are translated into USD at fiscal year-end exchange rates. Equity amounts are translated at historical exchange rates. Income and expense items are translated at average exchange rates during the fiscal year. Translation adjustments arising from these are reported as foreign currency translation adjustments and are shown as a component of other comprehensive income (loss).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d38951e1-c150-495a-aca9-0073beae85e3">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;g.	Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts, a money market mutual fund and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_12e4a0fd-20c7-42dc-a98f-28ec5808fa0e">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;h.	Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Debt securities have been classified as available-for-sale which may be sold before maturity as they are not classified as trading securities or as held-to-maturity securities. Marketable debt securities classified as available-for-sale are carried at fair value with unrealized gains or losses reported in other comprehensive income (loss). Exchange traded funds are equity securities, which are reported as marketable securities with readily determinable fair values, are also carried at fair value with unrealized gains and losses included in other (expense) income, net. Realized gains and losses on both debt and equity securities are included in other (expense) income, net.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For securities in an unrealized loss position, management considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. Management also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If management determines there is any other than temporary impairment, the entire difference between amortized cost and fair value is recognized as impairment through earnings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is exposed to credit losses primarily through its available-for-sale investments. The Company assesses whether its available-for sale investments are impaired at each reporting period. Unrealized losses or impairments resulting from the amortized cost basis of any available-for-sale debt security exceeding its fair value are evaluated for identification of credit losses and non-credit related losses. Any credit losses are charged to earnings against the allowance for credit losses of the debt security, limited to the difference between the fair value and the amortized cost basis of the debt security. Any difference between the fair value of the debt security and the amortized cost basis, less the allowance for expected credit losses, are reported in other comprehensive income (loss). Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for expected credit losses subject to the total allowance previously recognized. The Company&#x2019;s expected loss allowance methodology for the debt securities includes reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. As of December 31, 2024, the Company has not recognized an allowance for expected credit losses related to available-for-sale investments as the Company has not identified any unrealized losses for these investments attributable to credit factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest income includes amortization and accretion of purchase premium and discount. Premiums and discounts on debt securities are amortized on the effective-interest method. Gains and losses on sales are recorded on the settlement date and determined using the specific identification method.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b0963bbb-c386-47b6-9516-6910d72b41b3">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;i.	Acquisition of assets and businesses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in GAAP, no goodwill is recognized and acquired in-process research and development is expensed in acquired in-process research and development expenses. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described in Note 3 to the consolidated financial statements, on April 9, 2024, the Company completed its acquisition of AnHeart. The Company accounted for the transaction as an asset acquisition since the lead asset represented substantially all of the fair value of the gross assets acquired&lt;/span&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_1346a31d-4de2-4d8a-9cfa-33302055000a">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;j.	Concentration of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of customers&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Below customers represent more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.528%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.437%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.837%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Below customer represents more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's balances of accounts receivable as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_fc9be060-84df-4ca4-a092-cd372c06a151">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Below customers represent more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's net revenue for the years ended December 31, 2024 and 2023. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.528%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.437%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.837%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Below customer represents more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company's balances of accounts receivable as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;k.	&lt;/span&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <nuvb:ConcentrationRiskThresholdPercentage
      contextRef="C_418fbc05-c30f-4227-9cfe-1386e01c9955"
      decimals="2"
      id="F_d44afd55-b777-4ea5-b442-cdfba63b014d"
      unitRef="U_pure">0.10</nuvb:ConcentrationRiskThresholdPercentage>
    <nuvb:ConcentrationRiskThresholdPercentage
      contextRef="C_b3a3ed53-7933-4dff-be9b-82cf2713934b"
      decimals="2"
      id="F_e6001ef7-0335-415c-949f-84ea3d1851d7"
      unitRef="U_pure">0.10</nuvb:ConcentrationRiskThresholdPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_4b3274d8-aece-4320-b574-aac0c61b61d0"
      decimals="-6"
      id="F_a9251d0a-4bce-40e6-b252-be3d7f8e70b2"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_da21c4c3-938d-42bc-bc80-ba4f2ce5c849"
      decimals="-3"
      id="F_bd67f466-f7b4-4780-9e8b-14974b203914"
      unitRef="U_USD">5148000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_fe9e98bb-bd80-487d-b08c-3e44af1635e2"
      decimals="-3"
      id="F_682a7db5-99c5-4c1d-b417-c508cf7ee786"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_07f313fd-524b-46d2-99aa-b951b4324490"
      decimals="-3"
      id="F_e1de9d75-29f7-46d5-b1be-b2611ae3c48a"
      unitRef="U_USD">2725000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_8fd6169f-7ab5-46a7-a6cc-3a2bc4eb6868"
      decimals="-3"
      id="F_64d95218-119c-450c-89df-0010330ddf6f"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <nuvb:ConcentrationRiskThresholdPercentage
      contextRef="C_6a5444ea-1b3c-444f-8c39-856c8ccbdd74"
      decimals="2"
      id="F_56ec0254-c4aa-4457-9c0f-f0a633ff471d"
      unitRef="U_pure">0.10</nuvb:ConcentrationRiskThresholdPercentage>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_f6d0b85e-30b4-4e3d-90ba-0b428c795f3b"
      decimals="-3"
      id="F_909de292-f65b-4ff0-9097-b67368ce7844"
      unitRef="U_USD">12610000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b38457e7-2352-415f-94a5-0b245c071ad5">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;k.	&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets of generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for computers and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for furniture and equipment. The cost of leasehold improvements is amortized on the straight-line method over the lesser of the estimated asset life or remaining term of the lease. Maintenance costs are expensed as incurred, while major betterments are capitalized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_abb8df07-b97c-4a48-aefb-b20f734b97a2"
      id="F_aaaf0e5b-0349-4a41-905e-6439d3dedd5b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8d9345df-39ad-447f-a1af-a822c985ade5"
      id="F_9b93fe89-713f-47c5-a83c-033b764d0dfa">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_5017bff3-d058-414b-a5b1-fc9aa8f48902">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;l.	Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and an impairment assessment may be performed on the recoverability or the carrying amounts. If an impairment occurs, the loss is measured by comparing the fair value of the asset to its carrying amount.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <nuvb:WarrantsPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_dc93a43f-60c8-425d-bb51-0e740c3fe9f5">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;m.	Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the Merger, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787,472&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants to purchase common stock outstanding, consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,791,639&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Public Warrants, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Private Placement Warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;833,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Forward Purchase Warrants (as defined below). Each whole warrant entitles the registered holder to purchase one share of our Class A common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the consideration for AnHeart, the Company issued warrants collectively exercisable for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,893,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A Common Stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;Consideration Warrants&#x201d;). The fair value of the Consideration Warrants was determined to approximate the public warrant trading price as of closing of the Acquisition, yielding a fair value of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;stockholder &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approval and otherwise have terms identical to those of the Company&#x2019;s outstanding Public Warrants. Accordingly, the Company classified the Consideration Warrants as liabilities, consistent with the classification of the Company&#x2019;s Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer based on the stockholder approval from the 2024 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;) on September 3, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluated Public Warrants, Private Placement Warrants, Consideration Warrants, and Forward Purchase Warrants (the &#x201c;Warrants&#x201d;) under ASC 815-40, Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders&#x2019; equity. Specifically, the settlement value of the Warrants is dependent, in part, on the holder of the Warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on our Common Stock, the Warrants fail the indexation guidance in ASC 815-40, which would preclude classification in stockholders&#x2019; equity. Additionally, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#x2019;s Common Stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Because not all of the Company&#x2019;s stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Warrants do not meet the conditions to be classified in equity. Since the Warrants meet the definition of a derivative under ASC 815, the Company recorded these Warrants as liabilities on the balance sheet at fair value upon the closing of the Merger, with subsequent changes in their respective fair values recognized in the consolidated statement of operations and comprehensive loss at each reporting date. The fair value of Consideration, Public, and Forward Purchase Warrants was determined using the closing price of the publicly traded warrants on the NYSE market.  The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (see Note 4).&lt;/span&gt;&lt;/p&gt;</nuvb:WarrantsPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="0"
      id="F_a25666f9-d6eb-414d-a29a-f283c7c2e9dd"
      unitRef="U_shares">5787472</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9"
      decimals="0"
      id="F_fcd83e10-89a2-40b8-9cf5-fa1eae4359a9"
      unitRef="U_shares">4791639</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_38dfcba2-bd95-458c-a352-b4df776e9ce0"
      decimals="0"
      id="F_03e706aa-68bc-44a7-a666-299039f36ca0"
      unitRef="U_shares">162500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7"
      decimals="0"
      id="F_b2dfb6dd-ae5e-4093-891b-b5b60dc17250"
      unitRef="U_shares">833333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="2"
      id="F_481c9285-2d3c-486d-b08d-f63dc8589fd4"
      unitRef="U_USDollarShare">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1"
      decimals="0"
      id="F_bfe4a714-e401-4890-b42d-79e67d363f24"
      unitRef="U_shares">2893720</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1"
      decimals="2"
      id="F_b0d5a97c-1d91-4b24-a450-f5fb79512db7"
      unitRef="U_USDollarShare">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nuvb:FairValueOfWarrantsTradingPrice
      contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1"
      decimals="2"
      id="F_918d200a-bfe4-4410-b6f1-981e6caeb826"
      unitRef="U_USDollarShare">0.26</nuvb:FairValueOfWarrantsTradingPrice>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b3e650d5-f0e2-430f-9a21-aaaef677ecd0">the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company&#x2019;s Common Stock.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <nuvb:RevenueRecognitionPolicyPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_0325db27-7ff5-4d46-8abe-07036bd3045a">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;n.	Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies ASC Topic 606, "Revenue from Contracts with Customers" ("ASC 606") to account for its revenue transactions.  Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the five-step model. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.  Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.  Accounts receivable represent amounts invoiced and revenues recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment.&lt;/span&gt;&lt;/p&gt;</nuvb:RevenueRecognitionPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_cff6cf32-59b2-4cf2-880c-648d3ee76160">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;o.	Collaborative Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2018, the FASB issued Topic 808, "Collaborative Arrangements" ("ASC 808"): Clarifying the Interaction between ASC 808 and ASC 606. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The Company adopted this standard for all periods presented. The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. The Company assessed and determined that none of the collaboration agreements entered into during the periods presented were within the scope of ASC 808, as all of the agreements did not involve active participation by both parties in a joint research activity, and therefore did not qualify as collaborative arrangements under ASC 808.  The Company has determined that all the elements of the above collaborations are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. The Company recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.  The Company's collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as contract liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If a license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from the portion of the transaction price allocated to the license at a point in time, when the license is transferred to the customer and the customer is able to benefit from the license.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development services&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services occurs based on the use of an input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Customer options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A customer's right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or a discount. Optional future services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. The optional future services do not include a material right to be accounted for as performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's collaboration agreements include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company's collaboration agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company receives payments from its customers based on billing terms established in the contract. Up-front payments and fees are recorded as contract liabilities (e.g., deferred revenue) upon receipt or when due until the Company performs its obligations under the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all our obligations under the agreement have been fulfilled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a complete discussion of accounting for revenue, see Note 5, "Collaboration and License Agreements."&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_47231fea-f02b-4a2e-b4cf-2395c446dbb7">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;p.	Costs to Fulfill a Contract with a Customer&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not capitalized any costs for the years ended December 31, 2024 and 2023.  The Company is required to capitalize costs incurred to fulfill customer contracts. These costs are required to be amortized to expense on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates, compared to previously being expensed as incurred. Elements of the costs primarily include (i) payroll and other related costs of personnel related directly to the contract activities; (ii) costs related to pre-clinical testing and clinical trials such as payments to contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"), investigators, and clinical trial sites that conduct the contract activities; (iv) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses; and (v) other research and development costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <nuvb:LeasesPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d5d6ed07-b1ee-4c16-b4b9-379e90702273">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;q.	Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in operating lease right-of-use, or ROU assets; current operating lease liabilities; and non-current operating lease liabilities on its balance sheets. The Company currently does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made on or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company&#x2019;s leases generally do not provide an implicit rate. The incremental borrowing rate is reevaluated upon a lease modification. The operating lease ROU asset also includes any initial direct costs and prepaid lease payments made less any lease incentives. The Company considered information available at the adoption date of  Topic 842, "Leases" ("ASC 842") to determine the incremental borrowing rate for leases in existence as of this date. The incremental borrowing rate used was the weighted average rate between secured and unsecured lending arrangement.  Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the option will be exercised. Variable payments included in the lease agreement are expensed as incurred. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company elected to apply each of the practical expedients described in ASC 842-10-65-1(f) which allow companies not to reassess: (i) whether any expired or existing agreements contain leases, (ii) the classification of any expired or existing leases, and (iii) the capitalization of initial direct costs for any existing leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term operating leases. A short-term operating lease is a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.  The Company also elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.&lt;/span&gt;&lt;/p&gt;</nuvb:LeasesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_3505eb3c-d432-4747-8bcf-36eea5ad1d79">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;r.	Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s operations are focused on oncology development activities. Substantially all revenues were derived from customers located in China and Japan. For the year ended December 31, 2024, the revenues derived from customers located in China and Japan were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue in 2023 since the acquisition of AnHeart completed in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nuvation's Chief Executive Officer is the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The CODM utilizes the Company&#x2019;s strategic product development roadmaps and financial models, as a key input to resource allocation. The CODM is regularly provided with actual, budgeted and forecasted expense information to make decisions on resource&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;allocation and assess performance of the business and monitor budget versus actual results using income from operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant expenses within income from operations, as well as within net income, include cost of revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss. Other segment items within net income include interest income, interest expense, investment advisory fees, change in fair value of warrant liability, realized loss on marketable securities and other expense, net, and income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-lived assets consist primarily of property, plant and equipment, net. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of long-lived assets were in the U.S. As of December 31, 2024, no individual country other than the U.S. accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% or more of these assets.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_30c42ef8-e350-413e-8d4a-0cb11d19dd8f"
      decimals="-5"
      id="F_cf81bfd2-eadf-45e4-ba96-8e1be9971e62"
      unitRef="U_USD">5200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f54ce4b1-75d3-4c3a-841f-2d8ce4cc5489"
      decimals="-5"
      id="F_74805c62-3606-402e-9195-7314358daa61"
      unitRef="U_USD">2700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_4b3274d8-aece-4320-b574-aac0c61b61d0"
      decimals="-6"
      id="F_318749d1-1c75-4404-84cf-20b01324cf43"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <nuvb:PercentageOfLongLivedAssets
      contextRef="C_a2bdff39-def8-4415-a8b5-6832e22064e8"
      decimals="2"
      id="F_1d3ff474-19e2-4deb-a9b5-e2c54d1edf6a"
      unitRef="U_pure">0.90</nuvb:PercentageOfLongLivedAssets>
    <nuvb:PercentageOfLongLivedAssets
      contextRef="C_3d24e6c8-77cc-422b-ba78-255de1017179"
      decimals="2"
      id="F_b69ee61a-c54a-4b74-9eef-4e39d25b3cd9"
      unitRef="U_pure">0.10</nuvb:PercentageOfLongLivedAssets>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_5a3ad3dd-9189-4589-ad00-fb635f036967">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;s.	Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs incurred in connection with research and development activities are expensed as incurred. These costs include fees paid to consultants, vendors and various entities that perform certain research and testing on behalf of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new product compound, as well as pre-commercial milestone payments, are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new product compound did not also include processes or activities that would constitute a "business" as defined under U.S. GAAP, and the product candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval which meet the capitalization criteria would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. If the conditions enabling capitalization of development costs as an asset have not yet been met, all development expenditures are recognized in profit or loss when incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_04b1c791-466d-4d0b-9e08-49eaa4d2de1b">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;t.	Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes compensation cost for grants of employee stock options using a fair-value measurement method, that is recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines the fair value of stock-based awards that are based only on a service condition using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, volatility, dividend yield, and expected life of the options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines the fair value of stock-based awards that are based on both a service condition and achievement of the first to occur of a market or performance condition using a Monte Carlo simulation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_07c2339a-d33c-4ae3-9e08-31b3f98bf663">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;u.	Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. The difference between the financial statement and tax basis of assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the years in which they are expected to affect taxable income. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of the tax provision. Returns for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;tax &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years beginning with those filed for the period ended December 31, 2018 are open to federal and state tax examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_984d7f58-e9ef-49cd-b0cf-27d8e94b3072">&lt;p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;v.	Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07&#x2014;Segment Reporting (Topic 280):  Topic 280 "Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company adopted ASU 2023-07 effective December 31, 2024. The adoption of the guidance did not have a material effect on the Company&#x2019;s unaudited condensed consolidated financial statements. See Note 2(r) for further information on Nuvation's segment reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x2013; Income Taxes (Topic 740): "Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. This guidance is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_213f0f05-cd53-489d-9c3b-00059790ff49">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 3. ACQUISITION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 9, 2024, the Company completed the acquisition of AnHeart. Pursuant to the terms of the AnHeart Merger Agreement, at the effective time of the First Merger (as defined in the Merger Agreement) (the &#x201c;First Effective Time&#x201d;), the Company issued to AnHeart securityholders (i) approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,646,255&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Common Stock, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Series A Non-Voting Convertible Preferred Stock of the Company, and (iii) the Consideration Warrants. The shares of our Series A Non-Voting Convertible Preferred Stock were automatically convertible into an aggregate of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,120,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Common Stock upon the approval of such conversion by the Company&#x2019;s stockholders in accordance with the rules of the New York Stock Exchange. Since the preferred stock was not mandatorily redeemable and the exception for a deemed liquidation event was not met, all of the outstanding convertible preferred stock was classified as mezzanine equity in the balance sheet at the Acquisition Date. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#x2019;s outstanding Public Warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 3, 2024, the Company held its Annual Meeting at which the Company&#x2019;s stockholders approved for the purpose of complying with the listing rules of the New York Stock Exchange, the issuance of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,120,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Common Stock upon conversion of Series A Non-Voting Convertible Preferred Stock issued in April 2024. Additionally, the Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting. The conversion of the Convertible Preferred Stock into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,120,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Common Stock was completed and those shares were issued and outstanding as of September 30, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the First Effective Time, (i) each option to purchase shares of Ordinary Shares (as defined in the Merger Agreement) of AnHeart (an &#x201c;AnHeart Option&#x201d;) held by a Continuing Company Service Provider (as defined in the Merger Agreement), whether or not vested, was assumed and converted into an option to purchase Class A Common Stock (each such option, an &#x201c;Assumed Option&#x201d;), and (ii) each restricted stock unit reflecting the right to receive Ordinary Shares of AnHeart (an &#x201c;AnHeart RSU&#x201d;) held by a Continuing Company Service Provider (as defined in the Merger Agreement) was assumed and became a restricted stock unit with respect to a number of shares of Class A Common Stock (each such restricted stock unit, an &#x201c;Assumed RSU&#x201d;). Each Assumed Option and Assumed RSU is subject to the same terms and conditions (including vesting and exercise schedule) as were applicable to the corresponding AnHeart Option or AnHeart RSU immediately prior to the First Effective Time, subject to limited exceptions set forth in the Merger Agreement. Any other AnHeart Option and AnHeart RSU that remained unexercised and outstanding as of immediately prior to the First Effective Time was canceled without payment. From and after the Effective Time:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the number of shares of Class A Common Stock subject to each Assumed Option was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart Option immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio (as defined in the Merger Agreement) and rounding down to the nearest whole number of shares;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the per-share exercise price for Class A Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per-share exercise price of each AnHeart Option, as in effect immediately prior to the First Effective Time, by (B) the Equity Award Exchange Ratio and rounding up to the nearest whole cent; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the number of shares of Class A Common Stock subject to each Assumed RSU was determined by multiplying (A) the number of Ordinary Shares of AnHeart that are subject to such AnHeart RSU immediately prior to the First Effective Time, by (B) 1.7551 and rounding down to the nearest whole number of shares.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The final allocable purchase price consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Class A Common Stock &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A Non-Voting Convertible Preferred Stock &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consideration Warrants &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assumed share-based awards &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total allocable purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;____________________________&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)     &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,646,255&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share as of the Acquisition Date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)     &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued at as-converted value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3)     &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,893,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants issued at the estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2641&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4)	 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp;amp; Assumed RSUs) attributable to precombination services.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We accounted for the transaction as an asset acquisition since the lead asset, taletrectinib, represented substantially all of the fair value of the gross assets acquired, which excludes cash acquired. At the Acquisition Date, we recorded a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million charge representing an acquired in-process research and development asset with no alternative future use in acquired in-process research and development expenses, of which the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;425.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of assets acquired primarily consisting of cash and liabilities assumed were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4f00ab19-70eb-452a-a67c-0c577ad86cfe"
      decimals="0"
      id="F_625821e9-a895-41bd-9406-b05388f003c4"
      unitRef="U_shares">27646255</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b2ddc1f0-c371-4813-af10-cf895f6e3373"
      decimals="0"
      id="F_f2ebdd81-4cb0-447a-9186-76bc04c74b1a"
      unitRef="U_shares">851202</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_cfda41d6-83a3-4e48-ba69-343cbe55f56b"
      decimals="0"
      id="F_273f18a9-7af6-4d1c-98c2-4a70bce1a5e3"
      unitRef="U_shares">85120200</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_70942f4b-acda-4d74-b1c9-cadcea492b15"
      decimals="0"
      id="F_570c4cee-9de2-4bd1-84ca-1714792dfef2"
      unitRef="U_shares">85120200</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_c982e94f-abaf-48a7-a575-7a406ffb1b30"
      decimals="0"
      id="F_0f08df6e-17d6-47f1-ab6b-4c2965952f29"
      unitRef="U_shares">85120200</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_7e44956a-35eb-4622-a9ca-72eed49667d5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The final allocable purchase price consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Class A Common Stock &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A Non-Voting Convertible Preferred Stock &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consideration Warrants &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assumed share-based awards &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total allocable purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;____________________________&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)     &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,646,255&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share as of the Acquisition Date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)     &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued at as-converted value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3)     &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,893,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants issued at the estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2641&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4)	 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp;amp; Assumed RSUs) attributable to precombination services.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <nuvb:AllocablePurchasePrice
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      decimals="-3"
      id="F_801b7957-e7ce-45ce-af71-3084ea02dc16"
      unitRef="U_USD">89297000</nuvb:AllocablePurchasePrice>
    <nuvb:AllocablePurchasePrice
      contextRef="C_1632c343-8902-43c4-8df1-34be8034ddec"
      decimals="-3"
      id="F_73151569-7198-451b-a2ba-1634232ea74a"
      unitRef="U_USD">274938000</nuvb:AllocablePurchasePrice>
    <nuvb:AllocablePurchasePrice
      contextRef="C_7950894a-1811-4b80-ae40-787e405417b7"
      decimals="-3"
      id="F_27913815-f03d-44ad-ae06-0585e506afd5"
      unitRef="U_USD">764000</nuvb:AllocablePurchasePrice>
    <nuvb:AllocablePurchasePrice
      contextRef="C_b84b1da0-aedf-4620-881d-35579afeb08f"
      decimals="-3"
      id="F_c9f3c6cf-2103-4802-bf64-c4e3996706c0"
      unitRef="U_USD">24818000</nuvb:AllocablePurchasePrice>
    <nuvb:AllocablePurchasePrice
      contextRef="C_28c85cf7-f7fc-4376-b2ea-94cb2e1e8f60"
      decimals="-3"
      id="F_5315ce0f-4d5b-47f8-9b89-1be9a5be8d2a"
      unitRef="U_USD">7434000</nuvb:AllocablePurchasePrice>
    <nuvb:AllocablePurchasePrice
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_3f9fbe51-75bc-4605-b4f8-44b3e9fb04a1"
      unitRef="U_USD">397251000</nuvb:AllocablePurchasePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      decimals="0"
      id="F_d02963a2-fc87-44d3-9f4b-063d0af6b3c3"
      unitRef="U_shares">27646255</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="2"
      id="F_230504a1-4f52-444e-90b2-2d9ba1c2e6fb"
      unitRef="U_USDollarShare">3.23</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1632c343-8902-43c4-8df1-34be8034ddec"
      decimals="0"
      id="F_d70d6f58-69f8-4212-ab12-0806d7afe9f5"
      unitRef="U_shares">851202</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_d630f863-0d98-4a3a-a20e-783e2c04a4e9"
      decimals="0"
      id="F_eddbdf85-cc64-492b-b980-d9f629c382aa"
      unitRef="U_USDollarShare">323</us-gaap:SharesIssuedPricePerShare>
    <nuvb:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="0"
      id="F_e804059d-202e-4f35-a9e9-f7ec157b9b3c"
      unitRef="U_shares">2893720</nuvb:StockAndWarrantsIssuedDuringPeriodSharePreferredStockAndWarrants>
    <nuvb:EstimatedFairValueWarrantPerShare
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_6ed9906f-5207-49ab-98e9-6dba7aee0d72"
      unitRef="U_USDollarShare">0.2641</nuvb:EstimatedFairValueWarrantPerShare>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
      contextRef="C_0f03a15b-3abb-4776-a53a-0c003dafb17a"
      decimals="-5"
      id="F_a459de90-e8fc-480d-be5a-d7692589c314"
      unitRef="U_USD">425100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_0f03a15b-3abb-4776-a53a-0c003dafb17a"
      decimals="-5"
      id="F_d6ae818a-4e0c-4d2d-a281-bebd90933b12"
      unitRef="U_USD">425100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_a7fd337a-9497-4d90-be00-2699c0401c1b"
      decimals="-5"
      id="F_100180d7-578b-4a9f-9bf0-67d5905bf29f"
      unitRef="U_USD">25800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_a7fd337a-9497-4d90-be00-2699c0401c1b"
      decimals="-5"
      id="F_de14e972-f420-4182-9c22-0884930789b6"
      unitRef="U_USD">53700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_4d42af2f-ab66-442c-808a-1514a40fef55">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 4. FAIR VALUE MEASUREMENTS AND MARKETABLE SECURITIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &#x2014; Unobservable inputs that reflect the Company&#x2019;s estimates of the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;following table presents information about the Company&#x2019;s marketable securities and the Warrant liability as of December 31, 2024 and 2023, measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company&#x2019;s Warrant liabilities are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;included &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;within the Level 1 and Level 3 fair value hierarchy.  The fair value of the Consideration, Public and Forward Purchase Warrants is determined using the closing price of the warrants on the NYSE market. The fair value of the Private Placement Warrants is determined using the Black-Scholes option pricing formula. The primary unobservable input utilized in determining the fair value of the Private Warrants is the expected volatility. The expected volatility was estimated considering observable Public Warrant pricing, the Company's own historical volatility and the volatility of guideline public companies.  &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have not been any transfers between the levels during the periods.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;595,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;574,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities consist primarily of U.S. government and government agency, certificate of deposits, commercial paper, corporate bond and municipal securities ("Debt Securities"). Based on the Company&#x2019;s intentions regarding its marketable securities, all Debt Securities are classified as available-for-sale and are carried at fair value based on the price that would be received upon sale of the security.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides the amortized cost, aggregate fair value, and unrealized gains (losses) of marketable securities as of December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.438%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.447%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;452,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;594,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;595,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the activity related to the net gains (losses) on marketable securities included in other income (expense) on the consolidated statements of operations and comprehensive loss were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net realized gains (losses) on available-for-sale securities were as follows:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Realized gains from sales of available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Realized losses from sales of available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net realized losses on marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables provide marketable securities with continuous unrealized losses for less than 12 months and 12 months or greater and the related fair values as of December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.412%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.295%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;199,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;236,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;287,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturity information based on fair value of the available-for-sale securities is as follows as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;After one year&lt;br/&gt;through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_56bf933e-1864-485f-a5bf-36e9b930e41a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have not been any transfers between the levels during the periods.&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;595,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;574,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3c8db28e-2317-426a-ae9d-38906384d4dc"
      decimals="-3"
      id="F_d1b909a0-6c9d-4f38-8130-6710d27a36e9"
      unitRef="U_USD">11549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_feb7f3f7-75e8-4c18-a40f-52dbffc94964"
      decimals="-3"
      id="F_5ba7bc15-f756-4c78-8392-b856813c823a"
      unitRef="U_USD">11549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_71aaefa0-51ea-4664-bacf-7f5628476895"
      decimals="-3"
      id="F_35e20580-1fc3-4ee9-8344-eddf98f873ec"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_c5581c71-90c7-436b-aaba-8f1f78e6dc28"
      decimals="-3"
      id="F_644c104b-8f30-4a41-84f0-73601ec927dd"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_5273dea5-2a4d-4235-8fc2-f4549dcf4b3b"
      unitRef="U_USD">11549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68"
      decimals="-3"
      id="F_e92e8bba-1362-417a-a01c-03c11332d623"
      unitRef="U_USD">11549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0"
      decimals="-3"
      id="F_d8ac75a9-73f1-44d2-8bbb-485c96cc7cc9"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"
      decimals="-3"
      id="F_2878228d-4cb0-489a-9f01-98a7452d0da8"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_c9f1f463-5f55-47a1-9453-fbf0d567770e"
      unitRef="U_USD">12642000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_1fe9b1fa-5c06-41bc-904a-8d55067e5f76"
      decimals="-3"
      id="F_cbf07409-16ab-4ebf-8e3e-4ec34ffbab05"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_2da576e1-d49e-45c4-bfa3-24d20530d615"
      decimals="-3"
      id="F_8cce1312-4e88-4bed-a1ef-8b3fe3ea1243"
      unitRef="U_USD">12642000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_64371941-b776-4c3c-ab99-a54d91207dee"
      decimals="-3"
      id="F_f5f34afd-e680-483a-aac9-897ea57b2505"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868"
      decimals="-3"
      id="F_97f27e4d-f34f-459c-9f8b-213c43cc225b"
      unitRef="U_USD">18227000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_02eea57f-659f-4ea9-a9be-e8bf4cf97e78"
      decimals="-3"
      id="F_1bbe9b14-cef6-46cc-af48-d025c609cbe1"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_79e5ffa3-86c1-447a-bb2e-bece04e75439"
      decimals="-3"
      id="F_39941429-ca8f-41f7-ba1a-b7088ce0191b"
      unitRef="U_USD">18227000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_9c555376-54aa-4690-a07a-8995c5f1de8e"
      decimals="-3"
      id="F_8c05d48f-b74a-4bfa-9b51-0a30f2f5a414"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_5a5c4c8c-3a89-4f7f-8655-01ed753b171d"
      unitRef="U_USD">355170000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_529b7cca-f4b7-4116-a505-7babb7b8fa92"
      decimals="-3"
      id="F_51083e92-894c-41da-9d33-9ab056474302"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_532ddbb7-20a6-413d-b66d-5c3445bb8db6"
      decimals="-3"
      id="F_8a61d069-890c-44b6-ab7c-5ac79aea3955"
      unitRef="U_USD">355170000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_f65e2027-f5ac-4490-8e99-bc62d9e131dd"
      decimals="-3"
      id="F_ba013076-0088-4084-9d80-c7e734d0f220"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_3dd9a8a6-53f9-43ab-b803-c117bd10aab0"
      unitRef="U_USD">80930000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_5c1f1a22-82b1-4d98-9857-c486ab81f376"
      decimals="-3"
      id="F_ee82d514-314f-40ac-8716-a6779f00196d"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_f04153c5-2436-41de-9120-dcd4ef68be2a"
      decimals="-3"
      id="F_1d84abf6-da52-4c40-b3c0-ac8a1928b9f4"
      unitRef="U_USD">80930000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0ec4baa0-50bf-4ee8-bab3-3ce9c13fadb7"
      decimals="-3"
      id="F_a025dc42-829f-4241-ae4e-ca37e1244c85"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_f8d8af87-5fa4-4855-91e6-47e98e4edc90"
      unitRef="U_USD">466969000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68"
      decimals="-3"
      id="F_14f8e422-83c1-42eb-ad65-bf452532321c"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0"
      decimals="-3"
      id="F_6f6c9fdc-b247-49a4-95d6-db0479b7f7cd"
      unitRef="U_USD">466969000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"
      decimals="-3"
      id="F_2267d2fc-3c29-49d0-a640-2504dc0d7d90"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <nuvb:TotalFinancialAssets
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_9db134bf-2208-489b-b90a-61c4d565c130"
      unitRef="U_USD">478518000</nuvb:TotalFinancialAssets>
    <nuvb:TotalFinancialAssets
      contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68"
      decimals="-3"
      id="F_3bd77373-05c6-4215-b850-b7b9715b0317"
      unitRef="U_USD">11549000</nuvb:TotalFinancialAssets>
    <nuvb:TotalFinancialAssets
      contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0"
      decimals="-3"
      id="F_6ca6465b-8d73-4f6b-978d-48c3f492bb12"
      unitRef="U_USD">466969000</nuvb:TotalFinancialAssets>
    <nuvb:TotalFinancialAssets
      contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"
      decimals="-3"
      id="F_8b1b9fb2-bddb-4842-908e-156e067581f3"
      unitRef="U_USD">0</nuvb:TotalFinancialAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_6d474c18-e1a3-4b11-afd4-38240fee7fed"
      unitRef="U_USD">2053000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_cea28e49-6b66-4c9b-9a3b-52a55ebd3e68"
      decimals="-3"
      id="F_a1aaad65-86c5-4920-a3ba-14adb1fbdfbc"
      unitRef="U_USD">1959000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_12b28d30-7841-4345-96a7-0f6603d08fb0"
      decimals="-3"
      id="F_24aa59d7-60f1-4156-a42a-c809f95304b7"
      unitRef="U_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"
      decimals="-3"
      id="F_67a25d57-0df3-4fc8-8d6c-0f57408099cb"
      unitRef="U_USD">94000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_66e37e69-8ac7-4c73-be34-2b5741857629"
      decimals="-3"
      id="F_74e69c5c-70a7-4c09-9aa8-5a5edd309cbf"
      unitRef="U_USD">20574000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_57ac3f3b-9cda-4711-b678-dd10a4a451ad"
      decimals="-3"
      id="F_62faf4dc-a074-467a-94c6-b38e769fa6fd"
      unitRef="U_USD">20574000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_8e8cdc8e-8210-4b4d-9cd5-f1a28755b54e"
      decimals="-3"
      id="F_c6a76582-0088-4aed-865f-ed3eb8eb44d9"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_54b6680f-d764-4c4f-bd20-7ff2e11edc6d"
      decimals="-3"
      id="F_c0635ded-dbfe-429f-874a-215c30109ebd"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_8bb07401-5e55-46ff-9f2a-19f68edc5ea6"
      unitRef="U_USD">4988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0dded1bb-24a8-4a81-9bbe-145757df1e2c"
      decimals="-3"
      id="F_897bcef7-6746-435d-b09f-d19e29931bc5"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f600fe9a-155a-446b-92c8-a7fc4ddd37e1"
      decimals="-3"
      id="F_dbbfe3c1-e593-4b5d-a8ec-deecae1289e1"
      unitRef="U_USD">4988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_17baa364-63a5-4662-be7d-3a569f3f9131"
      decimals="-3"
      id="F_6444b151-4dee-4205-9c95-ffb7292fc715"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_431b0390-e3d0-4532-a399-e05d326d8770"
      unitRef="U_USD">947000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_ce6f0d2b-c086-4763-b947-870bbe14d4f9"
      decimals="-3"
      id="F_b1f89724-49fc-4936-8bea-9a8e52c270f5"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_b5fad4a0-b4e2-4fff-9d5d-16ef79716219"
      decimals="-3"
      id="F_46a5902d-a983-48ee-9cf5-f54e2c02654f"
      unitRef="U_USD">947000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_952278b9-3008-410e-b399-83d1341da7e8"
      decimals="-3"
      id="F_f6c7fbfa-4c06-4978-b137-8a56c186e1fa"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_9ec7d6dc-861e-4e26-9f6d-cef18a65202b"
      unitRef="U_USD">26509000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_b432f621-66c8-4177-856f-0710048eeb24"
      decimals="-3"
      id="F_0ad6e56c-3efc-49e0-82d6-cb7f256f829c"
      unitRef="U_USD">20574000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283"
      decimals="-3"
      id="F_97bfe77d-f8b1-42ec-9dde-3711ef14f021"
      unitRef="U_USD">5935000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5"
      decimals="-3"
      id="F_d12ebce7-59ae-4df0-b130-521435c46df4"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_72ee47f0-6c8b-4d8e-aa3c-839589843176"
      unitRef="U_USD">10176000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_16f76ae8-82d8-4ad7-884d-2c31f5e8ddc5"
      decimals="-3"
      id="F_2e6f75d5-f894-4577-874e-394f7a427478"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_07229a6d-6da2-40c2-88a0-037159cfa57e"
      decimals="-3"
      id="F_84bc6ba3-f385-43fd-a1e7-eac17147daeb"
      unitRef="U_USD">10176000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b68630d3-6944-4401-9af4-dc2436cb5eb7"
      decimals="-3"
      id="F_738ca240-9679-4d03-bdf0-4510c22a70ab"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_123340e2-5dbf-486a-b045-170384ec3d42"
      unitRef="U_USD">23628000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_673b8d54-13ef-4cf8-98c1-1882bd894e37"
      decimals="-3"
      id="F_2b329acb-7b21-41dc-94b1-2669e313b477"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_8c1b26be-f804-4b3f-992e-e5e76af52068"
      decimals="-3"
      id="F_0d6d573f-2eb6-48c3-bc8a-aab05e36200f"
      unitRef="U_USD">23628000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_3cba4440-12d3-4ee9-9032-9e8572c8aa7e"
      decimals="-3"
      id="F_ea4180dd-299a-4534-a400-6b3341f86f4a"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_0767f530-2d7f-40a9-8c83-c1b28915046e"
      unitRef="U_USD">453175000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0dded1bb-24a8-4a81-9bbe-145757df1e2c"
      decimals="-3"
      id="F_91d4903b-aab0-4e16-a98d-0c5f999136a8"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_f600fe9a-155a-446b-92c8-a7fc4ddd37e1"
      decimals="-3"
      id="F_b06026dc-cfd0-472e-bee2-6ff50619246a"
      unitRef="U_USD">453175000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_17baa364-63a5-4662-be7d-3a569f3f9131"
      decimals="-3"
      id="F_95b759f9-17bb-4e43-a94a-be2b42cd2678"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_33cdcdf4-b79c-4096-a365-5b34d28e67f5"
      unitRef="U_USD">81585000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_ce6f0d2b-c086-4763-b947-870bbe14d4f9"
      decimals="-3"
      id="F_0126c36c-bb7d-41e0-a35b-cc26b5fb58f5"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b5fad4a0-b4e2-4fff-9d5d-16ef79716219"
      decimals="-3"
      id="F_a2de7a66-9c9c-46c8-a982-f5af8b38a944"
      unitRef="U_USD">81585000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_952278b9-3008-410e-b399-83d1341da7e8"
      decimals="-3"
      id="F_ed96ff1f-f2c5-4296-8e31-5bb30dc98a3d"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_e76e9347-f496-48ec-8f38-874d493c3e2e"
      unitRef="U_USD">568564000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b432f621-66c8-4177-856f-0710048eeb24"
      decimals="-3"
      id="F_5848a80f-4a7d-46a0-b2ef-482dbee4f984"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283"
      decimals="-3"
      id="F_91014a36-5505-48e0-b3e7-2ea8390e2d54"
      unitRef="U_USD">568564000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5"
      decimals="-3"
      id="F_3cd49ad0-5320-4122-be38-5e91865f2b7b"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <nuvb:TotalFinancialAssets
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_fdfaae88-136e-47dd-83fb-e720c0faff92"
      unitRef="U_USD">595073000</nuvb:TotalFinancialAssets>
    <nuvb:TotalFinancialAssets
      contextRef="C_b432f621-66c8-4177-856f-0710048eeb24"
      decimals="-3"
      id="F_6fdcf5b7-06b1-4de9-a2de-493a7e270839"
      unitRef="U_USD">20574000</nuvb:TotalFinancialAssets>
    <nuvb:TotalFinancialAssets
      contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283"
      decimals="-3"
      id="F_06918515-9408-45bb-bbca-392b242a2a5a"
      unitRef="U_USD">574499000</nuvb:TotalFinancialAssets>
    <nuvb:TotalFinancialAssets
      contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5"
      decimals="-3"
      id="F_537972ad-5577-4829-aeaa-402ce8cc7aef"
      unitRef="U_USD">0</nuvb:TotalFinancialAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_5ae0010d-d5e4-4dee-8a25-f6cdbd55a4da"
      unitRef="U_USD">353000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_b432f621-66c8-4177-856f-0710048eeb24"
      decimals="-3"
      id="F_b487c56f-0280-4b5d-9867-1617e7ee32ef"
      unitRef="U_USD">338000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_f1bab928-2d56-4296-a932-20dbf7274283"
      decimals="-3"
      id="F_6bb7df95-9cc9-47a1-be0f-f4d63897dadd"
      unitRef="U_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5"
      decimals="-3"
      id="F_4310be93-1ebd-4f81-a5bf-16d88c0d9548"
      unitRef="U_USD">15000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_0796cf9c-c456-4c6e-a406-417952d13c3e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides the amortized cost, aggregate fair value, and unrealized gains (losses) of marketable securities as of December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.438%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.684000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.447%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.687999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;452,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;594,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;595,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a"
      decimals="-3"
      id="F_eb8974ba-4bf8-4584-af71-ba06eb8abc9a"
      unitRef="U_USD">11549000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a"
      decimals="-3"
      id="F_272b1e46-9b08-4659-a5e8-394e9461532a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a"
      decimals="-3"
      id="F_9f1b485b-cd22-4776-b791-3e693dad5663"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f77ce2c2-1105-4078-a520-6f9949541a3a"
      decimals="-3"
      id="F_b57d290d-98ae-4326-9704-75e66d92994f"
      unitRef="U_USD">11549000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873"
      decimals="-3"
      id="F_7da80998-38ec-4249-8ad4-d94a7ea9a575"
      unitRef="U_USD">11549000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873"
      decimals="-3"
      id="F_f08df3ba-515b-42e8-a2ce-eb86576702bf"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873"
      decimals="-3"
      id="F_70199e28-629b-486b-b634-563039f6f882"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_acea1f01-0d21-43fb-b399-83953ae01873"
      decimals="-3"
      id="F_d946391c-cdf9-41f6-be11-dcceaa5352e8"
      unitRef="U_USD">11549000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa"
      decimals="-3"
      id="F_821bce0b-29c6-4d2c-8e98-8f51905cdfbe"
      unitRef="U_USD">12628000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa"
      decimals="-3"
      id="F_b9d5e866-2c3e-4ff2-986b-b6f3a46c53d3"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa"
      decimals="-3"
      id="F_89a31881-9e72-4545-b8b6-f92ea15d3da2"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_331fb293-9d15-4ccd-b119-469a710b3daa"
      decimals="-3"
      id="F_178b8d0f-5bda-4381-9207-ad2a06dee3bb"
      unitRef="U_USD">12642000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0"
      decimals="-3"
      id="F_6434383c-91b3-4640-aa40-9cdc44f85748"
      unitRef="U_USD">18200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0"
      decimals="-3"
      id="F_736e48f7-a954-456c-bf08-04412149c767"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0"
      decimals="-3"
      id="F_8ad82065-d6ec-4fdc-8cc4-b4be66ea8164"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6a3be12f-f11b-49ce-9e81-0d1e3deb7ab0"
      decimals="-3"
      id="F_1972502f-83a8-4f72-8850-ec444c291863"
      unitRef="U_USD">18227000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484"
      decimals="-3"
      id="F_7f2d4a89-a360-4dc9-beb4-2ac2215ce5b1"
      unitRef="U_USD">355214000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484"
      decimals="-3"
      id="F_57377c37-a32a-465d-aa75-7fbd8e330b79"
      unitRef="U_USD">436000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484"
      decimals="-3"
      id="F_42b45c4f-3fa9-4124-b367-2885453f4c46"
      unitRef="U_USD">480000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8480017c-198b-4473-b4ab-8b7816a14484"
      decimals="-3"
      id="F_a8ee1150-1a2e-47b7-a21f-abecaf9e3d5f"
      unitRef="U_USD">355170000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42"
      decimals="-3"
      id="F_31e97a18-0162-46da-9149-9593d13b4408"
      unitRef="U_USD">80891000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42"
      decimals="-3"
      id="F_a4744eff-f77f-44a5-8846-82f9c24552c1"
      unitRef="U_USD">119000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42"
      decimals="-3"
      id="F_c85a0a28-f9f0-493f-86dc-64399863aa0c"
      unitRef="U_USD">80000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f2f2e11f-457d-4548-b1f4-29ab8b916f42"
      decimals="-3"
      id="F_d137fea7-a7f4-4ce3-a27e-75070dbc120f"
      unitRef="U_USD">80930000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97"
      decimals="-3"
      id="F_978c5834-ea2e-4cbe-9507-7062ae014010"
      unitRef="U_USD">466933000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97"
      decimals="-3"
      id="F_91c4fd77-0671-4acf-9925-46d0ae470da6"
      unitRef="U_USD">596000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97"
      decimals="-3"
      id="F_256d5e81-427d-48d8-8654-a40e6a1acd6c"
      unitRef="U_USD">560000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a4f8039e-3fbd-4dd4-a9d1-439c53996e97"
      decimals="-3"
      id="F_cb1d34b3-6006-4ffc-9359-761b1389e53f"
      unitRef="U_USD">466969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_7b7a7cfb-86af-4532-a9ce-500216842f60"
      unitRef="U_USD">478482000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_7ae15019-f861-4e52-a362-310e78e59535"
      unitRef="U_USD">596000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_957ff2bb-7be3-41ef-bdc3-6036aab5079b"
      unitRef="U_USD">560000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_1c9fcac8-88f5-4e7e-bf43-c814db0cd38f"
      unitRef="U_USD">478518000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546"
      decimals="-3"
      id="F_865fbe4b-5bf3-4ed0-b956-c7da1f7b8fb1"
      unitRef="U_USD">20574000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546"
      decimals="-3"
      id="F_b4e2fe15-a9ad-4a43-9e10-48d34a15c579"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546"
      decimals="-3"
      id="F_a401640c-6615-4229-8080-ff67652d7d88"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b5f38a77-58df-4c07-a7ce-d20e2e695546"
      decimals="-3"
      id="F_1c1aa8a2-d180-481b-9559-62471187101c"
      unitRef="U_USD">20574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48"
      decimals="-3"
      id="F_d8bbe3b2-a439-4f60-bae3-16a851aab99e"
      unitRef="U_USD">4987000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48"
      decimals="-3"
      id="F_f0d22dd5-0348-41a6-8960-3ccd90b77a1e"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48"
      decimals="-3"
      id="F_19120425-2cb4-47b0-accc-6ba1e6e0f40d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c8b27a13-1edb-4b9b-a459-fd05b5c67f48"
      decimals="-3"
      id="F_1c36d4b9-6076-4728-976a-0f2a9bae745d"
      unitRef="U_USD">4988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104"
      decimals="-3"
      id="F_e5dbd01d-96cb-49c8-ba12-f95d4a6b80a9"
      unitRef="U_USD">947000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104"
      decimals="-3"
      id="F_5378f222-1110-4dde-8cb4-c923b42689a3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104"
      decimals="-3"
      id="F_f404c542-b28f-4322-abd1-9cc5d1ac146c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_45bd99ee-0de4-4372-982f-a8a5b1dc1104"
      decimals="-3"
      id="F_b3a93ed7-ec41-478f-a3ae-54b69e4bb924"
      unitRef="U_USD">947000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa"
      decimals="-3"
      id="F_ea3c4cfb-1cdb-43e5-b08e-84282627ec11"
      unitRef="U_USD">26508000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa"
      decimals="-3"
      id="F_074dad0e-8efd-44b7-93e8-ab2c960b5718"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa"
      decimals="-3"
      id="F_170ceb0d-f306-4552-86ea-b10605a47cb1"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ea1e7f50-2c20-4523-a96b-2219dc690dfa"
      decimals="-3"
      id="F_8a230eca-1c4c-448a-a650-65918458a064"
      unitRef="U_USD">26509000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2"
      decimals="-3"
      id="F_3d19d179-6f02-4904-83ba-3603b003635d"
      unitRef="U_USD">10171000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2"
      decimals="-3"
      id="F_ddb4af51-0eae-46fb-b2f6-5c74a69d6429"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2"
      decimals="-3"
      id="F_c8647bfc-cbd4-49fe-ba0e-c70b39888788"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_16579bb7-fa4c-4d55-a3b8-b6de4cc44fe2"
      decimals="-3"
      id="F_fa3fc681-7f28-4d98-b8e3-f42000ce01ed"
      unitRef="U_USD">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886"
      decimals="-3"
      id="F_8451ba9e-a14b-414f-9391-c4c954beaf85"
      unitRef="U_USD">23609000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886"
      decimals="-3"
      id="F_88f9d01b-7860-49b7-aae4-9c2409bcf864"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886"
      decimals="-3"
      id="F_f19c9c77-af2c-4631-9b3b-29e12c64388f"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fd25faa1-dc18-456c-8ff2-cfd565b81886"
      decimals="-3"
      id="F_7c37fa64-29b4-4efa-8c4d-da0e671a905f"
      unitRef="U_USD">23628000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_26a84641-0351-4435-853e-2d9c28676213"
      decimals="-3"
      id="F_4def715e-f23d-4d44-9a94-2e4012127d77"
      unitRef="U_USD">452813000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_26a84641-0351-4435-853e-2d9c28676213"
      decimals="-3"
      id="F_0149b638-311b-41cd-bd64-50218395b1e9"
      unitRef="U_USD">1095000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_26a84641-0351-4435-853e-2d9c28676213"
      decimals="-3"
      id="F_c9f5e9e4-8930-4eec-adcc-df9a0f8421ff"
      unitRef="U_USD">733000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_26a84641-0351-4435-853e-2d9c28676213"
      decimals="-3"
      id="F_aa92f94e-f1b0-4020-bd31-739f7e5d2f7c"
      unitRef="U_USD">453175000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c"
      decimals="-3"
      id="F_00813b2f-04ec-45af-8237-e16a9244d031"
      unitRef="U_USD">81791000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c"
      decimals="-3"
      id="F_ff953a08-5509-4a7e-9818-faf2c4d03845"
      unitRef="U_USD">68000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c"
      decimals="-3"
      id="F_d2b32e6c-2e39-4711-9016-d56aad670499"
      unitRef="U_USD">274000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6a34b80a-eca5-42dc-b2f5-36b7f79a202c"
      decimals="-3"
      id="F_3ee00702-50df-4029-be5a-6c9de3e8253a"
      unitRef="U_USD">81585000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6"
      decimals="-3"
      id="F_016035d6-a6e5-41b9-8b46-e8baa3a044ba"
      unitRef="U_USD">568384000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6"
      decimals="-3"
      id="F_ab9a660c-d6ab-4cf5-945d-ddfcc90154cd"
      unitRef="U_USD">1192000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6"
      decimals="-3"
      id="F_1878efb6-5eca-4c3a-b1fb-21d574cf33c2"
      unitRef="U_USD">1012000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f7673a20-f5ba-4ae9-81eb-7cea09a03af6"
      decimals="-3"
      id="F_336afa57-c81d-4b8e-ae18-7fb913f5e311"
      unitRef="U_USD">568564000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_0f640365-a6bc-4171-bcae-e6c0d6a45e5f"
      unitRef="U_USD">594892000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_fdd462bf-112e-47fa-8a9f-aaebe9925f35"
      unitRef="U_USD">1193000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_979cffd4-ffa8-4ffa-a077-0ba863c8e5f9"
      unitRef="U_USD">1012000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_c0b2bbfc-9710-4d5a-b69a-9390b1615bd8"
      unitRef="U_USD">595073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfRealizedGainLossTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_627d4ed9-9235-4f11-97df-0e799071fefb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the activity related to the net gains (losses) on marketable securities included in other income (expense) on the consolidated statements of operations and comprehensive loss were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net realized gains (losses) on available-for-sale securities were as follows:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Realized gains from sales of available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Realized losses from sales of available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net realized losses on marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRealizedGainLossTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_db0b125b-99bb-497f-bc8f-68551200e26a"
      unitRef="U_USD">41000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_952d7aa5-4961-4af7-890e-ab2fb2132a01"
      unitRef="U_USD">70000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_874ad33b-0a47-49e7-b709-9ed8d443837d"
      unitRef="U_USD">53000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_4c900e4d-666c-4aaa-b93e-fa72500824ce"
      unitRef="U_USD">209000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_8e604827-0977-491e-905c-ee5607907112"
      unitRef="U_USD">-12000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_9a758002-a5c1-4770-b083-96cf3709249d"
      unitRef="U_USD">-139000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_206bce17-301d-4630-a84e-069f0010a6a2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables provide marketable securities with continuous unrealized losses for less than 12 months and 12 months or greater and the related fair values as of December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.412%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.219%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.712%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.295%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.172%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="22" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;199,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;236,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;287,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_856eb7b8-10f0-440f-8ceb-bc13779daa90"
      unitRef="U_USD">243000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_f6afe8c3-a786-4636-8030-aa77091983f7"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_98aaff29-373b-403e-b896-05849cde8c49"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_153895c6-94cc-4c55-84f3-636e7bac628c"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_1f855074-6f92-4bd4-b1b8-00cca94f737f"
      unitRef="U_USD">243000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_895dde7c-b1b2-410d-8111-3e16385e4341"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_9fe5368e-fcfb-4b36-8593-4ef82e186a5e"
      unitRef="U_USD">111021000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_33263703-820e-4a8f-9507-bb719da2e8d5"
      unitRef="U_USD">398000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_beb66c42-d683-44ed-8b9e-4c344a1f2d99"
      unitRef="U_USD">45099000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_18f566c4-2fde-42ff-8e3f-c716df5fd334"
      unitRef="U_USD">82000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_d21d9f7d-682c-455d-b7fc-fe81b6741ae4"
      unitRef="U_USD">156120000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_86b1261e-2530-44a9-8aab-766480dac51b"
      unitRef="U_USD">480000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_5e986897-a71b-49c8-a3bc-a4d89be2e59b"
      unitRef="U_USD">20659000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_3104536b-c566-4c2e-95b0-977d5df38ab6"
      unitRef="U_USD">33000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_83f991f2-d892-4f53-854f-08fdd1920043"
      unitRef="U_USD">9911000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_b100c444-cd99-42ef-9e71-a7116902a1b2"
      unitRef="U_USD">47000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_2068d7ed-7ee0-41ae-abe3-60009496137c"
      unitRef="U_USD">30570000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_8d91016c-657e-4242-a6a0-5a43e365113d"
      unitRef="U_USD">80000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_fbface63-2046-4fe6-a170-9d4a913ea4db"
      unitRef="U_USD">131923000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_a0f5d72c-e66b-4a67-bec0-6fb3cf0c37dc"
      unitRef="U_USD">431000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_84c87568-bf3e-4bb2-851c-2ebfca8ec5d7"
      unitRef="U_USD">55010000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_6cdb52b7-0708-4d6b-afe2-50539399133b"
      unitRef="U_USD">129000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_ca849331-8409-43c8-9017-f7cb53cfc48c"
      unitRef="U_USD">186933000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b6f16b7b-142f-4368-8720-e4800ca501f0"
      unitRef="U_USD">560000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_dcd72ffb-d883-470e-8f14-e0f9e1d9e7fb"
      unitRef="U_USD">5693000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_75f44bde-2416-4036-96b2-4cd8b6a10ebd"
      unitRef="U_USD">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_db4c2be2-c721-405a-8876-58639379dbd8"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_bfefb7c9-cd9d-4ade-9ad2-5ada53d05c21"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_5b1aeef8-edce-413d-91bd-0c5f334b50a7"
      unitRef="U_USD">5693000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_933286c8-e34a-49bc-beba-8abcc047b16c"
      decimals="-3"
      id="F_f34537c0-0228-4b69-9efb-46070cfc7c03"
      unitRef="U_USD">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_a0ac895a-3be9-4569-af22-02b67b8152b8"
      unitRef="U_USD">9101000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_af45f56d-d964-47a0-ba07-3bd80b082782"
      unitRef="U_USD">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_8996358b-fd49-4004-b2d8-236703228589"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_8d590c0f-9551-4568-b10f-195644b884c0"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_ab0abfa9-43bd-4f02-9598-c26aca4598c3"
      unitRef="U_USD">9101000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_d3cb777d-7311-46f3-bc92-9213fe38a5cc"
      decimals="-3"
      id="F_b448b848-6bd6-4822-acfc-21ba565746c0"
      unitRef="U_USD">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_9726097e-99b7-4b6a-a654-11071fd8a4ed"
      unitRef="U_USD">199552000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_2670f60c-1cbe-4fda-a810-1e0750a1760d"
      unitRef="U_USD">694000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_583d45fc-39ec-4e44-865f-577bac8c2746"
      unitRef="U_USD">24761000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_f634e3d4-cba7-4915-915c-351afd5dc71f"
      unitRef="U_USD">38000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_6381b9c9-5f79-4bcd-8b2d-bb59812324a6"
      unitRef="U_USD">224313000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_a71ef24e-0191-49b4-bc15-7c7bccfa4401"
      decimals="-3"
      id="F_31a21142-1f5f-4ae5-bb29-26f27b2d6e41"
      unitRef="U_USD">732000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_a5a45524-b22d-4d79-93a4-09b0d23a04a2"
      unitRef="U_USD">21844000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_7d11ca76-e556-4f7b-b1eb-e4e49e9d324f"
      unitRef="U_USD">28000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_0ccf6180-d2e6-49cb-a978-8a0997654076"
      unitRef="U_USD">26484000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_714236f0-19c4-467e-b719-35834f6ba6ba"
      unitRef="U_USD">246000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_7f3714c4-2262-4fbb-b562-b8f25bf7025c"
      unitRef="U_USD">48328000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_23ae5e67-6286-4db9-b7a3-bdb2076dc741"
      decimals="-3"
      id="F_2b406dd7-0368-4bc4-80ee-ffc42a82847a"
      unitRef="U_USD">274000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_476d9a55-4232-42bc-86bc-a36ef63e2a3c"
      unitRef="U_USD">236190000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_a3999450-39d6-4119-9271-59cc737190a6"
      unitRef="U_USD">727000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_4d3a179e-7d39-4f7a-8d77-7d6db86b3572"
      unitRef="U_USD">51245000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_be52b51a-d04f-4004-ab5d-a15e73241476"
      unitRef="U_USD">284000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_338c0553-5c74-4d73-9816-f3ec9779b40e"
      unitRef="U_USD">287435000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_2e195504-4c11-49bf-82ac-86ac5355bee1"
      unitRef="U_USD">1011000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <nuvb:ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_80845963-bf01-47e6-9a05-fb5fc988f158">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturity information based on fair value of the available-for-sale securities is as follows as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;After one year&lt;br/&gt;through five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government and government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</nuvb:ScheduleOfAvailableForSaleSecuritiesClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_7ffeee7d-f21b-4a17-acce-ae6be3aac6df"
      unitRef="U_USD">12642000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_2b0f0b39-be94-4aea-b244-6b526269fc15"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_19e7e972-cc1a-419a-b602-22f9acb2d4fa"
      decimals="-3"
      id="F_0dd16c63-8036-46cb-bc34-40bb405b0992"
      unitRef="U_USD">12642000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868"
      decimals="-3"
      id="F_196800ff-6632-4ae3-8518-57625659ce64"
      unitRef="U_USD">18227000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868"
      decimals="-3"
      id="F_77c76aef-0ddd-409c-9a2a-60c87c165e72"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_b15e2718-f40d-4bdc-b3db-1dc125497868"
      decimals="-3"
      id="F_54f0a3d8-b295-46ee-84fa-3f24c1dd97db"
      unitRef="U_USD">18227000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_257477d6-11db-4458-a00c-7b8ed85d6426"
      unitRef="U_USD">300295000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_252ea92a-9c2c-4764-86a6-9cc30717ef37"
      unitRef="U_USD">54875000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_5c20daec-2973-4bf0-afc3-2fa24dd2a228"
      decimals="-3"
      id="F_d128d04b-ef9e-4621-a032-99f691eabd21"
      unitRef="U_USD">355170000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_12caa9ee-afbd-4fe2-8b72-04439778ff60"
      unitRef="U_USD">52865000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_244d02a1-36a9-4691-920e-0fb09e8aed56"
      unitRef="U_USD">28065000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_48c47ce9-4d9f-4243-8ce4-e905a91f5685"
      decimals="-3"
      id="F_86ca1121-9158-43e4-9d5e-ffe3e858af9f"
      unitRef="U_USD">80930000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b05d3f9b-f7fe-4acb-90a2-b7621c952848"
      unitRef="U_USD">384029000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_41945ea7-a76d-4529-bf3e-ca057c9e5589"
      unitRef="U_USD">82940000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_ea2548cb-94c0-409f-8fef-cc1aeb973e05"
      unitRef="U_USD">466969000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <nuvb:CollaborationAndLicenseAgreementsTextblock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_fccdb240-df7b-471f-b578-136b01b9d4ad">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 5. COLLABORATION AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into collaborative arrangements for the research and development, and commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license and in-license compound to other parties. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost reimbursement arrangements and royalty payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;In-Licensing Arrangements with Daiichi Sankyo Company Ltd. ("DS")&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments and royalty payments. All upfront and development milestones were expensed in research and development expense as incurred. We have reached &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milestones in 2024, which require payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to DS under the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Out-Licensing Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's revenue related to its out-licensing collaborative agreements consist of upfront license fees and research and development services revenue from its collaboration agreements with Innovent Biologics Co. Ltd. ("Innovent") and Nippon Kayaku Co., Ltd. ("NK") for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Taletrectinib &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("AB-106").&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes total revenue recognized for the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.919999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There was no revenue for 2023 since the acquisition of AnHeart completed in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Exclusive License Agreement with NewG Lab&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2020, AnHeart entered into an agreement with NewG Lab. under which they will grant a sub-licensable, royalty-bearing, exclusive right and license to NewG Lab to develop and commercialize AB-106 in Korea (the " NewG Lab Territory"), with NewG Lab responsible for funding ongoing clinical trials of AB-106, regulatory submissions after development and for commercialization upon regulatory approvals. They also granted NewG Lab the option to obtain the same aforementioned rights to AB-106 in Malaysia (the "NewG Lab Option").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During July 2024, the Company terminated the agreement with NewG Lab.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaboration and License Agreement with Innovent&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2021, AnHeart entered into an agreement with Innovent, granting Innovent a sub-licensable, royalty-bearing, exclusive right and license to commercialize AB-106 in the People's Republic of China and Taiwan (the "Innovent Territory"). AnHeart is responsible for funding ongoing clinical trials of AB-106, regulatory submissions after development with Innovent responsible for commercialization upon regulatory approvals. They also granted Innovent the option to obtain a license to commercialize AB-329 once they provide proof of concept behind the compound in a region in the Innovent Territory (the "Innovent Option"). Under the agreement, AnHeart received a non-refundable upfront cash payment, is owed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for achievement of certain regulatory approval milestones,  and is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of additional regulatory milestones, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of commercial milestones, and tiered percentage royalties ranging from mid-teen to low-twenties on annual net sales of taletrectinib in the Innovent Territory subject to certain adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AnHeart determined that the license represents a single performance obligation. The research and development services represent a material promise and were determined to be a separate performance obligation at the outset of the agreement as the promise is distinct and has standalone value to Innovent. They concluded that, at the inception of the agreement, the Innovent Option did not constitute a material right as it does not represent a discount to the fair value of the exclusive license that Innovent would not have received without entering into the agreement and is therefore not considered a distinct performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company satisfied the license performance obligation at a point in time when the license was delivered and the transfer of know-how completed. The portion of the transaction price allocated to the research and development services was deferred and is being recognized as research and development service revenue using an input method. Estimated costs to complete are reassessed on a periodic basis and any updates to the revenue earned are recognized on a prospective basis. The China NMPA approvals for first and second line indications of ROS1+ NSCLC represent achievement of two regulatory milestones. As such, the Company is owed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments under the agreement, of which the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of license revenue at a point in time and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the milestone payments is deferred and recognized as research and development service revenue using an input method. For the year ended December 31, 2024, the Company recognized license revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and research and development service revenue of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million under the Innovent agreement.  As of December 31, 2024, the accounts receivable of Innovent was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaboration and License Agreement with NK&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, AnHeart entered into an agreement with NK, granting NK a sub-licensable, royalty-bearing, exclusive right and license to commercialize AB-106 in Japan (the "NK Territory"). AnHeart is responsible for funding ongoing clinical trials of AB-106 in the NK Territory, with NK responsible for funding regulatory submissions in the NK Territory. The Company also granted NK a sub-licensable, royalty-bearing, exclusive right and license to research, develop and commercialize any new indications of AB-106 in the NK Territory ("NK New Indication Right"). Under the agreement, AnHeart received a non-refundable upfront cash payment and is eligible to receive $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of a regulatory milestone, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of commercial milestones, and a lower-mid double digit percentage royalty on net sales of taletrectinib in the NK Territory.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AnHeart determined that the license represents a single performance obligation. The research and development services represent a material promise and were determined to be a separate performance obligation at the outset of the agreement as the promise is distinct and has standalone value to NK. They concluded that, at the inception of the agreement, the NK New Indication Right did not constitute a material right.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The portion of the transaction price allocated to the research and development services was deferred and is being recognized as research and development service revenue using an input method. Estimated costs to complete are reassessed on a periodic basis and any updates to the revenue earned are recognized on a prospective basis. The Company recognized research and development service revenue of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million for the year ended December 31, 2024. As of December 31, 2024, the accounts receivable of NK was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contract assets and contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the Company satisfies its performance obligations by providing services to a customer before the customer pays consideration and before payment is due, the Company recognizes its rights to consideration as a contract asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any contract assets as of December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When a customer pays consideration before the Company provide services, the Company records its obligation as a contract liability. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects to recognize all of this balance as revenue as research and development services are provided over the next 4 years.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contract liabilities of the Company as of December 31, 2024 is listed in the table below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue in 2024 that was included in the contract liability balance recorded upon the acquisition of AnHeart.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The balance of contract liabilities as of December 31, 2024 represents the transaction price allocated to the remaining performance obligations. The contract liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is expected to be recognized within one year and the rest in the following three years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The costs incurred to fulfill customer contracts were capitalized and amortized to cost of revenue on a systematic basis that is consistent with the transfer of research and development services to the customer to which the asset relates. For the year ended December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion of costs incurred to fulfill customer contracts were capitalized and expensed in the same period. There were no balances related to the costs incurred to fulfill customer contracts as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</nuvb:CollaborationAndLicenseAgreementsTextblock>
    <nuvb:NumberOfMilestones
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_3e89ede9-1d0b-4eb6-8563-69f8930c95c6">two</nuvb:NumberOfMilestones>
    <nuvb:MilestonesRequirePayments
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_d6cd8657-ebc4-4db9-88ad-ee32e3f4f1b2"
      unitRef="U_USD">6000000</nuvb:MilestonesRequirePayments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_1323a416-ab5e-4896-9d28-28856ed3eea3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes total revenue recognized for the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.919999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_59e21847-16f9-4084-92e3-35afa293d947"
      decimals="-3"
      id="F_7ea14c46-4ca2-42e6-bf19-7746c61763a5"
      unitRef="U_USD">2086000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_573fc90e-3384-4e88-bebb-411d7823adc7"
      decimals="-3"
      id="F_d400767f-8f10-43ee-9ead-380756ffb10e"
      unitRef="U_USD">5787000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_76c3c656-e3ce-4e21-91d8-0e0d971c289a"
      unitRef="U_USD">7873000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nuvb:RepaymentsOfNonRefundableUpfrontCashPayment
      contextRef="C_24401d38-47d2-484c-ba0b-f6174eb508ff"
      decimals="-5"
      id="F_548ca069-6fc5-4d0d-a532-bdeb166ca057"
      unitRef="U_USD">12000000</nuvb:RepaymentsOfNonRefundableUpfrontCashPayment>
    <nuvb:ReceivedNonRefundableUpfrontCashPayment
      contextRef="C_24401d38-47d2-484c-ba0b-f6174eb508ff"
      decimals="-5"
      id="F_738998c7-6044-4f25-9641-4ad57394bb10"
      unitRef="U_USD">17000000</nuvb:ReceivedNonRefundableUpfrontCashPayment>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="C_24401d38-47d2-484c-ba0b-f6174eb508ff"
      decimals="-5"
      id="F_22ee5020-6832-4975-8700-fcdc8f36d19d"
      unitRef="U_USD">105000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <nuvb:OwedMilestonePayments
      contextRef="C_60d2085a-baaf-4b22-8edb-e7cc340aab3b"
      decimals="-5"
      id="F_b09927ea-c4bb-462a-8c01-cf4724cc6303"
      unitRef="U_USD">12000000</nuvb:OwedMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_63c9b400-5728-40d4-a6f1-9117ecc729d2"
      decimals="-5"
      id="F_6058948f-9dbc-4e35-b9bf-8a851be54162"
      unitRef="U_USD">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_573fc90e-3384-4e88-bebb-411d7823adc7"
      decimals="-5"
      id="F_7c55e7ce-7a9b-4a2b-bb9f-2998f5d2b184"
      unitRef="U_USD">9900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a8df6974-75d8-4cdd-aa79-237e8cd65e90"
      decimals="-5"
      id="F_96b37548-fb34-4123-b606-5a3d1f9820bd"
      unitRef="U_USD">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_60d2085a-baaf-4b22-8edb-e7cc340aab3b"
      decimals="-5"
      id="F_e549c770-7275-46f7-8b17-5a05d7e122dc"
      unitRef="U_USD">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="C_39922b23-3d3c-4025-8814-7b066e6e395d"
      decimals="-5"
      id="F_b00bc862-d26a-4c09-b89f-aa9854532a10"
      unitRef="U_USD">12600000</us-gaap:AccountsReceivableNet>
    <nuvb:ReceivedNonRefundableUpfrontCashPayment
      contextRef="C_86eee26d-a7c8-4971-a02e-0c536e6bb91b"
      decimals="-5"
      id="F_0d838383-31c9-4a9f-9d97-45a75df0bbc1"
      unitRef="U_USD">25000000</nuvb:ReceivedNonRefundableUpfrontCashPayment>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="C_86eee26d-a7c8-4971-a02e-0c536e6bb91b"
      decimals="-5"
      id="F_f0c4660e-5e17-4212-83b0-2cc330d90ef7"
      unitRef="U_USD">35000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_123f4631-c9de-4408-9fbf-82e1d9db0a2e"
      decimals="-5"
      id="F_44ad2fe0-3d1f-40a6-bb1f-5b6cb0ded8e4"
      unitRef="U_USD">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="C_b3414614-96e7-4ae2-b1f7-055df470e8ab"
      decimals="-5"
      id="F_98b86e45-6314-4f38-80cf-58d51fadcfea"
      unitRef="U_USD">100000</us-gaap:AccountsReceivableNet>
    <nuvb:ContractWithCustomerAssets
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-6"
      id="F_c1357fa5-fb88-41bf-80dd-004a53cb7bb5"
      unitRef="U_USD">0</nuvb:ContractWithCustomerAssets>
    <us-gaap:RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_108f9e9b-7eb8-44d7-a409-e4d2157b4d00">The Company expects to recognize all of this balance as revenue as research and development services are provided over the next 4 years.</us-gaap:RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9d93533e-ee84-4ba6-a270-a9b619e865a8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contract liabilities of the Company as of December 31, 2024 is listed in the table below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue in 2024 that was included in the contract liability balance recorded upon the acquisition of AnHeart.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_101e91ce-9660-46bb-af18-7822809f659f"
      decimals="-3"
      id="F_e1ce9360-5597-4f32-aa7b-50596e4c1f16"
      unitRef="U_USD">26689000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0f03a15b-3abb-4776-a53a-0c003dafb17a"
      decimals="-5"
      id="F_837f6d3e-27f1-43c5-9f65-08c500f5b92f"
      unitRef="U_USD">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-5"
      id="F_c1c56b5a-4abd-4c21-aeb8-e49a21b81cf6"
      unitRef="U_USD">11100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-5"
      id="F_fd53e9c0-7d3f-42bf-9bd2-c6d26f6147b4"
      unitRef="U_USD">7100000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:SubordinatedBorrowingsDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d7955b66-5563-43af-b5eb-8a8764bffb31">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 6. BORROWING&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2020, AnHeart entered into loan agreements with Bank of Hangzhou to obtain short-term borrowings to supplement its working capital. As of December 31, 2024, the outstanding balance net of repayments was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; For the year ended December 31, 2024, the Company had drawn down $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and repaid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The fixed interest rate of these borrowings is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2022, AnHeart entered into loan agreements with China Merchants Bank to obtain short-term borrowings to supplement its working capital. As of December 31, 2024, the outstanding balance was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, the Company repaid &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million. The fixed interest rate of these borrowings was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 4, 2023, AnHeart entered into a Loan and Security Agreement ("2023 SSVB Agreement") with Shanghai Pudong Development Bank in Silicon Valley for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million RMB or equivalent in optional currency USD term loans ("SSVB Loan"). The SSVB Loan consists of a short-term working capital loan of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million RMB and a long-term loan of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million RMB, which matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 4, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 4, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; respectively, at which time all outstanding balances are due. Draws on the line of credit for the short-term loans are payable on the maturity date of the SSVB Loan. Draws on the line of credit for the long-term loans are payable in equal instalments monthly over the shorter of 24 months or from the date the draw took place till the SSVB loan matures. Outstanding balances will bear interest at a fixed rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. As of December 31, 2024, the outstanding line of credit balance net of repayments was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million. For the year ended December 31, 2024, the Company repaid &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubordinatedBorrowingsDisclosureTextBlock>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="C_c3e4516b-f8d6-469d-9172-f8b2294ea29b"
      decimals="-5"
      id="F_06951e2b-26a8-4448-82cf-eab524e67f1c"
      unitRef="U_USD">5600000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <nuvb:ShortTermBorrowingsDrawnDown
      contextRef="C_d7bd32b5-b034-49be-9ebf-85bf65031ef7"
      decimals="-5"
      id="F_8416d7d8-b68a-48fc-b63c-f2dc53707575"
      unitRef="U_USD">12600000</nuvb:ShortTermBorrowingsDrawnDown>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="C_c3e4516b-f8d6-469d-9172-f8b2294ea29b"
      decimals="-5"
      id="F_55f74d89-432d-4374-8ad4-25abfaffd6d4"
      unitRef="U_USD">12600000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="C_5915e704-6a60-4fe4-b048-5cb37f86d627"
      decimals="4"
      id="F_b37f2952-2147-420c-be1f-f2f96bcf6a46"
      unitRef="U_pure">0.035</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="C_85891461-e727-4c8a-a45e-24ce144694c7"
      decimals="4"
      id="F_fb38f8cb-c42e-4929-9fb4-7b196a0f3142"
      unitRef="U_pure">0.0405</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="C_aca3d405-cc0e-4215-b0e3-ff17e649ad8a"
      decimals="-6"
      id="F_51297f38-eaaf-4e0c-9504-ecaade25c6dc"
      unitRef="U_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="C_a9328880-f63c-496f-99d3-ea644af60276"
      decimals="-5"
      id="F_f9a70f7a-9aee-4601-b017-536981f35586"
      unitRef="U_USD">2800000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="C_a9328880-f63c-496f-99d3-ea644af60276"
      decimals="4"
      id="F_07dd1a8c-8a59-42de-bf74-13ba509e6a57"
      unitRef="U_pure">0.039</us-gaap:SubordinatedBorrowingInterestRate>
    <srt:BankLoans
      contextRef="C_3b40daf5-2951-4982-9dc4-35739b254bf0"
      decimals="-5"
      id="F_e8b8034f-87f0-44c5-b7c4-48aebe6556c1"
      unitRef="U_USD">40000000</srt:BankLoans>
    <nuvb:ShortTermWorkingCapital
      contextRef="C_3b40daf5-2951-4982-9dc4-35739b254bf0"
      decimals="-6"
      id="F_fefcf9fc-c8aa-427b-b3f8-dfea7bad7f91"
      unitRef="U_USD">20000000</nuvb:ShortTermWorkingCapital>
    <nuvb:LongTermBorroing
      contextRef="C_3b40daf5-2951-4982-9dc4-35739b254bf0"
      decimals="-6"
      id="F_9bfa9ef3-5426-4b69-91bd-877fdb78d150"
      unitRef="U_USD">20000000</nuvb:LongTermBorroing>
    <us-gaap:LongTermDebtMaturityDate
      contextRef="C_f3542591-19a8-4b91-a21e-e2ed9f8b23a8"
      id="F_49e5813b-7b75-4072-9959-169a595e2097">2024-04-04</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:LongTermDebtMaturityDate
      contextRef="C_3757f3f2-4eb9-4da5-87da-348aee145967"
      id="F_fbb1b9c7-c389-4e25-ac06-fea1a6a6cdb0">2025-04-04</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8"
      decimals="4"
      id="F_30053e94-a407-42c4-b4e4-df69de226208"
      unitRef="U_pure">0.0425</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8"
      decimals="-5"
      id="F_3adc2d16-c59e-45bf-bef2-5b66fa2973d9"
      unitRef="U_USD">700000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="C_26117e6c-01c9-4aec-ab24-63bd5f5810f8"
      decimals="-5"
      id="F_1562619a-909c-45bc-a9a3-58bc55e8062a"
      unitRef="U_USD">1700000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_fe3a13d6-62df-4ade-a073-d03ebba4199f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 7. PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense related to property and equipment was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 20223, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_4778f30c-8c1c-4b2f-a70a-18c710135d9d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_abb8df07-b97c-4a48-aefb-b20f734b97a2"
      decimals="-3"
      id="F_269ba596-335e-401c-867e-0c0d2ab5b3b7"
      unitRef="U_USD">629000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b84cd312-fd39-4b1d-8699-fda7c967c8b2"
      decimals="-3"
      id="F_056ac03b-3955-4618-919d-dd5292a61d64"
      unitRef="U_USD">488000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8d9345df-39ad-447f-a1af-a822c985ade5"
      decimals="-3"
      id="F_375627d3-20b6-413c-84e5-1ede1def72a8"
      unitRef="U_USD">478000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_da7ecdf1-4156-4924-8c2b-91c1bbf48649"
      decimals="-3"
      id="F_87499da2-dff0-41af-a5db-a743a9696f4c"
      unitRef="U_USD">553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e48fcc9a-b0c1-44cf-86db-3afdf6eb9d8c"
      decimals="-3"
      id="F_f0891070-97ca-47cd-8702-3aba16660907"
      unitRef="U_USD">353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9a955a31-b3a1-4541-96dc-cc575ee9a1d3"
      decimals="-3"
      id="F_e3cfd827-7094-4638-bbb3-fbcc4282dbf5"
      unitRef="U_USD">342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_f4e89764-84ce-441d-bd35-89bcd481c078"
      unitRef="U_USD">1460000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_1e36fab1-d7e8-499d-8202-45beb615d177"
      unitRef="U_USD">1383000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_e007f596-eeff-4b10-b284-e8f896fe1fa4"
      unitRef="U_USD">874000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_2fe7649f-129a-40f6-85bb-158bb9746692"
      unitRef="U_USD">666000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_a887ea05-63ae-4419-9c61-afc41f6819d5"
      unitRef="U_USD">586000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_9ca2c202-fb82-4800-986a-1424a33c5a4b"
      unitRef="U_USD">717000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_56fdaa9c-d895-4a90-95a9-878ce8a8c2a3"
      unitRef="U_USD">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-5"
      id="F_3c4642c0-1e83-4ce9-99b7-7b0bae3bcf82"
      unitRef="U_USD">200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b5942fe6-192f-400a-9688-54f8922a04ac">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 8. ACCRUED EXPENSES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued consultant fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9b749ede-8490-4217-9b3c-c332b7bfa596">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued consultant fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_1a8f7d09-2fa8-40bd-aabe-afb2ea53a550"
      unitRef="U_USD">16243000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_57106c20-7e84-4d9c-8659-380ae5464f9a"
      unitRef="U_USD">4917000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_f3350539-6920-481e-a756-e55fb923edf5"
      unitRef="U_USD">14818000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_0e2c4a04-2b84-491e-a9e0-e88cb7fa3d96"
      unitRef="U_USD">4349000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_356fd3c1-4eea-45e0-a233-976ea63daed8"
      unitRef="U_USD">827000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_5b1d00d0-d5cb-4351-8add-d2d1771998ed"
      unitRef="U_USD">280000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_deb0be03-47c6-4a03-91fe-77db85802cf0"
      unitRef="U_USD">679000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_5e50332f-ae07-4062-8928-a216ee2ac8bd"
      unitRef="U_USD">144000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_2d46aff4-e3d6-4518-b0c4-67159b94b001"
      unitRef="U_USD">266000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_0406f9f7-b81f-49fc-8830-4b29426e1d05"
      unitRef="U_USD">103000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_bca909a2-ea29-4b09-8fb6-17918be9baa9"
      unitRef="U_USD">32833000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_98ed353e-d45b-40a0-acc6-0f1f93405513"
      unitRef="U_USD">9793000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_8fccbd99-b8a9-417c-8ad6-139a275641e7">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 9. LEASES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our principal executive offices are located in New York, New York, where we lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,900&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space under a lease that terminates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with an option for us to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; which is not reasonably assured of exercise, and in San Francisco, where we lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,418&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space that terminates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We also occupy office space located in Burlington, Massachusetts, where we lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,235&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space under a lease that terminates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as well as a total of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,735&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square meters of office space in the People&#x2019;s Republic of China, in the cities of Beijing, Guangzhou, Hangzhou and Shanghai, under leases that terminate in 2026 through 2027.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively. Expense related to variable leases was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t significant for the years ended December 31, 2024 and 2023.  Operating cash flows for the year ended December 31, 2024 and 2023 included&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lion and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the future minimum lease analysis of the Company's operating lease liabilities showing the aggregate lease payments as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average incremental borrowing rate used to determine the operating lease liabilities was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The Company's weighted average remaining lease term was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; y&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ears as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_5634f3f1-5114-4a3c-9c5e-9f28b9b642a2"
      decimals="0"
      id="F_05a58829-29cd-480b-b4ec-6befb946c58f"
      unitRef="U_sqft">7900</us-gaap:AreaOfRealEstateProperty>
    <nuvb:LesseeOperatingLeaseExpirationYear
      contextRef="C_2fa726a6-4678-4715-b671-32d7fc4b3458"
      id="F_7171dfb9-9edc-4cce-b19b-ede04e8b6ce6">2027</nuvb:LesseeOperatingLeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_2fa726a6-4678-4715-b671-32d7fc4b3458"
      id="F_25ab8ff5-f14d-4644-afe7-ac91d39b4329">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <nuvb:LeaseAdditionalTerm
      contextRef="C_2fa726a6-4678-4715-b671-32d7fc4b3458"
      id="F_41c5f5ee-f8ea-4ece-8861-602022d563a4">P5Y</nuvb:LeaseAdditionalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_8b229bac-622e-41dd-87db-5a7e8d379dd4"
      decimals="0"
      id="F_1ec8d301-ccec-4733-8170-98e274c1cfcd"
      unitRef="U_sqft">19418</us-gaap:AreaOfRealEstateProperty>
    <nuvb:LesseeOperatingLeaseExpirationYear
      contextRef="C_474282e8-2bd8-473d-b449-c1749a573ed7"
      id="F_436cf2d6-94b8-4f19-9ded-3f0dce5e9c83">2029</nuvb:LesseeOperatingLeaseExpirationYear>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_d83e520c-196f-42be-bff1-f66d4956ab03"
      decimals="0"
      id="F_98e93af4-5ba9-49a9-a546-6daa8c671fe5"
      unitRef="U_sqft">2235</us-gaap:AreaOfRealEstateProperty>
    <nuvb:LesseeOperatingLeaseExpirationYear
      contextRef="C_2fcaddbe-59b4-4dd8-acff-d235bcf3608a"
      id="F_efc8984d-511e-4460-b979-db7be1ab9f55">2027</nuvb:LesseeOperatingLeaseExpirationYear>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_694fe0ae-e3fc-4dfc-a41f-7d05ec59e408"
      decimals="0"
      id="F_9d64d3f7-271e-44a6-889b-256a586e630e"
      unitRef="U_sqm">1735</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_55d46922-f213-414a-ac4e-0d01078273af"
      unitRef="U_USD">2500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-5"
      id="F_a750fe48-e4ed-463b-9d6e-f5fa7e8dbf0c"
      unitRef="U_USD">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-6"
      id="F_a1d98c94-a6c7-4a02-a4b2-6607663aa39c"
      unitRef="U_USD">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-6"
      id="F_2ef0236a-985a-4b16-b397-03fa826c874c"
      unitRef="U_USD">0</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_7cab8435-81fa-4998-a2c5-6dc024d6c644"
      unitRef="U_USD">2600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-5"
      id="F_7dd3138a-ef8b-4af6-88f4-0e4b513d9c57"
      unitRef="U_USD">1700000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_8db823f5-a28f-493b-8224-940ce73a7ed8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the future minimum lease analysis of the Company's operating lease liabilities showing the aggregate lease payments as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_1437834d-711b-4930-a6f7-1062021b1630"
      unitRef="U_USD">1767000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_3d02b626-f96c-42c2-bbc3-3e10a03fbb63"
      unitRef="U_USD">837000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_49d8e8eb-190d-45d1-b2fe-14df433da7f5"
      unitRef="U_USD">171000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b2f08386-b7c5-44bd-8ef0-b9278dff6788"
      unitRef="U_USD">2775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b9aab4a4-e099-4bad-9e10-eceaa0966b14"
      unitRef="U_USD">143000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_777d4034-ef16-4f2a-829a-760933493b4b"
      unitRef="U_USD">2632000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="3"
      id="F_bf370c14-0627-41f6-83eb-9f96f3265379"
      unitRef="U_pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      id="F_807e3fda-896c-4da5-8e5a-d95b7004c24b">P1Y7M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_772a0889-8ce7-42bf-8a0b-846c62c3703d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 10. STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Founder owns &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding Class B common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock Restriction Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the Merger, the shares subject to the &#x201c;Stock Restriction Agreement&#x201d; between the Company and the Founder was adjusted based on the Exchange Ratio. The number of shares, as adjusted, subject to repurchase per the terms of the Stock Restriction Agreement is reduced each month by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,101,240&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Class A common shares and no common shares will be subject to repurchase by June 2022. As of December 31, 2024, there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Common Stock subject to the repurchase option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Holders of Class A and Class B common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one vote per share on all matters&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, except that the holders of Class A common stock do not participate in the election of the directors who are elected exclusively by the holders of Class B common stock. Holders of Class A and Class B common stock vote together as a single class on all matters, except that (i) the holders of Class B common stock have the right, voting as a separate class, to elect and remove without cause three directors plus at least 50% of any directors in excess of seven, and (ii) the approval of the holders of a majority of Class B common stock, voting as a separate class, is required for approval by the stockholders of any acquisition (whether by merger, sale of shares or sale of assets) or liquidation. There are no cumulative voting rights.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Conversion&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each share of Class B common stock will automatically convert into one share of Class A common stock upon transfer to a non-authorized holder. In addition, the Class B common stock is subject to a &#x201c;sunset&#x201d; provision under which all outstanding shares of Class B common stock will automatically convert into an equal number of shares of Class A common stock if ownership of shares of Class A and Class B common stock held by our President and Chief executive Officer, David Hung, M.D., falls below an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,188,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares or if Dr. Hung dies, becomes disabled or ceases to be our Chief Executive Officer, unless he is terminated from such position by us without cause.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_30e55683-04d9-41a0-bd33-67d960b1716c"
      decimals="2"
      id="F_d88da15c-8238-4731-8274-a7296824630f"
      unitRef="U_pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <nuvb:NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      decimals="INF"
      id="F_edfca42f-0e9c-4485-9eb0-934f7cd7df68"
      unitRef="U_shares">1101240</nuvb:NumberOfSharesDecreasedSubjectToRepurchaseUnderStockRestrictionAgreement>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_a5a3ec93-d622-45c2-8770-84e991a7b996"
      decimals="INF"
      id="F_48317266-f652-4dc3-b2c0-f7fcd0437b12"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:BusinessCombinationControlObtainedDescription
      contextRef="C_4b9f43a9-9d6b-48e7-8cc3-ca1f86613de6"
      id="F_9dfdb655-45f9-473d-8584-4d509ad6920c">Holders of Class A and Class B common stock are entitled to one vote per share on all matters, except that the holders of Class A common stock do not participate in the election of the directors who are elected exclusively by the holders of Class B common stock. Holders of Class A and Class B common stock vote together as a single class on all matters, except that (i) the holders of Class B common stock have the right, voting as a separate class, to elect and remove without cause three directors plus at least 50% of any directors in excess of seven, and (ii) the approval of the holders of a majority of Class B common stock, voting as a separate class, is required for approval by the stockholders of any acquisition (whether by merger, sale of shares or sale of assets) or liquidation. There are no cumulative voting rights.</us-gaap:BusinessCombinationControlObtainedDescription>
    <us-gaap:CommonStockVotingRights
      contextRef="C_4b9f43a9-9d6b-48e7-8cc3-ca1f86613de6"
      id="F_bb1d0132-50f9-4bff-bdb3-fbcdfe2599c4">one vote per share on all matters</us-gaap:CommonStockVotingRights>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_d4d1928d-1758-446a-9b41-e8b4d12651af"
      decimals="INF"
      id="F_19687831-739e-41c4-82c6-09d1bf2289d6"
      unitRef="U_shares">43188000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_a7dd5898-d4c2-429c-b92b-6eeaeec29906">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 11. NET LOSS PER SHARE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic loss per share is computed by dividing net loss by the weighted-average number of shares of Class A and Class B common stock outstanding, but excluding shares of common stock subject to repurchase for the period. The number of common stock shares subject to repurchase was determined prospectively from the date of the Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restriction Agreement described in Note 10. Diluted loss per share reflects the potential dilution that could occur if the stock options to issue common stock were exercised. The Company had a net loss in all periods presented thus the dilutive net loss per common share is the same as the basic net loss per common share as the effect of any options or conversions is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The earnings per share amounts are the same for the different classes of common stock because the holders of each class are legally entitled to equal per share distributions whether through dividends or liquidation.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following securities outstanding at December 31, 2024 and 2023 have been excluded from the calculation of weighted average shares outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,681,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Class A common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,729,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,649,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,420,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_6461d9e5-dc10-41ad-921b-22dc33d53ad5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following securities outstanding at December 31, 2024 and 2023 have been excluded from the calculation of weighted average shares outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,681,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Class A common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,729,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,649,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,420,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e555de18-2b2c-49fe-b7c4-7fc47b8d8119"
      decimals="INF"
      id="F_1bd5d184-87ca-43c5-bd69-ff82c049bace"
      unitRef="U_shares">8681182</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a1fa561b-037b-48f9-b6e6-35db1b21440b"
      decimals="INF"
      id="F_1555809d-fbc5-4b91-84db-5d2164ba7a9e"
      unitRef="U_shares">5787462</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_612babb2-a261-40cd-b2ca-5ceb1ce31e71"
      decimals="INF"
      id="F_0f318ce7-ac01-403f-bf29-0db40a8740a0"
      unitRef="U_shares">57729709</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f4520a62-400d-4bbb-bc6f-dfcca29c01bc"
      decimals="INF"
      id="F_24c991c1-9150-43aa-acb8-a6d832c65c0c"
      unitRef="U_shares">30649239</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4681f739-9c28-49fc-bde8-0490bae0f771"
      decimals="0"
      id="F_25a0ac79-ccea-41a8-86bb-9f42f9960d83"
      unitRef="U_shares">1420131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_69989213-f1c9-4257-8e6c-cc9e8660ba6c"
      decimals="0"
      id="F_0fb3591f-b543-465a-ab1a-4487bcf21c1a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_7cb440da-7b7e-42ec-8202-331778e1a206">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 12. ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a rollforward of the changes in accumulated other comprehensive (loss) income for the years ended December 31, 2024 and 2023, which is all attributable to unrealized gains (losses) on available-for-sale securities. All amounts are net of tax.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized gain (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amount reclassified for realized loss on marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Currency translation adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_2e81dfba-91b1-432a-95d0-a24d8283d9fb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a rollforward of the changes in accumulated other comprehensive (loss) income for the years ended December 31, 2024 and 2023, which is all attributable to unrealized gains (losses) on available-for-sale securities. All amounts are net of tax.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized gain (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amount reclassified for realized loss on marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Currency translation adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_1755576a-e16e-4794-a5ce-3ff4debde5a5"
      unitRef="U_USD">181000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053"
      decimals="-3"
      id="F_854c2379-a06e-4d2f-b10a-89203619cf80"
      unitRef="U_USD">-5526000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_f6adb066-5d14-4cb0-9a38-530d32f6319e"
      unitRef="U_USD">-157000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_377e9a07-f1cb-492d-95d9-7996c054ef66"
      unitRef="U_USD">5568000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <nuvb:RealizedLossOnMarketableSecurities
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_8d39894b-b21f-44f7-94fa-f02e1f90c3fd"
      unitRef="U_USD">12000</nuvb:RealizedLossOnMarketableSecurities>
    <nuvb:RealizedLossOnMarketableSecurities
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_e9687d5f-6572-4a90-ba7a-6bd8ed924d79"
      unitRef="U_USD">139000</nuvb:RealizedLossOnMarketableSecurities>
    <nuvb:CurrencyTranslationAdjustmentValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_93790d04-f7fe-4d93-b5d0-901bf5fcf2fa"
      unitRef="U_USD">537000</nuvb:CurrencyTranslationAdjustmentValue>
    <nuvb:CurrencyTranslationAdjustmentValue
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_c894eb75-469e-45c1-a88e-77891c3b026c"
      unitRef="U_USD">0</nuvb:CurrencyTranslationAdjustmentValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_dd23b51c-be68-4829-883a-cd2a95e84262"
      unitRef="U_USD">573000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_990def73-bd57-48f6-b10a-500b456dd846"
      unitRef="U_USD">181000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_c882cfab-2dd4-4abd-b013-9f0be6605da3">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 13. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The 2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2019, the Company adopted the 2019 Equity Incentive Plan or (&#x201c;2019 Plan&#x201d;), which provided for the grant of options, stock appreciation rights, restricted stock, and other stock awards.  In January 2021, our board of directors adopted the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan was approved by our stockholders in February 2021 and became effective immediately upon the Closing Date of the Merger.  Shares available for future issuance under the 2019 Plan were canceled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Awards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The 2021 Plan provides for the grant of incentive stock options (&#x201c;ISOs&#x201d;), within the meaning of Section 422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#x201c;NSOs&#x201d;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Authorized Shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The maximum number of shares of Class A common stock that may be issued under the 2021 Plan was initially set at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,684,047&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31 of the preceding year, or (2) a lesser number of shares of Class A common stock determined by our board of directors prior to the date of the increase&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The maximum number of shares of Class A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;common &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;stock that may be issued on the exercise of ISOs under the 2021 Plan is three times the number of shares available for issuance upon the 2021 Plan becoming effective or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,052,141&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2021, our board of directors adopted the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP was approved by our stockholders in February 2021 and became effective immediately upon the Closing Date of the Merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share Reserve.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The maximum number of shares of Class A common stock that may be issued under the 2021 ESPP was initially set at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,750,354&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The number of shares of Class A common stock reserved for issuance under the 2021 ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31st of the preceding calendar year or such lesser number of shares of Class A common stock as determined by our board of directors.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Shares subject to purchase rights granted under the 2021 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the 2021 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The stock-based compensation expense included in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Options with Service Conditions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options granted with only service conditions generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and expire after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity with service condition only for employees and members of the Company&#x2019;s Board of Directors for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Issuable&lt;br/&gt;Pursuant to&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,834,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options assumed for acquisition of AnHeart&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,742,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,175,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,750,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,192,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,808,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,245,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All unvested options as of December 31, 2024 are expected to vest.  The weighted average grant-date fair value of stock options outstanding on December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share, respectively. Total&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;unrecognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;compensation costs related to non-vested stock options at December 31, 2024 was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion and is expected to be recognized within future operating results over a weighted-average period of&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;y&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ears.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For stock options granted with only service conditions during the years ended December 31, 2024 and 2023, the inputs in the Black-Scholes option-pricing model to determine the fair value is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.287%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.857%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.857%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company estimated its expected stock volatility based on the blended average of its historical volatility and of publicly traded set of peer companies.  The expected term of the Company&#x2019;s options has been determined utilizing the &#x201c;simplified&#x201d; method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Dividend yield is based on the expectation that the Company will not pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Options with Service, Market, and Performance Conditions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options granted with combined service, market, and performance conditions will vest based on achievement of various service conditions and either a market-based or performance-based goals in three tranches with multiple categories such as the Company&#x2019;s market capitalization, and clinical and regulatory milestones. The market-based and performance-based goals period ends in October 2030. The explicit service periods are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for tranche 1, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for tranche 2, and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for tranche 3. Upon the vesting requirement, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the options will vest for each of tranche 1 and 2, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the options granted for tranche 3 will vest. The Company recognizes the fair value of the options within each tranche over the longer of their explicit service period or derived service period. The achievement of the performance condition was not deemed probable on the date of grant. As of December 31, 2024, the performance condition was not deemed probable.  The expense recognized is based on the fair value of the market condition for the years ended December 31, 2024 and 2023. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity with combined service, market, and performance conditions for employees for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Issuable&lt;br/&gt;Pursuant to&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,815,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,921,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.74&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average grant-date fair value of stock options outstanding on December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. Total unrecognized compensation costs related to non-vested stock options at December 31, 2024 was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lion and is expected to be recognized within future operating results over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the stock options granted with combined service, market, and performance conditions was based on a Monte Carlo simulation with an embedded Black-Sholes pricing model. For the years ended December 31, 2024 and 2023, the fair value was computed using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.17&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The determination of expected volatility, risk- free rate, and dividend yield was the same approach as used for the above stock options granted with service only conditions. The expected term period represents the time used as an input in the embedded Black-Sholes pricing model which is based on the midpoint between the vest and expiration dates for each tranche.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the activity for the restricted stock units assumed in the AnHeart acquisition for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs assumed for the acquisition of AnHeart&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,201,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;618,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,420,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average grant-date fair value of stock options outstanding on December 31, 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Total unrecognized compensation costs related to non-vested stock options at December 31, 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and is expected to be recognized within future operating results over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <nuvb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement
      contextRef="C_eb8419be-c990-483e-98aa-581ed2dfd11f"
      decimals="INF"
      id="F_b80df18c-3546-4f5d-85aa-e672ec72a37f"
      unitRef="U_shares">50684047</nuvb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_efe682e8-6905-4a59-a9b1-a74dcdb4a136"
      id="F_1005448c-c3eb-46b3-90aa-11c97c120c9f">The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year, starting on January 1, 2022 through January 1, 2031, in an amount equal to (1) 4.0% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31 of the preceding year, or (2) a lesser number of shares of Class A common stock determined by our board of directors prior to the date of the increase</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_efe682e8-6905-4a59-a9b1-a74dcdb4a136"
      decimals="3"
      id="F_f50d38e8-953f-46fc-a97d-92769453ad3f"
      unitRef="U_pure">0.04</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3cb6dc20-b571-4ae0-9e67-6ab4aff1d9d2"
      decimals="INF"
      id="F_d5e24e88-faa5-4f26-8202-724ed23c3712"
      unitRef="U_shares">152052141</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nuvb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement
      contextRef="C_b5db802e-98fe-4d8f-8ce3-efda58046123"
      decimals="INF"
      id="F_9a96641f-d58b-4332-a3b2-8ae6cded627c"
      unitRef="U_shares">4750354</nuvb:NumberOfSharesIssuableUnderShareBasedPaymentArrangement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4"
      id="F_95125c33-4335-4426-94e2-5a8d8df9aa7a">The number of shares of Class A common stock reserved for issuance under the 2021 ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by 1.0% of the total number of shares of Class A common stock and Class B common stock outstanding or issuable upon conversion or exercise of outstanding instruments on December 31st of the preceding calendar year or such lesser number of shares of Class A common stock as determined by our board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4"
      decimals="3"
      id="F_465b4e0b-66b9-4be9-bf88-c50e58579f32"
      unitRef="U_pure">0.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_f87be34f-dc75-4ee4-b6ea-bfa60f6afc05">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The stock-based compensation expense included in the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_926d281c-c192-41fa-9469-55fc53c364ef"
      decimals="-3"
      id="F_e0a9681f-8008-44f1-9f3f-8523285a60fa"
      unitRef="U_USD">16450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80f9920f-001e-4ee0-bc41-726bea9c2be2"
      decimals="-3"
      id="F_636a040b-343a-4aef-9f70-48ef70c171fe"
      unitRef="U_USD">8797000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b09ceff4-bb66-4ef2-9cdf-6517cbd7196b"
      decimals="-3"
      id="F_54556b59-ef12-4b86-80ba-bf2adf71a744"
      unitRef="U_USD">15825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b1434390-9c27-4f94-8077-b738947d29fb"
      decimals="-3"
      id="F_7a6b4016-63ef-4194-8952-e5b133e9aa81"
      unitRef="U_USD">10716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_9b006c31-2394-46e5-8dc2-29e6b6f453ff"
      unitRef="U_USD">32275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_a1e48a0f-bec9-4ca9-81ae-52a2058b5bcc"
      unitRef="U_USD">19513000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4"
      id="F_bca5d2c4-d45e-4a24-9a00-462d8313ad6f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_3d7c16a0-e0a5-4475-8bef-3d0657ab21d4"
      id="F_cb4fd996-6cc9-4fbf-95b0-f93d08278f05">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      id="F_e7e4547b-1599-4106-bb6a-1f1b0cf00489">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity with service condition only for employees and members of the Company&#x2019;s Board of Directors for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Issuable&lt;br/&gt;Pursuant to&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,834,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options assumed for acquisition of AnHeart&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,742,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,175,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,750,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,192,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,808,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,245,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0c652882-855e-465e-8c03-230c6f70279d"
      decimals="INF"
      id="F_8a7c2b4d-001e-4668-a7e3-1acfe4391ca2"
      unitRef="U_shares">26834045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0c652882-855e-465e-8c03-230c6f70279d"
      decimals="2"
      id="F_87b5d2ed-922d-44d8-a6e9-3344fa47aa35"
      unitRef="U_USDollarShare">3.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="INF"
      id="F_7cbda862-eb78-4123-8d96-9169b5924a29"
      unitRef="U_shares">13742239</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="2"
      id="F_1aef2d74-ae6b-4849-af5b-bad9309f85ef"
      unitRef="U_USDollarShare">0.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="INF"
      id="F_54ff86f6-da0b-43f8-bb18-0e51ddbf1cf1"
      unitRef="U_shares">20175083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="2"
      id="F_627f3119-2f12-40de-ae84-f75b27d9e9d5"
      unitRef="U_USDollarShare">2.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="INF"
      id="F_ba580367-909d-47e1-a14e-ed718ca32202"
      unitRef="U_shares">1750547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="2"
      id="F_f4da625c-dbe1-439f-a1be-699a4ad999d2"
      unitRef="U_USDollarShare">4.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="INF"
      id="F_9672cfff-41a9-453a-b3a7-7e74ca054e02"
      unitRef="U_shares">5192263</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="2"
      id="F_f65d33d7-554f-43d8-9b1b-5231cf4350c2"
      unitRef="U_USDollarShare">0.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="INF"
      id="F_14a7cd52-fe6d-4b59-9475-51672b345d26"
      unitRef="U_shares">53808557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="2"
      id="F_301d4311-774e-48fe-9816-e1a0cf2004c5"
      unitRef="U_USDollarShare">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      id="F_a1cc583f-89dd-40a9-9322-025ddc444651">P7Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="-3"
      id="F_603732db-bf29-4ae6-bc4f-1e6b558a69ce"
      unitRef="U_USD">32475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="INF"
      id="F_09a79026-2c0f-41a3-a972-ebc90173a2a5"
      unitRef="U_shares">24245561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="2"
      id="F_8129f6f2-a52d-4d7d-8209-ea2e7d2b9345"
      unitRef="U_USDollarShare">2.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      id="F_bf2939bb-102c-4710-9da4-bb985580dae5">P6Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="-3"
      id="F_b6deec8f-5696-4280-867e-5b11c004813b"
      unitRef="U_USD">18147000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="2"
      id="F_5174f55d-f7b9-458f-9005-af049ad43d50"
      unitRef="U_USDollarShare">2.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="2"
      id="F_fa86898d-862f-45a0-8275-c3541e869738"
      unitRef="U_USDollarShare">2.57</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_ed2589a9-11fc-46c5-a588-1f840166c29f"
      decimals="-5"
      id="F_6cd967e1-ec09-42c7-931f-0f37d8087a0e"
      unitRef="U_USD">48400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      id="F_8f251158-1916-4c87-b11d-7da0a542c678">P2Y7M6D</nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      id="F_9017c98f-2fbe-4b45-b9a3-56c0cd01414c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For stock options granted with only service conditions during the years ended December 31, 2024 and 2023, the inputs in the Black-Scholes option-pricing model to determine the fair value is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.287%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.857%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.857%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.08&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_b7745198-d60e-4f1b-a9f3-33740d640e7b"
      decimals="2"
      id="F_243379a1-4669-44ef-94f6-5af23a4dfcc0"
      unitRef="U_USDollarShare">0.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_943111d4-1cca-4ec9-9b87-c18a3c9909ea"
      decimals="2"
      id="F_157c33b5-5aac-4029-b577-a203610a37ff"
      unitRef="U_USDollarShare">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_fdd8837c-b00d-4e16-b06b-aaf29e21f38f"
      decimals="2"
      id="F_754966d2-3049-4fc6-a055-4fa679665c61"
      unitRef="U_USDollarShare">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_6ed882e8-da6b-4efe-bc8b-354008a8cc06"
      decimals="2"
      id="F_bdde98c6-e686-4d43-8420-e445a5a6e30d"
      unitRef="U_USDollarShare">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_12761058-5ed6-4b90-92ad-003f0933b78a"
      decimals="4"
      id="F_e84134a1-7b60-4056-8def-b5dc3d21ddf6"
      unitRef="U_pure">0.0363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9"
      decimals="4"
      id="F_bf6e61db-a15a-4645-b155-27a83e54cf27"
      unitRef="U_pure">0.0474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832"
      decimals="4"
      id="F_ccff0117-391c-483f-acaa-4a4f6fca5709"
      unitRef="U_pure">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f73a9537-952a-476b-a1b9-94ceb77e4027"
      decimals="4"
      id="F_1853f3b5-599d-4097-ae7d-a94dcbe48ae0"
      unitRef="U_pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_12761058-5ed6-4b90-92ad-003f0933b78a"
      decimals="2"
      id="F_e45033e5-57a3-40ea-8f77-3b6bb05254b6"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9"
      decimals="2"
      id="F_c281080b-1ff5-44e2-b030-db65c899b96f"
      unitRef="U_pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832"
      decimals="2"
      id="F_1fe12a39-df1b-45fc-8bf8-f4f204054cb6"
      unitRef="U_pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f73a9537-952a-476b-a1b9-94ceb77e4027"
      decimals="2"
      id="F_63d8dda0-2a7b-40b2-9146-dcadc3766fca"
      unitRef="U_pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_12761058-5ed6-4b90-92ad-003f0933b78a"
      id="F_752c72c4-cb1e-4841-9d05-1042e0fe16d0">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5b5cd6b0-4d0f-459b-8cb6-7e73b0004ad9"
      id="F_01252936-ea49-4675-8bf8-357fab4111c1">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4af1d429-8e1d-40b6-b04b-f6538e5cd832"
      id="F_7ba1c22e-cb6d-4654-9333-ca8281fdf528">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f73a9537-952a-476b-a1b9-94ceb77e4027"
      id="F_41688a5b-0691-40d1-a35d-3bf95bc73c4c">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0c0e91e4-7e2e-42ad-976a-fc7071b208bd"
      decimals="2"
      id="F_7d793e86-1bde-49e6-af16-0fa7abf71569"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_abba69cb-6d7c-456b-a9e7-8c60b7df5832"
      decimals="2"
      id="F_51251392-d8b3-4b2c-9828-266d890cf4ee"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0727c878-248f-4686-86bc-a4597d7f4e1c"
      id="F_465fe6e3-ce6c-4cfe-a26b-22aebc0cb4b1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_44d82460-2e05-4f7c-9c55-b545075fb034"
      id="F_d342385b-0641-4334-b538-bff79cd52848">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_412486e3-9ba5-40f0-bf1b-da7b97f1b931"
      id="F_56d0c4f3-59aa-4920-9425-c965953ba8c7">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <nuvb:SharesBasedStockOptionGrantedVestingPercentage
      contextRef="C_0727c878-248f-4686-86bc-a4597d7f4e1c"
      decimals="2"
      id="F_10609f40-13e2-4d93-84bc-d093fb7aa7f1"
      unitRef="U_pure">0.20</nuvb:SharesBasedStockOptionGrantedVestingPercentage>
    <nuvb:SharesBasedStockOptionGrantedVestingPercentage
      contextRef="C_ca424ba3-3e9c-4fc8-943e-50b54d3eb6a4"
      decimals="2"
      id="F_2d3d2059-886c-4d6b-8753-6a5cf7d760d5"
      unitRef="U_pure">0.20</nuvb:SharesBasedStockOptionGrantedVestingPercentage>
    <nuvb:SharesBasedStockOptionGrantedVestingPercentage
      contextRef="C_412486e3-9ba5-40f0-bf1b-da7b97f1b931"
      decimals="2"
      id="F_f07b4edf-c9c7-4f1b-a609-962dd0e84f8b"
      unitRef="U_pure">0.60</nuvb:SharesBasedStockOptionGrantedVestingPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      id="F_4b3cf77f-316c-45ce-b157-6c7e4c1fdbb8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity with combined service, market, and performance conditions for employees for the year ended December 31, 2024 is as follows:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares Issuable&lt;br/&gt;Pursuant to&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,815,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,921,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.74&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f9007fb3-c6d1-4f58-99a8-9b1c076139b8"
      decimals="INF"
      id="F_bf86e1e9-e218-4495-933d-3315c3f77ae0"
      unitRef="U_shares">3815194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f9007fb3-c6d1-4f58-99a8-9b1c076139b8"
      decimals="2"
      id="F_a371c157-e8e8-4be6-946d-9c253a223050"
      unitRef="U_USDollarShare">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      decimals="INF"
      id="F_e815a871-0e5c-4ed0-9d90-5afa77d34a53"
      unitRef="U_shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      decimals="2"
      id="F_2a1a4bf1-23f1-41f9-8dc8-08cedda8e417"
      unitRef="U_USDollarShare">3.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      decimals="INF"
      id="F_d6658ff3-1b0c-4427-9b03-83b11d481bcf"
      unitRef="U_shares">144042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      decimals="2"
      id="F_e3831f96-12a0-4dd7-b368-c17e53a34137"
      unitRef="U_USDollarShare">4.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663"
      decimals="INF"
      id="F_c522bb84-9cb4-4cd7-95a1-1a38216ef710"
      unitRef="U_shares">3921152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663"
      decimals="2"
      id="F_d5c0237b-ec73-4da4-b89d-a7ae40b75f80"
      unitRef="U_USDollarShare">6.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      id="F_67bed1ad-2b18-4dcb-9046-b0f313a34898">P6Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663"
      decimals="-3"
      id="F_b2322fc2-bf1e-4a77-88a0-abb4ecc7923e"
      unitRef="U_USD">328000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663"
      decimals="0"
      id="F_adc52435-4972-4a96-b449-10b9553a9948"
      unitRef="U_shares">748375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663"
      decimals="2"
      id="F_9eaa6aeb-6bf3-4d4b-8f0f-d40b4528f828"
      unitRef="U_USDollarShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      id="F_bc348039-9338-4a5f-974b-c4ef8da8d2c6">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_308b572c-bcec-40d0-86b6-45262da0d663"
      decimals="-3"
      id="F_9b1c2726-2523-46c1-91c5-0fee88bb535f"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_e6904180-de0a-402e-a43d-2eb3649975e4"
      decimals="2"
      id="F_7aa891fb-5a72-4738-804a-f20b0b0b9c3d"
      unitRef="U_USDollarShare">3.95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_23995f85-8e92-4f98-835d-389f59c1c8ec"
      decimals="2"
      id="F_987b6e25-09c0-4302-87ba-e655571fb986"
      unitRef="U_USDollarShare">4.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f9dc1391-a88d-47a7-b7e3-f1a434ed0445"
      decimals="-5"
      id="F_92962dac-15df-4ec5-b721-cd96c382b5ad"
      unitRef="U_USD">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod
      contextRef="C_e6904180-de0a-402e-a43d-2eb3649975e4"
      id="F_3af63da1-ed4f-423c-96dc-ad5f4c077be0">P1Y9M18D</nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      id="F_5b17c851-4470-495c-b553-a7576fc67d19">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the stock options granted with combined service, market, and performance conditions was based on a Monte Carlo simulation with an embedded Black-Sholes pricing model. For the years ended December 31, 2024 and 2023, the fair value was computed using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.17&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_b647e270-1e2a-41ed-99c4-b1fdac51fdee"
      decimals="2"
      id="F_d448588c-d8bb-40c0-beb1-31461bc77e3d"
      unitRef="U_USDollarShare">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_60d86b53-364b-4bb8-a244-c7731ef29c6f"
      decimals="2"
      id="F_ca098fb3-7a37-4128-a153-431a30af0727"
      unitRef="U_USDollarShare">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_62336d85-1efb-4a6d-a379-5fc3378a8347"
      decimals="2"
      id="F_92f4a84f-5539-4ed2-9027-fb9315fc4c5b"
      unitRef="U_USDollarShare">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c671dc80-de5d-4aa6-a09f-d6f224165348"
      decimals="4"
      id="F_6e17ca42-ea74-4a05-b611-44ebeed9ba67"
      unitRef="U_pure">0.0427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_70f4ad29-01fb-4717-94fc-a3ad777c8950"
      decimals="4"
      id="F_35fc21e4-4a6e-4452-8693-1c5c0ff182a3"
      unitRef="U_pure">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa"
      decimals="4"
      id="F_7959da51-2cac-456b-a9ff-0a79f1b4b39e"
      unitRef="U_pure">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_c671dc80-de5d-4aa6-a09f-d6f224165348"
      decimals="2"
      id="F_9db993f3-9f5b-4535-bc42-78bc6b408b05"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_70f4ad29-01fb-4717-94fc-a3ad777c8950"
      decimals="2"
      id="F_ee078d72-848c-4a72-ab67-cbd018ceea65"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa"
      decimals="2"
      id="F_190942e0-156b-4f93-9f0f-bf84da1b15b7"
      unitRef="U_pure">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c671dc80-de5d-4aa6-a09f-d6f224165348"
      id="F_745608a1-199f-4f67-817f-75500fcb9dda">P6Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_70f4ad29-01fb-4717-94fc-a3ad777c8950"
      id="F_fb6e597f-2257-4890-a9e5-bcb6e9f1e514">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2e6ad1e1-6772-41e8-a0ba-d6a041e16aaa"
      id="F_e6b5f6ed-a1f6-48ef-ada8-1d7aa27c39c2">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_77f61e72-e151-4de9-96f4-7091dc97bbc3"
      decimals="2"
      id="F_1aab8c32-be86-4ec8-a45e-52432ca309d8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b05136ff-fb6b-4102-a36c-cf37b5c03746"
      decimals="2"
      id="F_e63baebc-7358-445d-83c4-6a8c06df0a60"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_0db439e0-65c7-400f-a3d4-351bec5c6deb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the activity for the restricted stock units assumed in the AnHeart acquisition for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs assumed for the acquisition of AnHeart&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,201,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;618,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,420,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_b98b6295-0101-48a0-af40-21586c6ade2e"
      decimals="0"
      id="F_2a616760-1425-4e5e-a1e1-a9372d03db44"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c"
      decimals="0"
      id="F_5c18f78d-7547-4656-b4ff-f5970974fa14"
      unitRef="U_shares">2201694</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c"
      decimals="0"
      id="F_bc72ec01-ee96-4265-8095-79beb671fcab"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c"
      decimals="0"
      id="F_e3a0bb76-32f6-44a6-98b4-97d02a710f12"
      unitRef="U_shares">618340</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c"
      decimals="0"
      id="F_a13a0c2a-c8d5-4bc6-86a7-53222c4ce01a"
      unitRef="U_shares">163223</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_5ef65c87-2f51-4661-a7fb-5e58e7086ef2"
      decimals="0"
      id="F_c9e5ec95-acb1-4ea3-bd4a-7875af493b63"
      unitRef="U_shares">1420131</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c"
      decimals="2"
      id="F_ded0037b-805a-4ec9-b200-314ede144642"
      unitRef="U_USDollarShare">3.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_5ef65c87-2f51-4661-a7fb-5e58e7086ef2"
      decimals="-5"
      id="F_3ecd6151-2456-44bb-80b8-f6569b37a522"
      unitRef="U_USD">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod
      contextRef="C_61525415-3259-4e81-b1a8-a96d13e75e0c"
      id="F_cea5343a-2b85-4727-93ce-4dbe853cfb0e">P3Y2M12D</nuvb:Sharebasedcompensationarrangementbysharebasedbyweightedaverageperiod>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_54961673-9bb2-41f6-868a-59c57f406720">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 14. 401(K) PLAN&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company sponsors a 401(k) plan (the &#x201c;Plan&#x201d;) covering substantially all employees of the Company. The Plan allows employees to contribute tax deferred salary deductions into the Plan under the provisions of Section 401(k) of the Internal Revenue Code. Matching contributions are made by the Company up to a maximum amount of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of employee contributions, subject to certain limitations as defined in the Plan. The Company made matching contributions o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively&lt;/span&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="2"
      id="F_04df22f4-f018-40eb-bfe1-c63d80ec2d2d"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_15dbea47-6a99-4c57-bf13-0f3214d6c65c"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-5"
      id="F_614ab884-3f38-4765-beb0-b6efedf7cb5a"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <nuvb:WarrantDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_21f543af-03c5-4f51-b2f6-cfbff3bac196">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 15. WARRANTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the Merger, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787,472&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants to purchase Common Stock outstanding, consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,791,639&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Public Warrants, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Private Placement Warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;833,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Forward Purchase Warrants. Each whole warrant entitles the registered holder to purchase one share of our Class A Common Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.  Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our Class A Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the Acquisition, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,893,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Consideration Warrants. The Consideration Warrants were restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#x2019;s outstanding Public Warrants. The Consideration Warrants are no longer restricted with respect to the exercise and transfer thereof based on the stockholder approval obtained at the Annual Meeting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, there were an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,681,182&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded that the Consideration Warrants, Public Warrants, Private Warrants and Forward Purchase Warrants do not meet the conditions to be classified in equity.  The warrants were recorded at fair value with subsequent changes in fair value reflected in earnings (see Note 4). The change in fair value resulted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in a loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of Consideration, Public and Forward Purchase Warrants is determined using the closing price of the warrants on the NYSE market and the related Warrant liability is included in Level 1 fair value measurements. The Company utilizes the Black-Scholes option pricing formula to determine the fair value of the Private Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liability for the Private Warrants is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The annualized volatility of the Warrant was based on a calibration to the publicly traded warrant price as of the valuation date. The risk-free interest rate was estimated using linear interpolation assuming a term consistent with the time until the warrants expire, and yield information was based on U.S. Treasury Constant Maturities.  The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aforementioned warrant liabilities are not subject to qualified hedge accounting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers between Levels 1, 2 or 3 during the period ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides quantitative assumptions regarding Level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Strike price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined the following fair values for the outstanding Warrants (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Public Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Private Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forward Purchase Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consideration Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following presents changes in liabilities classified in Level 3 of the fair value hierarchy for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of Private Warrants liability recognized in earnings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</nuvb:WarrantDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f"
      decimals="0"
      id="F_efd636aa-2af1-4eef-837a-2ad237346c3b"
      unitRef="U_shares">5787472</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9"
      decimals="0"
      id="F_e37e4c4a-2e25-4023-8401-91e850c9f40e"
      unitRef="U_shares">4791639</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_38dfcba2-bd95-458c-a352-b4df776e9ce0"
      decimals="0"
      id="F_4ba0c26c-0381-4959-865c-2718c3e701d4"
      unitRef="U_shares">162500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7"
      decimals="0"
      id="F_38e67249-0ee1-49cb-b24c-c3dd54434c82"
      unitRef="U_shares">833333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f"
      decimals="2"
      id="F_863bfc38-a3c9-40b6-bc79-cb0f767cdc5a"
      unitRef="U_USDollarShare">11.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7045ca99-96f1-4773-b5ed-c42ab07a67e1"
      decimals="0"
      id="F_60135ffe-f0d4-41d8-b6e9-c0dd3004a09b"
      unitRef="U_shares">2893720</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_cb385cb3-afc0-489c-8677-ab9f9a152e7f"
      decimals="0"
      id="F_cf2f0e2a-40ad-4ee6-aa7c-73ab91875820"
      unitRef="U_shares">8681182</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:MarketRiskBenefitChangeInFairValueGainLoss
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-5"
      id="F_f9672419-25e7-408e-9522-b8a5887e760c"
      unitRef="U_USD">900000</us-gaap:MarketRiskBenefitChangeInFairValueGainLoss>
    <nuvb:FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_873db7ab-a4e6-4c59-87d1-baa45d20f7b2">no</nuvb:FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_454a31b9-07a6-45a4-a960-72e00d47f73f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides quantitative assumptions regarding Level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Strike price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"
      decimals="2"
      id="F_0b5759d7-9557-498b-9aae-4ef1872468ea"
      unitRef="U_USDollarShare">2.66</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5"
      decimals="2"
      id="F_9de655fd-8428-45dc-b41d-8c2095ac3bf1"
      unitRef="U_USDollarShare">1.51</us-gaap:SharePrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_2168c91d-d91e-4b2d-88c3-486e5d82f9b3"
      decimals="2"
      id="F_82faf3cc-638d-4c62-8abb-5e386d07f66e"
      unitRef="U_USDollarShare">11.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_44998c3a-718b-48fb-8220-6e156a09eee5"
      decimals="2"
      id="F_7e73f7a7-b403-4aa7-84b8-5a834c48de1b"
      unitRef="U_USDollarShare">11.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574"
      id="F_0fa1b84a-fceb-42a2-9043-68089583c3a8">P1Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a"
      id="F_eb5c9530-2274-42af-b38f-227e9cab7d1a">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574"
      decimals="3"
      id="F_c6f277aa-b48c-4663-be4d-ad59a97ccc12"
      unitRef="U_pure">1.375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a"
      decimals="3"
      id="F_863324b1-aa1a-4268-93d4-7d0f44aa8d53"
      unitRef="U_pure">0.827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574"
      decimals="3"
      id="F_5c31e1a0-1a77-46ec-a025-78989e4dc548"
      unitRef="U_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a"
      decimals="3"
      id="F_11844513-6dd6-48d9-a163-470d5d7b47b2"
      unitRef="U_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b6964028-a1f5-4562-8dd6-ab7b2f917574"
      decimals="3"
      id="F_9213ec0b-3d5d-42b2-80dc-86e7dfb64a10"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_942a2b2b-70da-4457-a462-954c54372c8a"
      decimals="3"
      id="F_54a225bd-5918-4735-9c7c-e020d404ba6f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_7974b1f6-187d-4e2b-a591-697db5a6ad7b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined the following fair values for the outstanding Warrants (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Public Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Private Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forward Purchase Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consideration Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_ad4cbe74-d7b2-44e5-bc3a-347b707358f9"
      decimals="-3"
      id="F_4a0c3e91-3117-4ddf-a74c-d025e040cdc3"
      unitRef="U_USD">1102000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_38dfcba2-bd95-458c-a352-b4df776e9ce0"
      decimals="-3"
      id="F_a62c0f7f-7ef2-41ff-84be-1892812c5c59"
      unitRef="U_USD">94000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_94abf941-0ddf-46ac-94c7-efb0a5b185c7"
      decimals="-3"
      id="F_4abe300e-260c-4be0-97a2-adb770efd35f"
      unitRef="U_USD">192000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_93ac93d0-60a9-4a06-90a6-fd3ede540eb6"
      decimals="-3"
      id="F_f95e69e1-210c-4297-a4fa-b4121c4b4e00"
      unitRef="U_USD">665000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_e90815c2-445c-4f1b-b33a-ef4a5ce0b2a2"
      unitRef="U_USD">2053000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d88819ff-1327-4b2a-93e0-89a5bcb7614b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following presents changes in liabilities classified in Level 3 of the fair value hierarchy for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of Private Warrants liability recognized in earnings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_79f6d160-8817-4a92-aa5c-a0aa3030e8bc"
      unitRef="U_USD">15000</nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy>
    <nuvb:ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_24f2e584-c8a5-43f6-ba85-3ae5e9bab38a"
      unitRef="U_USD">79000</nuvb:ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings>
    <nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_82b4ecde-47e8-41a9-aa87-9489a1c23eb2"
      unitRef="U_USD">94000</nuvb:ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_6ee6846c-3268-40cc-8bed-530e3dfd4eae">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 16. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did not record a provision or benefit for income taxes for the years ended December 31, 2024 and 2023. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the net deferred tax asset as of December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under IRC 59(e) and $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;"&gt;70.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under IRC 174.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation between the Company&#x2019;s effective tax rate and the federal statutory rate for the years ended December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;True-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquisition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had federal net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The federal net operating losses have an unlimited carryover period and state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had federal research and development tax credit carryforwards of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion and state research and development tax credit carryforwards of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The federal resea&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rch and development tax credits begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and state research and development tax credits have an unlimited carryover period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had federal orphan drug tax credit carryforwards of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The federal orphan drug tax credits begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All of the federal and state net operating losses may be subject to change of ownership limitations provided by the Internal Revenue Code and similar state provisions. An annual loss limitation may result in the expiration or reduced utilization of the net operating losses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#x201c;ownership change,&#x201d; which is generally defined as a greater than 50 percentage-point cumulative change, by value, in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of AnHeart Therapeutics, Inc.'s previous mergers with AnHeart Hangzhou in March 2019 and AnHeart Ltd (Cayman) in September 2021, we are subject to the Section 382 limitation. Our utilization of these pre-merger NOL and tax credit carryforwards is limited to the amount of income that the related entity contributes to our consolidated taxable income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company maintained a full valuation allowance on its net deferred tax assets. The valuation allowance was determined in accordance with the provisions of ASC 740, Accounting for Income Taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. The Company&#x2019;s history of cumulative losses, along with expected future U.S. losses required that a full valuation allowance be recorded against all net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.	&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company&#x2019;s total amount of unrecognized tax benefits was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;llion, none of which would impact the Company&#x2019;s effective tax rate, if recognized. The Company does not anticipate that the amount of unrecognized tax benefit will significantly increase within the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the activity related to the unrecognized tax benefits were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross increases - current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross decreases - prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to taxation in the United States and various state jurisdictions. All tax years remain subject to examination for U.S. federal and state purposes. All net operating losses generated to date are subject to adjustment for U.S. federal and state purposes. The Company is not currently under examination in federal or state jurisdictions.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d4ea26c7-3ea4-418c-afc3-52566c89d6a1">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the net deferred tax asset as of December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under IRC 59(e) and $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;"&gt;70.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under IRC 174.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_2431b45c-1631-408c-8aa0-a3f800a3294f"
      unitRef="U_USD">107698000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_20ca2ec7-0986-491e-9b5c-790346bda01d"
      unitRef="U_USD">29290000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_a874d8b1-e447-47a5-9a77-af710ddcf436"
      unitRef="U_USD">19379000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_612f6787-d84d-4b27-b05a-9868cb40cab5"
      unitRef="U_USD">13133000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_7bd7a3ca-4745-4447-8ef4-f1bb5370e779"
      unitRef="U_USD">97294000</nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_4bd79f76-27a9-417e-b329-b47366d2c6dd"
      unitRef="U_USD">49156000</nuvb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_3c6fd469-9860-4291-9d26-b205a45fe78e"
      unitRef="U_USD">13172000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_fde3b27c-fa5c-4628-ac1c-9848ed663b7a"
      unitRef="U_USD">7307000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_ecc9c07f-a198-4bb0-a5b9-0b7a1a8117bc"
      unitRef="U_USD">4116000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_c3cd4c63-ac8c-4d24-932f-fb716e2b4306"
      unitRef="U_USD">1124000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <nuvb:DeferredTaxAssetsLeaseLiability
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_7f703a0a-a545-48e4-85fb-ff17b81b2a6f"
      unitRef="U_USD">930000</nuvb:DeferredTaxAssetsLeaseLiability>
    <nuvb:DeferredTaxAssetsLeaseLiability
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_d086f977-57dd-4785-a17b-ef0a38d4f133"
      unitRef="U_USD">1035000</nuvb:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_b102d183-03ef-4b87-a43a-1c3ffe6d272e"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_01ee3cf1-c756-4fdc-a3b8-8b22af7f9e25"
      unitRef="U_USD">367000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_6cb60681-5fdb-400d-8e33-38b51064ea46"
      unitRef="U_USD">242589000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_6b8cf332-9cc4-4577-a39e-527cf12da51d"
      unitRef="U_USD">101412000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_daf86816-2de9-4cd8-aa52-6a6052d51717"
      unitRef="U_USD">853000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_1ee07bd2-bc00-467f-b58c-87ee161900e9"
      unitRef="U_USD">931000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_cc25a3f1-9a49-489c-a49e-0977c07ca6ee"
      unitRef="U_USD">3591000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_f77a3e9f-f0bc-421d-982f-04d563c5e6a6"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_384007ce-354c-4784-9c91-0c4885bed19d"
      unitRef="U_USD">4444000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_67d79891-a677-4c60-bcf9-a3adc0c5cc08"
      unitRef="U_USD">931000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_6220e282-c01c-4bd9-9fbc-4b5e65a9545e"
      unitRef="U_USD">238145000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_824e6628-6d5e-4c59-bbba-1412171fab96"
      unitRef="U_USD">100481000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_dadbb427-a20d-4854-b585-1b53627242a7"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_ca5ea240-0aa3-472c-8945-b5d1fffca337"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_f4d88de7-a689-43dc-94ed-786f211f10b1"
      decimals="-5"
      id="F_7aebcf3e-5c9c-444b-a55d-08e0a49d8fa8"
      unitRef="U_USD">24800000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_acf04de5-17e7-45a9-89d8-b6eb52400fba"
      decimals="-5"
      id="F_714a7e53-6025-4659-b71f-04cd1fa84550"
      unitRef="U_USD">70400000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_bf6c5c47-0ce4-4e43-b549-7b2fd6bce9c7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation between the Company&#x2019;s effective tax rate and the federal statutory rate for the years ended December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;True-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquisition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_ba5b32d5-3fb0-4f22-aebd-43814da4a0ab"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_529cc618-f939-4852-9018-26aa435ae365"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_2233aa83-16cd-42af-bd37-233a382c0884"
      unitRef="U_pure">0.0506</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_7ce09176-84e9-479e-a025-5b3c18a0dacf"
      unitRef="U_pure">0.0484</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <nuvb:EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_ff61bb04-c404-43f5-9fed-f6145d141bff"
      unitRef="U_pure">-0.1965</nuvb:EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent>
    <nuvb:EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_563b652b-1e43-4b5a-9bf3-7e9ddd164baf"
      unitRef="U_pure">0</nuvb:EffectiveIncomeTaxRateReconciliationAcquiredIPRDOtherPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_f2c400d5-2260-4589-ad9e-b008f455af64"
      unitRef="U_pure">-0.0031</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_10bed00b-d6be-4d77-a771-76733a876088"
      unitRef="U_pure">-0.0133</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_eb912349-60a7-4537-9fa0-a5800b7c481a"
      unitRef="U_pure">0.0072</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_e0d93997-7529-46a6-a939-b1a92808193e"
      unitRef="U_pure">0.0305</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <nuvb:EffectiveIncomeTaxRateReconciliationTrueUp
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_2a077faf-21f9-4ad4-8454-797f79e3ffe6"
      unitRef="U_pure">0.0004</nuvb:EffectiveIncomeTaxRateReconciliationTrueUp>
    <nuvb:EffectiveIncomeTaxRateReconciliationTrueUp
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_d7f91287-38c0-4413-8910-a211a7215dbd"
      unitRef="U_pure">-0.0342</nuvb:EffectiveIncomeTaxRateReconciliationTrueUp>
    <nuvb:EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_b4354225-c2a4-4473-a298-16db52d5724a"
      unitRef="U_pure">0.1025</nuvb:EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent>
    <nuvb:EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_cf4b6ef8-5768-4db3-bf71-aa734033ed8d"
      unitRef="U_pure">0</nuvb:EffectiveIncomeTaxRateReconciliationAcquisitionRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_33ee00ee-9404-4d8f-a42c-23787b9d8b5f"
      unitRef="U_pure">0.0649</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_5046d76a-c7ef-4f14-b193-4178aa00223a"
      unitRef="U_pure">-0.0441</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_83579698-458f-4184-b84c-8b2cac1a03b6"
      unitRef="U_pure">0.0066</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_36c72841-ef1a-4e9f-a44c-6bae297158b6"
      unitRef="U_pure">0.0007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_54c2a5e3-d154-43e3-8af2-a80889ab5eb6"
      unitRef="U_pure">-0.2426</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_5ed6dfe1-7d20-4a10-b3d7-d76fe1f4025c"
      unitRef="U_pure">-0.198</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="4"
      id="F_fa398ed8-bcb6-4b34-b55a-0f764fcfb88b"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="4"
      id="F_2fd3b410-ea46-4825-b61e-b6b6ae21abe9"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_27aec131-424f-4703-abb2-81c1cfb32c8e"
      decimals="-5"
      id="F_bfe839b9-666b-4760-9e57-f6d0dbc3a361"
      unitRef="U_USD">194300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b4189f91-e001-4361-b114-dc6380eac776"
      decimals="-5"
      id="F_c814c435-a478-4857-97a7-12f602a691ef"
      unitRef="U_USD">270300000</us-gaap:OperatingLossCarryforwards>
    <nuvb:OperatingLossCarryforwardsExpiration
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_b4b1baa4-121f-4072-ba43-dae7f59599ab">2038</nuvb:OperatingLossCarryforwardsExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_27aec131-424f-4703-abb2-81c1cfb32c8e"
      decimals="-5"
      id="F_a90725ad-1b4f-4d70-aa4d-24314cad16ad"
      unitRef="U_USD">13900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b4189f91-e001-4361-b114-dc6380eac776"
      decimals="-5"
      id="F_5dc533f9-23f9-4cba-bfd7-483031c140fc"
      unitRef="U_USD">2900000</us-gaap:TaxCreditCarryforwardAmount>
    <nuvb:TaxCreditCarryforwardsExpiration
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_ba6036fb-22c4-4daa-8adc-f4eb93273c61">2039</nuvb:TaxCreditCarryforwardsExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_3321395a-631d-476b-8f7d-c59b5665b1b3"
      decimals="-5"
      id="F_e2726d7d-767a-4a7b-9fc3-bfe85ec96f37"
      unitRef="U_USD">9900000</us-gaap:TaxCreditCarryforwardAmount>
    <nuvb:TaxCreditCarryforwardsExpiration
      contextRef="C_54d22bf6-7851-4a61-9f26-acc23b794faa"
      id="F_59b1508c-9e09-4299-9563-72a419095cdc">2042</nuvb:TaxCreditCarryforwardsExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-5"
      id="F_952d1999-b369-4ae2-9140-cf810851ab5d"
      unitRef="U_USD">7400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_af93af72-7ff3-423c-8cd1-851d0e9e1fea">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the activity related to the unrecognized tax benefits were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross increases - current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross decreases - prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_58cdc74b-9007-4976-830a-42a9f6e0ceb4"
      unitRef="U_USD">5629000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1d6f3bfc-73fe-43b4-9e15-1077e52b8053"
      decimals="-3"
      id="F_5e12062b-3fe8-4380-9123-a41ab9f3b1ab"
      unitRef="U_USD">5068000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_d7227e58-8d12-46a0-865f-08396855eca5"
      unitRef="U_USD">1788000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_6c90d1c4-dd1d-467d-a0e9-a85d13e49508"
      unitRef="U_USD">1019000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      decimals="-3"
      id="F_7d5d670c-e9db-4ecd-9aa0-3c6cf699ed1a"
      unitRef="U_USD">26000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_f24bee32-709b-4a1b-b740-f6523eda2c0d"
      decimals="-3"
      id="F_f64c9dee-e45e-4b52-a6c8-607cc764d81a"
      unitRef="U_USD">458000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3d1a36dc-9c9c-4d3e-9173-db5b986762a6"
      decimals="-3"
      id="F_093e69f3-247d-4ce4-b762-ead5f29ecf06"
      unitRef="U_USD">7391000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2a8fdeac-e96f-4090-9037-5d3af26c4059"
      decimals="-3"
      id="F_9a04442c-37a7-48f3-aa68-cfd9f442d95a"
      unitRef="U_USD">5629000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_d6302108-d78b-4e1d-ba93-cb1cb1e3a3d6">&lt;p id="notes" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 17. COMMITMENTS AND CONTINGE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases its office space under non-cancellable operating lease agreements. The leases also require the Company to pay real estate taxes and other operational expenses associated with the leased location and is included in rent expense. The effect of graduating rents, net of the rent credits, is being amortized over the life of the lease so as to result in equal monthly rent expense over the lease term. Deferred rent liability reported in the accompanying consolidated balance sheets represents the cumulative excess of straight-line rental costs over the actual rental payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has standby letters of credit with banks in the aggregate amount of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million which serve as security for the New York and San Francisco spaces operating leases. The standby letters of credit automatically renew &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;annually&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party, for which management believes the ultimate outcome would have a material adverse effect on the Company&#x2019;s financial position.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCredit
      contextRef="C_39d9ef20-3367-48ef-9bd5-5cb516f43747"
      decimals="-5"
      id="F_87c46aa7-c9e3-4cd3-90fc-7b2ddc600f99"
      unitRef="U_USD">600000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityFrequencyOfCommitmentFeePayment
      contextRef="C_68c26585-4b66-4439-9588-4c1bd035ebe4"
      id="F_c1e44252-3249-4656-a178-d8c5153cd2f0">annually</us-gaap:LineOfCreditFacilityFrequencyOfCommitmentFeePayment>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_83ea97e0-ebd5-40bc-be56-aa30eff45d81"
      id="F_9c472d51-d825-46c6-8d7f-49bb7dd7c370">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NOTE 18. SUBSEQUENT EVENT&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 3, 2025, the Company announced the closing of a non-dilutive financing of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from Sagard. The financing is comprised of a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million synthetic royalty and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of senior secured debt.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;synthetic royalty and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of debt will be funded conditioned upon FDA&#x2019;s approval of taletrectinib on or prior to September 30, 2025. The transaction will support the U.S. launch of taletrectinib,  and general corporate purposes.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SecuredDebt
      contextRef="C_f196edb9-bd73-43fb-8ae1-2133c0857f5e"
      decimals="-5"
      id="F_03267d08-05ba-42eb-b89d-b34eb8f63a85"
      unitRef="U_USD">250000000</us-gaap:SecuredDebt>
    <us-gaap:RoyaltyExpense
      contextRef="C_0b0d4681-373d-40ee-a05b-cf4167b76104"
      decimals="-5"
      id="F_53f6a62a-7786-4bfd-9ffc-0b1039e5c5f5"
      unitRef="U_USD">150000000</us-gaap:RoyaltyExpense>
    <us-gaap:SecuredDebt
      contextRef="C_5ed535ca-023f-4c23-9afe-8ae365dc24de"
      decimals="-5"
      id="F_e69809e5-573a-4940-928f-06137cdb996e"
      unitRef="U_USD">100000000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="C_9748bbba-55ba-4df0-8e3a-bd402ef3408d"
      decimals="-5"
      id="F_475f6cd0-a98d-407f-a063-c76130da88ff"
      unitRef="U_USD">50000000</us-gaap:SecuredDebt>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_801b7957-e7ce-45ce-af71-3084ea02dc16"
          xlink:label="F_801b7957-e7ce-45ce-af71-3084ea02dc16"
          xlink:type="locator"/>
        <link:footnote id="FNT_4f3bb437-a8b3-4cff-8b4c-0918d5764aee" xlink:label="FNT_4f3bb437-a8b3-4cff-8b4c-0918d5764aee" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,646,255</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.23</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of the Acquisition Date.</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_801b7957-e7ce-45ce-af71-3084ea02dc16"
          xlink:to="FNT_4f3bb437-a8b3-4cff-8b4c-0918d5764aee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_73151569-7198-451b-a2ba-1634232ea74a"
          xlink:label="F_73151569-7198-451b-a2ba-1634232ea74a"
          xlink:type="locator"/>
        <link:footnote id="FNT_563dd183-07f4-4e61-8c2d-ef4770f63d0a" xlink:label="FNT_563dd183-07f4-4e61-8c2d-ef4770f63d0a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,202</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued at as-converted value of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_73151569-7198-451b-a2ba-1634232ea74a"
          xlink:to="FNT_563dd183-07f4-4e61-8c2d-ef4770f63d0a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_27913815-f03d-44ad-ae06-0585e506afd5"
          xlink:label="F_27913815-f03d-44ad-ae06-0585e506afd5"
          xlink:type="locator"/>
        <link:footnote id="FNT_227f6045-fd63-4e82-9ac3-e6f2c0dda3b3" xlink:label="FNT_227f6045-fd63-4e82-9ac3-e6f2c0dda3b3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,893,720</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued at the estimated fair value of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2641</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_27913815-f03d-44ad-ae06-0585e506afd5"
          xlink:to="FNT_227f6045-fd63-4e82-9ac3-e6f2c0dda3b3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_c9f3c6cf-2103-4802-bf64-c4e3996706c0"
          xlink:label="F_c9f3c6cf-2103-4802-bf64-c4e3996706c0"
          xlink:type="locator"/>
        <link:footnote id="FNT_37026355-c90c-4fba-bff4-dc06521eb3a1" xlink:label="FNT_37026355-c90c-4fba-bff4-dc06521eb3a1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The portion recorded in consideration transferred represents the fair value of replacement awards 			  (Assumed Options &amp; Assumed RSUs) attributable to precombination services.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c9f3c6cf-2103-4802-bf64-c4e3996706c0"
          xlink:to="FNT_37026355-c90c-4fba-bff4-dc06521eb3a1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_4bd79f76-27a9-417e-b329-b47366d2c6dd"
          xlink:label="F_4bd79f76-27a9-417e-b329-b47366d2c6dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7bd7a3ca-4745-4447-8ef4-f1bb5370e779"
          xlink:label="F_7bd7a3ca-4745-4447-8ef4-f1bb5370e779"
          xlink:type="locator"/>
        <link:footnote id="FNT_8344d213-e047-4112-8b2d-a4031ed59257" xlink:label="FNT_8344d213-e047-4112-8b2d-a4031ed59257" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Capitalized costs deferred tax asset includes research and development capitalized expenditures of $</xhtml:span><xhtml:span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">24.8</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 59(e) and $</xhtml:span><xhtml:span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:super;font-kerning:none;min-width:fit-content;">70.4</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under IRC 174.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4bd79f76-27a9-417e-b329-b47366d2c6dd"
          xlink:to="FNT_8344d213-e047-4112-8b2d-a4031ed59257"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7bd7a3ca-4745-4447-8ef4-f1bb5370e779"
          xlink:to="FNT_8344d213-e047-4112-8b2d-a4031ed59257"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
